P00001606T0076|0 9|Comparison
P00001606T0076|14 33|alkaline phosphatases
P00001606T0076|37 50|5-nucleotidase
P00008171T0000|0 19|Pharmacologic aspects
P00008171T0000|22 47|neonatal hyperbilirubinemia
P00008997A0472|4 6|CSF
P00008997A0472|8 11|HCO3
P00008997A0472|34 40|CSF PCO2
P00008997A0472|50 63|K-depleted rats
P00008997A0472|98 105|controls
P00008997A0472|132 143|greater slope
P00010943A0733|0 9|Flurazepam
P00010943A0733|27 47|effective hypnotic drug
P00010943A0733|55 65|optimum dose
P00010943A0733|74 88|general practice
P00010943A0733|96 97|mg
P00012653T0045|0 3|Beta
P00012653T0045|12 17|agents
P00013683A0210|4 27|extracorporeal CO2 removal
P00013683A0210|40 52|CO2 production
P00013683A0210|54 57|VCO2
P00013683A0210|60 78|alveolar ventilation
P00015731A0090|0 24|Intravenous administration
P00015731A0090|28 32|mg/kg
P00015731A0090|36 62|carbonic anhydrase inhibitors
P00015731A0090|36 52|carbonic anhydrase
P00015731A0090|64 76|acetazolamide
P00015731A0090|78 90|methazolamide
P00015731A0090|92 107|dichlorphenamide
P00015731A0090|109 117|sulthiame
P00015731A0090|133 145|important rise
P00015731A0090|148 156|cortical p
P00015731A0090|191 191|p
P00015731A0090|197 200|p CO2
P00015731A0090|214 215|pH
P00015731A0090|218 230|arterial blood
P00022143T0000|0 17|Teratological study
P00022143T0000|20 30|etoperidone
P00023348A0601|0 15|Colorectal polyps
P00024600A0522|3 26|variable HMG dosage regimen
P00024600A0522|44 53|advantages
P00024600A0522|73 98|standard daily dosage regimen
P00025557A0100|7 16|CO2 content
P00025557A0100|25 28|Vol%
P00025557A0100|32 38|animals
P00025557A0100|45 51|apathic
P00025557A0100|59 68|body weight
P00027739T0000|0 28|Serum gamma glutamyltransferase
P00027739T0000|45 56|liver disease
P00027967A0207|11 31|secretory HI antibodies
P00027967A0207|56 60|onset
P00027967A0207|80 87|patients
P00027967A0207|124 133|antibodies
P00027967A0207|141 153|maximal levels
P00027967A0207|161 164|days
P00027967A0207|170 174|onset
P00029555A0861|18 27|virus assay
P00029555A0861|31 42|quantitation
P00029555A0861|49 55|methods
P00029555A0861|68 84|inexpensive enough
P00029555A0861|95 134|typical shellfish microbiology laboratories
P00029953T0045|0 14|Characteristics
P00029953T0045|17 30|lipase activity
P00029953T0045|17 22|lipase
P00030183T0000|0 7|Takayasu
P00030183T0000|33 38|HLA-B5
P00030937A0119|0 3|SGPT
P00030937A0119|5 8|SGOT
P00030937A0119|13 45|alkaline phosphatase concentrations
P00030937A0119|13 31|alkaline phosphatase
P00030937A0119|72 79|subjects
P00033873T0001|0 26|Gamma glutamyl transpeptidase
P00033873T0001|28 31|GGTP
P00033873T0001|46 57|seminal fluid
P00034935A0545|0 7|Patients
P00034935A0545|12 20|Parkinson
P00034935A0545|47 59|high incidence
P00034935A0545|62 70|psychoses
P00034935A0545|77 89|drug treatment
P00034935A0545|96 96|%
P00038408T0000|0 19|Selective stimulation
P00038408T0000|22 47|central alpha-autoreceptors
P00038408T0000|70 85|alpha-methyldopa
P00038408T0000|89 91|FLA
P00039271T0000|0 17|Anti-anxiety action
P00039271T0000|20 27|diazepam
P00039271T0000|33 59|intra-amygdaloid application
P00041512T0067|0 8|Abstracts
P00048373A0377|0 6|Removal
P00048373A0377|26 38|altered mucoas
P00048373A0377|70 87|squamous epithelium
P00050628A0202|2 24|IgG monoclonal gammopathy
P00050628A0202|2 4|IgG
P00050628A0202|40 44|serum
P00050628A0202|48 55|patients
P00050628A0202|59 81|Bence-Joanes proteinuria
P00052597T0000|0 6|Studies
P00052597T0000|9 23|immunoglobulin E
P00052597T0000|37 43|sojourn
P00052597T0000|48 61|Professor Dan H.
P00054900A0226|0 23|Peroxydase reaction stains
P00054900A0226|0 9|Peroxydase
P00054900A0226|37 57|chloroacetate esterase
P00055040A0000|3 14|out-patients
P00055040A0000|19 36|pustulosis palmaris
P00055040A0000|64 87|direct immunofluorescence
P00055040A0000|104 113|deposition
P00055040A0000|116 125|fibrinogen
P00055040A0000|127 132|fibrin
P00055040A0000|138 156|degradation products
P00055040A0000|158 167|FR-antigen
P00055040A0000|182 195|unaffected skin
P00055040A0000|209 236|heparin-precipitable fraction
P00055040A0000|238 240|HPF
P00055040A0000|243 254|cryoglobulin
P00055040A0000|258 278|total plasma fibrinogen
P00055040A0000|269 278|fibrinogen
P00056837A0000|5 21|mediastinoscopies
P00056837A0000|74 84|operability
P00056837A0000|88 105|pulmonary carcinoma
P00056901A0308|10 21|human albumin
P00056901A0308|23 23|%
P00056901A0308|27 46|hydroxy-ethyl-starch
P00056901A0308|68 75|dilution
P00060529A0695|12 23|control group
P00060529A0695|27 42|acquisition-rate
P00060529A0695|49 59|symptomatic
P00060529A0695|63 85|asymptomatic 0acteriuria
P00060529A0695|95 95|%
P00060529A0695|98 110|figure similar
P00060529A0695|128 139|women present
P00060529A0695|145 162|practice population
P00060529A0695|180 188|transient
P00060529A0695|190 200|symptomatic
P00060529A0695|205 218|persistent A.B.
P00061478T0000|4 16|complications
P00061478T0000|19 33|catheterisation
P00061478T0000|37 56|intravenous nutrition
P00063680T0000|0 16|Prenatal diagnosis
P00063680T0000|19 31|galactosaemia
P00064414A1098|0 4|Sings
P00064414A1098|13 22|indicative
P00064414A1098|25 49|metaplastic erythropoiesis
P00064414A1098|53 58|absent
P00066874T0000|0 47|False positive amniotic fluid alpha fetoprotein levels
P00066874T0000|26 41|alpha fetoprotein
P00066874T0000|61 73|contamination
P00066874T0000|78 87|fetal blood
P00066874T0000|89 95|results
P00072928T0000|0 13|Serum-ferritin
P00072928T0000|27 42|haemochromatosis
P00073344A0367|3 10|subjects
P00073344A0367|14 35|phytomitogen reactivity
P00073344A0367|41 51|lymphocytes
P00074758T0000|0 7|Patients
P00074758T0000|16 29|hypothyroidism
P00083846T0000|0 6|Albumin
P00083846T0000|10 24|cyclic AMP levels
P00083846T0000|27 42|peritoneal fluids
P00084275T0063|0 6|Preface
P00086313A0000|11 17|strains
P00086313A0000|20 31|Legionnaires
P00086313A0000|33 47|disease bacteria
P00086313A0000|71 93|distinct serologic groups
P00086313A0000|106 113|findings
P00086313A0000|126 157|direct fluorescent antibody testing
P00088391A0181|5 19|other hand factor
P00088391A0181|43 59|coumarin treatment
P00088391A0181|72 78|antigen
P00089778A0000|18 37|alpha 2-macroglobulin
P00089778A0000|39 56|alpha 1-antitrypsin
P00089778A0000|58 68|plasminogen
P00089778A0000|70 82|C3-complement
P00089778A0000|84 112|fibrinogen degradation products
P00089778A0000|84 93|fibrinogen
P00089778A0000|114 116|FDP
P00089778A0000|121 140|fibrinolytic activity
P00089778A0000|158 170|aqueous humour
P00089778A0000|174 178|serum
P00089778A0000|187 194|patients
P00089778A0000|199 203|Fuchs
P00089778A0000|205 224|endothelial dystrophy
P00089778A0000|228 235|patients
P00089778A0000|240 266|uncomplicated senile cataract
P00089778A0000|275 290|secondary aqueous
P00089778A0000|298 313|cataract patients
P00092689A0352|6 6|%
P00092689A0352|12 19|patients
P00092689A0352|35 39|times
P00094639A0313|0 7|Prazosin
P00094639A0313|27 50|volume responsive patients
P00094639A0313|67 68|mg
P00096241A0087|0 1|T4
P00096241A0087|5 8|FT4I
P00096241A0087|17 31|parallel courses
P00096241A0087|38 43|groups
P00096241A0087|61 64|days
P00096241A0087|77 82|values
P00096241A0087|107 122|premature infants
P00096241A0087|130 134|weeks
P00096241A0087|136 138|EGA
P00096241A0087|145 155|term infants
P00096241A0087|157 161|P less
P00097989A0106|1 20|three-phased analysis
P00097989A0106|23 36|treatment plans
P00097989A0106|42 49|patients
P00100540T0000|0 17|Aspirin intolerance
P00100540T0000|19 41|unaltered susceptibility
P00100540T0000|44 66|platelet cyclo-oxygenase
P00100540T0000|69 78|inhibition
P00100540T0000|81 87|aspirin
P00100791A0425|5 11|results
P00100791A0425|24 40|cynomolgus monkeys
P00100791A0425|87 99|rhesus monkeys
P00100791A0425|111 132|pharmacological effects
P00100791A0425|135 144|norcocaine
P00101300A0257|2 6|cases
P00101300A0257|19 35|resectable cancers
P00101300A0257|37 38|T1
P00101300A0257|40 41|T2
P00101300A0257|43 44|T3
P00101300A0257|46 47|N0
P00101300A0257|49 50|N1
P00101300A0257|56 70|minimum followup
P00101300A0257|76 80|years
P00101300A0257|90 94|years
P00101300A0257|99 104|months
P00105401A0635|11 13|CBZ
P00105401A0635|17 19|DPH
P00105401A0635|36 47|interference
P00105401A0635|52 72|thyroid hormone binding
P00105401A0635|75 77|TBG
P00105401A0635|90 103|enzyme-induced
P00105401A0635|113 134|metabolic clearance rate
P00105401A0635|137 151|thyroid hormones
P00105401A0635|159 180|homeostatic maintenance
P00105401A0635|183 201|premedication levels
P00105401A0635|204 206|FT4
P00105401A0635|210 212|FT3
P00105903A0288|3 17|present research
P00105903A0288|45 62|polyethylene glycol
P00105903A0288|67 69|PEG
P00105903A0288|81 91|efficacious
P00111174A0351|16 35|functional properties
P00111174A0351|39 51|latter neurons
P00111174A0351|74 80|neurons
P00111174A0351|93 99|stimuli
P00111174A0351|107 110|eyes
P00111174A0351|115 121|neurons
P00111174A0351|133 152|complex visual stimuli
P00111174A0351|157 163|neurons
P00111174A0351|175 187|visual stimuli
P00112627A0542|0 12|Pentobarbital
P00112627A0542|28 32|mg/kg
P00112627A0542|64 83|rate-decreasing doses
P00112627A0542|86 98|normeperidine
P00112627A0542|104 108|mg/kg
P00112627A0542|111 121|anileridine
P00112627A0542|125 129|mg/kg
P00112627A0542|132 143|alphaprodine
P00112627A0542|147 151|mg/kg
P00112627A0542|157 164|fentanyl
P00112627A0542|169 173|mg/kg
P00113657A0628|0 5|Pb foil
P00113657A0628|11 15|gcm-2
P00113657A0628|28 49|best overall improvement
P00114144A0189|2 11|anatomical
P00114144A0189|15 32|histochemical study
P00114144A0189|56 69|result emphasis
P00114144A0189|79 94|recent hypotheses
P00114144A0189|114 125|similarities
P00114144A0189|130 133|Type
P00114144A0189|136 157|glycogen storage disease
P00114144A0189|159 166|Andersen
P00114144A0189|216 231|same enzyme defect
P00115974A0576|3 8|groups
P00115974A0576|22 38|Hebb-Williams maze
P00115974A0576|59 62|days
P00117748T0000|0 11|Erythromycin
P00117748T0000|15 35|clindamycin resistance
P00117748T0000|38 63|Corynebacterium diphtheriae
P00117748T0000|68 78|skin lesions
P00118044A0000|7 26|angular displacements
P00118044A0000|54 63|major peaks
P00118044A0000|75 81|terms M1
P00118044A0000|83 84|M2
P00118044A0000|89 95|M3 peaks
P00118044A0000|110 125|gross EMG activity
P00118044A0000|140 146|muscles
P00118810T0001|0 15|Hemolytic disease
P00118810T0001|18 31|African newborn
P00119339A0400|55 66|less virulent
P00119339A0400|75 87|T. cruzi stocks
P00119339A0400|112 128|severe myocarditis
P00119339A0400|134 153|myofibre degeneration
P00119339A0400|158 164|lesions
P00119339A0400|170 179|oesophagus
P00122718A0500|13 20|MRF units
P00122718A0500|37 47|incongruent
P00129659T0000|0 10|Variability
P00129659T0000|17 20|Down
P00129659T0000|32 41|trisomy-21
P00129659T0000|63 76|sex differences
P00129659T0000|79 81|IQs
P00130573T0054|0 2|VII
P00131739T0001|0 24|Several demographic indices
P00131739T0001|35 45|populations
P00131739T0001|48 57|Uzbekistan
P00133214T0064|4 11|concepts
P00133214T0064|14 34|higher nervous function
P00133214T0064|40 43|USSR
P00136175A1137|25 50|myocardial capillary density
P00136175A1137|60 72|similar amount
P00136175A1137|95 95|h
P00136175A1137|140 150|enlargement
P00136175A1137|153 155|ECA
P00137671A0896|5 16|observations
P00137671A0896|42 59|elevated VIII-ratio
P00137671A0896|67 84|sensitive indicator
P00137671A0896|87 110|intravascular coagulation
P00139624A0318|5 9|hours
P00139624A0318|34 43|colchicine
P00139624A0318|48 70|serum ceruloplasmin level
P00139624A0318|48 65|serum ceruloplasmin
P00139624A0318|89 98|female rats
P00139624A0318|108 115|male rats
P00139827A0000|0 16|Radioimmunoassays
P00139827A0000|19 30|pregnenolone
P00139827A0000|32 43|progesterone
P00139827A0000|45 66|dehydroepiandrosterone
P00139827A0000|68 70|DHA
P00139827A0000|74 90|alpha-hydroxy-DHA
P00139827A0000|92 98|estriol
P00139827A0000|103 110|cortisol
P00139827A0000|137 138|ml
P00139827A0000|142 152|fetal plasma
P00139827A0000|180 200|normal vaginal delivery
P00142718A0156|9 16|patients
P00142718A0156|40 56|changes suggestive
P00142718A0156|59 77|pulmonary metastases
P00142718A0156|81 87|earlier
P00142718A0156|93 102|99mTc-EHDP
P00142718A0156|115 130|chest radiographs
P00146327A0147|13 18|tumors
P00146327A0147|32 44|nasal cavities
P00146327A0147|54 74|significant incidences
P00146327A0147|93 98|larynx
P00146327A0147|100 106|trachea
P00146327A0147|110 120|stem bronchi
P00149899T0001|0 9|Prediction
P00149899T0001|15 19|times
P00149899T0001|22 39|sandfly development
P00150066A0100|0 20|Native human fibrinogen
P00150066A0100|11 20|fibrinogen
P00150066A0100|33 43|coagulation
P00150066A0100|52 59|thrombin
P00150066A0554|2 27|post-operative haemorrhages
P00150066A0554|35 44|prostheses
P00154430A0906|3 19|Southern technique
P00154430A0906|28 46|further localization
P00154430A0906|60 85|most extensive transcription
P00154430A0906|92 114|kb HindIII-EcoRI fragment
P00154430A0906|94 114|HindIII-EcoRI fragment
P00155973A0387|26 31|limits
P00155973A0387|34 48|maximized errors
P00155973A0387|56 56|%
P00155973A0387|112 141|mean carbon dioxide concentration
P00155973A0387|153 155|vol
P00155973A0387|157 157|%
P00155973A0387|167 183|fresh gas flow rates
P00155973A0387|194 198|min-1
P00155973A0387|213 229|minute ventilation
P00155973A0387|237 241|min-1
P00159600A0871|0 1|SV
P00159600A0871|17 19|SHR
P00159600A0871|47 65|diastolic compliance
P00159600A0871|84 86|SHR
P00159600A0871|91 99|ventricle
P00159600A0871|106 129|consequent rightward shift
P00159600A0871|135 153|Frank-Starling curve
P00163384A0000|3 9|carcass
P00163384A0000|13 26|great horned owl
P00163384A0000|28 42|Bubo virginianus
P00163384A0000|62 69|moribund
P00163384A0000|72 86|southern Ontario
P00163384A0000|103 110|necropsy
P00167544A0067|3 11|inner ears
P00167544A0067|25 39|microdissection
P00167544A0067|47 70|vestibular sensory regions
P00167544A0067|111 128|electron microscopy
P00167544A0067|132 139|prepared
P00167544A0067|157 180|surface specimen technique
P00168176A0000|0 6|Patulin
P00168176A0000|22 39|apple butter samples
P00168176A0000|44 55|ethyl acetate
P00168176A0000|62 68|extract
P00168176A0000|83 97|silica gel column
P00168176A0000|104 123|benzene-ethyl acetate
P00168176A0000|136 141|eluant
P00168431T0000|0 18|Steroid glucuronides
P00168431T0000|21 33|amniotic fluid
P00172199A0270|3 8|matrix
P00172199A0270|23 30|clusters
P00172199A0270|44 59|normal morphology
P00172199A0270|63 83|homogeneous appearance
P00172199A0270|96 115|faint cross striations
P00172199A0270|131 139|fibrillar
P00173860A0475|0 9|Riboflavin
P00173860A0475|37 60|aflatoxin-treated animals
P00173860A0475|37 45|aflatoxin
P00173860A0475|65 96|abnormal urinary excretion patterns
P00173860A0475|129 140|disturbances
P00173860A0475|143 153|elimination
P00173860A0475|156 164|kynurenic
P00173860A0475|168 183|xanthurenic acids
P00176742T0000|0 10|Polyglactin
P00176742T0000|14 29|suture absorption
P00176742T0000|42 56|cellular enzymes
P00183063A0300|3 11|incidence
P00183063A0300|14 26|DNCB reactions
P00183063A0300|35 38|cent
P00183063A0300|42 46|Stage
P00183063A0300|53 59|cancers
P00183063A0300|63 70|patinets
P00183063A0300|78 81|cent
P00183063A0300|85 99|resectable Stage
P00183063A0300|112 119|patients
P00183063A0300|130 133|cent
P00183063A0300|136 143|patients
P00183063A0300|148 159|unresectable
P00183063A0300|162 176|inoperable Stage
P00188387A0975|0 6|Studies
P00188387A0975|9 20|lipoproteins
P00188387A0975|44 51|children
P00188387A0975|56 63|families
P00188387A0975|75 76|FH
P00188387A0975|79 103|early coronary heart disease
P00193088A0196|7 25|other normal subjects
P00193088A0196|31 31|g
P00193088A0196|34 43|Metyrapone
P00193088A0196|51 59|responses
P00193587T0000|0 12|EEG theta waves
P00193587T0000|16 37|psychological phenomena
P00196255A0000|0 14|REM dream content
P00196255A0000|27 36|categories
P00196255A0000|50 69|predominant influence
P00196255A0000|75 88|left hemisphere
P00196255A0000|95 101|good ego
P00196255A0000|114 126|verbalization
P00196255A0000|133 147|right hemisphere
P00196255A0000|160 174|spatial salience
P00196255A0000|176 186|bizarreness
P00198510T0000|0 10|Innervation
P00198510T0000|16 31|ventral diaphragm
P00198510T0000|37 42|locust
P00198510T0000|44 60|Locusta migratoria
P00199012T0000|0 18|Ectopic ACTH syndrome
P00199012T0000|22 46|medullary thyroid carcinoma
P00201881A0487|1 15|striking finding
P00201881A0487|26 32|studies
P00201881A0487|37 55|positive correlation
P00201881A0487|63 68|PI ACTH
P00201881A0487|72 82|MSH contents
P00201881A0487|72 74|MSH
P00205074A0000|0 22|Chronic hypophosphatemia
P00205074A0000|32 41|common type
P00205074A0000|45 53|resistant
P00205074A0000|55 61|rickets
P00209664A0836|28 34|serum LH
P00209664A0836|38 50|chronological
P00209664A0836|53 59|bone age
P00209664A0836|66 73|age group
P00209664A0836|121 148|age-related parallel phenomena
P00210220X0000|0 22|Molecular neurochemistry
P00210220X0000|25 38|addictive drugs
P00211881A0602|0 6|Efforts
P00211881A0602|52 64|kidney lesions
P00211881A0602|103 115|potential site
P00211881A0602|126 128|PBB
P00216939T0001|0 5|Effect
P00216939T0001|8 15|succimer
P00216939T0001|32 70|tricarboxylic acid dehydrogenase reactions
P00216939T0001|32 61|tricarboxylic acid dehydrogenase
P00216939T0001|83 86|rats
P00216939T0001|99 114|mercuric chloride
P00219533T0001|0 11|Distribution
P00219533T0001|15 26|correlations
P00219533T0001|29 42|serum uric-acid
P00219533T0001|48 69|French adult populations
P00219533T0001|77 79|men
P00219533T0001|88 92|women
P00219565A0172|3 11|incidence
P00219565A0172|14 30|hepatitis B antigen
P00219565A0172|40 50|transfusion
P00219565A0172|65 68|cent
P00219674A0000|0 55|Technetium-99m stannous pyrophosphate myocardial scintigrams
P00219674A0000|83 96|stable patients
P00219674A0000|108 112|weeks
P00219674A0000|131 155|acute myocardial infarction
P00221136A0984|1 17|similar phenomenon
P00221136A0984|36 44|few humans
P00221725A0523|25 41|cytochrome oxidase
P00221725A0523|43 52|peroxidase
P00221725A0523|61 72|lipid content
P00221725A0523|75 95|peripheral neutrophils
P00221725A0523|123 140|phagocytic activity
P00222102A0227|0 8|Treatment
P00222102A0227|12 19|patients
P00222102A0227|24 51|pseudohypoparathyroidism type
P00222102A0227|57 67|vitamin-D-3
P00222102A0227|72 99|alpha-Hydroxycholecalciferol
P00222102A0227|124 141|nonuniform response
P00222102A0227|157 169|normalisation
P00222102A0227|172 184|serum-calcium
P00222827A0000|0 6|Workers
P00222827A0000|33 44|diisocyanate
P00222827A0000|46 48|TDI
P00222827A0000|86 95|mechanisms
P00222827A0000|98 121|bronchial hyperreactivity
P00224013A0661|0 7|Total VO2
P00224013A0661|26 31|groups
P00224013A0661|38 50|severe hypoxia
P00224013A0661|54 60|limb VO2
P00224013A0661|79 93|beta-block group
P00224013A0661|95 104|beta-Block
P00224013A0661|131 154|limb peripheral resistance
P00224013A0661|161 173|severe hypoxia
P00224013A0661|207 226|efficient utilization
P00224013A0661|275 283|whole body
P00224013A0661|286 291|higher
P00224013A0661|294 309|extraction ratios
P00224013A0661|313 323|lower venous
P00224013A0661|335 359|beta-Vasodilator receptors
P00224013A0661|377 386|active part
P00224013A0661|392 405|vasodilatation
P00224013A0661|416 428|severe hypoxia
P00225352T0000|0 31|Phenobarbital-induced alterations
P00225352T0000|37 46|metabolism
P00225352T0000|50 51|3H
P00225352T0000|53 61|vitamin D3
P00225352T0000|67 90|perfused rachitic rat liver
P00227393T0000|0 9|Modulation
P00227393T0000|12 45|25-hydroxyvitamin D3-24-hydroxylase
P00227393T0000|48 60|aminophylline
P00227393T0000|63 96|cytochrome P-450 monooxygenase system
P00227393T0000|63 90|cytochrome P-450 monooxygenase
P00227610A1593|11 18|respects
P00227610A1593|31 37|DBP mRNA
P00227610A1593|50 63|late messengers
P00227610A1593|66 69|SV40
P00227610A1593|73 86|polyoma viruses
P00231555T0001|0 5|Effect
P00231555T0001|8 61|corticosteroid-containing antirheumatic combination drugs
P00231555T0001|64 77|endogenous ACTH
P00231555T0001|74 77|ACTH
P00231555T0001|81 98|cortisol production
P00232354A0286|0 8|Serum ACTH
P00232354A0286|5 8|ACTH
P00232354A0286|24 30|insulin
P00232354A0286|34 43|metyrapone
P00232456T0000|0 6|Anatomy
P00232456T0000|12 14|RNA
P00232456T0000|18 29|gene products
P00232456T0000|32 35|MC29
P00232456T0000|39 41|MH2
P00232456T0000|46 71|defective avian tumor viruses
P00232456T0000|79 91|acute leukemia
P00232456T0000|95 103|carcinoma
P00232456T0000|117 124|new class
P00232456T0000|139 143|genes
P00234206T0000|0 7|Bertioga
P00234206T0000|9 18|Guama group
P00234206T0000|23 29|Anhembi
P00234206T0000|31 45|Bunyamwera group
P00234206T0000|51 64|new arboviruses
P00234206T0000|75 82|Sao Paulo
P00234206T0000|84 89|Brazil
P00234264A0164|0 34|Gamma glutamyl transpeptidase activity
P00234264A0164|0 26|Gamma glutamyl transpeptidase
P00234264A0164|53 57|times
P00234264A0164|66 81|upper normal limit
P00234264A0164|84 91|children
P00234264A0164|104 114|aminopyrine
P00234264A0164|121 125|weeks
P00234264A0164|128 133|longer
P00234626T0036|0 2|XXI
P00239014A0000|1 31|gas-liquid chromatographic method
P00239014A0000|53 77|p-chlorophenoxyisobutyric
P00239014A0000|79 82|CPIB
P00239014A0000|90 100|blood plasma
P00239169T0000|0 23|Dopamine receptor blockade
P00239169T0000|30 41|neuroleptics
P00239169T0000|44 64|crystallographic study
P00240016T0033|0 1|V.
P00240518A0000|1 26|rapid fluorimetric procedure
P00240518A0000|51 75|fungicide 5-fluorocytosine
P00240518A0000|78 82|serum
P00242427T0001|23 38|supervisory nurse
P00254537T0000|5 13|graduates
P00254537T0000|16 29|different types
P00254537T0000|32 39|programs
P00254537T0000|49 59|state boards
P00261981A0434|10 34|maternal serum somatomedin A
P00261981A0434|23 34|somatomedin A
P00261981A0434|60 63|rats
P00261981A0434|71 82|large litters
P00264240A1843|3 11|sequences
P00264240A1843|24 39|X. borealis oocyte
P00264240A1843|43 56|somatic 5S genes
P00264240A1843|85 92|residues
P00264240A1843|108 120|more T clusters
P00264240A1843|131 149|corresponding region
P00264240A1843|152 170|X. laevis oocyte 5S DNA
P00265964A0562|34 46|grain boundary
P00267764A0651|30 36|reasons
P00267764A0651|40 56|treatment failures
P00294502T0001|0 8|Diagnosis
P00294502T0001|12 28|treatment planning
P00294502T0001|31 37|Class II
P00300314A0132|9 25|serious infections
P00300314A0132|27 37|fever larger
P00300314A0132|54 78|degrees F. granulocytes less
P00300314A0132|89 90|mm
P00300314A0132|96 110|hospitalization
P00300314A0132|116 124|drug death
P00300314A0132|136 143|patients
P00300314A0132|145 165|oral calcium leucovorin
P00300314A0132|173 177|mg/m2
P00300314A0132|194 197|days
P00300314A0132|203 214|methotrexate
P00300314A0132|217 241|subsequent treatment cycles
P00303189A0247|24 28|drugs
P00303189A0247|45 58|serum chemistry
P00303189A0247|79 86|efficacy
P00303189A0247|110 128|inflammatory process
P00304240A0369|7 23|conventional tests
P00304240A0369|53 72|retrocochlear disease
P00304310A0000|3 11|end-stage
P00304310A0000|14 30|involutional phase
P00304310A0000|33 64|proliferative diabetic retinopathy
P00304310A0000|76 88|stabilization
P00304310A0000|100 110|long periods
P00304806A0760|12 36|serum alpha1AT quantitation
P00304806A0760|12 24|serum alpha1AT
P00304806A0760|38 51|newborn infants
P00304806A0760|73 78|groups
P00304806A0760|107 120|concentrations
P00304806A0760|136 138|mg%
P00313766A0666|2 9|patients
P00313766A0666|35 62|overall significant depression
P00313766A0666|80 80|%
P00313766A0666|103 103|%
P00313766A0666|105 109|p less
P00316723A0558|0 6|Changes
P00316723A0558|9 18|body weight
P00316723A0558|22 38|agonistic behavior
P00321261A0104|3 17|uterine response
P00321261A0104|20 34|prostaglandin E2
P00321261A0104|36 39|PGE2
P00321261A0104|44 63|prostaglandin F2alpha
P00321261A0104|79 89|intravenous
P00321261A0104|93 110|intrauterine routes
P00321261A0104|130 144|different phases
P00321261A0104|150 163|menstrual cycle
P00321261A0104|182 195|infertile women
P00330364A0132|10 19|BCG strains
P00330364A0132|32 50|Czechoslovak strains
P00330364A0132|64 71|cultures
P00330364A0132|74 76|BCG
P00330364A0132|79 92|different batch
P00330364A0132|95 101|strains
P00330364A0132|114 122|abscesses
P00330364A0132|125 132|children
P00330364A0132|138 152|BCG-vaccination
P00330364A0132|157 163|strains
P00330364A0132|168 177|fatal cases
P00330364A0132|183 197|BCG-vaccination
P00330364A0132|204 210|strains
P00330364A0132|223 241|foreign laboratories
P00331128A0000|0 9|High levels
P00331128A0000|12 26|serum calcitonin
P00331128A0000|17 26|calcitonin
P00331128A0000|38 45|patients
P00331128A0000|50 68|chronic renal failure
P00331936T0000|0 8|Detection
P00331936T0000|11 35|anti-lymphocyte antibodies
P00331936T0000|44 78|immunoperoxidase antiglobulin technic
P00331936T0000|44 59|immunoperoxidase
P00331936T0000|60 71|antiglobulin
P00336354A0543|13 19|serum GH
P00336354A0543|18 19|GH
P00336354A0543|22 37|arginine infusion
P00336354A0543|59 85|insulin-induced hypoglycemia
P00336354A0543|59 65|insulin
P00336547A0000|3 15|mortality rate
P00336547A0000|19 43|histopathological features
P00336547A0000|46 63|Nocardia asteroides
P00336547A0000|67 96|Nocardia brasiliensis infections
P00336547A0000|111 117|athymic
P00336547A0000|119 122|nude
P00336547A0000|124 127|mice
P00336547A0000|130 132|ICR
P00336547A0000|136 148|C3H/eB origins
P00336547A0000|185 198|Swiss white mice
P00336547A0000|202 224|other inbred mouse strains
P00336547A0000|233 241|C57/BL/6J
P00336547A0000|243 257|New Zealand Black
P00336547A0000|259 264|BALB/c
P00336547A0000|266 272|CBA/LAC
P00336547A0000|277 282|C3H/eB
P00337102T0058|0 7|Williams
P00337102T0058|10 15|August
P00339289T0049|0 2|Use
P00339289T0049|5 23|radioactive isotopes
P00339289T0049|40 47|proteins
P00340692T0033|1 8|Emeritus
P00340692T0033|10 37|John Henri Roosegaarde Bisschop
P00342623A0228|9 16|vaccines
P00342623A0228|20 38|whole-virus vaccines
P00342623A0228|49 60|type B antigen
P00342623A0228|76 96|significant reactivity
P00350465T0000|0 17|Antenatal diagnosis
P00350465T0000|20 42|haematological disorders
P00352569A0000|0 18|Hepatic oxygen supply
P00352569A0000|30 44|blood parameters
P00352569A0000|65 73|male rates
P00352569A0000|85 89|mg/kg
P00352569A0000|105 113|endotoxin
P00354315T0000|0 17|Gonadal dysfunction
P00354315T0000|20 27|patients
P00354315T0000|32 51|ataxia telangiectasia
P00358945A0225|3 15|maximum period
P00358945A0225|42 56|intraperitoneal
P00358945A0225|63 68|dermal
P00358945A0225|70 74|weeks
P00361059T0000|11 29|comparative efficacy
P00361059T0000|32 53|diflucortolone valerate
P00361059T0000|57 65|% ointment
P00361059T0000|69 88|clobetasol propionate
P00361059T0000|93 101|% ointment
P00361340A0529|0 3|Most
P00361340A0529|9 17|phenomena
P00361340A0529|20 42|azotaemic osteodystrophy
P00361340A0529|59 82|simple vitamin D deficiency
P00361340A0529|102 111|deficiency
P00361340A0529|114 142|1,25-dihydroxycholecalciferol
P00361340A0529|150 168|primary significance
P00361340A0529|178 205|secondary hyperparathyroidism
P00361340A0529|208 219|renal failure
P00369397A0280|0 7|Basal FSH
P00369397A0280|5 7|FSH
P00369397A0280|11 18|LH levels
P00369397A0280|11 12|LH
P00369397A0280|43 49|addicts
P00369397A0280|56 70|GnRH stimulation
P00369397A0280|56 59|GnRH
P00369397A0280|74 80|addicts
P00369397A0280|82 84|FSH
P00369397A0280|88 95|LH values
P00369397A0280|88 89|LH
P00369397A0280|134 141|controls
P00369683T0000|0 9|Adriamycin
P00369683T0000|24 37|5-week schedule
P00369683T0000|43 56|3-week schedule
P00369683T0000|73 84|breast cancer
P00377466A0188|0 16|Follow-up controls
P00377466A0188|19 36|luteinizing hormone
P00377466A0188|38 39|LH
P00377466A0188|42 67|follicle stimulating hormone
P00377466A0188|69 71|FSH
P00377466A0188|74 82|prolactin
P00377466A0188|84 87|HPRL
P00377466A0188|90 99|oestradiol
P00377466A0188|101 102|E2
P00377466A0188|105 116|progesterone
P00377466A0188|118 118|P
P00377466A0188|123 134|testosterone
P00377466A0188|136 136|T
P00377466A0188|143 151|catabolic
P00377466A0188|155 166|healing phase
P00378492A0475|0 11|Renin studies
P00378492A0475|25 44|hypertensive patients
P00378492A0475|51 62|control group
P00378492A0475|67 76|recipients
P00378492A0475|87 95|elevation
P00378492A0475|98 116|plasma renin activity
P00378492A0475|98 108|plasma renin
P00378492A0475|122 143|plasma aldosterone level
P00378492A0475|195 213|renal artery stenosis
P00378735A0000|11 23|clinical trial
P00378735A0000|35 47|adult patients
P00378735A0000|61 72|typhoid fever
P00378735A0000|90 102|marrow culture
P00378735A0000|114 124|amoxycillin
P00378735A0000|128 141|dosage schedule
P00378735A0000|145 153|g 8-hourly
P00378735A0000|171 174|days
P00378735A0000|188 202|chloramphenicol
P00378735A0000|226 244|temperature response
P00378735A0000|259 266|carriers
P00378735A0000|270 281|relapse rates
P00381783T0000|0 29|Bone marrow transplantation-1979
P00383169A0000|17 31|clinical actions
P00383169A0000|37 61|principal dopamine receptor
P00383169A0000|73 78|agents
P00383169A0000|80 90|apomorphine
P00383169A0000|97 107|derivatives
P00383169A0000|109 117|piribedil
P00383169A0000|119 138|rye-ergot derivatives
P00383169A0000|169 179|biochemical
P00383169A0000|183 207|pharmacological properties
P00384744T0000|3 34|unilateral vestibular hypofunction
P00385457A0187|8 17|inhibition
P00385457A0187|20 25|pepsin
P00385457A0187|28 44|human gastric juice
P00385457A0187|65 78|major influence
P00385457A0187|84 90|healing
P00385457A0187|93 105|duodenal ulcer
P00386251A0899|3 19|IDF standard method
P00386251A0899|26 34|detection
P00386251A0899|37 46|penicillin
P00386251A0899|72 80|detection
P00386251A0899|83 102|sulphonamide residues
P00390932T0001|0 15|Capsular antigens
P00393598A0198|11 24|endotoxin fever
P00393598A0198|33 44|uninfluenced
P00393598A0198|47 49|ALS
P00397806T0039|1 16|new Algerian cases
P00401521A0138|11 17|percent
P00401521A0138|20 27|patients
P00401521A0138|39 49|ticarcillin
P00401676A0414|0 24|Accurate pathologic staging
P00401676A0414|35 42|patients
P00401676A0414|60 66|curable
P00401676A0414|71 82|radiotherapy
P00406585T0001|0 17|Inherent hematology
P00406585T0001|20 25|old age
P00409927A0570|0 7|Neomycin
P00409927A0570|32 44|staphylococci
P00409927A0570|46 58|less effective
P00409927A0570|66 77|streptococci
P00409927A0570|104 135|gram-negative intestinal organisms
P00411465A0142|42 45|cent
P00411465A0142|51 60|trabeculae
P00411465A0142|78 93|vascular cavities
P00413854A0958|0 6|Changes
P00413854A0958|9 18|tissue PCO2
P00413854A0958|80 90|venous blood
P00414575T0000|0 19|Ultrasonic evaluation
P00414575T0000|22 33|renal calculi
P00415543A0320|0 10|Recognition
P00415543A0320|13 21|emphysema
P00415543A0320|33 43|radiographs
P00415543A0320|46 62|inadequate quality
P00415543A0320|76 95|anteroposterior films
P00415543A0320|98 102|films
P00415543A0320|107 114|patients
P00415543A0320|119 123|acute
P00415543A0320|126 143|chronic lung disease
P00416758T0001|0 8|Isolation
P00416758T0001|11 28|T. gambiense strains
P00416758T0001|31 35|Zaire
P00416758T0001|44 53|adaptation
P00416758T0001|56 72|laboratory animals
P00417166T0000|0 21|Pharmacokinetic profile
P00417166T0000|24 33|clonazepam
P00417166T0000|36 48|rhesus monkeys
P00417301T0001|0 20|Immunologic mechanisms
P00417301T0001|23 40|chronic brucellosis
P00417301T0001|43 48|humans
P00418341T0000|0 19|Intestinal adaptation
P00418341T0000|31 35|parts
P00420460A0291|2 9|patients
P00420460A0291|26 46|previous drug treatment
P00420460A0291|48 77|log baseline plasma renin activity
P00420460A0291|89 105|mean blood pressure
P00420460A0291|111 112|SQ
P00420460A0291|142 143|r =
P00420460A0291|150 154|P less
P00423649A0259|5 14|techniques
P00423649A0259|29 38|many people
P00423649A0259|42 50|many years
P00425547A0000|2 9|patients
P00425547A0000|14 33|chronic osteomyelitis
P00425547A0000|48 49|os
P00425547A0000|57 100|bactericidal beta-lactam-antibiotic cephalexin
P00425547A0000|112 116|weeks
P00427715A0000|10 17|patients
P00427715A0000|22 28|Hodgkin
P00427715A0000|55 63|diaphragm
P00427715A0000|65 70|Stages
P00427715A0000|82 82|B
P00427715A0000|99 114|radiation therapy
P00427715A0000|125 134|University
P00427715A0000|137 143|Florida
P00429151T0000|0 3|Year
P00429151T0000|12 46|first general practitioner medical unit
P00429151T0000|52 69|greater Glasgow area
P00429893A0000|4 26|multiple-electrode array
P00429893A0000|30 60|round window cochlear implantation
P00429893A0000|64 69|robust
P00429893A0000|71 84|reliable system
P00429893A0000|99 100|mm
P00429893A0000|109 120|scala tympani
P00429893A0000|157 174|bipolar stimulation
P00429949A0000|17 58|World Health Organization 29th Expert Committee
P00429949A0000|61 85|Biological Standardization
P00429949A0000|103 116|human prolactin
P00429949A0000|119 126|ampoules
P00429949A0000|161 193|International Reference Preparation
P00429949A0000|195 197|IRP
P00429949A0000|201 214|human prolactin
P00429949A0000|218 228|immunoassay
P00430889T0001|0 22|Biliary-enteric fistulas
P00431832T0001|0 15|Plasma ion changes
P00431832T0001|18 28|venous blood
P00431832T0001|42 61|beta receptor blockers
P00431832T0001|42 53|beta receptor
P00432615A0541|0 20|Such marked differences
P00432615A0541|57 77|heterophile antibodies
P00432615A0541|85 103|bovine gammaglobulin
P00432615A0541|134 145|interference
P00432615A0541|151 164|Sephadex system
P00432615A0541|167 170|RIST
P00435187T0000|14 25|flowers bloom
P00437749A0242|0 25|Various treatment modalities
P00437749A0242|75 84|physiology
P00437749A0242|87 107|severe intractable pain
P00439618T0001|0 15|Lethal Tachmalcor
P00439618T0001|23 36|diethylamino-2
P00439618T0001|39 51|hydroxypropyl
P00439618T0001|54 61|ajmaline
P00439618T0001|63 71|poisoning
P00439716T0001|0 29|Ophthalmosonographic evaluation
P00439716T0001|32 48|blood flow velocity
P00439716T0001|51 73|arteriocavernous fistula
P00445259T0000|0 25|Serum ferritin concentration
P00445259T0000|5 12|ferritin
P00445259T0000|29 48|bone marrow iron stores
P00445720A0263|3 26|systolic pressure gradient
P00445720A0263|28 30|SPG
P00445720A0263|42 54|left ventricle
P00445720A0263|56 57|LV
P00445720A0263|66 71|atrium
P00445720A0263|73 74|LA
P00445720A0263|91 122|high-fidelity pressure transducers
P00450367T0000|1 16|prospective trail
P00450367T0000|26 37|hysterectomy
P00450367T0000|39 50|hysterectomy
P00450367T0000|55 67|vaginal radium
P00450367T0000|72 84|uterine radium
P00450367T0000|89 100|hysterectomy
P00450367T0000|109 128|endometrial carcinoma
P00450559A0269|33 51|inaccurate Clinitemp
P00450559A0269|94 104|thermometer
P00450760T0001|0 15|Cryoglobulinemia
P00450760T0001|18 24|Raynaud
P00451192A0248|0 3|Data
P00451192A0248|22 50|semi-automatic computer program
P00451192A0248|66 85|averaged-volume curve
P00451192A0248|100 119|LV region-of-interest
P00453780A0430|3 30|preferential serum IgA response
P00453780A0430|20 22|IgA
P00453780A0430|44 60|patient population
P00453780A0430|73 81|bronchial
P00453780A0430|92 105|lymphoid tissue
P00453780A0430|111 122|diseased lung
P00453780A0430|127 141|important source
P00453780A0430|155 157|IgA
P00454780A0340|0 17|Ultimate strengthes
P00454780A0340|36 51|cast cobalt alloys
P00454780A0340|60 73|titanium alloys
P00454780A0340|81 82|Ta
P00454780A0340|84 84|V
P00454780A0340|97 112|high fatigue limit
P00454780A0340|118 126|corrosion
P00456424A0000|3 9|effects
P00456424A0000|12 34|intracisternal injection
P00456424A0000|36 41|i.c.i.
P00456424A0000|45 53|clonidine
P00456424A0000|56 68|microgram kg-1
P00456424A0000|72 84|blood pressure
P00456424A0000|88 96|heart rate
P00456424A0000|110 125|conscious rabbits
P00456424A0000|141 148|catheter
P00456424A0000|154 166|cisterna magna
P00463973A0000|0 13|Platelet number
P00463973A0000|17 24|life span
P00463973A0000|44 56|last trimester
P00463973A0000|72 76|women
P00463973A0000|95 118|small-for-gestational age
P00463973A0000|120 122|SGA
P00463973A0000|124 130|infants
P00463973A0000|138 142|women
P00463973A0000|147 153|infants
P00463973A0000|160 177|normal birth weights
P00464387A1185|0 17|Serial measurements
P00464387A1185|20 32|total serum IgE
P00464387A1185|45 55|useful index
P00464387A1185|58 72|disease activity
P00464387A1185|75 78|ABPA
P00465223A0373|6 13|patients
P00465223A0373|17 34|difference betweent
P00465223A0373|41 55|diastolic values
P00465223A0373|58 64|delta PU
P00465223A0373|68 74|delta PM
P00465223A0373|90 91|SD
P00465223A0373|93 96|mmHg
P00465681A0000|7 29|hemoglobin concentration
P00465681A0000|7 16|hemoglobin
P00465681A0000|58 66|total iron
P00465681A0000|72 81|blood serum
P00465681A0000|84 92|white mice
P00465681A0000|106 119|oxygen pressure
P00465681A0000|123 125|atm
P00465681A0000|136 153|preconvulsive state
P00465681A0000|159 161|atm
P00465681A0000|163 177|convulsive state
P00465829T0000|0 5|Nernst
P00465829T0000|8 28|Planck analog equations
P00465829T0000|32 72|stationary state membrane electric potentials
P00473229T0000|0 6|Effects
P00473229T0000|9 25|methylene chloride
P00473229T0000|27 41|trichloroethane
P00473229T0000|43 59|trichloroethylene
P00473229T0000|61 79|tetrachloroethylene
P00473229T0000|83 89|toluene
P00473229T0000|108 119|chick embryos
P00473249T0000|0 5|Effect
P00473249T0000|8 37|intraventricular administration
P00473249T0000|40 52|streptolysin O
P00473249T0000|58 77|electroencephalogram
P00473249T0000|80 86|rabbits
P00474064A0205|18 36|convlusion threshold
P00474064A0205|44 53|substances
P00474064A0205|66 74|pethidine
P00474064A0205|77 87|mg.kg-1 I.V.
P00474064A0205|89 99|piritramide
P00474064A0205|103 110|morphine
P00474064A0205|115 127|phenoperidine
P00474064A0205|130 130|R
P00474064A0205|138 145|fentanyl
P00474064A0205|148 157|sufentanil
P00474064A0205|162 162|R
P00474064A0205|170 180|mg.kg-1 I.V.
P00476020T0000|3 14|biochemistry
P00476020T0000|17 29|amniotic fluid
P00476020T0000|34 48|poor fetal growth
P00476572A0139|24 29|lesion
P00476572A0139|41 52|well-defined
P00476572A0139|56 61|benign
P00476572A0139|87 91|lytic
P00476572A0139|94 98|cases
P00476572A0139|106 124|central radiodensity
P00476572A0139|127 131|cases
P00477794T0000|0 6|Effects
P00477794T0000|26 35|tractotomy
P00477794T0000|41 56|response patterns
P00477794T0000|59 65|neurons
P00477794T0000|71 97|trigeminal nuclei principalis
P00477794T0000|101 106|oralis
P00478714T0000|0 7|Efficacy
P00478714T0000|24 55|five-week alcohol treatment program
P00479222A0682|0 9|Resistance
P00479222A0682|15 45|simulated physiologic environment
P00479222A0682|65 73|retention
P00479222A0682|76 95|mechanical properties
P00479222A0682|101 114|immersion times
P00479222A0682|117 141|pseudo-extracellular fluid
P00479222A0682|143 146|PECF
P00479222A0682|152 159|degrees C
P00479222A0682|176 180|years
P00479246T0000|8 40|calcaneal tuberculous osteomyelitis
P00481612A1121|17 31|opiate receptors
P00481612A1121|44 66|fourth cerebral ventricle
P00481612A1121|77 90|cardiovascular
P00481612A1121|94 107|hypnotic action
P00481612A1121|110 117|fentanyl
P00483716A0366|23 47|convoluted internal carotid
P00483716A0366|51 69|common carotid artery
P00483716A0366|73 80|resected
P00483716A0366|87 107|end-to-end anastomosis
P00484177A0242|26 43|laminar flow regimen
P00484177A0242|50 59|expiration
P00484177A0242|68 82|constant CT value
P00484177A0242|97 99|VT.
P00485615A0935|30 56|hyperlipemic abdominal crisis
P00485615A0935|60 73|distinct entity
P00485615A0935|141 150|occurrence
P00485615A0935|153 169|acute pancreatitis
P00485615A0935|189 199|unnecessary
P00485615A0935|214 227|harmful surgery
P00488534A0308|11 48|significant Treatment X Strain interaction
P00488534A0308|60 82|larger defecation numbers
P00488534A0308|97 126|taurine-injected MR rats relative
P00488534A0308|132 152|saline-injected MR rats
P00490336A0181|5 22|conduction velocity
P00490336A0181|43 47|m/sec
P00490336A0181|49 54|group C
P00493818A0422|3 10|failures
P00493818A0422|34 51|patient intolerance
P00493818A0422|54 70|poor mechanical fit
P00493818A0422|87 98|first few days
P00493818A0422|101 114|first few months
P00493818A0422|120 128|insertion
P00494659A0391|3 25|major urinary metabolites
P00494659A0391|33 47|3-carboxyphenyl
P00494659A0391|52 80|hydroxymethyl-2-oxazolidinone
P00494659A0391|85 95|glucuronide
P00494659A0391|98 107|toloxatone
P00495097A0663|5 19|characteristics
P00495097A0663|32 49|pronounced activity
P00495097A0663|52 76|collagenous fiber synthesis
P00495097A0663|83 88|matrix
P00495097A0663|94 106|osteoid tissue
P00497494A0112|3 13|ventilation
P00497494A0112|32 36|PACO2
P00499588T0000|0 21|Carbohydrate metabolism
P00499588T0000|28 39|semen profile
P00499588T0000|41 47|glucose
P00499588T0000|49 55|insulin
P00499588T0000|60 71|sperm studies
P00503336A0285|16 19|CAEC
P00503336A0285|29 30|CC
P00503336A0285|34 37|CIEC
P00503336A0285|45 51|attacks
P00503336A0285|54 65|biliary fever
P00503336A0285|69 78|high levels
P00503336A0285|81 99|alkaline phosphatase
P00503336A0285|103 115|transaminases
P00503336A0285|121 125|serum
P00503336A0285|132 146|helpful findings
P00503336A0285|150 170|preoperative diagnosis
P00506559A0000|3 29|sub-acute inhalation toxicity
P00506559A0000|32 39|furfural
P00506559A0000|52 71|Syrian golden hamsters
P00506649T0000|0 6|Changes
P00506649T0000|9 40|thirtynine serum protein components
P00506649T0000|50 63|surgical stress
P00509703A0581|5 15|differences
P00509703A0581|19 25|smaller
P00509703A0581|46 62|standard textbooks
P00510341T0036|11 20|E.O.R.T.C.
P00512215A0000|3 14|present study
P00512215A0000|26 35|dependence
P00512215A0000|38 56|difference tone level
P00512215A0000|58 58|L
P00512215A0000|60 64|f2-f1
P00512215A0000|81 90|parameters
P00512215A0000|96 108|two-tone input
P00512215A0000|110 111|f1
P00512215A0000|113 117|f2/f1
P00512215A0000|113 114|f2
P00512215A0000|116 117|f1
P00512215A0000|119 127|f2 greater
P00512215A0000|132 133|f1
P00512215A0000|136 137|L1
P00512215A0000|139 140|L2
P00512215A0000|145 149|L1 = L2
P00513284A0000|2 23|intravenous preparation
P00513284A0000|26 36|doxycycline
P00513284A0000|38 41|DOTC
P00513284A0000|43 52|Vibramycin
P00513284A0000|54 59|Pfizer
P00513284A0000|64 87|long-lasting tetracycline
P00513284A0000|112 123|drip infusion
P00513284A0000|146 160|pediatrics field
P00513284A0000|168 174|results
P00513284A0000|191 194|DOTC
P00513284A0000|199 200|mg
P00513284A0000|220 221|ml
P00513284A0000|224 238|glucose solution
P00513284A0000|246 250|mg/kg
P00513284A1255|14 17|days
P00513284A1255|23 34|DOTC infusion
P00513284A1255|36 50|laboratory tests
P00513284A1255|62 75|renal functions
P00516545T0001|0 24|Structural characteristics
P00516545T0001|30 48|erythrocyte membrane
P00516545T0001|50 70|peroxidation processes
P00516545T0001|74 92|antioxidant function
P00516545T0001|95 102|children
P00516545T0001|107 131|diffuse glomerulonephritis
P00517890A0468|3 14|enteric route
P00517890A0468|20 32|principal mode
P00517890A0468|50 59|hepatitis A
P00517890A0468|64 76|maximal levels
P00517890A0468|79 102|hepatitis A virus excretion
P00517890A0468|117 121|onset
P00517890A0468|124 131|jaundice
P00519173A0126|5 12|patients
P00519173A0126|19 36|endoscopic evidence
P00519173A0126|39 50|oesophagitis
P00521732T0000|0 15|Urinary excretion
P00521732T0000|18 25|oestrone
P00521732T0000|27 43|oestradiol-17 beta
P00521732T0000|47 54|oestriol
P00521732T0000|57 67|pregnancies
P00521732T0000|81 107|steroid sulphatase deficiency
P00521732T0000|81 97|steroid sulphatase
P00524451A0136|11 38|spontaneous locomotor activity
P00524451A0136|41 44|mice
P00524451A0136|72 82|amphetamine
P00524451A0136|90 97|toxicity
P00524451A0136|99 120|prolonged hexobarbitone
P00524451A0136|143 151|depletion
P00524451A0136|154 167|catecholamines
P00524451A0136|172 184|various organs
P00528144T0000|11 21|transferrin
P00528144T0000|27 32|uptake
P00528144T0000|35 41|gallium
P00528144T0000|44 53|tumor cells
P00534613A0000|0 10|Irradiation
P00534613A0000|13 31|human blood platelets
P00534613A0000|36 39|UV-A
P00534613A0000|68 76|aggregate
P00534613A0000|95 102|collagen
P00535520A0239|4 20|certain exceptions
P00535520A0239|56 88|routine intravenous cholangiography
P00540707A0255|12 30|satisfactory results
P00540707A0255|58 70|complications
P00540707A0255|88 94|low rate
P00540707A0255|99 103|cases
P00540707A0255|108 122|tip displacement
P00540707A0255|126 139|pouch haematoma
P00540707A0255|165 171|Authors
P00540707A0255|198 211|useful approach
P00540707A0255|215 229|PMK implantation
P00540707A0255|257 269|vena cephalica
P00541752A1032|7 20|determinations
P00541752A1032|38 44|samples
P00541752A1032|47 52|plasma
P00541752A1032|62 73|normal adults
P00541752A1032|76 82|October
P00541752A1032|87 92|values
P00541752A1032|128 129|SD
P00541752A1032|131 135|ng/ml
P00550399A0615|6 20|commonest causes
P00550399A0615|44 55|ethnic groups
P00553858A0000|8 12|Grice
P00553858A0000|53 69|systematic account
P00553858A0000|111 122|publications
P00553858A0000|195 204|principles
P00555492A1034|5 11|changes
P00555492A1034|29 50|gastric venous blood flow
P00555492A1034|53 82|continuous intravenous injection
P00555492A1034|85 94|cimetidine
P00555492A1034|101 114|rapid injection
P00555492A1034|129 137|augmented
P00555492A1034|144 164|systemic blood pressure
P00555495T0000|0 4|Study
P00555495T0000|7 22|re-establishment
P00555495T0000|25 33|ovulation
P00555495T0000|39 49|termination
P00555495T0000|52 73|sex-steroidal treatment
P00555495T0000|88 100|re-appearance
P00555495T0000|103 111|ovulation
P00555495T0000|128 144|premature delivery
P00555583T0000|0 15|Pharmacokinetics
P00555583T0000|18 30|Carbamazepine
P00557559A0170|5 13|compounds
P00557559A0170|21 37|alpha-(3-methyl-2
P00557559A0170|21 25|alpha
P00557559A0170|28 50|3-methyl-2-quinoxalinyl
P00557559A0170|53 78|N-methylnitrone 1,4-dioxide
P00557559A0170|92 102|active agent
P00557559A0170|119 131|gram-negative
P00557559A0170|138 159|gram-positive organisms
P00564032A0724|0 6|Changes
P00564032A0724|9 20|ionic content
P00564032A0724|26 31|mucous
P00564032A0724|43 63|cholinergic mechanisms
P00564032A0724|83 95|excretory duct
P00564032A0724|101 105|gland
P00564943A0444|0 5|Calves
P00564943A0444|9 16|MCT-milk
P00564943A0444|33 53|lower blood cholesterol
P00564943A0444|58 63|calves
P00564943A0444|67 67|T
P00564943A0444|71 78|SBO-milk
P00565136T0000|18 21|mice
P00565136T0000|31 40|inhalation
P00565136T0000|43 52|acute doses
P00565136T0000|55 58|CH2O
P00565136T0000|60 65|SO2Cl2
P00565136T0000|70 72|Br2
P00565314A0293|0 9|Guinea pigs
P00565314A0293|37 37|g
P00569989A0239|5 23|halothane anesthesia
P00569989A0239|28 47|flow pneumocardiogram
P00569989A0239|49 52|PnCG
P00569989A0239|60 73|time derivative
P00569989A0239|75 102|acceleration pneumocardiogram
P00569989A0239|105 110|dPn/dt
P00569989A0239|132 136|apnea
P00569989A0239|140 169|small high-gain pneumotachograph
P00574222T0000|0 14|Sensory kindling
P00574222T0000|16 27|implications
P00574222T0000|44 60|sensory prostheses
P00574956A0304|17 26|stereotypy
P00574956A0304|58 81|striatal dopaminergic tone
P00574956A0304|115 125|equilibrium
P00574956A0304|131 169|striatal cholinergic-dopaminergic systems
P00574956A0304|195 202|dopamine
P00574956A0304|243 265|behavioral manifestation
P00575231A0422|0 3|None
P00575231A0422|9 23|cystometrograms
P00575231A0422|30 60|uninhibited detrusor contractions
P00577440A0298|5 12|duodenum
P00577440A0298|14 22|small part
P00577440A0298|60 81|3H-alpha-acetyldigoxin
P00578648T0048|0 16|Functional effects
P00578648T0048|26 47|subacute administration
P00580106T0000|0 8|Treatment
P00580106T0000|11 16|Graves
P00580151A0706|61 72|testosterone
P00580151A0706|83 92|se-T levels
P00580151A0706|98 112|normal male range
P00580151A0706|171 189|possible side effects
P00580151A0706|195 204|large doses
P00583004A0445|0 7|Contrary
P00583004A0445|10 33|1,8-dihydroxy-9-anthrone
P00583004A0445|35 60|1,8,9-triacetoxyanthracene
P00583004A0445|64 87|1,8-diacetoxy-9-anthrone
P00583004A0445|107 122|psoriatic lesions
P00583004A0445|142 154|inflammations
P00583522T0001|0 15|Etiopathogenetic
P00583522T0001|19 37|therapeutic problems
P00583522T0001|40 63|acute orbital inflammation
P00587791T0054|0 6|Nursing
P00587791T0054|9 16|patients
P00587791T0054|21 41|gynecological diseases
P00589073A0000|10 43|basal plasma prolactin concentrations
P00589073A0000|47 53|samples
P00589073A0000|71 90|early follicular phase
P00589073A0000|111 115|women
P00589073A0000|122 133|similar group
P00589073A0000|138 145|patients
P00589073A0000|151 170|long-standing history
P00589073A0000|173 183|infertility
P00590594T0000|0 25|Ovarian allotransplantation
P00592887T0000|0 15|Allergic reaction
P00592887T0000|18 33|Patent Blue Violet
P00592887T0000|40 51|lymphography
P00593119T0001|0 8|Screening
P00593119T0001|11 24|asthma patients
P00593119T0001|42 44|IgE
P00593119T0001|50 62|comprehension
P00593119T0001|75 102|allergospecific IgE antibodies
P00594466T0001|3 11|induction
P00594466T0001|14 21|seizures
P00594466T0001|25 34|Papio papio
P00594466T0001|45 56|allylglycine
P00594466T0001|81 109|intermittent photic stimulation
P00594617A0192|7 28|significant correlation
P00594617A0192|57 87|fibrinolytic degradation products
P00594617A0192|89 91|FDP
P00594617A0192|99 107|incidence
P00594617A0192|110 120|nephropathy
P00594617A0192|124 141|renal insufficiency
P00594617A0192|171 184|fibrin monomers
P00594617A0192|186 190|Godal
P00594617A0192|193 216|ethanol-gelification test
P00594617A0192|224 237|evolutive signs
P00594617A0192|243 256|primary disease
P00594617A0192|275 277|ESR
P00597715A0256|0 8|One-third
P00597715A0256|14 16|men
P00597715A0256|21 31|azoospermia
P00597715A0256|39 50|sperm density
P00597715A0256|79 90|FSH elevation
P00597715A0256|79 81|FSH
P00597715A0256|148 160|poor prognosis
P00598012A0174|2 21|girls prolactin levels
P00598012A0174|7 15|prolactin
P00598012A0174|41 46|higher
P00598012A0174|52 59|menarche
P00598012A0174|63 66|boys
P00598012A0174|84 98|prolactin levels
P00598012A0174|84 92|prolactin
P00599601A0260|29 46|surgical procedures
P00599601A0260|64 75|pinealectomy
P00599601A0260|90 114|pineal-induced alterations
P00599601A0260|120 141|reproductive physiology
P00599601A0260|147 168|blind-anosmic female rat
P00600943T0001|1 5|cases
P00600943T0001|8 31|toxic lymphomononucleosis
P00601401A0181|6 23|hemoglobin solution
P00601401A0181|6 15|hemoglobin
P00601401A0181|42 53|high affinity
P00601401A0181|67 79|low Bohr effect
P00601401A0181|96 119|delta log Po2/delta pH ratio
P00602622A0362|1 20|one-week ulcer therapy
P00602622A0362|25 32|atropine
P00602622A0362|36 42|Vikalin
P00602622A0362|44 48|Roter
P00602622A0362|68 72|p less
P00602622A0362|96 123|nocturnal proteolytic activity
P00602702A0309|16 29|severe diarrhea
P00602702A0309|33 52|estriol concentration
P00602702A0309|55 59|serum
P00602702A0309|74 101|intestinal function normalised
P00602702A0309|108 127|estriol concentration
P00602702A0309|148 155|diarrhea
P00603783A0647|0 10|Serum levels
P00603783A0647|13 15|IgG
P00603783A0647|19 21|IgM
P00603783A0647|40 47|contrary
P00603783A0647|53 60|findings
P00603783A0647|63 85|other observers IgA levels
P00603783A0647|77 79|IgA
P00606849T0000|0 31|Experimental ischemic heart disease
P00606849T0000|41 53|thromboxane A2
P00606849T0000|56 62|rabbits
P00614915T0001|0 9|Vitrectomy
P00614915T0001|12 29|ocular traumatology
P00616575A0000|27 48|central brain structures
P00616575A0000|64 83|electromagnetic field
P00616575A0000|86 99|decimeter waves
P00616575A0000|101 103|EMF
P00616575A0000|106 107|DW
P00616575A0000|110 129|dynamic investigation
P00616575A0000|132 149|single unit activity
P00617815A0215|2 25|systematic L-R differences
P00618078A0367|14 29|lysozyme activity
P00618078A0367|14 21|lysozyme
P00618078A0367|46 64|clinical improvement
P00618078A0367|70 88|bacterial meningitis
P00619305A0759|18 23|groups
P00619305A0759|70 79|dimensions
P00619782A0058|0 7|Deep tans
P00619782A0058|26 30|backs
P00619782A0058|33 42|volunteers
P00619782A0058|65 92|longwave ultraviolet radiation
P00619782A0058|94 97|UV-A
P00619948A0000|4 10|effects
P00619948A0000|13 26|normal subjects
P00619948A0000|30 43|single oral dose
P00619948A0000|46 52|Motival
P00619948A0000|57 62|tablet
P00619948A0000|74 85|fluphenazine
P00619948A0000|89 90|mg
P00619948A0000|94 106|nortriptyline
P00619948A0000|109 110|mg
P00619948A0000|117 143|contingent negative variation
P00619948A0000|145 147|CNV
P00619948A0000|150 161|reaction time
P00619948A0000|163 171|heart rate
P00619948A0000|173 185|blood pressure
P00619948A0000|189 205|self-rating scales
P00619948A0000|209 217|alertness
P00619948A0000|235 244|detachment
P00619948A0000|281 288|diazepam
P00619948A0000|291 292|mg
P00619948A0000|299 300|mg
P00619948A0000|305 311|placebo
P00619948A0000|314 324|propranolol
P00619948A0000|328 329|mg
P00621626T0000|0 12|Stress effects
P00621626T0000|15 36|affiliation preferences
P00621626T0000|42 49|subjects
P00621626T0000|68 96|coronary-prone behavior pattern
P00622556A0111|16 23|collagen
P00622556A0111|64 69|tendon
P00623361A0221|0 6|Smoking
P00623361A0221|23 39|major contribution
P00623361A0221|42 61|pulmonary dysfunction
P00626014T0001|3 11|malignity
P00626014T0001|14 26|nevoid lentigo
P00627039T0000|0 10|Elimination
P00627039T0000|13 22|bagassosis
P00627039T0000|25 63|Louisiana paper manufacturing plant workers
P00627129A0944|5 13|responses
P00627129A0944|41 52|same subjects
P00627129A0944|61 74|same conditions
P00627129A0944|99 120|antihypertensive effect
P00627129A0944|123 131|labetalol
P00627129A0944|145 162|concurrent blockade
P00627129A0944|165 191|alpha-and beta-adrenoceptors
P00627202T0000|0 8|Diuretics
P00627202T0000|10 34|basic clinical pharmacology
P00627202T0000|38 51|therapeutic use
P00628990A0000|5 12|patients
P00628990A0000|21 37|renoureteral units
P00628990A0000|51 76|single-stage reconstruction
P00628990A0000|86 104|ureteroureterostomy
P00628990A0000|108 138|ipsilateral ureteroneocystostomy
P00628990A0000|148 181|temporary loop cutaneous ureterostomy
P00630713T0000|0 9|Evaluation
P00630713T0000|15 39|Du Pont aca ammonia procedure
P00633909A0000|18 25|patients
P00633909A0000|27 32|scores
P00633909A0000|35 40|Rotter
P00633909A0000|43 64|Internal-External Locus
P00633909A0000|67 78|Control Scale
P00633909A0000|135 142|patients
P00633909A0000|156 177|greater internal control
P00635143T0001|0 5|Action
P00635143T0001|8 19|strontium-90
P00635143T0001|23 30|metaphos
P00635143T0001|33 46|Cyprinus carpio
P00635194A0093|0 12|Kodak XV-2 film
P00635194A0093|29 58|cylindrical water-filled phantom
P00635194A0093|65 80|dose distribution
P00636526T0033|0 8|Diagnosis
P00636526T0033|12 32|differential diagnosis
P00637637T0000|3 17|multiple factors
P00637637T0000|27 45|plasma renin activity
P00637637T0000|27 37|plasma renin
P00637637T0000|48 68|essential hypertension
P00639410T0000|0 8|Cortisone
P00639410T0000|16 26|bone changes
P00639410T0000|43 61|lipid clearing agents
P00640584A0250|5 25|time-sharing principle
P00640584A0250|42 54|high stability
P00641395A0441|4 15|blood samples
P00641395A0441|18 25|patients
P00641395A0441|30 47|hyperbilirubinemia
P00641395A0441|61 77|direct measurement
P00641395A0441|80 82|ZPP
P00641395A0441|89 99|fluorimeter
P00641395A0441|120 131|higher levels
P00641395A0441|141 165|alternate extraction method
P00644314T0000|7 22|hypersensitivity
P00644314T0000|29 35|effects
P00644314T0000|38 60|systemic anticoagulation
P00644539A0783|18 27|inhalation
P00644539A0783|31 44|ml normal saline
P00644539A0783|53 56|FEV1
P00644539A0783|66 66|%
P00644539A0783|71 71|%
P00644539A0783|115 123|reactions
P00644539A0783|129 141|test solutions
P00646023T0058|0 18|Experimental studies
P00646023T0058|21 34|virus excretion
P00646023T0058|38 62|non-arthropod transmission
P00646193T0000|0 6|Potency
P00646193T0000|9 17|enflurane
P00646193T0000|20 23|dogs
P00646193T0000|39 47|halothane
P00646193T0000|51 60|isoflurane
P00656008T0000|0 9|Prevention
P00656008T0000|12 32|acute paraquat toxicity
P00656008T0000|35 38|rats
P00656008T0000|41 59|superoxide dismutase
P00657551T0000|0 10|Measurement
P00657551T0000|13 31|magnesium absorption
P00657551T0000|42 51|stable 26Mg
P00657551T0000|55 60|tracer
P00659962T0000|9 34|urinary riboflavin excretion
P00659962T0000|48 65|boric acid ingestion
P00663166A0000|0 22|Radionuclide angiography
P00663166A0000|26 47|static whole body imaging
P00663166A0000|61 94|technetium-99m-labeled particulates
P00663166A0000|116 135|differential shunting
P00663166A0000|138 145|patients
P00663166A0000|150 171|patent ductus arteriosus
P00663166A0000|173 175|PDA
P00663166A0000|181 201|Eisenmenger physiology
P00664320T0000|7 15|detectors
P00664320T0000|21 38|human visual pathway
P00665053A0276|14 37|single sero-anzymatic type
P00665053A0276|39 43|06a6b
P00665053A0276|45 47|K13
P00665053A0276|49 50|H1
P00665053A0276|67 80|group affection
P00665214A0374|45 54|physiology
P00665214A0374|60 69|nasal cycle
P00665336A0908|5 12|same time
P00665336A0908|29 57|understandable EEG-information
P00668122A0414|0 7|Analysis
P00668122A0414|10 29|liver biopsy specimens
P00668122A0414|34 41|patients
P00668122A0414|46 54|hepatitis
P00668122A0414|62 75|large variation
P00668122A0414|81 95|mean iron content
P00668122A0414|101 122|liver ferritin molecules
P00668122A0414|106 113|ferritin
P00669800A0579|0 9|Female mice
P00669800A0579|31 39|resistant
P00669800A0579|55 59|males
P00676416A0320|22 26|years
P00676416A0320|32 54|sequential liver biopsies
P00676790T0000|0 16|Angiotensin effect
P00676790T0000|0 10|Angiotensin
P00676790T0000|22 32|human kidney
P00681550A0000|0 12|Procion yellow
P00681550A0000|46 64|large auditory fibers
P00681550A0000|67 74|goldfish
P00681550A0000|113 124|response type
P00681550A0000|132 137|fibers
P00681550A0000|152 162|termination
P00681550A0000|168 181|saccular macula
P00681571T0028|0 17|Incidental findings
P00681571T0028|23 31|epidermis
P00681571T0028|40 74|intraepidermal eccrine sweat duct units
P00682762T0001|0 17|Silicosis mortality
P00685922A0451|26 35|strictures
P00685922A0451|47 69|intrahepatic biliary tree
P00685922A0451|71 73|IHB
P00686836A0000|0 6|Pentane
P00686836A0000|10 15|ethane
P00686836A0000|33 49|lipid peroxidation
P00686836A0000|71 87|gas chromatography
P00686836A0000|90 102|breath samples
P00686836A0000|105 108|rats
P00686836A0000|116 120|weeks
P00686836A0000|122 143|vitamin E-deficient diet
P00686836A0000|172 188|IU vitamin E acetate
P00686836A0000|192 193|kg
P00693987T0001|0 13|Thromboplastic
P00693987T0001|17 36|fibrynolytic activity
P00693987T0001|68 77|intralipid
P00693987T0001|80 82|men
P00693987T0001|96 115|myocardial infarction
P00696680A0000|3 9|authors
P00696680A0000|19 43|clinicopathologic findings
P00696680A0000|50 54|cases
P00696680A0000|57 66|adult women
P00696680A0000|71 87|rhabdomyosarcomas
P00696680A0000|107 117|endometrium
P00696680A0000|120 125|cervix
P00696858A0000|11 36|pure natural porcine secretin
P00696858A0000|39 47|endocrine
P00696858A0000|51 77|exocrine pancreatic secretion
P00696858A0000|108 130|perfused porcine pancreas
P00701144T0000|0 16|Biometric analysis
P00701144T0000|19 38|intraocular lens power
P00701144T0000|56 65|emmetropia
P00701144T0000|67 73|results
P00701144T0000|79 86|implants
P00701462A0722|0 14|Urine antibodies
P00701462A0722|42 51|other cases
P00702773A0327|0 9|Althoug RBF
P00702773A0327|65 81|significant change
P00702773A0327|84 86|RBF
P00702773A0327|88 90|GFR
P00702773A0327|94 106|cardiac output
P00703350A0418|0 11|99mTc phytate
P00703350A0418|13 24|198Au colloid
P00703350A0418|29 48|99mTc antimony sulfide
P00703350A0418|93 104|satisfactory
P00703932A0000|3 10|patients
P00703932A0000|15 32|glomerulonephritis
P00703932A0000|51 73|ventriculovascular shunt
P00703932A0000|94 103|basic modes
P00704675A0199|9 11|UO2
P00704675A0199|17 37|extrapulmonary bronchi
P00704675A0199|41 56|first bifurcation
P00704675A0199|84 84|d
P00704675A0199|90 99|inhalation
P00704675A0199|107 123|corresponding mass
P00704675A0199|129 135|trachea
P00710217T0001|0 12|Synovial cysts
P00710217T0001|18 25|hip joint
P00710372A0302|10 32|hypothalamic dysfunction
P00710372A0302|45 69|impaired pituitary function
P00710372A0302|82 93|GH deficiency
P00710372A0302|82 83|GH
P00710372A0302|103 132|common endocrinological features
P00712117A0521|1 13|sharp outbreak
P00712117A0521|16 25|influenza A
P00712117A0521|49 56|February
P00712117A0521|71 79|A/Texas/1
P00712117A0521|81 92|77-like virus
P00712117A0521|95 101|variant
P00712117A0521|107 118|A/Victoria/3
P00712117A0521|122 130|prototpye
P00713525A0268|7 15|decreases
P00713525A0268|21 35|disfluency rates
P00713525A0268|38 47|stutterers
P00713525A0268|91 103|stimulus words
P00713525A0268|130 141|operant model
P00715180T0074|0 5|Effect
P00715180T0074|21 31|alterations
P00715180T0074|41 50|inhalation
P00715180T0074|53 79|plutonium-239 dioxide aerosol
P00715753A0241|2 22|biopsies CK-MB fraction
P00715753A0241|25 42|total myocardial CPK
P00715753A0241|48 48|%
P00715753A0241|53 69|total-CPK activity
P00715753A0241|72 91|human skeletal muscles
P00715753A0241|104 112|% fraction
P00715753A0241|115 119|CK-MB
P00716366T0001|0 4|Value
P00716366T0001|22 50|alkaline phosphatase isoenzymes
P00716366T0001|54 74|differential diagnosis
P00716366T0001|77 95|obstructive jaundice
P00716366T0001|99 119|biliary liver cirrhosis
P00722298A0619|1 15|one-way analysis
P00722298A0619|18 25|variance
P00722298A0619|49 51|men
P00722298A0619|55 59|women
P00722298A0619|63 73|differences
P00722298A0619|87 98|phobic groups
P00722298A0619|101 115|field dependence
P00722298A0619|136 142|rho less
P00722298A0619|157 163|females
P00722298A0619|172 188|famale agoraphobic
P00722298A0619|194 211|more field dependent
P00722298A0619|219 242|female simple phobic groups
P00722298A0619|256 260|males
P00722652A0118|0 33|Several free 2nd-generation schizonts
P00722652A0118|48 55|diameter
P00722652A0118|68 77|micrometer
P00722652A0118|93 109|epithelial surface
P00722652A0118|115 119|cecum
P00725257A0452|13 21|pD2 values
P00725257A0452|32 32|E
P00725257A0452|40 42|DHE
P00725257A0452|52 53|M.
P00725336T0000|0 32|Newcastle disease virus surveillance
P00725336T0000|35 42|Hong Kong
P00725336T0000|61 67|poultry
P00725534A0888|19 37|persistent challenge
P00725534A0888|40 47|M. leprae
P00725534A0888|53 60|antigens
P00725534A0888|66 79|IgA immunocytes
P00725534A0888|66 68|IgA
P00725534A0888|85 104|intestinal epithelium
P00725534A0888|139 151|IgA deficiency
P00725534A0888|139 141|IgA
P00725534A0888|155 179|subsequent subtotal atrophy
P00725534A0888|185 199|intestinal villi
P00725534A0888|205 212|patients
P00725534A0888|217 234|lepromatous leprosy
P00725752T0001|0 8|Treatment
P00725752T0001|11 22|hypertension
P00725752T0001|44 74|adrenergic beta receptor blockader
P00725752T0001|44 65|adrenergic beta receptor
P00725752T0001|76 82|obsidan
P00725752T0001|90 100|vasodilator
P00725752T0001|102 109|apressin
P00726581T0122|0 5|Orthop
P00728718T0000|0 13|Thyroid disease
P00729003A1182|0 7|Residues
P00729003A1182|19 29|transcripts
P00729003A1182|32 39|splicing
P00733067A0188|10 15|reflux
P00733067A0188|23 31|blind loop
P00733067A0188|42 55|technical steps
P00733067A0188|69 81|indispensable
P00733067A0188|85 97|fluted section
P00733067A0188|103 114|jejunal stump
P00733067A0188|118 143|isoperistaltic construction
P00733067A0188|149 159|anastomosis
P00733067A0188|201 225|double valve system upstream
P00733067A0188|233 243|anastomosis
P00733067A0188|246 263|spiral introflexion
P00733067A0188|269 274|mucosa
P00733067A0188|280 305|seroserous stitches parallel
P00733067A0188|309 321|perpendicular
P00733067A0188|327 336|ileal lumen
P00736376A0371|15 35|eventual high mortality
P00736376A0371|38 50|acute ischemia
P00736376A0371|75 81|urgency
P00737422A0832|0 8|Pathogens
P00737422A0832|32 51|Gram-negative bacilli
P00737422A0832|91 102|small numbers
P00737422A0832|106 116|irregularly
P00737422A0832|128 139|large numbers
P00737422A0832|144 151|patients
P00740409A0000|3 16|histochemistry
P00740409A0000|20 33|ultrastructure
P00740409A0000|36 62|calcified cerebellar deposits
P00740409A0000|74 78|Tonge
P00741476A0000|3 15|year-old woman
P00741476A0000|24 41|Ergotamine Tartrate
P00741476A0000|45 50|mg p.d.
P00741476A0000|62 65|days
P00743335T0001|0 12|Reaction times
P00743335T0001|42 48|stimuli
P00743335T0001|51 59|diabetics
P00745775A0170|12 19|patients
P00745775A0170|30 57|selective spinal arteriography
P00745775A0170|67 100|transient neurological complications
P00745775A0170|110 118|injection
P00745775A0170|121 129|Urografin
P00745775A0170|133 134|M.
P00747722A0486|16 34|three-phase reaction
P00747722A0486|40 50|B1 injection
P00747722A0486|52 56|Phase
P00747722A0486|72 80|injection
P00747722A0486|98 107|parameters
P00747722A0486|120 122|sec
P00748978T0000|0 17|Serum relaxin levels
P00748978T0000|20 34|prostaglandin E2
P00748978T0000|42 50|abortions
P00753237A0000|4 31|natural hydrostatic phenomenon
P00753237A0000|48 51|ends
P00753237A0000|57 67|plantar arcs
P00753237A0000|77 86|body weight
P00753237A0000|90 93|PAIN
P00753237A0000|108 116|outsentry
P00753237A0000|118 120|fig
P00753237A0000|130 130|B
P00753237A0000|133 139|Plantar
P00753237A0000|151 160|ulceration
P00753237A0000|162 164|PPU
P00753237A0000|190 202|INSENSITIVITY
P00753237A0000|206 214|TRAUMATIS
P00753237A0000|219 219|C
P00753237A0000|243 252|body weight
P00753237A0000|254 263|traumatism
P00753237A0000|265 271|effects
P00753237A0000|282 301|cicatrization process
P00753237A0000|322 322|D
P00753237A0000|325 339|PNEUMATIC INSOLE
P00753237A0000|346 352|elastic
P00753237A0000|362 381|localized compression
P00753237A0000|387 390|ends
P00753237A0000|396 406|plantar arcs
P00753237A0000|415 423|attrition
P00753237A0000|430 451|easier blood circulation
P00753237A0000|468 478|prophylaxis
P00753237A0000|481 483|PPU
P00753237A0000|485 487|fig
P00755245A0000|0 5|Effect
P00755245A0000|8 16|indoramin
P00755245A0000|19 28|small doses
P00755245A0000|34 53|central vasomotor loci
P00755245A0000|70 95|chloralose anesthetized cats
P00755245A0000|115 126|central sites
P00755671A0485|14 20|heparin
P00755671A0485|40 59|recalcification times
P00755671A0485|79 109|occasional subcutaneous hematomas
P00755869A0216|0 21|Contingency contracting
P00755869A0216|29 35|clients
P00755869A0216|44 61|parents/caregivers
P00755869A0216|78 89|consequences
P00755869A0216|93 112|daily self-monitoring
P00755869A0216|121 133|caloric intake
P00755869A0216|135 144|weight loss
P00756511T0036|0 8|Dietetics
P00756511T0036|24 39|juvenile diabetes
P00757244A0000|3 9|results
P00757244A0000|13 29|quantitative study
P00757244A0000|32 56|vasculosyncytial membranes
P00757244A0000|62 70|placentas
P00759049A0185|3 13|micromethod
P00759049A0185|18 30|microcuvettes
P00759049A0185|45 53|ferrozine
P00759049A0185|60 87|bathophenanthroline chromogen
P00759049A0185|93 96|ICSH
P00759400T0000|0 16|Platelet serotonin
P00759400T0000|18 21|5-HT
P00759400T0000|26 44|5-HT releasing factor
P00759400T0000|26 29|5-HT
P00759400T0000|47 52|plasma
P00759400T0000|55 72|migrainous patients
P00762763A0253|3 18|overall incidence
P00762763A0253|21 24|SIDS
P00762763A0253|40 49|live births
P00764737X0000|3 15|vigilance task
P00764737X0000|35 53|attentional deficits
P00767155T0001|3 21|December armed revolt
P00767155T0001|24 29|Moscow
P00767155T0001|36 55|paramedical personnel
P00767161A0837|0 19|Significant increases
P00767161A0837|22 45|mean serum E2 concentration
P00767161A0837|55 59|pg/ml
P00767161A0837|77 81|hours
P00767161A0837|113 117|hours
P00768220X0000|3 11|motor unit
P00771729X0000|0 22|Avian reproductive system
P00771729X0000|24 38|daily variations
P00771729X0000|41 49|responses
P00771729X0000|52 59|hormones
P00775582T0000|0 19|Biological properties
P00775582T0000|22 30|sumithion
P00779272T0001|0 17|Serological studies
P00779272T0001|20 29|antibodies
P00779272T0001|32 48|Epstein-Barr virus
P00779272T0001|51 73|infectious mononucleosis
P00780639X0000|0 22|Carcinoembryonic antigen
P00780639X0000|24 26|CEA
P00780639X0000|28 37|procedures
P00780639X0000|41 58|clinical evaluation
P00792847A0000|21 42|antilymphocyte globulin
P00792847A0000|44 46|ALG
P00792847A0000|51 78|potent immunosuppressive agent
P00792847A0000|81 86|humans
P00799988A0554|13 36|global assessment patients
P00799988A0554|50 70|significant preference
P00799988A0554|74 83|imipramine
P00799988A0554|96 102|placebo
P00799988A0554|105 121|adjunctive therapy
P00803867A0315|0 7|Patients
P00803867A0315|29 45|age-matched groups
P00803867A0315|48 69|primary untreated cancer
P00803867A0315|75 89|recurrent cancer
P00803867A0315|105 112|patients
P00803867A0315|147 152|months
P00806295A0193|0 9|Absorption
P00806295A0193|33 36|cent
P00806295A0193|43 56|mean absorption
P00806295A0193|64 67|cent
P00806295A0193|86 105|non-pregnant subjects
P00807356T0001|0 13|Bacteriostatic
P00807356T0001|17 37|bacteriacidal activity
P00807356T0001|40 59|hydroxy-9 ellipticine
P00808266T0000|0 7|Advances
P00808266T0000|25 41|gynecologic cancer
P00808266T0000|44 59|radiation therapy
P00808898A0000|3 26|clinico-pathological data
P00808898A0000|43 77|irreversible post-partum renal failure
P00808898A0000|79 82|IPRF
P00811852T0001|0 19|Personal satisfaction
P00811852T0001|22 28|nursing
P00811852T0001|54 68|hostile patients
P00812183T0000|0 23|Dialyzable transfer factor
P00812183T0000|10 23|transfer factor
P00818380A0239|0 15|Rheumatoid factor
P00818380A0239|19 42|antinuclear antibody tests
P00818380A0239|69 77|reactions
P00818380A0239|80 90|gold therapy
P00818380A0239|95 106|more frequent
P00818380A0239|113 138|other rheumatoid populations
P00819176T0001|11 29|hydrostatic pressure
P00819176T0001|35 50|swimming activity
P00819176T0001|58 79|hyponeustonic crustacea
P00819176T0001|81 100|Anomalocera patersoni
P00819176T0001|102 121|Pontella mediterranea
P00819176T0001|123 142|Labidocera wollastoni
P00821833A0000|33 47|vocal repertoire
P00821833A0000|50 62|howler monkeys
P00821833A0000|64 79|Alouatta palliata
P00821833A0000|96 105|field study
P00821833A0000|108 125|southwestern Panama
P00822611A0467|18 25|patients
P00822611A0467|58 64|persons
P00822611A0467|77 89|binephrectomy
P00823087A0608|0 7|Deflunia
P00823087A0608|28 35|patients
P00825571T0031|0 2|III
P00827364A0000|1 13|new instrument
P00827364A0000|32 48|freeze-fracturing
P00827364A0000|51 68|biological material
P00827364A0000|71 85|ultra high vacuum
P00830568A0000|0 9|Pancreatic
P00830568A0000|13 28|biliary secretion
P00830568A0000|32 51|gastric emptying rates
P00830568A0000|55 68|liquid test meal
P00830568A0000|70 72|LTM
P00830568A0000|90 102|normal persons
P00830568A0000|106 113|patients
P00830568A0000|118 136|subtotal gastrectomy
P00830568A0000|141 158|gastroduodenostomy
P00830568A0000|160 165|STG-BI
P00830568A0000|173 189|gastrojejunostomy
P00830568A0000|191 197|STG-BII
P00830568A0000|205 212|patients
P00830568A0000|217 231|truncal vagotomy
P00830568A0000|235 246|pyloroplasty
P00830568A0000|248 250|V&P
P00832096T0000|0 24|Abnormal calcium metabolism
P00832096T0000|27 51|normocalcaemic sarcoidosis
P00833472A0907|35 44|gallstones
P00833472A0907|67 76|colestipol
P00833472A0907|78 87|saturation
P00833472A0907|90 104|gallbladder bile
P00836637A0000|1 20|five-phase experiment
P00836637A0000|55 79|contingent music-listening
P00836637A0000|91 100|reinforcer
P00836637A0000|111 131|arithmetic performance
P00836637A0000|134 144|EMR children
P00836637A0000|162 184|contingent reinforcement
P00836637A0000|213 222|reinforcer
P00837262A0000|3 16|responsiveness
P00837262A0000|19 30|visual cortex
P00837262A0000|32 33|VC
P00837262A0000|38 55|superior colliculus
P00837262A0000|57 58|SC
P00837262A0000|94 105|conditioning
P00837262A0000|107 108|ON
P00837262A0000|113 115|OFF
P00837262A0000|117 127|stimulation
P00837811A0675|12 13|MS
P00837811A0675|28 48|subtle neurologic signs
P00837811A0675|50 83|spinal fluid gamma globulin elevations
P00837811A0675|61 73|gamma globulin
P00837811A0675|88 100|abnormalities
P00837811A0675|103 127|neuropsychological testing
P00838152A0863|14 32|mean temperature rise
P00838152A0863|36 41|higher
P00838152A0863|47 54|degrees C
P00838152A0863|61 68|degrees C
P00838152A0863|109 121|disappearance
P00838152A0863|125 132|passable
P00838152A0863|134 147|qualifications
P00838152A0863|153 165|triplet groups
P00838152A0863|170 186|great predominance
P00838152A0863|203 216|qualifications
P00838152A0863|222 232|large groups
P00839378A0649|3 15|elevated Viso V
P00839378A0649|21 28|RDS group
P00839378A0649|49 78|small airway resistance secondary
P00842406A0771|3 20|psychological tests
P00842406A0771|33 47|free-recall task
P00842406A0771|57 78|visuomotor coordination
P00842406A0771|83 97|recognition task
P00842522T0000|0 27|Selective bronchial intubation
P00842522T0000|45 84|unilateral pulmonary interstitial emphysema
P00843232A0100|36 52|etiological factor
P00843232A0100|70 75|lesion
P00843232A0100|81 90|epithelium
P00843232A0100|105 115|dyshormonal
P00843232A0100|117 128|inflammatory
P00843232A0100|133 145|posttraumatic
P00846559A0000|6 12|strains
P00846559A0000|15 26|Fusarium poae
P00846559A0000|30 47|F. sporotrichioides
P00846559A0000|55 62|U.S.S.R.
P00846559A0000|67 73|strains
P00846559A0000|96 116|F. sporotrichioides var
P00846559A0000|118 127|tricinctum
P00846559A0000|132 137|U.S.A.
P00846559A0000|141 146|France
P00846559A0000|187 194|T-2 toxin
P00847967T0000|0 20|Current diagnostic uses
P00847967T0000|23 44|computerized tomography
P00847967T0000|47 62|clinical medicine
P00851041A0000|1 14|follow-up study
P00851041A0000|19 26|patients
P00851041A0000|31 37|Ebstein
P00851041A0000|40 46|anomaly
P00851286A0375|0 5|Deaths
P00851286A0375|15 19|hours
P00851286A0375|25 44|copper concentrations
P00851286A0375|62 64|ppm
P00851286A0375|68 72|signs
P00851286A0375|75 82|distress
P00851286A0375|101 107|pinfish
P00851286A0375|124 128|hours
P00851286A0375|137 145|last death
P00857024A0888|0 9|Recurrence
P00857024A0888|12 24|bladder tumors
P00857024A0888|42 46|cases
P00857024A0888|76 90|properdin levels
P00857024A0888|76 84|properdin
P00857024A0888|107 112|median
P00863184T0043|0 9|Adaptation
P00863184T0043|12 39|taurocholate transport maximum
P00863184T0043|51 63|secretory load
P00863773T0000|0 6|Dangers
P00863773T0000|14 31|live-virus vaccines
P00866577A0579|0 8|Treatment
P00866577A0579|13 19|heparin
P00866577A0579|21 41|plasminogen activators
P00866577A0579|45 66|fibrinogenolytic agents
P00866577A0579|70 82|disappointing
P00866577A0579|91 103|renal function
P00866577A0579|131 162|long term oral anticoagulant therapy
P00868301A0043|2 21|diethyl ether solution
P00868301A0043|25 32|main peak
P00868301A0043|41 72|2-benzylidenamio-1-phenylpropane
P00868301A0043|83 95|retention time
P00868301A0043|102 108|minutes
P00868903A0000|0 7|Amikacin
P00868903A0000|33 62|serious gram-negative infections
P00868903A0000|67 74|patients
P00870859A0121|27 38|insufficient
P00870859A0121|71 83|recirculation
P00871237A0601|37 42|angina
P00872442T0000|0 9|Estimation
P00872442T0000|12 20|L-alanine
P00872442T0000|23 27|serum
P00872442T0000|30 35|plasma
P00872442T0000|44 66|LKB reaction rate analyser
P00872922A0204|3 7|acids
P00872922A0204|22 31|hydrolysis
P00872922A0204|37 55|corresponding esters
P00872922A0204|65 89|anti-inflammatory activity
P00874942T0000|0 21|Unrecognized amnionitis
P00874942T0000|25 35|prematurity
P00874942T0000|38 54|preliminary report
P00875778T0000|0 9|Evaluation
P00875778T0000|15 38|new Gravigard IUCD inserter
P00876722T0000|0 27|Bacterial meningitis secondary
P00876722T0000|30 36|abscess
P00876722T0000|42 52|nasal septum
P00877857A0763|0 11|Serum amylase
P00877857A0763|26 33|elevated
P00877857A0763|40 47|CU/100 ml
P00877857A0763|58 65|serum FFA
P00877857A0763|72 80|mEq/liter
P00879329A0176|5 22|control preparation
P00879329A0176|56 86|isogravimetric capillary pressure
P00879329A0176|88 90|Pci
P00879329A0176|101 109|mmHg lower
P00879329A0176|114 135|colloid osmotic pressure
P00879329A0176|141 146|plasma
P00879329A0176|148 150|IIp
P00879829A0564|0 6|Infants
P00879829A0564|26 30|hours
P00879829A0564|36 38|IVH
P00879829A0564|55 73|severe birth asphyxia
P00879829A0564|99 109|main symptom
P00879829A0564|113 127|recurrent apnoea
P00881630A0000|3 22|morphological effects
P00881630A0000|28 38|snake venoms
P00881630A0000|40 45|N. naja
P00881630A0000|49 60|A. piscivorus
P00881630A0000|70 86|Direct Lytic Factor
P00881630A0000|90 104|Phospholipase-A
P00881630A0000|106 114|compounds
P00881630A0000|127 142|N. naja crude venom
P00881630A0000|169 184|cremaster vessels
P00881630A0000|187 190|rats
P00885562A0281|5 8|GAGs
P00885562A0281|15 24|components
P00885562A0281|27 41|cartilage matrix
P00885562A0281|46 54|depletion
P00885562A0281|78 91|osteoarthrosis
P00885562A0281|112 132|sulphated GAG synthesis
P00890028A0507|3 14|length scales
P00890028A0507|20 29|turbulence
P00890028A0507|51 64|Reynolds number
P00890028A0507|77 86|macroscale
P00890028A0507|98 99|mm
P00890028A0507|104 119|Taylor microscale
P00890028A0507|131 132|mm
P00890028A0507|140 155|Kolmogoroff scale
P00890028A0507|167 168|mm
P00891370A0000|0 26|Well-visualised arteriograms
P00891370A0000|32 36|limbs
P00891370A0000|52 66|xeroradiography
P00891370A0000|72 91|rapid manual injection
P00891370A0000|94 108|contrast-medium
P00891370A0000|115 121|arm vein
P00891370A0000|141 148|patients
P00892353A0686|2 12|hypotension
P00892353A0686|23 30|patients
P00892353A0686|35 41|toxemia
P00892353A0686|68 76|degrees C.
P00898500A0246|3 6|sera
P00898500A0246|10 24|nasal secretions
P00898500A0246|30 37|patients
P00898500A0246|56 57|HD
P00898500A0246|60 72|mites skin test
P00898500A0246|90 112|radioallergosorbent test
P00898500A0246|114 117|RAST
P00898500A0246|135 161|specific IgE antibody activity
P00898500A0246|143 153|IgE antibody
P00898500A0246|164 168|mites
P00903772A0359|0 7|Wherever
P00903772A0359|20 42|conditioning stimulation
P00903772A0359|49 61|modifications
P00903772A0359|78 86|ischaemia
P00909114A0000|0 17|Diallylnitrosamine
P00909114A0000|19 21|DAN
P00909114A0000|32 46|few nitrosamines
P00909114A0000|77 85|neoplasms
P00909114A0000|88 91|rats
P00909114A0000|100 112|high incidence
P00909114A0000|115 136|respiratory tract tumors
P00909114A0000|139 158|Syrian golden hamsters
P00909114A0000|166 167|sc
P00909114A0000|180 190|weekly doses
P00910823A0196|14 35|experimental conditions
P00910823A0196|37 44|maternal
P00910823A0196|48 62|fetal blood gases
P00910823A0196|64 65|pH
P00910823A0196|67 73|uterine
P00910823A0196|77 95|umbilical blood flows
P00911590T0000|0 20|Haemodynamic responses
P00911590T0000|23 32|antagonism
P00911590T0000|35 49|bocurarine block
P00911590T0000|54 80|atropine-neostigmine mixture
P00911590T0000|83 90|children
P00913623A0242|19 32|large molecules
P00913623A0242|43 72|diphosphonate 99mTc-labeled EHDP
P00913623A0242|75 100|99mTc-labeled pyrophosphate
P00913623A0242|113 123|capillaries
P00913623A0242|134 149|passive diffusion
P00915090A0536|11 14|days
P00915090A0536|20 28|injection
P00915090A0536|34 36|mCi
P00915090A0536|39 44|Tc-99m
P00915090A0536|58 61|rads
P00915090A0536|67 72|testis
P00915090A0536|85 93|sperm hads
P00915090A0536|107 107|%
P00916099A0000|0 16|Self-emasculation
P00916099A0000|22 30|end result
P00916099A0000|35 60|unusual psychiatric disorder
P00916099A0000|84 100|surgical treatment
P00917572T0001|0 10|Possibility
P00917572T0001|14 32|TSH-Screening method
P00917572T0001|14 16|TSH
P00917572T0001|36 44|detection
P00917572T0001|47 60|hypothyroidism
P00917572T0001|66 72|newborn
P00917721A0484|23 38|reliable evidence
P00917721A0484|43 70|conscious presleep suggestions
P00917721A0484|93 104|dream content
P00918556A0000|3 12|prevalence
P00918556A0000|15 38|hepatitis B surface antigen
P00918556A0000|40 44|HBsAg
P00918556A0000|49 56|anti-HBs
P00918556A0000|73 122|sensitive double-antibody radio-immunoassay technique
P00918556A0000|134 141|patients
P00918556A0000|146 165|chronic liver diseases
P00918965A0728|18 25|patients
P00918965A0728|30 52|acute respiratory failure
P00918965A0728|62 82|artificial ventilation
P00918965A0728|90 101|componenents
P00918965A0728|107 120|pulmonary shunt
P00918965A0728|125 132|parallel
P00918965A0728|171 174|PAO2
P00920381T0000|9 23|cardiac glycogen
P00920381T0000|33 51|phenformin injection
P00920381T0000|54 66|hyperglycemic
P00920381T0000|68 100|hyperinsulinemic anaesthetized rats
P00921032T0000|0 19|Biological evaluation
P00921032T0000|22 31|mibolerone
P00921032T0000|37 48|female Beagle
P00921911A0159|0 5|Levels
P00921911A0159|12 14|PGF
P00921911A0159|18 21|PGFM
P00921911A0159|39 44|higher
P00921911A0159|51 72|early spontaneous labour
P00921911A0159|77 94|cervical dilatation
P00921911A0159|106 107|cm
P00921911A0159|122 126|onset
P00921911A0159|129 134|labour
P00926272A0000|7 17|common cause
P00926272A0000|20 37|renal deterioration
P00926272A0000|43 52|spinal cord
P00926272A0000|69 100|irreversible vesicoureteral reflux
P00926604A0504|0 10|Propranolol
P00926604A0504|12 18|Inderal
P00926604A0504|53 76|beta-adrenergic apparatus
P00926604A0504|114 136|positive inotropic effect
P00926604A0504|139 154|therapeutic doses
P00926604A0504|157 169|strophanthin K
P00926604A0504|173 208|hypodynamic left ventricular myocardium
P00926751A0000|0 12|Recent studies
P00926751A0000|25 33|rat larynx
P00926751A0000|40 53|important organ
P00926751A0000|71 79|irritancy
P00926751A0000|89 97|materials
P00927633T0001|8 40|electron microscopic investigations
P00927633T0001|57 64|Reissner
P00927633T0001|74 85|Rattus rattus
P00928529T0001|0 14|Feeding behavior
P00928529T0001|16 35|circannual body weight
P00928529T0001|39 56|hibernation rhythms
P00928529T0001|59 74|European hamsters
P00928529T0001|88 100|noradrenergic
P00928529T0001|110 116|bundles
P00929418T0001|0 3|Role
P00929418T0001|9 36|infectious-disease specialist
P00929418T0001|40 49|polyclinic
P00929418T0001|63 71|incidence
P00929418T0001|74 93|communicable diseases
P00930947A0629|13 28|drug interactions
P00930947A0629|37 47|known effect
P00930947A0629|50 59|probenecid
P00930947A0629|67 75|secretion
P00930947A0629|78 80|PZA
P00930947A0629|129 133|drugs
P00931089T0001|0 16|Circulatory arrest
P00931089T0001|22 34|operating room
P00932738A0116|3 23|systolic blood pressure
P00932738A0116|25 26|BP
P00932738A0116|32 35|mmHg
P00932738A0116|37 53|C02 responsiveness
P00932738A0116|85 96|higher levels
P00932738A0116|99 100|BP
P00932817A0499|0 9|Iodine-123
P00932817A0499|44 46|MEC
P00932817A0499|50 67|pinhole collimators
P00932817A0499|87 105|MTF values comparable
P00932817A0499|124 128|99mTc
P00933251T0000|0 16|Petrous meningioma
P00933251T0000|19 24|plaque
P00933251T0000|38 56|right middle ear tumor
P00935526A0000|3 14|difficulties
P00935526A0000|24 37|prostaglandins
P00935526A0000|39 40|PG
P00935526A0000|44 67|gas-liquid chromatography
P00935526A0000|107 123|gas-chromatograph
P00935526A0000|131 136|higher
P00935526A0000|144 145|ng
P00935526A0000|155 168|poor resolution
P00935526A0000|174 186|packed columns
P00938594A0149|2 10|cessation
P00938594A0149|13 26|steroid therapy
P00938594A0149|51 74|radiologic manifestations
P00938594A0149|77 104|hypertrophic osteoarthropathy
P00938594A0149|106 108|HOA
P00938594A0149|129 146|laboratory features
P00938594A0149|149 167|rheumatoid arthritis
P00938594A0149|169 170|RA
P00941050T0000|17 38|procainamide absorption
P00947327A0000|34 53|antibiotic resistance
P00947327A0000|67 81|Northern Bavaria
P00947327A0000|121 136|sulfamethoxazole
P00947327A0000|138 140|SMZ
P00947327A0000|142 153|trimethoprim
P00947327A0000|155 157|TMP
P00947327A0000|189 199|antibiotics
P00947327A0000|203 224|chemotherapeutic agents
P00947327A0000|229 235|results
P00947327A0000|238 242|tests
P00947327A0000|250 263|new combination
P00947327A0000|266 267|N1
P00947327A0000|270 292|4,5-dimethyl-2-oxazolyl
P00947327A0000|295 307|sulfanilamide
P00947327A0000|310 320|sulfamoxole
P00947327A0000|325 337|2,4-diamino-5
P00947327A0000|340 362|3,4,5-trimethoxy-benzyl
P00947327A0000|365 374|pyrimidine
P00947327A0000|376 387|trimethoprim
P00947327A0000|403 404|CN
P00947327A0000|410 414|Nevin
P00947327A0000|416 424|Supristol
P00947327A0000|446 450|tests
P00947327A0000|455 461|TMP/SMZ
P00947834X0000|0 6|RESULTS
P00947834X0000|8 21|Total IgE levels
P00947834X0000|13 15|IgE
P00951909X0001|4 23|afferent loop syndrome
P00951909X0001|72 91|adducent loop syndrome
P00951909X0001|116 123|patients
P00951909X0001|135 156|Billroth-II gastrectomy
P00952734T0000|0 5|Letter
P00952734T0000|9 15|actinic
P00952734T0000|49 76|post-inflammatory elastolysis
P00952734T0000|80 88|cutis laxa
P00952734T0000|90 93|PECL
P00954819A1041|20 38|spontaneous recovery
P00954819A1041|41 66|central respiratory function
P00954819A1041|72 83|intoxication
P00954819A1041|88 92|Soman
P00954819A1041|95 99|Sarin
P00954819A1041|128 139|AChE activity
P00954819A1041|128 131|AChE
P00956364A0138|0 12|Batch cultures
P00956364A0138|15 30|S. mutans serotype
P00956364A0138|54 60|MSB agar
P00956554A0414|5 11|samples
P00956554A0414|14 18|serum
P00956554A0414|38 64|various solid-phase allergens
P00956554A0414|71 80|reactivity
P00956554A0414|95 107|IgE antibodies
P00958550T0001|0 5|Crisis
P00958550T0001|11 30|therapeutic community
P00958550T0001|33 44|Great Britain
P00959656A0250|0 12|Pregnant women
P00959656A0250|25 36|lowest levels
P00959656A0250|39 53|antithrombin III
P00959656A0250|39 50|antithrombin
P00961711T0000|0 16|Hematology problem
P00961711T0000|34 36|seg
P00962222A0633|16 31|cyclic variations
P00962222A0633|34 45|heme turnover
P00962222A0633|58 64|changes
P00962222A0633|67 92|erythrocyte characteristics
P00962222A0633|102 118|progesterone phase
P00962277T0000|0 12|Haemodilution
P00962277T0000|15 35|cardiopulmonary bypass
P00962277T0000|42 59|gelatine derivative
P00962277T0000|63 69|priming
P00964758T0001|0 25|Extramedullary plasmacytoma
P00964758T0001|31 42|parotid gland
P00967223T0059|0 1|I.
P00968181A0264|12 17|calves
P00968181A0264|31 38|immunity
P00968181A0264|41 65|homologous severe challenge
P00968181A0264|73 76|days
P00968181A0264|85 98|first infection
P00970320A0000|33 60|chemical cartridge respirators
P00970320A0000|64 66|SO2
P00970320A0000|90 99|conditions
P00970320A0000|103 115|copper smelter
P00970488A0105|3 29|neuroleptic-induced increase
P00970488A0105|32 48|central DA turnover
P00970488A0105|75 92|DA receptor blocking
P00970488A0105|75 84|DA receptor
P00970488A0105|133 149|therapeutic effect
P00970488A0105|152 163|neuroleptics
P00970488A0105|183 207|hypokinetic-rigid symptoms
P00970839A0118|0 11|Rainbow trout
P00970839A0118|29 47|commercial trout farm
P00970839A0118|70 76|feeding
P00970839A0118|79 97|experimental pellets
P00970839A0118|105 109|weeks
P00974901A0080|0 10|Stimulation
P00974901A0080|13 30|macrophage function
P00974901A0080|39 62|Bordetella pertussis cells
P00974901A0080|76 91|beneficial effect
P00974901A0080|105 118|susceptibility
P00975314T0001|0 17|Primary amenorrhoea
P00975314T0001|35 50|female individual
P00975314T0001|56 64|karyotype
P00975314T0001|68 69|xy
P00975314T0001|73 95|bilateral gonadoblastoma
P00975540T0000|6 20|absolute methods
P00975540T0000|23 39|clinical chemistry
P00975540T0000|54 72|mass fragmentography
P00975540T0000|75 95|high-accuracy analyses
P00980255T0000|0 10|Application
P00980255T0000|16 38|2-deoxy-D-glucose method
P00980255T0000|44 51|coupling
P00980255T0000|54 71|cerebral metabolism
P00980255T0000|75 83|blood flow
P00984209A0614|0 17|Serum gastrin levels
P00984209A0614|5 11|gastrin
P00984209A0614|52 87|background serum gastrin concentrations
P00984209A0614|67 73|gastrin
P00984209A0614|105 111|greater
P00984209A0614|115 125|V&P patients
P00984209A0614|130 140|V&A patients
P00985110T0001|0 18|Efferent projections
P00985110T0001|24 37|ventral portion
P00985110T0001|43 49|putamen
P00985110T0001|55 61|frontal
P00985110T0001|63 70|parietal
P00985110T0001|74 88|temporal regions
P00985110T0001|94 110|cat cerebral cortex
P00985276A0000|0 8|Preflight
P00985276A0000|10 17|inflight
P00985276A0000|22 52|postflight exercise response tests
P00985276A0000|71 80|astronauts
P00985276A0000|86 104|second Skylab mission
P00985276A0000|106 111|Skylab
P00985276A0000|136 158|physiological adaptation
P00985276A0000|161 183|long-term weightlessness
P00985279A0493|0 38|Mean corpuscular hemoglobin concentrations
P00985279A0493|15 24|hemoglobin
P00985279A0493|58 58|h
P00985279A0493|81 86|groups
P00985279A0493|91 98|CO2 group
P00985279A0493|109 122|larger decrease
P00986800A0325|3 10|Cu values
P00986800A0325|26 31|organs
P00986800A0325|55 69|saturation level
P00986800A0325|73 83|mug Cu/g diet
P00986800A0325|105 110|values
P00986800A0325|114 119|body Cu
P00986800A0325|130 133|dams
P00986925A0002|11 20|calcitonin
P00986925A0002|23 33|large amount
P00986925A0002|36 42|calcium
P00986925A0002|55 66|pentagastrin
P00986925A0002|70 77|glucagon
P00986925A0002|80 108|plasma 47Ca radioactivity curves
P00986925A0002|111 118|subjects
P00986925A0002|133 136|47Ca
P00987649T0001|0 4|State
P00987649T0001|16 24|disorders
P00987649T0001|27 53|diurnal physiological rhythms
P00987649T0001|57 76|long-term hypokinesia
P00988572A0000|0 12|Oxygen tension
P00988572A0000|18 34|small lymph vessels
P00988572A0000|36 39|PLO2
P00988572A0000|46 59|rabbit hind limb
P00988572A0000|80 103|flow-through micro chamber
P00988572A0000|108 147|polarographic catheter-tip oxygen electrode
P00988572A0000|156 171|experimental data
P00988572A0000|196 200|lymph
P00989973A0000|16 36|plasma fibrinogen level
P00989973A0000|22 31|fibrinogen
P00989973A0000|42 63|subucutaneous injection
P00989973A0000|66 75|turpentine
P00989973A0000|84 103|intravenous injection
P00989973A0000|106 114|endotoxin
P00989973A0000|128 140|normal rabbits
P00989973A0000|146 152|rabbits
P00989973A0000|157 172|granulocytopenic
P00989973A0000|176 191|thrombocytopenic
P00989973A0000|196 203|busulfan
P00992316A0178|10 34|rectilinear pressure curves
P00992316A0178|42 58|uterine activities
P00992316A0178|75 107|characteristic tocographic criteria
P00992316A0178|112 135|advanced ectopic gravidity
P00993176A0066|5 13|myoglobin
P00993176A0066|35 44|hemoglobin
P00993176A0066|50 61|heme pigments
P00993176A0066|91 97|extract
P00993176A0066|116 125|hemoglobin
P00993176A0066|132 132|%
P00993176A0066|134 136|NH4
P00993176A0066|138 149|2SO4 solution
P00996272A0397|16 22|sources
P00996272A0397|39 49|variability
P00996272A0397|55 74|present investigation
P00996272A0397|91 112|systematic instructions
P00996364X0000|0 0|E
P00999494A0000|3 10|patients
P00999494A0000|29 38|acute mania
P00999494A0000|54 62|high doses
P00999494A0000|68 82|beta-adrenergic
P00999494A0000|91 106|agent propranolol
P01000378T0000|0 5|Effect
P01000378T0000|16 29|plasma glucagon
P01000378T0000|22 29|glucagon
P01000378T0000|33 53|insulin concentrations
P01000378T0000|33 39|insulin
P01003819A0498|14 24|nomogram one
P01003819A0498|38 47|refraction
P01003819A0498|53 62|axis length
P01003819A0498|66 81|corneal curvature
P01004298A0744|4 13|up-grading
P01004298A0744|19 28|final score
P01004298A0744|34 44|CA component
P01004298A0744|47 53|greater
P01004298A0744|58 58|%
P01004298A0744|65 80|less able students
P01004298A0744|85 90|scores
P01004298A0744|99 107|mean level
P01009451A0728|10 17|controls
P01009451A0728|23 24|UB
P01009451A0728|28 34|OCS rats
P01009451A0728|50 83|significant post-operative reduction
P01009451A0728|89 100|nocturnality
P01009739T0001|0 5|Effect
P01009739T0001|8 19|indomethacin
P01009739T0001|22 40|coronary circulation
P01009739T0001|50 52|ECG
P01009841T0001|0 14|Dual innervation
P01009841T0001|17 26|fast fibers
P01009841T0001|29 40|trunk muscles
P01009841T0001|43 55|lamprey larvae
P01010638A0161|34 34|%
P01012640T0001|0 21|Certain characteristics
P01012640T0001|24 33|eye changes
P01012640T0001|36 43|patients
P01012640T0001|48 63|pheochromocytoma
P01012640T0001|73 78|Sipple
P01012904A0333|3 30|color-word interference effect
P01012904A0333|53 69|normal populations
P01012904A0333|82 91|Stroop test
P01012904A0333|134 146|special format
P01019207A0232|30 39|conditions
P01019207A0232|41 56|linear dependence
P01019207A0232|73 83|betaI% value
P01019207A0232|87 89|lgC
P01019207A0232|113 125|mug ruscogenin
P01021091T0000|14 29|adrenergic nerves
P01021091T0000|45 56|blood vessels
P01021091T0000|62 70|rabbit ear
P01021091T0000|76 108|phenylalanine-8-lysine vasopressin
P01021091T0000|110 120|Octapressin
P01027644T0001|0 13|Potscoital test
P01030985T0090|0 1|I.
P01035457A0623|5 10|tumour
P01035457A0623|13 34|present nipple discharge
P01035457A0623|39 54|little importance
P01036714A0072|0 6|Studies
P01036714A0072|9 19|biochemical
P01036714A0072|23 42|morphological changes
P01036714A0072|60 73|treated animals
P01036714A0072|83 92|chrysotile
P01036714A0072|115 136|lung free cell population
P01036714A0072|140 164|pulmonary surfactant levels
P01044338A0240|0 19|Infrared measurements
P01044338A0240|22 39|temperature changes
P01044338A0240|43 51|estimates
P01044338A0240|57 63|heating
P01044338A0240|77 81|mical
P01047417T0000|8 32|National Health Dis-service
P01047895T0001|13 32|patient care justified
P01047895T0001|46 61|educational value
P01047895T0001|63 70|Patients
P01047895T0001|102 112|patient care
P01048020T0000|0 7|Critique
P01048020T0000|11 28|Interactive Effects
P01048020T0000|31 41|Test Anxiety
P01048020T0000|45 59|Credit/No Credit
P01048020T0000|62 78|A-F Grade Condition
P01048020T0000|83 92|Short-term
P01048020T0000|96 104|Long-term
P01048020T0000|113 129|Course Information
P01048968A0152|5 11|studies
P01048968A0152|44 56|staphylococci
P01048968A0152|61 69|resistant
P01048968A0152|72 82|penicillin G
P01048968A0152|84 95|erythromycin
P01048968A0152|108 121|beta-lactamase
P01050144A0297|11 23|steep decrease
P01050144A0297|37 52|strains resistant
P01050144A0297|62 76|more antibiotics
P01050144A0297|78 95|multiple-resistant
P01050144A0297|102 108|strains
P01050144A0297|114 123|83A complex
P01050400T0000|0 10|Improvement
P01050400T0000|13 30|nursing instruction
P01050400T0000|51 59|discharge
P01050400T0000|67 70|ward
P01050400T0000|74 89|premature infants
P01057137A0192|17 37|clinical acceptability
P01057137A0192|69 74|groups
P01064124A0560|7 7|d
P01064124A0560|9 18|subsurface
P01064124A0560|20 47|radiolucent caries-like lesion
P01064124A0560|64 72|specimens
P01067493A0119|3 22|contraceptive pattern
P01067493A0119|28 32|women
P01067493A0119|51 57|percent
P01067493A0119|67 84|inefficient methods
P01071715A0903|0 24|Plethysmographic technique
P01071715A0903|28 58|indirect blood pressure recordings
P01075075T0038|0 1|I.
P01078982A0227|44 67|combined cyclophosphamide
P01078982A0227|69 90|antilymphocyte globulin
P01078982A0227|92 94|ALG
P01078982A0227|109 125|ALG administration
P01078982A0227|137 147|small dosage
P01078982A0227|150 165|cyclophosphamide
P01078982A0227|181 191|ineffective
P01080374A0709|0 7|Evidence
P01080374A0709|23 27|Leber
P01080374A0709|30 54|military aneurysm retinitis
P01080374A0709|61 74|separate entity
P01080374A0709|79 89|special form
P01080374A0709|92 96|Coats
P01081904A0198|0 5|Fibrin
P01081904A0198|22 29|catheter
P01081904A0198|42 49|patients
P01081904A0198|59 79|pull-out arteriography
P01081904A0198|86 97|unassociated
P01081904A0198|102 117|clinical symptoms
P01082726A0248|15 25|mobile pupil
P01082726A0248|44 49|DC-ERG
P01082833A0000|17 38|anti-inflammatory agent
P01082833A0000|40 45|Y-8004
P01082833A0000|59 75|greater inhibition
P01082833A0000|83 94|indomethacin
P01082833A0000|96 97|IM
P01082833A0000|102 125|inflammatory response such
P01082833A0000|128 146|ultraviolet erythema
P01082833A0000|149 158|guinea pigs
P01082833A0000|160 175|carrageenin edema
P01082833A0000|189 216|carrageenin-induced pleuritis
P01082833A0000|220 248|acetic acid-induced peritonitis
P01082833A0000|251 254|rats
P01083321X0000|2 7|stands
P01083321X0000|17 25|dominance
P01083321X0000|47 58|subalpine fir
P01083321X0000|96 100|rates
P01083321X0000|103 126|whole-forest productivity
P01083321X0000|132 137|stands
P01083321X0000|158 165|years old
P01083375T0000|0 17|Alpha-1 antitrypsin
P01083375T0000|21 44|Indian childhood cirrhosis
P01083784T0000|0 23|Lymphocyte subpopulations
P01083784T0000|25 32|serum IgE
P01083784T0000|30 32|IgE
P01083784T0000|36 56|total eosinophil counts
P01083784T0000|59 66|patients
P01083784T0000|71 85|bronchial asthma
P01084413A0271|8 36|normal ventricular measurements
P01084413A0271|43 45|EMI
P01087288T0000|24 43|cytogenetic estimates
P01087288T0000|46 58|radiation dose
P01087288T0000|61 68|patients
P01087288T0000|80 89|iodine-131
P01087288T0000|93 108|thyroid carcinoma
P01088654T0001|0 8|Technique
P01088654T0001|21 35|refined ceramics
P01088654T0001|40 48|dense mass
P01090210A0417|0 20|Mean total lung capacity
P01090210A0417|22 47|functional residual capacity
P01090210A0417|52 65|residual volume
P01090210A0417|95 111|mean closing volume
P01090210A0417|116 125|lung volume
P01090210A0417|131 144|residual volume
P01090210A0417|194 230|cm H20 continuous positive airway pressure
P01090210A0417|232 242|differences
P01090210A0417|246 250|cm H20
P01092248T0000|0 12|Current status
P01092248T0000|15 28|zinc deficiency
P01092248T0000|34 45|pathogenesis
P01092248T0000|48 59|neurological
P01092248T0000|61 74|dermatological
P01092248T0000|78 101|musculoskeletal disorders
P01093055T0000|0 6|Calcium
P01093055T0000|10 29|phosphorus metabolism
P01093055T0000|32 44|chronic uremia
P01093845A0208|0 12|Modern studies
P01093845A0208|27 37|Delta-9-THC
P01093845A0208|41 58|healthy voluntaries
P01093845A0208|107 119|modifications
P01093845A0208|128 135|cannabis
P01093847A0000|21 44|tropatepine hydrochloride
P01093847A0000|52 72|extrapyramidal effects
P01093847A0000|82 93|neuroleptics
P01093847A0000|112 131|acute psychotic states
P01096741X0000|0 15|Epididymal growth
P01096741X0000|29 35|animals
P01096741X0000|54 66|chickpea haulm
P01096741X0000|82 96|supplementation
P01097100A0217|3 10|patients
P01097100A0217|30 37|regimens
P01098179A0167|0 6|Results
P01098179A0167|18 55|chloramphenicol-containing preparations
P01098179A0167|76 92|dissolution curves
P01098179A0167|96 110|cup-plate assays
P01098179A0167|126 140|chloramphenicol
P01098179A0167|147 161|superior release
P01098179A0167|184 189|creams
P01098179A0167|198 216|ophthalmic ointments
P01098592A0567|0 8|IgG levels
P01098592A0567|0 2|IgG
P01098592A0567|45 51|samples
P01098592A0567|63 66|days
P01098592A0567|75 87|clinical onset
P01099693T0000|0 5|Letter
P01099693T0000|7 18|Perspectives
P01099693T0000|21 45|bone marrow transplantation
P01101272T0000|0 9|Assessment
P01101272T0000|15 29|carcinogenicity
P01101272T0000|32 53|non-nutritive sweetners
P01101272T0000|57 66|Cyclamates
P01101272T0000|70 84|cyclohexylamine
P01103390A0149|3 21|discordant behaviour
P01103390A0149|30 41|infected mice
P01103390A0149|53 62|occurrence
P01103390A0149|69 75|animals
P01103390A0149|79 89|second phase
P01103390A0149|92 108|more rapid increase
P01103390A0149|114 124|parasitemia
P01107226A0808|0 20|Residual amphotericin B
P01107226A0808|37 41|feces
P01107226A0808|47 50|mice
P01107226A0808|83 96|mg/ml dose level
P01113908A0475|9 22|slight increase
P01113908A0475|25 40|total transferrin
P01113908A0475|42 43|hr
P01113908A0475|50 55|tablet
P01113908A0475|59 64|values
P01116254A0000|9 33|intravenous administration
P01116254A0000|38 60|myocardial concentration
P01116254A0000|63 80|tracer thallium-201
P01116254A0000|82 93|potassium-43
P01116254A0000|98 108|rubidium-81
P01116254A0000|125 128|mice
P01116254A0000|130 137|thallium
P01116254A0000|153 173|greatest concentration
P01116254A0000|179 188|myocardium
P01116254A0000|194 194|%
P01116254A0000|207 207|%
P01116254A0000|211 219|potassium
P01116254A0000|227 227|%
P01116254A0000|231 238|rubidium
P01116254A0000|243 249|minutes
P01116466A0185|0 17|Thromboplastin time
P01116466A0185|0 13|Thromboplastin
P01116466A0185|19 43|partial thromboplastin time
P01116466A0185|26 39|thromboplastin
P01116466A0185|45 56|thrombin time
P01116466A0185|45 52|thrombin
P01116466A0185|58 77|heat-dependent fibrin
P01116466A0185|79 92|clot retraction
P01116466A0185|97 111|clotting factors
P01116466A0185|115 115|V
P01116466A0185|117 120|VIII
P01116466A0185|125 125|X
P01116466A0185|133 145|platelet count
P01118293A0150|27 37|suppression
P01118293A0150|40 45|images
P01118293A0150|52 67|binocular rivalry
P01118293A0150|87 90|eyes
P01119586A0337|0 18|Glycogen utilization
P01119586A0337|35 46|tissue levels
P01119586A0337|49 65|creatine phosphate
P01119586A0337|67 69|ATP
P01119586A0337|74 80|lactate
P01119586A0337|101 106|hearts
P01119586A0337|116 125|normal flow
P01119658A0000|3 9|records
P01119658A0000|44 60|untreated patients
P01119658A0000|65 85|squamous cell carcinoma
P01119658A0000|91 100|oral cavity
P01119658A0000|102 111|oropharynx
P01119658A0000|113 130|supraglottic larynx
P01119658A0000|134 144|hypopharynx
P01119658A0000|161 195|positive cervical lymph node metastases
P01119658A0000|202 203|N1
P01119658A0000|205 207|N2A
P01119658A0000|211 213|N2B
P01119658A0000|223 242|initial neck treatment
P01119658A0000|254 277|external radiation therapy
P01122015A0467|7 9|vol
P01122015A0467|12 12|%
P01122015A0467|17 35|corresponding values
P01122015A0467|43 49|mumol/1
P01122015A0467|55 62|mg/100 ml
P01122015A0467|70 76|mumol/1
P01122015A0467|82 89|mg/100 ml
P01123658A0000|3 9|authors
P01123658A0000|32 56|transverse axial tomography
P01123658A0000|75 93|detailed description
P01123658A0000|99 110|axial anatomy
P01123658A0000|116 132|normal lumbar spine
P01123658A0000|137 139|L-4
P01123658A0000|145 150|sacrum
P01124944A0830|7 22|parental attitude
P01124944A0830|25 38|low protein diet
P01124944A0830|43 46|g/kg
P01125117A0183|18 24|attacks
P01125117A0183|36 42|attacks
P01125117A0183|63 80|circulatory changes
P01125117A0183|112 117|groups
P01128985A0000|11 32|useful diagnostic method
P01128985A0000|76 82|periods
P01128985A0000|85 89|apnea
P01128985A0000|92 108|pediatric patients
P01130186A0568|3 27|other hypoglycaemic patient
P01130186A0568|36 60|exaggerated insulin release
P01130186A0568|47 53|insulin
P01130186A0568|73 83|tolbutamide
P01130531A0224|0 15|Nerve stimulation
P01130531A0224|23 30|cycles/s
P01130531A0224|40 68|frequency-dependent reductions
P01130531A0224|71 73|CBF
P01130531A0224|88 94|percent
P01130531A0224|111 126|highest frequency
P01131946T0001|0 5|Effect
P01131946T0001|8 16|ingestion
P01131946T0001|19 28|Norbiogest
P01131946T0001|38 52|quiescent period
P01131946T0001|58 70|genital organs
P01138215T0001|0 3|Risk
P01138215T0001|31 39|fractures
P01138330A0204|0 12|Bulbar pouches
P01138330A0204|29 37|solutions
P01138330A0204|43 47|% Na C1
P01138330A0204|52 55|N HC1
P01138330A0204|59 66|% glucose
P01138330A0204|70 74|% NaC1
P01138330A0204|81 88|% peptone
P01138330A0204|98 107|% solutions
P01138330A0204|110 130|acetylcholine chloride
P01140184A0342|0 14|Liver microsomes
P01140184A0342|30 36|smaller
P01140184A0342|42 42|%
P01140184A0342|48 69|epoxide hydrase activity
P01140184A0342|48 61|epoxide hydrase
P01140184A0342|73 79|smaller
P01140184A0342|86 86|%
P01140184A0342|115 129|liver microsomes
P01141114A0188|0 17|Prolonged heavy work
P01141114A0188|56 59|mmHg
P01141114A0188|68 70|P50
P01141114A0188|76 79|PH-v
P01141114A0188|83 92|degrees C-v
P01141114A0188|99 104|Pv-CO2
P01141114A0188|123 137|additive effects
P01141114A0188|149 165|venous temperature
P01141114A0188|170 170|H
P01145884T0028|10 20|serological
P01145884T0028|24 38|prognostic study
P01147436T0000|3 33|American Burkitt Lymphoma Registry
P01147436T0000|36 49|progress report
P01147502T0000|0 9|Vitrectomy
P01147502T0000|16 42|alternative instrument system
P01148868A0284|3 24|metabolic clearance rate
P01148868A0284|27 38|progesterone
P01148868A0284|51 54|S.E.
P01148868A0284|56 60|1/day
P01150658A0683|39 61|human luteinizing hormone
P01150658A0683|63 68|Sairam
P01150658A0683|70 71|M.
P01156631A0658|3 31|mean plasma sodium concentration
P01156631A0658|50 51|SD
P01156631A0658|57 62|mEq/kg
P01156631A0658|69 85|diuretic treatment
P01156631A0658|138 139|SD
P01156631A0658|145 150|mEq/kg
P01156631A0658|152 156|P less
P01156814T0000|0 8|Editorial
P01156814T0000|10 24|Low-dose heparin
P01156814T0000|43 69|venous thromboembolic disease
P01157191A0536|9 22|high dose levels
P01157191A0536|28 42|sodium saccharin
P01157191A0536|46 60|sodium cyclamate
P01157191A0536|65 87|weak solitary carcinogens
P01157191A0536|110 123|bladder tumours
P01157191A0536|155 161|tumours
P01157191A0536|187 191|weeks
P01157614T0000|0 6|Effects
P01157614T0000|9 26|perceptual salience
P01157614T0000|32 52|matrix task performance
P01157614T0000|63 82|six-year-old children
P01158512T0000|0 31|Glucose-6-phosphate dehydrogenase
P01158512T0000|33 38|G-6-PD
P01158512T0000|40 49|deficiency
P01158512T0000|55 61|newborn
P01158838A0438|3 16|eluting solvent
P01158838A0438|20 38|methanol-chloroform
P01158838A0438|49 56|flow rate
P01158838A0438|62 67|ml/min
P01159822A0353|3 20|bronchial epithelia
P01159822A0353|26 45|smoke-exposed animals
P01159822A0353|50 61|hyperplastic
P01159822A0353|71 84|ultrastructure
P01159822A0353|91 103|invaginations
P01159822A0353|105 108|tilt
P01159822A0353|111 121|nuclear axes
P01159822A0353|153 161|lysosomes
P01159822A0353|165 186|multivesiculated bodies
P01159822A0353|200 206|numbers
P01159822A0353|209 242|enlarged intramitochondrial granules
P01168607A0672|3 23|routine administration
P01168607A0672|26 44|fat-soluble vitamins
P01168607A0672|52 62|unnecessary
P01168607A0672|70 76|prudent
P01168607A0672|86 100|prothrombin time
P01168607A0672|86 96|prothrombin
P01168607A0672|104 116|serum vitamins
P01168607A0672|121 121|E
P01168607A0672|124 132|intervals
P01168908A0000|0 14|Prostaglandins F
P01168908A0000|16 18|PGF
P01168908A0000|34 44|uterine vein
P01168908A0000|46 58|ovarian artery
P01168908A0000|63 79|jugular vein plasma
P01168908A0000|88 105|endometrial tissues
P01168908A0000|108 119|various times
P01168908A0000|129 146|bovine estrous cycle
P01168908A0000|165 198|peripheral plasma progesterone levels
P01168956A0552|38 52|fetal weight gain
P01168956A0552|80 87|placenta
P01168956A0552|94 102|transient
P01168956A0552|121 141|maximum weight decrease
P01168956A0552|155 155|h
P01170143A0247|0 5|Groups
P01170143A0247|26 35|saline mice
P01170143A0247|66 79|dark conditions
P01170143A0247|92 107|covered cylinders
P01171020A0711|3 9|effects
P01171020A0711|26 46|nucleus accumbens septi
P01171020A0711|55 60|marked
P01171935A0313|15 41|dyskinetic movement disorders
P01171935A0313|44 49|humans
P01171935A0313|62 71|chronic use
P01171935A0313|74 81|levodopa
P01171935A0313|84 94|amphetamine
P01171935A0313|101 113|manifestation
P01171935A0313|134 164|dopamine receptor site sensitivity
P01171935A0313|174 181|striatum
P01172734T0035|0 10|Association
P01172734T0035|15 22|HL-A W-27
P01172917T0000|0 5|Letter
P01172917T0000|7 27|Lactose tolerance tests
P01172917T0000|31 39|predictor
P01172917T0000|42 54|milk tolerance
P01174873T0000|0 13|Retinoblastoma
P01174873T0000|23 36|natural history
P01174873T0000|40 48|prognosis
P01174873T0000|54 58|cases
P01176905A0094|4 18|pineal melatonin
P01176905A0094|20 33|serum melatonin
P01176905A0094|43 50|mid-dark
P01176905A0094|59 67|mid-light
P01178153A0056|0 1|D.
P01178637T0001|0 14|Atherosclerosis
P01185956A0722|3 9|authors
P01185956A0722|23 52|ultrasonic Doppler-cardiography
P01185956A0722|77 91|relative changes
P01185956A0722|97 108|stroke volume
P01186344A0303|3 12|attainment
P01186344A0303|15 28|sexual maturity
P01186344A0303|38 67|secondary sexual characteristics
P01186344A0303|84 94|spermatozoa
P01186344A0303|111 131|cyclical female pattern
P01186344A0303|145 147|ova
P01186344A0303|151 160|end-points
P01186344A0303|166 185|developmental process
P01190120A0832|15 26|% lengthening
P01190120A0832|32 56|partial thromboplastin time
P01190120A0832|39 52|thromboplastin
P01190120A0832|73 77|hours
P01190251A0335|0 6|Caution
P01190251A0335|39 42|dyes
P01190251A0335|46 56|lymphograms
P01191955A0077|12 18|new test
P01191955A0077|22 47|short saphenous incompetence
P01191955A0077|65 68|cent
P01191955A0077|71 77|varices
P01191955A0077|87 108|saphenopopliteal reflux
P01191964A0000|5 10|groups
P01191964A0000|13 20|patients
P01191964A0000|36 56|subtotal thyroidectomy
P01191964A0000|60 65|Graves
P01191964A0000|76 98|toxic multinodular goitre
P01191964A0000|102 128|euthyroid multinodular goitre
P01191964A0000|135 139|years
P01191964A0000|156 175|normal serum thyroxine
P01191964A0000|177 179|T-4
P01191964A0000|216 224|subgroups
P01191964A0000|253 282|serum thyrotrophin concentration
P01191964A0000|258 269|thyrotrophin
P01193458T0001|0 24|Routine isotope cystography
P01193458T0001|33 47|Tc sulfur colloid
P01193458T0001|51 59|detection
P01193458T0001|63 71|follow-up
P01193458T0001|74 94|vesico-ureteral reflux
P01193770T0000|0 11|Air ion action
P01194673A0652|28 46|negative chemography
P01201977T0000|19 45|antibiotic disc sensitivities
P01202616A0466|9 21|retransfusion
P01202616A0466|26 49|affected epithelial lining
P01202616A0466|81 103|oedematous lamina propria
P01202616A0466|115 126|complete loss
P01202616A0466|129 144|structural detail
P01206772T0000|8 18|chromosomes
P01206772T0000|21 31|lymphocytes
P01206772T0000|36 43|patients
P01206772T0000|55 64|hycanthone
P01206896T0001|0 14|Characteristics
P01206896T0001|17 26|anesthesia
P01206896T0001|30 42|resuscitation
P01206896T0001|45 64|emergency lung surgery
P01208811T0001|0 4|Study
P01208811T0001|10 30|physico-chemical state
P01208811T0001|33 45|plutonium-239
P01208811T0001|49 75|citrate solution-blood system
P01209618A0409|0 9|Tobramycin
P01209618A0409|12 13|mg
P01209618A0409|27 42|remarkable effect
P01209618A0409|47 55|dibecacin
P01209618A0409|59 60|mg
P01209618A0409|70 93|slight potentiating effect
P01209618A0409|107 120|d-tubocurarine
P01211754A0192|20 24|cases
P01211754A0192|47 51|tonal
P01211754A0192|55 70|vocal improvement
P01211754A0192|74 81|patients
P01211754A0192|95 123|progressive perceptive deafness
P01215067A0000|3 30|specific electrical resistance
P01215067A0000|36 53|cerebrospinal fluid
P01215067A0000|67 71|means
P01215067A0000|74 86|conductometry
P01215067A0000|91 95|cases
P01215067A0000|98 116|meningitis purulenta
P01215067A0000|120 124|cases
P01215067A0000|127 142|meningitis serosa
P01215067A0000|146 150|cases
P01215067A0000|153 164|encephalitis
P01215067A0000|172 186|control subjects
P01217450A0295|2 18|Chemical occlusion
P01217450A0295|75 78|dogs
P01224116A0576|18 25|patients
P01224116A0576|35 54|serum immunoglobulins
P01224116A0576|63 65|IgG
P01224116A0576|69 78|first Russe
P01224116A0576|80 84|Busey
P01224116A0576|88 94|Barbeau
P01224116A0576|110 135|large French-Canadian family
P01225339A0590|13 26|such occlusions
P01225339A0590|49 58|infarction
P01228258A0000|0 23|Streptococcal preparation
P01228258A0000|25 30|OK-432
P01228258A0000|34 40|new type
P01228258A0000|43 58|anti-cancer agent
P01228258A0000|73 80|patients
P01228258A0000|85 98|advanced cancer
P01228258A0000|116 126|Mitomycin-C
P01228258A0000|128 131|5-FU
P01228258A0000|135 153|Cytosine arabinoside
P01228882A0437|40 60|highest concentrations
P01228882A0437|63 80|CSF immunoglobulins
P01228882A0437|92 120|meningeal inflammatory response
P01228882A0437|147 171|other neurological diseases
P01233561T0001|0 16|Maternal lactation
P01235347T0001|0 25|Experimental cardiotoxicity
P01235347T0001|28 37|adriamycin
P01236224T0001|0 16|Muscular pathology
P01237206A0199|0 12|Demonstration
P01237206A0199|42 44|6th
P01237206A0199|50 60|11th day p.i.
P01237206A0199|63 86|direct microscopic methods
P01237206A0199|88 92|Stamp
P01237206A0199|96 111|auramine staining
P01237206A0199|113 140|fluorescent antibody technique
P01237206A0199|146 160|Coxiella content
P01237206A0199|176 184|titration
P01237206A0199|198 200|hen
P01237206A0199|203 206|eggs
P01241437A0152|3 10|patients
P01241437A0152|27 32|groups
P01241437A0152|42 46|NLA II
P01241437A0152|60 69|nalorphine
P01241437A0152|71 78|morphine
P01241437A0152|81 87|Micoren
P01241588A1470|3 13|alterations
P01241588A1470|16 19|5-HT
P01241588A1470|23 34|5-HIAA levels
P01241588A1470|37 50|several regions
P01241588A1470|69 78|conditions
P01241588A1470|102 105|IDPN
P01241588A1470|108 120|neurotoxicity
P01241588A1470|137 159|5-HT-containing neurones
P01241866A0682|15 30|leukocyte-counts
P01241866A0682|60 64|serum
P01241866A0682|89 95|phase-2
P01242636A0678|3 9|results
P01242636A0678|36 60|reticuloendothelial system
P01242636A0678|81 98|beryllium retention
P01243628A0286|6 10|cases
P01243628A0286|33 41|same level
P01243628A0286|44 65|blood carboxyhemoglobin
P01243628A0286|49 65|carboxyhemoglobin
P01243628A0286|67 70|COHb
P01243628A0286|80 80|%
P01244236A1122|3 9|results
P01244236A1122|31 48|pulmonary blood flow
P01244236A1122|61 87|pulmonary vascular resistance
P01244236A1122|101 109|gestation
P01244236A1122|133 143|total number
P01244236A1122|146 152|vessels
P01244236A1122|165 183|vasomotor reactivity
P01244236A1122|210 220|total amount
P01244236A1122|223 234|smooth muscle
P01244236A1122|243 251|thickness
P01244236A1122|262 278|individual vessels
P01245162A0262|0 8|Reduction
P01245162A0262|11 16|dosage
P01245162A0262|25 40|normal taste sense
P01245162A0262|105 126|high transaminase levels
P01246210A0648|3 14|calcium ratio
P01246210A0648|16 24|mean ratio
P01246210A0648|49 52|TBCa
P01246210A0648|56 58|men
P01246210A0648|73 73|%
P01246210A0648|79 83|women
P01246210A0648|95 95|%
P01247475A0000|1 13|late diagnosis
P01247475A0000|16 29|retinoblastoma
P01247475A0000|34 51|unquestionable fact
P01247475A0000|82 94|deterioration
P01247475A0000|100 106|outlook
P01248124A0281|0 15|Total cholesterol
P01248124A0281|29 42|amniotic fluids
P01248124A0281|54 68|different stages
P01248124A0281|71 79|gestation
P01249198A1097|3 23|serum FT3 concentration
P01249198A1097|40 45|higher
P01249198A1097|53 58|ranges
P01249198A1097|61 75|normal pregnancy
P01249198A1097|80 90|GTD patients
P01249198A1097|98 120|clinical hyperthyroidism
P01252223A0347|3 9|authors
P01252223A0347|35 43|pugnacity
P01252223A0347|47 75|husband-wife trait correlations
P01252223A0347|101 105|Winch
P01252223A0347|124 138|complementarity
P01253191T0000|10 43|phase-plane technique representation
P01253191T0000|46 68|cardiac action potentials
P01256410T0001|1 10|activities
P01256410T0001|37 49|newborn infant
P01259027A0416|13 37|structural identifiability
P01259027A0416|79 93|model parameters
P01259027A0416|144 159|input-output data
P01259027A0416|162 182|step-by-step procedure
P01259027A0416|239 253|overall approach
P01259027A0416|259 283|experimental design problem
P01261005A0711|19 37|lot-to-lot variation
P01261005A0711|41 51|differences
P01261005A0711|72 85|narrow bandpass
P01261005A0711|89 118|wide bandpass spectrophotometers
P01262596T0000|3 20|cochlear compromise
P01264640T0028|15 20|Saigon
P01265443A0159|0 16|Hypertonic glucose
P01265443A0159|45 63|Heidenhain pouch dogs
P01265443A0159|76 90|equal inhibition
P01265443A0159|93 125|pentagastrin-induced acid secretion
P01265443A0159|133 137|pouch
P01265443A0159|144 154|main stomach
P01265443A0159|163 178|hypertonic saline
P01265887T0001|8 26|factor VIII inhibitor
P01265887T0001|8 17|factor VIII
P01265887T0001|29 50|non-hemophilic patients
P01267446A0210|0 15|Biohydrogenation
P01267446A0210|18 29|linoleic acid
P01267446A0210|34 49|octadecenoic acid
P01272816A0000|10 26|calcium metabolism
P01272816A0000|32 51|thalassaemic children
P01272816A0000|69 76|controls
P01272816A0000|82 99|oral administration
P01272816A0000|102 105|47Ca
P01272816A0000|124 143|intestinal absorption
P01275335A0158|0 15|Chlamydial agents
P01275335A0158|35 39|semen
P01275335A0158|55 70|chlamydemic phase
P01275541A0405|21 31|CPK activity
P01275541A0405|21 23|CPK
P01275541A0405|39 52|normal newborns
P01275541A0405|66 95|Duchenne-type muscular dystrophy
P01275541A0405|117 124|few weeks
P01276105A0313|14 28|insulin response
P01276105A0313|14 20|insulin
P01276105A0313|45 61|non-pregnant value
P01276105A0313|67 75|second day
P01276105A0313|81 90|puerperium
P01278251A0000|3 9|authors
P01278251A0000|19 25|results
P01278251A0000|37 54|toxicological tests
P01278251A0000|66 81|plastic materials
P01278251A0000|83 94|polyethylene
P01278251A0000|109 128|tetraphenylbutadiene
P01278251A0000|130 132|TPB
P01278251A0000|136 143|additive
P01278251A0000|163 179|sensitizer capable
P01278251A0000|196 211|plastic materials
P01279197T0000|0 17|Mutational analysis
P01279197T0000|23 41|major homology region
P01279197T0000|44 66|Mason-Pfizer monkey virus
P01279197T0000|74 94|saturation mutagenesis
P01279352A0297|8 10|PAL
P01279352A0297|29 48|bp sequence GGGGAGGAGG
P01279352A0473|0 14|Nuclear extracts
P01279352A0473|31 36|neural
P01279352A0473|40 58|non-neural cell lines
P01279352A0473|60 69|mouse brain
P01279352A0473|74 83|mouse liver
P01279352A0473|91 98|proteins
P01279352A0473|124 127|PROX
P01279352A0473|131 142|PAL sequences
P01279352A0473|157 164|proteins
P01279352A0473|181 195|target sequences
P01279352A1197|16 17|NF
P01279352A1197|19 19|H
P01279352A1197|21 28|promoter
P01279352A1197|46 65|tissue specific manner
P01279352A1197|72 96|development transgenic mice
P01279352A1197|110 123|promoter region
P01279352A1197|133 162|beta-galactosidase reporter gene
P01279374A0396|23 34|more new genes
P01279374A0396|47 72|allele-specific suppressors
P01279374A0396|90 115|carboxy-terminal truncation
P01279374A0396|118 123|PET122
P01279696A0862|0 14|Previous studies
P01279696A0862|25 32|Hisanaga
P01279696A0862|34 35|S.
P01279696A0862|37 44|Kusubata
P01279696A0862|46 47|M.
P01279696A0862|49 55|Okumura
P01279696A0862|57 58|E.
P01279696A0862|60 68|Kishimoto
P01279696A0862|70 71|T.
P01280413T0001|0 8|Treatment
P01280413T0001|12 19|staining
P01280413T0001|22 27|smears
P01280413T0001|31 38|sections
P01280413T0001|42 50|detection
P01280413T0001|53 66|microorganisms
P01280807A0575|3 12|apparent Kd
P01280807A0575|18 41|MetRS/CAU operator complex
P01280807A0575|47 66|order magnitude higher
P01280807A0575|80 103|ThrRS/CGU operator complex
P01281322A0604|1 29|significant direct relationship
P01281322A0604|51 68|percent area density
P01281322A0604|71 82|smooth muscle
P01281322A0604|89 101|percent change
P01281322A0604|104 122|peak urinary flow rate
P01281472T0000|0 29|Rabbit skeletal muscle glycogenin
P01281771T0000|0 15|Characterization
P01281771T0000|21 29|human gene
P01281771T0000|38 48|cytokeratin
P01281771T0000|57 73|expression pattern
P01282014A0275|0 6|Animals
P01282014A0275|19 23|DSP-4
P01282014A0275|51 63|motor recovery
P01282014A0275|79 89|saline group
P01282638A0934|3 17|prophylactic use
P01282638A0934|20 32|new medication
P01282638A0934|36 43|patients
P01282638A0934|62 72|second cycle
P01282638A0934|75 86|chemotherapy
P01282638A0934|106 114|estimates
P01282638A0934|137 151|health care costs
P01282638A0934|188 195|patients
P01282638A0934|208 219|continuation
P01282638A0934|223 241|therapeutic schedule
P01282638A0934|249 260|interruption
P01282638A0934|279 292|life expectancy
P01284032A0213|0 1|AP
P01284032A0213|14 32|intraductal infusion
P01284032A0213|38 60|different concentrations
P01284032A0213|63 82|glycodeoxycholic acid
P01284032A0213|84 87|GDOC
P01284032A0213|90 93|mmol
P01284032A0213|99 102|mmol
P01284595A0102|54 64|Y-231 cosmid
P01284595A0102|77 92|CpG rich sequences
P01284595A0102|94 103|HTF islands
P01284595A0102|110 120|human insert
P01284828T0001|0 25|Tissue plasminogen activator
P01284828T0001|30 38|inhibitor
P01284828T0001|42 56|other parameters
P01284828T0001|59 70|fibrinolysis
P01284828T0001|80 87|patients
P01284828T0001|99 113|mild hypertrophy
P01284828T0001|119 126|prostate
P01285009A0000|0 13|Gene constructs
P01285009A0000|26 43|human growth hormone
P01285009A0000|45 47|hGH
P01285009A0000|61 87|promoter/regulatory sequence
P01285009A0000|90 109|mouse metallothionein
P01285009A0000|111 113|mMT
P01285009A0000|116 135|viral thymidine kinase
P01285009A0000|137 139|vTK
P01285009A0000|142 159|rat cholecystokinin
P01285009A0000|161 164|rCCK
P01285009A0000|169 185|chicken beta-actin
P01285009A0000|187 189|cBA
P01285009A0000|214 222|cytoplasm
P01285009A0000|235 244|medaka eggs
P01285009A0000|251 259|micropyle
P01285358A0396|0 11|Serum gastrin
P01285358A0396|5 11|gastrin
P01285358A0396|15 23|AFP levels
P01285358A0396|15 17|AFP
P01285358A0396|30 42|same evolution
P01285358A0396|61 72|same interest
P01285554T0000|0 8|Prospects
P01285554T0000|12 37|controlled-delivery systems
P01285807A0365|11 12|SD
P01285807A0365|14 17|PaO2
P01285807A0365|42 45|mmHg
P01285807A0365|65 68|mmHg
P01285807A0365|77 84|infusion
P01285807A0365|86 86|P
P01285807A0365|99 103|PaCO2
P01285807A0365|139 142|mmHg
P01285807A0365|144 144|P
P01286732A0572|6 17|hepatomegaly
P01286732A0572|21 33|mild elevation
P01286732A0572|36 42|enzymes
P01286732A0572|59 79|significant proportion
P01286732A0572|82 89|patients
P01286732A0572|118 131|acute hepatitis
P01286732A0572|134 150|liver cell necrosis
P01286732A0572|164 183|uncommon complication
P01286732A0572|186 204|P. falciparum malaria
P01287197A0761|6 15|first group
P01287197A0761|20 34|maximal decrease
P01287197A0761|37 51|plasma potassium
P01287197A0761|62 71|salbutamol
P01287197A0761|113 118|mmol/l
P01287197A0761|129 139|second group
P01287197A0761|141 156|maximal decrement
P01287197A0761|198 203|mmol/l
P01287197A0761|210 211|iv
P01287197A0761|213 214|po
P01292230A0283|6 10|drugs
P01292230A0283|28 48|early diastolic filling
P01294345A0591|14 38|significant improvement due
P01294345A0591|60 68|Bromergon
P01294345A0591|82 89|symptoms
P01294345A0591|104 119|overreactiveness
P01294345A0591|122 142|normal prolactin levels
P01294345A0591|128 136|prolactin
P01294345A0591|148 163|abdominal tension
P01294345A0591|165 169|edema
P01294345A0591|171 180|weight gain
P01294345A0591|184 199|breast tenderness
P01295373A0651|17 29|early response
P01295373A0651|41 41|%
P01295373A0651|44 44|A
P01295373A0651|46 56|% baseline RL
P01295373A0651|65 66|SE
P01295373A0651|91 91|B
P01295373A0651|100 100|%
P01295373A0651|105 105|C
P01295373A0651|115 115|%
P01295373A0651|118 118|p
P01295500A0366|0 3|Most
P01295500A0366|9 16|patients
P01295500A0366|30 53|Transient Ischemic Attacks
P01295500A0366|57 57|%
P01295500A0366|61 96|Reversible Ischemic Neurologic Deficits
P01295500A0366|100 100|%
P01296815A0059|11 24|third human gene
P01296815A0059|31 34|LD78
P01296815A0059|42 50|LD78 gamma
P01296815A0059|57 72|sequence analysis
P01296815A0059|100 109|pseudogene
P01297332A0983|44 47|SCBs
P01297332A0983|63 88|known SWI4,6-dependent genes
P01297332A0983|68 71|SWI4
P01297332A0983|73 88|6-dependent genes
P01297332A0983|118 134|consensus sequence
P01297332A0983|142 167|important regulatory element
P01297332T0000|0 17|Mutational analysis
P01297332T0000|21 31|DNA sequence
P01297332T0000|49 62|gene expression
P01297332T0000|68 76|cell cycle
P01298173A0153|3 16|natural history
P01298173A0153|24 30|lesions
P01298173A0153|32 53|locoregional efficiency
P01298173A0153|59 77|different treatments
P01298173A0153|98 109|chemotherapy
P01298173A0153|136 156|therapeutic modalities
P01298173A0153|164 174|last measure
P01298398A0461|40 55|nadolol racemate A
P01298398A0461|67 88|mobile phase composition
P01299489A0788|35 48|little evidence
P01299489A0788|62 76|supplementation
P01299489A0788|79 97|athletic performance
P01299489A0788|101 108|athletes
P01299489A0788|121 131|dietary RDIs
P01300914A1066|14 33|histological criteria
P01300914A1066|72 82|variability
P01300914A1066|85 91|results
P01300914A1066|95 110|potential dangers
P01300914A1066|113 132|endomyocardial biopsy
P01300914A1066|142 149|such thin
P01300914A1066|153 175|fragile ventricular walls
P01300914A1066|191 194|ACRV
P01300914A1066|209 228|concomitant existence
P01300914A1066|235 262|electrophysiological criteria
P01300914A1066|264 285|ventricular arrhythmias
P01300914A1066|289 321|particular sustained monomorphous VT
P01300914A1066|330 346|particular feature
P01300914A1066|354 363|high degree
P01300914A1066|379 399|adrenergic stimulation
P01300914A1066|425 438|late potentials
P01300914A1066|444 463|high amplification ECG
P01300914A1066|472 483|specific sign
P01300914A1066|506 520|poor sensitivity
P01300914A1066|523 536|localized froms
P01300914A1066|578 600|segmentary morphological
P01300914A1066|604 625|kinetic RV abnormalities
P01300914A1066|647 663|localized akinetic
P01300914A1066|666 691|dyskinetic parietal vaulting
P01300914A1066|697 702|stasis
P01301171A0979|6 10|cases
P01301171A0979|15 22|enhancer
P01301171A0979|35 55|c-myc bearing sequences
P01301171A0979|58 67|chromosome
P01302765A0999|5 14|components
P01302765A0999|23 30|median R2
P01302765A0999|48 56|median R2s
P01302765A0999|105 114|components
P01304515A0178|11 17|results
P01304515A0178|34 45|control group
P01304515A0178|49 64|female volunteers
P01304809T0001|3 7|years
P01304809T0001|10 18|dentistry
P01304809T0001|24 50|Friedrich Schiller University
P01304809T0001|53 56|Jena
P01309244A0798|25 33|positions
P01309244A0798|45 48|acts
P01309244A0798|78 95|different cell types
P01309244A0798|125 144|heterologous promoter
P01309587A0715|0 25|Synergistic transactivation
P01309587A0715|31 43|BMRF1 promoter
P01309587A0715|49 66|Z/c-myb combination
P01309587A0715|49 49|Z
P01309587A0715|51 55|c-myb
P01309587A0715|83 95|direct binding
P01309587A0715|101 108|Z protein
P01309587A0715|118 129|c-myb protein
P01309593A0095|3 17|UCR core sequence
P01309593A0095|19 27|CGCCATTTT
P01309593A0095|35 57|ubiquitous nuclear factor
P01309593A0095|69 86|negative regulation
P01309593A0095|89 108|MuLV promoter activity
P01309593A1092|5 11|studies
P01309593A1092|20 24|UCRBP
P01309593A1092|32 50|various target motifs
P01309593A1092|73 80|UCR motif
P01309593A1092|85 115|adeno-associated virus P5 promoter
P01309593A1092|119 126|elements
P01309593A1092|132 170|immunoglobulin light- and heavy-chain genes
P01309593A1092|132 150|immunoglobulin light
P01309593A1092|155 170|heavy-chain genes
P01309593A1092|180 187|elements
P01309593A1092|190 210|ribosomal protein genes
P01309815A0972|12 25|scr1-1 mutation
P01309815A0972|39 55|signal recognition
P01309815A0972|58 76|translational arrest
P01309815A0972|109 127|translational arrest
P01309815A0972|130 141|AEP synthesis
P01309815A0972|130 132|AEP
P01309860A0559|3 19|cellular sequences
P01309860A0559|27 46|viral integration site
P01309860A0559|62 70|% identity
P01309860A0559|73 88|several sequences
P01309860A0559|103 115|mouse L1 family
P01309860A0559|134 152|repetitive sequences
P01309894A0807|4 8|Rep78
P01309894A0807|12 16|Rep68
P01309894A0807|23 41|terminal AAV sequence
P01309894A0807|47 54|same site
P01309894A0807|56 65|nucleotide
P01309910A0428|0 25|Nucleotide sequence analysis
P01309910A0428|38 55|TAR-binding protein
P01309910A0428|74 85|CREB2 protein
P01310154A0879|5 11|results
P01310154A0879|28 28|N
P01310154A0879|33 51|C-terminal mutations
P01310154A0879|72 86|transrepression
P01310154A0879|89 98|FBR protein
P01310154A0879|106 132|multiple structural mutations
P01310154A0879|146 181|posttranslational protein modification
P01310154A0879|187 200|gene regulation
P01310154A0879|203 212|FBR protein
P01310178A0876|3 27|JS78 mutation changes Gln243
P01310178A0876|30 32|gp0
P01310178A0876|39 48|amber codon
P01310178A0876|91 120|30-kDa gp0.7-related polypeptide
P01310178A0876|138 159|11-kDa C-terminal domain
P01310178A0876|162 186|host transcription shut-off
P01310879A0000|1 16|patient suffering
P01310879A0000|21 54|heparin-associated thrombocytopenia
P01310879A0000|56 58|HAT
P01310879A0000|61 86|recurrent arteriothromboses
P01310879A0000|91 107|acute renal failure
P01310879A0000|126 140|standard heparin
P01310899A0339|12 28|receptor structure
P01310899A0339|38 69|cysteine-rich extracellular domain
P01310899A0339|72 107|single hydrophobic transmembrane domain
P01310899A0339|122 160|cytoplasmic serine/threonine kinase domain
P01310935T0000|0 14|Drosophila UbcD1
P01310935T0000|10 14|UbcD1
P01310935T0000|38 64|ubiquitin-conjugating enzyme
P01310935T0000|75 101|selective protein degradation
P01312005A0600|0 7|Analysis
P01312005A0600|13 33|entire 16.7-kb mt genome
P01312005A0600|49 52|MDP1
P01312005A0600|61 68|cleavage
P01312005A0600|71 80|chick mtDNA
P01312005A0600|95 95|H
P01312005A0600|103 145|L-strand sequence-specific target sites located
P01312005A0600|153 158|90-bp A
P01312005A0600|160 177|T-rich genomic tract
P01312005A0600|208 232|stable secondary structures
P01312005A0600|250 254|bases
P01312005A0600|270 283|H-strand origin
P01312005A0600|285 286|OH
P01312005A0600|290 300|replication
P01313715A0461|12 23|present study
P01313715A0461|41 51|feasibility
P01313715A0461|54 63|retrovirus
P01313715A0461|84 91|rp47phox
P01313715A0461|97 100|HL60
P01313715A0461|104 134|U937 human hematopoietic cell lines
P01313715A0461|143 159|Epstein-Barr virus
P01313715A0461|171 190|B-lymphocyte cell line
P01313715A0461|192 198|EBV-BCL
P01313715A0461|212 238|p47phox-deficient CGD patient
P01313715A0461|212 218|p47phox
P01313846A0850|0 9|Comparison
P01313846A0850|17 33|sequence databanks
P01313846A0850|42 48|Tactile
P01313846A0850|63 91|immunoglobulin gene superfamily
P01313846A0850|109 125|Drosophila amalgam
P01313846A0850|130 145|melanoma Ag MUC-18
P01313846A0850|147 153|members
P01313846A0850|159 182|carcinoembryonic Ag family
P01313846A0850|187 204|poliovirus receptor
P01313846A0850|212 237|neural cell adhesion molecule
P01313894A1179|7 20|similar pattern
P01313894A1179|23 29|results
P01313894A1179|54 72|LMP2B mRNA expression
P01313894A1179|54 62|LMP2B mRNA
P01313894A1179|74 88|such transcripts
P01313894A1179|94 103|detectable
P01313894A1179|111 116|subset
P01313894A1179|119 124|tumors
P01313894A1179|145 153|low levels
P01313909A0526|3 12|phenotypes
P01313909A0526|18 36|ICP0 nonsense mutants
P01313909A0526|18 21|ICP0
P01313909A0526|41 52|intermediate
P01313909A0526|70 83|wild-type virus
P01313909A0526|104 122|ICP0-coding sequence
P01313909A0526|140 153|nonsense mutant
P01313909A0526|162 174|wild type-like
P01313909A0526|181 189|phenotype
P01314457T0000|0 7|Analysis
P01314457T0000|10 27|nucleotide sequence
P01314457T0000|33 41|rightmost
P01314457T0000|44 46|kbp
P01314457T0000|49 66|herpesvirus saimiri
P01314457T0000|68 70|HVS
P01314457T0000|72 76|L-DNA
P01314457T0000|78 96|general conservation
P01314457T0000|99 117|genetic organization
P01314457T0000|125 127|HVS
P01314457T0000|131 147|Epstein-Barr virus
P01314841A0724|0 8|Treatment
P01314841A0724|13 18|MK-801
P01314841A0724|27 42|burst suppression
P01314841A0724|48 50|EEG
P01314841A0724|55 67|transient drop
P01314841A0724|79 82|mm Hg
P01314841A0724|89 108|mean arterial pressure
P01314953A1266|11 37|gel mobility shift experiments
P01314953A1266|60 63|HAP2
P01314953A1266|66 69|HAP3
P01314953A1266|90 102|hap3 mutations
P01314953A1266|90 93|hap3
P01314953A1266|112 120|complexes
P01315706A0000|0 22|Myogenic differentiation
P01315706A0000|42 61|adenovirus E1a protein
P01315706A0000|67 85|rat L6 muscle cell line
P01316125A0176|37 39|1O2
P01316125A0176|48 59|free radicals
P01316125A0176|66 67|OH
P01316125A0176|71 74|YHPD
P01316125A0176|99 102|YHPD
P01316125A0176|136 138|1O2
P01316125A0176|140 147|YHPD less
P01316125A0176|152 155|BHPD
P01316125A0176|183 184|OH
P01316125A0176|186 196|YHPD greater
P01316125A0176|201 204|BHPD
P01316125A0382|3 8|points
P01316125A0382|31 51|photosensitized damage
P01316125A0382|54 57|YHPD
P01316125A0382|81 83|1O2
P01316125A0382|92 103|free radicals
P01316125A0382|110 111|OH
P01316125A0382|115 118|YHPD
P01316125A0382|141 161|photosensitized damage
P01316125A0382|164 167|YHPD
P01316125A0382|170 177|stronger
P01316125A0382|188 191|BHPD
P01316125A0382|199 219|photosensitized damage
P01316125A0382|254 256|1O2
P01316125A0382|296 297|OH
P01316459A0311|0 3|Acad
P01316461A1083|6 31|vitro-synthesized S2 protein
P01316461A1083|35 51|synthetic peptides
P01316461A1083|67 68|S2
P01316461A1083|98 101|sera
P01316461A1083|114 132|EIAV-infected horses
P01316461A1083|146 164|first direct evidence
P01316461A1083|192 206|infected animals
P01316476A0842|0 25|Many canonical TATA sequences
P01316476A0842|53 80|VZV transcriptional start sites
P01316476A1428|3 10|ORF 4 gene
P01316476A1428|3 5|ORF
P01316476A1428|40 42|ORF
P01316476A1428|53 68|twofold induction
P01316476A1428|74 78|genes
P01316476A1428|107 115|induction
P01316680A0643|17 22|IR5 ORF
P01316680A0643|25 29|EHV-1
P01316680A0643|52 61|amino acids
P01316680A0643|63 75|CAYWCCLGHAFAC
P01316680A0643|84 95|perfect match
P01316680A0643|101 124|consensus zinc finger motif
P01316680A0643|126 141|C-X2-4-C-X2-15-C
P01316680A0643|143 150|H-X2-4-C
P01316680A0643|152 152|H
P01316900A0000|3 13|DNA sequence
P01316900A0000|19 40|sulfate activation locus
P01316900A0000|45 63|Escherichia coli K-12
P01316900A0000|60 63|K-12
P01316903A0296|3 22|unphosphorylated form
P01316903A0296|25 39|RNA polymerase II
P01316903A0296|25 37|RNA polymerase
P01316903A0296|52 54|IIA
P01316903A0296|66 83|phosphorylated form
P01316903A0296|96 98|IIO
P01316903A1040|0 15|RNA polymerase IIA
P01316903A1040|47 61|active complexes
P01316903A1040|64 72|reactions
P01316903A1040|83 93|input enzyme
P01316903A1040|97 112|RNA polymerase IIA
P01317376A0981|0 19|Fructokinase activity
P01317376A0981|0 11|Fructokinase
P01317376A0981|22 29|elevated
P01317376A0981|45 53|Z. mobilis
P01317376A0981|64 71|fructose
P01317376A0981|81 87|glucose
P01317376A0981|101 116|parallel increase
P01317376A0981|119 131|frk mRNA levels
P01317376A0981|119 125|frk mRNA
P01318310A0000|0 14|Plasma membranes
P01318310A0000|25 29|cells
P01318310A0000|37 57|high affinity receptors
P01318310A0000|61 82|high density lipoprotein
P01318310A0000|84 86|HDL
P01318310A0000|116 145|excess intracellular cholesterol
P01318739A0410|15 33|patients vincristine
P01318739A0410|47 56|teniposide
P01318739A0410|58 62|VM-26
P01318739A0410|69 81|neurotoxicity
P01320255A0795|5 11|results
P01320255A0795|26 52|internal short element located
P01320255A0795|64 71|terminal
P01320255A0795|74 83|L1 sequence
P01320255A0795|90 109|nuclear factor binding
P01320255A0795|90 102|nuclear factor
P01320255A0795|127 137|crucial role
P01320255A0795|143 155|transcription
P01320255A0795|158 164|human L1
P01320640A0336|0 9|Tumor cells
P01320640A0336|21 34|immunoreactive
P01320640A0336|38 59|neuron-specific enolase
P01320640A0336|61 67|insulin
P01320640A0336|69 76|glucagon
P01320640A0336|80 82|VIP
P01321277A0342|1 11|recombinant
P01321277A0342|26 28|src
P01321277A0342|42 44|ros
P01321277A0342|52 54|SRC
P01321277A0342|56 58|ROS
P01321277A0342|71 94|chicken embryo fibroblasts
P01321277A0342|96 98|CEF
P01321277A0342|103 124|spindle shape morphology
P01321277A0342|141 143|UR2
P01321277A0664|0 2|ROS
P01321277A0664|4 6|SRC
P01321277A0664|8 8|R
P01321277A0664|19 39|16-amino-acid deletion
P01321277A0664|66 84|transmembrane domain
P01321277A0664|87 89|ros
P01321280A0494|31 32|E6
P01321280A0494|36 49|E7 gene products
P01321280A0494|61 82|BPV-1-transformed cells
P01321280A0494|61 65|BPV-1
P01321280A0494|95 124|immunoprecipitation experiments
P01321280A0494|129 136|antisera
P01321280A0494|165 171|BPV-1 E6
P01321280A0494|175 190|E7 fusion proteins
P01321332A0970|0 26|Transient transfection assays
P01321332A0970|37 41|site A
P01321332A0970|69 100|RXR alpha-mediated transactivation
P01321332A0970|69 76|RXR alpha
P01321332A0970|106 127|apoAI gene basal promoter
P01321332A0970|130 152|human hepatoma HepG2 cells
P01321332A0970|168 169|RA
P01321332A0970|181 195|transactivation
P01321332A0970|219 225|amounts
P01321332A0970|241 245|ARP-1
P01321336A0000|3 16|enhancer region
P01321336A0000|19 40|Akv murine leukemia virus
P01321336A0000|52 72|sequence motif ACAGATGG
P01321336A0731|3 16|splice variants
P01321336A0731|19 26|ALF1 cDNA
P01321336A0731|53 66|72-bp insertion
P01321336A0731|77 92|putative proteins
P01321336A0731|104 113|amino acids
P01321337A0318|1 23|third prominent component
P01321337A0318|26 46|apparent molecular mass
P01321337A0318|49 51|kDa
P01321337A0318|61 77|several properties
P01321337A0318|101 105|45Ca2
P01321337A0318|145 145|B
P01321337A0318|147 153|subunit
P01321337A0318|156 175|mammalian calcineurin
P01321337A0318|196 204|antiserum
P01321337A0318|218 234|bovine calcineurin
P01321337A1161|26 50|MATa cna1 cna2 double mutants
P01321337A1161|26 29|MATa
P01321337A1161|30 33|cna1
P01321337A1161|52 66|MATa cnb1 mutants
P01321337A1161|52 55|MATa
P01321337A1161|56 66|cnb1 mutants
P01321337A1161|71 79|defective
P01321337A1161|107 138|alpha-factor-induced growth arrest
P01321337A1161|107 118|alpha-factor
P01324172A0880|0 9|Antibodies
P01324172A0880|44 47|RIM1
P01324172A0880|50 61|mitochondria
P01324385A0329|0 6|METHODS
P01324385A0329|8 20|IgG antibodies
P01324385A0329|23 27|HHV-6
P01324385A0329|29 42|anti-HHV-6-IgG
P01324385A0329|60 85|indirect immunofluorescence
P01324385A0329|91 94|IVDA
P01324385A0329|98 109|seronegative
P01324385A0329|115 126|seropositive
P01324385A0329|130 134|HIV-1
P01324385A0329|164 168|IV-C1
P01324385A0329|171 173|CDC
P01324385A0329|188 202|healthy subjects
P01324385A0329|206 215|similar age
P01324385A0329|217 228|control group
P01324404A0813|1 36|position-independent activation domain
P01324404A0813|60 66|regions
P01324404A0813|93 108|carboxyl terminus
P01324404A0813|114 129|HNF-3 beta protein
P01324404A0813|131 140|amino acids
P01324404A1208|0 31|HNF-3 beta amino-terminal sequences
P01324404A1208|75 89|transactivation
P01324404A1208|139 156|region II-III domain
P01324406A1250|0 12|Possible roles
P01324406A1250|15 52|RAD5 putative ATPase/DNA helicase activity
P01324406A1250|55 63|DNA repair
P01324406A1250|85 98|wild-type rates
P01324406A1250|101 111|instability
P01324406A1250|114 138|simple repetitive sequences
P01324639T0000|0 15|Susceptibilities
P01324639T0000|21 49|anaerobic gram-negative bacilli
P01324639T0000|52 62|amoxicillin
P01324639T0000|64 78|amoxicillin-BRL
P01324639T0000|85 107|amoxicillin-clavulanate
P01324639T0000|109 120|temafloxacin
P01324639T0000|125 135|clindamycin
P01325221A0870|0 15|Nocodazole arrest
P01325221A0870|18 27|DU249 cells
P01325221A0870|46 54|detection
P01325221A0870|59 84|M-phase-activated MBP kinase
P01325221A0870|104 115|p41 MAP kinase
P01325221A0870|118 146|phenyl-Superose chromatography
P01325386A0766|3 16|hit1-1 mutation
P01325386A0766|24 29|defect
P01325386A0766|32 40|synthesis
P01325386A0766|44 64|74-kD heat shock protein
P01326329A0703|6 19|base pair region
P01326329A0703|44 50|CAP site
P01326329A0703|78 92|proximal TATA box
P01326329A0703|109 124|sequences similar
P01326329A0703|127 133|GC boxes
P01326329A0703|135 144|CACCC boxes
P01326329A0703|146 155|CCAAT boxes
P01326329A0703|157 172|activator protein
P01326329A0703|175 178|Ap-2
P01326329A0703|180 184|sites
P01326329A0703|186 222|partial glucocorticoid response elements
P01326329A0703|193 222|glucocorticoid response elements
P01326329A0703|224 227|GREs
P01326329A0703|233 264|partial cyclic AMP response elements
P01326329A0703|240 264|cyclic AMP response elements
P01326329A0703|266 269|CREs
P01326557T0000|0 6|Cloning
P01326557T0000|10 25|primary structure
P01326557T0000|28 35|neurocan
P01326557T0000|74 103|chondroitin sulfate proteoglycan
P01327280A0000|2 5|rats
P01327280A0000|25 34|chloralose
P01327280A0000|38 44|changes
P01327280A0000|47 61|extracellular pH
P01327280A0000|65 65|K
P01327280A0000|69 88|spinal cord dorsal horn
P01327280A0000|105 106|pH
P01327280A0000|110 110|K
P01327280A0000|112 134|ion-selective electrodes
P01327758A0000|0 10|Replication
P01327758A0000|13 34|bovine papillomavirus-1
P01327758A0000|36 40|BPV-1
P01327758A0000|56 72|viral gene products
P01327758A0000|77 85|E1 protein
P01327758A0000|92 111|full-length E2 protein
P01327967A0668|0 22|Insertional inactivation
P01327967A0668|25 27|sms
P01327967A0668|58 94|alkylating agent methylmethane sulfonate
P01327967A0668|119 124|serine
P01327967A0668|127 142|other metabolites
P01328197A0985|5 12|findings
P01328197A0985|27 60|MAP kinase activator/MAP kinase system
P01328197A0985|27 44|MAP kinase activator
P01328197A0985|46 54|MAP kinase
P01328197A0985|69 88|downstream components
P01328197A0985|91 119|ras signal transduction pathways
P01328197A0985|91 93|ras
P01328219A1397|0 5|NSCL-1
P01328219A1397|20 31|larger number
P01328219A1397|39 47|cell lines
P01328681A0149|0 24|Labile LTR-binding proteins
P01328681A0149|6 24|LTR-binding proteins
P01328681A0149|47 66|c-myc hyperexpression
P01328681A0149|47 51|c-myc
P01328681A0149|77 101|LTR-enhanced transcription
P01328681A0149|108 117|activities
P01328681A0149|120 138|LTR-binding proteins
P01328681A0149|168 177|inhibition
P01328681A0149|180 195|protein synthesis
P01328681A0149|197 198|A.
P01328681A0348|0 6|Ruddell
P01328681A0348|8 9|M.
P01328854T0000|1 15|single MEF-2 site
P01328854T0000|7 15|MEF-2 site
P01328854T0000|19 48|major positive regulatory element
P01328854T0000|60 72|transcription
P01328854T0000|78 99|muscle-specific subunit
P01328854T0000|105 135|human phosphoglycerate mutase gene
P01328854T0000|138 145|skeletal
P01328854T0000|149 166|cardiac muscle cells
P01328884T0000|0 17|Truncation variants
P01328884T0000|20 27|peptides
P01328884T0000|40 58|MHC class II molecules
P01328884T0000|40 47|MHC class
P01328884T0000|50 58|molecules
P01328884T0000|66 79|sequence motifs
P01329039A0239|11 24|E-box consensus
P01329039A0239|45 50|CANNTG
P01329039A0239|55 73|adjacent nucleotides
P01329039A0239|76 92|functional E-boxes
P01329039A0239|107 111|genes
P01329039A0239|126 137|bHLH proteins
P01329039A0951|0 17|Intermediate levels
P01329039A0951|20 31|gene activity
P01329039A0951|47 58|TnI enhancers
P01329039A0951|69 75|E-boxes
P01329039A0951|90 105|MCK left E-box site
P01329039A0951|90 92|MCK
P01329039A0951|97 105|E-box site
P01329039A0951|115 128|Ig kappa E2 E-box
P01330077A0000|0 17|T-cell receptor beta
P01330077A0000|19 25|TCR beta
P01330077A0000|27 44|gene rearrangements
P01330077A0000|60 97|early B-cell acute lymphoblastic leukemias
P01330077A0000|99 102|ALLs
P01330309A1134|3 14|CANNTG motifs
P01330309A1134|30 33|MyoD
P01330309A1134|37 58|myogenin fusion proteins
P01330309A1134|76 83|proteins
P01330309A1134|86 100|nuclear extracts
P01330309A1134|113 120|myotubes
P01330975T0000|0 23|Peripheral polyneuropathy
P01330975T0000|38 52|multiple myeloma
P01331057A0000|24 28|COX12
P01331057A0000|33 43|nuclear gene
P01331057A0000|47 56|subunit VIb
P01331057A0000|59 99|Saccharomyces cerevisiae cytochrome c oxidase
P01331057A0000|82 99|cytochrome c oxidase
P01331060A0768|17 32|calcineurin A gene
P01331060A0768|63 69|genomic
P01331060A0768|73 85|cDNA sequences
P01331086T0000|3 23|basal promoter elements
P01331086T0000|26 62|murine cytochrome c oxidase subunit IV gene
P01331086T0000|26 56|murine cytochrome c oxidase subunit
P01331086T0000|80 98|duplicated ets motifs
P01331086T0000|90 98|ets motifs
P01331086T0000|109 140|GABP-related transcription factors
P01331292A1425|15 31|multiple instances
P01331292A1425|39 71|short oligonucleotide direct repeats
P01331292A1425|78 89|region absent
P01331292A1425|100 106|variola
P01331292A1425|109 121|vaccinia virus
P01331501A0397|14 35|short synthetic peptides
P01331501A0397|49 68|pRB-binding sequences
P01331501A0397|71 73|E1A
P01331501A0397|105 108|p107
P01331501A0397|110 116|cyclin A
P01331501A0397|121 124|p130
P01331516A0103|5 11|mutants
P01331516A0103|26 48|3T6 mouse fibroblast cells
P01331516A0103|75 88|wild-type virus
P01331516A0103|91 112|coinfection experiments
P01331516A0103|115 125|C2 myoblasts
P01332589A0666|3 6|MICs
P01332589A0666|30 30|%
P01332589A0666|38 46|organisms
P01332589A0666|57 85|methicillin-resistant S. aureus
P01332589A0666|125 137|micrograms/ml
P01332964A0247|3 17|minimal promoter
P01332964A0247|23 33|RII beta gene
P01332964A0247|50 75|adjacent functional elements
P01333035T0000|0 6|Mapping
P01333035T0000|10 39|cAMP receptor protein contact site
P01333035T0000|45 56|alpha subunit
P01333035T0000|59 86|Escherichia coli RNA polymerase
P01333035T0000|74 86|RNA polymerase
P01333047A0404|14 34|epidermal growth factor
P01333047A0404|37 75|platelet-derived growth factor stimulation
P01333047A0404|37 64|platelet-derived growth factor
P01333047A0404|78 88|intact human
P01333047A0404|91 101|murine cells
P01333047A0404|109 123|phosphorylation
P01333047A0404|126 135|Nck protein
P01333047A0404|138 145|tyrosine
P01333047A0404|147 152|serine
P01333047A0404|157 173|threonine residues
P01333053A0110|1 14|major mechanism
P01333053A0110|22 56|steroid hydroxylase gene transcription
P01333053A0110|22 43|steroid hydroxylase gene
P01333053A0110|73 85|adrenal cortex
P01333053A0110|97 119|pituitary peptide hormone
P01333053A0110|121 124|ACTH
P01333053A0110|138 141|cAMP
P01333125A0000|14 40|comparative sequence analysis
P01333125A0000|44 63|thermodynamic methods
P01333125A0000|88 112|tertiary structure elements
P01333125A0000|120 137|untranslated region
P01333125A0000|139 141|UTR
P01333125A0000|145 162|human enteroviruses
P01333125A0000|166 177|rhinoviruses
P01333317A1008|38 40|Sp1
P01333317A1008|46 64|unidentified protein
P01333317A1008|66 66|s
P01333317A1008|69 92|proximal regulatory factor
P01333317A1008|94 94|s
P01333317A1008|98 102|PRF-I
P01334428A1102|0 1|Km
P01334428A1102|5 8|Vmax
P01334428A1102|15 24|substrates
P01334428A1102|26 43|src-related peptide
P01334428A1102|47 50|poly
P01334428A1102|52 54|Glu
P01334428A1102|56 58|Tyr
P01334428A1102|73 74|mM
P01334428A1102|81 94|mumol min-1 mg-1
P01334428A1102|102 103|mM
P01334428A1102|110 123|mumol min-1 mg-1
P01334493A0289|4 14|soluble form
P01334493A0289|20 23|HGFr
P01334493A0289|25 29|sHGFr
P01334493A0289|36 38|HGF
P01334493A0289|45 59|affinity similar
P01334493A0289|71 79|authentic
P01334493A0289|81 107|membrane-associated receptor
P01334518T0000|0 9|Strategies
P01334518T0000|13 26|blood screening
P01334518T0000|33 47|hepatitis C virus
P01334518T0000|57 82|human immunodeficiency virus
P01334518T0000|85 98|high risk groups
P01337142A2043|8 45|human glycoprotein alpha-subunit promoter
P01337142A2043|65 67|FSK
P01337142A2043|70 89|GH4 rat pituitary cells
P01337142A2043|92 99|ABSTRACT
P01337142A2043|114 118|WORDS
P01338867A0503|0 9|Comparison
P01338867A0503|31 37|results
P01338867A0503|40 55|chronic treatment
P01338867A0503|63 78|opioid antagonist
P01338867A0503|103 117|chronic blockade
P01338867A0503|130 142|fatiguability
P01338867A0503|146 156|great extent
P01338867A0503|161 177|chronic activation
P01338867A0503|180 191|opioid system
P01339125A0153|0 16|Laboratory studies
P01339125A0153|22 25|Ca45
P01339125A0153|33 37|teeth
P01339125A0153|60 64|teeth
P01339125A0153|81 90|dentifrice
P01339125A0153|97 111|decalcify enamel
P01339125A0153|114 124|bleach teeth
P01339373T0000|0 8|Structure
P01339373T0000|33 51|Arabidopsis thaliana
P01339373T0000|61 74|protein related
P01339373T0000|77 93|SNF1 protein kinase
P01339391A0000|29 39|55-kb region
P01339391A0000|42 60|DNA surrounding HRAS1
P01339468A0272|3 13|ORF1 protein
P01339468A0272|32 41|homologous
P01339468A0272|47 77|putative potexvirus RNA replicases
P01339468A0272|55 77|potexvirus RNA replicases
P01339468A0272|79 82|ORF2
P01339468A0272|94 101|proteins
P01339468A0272|110 118|analogues
P01339468A0272|127 131|potex
P01339468A0272|139 164|carlavirus-encoded proteins
P01339773A0000|11 18|patients
P01339773A0000|34 39|groups
P01339773A0000|56 72|clinical diagnosis
P01339773A0000|93 103|capnography
P01339773A0000|105 114|spirometry
P01339773A0000|118 134|blood-gas analysis
P01339773A0778|3 15|relationships
P01339773A0778|26 41|partial pressures
P01339773A0778|49 51|CO2
P01339773A0778|72 80|gradients
P01339773A0778|88 95|stronger
P01339773A0778|116 141|ventilation-perfusion ratio
P01339815A1545|2 24|significant correlations
P01339815A1545|27 33|peak VO2
P01339815A1545|57 61|tests
P01340470A0000|2 23|RNA-binding protein gene
P01340470A0000|25 28|rbp1
P01340470A0000|67 85|RNA recognition motif
P01340470A0000|91 101|Arg-Ser rich
P01340470A0000|103 104|RS
P01341119A0450|4 18|research studies
P01341119A0450|40 45|tumors
P01341119A0450|50 67|prolonged ingestion
P01341119A0450|70 81|H2 inhibitors
P01341119A0450|70 71|H2
P01341119A0450|85 97|others antacid
P01346262A0377|1 16|comparative study
P01346262A0377|22 41|total protein profiles
P01346262A0377|44 68|wild-type S. entomophila UC9
P01346262A0377|72 81|mutant UC21
P01346262A0377|97 102|mutant
P01346262A0377|124 136|44-kDa protein
P01346262A0377|168 180|20-kDa protein
P01346534T0000|0 15|Characterization
P01346534T0000|21 27|regulon
P01346534T0000|43 77|leucine-responsive regulatory protein
P01347476T0000|0 6|Mapping
P01347476T0000|12 60|mouse ornithine decarboxylase-related sequence family
P01347476T0000|12 54|mouse ornithine decarboxylase-related sequence
P01347664A1026|4 11|mutation
P01347664A1026|42 47|levels
P01347664A1026|50 56|CAD mRNA
P01347664A1026|72 77|mutant
P01347908T0000|3 11|rationale
P01347908T0000|15 47|continuous dopaminergic stimulation
P01347908T0000|50 57|patients
P01347908T0000|62 70|Parkinson
P01347944A0964|0 16|Mutational studies
P01347944A0964|37 68|homeodomain binding site II sequence
P01347944A0964|37 58|homeodomain binding site
P01348504A0757|8 30|pol alpha-primase complex
P01348504A0757|63 75|short distance
P01348508A0313|17 25|positions
P01348508A0313|33 39|introns
P01348508A0313|76 80|genes
P01348508A0313|86 121|other transglutaminase-like activities
P01348508A0313|153 160|TGM1 gene
P01348508A0313|171 178|smallest
P01348508A0313|208 214|introns
P01348508A0313|228 234|smaller
P01348590A0000|3 23|retrospective analysis
P01348590A0000|36 40|cases
P01348590A0000|45 61|malignant lymphoma
P01348590A0000|67 72|cohort
P01348590A0000|79 98|HIV-infected patients
P01348590A0000|110 120|HIV-disease
P01348590A0000|125 127|CD4
P01348590A0000|166 185|antineoplastic agents
P01348590A0000|188 199|radiotherapy
P01349705T0000|0 6|Effects
P01349705T0000|9 15|dioxins
P01349705T0000|18 32|thyroid function
P01349705T0000|35 47|newborn babies
P01349837T0000|0 9|cDNA clones
P01349837T0000|18 36|Arabidopsis thaliana
P01349837T0000|40 74|Zea mays mitochondrial chaperonin HSP60
P01349837T0000|40 69|Zea mays mitochondrial chaperonin
P01349837T0000|70 81|HSP60 and gene
P01349837T0000|78 91|gene expression
P01349837T0000|98 112|seed germination
P01349837T0000|116 124|heat shock
P01350780A0184|0 26|Amino acid sequence comparison
P01350780A0184|35 53|significant homology
P01350780A0184|64 68|yeast
P01350780A0184|87 107|gamma-glutamyl kinases
P01350780A0184|123 129|lengths
P01350932A1123|3 12|single site
P01350932A1123|15 27|glycosylation
P01350932A1123|30 36|located
P01350932A1123|44 53|C-terminus
P01350932A1123|59 79|N-glycosylation sequon
P01350932A1123|81 91|Asn-Cys-Ser
P01350932A1123|100 102|Cys
P01350932A1123|115 130|disulphide bridge
P01352113A0002|3 22|pulmonary toxic events
P01352113A0002|32 51|acute nitrogen dioxide
P01352113A0002|53 54|NO
P01352113A0002|95 109|inhalation model
P01352113A0002|123 141|therapeutic measures
P01352113A0231|3 18|pulmonary effects
P01352113A0231|38 47|pronounced
P01352113A0231|62 78|NO2 concentrations
P01352113A0231|100 102|ppm
P01352113A0231|105 111|ppm NO2 =
P01352113A0231|116 123|mg m-3 NO2
P01352113A0231|128 140|exposure times
P01352113A0231|153 155|min
P01353478T0000|0 10|Interaction
P01353478T0000|13 17|H-2Eb
P01353478T0000|24 41|IAP retrotransposon
P01353478T0000|47 65|A20/2J B cell lymphoma
P01354506T0000|0 31|Gestational trophoblastic diseases
P01354506T0000|33 46|recent advances
P01354506T0000|67 78|cytogenetics
P01354506T0000|80 93|histopathology
P01354506T0000|98 111|natural history
P01357190A0726|18 24|mutants
P01357190A0726|38 57|membrane anchor domain
P01357190A0726|67 85|mutant glycoproteins
P01357190A0726|111 116|fusion
P01357190A0726|119 134|CD4-bearing cells
P01357190A0726|119 121|CD4
P01357528A0084|3 16|subunit protein
P01357528A0084|19 23|curli
P01357528A0084|33 42|homologous
P01357528A0084|48 60|amino terminus
P01357528A0084|63 68|SEF-17
P01357528A0084|73 86|subunit protein
P01357528A0084|94 112|aggregative fimbriae
P01357528A0084|141 148|strain 3b
P01357528A0084|169 174|fibres
P01357528A0084|180 189|novel class
P01357528A0084|192 208|surface organelles
P01357528A0084|211 224|enterobacteria
P01358190A0654|0 11|Substitution
P01358190A0654|17 28|DR1 beta chain
P01358190A0654|33 41|H-2E beta k
P01358190A0654|48 59|dramatic loss
P01358190A0654|74 95|alpha chain substitution
P01358190A0654|104 115|marked effect
P01358592A0752|4 28|negative regulatory pathway
P01358592A0752|57 64|cell fate
P01358592A0752|80 93|inducible state
P01358592A0752|99 119|ventroposterior region
P01358592A0752|125 130|embryo
P01358758A0000|3 15|distal portion
P01358758A0000|21 35|rat insulin I gene
P01358758A0000|39 49|flanking DNA
P01358758A0000|61 76|sequence elements
P01358758A0000|81 83|Far
P01358758A0000|87 98|FLAT elements
P01358758A0000|149 189|beta-cell-specific transcriptional enhancer
P01358880A0251|10 26|amino acid sequence
P01358880A0251|38 46|% identity
P01358880A0251|52 88|human cellular transglutaminase sequence
P01359588A0375|4 14|computation
P01359588A0375|29 43|parallel network
P01359588A0375|62 80|neuron-like elements
P01360180A0513|0 14|Repeated efforts
P01360180A0513|24 47|recombinant baculoviruses
P01360180A0513|59 73|wild-type kinase
P01360180A0513|88 99|recombinants
P01360180A0513|111 129|nonfunctional kinase
P01360180A0513|135 149|catalytic domain
P01360180A0513|152 159|mutation
P01360180A1568|27 42|P68 amino terminus
P01360180A1568|82 86|dsRNA
P01360180A1568|109 131|dsRNA-binding properties
P01360180A1568|135 153|reporter gene product
P01360180A1568|176 178|RNA
P01360294A0000|4 9|August
P01360294A0000|16 22|October
P01360294A0000|30 49|pregnant Chinese women
P01360294A0000|57 64|subjects
P01360294A0000|80 85|levels
P01360294A0000|88 115|plasma functional antithrombin
P01360294A0000|104 118|antithrombin III
P01363080A0710|0 11|Visual acuity
P01363080A0710|28 43|transient changes
P01363080A0710|46 60|refractive error
P01363080A0710|69 80|sulfonamides
P01363080A0710|85 112|antifungal agent metronidazole
P01363080A0710|114 130|thiazide diuretics
P01363080A0710|135 161|carbonic anhydrase inhibitors
P01363080A0710|135 151|carbonic anhydrase
P01363166T0001|0 14|Currents aspects
P01363166T0001|17 37|H2 receptor antagonists
P01363166T0001|17 26|H2 receptor
P01363166T0001|54 59|ulcers
P01364100A0377|12 35|21-mer subrepeat structure
P01370281A0461|0 9|Sequencing
P01370281A0461|21 41|large open reading frame
P01370281A0461|51 63|39-kDa protein
P01370446A0818|5 9|sites
P01370446A0818|17 54|potential keratan sulfate attachment sites
P01371181A0688|13 20|plasmids
P01371181A0688|26 35|pLS1 family
P01371181A0688|37 41|pE194
P01371181A0688|43 49|pADB201
P01371181A0688|54 57|pLB4
P01371181A0688|59 73|share functional
P01371181A0688|77 101|structural characteristics
P01371181A0688|125 135|copy numbers
P01371272A1167|0 11|Perturbation
P01371272A1167|14 22|dNTP pools
P01371272A1167|38 55|frameshift fidelity
P01371272A1167|61 94|replicative yeast DNA polymerase alpha
P01371272A1167|72 94|yeast DNA polymerase alpha
P01371275T0000|0 21|Differential expression
P01371275T0000|28 28|B
P01371275T0000|30 36|subunit
P01371275T0000|42 60|vacuolar H(+)-ATPase
P01371275T0000|42 50|vacuolar H
P01371275T0000|55 60|ATPase
P01371275T0000|63 75|bovine tissues
P01371413A0742|14 23|hGCSFR gene
P01371413A0742|40 48|localized
P01371413A0742|51 70|Southern blot analysis
P01371413A0742|76 93|segregation pattern
P01371413A0742|104 125|rodent-human hybrid DNAs
P01371413A0742|146 154|cDNA probe
P01371863A0000|31 64|differentially-regulated gene family
P01371863A0000|70 101|protozoan parasite Leishmania major
P01372365A1202|6 10|sites
P01372365A1202|12 13|%T
P01372365A1202|34 35|Cl
P01372365A1202|37 50|concentrations
P01372365A1202|56 56|M
P01372365A1202|65 76|other sites %T
P01372365A1202|105 114|conditions
P01372456A0426|0 7|Necrosis
P01372456A0426|16 16|h
P01372456A0426|22 31|TA infusion
P01372456A0426|42 42|%
P01372456A0426|58 58|h
P01372456A0426|64 64|%
P01372456A0426|72 72|h
P01372456A0426|76 82|animals
P01372456A0426|102 110|% necrosis
P01372802A1481|13 20|segments
P01372802A1481|23 24|C3
P01372802A1481|38 54|amino acid residues
P01372802A1481|107 108|C3
P01372802A1481|110 110|D
P01372802A1481|112 119|epitopes
P01372802A1481|138 165|erythrocyte-bound C3 fragments
P01372802A1481|155 165|C3 fragments
P01372802A1481|178 209|corresponding fluid-phase fragment
P01372802A1481|221 228|segments
P01372802A1481|237 244|residues
P01372802A1481|272 273|C3
P01372802A1481|275 275|D
P01372802A1481|277 284|epitopes
P01372802A1481|321 322|C3
P01372802A1481|343 364|physiological fragments
P01372900A0448|5 9|exons
P01372900A0448|30 34|exons
P01372900A0448|65 88|amino acid residues present
P01372900A0448|91 112|alpha s1-casein variant A
P01372900A0448|125 133|variant F.
P01372900A1017|19 48|complete structural organization
P01372900A1017|54 88|goat alpha s1-casein transcription unit
P01372900A1017|101 134|polymerase chain reaction experiments
P01373374A0735|0 9|Homodimers
P01373374A0735|20 27|proteins
P01373374A0735|52 61|G-box motif
P01373374A0735|67 70|GBF1
P01373374A0735|74 84|GBF3 binding
P01373374A0735|74 77|GBF3
P01373374A0735|104 122|palindromic sequence
P01374331A0636|21 52|distinct transcriptional start site
P01374331A0636|62 79|nuclease S1 analysis
P01374392A0341|3 20|hydrophobicity plot
P01374392A0341|23 27|NHE-3
P01374392A0341|49 53|NHE-1
P01374392A0341|57 61|NHE-2
P01374398A0951|3 27|initial translation protein
P01374398A0951|40 43|cDNA
P01374398A0951|52 54|kDa
P01374398A0951|68 98|hydrophilic amino acid composition
P01374398A0951|103 114|glutamic acid
P01374398A0951|127 127|%
P01374398A0951|133 154|total amino acid residues
P01374688A0471|19 23|ml/kg
P01374688A0471|33 46|% pentafraction
P01374688A0471|49 60|% pentastarch
P01374688A0471|64 69|plasma
P01374688A0471|81 85|hours
P01374688A0471|96 110|micrograms/kg/0
P01374688A0471|113 116|hr E.
P01375224A0152|0 6|Genetic
P01375224A0152|10 28|biochemical evidence
P01375224A0152|41 45|v-Crk
P01375224A0152|71 94|chicken embryo fibroblasts
P01375224A0152|121 136|cellular proteins
P01375224A0152|147 162|growth regulation
P01375913A0484|23 50|synthetic DNA oligonucleotides
P01375913A0484|53 64|U14 snRNA gene
P01375913A0484|94 120|T7 RNA polymerase promoter site
P01375913A0484|141 147|plasmid
P01376319T0000|0 3|Gene
P01376319T0000|7 16|pseudogene
P01376319T0000|22 68|mouse cation-dependent mannose 6-phosphate receptor
P01377696A0000|3 52|chick axon-associated surface glycoprotein neurofascin
P01377696A0000|42 52|neurofascin
P01377696A0000|67 78|axonal growth
P01377696A0000|82 94|fasciculation
P01377696A0000|107 137|antibody perturbation experiments
P01377764A0309|3 11|carcinoma
P01377764A0309|15 24|restricted
P01377764A0309|34 43|epithelium
P01377764A0309|53 64|mucosal layer
P01377764A0309|78 92|submucosal layer
P01377818A0468|11 19|C/EBP beta
P01377818A0468|23 32|C/EBP gamma
P01377818A0468|79 88|C/EBP alpha
P01377962A1012|11 21|tobacco GS-2
P01377962A1012|34 41|subunits
P01377962A1012|44 56|identical size
P01377962A1012|62 67|organs
P01378052A0594|7 10|acoR
P01378052A0594|14 20|acoXABC
P01378052A0594|25 38|different types
P01378052A0594|41 49|sequences
P01378052A0594|54 75|dual rotational symmetry
P01378052A0594|77 79|CAC
P01378052A0594|82 84|N11
P01378052A0594|87 89|N18
P01378052A0594|92 94|GTG
P01378052A0594|98 100|TGT
P01378052A0594|103 105|N10
P01378052A0594|108 110|N14
P01378052A0594|113 115|ACA
P01378052A0594|132 140|sequences
P01378052A0594|153 156|NtrC
P01378052A0594|160 189|NifA upstream activator sequences
P01378127A0841|11 17|effects
P01378127A0841|23 39|calcium supplement
P01378127A0841|42 58|calcium antagonist
P01378127A0841|80 103|such hypotensive responses
P01378127A0841|111 117|optimal
P01378127A0841|120 130|predictable
P01378127A0841|140 153|dose-dependent
P01378431A0202|0 1|C.
P01378431A0202|3 5|Sun
P01378431A0202|7 8|J.
P01378431A0202|10 12|Hsu
P01378431A0202|14 18|M.-Y.
P01378431A0202|20 34|Vallejo-Ramirez
P01378431A0202|36 37|J.
P01378431A0202|39 44|Inouye
P01378431A0202|46 47|S.
P01378431A0202|52 57|Inouye
P01378431A0202|59 60|M.
P01378506A0884|16 34|full-deletion mutant
P01378506A0884|42 52|strong block
P01378506A0884|55 66|virus release
P01378506A0884|82 83|NC
P01378506A0884|96 108|virus assembly
P01378526A0535|29 45|FK506 plasma levels
P01378526A0535|78 87|side effect
P01379032A0495|6 12|percent
P01379032A0495|15 22|patients
P01379032A0495|40 47|steroids
P01379032A0495|55 72|average steroid dose
P01379032A0495|94 101|steroids
P01379032A0495|108 109|mg
P01379032A0495|112 121|prednisone
P01379150A0996|5 15|cibenzoline
P01379150A0996|20 47|effective antiarrhythmic agent
P01379150A0996|53 84|favourable pharmacokinetic profile
P01379150A0996|108 117|other class
P01379150A0996|119 123|drugs
P01379150A0996|126 133|patients
P01379150A0996|153 171|high risk arrhythmias
P01380062A0097|0 7|T antigen
P01380062A0097|20 55|H-2Db-restricted cytotoxic T lymphocyte
P01380062A0097|57 59|CTL
P01380062A0097|61 79|recognition epitopes
P01380062A0097|87 93|targets
P01380062A0097|97 108|CTL clones Y-1
P01380062A0097|110 112|Y-2
P01380062A0097|114 116|Y-3
P01380062A0097|121 123|Y-5
P01380076A0165|18 37|reversed-phase column
P01380076A0165|42 60|paired-ion technique
P01380076A0165|63 84|separate docusate sodium
P01380076A0165|89 103|other components
P01380454A0451|24 37|protein product
P01380454A0451|43 51|ref-1 gene
P01380454A0451|65 82|DNA binding activity
P01380454A0451|85 103|Fos-Jun heterodimers
P01380454A0451|105 121|Jun-Jun homodimers
P01380454A0451|125 144|Hela cell AP-1 proteins
P01380454A0451|159 190|several other transcription factors
P01380454A0451|200 208|NF-kappa B
P01380454A0451|210 212|Myb
P01380454A0451|216 222|members
P01380454A0451|228 241|ATF/CREB family
P01380454A0451|228 230|ATF
P01380454A0451|232 235|CREB
P01380716A0174|3 15|pulpal tissues
P01380716A0174|21 45|permanent mandibular molars
P01380716A0174|77 90|calcium hydrate
P01380825A0622|0 19|Northern blot analyses
P01380825A0622|42 56|5-kilobase mRNAs
P01380825A0622|75 78|cDNA
P01380825A0622|95 101|tissues
P01380825A0622|153 172|housekeeping function
P01383690A1023|3 14|ARG SH2 domain
P01383690A1023|34 45|weak affinity
P01383690A1023|49 51|BCR
P01383690A1023|105 116|ABL SH2 domain
P01383695A0100|12 25|EBV B-cell clone
P01383695A0100|27 31|E29.1
P01383695A0100|48 61|week-old embryo
P01383695A0100|79 98|IgM kappa and IgM lambda
P01383695A0100|79 86|IgM kappa
P01383695A0100|90 98|IgM lambda
P01384040A1043|18 27|activation
P01384040A1043|47 53|regions
P01384040A1043|69 91|same relative orientation
P01384040A1043|110 123|wild-type pCF10
P01384165A0000|2 5|rats
P01384165A0000|30 36|omentum
P01384165A0000|50 64|vascularization
P01384165A0000|70 76|trachea
P01384165A0000|82 93|regeneration
P01384165A0000|99 115|mucosal epithelium
P01384165A0000|125 134|early stage
P01384165A0000|140 159|free tracheal grafting
P01384229A0175|8 29|possible functional role
P01384229A0175|36 53|putative chicken ICS
P01384229A0175|57 71|oligonucleotide
P01384229A0175|83 99|upstream sequences
P01384229A0175|105 113|BF-IV gene
P01384229A0175|144 157|multiple copies
P01384229A0175|167 182|herpes TK promoter
P01384229A0175|197 228|chloramphenicol acetyl transferase
P01384229A0175|230 237|CAT) gene
P01384229A0175|230 232|CAT
P01384229A0175|239 245|pBLCAT2
P01385462A0151|13 61|separate high-performance liquid chromatographic runs
P01385462A0151|85 119|gamma-aminobutyric acid determination
P01385462A0151|150 159|monoamines
P01386210A0293|11 23|successful use
P01386210A0293|26 49|electroconvulsive therapy
P01386210A0293|64 79|severe depression
P01386210A0293|83 90|young man
P01386210A0293|95 116|adult GM2 gangliosidosis
P01386897A0000|0 4|Entry
P01386897A0000|7 16|yeast cells
P01386897A0000|24 39|mitotic cell cycle
P01386897A0000|41 45|Start
P01386897A0000|65 75|CDC28 kinase
P01386897A0000|94 111|G1-specific cyclins
P01386897A0000|121 124|CLN1
P01386897A0000|128 131|CLN2
P01386897A0000|133 135|ref
P01387105A0933|7 26|Southern blot analyses
P01387105A0933|36 44|backcross
P01387105A0933|48 58|cogenic mice
P01387105A0933|60 83|recombinant inbred strains
P01387105A0933|88 105|somatic cell hybrids
P01387105A0933|110 120|genetic loci
P01387105A0933|135 159|cyclin B1-related sequences
P01387105A0933|171 183|loci Cycb1-rs1
P01387105A0933|186 194|Cycb1-rs9
P01387105A0933|208 223|mouse chromosomes
P01387105A0933|241 241|X
P01388160A1102|5 18|residue Glu-381
P01388160A1102|21 24|beta
P01388160A1102|54 60|residue
P01388160A1102|68 81|epsilon peptide
P01388160A1102|106 120|peptide sequence
P01388160A1102|131 145|possible choices
P01388160A1102|148 154|Ser-106
P01388160A1102|156 162|Ser-107
P01388160A1102|166 172|Ser-108
P01389362T0000|0 8|Porcelain
P01389362T0000|17 28|bond strength
P01389362T0000|34 47|dentin adhesive
P01389573A1071|0 3|TBPf
P01389573A1071|16 23|quotient
P01389573A1071|55 71|second measurement
P01389573A1071|73 77|TBPf =
P01389573A1071|79 80|P1
P01389573A1071|82 83|P2
P01389573A1071|87 88|A1
P01389573A1071|90 91|A2
P01389585A0825|18 27|Scotchbond
P01389585A0825|32 50|Prisma Universal Bond
P01389585A0825|73 92|dentine bonding agents
P01391001A0583|17 38|important yeasts species
P01391001A0583|50 50|%
P01391001A0583|67 75|ATB method
P01391001A0583|87 105|conventional methods
P01392012A0228|3 29|neurohypophysial vasopressin
P01392012A0228|19 29|vasopressin
P01392012A0228|33 47|oxytocin content
P01392012A0228|33 40|oxytocin
P01392012A0228|63 75|pressor effect
P01392012A0228|85 92|Dekanski
P01392012A0228|95 115|milk-ejection activity
P01392012A0228|132 140|van Dongen
P01392012A0228|144 147|Hays
P01392277A0000|0 7|Comments
P01392277A0000|21 33|present status
P01392277A0000|36 46|regulations
P01392277A0000|64 76|swimming pools
P01392277A0000|80 84|baths
P01392277A0000|113 126|KOK regulations
P01392277A0000|141 161|Federal German standard
P01392277A0000|163 165|DIN
P01392277A0000|167 169|No.
P01392358A0389|21 36|telephone contact
P01392358A0389|39 48|home visits
P01394200A0592|3 16|treatment group
P01394200A0592|33 48|T-cell activation
P01394200A0592|55 72|initial lymphopenia
P01394200A0592|84 103|rebound lymphocytosis
P01394200A0592|107 118|upregulation
P01394200A0592|124 140|subset markers CD25
P01394200A0592|137 140|CD25
P01394200A0592|142 152|interleukin
P01394200A0592|154 161|receptor
P01394200A0592|166 171|CD45RO
P01394200A0592|173 185|T-memory cells
P01394200A0592|173 173|T
P01394655A0615b|0 13|Urease activity
P01394655A0615b|0 5|Urease
P01394655A0615b|34 50|ammonia production
P01394655A0615b|55 58|urea
P01394655A0615b|79 80|ng
P01394655A0615b|89 92|S/N =
P01394655A0615b|101 118|Jack bean meal urease
P01395755A1023|13 34|significant differences
P01395755A1023|66 72|methods
P01395755A1023|84 95|oxygen uptake
P01395755A1023|105 110|ml/min
P01395755A1023|121 126|ml/min
P01395755A1023|128 128|p
P01395755A1023|137 150|oxygen delivery
P01395755A1023|161 166|ml/min
P01395755A1023|178 183|ml/min
P01395755A1023|185 185|p
P01395755A1023|197 209|cardiac output
P01395755A1023|220 224|L/min
P01395755A1023|236 240|L/min
P01395755A1023|242 242|p
P01396432A0388|9 17|wide range
P01396432A0388|20 37|cognitive functions
P01396432A0388|61 67|seizure
P01396432A0388|94 110|memory performance
P01396444A0934|3 13|experiments
P01396444A0934|29 39|micromilieu
P01396444A0934|45 51|alveoli
P01396444A0934|75 110|certain physiological activation states
P01396444A0934|118 135|phagocytic activity
P01396572A0320|10 32|supercoiled plasmid pUC19
P01396572A0320|65 85|identical plasmid pUC19
P01396572A0320|87 88|CG
P01396572A0320|107 111|dG-dC
P01396572A0320|126 131|Z-form
P01396572A0320|137 155|excellent competitor
P01396583A0204|1 11|cDNA library
P01396583A0204|14 24|tumour cells
P01396583A0204|42 57|interleukin 2 gene
P01396583A0204|42 52|interleukin
P01396583A0204|54 71|gene-specific probe
P01396592A1113|3 13|experiments
P01396592A1113|28 34|SCL gene
P01396592A1113|53 86|erythroid transcription factor GATA-1
P01396592A1113|97 110|SCL gene product
P01396592A1113|120 136|positive regulator
P01396592A1113|139 162|erythroid differentiation
P01396601A0986|14 27|lumenal domains
P01396601A0986|30 35|Sec12p
P01396601A0986|37 41|Stl1p
P01396601A0986|45 49|Stl2p
P01396601A0986|87 105|appreciable homology
P01398068A0948|0 8|Complexes
P01398068A0948|19 27|wild-type
P01398068A0948|37 42|his175
P01398068A0948|45 67|his273 mutant p53 proteins
P01398068A0948|98 111|RGC DNA sequence
P01398071A0526|20 40|cold-sensitive strains
P01398071A0526|58 74|extracts deficient
P01398071A0526|77 88|BRF1 activity
P01398071A0526|77 80|BRF1
P01398071A0526|105 127|transcriptional activity
P01398071A0526|130 143|RNA polymerases
P01398071A0526|152 154|III
P01398073A0986|5 11|results
P01398073A0986|36 65|single multisubunit TFIID protein
P01398073A0986|74 99|transcriptional stimulation
P01398073A0986|102 125|diverse activation domains
P01398073A0986|134 150|TATA-less promoter
P01398074A0697|3 14|gene sequence
P01398074A0697|30 46|340-nucleotide RNA
P01398074A0697|49 61|total yeast RNA
P01398074A0697|75 100|RNase MRP enzyme preparations
P01398074A0697|75 88|RNase MRP enzyme
P01398074A1081|3 17|RNase MRP RNA gene
P01398074A1081|30 51|insertional replacement
P01398074A1081|76 92|cellular viability
P01398074A1081|105 123|critical nuclear role
P01398074A1081|127 134|RNase MRP
P01398098A0770|0 17|Clone pSRc200 hybrid
P01398098A0770|28 31|mRNA
P01398098A0770|38 57|cell-free translation
P01398098A0770|67 83|38-kDa polypeptide
P01398104A0834|9 15|results
P01398104A0834|17 21|CBF-A
P01398104A0834|25 36|novel CArG box
P01398104A0834|39 43|ssDNA
P01398104A0834|48 65|RNA-binding protein
P01398104A0834|76 106|repressive transcriptional factor
P01398106A0754|0 7|Cleavage
P01398106A0754|13 32|intron-encoded enzyme
P01398106A0754|34 39|I-CreI
P01398106A0754|48 49|bp
P01398106A0754|54 55|bp
P01398106A0754|63 81|intron insertion site
P01398106A0754|91 94|exon
P01398106A0754|119 125|strands
P01398106A0754|151 178|4-nt single-stranded overhangs
P01398106A0754|186 194|OH termini
P01398140A0488|16 28|Xenopus U7 gene
P01398140A0488|40 75|adjacent octamer-binding motifs located
P01398140A0488|87 88|bp
P01398140A0488|104 106|PSE
P01398140A0488|120 132|usual location
P01398140A0488|146 147|bp
P01399206A0375|3 9|results
P01399206A0375|17 30|earlier reports
P01399206A0375|35 55|collagenase inhibitors
P01399206A0375|35 45|collagenase
P01399206A0375|78 93|blister formation
P01399206A0375|96 134|recessive dystrophic epidermolysis bullosa
P01400217T0000|0 17|Mutational analysis
P01400217T0000|20 61|essential IncP alpha plasmid transfer genes traF
P01400217T0000|58 61|traF
P01400217T0000|65 68|traG
P01400217T0000|85 88|traF
P01400217T0000|91 106|phage sensitivity
P01400396A1265|3 10|promoter
P01400396A1265|35 47|phorbol esters
P01400396A1265|82 106|transcriptional activation
P01400396A1265|109 126|protein kinase C beta
P01400401A0065|2 7|humans
P01400401A0065|13 32|AMP deaminase variants
P01400401A0065|40 40|M
P01400401A0065|50 50|L
P01400401A0065|59 60|E1
P01400401A0065|65 66|E2
P01400401A0065|68 78|erythrocyte
P01400401A0065|110 120|biochemical
P01400401A0065|124 144|immunological criteria
P01400401A0854|0 18|Western blot analyses
P01400401A0854|25 55|anti-E-specific immunoreactivity
P01400401A0854|25 30|anti-E
P01400401A0854|58 82|affinity-purified extracts
P01400401A0854|97 115|bacterial expression
P01400401A0854|128 136|AMPD3 cDNA
P01400775A0435|5 11|results
P01400775A0435|27 49|endogenous N-methylation
P01400775A0435|52 61|salsolinol
P01400775A0435|66 83|N-methylsalsolinol
P01402647A0114|0 11|DR1 molecules
P01402647A0114|24 51|human lymphoblastoid cell lines
P01402647A0114|80 95|peptide sequences
P01402647A0114|110 121|phage surface
P01403222A0391|23 39|collaborative care
P01403222A0391|65 85|maternal blood donation
P01403222A0391|89 111|intrauterine transfusion
P01403391T0000|0 16|Chronic hepatitis B
P01403391T0000|26 41|Romanian children
P01404401A0740|9 21|ATPase cluster
P01404401A0740|26 42|open reading frames
P01404401A0740|65 74|homologous
P01404401A0740|80 99|known chloroplast gene
P01404612A0303|10 28|recombinant human Ads
P01404612A0303|40 55|noninfectious HIV
P01404612A0303|58 79|other microbial proteins
P01404612A0303|83 109|attractive vaccine candidates
P01406630A0545|0 8|Alignment
P01406630A0545|22 30|sequences
P01406630A0545|50 66|consensus sequence
P01406630A0545|70 76|binding
P01406630A0545|82 121|individual homodimeric Rel-related proteins
P01406630A0545|103 121|Rel-related proteins
P01406630A0545|126 151|DNA-protein binding analysis
P01406630A0545|126 136|DNA-protein
P01406630A0545|165 176|DNA sequences
P01406630A0545|185 203|sequence specificity
P01406630A0545|209 216|proteins
P01406630A0965|12 14|p50
P01406630A0965|18 40|p65-selected kappa B motif
P01406630A0965|56 74|differential binding
P01406630A0965|91 102|other protein
P01406630A0965|114 120|binding
P01406630A0965|139 167|heterodimeric NF-kappa B complex
P01406656A1075|9 19|cosmid clone
P01406656A1075|33 48|entire mouse alpha
P01406656A1075|39 49|mouse alpha 1
P01406656A1075|70 71|kb
P01406656A1075|81 82|kb
P01406656A1075|88 98|flanking DNA
P01406656A1075|121 126|levels
P01406656A1075|129 139|fibroblasts
P01406656A1075|154 165|oncogenic ras
P01406677A0000|8 48|transcriptional control elements responsible
P01406677A0000|52 76|muscle-specific expression
P01406677A0000|82 99|human myoglobin gene
P01406677A0000|112 129|mutational analysis
P01406677A0000|132 148|upstream sequences
P01406677A0000|150 168|nucleotide positions
P01406677A0000|190 213|transcriptional start site
P01406677A0000|224 244|firefly luciferase gene
P01406677A0000|231 244|luciferase gene
P01406688A0898|0 17|Sequencing analysis
P01406688A0898|34 44|rap1t allele
P01406688A0898|54 69|nonsense mutation
P01406688A0898|77 90|discrete region
P01406688A0898|98 107|amino acids
P01406703A1435|12 28|Y1 cell cDNA library
P01406703A1435|36 52|DNA-binding region
P01406703A1435|58 91|H-2RIIBP nuclear hormone receptor cDNA
P01406703A1435|104 107|cDNA
P01406703A1435|136 153|steroidogenic cells
P01407286A0427|0 6|Autopsy
P01407286A0427|19 30|good survival
P01407286A0427|48 52|cells
P01407286A0427|57 71|good integration
P01407286A0427|101 106|traces
P01407286A0427|109 142|positive immunocytochemical reaction
P01407286A0427|146 164|tyrosine hydroxylase
P01408090A0572|17 32|TEE visualization
P01408090A0572|38 61|proximal coronary arteries
P01408137A0974|28 41|high G+C content
P01408137A0974|45 45|%
P01408137A0974|85 86|bp
P01408137A0974|102 110|mRNA start
P01408137A0974|114 117|% G+C
P01408219A0670|10 17|patients
P01408219A0670|22 31|persistent
P01408219A0670|43 58|lymph-adenopathy
P01408219A0670|60 62|PGL
P01408219A0670|67 75|nontender
P01408219A0670|77 93|nonenlarging nodes
P01408219A0670|95 112|pathologic analysis
P01408219A0670|121 139|lymphoid hyperplasia
P01408474A0531|0 12|PaO2 threshold
P01408474A0531|35 44|indwelling
P01408474A0531|47 60|sensor catheter
P01409581A0206|18 38|E26 virus-encoded v-ets
P01409581A0206|45 75|myeloid/B-cell-specific factor PU
P01409643A0618|7 26|lambda gt11 expression
P01409643A0618|38 53|oligonucleotides
P01409643A0618|72 97|human immunodeficiency virus
P01409643A0618|99 109|TATA element
P01409643A0618|139 153|cellular protein
P01409643A0618|169 181|molecular mass
P01409643A0618|187 189|kDa
P01409643A0618|205 231|TATA element modulatory factor
P01409643A0618|233 235|TMF
P01410071T0000|0 10|Blood levels
P01410071T0000|13 21|melatonin
P01410071T0000|23 31|serotonin
P01410071T0000|33 40|cortisol
P01410071T0000|45 53|prolactin
P01410071T0000|69 83|circadian rhythm
P01410071T0000|86 108|platelet serotonin uptake
P01413984A0737|27 46|n-3 FA supplementation
P01413984A0737|49 64|total cholesterol
P01413984A0737|66 79|HDL cholesterol
P01413984A0737|81 94|LDL cholesterol
P01413984A0737|96 100|apo A1
P01413984A0737|102 103|Lp
P01413984A0737|108 112|HbA1C
P01413984A0737|114 120|glucose
P01413984A0737|122 131|fibrinogen
P01413984A0737|133 142|factor VIII
P01413984A0737|144 158|antithrombin III
P01413984A0737|144 155|antithrombin
P01413984A0737|160 188|plasminogen activator inhibitor
P01413984A0737|190 215|tissue plasminogen activator
P01413984A0737|219 250|von Willebrand factor concentration
P01413984A0737|219 237|von Willebrand factor
P01413984A0737|254 265|bleeding time
P01413984A0737|270 277|systolic
P01413984A0737|280 301|diastolic blood pressure
P01414219A0319|3 19|healthy volunteers
P01414219A0319|31 52|significant differences
P01414219A0319|55 57|AUC
P01414219A0319|59 82|peak plasma concentrations
P01414219A0319|112 114|OXC
P01414219A0319|149 151|ERY
P01418272A1072|6 10|ng/mL
P01418272A1072|16 21|cutoff
P01418272A1072|39 41|CEA
P01418272A1072|47 47|%
P01418494T0000|0 13|Rolandic spikes
P01418494T0000|17 33|cognitive function
P01418542A0000|19 36|beta-glycyrrhetate
P01418542A0000|38 40|SGA
P01418542A0000|44 65|experimental arrhythmia
P01418834A0987|5 29|chronic hematocrit decrease
P01418834A0987|39 39|H
P01418834A0987|42 42|P
P01418834A0987|54 68|significant fall
P01418834A0987|71 83|blood pressure
P01418834A0987|125 128|mm Hg
P01418834A0987|143 143|P
P01418860A0797|3 9|effects
P01418860A0797|12 20|diltiazem
P01418860A0797|25 39|stereoselective
P01418860A0797|48 59|potentiation
P01418860A0797|69 82|d-cis diltiazem
P01418860A0797|99 105|greater
P01418860A0797|111 115|cases
P01418860A0797|133 146|l-cis diltiazem
P01418860A0797|165 186|calcium channel blockade
P01418860A0797|204 215|interactions
P01419945A1386|0 11|Localization
P01419945A1386|17 30|brachial plexus
P01419945A1386|38 52|nerve stimulator
P01419945A1386|76 87|interscalene
P01419945A1386|89 103|supraclavicular
P01419945A1386|108 120|axillary sites
P01420177A1065|0 11|Substitution
P01420177A1065|20 24|Val33
P01420177A1065|28 30|Gly
P01420177A1065|34 38|Gly28
P01420177A1065|42 44|Ser
P01420177A1065|68 75|residues
P01420177A1065|81 94|protein kinases
P01420177A1065|106 111|enzyme
P01420177A1065|126 143|detectable activity
P01420223T0000|0 11|Significance
P01420223T0000|17 26|biopsy site
P01420223T0000|32 52|latissimus dorsi muscle
P01420223T0000|56 66|fiber typing
P01420363A0818|3 6|TIMP
P01420363A0818|16 22|AP1 site
P01420363A0818|26 41|promiscuous motif
P01420363A0818|51 64|c-Fos/c-Jun AP1
P01420363A0818|51 55|c-Fos
P01420363A0818|89 107|effective competitor
P01420363A0818|111 117|binding
P01420363A0818|120 136|nuclear AP1 factors
P01420363A0818|142 153|consensus TRE
P01420363A0818|175 181|factors
P01420363A0818|207 218|consensus TRE
P01420363T0000|0 10|Involvement
P01420363T0000|13 15|AP1
P01420363T0000|19 34|PEA3 binding sites
P01420363T0000|52 94|murine tissue inhibitor of metalloproteinases-1
P01420363T0000|52 72|murine tissue inhibitor
P01420363T0000|75 94|metalloproteinases-1
P01420363T0000|96 101|TIMP-1
P01420363T0000|103 115|transcription
P01420579A0292|5 21|serum neutralizing
P01420579A0292|23 24|SN
P01420579A0292|26 47|antibody negative calves
P01420579A0292|52 52|%
P01420579A0292|67 67|%
P01420579A0292|84 93|SN antibody
P01420579A0292|105 114|intranasal
P01420579A0292|118 141|intramuscular vaccination
P01421145A1190|0 12|Fractionation
P01421145A1190|15 34|crude nuclear extracts
P01421145A1190|37 65|heparin-agarose chromatography
P01421145A1190|79 84|PCAT-1
P01421145A1190|91 99|prevalent
P01421145A1190|102 109|extracts
P01421145A1190|122 144|salt-stressed leaf tissue
P01421390T0000|1 15|controlled trial
P01421390T0000|18 79|recombinant human granulocyte-macrophage colony-stimulating factor
P01421390T0000|85 104|total body irradiation
P01421390T0000|106 126|high-dose chemotherapy
P01421390T0000|131 165|autologous bone marrow transplantation
P01421390T0000|169 194|acute lymphoblastic leukemia
P01421390T0000|197 213|malignant lymphoma
P01421609A1067|24 27|DMVA
P01421609A1067|40 59|more myocardial trauma
P01421609A1067|64 66|CPB
P01421609A1067|84 114|resuscitative circulatory support
P01422265A0263|3 20|IgG subclass profile
P01422265A0263|3 5|IgG
P01422265A0263|23 45|untreated coeliac disease
P01422265A0263|69 83|healthy controls
P01422265A0263|85 88|IgG1
P01422265A0263|102 105|IgG2
P01422265A0263|107 110|IgG3
P01422265A0263|112 115|IgG4
P01422265A0263|143 169|individual subclass responses
P01422265A0263|186 200|coeliac patients
P01423454A0309|0 10|Examination
P01423454A0309|13 16|ANCA
P01423454A0309|27 49|significant contribution
P01423454A0309|62 78|accurate diagnosis
P01423454A0309|81 95|renal vasculitis
P01423454A0309|167 192|immunosuppressive treatment
P01423738A0639|5 13|other hand
P01423738A0639|15 31|total pinealectomy
P01423738A0639|62 75|blinded rabbits
P01423738A0639|93 115|substantial deceleration
P01423738A0639|121 127|rhythms
P01423738A0639|129 141|mean delta tau =
P01423738A0639|147 147|h
P01424674A0000|0 20|Cicatricial pemphigoid
P01424674A0000|25 49|autoimmune systemic disease
P01424674A0000|65 96|chronic conjunctival cicatrization
P01425653T0000|3 9|effects
P01425653T0000|15 20|levels
P01425653T0000|23 39|caffeine ingestion
P01425653T0000|42 76|excess postexercise oxygen consumption
P01425653T0000|79 92|untrained women
P01425921A1286|17 24|features
P01425921A1286|38 53|amino acid changes
P01425921A1286|65 92|single lysine deletion relative
P01425921A1286|96 119|primate consensus sequence
P01425921A1286|125 158|first complementary-determing region
P01425921A1286|161 164|V1J1
P01426635A0496|18 22|ZFH-2
P01426635A0496|28 36|larval CNS
P01426635A0496|42 51|intriguing
P01426635A0496|63 65|DDC
P01426635A0496|68 84|specific serotonin
P01426635A0496|88 102|dopamine neurons
P01427034A0440|9 15|introns
P01427034A0440|18 53|other duplicated ribosomal protein genes
P01427034A0440|33 53|ribosomal protein genes
P01427034A0440|68 75|diverged
P01427034A0440|80 97|duplicated S13 genes
P01427034A0440|90 97|S13 genes
P01427034A0440|111 131|identical DNA sequences
P01427034A0440|141 142|bp
P01427034A0440|162 168|introns
P01427457A0000|3 13|prospective
P01427457A0000|15 37|randomized clinical trial
P01427457A0000|51 58|efficacy
P01427457A0000|76 77|SC
P01427457A0000|98 98|h
P01427457A0000|100 113|calcium heparin
P01427457A0000|116 126|intravenous
P01427457A0000|131 143|sodium heparin
P01427457A0000|160 186|proximal deep-vein thrombosis
P01427457A0000|188 190|DVT
P01428490A0671|3 19|highest prevalence
P01428490A0671|30 39|pet allergy
P01428490A0671|41 52|chronic cough
P01428490A0671|54 59|wheeze
P01428490A0671|61 67|attacks
P01428490A0671|70 78|shortness
P01428490A0671|103 124|doctor-diagnosed asthma
P01428490A0671|135 142|children
P01428490A0671|149 152|pets
P01428513A0440|19 30|advantageous
P01428513A0440|41 51|such persons
P01429596A1669|17 32|unique properties
P01429596A1669|55 67|hemagglutinin
P01429596A1669|81 121|Limulus 18K agglutination-aggregation factor
P01429596A1669|123 129|18K-LAF
P01429624A0328|13 36|nonpermissive temperature
P01429624A0328|61 94|guanyl nucleotide-dependent activity
P01429624A0328|97 111|adenylylcyclase
P01429714A0730|0 3|Clin
P01429724A0664|22 43|minimal catalytic domain
P01429724A0664|46 50|Nmt1p
P01429724A0664|53 59|located
P01429724A0664|67 71|Ile59
P01429724A0664|75 79|Phe96
P01429724A0664|83 88|Gly451
P01429724A0664|92 97|Leu455
P01429740A1065|18 49|complete mitochondrial presequence
P01429740A1065|56 75|lipoyl-bearing domain
P01429740A1065|92 96|exons
P01429740A1065|112 127|functional E2 gene
P01429768T0000|0 22|Human neutrophil response
P01429768T0000|25 42|short-term exposure
P01429768T0000|45 65|F-75 cobalt-based alloy
P01429836A0457|0 9|Disruption
P01429836A0457|12 23|microtubules
P01429836A0457|39 46|fidelity
P01429836A0457|49 56|kinetics
P01429836A0457|59 80|vacuolar protein sorting
P01429836A0457|96 108|Vps1p function
P01429836A0457|96 100|Vps1p
P01429836A0457|125 136|microtubules
P01429836A1205|1 10|mutant form
P01429836A1205|13 17|Vps1p
P01429836A1205|28 50|entire GTP-binding domain
P01429836A1205|65 86|vacuolar protein sorting
P01429836A1205|89 102|wild-type cells
P01431380A0244|14 26|field research
P01431380A0244|31 39|tick fauna
P01431380A0244|78 94|permissible enough
P01431380A0244|106 110|ticks
P01431380A0244|116 122|vectors
P01431380A0244|140 162|anti-SF group rickettsiae
P01431380A0244|164 167|SFGR
P01431380A0244|169 176|antibody
P01431380A0244|179 182|mice
P01431380A0244|201 213|tick emulsions
P01431380A0244|215 222|findings
P01431380A0244|225 243|rickettsiae reactive
P01431380A0244|246 256|patient sera
P01431380A0244|260 293|species-specific monoclonal antibody
P01431380A0244|296 299|JSFR
P01431380A0244|305 318|hemolymph cells
P01431380A0244|325 329|ticks
P01431380A0244|334 366|electron microscopical observations
P01431380A0244|369 372|SFGR
P01431380A0244|375 395|various internal organs
P01431380A0244|408 420|salivary gland
P01431380A0244|423 427|ticks
P01431602A0229|3 14|second method
P01431602A0229|20 24|macro
P01431602A0229|26 30|assay
P01431602A0229|36 51|sensitivity range
P01431602A0229|62 81|micrograms phosphorus
P01431602A0229|93 108|microliters HClO4
P01431809T0000|0 17|Nucleotide sequence
P01431809T0000|21 43|transcriptional analysis
P01431809T0000|49 62|polyhedrin gene
P01431809T0000|65 104|Spodoptera exigua nuclear polyhedrosis virus
P01432453T0000|0 9|Validation
P01432453T0000|21 27|systems
P01432453T0000|30 45|system definition
P01433391A0594|16 26|dark rearing
P01433391A0594|31 46|numerical density
P01433391A0594|49 63|cortical neurons
P01433391A0594|127 133|kittens
P01433391A0594|157 162|higher
P01433502A1163|5 11|results
P01433502A1163|32 45|class I enhancer
P01433502A1163|38 53|enhancer activity
P01433502A1163|56 76|Ad12-transformed cells
P01433502A1163|105 116|higher levels
P01433502A1163|119 143|an enhancer-specific factor
P01433502A1163|121 143|enhancer-specific factor
P01433502A1163|162 170|repressor
P01433524A0788|1 12|second domain
P01433524A0788|14 20|located
P01433524A0788|26 35|C-terminal
P01433524A0788|39 48|amino acids
P01433524A0788|51 53|IE1
P01433524A0788|68 77|inhibitory
P01433524A0788|81 101|DNA-binding activities
P01435698A0000|23 40|blood compatibility
P01435698A0000|43 61|autogenous vein graft
P01435698A0000|63 65|AVG
P01435698A0000|68 74|changes
P01435698A0000|77 88|prostacyclin
P01435698A0000|90 93|PGI2
P01435698A0000|114 123|harvesting
P01435698A0000|127 146|arterial implantation
P01436261A0145|0 25|Subcutaneous administration
P01436261A0145|31 50|somatostatin analogue
P01436261A0145|31 42|somatostatin
P01436261A0145|52 61|octreotide
P01436261A0145|66 75|micrograms
P01436261A0145|99 118|sustained improvement
P01436261A0145|121 129|diarrhoea
P01436261A0145|133 145|disappearance
P01436261A0145|148 165|faecal incontinence
P01436261A0145|181 196|calcitonin levels
P01436261A0145|181 190|calcitonin
P01437562A0462|0 17|Anti-CRK antibodies
P01437562A0462|25 36|53kDa protein
P01437562A0462|39 46|extracts
P01437562A0462|49 61|C.fasciculata
P01437562A0462|100 117|nucleotide sequence
P01438224A0749|49 50|J.
P01438287T0000|14 27|vaccinia vector
P01438287T0000|48 63|recombinant genes
P01441120T0000|0 2|Use
P01441120T0000|5 23|free-access minerals
P01441818T0001|0 14|Interferon type I
P01441818T0001|0 13|Interferon type
P01441818T0001|17 39|protective body reactions
P01441818T0001|44 74|experimental Klebsiella infection
P01443047A0773|2 13|other changes
P01443047A0773|16 49|hematopoietic differentiation status
P01443047A0773|79 94|Id-SCL expression
P01443047A0773|79 84|Id-SCL
P01443745T0000|0 21|Respiratory interaction
P01443745T0000|27 42|spinal anesthesia
P01443745T0000|46 53|sedation
P01443745T0000|58 66|midazolam
P01443748A1190|3 17|pressure greater
P01443748A1190|25 30|atm abs
P01443748A1190|43 54|excitability
P01443748A1190|60 67|tadpoles
P01443748A1190|107 112|reflex
P01443748A1190|117 136|involuntary movements
P01446132A0328|3 13|air embolism
P01446132A0328|33 42|only filter
P01446132A0328|46 74|retrieval-related complication
P01446828A1088|13 16|ADH5
P01446828A1088|25 45|consensus binding sites
P01446828A1088|52 84|transcriptional regulatory proteins
P01446828A1088|86 88|Sp1
P01446828A1088|90 92|AP2
P01446828A1088|94 98|LF-A1
P01446828A1088|100 103|NF-1
P01446828A1088|105 109|NF-A2
P01446828A1088|114 118|NF-E1
P01447139A0208|0 1|V.
P01447189A1546|21 29|RNK-Met-1
P01447189A1546|33 46|serine protease
P01447189A1546|51 64|unique activity
P01447189A1546|85 92|granules
P01447189A1546|95 118|large granular lymphocytes
P01447189T0000|0 11|Purification
P01447189T0000|15 21|cloning
P01447189T0000|25 43|novel serine protease
P01447189T0000|30 43|serine protease
P01447189T0000|45 53|RNK-Met-1
P01447189T0000|62 69|granules
P01447189T0000|73 100|rat natural killer cell leukemia
P01448107A0361|16 36|dominant GCN2 mutations
P01448107A0361|47 58|derepression
P01448107A0361|61 74|GCN4 expression
P01448107A0361|61 64|GCN4
P01448107A0361|89 107|amino acid starvation
P01448806A0135|0 13|Administration
P01448806A0135|16 28|growth hormone
P01448806A0135|36 47|faster growth
P01448806A0135|62 75|bone maturation
P01448917A0775|0 10|Comparisons
P01448917A0775|18 42|available amino acid residue
P01448917A0775|44 45|aa
P01448917A0775|47 65|sequence information
P01448917A0775|73 87|complete CPMV RNA
P01448917A0775|81 96|CPMV RNA 1 sequence
P01448917A0775|103 117|partial sequence
P01448917A0775|120 143|red clover mottle virus RNA 1
P01448917A0775|120 142|red clover mottle virus RNA
P01448917A0775|155 163|CPSMV RNA 1
P01448917A0775|155 162|CPSMV RNA
P01448917A0775|193 206|mature proteins
P01448917A0775|208 228|32K proteinase cofactor
P01448917A0775|211 228|proteinase cofactor
P01448917A0775|230 248|58K presumed helicase
P01448917A0775|230 232|58K
P01448917A0775|241 248|helicase
P01448917A0775|250 252|VPg
P01448917A0775|274 284|genomic RNAs
P01448917A0775|286 298|24K proteinase
P01448917A0775|303 323|87K presumed polymerase
P01448917A0775|340 352|cleavage sites
P01448932T0000|0 41|Rice dwarf phytoreovirus segment S12 transcript
P01448932T0000|44 55|tricistronic
P01449183A0795|23 38|beta 2 transferrin
P01449183A0795|23 26|beta
P01449183A0795|28 43|transferrin assay
P01449183A0795|60 85|cerebrospinal fluid otorrhea
P01449301A0710|0 15|Cold cardioplegia
P01449301A0710|35 38|mm Hg
P01449301A0710|46 52|minutes
P01449301A0710|57 61|hours
P01450815A0337|13 23|diatrizoate
P01450815A0337|29 32|IPRK
P01450815A0337|39 66|dose-dependent biphasic change
P01450815A0337|69 71|RPF
P01450815A0337|75 77|GFR
P01450815A0337|95 118|initial transient increase
P01450815A0337|130 135|marked
P01450815A0337|139 155|sustained decrease
P01451771A0619|12 19|analyses
P01451771A0619|27 41|family variables
P01451771A0619|49 70|present descriptive data
P01451771A0619|78 112|separate principal components analysis
P01451771A0619|114 116|PCA
P01451771A0619|121 151|multidimensional scaling analysis
P01451771A0619|153 155|MDS
P01451771A0619|161 185|self-reported health scores
P01451771A0619|189 196|husbands
P01451771A0619|203 207|wives
P01452037A0000|3 17|structural genes
P01452037A0000|26 64|glyceraldehyde-3-phosphate dehydrogenase
P01452037A0000|66 70|GAPDH
P01452037A0000|73 96|3-phosphoglycerate kinase
P01452037A0000|98 100|PGK
P01452037A0000|108 121|N-terminal part
P01452037A0000|124 147|triosephosphate isomerase
P01452037A0000|149 151|TIM
P01452037A0000|157 190|mesophilic Bacillus megaterium DSM319
P01452037A0000|208 218|gene cluster
P01452037A0000|220 228|gap operon
P01452037A0000|232 246|complementation
P01452037A0000|266 279|gap amber mutant
P01452584T0000|0 29|Pseudomonas aeruginosa exotoxin A
P01452584T0000|21 29|exotoxin A
P01452584T0000|40 50|retardation
P01452584T0000|53 64|wound healing
P01452584T0000|73 85|Lindberg Award
P01452703A0782|0 16|Laboratory studies
P01452703A0782|30 59|direct fluorescent-antibody kits
P01452703A0782|67 80|least sensitive
P01452703A0782|120 135|elementary bodies
P01452703A0782|139 140|ml
P01452703A0782|147 159|most ELISA kits
P01452703A0782|184 199|elementary bodies
P01452703A0782|203 204|ml
P01454518A0336|29 35|domains
P01454518A0336|42 72|overall evolutionary conservation
P01454518A0336|86 92|homolog
P01454518A0336|132 158|low stringency hybridizations
P01454518A0336|167 180|flanking probes
P01454518A0336|186 199|human ERCC3 cDNA
P01454819A0000|0 20|Mono-ADP-ribosylation
P01454819A0000|24 45|reversible modification
P01454819A0000|48 55|proteins
P01454819A0000|61 95|NAD:arginine ADP-ribosyltransferases
P01454819A0000|61 63|NAD
P01454819A0000|65 95|arginine ADP-ribosyltransferases
P01454819A0000|97 106|EC 2.4.2.31
P01454819A0000|97 98|EC
P01454819A0000|111 139|ADP-ribosylarginine hydrolases
P01454819A0000|141 150|EC 3.2.2.19
P01454819A0000|141 142|EC
P01454819A0000|173 181|reactions
P01454819A0000|186 206|ADP-ribosylation cycle
P01456888A0074|42 52|derivatives
P01456888A0074|58 92|HIV-1 group specific core antigen p55 gag
P01456888A0074|125 148|various expression systems
P01456888A0074|150 168|recombinant bacteria
P01456888A0074|170 177|vaccinia
P01456888A0074|182 194|baculoviruses
P01456888A0074|221 240|entire core protein p55
P01456888A0074|252 268|authentic sequence
P01456888A0074|281 308|myristylation consensus signal
P01457380A0000|3 11|tramtrack
P01457380A0000|13 15|ttk
P01457380A0000|40 45|69-kDa
P01457380A0000|49 62|88-kDa proteins
P01457380A0000|70 88|alternative splicing
P01457380A0000|94 113|primary ttk transcript
P01457695T0000a|0 6|Removal
P01457695T0000a|9 27|beta 2-microglobulin
P01457695T0000a|30 41|hemodialysis
P01457695T0000a|45 58|hemofiltration
P01457695T0000b|0 6|Removal
P01457695T0000b|9 27|beta 2-microglobulin
P01457695T0000b|30 41|hemodialysis
P01457695T0000b|45 58|hemofiltration
P01458170A0155|0 9|Adapromine
P01458170A0155|45 53|amplitude
P01458170A0155|59 70|dominant peak
P01458170A0155|74 95|dominant theta-activity
P01458170A0155|98 109|power spectra
P01458170A0155|115 117|EEG
P01458170A0155|123 128|cortex
P01458170A0155|132 140|hippocamp
P01458170A0155|158 174|rapid wave activity
P01458170A0155|180 183|beta
P01458170A0155|195 205|right cortex
P01458170A0155|209 217|hippocamp
P01459447A0484|5 13|sequences
P01459447A0484|28 32|clone
P01459447A0484|36 51|full-length genes
P01459447A0484|57 75|yeast genomic library
P01459451A0478|0 31|GAL4-VP16-mediated antirepression
P01459451A0478|0 3|GAL4
P01459451A0478|5 8|VP16
P01459451A0478|42 56|auxiliary factor
P01459451A0478|68 83|co-antirepressor
P01459451A0478|124 130|embryos
P01459885A0705|7 10|days
P01459885A0705|13 32|haloperidol treatment
P01459885A0705|34 47|similar changes
P01459885A0705|63 67|delta
P01459885A0705|93 98|alpha 1
P01459885A0705|93 97|alpha
P01459885A0705|114 121|fast beta
P01459921A0000|36 51|Hampshire wethers
P01459921A0000|66 86|Latin square experiment
P01459921A0000|105 123|linoleoyl methionine
P01459921A0000|127 142|calcium linoleate
P01459921A0000|156 167|duodenal flow
P01459921A0000|170 190|unsaturated fatty acids
P01459921A0000|192 196|C18:2
P01459921A0000|198 203|cis C18
P01460054A0478|9 13|ICSBP
P01460054A0478|31 54|amino-terminal amino acids
P01460054A0478|71 73|ICS
P01460054A0478|91 99|least part
P01460054A0478|105 120|DNA binding domain
P01460054A0478|123 129|located
P01460054A0478|152 164|amino terminus
P01460054A0968|10 14|ICSBP
P01460054A0968|41 73|submaximal transcriptional activity
P01460054A0968|76 93|IFN-inducible genes
P01460054A0968|96 113|hematopoietic cells
P01460772T0001|7 23|chronic hepatitis C
P01460772T0001|28 48|primary hypothyroidism
P01460772T0001|65 83|interferon treatment
P01462786T0000|0 20|Dynamic decision making
P01462786T0000|22 33|human control
P01462786T0000|36 49|complex systems
P01464329T0000|1 33|coiled-coil related protein specific
P01464329T0000|37 51|synapsed regions
P01464329T0000|54 79|meiotic prophase chromosomes
P01464606A0344|0 16|Comparable amounts
P01464606A0344|19 37|alpha 5 beta 1 integrin
P01464606A0344|19 23|alpha
P01464606A0344|25 28|beta
P01464606A0344|30 37|integrin
P01464606A0344|59 63|cells
P01464606A0344|66 79|chromatography
P01464606A0344|82 98|detergent extracts
P01464606A0344|102 146|fibronectin cell-binding fragment affinity column
P01464606A0344|102 132|fibronectin cell-binding fragment
P01464606A0344|150 156|elution
P01464606A0344|161 164|EDTA
P01467088T0075|0 8|Abstracts
P01467828A0542|5 11|results
P01467828A0542|21 39|possible involvement
P01467828A0542|42 65|endogenous opioid peptides
P01467828A0542|71 87|cardiac effects due
P01467828A0542|90 108|myocardial ischaemia
P01467828A0542|112 122|reperfusion
P01467828A0542|134 148|opiate receptors
P01467828A0542|156 171|opiate antagonism
P01468625A0282|16 19|LEU2
P01468625A0282|23 31|HIS3 cDNAs
P01468625A0282|86 90|cases
P01468625A0282|112 136|galactose-dependent manner
P01468625A1080|11 14|ACT1
P01468625A1080|30 34|times
P01468625A1080|39 42|NSR1
P01468625A1080|48 52|times
P01469042A0355|5 14|CENP-B gene
P01469042A0355|28 43|mammalian species
P01469042A0355|47 57|CENP-B boxes
P01469042A0355|72 98|mouse centromere satellite DNA
P01469042A0355|100 113|minor satellite
P01469042A0355|120 158|sequence-specific DNA-protein interaction
P01469042A0355|137 147|DNA-protein
P01469042A0355|186 209|common centromere function
P01469047A1606|27 36|tail domain
P01469047A1606|38 39|aa
P01469047A1606|53 58|shares
P01469047A1606|61 86|% amino acid sequence identity
P01469047A1606|92 104|723-aa protein
P01469047A1606|109 118|mouse brain
P01469047A1606|132 156|glutamic acid decarboxylase
P01470243A0871|13 20|subgroup
P01470243A0871|25 32|normal Ht
P01470243A0871|39 41|l/l
P01470243A0871|43 44|n =
P01470243A0871|58 77|significant reduction
P01470243A0871|79 79|p
P01470243A0871|106 111|months
P01470243A0871|115 115|%
P01470243A0871|121 121|%
P01470243A0871|172 172|%
P01470243A0871|178 178|%
P01470243A0871|213 221|viscosity
P01470243A0871|224 228|means
P01470243A0871|231 243|haemodilution
P01470243A0871|248 254|albumin
P01470243A0871|257 279|specific viscosity effect
P01470243A0871|285 302|normovolaemic group
P01470741T0062|0 11|Distribution
P01470741T0062|23 41|morphological course
P01471602A0362|3 16|appropriate use
P01471602A0362|20 27|benefits
P01471602A0362|30 49|bile acid sequestrants
P01471602A0362|51 63|nicotinic acid
P01471602A0362|65 75|fibric acids
P01471602A0362|77 111|3-hydroxy-3-methylglutaryl coenzyme A
P01471602A0362|113 129|HMG-CoA) reductase
P01471602A0362|113 119|HMG-CoA
P01471602A0362|121 139|reductase inhibitors
P01471602A0362|144 151|probucol
P01471602A0362|184 209|nonpharmacologic approaches
P01471602A0362|216 226|conjunction
P01471602A0362|234 238|drugs
P01473196A1016|15 30|more reabsorption
P01473196A1016|46 59|renal clearance
P01473207A0582|3 27|major pathological findings
P01473207A0582|33 40|placenta
P01473207A0582|45 57|prematuration
P01473207A0582|61 70|hypoplasia
P01473234A1001|0 10|Green pepper
P01473234A1001|33 85|N-nitrosothiazolidine-carboxylic acid formation relative
P01473234A1001|88 99|ascorbic acid
P01474990A0000|1 12|genomic clone
P01474990A0000|14 18|pTt21
P01474990A0000|68 98|Trypanosoma cruzi trypomastigotes
P01474990A0000|137 150|genomic library
P01474990A0000|155 168|trypomastigote
P01474990A0000|172 187|epimastigote cDNA
P01475381T0001|0 10|Brucellosis
P01476376T0000|0 4|Assay
P01476376T0000|7 10|urea
P01476376T0000|24 29|urease
P01476376T0000|40 59|differential pH-meter
P01477021A0394|0 6|RESULTS
P01477021A0394|13 20|AGA group
P01477021A0394|26 30|fetal
P01477021A0394|34 68|maternal serum prolactin concentration
P01477021A0394|47 55|prolactin
P01477021A0394|95 103|gestation
P01477021A0394|105 105|P
P01477021A0394|115 115|P
P01478672A0795|3 12|phage clone
P01478672A0795|22 29|junction
P01478672A0795|37 53|alpha satellite DNA
P01478672A0795|58 70|novel low-copy
P01480183A0000|6 19|flanking region
P01480183A0000|25 44|human lactoferrin gene
P01480183A0000|61 88|human placental genomic library
P01480183A1689|13 31|molecular mechanisms
P01480183A1689|37 50|estrogen action
P01480183A1689|64 88|lactoferrin gene expression
P01480183A1689|64 78|lactoferrin gene
P01480470A0323|0 5|BiP670
P01480470A0323|13 17|basal
P01480470A0323|21 23|Ca2
P01480470A0323|25 59|ionophore A23187-inducible activities
P01482912A0617|3 5|CEM
P01482912A0617|14 32|registration updates
P01482912A0617|38 47|HL7 message
P01482912A0617|60 75|data dependencies
P01482912A0617|78 82|rules
P01482912A0617|88 96|interface
P01482912A0617|102 119|relational database
P01483755A0000|0 28|Magnetic resonance spectroscopy
P01483755A0000|30 32|MRS
P01483755A0000|37 43|imaging
P01483755A0000|45 47|MRI
P01483755A0000|70 79|techniques
P01483755A0000|93 110|cellular metabolism
P01483755A0000|114 127|gross structure
P01483771A1335|15 23|greater NA
P01483771A1335|46 70|plasma epinephrine response
P01485648A0000|17 31|diagnostic value
P01485648A0000|50 67|Pharmacia CAP System
P01485648A0000|69 90|Pharmacia Diagnostics AB
P01485648A0000|92 98|Uppsala
P01485648A0000|100 105|Sweden
P01485648A0000|114 136|quantitative measurement
P01485648A0000|139 168|allergen-specific IgE antibodies
P01485648A0000|185 188|RAST
P01485648A0000|192 197|groups
P01485648A0000|200 207|patients
P01485648A0000|211 216|atopic
P01485648A0000|222 231|non-atopic
P01486836A0774|0 7|Patients
P01486836A0774|17 19|VPA
P01486836A0774|26 36|differences
P01486836A0774|49 69|visuomotor performance
P01486836A0774|71 80|verbal span
P01486836A0774|84 109|sensory discrimination tasks
P01486836A0774|112 113|T1
P01486836A0774|117 137|visuomotor performance
P01486836A0774|140 141|T2
P01486836A0774|147 157|spatial span
P01486836A0774|160 161|T3
P01486836A0774|172 182|differences
P01486836A0774|197 198|T4
P01487144A0505|14 24|gene segment
P01487144A0505|38 44|mu m poly
P01487144A0505|46 46|A
P01487144A0505|48 54|signals
P01487144A0505|68 69|bp
P01487144A0505|72 97|downstream flanking sequence
P01487144A0505|107 129|transcription terminator
P01487144A0505|136 147|myeloma cells
P01487144A0505|151 166|L cell fibroblasts
P01490493A0416|10 25|large examination
P01490493A0416|35 54|free serum cholesterol
P01490493A0416|56 65|total lipid
P01490493A0416|69 86|triglyceride levels
P01492463T0001|0 4|Alena
P01492463T0001|15 20|Prague
P01492463T0001|34 44|higher wages
P01493864A0619|0 14|Dopamine neurons
P01493864A0619|17 24|subjects
P01493864A0619|37 42|6-OHDA
P01493864A0619|58 70|pre-treatment
P01493864A0619|75 83|GBR-12909
P01495069A0392|0 3|DIBA
P01495069A0392|27 55|better negative predictive value
P01495069A0392|60 87|lower false negative percentage
P01495069A0392|92 95|DFAT
P01496348A0000|0 5|Caries
P01496348A0000|9 20|parodontitis
P01496348A0000|47 54|diseases
P01496348A0000|57 63|mankind
P01496784A0939|3 9|results
P01496784A0939|36 51|strongyloidiasis
P01496784A0939|65 75|sudden death
P01497582A0593|1 16|second large group
P01497582A0593|19 27|disorders
P01497582A0593|49 55|effects
P01497582A0593|58 67|infections
P01497582A0593|86 94|pathogens
P01497582A0593|116 121|embryo
P01497582A0593|127 134|placenta
P01498607A0000|4 27|short nucleotide sequences
P01498607A0000|29 33|boxes
P01498607A0000|55 73|light responsiveness
P01498607A0000|79 109|parsley chalcone synthase promoter
P01499213A0185|25 38|72-year-old man
P01499213A0185|43 52|ochronosis
P01499213A0185|65 84|hyperextension injury
P01499213A0185|115 122|fracture
P01499213A0185|132 154|ankylosed L2-L3 disk space
P01499616A0136|3 15|mean blood flow
P01499616A0136|21 34|penile foreskin
P01499616A0136|63 63|g
P01499616A0136|87 87|%
P01499616A0136|96 104|induction
P01499616A0136|107 116|anesthesia
P01499616A0136|138 138|%
P01499616A0136|159 180|parameatal foreskin flap
P01502157A0000|0 4|ME1a1
P01502157A0000|7 42|16-base-pair nuclear factor binding site
P01502157A0000|61 67|c-MYC P1
P01502157A0000|71 100|P2 transcription initiation sites
P01502157A0000|115 124|P2 activity
P01502157A0000|115 116|P2
P01504178T0000|13 17|years
P01504178T0000|32 44|Indian country
P01504178T0000|46 54|visionary
P01504853A0299|0 12|Exogenous LHRH
P01504853A0299|9 12|LHRH
P01504853A0299|36 49|mating behavior
P01504853A0299|52 65|several species
P01505488A0231|11 29|consecutive patients
P01505488A0231|41 43|EVL
P01505488A0231|63 68|August
P01505488A0231|76 79|July
P01505516A0928|12 23|aspartic acid
P01505516A0928|29 34|lysine
P01505516A0928|47 53|alanine
P01505516A0928|56 68|valine residue
P01505516A0928|87 108|disulfide-linked dimers
P01506705A0282|6 14|V-A bypass
P01506705A0282|16 27|hemodynamics
P01506746A0476|0 18|Greater rupture force
P01506746A0476|35 43|adult pigs
P01506746A0476|53 61|young pigs
P01509798A0520|2 8|rest AFF
P01509798A0520|25 30|higher
P01509798A0520|33 34|UT
P01509798A0520|38 38|%
P01509798A0520|52 53|AT
P01509798A0520|57 57|%
P01509798A0520|62 64|UEA
P01509798A0520|68 68|%
P01511231A0085|17 29|smoking habits
P01511231A0085|32 40|relapsers
P01511231A0085|62 82|smoking cessation trial
P01511231A0085|88 95|nicotine
P01511231A0085|98 111|placebo patches
P01511950T0000|0 7|Exposure
P01511950T0000|10 24|hepatitis B virus
P01511950T0000|30 46|general population
P01511950T0000|49 56|Hisayama
P01511950T0000|58 62|Japan
P01511950T0000|86 93|antibody
P01511950T0000|96 119|hepatitis B surface antigen
P01511950T0000|122 138|general population
P01512259A0867|13 28|latter phenomenon
P01512259A0867|51 73|particular cysteine motif
P01512259A0867|89 101|multiple times
P01512259A0867|104 110|Dfurin2
P01512259A0867|132 145|mammalian furin
P01512654A0503|5 13|other hand
P01512654A0503|22 30|phosphate
P01512654A0503|39 53|saline injection
P01512654A0503|61 62|ES
P01512654A0503|66 85|primary KLH challenges
P01512654A0503|91 92|ES
P01512654A0503|118 131|threshold level
P01512654A0503|146 152|latency
P01512941A0000|15 43|broad-spectrum fluoroquinolone
P01512941A0000|45 56|levofloxacin
P01512941A0000|58 61|LVFX
P01512941A0000|63 69|DR-3355
P01512941A0000|116 128|ciprofloxacin
P01512941A0000|130 133|CPFX
P01512941A0000|136 144|ofloxacin
P01512941A0000|146 149|OFLX
P01512941A0000|154 164|norfloxacin
P01512941A0000|166 169|NFLX
P01513114A1133|3 27|mean serum creatinine levels
P01513114A1133|49 51|SPK
P01513114A1133|56 58|KTA
P01513114A1133|62 65|mg/d
P01513114A1133|69 76|ABSTRACT
P01513114A1133|91 95|WORDS
P01513213A0231|0 15|Model predictions
P01513213A0231|22 27|accord
P01513213A0231|35 61|nine-year survival experience
P01513213A0231|64 68|women
P01513213A0231|74 81|HIP trial
P01513213A0231|105 109|women
P01513213A0231|115 122|years old
P01513213A0231|128 134|HIP data
P01513213A0231|137 151|18-year survival
P01516427T0000|0 14|High-resolution
P01516427T0000|23 32|tomography
P01516427T0000|49 67|miliary tuberculosis
P01516829A0113|23 26|SNF2
P01516829A0113|28 31|SNF5
P01516829A0113|36 47|SNF6 function
P01516829A0113|36 39|SNF6
P01516829A0113|66 90|transcriptional activation
P01516829A0113|108 125|heteromeric complex
P01516829A0460|10 18|LexA-GAL4
P01516829A0460|22 46|LexA-Bicoid fusion proteins
P01516829A0460|65 68|SNF2
P01516829A0460|70 73|SNF5
P01516829A0460|78 81|SNF6
P01516829A0460|85 94|activation
P01516829A0460|97 107|target genes
P01516829A0460|123 143|multiple lexA operators
P01516829A0460|131 143|lexA operators
P01518396T0000|0 7|George T.
P01518833A0397|1 21|lambda gt10 cDNA library
P01518833A0397|40 43|poly
P01518833A0397|45 45|A
P01518833A0397|48 50|RNA
P01518833A0397|53 68|young green leaves
P01518833A0397|71 77|spinach
P01518849A0165|0 1|NE
P01518849A0165|5 7|PR3
P01518849A0165|32 57|phagocytosed microorganisms
P01518849A0165|68 107|important connective-tissue protein elastin
P01518849A0165|88 107|tissue protein elastin
P01518849A0165|120 140|chemotactic activities
P01518849A0165|150 184|alpha 1-proteinase inhibitor complexes
P01518849A0165|188 202|elastin peptides
P01518926T0000|8 13|topics
P01518926T0000|16 39|pediatric ultrasonography
P01522699A0092|0 6|Methods
P01522699A0092|15 34|24-hour dietary recall
P01522699A0092|36 46|menu weights
P01522699A0092|51 64|recipe analysis
P01523111A0769|0 6|Factors
P01523111A0769|21 29|afterdrop
P01523111A0769|42 66|end-of-surgery temperature
P01523111A0769|86 93|body mass
P01524549A0241|4 15|GH deficiency
P01524549A0241|4 5|GH
P01524549A0241|19 38|impaired spinal growth
P01524549A0241|50 61|short stature
P01524549A0241|73 82|occurrence
P01524549A0241|85 96|early puberty
P01524549A0241|114 125|GH deficiency
P01524549A0241|114 115|GH
P01524549A0241|136 148|time available
P01524549A0241|152 160|GH therapy
P01524549A0241|152 153|GH
P01525153A0359|11 19|d(T2AG3T)
P01525153A0359|11 11|d
P01525153A0359|13 18|T2AG3T
P01525153A0359|23 23|d
P01525153A0359|25 29|T2G4T
P01525153A0359|42 81|G-quadruplex monomer structures independent
P01525153A0359|84 103|K cation concentration
P01525153A0359|125 127|Sen
P01525153A0359|129 130|D.
P01525153A0359|133 139|Gilbert
P01525153A0359|141 142|W.
P01525966T0000|20 30|renal stones
P01526658A0454|0 8|IFI 16 mRNA
P01526658A0454|0 2|IFI
P01526658A0454|5 8|mRNA
P01526658A0454|46 58|lymphoid cells
P01526658A0454|64 72|cell lines
P01526658A0454|82 82|T
P01526658A0454|86 94|B lineages
P01526690T0000|0 23|Mitochondria-lytic action
P01526690T0000|26 33|warfarin
P01526690T0000|36 46|lymphocytes
P01527020A0511|0 19|Exon-intron junctions
P01527020A0511|33 59|rat AdoMet decarboxylase genes
P01527020A0511|66 83|identical positions
P01527020A0511|94 98|exons
P01527020A0511|109 117|human gene
P01527020A0511|125 134|single exon
P01527020A0511|140 146|rat gene
P01529530T0000|0 37|Interferon-alpha-induced gene expression
P01529530T0000|0 27|Interferon-alpha-induced gene
P01529530T0000|51 65|selective effect
P01529530T0000|68 74|ouabain
P01529530T0000|77 86|activation
P01529530T0000|92 116|ISGF3 transcription complex
P01531086A0127|3 6|cDNA
P01531086A0127|12 27|open reading frame
P01531086A0127|33 49|amino acids capable
P01531086A0127|61 73|97-kDa protein
P01531214A0885|9 12|LD50
P01531214A0885|15 18|mice
P01531214A0885|21 26|RP-170
P01531214A0885|31 34|g/kg
P01531214A0885|37 40|i.v.
P01531214A0885|59 62|g/kg
P01531214A0885|65 82|oral administration
P01531632A0000|8 18|few proteins
P01531632A0000|24 42|eukaryotic nucleolus
P01531632A0000|73 80|proteins
P01531632A0000|82 90|nucleolin
P01531632A0000|92 102|fibrillarin
P01531632A0000|104 107|SSB1
P01531632A0000|111 114|NSR1
P01531632A0000|124 144|common structural motif
P01531632A0000|149 157|GAR domain
P01531632A0000|172 178|glycine
P01531632A0000|182 197|arginine residues
P01532229A1264|41 56|ubiquitous factor
P01532229A1264|58 62|HF-1a
P01532229A1264|68 79|muscle factor
P01532229A1264|81 85|HF-1b
P01532229A1264|87 91|MEF-2
P01532229A1264|107 130|E-box-independent pathway
P01532229A1264|134 158|muscle-specific expression
P01532229A1264|161 189|ventricular cardiac muscle cells
P01532796A0107|0 8|Mutations
P01532796A0107|30 44|crucial late step
P01532796A0107|57 58|F1
P01532796A0107|70 74|alpha
P01532796A0107|78 89|beta subunits
P01532796A0107|104 115|mitochondria
P01532796A0107|118 135|inactive aggregates
P01532796A0107|137 144|Ackerman
P01532796A0107|146 147|S.
P01532914A0067|0 6|Expense
P01532914A0067|21 38|hepatitis B vaccines
P01532914A0067|43 73|low-dose intradermal immunization
P01532914A0067|93 111|cost-saving strategy
P01532914A0067|114 128|numerous studies
P01533760T0000|0 25|Estrogen replacement therapy
P01533760T0000|35 46|breast cancer
P01533760T0000|48 54|results
P01533760T0000|60 72|meta-analyses
P01535242A0557|9 14|FDC-P1
P01535242A0557|16 23|MAC cells
P01535242A0557|36 40|M-CSF
P01535242A0557|43 48|GM-CSF
P01535242A0557|58 77|selective degradation
P01535242A0557|80 88|c-fms mRNA
P01535242A0557|96 96|h
P01535242A0557|102 116|factor switching
P01536153A0574|18 38|significant difference
P01536153A0574|44 53|prevalence
P01536153A0574|56 81|chronic respiratory symptoms
P01536153A0574|89 105|animal food workers
P01536153A0574|121 137|negative skin tests
P01536153A0574|153 161|fish flour
P01536153A0574|189 197|normal IgE
P01536153A0574|195 197|IgE
P01536153A0574|208 214|dyspnea
P01536575A1213|2 18|unexpected finding
P01536575A1213|56 86|putative dioxin responsive element
P01536575A1213|123 131|induction
P01536575A1213|134 146|transcription
P01536575A1213|152 172|cytochrome P450IA1 gene
P01536575A1213|174 179|CYPIA1
P01536575A1213|184 193|other genes
P01536575A1213|204 228|detoxification/activation
P01536575A1213|231 260|polycyclic aromatic hydrocarbons
P01537334A0507|15 23|TRP-2 maps
P01537334A0507|15 19|TRP-2
P01537334A0507|26 40|mouse chromosome
P01537334A0507|60 82|coat colour mutation slaty
P01537334A0507|60 77|coat colour mutation
P01537845A0571|5 10|bovine
P01537845A0571|14 30|murine c-myb clones
P01537845A0571|51 72|c-myb gene transcription
P01537845A0571|51 59|c-myb gene
P01537845A0571|75 87|mRNA stability
P01537845A0571|108 116|cell cycle
P01538401A1244|3 26|base-pair oligonucleotide
P01538401A1244|35 45|nucleotides
P01538401A1244|60 67|S RNA gene
P01538401A1244|87 106|high-affinity binding
P01538401A1244|152 169|longer DNA fragments
P01538403A1058|12 25|reconstitution
P01538403A1058|28 31|eUSF
P01538403A1058|35 70|TFIID-depleted transcription complexes
P01538403A1058|35 39|TFIID
P01538403A1058|83 98|protein fractions
P01538403A1058|121 125|TFIID
P01538403A1058|133 136|eUSF
P01538403A1058|162 177|complex formation
P01538403A1058|184 202|H5 promoter mutations
P01538403A1058|213 220|TATA-box
P01539996A0588|16 32|amino acid sequence
P01539996A0588|38 57|T. thermophilus enzyme
P01539996A0588|71 91|Escherichia coli enzyme
P01539996A0588|86 91|enzyme
P01539996A0588|104 121|% overall similarity
P01539996A0588|147 156|Ser residue
P01539996A0588|193 204|E. coli enzyme
P01539996A0588|199 204|enzyme
P01539996A0588|214 232|surrounding sequence
P01539996A0588|258 270|extra residues
P01539996A0588|276 284|C terminus
P01539996A0588|290 309|T. thermophilus enzyme
P01541556A1040|0 21|Radiolabelled palmitate
P01541556A1040|73 89|lipid modification
P01541556A1040|101 113|Cys-22 residue
P01541577A0000|2 16|volunteer deaf Ss
P01541577A0000|35 52|volunteer hearing Ss
P01541577A0000|58 86|Stanford Hypnotic Clinical Scale
P01541577A0000|88 91|SHCS
P01541577A0000|95 100|Morgan
P01541577A0000|104 105|J.
P01542565A0220|0 22|Mature tobacco L12 protein
P01542565A0220|28 45|% amino acid identity
P01542565A0220|50 71|ribosomal protein L7/L12
P01542565A0220|69 71|L12
P01542565T0000|0 44|Nuclear-encoded chloroplast ribosomal protein L12
P01542565T0000|47 62|Nicotiana tabacum
P01542565T0000|64 79|characterization
P01542565T0000|82 94|mature protein
P01542565T0000|110 125|sequence analysis
P01542565T0000|128 137|cDNA clones
P01542565T0000|149 168|cytoplasmic precursor
P01542667A0125|15 23|IFN-gamma
P01542667A0125|53 75|intronic enhancer element
P01542667A0125|86 100|tissue-specific
P01542667A0125|125 144|restricted expression
P01542667A0125|150 177|intact IFN-gamma-encoding gene
P01542667A0125|156 177|IFN-gamma-encoding gene
P01542686A0000|0 15|Molecular cloning
P01542686A0000|21 40|polypeptide component
P01542686A0000|46 84|Rel-related human p75 nucleoprotein complex
P01542686A0000|114 119|65-kDa
P01542686A0000|121 123|p65
P01542686A0000|125 131|subunit
P01542686A0000|134 143|NF-kappa B.
P01542686A0000|134 142|NF-kappa B
P01542730A1982|7 45|single-chamber rate-adaptive atrial pacing
P01542730A1982|80 96|future development
P01542730A1982|99 105|AV block
P01542730A1982|109 117|DDD pacing
P01542730A1982|132 150|chronotropic support
P01542730A1982|169 196|new rate-adaptive dual-chamber
P01542730A1982|198 201|DDDR
P01542730A1982|203 209|devices
P01542730A1982|223 239|significant number
P01542730A1982|247 254|patients
P01542730A1982|257 264|ABSTRACT
P01542730A1982|279 283|WORDS
P01543909A0787|30 38|K562 cells
P01543909A0787|44 57|Lg genomic clone
P01543909A0787|117 131|characteristics
P01543909A0787|144 153|pseudogene
P01543909A0787|198 215|new ferritin subunit
P01543909A0787|201 208|ferritin
P01544854A0699|5 9|drugs
P01544854A0699|29 37|WR-168643
P01544854A0699|44 56|best protector
P01544854A0699|62 64|DMF
P01544918A1240|0 15|Characterization
P01544918A1240|23 31|R subunits
P01544918A1240|39 71|8-azido-cAMP photoaffinity labeling
P01544918A1240|75 90|immunoreactivity
P01544918A1240|103 140|phosphorylation-dependent mobility shift
P01544918A1240|143 195|sodium dodecyl sulfate-polyacrylamide gel electrophoresis
P01544918A1240|197 204|SDS-PAGE
P01544918A1240|216 227|subunit sizes
P01544918A1240|230 236|RII beta
P01544918A1240|240 242|kDa
P01544918A1240|244 250|greater
P01544918A1240|255 275|RII alpha dephosphoform
P01544918A1240|255 262|RII alpha
P01544918A1240|279 281|kDa
P01544918A1240|283 289|greater
P01544918A1240|294 300|RI alpha
P01544918A1240|304 306|kDa
P01544928A1252|0 9|Comparison
P01544928A1252|15 32|genomic DNA sequence
P01544928A1252|50 63|different mRNAs
P01544928A1252|82 92|transcripts
P01544928A1252|106 124|alternative splicing
P01544928A1252|130 143|murine pre-mRNA
P01544928A1252|156 168|cassette model
P01545523A0000|16 30|quantifications
P01545523A0000|33 57|immunoserological testings
P01545523A0000|69 84|C reactive protein
P01545523A0000|86 101|rheumatoid factor
P01545523A0000|105 121|antistreptolysin O
P01545787A0345|9 21|human enhancer
P01545787A0345|31 35|sites
P01545787A0345|39 45|located
P01545787A0345|72 76|DNase
P01545787A0345|78 87|footprints
P01545787A0345|89 94|NFAT-1
P01545787A0345|98 104|NFIL-2B
P01545792A0000|3 27|cardiac myosin light chain-2
P01545792A0000|29 46|MLC-2) gene promoter
P01545792A0000|29 33|MLC-2
P01545792A0000|35 46|gene promoter
P01545792A0000|55 69|several positive
P01545792A0000|73 99|negative cis-acting sequences
P01545792A0492|0 18|Deletion mutagenesis
P01545792A0492|43 50|elements
P01545792A0492|67 84|positive regulation
P01545792A0492|87 108|MLC-2 gene transcription
P01545792A0492|87 95|MLC-2 gene
P01545797A0587|0 18|Disruption mutations
P01545797A0587|43 50|SLK1 gene
P01545797A0587|52 66|slk1 null mutants
P01545797A0587|81 88|degrees C
P01545797A0587|93 101|many cells
P01545797A0587|122 130|degrees C.
P01545806T0000|0 8|Molecular
P01545806T0000|12 26|genetic analysis
P01545806T0000|32 72|yeast early meiotic recombination genes REC102
P01545806T0000|76 86|REC107/MER2
P01545806T0000|76 81|REC107
P01545806T0000|83 86|MER2
P01545818A0696|3 6|p130
P01545818A0696|10 43|p62 tyrosine-phosphorylated proteins
P01545818A0696|57 64|v-Src SH2
P01545818A0696|57 61|v-Src
P01545818A0696|62 64|SH2
P01545818A0696|90 94|v-Src
P01545818A0696|97 123|v-src-transformed Rat-2 cells
P01545818A0696|97 101|v-src
P01545818A0696|135 141|binding
P01545818A0696|159 172|v-Src SH2 domain
P01546522A0000|0 47|Probable progressive multifocal leukoencephalopathy
P01546522A0000|49 51|PML
P01546522A0000|77 91|clinical picture
P01546522A0000|95 118|magnetic resonance imaging
P01546522A0000|122 135|63-year-old man
P01546522A0000|141 157|complete remission
P01546522A0000|161 171|non-Hodgkin
P01546522A0000|174 181|lymphoma
P01547775A1024|17 46|possible biological significance
P01547775A1024|52 61|frameshift
P01547775A1024|114 144|putative RNA template-binding site
P01547775A1024|150 162|PLRV replicase
P01547775A1024|168 195|ORF2a/ORF2b transframe protein
P01547787A0548|0 19|Proprotein processing
P01547942A0120|1 25|32P-labeled LAP DNA-binding
P01547942A0120|29 46|dimerization domain
P01547942A0120|48 58|zipper probe
P01547942A0120|77 81|clone
P01547942A0120|94 119|new C/EBP-homologous protein
P01547942A0120|97 119|C/EBP-homologous protein
P01547942A0120|121 127|CHOP-10
P01547957A1083|6 39|degenerate oligodeoxyribonucleotide
P01547957A1083|41 45|oligo
P01547957A1083|57 76|N-terminal aa sequence
P01547957A1083|84 106|internal oligo homologous
P01547957A1083|143 146|CYP1
P01547957A1083|150 153|CYP2
P01547957A1083|177 182|genome
P01547957A1083|185 208|CYP3-specific DNA fragment
P01547957A1083|226 248|polymerase chain reaction
P01547957A1083|250 252|PCR
P01547957A1083|259 272|GL81 genomic DNA
P01547957A1083|276 284|substrate
P01548756A1102|0 21|Stringent hybridization
P01548756A1102|24 28|EHS-1
P01548756A1102|35 51|primate genomic DNA
P01548756A1102|64 80|distinct EHS-1 loci
P01548756A1102|72 80|EHS-1 loci
P01548756A1102|83 96|normal human DNA
P01548756A1102|100 119|identical band pattern
P01548756A1102|122 134|chimpanzee DNA
P01548756A1102|140 150|single locus
P01548756A1102|153 167|rhesus monkey DNA
P01548891A0635|10 44|carboxyl-terminal parathyroid hormone
P01548891A0635|50 57|patients
P01548891A0635|62 77|thyroid carcinoma
P01548891A0635|81 86|higher
P01548891A0635|100 107|patients
P01548891A0635|115 130|thyroid carcinoma
P01548891A0635|132 136|P less
P01549118A0000|3 40|Caenorhabditis elegans vitellogenin genes
P01549118A0000|68 92|tissue-specific regulation
P01549118A0000|121 147|adult hermaphrodite intestine
P01549123A0480|3 10|MET4 gene
P01549123A0480|3 6|MET4
P01549123A0480|56 69|protein related
P01549123A0480|86 114|bZIP transcriptional activators
P01549125A0140|3 11|functions
P01549125A0140|22 29|portions
P01549125A0140|35 41|insulin
P01549125A0140|43 46|IAPP
P01549125A0140|51 65|beta GK promoters
P01549125A0140|84 102|transient expression
P01549125A0140|106 121|DNA binding assays
P01549129A0356|21 27|domains
P01549129A0356|52 95|specific protein-protein interactions necessary
P01549129A0356|60 74|protein-protein
P01549129A0356|102 118|proper functioning
P01549129A0356|121 123|Src
P01549346A0000|3 20|c-Ets-1 oncoprotein
P01549346A0000|24 45|transcription activator
P01549465A0122|0 33|Previous transactivation experiments
P01549465A0122|52 61|amino acids
P01549465A0122|83 85|Gly
P01549465A0122|87 89|Ser
P01549465A0122|93 95|Val
P01549465A0122|118 142|target-site discrimination
P01551176A0000|0 7|GR63178A
P01551176A0000|11 31|water-soluble analogue
P01551176A0000|34 44|mitoquidone
P01551176A0000|47 71|pentacyclic pyrroloquinone
P01551568A1476|0 19|Marker rescue analysis
P01551568A1476|23 34|localized ts8
P01551568A1476|32 34|ts8
P01551568A1476|38 58|910-bp internal segment
P01551568A1476|61 64|rpoB
P01551568A1476|79 87|Rif domain
P01551898A1084|4 9|vector
P01551898A1084|28 32|yeast
P01551898A1084|84 96|mature protein
P01551898A1084|99 104|levels
P01551898A1084|112 113|mg
P01551898A1084|116 125|LAPP/liter
P01551898A1084|128 140|culture medium
P01551910A0313|0 18|Competition analysis
P01551910A0313|21 51|gel mobility shift electrophoresis
P01551910A0313|69 90|DNA-protein interaction
P01551910A0313|113 136|many transcription factors
P01551910A0978|4 11|DNA motif
P01551910A0978|23 50|novel protein-binding sequence
P01551910A0978|28 50|protein-binding sequence
P01552052A0139|0 8|OBJECTIVE
P01552052A0139|56 66|alterations
P01552052A0139|69 83|serum creatinine
P01552052A0139|86 93|patients
P01552052A0139|98 106|psoriasis
P01552052A0139|117 125|mg/kg/day
P01552052A0139|128 139|cyclosporine
P01552457T0000|0 22|Intrapocket chemotherapy
P01552457T0000|25 42|adult periodontitis
P01552457T0000|49 75|new controlled-release insert
P01552457T0000|86 94|ofloxacin
P01552457T0000|96 100|PT-01
P01552662A0398|0 23|Electromagnetic blood flow
P01552662A0398|25 26|BF
P01552662A0398|28 32|probe
P01552662A0398|48 59|left anterior
P01552662A0398|70 75|artery
P01552662A0398|77 79|LAD
P01552853A1377|19 22|virF
P01552853A1377|44 52|induction
P01552853A1377|58 67|yop regulon
P01553407T0000|0 7|Problems
P01553407T0000|37 62|quantitative risk assessment
P01554334A0000|20 35|gamma-interferon
P01554334A0000|37 45|IFN-gamma
P01554334A0000|47 57|assay system
P01554334A0000|75 92|bovine tuberculosis
P01554334A0000|131 139|Committee
P01554334A0000|142 152|Agriculture
P01554334A0000|161 169|Australia
P01555556A0565|0 13|Control Tmuscle
P01555556A0565|27 34|degrees C
P01555556A0565|40 48|control Wi
P01555556A0565|50 52|max
P01555556A0565|63 64|SD
P01555556A0565|69 74|W.kg-1
P01556068A0000|3 29|Klebsiella aerogenes gene maoA
P01556068A0000|51 59|synthesis
P01556068A0000|62 77|monoamine oxidase
P01556068A0000|91 98|tyramine
P01556068A0000|105 120|related compounds
P01556068A0000|133 142|catabolite
P01556068A0000|146 166|ammonium ion repression
P01556111A0241|8 19|other regions
P01556111A0241|25 31|plasmid
P01557217A0272|9 18|infectious
P01557217A0272|21 39|inflammatory lesions
P01557217A0272|73 77|h p.i.
P01557411A1282|8 19|human D1A gene
P01557411A1282|42 56|tissue-specific
P01557411A1282|58 71|regulated genes
P01557411A1282|80 105|housekeeping-type promoters
P01558942A1369|0 18|Similar observations
P01558942A1369|44 53|other genes
P01559209T0000|0 12|Preceptorship
P01559209T0000|15 25|CNS students
P01559209T0000|29 44|exploratory study
P01560021A0379|14 25|genetic basis
P01560021A0379|32 42|differences
P01560021A0379|53 59|cardiac
P01560021A0379|63 78|brain AE3 variants
P01560021A0379|109 115|rat gene
P01560774A0885|6 7|kb
P01560774A0885|54 67|entire fliA gene
P01560774A0885|60 67|fliA gene
P01562659A0676|0 10|Institution
P01562659A0676|17 27|intravenous
P01562659A0676|31 58|intracisternal administration
P01562659A0676|61 73|amphotericin B
P01562659A0676|85 120|concomitant intravenous administration
P01562659A0676|123 135|dexamethasone
P01562659A0676|152 161|situations
P01562659A0676|185 193|C. immitis
P01562659A0676|198 210|CNS vasculitis
P01562659A0676|213 224|encephalitis
P01562659A0676|244 252|serologic
P01562659A0676|255 274|cultural confirmation
P01562659A0676|277 294|C. immitis infection
P01562659A0676|307 309|CNS
P01563343A0548|0 11|Lac operators
P01563343A0548|30 45|several positions
P01563343A0548|55 65|CAB promoter
P01563343A0548|69 88|operator-free plasmid
P01563635T0000|0 13|Overproduction
P01563635T0000|15 26|purification
P01563635T0000|30 45|characterization
P01563635T0000|48 71|M.HinfI methyltransferase
P01563635T0000|78 91|deletion mutant
P01564653A0307|0 15|Various companies
P01565093A0179|4 8|March
P01565093A0179|17 23|October
P01565093A0179|37 43|persons
P01565093A0179|61 83|elevated blood lead levels
P01565093A0179|85 88|BLLs
P01565093A0179|93 105|local hospital
P01565093A0179|126 160|notifiable disease surveillance system
P01565093A0179|176 192|Alabama Department
P01565093A0179|195 206|Public Health
P01565093A0179|208 211|ADPH
P01565882A0737|14 20|changes
P01565882A0737|23 38|perfusion defects
P01565882A0737|49 50|RD
P01565882A0737|54 62|ReI images
P01565882A0737|87 91|types
P01565882A0737|93 96|Type
P01565882A0737|99 113|perfusion defect
P01565882A0737|119 125|RD image
P01565882A0737|151 151|%
P01565882A0737|153 156|Type
P01565882A0737|173 181|subgroups
P01565882A0737|189 203|perfusion defect
P01565882A0737|211 219|unchanged
P01565882A0737|221 222|Ia
P01565882A0737|226 226|%
P01565882A0737|239 240|Ib
P01565882A0737|244 244|%
P01565882A0737|251 257|RD image
P01566576A0605|0 3|Keck
P01566576A0605|5 8|C.J.
P01567649A0139|16 16|%
P01567649A0139|18 24|infants
P01567649A0139|32 56|periventricular hemorrhage
P01567649A0139|77 96|spastic cerebral palsy
P01567649A0139|99 126|neurodevelopmental evaluation
P01567649A0139|129 140|later infancy
P01568960A1129|1 17|possible mechanism
P01568960A1129|24 47|elevated alveolar pressure
P01568960A1129|60 72|cardiac output
P01568960A1129|82 90|blood flow
P01568960A1129|95 107|corner vessels
P01568960A1129|110 136|nondependent high VA/Q regions
P01569015A0120|0 13|Computer-aided
P01569015A0120|15 19|FRAME
P01569015A0120|41 65|possible open reading frames
P01569015A0120|67 70|ORFs
P01569015A0120|103 119|opposite direction
P01569102A0708|0 5|Domain
P01569102A0708|16 25|homologous
P01569102A0708|31 41|LDL receptor
P01569102A0708|57 63|repeats
P01569102A0708|68 86|perfect conservation
P01569102A0708|93 112|consecutive cysteines
P01569344A0404|6 11|cities
P01569344A0404|13 31|HTLV-I/II prevalence
P01569344A0404|68 80|New Orleans age
P01569344A0404|85 115|sex-adjusted HTLV-I/II prevalence
P01569344A0404|132 137|higher
P01569344A0404|148 156|Baltimore
P01569344A0404|158 162|P less
P01569581A0482|38 41|mRNA
P01569581A0482|64 74|nucleotides
P01569581A0482|92 101|start codon
P01569581A0482|118 126|base-pair
P01569581A0482|135 161|translation initiation region
P01569581A0482|183 212|translation initiation frequency
P01569584A0672|0 16|Hybridization data
P01569584A0672|29 33|6F6.2
P01569584A0672|73 85|m6F6 cDNA clone
P01569584A0672|73 80|m6F6 cDNA
P01569584A0672|93 97|6F6.1
P01569584A0672|101 105|6F6.3
P01569584A0672|113 117|6F6.2
P01569584A0672|122 129|adjacent
P01569584A0672|132 146|alpha-type genes
P01569945A0529|3 10|SEN1 gene
P01569945A0529|25 48|6,336-bp open reading frame
P01569945A0529|59 81|2,112-amino-acid protein
P01569945A0529|83 95|molecular mass
P01569945A0529|100 102|kDa
P01572549A0000|0 21|Protein tyrosine kinases
P01572549A0000|23 26|PTKs
P01572549A0000|55 64|cell growth
P01572549A0000|80 97|frequent appearance
P01572549A0000|100 107|products
P01572549A0000|110 128|retroviral oncogenes
P01572549A0000|132 161|intracellular signal transducers
P01572549A0000|168 188|growth factor receptors
P01572549A0000|191 200|components
P01573270A0000|3 8|IA4 mAb
P01573270A0000|36 45|antibodies
P01573270A0000|54 63|BALB/c mice
P01573270A0000|69 80|immunization
P01573270A0000|89 107|HLA class I-deficient
P01573270A0000|89 97|HLA class I
P01573270A0000|109 134|lymphokine-activated killer
P01573270A0000|136 138|LAK
P01573270A0000|141 170|susceptible EBV-B lymphocyte line
P01577056A0178|13 39|double-blind cross-over study
P01577056A0178|44 51|subjects
P01577056A0178|60 71|theophylline
P01577056A0178|73 79|mg.kg-1
P01577056A0178|90 99|omeprazole
P01577056A0178|102 103|mg
P01577056A0178|112 127|identical placebo
P01577056A0178|137 143|periods
P01577056A0178|152 155|days
P01577056A0178|169 181|washout period
P01577056A0178|185 188|days
P01577740A1111|0 14|Primer extension
P01577740A1111|18 25|mung bean
P01577740A1111|29 45|S1 nuclease mapping
P01577740A1111|55 90|multiple transcription initiation sites
P01577740A1111|112 127|Northern analyses
P01577819A0709|3 29|variant PRP-precursor alleles
P01577819A0709|10 29|PRP-precursor alleles
P01577819A0709|67 73|repeats
P01577819A0709|76 83|domain C.
P01579472A1018|9 30|typical enhancer element
P01579472A1018|55 81|orientation-dependent manner
P01579537A0000|11 15|years
P01579537A0000|20 34|therapeutic uses
P01579537A0000|37 50|botulinum toxin
P01579537A0000|53 68|potent neurotoxin
P01580738T0001|0 8|Allagille
P01580738T0001|33 48|antenatal ascites
P01581409A0398|0 10|Sensitivity
P01581409A0398|14 24|specificity
P01581409A0398|45 62|Pharmacia CAP System
P01581409A0398|69 84|DPC AlaSTAT System
P01581409A0398|101 107|results
P01581577A1186|0 4|PSI-G
P01581577A1186|8 12|PSI-K
P01581577A1186|37 51|gene duplication
P01581577A1186|56 68|ancestral gene
P01581965A0388|5 14|C-terminus
P01581965A0388|48 56|sequences
P01581965A0388|85 118|breakpoint cluster region gene product
P01581965A0388|120 129|n-chimerin
P01581965A0388|134 139|rho GAP
P01581965A0388|173 192|intrinsic GAP activity
P01581965A0388|182 184|GAP
P01581965A0388|195 206|small GTPases
P01582413A0192|0 23|Site-directed mutagenesis
P01582413A0192|39 46|clusters
P01582413A0192|49 63|basic amino acids
P01582413A0192|80 90|basic region
P01582413A0192|97 114|amphipathic helices
P01582413A0192|124 140|adjacent HLH domain
P01582413A0192|156 182|sequence-specific DNA binding
P01582413A0192|186 207|hetero-oligomerization
P01582413A0759|0 11|Dimerization
P01582413A0759|14 18|Myf-5
P01582413A0759|47 60|bHLH protein E12
P01582413A0759|80 87|affinity
P01582413A0759|111 125|transactivation
P01582413A0759|141 150|DNA binding
P01582500A0178|3 22|circadian rhythmicity
P01582500A0178|33 42|pronounced
P01583819A0377|0 2|SEA
P01583819A0377|18 37|bidirectional filters
P01583819A0377|46 47|HZ
P01583819A0377|57 58|Hz
P01583819A0377|64 75|Simson method
P01584812T0000|0 24|Neural-specific expression
P01584812T0000|26 41|genomic structure
P01584812T0000|46 68|chromosomal localization
P01584812T0000|89 124|zinc-finger transcription factor NGFI-C
P01585014A0000|23 29|effects
P01585014A0000|45 73|gonadotrophin releasing hormone
P01585014A0000|45 57|gonadotrophin
P01585014A0000|78 91|micrograms GnRH
P01585014A0000|102 102|h
P01585014A0000|108 131|progestagen sponge removal
P01585014A0000|152 157|autumn
P01585014A0000|179 191|supplementary
P01585014A0000|203 212|lupin grain
P01585014A0000|216 221|autumn
P01585014A0000|233 236|days
P01585014A0000|249 252|days
P01585014A0000|258 270|sponge removal
P01585014A0000|283 291|ovulation
P01585014A0000|297 312|mature Merino ewes
P01585014A0000|347 380|I.U. pregnant mare serum gonadotrophin
P01585014A0000|382 385|PMSG
P01585014A0000|392 419|mg follicle stimulating hormone
P01585014A0000|394 419|follicle stimulating hormone
P01585014A0000|421 425|FSH-P
P01585014A0000|421 423|FSH
P01585014A0000|425 425|P
P01586901A0000|0 20|Drug-drug interactions
P01586901A0000|43 50|patients
P01586901A0000|60 78|multiple medications
P01586901A0000|86 90|drugs
P01586901A0000|100 122|narrow therapeutic window
P01587267A1144|3 14|sequence data
P01587267A1144|25 46|detailed interpretation
P01587267A1144|52 81|X-ray crystallographic structure
P01587267A1144|87 92|enzyme
P01587267A1144|99 105|cloning
P01587267A1144|124 138|clostridial gene
P01587267A1144|153 176|site-directed mutagenesis
P01587763A0402|0 19|Total body irradiation
P01587763A0402|71 79|fractions
P01587763A0402|97 98|hr
P01587763A0402|108 111|days
P01588270A1029|12 24|blood pressure
P01588270A1029|95 96|.9
P01588270A1029|103 106|mmHg
P01588270A1029|108 112|P less
P01588270A1029|124 126|DBP
P01588315A0356|0 5|AgMNPV
P01588315A0356|9 31|Orgyia pseudotsugata MNPV
P01588315A0356|33 38|OpMNPV
P01588315A0356|59 75|promoter structure
P01588315A0356|79 103|polyhedrin primary sequence
P01588315A0356|111 124|polyhedrin gene
P01588315A0356|131 137|viruses
P01588315A0356|156 178|anti-clockwise direction
P01588315A0356|196 207|physical maps
P01588913A0000|1 14|gene homologous
P01588913A0000|20 42|Escherichia coli dnaA gene
P01588913A0000|35 42|dnaA gene
P01588913A0000|81 93|transcription
P01588913A0000|127 134|P. putida
P01588961A0000|0 3|STP1
P01588961A0000|8 27|unessential yeast gene
P01588961A0000|61 69|sequences
P01588961A0000|89 96|families
P01588961A0000|110 137|sequence-containing pre-tRNAs
P01588963A1153|10 19|antibodies
P01588963A1153|42 51|conditions
P01588963A1153|77 88|Cdc25 protein
P01588965A0000|0 15|GCR1 gene function
P01588965A0000|0 7|GCR1 gene
P01588965A0000|29 62|high-level glycolytic gene expression
P01589576A0170|3 13|decay curves
P01589576A0170|16 38|chlorophyll fluorescence
P01589576A0170|46 58|superposition
P01589576A0170|87 96|components
P01589576A0170|101 113|time constants
P01589576A0170|116 118|T1 =
P01589576A0170|126 127|ps
P01589576A0170|129 131|T2 =
P01589576A0170|139 140|ps
P01589576A0170|144 146|T3 =
P01589576A0170|154 155|ns
P01592545A0726|13 33|systolic blood pressure
P01592545A0726|51 51|%
P01592545A0726|54 61|patients
P01592545A0726|85 86|p =
P01592545A0726|103 103|%
P01592545A0726|124 131|patients
P01594554A0845|5 11|results
P01594554A0845|32 36|roles
P01594554A0845|41 43|CCK
P01594554A0845|47 63|trypsin inhibitors
P01594554A0845|47 53|trypsin
P01594554A0845|86 108|negative feedback control
P01594554A0845|111 136|pancreatic exocrine function
P01596007A0908|0 15|Most apneic events
P01596007A0908|30 35|Stages
P01596007A0908|46 48|REM
P01596007A0908|83 94|gamma OH study
P01596007A0908|106 106|%
P01596007A0908|121 134|control studies
P01596007A0908|159 159|%
P01596007A0908|187 189|SWS
P01596007A0908|194 200|gamma OH
P01596007A0908|203 210|ABSTRACT
P01596007A0908|225 229|WORDS
P01597170A0000|5 11|rabbits
P01597170A0000|34 41|mg/m3 Co2
P01597170A0000|45 49|CoCl2
P01597170A0000|62 69|mg/m3 Cr3
P01597170A0000|73 74|Cr
P01597170A0000|76 78|NO3
P01597170A0000|82 88|group Co
P01597170A0000|90 91|Cr
P01597170A0000|110 117|mg/m3 Co2
P01597170A0000|120 126|group Co
P01597170A0000|151 162|control group
P01597170A0000|169 174|months
P01597170A0000|177 185|days/week
P01597170A0000|191 196|hr/day
P01597272A0077|2 6|women
P01597272A0077|22 30|methadone
P01597272A0077|40 57|withdrawal symptoms
P01597462A0457|0 9|Disruption
P01597462A0457|26 30|CDC14
P01597462A0457|35 47|essential gene
P01600531A0483|0 11|Coronary flow
P01600531A0483|26 26|%
P01600531A0483|32 46|phosphocreatine
P01600531A0483|54 54|%
P01600531A0483|60 71|control group
P01601181A0842|3 16|60A transcripts
P01601181A0842|48 52|onset
P01601181A0842|55 66|gastrulation
P01601181A0842|82 89|mesoderm
P01601181A0842|104 111|germ band
P01601869A1389|1 13|724-bp segment
P01601869A1389|22 35|flanking region
P01601869A1389|51 63|proximal E-box
P01601869A1389|82 111|mammalian-specific 352-bp region
P01601869A1389|128 159|maximal transcriptional activation
P01601869A1389|162 188|postconfluent BC3H1 myoblasts
P01603088A1121|5 11|results
P01603088A1121|24 46|baculovirus-expressed TR
P01603088A1121|45 46|TR
P01603088A1121|55 79|transcriptional activation
P01603088A1121|83 92|repression
P01603088A1121|96 118|promoter-specific manner
P01605038T0001|0 8|Influence
P01605038T0001|11 26|neural regulation
P01605038T0001|29 50|anti-arrhythmic effects
P01605038T0001|53 56|GABA
P01605038T0001|59 62|rats
P01607223A0000|0 19|Recent investigations
P01607223A0000|33 41|selective
P01607223A0000|45 60|release technique
P01607223A0000|76 85|laser light
P01607223A0000|106 116|fluorescent
P01607223A0000|124 153|temperature-sensitive liposomes
P01607223A0000|170 187|retinal vasculature
P01608239T0001|6 20|natural barriers
P01611699A0000|5 25|pyridoxine derivatives
P01611699A0000|49 61|fresh stem bark
P01611699A0000|64 88|Albizzia julibrissin DURAZZ
P01612085A0624|3 21|serum erythropoietin
P01612085A0624|23 25|EPO
P01612085A0624|27 40|concentrations
P01612085A0624|45 59|male triathletes
P01612085A0624|65 70|U.ml-1
P01612085A0624|107 125|male distance runners
P01612085A0624|131 136|U.ml-1
P01612085A0624|138 142|P less
P01613640A0158|3 18|coating materials
P01613640A0158|23 32|poloxamine
P01613640A0158|37 46|poloxamine
P01613640A0158|51 60|poloxamine
P01613640A0158|66 74|poloxamer
P01613640A0158|82 85|Brij
P01615049A0000|12 27|drinking patterns
P01615049A0000|30 39|pygmy goats
P01615049A0000|43 47|ad lib
P01615049A0000|60 78|h light/12 h dark cycle
P01615182A0206|3 14|present study
P01615182A0206|41 57|sputum amoxycillin
P01615182A0206|59 63|amoxy
P01615182A0206|65 70|levels
P01615182A0206|76 92|combination tablet
P01615182A0206|94 98|amoxy
P01615182A0206|102 103|mg
P01615182A0206|108 118|bromhexeine
P01615182A0206|120 121|mg
P01615182A0206|149 158|plain amoxy
P01615182A0206|162 163|mg
P01615493A0408|3 6|HC II
P01615493A0408|3 4|HC
P01615493A0408|18 30|antigen levels
P01615493A0408|37 37|%
P01615493A0408|43 43|%
P01615493A0408|82 97|similar low levels
P01615493A0975|0 9|Argatroban
P01615493A0975|33 37|low HC
P01615493A0975|40 49|conditions
P01615493A0975|62 77|potent inhibition
P01615493A0975|80 95|thrombin activity
P01615493A0975|80 87|thrombin
P01615493A0975|98 102|sites
P01615493A0975|105 122|vascular wall damage
P01616475A0756|5 11|results
P01616475A0756|22 39|diagnostic validity
P01616475A0756|42 45|NFPD
P01616475A0756|48 61|CP/NCA patients
P01616475A0756|70 81|such patients
P01616475A0756|86 98|family history
P01616475A0756|101 120|panic disorder similar
P01616475A0756|123 130|patients
P01616475A0756|140 173|classical panic disorder presentation
P01617242T0000|0 13|FDA regulations
P01617242T0000|17 29|growth factors
P01617242T0000|33 47|related products
P01617776A0343|10 32|adrenergic nervous system
P01617776A0343|43 60|cardiac arrhythmias
P01617776A0343|64 83|myocardial infarction
P01617776A0343|101 122|sympathetic innervation
P01617776A0343|160 183|sympathetic nervous system
P01617776A0343|186 192|reentry
P01617776A0343|198 208|canine heart
P01617776A0343|210 213|days
P01617776A0343|219 228|infarction
P01617801A0088|0 5|DESIGN
P01617801A0088|7 22|Serum aldosterone
P01617801A0088|26 44|plasma renin activity
P01617801A0088|26 36|plasma renin
P01617801A0088|57 62|supine
P01617801A0088|82 88|minutes
P01617801A0088|94 106|oral captopril
P01617801A0088|110 111|mg
P01618027A1108|14 24|transcripts
P01618027A1108|30 37|same size
P01618027A1108|50 73|same developmental profile
P01618027A1108|95 114|wild-type E10 fragment
P01618027A1108|131 136|probes
P01618027A1108|148 156|remainder
P01618243T0000|0 27|Intravenous amine pressor tests
P01618243T0000|30 46|healthy volunteers
P01618256A0521|3 38|mean minimum steady-state concentration
P01618256A0521|47 57|oral regimen
P01618256A0521|61 74|micrograms.l-1
P01618256A0521|72 74|l-1
P01618256A0521|81 81|%
P01618256A0521|96 114|intramuscular regime
P01618256A0521|118 131|micrograms.l-1
P01618256A0521|129 131|l-1
P01619114A0383|4 15|ongoing study
P01619114A0383|35 38|SMSP
P01619114A0383|67 85|Mini Speech Processor
P01619114A0383|87 89|MSP
P01619642A0131|4 10|parents
P01619642A0131|33 41|unrelated
P01620118A0470|5 18|mutant proteins
P01620118A0470|59 98|kappa B-mediated transcriptional activation
P01620118A0470|59 64|kappa B
P01620118A0470|104 147|human immunodeficiency virus long terminal repeat
P01620118A0470|179 198|chicken lymphoid cells
P01620129A0417|3 30|sequence-specific interaction
P01620129A0417|33 51|nuclear factor HiNF-D
P01620129A0417|60 85|key proximal promoter element
P01620129A0417|91 102|H4-FO108 gene
P01620129A0417|105 113|cell cycle
P01620129A0417|125 142|normal diploid cells
P01620129A0417|144 145|J.
P01620610A1070|31 62|TI region-based expression problems
P01620610A1070|67 76|worthwhile
P01620610A1070|92 106|versatile vector
P01620610A1070|117 135|exhaustive mutations
P01620610A1070|141 167|periShine-Dalgarno sequences
P01620610A1070|185 196|MTI subregion
P01620610A1070|206 214|unchanged
P01620781A0611|15 22|subjects
P01620781A0611|36 49|mixed sequences
P01620781A0611|55 72|conditional control
P01620781A0611|78 82|words
P01620781A0611|89 90|A1
P01620781A0611|95 96|B2
P01620781A0611|101 102|A3
P01620781A0611|107 108|B4
P01620781A0611|113 114|A5
P01620781A0611|121 128|reversal
P01620781A0611|147 153|stimuli
P01620781A0611|170 181|same position
P01620781A0611|200 206|members
P01620781A0611|212 220|same class
P01621584A0183|0 23|UF-021 ophthalmic solution
P01621584A0183|35 35|%
P01621584A0183|63 66|eyes
P01621584A0183|69 75|rabbits
P01621584A0183|83 108|dose-dependent IOP reduction
P01621584A0183|118 121|mmHg
P01621584A0183|131 146|transient IOP rise
P01623900A0670|5 17|blood pressure
P01623900A0670|21 41|noradrenergic activity
P01623900A0670|53 59|changes
P01623900A0670|65 76|plasma levels
P01623900A0670|80 95|urinary excretion
P01623900A0670|98 111|norepinephrine
P01623900A0670|121 130|unaffected
P01623900A0670|136 142|Pl group
P01623900A0670|145 159|significant drop
P01623900A0670|165 178|supine systolic
P01623900A0670|182 204|diastolic blood pressures
P01623900A0670|226 250|venous norepinephrine level
P01623900A0670|256 285|urinary norepinephrine excretion
P01623900A0670|302 311|first month
P01623900A0670|314 329|dF administration
P01624425A0907|0 15|Wild-type protein
P01624425A0907|21 29|azido-ATP
P01624425A0907|38 44|mutants
P01624425A0907|49 61|substitutions
P01624425A0907|67 85|consensus amino acids
P01624425A0907|102 110|azido-ATP
P01625131A0452|15 20|biopsy
P01625131A0452|28 36|stoma site
P01625131A0452|58 71|early rejection
P01625527A0000|0 24|Whole blood serotonin levels
P01625527A0000|44 55|control group
P01625527A0000|57 58|n =
P01625527A0000|75 101|chronic renal failure patients
P01625527A0000|103 104|n =
P01625527A0000|111 133|various treatment regimen
P01625527A0000|138 158|conservative treatment
P01625527A0000|160 161|n =
P01625527A0000|166 189|maintenance haemodialysis
P01625527A0000|191 192|n =
P01625527A0000|204 223|renal transplantation
P01625527A0000|225 226|n =
P01626372T0000|0 6|Tissues
P01626372T0000|10 17|exudates
P01626372T0000|25 43|sufficient thymidine
P01626372T0000|55 71|anaerobic bacteria
P01626372T0000|87 102|inhibitory levels
P01626372T0000|105 133|trimethoprim-sulfamethoxazole
P01626430A1112|3 12|homologies
P01626430A1112|20 24|RAD16
P01626430A1112|26 30|RAD54
P01626430A1112|34 37|SNF2
P01626430A1112|53 69|several additional
P01626430A1112|87 91|yeast
P01626430A1112|95 109|Drosophila genes
P01626440A0449|6 25|application solutions
P01626440A0449|28 50|instrument disinfectants
P01626440A0449|66 71|longer
P01626631A0557|5 16|Rett syndrome
P01626631A0557|45 56|disturbances
P01626631A0557|62 70|brain stem
P01626631A0557|104 112|reticular
P01626631A0557|145 153|elevation
P01626631A0557|159 172|conscious level
P01627106A0320|3 19|similar experiment
P01627106A0320|21 59|simultaneous nitrofurazone administration
P01627106A0320|63 84|S. enteritidis challenge
P01627106A0320|97 118|significant differences
P01627106A0320|121 122|S.
P01627106A0320|134 151|isolation frequency
P01627828A0475|19 34|southern blotting
P01627828A0475|37 44|mouse DNA
P01627828A0475|49 57|SmN probes
P01627828A0475|49 51|SmN
P01627828A0475|65 69|bands
P01627828A0475|102 111|pseudogene
P01627828A0475|139 162|intron-containing SmN gene
P01627828A0475|156 162|SmN gene
P01627830A0000|3 7|cDNAs
P01627830A0000|16 29|casein kinase-1
P01627830A0000|51 66|yeast cDNA library
P01627830A0000|76 79|CKI1
P01627830A0000|83 86|CKI2
P01628201A0824|0 12|Incidence rate
P01628201A0824|92 102|raw datasets
P01628806A1347|11 27|sequence variation
P01628806A1347|39 46|first ORF
P01628806A1347|49 53|many Y
P01628806A1347|70 78|second ORF
P01628806A1347|91 112|putative helicase region
P01628806A1347|99 112|helicase region
P01628806A1347|115 124|unaffected
P01628904A0386|3 16|final screening
P01628904A0386|25 29|clone
P01628904A0386|42 49|kilobase
P01628904A0386|51 52|kb
P01629768A0131|0 6|Lesions
P01629768A0131|17 33|pressure injection
P01629768A0131|36 45|kainic acid
P01629768A0131|53 55|SOC
P01629768A0131|79 105|positioned glass micropipette
P01630454A0635|1 9|38-bp poly
P01630454A0635|11 15|dA-dT
P01630454A0635|36 52|positive regulator
P01630454A0635|55 74|Act1 promoter activity
P01630454A0635|55 66|Act1 promoter
P01630455A0448|27 37|NFIL-1 beta A
P01630455A0448|39 45|NF beta A
P01630455A0448|75 90|12-bp DNA sequence
P01630455A0448|101 107|located
P01630455A0448|121 132|TATA box motif
P01630455A0448|150 168|murine IL-1 beta genes
P01630569A0605|7 19|amphotericin B
P01630569A0605|21 23|AmB
P01630569A0605|29 37|remission
P01631229T0000|0 11|Cutis aplasia
P01633435A0743|3 21|DRF-2 nuclear protein
P01633435A0743|25 46|characteristics similar
P01633435A0743|59 89|muscle-specific regulatory factor
P01633435A0743|91 95|MEF-2
P01633435A0743|97 102|Buskin
P01633435A0743|106 113|Hauschka
P01633435A0743|119 125|Gossett
P01633816A0667|7 16|15-kb clone
P01633816A0667|18 34|4-kb EcoRI fragment
P01633816A0667|56 60|exons
P01633816A0667|67 68|kb
P01633816A0667|76 89|flanking region
P01633816A0667|95 101|opn gene
P01633816A0667|121 144|transcriptional start site
P01633816A0667|157 179|primer extension analysis
P01633816A0667|183 199|S1 nuclease mapping
P01633816A0667|183 192|S1 nuclease
P01634308A0191|0 24|Cardiovascular risk factors
P01634308A0191|39 60|standardized techniques
P01634400A1101|0 14|Production costs
P01634400A1101|28 44|non-feed operating
P01634400A1101|55 75|replacement stock costs
P01634464A0163|26 43|factor VII inhibitor
P01634464A0163|65 88|penicillin administration
P01634464A0163|102 117|fatal haemorrhage
P01634861A1336|33 52|oxygen debt hypothesis
P01634861A1336|73 82|oxygen debt
P01634861A1336|86 101|lactate clearance
P01636339A0200|0 6|Account
P01636339A0200|17 27|noncellular
P01636339A0200|31 46|nonhuman elements
P01636339A0200|52 57|smears
P01636339A0200|71 75|mucus
P01636339A0200|77 98|Charcot-Layden crystals
P01636339A0200|100 111|pollen grains
P01636339A0200|113 128|vegetal fragments
P01636339A0200|132 136|fungi
P01636714A0845|3 9|results
P01636714A0845|25 44|carbon-perfused areas
P01636714A0845|48 50|MBF
P01636714A0845|62 72|renal cortex
P01636714A0845|74 79|spleen
P01636714A0845|84 104|small intestinal serosa
P01636714A0845|110 112|MBF
P01636714A0845|137 137|h
P01636714A0845|143 145|CLP
P01637758A0532|11 27|greater proportion
P01637758A0532|30 34|women
P01637758A0532|40 52|sweeping group
P01637758A0532|57 74|cervical dilatation
P01637758A0532|78 79|cm
P01637758A0532|91 113|first vaginal examination
P01637758A0532|119 128|labour ward
P01637758A0532|138 138|%
P01637758A0532|149 149|%
P01637758A0532|152 153|OR
P01637758A0532|161 163|% CI
P01637758A0532|176 177|P =
P01639092A0776|0 4|Lewis
P01639092A0776|6 7|N.
P01639724A0452|1 12|control group
P01639724A0452|19 23|women
P01639724A0452|33 37|years
P01639724A0452|41 58|oral contraceptives
P01639724A0452|60 70|Nordette-28
P01639724A0452|90 94|times
P01639724A0452|102 110|pill cycle
P01640778A0485|15 25|rapid method
P01640778A0485|34 41|MLPA test
P01640778A0485|54 61|feasible
P01640778A0485|65 84|large-scale screening
P01641628A0869|3 12|modalities
P01641628A0869|21 35|reference values
P01641628A0869|39 56|individual subjects
P01641628A0869|68 73|groups
P01641628A0869|96 105|main points
P01641628A0869|137 146|near future
P01641628A0869|156 170|reference values
P01642060A0471|3 21|clinical application
P01642060A0471|27 57|antibody-targeted Phthalocyanine
P01642060A0471|73 80|patients
P01642060A0471|96 119|advanced ovarian carcinoma
P01642060A0471|121 127|FIGO III
P01643943A0300|11 27|lung cancer tissues
P01643943A0300|30 41|positive 67Ga
P01643943A0300|55 57|TFR
P01644751A0590|4 19|open reading frame
P01644751A0590|47 82|direct amino-terminal sequence analysis
P01644751A0590|88 114|overproduced msgB gene product
P01644796A0374|41 56|recombinant furin
P01644796A0374|64 80|conditioned medium
P01644796A0374|88 92|cells
P01644814A0068|16 28|40-kDa protein
P01644814A0068|30 32|tax
P01644814A0068|55 69|immortalization
P01644814A0068|72 77|T cells
P01644821A1259|8 15|butyrate
P01644821A1259|58 68|CAT activity
P01644821A1259|58 60|CAT
P01644821A1259|71 81|fusion genes
P01644821A1259|92 108|upstream sequences
P01644821A1259|140 156|proximal sequences
P01644821A1259|183 189|regions
P01644821A1259|195 204|PSG1-I gene
P01644821A1259|219 234|butyrate response
P01644831A0824|27 42|carboxyl terminus
P01644831A0824|55 83|NGFI-B transcriptional activity
P01644831A0824|55 60|NGFI-B
P01644831A0824|99 108|accordance
P01644831A0824|113 133|other nuclear receptors
P01644831A0824|118 133|nuclear receptors
P01644831A0824|135 141|mutants
P01644831A0824|149 156|portions
P01644831A0824|162 177|carboxyl terminus
P01645902A1462|15 21|results
P01645902A1462|37 39|Syn
P01645902A1462|41 45|locus
P01645902A1462|77 78|gH
P01645902A1462|101 108|portions
P01645902A1462|114 115|TK
P01645902A1462|119 127|UL 24 genes
P01645902A1462|119 120|UL
P01645902A1462|123 127|genes
P01645902A1462|139 149|syn mutation
P01645902A1462|188 189|TK
P01645905A0341|0 12|Nucleoprotein
P01645905A0341|14 14|N
P01645905A0341|31 54|recombinant vaccinia virus
P01645905A0341|58 61|TGEV
P01645905A0341|66 86|relative molecular mass
P01645905A0341|105 115|susceptible
P01645905A0341|118 128|degradation
P01645905A0341|134 143|C-terminus
P01645905A0341|152 176|discrete breakdown products
P01646157A0414|12 52|3.6-kb full-length alpha-GalNAc cDNA sequence
P01646157A0414|18 52|full-length alpha-GalNAc cDNA sequence
P01646157A0414|78 97|remarkable nucleotide
P01646157A0414|110 126|amino acid homology
P01646157A0414|139 139|%
P01646157A0414|161 185|human alpha-galactosidase A
P01646157A0414|187 196|alpha-Gal A
P01646157A0414|198 201|cDNA
P01646487A0874|0 7|Patients
P01646487A0874|14 30|enzymatic activity
P01646487A0874|36 36|X
P01646487A0874|73 75|IgA
P01646487A0874|77 79|IgG
P01646487A0874|81 83|IgM
P01646487A0874|85 85|T
P01646487A0874|89 100|B lymphocytes
P01646487A0874|107 124|phagocytic activity
P01646487A0874|127 137|neutrophils
P01646487A0874|150 157|patients
P01646487A0874|169 189|high enzymatic activity
P01646753A0336|20 24|oxide
P01646753A0336|39 54|hydroxyl radicals
P01646753A0336|76 104|one-electron reduction proceeds
P01646753A0336|114 116|N2O
P01646753A0336|118 129|intermediate
P01646753A0336|154 165|unfavourable
P01646753A0336|167 168|EO
P01646753A0336|170 176|N2O/N2O
P01646753A0336|179 179|=
P01646753A0336|184 185|V.
P01647070A0232|3 20|mutant JCV T antigens
P01647070A0232|28 30|JCV
P01647070A0232|34 44|SV40 origins
P01647070A0232|47 60|DNA replication
P01647656A0000|18 50|myocardial beta-adrenergic receptor
P01647656A0000|58 68|ventricular
P01647656A0000|70 71|LV
P01647656A0000|95 102|patients
P01647656A0000|104 107|aged
P01647656A0000|114 118|years
P01647656A0000|135 150|LV volume overload
P01647656A0000|162 187|chronic mitral regurgitation
P01647813A0512|9 18|transcript
P01647813A0512|37 47|same protein
P01647813A0512|83 98|lineage-specific
P01647813A0512|101 132|differentiation-dependent control
P01648142A1170|2 9|patients
P01648142A1170|14 27|limited disease
P01648142A1170|101 106|CAV arm
P01648142A1170|108 109|P =
P01648142A1170|133 137|PE arm
P01648142A1170|139 140|P =
P01648530A0000|14 20|M region
P01648530A0000|27 72|muscle-specific Xenopus cardiac actin gene promoter
P01648530A0000|104 122|embryonic expression
P01648530A0000|126 161|cardiac actin-beta-globin reporter gene
P01648530A0000|184 187|eggs
P01649173A0160|51 60|attenuator
P01649173A0160|72 82|nucleotides
P01649173A0160|100 130|major late transcription start site
P01649173A0160|133 148|second attenuator
P01649173A0160|150 159|attenuator
P01649173A0160|172 182|nucleotides
P01649318A0734|0 5|EBNA-2
P01649318A0734|12 32|cis-acting CD23 element
P01649318A0734|22 32|CD23 element
P01649318A0734|42 56|TK-promoted mRNA
P01649318A0734|42 43|TK
P01649318A0734|74 123|herpes simplex virus TK promoter transcription start site
P01649318A0734|74 101|herpes simplex virus TK promoter
P01649318A1222|5 15|experiments
P01649318A1222|26 31|186-bp
P01649318A1222|33 64|EBNA-2-responsive cell DNA fragment
P01649318A1222|75 86|firm evidence
P01649318A1222|91 96|EBNA-2
P01649318A1222|111 123|transcription
P01649318A1222|126 134|cell genes
P01649539T0000|0 13|Plasma vitamin E
P01649539T0000|15 25|total lipids
P01649539T0000|29 49|myeloperoxidase levels
P01649539T0000|29 43|myeloperoxidase
P01649539T0000|56 68|spinal surgery
P01649835A0822|21 37|bovine PBR/IBP cDNA
P01649835A0822|27 29|PBR
P01649835A0822|31 33|IBP
P01649835A0822|42 51|COS-7 cells
P01649835A0822|64 78|11-fold increase
P01649835A0822|93 104|high affinity
P01649835A0822|106 107|3H
P01649835A0822|109 110|PK
P01649835A0822|116 127|binding sites
P01649835A0822|140 150|low affinity
P01649835A0822|154 161|Ro5-4864
P01650524A0837|3 14|initial phase
P01650524A0837|26 45|vascular permeability
P01650524A0837|51 66|peritoneal cavity
P01650524A0837|70 83|LTB4 production
P01650524A0837|116 138|5-LO inhibitors phenidone
P01650524A0837|140 144|BW A4C
P01650524A0837|146 151|A63162
P01650524A0837|156 158|ICI
P01650524A0837|173 185|dexamethasone
P01650524A0837|188 197|colchicine
P01650557T0000|0 16|Discrepant results
P01650557T0000|22 43|latex agglutination test
P01650557T0000|61 89|cytomegalovirus antibody status
P01650557T0000|92 114|cardiac transplant donors
P01651232A0152|4 7|mRNA
P01651232A0152|26 48|internal uridine residues
P01651232A0152|85 87|UTP
P01651232A0152|91 98|thio-UTP
P01651918A0000|40 52|cDNA fragments
P01651918A0000|72 96|complete amino acid sequence
P01651918A0000|99 127|rat testis fructose-6-phosphate
P01651918A0000|131 136|kinase
P01651918A0000|138 147|fructose-2
P01651918A0000|151 164|bisphosphatase
P01652372A0153|16 19|SWI5
P01652372A0153|22 46|nuclear localization signal
P01652372A0153|48 50|NLS
P01652372A0153|74 104|cell cycle-dependent nuclear entry
P01652372A0153|108 126|heterologous protein
P01652515A0379|12 30|behavioral deviation
P01652515A0379|35 55|avoidance conditioning
P01652515A0379|65 103|haloperidol intrastriatal microinjections
P01652515A0379|119 133|DA synaptic level
P01652515A0379|136 153|rostral neostriatum
P01652755A1492|2 40|similar transient transfection experiments
P01652755A1492|43 51|HeLa cells
P01652755A1492|53 66|overexpression
P01652755A1492|72 117|wt human retinoblastoma susceptibility gene product
P01652755A1492|79 117|retinoblastoma susceptibility gene product
P01652755A1492|119 120|RB
P01652755A1492|142 158|serum-induced IL-6
P01652755A1492|155 158|IL-6
P01652755A1492|171 175|c-fos
P01652755A1492|191 200|beta-actin
P01652755A1492|214 222|promoters
P01652755A1492|232 246|PRV-induced IL-6
P01652755A1492|263 278|serum-induced MHC
P01652755A1492|276 278|MHC
P01652755A1492|290 298|promoters
P01653173A0619|4 13|repression
P01653173A0619|32 38|binding
P01653173A0619|44 60|E2 DNA-binding site
P01653173A0619|85 103|P105 promoter TATA box
P01653173A0619|85 88|P105
P01653173A0619|125 137|preincubation
P01653173A0619|143 168|HPV-18 P105 promoter template
P01653173A0619|176 189|nuclear extract
P01653173A0619|215 234|preinitiation complex
P01653236A0895|14 16|p50
P01653236A0895|34 61|native glucocorticoid receptor
P01653236A0895|64 69|L cells
P01653236A0895|79 113|overexpressed glucocorticoid receptor
P01653236A0895|92 113|glucocorticoid receptor
P01653236A0895|116 139|Chinese hamster ovary cells
P01653238A1062|3 47|putative 12-O-tetradecanoyl-phorbol-13-acetate
P01653238A1062|49 51|TPA
P01653238A1062|53 68|response elements
P01653238A1062|93 97|sites
P01653238A1062|104 126|transcription factor AP-1
P01653238A1062|131 147|consensus sequence
P01653238A1062|151 179|transforming growth factor beta 1
P01653238A1062|163 178|growth factor beta
P01653238A1062|181 189|TGF-beta 1
P01653238A1062|181 188|TGF-beta
P01653238A1062|191 207|inhibitory element
P01653238A1062|222 235|promoter region
P01653238A1715|0 2|TPA
P01653238A1715|6 14|TGF-beta 1
P01653238A1715|6 13|TGF-beta
P01653238A1715|38 47|activities
P01653238A1715|53 64|72-kDa enzyme
P01653918A0286|45 61|ipsilateral cornea
P01653918A0286|70 76|corneas
P01653918A0286|100 124|human corneal pain threshold
P01654349A0327|0 9|Feed intake
P01654349A0327|26 35|dietary KCl
P01654349A0327|38 58|NaHCO3 supplementation
P01654349A0327|63 78|average daily gain
P01654349A0327|101 101|K
P01654349A0327|124 136|dietary NaHCO3
P01655126T0000|0 18|Extraction procedure
P01655126T0000|38 54|butyltin compounds
P01655126T0000|57 73|biological tissues
P01655126T0000|79 85|toluene
P01655126T0000|87 89|HBr
P01655126T0000|94 102|tropolone
P01655713A0294|49 77|exoenzyme S-deficient phenotype
P01655713A0294|89 92|exs1
P01655713A0294|95 97|Tn1
P01655713A0294|100 132|chromosomal Tn1 insertional mutation
P01656220T0000|0 2|axl
P01656220T0000|33 64|primary human myeloid leukemia cells
P01656220T0000|74 100|novel receptor tyrosine kinase
P01656220T0000|79 100|receptor tyrosine kinase
P01656221A1319|0 8|Alignment
P01656221A1319|14 31|amino acid sequences
P01656221A1319|43 49|Tyr-766
P01656221A1319|54 73|corresponding regions
P01656221A1319|76 85|other FGFRs
P01656221A1319|81 85|FGFRs
P01656221A1319|103 118|tyrosine residues
P01656221A1319|129 135|members
P01656221A1319|141 150|FGFR family
P01656235A0946|13 28|important element
P01656235A0946|32 54|linker-scanning analysis
P01656235A0946|59 69|10-bp region
P01656235A0946|83 92|CCAAT motif
P01656675A0236|0 16|Capnography curves
P01656675A0236|21 31|HVS patients
P01656675A0236|35 49|non-HVS patients
P01656675A0236|54 77|psycho-somatic complaints
P01656675A0236|83 97|healthy controls
P01657246A0325|3 29|transcription initiation site
P01657246A0325|52 61|bp upstream
P01657246A0325|77 79|Met
P01657249A1019|3 8|anti-I
P01657249A1019|12 19|anti-i CA
P01657249A1019|38 51|VH4 heavy chains
P01657249A1019|62 63|CA
P01657249A1019|93 131|VH4 second hypervariable region determinant
P01657249A1019|139 146|VH4-HV2a
P01657415A0837|0 13|Intron K1 cox1.2
P01657415A0837|6 13|K1 cox1.2
P01657415A0837|52 65|unique location
P01657415A0837|68 75|K. lactis
P01657594A0472|23 29|mutants
P01657594A0472|39 59|complementation groups
P01657594A0472|71 75|cgs1+
P01657594A0472|71 74|cgs1
P01657594A0472|79 83|cgs2+
P01657594A0472|79 82|cgs2
P01657594A0472|102 111|stationary
P01657969A1420|8 18|alterations
P01657969A1420|21 33|electrostatic
P01657969A1420|37 59|hydrophobic interactions
P01657969A1420|77 98|amino acid substitutions
P01657969A1420|109 128|conformational change
P01657969A1420|134 139|enzyme
P01657969A1420|157 173|calmodulin binding
P01657969A1420|157 166|calmodulin
P01658356A1369|3 9|results
P01658356A1369|19 30|coexpression
P01658356A1369|50 64|rapid generation
P01658356A1369|67 82|FeLV recombinants
P01658356A1369|87 92|FeLV-C
P01658356A1369|111 129|feline 3201B cell line
P01658356A1369|157 166|high levels
P01658356A1369|169 196|endogenous FeLV-specific mRNAs
P01658356T0000|0 12|Recombination
P01658356T0000|20 47|feline leukemia virus subgroup B
P01658356T0000|50 50|C
P01658356T0000|54 74|endogenous env elements
P01658356T0000|64 74|env elements
P01658356T0000|91 110|biological activities
P01658356T0000|116 122|viruses
P01658375A0854|3 21|nucleotide sequences
P01658375A0854|34 37|ends
P01658375A0854|45 51|introns
P01658375A0854|78 88|transcripts
P01658375A0854|93 123|eukaryotic protein-encoding genes
P01658375A0854|132 152|significant difference
P01658375A0854|172 180|LAT intron
P01658375A0854|183 184|GC
P01658375A0854|197 215|consensus sequence GT
P01658468A0123|10 15|months
P01658468A0123|21 36|initial isolation
P01658468A0123|39 49|C. kutscheri
P01658468A0123|57 66|oral cavity
P01658468A0123|68 75|hamsters
P01658468A0123|96 103|attempts
P01658468A0123|138 152|additional sites
P01658741A1047|36 44|kilobases
P01658741A1047|47 64|nucleotide sequence
P01658741A1047|93 95|ADE
P01658741A1047|97 101|locus
P01659685T0000|3 22|independent promoters
P01659685T0000|33 51|untranslated regions
P01659685T0000|60 74|Dd ras expression
P01659685T0000|60 64|Dd ras
P01659685T0000|77 89|Dictyostelium
P01660486A1756|3 9|results
P01660486A1756|40 47|cell type
P01660486A1756|49 62|gene cotransfer
P01660486A1756|68 91|aminoglycoside resistance
P01660486A1756|95 110|selectable marker
P01660486A1756|130 167|important cellular control mechanisms such
P01660486A1756|173 182|PKC pathway
P01660486A1756|173 175|PKC
P01660486A1756|192 201|activation
P01660486A1756|204 217|gene expression
P01660925T0000|0 15|Transfer RNA genes
P01660925T0000|20 42|Dictyostelium discoideum
P01660925T0000|70 87|repetitive elements
P01660925T0000|98 111|consensus boxes
P01660925T0000|127 141|flanking regions
P01661369A0825|13 16|strD
P01661369A0825|20 28|strE genes
P01661369A0825|41 65|universal probes indicative
P01661369A0825|81 100|biosynthetic capacity
P01661369A0825|104 124|6-deoxyhexose moieties
P01662609A0398|6 10|genes
P01662609A0398|18 29|polypeptides
P01662609A0398|35 44|amino acids
P01662609A0398|46 53|M.HgiCI)
P01662609A0398|46 52|M.HgiCI
P01662609A0398|60 69|amino acids
P01662609A0398|71 77|R.HgiCI
P01662794A0640|0 9|Expression
P01662794A0640|15 21|wt1 gene
P01662794A0640|25 45|transient transfection
P01662794A0640|48 57|COS-1 cells
P01662794A0640|69 78|kDa protein
P01662794A0640|114 123|N-terminal
P01662794A0640|128 154|C-terminal-specific antisera
P01662807A1182|24 46|TR promoter co-sedimented
P01662807A1182|24 33|TR promoter
P01662807A1182|51 65|SV40 chromosomes
P01662884A1029|0 11|Temafloxacin
P01662884A1029|15 22|mg b.i.d.
P01662884A1029|46 49|days
P01662884A1029|68 85|effective treatment
P01662884A1029|89 115|chronic bacterial prostatitis
P01664192A1577|3 22|neuromuscular effects
P01664192A1577|36 49|single ED90 dose
P01664192A1577|52 61|vecuronium
P01669611A0142|15 28|prolonged fever
P01669611A0142|47 54|aneurysm
P01669611A0142|60 64|aorta
P01669611A0142|71 85|pleuropneumonia
P01669611A0142|95 106|real diseases
P01671675A0483|12 21|clone pKB11
P01671675A0483|17 21|pKB11
P01671675A0483|32 44|1369-base pair
P01671675A0483|46 47|bp
P01671675A0483|49 58|cDNA insert
P01671675A0483|71 77|pCAD142
P01671675A0483|83 84|bp
P01671675A0483|101 120|hybridization methods
P01671675A0483|124 139|sequence analysis
P01671675A0483|160 177|entire cDNA sequence
P01671675A0483|184 191|amino end
P01671675A0483|197 210|CAD polypeptide
P01671675A0905|28 51|Northern blotting analysis
P01671675A0905|60 73|flanking region
P01671675A0905|76 82|CAD gene
P01673220A0578|22 28|genomic
P01673220A0578|32 41|cDNA clones
P01673220A0578|47 65|light-independent Sn
P01673220A0578|64 76|Sn: bol3 allele
P01673220A0578|67 76|bol3 allele
P01674177T0001|0 18|Histamine-2 blockade
P01674177T0001|21 29|psoriasis
P01674242A0358|3 11|clearance
P01674242A0358|57 57|%
P01674242A0358|79 90|erythromycin
P01674242A0358|92 105|troleandomycin
P01674242A0358|107 127|triacetyloleandomycin
P01674242A0358|130 142|roxithromycin
P01674242A0358|144 151|enoxacin
P01674242A0358|153 165|ciprofloxacin
P01674242A0358|167 176|pefloxacin
P01674242A0358|178 188|norfloxacin
P01674242A0358|190 198|ofloxacin
P01674242A0358|200 220|fluoroquinolone T-3262
P01674242A0358|222 234|pipemidic acid
P01674242A0358|236 245|cimetidine
P01674242A0358|247 256|etintidine
P01674242A0358|258 268|propranolol
P01674242A0358|270 278|verapamil
P01674242A0358|280 288|diltiazem
P01674242A0358|290 299|nifedipine
P01674242A0358|301 310|furosemide
P01674242A0358|312 320|frusemide
P01674242A0358|334 348|anovulent agents
P01674242A0358|350 359|viloxazine
P01674242A0358|361 371|allopurinol
P01674242A0358|373 383|ticlopidine
P01674242A0358|385 396|idrocilamide
P01674242A0358|398 410|thiabendazole
P01674242A0358|412 421|disulfiram
P01674242A0358|423 431|influenza
P01674242A0358|436 450|BCG-vaccination
P01674242A0358|452 461|interferon
P01674242A0358|466 473|caffeine
P01674242A0358|475 491|half-life increase
P01674369A0417|9 22|partial element
P01674369A0417|37 67|probable internal restriction site
P01674369A0417|75 81|cloning
P01674662A0000|13 45|HIV-antibody positive heroin addicts
P01674662A0000|53 70|HIV-related disease
P01674662A0000|72 73|n =
P01674662A0000|83 92|persistent
P01674662A0000|104 118|lymphadenopathy
P01674662A0000|120 121|n =
P01674662A0000|129 144|prospective study
P01674662A0000|155 173|clinical progression
P01674662A0000|176 193|AIDS related complex
P01674662A0000|195 197|ARC
P01674662A0000|218 224|factors
P01674662A0000|227 253|possible prognostic relevance
P01674817A0862|2 9|homology
P01674817A0862|25 29|RNA14
P01674817A0862|33 37|RNA15
P01674817A0862|47 51|RNA14
P01674817A0862|55 67|other proteins
P01674817A0862|79 87|data banks
P01674817T0000|0 8|Mutations
P01674817T0000|14 23|yeast RNA14
P01674817T0000|27 36|RNA15 genes
P01674817T0000|47 67|abnormal mRNA decay rate
P01674817T0000|69 84|sequence analysis
P01674817T0000|94 110|RNA-binding domain
P01674817T0000|116 127|RNA15 protein
P01675154T0000|0 19|Myocardial infarction
P01675154T0000|22 29|patients
P01675154T0000|34 54|previous bypass surgery
P01675424A0991|7 24|striking difference
P01675424A0991|30 52|birch NAD(P)H-NR sequence
P01675424A0991|30 37|birch NAD
P01675424A0991|39 39|P
P01675424A0991|41 52|H-NR sequence
P01675424A0991|67 82|NADH-NR sequences
P01675424A0991|96 121|putative pyridine nucleotide
P01675637T0033|1 25|single amino acid difference
P01675637T0033|31 46|C-terminal region
P01675637T0033|57 80|dominant negative activity
P01675637T0033|84 105|receptor dimer formation
P01675763A1389|2 13|such benefits
P01675763A1389|25 32|children
P01675763A1389|37 40|CD4+
P01675763A1389|37 39|CD4
P01675763A1389|64 68|liter
P01678287A1308|10 37|human Antp TATAA binding protein
P01678287A1308|55 62|lymphoid
P01678287A1308|66 82|non-lymphoid cells
P01678287A1308|101 112|homeobox gene
P01678287A1308|128 167|general transcriptional regulatory function
P01678287A1308|170 190|higher eukaryotic cells
P01678392A0648|5 21|% confidence values
P01678392A0648|23 25|2SD
P01678392A0648|41 43|Ros
P01678392A0648|61 78|natural variability
P01678392A0648|99 107|cmH2O l-1 s
P01679068A0000|8 14|infants
P01679068A0000|19 35|neonatal care units
P01679068A0000|46 46|%
P01679068A0000|48 58|median value
P01679068A0000|111 135|distinct nosocomial strains
P01679068A0000|154 163|Klebsiella
P01679068A0000|166 180|Enterobacter spp
P01679124A1368|0 17|Biochemical studies
P01679124A1368|29 40|expected loss
P01679124A1368|43 54|ChAT activity
P01679124A1368|43 46|ChAT
P01679124A1368|60 65|dorsal
P01679124A1368|69 85|ventral hippocampi
P01679124A1368|88 102|lesioned animals
P01679124A1368|112 125|elevated levels
P01679124A1368|128 141|norepinephrine
P01679124A1368|143 144|NE
P01679124A1368|151 167|dorsal hippocampus
P01679124A1368|170 182|MS/HSI animals
P01679124A1368|185 192|ABSTRACT
P01679124A1368|207 211|WORDS
P01679749A1171|3 14|localization
P01679749A1171|21 37|proteoglycan locus
P01679749A1171|43 53|human genome
P01679749A1171|74 81|new RFLPs
P01679749A1171|92 96|tools
P01679749A1171|100 112|future studies
P01679749A1171|115 127|human diseases
P01679749A1171|136 156|HSPG2 proteoglycan gene
P01681075A0429|6 8|min
P01681075A0429|11 29|dobutamine injection
P01681075A0429|40 42|min
P01681075A0429|45 63|pimobendan injection
P01681075A0429|68 77|myocardium
P01681075A0429|117 128|tissue levels
P01681075A0429|131 141|metabolites
P01681075A0429|153 174|carbohydrate metabolism
P01682484A0680|6 21|coronary stenosis
P01682484A0680|28 35|contrary
P01682484A0680|37 59|intracoronary procaterol
P01682484A0680|65 72|same dose
P01682484A0680|86 126|deteriorated regional myocardial dysfunction
P01682484A0680|142 148|LCX flow
P01682484A0680|150 167|global hemodynamics
P01682484A0680|171 194|cardiac lactate metabolism
P01682509A0539|25 43|major IE proteins IE86
P01682509A0539|40 43|IE86
P01682509A0539|45 48|IE72
P01682509A0539|53 56|IE55
P01682509A0539|69 84|trans-activating
P01682509A0539|88 93|HIV LTR
P01682509A0539|97 106|T-cell line
P01682509A0539|108 113|HUT-78
P01682542A0690|15 34|general HIV prevalence
P01682542A0690|54 67|cost-effective
P01682542A0690|82 92|counselling
P01682542A0690|106 128|seropositive individuals
P01684791A0000|3 19|cis-acting element
P01684791A0000|29 54|glucocorticoid inducibility
P01684791A0000|60 89|chicken glutamine synthetase gene
P01686909A0299|21 36|biliary excretion
P01686909A0299|66 76|elimination
P01686909A0299|79 87|bretylium
P01686909A0299|91 108|hexylsalicylic acid
P01686909A0299|115 120|kidney
P01687050T0000|0 14|Diagnostic value
P01687050T0000|17 49|cerebrospinal fluid immunoglobulin G
P01687050T0000|35 49|immunoglobulin G
P01687050T0000|51 53|IgG
P01687050T0000|57 85|pediatric neurological diseases
P01688841A0430|0 9|Expression
P01688841A0430|15 19|genes
P01688841A0430|21 24|ipaB
P01688841A0430|26 29|ipaC
P01688841A0430|31 34|invE
P01688841A0430|36 39|invG
P01688841A0430|41 44|invJ
P01688841A0430|49 52|invK
P01688841A0430|81 101|positive regulator virF
P01688841A0430|98 101|virF
P01688972A0803|0 10|Inducible VT
P01690703A0285|0 9|Venkatesan
P01690703A0285|14 15|D.
P01690728A1166|16 49|corresponding mature mRNA transcripts
P01690728A1166|58 70|kilobase pairs
P01690728A1166|72 73|kb
P01690728A1166|77 92|human fibroblasts
P01690728A1166|103 127|Northern blot hybridization
P01690728A1166|129 153|S1 nuclease protection assay
P01690728A1166|129 138|S1 nuclease
P01690728A1166|161 183|polymerase chain reaction
P01690812A0000|15 15|%
P01690812A0000|21 37|ribosomal DNA (rDNA
P01690812A0000|21 32|ribosomal DNA
P01690812A0000|34 37|rDNA
P01690812A0000|39 43|units
P01690812A0000|98 124|S RNA ribosomal gene insertions
P01691184A0995|0 4|Gap b3
P01691184A0995|18 34|polypeptide chains
P01691184A0995|36 38|Mr =
P01691184A0995|70 96|proteolytic cleavage products
P01691184A0995|108 121|disulfide bonds
P01691184A0995|127 142|precursor protein
P01692135A0783|11 34|rtFc gamma R alpha cDNA clone
P01692135A0783|37 49|complementary
P01692135A0783|62 81|different-sized mRNAs
P01692135A0783|93 104|CRNK-16 cells
P01692135A0783|120 152|single Fc gamma R-related mRNA species
P01692135A0783|126 145|Fc gamma R-related mRNA
P01692135A0783|172 194|mouse natural killer cells
P01692837A0390|4 8|genes
P01692837A0390|22 26|exons
P01692837A0390|31 37|introns
P01692837A0390|59 76|untranslated region
P01692837A0390|81 93|kilobase pairs
P01692837A0390|109 112|mRNA
P01692837A0390|131 139|kilobases
P01692962A0980|0 15|Stable expression
P01692962A0980|21 33|chimeric alpha
P01692962A0980|40 51|s polypeptide
P01692962A0980|54 72|Chinese hamster ovary
P01692962A0980|74 76|CHO
P01692962A0980|78 82|cells
P01692962A0980|110 122|cAMP synthesis
P01692962A0980|126 160|cAMP-dependent protein kinase activity
P01692962A0980|126 152|cAMP-dependent protein kinase
P01694009A0112|4 7|exon
P01694009A0112|18 21|exon
P01694009A0112|44 61|untranslated region
P01694009A0112|68 91|N-terminal signal sequence
P01694009A0112|97 107|polypeptide
P01694014A0716|0 8|Treatment
P01694014A0716|11 36|human myeloid cell lines HL-60
P01694014A0716|40 43|U937
P01694014A0716|48 76|phorbol 12-myristate 13-acetate
P01694014A0716|78 80|PMA
P01694014A0716|98 112|h cellular levels
P01694014A0716|118 132|RNA hybridizable
P01694014A0716|135 142|LD78 cDNA
P01694280A0000|5 37|flexible fiberoptic ventriculoscope
P01694280A0000|57 66|ventricles
P01694280A0000|70 82|major cisterns
P01694525A0000|0 22|Isopenicillin N isomerase
P01694525A0000|24 32|epimerase
P01694525A0000|84 100|amino acid sequence
P01694525A0000|106 115|N-terminus
P01695098A1116|0 7|Serum IgG
P01695098A1116|5 7|IgG
P01695098A1116|20 27|elevated
P01695098A1116|31 38|patients
P01695116A0078|27 43|complete remission
P01695116A0078|45 47|CR1
P01695116A0078|53 76|conventional chemotherapy
P01695116A0078|94 99|months
P01695314A0762|8 12|mg/dl
P01695314A0762|14 15|NS
P01695314A0762|18 30|glucose levels
P01695314A0762|35 39|basal
P01695314T0000|0 18|Platelet aggregation
P01695314T0000|22 37|metabolic control
P01695314T0000|54 79|calcium antagonist treatment
P01695314T0000|88 103|diabetes mellitus
P01695322A0000|0 4|Wnt-1
P01695322A0000|6 10|int-1
P01695322A0000|15 30|cellular oncogene
P01695322A0000|47 55|insertion
P01695322A0000|58 68|proviral DNA
P01695322A0000|74 95|mouse mammary tumor virus
P01695378A1406|0 8|Induction
P01695378A1406|11 30|Jurkat leukemic T cells
P01695378A1406|35 63|phorbol 12-myristate 13-acetate
P01695378A1406|67 75|ionomycin
P01695378A1406|98 105|FKBP mRNA
P01695905A0480|0 8|GLUT5 mRNA
P01695905A0480|22 34|highest levels
P01695905A0480|37 50|small intestine
P01695905A0480|60 70|lower levels
P01695905A0480|73 78|kidney
P01695905A0480|80 93|skeletal muscle
P01695905A0480|98 110|adipose tissue
P01697611A0738|20 25|tumors
P01697611A0738|38 67|congenital hamartomatous growths
P01697683T0000|0 13|Identification
P01697683T0000|17 32|characterization
P01697683T0000|38 45|promoter
P01697683T0000|52 65|cytotactin gene
P01697928A1214|22 37|sequence homology
P01697928A1214|57 61|Ly-6E
P01697928A1214|68 87|established consensus
P01697928A1214|94 129|interferon-stimulated response element
P01697928A1214|197 235|alpha/beta interferon-inducible promoters
P01698761A1059|10 31|large DNA rearrangements
P01698761A1059|53 71|tandem direct repeats
P01698761A1059|83 121|carboxy-terminal histone H1-like structure
P01698761A1059|124 127|AlgP
P01698761A1059|142 155|several strains
P01698761A1059|177 182|mucoid
P01698761A1059|188 205|nonmucoid phenotype
P01698772A0238|6 7|J.
P01699944A1538|5 11|results
P01699944A1538|59 80|CArG box binding proteins
P01699944A1538|108 131|different promoter element
P01699944A1538|137 140|VLC1
P01699944A1538|142 159|cardiac alpha-actin
P01699944A1538|164 173|c-fos genes
P01700272A0838|0 14|Polyadenylation
P01700272A0838|17 21|B4 RNA
P01700272A0838|49 58|maturation
P01700272A0838|74 81|residues
P01700272A0838|117 136|polysomal recruitment
P01701088A1335|0 11|Co-existence
P01701088A1335|19 36|regulatory elements
P01701088A1335|41 53|other elements
P01701088A1335|64 74|AP-2 element
P01701088A1335|77 84|CCAAT box
P01702361A0621|9 15|studies
P01702361A0621|18 23|agents
P01702361A0621|35 51|collagen synthesis
P01702361A0621|35 42|collagen
P01702361A0621|55 64|deposition
P01702361A0621|76 107|several new angiogenesis inhibitors
P01702426A0196|11 24|flanking region
P01702426A0196|53 70|hormonal regulation
P01702426A0196|128 153|avian fatty acid synthase gene
P01702426A1006|1 6|new set
P01702426A1006|9 18|cDNA clones
P01702426A1006|43 44|kb
P01702426A1006|61 91|lambda-ZAP goose liver cDNA library
P01702426A1006|107 129|exon-containing fragment
P01702426A1006|142 156|genomic DNA clone
P01702432A1296|0 23|Northern blotting analysis
P01702432A1296|52 56|genes
P01702432A1296|77 82|clones
P01702432A1296|95 106|pollen tissue
P01702972A0613|7 23|cDNA hybridization
P01702972A0613|26 40|genomic DNA blots
P01702972A0613|51 64|small subfamily
P01702972A0613|67 76|G0S19 genes
P01702972A0613|78 91|simple patterns
P01702972A0613|94 98|bands
P01702972A0613|112 120|most cDNAs
P01702972A0613|131 139|G0S30 cDNA
P01702972A0613|155 170|single-copy genes
P01703335T0000|0 27|Lymphoproliferative disorders
P01703335T0000|40 56|immunosuppression
P01703335T0000|61 62|FK
P01703335T0000|67 85|initial observations
P01703335T0000|89 113|large transplant population
P01703632T0000|3 33|Drosophila suppressor of sable gene
P01703632T0000|13 22|suppressor
P01703632T0000|25 33|sable gene
P01703632T0000|42 52|polypeptide
P01703632T0000|57 70|regions similar
P01703632T0000|80 98|RNA-binding proteins
P01707659A0458|22 31|homologous
P01707659A0458|41 53|non-classical
P01707659A0458|60 66|HLA-5.4
P01707659A0458|76 89|chimpanzee gene
P01707659A0458|91 94|Ch28
P01707800A0354|11 34|N13-N20 interpeak interval
P01707800A0354|61 73|parallel shift
P01707800A0354|80 84|peaks
P01707800A0354|89 109|central conduction time
P01707800A0354|122 135|onset latencies
P01707800A0354|138 140|N11
P01707800A0354|144 146|N20
P01708098A0922|5 40|avidin-biotin complex DNA binding assays
P01708098A0922|5 10|avidin
P01708098A0922|12 17|biotin
P01708098A0922|62 86|alpha promoter DNA sequences
P01708098A0922|102 110|basepairs
P01708098A0922|141 142|GR
P01708098A0922|152 161|control GRE
P01708098A0922|173 180|receptor
P01708771A1215|0 20|Sequence determination
P01708771A1215|31 38|peptides
P01708771A1215|52 57|Asn120
P01708771A1215|73 77|Asn65
P01708771A1215|81 86|Asn109
P01708771A1215|105 113|molecules
P01708771A1215|132 136|Asn72
P01708774A0203|3 13|DNA sequence
P01708774A0203|24 35|AP-1 activity
P01708774A0203|24 27|AP-1
P01708774A0203|39 45|located
P01708774A0203|51 72|proximal promoter region
P01709486A0000|3 29|murine mutation dominant white
P01709486A0000|39 39|W
P01709486A0000|48 61|proto-oncogene
P01709486A0000|63 67|c-kit
P01709933T0000|0 8|Isolation
P01709933T0000|12 27|characterization
P01709933T0000|33 50|rat chromosomal gene
P01709933T0000|55 65|polypeptide
P01709933T0000|67 69|pS1
P01709933T0000|93 98|statin
P01710766A0349|3 10|proteins
P01710766A0349|42 69|21-amino-acid sequence located
P01710766A0349|72 90|amino acids C terminal
P01710766A0349|96 123|translational initiation codon
P01710768A1172|3 9|results
P01710768A1172|36 44|sequences
P01710768A1172|62 63|kb
P01710768A1172|93 117|tissue-specific expression
P01710768A1172|123 132|HLA-B7 gene
P01710768A1172|167 181|gamma interferon
P01710979T0000|3 5|SH2
P01710979T0000|9 18|SH3 domains
P01710979T0000|21 50|pp60src direct stable association
P01710979T0000|21 27|pp60src
P01710979T0000|55 88|tyrosine phosphorylated proteins p130
P01710979T0000|85 88|p130
P01710979T0000|92 95|p110
P01710985A0315|0 3|Chem
P01711041A0348|5 10|clones
P01711041A0348|36 49|structural gene
P01711041A0348|61 81|complete C5 alpha-chain
P01711041A0348|69 81|C5 alpha-chain
P01711041A0348|87 87|%
P01711041A0348|93 102|beta-chain
P01711041A0962|3 15|C5 alpha-chain
P01711041A0962|30 38|kilobases
P01711041A0962|51 55|exons
P01711041A0962|60 69|beta-chain
P01711041A0962|84 92|kilobases
P01711041A0962|105 109|exons
P01711048T0000|0 19|Heterozygous mutation
P01711048T0000|25 25|G
P01711048T0000|38 43|intron
P01711048T0000|51 59|pro-alpha
P01711048T0000|62 67|I) gene
P01711048T0000|69 74|COL1A2
P01711048T0000|86 104|aberrant RNA splicing
P01711048T0000|108 135|lethal osteogenesis imperfecta
P01712296A0157|3 21|nucleotide sequences
P01712296A0157|29 33|genes
P01712296A0157|50 58|positions
P01712296A0157|76 95|amino acid differences
P01713213A0000|37 83|human pim-1 proto-oncogene shares extensive homology
P01713213A0000|37 60|human pim-1 proto-oncogene
P01713213A0000|88 122|known serine/threonine protein kinases
P01713213A0000|93 122|serine/threonine protein kinases
P01713213A0000|133 148|human Pim-1 enzyme
P01713213A0000|183 211|protein tyrosine kinase activity
P01713213A0000|183 203|protein tyrosine kinase
P01713213A0488|1 25|full-length human pim-1 cDNA
P01713213A0488|45 66|bacterial vector pGEX-2T
P01713213A0488|73 84|Pim-1 protein
P01713213A0488|97 109|fusion product
P01713213A0488|114 146|bacterial glutathione S-transferase
P01713213A0488|148 150|GST
P01714322A0969|44 50|kDa hsps
P01714322A0969|53 57|maize
P01714322A0969|61 68|products
P01714322A0969|83 94|related genes
P01714358A0990|5 18|kDa polypeptide
P01714358A0990|55 77|wheat etioplast membranes
P01714358A0990|83 90|gamma 32P
P01714358A0990|92 94|ATP
P01714452A0559|0 7|Homology
P01714452A0559|15 26|human protein
P01714452A0559|35 35|%
P01714452A0559|41 58|tandem repeat domain
P01714452A0559|87 93|serines
P01714452A0559|97 106|threonines
P01714452A0559|116 120|sites
P01714452A0559|123 152|O-linked carbohydrate attachment
P01714902A0221|39 82|Ti alpha-beta CD3 gamma delta epsilon TCR complexes
P01714902A0221|88 98|cell surface
P01714902A0221|100 106|CD3 zeta
P01714902A0221|130 152|interleukin-2 production
P01714902A0221|130 142|interleukin-2
P01714902A0221|158 171|TCR stimulation
P01714902A0221|158 160|TCR
P01714902A0221|176 213|antigen/major histocompatibility complex
P01715593A0838|4 14|desipramine
P01715593A0838|28 30|hrs
P01715593A0838|36 54|fluoxetine injection
P01715593A0838|56 66|brain levels
P01715593A0838|69 79|desipramine
P01715593A0838|92 99|elevated
P01715975A0885|0 14|Opposite effects
P01715975A0885|17 20|CYP1
P01715975A0885|34 40|aerobic
P01715975A0885|42 61|heme-sufficient cells
P01716292A0000|1 17|segmental analysis
P01716292A0000|23 32|key regions
P01716292A0000|35 41|HLA-DR1
P01716292A0000|53 72|T cell allorecognition
P01716292A0000|112 120|cell lines
P01716292A0000|134 141|products
P01716292A0000|144 159|recombinant DRB/H
P01716292A0000|155 157|DRB
P01716292A0000|159 163|H-2Eb
P01716292A0000|162 168|Eb genes
P01716292A0000|186 192|DR alpha
P01716292A0000|195 203|H-2E alpha
P01716629A0000|15 32|cDNA clones specific
P01716629A0000|39 76|extracellular matrix glycoprotein undulin
P01716629A0000|70 76|undulin
P01717718A1255|12 25|point mutations
P01717718A1255|31 45|Gag-Pol PR domain
P01717718A1255|31 33|Gag
P01717718A1255|35 45|Pol PR domain
P01717718A1255|55 64|activation
P01717718A1255|67 68|RT
P01717718A1255|71 75|trans
P01717718A1255|79 89|wild-type PR
P01717718A1255|108 126|correct conformation
P01717718A1255|132 139|PR domain
P01717718A1255|142 148|Gag-Pol
P01717718A1255|142 144|Gag
P01717718A1255|146 148|Pol
P01717718A1255|151 162|prerequisite
P01717718A1255|166 175|activation
P01717718A1255|178 179|RT
P01717833A1223|3 22|alpha inhibin promoter
P01717833A1223|41 43|CRE
P01717833A1223|61 69|forskolin
P01717833A1223|72 85|granulosa cells
P01717833A1223|102 112|CREB protein
P01717833T0000|0 9|Regulation
P01717833T0000|15 30|alpha inhibin gene
P01717833T0000|33 47|cyclic adenosine
P01717833T0000|54 66|monophosphate
P01717833T0000|72 83|transfection
P01717833T0000|88 104|rat granulosa cells
P01717925A0477|0 9|Comparison
P01717925A0477|15 33|nucleotide sequences
P01717925A0477|52 60|bovine DNA
P01717925A0477|74 91|sequence similarity
P01717925A0477|104 105|bp
P01717994T0000|0 6|Cloning
P01717994T0000|10 18|human cDNA
P01717994T0000|28 45|CDC2-related kinase
P01717994T0000|48 62|complementation
P01717994T0000|73 90|yeast cdc28 mutation
P01717994T0000|78 82|cdc28
P01718043A0384|2 9|patients
P01718043A0384|14 26|osteomyelitis
P01718043A0384|30 41|joint empyema
P01718043A0384|43 44|n =
P01718043A0384|48 58|PMN elastase
P01718043A0384|78 78|%
P01718043A0384|111 148|unspecific erythrocyte sedimentation rate
P01718043A0384|163 163|%
P01718983A1640|0 1|E.
P01718983A1640|3 9|Hession
P01718983A1640|11 12|C.
P01718983A1640|14 17|Goff
P01718983A1640|19 20|D.
P01718983A1640|22 30|Griffiths
P01718983A1640|32 33|B.
P01718983A1640|35 40|Tizard
P01718983A1640|42 43|R.
P01718983A1640|45 50|Newman
P01718983A1640|52 53|B.
P01718983A1640|55 63|Chi-Rosso
P01718983A1640|65 66|G.
P01718983A1640|71 74|Lobb
P01718983A1640|76 77|R.
P01718983A1640|85 88|Cell
P01719684A0494|3 14|above results
P01719684A0494|36 60|alpha-adrenergic receptors
P01719684A0494|69 76|prostate
P01719684A0494|111 121|less elastic
P01719684A0494|133 164|external urinary sphincter function
P01720555A1087|15 36|2-kilobase B2 transcript
P01720555A1087|54 66|alfalfa organs
P01720843A1506|5 11|results
P01720843A1506|27 41|sulfhydryl group
P01720843A1506|44 61|certain angiotensin
P01720843A1506|51 77|angiotensin converting enzyme
P01720843A1506|72 87|enzyme inhibitors
P01720843A1506|117 146|endogenous nitrovasodilator EDRF
P01720843A1506|143 146|EDRF
P01721261T0000|0 15|Pharmacokinetics
P01721261T0000|18 19|FK
P01721261T0000|25 42|transplant patients
P01721884A0962|15 30|significant match
P01721884A0962|62 84|retroviral ribonuclease H
P01721884A0962|86 91|RNase H
P01721884A0962|152 172|previous investigators
P01721884A0962|180 191|E. coli RNase H
P01721884A0962|186 191|RNase H
P01721884A0962|207 209|Pol
P01721884A0962|211 218|helices O
P01721884A0962|222 222|P
P01721884A0962|226 235|homologous
P01721884A0962|238 244|helices
P01721884A0962|249 249|D
P01721884A0962|255 276|RNase H crystal structure
P01721884A0962|255 260|RNase H
P01722319A0849|0 7|Analysis
P01722319A0849|20 36|amino acid sequence
P01722319A0849|49 61|CHIP28 protein
P01722319A0849|73 95|bilayer-spanning domains
P01722319A0849|100 137|exofacial potential N-glycosylation sites
P01722319A0849|142 155|intracellular N
P01722319A0849|159 166|C termini
P01722479A0302|3 27|qualitative concentrations
P01722479A0302|30 32|HCG
P01722479A0302|54 54|%
P01722479A0302|59 69|specificity
P01722479A0302|75 75|%
P01723619A0766|16 26|F absorption
P01723619A0766|30 39|slower rise
P01723619A0766|42 61|plasma F concentration
P01723619A0766|81 95|gastric emptying
P01723619A0766|117 117|F
P01723619A0766|125 138|small intestine
P01723619A0766|144 154|major factor
P01723619A0766|157 172|rapid F absorption
P01723962A0165|13 23|serum lipase
P01723962A0165|27 33|amylase
P01723962A0165|56 56|h
P01723962A0165|82 82|h
P01723962A0165|88 96|injection
P01723962A0165|99 103|Na-Tc
P01724982A0237|18 25|anti-HCV
P01724982A0237|27 37|anti-C100-3
P01724982A0237|43 51|HCV EIA kit
P01724982A0237|53 62|Abbott Lab.
P01724982A0237|64 75|North Chicago
P01724982A0237|77 78|IL
P01725547A0354|0 8|Diltiazem
P01725547A0354|20 38|significant increase
P01725547A0354|41 58|epicardial diameter
P01725547A0354|63 63|%
P01725547A0354|65 66|p =
P01725547A0354|78 94|coronary blood flow
P01725547A0354|96 98|CBF
P01725547A0354|104 104|%
P01725547A0354|106 107|p =
P01725622A0292|3 18|first transfusion
P01725622A0292|30 46|platelet increment
P01725622A0292|51 55|Gpt/l
P01725622A0292|57 59|CCI
P01726211A0502|5 15|risk factors
P01726211A0502|33 38|groups
P01726211A0502|40 69|local vessel wall-related factors
P01726211A0502|80 90|focal action
P01726211A0502|92 106|systemic factors
P01726631T0001|0 11|Epidemiology
P01726631T0001|27 44|hospital infections
P01726631T0001|50 64|Local Health Unit
P01726631T0001|67 73|Sassari
P01726631T0001|84 102|bacterial resistance
P01726631T0001|106 124|antimicrobial agents
P01726631T0001|127 136|large usage
P01727488A1146|0 21|PRDII-BF1-derived cDNAs
P01727488A1146|36 46|stimulation
P01727488A1146|55 59|basal
P01727488A1146|62 85|tat-induced activated gene
P01727488A1146|62 72|tat-induced
P01727488A1146|82 95|gene expression
P01727494A0000|0 12|Vaccinia virus
P01727494A0000|14 15|VV
P01727494A0000|20 34|potent immunogen
P01727494A0000|50 59|VV proteins
P01727494A0000|73 82|activation
P01727494A0000|88 101|immune response
P01730412T0000|0 2|Max
P01730412T0000|4 20|functional domains
P01730412T0000|39 43|c-Myc
P01730747A0205|15 16|G1
P01730747A0205|19 24|S phase
P01730747A0205|26 31|Reilly
P01730747A0205|33 34|C.
P01731107A0928|0 12|Substitutions
P01731107A0928|25 29|bases
P01731107A0928|44 52|ICR2 motif
P01731107A0928|60 65|levels
P01731107A0928|68 82|pRNA replication
P01731107A0928|124 131|putative
P01731107A0928|134 151|stem-loop structure
P01731107A0928|157 170|positive strand
P01731107A0928|176 186|viral genome
P01731933T0000a|0 4|Zn(II
P01731933T0000a|0 1|Zn
P01731933T0000a|6 30|coordination domain mutants
P01731933T0000a|33 38|T4 gene
P01731933T0000b|0 4|Zn(II
P01731933T0000b|0 1|Zn
P01731933T0000b|6 30|coordination domain mutants
P01731933T0000b|33 38|T4 gene
P01731979A1408|3 19|tissue specificity
P01731979A1408|22 35|gene expression
P01731979A1408|79 107|CaMV 35S domain B enhancer element
P01732033A0000|3 17|pathophysiology
P01732033A0000|21 38|clinical management
P01732033A0000|41 56|acute brain injury
P01732033A0000|59 65|infancy
P01732033A0000|95 119|acute traumatic brain injury
P01732736A1076|0 10|Transcripts
P01732736A1076|16 35|second POU-domain gene
P01732736A1076|22 35|POU-domain gene
P01732736A1076|37 42|Oct-25
P01732736A1076|57 65|low levels
P01732736A1076|68 74|oocytes
P01732736A1076|78 89|early embryos
P01732736A1076|126 142|early gastrulation
P01732752A0156|6 16|early B cells
P01732752A0156|20 72|Abelson murine leukemia virus-transformed pre-B-cell lines
P01732752A0156|74 79|LT mRNA
P01733105A0127|3 8|genome
P01733105A0127|11 22|Thogoto virus
P01733105A0127|35 42|segments
P01733105A0127|45 59|single-stranded
P01733105A0127|61 76|negative sense RNA
P01733358A0240|5 10|tumors
P01733358A0240|34 44|broad groups
P01733358A0240|48 58|cystadenoma
P01733358A0240|63 80|cystadenocarcinoma
P01733358A0240|85 87|III
P01733358A0240|89 102|adenocarcinoma
P01733358A0240|107 121|mucin production
P01733358A0240|136 139|cyst
P01734020A1318|0 13|Immunostaining
P01734020A1318|16 20|cells
P01734020A1318|41 50|constructs
P01734020A1318|102 108|mutants
P01734020A1318|113 121|localized
P01734020A1318|124 129|nuclei
P01734020A1318|138 154|wild-type PKC alpha
P01734020A1318|167 177|cytoplasmic
P01734020A1318|181 191|perinuclear
P01734283A0817|27 38|RAP74 protein
P01734283A0817|51 59|HeLa cells
P01734283A0817|70 85|complementary DNA
P01734283A0817|101 118|translation product
P01734283A0817|134 138|RAP30
P01734570T0000|0 6|Effects
P01734570T0000|9 39|thromboxane synthetase inhibition
P01734570T0000|9 29|thromboxane synthetase
P01734570T0000|42 77|postburn mesenteric vascular resistance
P01734570T0000|90 111|bacterial translocation
P01734570T0000|115 133|chronic porcine model
P01735347A0482|3 25|primary pancreatic insult
P01735347A0482|36 45|unaffected
P01735347A0482|84 95|plasma lipase
P01735347A0482|115 121|ascites
P01735347A0482|141 158|pancreatic necrosis
P01735447A0271|12 25|mutant molecule
P01735447A0271|42 72|unprocessed cytoplasmic precursor
P01735447A0271|74 90|pre-super-pro-PrB
P01735447A0271|105 116|sec61 mutants
P01735447A0271|122 134|translocation
P01735447A0271|142 161|endoplasmic reticulum
P01735447A0833|8 26|active-site mutation
P01735447A0833|38 56|wild-type processing
P01735447A0833|62 90|N-glycosylated 73-kDa precursor
P01735447A0833|93 95|PrB
P01735447A0833|101 114|41.5 kDa pro-PrB
P01735447A0833|105 114|kDa pro-PrB
P01735447A0833|120 139|endoplasmic reticulum
P01735721A0185|12 28|amino acid sequence
P01735721A0185|40 48|% identity
P01735721A0185|57 87|Bacillus stearothermophilus TyrTS
P01735721A0185|93 101|% identity
P01735721A0185|110 120|E. coli TyrTS
P01735721A0185|116 120|TyrTS
P01735721A0185|138 169|second cryptic B. subtilis TyrTS gene
P01735721A0185|151 169|B. subtilis TyrTS gene
P01735721A0185|181 184|tyrZ
P01735721A0185|195 195|%
P01736093A0731|0 24|Heat-inducible CAT activity
P01736093A0731|14 16|CAT
P01736093A0731|28 37|detectable
P01736093A0731|42 60|additional sequences
P01736093A0731|68 81|native promoter
P01736093A0731|97 106|CCAAT boxes
P01736093A0731|111 119|single HSE
P01736093A0731|136 148|constructions
P01736651A0104|9 13|Women
P01736651A0104|15 21|Infants
P01736651A0104|26 40|Children clinics
P01736651A0104|43 53|Minneapolis
P01736651A0104|55 59|Minn.
P01736844T0000|0 11|Testosterone
P01736844T0000|13 28|free testosterone
P01736844T0000|30 77|non-sex hormone-binding globulin-bound testosterone
P01736844T0000|30 59|non-sex hormone-binding globulin
P01736844T0000|82 98|free androgen index
P01736844T0000|105 127|testosterone measurement
P01736844T0000|144 155|reproductive
P01736844T0000|159 172|sexual function
P01736844T0000|175 177|men
P01736844T0000|182 189|epilepsy
P01737741A0000|0 9|BACKGROUND
P01737741A0000|29 54|monoamine oxidase inhibitors
P01737741A0000|29 44|monoamine oxidase
P01737741A0000|56 60|MAOIs
P01737741A0000|64 91|tricyclic resistant depression
P01737741A0000|115 135|little systematic study
P01737789A0800|3 31|upstream delta-alpha breakpoint
P01737789A0800|46 58|direct repeats
P01737789A0800|64 81|acceptor splice site
P01737789A0800|93 124|down-stream alpha-delta breakpoint
P01737789A0800|127 133|located
P01737789A0800|139 152|adjacent intron
P01738470A0441|0 7|Patients
P01738470A0441|12 24|moderate PDDAT
P01738470A0441|29 36|impaired
P01738470A0441|42 56|serial positions
P01738470A0441|64 75|spatial order
P01738470A0441|79 102|spatial recognition memory
P01738653T0014|0 3|Bone
P01738653T0014|7 11|bones
P01738936A0292|3 10|patients
P01738936A0292|14 35|plasma C-peptide greater
P01738936A0292|41 42|pM
P01739439A0257|0 26|Complex repetitive discharges
P01739439A0257|41 47|muscles
P01739439A0257|50 56|mdx mice
P01739439A0257|62 88|complex repetitive discharges
P01739439A0257|91 108|other abnormalities
P01739439A0257|123 129|muscles
P01739439A0257|132 148|normal control mice
P01739956A0638|0 9|Management
P01739956A0638|23 26|beta
P01739956A0638|31 44|calcium channel
P01739956A0638|53 57|drugs
P01739956A0638|60 84|type IC antiarrhythmic drugs
P01740121A0136|41 45|Kex2p
P01740121A0136|54 91|baculovirus/insect cell expression system
P01740330A0329|0 1|J.
P01740437A0851|3 24|major 49-kDa core protein
P01740437A0851|30 49|liver HSPG preparation
P01740437A0851|62 69|reactive
P01740437A0851|74 81|antibody
P01740437A0851|111 127|cytoplasmic domain
P01740437A0851|130 140|fibroglycan
P01740448A1735|7 33|obvious transmembrane regions
P01740448A1735|49 89|several short hydrophobic amino acid stretches
P01740448A1735|103 111|localized
P01740448A1735|126 136|Pro II region
P01740448A1735|165 174|attachment
P01740448A1735|177 186|precursors
P01740448A1735|189 197|membranes
P01740682A0703|0 7|Toxicity
P01740682A0703|34 39|emesis
P01740682A0703|43 43|%
P01740682A0703|49 56|patients
P01740682A0703|60 60|%
P01740682A0703|66 72|courses
P01740682A0703|75 84|leukopenia
P01740682A0703|87 109|World Health Organization
P01740682A0703|127 127|%
P01740682A0703|133 140|patients
P01740682A0703|144 144|%
P01740682A0703|150 156|courses
P01740682A0703|162 177|thrombocytopenia
P01740682A0703|181 181|%
P01740682A0703|187 194|patients
P01740682A0703|197 197|%
P01740682A0703|203 209|courses
P01741249A0177|0 3|W.G.
P01742341A0499|26 43|individual reaction
P01742341A0499|83 96|potent stressor
P01742341A0499|100 109|Beagle dogs
P01742606A0000|1 23|mouse brain beta-spectrin
P01742606A0000|26 29|cDNA
P01742606A0000|50 76|lambda Gt11 expression library
P01742606A0000|84 91|antibody
P01742606A0000|121 146|235 kDa spectrin beta-subunit
P01742606A0000|124 146|kDa spectrin beta-subunit
P01742879A0471|0 6|RESULTS
P01742879A0471|8 25|Plasma AVP responses
P01742879A0471|8 16|Plasma AVP
P01742879A0471|28 45|osmotic stimulation
P01742879A0471|50 70|non-osmotic inhibition
P01742879A0471|94 101|patients
P01742879A0471|106 128|compulsive water drinking
P01744039A0511|3 11|fragments
P01744039A0511|39 61|polymerase chain reaction
P01744039A0511|75 92|gel electrophoresis
P01744039A0511|101 137|single-strand conformation polymorphism
P01744042A1355|3 12|csbA fusion
P01744042A1355|40 59|early stationary phase
P01744042A1355|62 66|cells
P01744042A1355|74 83|Luria broth
P01744042A1355|95 102|% glucose
P01744042A1355|109 118|% glutamine
P01744119A0757|3 13|constraints
P01744119A0757|16 42|primase recognition sequences
P01744119A0757|44 74|nucleotide substrate requirements
P01744119A0757|82 88|effects
P01744119A0757|91 108|additional proteins
P01744119A0757|111 138|oligoribonucleotide synthesis
P01744119A0757|144 161|63-kDa gene 4 protein
P01744119A0757|144 153|63-kDa gene
P01744119A0757|183 191|templates
P01747972T0000|0 18|Thrombolytic therapy
P01747972T0000|21 55|spontaneous coronary artery dissection
P01748067A0000|1 16|prospective trial
P01748067A0000|35 52|unselected patients
P01748067A0000|56 58|men
P01748067A0000|71 75|years
P01748067A0000|80 84|women
P01748067A0000|97 101|years
P01748067A0000|118 141|total hip joint replacement
P01748067A0000|151 162|degenerative
P01748067A0000|165 185|inflammatory arthritis
P01748067A0000|188 195|fracture
P01748067A0000|210 214|femur
P01748194A0767|8 14|lesions
P01748194A0767|19 45|complete lateral hemisections
P01748194A0767|48 55|weanling
P01748194A0767|65 88|little behavioral recovery
P01748194A0767|118 138|spinal cord transection
P01748194A0767|140 141|N =
P01748287T0000|0 23|Human SRF-related proteins
P01748287T0000|25 45|DNA-binding properties
P01748287T0000|49 74|potential regulatory targets
P01748292A0000|14 18|cDNAs
P01748292A0000|37 56|G protein alpha subunit
P01748292A0000|68 89|Lycopersicon esculentum
P01748292A0000|91 92|cv
P01748630A0125|0 22|Growth factor stimulation
P01748630A0125|25 29|cells
P01748630A0125|39 53|phosphorylation
P01748630A0125|59 94|c-Myc transcriptional activation domain
P01748630A0125|59 63|c-Myc
P01748630A0125|97 101|Ser62
P01748630A0125|109 126|proline-rich region
P01748630A0125|153 159|members
P01748630A0125|165 173|Myc family
P01748630A0125|175 181|Alvarez
P01748630A0125|183 184|E.
P01748630A0125|186 194|Northwood
P01748630A0125|196 199|I.C.
P01748630A0125|201 208|Gonzalez
P01748630A0125|210 211|F.
P01751163A0000|3 9|authors
P01751163A0000|34 56|thrombotic complications
P01751163A0000|68 79|implantation
P01751163A0000|83 93|ventricular
P01751163A0000|107 118|Sarns/3M-VAD
P01751163A0000|126 131|calves
P01751255A0529|0 12|Cardiac output
P01751255A0529|14 15|CO
P01751255A0529|33 38|higher
P01751255A0529|40 44|p less
P01751255A0529|61 69|MBBF group
P01751970A0209|0 16|Amino acid residues
P01751970A0209|68 78|new residues
P01752441A0000|0 24|Transcriptional activation
P01752441A0000|30 44|HIV-1 Tat protein
P01752441A0000|53 68|specific residues
P01752441A0000|74 91|hexanucleotide loop
P01752441A0000|95 112|trinucleotide bulge
P01752441A0000|118 141|TAR RNA stem-loop structure
P01752441A0000|155 172|untranslated leader
P01752441A0000|178 193|viral transcripts
P01752792A0000|10 29|quantitative evidence
P01752792A0000|35 40|coding
P01752792A0000|43 67|interaural time differences
P01752792A0000|69 72|ITDs
P01752792A0000|81 87|stimuli
P01752792A0000|92 104|single neurons
P01752792A0000|110 123|auditory cortex
P01752792A0000|126 147|anesthetized albino rats
P01753317A0879|5 11|results
P01753317A0879|31 48|locally-applied TTC
P01753317A0879|66 69|FDBA
P01753317A0879|78 93|new bone formation
P01753317A0879|96 126|experimental alveolar bone defects
P01754381A0000|4 14|initial step
P01754381A0000|25 40|characterization
P01754381A0000|43 67|replicative DNA polymerases
P01754381A0000|70 81|trypanosomes
P01754381A0000|134 144|Trypanosoma
P01754381A0000|146 156|Trypanozoon
P01754381A0000|188 218|DNA polymerase alpha catalytic core
P01754381A0000|220 227|pol alpha
P01756195A1117|20 38|significant increase
P01756195A1117|41 79|postdexamethasone cortical concentrations
P01756195A1117|88 92|p less
P01756195A1117|102 103|r =
P01756539A0354|0 20|Pulmonary hypertension
P01756539A0354|35 59|coronary arterial narrowing
P01756539A0354|66 79|major condition
P01756539A0354|97 112|atrial infarction
P01757341A0591|3 16|volume fraction
P01757341A0591|18 19|Vv
P01757341A0591|24 33|number/mm2
P01757341A0591|35 36|Na
P01757341A0591|43 53|capillaries
P01757341A0591|55 62|perfused
P01757341A0591|66 76|nonperfused
P01757341A0591|127 145|alkaline phosphatase
P01758750A0000|0 13|Airway pressure
P01758750A0000|17 23|air flow
P01758750A0000|41 56|endotracheal tube
P01758750A0000|61 68|children
P01758750A0000|81 91|ventilators
P01759052A0786|0 3|Appl
P01759282A0000|0 5|Issues
P01759282A0000|22 34|kinetic energy
P01759282A0000|57 80|direct contact interaction
P01759282A0000|127 138|biomechanics
P01760166A0963|0 9|CONCLUSION
P01760166A0963|21 24|SpO2
P01760166A0963|30 44|nasal septum site
P01760166A0963|80 89|finger site
P01760166A0963|92 110|hypothermic patients
P01761736A0158|0 8|Diltiazem
P01761736A0158|21 38|total body clearance
P01761736A0158|65 70|mL/min
P01761736A0158|72 76|P less
P01761736A0158|101 120|elimination half-life
P01761736A0158|147 151|hours
P01761736A0158|153 157|P less
P01761736A0158|168 177|antipyrine
P01761736A0158|188 194|changes
P01762053A0557|3 10|granules
P01762053A0557|20 33|melted material
P01762053A0557|49 57|void space
P01762053A0557|66 81|adhered particles
P01762914A1218|9 19|uPA promoter
P01762914A1218|28 57|multiple weak cis-acting elements
P01762914A1218|76 77|kb
P01762914A1218|85 104|translation start site
P01762917A0615|13 15|Ser
P01762917A0615|19 23|Gly69
P01762917A0615|27 29|Glu
P01762917A0615|33 35|Lys
P01762917A0615|52 67|TGEK tetrapeptide
P01762917A0615|80 85|TFIIIA
P01762917A0615|105 114|DNA binding
P01763065A0913|0 1|P.
P01763106A0070|6 24|exploratory behavior
P01763106A0070|49 58|locomotion
P01763106A0070|78 94|10-min test session
P01764899A0399|40 56|water fluoridation
P01764899A0399|59 74|caries prevalence
P01764899A0399|81 90|pronounced
P01764899A0399|95 100|caries
P01764899A0399|114 124|cavity level
P01765095A0680|0 34|12-O-Tetradecanoylphorbol 13-acetate
P01765095A0680|85 89|mRNAs
P01765095A0680|102 123|myogenic regulators CMD1
P01765095A0680|120 123|CMD1
P01765095A0680|127 134|myogenin
P01765266A0000|2 14|Xenopus laevis
P01765266A0000|34 73|elongation factor 1-alpha variant EF-1 alpha O
P01765266A0000|80 80|O
P01765266A0000|90 95|oocyte
P01765266A0000|110 116|oocytes
P01765266A0000|120 131|early embryos
P01765269A0308|5 11|introns
P01765269A0308|30 51|nuclear pre-mRNA introns
P01765269A0308|78 95|consensus sequences
P01765269A0308|105 118|unique features
P01765375A0290|3 6|mRNA
P01765375A0290|31 38|rat cells
P01765375A0290|46 63|human clathrin clone
P01765375A0290|72 82|transcripts
P01765375A0290|101 102|kb
P01765375A0290|140 157|kDa molecular weight
P01765375A0290|163 180|clathrin heavy chain
P01765386A0305|20 21|kb
P01765386A0305|24 34|DNA sequence
P01765386A0305|60 61|bp
P01765386A0305|79 80|kb
P01765386A0305|83 86|exon
P01765386A0305|90 109|exon-intron junctions
P01765386A0305|117 118|bp
P01765407A0866|2 12|8-h exposure
P01765407A0866|17 25|mg DMEA/m3
P01765407A0866|40 70|postexposure plasma concentration
P01765407A0866|74 104|2-h postexposure urinary excretion
P01765407A0866|110 116|mumol/l
P01765407A0866|122 139|mmol/mol creatinine
P01766666A0788|0 17|Antibodies specific
P01766666A0788|20 23|rE12
P01766666A0788|27 33|rNFIL-6
P01766666A0788|41 62|nucleoprotein complexes
P01766666A0788|72 87|DNA-binding sites
P01766666A0788|127 133|factors
P01766876A0000|38 43|events
P01766876A0000|49 64|mu heavy chain gene
P01766876A0000|78 90|co-conversion
P01766876A0000|94 104|co-exchange
P01766876A0000|109 121|point mutation
P01766876A0000|127 142|selectable marker
P01766876A0000|155 171|replacement vector
P01766999A0000|0 17|Allergenic activity
P01766999A0000|20 49|allergen extract Ambrosia elatior
P01766999A0000|51 52|AE
P01766999A0000|72 81|volunteers
P01766999A0000|105 112|allergen
P01767060A0000|35 53|c-DDP administration
P01767060A0000|71 82|radiotherapy
P01767060A0000|108 115|duration
P01767060A0000|118 135|objective responses
P01767060A0000|156 163|patients
P01767060A0000|183 196|advanced stages
P01767060A0000|199 216|squamous carcinomas
P01767592A0682|3 30|potential regulatory sequences
P01767592A0682|34 51|DNA binding proteins
P01767592A0682|66 75|non-coding
P01767592A0682|86 122|HAP2/HAP3 consensus recognition sequence
P01767592A0682|86 89|HAP2
P01767592A0682|91 94|HAP3
P01767592A0682|125 138|nucleotide-154
P01767592A0682|143 174|BAF1 consensus recognition sequence
P01767592A0682|177 190|nucleotide-136
P01767899A0136|0 21|Marked thrombocytopenia
P01767899A0136|23 31|depletion
P01767899A0136|34 48|serum fibrinogen
P01767899A0136|39 48|fibrinogen
P01767899A0136|52 71|prolonged prothrombin
P01767899A0136|61 71|prothrombin
P01767899A0136|84 108|partial thromboplastin time
P01767899A0136|91 104|thromboplastin
P01767899A0136|138 144|minutes
P01767899A0136|150 172|intravenous envenomation
P01768648A0853|12 21|properties
P01768648A0853|24 41|LexA fusion proteins
P01768648A0853|52 63|dimerization
P01768648A0853|67 87|DNA-contacting domains
P01768648A0853|90 93|cRel
P01769189A0000|0 10|Plasma lipid
P01769189A0000|14 32|lipoprotein profiles
P01769189A0000|47 66|elderly female runners
P01769189A0000|68 69|RU
P01769189A0000|71 72|n =
P01769189A0000|76 79|aged
P01769189A0000|86 90|years
P01769189A0000|92 98|body fat
P01769189A0000|105 105|%
P01769189A0000|107 122|training distance
P01769189A0000|130 137|km week-1
P01769189A0000|139 144|VO2max
P01769189A0000|151 161|ml kg-1 min-1
P01769189A0000|170 171|SD
P01769189A0000|176 200|age-matched untrained women
P01769189A0000|202 203|UT
P01769189A0000|205 206|n =
P01769189A0000|216 220|years
P01769189A0000|222 228|body fat
P01769189A0000|235 235|%
P01769189A0000|237 242|VO2max
P01769189A0000|249 259|ml kg-1 min-1
P01769919A0393|0 22|Auditory threshold shifts
P01769919A0393|39 46|auditory
P01769919A0393|53 69|brainstem response
P01769919A0393|104 106|kHz
P01770651T0001|0 10|Fundamental
P01770651T0001|14 31|clinical evaluation
P01770651T0001|34 52|equilibrium dialysis
P01770651T0001|55 76|radioimmunoassay system
P01770651T0001|93 110|serum free thyroxine
P01771593A1152|14 15|TA
P01771593A1152|23 38|specific decrease
P01771593A1152|41 43|AGD
P01771593A1152|46 47|GD
P01771593A1152|74 76|PCD
P01771593A1232|14 19|adults
P01771593A1232|22 29|weeks old
P01771593A1232|35 51|external genitalia
P01771593A1232|54 72|TA-exposed offspring
P01771959A0442|5 8|PTCA
P01771959A0442|10 25|ejection fraction
P01771959A0442|45 45|%
P01771959A0442|54 54|%
P01771959A0442|56 60|p less
P01771959A0442|73 88|regional function
P01771959A0442|111 134|maximal standard deviation
P01771959A0442|141 144|PTCA
P01771959A0442|161 164|PTCA
P01771959A0442|176 183|segments
P01771959A0442|192 213|first standard deviation
P01771959A0442|220 223|PTCA
P01771959A0442|238 241|PTCA
P01772201T0001|3 18|alcoholic patient
P01772201T0001|33 44|subjectivity
P01772341A0852|23 39|combined treatment
P01772341A0852|45 74|thromboxane synthetase inhibitor
P01772341A0852|45 65|thromboxane synthetase
P01772341A0852|79 107|thromboxane receptor antagonist
P01772341A0852|79 97|thromboxane receptor
P01772341A0852|117 132|better protection
P01772341A0852|140 158|digoxin intoxication
P01774062A0257|1 9|330-kb YAC
P01774062A0257|11 16|A148A7
P01774062A0257|32 44|HLA-DQA1 locus
P01774062A0257|32 39|HLA-DQA1
P01774062A0257|55 61|Y3/Ring
P01774062A0257|63 67|locus
P01774062A0257|89 101|kb centromeric
P01774062A0257|104 111|YAC B1D12
P01774063A0161|0 29|Interspecific backcross analysis
P01774063A0161|35 41|progeny
P01774063A0161|53 59|matings
P01774063A0161|63 81|C57BL/6J x Mus spretus
P01774063A0161|83 84|F1
P01774063A0161|86 97|C57BL/6J mice
P01774063A0161|114 131|thrombospondin gene
P01774063A0161|152 155|Fshb
P01774063A0161|157 161|Actcl
P01774063A0161|163 165|Ltk
P01774063A0161|170 176|B2M loci
P01774063A0161|179 194|murine chromosome
P01774093T0000|0 19|Adverse foetal outcome
P01774093T0000|22 69|specific IgM positive Chlamydia trachomatis infection
P01774093T0000|30 32|IgM
P01774822A0289|7 30|image-processing computer
P01774822A0289|32 59|regional LV time-density curves
P01774822A0289|81 92|cardiac cycle
P01776306A0572|3 15|second patient
P01776306A0572|19 20|VT
P01776306A0572|27 38|nonsustained
P01776715A0489|25 38|centrifugation
P01776715A0489|64 78|substantial loss
P01776715A0489|81 83|CO2
P01776715A0489|85 97|equilibration
P01776715A0489|114 123|gas mixture
P01776715A0489|139 143|PCO2 =
P01776715A0489|147 149|kPa
P01777841A0744|3 20|possible mechanisms
P01777841A0744|31 41|differences
P01777841A0744|44 62|post-tetanic effects
P01777841A0744|76 93|cutaneous afferents
P01777841A0744|96 101|adults
P01777841A0744|105 112|neonates
P01779299A0000|10 30|behavioral alterations
P01779299A0000|36 49|brown cockroach
P01779299A0000|51 68|Periplaneta brunnea
P01779299A0000|85 99|acanthocephalan
P01779299A0000|101 124|Moniliformis moniliformis
P01779433A0694|19 42|monomeric Alu family repeat
P01779433A0694|28 30|Alu
P01779433A0694|48 55|junction
P01779433A0694|63 79|nonhomology block I
P01779433A0694|83 90|homology
P01779433A0694|96 96|Y
P01779433A0694|102 106|alpha
P01779433A0694|108 126|gene-containing unit
P01779433A0694|129 141|rhesus macaque
P01779433A0694|157 178|dimeric Alu family repeat
P01779433A0694|180 182|Alu
P01779433A0694|190 208|orthologous position
P01779433A0694|230 238|insertion
P01779433A0694|242 265|monomeric Alu family repeat
P01779433A0694|251 253|Alu
P01779433A0694|298 312|Alu family repeat
P01779433A0694|298 300|Alu
P01779769A0000|16 29|repressor locus
P01779769A0000|31 31|c
P01779769A0000|38 63|Streptomyces temperate phage
P01779769A0000|65 70|phi C31
P01779769A0000|101 116|open reading frame
P01779769A0000|128 137|kDa protein
P01780235A0094|3 11|EPO levels
P01780235A0094|3 5|EPO
P01780235A0094|41 51|transfusion
P01780235A0094|91 101|transfusion
P01781923A0744|4 26|differential sensitivity
P01781923A0744|29 30|DB
P01781923A0744|45 62|lower concentration
P01781923A0744|65 66|DB
P01781923A0744|84 91|righting
P01781923A0744|94 95|LS
P01781923A0744|115 123|equal rate
P01781923A0744|126 166|water-soluble barbiturate brain distribution
P01781923A0744|170 180|elimination
P01781923A0744|189 193|lines
P01782424A0278|14 36|threshold concentrations
P01782424A0278|48 63|certain phenomena
P01782424A0278|93 101|sentinels
P01782669A0496|30 41|temperatures
P01782669A0496|57 62|A23187
P01782982A0155|0 9|Felodipine
P01782982A0155|24 35|baseline FEV1
P01782982A0155|47 78|small significant inhibitory effect
P01782982A0155|83 91|histamine
P01782982A0155|95 97|AMP
P01782982A0155|105 123|bronchoconstriction
P01783088A1136|10 17|patients
P01783088A1136|22 39|progressive disease
P01783088A1136|43 58|mast cells greater
P01783088A1136|75 75|%
P01783088A1136|77 93|hyaluronan greater
P01783088A1136|109 122|micrograms.l-1
P01783088A1136|120 122|l-1
P01783088A1136|126 143|fibronectin greater
P01783088A1136|126 136|fibronectin
P01783088A1136|160 173|micrograms.l-1
P01783088A1136|196 203|patients
P01783088A1136|216 232|regressive disease
P01783088A1136|235 242|ABSTRACT
P01783088A1136|257 261|WORDS
P01783375A1066|3 9|mapping
P01783375A1066|69 84|genetic disorders
P01783375A1066|89 137|known neoplasia-associated translocation breakpoints
P01784589A0000|41 61|5-HT2 receptor activity
P01784589A0000|41 53|5-HT2 receptor
P01784589A0000|64 84|male rat sexual behavior
P01785749A0695|5 11|changes
P01785749A0695|44 56|obese children
P01786094T0001|0 14|Arsenic contents
P01786094T0001|17 28|native copper
P01787085A0331|5 20|other experiments
P01787085A0331|39 49|control rats
P01787085A0331|51 69|99mTc-sulfur colloid
P01788002T0001|0 13|Magnetotherapy
P01788002T0001|16 25|hepatitis A
P01788002T0001|29 29|B
P01788002T0001|32 39|children
P01791363A0208|5 11|results
P01791363A0208|35 42|patients
P01791363A0208|47 75|conventional end-to-end sutures
P01791363A0208|78 92|clinical testing
P01791754T0000|0 17|Mutational analysis
P01791754T0000|34 59|multiple structural features
P01791754T0000|65 89|C-terminal secretion signal
P01791754T0000|92 116|Escherichia coli haemolysin
P01791754T0000|107 116|haemolysin
P01792580A0198|5 15|blood donors
P01792580A0198|21 28|Republic
P01792580A0198|31 36|Serbia
P01792580A0198|59 72|blood donations
P01792580A0198|89 100|female donors
P01792580A0198|146 160|male blood donors
P01792914T0000|0 20|Extramedullary relapse
P01792914T0000|23 39|childhood leukemia
P01797459A0103|0 9|Mycoplasma
P01797459A0103|38 49|pleural fluid
P01797467A0000|0 4|RU486
P01797467A0000|8 10|ONO
P01797467A0000|55 70|early termination
P01798407A1011|13 30|local abnormalities
P01798407A1011|37 44|patients
P01798407A1011|75 80|cortex
P01798407A1011|97 116|temporal anterior lobe
P01798407A1011|144 159|laughing seizures
P01804671A1001|13 23|small values
P01804671A1001|27 31|QS/QC
P01804671A1001|36 42|results
P01804671A1001|72 84|well-perfused
P01804671A1001|86 102|occluded air spaces
P01804671A1001|140 172|ventilation/perfusion distribution
P01804671A1001|185 196|inert gas data
P01804671A1001|201 206|CDCSF6
P01804671A1001|217 224|ml.min-1
P01804671A1001|226 231|mmHg-1
P01806314A0322|0 8|Many cells
P01806314A0322|24 46|endothelial-cell markers
P01806314A0322|67 84|monoclonal antibody
P01806314A0322|92 102|muscle actin
P01808049A0262|0 14|CT abnormalities
P01808049A0262|22 31|term babies
P01808049A0262|40 49|hemorrhage
P01808049A0262|51 62|subarachnoid
P01808049A0262|66 66|%
P01808049A0262|68 80|intracerebral
P01808049A0262|85 85|%
P01808049A0262|88 98|hypodensity
P01808049A0262|108 108|%
P01808049A0262|122 128|% severe
P01808049A0262|132 132|%
P01808049A0262|135 145|hypodensity
P01808049A0262|150 159|hemorrhage
P01808049A0262|163 163|%
P01808049A0262|167 181|cerebral atrophy
P01808049A0262|185 185|%
P01808136T0000|3 9|effects
P01808136T0000|12 24|contrast media
P01808136T0000|27 46|coagulation factor XII
P01808186A0984|0 3|Pigs
P01808186A0984|57 58|kg
P01808186A0984|61 63|Exp
P01808602A0000|9 16|patients
P01808602A0000|21 49|moderate essential hypertension
P01808602A0000|53 59|effects
P01808602A0000|62 86|10-day nifedipine treatment
P01808602A0000|89 101|serum uric acid
P01808602A0000|105 118|renal excretion
P01808602A0000|121 128|uric acid
P01808829A0510|0 3|TPTA
P01808829A0510|12 26|brain congestion
P01808829A0510|31 37|hepatic
P01808829A0510|41 58|pulmonary petechial
P01808829A0510|73 83|hemorrhages
P01809854A0106|0 7|Examples
P01809854A0106|20 27|subjects
P01809854A0106|32 53|improved research design
P01809854A0106|65 83|consensus statements
P01809854A0106|91 103|meta-analysis
P01810108A0000|4 36|phase slug flow tubular heat exchanger
P01810108A0000|50 68|thermal inactivation
P01810108A0000|71 91|Listeria monocytogenes
P01810108A0000|94 112|natural infected milk
P01810108A0000|122 125|cows
P01810154A0491|7 14|children
P01811243A0000|0 24|Regional cerebral blood flow
P01811243A0000|26 29|rCBF
P01811243A0000|31 42|measurements
P01811243A0000|46 63|psychiatric ratings
P01811243A0000|84 104|schizophrenic patients
P01811243A0000|110 113|age =
P01811243A0000|118 122|years
P01811243A0000|144 148|years
P01811243A0000|175 199|similar psychiatric ratings
P01811243A0000|204 226|comparable rCBF technique
P01811948A0289|5 16|present study
P01811948A0289|31 65|strong positive cis-regulatory element
P01811948A0289|71 72|bp
P01811948A0289|78 79|bp
P01811948A0289|85 100|LpS1 beta promoter
P01811948A0289|117 117|G
P01811948A0289|136 152|distal cis-element
P01811948A0289|159 160|bp
P01811948A0289|167 168|bp
P01812102A0101|3 27|present study reports visual
P01812102A0101|34 51|potential responses
P01812102A0101|54 68|pattern reversal
P01812102A0101|70 74|VEP-P
P01812102A0101|81 107|third trimester pregnant women
P01812102A0101|111 117|changes
P01812102A0101|120 126|latency
P01812102A0101|129 138|NPN complex
P01812102A0101|160 168|responses
P01812102A0101|174 189|non pregnant state
P01812690A0475|8 10|SMF
P01812690A0475|23 45|expansive tumorous growth
P01814182A0000|0 13|Different doses
P01814182A0000|16 34|15-methyl-PGF2 alpha
P01814182A0000|44 45|mg
P01814182A0000|63 72|luteolysis
P01814182A0000|76 82|oestrus
P01814182A0000|86 92|heifers
P01814182A0000|99 108|treatments
P01814182A0000|123 135|oestrous cycle
P01816655T0000|0 5|Review
P01816655T0000|40 50|dermoid cyst
P01817497A0715|0 9|Resolution
P01817497A0715|12 33|thermographic asymmetry
P01817497A0715|50 55|Delta T
P01817497A0715|88 88|%
P01817497A0715|94 117|post-treatment population
P01822581A0533|5 13|instances
P01822581A0533|17 40|apparent alcohol responses
P01822581A0533|81 95|microgram/100ml
P01822581A0533|99 111|breath samples
P01822581A0533|120 137|10min post-exposure
P01822995T0000|0 24|Maize rbcS promoter activity
P01822995T0000|0 16|Maize rbcS promoter
P01822995T0000|34 49|sequence elements
P01822995T0000|60 77|dicot rbcS promoters
P01823520A0183|0 11|Measurements
P01823520A0183|25 61|commercial haematofluorometer Buchler ZF
P01823520A0183|85 107|average haematocrit value
P01823524A0238|13 24|scanty number
P01823524A0238|27 34|examples
P01823524A0238|84 99|combined exposure
P01823524A0238|121 137|life-style factors
P01823524A0238|142 162|considerable influence
P01823524A0238|165 190|interindividual differences
P01823524A0238|193 206|susceptibility
P01823524A0238|209 227|xenobiotics toxicity
P01824713A0964|3 15|12S E1A product
P01824713A0964|32 42|TRE sequence
P01824713A0964|47 60|cotransfection
P01824713A0964|65 69|c-jun
P01824713A0964|91 101|stimulation
P01824944A0988|18 28|tunicamycin
P01824944A0988|33 45|transfectants
P01824944A0988|54 85|unglycosylated 18-kDa polypeptides
P01824944A0988|104 106|IgE
P01825027T0000|0 3|PAS1
P01825027T0000|6 14|yeast gene
P01825027T0000|26 45|peroxisome biogenesis
P01825027T0000|64 74|novel family
P01825027T0000|77 91|putative ATPases
P01825027T0000|85 91|ATPases
P01826003A0694|14 22|base pairs
P01826003A0694|24 25|bp
P01826003A0694|40 51|other members
P01826003A0694|57 65|SIG family
P01826003A0694|70 79|beta TG gene
P01826003A0694|94 98|exons
P01826043A0431|3 31|pp90rsk-protein kinase activity
P01826043A0431|3 23|pp90rsk-protein kinase
P01826043A0431|45 54|rsk-kinase
P01826043A0431|74 126|cofactor-dependent signal transducing protein kinases such
P01826043A0431|132 164|cyclic AMP-dependent protein kinases
P01826043A0431|166 172|members
P01826043A0431|178 197|protein kinase C family
P01826043A0431|201 208|other Ca2
P01826043A0431|206 235|Ca2(+)-dependent protein kinases
P01826043A0431|213 235|dependent protein kinases
P01827068T0000|0 10|Human GATA-3
P01827068T0000|13 49|lineage-restricted transcription factor
P01827068T0000|81 102|T cell receptor alpha gene
P01827203A0136|4 37|many eukaryotic transcription factors
P01827203A0136|44 51|proteins
P01827203A0136|63 68|dimers
P01828248A0189|15 25|UvrA protein
P01828248A0189|42 52|UvrB protein
P01828248A0189|66 75|activities
P01828248A0189|123 134|UvrAB complex
P01828248A0189|145 160|helicase activity
P01828248A0189|145 152|helicase
P01829060A0649|3 12|ED30 values
P01829060A0649|26 30|mg/kg
P01829060A0649|46 61|respective values
P01829060A0649|64 73|nifedipine
P01829060A0649|75 76|ED
P01829060A0649|87 91|mg/kg
P01829460A0329|0 23|Southwestern blot analysis
P01829460A0329|44 57|phosphoprotein
P01829460A0329|68 80|kappa B element
P01830114A1587|8 21|positive effect
P01830114A1587|24 26|NS1
P01830114A1587|32 49|steady-state levels
P01830114A1587|52 64|P4 transcripts
P01830114A1587|77 89|amplification
P01830114A1587|92 105|gene copy number
P01830114A1587|126 140|terminal repeats
P01830928A0361|3 37|minus-end-directed microtubule motors
P01830928A0361|42 48|dyneins
P01830928A0361|68 78|superfamily
P01830928A0361|81 104|force-generating proteins
P01830928A0361|109 133|distinct attachment domains
P01832019A0265|4 14|transparent
P01832019A0265|61 67|animals
P01832019A0265|81 85|weeks
P01832152A0000|3 33|incompatibility group W plasmid pSa
P01832152A0000|44 79|Agrobacterium tumefaciens oncogenicity
P01832152A0000|81 82|J.
P01832152A0902|0 33|Potential translational start signals
P01832152A0902|37 44|upstream
P01832152A0902|47 50|ORF1
P01832152A0902|54 57|ORF2
P01832197T0001|0 6|Imaging
P01832197T0001|9 26|D2 dopamine receptor
P01833185A0547|3 19|Thr161Val mutation
P01833185A0547|27 41|lethal phenotype
P01833185A0547|47 58|fission yeast
P01833185A0547|102 107|Thr161
P01833185A0547|112 123|glutamic acid
P01833185A0547|145 159|phosphorylation
P01833185A0547|167 180|uncoordination
P01833185A0547|183 189|mitosis
P01833185A0547|193 211|multiple cytokinesis
P01833637A0531|3 11|abundance
P01833637A0531|14 24|transcripts
P01833637A0531|29 49|several unrelated genes
P01833637A0531|63 80|cdc68-1 mutant cells
P01833637A0531|99 120|restrictive temperature
P01833637A0531|137 146|transcript
P01833637A0531|155 163|HSP82 gene
P01833637A0531|177 191|aberrant fashion
P01833716A0990|0 11|Deregulation
P01833716A0990|44 66|malignant transformation
P01833716A0990|81 95|HTLV-1 infection
P01837787T0000|3 18|murine Mov-34 gene
P01837787T0000|20 34|full-length cDNA
P01837787T0000|38 56|genomic organization
P01837842A1410|0 3|CREB
P01837842A1410|27 43|protein components
P01837842A1410|58 74|gel shift complexes
P01837842A1410|88 97|variant CRE
P01839414T0000|36 53|malignant neoplasms
P01839414T0000|56 60|Sabah
P01840513A1019|29 37|SL-2 cells
P01840513A1019|39 49|pCAT plasmid
P01840513A1019|65 66|bp
P01840513A1019|72 85|flanking region
P01840513A1019|98 113|3.5-fold increase
P01840513A1019|116 155|chloramphenicol acetyltransferase activity
P01840513A1019|116 147|chloramphenicol acetyltransferase
P01840513A1019|161 169|induction
P01840513A1019|174 185|retinoic acid
P01840513A1019|192 203|8-bromo-cAMP
P01840607A0294|25 28|UTRs
P01840607A0294|66 67|bp
P01840607A0294|105 107|PFP
P01840608A0823|3 12|N-terminus
P01840608A0823|22 37|open reading frame
P01840608A0823|52 55|nifA
P01840608A0823|82 85|nifB
P01840608A0823|88 114|amino acid sequence comparison
P01840711A0000|3 11|RNA genome
P01840711A0000|14 42|rabbit hemorrhagic disease virus
P01840711A0000|44 47|RHDV
P01840902A1089|57 62|plants
P01840902A1089|88 112|nuclear transport machinery
P01840902A1089|124 131|monocots
P01840902A1089|135 140|dicots
P01842498A0000|1 14|novel cDNA clone
P01842498A0000|21 22|R2
P01842498A0000|36 59|subtractive hybridization
P01842498A0000|63 73|cDNA library
P01842498A0000|76 93|phytohemagglutinin
P01842498A0000|95 97|PHA
P01842498A0000|100 144|phorbol myristate acetate-stimulated Jurkat cells
P01842498A0000|162 172|cDNA library
P01842498A0000|175 214|PHA-stimulated peripheral blood lymphocytes
P01842498A0000|175 177|PHA
P01842867A0696|24 47|great regeneration ability
P01842867A0696|57 72|mechanical injury
P01842867A0696|78 88|nasal mucosa
P01844017A0410|14 31|linear relationship
P01844017A0410|48 89|glucose-6-phosphatase dehydrogenase activity
P01844017A0410|48 81|glucose-6-phosphatase dehydrogenase
P01844017A0410|95 107|vitamin E level
P01844017A0410|125 132|duration
P01844017A0410|135 143|poisoning
P01844017A0410|148 160|sodium nitrite
P01844878A0000|1 6|vector
P01844878A0000|35 68|inactive neomycin phosphotransferase
P01844878A0000|43 74|neomycin phosphotransferase II gene
P01844878A0000|84 106|select promoter sequences
P01844878A0000|118 142|random genomic DNA fragments
P01844982A0324|0 5|Chagas
P01844982A0324|15 35|visceral leishmaniasis
P01844982A0324|37 54|anti-nuclear factor
P01844982A0324|56 70|schistosomiasis
P01844982A0324|72 87|rheumatoid factor
P01844982A0324|91 104|normal controls
P01845829A0158|0 15|Previous analysis
P01845829A0158|21 33|98-bp sequence
P01845829A0158|47 75|several protein-binding domains
P01845829A0158|95 115|nuclear factors present
P01845829A0158|118 132|human brain cells
P01845885A1003|3 27|second transcriptional unit
P01845885A1003|39 44|UL26.5
P01845885A1003|39 42|UL26
P01845885A1003|77 86|amino acids
P01845885A1003|106 113|proteins
P01845885A1003|134 137|mRNA
P01845885A1003|167 176|nucleotide
P01845885A1003|187 217|UL26 transcription initiation site
P01845885A1003|240 271|methionine initiation codon located
P01845885A1003|292 314|UL26 transcriptional unit
P01845899A0000|3 23|adeno-associated virus
P01845899A0000|25 27|AAV
P01845899A0000|29 35|rep gene
P01845899A0000|47 54|proteins
P01845899A0000|56 60|Rep78
P01845899A0000|62 66|Rep68
P01845899A0000|68 72|Rep52
P01845899A0000|77 81|Rep40
P01845899A0000|94 110|AAV DNA replication
P01845899A0000|114 130|AAV gene regulation
P01846206A0665|1 20|larger region upstream
P01846206A0665|23 33|human CMV dbp
P01846206A0665|46 56|replication
P01846206A0665|59 73|transient assays
P01846489A1119|15 47|picornaviral 3C-like protease domain
P01846489A1119|54 79|papain-like protease domains
P01846491A0459|11 27|relative positions
P01846491A0459|33 39|VV genes
P01846491A0459|41 58|genus Orthopoxvirus
P01846491A0459|86 102|corresponding ORFs
P01846491A0459|105 107|SFV
P01846491A0459|109 127|genus Leporipoxvirus
P01846491A0459|140 160|complex rearrangements
P01846491A0459|171 176|genome
P01846491A0459|195 211|viruses subsequent
P01846491A0459|219 228|divergence
P01846491A0459|234 247|common ancestor
P01846803A0688|22 36|phosphorylation
P01846803A0688|39 41|Thr
P01846803A0688|50 52|Tyr
P01846803A0688|63 83|p34cdc2 kinase activity
P01846803A0688|63 75|p34cdc2 kinase
P01846803A0688|113 120|residues
P01846803A0688|130 151|putative ATP binding site
P01846803A0688|157 162|kinase
P01847464A0856|2 26|short-term cotransfections
P01847464A0856|29 43|pFRTK-CAT target
P01847464A0856|29 33|pFRTK
P01847464A0856|35 37|CAT
P01847464A0856|54 72|EBNA-1-binding sites
P01847464A0856|80 88|EBV origin
P01847464A0856|91 108|plasmid replication
P01847464A0856|110 114|ori-P
P01847464A0856|136 169|carboxy-terminal EBNA-1 construction
P01847464A0856|171 180|amino acids
P01847464A0856|206 235|c-myc nuclear localization signal
P01847464A0856|206 210|c-myc
P01847665A1079|3 10|findings
P01847665A1079|14 23|compatible
P01847665A1079|42 46|genes
P01847665A1079|55 67|PDGF receptors
P01847665A1079|70 80|glioma cells
P01847665A1079|106 115|other genes
P01847665A1079|150 169|developmental program
P01847665A1079|172 193|normal glia cell lineages
P01848300A0910|0 17|Suggestive evidence
P01848300A0910|33 36|cstA
P01848300A0910|49 66|peptide utilization
P01848871A0392|32 44|sodium channel
P01848871A0392|53 57|drugs
P01848871A0392|79 91|late potential
P01848871A0392|95 120|terminal low amplitude signal
P01848871A0392|134 158|signal-averaged QRS complex
P01848871A0392|166 177|prolongation
P01848871A0392|183 195|late potential
P01848871A0392|214 220|slowing
P01848871A0392|223 244|ventricular tachycardia
P01849509T0000|0 13|Identification
P01849509T0000|17 34|nucleotide sequence
P01849509T0000|37 75|Rhizobium meliloti insertion sequence ISRm3
P01849509T0000|97 115|putative transposase
P01849509T0000|105 115|transposase
P01849509T0000|125 129|ISRm3
P01849509T0000|147 171|Staphylococcus aureus IS256
P01849509T0000|167 171|IS256
P01849509T0000|175 202|Thiobacillus ferrooxidans IST2
P01849675A0167|33 39|viruses
P01849675A0167|44 62|complete DNA sequence
P01849675A0167|65 66|KV
P01849675A0167|83 84|bp
P01849734A1063|8 25|PR55 beta transcript
P01849734A1063|36 37|kb
P01849734A1063|51 60|high levels
P01849734A1063|66 78|neuroblastoma
P01849734A1063|86 99|cell line LA-N-1
P01849734A1063|94 99|LA-N-1
P01849734A1063|114 117|mRNA
P01849734A1063|133 151|other human cell lines
P01850096A0662|0 11|Heterodimers
P01850096A0662|14 21|myogenin
P01850096A0662|25 27|E12
P01850096A0662|31 34|MyoD
P01850096A0662|38 40|E12
P01850096A0662|60 78|restriction fragment
P01850096A0662|122 152|cardiac alpha-actin transcription
P01850096A0662|122 139|cardiac alpha-actin
P01850105A1093|3 9|effects
P01850105A1093|12 16|c-myc
P01850105A1093|21 27|further
P01850105A1093|50 54|c-myc
P01850105A1093|65 79|differentiation
P01850105A1093|95 96|Id
P01850105A1093|99 115|negative regulator
P01850105A1093|118 138|muscle differentiation
P01850127A0000|0 16|Stable association
P01850127A0000|19 25|U2 snRNP
P01850127A0000|33 51|branchpoint sequence
P01850127A0000|54 71|mammalian pre-mRNAs
P01850127A0000|80 86|binding
P01850127A0000|90 105|non-snRNP protein
P01850127A0000|111 129|polypyrimidine tract
P01850893A0286|17 26|antibodies
P01850893A0286|49 55|rabbits
P01850893A0286|62 76|commercial farms
P01851386T0092|3 28|Italian Lung Cancer Task Force
P01851386T0092|30 36|FONICAP
P01851527T0000|3 18|promoter activity
P01851527T0000|24 72|gene encoding Alzheimer beta-amyloid precursor protein
P01851527T0000|36 72|Alzheimer beta-amyloid precursor protein
P01851527T0000|74 76|APP
P01851527T0000|94 99|blocks
P01851527T0000|102 118|upstream sequences
P01851756A0743|0 3|Biol
P01851862A0273|0 18|Nucleotide sequences
P01851862A0273|29 35|env gene
P01851862A0273|42 44|LTR
P01851862A0273|47 51|SFV-1
P01851876A0129|28 51|EMBL3 mouse genomic library
P01852438A0928|3 11|MVV-value
P01852438A0928|47 58|67-76 percent
P01852603A0000|3 25|rad9.192 DNA repair mutant
P01852603A0000|3 6|rad9
P01852603A0000|11 25|DNA repair mutant
P01852603A0000|33 44|fission yeast
P01852603A0000|88 89|UV
P01853796T0000|0 5|Review
P01853796T0000|7 19|deterioration
P01853796T0000|22 37|glucose tolerance
P01853796T0000|55 71|insulin resistance
P01853796T0000|55 61|insulin
P01854339A0221|16 39|strong sequence similarity
P01854339A0221|42 74|Escherichia coli consensus promoters
P01854339A0221|57 74|consensus promoters
P01854339A0221|78 102|ribosome-binding sequences
P01854339A0221|112 121|high levels
P01855255T0000|0 18|Premature initiation
P01855255T0000|21 27|mitosis
P01855255T0000|30 34|yeast
P01855255T0000|42 45|RCC1
P01855255T0000|48 66|an interacting GTPase
P01855255T0000|61 66|GTPase
P01856021A0577|69 85|reliable procedure
P01856021A0577|92 108|biological control
P01856021A0577|111 130|occupational exposure
P01856021A0577|133 139|toluene
P01856021A0577|146 151|xylene
P01857143A0351|14 28|78-year-old male
P01857143A0351|35 45|skin lesions
P01857143A0351|68 80|myelofibrosis
P01857326A0160|0 9|Oculus-500
P01857326A0160|20 46|high resolution imaging boards
P01857326A0160|57 62|IBM-AT
P01857326A0160|66 84|compatible computers
P01860846A0663|3 11|human cDNA
P01860846A0663|36 60|tumor necrosis factor-alpha
P01860846A0663|82 104|MARCKS gene transcription
P01860846A0663|82 91|MARCKS gene
P01860846A0663|110 147|human promyelocytic leukemia cell line HL60
P01861034A0798|5 13|resection
P01861034A0798|19 34|proximal fragment
P01861034A0798|39 57|scaphoid contact area
P01861034A0798|81 102|distal scaphoid fragment
P01861188A0000|0 10|Plate luting
P01861188A0000|30 51|polymethylmethacrylate
P01861188A0000|53 56|PMMA
P01861188A0000|112 121|screw heads
P01861188A0000|157 172|internal fixation
P01861188A0000|196 227|paired equine third metacarpal bones
P01861188A0000|232 256|mid-diaphyseal osteotomies
P01861188A0000|267 300|six-hole broad ASIF compression plates
P01862027A0212|5 12|features
P01862027A0212|53 76|Rothmund-Thomson syndrome
P01862455T0000|0 14|Thyroid lymphoma
P01863768A0649|19 24|ORF113
P01863768A0649|34 52|transmembrane domain
P01863887A0174|0 15|Space limitations
P01863887A0174|25 40|exhaustive review
P01863887A0174|46 68|biologic pharmaceuticals
P01863887A0174|76 111|tissue plasminogen activating substance
P01863887A0174|76 92|tissue plasminogen
P01863887A0174|113 120|hormones
P01863887A0174|127 133|thyroid
P01863887A0174|135 141|insulin
P01863887A0174|143 155|growth hormone
P01863887A0174|157 170|erythropoietin
P01863887A0174|173 187|clotting factors
P01863887A0174|192 204|blood products
P01864510A0946|0 7|Dd PK1 RNA
P01864510A0946|23 23|h
P01864510A0946|26 35|starvation
P01864510A0946|58 62|cells
P01864821A0000|3 14|various forms
P01864821A0000|17 33|sickle cell disease
P01864821A0000|42 54|common feature
P01864821A0000|59 77|abnormal globin chain
P01864821A0000|67 77|globin chain
P01864821A0000|88 108|certain conditions such
P01864821A0000|111 117|hypoxia
P01864821A0000|131 138|sickling
P01864821A0000|141 153|red blood cells
P01864821A0000|157 167|obstruction
P01864821A0000|170 181|blood vessels
P01864837A1029|3 18|primary structure
P01864837A1029|35 42|proteins
P01864837A1029|53 61|% homology
P01864837A1029|72 86|mouse contrapsin
P01864837A1029|105 113|% homology
P01864837A1029|124 150|rat alpha 1-protease inhibitor
P01864837A1029|124 141|rat alpha 1-protease
P01865010A0000|0 7|Patterns
P01865010A0000|10 20|connections
P01865010A0000|31 55|cross-modality integration
P01865010A0000|78 92|distinguishable
P01865010A0000|94 110|retrograde tracers
P01865010A0000|112 122|Fluoro-Gold
P01865010A0000|126 140|diamidino yellow
P01865010A0000|144 157|pairwise manner
P01865010A0000|162 192|different sensory representations
P01865010A0000|201 213|somatosensory
P01865010A0000|218 225|auditory
P01865010A0000|232 245|cerebral cortex
P01867069A0000|0 12|Young CD-1 mice
P01867069A0000|15 21|days old
P01867069A0000|35 50|% nicotine sulfate
P01867069A0000|53 67|gestational days
P01867069A0000|88 100|untreated pups
P01867069A0000|106 112|same age
P01867069A0000|151 171|mandibular first molars
P01869565A1254|0 2|USF
P01869565A1254|25 37|transcription
P01869565A1254|41 57|translation system
P01869565A1254|72 82|ADH promoter
P01869565A1254|96 98|MLP
P01869907A2146|3 21|across-fiber pattern
P01869907A2146|27 35|responses
P01869907A2146|38 59|hypotonic NaCl solutions
P01869907A2146|103 105|H2O
P01869907A2146|108 115|ABSTRACT
P01869907A2146|130 134|WORDS
P01869968A0000|0 27|Arterial radioactivity content
P01869968A0000|36 60|intravenous administration
P01869968A0000|63 67|HMPAO
P01869968A0000|75 87|human subjects
P01869968A0673|0 23|Linear regression analysis
P01869968A0673|69 77|clearance
P01869968A0673|79 83|HMPAO
P01869968A0673|85 85|=
P01869968A0673|96 99|rCBF
P01869968A0673|105 120|high significance
P01869968A0673|122 126|p less
P01870194A0302|0 30|Human immunodeficiency virus type 1
P01870194A0302|0 29|Human immunodeficiency virus type
P01870194A0302|32 36|HIV-1
P01870194A0302|85 95|homogeneity
P01870428A0677|0 9|Thigh girth
P01870428A0677|34 36|HDL
P01870428A0677|40 45|HDL2-C
P01870428A0677|61 75|LDL particle size
P01870428A0677|61 63|LDL
P01870428A0677|81 85|women
P01870500A0276|0 12|Contributions
P01870500A0276|17 21|pairs
P01870500A0276|33 52|target volume elements
P01870500A0276|68 74|S values
P01870500A0276|119 134|healthy host organ
P01870500A0276|178 193|healthy host organ
P01870500A0276|202 219|reciprocity theorem
P01871033A0434|0 4|Tests
P01871033A0434|17 33|overall impression
P01871033A0434|71 90|laboratory simulation
P01871033A0434|99 112|clearing cement
P01871033A0434|116 128|testing cement
P01871135A0295|3 6|cDNA
P01871135A0295|18 33|open reading frame
P01871135A0295|40 41|bp
P01871135A0295|68 77|amino acids
P01871135A0295|82 94|molecular mass
P01871135A0295|99 101|kDa
P01871135A0295|119 127|% identity
P01871135A0295|130 148|rat liver glucokinase
P01871971A0836|0 7|Analysis
P01871971A0836|10 21|viral mutants
P01871971A0836|47 55|NFIII/OCT
P01871971A0836|47 51|NFIII
P01871971A0836|53 68|OCT-1 binding site
P01871971A0836|58 68|binding site
P01871971A0836|82 89|ATF motif
P01871971A0836|106 125|efficient viral growth
P01872856A0277|0 7|Recovery
P01872856A0277|10 24|radiolabelled BA
P01872856A0277|32 36|urine
P01872856A0277|40 40|%
P01872856A0277|45 50|faeces
P01872856A0277|54 54|%
P01872856A0277|62 64|hrs
P01872856A0277|75 75|%
P01872856A0277|84 104|residual radioactivity
P01872856A0277|115 120|testis
P01872856A0277|145 145|%
P01872856A0277|148 163|scorbutic animals
P01873999A0000|47 57|model system
P01873999A0000|74 84|biochemical
P01873999A0000|97 112|molecular details
P01873999A0000|115 128|gene expression
P01873999A0000|135 150|secretion process
P01873999A0000|180 199|heterologous proteins
P01873999A0000|202 225|biotechnological interest
P01874195A0139|25 34|GH receptor
P01874195A0139|60 77|sequence similarity
P01874195A0139|80 88|receptors
P01874195A0139|93 125|known signal transduction mechanisms
P01874195A0139|151 188|ligand-activated tyrosine kinase activity
P01874195A0139|167 180|tyrosine kinase
P01874752A0948|22 58|certain experimental conditions cdc2/p58
P01874752A0948|51 54|cdc2
P01874752A0948|56 58|p58
P01874752A0948|62 69|cdc2/p62
P01874752A0948|62 65|cdc2
P01874752A0948|67 69|p62
P01874752A0948|84 94|differences
P01874752A0948|102 118|catalytic activity
P01875922A0770|0 15|Mutation analysis
P01875922A0770|26 41|multiple segments
P01875922A0770|49 66|untranslated region
P01875922A0770|86 101|inhibitory effect
P01876836T0000|0 13|Identification
P01876836T0000|16 18|Ets
P01876836T0000|23 43|notch-related subunits
P01876836T0000|46 61|GA binding protein
P01878489A0959|3 19|enzymatic response
P01878489A0959|22 32|neutrophils
P01878489A0959|36 44|monocytes
P01878489A0959|80 99|NADPH oxidase activity
P01878489A0959|80 91|NADPH oxidase
P01878489A0959|116 121|higher
P01878489A0959|124 134|neutrophils
P01878489A0959|141 149|monocytes
P01878755A0496|5 9|ileum
P01878755A0496|11 21|enterotoxin
P01878755A0496|34 53|luminal disappearance
P01878755A0496|55 59|P less
P01878755A0496|72 96|peripheral blood appearance
P01878755A0496|98 102|P less
P01878755A0496|115 125|chloroquine
P01881595A0476|0 7|Formalin
P01881595A0476|21 25|SNO NS
P01881595A0476|29 39|NnS neurones
P01881595A0476|63 72|NS neurones
P01881595A0476|74 75|n =
P01881595A0476|91 100|first phase
P01881595A0476|116 126|NnS neurones
P01881595A0476|143 144|n =
P01881595A0476|153 158|phases
P01881595A0476|160 161|n =
P01881671T0001|0 5|Uptake
P01881671T0001|8 16|ofloxacin
P01882240A0526|33 38|issues
P01882240A0526|84 103|AIDS related behaviors
P01882240A0526|106 121|Black communities
P01882386A0000|18 36|alpha-mercapto-beta
P01882386A0000|39 45|2-furyl
P01882386A0000|47 57|acrylic acid
P01882386A0000|59 61|MFA
P01882386A0000|66 101|N-benzyl-N-dithiocarboxy-D-glucamine
P01882386A0000|103 105|NaB
P01882386A0000|131 142|mobilization
P01882386A0000|146 154|excretion
P01882386A0000|178 181|rats
P01883992A0922|5 11|results
P01883992A0922|23 28|beta-1
P01883992A0922|38 52|tissue-specific
P01883992A0922|54 74|trans-acting regulator
P01883992A0922|95 107|beta-zein gene
P01883992A0922|120 133|maize endosperm
P01884435A0088|20 26|effects
P01884435A0088|29 39|hypovolemia
P01884435A0088|45 61|extracellular ptO2
P01884435A0088|65 80|ptH distributions
P01884435A0088|83 101|multiple tissue sites
P01884435A0088|125 148|multipoint microelectrode
P01884435A0088|162 185|simultaneous measurements
P01884435A0088|188 191|ptO2
P01884435A0088|195 197|ptH
P01884998A1135|3 9|members
P01884998A1135|42 54|transcription
P01884998A1135|59 67|promoters
P01884998A1135|80 96|C/EBP-binding site
P01885006A0995|3 9|domains
P01885006A0995|20 34|superactivation
P01885006A0995|46 51|subset
P01885006A0995|77 97|synergistic activation
P01885613A1298|0 10|Information
P01885613A1298|22 39|noncoding sequences
P01885613A1298|50 56|studies
P01885613A1298|77 84|pro alpha
P01885613A1298|90 101|collagen gene
P01885752A0198|0 19|Chlamydia trachomatis
P01885752A0198|23 39|Chlamydia psittaci
P01885752A0198|57 72|methanol fixation
P01885915A0000|8 22|human infections
P01885915A0000|27 40|bacteraemia due
P01885915A0000|43 62|Pasteurella multocida
P01885915A0000|69 76|uncommon
P01885915A0000|78 89|endocarditis
P01885915A0000|104 116|P. haemolytica
P01886043A0380|3 5|SMX
P01886043A0380|8 9|pH
P01886043A0380|39 40|pH
P01886043A0380|44 47|HPCD
P01886043A0380|51 62|little effect
P01886043A0380|68 77|solubility
P01886043A0380|96 98|SMX
P01886043A0380|119 137|un-ionized molecules
P01886043A0380|145 162|inclusion complexes
P01886043A0380|170 173|HPCD
P01886368A0000|0 14|PO2 measurements
P01886368A0000|36 60|recess type microelectrodes
P01886368A0000|78 91|optic nerve head
P01886368A0000|94 106|miniature pigs
P01886368A0000|109 116|normoxia
P01886368A0000|120 128|hyperoxia
P01886774A0000|0 11|POU-specific
P01886774A0000|15 30|POU-homeo domains
P01886774A0000|33 36|Oct3
P01886774A0000|51 64|Echerichia coli
P01886774A0000|68 83|characterization
P01886774A0000|86 95|DNA binding
P01886774A0000|101 115|octamer sequence
P01888896A0505|1 14|deletion series
P01888896A0505|22 35|flanking region
P01888896A0505|81 109|transcriptional initiation site
P01888896A0505|132 148|transgenic tobacco
P01889753A0441|3 12|nucleotide
P01889753A0441|14 15|nt
P01889753A0441|17 25|sequences
P01889753A0441|31 35|exons
P01889753A0441|37 57|exon/intron boundaries
P01889753A0441|70 88|untranslated regions
P01890362A0305|7 14|patients
P01890362A0305|38 56|eye complications due
P01890362A0305|59 65|leprosy
P01890362A0305|69 76|patients
P01890362A0305|101 105|years
P01890989A1392|12 38|different regulatory elements
P01890989A1392|55 71|estrogen induction
P01890989A1392|74 85|related genes
P01890989A1392|88 95|chickens
P01890989A1392|99 108|amphibians
P01892680A0907|0 7|Toxicity
P01892680A0907|27 34|regimens
P01892680A0907|44 51|sedation
P01892680A0907|68 73|higher
P01892680A0907|76 79|arm B
P01892680A0907|81 85|p less
P01893195A0000|16 27|green monkeys
P01893195A0000|29 42|Syrian hamsters
P01893195A0000|46 54|white mice
P01893195A0000|58 64|authors
P01893195A0000|75 94|pathogenic properties
P01893195A0000|98 114|new virus Issyk-Kul
P01893927A0704|10 29|mean arterial pressure
P01893927A0704|32 52|phenylephrine infusion
P01893927A0704|55 60|levels
P01893927A0704|65 71|greater
P01893927A0704|86 88|NMA
P01893927A0704|92 94|NNA
P01893927A0704|105 119|small reductions
P01893927A0704|122 134|cardiac output
P01894696A0301|0 1|J.
P01895358A0000|0 5|Limits
P01895358A0000|8 21|energy turnover
P01895358A0000|34 52|physical performance
P01895358A0000|83 92|lower limit
P01895358A0000|94 100|changes
P01895358A0000|108 124|training programme
P01895358A0000|141 153|energy balance
P01895358A0000|165 178|energy turnover
P01895370A0199|4 21|stepwise reductions
P01895370A0199|37 37|S
P01895370A0199|42 47|trough
P01895370A0199|49 49|D
P01895370A0199|51 56|points
P01895370A0199|62 93|maximum shifted-frequency envelope
P01895370A0199|100 107|parallel
P01895370A0199|111 123|linear fashion
P01895370A0199|129 129|D
P01895384A0746|3 16|IE0 gene product
P01895384A0746|38 48|IE1 promoter
P01895384A0746|81 91|own promoter
P01895393A0745|9 17|promoters
P01895393A0745|29 35|TATA box
P01895393A0745|50 57|Sp1 sites
P01895393A0745|60 67|Sp1 sites
P01895393A0745|83 89|TATA box
P01895393A0745|101 109|inducible
P01895393A0745|125 137|RNA polymerase
P01895393A0745|141 148|promoter
P01895555T0001|0 9|Evaluation
P01895555T0001|12 34|left ventricular function
P01895555T0001|40 67|gated planar myocardial imaging
P01895555T0001|72 82|Tc-99m-MIBI
P01896777T0000|0 15|Ivermectin uptake
P01896777T0000|36 41|plasma
P01896777T0000|53 60|Sudanese
P01896777T0000|64 78|Mexican patients
P01896777T0000|91 108|Onchocerca volvulus
P01897515A0348|0 22|Bone marrow abnormalities
P01897515A0348|25 31|Hodgkin
P01897515A0348|58 77|current understanding
P01897515A0348|83 104|pathological mechanisms
P01897515A0348|114 127|aplastic anemia
P01898113A0265|3 19|smaller uptake rate
P01898113A0265|23 41|faster clearance rate
P01898113A0265|55 62|lower BCF
P01898113A0265|66 77|SWA killifish
P01898164A0839|28 37|arch repair
P01898164A0839|60 69|small group
P01898164A0839|72 78|infants
P01898164A0839|83 102|transverse aortic arch
P01898164A0839|114 132|aorta diameter ratios
P01898164A0839|134 144|arch indices
P01898928A0260|0 23|DNA hybridization analysis
P01898928A0260|40 48|pigmented
P01898928A0260|52 68|nonpigmented cells
P01898928A0260|71 72|Y.
P01898928A0260|87 104|DNA locus homologous
P01898928A0260|110 131|Escherichia coli fur gene
P01898928A0260|125 131|fur gene
P01899209A0883|0 8|Increases
P01899209A0883|14 26|perfusate PCO2
P01899209A0883|38 47|perfusate H
P01899209A0883|73 81|decreases
P01899209A0883|88 110|myocardial contractility
P01899209A0883|114 130|oxygen consumption
P01899209A0883|132 134|r2 =
P01899287A0726|0 9|Expression
P01899287A0726|13 31|cell cycle controlled
P01899287A0726|37 57|steady-state RNA levels
P01899287A0726|71 76|higher
P01899287A0726|79 93|growth-arrested
P01899287A0726|100 121|growth-stimulated cells
P01899409T0000a|0 11|Determinants
P01899409T0000a|14 31|recurrent ischaemia
P01899409T0000a|35 61|revascularisation procedures
P01899409T0000a|67 78|thrombolysis
P01899409T0000a|83 119|recombinant tissue plasminogen activator
P01899409T0000a|122 145|primary coronary occlusion
P01899846A0862|13 26|rbcL-rbcS locus
P01899846A0862|57 73|standard condition
P01899846A0862|77 98|photoautotrophic growth
P01900194T0000|0 11|Relationship
P01900194T0000|19 55|mitochondrial NADH-ubiquinone reductase
P01900194T0000|60 91|bacterial NAD-reducing hydrogenase
P01901405A0694|0 7|Analysis
P01901405A0694|10 23|mRNA expression
P01901405A0694|33 38|AT-BP1
P01901405A0694|42 47|AT-BP2
P01901405A0694|68 74|tissues
P01901443A0297|11 18|patients
P01901443A0297|28 47|maintenance valproate
P01901443A0297|65 79|acute hepatitis C
P01901443A0297|95 121|chronic persistent hepatitis C
P01901443A0297|127 159|incidental microvesicular steatosis
P01901443A0297|174 187|oil-red O stains
P01901664T0064|1 5|cases
P01901859A0000|0 59|UDP-Gal:Gal beta 1----4GlcNAc alpha 1----3-galactosyltransferase
P01901859A0000|0 6|UDP-Gal
P01901859A0000|8 14|Gal beta
P01901859A0000|20 31|4GlcNAc alpha
P01901859A0000|37 59|3-galactosyltransferase
P01901859A0000|63 89|terminal glycosyltransferase
P01901859A0000|123 138|mammalian species
P01901859A0000|147 162|notable exception
P01901859A0000|169 172|apes
P01901859A0000|177 191|Old World monkeys
P01901946A0243|1 24|synthetic oligonucleotide
P01901946A0243|38 48|SRE sequence
P01901946A0243|56 77|mouse c-fos gene promoter
P01901946A0243|121 125|probe
P01901946A0243|132 149|mobility shift assay
P01901946A0243|153 164|Southwestern
P01901946A0243|166 176|DNA-protein
P01901946A0243|178 185|blotting
P01901946A0243|201 239|sequence-specific affinity chromatography
P01901950T0000|0 19|Sequence requirements
P01901950T0000|23 50|premature transcription arrest
P01901950T0000|60 70|first intron
P01901950T0000|76 89|mouse c-fos gene
P01903404A0688|0 30|Infarct regional ejection fraction
P01903404A0688|51 51|%
P01903404A0688|67 77|late studies
P01903404A0688|85 105|infarct-related artery
P01903404A0688|129 129|%
P01903404A0688|137 144|occluded
P01903404A0688|146 147|p =
P01903404A0688|155 161|changes
P01903404A0688|173 206|noninfarct regional ejection fraction
P01903404A0688|211 229|similar irrespective
P01903404A0688|232 246|perfusion status
P01903841A0125|8 21|lysine residues
P01903841A0125|34 43|spermidine
P01903841A0125|50 57|hypusine
P01903841A0125|60 94|posttranslational modification unique
P01903841A0125|97 102|eIF-5A
P01903841A1449|3 25|plasmid shuffle technique
P01903841A1449|45 57|wild-type gene
P01903841A1449|65 74|mutant form
P01903841A1449|99 108|yeast cells
P01904154A0164|33 48|characterization
P01904154A0164|51 61|transcripts
P01904154A0164|69 74|Ig loci
P01904154A0164|88 106|better understanding
P01904154A0164|112 135|gene rearrangement process
P01904437A0000|0 12|Transcription
P01904437A0000|18 25|metH gene
P01904437A0000|93 107|metR gene product
P01904437A0000|110 126|DNA binding protein
P01904546A0671|0 9|Disruption
P01904546A0671|15 33|chromosomal AAR1 gene
P01904546A0671|36 40|alpha
P01904546A0671|44 55|a/alpha cells
P01904546A0671|68 85|nonmating phenotype
P01904546A0671|93 107|a/alpha diploids
P01905199A0210|11 18|ICRF-187
P01905199A0210|24 40|antitumor response
P01905199A0210|66 68|ADR
P01905199A0210|72 74|WBH
P01905199A0210|109 119|alterations
P01905199A0210|125 140|therapeutic index
P01905199A0210|147 182|combined therapeutic modality treatment
P01905517A1076|3 5|ORF
P01905517A1076|20 46|secondary structural features
P01905517A1076|54 70|sequence data bases
P01905517A1076|86 95|homologies
P01906111A1295|26 44|dose-intense regimen
P01906111A1295|91 96|marrow
P01906111A1295|104 128|acceptable toxicity profile
P01906166A0119|0 10|Mitomycin-C
P01906166A0119|19 32|severe necrosis
P01906166A0119|36 45|ulceration
P01906166A0119|86 96|soft tissues
P01906166A0119|108 125|drug administration
P01906509A0072|30 43|flanking region
P01906509A0072|49 64|human nidogen gene
P01906692A0321|0 12|INTERVENTIONS
P01906692A0321|14 21|Patients
P01906692A0321|30 34|rt-PA
P01906692A0321|36 42|heparin
P01906692A0321|47 53|aspirin
P01907265A0670|0 9|Consistent
P01907265A0670|33 60|pseudorevertant endonucleases
P01907265A0670|66 81|crude cell extract
P01907265A0670|89 127|site-specific partial DNA cleavage activity
P01907941A0275|13 23|I kappa B beta
P01907941A0275|31 42|I kappa B alpha
P01907941A0275|60 66|binding
P01907941A0275|69 71|Rel
P01907941A0275|77 86|kappa B site
P01909027A0922|0 15|Sequence analysis
P01909027A0922|30 45|DNA binding domain
P01909027A0922|48 50|ILF
P01909027A0922|54 67|strong homology
P01909027A0922|90 113|fork head DNA binding domain
P01909027A0922|134 156|homeotic protein fork head
P01909027A0922|169 192|hepatocyte nuclear factors
P01909027A0922|194 198|HNF-3
P01909621A0119|0 6|Lengthy
P01909621A0119|10 29|repeated hemodialyses
P01909621A0119|44 56|lower lithemia
P01909621A0119|59 72|nontoxic ranges
P01909960A0134|11 19|injection
P01909960A0134|22 33|d,l-baclofen
P01909960A0134|36 40|mg/kg
P01909960A0134|52 64|noradrenaline
P01909960A0134|66 67|NA
P01909960A0134|69 80|biosynthesis
P01909960A0134|90 90|%
P01909960A0134|98 120|endogenous concentration
P01909960A0134|123 137|normetanephrine
P01909960A0134|139 141|NMN
P01909960A0134|146 146|%
P01909960A0134|160 167|NA levels
P01909960A0134|171 171|%
P01910505A0000|0 21|Fufang wuzi yanzong pills
P01910505A0000|26 47|strong leukogenic effect
P01910505A0000|50 65|cyclophosphamide
P01910505A0000|73 82|leukopenia
P01910505A0000|85 88|mice
P01911767T0000|0 8|Mutations
P01911767T0000|14 25|small subunit
P01911767T0000|28 58|ribulosebisphosphate carboxylase
P01911767T0000|65 78|subunit binding
P01911767T0000|82 90|catalysis
P01913955A0177|3 19|structural changes
P01913955A0177|22 39|intra-acinar artery
P01913955A0177|78 91|muscular artery
P01913955A0177|105 119|muscularization
P01913955A0177|122 135|precursor cells
P01913955A0177|137 145|pericytes
P01913955A0177|149 165|intermediate cells
P01913955A0177|167 173|located
P01913955A0177|189 196|muscular
P01913955A0177|200 222|nonmuscular arterial wall
P01913955A0177|231 240|muscle cell
P01913955A0177|250 259|medial wall
P01913955A0177|274 284|hypertrophy
P01913955A0177|288 298|hyperplasia
P01913955A0177|301 317|smooth muscle cells
P01913955A0177|326 337|accumulation
P01913955A0177|341 351|large amount
P01913955A0177|354 361|collagen
P01913955A0177|376 388|type 1 collagen
P01913955A0177|381 388|collagen
P01915580A0889|5 11|results
P01915580A0889|23 28|NZ-107
P01915580A0889|35 44|useful drug
P01915580A0889|62 76|bronchial asthma
P01915580A0889|87 111|late-phase airway responses
P01915580A0889|115 135|airway hyperreactivity
P01916168A0969|12 34|correlation coefficients
P01916168A0969|45 60|ISO2 measurements
P01916168A0969|74 84|ulcer margin
P01916168A0969|93 112|adjacent normal mucosa
P01916168A0969|117 125|delta ISO2
P01916168A0969|139 157|experienced observer
P01916168A0969|174 181|learners
P01916405A0242|0 23|Bronchial mucosa tattooing
P01916405A0242|26 32|persons
P01916405A0242|42 68|different industrial aerosols
P01916405A0242|86 90|forms
P01916405A0242|96 97|DB
P01916405A0242|104 111|diseases
P01916405A0242|113 118|stages
P01916632A0431|0 17|Anti-HBc production
P01916632A0431|0 7|Anti-HBc
P01916632A0431|20 23|PBMC
P01917943A0621a|0 15|Sequence analysis
P01917943A0621a|21 49|sMtCK genomic upstream sequences
P01917943A0621a|58 72|typical TATAA box
P01917943A0621a|84 92|base pairs
P01917943A0621a|94 95|bp
P01917943A0621a|104 126|transfection experiments
P01917943A0621a|162 177|chimeric plasmids
P01917943A0621a|185 224|chloramphenicol acetyltransferase reporter
P01917943A0621b|0 15|Sequence analysis
P01917943A0621b|21 49|sMtCK genomic upstream sequences
P01917943A0621b|58 72|typical TATAA box
P01917943A0621b|84 92|base pairs
P01917943A0621b|94 95|bp
P01917943A0621b|104 126|transfection experiments
P01917943A0621b|162 177|chimeric plasmids
P01917943A0621b|185 224|chloramphenicol acetyltransferase reporter
P01917962A0152|3 13|cDNA segment
P01917962A0152|28 73|immunoglobulin gene recombination signal sequences
P01917962A0152|28 45|immunoglobulin gene
P01917962A0152|83 93|cDNA segment
P01917962A0152|109 124|human IL-2R L chain
P01917962A0152|168 179|SV40 promoter
P01918010A0000|0 16|Lipoprotein lipase
P01918010A0000|18 20|LPL
P01918010A0000|24 32|key enzyme
P01918010A0000|35 61|normal lipoprotein metabolism
P01918010A0000|67 80|complex pattern
P01918010A0000|96 120|tissue-specific expression
P01918010A1730|0 7|Deletion
P01918010A1730|13 39|proximal octanucleotide motif
P01918010A1730|47 53|plasmid
P01918010A1730|84 94|LPL promoter
P01918010A1730|114 122|% decrease
P01918010A1730|158 173|3T3-L1 adipocytes
P01918010A1730|177 192|HepG2 hepatocytes
P01918070A0281|13 19|binding
P01918070A0281|30 44|T3 receptor alpha
P01918070A0281|46 53|T3R alpha
P01918070A0281|89 97|wild-type
P01918070A0281|110 118|mutations
P01918070A0281|124 130|rGH T3RE
P01918070A0281|124 126|rGH
P01918070A0281|127 130|T3RE
P01918070A0281|148 169|transcriptional potency
P01918070A0281|184 190|changes
P01918070A0281|193 202|T3R binding
P01918070A0281|193 195|T3R
P01918073A0150|0 9|Comparison
P01918073A0150|15 61|cDNA-predicted avian TnIcardiac amino acid sequences
P01918073A0150|29 61|avian TnIcardiac amino acid sequences
P01918073A0150|66 82|known TnI sequences
P01918073A0150|71 82|TnI sequences
P01918073A0150|113 139|N-terminal extension sequence
P01918073A0150|149 191|dual protein kinase A phosphorylation target site
P01918073A0150|153 166|protein kinase A
P01918073A0150|197 223|adjacent proline-rich segment
P01918073A0150|228 257|ancient cardiac-specific feature
P01918073A0150|260 262|TnI
P01918073A0150|292 312|bird/mammal divergence
P01918073A0150|333 356|near-N-terminal troponin C
P01918073A0150|358 360|TnC
P01918073A0150|370 381|site sequence
P01918073A0150|389 414|isoform-specific adaptation
P01918073A0150|417 419|TnI
P01918073A0150|423 425|TnC
P01918073A0150|439 507|avian TnIcardiac internal actin/TnC-binding, actomyosin-inhibitory, domain
P01918073A0150|439 478|avian TnIcardiac internal actin/TnC-binding
P01918073A0150|480 500|actomyosin-inhibitory
P01918073A0150|513 541|significant sequence divergence
P01918073A0150|546 573|mammalian TnIcardiac sequences
P01918073A0150|597 620|protein kinase C target site
P01918073A0150|629 651|cardiac-specific feature
P01918073A0150|654 656|TnI
P01918073A0150|659 665|mammals
P01919831T0000|0 28|Ventilatory management casebook
P01921463T0000|2 17|ASSEMBLER routine
P01921463T0000|21 41|on-line graphic display
P01921463T0000|45 53|averaging
P01921463T0000|71 91|personal microcomputer
P01922082A0149|0 9|Expression
P01922082A0149|15 30|mouse TSH beta gene
P01922082A0149|53 65|multiple mRNAs
P01922082A0149|85 102|untranslated region
P01922734T0000|0 10|Habituation
P01922734T0000|31 37|neurons
P01922734T0000|43 53|edible snail
P01922734T0000|56 76|electrical stimulation
P01922739A0336|17 20|ROSP
P01922739A0336|39 50|fluctuations
P01922739A0336|67 84|positive directions
P01922739A0336|109 117|amplitude
P01922739A0336|135 138|days
P01922739A0336|181 200|stable negative values
P01922739A0336|206 209|ROSP
P01922739A0336|238 247|electrodes
P01922739A0336|272 280|dura mater
P01922739A0336|285 298|positive values
P01922739A0336|301 310|electrodes
P01922739A0336|335 342|pia mater
P01923167A0000|0 25|Blood flow velocity waveforms
P01923167A0000|40 63|pulsed Doppler examination
P01923167A0000|69 88|fetal internal carotid
P01923167A0000|92 113|middle cerebral arteries
P01923167A0000|122 151|established transabdominal route
P01923167A0000|161 183|new transvaginal approach
P01923628T0001|0 19|Quantitative analysis
P01923628T0001|30 42|flow cytometry
P01923628T0001|46 71|immunocytochemical findings
P01923628T0001|76 80|cases
P01923628T0001|83 96|cardiac myxomas
P01923766A0485|0 15|Sequence analysis
P01923766A0485|43 60|non-spliced variant
P01923766A0485|62 80|multiple mRNA species
P01923766A0485|96 114|alternative splicing
P01923766A0485|129 137|exclusion
P01923766A0485|160 170|nucleotides
P01923766A0485|172 173|nt
P01923766A0485|193 196|exon
P01923803A0609|0 7|Position
P01923803A0609|14 23|isoleucine
P01923803A0609|29 57|complete SsoL12 protein sequence
P01923803A0609|68 75|AUA codon
P01923985A0111|0 10|Symptoms due
P01923985A0111|24 41|mastocyte mediators
P01924315A0158|5 9|yeast
P01924315A0158|34 45|copper levels
P01924315A0158|76 89|SOD1 expression
P01924315A0158|76 79|SOD1
P01924920A0115|10 16|samples
P01924920A0115|18 29|Mobiluncus SP
P01924920A0115|50 50|%
P01924920A0115|57 68|Gram staining
P01924920A0115|81 81|%
P01924920A0115|87 99|microorganism
P01924920A0115|113 119|agar RLK
P01924920A0115|123 141|anaerobic atmosphere
P01925092A0000|0 20|Previous investigators
P01925092A0000|38 52|subretinal blood
P01925092A0000|63 68|retina
P01925092A0000|87 105|solid fibrin meshwork
P01925092A0000|92 97|fibrin
P01925092A0304|11 15|hours
P01925092A0304|25 31|animals
P01925092A0304|48 66|subretinal treatment
P01925092A0304|74 83|micrograms
P01925092A0304|86 111|tissue plasminogen activator
P01925092A0304|115 127|similar volume
P01925092A0304|130 146|physiologic saline
P01927421A0181|0 27|Neuro-otological examinations
P01927421A0181|36 63|spontaneous downbeat nystagmus
P01927421A0181|65 73|bilateral
P01927421A0181|78 86|nystagmus
P01927421A0181|97 105|nystagmus
P01927845A0107|8 17|morphology
P01927845A0107|23 29|lesions
P01927845A0107|44 66|other cutaneous disorders
P01927845A0107|68 72|Bowen
P01928923A0000|0 11|Equine amnion
P01928923A0000|19 37|yeast cell derivative
P01928923A0000|78 99|topical wound medicament
P01928923A0000|140 145|wounds
P01928923A0000|151 163|distal portion
P01928923A0000|169 173|limbs
P01928923A0000|176 181|horses
P01930470A0337|10 29|current high incidence
P01930470A0337|32 46|NANB-induced PTH
P01930470A0337|44 46|PTH
P01930470A0337|58 76|American Association
P01930470A0337|79 88|Blood Banks
P01930470A0337|90 93|AABB
P01930470A0337|121 134|PTH-associated
P01930470A0337|136 144|surrogate
P01930470A0337|146 152|markers
P01930470A0337|165 169|units
P01930660T0000|0 24|Insulin-like growth factor 1
P01930660T0000|0 23|Insulin-like growth factor
P01930660T0000|26 30|IGF-1
P01930660T0000|38 45|patients
P01931966A0490|0 5|Fusion
P01931966A0490|8 16|ubiquitin
P01931966A0490|19 24|pADPRP
P01931966A0490|44 49|pADPRP
P01931966A0490|89 101|unfused enzyme
P01932650A0435|11 18|patients
P01932650A0435|36 62|own mediastinal drainage blood
P01932650A0435|72 76|hours
P01932650A0435|123 126|MBRS
P01932695A1155|3 13|suppression
P01932695A1155|36 59|transient expression assay
P01932695A1155|79 94|barley endosperms
P01933614A0406|11 36|salmon calcitonin nasal spray
P01933614A0406|11 26|salmon calcitonin
P01933614A0406|39 43|women
P01933614A0406|48 70|established osteoporosis
P01934378A1219|0 36|Skeletal muscle metaboreceptor responses
P01934378A1219|40 47|impaired
P01934378A1219|50 61|heart failure
P01934378T0000|0 44|Skeletal muscle metaboreceptor exercise responses
P01934378T0000|60 71|heart failure
P01936213T0000|0 9|Evaluation
P01936213T0000|12 34|antiepileptic drug effect
P01936213T0000|37 52|membrane fluidity
P01936348A0155|3 14|examinations
P01936348A0155|33 38|groups
P01936348A0155|49 56|AmF/SnF2
P01936348A0155|60 63|resp
P01936997A0795|0 16|RNA gel retardation
P01936997A0795|20 38|competition analyses
P01936997A0795|51 64|TRP-185 binding
P01936997A0795|51 57|TRP-185
P01936997A0795|89 107|TAR RNA loop sequences
P01937790A0292|26 36|immunogenic
P01937790A0292|40 52|older children
P01937790A0292|56 61|adults
P01937989A0383|4 9|groups
P01937989A0383|23 39|hypnotic induction
P01937989A0383|66 67|R2
P01938178T0000|0 11|Applications
P01938178T0000|14 38|three-dimensional analysis
P01938178T0000|44 55|auditory P300
P01939131A0871|29 34|BW2001
P01939131A0871|36 41|xth-11
P01939131A0871|43 47|nfo-2
P01939131A0871|49 59|strain cells
P01939199A0588|0 20|Recombinant human TFIID
P01939199A0588|16 20|TFIID
P01939199A0588|30 51|weak basal transcription
P01939199A0588|54 80|heat-treated nuclear extracts
P01939199A0588|106 118|TFIID fraction
P01939199A0588|106 110|TFIID
P01939199A0588|123 131|HeLa cells
P01939199A0588|146 157|maximal level
P01939199A0588|160 172|transcription
P01939827A0150|10 21|pretreatment
P01939827A0150|42 58|oxide surface layer
P01939827A0150|62 75|titanium powder
P01939827A0150|96 108|precipitation
P01939827A0150|113 121|solutions
P01939827A0150|133 143|mmol/L CaCl2
P01939827A0150|146 157|mmol/L KH2PO4
P01939827A0150|161 171|mmol/L Hepes
P01939827A0150|173 174|pH
P01939827A0150|190 202|precipitation
P01939827A0150|207 225|metastable solutions
P01939827A0150|239 249|mmol/L CaCl2
P01939827A0150|254 265|mmol/L KH2PO4
P01939827A0150|269 279|mmol/L Hepes
P01939827A0150|281 282|pH
P01939827A0150|291 299|degrees C.
P01939878A0765|14 27|solidification
P01939878A0765|58 63|casein
P01939878A0765|107 114|patients
P01939878A0765|128 141|gastric acidity
P01939899A2043|32 50|satisfactory account
P01939899A2043|56 62|effects
P01939899A2043|68 80|main variables
P01939899A2043|91 95|tones
P01939899A2043|107 118|perturbation
P01939899A2043|121 128|ABSTRACT
P01939899A2043|143 147|WORDS
P01939906A0233|4 17|generalization
P01939906A0233|20 22|MFP
P01939906A0233|41 78|appropriate high-resolution cost function
P01939906A0233|96 106|search space
P01939906A0233|145 153|solutions
P01939906A0233|159 170|wave equation
P01939906A0233|185 211|nonlinear optimization method
P01939906A0233|223 240|parameter landscape
P01939906A0233|247 259|global minimum
P01939906A0233|265 276|cost function
P01942033T0000|0 12|Determination
P01942033T0000|17 28|RNA structure
P01942033T0000|39 56|splicing inhibition
P01942033T0000|60 78|muscle-specific exon
P01943184A1050|0 15|Endothelial cells
P01943184A1050|26 35|University
P01943184A1050|38 54|Wisconsin solution
P01943184A1050|63 78|trypan blue better
P01943184A1050|83 83|%
P01943184A1050|90 95|% cells
P01943184A1050|104 108|p less
P01945430A0660|3 19|original technique
P01945430A0660|55 67|inner ear fluid
P01945430A0660|71 89|diagnostic procedure
P01945430A0660|96 119|diagnostic labyrinthotomy
P01945430A0660|123 145|acoustic neuroma suspects
P01947449A0191|11 29|diffusion limitation
P01947449A0191|62 81|uptake/O2 requirement
P01947449A0191|83 91|= fraction
P01947449A0191|94 112|cross-sectional area
P01947449A0191|158 167|unit volume
P01947449A0191|196 198|PO2
P01947449A0191|201 210|PO2 greater
P01947449A1082|3 21|Diffusion limitation
P01947449A1082|27 48|heterogeneous model sets
P01947449A1082|61 76|requirement value
P01947449A1082|140 169|corresponding homogeneous models
P01947449A1082|177 203|same average cylinder diameter
P01948783A0000|3 24|antihypertensive effect
P01948783A0000|27 33|Estulic
P01948783A0000|54 67|12-month period
P01948783A0000|73 92|hypertensive patients
P01952827A0215|14 20|seizure
P01952827A0215|47 56|test phrase
P01954355A0997|0 17|Monitoring patients
P01954355A0997|22 34|acute leukemia
P01954355A0997|38 41|IL-1
P01954355A0997|45 53|TNF levels
P01954355A0997|45 47|TNF
P01954355A0997|67 80|clinical course
P01954355A0997|107 112|causes
P01954355A0997|115 129|febrile episodes
P01954835A0000|0 21|Echinococcus granulosus
P01954835A0000|36 64|fine-needle aspiration cytology
P01954835A0000|68 75|lung cyst
P01954835A0000|79 97|6-yr-old white female
P01954835A0000|100 114|central Missouri
P01956285A0000|30 40|nucleotides
P01956285A0000|56 63|bet genes
P01956285A0000|95 137|osmoregulatory choline-glycine betaine pathway
P01956491A0095|1 14|7-day treatment
P01956491A0095|17 29|amphotericin B
P01956491A0095|32 40|mg/kg/day
P01956491A0095|69 92|glomerular filtration rate
P01956491A0095|94 96|GFR
P01956491A0095|108 123|inuline clearance
P01956491A0095|127 145|creatinine clearance
P01956491A0095|172 177|ml/min
P01956491A0095|206 224|vehicle-treated rats
P01956491A0095|251 256|ml/min
P01958368A0556|0 8|Evolution
P01958368A0556|11 17|lesions
P01958368A0556|42 59|regular progression
P01958368A0556|70 80|later stages
P01958368A0556|86 110|vitelliform classification
P01958821T0000|0 29|Confocal fluorescence microscopy
P01958821T0000|32 48|modern cell biology
P01960974A0000|0 6|Toluene
P01960974A0000|43 47|cases
P01960974A0000|57 72|volatile solvents
P01961213A0150|23 32|HCB-levels
P01961213A0150|44 53|breast milk
P01961213A0150|63 71|last years
P01961747A0000|1 29|herpesvirus proteinase activity
P01961747A0000|88 93|enzyme
P01961747A0000|97 110|substrate genes
P01961747A0000|113 139|transient transfection assays
P01961996A0522|0 5|Adult H
P01961996A0522|13 13|R
P01963419A0501|3 25|rear silver liquid chamber
P01963419A0501|29 42|threefold thick
P01963419A0501|47 56|MeV protons
P01963419A0501|94 96|13N
P01963419A0501|102 104|16O
P01963419A0501|106 106|p
P01963419A0501|108 112|alpha
P01963419A0501|114 124|13N reaction
P01963419A0501|128 130|18F
P01963419A0501|132 142|fluoride ion
P01963419A0501|148 150|18O
P01963419A0501|152 152|p
P01963419A0501|154 154|n
P01963419A0501|156 166|18F reaction
P01963438T0000|0 28|Heterogeneous electron transfer
P01963438T0000|31 41|cytochrome c
P01963438T0000|55 65|polypyrrole
P01963438T0000|69 96|methylene blue polypyrrole film
P01963438T0000|105 114|electrodes
P01963858T0001|0 18|Selective activation
P01963858T0001|21 39|adrenaline secretion
P01963858T0001|45 54|rat adrenal
P01963858T0001|57 71|neuroglycopenia
P01963858T0001|83 95|microdialysis
P01964989A0145|0 13|Urine specimens
P01964989A0145|30 42|phencyclidine
P01964989A0145|44 46|PCP
P01964989A0145|50 100|11-nor-delta 9-tetrahydrocannabinol-9-carboxylic acid
P01964989A0145|102 111|9-THC-COOH
P01964989A0145|132 145|sodium chloride
P01964989A0145|147 152|bleach
P01964989A0145|154 160|vinegar
P01964989A0145|162 179|potassium hydroxide
P01964989A0145|181 190|liquid soap
P01964989A0145|192 201|2-propanol
P01964989A0145|206 212|ammonia
P01967130A0645|3 23|1489-base pair EFIA cDNA
P01967130A0645|16 23|EFIA cDNA
P01967130A0645|32 51|322-amino acid protein
P01967130A0645|98 120|human DNA binding proteins
P01968043A0908|4 29|putative positive cDNA clones
P01968043A0908|49 61|largest insert
P01968043A0908|63 68|pASB-1
P01968043A0908|88 99|orientations
P01968061A0371|0 2|Sci
P01968156T0000|0 18|Dose standardisation
P01968156T0000|21 34|botulinum toxin
P01968224A0119|3 16|coding sequence
P01968224A0119|21 52|260-amino-acid residue polypeptide
P01968224A0119|70 86|single short intron
P01968224A0119|91 99|base pairs
P01968224A0119|101 102|bp
P01968224A0119|115 115|%
P01968224A0119|128 144|amino acid sequence
P01968224A0119|150 163|Drosophila PCNA
P01968224A0119|160 163|PCNA
P01968224A0119|187 207|human PCNA polypeptides
P01968224A0119|222 234|unique repeats
P01968224A0119|237 243|leucine
P01968224A0119|249 264|C-terminal region
P01970560A1024|0 19|Translational fusions
P01970560A1024|25 45|aroF regulatory regions
P01970560A1024|48 51|lacZ
P01970560A1024|86 95|single copy
P01970560A1024|109 118|chromosome
P01970560A1024|120 143|beta-Galactosidase assays
P01970560A1024|147 169|tyrR-mediated regulation
P01970560A1024|172 190|aroF-lacZ expression
P01970560A1024|172 175|aroF
P01970560A1024|177 180|lacZ
P01970560A1024|206 224|E. coli TyrR repressor
P01970560A1024|212 224|TyrR repressor
P01970560A1024|248 256|operators
P01970560A1024|263 271|organisms
P01970560A1024|281 295|equal efficiency
P01970801A0925|25 29|genes
P01970801A0925|39 42|Ly-1
P01970801A0925|46 49|CD20
P01970801A0925|51 54|OSBP
P01970801A0925|75 87|syntenic group
P01970801A0925|93 99|long arm
P01970801A0925|102 111|chromosome
P01970801A0925|130 140|proximal end
P01970801A0925|143 152|chromosome
P01970926A0000|6 14|exercise K
P01970926A0000|50 56|plasma K
P01970926A0000|58 75|concentration rises
P01970984A0668|19 38|serum estradiol levels
P01970984A0668|43 48|higher
P01970984A0668|51 57|groups E
P01970984A0668|59 59|T
P01970984A0668|63 63|E
P01970984A0668|70 76|group C.
P01971191A1271|17 38|beta-adrenergic agonist
P01971191A1271|40 52|isoproterenol
P01971191A1271|57 71|little influence
P01971191A1271|74 92|vascular capacitance
P01971191A1271|95 105|liver volume
P01971191A1271|108 111|dogs
P01971191A1271|122 145|hepatic outflow resistance
P01971191A1271|148 155|elevated
P01971191A1271|158 167|agents such
P01971191A1271|170 178|histamine
P01972379T0042|0 10|DNA sequence
P01972379T0042|28 36|CPS domain
P01972379T0042|42 79|Syrian hamster multifunctional protein CAD
P01973384A0206|19 39|synthetic binding sites
P01973384A0206|45 58|more restricted
P01973384A0206|62 76|specific ability
P01973384A0206|86 98|transcription
P01973384A0206|123 129|embryos
P01974550A0362|5 16|base-line CBF
P01974550A0362|32 51|hexamethonium bromide
P01974550A0362|54 60|mg/kg iv
P01974550A0362|63 80|ipratropium bromide
P01974550A0362|85 98|microgram/kg iv
P01974550A0362|101 112|indomethacin
P01974550A0362|115 121|mg/kg iv
P01974550A0362|126 136|intravenous
P01974550A0362|140 146|% saline
P01974876A1051|15 51|restriction fragment length polymorphism
P01974876A1051|76 95|unrelated individuals
P01974876A1051|104 114|enzyme BglII
P01974876A1051|110 114|BglII
P01975157A0836|3 23|antilog transformation
P01975157A0836|26 27|pH
P01975157A0836|44 50|results
P01975428A0151|0 8|Telomeres
P01975428A0151|16 32|end-to-end fusions
P01975428A0151|36 60|exonucleolytic degradation
P01975428A0151|79 95|linear DNA molecule
P01975428A0151|121 132|cell division
P01976638A1135|12 18|located
P01976638A1135|27 44|untranslated region
P01976638A1135|58 76|regulatory sequences
P01977585A0222|3 14|native enzyme
P01977585A0222|27 67|protease-B-deficient URA2-transformed cells
P01977585A0222|27 36|protease-B
P01977585A0222|47 50|URA2
P01977585A0222|98 114|catalytic subunits
P01977585A0222|117 147|pure cAMP-dependent protein kinase
P01977585A0222|121 147|cAMP-dependent protein kinase
P01977856A1036|21 25|BSPMs
P01977856A1036|52 54|AMI
P01977856A1036|93 109|myocardial infarct
P01978834A0076|1 35|bovine abomasum lambda gt11 cDNA library
P01978834A0076|52 69|monoclonal antibody
P01978834A0076|86 112|rabbit H,K-ATPase beta subunit
P01978857A0504|0 11|Judicious use
P01978857A0504|14 30|laboratory testing
P01978857A0504|41 50|monitoring
P01978857A0504|53 65|CD4 cell counts
P01978857A0504|53 55|CD4
P01982061A0615|9 15|TATA box
P01982061A0615|50 76|transcription initiation site
P01982061T0000|0 15|Characterization
P01982061T0000|31 66|growth-regulated Syrian hamster CAD gene
P01982190T0001|5 13|cirrhosis
P01982190T0001|17 29|early modality
P01982190T0001|46 59|acute hepatitis
P01982997A1104|0 10|Examination
P01982997A1104|13 56|immediate-early transcription factor expression
P01982997A1104|13 46|immediate-early transcription factor
P01982997A1104|66 75|MDI regimen
P01982997A1104|88 89|RA
P01982997A1104|100 107|elevated
P01982997A1104|109 127|prolonged expression
P01982997A1104|130 138|c-Jun mRNA
P01982997A1104|174 178|c-Fos
P01982997A1104|182 191|Jun-B mRNAs
P01983026A0483|8 16|heart rate
P01983026A0483|20 36|diastolic pressure
P01983026A0483|54 56|min
P01983026A0483|62 71|intubation
P01983026A0483|80 100|total CA concentrations
P01983026A0483|121 131|study period
P01984665T0000|0 9|Processing
P01984665T0000|11 19|secretion
P01984665T0000|24 39|immunoreactivity
P01984665T0000|42 96|carboxy terminally truncated dengue-2 virus envelope proteins
P01984665T0000|42 48|carboxy
P01984665T0000|68 96|dengue-2 virus envelope proteins
P01984665T0000|108 118|insect cells
P01984665T0000|121 144|recombinant baculoviruses
P01985301T0000|19 24|MK-801
P01985301T0000|28 37|nimodipine
P01985301T0000|53 71|ischemic brain damage
P01985920A0156|0 15|Initial screening
P01985920A0156|19 37|rat liver cDNA library
P01985920A0156|44 63|oligonucleotide probe
P01985920A0156|78 99|rat SCP2 protein sequence
P01985920A0156|110 130|825-base pair cDNA clone
P01985920A0156|143 169|complete SCP2 protein sequence
P01985920A0156|151 154|SCP2
P01985920T0000|0 6|Cloning
P01985920T0000|22 39|nucleotide sequence
P01985920T0000|42 69|rat liver sterol carrier protein
P01985920T0000|71 75|cDNAs
P01985924A0554|15 30|equimolar complex
P01985924A0554|45 66|seventh largest subunits
P01985924A0554|80 94|pol II holoenzyme
P01985924A0554|80 82|pol
P01985924A0554|85 94|holoenzyme
P01985924A0554|97 122|ion-exchange chromatography
P01985924A0554|138 141|urea
P01985924A0554|151 185|promoter-directed initiation activity
P01985924A0554|188 190|pol
P01985924A0554|193 197|delta
P01986225A0250|31 33|HSF
P01986225A0250|39 50|fission yeast
P01986241A0117|0 8|Induction
P01986241A0117|20 34|ACE1 gene product
P01986241A0117|48 60|specific sites
P01986241A0117|66 79|promoter region
P01986241A0117|85 92|CUP1 gene
P01986254A0452|0 21|Gel mobility shift assays
P01986254A0452|28 43|synthetic E6 motif
P01986254A0452|53 74|B-cell-specific complex
P01986254A0452|88 101|ubiquitous band
P01986254A0452|113 118|T cells
P01986254A0452|122 130|HeLa cells
P01986360A0000|5 10|clones
P01986360A0000|19 57|interferon response element binding factors
P01986360A0000|79 114|mouse fibroblast lambda gt11 cDNA library
P01986360A0000|123 148|32P end-labeled tandem trimer
P01986360A0000|166 218|oligoadenylate synthetase gene interferon response element
P01986360A0000|222 226|probe
P01988041A0281|17 22|clones
P01988041A0281|48 70|3018-bp BAL cDNA structure
P01989561A0100|21 31|instruments
P01989561A0100|38 46|occlusion
P01989561A0100|61 65|aorta
P01989561A0100|80 95|perfusion cannula
P01989561A0100|124 127|apex
P01989561A0100|146 179|simultaneous left ventricular venting
P01989999A0000|0 25|Adenylosuccinate synthetase
P01989999A0000|27 29|IMP
P01989999A0000|31 47|L-aspartate ligase
P01989999A0000|49 51|GDP
P01989999A0000|54 62|EC 6.3.4.4
P01989999A0000|54 55|EC
P01989999A0000|71 83|important role
P01989999A0000|86 103|purine biosynthesis
P01989999A0000|117 139|GTP-dependent conversion
P01989999A0000|142 144|IMP
P01989999A0000|147 149|AMP
P01990254A0791|0 16|Immunophenotyping
P01990254A0791|23 27|cases
P01990254A0791|41 45|non-B
P01990254A0791|47 61|non-T cell origin
P01990254A0791|72 86|pre-B cell origin
P01990266A0678|0 32|DNA-protein UV cross-linking studies
P01990266A0678|46 50|UHF-1
P01990266A0678|56 78|electrophoretic mobility
P01990266A0678|81 115|sodium dodecyl sulfate-acrylamide gels
P01990266A0678|133 135|kDa
P01990266A0678|152 169|additional proteins
P01990266A0678|185 192|promoter
P01991521A0481|3 9|results
P01991521A0481|50 64|dynamic activity
P01991521A0481|77 85|G4 content
P01991521A0481|77 78|G4
P01991521A0481|88 114|mature innervated fast muscles
P01992459A0000|3 21|specific interaction
P01992459A0000|37 53|structural element
P01992459A0000|59 88|human immunodeficiency virus mRNA
P01992459A0000|90 92|RRE
P01992459A0000|97 114|Rev response element
P01992459A0000|122 144|virus-encoded protein Rev
P01992459A0000|190 198|unspliced
P01992459A0000|214 217|mRNA
P01992459A0000|225 231|nucleus
P01992459A0000|237 245|cytoplasm
P01992742A0000|13 19|records
P01992742A0000|25 32|patients
P01992742A0000|37 49|optic neuritis
P01992742A0000|64 79|eight-year period
P01992953A0247|0 12|Cut-off levels
P01992953A0247|23 33|abnormality
P01992953A0247|43 51|arbitrary
P01992953A0247|71 81|specificity
P01992953A0247|103 117|healthy patients
P01992953T0000|0 22|Alanine aminotransferase
P01992953T0000|25 40|clinical practice
P01993181T0000|0 25|Nucleotide sequence analysis
P01993181T0000|31 76|Pseudomonas putida PpG7 salicylate hydroxylase gene
P01993181T0000|48 76|PpG7 salicylate hydroxylase gene
P01993181T0000|78 81|nahG
P01993181T0000|92 105|flanking region
P01993656A1860|6 13|ARF cDNAs
P01993656A1860|63 101|20-kDa guanine nucleotide-binding proteins
P01993656A1860|69 101|guanine nucleotide-binding proteins
P01995951A0000|3 20|long terminal repeat
P01995951A0000|22 24|LTR
P01995951A0000|31 56|human immunodeficiency virus
P01995951A0000|58 60|HIV
P01995951A0000|82 86|sites
P01995951A0000|93 116|transcriptional factor Sp1
P01995951A0000|114 116|Sp1
P01996312A0454|7 9|PCR
P01996312A0454|36 62|several lambda gt11 cDNA clones
P01996312A0454|76 86|full-length
P01996312A0454|91 100|Dd kinase-2
P01997465A0276|0 23|Radiation-induced changes
P01997465A0276|35 41|alveoli
P01997465A0276|45 49|septa
P01997465A0276|58 72|collagen content
P01997465A0276|58 65|collagen
P01997465A0276|83 87|weeks
P01997465A0276|93 103|irradiation
P01999035A0383|3 16|first follow-up
P01999035A0383|29 44|constant interval
P01999035A0383|50 54|years
P01999035A0383|57 66|Caerphilly
P01999035A0383|73 77|years
P01999035A0383|80 88|Speedwell
P01999035A0383|93 106|major IHD events
P01999459A0795|0 1|A.
P01999999T0001|0 16|Perilunar luxation
P01999999T0001|21 33|unusual injury
P01999999T0001|55 70|correct treatment
P02000093A0794|0 8|Landsberg
P02000093A0794|10 13|La-O
P02000093A0794|18 19|cv
P02001033A1907|12 39|equianesthetic concentrations
P02001033A1907|41 50|desflurane
P02001033A1907|54 63|isoflurane
P02001033A1907|72 96|similar hemodynamic effects
P02001033A1907|120 124|drugs
P02001033A1907|136 152|autonomic reflexes
P02001033A1907|154 163|desflurane
P02001033A1907|171 195|negative inotropic activity
P02001033A1907|207 218|less decrease
P02001033A1907|221 236|arterial pressure
P02002051A0276|27 46|full-length cDNA clone
P02002051A0276|27 41|full-length cDNA
P02002051A0276|65 83|undiscovered isoform
P02002051A0276|89 103|bovine C-subunit
P02002051T0000|0 12|Isoform C beta 2
P02002051T0000|0 11|Isoform C beta
P02002051T0000|16 26|unusual form
P02002051T0000|32 53|bovine catalytic subunit
P02002051T0000|56 82|cAMP-dependent protein kinase
P02002511A0637|0 18|Salient applications
P02002511A0637|21 33|PB-PK modeling
P02002511A0637|36 56|toxicological problems
P02002511A0637|75 82|examples
P02004521A0266|0 7|Patients
P02004521A0266|22 41|minor CT abnormalities
P02004521A0266|49 74|significant epidural disease
P02004705A0686|3 14|cdr1 sequence
P02004705A0686|38 47|amino acids
P02004705A0686|53 70|contiguous fragment
P02005547A0121|10 27|clear understanding
P02005547A0121|33 56|pathophysiologic pathways
P02005547A0121|103 132|unconjugated hyperbilirubinemia
P02005547A0121|149 156|jaundice
P02006558A0000|0 21|Displacement thresholds
P02006558A0000|24 38|peripheral sites
P02006558A0000|41 60|monocular human vision
P02007045A0092|3 9|authors
P02007045A0092|28 49|stereotactic irrigation
P02007045A0092|53 61|brain cyst
P02007045A0092|89 107|respiratory distress
P02008982A0463|0 4|ELISA
P02008982A0463|48 66|tuberculosis similar
P02008982A0463|75 85|sputum smear
P02010912A0366|21 33|detailed study
P02010912A0366|54 67|functional role
P02010912A0366|73 95|MalT binding sites located
P02010912A0366|73 88|MalT binding sites
P02010912A0366|101 108|adjacent
P02010912A0366|112 125|divergent pulAp
P02010912A0366|121 125|pulAp
P02010912A0366|129 142|pulCp promoters
P02011924A0729|10 20|small number
P02011924A0729|23 30|patients
P02011924A0729|74 79|MU/day
P02011924A0729|82 90|alpha-IFN
P02011924A0729|95 111|adequate treatment
P02011924A0729|115 122|patients
P02011924A0729|127 143|hairy cell leukemia
P02012097T0000|0 21|Paroxysmal fluctuations
P02012097T0000|32 42|parasitemia
P02012097T0000|45 71|Plasmodium falciparum malaria
P02012789A0051|2 22|positive family history
P02014928T0000|0 17|Occupational asthma
P02014928T0000|21 39|rhinoconjunctivitis
P02014928T0000|44 53|inhalation
P02014928T0000|56 90|crystalline bovine serum albumin powder
P02015921A0523|1 18|further subdivision
P02015921A0523|21 31|Category pN1
P02015921A0523|36 39|pN1a
P02015921A0523|41 50|metastasis
P02015921A0523|53 62|single node
P02015921A0523|67 70|pN1b
P02015921A0523|77 85|more nodes
P02016053A0752|0 27|Amino acid sequence comparisons
P02016053A0752|33 43|E74A protein
P02016053A0752|66 81|C-terminal region
P02016053A0752|94 115|basic amino acid residues
P02016053A0752|148 182|sequence-specific DNA binding activity
P02016769A0720|14 30|relative strengths
P02016769A0720|36 44|promoters
P02016769A0720|58 74|different contexts
P02017159A0646|0 5|Grasso
P02017159A0646|10 11|A.
P02017271A0502|6 11|months
P02017271A0502|13 31|definite improvement
P02017271A0502|56 80|carnitine-treated patients
P02017271A0502|93 100|controls
P02017414A0307|0 2|Age
P02017414A0307|5 7|POI
P02017414A0307|11 19|asymptote
P02017414A0307|40 47|Line RBC2
P02017414A0307|55 60|Line F.
P02019572A0000|13 24|DNA sequences
P02019572A0000|59 80|rat liver pyruvate kinase
P02019572A0000|82 85|L-PK
P02019572A0000|87 91|genes
P02019572A0000|102 111|constructs
P02019572A0000|122 166|chloramphenicol acetyltransferase reporter genes
P02019572A0000|191 199|fragments
P02019572A0000|209 217|base pairs
P02019572A0000|219 220|bp
P02019572A0000|222 229|upstream
P02019572A0000|235 249|L-PK gene cap site
P02019572A0000|268 286|transient expression
P02019572A0000|308 325|hepatoma HepG2 cells
P02019572A0000|327 340|rat hepatocytes
P02019572A0000|343 356|primary culture
P02019572A0000|358 370|fibroblast LTK
P02019572A0000|372 376|cells
P02019572A0000|378 395|myogenic C2C12 cells
P02019572A0000|400 407|CHO cells
P02020082A0356|3 13|disturbance
P02020082A0356|16 35|pulmonary gas exchange
P02020082A0356|52 60|high value
P02020082A0356|63 67|AaDO2
P02020082A0356|83 108|left ventricular dysfunction
P02020082A0356|113 117|AaDO2
P02020082A0356|123 145|significant relationship
P02020082A0356|158 178|hemodynamic parameters
P02020082A0356|208 235|plasma colloid osmotic pressure
P02020082A0356|239 241|PCW
P02020314A1290|12 34|micrograms/kg/day GM-CSF
P02020314A1290|29 34|GM-CSF
P02020314A1290|45 52|severity
P02020314A1290|55 65|neutropenia
P02020314A1290|69 84|thrombocytopenia
P02020314A1290|90 129|carboplatin-cyclophosphamide chemotherapy
P02020314A1290|149 169|effective chemotherapy
P02020314A1290|173 185|ovarian cancer
P02021630A1104|5 15|differences
P02021630A1104|23 58|specific hydrogen-bonding interactions
P02021630A1104|92 105|guanine N7 sites
P02021630A1104|111 121|major groove
P02021630A1104|131 141|alterations
P02021630A1104|144 172|DNA phosphodiester conformation
P02021630A1104|182 195|protein binding
P02022188A0112|0 18|Biochemical analysis
P02022188A0112|38 47|BJ1 protein
P02022188A0112|64 74|nucleosomes
P02022188A0112|92 100|chromatin
P02022188A0112|103 108|agents
P02022188A0112|156 180|high mobility group proteins
P02022188A0112|182 185|HMGs
P02022188A1463|17 28|gene products
P02022188A1463|38 46|chromatin
P02022188A1463|69 94|proper higher order structure
P02022188A1463|98 109|prerequisite
P02022188A1463|123 136|gene expression
P02022920A0334|3 15|C4BP alpha gene
P02022920A0334|40 53|first exon codes
P02022920A0334|68 78|nucleotides
P02022920A0334|86 88|UTR
P02023097A0000|3 33|human immunodeficiency virus type 1
P02023097A0000|3 32|human immunodeficiency virus type
P02023097A0000|35 39|HIV-1
P02023097A0000|41 50|Rev protein
P02023097A0000|54 89|positive posttranscriptional regulator
P02023097A0000|92 120|viral structural gene expression
P02023097A0000|92 110|viral structural gene
P02023097A0000|136 151|virus replication
P02023421A0343|7 19|proliferation
P02023421A0343|22 32|fibroblasts
P02023421A0343|36 52|collagen synthesis
P02023421A0343|36 43|collagen
P02023421A0343|73 90|mechanical strength
P02023421A0343|94 107|negative effect
P02023421A0343|110 121|wound healing
P02023421A0343|148 173|same chemotherapeutic agents
P02023904A0120|3 10|CDC7 gene
P02023904A0120|25 33|AUG codons
P02023904A0120|36 64|possible translation start sites
P02023904A0120|89 102|56-kDa proteins
P02024252A0000|9 13|years
P02024252A0000|32 38|persons
P02024252A0000|47 64|disability pensions
P02024252A0000|70 81|municipality
P02024252A0000|84 92|Nordreisa
P02024252A0000|95 108|northern Norway
P02024488A0506|0 3|HeLa
P02024488A0506|7 21|Jurkat cell lines
P02024488A0506|33 39|nef gene
P02024488A0506|51 61|CMV promoter
P02024488A0506|67 74|HIV-1 LTR
P02024488A0506|89 99|coselection
P02024488A0506|103 120|neomycin resistance
P02024625A0202|0 10|Differences
P02024625A0202|16 35|clinical presentation
P02024625A0202|42 56|gross appearance
P02024625A0202|65 69|cases
P02024625A0202|86 97|similarities
P02024625A0202|103 121|microscopic features
P02024791A0582|0 11|MEASUREMENTS
P02024791A0582|15 25|MAIN RESULTS
P02024791A0582|33 38|groups
P02024791A0582|79 98|mean FEV1 measurements
P02024791A0582|104 114|L atropine/0
P02024791A0582|118 132|L metaproterenol
P02024791A0582|134 141|P greater
P02024816A0521|7 11|ELISA
P02024816A0521|24 41|surfactant protein A
P02024816A0521|43 46|SP-A
P02024816A0521|59 66|elevated
P02024816A0521|72 88|pneumonia patients
P02025515A0979|11 19|short t1/2
P02025515A0979|32 40|doses/day
P02026144A0741|0 14|Temporal control
P02026144A0741|17 29|GUS expression
P02026144A0741|17 19|GUS
P02026144A0741|50 76|negative regulatory sequences
P02026144A0741|78 81|NRS1
P02026144A0741|97 100|NRS2
P02026144A0741|125 142|positive domain UAS1
P02026147A0000|11 14|Ca2+
P02026147A0000|11 13|Ca2
P02026147A0000|16 25|calmodulin
P02026147A0000|27 29|CaM
P02026147A0000|32 53|dependent protein kinase
P02026147A0000|55 63|CaM kinase
P02026147A0000|72 76|yeast
P02026147A0000|104 120|properties similar
P02026147A0000|123 147|mammalian type II CaM kinases
P02026147A0000|123 135|mammalian type
P02026147A0000|138 147|CaM kinases
P02026461A0760|2 10|most cases
P02026461A0760|12 25|DR4-homozygous
P02026461A0760|27 54|DRB1-heterozygous individuals
P02026461A0760|27 30|DRB1
P02026461A0760|85 90|probes
P02026491A0399|3 10|patients
P02026491A0399|14 36|immediate adverse effects
P02026491A0399|41 43|NMF
P02026491A0399|52 66|grand mal seizure
P02026491A0399|73 105|other developed severe abdominal pain
P02027839A0250|3 9|muscles
P02027839A0250|17 29|ischemic group
P02027839A0250|52 56|P less
P02027839A0250|65 70|values
P02027839A0250|74 89|capillary density
P02027839A0250|93 101|capillary
P02027839A0250|104 113|fiber ratio
P02027839A0250|130 157|higher intercapillary distance
P02027839A0250|174 184|normal group
P02028125A0101|3 12|prevalence
P02028125A0101|15 36|opportunistic infection
P02028125A0101|51 62|AIDS patients
P02028125A0101|69 79|probability
P02028125A0101|89 102|tumour response
P02028125A0101|112 135|cancer therapy conditional
P02028125A0101|154 161|examples
P02028125A0101|164 176|such functions
P02029468A0296|0 21|Serum TNF concentrations
P02029468A0296|5 7|TNF
P02029468A0296|26 33|elevated
P02029468A0296|75 89|reference limits
P02030910A0000|0 12|Genomic clones
P02030910A0000|28 40|human ETS1 gene
P02030910A0000|75 95|molecular organization
P02030910A1070|0 30|Polymerase chain reaction analysis
P02030910A1070|33 40|ETS1 cDNA
P02030910A1070|67 74|products
P02030910A1070|86 104|alternative splicing
P02033038A0309|0 3|Most
P02033038A0309|18 36|human E3 polypeptides
P02033038A0309|42 46|bands
P02033038A0309|62 76|insoluble pellet
P02033038A0309|91 109|full-length mature E3
P02033038A0309|123 137|soluble fraction
P02033062A1169|6 21|promotor function
P02033062A1169|23 35|chimeric genes
P02033062A1169|58 66|fragments
P02033062A1169|69 80|chicken IGF-I
P02033062A1169|84 94|flanking DNA
P02033062A1169|98 124|promoterless reporter plasmid
P02034655A1224|3 7|alpha
P02034655A1224|15 28|flanking region
P02034655A1224|37 44|promoter
P02034655A1224|47 64|transfection assays
P02034655T0000|0 15|Characterization
P02034655T0000|21 25|alpha
P02034655T0000|27 46|integrin gene promoter
P02034669A0293|7 22|3.0-kb transcript
P02034669A0293|36 47|adult tissues
P02034669A0293|70 79|restricted
P02034669A0293|102 121|central nervous system
P02034676A0267|3 12|homologues
P02034676A0267|18 30|rhombotin gene
P02035805T0000|0 25|Angina haemorrhagica bullosa
P02035805T0000|33 54|respiratory obstruction
P02036066A0000|13 19|effects
P02036066A0000|22 39|long-term perfusion
P02036066A0000|44 90|pyridoxalated hemoglobin polyoxyethylene conjugate
P02036066A0000|57 66|hemoglobin
P02036066A0000|92 94|PHP
P02036066A0000|106 120|cardiac function
P02036066A0000|131 139|rat hearts
P02038293A0919|0 9|Conclusion
P02038293A0919|11 22|inlet type VSD
P02038293A0919|26 46|perimembranous type TOF
P02038293A0919|51 66|anatomic features
P02038293A0919|77 84|proximal
P02038293A0919|88 93|bundle
P02038293A0919|127 136|VSD closure
P02038326A0538|3 18|gcd2-503 mutation
P02038326A0538|3 10|gcd2-503
P02038326A0538|32 45|polysome runoff
P02038326A0538|47 58|accumulation
P02038326A0538|61 87|inactive 80S ribosomal couples
P02038326A0538|69 87|80S ribosomal couples
P02038326A0538|92 103|accumulation
P02038326A0538|121 128|subunits
P02038326A0538|134 168|general translation initiation factor 2
P02038326A0538|134 167|general translation initiation factor
P02038326A0538|170 179|eIF-2 alpha
P02038326A0538|183 198|43S-48S particles
P02038326A0538|183 185|43S
P02038326A0538|187 189|48S
P02038326A0538|219 240|restrictive temperature
P02038784A0317|5 12|patients
P02038784A0317|17 19|ARC
P02038784A0317|23 34|renal failure
P02041088A1053|12 27|enhancer activity
P02041088A1053|30 33|DR60
P02041088A1053|36 50|reporter plasmid
P02041088A1053|78 81|DR60
P02041088A1053|101 144|reporter chloramphenicol acetyltransferase gene
P02041088A1053|109 144|chloramphenicol acetyltransferase gene
P02041088A1053|165 188|delayed-early 39K promoter
P02044785A0000|1 10|single case
P02044785A0000|15 28|adenocarcinoma
P02044785A0000|40 70|retroperitoneal enterogenous cyst
P02044785A0000|91 103|left renal cyst
P02044950A0258|8 30|polymerase chain reaction
P02044950A0258|45 54|U6 RNA genes
P02044950A0258|59 67|organisms
P02044975A0380|52 56|P less
P02044975A0380|81 81|h
P02044975A0380|87 98|instillation
P02044975A0380|118 120|min
P02044975A0380|152 152|%
P02044975A0380|166 166|%
P02045366A1149|0 21|Hydrophobicity analysis
P02045366A1149|38 41|KlaA
P02045366A1149|45 60|KlaB polypeptides
P02045366A1149|74 80|soluble
P02045366A1149|92 106|KlaC polypeptide
P02045366A1149|129 161|potential membrane-spanning domains
P02045524A0000|29 57|important new therapeutic agents
P02045524A0000|62 65|Food
P02045524A0000|69 86|Drug Administration
P02045524A0000|88 90|FDA
P02045524A0000|97 105|mid-1970s
P02045524A0000|120 137|therapeutic ratings
P02045524A0000|140 162|investigational new drugs
P02045524A0000|173 184|end-of-phase
P02045524A0000|187 197|conferences
P02045524A0000|202 213|drug sponsors
P02045809A0331|11 22|similar rates
P02045809A0331|25 44|B. sphaericus products
P02045809A0331|46 68|ABG-6184 technical powder
P02045809A0331|72 95|BSP-2 flowable concentrate
P02045809A0331|107 126|significant reduction
P02046202A0625|3 11|remainder
P02046202A0625|17 17|%
P02046202A0625|26 39|IgA nephropathy
P02046202A0625|26 28|IgA
P02047597A0149|11 30|experimental vulvitis
P02047597A0149|48 61|field condition
P02047597A0149|66 90|bacteria indistinguishable
P02047597A0149|108 114|strains
P02052544A0641|15 27|DNA polymerase
P02052544A0641|61 77|dpb2-1 mutant cells
P02052544A0641|94 112|stable DNA polymerase
P02052544A0641|130 133|DPB2
P02052544A0641|151 172|chromosomal replication
P02052592A0000|18 49|mononuclear cell secretory products
P02052592A0000|65 71|changes
P02052592A0000|74 85|bone turnover
P02052592A0000|118 143|postmenopausal osteoporosis
P02052592A0000|159 165|effects
P02052592A0000|168 179|oophorectomy
P02052592A0000|183 211|subsequent estrogen replacement
P02052592A0000|217 236|spontaneous secretion
P02052592A0000|239 250|interleukin 1
P02052592A0000|239 249|interleukin
P02052592A0000|252 255|IL-1
P02052592A0000|260 283|tumor necrosis factor alpha
P02052592A0000|285 293|TNF-alpha
P02052592A0000|303 338|phytohemagglutinin A-induced secretion
P02052592A0000|303 320|phytohemagglutinin
P02052592A0000|341 386|granulocyte-macrophage colony-stimulating factor
P02052592A0000|388 393|GM-CSF
P02052592A0000|399 429|peripheral blood mononuclear cells
P02053289A0701|15 27|nt differences
P02053289A0701|38 45|virulent
P02053289A0701|49 63|avirulent groups
P02053289A0701|83 95|nt differences
P02053289A0701|105 120|avirulent strains
P02054754A0919|3 20|standard principles
P02054754A0919|23 40|surgical management
P02054754A0919|65 75|Sandostatin
P02054754A0919|83 90|patients
P02054754A0919|100 108|disorders
P02055484A0538|9 19|PCR products
P02055484A0538|29 37|mutations
P02055484A0538|40 43|ATG1
P02055484A0538|50 53|ATG2
P02056553T0000|0 15|Hemorrhagic shock
P02056553T0000|19 40|bacterial translocation
P02056553T0000|44 53|swine model
P02060052A0954|23 28|levels
P02060052A0954|31 48|oxygen free radicals
P02060052A0954|64 74|hepatocytes
P02060052A0954|78 89|mitochondria
P02061282A0447|16 27|pMxL1 plasmid
P02061282A0447|41 56|invertible region
P02061282A0447|66 84|perfect tandem repeat
P02061282A0447|89 90|bp
P02061282A0447|108 128|nonexpressed pilin gene
P02061282A0447|120 128|pilin gene
P02061282A0447|145 169|recombination junction site
P02061333A0784|26 32|introns
P02061333A0784|42 49|acvA gene
P02061333A1359|5 16|observations
P02061333A1359|33 42|occurrence
P02061333A1359|45 52|putative
P02061333A1359|56 89|phosphopantetheine-attachment sites
P02061333A1359|94 117|putative thioesterase site
P02061333A1359|102 117|thioesterase site
P02061333A1359|149 164|reaction sequence
P02061333A1359|189 201|ACV tripeptide
P02062116A0688|0 8|Pargyline
P02062116A0688|11 35|monoamine oxidase inhibitor
P02062116A0688|11 26|monoamine oxidase
P02062116A0688|61 63|max
P02062933A0738|27 39|estrous female
P02062933A0738|52 61|active male
P02062933A0738|67 69|AOF
P02062933A0738|71 86|flutamide females
P02062933A0738|96 103|controls
P02062933A0738|117 127|male partner
P02064119A1172|0 26|Hypoxic ventilatory responses
P02064119A1172|43 47|L/min
P02064119A1172|49 53|% SaO2
P02064119A1172|59 67|relatives
P02064119A1172|83 87|L/min
P02064119A1172|89 93|% SaO2
P02064119A1172|99 113|control subjects
P02064119A1172|116 123|ABSTRACT
P02064119A1172|138 142|WORDS
P02065022A0747|4 17|small deletions
P02065022A0747|61 80|transforming activity
P02065022A0747|83 85|dbl
P02065022A0747|92 108|extensive deletion
P02066246A0258|4 19|computerized list
P02066246A0258|34 45|central files
P02066246A0258|51 77|Massachusetts Cancer Registry
P02066246A0258|81 85|cases
P02068085A1273|25 49|negative regulatory element
P02068085A1273|57 70|flanking region
P02068085A1273|76 105|Mlu I upstream activation sequence
P02068085A1273|76 78|Mlu
P02068085A1273|80 105|upstream activation sequence
P02069738A0000|22 36|stimulus control
P02069738A0000|39 45|ethanol
P02069873X0000|0 8|Mechanism
P02069873X0000|11 20|activation
P02069873X0000|26 41|vav protooncogene
P02069873X0000|43 45|vav
P02069873X0000|49 58|human locus
P02069873X0000|97 101|cells
P02069873X0000|104 122|hematopoietic origin
P02069873X0000|140 161|differentiation lineage
P02070227T0000|0 21|Endothelial cell seeding
P02072238T0000|0 15|Menetrier disease
P02072798A0330|5 28|hemodynamic stabilization
P02072798A0330|73 77|ulcer
P02073222A0269|11 18|patients
P02073222A0269|20 34|amitriptyline n =
P02073222A0269|38 50|moclobemide n =
P02073222A0269|69 80|week protocol
P02073222A0269|104 124|double blind conditions
P02075876A0408|3 19|stimulus threshold
P02075876A0408|23 25|EER
P02075876A0408|37 55|individual variation
P02075876A0408|60 68|amplitude
P02075876T0001|0 7|Analysis
P02075876T0001|37 39|EER
P02075876T0001|56 75|central visual pathway
P02075876T0001|81 85|cat (1
P02076620A0548|12 33|plasma fibrinogen levels
P02076620A0548|18 27|fibrinogen
P02076620A0548|56 56|%
P02076620A0548|70 82|adverse effect
P02076620A0548|85 95|gemfibrozil
P02076620T0000|0 10|Gemfibrozil
P02076620T0000|13 35|hyperlipidaemic patients
P02076620T0000|40 64|peripheral arterial disease
P02076620T0000|70 88|undiscovered actions
P02076816T0000|2 24|RME1-independent pathway
P02076816T0000|2 5|RME1
P02076816T0000|28 45|sporulation control
P02076816T0000|82 107|IME1 transcript accumulation
P02077560T0000|9 32|pharmacological profiling
P02077560T0000|35 50|safety assessment
P02078080T0040|16 25|Madagascar
P02078080T0040|27 36|advantages
P02078080T0040|40 52|disadvantages
P02078570A0287|5 9|cases
P02078570A0287|11 30|high-level expression
P02078570A0287|45 58|avian integrins
P02079811A0407|3 9|authors
P02079811A0407|21 36|clinical efficacy
P02079811A0407|39 44|EMB AZS
P02079811A0407|47 60|recurrent ulcer
P02079811A0407|96 104|high level
P02079811A0407|107 120|acid production
P02079811A0407|124 155|ulcerative gastroduodenal bleeding
P02080902A0183|2 10|adulthood
P02080902A0183|16 19|rats
P02080902A0183|24 34|hyperactive
P02080902A0183|48 70|active avoidance response
P02080902A0183|83 90|controls
P02081463A0110|28 43|Spec gene activity
P02081463A0110|28 35|Spec gene
P02081463A0110|63 96|Spec1 transcriptional initiation site
P02081463A0110|111 115|sites
P02081463A0110|118 139|protein-DNA interaction
P02083199A1175|0 20|Phosphopeptide mapping
P02083199A1175|32 59|same autophosphorylation sites
P02083199A1175|70 76|EGFR-IC
P02083199A1175|96 108|wild-type EGFR
P02083230A0938|27 46|typical signal peptide
P02083230A0938|62 72|hydrophilic
P02083230A0938|76 97|amino acid residue domain
P02083230A0938|103 122|N-glycosylation sites
P02083230A0938|125 143|transmembrane domain
P02083230A0938|149 164|C-terminal domain
P02083230A0938|169 178|amino acids
P02083253A1512|3 23|TCF-1 alpha binding site
P02083253A1512|42 65|TCR alpha enhancer activity
P02083253A1512|42 57|TCR alpha enhancer
P02083253A1512|85 98|active extracts
P02083253A1512|103 108|Jurkat
P02083253A1512|115 123|HeLa cells
P02083253A1512|139 148|TCF-1 alpha
P02083253A1512|152 185|T-cell-specific transcription factor
P02083546A0000|1 23|new semi-automatic method
P02083546A0000|38 59|regional cerebral uptake
P02083546A0000|65 104|technetium-hexamethylpropylene amine oxime
P02083546A0000|106 116|99mTc-HMPAO
P02083546A0000|133 161|single photon emission tomograms
P02083546A0000|167 180|normal subjects
P02083546A0000|184 191|patients
P02083546A0000|196 204|Alzheimer
P02083546A0000|217 224|patients
P02083546A0000|229 236|dementia
P02083546A0000|239 253|frontal lobe type
P02083546A0000|258 265|patients
P02083546A0000|270 277|dementia
P02083546A0000|282 300|motor neurone disease
P02088781A0653|3 9|results
P02088781A0653|52 70|optical density units
P02088781A0653|91 108|diagnostic accuracy
P02089054A0121|0 2|IdB
P02089054A0121|26 46|liquid-solid partition
P02089054A0121|53 60|extracts
P02089054A0121|89 108|reversed-phase column
P02089054A0121|114 132|isocratic conditions
P02089054A0121|147 161|electrochemical
P02089054A0121|165 174|UV detector
P02091890A0614|12 22|eltoprazine
P02091890A0614|31 53|specific anti-aggressive
P02091890A0614|55 61|serenic
P02091890A0614|96 112|social interaction
P02091890A0614|158 167|inactivity
P02091890A0614|180 187|sedation
P02092131T0000|1 9|new method
P02092131T0000|40 55|hypersensitivity
P02092131T0000|58 79|dialysed transfer factor
P02093033T0001|0 5|Effect
P02093033T0001|19 33|combined effects
P02093033T0001|36 48|plutonium-239
P02093033T0001|50 68|hexachlorobutadiene
P02093033T0001|72 88|tributyl phosphate
P02093033T0001|94 104|thymus gland
P02093033T0001|107 110|rats
P02093741A0211|0 13|Data collection
P02093741A0211|26 38|query language
P02093741A0211|43 54|data analysis
P02093741A0211|70 110|interactive knowledge-based statistical tool
P02093741A0211|112 118|MAXITAB
P02093741A0211|130 165|multivariate tabular analysis technique
P02093888A0293|0 4|ARPIA
P02093888A0293|31 44|relational DBMS
P02093888A0293|74 90|personal computers
P02094221A0247|0 7|Diuresis
P02094221A0247|46 49|ml/h
P02094257T0000|0 14|Diagnostic value
P02094257T0000|17 42|adenosine deaminase activity
P02094257T0000|17 34|adenosine deaminase
P02094257T0000|45 64|tuberculous effusions
P02095150T0000|0 22|Femoral strain adaptation
P02095150T0000|28 46|total hip replacement
P02095150T0000|72 95|porous ingrowth components
P02095150T0000|98 104|canines
P02099622A1046|0 19|Immuno-cytochemistry
P02099622A1046|26 33|antisera
P02099622A1046|41 59|Campylobacter jejuni
P02099622A1046|74 89|positive staining
P02099622A1046|92 113|altered epithelial cells
P02099622A1046|118 127|restricted
P02099622A1046|130 151|intracellular organisms
P02099622A1046|178 193|Campylobacter spp
P02102823A0492|0 17|Promoter activities
P02102823A0492|36 53|beta-glucuronidase
P02102823A0492|57 82|neomycin phosphotransferase
P02102823A0492|85 103|reporter gene systems
P02102831A1282|5 11|regions
P02102831A1282|22 38|soybean actin genes
P02102831A1282|46 64|many unusual features
P02102831A1282|75 76|CT
P02102831A1282|78 84|repeats
P02102831A1282|88 100|long stretches
P02102831A1282|103 120|pyrimidine-rich DNA
P02103140A1088|8 8|%
P02103140A1088|10 17|patients
P02103140A1088|22 44|fulminant hepatic failure
P02103140A1088|56 61|grafts
P02103140A1088|92 113|ABO-incompatible grafts
P02103140A1088|149 165|retransplantation
P02103403A0149|22 40|excess alcohol intake
P02103403A0149|44 58|prolonged intake
P02103403A0149|61 76|hepatotoxic drugs
P02103403A0149|80 87|steroids
P02103403A0149|99 103|obese
P02103403A0149|106 117|malnourished
P02105497A1092|2 23|evolutionary comparison
P02105497A1092|26 43|amino acid sequences
P02105497A1092|48 60|HSP70 proteins
P02105497A1092|86 93|BiP genes
P02105497A1092|100 113|common ancestor
P02105497A1092|132 146|other HSP70 genes
P02105497A1092|137 146|HSP70 genes
P02105497A1092|162 171|eukaryotes
P02106287A0478|0 11|Spore inocula
P02106287A0478|32 37|coupon
P02106287A0478|52 57|0.5-in
P02107073A0584|8 21|overexpression
P02107073A0584|31 34|STE4
P02107073A0584|38 50|STE18 proteins
P02107073A0584|66 90|stronger pheromone response
P02107073A0584|95 108|overexpression
P02107073A0584|111 114|STE4
P02107073A0584|130 144|wild-type levels
P02107073A0584|130 138|wild-type
P02107073A0584|147 151|STE18
P02107548A0727|0 23|Reverse transcription-PCR
P02107548A0727|37 41|clone
P02107548A0727|46 54|human poly
P02107548A0727|56 56|A
P02107548A0727|59 61|RNA
P02107548A0727|65 68|cDNA
P02107548A0727|96 102|homolog
P02107548A0727|105 111|psi ARF 4
P02107548A0727|105 110|psi ARF
P02107548A0727|125 132|human ARF
P02109544A0000|20 27|benefits
P02109544A0000|30 43|screening tests
P02109544A0000|47 66|Chlamydia trachomatis
P02109544A0000|69 83|adolescent males
P02109544A0000|97 117|decision analysis model
P02109544A0000|132 165|leukocyte esterase urine dipstick test
P02109544A0000|182 212|direct-smear fluorescent antibody
P02109544A0000|214 216|DFA
P02110145T0000|0 9|Sequencing
P02110145T0000|22 57|imipenem-cefoxitin-hydrolyzing enzyme
P02110145T0000|59 62|CfiA
P02110145T0000|68 78|Bacteroides
P02110145T0000|87 93|TAL2480
P02110145T0000|101 116|strong similarity
P02110145T0000|124 127|CfiA
P02110145T0000|131 160|Bacillus cereus beta-lactamase II
P02110145T0000|131 158|Bacillus cereus beta-lactamase
P02110148A0423|9 23|HindIII fragment
P02110148A0423|40 58|DNA sequence analysis
P02110148A0423|70 83|N-terminal half
P02110148A0423|89 108|B. subtilis IF2 protein
P02110148A0423|115 116|kb
P02110148A0423|119 142|upstream flanking sequence
P02110148A0423|158 172|homologous probe
P02110148A0423|175 179|clone
P02110148A0423|193 222|2.76-kb ClaI chromosomal fragment
P02110148A0423|236 258|entire IF2 structural gene
P02111015A0574|3 12|N-terminal
P02111015A0574|16 25|amino acids
P02111015A0574|39 63|putative DNA-binding domain
P02111015A0574|47 63|DNA-binding domain
P02111015A0574|71 99|significant sequence similarity
P02111015A0574|115 132|IFN response factors
P02111015A0574|134 138|IRF-1
P02111015A0574|142 146|IRF-2
P02113015A0295|0 15|Maternal seizures
P02113015A0295|49 52|cent
P02113174A0064|26 43|zinc fingers similar
P02113174A0064|56 77|transcription factor Sp1
P02113174A0957|0 6|Krox-24
P02113174A0957|19 59|sequence-specific transcriptional activator
P02113455A0207|3 28|interindividual variability
P02113455A0207|34 43|parameters
P02113455A0207|97 111|threshold levels
P02113699A0372|3 10|patients
P02113699A0372|27 35|subgroups
P02113699A0372|41 41|N
P02113699A0372|43 50|patients
P02113699A0372|55 70|multiple hot spots
P02113699A0372|72 78|greater
P02113699A0372|86 86|N
P02113699A0372|88 89|IM
P02113699A0372|96 96|N
P02113699A0372|98 105|patients
P02113699A0372|110 123|single hot spots
P02113699A0372|145 145|N
P02113699A0372|155 155|N
P02113699A0372|157 164|patients
P02113699A0372|169 182|single hot spots
P02113699A0372|204 204|N
P02113901A0000|8 10|CO2
P02113901A0000|18 24|changes
P02113901A0000|29 32|hypo
P02113901A0000|36 46|normocapnia
P02113901A0000|78 85|arterial
P02113901A0000|96 99|PaO2
P02113901A0000|112 128|alveolar-arterial
P02115111T0000|0 9|Expression
P02115111T0000|11 28|nucleotide sequence
P02115111T0000|32 49|mutational analysis
P02115111T0000|55 71|open reading frames
P02115111T0000|77 115|nif gene region of Anabaena sp. strain PCC7120
P02115111T0000|77 89|nif gene region
P02115111T0000|92 101|Anabaena sp
P02115111T0000|103 115|strain PCC7120
P02115115A1053|46 60|sites homologous
P02115115A1053|66 72|CAR1 URS
P02115115A1053|94 108|flanking regions
P02115115A1053|111 137|multiple unrelated yeast genes
P02115116A1137|3 9|results
P02115116A1137|22 34|sequence match
P02115116A1137|42 50|enhancers
P02115116A1137|54 76|certain promoter elements
P02115118A0565|35 44|smg p25A GDI
P02115118A0565|56 108|sodium dodecyl sulfate-polyacrylamide gel electrophoresis
P02115118A0565|112 152|sucrose density gradient ultracentrifugation
P02115121A0000|0 11|Yeast mutants
P02115121A0000|25 51|pet complementation group G104
P02115121A0000|67 106|alpha-ketoglutarate dehydrogenase activity
P02115121A0000|67 98|alpha-ketoglutarate dehydrogenase
P02115121A0000|118 126|mutations
P02115121A0000|132 160|dihydrolipoyl transsuccinylase
P02115121A0000|162 164|KE2
P02115122A0562|0 15|Critical residues
P02115122A0562|27 36|repression
P02115122A0562|40 46|located
P02115122A0562|56 65|C-terminal
P02115122A0562|68 77|amino acids
P02115122A0562|80 84|c-Fos
P02115122A0562|91 95|v-Fos
P02115122A0562|99 119|C-terminal truncations
P02115122A0562|122 126|c-Fos
P02115572A1323|17 33|V lambda pseudogene
P02115572A1323|41 51|psi V lambda 1
P02115572A1323|41 50|psi V lambda
P02115572A1323|54 55|kb
P02115572A1323|69 82|U266 lambda gene
P02115889A0436|40 48|human gene
P02115889A0436|52 58|Gx alpha
P02115889A0436|80 88|kilobases
P02116071A0000|1 18|long follow-up study
P02116071A0000|31 55|convalescent stage children
P02116071A0000|68 74|potency
P02116071A0000|83 119|immediate type hypersensitivity reaction
P02116071A0000|132 142|mite antigen
P02116071A0000|149 157|high titer
P02116071A0000|160 174|mite specific IgE
P02116071A0000|182 185|sera
P02116071A0000|205 220|asthmatic attacks
P02116071A0000|255 265|mite antigen
P02116071A0000|310 324|mite specific IgG
P02116537A1237|27 45|lower concentrations
P02116537A1237|53 55|MIC
P02116537A1237|58 60|AMK
P02117799T0000a|0 3|Uses
P02117799T0000a|6 19|orthoclone OKT3
P02117799T0000a|23 33|prophylaxis
P02117799T0000a|36 44|rejection
P02117799T0000a|48 56|induction
P02117799T0000a|59 76|initial nonfunction
P02117799T0000a|79 99|kidney transplantation
P02117799T0000b|0 3|Uses
P02117799T0000b|6 19|orthoclone OKT3
P02117799T0000b|23 33|prophylaxis
P02117799T0000b|36 44|rejection
P02117799T0000b|48 56|induction
P02117799T0000b|59 76|initial nonfunction
P02117799T0000b|79 99|kidney transplantation
P02118519A0516|23 46|potential consensus motifs
P02118519A0516|66 87|corresponding positions
P02118519A0516|93 97|genes
P02118519A0516|104 128|nerve growth factor receptor
P02118519A0516|135 160|68-kDa neurofilament protein
P02118525A0737|36 46|CCK promoter
P02118525A0737|56 78|transcriptional enhancer
P02118525A0737|97 109|transcription
P02118525A0737|117 157|herpes simplex virus thymidine kinase promoter
P02118525A0737|173 201|orientation-independent manner
P02118612A0629|6 12|minutes
P02118612A0629|15 29|supine restraint
P02118612A0629|39 57|DOPAC concentrations
P02118612A0629|63 76|median eminence
P02118612A0629|79 88|female rats
P02118612A0629|118 130|brief exposure
P02118612A0629|133 137|ether
P02119530T0000|0 8|Influence
P02119530T0000|11 29|metoprolol treatment
P02119530T0000|32 57|sympatho-adrenal activation
P02119530T0000|60 71|fibrinolysis
P02119626A0471|8 12|scars
P02119626A0471|38 38|%
P02119626A0471|41 56|linear dimensions
P02119946T0000|8 16|dysphagia
P02119946T0000|20 37|chronic care setting
P02120707A0594|0 23|Gel-mobility-shift assays
P02120707A0594|40 58|Raji nuclear proteins
P02120707A0594|70 70|W
P02120707A0594|74 82|V elements
P02120707A0594|103 129|HLA-DRA X-box oligonucleotide
P02120707A0594|103 110|HLA-DRA X
P02120833A0000|2 8|Denmark
P02120833A0000|16 20|cases
P02120833A0000|23 57|transfusion-associated hepatitis NANB
P02120833A0000|59 66|TAH-NANB
P02120833A0000|111 115|units
P02121371T0000|3 10|NF1 locus
P02121371T0000|47 58|mammalian GAP
P02121371T0000|62 77|yeast IRA proteins
P02122454A1042|22 27|Phe-62
P02122454A1042|32 34|Ser
P02122454A1042|55 65|determinant
P02122454A1042|71 87|lambda I light chain
P02122454A1042|71 76|lambda
P02122454A1042|78 87|light chain
P02122454A1042|109 130|intracellular transport
P02123029A0478|1 13|second isotype
P02123029A0478|16 48|Raja immunoglobulin heavy chain genes
P02123029A0478|76 92|spleen cDNA library
P02123029A0478|97 112|homologous Raja VH
P02123029A0478|117 134|CH1-specific probes
P02123029A0478|151 167|respective regions
P02123029A0478|173 186|mu-like isotype
P02123293A0227|0 4|Petko
P02123293A0227|9 10|S.
P02123295A0645|0 9|Disruption
P02123295A0645|12 15|ARF2
P02123295A0645|24 42|detectable phenotype
P02123300T0000|0 46|Human recombinant DNA-derived antihemophilic factor
P02123300T0000|27 57|antihemophilic factor (factor VIII
P02123300T0000|75 117|hemophilia A. recombinant Factor VIII Study Group
P02123466A0272|4 15|other members
P02123466A0272|32 43|AP-4 HLH motif
P02123466A0272|50 68|adjacent basic domain
P02123466A0272|102 124|site-specific DNA binding
P02123467A0811|27 34|promoter
P02123467A0811|37 45|embryonic
P02123467A0811|68 72|cells
P02123467A0811|81 85|MyoD1
P02123467A0811|89 91|Sp1
P02123467A0811|121 125|sites
P02123467A0811|178 180|Sp1
P02123467A0811|184 188|MyoD1
P02123820A0000|0 6|Effects
P02123820A0000|10 34|selective monoamine oxidase
P02123820A0000|19 34|monoamine oxidase
P02123820A0000|36 38|MAO
P02123820A0000|43 51|inhibitor
P02123820A0000|53 62|clorgyline
P02123820A0000|65 87|selective MAO-B inhibitor
P02123820A0000|89 96|deprenyl
P02123820A0000|102 126|non-selective MAO inhibitor
P02123820A0000|115 117|MAO
P02123820A0000|128 136|nialamide
P02123820A0000|156 182|footshock-induced aggression
P02123820A0000|184 186|FIA
P02123820A0000|190 199|paired rats
P02123875A0223|10 27|structural features
P02123875A0223|30 37|residues
P02123875A0223|49 56|c-region
P02123875A0223|73 80|fidelity
P02123875A0223|96 118|signal peptidase cleavage
P02123875A0223|127 155|co-translational translocation
P02123875A0223|172 193|amino acid substitutions
P02123875A0223|201 212|COOH terminus
P02123875A0223|218 232|hydrophobic core
P02123875A0223|241 253|substitutions
P02123875A0223|259 269|NH2 terminus
P02123875A0223|275 286|mature region
P02123875A0223|291 300|+1 position
P02123875A0223|305 338|model eukaryotic preprotein-human pre
P02123875A0223|340 347|delta pro
P02123875A0223|349 355|apoA-II
P02123877A1452|21 25|c-fos
P02123877A1452|29 38|egr-1 mRNAs
P02123877A1452|53 66|elevated levels
P02123877A1452|79 88|liver cells
P02123877A1452|90 94|fos-B
P02123877A1452|96 100|fra-1
P02123877A1452|105 109|egr-2
P02123877A1452|134 140|factors
P02123877A1452|156 174|serum response factor
P02123877A1452|203 230|immediate-early gene induction
P02123877A1452|203 221|immediate-early gene
P02124433A0235|5 12|patients
P02124433A0235|17 21|cases
P02124433A0235|26 44|complete description
P02124433A0235|70 78|evaluable
P02124433A0235|80 85|Group A
P02124433A0235|95 97|MMC
P02124433A0235|99 102|5-FU
P02124433A0235|104 115|chemotherapy
P02124433A0235|120 124|cases
P02124433A0235|126 131|group B
P02124433A0235|141 143|MMC
P02124433A0235|145 148|5-FU
P02124433A0235|150 155|OK-432
P02124433A0235|158 160|PSK
P02124433A0235|162 179|immunochemotherapy
P02124433A0235|187 192|group C
P02124710A0193|3 17|nuclear proteins
P02124710A0193|30 34|c-fos
P02124710A0193|38 56|c-jun protooncogenes
P02124710A0193|78 96|proliferation period
P02124710A0193|99 128|osteoblast phenotype development
P02124710A1624|11 17|further
P02124710A1624|29 35|binding
P02124710A1624|41 54|Fos-Jun complex
P02124710A1624|59 66|AP-1 site
P02124710A1624|72 97|type alpha I collagen promoter
P02124710A1624|72 80|type alpha
P02124710A1624|82 97|collagen promoter
P02124710A1624|104 113|contiguous
P02124710A1624|140 143|VDRE
P02125016A0145|0 3|PBSX
P02125016A0145|15 20|agents
P02125016A0145|35 45|SOS response
P02125153A0410|1 22|bacteriological relapse
P02125153A0410|52 56|years
P02125153A0410|63 63|%
P02125153A0410|69 70|R3
P02125153A0410|75 75|%
P02125153A0410|80 81|R5
P02125153A0410|90 90|%
P02125153A0410|96 105|Z5 patients
P02125153A0410|110 127|organisms sensitive
P02125153A0410|130 141|streptomycin
P02125153A0410|145 153|isoniazid
P02126417A0408|5 12|controls
P02126417A0408|31 42|right-handed
P02126417A0408|55 80|left-handed control subjects
P02126417A0408|88 95|right VHF
P02126417A0408|106 115|hemisphere
P02126504A0602|10 22|Rh-antibodies
P02126504A0602|27 38|demonstrable
P02126504A0602|41 56|similar mechanism
P02126504A0602|78 86|Rh-system
P02129338A0568|10 26|amino acid sequence
P02129338A0568|33 48|greatest homology
P02129338A0568|52 52|%
P02129338A0568|59 97|green alga Scenedemus obliquus plastocyanin
P02131652A0883|0 37|Higher fasting serum gastrin concentration
P02131652A0883|18 24|gastrin
P02131652A0883|63 68|ng.l-1
P02131652A0883|66 68|l-1
P02131652A0883|74 106|greater postprandial gastrin release
P02131652A0883|108 115|AUC0-120
P02131652A0883|143 151|ng.l-1 min
P02131652A0883|170 175|VTP-HM
P02131652A0883|185 191|VTP-Cas
P02131666A0483|3 19|experimental group
P02131666A0483|33 70|examinees class II/2 orthodontic anomalies
P02131902A0000|44 75|transesophageal echocardiographic
P02131902A0000|77 79|TEE
P02131902A0000|81 90|transducer
P02131902A0000|107 120|short-axis view
P02131902A0000|126 138|left ventricle
P02131902A0000|140 143|S-LV
P02132636A0188|0 7|Subjects
P02132636A0188|14 38|male chronic schizophrenics
P02132636A0188|52 65|DST suppressors
P02132636A0188|70 83|nonsuppressors
P02133731A1572|4 5|S3
P02133731A1572|7 9|CBF
P02133731A1572|16 16|%
P02133731A1572|20 21|S5
P02133731A1572|23 25|CBF
P02133731A1572|31 31|%
P02133731A1572|34 37|%WTh
P02133731A1572|39 43|1/TPC
P02133731A1572|47 49|1/T
P02133731A1572|90 102|control levels
P02133731A1572|107 111|p less
P02135343A0131|46 60|normal occlusion
P02135343A0131|81 92|maloclusions
P02135343A0131|108 134|anteroposterior relationship
P02135343A0131|145 155|dental archs
P02135343A0131|169 188|ANGLE3 classification
P02135536A0621|21 33|brush abrasion
P02135536A0621|43 53|compressive
P02135536A0621|57 74|transverse strength
P02135536A0621|88 90|MPa
P02135536A0621|104 111|hardness
P02135536A0621|117 118|Hk
P02135536A0621|120 134|water absorption
P02135536A0621|139 152|micrograms/mm3
P02135536A0621|156 182|thermal expansion coefficient
P02135536A0621|196 204|degrees C.
P02137704A0000|9 19|select group
P02137704A0000|22 47|stable hypertensive patients
P02137704A0000|94 125|various blood pressure measurements
P02137704A0000|129 168|h average automated ambulatory blood pressure
P02137704A0000|171 171|h
P02137704A0000|181 217|ambulatory morning average blood pressure
P02137704A0000|219 257|multiple office visit average blood pressure
P02137704A0000|263 299|single office visit average blood pressure
P02137704A0000|304 334|various echocardiographic indices
P02137704A0000|337 372|hypertensive cardiac target organ damage
P02137704A0000|374 391|left atrial diameter
P02137704A0000|397 427|ventricular end diastolic diameter
P02137704A0000|429 450|posterior wall thickness
P02137704A0000|460 472|wall thickness
P02137704A0000|474 494|relative wall thickness
P02137704A0000|500 514|ventricular mass
P02137704A0000|518 526|mass index
P02137704A0000|539 589|wall thickness/left ventricular diastolic diameter ratio
P02138707A0198|39 65|lambda gt11 expression library
P02138707A0198|67 83|murine protein mXBP
P02138707A0198|132 142|murine class
P02138707A0198|145 188|major histocompatibility complex A alpha gene X box
P02138707A0198|200 219|transcription element
P02138707A0198|245 249|genes
P02138915A1060|3 9|p36 gene
P02138915A1060|21 22|kb
P02138915A1060|68 69|kb
P02138915A1060|90 90|%
P02138915A1060|102 109|ABSTRACT
P02138915A1060|124 128|WORDS
P02138992A0911|4 25|multimodality treatment
P02138992A0911|44 60|gynecologic tumors
P02138992A0911|68 75|feasible
P02138992A0911|80 91|modification
P02139473A1603|1 10|contiguous
P02139473A1603|34 57|secondary Fur-binding site
P02139473A1603|43 57|Fur-binding site
P02139473A1603|60 63|entC
P02139473A1603|78 100|higher Fur concentrations
P02139473A1603|84 86|Fur
P02139473A1603|114 128|protected region
P02139473A1603|153 182|putative Shine-Dalgarno sequence
P02139891A0532|3 15|major promoter
P02139891A0532|34 64|virus-encoded trans activators EIA
P02139891A0532|62 64|EIA
P02139891A0532|68 70|EIV
P02139891A0532|86 93|elements
P02139891A0532|96 113|TAGA motif analogous
P02139891A0532|119 125|TATA box
P02139891A0532|130 145|EIIF sites present
P02139891A0532|130 138|EIIF sites
P02139891A0532|150 168|inverted orientation
P02139891A0532|175 186|ATF/CREB site
P02139891A0532|175 177|ATF
P02141425A0175|15 32|fingertip-to-floor
P02141425A0175|34 37|MFTF
P02141425A0175|46 53|patients
P02141425A0175|62 66|stool
P02141425A0175|87 98|measurements
P02141425A0175|111 118|patients
P02142240A0506|2 23|significant differences
P02142240A0506|37 49|response rates
P02142240A0506|79 95|estrogen receptors
P02142240A0506|108 127|progesteron receptors
P02142240A0506|141 148|patients
P02142486A0367|0 10|Teicoplanin
P02142486A0367|37 51|persistent fever
P02142486A0367|54 84|initial Gram-positive bacteraemia
P02142486A0367|108 112|cases
P02142921T0000|0 34|Luteinizing hormone-releasing hormone
P02142921T0000|11 47|hormone-releasing hormone analog therapy
P02142921T0000|50 63|uterine fibroid
P02142921T0000|75 81|results
P02142921T0000|94 102|buserelin
P02142921T0000|130 138|goserelin
P02142921T0000|168 179|monthly depot
P02142955A0248|2 12|Experiments
P02142955A0248|19 25|infants
P02142955A0248|31 36|adults
P02142955A0248|58 69|novel objects
P02142955A0248|82 99|physical appearance
P02142955A0248|121 137|multiple exemplars
P02142955A0248|144 149|delays
P02142955A0248|157 160|days
P02142993A0176|3 17|clinical picture
P02142993A0176|59 93|anthropogenic cutaneous leishmaniasis
P02142993A0176|102 110|L. tropica
P02142993A0176|123 139|cutaneous patterns
P02142993A0176|148 157|L. infantum
P02142993A0176|167 182|prevalent pattern
P02142993A0176|188 201|southern France
P02143023A0729|18 32|octamer elements
P02143023A0729|38 53|adenovirus genome
P02143023A0729|82 94|transcription
P02143023A0729|104 118|octamer elements
P02143023A0729|124 151|viral terminal repeat sequences
P02143186A0867|21 27|introns
P02143186A0867|38 41|AHA3
P02143186A0867|43 46|AHA2
P02143186A0867|59 64|intron
P02143186A0867|73 90|untranslated region
P02143186A0867|95 106|second intron
P02143186A0867|112 133|C-terminal coding region
P02143186A1306|0 19|Northern blot analysis
P02143186A1306|33 48|AHA2 mRNA relative
P02143186A1306|33 36|AHA2
P02143186A1306|51 66|total cellular RNA
P02143186A1306|93 104|higher levels
P02143186A1306|107 116|root tissue
P02143186A1306|131 141|shoot tissue
P02143768T0000|0 8|Impaction
P02143768T0000|11 25|gastrostomy tube
P02143768T0000|31 43|abdominal wall
P02143961A0400|4 18|antidepressants
P02143961A0400|30 42|pain threshold
P02143961A0400|56 67|pretreatment
P02143961A0400|72 75|pCPA
P02143961A0400|93 101|analgesia
P02144290A1444|0 2|Sci
P02144558A1022|1 15|needs assessment
P02144558A1022|23 30|families
P02144610A1306|0 7|TCR alpha
P02144610A1306|11 28|beta gene expression
P02144610A1306|11 18|beta gene
P02144610A1306|46 54|common set
P02144610A1306|57 77|T-cell nuclear proteins
P02144610A1306|87 99|T beta 2 element
P02144610A1306|87 91|T beta
P02144610A1306|113 152|cyclic AMP response element-binding proteins
P02144610A1306|174 187|T alpha 1 element
P02144610A1306|174 179|T alpha
P02144610A1306|193 213|human TCR alpha enhancer
P02144610A1306|220 240|decamer element present
P02144610A1306|244 254|large number
P02144610A1306|265 286|murine TCR beta promoters
P02145195A0253|5 13|stem-loop
P02145195A0253|22 30|divergent
P02145195A0253|72 79|upstream
P02145195A0253|85 95|binding site
P02145195A0253|99 108|Sm proteins
P02145268A0746|10 27|nucleotide sequence
P02145268A0746|42 50|sequences
P02145268A0746|58 64|analogy
P02145268A0746|87 104|type I collagen genes
P02145268A0746|92 104|collagen genes
P02145268A0746|132 135|exon
P02145268A0746|143 152|COL3A1 gene
P02145268A1454|5 10|losses
P02145268A1454|36 49|EDS-IV collagen
P02145268A1454|52 66|cyanogen bromide
P02145268A1454|70 98|mammalian collagenase digestion
P02145268A1454|70 89|mammalian collagenase
P02146266A0000|1 33|4.8-kilobase BamHI-HindIII fragment
P02146266A0000|13 33|BamHI-HindIII fragment
P02146266A0000|45 93|entire Neurospora crassa CuZn superoxide dismutase gene
P02146266A0000|111 115|sod-1
P02146266A0000|133 146|genomic library
P02146266A0000|155 187|60-base deoxyoligonucleotide probes
P02146266A0000|215 239|N. crassa amino acid sequence
P02146495A0706|3 15|other peptides
P02146495A0706|51 61|basic region
P02146495A0706|79 103|intact leucine zipper domain
P02146495A0706|116 121|dimers
P02146495A0706|139 141|CRE
P02147223A1047|14 16|CRE
P02147223A1047|22 46|human c-fos promoter located
P02147223A1047|70 73|cAMP
P02147223A1047|77 79|E1a
P02147223A1047|86 89|HeLa
P02147223A1047|93 101|PC12 cells
P02147422A0000|44 66|human U1-70K snRNP protein
P02148219A0508|54 66|clinical facts
P02148219A0508|78 85|rigidity
P02148219A0508|95 102|extensor
P02148219A0508|106 111|flexor
P02148219A0508|113 120|proximal
P02148219A0508|124 136|distal muscles
P02148291A0173|5 43|appropriate synthetic HSE oligonucleotides
P02148291A0173|50 54|types
P02148291A0173|57 62|clones
P02148291A0173|67 92|potential HSE binding domains
P02148291A0173|110 142|tomato lambda gt11 expression library
P02148291A0173|145 163|DNA-ligand screening
P02148508A0374|0 4|Fluid
P02148508A0374|6 9|AVLF
P02148508A1478|3 9|results
P02148508A1478|22 41|therapeutic principle
P02148508A1478|44 46|TCM
P02148508A1478|56 63|patients
P02148508A1478|80 105|pathophysiological patterns
P02148799A0000|3 9|nmr gene
P02148799A0000|15 41|major negative regulatory gene
P02148799A0000|47 68|nitrogen control circuit
P02148799A0000|71 86|Neurospora crassa
P02148799A0000|106 128|positive regulatory genes
P02148799A0000|152 182|multiple unlinked structural genes
P02149487A0348|4 35|days dexamethasone suppression test
P02149487A0348|52 63|% suppression
P02149487A0348|66 96|dehydroepiandrosterone-sulphate
P02149487A0348|115 115|%
P02149487A0348|128 139|testosterone
P02149487A0348|143 163|androstenedione levels
P02149566A0478|10 18|P-31 NMR-S
P02149566A0478|26 44|inorganic phosphates
P02149566A0478|46 47|Pi
P02149566A0478|51 65|phosphocreatine
P02149566A0478|67 69|PCr
P02149566A0478|87 93|greater
P02149566A0478|102 111|LVH baboons
P02149566A0478|138 138|=
P02149566A0478|151 155|P less
P02149570T0000|0 16|Cutaneous necrosis
P02149570T0000|31 48|protein S deficiency
P02150473T0067|0 12|Critical study
P02151229A0000|0 24|Regional cerebral blood flow
P02151229A0000|41 72|N-isopropyl-123I-iodoamphetamine
P02151229A0000|77 97|single-photon emission
P02151229A0000|106 115|tomography
P02151229A0000|117 118|CT
P02151229A0000|124 135|aged patients
P02151229A0000|140 175|noninsulin-dependent diabetes mellitus
P02151229A0000|177 181|NIDDM
P02151229A0000|183 192|average age
P02151229A0000|197 201|years
P02151229A0000|203 229|average fasting plasma glucose
P02151229A0000|233 238|mmol/L
P02151229A0000|246 264|nondiabetic subjects
P02151229A0000|270 274|years
P02151229A0000|279 284|mmol/L
P02151229A0921|0 15|Mean ROI-A/B ratio
P02151229A0921|29 29|%
P02151229A0921|35 47|diabetic group
P02151229A0921|84 84|%
P02151229A0921|90 105|nondiabetic group
P02151229A0921|107 111|p less
P02153243A0965|29 41|normal product
P02153243A0965|47 55|int-2 gene
P02153243A0965|76 103|fibroblast growth factor family
P02153243A0965|108 125|contributory factor
P02153243A0965|142 154|mammary tumors
P02153683A1579|23 39|separate complexes
P02153683A1579|55 61|ankyrin
P02153683A1579|65 70|fodrin
P02153683A1579|81 90|uvomorulin
P02153683A1579|93 95|Na+
P02153683A1579|93 94|Na
P02153683A1579|97 105|K+-ATPase
P02153683A1579|97 97|K
P02153683A1579|100 105|ATPase
P02153977A0364|5 9|genes
P02153977A0364|29 36|few hours
P02153977A0364|42 51|initiation
P02153977A0364|71 75|mRNAs
P02153977A0364|97 98|hr
P02153977A0364|114 124|culmination
P02154467A0709|3 12|PC2 protein
P02154467A0709|22 36|great similarity
P02154467A0709|42 71|incomplete NH2-terminal sequence
P02154467A0709|77 97|human furin gene product
P02154467A0709|100 145|putative membrane-inserted receptor-like molecule
P02154474A1504|20 28|sequences
P02154474A1504|39 56|cAMP responsiveness
P02154474A1504|77 84|P-450scc
P02154474A1504|91 118|other steroidogenic P-450 genes
P02154474A1504|96 118|steroidogenic P-450 genes
P02154599A0382|18 29|footprinting
P02154599A0382|33 60|gel mobility retardation assays
P02154599A0382|95 111|Zta fusion proteins
P02154599A0382|130 147|TGTGCAA-like motifs
P02154599A0382|154 156|DSL
P02154599T0000|3 19|zta transactivator
P02154599T0000|30 38|induction
P02154599T0000|41 64|lytic cycle gene expression
P02154599T0000|67 103|Epstein-Barr virus-infected lymphocytes
P02154599T0000|115 118|AP-1
P02154599T0000|122 129|ZRE sites
P02154599T0000|132 145|target promoter
P02154599T0000|149 163|enhancer regions
P02154602A0092|7 18|human homolog
P02154602A0092|24 37|mouse Mx protein
P02154602A0092|60 73|influenza virus
P02154686A0185|0 8|Fragments
P02154686A0185|22 45|21-base-pair repeat region
P02154686A0185|50 57|enhancer
P02154686A0185|60 70|simian virus
P02154686A0185|97 123|beta-galactosidase synthesis
P02154686A0185|97 114|beta-galactosidase
P02154686A0185|133 141|fragments
P02154686A0185|149 174|polyomavirus enhancer region
P02154686A0185|185 198|moderate levels
P02154885A0153|3 7|sites
P02154885A0153|19 29|mutagenesis
P02154885A0153|31 38|residues
P02154885A0153|54 60|located
P02154885A0153|68 95|putative helical loop structure
P02154885A0153|116 135|substrate recognition
P02154885A0153|141 146|enzyme
P02155017A1106|3 18|possible benefits
P02155017A1106|21 30|LMW heparin
P02155017A1106|50 57|bleeding
P02155017A1106|59 69|alleviation
P02155017A1106|72 91|hypertriglyceridemia
P02155017A1106|138 159|short observation period
P02155017A1106|166 177|low incidence
P02155017A1106|180 203|hemorrhagic complications
P02155017A1106|206 220|routine dialyses
P02156828A0164|10 26|amino acid sequence
P02156828A0164|29 35|destrin
P02156828A0164|41 48|residues
P02156828A0164|72 81|% identical
P02156828A0164|91 97|cofilin
P02156828A0164|118 152|pH-sensitive actin-modulating protein
P02157067A0610|0 6|Summers
P02157067A0610|8 15|Virology
P02157141A0923|16 23|T antigen
P02157141A0923|39 52|topoisomerase I
P02157141A0923|39 51|topoisomerase
P02157141A0923|73 94|ori-auxiliary sequences
P02157141A0923|114 166|T-antigen-dependent DNA conformational changes consistent
P02157141A0923|188 196|base pairs
P02157764A1115|1 15|rabbit antiserum
P02157764A1115|33 48|synthetic peptide
P02157764A1115|65 82|hydrophilic portion
P02157764A1115|98 115|murine cDNA sequence
P02157882T0000|0 11|Conservation
P02157882T0000|24 48|Drosophila melanogaster abl
P02157882T0000|46 48|abl
P02157882T0000|52 70|murine v-abl proteins
P02157882T0000|89 102|mammalian cells
P02158099A0487|2 30|transient cotransfection assays
P02158099A0487|36 50|Chang liver cells
P02158099A0487|52 54|CCL
P02158099A0487|59 64|pM1 DNA
P02158099A0487|83 104|trans-activating effect
P02158099A0487|125 146|pSV2CAT reporter plasmid
P02158927A0000|19 28|nucleotide
P02158927A0000|30 31|nt
P02158927A0000|46 61|7.5-kb COR segment
P02158927A0000|87 94|six genes
P02158927A0000|90 94|genes
P02158927A0000|96 99|CYC1
P02158927A0000|101 104|UTR1
P02158927A0000|106 109|UTR3
P02158927A0000|111 114|OSM1
P02158927A0000|116 119|tRNA
P02158927A0000|121 123|Gly
P02158927A0000|128 131|RAD7
P02158927A0000|133 139|located
P02158927A0000|142 152|chromosome X
P02158927A0000|158 162|yeast
P02159470A1432|0 14|Specific binding
P02159470A1432|20 33|protein factors
P02159470A1432|39 43|sites
P02159470A1432|63 73|Mt sequences
P02159470A1432|84 96|important role
P02159470A1432|102 121|coordinate regulation
P02159470A1432|127 139|transcription
P02159470A1432|142 153|nuclear genes
P02159470A1432|162 180|subunits responsible
P02159470A1432|184 220|mitochondrial oxidative phosphorylation
P02159559A0779|13 32|specific interference
P02159559A0779|37 63|HSV-induced DNA amplification
P02160502A0471|2 29|recombination signal sequences
P02160502A0471|43 52|contiguous
P02160502A0471|58 75|recombination point
P02160622A0000|3 27|antinociceptive properties
P02160622A0000|44 53|tail-flick
P02160622A0000|57 70|hot-plate tests
P02160622A0000|78 89|motor effects
P02160622A0000|94 149|intrathecally-administered benzodiazepine agonist midazolam
P02160622A0000|177 184|morphine
P02160622A0000|199 202|rats
P02160955A0899|0 9|Constructs
P02160955A0899|27 32|AATAAA
P02160955A0899|39 51|GT-rich region
P02160955A0899|67 82|various distances
P02160955A0899|99 100|bp
P02162049A0291|29 35|factor Y
P02162049A0291|66 76|DNA sequence
P02162103A0000|23 27|cDNAs
P02162103A0000|35 44|genomic RNA
P02162103A0000|48 51|mRNA
P02162103A0000|55 68|phosphoprotein
P02162103A0000|70 70|P
P02162103A0000|74 95|human parainfluenza type
P02162103A0000|103 107|PIV-2
P02162103A0000|110 118|cDNA clone
P02162103A0000|123 132|genomic RNA
P02162103A0000|140 150|nucleotides
P02162103A0000|168 171|poly
P02162103A0000|173 173|A
P02162103A0000|195 216|small open reading frames
P02162103A0000|225 232|proteins
P02162103A0000|244 253|amino acids
P02162467A0311|10 23|cytR expression
P02162467A0311|10 13|cytR
P02162467A0311|51 61|CytR protein
P02162467A0311|88 102|cAMP/CAP complex
P02162754A0339|15 19|sites
P02162754A0339|31 47|amino acid sequence
P02162754A0339|53 82|3T3-L1 adipocyte insulin receptor
P02162754A0339|59 82|adipocyte insulin receptor
P02162754A0801|0 2|PAO
P02162754A0801|9 16|turnover
P02162754A0801|22 36|phosphoryl group
P02162754A0801|39 42|pp15
P02162754A0801|54 65|accumulation
P02162754A0801|95 112|signal transmission
P02162754A0801|120 127|receptor
P02162754A0801|133 155|glucose-transport system
P02162835A0989|17 36|sequence similarities
P02162835A0989|45 71|common molecular architecture
P02162835A0989|80 95|heme binding sites
P02162835A0989|102 118|copper binding site
P02162835A0989|126 132|enzymes
P02163347A0472|3 14|cDNA sequence
P02163347A0472|20 41|813-bp open reading frame
P02163347A0472|43 45|ORF
P02163347A0472|61 77|amino acid sequence
P02163347A0472|84 93|% identical
P02163347A0472|102 127|carboxy-terminal amino acids
P02163347A0472|133 149|human ets-1 protein
P02163382A0169|17 28|O7-LPS region
P02163382A0169|33 57|recombinant cosmids pJHCV31
P02163382A0169|61 67|pJHCV32
P02163382A0169|85 105|transposon mutagenesis
P02163382A0169|110 117|Tn3HoHo1
P02163382A0169|132 152|promoterless lac operon
P02163382A0169|144 152|lac operon
P02163382A0169|176 201|lacZ transcriptional fusions
P02163382A0169|206 223|target DNA sequences
P02163394T0000|3 10|sacT gene
P02163394T0000|24 34|sacPA operon
P02163394T0000|37 72|Bacillus subtilis shares strong homology
P02163394T0000|77 106|transcriptional antiterminators
P02164585A0416|3 23|TraD protein (83,899 Da)
P02164585A0416|3 13|TraD protein
P02164585A0416|21 22|Da
P02164585A0416|37 54|hydrophobic regions
P02164585A0416|69 75|located
P02164585A0416|83 102|amino-terminal region
P02164585A0814|3 16|protein product
P02164585A0814|19 22|orfD
P02164585A0814|40 49|new tra gene
P02164585A0814|43 49|tra gene
P02164585A0814|56 59|traX
P02164585A0814|72 93|% hydrophobic amino acids
P02164585A0814|111 117|alanine
P02164585A0814|121 127|leucine
P02164588A0266|0 19|Various mutant HN genes
P02164588A0266|13 19|HN genes
P02164588A0266|53 60|residues
P02164588A0266|72 90|signal-anchor domain
P02164588A0266|104 118|cytoplasmic tail
P02164588A0266|133 154|intracellular transport
P02164588A0266|160 173|HN glycoprotein
P02164604A0399|3 9|studies
P02164604A0399|21 28|findings
P02164604A0399|43 63|E2 transactivation gene
P02164604A0399|79 95|multiple promoters
P02164604A1574|25 41|E2 proteins present
P02164604A1574|25 34|E2 proteins
P02164604A1574|44 59|various cell lines
P02164604A1574|69 88|specific BPV-1 mutants
P02164604A1574|77 88|BPV-1 mutants
P02164604A1574|106 119|acceptor mutant
P02164604A1574|131 144|alternate modes
P02164604A1574|147 158|E2 expression
P02164604A1574|147 148|E2
P02164637A0515|0 9|Disruption
P02164637A0515|15 22|IRA2 gene
P02164637A0515|58 66|heat shock
P02164637A0515|70 87|nitrogen starvation
P02164637A0515|93 110|sporulation defects
P02164637A0515|120 130|suppression
P02164637A0515|136 144|lethality
P02164637A0515|150 160|cdc25 mutant
P02165181A0299|4 9|cohort
P02165181A0299|12 19|patients
P02165181A0299|43 55|clinical stage
P02165589A0000|52 56|2C1-3
P02165589A0000|62 74|distal portion
P02165589A0000|80 91|X-chromosome
P02165589A0000|111 151|steroid/thyroid hormone receptor superfamily
P02165589A0888|10 17|Region II
P02165589A0888|40 60|human c-jun oncoprotein
P02165589A0888|63 75|leucine zipper
P02165589A0888|115 136|heterodimerization site
P02165589A0888|147 149|jun
P02165589A0888|153 167|fos oncoproteins
P02166040A0385|18 25|vanadate
P02166040A0385|38 59|PEPCK gene transcription
P02166040A0385|38 46|PEPCK gene
P02166040A0385|70 82|chimeric genes
P02166040A0385|93 108|several deletions
P02166040A0385|114 149|P-enolypyruvate carboxykinase promoter
P02166040A0385|181 195|structural genes
P02166040A0385|205 238|amino-3-glycosyl phosphotransferase
P02166040A0385|240 242|neo
P02166040A0385|246 277|chloramphenicol acetyltransferase
P02166040A0385|295 307|hepatoma cells
P02166040A0385|318 324|methods
P02166040A0385|343 384|Moloney murine leukemia virus-based retrovirus
P02166040A0385|389 400|transfection
P02166040A0385|404 418|stable selection
P02166040A0385|422 434|neo expression
P02166040A0385|441 459|transient expression
P02166040A0385|462 494|chloroamphenicol acetyltransferase
P02166416A0419|14 32|miliary tuberculosis
P02166416A0419|67 70|ARDS
P02166416A0419|73 85|unknown origin
P02166825A0198|24 41|functional elements
P02166825A0198|47 54|promoter
P02166825A0198|86 102|regulatory signals
P02166825A0198|113 129|promoter mutations
P02166825A0198|161 184|linker-scanning mutations
P02166825A0198|194 213|entire promoter region
P02167321T0000|1 15|DNA motif related
P02167321T0000|21 42|cAMP-responsive element
P02167321T0000|48 77|exon-located activator protein-2
P02167321T0000|94 141|human tissue-type plasminogen activator gene promoter
P02167321T0000|153 167|basal expression
P02167321T0000|177 186|activation
P02167321T0000|189 200|phorbol ester
P02167321T0000|204 207|cAMP
P02167467T0000|3 42|26S rRNA binding ribosomal protein equivalent
P02167467T0000|3 32|26S rRNA binding ribosomal protein
P02167467T0000|45 63|bacterial protein L11
P02167467T0000|75 98|unspliced duplicated genes
P02167784A0109|4 22|healthy male subjects
P02167784A0109|39 41|min
P02167784A0109|50 50|%
P02167784A0109|57 57|%
P02167784A0109|65 67|min
P02167784A0109|86 88|min
P02167784A0109|106 140|steady-state end-tidal CO2 measurement
P02168640A0268|0 22|Significant correlations
P02168640A0268|42 48|changes
P02168640A0268|51 54|SSEP
P02168640A0268|67 68|AS
P02168640A0268|88 119|deep residual-organic disturbances
P02168640A0268|140 159|psychogenic disorders
P02169887A0360|3 13|transcripts
P02169887A0360|57 68|capstructure
P02169887A0360|85 92|EMCV-RNA
P02169887A0360|103 114|mRNAs capable
P02169887A0360|117 134|internal initiation
P02170687A0000|3 15|E6/E7 promoter
P02170687A0000|3 4|E6
P02170687A0000|6 7|E7
P02170687A0000|21 48|genital human papillomaviruses
P02170687A0000|80 101|viral transforming genes
P02172672T0001|7 17|Goodpasture
P02173399A0333|15 30|negative controls
P02173399A0333|37 50|positive blocks
P02173399A0333|59 79|soft tissue radiographs
P02173399A0333|81 84|STRs
P02173399A0333|105 115|specificity
P02173399A0333|120 120|%
P02173399A0333|136 136|%
P02173405A0270|2 23|symptomatic abnormality
P02173405A0270|41 54|neonatal period
P02173405A0270|61 89|periventricular calcifications
P02174105A1232|0 26|Immunohistochemical analysis
P02174105A1232|29 44|several rat organs
P02174105A1232|55 62|staining
P02174105A1232|65 79|epithelial cells
P02174427A1574|4 10|strains
P02174427A1574|39 65|nonfermentable carbon sources
P02174427A1574|91 91|%
P02174427A1574|94 145|wild-type ubiquinol-cytochrome c oxidoreductase activity
P02174427A1574|94 137|wild-type ubiquinol-cytochrome c oxidoreductase
P02174861A0736|0 9|Regulation
P02174861A0736|12 15|irgA
P02174861A0736|24 33|V. cholerae
P02174861A0736|45 64|transcriptional level
P02174861A0736|78 109|interrupted dyad symmetric sequence
P02174861A0736|115 122|vicinity
P02174861A0736|128 135|promoter
P02174861A0736|142 151|homologous
P02174861A0736|154 156|Fur
P02174861A0736|164 168|sites
P02174974A0000|0 12|Transcription
P02174974A0000|18 28|first operon
P02174974A0000|38 62|m-xylene-degrading enzymes
P02174974A0000|68 77|TOL plasmid
P02174974A0000|113 127|xylR gene product
P02174974A0000|143 150|m-xylene
P02175433A0575|3 13|recombinant
P02175433A0575|25 46|normal beta A-globin gene
P02175433A0575|31 46|beta A-globin gene
P02175433A0575|51 60|mutant gene
P02175433A0575|64 81|Ylp vector sequences
P02175433A0575|95 100|copies
P02175908A0805|9 17|mutations
P02175908A0805|48 61|Ulysses element
P02175908A0805|67 77|mutant locus
P02175908A0805|94 121|different transposable element
P02175908A0805|144 151|mutation
P02176021T0000|0 12|Determination
P02176021T0000|15 20|diquat
P02176021T0000|23 41|biological materials
P02176021T0000|44 76|electron spin resonance spectroscopy
P02176152A0896|14 15|RA
P02176152A0896|28 50|transcriptional activity
P02176152A0896|54 65|reporter gene
P02176152A0896|77 79|TPA
P02176152A0896|90 103|AP1 binding site
P02176152A0896|114 126|HSV tk promoter
P02176209A0954|21 23|EFI
P02176209A0954|25 28|NF-Y
P02176209A0954|32 38|CBF DNAs
P02176209A0954|49 79|identical gel retardation patterns
P02176209A0954|82 89|extracts
P02176209A0954|104 121|different cell types
P02176232T0001|0 10|Risk factors
P02176232T0001|22 41|lymph nodes metastasis
P02176232T0001|44 53|lung cancer
P02176232T0001|69 72|IIIA
P02176822A0000|0 27|Multifunctional protein kinase
P02176822A0000|29 32|MFPK
P02176822A0000|48 63|ATP-citrate lyase
P02176822A0000|66 73|peptide B
P02176822A0000|79 83|sites
P02176822A0000|85 86|BT
P02176822A0000|90 91|BS
P02176822A0000|95 103|threonine
P02176822A0000|107 112|serine
P02176822A0000|127 135|inhibitor
P02176822A0000|140 154|threonyl residue
P02176822A0000|159 174|glycogen synthase
P02176822A0000|177 181|sites
P02179052A1044|16 16|Y
P02179052A1044|26 41|sequence families
P02179052A1044|51 68|experimental system
P02179052A1044|84 103|sequence interactions
P02179052A1044|107 125|subsequent evolution
P02179188A1223|22 36|motile responses
P02179188A1223|69 81|dinitrophenol
P02179188A1223|84 97|cytochalasin B.
P02179815A0582|6 13|p59v-rel
P02179815A0582|6 9|p59v
P02179815A0582|11 13|rel
P02179815A0582|23 36|nuclear protein
P02179815A0582|39 41|CEF
P02179815A0582|43 68|indirect immunofluorescence
P02179815A0582|79 86|p68c-rel
P02179815A0582|79 82|p68c
P02179815A0582|89 109|JD214c-rel infected CEF
P02179815A0582|112 118|located
P02179815A0582|135 143|cytoplasm
P02179815A0582|151 155|cells
P02179815A0582|180 187|p68c-rel
P02179815A0582|180 183|p68c
P02179815A0582|185 187|rel
P02179815A0582|226 242|sequence identical
P02179815A0582|273 280|p59v-rel
P02179815A0582|273 276|p59v
P02180935A0535|0 17|Kinetic experiments
P02180935A0535|38 40|min
P02180935A0535|57 72|precursor protein
P02180935A0535|87 96|HL-60 cells
P02180935A0535|125 166|chondroitin sulfate proteoglycan intermediate
P02181760A0311|0 8|Blood flow
P02181760A0311|12 19|velocity
P02181760A0311|34 50|Doppler ultrasound
P02181760A0311|76 83|diastole
P02181760A0311|118 136|cotyledon resistance
P02182240A0355|11 18|patients
P02182240A0355|27 38|anistreplase
P02182240A0355|53 59|heparin
P02182240A0355|67 76|mean period
P02182240A0355|87 89|min
P02182240A0355|102 106|onset
P02182240A0355|109 116|symptoms
P02182323A0121|8 25|primary transcripts
P02182323A0121|29 39|variant tRNA
P02182323A0121|41 43|Val
P02182323A0121|46 48|UAC
P02182323A0121|67 75|deficient
P02182323A0121|81 104|standard growth conditions
P02182323A0121|108 115|degrees C
P02182323A0121|132 138|altered
P02182323A0121|141 154|flanking region
P02182618A0168|3 18|promoter activity
P02182618A0168|33 51|transient expression
P02182618A0168|55 86|chloramphenicol acetyltransferase
P02182618A0168|88 90|CAT
P02182618A0168|119 133|deletion mutants
P02182618A0168|142 155|flanking region
P02183467A0668|10 18|short ORFs
P02183467A0668|24 36|central region
P02183467A0668|39 41|BIV
P02183467A0668|73 92|structural similarity
P02183467A0668|98 126|nonstructural/regulatory genes
P02183467A0668|128 130|vif
P02183467A0668|132 134|tat
P02183467A0668|139 141|rev
P02183467A0668|145 161|other lentiviruses
P02183467A0668|182 191|unique ORFs
P02183467A0668|199 199|W
P02183467A0668|203 203|Y
P02183467A0668|220 224|exons
P02183467A0668|228 237|novel genes
P02185140A0000|3 33|Saccharomyces cerevisiae 14DM gene
P02185140A0000|26 33|14DM gene
P02185140A0000|43 85|cytochrome P450 lanosterol 14 alpha-demethylase
P02185140A0000|43 66|cytochrome P450 lanosterol
P02185140A0000|69 85|alpha-demethylase
P02185140A0000|87 90|14DM
P02185140A0000|130 136|strains
P02185140A0000|159 203|strong heterologous yeast transcription promoters
P02185140A0000|177 203|yeast transcription promoters
P02185140A0000|205 209|pADC1
P02185140A0000|211 214|pGPD
P02185140A0000|216 220|pPHO5
P02185140A0000|245 255|own promoter
P02185250A0726|0 10|Truncations
P02185250A0726|28 37|amino acids
P02185250A0726|63 90|endoplasmic reticulum membrane
P02185250A0726|95 107|translocation
P02185250A0726|128 143|co-translational
P02185250A0726|147 159|SRP-dependent
P02187091A0721|0 26|Pulmonary vascular resistance
P02187091A0721|41 56|ejection fraction
P02187091A0721|65 73|unchanged
P02187091A0721|77 102|isovolumic relaxation period
P02187091A0721|144 148|P less
P02187871T0000|3 11|ANB1 locus
P02187871T0000|14 36|Saccharomyces cerevisiae
P02187871T0000|47 84|protein synthesis initiation factor eIF-4D
P02188096A0955|19 43|alternative splicing events
P02188096A0955|46 60|c-myb expression
P02188096A0955|46 50|c-myb
P02188096A0955|70 82|c-myb function
P02188096A0955|70 74|c-myb
P02188168A0000|0 29|Serum beta 2-microglobulin levels
P02188168A0000|31 38|beta-2-M
P02188168A0000|56 66|drug addicts
P02188168A0000|76 95|asymptomatic carriers
P02188168A0000|98 116|anti HIV-1 antibodies
P02188168A0000|120 138|symptomatic carriers
P02188168A0000|143 152|persistent
P02188168A0000|164 178|lymphadenopathy
P02188168A0000|180 185|P.G.L.
P02188168A0000|192 212|serum negative patients
P02188168A0000|232 246|closed community
P02188168A0000|258 262|years
P02190122A0633|4 15|emancipation
P02190122A0633|42 58|hormonal influence
P02190122A0633|64 85|female sexual motivation
P02190122A0633|89 104|primary regulator
P02190122A0633|107 112|mating
P02190122A0633|115 122|primates
P02190134A0572|28 38|progression
P02190134A0572|58 74|possible exception
P02190134A0572|77 106|laser photocoagulation treatment
P02190134A0572|119 148|subretinal neovascular membranes
P02190134A0572|167 179|complications
P02190134A0572|182 202|subretinal hemorrhages
P02193033A0195|0 1|R.
P02194273A0913|0 27|Specific hyperimmune globulins
P02194273A0913|8 27|hyperimmune globulins
P02194273A0913|30 42|pathogens such
P02194273A0913|45 65|Haemophilus influenzae
P02194273A0913|69 81|Streptococcus
P02194972T0000|0 17|Therapeutic effects
P02194972T0000|20 28|cefpirome
P02194972T0000|30 31|HR
P02194972T0000|38 64|experimental mixed infections
P02194972T0000|69 88|Enterococcus faecalis
P02194972T0000|109 112|mice
P02195025T0000|0 9|Regulation
P02195025T0000|12 20|yeast LEU2
P02195715A0143|0 20|Homozygous individuals
P02195715A0143|35 50|purpura fulminans
P02195715A0143|53 60|newborns
P02195715A0143|62 102|heterozygous protein C-deficient individuals
P02195715A0143|124 139|venous thrombosis
P02195715A0143|143 159|pulmonary embolism
P02195715T0000|0 16|Ischemic stroke due
P02195715T0000|19 36|protein C deficiency
P02196176A0749|0 4|TREB7
P02196176A0749|8 13|TREB36
P02196176A0749|31 37|repeats
P02196176A0749|45 46|bp
P02196176A0749|51 55|TREB5
P02196176A0749|72 83|second repeat
P02196311A1034|5 11|results
P02196311A1034|24 29|KE X 3/W
P02196311A1034|38 51|optimal regimen
P02196311A1034|64 80|antitumor immunity
P02196311A1034|83 85|RNL
P02196450A0870|0 7|Analysis
P02196450A0870|10 31|various deletion mutants
P02196450A0870|48 67|sequence requirements
P02196450A0870|71 77|binding
P02196450A0870|80 82|QBP
P02196450A0870|93 109|indistinguishable
P02196450A0870|131 139|Q activity
P02196450A0870|169 171|QBP
P02196450A0870|202 225|TATA-independent promoter
P02196565A0606|5 28|general regulatory factor I
P02196565A0606|30 33|GRFI
P02196565A0606|36 72|repressor/activator site binding protein
P02196565A0606|75 105|RAP1)/translation upstream factor
P02196565A0606|75 78|RAP1
P02196565A0606|81 105|translation upstream factor
P02196565A0606|107 109|TUF
P02196565A0606|127 135|activator
P02196565A0606|138 155|MAT alpha expression
P02196565A0606|138 145|MAT alpha
P02196565A0606|174 177|PYK1
P02196565A0606|206 218|GRFI/RAP1/TUF
P02196565A0606|206 209|GRFI
P02196565A0606|211 214|RAP1
P02196565A0606|216 218|TUF
P02196565A0606|239 251|gal11 mutation
P02196565T0000|0 16|Yeast Gal11 protein
P02196565T0000|28 58|transcriptional activation signal
P02196565T0000|84 90|factors
P02196565T0000|92 95|Gal4
P02196565T0000|99 187|general regulatory factor I/repressor/activator site binding protein 1/translation upstream factor
P02198259A0685|0 7|Deletion
P02198259A0685|21 21|N
P02198259A0685|25 38|C-terminal ends
P02198259A0685|41 44|repA
P02198259A0685|53 58|codons
P02198259A0685|81 105|286-codon open reading frame
P02198259A0685|118 126|initiator
P02198259A0685|136 153|inhibitory activity
P02198289A0436|6 19|larger peptides
P02198289A0436|34 43|amino acids
P02198289A0436|70 79|amino acids
P02198289A0436|93 98|dimers
P02198289A0436|135 139|dimer
P02199311A0620|7 27|transcription extracts
P02199311A0620|32 42|ret1-1 cells
P02199311A0620|32 37|ret1-1
P02199311A0620|69 103|weak transcription termination signals
P02199311A0620|117 125|RET1 cells
P02199311A0620|117 120|RET1
P02199311A0620|142 154|tRNA templates
P02200150A1381|7 14|patients
P02200150A1381|42 62|multidisciplinary team
P02200150A1381|74 91|surgical oncologist
P02200150A1381|93 102|geneticist
P02200150A1381|104 114|pathologist
P02200150A1381|116 130|psychotherapist
P02200150A1381|134 147|plastic surgeon
P02200315A0278|0 2|IgG
P02200315A0278|6 24|IgM antibody activity
P02200315A0278|52 59|dilution
P02200315A0278|62 66|serum
P02200315A0278|69 74|plates
P02200315A0278|85 94|A60 antigen
P02200736A1003|5 11|factors
P02200736A1003|37 53|distinct molecules
P02200736A1003|64 67|AP-4
P02200736A1003|71 74|MLTF
P02200736A1003|89 101|CACCTGTC motif
P02200736A1003|104 119|related sequences
P02201770A0188|5 19|known flea larvae
P02201770A0188|24 41|genus Anomiopsyllus
P02201770A0188|43 57|Anomiopsyllinae
P02201770A0188|59 72|Anomiopsyllini
P02201770A0188|91 100|larval form
P02201770A0188|109 114|adults
P02201901A0229|15 30|specific antibody
P02201901A0229|59 69|SSN6 protein
P02201905A1004|5 17|latter results
P02201905A1004|31 41|ABFI protein
P02201905A1004|50 60|RAP1 protein
P02201905A1004|67 75|sequences
P02201905A1004|103 120|negative regulation
P02201905A1004|123 136|gene expression
P02202496T0000|0 16|Clinical nutrition
P02202496T0000|19 29|adult horses
P02203672A1542|3 35|computer-programmed cytocentrifuge
P02204029A0184|0 20|RNase protection assays
P02204029A0184|0 4|RNase
P02204029A0184|40 42|unr
P02204029A0184|62 74|same direction
P02204029A0184|77 81|N-ras
P02204029A0184|99 105|located
P02204029A0184|113 121|base pairs
P02204029A0184|145 162|N-ras transcription
P02204029A0184|145 149|N-ras
P02204621T0000|0 8|Isolation
P02204621T0000|12 38|temperature-sensitive mutant
P02204621T0000|45 77|altered tRNA nucleotidyltransferase
P02204621T0000|52 77|tRNA nucleotidyltransferase
P02204621T0000|81 87|cloning
P02204621T0000|105 130|tRNA nucleotidyltransferase
P02204621T0000|136 140|yeast
P02204623A0000|3 21|juxtamembrane region
P02204623A0000|27 41|insulin receptor
P02204623A0000|43 44|IR
P02204623A0000|46 57|beta-subunit
P02204623A0000|68 97|unphosphorylated tyrosyl residue
P02204623A0000|99 104|Tyr960
P02204623A0000|124 163|insulin-stimulated tyrosyl phosphorylation
P02204623A0000|124 130|insulin
P02204623A0000|170 189|endogenous substrates
P02204623A0000|193 218|certain biological responses
P02204623A0000|220 224|White
P02204623A0000|226 229|M.F.
P02204623A0000|231 240|Livingston
P02204623A0000|242 245|J.N.
P02204623A0000|247 252|Backer
P02204623A0000|254 257|J.M.
P02204623A0000|259 264|Lauris
P02204623A0000|266 267|V.
P02204623A0000|269 272|Dull
P02204623A0000|274 277|T.J.
P02204623A0000|279 285|Ullrich
P02204623A0000|287 288|A.
P02204623A0000|293 296|Kahn
P02204623A0000|298 301|C.R.
P02204625A1130|23 27|genes
P02204625A1130|33 39|members
P02204625A1130|73 79|insulin
P02204625A1130|83 95|other mitogens
P02204810A1080|12 14|GA2
P02204810A1080|30 46|maximal expression
P02206430A0197|0 3|Pups
P02206430A0197|17 32|novel environment
P02206430A0197|42 48|mothers
P02206430A0197|60 76|intermediate level
P02206430A0197|79 88|DA turnover
P02206789A0002|3 10|efficacy
P02206789A0002|23 61|novel percutaneous anaesthetic preparation
P02206789A0002|69 79|amethocaine
P02206789A0002|104 132|paediatric clinical environment
P02206858A0000|0 17|Homozygous protein C
P02206858A0000|22 31|deficiency
P02206858A0000|47 54|siblings
P02206858A0000|83 97|proper diagnoses
P02206858A0000|103 106|ages
P02206858A0000|122 126|years
P02208762A0228|20 32|granddaughter
P02208762A0228|40 47|microtia
P02208762A0228|51 63|meatal atresia
P02208762A0228|87 100|normal outer ear
P02208762A0228|111 122|narrow meatus
P02208762A0228|126 144|auricular appendages
P02209237A0239|0 29|Abnormal intrapulmonary shunting
P02209237A0239|31 33|IPS
P02209237A0239|53 57|cases
P02209237A0239|60 89|whole-body radionuclide scanning
P02209237A0239|94 102|99mTc-MAA
P02209237A0239|120 129|major cause
P02209237A0239|132 139|cyanosis
P02209237A0239|142 155|liver cirrhosis
P02209243A0237|3 16|urinary protein
P02209243A0237|18 29|serum albumin
P02209243A0237|31 33|BUN
P02209243A0237|37 39|SCr
P02209243A0237|50 71|significant improvement
P02209540A1362|14 17|Ets1
P02209540A1362|21 24|Ets2
P02209540A1362|38 50|transcription
P02209540A1362|53 65|cellular genes
P02209605A0510|21 28|MSAS gene
P02209605A0510|45 72|5322-bp-long open reading frame
P02209605A0510|96 105|amino acids
P02209605A0510|116 130|Da molecular mass
P02209811T0000|0 20|Horseradish peroxidase
P02209811T0000|24 41|permeability marker
P02209811T0000|44 59|injured rat caudal
P02209811T0000|63 75|iliac arteries
P02212540A0473|0 31|Standardized gastric wall specimens
P02212540A0473|58 63|ulcers
P02212540A0473|101 115|light microscopy
P02212540A0473|121 150|transmission electron microscopy
P02213566A0000|3 9|effects
P02213566A0000|12 22|coenzyme Q10
P02213566A0000|24 26|CoQ
P02213566A0000|31 39|captopril
P02213566A0000|42 59|functional capacity
P02213566A0000|61 72|hemodynamics
P02213566A0000|100 103|rats
P02213566A0000|122 153|experimental myocardial infarction
P02217307T0000|0 7|Evidence
P02217307T0000|12 33|therapeutic alterations
P02217307T0000|37 51|circadian rhythm
P02217307T0000|55 77|gastric emptying response
P02217741T0001|3 15|interrelation
P02217741T0001|21 26|levels
P02217741T0001|29 43|glucocorticoids
P02217741T0001|47 53|insulin
P02217741T0001|66 82|irradiated animals
P02218094A0395|33 34|Ft
P02218094A0395|40 52|mitochondrial
P02218094A0395|55 65|utilization
P02218094A0395|67 68|Fm
P02219751A0517|9 16|saccades
P02219751A0517|50 58|other FEMs
P02220102A0271|0 8|Incidence
P02220102A0271|33 64|oral hygiene und periodontal disease
P02220304A0501|26 30|Alcoy
P02220304A0501|34 51|medium MS risk region
P02220304A0501|66 71|thesis
P02220304A0501|74 79|Kurzke
P02220304A0501|89 99|high MS areas
P02220304A0501|129 142|MS distribution
P02220304A0501|145 158|southern Europe
P02223652A0939|4 24|antithrombin unit basis
P02223652A0939|26 27|CY
P02223652A0939|34 35|CY
P02223652A0939|60 65|potent
P02223652A0939|70 71|UH
P02223773A0000|0 34|Chick brain actin depolymerizing factor
P02223773A0000|36 38|ADF
P02223773A0000|43 55|19-kDa protein
P02223773A0000|66 79|actin filaments
P02223773A0000|88 100|actin monomers
P02223928T0069|0 16|Initial experience
P02223928T0069|22 37|serotonin agonist
P02225687A0546|0 16|Comprehensive care
P02225687A0546|39 52|human teratogen
P02225687A0546|79 106|prenatal diagnostic procedures
P02225687A0546|110 140|other pregnancy management options
P02227438A0492|0 22|Primer extension analysis
P02227438A0492|26 38|RNA sequencing
P02227438A0492|58 80|transcription start point
P02227438A0492|83 92|rat ODC mRNA
P02227438A0492|95 101|located
P02227438A0492|105 106|nt
P02227438A0492|122 129|A residue
P02227438A0492|135 144|start codon
P02228615A0974|3 6|85Sr
P02228615A0974|8 51|larger-than-expected distribution coefficients
P02228615A0974|69 89|desorption experiments
P02228615A0974|108 128|irreversible formation
P02228615A0974|131 149|metal-oxyhydroxides
P02228615A0974|157 168|slow reaction
P02229068A0156|0 13|Gene constructs
P02229068A0156|27 37|complete tat
P02229068A0156|35 37|tat
P02229068A0156|39 41|rev
P02229068A0156|43 45|tat
P02229068A0156|47 49|rev
P02229068A0156|55 62|env genes
P02229068A0156|89 98|COS-1 cells
P02229068A0156|101 114|precursor SU-TM
P02229068A0156|116 120|gp160
P02229068A0156|123 127|SU.TM
P02229068A0156|123 124|SU
P02229068A0156|126 127|TM
P02229068A0156|129 134|gp120 x
P02229068A0156|142 160|nucleolar rev protein
P02229072A1012|4 15|growth arrest
P02229072A1012|36 48|minimal medium
P02229072A1012|56 65|conditions
P02229072A1012|76 80|cells
P02229072A1012|99 121|mitochondrial metabolism
P02229282A0454|0 7|Patients
P02229282A0454|12 35|detectable serum TNF levels
P02229282A0454|27 29|TNF
P02229282A0454|52 77|lower serum T3 concentrations
P02229282A0454|97 114|undetectable levels
P02229541T0000|0 4|Giant
P02229541T0000|15 23|carcinoma
P02231162T0000|0 13|Further studies
P02231162T0000|16 33|mandibular movement
P02231162T0000|36 54|initial tooth contact
P02231479A0585|33 45|5-year-old son
P02231479A0585|67 79|conversations
P02231479A0585|82 93|unstructured
P02231479A0585|95 112|social conversation
P02231479A0585|128 139|task activity
P02233626T0000|0 39|Droperidol-induced extrapyramidal symptoms
P02233626T0000|63 79|strabismus surgery
P02233680A1115|5 11|results
P02233680A1115|27 48|cis-regulatory elements
P02233680A1115|60 79|developmental control
P02233680A1115|85 106|HaG3-A helianthinin gene
P02233680A1115|110 116|located
P02233680A1115|123 138|kb upstream region
P02233715A0914|3 11|induction
P02233715A0914|14 30|pseudorabies virus
P02233715A0914|35 47|IL-6 construct
P02233715A0914|61 71|IL-6 TATA box
P02233715A0914|78 89|RNA start site
P02233715A0914|92 100|initiator
P02233715A0914|104 113|Inr element
P02233715A0914|124 132|MRE region
P02233715A0914|151 153|Dex
P02233715A0914|169 179|wild-type GR
P02233729A1065|4 12|mutations
P02233729A1065|21 24|Dhfr
P02233729A1065|28 44|qualitative manner
P02233729A1065|65 74|startpoint
P02233729A1065|85 104|major Dhfr transcripts
P02233729A1065|90 104|Dhfr transcripts
P02233729A1065|118 134|relative abundance
P02233729A1065|143 162|major Dhfr transcripts
P02233729A1065|148 162|Dhfr transcripts
P02234345A0215|3 15|glial cyst wall
P02234345A0215|43 60|cuboidal epithelium
P02234731A0503|20 34|cytologic smears
P02234731A0503|49 66|severe inflammation
P02234731A0503|86 93|findings
P02234731A0503|96 106|condylomata
P02234731A0503|110 126|cervical dysplasia
P02236002A0958|4 10|mammals
P02236002A0958|12 42|considerable nucleotide diversity
P02236002A0958|59 67|junctions
P02236002A0958|102 109|elements
P02236002A0958|112 130|chicken TCR beta cDNAs
P02236022A0000|3 20|protooncogene c-myb
P02236022A0000|16 20|c-myb
P02236022A0000|29 54|nuclear transcription factor
P02236022A0000|72 94|sequence-specific manner
P02236022A0000|112 124|transcription
P02236022A0000|127 138|several viral
P02236022A0000|142 154|cellular genes
P02236060A1671|0 11|Modification
P02236060A1671|18 31|latter compound
P02236060A1671|61 101|membrane-associated N-myristoylated protein
P02236064A1178|0 17|S6 kinase activation
P02236064A1178|0 7|S6 kinase
P02236064A1178|26 37|displacement
P02236064A1178|44 60|inhibitory segment
P02236064A1178|84 93|consequent
P02236064A1178|99 121|multiple phosphorylation
P02236276T0000|0 3|Rats
P02236276T0000|11 23|olfactory bulb
P02236276T0000|37 54|contralateral naris
P02236276T0000|70 74|odors
P02237431A0000|0 9|Expression
P02237431A0000|15 32|human T cell receptor
P02237431A0000|34 46|TCR) alpha gene
P02237431A0000|34 36|TCR
P02237431A0000|38 46|alpha gene
P02237431A0000|61 97|T cell-specific transcriptional enhancer
P02237431A0000|104 110|located
P02237431A0000|114 122|kilobases
P02237431A0000|124 125|kb
P02237431A0000|134 150|C alpha gene segment
P02237431A0833|3 18|Ets-1 binding site
P02237431A0833|22 30|localized
P02237431A0833|34 44|17-base pair
P02237431A0833|46 47|bp
P02237431A0833|69 75|T alpha 2
P02237431A0833|69 74|T alpha
P02241742A0766|0 11|Cerebral flow
P02241742A0766|31 45|minor reductions
P02241742A0766|50 51|HD
P02241892A0681|0 10|Utilization
P02241892A0681|13 45|alternative polyadenylation signals
P02241892A0681|77 92|sialophorin mRNAs
P02241892A0681|104 105|kb
P02241892A0681|138 156|untranslated regions
P02242222T0000|0 18|Presidential address
P02243093A0000|0 28|Human T-cell leukemia virus type I
P02243093A0000|0 27|Human T-cell leukemia virus type
P02243093A0000|30 35|HTLV-I
P02243093A0000|45 64|40-kDa nuclear protein
P02243093A0000|66 68|Tax
P02243093A0000|85 97|transcription
P02243093A0000|107 117|21-base pair
P02243093A0000|119 120|bp
P02243093A0000|122 128|repeats
P02243093A0000|134 141|U3 region
P02243386A0113|27 49|serial undiluted passages
P02243386A0113|52 54|MHV
P02243386A0113|57 66|small DI RNA
P02243386A0113|68 72|DIssF
P02243386A0113|104 110|virions
P02246362T0000|3 23|Jenkins Activity Survey
P02246362T0000|30 40|CPI-revised
P02246362T0000|42 56|further evidence
P02246362T0000|59 66|adaptive
P02246362T0000|70 84|maladaptive type
P02246362T0000|86 91|traits
P02246447A0460|28 43|regression slopes
P02246447A0460|70 81|portion sizes
P02246447A0460|93 102|food groups
P02246447A0460|112 119|r2 values
P02246447A0460|134 145|portion sizes
P02246803A0692|25 45|non-invasive TTD method
P02246803A0692|87 113|intraoperative cardiac output
P02247069A0261|3 10|TUP1 gene
P02247069A0261|34 38|genes
P02247069A0261|51 60|mating type
P02247069A0261|62 65|V.L.
P02247072A0794|3 25|SUP44 suppressor mutation
P02247072A0794|75 88|known positions
P02247072A0794|91 101|alterations
P02247072A0794|112 123|ram mutations
P02247081A0223|14 23|disruption
P02247081A0223|29 38|VPS34 locus
P02247081A0223|50 82|temperature-sensitive growth defect
P02247081A0223|101 109|VPS34 gene
P02247081A0223|124 139|vegetative growth
P02247081A0223|146 171|elevated growth temperatures
P02247924A0078|18 35|perinephric abscess
P02247924A0078|47 59|amphotericin B
P02247924A0078|63 73|nephrectomy
P02248732A1113|36 46|haloperidol
P02248732A1113|61 75|minimal increase
P02248732A1113|81 90|firing rate
P02248732A1113|93 99|LC cells
P02248732A1113|105 105|%
P02248732A1113|142 149|turnover
P02248732A1113|152 153|NA
P02248732A1113|167 178|DOPAC changes
P02249872A1051|26 34|wide range
P02249872A1051|41 50|parameters
P02249872A1051|55 67|charge density
P02249872A1051|86 95|microC/cm2
P02249872A1051|138 143|microC
P02250919A0404|0 10|Perceptions
P02250919A0404|13 32|illness intrusiveness
P02250919A0404|50 55|higher
P02250919A0404|64 74|muscle cramp
P02250919A0404|78 93|headache symptoms
P02250919A0404|113 135|more assessment intervals
P02250919A0404|152 163|muscle cramps
P02250919A0404|166 174|headaches
P02251119A0319|0 6|Results
P02251119A0319|49 74|U14 snRNA-homologous regions
P02251119A0319|91 97|introns
P02251119A0319|111 140|mouse cognate hsc70 heat shock gene
P02251119A0319|123 127|hsc70
P02252891T0000|0 19|65-kilodalton protein
P02252891T0000|36 47|interleukin 2
P02252891T0000|36 46|interleukin
P02252891T0000|48 58|stimulation
P02252891T0000|67 92|putative actin-binding sites
P02252891T0000|75 92|actin-binding sites
P02252891T0000|99 118|calcium-binding sites
P02252953A0300|9 23|restrained girls
P02252953A0300|41 54|higher EAT score
P02252953A0300|62 80|low-restrained girls
P02252953A0300|100 106|mothers
P02252953A0300|108 121|susceptibility
P02252953A0300|127 146|disinhibitory effects
P02252953A0300|149 166|negative mood states
P02252953A0300|174 188|eating behaviour
P02253274A0000|3 14|Mauriceville
P02253274A0000|18 44|Varkud mitochondrial plasmids
P02253274A0000|63 81|closed-circular DNAs
P02253274A0000|92 93|kb
P02253274A0000|116 130|characteristics
P02253274A0000|133 144|mtDNA introns
P02253274A0000|148 162|retroid elements
P02253663A0687|3 17|circadian rhythm
P02253663A0687|77 77|h
P02253663A0687|95 95|h
P02253663A0687|97 115|serum concentrations
P02253663A0687|123 123|%
P02254282T0000|0 7|Sequence
P02254282T0000|11 29|genetic organization
P02254282T0000|33 59|Zymomonas mobilis gene cluster
P02254282T0000|71 84|several enzymes
P02254282T0000|87 103|glucose metabolism
P02254418A0641|0 10|Most strains
P02254418A0641|14 14|%
P02254418A0641|18 30|S. lugdunensis
P02254418A0641|40 53|delta hemolysin
P02254418A0641|74 85|other species
P02254418A0641|88 90|CNS
P02254749A0133|8 12|cDNAs
P02254749A0133|26 28|60K
P02254749A0133|30 32|87K
P02254749A0133|34 37|110K
P02254749A0133|41 51|170K protein
P02254749A0133|58 66|sequences
P02254749A0133|89 101|ATG start codon
P02254749A0133|108 111|cDNA
P02254749A0133|125 127|60K
P02254749A0133|147 149|TAA
P02254749A0133|154 158|codon
P02256678A1224|9 41|complementary footprinting analysis
P02256678A1224|47 60|upstream region
P02256678A1224|89 97|HSC82 gene
P02256678A1224|123 146|discrete protein complexes
P02257251T0000|0 14|Pathophysiology
P02257251T0000|17 24|bone loss
P02257251T0000|27 42|castrated animals
P02257899T0000|0 25|Auditory-visual interaction
P02257899T0000|43 50|saccades
P02258918A0242|24 29|slices
P02258918A0242|40 55|primary disectors
P02258918A0242|86 106|known sampling fraction
P02259334A0205|3 18|upstream promoter
P02259334A0205|21 27|located
P02259334A0205|54 66|divergent gene
P02259334A0205|91 93|kDa
P02259334A0205|96 110|unknown function
P02259795A0570|55 66|calculations
P02259795A0570|81 88|water PO2
P02259795A0570|100 103|mm Hg
P02259795A0570|113 113|%
P02259795A0570|116 129|total cutaneous
P02259795A0570|132 137|uptake
P02261254A0168|0 10|Experiments
P02261254A0168|21 35|temporary arrest
P02261254A0168|38 57|pulmonary circulation
P02261254A0168|63 72|conditions
P02261254A0168|75 99|extracorporeal circulation
P02261254A0168|128 135|ischemia
P02261254A0168|141 166|respiratory pulmonary tissue
P02262439A0508|0 10|MCh infusion
P02262439A0508|18 48|concentration-dependent increase
P02262439A0508|51 66|airway resistance
P02262439A0508|69 79|constant QBA
P02264601A0000|0 19|Taste reactivity tests
P02264601A0000|40 57|orofacial responses
P02264601A0000|78 78|P
P02264601A0000|80 83|rats
P02264601A0000|87 106|alcohol nonpreferring
P02264601A0000|108 109|NP
P02264601A0000|111 114|rats
P02265055A0417|0 19|Plasma concentrations
P02265055A0417|22 31|atracurium
P02265055A0417|35 45|laudanosine
P02265055A0417|59 72|micrograms ml-1
P02265055A0417|85 98|micrograms ml-1
P02265055A0417|113 128|CSF concentration
P02265055A0417|131 141|laudanosine
P02265055A0417|151 156|ng ml-1
P02266679A0740|0 7|Plasma Al
P02266679A0740|29 36|baseline
P02266679A0740|40 49|drug course
P02268461A0224|27 34|patients
P02268461A0224|49 53|years
P02269281A1276|3 12|occurrence
P02269281A1276|28 46|possible involvement
P02269281A1276|62 70|sequences
P02269281A1276|88 112|stable secondary structures
P02269281A1276|164 177|control signals
P02269426A0428|0 2|IST
P02269426A0428|11 19|RNA target
P02269426A0428|21 23|TAR
P02269426A0428|28 46|Tat trans-activation
P02269426A0428|28 30|Tat
P02269426A0428|81 95|cellular factors
P02269426A0428|108 110|IST
P02269426A0428|128 145|abundant RNA targets
P02269426A0428|149 167|Tat trans-activation
P02269426A0428|149 151|Tat
P02269426A0428|190 219|full-length viral mRNA expression
P02269426A0428|190 209|full-length viral mRNA
P02270096T0000|0 16|Genotoxic activity
P02270096T0000|20 46|tobacco-specific nitrosamine
P02270587A0000|3 25|endodontal treatment need
P02270587A0000|41 53|clinical order
P02270834A0123|3 12|long method
P02270834A0123|21 29|HML method
P02272095A0832|5 11|results
P02272095A0832|35 55|peripheral enkephalins
P02272095A0832|58 71|pain modulation
P02272095A0832|74 81|patients
P02272095A0832|86 108|episodic cluster headache
P02273690T0001|0 6|Effects
P02273690T0001|9 17|cisapride
P02273690T0001|20 49|upper-gastrointestinal motility
P02273690T0001|53 69|digestive hormones
P02274343A0064|0 20|Common foot pathologies
P02274343A0064|24 31|heel pain
P02274343A0064|33 45|metatarsalgia
P02274343A0064|47 56|hammertoes
P02274343A0064|60 67|clawtoes
P02274343A0064|69 75|bunions
P02274343A0064|77 89|hallux rigidus
P02274343A0064|91 95|corns
P02274343A0064|99 106|calluses
P02274343A0064|108 122|nail pathologies
P02274343A0064|124 132|arthritis
P02274343A0064|137 148|neuropathies
P02274509A0623|0 15|Liver dysfunction
P02274509A0623|31 55|different adverse reactions
P02274509A0623|70 83|higher activity
P02274509A0623|89 98|blood serum
P02274509A0623|101 121|indicator liver enzymes
P02274509A0623|128 158|impaired protein-forming function
P02276891T0000|0 10|Coenzyme Q10
P02276891T0000|12 22|blood levels
P02276891T0000|26 40|metabolic demand
P02277005A0227|3 19|CT characteristics
P02277005A0227|38 53|recent literature
P02277319A0211|19 31|preservatives
P02277319A0211|52 72|microbiological assays
P02277319A0211|88 103|product sterility
P02277319A0211|106 120|bioburden levels
P02277452A0116|4 11|patients
P02277452A0116|16 29|angina pectoris
P02277452A0116|34 40|changes
P02277452A0116|43 46|LVEF
P02277452A0116|48 52|LVESV
P02277452A0116|56 64|PSP/LVESV
P02277452A0116|88 96|detection
P02277452A0116|99 122|exercise-induced ischemia
P02277452A0116|142 150|chest pain
P02277452A0116|157 163|changes
P02277452A0116|166 168|ECG
P02278217A0372|6 11|groups
P02278217A0372|22 38|management failure
P02278217A0372|55 75|alternative medication
P02278217A0372|79 97|cesarean section lead
P02278474A0000|0 29|Serum Fibrin Degradation Products
P02278474A0000|5 29|Fibrin Degradation Products
P02278474A0000|31 33|FDP
P02278474A0000|53 70|oral cancer patients
P02278474A0000|76 92|normal individuals
P02280777T0000|3 21|uteroglobin promoter
P02280777T0000|31 67|noncanonical estrogen responsive element
P02281118A1191|0 31|Prostaglandin synthesis inhibitors
P02281118A1191|52 58|healing
P02281118A1191|80 90|limitations
P02281118A1191|117 126|situations
P02281330A0556|3 32|inspiratory oxygen concentration
P02281330A0556|40 43|FiO2
P02281330A0556|51 66|Horowitz quotient
P02281330A0556|84 100|significant manner
P02281330A0556|115 120|1st day
P02281948A0245|10 28|mineral oil emulsions
P02281948A0245|59 71|less effective
P02281948A0245|76 82|sucrose
P02281948A0245|87 87|M
P02281948A0245|102 110|ingestion
P02282815T0000|0 11|Significance
P02282815T0000|14 44|thin glomerular basement membranes
P02282815T0000|47 63|hematuric children
P02283148T0000|0 11|Significance
P02283148T0000|14 31|cytokine production
P02283148T0000|35 51|adhesion molecules
P02283148T0000|54 76|malarial immunopathology
P02283378A0385|3 17|former procedure
P02283378A0385|20 29|economical
P02283378A0385|72 84|labour-saving
P02283378A0385|90 115|special ultrafiltration tube
P02283378T0000|0 11|Simple method
P02283378T0000|33 52|cephalosporin DQ-2556
P02283378T0000|55 70|biological fluids
P02283378T0000|73 108|high-performance liquid chromatography
P02283873A0308|15 25|adolescents
P02283873A0308|63 74|parents smoke
P02283873A0308|76 94|parental involvement
P02283873A0308|97 113|smoking prevention
P02283873A0308|120 135|powerful enhancer
P02284393A0751|0 14|Further research
P02284393A0751|41 52|coping styles
P02284393A0751|70 103|high EE/low EE research classification
P02284573A0943|14 17|MoAB
P02284573A0943|25 32|BAL fluid
P02284573A0943|68 92|silver methenamine staining
P02284573A0943|95 97|BAL
P02284573A0943|99 101|TBB
P02284573A0943|105 120|brushing material
P02287860T0001|0 14|Ultrastructural
P02287860T0001|18 34|morphometric study
P02287860T0001|40 61|myeloid parenchyma cells
P02287860T0001|64 67|mice
P02287860T0001|81 93|X-ray exposure
P02289102A0114|7 23|audiotape cassette
P02289102A0114|27 36|headphones
P02289102A0114|40 47|duration
P02289102A0114|53 66|hallucinations
P02289639A0989|3 12|mean change
P02289639A0989|15 18|HbA1
P02289639A0989|34 45|initial value
P02289639A0989|54 54|%
P02289639A0989|79 79|%
P02289639A0989|85 96|control group
P02289639A0989|98 102|p less
P02290216T0001|0 5|Effect
P02290216T0001|8 25|biliary obstruction
P02290216T0001|29 39|cholangitis
P02290216T0001|42 57|serum SPan-1 level
P02291144A0493|4 15|good accuracy
P02291144A0493|17 24|r greater
P02291144A0493|60 60|H
P02291144A0493|70 81|other machine
P02291144A0493|88 103|reference methods
P02291144A0493|114 118|MCHCH
P02291144A0493|122 134|basophil count
P02291628A0264|3 12|second part
P02291628A0264|33 51|medical applications
P02291628A0264|62 68|aspects
P02291628A0264|71 73|NMR
P02291628A0264|89 96|examples
P02291628A0264|151 163|endocrinology
P02292272T0000|0 20|Interlimb coordination
P02292272T0000|27 43|fictive locomotion
P02292272T0000|49 59|thalamic cat
P02293019A0000|0 18|Antileukoproteinase
P02293019A0000|20 22|ALP
P02293019A0000|27 57|low mol wt mucosal secretory protein
P02293019A0000|66 77|human tissues
P02293019A0000|90 99|activities
P02293019A0000|105 145|neutral serine lysosomal proteinases elastase
P02293019A0000|112 145|serine lysosomal proteinases elastase
P02293019A0000|149 159|cathepsin-G
P02293664A0946|22 30|deletions
P02293664A0946|36 51|vimentin promoter
P02293664A0946|36 43|vimentin
P02293664A0946|75 83|sequences
P02293664A0946|88 96|base pairs
P02293664A0946|98 104|located
P02293664A0946|121 137|base pairs upstream
P02293664A0946|143 153|mRNA cap site
P02294048A0881|20 49|% amino acid sequence similarities
P02294048A0881|68 72|hsp70
P02294048A0881|93 110|Bacillus megaterium
P02295521A0922|2 16|causal relations
P02295521A0922|65 81|trapezius activity
P02295521A0922|85 94|complaints
P02295521A0922|128 160|inexpedient muscle activity patterns
P02295521A0922|176 194|important risk factor
P02295521A0922|211 236|musculo-skeletal complaints
P02296509A0997|18 33|household members
P02296509A0997|38 57|anti-HIV seronegative
P02296509A0997|81 103|serum p24 antigen negative
P02298741A0809|0 7|Analysis
P02298741A0809|12 51|additional anti-peptide antibodies specific
P02298741A0809|55 59|alpha
P02298741A0809|61 64|beta
P02298741A0809|68 75|gamma PKC
P02298741A0809|97 101|types
P02298741A0809|104 106|PKC
P02298741A0809|121 127|JK cells
P02298741A0809|137 145|JKPE cells
P02298741A0809|171 213|kDa immunoreactive cytosolic protein detectable
P02298741A0809|218 238|anti-PKC alpha antibody
P02299543A0317|36 49|present outlook
P02300541A0000|14 20|effects
P02300541A0000|26 41|pulmonary barrier
P02300541A0000|44 69|several surface active agents
P02300541A0000|80 98|metered dose inhalers
P02300541A0000|100 103|MDIs
P02300541A0000|125 149|dose aerosolized surfactant
P02300541A0000|155 161|airways
P02300541A0000|172 187|perfused rat lungs
P02300577A0852|3 11|beta chain
P02300577A0852|24 58|potential N-linked glycosylation sites
P02300577A0852|63 86|endoglycosidase digestion
P02300577A0852|63 77|endoglycosidase
P02300577A0852|103 111|beta chain
P02300577A0852|121 157|multiple complex carbohydrate side chains
P02300759A0000|3 22|therapeutic protocole
P02300759A0000|32 53|Gustave Roussy Institute
P02300759A0000|57 75|invasive epithelioma
P02300759A0000|81 93|uterine cervix
P02300759A0000|103 114|limited forms
P02300759A0000|116 129|T1B-T2 proximal
P02300759A0000|142 150|radiology
P02303158T0000|0 28|Thyrotropin-induced expression
P02303158T0000|0 10|Thyrotropin
P02303158T0000|40 55|ribosomal protein
P02303158T0000|68 78|trk oncogene
P02303470A0242|3 9|introns
P02303470A0242|20 22|kbp
P02303874A1643|7 28|initial titration period
P02303874A1643|47 61|therapeutic dose
P02303874A1643|66 80|individual doses
P02303874A1643|96 111|micrograms/24 hrs
P02303874A1643|120 135|micrograms/24 hrs
P02305014A0226|5 15|first series
P02305014A0226|18 28|experiments
P02305014A0226|30 51|Sprague-Dawley male rats
P02305014A0226|81 93|guide cannulas
P02305014A0226|104 119|lateral ventricle
P02306539T0000|0 2|Use
P02306539T0000|5 28|Selenastrum capricornutum
P02306539T0000|32 41|Microfeast
P02306539T0000|51 62|Daphnia pulex
P02307067A1348|3 13|persistence
P02307067A1348|16 22|members
P02307067A1348|28 55|prostigmatid families Tydeidae
P02307067A1348|57 70|Nanorchestidae
P02307067A1348|74 85|Tarsonemidae
P02307067A1348|91 108|moisture-deficient
P02307067A1348|111 111|%
P02307067A1348|113 135|concentration treatments
P02307067A1348|144 159|previous evidence
P02307067A1348|162 172|adaptations
P02307067A1348|175 199|low-water-content habitats
P02307371A0263|11 30|mechanism responsible
P02307371A0263|43 73|transcription elongation blockage
P02307371A0263|86 102|c-myc deregulation
P02307371A0263|86 90|c-myc
P02307371A0263|105 111|Burkitt
P02307371A0263|114 121|lymphoma
P02307371A0263|133 153|transcription patterns
P02307371A0263|178 184|Burkitt
P02307371A0263|187 206|lymphoma c-myc alleles
P02307371A0263|195 206|c-myc alleles
P02307371A0263|211 221|murine cells
P02307371A0263|225 253|Xenopus oocyte germinal vesicles
P02307613A0783|0 37|Erythrocyte protoporphyrin concentration
P02307613A0783|61 65|P less
P02307613A0783|79 82|days
P02307613A0783|85 88|dogs
P02307613A0783|95 103|basal diet
P02307613A0783|129 140|high relative
P02307613A0783|149 152|dogs
P02307613A0783|158 175|other dietary groups
P02307613A0783|182 190|remainder
P02307848A0347|9 17|sequences
P02307848A0347|23 30|Crry gene
P02307848A0347|46 47|kb
P02307848A0347|64 79|Crry-ps sequences
P02307848A0347|98 123|single 5.6-kb Eco-R1 fragment
P02307848T0042|3 9|genomic
P02307848T0042|13 37|transcriptional complexity
P02307848T0042|43 46|Crry
P02307848T0042|50 61|Crry-ps genes
P02307850A0000|6 29|RNK-16 lambda-gt11 library
P02307850A0000|58 83|novel cDNA rat NK cell protease
P02307850A0000|70 84|NK cell protease 1
P02307850A0000|86 91|RNKP-1
P02307850A0000|100 120|characteristics unique
P02307850A0000|123 137|serine proteases
P02307850A1197|3 11|induction
P02307850A1197|14 29|RNKP-1 expression
P02307850A1197|14 19|RNKP-1
P02307850A1197|35 58|Con A-cultured spleen cells
P02307850A1197|74 82|increases
P02307850A1197|89 90|NK
P02307850A1197|94 139|lymphokine-activated killer lymphocyte activities
P02308496A0000|43 52|blood level
P02308496A0000|55 58|ACTH
P02308496A0000|60 62|STH
P02308496A0000|64 66|TSH
P02308496A0000|68 75|cortisol
P02308496A0000|77 78|T3
P02308496A0000|80 86|insulin
P02308496A0000|88 96|C-peptide
P02308496A0000|104 119|25-minute session
P02308496A0000|122 132|respiration
P02308496A0000|139 159|gaseous hypoxic mixture
P02308496A0000|166 172|% oxygen
P02308496A0000|174 179|GHM-10
P02310261A0115|3 9|abscess
P02310261A0115|27 32|septum
P02310261A0115|48 58|single layer
P02310261A0115|61 81|autologous pericardium
P02310300A0298|4 16|% lymphography
P02310300A0298|38 47|CT negative
P02310350A0221|3 14|present study
P02310350A0221|52 59|polarity
P02310350A0221|65 79|spectral content
P02310350A0221|82 85|ABRs
P02310350A0221|90 111|normal-hearing subjects
P02310496X0000|0 23|Similar memory impairments
P02310496X0000|31 63|medial septal-vertical diagonal band
P02310496X0000|66 70|Broca
P02310496X0000|74 87|nucleus basalis
P02310496X0000|96 99|rats
P02310496X0000|104 116|memory defects
P02310496X0000|126 146|nucleus basalis lesions
P02310496X0000|167 197|non-specific subcortical cell loss
P02310496X0000|212 225|nucleus basalis
P02310496X0000|227 228|NB
P02310496X0000|233 265|medial septal-vertical diagonal band
P02310496X0000|268 272|Broca
P02310496X0000|274 280|MS-VDBB
P02310496X0000|285 303|place navigation task
P02310496X0000|313 327|reference memory
P02311544A0086|0 6|Studies
P02311544A0086|47 54|MSMR cyst
P02311544A0086|58 69|certain signs
P02311544A0086|72 79|symptoms
P02312470A0774|3 31|BAL-to-plasma specific activity
P02312470A0774|34 37|urea
P02312470A0774|57 58|Na
P02312470A0774|75 78|urea
P02312470A0774|94 96|ELF
P02312470A0774|112 113|Na
P02312470A0774|126 126|s
P02312470A0774|155 169|radioactive urea
P02312470A0774|173 174|Na
P02312470A0774|195 205|circulation
P02312470A0774|220 225|lavage
P02312689A0360|3 18|kappa coefficient
P02312689A0360|40 49|Patho Dx Kit
P02312689A0360|56 69|standard method
P02315151T0020|0 12|Senior systems
P02315151T0020|18 29|Mental health
P02315151T0020|42 47|old age
P02315472A0583|17 27|imaging time
P02315472A0583|32 41|parameters
P02315472A0583|58 63|higher
P02315472A0583|68 71|RASE
P02315472A0583|78 80|C/A
P02315472A0583|84 91|unit time
P02315472A0583|102 108|% higher
P02317413A0364|0 7|Patients
P02317413A0364|12 36|acute myocardial infarction
P02317413A0364|40 65|higher plasma concentrations
P02317413A0364|68 85|neutrophil elastase
P02317413A0364|92 108|non-peroxide diene
P02317413A0364|119 124|isomer
P02317413A0364|127 138|linoleic acid
P02317413A0364|143 158|normal volunteers
P02317413A0364|161 168|patients
P02317413A0364|173 199|stable ischaemic heart disease
P02317554T0000|0 12|Determination
P02317554T0000|15 48|three-dimensional imaging properties
P02317554T0000|52 72|light microscope system
P02318208A0817|3 19|cis-acting element
P02318208A0817|33 43|CACGTGACCCG
P02318208A0817|47 53|located
P02318208A0817|56 57|bp
P02318208A0817|73 99|transcription initiation site
P02318208A0817|115 126|core sequence
P02318208A0817|132 155|upstream promoter sequence
P02318208A0817|158 163|Ad2MLP
P02319610A1527|3 19|clinical relevance
P02319610A1527|27 34|findings
P02319610A1527|69 82|similar results
P02319610A1527|99 103|P.HCl
P02319610A1527|117 132|intravenous route
P02320008A0651|0 5|TMBr-1
P02320008A0651|19 49|striated muscle alpha-tropomyosin
P02320008A0651|54 63|amino acids
P02320008A0651|87 110|novel COOH-terminal region
P02320008A0651|115 124|amino acids
P02320999A0606|33 41|materials
P02320999A0606|43 55|particle board
P02320999A0606|67 77|gypsum board
P02320999A0606|82 90|wallpaper
P02320999A0606|95 101|plywood
P02320999A0606|106 124|polyurethane lacquer
P02320999A0606|137 163|steady-state emission factors
P02320999A0606|165 172|mg m-2 h-1
P02320999A0606|167 172|m-2 h-1
P02320999A0606|176 191|several compounds
P02322535A0658|0 5|Intron
P02322535A0658|12 13|kb
P02322535A0658|25 36|minimal sizes
P02322535A0658|39 45|introns
P02322535A0658|69 70|kb
P02323517A0557|6 6|h
P02323517A0557|8 14|lesions
P02323517A0557|20 32|secretory part
P02323517A0557|58 88|mucosal prostaglandin E2 synthesis
P02323517A0557|113 144|prostaglandin generation technique
P02324102A1157|0 9|Comparison
P02324102A1157|12 24|transmembrane
P02324102A1157|28 45|cytoplasmic domains
P02324102A1157|49 77|third cell-surface proteoglycan
P02324102A1157|79 82|48K5
P02324102A1157|87 106|human lung fibroblasts
P02324102A1157|108 114|Marynen
P02324102A1157|116 117|P.
P02324102A1157|119 123|Zhang
P02324102A1157|125 126|J.
P02324102A1157|128 135|Cassiman
P02324102A1157|137 138|J.
P02324102A1157|140 151|Vanden Berghe
P02324102A1157|153 154|H.
P02324102A1157|159 163|David
P02324102A1157|165 166|C.
P02324104A0151|15 15|%
P02324104A0151|21 65|total cAMP-dependent phosphotransferase activity
P02324104A0151|26 57|cAMP-dependent phosphotransferase
P02324104A0151|79 98|particulate fractions
P02324104A0151|101 111|homogenates
P02324104A0151|124 146|asynchronous populations
P02324104A0151|149 157|C. elegans
P02324104A0516|0 9|High levels
P02324104A0516|12 20|C subunits
P02324104A0516|34 56|several subsequent larval
P02324104A0516|60 70|adult stages
P02324104A0929|8 20|novel C subunit
P02324104A0929|13 20|C subunit
P02324104A0929|22 31|CeCAT alpha
P02324104A0929|37 44|residues
P02324104A0929|50 88|unique 56-residue carboxyl-terminal region
P02324104A0929|109 127|alternative splicing
P02324104A0929|133 141|C pre-mRNA
P02324104A1195|3 17|alternative exon
P02324104A1195|31 51|novel carboxyl terminus
P02324104A1195|56 79|new translation stop signal
P02324104A1195|132 156|carboxyl-terminal residues
P02324104A1195|159 168|CeCAT alpha
P02324104A1195|176 198|untranslated nucleotides
P02325208A0209|7 8|M.
P02325895T0000b|19 42|mechanoreceptor discharge
P02325895T0000b|56 67|dynamic force
P02325895T0000b|74 92|dynamic displacement
P02325895T0000b|95 106|glabrous skin
P02325895T0000b|109 115|raccoon
P02325895T0000b|119 136|squirrel monkey hand
P02326716A0139|0 6|Methods
P02326716A0139|18 26|Cobb angle
P02326716A0139|31 49|segmental evaluation
P02326716A0139|51 56|T7-T12
P02326716A0139|66 71|convex
P02326716A0139|75 99|concave rib-vertebra angles
P02326716A0139|101 104|RVAs
P02326716A0139|107 134|rib-vertebra angle differences
P02326716A0139|136 140|RVADs
P02326716A0139|143 159|vertebral rotation
P02326716A0139|161 164|tilt
P02326716A0139|168 179|displacement
P02326946T0000|0 40|Plasma lecithin/cholesterol acyltransferase
P02326946T0000|15 40|cholesterol acyltransferase
P02326946T0000|42 45|LCAT
P02326946T0000|57 76|multiple-organ donors
P02326946T0000|79 87|predictor
P02326946T0000|90 107|allograft viability
P02326946T0000|110 137|clinical liver transplantation
P02327159T0001|0 3|Lars
P02327159T0001|18 30|dignified life
P02328328A0419|0 18|Axillary nodal status
P02328328A0419|20 51|tumour progesterone receptor status
P02328328A0419|64 78|tumour detection
P02328328A0419|116 120|older
P02328328A0419|122 128|greater
P02328328A0419|135 137|yrs
P02328328A0419|142 148|younger
P02328328A0419|160 162|yrs
P02328328A0419|164 171|patients
P02329840A0383|21 35|microelectrodes
P02329840A0383|60 75|transient changes
P02329840A0383|78 84|retinal
P02329840A0383|86 86|K
P02329840A0383|89 89|o
P02330041A0335|0 9|Expression
P02330041A0335|11 30|cellular localization
P02330041A0335|41 60|transcription studies
P02330041A0335|74 83|cloned hUBF
P02330041A0335|80 83|hUBF
P02330041A0335|92 106|nucleolar factor
P02330041A0335|133 154|upstream control element
P02330041A0335|167 182|rRNA gene promoter
P02330041A0335|193 205|transcription
P02330041A0335|209 235|binding site-dependent manner
P02330110A1085|9 33|multiple laboratory studies
P02330110A1085|65 79|eventual outcome
P02330110A1085|82 94|near-drowning
P02330333A0325|0 12|Accumulations
P02330333A0325|15 18|Tl+1
P02330333A0325|20 29|202Tl label
P02330333A0325|36 40|times
P02330333A0325|49 50|Ga
P02330333A0325|68 74|muscles
P02330333A0325|81 85|times
P02330333A0325|88 93|plasma
P02331361A0268|9 23|gradual increase
P02331361A0268|29 43|myocyte diameter
P02331361A0268|63 68|biopsy
P02331361A0268|72 87|autopsy specimens
P02332018A0538|19 40|exercise-induced asthma
P02332018A0538|42 44|EIA
P02332018A0538|60 64|WH air
P02332018A0538|66 82|asthmatic patients
P02332018A0538|104 125|higher mean GH increments
P02332018A0538|130 143|normal subjects
P02332018A0538|153 157|ng/ml
P02332018A0538|159 163|P less
P02332798A0725|3 11|afferents
P02332798A0725|31 40|unmodified
P02332798A0725|43 66|electrical EVS stimulation
P02333239T0000|9 21|age old problem
P02333545A0313|22 37|fibrinogen levels
P02333545A0313|22 31|fibrinogen
P02333545A0313|41 48|Gaussian
P02333545A0313|57 66|wide-based
P02333545A0313|91 104|normal controls
P02333749A0411|3 36|stepwise logistic regression analysis
P02333749A0411|39 41|SPT
P02333749A0411|45 52|RAST data
P02333749A0411|57 66|occurrence
P02333749A0411|69 86|serum IgE antibodies
P02333749A0411|89 100|P. orbiculare
P02333749A0411|107 129|highest explanatory value
P02333749A0411|133 145|current eczema
P02334972A0145|38 51|different types
P02334972A0145|54 59|drusen
P02334972A0145|92 100|incidence
P02334972A0145|103 113|risk factors
P02334972A0145|123 135|complications
P02334972A0145|145 157|central vision
P02335034A0584|23 42|whole-body heat stress
P02335034A0584|44 62|water-perfused suits
P02335034A0584|72 78|minutes
P02335034A0584|81 84|LBNP
P02335521T0000|2 40|NF1-related vitellogenin activator element
P02335521T0000|49 61|transcription
P02335521T0000|69 119|estrogen-regulated Xenopus laevis vitellogenin promoter
P02335521T0000|87 119|Xenopus laevis vitellogenin promoter
P02335713A0905|1 15|poor correlation
P02335713A0905|38 40|PbB
P02335713A0905|44 55|ALAD activity
P02335713A0905|44 47|ALAD
P02335713A0905|61 75|stearate workers
P02335815A0530|5 20|carboxyl terminus
P02335815A0530|22 29|deletion
P02335815A0530|37 43|residue
P02335815A0530|66 68|TRF
P02335815A0530|70 78|C assembly
P02335815A0530|88 111|trans-activating activity
P02336338A0931|3 9|effects
P02336338A0931|12 24|mean luminance
P02336338A0931|45 61|general expression
P02339005T0000|0 5|Effect
P02339005T0000|8 20|hyperglycemia
P02339005T0000|23 35|pain threshold
P02339005T0000|38 57|alloxan-diabetic rats
P02339447A0162|18 24|7,7-2H2
P02339447A0162|30 32|OHA
P02339447A0162|37 56|high deuterium content
P02339447A0162|74 80|7,7-2H2
P02339447A0162|82 82|A
P02339447A0162|87 94|9,11-2H2
P02339447A0162|96 102|estrone
P02339447A0162|104 105|E1
P02339447A0162|122 138|quantitative assay
P02339447A0162|141 156|serum level 19-OHA
P02339447A0162|158 158|A
P02339447A0162|163 164|E1
P02339447A0162|173 232|gas chromatography/mass spectrometry-mass fragmentography method
P02339447A0162|242 259|individual subjects
P02340595A0124|0 15|Sequence analysis
P02340595A0124|23 27|genes
P02340595A0124|36 55|surrounding sequences
P02340595A0124|83 101|other known tRNA genes
P02340595A0124|93 101|tRNA genes
P02340595A0124|106 122|plant mitochondria
P02341669A0000|0 10|Experiments
P02341669A0000|31 64|brain-stem auditory-evoked responses
P02341669A0000|66 70|BAERs
P02341669A0000|89 93|types
P02341669A0000|96 118|pseudorandom pulse trains
P02341669A0000|120 141|maximum length sequences
P02341669A0000|143 145|MLS
P02341669A0000|150 166|Legendre sequences
P02341669A0000|168 170|LGS
P02342477A1292|8 11|UfAP
P02342477A1292|15 18|UTMP
P02342477A1292|24 39|many biosynthetic
P02342477A1292|43 60|structural features
P02342477A1292|78 89|biosynthesis
P02342477A1292|95 105|endometrium
P02342477A1292|107 123|P4-responsiveness
P02342477A1292|141 184|mannose 6-phosphate lysosomal recognition marker
P02342477A1292|189 218|considerable sequence similarity
P02342477A1292|223 226|UfAP
P02342477A1292|233 236|UTMP
P02342477A1292|244 261|homologous function
P02342477A1292|286 292|obscure
P02343033A0000|15 26|dates infants
P02343033A0000|35 43|placentae
P02343033A0000|60 76|well-grown infants
P02343033A0000|85 93|placentae
P02344529T0000|8 19|renal anaemia
P02344529T0000|24 53|recombinant human erythropoietin
P02347102A0000|3 24|pseudolymphoma syndrome
P02347102A0000|28 54|reversible reactive condition
P02347102A0000|73 87|lymphadenopathy
P02347102A0000|102 105|rash
P02347407A0217|5 25|local geomagnetic field
P02347407A0217|30 36|animals
P02347407A0217|49 57|SE-sector
P02347655A0193|5 18|artificial lung
P02347655A0193|29 39|natural lung
P02347655A0193|43 59|peripheral tissues
P02347655A0193|61 72|gas exchanges
P02347655A0193|81 97|several parameters
P02347655A0193|99 118|blood inlet conditions
P02347655A0193|120 132|blood flow rate
P02347655A0193|162 171|gas mixture
P02347655A0193|179 189|ventilation
P02347655A0193|191 210|blood tissue perfusion
P02348225A0192|0 3|Mean
P02348225A0192|8 9|SE
P02348225A0192|11 22|measurements
P02348225A0192|25 33|clearance
P02348225A0192|58 66|mL/min/m2
P02348225A0192|69 77|half-life
P02348225A0192|98 102|hours
P02348225A0192|150 153|L/m2
P02348225A0192|186 193|patients
P02348225A0192|198 205|jaundice
P02348225A0192|222 229|controls
P02348408A0126|0 8|Attitudes
P02348408A0126|22 37|multidimensional
P02348408A0126|43 59|similar dimensions
P02348408A0126|81 87|samples
P02348728A1153|14 22|DNA ploidy
P02348728A1153|26 55|major objective prognostic factor
P02348728A1153|59 80|therapeutic determinant
P02348728A1153|84 103|endometrial carcinoma
P02349827A0193|1 26|semiautomatic digital system
P02349827A0193|28 36|Videoplan
P02349942A0287|0 19|Environmental factors
P02349942A0287|42 53|older cohorts
P02349942A0287|71 88|less reliable recall
P02349998A0297|0 18|Dopamine SERS spectra
P02349998A0297|28 37|electrodes
P02349998A0297|65 82|uncoated electrodes
P02351239A0693|5 12|findings
P02351239A0693|25 40|hypergastrinemia
P02351239A0693|50 64|surgical removal
P02351239A0693|67 86|acid-producing mucosa
P02351239A0693|101 111|same effects
P02351239A0693|114 140|oxyntical mucosal HDC activity
P02351239A0693|123 132|mucosal HDC
P02351239A0693|142 163|histamine concentration
P02351239A0693|167 180|ECL cell density
P02351239A0693|183 198|hypergastrinemia
P02351239A0693|208 232|continuous gastrin infusion
P02351239A0693|237 254|long-term treatment
P02351239A0693|259 284|effective antisecretagogues
P02351297A0000|8 35|experimental toxicity research
P02351297A0000|64 97|atmosphere metal corrosion inhibitors
P02351297A0000|108 111|cent
P02351297A0000|130 138|hazardous
P02351297A0000|145 148|cent
P02351297A0000|153 170|high level hazardous
P02351297A0000|174 180|percent
P02351297A0000|201 204|cent
P02351297A0000|209 220|low hazardous
P02353453A1249|13 25|helicase motif
P02353453A1249|32 49|nsP3 homology region
P02353453A1249|55 63|RUB genome
P02353453A1249|90 105|alphavirus genome
P02353453A1249|121 140|genetic rearrangement
P02353453A1249|177 183|viruses
P02353875A0800|3 9|results
P02353875A0800|17 26|followings
P02353875A0800|35 45|eosinophils
P02353875A0800|49 59|neutrophils
P02353875A0800|73 86|hypersecretion
P02353875A0800|89 94|type Ib
P02353875A0800|97 107|atopic cases
P02353875A0800|116 126|eosinophils
P02353875A0800|129 143|non-atopic cases
P02354381A0207|10 19|treatments
P02354381A0207|29 29|C
P02354381A0207|52 61|rear corner
P02354381A0207|72 72|S
P02354381A0207|76 99|fiberglass rollaway hollow
P02354381A0207|105 114|rear corner
P02354381A0207|125 125|H
P02354381A0207|129 134|hollow
P02354381A0207|148 150|H/S
P02354381A0207|154 160|nest box
P02354381A0207|199 204|hollow
P02354381A0207|206 206|N
P02355293A0749|7 28|significant differences
P02355293A0749|34 49|tensile responses
P02355293A0749|52 73|failure characteristics
P02355293A0749|86 95|irradiated
P02355293A0749|99 117|nonirradiated grafts
P02355293A0749|123 126|drip
P02355293A0749|133 147|bath environment
P02355293A0749|151 170|nonirradiated tissues
P02355293A0749|174 188|greater strength
P02355293A0749|192 198|modulus
P02355765A0220|24 43|benzathine penicillin
P02355765A0220|54 60|U weekly
P02355765A0220|69 73|weeks
P02355920A0681|1 20|consensus binding site
P02355920A0681|27 48|transcription factor SP1
P02355920A0681|64 69|intron
P02355920A0681|72 81|downstream
P02355920A0681|87 120|proenkephalin germ cell cap site region
P02355920A0681|87 114|proenkephalin germ cell cap site
P02356823A0063|4 17|proposed method
P02356823A0063|43 55|sets technique
P02356823A0063|96 110|alarm properties
P02357537A0451|3 9|effects
P02357537A0451|12 26|reflex latencies
P02357537A0451|35 39|paCO2
P02357537A0451|42 44|pHa
P02357537A0451|58 65|naloxone
P02357537A0451|68 72|mg/kg
P02357537A0451|94 117|morphine-tolerant animals
P02358975A0709|53 66|strong symptoms
P02358975A0709|92 103|gluten intake
P02358975A0709|92 97|gluten
P02358975A0709|120 132|IgA deficiency
P02358975A0709|120 122|IgA
P02360336A0574|0 3|Drug
P02360336A0574|7 20|personnel costs
P02360336A0574|36 53|batch manufacturing
P02360336A0574|58 76|40-mL multidose vials
P02360336A0574|92 105|extemporaneous
P02360336A0574|121 134|unit-dose vials
P02361008T0000|0 6|Changes
P02361008T0000|9 17|prognosis
P02361008T0000|20 29|twin births
P02361008T0000|36 40|years
P02361575T0000|0 13|Dermal toxicity
P02361575T0000|17 31|carcinogenicity
P02361575T0000|34 63|4-vinyl-1-cyclohexene diepoxide
P02361575T0000|66 76|Fischer rats
P02361575T0000|80 89|B6C3F1 mice
P02361812A1110|3 10|kg FFM SMR
P02361812A1110|30 43|baseline values
P02361812A1110|50 56|EX group
P02361812A1110|68 89|non-exercising subjects
P02361812A1110|101 115|depressed values
P02361812A1110|117 118|EX
P02361812A1110|125 128|cent
P02361812A1110|132 132|D
P02361812A1110|134 135|DE
P02361812A1110|143 151|cent lower
P02361812A1110|172 176|P less
P02362161T0000|0 5|MK-927
P02362161T0000|17 65|active ocular hypotensive carbonic anhydrase inhibitor
P02362161T0000|40 56|carbonic anhydrase
P02362803A0608|0 19|PCR-derived fragments
P02362803A0608|30 35|probes
P02362803A0608|56 67|U3 snRNA genes
P02362803A0608|73 86|genomic library
P02362803A0608|89 99|Arabidopsis
P02368931A0587|2 31|addition serum IgE concentrations
P02368931A0587|15 17|IgE
P02370571A0663|3 10|findings
P02370571A0663|31 46|iodine deficiency
P02370571A0663|56 68|probable cause
P02370571A0663|71 76|goiter
P02370571A0663|82 91|immigrants
P02370571A0663|101 106|cohort
P02370571A0663|116 131|native population
P02370571A0663|148 150|men
P02370571A0663|154 158|women
P02370571A0663|165 186|other goitrogenic factor
P02370571A0663|188 188|s
P02371273A0144|3 21|transcriptional unit
P02371273A0144|28 44|chromosomal region
P02371273A0144|54 66|kilobase pairs
P02371273A0144|68 70|kbp
P02371517A0747|8 15|patients
P02372496A0782|0 16|Co-administration
P02372496A0782|19 21|5FU
P02372496A0782|23 35|angiotensin II
P02372496A0782|23 33|angiotensin
P02372496A0782|39 50|microspheres
P02372496A0782|57 69|hepatic artery
P02372496A0782|79 90|drug exposure
P02372496A0782|96 114|systemic compartment
P02372496A0782|141 156|therapeutic ratio
P02372496A0782|159 175|5FU administration
P02372496A0782|182 194|hepatic artery
P02372712A0002|3 9|effects
P02372712A0002|16 17|TW
P02372712A0002|32 33|CW
P02372712A0002|42 51|arterial pH
P02372712A0002|53 67|partial pressure
P02372712A0002|70 82|carbon dioxide
P02372712A0002|84 87|PCO2
P02372712A0002|92 104|plasma lactate
P02372712A0002|121 141|heat-stressed broilers
P02373686T0000|0 18|Transient expression
P02373686T0000|29 56|chicken progesterone receptors
P02373686T0000|71 104|alternative translational initiation
P02373686T0000|110 119|single mRNA
P02373686T0000|147 162|receptor isoforms
P02373810A1118|19 19|%
P02373810A1118|29 43|more risk factors
P02373810A1118|48 54|low risk
P02373810A1118|68 68|%
P02373810A1118|76 80|weeks
P02373810A1118|82 86|p less
P02374886A0305|3 26|Community Adjustment Scale
P02374886A0305|35 45|outcome data
P02374886A0305|58 65|subjects
P02374886A0305|105 122|close relationships
P02374886A0305|127 142|presence/absence
P02374886A0305|145 158|symptomatology
P02374886A0305|172 176|years
P02374886A0305|182 197|initial admission
P02376023A0307|12 17|months
P02376023A0307|37 48|higher levels
P02376023A0307|51 54|IgG1
P02376023A0307|56 60|P less
P02376023A0307|75 78|IgG4
P02376023A0307|80 84|P less
P02376023A0307|105 111|infants
P02376023A0307|118 128|elevated IgE
P02376023A0307|126 128|IgE
P02376023A0307|130 136|greater
P02376023A0307|153 156|kU/l
P02376023A0307|174 183|lower level
P02378615A0807|3 17|protein sequence
P02378615A0807|31 65|potential N-linked glycosylation sites
P02378615A0807|70 96|threonine/serine-rich region
P02378615A0807|105 117|potential site
P02378615A0807|121 130|attachment
P02378615A0807|133 152|O-linked carbohydrate
P02378945A0487|4 13|adaptation
P02378945A0487|16 35|continuous mild stress
P02378945A0487|40 65|potent antiarrhythmic effect
P02378945A0487|94 102|vagal tone
P02383693A0301|3 8|eluent
P02383693A0301|37 60|chemiluminescent solution
P02383693A0301|71 79|lucigenin
P02383693A0301|83 93|Triton X-100
P02383693A0301|102 113|M KOH solution
P02383693A0301|116 120|pumps
P02383693A0301|136 160|chemiluminescence detector
P02383771A0544|2 22|histologic examination
P02383771A0544|26 43|cuboidal epithelium
P02383771A0544|49 62|mucous membrane
P02383771A0544|86 103|columnar epithelium
P02383771A0544|109 126|uneven distribution
P02383771A0544|129 142|enlarged nuclei
P02383771A0544|158 166|cytoplasm
P02384265A0947|5 11|results
P02384265A0947|57 69|polyp patients
P02384265A0947|89 106|prophylactic effect
P02384265A0947|109 119|polypectomy
P02384265A0947|127 142|subsequent cancer
P02384389A0854|3 11|same trend
P02384389A0854|27 28|YG
P02384389A0854|32 38|heifers
P02384389A0854|42 43|YG
P02384389A0854|65 85|sex-related deposition
P02384389A0854|88 94|seam fat
P02384389A0854|97 105|fed cattle
P02386485A0554|3 20|nucleotide sequence
P02386485A0554|33 34|bp
P02386485A0554|43 58|non-coding region
P02386485A0554|64 65|bp
P02386485A0554|86 87|bp
P02386485A0554|96 111|non-coding region
P02386485A0554|124 129|bp poly
P02386485A0554|131 131|A
P02386895A0496|0 9|Toxicities
P02386895A0496|19 33|nausea/vomiting
P02386895A0496|37 37|%
P02386895A0496|51 51|%
P02386895A0496|54 59|chills
P02386895A0496|63 63|%
P02386895A0496|72 81|tumor sites
P02386895A0496|85 85|%
P02386895A0496|88 98|hypotension
P02386895A0496|102 102|%
P02386895A0496|108 119|hypertension
P02386895A0496|123 123|%
P02388685A0577|3 9|results
P02388685A0577|32 57|oyster shell supplementation
P02388685A0577|76 102|alkaline phosphatase activity
P02388685A0577|76 94|alkaline phosphatase
P02388685A0577|104 121|bone mineralization
P02388685A0577|135 146|uninfluenced
P02388685A0577|160 174|low coefficients
P02388685A0577|187 188|CV
P02388685A0577|201 201|%
P02388685A0577|214 214|%
P02388685A0577|218 224|calcium
P02388685A0577|228 244|phosphorus content
P02388685A0577|250 254|femur
P02388685A0577|258 262|tibia
P02390538A0000|7 13|infants
P02390538A0000|22 35|27th-40th weeks
P02390538A0000|38 46|gestation
P02390538A0000|60 88|congenital structural anomalies
P02390538A0000|94 100|airways
P02390538A0000|119 145|ultrathin flexible fiberscope
P02390538A0000|147 158|Olympus PF18 S
P02390538A0000|163 164|mm
P02390633T0000|0 16|Fatal encephalitis
P02390633T0000|31 61|chronic graft-versus-host disease
P02390989A0745|29 35|GPB gene
P02390989A0745|37 40|exon
P02390989A0745|47 53|GPE gene
P02390989A0745|62 82|several point mutations
P02390989A0745|86 94|insertion
P02390989A0745|99 100|bp
P02390989A0745|106 114|stop codon
P02390989A0745|131 142|reading frame
P02391344T0000|0 15|Molecular cloning
P02391344T0000|19 22|cDNA
P02391344T0000|31 59|rat NADH-cytochrome b5 reductase
P02391344T0000|66 82|corresponding gene
P02392032A0657|3 9|results
P02392032A0657|46 61|relaxation curves
P02392032A0657|86 98|distance scale
P02392032A0657|124 132|pore space
P02392032A0657|171 181|ambiguities
P02392511T0000|0 28|Serotonin 5-HT2 receptor binding
P02392511T0000|0 21|Serotonin 5-HT2 receptor
P02392511T0000|31 44|blood platelets
P02392511T0000|48 67|state dependent marker
P02392511T0000|70 91|major affective disorder
P02393001A0324|8 10|%BF
P02393001A0324|34 37|BMIs
P02393001A0324|39 40|r =
P02393001A0324|60 79|objective definitions
P02393001A0324|82 88|obesity
P02393001A0324|96 99|BMIs
P02393001A0324|102 104|%BF
P02393001A0324|107 118|densitometry
P02393001A0324|132 149|conflicting results
P02393895A0918|3 10|RF values
P02393895A0918|32 64|angiographic semiquantitative scale
P02393895A0918|67 74|severity
P02393895A0918|77 95|aortal insufficiency
P02393895A0918|97 98|r =
P02393895A0918|105 109|p less
P02393895A0918|143 149|authors
P02393895A0918|161 182|partial differentiation
P02393895A0918|201 220|severe regurgitations
P02393895A0918|230 246|insignificant ones
P02394707A0789|0 15|Promoter elements
P02394707A0789|25 39|atypical TATA box
P02394707A0789|41 44|GTTA
P02394707A0789|50 57|CCAAT box
P02394707A0789|76 89|initiation site
P02394707A0789|96 113|reverse compliments
P02394707A0789|116 120|CCAAT
P02394707A0789|122 126|ATTGG
P02394707A0789|135 168|pyrimidine-rich nucleotide stretches
P02394718A0130|9 13|genes
P02394718A0130|30 45|genetic libraries
P02394718A0130|48 69|hybridization screening
P02394718A0130|79 104|deoxyoligonucleotide probes
P02394718A0130|127 150|partial amino acid sequence
P02394718A0130|164 169|enzyme
P02395868A0322|13 30|catalytic zinc sites
P02395868A0322|42 48|ligands
P02395868A0322|66 87|sequence-distant ligand
P02395868A0322|93 114|main-chain hydrogen bond
P02395868A0322|125 131|ligands
P02396415T0001|0 6|Results
P02396415T0001|12 31|long-term observation
P02396415T0001|46 53|patients
P02396415T0001|58 77|arterial hypertension
P02398897A0000|0 29|Eucaryotic transcription factors
P02398897A0000|43 57|RNA polymerase II
P02398897A0000|43 55|RNA polymerase
P02398897A0000|85 94|elongation
P02398897A0000|128 136|RNA chains
P02399053A0153|0 24|Sprague-Dawley newborn rats
P02399053A0153|26 27|n =
P02399053A0153|42 48|% oxygen
P02399053A0153|55 61|room air
P02399053A0153|63 64|RA
P02399053A0153|81 84|days
P02399053A0153|99 100|RA
P02399053A1032|3 4|Lm
P02399053A1032|20 30|alveoli/mm2
P02399053A1032|34 54|elastic recoil pressure
P02400070T0000|0 9|Comparison
P02400070T0000|12 19|propofol
P02400070T0000|23 33|thiopentone
P02400070T0000|36 52|anaesthetic agents
P02400070T0000|56 79|electroconvulsive therapy
P02400457A0469|2 11|Experiment
P02400457A0469|27 47|moderate supine cycling
P02400457A0469|51 57|% VO2 max
P02400457A0469|64 70|minutes
P02400457A0469|76 96|several LBNP conditions
P02400457A0469|100 113|sedentary women
P02400457A0469|154 160|manners
P02400457A0469|166 190|cardiovascular adjustments
P02400457A0469|202 207|phases
P02400457A0469|215 226|Experiment I.
P02402678A0463|12 32|available formulations
P02402678A0463|38 38|%
P02402678A0463|43 60|% lambdacyhalothrin
P02402678A0463|91 118|ULV cold aerosol space-spraying
P02402678A0463|125 139|diesel/kerosene
P02402678A0463|143 156|thermal fogging
P02402678A0463|170 185|application rates
P02402678A0463|193 198|g ai/ha
P02402678A0463|202 216|mosquito control
P02402678A0463|221 226|g ai/ha
P02402678A0463|230 244|housefly control
P02403035A0621|9 20|reading frame
P02403035A0621|44 52|precursor
P02403035A0621|55 75|mitochondrial fumarase
P02403634A0788|0 15|Sequence analysis
P02403634A0788|43 45|ATA
P02403634A0788|49 53|GC box
P02403634A0788|73 79|domains
P02403634A0788|119 143|other muscle-specific genes
P02403634A0788|146 152|CArG box
P02403634A0788|158 159|bp
P02403634A0788|161 205|myocyte-specific enhancer-binding nuclear factor
P02403634A0788|207 227|binding site homologies
P02403634A0788|246 247|bp
P02403634A0788|253 280|muscle-CAAT consensus sequence
P02403634A0788|287 296|bp relative
P02403634A0788|302 308|cap site
P02403926A0000|3 16|trk-2h oncogene
P02403926A0000|33 66|human breast carcinoma cell line MDA-MB
P02403926A0000|72 94|genomic DNA-transfection
P02403926A0000|99 109|NIH3T3 cells
P02403926A0000|124 160|trk proto-oncogene receptor kinase domain
P02403926A0000|169 178|N-terminal
P02403926A0000|181 189|amino acid
P02403926A0000|209 213|Kozma
P02403926A0000|215 218|S.C.
P02403926A0000|220 226|Redmond
P02403926A0000|228 233|S.M.S.
P02403926A0000|235 244|Xiao-Chang
P02403926A0000|246 247|F.
P02403926A0000|249 254|Saurer
P02403926A0000|256 259|S.M.
P02403926A0000|261 266|Groner
P02403926A0000|268 269|B.
P02403926A0000|273 277|Hynes
P02403926A0000|279 282|N.E.
P02403926A0307|0 9|Antibodies
P02403926A0307|43 80|beta gal-trk receptor kinase fusion protein
P02403926A0307|94 109|kd phosphoprotein
P02403926A0307|126 131|serine
P02403926A0307|133 141|threonine
P02403926A0307|145 152|tyrosine
P02403926A0307|155 162|extracts
P02403926A0307|165 170|trk-2h
P02403926A0307|182 192|NIH3T3 cells
P02404451A1532|9 39|recent scanning-deletion analysis
P02404451A1532|61 74|critical region
P02404451A1532|90 96|Cys-118
P02404451A1532|104 110|Cys-118
P02404451A1532|125 139|maximal activity
P02404451A1532|158 171|Cys-118 residue
P02404451A1532|186 204|proper glycosylation
P02404451A1532|208 230|maximal biologic activity
P02404451A1532|233 238|GM-CSF
P02405393T0000|0 8|Molecular
P02405393T0000|12 37|functional characterization
P02405393T0000|43 50|promoter
P02405393T0000|53 56|ETS2
P02405393T0000|61 76|human c-ets-2 gene
P02405589A0000|0 10|Information
P02405589A0000|16 42|immunologic drug interactions
P02405589A0000|53 63|pharmacists
P02405589A0000|70 94|rational drug-use decisions
P02405818A0550|0 14|Branch occlusion
P02405818A0550|17 23|Heubner
P02405818A0550|26 31|artery
P02405818A0550|35 45|perforators
P02405818A0550|53 68|proximal anterior
P02405818A0550|71 92|middle cerebral arteries
P02405818A0550|100 115|posited mechanism
P02405818A0550|118 127|infarction
P02406570A0466|3 19|ABFI-binding sites
P02406570A0466|48 54|weak UAS
P02406570A0466|83 94|test plasmids
P02406570A0898|18 27|properties
P02406570A0898|30 38|sequences
P02406570A0898|50 53|ARS1
P02406570A0898|80 83|ABFI
P02406570A0898|95 104|initiation
P02406570A0898|107 120|DNA replication
P02406570A0898|123 126|ARS1
P02406570A0898|129 153|transcriptional activation
P02406992A0192|0 20|Nonvascular ophthalmic
P02406992A0192|24 42|neurologic disorders
P02406992A0192|64 77|amaurosis fugax
P02406992A0192|93 101|algorithm
P02406992A0192|129 149|ophthalmic examination
P02406992A0192|151 167|laboratory studies
P02406992A0192|172 202|noninvasive carotid artery studies
P02408248A0414|24 40|hypotensive action
P02408248A0414|53 68|enzyme inhibitors
P02408248A0414|71 81|age-related
P02409297A0984|0 18|Polyclonal antiserum
P02409297A0984|33 45|fusion protein
P02409297A0984|73 97|46-kilodalton polypeptides
P02409297A0984|102 115|virus particles
P02409297A0984|121 132|polypeptides
P02409297A0984|155 171|HBsAg determinants
P02409297A0984|155 159|HBsAg
P02411513A0667|5 19|characteristics
P02411513A0667|22 28|N22/P22
P02411513A0667|46 54|localized
P02411513A0667|67 80|dependent event
P02411513A0667|94 109|transverse dipole
P02411513A0667|114 129|dorsal negativity
P02411513A0667|134 163|simultaneous anterior positivity
P02417023T0001|0 3|Role
P02417023T0001|6 24|superoxide dismutase
P02417023T0001|27 52|cellular oxidative processes
P02417023T0001|82 100|biological materials
P02417669A0218|2 24|maximum photosensitivity
P02417669A0218|28 69|inhibitory amino acids gamma-aminobutyric acid
P02417669A0218|73 79|taurine
P02417669A0218|100 109|asparagine
P02417669A0218|111 120|metabolite
P02417669A0218|126 153|excitatory amino acid aspartate
P02417669A0218|159 164|higher
P02417669A0218|177 183|animals
P02417669A0218|191 204|photosensitive
P02418701A0000|26 32|tissues
P02418701A0000|48 70|carcinoembryonic antigen
P02418701A0000|88 118|carcinoembryonic antigen staining
P02418701A0000|88 110|carcinoembryonic antigen
P02418701A0000|121 129|specimens
P02418701A0000|132 146|villous adenomas
P02418701A0000|148 175|mixed polypoid villous adenomas
P02418701A0000|177 192|polypoid adenomas
P02418701A0000|197 210|diverticulitis
P02418701A0000|219 252|peroxidase-antiperoxidase technique
P02418701A0000|219 228|peroxidase
P02418701A0000|230 243|antiperoxidase
P02419327A0998|3 17|priming activity
P02419327A0998|43 59|Drosophila enzymes
P02419327A0998|53 59|enzymes
P02419327A0998|86 105|additional incubation
P02419327A0998|110 129|E. coli endonuclease IV
P02419327A0998|181 192|apurinic site
P02419588A0284|0 1|A.
P02420432A1060|12 22|conjunction
P02420432A1060|28 48|positive pregnancy test
P02420432A1060|64 78|clinical history
P02420432A1060|100 121|absent serum PAPP-A level
P02420432A1060|111 116|PAPP-A
P02420432A1060|144 164|extrauterine pregnancy
P02423533A1314|3 8|levels
P02423533A1314|15 48|MAP1-specific and MAP2-specific mRNAs
P02423533A1314|15 27|MAP1-specific
P02423533A1314|31 48|MAP2-specific mRNAs
P02423533A1314|61 69|postnatal
P02423533A1314|96 112|MAP1-specific mRNA
P02423533A1314|136 147|rat PC12 cells
P02423533A1314|162 178|nerve growth factor
P02423533A1790|3 7|cDNAs
P02423533A1790|27 42|genomic sequences
P02423533A1790|58 67|chicken DNA
P02423533A1790|86 89|frog
P02423533A1790|104 112|sea urchin
P02423773T0001|0 17|Colorimetric method
P02423773T0001|31 38|glycerin
P02423850A0292|0 15|Deletion analysis
P02423850A0292|48 61|flanking region
P02423850A0292|69 76|homology
P02423850A0292|82 95|upstream region
P02423850A0292|101 113|yeast CYC1 gene
P02424743A0280|3 4|N1
P02424743A0280|8 9|P2
P02424743A0280|26 34|amplitude
P02424743A0280|54 70|refractory periods
P02427024X0000|0 8|Tolerance
P02427024X0000|11 30|fenfluramine anorexia
P02427024X0000|46 59|Recent findings
P02427024X0000|99 118|fenfluramine anorexia
P02427024X0000|143 152|generality
P02427024X0000|158 178|behavioural phenomenon
P02427797A0199|4 7|dogs
P02427797A0199|11 18|left limb
P02427797A0199|30 37|pancreas
P02427797A0199|60 74|abdominal cavity
P02427797A0199|80 88|cessation
P02427797A0199|91 99|blood flow
P02427797A0199|109 120|warm ischemia
P02427797A0199|136 138|min
P02427797A0199|142 145|dogs
P02427797A0199|152 160|time point
P02427797A0199|184 194|cold Ringers
P02427797A0199|196 202|lactate
P02427797A0199|223 234|iliac vessels
P02427812A0865|5 11|results
P02427812A0865|30 38|clonidine
P02427812A0865|42 47|6-OHDA
P02427812A0865|55 62|alpha-MD
P02427812A0865|68 88|central pressor actions
P02427812A0865|112 133|antihypertensive action
P02427869A0939|12 40|beta 2-adrenoceptor sensitivity
P02427869A0939|12 29|beta 2-adrenoceptor
P02427869A0939|52 60|unaltered
P02427869A0939|63 65|BHT
P02431314A0834|14 19|Hansel
P02431314A0834|64 77|eosinophiluria
P02431314A0834|92 97|Wright
P02436005A0707|5 11|results
P02436005A0707|26 48|negative inotropic action
P02436005A0707|51 60|nicorandil
P02436005A0707|71 80|inhibition
P02436005A0707|83 90|Ca influx
P02436005A0707|94 118|intracellular mobilization
P02436005A0707|121 122|Ca
P02437625A0197|19 22|eyes
P02437625A0197|27 62|presumed ocular histoplasmosis syndrome
P02437625A0197|64 67|POHS
P02437625A0197|72 101|age-related macular degeneration
P02437625A0197|103 105|AMD
P02437792T0000|0 9|Comparison
P02437792T0000|12 21|elastase-1
P02437792T0000|26 32|amylase
P02437792T0000|34 39|lipase
P02437792T0000|44 71|trypsin-like immunoreactivity
P02437792T0000|44 50|trypsin
P02437792T0000|88 104|acute pancreatitis
P02437895A0000|1 5|probe
P02437895A0000|12 30|potentials procedure
P02437895A0000|49 66|relative engagement
P02437895A0000|73 91|cerebral hemispheres
P02437895A0000|99 110|language task
P02437895A0000|129 134|groups
P02437895A0000|137 149|dextral adults
P02437895A0000|151 164|left hemisphere
P02437895A0000|166 167|LH
P02437895A0000|177 184|aphasics
P02437895A0000|206 216|dysarthrics
P02437895A0000|218 232|right hemisphere
P02437895A0000|234 235|RH
P02437895A0000|245 262|nonaphasic patients
P02437895A0000|267 287|normal control subjects
P02438637T0000|0 16|Mucolipidosis type
P02438637T0000|20 35|clinical spectrum
P02438637T0000|39 52|natural history
P02442837A0060|13 18|groups
P02442837A0060|35 43|dauricine
P02442837A0060|48 71|new calcium channel blocker
P02442837A0060|76 84|verapamil
P02442837A0060|108 128|calcium channel blocker
P02442837A0060|149 155|minutes
P02442837A0060|179 193|bypass procedure
P02442837A0060|206 212|minutes
P02443028A0695|2 7|reflow
P02443028A0695|33 39|percent
P02443028A0695|45 66|muscle microvasculature
P02443028A0695|71 81|reperfusion
P02443924A0083|7 14|patients
P02443924A0083|35 48|uncontrollable
P02443924A0083|50 78|non-metastatic prostatic cancer
P02443924A0083|84 100|prolonged survival
P02444507A0240|0 15|Lysozyme activity
P02444507A0240|0 7|Lysozyme
P02444507A0240|45 53|undiluted
P02444507A0240|65 68|sera
P02444507A0240|83 90|patients
P02445751A0925|3 27|first involved measurements
P02445751A0925|33 49|steady state levels
P02445751A0925|52 56|mRNAs
P02445751A0925|60 66|subunit
P02445751A0925|70 86|cytochrome oxidase
P02445751A0925|93 103|beta subunit
P02445751A0925|106 113|F1 ATPase
P02445751A0925|116 123|wild type
P02445751A0925|130 139|hem2 mutant
P02446871A1021|1 18|5.8S-like structure
P02446871A1021|40 53|terminal region
P02446871A1021|64 90|fungal mitochondrial LSU rRNAs
P02446871A1021|105 122|4.5S-like structure
P02446871A1021|149 157|molecules
P02449431A1121|0 18|ATP gamma S inhibition
P02449431A1121|34 51|high concentrations
P02449431A1121|54 56|ATP
P02449431A1121|58 61|dATP
P02449431A1121|63 68|araATP
P02449431A1121|72 76|ddATP
P02451872A0391|21 35|methoxydextrane
P02451872A0391|44 44|%
P02452313A0114|0 7|ASL-8123
P02452313A0114|20 69|weak competitive beta-adrenoreceptor blocking activity
P02452313A0114|35 53|beta-adrenoreceptor
P02452313A0114|80 98|guinea pig right atria
P02452313A0114|104 106|pA2
P02452313A0114|123 142|agonist-like activity
P02452313A0114|168 181|concentrations
P02452313A0114|184 191|ASL-8123
P02452313A0114|197 197|X
P02452313A0114|207 207|X
P02452313A0114|214 215|M.
P02454390T0000|0 7|Enhancer
P02454390T0000|11 26|promoter elements
P02454390T0000|36 45|activation
P02454390T0000|49 72|glucocorticoid repression
P02454390T0000|78 99|alpha 1-fetoprotein gene
P02454390T0000|102 112|hepatocytes
P02454976A0944|12 18|results
P02454976A0944|31 45|previous systems
P02454976A0944|64 88|posterior ectosylvian gyrus
P02454976A0944|126 134|divisions
P02454976A0944|140 170|feline posterior ectosylvian gyrus
P02454976A0944|191 195|areas
P02454976A0944|207 227|superior temporal gyrus
P02454976A0944|230 237|primates
P02455821A0099|25 72|1.8-kilobase AccI-EcoRI restriction fragment mapping
P02455821A0099|37 40|AccI
P02455821A0099|42 65|EcoRI restriction fragment
P02455821A0099|106 113|UL region
P02455821A0099|119 129|EHV-1 genome
P02456827A0899|3 6|4-AP
P02456827A0899|12 13|mM
P02456827A0899|45 59|sensory activity
P02456827A0899|84 86|TEA
P02456827A0899|89 91|Ba2
P02457922A0991|0 12|Hybridization
P02457922A0991|16 20|probe
P02457922A0991|37 56|electrophoretic blots
P02457922A0991|59 62|RNAs
P02457922A0991|67 87|different human tissues
P02457922A0991|95 117|predominant 2.8-kilobase
P02457922A0991|119 120|kb
P02457922A0991|142 152|weaker bands
P02457922A0991|162 163|kb
P02458080T0000|0 8|Prognosis
P02458080T0000|11 37|asymptomatic multiple myeloma
P02458234T0000|1 9|new method
P02458234T0000|16 35|quantitative analysis
P02458234T0000|38 50|sleep spindles
P02458234T0000|57 88|continuous overnight EEG recordings
P02458699A0650|0 7|Svensson
P02459309T0000|0 16|Endogenous release
P02459309T0000|19 35|neuronal serotonin
P02459309T0000|39 63|5-hydroxyindoleacetic acid
P02459309T0000|69 83|caudate-putamen
P02459309T0000|104 124|intracerebral dialysis
P02459309T0000|134 169|high-performance liquid chromatography
P02459309T0000|174 194|fluorimetric detection
P02461368A0162|28 36|first time
P02461368A0162|40 63|complete primary structure
P02461368A0162|66 78|type X collagen
P02461368A0162|87 93|cloning
P02461368A0162|97 106|sequencing
P02461368A0162|109 112|cDNA
P02461368A0162|116 125|genomic DNA
P02462047A0208|0 14|Viable flap areas
P02462047A0208|39 61|vascular pedicle ligation
P02462047A0208|67 73|vessels
P02462047A0208|80 85|artery
P02462047A0208|88 91|vein
P02462047A0208|99 106|third day
P02462047A0208|112 127|flap replantation
P02462047A0208|143 151|free flaps
P02462305A1071|3 17|size discrepancy
P02462305A1071|28 40|glycosylation
P02462305A1071|43 57|phosphorylation
P02462305A1071|60 63|Ag35
P02462305A1071|81 100|proline-rich sequence
P02462305A1071|118 128|polypeptide
P02462523A0394|1 23|9.5-kb KpnI-SalI fragment
P02462523A0394|7 10|KpnI
P02462523A0394|12 23|SalI fragment
P02462523A0394|36 45|DNA changes
P02462523A0394|60 61|su
P02462523A0394|63 64|Hw
P02462523A0394|66 74|mutations
P02462523A0394|104 115|su(Hw) mutant
P02462523A0394|104 105|su
P02462523A0394|107 108|Hw
P02462523A0394|110 124|mutant phenotype
P02462523A0394|130 170|P-element-mediated germ-line transformation
P02463050A0514|3 44|corticosterone synthesis inhibitor metyrapone
P02463050A0514|48 52|mg/kg
P02463050A0514|86 99|corticosterone
P02463050A0514|103 114|level typical
P02463050A0514|117 129|stressed males
P02464097T0000|3 9|effects
P02464097T0000|12 15|L655
P02464097T0000|22 41|selective thromboxane
P02464097T0000|45 79|prostaglandin endoperoxide antagonist
P02464097T0000|83 90|ischemia
P02464097T0000|95 131|reperfusion-induced cardiac arrhythmias
P02466414A0000|4 24|pentobarbitalized dogs
P02466414A0000|26 40|plasma viscosity
P02466414A0000|42 43|Ep
P02466414A0000|67 88|apparent blood viscosity
P02466414A0000|90 91|Ea
P02466414A0000|119 123|steps
P02466414A0000|126 144|exchange transfusion
P02466414A0000|150 151|ml
P02466414A0000|154 159|plasma
P02466414A0000|164 169|plasma
P02466414A0000|180 205|high molecular weight dextran
P02466414A0000|207 211|mol wt
P02466414A0000|222 228|% wt/vol
P02466665A0202|3 25|small IGF-binding protein
P02466665A0202|28 35|abundant
P02466665A0202|38 55|human amniotic fluid
P02468795A1086|0 34|Serum prostatic acid phosphatase levels
P02468795A1086|5 28|prostatic acid phosphatase
P02468795A1086|55 71|weaker correlation
P02468795A1086|76 87|cancer volume
P02468795A1086|89 89|r
P02468795A1086|109 134|other pathological parameter
P02469451A0239|42 52|open fashion
P02469451A0239|77 82|mg dose
P02469451A0239|88 109|MAO-B inhibitor deprenyl
P02469451A0239|88 92|MAO-B
P02469451A0239|115 126|same subjects
P02470955A0101|5 11|studies
P02470955A0101|25 44|considerable increase
P02470955A0101|47 59|CSF AP activity
P02470955A0101|47 51|CSF AP
P02470955A0101|62 81|purulent meningitides
P02470955A0101|91 108|serous meningitides
P02473156A0000|1 4|cDNA
P02473156A0000|14 50|new human lymphocyte cell surface molecule
P02473156A0000|85 96|fourth member
P02473156A0000|126 141|adhesion proteins
P02473198A0613|0 7|Dopamine
P02473198A0613|15 38|prominent potassium efflux
P02473198A0613|49 52|86Rb
P02473198A0613|54 59|efflux
P02473198A0613|64 76|control glands
P02473198A0613|99 114|denervated glands
P02473619A0202|0 23|Spontaneous sensitization
P02473619A0202|40 48|chemicals
P02473619A0202|64 77|control animals
P02473619A0202|106 109|akin
P02473619A0202|112 135|spontaneous sensitization
P02473619A0202|138 145|patients
P02473619A0202|150 171|anaphylactoid reactions
P02473619A0202|174 194|neuromuscular blockers
P02473619A0202|197 209|first exposure
P02473619A0202|220 232|IgE antibodies
P02473693A0174|35 46|fetal protein
P02473693A0174|48 52|HGB F.
P02473693A0174|48 51|HGB F
P02473718A0000|19 21|apt
P02473718A0000|54 71|urinary metabolites
P02473718A0000|74 82|serotonin
P02473718A0000|86 98|catecholamine
P02473718A0000|100 105|5-HIAA
P02473718A0000|109 111|VMA
P02473718A0000|114 120|T-cells
P02473718A0000|122 125|OKT3
P02473718A0000|129 136|T-helper
P02473718A0000|138 141|OKT4
P02473718A0000|145 156|T-suppressor
P02473718A0000|158 161|OKT8
P02473718A0000|167 173|B-cells
P02473718A0000|175 185|EAC-rosette
P02473718A0000|193 197|cells
P02473718A0000|210 217|subjects
P02473718A0000|242 246|years
P02473718A0000|269 276|subjects
P02473718A0000|280 287|subjects
P02473718A0000|313 317|years
P02473907A1338|3 10|84.1C mAb
P02473907A1338|7 10|C mAb
P02473907A1338|28 30|IgE
P02473907A1338|63 83|Fc epsilon R binding site
P02473907A1338|63 72|Fc epsilon R
P02473907A1338|109 111|IgE
P02473907A1338|147 167|Fc epsilon R binding site
P02473907A1338|147 156|Fc epsilon R
P02473942A1207|5 20|hydropathic plots
P02473942A1207|54 72|hydrophobic segments
P02473942A1207|80 119|likely alpha-helical transmembrane segments
P02474093T0000|0 26|Angiotensin converting enzyme
P02474093T0000|0 10|Angiotensin
P02474093T0000|21 36|enzyme inhibitors
P02474093T0000|47 70|antihypertensive efficacy
P02474093T0000|73 81|diuretics
P02474093T0000|85 89|blunt
P02474093T0000|99 121|adverse metabolic effects
P02474110A1039|15 34|significant reduction
P02474110A1039|37 49|blood pressure
P02474110A1039|54 80|angiotensin converting enzyme
P02474110A1039|54 64|angiotensin
P02474110A1039|75 80|enzyme
P02474110A1039|82 84|ACE
P02474110A1039|86 102|inhibitor ramipril
P02474110A1039|110 130|significant regression
P02474110A1039|133 168|pathologic left ventricular hypertrophy
P02474110A1039|183 206|magnetic resonance imaging
P02474110A1039|210 225|echocardiography
P02474204A0105|0 13|Endocrine cells
P02474204A0105|27 31|means
P02474204A0105|34 42|Grimelius
P02474204A0105|44 57|silver staining
P02474204A0105|61 74|immunostaining
P02474204A0105|78 89|chromogranin
P02474204A0105|92 104|general marker
P02474204A0105|107 120|endocrine cells
P02474356A0559|10 22|radioactivity
P02474356A0559|25 30|tumour
P02474356A0559|43 54|normal tissue
P02474356A0559|56 56|T
P02474356A0559|58 63|N ratio
P02474356A0559|106 117|microspheres
P02474356A0559|125 130|portal
P02474356A0559|134 152|arterial circulation
P02475506A0878|3 6|mRNA
P02475506A0878|21 24|cDNA
P02475506A0878|42 73|polymerase chain reaction technique
P02475717A0565|0 13|Tissue necrosis
P02475717A0565|31 58|triphenyltetrazolium staining
P02475717A0565|77 99|major baseline predictors
P02475717A0565|102 112|infarct size
P02475717A0565|114 133|anatomic risk zone size
P02475717A0565|137 158|coronary collateral flow
P02476030A0000|10 23|retinal surface
P02476030A0000|29 36|human eye
P02476030A0000|48 61|diseased states
P02476030A0000|68 90|laser scanning tomography
P02476664A0563|49 56|human K14
P02476664A0563|58 59|D.
P02477373A0930|1 16|potential TATA box
P02477373A0930|19 25|located
P02477373A0930|28 44|base pairs upstream
P02477373A0930|50 81|first transcription initiation site
P02479635A0659|0 13|Cotransfection
P02479635A0659|35 42|plasmids
P02479635A0659|51 53|PKI
P02479635A0659|68 82|cAMP-stimulated
P02479635A0659|89 93|basal
P02479635A0659|97 129|phorbol ester-stimulated expression
P02479823A0727|0 15|Sequence analysis
P02479823A0727|23 36|flanking region
P02479823A0727|45 58|several GC boxes
P02479823A0727|64 82|identifiable TATA box
P02480419A0735|13 21|cirrhosis
P02480419A0735|25 33|alcoholic
P02480419A0735|43 43|%
P02480419A0735|46 56|cryptogenic
P02480419A0735|65 65|%
P02480419A0735|71 96|hepatitis B chronic infection
P02480419A0735|112 112|%
P02480959A0470|4 15|P-450scc mRNA
P02480959A0470|44 54|LH/hCG surge
P02480959A0470|44 45|LH
P02480959A0470|47 49|hCG
P02480959A0470|85 99|luteinized cells
P02480959A0470|110 113|days
P02480959A0470|129 132|days
P02480959A0470|148 160|gonadotropins
P02480959A0470|164 174|susceptible
P02480959A0470|177 186|modulation
P02480959A0470|189 197|prolactin
P02480959A0470|222 225|cAMP
P02481230A1258|23 42|bovine alpha transgene
P02481230A1258|57 64|placenta
P02481230A1258|67 80|transgenic mice
P02481429T0000|1 22|rapid staining technique
P02481429T0000|26 44|Leishmania parasites
P02481429T0000|47 67|splenic aspirate smears
P02481779A0213|0 6|NIK-244
P02481779A0213|17 32|coronary ligation
P02481779A0213|37 64|digitalis-induced arrhythmias
P02481779A0213|72 107|minimum effective plasma concentrations
P02481779A0213|111 121|arrhythmias
P02481779A0213|131 134|24-h
P02481779A0213|138 157|48-h coronary ligation
P02481779A0213|161 169|digitalis
P02481779A0213|189 197|mg/kg i.v.
P02481779A0213|215 223|mg/kg i.v.
P02481779A0213|246 254|mg/kg i.v.
P02481779A0213|256 267|microgram/ml
P02481779A0213|289 290|SD
P02481779A0213|301 302|n =
P02482293A1518|2 38|TNF-resistant T24 bladder carcinoma cells
P02482293A1518|2 4|TNF
P02482293A1518|40 42|TNF
P02482293A1518|56 89|EGF-R tyrosine protein kinase activity
P02482293A1518|102 104|EGF
P02482293A1518|108 119|phorbol ester
P02482293A1518|142 158|enzymatic activity
P02482293A1518|164 171|receptor
P02482293A1518|179 183|cells
P02482511A0860|5 31|phosphodiesterase inhibitors
P02482511A0860|45 74|opiate quasi-withdrawal syndrome
P02482511A0860|85 104|interoceptive stimuli
P02482511A0860|108 117|weight loss
P02482511A0860|135 152|withdrawal syndrome
P02482511A0860|167 176|naltrexone
P02482511A0860|179 200|morphine-dependent rats
P02483210A0000|3 17|diagnostic value
P02483210A0000|20 29|blood serum
P02483210A0000|33 46|urinary amylase
P02483210A0000|48 53|lipase
P02483210A0000|58 64|trypsin
P02483210A0000|67 79|exacerbations
P02483210A0000|82 109|chronic relapsing pancreatitis
P02483438A0498|36 41|groups
P02483438A0498|44 54|inodilators
P02483438A0498|75 101|phosphodiesterase inhibitors
P02483438A0498|108 125|dopaminergic agents
P02484714T0000|0 21|Structural organization
P02484714T0000|40 60|mouse estrogen receptor
P02484994T0001|0 24|Intravenous gamma globulins
P02484994T0001|11 24|gamma globulins
P02485188A0415|9 24|chondroitinase AC
P02485188A0415|28 39|ABC digestion
P02485188A0415|28 30|ABC
P02485188A0415|49 57|reactions
P02485188A0415|74 86|highest levels
P02485188A0415|89 103|dermatan sulfate
P02485188A0415|113 134|diabetes resistant group
P02485188A0415|136 140|p less
P02485188A0415|160 167|diabetic
P02485188A0415|169 173|p less
P02485188A0415|193 205|diabetes prone
P02485188A0415|213 225|highest levels
P02485188A0415|228 246|chondroitin sulfates
P02485188A0415|256 273|diabetes prone group
P02485188A0415|275 279|p less
P02486634A0632|0 18|Myocardial perfusion
P02486634A0632|47 55|gray level
P02486634A0632|61 77|contrast injection
P02486634A0632|108 117|morphology
P02486634A0632|129 149|collateral development
P02487898A0315|4 20|NGF administration
P02487898A0315|4 6|NGF
P02487898A0315|63 77|alternative ways
P02487898A0315|80 96|NGF administration
P02487898A0315|80 82|NGF
P02488148A1156|26 36|RSNA meeting
P02488148A1156|59 74|correct diagnosis
P02488148A1156|89 89|%
P02489032A0000|0 23|Immunoglobulin light chain
P02489032A0000|25 27|IgL
P02489032A0000|63 75|recombination
P02489032A0000|86 109|single functional variable
P02489032A0000|111 112|VL
P02489032A0000|125 126|JL
P02489032A0000|128 139|gene segments
P02489032A0000|143 174|subsequent somatic diversification
P02489032A0000|190 197|VL region
P02489753A0581|3 9|results
P02489753A0581|26 30|Total
P02489753A0581|41 51|EMG activity
P02489753A0581|54 60|FB group
P02489753A0581|87 102|occluded position
P02489753A0581|117 118|CG
P02489753A0581|122 128|GF group
P02489895T0001|0 20|Muscle action potential
P02489895T0001|24 40|masticatory rhythm
P02489895T0001|43 58|anterior temporal
P02489895T0001|62 76|masseter muscles
P02489895T0001|79 86|children
P02489895T0001|90 95|adults
P02492111A0670|4 4|%
P02492111A0670|9 26|lead-toxic children
P02492111A0670|28 41|bone lead values
P02492111A0670|52 55|LXRF
P02492111A0670|69 75|greater
P02492111A0670|123 128|adults
P02492111A0868|21 42|known neurotoxic effects
P02492111A0868|45 52|children
P02492111A0868|56 64|low levels
P02492111A0868|88 94|results
P02492111A0868|129 140|narrow margin
P02492111A0868|151 168|insufficient safety
P02492111A0868|181 201|present U.S. guidelines
P02492111A0868|218 247|elevated blood lead concentration
P02492111A0868|252 264|micrograms/dl
P02492111A0868|267 273|greater
P02493644A0588|9 16|3T3 cells
P02493644A0588|18 22|jun-D
P02493644A0588|37 47|higher level
P02493644A0588|58 62|c-jun
P02493644A0588|66 70|jun-B
P02493644A0588|78 90|transcription
P02493644A0588|117 134|serum growth factors
P02495745T0000|3 21|thrombolytic effects
P02495745T0000|24 60|native tissue-type plasminogen activator
P02495745T0000|30 60|tissue-type plasminogen activator
P02495745T0000|62 67|AK-124
P02495745T0000|71 106|experimental canine coronary thrombosis
P02496090A0252|5 7|CO2
P02496090A0252|13 28|tracheostomy tube
P02496090A0252|56 71|mass spectrometry
P02496090A0252|78 124|special sample-hold phase-locked sampling technique
P02496100T0000|0 30|Enzyme-linked immunosorbent assay
P02496100T0000|43 53|aflatoxin B1
P02496100T0000|56 73|cottonseed products
P02496100T0000|77 85|mixed feed
P02496100T0000|87 104|collaborative study
P02496109A0754|8 18|experiments
P02496109A0754|23 31|S1 mapping
P02496109A0754|40 50|transcripts
P02496109A0754|52 66|gene disruptions
P02496109A0754|72 82|alpha region
P02496109A0754|88 125|single-copy transcriptional fusion vector
P02496109A0754|147 163|possible promoters
P02496109A0754|175 182|inactive
P02496109A0754|189 205|logarithmic growth
P02496109A0754|214 226|major promoter
P02496109A0754|233 243|alpha operon
P02496109A0754|285 289|genes
P02496109A0754|295 297|IF1
P02496109A0754|300 310|L17 interval
P02497340A0989|0 32|Functional rearranged antibody genes
P02497340A0989|49 50|JH
P02497340A0989|54 71|VH heavy chain probes
P02497340A0989|54 65|VH heavy chain
P02497340A0989|79 80|Jk
P02497340A0989|84 101|Vk light chain probes
P02497340A0989|84 95|Vk light chain
P02498322A0226|3 30|specific DNA-protein complexes
P02498322A0226|47 66|gel retardation assays
P02498322A0226|72 94|HeLa cell nuclear extracts
P02498322A0226|100 119|oligonucleotide probe
P02498322A0226|131 147|footprinted region
P02498652A0460|5 16|transfection
P02498652A0460|18 48|specific TSH beta promoter activity
P02498652A0460|26 40|TSH beta promoter
P02498652A0460|65 98|TRH-responsive pituitary-derived GH3
P02498652A0460|65 67|TRH
P02498652A0460|102 129|primary pituitary cell cultures
P02500432A1416|20 44|constitutive CAT expression
P02500432A1416|32 34|CAT
P02500432A1416|74 81|kilobase
P02500432A1416|104 122|1.6-kilobase segment
P02500432A1416|138 155|correct orientation
P02500432A1416|168 174|CAT gene
P02502096A0462|13 26|renal blood flow
P02502096A0462|36 45|glomerular
P02502096A0462|49 73|tubular excretion processes
P02502602A0323|0 8|Tonometry
P02502602A0323|11 22|blood samples
P02502602A0323|27 34|patients
P02502602A0323|68 86|acid-base quantities
P02502602A0323|90 114|hemoglobin-oxygen affinity
P02502602A0323|90 99|hemoglobin
P02502602A0323|119 121|p50
P02502960A0762|8 9|p.
P02504603T0000|0 8|Isolation
P02504603T0000|11 25|Weeksella virosa
P02504603T0000|35 45|CDC group IIf
P02504603T0000|52 64|vaginal sample
P02505087A1037|15 37|dimerization specificity
P02505087A1037|40 42|Fos
P02505087A1037|66 78|leucine zipper
P02505087A1037|91 94|GCN4
P02506390T0001|0 5|Growth
P02506390T0001|8 26|tracheal anastomoses
P02506390T0001|36 42|animals
P02506740A0742|0 5|Fourth
P02506740A0742|28 32|hours
P02506740A0742|74 87|chronic hypoxia
P02506740A0742|90 106|cerebral blood flow
P02507523A0791|3 13|ORF1 product
P02507523A0791|28 37|competence
P02507523A0791|44 47|ORF2
P02507523A0791|74 77|ORF1
P02507523A0791|110 119|amino acids
P02507815A0000|0 7|Kindling
P02507815A0000|13 31|primary visual cortex
P02507815A0000|33 34|VC
P02507815A0000|60 67|amygdala
P02507815A0000|70 73|cats
P02508306A0528|0 19|Abundant infiltration
P02508306A0528|22 32|lymphocytes
P02508306A0528|36 46|plasma cells
P02508306A0528|54 64|wide-spread
P02508306A0528|75 83|carcinoma
P02508306A0528|106 122|lymphoid follicles
P02508726A0498|5 15|case reports
P02508726A0498|23 37|further evidence
P02508726A0498|42 46|LiCO3
P02508726A0498|53 68|useful medication
P02508726A0498|85 102|aggressive behavior
P02508726A0498|106 125|affective instability
P02508726A0498|131 141|brain injury
P02508726A0498|155 174|significant potential
P02508726A0498|178 190|neurotoxicity
P02508726A0498|230 240|conjunction
P02508726A0498|245 261|neuroleptic agents
P02509123A0371|5 12|sessions
P02509123A0371|18 20|IFN
P02509123A0371|25 31|latency
P02509123A0371|37 49|P100 component
P02509123A0371|55 57|VEP
P02509123A0371|82 99|baseline conditions
P02510242A0313|8 12|cases
P02510242A0313|15 39|post-transfusion hepatitis
P02510242A0313|54 68|hepatitis B virus
P02510242A0313|77 92|systematic search
P02510242A0313|96 100|HBs Ag
P02510242A0313|121 137|non-A non-B viruses
P02510242A0313|142 151|detectable
P02510242A0313|154 177|specific serological tests
P02510242A0313|185 198|several viruses
P02510242A0313|209 211|CMV
P02511069A0532|0 23|Recessive lethal mutations
P02511069A0532|67 84|recessive lethality
P02511069A0532|87 88|Df
P02511069A0532|90 91|3L
P02511069A0532|93 95|RR2
P02511069A0532|98 105|deletion
P02511069A0532|111 119|DRE region
P02511069A0532|136 158|polytene chromosome bands
P02511150T0025|0 12|Current status
P02511150T0025|16 33|future perspectives
P02511207A0282|0 1|K.
P02511430A0000|1 13|215-base-pair
P02511430A0000|15 16|bp
P02511430A0000|29 81|mouse MOPC 41 kappa light-chain immunoglobulin gene enhancer
P02511430A0000|29 37|mouse MOPC
P02511430A0000|40 81|kappa light-chain immunoglobulin gene enhancer
P02511430A0000|100 114|specific binding
P02511430A0000|117 124|lymphoid
P02511430A0000|128 152|nonlymphoid nuclear factors
P02511898A0000|20 26|reasons
P02511898A0000|30 38|countries
P02511898A0000|46 58|Chagas disease
P02511898A0000|61 67|endemic
P02511898A0000|85 100|relevant research
P02512010A0801|3 19|PETCO2 measurement
P02512010A0801|26 46|precordial compression
P02512010A0801|68 81|defibrillation
P02512010A0801|94 115|spontaneous circulation
P02514498A0000|0 14|Gastric CO2/HCO3
P02514498A0000|39 60|simultaneous inhibition
P02514498A0000|63 75|acid secretion
P02514498A0000|78 82|intra
P02514498A0000|87 117|extragastric pCO2/pH measurements
P02514498A0000|122 128|persons
P02514498A0000|160 180|Henderson-Hasselbalch
P02514498A0000|182 185|pCO2
P02514498A0000|207 218|new electrode
P02515953A0459|0 13|Follow-up study
P02515953A0459|22 22|%
P02515953A0459|30 37|patients
P02517008A0481|3 15|other patients
P02517008A0481|37 52|single daily doses
P02517008A0481|55 65|monotherapy
P02518645T0001|0 20|Neonatal Chagas disease
P02518645T0001|22 40|laboratory diagnosis
P02518645T0001|50 58|first year
P02518691A0251|12 38|IL2R alpha promoter constructs
P02518691A0251|41 61|transient transfection
P02518691A0251|65 80|DNA binding assays
P02518691A0251|102 117|sequences located
P02518691A0251|129 136|upstream
P02518691A0251|140 149|downstream
P02518691A0251|155 168|kappa B enhancer
P02518691A0251|200 222|IL2R alpha gene expression
P02518691A0251|200 212|IL2R alpha gene
P02519327T0001|0 20|Palindromic rheumatism
P02519679T0000|0 9|Inefficacy
P02519679T0000|12 30|phosphine fumigation
P02519679T0000|38 42|ticks
P02520622A0200|5 12|patients
P02520622A0200|37 76|initial total gastrointestinal transit times
P02520622A0200|90 97|symptoms
P02520622A0200|114 131|cimetropium bromide
P02520622A0200|134 141|mg t.d.s.
P02520622A0200|144 150|placebo
P02520622A0200|172 183|double-blind
P02520622A0200|185 203|parallel group design
P02521217A1035|17 30|related protein
P02521217A1035|44 51|ribosome
P02521217A1035|55 71|membrane fractions
P02521217A1035|74 85|mitochondria
P02521674T0000|0 6|Mapping
P02521674T0000|9 11|RNA
P02521674T0000|13 40|temperature-sensitive mutants
P02521674T0000|43 54|Sindbis virus
P02521674T0000|56 83|complementation group F mutants
P02521674T0000|88 94|lesions
P02521674T0000|97 100|nsP4
P02522297A0000|14 26|thromboxane A2
P02522297A0000|28 31|TXA2
P02522297A0000|34 76|prostaglandin endoperoxide receptor antagonist
P02522297A0000|78 79|SQ
P02522297A0000|88 109|pacing-induced ischemia
P02522297A0000|125 150|anesthetized open-chest dogs
P02523800A1178|36 43|CHS1 gene
P02523800A1178|69 75|repeats
P02523800A1178|79 102|TGAAACA consensus sequence
P02523800A1178|128 161|alpha-factor-inducible BAR1 promoter
P02523800A1178|128 139|alpha-factor
P02523800A1178|150 161|BAR1 promoter
P02523800A1178|163 170|Kronstad
P02523800A1178|172 173|J.
P02525044A1026|3 15|recovery index
P02525044A1026|17 23|T25-T75
P02525044A1026|33 40|infusion
P02525044A1026|60 67|patients
P02525044A1026|79 88|mivacurium
P02525044A1026|108 120|suxamethonium
P02526165X0000|9 20|Leser-Trelat
P02526165X0000|43 54|Leser-Trelat
P02526165X0000|75 97|reliable cutaneous marker
P02526165X0000|100 117|internal malignancy
P02527365T0000|0 13|Xenopus homolog
P02527365T0000|19 34|mos protooncogene
P02527365T0000|45 64|mammalian fibroblasts
P02527365T0000|75 84|maturation
P02527365T0000|87 100|Xenopus oocytes
P02527745A0865|0 19|Southern blot analyses
P02527745A0865|49 58|copy number
P02527745A0865|99 114|other vertebrates
P02528329A0000|5 19|missense mutants
P02528329A0000|22 28|subunit
P02528329A0000|35 60|Escherichia coli F1F0-ATPase
P02528329A0000|50 60|F1F0-ATPase
P02528329A0000|94 117|hydroxylamine mutagenesis
P02528329A0000|121 127|plasmid
P02528329A0000|139 142|uncB
P02528329A0000|144 150|subunit
P02528730A1073|9 15|exons 2a
P02528730A1073|19 25|2b share
P02528730A1073|78 101|distinct donor splice sites
P02528730A1073|105 106|bp
P02529378A0536|0 17|S1 nuclease analysis
P02529378A0536|0 9|S1 nuclease
P02529378A0536|20 22|RNA
P02529378A0536|36 47|transfection
P02529378A0536|55 67|HIV constructs
P02529378A0536|72 80|HeLa cells
P02529378A0536|93 111|wild-type adenovirus
P02529378A0536|128 135|enhancer
P02529378A0536|137 139|SP1
P02529378A0536|141 144|TATA
P02529378A0536|162 194|transactivation-responsive element
P02529378A0536|214 247|complete E1A/E1B-mediated activation
P02529378A0536|222 224|E1A
P02529378A0536|226 228|E1B
P02529378A0536|253 258|HIV LTR
P02530413A0195|2 15|supine position
P02530413A0195|17 31|plasma ANP levels
P02530413A0195|23 25|ANP
P02530413A0195|44 48|pg/ml
P02530413A0195|55 59|pg/ml
P02530413A0195|67 78|average level
P02530413A0195|92 96|pg/ml
P02530470A0604|3 19|overall prevalence
P02530470A0604|22 31|HBV markers
P02530470A0604|35 40|higher
P02530470A0604|46 57|staff members
P02530470A0604|67 77|blood donors
P02531203A0241|0 22|Quantitative predictions
P02531203A0241|41 57|positive responses
P02531203A0241|71 79|negatives
P02531203A0241|98 106|SSTS model
P02531203A0241|109 117|incorrect
P02532032A0385|0 19|Plasma concentrations
P02532032A0385|22 24|ANF
P02532032A0385|26 29|pANF
P02532032A0385|32 42|aldosterone
P02532032A0385|44 46|PAC
P02532032A0385|51 55|renin
P02532032A0385|57 59|PRC
P02532032A0385|85 105|hemodynamic parameters
P02532210A0000|3 19|adenovirus E1A gene
P02532210A0000|65 79|viral early genes
P02534067A0316|0 13|Administration
P02534067A0316|16 28|dexamethasone
P02534067A0316|46 61|progressive rises
P02534067A0316|64 69|plasma
P02534067A0316|72 90|alpha OH progesterone
P02534067A0316|94 112|beta-desoxycortisol
P02534067A0316|114 125|DHEA sulphate
P02534067A0316|127 141|androstenedione
P02534067A0316|145 156|testosterone
P02534067A0316|179 194|urinary excretion
P02534067A0316|197 208|androsterone
P02534067A0316|212 229|beta OH androsterone
P02534067A0316|231 245|etiocholanolone
P02534067A0316|247 250|DHEA
P02534067A0316|257 267|alpha OH DHEA
P02535460A1443|0 13|RNA transcripts
P02535460A1443|42 52|foreign gene
P02536096A0327|2 10|HeLa cells
P02536096A0327|23 35|transcription
P02536096A0327|43 64|herpes simplex virus type
P02536096A0327|66 88|thymidine kinase promoter
P02536096A0327|100 135|chloramphenicol acetyltransferase gene
P02536096A0327|149 167|inverted orientation
P02536096A0327|181 203|thymidine kinase promoter
P02536096A0327|206 215|downstream
P02536096A0327|221 256|chloramphenicol acetyltransferase gene
P02536160A0518|5 30|basal unstimulated condition
P02536160A0518|32 54|Ren1d 5' flanking sequence
P02536160A0518|32 36|Ren1d
P02536160A0518|39 54|flanking sequence
P02536160A0518|60 75|sense orientation
P02536160A0518|85 102|basal CAT expression
P02536160A0518|90 92|CAT
P02536160A0518|110 119|TK promoter
P02536160A0518|122 128|pUTKAT1
P02536160A0518|140 151|same sequence
P02536160A0518|157 176|antisense orientation
P02537441A0231|0 3|None
P02537441A0231|22 35|clinical duties
P02537441A0231|46 75|varicella-zoster immune globulin
P02537485A0841|5 16|formalin test
P02537485A0841|26 33|naloxone
P02537485A0841|44 60|morphine analgesia
P02537485A0841|66 75|lower doses
P02537485A0841|86 90|mg/kg
P02537485A0841|106 122|morphine analgesia
P02537485A0841|128 138|highest dose
P02537485A0841|142 146|mg/kg
P02538450A0000|14 23|cDNA clones
P02538450A0000|28 35|rat brain
P02538450A0000|39 48|human liver
P02538450A0000|58 72|putative isoform
P02538450A0000|78 99|Na,K-ATPase beta subunit
P02538656A0172|20 35|several E1 mutants
P02538656A0172|52 52|M
P02538656A0172|56 63|R regions
P02538656A0172|68 79|single mutant
P02538656A0172|85 108|upstream regulatory region
P02538656A0172|114 139|higher transforming activity
P02538656A0172|142 155|mouse C127 cells
P02538656A0172|163 177|wild-type genome
P02538720A0582|0 3|UbiA
P02538720A0582|21 43|known polyubiquitin genes
P02538720A0582|26 43|polyubiquitin genes
P02538720A0582|60 77|cis-spliced introns
P02541251A1327|9 14|T2 gene
P02541251A1327|23 44|numerous potential sites
P02541251A1327|58 88|mammalian transcription factor SP1
P02541251A1327|95 98|TATA
P02541251A1327|101 114|CCAAT sequences
P02541251A1327|153 166|latter features
P02541251A1327|187 197|human T1 gene
P02541882A0251|0 15|Radiation therapy
P02541882A0251|41 61|symptomatic metastasis
P02541882A0251|72 79|patients
P02542194A1496|5 11|results
P02542194A1496|24 31|patients
P02542194A1496|42 65|postoperative irradiation
P02542194A1496|69 94|low grade spinal astrocytomas
P02542194A1496|98 123|localized spinal ependymomas
P02542194A1496|131 147|excellent survival
P02542270A0000|3 13|methylation
P02542270A0000|26 40|chloroplast DNAs
P02542270A0000|71 97|known differential expression
P02542270A0000|100 120|C4 photosynthesis genes
P02542270A0000|126 137|bundle sheath
P02542270A0000|141 154|mesophyll cells
P02542270A0000|167 174|greening
P02542270A0000|184 193|green maize
P02542612A0530|0 17|S1 nuclease analysis
P02542612A0530|0 9|S1 nuclease
P02542612A0530|20 22|RNA
P02542612A0530|44 53|B95-8 cells
P02542612A0530|61 69|Vero cells
P02542612A0530|87 108|NotI repeat promoter-CAT
P02542612A0530|87 104|NotI repeat promoter
P02542612A0530|106 108|CAT
P02542612A0530|112 112|Z
P02542612A0530|123 138|Z transactivation
P02542612A0530|123 123|Z
P02542612A0530|177 196|stable RNA transcripts
P02543226A1559|41 49|carcinoma
P02543226A1559|52 70|atypical hyperplasia
P02543226A1559|87 108|adipose tissue component
P02543226A1559|118 137|benign breast biopsies
P02543226A1559|160 187|possible cost-effective method
P02543226A1559|190 197|sampling
P02543226A1559|205 224|benign breast biopsies
P02543226A1559|266 271|blocks
P02543226A1559|274 290|fibrous parenchyma
P02543226A1559|354 362|carcinoma
P02543226A1559|365 383|atypical hyperplasia
P02543226A1559|401 406|blocks
P02543621A0788|0 7|Analysis
P02543621A0788|22 26|cases
P02543621A0788|29 36|sporadic
P02543621A0788|40 52|familial Wilms
P02543621A0788|74 80|changes
P02543621A0788|99 121|translocation breakpoint
P02543679A1291|35 41|lambda O
P02543679A1291|45 55|P initiators
P02543679A1291|62 71|E. coli DnaJ
P02543679A1291|68 71|DnaJ
P02543679A1291|75 95|DnaK heat shock proteins
P02543679A1291|75 78|DnaK
P02543679A1291|101 110|direct role
P02543679A1291|116 126|propagation
P02543679A1291|129 145|lambda replication
P02543734A0414|0 24|Synthetic oligonucleotides
P02543734A0414|42 53|bp repeat unit
P02543734A0414|85 106|IE1/2 enhancer/promoter
P02543734A0414|109 128|cotransfection assays
P02543734A0414|134 152|transient expression
P02544059A0377|0 6|Effects
P02544059A0377|9 16|nitrogen
P02544059A0377|18 20|PN2
P02544059A0377|28 30|MPa
P02544059A0377|35 40|helium
P02544059A0377|42 44|PHe
P02544059A0377|53 55|MPa
P02545357A0000|3 29|mustard chloroplast gene rps16
P02545357A0000|44 50|bp group
P02545357A0000|60 65|intron
P02545903A0639|0 9|Antibodies
P02545903A0639|30 32|NS3
P02545903A0639|35 46|immunization
P02545903A0639|49 52|mice
P02545903A0639|65 67|NS3
P02545903A0639|71 74|NS3A
P02545903A0639|77 99|BTV-10-infected BHK cells
P02545903A0639|116 135|BTV-10 virus particles
P02546234A1382|10 36|supraventricular tachycaydia
P02546234A1382|46 65|resuscitative efforts
P02546234A1382|93 107|negative outcome
P02547079A0910|3 24|negative calcium balance
P02547079A0910|29 48|hyperparathyroidemia
P02547079A0910|62 89|continuous oral administration
P02547079A0910|92 93|Cd
P02547079A0910|118 133|urinary excretion
P02547079A0910|136 142|calcium
P02547611A0318|0 6|Clone 4c
P02547611A0318|12 13|bp
P02547611A0318|25 39|region identical
P02547611A0318|48 55|clone 22c
P02547611A0318|70 83|putative intron
P02547611A0318|89 90|bp
P02547706A0928|16 18|ISH
P02547706A0928|22 24|IHC
P02547706A0928|53 83|routine histologic classification
P02547706A0928|86 95|pneumonias
P02547706A0928|100 105|CMV-IP
P02547706A0928|109 111|IIP
P02547706T0001|0 7|Validity
P02547706T0001|10 24|immunohistology
P02547706T0001|34 46|hybridization
P02547706T0001|52 72|differential diagnosis
P02547706T0001|75 98|cytomegalovirus pneumonia
P02547706T0001|102 132|idiopathic interstitial pneumonia
P02547706T0001|138 171|allogenic bone marrow transplantation
P02547778A0786|3 14|unique nature
P02547778A0786|34 67|ANT1 transcriptional control elements
P02547778A0786|85 106|differential expression
P02548683T0001|1 12|brief account
P02548683T0001|31 38|Shanghai
P02548683T0001|41 55|viral hepatitis A
P02549036A0000|3 38|Bacillus subtilis phage phi 105 repressor
P02549036A0000|3 26|Bacillus subtilis phage phi
P02549036A0000|30 38|repressor
P02549036A0000|41 92|lambda repressor-like transcriptional regulatory protein
P02549036A0000|143 153|homogeneity
P02549036A0000|180 200|DNA-binding properties
P02549343A1008|17 19|gpI
P02549343A1008|31 35|cells
P02549343A1008|48 51|mO74
P02549343A1008|58 88|antigenic characteristics similar
P02549343A1008|98 100|gpI
P02549343A1008|105 121|VZV-infected cells
P02549343A1008|141 166|immunoprecipitation pattern
P02549343A1008|179 193|molecular weight
P02549343A1008|200 210|polypeptide
P02549343A1008|227 234|antibody
P02549343A1008|245 251|rabbits
P02549343A1008|264 279|recombinant virus
P02549343A1008|284 307|high neutralizing activity
P02549343A1008|340 349|complement
P02549417A0000|0 17|Erythrocytic stages
P02549417A0000|20 45|mammalian malarial parasites
P02549417A0000|53 73|acristate mitochondria
P02549417A0000|79 87|functions
P02550118A0610|8 45|bilateral diffuse pulmonary infiltrations
P02550118A0610|57 60|days
P02550682A0411|11 19|incidence
P02550682A0411|23 38|type IIc carcinoma
P02550682A0411|46 46|%
P02550682A0411|57 59|IIc
P02550682A0411|75 75|%
P02551886A0332|0 14|Restriction maps
P02551886A0332|26 33|plasmids
P02551886A0332|51 68|chromosomal inserts
P02551886A0332|91 99|fragments
P02552143A0748|0 2|VP5
P02552143A0748|19 36|major capsid protein
P02552143A0748|52 87|chloramphenicol acetyltransferase gene
P02552316A0526|14 35|seronegative caretakers
P02552316A0526|62 65|days
P02552316A0526|97 120|annual seroconversion rate
P02552316A0526|125 131|percent
P02554310A0419|12 26|similar fragment
P02554310A0419|37 54|38-base-pair region
P02555177A0488|7 11|pet54
P02555177A0488|14 28|LEU2 cytoductant
P02555177A0488|14 17|LEU2
P02555177A0488|46 64|mitochondrial genome
P02555177A0488|78 96|COX1 introns aI5 alpha
P02555177A0488|78 88|COX1 introns
P02555177A0488|89 96|aI5 alpha
P02555177A0488|100 106|aI5 beta
P02555177A0488|109 117|defective
P02555177A0488|124 141|COX3 gene expression
P02555177A0488|124 131|COX3 gene
P02555177A0488|150 165|COX1 mRNA splicing
P02555177A0488|168 182|mRNA translation
P02555418A0973|0 6|Insert2
P02555418A0973|15 47|repetitive non-Ig-related sequences
P02555418A0973|52 74|small Ig-related sequence
P02555519A0798|5 26|considerable variations
P02555519A0798|38 52|primary sequence
P02555519A0798|58 61|CDR3
P02555519A0798|63 94|complementarity determining region
P02555519A0798|96 103|peptides
P02555519A0798|112 119|H-chains
P02555519A0798|148 164|D-region structure
P02555519A0798|194 215|effective hapten binding
P02555703T0000|0 22|Tyrosine kinase oncogenes
P02555703T0000|31 53|interleukin-3 dependence
P02555703T0000|31 43|interleukin-3
P02555703T0000|56 73|murine myeloid cells
P02555703T0000|81 97|signaling pathways
P02555703T0000|107 111|c-myc
P02555703T0000|113 133|conditional regulation
P02555703T0000|136 153|c-myc transcription
P02555703T0000|136 140|c-myc
P02555703T0000|156 181|temperature-sensitive v-abl
P02555703T0000|177 181|v-abl
P02556264A0278|4 16|TC-II enhanson
P02556264A0278|39 49|kappa B motif
P02556264A0278|57 74|kappa chain enhancer
P02556264A0278|91 98|lymphoid
P02556264A0278|102 118|non-lymphoid cells
P02556264A0278|159 181|lymphoid cell specificity
P02556264A0278|187 197|kappa B motif
P02556269A0187|3 10|DNA helix
P02556269A0187|16 23|tandemly
P02556269A0187|33 45|13mer sequence
P02556269A0187|65 72|unstable
P02556269A0187|87 102|hypersensitivity
P02556269A0187|105 134|single-strand-specific nuclease
P02556269A0187|148 165|supercoiled plasmid
P02556269A0187|184 192|stable DNA
P02556269A0187|211 243|two-dimensional gel electrophoresis
P02556269A0187|246 256|topoisomers
P02556603A0606|12 29|similar improvement
P02556603A0606|40 48|ampullary
P02556603A0606|52 70|periampullary cancer
P02556603A0606|72 88|gallbladder cancer
P02556603A0606|92 117|extrahepatic bile duct cancer
P02557217A0000|0 13|Beta-endorphin
P02557217A0000|15 18|ACTH
P02557217A0000|22 38|cortisol secretion
P02557217A0000|59 75|healthy adult males
P02557217A0000|81 104|nasal spray administration
P02557217A0000|108 125|IU salmon calcitonin
P02557217A0000|110 125|salmon calcitonin
P02557217A0398|19 28|calcitonin
P02557217A0398|37 69|beta-endorphin increase independent
P02557217A0398|37 50|beta-endorphin
P02557217A0398|80 109|corticotrophin-cortisol release
P02557217A0398|80 93|corticotrophin
P02557350A0632|3 14|DNA sequences
P02557350A0632|22 29|proteins
P02557350A0632|33 39|SRP54sc
P02557350A0632|43 49|SRP54sp
P02557350A0632|59 59|%
P02557350A0632|65 74|% identical
P02557350A0632|77 84|SRP54mam
P02559630A0270|0 20|Other hemostatic values
P02559630A0270|43 68|partial thromboplastin times
P02559630A0270|50 63|thromboplastin
P02559630A0270|70 85|prothrombin times
P02559630A0270|70 80|prothrombin
P02559630A0270|87 99|thrombin times
P02559630A0270|87 94|thrombin
P02559630A0270|101 110|fibrinogen
P02559630A0270|112 125|platelet counts
P02559630A0270|130 165|fibrin/fibrinogen degradation products
P02559630A0270|130 135|fibrin
P02559630A0270|137 146|fibrinogen
P02560415T0012|0 18|Rare neurogenic tumor
P02560415T0012|23 32|metastasis
P02560415T0012|47 57|face regions
P02562787A0637|27 37|cellular NBP
P02562787A0637|40 43|CNBP
P02562825A0413|0 13|Responsiveness
P02562825A0413|16 35|beta-2 agonist therapy
P02562825A0413|16 21|beta-2
P02562825A0413|55 60|agents
P02562825A0413|62 66|p less
P02565405T0000|0 6|Drug use
P02565405T0000|9 21|trauma victims
P02565683A0841|1 17|critical heart rate
P02565683A0841|24 50|appropriate sympathetic state
P02565683A0841|71 79|instances
P02565683A0841|82 90|reentrant
P02565683A0841|93 118|automatic atrial tachycardia
P02565683A0841|122 150|atypical junctional tachycardia
P02565807A1198|14 30|neu proto-oncogene
P02565807A1198|41 54|kinase activity
P02565807A1198|69 78|properties
P02565807A1198|94 106|similar levels
P02565807A1198|109 119|NIH 3T3 cells
P02565807A1198|122 129|ABSTRACT
P02565807A1198|144 148|WORDS
P02566613A0831|3 15|65-bp sequence
P02566613A0831|27 58|octameric cAMP-responsive enhancer
P02566613A0831|60 62|CRE
P02566613A0831|64 71|TGACGTCA
P02566613A0831|73 83|nucleotides
P02566613T0000|0 25|Somatostatin gene expression
P02566613T0000|0 15|Somatostatin gene
P02566613T0000|28 47|pancreatic islet cells
P02566613T0000|60 90|cell-specific DNA control elements
P02566613T0000|94 112|DNA-binding proteins
P02566680A0820|14 42|full mu-opioid agonists fentanyl
P02566680A0820|44 51|morphine
P02566680A0820|53 63|I-methadone
P02566680A0820|67 77|levorphanol
P02566680A0820|88 108|% fentanyl-appropriate
P02566680A0820|121 125|doses
P02566680A0820|139 150|times smaller
P02566680A0820|178 190|response rates
P02566680A0820|195 195|%
P02567030A0482|22 43|original discrimination
P02567030A0482|48 55|controls
P02567030A0482|65 80|normal difficulty
P02567030A0482|94 106|first reversal
P02568930T0000|0 8|Isolation
P02568930T0000|12 27|characterization
P02568930T0000|31 34|cDNA
P02568930T0000|44 59|putative cytokine
P02568930T0000|76 86|stimulation
P02568930T0000|93 104|CD2 structure
P02568930T0000|107 123|human T lymphocytes
P02569411A0151|5 15|termination
P02569411A0151|31 37|animals
P02569411A0151|66 80|nucleus amygdala
P02571924A0000|0 11|Haploid cells
P02571924A0000|14 24|mating type A
P02571924A0000|30 73|basidiomycetous yeast Rhodosporidium toruloides
P02571924A0000|82 96|mating pheromone
P02571924A0000|98 111|rhodotorucine A
P02571924A0000|122 134|undecapeptide
P02571924A0000|145 162|S-farnesyl cysteine
P02571924A0000|168 182|carboxy terminus
P02572777T0000|0 19|Tumour necrosis factor
P02572777T0000|23 54|adult respiratory distress syndrome
P02572928T0000|0 9|Monitoring
P02572928T0000|12 30|rheumatoid arthritis
P02573303A0000|13 27|left ventricular
P02573303A0000|29 30|LV
P02573303A0000|32 43|stroke volume
P02573303A0000|50 79|positive end-expiratory pressure
P02573303A0000|81 84|PEEP
P02573303A0000|112 113|LV
P02573303A0000|134 149|contractile state
P02573336A0000|17 30|return-of-fear
P02573336A0000|32 34|ROF
P02573336A0000|61 81|spider-phobic subjects
P02573336A0000|145 150|retest
P02573336A0000|178 180|ROF
P02573829T0000|0 23|Evolutionary conservation
P02573829T0000|26 49|homeodomain-binding sites
P02573829T0000|53 74|other sequences upstream
P02573829T0000|87 108|major transcription unit
P02573829T0000|114 148|Drosophila segmentation gene engrailed
P02573829T0000|124 139|segmentation gene
P02573836A0244|11 30|functional importance
P02573836A0244|38 40|NBS
P02573836A0244|46 75|overall drug resistance phenotype
P02573836A0244|87 90|mdr1
P02573836A0244|104 125|amino acid substitutions
P02573836A0244|131 151|core consensus sequence
P02573836A0244|155 171|nucleotide binding
P02573836A0244|173 178|GXGKST
P02574016A0428|20 22|TOF
P02574016A0428|49 49|%
P02574016A0428|52 63|control value
P02574016A0428|65 75|neostigmine
P02574016A0428|90 102|micrograms/kg
P02574016A0428|105 110|adults
P02574016A0428|114 126|micrograms/kg
P02574016A0428|129 135|infants
P02574016A0428|139 146|children
P02574052A0910|2 23|significant differences
P02574052A0910|45 58|Type A behaviour
P02574052A0910|62 86|beta-adrenoceptor blockade
P02574052A0910|62 78|beta-adrenoceptor
P02574193A0663|0 8|Selection
P02574193A0663|16 20|items
P02574193A0663|26 78|Clinical Institute Withdrawal Assessment-Benzodiazepines
P02574193A0663|80 85|CIWA-B
P02574193A0663|110 131|significant differences
P02574193A0663|139 146|baseline
P02574193A0663|150 174|critical withdrawal periods
P02574193A0663|177 193|high-dose subjects
P02574193A0663|204 211|symptoms
P02574193A0663|226 232|placebo
P02574193A0663|236 243|diazepam
P02574193A0663|246 261|low-dose subjects
P02574193A0663|268 284|contingency tables
P02574193A0663|288 313|logistic regression analysis
P02574551T0000|0 13|Antihistamines
P02574551T0000|16 21|asthma
P02575174A0229|27 34|efficacy
P02575174A0229|46 54|doxazosin
P02575174A0229|66 85|active selective alpha
P02575174A0229|87 93|blocker
P02575174A0229|97 104|patients
P02575174A0229|109 128|systemic hypertension
P02575174A0229|133 160|concomitant airflow limitation
P02575490A1021|0 19|Northern blot analysis
P02575490A1021|28 52|multiple oIGF-I transcripts
P02575490A1021|36 52|oIGF-I transcripts
P02575490A1021|56 64|broad band
P02575490A1021|76 86|nucleotides
P02575490A1021|90 105|other transcripts
P02575490A1021|108 128|higher molecular weight
P02575567T0001|0 22|Materials science studies
P02575567T0001|28 36|soldering
P02575567T0001|39 63|different orthodontic wires
P02575959A0643|3 13|latency time
P02575959A0643|20 39|lactate concentration
P02575959A0643|50 58|top values
P02575959A0643|71 85|aerobic training
P02575959A0643|87 88|T2
P02576405A0223|2 18|patients resistant
P02576405A0223|21 23|VAD
P02576405A0223|25 42|high-dose therapies
P02576405A0223|47 66|intravenous melphalan
P02576405A0223|69 82|CBV combination
P02576405A0223|84 110|cyclophosphamide-BCNU-VP-16
P02576405A0223|116 126|EDAP regimen
P02576405A0223|128 132|VP-16
P02576405A0223|134 141|platinum
P02576405A0223|151 159|responses
P02576405A0223|169 169|%
P02576405A0223|172 179|patients
P02577458A0412|34 43|newer drugs
P02577458A0412|48 74|angiotensin converting enzyme
P02577458A0412|48 58|angiotensin
P02577458A0412|69 84|enzyme inhibitors
P02577458A0412|86 117|alpha-adrenergic receptor blockers
P02577458A0412|86 109|alpha-adrenergic receptor
P02577458A0412|122 139|calcium antagonists
P02577867T0000|3 22|avian cellular homolog
P02577867T0000|28 39|oncogene jun.
P02577867T0000|28 38|oncogene jun
P02580830A1131|1 14|736-bp sequence
P02580830A1131|22 43|flanking region adjacent
P02580830A1131|49 55|cap site
P02580830A1131|61 72|human AFP gene
P02580830A1131|81 91|% similarity
P02580830A1131|99 117|corresponding region
P02580830A1131|123 134|mouse AFP gene
P02582240A1009|0 16|High ATP/GTP ratios
P02582240A1009|25 34|initiation
P02582240A1009|37 54|RNA primer synthesis
P02582240A1009|60 69|dCTTT sites
P02582240A1009|78 93|low ATP/GTP ratios
P02582240A1009|102 111|initiation
P02582240A1009|117 125|dCCC sites
P02582918A0000|5 33|hepatitis B vaccine immunization
P02582918A0000|35 55|serum antibody response
P02582918A0000|61 71|primary type
P02582918A0000|76 80|cases
P02582918A0000|85 96|anti-HBs less
P02582918A0000|85 92|anti-HBs
P02582918A0000|104 106|S/N
P02582918A0000|108 119|S/N Ratio Unit
P02582918A0000|123 124|T0
P02582918A0000|129 148|anti-HBs positive rate
P02582918A0000|129 136|anti-HBs
P02582918A0000|156 156|%
P02582918A0000|162 162|%
P02582918A0000|168 168|%
P02582918A0000|176 176|%
P02582918A0000|179 180|T1
P02582918A0000|182 183|T2
P02582918A0000|185 186|T0
P02582918A0000|190 192|T12
P02584969A0119|3 20|experimental design
P02584969A0119|34 56|multiple regression model
P02584969A0119|58 77|sequential treatments
P02584969A0119|82 101|proportional end point
P02584969A0119|105 105|%
P02584969A0119|110 123|protection time
P02585492A1005|0 32|Interspecific complementation tests
P02585492A1005|46 55|P7 proteins
P02585492A1005|77 82|P1 parA
P02585492A1005|79 82|parA
P02585492A1005|85 95|parB mutants
P02585492A1005|103 112|P1 proteins
P02585492A1005|132 142|P7 mutations
P02586485A0511|0 4|GN101
P02586485A0511|6 12|YC819-9
P02586485A0511|17 19|SB3
P02586513A0622|0 7|Analysis
P02586513A0622|21 45|1,859-residue ama-1 product
P02586513A0622|52 71|considerable identity
P02586513A0622|79 92|largest subunit
P02586513A0622|95 100|RNAP II
P02586513A0622|95 98|RNAP
P02586513A0622|105 118|other organisms
P02586513A0622|143 157|zinc finger motif
P02586513A0622|165 177|amino terminus
P02586513A0622|183 205|carboxyl-terminal domain
P02586513A0622|228 236|heptamers
P02586513A0622|244 258|consensus Tyr Ser
P02586513A0622|262 267|Thr Ser
P02586513A0622|271 273|Ser
P02590097A0093|0 17|Nodular involvement
P02590097A0093|23 30|left lung
P02590097A0093|34 45|infiltration
P02590097A0093|51 56|mucosa
P02590097A0093|66 82|lower lobe bronchus
P02590097A0093|108 127|monoclonal gammopathy
P02590097A0093|129 142|IgA--Type Kappa
P02590097A0093|129 131|IgA
P02590097A0093|134 142|Type Kappa
P02590391A0442|0 3|None
P02590391A0442|17 26|parameters
P02590391A0442|28 40|heart contents
P02590391A0442|43 55|neutral lipids
P02590391A0442|57 74|total phospholipids
P02590391A0442|76 94|phosphatidylcholine
P02590391A0442|96 119|phosphatidylethanolamine
P02590391A0442|121 142|diphosphatidylglycerol
P02590391A0442|144 156|sphingomyelin
P02590391A0442|160 179|fatty acid composition
P02590391A0442|186 202|phospholipid class
P02590391A0442|230 236|grading
P02590391A0442|242 248|lesions
P02590540A0741|5 9|women
P02590540A0741|14 35|non-malignant diagnoses
P02590540A0741|41 41|%
P02590540A0741|46 47|CA
P02590540A0741|51 56|levels
P02590540A0741|59 64|excess
P02590540A0741|69 72|U/ml
P02590540A0741|79 79|%
P02590540A0741|81 87|greater
P02590540A0741|94 97|U/ml
P02590615A0636|16 26|steady state
P02590615A0636|39 47|light meal
P02590615A0636|80 94|important manner
P02590615A0636|98 113|pharmacokinetics
P02590615A0636|116 125|nifedipine
P02590615A0636|139 146|biphasic
P02590615A0636|148 154|tablets
P02590869A0743|3 19|GALT-primed calves
P02590869A0743|32 39|serum IgG
P02590869A0743|37 39|IgG
P02590869A0743|41 49|lavage IgG
P02590869A0743|47 49|IgG
P02590869A0743|53 55|IgA
P02590869A0743|68 76|LNA titers
P02590869A0743|83 94|lavage fluids
P02590869A0743|98 102|serum
P02590869A0743|115 120|SC dose
P02591078A0000|0 19|Recent investigations
P02591078A0000|33 41|Grenz rays
P02591078A0000|56 88|allergic contact dermatitis reaction
P02591078A0000|106 120|Langerhans cells
P02591078A0000|134 147|OKT6 antibodies
P02591078A0000|151 168|electron microscopy
P02591078A0000|186 194|epidermis
P02591078A0000|200 207|same time
P02591969A0961|3 21|elements responsible
P02591969A0961|25 49|glucocorticoid stimulation
P02591969A0961|52 71|ADH gene transcription
P02591969A0961|52 58|ADH gene
P02592543A0106|3 16|present studies
P02592543A0106|27 52|biochemical characteristics
P02592543A0106|54 79|Kanagawa hemolysin reactions
P02592543A0106|62 70|hemolysin
P02592543A0106|84 98|plasmid profiles
P02592543A0106|116 136|environmental isolates
P02592640A0466|0 9|High values
P02592640A0466|16 22|retinol
P02592640A0466|26 38|beta-carotene
P02592640A0466|50 63|full fat cheeses
P02592640A0466|67 79|whipping cream
P02592640A0466|98 106|Edam-type
P02592640A0466|129 129|g
P02592640A0466|131 143|whipping cream
P02592640A0466|164 172|Edam-type
P02592640A0466|195 195|g
P02592640A0466|197 209|whipping cream
P02592640A0466|214 229|all-trans retinol
P02592640A0466|233 250|total beta-carotene
P02592961A0327|0 5|COGLAB
P02592961A0327|14 21|measures
P02592961A0327|24 37|preattentional
P02592961A0327|39 49|attentional
P02592961A0327|51 60|conceptual
P02592961A0327|65 86|psychomotor performance
P02595451A1136|18 29|aniridia gene
P02595451A1136|31 33|AN2
P02595451A1136|39 71|recurrent T-cell leukemia breakpoint
P02595451A1136|73 76|TCL2
P02595451A1136|83 96|marker sequence
P02595451A1136|100 112|opposite sides
P02595451A1136|115 118|MIC1
P02595451T0000|1 25|fine-structure deletion map
P02595451T0000|28 45|human chromosome 11p
P02595451T0000|57 71|J1 series hybrids
P02597484A0624|13 32|effective diffusivity
P02597484A0624|35 43|platelets
P02597484A0624|45 46|De
P02597484A0624|54 78|surface reactivity constant
P02597484A0624|80 80|K
P02597484A0624|83 108|less significant differences
P02597484A0624|123 141|artificial materials
P02597549A0964|10 23|recent patients
P02597549A0964|33 36|days
P02597549A0964|50 65|oral dipyridamole
P02597549A0964|69 76|mg X 3/day
P02597549A0964|81 87|aspirin
P02597549A0964|91 96|mg/day
P02597549A0964|106 124|early recovery period
P02597549A0964|126 137|four-six days
P02597549A0964|151 167|normal prothrombin
P02597549A0964|157 167|prothrombin
P02597549A0964|171 196|partial thromboplastin times
P02597549A0964|178 191|thromboplastin
P02598034A0000|0 21|Middle-latency auditory
P02598034A0000|28 37|potentials
P02598034A0000|39 43|MAEPs
P02598034A0000|59 66|controls
P02598034A0000|70 77|patients
P02598034A0000|82 93|focal lesions
P02598034A0000|96 123|dorsolateral prefrontal cortex
P02598745A0251|0 3|Most
P02598745A0251|24 37|Sylvius fissure
P02598745A0251|41 45|cases
P02599995A1031|0 27|Intracellular activity studies
P02599995A1031|47 54|times MBC
P02599995A1031|60 69|penicillin
P02599995A1031|76 94|significant activity
P02599995A1031|102 127|intracellular staphylococci
P02599995A1031|149 149|%
P02600306A0140|48 56|detection
P02600306A0140|59 80|envelope phase disparity
P02600306A0140|115 127|single channel
P02600306A0140|138 144|AM tones
P02601707A0986|0 19|Gel retardation assays
P02601707A0986|32 37|DNase I
P02601707A0986|32 36|DNase
P02601707A0986|38 49|footprinting
P02601707A0986|53 84|diethyl pyrocarbonate interference
P02601707A0986|96 108|nuclear factor
P02601707A0986|127 136|C2 myotubes
P02601707A0986|140 152|BC3H1 myocytes
P02601707A0986|173 173|A
P02601707A0986|175 188|T-rich sequence
P02601707A0986|198 207|peripheral
P02602150A0993|0 19|Such transgenic plants
P02602150A0993|42 59|mutational analysis
P02602150A0993|62 77|sequence elements
P02602150A0993|87 109|replication origin region
P02602150A0993|136 148|new generation
P02602150A0993|151 157|vectors
P02602150A0993|161 177|gene amplification
P02602150A0993|180 185|plants
P02602150A0993|195 214|minimal virus replicon
P02603374A0383|0 15|Ventral rhinotomy
P02603374A0383|37 51|dorsal rhinotomy
P02603374A0383|56 75|less patient morbidity
P02603374A0383|79 109|fewer postoperative complications
P02603923A0220|4 30|full-thickness skin incisions
P02603923A0220|52 61|female pigs
P02603923A0220|87 90|days
P02603923A0220|96 97|ml
P02603923A0220|100 120|epidermal growth factor
P02603923A0220|125 129|ng/ml
P02603923A0220|134 135|ml
P02603923A0220|138 143|Ringer
P02603923A0220|146 160|lactate solution
P02603923A0220|164 175|single-blind
P02603923A0220|177 193|randomized fashion
P02604420A0234|16 23|rebiopsy
P02604420A0234|35 53|reticulin antibodies
P02604420A0234|76 80|years
P02604420A0234|92 93|.0
P02604420A0234|113 121|year study
P02605160A0000|11 20|iron intake
P02605160A0000|23 36|59Fe absorption
P02605160A0000|62 69|maternal
P02605160A0000|73 85|fetal Fe status
P02605160A0000|128 131|rats
P02605182A0936|10 24|protein sequence
P02605182A0936|43 87|putative 16-residue amino-terminal signal peptide
P02605182A0936|114 135|239-residue polypeptide
P02605679A0306|0 7|Analysis
P02605679A0306|13 25|rate constants
P02605679A0306|42 61|isomerization rate k12
P02605679A0306|88 110|apparent degradation rate
P02605679A0306|116 120|delta
P02605679A0306|122 130|ester kdeg
P02605679A0306|135 140|slower
P02605679A0306|148 161|hydrolysis rate
P02605679A0306|167 171|delta
P02605679A0306|173 180|ester k24
P02607766A0000|41 56|characterization
P02607766A0000|60 81|quality control material
P02607766A0000|83 85|QCM
P02607766A0000|97 118|intrinsic concentration
P02607766A0000|121 127|cadmium
P02607766A0000|129 130|Cd
P02607766A0000|136 146|microgram/L
P02607766A0000|156 157|Pb
P02607766A0000|164 176|micrograms/dL
P02607766A0000|182 192|bovine blood
P02607766A0000|198 208|elevated QCM
P02607766A0000|219 220|Cd
P02607766A0000|225 236|micrograms/L
P02607766A0000|239 245|mercury
P02607766A0000|247 248|Hg
P02607766A0000|255 266|micrograms/L
P02607766A0000|272 273|Pb
P02607766A0000|279 291|micrograms/dL
P02607766A0000|297 307|bovine blood
P02607766A0000|318 341|aqueous spiking-solutions
P02607766A0000|354 358|salts
P02607766A0000|361 362|Cd
P02607766A0000|364 365|Hg
P02607766A0000|370 371|Pb
P02609112A0000|0 12|Reagent strips
P02609112A0000|45 62|laboratory medicine
P02609112A0000|81 104|professional laboratories
P02614668A0971|3 31|lowest detectable concentration
P02614668A0971|38 42|ng/ml
P02614668A0971|48 52|serum
P02615078A0283|13 22|antibodies
P02615078A0283|26 50|Thermophilic actinomycetes
P02615078A0283|54 57|M.f.
P02617623A0740|0 5|LON-72
P02617623A0740|9 16|isolates
P02617623A0740|19 24|LON-73
P02617623A0740|29 34|LON-71
P02617623A0740|41 46|LON-10
P02617623A0740|61 69|altitudes
P02617623A0740|80 80|m
P02617623A0740|92 104|single village
P02620085A0656|0 17|Animal experimental
P02620085A0656|21 40|clinical applications
P02620085A0656|43 48|plates
P02620085A0656|50 55|screws
P02620085A0656|59 92|spinal segmental replacement implants
P02620085A0656|103 119|composite material
P02620085A0656|129 139|good results
P02621983T0001|0 11|Significance
P02621983T0001|14 45|delta-aminolevulinic acid analysis
P02621983T0001|48 60|clinical tests
P02623038A0632|2 8|changes
P02623038A0632|25 42|FR-task performance
P02623038A0632|45 52|controls
P02623038A0632|65 85|daily saline injections
P02627159A0899|3 30|antigen-specific IgG4 antibody
P02627159A0899|59 71|immunotherapy
P02629109A0000|11 26|fertility decline
P02629109A0000|32 46|black population
P02629109A0000|52 67|Mississippi Delta
P02629109A0000|128 150|national black population
P02629109A0000|206 215|1880 levels
P02630543A0210|16 31|staining affinity
P02630543A0210|35 50|anti-T antibodies
P02630543A0210|55 74|glandular tissue cells
P02630543A0210|91 91|T
P02630543A0210|94 94|T
P02630543A0210|97 97|T
P02630543A0210|104 104|T
P02630543A0210|111 123|annual changes
P02630543A0210|129 135|numbers
P02630543A0210|143 157|cell populations
P02630543A0210|191 205|glandular tissue
P02631505A0382|0 9|Ampicillin
P02631505A0382|11 13|AMP
P02631505A0382|28 41|aminoglycoside
P02631505A0382|43 45|AMI
P02631505A0382|70 74|cases
P02631566A0151|0 13|Alkoxymetgyl-3
P02631566A0151|17 43|dimethylpyridinium chlorides
P02631566A0151|69 88|3,4-dimethylpyridine
P02631566A0151|93 115|chloromethyl alkyl ethers
P02631566A0151|122 175|1-ethyloxymethyl-3-alkylthiomethylimidazolium chlorides
P02631566A0151|190 198|reactions
P02631566A0151|201 224|1-ethyloxymethylimidazol
P02631566A0151|229 253|chloromethyl alkyl sulfides
P02631743A0275|17 25|incidence
P02631743A0275|28 52|congenital color deficiency
P02631743A0275|58 64|Koreans
P02631743A0275|75 103|H-R-R pseudoisochromatic plates
P02631743A0275|75 77|H-R
P02631887A0000|6 13|patients
P02631887A0000|26 29|HGGM
P02631887A0000|34 44|non-Hodgkin
P02631887A0000|47 55|lymphomas
P02632904A0619|18 23|VE/VO2
P02632904A0619|27 31|Q/VO2
P02632904A0619|39 68|significant negative correlation
P02632904A0619|70 71|r =
P02632904A0619|78 82|p less
P02634490A0186|3 23|differential diagnosis
P02634490A0186|30 39|affections
P02634490A0186|52 65|clinical course
P02634490A0186|67 77|sialography
P02634490A0186|81 93|CT examination
P02634490A0186|108 125|modern ATB treatment
P02634490A0186|157 171|surgical therapy
P02634872A0000|0 9|Retrograde
P02634872A0000|34 50|endodontics system
P02634872A0000|64 73|apical zone
P02634872A0000|79 94|surgical approach
P02636920T0001|0 17|Collaborative study
P02636920T0001|20 70|Japanese Pharmacopoeia Heparin Sodium Reference Standard
P02637597A0362|0 17|Serological studies
P02637597A0362|23 39|early relapse stage
P02637597A0362|68 75|serum ANA
P02637597A0362|77 79|IgA
P02637597A0362|83 90|IgM level
P02637597A0362|83 85|IgM
P02637597A0362|95 103|normal IgG
P02637597A0362|101 103|IgG
P02637597A0362|117 118|C3
P02637597A0362|122 123|C4
P02638964A0372|3 18|maximum stress due
P02638964A0372|24 45|hygroscopic examination
P02638964A0372|51 59|composite
P02638964A0372|67 72|kg/mm2
P02638964A0372|75 85|equilibrium
P02638964A0372|109 117|composite
P02641762T0001|0 19|Ischemic heart disease
P02641762T0001|31 78|exercise stress thallium-201 myocardial scintigraphy
P02641762T0001|93 97|SPECT
P02641762T0001|107 116|eye display
P02642466T0000|0 15|Sequence analysis
P02642466T0000|21 63|47-kilodalton major integral membrane immunogen
P02642976A1474|0 26|Potential consensus sequences
P02642976A1474|38 59|late regulatory elements
P02644735A0427|2 9|FP mutant
P02644735A0427|11 19|AcFP875-2
P02644735A0427|25 40|1.6-kbp insertion
P02644735A0427|43 57|S. frugiperda DNA
P02644735A0427|77 87|transcripts
P02644735A0427|95 104|S1 analysis
P02644735A0427|133 148|host cell sequence
P02645276T0088|0 11|Construction
P02645276T0088|15 32|RIP1 deletion strain
P02645276T0088|15 18|RIP1
P02645276T0088|47 74|temperature-sensitive mutants
P02645431A1562|20 33|hypocitraturia
P02645431A1562|41 60|renal tubular acidosis
P02645431A1562|72 77|defect
P02645431A1562|80 101|proximal tubule function
P02646007T0000|0 36|Concomitant chronic lymphocytic leukemia
P02646007T0000|38 57|acute myeloid leukemia
P02646007T0000|62 71|thrombosis
P02646007T0000|76 93|protein C deficiency
P02647403A0000|0 24|Vivid visual hallucinations
P02647403A0000|32 51|other psychopathology
P02647403A0000|85 89|years
P02647918A0423|5 14|whole group
P02647918A0423|16 22|basal GH
P02647918A0423|21 22|GH
P02647918A0423|26 44|somatomedin-C levels
P02647918A0423|26 38|somatomedin-C
P02647918A0423|67 79|standard error
P02647918A0423|115 119|ng/ml
P02647918A0423|147 150|U/ml
P02647918A0588|0 10|Application
P02647918A0588|13 29|different criteria
P02647918A0588|50 57|patients
P02647918A0588|61 61|%
P02647918A0588|66 78|basal GH levels
P02647918A0588|71 72|GH
P02647918A0588|85 89|ng/ml
P02647918A0588|93 100|patients
P02647918A0588|104 104|%
P02647918A0588|109 133|normal somatomedin-C values
P02647918A0588|115 127|somatomedin-C
P02647918A0588|137 144|patients
P02647918A0588|148 148|%
P02647918A0588|153 173|complete GH suppression
P02647918A0588|161 162|GH
P02647918A0588|184 188|ng/ml
P02647918A0588|196 199|OGTT
P02647918A0588|206 213|patients
P02647918A0588|217 217|%
P02647918A0588|225 247|above-mentioned criteria
P02647918A0588|252 264|disappearance
P02647918A0588|270 290|paradoxical GH response
P02647918A0588|281 282|GH
P02647918A0588|293 304|TRH/GnRH test
P02647918A0588|293 295|TRH
P02647918A0588|297 300|GnRH
P02647937A0191|21 36|surgical planning
P02647937A0191|68 71|ways
P02647937A0191|88 95|problems
P02648396A0565|2 12|Rat-1a cells
P02648396A0565|28 41|human c-jun mRNA
P02648396A0565|71 75|clone
P02648396A0565|78 88|soft agarose
P02648396A0565|92 101|form tumors
P02648396A0565|104 111|nude mice
P02648396A1033|23 26|foci
P02648396A1033|40 43|RECs
P02648396A1033|49 68|c-jun/ras combination
P02648396A1033|49 53|c-jun
P02648396A1033|55 57|ras
P02648396A1033|72 80|augmented
P02648396A1033|92 138|tumor promoter phorbol 12-tetradecanoate 13-acetate
P02648646A0216|0 23|Platelet activating factor
P02648646A0216|37 41|doses
P02648646A0216|46 60|minute intervals
P02648646A0216|64 77|airway response
P02648646A0216|96 116|partial expiratory flow
P02648646A0216|121 121|%
P02648646A0216|124 136|vital capacity
P02648646A0216|138 141|Vp30
P02648646A0932|10 31|significant correlation
P02648646A0932|39 62|baseline PC40 methacholine
P02648646A0932|69 79|maximal fall
P02648646A0932|82 85|Vp30
P02648646A0932|108 117|micrograms
P02648646A0932|124 133|second dose
P02648646A0932|137 146|micrograms
P02648646A0932|150 173|platelet activating factor
P02649445A0412|4 5|BG
P02649445A0412|9 25|IRI concentrations
P02649445A0412|9 11|IRI
P02649445A0412|35 38|OGTT
P02649445A0412|46 51|lowest
P02649445A0412|54 65|body builders
P02649445A0412|75 82|controls
P02649445A0412|90 96|highest
P02649445A0412|99 106|obese men
P02649811T0000|0 22|Postcoital contraception
P02649811T0000|25 43|family planning study
P02650663A0178|35 42|subjects
P02650663A0178|49 74|mild cognitive impairment due
P02650663A0178|77 90|senile dementia
P02650663A0178|96 108|Alzheimer type
P02650663A0178|127 138|insufficient
P02650663A0178|168 183|definite dementia
P02651448A0000|32 50|diffusion concurrent
P02651448A0000|55 65|dissolution
P02651448A0000|71 79|polymeric
P02651448A0000|102 117|depolymerization
P02651448A0000|119 123|Type A
P02651448A0000|129 138|bioerosion
P02651448A0000|148 163|depolymerization
P02651448A0000|165 169|Type B
P02651487A0000|25 46|calcium channel blockers
P02651487A0000|59 69|contraction
P02651487A0000|72 91|vascular smooth muscle
P02651487A0000|100 112|less knowledge
P02651487A0000|126 154|excitation contraction coupling
P02651487A0000|160 174|endocrine glands
P02651487A0000|196 202|insulin
P02651487A0000|206 220|glucagon release
P02651487A0000|206 213|glucagon
P02655381A0000|0 10|Many studies
P02655381A0000|49 62|organic factors
P02655381A0000|65 81|erectile impotence
P02655381A0000|83 92|detectable
P02655381A0000|99 103|means
P02655381A0000|106 129|laboratory investigations
P02655381A0000|131 146|mild hypogonadism
P02655381A0000|148 165|hyperprolactinemia
P02655381A0000|167 176|occlusions
P02655381A0000|188 194|located
P02655381A0000|209 222|sexual arteries
P02655381A0000|224 241|venous incompetence
P02655381A0000|243 265|subclinical neuropathies
P02656257A0000|3 36|site-specific DNA inversion system Cin
P02656257A0000|49 63|bacteriophage P1
P02656257A0000|75 85|recombinase
P02656257A0000|90 115|inverted crossing-over sites
P02656257A0000|120 142|recombinational enhancer
P02657388A1011|3 18|terminator region
P02657388A1011|28 38|termination
P02657388A1011|41 51|transcripts
P02657388A1011|63 76|RNA polymerase I
P02657883A0000|0 9|US-Doppler
P02657883A0000|39 55|noninvasive method
P02657883A0000|62 81|functional evaluation
P02657883A0000|84 104|arteriovenous fistulas
P02657883A0000|106 108|FAV
P02657883T0001|0 6|Doppler
P02657883T0001|23 43|arteriovenous fistulae
P02657883T0001|47 54|dialysis
P02664229A0138|8 15|cosmesis
P02664229A0138|41 48|problems
P02664229A0138|103 131|distal urethrocutaneous fistula
P02664229A0138|155 167|Arap procedure
P02664229A0138|188 197|advantages
P02664229A0138|222 257|other 1-stage distal hypospadias repairs
P02666034A1520|12 19|patients
P02666034A1520|47 83|selective vasodilator calcium antagonist
P02666034A1520|88 120|beta-adrenergic reflex vasodilation
P02666034A1520|172 184|placebo course
P02666404A0220|3 22|galactose transporter
P02666404A0220|43 60|structural homology
P02666404A0220|66 76|superfamily
P02666404A0220|79 95|sugar transporters
P02666404A0220|112 133|human HepG2-erythrocyte
P02666404A0220|137 166|fetal muscle glucose transporters
P02666404A0220|171 205|rat brain and liver glucose transporters
P02666404A0220|171 178|rat brain
P02666404A0220|182 205|liver glucose transporters
P02666404A0220|210 251|Escherichia coli xylose and arabinose permeases
P02666404A0220|225 230|xylose
P02666404A0220|234 251|arabinose permeases
P02666404A0220|271 277|glucose
P02666404A0220|279 285|maltose
P02666404A0220|290 310|galactose transporters
P02666568A0000|15 31|untreated patients
P02666568A0000|55 68|protocol TCL821
P02666568A0000|76 84|evaluable
P02667259A0331|20 23|cent
P02667259A0331|25 40|adverse reactions
P02667259A0331|42 45|ADRs
P02667259A0331|64 69|nausea
P02667259A0331|71 79|dizziness
P02667259A0331|92 104|menstrual flow
P02668691A0570|4 7|mRNA
P02668691A0570|23 26|nagB
P02668691A0570|30 33|nagA
P02668691A0570|70 80|distal genes
P02668691A0570|82 85|nagC
P02668691A0570|89 92|nagD
P02669199A0000|0 18|Tumor necrosis factor
P02669199A0000|20 22|TNF
P02669199A0000|42 61|shock syndrome similar
P02669199A0000|78 86|endotoxin
P02669199A0000|88 90|LPS
P02670457T0000|3 20|calcium requirement
P02670457T0000|24 41|hypothermic storage
P02670457T0000|47 60|cardiac explant
P02674141A1202|3 24|seventh cysteine residue
P02674141A1202|27 30|CTSE
P02674141A1202|33 39|located
P02674141A1202|49 71|activation peptide region
P02674141A1202|77 85|proenzyme
P02674327A0493|3 11|p34.8 gene
P02674327A0493|3 5|p34
P02674327A0493|16 35|strong codon usage bias
P02674327A0493|75 88|polyhedrin gene
P02674671A0601|5 35|single-stranded DNA transformants
P02674671A0601|39 39|%
P02674671A0601|68 87|resident met2 mutation
P02674671A0601|93 116|exogenous wild-type allele
P02674671A0601|102 116|wild-type allele
P02674674A1308|3 9|results
P02674674A1308|41 57|OBF1-binding sites
P02674674A1308|64 74|OBF1 protein
P02674674A1308|90 106|normal ARS function
P02674674A1308|119 129|replication
P02674679A1237|12 39|S1 nuclease protection analysis
P02674679A1237|12 21|S1 nuclease
P02674679A1237|42 56|RNA preparations
P02674679A1237|61 79|several mouse tissues
P02674679A1237|85 88|dhfr
P02674679A1237|92 105|divergent genes
P02674679A1237|112 124|similar levels
P02674679A1237|151 161|specificity
P02674679A1237|164 183|start site utilization
P02675492A0806|11 18|patients
P02675492A0806|25 43|clinical improvement
P02675492A0806|55 67|Ritchie-Index
P02675492A0806|69 77|pain score
P02675492A0806|79 81|ESR
P02675492A0806|85 87|CRP
P02677002A0205|8 16|wild-type
P02677002A0205|23 35|mutant enzymes
P02677002A0205|37 39|ATP
P02677002A0205|54 56|14C
P02677002A0205|58 60|Asp
P02677002A0205|63 95|equilibrium N-carbamyl-L-aspartate
P02677002A0205|97 101|C-Asp
P02677002A0205|110 112|32P
P02677002A0205|114 130|carbamyl phosphate
P02677002A0205|132 134|C-P
P02677002A0205|138 159|equilibrium Pi exchanges
P02677429A0366|0 12|Survival rates
P02677429A0366|19 40|original treatment group
P02677429A0366|49 49|%
P02677429A0366|57 57|%
P02677429A0366|67 72|months
P02677429A0366|100 113|treatment group
P02677429A0366|119 119|%
P02677429A0366|127 127|%
P02677429A0366|137 142|months
P02677429A0366|164 164|%
P02677429A0366|172 172|%
P02677429A0366|182 187|months
P02677429A0366|207 214|subjects
P02677429A0366|230 230|%
P02677429A0366|238 238|%
P02677429A0366|258 265|subjects
P02677429A0366|270 288|AIDS-related complex
P02677429A0366|294 315|original treatment group
P02677666A0356|0 6|Mapping
P02677666A0356|30 49|complementation group
P02677666A0356|67 73|mutants
P02677666A0356|76 82|allelic
P02677666A0356|88 94|ag alpha
P02677666A0356|96 103|mutation
P02679804A2000|3 10|products
P02679804A2000|13 22|genes ura10
P02679804A2000|18 22|ura10
P02679804A2000|26 29|ura3
P02679804A2000|59 68|channeling
P02679804A2000|71 92|orotidine monophosphate
P02680843A0724|21 22|RS
P02680843A0724|26 35|REM latency
P02680843A0724|53 58|groups
P02684159A0870|0 20|Hybridization analysis
P02684159A0870|43 46|mRNA
P02684159A0870|57 65|kilobases
P02684585T0001|0 23|Agranulocytosis treatment
P02684585T0001|28 35|rhGM-CSF
P02685331A0523|3 24|R. meliloti nifH promoter
P02685331A0523|34 57|K. pneumoniae nifH promoter
P02685331A0523|34 35|K.
P02685331A0523|46 57|nifH promoter
P02685331A0523|64 101|sigma 54-dependent methylation protection
P02685331A0523|104 118|guanine residues
P02685331A0523|151 175|nucleotides characteristic
P02685331A0523|178 203|sigma 54-dependent promoters
P02685461A0380|0 20|Major clinical symptoms
P02685461A0380|57 64|patients
P02685565A0165|37 53|c-myb-encoded mRNA
P02685565A0165|73 83|murine cells
P02685565A0165|108 127|rearranged c-myb genes
P02686588A0592|0 22|Routine clinical analysis
P02686588A0592|31 45|lower hematocrit
P02686588A0592|49 58|hemoglobin
P02686588A0592|63 73|elevated BUN
P02686588A0592|77 95|alkaline phosphatase
P02686588A0592|101 112|treated group
P02686749A0000|11 28|health significance
P02686749A0000|34 50|early renal changes
P02686749A0000|56 70|chronic exposure
P02686749A0000|73 79|cadmium
P02686749A0000|83 89|workers
P02686749A0000|143 158|urinary excretion
P02686749A0000|161 179|beta 2-microglobulin
P02686749A0000|182 202|retinol binding protein
P02686749A0000|243 247|years
P02686980A0000|30 51|functional organization
P02686980A0000|57 75|eukaryotic nucleolus
P02686980A0000|114 132|nucleolar components
P02686980A0000|138 142|yeast
P02686985A0811|1 33|transcription factor exclusion assay
P02686985A0811|54 65|PCF1 mutation
P02686985A0811|76 89|distinct stages
P02686985A0811|92 104|transcription
P02686985A0811|127 148|stable complex formation
P02686985A0811|162 168|effects
P02686985A0811|197 209|stable complex
P02688772T0000|0 9|Psychiatry
P02689136A1851|5 18|adverse effects
P02689439A0000|3 36|cytosolic glutathione S-transferases
P02689439A0000|38 41|GSTs
P02689439A0000|43 52|EC 2.5.1.18
P02689439A0000|43 44|EC
P02689439A0000|58 68|superfamily
P02689439A0000|71 87|dimeric isoenzymes
P02689439A0000|104 114|conjugation
P02689439A0000|117 139|electrophilic substrates
P02689439A0000|144 154|glutathione
P02689439A0402|18 36|untranslated regions
P02689439A0402|39 44|pmGT10
P02689439A0402|53 64|marked degree
P02689439A0402|67 74|homology
P02689439A0402|93 102|rat Yb1 gene
P02689439A0402|121 125|pmGT2
P02689439A0402|134 147|marked homology
P02689439A0402|153 171|corresponding region
P02689439A0402|177 186|rat Yb2 gene
P02689544A0456|0 4|Model
P02689544A0456|8 23|primary abutments
P02689544A0456|31 44|lateral incisor
P02689544A0456|51 61|second molar
P02689544A0456|64 81|secondary abutments
P02691557A0273|3 11|incidence
P02691557A0273|14 36|fetal breathing movements
P02691557A0273|49 49|h
P02691557A0273|74 87|gestational age
P02691557A0273|93 119|fetal arterial concentrations
P02691557A0273|122 130|plasma PGE
P02691557A0273|160 169|same period
P02691557A0273|172 180|gestation
P02691811A0355|15 17|min
P02691811A0355|29 43|plasma potassium
P02691811A0355|70 91|unchanged blood acidosis
P02691811A0355|118 141|bicarbonate concentration
P02691998A0672|3 13|present data
P02691998A0672|46 64|systemic vascular bed
P02691998A0672|69 88|pulmonary vascular bed
P02691998A0672|95 104|responsive
P02691998A0672|107 125|bolus administration
P02691998A0672|128 131|ET-1
P02692881A0354|16 34|normal pregnant women
P02692881A0354|38 60|normal non-pregnant women
P02692881A0354|62 66|women
P02692881A0354|71 73|PIH
P02692881A0354|92 100|heart rate
P02692881A0354|123 147|peripheral sympathetic tone
P02692881A0354|154 171|initial derangement
P02692881A0354|174 186|renal function
P02692881A0354|209 221|serum uric acid
P02692881A0354|236 250|sodium excretion
P02692881A0354|262 287|fractional calcium excretion
P02692881A0354|305 319|sodium excretion
P02693208A0166|26 38|recombination
P02693208A0166|43 67|repair-defective mutations
P02693208A0166|69 72|rad1
P02693208A0166|76 80|rad52
P02693208A0166|84 108|direct repeat recombination
P02693208A0166|137 153|inactive sequences
P02693593A0866|21 34|leader sequence
P02693593A0866|39 48|amino acids
P02694731A0241|5 13|other hand
P02694731A0241|29 40|epidemiology
P02694731A0241|43 51|Parkinson
P02694731A0241|82 102|etiological hypotheses
P02694731A0241|113 132|hypotheses consistent
P02694731A0241|140 161|epidemiological profile
P02694731A0241|169 182|careful testing
P02695914T0000|3 19|stereoselectivity
P02695914T0000|22 31|drug action
P02700977A0444|0 9|Scotchbond
P02700977A0444|28 38|penetration
P02700977A0444|69 80|XR bond/Silus
P02702566A0000|14 22|cisplatin
P02702566A0000|26 39|5-fluorouracil
P02702566A0000|58 61|days
P02702566A0000|76 83|infusion
P02702566A0000|98 109|advanced head
P02702566A0000|113 122|neck cancer
P02702849A0418|0 28|Metformin plasma concentrations
P02702849A0418|37 45|unchanged
P02702849A0418|55 62|patients
P02702849A0418|86 91|g daily
P02702849A0418|97 98|mg
P02702849A0418|117 144|patients plasma concentrations
P02702849A0418|182 193|micrograms/l
P02702849A0418|195 199|p less
P02703121T0000|0 8|Diagnosis
P02703121T0000|11 38|primary sclerosing cholangitis
P02703121T0000|42 51|blood donor
P02703121T0000|56 91|elevated serum alanine aminotransferase
P02703925A0359|27 45|various subgroupings
P02703925A0359|58 89|average sedimentation coefficients
P02703925A0359|93 114|polydispersity profiles
P02703925A0359|136 146|conclusions
P02703925A0359|157 179|proteoglycan aggregation
P02703925A0359|183 197|sedimentability
P02703925A0359|214 224|primary sign
P02703925A0359|227 252|cartilage matrix degradation
P02703925A0359|257 269|higher S values
P02703925A0359|273 285|proteoglycans
P02703925A0359|291 300|high weight
P02703925A0359|302 303|HW
P02703925A0359|313 317|areas
P02703925A0359|321 331|lower values
P02703925A0359|345 353|low weight
P02703925A0359|355 356|LW
P02703925A0359|366 370|areas
P02703925A0359|376 389|typical finding
P02703925A0359|392 413|normal cartilage samples
P02703925A0359|418 426|inversion
P02703925A0359|443 452|indicative
P02703925A0359|455 471|matrix degradation
P02703925A0359|490 498|HW regions
P02703925A0359|506 513|affected
P02703925A0359|521 535|LW-bearing areas
P02703925A0359|543 567|average S value distribution
P02703925A0359|574 591|cartilage thickness
P02703925A0359|611 642|corresponding proteoglycan content
P02703925A0359|661 676|articular surface
P02703925A0359|687 707|deepest cartilage layer
P02703925A0359|714 722|most cases
P02703925A0359|727 740|smallest amount
P02703925A0359|743 752|aggregates
P02703925A0359|761 789|highest average sedimentability
P02703925A0359|806 815|middle zone
P02703925A0359|821 833|normal samples
P02704579A1078|1 23|significant relationship
P02704579A1078|68 73|CRS/BW
P02704579A1078|77 97|gas exchange parameters
P02704579A1078|99 102|FIO2
P02704579A1078|106 115|a/AO2 ratio
P02704579A1078|118 122|P less
P02704579A1078|136 146|gas exchange
P02704579A1078|155 161|earlier
P02704579A1078|166 178|lung mechanics
P02705072A0464|0 8|End points
P02705072A0464|21 33|perioperative
P02705072A0464|35 40|30-day
P02705072A0464|42 61|myocardial infarction
P02705072A0464|63 64|MI
P02705296A0231|12 26|molecular weight
P02705296A0231|32 42|polyprotein
P02705296A0231|52 55|ORF1
P02705296A0231|60 70|kilodaltons
P02705296A0231|72 74|kDa
P02705556A1049|4 5|RV
P02705556A1049|22 23|RC
P02705556A1049|52 62|flow reserve
P02707909A0209|2 18|alternative method
P02707909A0209|21 23|UKM
P02707909A0209|52 64|small fraction
P02707909A0209|72 84|dialysate flow
P02707909A0209|89 107|consecutive dialyses
P02708288A0139|0 19|Liquid chromatography
P02708288A0139|24 44|amperometric detection
P02708288A0139|46 50|LC/AD
P02708288A0139|69 81|fluazifop acid
P02708288A0139|97 106|metabolism
P02708288A0139|109 122|base hydrolysis
P02708288A0139|125 139|fluazifop-butyl
P02708288A0139|142 149|soybeans
P02708288A0139|153 162|soybean oil
P02708288A0621|3 17|dichloromethane
P02708288A0621|28 45|mobile phase solvent
P02708288A0621|57 64|aliquots
P02708288A0621|81 112|PRP-1 liquid chromatographic column
P02708288A0621|114 126|fluazifop acid
P02708288A0621|142 161|coextracted compounds
P02708288A0621|200 200|V
P02708288A0621|209 243|amperometric electrochemical detector
P02708288A0621|249 261|oxidation mode
P02708353A1080|0 25|Primer extension experiments
P02708353A1080|42 68|transcription initiation site
P02708353A1080|101 109|analogous
P02708353A1080|142 158|similar P-450e gene
P02708353A1080|149 158|P-450e gene
P02708353A1452|17 39|polymerase chain reaction
P02708353A1452|69 79|transcripts
P02708353A1452|98 121|hepatic polysome fractions
P02708353A1452|138 154|active utilization
P02709081T0000|0 9|Validation
P02709081T0000|23 32|work styles
P02709081T0000|35 48|profile measure
P02709081T0000|54 74|type A behaviour pattern
P02709819A0495|7 9|ADR
P02709819A0495|32 51|ciprofloxacin therapy
P02711145T0000|0 16|HIV infectiousness
P02711145T0000|23 34|AIDS epidemic
P02711167A0818|14 20|turnout
P02711167A0818|25 33|PFB-group
P02711167A0818|50 75|lower serum pepsinogen levels
P02711167A0818|93 101|low degree
P02711167A0818|104 117|abomasal damage
P02711167A0818|125 131|animals
P02711601A0601|3 25|corresponding inhibition
P02711601A0601|28 50|acid phosphatase activity
P02711601A0601|28 42|acid phosphatase
P02711601A0601|53 63|control male
P02711601A0601|67 82|female guinea pigs
P02711601A0601|91 91|%
P02711601A0601|100 100|%
P02712246T0042|14 43|histopathologic characteristics
P02712450A0989|0 10|Normocapnic
P02712450A0989|12 17|PACO2 =
P02712450A0989|20 23|mm Hg
P02712450A0989|25 40|ventilatory drive
P02712450A0989|64 68|p less
P02712450A0989|83 90|subjects
P02712450A0989|92 95|Type
P02712450A0989|143 146|Type
P02712450A0989|162 172|hypercapnia
P02712450A0989|177 183|changes
P02712450A0989|211 216|groups
P02713310T0000|0 12|Fundus changes
P02713310T0000|23 57|mesangiocapillary glomerulonephritis
P02713310T0000|68 73|drusen
P02713310T0000|76 98|histopathological report
P02713520T0000|0 17|Chronic dose effects
P02713520T0000|20 34|methyl parathion
P02713520T0000|37 46|nuthatches
P02713520T0000|48 61|cholinesterase
P02713520T0000|65 79|ptilochronology
P02713994A0482|3 7|titer
P02713994A0482|10 21|anti HSV type 1
P02713994A0482|10 20|anti HSV type
P02713994A0482|25 46|anti HSV type 2 antibodies
P02713994A0482|25 35|anti HSV type
P02713994A0482|37 46|antibodies
P02713994A0482|52 58|mothers
P02713994A0482|63 71|cord blood
P02714525A0529|0 11|Kidney weight
P02714525A0529|15 39|kidney-to-body weight ratio
P02714525A0529|57 64|elevated
P02714525A0529|70 85|highest dose level
P02714525A0529|93 97|weeks
P02714525A0529|109 124|higher dose levels
P02714525A0529|132 136|weeks
P02714852T0000|0 15|Allelic variation
P02714852T0000|18 22|HLA-B
P02714852T0000|26 39|HLA-C sequences
P02714852T0000|60 71|HLA-B alleles
P02717133T0001|21 48|optimal development conditions
P02717133T0001|51 74|summary oxygen consumption
P02717349A0311|0 2|Men
P02717349A0311|29 43|physical fitness
P02717349A0311|48 52|women
P02718683A0142|0 18|Handgrip dynamometry
P02718683A0142|46 53|patients
P02720966A0455|2 19|cerebrospinal fluid
P02720966A0455|23 47|ADA catalytic concentration
P02720966A0455|57 63|mu kat/L
P02720966A0455|80 100|tuberculous meningitis
P02720966A0455|103 115|patients older
P02720966A0455|121 125|years
P02720966A0455|143 153|specificity
P02721169A0171|0 8|NERVTRACK
P02721169A0171|21 39|anatomical data items
P02721169A0171|51 65|tree-like manner
P02721169A0171|89 111|functional relationships
P02723503T0000|0 8|Swim-over
P02723503T0000|12 28|alternative method
P02723503T0000|42 58|motile spermatozoa
P02724227T0000|0 15|Perfusion washout
P02724227T0000|28 57|microvascular free flap tolerance
P02724227T0000|60 67|ischemia
P02725495A0929|26 36|U2 RNA region
P02725495A0929|56 85|pre-mRNA branchpoint recognition
P02725495A0929|88 92|yeast
P02725495A0929|115 128|metazoan U2 RNAs
P02725495A0929|140 148|divergent
P02725495A0929|151 162|trypanosomes
P02725513A0617|19 41|active CHO spacer promoter
P02725513A0617|62 74|universal rule
P02725513A0617|79 99|metazoan RNA polymerase
P02725513A0617|101 109|promoters
P02725513A0617|118 125|G residue
P02727909A0383|7 15|amplitude
P02727909A0383|21 31|aggregation
P02727909A0383|34 39|plates
P02727909A0383|86 88|ADP
P02727909A0383|109 115|persons
P02727909A0383|120 127|types IIa
P02727909A0383|131 136|IIb HLP
P02727909A0383|142 144|CHD
P02727909A0383|152 154|HLP
P02729666A0267|0 31|Significant intergroup differences
P02729666A0267|61 73|dentoskeletal
P02729666A0267|77 102|soft tissue profile variables
P02731611A0134|18 26|rationale
P02731611A0134|32 48|interactional view
P02731611A0134|72 91|post-surgical hiccups
P02731611A0134|121 130|principles
P02731611A0134|145 167|Mental Research Institute
P02731671A0000|3 18|relative toxicity
P02731671A0000|21 31|nickel oxide
P02731671A0000|33 35|NiO
P02731671A0000|38 61|nickel sulfate hexahydrate
P02731671A0000|63 67|NiSO4
P02731671A0000|70 72|H2O
P02731671A0000|78 93|nickel subsulfide
P02731671A0000|95 99|Ni3S2
P02731671A0000|113 122|F344/N rats
P02731671A0000|126 135|B6C3F1 mice
P02731671A0000|141 158|inhalation exposure
P02731671A0000|163 168|hr/day
P02731671A0000|171 179|days/week
P02731671A0000|186 190|weeks
P02732341A0000|0 17|Light microscopical
P02732341A0000|21 53|routine immunohistochemical studies
P02732341A0000|57 72|cervical neoplasm
P02732341A0000|78 89|year old woman
P02732341A0000|109 127|histiocytic lymphoma
P02732341A0000|132 152|histochemical staining
P02732341A0000|156 176|chloroacetate esterase
P02732341A0000|191 206|correct diagnosis
P02733116T0000|7 24|National Institutes
P02733116T0000|27 32|Health
P02733690T0000|0 15|Molecular cloning
P02733690T0000|19 34|characterisation
P02733690T0000|43 57|homologous genes
P02733690T0000|67 82|nitrate reductase
P02735364A1330|5 14|final model
P02735364A1330|22 23|p =
P02735364A1330|32 57|peritoneal cytologic results
P02735364A1330|59 60|p =
P02735364A1330|69 94|progesterone receptor status
P02735364A1330|96 97|p =
P02735364A1330|114 131|continuous variable
P02735364A1330|133 134|p =
P02735364A1330|170 189|disease-free survival
P02736482A0550|18 41|external radiation therapy
P02736482A0550|43 57|brain metastases
P02739739T0000|0 22|COUP transcription factor
P02739739T0000|37 62|steroid receptor superfamily
P02740196A0704|2 11|Experiment
P02740196A0704|25 38|classification
P02740196A0704|46 58|fixed standard
P02740196A0704|90 102|target numbers
P02740347A0644|0 11|Cosmid clones
P02740347A0644|26 38|VNTR sequences
P02740347A0644|57 74|restriction mapping
P02740347A0644|99 100|kb
P02740627A0137|3 14|oxygen uptake
P02740627A0137|16 18|VO2
P02740627A0137|21 39|carbon dioxide output
P02740627A0137|41 44|VCO2
P02740627A0137|47 61|respiratory rate
P02740627A0137|63 64|fR
P02740627A0137|67 83|minute ventilation
P02740627A0137|85 86|VE
P02740627A0137|89 107|alveolar ventilation
P02740627A0137|109 110|VA
P02740627A0137|113 134|alveolar oxygen pressure
P02740627A0137|136 139|PAO2
P02740627A0137|145 155|VE/VO2 ratio
P02740627A0137|160 165|higher
P02740627A0137|171 174|cows
P02740627A0137|184 194|tidal volume
P02740627A0137|196 197|VT
P02740627A0137|202 223|physiological dead space
P02740627A0137|225 226|VD
P02740627A0137|232 237|larger
P02740627A0137|243 248|horses
P02740874A0957|0 15|Epithelial damage
P02740874A0957|35 42|controls
P02740874A0957|54 60|tissues
P02740874A0957|70 72|SO2
P02740955A0333|11 18|patients
P02740955A0333|22 42|maternal mortality rate
P02740955A0333|58 73|unbooked patients
P02740955A0333|86 95|deliveries
P02743842A0000|3 14|present study
P02743842A0000|34 47|prostaglandins
P02743842A0000|49 59|cytoprotect
P02743842A0000|64 76|gastric mucosa
P02743842A0000|84 117|hemorrhage-induced stress ulceration
P02743842A0000|143 171|16,16-dimethyl prostaglandin E2
P02743842A0000|173 184|16,16-dm PGE2
P02743842A0000|196 221|microscopic lesion formation
P02743842A0000|223 242|intramucosal tissue pH
P02743842A0000|244 244|H
P02743842A0000|246 259|back-diffusion
P02743842A0000|264 279|mucosal blood flow
P02743842A0000|282 297|rat gastric mucosa
P02743842A0000|307 317|luminal acid
P02743842A0000|322 326|mM HCl
P02743842A0000|334 349|hemorrhagic shock
P02743842A0000|353 357|ml/kg
P02743842A0000|363 365|min
P02743981A0347|0 10|Transcripts
P02743981A0347|34 58|abundant monocistronic L11e
P02743981A0347|55 58|L11e
P02743981A0347|62 97|tricistronic L1e-L10e-L12e transcripts
P02743981A0347|74 76|L1e
P02743981A0347|78 81|L10e
P02743981A0347|107 133|abundant bicistronic NAB-L11e
P02743981A0347|126 128|NAB
P02743981A0347|130 133|L11e
P02743981A0347|137 163|monocistronic NAB transcripts
P02743981A0347|150 163|NAB transcripts
P02743981A0347|177 206|rare ORF monocistronic transcript
P02743981A0347|181 206|ORF monocistronic transcript
P02744123A0237|17 23|results
P02744123A0237|55 66|rhesus monkey
P02744123A0237|77 84|photopic
P02744123A0237|88 103|scotopic branches
P02744123A0237|133 140|same time
P02744123A0237|171 193|same background luminance
P02744490A0894|0 7|Evidence
P02744490A0894|35 44|cDNA clones
P02744490A0894|54 63|S1 nuclease
P02744490A0894|67 88|primer extension studies
P02744490A0894|117 125|PTHrP gene
P02744490A0894|144 171|mRNA transcription start points
P02744490A0894|185 209|putative regulatory domains
P02745280A0276|13 16|PaO2
P02745280A0276|27 46|simultaneous measures
P02745280A0276|49 56|arterial
P02745280A0276|60 75|venous blood gases
P02745280A0276|77 102|venous lactate concentration
P02745280A0276|107 113|changes
P02745280A0276|119 140|relative concentrations
P02745280A0276|143 160|inorganic phosphate
P02745280A0276|162 176|phosphocreatine
P02745280A0276|181 183|ATP
P02745280A0276|196 227|31P magnetic resonance spectroscopy
P02745444A0391|3 29|transcription initiation site
P02745444A0391|45 61|S1 nuclease mapping
P02745444A0391|45 54|S1 nuclease
P02745666A0000|0 18|Endometrial biopsies
P02745666A0000|22 37|plasma oestradiol
P02745666A0000|39 40|E2
P02745666A0000|45 56|progesterone
P02745666A0000|58 59|P4
P02745666A0000|61 66|levels
P02745666A0000|71 78|patients
P02745666A0000|100 123|replacement therapy cycles
P02745666A0000|127 149|premature ovarian failure
P02746099A0000|3 10|mobility
P02746099A0000|24 37|lower premolars
P02746099A0000|77 96|interproximal contact
P02746099A0000|100 113|occlusal facets
P02747653A0910|1 25|larval albumin-like protein
P02747653A0910|32 41|detectable
P02747653A0910|44 57|silver staining
P02747653A0910|60 64|serum
P02747653A0910|67 74|tadpoles
P02747653A0910|95 107|metamorphosis
P02748188A0091|14 31|pain-tolerant group
P02748188A0091|33 35|PT =
P02748188A0091|38 39|Ss
P02748188A0091|53 67|entire 3-min test
P02748188A0091|69 74|means =
P02748188A0091|82 84|sec
P02748188A0091|93 111|pain-sensitive group
P02748188A0091|113 115|PS =
P02748188A0091|118 119|Ss
P02748188A0091|146 148|sec
P02748188A0091|154 169|cold-pressor test
P02748188A0091|171 172|t =
P02748188A0091|179 183|P less
P02748188A0091|210 223|earlier studies
P02748595A0492|17 36|baboon liver class I ADH
P02748595A0492|17 32|baboon liver class
P02748595A0492|34 36|ADH
P02748595A0492|44 63|same ancestral lineage
P02748595A0492|69 81|human ADH-beta
P02749215A0000|8 18|proteinuria
P02749215A0000|31 39|hematuria
P02749215A0000|46 51|pyuria
P02749215A0000|56 70|frequent finding
P02751080A0176|4 17|individual shot
P02751080A0176|20 26|bullets
P02751080A0176|35 41|minutes
P02751080A0176|47 60|intensity level
P02751080A0176|76 77|dB
P02752303A0000|0 12|Lithium delays
P02752303A0000|16 30|circadian rhythm
P02752303A0000|33 45|wheel-running
P02752303A0000|48 61|Syrian hamsters
P02752303A0000|64 83|plasma concentrations
P02752303A0000|94 95|mM
P02752303A0000|110 124|toxic weight loss
P02752629A0163|0 6|Dynamic
P02752629A0163|10 26|static scintigrams
P02752629A0163|46 67|methylene diphosphonate
P02752629A0163|97 101|weeks
P02752629A0163|107 114|fracture
P02752651A0480|28 36|September
P02752651A0480|56 60|alert
P02752651A0480|67 84|spastic paraparesis
P02752651A0480|89 98|impairment
P02752651A0480|104 120|sensory modalities
P02752651A0480|136 137|Th
P02752651A0480|143 160|urinary disturbance
P02756731T0001|0 13|Prostaglandins
P02756731T0001|17 26|gallstones
P02756878A0075|32 52|successive occurrences
P02756878A0075|59 68|arrhythmia
P02756878A0075|82 89|patients
P02756878A0075|104 126|symptomatic paroxysmal AF
P02757033A0905|41 45|genes
P02757033A0905|60 74|long arm adjacent
P02757033A0905|80 105|centromeric heterochromatin
P02757033A0905|127 140|position effect
P02757033A0905|144 156|transcription
P02757033A0905|164 168|genes
P02757862T0000|0 16|Initial experience
P02757862T0000|22 35|microprocessor
P02757862T0000|58 70|defibrillator
P02758382A0478|0 6|Obesity
P02758382A0478|35 45|proportions
P02758382A0478|48 63|nonprotein-bound
P02758382A0478|67 88|albumin-bound estradiol
P02758382A0478|67 73|albumin
P02758382A0478|116 140|sex hormone binding globulin
P02758382A0478|142 145|SHBG
P02758382A0478|147 152|levels
P02758382A0478|171 189|SHBG-bound estradiol
P02758382A0478|171 174|SHBG
P02760922A0000|0 56|Heterogeneous nuclear ribonucleoprotein (hnRNP) core protein A1
P02760922A0000|0 36|Heterogeneous nuclear ribonucleoprotein
P02760922A0000|38 42|hnRNP
P02760922A0000|44 56|core protein A1
P02760922A0000|60 73|major component
P02760922A0000|76 89|mammalian hnRNP
P02760922A0000|92 101|S particles
P02761008X0000|0 26|Brain cholinesterase activity
P02761008X0000|0 18|Brain cholinesterase
P02761008X0000|37 47|great egrets
P02761008X0000|49 59|snowy egrets
P02761008X0000|63 87|black-crowned night-herons
P02761008X0000|89 98|inhibition
P02761008X0000|101 119|brain cholinesterase
P02761008X0000|121 123|ChE
P02761008X0000|135 139|birds
P02761008X0000|180 195|organophosphorus
P02761008X0000|198 216|carbamate pesticides
P02761150A0000|11 24|zinc deficiency
P02761150A0000|27 37|trace metals
P02761150A0000|49 54|spleen
P02761150A0000|56 61|kidney
P02761150A0000|63 70|pancreas
P02761150A0000|74 81|duodenum
P02761150A0000|112 129|zinc-deficient rats
P02761150A0000|134 137|days
P02761150A0000|143 146|days
P02761492A0124|3 10|findings
P02761492A0124|28 48|multifactorial genesis
P02761492A0124|54 71|cardiac involvement
P02761492A0124|74 87|uremic patients
P02761537A0168|0 11|Heating cells
P02761537A0168|16 23|degrees C
P02761537A0168|60 63|rRNA
P02761537A0168|75 75|%
P02761537A0168|81 92|control level
P02761537A0168|101 107|greater
P02761537A0168|114 124|% inhibition
P02761537A0168|127 150|transcription termination
P02761537A0168|168 178|nucleotides
P02761537A0168|201 207|28S rRNA
P02761537A0168|213 223|readthrough
P02761537A0168|241 261|next transcription unit
P02761540A0873|0 15|Deletion analysis
P02761540A0873|29 34|NF-4FA
P02761540A0873|36 41|NF-4FB
P02761540A0873|46 58|AP-1 sequences
P02761540A0873|78 97|full enhancer activity
P02761540A0873|78 89|full enhancer
P02762006A0071|0 3|Cord
P02762006A0071|26 33|patients
P02762006A0071|46 60|complete lesions
P02762198T0001|0 3|Reye
P02762198T0001|15 21|reports
P02762198T0001|25 29|cases
P02763467A0903|4 58|two-dimensional polyacrylamide gel electrophoretic patterns
P02763467A0903|62 64|35S
P02763467A0903|66 91|methionine-labeled proteins
P02763467A0903|104 108|cells
P02763467A0903|132 149|recombinant viruses
P02763467A0903|202 210|molecular
P02763467A0903|219 234|isoelectric point
P02763467A0903|259 264|N1L ORF
P02764797A0182|0 4|PULSE
P02764797A0182|16 45|such NMR spectroscopic parameters
P02764797A0182|59 66|duration
P02764797A0182|69 70|rf
P02764797A0182|89 93|gates
P02764797A0182|95 101|rf phase
P02764797A0182|103 115|sampling times
P02764797A0182|120 140|such imaging parameters
P02764797A0182|143 154|rf pulse shape
P02764797A0182|158 174|gradient waveforms
P02765001A0105|0 11|Definite JPsA
P02765001A0105|15 22|patients
P02765001A0105|36 44|arthritis
P02765001A0105|73 82|coincident
P02765001A0105|89 108|typical psoriatic rash
P02765001A0105|112 120|arthritis
P02765001A0105|136 148|minor criteria
P02765001A0105|150 159|dactylitis
P02765001A0105|173 190|psoriasis-like rash
P02765001A0105|194 206|family history
P02765001A0105|209 217|psoriasis
P02765214A0486|12 16|Kurti
P02765214A0486|34 54|appropriate importance
P02765214A0486|60 68|arguments
P02766330A0779|25 37|antipsychotic
P02766330A0779|39 47|analgetic
P02766330A0779|49 59|myorelaxing
P02766330A0779|63 83|vasodilatating effects
P02766330A0779|90 107|calcium antagonists
P02766330A0779|117 135|clinical application
P02766508A0421|1 22|correlation coefficient
P02766508A0421|61 70|map pattern
P02766508A0421|78 95|normal mean IQRST map
P02766745T0000|1 19|hospital-based study
P02766745T0000|52 59|placenta
P02766745T0000|63 70|mastitis
P02766745T0000|73 81|dairy cows
P02767166A0368|17 33|lipid peroxidation
P02767166A0368|65 78|senile cataract
P02767166A0368|86 102|direct consequence
P02767166A0368|105 117|retinal damage
P02767166A0368|128 139|pathogenesis
P02767166A0368|142 149|cataract
P02767166A0368|165 176|severe myopia
P02767733A0690|3 21|histological grading
P02767733A0690|38 42|cases
P02767733A0690|46 47|G1
P02767733A0690|51 52|G2
P02767733A0690|56 57|G3
P02767733A0690|59 77|extracapsular spread
P02767733A0690|93 97|cases
P02767733A0690|101 101|%
P02772495A0641|0 5|Asthma
P02772495A0641|45 52|ASA group
P02772495A0641|56 56|%
P02772495A0641|62 62|%
P02772495A0641|65 66|AT
P02772495A0641|78 78|%
P02772495A0641|81 89|INTR group
P02773507A0750|11 14|l/kg
P02773507A0750|25 25|V
P02773507A0750|42 62|single sample estimates
P02773507A0750|65 73|clearance
P02773507A0750|75 76|CL
P02773507A0750|93 96|l/kg
P02773507A0750|115 135|single sample estimates
P02773507A0750|138 146|clearance
P02773507A0750|149 165|plasma unbound drug
P02773507A0750|167 171|CLunb
P02773930T0000|3 16|solitary kidney
P02773930T0000|26 47|chronic hyperfiltration
P02773930T0000|50 55|humans
P02774271A0000|0 8|Halothane
P02774271A0000|26 41|oxidative pathway
P02774271A0000|51 72|nonvolatile end products
P02774271A0000|74 92|trifluoroacetic acid
P02774271A0000|94 97|TFAA
P02774271A0000|102 108|bromide
P02774271A0000|110 111|Br
P02774271A0000|120 136|reductive pathways
P02774271A0000|139 161|Br-and inorganic fluoride
P02774271A0000|163 163|F
P02774808A0194|3 8|values
P02774808A0194|31 35|P less
P02774808A0194|69 84|micrograms/100 ml
P02775136A1151|5 11|results
P02775136A1151|23 30|HAPE-S-S
P02775136A1151|34 38|prone
P02775136A1151|41 75|irregular nocturnal breathing patterns
P02775136A1151|78 89|high altitude
P02775136A1151|128 130|AMS
P02775136A1151|174 198|abnormal breathing patterns
P02775136A1151|220 222|AMS
P02775333A1137|0 9|Buflomedil
P02775333A1137|11 14|i.v.
P02775333A1137|24 45|dose-dependent increase
P02775333A1137|48 60|cardiac output
P02775333A1137|72 76|mg/kg
P02775333A1137|78 92|biphasic changes
P02775333A1137|106 110|mg/kg
P02775333A1137|115 128|marked decrease
P02775333A1137|132 155|subsequent slight increase
P02775333A1137|159 167|large dose
P02775333A1137|174 178|mg/kg
P02776471A0235|26 32|animals
P02776471A0235|44 56|low responders
P02776471A0235|80 100|humoral immune response
P02776742A0000|0 8|Heart rate
P02776742A0000|10 11|HR
P02776742A0000|14 30|rectal temperature
P02776742A0000|32 34|Tre
P02776742A0000|37 49|blood pressure
P02776742A0000|65 87|relative humidity changes
P02776742A0000|118 136|professional firemen
P02776742A0000|155 156|yr
P02776742A0000|158 163|VO2 max
P02776742A0000|172 182|ml kg-1 min-1
P02776742A0000|191 201|fire fighter
P02776742A0000|204 211|uniforms
P02776742A0000|213 214|SU
P02776742A0000|218 227|aluminized
P02776742A0000|229 241|fire resistant
P02776742A0000|243 261|impermeable clothing
P02776742A0000|279 296|breathing apparatus
P02776742A0000|298 299|FE
P02776823A0000|3 19|clinical tolerance
P02776823A0000|23 38|pharmacokinetics
P02776823A0000|41 43|FCE
P02776823A0000|57 58|5R
P02776823A0000|60 69|6S)-6-[(1R
P02776823A0000|60 61|6S
P02776823A0000|68 69|1R
P02776823A0000|72 83|hydroxyethyl
P02776823A0000|88 127|carbamoyloxymethyl-2-penem-3-carboxylate
P02776823A0000|131 148|new penem antibiotic
P02776823A0000|177 190|single i.v. dose
P02776823A0000|194 200|mg.kg-1
P02776823A0000|206 226|healthy male volunteers
P02777797A0720|0 19|DNA blot hybridization
P02777797A0720|35 43|rat genome
P02777797A0720|77 97|PtdIns transfer protein
P02778237A0585|8 37|term corticosteroid-dependent IA
P02778237A0585|50 63|serious problem
P02778237A0585|66 74|chronic IA
P02778237A0585|84 111|maintenance prednisone therapy
P02778873A0761|16 19|CRL3
P02778873A0761|47 62|enhancer function
P02778873A0761|73 78|tandem
P02778873A0761|87 95|sequences
P02778873A0761|97 101|DR-A1
P02778873A0761|105 109|DR-A2
P02779752A0000|0 3|1-(1
P02779752A0000|3 12|1-Naphthyl
P02779752A0000|14 23|piperazine
P02779752A0000|25 28|1-NP
P02779752A0000|51 79|serotonin antagonist properties
P02779752A0000|85 96|5-HT2 subtype
P02779752A0000|99 106|receptor
P02779752A0000|142 155|agonist actions
P02779752A0000|161 169|5-HT1 site
P02779752A0776|3 16|m-Chlorophenyl
P02779752A0776|18 27|piperazine
P02779752A0776|29 32|mCPP
P02779752A0776|41 45|mg/kg
P02779752A0776|53 75|m-trifluoromethylphenyl
P02779752A0776|77 86|piperazine
P02779752A0776|88 92|TFMPP
P02779752A0776|101 105|mg/kg
P02779752A0776|135 144|5-HT1 sites
P02779752A0776|194 205|methysergide
P02779752A0776|211 214|1-NP
P02779752A0776|224 233|ketanserin
P02780157A0576|3 23|characteristic feature
P02780157A0576|34 49|spleen MP function
P02780157A0576|52 59|patients
P02780157A0576|64 66|VHA
P02780157A0576|81 96|HBsAg carriership
P02780157A0576|81 85|HBsAg
P02780157A0576|120 139|compensatory reaction
P02780157A0576|151 158|spleen MP
P02780157A0576|191 200|overstrain
P02780157A0576|203 214|long standing
P02780157A0576|218 226|depletion
P02780157A0576|232 242|MP system due
P02780157A0576|245 273|permanent antigenic stimulation
P02780157A0576|276 280|HBsAg
P02781495T0001|0 6|Changes
P02781495T0001|9 31|xanthine oxidase activity
P02781495T0001|9 23|xanthine oxidase
P02781495T0001|34 41|patients
P02781495T0001|46 63|circulatory failure
P02781567A0544|18 20|v/v
P02781567A0544|55 76|powdered stratum corneum
P02783181A0000|3 16|cytoprotective
P02783181A0000|20 38|antiulcer activities
P02783181A0000|44 60|antacid magaldrate
P02783181A0000|62 69|ES Riopan
P02783181A0000|82 88|effects
P02783181A0000|91 113|gastric mucosal blood flow
P02783181A0000|117 131|mucus secretions
P02784507A0000|3 33|human immunodeficiency virus type 1
P02784507A0000|3 32|human immunodeficiency virus type
P02784507A0000|35 39|HIV-1
P02784507A0000|62 65|CD4+
P02784507A0000|62 64|CD4
P02784507A0000|66 77|T lymphocytes
P02784507A0000|92 105|latent provirus
P02784507A0000|117 121|cells
P02784507A0000|125 139|extended periods
P02787430A0124|0 22|Histiocytic panniculitis
P02787430A0124|36 50|biopsy specimens
P02787430A0124|55 70|cytophagocytosis
P02789062A0000|17 34|human 4F2 heavy chain
P02789062A0000|36 40|4F2HC
P02789062A0000|49 59|model system
P02789062A0000|62 68|studies
P02789062A0000|91 105|molecular events
P02789062A0000|126 148|inducible gene expression
P02789062A0000|155 181|normal human T-cell activation
P02789062A1420|1 4|cDNA
P02789062A1420|16 43|NF-4FB enhancer binding protein
P02789062A1420|69 89|lambda gt11 cDNA library
P02789062A1420|95 122|rabiolabelled oligonucleotide
P02789062A1420|141 165|NF-4FB recognition sequence
P02789180A0407|0 46|Electrocardiographic right ventricular hypertrophy
P02789180A0407|61 84|biventricular hypertrophy
P02789180A0407|88 95|patients
P02789217A1323|6 19|IL6 mRNA species
P02789217A1323|6 12|IL6 mRNA
P02789217A1323|34 59|alternative polyadenylation
P02789217A1323|62 66|sites
P02789217A1323|92 100|kilobases
P02790009A0375|0 17|Sequencing analysis
P02790009A0375|41 55|0.4-kb fragments
P02790009A0375|80 90|nucleotides
P02790009A0375|116 129|0.4-kb fragment
P02790009A1052|3 15|mature protein
P02790009A1052|29 41|cysteine-rich
P02790009A1052|49 75|hydrophilic region homologous
P02790009A1052|81 113|ovomucoid serine protease inhibitors
P02790009A1052|81 103|ovomucoid serine protease
P02790009A1052|115 122|residues
P02792270A1220|0 26|Oligosynaptic EPSP components
P02792270A1220|61 88|superficial peroneal responses
P02792270A1220|91 107|flexor motoneurons
P02792270A1220|131 139|amplitude
P02792270A1220|149 160|flexion phase
P02792430A0000|0 10|Experiments
P02792430A0000|15 23|white rats
P02792430A0000|29 38|guinea pigs
P02792430A0000|65 94|indomethacin-induced inhibition
P02792430A0000|97 119|prostaglandins synthesis
P02792430A0000|142 156|pulmonary oedema
P02792430A0000|166 182|heterologous serum
P02792430A0000|185 188|rats
P02792430A0000|194 201|vagotomy
P02792430A0000|204 213|guinea pigs
P02793216A0876|5 13|other hand
P02793216A0876|38 92|membrane attachment sequence arginine-glycine-aspartic acid
P02793216A0876|109 128|functional importance
P02793216A0876|131 133|CgA
P02793620A0214|9 24|later-parity cows
P02793620A0214|54 64|parturition
P02793620A0214|67 75|Charolais
P02793620A0214|79 90|Red Poll bulls
P02793620A0214|93 113|multiple-sire pastures
P02793753A0354|10 13|lobe
P02793753A0354|18 29|PA dispersion
P02793753A0354|39 43|cmH2O
P02793753A0354|46 48|CFV
P02793753A0354|53 57|l/min
P02793753A0354|77 78|PA
P02793753A0354|84 88|sites
P02793753A0354|107 126|intralobar dispersion
P02794828A0214|23 39|intact canine heart
P02794828A0214|52 64|microcomputer
P02794828A0214|91 111|parasystolic pacemaker
P02795923A0000|31 48|basic CT appearances
P02795923A0000|51 71|interstitial pneumonia
P02795923A0000|73 82|radiologic
P02795923A0000|84 109|pathologic correlative study
P02795923A0000|127 134|inflated
P02795923A0000|138 147|fixed lungs
P02795923A0000|152 158|autopsy
P02796216A0063|15 28|atypical course
P02796216A0063|34 54|early jaundice syndrome
P02796216A0063|56 74|severe enterorrhagia
P02796216A0063|78 91|late appearance
P02796216A0063|94 100|roseola
P02796988A0735|3 24|transcription factor Sp1
P02796988A0735|22 24|Sp1
P02796988A0735|37 41|sites
P02796988A0735|59 76|footprinting assays
P02796988A0735|80 95|gel shift analysis
P02796988A0735|108 110|Sp1
P02797877A0475|3 16|combination PIP
P02797877A0475|19 28|micrograms
P02797877A0475|30 32|PEF
P02797877A0475|34 43|micrograms
P02797877A0475|55 79|frequent secondary regrowth
P02797877A0475|90 94|hours
P02797877A0475|102 112|antibiotics
P02798953A0307|13 19|mothers
P02798953A0307|22 35|healthy infants
P02798953A0307|45 53|subscales
P02798953A0307|77 81|WPL-R
P02798953A0307|86 101|acceptable levels
P02798953A0307|104 122|internal consistency
P02798953A0307|135 148|days postpartum
P02798953A0307|168 182|administrations
P02799892A0154|18 38|saline-washed red cells
P02799892A0154|40 44|WRBCs
P02799892A0154|72 80|hemolysis
P02799892A0154|86 96|transfusion
P02799892A0154|99 106|patients
P02799892A0154|111 113|PNH
P02800417A0332|12 21|asthmatics
P02800417A0332|35 56|significant correlation
P02800417A0332|72 84|PC20 PGF2 alpha
P02800417A0332|88 102|histamine values
P02800417A0332|104 105|r =
P02800417A0332|112 116|p less
P02800435A0000|0 15|Acute experiments
P02800435A0000|18 42|nembutal-anesthetized cats
P02800435A0000|46 50|mg/kg
P02800435A0000|89 111|T pulsating magnetic field
P02800435A0000|113 115|PMF
P02800435A0000|119 137|neuromuscular system
P02802280A0495|2 23|significant differences
P02802280A0495|43 44|TS
P02802280A0495|51 53|PTS
P02805945A0000|3 13|percentages
P02805945A0000|22 26|cysts
P02805945A0000|30 40|growth rates
P02805945A0000|91 97|cosinor
P02805945A0000|102 115|clonal cultures
P02805945A0000|118 143|Scripsiella trochoidea Stein
P02805945A0000|153 157|years
P02805945A0000|163 182|laboratory conditions
P02805945A0000|217 225|view point
P02805945A0000|228 251|environmental temperature
P02805945A0000|259 265|degree C
P02805945A0000|279 292|microEin m-2 s-1
P02805945A0000|298 315|artificial seawater
P02806916A0000|1 15|genomic DNA clone
P02806916A0000|24 36|oryzacystatin
P02806916A0000|38 39|Oc
P02806916A0000|43 69|cysteine proteinase inhibitor
P02806916A0000|71 78|cystatin
P02806916A0000|103 125|lambda EMBL3 phage library
P02806916A0000|141 160|Sau3AI partial digests
P02806916A0000|141 146|Sau3AI
P02806916A0000|163 180|rice chromosomal DNA
P02806916A0000|199 204|oc cDNA
P02806916A0000|208 212|probe
P02807780A0143|10 28|appropriate solution
P02807780A0143|31 43|methylene blue
P02807780A0143|48 48|%
P02807780A0143|54 58|M NaCl
P02807780A0143|64 66|min
P02807780A0143|78 85|staining
P02807780A0143|88 104|premalignant areas
P02807780A0143|108 110|CIS
P02807780A0143|120 133|early diagnosis
P02808232A0681|0 10|Lower limits
P02808232A0681|16 28|micrograms/kg
P02808232A0681|34 43|detectable
P02808232A0681|52 67|lower reliability
P02808232A0681|71 71|%
P02809116A0237|12 31|small negative effects
P02809116A0237|65 71|effects
P02809116A0237|74 81|husbands
P02809116A0237|98 116|marital satisfaction
P02809116A0237|127 131|wives
P02809651A0492|37 49|meta-analysis
P02809651A0492|59 68|clinicians
P02809651A0492|72 83|policy makers
P02809651A0492|90 106|clinical questions
P02809722A0926|5 39|acromegalic patient visual improvement
P02809722A0926|59 77|abnormal GH secretion
P02809722A0926|67 68|GH
P02809722A0926|86 94|unaltered
P02809831A0799|14 17|PPSF
P02809831A0799|19 25|DBP side
P02809831A0799|32 43|large amounts
P02809831A0799|46 58|bone formation
P02810911A0372|3 12|accuracies
P02810911A0372|34 46|neuroblastoma
P02810911A0372|66 81|131I-MIBG imaging
P02810911A0372|85 103|several tumor markers
P02811378A0250|3 17|congenital forms
P02811378A0250|20 24|cases
P02811378A0250|39 51|female infants
P02811378A0250|66 71|mucosa
P02811378A0250|90 102|anterior ridge
P02811378A0250|108 114|maxilla
P02811378A0250|120 127|mandible
P02811378A0379|0 25|Immunohistochemical studies
P02811378A0379|34 49|positive staining
P02811378A0379|53 63|S100 protein
P02811378A0379|72 89|granular cell tumors
P02811378A0379|114 143|congenital granular cell epulides
P02813369A0390|18 26|same males
P02813369A0390|38 51|different years
P02813369A0390|57 71|same territories
P02813369A0390|89 100|larger harems
P02813369A0390|106 110|years
P02813369A0390|118 134|familiar neighbors
P02813404T0000|0 23|Male-enhanced antigen gene
P02813404T0000|65 74|late stages
P02813404T0000|77 91|spermatogenesis
P02814182A1211|2 5|rats
P02814182A1211|13 42|Walker-256-carcinosarcoma 4-EPI
P02814182A1211|57 64|ABSTRACT
P02814182A1211|79 83|WORDS
P02814820A0967|9 16|Roux limb
P02814820A0967|29 45|ectopic pacemakers
P02814820A0967|58 69|slow emptying
P02814820A0967|72 78|liquids
P02814820A0967|88 96|rapid rate
P02814820A0967|107 118|Billroth dogs
P02814820A0967|120 123|t1/2
P02814820A0967|130 133|Roux
P02814820A0967|142 148|minutes
P02814820A0967|150 157|Billroth
P02814820A0967|165 171|minutes
P02814820A0967|173 180|p greater
P02814820A0967|215 220|solids
P02815229A0139|3 12|treatments
P02815229A0139|19 26|mg t.i.d.
P02815229A0139|33 40|mg t.i.d.
P02815229A0139|49 52|days
P02815229A0139|71 84|last dose pulsed
P02815229A0139|93 95|MBq
P02815229A0139|97 99|14C
P02815229A0139|101 109|diltiazem
P02816251A0397|3 35|subepicardial lymphatic capillaries
P02816251A0397|92 103|dense network
P02816251A0397|124 136|entire surface
P02816251A0397|143 152|ventricles
P02817724A0075|25 26|T1
P02817724A0075|30 40|T2 sequences
P02817724A0075|44 48|scans
P02817724A0075|56 61|planes
P02818122A0000|1 9|great deal
P02818122A0000|39 48|morphology
P02818122A0000|54 62|claustrum
P02818122A0000|65 84|various animal species
P02818122A0000|99 118|neuronal distribution
P02818122A0000|122 134|relationships
P02818122A0000|142 155|cerebral cortex
P02818122A0000|159 169|other nuclei
P02818260T0000|0 14|Low-grade glioma
P02820128A1333|9 27|sequence repetitions
P02820128A1333|50 55|copies
P02820128A1333|61 80|hexanucleotide ATTGTT
P02820128A1333|89 103|flanking regions
P02820128A1333|106 117|dyad symmetry
P02820128A1333|136 141|ORF T3C
P02820128A1670|22 39|palindromic domains
P02820128A1670|46 48|ORF
P02820128A1670|51 57|unclear
P02820128A1670|64 74|coincidence
P02820128A1670|88 103|larger palindrome
P02820128A1670|129 143|protein sequence
P02820128A1670|151 158|homology
P02820128A1670|166 171|B chain
P02820128A1670|174 180|insulin
P02820128A1670|196 206|palindromes
P02820128A1670|219 227|T2 protein
P02820128A1670|232 253|several functional units
P02821340A0434|6 24|sub-maximal exercise
P02821340A0434|26 28|DCR
P02821340A0434|34 39|UT dogs
P02821340A0434|79 93|mm Hg X ml-1 X min-1
P02821340A0434|107 121|mm Hg X ml-1 X min-1
P02821340A0434|125 132|workload
P02821340A0434|138 140|kph
P02821340A0434|151 151|%
P02824334A0972|23 41|G-protein gene family
P02824334A0972|72 87|human chromosomes
P02825139A0661|24 42|significant homology
P02825139A0661|54 78|human nucleic acid sequences
P02825750A0260|4 20|evaluable patients
P02825750A0260|24 35|response rate
P02825750A0260|41 41|%
P02825750A0260|50 65|complete response
P02826127A0709|50 65|SV40 octamer motif
P02826127A0709|72 105|lymphoid cell-specific protein oct-B2
P02826127A0709|131 146|component present
P02826127A0709|152 166|nuclear extracts
P02826127A0709|171 194|several lymphoid cell lines
P02826717A0179|0 5|Anoxia
P02826717A0179|33 36|gill
P02826717A0179|76 84|water flow
P02826717A0179|90 93|gill
P02826729A0790|0 5|Growth
P02826729A0790|7 10|4-PA
P02826729A0790|14 28|14C turnover data
P02826729A0790|42 43|WB
P02826729A0790|57 65|B-6 intake
P02826729A0790|73 76|rats
P02828926A1870|5 27|multiple myogenic factors
P02828926A1870|100 124|complex modulatory programs
P02828926A1870|127 145|actin gene expression
P02828926A1870|127 135|actin gene
P02828926A1870|166 186|muscle differentiation
P02829183A0117|0 18|DNA sequence analysis
P02829183A0117|36 41|clones
P02829183A0117|51 63|distinct forms
P02829183A0117|66 76|translocase
P02830214A0000|11 23|acetazolamide
P02830214A0000|25 27|ACZ
P02830214A0000|31 34|HCO3
P02830214A0000|39 40|Cl
P02830214A0000|42 51|activities
P02830214A0000|54 66|inner ear fluid
P02830214A0000|84 117|ion-selective microelectrode methods
P02830265A0341|0 5|RPA190
P02830265A0341|14 29|polypeptide chain
P02830265A0341|39 45|daltons
P02830265A0341|49 78|large uninterrupted reading frame
P02830282A0155|7 21|intact A1 protein
P02830282A0155|28 46|proteolytic fragment
P02830282A0155|51 60|UP1 protein
P02830282A0155|96 106|V-8 protease
P02830282A0155|119 130|polypeptides
P02830282A0155|135 144|amino acids
P02831398A0346|0 6|Irmiere
P02831398A0346|11 12|W.
P02831556A0173|5 13|offspring
P02831556A0173|19 27|alpha-MSH
P02831556A0173|35 41|mothers
P02831556A0173|70 75|adults
P02831556A0173|90 106|analgesic response
P02831556A0173|109 116|morphine
P02831796A0000|0 26|Simian immunodeficiency virus
P02831796A0000|28 30|SIV
P02831796A0000|35 44|lentivirus
P02831796A0000|49 61|morphological
P02831796A0000|65 85|antigenic similarities
P02831796A0000|88 113|human immunodeficiency virus
P02831796A0000|118 131|causative agent
P02831796A0000|142 165|immunodeficiency syndrome
P02831796A0000|174 179|humans
P02832149A1009|40 47|products
P02832149A1009|94 96|myb
P02832149A1009|120 128|insertion
P02832149A1009|143 152|amino acids
P02832149A1009|158 177|larger myb transcripts
P02832149A1009|197 220|tumor-specific activation
P02832149A1009|226 241|mouse myb oncogene
P02832293T0000|8 13|CRF-41
P02832293T0000|19 39|differential diagnosis
P02832293T0000|42 48|Cushing
P02832293T0000|62 68|obesity
P02832744A0403|10 23|mos transcripts
P02832744A0403|26 33|Northern
P02832744A0403|35 37|RNA
P02832744A0403|39 46|analyses
P02832744A0403|49 51|RNA
P02832744A0403|74 85|quail ovaries
P02832744A0403|89 94|testes
P02833012A0428|12 16|L mRNA
P02833012A0428|24 34|nucleotides
P02833012A0428|52 73|single open reading frame
P02833012A0428|91 98|L protein
P02833012A0428|115 124|amino acids
P02833012A0428|130 131|MW
P02833021A1185|3 9|results
P02833021A1185|38 52|functional units
P02833021A1185|58 68|72-bp repeat
P02833021A1185|80 105|transcriptional enhancement
P02833021A1185|111 123|early promoter
P02833021A1185|154 173|late promoter function
P02833049A0630|0 9|Variations
P02833049A0630|23 24|U3
P02833049A0630|43 52|insertions
P02833049A0630|56 64|deletions
P02833049A1041|15 34|steady state RNA levels
P02833049A1041|37 55|T-lymphoid cell lines
P02833049A1041|78 115|different incomplete proviral transcripts
P02833049A1041|131 138|products
P02833049A1041|167 176|RD-114 mRNA
P02833049A1041|220 231|proviral loci
P02833049A1041|269 276|vigorous
P02833049A1041|279 300|certain feline cell types
P02833101T0000|0 13|Aplastic crisis
P02833101T0000|16 34|sickle cell disorders
P02833101T0000|36 53|bone marrow necrosis
P02833101T0000|57 80|human parvovirus infection
P02833517A0467|11 32|more different sequences
P02833517A0467|43 50|cleavage
P02833517A0467|55 67|single element
P02833517A0467|88 94|diffuse
P02834478A0000|0 25|Low molecular weight heparins
P02834478A0000|40 51|much interest
P02834478A0000|80 94|selective action
P02834478A0000|97 104|Xa factor
P02834843A0000|3 22|bactericidal activity
P02834843A0000|28 50|new rifamycin derivatives
P02834843A0000|53 61|rifabutin
P02834843A0000|63 65|RBU
P02834843A0000|68 70|FCE
P02834843A0000|77 79|F22
P02834843A0000|82 92|rifapentine
P02834843A0000|94 96|RPE
P02834843A0000|99 101|CGP
P02834843A0000|108 110|C29
P02834843A0000|113 115|CGP
P02834843A0000|121 123|C70
P02834843A0000|128 130|CGP
P02834843A0000|137 139|C27
P02834843A0000|144 153|rifampicin
P02834843A0000|155 157|RMP
P02834843A0000|184 191|log phase
P02834843A0000|199 208|better test
P02834843A0000|238 260|stationary phase cultures
P02834843A0000|263 287|Mycobacterium tuberculosis
P02834843A0000|289 293|H37Rv
P02836623A1094|0 1|Mo
P02836623A1094|3 28|SV M-MuLV-inoculated animals
P02836623A1094|35 42|moribund
P02836623A1094|50 70|months postinoculation
P02836623A1094|79 85|delta Mo
P02836623A1094|87 112|SV M-MuLV-inoculated animals
P02836623A1094|119 126|moribund
P02836623A1094|134 154|months postinoculation
P02837575A0979|0 36|Sodium dodecyl sulphate-induced cleavage
P02837575A0979|39 62|eukaryotic topoisomerase I
P02837575A0979|39 61|eukaryotic topoisomerase
P02837575A0979|77 82|enzyme
P02837763A0259|0 16|Amino acid sequence
P02837763A0259|22 36|human liver clone
P02837763A0259|38 42|HL-14
P02837763A0259|61 97|rabbit skeletal muscle phosphatase 2A cDNA
P02837763A0259|105 123|% nucleotide identity
P02838246A0225|0 19|Herpes virus infection
P02838246A0225|38 46|inversion
P02838246A0225|52 61|T4/T8 ratio
P02838246A0225|84 84|%
P02838246A0225|86 96|specificity
P02838246A0225|99 99|%
P02838246A0225|110 122|proliferation
P02838246A0225|128 142|T8 subpopulation
P02838246A0225|166 173|findings
P02838246A0225|176 183|patients
P02838246A0225|188 202|rejection crises
P02838246A0225|228 232|P less
P02838319A0527|0 3|RVEF
P02838319A0527|7 10|LVEF
P02838319A0527|33 33|%
P02838319A0527|35 39|p less
P02838319A0527|51 55|p less
P02838710A0299|3 8|levels
P02838710A0299|11 16|NPY-ir
P02838710A0299|11 13|NPY
P02838710A0299|59 66|surgical
P02838710A0299|69 92|pharmacological treatment
P02839488A1314|0 17|Quantitative assays
P02839488A1314|41 57|synthetic alpha s-1
P02839488A1314|91 114|human erythrocyte type-1 Gs
P02839488A1314|135 142|products
P02839488A1314|146 155|equipotent
P02839488A1314|163 174|2-fold margin
P02839716A0673|7 11|cells
P02839716A0673|13 22|E2 proteins
P02839716A0673|36 52|stimulatory effect
P02839716A0673|58 80|transcriptional activity
P02839716A0673|86 112|HPV-11 enhancer-SV40 promoter
P02839716A0673|86 99|HPV-11 enhancer
P02839716A0673|101 112|SV40 promoter
P02839716A1907|19 22|E2-C
P02839716A1907|32 59|E2-dependent enhancer activity
P02839716A1907|32 51|E2-dependent enhancer
P02839716A1907|93 94|E2
P02839716A1907|108 142|common transcriptional regulatory site
P02839716A1907|145 152|ABSTRACT
P02839716A1907|167 171|WORDS
P02840034A1266|0 17|Accurate evaluation
P02840034A1266|41 70|unresectable lung cancer patients
P02840034A1266|82 104|strong prognostic factors
P02840376A0461|1 8|anti-IIa
P02840376A0461|13 18|Holmer
P02843495A0544|0 11|Introduction
P02843495A0544|14 18|v-fms
P02843495A0544|24 61|CSF-1 dependent murine macrophage cell line
P02843495A0544|24 28|CSF-1
P02843495A0544|69 86|factor independence
P02843495A0544|90 103|tumorigenicity
P02843495A0544|107 127|nonautocrine mechanism
P02843694T0001|0 23|Chronic E-B virus infection
P02843694T0001|36 52|malignant lymphoma
P02843694T0001|55 64|case report
P02844767A0191|3 18|primary structure
P02844767A0191|22 36|cotranscription
P02844767A0191|42 51|petCA genes
P02844767A0191|63 72|Rieske-FeS
P02844767A0191|90 95|plants
P02844767A0191|100 121|apocytochrome f proteins
P02844767A0191|100 112|apocytochrome
P02844767A0191|114 121|proteins
P02844767A0191|149 154|Kallas
P02844767A0191|156 157|T.
P02844767A0191|159 165|Spiller
P02844767A0191|167 168|S.
P02844767A0191|173 178|Malkin
P02844767A0191|180 181|R.
P02844767A0596|3 18|Nostoc petBD genes
P02844767A0596|9 18|petBD genes
P02844767A0596|43 50|psbB gene
P02844767A0596|63 92|51-kDa photosystem II polypeptide
P02844767A0596|63 79|51-kDa photosystem
P02844767A0596|82 92|polypeptide
P02844767A0596|109 115|introns
P02844767A0596|130 152|related chloroplast genes
P02844767A1022|0 20|RNA blot hybridizations
P02844767A1022|33 48|1.8-kb mRNA common
P02844767A1022|51 62|cytochrome b6
P02844767A1022|66 72|subunit
P02844767A1022|101 118|0.8-kb mRNA specific
P02844767A1022|124 130|subunit
P02844767A1022|133 141|gene probe
P02844797A1225|10 22|muscle isoform
P02844797A1225|36 45|amino acids
P02844797A1225|66 88|sequence Ala-Ile-Leu-Glu
P02844797A1225|93 105|second isoform
P02844797A1225|112 121|amino acids
P02844797A1225|124 132|length due
P02844797A1225|161 170|amino acids
P02844797A1225|176 195|50-amino acid sequence
P02844797A1225|209 236|potential transmembrane domain
P02844797A1225|248 264|consensus sequence
P02844797A1225|270 294|N-linked glycosylation site
P02845654A0510|0 11|Substitution
P02845654A0510|15 30|threonine residue
P02845654A0510|35 48|alanine residue
P02845654A0510|62 63|P2
P02845654A0510|71 82|cleavage site
P02845654A0510|92 99|cleavage
P02845654A0510|108 119|substitution
P02845654A0510|123 137|tyrosine residue
P02845654A0510|141 160|phenylalanine residue
P02845654A0510|163 179|amino acid position
P02845654A0510|183 184|P1
P02845654A0510|191 202|cleavage site
P02846640A0643|8 31|indigo-producing bacteria
P02846640A0643|37 54|indoxyl phosphatase
P02846640A0643|60 61|pI
P02846852A1459|11 27|polymerases active
P02846852A1459|40 54|E strand promoter
P02846852A1459|78 88|polymerases
P02846852A1459|94 108|L strand promoter
P02848842A0643|9 20|RNA molecules
P02848842A0643|31 32|.2
P02848842A0643|34 46|kilobase range
P02848842A0643|62 66|probe
P02848842A0643|100 113|resistant cells
P02849100A0441|7 32|hydrophobic sequence located
P02849100A0441|40 65|carboxyl-terminal extremity
P02849100A0441|103 108|anchor
P02849100A0441|114 127|plasma membrane
P02849759A0865|3 14|SV40 enhancer
P02849759A0865|24 34|replication
P02850472A0112|14 23|origin core
P02850472A0112|42 55|DNA replication
P02850967T0000|0 8|Induction
P02850967T0000|11 40|proto-oncogene fos transcription
P02850967T0000|11 27|proto-oncogene fos
P02850967T0000|51 73|adenylate cyclase pathway
P02850967T0000|51 66|adenylate cyclase
P02850967T0000|75 90|characterization
P02850967T0000|94 115|cAMP-responsive element
P02850971A0180|1 26|17-mer oligodeoxynucleotide
P02850971A0180|55 75|VtHb amino acid sequence
P02850971A0180|86 103|hybridization probe
P02850971A0180|113 138|Vitreoscilla genomic library
P02850971A0180|152 185|broad-host-range cosmid vector pVK102
P02852805A0216|1 18|total soluble solids
P02852805A0216|23 49|organoleptic characteristics
P02852805A0216|69 87|different treatments
P02852894T0000|0 5|Causes
P02852894T0000|22 41|epidemiological study
P02852894T0000|44 57|native chickens
P02852894T0000|60 71|Thai villages
P02853799T0001|3 13|progression
P02853799T0001|16 20|non-A
P02853799T0001|22 35|non-B hepatitis
P02853799T0001|38 52|chronic diseases
P02853799T0001|76 98|hepatocellular carcinoma
P02853922A0596|0 10|Elevated IOP
P02853922A0596|24 31|patients
P02853922A0596|35 38|eyes
P02856622T0001|0 2|Use
P02856622T0001|5 35|serum thyroglobulin determination
P02856622T0001|10 22|thyroglobulin
P02856622T0001|41 49|follow-up
P02856622T0001|66 75|carcinomas
P02856622T0001|81 87|thyroid
P02859434T0000|0 11|Poor response
P02859434T0000|45 56|serum lithium
P02861067A0000|36 42|effects
P02861067A0000|45 64|nebulized ipratropium
P02861067A0000|67 74|patients
P02861067A0000|79 89|acute asthma
P02861067A0000|128 147|bronchodilator effect
P02861067A0000|151 165|beta agonist drug
P02861144A0242|0 14|Further analysis
P02861144A0242|21 31|DNA fragment
P02861144A0242|46 50|genes
P02861144A0242|54 76|present encoding proteins
P02861144A0242|94 97|kDal
P02861238T0000|0 11|Hantaan virus
P02862656T0000|0 6|Changes
P02862656T0000|9 35|dopamine receptor sensitivity
P02862656T0000|38 43|humans
P02862656T0000|49 66|heavy alcohol intake
P02863492A0544|2 23|significant differences
P02863492A0544|37 51|treatment groups
P02863492A0544|65 79|rapid responders
P02863492A0544|84 128|smaller mean initial platelet-associated IgG index
P02863492A0544|189 202|slow responders
P02863747T0000|0 29|Replacement variant histone genes
P02863747T0000|18 29|histone genes
P02863747T0000|48 56|sequences
P02865502T0000|0 26|Double-blind randomised trial
P02865502T0000|29 70|intravenous tissue-type plasminogen activator
P02865502T0000|40 70|tissue-type plasminogen activator
P02865502T0000|77 83|placebo
P02865502T0000|86 110|acute myocardial infarction
P02868446A0184|3 19|C-terminal domains
P02868446A0184|21 24|CTDs
P02868446A0184|31 46|RPase beta subunit
P02868446A0184|50 59|DNA primase
P02868446A0184|61 71|dnaG protein
P02868446A0184|92 101|homologous
P02868446A0184|132 141|homologous
P02868446A0184|147 156|RPase alpha
P02868446A0184|174 196|alpha subunit-like enzyme
P02868446A0184|217 225|ancestral
P02868446A0184|228 245|core enzyme subunits
P02868446A0184|249 255|primase
P02868848A0167|8 17|vancomycin
P02868848A0167|21 30|fosfomycin
P02868848A0167|45 54|suboptimal
P02868848A0167|62 81|bactericidal activity
P02868848A0167|91 101|efficacious
P02868848A0167|104 114|penicillin G
P02868848A0167|118 125|imipenem
P02868848A0167|130 145|experimental mode
P02868848A0167|148 164|murine gas gangrene
P02869125A0120|0 7|Fentanyl
P02869125A0120|10 43|prototypic mu-opiate receptor agonist
P02869125A0120|20 36|mu-opiate receptor
P02869125A0120|100 114|marked analgesia
P02869125A0120|118 137|locomotor stimulation
P02869125A0120|146 156|tachycardia
P02869125A0120|158 167|tachypnoea
P02869125A0120|171 188|behavioural arousal
P02870249T0000|0 23|Intravesical chemotherapy
P02870720A0188|0 9|Bisoprolol
P02870720A0188|24 59|effective beta-adrenoceptor antagonist
P02870720A0188|33 49|beta-adrenoceptor
P02870720A0188|64 72|pA2 values
P02870720A0188|90 101|isoprenaline
P02870720A0188|104 117|guinea pig atria
P02870720A0188|121 134|tracheal muscle
P02870851A0349|0 5|Output
P02870851A0349|8 15|99mTcO-4
P02870851A0349|21 32|parotid gland
P02870851A0349|48 59|fluctuations
P02870851A0349|62 82|parotid saliva flow rate
P02872786A0147|3 26|Hagen-Poiseuille equation
P02872786A0147|44 50|effects
P02872786A0147|61 69|parasites
P02872786A0147|75 81|foregut
P02872786A0147|84 111|Leishmania-infected sandflies
P02872786A0147|114 122|blood flow
P02873593A0581|11 14|rats
P02873593A0581|33 38|T-maze
P02873593A0581|46 64|immediate-but-small
P02873593A0581|68 90|delayed-but-large reward
P02873593A0581|92 94|BZP
P02873593A0581|168 185|5-HT uptake blockers
P02873593A0581|195 209|opposite effects
P02874078A0252|2 33|endometrial luteal phase deficiency
P02874078A0252|52 52|%
P02874078A0252|64 71|patients
P02874635T0000|0 15|Prenatal exposure
P02874635T0000|21 36|fungicide dinocap
P02874635T0000|43 63|behavioral torticollis
P02874635T0000|65 74|ballooning
P02874635T0000|78 88|cleft palate
P02874635T0000|91 94|mice
P02874635T0000|102 105|rats
P02874635T0000|108 115|hamsters
P02875224A1059|0 10|Reperfusion
P02875224A1059|15 25|normal blood
P02875224A1059|31 37|beating
P02875224A1059|46 51|hearts
P02875224A1059|58 82|extensive structural damage
P02875224A1059|91 96|reflow
P02875224A1059|116 128|contractility
P02875224A1059|146 154|% systolic
P02875224A1059|166 170|p less
P02875967A0377|32 41|adrenaline
P02875967A0377|58 76|scorbutic guinea pigs
P02875967A0377|97 109|fertility rate
P02876820A0841|2 18|metabolic acidosis
P02876820A0841|28 44|marked stimulation
P02876820A0841|67 68|mV
P02876899A0568|2 5|Days
P02876899A0568|13 21|most young
P02876899A0568|25 39|elderly subjects
P02876899A0568|49 70|monoexponential decline
P02876899A0568|73 102|bevantolol plasma concentrations
P02876899A0568|108 122|absorption phase
P02877124A0000|0 5|Mature
P02877124A0000|9 16|old B6AF1
P02877124A0000|20 29|B6D2F1 mice
P02877124A0000|48 55|tap water
P02877124A0000|58 72|promethazine HCl
P02877124A0000|75 87|phenothiazine
P02877124A0000|92 117|H1 receptor blocking activity
P02877124A0000|92 101|H1 receptor
P02877124A0000|120 135|chlorpheniramine
P02877124A0000|139 147|H1 blocker
P02877124A0000|151 165|trifluoperazine
P02877124A0000|168 180|phenothiazine
P02877124A0000|187 204|H1 blocking activity
P02877124A0000|213 225|drinking water
P02877124A0000|233 239|effects
P02877124A0000|247 252|agents
P02877124A0000|255 272|bone mineral content
P02877124A0000|313 334|24-h whole body retention
P02877124A0000|337 338|Tc
P02877124A0000|342 363|methylene diphosphonate
P02877124A0000|365 366|Tc
P02877124A0000|370 372|MDP
P02877124A0000|387 400|bone metabolism
P02877124A0000|418 424|studies
P02877124A0000|438 447|ash weights
P02877124A0000|450 454|femur
P02877124A0000|456 460|ilium
P02877124A0000|464 469|sacrum
P02878100A0674|0 13|Present results
P02878100A0674|21 49|frequency-dependent inhibition
P02878100A0674|52 73|ganglionic transmission
P02878100A0674|76 84|diltiazem
P02878100A0674|100 108|diltiazem
P02878100A0674|119 146|excessive sympathetic activity
P02878100A0674|163 190|normal ganglionic transmission
P02879906A0000|0 6|Studies
P02879906A0000|22 44|several superficial veins
P02879906A0000|52 61|rabbit face
P02879906A0000|93 127|beta adrenoceptor subtype distribution
P02879906A0000|93 108|beta adrenoceptor
P02879906A0000|129 149|intrinsic myogenic tone
P02879906A0000|153 179|sympathetic nerve innervation
P02879951T0000|0 6|Effects
P02879951T0000|10 33|new antihypertensive agent
P02879951T0000|35 42|SGB-1534
P02879951T0000|46 67|rat platelet aggregation
P02880841A0313|19 21|TF1
P02880841A0313|34 49|primary structure
P02880841A0313|73 75|TF1
P02880841A0313|83 98|primary structure
P02880841A0313|104 114|beta subunit
P02880841A0313|132 149|nucleotide sequence
P02880841A0313|190 193|beta
P02880841A0313|203 217|major categories
P02880841A0313|220 221|F1
P02880841A0313|225 244|prokaryotic membranes
P02880841A0313|246 257|chloroplasts
P02880841A0313|262 273|mitochondria
P02882893A0301|0 14|Body temperature
P02882893A0301|18 35|overall conductance
P02882893A0301|69 81|P. s. campbelli
P02882893A0301|88 99|nominative sp
P02883327A0413|3 22|polyadenylation sites
P02883327A0413|54 54|E
P02883327A0413|67 74|viral DNA
P02883327A0413|102 102|L
P02883871A1075|9 11|ISA
P02883871A1075|27 39|beta receptors
P02883871A1075|77 114|post-beta-blocking drug hypersensitivity
P02883871A1075|127 132|agents
P02883871A1075|140 142|ISA
P02883963A0000|3 10|patients
P02883963A0000|15 47|human T-cell lymphotropic virus type I
P02883963A0000|15 46|human T-cell lymphotropic virus type
P02883963A0000|49 54|HTLV-I
P02883963A0000|67 76|myelopathy
P02883963A0000|78 80|HAM
P02883963A0000|95 119|electrophysiologic methods
P02884860A0329|0 8|Terazosin
P02884860A0329|11 26|structural analog
P02884860A0329|29 36|prazosin
P02884860A0329|50 68|alpha 1 adrenoceptors
P02884860A0329|50 54|alpha
P02884860A0329|56 68|adrenoceptors
P02884860A0329|93 110|twice-daily therapy
P02885517T0000|7 17|blood donors
P02885517T0000|21 25|non-A
P02885517T0000|27 40|non-B hepatitis
P02885517T0000|42 51|irrational
P02885517T0000|64 74|inescapable
P02889352A0000|0 11|Most patients
P02889352A0000|16 32|high blood pressure
P02889352A0000|34 35|BP
P02889352A0000|62 68|classes
P02889352A0000|71 79|compounds
P02889352A0000|82 89|diuretic
P02889352A0000|91 101|beta blocker
P02889352A0000|113 127|enzyme inhibitor
P02889352A0000|130 146|calcium antagonist
P02889495A0000|3 29|randomised double-blind study
P02889495A0000|33 58|first episode schizophrenics
P02889495A0000|68 75|pimozide
P02889495A0000|78 89|flupenthixol
P02889495A0000|98 102|weeks
P02889495A0000|107 119|mean daily dose
P02889495A0000|135 144|mg pimozide
P02889495A0000|150 163|mg flupenthixol
P02890200T0001|0 45|Somatostatin-producing endocrine pancreatic tumor
P02890200T0001|48 61|Recklinghausen
P02890200T0001|64 80|neurofibromatosis
P02892762A0296|0 5|Direct
P02892762A0296|9 30|inverted repeat elements
P02892762A0296|50 60|nucleotides
P02892762A0296|62 63|nt
P02892762A0296|73 84|promoter site
P02894689A0000|19 38|specific DNA fragments
P02894689A0000|44 48|bases
P02894689A0000|51 64|chromatin loops
P02894689A0000|79 102|novel extraction procedure
P02894689A0000|110 118|lithium-3
P02894689A0000|124 139|diiodosalicylate
P02894741A0000|11 28|supplementary doses
P02894741A0000|31 40|vecuronium
P02894741A0000|52 67|muscle relaxation
P02894741A0000|75 99|22-h-long NLA II anaesthesia
P02894789A0954|11 25|recovery indexes
P02894789A0954|42 46|times
P02894789A0954|58 62|T1/T0
P02894789A0954|58 59|T1
P02894789A0954|61 62|T0
P02894789A0954|66 70|T4/T1
P02894789A0954|66 67|T4
P02894789A0954|69 70|T1
P02894789A0954|83 83|%
P02894789A0954|88 88|%
P02895472A0178|11 27|bacterial colonies
P02895472A0178|43 61|recombinant plasmids
P02895472A0178|72 75|cDNA
P02895472A0178|85 87|BiP
P02895472A0178|90 119|hybrid-selected mRNA translation
P02895566A0187|0 2|DPA
P02895566A0187|43 50|ischemic
P02895566A0187|54 75|pressure pain components
P02895566A0187|90 105|ischemia duration
P02895566A0187|128 148|pressure pain component
P02895754A0000|0 6|Topical
P02895754A0000|8 27|percent isoproterenol
P02895754A0000|46 83|phosphodiesterase inhibitor theophylline
P02895754A0000|126 141|aqueous humor flow
P02895754A0000|152 166|anterior chamber
P02895754A0000|217 224|human eye
P02895754A0000|226 231|Horner
P02897651A0000|0 14|Hyperthyroidism
P02897651A0000|25 38|numerous causes
P02897651A0000|41 51|infertility
P02897651A0000|55 71|recurrent abortion
P02898752A0683|1 17|strong correlation
P02898752A0683|34 40|numbers
P02898752A0683|43 48|CFU-GM
P02898752A0683|71 82|granulocytes
P02898752A0683|86 102|platelets recovery
P02899177A0605|27 47|low-frequency kindling
P02899177A0605|51 73|useful experimental model
P02899177A0605|88 94|effects
P02899177A0605|97 109|antipsychotic
P02899177A0605|112 129|antiepileptic drugs
P02899177A0605|135 146|excitability
P02899177A0605|152 164|limbic regions
P02899792T0000|0 8|Oestrogen
P02899792T0000|16 23|overdose
P02900760A0073|5 20|sequence elements
P02900760A0073|55 87|efficient transcription termination
P02900760A0073|90 103|RNA polymerase I
P02900760A0073|105 108|pol I
P02900760A0073|124 151|cell-free transcription system
P02900760A0073|166 177|transfection
P02900760A0073|180 201|rDNA minigene constructs
P02900760A0073|206 213|3T6 cells
P02901498A0354|3 14|biosynthesis
P02901498A0354|37 50|mutant proteins
P02901498A0354|74 93|wild-type erbB protein
P02901498A0354|135 158|chicken embryo fibroblasts
P02901763A0977|0 9|Codon usage
P02901763A0977|12 36|C. reinhardtii mitochondria
P02901763A0977|61 66|codons
P02901763A0977|75 80|absent
P02901763A0977|88 106|protein-coding genes
P02901763A0977|126 135|codon usage
P02901763A0977|138 147|restricted
P02901763A0977|162 179|C. reinhardtii mtDNA
P02901763A0977|195 207|minimum number
P02901763A0977|210 214|tRNAs
P02901763A0977|230 258|mitochondrial protein synthesis
P02902615A0000|1 30|new physiopathological treatment
P02902615A0000|33 56|HBV-related polyarteritis
P02902615A0000|67 74|advances
P02902615A0000|91 113|chronic active hepatitis B
P02902615A0000|126 133|patients
P02902656A0481|4 16|scrotal testes
P02902656A0481|18 34|undescended testes
P02902656A0481|39 49|hypointense
P02902656A0481|57 65|sequences
P02902656A0481|71 89|short repetition time
P02902656A0481|91 92|TR
P02902656A0481|106 107|TE
P02902656A0481|114 118|cases
P02902656A0481|123 134|hyperintense
P02902656A0481|137 146|isointense
P02902656A0481|154 171|long TR/TE sequences
P02902656A0481|183 187|cases
P02902844A1219|3 15|subunit-a gene
P02902844A1219|43 65|small hydrophobic protein
P02902844A1219|99 108|atp operons
P02902844A1219|118 129|bacterium PS3
P02902844A1219|133 145|cyanobacteria
P02902927A0145|29 34|bovine
P02902927A0145|38 55|rat GHF-1 cDNA clones
P02903500A0278|12 31|functional properties
P02903500A0278|53 55|neu
P02903500A0278|67 76|fusion gene
P02903500A0278|89 105|cytoplasmic domain
P02903500A0278|108 110|neu
P02903500A0278|116 135|extracellular portion
P02903500A0278|140 163|immunoglobulin heavy chain
P02904322A0002|3 28|East African dik-dik antelope
P02904322A0002|40 61|miniature model ruminant
P02904322A0002|65 82|comparative studies
P02906027A0553|2 19|sequence comparison
P02906027A0553|23 28|blocks
P02906027A0553|31 38|homology
P02906027A0553|57 70|terminal region
P02906027A0553|92 100|CpG island
P02906027A0553|128 143|CpG dinucleotides
P02906027A1156|5 19|unusual features
P02906027A1156|29 42|numerous large G
P02906027A1156|44 49|C-rich
P02906027A1156|59 74|sequences located
P02906027A1156|80 90|first intron
P02906249A1195|5 14|first group
P02906249A1195|20 28|% Prazosin
P02906249A1195|33 37|mg/kg
P02906249A1195|73 77|hours
P02906249A1195|100 105|Oxy-Hb
P02906249A1195|108 116|PGF2 alpha
P02906673T0000|0 7|Efficacy
P02906673T0000|11 25|field evaluation
P02906673T0000|28 48|Bacillus thuringiensis
P02906673T0000|50 53|H-14
P02906673T0000|58 69|B. sphaericus
P02906673T0000|77 96|floodwater mosquitoes
P02906673T0000|99 108|California
P02907308T0001|1 5|cases
P02907308T0001|14 24|tyrosinosis
P02907308T0001|26 48|Richner-Hanhart syndrome
P02907533A0362|24 40|drug concentration
P02907533A0362|45 60|correction factor
P02907533A0362|86 114|true free diazepam concentration
P02907533T0000|0 6|Effects
P02907533T0000|10 41|perfluorochemical blood substitute
P02907533T0000|44 58|diazepam binding
P02907533T0000|61 72|human albumin
P02909528A1081|1 22|second promoter activity
P02909528A1081|60 89|major transcriptional start sites
P02910496A0583|1 15|decamer sequence
P02910496A0583|20 32|CGA-CCCCUCC-3
P02910496A0583|35 47|complementary
P02910496A0583|60 75|sequence adjacent
P02910496A0583|81 101|enzymatic cleavage site
P02910496A0583|107 131|mitochondrial RNA substrate
P02910496A0583|147 158|RNAase MRP RNA
P02910989T0000|0 6|Effects
P02910989T0000|9 13|aging
P02910989T0000|17 40|beta-adrenergic-blockade
P02910989T0000|43 71|standing-induced QT/QS2 changes
P02911540A0478|14 26|infected wound
P02911540A0478|35 45|primary area
P02911540A0478|47 51|hands
P02911540A0478|53 56|feet
P02911540A0478|65 72|perineum
P02911540A0478|105 114|proper care
P02913368A1037|0 18|Pharmacology studies
P02913368A1037|23 39|potassium chloride
P02913368A1037|43 55|acetylcholine
P02913368A1037|67 73|raveron
P02913368A1037|81 97|calcium antagonist
P02913368A1037|111 116|influx
P02913368A1037|119 138|extracellular calcium
P02914422A0409|0 15|Computer analysis
P02914422A0409|24 39|digital averaging
P02914422A0409|69 91|different frequency bands
P02914422A0409|113 126|frequency range
P02914422A0409|142 148|notches
P02914422A0409|152 156|slurs
P02914492A0183|16 18|ICU
P02914492A0183|23 30|patients
P02914492A0183|34 40|percent
P02914492A0183|45 58|hypomagnesemia
P02914492A0183|60 70|serum Mg less
P02914492A0183|78 83|mEq/dl
P02914492A0183|88 95|patients
P02914492A0183|99 105|percent
P02914492A0183|110 124|normomagnesemia
P02914492A0183|134 139|mEq/dl
P02914492A0183|148 155|patients
P02914492A0183|158 164|percent
P02914492A0183|169 183|hypermagnesemia
P02914492A0183|185 191|greater
P02914492A0183|199 204|mEq/dl
P02916764A0253|3 13|risk factors
P02916764A0253|25 31|male sex
P02916764A0253|33 44|hypertension
P02916764A0253|46 61|diabetes mellitus
P02916764A0253|63 82|hypercholesterolemia
P02916764A0253|84 99|cigarette smoking
P02916764A0253|101 119|sedentary life-style
P02916764A0253|124 136|family history
P02918474A0817|7 15|verapamil
P02918474A0817|19 28|nifedipine
P02918474A0817|36 64|collateral myocardial blood flow
P02918474A0817|85 98|subendocardium
P02918474A0817|113 120|ml/min/g
P02918474A0817|126 138|subepicardium
P02919483A0091|11 14|boys
P02919483A0091|20 24|girls
P02919483A0091|31 37|mean age
P02919483A0091|48 56|half years
P02919530A0000|16 38|uncontrolled reperfusion
P02919530A0000|41 58|ischemic myocardium
P02919530A0000|64 98|experimental coronary artery occlusion
P02919530A0000|131 159|regional ventricular wall motion
P02919530A0000|173 194|biochemical alterations
P02919832A0144|0 13|Cardiac disease
P02919832A0144|32 37|M-mode
P02919832A0144|39 60|2-dimensional real-time
P02919832A0144|63 96|pulsed-wave Doppler echocardiography
P02920591A0251|0 20|Hemodynamic assessment
P02920591A0251|66 72|digoxin
P02920591A0251|75 87|micrograms/kg
P02920591A0251|92 99|dopamine
P02920591A0251|106 122|micrograms/kg/min
P02923687A0218|45 53|sinusitis
P02923687A0218|60 68|cleft side
P02923687A0218|71 78|patients
P02923687A0218|83 103|unilateral cleft palate
P02925013A1112|21 29|low levels
P02925013A1112|59 74|intestinal tissue
P02925013A1112|87 98|accumulation
P02925013A1112|111 123|citrate ligand
P02925568A0460|8 14|effects
P02925568A0460|17 29|father absence
P02925568A0460|35 51|routine conditions
P02925568A0460|64 77|healthy samples
P02925568A0460|88 116|significant effects independent
P02925568A0460|130 144|family stressors
P02925568A0460|147 169|maternal psychopathology
P02926499A0340|11 42|electrical-mechanical analog model
P02926499A0340|45 52|heat flow
P02926499A0340|107 109|CBF
P02926499A0340|125 130|CBF = Cb
P02926499A0340|139 139|c
P02926499A0340|146 148|tau
P02926499A0340|154 173|thermal decay constant
P02926499A0340|175 177|rho
P02926499A0340|201 201|c
P02926499A0340|207 218|specific heat
P02927391A0238|21 30|proviruses
P02927391A0238|43 69|mosaic founder SWR/J-RF/J mice
P02927391A0238|102 109|germ line
P02927391A0238|127 140|somatic tissues
P02927391A0238|159 174|viral integration
P02927391A0238|192 199|germ line
P02927391A0238|218 232|somatic lineages
P02928112T0000|0 15|Molecular cloning
P02928112T0000|21 24|cDNA
P02928112T0000|31 52|human U2 snRNA-specific A
P02928376A0312|6 16|present work
P02928376A0312|23 36|water saturated
P02928376A0312|56 57|H2
P02928376A0312|63 67|gases
P02928376A0312|80 89|heat defect
P02928376A0312|110 110|%
P02929056T0000|0 12|Successful use
P02929056T0000|15 38|transureteroureterostomy
P02929056T0000|48 67|ureterosigmoidostomy
P02929056T0000|73 90|anastomotic failure
P02930623A0404|6 20|flexion whiplash
P02930623A0404|25 30|torque
P02930623A0404|36 51|occipital condyle
P02930623A0404|81 82|ms
P02934778A0702|29 54|5-HT2 serotonergic receptors
P02934778A0702|60 74|bronchial artery
P02934889A0558|0 10|Oxfendazole
P02934889A0558|32 43|shortest time
P02934889A0558|52 55|days
P02934889A0558|71 77|grazing
P02934889A0558|79 81|May
P02934889A0558|101 113|cent reduction
P02934889A0558|116 132|Ostertagia species
P02934889A0558|145 157|cent reduction
P02934889A0558|160 169|D viviparus
P02934891A0845|20 35|DNA-footprinting
P02934891A0845|41 54|impure extracts
P02934891A0845|57 59|ner
P02934891A0845|73 77|cells
P02934891A0845|107 122|ner-binding sites
P02934891A0845|126 132|located
P02934891A0845|140 150|nucleotides
P02934891A0845|169 170|Mu
P02935638A0000|49 57|Spec1 gene
P02935638A0000|63 99|sea urchin Strongylocentrotus purpuratus
P02936163T0000|0 15|Platelet function
P02936163T0000|19 66|platelet-polymorphonuclear-neutrophil interaction
P02936163T0000|69 76|patients
P02936163T0000|81 117|deficient platelet lipoxygenase activity
P02936163T0000|90 109|platelet lipoxygenase
P02936284A0357|0 21|Spontaneous degradation
P02936284A0357|24 33|atracurium
P02936284A0357|36 41|plasma
P02936284A0357|47 56|major route
P02936284A0357|59 69|elimination
P02936284A0357|92 116|short elimination half-life
P02936284A0357|135 137|min
P02938185A0223|11 19|cell lines
P02938185A0223|36 38|E1a
P02938185A0223|41 43|E1a
P02938185A0223|47 61|E1b gene products
P02938185A0223|78 84|viruses
P02938185A0223|100 126|anchorage-independent growth
P02938185A0223|131 138|degrees C
P02938185A0223|147 154|degrees C
P02938185A0223|166 189|cytoskeletal architecture
P02938185A0223|200 233|untransformed fibroblastic CREF cells
P02939260A1553|0 41|Partial N-terminal amino acid sequence analysis
P02939260A1553|55 72|43K and 42K T antigens
P02939260A1553|55 57|43K
P02939260A1553|61 72|42K T antigens
P02939260A1553|80 89|methionine
P02939260A1553|92 99|residues
P02939260A1553|124 134|DNA sequence
P02939260A1553|145 154|methionine
P02939260A1553|173 183|39K T antigen
P02939260A1553|201 206|cycles
P02939260A1553|209 224|Edman degradation
P02940334A0141|0 5|Group A
P02940334A0141|31 35|doses
P02940334A0141|38 61|hepatitis B immune globulin
P02940334A0141|63 66|HBIG
P02940334A0141|80 97|different schedules
P02941237A0160|5 18|former instance
P02941237A0160|32 43|serum calcium
P02941237A0160|47 74|phosphorous ion concentrations
P02941237A0160|76 83|tissue pH
P02941237A0160|85 95|blood supply
P02941237A0160|97 104|hormones
P02941237A0160|111 118|vitamin D
P02941237A0160|120 127|vitamin A
P02941237A0160|132 145|various enzymes
P02941237A0160|152 170|alkaline phosphatase
P02941237A0160|174 188|pyrophosphatase
P02941237A0160|212 220|ancillary
P02941237A0160|222 235|time-dependent
P02941237A0160|245 261|undetermined roles
P02943562T0000|0 22|Penicillinase production
P02943562T0000|0 12|Penicillinase
P02943562T0000|45 51|strains
P02943562T0000|54 71|clinical importance
P02947866A1416|5 24|quantitative analysis
P02947866A1416|27 44|thallium-201 uptake
P02947866A1416|48 54|washout
P02947866A1416|63 79|objective evidence
P02947866A1416|91 109|myocardial perfusion
P02947866A1416|115 133|coronary angioplasty
P02949170A0184|19 25|effects
P02949170A0184|46 71|micrograms ethinyl estradiol
P02949170A0184|76 95|mg cyproterone acetate
P02949170A0184|98 110|gonadotropins
P02949170A0184|112 120|prolactin
P02949170A0184|122 133|testosterone
P02949170A0184|135 159|sex hormone binding globulin
P02949170A0184|161 164|SHBG
P02949170A0184|167 181|androstenedione
P02949170A0184|196 216|free testosterone index
P02949170A0184|234 239|months
P02950216A0084|0 13|Functional flow
P02950216A0084|31 51|laser Doppler flowmetry
P02950216A0084|53 55|LDF
P02950216A0084|69 80|output signal
P02950216A0084|82 94|blood cell flux
P02950216A0084|96 98|BCF
P02950216A0084|121 125|volts
P02957125A0601|6 13|patients
P02957125A0601|18 49|renal failure routine haemodialysis
P02957125A0601|72 84|cent reduction
P02957125A0601|87 108|plasma ANP concentration
P02957125A0601|93 95|ANP
P02958204A0175|16 22|effects
P02958204A0175|25 36|isotretinoin
P02958204A0175|39 41|HDL
P02958204A0175|53 57|HDL-C
P02958204A0175|59 74|HDL phospholipids
P02958204A0175|59 61|HDL
P02958204A0175|76 81|HDL-PL
P02958204A0175|84 95|apoprotein A1
P02958204A0175|97 102|apo A-1
P02958204A0175|108 124|HDL-C subfractions
P02958204A0175|108 112|HDL-C
P02958204A0175|126 131|HDL2-C
P02958204A0175|135 140|HDL3-C
P02958204A0175|154 165|male patients
P02958204A0175|176 188|16-week course
P02958204A0175|191 202|isotretinoin
P02958204A0175|207 215|mg/kg/day
P02958204A0175|231 248|severe acne vulgaris
P02958233A0123|3 17|clinical picture
P02958233A0123|21 40|laboratory parameters
P02958233A0123|60 80|serum sickness reaction
P02958660A1094|44 59|conversion factor
P02958660A1094|63 71|LDF signal
P02958660A1094|74 91|absolute flow values
P02959089T0000|0 15|Preventive effect
P02959089T0000|18 25|ONO-3708
P02959089T0000|28 37|thrombosis
P02959089T0000|41 50|vasospasms
P02960012A0838|14 24|PPNG strains
P02960012A0838|41 41|%
P02960012A0838|53 53|%
P02962859A0276|0 21|Monospecific antibodies
P02962859A0276|36 66|beta-galactosidase fusion protein
P02962859A0276|36 53|beta-galactosidase
P02962859A0276|75 79|clone
P02962859A0276|94 117|U1 snRNP-specific A antigen
P02963517A0453|0 19|Quantitative analysis
P02963517A0453|25 40|coronary stenosis
P02963517A0453|66 69|PTCA
P02963517A0453|77 86|dilatation
P02963517A0453|109 141|minimal luminal cross-sectional area
P02963517A0453|166 168|mm2
P02964329A0000|3 14|pathogenesis
P02964329A0000|17 36|Limited Joint Mobility
P02964329A0000|38 40|LJM
P02964329A0000|68 78|abnormality
P02964329A0000|114 122|incidence
P02964329A0000|125 139|microangiopathy
P02965149A0727|3 15|previous study
P02965149A0727|17 22|Brandl
P02965149A0727|24 25|C.
P02966671A0151|3 23|experimental end points
P02966671A0151|46 58|treated tumors
P02966671A0151|67 71|times
P02966671A0151|77 89|treatment size
P02966671A0151|104 112|stem cells
P02966671A0151|118 131|duodenal crypts
P02966671A0151|139 151|breathing rate
P02966671A0151|171 175|weeks
P02966671A0151|190 194|weeks
P02966671A0551|0 7|Schedule
P02966671A0551|20 29|mg/kg c-DDP
P02966671A0551|62 66|X-ray
P02966671A0551|70 84|consecutive days
P02966671A0551|96 108|highest degree
P02966671A0551|111 121|enhancement
P02966671A0551|124 138|radiation effect
P02966671A0551|151 167|dose-effect factor
P02966671A0551|176 198|next greatest enhancement
P02966671A0551|214 223|mg/kg c-DDP
P02966671A0551|238 238|h
P02966671A0551|267 283|daily radiotherapy
P02967496A0182|3 25|cpc-1-encoded transcript
P02967496A0182|39 55|open reading frames
P02967496A0182|70 76|located
P02967496A0182|82 108|720-nucleotide leader segment
P02967496A0182|121 125|cpc-1
P02967915A0000|3 44|seco-steroid hormone 1,25-dihydroxyvitamin D3
P02967915A0000|76 96|calcium binding protein
P02967915A0000|103 116|calbindin-D28K
P02967915A0000|129 141|target tissues
P02967915A0968|14 35|calbindin-D28K promoter
P02967915A0968|72 80|sequences
P02967915A0968|96 105|components
P02967915A0968|108 132|putative regulatory signals
P02968055A0984|3 5|HOI
P02968055A0984|20 35|fourfold increase
P02968055A0984|38 40|ANF
P02969316A0002|23 27|atria
P02969316A0002|38 65|elevated plasma concentrations
P02969316A0002|68 91|atrial natriuretic peptide
P02969316A0002|93 95|ANP
P02969316A0002|101 115|temporal changes
P02969316A0002|118 140|plasma ANP concentrations
P02969316A0002|124 126|ANP
P02969316A0002|159 186|chloralose-anaesthetized dogs
P02969316A0002|194 194|h
P02969316A0002|197 223|sustained rapid cardiac pacing
P02969819A0814|0 19|Ig D-JH recombinations
P02969819A0814|0 2|Ig D
P02969819A0814|4 5|JH
P02969819A0814|30 49|TcR gene recombination
P02969819A0814|30 36|TcR gene
P02969819A0814|57 71|early T cell lines
P02969819A0814|96 116|sterile Cmu transcripts
P02969819A0814|103 116|Cmu transcripts
P02970061A0271|3 27|RAD18 gene open reading frame
P02970061A0271|3 11|RAD18 gene
P02970061A0271|48 57|amino acids
P02970061A0271|74 88|molecular weight
P02970640A0341|0 32|Atomic absorption spectrophotometry
P02970640A0341|62 72|E1A proteins
P02970640A0341|88 107|289-amino acid protein
P02970640A0341|116 122|zinc ion
P02970640A0341|134 153|243-amino acid protein
P02970640A0341|161 164|zinc
P02971603A0883|0 11|Most patients
P02971603A0883|21 27|tablets
P02971603A0883|30 38|injection
P02971710A0734|0 4|Plots
P02971710A0734|7 8|RV
P02971710A0734|10 11|LV
P02971710A0734|13 13|S
P02971710A0734|17 24|2A weight
P02971710A0734|27 40|real hematocrit
P02971710A0734|47 68|sharp upward inflections
P02971710A0734|71 84|real hematocrit
P02971710A0734|87 87|%
P02971710A0734|100 111|possible role
P02971710A0734|123 131|viscosity
P02971710A0734|134 135|CO
P02971710A0734|153 168|higher hematocrit
P02971957A0287|3 27|absorbable perisplenic mesh
P02971957A0287|32 51|important improvement
P02971957A0287|62 66|cases
P02971957A0287|79 93|other techniques
P02971957A0287|106 120|splenic bleeding
P02973304A0000|1 17|rare chronic course
P02973304A0000|20 38|Budd-Chiari syndrome
P02973304A0000|53 62|thrombosis
P02973304A0000|68 77|portal vein
P02973304A0000|92 122|30-year-old male patient suffering
P02973304A0000|127 156|postmyocarditic cardiosclerosis
P02975680A0000|8 25|accommodation night
P02975680A0000|27 44|sleep EEG recordings
P02975680A0000|69 85|consecutive nights
P02975680A0000|91 109|drug-free inpatients
P02975680A0000|131 145|anxiety disorder
P02975680A0000|147 149|GAD
P02975680A0000|155 175|significant depression
P02975680A0000|197 212|sex-matched group
P02975680A0000|215 222|patients
P02975680A0000|227 229|GAD
P02975680A0000|241 270|primary major depressive disorder
P02975680A0000|272 274|MDD
P02975680A0000|276 283|patients
P02975753A1333|0 25|Oligonucleotide mutagenesis
P02975753A1333|33 46|binding domains
P02975753A1333|76 100|transcriptional regulation
P02975753A1333|106 115|E3 promoter
P02975753A1333|118 127|yeast cells
P02976332A1277|18 21|PGI2
P02976332A1277|27 52|newly-formed luminal surface
P02979426T0000|0 19|Organ transplantation
P02979426T0000|22 28|Denmark
P02979834T0000|0 6|Effects
P02979834T0000|18 59|combined maltose tetrapalmitate immunotherapy
P02979834T0000|61 88|cyclophosphamide chemotherapy
P02979834T0000|92 103|radiotherapy
P02979834T0000|106 119|ethyl carbamate
P02979834T0000|131 147|primary lung cancer
P02979834T0000|150 156|A/J mice
P02981457A0368|0 1|D.
P02981840A0907|1 20|114-base pair sequence
P02981840A0907|45 72|purine-pyrimidine nucleotides
P02981840A0907|90 90|d
P02981840A0907|92 93|AC
P02981840A0907|95 101|repeats
P02982332T0001|0 4|Phase
P02982332T0001|14 18|VP-16
P02982332T0001|20 26|capsule
P02982332T0001|30 40|solid tumors
P02983316A0310|13 20|segments
P02983316A0310|47 80|complementarity-determining regions
P02983316A0310|89 93|genes
P02983316A0310|100 119|murine probe sequences
P02983316A0310|133 146|metric analysis
P02983316A0310|167 177|caiman genes
P02983316A0310|224 240|mammalian sequence
P02983316A0310|256 278|significant preservation
P02983316A0310|281 298|nucleotide sequence
P02983316A0310|305 318|extended period
P02983316A0310|321 336|phylogenetic time
P02983331T0000|0 7|Evidence
P02983331T0000|18 56|endogenous corticotropin-releasing factor
P02983331T0000|64 68|ether
P02983331T0000|70 83|immobilization
P02983331T0000|88 102|traumatic stress
P02985812A0984|2 15|unusual feature
P02985812A0984|23 38|replicative genes
P02985812A0984|48 58|smaller mRNA
P02985812A0984|76 91|open reading frame
P02985812A0984|97 106|larger mRNA
P02985820A1287|0 24|Different sequence elements
P02985820A1287|34 50|retroviral vectors
P02985820A1287|57 65|c-myc gene
P02985820A1287|82 88|genesis
P02985820A1287|97 121|oncogenic retroviruses CMII
P02985820A1287|123 126|MC29
P02985820A1287|130 132|MH2
P02986279A0000|2 12|milk samples
P02986279A0000|28 33|donors
P02986279A0000|35 38|days
P02986279A0000|42 47|months
P02986279A0000|79 88|occurrence
P02986279A0000|91 105|cytomegalovirus
P02986279A0000|107 109|CMV
P02987220A0472|0 9|Subcloning
P02987220A0472|12 23|DNA fragments
P02987220A0472|31 42|8.5-kilobase
P02987220A0472|44 45|kb
P02987220A0472|55 59|pAVO4
P02987220A0472|68 82|4-kb DNA fragment
P02987220A0472|100 112|functional FBP
P02987220A0472|110 117|FBP+ gene
P02987220A0472|124 139|regulatory region
P02987777A0000|5 9|cases
P02987777A0000|12 42|primary signet-ring cell carcinoma
P02987777A0000|48 53|rectum
P02988457A0650|36 53|future potentiality
P02988457A0650|56 72|Bestatin treatment
P02988457A0650|81 85|types
P02988457A0650|88 97|malignancy
P02989637A0671|20 41|dopaminergic regulation
P02989637A0671|44 79|adrenal zona glomerulosa corticosteroid
P02989637A0671|83 101|renal renin secretion
P02989637A0671|83 92|renal renin
P02989637A0671|104 109|absent
P02989637A0671|112 119|patients
P02989637A0671|124 149|high spinal cord transections
P02989637A0671|165 184|intact neural pathways
P02989637A0671|192 211|central nervous system
P02989637A0671|227 251|metoclopramide stimulation
P02989637A0671|254 264|aldosterone
P02989637A0671|268 281|renin secretion
P02989637A0671|268 272|renin
P02989637A0671|284 286|men
P02989786A0328|14 30|enhancer sequences
P02989786A0328|35 51|adenovirus E1A gene
P02989786A0328|67 81|CATase synthesis
P02989786A0328|67 72|CATase
P02991060A0465|5 17|IgG antibodies
P02991060A0465|23 28|babies
P02991060A0465|67 76|detectable
P02991060A0465|84 88|cases
P02991060A0465|99 104|months
P02991060A0465|107 110|ages
P02991060A0465|118 123|babies
P02991060A0465|130 135|months
P02993630A1190|0 11|Fine analysis
P02993630A1190|17 31|nucleotide level
P02993630A1190|37 47|early events
P02993630A1190|53 61|digestion
P02993630A1190|66 75|nuclease S1
P02993630A1190|88 100|enzyme attacks
P02993630A1190|127 129|G-A
P02993630A1190|138 163|message complementary strand
P02994253A0482|5 11|dosages
P02994253A0482|25 39|mean NTE activity
P02994253A0482|42 58|spinal cord greater
P02994253A0482|74 74|%
P02994253A0482|78 89|brain greater
P02994253A0482|105 105|%
P02994253A0482|108 120|control values
P02994253A0482|129 142|hr postexposure
P02994253A0482|151 175|marked spinal cord pathology
P02994253A0482|178 193|days postexposure
P02994253A0482|196 202|greater
P02994253A0482|218 218|%
P02994253A0482|235 241|animals
P02994336A0864|0 1|FK
P02994336A0864|10 38|methionine-enkephalin analogue
P02994336A0864|50 59|plasma ACTH
P02994336A0864|56 59|ACTH
P02994336A0864|64 64|%
P02994336A0864|67 76|basal level
P02994336A0864|83 95|bromocriptine
P02994336A0864|97 102|CB-154
P02994336A0864|112 128|significant change
P02995967T0000|1 27|v-erbB-related protooncogene
P02995967T0000|29 36|c-erbB-2
P02995967T0000|55 62|c-erbB-1
P02995967T0000|64 97|epidermal growth factor-receptor gene
P02995967T0000|115 146|human salivary gland adenocarcinoma
P02995999A0000|3 18|sequence analysis
P02995999A0000|25 32|products
P02995999A0000|35 47|individual phi
P02995999A0000|50 81|site-specific recombination events
P02995999A0000|97 109|recombination
P02995999A0000|115 133|secondary attachment
P02995999A0000|135 137|att
P02995999A0000|152 178|several different novel joints
P02995999A0000|184 201|mismatched position
P02995999A0000|206 223|recombination event
P02995999A0000|235 257|single base-pair deletion
P02995999A0000|264 287|other recombination events
P02995999A0000|301 337|different single base-pair substitutions
P02997622A0916|4 16|L-myc sequence
P02997622A0916|44 59|SCLC cell line DNAs
P02997622A0916|68 85|SCLC tumour specimen
P02997777A0609|0 27|Temperature-shift experiments
P02997777A0609|51 55|cells
P02997777A0609|59 92|delta top1 top2 temperature-sensitive
P02997777A0609|94 95|ts
P02997777A0609|97 108|double mutant
P02997777A0609|115 134|isogenic top2 ts strain
P02997777A0609|123 128|top2 ts
P02997777A0609|151 163|mitotic blocks
P02997777A0609|186 197|top2 ts mutant
P02997777A0609|201 224|nonpermissive temperature
P02997777A0609|229 242|same treatments
P02997777A0609|246 256|ineffective
P02997777A0609|269 277|cell death
P02997777A0609|283 309|delta top1 top2 ts double mutant
P02997777A0609|283 291|delta top1
P02998016A0527|3 10|homology
P02998016A0527|13 17|v-mil
P02998016A0527|49 52|exon
P02998016A0527|72 89|untranslated region
P02998016A0527|92 95|exon
P02998016A0527|101 111|nucleotides
P02998016A0527|129 141|nonsense codon
P02998016A0527|156 176|large open reading frame
P02998016A0527|190 194|c-mil
P02998016A0527|198 202|v-mil
P02998043A1199|0 10|Examination
P02998043A1199|29 49|Punta Toro M gene product
P02998043A1199|70 97|multiple hydrophobic sequences
P02998043A1199|108 119|19-amino acid
P02998043A1199|121 136|carboxy-proximal
P02998043A1199|138 154|hydrophobic region
P02998043A1199|156 157|G2
P02999267A0606|8 10|FAP
P02999267A0606|15 32|primary amyloidosis
P02999267A0606|50 74|positive myocardial uptakes
P02999267A0606|111 117|sternum
P02999267A0885|14 29|myocardial uptake
P02999267A0885|32 41|Tc-99m-PYP
P02999267A0885|44 51|patients
P02999267A0885|56 98|echocardiographic left ventricular hypertrophy
P02999267A0885|111 136|refractile myocardial echoes
P02999267A0885|138 173|so-called granular sparkling appearance
P02999267A0885|175 176|GS
P02999267A0885|189 195|greater
P02999267A0885|206 213|patients
P02999267A0885|225 245|myocardial hypertrophy
P02999267A0885|249 250|GS
P03000457A1554|6 17|kDa precursor
P03000457A1554|36 36|t
P03000457A1554|40 40|=
P03000457A1554|42 42|h
P03000457A1554|46 66|proteolytic processing
P03000457A1554|75 77|kDa
P03000457A1554|79 83|alpha
P03000457A1554|91 93|kDa
P03000457A1554|95 98|beta
P03000489A0822|0 18|Alveolar lymphocytes
P03000489A0822|46 57|most patients
P03000489A0822|82 82|%
P03000489A0822|93 93|%
P03000489A0822|98 100|CGL
P03000489A0822|117 117|%
P03000489A0822|128 128|%
P03000489A0822|144 153|activation
P03000489A0822|172 187|blood lymphopenia
P03001054A0703|25 29|nicks
P03001054A0703|44 52|wild-type
P03001054A0703|59 69|mutant sites
P03001084A0406|28 40|4024-base pair
P03001084A0406|42 43|bp
P03001084A0406|70 71|bp
P03001084A0406|79 85|cap site
P03001084A0406|88 93|alpha 1
P03001084A0406|88 92|alpha
P03001084A0406|99 100|bp
P03001084A0406|105 112|psi alpha
P03001086A0587|12 28|amino acid sequence
P03001086A0587|34 50|extensive homology
P03001086A0587|60 74|Drosophila hsp70
P03001086A0587|70 74|hsp70
P03001086A0587|76 85|trout hsp70
P03001086A0587|87 98|Xenopus hsp70
P03001086A0587|100 109|yeast hsp70
P03001086A0587|118 125|homology
P03001086A0587|131 159|heat-inducible dnaK gene product
P03001110A0546|4 18|phosphorylation
P03001110A0546|21 46|exogenous peptide substrates
P03001110A0546|71 98|receptor self-phosphorylation
P03001110A0546|100 121|tyrosine kinase activity
P03001110A0546|100 113|tyrosine kinase
P03001110A0546|161 163|mol
P03001110A0546|166 174|phosphate
P03001110A0546|178 180|mol
P03001110A0546|183 190|receptor
P03001353A0146|2 23|temperatures permissive
P03001353A0146|42 49|6m2 cells
P03001353A0146|57 62|P58gag
P03001353A0146|78 89|4.0-kilobase
P03001353A0146|91 92|kb
P03001353A0146|94 107|viral RNA genome
P03001353A0146|111 120|P85gag-mos
P03001353A0146|111 116|P85gag
P03001353A0146|118 120|mos
P03001353A0146|136 141|3.5-kb
P03001353A0146|149 152|mRNA
P03001645A0785|3 7|pet56
P03001645A0785|11 19|his3 genes
P03001645A0785|49 63|initiation sites
P03001645A0785|89 90|bp
P03001705T0000|0 22|Multistep transformation
P03001705T0000|32 40|fragments
P03001705T0000|43 64|herpes simplex virus type
P03001705T0000|70 84|oncogenic region
P03001705T0000|91 101|gene product
P03001952A0958|19 26|patients
P03001952A0958|31 55|first-attack genital herpes
P03001952A0958|66 68|HSV
P03001952A0958|78 97|important determinant
P03001952A0958|100 120|subsequent recurrences
P03001952A0958|128 147|intravenous acyclovir
P03001952A0958|151 162|little effect
P03001952A0958|165 185|subsequent recurrences
P03002501A1327|0 9|Comparison
P03002501A1327|12 20|sequences
P03002501A1327|23 27|ovine
P03002501A1327|31 36|bovine
P03002501A1327|44 72|guinea-pig alpha s1-casein mRNAs
P03002501A1327|85 99|greater homology
P03002501A1327|122 124|non
P03002501A1327|131 137|regions
P03002786A0143|9 10|n =
P03002786A0143|32 40|midazolam
P03002786A0143|45 50|mg kg-1
P03002786A0143|55 62|atropine
P03002786A0143|70 75|mg i.m.
P03003695A0395|0 9|Comparison
P03003695A0395|32 45|c-sis cDNA clone
P03003695A0395|32 40|c-sis cDNA
P03003695A0395|47 53|Collins
P03003695A0395|60 65|Nature
P03003695A0395|102 113|kbp DNA region
P03003695A0395|131 139|c-sis exon
P03003695A0395|153 154|bp
P03004364A0775|25 44|biological activities
P03004364A0775|47 50|5-FU
P03004364A0775|52 54|ADM
P03004364A0775|58 60|MMC
P03004364A0775|63 68|FAMLIP
P03004364A0775|81 85|FULIP
P03004364A0775|87 92|ADRLIP
P03004364A0775|96 101|MMCLIP
P03004739A0753|14 14|C
P03004739A0753|17 29|G transversion
P03004739A0753|35 46|first residue
P03004739A0753|52 69|CAT pentanucleotide
P03004739A0753|108 116|promoters
P03004739A0753|135 142|affinity
P03004739A0753|148 164|CAT binding protein
P03004982A0199|3 20|nucleotide sequence
P03004982A0199|27 28|bp
P03004982A0199|37 63|R. sphaeroides chromosomal DNA
P03004982A0199|82 100|structural genes fbcF
P03004982A0199|97 100|fbcF
P03004982A0199|102 105|fbcB
P03004982A0199|109 112|fbcC
P03004982A1094|3 20|N-terminal sequence
P03004982A1094|26 43|hydrophilic peptide
P03004982A1094|49 58|FeS protein
P03004982A1094|91 106|fbcF reading frame
P03004982A1094|91 94|fbcF
P03005231A0649|10 30|untranslated sequences
P03005231A0649|38 60|characteristic sequences
P03005231A0649|81 90|initiation
P03005231A0649|94 104|termination
P03005231A0649|107 119|transcription
P03005231A0649|133 149|possible promoters
P03005231A0649|188 196|sequences
P03006066A0653|6 20|P135gag-myb-ets
P03006066A0653|6 12|P135gag
P03006066A0653|35 52|translation product
P03006066A0653|55 59|c-myb
P03006066A0653|61 68|P75c-myb
P03006066A0653|79 93|nuclear proteins
P03006066A0653|95 102|P54c-ets
P03006066A0653|128 138|cytoplasmic
P03007281A0905|3 13|Dox-A2 locus
P03007281A0905|30 31|kb
P03007281A0905|37 38|Df
P03007281A0905|40 41|2L
P03007281A0905|43 56|OD15 breakpoint
P03007281A0905|74 82|vital loci
P03007281A0905|103 104|kb
P03008094A0697|3 15|C-terminal end
P03008094A0697|22 32|polypeptide
P03008094A0697|45 49|types
P03008094A0697|60 68|sequences
P03008405A0532|0 15|Further outbreaks
P03008405A0532|18 30|ocular disease
P03008405A0532|33 51|farmed red deer calves
P03008405A0532|60 64|HVC-1
P03009366A0438|7 21|ultrastructural
P03009366A0438|25 42|biochemical studies
P03009366A0438|59 62|Type
P03009366A0438|65 75|pneumocytes
P03009366A0438|81 91|early target
P03009366A0438|118 127|surfactant
P03009366A0438|135 142|alveolus
P03009366A0438|174 177|days
P03009366A0438|181 185|weeks
P03009826A0201|11 16|clones
P03009826A0201|38 55|base-pair dimer unit
P03010281A0220|3 8|copies
P03010281A0220|14 24|72-bp repeat
P03010281A0220|33 51|efficient activation
P03010281A0220|54 67|gene expression
P03011793A0582|3 19|open reading frames
P03011793A0582|22 25|rbsD
P03011793A0582|27 30|rbsA
P03011793A0582|35 38|rbsC
P03011793A0582|45 52|proteins
P03011793A0582|69 85|amino acid residues
P03013477A0000|28 39|iron overload
P03013477A0000|45 70|polymorphonuclear leucocyte
P03013477A0000|72 74|PMN
P03013477A0000|76 85|metabolism
P03013477A0000|88 95|patients
P03013477A0000|98 116|chronic hemodialysis
P03013477A0000|130 144|superoxide anion
P03013477A0000|152 154|PMN
P03013477A0000|157 166|whole blood
P03013477A0000|183 188|groups
P03013477A0000|191 210|hemodialyzed patients
P03013477A0000|239 249|individuals
P03013477A0000|254 272|serum ferritin levels
P03013477A0000|282 286|ng/ml
P03013477A0000|290 295|group B
P03013477A0000|306 316|individuals
P03013477A0000|321 339|serum ferritin levels
P03013477A0000|349 353|ng/ml
P03013841A0207|0 7|Cattaneo
P03013841A0207|12 13|J.
P03014515T0000|0 24|Human alpha-galactosidase A
P03014515T0000|26 43|nucleotide sequence
P03014515T0000|47 55|cDNA clone
P03014515T0000|67 78|mature enzyme
P03014593A0681|0 7|Diazepam
P03014593A0681|10 14|mg/kg
P03014593A0681|29 30|Ro
P03014593A0681|60 74|related Ro 5-4864
P03014593A0681|77 81|mg/kg
P03014593A0681|87 91|mg/kg
P03015611A0331|3 19|amino acid sequence
P03015611A0331|37 44|residues
P03015611A0331|60 72|lysine residue
P03015611A0331|78 84|located
P03015611A0331|94 108|ATP-binding site
P03015628A1078|0 10|Osteocalcin
P03015628A1078|15 35|urinary hydroxyproline
P03015628A1078|44 51|elevated
P03015628A1078|62 81|hyperphosphatasaemia
P03015628A1078|97 111|mechanisms other
P03015628A1078|125 136|bone turnover
P03015628A1078|161 200|elevated serum alkaline phosphatase activity
P03015628A1078|208 215|subjects
P03015953T0000|0 7|Analysis
P03015953T0000|10 47|glucocorticoid unresponsive cell variants
P03015953T0000|54 101|mouse glucocorticoid receptor complementary DNA clone
P03016301A0605|8 18|v-myc codons
P03016301A0605|8 12|v-myc
P03016301A0605|46 54|noncoding
P03016301A0605|57 64|terminus
P03016301A0605|70 84|second c-myc exon
P03016301A0605|76 80|c-myc
P03016301A0605|92 97|codons
P03016301A0605|113 117|c-myc
P03016506A0611|1 17|recombinant vector
P03016506A0611|19 22|p410
P03016506A0611|54 68|BamHI-K fragment
P03016506A0611|70 80|nucleotides
P03016506A0611|100 110|B95-8 strain
P03016506A0611|123 156|EBV-associated nuclear antigen EBNA-1
P03016506A0611|162 179|cis-acting sequence
P03016506A0611|187 201|BamHI-C fragment
P03016506A0611|207 234|dominant selectable marker gene
P03016506A0611|243 257|G-418 resistance
P03016506A0611|260 270|animal cells
P03016883A0000|2 4|men
P03016883A0000|19 56|recurrent genital herpes simplex virus type
P03016883A0000|35 57|herpes simplex virus type 2
P03016883A0000|59 63|HSV-2
P03016883A0000|95 99|weeks
P03016883A0000|104 110|samples
P03016883A0000|123 129|urethra
P03016883A0000|133 146|virus isolation
P03017225A0706|9 17|carcinoma
P03017225A0706|29 41|leather bottle
P03017225A0706|43 61|linitis plastica type
P03017225A0706|85 94|II c portion
P03017225A0706|118 129|fundic glands
P03017225A0706|131 155|undifferentiated carcinoma
P03017225A0706|171 182|primary focus
P03017225A0706|193 200|Nakamura
P03017996A0731|9 20|biosynthesis
P03017996A0731|31 48|mutant polypeptides
P03017996A0731|53 65|signal peptide
P03017996A0731|106 119|nascent protein
P03017996A0731|133 141|mutants X2
P03017996A0731|145 146|X3
P03017996A0731|150 161|cleavage site
P03018491A0840|3 16|hexanucleotide
P03018491A0840|20 27|TGTCCT-3
P03018491A0840|53 63|GRE activity
P03018491A0840|105 118|flanking region
P03018491A0840|175 197|specific receptor binding
P03019505A0390|4 11|patients
P03019505A0390|21 36|metastatic spread
P03020001A0781|3 10|smallest
P03020001A0781|16 30|mini-Mu elements
P03020001A0781|40 52|kilobase pairs
P03020001A0781|69 75|cloning
P03020001A0781|78 89|DNA fragments
P03020001A0781|100 112|kilobase pairs
P03020001A0781|120 126|largest
P03020001A0781|139 151|kilobase pairs
P03020001A0781|166 171|clones
P03020001A0781|177 186|insertions
P03020001A0781|201 213|kilobase pairs
P03020513T0000|3 19|52-protein subunit
P03020513T0000|22 39|T4 DNA topoisomerase
P03020513T0000|42 51|homologous
P03020513T0000|57 68|gyrA-protein
P03020513T0000|71 76|gyrase
P03021050A0501|22 26|peaks
P03021050A0501|32 43|quantitation
P03021050A0501|46 54|sulbactam
P03021088A0135|3 15|latent periods
P03021088A0135|23 37|antral exclusion
P03021088A0135|43 52|occurrence
P03021088A0135|55 71|anastomotic ulcers
P03021088A0135|78 96|subtotal gastrectomy
P03021088A0135|101 108|Billroth
P03021088A0135|117 130|reconstruction
P03021088A0135|142 148|few days
P03021088A0135|153 157|years
P03021088A0135|177 181|years
P03022129A0842|3 19|nucleosomal arrays
P03022129A0842|30 35|MPE X Fe
P03022129A0842|37 38|II
P03022129A0842|60 75|considerable loss
P03022129A0842|108 120|accessibility
P03022129A0842|158 182|relative transcription rate
P03023067A0779|0 10|Translation
P03023067A0779|13 33|specific cellular genes
P03023067A0779|41 73|chimeric viral-cellular transcripts
P03023679A0624|3 17|molecular weight
P03023679A0624|22 41|vivo-labeled proteins
P03023679A0624|72 95|vitro-translated proteins
P03023679A0624|112 140|posttranslational modification
P03023682A0271|0 8|Insertion
P03023682A0271|12 13|bp
P03023682A0271|21 79|SV40 early promoter-dependent chloramphenicol acetyltransferase
P03023682A0271|81 83|CAT
P03023859A0000|5 8|DNAs
P03023859A0000|14 58|Ph1-positive chronic myelocytic leukemia patients
P03023859A0000|74 83|breakpoint
P03023859A0000|86 95|chromosome
P03023859A0000|102 114|Ph1 chromosome
P03023859A0000|138 142|probe
P03023859A0000|150 152|bcr
P03023859A0000|154 176|breakpoint cluster region
P03023887A0470|0 19|Nuclease footprinting
P03023887A0470|40 61|glucocorticoid receptor
P03023887A0470|69 89|multiple discrete sites
P03023887A0470|104 110|borders
P03023887A0470|132 144|sequence motif
P03023887A0470|156 157|Sa
P03023970A0922|3 13|96-bp insert
P03023970A0922|24 40|termination signal
P03023970A0922|55 74|premature termination
P03023970A0922|113 122|p53 product
P03023970A0922|124 140|amino acids shorter
P03024343A0372|3 8|tumors
P03024343A0372|33 46|neuroendocrine
P03024703A1036|21 31|nucleotides
P03024703A1036|46 61|polypeptide chain
P03024703A1036|67 76|amino acids
P03024703A1036|85 99|molecular weight
P03024703A1036|114 126|hsp108 protein
P03025606T0000|0 28|Transcriptional control signals
P03025606T0000|32 53|herpes simplex virus type
P03025606T0000|60 64|gamma
P03025606T0000|67 73|gene lie
P03025606T0000|80 84|bases
P03025606T0000|109 116|terminus
P03025606T0000|122 125|mRNA
P03025655T0000|1 18|noncatalytic domain
P03025655T0000|33 66|cytoplasmic protein-tyrosine kinases
P03025655T0000|78 91|kinase function
P03025655T0000|95 114|transforming activity
P03025655T0000|117 147|Fujinami sarcoma virus P130gag-fps
P03025655T0000|117 143|Fujinami sarcoma virus P130gag
P03025655T0000|145 147|fps
P03025661A0260|0 6|Gluzman
P03025661A0260|8 13|EMBO J.
P03025862A0860|1 10|single exon
P03025862A0860|21 37|carboxyl-terminal
P03025862A0860|40 49|amino acids
P03025862A0860|55 62|ssd chain
P03025862A0860|71 88|untranslated region
P03025862A0860|94 97|mRNA
P03025862A0860|110 113|poly
P03025862A0860|115 115|A
P03025862A0860|118 129|addition site
P03026915A1024|6 27|nontranslated sequences
P03026915A1024|31 35|parts
P03026915A1024|47 55|sequences
P03026915A1024|58 74|various yeast genes
P03026915A1024|93 123|representative lacZ fusion vectors
P03026915A1024|107 110|lacZ
P03027661A0000|3 12|activities
P03027661A0000|18 25|D protein
P03027661A0000|31 42|miniF plasmid
P03027779A0000|0 15|SPECT examination
P03027779A0000|21 23|TMJ
P03027779A0000|32 37|Tc-MDP
P03027779A0000|54 61|patients
P03027779A0000|89 107|anterior dislocation
P03027779A0000|124 130|normals
P03027905A0632|0 18|Plasma renin activity
P03027905A0632|29 50|plasma aldosterone level
P03027905A0632|66 75|lisinopril
P03029111A0155|3 9|mutants
P03029111A0155|32 62|separate pet complementation group
P03031602A1001|3 13|second group
P03031602A1001|16 33|homologous elements
P03031602A1001|48 61|upstream region
P03031602A1001|68 72|genes
P03032143A0218|1 10|centromere
P03032143A0218|64 65|bp
P03032143A0218|90 114|important sequence elements
P03032143A0218|134 141|proteins
P03032143A0218|147 166|specific conformation
P03032143A0218|172 180|chromatin
P03032143A0218|185 200|yeast kinetochore
P03032964T0000|0 19|Constitutive function
P03032964T0000|42 49|promoter
P03032964T0000|57 77|new sequences essential
P03033283A0837|3 25|separate NF1-binding loci
P03033283A0837|11 25|NF1-binding loci
P03033283A0837|44 61|equivalent IE68 gene
P03033283A0837|54 61|IE68 gene
P03033283A0837|64 67|HCMV
P03033283A0837|69 73|Towne
P03033283A0837|95 105|DNA sequence
P03033283A0837|109 143|competition filter binding experiments
P03033283A0837|177 197|consensus binding sites
P03033283A0837|213 235|promoter-enhancer region
P03033283A1415|26 29|sets
P03033283A1415|37 48|18-base-pair
P03033283A1415|61 74|repeat elements
P03033283A1415|108 139|high basal transcriptional strength
P03033283A1415|164 178|further upstream
P03033283A1415|195 210|NF1-binding sites
P03033283A1415|250 268|biological host range
P03033283A1415|284 291|SCMV IE94
P03033283A1415|304 311|HCMV IE68
P03034570A0943|10 14|genes
P03034570A0943|17 28|gene segments
P03034570A0943|44 84|bacterial chloramphenicol acetyltransferase
P03034570A0943|89 101|bacterial gene
P03034570A0943|129 138|hygromycin
P03034570A0943|146 150|ORF E7
P03034570A0943|156 180|human papillomavirus type 18
P03034570A0943|156 178|human papillomavirus type
P03034570A0943|190 196|vectors
P03034956A0666|16 41|basal adrenal androgen levels
P03034956A0666|85 98|normal subjects
P03034956A0666|125 134|prednisone
P03034956A0666|136 140|P less
P03035056T0000|0 11|Active lambda
P03035056T0000|15 44|kappa antibody gene rearrangement
P03035056T0000|47 98|Abelson murine leukemia virus-transformed pre-B cell lines
P03035218T0000|0 13|Identification
P03035218T0000|16 49|p40x-responsive regulatory sequences
P03035218T0000|59 86|human T-cell leukemia virus type
P03035218T0000|88 105|long terminal repeat
P03035658A0355|6 28|pentobarbital anesthesia
P03035658A0355|33 40|basal VO2
P03035658A0355|48 56|ml/kg/min
P03035658A0355|74 84|epinephrine
P03035658A0355|88 106|dose dependent manner
P03035658A0355|109 128|plasma concentrations
P03035658A0355|139 143|ng/ml
P03035658A0355|145 148|VO2 =
P03035658A0355|153 161|ml/kg/min
P03035658A0355|170 174|ng/ml
P03035658A0355|176 179|VO2 =
P03035658A0355|184 192|ml/kg/min
P03036415T0000|0 8|Influence
P03036415T0000|11 35|cyclo-oxygenase inhibition
P03036415T0000|11 25|cyclo-oxygenase
P03036415T0000|41 67|leukotriene receptor blockade
P03036415T0000|41 59|leukotriene receptor
P03036415T0000|70 120|pulmonary vascular pressure/cardiac index relationships
P03036415T0000|123 131|hyperoxic
P03036415T0000|137 147|hypoxic dogs
P03036817A0213|0 34|Oligonucleotide-directed mutagenesis
P03036817A0213|52 70|NdeI restriction site
P03036817A0213|76 85|natural ATG
P03036817A0213|91 97|yeast R.
P03036933A0774|0 10|ACTH release
P03036933A0774|0 3|ACTH
P03036933A0774|40 47|children
P03036933A0774|53 74|exogenous ACTH treatment
P03036933A0774|62 65|ACTH
P03037334A0932|25 47|upstream promoter element
P03037334A0932|53 66|yeast RP39A gene
P03037334A0932|82 104|identical sequence motifs
P03038643A1374|20 51|mammalian erythroid alpha-spectrin
P03038643A1374|61 71|duplication
P03038643A1374|75 89|rapid divergence
P03038643A1374|96 125|ancestral alpha-fodrin-like gene
P03038643A1374|105 125|alpha-fodrin-like gene
P03038891A0935|0 15|Northern analyses
P03038891A0935|18 21|RNAs
P03038891A0935|26 37|mouse tissues
P03038891A0935|41 49|cell lines
P03038891A0935|63 75|p11 mRNA levels
P03038891A0935|63 69|p11 mRNA
P03039177A0503|13 22|cDNA clones
P03039177A0503|38 64|2.9-kilobase early transcript
P03039177A0503|77 92|IR2 repeat element
P03039177A0503|102 128|restriction site polymorphism
P03039177A0503|135 144|enzyme SmaI
P03039177A0503|141 144|SmaI
P03039387A0920|8 25|immunochemotherapy
P03039387A0920|30 45|cyclophosphamide
P03039387A0920|50 52|BCG
P03039387A0920|58 74|better enhancement
P03039387A0920|80 94|antitumor effect
P03039387A0920|100 109|cytostatic
P03039387A0920|136 147|methotrexate
P03039387A0920|152 154|BCG
P03039387A0920|158 173|cyclophosphamide
P03039387A0920|178 187|levamisole
P03040023A0113|0 7|Morphine
P03040023A0113|17 41|dose-dependent bradycardia
P03040023A0113|52 62|tachycardia
P03040403A0155|3 9|PSS gene
P03040403A0155|27 40|1.1-kb fragment
P03040403A0155|46 53|yeast DNA
P03040403A0155|59 69|YEp13 vector
P03041046A0127|7 12|A-MuLV
P03041046A0127|32 38|viruses
P03041046A0127|49 59|Moloney MuLV
P03041046A0127|83 93|lymphogenic
P03041046A0127|102 107|A-MuLV
P03041046A0127|123 134|other viruses
P03041046A0127|145 172|BALB/c endogenous N-tropic MuLV
P03041046A0127|190 195|devoid
P03041046A0127|198 217|lymphogenic potential
P03041046A0127|219 220|N.
P03041802A0975|24 41|platelet aggregates
P03041802A0975|45 58|elevated levels
P03041802A0975|61 75|fibrinopeptide A
P03041802A0975|78 92|cleavage product
P03041802A0975|95 100|fibrin
P03041802A0975|114 131|platelet activation
P03041802A0975|135 150|fibrin deposition
P03041802A0975|135 140|fibrin
P03041802A0975|168 179|pathogenesis
P03042778A0643|21 41|yeast vegetative growth
P03045117A0936|13 18|values
P03045117A0936|35 41|methods
P03045117A0936|73 93|epidermal growth factor
P03045117A0936|114 128|wild type greater
P03045117A0936|133 137|Glu24
P03045117A0936|145 151|greater
P03045117A0936|156 160|Asp27
P03045117A0936|172 178|greater
P03045117A0936|183 186|Pro7
P03045117A0936|191 200|Thr greater
P03045117A0936|205 209|Tyr29
P03045117A0936|217 223|greater
P03045117A0936|228 232|Leu47
P03045725A0872|17 27|suppression
P03045725A0872|30 52|elevated prolactin levels
P03045725A0872|38 46|prolactin
P03045725A0872|55 95|progressive metastatic breast cancer patients
P03045725A0872|121 136|tumor sensitivity
P03045725A0872|139 150|chemotherapy
P03046655A0000|9 23|prevalence study
P03046655A0000|29 44|best visual acuity
P03046655A0000|74 81|patients
P03046655A0000|86 102|herpetic keratitis
P03046655A0000|114 127|two-year period
P03046931A0247|13 38|eIF-4A intronless retroposon
P03046931A0247|13 18|eIF-4A
P03046931A0247|62 65|cDNA
P03046931A0247|76 101|single nucleotide difference
P03048024A0418|0 19|Bacteriologic culture
P03048024A0418|22 37|pancreatic tissue
P03048024A0418|54 55|IB
P03048024A0418|63 69|NIB rats
P03048024A0418|71 75|p less
P03049570A1242|5 16|similarities
P03049570A1242|33 42|E2 proteins
P03050147A0896|19 23|cells
P03050147A0896|37 65|complementary E1a-E1b functions
P03050147A0896|50 52|E1a
P03050147A0896|54 56|E1b
P03050147A0896|72 78|viruses
P03050147A0896|87 98|equal amounts
P03050147A0896|101 129|P/C-specific mRNA transcription
P03050147A1520|37 49|scanning model
P03050147A1520|53 71|ribosomal initiation
P03050147A1520|87 95|ribosomes
P03050147A1520|120 135|internal mRNA site
P03050147A1520|147 163|initiator AUG codon
P03050147A1520|170 177|C protein
P03052327A1474|13 19|results
P03052327A1474|21 62|simultaneous pancreas-kidney transplantation
P03052327A1474|97 100|Type
P03052327A1474|102 117|diabetic patients
P03052641A0204|14 32|compounds attractive
P03052641A0204|35 42|vehicles
P03052641A0204|54 70|other gases in-vivo
P03053713A0752|0 12|DNA sequencing
P03053713A0752|18 25|DPM1 gene
P03053713A0752|36 51|open reading frame
P03053713A0752|57 61|bases
P03057259A0514|22 45|primary malignant lymphoma
P03057259A0514|51 57|thyroid
P03057259A0514|61 78|chronic thyroiditis
P03059171A1232|0 13|Administration
P03059171A1232|16 29|anticoagulants
P03059171A1232|36 42|heparin
P03059171A1232|44 58|prostaglandin E1
P03059171A1232|62 72|ticlopidine
P03059171A1232|104 111|symptoms
P03059171A1232|127 146|further deterioration
P03060846T0000|0 17|Mutational analysis
P03060846T0000|23 35|L1 binding site
P03060846T0000|38 44|23S rRNA
P03060953A0481|0 6|Animals
P03060953A0481|23 37|oral vaccination
P03060953A0481|42 58|natural mechanisms
P03060953A0481|79 87|outbreaks
P03061301A0624|0 20|Prostacyclin formation
P03061301A0624|36 48|excretion rate
P03061301A0624|54 96|stable metabolite 6-keto-prostaglandin F1 alpha
P03061301A0624|111 115|means
P03061301A0624|118 133|radioimmunoassay
P03061301A0624|136 155|4-hour urine specimens
P03061301A0624|171 188|smoking-free period
P03061301A0624|197 208|participants
P03061301A0624|232 254|high-nicotine cigarettes
P03061301A1409|8 16|excretion
P03061301A1409|19 45|6-keto-prostaglandin F1 alpha
P03061301A1409|68 74|smokers
P03061301A1409|82 99|oral contraceptives
P03061301A1409|117 121|ng/gm
P03061301A1409|124 133|creatinine
P03061301A1409|135 139|p less
P03061383A0000|20 29|mecillinam
P03061383A0000|33 58|amoxicillin/clavulanic acid
P03061383A0000|81 87|strains
P03061383A0000|97 111|beta-lactamases
P03061383A0000|117 121|TEM-1
P03061383A0000|123 127|Oxa-1
P03061383A0000|131 145|chromosomal type
P03061383A0000|165 169|broth
P03061383A0000|173 193|agar dilution technique
P03062370A0000|0 3|GCN4
P03062370A0000|12 35|transcriptional activator
P03062370A0000|38 63|amino acid biosynthetic genes
P03062370A0384|5 11|results
P03062370A0384|24 34|GCN3 product
P03062370A0384|51 60|repression
P03062370A0384|63 72|activation
P03062370A0384|75 88|GCN4 expression
P03062370A0384|75 78|GCN4
P03062370A0384|100 120|amino acid availability
P03064524A0160|3 10|efficacy
P03064524A0160|18 39|immunosuppressive drugs
P03064811A0485|3 19|amino acid sequence
P03064811A0485|25 39|S. aureus peptide
P03064811A0485|51 65|phosphoryl group
P03064811A0485|78 148|Gln-Val-Val-Ser-Thr-Phe-Met-Gly-Asn-Gly-Leu-Ala-Ile-Pro-His-Gly-Thr-Asp
P03064811A0485|150 152|Asp
P03065140A0273|5 13|mutations
P03065140A0273|22 28|regions
P03065140A0273|31 41|GAL4 protein
P03065140A0273|46 61|DNA binding domain
P03065140A0273|69 97|transcription activation domain
P03065141A0448|3 9|results
P03065141A0448|26 30|genes
P03065141A0448|32 35|citA
P03065141A0448|39 42|citB
P03065141A0448|48 64|separate promoters
P03065141A0448|85 92|promoter
P03065141A0448|99 106|citB gene
P03065141A0448|112 135|Tn3411 nucleotide sequence
P03065141A0448|112 117|Tn3411
P03065141A0448|158 163|pMS185
P03065610A0375|3 9|rci gene
P03065610A0375|22 25|lacZ
P03065610A0375|32 42|gene product
P03065610A0375|58 76|Western blot analysis
P03065621T0000|0 8|Structure
P03065621T0000|25 35|nuclear gene
P03065621T0000|74 78|MRP13
P03065621T0000|93 104|small subunit
P03065621T0000|110 130|mitochondrial ribosome
P03066131A0000|17 26|anatomical
P03066131A0000|30 47|physiological basis
P03066131A0000|50 67|operative treatment
P03066131A0000|70 87|behaviour disorders
P03066131A0000|90 108|stereotactic lesions
P03066131A0000|114 121|amygdala
P03066131A0000|128 154|posterior medial hypothalamus
P03066131A0000|176 189|own experiences
P03066131A0000|197 206|operations
P03066131A0000|233 257|untreatable aggressiveness
P03066208A0310|0 22|Histological examination
P03066208A0310|32 51|small simple renal cyst
P03066208A0310|66 83|renal cell carcinoma
P03066625A0756|8 32|large epidemiologic studies
P03066625A0756|57 77|relative contributions
P03066625A0756|80 98|specific risk factors
P03066625A0756|118 133|other risk factors
P03066625A0756|135 144|new studies
P03066625A0756|158 185|important unresolved questions
P03067505A0688|5 16|prostacyclin
P03067505A0688|28 49|autoregulative property
P03067505A0688|55 69|inner ear vessels
P03069046A0126|24 36|good precision
P03069046A0126|40 58|adequate sensitivity
P03069980T0000|0 6|Factors
P03069980T0000|21 32|bond strength
P03069980T0000|40 57|glass polyalkenoate
P03069980T0000|59 65|ionomer
P03069980T0000|67 73|cements
P03069980T0000|77 83|dentine
P03072021A0696|3 20|amino acid sequences
P03072021A0696|26 30|yeast
P03072021A0696|34 73|mammalian mitochondrial targeting sequences
P03072021A0696|105 122|mature polypeptides
P03072580A0455|0 9|Van der Ende
P03072580A0455|11 12|R.
P03073091A0338|6 20|insulin infusion
P03073091A0338|25 41|% dextrose solution
P03073091A0338|55 63|Biostator
P03073091A0338|93 100|glycemia
P03073091A0338|105 109|mg/dl
P03073091A0449|0 6|Amounts
P03073091A0449|9 15|glucose
P03073091A0449|38 40|min
P03073091A0449|48 66|hour insulin infusion
P03073091A0449|52 58|insulin
P03073091A0449|80 87|m/kg/min
P03073091A0449|118 118|K
P03073091A0449|120 120|=
P03073091A0449|124 129|mmol/l
P03073091A0449|141 149|mg/kg/min
P03073091A0449|156 169|spironolactone
P03073091A0449|171 171|K
P03073091A0449|173 173|=
P03073091A0449|177 182|mmol/l
P03073091A0449|195 203|mg/kg/min
P03073091A0449|210 222|indomethacine
P03073091A0449|224 224|K
P03073091A0449|226 226|=
P03073091A0449|230 235|mmol/l
P03073091A0449|244 252|mg/kg/min
P03073091A0449|266 270|drugs
P03073091A0449|272 272|K
P03073091A0449|274 274|=
P03073091A0449|278 283|mmol/l
P03073091A0449|295 303|mg/kg/min
P03073192T0000|0 49|Mycobacterium avium-intracellulare complex infections
P03073192T0000|63 86|immunodeficiency syndrome
P03075154T0000|0 9|Recurrence
P03075154T0000|12 28|oxalate deposition
P03075154T0000|32 46|renal transplant
P03075154T0000|53 71|ciclosporin A therapy
P03076124A0496|3 22|bile acid sequestrants
P03076124A0496|24 37|cholestyramine
P03076124A0496|41 50|colestipol
P03076124A0496|53 65|nicotinic acid
P03076124A0496|67 77|fenofibrate
P03076124A0496|81 90|inhibitors
P03076124A0496|93 122|hydroxymethylglutaryl coenzyme A
P03076124A0496|124 139|HMG CoA) reductase
P03076124A0496|124 129|HMG CoA
P03076124A0496|131 139|reductase
P03076124A0496|145 154|lovastatin
P03076124A0496|157 167|simvastatin
P03076124A0496|179 192|effective drugs
P03076124A0496|201 208|patients
P03076124A0496|213 240|primary hypercholesterolaemia
P03076124A0496|247 252|agents
P03076124A0496|259 278|plasma concentrations
P03076124A0496|289 303|LDL-cholesterol
P03076124A0496|312 312|%
P03078268A0529|11 35|pathophysiological aspects
P03078268A0529|38 57|urinary acidification
P03078268A0529|81 106|renal tubular acidosis models
P03078268A0529|117 123|maleate
P03078268A0529|127 148|amphotericin B treatment
P03078268A0529|158 175|cellular mechanisms
P03078268A0529|194 208|adrenal steroids
P03078268A0529|211 230|urinary acidification
P03079276T0029|0 7|Analysis
P03079276T0029|11 16|groups
P03079276T0029|19 26|patients
P03079276T0029|40 50|simple acute
P03079276T0029|54 80|pernicious malarial flare-ups
P03080793T0000|0 8|Statement
P03080793T0000|27 36|guidelines
P03080793T0000|55 70|AIDS transmission
P03083441T0000|0 12|Modifications
P03083441T0000|18 43|involuntary postcontraction
P03083441T0000|46 59|diseased people
P03088643A0000|0 18|Cocaine-treated rats
P03088643A0000|41 75|cocaine-associated contextual stimuli
P03088643A0000|77 78|CS
P03088643A0000|90 115|saline-injected control rats
P03090237A0202|10 18|schedules
P03090237A0202|31 41|response run
P03090237A0202|80 84|times
P03090237A0202|90 100|response key
P03090237A0202|102 108|work key
P03090237A0202|134 150|second response key
P03090372A0607|0 31|Intravenous glucose tolerance tests
P03090372A0607|75 77|CyA
P03090372A0607|87 91|weeks
P03091849A0000|3 9|effects
P03091849A0000|12 25|glutaraldehyde
P03091849A0000|28 37|dimensions
P03091849A0000|41 54|ultrastructure
P03091849A0000|57 73|microvascular beds
P03091849A0000|76 87|rat mesentery
P03091849A0000|104 108|kinds
P03091849A0000|138 145|fixative
P03091849A0000|148 170|intra-arterial perfusion
P03091849A0000|186 189|mm Hg
P03091849A0000|195 205|superfusion
P03091849A0000|211 240|exteriorized mesenteric membrane
P03097509A0654|14 25|RNA molecules
P03097509A0654|33 51|untranslated regions
P03097509A0654|75 83|base pairs
P03097643A1357|8 17|BALB/c gene
P03097643A1357|27 44|single substitution
P03097643A1357|57 71|octamer sequence
P03097643A1357|95 113|nucleotides upstream
P03098018A0139|0 15|Clinical findings
P03098018A0139|30 31|cm
P03098018A0139|41 42|kg
P03098018A0139|61 70|lower limbs
P03098018A0139|72 84|P2-A2 pilosity
P03098018A0139|88 97|micropenis
P03102289A0786|48 64|hCG administration
P03102289A0786|48 50|hCG
P03102289A0786|67 74|midcycle
P03102289A0786|99 114|follicles greater
P03102289A0786|120 121|cm
P03102289A0786|124 133|ultrasound
P03102289A0786|136 143|cycle day
P03102289A0786|159 161|hCG
P03102289A0786|166 178|serum E2 levels
P03102289A0786|171 172|E2
P03102289A0786|194 199|pmol/l
P03102289A0786|203 210|follicle
P03104245A0402|4 11|patients
P03104245A0402|21 25|Ir192
P03104245A0402|45 61|external radiation
P03104245A0402|77 78|p =
P03104245A0402|128 133|median
P03104245A0402|136 141|months
P03104245A0402|155 160|months
P03104245A0402|169 174|months
P03104245A0402|187 192|months
P03104248A0322|6 12|Stage IA
P03104248A0322|17 24|patients
P03104248A0322|52 53|G1
P03104248A0322|95 96|G2
P03104248A0322|104 111|patients
P03104248A0322|136 137|G3
P03104914T0000|0 8|Mechanism
P03104914T0000|14 14|t
P03104914T0000|22 45|chromosomal translocation
P03104914T0000|47 64|structural analysis
P03104914T0000|71 80|derivative
P03104914T0000|88 105|reciprocal partners
P03104982A0690|15 30|hemoglobin levels
P03104982A0690|15 24|hemoglobin
P03104982A0690|34 36|men
P03104982A0690|67 71|women
P03104982A0690|86 98|sex difference
P03104982A0690|116 120|years
P03108171A0088|0 9|Ritanserin
P03108171A0088|13 24|new substance
P03108171A0088|35 59|selective blocking activity
P03108171A0088|62 72|S2 receptors
P03108171A0088|76 79|5-HT
P03108171A0088|85 104|central nervous system
P03109147A0000|0 13|Ethylene glycol
P03109147A0000|17 32|diethylene glycol
P03109147A0000|79 84|groups
P03109147A0000|90 103|female NMRI mice
P03109147A0000|107 113|dosages
P03109147A0000|120 122|und
P03109147A0000|124 135|mg single dose
P03109147T0127|0 7|Research
P03109147T0127|10 23|ethylene glycol
P03109147T0127|27 42|diethylene glycol
P03109147T0127|46 64|carcinogenic effects
P03109954A0945|3 9|results
P03109954A0945|24 49|greater estrogenic influence
P03109954A0945|67 95|ethinyl estradiol-containing OC
P03109954A0945|106 115|inhibition
P03109954A0945|118 146|coronary artery atherosclerosis
P03109954A0945|155 189|pronounced progestin-induced lowering
P03109954A0945|192 224|plasma HDL cholesterol concentration
P03109954A0945|198 211|HDL cholesterol
P03109954A0945|241 255|hormonal balance
P03109954A0945|264 278|marked influence
P03109954A0945|303 314|plasma lipids
P03109954A0945|318 330|atherogenesis
P03110119A0267|6 7|BH
P03110119A0267|11 20|ventilator
P03110119A0267|40 47|bias flow
P03110119A0267|52 52|%
P03110119A0267|60 64|l/min
P03110119A0267|87 95|side ports
P03110119A0267|99 111|small catheter
P03110119A0267|134 143|cm cephalad
P03110119A0267|149 154|carina
P03110678A0702|0 9|Comparison
P03110678A0702|12 37|beta 2-microglobulin removal
P03110678A0702|12 30|beta 2-microglobulin
P03110678A0702|46 69|same polysulphone membrane
P03110678A0702|73 85|haemodialysis
P03110678A0702|89 103|haemofiltration
P03110678A0702|113 131|beta 2-microglobulin
P03110678A0702|158 167|convection
P03110678A0702|174 182|diffusion
P03110678A0702|191 204|treatment modes
P03110678A0702|218 226|blood flow
P03110678A0702|230 242|urea clearance
P03110692A0156|11 14|mg/l
P03110692A0156|16 17|SD
P03110692A0156|32 36|P less
P03110692A0156|47 52|beta 2m
P03110692A0156|72 77|higher
P03110692A0156|80 87|patients
P03110692A0156|92 100|bone cysts
P03110692A0156|113 116|mg/l
P03110692A0156|135 148|median duration
P03110692A0156|151 158|dialysis
P03110692A0156|176 180|P less
P03110692A0156|198 205|patients
P03110692A0156|210 218|bone cysts
P03110692A0156|226 231|months
P03110692A0156|234 239|beta 2m
P03110692A0156|250 257|patients
P03110692A0156|270 277|dialysis
P03110692A0156|302 320|residual urine volume
P03110692A0156|324 330|greater
P03110692A0156|338 342|litre
P03110746A0146|3 16|mean percentage
P03110746A0146|19 30|linoleic acid
P03110746A0146|36 48|triglycerides
P03110746A0146|54 78|subcutaneous adipose tissue
P03110746A0146|80 85|PLASAT
P03110746A0146|94 101|subjects
P03110746A0146|118 123|higher
P03110746A0146|135 146|similar group
P03110794A0991|2 10|overdoses
P03110794A0991|16 27|g fluvoxamine
P03110794A0991|30 48|lasting toxic effects
P03110801A0532|20 42|plasma prolactin response
P03110801A0532|49 58|micrograms
P03112028A0404|15 22|patients
P03112028A0404|44 45|n =
P03112028A0404|57 58|n =
P03112028A0404|61 77|seminal parameters
P03112412A0985|12 26|wild-type strain
P03112412A0985|38 89|temperature-sensitive threonyl-tRNA synthetase mutation
P03112412A0985|105 123|thr operon expression
P03112412A0985|105 113|thr operon
P03112412A0985|129 153|non-permissive temperature
P03112412A0985|171 177|mutants
P03114188A0907|0 35|Significant treatment-related problems
P03114188A0907|53 64|second decade
P03114188A0907|68 75|patients
P03114188A0907|89 104|chest wall sarcoma
P03114188A0907|116 123|patients
P03114188A0907|144 145|Gy
P03114188A0907|157 174|regional nodal areas
P03114829T0000|0 7|Clinical
P03114829T0000|11 30|biological correlates
P03114829T0000|33 43|panic states
P03114995T0000|0 6|Effects
P03114995T0000|9 36|long-term parenteral nutrition
P03114995T0000|39 52|gastrin release
P03114995T0000|39 45|gastrin
P03114995T0000|55 58|dogs
P03115087A0515|3 12|mean weight
P03115087A0515|16 31|height velocities
P03115087A0515|39 39|%
P03115087A0515|46 46|%
P03115787A0633|3 10|patients
P03115787A0633|22 37|cyclophosphamide
P03115787A0633|39 56|hexamethylmelamine
P03115787A0633|58 67|adriamycin
P03115787A0633|71 79|cisplatin
P03115787A0633|81 86|CHAP-5
P03115787A0633|93 109|measurable disease
P03115787A0633|136 152|complete responses
P03115787A0633|164 169|months
P03115787A0633|174 189|partial responses
P03115787A0633|200 205|months
P03117046T0000|0 8|Isolation
P03117046T0000|12 27|characterization
P03117046T0000|31 42|vinculin cDNA
P03117046T0000|47 69|chick-embryo fibroblasts
P03117147A1059|1 18|complementary study
P03117147A1059|28 40|good agreement
P03117147A1059|58 72|oesophageal EMGd
P03117147A1059|91 101|surface EMGd
P03117147A1059|114 126|promising tool
P03117147A1059|130 150|clinical investigation
P03118631A0140|2 12|differences
P03118631A0140|15 29|fixation quality
P03118631A0140|49 56|cochleas
P03118631A0140|64 85|intravascular perfusion
P03118631A0140|89 96|cochleas
P03118631A0140|104 129|intralabyrinthine perfusion
P03119227A0079|3 13|DNA sequence
P03119227A0079|35 44|amino acids
P03119227A0079|49 64|sequence homology
P03119227A0079|70 100|human c-abl proto-oncogene product
P03119227A0079|116 128|amino terminus
P03119227A0079|144 153|amino acids
P03119227A0079|164 178|region essential
P03119227A0079|182 203|tyrosine kinase activity
P03119227A0079|182 195|tyrosine kinase
P03119485A0476|16 43|different essential fatty acids
P03119485A0476|46 53|patients
P03119485A0476|58 81|total parenteral nutrition
P03119485A0476|87 97|heavy injury
P03119485A0476|102 116|special interest
P03119485A0476|147 155|prognosis
P03119485A0476|164 169|sepsis
P03119485A0476|172 203|adult respiratory distress syndrome
P03120334A0893|4 4|%
P03120334A0893|6 21|small cardiac vein
P03120334A0893|51 67|right marginal vein
P03120334A0893|85 104|anterior cardiac veins
P03123310A0000|3 32|Drosophila melanogaster Gart gene
P03123310A0000|25 32|Gart gene
P03123310A0000|45 63|enzymatic activities
P03123310A0000|69 75|pathway
P03123310A0000|79 84|purine
P03123310A0000|91 99|synthesis
P03123983T0000|9 23|neuroplasticity
P03123983T0000|39 43|drugs
P03125420A0421|0 3|Biol
P03125422A0202|3 9|results
P03125422A0202|17 27|experiments
P03125422A0202|50 75|upstream activator sequences
P03125422A0202|77 79|UAS
P03125422A0202|88 103|maximum induction
P03125422A0202|106 114|galactose
P03126531T0000|0 7|Reversal
P03126531T0000|23 51|apomorphine-induced stereotypy
P03126531T0000|67 74|REM sleep
P03126531T0000|83 86|rats
P03126531T0000|89 116|dopamine agonist pretreatments
P03127034A0591|3 11|heart rate
P03127034A0591|13 27|respiratory rate
P03127034A0591|29 36|arterial
P03127034A0591|42 67|systemic vascular resistance
P03127463A1017|0 9|Human rIL-3
P03127463A1017|21 29|COS7 cells
P03127463A1017|33 57|multipotential CSF activity
P03127463A1017|47 49|CSF
P03127463A1017|60 76|semisolid cultures
P03127463A1017|79 93|bone marrow cells
P03127463A1017|119 131|proliferation
P03127463A1017|134 138|My-10
P03127463A1017|140 145|marrow
P03127463A1017|148 161|cord blood cells
P03127463A1017|164 177|liquid cultures
P03132498A0730|4 11|patients
P03132498A0730|17 21|PaCO2
P03132498A0730|25 31|greater
P03132498A0730|47 50|torr
P03132498A0730|63 66|torr
P03132498A0730|71 89|clinical asthma score
P03132498A0730|96 102|greater
P03132498A0730|104 108|PaCO2
P03132498A0730|129 132|torr
P03132498A0730|149 153|hours
P03133250A0000|12 27|prospective study
P03133250A0000|49 66|ovarian stimulation
P03133250A0000|71 97|human menopausal gonadotropin
P03133250A0000|99 101|hMG
P03133250A0000|106 137|human follicle-stimulating hormone
P03133250A0000|139 142|hFSH
P03133250A0000|155 167|fertilization
P03133250A0000|171 184|embryo transfer
P03133250A0000|186 191|IVF-ET
P03133360A1215|3 10|findings
P03133360A1215|25 34|mtr product
P03133360A1215|45 68|transcription attenuation
P03133360A1215|72 81|inhibition
P03133360A1215|97 104|trpE mRNA
P03134872T0029|0 6|Apropos
P03137105A0146|1 21|prostaglandin analogue
P03137105A0146|29 42|early pregnancy
P03137105A0146|46 71|human chorionic gonadotropin
P03137105A0146|99 113|follicular phase
P03137105A0146|139 155|reproductive cycle
P03137105A0146|163 178|oocyte collection
P03137105A0146|199 204|cycles
P03137105A0146|207 218|oocyte donors
P03137105A0146|222 237|embryo recipients
P03137346A0319|3 15|nucleolin gene
P03137346A0319|31 40|base-pairs
P03137346A0319|57 61|exons
P03137346A0319|78 94|amino acid residues
P03137601A0212|8 36|L-threo-dihydroxyphenylserine
P03137601A0212|38 41|DOPS
P03137601A0212|46 69|artificial norepinephrine
P03137601A0212|71 72|NE
P03137601A0212|74 82|precursor
P03137601A0212|96 105|immobility
P03137601A0212|108 117|intact mice
P03137601A0212|119 122|DOPS
P03137601A0212|143 152|immobility
P03137601A0212|155 158|mice
P03137601A0212|176 200|selective NE neurotoxin DSP4
P03138190A0347|0 17|Substantial amounts
P03138190A0347|20 38|liposomal ampicillin
P03138190A0347|64 75|Kupffer cells
P03138190A0347|80 90|target cells
P03138190A0347|113 134|intravenous inoculation
P03138449A0759|17 21|delta
P03138449A0759|26 30|delta
P03138449A0759|32 53|desaturation activities
P03138449A0759|70 79|conditions
P03138449A0759|88 90|C18
P03138449A0759|93 100|w6 supply
P03139750A0000|3 14|genetic basis
P03139750A0000|34 49|latent VH allotype
P03142875A0366|15 44|complete 6-kilobase cDNA sequence
P03142875A0366|66 75|amino acids
P03142875A0366|88 103|genomic structure
P03143048A1091|0 14|HDL-cholesterol
P03143048A1091|18 18|%
P03143048A1091|20 24|P less
P03143048A1091|36 52|apolipoprotein A-I
P03143048A1091|56 56|%
P03143048A1091|58 62|P less
P03143048A1091|71 84|concentrations
P03143485A0366|3 36|Euglena ribosomal protein gene cluster
P03143485A0366|49 74|S-10 ribosomal protein operon
P03143485A0366|94 109|gene organization
P03143485A0366|123 138|exact linear order
P03143485A0366|144 157|analogous genes
P03143485A0366|173 199|liverwort chloroplast genomes
P03144705A0859|20 24|sites
P03144705A0859|27 51|recombinational resolution
P03144705A0859|86 93|gradient
P03144705A0859|96 113|sequence divergence
P03144705A0859|137 137|%
P03144705A0859|143 143|X
P03144705A0859|185 185|X
P03144705A0859|200 223|diverged Alu family repeats
P03146017A0983|3 20|nucleotide sequence
P03146017A0983|26 39|region upstream
P03146017A0983|44 58|M. voltae ORFtrpA
P03146017A0983|44 45|M.
P03146017A0983|52 58|ORFtrpA
P03146017A0983|98 100|ORF
P03146017A0983|107 117|nucleotides
P03146017A0983|119 125|ORFtrpB
P03146017A0983|139 158|amino acid polypeptide
P03146017A0983|161 163|mol
P03146017A0983|165 166|wt
P03146150T0000|0 11|Potentiation
P03146150T0000|17 36|thrombolytic efficacy
P03146150T0000|39 59|single-chain urokinase
P03146150T0000|61 73|Pro-urokinase
P03146150T0000|77 83|heparin
P03146784A0158|4 12|receptors
P03146784A0158|34 44|ventilation
P03146784A0158|59 67|mammalian
P03146784A0158|83 107|pulmonary stretch receptors
P03146784A0158|115 123|mammalian
P03146784A0158|138 162|pulmonary stretch receptors
P03146784A0158|164 166|PSR
P03146784A0158|178 223|avian intrapulmonary CO2-sensitive chemoreceptors
P03146784A0158|225 227|IPC
P03147912A0422|0 26|Symptomatic hyperventilators
P03147912A0422|31 42|larger number
P03147912A0422|45 49|sighs
P03147912A0422|63 78|wide fluctuations
P03147912A0422|81 88|baseline
P03147912A0422|92 106|inspiratory time
P03147912A0422|108 121|expiratory time
P03147912A0422|126 131|PETCO2
P03149774A0173|5 10|IA task
P03149774A0173|12 49|post-training intraperitoneal injections
P03149774A0173|52 61|picrotoxin
P03149774A0173|65 75|bicuculline
P03149774A0173|84 108|dose-dependent enhancement
P03149774A0173|111 119|retention
P03149774A0173|130 130|h
P03149774A0173|153 161|retention
P03149774A0173|178 198|bicuculline methiodide
P03149774A0173|201 222|GABA receptor antagonist
P03149774A0173|201 212|GABA receptor
P03149774A0173|249 266|blood-brain barrier
P03150015T0001|0 15|Clinical research
P03150015T0001|18 22|non-A
P03150015T0001|24 53|non-B post-transfusion hepatitis
P03150296A0594|25 53|endogenous creatinine clearance
P03150296A0594|67 90|glomerular filtration rate
P03150296A0594|92 94|GFR
P03150296A0594|104 110|caution
P03150296A0594|133 143|limitations
P03150296A0594|163 179|simpler techniques
P03150296A0594|181 195|serum creatinine
P03150296A0594|207 235|endogenous creatinine clearance
P03150296A0594|240 249|preferable
P03150296A0594|252 266|routine practice
P03154072A0862|3 17|protein mixtures
P03154072A0862|20 30|sesame flour
P03154072A0862|34 45|soybean flour
P03159903A0352|28 34|located
P03159903A0352|65 81|amino acid sequence
P03159903A0352|87 119|actual N-terminal amino acid sequence
P03159903A0352|122 124|IHF
P03166458A1356|1 16|protein footprint
P03166458A1356|38 49|GC box element
P03166458A1356|52 62|nucleotides
P03167060A0000|0 25|Insulin-like growth factor II
P03167060A0000|0 23|Insulin-like growth factor
P03167060A0000|27 31|IGFII
P03167060A0000|36 55|mitogenic polypeptide
P03167060A0000|60 64|mRNAs
P03167060A0000|84 96|multiple forms
P03167060A0000|105 114|derivation
P03167060A0000|120 129|single gene
P03168709A0000|3 21|central visual fields
P03168709A0000|40 51|glaucoma eyes
P03168709A0000|70 107|threshold related suprathreshold strategy
P03171221A0531|3 13|variability
P03171221A0531|35 53|alternative splicing
P03171221A0531|56 60|exons
P03171221A0531|68 92|primary elastin transcripts
P03171221A0531|75 92|elastin transcripts
P03171279A0158|29 44|metatarsal artery
P03171279A0158|60 75|toe MP joint grafts
P03171279A0158|85 113|unilateral proper digital artery
P03171279A0158|127 143|toe PIP joint grafts
P03171279A0158|157 167|concomitant
P03171279A0158|170 188|dorsal cutaneous vein
P03172863T0000|0 5|Effect
P03172863T0000|8 28|chronic undernutrition
P03172863T0000|31 44|susceptibility
P03172863T0000|47 56|cold stress
P03172863T0000|59 68|young adult
P03172863T0000|72 79|aged rats
P03175942A0706|32 36|doses
P03175942A0706|51 54|dams
P03175942A0706|68 83|second experiment
P03175942A0706|98 107|lower doses
P03178097A0000|3 19|CHARGE association
P03178097A0000|35 64|multisystem congenital anomalies
P03178097A0000|74 87|choanal atresia
P03178161A0000|0 34|Esophageal brush cytological screening
P03178161A0000|51 69|blood concentrations
P03178161A0000|72 85|micronutrients
P03178161A0000|87 94|vitamin A
P03178161A0000|96 96|E
P03178161A0000|98 100|B12
P03178161A0000|102 110|folic acid
P03178161A0000|114 123|methionine
P03178161A0000|139 144|adults
P03178161A0000|154 172|esophageal carcinoma
P03178161A0000|174 175|EC
P03178161A0000|179 186|Transkei
P03178161A0000|190 195|Ciskei
P03178161A0000|197 210|Southern Africa
P03178626A0137|0 7|Aviators
P03178626A0137|15 29|Light Attack Wing
P03178626A0137|31 37|Pacific
P03178626A0137|56 62|results
P03178626A0137|80 91|aircraft type
P03179496T0000|0 9|Evaluation
P03179496T0000|20 52|bovine modified-hemoglobin solution
P03179496T0000|35 44|hemoglobin
P03179496T0000|55 74|oxygen-carrying fluid
P03179496T0000|78 99|blood volume replacement
P03180595A1040|7 30|gallbladder visualization
P03180595A1040|45 60|ejection fraction
P03180595A1040|77 97|nonspecific indicators
P03180595A1040|100 113|biliary disease
P03181276A0422|2 14|micrograms PAF
P03181276A0422|17 23|placebo
P03181276A0422|42 52|nasal cavity
P03181276A0422|54 54|h
P03181276A0422|59 59|h
P03181276A0422|67 88|nasal allergen challenge
P03182802A0278|0 2|Sci
P03182872A1122|0 3|Chem
P03183103A0000|0 23|Sequential MR examinations
P03183103A0000|29 39|nasal cavity
P03183103A0000|43 58|paranasal sinuses
P03183103A0000|82 88|h period
P03183103A0000|95 110|normal volunteers
P03183127A0068|0 9|Comparison
P03183127A0068|21 59|other neuroradiological imaging modalities
P03183127A0068|69 70|CT
P03183127A0068|72 82|myelography
P03183127A0068|84 101|CT ventriculography
P03183127A0068|106 126|CT myelocisternography
P03184267A0000|14 33|young broiler chickens
P03184267A0000|85 92|serotype
P03184267A0000|111 131|subclinical infections
P03184267A0000|152 159|chickens
P03184267A0000|163 175|food poisoning
P03184267A0000|178 183|humans
P03185322A1305|1 15|poor correlation
P03185322A1305|32 46|mildly-atypical
P03185322A1305|48 59|inflammatory
P03185322A1305|61 77|cytological result
P03185322A1305|90 116|benign histological diagnosis
P03185322A1305|120 120|%
P03185322A1305|123 135|class-2 smears
P03185322A1305|165 173|dysplasia
P03185322A1305|176 180|worse
P03185540T0000|0 6|Factors
P03185540T0000|17 37|specific transcription
P03185540T0000|40 63|mammalian RNA polymerase II
P03185540T0000|40 61|mammalian RNA polymerase
P03185540T0000|65 76|purification
P03185540T0000|78 95|genetic specificity
P03185540T0000|100 127|TATA box-promoter interactions
P03185540T0000|100 115|TATA box-promoter
P03185540T0000|130 134|TFIID
P03186091T0000|0 5|Change
P03186091T0000|8 33|plasma cystyl aminopeptidase
P03186091T0000|35 45|oxytocinase
P03186091T0000|59 63|weeks
P03186091T0000|65 73|gestation
P03186091T0000|77 85|predictor
P03186091T0000|88 116|pregnancy-induced hypertension
P03190481A0292|10 31|alpha-naphthyl esterase
P03190481A0292|35 46|quantitation
P03190481A0292|49 59|macrophages
P03190481A0292|61 74|absolute number
P03190481A0292|79 106|infiltration area unit adjacent
P03190481A0292|112 118|abscess
P03190481A0292|127 143|direct correlation
P03190481A0292|154 167|absolute number
P03190481A0292|170 180|macrophages
P03190481A0292|187 191|width
P03190481A0292|197 203|capsule
P03190914A0149|12 33|migration differentials
P03190914A0149|35 45|chemotactic
P03190914A0149|49 74|chemokinetic responsiveness
P03190914A0149|85 90|higher
P03190914A0149|96 111|neutropenic group
P03192537A0370|10 28|96-residue amino acid
P03192537A0370|48 58|murine HMG-I
P03192537A0370|60 60|Y
P03192537A0370|62 65|cDNA
P03192537A0370|92 108|amino acid sequence
P03192537A0370|111 120|human HMG-I
P03192537A0370|141 158|internal amino acids
P03192537A0370|172 183|human protein
P03192724A0000|0 28|Interpersonal style differences
P03192724A0000|34 44|drug abusers
P03192724A0000|62 65|Ryan
P03192724A0000|74 90|typological system
P03192724A0000|93 112|FIRO-B interpretation
P03192799T0000|0 8|Statement
P03192799T0000|14 28|American Academy
P03192799T0000|31 46|Implant Dentistry
P03192950A0566|0 3|Sera
P03192950A0566|8 31|euthyroid post-menopausal
P03192950A0566|34 46|pregnant women
P03192950A0566|54 62|TSH levels
P03192950A0566|54 56|TSH
P03192950A0566|72 82|normal range
P03194410A0771|2 11|UOxase mRNA
P03194410A0771|27 43|nonhepatic tissues
P03194410A0771|60 76|tissue specificity
P03194410A0771|95 104|UOxase gene
P03195167A0104|3 22|platelet adhesion rate
P03195167A0104|30 35|layers
P03195167A0104|59 67|valuation
P03195167A0104|73 90|haemocompatibility
P03195167A0104|96 121|basic-polymers polyurethane
P03195167A0104|123 125|PUR
P03195167A0104|128 144|polyvinylchloride
P03195167A0104|146 148|PVC
P03195167A0104|154 164|polystyrene
P03195167A0104|166 167|PS
P03195167A0104|189 200|test chambers
P03198436T0000|0 20|Conservative treatment
P03198436T0000|23 38|bladder carcinoma
P03198436T0000|41 57|partial cystectomy
P03198436T0000|61 79|interstitial iridium
P03198525A0164|3 19|112-d feedlot trial
P03198525A0164|24 30|heifers
P03198525A0164|60 70|heavy weight
P03198525A0164|83 92|treatments
P03198525A0164|94 103|dietary MGA
P03198525A0164|107 113|mg.hd-1
P03198525A0164|115 117|d-1
P03198525A0164|130 132|MGA
P03198525A0164|136 143|DEPO-MGA
P03198525A0164|146 146|d
P03198525A0164|161 165|ml/hd
P03198525A0164|176 183|mg MGA/hd
P03199043A0248|0 8|Existence
P03199043A0248|12 21|uniqueness
P03199043A0248|24 32|solutions
P03199043A0248|38 69|appropriate boundary value problems
P03199043A0248|96 124|small permeability coefficients
P03199043A0248|128 141|transport rates
P03199043A0248|145 170|large diffusion coefficients
P03199043A0248|174 188|small resistance
P03199043A0248|195 203|constants
P03199436A1060|9 20|gene clusters
P03199436A1060|29 56|photosynthesis components such
P03199436A1060|62 80|psbB-psbH-petB-petD
P03199436A1060|62 65|psbB
P03199436A1060|67 70|psbH
P03199436A1060|72 75|petB
P03199436A1060|77 80|petD
P03199436A1060|87 103|psbE-psbF clusters
P03200488A0439|3 9|results
P03200488A0439|30 32|TIQ
P03200488A0439|43 54|turnover rate
P03200488A0439|60 87|nigrostriatal dopamine neurons
P03200488A0439|119 128|long period
P03200488A0439|131 134|mice
P03200844A1211|3 17|partial sequence
P03200844A1211|23 51|62-kDa nuclear pore glycoprotein
P03200844A1211|57 72|little similarity
P03200844A1211|93 100|proteins
P03200844A1211|114 131|structural features
P03200844A1211|154 177|nuclear pore glycoproteins
P03207975A0709|11 15|hours
P03207975A0709|37 45|vitamin K1
P03207975A0709|47 66|plasma concentrations
P03208493A0849|3 26|glomerular filtration rate
P03208493A0849|42 57|lithium clearance
P03208493A0849|66 66|%
P03209019A0662|7 30|28-week promotion bioassay
P03209019A0662|32 37|groups
P03209019A0662|42 53|male CD-1 mice
P03209019A0662|75 84|microliter
P03209019A0662|93 96|DMBA
P03209019A0662|101 105|mg/ml
P03209019A0662|109 115|acetone
P03209019A0662|127 131|weeks
P03209019A0662|163 174|test material
P03209019A0662|192 196|weeks
P03212551T0001|3 14|pathogenesis
P03212551T0001|17 25|Dupuytren
P03212551T0001|28 38|contracture
P03212929A0000|2 15|ELISA procedure
P03212929A0000|44 62|specific IgE response
P03212929A0000|52 54|IgE
P03212929A0000|65 68|dogs
P03212929A0000|71 97|Dirofilaria immitis infection
P03214709A0559|5 7|min
P03214709A0559|42 67|plasma corticosterone levels
P03214709A0559|128 142|non-biting group
P03216131A0559|3 13|only isolate
P03216131A0559|16 34|Aeromonas hydrophila
P03216131A0559|43 62|cytotoxic enterotoxin
P03216131A0559|69 76|invasive
P03218714A0000|2 17|11-month-old girl
P03218714A0000|31 54|Dandy-Walker malformation
P03218714A0000|56 58|DWM
P03218714A0000|74 82|tetralogy
P03218714A0000|85 90|Fallot
P03218714A0000|92 94|TOF
P03219107A0212|3 11|incidence
P03219107A0212|14 37|early neonatal convulsions
P03219107A0212|41 52|inborn babies
P03219107A0212|64 73|live births
P03220077A0274|3 16|median survival
P03220077A0274|34 52|median follow-up time
P03220077A0274|58 62|years
P03223123T0001|0 17|Critical evaluation
P03223123T0001|20 33|various methods
P03223123T0001|47 53|markers
P03223123T0001|56 68|fetal maturity
P03223123T0001|71 83|amniotic fluid
P03227288A0542|7 13|infants
P03227288A0542|20 27|probable
P03227288A0542|55 60|months
P03227568T0001|0 6|Variety
P03227568T0001|9 12|cows
P03227568T0001|16 20|sires
P03227568T0001|32 36|types
P03227568T0001|39 53|dermatoglyphics
P03227568T0001|55 62|patterns
P03227568T0001|69 85|nose-labial mirror
P03228518A0339|38 44|samples
P03228518A0339|46 62|secondary Academic
P03228518A0339|64 85|Personal Responsibility
P03228518A0339|90 119|Community/Vocational dimensions
P03228785A1047|0 7|Recovery
P03228785A1047|26 45|rapid improvement such
P03228785A1047|61 70|parameters
P03228785A1047|98 123|cross-sectional cardiac area
P03228785A1047|149 153|weeks
P03228785A1047|161 163|cm2
P03228785A1047|165 169|p less
P03228785A1047|194 201|ABSTRACT
P03228785A1047|216 220|WORDS
P03229917A0099|7 34|extensive pancreatic resection
P03229917A0099|47 72|pancreatic remnant infection
P03232410A1467|30 37|new cases
P03232410A1467|40 49|lung cancer
P03232410A1467|89 95|smoking
P03233862T0000|0 18|Neuromyelitis optica
P03233862T0000|20 24|Devic
P03233862T0000|46 62|multiple sclerosis
P03234790T0001|0 5|Effect
P03234790T0001|11 17|methods
P03234790T0001|20 42|cutaneous administration
P03234790T0001|45 64|methyl isobutyl ketone
P03234790T0001|70 77|toxicity
P03235487A0404|0 12|Incorporation
P03235487A0404|23 48|M sodium dihydrogen phosphate
P03235487A0404|54 67|sugar solutions
P03235487A0404|92 101|shelf-life
P03235487A0404|104 112|diltiazem
P03237446A0377|0 3|None
P03237446A0377|8 18|past history
P03237446A0377|21 43|opportunistic infections
P03237446A0377|62 72|lymphopenia
P03239106A0856|13 29|phosphorus content
P03239106A0856|50 61|reabsorption
P03239106A0856|64 70|calcium
P03239106A0856|74 82|magnesium
P03243027T0000|0 29|Post-transcriptional regulation
P03243027T0000|32 61|ribosomal protein gene expression
P03243027T0000|32 51|ribosomal protein gene
P03243027T0000|81 103|Dictyostelium discoideum
P03243920A0591|3 10|temporal
P03243920A0591|14 58|static plasma concentration-effect relationships
P03243920A0591|74 96|pharmacodynamic modeling
P03243920A0591|100 115|linear regression
P03246999A0483|13 22|amplitudes
P03246999A0483|28 33|b-wave
P03246999A0483|43 58|adaptation period
P03246999A0483|77 96|lead-exposed subjects
P03246999A0483|103 110|controls
P03249792A0241|0 14|Possible factors
P03249792A0241|34 56|psychotic symptomatology
P03249792A0241|63 77|group activities
P03249792A0241|90 102|group dynamics
P03249792A0241|111 123|stress factors
P03249792A0241|137 155|functional psychoses
P03249792A0241|167 187|bipolar manifestations
P03249840A0411|0 19|Baseline measurements
P03249840A0411|22 43|forced expiratory volume
P03249840A0411|47 47|s
P03249840A0411|49 52|FEV1
P03249840A0411|55 79|specific airway conductance
P03249840A0411|81 84|SGaw
P03249840A0411|92 106|provocative dose
P03249840A0411|109 117|carbachol
P03249840A0411|128 137|% reduction
P03249840A0411|140 143|SGaw
P03249840A0411|145 148|PD35
P03249840A0411|157 166|% reduction
P03249840A0411|169 172|FEV1
P03249840A0411|174 177|PD20
P03249840A0411|225 231|smoking
P03251210A0981|0 11|Many children
P03251210A0981|16 18|BGC
P03251210A0981|51 64|calcifications
P03251210A0981|88 100|specific forms
P03251210A0981|103 123|neurologic dysfunction
P03253219T0000|0 12|R-wave voltage
P03253219T0000|18 37|right precordial leads
P03253219T0000|40 66|anthracycline cardiomyopathy
P03253219T0000|69 81|clinical study
P03256150A1866|3 9|results
P03256150A1866|32 43|requirements
P03256150A1866|47 59|task dependent
P03257146A1037|5 11|results
P03257146A1037|24 28|CSFHU
P03257146A1037|40 55|neutrophil counts
P03257146A1037|80 87|maturity
P03257146A1037|93 118|marrow neutrophil precursors
P03257146A1037|125 129|types
P03257146A1037|132 158|childhood chronic neutropenia
P03258069A0000|3 10|purposes
P03258069A0000|48 60|high intensity
P03258069A0000|62 113|low frequency transcutaneous electrical nerve stimulation
P03258069A0000|116 141|auricular acupuncture points
P03258069A0000|144 168|experimental pain threshold
P03258069A0000|206 212|changes
P03259437A0140|5 43|infected neonates serum alpha-amylase value
P03259437A0140|26 38|alpha-amylase
P03259437A0140|62 77|blue starch method
P03259437A0140|88 88|%
P03259437A0140|95 109|healthy controls
P03259437A0140|114 122|mean value
P03259437A0140|137 140|IU/l
P03259437A0140|144 158|healthy neonates
P03259437A0140|175 180|higher
P03259437A0140|182 186|p less
P03259437A0140|223 226|IU/l
P03259437A0140|233 248|infected neonates
P03261005A0216|0 6|Records
P03261005A0216|11 18|children
P03261005A0216|29 47|AIDS-related complex
P03261005A0216|61 86|pediatric intensive care unit
P03261005A0216|90 112|acute respiratory failure
P03261005A0216|124 137|46-month period
P03261223A0644|8 15|patients
P03261223A0644|25 46|multifocal disease group
P03261223A0644|64 68|SPECT
P03261223A0644|76 78|TCT
P03261331A0563|0 4|SPECT
P03261331A0563|9 20|important aid
P03261331A0563|37 55|AIDS dementia complex
P03261331A0563|93 120|pathophysiological mechanisms
P03263357A0112|51 65|circadian rhythm
P03263357A0112|68 82|body temperature
P03263357A0112|86 99|24-h variations
P03263357A0112|102 121|plasma concentrations
P03263357A0112|129 132|zinc
P03263357A0112|145 159|leukocyte counts
P03263357A0112|164 180|plasma interleukin
P03263357A0112|170 181|interleukin 1
P03263357A0112|183 186|IL-1
P03263465T0000|3 16|murine MHC class
P03263465T0000|18 22|genes
P03263465T0000|24 28|H-2Dq
P03263465T0000|32 36|H-2Lq
P03263465T0000|51 60|homologous
P03263465T0000|73 77|H-2Ld
P03263465T0000|85 89|genes
P03263465T0000|106 127|tumor-specific antigens
P03264073A0224|3 19|active derivatives
P03264073A0224|25 37|present series
P03264073A0224|60 76|analgesic activity
P03264073A0224|84 100|aconitine-induced
P03264073A0224|111 120|albino mice
P03264073A0224|124 142|ulcerogenic activity
P03264073A0224|145 154|albino rats
P03264299A0679|2 14|untreated mice
P03264299A0679|16 35|bactericidal activity
P03264299A0679|38 58|peritoneal macrophages
P03264299A0679|81 84|days
P03264299A0679|90 100|ip injection
P03264886A0000|24 31|children
P03264886A0000|38 42|years
P03264886A0000|61 65|towns
P03264886A0000|69 78|rural areas
P03264886A0000|81 100|south-western Germany
P03264886A0000|109 109|%
P03264886A0000|111 115|cases
P03264886A0000|118 122|croup
P03264886A0000|146 157|months period
P03264886A0000|174 183|physicians
P03267732A0788|15 32|Ga-fbg scintigraphy
P03267732A0788|40 51|simple method
P03267732A0788|85 112|active left ventricular thrombi
P03267732A0788|140 159|anticoagulant therapy
P03268555T0000|22 37|biocompatibility
P03268555T0000|40 54|dental materials
P03268555T0000|60 80|millipore filter method
P03270085A0382|0 13|Hypomagnesemia
P03270085A0382|22 37|magnesium wasting
P03270085A0382|43 48|kidney
P03274204A0642|0 11|Dentalplaque
P03274204A0642|30 46|oral higienic index
P03274204A0642|52 65|whole dentition
P03274204A0642|93 109|cent alkaline fuxin
P03275867A0187|0 3|GRFI
P03275867A0187|11 19|sequences
P03275867A0187|25 50|negative regulatory elements
P03275867A0187|52 60|silencers
P03275867A0187|67 90|silent mating type loci HML E
P03275867A0187|67 86|silent mating type loci
P03275867A0187|87 90|HML E
P03275867A0187|94 97|HMR E
P03275867A0187|106 113|upstream
P03275867A0187|133 135|UAS
P03275867A0187|148 160|transcription
P03275867A0187|166 178|MAT alpha genes
P03275873A0379|3 9|effects
P03275873A0379|17 25|mutations
P03275873A0379|28 42|RNA polymerase II
P03275873A0379|28 40|RNA polymerase
P03275873A0379|85 95|mutant genes
P03275873A0379|104 127|alpha-amanitin resistance
P03275873A0379|104 117|alpha-amanitin
P03275873A0379|133 144|transfection
P03275873A0379|147 168|susceptible rodent cells
P03276246A0037|17 62|new technetium-99m-albumin colloid white blood cell
P03276246A0037|35 41|albumin
P03276246A0037|64 70|TAC-WBC
P03276246A0037|93 104|appendicitis
P03276924A0090|12 17|tumors
P03276924A0090|29 41|rearrangement
P03276924A0090|56 64|insertion
P03276924A0090|69 88|intact MoMuLV provirus
P03278829A0082|3 13|indications
P03278829A0082|45 73|secondary rhinoplasty candidate
P03278829A0082|80 88|tip grafts
P03278829A0082|120 128|deformity
P03280021A1615|3 10|SSB-poly
P03280021A1615|12 13|dT
P03280021A1615|15 22|affinity
P03280021A1615|43 49|buffers
P03280021A1615|65 69|M NaCl
P03280021A1615|88 92|M NaBr
P03280021A1615|96 124|measure alpha log Kobsd/alpha log
P03280021A1615|126 129|NaBr
P03280021A1615|131 131|=
P03280021A1615|148 157|lower value
P03280021A1615|160 168|omega T/O =
P03280807A0000|0 8|Mutations
P03280807A0000|14 23|suf12 locus
P03280807A0000|63 83|extragenic suppressors
P03280807A0000|88 106|frameshift mutations
P03280807A0000|109 115|glycine
P03280807A0000|117 119|GGX
P03280807A0000|124 130|proline
P03280807A0000|132 134|CCX
P03280807A0000|136 141|codons
P03280807A0000|151 153|UGA
P03280807A0000|157 176|UAG nonsense mutations
P03280807A1447|13 42|suf12-null/SUF12+ heterozygotes
P03280807A1447|13 28|suf12-null/SUF12
P03280807A1447|30 42|heterozygotes
P03280807A1447|56 60|suf12
P03280807A1447|100 130|suf12 allele-specific suppression
P03280807A1447|100 110|suf12 allele
P03280807A1447|156 177|distinct mutant proteins
P03280807A1447|199 220|residual wild-type SUF12
P03280807A1447|207 221|wild-type SUF12+
P03280912T0000|0 21|Antituberculosis agents
P03280946A0375|3 25|putative immunity protein
P03280946A0375|46 48|35S
P03280946A0375|50 76|methionine-labelled proteins
P03280946A0375|87 95|minicells
P03280946A0375|104 106|cni
P03280946A0375|118 135|lac promoter control
P03280946A0375|167 183|expression vectors
P03280946A0375|202 224|bacteriophage T7 promoter
P03282232A0743|0 9|Antibodies
P03282232A0743|21 33|fusion protein
P03282232A0743|47 55|DP1A clone
P03282232A0743|47 50|DP1A
P03282232A0743|79 82|DP-I
P03282232A0743|91 101|immunoblots
P03282813A0794|13 24|similar range
P03282813A0794|27 29|QO2
P03282813A0794|31 46|oxygen extraction
P03282813A0794|50 56|greater
P03282813A0794|59 66|patients
P03282813A0794|71 74|ARDS
P03282813A0794|85 92|patients
P03282813A0794|97 122|non-ARDS respiratory failure
P03282813A0794|124 125|r =
P03282813A0794|134 139|slope =
P03282813A0794|147 148|r =
P03282813A0794|157 162|slope =
P03282813A0794|169 173|p less
P03283881A0216|0 13|Stable patients
P03283881A0216|18 37|mucous hypersecretion
P03283881A0216|41 54|little evidence
P03283881A0216|57 73|acute inflammation
P03285764A0675|0 18|Hyperprolactinaemia
P03285764A0675|20 39|moderate hypogonadism
P03285764A0675|41 65|infraclinical neuropathies
P03285764A0675|67 82|arterial stenoses
P03285764A0675|86 107|moderate venous leakages
P03285764A0675|119 129|partial role
P03285764A0675|132 145|organic starter
P03285764A0675|148 155|cofactor
P03285764A0675|160 177|sexual consequences
P03285764A0675|199 218|psychological factors
P03285764A0675|240 260|initial sexual failures
P03286611A1198|0 3|Yang
P03286611A1198|7 8|H.
P03287597T0000|0 16|Secretory function
P03287597T0000|22 34|prostate gland
P03292076A0820|0 17|Chronic endotoxemia
P03292076A0820|45 86|elevated pulmonary microvascular permeability
P03292076A0820|106 128|hyperdynamic circulation
P03292076A0820|138 154|appreciable degree
P03292076A0820|157 170|refractoriness
P03292076A0820|185 204|regional hemodynamics
P03292076A0820|208 229|eicosanoid biosynthesis
P03292082A0486|21 38|high concentrations
P03292082A0486|47 54|patients
P03292082A0486|59 64|tumors
P03292082A0486|70 89|central nervous system
P03292082A0486|103 112|meningioma
P03292082A0486|119 130|glioblastoma
P03292082A0486|141 149|neurinoma
P03293844T0000|0 3|Diet
P03293844T0000|7 18|atopic eczema
P03296019T0000|0 15|Time delay effects
P03296019T0000|21 39|tensile bond strength
P03296019T0000|54 63|Silicoater
P03296212A0603|23 32|interferon
P03296212A0603|54 58|areas
P03296212A0603|60 66|Efforts
P03296212A0603|116 122|synergy
P03296212A0603|137 151|meaningful terms
P03296212A0603|172 187|fullest potential
P03296212A0603|190 192|IFN
P03296212A0603|256 263|adjuvant
P03296212A0603|269 282|tumor debulking
P03296212A0603|290 305|initial diagnosis
P03296212A0603|310 325|medical community
P03296212A0603|340 353|natural history
P03296212A0603|360 367|diseases
P03296212A0603|379 394|fullest potential
P03296212A0603|400 413|biologic agents
P03296212A0603|422 435|likely manifest
P03296212A0603|451 456|agents
P03296254A0556|0 15|Minor differences
P03296254A0556|29 37|latamoxef
P03296254A0556|47 69|mild persistant elevation
P03296254A0556|72 86|prothrombin time
P03296254A0556|72 82|prothrombin
P03296254A0556|135 143|factor VII
P03297181A0127|3 21|healthy male subjects
P03297181A0127|30 44|single oral doses
P03297181A0127|47 60|regular release
P03297181A0127|62 63|RR
P03297181A0127|65 80|quinidine sulfate
P03297181A0127|82 97|sustained release
P03297181A0127|99 100|SR
P03297181A0127|102 119|quinidine bisulfate
P03297181A0127|126 133|same dose
P03297181A0127|139 147|SR product
P03297181A0127|157 160|SR-F
P03298134A0000|19 30|previous work
P03298134A0000|35 76|interferon alfa-2b (Intron A; Schering-Plough)
P03298134A0000|35 51|interferon alfa-2b
P03298134A0000|53 59|Intron A
P03298134A0000|61 75|Schering-Plough
P03298134A0000|93 109|hairy cell leukemia
P03298134A0000|111 113|HCL
P03300118A0392|0 13|Oxygen delivery
P03300118A0392|17 26|base excess
P03300118A0392|56 59|pigs
P03304015T0000|0 16|Clinical chemistry
P03304866T0001|0 16|Revascularization
P03304866T0001|22 38|anterior maxillary
P03304866T0001|42 60|mandibular osteotomy
P03305875T0000|0 13|Static orthoses
P03305875T0000|32 42|microstomia
P03306340A0537|3 23|intrapancreatic spread
P03306340A0537|29 37|carcinoma
P03306340A0537|52 65|portal invasion
P03306340A0537|68 76|carcinoma
P03306340A0537|78 85|hardness
P03306340A0537|103 113|obstruction
P03306340A0537|116 133|main pancreatic duct
P03306340A0537|137 160|irregular pancreaticogram
P03308909A0485|0 15|Lysosomal enzymes
P03308909A0485|27 35|cartilage
P03309892A0637|0 7|Contrary
P03309892A0637|32 38|other S.
P03309892A0637|44 48|genes
P03309892A0637|72 76|yeast
P03309892A0637|81 111|heterologous actin gene transcript
P03309892A0637|93 111|actin gene transcript
P03309892A0637|125 143|nucleotides upstream
P03309892A0637|149 167|initiation start site
P03309892A0637|177 191|homologous yeast
P03311954A0000|1 16|multicentre study
P03311954A0000|27 45|Italian institutions
P03311954A0000|71 78|efficacy
P03311954A0000|90 99|ranitidine
P03311954A0000|103 110|mg b.i.d.
P03311954A0000|114 123|ranitidine
P03311954A0000|127 133|mg nocte
P03311954A0000|150 167|reflux oesophagitis
P03312033A0501|0 10|Monotherapy
P03312033A0501|15 25|ceftazidime
P03312033A0501|73 90|combination therapy
P03312033A0501|95 103|cefazolin
P03312033A0501|107 116|tobramycin
P03312514A0756|3 8|N3 wave
P03312514A0756|14 17|SSEP
P03312514A0756|57 76|neurological recovery
P03312514A0756|90 90|%
P03312514A0756|96 96|%
P03312514A0756|102 121|preischemia amplitude
P03312514A0756|127 148|insulin-treated animals
P03312514A0756|127 133|insulin
P03312514A0756|162 162|%
P03312514A0756|168 168|%
P03312514A0756|174 184|fasted group
P03312514A0756|190 190|%
P03312514A0756|196 196|%
P03312514A0756|202 215|control animals
P03315359A0732|0 10|Proctoscopy
P03315359A0732|14 36|roentgenographic studies
P03315359A0732|44 56|important part
P03315359A0732|82 89|patients
P03315359A0732|104 122|perianal suppuration
P03315359A0732|124 129|masses
P03315359A0732|133 144|anal fissures
P03317796A0853|5 16|control group
P03317796A0853|20 38|histological picture
P03317796A0853|48 61|osteoarthritis
P03319621A0707|16 19|mRNA
P03319621A0707|23 23|%
P03319621A0707|26 30|alpha
P03319621A0707|34 47|beta actin mRNAs
P03319621A0707|68 76|myoblasts
P03319621A0707|80 87|myotubes
P03319646T0000|0 18|Plasma renin activity
P03319646T0000|36 59|antihypertensive efficacy
P03319646T0000|62 75|chlorthalidone
P03319912A0000|0 9|Cephradine
P03319912A0000|13 14|mg
P03319912A0000|27 32|months
P03319912A0000|44 62|prophylactic measure
P03319912A0000|67 80|female patients
P03319912A0000|83 89|mean age
P03319912A0000|94 98|years
P03319912A0000|130 135|months
P03319912A0000|156 162|median =
P03319912A0000|165 172|episodes
P03319912A0000|190 196|dysuria
P03320875A2090|8 18|unavailable
P03320875A2090|24 31|Supramid
P03320875A2090|36 47|proven record
P03320875A2090|51 73|good tissue compatibility
P03322829A0952|31 52|good compliance category
P03322829A0952|66 78|digoxin marker
P03322829A0952|108 115|patients
P03322829A0952|140 140|%
P03322829A0952|173 181|deviation
P03322829A0952|193 193|%
P03325081A0524|0 17|Bullous keratopathy
P03325081A0524|28 34|aphakic
P03325081A0524|62 91|pseudophakic bullous keratopathy
P03325081A0524|93 95|PBK
P03325081A0524|107 117|common cause
P03325081A0524|120 137|bullous keratopathy
P03326381A0423|3 25|ultrastructural findings
P03326381A0423|38 62|urinary C-peptide excretion
P03326381A0423|80 94|glycemic effects
P03326381A0423|123 134|direct action
P03326381A0423|140 144|drugs
P03326381A0423|154 170|endocrine pancreas
P03329716A0187|16 34|EGF receptor promoter
P03329716A0187|51 60|E1A protein
P03329716A0187|64 80|receptor RNA levels
P03329716A0187|92 102|stimulation
P03329716A0187|107 118|phorbol ester
P03329716A0187|121 134|fetal calf serum
P03330711T0000|7 26|antimalarial activity
P03330711T0000|29 32|neem
P03330711T0000|34 52|Azadirachta indica A.
P03331525T0001|16 29|dentin adhesion
P03331525T0001|32 40|adhesives
P03331525T0001|49 65|urethane molecules
P03331525T0001|70 79|free groups
P03331525T0001|82 91|isocyanate
P03331933T0048|2 14|Felix Lagrange
P03332022A1094|8 31|cysteine clustering region
P03332022A1094|36 51|N-terminal region
P03332022A1094|57 61|c-raf
P03332022A1094|87 104|nucleotide sequence
P03332022A1094|113 136|cysteine clustering region
P03332022A1094|155 164|homologous
P03332022A1094|182 197|N-terminal region
P03332022A1094|200 213|protein kinase C
P03332022A1094|229 250|latter cysteine clusters
P03332848A0000|0 8|Hand-held
P03332848A0000|10 37|continuous-wave Doppler probes
P03332848A0000|50 70|sound spectral analysis
P03332848A0000|94 114|carotid artery stenosis
P03334950A0000|3 15|German Society
P03334950A0000|18 34|Pediatric Oncology
P03334950A0000|53 68|Cooperative Ewing
P03334950A0000|71 82|Sarcoma Study
P03334950A0000|84 87|CESS
P03334950A0000|97 116|four-drug combination
P03334950A0000|119 130|chemotherapy
P03334950A0000|138 159|definitive local control
P03335127A0176|27 38|generic BASIC
P03335127A0176|55 76|procedure user-friendly
P03335398A0568|5 14|high levels
P03335398A0568|17 31|immunoglobulin G
P03335398A0568|70 72|NVS
P03335398A0568|78 89|immunization
P03335398A0568|91 116|passive transfer experiments
P03335444A0000|21 29|human male
P03335444A0000|53 57|241Am
P03335444A0000|61 62|Pu
P03335651A0000|2 15|analytic method
P03335651A0000|19 47|comparative parameter weighting
P03335651A0000|50 66|magnetic resonance
P03335651A0000|68 69|MR
P03335651A0000|71 77|imaging
P03335651A0000|112 132|fractional sensitivity
P03335651A0000|139 149|new approach
P03335651A0000|175 181|indexes
P03335651A0000|185 186|T1
P03335651A0000|188 189|T2
P03335651A0000|194 210|hydrogen weighting
P03335923A0257|10 17|patients
P03335923A0257|33 38|groups
P03335923A0257|55 74|clinical presentation
P03335923A0257|81 102|asymptomatic volunteers
P03335923A0257|106 113|patients
P03335923A0257|118 150|duodenal-gastric reflux gastropathy
P03335923A0257|152 154|DRG
P03335923A0257|159 166|patients
P03335923A0257|171 185|recurrent ulcers
P03335923A0257|191 202|duodenal bulb
P03335923A0257|204 206|RUD
P03335923A0257|214 221|patients
P03335923A0257|226 233|Moynihan
P03337024A0000|2 16|previous studies
P03337024A0000|34 50|pharmaco-dynamics
P03337024A0000|53 75|intravenous procainamide
P03337024A0000|103 107|mg/kg
P03337024A0000|122 127|mg/min
P03337024A0000|133 146|common practice
P03337024A0000|153 179|electropharmacologic testing
P03338154T0000|0 17|High concentrations
P03338154T0000|20 51|tumor-associated trypsin inhibitor
P03338154T0000|20 42|tumor-associated trypsin
P03338154T0000|54 73|hemodialyzed patients
P03340548A1018|5 16|chicken liver
P03340548A1018|18 23|levels
P03340548A1018|26 38|chicken MT mRNA
P03340548A1018|59 64|metals
P03340548A1018|66 68|Cd2
P03340548A1018|71 73|Zn2
P03340548A1018|76 78|Cu2
P03340548A1018|82 96|glucocorticoids
P03340548A1018|100 117|lipopolysaccharide
P03340726A1103|4 12|histology
P03340726A1103|16 34|Evans blue injections
P03340726A1103|36 64|blood-brain barrier alterations
P03340726A1103|83 86|days
P03340726A1103|101 102|Gy
P03340774A0328|0 18|Dosimetric estimates
P03340774A0328|27 32|organs
P03340774A0328|58 60|rad
P03340774A0328|71 72|Gy
P03340774A0328|93 110|whole-body estimate
P03340774A0328|117 119|rad
P03340774A0328|125 126|Gy
P03343730A0486|1 22|significant association
P03343730A0486|31 43|family history
P03343730A0486|48 62|higher urinary pH
P03343730A0486|82 107|female calcium stone patients
P03344586T0000|0 14|New technologies
P03344586T0000|29 42|classification
P03344586T0000|45 54|malignancy
P03344812A0924|7 17|present data
P03344812A0924|33 34|BP
P03344812A0924|38 51|HR measurements
P03344812A0924|74 95|state-dependent factors
P03344812A0924|117 132|different factors
P03344812A0924|176 177|BP
P03344812A0924|181 188|HR values
P03344812A0924|269 275|ranking
P03344812A0924|293 294|BP
P03344812A0924|298 305|HR levels
P03344812A0924|298 299|HR
P03345706A0561|21 25|PaCO2
P03345706A0561|29 33|PtcO2
P03345706A0561|36 38|RDS
P03345706A0561|42 53|insufficient
P03345706A0561|60 76|clinical judgement
P03346157A0000|14 18|times
P03346157A0000|26 66|biennial ABCC/RERF radiological examinations
P03346157A0000|71 86|Adult Health Study
P03346157A0000|88 90|AHS
P03346157A0000|92 99|subjects
P03346157A0000|133 141|exposures
P03346157A0000|144 156|medical x-rays
P03346157A0000|174 190|institutions other
P03346157A0000|195 198|RERF
P03346157A0000|219 225|numbers
P03346157A0000|228 239|examinations
P03346157A0000|243 260|corresponding doses
P03346210A0000|3 23|epidermal growth factor
P03346210A0000|25 27|EGF
P03346210A0000|29 36|receptor
P03346210A0000|51 88|intrinsic protein tyrosine kinase activity
P03346210A0000|60 80|protein tyrosine kinase
P03346210A0000|106 147|intramolecular self-phosphorylation reaction
P03346210A0000|157 169|EGF activation
P03346210A0000|157 159|EGF
P03348382A0785|3 19|millimolar ouabain
P03348382A0785|39 45|net HCO3
P03348382A0785|47 55|secretion
P03351478A0371|8 14|regions
P03351478A0371|19 26|long runs
P03351478A0371|35 36|% C
P03351478A0371|41 50|% G residues
P03352254A0203|3 23|same rhythmic structure
P03352254A0203|64 69|vowels
P03352254A0203|72 88|stressed syllables
P03352439T0000|0 31|Vocal cord abduction rehabilitation
P03352439T0000|34 60|nervous selective anastomosis
P03352727T0000|0 1|UK
P03352727T0000|4 16|biotechnology
P03352727T0000|24 34|specialists
P03352947T0001|7 25|AIDS-related complex
P03352947T0001|27 33|ARC/LAS
P03352947T0001|27 29|ARC
P03352947T0001|31 33|LAS
P03352947T0001|38 49|health worker
P03354295A0157|0 12|Distant spread
P03354295A0157|25 32|patients
P03354295A0157|36 36|%
P03354295A0157|50 63|serum Tg greater
P03354295A0157|70 81|micrograms/l
P03354341A0177|3 26|glomerular filtration rate
P03354341A0177|30 53|effective renal plasma flow
P03354341A0177|71 93|standard clearance method
P03354341A0177|104 121|continuous infusion
P03354341A0177|124 129|inulin
P03354341A0177|133 154|para-aminohippuric acid
P03355122A0238|29 47|plasma glucose levels
P03355122A0238|73 75|min
P03355122A0238|88 100|initial levels
P03355122A0238|105 105|h
P03359860A0000|3 11|relations
P03359860A0000|17 40|various negative emotional
P03359860A0000|44 68|behavioral characteristics
P03359860A0000|94 108|undercompliance
P03359860A0000|110 123|depressive mood
P03359860A0000|173 207|31-year-old New York Longitudinal Study
P03360667A0000|21 28|altitude
P03360667A0000|31 46|adolescent growth
P03360667A0000|67 72|groups
P03360667A0000|83 101|well-nourished youth
P03360667A0000|104 129|similar socioeconomic status
P03360667A0000|133 146|ethnic grouping
P03360667A0000|159 166|sea level
P03360667A0000|168 169|n =
P03360667A0000|174 181|subjects
P03360667A0000|184 195|mid-altitude
P03360667A0000|197 198|n =
P03360667A0000|203 210|subjects
P03360667A0000|216 227|high altitude
P03360667A0000|229 230|n =
P03360667A0000|235 242|subjects
P03360948A0477|10 12|CAP
P03360948A0477|21 39|variables predictive
P03360948A0477|42 56|abusive behavior
P03360948A0477|59 81|substantial relationship
P03360948A0477|103 105|CAP
P03360948A0477|112 118|MHI Loss
P03360948A0477|121 152|Behavioral/Emotional Control scale
P03361653A0459|26 51|nuclear contour digitization
P03361653A0459|68 89|theoretical limitations
P03361653A0459|102 120|standardized objects
P03366720A1335|30 47|mammary utilization
P03366720A1335|50 78|pre-formed long-chain fatty acid
P03366720A1335|91 100|metabolism
P03366720A1335|103 109|glucose
P03366720A1335|113 122|glycolysis
P03366864A0099|3 10|skin site
P03366864A0099|12 22|6-cm-distal
P03366864A0099|27 54|proximal subcutaneous segments
P03366864A0099|60 67|catheter
P03368701A0113|12 27|great reliability
P03368701A0113|29 53|conventional arteriography
P03368701A0113|84 107|medical imaging techniques
P03370815T0000|0 13|Rapid detection
P03370815T0000|45 53|test serum
P03370815T0000|60 69|radioassay
P03370815T0000|72 81|vitamin B12
P03371139A0829|3 13|former group
P03371139A0829|24 43|less dry fecal material
P03371139A0829|58 68|other groups
P03371806A0000|0 23|Electronic data processing
P03371806A0000|25 27|EDP
P03371806A0000|29 44|latex immunoassay
P03371806A0000|50 81|anti-human seminal acid phosphatase
P03371806A0000|83 91|anti-HSAP
P03371806A0000|93 103|immune serum
P03371806A0000|130 148|organ identification
P03371806A0000|151 168|human seminal stains
P03371894A0355|0 17|Vimentin positivity
P03371894A0355|0 7|Vimentin
P03371894A0355|31 46|undifferentiated
P03371894A0355|50 71|fibroblastic components
P03372422A0558|3 20|maximum deflections
P03372422A0558|33 34|Ar
P03372422A0558|38 39|N2
P03372422A0558|64 69|slopes
P03372422A0558|74 80|smaller
P03372422A0558|86 98|prone position
P03372422A0558|110 143|more uniform tracer gas concentrations
P03372422A0558|153 157|lungs
P03373755T0001|0 17|Recent developments
P03373755T0001|20 36|drugs antagonistic
P03373755T0001|39 45|factors
P03373755T0001|53 63|peptic ulcer
P03373755T0001|66 81|clinical efficacy
P03373755T0001|85 92|problems
P03373755T0001|94 118|gastrin receptor blockaders
P03373755T0001|94 108|gastrin receptor
P03375184A0000|3 23|spermicide nonoxynol-9
P03375184A0000|36 51|homologous series
P03375184A0000|54 76|alkylphenol-ethoxylates
P03375184A0000|78 95|polyethoxyethanols
P03375184A0000|99 124|general formula C9H19-C6H6-O
P03375184A0000|127 133|CH2CH2O
P03375184A0000|135 145|n-1 CH2CH2OH
P03377864A0000|0 19|Static magnetic fields
P03377864A0000|29 37|diffusion
P03377864A0000|40 58|biological particles
P03377864A0000|61 69|solutions
P03377864A0000|80 91|Lorentz force
P03377864A0000|95 107|Maxwell stress
P03377891A0652|0 23|Psychological disturbance
P03377891A0652|27 33|greater
P03377891A0652|39 57|high life stress group
P03377891A0652|71 91|significant elevations
P03377891A0652|97 115|global severity index
P03377891A0652|121 139|Symptom Checklist-90
P03377891A0652|143 152|elevations
P03377891A0652|155 166|somatization
P03377891A0652|168 186|obsessive compulsive
P03377891A0652|188 211|interpersonal sensitivity
P03377891A0652|234 254|psychoticism subscales
P03378994T0000|0 20|Chronic administration
P03378994T0000|23 35|sodium cyanate
P03378994T0000|47 61|extraction ratio
P03378994T0000|64 67|dogs
P03379058A0188|0 19|Nucleotide sequencing
P03379058A0188|37 52|E1 alpha cDNA clone
P03379058A0188|59 67|base pairs
P03379058A0188|69 70|bp
P03379058A0188|86 101|open reading frame
P03379058A0188|108 109|bp
P03379058A0188|117 134|untranslated region
P03379058A0188|140 141|bp
P03380547A0169|0 2|SPA
P03380547A0169|7 14|PAG sites
P03380547A0169|32 39|aversion
P03381039A0364|14 16|MAN
P03381039A0364|24 31|unimodal
P03381039A0364|33 50|skewed distribution
P03381039A0364|84 89|micron
P03381039A0364|106 111|micron
P03382310A0903|0 19|Abnormal technetium Tc
P03382310A0903|23 36|medronate scans
P03382310A0903|39 46|patients
P03382310A0903|61 86|undiagnosed polyarthralgias
P03382310A0903|96 118|inflammatory arthropathy
P03382310A0903|132 150|management decisions
P03382310A0903|155 182|favorable therapeutic outcomes
P03382772A0319|0 16|Practical interest
P03382772A0319|19 29|such studies
P03382772A0319|47 71|pharmacokinetic parameters
P03382772A0319|115 120|trials
P03382855A0368|3 12|artery cuff
P03382855A0368|37 43|fat wrap
P03382855A0368|65 78|fewer adhesions
P03382855A0368|83 107|better histological picture
P03383897A0189|0 22|Lithium-carbonate action
P03383897A0189|29 44|radiation therapy
P03383897A0189|70 83|positive effect
P03383897A0189|86 97|leukopoiesis
P03383897A0189|104 137|consequent better clinical conditions
P03383897A0189|143 150|patients
P03384033A0155|7 11|units
P03384033A0155|24 39|sinusoidal motion
P03384033A0155|46 47|Hz
P03384033A0155|52 55|cm/s
P03384033A0155|63 63|%
P03384033A0155|68 77|responsive
P03384033A0155|83 94|otolith input
P03384033A0155|107 107|%
P03384033A0155|128 138|visual input
P03384033A0155|153 153|%
P03384033A0155|170 179|modalities
P03384272A0145|40 48|wide range
P03384272A0145|51 71|clinical presentations
P03384272A0145|91 96|lesion
P03387665A0000|31 51|Trypanosoma congolense
P03387665A0000|53 58|T vivax
P03387665A0000|62 68|T brucei
P03387665A0000|80 84|goats
P03387665A0000|104 110|animals
P03387665A0000|123 156|infected Glossina morsitans centralis
P03390074A0000|0 18|Electroglottography
P03390074A0000|29 49|non-invasive technique
P03390074A0000|80 99|vocal fold dysfunction
P03395009A1750|0 18|Statistical analysis
P03395009A1750|24 30|degrees
P03395009A1750|33 62|secondary spinal cord compression
P03395009A1750|77 87|group-1 dogs
P03395009A1750|111 116|ratios
P03395009A1750|135 153|horizontal diameters
P03395009A1750|159 186|transverse spinal cord sections
P03395009A1750|191 199|locations
P03395009A1750|207 209|T12
P03395009A1750|212 213|L1
P03395009A1750|224 226|T11
P03395009A1750|228 233|T11-12
P03395009A1750|235 238|L1-2
P03395009A1750|243 244|L2
P03395009A1750|257 276|surgical intervention
P03395164A0000|3 24|pharmacological effects
P03395164A0000|30 45|novel compound WEB
P03395164A0000|50 51|FU
P03395164A0000|53 102|4-amino-methyl-1-benzyl-pyrrolidine-2-one-fumarate
P03395249A1044|0 27|Histopathological examination
P03395249A1044|36 60|dose-related proliferation
P03395249A1044|69 79|pneumocytes
P03395249A1044|82 85|dams
P03395249A1044|89 101|proliferation
P03395249A1044|104 120|interstitial cells
P03395249A1044|131 157|septal/capillary development
P03395249A1044|160 167|neonates
P03395249A1044|170 177|ABSTRACT
P03395249A1044|192 196|WORDS
P03396437A0321|7 14|problems
P03396437A0321|27 42|resistant strains
P03396628A0207|9 25|observation period
P03396628A0207|34 38|weeks
P03396628A0207|40 56|cardiac white spots
P03396628A0207|62 75|right ventricle
P03396628A0207|78 87|BALB/c mice
P03396628A0207|112 116|weeks
P03396628A0207|123 126|mice
P03396628A0207|130 130|%
P03396628A0207|139 154|maximal incidence
P03396628A0207|157 173|cardiac white spots
P03396628A0207|191 195|weeks
P03396628A0207|203 206|mice
P03396628A0207|210 210|%
P03398433T0001|20 35|generalized forms
P03398433T0001|38 59|meningococcal infection
P03398714A0594|13 14|RH
P03398714A0594|23 23|%
P03398714A0594|34 42|solvation
P03398714A0594|48 60|peroxy radical
P03398714A0594|106 131|propagation transition state
P03398823A0459|3 9|effects
P03398823A0459|20 37|oral administration
P03398823A0459|43 55|mg/kg p-xylene
P03398823A0459|58 64|toluene
P03398823A0459|79 80|hr
P03398823A0459|105 112|p-xylene
P03398823A0459|131 133|min
P03400694A0245|0 7|PATIENTS
P03400694A0245|11 17|METHODS
P03400694A0245|19 52|Thallium-201 myocardial scintigraphy
P03400694A0245|83 110|mg/kg intravenous dipyridamole
P03400694A0245|121 127|minutes
P03400694A0245|132 139|patients
P03400694A0245|144 154|sarcoidosis
P03401060A0000|0 12|Thin melanomas
P03401060A0000|32 37|lethal
P03402183A0171|3 10|TA muscle
P03402183A0171|28 32|forms
P03402183A0171|43 63|isometric contractions
P03402183A0171|68 95|maximal voluntary contractions
P03402183A0171|97 99|MVC
P03402183A0171|105 107|MVC
P03402183A0171|112 122|circulation
P03402183A0171|153 164|contractions
P03402183A0171|171 202|Hz supramaximal voltage stimulation
P03402183A0171|227 238|contractions
P03402183A0171|243 253|circulation
P03403313A0298|3 28|actuarial local control rates
P03403313A0298|33 37|years
P03403313A0298|49 63|treatment groups
P03403313A0298|78 93|subtotal excision
P03403313A0298|102 102|%
P03403313A0298|104 119|subtotal excision
P03403313A0298|124 152|postoperative radiation therapy
P03403313A0298|156 156|%
P03403313A0298|161 173|total excision
P03403313A0298|182 182|%
P03403412A0000|3 9|effects
P03403412A0000|12 27|anabolic implants
P03403412A0000|49 67|energetic efficiency
P03403412A0000|98 105|fed diets
P03403412A0000|115 120|forage
P03403412A0000|124 135|grain content
P03403480A0299|0 18|Prolonged suspension
P03403480A0299|27 43|significant change
P03403480A0299|49 70|geometric configuration
P03403480A0299|76 92|femur middiaphysis
P03403480A0299|108 122|minimum diameter
P03403480A0299|126 126|%
P03403480A0299|138 159|significant alterations
P03403480A0299|162 173|cortical area
P03403480A0299|194 215|collagen concentrations
P03403480A0299|194 201|collagen
P03403826T0000|33 48|anatomic variable
P03403826T0000|67 88|functional measurements
P03403826T0000|91 106|stenosis severity
P03403826T0000|121 140|quantitative analysis
P03403826T0000|146 166|coronary cineangiogram
P03403826T0000|179 197|coronary flow reserve
P03403826T0000|201 247|exercise/redistribution thallium-201 scintigraphy
P03404334T0000|0 11|Water content
P03404334T0000|15 39|equilibrium water partition
P03404334T0000|42 58|immature cartilage
P03404495A0172|0 19|Thyroid function tests
P03404495A0172|38 47|admissions
P03404495A0172|59 66|untested
P03406054A0351|0 3|Data
P03406054A0351|9 26|line spread function
P03406054A0351|28 30|LSF
P03406054A0351|62 71|mm wide slit
P03406054A0351|79 86|tungsten
P03406054A0351|116 124|isocentre
P03406054A0351|135 152|polystyrene phantom
P03407676A0585|0 15|Primary infection
P03407843T0000|0 5|Papers
P03407843T0000|11 17|Society
P03407843T0000|21 43|Clinical Vascular Surgery
P03413681A0659|0 19|Ischemic heart disease
P03413681A0659|36 40|years
P03413681A0659|79 99|independent predictors
P03413681A0659|102 120|poor cardiac function
P03413890T0001|0 8|Prognosis
P03413890T0001|11 15|Bowen
P03413890T0001|39 55|ano-genital region
P03417104A0536|17 23|results
P03417104A0536|35 50|chlorphentermine
P03417104A0536|74 92|dual stimulus effects
P03417104A0536|95 101|animals
P03417588T0000|0 26|Liquid chromatographic method
P03417588T0000|45 57|citreoviridin
P03417668A1233|5 12|findings
P03417668A1233|25 43|autophosphorylation
P03417668A1233|46 51|Thr286
P03417668A1233|53 64|alpha subunit
P03417668A1233|69 74|Thr287
P03417668A1233|76 86|beta subunit
P03417668A1233|116 127|CaM-kinase II
P03417668A1233|133 135|Ca2
P03417668A1233|138 152|independent form
P03418727A0992|12 31|extensive penetration
P03418727A0992|59 70|chemotherapy
P03418727A0992|93 102|myelopathy
P03418727A0992|120 129|treatments
P03420266A0000|28 39|hyperthermia
P03420266A0000|69 104|Dunning R3327G prostatic adenocarcinoma
P03420266A0000|109 129|preeminent animal model
P03420266A0000|133 152|human prostatic cancer
P03420324A0178|0 11|Pregnant rats
P03420324A0178|48 48|%
P03420324A0178|53 54|N2
P03420324A0178|60 60|%
P03420324A0178|67 70|days
P03420324A0178|114 114|%
P03420324A0178|119 120|N2
P03420324A0178|126 126|%
P03420324A0178|134 147|h/day beginning
P03420324A0178|165 165|%
P03420324A0178|170 171|N2
P03420466A0000|3 11|incidence
P03420466A0000|14 30|cryptosporidiosis
P03420466A0000|33 45|young children
P03420466A0000|61 68|staining
P03420466A0000|71 85|faecal specimens
P03420466A0000|99 105|Kinyoun
P03421425A0878|5 12|patients
P03421425A0878|17 23|percent
P03421425A0878|28 47|latent hypothyroidism
P03421425A0878|64 85|hormonal determinations
P03423732A0341|0 7|Addition
P03423732A0341|10 19|sucralfate
P03423732A0341|22 27|De-Nol
P03423732A0341|38 47|increments
P03423732A0341|50 69|gastric HCO3 secretion
P03423732A0341|86 86|%
P03423732A0341|92 92|%
P03423732A0341|112 130|maximal HCO3 response
P03423732A0341|133 150|16,16-dimethyl PGE2
P03423732A0341|152 157|dmPGE2
P03427474A0853|15 25|control rats
P03427474A0853|34 40|animals
P03427474A0853|51 58|aversion
P03427474A0853|64 84|highest concentrations
P03427474A0853|87 104|saccharin solutions
P03427613A0659|19 35|specialized system
P03427613A0659|38 50|portal vessels
P03427613A0659|75 85|pineal organ
P03427613A0659|89 101|other portions
P03428084A0430|4 17|degrees stimuli
P03428084A0430|35 52|scalp distributions
P03428084A0430|59 77|pattern reversal P100
P03428084A0430|84 107|pattern onset C1 consistent
P03428084A0430|112 118|striate
P03428084A0430|122 154|extrastriate visual cortical origins
P03428274A0000|0 15|Nuclear factor III
P03428274A0000|0 12|Nuclear factor
P03428274A0000|17 21|NFIII
P03428274A0000|37 45|HeLa cells
P03428274A0000|63 72|initiation
P03428274A0000|75 89|adenovirus type 2
P03428274A0000|75 88|adenovirus type
P03428274A0000|91 93|Ad2
P03428274A0000|95 108|DNA replication
P03428274A0000|121 146|specific nucleotide sequence
P03428274A0000|159 166|adjacent
P03428274A0000|172 200|nuclear factor I recognition site
P03428274A0000|172 184|nuclear factor
P03428274A0000|186 200|recognition site
P03429306T0000|1 10|Golgi study
P03429306T0000|16 25|sixth layer
P03429306T0000|31 44|cerebral cortex
P03429371A1051|14 33|cephalothin clearance
P03429371A1051|49 62|site accessible
P03429371A1051|65 74|phagocytes
P03429371A1051|100 125|phagocyte-inaccessible site
P03430221A1236|3 10|findings
P03430221A1236|37 51|known properties
P03430221A1236|54 74|cortical-bar detectors
P03434347A0358|0 7|Mean rCBF
P03434347A0358|23 30|patients
P03434347A0358|34 38|weeks
P03434347A0358|56 70|ipsilateral side
P03436119A0000|0 29|Quantitative computed tomography
P03436119A0000|42 68|vertebral bone mineral content
P03436119A0000|75 89|high sensitivity
P03436119A0000|93 107|reproducibility
P03436529A1066|17 24|enhancer
P03436529A1066|56 98|complementary synthetic oligodeoxynucleotides
P03436529A1066|131 141|nt positions
P03436529A1066|167 174|template
P03436529A1066|189 196|enhancer
P03436877A0950|0 1|Kf
P03436877A0950|3 3|c
P03436877A0950|7 8|CT
P03436877A0950|25 39|initial lung mass
P03436877A0950|62 71|reductions
P03436877A0950|74 89|lung mass % delta Kf
P03436877A0950|91 92|c =
P03436877A0950|102 106|% mass
P03436877A0950|115 116|r =
P03436877A0950|122 126|P less
P03436877A0950|139 147|% delta CT =
P03436877A0950|158 162|% mass
P03436877A0950|171 172|r =
P03436877A0950|178 182|P less
P03436877A0950|192 204|relationships
P03436877A0950|225 243|blocker pretreatment
P03436877A0950|246 253|ABSTRACT
P03436877A0950|268 272|WORDS
P03439248A0000|3 22|scintigraphic methods
P03439248A0000|31 42|dipyridamole
P03439248A0000|46 91|exercise thallium-201 myocardial perfusion imaging
P03439248A0000|112 133|coronary artery stenosis
P03439248A0000|150 157|patients
P03439248A0000|171 191|coronary artery disease
P03440780A0779|9 15|results
P03440780A0779|34 37|EDLF
P03440780A0779|41 70|clear vasoconstrictor properties
P03440780A0779|87 96|adrenergic
P03440780A0779|99 120|calcium entry mechanisms
P03440780A0779|136 146|differences
P03440780A0779|152 173|vasoconstrictor effects
P03440780A0779|176 180|EDLFs
P03440780A0779|194 214|different vascular beds
P03441587A0000|0 7|Research
P03441587A0000|26 42|rheumatoid factors
P03441587A0000|48 52|serum
P03441587A0000|58 65|patients
P03441587A0000|68 72|means
P03441587A0000|78 82|tests
P03441587A0000|92 102|polystyrene
P03441587A0000|113 124|erythrocytes
P03441587A0000|132 138|results
P03443144A0409|1 26|low aspirin esterase activity
P03443144A0409|4 18|aspirin esterase
P03443144A0409|33 50|contributory factor
P03443144A0409|71 95|aspirin sensitive reactions
P03443566A0675|6 16|experiments
P03443566A0675|18 33|average daily gain
P03443566A0675|37 53|gain-to-feed ratio
P03443566A0675|68 69|TR
P03443566A0675|73 74|CR
P03443573A0329|0 19|Overall least-squares
P03443573A0329|28 35|uncooked
P03443573A0329|45 61|longissimus muscle
P03443573A0329|65 79|subcutaneous fat
P03443573A0329|103 104|mg
P03443573A0329|122 122|g
P03443609A0000|9 40|supercritical fluid chromatography
P03443609A0000|42 44|SFC
P03443609A0000|49 63|viable technique
P03443609A0000|76 95|agricultural products
P03443609A0000|120 125|packed
P03443609A0000|129 154|capillary column methodology
P03446332A0831|0 12|Nitrofurazone
P03446332A0831|42 43|LH
P03446332A0831|53 56|LHRH
P03448035T0000|0 12|Ovarian tumors
P03449358T0001|0 19|Ultrastructural study
P03449358T0001|22 34|polyarteritis
P03450438A0446|0 5|X2 test
P03450438A0446|11 25|Yates correction
P03451761A0215|6 18|baseline study
P03451761A0215|20 30|WPW syndrome
P03451761A0215|34 42|simulated
P03451761A0215|45 55|stimulation
P03451761A0215|63 76|different sites
P03451761A0215|95 104|ventricles
P03451761A0215|109 111|RNV
P03452920T0001|0 2|Man
P03457330A0271|3 10|patients
P03457330A0271|17 18|CA
P03457330A0271|22 26|assay
P03457330A0271|60 79|second-look operation
P03459385T0000|0 6|Allergy
P03459385T0000|10 17|Tourette
P03459736A0184|3 11|criterion
P03459736A0184|30 37|sessions
P03459736A0184|41 54|generalization
P03459736A0184|67 71|pills
P03459736A0184|75 82|capsules
P03463537T0001|0 13|Clinical method
P03463537T0001|31 35|Class
P03463537T0001|38 54|occlusal anomalies
P03463537T0001|59 66|open bite
P03463543A1613|0 7|Enoxacin
P03463543A1613|46 59|complicated UTI
P03465957A1008|0 18|Mean fluorosis scores
P03466730A0210|0 20|Autonomic dysfunctions
P03466730A0210|25 34|restricted
P03466730A0210|37 47|tonic pupils
P03473253A0000|2 47|industry-wide retrospective cohort mortality study
P03473253A0000|67 81|chemical workers
P03473253A0000|103 112|nonexposed
P03473253A0000|123 150|chloromethyl ether manufacture
P03473253A0000|154 171|major U.S. companies
P03473379A0183|14 24|amyloidosis
P03473379A0183|43 67|labial salivary gland biopsy
P03476002A0148|0 3|Hair
P03476002A0148|7 18|blood samples
P03476002A0148|34 41|vitamin C
P03476002A0148|44 65|placebo supplementation
P03476002A0148|81 96|monthly intervals
P03476002A0148|115 120|months
P03478354A0436|9 13|herds
P03478354A0436|15 22|cows more
P03478354A0436|29 39|d postpartum
P03478354A0436|45 56|corpus luteum
P03478354A0436|65 84|prostaglandin F2 alpha
P03479897A0961|5 13|other hand
P03479897A0961|28 35|angle ANB
P03479897A0961|38 44|smaller
P03479897A0961|71 86|skeletal relation
P03479897A0961|89 96|Class III
P03484075T0001|0 17|Emergency treatment
P03484075T0001|20 25|facial
P03484075T0001|29 56|maxillary/mandibular injuries
P03484894A0782|4 8|cases
P03484894A0782|10 17|isolates
P03484894A0782|47 53|biotype
P03484894A0782|65 71|biotype
P03484894A0782|90 97|biotypes
P03484894A0782|103 104|V.
P03485064A0135|11 23|EVS treatments
P03485064A0135|41 48|patients
P03486405A0341|0 3|Most
P03486405A0341|9 25|prepeptide portion
P03486405A0341|31 50|precursor polypeptide
P03486405A0341|74 78|exons
P03486405A0341|86 95|mature form
P03486405A0341|98 106|IL-1 alpha
P03486405A0341|135 139|exons
P03487348A0000|1 17|stochastic version
P03487348A0000|20 26|Kernell
P03487348A0000|49 80|cumulative afterhyperpolarization
P03487348A0000|82 84|AHP
P03487348A0000|89 97|simulated
P03488532A0235|3 23|previous interim report
P03488532A0235|35 50|prompt resolution
P03488532A0235|53 67|dermatomal signs
P03488532A0235|71 78|symptoms
P03488532A0235|83 100|acyclovir treatment
P03491190A0233|3 15|detectability
P03491190A0233|21 27|defects
P03491190A0233|30 32|RCA
P03491190A0233|35 43|LAD region
P03491190A0233|49 49|%
P03491190A0233|52 71|single-position scans
P03491190A0233|74 86|stress studies
P03493240T0000|0 22|Pharmacologic properties
P03493240T0000|25 42|serotonergic agents
P03493240T0000|46 64|antidepressant drugs
P03494649A0472|4 28|brief hypercapnic challenge
P03494649A0472|37 49|rapid increase
P03494649A0472|52 54|CBF
P03494649A0472|80 83|MABP
P03499608A1054|35 42|reagents
P03499608A1054|46 66|heterozygote detection
P03499608A1054|70 86|prenatal diagnosis
P03499608A1054|89 106|11 beta-hydroxylase
P03499608A1054|91 116|beta-hydroxylase deficiency
P03499608A1054|131 143|frequent cause
P03499608A1054|146 173|congenital adrenal hyperplasia
P03499657A0000|0 10|Osteocalcin
P03499657A0000|12 31|serum bone-Gla protein
P03499657A0000|33 36|sBGP
P03499657A0000|39 62|serum alkaline phosphatase
P03499657A0000|64 66|sAP
P03499657A0000|71 107|urinary hydroxyproline/creatinine ratio
P03499657A0000|109 127|uOH-Prol/creatinine
P03499657A0000|149 156|patients
P03499657A0000|161 186|primary hyperparathyroidism
P03499657A0000|188 191|PHPT
P03499657A0000|202 209|patients
P03499657A0000|214 227|hypercalcaemia
P03499657A0000|230 239|malignancy
P03499657A0000|241 242|HM
P03499822A0182|0 37|Multivariate logistic regression analysis
P03499822A0182|51 64|seropositivity
P03499822A0182|93 102|prevalence
P03499822A0182|105 114|hepatitis B
P03504971A0000|0 5|Hexsyn
P03504971A0000|11 22|Goodyear Tire
P03504971A0000|26 47|Rubber Company tradename
P03504971A0000|52 67|polyolefin rubber
P03504971A0000|83 90|1-hexene
P03504971A0000|98 113|% methylhexadiene
P03504971A0000|127 145|residual double bonds
P03504971A0000|149 161|vulcanization
P03507689A0000|0 37|Chimeric phage-plasmid expression vectors
P03507689A0000|57 72|pUC18/19 plasmids
P03507689A0000|83 100|single-stranded DNA
P03507689A0000|102 106|ssDNA
P03507689A0000|116 126|replication
P03507689A0000|131 145|bacteriophage f1
P03507689A0000|159 181|bacteriophage T7 promoter
P03507689A0000|191 212|beta-galactosidase gene
P03508698A0535|24 36|finger flexors
P03508698A0535|49 57|adductors
P03508698A0535|62 76|triceps reflexes
P03508698A0535|109 114|groups
P03510185A0187|0 4|Natl.
P03513989A0580|7 13|ethanol
P03513989A0580|17 24|estrogen
P03513989A0580|44 58|UROD-deficiency
P03513989A0580|44 47|UROD
P03513989A0580|61 67|animals
P03513989A1149|57 67|disturbance
P03513989A1149|70 88|porphyrin metabolism
P03513989A1149|91 103|many countries
P03513989A1149|129 147|unusual pathogenesis
P03513989A1149|161 178|hepatotoxic effects
P03513989A1149|185 199|etiologic agents
P03515840A0000|14 29|consecutive cases
P03515840A0000|34 48|initial symptoms
P03515840A0000|53 68|midline granuloma
P03515840A0000|86 107|malignant histiocytosis
P03515840A0000|109 126|histiocytic sarcoma
P03515840A0000|140 145|months
P03515840A0000|149 153|years
P03515840A0000|159 172|generalization
P03516189A0406|3 10|patients
P03516189A0406|23 35|suxamethonium
P03516189A0406|39 48|mg kg-1 i.v.
P03517388A0763|3 32|highest postoperative CK-MB level
P03517388A0763|23 27|CK-MB
P03517388A0763|45 46|BC
P03517388A0763|48 49|BC
P03517388A0763|58 60|U/L
P03517388A0763|62 63|CC
P03517388A0763|72 74|U/L
P03517388A0763|76 80|p less
P03520729A0381|2 16|relevant changes
P03520729A0381|19 27|heart rate
P03520729A0381|29 38|body weight
P03520729A0381|43 54|plasma levels
P03520729A0381|57 69|renin activity
P03520729A0381|57 61|renin
P03520729A0381|73 96|aldosterone concentration
P03522105A1011|0 31|High trough serum TOB concentrations
P03522105A1011|62 70|low levels
P03526279T0000|0 20|State-approved schools
P03526279T0000|23 33|nursing R.N.
P03528748A0414|3 16|maxicell system
P03528748A0414|31 56|approximate molecular weight
P03531317A0930|22 31|recessives
P03531317A0930|56 69|hypergeometric
P03531317A0930|77 89|binomial model
P03531317A0930|92 97|Fisher
P03534581A0976|3 11|incidence
P03534581A0976|14 37|second malignant neoplasms
P03534581A0976|50 50|%
P03534581A0976|73 86|5-fluorouracil
P03534581A0976|88 98|doxorubicin
P03534581A0976|103 118|cyclophosphamide
P03534581A0976|128 149|historical control group
P03534581A0976|154 154|%
P03536682A0572|0 8|Ovulation
P03536682A0572|27 27|%
P03536682A0572|29 36|patients
P03536864A0000|2 13|previous work
P03537686A0099|3 11|small size
P03537686A0099|29 45|mutagenesis marker
P03537686A0099|50 71|supF suppressor tRNA gene
P03537686A0099|101 106|vector
P03537686A0099|141 160|spontaneous mutations
P03537686A0099|182 193|transfection
P03537686A0099|196 209|mammalian cells
P03537686A0099|214 223|plasmid DNA
P03537686A0099|231 249|UV-induced mutations
P03537686A0099|278 298|spontaneous background
P03537711A0181|0 1|W.
P03537721A0491|0 13|Tetrad analysis
P03537721A0491|17 47|mitotic recombination experiments
P03537721A0491|60 75|PEP4 gene proximal
P03537721A0491|60 67|PEP4 gene
P03537721A0491|78 81|GAL4
P03537721A0491|84 96|chromosome XVI
P03537721A0876|10 21|observations
P03537721A0876|45 70|inactive precursor molecules
P03537721A0876|86 106|PEP4 gene self-activate
P03537721A0876|86 93|PEP4 gene
P03537721A0876|116 127|yeast vacuole
P03537721A0876|151 173|other vacuolar hydrolases
P03537721A0876|156 173|vacuolar hydrolases
P03537727A0243|3 6|poly
P03537727A0243|8 8|A
P03537727A0243|22 24|RNA
P03537727A0243|56 85|72,000-molecular-weight protein
P03540591A0330|20 22|RNA
P03540591A0330|47 51|cDNAs
P03540591A0330|64 76|P0 transcripts
P03540591A0330|95 121|novel 12.5-kilodalton protein
P03540591A0330|140 160|first open reading frame
P03540853A0652|3 29|N-terminal amino acid sequence
P03540853A0652|32 34|Mop
P03540853A0652|38 53|sequence homology
P03540853A0652|58 75|DNA binding proteins
P03541263A0368|0 19|Several new techniques
P03542945T0000|0 12|Ciprofloxacin
P03542945T0000|16 23|overview
P03542945T0000|26 43|adverse experiences
P03543485A0069|0 29|Possible pathogenetic mechanisms
P03543485A0069|32 49|hemopoietic changes
P03543485A0069|62 79|space flight effects
P03543936A0000|3 10|rho genes
P03543936A0000|54 72|significant homology
P03543936A0000|78 94|ras oncogene family
P03544858A0374|49 55|insulin
P03544858A0374|59 64|VO2 max
P03544858A0374|72 76|sexes
P03544858A0374|84 98|basal metabolism
P03544858A0374|102 116|HDL-cholesterol
P03544858A0374|120 126|females
P03544858A0374|130 134|males
P03545955A0751|3 14|glucose areas
P03545955A0751|27 35|ingestion
P03545955A0751|41 45|foods
P03545955A0751|51 55|Study
P03545955A0751|58 64|glucose
P03545955A0751|70 80|orange juice
P03545955A0751|85 91|sucrose
P03545955A0751|96 102|glucose
P03545955A0751|104 111|fructose
P03545955A0751|119 126|fructose
P03545955A0751|130 137|mmol X h/l
P03545955A0751|139 143|Study
P03545955A0751|146 152|glucose
P03545955A0751|158 168|orange juice
P03545955A0751|173 178|apples
P03545955A0751|186 195|apple juice
P03545955A0751|199 206|mmol X h/l
P03545955A0751|208 212|Study
P03545955A0751|215 221|glucose
P03545955A0751|227 234|ice cream
P03545955A0751|250 256|lactose
P03545955A0751|260 267|mmol X h/l
P03545955A1378|3 22|serum insulin response
P03545955A1378|8 14|insulin
P03549045A0878|0 2|SCL
P03549045A0878|25 33|verapamil
P03549045A0878|38 48|sinus arrest
P03549045A0878|91 97|animals
P03550444T0000|0 10|Development
P03550444T0000|14 24|yeast system
P03550444T0000|27 52|assay mutational specificity
P03552363A0568|0 28|Postglucose serum insulin levels
P03552363A0568|11 22|serum insulin
P03552363A0568|37 59|significant correlations
P03552363A0568|64 71|systolic
P03552363A0568|74 101|diastolic blood pressure levels
P03552363A0568|104 106|men
P03552363A0568|113 126|female diabetic
P03552363A0568|130 172|non-diabetic subjects significant correlations
P03552363A0568|198 223|systolic blood pressure level
P03553149A0299|6 40|oligonucleotide-directed mutagenesis
P03553149A0299|55 68|MucA homologous
P03553149A0299|55 58|MucA
P03553149A0299|74 92|Ala-Gly cleavage site
P03553149A0299|95 98|LexA
P03553439A0404|32 53|Type I-solid tumor tissue
P03553439A0404|61 81|significant peripheral
P03553439A0404|90 99|tumor cells
P03553439A0404|101 123|Type II-solid tumor tissue
P03553439A0404|138 147|peripheral
P03553439A0404|156 165|tumor cells
P03553439A0404|167 192|Type III-isolated tumor cells
P03555318T0000|3 14|pharmacology
P03555318T0000|17 25|carnitine
P03556834T0000|0 22|Acute inhalation toxicity
P03556834T0000|25 36|T-2 mycotoxin
P03556834T0000|39 42|mice
P03559193A0000|3 22|present investigation
P03559193A0000|42 60|principal dimensions
P03559193A0000|66 79|Framingham Type
P03559193A0000|87 90|FTAS
P03559193A0000|113 125|physiological
P03559193A0000|129 151|psychological correlates
P03559232T0000|1 16|preliminary study
P03559232T0000|19 35|pyogenic arthritis
P03559287T0000|0 9|Legionella
P03559287T0000|11 26|microbial ecology
P03559287T0000|31 54|inconspicuous consumption
P03561036T0000|0 9|Lymphatics
P03561036T0000|15 19|aorta
P03561036T0000|22 25|rats
P03561036T0000|38 55|soy-bean oil extract
P03561036T0000|57 66|lipofundin
P03561622A0659|3 12|last resort
P03561622A0659|49 56|dialysis
P03561622A0659|59 74|reasonable health
P03561622A0659|80 103|DiaTAP button graft complex
P03561622A0659|144 176|intermittent positive blood cultures
P03561622A0659|182 206|long term vancomycin therapy
P03563399A0534|3 21|signal durations less
P03563399A0534|28 29|ms
P03563399A0534|42 45|SoNo
P03563399A0534|49 62|S pi No threshold
P03563399A0534|87 109|masking-level difference
P03563604A1075|3 12|spleen rate
P03563604A1075|23 31|villagers
P03563604A1075|34 35|RK
P03563604A1075|52 52|%
P03563604A1075|59 70|parasite rate
P03563604A1075|75 75|%
P03563604A1075|85 100|drug intervention
P03567017A0000|0 13|Multiple dosing
P03567017A0000|18 22|times
P03567017A0000|32 35|days
P03567017A0000|38 47|indoprofen
P03567017A0000|51 52|mg
P03567017A0000|55 88|non-steroidal anti-inflammatory drug
P03567017A0000|94 107|short half-life
P03567017A0000|109 112|t1/2
P03567017A0000|123 138|drug accumulation
P03567017A0000|146 160|elderly subjects
P03568311A0273|4 11|patients
P03568311A0273|16 39|subacute cardiac tamponade
P03568311A0273|41 62|pulmonary wedge pressure
P03568311A0273|64 66|PWP
P03568311A0273|69 71|RAP
P03568311A0273|76 78|IPP
P03568311A0273|100 106|indexes
P03568311A0273|109 124|systolic function
P03568311A1361|12 20|tamponade
P03568311A1361|24 45|pericardiocentesis data
P03568311A1361|51 76|ventricular stroke work index
P03568311A1361|83 101|positive correlation
P03568311A1361|106 110|TMFP1
P03568311A1361|112 113|r =
P03568311A1361|121 125|TMFP2
P03568311A1361|127 128|r =
P03568311A1361|143 147|TMFP3
P03570455A0433|0 6|Rabbits
P03570455A0433|16 35|profound hypocalcemia
P03570455A0433|41 46|levels
P03570455A0433|79 83|mg/dl
P03570455A0433|103 108|TSST-1
P03571135T0000|13 28|prosodic features
P03571135T0000|42 49|autistic
P03571135T0000|59 66|retarded
P03571135T0000|71 84|normal children
P03572706A0329|10 33|actuarial interpretations
P03572706A0329|40 54|second protocols
P03572706A0329|86 95|therapists
P03572706A0329|98 106|more valid
P03572706A0329|120 137|treatment condition
P03572706A0329|141 149|elevation
P03572706A0329|155 155|F
P03572706A0329|159 168|F-K indices
P03572706A0329|159 159|F
P03572706A0329|174 189|first MMPI profile
P03575656A0120|0 2|Due
P03575656A0120|18 36|soluble chemical form
P03575656A0120|38 41|90Sr
P03575656A0120|84 101|substantial portion
P03575656A0120|117 126|long period
P03577670A0102|28 34|atrophy
P03577670A0102|38 77|diffuse symmetric white matter hypodensities
P03577670A0236|14 40|metachromatic leukodystrophy
P03577670A0236|42 44|MLD
P03577670A0236|72 88|low arylsulfatase A
P03577670A0236|75 88|arylsulfatase A
P03577670A0236|90 92|ASA
P03577670A0236|94 99|levels
P03577670A0236|110 120|fibroblasts
P03577670A0236|127 133|sisters
P03578948A0448|0 20|Artificial ventilation
P03578948A0448|39 49|tidal volume
P03578948A0448|54 60|ml X kg-1
P03578948A0448|77 83|c X min-1
P03581160A0583|13 36|lower heart rate reactivity
P03581160A0583|57 107|pronounced left temporal artery pulse amplitude responses
P03581160A0583|119 141|non-medicated TH subjects
P03581160A0583|148 155|controls
P03582149T0001|2 22|epidemiological survey
P03582149T0001|25 45|rheumatic valve disease
P03582149T0001|49 62|rheumatic fever
P03582149T0001|75 97|secondary school students
P03582149T0001|100 114|Jiangxi Province
P03582184A0448|0 4|Drugs
P03582184A0448|33 41|reactions
P03582184A0448|61 76|dosage adjustment
P03582982A0000|8 17|human genes
P03582982A0000|27 43|U4 small nuclear RNA
P03583001A0111|8 27|balloon-gas procedure
P03583001A0111|33 50|single gas injection
P03583001A0111|116 128|prior drainage
P03583001A0111|131 145|subretinal fluid
P03583001A0111|148 157|vitrectomy
P03584426A0706|0 26|Heat-labile-like enterotoxin
P03584426A0706|28 29|LT
P03584426A0706|50 62|stool isolates
P03584426A0706|66 66|%
P03584426A0706|86 93|isolates
P03584426A0706|96 96|%
P03584426A0706|106 128|enterotoxinlike activity
P03584426A0706|131 142|suckling mice
P03584426A0706|146 146|%
P03584426A0706|152 177|cytotoxin-producing strains
P03584426A0706|192 206|LT-like material
P03586925T0001|0 10|Development
P03586925T0001|14 63|provisional information-retrieval descriptor language
P03586925T0001|68 99|Roentgenology and Medical Radiology
P03586925T0001|112 126|Medinform system
P03590911T0001|0 31|Persistent acantholytic dermatosis
P03590911T0001|45 60|light sensitivity
P03591464A0840a|6 17|negative test
P03591464A0840a|20 29|compatible
P03591464A0840a|34 51|low disease activity
P03591464A0840a|58 65|efficacy
P03591464A0840a|68 93|calcium antagonist treatment
P03591464A0840b|6 17|negative test
P03591464A0840b|20 29|compatible
P03591464A0840b|34 51|low disease activity
P03591464A0840b|58 65|efficacy
P03591464A0840b|68 93|calcium antagonist treatment
P03592297A0138|0 14|Dorsal foot TcpO2
P03592297A0138|33 56|oxygen-sensing electrodes
P03592297A0138|61 79|surface temperatures
P03592297A0138|84 91|degrees C
P03592297A0138|97 104|degrees C
P03592297A0138|115 121|changes
P03592297A0138|124 142|sympathetic activity
P03592297A0138|155 167|vasomotor tone
P03592297A0138|171 175|TcpO2
P03592297A0138|191 199|electrode
P03592297A0138|204 211|degrees C
P03592297A0138|213 234|submaximal vasodilation
P03592297A0138|247 254|degrees C
P03592297A0138|256 274|maximal vasodilation
P03592297A0679|2 9|subjects
P03592297A0679|11 12|n =
P03592297A0679|19 30|quadriplegia
P03592297A0679|41 64|sympathetic tone secondary
P03592297A0679|67 84|cervical cord trauma
P03592297A0679|86 90|TcpO2
P03592297A0679|95 102|degrees C
P03592297A0679|106 122|vasodilation index
P03592297A0679|141 144|mmHg
P03592297A0679|154 158|TcpO2
P03592297A0679|163 170|degrees C
P03595418A0688|3 21|nucleotide sequences
P03595418A0688|35 67|murine ornithine decarboxylase mRNAs
P03595418A0688|77 85|% homology
P03595418A0688|101 116|noncoding regions
P03597218A0901|3 24|absolute concentrations
P03597218A0901|27 49|alpha 2-plasmin inhibitor
P03597218A0901|27 40|alpha 2-plasmin
P03597218A0901|51 70|alpha 2-macroglobulin
P03597218A0901|75 89|antithrombin III
P03597218A0901|75 86|antithrombin
P03597218A0901|115 119|P less
P03597218A0901|138 151|concentrations
P03597218A0901|168 178|acute shifts
P03597218A0901|181 191|plasma water
P03597218A0901|225 234|inhibitors
P03597218A0901|256 260|P less
P03597269A0409|3 12|other model
P03597269A0409|17 37|continuous exponential
P03597269A0409|55 60|form La
P03597269A0409|62 62|=
P03597269A0409|65 65|b
P03597269A0409|67 69|exp
P03597269A0409|71 74|cVO2
P03600633A1069|0 3|Cell
P03600705T0000|0 5|Timing
P03600705T0000|8 15|symptoms
P03600705T0000|19 33|oocyst excretion
P03600705T0000|36 57|human cryptosporidiosis
P03601275A0601|5 20|dopamine infusion
P03601275A0601|23 27|women
P03601275A0601|32 54|polycystic ovary syndrome
P03601275A0601|67 74|controls
P03601275A0601|76 92|steady state levels
P03601275A0601|95 108|plasma dopamine
P03601275A0601|110 123|norepinephrine
P03601275A0601|138 160|dopamine/norepinephrine
P03601275A0601|180 185|groups
P03601533T0001|0 19|Diagnostic importance
P03601533T0001|36 57|complement constituents
P03601533T0001|60 67|children
P03601533T0001|72 92|autoimmune thyroiditis
P03602261A0238|12 16|basal
P03602261A0238|18 29|unstimulated
P03602261A0238|51 73|significant correlations
P03602261A0238|75 82|p greater
P03602261A0238|102 122|systolic blood pressure
P03602261A0238|126 133|dopamine
P03602261A0238|135 136|r =
P03602261A0238|143 156|norepinephrine
P03602261A0238|158 159|r =
P03602261A0238|168 178|epinephrine
P03602261A0238|180 181|r =
P03602261A0238|200 222|significant correlations
P03602261A0238|230 238|melatonin
P03602261A0238|242 249|dopamine
P03602261A0238|251 252|r =
P03602261A0238|260 273|norepinephrine
P03602261A0238|275 276|r =
P03602261A0238|286 298|growth hormone
P03602261A0238|300 301|r =
P03605895A0888|4 11|patients
P03605895A0888|16 38|carboxyhemoglobin levels
P03605895A0888|16 32|carboxyhemoglobin
P03605895A0888|41 46|excess
P03605895A0888|51 51|%
P03605895A0888|64 92|occult carbon monoxide poisoning
P03607109A0370|8 16|processes
P03607109A0370|44 52|last month
P03607109A0370|76 86|same picture
P03607109A0370|92 99|controls
P03607961T0001|0 17|Hypoglycemic action
P03607961T0001|28 39|zhuang qi gong
P03607961T0001|58 73|diabetes mellitus
P03608916A0790|2 6|cases
P03608916A0790|10 19|degrees HPT
P03608916A0790|24 29|plasma
P03608916A0790|36 37|OH
P03608916A0790|39 45|2D level
P03608916A0790|68 72|cases
P03608916A0790|74 78|P less
P03608989A0668|14 23|amino acids
P03608989A0668|39 68|coiled-coil interactions similar
P03608989A0668|93 109|filament formation
P03608989A0668|115 123|rod region
P03610663A0201|22 28|sources
P03610663A0201|54 72|nutrient utilization
P03610663A0201|111 119|precision
P03610663A0201|134 153|different nutritional
P03610663A0201|157 171|metabolic states
P03610674T0000|11 31|dietary zinc deficiency
P03610674T0000|37 57|mossy fiber zinc content
P03610674T0000|63 76|rat hippocampus
P03612316A0102|6 9|rats
P03612316A0102|18 27|normal diet
P03612316A0102|31 41|low-protein
P03612316A0102|43 56|low-energy diet
P03612316A0102|73 78|saline
P03612316A0102|81 89|thyroxine
P03612316A0102|106 108|g BW
P03612316A0102|115 118|days
P03612648A0085|22 39|lupus anticoagulant
P03612648A0085|61 85|partial thromboplastin time
P03612648A0085|68 81|thromboplastin
P03612648A0085|93 100|antibody
P03612648A0085|103 113|cardiolipin
P03615550A0000|3 9|effects
P03615550A0000|12 32|several opioid agonists
P03615550A0000|39 62|opioid antagonist naloxone
P03615550A0000|77 80|rats
P03615550A0000|97 120|fixed-consecutive-number
P03615550A0000|122 124|FCN
P03615550A1094|3 24|rate-decreasing effects
P03615550A1094|27 34|morphine
P03615550A1094|38 43|U50488
P03615550A1094|79 87|mg/kg dose
P03615550A1094|90 97|naloxone
P03615763A0170|0 3|Data
P03615763A0170|11 13|men
P03615763A0170|19 23|women
P03615763A0170|34 52|coronary angiography
P03615763A0170|87 98|associations
P03615763A0170|121 137|continuous measure
P03615763A0170|140 154|atherosclerosis
P03615763A0170|189 200|hypertension
P03615763A0170|202 217|serum cholesterol
P03615763A0170|219 225|smoking
P03615763A0170|227 232|angina
P03615763A0170|243 255|family history
P03615763A0170|258 269|heart disease
P03615763A0170|271 290|Type A behavior pattern
P03615763A0170|295 303|hostility
P03616174A1069|2 17|intralobar change
P03616174A1069|45 52|degrees C
P03616174A1069|69 91|lobar bronchial blood flow
P03616174A1069|111 119|blood flow
P03616174A1069|122 139|other nearby tissues
P03616174A1069|171 190|bronchial circulation
P03616237T0001|0 26|Convulsive status epilepticus
P03616237T0001|32 39|infusion
P03616237T0001|42 50|cisplatin
P03618039A0126|13 24|such patients
P03618039A0126|27 36|antibodies
P03618039A0126|39 48|adrenaline
P03618039A0126|52 64|noradrenaline
P03618039A0126|67 76|indicative
P03618039A0126|79 100|considerable disruption
P03618039A0126|103 132|catecholamine biotransformation
P03619249A0428|12 18|markers
P03619249A0428|37 41|serum
P03619249A0428|60 67|patients
P03619249A0428|72 87|chronic hepatitis
P03619249A0428|89 91|HBV
P03619249A0428|93 97|HBs Ag
P03619249A0428|101 105|HBe Ag
P03619249A0428|107 114|anti-HBs
P03619249A0428|116 123|anti-HBe
P03619249A0428|127 134|anti-HBc
P03619249A0428|140 148|serum, HBs
P03619249A0428|140 144|serum
P03619249A0428|146 148|HBs
P03619249A0428|152 156|HBc Ag
P03619249A0428|169 178|non-A non-B
P03619249A0428|180 184|non-A
P03619249A0428|186 192|non-B Ag
P03619249A0428|196 203|antibody
P03619249A0428|205 219|anti non-A non-Bc
P03619249A0428|225 229|serum
P03619249A0428|231 235|non-A
P03619249A0428|237 244|non-Bc Ag
P03622423A0000|0 5|Groups
P03622423A0000|15 27|female Fischer
P03622423A0000|31 34|rats
P03622423A0000|36 45|B6C3F1 mice
P03622423A0000|50 66|Hartley guinea pigs
P03622423A0000|86 87|hr
P03622423A0000|94 107|concentrations
P03622423A0000|139 141|ppm
P03622423A0000|144 159|methyl isocyanate
P03622423A0000|161 163|MIC
P03622423A0000|165 169|vapor
P03622571A0208|0 16|Radionuclide study
P03622571A0208|20 39|endomyocardial biopsy
P03622571A0208|48 69|remarkable degeneration
P03622571A0208|72 81|myocardium
P03625688A0372|0 13|Immobilization
P03625688A0372|19 26|fracture
P03625688A0372|39 47|cuff sling
P03625688A0372|64 83|more elaborate methods
P03625762A0308|0 9|Comparison
P03625762A0308|12 19|patients
P03625762A0308|29 37|phenytoin
P03625762A0308|75 84|lower serum
P03625762A0308|96 104|sub-group
P03625762A0308|114 122|phenytoin
P03625762A0308|137 157|significant difference
P03625762A0308|168 177|sub-groups
P03625762A0308|191 200|vitamin B12
P03625762A0308|203 224|behaviour problem rating
P03626129T0001|0 6|Effects
P03626129T0001|10 28|low-energy laser beam
P03626129T0001|34 38|cells
P03626129T0001|44 53|newt embryo
P03627720A0196|0 6|Typical
P03627720A0196|10 33|atypical clinical features
P03627720A0196|40 54|lacrimal sac cyst
P03628532A0000|9 14|saliva
P03628532A0000|17 35|sour taste perception
P03628532A0000|63 73|experiments
P03628596A0000|0 6|Samples
P03628596A0000|15 34|neurological patients
P03628596A0000|53 67|diagnostic value
P03628596A0000|70 92|acid alpha 1-glycoprotein
P03628596A0000|98 121|lumbar cerebrospinal fluid
P03628713A0961|0 18|Separate experiments
P03628713A0961|27 29|AIB
P03628713A0961|33 44|86RbCl uptake
P03628713A0961|47 57|36B-10 cells
P03628713A0961|70 73|days
P03628713A0961|85 97|Gy irradiation
P03628713A0961|117 129|radiation dose
P03628713A0961|150 159|tumor cells
P03628713A0961|162 168|trap AIB
P03628713A0961|171 172|Rb
P03628794A0648|3 10|patients
P03628794A0648|15 23|recurrent
P03628794A0648|26 42|metastatic disease
P03628794A0648|62 82|I-131 MIBG scintigraphy
P03629973A0240|0 1|W.
P03629974A1468|0 9|Comparison
P03629974A1468|15 31|amino acid sequence
P03629974A1468|37 63|M RNA product of Uukuniemi virus
P03629974A1468|37 47|M RNA product
P03629974A1468|50 63|Uukuniemi virus
P03629974A1468|74 82|Punta Toro
P03629974A1468|86 107|Rift Valley fever viruses
P03629974A1468|120 124|cases
P03629974A1468|126 137|weak homology
P03629974A1468|149 158|pronounced
P03629974A1468|165 179|proteins located
P03629974A1468|185 200|COOH-terminal end
P03629974A1468|206 214|precursor
P03632739T0000|0 20|Cyclosporine treatment
P03632739T0000|24 46|intractable polymyositis
P03635597A0377|16 21|Cohler
P03635597A0377|24 36|maternal scale
P03635597A0377|38 50|Korean mothers
P03635597A0377|71 77|infants
P03635597A0377|80 90|more passive
P03635597A0377|107 121|American mothers
P03635597A0377|126 130|P less
P03637037T0000|1 27|preoperative teaching booklet
P03637037T0000|31 47|pediatric patients
P03645733T0001|0 14|Hyperthyroidism
P03649340A1119|17 39|mono-intronic precursors
P03649340A1119|69 79|splice sites
P03649340A1119|90 102|exon sequences
P03649340A1119|137 151|splicing process
P03651330T0000|0 28|UVA-induced melanocytic lesions
P03651840A0266|6 22|MAO inhibition data
P03651840A0266|32 37|DPGPEA
P03651840A0266|44 52|inhibitor
P03651840A0266|55 59|MAO-B
P03651840A0266|81 90|much weaker
P03651840A0266|103 117|tranylcypromine
P03651840A0266|120 128|pargyline
P03652083A0720|21 38|vessel pyridinoline
P03652083A0720|68 76|crosslink
P03652083A0720|79 86|collagen
P03653226A0833|9 45|radiolabelled tissue-distribution study
P03653226A0833|71 94|complicated metabolic fate
P03653226A0833|97 107|perhexiline
P03658866A0081|0 25|Systemic lupus erythematosus
P03659603A0797|16 24|amplitude
P03659603A0797|30 38|responses
P03659603A0797|50 52|CO2
P03659603A0797|78 91|CO2 sensitivity
P03659805A0404|3 25|statistical significance
P03659805A0404|31 46|prognosis factors
P03659805A0404|59 61|uni
P03659805A0404|66 86|multivariative methods
P03659805A0404|109 111|Cox
P03659805A0404|128 138|IMB computer
P03659994A0150|5 11|changes
P03659994A0150|23 31|injection
P03659994A0150|42 57|focal abnormality
P03659994A0150|74 87|slight increase
P03659994A0150|90 104|signal intensity
P03659994A0150|107 122|T1 weighted images
P03659994A0150|143 157|signal intensity
P03659994A0150|160 175|T2 weighted images
P03663789A0568|5 11|results
P03663789A0568|23 50|less antidopaminergic activity
P03663789A0568|53 56|RHAL
P03663789A0568|63 77|neuroleptic test
P03663789A0568|99 114|lesser conversion
P03663789A0568|117 120|RHAL
P03663789A0568|123 125|HAL
P03664038A0000|44 55|parallel form
P03664038A0000|61 89|Gudjonsson Suggestibility Scale
P03664038A0000|91 93|GSS
P03664038A0000|95 98|Form
P03664038A0000|112 135|test-retest reliabilities
P03664038A0000|138 164|interrogative suggestibility
P03666957A0219|0 8|Organisms
P03666957A0219|29 39|conjunctiva
P03666957A0219|43 54|several weeks
P03666957A0219|59 75|persistent genital
P03666957A0219|79 103|gastrointestinal infection
P03666957A0219|123 137|ocular infection
P03666957A0219|144 147|cats
P03668003T0000|21 30|microscopy
P03668003T0000|33 52|pigmented skin lesions
P03668396A0171|5 24|equilibrium solutions
P03668396A0171|51 58|vertices
P03668396A0171|62 87|particular convex polyhedron
P03668736A0177|3 19|average deviations
P03668736A0177|25 35|X-ray counts
P03668736A0177|41 56|constant elements
P03668736A0177|113 127|variable element
P03672532A1111|13 30|significant effects
P03672532A1111|42 46|doses
P03673640A0533|0 13|Low MAO subjects
P03673640A0533|30 41|higher scores
P03673640A0533|44 59|KSP Impulsiveness
P03673640A0533|61 74|EPQ Neuroticism
P03673640A0533|79 95|KSP Somatic Anxiety
P03673640A0533|99 110|Irritability
P03673640A0533|114 124|lower scores
P03673640A0533|127 142|KSP Socialization
P03673640A0533|154 172|personality profiles
P03673640A0533|180 189|alcoholics
P03673640A0533|191 201|psychopaths
P03673640A0533|206 222|suicide attempters
P03673640A0533|240 261|low platelet MAO activity
P03673881A0000|13 28|relative accuracy
P03673881A0000|31 44|continuous wave
P03673881A0000|46 47|CW
P03673881A0000|52 79|high pulse repetition frequency
P03673881A0000|81 84|HPRF
P03673881A0000|86 92|Doppler
P03673881A0000|106 141|aortic transvalvular pressure gradients
P03673881A0000|143 161|Doppler examinations
P03673881A0000|170 176|devices
P03673881A0000|193 211|consecutive patients
P03673881A0000|216 233|aortic valve disease
P03676054A0865|9 11|Paw
P03676054A0865|13 18|delta V
P03676054A0865|20 23|PaO2
P03676054A0865|25 28|Vinj
P03676054A0865|32 33|VT
P03676054A0865|83 83|E
P03676054A0865|113 128|internal diameter
P03676054A0865|134 148|injector cannula
P03676174A0730|2 7|calves
P03676174A0730|17 36|milk-substitute diets
P03676174A0730|53 58|g DM/kg
P03676174A0730|60 70|milk intakes
P03676174A0730|90 90|%
P03676174A0730|96 101|1st day
P03676174A0730|106 111|calves
P03678269A0633|0 4|Today
P03678269A0633|31 53|plasma cholesterol levels
P03678269A0633|76 94|dietary modification
P03678269A0633|101 114|early childhood
P03678269A0633|138 142|years
P03678372A0170|11 22|fecal pellets
P03678372A0170|43 50|weeks old
P03678372A0170|54 64|pellets/day
P03678372A0170|102 108|pellets
P03678372A0170|113 120|weeks old
P03678372A0170|125 131|pellets
P03678372A0170|137 144|weeks old
P03679407A0556|5 11|results
P03679407A0556|23 40|N-nitroso compounds
P03679407A0556|63 77|infected bladder
P03679407A0556|117 139|urinary-tract infections
P03679407A0556|159 171|bladder cancer
P03679756A0830|0 26|Epithelial nerve fiber defects
P03679756A0830|44 64|distorted architecture
P03679756A0830|70 90|basal epithelial plexus
P03679756A0830|94 118|intra-epithelial terminals
P03680791A0230|3 17|histologic grade
P03680791A0230|24 39|same anatomic site
P03680791A0230|51 56|hearts
P03680791A0230|65 86|different anatomic sites
P03680791A0230|92 100|same heart
P03682805A0375|0 10|Serum levels
P03682805A0375|13 19|albumin
P03682805A0375|21 28|globulin
P03682805A0375|33 58|coagulation protein activity
P03682805A0375|33 50|coagulation protein
P03682805A0375|71 78|preshock
P03682805A0375|80 88|postshock
P03682805A0375|102 105|days
P03682805A0375|107 121|skin lymph levels
P03682805A0375|136 138|Day
P03684378A0653|3 15|colostral milk
P03684378A0653|25 46|significant correlation
P03684378A0653|49 57|vitamin K1
P03684378A0653|72 73|r =
P03684378A0653|87 96|total lipid
P03684378A0653|99 110|phospholipid
P03684378A0653|145 153|secretion
P03684378A0653|156 164|vitamin K1
P03684378A0653|169 181|colostral milk
P03684517A0462|0 16|Endurance training
P03684517A0462|39 47|stiffness
P03684517A0462|79 84|fibers
P03685073A0200|1 19|rate-decreasing dose
P03685073A0200|22 34|physostigmine
P03685073A0200|38 66|acetylcholinesterase inhibitor
P03685073A0200|38 57|acetylcholinesterase
P03685073A0200|105 117|atropine doses
P03687078T0001|0 9|References
P03687078T0001|13 31|occupational fitness
P03687078T0001|34 44|adolescents
P03687078T0001|49 56|diseases
P03687078T0001|62 77|respiratory tract
P03687078T0001|81 85|lungs
P03687148T0187|0 7|Salzburg
P03687148T0187|13 21|September
P03687313A0000|3 26|new glucosidase inhibitors
P03687313A0000|6 16|glucosidase
P03687313A0000|28 31|BAY m
P03687313A0000|39 42|BAY o
P03687313A0000|61 70|volunteers
P03687313A0000|80 88|diabetics
P03687313A0000|94 110|various conditions
P03688202A0377|3 8|models
P03688202A0377|31 46|common boundaries
P03688202A0377|57 59|PBB
P03688202A0377|63 64|CN
P03688301A0129|13 17|cases
P03688301A0129|24 36|mucosal spread
P03688301A0129|44 58|stromal invasion
P03688301A0129|60 64|type A
P03688301A0129|83 87|cases
P03688301A0129|98 112|direct extension
P03688301A0129|114 118|type B
P03688301A0129|124 148|muscle-invasive carcinomas
P03688301A0129|154 160|bladder
P03688676A0487|8 18|conversions
P03688676A0487|23 24|mm
P03688676A0487|46 59|negative result
P03690262A0428|3 18|maximum amplitude
P03690262A0428|27 35|responses
P03690262A0428|41 64|cervical sympathetic trunk
P03690262A0428|83 94|T2 white ramus
P03690262A0428|146 156|stimulation
P03690262A0428|159 160|T1
P03690262A0428|162 163|T3
P03690262A0428|165 166|T4
P03690262A0428|170 180|T5 white rami
P03691316A0560|17 30|contact allergy
P03691316A0560|33 36|K-CG
P03692331A0000|12 38|beta-adrenoceptor antagonist
P03692331A0000|12 28|beta-adrenoceptor
P03692331A0000|40 47|pindolol
P03692331A0000|51 69|uterine smooth muscle
P03692331A0000|72 88|term pregnant women
P03692331A0000|118 134|hypertensive women
P03693543A0405|3 52|less-polar mycolic acid-containing Rhodococcus species
P03693543A0405|59 81|chromatographic patterns
P03693543A0405|108 119|elution times
P03693543A0405|124 131|patterns
P03693543A0405|134 151|Nocardia asteroides
P03693543A0405|153 170|N. otitidiscaviarum
P03693543A0405|175 188|N. brasiliensis
P03693543A0405|196 207|larger number
P03693543A0405|210 214|peaks
P03693543A0405|220 230|last species
P03693543A0405|255 268|genera possible
P03694102A0000|17 24|data base
P03694102A0000|52 66|common reference
P03694102A0000|70 88|ECG computer programs
P03694102A0000|126 130|leads
P03696899T0001|0 28|Blood serum erythropoietin level
P03696899T0001|10 23|erythropoietin
P03696899T0001|32 56|basic hematological indices
P03696899T0001|66 75|adaptation
P03696899T0001|78 98|healthy newborn infants
P03697587T0000|3 24|XXXXY chromosome anomaly
P03697587T0000|28 41|unusual variant
P03697587T0000|44 54|Klinefelter
P03697798T0001|0 10|Contraction
P03697798T0001|16 29|tracheal muscle
P03697798T0001|46 61|stretch receptors
P03697798T0001|67 73|trachea
P03697971A0311|3 15|selenium level
P03697971A0311|19 47|glutathione peroxidase activity
P03697971A0311|19 39|glutathione peroxidase
P03697971A0311|68 80|stomach mucosa
P03697971A0311|98 103|higher
P03697971A0311|109 130|high-selenium diet group
P03697971A0311|140 160|low-selenium diet group
P03698251T0000|0 13|Oxygen delivery
P03698251T0000|31 33|P50
P03698251T0000|36 43|patients
P03698251T0000|48 72|acute myocardial infarction
P03700952A0273|0 6|Infants
P03700952A0273|22 53|monocular PL visual acuities similar
P03700952A0273|74 81|McDonald
P03700952A0273|90 106|laboratory setting
P03701640A1178|5 11|results
P03701640A1178|38 44|isomers
P03701640A1178|47 59|pentobarbital
P03701640A1178|63 74|secobarbital
P03701640A1178|77 89|mult FR30 FI600
P03701640A1178|150 157|ABSTRACT
P03701640A1178|172 176|WORDS
P03703493A0654|11 29|crystalline deposits
P03703493A0654|41 61|advanced atrophic areas
P03703493A0654|67 93|RPE-choriocapillaris complex
P03704087A0394|5 12|subjects
P03704087A0394|22 44|psychometric instruments
P03704087A0394|57 73|various components
P03704087A0394|92 102|Spielberger
P03704087A0394|105 135|State-Trait Personality Inventory
P03704087A0394|140 159|Anger Expression Scale
P03704087A0394|167 189|State Anger Reaction Scale
P03709191A0125|17 35|primary visual cortex
P03709191A0125|46 57|asymmetrical
P03709191A0125|77 85|asymmetry
P03709191A0125|94 108|side differences
P03709191A0125|122 128|neurons
P03709627A0247|3 10|subjects
P03709627A0247|29 34|mg dose
P03709627A0247|37 53|acetaminophen i.v.
P03709627A0247|57 70|concentrations
P03709627A0247|73 78|plasma
P03709627A0247|97 103|minutes
P03709627A0247|109 113|urine
P03709627A0247|119 119|h
P03709627A0247|152 162|metabolites
P03710973A0817|0 26|Mean weighted skin temperature
P03710973A0817|28 30|Tsk
P03710973A0817|41 45|P less
P03710973A0817|64 74|acclimation
P03710973A0817|89 99|acclimation
P03710973A0817|111 116|larger
P03710973A0817|118 122|P less
P03710973A0817|132 149|Tre-to-Tsk gradient
P03712050T0000|0 25|Indium-111 leukocyte imaging
P03712050T0000|28 35|patients
P03712050T0000|40 58|rheumatoid arthritis
P03712106A0000|11 37|L-methionine supplementation
P03712106A0000|43 53|utilization
P03712106A0000|57 73|soy protein isolate
P03712106A0000|75 77|SPI
P03712106A0000|93 124|short-term nitrogen balance studies
P03712106A0000|127 136|young women
P03712153T0000|0 47|Primary invasive Haemophilus influenzae type b disease
P03712153T0000|50 75|population-based assessment
P03712153T0000|78 88|risk factors
P03713187A0691|8 14|lesions
P03713187A0691|30 46|deep lamina propria
P03713187A0691|78 87|occurrence
P03713187A0691|98 104|lesions
P03713187A0691|120 133|skeletal muscle
P03713187A0691|143 152|carcinomas
P03713187A0691|162 175|other oral sites
P03713187A0691|219 225|lesions
P03713187A0691|240 261|more superficial lesions
P03714348A0833|0 6|Factors
P03714348A0833|17 38|significant correlation
P03714348A0833|41 51|elevated CIC
P03714348A0833|65 79|elevated portion
P03714348A0833|85 97|CIC population
P03714348A0833|102 113|poor NIH score
P03714348A0833|124 133|patient age
P03714348A0833|135 159|low peak expiratory flow rate
P03714348A0833|164 184|elevated total serum IgG
P03714473A0496|0 8|Induction
P03714473A0496|15 34|potential transcripts
P03714473A0496|42 50|heat shock
P03717475A0208|0 2|New
P03717475A0208|6 20|successful steps
P03717475A0208|35 51|immunodiagnostics
P03717475A0208|53 65|immunotherapy
P03717475A0208|70 86|immunoprophylaxis
P03717475A0208|115 125|infertility
P03717936A0252|0 7|Amikacin
P03717936A0252|27 36|tobramycin
P03717936A0252|43 67|least stable aminoglycoside
P03717936A0252|76 85|conditions
P03720615A0434|21 32|secular trend
P03720615A0434|47 57|birthweight
P03720615A0434|61 69|gestation
P03720615A0434|72 85|preterm infants
P03720966A1043|9 30|nucleic acid N absorption
P03720966A1043|36 36|%
P03720966A1043|39 45|N intake
P03721594A0000|0 7|Adhesion
P03721594A0000|9 20|phagocytosis
P03721594A0000|22 32|chemotactic
P03721594A0000|36 50|random migration
P03721594A0000|52 71|nitroblue tetrazolium
P03721594A0000|86 113|peritoneal exudate neutrophils
P03721594A0000|117 127|macrophages
P03721594A0000|129 143|fibrinogen level
P03721594A0000|129 138|fibrinogen
P03721594A0000|145 152|gelation
P03721594A0000|155 167|soluble fibrin
P03721594A0000|162 167|fibrin
P03721594A0000|171 204|serial dilution protamine sulfate test
P03721594A0000|226 247|New Zealand white rabbits
P03721594A0000|273 292|Shwartzman phenomenon
P03721594A0000|298 302|colon
P03721594A0000|309 322|control animals
P03721666A0000|0 5|Nickel
P03721666A0000|15 25|common cause
P03721666A0000|28 52|allergic contact dermatitis
P03721666A0000|55 63|Singapore
P03721666A0000|76 92|positive reactions
P03721666A0000|95 104|patch tests
P03721666A0000|118 118|%
P03722016A0797|3 11|FFA levels
P03722016A0797|28 35|P greater
P03722016A0797|45 56|meal interval
P03728230A0104|27 43|solitary renal cyst
P03732252A0556|8 22|further analyses
P03732252A0556|54 56|VO2
P03732252A0556|60 61|r =
P03732252A0556|68 72|P less
P03732252A0556|92 97|VO2max
P03732252A0556|99 100|r =
P03732252A0556|138 153|m race performance
P03732252A0556|157 168|larger extent
P03732252A0556|180 193|absolute amount
P03732252A0556|203 207|delta
P03732252A0556|220 227|m run time
P03732252A0556|262 269|delta VO2
P03732252A0556|275 279|delta
P03732252A0556|285 292|m run time
P03733563A0716|1 33|significant herd X period interaction
P03733563A0716|44 50|liver TG
P03733563A0716|54 102|serum dextran precipitable cholesterol concentrations
P03733563A0820|0 6|Liver TG
P03733563A0820|10 32|serum NEFA concentrations
P03734641A0203|3 9|results
P03734641A0203|26 30|roots
P03734641A0203|95 111|other biomechanics
P03736081A0465|7 27|coronary sinus pressure
P03736081A0465|37 40|torr
P03736081A0465|51 69|significant decrease
P03736081A0465|72 83|cardiac index
P03736081A0465|107 114|L/min/m2
P03736081A0465|116 120|p less
P03736081A0465|132 148|coronary blood flow
P03736081A0465|171 176|ml/min
P03736081A0465|178 182|p less
P03736081A0465|206 228|left ventricular pressure
P03736081A0465|255 259|p less
P03736081A0465|285 315|coronary arteriovenous difference
P03736081A0465|321 321|%
P03736081A0465|328 328|%
P03736081A0465|335 335|%
P03736081A0465|342 352|% saturation
P03736081A0465|354 358|p less
P03738919A0000|0 13|Calcifications
P03738919A0000|19 31|thoracic aorta
P03738919A0000|47 50|11th
P03738919A0000|57 77|12th thoracic vertebrae
P03738919A0000|83 85|men
P03738919A0000|92 96|women
P03738919A0000|113 130|computed tomography
P03743683A0000|14 33|consecutive autopsies
P03743683A0000|35 56|parietal pleural plaques
P03743683A0000|58 59|PP
P03743683A0000|74 84|individuals
P03743683A0000|92 96|years
P03743702A0158|15 15|%
P03743702A0158|18 27|cell bodies
P03743702A0158|30 43|primary neurons
P03743702A0158|58 62|intra
P03743702A0158|66 83|perioral structures
P03743702A0158|94 109|inferior alveolar
P03743702A0158|111 117|lingual
P03743702A0158|129 140|buccal nerves
P03743702A0158|171 176|micron
P03743702A0158|180 198|cross-sectional area
P03743702A0158|207 208|SD
P03743702A0158|218 223|micron
P03743702A0158|235 240|micron
P03743702A0158|252 257|micron
P03743702A0158|272 277|micron
P03744168T0001|0 20|Pharmacological action
P03744168T0001|23 32|eptazocine
P03744168T0001|34 36|l-1
P03744168T0001|40 60|dimethyl-10-hydroxy-2
P03744168T0001|72 82|hexahydro-1
P03744168T0001|86 109|methano-1H-4-benz azonine
P03745833A0258|22 31|low voltage
P03745833A0258|41 55|significant fall
P03745833A0258|58 73|arterial pressure
P03745833A0258|76 76|%
P03745833A0258|103 103|%
P03745833A0258|107 111|areas
P03745833A0258|140 151|arborization
P03745833A0258|157 174|reticular formation
P03745833A0258|192 199|cerebrum
P03745833A0258|203 212|cerebellum
P03746053A0670|0 7|Findings
P03746053A0670|10 27|positive potentials
P03746053A0670|38 39|N1
P03746053A0670|61 77|ventral gray matter
P03746053A0670|88 107|ventro-lateral column
P03746053A0670|111 112|N2
P03746053A0670|123 134|dorsal column
P03746107A0192|23 26|cent
P03746107A0192|28 47|second primary tumours
P03746508A0390|0 7|Failures
P03746508A0390|10 31|colorimetric additivity
P03746508A0390|42 63|experimental conditions
P03746601A0299|17 24|problems
P03746601A0299|26 38|extravasation
P03746601A0299|50 55|sepsis
P03746601A0299|61 68|hematoma
P03746601A0299|90 93|days
P03746896A0890|22 28|results
P03746896A0890|40 61|interesting possibility
P03746896A0890|74 78|means
P03746896A0890|92 98|greater
P03746896A0890|101 120|lesser susceptibility
P03746896A0890|126 140|coronary effects
P03746896A0890|143 155|Type A behavior
P03746906A0000|3 9|studies
P03746906A0000|21 25|types
P03746906A0000|44 71|student Jenkins Activity Survey
P03746906A0000|73 75|JAS
P03746906A0000|78 97|questionnaire measure
P03746906A0000|100 112|Type A behavior
P03747493A0000|0 21|Splenectomized patients
P03747493A0000|52 82|overwhelming bacterial infections
P03749226A0506|4 16|phencyclidine
P03749226A0506|38 56|overall response rate
P03749226A0506|69 81|percent errors
P03749226A0506|105 109|doses
P03750700T0001|0 12|Possibilities
P03750700T0001|16 22|outlook
P03750700T0001|26 49|wrist joint endoprosthesis
P03751308T0001|0 4|Study
P03751308T0001|10 25|energy metabolism
P03751308T0001|31 46|sensomotor cortex
P03751308T0001|50 60|hippocampus
P03751308T0001|67 69|14C
P03751308T0001|71 90|2-deoxyglucose method
P03751308T0001|124 129|states
P03753022A0000|0 16|Malignant lymphoma
P03753022A0000|23 35|heterogeneous
P03753022A0000|48 65|biological behavior
P03755623A1233|0 20|Further investigations
P03755623A1233|47 57|biochemical
P03755623A1233|61 83|physiological properties
P03755623A1233|86 89|DLIS
P03755673A0054|12 16|cases
P03755673A0054|21 26|benign
P03755673A0054|32 40|malignant
P03757294A0414|5 9|cases
P03757294A0414|14 16|PLD
P03757294A0414|20 20|%
P03757294A0414|34 43|renal cysts
P03757294A0414|49 49|%
P03757294A0414|55 59|cases
P03757294A0414|64 67|APCD
P03757294A0414|81 90|liver cysts
P03758250A0000|0 34|Fast goal-directed voluntary movements
P03758250A0000|40 58|human upper extremity
P03758250A0000|90 103|distinct bursts
P03758250A0000|106 116|EMG activity
P03758250A0000|119 137|antagonistic muscles
P03759330A0713|16 17|F1
P03759330A0713|21 22|F2
P03759330A0713|34 46|best predictor
P03759330A0713|49 51|CHD
P03759330A0713|69 70|G1
P03759330A0713|102 115|trunk adiposity
P03759330A0713|122 130|abdominal
P03759731A0992|0 13|Renal clearance
P03759731A0992|32 39|ml/min/1
P03759731A0992|43 44|m2
P03759731A0992|64 71|ml/min/1
P03759731A0992|75 76|m2
P03761122T0000|3 11|relations
P03761122T0000|19 31|type A behavior
P03761122T0000|43 58|relevant behavior
P03761122T0000|60 78|academic achievement
P03761122T0000|83 84|IQ
P03761122T0000|87 94|children
P03761523A0000|3 6|rats
P03761523A0000|31 37|effects
P03761523A0000|40 45|sepsis
P03761523A0000|51 61|utilization
P03761523A0000|64 83|exogenous fat emulsion
P03763241A0446|10 23|slight weakness
P03763241A0446|29 44|upper extremities
P03763836T0001|0 6|Results
P03763836T0001|9 23|electron therapy
P03763836T0001|26 31|tumors
P03763836T0001|34 47|different sites
P03765552A0582|68 92|reticuloendothelial system
P03765552A0582|94 96|RES
P03765552A0582|98 115|Fc receptor blockade
P03765552A0582|98 107|Fc receptor
P03765552A0582|119 129|suppression
P03765552A0582|132 160|antiplatelet antibody synthesis
P03765731A0918|0 9|Incidences
P03765731A0918|12 25|nonfatal stroke
P03765731A0918|27 46|myocardial infarction
P03765731A0918|48 64|angina pectoris und
P03765731A0918|69 90|ventricular hypertrophy
P03766370A0546|0 16|High radial r values
P03766370A0546|21 43|small standard deviations
P03766370A0546|58 65|normal LV
P03766370A0546|86 98|non-MI regions
P03766370A0546|135 151|homogeneous radial
P03768208A0879|5 11|results
P03768208A0879|47 55|increases
P03768208A0879|58 75|bone formation rates
P03768208A0879|93 101|increases
P03768208A0879|104 115|skeletal mass
P03769224A0000|20 27|patients
P03769224A0000|32 57|Systemic Lupus Erythematosus
P03769224A0000|59 61|SLE
P03769224A0000|69 81|renal biopsies
P03770143A1209|17 34|hereditary disorder
P03770143A1209|45 55|minor defect
P03770143A1209|58 78|elastic fibre structure
P03770143A1209|108 125|spontaneous lesions
P03771670T0058|0 9|Prevention
P03771670T0058|13 32|heparin-antithrombin
P03771670T0058|21 35|antithrombin III
P03771703A0000|0 36|N-Substituted trimethylsilylcarbamates
P03771703A0000|61 68|reagents
P03771703A0000|72 97|gas chromatographic analysis
P03771749A0465|0 3|MICs
P03771749A0465|10 25|antifungal agents
P03771749A0465|27 42|5-fluorocytosine
P03771749A0465|44 53|miconazole
P03771749A0465|55 66|ketoconazole
P03771749A0465|71 83|amphotericin B
P03771749A0465|90 105|clinical isolates
P03771749A0465|108 128|various Candida species
P03771749A0465|162 173|agar dilution
P03771749A0465|177 206|microtiter broth dilution systems
P03772471A1054|11 18|patients
P03772471A1054|23 29|Group II
P03772471A1054|33 38|tumors
P03772471A1054|48 58|tumor biopsy
P03772471A1054|86 106|pathological diagnosis
P03774111T0000|0 7|Evidence
P03774111T0000|18 26|addiction
P03774111T0000|37 50|immune response
P03776080A0400|0 36|Parasitological post-mortem examination
P03776080A0400|42 60|seropositive animals
P03776080A0400|79 99|false-positive animals
P03776080A0400|104 106|E/S
P03776080A0400|110 120|CWE antigens
P03776438A0000|0 13|Glucocorticoid
P03776438A0000|21 32|hypertension
P03776438A0000|70 71|Na
P03776438A0000|86 102|mineralocorticoid
P03776438A0000|110 121|hypertension
P03776438A0000|130 131|Na
P03776779A0238|34 49|systemic steroids
P03777398A0156|0 7|Examples
P03777398A0156|21 40|intensive therapy unit
P03779182A0370|10 20|drug problem
P03779182A0370|59 63|cases
P03779182A0370|66 75|hepatitis B
P03779182A0370|81 98|drug-related deaths
P03779205A0459|9 16|patients
P03779205A0459|32 48|metastatic disease
P03779205A0459|67 71|years
P03779205A0459|77 93|first presentation
P03779205A0459|99 106|patients
P03779205A0459|120 130|secondaries
P03779205A0459|143 147|years
P03780248A0274|8 18|differences
P03780248A0274|38 44|infants
P03780248A0274|50 66|experimental group
P03780248A0274|74 80|changes
P03780248A0274|86 117|intermittent mandatory ventilation
P03780248A0274|119 121|IMV
P03780248A0274|123 130|settings
P03780248A0274|154 164|such infants
P03780248A0274|198 209|acceptable pH
P03780248A0274|213 222|PCO2 values
P03780371A0792|0 18|Repetitive sequences
P03780371A0792|43 49|introns
P03780371A0792|55 77|cytochrome P-450PBc2 gene
P03780371A0792|87 91|exons
P03780371A0792|100 113|flanking region
P03780704A0573|1 13|large increase
P03780704A0573|16 27|serum ketones
P03780704A0573|44 53|conditions
P03780704A0573|61 87|exercise respiratory quotient
P03780704A0573|111 124|fat utilization
P03780704A0573|126 127|WW
P03780704A0573|141 142|CW
P03780704A0573|151 152|CC
P03781000A0101|31 40|variations
P03781000A0101|46 62|metabolic activity
P03781000A0101|68 95|endometriotic implants present
P03781000A0101|98 112|different stages
P03781948T0000|0 20|Respiratory adaptation
P03781948T0000|23 36|chronic hypoxia
P03781948T0000|39 49|newborn rats
P03783160A0285|0 7|Compound
P03783160A0285|17 29|21-O-angeloyl
P03783160A0285|31 55|22-O-tigloyl R1-barrigenol
P03783160A0285|59 70|21-O-tigloyl
P03783160A0285|72 97|22-O-angeloyl R1-barrigenol
P03785212A0091|0 4|Human
P03785212A0091|8 40|Chinese hamster S14 protein sequences
P03785212A0091|55 59|cDNAs
P03785212A1128|0 11|RPS14 introns
P03785212A1128|0 4|RPS14
P03785212A1128|28 39|Alu sequences
P03788231A0802|12 26|relevant aspects
P03788231A0802|41 58|consistent survival
P03788231A0802|82 105|experimental implantation
P03788231A0802|109 128|total artificial heart
P03788231A0802|152 175|correct anatomic placement
P03788231A0802|178 197|prosthetic ventricles
P03789052A0527|2 34|exaggerated tissue response adjacent
P03789052A0527|40 56|cyanoacrylate site
P03789052A0527|67 88|potential toxic chemical
P03789052A0527|91 105|thermal reaction
P03789052A0527|119 132|tissue adhesive
P03789052A0527|160 179|distant ocular effects
P03791645A1124|5 12|findings
P03791645A1124|57 68|pathogenesis
P03791645A1124|71 73|MAL
P03791645A1124|75 84|narcolepsy
P03791645A1124|89 91|OSA
P03795488A0487|7 24|superficial lesions
P03795488A0487|50 51|CR
P03795488A0487|73 74|PR
P03795488A0487|81 92|response rate
P03795488A0487|99 99|%
P03799323A0501|8 21|same hematocrit
P03799323A0501|25 38|flow conditions
P03799323A0501|49 72|oxygen saturation decrease
P03799323A0501|89 94|higher
P03799323A0501|101 111|sickle cells
P03799323A0501|119 129|normal cells
P03799790A0146|8 15|examiner
P03799790A0146|47 68|indirect ophthalmoscopy
P03799790A0146|73 83|point source
P03799790A0146|98 116|fiberoptic light pipe
P03799790A0146|133 139|margins
P03799790A0146|145 160|episcleral plaque
P03802195A0481|5 18|fusion proteins
P03802195A0481|33 44|localization
P03802195A0481|50 74|transcriptional activation
P03802195A0481|78 94|DNA binding domains
P03802195A0481|100 110|ToxR protein
P03802195A0481|131 154|located N-terminal portion
P03805090A0645|4 21|life-table analyses
P03805090A0645|29 36|patients
P03805090A0645|56 64|incidence
P03805090A0645|67 89|secondary chondrosarcoma
P03805090A0645|92 99|patients
P03805090A0645|107 119|Ollier disease
P03805090A0645|132 135|cent
P03805090A0645|151 155|years
P03805090A0645|164 184|malignant degeneration
P03805090A0645|194 202|certainty
P03805090A0645|205 212|patients
P03805090A0645|220 235|Maffucci syndrome
P03806696A0000|3 16|lethal toxicity
P03806696A0000|19 27|inorganic
P03806696A0000|29 33|HgCl2
P03806696A0000|46 52|CH3HgCl
P03806696A0000|54 68|mercury chloride
P03806696A0000|83 90|Coturnix
P03806696A0000|92 104|Japanese quail
P03806696A0000|106 121|Coturnix japonica
P03806696A0000|125 137|different ages
P03806696A0000|142 146|hatch
P03806696A0000|154 162|adulthood
P03806696A0000|165 184|single-dose acute oral
P03806696A0000|188 210|intramuscular injections
P03806696A0000|217 231|5-d dietary trial
P03810361A0576|18 52|13h00-16h00 plasma cortisol estimation
P03810361A0576|55 61|cheaper
P03810361A0576|65 71|simpler
P03810361A0576|79 117|mean 13h00-16h00 plasma cortisol estimation
P03810361A0576|136 142|adjunct
P03810361A0576|159 165|Cushing
P03810867A0305|0 3|Most
P03810867A0305|9 16|patients
P03810867A0305|27 41|advanced lesions
P03810867A0305|45 48|T3-4
P03810867A0305|54 54|%
P03810867A0305|77 85|TNM system
P03810867A0305|87 103|Lederman-Gadeberg
P03810867A0305|105 116|Sisson-Jesse
P03811852A0109|15 27|complications
P03811852A0109|44 59|following factors
P03811852A0109|61 77|multiple gestation
P03811852A0109|95 110|magnesium sulfate
P03811852A0109|114 135|beta-adrenergic agonist
P03811852A0109|148 169|adrenocortico-steroids
P03811852A0109|178 199|fetal pulmonary maturity
P03814493T0000|0 11|Chlorambucil
P03814493T0000|15 24|interferon
P03814493T0000|28 46|low grade non-Hodgkin
P03814493T0000|49 56|lymphoma
P03818467A0180|0 7|Selenium
P03818467A0180|11 13|ppm
P03818467A0180|18 18|E
P03818467A0180|22 26|IU/kg
P03818467A0180|28 42|supplementation
P03818467A0180|69 84|plasma tocopherol
P03818467A0180|88 103|Se concentrations
P03818467A0180|122 148|plasma glutathione peroxidase
P03818467A0180|128 148|glutathione peroxidase
P03818467A0180|150 155|GSH-Px
P03818866A0116|0 13|Framingham Type
P03818866A0116|50 71|diastolic blood pressure
P03818866A0116|73 74|r =
P03818866A0116|80 84|p less
P03818866A0116|102 106|women
P03820222A0203|10 29|antibacterial potency
P03820222A0203|47 59|1-substituent
P03820222A0203|62 79|2,4-difluorophenyl
P03820222A0203|86 98|7-substituent
P03820222A0203|102 128|3-amino-1-pyrrolidinyl group
P03824908A0116|3 15|M reading frame
P03824908A0116|50 65|single nucleotide
P03824908A0116|82 99|conservative lysine
P03824908A0116|102 130|arginine amino acid substitution
P03824908A0116|138 153|carboxy-terminus
P03824908A0116|171 179|M proteins
P03824908A0116|182 196|paramyxoviruses
P03826871A0000|2 25|ion chromatographic method
P03826871A0000|44 48|Br ion
P03826871A0000|54 58|urine
P03826871A0000|61 70|Greyhounds
P03827071T0040|0 1|II
P03828209T0000|0 20|Laryngographic changes
P03828209T0000|30 51|endotracheal intubation
P03828209T0000|54 59|adults
P03828500T0001|0 14|Intensification
P03828500T0001|17 50|human myocardial contractile activity
P03828500T0001|63 72|blood serum
P03829848T0001|0 18|Autotransplantation
P03829848T0001|22 32|vein segment
P03829848T0001|37 41|valve
P03829848T0001|58 86|deep vein valvular insufficiency
P03829848T0001|92 105|lower extremity
P03830147A0000|3 15|relationships
P03830147A0000|25 35|descriptors
P03830147A0000|38 52|lactate increase
P03830147A0000|54 69|lactate threshold
P03830147A0000|71 72|LT
P03830147A0000|78 80|VO2
P03830147A0000|88 112|blood lactate concentration
P03830147A0000|157 179|incremental exercise test
P03830147A0000|182 184|LT1
P03830147A0000|189 191|VO2
P03830147A0000|199 210|blood lactate
P03830147A0000|221 222|mM
P03830147A0000|245 247|LT2
P03830147A0000|252 254|VO2
P03830147A0000|262 286|blood lactate concentration
P03830147A0000|295 304|fixed value
P03830147A0000|308 309|mM
P03830147A0000|312 316|onset
P03830147A0000|319 342|blood lactate accumulation
P03830147A0000|344 347|OBLA
P03830147A0000|352 354|VO2
P03830147A0000|362 373|blood lactate
P03830147A0000|398 399|mM
P03830147A0000|418 432|aerobic capacity
P03830147A0000|434 439|VO2max
P03830147A0000|446 448|min
P03830147A0000|471 493|untrained female students
P03830255A0074|37 66|multivariate normal distribution
P03835413A0616|16 26|late effects
P03835413A0616|32 43|irradiations
P03835413A0616|51 62|space flights
P03835413A0616|70 81|difficulties
P03835413A0616|104 117|radiative risks
P03835413A0616|124 147|long duration space flights
P03836777T0001|0 11|Practical use
P03836777T0001|31 52|viral hepatitis B markers
P03836777T0001|56 68|hepatic biopsy
P03836777T0001|71 83|HBs Ag carriers
P03836777T0001|71 75|HBs Ag
P03836777T0001|92 112|chronic hepatitis stage
P03836853A0204|12 28|year survival rates
P03836853A0204|35 35|%
P03836853A0204|39 39|%
P03836853A0204|43 43|%
P03836853A0204|49 49|%
P03836854T0000|0 9|Inhibition
P03836854T0000|12 46|histalog-stimulated gastric secretion
P03836854T0000|54 55|RP
P03836854T0000|58 96|new long-acting gastric antisecretory agent
P03837609T0000|0 24|Five-year prospective study
P03837609T0000|27 51|peripheral white blood cells
P03837609T0000|54 76|infectious mononucleosis
P03838797A0903|0 15|Northern blotting
P03838797A0903|21 47|unique 17-mer oligonucleotide
P03838797A0903|75 88|mutant sequence
P03838797A0903|94 97|mRNA
P03838797A0903|110 120|cDNA library
P03838797A0903|136 145|mutant cDNA
P03840480T0000|0 21|Novel multigene families
P03840480T0000|36 61|repetitive peptide sequences
P03841627T0001|0 11|Chemotherapy
P03841627T0001|27 38|breast cancer
P03843496A0919|2 12|recent years
P03843496A0919|14 42|successful physiological models
P03843496A0919|73 80|volatile
P03843496A0919|84 103|nonvolatile chemicals
P03843496A0919|132 145|extrapolations
P03843496A0919|154 167|risk assessment
P03843676A0381|0 18|Linear extrapolation
P03843676A0381|33 48|experimental data
P03843676A0381|79 94|carcinogenic risk
P03843676A0381|97 104|low doses
P03848527T0020|0 11|Hisako Minowa
P03848527T0020|27 47|psychiatric counsellor
P03848527T0020|70 74|years
P03857577A0413|0 21|Deletion mapping studies
P03857577A0413|37 56|upstream DNA sequences
P03857577A0413|84 113|optimal basal level transcription
P03857577A0413|116 124|HeLa cells
P03857577A0413|138 161|EIA-induced transcription
P03860162A0000|0 12|Incorporation
P03860162A0000|18 47|polyene antibiotic amphotericin B
P03860162A0000|49 51|AMB
P03860162A0000|55 63|liposomes
P03860162A0000|74 88|marked reduction
P03860162A0000|91 102|drug toxicity
P03860162A0000|115 131|antifungal potency
P03861687A0000|14 30|normotensive males
P03861687A0000|41 68|routine restorative dental care
P03861687A0000|100 129|possible hemodynamic alterations
P03861687A0000|142 185|potential sympathetic nervous system stimulation
P03862898A0563|0 7|Serum IgM
P03862898A0563|5 7|IgM
P03862898A0563|11 27|IgE concentrations
P03862898A0563|11 13|IgE
P03862898A0563|29 54|allergen-specific IgE scores
P03862898A0563|62 75|tumor E2R status
P03862898A0563|100 128|three-level risk classification
P03862898A0563|140 149|prognostic
P03862898A0563|162 181|individual components
P03863231A0530|3 12|M-3 subtype
P03863231A0530|18 40|adverse prognostic factor
P03863561A0405|9 13|Strep
P03863561A0405|15 25|mutans group
P03863561A0405|35 62|highly-significant difference
P03863561A0405|70 74|Strep
P03863561A0405|76 87|mutans/Strep
P03863561A0405|89 96|cricetus
P03863561A0405|98 102|p less
P03863561A0405|129 137|clump size
P03865743A0859|5 11|results
P03865743A0859|24 27|T.C.
P03865743A0859|29 34|LDL-C.
P03865743A0859|36 41|HDL-C.
P03865743A0859|43 49|HDL2-C.
P03865743A0859|51 54|apo B
P03865743A0859|56 68|apo A-I/B ratio
P03865743A0859|72 85|apo A-II/B ratio
P03865743A0859|89 109|predictive risk factors
P03865743A0859|115 134|coronary heart disease
P03866085A0795|20 47|unique suppository formulation
P03866085A0795|50 54|CZX-S
P03866085A0795|79 88|infections
P03866085A0795|91 98|children
P03866085A0795|103 133|heavy psychophysiologic disorders
P03866085A0795|139 146|children
P03866085A0795|160 168|oral drugs
P03866085A0795|178 191|severe vomiting
P03869442A0223|11 28|marked hypertension
P03869442A0223|58 70|abnormalities
P03869442A0223|84 95|hypertension
P03869442A0223|108 148|1-desamino-8-D-arginine vasopressin therapy
P03869442A0223|108 141|1-desamino-8-D-arginine vasopressin
P03871298A0217|0 41|Single photon emission computerized tomography
P03871298A0217|43 47|SPECT
P03871298A0217|61 91|three-dimensional representation
P03871298A0217|94 109|myocardial Tl-201
P03871298A0217|135 146|localization
P03871298A0217|149 151|CAD
P03871445T0000|0 7|Computer
P03871445T0000|16 22|mapping
P03871445T0000|25 44|quantitative analysis
P03871445T0000|47 79|cerebral positron emission tomograms
P03873141A0304|4 19|patients vagotomy
P03873141A0304|36 43|bleeding
P03873141A0304|55 71|definitive therapy
P03873141A0304|73 78|Visick
P03873141A0304|86 93|patients
P03873141A0304|99 111|mortality rate
P03873141A0304|114 114|%
P03874921A0862|0 12|Documentation
P03874921A0862|16 50|successful intrauterine fertilization
P03874921A0862|66 73|term baby
P03874921A0862|85 106|theoretical feasibility
P03874921A0862|112 113|EP
P03874921A0862|123 133|anovulation
P03874921A0862|170 182|major drawback
P03875231A0627|0 2|MRI
P03875231A0627|35 47|abnormalities
P03875231A0627|55 55|%
P03875231A0627|68 74|kidneys
P03875231A0627|85 115|corticomedullary differentiation
P03875231A0627|120 133|perirenal fluid
P03875231A0627|138 156|subcapsular hematoma
P03875231A0627|161 170|hemorrhage
P03875231A0627|176 184|renal cyst
P03875231A0627|192 215|unexplained abnormalities
P03877298A0718|3 9|results
P03877298A0718|51 78|previous Cremophor formulation
P03877298A0718|87 104|greater variability
P03877298A0718|107 115|induction
P03877298A0718|119 131|recovery times
P03877298A0718|147 165|emulsion formulation
P03878585A0507|3 24|percentage RFR reduction
P03878585A0507|35 37|CPB
P03878585A0507|44 65|significant correlation
P03878585A0507|72 82|CPB duration
P03878585A0507|84 85|r =
P03878585A0507|94 112|oxygen flow rate index
P03878585A0507|114 117|OFRI
P03878585A0507|137 158|bubble oxygenator/m2 bsa
P03878585A0507|160 161|r =
P03878585A0507|173 190|blood flow rate index
P03878585A0507|192 195|BFRI
P03878585A0507|202 214|average volume
P03878585A0507|238 271|heart-lung machine/min CPB time/m2 bsa
P03878585A0507|273 274|r =
P03880838T0000|0 8|Diagnosis
P03880838T0000|11 38|unilateral renal artery lesions
P03880838T0000|44 66|captopril administration
P03881260A0000|1 16|yeast DNA fragment
P03881260A0000|28 35|gene CP A1
P03881260A0000|47 58|small subunit
P03881260A0000|64 107|arginine pathway carbamoyl-phosphate synthetase
P03881260A0000|79 107|carbamoyl-phosphate synthetase
P03882029A0000|1 18|retrospective study
P03882029A0000|21 30|banked sera
P03882029A0000|37 40|cats
P03882029A0000|48 75|eosinophilic granuloma complex
P03882029A0000|90 90|%
P03882029A0000|101 104|cats
P03882029A0000|119 128|antibodies
P03882029A0000|131 140|components
P03882029A0000|143 161|normal cat epithelium
P03883052T0001|10 27|Magdelaine Comtesse
P03883541A0200|3 23|H2 receptor antagonists
P03883541A0200|3 12|H2 receptor
P03883541A0200|27 40|sucralfate cost
P03883541A0200|60 73|few side effects
P03885983A0254|5 11|results
P03885983A0254|23 31|indoramin
P03885983A0254|39 68|Class III antiarrhythmic activity
P03887085A0000|1 12|high efficacy
P03887085A0000|31 43|nontoxic doses
P03887085A0000|49 63|pharmaceuticals
P03887085A0000|65 73|cystamine
P03887085A0000|77 81|mg/kg
P03887085A0000|86 93|mexamine
P03887085A0000|97 101|mg/kg
P03887085A0000|111 120|conditions
P03887085A0000|123 148|short-term exogenous hypoxia
P03887085A0000|153 153|%
P03887085A0000|168 176|CBA X C57Bl
P03887085A0000|178 183|F1 mice
P03887769A0093|3 6|Mean
P03887769A0093|21 35|micrograms J/g Cr
P03887769A0093|40 45|Median
P03887769A0093|48 62|micrograms J/g Cr
P03887769A0584|21 51|mixed industrial-rural population
P03887769A0584|54 69|iodine deficiency
P03887769A0584|83 83|%
P03887769A0584|89 104|iodine deficiency
P03887769A0584|111 111|%
P03888621A0185|3 16|structural gene
P03888621A0185|20 30|hydrogenase
P03888621A0185|39 52|protein product
P03888621A0185|55 67|molecular mass
P03888621A0185|73 74|Da
P03890486A0000|0 38|Pancreaticoduodenal lymph node enlargement
P03890486A0000|74 89|imaging confusion
P03890486A0000|102 111|propensity
P03890486A0000|119 138|pancreatic malignancy
P03890486A0000|150 167|biliary obstruction
P03891766A1473|0 11|Interference
P03891766A1473|16 31|rheumatoid factor
P03891766A1473|52 56|ELISA
P03891766A1473|68 71|sera
P03891766A1473|93 107|latex adsorbents
P03894482A0549|3 10|patients
P03894482A0549|14 27|elevated levels
P03894482A0549|30 47|serum IgE antibodies
P03894482A0549|53 71|crude soybean extract
P03894482A0549|73 85|binding values
P03894482A0549|105 109|times
P03894482A0549|117 136|negative control serum
P03896991T0000|0 12|New techniques
P03896991T0000|19 34|mass spectrometry
P03896991T0000|37 51|natural products
P03898382A0000|0 33|Dual radionuclide subtraction imaging
P03898382A0000|39 44|spleen
P03898382A0000|50 60|67Ga citrate
P03898382A0000|64 68|99mTc
P03898382A0000|79 85|further
P03898382A0000|97 103|lesions
P03898382A0000|130 154|routine radiogallium survey
P03898382A0000|160 201|conventional sulfur colloid liver-spleen image
P03904004A1577|0 3|Such
P03904004A1577|23 31|low energy
P03904004A1577|34 56|medium energy collimation
P03904004A1577|83 98|keV 123I photopeak
P03904004A1577|106 141|appreciable septal breakthrough signals
P03904004A1577|157 170|Compton scatter
P03904004A1577|173 189|high energy photons
P03904004A1577|203 206|124I
P03904952T0000|0 15|Nursing education
P03904952T0000|21 38|computer obligation
P03908196T0000|0 16|Shear bond strength
P03908196T0000|20 33|composite resin
P03908196T0000|38 55|etched glass ionomer
P03908493A0246|2 20|additional advantage
P03908493A0246|30 34|resin
P03908493A0246|53 77|immunoperoxidase technique
P03908493A0246|53 68|immunoperoxidase
P03908493A0246|90 101|thin sections
P03910310A0666|44 52|pathology
P03910310A0666|55 60|ageing
P03911052A0909|14 19|DIL-CP
P03911052A0909|30 40|excellent CP
P03911052A0909|43 53|CABG surgery
P03911052A0909|78 79|CP
P03911052A0909|85 92|patients
P03911052A0909|102 112|CABG surgery
P03911702A0530|6 12|earlier
P03911702A0530|22 38|experimental model
P03911702A0530|41 45|means
P03911702A0530|74 94|microembolism syndrome
P03911702A0530|112 145|reproducible musculo-skeletal trauma
P03911702A0530|148 151|pigs
P03911702A0530|165 183|long-term anesthesia
P03911702A0530|189 210|standardized conditions
P03911965A0513|10 32|statistical significance
P03911965A0513|72 81|clear trend
P03911965A0513|88 98|superiority
P03911965A0513|101 111|Galphimia D6
P03911965A0513|120 136|Galphimia dilution
P03911965A0513|179 185|placebo
P03912247A0282|21 24|flap
P03912247A0282|39 44|ml/min
P03912247A0282|46 66|collateral circulation
P03912247A0282|72 75|flap
P03912247A0282|88 97|negligible
P03912247A0282|109 120|little change
P03912247A0282|126 143|capillary blood flow
P03912247A0282|149 156|flap ages
P03913522A0000|4 8|aging
P03913522A0000|10 20|many aspects
P03913522A0000|23 42|immune function change
P03914875T0001|0 14|Oral candidiasis
P03915540A0863|14 29|gcd1-101 mutation
P03915540A0863|43 68|low translational efficiency
P03915540A0863|71 83|GCN4-lacZ mRNA
P03915540A0863|71 74|GCN4
P03915540A0863|76 79|lacZ
P03915540A0863|94 97|gcn2
P03915540A0863|102 105|gcn3
P03915540A0863|107 111|cells
P03920700A0491|16 26|alaproclate
P03920700A0491|46 59|responsiveness
P03920700A0491|62 83|postsynaptic muscarinic
P03920700A0491|74 105|muscarinic and alpha 1 adrenoceptors
P03920700A0491|87 91|alpha
P03920700A0491|93 105|adrenoceptors
P03921727A0523|3 16|concentrations
P03921727A0523|19 24|apo A-I
P03921727A0523|28 34|apo A-II
P03921727A0523|37 46|abstainers
P03921727A0523|84 103|corresponding changes
P03921727A0523|106 113|controls
P03922116A0197|17 24|patients
P03922116A0197|46 65|complex gamma-therapy
P03922116A0197|69 73|cases
P03922116A0197|84 103|complex gamma-therapy
P03922116A0197|108 127|iliac lymphadenectomy
P03922116A0197|131 135|cases
P03922116A0197|148 172|complex radiation treatment
P03922116A0197|177 202|megavolt bremsstrahlung beam
P03922116A0197|210 228|luc type installation
P03922116A0197|232 251|iliac lymphadenectomy
P03922116A0197|255 259|cases
P03923828A1031|17 31|cryoprecipitate
P03923828A1031|35 39|DDAVP
P03923828A1031|62 79|effective treatment
P03923828A1031|86 102|temporary reversal
P03923828A1031|105 118|uremic bleeding
P03923828A1031|121 128|patients
P03923828A1031|139 162|urgent invasive procedures
P03923976T0001|0 15|Thrombophlebitis
P03923976T0001|19 35|pulmonary embolism
P03923976T0001|38 66|congenital factor XII deficiency
P03925712A0229|0 7|Biopsies
P03925712A0229|13 25|jejunal mucosa
P03925712A0229|35 56|abnormal enzyme activity
P03925712A0229|59 70|deficiencies
P03925712A0229|73 91|transport mechanisms
P03928357A0340|0 18|Laboratory pyrolyses
P03928357A0340|38 41|PCBs
P03928357A0340|46 62|significant yields
P03928357A0340|65 69|PCDFs
P03928357A0340|74 87|chlorobenzenes
P03928357A0340|96 100|PCDFs
P03928357A0340|104 108|PCDDs
P03928442A0463|1 17|significant degree
P03928442A0463|20 27|homology
P03928442A0463|50 54|genes
P03928442A0463|61 69|Mtase gene
P03928442A0463|72 86|related phage SPR
P03928442A0463|103 108|enzyme
P03928442A0463|113 144|different modification specificity
P03928678T0000|0 27|Thyrotropin-releasing hormone
P03928678T0000|21 46|hormone-induced contraction
P03928678T0000|49 56|urethral
P03928678T0000|60 72|vaginal muscle
P03929486A0309|3 22|blind controlled trial
P03929486A0309|26 33|patients
P03929486A0309|38 41|COCM
P03929486A0309|43 52|NYHA II-III
P03929486A0309|58 68|sinus rhythm
P03929486A0309|73 103|left ventricular ejection fraction
P03929486A0309|105 109|LV-EF
P03929486A0309|123 123|%
P03929486A0309|145 145|D
P03929486A0309|155 158|mg/d
P03929486A0309|161 167|placebo
P03929486A0309|169 172|PLAC
P03929486A0309|175 175|P
P03929486A0309|177 191|slow releases = SR
P03929486A0309|196 201|mg/d SR
P03929486A0309|210 214|drugs
P03929486A0309|225 239|respective doses
P03929610A0268|0 20|Mild orbital discomfort
P03929610A0268|35 42|patients
P03930549A0209|32 57|centrifugation valproic acid
P03930549A0209|63 73|supernatant
P03930549A0209|89 96|free form
P03930549A0209|99 113|direct injection
P03930549A0209|121 136|gas chromatograph
P03930894T0000|0 6|Changes
P03930894T0000|9 40|muscarinic acetylcholine receptors
P03930894T0000|43 56|guinea-pig lung
P03930894T0000|58 64|effects
P03930894T0000|67 71|aging
P03930894T0000|73 82|inhalation
P03930894T0000|87 94|allergen
P03930894T0000|112 116|drugs
P03930894T0000|121 128|vagotomy
P03931293A0437|14 29|other stabilizers
P03931293A0437|40 46|sucrose
P03931293A0437|66 81|thermoresistance
P03931293A0437|97 104|% albumin
P03931797A0134|3 19|overall prevalence
P03931797A0134|22 30|psoriasis
P03931797A0134|38 38|%
P03931797A0134|41 43|men
P03931797A0134|51 51|%
P03931797A0134|54 58|women
P03933232T0000|0 14|Greek classicism
P03933232T0000|37 53|deductive pathways
P03933232T0000|56 71|animal morphology
P03933784A0420|3 16|possible origin
P03933784A0420|26 37|CSF prolactin
P03934667A0124|5 28|chromosomal crsA mutations
P03934667A0124|30 34|crsA1
P03934667A0124|36 40|crsA4
P03934667A0124|45 50|crsA47
P03934667A0124|73 86|gene conversion
P03934667A0124|97 119|B. subtilis plasmid pRPD11
P03934667A0124|139 157|entire wild-type rpoD
P03934667A0124|145 171|wild-type rpoD coding sequence
P03934667A0124|184 193|major sigma
P03934667A0124|204 226|B. subtilis RNA polymerase
P03934667A0124|231 236|pUB110
P03935117T0000|0 14|Selective effect
P03935117T0000|17 31|pulmonary oedema
P03935117T0000|34 64|prostaglandin E2 pharmacokinetics
P03935117T0000|67 73|rat lung
P03935375A0414|49 58|morphology
P03935375A0414|72 83|biochemistry
P03935375A0414|89 106|normal renal medulla
P03935375A0414|113 121|pathology
P03935375A0414|136 138|RPN
P03935375A0414|155 170|secondary changes
P03935375A0414|186 205|cortical degeneration
P03935375A0414|208 226|epithelial carcinoma
P03935797A0183|60 85|sry messenger RNAs detectable
P03935797A0183|88 99|early embryos
P03935797A0183|119 131|separate sites
P03935797A0183|145 152|upstream
P03935797A0183|170 190|protein-coding regions
P03935797A0183|217 220|beta
P03935797A0183|222 226|alpha
P03935797A0183|230 234|delta
P03936828T0000|0 17|Chronic thyroiditis
P03936828T0000|21 30|risk factor
P03936828T0000|33 46|B-cell lymphoma
P03936828T0000|52 63|thyroid gland
P03937294A0404|0 19|Plasma secretin levels
P03937294A0404|0 13|Plasma secretin
P03937294A0404|57 72|ethanol solutions
P03937294A0404|106 110|onset
P03937294A0404|113 125|acid secretion
P03937481T0001|0 30|Spectrophotometric microanalysis
P03937481T0001|33 61|ethylenediaminotetracetic acid
P03937481T0001|64 89|pharmaceutical preparations
P03939317A0352|21 35|flanking regions
P03939317A0352|51 71|presumptive HS promoter
P03939317A0352|77 98|soybean HS-protein genes
P03939317A0352|134 143|homologous
P03940426A0618|0 6|Results
P03940426A0618|30 32|GLC
P03940426A0618|35 54|short chain fatty acids
P03940426A0618|65 74|agar medium
P03940426A0618|77 85|anaerobes
P03940426A0618|99 113|simple tests such
P03940426A0618|116 119|Gram
P03940426A0618|130 147|colonial morphology
P03940426A0618|157 195|fir direct presumptive genus identification
P03940426A0618|202 223|initial pure agar culture
P03940733A0755|26 35|absorption
P03940733A0755|38 45|low doses
P03940733A0755|48 55|vitamin A
P03940733A0755|77 97|physiological approach
P03940733A0755|112 127|fat malabsorption
P03940818T0000|0 18|Fulminant hepatitis A
P03940818T0000|21 37|chronic HBV carrier
P03944212A0166|0 13|Tissue pressure
P03944212A0166|15 18|rCBF
P03944212A0166|23 34|water content
P03944212A0166|51 60|gray matter
P03944212A0166|66 76|central core
P03944212A0166|83 98|peripheral margin
P03944212A0166|104 115|MCA territory
P03944212A0166|121 121|h
P03944212A0166|127 130|MCAO
P03944239A0780|18 25|patients
P03944239A0780|35 75|characteristic plasma thyroid hormone changes
P03944239A0780|90 106|amiodarone therapy
P03944239A0780|121 122|T4
P03944239A0780|124 129|free T4
P03944239A0780|134 136|rT3
P03944239A0780|149 150|T3
P03944239A0780|176 184|euthyroid
P03946125T0000|0 3|Drug
P03946125T0000|7 26|nutrient interactions
P03952387A0336|6 16|compartment
P03952387A0336|33 39|tissues
P03952387A0336|43 58|chemical reaction
P03952387A0336|81 93|oxyhemoglobin
P03952387A0336|95 98|HbO2
P03953361A0000|13 19|effects
P03953361A0000|22 32|propranolol
P03953361A0000|35 54|myocardial metabolism
P03953361A0000|60 78|coronary reperfusion
P03953361A0000|80 97|serial measurements
P03953361A0000|100 123|myocardial creatine kinase
P03953361A0000|125 126|CK
P03953361A0000|131 137|calcium
P03953361A0000|139 140|Ca
P03953361A0000|142 149|contents
P03953361A0000|153 154|CK
P03953361A0000|158 167|lactic acid
P03953361A0000|169 170|LA
P03953361A0000|172 185|concentrations
P03953361A0000|188 205|coronary sinus blood
P03953361A0000|224 237|open-chest dogs
P03956647A1063|0 10|Dissolution
P03956647A1063|16 40|Pt-30%Ir microelectrode tip
P03956647A1063|54 79|scanning electron microscopy
P03956647A1063|82 96|charge densities
P03956647A1063|107 119|microC/cm2 X ph
P03956647A1063|122 126|A/cm2
P03956647A1063|136 142|erosion
P03956647A1063|154 175|iridium microelectrodes
P03956647A1063|193 205|highest charge
P03956647A1063|209 224|current densities
P03956647A1063|230 242|microC/cm2 X ph
P03956647A1063|246 250|A/cm2
P03956695A0617|0 16|Cortisol excretion
P03956695A0617|65 80|other factors such
P03956695A0617|92 110|environmental stress
P03959045A0000|3 9|studies
P03959045A0000|41 64|commercial coaching course
P03959045A0000|84 110|Medical College Admission Test
P03959045A0000|112 115|MCAT
P03963860A0137|10 17|patients
P03963860A0137|49 52|MY-1
P03963860A0137|64 77|untreated group
P03964489A1195|7 15|% decrease
P03964489A1195|18 21|PaO2
P03964489A1195|23 26|NADH
P03964855A0254|0 10|Angiography
P03964855A0254|35 43|rCBF study
P03964855A0254|58 66|vasospasm
P03964855A0254|83 92|angiograms
P03965012A0163|3 9|results
P03965012A0163|26 30|years
P03965012A0163|54 76|4.7-fold excess mortality
P03965012A0163|80 88|ischaemic
P03965012A0163|92 109|other heart diseases
P03965012A0163|111 120|ICD A83-A84
P03965012A0163|135 159|comparable reference cohort
P03965012A0163|162 177|paper mill workers
P03966687A0000|3 17|financial impact
P03966687A0000|20 34|childhood asthma
P03966687A0000|58 62|Vance
P03966687A0000|66 71|Taylor
P03966687A0000|91 96|Annals
P03966687A0000|99 105|Allergy
P03966687A0000|108 112|years
P03967144T0001|0 12|Hypersplenism
P03970191A0275|0 17|Electrical activity
P03970191A0275|45 69|general electrocorticogram
P03970191A0275|71 74|ECoG
P03970191A0275|84 105|local DC steady potential
P03970191A0275|110 114|sites
P03972038A0000|3 12|topography
P03972038A0000|16 27|trajectories
P03972038A0000|33 49|commissural fibers
P03972038A0000|55 76|superior temporal region
P03972038A0000|78 80|STR
P03972038A0000|100 124|autoradiographic technique
P03972185A0137|3 15|diabetic state
P03972185A0137|34 54|mild insulin deficiency
P03972185A0137|38 44|insulin
P03972185A0137|56 67|plasma levels
P03972185A0137|75 75|%
P03972185A0137|78 85|controls
P03972185A0137|90 106|mild hyperglycemia
P03972185A0137|112 140|nonfasting plasma glucose levels
P03972185A0137|146 156|times normal
P03974790A0053|3 19|primary CT findings
P03974790A0053|41 52|brain infarct
P03974790A0053|64 69|tumour
P03976323A0821|2 22|consistent correlation
P03976323A0821|30 48|blood pressure change
P03976323A0821|52 61|SCR-change
P03977577T0000|0 21|Shoulder forearm support
P03977603A0326|0 8|Piroxicam
P03977603A0326|18 31|lower incidence
P03977603A0326|34 46|gastric ulcers
P03977603A0326|51 65|equivalent doses
P03977603A0326|68 79|indomethacin
P03978045A0857|5 12|findings
P03978045A0857|33 43|early stages
P03978045A0857|45 46|0T
P03978045A0857|48 49|0N
P03978045A0857|60 71|severe stages
P03978045A0857|74 76|VWF
P03978045A0857|78 83|stages
P03978045A0857|99 113|hyperreactivity
P03978045A0857|119 132|digital vessels
P03978045A0857|136 142|Raynaud
P03978045A0857|156 172|vascular disorders
P03978045A0857|175 190|functional origin
P03978045A0857|210 233|prethrombotic alterations
P03978132A0108|2 14|MCCP functions
P03978132A0108|20 33|source emission
P03978132A0108|35 51|surface reflection
P03978132A0108|53 76|photoacceptor sensitivity
P03978132A0108|97 120|normal distribution curves
P03979084A1019|8 14|kidneys
P03979084A1019|28 29|hr
P03979084A1019|46 66|similar renal functions
P03979084A1019|85 88|IMPK
P03979084A1019|91 94|IBPK
P03980386A0000|11 17|effects
P03980386A0000|20 34|alveolar hypoxia
P03980386A0000|38 50|angiotensin II
P03980386A0000|38 48|angiotensin
P03980386A0000|51 58|infusion
P03980386A0000|75 83|blood flow
P03980386A0000|104 116|perfusion lung
P03980386A0000|124 135|anesthetized
P03980386A0000|158 162|lambs
P03981421A0246|1 8|flow rate
P03981421A0246|19 22|mL/h
P03981421A0246|43 50|receptor
P03981421A0246|62 63|mL
P03981421A0246|68 82|accurate results
P03981640A0168|9 15|located
P03981640A0168|21 24|ends
P03981640A0168|42 50|late mRNAs
P03981952T0000|3 10|efficacy
P03981952T0000|13 24|quantitative
P03981952T0000|28 55|qualitative chloride titrators
P03981952T0000|61 70|estimation
P03981952T0000|73 87|human salt intake
P03982288T0000|0 13|Doctor Berglund
P03982288T0000|19 25|members
P03982288T0000|28 40|union pitfalls
P03984683A0000|0 14|Acute appearance
P03984683A0000|17 27|hemiparesis
P03984683A0000|30 39|hemiplegia
P03984683A0000|44 66|initial marked spasticity
P03984683A0000|81 94|stroke patients
P03985849A0221|0 27|Recurrent acute rhinosinusitis
P03985849A0221|43 48|groups
P03985849A0221|51 58|patients
P03985849A0221|79 99|chronic rhinosinusitis
P03985849A0221|114 121|patients
P03985849A0221|126 129|CVID
P03985849A0221|148 159|severe nature
P03985849A0221|187 208|selective IgA deficiency
P03985849A0221|196 198|IgA
P03987818A0440|20 23|AP-A
P03987818A0440|63 74|heart failure
P03987857A0733|3 16|various muscles
P03987857A0733|22 38|pelvic floor region
P03987857A0733|86 93|mass unit
P03987857A0733|119 129|stimulation
P03988001A0227|21 44|rat blood chloroform levels
P03988001A0227|89 92|ClO2
P03989827T0000|14 30|lactase phenotypes
P03989827T0000|33 46|Aymara children
P03992022A0330|0 9|Activities
P03992022A0330|12 43|hepatic cytochrome P-450-dependent
P03992022A0330|12 33|hepatic cytochrome P-450
P03992022A0330|56 66|enzymes such
P03992022A0330|69 99|aminopyrine- and TMO N-demethylase
P03992022A0330|69 79|aminopyrine
P03992022A0330|84 99|TMO N-demethylase
P03992022A0330|103 128|aniline hydroxylase activity
P03992022A0330|103 120|aniline hydroxylase
P03992022A0330|144 155|pretreatment
P03992022A0330|158 161|rats
P03992022A0330|166 175|cimetidine
P03992022A0330|189 192|rats
P03992022A0330|207 216|ranitidine
P03992022A0330|223 238|enzyme activities
P03995513T0000|0 10|Doxorubicin
P03995513T0000|12 22|dacarbazine
P03995513T0000|24 34|vincristine
P03995513T0000|39 54|cyclophosphamide
P03995513T0000|71 108|advanced gastrointestinal leiomyosarcoma
P03997467A0000|14 37|opiate antagonist naloxone
P03997467A0000|54 71|unselected patients
P03997467A0000|76 91|cerebral ischemia
P03998071T0000|0 23|Electrochemical detection
P03998071T0000|46 51|levels
P03998071T0000|54 62|vitamin K1
P03998071T0000|65 76|osteoporosis
P03998813A0406|5 22|present experiments
P03998813A0406|55 69|temporal pattern
P03998813A0406|72 85|neural activity
P03998813A0406|95 102|ontogeny
P03998813A0406|105 119|frequency tuning
P03998813A0406|125 150|mouse central auditory system
P03999219A0463|0 13|Ultrastructure
P03999219A0463|40 61|transurethral resection
P03999219A0463|75 79|weeks
P03999219A0463|85 98|alum irrigation
P03999219A0463|111 135|preserved nuclear chromatin
P03999219A0463|164 170|changes
P03999219A0463|181 194|alum irrigation
P03999219A0463|198 208|short-lived
P04000347A0442|56 62|persons
P04000347A0442|80 85|groups
P04000347A0442|102 109|diseased
P04000347A0442|112 114|BEN
P04000347A0442|130 137|diseased
P04000347A0442|140 142|BEN
P04000347A0442|150 160|individuals
P04000347A0442|168 172|signs
P04000347A0442|176 187|renal disease
P04001413A0093|16 46|simple respiration-control device
P04001413A0093|93 106|breath-holding
P04001413A0093|113 127|successive scans
P04001490T0001|3 15|POEMS syndrome
P04001490T0001|17 30|Polyneuropathy
P04001490T0001|32 43|Organomegaly
P04001490T0001|45 58|Endocrinopathy
P04001490T0001|60 78|Monoclonal component
P04001490T0001|80 83|Skin
P04002131A0506|7 22|disease remission
P04002131A0506|43 54|GAG secretion
P04002131A0506|59 63|urine
P04002131A0506|75 90|hyperheparinuria
P04002131A0506|102 106|P less
P04002667A0181|2 24|metastasis-free patients
P04002667A0181|29 39|best results
P04002667A0181|56 69|tumor diameters
P04002667A0181|76 77|cm
P04002667A0181|95 106|localization
P04002667A0181|109 118|lung tissue
P04002667A0181|132 139|cm tumors
P04002667A0181|150 163|lung parenchyma
P04004168A0000|3 10|siblings
P04004168A0000|15 29|hemolytic anemia
P04004168A0000|38 71|triosephosphate isomerase deficiency
P04004168A0000|38 61|triosephosphate isomerase
P04004168A0000|82 112|progressive neurological syndrome
P04004168A0000|122 138|dystonic movements
P04004168A0000|140 145|tremor
P04004168A0000|147 165|pyramidal tract signs
P04004168A0000|180 207|spinal motor neuron involvement
P04005190A1288|3 9|extract
P04005190A1288|17 32|lowest PCA content
P04005190A1288|36 51|non-carcinogenic
P04011338A0620|7 14|patients
P04011338A0620|24 35|severe degree
P04011338A0620|38 48|steatorrhea
P04011338A0620|62 68|fat loss
P04011338A0620|81 81|%
P04011338A0620|86 102|close relationship
P04011338A0620|112 113|r =
P04011338A0620|119 123|p less
P04011338A0620|154 166|fatty acid loss
P04011338A0620|169 175|placebo
P04011338A0620|202 208|taurine
P04011466T0000|0 14|Aortic diameters
P04011466T0000|17 23|infants
P04011466T0000|27 39|young children
P04011466T0000|41 65|normative angiographic data
P04013576A0981|3 22|present investigation
P04013576A0981|58 71|main fatty acids
P04013576A0981|74 96|Leptospira phospholipids
P04013576A0981|127 149|Leptospira neutral lipids
P04013576A0981|168 187|unsaturated fatty acid
P04013576A0981|194 204|carbon atoms
P04013576A0981|223 235|phospholipids
P04013604A0412|23 49|potassium-induced ulceration
P04013604A0412|63 67|cases
P04013604A0412|77 89|patient-years
P04013604A0412|92 112|slow-release tablet use
P04014833A0400|0 13|Hydrocortisone
P04014833A0400|20 30|lymphopenia
P04014833A0400|46 64|blastogenic response
P04014833A0400|67 92|peripheral blood lymphocytes
P04014833A0400|95 112|phytohemagglutinin
P04014833A0400|116 128|concanavalin A
P04014833A0400|116 127|concanavalin
P04014833A0400|129 136|mitogens
P04014861A0000|9 19|feasibility
P04014861A0000|27 35|liposomes
P04014861A0000|45 61|therapeutic agents
P04014861A0000|67 71|lungs
P04014861A0000|84 123|liposome-encapsulated superoxide dismutase
P04014861A0000|105 123|superoxide dismutase
P04014861A0000|125 127|SOD
P04014861A0000|131 138|catalase
P04014861A0000|141 163|pulmonary oxygen toxicity
P04014861A0000|176 179|rats
P04015988T0000|0 17|Marrow cell necrosis
P04015988T0000|20 34|anorexia nervosa
P04015988T0000|38 58|involuntary starvation
P04017295A0139|3 31|comparison conventional heparin
P04017295A0139|47 54|dialyses
P04017295A0139|60 71|same patients
P04018444A0000|0 19|Chenodeoxycholic acid
P04018444A0000|21 25|cheno
P04018444A0000|30 48|ursodeoxycholic acid
P04018444A0000|50 53|urso
P04018444A0000|63 83|cholesterol gallstones
P04019066A0000|0 6|Sensory
P04019066A0000|13 27|field potentials
P04019066A0000|47 77|mesencephalic reticular formation
P04019066A0000|79 81|MRF
P04019066A0000|84 94|central gray
P04019066A0000|96 97|CG
P04019066A0000|102 120|somatosensory cortex
P04019066A0000|122 124|SCX
P04019066A0000|136 151|incremental doses
P04019066A0000|154 162|halothane
P04019066A0000|165 181|freely-moving rats
P04021281T0001|0 13|Ultrastructure
P04021281T0001|19 29|heart muscle
P04021281T0001|32 60|experimental myocardial infarct
P04021281T0001|70 85|physical training
P04021305A0530|0 30|Pharmacological desympathization
P04021305A0530|54 69|hyper-reactivity
P04021305A0530|75 88|true pacemakers
P04021305A0530|91 103|noradrenaline
P04021305A0530|107 114|dopamine
P04021305A0530|129 135|changes
P04021305A0530|156 171|electric activity
P04021305A0530|179 183|cells
P04021305A0530|186 199|catecholamines
P04021431A0000|0 3|OODG
P04021431A0000|7 22|diagnostic method
P04021431A0000|45 61|ocular pulse curves
P04021431A0000|65 86|objective determination
P04021431A0000|89 102|blood pressures
P04021431A0000|108 134|ophthalmic circulatory system
P04021431A0000|136 142|retinal
P04021431A0000|146 174|ciliary arterial blood pressures
P04021431A0000|197 200|eyes
P04021431A0000|209 218|dilatation
P04021431A0000|224 229|pupils
P04021437A0000|0 14|Viral infections
P04021437A0000|40 54|causative agents
P04021437A0000|66 85|inner ear dysfunctions
P04024685A0650|7 7|%
P04024685A0650|13 27|other parameters
P04024685A0650|35 53|significant increase
P04024685A0650|55 61|RS index
P04024685A0650|71 75|mVolt
P04024685A0650|87 91|mVolt
P04024685A0650|93 97|p less
P04024685A0650|108 110|EDD
P04024685A0650|131 132|cm
P04024685A0650|134 138|p less
P04024685A0650|150 151|HV
P04024685A0650|162 163|ml
P04024685A0650|176 177|ml
P04024685A0650|179 183|p less
P04024685A0650|194 196|EDV
P04024685A0650|206 207|ml
P04024685A0650|219 220|ml
P04024685A0650|222 226|p less
P04024685A0650|238 240|RBV
P04024685A0650|249 250|ml
P04024685A0650|261 262|ml
P04024685A0650|264 268|p less
P04025178A0126|0 20|Retrospective analyses
P04025178A0126|41 59|significant decrease
P04025178A0126|65 79|left ventricular
P04025178A0126|81 82|LV
P04025178A0126|84 107|end-diastolic volume index
P04025178A0126|109 112|EDVI
P04025178A0126|118 122|ml/m2
P04025178A0126|126 126|%
P04025179A0955|8 13|adults
P04025179A0955|25 33|variables
P04026903A0512|0 10|Polysorbate
P04026903A0512|24 38|direct stimulant
P04026903A0512|41 54|relaxant effect
P04026903A0512|63 76|guinea pig ileum
P04026903A0512|79 87|rat uterus
P04026903A0512|113 124|contractions
P04026903A0512|134 146|acetylcholine
P04026903A0512|148 156|histamine
P04026903A0512|158 163|barium
P04026903A0512|165 183|5-hydroxytryptamine
P04026903A0512|187 195|carbachol
P04026903A0512|199 218|dose-dependent manner
P04026972T0000|0 32|Individual alcohol reaction profiles
P04027182T0000|0 7|Vitiligo
P04027182T0000|10 25|diabetes mellitus
P04028871A0133|3 18|pharmacokinetics
P04028871A0133|25 36|tetracycline
P04028871A0133|39 43|serum
P04028871A0133|47 52|dermal
P04028871A0133|54 72|suction blister fluid
P04028871A0133|92 100|oral doses
P04028871A0133|106 118|mg lymecycline
P04028871A0133|124 136|mg doxycycline
P04028871A0133|142 147|3rd day
P04031488A1091|1 10|high degree
P04031488A1091|39 55|classic conception
P04031488A1091|58 74|brain localization
P04031488A1091|77 103|neuropsychological syndromes
P04032268A0358|7 16|UV detector
P04032268A0358|25 26|nm
P04032268A0358|31 45|electrochemical
P04032268A0358|47 48|EC
P04032268A0358|50 57|detector
P04032268A0358|79 79|V
P04032268A0358|87 100|Ag/AgCl/3 M NaCl
P04032349A0000|2 9|patients
P04032349A0000|14 36|acute arterial occlusions
P04032349A0000|44 58|graft thromboses
P04032349A0000|86 99|recent ischemia
P04032349A0000|114 132|fibrinolytic therapy
P04032349A0000|134 142|Urokinase
P04032349A0000|148 160|units/kg/hour
P04032349A0000|165 178|Lys Plasminogen
P04032349A0000|168 178|Plasminogen
P04032716A0299|3 20|mean transfer ratios
P04032716A0299|37 50|genital tissues
P04032716A0299|74 93|uterine arterial blood
P04032716A0299|109 121|transfer ratio
P04032716A0299|150 156|highest
P04032716A0299|171 183|uterine cervix
P04032716A0299|190 199|myometrium
P04032716A0299|215 221|oviduct
P04032716A0299|228 233|lowest
P04033402A1112|14 31|androgenic hormones
P04033402A1112|38 66|HDL-cholesterol concentrations
P04033402A1112|38 52|HDL-cholesterol
P04033402A1112|73 99|HDL2-cholesterol subfraction
P04033402A1112|73 88|HDL2-cholesterol
P04033402A1112|120 152|hepatic triglyceride lipase activity
P04033402A1112|120 144|hepatic triglyceride lipase
P04034220A0205|12 23|wide spectrum
P04034220A0205|53 78|ampicillin resistant strains
P04034220A0205|81 92|H. influenzae
P04034220A0205|108 128|good tolerance Cefaclor
P04034220A0205|154 179|respiratory tract infections
P04034220A0205|182 189|children
P04034666T0000|0 26|Lower extremity weight bearing
P04034666T0000|32 56|various standing conditions
P04034666T0000|72 89|ambulatory patients
P04034666T0000|94 104|hemiparesis
P04036838A0918|29 43|hemodynamic data
P04036838A0918|47 73|RV/LV systolic pressure ratios
P04036838A0918|75 76|r =
P04036838A0918|82 86|p less
P04036838A0918|110 144|interventricular pressure differences
P04036838A0918|146 147|r =
P04036838A0918|154 158|p less
P04037809A0964|15 35|low toxic dose schedules
P04037809A0964|38 44|KW-2083
P04038454A0984|15 39|initial plasma retinol level
P04038454A0984|42 52|conjunction
P04038454A0984|57 59|RBP
P04038454A0984|85 92|patients
P04038454A0984|98 111|micrograms dl-1
P04038454A0984|116 121|mg dl-1
P04038454A0984|141 156|cancer recurrence
P04038454A0984|185 198|apparent cancer
P04038454A0984|204 217|micrograms dl-1
P04038454A0984|222 227|mg dl-1
P04038702A0768|3 9|results
P04038702A0768|28 42|initial response
P04038702A0768|45 53|tethering
P04038702A0768|71 85|previous penning
P04038702A0768|121 135|circadian rhythm
P04038702A0768|138 145|cortisol
P04038702A0768|155 161|altered
P04038702A0768|179 184|estrus
P04038702A0768|186 200|such disruptions
P04038702A0768|244 249|stalls
P04038702A0768|272 293|cortisol concentrations
P04038702A0768|296 300|gilts
P04039109A0139|17 31|sufficient power
P04039109A0139|36 54|amniotic fluid medium
P04039109A0139|64 79|placental vessels
P04039109A0139|90 91|mm
P04039109A0139|94 101|diameter
P04039109A0139|109 115|seconds
P04039109A0139|119 130|power density
P04039109A0139|137 141|W/cm2
P04039307A0613|2 2|d
P04039307A0613|7 18|progesterone
P04039307A0613|22 27|higher
P04039307A0613|29 33|P less
P04039307A0613|59 65|heifers
P04039307A0613|72 91|other treatment groups
P04039439A0000|0 16|Male Japanese quail
P04039439A0000|45 56|ppm manganese
P04039439A0000|58 59|Mn
P04039439A0000|63 87|particulate manganese oxide
P04039439A0000|89 93|Mn3O4
P04039439A0000|122 125|days
P04039439A0842|25 37|Japanese quail
P04039439A0842|56 79|particulate Mn3O4 exposure
P04039439A0842|84 90|rodents
P04039525A0475|0 5|Plasma
P04039525A0475|9 36|bladder platinum concentration
P04039525A0475|58 72|intravesical DDP
P04039525A0475|81 108|histopathological examination
P04039525A0475|110 119|urinalysis
P04039525A0475|121 138|complete blood count
P04039525A0475|142 155|blood chemistry
P04039525A0475|185 192|toxicity
P04039525A0475|195 209|intravesical DDP
P04039667T0000|0 25|Scintigraphic visualisation
P04039667T0000|28 46|Walker carcinoma-256
P04039667T0000|49 66|Sprague-Dawley rats
P04039667T0000|69 73|means
P04039667T0000|76 98|99mTc-labelled monocytes
P04039744A0141|5 11|results
P04039744A0141|44 51|D mothers
P04039744A0141|55 58|pups
P04039744A0141|74 80|mothers
P04039744A0141|83 96|oral supplement
P04039744A0141|100 116|i.u. vitamin D3/day
P04039744A0141|135 143|lactation
P04039744A0141|147 150|days
P04040083A0000|0 9|Rabbit eyes
P04040083A0000|30 58|temperature-regulated chambers
P04040083A0000|62 70|irrigated
P04040083A0000|75 80|saline
P04040307A0145|22 52|few perivascular adrenergic nerves
P04040307A0145|71 88|low ovarian NE levels
P04040339T0001|0 16|Monitoring changes
P04040339T0001|22 30|heart rate
P04040339T0001|36 49|premature fetus
P04040339T0001|56 64|tocolysis
P04040339T0001|72 101|beta-adrenomimetics partusisten
P04040339T0001|105 111|Pre-par
P04040858A0000|5 13|September
P04040858A0000|20 23|June
P04040858A0000|43 50|patients
P04040858A0000|55 67|ovarian cancer
P04041307A0614|3 9|results
P04041307A0614|24 40|calcium antagonist
P04041307A0614|42 50|diltiazem
P04041307A0614|64 70|effects
P04041307A0614|73 82|isoflurane
P04041307A0614|85 102|myocardial function
P04041346T0000|0 26|Supraventricular arrhythmias
P04041346T0000|29 35|digoxin
P04041346T0000|39 47|quinidine
P04043489A0648|0 6|Visidex
P04043489A0648|10 19|unsuitable
P04043489A0648|33 42|re-reading
P04048245A0331|0 8|Treatment
P04048245A0331|13 29|oxyphenylbutazone
P04048245A0331|33 46|hydrocortisone
P04048245A0331|71 84|serum CPN levels
P04050771A0474|3 29|Cox proportional hazards model
P04050771A0474|70 86|prognostic factors
P04050771A0474|90 106|long-term survival
P04050821A0531|16 30|mechanisms other
P04050821A0531|37 53|excessive increase
P04050821A0531|56 77|myocardial oxygen demand
P04050821A0531|100 111|many episodes
P04051521T0001|0 7|Duration
P04051521T0001|10 18|remission
P04051521T0001|21 49|advanced gastric cancer patients
P04051521T0001|62 75|sequential dose
P04051521T0001|78 80|MTX
P04051521T0001|84 87|5-FU
P04052919A0205|20 40|progesterone secretion
P04052919A0205|43 51|pulsatile
P04052919A0205|65 80|human luteal phase
P04052919A0205|86 101|maximum frequency
P04052919A0205|107 121|mid-luteal phase
P04052919A0205|136 150|mid-luteal phase
P04052919A0205|155 162|subjects
P04052919A0205|166 183|progesterone levels
P04052919A0205|218 236|ovulatory thresholds
P04052919A0205|247 263|single measurement
P04052919A0205|266 277|progesterone
P04052919A0205|283 297|mid-luteal phase
P04052919A0205|310 326|reliable indicator
P04052919A0205|329 337|ovulation
P04052919A0205|340 355|threshold greater
P04052919A0205|362 367|nmol/l
P04052919A0205|378 395|unacceptable number
P04052919A0205|398 417|false negative results
P04055593A0523|3 32|fast real-time digital processing
P04055593A0523|38 39|N2
P04055593A0523|43 53|flow signals
P04055593A0523|97 107|corrections
P04055593A0523|114 120|effects
P04055593A0523|123 129|changes
P04055593A0523|132 145|gas composition
P04056218A0463|19 24|higher
P04056218A0463|42 46|dB/dB
P04056218A0463|51 62|L1 = L2 greater
P04056218A0463|69 70|dB
P04056256A0416|0 18|Histamine reactivity
P04056256A0416|50 66|nifedipine aerosol
P04056256A0416|71 107|geometric mean provocative concentration
P04056256A0416|118 122|% fall
P04056256A0416|125 149|specific airway conductance
P04056256A0416|170 174|mg/ml
P04056256A0416|177 185|histamine
P04056256A0416|187 191|p less
P04058985A0000|0 17|Pharmacologic doses
P04058985A0000|20 28|vitamin B6
P04058985A0000|43 56|lactating women
P04058985A0000|83 97|plasma prolactin
P04061342A0512|23 38|similar elevation
P04061342A0512|47 52|uptake
P04061342A0512|61 75|min postexercise
P04061342A0512|82 82|%
P04061342A0512|99 103|p less
P04061342A0512|126 130|p less
P04062128T0028|0 17|National Institutes
P04062128T0028|20 64|Health Consensus Development Conference Statement
P04063732A0509|2 9|controls
P04063732A0509|33 39|conduit
P04063732A0509|75 75|%
P04066194A0163|0 17|Greater attenuation
P04066194A0163|23 27|N1-P2
P04066194A0163|31 50|baseline-P2 amplitude
P04066194A0163|56 63|probe EPs
P04066194A0163|82 94|probe stimulus
P04066194A0163|112 119|right ear
P04066194A0163|126 139|verbal material
P04066194A0163|154 160|left ear
P04066194A0163|172 201|opposite stimulation arrangement
P04066274A0265|11 18|patients
P04066274A0265|24 24|%
P04066274A0265|30 43|mixed neoplasms
P04066274A0265|60 89|total conservative parotidectomy
P04066274A0265|91 96|T.C.P.
P04066274A0265|104 104|%
P04066274A0265|108 111|S.P.
P04066274A0265|120 120|%
P04066274A0265|124 125|En
P04067540A0413|3 13|comparisons
P04067540A0413|26 59|female homicide-suicide perpetrators
P04067540A0413|78 106|female homicide-suicide victims
P04067540A0413|115 125|mobile homes
P04067540A0413|143 150|ex-lover
P04067540A0413|195 205|suicide note
P04067540A0413|257 285|female homicide-suicide victims
P04068663A0452|0 15|Germ-free rabbits
P04068663A0452|21 34|mouse CRF-flora
P04068663A0452|41 46|values
P04068663A0452|65 78|control animals
P04068663A0452|82 95|most parameters
P04068663A0452|107 119|unsuitability
P04068663A0452|122 134|mouse CRF flora
P04068663A0452|148 154|rabbits
P04068774A1292|3 19|weak relationships
P04068774A1292|27 27|F
P04068774A1292|31 32|Zn
P04068774A1292|35 36|Mg
P04068774A1292|50 66|significant effect
P04068774A1292|72 79|contents
P04068774A1292|87 94|elements
P04068969A0300|0 19|L3-L4 compressive load
P04068969A0300|49 55|anatomy
P04068969A0300|61 86|trunk musculoskeletal system
P04069756T0025|0 8|Diagnosis
P04069756T0025|10 49|progressive multifocal leukoencephalopathy
P04070725A0442|0 12|Component P100
P04070725A0442|31 47|frontal negativity
P04070725A0442|50 63|similar latency
P04070725A0442|88 112|dipolar occipital generator
P04071063A0863|10 20|differences
P04071063A0863|45 58|platelet counts
P04071063A0863|72 77|groups
P04071063A0863|79 94|fibrinogen levels
P04071063A0863|79 88|fibrinogen
P04071063A0863|98 121|alpha 2-antiplasmin levels
P04071063A0863|98 115|alpha 2-antiplasmin
P04071063A0863|150 174|antithrombin-treated group
P04071063A0863|150 161|antithrombin
P04073848T0000|0 6|Failure
P04073848T0000|9 29|stapedius reflexometry
P04073848T0000|46 61|myasthenia gravis
P04074214A0000|0 6|Factors
P04074214A0000|18 37|semen characteristics
P04074214A0000|40 49|young boars
P04074214A0000|59 80|subtropical environment
P04075021T0000|1 3|14C
P04075021T0000|6 24|beta-phenethylamine
P04075021T0000|62 74|various routes
P04075021T0000|77 80|cats
P04075021T0000|88 94|effects
P04075021T0000|97 122|monoamine oxidase inhibitors
P04075021T0000|97 112|monoamine oxidase
P04075061A0355|3 9|runners
P04075061A0355|26 26|L
P04079738A0677|3 7|rates
P04079738A0677|10 23|total energy use
P04079738A0677|32 34|SD =
P04079738A0677|57 64|kJ X min-1
P04079738A0677|66 70|P less
P04079738A0677|97 102|higher
P04079738A0677|108 115|degrees C
P04079738A0677|124 132|degrees C.
P04081425T0016|0 14|Clinical aspects
P04082267A0720|14 17|days
P04082267A0720|19 28|incubation
P04082267A0720|37 44|degrees C
P04082267A0720|50 57|degrees C
P04082267A0720|59 60|Ae
P04082267A0720|62 67|vexans
P04082592T0000|0 15|Blood eosinophils
P04082592T0000|18 25|patients
P04082592T0000|30 35|Taenia
P04084607A0663|3 13|imino proton
P04084607A0663|16 17|T3
P04084607A0663|23 27|O6meG
P04084607A0663|29 35|T 12-mer
P04084607A0663|39 40|G3
P04084607A0663|46 50|O6meG
P04084607A0663|52 63|N 12-mer helix
P04084607A0663|90 105|modification site
P04084607A0663|126 134|high field
P04084607A0663|144 146|ppm
P04084607A0663|158 169|imino protons
P04084607A0663|172 192|Watson-Crick base pairs
P04084607A0663|204 206|ppm
P04084896A0569|27 44|specific sub-groups
P04084896A0569|47 56|attempters
P04084896A0569|88 120|specialized intervention strategies
P04085589A0264a|28 41|secretor status
P04085589A0264a|45 58|clinical status
P04085589A0264a|60 81|spirometry measurements
P04085589A0264a|83 90|salivary
P04085589A0264a|94 112|serum lysozyme levels
P04085589A0264a|94 106|serum lysozyme
P04085589A0264a|115 119|rates
P04085589A0264a|122 149|respiratory tract colonization
P04085589A0264b|28 41|secretor status
P04085589A0264b|45 58|clinical status
P04085589A0264b|60 81|spirometry measurements
P04085589A0264b|83 90|salivary
P04085589A0264b|94 112|serum lysozyme levels
P04085589A0264b|94 106|serum lysozyme
P04085589A0264b|115 119|rates
P04085589A0264b|122 149|respiratory tract colonization
P04086403A1016|0 4|Gains
P04086403A1016|17 17|%
P04086403A1016|19 23|P less
P04086403A1016|35 48|feed conversion
P04086403A1016|60 60|%
P04086403A1016|62 66|P less
P04086403A1016|83 85|fed
P04086403A1016|89 95|% AS-VFA
P04086403A1016|115 128|feed conversion
P04086657T0000|0 29|Postnatal volumetric development
P04086657T0000|35 50|prefrontal cortex
P04086993T0000|0 4|Daily
P04086993T0000|8 26|seasonal rhythmicity
P04086993T0000|32 42|methylation
P04086993T0000|45 66|pineal indolic compounds
P04086993T0000|69 91|adult male golden hamsters
P04086993T0000|102 118|natural conditions
P04088233A0309|3 13|transit time
P04088396A0145|8 26|patients grades 1-2-3
P04088396A0145|30 30|%
P04088396A0145|56 78|neurological abnormality
P04088396A0145|88 95|patients
P04088396A0145|112 112|%
P04088733T0001|0 7|Activity
P04088733T0001|10 23|acid hydrolases
P04088733T0001|26 50|peripheral blood leukocytes
P04088733T0001|53 57|focal
P04088733T0001|61 78|segmental pneumonia
P04088733T0001|81 88|children
P04088936T0001|0 17|Comparative studies
P04088936T0001|23 37|antithrombin III
P04088936T0001|23 34|antithrombin
P04088936T0001|46 73|plasminogen activator activity
P04088936T0001|46 65|plasminogen activator
P04088936T0001|76 83|patients
P04088936T0001|88 103|thrombophlebitis
P04093211A0560|21 37|predictive ability
P04093211A0560|51 59|attitudes
P04093211A0560|63 74|orientations
P04101003T0001|0 8|Relations
P04101003T0001|16 41|cellular electrical activity
P04101003T0001|45 69|cardiac mechanical activity
P04102280T0000|0 8|Treatment
P04102280T0000|11 15|Paget
P04103248T0000|0 10|Improvement
P04103248T0000|16 25|CRT display
P04103248T0000|30 37|averager
P04113011T0000|2 16|desensitization
P04113011T0000|21 35|ragweed hay fever
P04114211T0000|0 13|Renal excretion
P04114211T0000|16 29|sulphadimidine
P04114211T0000|41 55|uraemic subjects
P04115870T0000|0 10|Experiences
P04115870T0000|29 43|experimental use
P04115870T0000|46 63|Urat-I lithotriptor
P04123217T0000|0 8|Formation
P04123217T0000|11 16|hyphae
P04123217T0000|20 33|chlamydospores
P04123217T0000|36 56|Cryptococcus laurentii
P04123662T0000|0 9|Evaluation
P04123662T0000|12 26|thyroid function
P04138224T0095|12 25|tissue emulsion
P04138224T0095|27 34|vitamin A
P04138224T0095|38 62|nonspecific gamma-globulin
P04138224T0095|49 62|gamma-globulin
P04138224T0095|68 81|blood clearance
P04138224T0095|84 90|rabbits
P04139081T0001|0 13|HL-A antibodies
P04139081T0001|16 37|polytransfused patients
P04139943T0001|0 12|Demonstration
P04139943T0001|15 27|fine structure
P04139943T0001|33 46|guinea pig organ
P04139943T0001|49 53|Corti
P04139943T0001|59 91|electron microscopic silver staining
P04140567T0001|0 18|Histamine metabolism
P04140567T0001|21 48|hemorrhagic-hypotensive shock
P04143528A0394|26 37|nomenclature
P04145244T0000|0 9|Relaxation
P04145244T0000|20 40|molluscan smooth muscle
P04152725T0001|0 6|Studies
P04152725T0001|9 28|alcoholic liver injury
P04160980T0000|0 18|Hypothalamic control
P04160980T0000|21 39|coronary circulation
P04164595T0020|0 7|Evidence
P04164595T0020|14 32|distinctive clinical
P04164595T0020|34 48|epidemiological
P04164595T0020|53 70|immunological types
P04164669T0000|0 37|Ultraviolet light-induced kinin formation
P04164669T0000|24 28|kinin
P04164669T0000|40 48|human skin
P04172166T0000|0 12|Poliomyelitis
P04175007T0001|17 27|stimulation
P04175007T0001|41 60|transplantable tumors
P04175007T0001|63 69|animals
P04175007T0001|91 115|antineoplastic antibiotics
P04176249T0001|0 9|Assessment
P04176249T0001|12 24|nutrient media
P04176249T0001|41 49|diptheria
P04176268T0000|0 13|Aluminium resin
P04176268T0000|34 45|hyperkalamia
P04176268T0000|48 59|renal failure
P04176625T0000|0 4|Value
P04176625T0000|10 12|EMG
P04176625T0000|30 43|cardiomyopathy
P04176625T0000|59 74|myotonic myopathy
P04179445T0036|0 1|D.
P04189158T0000|0 9|Prevention
P04189158T0000|12 34|maternal Rh sensitization
P04189158T0000|36 56|anti-Rh immune globulin
P04194466T0000|0 14|Serotonin levels
P04194466T0000|17 36|infant hypothyroidism
P04196986T0000|0 28|Cerebrospinal fluid transferrin
P04196986T0000|31 37|studies
P04196986T0000|40 56|ischemic disorders
P04196986T0000|62 81|central nervous system
P04213917T0001|0 10|High dosages
P04213917T0001|13 27|D-penicillamine
P04213917T0001|30 46|pulmonary fibroses
P04214345T0000|0 14|Inverse relation
P04214345T0000|22 42|serum IgG concentration
P04214345T0000|46 52|glucose
P04214345T0000|56 71|xylose absorption
P04214345T0000|74 93|Zambian African adults
P04226360T0001|0 8|Disorders
P04226360T0001|11 26|platelet function
P04226360T0001|29 51|chronic myeloid leukemias
P04239041T0045|11 25|anticonvulsants
P04239041T0045|28 59|sodium-potassium-activated ATPase
P04239041T0045|54 59|ATPase
P04239041T0045|71 78|potassim
P04239041T0045|81 86|cortex
P04246054T0028|0 5|Effect
P04246054T0028|8 24|immune lymphocytes
P04246054T0028|30 59|rabbit-anti-lymphocyte globulin
P04246054T0028|61 65|RAMLG
P04246054T0028|69 87|infected macrophages
P04246054T0028|106 126|incubation temperature
P04247472T0001|0 10|Estral cycle
P04247472T0001|13 21|white rats
P04247472T0001|33 45|high mountains
P04247472T0001|48 56|Kirghizia
P04247966T0000|0 8|Lactation
P04247966T0000|11 17|baboons
P04247966T0000|22 46|low protein maintenance diet
P04262268T0001|0 6|Studies
P04262268T0001|12 24|organic matrix
P04262268T0001|27 42|human ear ossicles
P04263748T0042|1 26|medical-geographical review
P04281856T0001|0 2|Age
P04281856T0001|6 17|sex structure
P04281856T0001|23 39|natural population
P04281856T0001|42 65|Ornithodoros tatarovski Ol
P04282315T0001|0 12|Sensitization
P04282315T0001|15 29|hyperlactatemia
P04282315T0001|39 48|phenformin
P04282315T0001|54 69|subtotal ablation
P04282315T0001|75 82|pancreas
P04284435T0000|0 8|Vitamin D3
P04284435T0000|12 28|calcium absorption
P04284435T0000|34 38|chick
P04289156T0000|3 11|incidence
P04289156T0000|14 20|tumours
P04289156T0000|23 35|young chickens
P04291759T0048|0 16|Laboratory aspects
P04291759T0048|21 39|particular reference
P04291759T0048|42 53|chemotherapy
P04295031T0062|16 24|guinea pig
P04305850T0000|0 8|Androgens
P04308979T0000|0 5|Effect
P04308979T0000|8 17|variations
P04308979T0000|20 31|time interval
P04308979T0000|52 54|BCG
P04308979T0000|58 67|quartz dust
P04308979T0000|70 82|translocation
P04308979T0000|85 94|quartz dust
P04308979T0000|102 106|lungs
P04308979T0000|114 131|regional lymph nodes
P04311951T0001|0 16|Therapeutic action
P04311951T0001|20 53|new antibiotic-corticoid association
P04311951T0001|61 73|instillations
P04311951T0001|76 82|otology
P04315233T0128|0 30|Clinico-physiological experiment
P04316696T0001|0 26|Enzyme histochemical findings
P04316696T0001|32 50|ultimobranchial body
P04321861T0001|0 37|Familial glutathione reductase deficiency
P04321861T0001|8 27|glutathione reductase
P04321861T0001|51 70|glutathione synthesis
P04321861T0001|76 86|erythrocyte
P04323641T0000|0 6|Studies
P04323641T0000|9 26|swine enteroviruses
P04325736T0001|0 12|Serodiagnosis
P04325736T0001|15 24|ectromelia
P04325736T0001|27 40|laboratory mice
P04328746T0073|0 15|Ultrasound effect
P04328746T0073|21 45|cytochrome oxidase activity
P04328746T0073|21 37|cytochrome oxidase
P04335965T0000|0 9|Metastasis
P04335965T0000|12 25|colon carcinoma
P04350410T0000|0 6|Genesis
P04350410T0000|9 17|foam cells
P04350410T0000|26 29|rats
P04350410T0000|51 58|Cloforex
P04364369T0000|0 20|Pre-beta-1 lipoprotein
P04364369T0000|24 37|early detection
P04364369T0000|40 50|risk factors
P04364369T0000|54 73|coronary heart disease
P04369884T0000|0 9|Conditions
P04369884T0000|21 30|inhibitors
P04369884T0000|36 59|colony-stimulating factor
P04369884T0000|61 63|CSF
P04371279T0000|0 6|Absence
P04371279T0000|9 24|action potentials
P04371279T0000|27 46|frog slow muscle fibres
P04371279T0000|58 71|botulinum toxin
P04377003A0000|23 42|quantitative analysis
P04377003A0000|48 67|polyamines putrescine
P04377003A0000|69 78|spermidine
P04377003A0000|82 89|spermine
P04377003A0000|92 109|cerebrospinal fluid
P04377003A0000|111 113|CSF
P04377003A0000|131 140|CSF samples
P04377003A0000|147 154|patients
P04377003A0000|159 178|central nervous system
P04377003A0000|180 182|CNS
P04377003A0000|184 189|tumors
P04377003A0000|199 206|patients
P04377003A0000|214 219|tumors
P04377328T0027|0 1|I.
P04385060T0000|0 9|Disulfiram
P04385060T0000|16 34|drug-induced effects
P04385060T0000|37 44|motility
P04387103T0000|0 8|Particles
P04387103T0000|19 29|microbodies
P04387103T0000|41 64|neoplastic perianal glands
P04387103T0000|67 70|dogs
P04392584T0000|0 6|Natural
P04392584T0000|10 24|induced malarias
P04392584T0000|27 50|western hemisphere monkeys
P04394290T0000|14 32|adrenergic receptors
P04394290T0000|38 43|rectum
P04394290T0000|63 71|sphincter
P04407649T0000|0 24|Intracranial arachnoid cyst
P04407649T0000|30 40|middle fossa
P04407649T0000|55 84|positive 99mTc brainscintigraphy
P04418687T0000|0 6|Effects
P04418687T0000|9 16|estrogen
P04418687T0000|20 34|glucocorticoids
P04418687T0000|40 57|adrenal development
P04418687T0000|63 67|fetus
P04423347T0001|0 5|Copper
P04423347T0001|9 28|ceruloplasmin content
P04423347T0001|9 21|ceruloplasmin
P04423347T0001|31 43|pregnant women
P04423347T0001|49 53|women
P04423347T0001|58 85|certain gynecological diseases
P04428800T0001|0 5|Effect
P04428800T0001|15 33|CO-induced increases
P04428800T0001|36 38|LAP
P04428800T0001|42 52|GPT activity
P04428800T0001|42 44|GPT
P04428800T0001|58 63|plasma
P04428800T0001|66 69|rats
P04428981T0000|0 7|Kinetics
P04428981T0000|10 26|calcium metabolism
P04429269T0000|16 20|mucus
P04429269T0000|27 44|rheologic simulants
P04429269T0000|47 61|ciliated systems
P04437406T0000|1 23|hydrodynamic description
P04437406T0000|29 56|osmotic reflection coefficient
P04437406T0000|77 86|pore theory
P04437406T0000|89 110|transcapillary exchange
P04445874T0001|0 8|Pathology
P04445874T0001|11 18|neuritis
P04446923T0001|0 22|Abnormal characteristics
P04446923T0001|26 39|verticillation
P04446923T0001|42 61|Platynothrus peltifer
P04460692T0000|8 13|topics
P04460692T0000|16 39|laboratory animal medicine
P04468264T0053|0 13|Problems common
P04468264T0053|16 25|pediatrics
P04468264T0053|29 42|anesthesiology
P04482661T0001|0 13|Clinical course
P04482661T0001|17 27|nursing care
P04482661T0001|30 37|patients
P04482661T0001|42 55|decubitus ulcer
P04482661T0001|63 69|pillows
P04482661T0001|81 94|buckwheat chaff
P04487835T0001|2 8|parents
P04487920T0001|7 33|Icelandic Red Cross activities
P04488232T0001|0 6|Effects
P04488232T0001|9 18|alcoholism
P04488271T0001|0 8|Treatment
P04488271T0001|18 38|adult diabetes mellitus
P04488271T0001|46 49|coma
P04495034T0000|12 24|methylbenzene
P04495034T0000|26 32|toluene
P04495034T0000|49 67|Ancylostomum caninum
P04506738T0000|0 8|Junctions
P04506738T0000|16 20|cells
P04506738T0000|26 41|human enamel organ
P04510102T0000|0 17|Electrocardiograms
P04511139T0001|0 9|Composites
P04511139T0001|12 31|restoration materials
P04512496T0000|0 6|Hodgkin
P04515631T0000|0 4|Value
P04515631T0000|7 15|Normotest
P04515631T0000|19 31|antithrombin 3
P04515631T0000|19 30|antithrombin
P04515631T0000|49 61|liver function
P04518624T0000|0 20|Glutathione peroxidase
P04518624T0000|23 35|human red cells
P04524081T0000|0 22|Histopathologic response
P04524081T0000|25 39|gingival tissues
P04524081T0000|42 49|hemodent
P04524081T0000|53 77|aluminum chloride solutions
P04524081T0000|80 106|tissue displacement materials
P04533208T0083|0 6|Changes
P04533208T0083|16 33|periodontal surgery
P04536964T0000|0 14|Intracellular pH
P04536964T0000|16 23|H ion flux
P04536964T0000|27 53|H ion permeability coefficient
P04536964T0000|56 72|bullfrog toe muscle
P04539552T0001|0 19|Teratological studies
P04539552T0001|22 27|SF-837
P04543036T0001|0 9|Directives
P04543036T0001|20 30|medical care
P04544430T0001|0 10|Proceedings
P04544430T0001|12 39|Reversible complete heart block
P04544430T0001|58 79|congenital heart defects
P04544704T0001|0 5|Method
P04544704T0001|8 16|synthesis
P04544704T0001|22 37|rheumatoid factor
P04544704T0001|40 67|clinico-immunological studies
P04546974T0000|0 9|Variations
P04546974T0000|23 33|deflections
P04546974T0000|42 57|bundle recordings
P04547933T0000|0 27|Extracellular fibril formation
P04547933T0000|30 44|neuroglial cells
P04547933T0000|50 70|vitreoretinal junction
P04547933T0000|76 83|human eye
P04548483T0001|0 13|Blood platelets
P04548483T0001|15 32|coagulation factors
P04548483T0001|36 58|morphologic organ changes
P04548483T0001|68 80|scalding shock
P04548483T0001|83 95|rhesus monkeys
P04551650T0001|0 12|Cell viability
P04551650T0001|16 31|lysosomal enzymes
P04552263T0000|0 20|State-approved schools
P04552263T0000|23 29|nursing
P04552263T0000|32 35|R.N.
P04562038T0001|0 19|Further investigation
P04562038T0001|25 44|chemotactic influence
P04562038T0001|47 59|thymic hormone
P04562038T0001|62 72|lymphocytes
P04563045T0000|0 8|1,3-bis(2
P04563045T0000|0 6|1,3-bis
P04563045T0000|8 20|2-chloroethyl
P04563045T0000|25 35|nitrosourea
P04563045T0000|37 40|bcnu
P04563045T0000|45 61|other nitrosoureas
P04563045T0000|64 78|cancer treatment
P04578686T0000|0 11|Pneumothorax
P04578686T0000|21 31|lung abscess
P04578686T0000|37 58|renal transplant patient
P04579436T0000|13 36|significant colour changes
P04579436T0000|39 58|Brevibacterium linens
P04579436T0000|82 103|carotenoid-like pigment
P04580044T0047|0 20|Temporal relationships
P04580044T0047|27 42|development phase
P04583791T0000|1 12|short history
P04583791T0000|15 25|dermatology
P04583791T0000|28 32|Lagos
P04583791T0000|34 40|Nigeria
P04598670T0000|0 20|Local graft irradiation
P04598670T0000|25 31|adjunct
P04598670T0000|34 63|pharmacologic immunosuppression
P04600603T0001|0 5|Letter
P04600603T0001|17 25|detection
P04613073T0001|0 3|Role
P04613073T0001|6 15|biocenosis
P04613073T0001|21 33|manifestation
P04613073T0001|36 52|Shigella virulence
P04615525T0001|11 28|antilymphocyte sera
P04615525T0001|42 56|transplantation
P04615525T0001|60 81|anti-infection immunity
P04615525T0001|84 87|mice
P04615828T0001|0 11|60th birthday
P04615828T0001|14 36|colonel prof. e.cerny m.d.
P04621188T0000|0 9|Morphology
P04621188T0000|12 25|bacteriophages
P04621188T0000|28 44|Klebsiella bacilli
P04622430T0000|0 16|Cortical afferents
P04622430T0000|22 37|entorhinal cortex
P04622430T0000|43 54|Rhesus monkey
P04624863T0001|0 8|Mechanism
P04624863T0001|11 23|immunogenesis
P04624863T0001|26 36|vaccination
P04624863T0001|41 69|streptomycin-dependent mutants
P04624863T0001|72 82|salmonellae
P04624863T0001|86 94|shigellae
P04627477T0001|0 16|Resistance pattern
P04627477T0001|19 43|Mycobacterium tuberculosis
P04627477T0001|45 45|H
P04627477T0001|48 49|Rv
P04627477T0001|54 66|new antibiotic
P04627477T0001|68 78|lividomycin
P04632967T0000|0 24|Pulmonary arterial pressure
P04632967T0000|42 52|patas monkey
P04632967T0000|58 80|prolonged administration
P04632967T0000|83 98|aminorex fumarate
P04638365T0001|0 5|Effect
P04638365T0001|8 16|triftazin
P04638365T0001|20 27|aminazin
P04638365T0001|30 59|hippocampal bioelectric activity
P04640155T0045|0 7|Sex ratio
P04645078T0001|0 20|Pathological processes
P04645078T0001|26 36|cervix uteri
P04646045T0001|0 21|Benign intramural tumors
P04646045T0001|27 35|esophagus
P04653144T0000|0 14|General formulae
P04653144T0000|28 39|heritability
P04653144T0000|57 70|related parents
P04654249T0000|0 10|Measurement
P04654249T0000|13 30|open-loop responses
P04654249T0000|33 53|electrical stimulation
P04654249T0000|56 68|olfactory bulb
P04656185T0000|0 23|Glucose disappearance rate
P04656185T0000|27 33|changes
P04656185T0000|36 50|plasma nutrients
P04656185T0000|56 67|intravenouly
P04656185T0000|76 82|glucose
P04656185T0000|85 98|normoglycaemic
P04656185T0000|102 133|hypoglycaemic underweight newborns
P04661961T0001|0 11|Normal values
P04661961T0001|18 32|peripheral blood
P04661961T0001|36 45|bone marrow
P04661961T0001|51 54|grey
P04661961T0001|56 63|Armenian
P04661961T0001|65 71|hamster
P04676734T0000|17 38|human umbilical arterial
P04676734T0000|42 59|venous plasma levels
P04676734T0000|62 76|corticosteroids
P04676734T0000|79 92|gestational age
P04679438T0001|0 15|Antibiotic effect
P04679438T0001|28 32|heviz
P04679807T0000|0 24|Sulfuric acid concentration
P04679807T0000|39 57|breathalyzer ampules
P04704137T0001|0 3|Role
P04704137T0001|6 25|histoclinical studies
P04704137T0001|31 41|prophylaxis
P04704137T0001|44 63|spontaneous abortions
P04704186T0000|0 12|Range behavior
P04704186T0000|15 22|Hereford
P04704186T0000|24 31|Hereford
P04704186T0000|33 40|Holstein
P04704186T0000|44 71|Holstein non-lactating heifers
P04712626T0000|0 19|Chemical constituents
P04712626T0000|25 37|gentianaceae V
P04712626T0000|54 62|xanthones
P04712626T0000|65 87|Swertia chirata Buch.-Ham
P04718233T0000|0 24|Methyl mercury intoxication
P04718233T0000|27 36|rat kidneys
P04727344T0000|0 17|Microdetermination
P04727344T0000|20 41|adrenocortical steroids
P04727344T0000|44 62|double isotope method
P04729063T0000|0 18|Compensative justice
P04729063T0000|22 36|moral investment
P04729063T0000|62 68|Koreans
P04730467T0000|0 6|Effects
P04730467T0000|9 17|cortisone
P04730467T0000|19 28|starvation
P04730467T0000|33 39|rickets
P04730467T0000|42 66|oxidative enzyme activities
P04730467T0000|69 87|epiphyseal cartilage
P04730467T0000|92 95|rats
P04733391T0000|0 25|Metal coordination compounds
P04733391T0000|28 40|thiabendazole
P04746559T0053|0 9|Estimation
P04746559T0053|12 29|renin secretion rate
P04746559T0053|12 16|renin
P04746559T0053|33 47|renal plasma flow
P04746559T0053|52 61|peripheral
P04746559T0053|65 84|renal vein renin levels
P04746559T0053|65 78|renal vein renin
P04752455T0000|0 18|Disability insurance
P04752455T0000|24 37|social security
P04753073T0000|0 5|Choice
P04753286T0000|0 10|Suppression
P04753286T0000|13 22|food intake
P04753286T0000|33 39|tung oil
P04757217T0000|0 6|Studies
P04757217T0000|9 21|lipoprotein-X
P04757217T0000|23 26|LP-X
P04757217T0000|31 39|bile acids
P04757217T0000|42 63|familial LCAT deficiency
P04757217T0000|50 53|LCAT
P04758799T0000|0 11|Pneumothorax
P04758799T0000|25 47|chronic steroid treatment
P04759722T0000|0 16|Polycythemia-1973
P04760826T0000|0 14|Manifest anxiety
P04760826T0000|17 32|Vietnam returnees
P04760826T0000|36 49|undergraduates
P04764049T0001|0 31|Familial juvenile nephronophthisis
P04766888T0000|5 18|heparin therapy
P04766888T0000|23 30|children
P04766888T0000|35 54|acute meningococcemia
P04778129T0000|0 16|9,11-Seco steroids
P04778129T0000|28 49|estradiol 3-methyl ether
P04782788T0001|0 24|Psychological examinations
P04782788T0001|27 34|patients
P04782788T0001|39 64|chronic kidney insufficiency
P04784432T0001|0 12|Possibilities
P04784432T0001|15 38|needleless administration
P04784432T0001|41 57|various substances
P04784432T0001|60 66|animals
P04787472T0001|0 5|Change
P04787472T0001|37 57|short-term local action
P04787472T0001|61 82|permanent magnetic field
P04787472T0001|88 96|human body
P04787716T0000|0 11|Observations
P04787716T0000|17 32|flight activities
P04787716T0000|35 54|Chrysops caecutiens L.
P04788701T0001|0 10|Combination
P04788701T0001|14 37|multiple primary malignant
P04788701T0001|41 52|benign tumors
P04788701T0001|58 64|breasts
P04788701T0001|68 73|uterus
P04789916T0001|0 7|Analysis
P04789916T0001|10 23|clearance curve
P04789916T0001|30 41|bengal-I-131
P04791420T0000|0 10|Proceedings
P04791420T0000|12 18|Barrels
P04791420T0000|22 31|somatotopy
P04791420T0000|34 34|S
P04791420T0000|36 44|neocortex
P04791420T0000|50 67|brush-tailed possum
P04794218T0001|0 17|Antivitamin K agents
P04796997T0000|0 17|Canine reproduction
P04796997T0000|19 25|effects
P04796997T0000|29 43|single injection
P04796997T0000|46 71|medroxyprogesterone acetate
P04796997T0000|77 94|reproductive organs
P04796997T0000|100 104|bitch
P04801663T0049|0 11|Hypoglycemic
P04801663T0049|15 36|antidiabetic properties
P04803629T0001|0 18|Hematopoietic system
P04803629T0001|21 40|streptococcal allergy
P04810131T0000|0 5|Letter
P04810131T0000|7 32|Aryl hydrocarbon hydroxylase
P04810131T0000|36 42|smoking
P04813394T0000|0 9|Evaluation
P04813394T0000|12 30|1,10-phenanthroline
P04813394T0000|34 40|reagent
P04813394T0000|44 67|sialic acid determinations
P04820791T0001|0 23|Delta-aminolevulinic acid
P04820791T0001|26 48|physiological conditions
P04820791T0001|56 63|diseases
P04820791T0001|66 73|children
P04824747T0000|0 16|Nonteratogenicity
P04824747T0000|19 22|rats
P04824747T0000|25 40|blighted potatoes
P04824747T0000|44 52|compounds
P04826272T0074|0 2|VII
P04828587T0000|0 8|Isolation
P04828587T0000|11 42|tha avian reticuloendothelial virus
P04828587T0000|44 50|strain T
P04837183T0000|0 11|Observations
P04837183T0000|14 21|saccules
P04837183T0000|24 27|rats
P04837183T0000|37 57|long-term hypergravity
P04839176T0001|0 5|Effect
P04839176T0001|9 30|high-intensity SHF field
P04839176T0001|36 57|blood coagulation system
P04843031T0000|3 8|levels
P04843031T0000|11 39|galactosyltransferase activity
P04843031T0000|11 31|galactosyltransferase
P04843031T0000|42 45|sera
P04843031T0000|50 63|normal children
P04843031T0000|67 74|patients
P04843031T0000|79 92|cystic fibrosis
P04852635T0000|0 3|Lack
P04852635T0000|17 42|appetite stimulant pizotifen
P04852635T0000|44 45|BC
P04852635T0000|55 64|absorption
P04852635T0000|67 87|isonicotinylhydrazine
P04863895T0000|0 11|Relationship
P04863895T0000|19 30|gross lesions
P04863895T0000|49 57|serotypes
P04863895T0000|60 84|chronic respiratory disease
P04863895T0000|86 88|CRD
P04863895T0000|92 98|poultry
P04871589T0001|0 14|Plastic solution
P04871589T0001|17 35|elbow joint ankylosis
P04871589T0001|53 67|cylindrical flap
P04878680T0000|0 6|Effects
P04878680T0000|31 45|human oral cavity
P04878680T0000|49 58|oropharynx
P04878680T0000|60 66|results
P04884060T0000|3 22|Twentieth Anniversary
P04884060T0000|28 51|Pomeranian Medical Academy
P04890336T0001|0 26|Immunelectrophoretic pattern
P04890336T0001|29 44|Wassermann reagin
P04890336T0001|63 76|appearance time
P04890336T0001|84 87|RPCF
P04890336T0001|91 103|FTA antibodies
P04909355T0000|0 29|Motile nocardoid Actinomycetales
P04911925T0001|0 31|Electrocardiographic QRS complexes
P04911925T0001|35 60|vectorcardiographic QRS loop
P04919613T0001|0 4|Study
P04919613T0001|7 31|antinuclear autoantibodies
P04919613T0001|34 58|immunofluorescence technic
P04919613T0001|61 76|collagen diseases
P04921762T0000|0 18|Cardiac preservation
P04925617T0000|0 8|Labial bar
P04941419T0000|0 24|Yusuf Dawood Docrat L.R.C.P.
P04941951T0000|0 2|Dr.
P04942414T0000|3 12|metabolism
P04942414T0000|16 27|pharmacology
P04942414T0000|30 43|5-fluorouracil
P04947347T0000|0 11|Spleen weight
P04947347T0000|14 17|rats
P04947347T0000|24 35|tumour growth
P04947347T0000|41 58|homograft rejection
P04948325T0000|0 8|Isolation
P04948325T0000|11 17|Proteus
P04948325T0000|26 30|MC-63
P04948325T0000|35 43|carcinoma
P04948325T0000|52 66|antitumor effect
P04948325T0000|69 82|Crocker sarcoma
P04948325T0000|89 104|Ehrlich carcinoma
P04959816T0000|0 17|Human synovial fluid
P04959816T0000|19 27|detection
P04959816T0000|31 42|new component
P04967824T0000|0 6|Effects
P04967824T0000|23 35|moulting cycle
P04967824T0000|38 53|melanin synthesis
P04967824T0000|59 62|newt
P04970131T0001|4 20|reflexions apropos
P04970131T0001|24 47|personal statistical study
P04970131T0001|53 69|arterial embolisms
P04970918T0069|0 9|LA-3848-MS
P04973523T0000|0 20|Immunochemical studies
P04973523T0000|25 40|filarial antigens
P04975676T0000|0 12|Morphological
P04975676T0000|16 36|functional alterations
P04975676T0000|47 76|baboon renal allotransplantation
P04976988T0000|0 12|Heterogeneity
P04976988T0000|15 31|human serum albumin
P04989251T0000|0 7|Analysis
P04989251T0000|10 24|corticosteroids
P04990556T0000|0 11|Reactivities
P04990556T0000|14 41|horse anti-lymphocyte globulin
P04992478T0000|0 16|Plasma histaminase
P04992478T0000|19 26|patients
P04992478T0000|29 43|bronchial asthma
P04992478T0000|58 83|prednisolone administration
P04999086T0001|1 16|comparative study
P04999086T0001|22 32|cortical end
P04999086T0001|38 53|auditory analyzer
P04999086T0001|60 79|postnatal ontogenesis
P04999086T0001|82 93|lower monkeys
P05000171T0000|11 21|osmotic flow
P05000171T0000|41 61|horseradish peroxidase
P05000171T0000|71 89|intercellular spaces
P05000171T0000|92 112|toad bladder epithelium
P05005311T0000|0 13|Immunogenicity
P05005311T0000|16 34|various mycobacteria
P05005311T0000|41 59|corresponding levels
P05005311T0000|62 77|cross-protection
P05012220T0000|0 17|Ten-year experience
P05012220T0000|22 45|one-stage proctocolectomy
P05012220T0000|49 61|anal ileostomy
P05015678T0000|0 27|Nitrogen-hydrogen tautomerism
P05015678T0000|30 39|porphyrins
P05015678T0000|43 50|chlorins
P05020660T0000|0 6|Factors
P05020660T0000|19 28|inhibition
P05020660T0000|31 42|phagocytosis
P05020660T0000|45 58|chlorpromazine
P05021912T0000|0 26|Photopic spectral sensitivity
P05021912T0000|67 75|pigeon eye
P05025918T0000|0 10|Angiography
P05025918T0000|13 30|aneurysmal bone cyst
P05027295T0034|0 13|Cholinesterase
P05027799T0000|0 16|Sodium restriction
P05027799T0000|19 32|cardiac failure
P05028628T0001|0 7|Clinical
P05028628T0001|11 34|angiographic examinations
P05028628T0001|37 52|occlusion disease
P05028628T0001|58 80|great intestinal arteries
P05031074T0001|0 16|Serum lipid changes
P05031074T0001|23 34|pregnancy due
P05031074T0001|37 61|oral calcium administration
P05031659T0000|0 18|Successful treatment
P05031659T0000|21 31|candidiasis
P05031659T0000|36 49|transfer factor
P05034373T0000|1 12|possible role
P05034373T0000|19 50|mixed function oxidase enzyme system
P05034373T0000|70 77|selenium
P05045351T0000|0 16|Periodic breathing
P05045351T0000|20 24|apnea
P05045351T0000|27 40|preterm infants
P05049711T0000|7 19|session report
P05060388T0000|0 23|Clinicopathologic studies
P05060388T0000|36 41|tumors
P05060388T0000|47 51|ovary
P05065548T0075|5 16|constituents
P05065548T0075|19 37|Dryopteris polylepis
P05066316T0001|0 7|Relation
P05066316T0001|28 39|raw materials
P05066316T0001|56 63|products
P05066316T0001|69 77|synthesis
P05066316T0001|80 95|aluminosilicates
P05068271T0000|0 8|Influence
P05068271T0000|17 35|urinary VMA excretion
P05075857T0000|0 28|Oscilloscope triggering circuit
P05075857T0000|41 54|long transients
P05075857T0000|57 71|fast sweep speeds
P05081814T0000|0 10|Derivatives
P05081814T0000|13 26|boswellic acids
P05083872T0000|23 38|training programs
P05083872T0000|41 55|speech pathology
P05083872T0000|59 67|audiology
P05087496T0000|0 15|Coronary arteries
P05091970T0000|0 14|Antiviral agents
P05093030T0001|0 9|Separation
P05093030T0001|12 38|ninhydrin-positive compounds
P05093030T0001|41 45|urine
P05093030T0001|51 65|combined methods
P05093030T0001|68 93|medium-tension intophoresis
P05093030T0001|97 119|partition chromatography
P05095988T0001|0 20|Conservative treatment
P05095988T0001|23 50|central nervous system injuries
P05101762T0000|0 12|Spasmus nutans
P05101762T0000|25 36|auto-arousal
P05110049T0001|0 6|1st data
P05110049T0001|12 35|immunosuppressive therapy
P05110049T0001|38 48|scleroderma
P05114515T0000|6 27|lysosomal enzyme release
P05114515T0000|6 20|lysosomal enzyme
P05114515T0000|34 46|normalization
P05114515T0000|49 53|drugs
P05114515T0000|56 84|adjuvant-induced polyarthritis
P05119546T0001|0 8|Treatment
P05119546T0001|11 26|ovarian neoplasms
P05120197T0000|0 23|Experimental pancreatitis
P05120197T0000|26 29|pigs
P05123884T0000|0 18|Bacterial metabolism
P05123884T0000|21 42|4-chlorophenoxyacetate
P05124707T0001|0 7|Dynamics
P05124707T0001|10 21|hospital stay
P05124707T0001|24 42|peptic ulcer patients
P05124972T0042|0 1|I.
P05128149T0001|0 16|Surgical treatment
P05128149T0001|19 33|pathologic scars
P05128149T0001|36 52|myocardial infarct
P05132558T0000|16 23|caffeine
P05132558T0000|25 36|theophylline
P05132558T0000|40 50|theobromine
P05132558T0000|55 80|monoamine oxidase inhibitors
P05132558T0000|55 70|monoamine oxidase
P05133723T0000|0 5|Effect
P05133723T0000|8 17|phenformin
P05133723T0000|20 34|gluconeogenesis
P05133723T0000|37 52|perfused rat liver
P05135168T0000|0 11|New alkaloids
P05135168T0000|16 19|bark
P05135168T0000|22 42|Erythrophleum ivorense
P05138738T0001|7 21|M hemoglobinosis
P05145925T0000|0 19|Radiosensitive nature
P05145925T0000|22 62|paravascular infiltrate-producing potential
P05145925T0000|65 83|parental spleen cells
P05152314T0001|0 21|Sinusoidal oscillations
P05152314T0001|25 44|gas dilution indicator
P05154132T0000|10 25|different sources
P05154132T0000|28 35|nitrogen
P05154132T0000|38 42|diets
P05154132T0000|49 64|early-weaned calf
P05162342T0001|0 14|Abdominal tumors
P05170106T0034|0 6|Results
P05170106T0034|12 29|official inspection
P05170106T0034|35 79|commercial anti-inflammatory enzyme preparations
P05170106T0034|90 101|chymotrypsin
P05170106T0034|105 111|trypsin
P05170106T0034|114 118|means
P05170106T0034|129 130|NF
P05170106T0034|133 139|methods
P05172320T0001|0 6|Studies
P05172320T0001|12 27|hereditary nature
P05172320T0001|30 39|sole prints
P05172320T0001|46 61|special reference
P05172320T0001|64 75|interdigital
P05172320T0001|79 86|triradii
P05172970T0001|12 25|disablement due
P05172970T0001|28 48|pulmonary tuberculosis
P05172970T0001|89 93|cases
P05172970T0001|106 111|Gdansk
P05172970T0001|117 121|years
P05174753T0001|0 22|Cleidocranial dysostosis
P05177935T0001|0 8|Proposals
P05177935T0001|11 23|authorization
P05177935T0001|35 40|nurses
P05177935T0001|45 64|psychiatric hospitals
P05203499T0001|0 31|Successive abdominal scintillation
P05203499T0001|36 50|131-I-tagged BSP
P05203499T0001|69 80|thyroid gland
P05203499T0001|82 87|kidney
P05203499T0001|91 96|spleen
P05203499T0001|112 119|131-I-RB
P05210791T0001|0 8|Pneumonia
P05210791T0001|11 18|children
P05253274T0001|0 11|Osteosarcoma
P05253274T0001|20 34|3,4-benzopyrene
P05274128T0001|12 22|glucosamine
P05274128T0001|26 38|galactosamine
P05274128T0001|41 46|tartar
P05274526T0000|0 6|Relapse
P05274526T0000|9 16|leukemia
P05274526T0000|22 39|prolonged remission
P05276380T0000|0 8|Influence
P05276380T0000|11 26|cigarette smoking
P05276380T0000|33 53|blood coagulation tests
P05284310T0000|3 10|non-role
P05284310T0000|13 20|fluoride
P05284310T0000|35 47|plasma calcium
P05284310T0000|53 75|parathyroidectomized rat
P05285978T0076|0 11|Second report
P05285978T0076|17 38|Norwegian Cancer Society
P05299993T0000|0 11|Modification
P05299993T0000|25 35|Tetrahymena
P05299993T0000|38 46|compounds
P05299993T0000|61 79|adrenergic mechanism
P05303700T0066|0 11|SAM-TR-68-54
P05305671T0000|1 15|brief discussion
P05305671T0000|18 34|color deficiencies
P05308271T0000|0 2|BIM
P05309471T0000|0 7|Problems
P05309471T0000|31 46|antigenic content
P05309471T0000|49 65|influenza vaccines
P05316745T0000|0 11|Aedes aegypti
P05316745T0000|13 14|L.
P05316745T0000|19 33|Aedes albopictus
P05316745T0000|35 39|Skuse
P05316745T0000|43 55|Singapore City
P05322558T0000|0 16|Homograft response
P05322558T0000|20 42|hemagglutinin production
P05322558T0000|20 32|hemagglutinin
P05322558T0000|55 86|thymectomized irradiated adult mice
P05322747T0034|0 15|Comparative study
P05322747T0034|18 34|acute oral overload
P05322747T0034|40 50|tolbutamide
P05322747T0034|54 63|tolazamide
P05322747T0034|75 90|diabetic subjects
P05340801T0000|0 9|Mycotoxins
P05340801T0000|20 24|foods
P05344097T0000|0 6|Factors
P05344097T0000|25 56|skin permeability factor production
P05344097T0000|59 72|Vibrio cholerae
P05353667T0000|0 23|Spinal cord representation
P05353667T0000|29 45|micturition reflex
P05356107T0001|0 15|Biological action
P05356107T0001|19 26|kinetics
P05356107T0001|32 42|elimination
P05356107T0001|45 56|tritium oxide
P05356107T0001|59 62|dogs
P05357390T0001|0 3|Auto
P05357390T0001|8 14|isotopy
P05357390T0001|20 30|conjunctiva
P05359464T0000|0 7|Pitfalls
P05359464T0000|18 45|chromosome aberration analysis
P05359464T0000|49 76|biological radiation dosimetry
P05362866T0000|0 13|Renin secretion
P05362866T0000|0 4|Renin
P05362866T0000|39 50|hypertension
P05363816T0001|19 42|forensic medical expertise
P05363816T0001|54 87|urgent criminal investigative actions
P05364951T0001|0 13|Histopathology
P05364951T0001|17 28|pathogenesis
P05364951T0001|31 50|exanthematous viroses
P05368978T0000|0 9|CNS effects
P05368978T0000|12 27|local anesthetics
P05368978T0000|52 74|biogenic amine mechanisms
P05372511T0105|0 16|Diethylene benzene
P05379901T0000|0 11|Midge control
P05379901T0000|14 26|flood channels
P05388567T0000|3 9|effects
P05388567T0000|12 21|taloximine
P05388567T0000|25 37|aminophylline
P05388567T0000|48 64|human smooth muscle
P05389125T0000|3 22|exploratory behaviour
P05389125T0000|34 47|aggressive mice
P05394352T0000|0 11|Genitography
P05394352T0000|14 30|intersexual states
P05394461T0001|0 12|Tolerance test
P05394461T0001|15 16|HB
P05394461T0001|22 38|animal experiments
P05410590T0000|9 20|ascorbic acid
P05410590T0000|38 58|bladder tumor formation
P05410641T0000|6 12|percent
P05410641T0000|14 24|Venturi mask
P05410641T0000|27 50|obstructive airway disease
P05412122T0000|3 8|Methyl
P05412122T0000|10 17|8-methyl
P05412122T0000|22 40|8-phenyl derivatives
P05412122T0000|43 58|5,9-dimethyl-6,7
P05412122T0000|60 72|benzomorphans
P05412687T0000|0 17|Antidromic invasion
P05412687T0000|20 27|impulses
P05412687T0000|31 59|recurrent collateral inhibition
P05412687T0000|62 83|pyramidal tract neurones
P05413428T0000|17 26|body fluids
P05413428T0000|36 45|hemorrhage
P05413428T0000|49 61|resuscitation
P05413428T0000|64 79|combat casualties
P05414186T0001|8 24|Hong Kong influenza
P05414186T0001|30 40|Netherlands
P05417431T0001|5 14|disagnosis
P05417431T0001|30 33|cent
P05417431T0001|39 46|patients
P05421537T0001|0 11|Difficulties
P05421537T0001|30 44|sputum viscosity
P05424220T0001|0 17|Lipid concentration
P05424220T0001|21 34|lipase activity
P05424220T0001|21 26|lipase
P05424220T0001|40 48|epiphysis
P05424220T0001|51 70|adrenalectomized rats
P05424220T0001|88 109|different sodium content
P05425195T0001|0 7|Behavior
P05425195T0001|10 34|aspartate aminotransferase
P05425195T0001|36 44|EC 2.6.1.1
P05425195T0001|36 37|EC
P05425195T0001|49 71|alanine aminotransferase
P05425195T0001|73 81|EC 2.6.1.2
P05425195T0001|73 74|EC
P05425195T0001|85 92|rat serum
P05425195T0001|110 131|acute radiation syndrome
P05425195T0001|141 162|whole body X-irradiation
P05437405T0000|10 41|forearm arteriolar dilator capacity
P05437405T0000|52 89|mineralocorticoid-induced salt retention
P05441564T0001|0 6|Studies
P05441564T0001|12 24|pathogenicity
P05441564T0001|27 30|ECHO
P05441564T0001|33 36|HILL
P05441564T0001|49 55|mutants
P05441564T0001|59 70|suckling mice
P05445187T0000|0 26|Counter-current heat exchange
P05445187T0000|32 50|respiratory passages
P05445187T0000|68 78|heat balance
P05451324T0000|0 10|Calibration
P05451324T0000|15 24|correction
P05451324T0000|51 53|Po2
P05451324T0000|57 68|CO saturation
P05456002T0000|0 6|Mae West
P05456002T0000|13 26|doctor shortage
P05460466T0001|0 10|Elimination
P05460466T0001|13 29|gamma-irradiation
P05460466T0001|37 45|oxidation
P05460466T0001|48 70|aqueous drug preparations
P05463837T0023|3 23|absolute configuration
P05463837T0023|26 28|C-2
P05463837T0023|31 46|monocrotalic acid
P05466177T0001|0 17|Teratogenic effects
P05466177T0001|20 31|actinomycin D
P05466177T0001|34 37|rats
P05471866T0000|3 34|plasma growth hormone concentration
P05471866T0000|40 49|foetal lamb
P05472485T0000|0 28|Bimodal cochlear response curves
P05472485T0000|31 37|rodents
P05474466T0001|1 23|new hemagglutination test
P05474466T0001|30 42|on-slide assay
P05474466T0001|45 60|rheumatoid factor
P05488121T0000|0 14|CO2 assimilation
P05488121T0000|17 28|chloroplasts
P05488121T0000|42 52|filter paper
P05492285T0000|12 30|Hyostrongylus ruidus
P05496619T0000|0 14|Foreign profiles
P05496619T0000|17 45|air pollution control activities
P05497793T0000|0 6|Effects
P05497793T0000|9 35|chronic metaraminol treatment
P05497793T0000|41 59|sympathetic activity
P05497793T0000|71 93|adrenal demedullated rats
P05497793T0000|106 121|cold environments
P05500957T0001|16 24|clopamide
P05500957T0001|28 36|hydergine
P05500957T0001|38 46|Brinedine
P05500957T0001|67 88|vasculo-renal syndromes
P05501347T0001|11 28|low dosage radiation
P05501347T0001|31 40|metabolism
P05501347T0001|57 65|rat kidney
P05501347T0001|75 82|ischemia
P05502054T0000|0 7|Leukemia
P05502054T0000|10 14|twins
P05502054T0000|16 31|world-wide review
P05502054T0000|34 46|clinical cases
P05525652T0064|0 16|Preliminary report
P05529283T0000|0 11|Quantitation
P05529283T0000|14 24|exocrine IgA
P05529283T0000|27 36|human serum
P05532854T0001|0 29|Gastrointestinal manifestations
P05532854T0001|32 48|systemic sclerosis
P05533214T0001|0 15|Iodine metabolism
P05533214T0001|18 35|chronic thyroiditis
P05536803T0001|0 13|Total body water
P05536803T0001|15 28|rhodanide space
P05536803T0001|32 49|I-131-albumin space
P05536803T0001|32 44|I-131-albumin
P05536803T0001|58 68|acute effect
P05536803T0001|71 80|furosemide
P05544291T0031|0 1|V.
P05552149T0000|0 2|18F
P05552149T0000|6 20|85Sr scintimetry
P05552149T0000|33 52|primary arthropathies
P05552642T0000|0 10|Propagation
P05552642T0000|14 30|hormone production
P05552642T0000|33 43|human normal
P05552642T0000|47 66|malignant trophoblast
P05552642T0000|69 72|rats
P05553261T0000|0 5|Health
P05553261T0000|9 28|integrative reticulum
P05555149T0001|0 26|Sensitive fluorometric method
P05555149T0001|40 41|SH
P05555149T0001|46 55|S-S-groups
P05556977T0001|0 12|Morphogenesis
P05556977T0001|18 27|trochanter
P05556977T0001|38 56|femoral regeneration
P05556977T0001|62 86|phasmid Carausius morosus Br
P05560428T0001|0 9|Behavioral
P05560428T0001|13 36|electrographic expression
P05560428T0001|39 50|natural sleep
P05560428T0001|54 64|wakefulness
P05560428T0001|67 74|reptiles
P05567721T0000|0 12|Sensitivities
P05567721T0000|15 29|thromboplastins
P05567721T0000|32 50|factor VII deficiency
P05567721T0000|32 40|factor VII
P05572662T0000|0 20|Central venous catheter
P05572662T0000|37 65|intracardiac electrocardiogram
P05574818T0000|3 5|Lab
P05574818T0000|7 24|computer programmes
P05574818T0000|46 54|isometric
P05574818T0000|58 91|isotonic contractile characteristics
P05574818T0000|94 107|skeletal muscle
P05593469T0001|4 21|head-brain injuries
P05594277T0051|3 14|modification
P05594277T0051|17 25|P32 uptake
P05594277T0051|33 45|Jensen sarcoma
P05594277T0051|63 70|peroxide
P05594277T0051|76 90|nutritive medium
P05595036T0001|0 7|Students
P05595036T0001|9 15|parents
P05595036T0001|17 24|teachers
P05595036T0001|35 43|disorders
P05621339T0001|21 25|doses
P05621339T0001|28 43|Cs137 irradiation
P05627251T0000|0 13|Positive shifts
P05627251T0000|16 34|basal skin potentials
P05627251T0000|41 50|human sleep
P05642051T0000|10 36|dietary department management
P05671267T0000|3 21|Dimethylaminopropyl
P05671267T0000|30 45|dihydro-5H-benzo
P05671267T0000|51 56|pyrido
P05671267T0000|58 62|6,7-b
P05671267T0000|64 70|azepine
P05672903T0001|0 21|Osteogenesis imperfecta
P05683363T0001|0 12|Investigation
P05683363T0001|28 31|Ca45
P05683363T0001|43 52|burned rats
P05683363T0001|58 78|kinetic analysis method
P05683809T0000|0 5|Effect
P05683809T0000|8 17|thrombotic
P05683809T0000|21 39|antithrombotic drugs
P05683809T0000|45 72|surface charge characteristics
P05683809T0000|75 92|canine blood vessels
P05683809T0000|110 116|studies
P05684081T0001|0 11|Measurements
P05684081T0001|29 58|radioprotective chamber VA-K-254
P05684081T0001|64 77|osimeter VA-J18
P05689427T0052|3 36|N-Alkyl-N-2-chloroethylaminomethyl
P05689427T0052|43 57|7-halogenobenzo
P05689427T0052|59 59|b
P05689427T0052|61 82|thiophen hydrochlorides
P05692759T0001|0 10|Nephrectomy
P05693602T0001|0 9|Evaluation
P05693602T0001|12 37|automatic blood cell counters
P05693605T0001|0 12|Determination
P05693605T0001|15 27|transaminases
P05693605T0001|34 45|autoanalyzer
P05715613T0000|0 6|Sterols
P05715613T0000|9 14|pollen
P05718386T0001|0 10|Dermoid cyst
P05718386T0001|14 25|free skin flap
P05718386T0001|31 42|complication
P05718386T0001|68 73|hernia
P05718500T0001|0 23|Histological observations
P05718500T0001|29 35|decidua
P05718500T0001|41 50|second half
P05718994T0000|0 25|Endocardial fibro-elastosis
P05718994T0000|27 44|mitral incompetence
P05718994T0000|49 59|coarctation
P05718994T0000|62 75|abdominal aorta
P05719031T0000|0 6|Studies
P05719031T0000|20 32|size reduction
P05719031T0000|35 52|medicinal compounds
P05719746T0001|0 7|Children
P05719746T0001|12 26|defective vision
P05722341T0000|0 13|Identification
P05722341T0000|17 26|estimation
P05722341T0000|29 43|monosaccharides
P05722341T0000|47 59|disaccharides
P05722341T0000|62 66|urine
P05722341T0000|69 92|gas-liquid chromatography
P05725509T0000|0 7|Steroids
P05725509T0000|10 17|germfree
P05725509T0000|21 36|conventional rats
P05727222T0000|3 9|effects
P05727222T0000|22 37|respiratory pumps
P05727222T0000|43 59|oxygen consumption
P05727222T0000|62 76|Callionymus lyra
P05732641T0001|0 5|Trials
P05732641T0001|8 21|sevine activity
P05732641T0001|29 42|mosquito larvae
P05733952T0001|17 35|structural integrity
P05733952T0001|38 51|lymphoid tissue
P05733952T0001|55 72|antibody production
P05733953T0001|12 32|constant magnetic field
P05733953T0001|38 55|phagocytic activity
P05733953T0001|58 66|Paramecia
P05734847T0000|0 6|Studies
P05734847T0000|24 46|Glossina morsitans colony
P05734847T0000|49 54|Lisbon
P05740389T0001|0 8|Relations
P05740389T0001|16 35|adrenergic mechanisms
P05740389T0001|39 54|analgesic effects
P05742879T0000|0 14|Transformations
P05742879T0000|20 33|morphine series
P05749438T0001|0 22|Dissociative anesthetics
P05749438T0001|26 39|o-chlorophenyl
P05749438T0001|44 69|methyl-amino cyclohexane HCL
P05749438T0001|71 76|CI-581
P05750950T0001|0 5|Estrus
P05750950T0001|9 27|copulative abilities
P05750950T0001|30 52|androgen-sterilized rats
P05751819T0000|3 9|bearing
P05751819T0000|31 37|calving
P05751819T0000|65 77|total calvings
P05751819T0000|80 90|Hariana cows
P05758469T0001|0 18|Hemodynamics changes
P05760665T0000|0 15|Caries prevention
P05760665T0000|21 32|dental office
P05763287T0063|0 1|I.
P05763347T0000|0 19|Clinical applications
P05763347T0000|22 31|inhibition
P05763347T0000|34 57|beta-adrenergic receptors
P05763347T0000|62 72|propranolol
P05769307T0000|0 15|Automatic view box
P05774062T0000|0 10|Measurement
P05774062T0000|13 32|gastric acid secretion
P05774062T0000|35 46|conductivity
P05779953T0000|0 5|Effect
P05779953T0000|8 17|castration
P05779953T0000|20 28|pituitary
P05779953T0000|32 38|serum LH
P05779953T0000|37 38|LH
P05779953T0000|42 44|FSH
P05779953T0000|47 73|testosterone-sterilized rats
P05781385T0000|20 48|phenolphthalein sulphatase test
P05781385T0000|20 44|phenolphthalein sulphatase
P05781385T0000|55 69|differentiation
P05781385T0000|89 103|Nocardia species
P05782943T0001|0 11|Relationship
P05782943T0001|14 22|mast cells
P05782943T0001|25 44|sarcoidosis granuloma
P05787318T0000|0 15|Long-term effects
P05787318T0000|18 27|clofibrate
P05787318T0000|29 37|Atromid-S
P05787318T0000|41 51|serum lipids
P05789870T0001|0 38|Phosphate glucose dehydrogenase deficiency
P05789870T0001|0 28|Phosphate glucose dehydrogenase
P05789870T0001|46 63|hyperbilirubinemia
P05789870T0001|69 75|newborn
P05792868T0000|0 33|Evidence forthe electroosmosis theory
P05792868T0000|50 55|phloem
P05792911T0000|0 6|Effects
P05792911T0000|9 39|beta-adrenergic receptor blockade
P05792911T0000|9 31|beta-adrenergic receptor
P05792911T0000|42 58|airway conductance
P05792911T0000|62 71|lung volume
P05792911T0000|83 99|asthmatic subjects
P05794247T0000|0 5|Effect
P05794247T0000|8 14|heparin
P05794247T0000|20 31|inactivation
P05794247T0000|34 55|serum lipoprotein lipase
P05794247T0000|68 85|unanesthetized dogs
P05796272T0000|0 34|Experimental chlorpromazine cataracts
P05797287T0069|0 1|I.
P05798063T0000|0 9|Specialist
P05798063T0000|12 25|family practice
P05798063T0000|28 36|prototype
P05799686T0001|16 36|selective chemotherapy
P05799686T0001|59 74|ovarian carcinoma
P05799686T0001|87 99|cytodiagnosis
P05799686T0001|103 115|incorporation
P05799686T0001|124 134|idoxuridine
P05805644T0001|0 8|Variation
P05805644T0001|14 41|temporal-spatial distribution
P05805644T0001|44 48|228Ra
P05805644T0001|52 56|224Ra
P05805644T0001|62 64|RES
P05805644T0001|68 86|marrow-free skeleton
P05805644T0001|92 104|incorporation
P05805644T0001|107 119|colloidal ThO2
P05806615T0001|0 19|Oxidative degradation
P05806615T0001|22 40|adrenaline solutions
P05806615T0001|52 69|intermediate stages
P05806615T0001|78 90|analytic value
P05806615T0001|110 115|solute
P05806936T0000|0 9|Absorption
P05806936T0000|12 23|electrolytes
P05806936T0000|31 35|colon
P05806936T0000|38 42|cases
P05806936T0000|45 61|ulcerative colitis
P05806936T0000|67 81|control subjects
P05807222T0052|0 11|Ion injection
P05810259T0001|0 15|Polyvinyl alcohol
P05810259T0001|19 34|solution mediator
P05819249T0000|0 5|Mining
P05819249T0000|9 25|diagnostic iron ore
P05822499T0034|14 25|digiprogenin
P05823624T0031|12 24|small hospital
P05826818T0098|0 1|I.
P05833022T0001|16 22|changes
P05833022T0001|28 41|enzyme activity
P05833022T0001|47 57|brain tissue
P05833022T0001|64 77|reflex epilepsy
P05836483T0000|1 21|malignant true teratoma
P05837169T0001|0 13|Methoxyflurane
P05837169T0001|17 29|renal function
P05839844T0000|0 13|Histochemistry
P05839844T0000|17 34|electron microscopy
P05839844T0000|37 53|acute liver lesions
P05839844T0000|63 73|Aflatoxin B1
P05839844T0000|76 84|ducklings
P05847772T0001|0 18|Functional disorders
P05847772T0001|24 29|ureter
P05847772T0001|39 56|gynecologic surgery
P05850652T0001|0 4|Study
P05850652T0001|10 20|alterations
P05850652T0001|23 42|intestinal absorption
P05850652T0001|46 50|means
P05850652T0001|53 66|I-131-triolein
P05850652T0001|73 94|whole body irradiated rat
P05857301T0000|0 17|Chemical histologic
P05857301T0000|21 40|immunologic responses
P05857301T0000|43 46|rats
P05857301T0000|49 53|CC1-4
P05857301T0000|56 70|different routes
P05858571T0000|0 13|Clinical trials
P05858571T0000|18 24|1,3-bis
P05858571T0000|26 38|2-chloroethyl
P05858571T0000|43 53|nitrosourea
P05858571T0000|55 64|NSC-409962
P05859016T0000|0 24|Hydroxypropyl methacrylate
P05859016T0000|27 58|new water-miscible embedding medium
P05859016T0000|62 79|electron microscopy
P05879595T0094|0 9|Statistics
P05879595T0094|20 24|years
P05881833T0001|16 29|bovine leucosis
P05881833T0001|45 63|southern Lower Saxony
P05884183T0001|0 9|Experience
P05884183T0001|17 27|restoration
P05884183T0001|30 52|agglutination properties
P05884183T0001|55 90|non-agglutinating dysenterial cultures
P05884183T0001|103 111|Rzhaninov
P05890093T0000|0 4|Study
P05890093T0000|7 17|micromelias
P05890093T0000|23 32|mouse fetus
P05890093T0000|41 51|x-radiation
P05890093T0000|53 59|hypoxia
P05890093T0000|61 79|trypan blue injection
P05890093T0000|82 99|hypervitaminosis-A
P05890093T0000|104 116|mother animals
P05890351T0001|0 20|Human antitetanus serum
P05890351T0001|24 35|unused wealth
P05893495T0001|0 6|Studies
P05893495T0001|12 34|intracutaneous infection
P05893495T0001|37 43|rabbits
P05896996T0001|2 11|catabolism
P05896996T0001|14 25|aminoketones
P05896996T0001|28 41|climacteric age
P05901778T0000|18 25|patterns
P05901778T0000|28 40|fat deposition
P05901778T0000|43 46|mice
P05902458T0001|0 10|Naphthalene
P05902458T0001|14 32|paradichlorobenzene
P05902458T0001|35 52|clinical toxicology
P05909034T0000|0 6|Studies
P05909034T0000|9 28|powdered preparations
P05917315T0026|1 10|case report
P05917315T0026|15 40|angiographic follow-up study
P05919308T0001|0 11|Interactions
P05919308T0001|19 29|adrenergics
P05919308T0001|31 42|adrenolytics
P05919308T0001|46 71|monoamine oxidase inhibitors
P05930797T0000|0 13|Further studies
P05930797T0000|22 45|human isoprecipitin system
P05930797T0000|27 39|isoprecipitin
P05930797T0000|47 62|Australia antigen
P05933228T0000|0 16|Pigmentary rhythms
P05933228T0000|19 28|indicators
P05933228T0000|31 44|neurosecretion
P05938720T0000|0 4|Story
P05938720T0000|29 54|employee orientation program
P05939748T0000|7 22|cervical Pap smear
P05942953T0049|0 1|I.
P05947377T0001|3 18|3-hour test iodine
P05947377T0001|20 24|I-132
P05947377T0001|26 31|uptake
P05947377T0001|37 43|thyroid
P05947377T0001|46 53|children
P05947377T0001|58 73|growth deficiency
P05949971T0000|0 10|Persistence
P05949971T0000|13 21|toxaphene
P05949971T0000|31 35|lakes
P05959588T0000|0 6|Studies
P05959588T0000|9 22|Coxsackie B Type
P05959588T0000|24 38|virus infections
P05960999T0001|0 4|Value
P05960999T0001|18 40|passive hemagglutination
P05960999T0001|45 59|polysaccharide C
P05960999T0001|71 87|C-reactive protein
P05960999T0001|100 112|precipitation
P05960999T0001|115 125|capillaries
P05960999T0001|129 142|slide latex test
P05960999T0001|147 159|anti-CRP serum
P05960999T0001|147 154|anti-CRP
P05967610T0000|0 22|Adrenergic nerve function
P05967610T0000|24 41|noradrenaline level
P05967610T0000|45 63|noradrenaline uptake
P05967610T0000|66 87|cat nictitating membrane
P05967610T0000|93 110|reserpine treatment
P05969185T0001|0 9|Concussion
P05969185T0001|15 24|spinal cord
P05982700T0000|0 4|Study
P05982700T0000|10 20|evagination
P05982700T0000|23 43|Cysticercus pisiformis
P05985275T0000|0 21|Antimicrobial substance
P05985275T0000|36 47|acorn extract
P05992157T0001|3 15|pathogenicity
P05992157T0001|18 38|Achromobacter puntatum
P05992157T0001|42 52|cold blooded
P05992157T0001|56 73|warm blooded animals
P05994421T0045|0 12|Consanguinity
P05994421T0045|30 38|marriages
P05994421T0045|52 56|Nunoa
P05994421T0045|58 65|Santiago
P05995140T0001|31 51|effective glucose level
P05995140T0001|54 59|tumors
P05999607T0001|0 6|Studies
P05999607T0001|9 19|lipogenesis
P05999607T0001|30 39|precursors
P05999607T0001|45 55|pregnant rat
P06012827T0000|0 21|Pharmacodynamic studies
P06012827T0000|27 46|cardiovascular system
P06012827T0000|62 77|hypertensive rats
P06027841T0000|0 10|Nuclear spin
P06027841T0000|13 17|249Bk
P06027841T0000|25 42|hyperfine structure
P06027841T0000|48 63|emission spectrum
P06035001T0000|0 18|Further observations
P06035001T0000|21 30|resorption
P06035001T0000|33 42|guinea pigs
P06035001T0000|52 61|injections
P06035001T0000|64 73|trypan blue
P06048505T0000|0 10|Derivatives
P06048505T0000|13 20|fluorene
P06051644T0000|6 9|Slot
P06051644T0000|24 44|specific determination
P06051644T0000|47 56|creatinine
P06054411T0000|0 16|Retention behavior
P06054411T0000|19 26|steroids
P06054411T0000|29 45|gas chromatography
P06054411T0000|59 76|combination columns
P06065507T0000|0 27|Compensatory renal hypertrophy
P06065507T0000|30 43|parabiotic rats
P06070204T0025|0 2|XXI
P06072512T0000|22 36|mucolytic action
P06072512T0000|39 42|urea
P06073427T0001|0 30|Electrophoretic characteriaztion
P06073427T0001|33 55|virus-induced interferon
P06073427T0001|46 55|interferon
P06073427T0001|69 73|urine
P06073427T0001|76 82|rabbits
P06074093T0001|0 3|Iron
P06074093T0001|7 22|folate deficiency
P06074640T0001|0 8|Symposium
P06074640T0001|11 41|presenile spongy encephalopathies
P06084279A0218|17 24|patients
P06084279A0218|38 54|total serum amylase
P06084279A0218|64 67|ERCP
P06084810A0169|3 21|immuno-purified mRNA
P06084810A0169|27 41|polysome complex
P06084810A0169|58 61|cDNA
P06084810A0169|79 80|D.
P06084810A0169|93 106|genomic library
P06084864T0001|0 32|Elevated maternal alpha fetoproteins
P06084864T0001|36 46|oligoamnios
P06084864T0001|48 61|fetal prognosis
P06085839A0721|32 46|combined genetic
P06085839A0721|50 70|environmental etiology
P06088722A0171|0 6|Courses
P06088722A0171|40 55|myelosuppression
P06089575A0464|0 10|Stimulation
P06089575A0464|15 17|MCh
P06089575A0464|27 56|Ca-dependent transient elevation
P06089575A0464|59 67|cGMP level
P06089575A0464|78 87|fmol/gland
P06089575A0464|101 103|min
P06089575A0464|121 130|basal level
P06089575A0464|134 136|min
P06090369A0000|21 28|patients
P06090369A0000|41 47|WR-2721
P06090369A0000|50 54|Phase
P06090369A0000|59 65|studies
P06090458A0407|3 23|PEPCK promoter fragment
P06090458A0407|48 64|proper orientation
P06090458A0407|68 80|transcription
P06090458A0407|86 91|TK gene
P06090458A0407|99 117|opposite orientation
P06091914A0000|0 16|Many mammary tumors
P06091914A0000|26 47|mouse mammary tumor virus
P06091914A0000|49 52|MMTV
P06091914A0000|62 69|provirus
P06091914A0000|75 84|same region
P06091914A0000|90 104|host-cell genome
P06091914A0000|128 151|putative cellular oncogene
P06091914A0000|158 162|int-1
P06092048A1111|7 11|cases
P06092048A1111|13 20|asbestos
P06092048A1111|23 43|erionite-tissue burden
P06092048A1111|54 61|fibrosis
P06092588T0000|0 14|Hepatitis B virus
P06092588T0000|18 25|hepatoma
P06093354A0000|5 24|recombinant DNA clones
P06093354A0000|27 55|endogenous murine leukemia virus
P06093354A0000|57 60|MuLV
P06093354A0000|63 81|related DNA sequences
P06093354A0000|103 127|lambdaphage genomic library
P06093354A0000|130 143|Balb/c mouse DNA
P06093363A0612|0 2|USA
P06093363A0612|22 29|proteins
P06093363A0612|36 46|% identities
P06093363A0612|54 70|amino acid sequence
P06093363A0612|76 84|alignment
P06093363A0612|97 100|gaps
P06094591A0000|3 23|envelope glycoproteins
P06094591A0000|26 46|Rous sarcoma virus (RSV)
P06094591A0000|26 41|Rous sarcoma virus
P06094591A0000|43 45|RSV
P06094591A0000|48 51|gp85
P06094591A0000|55 58|gp37
P06094591A0000|76 83|membrane
P06094591A0000|87 98|27-amino acid
P06094591A0000|100 116|hydrophobic domain
P06094591A0000|125 132|adjacent
P06094591A0000|136 147|22-amino acid
P06094591A0000|149 165|cytoplasmic domain
P06094591A0000|171 185|carboxy terminus
P06094591A0000|188 191|gp37
P06095372A0435|18 30|daily oral dose
P06095372A0435|36 39|g/m2
P06095372A0435|44 44|h
P06095372A0435|56 73|radiation treatment
P06095774T0001|0 18|Histogenetic aspects
P06095774T0001|21 39|mesoblastic nephroma
P06096246T0000|0 5|Effect
P06096246T0000|8 12|acute
P06096246T0000|16 39|chronic psychogenic stress
P06096246T0000|42 55|corticoadrenal
P06096246T0000|59 83|pituitary-thyroid hormones
P06096246T0000|86 93|male rats
P06096380A0662|0 9|Mature mRNA
P06096380A0662|13 53|cytosolic phosphoenolpyruvate carboxykinase
P06096380A0662|71 79|kilobases
P06096380A0662|120 123|mRNA
P06096380A0662|136 145|same enzyme
P06096863T0000|0 22|Upstream activation sites
P06096863T0000|28 35|CYC1 gene
P06096863T0000|114 120|TATA box
P06097027A0000|2 21|intact 5.7-kb provirus
P06097027A0000|27 55|avian erythroblastosis virus E26
P06097027A0000|83 93|comparisons
P06097027A0000|98 121|avian myeloblastosis virus
P06097027A0000|123 125|AMV
P06097027A0000|130 151|other avian tumor viruses
P06097285A1077|17 27|haloperidol
P06097285A1077|77 88|non-stimulus
P06097285A1077|97 110|motor behaviour
P06098719A0369|7 16|side effect
P06098719A0369|20 48|abnormal laboratory findings due
P06098828A0352|3 9|results
P06098828A0352|45 65|SV40 G-C-rich sequences
P06098828A0352|79 102|independent RNA polymerase
P06098828A0352|90 104|RNA polymerase II
P06098828A0352|105 135|transcriptional-control elements
P06099656T0000|0 11|Construction
P06099656T0000|14 27|human cell lines
P06099656T0000|53 83|adenovirus DNA binding protein gene
P06099656T0000|86 101|cotransformation
P06099656T0000|109 119|HSV-1 tk gene
P06101359T0000|0 8|Diagnosis
P06101359T0000|23 46|insulin-secreting tumours
P06101359T0000|23 29|insulin
P06108610A0518|0 7|Theories
P06108610A0518|32 50|modality shift effect
P06109017A0000|3 9|effects
P06109017A0000|12 49|cardioselective beta-1 adrenergic agonist
P06109017A0000|54 69|4-hydroxyphenoxy
P06109017A0000|72 96|isopropylamino-2-propanol
P06109017A0000|104 114|prenalterol
P06109017A0000|139 160|continuous measurements
P06109017A0000|163 177|left ventricular
P06109017A0000|179 180|LV
P06109017A0000|191 198|diameter
P06109017A0000|200 204|dP/dt
P06109017A0000|206 213|velocity
P06109017A0000|227 242|arterial pressure
P06109017A0000|244 257|iliac blood flow
P06109017A0000|261 269|heart rate
P06109017A0000|274 286|conscious dogs
P06110026T0000|0 9|Endorphins
P06111283T0032|0 13|Trial treatment
P06111283T0032|16 28|schizophrenia
P06111283T0032|33 55|des-Tyr-gamma-endorphin
P06113084T0000|0 19|Cardiac taurine levels
P06113084T0000|23 55|sarcolemmal calcium binding activity
P06113084T0000|58 91|furazolidone-induced cardiomyopathy
P06113443T0000|0 9|Separation
P06113443T0000|12 39|malaria-infected erythrocytes
P06113443T0000|44 53|whole blood
P06113443T0000|61 109|selective high-gradient magnetic separation technique
P06119262T0000|3 15|roll-over test
P06119262T0000|25 31|toxemia
P06120429T0000|3 20|thyroglobulin assay
P06120429T0000|3 15|thyroglobulin
P06120429T0000|27 45|supplant radioiodine
P06120429T0000|53 60|patients
P06120429T0000|79 91|thyroid cancer
P06121577A0280|1 21|Significant reductions
P06121577A0280|29 53|mean arterial blood pressure
P06121577A0280|70 79|daily doses
P06121577A0280|85 86|mg
P06121577A0280|90 90|%
P06121577A0280|96 97|mg
P06121577A0280|102 102|%
P06121577A0280|110 111|mg
P06121577A0280|116 116|%
P06121577A0280|140 159|significant decreases
P06121577A0280|162 170|heart rate
P06121577A0280|174 192|plasma renin activity
P06121577A0280|174 184|plasma renin
P06130348T0000|0 8|Isolation
P06130348T0000|11 19|Aeromonas
P06130348T0000|24 29|faeces
P06131038A0000|0 5|Plasma
P06131038A0000|9 30|erthrocyte lipid profile
P06131038A0000|34 58|lipoprotein lipase activity
P06131038A0000|34 50|lipoprotein lipase
P06131038A0000|61 77|postheparin plasma
P06131038A0000|80 98|vasectomized rabbits
P06131038A0000|120 128|incidence
P06131038A0000|131 145|atherosclerosis
P06131038A0000|148 168|different arterial beds
P06131378A0818|8 11|mRNA
P06131378A0818|28 41|polyadenylated
P06131378A0818|44 52|sequences
P06131378A0818|68 75|DHFR cDNA
P06131378A0818|89 110|polyadenylation signals
P06131378A0818|128 135|DHFR cDNA
P06136374A0151|6 22|water temperatures
P06136374A0151|24 26|VO2
P06136374A0151|58 73|swimming velocity
P06137028A0624|0 10|Propranolol
P06137028A0624|39 52|familial tremor
P06138015T0114|0 10|Brief report
P06138313A0948|3 19|distribution phase
P06138313A0948|34 49|elimination phase
P06138313A0948|59 73|longer half-life
P06138313A0948|75 83|mean value
P06138313A0948|87 89|min
P06138313A0948|130 136|200-400
P06141764A0339|0 26|Hybrid-selection experiments
P06141764A0339|34 53|total PB-inducible RNA
P06141764A0339|71 80|plasmid DNA
P06141764A0339|92 97|clones
P06141764A0339|108 130|PB-inducible information
P06142279T0000|0 3|Risk
P06142279T0000|6 18|HTLV infection
P06142279T0000|21 28|patients
P06142279T0000|31 43|haemodialysis
P06143734T0000|7 16|metabolism
P06143734T0000|19 30|progesterone
P06143734T0000|36 57|human undescended testis
P06147504A0086|3 10|patients
P06147504A0086|37 51|personal reasons
P06147504A0086|66 79|paraspinal mass
P06150069A0422|3 10|patients
P06150069A0422|19 21|VCR
P06150069A0422|25 35|mg/m2 weekly
P06150069A0422|40 44|weeks
P06150069A0422|49 64|dose modification
P06150069A0422|68 80|neurotoxicity
P06151518A0000|0 11|Glutamic acid
P06151518A0000|31 34|LD50
P06151518A0000|57 66|sodium salt
P06151518A0000|78 93|female Wistar rats
P06151518A0000|98 101|days
P06151518A0000|112 127|12-day injections
P06151518A0000|130 137|dexazone
P06151942A0235|0 16|Serum ascorbic acid
P06151942A0235|22 28|inverse
P06151942A0235|35 54|strongest association
P06151942A0235|59 79|systolic blood pressure
P06151942A0235|88 98|risk factors
P06151942A0235|108 120|blood pressure
P06151942A0235|122 137|total cholesterol
P06151942A0235|139 150|triglyceride
P06151942A0235|152 160|gamma-GTP
P06151942A0235|164 170|obesity
P06152670T0000|0 13|Plasma secretin
P06152670T0000|15 26|pancreozymin
P06152670T0000|31 54|somatostatin-like hormone
P06152670T0000|57 83|chronic renal failure patients
P06152844T0000|0 5|Effect
P06152844T0000|8 17|bromazepam
P06152844T0000|20 32|growth hormone
P06152844T0000|36 53|prolactin secretion
P06152844T0000|36 44|prolactin
P06152844T0000|56 69|normal subjects
P06153936A0784|2 13|several cases
P06153936A0784|16 26|definite SjS
P06153936A0784|28 58|labial salivary gland examinations
P06153936A0784|76 87|year interval
P06153936A0784|106 114|occasions
P06153936A0784|133 156|histopathological changes
P06155967A1132|3 14|radiologists
P06155967A1132|42 58|reporting terminal
P06155967A1132|99 111|abnormalities
P06155967A1132|143 152|longer time
P06158844A0000|0 10|Thalamotomy
P06158844A0000|22 33|CM-Pf complex
P06158844A0000|42 69|stereotactic gamma irradiation
P06158844A0000|99 106|patients
P06158844A0000|111 123|severe pain due
P06158844A0000|126 135|malignancy
P06161823A0129|1 16|Silastic capsules
P06161823A0129|37 38|mg
P06161823A0129|41 56|ethinyl estradiol
P06161823A0129|87 89|men
P06161823A0129|94 119|benign prostatic hypertrophy
P06162419A0118|55 59|doses
P06162419A0118|63 72|antibiotic
P06162419A0118|98 115|lymphadenosis NK/Li
P06162419A0118|128 131|cent
P06163433T0000|0 5|Effect
P06163433T0000|11 24|p-chlorophenyl
P06163433T0000|26 41|cyclopropylamine
P06163433T0000|44 71|5-hydroxyindole concentration
P06163433T0000|75 98|monoamine oxidase activity
P06163433T0000|75 90|monoamine oxidase
P06163433T0000|101 108|rat brain
P06165068A0547|5 23|pure pancreatic juice
P06165068A0547|41 48|duodenum
P06165132A0000|34 38|fowls
P06165132A0000|42 49|broilers
P06165132A0000|55 69|industrial farms
P06165132A0000|85 94|spray lento
P06165132A0000|98 114|mesogenic vaccines
P06165132A0000|130 137|immunity
P06165132A0000|145 154|pseodopest
P06165132A0000|162 165|RIHA
P06165132A0000|178 189|pseudoplague
P06165132A0000|195 209|pathogenic virus
P06165551A0793|6 22|inappropriateness
P06165551A0793|25 44|adaptive segmentation
P06165551A0793|62 67|spikes
P06165551A0793|71 80|sharp waves
P06165551A0793|116 128|short duration
P06165551A0793|131 144|such transients
P06165551A0793|181 183|sec
P06165551A0793|195 209|autocorrelation
P06165551A0793|232 252|segmentation algorithm
P06167806A0000|12 24|chronic UM-272
P06167806A0000|26 44|dimethylpropranolol
P06167806A0000|67 75|induction
P06167806A0000|78 113|reentrant ventricular tachyarrhythmias
P06167806A0000|130 141|conscious dog
P06167806A0000|153 158|serial
P06167806A0000|169 189|electrical stimulation
P06167806A0000|192 195|days
P06167806A0000|205 224|myocardial infarction
P06173032T0000|11 23|echothiophate
P06173032T0000|29 44|biphasic response
P06173032T0000|47 66|rabbit ocular pressure
P06173032T0000|69 78|dipivefrin
P06173860A0000|2 10|most cases
P06173860A0000|13 37|acute transmural infarction
P06173860A0000|42 71|reciprocal ST segment depressions
P06173860A0000|82 99|contralateral leads
P06173860A0000|107 112|marked
P06173860A0000|120 145|primary ST segment elevations
P06175691T0000|0 28|Bacillus cereus cross-infection
P06175691T0000|32 45|maternity-unit
P06181216A0070|16 40|phenytoin-treated patients
P06181216A0070|52 73|serum IgA concentrations
P06181216A0070|57 59|IgA
P06181216A0070|80 84|years
P06182979A0807|5 36|latter category particular emphasis
P06182979A0807|52 76|new anthracycline analogues
P06182979A0807|79 89|doxorubicin
P06182979A0807|93 101|analogues
P06182979A0807|104 132|cisplatinum diammine dichloride
P06184276T0001|0 12|Unusual course
P06184276T0001|15 27|plasmocytosis
P06184487A1485|4 7|mRNA
P06184487A1485|19 32|cDNA homologous
P06184487A1485|38 60|HindIII-P/EcoRI-B region
P06184487A1485|66 73|AcNPV map
P06184487A1485|85 93|synthesis
P06184487A1485|96 98|31K
P06184487A1485|102 112|30K proteins
P06184487A1485|135 137|31K
P06184487A1485|141 151|30K proteins
P06184487A1485|166 168|RNA
P06184487A1485|182 209|HindIII-A/EcoRI-C/SstI-G cDNA
P06184487A1485|182 190|HindIII-A
P06184487A1485|192 198|EcoRI-C
P06184487A1485|200 209|SstI-G cDNA
P06185014A0642|19 37|complement factor C3c
P06185014A0642|51 51|%
P06185014A0642|58 75|alpha 1-antitrypsin
P06185014A0642|111 111|%
P06185493A0468|1 16|polypeptide chain
P06185493A0468|21 28|residues
P06185493A0468|41 62|yeast amino acid sequence
P06185493A0468|80 94|peptide sequence
P06185493A0468|100 113|ADP binding site
P06185493A0468|116 141|bovine muscle pyruvate kinase
P06189698A0246|3 15|P165 component
P06189698A0246|56 70|later components
P06189698A0246|89 97|amplitude
P06189698A0246|111 121|task demands
P06189698A0246|130 131|N2
P06189698A0246|135 146|P3 amplitudes
P06191243T0000|0 22|Differential drawing size
P06191243T0000|37 57|unilateral brain damage
P06193351A1010|3 29|intracoronary administration
P06193351A1010|36 40|drugs
P06193351A1010|59 67|incidence
P06193351A1010|70 71|VF
P06193351A1010|94 122|40-min coronary artery occlusion
P06198241A0209|5 11|fusions
P06198241A0209|26 33|plasmids
P06198241A0209|47 51|yeast
P06198241A0209|61 78|replication origins
P06198241A0209|82 98|selectable markers
P06198241A0209|139 143|yeast
P06198241A0209|152 156|cells
P06198532A0982|28 45|thrombotic tendency
P06198532A0982|64 71|patients
P06198532A0982|76 77|MS
P06198532A0982|97 102|non RHD
P06198532A0982|123 128|causes
P06198532A0982|147 159|high incidence
P06198532A0982|162 176|thromboembolism
P06198532A0982|193 198|non RHD
P06199132A0179|0 7|Toxicity
P06199132A0179|32 36|cases
P06199132A0179|43 50|patients
P06199132A0179|60 62|WBC
P06199132A0179|99 106|patients
P06199132A0179|115 120|sepsis
P06200300A0409|0 17|Subdural electrodes
P06200300A0409|26 44|larger VEP amplitudes
P06200300A0409|56 70|scalp electrodes
P06203843A0757|0 7|Products
P06203843A0757|10 24|immune cells such
P06203843A0757|27 40|transfer factor
P06203843A0757|44 54|lymphokines
P06203843A0757|82 95|important group
P06203843A0757|98 121|immune-stimulating agents
P06204120T0001|0 2|Use
P06204120T0001|8 31|immunofluorescence method
P06204120T0001|51 63|enteroviruses
P06204120T0001|66 77|cell cultures
P06208024A0168|14 22|resistant
P06208024A0168|25 34|digestions
P06208024A0168|37 42|DNase I
P06208024A0168|37 41|DNase
P06208024A0168|46 52|RNase T1
P06208024A0168|80 95|alkali hydrolysis
P06208477A0000|18 29|small library
P06208477A0000|32 49|mouse repetitive DNA
P06208477A0000|76 82|Pietras
P06208477A0000|89 103|Nucleic Acids Res
P06209403A0562|2 14|direct repeats
P06209403A0562|23 32|pseudogene
P06209403A0562|38 46|U2/4 locus
P06209499A0682|3 15|direct effects
P06209499A0682|18 35|transmitter release
P06209499A0682|45 53|early fall
P06209499A0682|56 58|MAP
P06209499A0682|70 86|late pressor effect
P06209499A0682|96 111|early bradycardia
P06209499A0682|123 137|late tachycardia
P06212776A0000|2 7|Cabras
P06212776A0000|9 16|Oristano
P06212776A0000|40 52|high incidence
P06212776A0000|55 66|thalassaemia
P06212776A0000|70 87|G6PD deficiency less
P06212776A0000|70 73|G6PD
P06212776A0000|124 136|fair knowledge
P06212776A0000|139 153|genetic diseases
P06214605A0123|11 18|elements
P06214605A0123|27 39|sizes relative
P06214605A0123|45 57|configuration
P06214605A0123|83 93|experiments
P06216125A0470|14 26|overall chance
P06216125A0470|51 52|ET
P06216125A0470|56 62|greater
P06216125A0470|89 96|follicle
P06216125A0470|99 100|mm
P06216125A0470|103 108|larger
P06216125A0470|142 160|single large follicle
P06217859T0000|0 9|Experience
P06217859T0000|17 29|tensor fasciae
P06217859T0000|35 42|free flap
P06218005A0948|9 16|patients
P06218005A0948|30 36|L-L size
P06218005A0948|41 57|normal A-P diameter
P06223586A0000|0 17|Immunochemotherapy
P06223586A0000|22 34|schizophyllan
P06223586A0000|36 38|SPG
P06223586A0000|52 73|chemotherapeutic agents
P06223586A0000|91 108|syngeneic tumor-C3H
P06223586A0000|112 123|mouse systems
P06223586A0460|24 33|mitomycin C
P06223586A0460|46 59|5-days interval
P06223586A0460|64 87|concurrent administration
P06223586A0460|90 92|SPG
P06223586A0460|118 126|life-span
P06223586A0460|132 148|tumor-bearing mice
P06224974A0833|0 3|Data
P06224974A0833|32 43|beta-hydroxy
P06224974A0833|46 55|metabolite
P06224974A0833|58 60|CPA
P06224974A0833|89 99|active agent
P06225279A0498|3 18|abluminal surface
P06225279A0498|52 61|thick layer
P06225279A0498|64 89|fibrillary connective tissue
P06227570A0523|13 22|LL patients
P06227570A0523|29 31|ENL
P06227570A0523|35 64|ConA-induced suppressor response
P06227570A0523|35 38|ConA
P06229542T0045|0 25|Functional characterization
P06229542T0045|63 87|second template rescue assay
P06230499A0128|24 46|preoperative irradiation
P06230499A0128|61 73|fractionation
P06230499A0128|77 91|single focal dose
P06230499A0128|95 96|Gy
P06230499A0128|102 109|other day
P06230499A0128|114 124|summary dose
P06230499A0128|129 130|Gy
P06230499A0128|141 144|days
P06230499A0128|165 168|days
P06230499A0128|174 184|irradiation
P06230499A0128|238 256|postoperative period
P06230499A0128|275 290|long-term results
P06230499A0128|297 301|worse
P06230499A0128|309 332|routine dose fractionation
P06233924T0000|0 9|Fibrin gels
P06233924T0000|0 5|Fibrin
P06233924T0000|18 36|possible implication
P06233924T0000|40 58|surface hemorheology
P06234369T0000|0 21|Hepatitis-B vaccination
P06234786A0606|0 18|Radiogallium imaging
P06234786A0606|27 36|limited use
P06234786A0606|60 74|giant cell tumors
P06237518A0117|3 40|customary coupling reagent sulfanilic acid
P06237518A0117|58 83|1,3-dimethylbarbituric acid
P06237518A0117|85 88|CNCl
P06237518A0117|133 135|KCN
P06237518A0117|139 148|chloramine
P06238540A0798|0 25|Ventricular volume stiffness
P06238540A0798|32 57|mean wall stress relationship
P06238540A0798|60 62|LVH
P06238540A0798|97 115|wall muscle stiffness
P06238540A0798|122 147|mean wall stress relationship
P06238540A0798|150 152|LVH
P06238540A0798|160 171|smaller slope
P06238704T0001|0 8|Synthesis
P06238704T0001|15 46|lysergic acid diethylamide tartrate
P06239545A0649|0 9|Weight loss
P06239545A0649|17 32|arterial pressure
P06239545A0649|46 64|intravascular volume
P06239545A0649|68 80|cardiac output
P06239545A0649|102 120|sympathetic activity
P06240448A0652|43 52|main phases
P06240448A0652|57 68|initial phase
P06240448A0652|85 90|LV mass
P06240448A0652|106 118|cardiac output
P06240448A0652|132 156|total peripheral resistance
P06240448A0652|163 173|second phase
P06240448A0652|179 192|constant LV mass
P06240448A0652|208 220|cardiac output
P06240448A0652|226 242|pretreatment level
P06240448A0652|252 270|concomitant decrease
P06240448A0652|273 297|total peripheral resistance
P06241900A0000|33 39|effects
P06241900A0000|42 52|hypothermia
P06241900A0000|56 75|chemical cardioplegia
P06241900A0000|81 98|functional recovery
P06241900A0000|101 133|hypertrophied non-failing rat hearts
P06241900A0000|147 160|extended period
P06241900A0000|163 177|global ischaemia
P06241980A0855|0 13|Oxygen profiles
P06241980A0855|30 39|Krogh model
P06241980A0855|44 61|excentric diffusion
P06241980A0855|96 101|models
P06241980A0855|104 122|concentric diffusion
P06242113T0001|0 18|Cultivation technics
P06242113T0001|22 39|Codonopsis pilosula
P06244732T0000|0 15|Radioimmunoassay
P06244732T0000|18 46|serum creatine kinase B isoenzyme
P06244732T0000|63 87|acute myocardial infarction
P06245672T0000|0 28|Selective macrophage inhibition
P06245672T0000|38 62|warfarin-induced reduction
P06245672T0000|65 74|metastasis
P06246254A0676|0 16|Restriction enzyme
P06246254A0676|20 39|heteroduplex analyses
P06246254A0676|53 67|sequences unique
P06246254A0676|70 73|FeSV
P06246254A0676|75 86|src sequences
P06246254A0676|91 97|located
P06246254A0676|114 123|FeSV genome
P06246254A0676|146 158|kilobase pairs
P06251469A0830|8 31|different library isolates
P06251469A0830|48 59|7-kb IAP units
P06251469A0830|65 80|restriction sites
P06251469A0830|125 134|occurrence
P06252520T0000|0 13|Catecholamines
P06252520T0000|17 32|aversive learning
P06252883A0100|1 31|haemolytic enterotoxigenic strain
P06252883A0100|41 44|O149
P06252883A0100|46 48|K88
P06252883A0100|50 52|H10
P06252883A0100|79 85|piglets
P06252883A0100|90 92|PWD
P06252883A0100|98 106|rotavirus
P06252883A0100|133 141|occasions
P06254403A0000|3 15|antibody titer
P06254403A0000|21 28|chickens
P06254403A0000|31 44|SA-11 rotavirus
P06254403A0000|60 98|enzyme-linked immunosorbent blocking assay
P06254973A1757|0 3|Poly
P06254973A1757|5 6|dT
P06254973A1757|20 32|calf thymus DNA
P06254973A1757|58 77|other polynucleotides
P06254973A1757|95 106|accumulation
P06254973A1757|111 113|HDP
P06254973A1757|117 118|dT
P06254973A1757|141 155|longer molecules
P06254973A1757|159 160|dT
P06254973A1757|162 162|n
P06254973A1757|168 169|dT
P06254973A1757|176 177|dT
P06254973A1757|219 229|binding site
P06254973A1757|242 244|HDP
P06254973A1757|246 257|accumulation
P06254973A1757|277 284|residues
P06254973A1757|288 289|dT
P06254973A1757|291 292|n.
P06258699T0000|1 17|double-blind trial
P06258699T0000|20 69|half-strength Polybactrin Soluble GU bladder irrigation
P06258699T0000|72 81|cystoscopy
P06258806A0963|17 25|insertion
P06258806A0963|29 47|transposable element
P06258806A0963|57 64|terminus
P06258806A0963|70 83|structural gene
P06258806A0963|94 115|constitutive expression
P06258806A0963|127 149|glucose-repressed enzyme
P06259220A0000|4 14|experiments
P06259220A0000|37 53|opiate antagonists
P06259220A0000|63 89|short-term analgesic reaction
P06259220A0000|101 103|min
P06259220A0000|119 134|inescapable shock
P06259220A0000|141 166|long-term analgesic reaction
P06259220A0000|181 190|reexposure
P06259220A0000|200 201|hr
P06259220A0000|207 230|inescapable shock exposure
P06259220A0464|0 9|Experiment
P06259220A0464|24 49|long-term analgesic reaction
P06259220A0464|86 95|naltrexone
P06259220A0464|103 112|reexposure
P06259389A0000|19 21|May
P06259389A0000|24 29|August
P06259389A0000|60 71|mouth disease
P06259389A0000|73 76|HFMD
P06259389A0000|88 101|Gifu prefecture
P06270347A0740|1 14|22K polypeptide
P06270347A0740|29 46|translation product
P06270347A0740|49 55|late RNA
P06270347A0740|76 86|DNA fragment
P06272844A0000|11 21|simian virus
P06272844A0000|25 28|SV40
P06272844A0000|30 40|chromosomes
P06272844A0000|63 88|other eukaryotic chromosomes
P06272844A0000|113 131|micrococcal nuclease
P06272844A0000|133 137|MNase
P06272844A0000|139 147|digestion
P06272844A0000|152 158|greater
P06272844A0000|182 214|nonreplicating mature SV40 chromatin
P06278424A0145|21 32|requirements
P06278424A0145|38 49|CH gene switch
P06278424A0145|69 90|rearranged gamma 2b genes
P06278424A0145|96 102|gamma 2b
P06278424A0145|112 123|mouse myeloma
P06278424A0145|125 130|MPC-11
P06278544T0027|0 9|Physiology
P06278544T0027|13 27|Physiopathology
P06279309A0000|3 8|genome
P06279309A0000|11 36|avian erythroblastosis virus
P06279309A0000|70 80|genetic loci
P06279309A0000|82 87|v-erbA
P06279309A0000|91 96|v-erbB
P06279309A0000|103 112|activities
P06279309A0000|138 148|oncogenesis
P06281759A1086|7 25|RNase III host mutants
P06281759A1086|7 11|RNase
P06281759A1086|15 25|host mutants
P06281759A1086|29 37|defective
P06281759A1086|40 52|sib regulation
P06281759A1086|40 42|sib
P06281759A1086|69 74|PL mRNA
P06281759A1086|77 79|sib
P06281759A1086|86 101|endoribonuclease
P06281759A1086|110 121|int mRNA decay
P06281759A1086|133 144|int synthesis
P06281786A1222|10 14|clone
P06281786A1222|16 24|lambda HHG
P06281786A1222|52 63|histone genes
P06281786A1222|91 104|cytoplasmic RNA
P06281786A1222|121 131|nucleotides
P06281891A0399|4 9|neural
P06281891A0399|13 28|hormonal pathways
P06281891A0399|36 41|opiate
P06281891A0399|45 63|nonopiate substances
P06281891A0399|68 72|roles
P06281891A0399|78 94|complex modulation
P06281891A0399|97 112|pain transmission
P06286191T0000|0 10|Restoration
P06286191T0000|13 35|impaired immune functions
P06286191T0000|43 49|animals
P06286443A0498|0 27|Postoperative serum ACTH levels
P06286443A0498|18 21|ACTH
P06286549A0000|0 6|WR-2721
P06286549A0000|8 10|S-2
P06286549A0000|14 29|aminopropylamino
P06286549A0000|31 54|ethylphosphorothioic acid
P06286549A0000|109 114|testis
P06286549A0000|124 135|fibrosarcoma
P06286549A0000|137 139|FSa
P06286549A0000|141 152|tumor nodules
P06286549A0000|159 163|lungs
P06286549A0000|166 169|mice
P06286549A0000|174 194|gamma-radiation injury
P06287212A1352|7 14|families
P06287212A1352|17 28|polypeptides
P06287212A1352|43 52|initiation
P06287212A1352|68 76|AUG codons
P06287212A1352|83 91|sequences
P06287212A1352|101 103|VP1
P06287212A1352|107 107|T
P06287212A1352|130 158|transcription initiation events
P06287212A1352|206 209|AUGs
P06287231A0914|11 25|TRP1 RI Circle DNA
P06287231A0914|11 14|TRP1
P06287231A0914|41 51|nucleosomes
P06287231A0914|64 70|spacing
P06287231A0914|74 90|indistinguishable
P06287231A0914|101 118|bulk yeast chromatin
P06287737A0477|14 32|previous transfusion
P06287737A0477|35 50|chronic hepatitis
P06287737A0477|52 60|cirrhosis
P06287737A0477|64 86|hepatocellular carcinoma
P06287737A0477|89 96|type NANB
P06287737A0477|116 116|%
P06287737A0477|141 149|incidence
P06287737A0477|152 180|early posttransfusion hepatitis
P06287737A0477|197 197|%
P06287737A0477|214 233|chronic liver diseases
P06287737A0477|248 255|jaundice
P06287737A0477|262 270|hepatitis
P06287737A0477|272 291|previous transfusions
P06287737A0477|323 330|type NANB
P06287737A0477|339 350|type B disease
P06290859A0426|5 22|hepatitis B patients
P06290859A0426|31 36|months
P06290859A0426|39 39|%
P06290859A0426|43 72|chronic hepatitis Bs antigenaemia
P06290859A0426|76 76|%
P06290859A0426|89 106|anti-HBs antibodies
P06290859A0426|114 114|%
P06290859A0426|123 143|abnormal liver function
P06290899T0000|0 5|Survey
P06290899T0000|8 15|antibody
P06290899T0000|23 47|egg drop syndrome-1976 virus
P06290899T0000|53 65|chicken flocks
P06290899T0000|68 72|Japan
P06291369A0000|4 11|patients
P06291369A0000|23 49|equilibrium ventriculography
P06291369A0000|53 74|cardiac catheterization
P06291369A0000|96 106|day interval
P06291369A0000|116 133|fractional portions
P06291369A0000|145 184|regional right ventricular ejection fraction
P06291369A0000|186 189|RVEF
P06291369A0000|209 241|pulmonary arterial systolic pressure
P06295429A0412|16 19|MISO
P06295429A0412|23 29|WR-2721
P06295429A0412|36 55|intermediate response
P06295429A0412|103 115|sensitization
P06295429A0412|120 130|single doses
P06295429A0412|136 152|overall protection
P06295429A0412|165 174|small doses
P06296833A0000|3 11|mutations
P06296833A0000|22 55|larval cuticle protein gene expression
P06296833A0000|22 45|larval cuticle protein gene
P06296833A0000|64 70|variant
P06298014A0647|3 11|ensembles
P06298014A0647|37 41|forms
P06298014A0647|57 95|structured morphofunctional cortical units
P06298014A0647|104 110|columns
P06298720A0893|3 20|strong conservation
P06298720A0893|26 55|inverted terminal repeat sequence
P06298720A0893|67 92|common integration mechanism
P06298720A0893|96 107|VL30 elements
P06298720A0893|111 124|MuLV proviruses
P06300662T0000|1 17|cDNA cloning vector
P06300662T0000|41 51|cDNA inserts
P06300662T0000|54 67|mammalian cells
P06300836A0285|0 12|Hybridization
P06300836A0285|15 33|plasmid-transformed
P06300836A0285|49 59|RR1 colonies
P06300836A0285|64 89|32P-labeled viral genome RNAs
P06300836A0285|115 137|DNA clones representative
P06300836A0285|151 162|reovirus RNAs
P06300836A0285|175 193|constituent segments
P06300836A0285|199 213|rotavirus genome
P06304771A1284|16 23|GGGXGGAG
P06304771A1284|40 51|several times
P06304771A1284|54 71|many polyomaviruses
P06304771A1284|75 86|adenoviruses
P06304771A1284|118 131|DNA replication
P06304771A1284|138 150|transcription
P06304771A1284|167 177|JCV sequence
P06306342A1156|18 24|studies
P06306342A1156|37 40|LiCl
P06306342A1156|53 92|histamine-stimulated gastric acid secretion
P06306342A1156|110 131|bile-induced disruption
P06306342A1156|137 157|gastric mucosal barrier
P06306342A1156|163 183|canine Heidenhain pouch
P06307099A1005|0 10|Lung density
P06307099A1005|22 35|quartz-exposed
P06307099A1005|45 71|volcanic-ash-exposed animals
P06308536T0001|3 25|hepatitis A virus antibody
P06308536T0001|27 34|anti-HAV
P06308536T0001|38 64|chronic diffuse liver diseases
P06308607A0375|3 11|junctions
P06308607A0375|19 23|viral
P06308607A0375|27 43|cellular sequences
P06308607A0375|60 78|DNA sequence analysis
P06308607A0375|86 96|nucleotides
P06308607A0375|104 114|p30 sequence
P06308607A0375|123 133|nucleotides
P06308607A0375|141 158|polymerase sequence
P06309020A0473|0 7|Naloxone
P06309020A0473|10 19|mg/kg bolus
P06309020A0473|22 32|mg X kg-1 X h-1
P06309020A0473|57 61|doses
P06309020A0473|67 84|lipopolysaccharide
P06309855T0000|0 18|Gel route preparation
P06309855T0000|21 48|low fusing dental porcelain frit
P06309969T0055|0 1|I.
P06310159A0000|0 7|Viral RNA
P06310159A0000|26 36|proviral DNA
P06310159A0000|41 61|virus-specific protein
P06310159A0000|64 81|avian retrovirus MH2
P06310457A0000|0 22|Intracellular recordings
P06310457A0000|41 51|optic tectum
P06310457A0000|57 60|carp
P06310553T0000|0 17|Molecular structure
P06310553T0000|21 38|evolutionary origin
P06310553T0000|41 67|human cardiac muscle actin gene
P06310608A0749|3 9|mutants
P06310608A0749|24 35|substitution
P06310608A0749|41 54|molecular clone
P06310608A0749|57 65|M-MuLV DNA
P06310608A0749|97 103|viruses
P06310608A0749|105 115|Ableson MuLV
P06310608A0749|117 123|Ab-MuLV
P06310608A0749|128 152|Moloney murine sarcoma virus
P06310608A0749|154 158|M-MSV
P06314276T0000|0 7|Plasmids
P06314276T0000|14 20|cloning
P06314276T0000|36 66|full-length double-stranded cDNAs
P06314276T0000|84 92|SV40 early
P06314276T0000|95 110|late gene promoter
P06314312A0359|14 27|soybean protein
P06314312A0359|31 47|sucrose-based diet
P06314312A0359|52 57|levels
P06314312A0359|72 74|ppm
P06314312A0359|80 89|antibiotic
P06314312A0359|101 107|sources
P06314312A0359|119 135|different purities
P06314312A0359|145 154|weight gain
P06314312A0359|157 162|chicks
P06314312A0359|176 176|%
P06314312A0359|188 201|feed efficiency
P06314312A0359|215 215|%
P06314312A0359|221 232|higher levels
P06314312A0359|237 241|P less
P06316347A0852|3 11|dnaQ-lacZ
P06316347A0852|3 6|dnaQ
P06316347A0852|8 11|lacZ
P06316347A0852|18 25|rnh-lacZ
P06316347A0852|18 20|rnh
P06316347A0852|22 25|lacZ
P06316347A0852|31 35|genes
P06316347A0852|54 67|hybrid proteins
P06316347A0852|72 97|beta-galactosidase activity
P06316347A0852|72 89|beta-galactosidase
P06316623A0188|0 17|Overall prevalences
P06316623A0188|20 27|antibody
P06316623A0188|37 40|cent
P06316623A0188|55 58|cent
P06316623A0188|74 77|cent
P06316623A0188|80 84|goats
P06316623A0188|99 117|immunodiffusion test
P06318078T0000|0 9|Expression
P06318078T0000|12 33|herpes simplex virus beta
P06318078T0000|37 46|gamma genes
P06318078T0000|59 72|mammalian cells
P06318078T0000|81 89|induction
P06318078T0000|94 109|alpha gene product
P06318091A0395|3 20|splice acceptor site
P06318322A0350|39 41|SSV
P06318322A0350|56 68|recombination
P06318322A0350|76 86|proviral DNA
P06318322A0350|90 102|simian sarcoma
P06318322A0350|121 129|proto-sis
P06318322A0350|137 143|introns
P06318322A0350|180 200|viral-sis messenger RNA
P06319040A1627|19 54|autonomic nervous system activity intact
P06319040A1627|56 91|carotid chemoreceptor reflex activation
P06319040A1627|103 135|absolute reflexly mediated reduction
P06319040A1627|138 154|coronary blood flow
P06319040A1627|167 178|conscious dog
P06319040A1627|199 214|arterial pressure
P06319071A0173|0 13|Female subjects
P06319071A0173|28 41|normal subjects
P06319071A0173|45 74|idiopathic calcium stone-formers
P06319071A0173|80 107|higher urinary cyclic AMP levels
P06319071A0173|117 132|male counterparts
P06319071A0173|168 183|urinary cyclic AMP
P06319071A0173|200 211|units mumol/g
P06319071A0173|214 223|creatinine
P06319072A0711|18 27|morning dip
P06319072A0711|39 55|asthmatic patients
P06319072A0711|81 87|changes
P06319072A0711|90 107|cell receptor number
P06319072A0711|110 117|affinity
P06319072A0711|124 130|results
P06319072A0711|146 151|groups
P06319072A0711|156 186|intact beta-adrenoceptor function
P06319072A0711|162 178|beta-adrenoceptor
P06319421A0937|11 21|desipramine
P06319421A0937|40 49|inhibition
P06319421A0937|52 65|neuronal uptake
P06319421A0937|75 87|amitriptyline
P06319421A0937|91 107|mianserin blockade
P06319421A0937|110 123|neuronal uptake
P06319421A0937|127 161|prejunctional alpha 2-adrenoreceptors
P06319421A0937|140 161|alpha 2-adrenoreceptors
P06319740A1331|17 34|gp54 structural gene
P06319740A1331|48 57|initiation
P06319740A1331|60 72|amplification
P06319740A1331|78 107|splenic erythroblast hyperplasia
P06319740A1331|129 144|preleukemic phase
P06319740A1331|147 161|Rauscher disease
P06320380T0001|0 16|Surgical treatment
P06320380T0001|19 37|pulmonary metastases
P06321505A0401|1 16|promoter sequence
P06321505A0401|18 33|Goldberg-Hogness
P06321505A0401|36 42|TATA box
P06321505A0401|56 64|base pairs
P06321505A0401|87 96|initiation
P06321505A0401|99 111|transcription
P06321505A0401|127 143|S1 nuclease mapping
P06321505A0401|127 136|S1 nuclease
P06321505A0401|149 190|oligonucleotide-primed reverse transcription
P06321505A0401|193 202|rat PTH mRNA
P06321634A0123|18 22|mRNAs
P06321634A0123|28 53|untranslated leader sequence
P06321634A0123|59 63|bases
P06321634A0123|68 79|single intron
P06321634A0123|98 102|bases
P06321634A0123|134 149|TRs/IRs sequences
P06321770A1353|15 46|chloramphenicol acetyltransferase
P06321770A1353|65 65|h
P06321770A1353|82 86|cells
P06321770A1353|91 106|recombinant virus
P06321770A1353|121 131|early nature
P06321770A1353|137 145|promoters
P06322183A1070|0 13|NPT II synthesis
P06322183A1070|0 4|NPT II
P06322183A1070|25 39|agar plate assays
P06322183A1070|42 60|kanamycin resistance
P06322183A1070|66 84|immunoprecipitation
P06322183A1070|90 101|NPT II protein
P06322183A1070|130 137|cysteine
P06323556A0126|1 19|computed tomographic
P06323556A0126|37 50|EOE-13 infusion
P06323556A0126|70 85|perfusion pattern
P06323556A0126|100 107|catheter
P06324089A0453|3 18|primary structure
P06324089A0453|24 43|GAL7 5' flanking region
P06324089A0453|24 27|GAL7
P06324089A0453|30 43|flanking region
P06324089A0453|47 64|many features common
P06324089A0453|74 101|multicellular eukaryotic genes
P06324121A0256|3 28|12,000 MW (12K) IE polypeptide
P06324121A0256|9 10|MW
P06324121A0256|12 14|12K
P06324121A0256|16 28|IE polypeptide
P06324121A0256|38 45|IEmRNA-5
P06324121A0256|66 86|codon open reading frame
P06324121A0256|106 125|non-translated region
P06325415A0757|3 20|greatest difference
P06325415A0757|31 33|Ad7
P06325415A0757|37 43|Ad5 DBPs
P06325415A0757|62 71|Ad7 protein
P06325415A0757|77 93|amino acids located
P06325415A0757|107 123|functional domains
P06325415A0757|129 138|Ad5 protein
P06325415A0757|140 149|amino acids
P06327039A0743|2 23|significant correlation
P06327039A0743|39 41|LVM
P06327039A0743|44 56|wall thickness
P06327039A0743|60 74|body surface area
P06327039A0743|80 92|blood pressure
P06327039A0743|94 102|heart rate
P06327039A0743|104 116|cardiac output
P06327039A0743|118 142|total peripheral resistance
P06327039A0743|150 178|ventricular systolic wall stress
P06327039A0743|187 190|CD25
P06327039A0743|208 228|urinary catecholamines
P06327039A0743|235 254|hypertensive patients
P06327039A0743|256 257|r =
P06327039A0743|264 268|p less
P06327292A0846|14 36|Shine-Dalgarno sequences
P06327292A0846|40 54|present upstream
P06327292A0846|60 91|presumed translational start codons
P06327638A0155|3 12|gene cat-86
P06327638A0155|24 80|chloramphenicol-inducible chloramphenicol acetyltransferase
P06327638A0155|84 90|located
P06327638A0155|96 107|1.1-kilobase
P06328002A0000|3 32|myeloproliferative sarcoma virus
P06328002A0000|34 37|MPSV
P06328002A0000|60 78|Moloney sarcoma virus
P06328002A0000|80 86|Mo-MuSV
P06328002A0000|90 98|adult mice
P06328012A0549|3 23|same-sized EBNA protein
P06328012A0549|13 23|EBNA protein
P06328012A0549|57 68|transfection
P06328012A0549|73 79|BamHI-K
P06328012A0549|84 96|kilobase pairs
P06328012A0549|98 100|kbp
P06328012A0549|108 121|I1f subfragment
P06328012A0549|126 128|kbp
P06328485A0277|23 40|nucleotide sequence
P06328485A0277|46 47|kb
P06328485A0277|62 69|delta gag
P06328485A0277|99 112|proviral MH2 DNA
P06328485A0277|135 150|genetic structure
P06328485A0277|179 186|other mht
P06328485A0277|191 220|myc-containing oncogenic viruses
P06328485A0277|236 255|chicken proto-myc gene
P06328504A0161|0 2|USA
P06328504A0161|31 53|genomic clone lambda PGK-1
P06328504A0161|76 89|autosomal locus
P06328504A0161|93 114|phosphoglycerate kinase
P06328504A0161|116 118|PGK
P06330082A0329|0 1|A.
P06330478A0304|3 10|patients
P06330478A0304|19 28|cimetidine
P06330478A0304|32 39|mg q.i.d.
P06330478A0304|61 67|mg daily
P06330478A0304|83 87|doses
P06331684A0607|2 16|immunologic test
P06331684A0607|32 44|tumor antigens
P06331684A0607|66 73|high risk
P06331684A0607|77 89|stomach cancer
P06333433A0000|6 13|isolates
P06333433A0000|16 41|Haemophilus influenzae type b
P06333433A0000|62 69|outbreak
P06333433A0000|72 103|invasive H. influenzae type b disease
P06333433A0000|126 147|electrophoretic profile
P06333433A0000|155 172|lipopolysaccharide
P06333433A0000|174 176|LPS
P06333878T0000|0 22|Tiaprofenic acid overdose
P06336045A0261a|0 7|Frog type
P06336045A0261a|10 12|Ft I
P06336045A0261a|17 24|frog type
P06336045A0261a|28 29|Ft
P06336045A0261a|48 49|SA
P06336045A0261a|51 55|units
P06336045A0261a|64 69|spikes
P06336045A0261a|79 94|indentation phase
P06336045A0261a|102 123|threshold response phase
P06336045A0261a|125 127|TRP
P06336045A0261a|148 157|first spike
P06336045A0261b|0 7|Frog type
P06336045A0261b|10 12|Ft I
P06336045A0261b|17 24|frog type
P06336045A0261b|28 29|Ft
P06336045A0261b|48 49|SA
P06336045A0261b|51 55|units
P06336045A0261b|64 69|spikes
P06336045A0261b|79 94|indentation phase
P06336045A0261b|102 123|threshold response phase
P06336045A0261b|125 127|TRP
P06336045A0261b|148 157|first spike
P06340643A0598|0 3|DMCM
P06340643A0598|29 41|possibilities
P06340643A0598|69 79|donor organs
P06340703A0324|0 8|Grimelius
P06340703A0324|26 38|Masson Fontana
P06341139A0213|0 11|Blood glucose
P06341139A0213|15 27|plasma insulin
P06341139A0213|21 27|insulin
P06341139A0213|76 78|min
P06341139A0213|84 92|ingestion
P06341139A0213|97 104|g glucose
P06341139A0213|106 113|fructose
P06341139A0213|116 122|lactose
P06341139A0213|128 133|g honey
P06341139A0213|137 147|g white bread
P06341139A0213|152 161|g white rice
P06341139A0213|164 171|potatoes
P06341139A0213|176 182|g apples
P06341139A0213|188 195|g carrots
P06341661T0001|0 10|Clinical use
P06341661T0001|13 44|absorbable polyglycolic acid suture
P06341661T0001|47 61|Blalock-Taussig
P06342141A0226|24 46|sufficient understanding
P06342141A0226|49 69|family pathophysiology
P06342141A0226|90 100|specificity
P06342141A0226|103 122|diagnostic techniques
P06342141A0226|140 147|efficacy
P06342141A0226|150 170|therapeutic modalities
P06342141A0226|177 204|true family health care possible
P06342141A0226|245 249|needs
P06342141A0226|267 283|individual members
P06342141A0226|290 304|value judgements
P06342141A0226|319 336|relative importance
P06342141A0226|354 365|consequences
P06342141A0226|372 395|health care delivery system
P06342141A0226|415 439|extensive literature review
P06342141A0226|470 476|queries
P06342141A0226|487 495|questions
P06342141A0226|499 510|further study
P06345840A0348|2 9|patients
P06345840A0348|12 17|group A
P06345840A0348|27 28|CI
P06345840A0348|34 35|CI
P06345840A0348|37 45|heart rate
P06345840A0348|52 75|mean circumferential fiber
P06345840A0348|86 93|velocity
P06345840A0348|95 98|mVCF
P06345840A0348|117 119|TPR
P06346427A0000|15 35|reactive insulin levels
P06346427A0000|23 29|insulin
P06346427A0000|52 74|freely-moving normal rats
P06346427A0000|87 105|different test-meals
P06349364A1051|5 11|results
P06349364A1051|48 54|passive
P06349364A1051|64 82|immune serum globulin
P06349364A1051|84 93|antibodies
P06349364A1051|103 128|group B Streptococcus antigen
P06349364A1051|158 180|intra-amniotic infection
P06350092A0916|5 21|posthospital phase
P06350092A0916|24 26|AMI
P06350092A0916|38 41|CCHD
P06350092A0916|46 55|occurrence
P06350092A0916|58 71|high-grade VPBs
P06350092A0916|88 106|more advanced degrees
P06350092A0916|113 120|coronary
P06350092A0916|128 145|ventricular disease
P06350092A0916|170 176|cardiac
P06350092A0916|183 193|sudden death
P06354594A0114|0 11|Sweet oranges
P06354594A0114|13 20|mandarin
P06354594A0114|22 31|grapefruit
P06354594A0114|42 45|lime
P06355483A0134|3 7|genes
P06355483A0134|14 18|locus
P06355483A0134|56 64|sequences
P06355483A0134|82 91|base-pairs
P06355483A0134|97 101|locus
P06355483A0134|108 117|base-pairs
P06360426A0501|3 19|enzymic hydrolysis
P06360426A0501|22 25|urea
P06360426A0501|34 40|ammonia
P06360426A0501|53 63|vivid yellow
P06360426A0501|66 83|purple colour change
P06360426A0501|89 99|pH indicator
P06361318A0440|3 23|clinical efficacy rates
P06361318A0440|38 42|cases
P06361318A0440|44 53|KS-R1 group
P06361318A0440|58 62|cases
P06361318A0440|64 72|oral group
P06361318A0440|77 81|cases
P06361318A0440|85 100|standard criteria
P06361318A0440|103 118|committee members
P06361318A0440|127 127|%
P06361318A0440|134 143|KS-R1 group
P06361318A0440|151 151|%
P06361318A0440|158 166|oral group
P06361318A1127|0 9|Side effect
P06361318A1127|19 28|subjective
P06361318A1127|32 48|objective symptoms
P06361318A1127|75 79|cases
P06361318A1127|81 90|KS-R1 group
P06361318A1127|95 99|cases
P06361318A1127|101 109|oral group
P06361318A1127|114 118|cases
P06361318A1127|127 139|incidence rate
P06361318A1127|152 152|%
P06361318A1127|159 168|KS-R1 group
P06361318A1127|176 176|%
P06361318A1127|183 191|oral group
P06361318A1127|200 220|significant difference
P06362143A0565|0 18|Plasma renin activity
P06362143A0565|43 53|head-up tilt
P06362143A0565|56 75|isoprenaline infusion
P06362143A0565|81 88|patients
P06362239T0001|0 11|Martin Luther
P06362239T0001|18 27|physicians
P06362602T0001|0 10|Enhancement
P06362602T0001|16 29|immune response
P06362602T0001|32 46|aspecific action
P06362602T0001|49 64|vaccine additives
P06362602T0001|70 90|aerogenic immunization
P06362602T0001|93 97|swine
P06362602T0001|105 109|swine
P06364265T0062|7 27|gamma-ray spectroscopy
P06367414A0000|0 7|Bepridil
P06367414A0000|10 26|calcium antagonist
P06367414A0000|32 40|half-life
P06367414A0000|58 62|hours
P06367414A0000|79 85|placebo
P06367414A0000|89 100|double-blind
P06367414A0000|113 126|crossover trial
P06369355A0834|0 7|Analysis
P06369355A0834|10 17|proteins
P06369355A0834|31 38|plasmids
P06369355A0834|49 60|deleted forms
P06369355A0834|66 75|trfA region
P06369355A0834|92 100|A2 protein
P06369355A0834|106 144|essential trfA-encoded replication protein
P06369355A0834|115 144|trfA-encoded replication protein
P06369355A0834|147 156|plasmid RK2
P06369954T0000|0 6|Effects
P06369954T0000|9 31|negative pleural pressure
P06369954T0000|34 60|left ventricular hemodynamics
P06370553A0444|7 26|plasma norepinephrine
P06370553A0444|28 29|NE
P06370553A0444|34 44|epinephrine
P06370553A0444|46 46|E
P06370553A0444|48 53|levels
P06370553A0444|69 81|active therapy
P06370553A0444|87 88|wk
P06370553A0444|105 114|guanfacine
P06370553A0444|126 133|plasma NE
P06370553A0444|158 162|ng/ml
P06370553A0444|164 170|plasma E
P06370553A0444|195 199|ng/ml
P06372563T0000|0 12|Renal response
P06372563T0000|15 23|captopril
P06372563T0000|26 43|severe heart failure
P06372563T0000|51 60|furosemide
P06372563T0000|63 73|natriuresis
P06372563T0000|77 84|reversal
P06372563T0000|87 98|hyponatremia
P06373409A1163|0 8|Lauciello
P06373409A1163|66 72|amalgam
P06373409A1163|80 91|restorations
P06373409A1163|98 119|mandibular acrylic teeth
P06373855A0000|6 20|biopsy specimens
P06373855A0000|26 32|papules
P06373855A0000|39 43|dusky
P06373855A0000|53 59|lesions
P06373855A0000|69 76|patients
P06373855A0000|81 101|pityriasis lichenoides
P06373855A0000|117 121|acuta
P06373855A0000|123 127|PLEVA
P06373855A0000|142 165|direct immunofluorescence
P06373855A0000|169 192|immunoperoxidase technics
P06373855A0000|169 184|immunoperoxidase
P06374369A1112|21 29|major part
P06374369A1112|46 55|food intake
P06374369A1112|58 72|hyperphagic rats
P06374369A1112|80 102|quinine-adulterated diet
P06374369A1112|110 130|postingestional events
P06374418A0877|3 10|aspirate
P06374418A0877|16 30|parathyroid cyst
P06374418A0877|34 44|watery clear
P06374418A0877|57 66|high amount
P06374418A0877|69 86|parathyroid hormone
P06376227A0217|0 2|EGV
P06376227A0217|8 23|detectable effect
P06376227A0217|26 36|PP secretion
P06376227A0217|42 46|basal
P06376227A0217|49 68|stimulated conditions
P06379363A0415|3 15|numerous tests
P06379363A0415|34 39|HDL-2M
P06379363A0415|87 119|insulin-dependent diabetes mellitus
P06379363A0415|87 93|insulin
P06379363A0415|122 137|clinical practice
P06381438A1280|0 25|Lung prostacyclin production
P06382374A0206|13 15|min
P06382374A0206|25 45|insulin administration
P06382374A0206|64 76|glucose levels
P06382374A0206|105 112|patients
P06382374A0206|117 139|major depressive disorder
P06382374A0206|158 165|patients
P06382374A0206|170 186|dysthymic disorder
P06382374A0206|192 212|normal control subjects
P06384983T0000|0 9|Management
P06384983T0000|12 23|hypertension
P06385474T0001|0 16|Climatic treatment
P06385474T0001|19 26|children
P06385474T0001|31 48|respiratory allergy
P06388189T0001|0 14|Transplantation
P06388189T0001|17 23|kidneys
P06388189T0001|26 39|juvenile donors
P06388189T0001|42 56|adult recipients
P06388818A0000|3 10|patients
P06388818A0000|24 37|diffuse Hodgkin
P06388818A0000|43 53|non-Hodgkin
P06388818A0000|56 64|lymphomas
P06388818A0000|104 130|primary chemotherapy regimens
P06388818A0000|147 167|high-dose chemotherapy
P06388818A0000|169 171|HDC
P06388818A0000|193 230|non-frozen autologous bone marrow infusion
P06388818A0000|232 235|ABMT
P06391496T0000|0 5|Effect
P06391496T0000|8 25|proteolytic enzymes
P06391496T0000|29 40|polypeptides
P06391496T0000|46 60|antacid activity
P06391496T0000|63 70|almagate
P06391496T0000|74 86|other antacids
P06394228T0073|0 6|Results
P06394228T0073|10 24|controlled study
P06394347A1024|0 11|Hydrallazine
P06394347A1024|23 36|slight increase
P06394347A1024|39 57|plasma renin activity
P06394347A1024|61 76|urinary excretion
P06394347A1024|79 91|noradrenaline
P06395804A0382|0 13|Urease activity
P06395804A0382|0 5|Urease
P06395804A0382|18 18|%
P06395804A0382|26 34|organisms
P06395804A0382|56 58|min
P06397009A0204|21 29|short life
P06397009A0204|51 71|light conductor Bozzini
P06397009A0204|108 121|first physician
P06397009A0204|144 184|medicine endoscopic diagnostic possibilities
P06401749T0000|11 17|lithium
P06401749T0000|23 36|osmoregulation
P06401749T0000|39 66|arginine vasopressin secretion
P06401749T0000|39 57|arginine vasopressin
P06402480A0373|3 16|susceptibility
P06402480A0373|22 32|PPNG strains
P06402480A0373|45 63|relevant antibiotics
P06402480A0373|77 90|plasmid pattern
P06402480A0373|118 138|permanent surveillance
P06402480A0373|141 160|gonococcal infections
P06402480A0373|166 182|regular evaluation
P06402480A0373|188 202|recommendations
P06402480A0373|206 227|antimicrobial treatment
P06402859A0000|0 14|Antithrombin III
P06402859A0000|25 37|plasma protein
P06402859A0000|52 69|principal inhibitor
P06402859A0000|72 79|thrombin
P06402859A0000|86 99|major modulator
P06402859A0000|102 125|intravascular coagulation
P06404842A0127|8 15|patients
P06404842A0127|20 28|untreated
P06404842A0127|46 62|previous treatment
P06404842A0127|67 83|depot testosterone
P06404842A0127|87 88|mg
P06404842A0127|112 116|weeks
P06404842A0127|122 136|average duration
P06404842A0127|142 146|years
P06406060A0000|0 22|195mPt-labeled cisplatin
P06406060A0000|38 39|iv
P06406060A0000|43 44|ip
P06406060A0000|54 57|mice
P06406060A0000|63 66|mice
P06406060A0000|74 80|Sarcoma
P06407348A0516|0 20|New beta-blocking drugs
P06407348A0516|52 61|beneficial
P06407348A0516|64 88|certain clinical situations
P06407348A0516|107 123|selective blockade
P06407348A0516|129 144|cardiac receptors
P06407348A0516|146 150|beta1
P06407348A0516|163 183|smooth muscle receptors
P06407348A0516|169 183|muscle receptors
P06407348A0516|185 189|beta2
P06411659A0264|2 11|facilities
P06411659A0264|15 26|measurements
P06411659A0264|50 62|metabolic rate
P06411659A0793|20 31|energy intake
P06411659A0793|42 46|times
P06411659A0793|50 66|energy expenditure
P06411659A0793|73 79|N intake
P06411659A0793|90 98|mg/kg/day
P06412385A0356|7 14|patients
P06412385A0356|22 57|lung disease respiratory muscle weakness
P06412385A0356|74 93|significant decreases
P06412385A0356|96 108|vital capacity
P06412385A0356|110 126|total lung capacity
P06412385A0356|131 157|maximum voluntary ventilation
P06412385A0356|161 180|significant increases
P06412385A0356|183 196|residual volume
P06412385A0356|200 227|arterial carbon dioxide tension
P06412385A0356|229 233|PaCO2
P06412385A0356|239 255|greater likelihood
P06412385A0356|258 267|dependence
P06412385A0356|270 280|ventilators
P06412385A0356|282 292|atelectasis
P06412385A0356|297 305|pneumonia
P06413492A0990|0 5|Commun
P06414990A0057|3 21|statistical analysis
P06414990A0057|30 36|TRH test
P06414990A0057|50 66|healthy volunteers
P06414990A0057|96 106|upper limits
P06414990A0057|112 136|normal thyrotropin response
P06414990A0057|118 128|thyrotropin
P06414990A0057|141 153|secretory area
P06415299A0233|0 19|Total cumulative doses
P06415299A0233|22 32|doxorubicin
P06415299A0233|51 52|mg
P06415299A0233|55 56|m.
P06419251T0000|0 18|Movement programming
P06419251T0000|43 64|behavioral requirements
P06426493A0331|11 13|min
P06426493A0331|16 37|steady state anaesthesia
P06426493A0331|49 60|measurements
P06426493A0331|63 65|IOP
P06426493A0331|67 82|arterial pressure
P06426493A0331|84 92|heart rate
P06426493A0331|94 97|FIO2
P06426493A0331|99 103|FE'CO
P06426493A0331|108 110|CVP
P06426493A0331|134 141|patients
P06426493A0331|150 159|atracurium
P06426493A0331|164 169|mg kg-1
P06426493A0331|176 191|other pancuronium
P06426493A0331|195 200|mg kg-1
P06428116T0000|0 20|Transitory subclinical
P06428116T0000|24 46|permanent hypothyroidism
P06428116T0000|60 78|subacute thyroiditis
P06429992T0000|0 17|Gonadotropin levels
P06429992T0000|0 11|Gonadotropin
P06429992T0000|20 26|mothers
P06429992T0000|40 43|sets
P06429992T0000|46 52|DZ twins
P06433442T0000|0 7|Freezing
P06433442T0000|10 15|plasma
P06433442T0000|24 34|better yield
P06433442T0000|37 46|factor VIII
P06433442T0000|48 49|C.
P06434572A0157|5 12|children
P06434572A0157|32 51|diagnostic categories
P06434572A0157|55 76|idiopathic GH deficiency
P06434572A0157|78 79|n =
P06434572A0157|86 107|organic hypopituitarism
P06434572A0157|109 110|n =
P06434572A0157|116 144|intrauterine growth retardation
P06434572A0157|146 147|n =
P06434572A0157|156 174|constitutional delay
P06434572A0157|189 208|familial short stature
P06434572A0157|210 211|n =
P06434572A0157|218 241|standard clinical criteria
P06434572A0157|245 257|physiological
P06434572A0157|261 280|pharmacological tests
P06434572A0157|283 291|GH reserve
P06434572A0157|283 284|GH
P06434587A0551|14 25|measurable LH
P06434587A0551|24 25|LH
P06434587A0551|29 37|FSH levels
P06434587A0551|29 31|FSH
P06434587A0551|43 66|pulsed nocturnal secretion
P06434587A0551|71 80|pubertal LH
P06434587A0551|79 80|LH
P06434587A0551|84 95|FSH responses
P06434587A0551|84 86|FSH
P06434587A0551|98 100|LRH
P06435565A0648|5 11|changes
P06435565A0648|38 46|afterload
P06435565A0648|52 65|aortic pressure
P06435565A0648|94 97|mmHg
P06435565A0648|99 103|p less
P06435565A0648|116 141|systemic arterial resistance
P06435565A0648|172 179|dynes/cm
P06435565A0648|183 187|sec/m
P06435565A0648|191 195|p less
P06437579A0727|0 9|Cimetidine
P06437579A0727|13 14|mg
P06437579A0727|45 46|mg
P06437579A0727|61 77|single dose regimen
P06437579A0727|88 104|patient compliance
P06439114A0677|0 10|Ceftazidime
P06439114A0677|25 43|single-agent therapy
P06439114A0677|47 85|serious gram-negative bacillary infections
P06439135A0250|0 10|Regional CBF
P06439135A0250|26 34|clearance
P06439135A0250|37 41|xenon
P06439135A0250|49 56|patients
P06439135A0250|67 80|coronary bypass
P06439135A0250|89 98|procedures
P06441624A0263|3 9|results
P06441624A0263|22 29|serum BGP
P06441624A0263|33 51|valuable measurement
P06441624A0263|54 67|bone metabolism
P06443639T0001|0 4|Study
P06443639T0001|7 23|bacterial motility
P06443639T0001|47 69|closed circuit television
P06443714T0001|9 28|Rhodnius prolixus Stal
P06443714T0001|37 52|babassu palm trees
P06444119A0340|4 20|causative organism
P06444119A0340|25 50|species-specific preference
P06444119A0340|80 87|salinity
P06444119A0340|89 90|pH
P06444119A0340|95 108|basic nutrients
P06444119A0340|113 125|growth factors
P06444119A0340|133 146|toxin formation
P06444119A0340|164 183|environmental factors
P06446048A0356|17 38|axillo-axillary by-pass
P06446048A0356|42 55|simple solution
P06446048A0356|60 78|complex haemodynamic
P06446048A0356|91 108|therapeutic problem
P06451557A0777|0 10|Deformities
P06451557A0777|24 32|olecranon
P06451557A0777|41 55|coronoid process
P06451557A0777|73 79|De Palma
P06451557A0777|85 90|Jordan
P06451557A0777|96 102|Ahlberg
P06451557A0777|108 114|Weseloh
P06452461A0930|8 29|significant correlation
P06452461A0930|32 37|LVM/M2
P06452461A0930|41 44|PWVn
P06452461A0930|48 54|pre-AVR
P06452461A0930|58 71|post AVR studies
P06452827T0001|0 25|Statokinesimetric recording
P06452827T0001|28 44|Huntington choreas
P06453290A0000|17 43|histostructural organization
P06453290A0000|46 69|intrahepatic biliary ducts
P06453290A0000|84 107|human embryofetal material
P06453290A0000|113 120|weeks old
P06454625A0000|18 33|animal experiment
P06454625A0000|38 48|alterations
P06454625A0000|54 69|renal vasculature
P06454625A0000|73 82|parenchyma
P06454625A0000|88 97|hemostasis
P06454625A0000|109 136|Infrared-Contact-Coagulation
P06454625A0000|151 184|intravital magnification angiography
P06454625A0000|186 204|magnification factor
P06459831T0001|0 13|Cardiovascular
P06459831T0001|17 51|adrenal medullo-sympathetic reactions
P06459831T0001|54 74|acute tobacco poisoning
P06460889A0111|0 20|Intravenous injections
P06460889A0111|23 27|SG-75
P06460889A0111|35 39|mg/kg
P06460889A0111|50 70|systemic blood pressure
P06460889A0111|72 74|SBP
P06460889A0111|88 97|peripheral
P06460889A0111|99 106|coronary
P06460889A0111|108 112|renal
P06460889A0111|114 123|mesenteric
P06460889A0111|127 133|femoral
P06460889A0111|135 143|blood flow
P06460889A0111|145 147|PBF
P06460889A0512|2 6|doses
P06460889A0512|15 25|.3 mg/kg i.v.
P06460889A0512|27 31|SG-75
P06460889A0512|57 69|pulse pressure
P06460889A0512|71 79|heart rate
P06460889A0512|81 95|aortic blood flow
P06460889A0512|101 119|ventricular pressure
P06460889A0512|121 123|LVP
P06460889A0512|128 137|LVdP/dt max
P06463429A0414|7 8|VE
P06463429A0414|14 24|luteal phase
P06463429A0414|31 38|% greater
P06463429A0414|52 66|follicular phase
P06466804A0686|0 7|Exposure
P06466804A0686|10 20|endothelium
P06466804A0686|32 44|shear stresses
P06466804A0686|58 70|tape recording
P06466804A0686|73 98|physiological flow waveforms
P06466804A0686|100 123|electromagnetic flowmeter
P06466804A0686|136 146|gross injury
P06466804A0686|149 158|denudation
P06466804A0686|167 175|peak shear
P06466804A0686|188 195|dyne/cm2
P06467241A0000|0 18|Modern cancer therapy
P06467241A0000|38 49|radiotherapy
P06467241A0000|51 62|chemotherapy
P06467241A0000|80 92|immunotherapy
P06467241A0000|96 107|hyperthermia
P06467797A0233|9 24|close correlation
P06467797A0233|32 46|plasma clearance
P06467797A0233|49 50|NT
P06467797A0233|53 68|10-hydroxylation
P06467797A0233|75 89|D metabolic ratio
P06467797A0233|91 98|D/4-OH-D
P06467797A0233|101 105|urine
P06467797A0233|112 120|Ghanaians
P06467797A0233|122 124|rs =
P06467797A0233|131 135|P less
P06467797A0233|148 153|Swedes
P06467797A0233|155 157|rs =
P06467797A0233|164 168|P less
P06468565A0000|3 20|response properties
P06468565A0000|23 49|cat horizontal canal afferents
P06468565A0000|51 52|N =
P06468565A0000|80 89|parameters
P06468565A0000|96 112|long time constants
P06468565A0000|114 116|tau
P06468565A0000|119 143|low frequency gain constants
P06468565A0000|145 146|G1
P06468565A0000|152 179|middle frequency gain constants
P06468565A0000|181 182|Gm
P06468632A0135|0 10|Endothelium
P06468632A0135|16 31|central ear artery
P06468632A0135|36 53|anesthetized rabbit
P06468632A0135|72 84|artery forceps
P06468673A0358|7 38|supraphysiologic E2 concentrations
P06468673A0358|48 66|cervical mucus scores
P06468673A0358|96 110|CC-treated group
P06468673A0358|112 116|P less
P06468694A0441|0 10|Stimulation
P06468694A0441|16 29|caudate nucleus
P06468694A0441|31 54|dophamine-reactive system
P06468694A0441|57 60|dogs
P06468694A0441|63 67|means
P06468694A0441|86 94|dophamine
P06468694A0441|98 107|micrograms
P06468694A0441|112 120|phenamine
P06468694A0441|126 138|deterioration
P06468694A0441|141 151|conditioned
P06468694A0441|155 177|unconditioned components
P06468694A0441|187 195|behaviour
P06473219T0000|0 4|Value
P06473219T0000|7 23|urine glucose tests
P06473219T0000|47 62|diabetes mellitus
P06473252A1073|47 65|actual egg production
P06473252A1073|72 86|important factor
P06473252A1073|89 96|ABSTRACT
P06473252A1073|111 115|WORDS
P06479362A0680|0 13|Hydrocortisone
P06479362A0680|40 61|postdenervation changes
P06479362A0680|67 80|muscle membrane
P06479362A0680|88 96|high doses
P06479362A0680|124 130|changes
P06479362A0680|136 149|muscle membrane
P06479976A0386|0 29|Significant clinical differences
P06479976A0386|40 47|patients
P06479976A0386|69 71|AMB
P06479976A0386|76 93|longer survival time
P06479976A0386|122 126|P less
P06479976A0386|143 167|frequent cranial nerve signs
P06479976A0386|173 187|treated patients
P06479976A0386|189 190|P =
P06480542A0000|1 20|pharmacokinetic study
P06480542A0000|23 32|apalcillin
P06480542A0000|49 56|patients
P06480542A0000|61 78|intensive-care unit
P06482179A0497|0 13|Catch-up growth
P06482179A0497|33 46|12-month period
P06482179A0497|50 57|children
P06482179A0497|63 69|bone age
P06482179A0497|76 80|years
P06482318A0117|0 18|Thrombocyte function
P06482318A0117|22 29|impaired
P06482318A0117|35 42|patients
P06482318A0117|70 88|platelet shape change
P06482665A0735|3 10|findings
P06482665A0735|26 43|AMPH administration
P06482665A0735|52 70|significant increase
P06482665A0735|85 106|major electroactive peak
P06482665A0735|112 125|caudate nucleus
P06482665A0735|128 141|pigtail monkeys
P06482665A0735|157 188|such amphetamine-induced increases
P06482665A0735|218 226|affective
P06482665A0735|233 246|emotional state
P06483863A0000|5 15|experiments
P06483863A0000|17 40|neonatal female BALB/cCrgl
P06483863A0000|43 60|BALB/cfC3HCrgl mice
P06483863A0000|70 91|subcutaneous injections
P06483863A0000|95 104|micrograms
P06483863A0000|107 120|beta-estradiol
P06483863A0000|123 131|sesame oil
P06483863A0000|144 147|days
P06483863A0000|179 182|days
P06483863A0000|196 217|time vaginal concretions
P06483863A0000|219 229|Experiments
P06483863A0000|239 244|silica
P06483863A0000|246 255|Experiment
P06486932A0000|11 16|deaths
P06486932A0000|20 20|%
P06486932A0000|22 30|occurring
P06486932A0000|49 56|known age
P06486932A0000|62 75|Malumfashi area
P06486932A0000|78 92|northern Nigeria
P06486932A0000|113 127|symptoms present
P06487290A0000|0 16|Salivary estradiol
P06487290A0000|19 22|beta
P06487290A0000|24 32|E2-17 beta
P06487290A0000|37 48|progesterone
P06487290A0000|50 50|P
P06487290A0000|73 98|radioimmunoassay techniques
P06487290A0000|103 117|pregnant females
P06487290A0000|138 152|third trimesters
P06487290A0000|165 184|non-pregnant controls
P06487290A0000|194 204|luteal phase
P06487290A0000|210 223|menstrual cycle
P06492188A0615|0 4|Other
P06492188A0615|9 9|d
P06492188A0615|22 38|significant effect
P06492188A0615|52 59|implants
P06493655A0415|0 23|Variable FHR decelerations
P06493655A0415|26 37|bradycardias
P06493655A0415|57 70|nonstress tests
P06493655A0415|76 76|%
P06493655A0415|87 87|%
P06493655A0415|97 104|patients
P06494215A0248|3 15|response chain
P06494215A0248|46 61|food presentation
P06494215A0248|68 86|fixed-ratio schedule
P06494297A0939|3 9|results
P06494297A0939|19 26|kindling
P06494297A0939|77 81|HPC SS
P06494297A0939|93 108|disruptive effect
P06494297A0939|114 124|stimulation
P06494766A0241|3 27|persistent fetal dispersion
P06494766A0241|30 34|nodal
P06494766A0241|38 56|Hiss bundle fragments
P06494766A0241|66 82|ventricular septum
P06494766A0241|96 114|possible explanation
P06495195A0536|14 29|biochemical tests
P06495195A0536|31 42|high activity
P06495195A0536|51 53|U/l
P06495195A0536|57 75|alkaline phosphatase
P06495195A0536|100 107|patients
P06495195A0536|115 153|lymphogranulomatosis-induced liver damage
P06497671T0001|0 6|Changes
P06497671T0001|9 27|plasma cortisol level
P06497671T0001|30 51|late asthmatic responses
P06501086A0165|0 21|Significant alterations
P06501086A0165|39 42|rats
P06501086A0165|47 54|sham rats
P06501086A0165|64 73|testicular
P06501086A0165|77 97|epididymal hypertrophy
P06501086A0165|110 140|pathologic vas deferens granulomas
P06501086A0165|151 167|total serum protein
P06501086A0165|156 167|serum protein
P06501086A0165|176 195|alpha-globulin levels
P06501086A0165|176 189|alpha-globulin
P06501086A0165|205 224|serum electrophoresis
P06501086A0165|238 266|sperm agglutinin antibody titers
P06501086A0165|243 252|agglutinin
P06503132A0784|0 2|SFP
P06503132A0784|19 26|elevated
P06503132A0784|29 30|Hn
P06503132A0784|32 32|s
P06503329A0588|3 18|average birth mass
P06503329A0588|26 33|newborns
P06503329A0588|47 48|SD
P06503329A0588|54 54|g
P06503329A0588|67 78|control group
P06503329A0588|90 91|SD
P06503329A0588|97 97|g
P06503329A0588|99 103|P less
P06503885A0342|4 15|machine drift
P06503885A0342|49 71|water phantom temperature
P06503885A0342|115 127|x-ray tube heat
P06503885A0342|143 167|significant overestimation
P06503885A0342|170 194|regional cerebral blood flow
P06503885A0342|196 199|rCBF
P06503885A0342|205 224|xenon/CT rCBF protocol
P06503885A0342|237 251|sequential scans
P06503885A0342|262 284|1-min interscan intervals
P06505014A1192|0 17|Other uncertainties
P06505014A1192|23 31|dosimetry
P06505014A1192|34 37|Y-12
P06505014A1192|41 45|Vinca
P06505014A1192|49 57|unaltered
P06506074A0456|0 30|E2 treatments elevated hen plasma TG
P06506074A0456|34 34|X
P06506074A0456|36 37|PL
P06506074A0456|41 41|X
P06506074A0456|46 46|C
P06506074A0456|50 50|X
P06506074A0456|55 68|pullet plasma TG
P06506074A0456|72 72|X
P06506074A0456|74 75|PL
P06506074A0456|79 79|X
P06506074A0456|84 84|C
P06506074A0456|88 89|X.
P06507629A0717|11 17|kidneys
P06507629A0717|22 25|rats
P06507629A0717|30 53|chronic metabolic acidosis
P06507629A0717|75 81|more NH3
P06507629A0717|95 100|groups
P06507629A0717|113 127|mumol X min-1 X g-1
P06508393T0000|0 12|Serodiagnosis
P06508393T0000|15 29|trypanosomiasis
P06508393T0000|32 46|dromedary camels
P06508393T0000|53 76|card agglutination test set
P06508393T0000|78 88|Testryp CATT
P06513456T0001|0 20|Adenyl cyclase activity
P06513456T0001|0 12|Adenyl cyclase
P06513456T0001|23 35|gastric mucosa
P06513456T0001|38 45|patients
P06513456T0001|50 62|duodenal ulcer
P06516369T0001|0 10|Proteinuria
P06516369T0001|21 38|physiopathological
P06516369T0001|42 57|clinical problems
P06516847A0393|34 44|pneumococci
P06516847A0393|50 63|lower mortality
P06516847A0393|68 78|pneumococci
P06516977T0000|0 7|Reaction
P06516977T0000|10 22|human organism
P06517816A0388|0 1|HA
P06517816A0388|22 26|p less
P06517816A0388|36 38|Tre
P06517816A0388|43 50|degrees C
P06517816A0388|55 56|HR
P06517816A0388|60 66|b X min-1
P06517816A0388|82 86|p less
P06517816A0388|96 98|Msw
P06517816A0388|102 110|g X m-2 X h-1
P06517816A0388|121 137|saline experiments
P06520418A0325|3 9|results
P06520418A0325|35 56|mitral valve orifice area
P06520418A0325|58 60|MVA
P06520418A0325|78 84|smaller
P06520418A0325|87 94|patients
P06520418A0325|111 133|LVIT flow velocity pattern
P06520418A0325|140 147|patients
P06520418A0325|158 162|p less
P06521802A0251|0 20|Scientific cooperation
P06521802A0251|23 41|CMEA member countries
P06521802A0251|76 86|sponsorship
P06521802A0251|92 114|Cancer Research Institute
P06521802A0251|116 128|Slovak Academy
P06521802A0251|131 138|Sciences
P06521802A0251|140 153|Czechoslovakia
P06521802A0251|175 178|CMEA
P06521999A0677|23 29|results
P06521999A0677|46 54|melanomas
P06521999A0677|64 74|enucleation
P06524202A0167|1 10|new variant
P06524202A0167|16 28|EMG-BFB method
P06524202A0167|30 41|multichannel
P06524202A0167|114 120|muscles
P06524202A0167|132 141|spasticity
P06524202A0167|149 159|antagonists
P06524202A0167|179 195|motor coordination
P06524727A0601|0 10|Lymphocytes
P06524727A0601|33 48|maximum responses
P06524727A0601|54 68|48-hour prelabel
P06524727A0601|80 108|hour postlabel incubation period
P06524727A0601|113 113|C
P06524727A0601|121 133|blood dilution
P06524761A0596|41 48|immunity
P06524761A0596|58 71|body weight loss
P06524761A0596|82 89|hamsters
P06524761A0596|107 130|killed-toxoplasma vaccine
P06524761A0596|164 172|T-1 strain
P06524761A0596|164 166|T-1
P06524761A0596|186 192|changes
P06524761A0596|209 216|hamsters
P06524761A0596|225 246|live-toxoplasma vaccine
P06524761A0596|274 281|RH strain
P06527379T0044|11 33|proline/alanine sequence
P06527379T0044|36 48|beta B1 subunit
P06527379T0044|64 84|repetitive DNA sequence
P06527872T0000|3 11|segmental
P06527872T0000|15 33|regional projections
P06527872T0000|39 45|sciatic
P06527872T0000|47 52|tibial
P06527872T0000|56 75|common peroneal nerves
P06527872T0000|81 100|substantia gelatinosa
P06527872T0000|106 115|spinal cord
P06527872T0000|118 121|rats
P06527872T0000|126 142|experimental study
P06527872T0000|145 149|means
P06527872T0000|152 168|an acid phosphatase
P06527872T0000|154 168|acid phosphatase
P06527872T0000|170 172|ACP
P06531286A0382|0 6|Removal
P06531286A0382|9 22|lipid fractions
P06531286A0382|25 40|plant extractions
P06531286A0382|45 50|hexane
P06531286A0382|82 91|HPLC column
P06535384A1115|5 21|Arithmetic subtest
P06535384A1115|30 34|items
P06535384A1115|87 91|items
P06535384A1115|101 117|little possibility
P06535384A1115|133 140|subjects
P06535384A1115|143 150|ABSTRACT
P06535384A1115|165 169|WORDS
P06539738T0000|3 25|toxicological evaluation
P06539738T0000|28 45|chlorofluorocarbon
P06539738T0000|49 51|CFC
P06541019A0555|3 10|patients
P06541019A0555|15 23|evaluable
P06541019A0555|27 34|toxicity
P06541932A0000|0 6|Methods
P06541932A0000|20 42|experimental algesimetry
P06541932A0000|81 87|effects
P06541932A0000|120 129|analgesics
P06542372A0159|3 14|present paper
P06542372A0159|36 48|discrepancies
P06542372A0159|60 80|consistent terminology
P06542372A0159|98 106|such terms
P06542372A0159|110 119|additivity
P06542372A0159|123 134|potentiation
P06542372A0159|141 156|simple similarity
P06542918A1131|16 38|ambiguous discrimination
P06542918A1131|48 58|greater time
P06542918A1131|62 78|simulus evaluation
P06542918A1131|114 124|P3 latencies
P06545651A0346|0 19|Ammonia concentration
P06545651A0346|45 54|treatments
P06545651A0346|78 93|protective effect
P06545651A0346|96 121|protein nitrogen degradation
P06545651A0346|124 142|non-protein nitrogen
P06545651A0346|144 146|NH3
P06546392A0542|6 42|respect C reactive protein concentrations
P06546392A0542|56 69|white cell count
P06546392A0542|71 98|erythrocyte sedimentation rate
P06546392A0542|120 133|concentrations
P06546392A0542|136 148|antiproteases
P06548953T0001|0 21|Human thyroid stimulator
P06548953T0001|23 25|HTS
P06548953T0001|29 43|thyroid diseases
P06555107A1227|33 58|calcium antagonist Verapamil
P06555107A1227|65 79|additional value
P06555107A1227|82 99|tocolytic treatment
P06555107A1227|104 116|beta-mimetics
P06568939A0000|0 16|Brainstem auditory
P06568939A0000|23 31|responses
P06568939A0000|33 37|BAERs
P06568939A0000|42 79|quantitative saccadic eye movement studies
P06568939A0000|114 121|pathways
P06568939A0000|135 143|brainstem
P06571587T0000|0 6|Effects
P06571587T0000|9 16|ketamine
P06571587T0000|22 41|circulatory functions
P06571587T0000|45 65|body tissue oxygenation
P06571587T0000|68 71|dogs
P06571587T0000|86 106|hypovolemic conditions
P06579147A0060|3 25|salient clinical features
P06579147A0060|30 37|problems
P06579147A0060|56 71|modern approaches
P06579147A0060|77 90|reconstruction
P06579147A0060|93 109|facial deformities
P06579152A1061|30 32|NPF
P06579152A1061|37 46|useful tool
P06579152A1061|50 59|activation
P06579152A1061|62 83|velopharyngeal activity
P06579152A1061|91 112|visual feed-back control
P06582285A0222|13 29|comparative safety
P06582285A0222|32 34|U-P
P06582285A0222|38 40|D&E
P06582285A0222|57 59|U-P
P06582285A0222|68 79|D&E abortions
P06582285A0222|88 101|menstrual weeks
P06582285A0222|103 111|gestation
P06584416A0157|5 16|radiologists
P06584416A0157|35 42|patients
P06584416A0157|70 79|angiograms
P06584416A0157|89 100|examinations
P06584416A0157|108 110|PGF
P06585277A0000|10 31|myelomonocytic leukemia
P06585277A0000|58 89|prostatic acid phosphatase activity
P06585277A0000|58 81|prostatic acid phosphatase
P06585277A0000|92 96|serum
P06585277A0000|113 130|typical bone lesions
P06585277A0000|133 147|roentgenography
P06585277A0000|183 200|prostatic carcinoma
P06588306A0076|17 37|prophylactic treatment
P06588306A0076|54 65|meningopathy
P06588306A0076|69 71|AIL
P06588306A0076|73 86|AIEOP protocols
P06588501T0059|2 27|experimental long-term study
P06591992A0569|2 13|anisotropism
P06591992A0569|28 50|tetrahydrofuran solution
P06593862T0001|0 16|Hepatitis B vaccine
P06594105A0560|3 18|calculated values
P06594105A0560|21 28|lambda tb
P06594105A0560|33 40|degrees C
P06594105A0560|49 63|cent haematocrit
P06594105A0560|79 82|pulp
P06594105A0560|113 130|submandibular gland
P06594105A0560|145 151|gingiva
P06594105A0560|161 168|lambda cp
P06594105A0560|181 188|lambda tp
P06594105A0560|233 241|degrees C.
P06597709A0596|2 8|pleural
P06597709A0596|35 44|asbestosis
P06597709A0596|60 70|lung volumes
P06597709A0596|84 97|transfer factor
P06597709A0596|100 122|effective alveolar volume
P06597709A0596|127 133|results
P06597709A0596|141 152|measurements
P06597709A0596|174 178|cases
P06597709A0596|186 191|absent
P06597709A0596|194 207|minimal pleural
P06599282T0001|3 17|invasive pattern
P06599282T0001|20 40|squamous cell carcinoma
P06599282T0001|46 62|mandibular gingiva
P06600533T0000|0 9|Azygos vein
P06600533T0000|21 33|posterior wall
P06600533T0000|39 47|right main
P06600533T0000|51 66|upper lobe bronchi
P06600533T0000|69 83|normal CT variant
P06602580A0664|20 43|acute severe complications
P06602580A0664|48 58|otitis media
P06602580A0664|68 82|higher frequency
P06602580A0664|90 100|individuals
P06602580A0664|105 132|alpha 1-antitrypsin deficiency
P06602580A0664|105 122|alpha 1-antitrypsin
P06602580A0664|145 151|normals
P06602600A0582|3 27|Sarns 51F cavoatrial cannula
P06602600A0582|43 54|venous system
P06602600A0582|73 91|double caval cannulas
P06606043A0598|3 14|other changes
P06606043A0598|29 39|6-positions
P06606043A0598|68 78|phenyl group
P06606043A0598|98 111|marked decrease
P06607427A0000|5 15|experiments
P06607427A0000|29 35|effects
P06607427A0000|38 69|6-hydroxydopamine-induced lesions
P06607427A0000|75 94|ventral noradrenergic
P06607427A0000|98 127|dorsal noradrenergic projections
P06607427A0000|144 155|hypothalamus
P06607427A0000|159 164|cortex
P06607427A0000|183 199|body weight changes
P06607427A0000|203 223|food-related behaviour
P06607714T0000|0 13|Limb allografts
P06607714T0000|16 19|rats
P06607714T0000|40 52|cyclosporin A.
P06609166A0209|31 37|samples
P06609166A0209|45 51|volumes
P06609166A0209|54 65|acetonitrile
P06609166A0209|76 84|injection
P06609166A0209|88 98|microliters
P06609166A0209|101 124|deproteinized supernatant
P06609166A0209|130 152|C18 reversed-phase column
P06610347A0581|0 16|Refractory periods
P06610347A0581|22 31|AV junction
P06610347A0581|46 62|comparable fashion
P06610347A0581|65 74|conduction
P06610347A0581|85 90|AV node
P06612373A0000|50 56|sources
P06612373A0000|91 107|psychotropic drugs
P06612373A0000|113 121|late 1960s
P06612373A0000|125 134|early 1970s
P06615053A0202|7 14|patients
P06615053A0202|34 38|hours
P06615053A0202|41 53|resuscitation
P06615053A0202|66 98|depressed right ventricular ejection
P06615053A0202|100 103|RVEF
P06615053A0202|122 140|end-diastolic volume
P06615053A0202|142 147|RVEDVI
P06615403A0718|7 24|single LAD occlusion
P06615403A0718|34 40|minutes
P06615403A0718|50 51|n =
P06615403A0718|56 65|microns TMs
P06615403A0718|93 99|minutes
P06615403A0718|105 112|ligation
P06615403A0718|116 125|microns TMs
P06615403A0718|148 154|minutes
P06625058A0666|48 55|unstable
P06625058A0666|67 72|capita
P06627123A0000|0 15|Female Wistar rats
P06627123A0000|24 33|liquid diet
P06627123A0000|35 42|Sustacal
P06627123A0000|58 64|ethanol
P06627123A0000|68 68|%
P06627123A0000|71 78|calories
P06627123A0000|82 98|isocaloric sucrose
P06627569T0001|0 1|HL
P06627569T0001|4 27|type oculomotor stimulator
P06629370A0252|4 11|patients
P06629370A0252|28 54|basement membrane nephropathy
P06629370A0252|71 76|marked
P06629370A0252|90 100|lamellation
P06629370A0252|106 121|basement membrane
P06629370A0252|148 153|Alport
P06630319A0244|0 6|Brain pH
P06630319A0244|17 17|h
P06630319A0244|20 40|cerebral focal ischemia
P06630319A0244|53 63|normal value
P06630319A0244|82 88|animals
P06630319A0244|101 111|barbiturate
P06630319A0244|115 133|halothane anesthesia
P06634712A0557|3 9|results
P06634712A0557|36 44|phosphate
P06634712A0557|48 54|calcium
P06634712A0557|71 79|secretion
P06634712A0557|82 84|PTH
P06634712A0557|88 89|CT
P06634712A0557|92 97|uremia
P06643612A0000|0 31|Thin-layer chromatographic methods
P06643612A0000|36 43|up-dated
P06643612A0000|47 68|pharmacokinetic studies
P06643612A0000|71 80|imipramine
P06643612A0000|83 88|plasma
P06643612A0000|92 96|urine
P06648156T0034|0 18|Introductory remarks
P06652293A0353|13 24|cut-off point
P06652293A0353|28 44|positive responses
P06652293A0353|72 72|%
P06652293A0353|88 98|specificity
P06652293A0353|103 103|%
P06653755A0192|5 26|clofelin administration
P06653755A0192|30 50|autoregulation borders
P06653755A0192|63 71|right i. e.
P06653755A0192|79 92|higher AP levels
P06654047A0694|30 36|variant
P06654047A0694|39 66|selective individual cell death
P06654047A0694|89 97|apoptosis
P06654047A0694|141 165|embryonal rhabdomyosarcoma
P06654686T0001|0 10|Combination
P06654686T0001|14 30|Shwachman syndrome
P06654686T0001|35 68|complex granulocyte function disorder
P06655634A0195|1 14|combined series
P06655634A0195|17 24|patients
P06655634A0195|37 39|TOL
P06655634A0195|50 79|more previous cesarean deliveries
P06655634A0195|90 104|vaginal delivery
P06655634A0195|110 110|%
P06655634A0195|134 142|morbidity
P06656249T0000|0 20|Nursing home discharges
P06656249T0000|23 38|clinical practice
P06657559A0489|0 4|Trial
P06657559A0489|6 20|broiler chickens
P06657559A0489|37 47|control feed
P06657559A0489|65 69|weeks
P06657559A0489|114 115|hr
P06657559A0489|137 147|control feed
P06657559A0489|167 180|ppm ochratoxin A
P06657559A0489|185 193|heart rate
P06657559A0489|197 209|blood pressure
P06657559A0489|227 234|half hour
P06657559A0489|243 244|hr
P06658029A0086|3 20|carcinogen bioassay
P06658029A0086|37 54|important component
P06658029A0086|69 86|toxicological tests
P06658029A0086|93 108|hazard evaluation
P06658445A0140|0 13|Harmful effects
P06658445A0140|16 22|animals
P06658445A0140|46 54|deficient
P06658445A0140|57 72|excessive amounts
P06658445A0140|75 80|intake
P06658586T0001|0 22|Angionephroscintigraphy
P06658586T0001|39 46|diseases
P06658586T0001|52 57|kidney
P06659982A0231|30 40|sleep period
P06659982A0231|85 99|delta-wave stage
P06659982A0231|101 102|DS
P06659982A0231|109 110|QS
P06659982A0231|131 151|polygraphic parameters
P06659982A0231|153 161|increases
P06659982A0231|171 186|paradoxical phase
P06659982A0231|195 196|PS
P06659982A0231|227 236|pronounced
P06659982A0231|254 259|months
P06659982A0231|273 282|second ones
P06659982A0231|288 296|first year
P06662623A0124|1 4|82Br
P06662623A0124|6 9|MISO
P06662623A0124|34 40|samples
P06662623A0124|43 49|Br-MISO
P06662623A0124|53 67|SLOWPOKE reactor
P06662623A0124|72 72|h
P06662623A0124|76 93|thermal neutron flux
P06662623A0124|102 109|n cm-2 s-1
P06667015A0832|10 17|findings
P06667015A0832|45 63|thick myocardial wall
P06667015A0832|66 74|ischaemia
P06667015A0832|92 112|postoperative recovery
P06667015A0832|131 145|serum CK-MB level
P06667868T0001|0 21|Morphofunctional status
P06667868T0001|33 40|elements
P06667868T0001|53 56|rats
P06667868T0001|68 84|different variants
P06667868T0001|116 126|BR-1 benzene
P06668316A0178|6 37|MOS-Hypersil reversed-phase column
P06668316A0178|43 57|phosphate buffer
P06668316A0178|60 82|acetonitrile mobile phase
P06668316A0178|84 101|baseline separation
P06668316A0178|104 113|antipyrine
P06668316A0178|118 153|metabolites 3-hydroxymethylantipyrine
P06668316A0178|155 167|norantipyrine
P06668316A0178|171 189|4-hydroxyantipyrine
P06668316A0178|197 212|internal standard
P06668316A0178|214 223|phenacetin
P06668316A0178|243 245|min
P06670732A0000|23 30|patients
P06670732A0000|32 34|ASA
P06670732A0000|47 55|induction
P06670732A0000|58 68|anaesthesia
P06670732A0000|73 79|effects
P06670732A0000|82 89|Fentanyl
P06670732A0000|94 95|mg
P06670732A0000|114 121|Fentanyl
P06670732A0000|126 127|mg
P06670732A0000|132 141|Droperidol
P06670732A0000|144 145|mg
P06670732A0000|148 154|Innovar
P06670732A0000|156 165|Thalamonal
P06670732A0000|170 177|Atropine
P06670732A0000|183 191|mg/kg b.w.
P06670732A0000|200 226|cardiocirculatory parameters
P06671047A1124|5 11|results
P06671047A1124|25 36|high validity
P06671047A1124|39 41|NOM
P06671047A1124|72 103|tumoural hyperprolactinemic states
P06671047A1124|111 132|contradictory responses
P06671047A1124|135 139|CD/LD
P06671047A1124|135 136|CD
P06671047A1124|138 139|LD
P06671047A1124|141 142|LD
P06671047A1124|146 148|DOM
P06671047A1124|176 184|sub-group
P06671047A1124|187 199|Prolactinomas
P06671047A1124|215 238|maintained DA central tonus
P06671047A1124|265 298|different etiopathogenetical factors
P06671047A1124|310 341|tumoural hyperprolactinemic states
P06671065A0000|0 10|Serum lipids
P06671065A0000|14 25|lipoproteins
P06671065A0000|30 61|insulin dependent diabetic children
P06671065A0000|95 109|metabolic status
P06671065A0000|115 122|patients
P06671385A0856|0 4|Low NA
P06671385A0856|8 8|A
P06671385A0856|36 54|plasma renin activity
P06671385A0856|36 46|plasma renin
P06671385A0856|62 63|PA
P06671385A0856|109 131|actual body sodium content
P06671925T0000|0 21|Amikacin concentrations
P06671925T0000|24 28|serum
P06671925T0000|32 43|blister fluid
P06671925T0000|46 62|healthy volunteers
P06671925T0000|68 75|patients
P06671925T0000|80 94|renal impairment
P06672094A0390|3 10|subgroup
P06672094A0390|25 36|medial rectus
P06672094A0390|60 69|medial face
P06672094A0390|75 91|oculomotor nucleus
P06672094A0390|99 113|aberrant neurons
P06672094A0390|119 146|medial longitudinal fasciculus
P06672094A0390|165 176|other mammals
P06674374T0000|0 28|Hepatitis B vaccination strategy
P06674374T0000|32 49|health-care workers
P06674374T0000|62 93|intermediate hepatitis B endemicity
P06674516A0350|2 24|intravenous drip infusion
P06674516A0350|27 29|AMK
P06674516A0350|32 45|adequate dosage
P06674516A0350|53 62|beneficial
P06674516A0350|79 96|infectious diseases
P06674516A0350|99 123|otorhinolaryngologic field
P06674977A1181|10 17|families
P06674977A1181|22 22|%
P06674977A1181|30 42|next pregnancy
P06674977A1181|57 57|%
P06674977A1181|70 86|prenatal diagnosis
P06674977A1181|88 94|table VI
P06675047A0000|3 9|authors
P06675047A0000|23 34|interference
P06675047A0000|40 49|hemoglobin
P06675047A0000|55 68|routine methods
P06675047A0000|70 85|Berthelot classic
P06675047A0000|89 97|Berthelot
P06675047A0000|128 140|plasmatic urea
P06683807A0160|0 19|Parkinsonian patients
P06683807A0160|37 51|lower prevalence
P06683807A0160|54 63|alcohol use
P06683876A0244|5 9|cells
P06683876A0244|20 26|microns
P06683876A0244|29 36|diameter
P06683876A0244|52 58|fission
P06683876A0244|67 74|clusters
P06683876A0244|86 98|daughter cells
P06684624A0298|0 5|Female
P06684624A0298|12 26|male mortalities
P06684624A0298|44 49|higher
P06684624A0298|53 64|cake-fed rats
P06684624A0298|80 86|diet 41B
P06684624A0736|0 37|Urinary N-acetylglucosaminidase activity
P06684624A0736|0 29|Urinary N-acetylglucosaminidase
P06684624A0736|41 52|mg creatinine
P06684624A0736|85 90|groups
P06685004A0000|3 14|associations
P06685004A0000|22 56|sex-hormone-binding globulin capacity
P06685004A0000|22 48|sex-hormone-binding globulin
P06685004A0000|58 61|SHBG
P06685004A0000|68 80|body mass index
P06685004A0000|82 84|BMI
P06685004A0000|90 104|physical fitness
P06685004A0000|124 126|men
P06685004A0000|132 136|women
P06685177T0000|0 11|Dipetalonema
P06685177T0000|13 22|Alafilaria
P06685177T0000|24 41|hydrochoerus subgen
P06685177T0000|48 49|n.
P06685536A0502|8 12|years
P06685536A0502|15 38|such photoperiodic control
P06685536A0502|43 46|ewes
P06685536A0502|60 86|bilateral orbital enucleation
P06685643A0179|3 16|concentrations
P06685643A0179|19 20|C4
P06685643A0179|24 29|C1-INH
P06685643A0179|78 93|normal mean values
P06685643A0179|99 104|stages
P06686454A0585|4 24|antibacterial activity
P06686454A0585|42 61|Gram-negative bacilli
P06686454A0585|80 102|Klebsiella-Enterobacter
P06686454A0585|104 111|Shigella
P06686454A0585|129 146|Serratia marcescens
P06686454A0585|150 156|Proteus
P06687953T0000|3 24|mucosal defence capacity
P06687953T0000|32 58|proteolytic leukocyte enzymes
P06689413A0174|3 11|apparatus
P06689413A0174|24 43|Am-241 exciting source
P06689413A0174|48 50|mCi
P06689413A0174|55 68|pure Ge detector
P06689413A0174|72 75|mm2 X
P06689413A0174|77 78|mm
P06689413A0174|92 114|K alpha fluorescent x-rays
P06689413A0174|127 129|KeV
P06689413A0174|148 153|iodine
P06689513T0001|0 21|Ultrastructural studies
P06689513T0001|24 34|retinopathy
P06689513T0001|37 52|premature infants
P06691304A0284|10 28|serum concentrations
P06691304A0284|34 39|values
P06691304A0284|41 52|median values
P06691304A0284|57 74|standard deviations
P06691304A0284|82 88|analyte
P06691304A0284|103 107|males
P06691304A0284|111 117|females
P06691304A0284|129 137|age groups
P06692517T0000|3 9|effects
P06692517T0000|12 30|antithrombotic drugs
P06692517T0000|33 40|patients
P06692517T0000|45 66|left ventricular thrombi
P06692517T0000|82 106|indium-111 platelet imaging
P06692517T0000|110 140|two-dimensional echocardiography
P06692631A0129|1 15|stable interface
P06692631A0129|25 37|overall stress
P06692631A0129|41 63|microstress distribution
P06692631A0129|86 99|trabecular bone
P06694380A1483|0 7|Plasma NE
P06694380A1483|23 35|anephric group
P06694380A1483|40 47|mg/liter
P06694380A1483|56 57|SD
P06694380A1483|71 72|P =
P06694380A1483|89 96|ABSTRACT
P06694380A1483|111 115|WORDS
P06694778A0000|2 30|long-term hemodialysis patients
P06694778A0000|46 88|redistribution thallium-201 myocardial imaging
P06694778A0000|112 123|hemodialysis
P06698047A0445|3 17|Prolactin levels
P06698047A0445|3 11|Prolactin
P06698047A0445|31 48|physiological norms
P06698047A0445|53 61|responses
P06698047A0445|64 66|TRH
P06698047A0445|96 103|few cases
P06700231A0259|7 25|total tumor resection
P06700231A0259|27 61|multiple intraperitoneal tumor nodules
P06700231A0259|71 75|sizes
P06700231A0259|88 95|resected
P06700231A0259|99 104|months
P06700469T0000|0 27|Private hospital accreditation
P06702257T0001|0 14|Antithrombin III
P06702257T0001|17 26|hip surgery
P06702643A0000|8 19|infant hearts
P06702643A0000|23 23|%
P06702643A0000|29 50|aortic arch interruption
P06702643A0000|61 77|left common carotid
P06702643A0000|85 102|subclavian arteries
P06702643A0000|104 108|type B
P06702643A0000|111 117|Celoria
P06702643A0000|121 126|Patton
P06702643A0000|132 152|right subclavian artery
P06702643A0000|154 155|SA
P06704467A0539|26 36|photoperiod
P06704467A0539|39 48|pallid bats
P06704467A0539|54 72|several other mammals
P06704467A0539|89 99|pineal gland
P06705456A0346|0 9|Absorption
P06705456A0346|24 31|mean time
P06705456A0346|42 44|min
P06707357A0180|13 24|observations
P06707357A0180|29 36|patients
P06707357A0180|41 46|mitral
P06707357A0180|53 71|aortic regurgitation
P06707357A0180|92 107|valve replacement
P06707357A0180|119 129|differences
P06707357A0180|164 168|types
P06707357A0180|171 184|volume overload
P06709310A0000|7 29|manifest latent nystagmus
P06709310A0000|32 40|late onset
P06709310A0000|44 58|13-year-old girl
P06709700A0230|9 19|compartment
P06709700A0230|33 40|severity
P06709700A0230|54 61|subscale
P06709700A0230|67 89|Hamilton Depression Scale
P06709700A0230|96 111|Melancholia Scale
P06709700A0230|136 157|instrumental perfection
P06709700A0230|167 180|outcome measure
P06709700A0230|183 205|antidepressant treatment
P06711642A0093|0 28|Significant immunoglobulinuria
P06711642A0093|61 68|azotemia
P06711642A0093|92 110|creatinine clearance
P06711642A0093|112 133|significant proteinuria
P06711642A0093|135 141|greater
P06711642A0093|157 164|dipstick
P06711642A0093|167 173|greater
P06711642A0093|188 189|gm
P06711642A0093|193 214|24-hour urine collection
P06711642A0093|219 226|oliguria
P06712314A0148|1 11|total number
P06712314A0148|18 22|cases
P06712314A0148|43 61|medical institutions
P06713200A0630|0 19|Epileptiform activity
P06713200A0630|32 49|superficial laminae
P06713200A0630|86 103|primary projections
P06713200A0630|142 150|phenytoin
P06713204A0867|3 14|AD components
P06713204A0867|45 58|affective state
P06713204A0867|77 87|V1 component
P06714298X0000|2 19|nisoldipine capable
P06714298X0000|30 51|left ventricular preload
P06714298X0000|58 73|anesthetized pigs
P06714298X0000|75 85|nisoldipine
P06714298X0000|90 110|micrograms X kg-1 X min-1
P06714298X0000|114 134|calcium channel blocker
P06714298X0000|156 165|nifedipine
P06714298X0000|174 204|left ventricular systolic pressure
P06714298X0000|208 208|%
P06714298X0000|213 238|systemic vascular resistance
P06714298X0000|242 242|%
P06714298X0000|252 261|maxLVdP/dt
P06714298X0000|275 275|%
P06714298X0000|279 291|cardiac output
P06714298X0000|295 303|unchanged
P06714354A0194|0 6|Monkeys
P06714354A0194|34 43|unilateral
P06714354A0194|47 68|serial bilateral removal
P06714354A0194|71 92|superior temporal cortex
P06715792A0295|0 15|HBB concentration
P06715792A0295|21 27|fetuses
P06715792A0295|49 60|accumulation
P06716977A0136|3 9|samples
P06716977A0136|29 48|ethanol concentration
P06716977A0136|54 63|most losses
P06716977A0136|94 101|mg% range
P06718064T0001|0 16|Plasma lactoferrin
P06718064T0001|23 32|blood count
P06718064T0001|35 56|polynuclear neutrophils
P06719057A0181|15 44|selective renal vein phlebography
P06719057A0181|62 81|unexplained hematuria
P06719057A0181|85 97|filing defects
P06719057A0181|103 118|excretory urogram
P06720371T0000|0 9|Pilot study
P06720371T0000|12 27|blood coagulation
P06720371T0000|30 41|gout patients
P06721188A0200|3 21|statistical analysis
P06721188A0200|34 38|F test
P06721188A0200|49 56|Snedecor
P06721188A0200|59 70|contrast test
P06723849A0197|3 16|pyramidal tract
P06723849A0197|20 50|Mesencephalic Reticular Formation
P06723849A0197|52 54|MRF
P06723849A0197|87 97|transection
P06726257A1179|22 40|5-hydroxytryptophan
P06726257A1179|42 46|5-HTP
P06726257A1179|48 59|accumulation
P06726257A1179|62 64|LSD
P06726257A1179|71 89|regional differences
P06726257A1179|92 101|inhibition
P06726257A1179|104 115|methiothepin
P06726257A1179|117 135|hypothalamus greater
P06726257A1179|140 152|cortex greater
P06726257A1179|157 164|striatum
P06726257A1179|184 213|autoreceptor antagonist activity
P06726257A1179|216 227|methiothepin
P06726257A1179|237 244|ABSTRACT
P06726257A1179|259 263|WORDS
P06726257T0000|0 6|Effects
P06726257T0000|9 20|methiothepin
P06726257T0000|24 47|lysergic acid diethylamide
P06726257T0000|50 65|serotonin release
P06726257T0000|76 93|serotonin synthesis
P06726257T0000|101 116|possible relation
P06726257T0000|119 147|serotonin autoreceptor function
P06728580A0291|3 23|recent measles epidemic
P06728580A0291|26 31|El Paso
P06728580A0291|33 34|TX
P06728580A0291|43 49|records
P06728580A0291|99 106|students
P06731302A0930|13 27|bradyarrhythmia
P06731302A0930|29 38|related SCD
P06731302A0930|42 70|manifest atrioventricular block
P06731302A0930|73 89|bundle branch block
P06732946A0281|19 23|areas
P06732946A0281|26 31|fibrin
P06732946A0281|44 55|fibrinolysis
P06732946A0281|76 80|times
P06732946A0281|99 119|standard magnification
P06732946A0281|123 123|X
P06732946A0281|129 141|image analyser
P06732946A0281|143 151|Videoplan
P06734713T0000|0 38|Diclofenac sodium-chlormezanone poisoning
P06735247A0803|0 44|Postprandial plasma enteroglucagon concentration
P06735247A0803|12 31|plasma enteroglucagon
P06735247A0803|52 58|minutes
P06735247A0803|61 77|untreated patients
P06735247A0803|103 120|faecal fat excretion
P06735247A0803|122 123|r =
P06735247A0803|129 133|p less
P06738410T0000|0 12|Blood pressure
P06738410T0000|15 22|children
P06740373A0891|28 34|captive
P06740373A0891|39 48|cynomolgus
P06740373A0891|83 88|rhesus
P06740373A0891|93 120|antimalarial drug testing model
P06740697A0318|3 9|results
P06740697A0318|45 60|guinea pig strains
P06740919A0162|0 20|Adult Amblyomma lepidum
P06740919A0162|31 36|nymphs
P06740919A0162|58 67|heartwater
P06740919A0162|71 78|Friesian
P06740919A0162|80 82|Bos
P06740919A0162|90 93|calf
P06743061A0239|10 16|percent
P06743061A0239|24 31|patients
P06743061A0239|35 51|neurologic disease
P06743061A0239|85 92|tinnitus
P06744024A0000|0 7|Morphine
P06744024A0000|23 38|lateral ventricle
P06744024A0000|55 73|unilateral analgesia
P06744024A0000|79 90|formalin test
P06744024A0000|116 127|moderate pain
P06748227A0423|3 6|maps
P06748227A0423|9 13|Case 2
P06748227A0423|9 12|Case
P06748227A0423|50 59|upper right
P06748227A0423|83 91|right side
P06748227A0423|97 111|posterior thorax
P06749072A0116|0 20|Urinary urate excretion
P06749072A0116|22 35|urate clearance
P06749072A0116|40 58|fractional excretion
P06749072A0116|61 65|urate
P06749072A0116|97 110|water immersion
P06749072A0116|142 155|water immersion
P06750608A1442|0 8|Mutations
P06750608A1442|16 28|other lts genes
P06750608A1442|45 47|mak
P06750608A1442|49 57|phenotype
P06751455A0117|26 35|gallstones
P06751455A0117|55 63|remainder
P06751455A0117|67 74|patients
P06751455A0117|83 90|glucagon
P06751455A0117|96 102|placebo
P06753902A0437|5 12|patients
P06753902A0437|33 41|captopril
P06753902A0437|68 73|months
P06753902A0437|99 106|class IIM
P06753902A0437|115 117|IIS
P06754662T0001|0 30|Bullous angiolymphoid hyperplasia
P06754662T0001|35 46|eosinophilia
P06755468A0180|0 6|Regions
P06755468A0180|22 38|open reading frames
P06755468A0180|41 44|cobA
P06755468A0180|51 61|third intron
P06755468A0180|67 73|cob gene
P06755468A0180|76 80|yeast
P06755468A0180|85 105|high amino acid homology
P06755986A0382|0 20|Multiresistant strains
P06755986A0382|33 38|humans
P06755986A0382|41 64|enteral toxico-infections
P06755986A0382|75 86|infected mice
P06755986A0382|105 111|strains
P06755986A0382|122 139|hospital infections
P06760394T0001|0 21|Single tooth replacement
P06760394T0001|37 39|ITI
P06760394T0001|41 73|International Team fur Implantologie
P06760394T0001|75 94|type F hollow-cylinder
P06762025A0171|3 35|13,14-dihydro-15-keto-metabolites
P06762025A0171|38 41|PGE2
P06762025A0171|45 53|PGF2 alpha
P06762025A0171|72 102|significant antiarrhythmic effect
P06762321T0000|0 17|Nucleotide sequence
P06762321T0000|20 43|DNA controlling expression
P06762321T0000|46 50|genes
P06762321T0000|54 79|maltosaccharide utilization
P06762321T0000|82 94|Streptococcus
P06763897A0216|3 14|hypertension
P06763897A0216|19 29|elevated PRA
P06763897A0216|42 50|resistant
P06763897A0216|56 68|angiotensin II
P06763897A0216|56 66|angiotensin
P06763897A0216|70 72|AII
P06763897A0216|74 79|analog
P06763897A0216|81 84|Sar1
P06763897A0216|86 89|Ile8
P06763897A0216|91 93|ALL
P06764669T0001|0 24|Colorimetric determination
P06764669T0001|27 37|urinary iron
P06764669T0001|51 63|deferoxamine B
P06764669T0001|71 83|single reagent
P06767648A0734|0 11|Measurements
P06767648A0734|14 22|perfusion
P06767648A0734|46 57|higher values
P06767648A0734|63 75|active therapy
P06772370A0342|0 5|Volume
P06772370A0342|22 30|total DMDZ
P06772370A0342|48 51|l/kg
P06772370A0342|58 68|unbound DMDZ
P06772370A0342|74 83|correction
P06772370A0342|87 100|protein binding
P06772370A0342|115 118|l/kg
P06772370A0342|123 128|larger
P06772370A0342|131 135|women
P06772370A0342|142 144|men
P06772370A0342|150 153|ages
P06772612A0000|0 6|Effects
P06772612A0000|9 16|dopamine
P06772612A0000|23 41|dopaminergic blocker
P06772612A0000|43 53|haloperidol
P06772612A0000|60 68|responses
P06772612A0000|71 95|carotid body chemoreceptors
P06772612A0000|98 104|hypoxia
P06772612A0000|108 118|hypercapnia
P06772612A0000|139 154|anesthetized cats
P06775834A0000|0 4|HLA-A
P06775834A0000|8 18|B phenotypes
P06775834A0000|24 31|patients
P06775834A0000|45 62|malignant melanomas
P06775834A0000|82 94|special regard
P06775834A0000|98 111|metastatic form
P06775834A0000|114 120|relapse
P06776918T0000|0 15|Trypanosoma cruzi
P06777229A0243|3 10|subjects
P06777229A0243|27 40|normal subjects
P06777229A0243|46 53|patients
P06777229A0243|58 78|gastroduodenal disease
P06781339A0501|36 53|long-term follow-up
P06781339A0501|84 91|patients
P06781339A0501|96 118|alveolar hypoventilation
P06781728A0690|3 13|alterations
P06781728A0690|16 30|differentiation
P06781728A0690|33 52|osteoprogenitor cells
P06781728A0690|78 91|mineralization
P06781728A0690|116 125|lower rates
P06781728A0690|128 140|bone formation
P06781728A0690|154 173|fluorochrome labeling
P06781728A0690|180 202|magnesium-deficient rats
P06782612A0142|1 17|convenient measure
P06782612A0142|24 33|impairment
P06782612A0142|62 72|urine volume
P06782612A0142|74 74|V
P06782612A0142|85 100|lithium clearance
P06782612A0142|102 104|CLi
P06782869A0263|0 14|Nitrogen balance
P06782869A0263|30 51|metabolic complications
P06782869A0263|77 79|BUN
P06782869A0263|81 95|serum creatinine
P06782869A0263|97 115|creatinine clearance
P06782869A0263|117 124|serum CO2
P06782869A0263|126 129|SGOT
P06782869A0263|131 134|SGPT
P06782869A0263|136 143|serum LDH
P06782869A0263|141 143|LDH
P06782869A0263|148 171|serum alkaline phosphatase
P06784123A0286|0 9|Production
P06784123A0286|12 18|C mu RNAs
P06784123A0286|26 32|mu mRNAs
P06784123A0286|48 60|recombination
P06784123A0286|82 83|JH
P06784123A0286|85 89|locus
P06784123A0771|3 14|1.9-kb C mu RNA
P06784123A0771|9 14|C mu RNA
P06784123A0771|28 49|sequence characteristic
P06784123A0771|60 66|mu chain
P06784123A0771|78 90|longer species
P06784123A0771|101 120|membrane-bound mu chin
P06784123T0000|0 10|Transcripts
P06784123T0000|16 36|immunoglobulin C mu gene
P06784123T0000|55 62|splicing
P06784123T0000|69 87|lymphoid development
P06785113A0337|0 49|Non-complement-dependent sperm-immobilizing activity
P06785113A0337|70 82|cervical mucus
P06785113A0337|85 99|several patients
P06786756T0000|9 24|DNA rearrangement
P06786756T0000|28 51|alternative RNA processing
P06786756T0000|69 92|immunoglobulin delta genes
P06788388A0000|30 37|ICRF-159
P06788388A0000|88 98|preclinical
P06788388A0000|102 121|early clinical studies
P06788388A0000|131 139|compounds
P06790572A0330|5 12|isolates
P06790572A0330|17 25|resistant
P06790572A0330|28 37|lincomycin
P06790572A0330|39 46|colistin
P06790572A0330|48 55|nystatin
P06790572A0330|57 69|amphotericin B
P06790572A0330|71 89|trimethoprim lactate
P06790572A0330|91 100|polymyxin B
P06790572A0330|105 114|anisomycin
P06791500A0622|15 37|amniotic fluid delta OD450
P06791500A0622|57 67|cornerstone
P06791500A0622|70 87|clinical management
P06793764T0001|0 9|Host lipids
P06793764T0001|12 31|tuberculous infection
P06794480A0785|11 33|significative difference
P06794480A0785|41 48|age group
P06794480A0785|65 65|p
P06794666A0208|3 35|sympathetic neuroeffector influence
P06794666A0208|41 50|myocardium
P06794666A0208|55 58|ATCI
P06794666A0208|69 80|large measure
P06794666A0208|100 127|neurotransmitter biosynthesis
P06794666A0208|141 168|cardiomyocyte adrenoreceptors
P06795119T0000|0 18|Lens aldose reductase
P06795119T0000|21 28|diabetic
P06795119T0000|32 52|galactosemic cataracts
P06795654A0434|0 11|Fenfluramine
P06795654A0434|15 19|doses
P06795654A0434|41 54|mg/kg/infusion
P06795654A0434|70 96|self-administration behavior
P06795654A0434|109 126|minimum requirement
P06795654A0434|128 129|FR
P06795832A0148|13 22|Hepatitis A
P06795832A0148|30 40|HBe-antigen
P06795832A0148|49 51|HBc
P06795832A0148|53 55|IgM
P06795832A0148|59 61|IgG
P06795832A0148|65 85|HBs- and HBe-antibodies
P06795832A0148|72 85|HBe-antibodies
P06795900A0000|14 58|fatty acid cyclo-oxygenase inhibitor indomethacin
P06795900A0000|14 37|fatty acid cyclo-oxygenase
P06795900A0000|61 77|cerebral blood flow
P06795900A0000|79 81|CBF
P06795900A0000|89 101|metabolic rate
P06795900A0000|112 116|CMRO2
P06795900A0000|130 138|paralyzed
P06795900A0000|164 167|rats
P06795971A0000|3 12|rat incisor
P06795971A0000|17 36|excellent model system
P06795971A0000|51 61|amelgenesis
P06796300A0759|10 32|elevated prolactin levels
P06796300A0759|18 26|prolactin
P06796300A0759|35 46|nursing women
P06796300A0759|66 96|chronic oestradiol administration
P06797063A0000|0 9|Factor VIII
P06797063A0000|0 5|Factor
P06797063A0000|10 29|procoagulant activity
P06797063A0000|31 50|antigen concentration
P06797063A0000|54 74|von Willebrand activity
P06797063A0000|54 66|von Willebrand
P06797063A0000|77 94|ristocetin cofactor
P06797063A0000|109 120|several times
P06797063A0000|125 132|patients
P06797063A0000|137 139|DIC
P06798609A0000|0 17|Morphine-dependent
P06798609A0000|21 31|control rats
P06798609A0000|36 58|oral free-choice protocol
P06798609A0000|74 88|gamma-vinyl GABA
P06798609A0000|90 92|GVG
P06798609A0000|107 113|mg/kg IP
P06798609A0000|119 122|days
P06798609A0000|132 148|successive periods
P06801778T0001|0 11|Significance
P06801778T0001|17 44|pulmonary gas exchange reaction
P06801778T0001|47 61|physical loading
P06801778T0001|92 111|mitral commissurotomy
P06802500T0001|0 16|Thyreoliberin VUFB
P06802500T0001|0 12|Thyreoliberin
P06802500T0001|19 36|thyroid gammagraphy
P06803634A0810|2 10|silicosis
P06803634A0810|12 35|significant relationships
P06803634A0810|43 50|patients
P06803634A0810|54 57|sons
P06803634A0810|82 111|arterial blood gas determinations
P06803634A0810|115 134|ventilatory responses
P06803634A0810|144 148|Paco2
P06803634A0810|151 158|patients
P06803634A0810|162 192|hypercapnic ventilatory responses
P06803634A0810|195 198|sons
P06805504A0629|12 25|urinary N values
P06805504A0629|39 45|mg/kg W0
P06805504A0629|60 71|kg live weight
P06805504A0629|87 101|total N excretion
P06805504A0629|111 117|faecal N
P06805504A0629|130 136|mg/kg W0
P06805537T0001|0 7|Advances
P06805537T0001|10 28|hemophilia treatment
P06805537T0001|31 50|hepatitis-safe factor
P06805537T0001|45 54|factor VIII
P06807149A0222|55 68|different forms
P06807149A0222|71 73|DSG
P06807149A0222|81 83|EIB
P06807149T0000|0 9|Comparison
P06807149T0000|17 37|different preparations
P06807149T0000|40 59|disodium cromoglycate
P06807149T0000|77 104|exercise-induced bronchospasm
P06807149T0000|107 123|double-blind study
P06807192A0312|0 3|LCBF
P06807192A0312|15 28|hypoxic puppies
P06807192A0312|46 76|local cerebral glucose utilization
P06807192A0312|78 81|LCGU
P06807192A0312|99 124|same experimental conditions
P06807192A0312|126 130|Duffy
P06807659T0001|0 11|Phagocytosis
P06807659T0001|14 28|tubercle bacilli
P06807659T0001|31 41|macrophages
P06808287T0001|0 8|Detection
P06808287T0001|11 29|hemophilia A carriers
P06808529A0167|14 31|isoniazid solutions
P06808529A0167|63 65|NTA
P06808529A0167|68 84|EDTA concentration
P06808529A0167|90 95|mmol/l
P06809474A1156|0 12|Bile bilirubin
P06809474A1156|31 31|h
P06809474A1156|37 48|haem infusion
P06809474A1156|70 89|further investigation
P06809586T0000|0 51|Autoimmune manipulation aids juvenile diabetes management
P06810070A0502|0 14|Other properties
P06810070A0502|17 18|Hg
P06810070A0502|23 31|Cd-spores
P06810070A0502|52 64|control spores
P06810694A0328|13 27|HDL-cholesterol
P06810694A0328|42 59|VLDL-triglycerides
P06810694A0328|73 82|much larger
P06810694A0328|90 108|concomitant decrease
P06810694A0328|111 116|apo A-I
P06810694A1000|0 10|Apo A-I level
P06810694A1000|0 5|Apo A-I
P06810694A1000|14 22|unrelated
P06810694A1000|45 62|ethanol consumption
P06810694A1000|79 87|adiposity
P06812389A0658|0 4|TEMTU
P06812389A0658|8 11|DPTU
P06812389A0658|23 38|potent teratogens
P06815368A0203|3 25|osmotic diuretic mannitol
P06815368A0203|45 52|patients
P06816053A0849|5 12|patients
P06816053A0849|17 41|well-defined drug reactions
P06816053A0849|52 55|cent
P06816053A0849|62 77|positive response
P06816053A0849|83 94|mast cell test
P06816123A0526|0 7|Selenium
P06816123A0526|12 22|constituent
P06816123A0526|25 45|glutathione peroxidase
P06816123A0526|62 86|antioxidant defense systems
P06816123A0526|100 118|other metabolic roles
P06816123A0526|122 129|selenium
P06816442T0001|0 14|Diagnostic value
P06816442T0001|17 30|serum myoglobin
P06816442T0001|33 37|cases
P06816442T0001|40 59|neuromuscular disease
P06816609A0639|4 26|% blood pressure reduction
P06816609A0639|28 31|PCO2
P06816609A0639|42 44|kPa
P06816609A0639|86 92|CBF fall
P06816609A0639|97 97|%
P06817410A0982|14 19|months
P06817410A0982|31 44|striking change
P06817410A0982|47 58|epidemiology
P06817410A0982|69 78|hepatitis A
P06817410A0982|106 118|steep increase
P06817410A0982|124 132|incidence
P06817410A0982|145 153|hepatitis
P06817410A0982|159 169|drug addicts
P06818113A0384|0 16|Asthmatic patients
P06818113A0384|23 38|greater responses
P06818113A0384|45 54|parameters
P06818113A0384|57 66|adrenaline
P06818113A0384|71 78|controls
P06818113A0384|93 124|long-term corticosteroid treatment
P06818113A0384|136 149|acute responses
P06818113A0384|152 171|plasminogen activator
P06818113A0384|175 192|clotting factor VIII
P06818113A0384|175 188|clotting factor
P06818113A0384|195 212|adrenaline infusion
P06821147A0468|0 16|Sulphur amino acids
P06821147A0468|22 23|g N
P06821147A0468|29 34|higher
P06821147A0468|40 47|isolates
P06821147A0468|57 62|flours
P06822645T0039|0 3|Time
P06822645T0039|10 37|increase growth hormone release
P06823837A0562|16 41|right ventricular wavefronts
P06823837A0562|56 101|right ventricular anterior atrioventricular groove
P06823837A0562|105 116|outflow tract
P06825641A0076|0 3|Many
P06825641A0076|11 28|landfill operations
P06825641A0076|99 118|prolonged containment
P06825641A0076|138 148|nonexistent
P06826813A0264|0 7|Vesicles
P06826813A0264|30 46|multiple exposures
P06826813A0264|49 51|UVA
P06828396A0095|10 22|contamination
P06828396A0095|55 82|rapid biopsy fixation technique
P06829082A0187|17 31|deep hypothermia
P06829082A0187|35 42|degrees C
P06829082A0187|51 70|considerable increase
P06829082A0187|76 106|brain tissues glutaminase activity
P06829082A0187|119 140|incubation temperatures
P06829082A0187|155 162|degrees C
P06829082A0187|183 186|rats
P06829082A0187|190 193|rats
P06829082A0187|199 209|hypothermia
P06830033A0661|0 18|Similar observations
P06830033A0661|31 52|unilateral pneumothorax
P06830033A0661|57 61|cmH2O
P06830033A0661|67 69|min
P06830351A0397|11 17|Sugiura
P06830351A0397|20 33|classification
P06830351A0397|50 55|Type Ia
P06830351A0397|60 60|%
P06830351A0397|62 67|Type Ib
P06830351A0397|72 72|%
P06830351A0397|74 77|Type
P06830351A0397|84 84|%
P06830351A0397|89 92|Type
P06830351A0397|100 100|%
P06833047A0000|48 68|respiratory inhibition
P06833047A0000|97 118|oscillatory ventilation
P06833047A0000|120 123|HFOV
P06833422T0000|0 12|Determination
P06833422T0000|15 35|20 alpha-hydroxy-9 beta
P06833422T0000|17 35|alpha-hydroxy-9 beta
P06833422T0000|39 52|alpha-pregna-4
P06833422T0000|56 65|dien-3-one
P06833422T0000|68 73|plasma
P06833422T0000|84 96|ion monitoring
P06835516A0000|8 26|dense epidermoid cyst
P06835516A0000|32 49|suprasellar cistern
P06835914A0192|0 15|Copper treatments
P06835914A0192|41 55|different levels
P06835914A0192|58 69|copper intake
P06835914A0192|89 99|differences
P06835914A0192|102 123|daily feed intake similar
P06835914A0192|149 166|commercial industry
P06837312A0000|0 19|Fibromuscular intimal
P06837312A0000|54 66|thoracic aorta
P06837312A0000|72 76|swine
P06837312A0000|86 87|IU
P06837312A0000|90 101|vitamin D3/kg
P06837312A0000|116 129|months duration
P06837312A0000|140 145|months
P06837312A0000|148 166|vitamin D3 withdrawal
P06837312A0000|168 189|atherosclerotic lesions
P06838388A0896|10 25|rapid development
P06838388A0896|31 51|connective tissue scars
P06838388A0896|85 108|glandular parenchyma areas
P06838388A0896|119 131|normalization
P06838388A0896|169 174|42d day
P06840803A0397|0 16|Histological signs
P06840803A0397|22 37|flare-up reaction
P06840803A0397|59 60|hr
P06840803A0397|66 78|i.v. challenge
P06840803A0397|99 102|days
P06842629A0446|0 24|Significant GMBF reductions
P06842629A0446|35 44|early shock
P06842629A0446|51 65|treatment groups
P06848729A0000|5 12|children
P06848729A0000|17 29|neuroblastoma
P06848729A0000|39 41|St.
P06849842T0000|0 30|Penicillin-G degradation products
P06849842T0000|45 58|granulopoiesis
P06851280A0144|0 15|Plasma fibrinogen
P06851280A0144|6 15|fibrinogen
P06851280A0144|32 50|turbidimetric method
P06851280A0144|53 75|timol turbidimetric units
P06851327A0000|4 11|patients
P06851327A0000|23 46|musculoskeletal infection
P06851327A0000|51 79|nongonococcal Neisseria species
P06851327A0000|99 112|13-month period
P06853042A0282|0 25|Distal tubular acidification
P06853042A0282|44 81|proximal tubular bicarbonate reabsorption
P06853042A0282|98 102|urine
P06854957T0066|0 8|Detection
P06854957T0066|11 34|exercise-induced asynergy
P06854957T0066|37 58|M-mode echocardiography
P06856306T0000|3 18|Tullio phenomenon
P06856306T0000|20 30|fistula test
P06856306T0000|35 43|Hennebert
P06856306T0000|51 70|clinical significance
P06856669A1004|5 11|results
P06856669A1004|24 53|significant pulmonary metabolism
P06856669A1004|56 59|5-HT
P06856669A1004|70 75|efflux
P06856669A1004|78 83|5-HIAA
P06856669A1004|88 99|venous output
P06856669A1004|112 133|single-pass circulation
P06858449A0335|0 11|Disturbances
P06858449A0335|14 32|placental maturation
P06858640A0262|12 36|histopathological findings
P06858640A0262|49 55|amyloid
P06858640A0262|87 97|fibroblasts
P06858805A0314|4 9|groups
P06858805A0314|25 29|tests
P06858805A0314|39 54|hypersensitivity
P06858805A0314|59 66|Candidin
P06858805A0314|68 78|Trycophytin
P06858805A0314|82 91|Tuberculin
P06858967A0167|0 24|Serum lactate dehydrogenase
P06858967A0167|28 44|haptoglobin levels
P06858967A0167|28 38|haptoglobin
P06858967A0167|59 72|total bilirubin
P06858967A0167|88 95|elevated
P06863087A0664|0 8|Low-dose D
P06863087A0664|17 18|mg
P06863087A0664|23 24|DB
P06863087A0664|33 34|mg
P06863087A0664|63 71|parameter
P06864837T0000|0 7|Efficacy
P06864837T0000|10 43|cervical spine immobilization methods
P06864955T0000|12 15|MMWR
P06868345A0000|13 23|visna-maedi
P06868345A0000|26 30|Italy
P06868345A0000|47 55|first time
P06869215A0347|0 9|High levels
P06869215A0347|12 13|IC
P06869215A0347|27 52|relative hypocomplementemia
P06869986A0000|11 19|platelets
P06869986A0000|43 64|triple-helical collagen
P06869986A0000|57 64|collagen
P06869986A0000|67 88|atherosclerotic lesions
P06869986A0000|91 111|Mg-deficient ruminants
P06872800T0000|0 8|Acute type
P06872800T0000|10 18|hepatitis
P06872800T0000|26 33|patients
P06872800T0000|38 56|chronic HBV infection
P06873504T0000|0 24|Pathogenetic relationships
P06873504T0000|32 51|renal tubular acidosis
P06873504T0000|55 81|sodium metabolism alterations
P06873504T0000|84 97|liver cirrhosis
P06875478A0542|1 19|microU/l thyrotropin
P06875478A0542|9 19|thyrotropin
P06875478A0542|23 23|%
P06875478A0542|33 33|%
P06875478A0542|45 45|%
P06876006A0930|0 14|Echosismography
P06876006A0930|59 77|classical sonography
P06876006A0930|87 87|%
P06876006A0930|90 94|cases
P06876317T0033|0 12|Relationships
P06876317T0033|28 51|immune deficiency syndrome
P06880563A0516|3 12|prevalence
P06880563A0516|15 18|CPAF
P06880563A0516|56 62|greater
P06880563A0516|65 69|women
P06880563A0516|76 78|men
P06880563A0516|99 105|greater
P06880563A0516|119 133|administrations
P06880563A0516|146 165|single administration
P06880563A0516|168 181|chlorpropamide
P06880604A0167|1 12|reassessment
P06880604A0167|18 31|prevalence data
P06880604A0167|50 65|southern province
P06880604A0167|68 74|Uusimaa
P06880604A0167|83 97|western province
P06880604A0167|100 104|Vaasa
P06880604A0167|109 121|prevalence day
P06880604A0167|127 133|January
P06880650A0316|3 9|results
P06880650A0316|26 37|previous work
P06880650A0316|40 55|other researchers
P06882578A0464|5 23|ultramarathon runner
P06882578A0464|27 44|testosterone levels
P06882578A0464|75 89|training session
P06882578A0464|102 106|ng/ml
P06882578A0464|114 118|ng/ml
P06882578A0464|166 170|hours
P06882578A0464|176 180|ng/ml
P06882578A0464|199 211|hours training
P06882578A0464|217 221|ng/ml
P06883385A0509|2 9|patients
P06883385A0509|24 39|partial remission
P06883385A0509|54 72|neopterine excretion
P06883385A0509|82 93|normal values
P06884450A0234|2 15|visible tumours
P06884450A0234|19 29|best results
P06884450A0234|46 47|FB
P06884450A0234|51 51|%
P06884450A0234|58 60|TBN
P06884450A0234|76 76|%
P06886031A0898|0 13|Total PGE levels
P06886031A0898|16 28|synovial fluid
P06886031A0898|64 75|patient group
P06886031A0898|81 85|hours
P06886031A0898|94 107|400-mg test dose
P06886031A0898|110 117|tolmetin
P06886948A0750|0 10|Normal rates
P06886948A0750|13 22|weight gain
P06886948A0750|43 55|energy intakes
P06886948A0750|70 70|%
P06886948A0750|73 84|requirements
P06890622A0067|3 14|vasodilatory
P06890622A0067|16 31|anti-vasopressor
P06890622A0067|36 43|platelet
P06890622A0067|55 61|effects
P06890622A0067|92 108|placental ischemia
P06890622A0067|110 121|hypertension
P06890622A0067|125 144|excessive coagulation
P06890622A0067|158 170|pre-eclampsia
P06890935T0001|0 5|Behcet
P06891051A0587|0 7|Survival
P06891051A0587|13 46|Indium-labelled autologous platelets
P06891051A0587|60 67|patients
P06891051A0587|73 82|correction
P06891051A0587|85 97|platelet count
P06891270A0000|11 33|emotional-painful stress
P06891270A0000|35 37|EPS
P06891270A0000|41 63|myocardial extensibility
P06891270A0000|67 79|contractility
P06891270A0000|102 110|rat atrium
P06895559A0000|0 10|Terbutaline
P06895559A0000|13 35|beta2-adrenergic agonist
P06895559A0000|40 51|aminophyllin
P06895559A0000|54 79|phosphodiesterase inhibitor
P06895559A0000|119 131|rabbit fetuses
P06895559A0000|137 143|28th day
P06895559A0000|146 154|gestation
P06895663A0810|51 53|RBT
P06895663A0810|57 59|RLF
P06895663A0810|73 95|statistical significance
P06895663A0810|97 98|P =
P06897114A0240|4 17|two-helix motif
P06897114A0240|41 70|specific DNA sequence recognition
P06897114A0240|73 75|CAP
P06902722T0000|3 17|hyperacute phase
P06902722T0000|20 53|posterolateral myocardial infarction
P06911559T0000|0 9|Statistics
P06911559T0000|13 25|nurse managers
P06916588A0304|3 15|infection rate
P06916588A0304|23 34|times greater
P06916588A0304|37 44|patients
P06916588A0304|49 64|Hickman catheters
P06916588A0304|80 95|Broviac catheters
P06916588A0304|97 98|p =
P06919347T0001|25 44|Laboratory Assistants
P06919347T0001|46 51|School
P06919347T0001|54 62|Stockholm
P06919347T0001|64 75|new education
P06919347T0001|79 98|laboratory assistants
P06928974T0000|3 19|electrocardiogram
P06931124A0109|24 39|complex formation
P06931124A0109|43 50|NH4Mg PO4
P06931124A0109|53 55|H2O
P06931124A0109|57 57|n
P06931124A0109|59 73|excess reactants
P06935514A0000|3 9|Authors
P06935514A0000|86 95|cortisonic
P06935514A0000|100 111|desametazone
P06935514A0000|133 143|alterations
P06935514A0000|149 162|dentinogenesis
P06935514A0000|179 191|such component
P06938948T0001|0 11|Secretory IgA
P06938948T0001|15 34|serum immunoglobulins
P06938948T0001|37 43|indices
P06938948T0001|49 61|local immunity
P06938948T0001|67 82|intestinal mucosa
P06938948T0001|85 98|acute leukemias
P06946314T0000|0 13|Serum IgE levels
P06946314T0000|5 7|IgE
P06946314T0000|16 31|Tauranga children
P06946693T0000|0 2|Use
P06946693T0000|5 24|prostaglandin F2 alpha
P06946693T0000|26 34|PGF2 alpha
P06948398A0523|58 72|great importance
P06948493T0026|0 4|Range
P06948493T0026|6 15|variations
P06948493T0026|19 37|neoplastic potential
P06948868A0082|3 8|scores
P06948868A0082|45 62|faculty evaluations
P06950004T0047|0 4|Study
P06950004T0047|31 35|teeth
P06950004T0047|45 57|iontophoresis
P06950004T0047|62 81|transparent specimens
P06953957A0503|7 28|creatine kinase activity
P06953957A0503|7 20|creatine kinase
P06953957A0503|55 64|single peak
P06953957A0503|66 74|myoglobin
P06953957A0503|85 100|multiple episodes
P06953957A0503|127 141|single peak value
P06953957A0503|153 176|clear clinical correlation
P06957125T0000|0 23|Utero-placental blood flow
P06957125T0000|38 71|beta 2-adrenoceptor stimulating drugs
P06957125T0000|38 55|beta 2-adrenoceptor
P06957633T0001|0 10|Development
P06957633T0001|13 30|basophilic leukemia
P06957633T0001|35 41|trisomy
P06957633T0001|46 69|atypical erythroblastosis
P06957633T0001|94 107|aplastic anemia
P06957633T0001|110 114|years
P06959130A0996|3 21|arginyl peptide bonds
P06959130A0996|53 63|human factor
P06959130A0996|74 76|IXa
P06959130A0996|79 87|factor XIa
P06959130A0996|104 116|Arg145-Ala146
P06959130A0996|120 132|Arg180-Val181
P06962492A0612|0 13|Alveolar growth
P06962492A0612|31 44|dental eruption
P06962492A0612|70 87|possible hypotrophy
P06962492A0612|90 107|maxillary bone bases
P06962634A0190|0 18|Fluorometric methods
P06962634A0190|49 69|porphyrin binding sites
P06962634A0190|97 114|porphyrin transport
P06962634A0190|118 126|clearance
P06963337T0000|0 4|Renal
P06963337T0000|8 49|extrarenal arterial fibromuscular hyperplasia
P06963337T0000|54 65|hypertension
P06966678A0523|3 21|monoexponential rate
P06966678A0523|24 32|clearance
P06966678A0523|35 40|tracer
P06966678A0523|70 91|residue-detection curve
P06966678A0523|102 111|metabolism
P06966678A0523|114 122|fatty acid
P06966678A0523|139 151|neutral lipids
P06966678A0523|183 189|changes
P06966678A0523|192 208|tension-time index
P06966678A0523|214 223|injections
P06966678A0523|231 240|left atrium
P06966678A0523|242 243|r =
P06966678A0523|249 250|n =
P06966678A0523|255 265|right atrium
P06966678A0523|267 268|r =
P06966678A0523|274 275|n =
P06966678A0523|283 289|ear vein
P06966678A0523|291 292|r =
P06966678A0523|298 299|n =
P06969638A0180|4 15|examinations
P06969638A0180|19 37|sensitive indicators
P06969638A0180|40 55|CNS abnormalities
P06969638A0180|70 97|bacterial meningeal infections
P06969638A0180|104 124|important determinants
P06969638A0180|140 156|ultimate prognosis
P06969638A0180|159 175|such complications
P06972179A0556|0 16|Specific IgE levels
P06972179A0556|8 10|IgE
P06972179A0556|61 77|pathological range
P06972443A0375|0 24|Similar clinical evaluation
P06972443A0375|29 43|obligate carrier
P06972443A0375|54 72|ocular abnormalities
P06972501A0615|0 10|Correlation
P06972501A0615|18 39|intraocular involvement
P06972501A0615|43 57|systemic outcome
P06973664A0000|7 30|anterior cleavage syndrome
P06973664A0000|34 57|27-year-old female patient
P06975206A0279|3 21|daily administration
P06975206A0279|24 36|betamethasone
P06975206A0279|45 49|weeks
P06975206A0279|68 77|absorption
P06975206A0279|80 86|calcium
P06975206A0279|90 98|phosphate
P06975206A0279|110 119|growth rate
P06977605T0000|0 9|Endorphins
P06977605T0000|13 23|legal issues
P06978566A0197|2 9|necropsy
P06978566A0197|12 31|days post-inoculation
P06978566A0197|33 40|F344 rats
P06978566A0197|46 61|gross lung lesions
P06978566A0197|80 90|maximum dose
P06978566A0197|96 96|X
P06978566A0197|102 120|colony-forming units
P06978566A0197|123 132|M. pulmonis
P06981991A0756|0 13|Aneurysmectomy
P06981991A0756|33 36|CABG
P06981991A0756|71 93|postoperative ECG changes
P06981991A0756|102 113|bypass grafts
P06981991A0756|153 175|postoperative ECG changes
P06981991A0756|191 211|coronary artery disease
P06984225A0367|0 3|REV I
P06984225A0367|8 14|vessels
P06984225A0367|21 21|%
P06984225A0367|35 45|patent graft
P06986168A0304|0 16|Complete sequences
P06986168A0304|40 60|large thrombic peptides
P06986168A0304|88 95|peptides
P06986168A0304|103 112|V8 protease
P06992600A0405|3 24|extraction measurements
P06992600A0405|42 67|extracerebral contamination
P06992600A0405|70 82|venous outflow
P06993660A0000|0 19|Contractile responses
P06993660A0000|22 35|norepinephrine
P06993660A0000|37 45|serotonin
P06993660A0000|49 57|potassium
P06993660A0000|59 59|K
P06993660A0000|65 81|relaxant responses
P06993660A0000|84 96|isoproterenol
P06993660A0000|100 109|papaverine
P06993660A0000|143 162|thoracic aortic strips
P06993660A0000|167 196|aortic coarcted hypertensive rats
P06993660A0000|198 200|AHR
P06993660A0000|213 216|days
P06993660A0000|245 256|time-matched
P06993660A0000|258 290|sham-operated normotensive controls
P06994035T0001|2 16|line calculation
P06994035T0001|19 39|steroid concentrations
P06994035T0001|42 57|radioimmunoassay
P06994049T0001|0 8|Detection
P06994049T0001|11 34|congenital hypothyroidism
P06994049T0001|43 56|newborn infants
P06997203A0325|2 16|rubella patients
P06997203A0325|21 41|serologic confirmation
P06997203A0325|44 45|HI
P06997203A0325|64 79|significant rises
P06997203A0325|90 90|%
P06997203A0325|97 104|patients
P06997203A0325|111 117|PHA test
P06997203A0325|126 143|antibody conversion
P06997203A0325|151 151|%
P06997203A0325|157 164|patients
P07004236A0741|3 9|results
P07004236A0741|22 36|folate compounds
P07004236A0741|45 63|formate accumulation
P07004236A0741|69 76|methanol
P07004236A0741|90 105|formate oxidation
P07004236A0741|108 118|utilization
P07004236A0741|130 140|possible use
P07004236A0741|144 150|folates
P07004236A0741|167 178|certain cases
P07004236A0741|181 202|human methanol poisoning
P07007181T0000|11 25|sodium saccharin
P07007181T0000|37 52|caecal microflora
P07007591A0324|3 18|residue functions
P07007591A0324|20 20|R
P07007591A0324|22 22|t
P07007591A0324|28 34|C-11 CPZ
P07007591A0324|38 55|In-113m transferrin
P07007591A0324|89 93|areas
P07007591A0324|111 136|CPZ area-weighted extraction
P07007591A0324|138 138|E
P07007591A0324|140 140|t
P07007591A0324|160 168|same areas
P07007591A0324|177 180|msec
P07007591A0324|197 197|E
P07007591A0324|199 199|t
P07007591A0324|201 201|=
P07007591A0324|203 204|RT
P07007591A0324|206 206|t
P07007591A0324|209 210|RR
P07007591A0324|212 212|t
P07007591A0324|219 220|RR
P07007591A0324|222 222|t
P07007591A0324|231 232|RT
P07007591A0324|236 237|RR
P07007591A0324|254 269|residue functions
P07007591A0324|273 275|CPZ
P07007591A0324|279 289|transferrin
P07015018A0395|0 18|Synchronous extracts
P07015018A0395|27 56|significant migration inhibition
P07015018A0395|59 74|allogeneic assays
P07015262A0396|3 6|days
P07015262A0396|9 25|cefadroxil therapy
P07015262A0396|42 49|children
P07015262A0396|54 74|urinary tract infection
P07015262A0396|78 93|CRP values greater
P07015262A0396|109 120|microgram/ml
P07015262A0396|122 138|CRP-positive group
P07015262A0396|122 124|CRP
P07016141A0238|11 19|blood flow
P07016141A0238|21 23|RBF
P07016141A0238|28 43|maximal blood flow
P07016141A0238|45 47|NBF
P07016141A0238|62 66|Xenon
P07016141A0238|70 78|clearance
P07018810A0002|0 23|Plasma renin concentration
P07018810A0002|39 44|higher
P07018810A0002|50 73|subcapsular venous outflow
P07018810A0002|89 105|superficial cortex
P07018810A0002|116 132|deep venous outflow
P07018810A0002|148 156|inner half
P07018810A0002|162 167|cortex
P07018810A0002|171 177|medulla
P07018810A0002|183 191|cat kidney
P07021505A0510|5 15|acclimation
P07021505A0510|24 29|supine
P07021505A0510|40 42|DPB
P07021505A0510|53 57|P less
P07021505A0510|74 77|mmHg
P07026328A0369|5 13|diabetics
P07026328A0369|15 17|Ca2
P07026328A0369|19 27|infusions
P07026328A0369|42 50|plasma Ca2
P07026328A0369|65 70|mmol/1
P07026328A0369|92 99|glucagon
P07026328A0369|112 112|%
P07026328A0369|114 118|p less
P07026328A0369|132 138|glucose
P07026328A0369|151 151|%
P07026328A0369|153 157|p less
P07034479A1050|11 13|RMI
P07034479A1050|29 40|placebo group
P07034479A1050|68 74|AC group
P07034479A1050|76 80|p less
P07037479T0000|4 16|cracked-tooth
P07038189A2301|3 18|foregoing results
P07038189A2301|27 29|CXD
P07038189A2301|33 44|high efficacy
P07038189A2301|94 107|pediatric field
P07038684A1050|7 28|peptide map similarities
P07038684A1050|30 62|partial amino-terminal sequence data
P07038684A1050|67 85|common genetic origin
P07038684A1050|104 106|p60
P07038684A1050|110 112|p62
P07038684A1050|117 159|identical amino acid sequences carboxy-terminal
P07038684A1050|165 186|p60 initiator methionine
P07038684A1050|165 167|p60
P07038684A1050|188 194|residue
P07038684A1050|199 201|p62
P07040659A0212|3 10|patients
P07040659A0212|16 27|control group
P07040659A0212|35 56|significant improvement
P07040659A0212|64 67|PEFR
P07040659A0212|78 85|patients
P07040659A0212|91 102|treated group
P07044389T0000|0 4|Facts
P07044389T0000|10 31|Economic Recovery Tax Act
P07044389T0000|41 67|speech-language pathologists
P07044389T0000|71 82|audiologists
P07044562T0000|4 6|Pap
P07044562T0000|9 12|ApUp
P07044842A2062|25 41|rare complications
P07044842A2062|62 76|pathophysiology
P07044842A2062|79 85|Bartter
P07044842A2062|103 109|obscure
P07045156A0204|7 36|opsonophagocytic bacterial assay
P07045156A0204|41 56|suckling rat model
P07045156A0204|59 67|GBS sepsis
P07045156A0204|88 106|human immunoglobulin
P07045156A0204|110 116|opsonic
P07045156A0204|120 137|protective antibody
P07049690T0000|0 16|Glomerular lesions
P07049690T0000|19 33|renal allografts
P07053251A0666|16 35|systemic toxic effects
P07053251A0666|37 46|bone marrow
P07053251A0666|48 68|gastrointestinal tract
P07061263A0293|4 19|vascular pressure
P07061263A0293|21 24|Pvas
P07061263A0293|54 58|cmH2O
P07061263A0293|61 72|air inflation
P07061263A0293|78 80|min
P07061263A0293|82 83|Px
P07061263A0293|85 85|f
P07061263A0293|101 112|less negative
P07061350A0042|7 13|Science
P07061350A0042|49 67|olivocochlear bundle
P07061350A0042|69 72|COCB
P07061350A0042|100 116|distortion product
P07061350A0042|118 122|f2-f1
P07061350A0042|129 150|ear-canal sound pressure
P07062036A0072|0 3|Rats
P07062036A0072|25 28|% JIB
P07062036A0072|32 44|sham operation
P07062269A0798|7 27|l-methadone-sensitive
P07062269A0798|29 42|opioid receptor
P07062269A0798|54 61|naloxone
P07062269A0798|90 100|l-methadone
P07062269A0798|111 127|behavioral effects
P07062269A0798|131 148|nonopioid mechanism
P07063606T0000|0 57|Microwave hyperthermia-induced blood-brain barrier alterations
P07064662A0222|0 4|Large
P07064662A0222|8 28|small medullary lesions
P07064662A0222|41 50|occurrence
P07064662A0222|53 64|target fibres
P07064662A0222|81 87|muscles
P07064662A0222|92 99|smallest
P07064662A0222|108 117|neurolysis
P07064662A0222|123 133|dorsal roots
P07064923T0000|0 8|Diagnosis
P07064923T0000|11 44|phenylalanine hydroxylase deficiency
P07064923T0000|11 34|phenylalanine hydroxylase
P07064923T0000|46 60|phenylketonuria
P07065206A0398|4 15|control sheep
P07065206A0398|20 42|plasma TXB2 concentration
P07065206A0398|60 73|ng/ml prebypass
P07065206A0398|84 88|ng/ml
P07065206A0398|97 99|min
P07065206A0398|102 107|bypass
P07068493A0414|3 17|respiratory rate
P07068493A0414|27 37|breaths/min
P07068493A0414|48 48|%
P07068493A0414|54 69|respiratory cycle
P07068493A0414|89 108|end-tidal CO2 pressure
P07068493A0414|129 132|Torr
P07068493A0414|139 142|runs
P07068493A0414|145 147|SIP
P07068493A0636|10 24|further increase
P07068493A0636|27 43|oxygen consumption
P07068493A0636|53 60|subjects
P07068493A0636|73 92|inspiratory pressures
P07068493A0636|98 100|SIP
P07068496A0000|24 45|pulmonary extravascular
P07068496A0000|47 69|extracellular water space
P07068496A0000|84 100|sucrose indicators
P07068496A0000|115 134|edematous rabbit lungs
P07068496A0000|137 158|steady-state techniques
P07068887A0000|38 51|dimensionality
P07068887A0000|54 59|scores
P07068887A0000|70 95|acute psychiatric inpatients
P07068887A0000|97 98|N =
P07068887A0000|108 138|Michigan Alcoholism Screening Test
P07068887A0000|165 185|current symptomatology
P07072635A0000|1 12|simple method
P07072635A0000|25 35|urinary iron
P07072635A0000|64 78|desferrioxamine
P07072635A0000|80 81|DF
P07073520A0153|6 31|conventional hemofiltration
P07073520A0153|37 53|substitution fluid
P07073520A0153|59 60|Na
P07073520A0153|80 84|mEq/L
P07073520A0153|97 120|extracellular fluid volume
P07073520A0153|139 162|intracellular fluid volume
P07073520A0153|166 174|unaltered
P07075024A0540|3 20|uncomplicated cases
P07075024A0540|23 34|typhoid fever
P07075024A0540|52 61|intact CMIR
P07075024A0540|77 92|complicated cases
P07075438T0000|0 31|Transvenous serial xeroradiography
P07076222A0543|0 14|Recommendations
P07076222A0543|33 45|related issues
P07078263T0000|0 2|Use
P07078263T0000|5 28|subcutaneous deferoxamine
P07078263T0000|41 55|hemochromatosis
P07078263T0000|70 102|congenital dyserythropoietic anemia
P07078263T0000|104 109|type I.
P07079595A0848|9 30|significant correlation
P07079595A0848|38 52|tubular diameter
P07079595A0848|56 58|spg
P07079595A0848|60 61|r =
P07079595A0848|67 71|P less
P07079595A0848|96 122|tubular diameter measurements
P07079595A0848|125 144|histological sections
P07079595A0848|165 179|sperm production
P07080496A0097|3 27|differential investigation
P07080496A0097|30 41|lipoproteins
P07080496A0097|64 86|high-density lipoprotein
P07080496A0097|88 90|HDL
P07080496A0097|92 100|fractions
P07080496A0097|148 170|low-density lipoproteins
P07080496A0097|172 174|LDL
P07080496A0097|178 193|cerebral infarcts
P07080496A0097|199 223|transient ischaemic attacks
P07081327A0546|8 25|noninhibitory fluid
P07081327A0546|29 52|higher mean concentrations
P07081327A0546|55 64|phosphorus
P07081327A0546|68 71|zinc
P07081327A0546|78 88|differences
P07081327A0546|104 126|meconium-stained samples
P07084198T0000|0 13|Selenium status
P07084198T0000|16 28|thoroughbreds
P07084198T0000|34 46|United Kingdom
P07084617A0204|8 20|8-wk follow-up
P07084617A0204|22 30|parasites
P07084617A0204|45 52|patients
P07084617A0204|81 82|wk
P07084814T0000|0 10|Preparation
P07084814T0000|14 38|stable phospholipid reagent
P07084814T0000|42 58|coagulation assays
P07088195T0019|11 22|consequences
P07088195T0019|25 32|UV vision
P07088195T0019|35 39|birds
P07090151A0165|6 12|turnout
P07090151A0165|15 22|morantel
P07090151A0165|32 43|release bolus
P07090151A0165|45 48|MSRB
P07094856A0115|3 19|longitudinal study
P07094856A0115|23 37|low-risk fetuses
P07094856A0115|51 65|2-week intervals
P07094856A0115|72 76|weeks
P07094856A0115|79 87|gestation
P07094905A0644|8 40|intracerebroventricular injections
P07094905A0644|43 44|KA
P07094905A0644|58 72|substantial loss
P07094905A0644|75 88|pyramidal cells
P07094905A0644|94 106|whole CA3 field
P07094905A0644|112 122|hippocampus
P07096587A0267|16 23|patients
P07096587A0267|52 66|training program
P07096587A0267|68 74|lasting
P07096587A0267|115 132|systematic strategy
P07096587A0267|145 165|complex visual material
P07097182A0480|3 10|duration
P07097182A0480|17 25|amplitude
P07097182A0480|31 47|negative potential
P07097182A0480|85 88|ears
P07097182A0480|93 102|overgrowth
P07097182A0480|104 110|smaller
P07097182A0480|135 138|ears
P07097182A0480|143 150|smallest
P07097182A0480|157 175|nonregenerating ears
P07105635A0412|0 6|Samples
P07105635A0412|19 34|normal volunteers
P07105635A0412|45 57|great majority
P07105635A0412|63 70|patients
P07105635A0412|90 95|asthma
P07105635A0412|110 123|ciliary beating
P07106323A0560|5 11|results
P07106323A0560|42 46|fetus
P07106323A0560|78 84|E3-16-G
P07106323A0560|87 100|early pregnancy
P07106534A0160|34 47|growth function
P07106534A0160|53 68|embryofetal curve
P07107287A1083|3 14|highest doses
P07107287A1083|27 33|drivers
P07107287A1083|48 59|large numbers
P07107287A1083|62 75|99Mo generators
P07107462A0202|3 11|steepness
P07107462A0202|27 43|dissociation curve
P07107462A0202|51 57|greater
P07107462A0202|67 80|training period
P07107462A0202|92 95|Hill
P07107462A0202|98 98|n
P07107773A0000|13 40|unconjugated phenylacetic acid
P07107773A0000|44 44|m
P07107773A0000|49 73|p-hydroxyphenylacetic acid
P07107773A0000|97 102|plasma
P07107773A0000|112 126|healthy subjects
P07107773A0000|161 169|ingestion
P07107773A0000|172 180|deuterium
P07107773A0000|189 203|amine precursors
P07107773A0000|207 238|high-resolution gas chromatography
P07107773A0000|241 270|high resolution mass spectrometry
P07107773A0000|283 295|ion monitoring
P07107773A0000|303 348|trifluoroethyl-pentafluoropropionyl derivatives
P07109788A0333|13 20|patients
P07109788A0333|36 52|selective vagotomy
P07109788A0333|56 67|pyloroplasty
P07110999A0160|15 34|behavioural disorders
P07110999A0160|36 47|tetraparesis
P07110999A0160|49 60|incontinence
P07110999A0160|64 82|oculomotor paralysis
P07112320A0086|0 28|CSF adenosine deaminase activity
P07112320A0086|0 20|CSF adenosine deaminase
P07112320A0086|30 32|ADA
P07112320A0086|50 57|same time
P07112471A0639|0 18|Histamine reactivity
P07112471A0639|47 53|workers
P07112471A0639|69 85|original factories
P07112471A0639|125 139|original factory
P07112654A0388|27 47|significant difference
P07112654A0388|58 67|prevalence
P07112654A0388|70 82|nasal carriage
P07112654A0388|103 115|hospital staff
P07112654A0388|122 129|patients
P07113365A0737|0 4|Ficat
P07113365A0737|8 12|Bizou
P07113365A0737|15 32|condylar depth index
P07113365A0737|39 64|condylar-joint surface angle
P07113365A0737|67 76|Brattstrom
P07113365A0737|103 117|suitable methods
P07113897A0285|11 32|significant differences
P07113897A0285|35 36|EF
P07113897A0285|50 56|studies
P07113897A0285|80 80|%
P07113897A0285|94 94|%
P07113897A0285|96 99|p = NS
P07113897A0285|128 128|%
P07113897A0285|142 142|%
P07113897A0285|144 147|p = NS
P07113897A0285|159 180|significant correlation
P07113897A0285|202 207|groups
P07113897A0285|210 215|values
P07113897A0285|217 222|rest r =
P07113897A0285|228 237|exercise r =
P07113897A0285|243 247|p less
P07114083A0153|5 15|MOPP therapy
P07114083A0153|17 33|complete remission
P07114083A0153|36 42|Hodgkin
P07114083A0153|68 80|normalization
P07114083A0153|86 108|glucocerebrosidase level
P07114083A0153|86 103|glucocerebrosidase
P07114083A0153|112 124|disappearance
P07114083A0153|127 133|Gaucher
P07114083A0153|136 140|cells
P07116298A1079|24 38|adjuvant therapy
P07116298A1079|43 68|median disease-free interval
P07116298A1079|84 91|stage IVA
P07116298A1079|97 104|patients
P07116298A1079|114 134|Corynebacterium parvum
P07116298A1079|147 152|months
P07116298A1079|159 166|patients
P07116298A1079|176 178|BCG
P07116298A1079|185 190|months
P07116298A1079|196 201|months
P07116298A1079|208 215|patients
P07116298A1079|225 227|BCG
P07116298A1079|229 232|DTIC
P07116298A1079|246 251|months
P07116298A1079|264 267|DTIC
P07116298A1079|275 282|patients
P07116298A1079|293 298|months
P07116962A0299|3 18|COP-PAWP gradient
P07116962A0299|53 69|non-shock patients
P07116962A0299|74 87|pulmonary edema
P07119890T0000|0 1|Re
P07119890T0000|3 3|A
P07119890T0000|30 37|labeling
P07119890T0000|40 52|red blood cells
P07119890T0000|57 62|Tc-99m
P07124743A1223|1 12|limited study
P07124743A1223|16 31|glassware factory
P07124743A1223|33 45|As2O3 exposure
P07124743A1223|72 91|total airborne arsenic
P07124743A1223|111 124|urinary arsenic
P07124743A1223|151 168|mouth contamination
P07124743A1223|171 177|arsenic
P07124743A1223|195 203|workshift
P07124743A1223|219 242|high urinary arsenic levels
P07124743A1223|247 267|microgram/g creatinine
P07124743A1223|306 315|oral intake
P07124743A1223|332 336|hands
P07124743A1223|354 363|absorption
P07124743A1223|371 375|lungs
P07125064T0000|0 14|Parasitological
P07125064T0000|18 37|pathological findings
P07125064T0000|40 54|capuchin monkeys
P07125064T0000|67 86|Schistosoma japonicum
P07125064T0000|89 106|Schistosoma mansoni
P07125238T0000|3 10|pia mater
P07125238T0000|32 43|blood vessels
P07125238T0000|51 70|central nervous system
P07126067T0000|0 23|Experimental reproduction
P07126067T0000|26 48|malignant catarrhal fever
P07126067T0000|51 60|Bali cattle
P07126413A0000|2 22|colonic delivery system
P07126413A0000|57 61|drugs
P07126413A0000|67 71|colon
P07126413A0000|98 104|coating
P07126413A0000|111 117|acrylic
P07126413A0000|123 127|resin
P07126413A0000|129 137|Eudragit S
P07130335A1081|0 13|Administration
P07130335A1081|19 46|dopamine agonist bromocriptine
P07130335A1081|51 52|mg
P07130335A1081|58 62|times
P07130335A1081|71 74|days
P07130335A1081|87 91|P less
P07130335A1081|105 126|24-h plasma 18-OHB levels
P07130335A1081|153 157|ng/dl
P07132408A0387|30 50|magnesium cardioplegia
P07134924A0640|7 17|common types
P07134924A0640|20 32|malformations
P07134924A0640|37 46|eye defects
P07134924A0640|50 60|open coeloms
P07135112T0000|0 5|Repair
P07135112T0000|9 22|cosmetic defect
P07135112T0000|28 35|lower leg
P07135112T0000|41 60|myocutaneous free flap
P07136524A0180|25 56|second malignant epithelial tumours
P07136524A0180|73 94|mesenchymal tumours such
P07136524A0180|97 108|osteosarcoma
P07136524A0180|120 142|retinoblastoma survivors
P07136569A0000|2 6|Malmo
P07136569A0000|8 13|Sweden
P07136569A0000|21 34|school children
P07136569A0000|44 48|years
P07136569A0000|73 81|scoliosis
P07136569A0000|101 104|ages
P07136569A0000|113 117|years
P07137927A0000|10 19|immunology
P07137927A0000|22 30|Singapore
P07137927A0000|50 57|serology
P07137927A0000|75 99|certain infectious diseases
P07140060T0000|0 25|Intra-articular dislocation
P07140060T0000|31 37|patella
P07140493A1045|21 29|secretion
P07140493A1045|32 42|bicarbonate
P07140493A1045|48 59|human stomach
P07140493A1045|69 82|rate equivalent
P07140493A1045|91 91|%
P07140493A1045|94 111|basal acid secretion
P07141130A0615|0 21|Histological evaluation
P07141130A0615|39 53|twofold increase
P07141130A0615|67 97|interepithelial mononuclear cells
P07141130A0615|99 103|p less
P07141130A0615|131 156|epithelial cells/100 microns
P07141130A0615|159 171|villous mucosa
P07141130A0615|178 187|mean height
P07141130A0615|193 207|epithelial cells
P07141130A0615|228 233|groups
P07143347T0000|0 5|Cramps
P07143347T0000|8 30|extrapyramidal disorders
P07147622T0000|10 26|new storage disease
P07149047A0260|3 19|various dog vessels
P07149047A0260|27 30|Q/Dk
P07149047A0260|49 49|X
P07149047A0260|55 62|Torr/cm2
P07149303T0000|3 19|tetraphasic action
P07149303T0000|22 30|lidocaine
P07149303T0000|33 53|CNS electrical activity
P07149303T0000|67 70|cats
P07154928T0001|0 11|Modification
P07154928T0001|14 30|enteral resorption
P07154928T0001|33 49|cytostatic therapy
P07155579T0001|0 26|Asymptomatic bacteriospermia
P07155579T0001|30 38|fertility
P07158726T0001|0 6|Triumph
P07158726T0001|9 30|Leninist national policy
P07160491A0547|3 18|favourable effect
P07160491A0547|21 26|thymic
P07160491A0547|55 73|significant increase
P07160491A0547|76 82|LD50/30
P07160491A0547|90 108|dose reduction factor
P07162146A0000|16 30|ultrafiltration
P07162146A0000|33 49|sample preparation
P07162146A0000|55 63|detection
P07162146A0000|67 80|quantification
P07162146A0000|83 96|ethylene glycol
P07162146A0000|99 104|plasma
P07162146A0000|107 123|gas chromatography
P07165767T0000|0 11|Mastocytosis
P07168531T0001|1 20|new Onchocerca species
P07168531T0001|23 30|parasite
P07168531T0001|33 46|domestic cattle
P07168531T0001|50 56|Senegal
P07169630A0983|30 50|pronounced differences
P07169630A0983|58 67|conditions
P07172690A0547|19 30|disturbances
P07172690A0547|44 58|energy transport
P07172690A0547|60 76|creatine phosphate
P07172690A0547|78 98|creatine phosphokinase
P07172690A0547|108 118|calcium pump
P07172690A0547|120 130|Ca++-ATPase
P07172690A0547|120 121|Ca
P07172690A0547|125 130|ATPase
P07172690A0547|136 156|sarcoplasmic reticulum
P07172690A0547|158 160|SPR
P07172690A0547|196 214|inotropic properties
P07172690A0547|220 229|myocardium
P07172690A0547|234 245|% restriction
P07172690A0547|248 264|coronary blood flow
P07173729A0000|7 22|penetration tests
P07173729A0000|25 34|human sperm
P07173729A0000|39 51|cervical mucus
P07173729A0000|101 105|sperm
P07173729A0000|109 121|cervical mucus
P07174046T0000|0 14|Vibrio fluvialis
P07174046T0000|16 27|group F vibrio
P07174046T0000|31 41|Maharashtra
P07174122A0000|0 18|Serum creatine kinase
P07174122A0000|20 22|SCK
P07174122A0000|40 47|subjects
P07174122A0000|93 108|bicycle ergometry
P07174122A0000|113 123|lifting task
P07174437A0181|0 8|Organisms
P07174437A0181|30 36|bobcats
P07174437A0181|47 59|other counties
P07175474A0102|42 53|pathological
P07175474A0102|57 77|toxicological findings
P07179412A1131|3 19|average annual cost
P07179412A1131|42 43|US
P07179412A1131|46 46|X
P07180901A0539|18 33|altered blood flow
P07180901A0539|53 102|well-known prostaglandin synthetase inhibitory effects
P07180901A0539|105 113|ibuprofen
P07180901A0539|125 139|tubular necrosis
P07181985A0107|8 37|mg mitomycin/20 ml distilled water
P07181985A0107|42 62|mg/40 ml distilled water
P07181985A0107|89 95|bladder
P07181985A0107|101 108|catheter
P07181985A0107|142 150|25-l20 min
P07182523A0462|4 9|groups
P07182523A0462|31 33|SOA
P07182523A0462|45 57|mouthing times
P07182523A0462|60 75|SOA concentration
P07183576A0157|31 44|flucloxacillin
P07183576A0157|71 83|micrograms/ml
P07183576A0157|85 86|SD
P07183576A0157|94 106|synovial fluid
P07183576A0157|111 122|micrograms/g
P07183576A0157|124 125|SD
P07183576A0157|133 140|synovium
P07183576A0157|145 156|micrograms/g
P07183576A0157|158 159|SD
P07183576A0157|167 180|cancellous bone
P07183576A0157|187 198|micrograms/g
P07183576A0157|200 201|SD
P07183576A0157|209 220|cortical bone
P07184375T0001|1 16|preliminary study
P07184375T0001|19 29|vincristine
P07184375T0001|31 42|methotrexate
P07184375T0001|47 58|prednisolone
P07184375T0001|60 61|VM
P07184375T0001|63 63|P
P07184375T0001|65 87|combination chemotherapy
P07184375T0001|91 114|advanced adult non-Hodgkin
P07184375T0001|117 124|lymphoma
P07184598T0001|0 16|Lacrimal secretion
P07184598T0001|19 33|hyperthyroidism
P07184774T0000|0 13|Re-examination
P07184774T0000|19 27|ED01 study
P07184795A0517|10 23|determinations
P07184795A0517|39 54|serum CPK activity
P07184795A0517|44 46|CPK
P07184795A0517|67 70|I.U.
P07184795A0517|72 76|liter
P07190627T0000|1 12|further study
P07190627T0000|15 41|plasminogen activator release
P07190627T0000|15 34|plasminogen activator
P07190627T0000|44 59|vasoactive agents
P07190627T0000|73 86|perfused dog leg
P07190869A0316|0 3|CDDP
P07190869A0316|15 25|single agent
P07190869A0316|28 38|non-Hodgkin
P07190869A0316|41 48|lymphoma
P07191183A0505|0 8|Treatment
P07191183A0505|11 20|meat muscle
P07191183A0505|24 24|V
P07191183A0505|30 30|s
P07191183A0505|74 85|autoxidation
P07191183A0505|88 93|lipids
P07191804A0000|3 18|hormonal response
P07191804A0000|22 52|standardized bicycle exercise test
P07191804A0000|67 76|male cadets
P07191804A0000|98 98|h
P07191804A0000|101 118|continuous activity
P07191804A0000|132 137|h sleep
P07191972A0391|4 21|ambient temperature
P07191972A0391|26 33|degrees C
P07191972A0391|38 46|responses
P07191972A0391|49 61|spinal cooling
P07191972A0391|81 89|dark phase
P07192369T0000|21 48|cumulative behavioral toxicity
P07192369T0000|54 78|chronic oral administration
P07192369T0000|81 102|l-alpha-acetylmethadol
P07192369T0000|81 87|l-alpha
P07192369T0000|105 114|female rats
P07192722A0682|5 39|successful subtotal parathyroidectomy
P07192722A0682|63 77|serum iPTH levels
P07192722A0682|68 71|iPTH
P07192722A0682|86 87|CL
P07192722A0682|96 99|PMNs
P07192722A0682|121 124|sera
P07192722A0682|133 143|augmented CL
P07192722A0682|146 155|normal PMNs
P07192722A0682|166 166|p
P07194905A0332|0 2|TCZ
P07194905A0332|17 27|inexpensive
P07194905A0332|29 49|noninvasive indication
P07194905A0332|52 65|tissue necrosis
P07194905A0332|67 106|moderate-to-severe intracranial hemorrhage
P07194905A0332|118 132|brain maturation
P07195615A0087|11 23|muricidal rats
P07195615A0087|50 57|duration
P07195615A0087|60 75|Cd administration
P07195615A0087|93 111|greater accumulation
P07195615A0087|114 115|Cd
P07195615A0087|121 133|olfactory bulb
P07195615A0087|143 153|other region
P07195880A0621|28 41|practical means
P07195880A0621|49 55|leprosy
P07202224A0452|3 13|preferences
P07202224A0452|21 35|intact vis-a-vis
P07202224A0452|45 49|males
P07202224A0452|57 66|injections
P07202224A0452|69 70|TP
P07202224A0452|82 90|castrates
P07202224A0452|92 105|attractiveness
P07202224A0452|111 117|females
P07202525A0200|28 33|buzzer
P07202525A0200|41 47|seconds
P07202525A0200|50 67|conditioned stimuli
P07202525A0200|71 83|electric shock
P07202525A0200|91 97|seconds
P07202525A0200|102 122|unconditioned stimulus
P07202919A0142|0 4|Ulcer
P07202919A0142|18 24|angulus
P07202919A0142|42 49|28th week
P07202919A0142|63 71|ulcer scar
P07202919A0142|77 84|42nd week
P07203410T0000|0 11|Family visits
P07203410T0000|39 46|patients
P07203410T0000|50 62|state hospital
P07205120T0000|1 18|transparent overlay
P07205120T0000|31 39|amplitude
P07205120T0000|42 53|ECG wave forms
P07205967T0000|0 14|Adverse reaction
P07205967T0000|30 43|healthy partner
P07205967T0000|79 98|dysfunctional partner
P07208984A0000|0 4|Brain
P07208984A0000|13 48|99mTc-labelled macroaggregated albumin
P07208984A0000|27 48|macroaggregated albumin
P07208984A0000|50 57|MAA brain
P07208984A0000|74 90|tomography studies
P07208984A0000|92 93|CT
P07208984A0000|112 119|patients
P07208984A0000|124 143|intracranial diseases
P07214230T0000|0 9|Inhibition
P07214230T0000|12 33|Fusarium moniliforme var
P07214230T0000|35 46|subglutinans
P07214230T0000|51 61|causal agent
P07214230T0000|68 78|pitch canker
P07214230T0000|85 111|soil bacterium Arthrobacter sp
P07214665A0000|3 22|five-drug combination
P07214665A0000|25 72|fluorouracil imidazole carboxamide dimethyl triazeno
P07214665A0000|74 84|vincristine
P07214665A0000|86 111|bis-chloroethyl nitrosourea
P07214665A0000|116 125|prednisone
P07214665A0000|127 130|FIVB
P07214665A0000|132 132|P
P07214665A0000|147 151|women
P07214665A0000|156 177|metastatic breast cancer
P07217329A0000|24 48|simultaneous determination
P07217329A0000|53 72|alpha-acetylmethadol
P07217329A0000|74 77|LAAM
P07217329A0000|86 102|active metabolites
P07217329A0000|105 121|noracetylmethadol
P07217329A0000|123 141|dinoracetylmethadol
P07217329A0000|143 150|methadol
P07217329A0000|152 162|normethadol
P07217329A0000|167 179|dinormethadol
P07217329A0000|184 192|biofluids
P07217329A0000|195 230|high-performance liquid chromatography
P07217329A0000|237 254|normal-phase column
P07217329A0000|259 268|UV detector
P07217329A0000|274 275|nm
P07217523A0364|0 6|Results
P07217523A0364|12 26|recognition task
P07217523A0364|35 52|significant effects
P07217523A0364|55 70|consonant voicing
P07217523A0364|83 94|vowel context
P07217523A0364|97 115|syllable recognition
P07218008T0000|0 23|Visual response properties
P07218008T0000|26 32|neurons
P07218008T0000|39 61|extrastriate visual areas
P07218008T0000|67 75|owl monkey
P07218008T0000|77 92|Aotus trivirgatus
P07218008T0000|96 117|quantitative comparison
P07218008T0000|120 125|medial
P07218008T0000|127 137|dorsomedial
P07218008T0000|139 150|dorsolateral
P07218008T0000|155 173|middle temporal areas
P07219297T0000|1 15|unified approach
P07219297T0000|21 35|standardization
P07219297T0000|38 46|allergens
P07219821T0028|0 7|Clinical
P07219821T0028|11 34|anatomical considerations
P07221179A0156|1 18|dose-dependent fall
P07221179A0156|21 31|GABA content
P07221179A0156|44 55|GABA decrease
P07221179A0156|68 70|min
P07221179A0156|104 108|nadir
P07221179A0156|113 115|min
P07221179A0156|135 141|minutes
P07221354T0000|0 5|Theory
P07221354T0000|9 20|applications
P07221354T0000|23 33|pulse dosing
P07221354T0000|48 56|symposium
P07225300A0968|5 11|results
P07225300A0968|23 29|neonate
P07225300A0968|75 81|effects
P07225540A0193|13 60|gas chromatographic electron capture detection method
P07225540A0193|80 92|plasma samples
P07225540A0193|115 124|techniques
P07226440T0000|3 14|hemodynamics
P07226440T0000|17 51|isoproterenol-induced cardiac failure
P07228955A0000|0 13|Several authors
P07228955A0000|34 45|interference
P07228955A0000|48 67|theophylline analysis
P07228955A0000|70 81|paraxanthine
P07228955A0000|83 102|1,7-dimethylxanthine
P07228955A0000|107 125|important metabolite
P07228955A0000|128 135|caffeine
P07234308A0121|0 16|Multi drug regimens
P07234308A0121|21 26|C-MOPP
P07234308A0121|28 31|CHOP
P07234308A0121|35 39|BACOP
P07234308A0121|45 62|high remission rates
P07234308A0121|72 76|cases
P07234755A0838|3 11|monocytes
P07234755A0838|28 35|Hematrak
P07234755A0838|46 46|%
P07234974T0000|0 20|Morphological features
P07234974T0000|23 34|Jat dentition
P07235317T0000|0 15|Clinical accuracy
P07235317T0000|37 52|Phadebas RAST test
P07235355A0462|4 18|control subjects
P07235355A0462|23 26|COPD
P07235355A0462|43 54|same sequence
P07235355A0462|57 61|tests
P07235355A0462|80 80|%
P07235355A0462|100 108|flow rates
P07235355A0462|111 127|density dependence
P07236351A0812|9 38|extended recovery hippocampal EEG
P07236351A0812|55 75|extensive cellular loss
P07236351A0812|78 85|areas CA3
P07236351A0812|89 91|CA4
P07237123T0000|18 36|single unit responses
P07237123T0000|39 59|olfactory nerve volleys
P07237123T0000|73 91|turtle olfactory bulb
P07237560A1038|8 16|deletions
P07237560A1038|46 55|mature tRNA
P07237560A1038|61 70|inactivity
P07237560A1038|83 87|genes
P07237560A1038|89 100|substitution
P07237560A1038|106 119|central portion
P07237560A1038|134 147|Hind III linkers
P07237560A1038|156 170|gene units active
P07237560A1038|173 185|transcription
P07237817T0000|0 14|Cross reactivity
P07237817T0000|17 34|theophylline RIA kit
P07240343A0000|0 11|Strontium-90
P07240343A0000|21 24|i.v.
P07240343A0000|29 40|pregnant rats
P07240343A0000|48 61|post conception
P07240343A0000|63 66|p.c.
P07242929T0001|0 8|Recording
P07242929T0001|14 36|digital sphygmic activity
P07242929T0001|42 57|lower extremities
P07242929T0001|65 85|photoplethysmographic
P07242929T0001|89 107|strain-gauge methods
P07243380A0327|5 6|hr
P07243380A0327|9 16|acidosis
P07243380A0327|36 40|P less
P07243380A0327|60 62|P50
P07243380A0327|93 96|torr
P07247059A0775|0 14|Catheter transit
P07247059A0775|34 45|step increase
P07247059A0775|72 72|s
P07247059A0775|83 89|cent-90
P07247059A0775|93 96|cent
P07247059A0775|112 122|transit time
P07247059A0775|133 140|catheter
P07247059A0775|145 162|volatile anesthetic
P07247059A0775|174 174|s
P07247059A0775|183 184|N2
P07249497A0688|5 9|women
P07249497A0688|29 46|current estrogen PPI
P07249497A0688|70 74|women
P07249497A0688|80 84|risks
P07249497A0688|87 106|long-term estrogen use
P07249497A0688|109 111|PPI
P07249497A0688|142 149|patients
P07249497A0688|159 170|short courses
P07249544A0343|3 17|oral temperature
P07249544A0343|28 52|serum creatine kinase levels
P07249544A0343|68 75|patients
P07249660T0000|0 12|Determination
P07249660T0000|15 34|aortic distensibility
P07249660T0000|41 50|variations
P07249660T0000|53 72|arterial hypertension
P07249895A0177|18 31|prostaglandins
P07249895A0177|34 56|acid-induced esophagitis
P07249895A0177|73 86|LES hypotension
P07249895A0177|89 109|simultaneous treatment
P07249895A0177|116 122|animals
P07249895A0177|127 138|indomethacin
P07249895A0177|143 166|micrograms/kg intravenous
P07249895A0177|170 186|specific inhibitor
P07249895A0177|189 210|prostaglandin synthesis
P07249895A0177|236 246|esophagitis
P07251564A0569|11 11|%
P07251564A0569|82 93|ASDC nosology
P07252346A0223|1 17|surgical technique
P07253335T0000|0 6|Effects
P07253335T0000|9 31|prostaglandin inhibitors
P07253335T0000|37 41|onset
P07253335T0000|44 54|proteinuria
P07253335T0000|66 77|stroke-prone
P07253335T0000|91 106|hypertensive rats
P07256543A0814|15 37|general clinical criteria
P07256543A0814|41 56|inhalation injury
P07256543A0814|69 74|facial
P07256543A0814|77 94|oropharyngeal burns
P07256543A0814|96 118|carboxyhemoglobin levels
P07256543A0814|96 112|carboxyhemoglobin
P07256543A0814|120 137|carbonaceous sputum
P07256543A0814|147 157|space injury
P07256543A0814|179 186|patients
P07256543A0814|191 202|airway injury
P07256543A0814|220 236|parenchymal injury
P07259325A0394|0 7|Survival
P07259325A0394|38 42|onset
P07260389A0221|0 11|Methisergide
P07260389A0221|16 20|mg/kg
P07260389A0221|29 35|blocker
P07260389A0221|38 55|serotonin receptors
P07260389A0221|85 105|antinociceptive effect
P07260389A0221|108 116|serotonin
P07260987A0336|3 17|plasma half-life
P07260987A0336|20 47|slow disposition phase t1/2 beta
P07260987A0336|72 78|rabbits
P07260987A0336|83 101|normal renal function
P07260987A0336|108 112|hours
P07260987A0336|115 121|rabbits
P07260987A0336|126 146|severe renal impairment
P07262239T0000|0 6|Effects
P07262239T0000|9 33|early monocular deprivation
P07262239T0000|49 77|cortico-geniculate projections
P07262625A0000|0 20|Corticosteroid therapy
P07262625A0000|32 40|hazardous
P07262625A0000|43 50|patients
P07262625A0000|55 69|occult infection
P07262625A0000|95 118|host parasite relationship
P07262625A0000|130 137|steroids
P07262625A0000|161 187|intestinal protozoal parasite
P07262625A0000|189 200|Giardia muris
P07262625A0000|214 220|effects
P07262625A0000|223 237|corticosteroids
P07262625A0000|251 259|parasites
P07262625A0000|265 273|intestine
P07262625A0000|288 303|primary infection
P07263374T0000|0 17|Static lung function
P07263374T0000|20 26|puppies
P07263374T0000|32 44|pneumonectomy
P07263421A0351|4 7|Sair
P07263421A0351|11 13|So2
P07263421A0351|19 31|vital capacity
P07263421A0351|46 46|%
P07263745T0000|0 28|Bilateral Charnley arthroplasty
P07263745T0000|32 46|single procedure
P07264787A0351|8 15|patients
P07264787A0351|33 49|serologic evidence
P07264787A0351|52 69|chronic thyroiditis
P07264787A0351|95 95|%
P07264787A0351|100 114|hyperthyroidism
P07264787A0351|123 123|%
P07264787A0351|129 139|hypothyroid
P07266969A0246|22 41|estrogenic properties
P07266969A0246|44 52|Tamoxifen
P07266969A0246|56 77|breast cancer management
P07267675A0000|3 36|new semi-synthetic oral cephalosporin
P07267675A0000|38 40|CGP
P07267675A0000|66 76|large number
P07267675A0000|91 98|patients
P07267675A0000|103 119|urinary infections
P07268828A0000|1 17|fluoroimmunoassay
P07268828A0000|39 43|serum
P07268828A0000|46 57|plasma levels
P07268828A0000|60 70|propranolol
P07268828A0000|88 97|antibodies
P07268828A0000|100 110|propranolol
P07268828A0000|120 151|magnetizable solid-phase particles
P07268828A0000|155 184|fluorescein-labeled propranolol
P07268828A0000|187 192|tracer
P07270163A0684|3 34|syncytial microvillous projections
P07270163A0684|68 70|CNF
P07270163A0684|98 115|trophoblastic layer
P07270163A0684|121 125|villi
P07270163A0684|132 137|lining
P07270163A0684|143 165|subtrophoblastic vessels
P07270163A0684|181 183|CNF
P07270163A0684|187 194|controls
P07270991A0149|4 17|pollen allergen
P07270991A0149|27 38|grass species
P07270991A0149|51 66|RAST-test results
P07270991A0149|92 97|values
P07274042A0249|0 2|DMI
P07274042A0249|6 27|2-OH-DMI concentrations
P07274042A0249|45 56|similar group
P07274042A0249|61 79|DMI-treated patients
P07274428A0000|16 26|experiments
P07274428A0000|41 66|hepatotrophic organic anions
P07274428A0000|71 95|radiographic contrast agent
P07274428A0000|97 99|RCA
P07274428A0000|101 109|bilignost
P07274428A0000|116 131|cholecystography
P07274428A0000|135 144|Bengal pink
P07274428A0000|152 159|affinity
P07274428A0000|170 191|urographic RCA triombrin
P07274428A0000|195 205|renotrophic
P07274428A0000|209 222|indigo-carmine
P07274428A0000|230 247|plasmatic membranes
P07274428A0000|254 263|liver cells
P07274482A0000|9 15|neurons
P07274482A0000|21 43|cat medial geniculate body
P07274482A0000|55 65|selectivity
P07274482A0000|73 87|afterdischarges
P07274482A0000|109 116|velocity
P07274482A0000|148 152|deg/s
P07274505A0660|2 9|controls
P07274505A0660|15 31|modest differences
P07276210T0000|0 4|Assay
P07276210T0000|7 32|serum immunoreactive trypsin
P07276210T0000|40 49|blood spots
P07276210T0000|56 69|early detection
P07276210T0000|72 85|cystic fibrosis
P07277222A1391|0 11|Similar waves
P07277222A1391|40 48|motor unit
P07277222A1391|55 74|electronic oscillator
P07277222A1391|95 104|occurrence
P07277222A1391|148 171|active neural interactions
P07278104T0001|0 22|Leukocyte enzyme activity
P07278104T0001|26 59|blood lymphocyte blast transformation
P07278104T0001|62 78|chronic bronchitis
P07278578T0001|0 12|Current status
P07278578T0001|15 26|chemotherapy
P07278578T0001|30 36|Hodgkin
P07280654A0000|16 18|HBE
P07280654A0000|53 67|averaging method
P07282444A0075|10 14|cases
P07282444A0075|31 44|direct approach
P07282444A0075|50 55|tumour
P07282444A0075|65 69|cases
P07282444A0075|90 94|shunt
P07282552A0990|2 7|Group V
P07282552A0990|38 50|subepicardial
P07282552A0990|66 76|lateral zone
P07282552A0990|109 121|subepicardium
P07282552A0990|132 145|subendocardium
P07282943A0097|0 35|Progressive 100-mmHg stepwise decreases
P07282943A0097|38 69|superfusate oxygen partial pressure
P07282943A0097|71 73|PO2
P07282943A0097|89 89|%
P07282943A0097|92 99|aeration
P07282943A0097|101 103|PO2
P07282943A0097|112 115|mmHg
P07282943A0097|133 149|subsequent changes
P07282943A0097|152 166|isometric active
P07283110A0000|3 9|known B1
P07283110A0000|11 20|deficiency
P07283110A0000|28 46|excessive high values
P07283110A0000|51 63|light exercise
P07286057A0159|7 25|AUC infinity analyses
P07286057A0159|30 45|pharmacokinetics
P07286057A0159|48 57|buflomedil
P07286057A0159|71 76|linear
P07286057A0159|111 112|mg
P07286057A0159|116 117|i.
P07286057A0159|120 128|injection
P07286057A0159|140 141|mg
P07286057A0159|145 162|oral administration
P07293100T0001|0 15|Gastrin secretion
P07293100T0001|0 6|Gastrin
P07293100T0001|22 36|food stimulation
P07293100T0001|39 61|digestive system diseases
P07293327T0001|0 22|Fibrinogen determination
P07293327T0001|0 9|Fibrinogen
P07293327T0001|31 40|KZM-1 meter
P07295033A0513|15 18|days
P07295033A0513|21 21|%
P07295033A0513|58 63|faeces
P07295033A0513|70 70|%
P07295033A0513|76 80|urine
P07295417A0092|30 36|regions
P07295417A0092|42 54|left ventricle
P07295417A0092|80 98|new nuclear technique
P07295417A0092|101 112|phase imaging
P07296303A0418|0 8|Responses
P07296303A0418|11 19|brainstem
P07296303A0418|22 43|nuclei medialis dorsalis
P07296303A0418|45 62|lateralis posterior
P07296303A0418|81 93|longer latency
P07296997A0125|8 15|patients
P07296997A0125|20 44|non-visualized gallbladder
P07296997A0125|49 51|OCG
P07296997A0125|67 93|Tc-99m-PyG cholescintigraphy
P07297576A0454|13 39|fresh drinking water ad libitum
P07297576A0454|62 68|Aludrox
P07297576A0454|76 88|drinking water
P07297978A0570|0 13|Anamnestic data
P07297978A0570|30 40|case history
P07297978A0570|42 54|smoking habits
P07297978A0570|69 79|collective A
P07297978A0570|83 84|C.
P07298209A0291|18 44|physical performance capacity
P07298209A0291|55 58|W170
P07298209A0291|63 63|%
P07298209A0291|78 83|VO2 max
P07298209A0291|118 125|work load
P07298209A0291|129 144|bicycle ergometer
P07298259T0000|0 12|Determination
P07298523T0000|0 5|Effect
P07298523T0000|8 19|indomethacin
P07298523T0000|23 42|prostaglandin F2 alpha
P07298523T0000|45 55|parturition
P07298523T0000|58 62|swine
P07299857A0294|0 9|LD50 values
P07299857A0294|19 20|KP
P07299857A0294|27 31|mg/kg
P07299857A0294|34 41|male rats
P07299857A0294|48 52|mg/kg
P07299857A0294|55 64|female rats
P07299857A0294|69 74|KP-CMC
P07299857A0294|110 114|mg/kg
P07299857A0294|126 130|mg/kg
P07299857A0294|143 148|KP-T10
P07299857A0294|164 177|intrarectally.
P07299857A0294|184 204|peroral administration
P07299857A0294|207 212|KP-CMC
P07299857A0294|219 228|LD50 values
P07299857A0294|233 237|mg/kg
P07299857A0294|240 244|males
P07299857A0294|250 254|mg/kg
P07299857A0294|257 263|females
P07299857A0294|273 274|KP
P07304905A0336|0 14|Autotransfusion
P07304905A0336|37 49|Heparin-ACD-B
P07304905A0336|51 61|Heparin-DPD
P07304905A0336|63 79|Heparin-ACD-B etc.
P07306839T0001|0 25|Electron microscopic picture
P07306839T0001|31 44|cerebral cortex
P07306839T0001|47 50|rats
P07306839T0001|61 68|degrees C
P07308849A0817|12 22|differences
P07308849A0817|30 37|short gut
P07308849A0817|41 60|sham operation animals
P07308849A0817|100 112|mucosal weight
P07309562T0000|11 48|thin-layer chromatographic determination
P07309562T0000|51 62|hippuric acid
P07309562T0000|66 84|methylhippuric acids
P07310206A0154|17 32|microvasculature
P07310206A0154|43 49|regions
P07310206A0154|67 92|scanning electron microscopy
P07310206A0154|102 119|resin casting method
P07311881T0000|0 10|MSMS Council
P07311881T0000|16 38|new public health director
P07312707T0000|0 7|Chordoma
P07312707T0000|13 22|spinal cord
P07312707T0000|26 32|F344 rat
P07320153T0000|0 47|Micro high-performance liquid chromatographic system
P07320153T0000|52 65|micro precolumn
P07320153T0000|69 95|dual electrochemical detector
P07320153T0000|99 121|direct injection analysis
P07320153T0000|124 137|catecholamines
P07320153T0000|140 149|body fluids
P07323063A0000|10 20|age-matched
P07323063A0000|32 37|virgin
P07323063A0000|39 60|male Sprague-Dawley rats
P07323063A0000|77 92|hypertensive rats
P07323063A0000|94 97|SHRs
P07323063A0000|128 149|single subcutaneous dose
P07323063A0000|154 174|mg/kg dl-isoproterenol
P07323063A0000|198 207|time course
P07323063A0000|210 235|drug-induced cardiac failure
P07323063A0000|239 256|functional recovery
P07323573A0644|1 10|narrow zone
P07323573A0644|13 37|myelin-axonal dissociation
P07326596A0061|3 15|IgA deficiency
P07326596A0061|3 5|IgA
P07326596A0061|33 35|IgE
P07327097A0647|2 7|PB mice
P07327097A0647|22 33|small deficit
P07327097A0647|50 76|hippocampal pyramidal neurons
P07327097A0647|87 94|controls
P07327097A0647|98 98|%
P07327097A0647|100 104|p less
P07327097A0647|132 143|granule cells
P07328000T0000|0 19|Nutritional cataracts
P07328000T0000|22 33|timber wolves
P07330073T0000|0 9|Prevention
P07330073T0000|12 31|transfusion reactions
P07330073T0000|42 47|saline
P07330073T0000|54 66|red blood cells
P07337609A0531|3 56|geometric mean hemagglutination-inhibition antibody titers
P07337609A0531|58 60|GMT
P07337609A0531|64 76|non-immunized
P07337609A0531|78 91|once-immunized
P07337609A0531|96 118|twice-immunized chickens
P07337609A0531|133 147|2-week intervals
P07337609A0531|157 175|primary immunization
P07337609A0531|177 197|secondary immunization
P07340196T0001|3 27|quantitative determination
P07340196T0001|30 34|HBSAG
P07340196T0001|38 48|valuable aid
P07340196T0001|64 77|infectiousness
P07340196T0001|80 102|hepatitis B virus carriers
P07341346A0174|2 27|numerous narrow shunt vessels
P07341346A0174|56 70|primary arteries
P07341346A0174|78 100|secondary arterial system
P07345217A0000|0 22|Urological complications
P07345217A0000|62 84|gynecological malignancy
P07347728T0000|0 12|Arachnoid cyst
P07349416A0337|16 25|summer coat
P07354367A0162|0 10|Hypotension
P07354367A0162|30 33|tilt
P07355527A0467|23 34|Lich-Gregoir
P07355527A0467|57 62|adults
P07356273T0022|0 13|Mucoepidermoid
P07356273T0022|17 37|acinous cell carcinomas
P07356273T0022|40 54|salivary tissues
P07365183A0000|6 17|patients aged
P07365183A0000|22 26|older
P07365183A0000|45 64|endogenous depression
P07365183A0000|96 103|efficacy
P07365183A0000|121 161|multiple monitored electroconvulsive therapy
P07365183A0000|163 167|MMECT
P07365183A0000|175 204|single electroconvulsive therapy
P07365183A0000|206 209|SECT
P07369183T0000|3 14|new artifacts
P07369183T0000|26 43|coagulation testing
P07369458A0606|58 78|deep muscle temperature
P07369458A0606|91 103|useful adjunct
P07369458A0606|117 131|amputation level
P07372433A0000|0 36|Longitudinal force-length relationships
P07372433A0000|39 53|guinea pig ureter
P07372433A0000|74 80|animals
P07372433A0000|82 86|weeks
P07372433A0000|89 94|months
P07372433A0000|100 104|years
P07372928A0105|0 4|Tests
P07372928A0105|30 44|Mossbauer source
P07372928A0105|61 75|basilar membrane
P07372928A0105|94 122|signal-transmission properties
P07372928A0105|128 134|cochlea
P07372928A0105|163 177|basilar membrane
P07375836T0000|0 18|Angiographic work-up
P07375836T0000|33 53|late vaginal metastasis
P07375836T0000|59 72|renal carcinoma
P07375864A0431|3 9|authors
P07375864A0431|22 35|nonspecificity
P07375864A0431|38 51|low platelet MAO
P07375864A0431|55 71|possible correlate
P07375864A0431|74 97|bipolar affective disorder
P07375864A0431|107 119|schizophrenia
P07375864A0431|141 154|proof necessary
P07375864A0431|161 168|findings
P07375864A0431|171 184|low platelet MAO
P07376165T0001|0 6|Ecthyma
P07376165T0001|9 20|known disease
P07377378A0143|0 18|Estrogen replacement
P07377378A0143|30 43|beta-estradiol
P07377378A0143|46 70|beta-estradiol-3-benzoate
P07377378A0143|74 101|subcutaneous Silastic capsules
P07377378A0143|120 132|elevated rates
P07377378A0143|135 148|heat production
P07377378A0143|152 170|dry heat loss relative
P07377378A0143|173 181|untreated
P07377378A0143|196 203|controls
P07377954A0117|12 18|aspects
P07377954A0117|49 68|cardiovascular system
P07377954A0117|78 101|brachial arterial pressure
P07377954A0117|103 111|pulse rate
P07377954A0117|116 132|oxygen consumption
P07377954A0117|134 136|VO2
P07377954A0117|155 170|health volunteers
P07377954A0117|175 185|emg activity
P07377954A0117|191 206|tibialis anterior
P07377954A0117|210 229|gastrocnemius muscles
P07377954A0117|254 263|volunteers
P07377954A0117|271 302|postexercise ankle pressure changes
P07377954A0117|307 314|subjects
P07377954A0117|341 365|occlusive arterial diseases
P07377954A0117|371 386|lower extremities
P07379334A0503|0 6|Changes
P07379334A0503|9 29|immunologic reactivity
P07379334A0503|32 39|subjects
P07379334A0503|49 62|transfer factor
P07379334A0503|97 104|subjects
P07379334A0503|114 120|placebo
P07380615A0478|57 70|blue collar jobs
P07380615A0478|96 111|myocardial tissue
P07380615A0478|159 172|work efficiency
P07380615A0478|221 237|more sedentary jobs
P07380615A0478|240 257|white collar workers
P07385543T0001|0 9|Importance
P07385543T0001|26 46|blood sulfhydryl groups
P07385543T0001|49 57|fractures
P07385543T0001|63 78|long tubular bones
P07385920A0189|3 9|results
P07385920A0189|27 40|blood lead level
P07385920A0189|64 79|blood haemoglobin
P07385920A0189|69 79|haemoglobin
P07385920A0189|92 107|urinary excretion
P07385920A0189|110 132|delta amino levulinic acid
P07385933A0085|9 19|iv injection
P07385933A0085|25 34|g galactose
P07385933A0085|38 49|kg body weight
P07385933A0085|64 67|mu Ci
P07385933A0085|77 97|14C-labelled galactose
P07385933A0085|99 103|14CO2
P07385933A0085|117 132|regular intervals
P07386500A0174|0 27|Specific clotting factor assays
P07386500A0174|44 53|deficiency
P07386500A0174|56 62|factor X
P07386500A0174|82 85|cent
P07386500A0174|93 106|determinations
P07386864T0000|0 27|Charcoal-facilitated dialysis
P07387242A0236|0 13|Blood variables
P07387242A0236|29 37|intervals
P07387242A0236|88 101|plasma proteins
P07387242A0236|103 116|free hemoglobin
P07387242A0236|107 116|hemoglobin
P07387242A0236|124 131|elements
P07387242A0236|136 152|clotting functions
P07392519T0001|0 13|Retinal changes
P07392519T0001|16 36|pigmentary retinopathy
P07392519T0001|39 46|children
P07393856A0314|10 19|beta-apo-8
P07393856A0314|22 45|carotenoic acid ethyl ester
P07393856A0314|47 52|apo-EE
P07393856A0314|64 80|reference standard
P07393856A0314|83 93|Experiments
P07393976A0000|12 30|sodium phenobarbital
P07393976A0000|34 38|mg/kg
P07393976A0000|43 56|sodium barbital
P07393976A0000|60 64|mg/kg
P07393976A0000|76 88|taste aversion
P07393976A0000|93 99|hr fluid
P07393976A0000|108 111|rats
P07393976A0000|148 170|bottle taste aversion task
P07393976A0000|177 200|% sodium saccharin solution
P07394364A0738|16 45|pulmonary gas exchange parenchyma
P07394364A0738|53 67|smallest mammals
P07394364A0738|119 128|high levels
P07394364A0738|146 163|high metabolic rates
P07394364A0738|176 195|structural adaptation
P07394364A0738|207 215|higher VO2
P07395750A0294|0 15|Underestimations
P07395750A0294|28 28|%
P07395750A0294|45 52|problems
P07395750A0294|66 78|methodologies
P07396545A0217|0 11|Chemotherapy
P07397066T0000|0 13|Drug inhibition
P07397066T0000|16 40|whole blood aspirin esterase
P07401318A0823|10 25|lower temperature
P07401318A0823|29 45|positive staircase
P07401318A0823|66 82|negative staircase
P07401318A0823|96 97|Hz
P07405701T0000|0 5|Visual
P07405701T0000|20 28|responses
P07405701T0000|32 55|platelet monoamine oxidase
P07405701T0000|58 65|patients
P07405701T0000|79 88|alcoholism
P07406527A0212|26 50|urinary porphyrin excretion
P07406527A0212|57 72|porphyrin content
P07406527A0212|75 80|lijver
P07406527A0212|104 124|HCB-CQ-treated animals
P07406527A0212|134 134|%
P07406527A0212|148 158|HCB controls
P07408970A0706|3 7|hours
P07408970A0706|16 33|last administration
P07408970A0706|35 40|uterus
P07408970A0706|43 44|Gf
P07408970A0706|48 53|Cv mice
P07408970A0706|69 71|mg%
P07408970A0706|80 82|mg%
P07408970A0706|137 141|p less
P07410037A0752|8 20|stone-formers
P07410037A0752|45 52|features
P07410037A0752|55 73|magnesium metabolism
P07410037A0752|105 116|control group
P07410037A0752|123 143|lower urinary excretion
P07410037A0752|146 154|magnesium
P07410037A0752|167 173|calcium
P07410037A0752|202 224|stone-forming propensity
P07413144T0018|0 7|Analysis
P07413144T0018|12 28|autopsy population
P07413242A0000|1 21|16-year follow-up study
P07413242A0000|26 36|paraplegics
P07413242A0000|41 55|complete lesions
P07413242A0000|60 64|T1-L3
P07413441T0070|0 27|Autoradiographic localisation
P07413441T0070|33 52|cellular distribution
P07413441T0070|58 63|kidney
P07413781A0169|0 21|Hippocampal stimulation
P07413781A0169|33 62|conditioned stimulus preexposure
P07413781A0169|71 81|attenuation
P07413781A0169|84 99|latent inhibition
P07413781A0169|106 116|stimulation
P07413781A0169|132 143|conditioning
P07413781A0169|149 159|preexposure
P07413806T0000|3 22|centromedial amygdala
P07413806T0000|26 41|gastric pathology
P07413806T0000|44 47|rats
P07414817T0001|0 17|Cataract extraction
P07414817T0001|20 34|primary glaucoma
P07415340A0280|0 5|Number
P07415340A0280|18 33|myelin structures
P07415340A0280|39 52|pneumocytes typ
P07416204A0437|5 16|intact animal
P07416204A0437|18 46|postextrasystolic potentiation
P07416204A0437|60 78|basic pacing interval
P07416204A0437|80 81|t0
P07416204A0437|100 111|extrasystole
P07416204A0437|113 114|t1
P07416204A0437|120 121|t0
P07416204A0437|140 141|t1
P07416204A0437|155 166|potentiation
P07416204A0437|181 182|t1
P07416204A0437|201 202|t0
P07416204A0437|216 227|potentiation
P07418498A0217|16 33|other complications
P07418498A0217|36 50|corticosteroids
P07418498A0217|60 71|full recovery
P07418498A0217|79 93|fungal infection
P07418498A0217|116 128|amphotericin B
P07418498A0217|132 147|surgical excision
P07418498A0217|153 163|lung abscess
P07418829A0191|0 11|Implications
P07418829A0191|32 41|pediatrics
P07419485A0158|34 43|short waves
P07419485A0158|45 59|deep-water waves
P07419485A0158|62 80|closed-form solution
P07419485A0158|83 94|advantageous
P07419485A0158|137 157|further simplification
P07423803T0001|0 8|Treatment
P07423803T0001|11 32|suppurative peritonitis
P07425838A0182|15 30|pheochromocytoma
P07425838A0182|51 64|third trimester
P07426101A0124|7 12|plasma
P07426101A0124|16 45|lipoprotein lipid concentrations
P07426101A0124|47 84|adipose tissue lipoprotein lipase activity
P07426101A0124|47 76|adipose tissue lipoprotein lipase
P07426101A0124|86 103|anthropometric data
P07426101A0124|105 122|alcohol consumption
P07426101A0124|124 136|smoking habits
P07426101A0124|138 153|weekly mileage run
P07426101A0124|171 186|bicycle ergometer
P07426101A0124|216 229|training period
P07426604A0397|3 7|C18:1
P07426604A0397|9 16|C10 value
P07426604A0397|20 36|convenient measure
P07426604A0397|44 50|changes
P07426604A0397|101 115|lower fatty acids
P07426745A0177|1 17|progressive growth
P07426745A0177|20 49|blood erythrocyte membrane injury
P07426745A0177|74 77|rats
P07426745A0177|91 106|gamma-irradiaton
P07426745A0177|124 125|Gy
P07428037A0989|11 18|terminal
P07428037A0989|21 31|nucleotides
P07428037A0989|36 49|mouse mt 12S rRNA
P07428037A0989|70 87|bp hairpin structure
P07428037A0989|104 131|consecutive nucleotides common
P07428037A0989|137 139|RNA
P07428037A0989|145 165|small ribosomal subunit
P07428037A0989|171 177|systems
P07428037A0989|199 213|mRNA binding site
P07428037A0989|215 220|ACCUCC
P07428037A0989|238 257|corn chloroplast rRNAs
P07429009T0121|0 17|Microscopic anatomy
P07429009T0121|21 42|cell population dynamics
P07431059A0000|6 18|cadaver brains
P07431059A0000|36 36|X
P07431059A0000|42 54|magnification
P07431059A0000|73 92|microsurgical anatomy
P07431059A0000|98 109|pineal region
P07431059A0000|143 152|pineal body
P07431059A0000|154 176|posterior cerebral artery
P07431059A0000|178 201|superior cerebellar artery
P07431059A0000|203 206|vein
P07431059A0000|209 213|Galen
P07431059A0000|215 223|basal vein
P07431059A0000|226 234|Rosenthal
P07431059A0000|236 255|internal cerebral vein
P07431059A0000|257 269|straight sinus
P07431059A0000|279 282|vein
P07431059A0000|296 309|tentorial notch
P07431059A0000|328 346|fourth cranial nerves
P07432288A0218|0 17|Serum antibody titre
P07432288A0218|54 67|recurrence rate
P07432288A0218|73 80|duration
P07434431A0203|13 21|refeeding
P07434431A0203|29 46|important mechanism
P07434431A0203|50 59|activation
P07434431A0203|62 83|certain viral infections
P07434431A0203|106 111|famine
P07434456A0286|16 20|units
P07434456A0286|37 49|red blood cells
P07434456A0286|59 66|glycerol
P07434456A0286|97 112|% glycerol content
P07434456A0286|117 128|measurements
P07434456A0286|138 162|post-wash supernatant fluid
P07434456A0286|165 179|refractive index
P07434456A0286|183 191|osmometry
P07435185A0074|3 10|symptoms
P07435185A0074|14 30|objective findings
P07435185A0074|44 60|malignant lymphoma
P07435185A0074|96 106|drill biopsy
P07436187A0147|19 33|previous studies
P07436187A0147|56 71|diagnostic entity
P07436187A0147|81 88|same time
P07436187A0147|99 108|broad range
P07436187A0147|120 138|work-related factors
P07436459A0245|24 68|hydroxykynurenine/hydroxyanthranilic acid ratio
P07436459A0245|95 113|vitamin B6 deficiency
P07436459A0245|130 148|nonspecific response
P07436459A0245|151 170|tryptophan metabolism
P07436702A0156|3 16|control persons
P07436702A0156|21 34|normal reaction
P07436702A0156|37 40|DNFB
P07436794A0148|3 14|control group
P07436794A0148|19 39|common carotid arteries
P07436794A0148|41 43|CCA
P07438346A0381|2 3|pH
P07438346A0381|11 37|same lidocaine concentrations
P07438346A0381|79 79|%
P07438346A0381|82 105|action potential amplitude
P07438346A0381|110 110|%
P07438346A0381|115 118|Vmax
P07438346A0381|125 125|%
P07438482A0145|0 16|Simultaneous right
P07438482A0145|24 30|adrenal
P07438482A0145|34 55|peripheral blood samples
P07438482A0145|87 94|oestrone
P07438482A0145|96 97|E1
P07438482A0145|102 111|oestradiol
P07438482A0145|113 114|E2
P07440085T0061|0 15|Arm function tests
P07440430A1074|3 7|lambs
P07440430A1074|12 20|B breeding
P07440430A1074|37 50|higher Hb levels
P07440430A1074|43 44|Hb
P07440430A1074|81 87|NB lambs
P07440430A1074|89 89|b
P07440430A1074|93 100|S x B lambs
P07440430A1074|104 109|higher
P07440430A1074|111 111|P
P07440430A1074|117 124|Hb levels
P07440430A1074|117 118|Hb
P07440430A1074|132 139|D x B lambs
P07440430A1074|144 149|B lambs
P07440430A1074|156 162|highest
P07440430A1074|164 164|P
P07440430A1074|174 208|corpuscular hemoglobin concentrations
P07440430A1074|185 194|hemoglobin
P07445971A0241|3 14|same response
P07445971A0241|28 37|acrylamide
P07445971A0241|61 73|nerve ligation
P07449221A0086|25 32|excision
P07449221A0086|36 37|mm
P07449221A0086|40 50|central slip
P07449221A0086|61 76|end-to-end repair
P07449221A0086|82 87|tendon
P07449253A0411|5 34|unclipped group arterial pressure
P07449253A0411|46 49|mmHg
P07449253A0411|62 62|h
P07449253A0411|92 99|diuresis
P07449253A0411|104 116|small decrease
P07449253A0411|119 129|blood volume
P07449253A0411|134 134|%
P07450031A0691|0 21|Marked sedative activity
P07450031A0691|37 61|9-methoxy-5-phenylpyrrolo
P07450031A0691|63 67|2,1-d
P07450031A0691|74 89|benzothiazepin-6
P07450031A0691|93 99|dioxide
P07450031A0691|101 104|NF19
P07450031A0691|109 139|9-chloro-5-p-nitrophenylpyrrolo
P07450031A0691|141 145|2,1-d
P07450031A0691|152 167|benzothiazepin-6
P07450031A0691|171 177|dioxide
P07450031A0691|179 182|NF20
P07450388A0406|2 9|patients
P07450388A0406|22 27|CCK-PZ
P07450388A0406|22 24|CCK
P07450388A0406|26 27|PZ
P07450388A0406|46 57|terminal part
P07450388A0406|63 70|bile duct
P07450388A0406|87 100|pressure sensor
P07450388A0406|107 123|duodenofiberscope
P07453919A0000|4 11|patients
P07453919A0000|16 21|Horton
P07453919A0000|24 58|headache morphological investigations
P07453919A0000|60 90|differential white blood cell count
P07453919A0000|93 119|cytoenzymatic determinations
P07453919A0000|121 146|alkaline and acid phosphatase
P07453919A0000|121 128|alkaline
P07453919A0000|132 146|acid phosphatase
P07453919A0000|148 167|non-specific esterase
P07453919A0000|172 193|cytoimmunological tests
P07453919A0000|195 197|IgM
P07453919A0000|201 210|IgG binding
P07453919A0000|228 252|capillary blood neutrophils
P07453919A0000|279 293|non-painful area
P07453919A0000|317 333|contralateral side
P07455042A0457|2 11|high-speed
P07455042A0457|13 29|volumetric imaging
P07455042A0457|39 49|tomographic
P07455042A0457|54 65|machines such
P07455042A0457|71 97|Dynamic Spatial Reconstructor
P07455042A0457|117 139|higher density resolution
P07455042A0457|149 163|single injection
P07455042A0457|166 178|contrast agent
P07455042A0457|186 196|right atrium
P07455042A0457|204 217|peripheral vein
P07455042A0457|247 258|measurements
P07455521A0414|3 6|ESEG
P07455521A0414|13 24|direct result
P07455521A0414|30 38|NEXT study
P07456774A0448|14 30|SLE-inducing drugs
P07457931A0655|1 11|third series
P07457931A0655|14 17|mice
P07457931A0655|28 42|single injection
P07457931A0655|45 51|5-OH-DA
P07457931A0655|78 97|ultrastructural study
P07458171A0086|8 23|different species
P07458171A0086|30 43|Platyhelmintha
P07458171A0086|48 55|Nematoda
P07458171A0086|63 71|Crustacea
P07461226A0958|2 14|symptoms other
P07461226A0958|19 26|hot flush
P07461226A0958|33 58|such significant correlation
P07461226A0958|63 79|plasma epinephrine
P07461226A0958|82 101|norepinephrine levels
P07461848A0230|3 12|mean values
P07461848A0230|18 31|concentrations
P07461848A0230|37 49|components due
P07461848A0230|52 63|tobacco smoke
P07461848A0230|68 70|CO =
P07461848A0230|74 76|ppm
P07461848A0230|78 80|NO =
P07461848A0230|83 85|ppb
P07461848A0230|87 90|NO2 =
P07461848A0230|93 95|ppb
P07461848A0230|97 105|nicotine =
P07461848A0230|109 121|micrograms/m3
P07461848A0230|123 140|particulate matter =
P07461848A0230|144 156|micrograms/m3
P07462481A0422|3 31|average backscatter coefficient
P07462481A0422|38 47|time larger
P07462481A0422|50 56|regions
P07462481A0422|59 65|infarct
P07462481A0422|78 82|weeks
P07462481A0422|88 96|occlusion
P07462481A0422|107 113|regions
P07462481A0422|116 122|infarct
P07462481A0422|134 138|weeks
P07462481A0422|144 152|occlusion
P07463294A1216|3 4|wk
P07463294A1216|13 24|tumor relapse
P07463294A1216|45 54|responders
P07463294A1216|104 113|responders
P07463294A1216|115 119|p less
P07463465A0297|34 45|control women
P07463465A0297|61 73|healthy infant
P07466831A0714|0 16|Pentachlorophenol
P07466831A0714|31 35|onset
P07466831A0714|38 49|HCB porphyria
P07466831A0714|53 62|other words
P07466831A0714|77 106|total urinary porphyrin excretion
P07466831A0714|118 135|earlier disturbance
P07466831A0714|141 156|porphyrin pattern
P07467975A0316|0 13|Family planning
P07467975A0316|30 38|minor role
P07467975A0316|54 57|cent
P07467975A0316|63 70|patients
P07467975A0316|85 102|oral contraceptives
P07467975A0316|106 112|shorter
P07467975A0316|115 127|longer periods
P07467975A0316|139 149|percentages
P07467975A0316|152 161|primiparae
P07467975A0316|165 176|secundiparae
P07467975A0316|182 187|births
P07467975A0316|199 212|high percentage
P07467975A0316|215 228|multigravidity
P07467975A0316|232 241|parameters
P07467975A0316|262 273|reproduction
P07467975A0316|298 314|behaviour patterns
P07467975A0316|317 322|Europe
P07469692A0000|3 23|term osteomesopycnosis
P07469692A0000|48 58|bone disease
P07469692A0000|63 81|dominant inheritance
P07469692A0000|109 115|members
P07469692A0000|122 138|different families
P07471210A0384|3 12|87K protein
P07471210A0384|26 33|proteins
P07471210A0384|52 58|daltons
P07471210A0384|77 84|leftward
P07471210A0384|97 104|1-strand
P07471210A0384|106 118|messenger RNAs
P07471210A0384|126 138|complementary
P07471210A0384|144 154|viral genome
P07471210A0384|162 170|positions
P07472582A0993|19 34|viable myocardium
P07472582A0993|43 59|99mTc-tetrofosmin
P07472582A0993|63 67|201Tl
P07472582A0993|91 103|similar degree
P07472582A0993|109 116|severity
P07472582A0993|144 163|nonreversible defects
P07472736A0278|3 19|temporal component
P07472736A0278|27 41|mandibular fossa
P07472736A0278|50 66|articular eminence
P07473169A0133|0 4|EUK-8
P07473169A0133|14 22|synthetic
P07473169A0133|24 65|low-molecular-weight salen-manganese complex
P07473169A0133|82 100|superoxide dismutase
P07473169A0133|104 121|catalase activities
P07473169A0133|104 111|catalase
P07473742A0187|3 14|protein ELT-1
P07473742A0187|26 50|single-copy gene homologous
P07473742A0187|56 65|GATA family
P07473742A0187|68 97|vertebrate transcription factors
P07474078A0838|37 63|cell-free integration studies
P07474078A0838|65 74|alteration
P07474078A0838|95 108|CA dinucleotide
P07474078A0838|120 125|mutant
P07474078A0838|146 146|%
P07474078A0838|149 176|wild-type integration activity
P07474085A0932|12 19|R protein
P07474085A0932|34 39|codons
P07474085A0932|55 68|frameshift site
P07474085A0932|74 81|V protein
P07474085A0932|86 90|codon
P07474124A1360|5 11|results
P07474124A1360|35 37|PI2
P07474124A1360|41 50|PI3 viruses
P07474124A1360|62 88|same parainfluenza virus genus
P07474124A1360|95 101|viruses
P07474124A1360|106 122|marked differences
P07474124A1360|136 157|functional requirements
P07474124A1360|164 178|cytoplasmic tail
P07474124A1360|184 196|F glycoprotein
P07474140A1036|2 25|site-specific mutagenesis
P07474140A1036|41 82|individual ICP27 C-terminal amino acid residues
P07474140A1036|51 56|ICP27 C
P07474140A1036|113 125|ICP27 homologs
P07474140A1036|128 145|other herpesviruses
P07474140A1036|147 151|D-357
P07474140A1036|153 157|E-358
P07474140A1036|159 163|H-479
P07474140A1036|165 169|C-400
P07474140A1036|171 175|C-483
P07474140A1036|180 184|C-488
P07474140A1036|200 223|trans-regulatory activity
P07474451A0000|0 23|Magnetic resonance imaging
P07474451A0000|25 27|MRI
P07474451A0000|49 77|spinal intramedullary pathology
P07474451A0000|80 90|differences
P07474451A0000|93 107|signal intensity
P07474617A1035|0 7|Patients
P07474617A1035|12 28|psychotropic drugs
P07474617A1035|48 62|higher PRL levels
P07474617A1035|54 56|PRL
P07474772A0274|3 29|Laser Scanning Ophthalmoscope
P07474772A0274|38 60|fundus-based examination
P07474772A0274|79 93|exact comparison
P07474772A0274|101 121|morphologic appearance
P07474772A0274|125 145|corresponding function
P07475733T0000|0 6|Malaria
P07475733T0000|8 14|anaemia
P07475733T0000|19 35|HIV-1 transmission
P07475733T0000|38 50|central Africa
P07475793T0000|0 2|BSE
P07475793T0000|6 16|farmworkers
P07476164A1602|11 56|two-dimensional nuclear magnetic resonance studies
P07476164A1602|61 64|F17A
P07476164A1602|66 69|K13Q
P07476164A1602|71 74|F15Y
P07476164A1602|78 81|F27Y
P07476164A1602|97 103|mutants
P07476164A1602|111 130|same overall structure
P07476164A1602|136 155|wild-type CspB protein
P07476701A0654|12 21|high levels
P07476701A0654|24 36|IgE antibodies
P07476701A0654|60 71|other pollens
P07476701A0654|82 99|such correspondence
P07476963A0000|0 40|Peroxisome proliferator-activated receptors
P07476963A0000|42 46|PPARs
P07476963A0000|51 68|retinoid X receptors
P07476963A0000|70 73|RXRs
P07476963A0000|78 100|nuclear hormone receptors
P07476963A0000|119 128|fatty acids
P07476963A0000|132 149|9-cis-retinoic acid
P07476971A0381|18 27|intriguing
P07476971A0381|35 49|SKUT-1B-20 cells
P07476971A0381|57 80|transcription factor Pit-1
P07476971A0381|76 80|Pit-1
P07476975A0492|11 21|lactotropes
P07476975A0492|23 34|somatotropes
P07476975A0492|36 46|thyrotropes
P07476975A0492|51 62|gonadotropes
P07476975A0492|88 95|controls
P07476975A0492|116 129|adult pituitary
P07476975A0492|131 142|POMC products
P07476975A0492|184 192|cell types
P07477245A0625|4 10|strains
P07477245A0625|13 25|A. parasiticus
P07477245A0625|41 58|aflatoxins B1 B2 G1 G2
P07477245A0625|68 76|other ones
P07477245A0625|85 88|AF B1
P07477245A0625|90 91|G1
P07477245A0625|101 114|concentrations
P07477245A0625|117 126|aflatoxins
P07477245A0625|139 143|mg/kg
P07478514A0237|19 44|larger rat B-myc genomic clone
P07478523A0551|24 45|terminal amino acid forms
P07478523A0551|83 100|terminal amino acids
P07478523A0551|119 140|novel RET protein isoform
P07478525A1177|4 10|classes
P07478525A1177|13 25|MHBst proteins
P07478525A1177|41 46|dimers
P07478525A1177|79 90|dimerization
P07479004A0421|2 35|electrophoretic mobility shift assays
P07479004A0421|40 43|PERE
P07479004A0421|55 68|major complexes
P07479004A0421|70 71|P1
P07479004A0421|73 74|P2
P07479004A0421|78 79|P3
P07479004A0421|85 92|proteins
P07479004A0421|95 109|nuclear extracts
P07479004A0421|114 117|HeLa
P07479004A0421|123 127|cells
P07482069A0606|19 21|MTX
P07482069A0606|25 31|mg/week
P07482069A0606|38 43|months
P07482069A0606|56 73|vasculitis symptoms
P07483276A0139|0 7|Analysis
P07483276A0139|35 51|open reading frames
P07483276A0139|53 56|ORFs
P07483276A0139|76 78|UL1
P07483276A0139|80 82|UL2
P07483276A0139|84 86|UL3
P07483276A0139|91 93|UL3
P07483276A0139|108 115|homology
P07483276A0139|120 127|proteins
P07483276A0139|130 149|herpes simplex virus-1
P07483276A0139|151 155|HSV-1
P07483276A0139|158 174|pseudorabies virus
P07483276A0139|176 178|PRV
P07483276A0139|181 199|equine herpesvirus-1
P07483276A0139|204 224|varicella-zoster virus
P07483285A0322|5 19|HPV16 E6/E7 cDNAs
P07483285A0322|10 11|E6
P07483285A0322|38 58|SV40 enhancer/promoter
P07483285A0322|65 71|MMTV LTR
P07483285A0322|84 93|activities
P07483285A0322|96 126|ras-collaborative transformation
P07483285A0322|96 98|ras
P07483285A0322|130 138|induction
P07483285A0322|141 160|cellular DNA synthesis
P07483285A0322|184 196|E7 gene product
P07483857A0350|0 22|Correlation coefficients
P07483857A0350|33 48|reference methods
P07483857A0350|52 54|NIT
P07483857A0350|62 62|=
P07483857A0350|80 91|crude protein
P07483857A0350|95 134|connective-tissue-protein frei meat protein
P07483857A0350|142 142|=
P07483857A0350|150 174|connective-tissue-protein
P07487067A0592|3 21|translation products
P07487067A0592|28 33|clones
P07487067A0592|43 52|homologous
P07487067A0592|55 58|APS1
P07487067A0592|67 75|% identity
P07487067A0592|99 111|entire lengths
P07487067A0592|122 143|amino terminal sequences
P07487067A0592|154 168|transit peptides
P07487067A0592|172 190|plastid localization
P07487363A0447|3 13|serum levels
P07487363A0447|16 18|IgE
P07487363A0447|23 27|asIgE
P07487363A0447|31 35|IgG-4
P07487363A0447|31 33|IgG
P07487363A0447|45 63|common food allergens
P07487811A0000|3 13|experiments
P07487811A0000|30 36|effects
P07487811A0000|39 59|short-term spaceflight
P07487811A0000|62 83|cancellous bone turnover
P07487811A0000|99 130|Physiological Systems Experiment-1
P07487811A0000|132 136|PSE-1
P07487811A0000|140 160|4-d orbital spaceflight
P07487811A0000|165 169|PSE-2
P07487811A0000|172 181|10-d flight
P07487908A0230|31 43|transcription
P07487908A0230|49 91|promotorless chloramphenicol acetyltranferase
P07487908A0230|61 91|chloramphenicol acetyltranferase
P07487908A0230|93 95|CAT
P07487908A0230|103 107|cells
P07487908A0230|110 125|pancreatic origin
P07487908A0230|127 132|AR-42J
P07487908A0230|142 146|cells
P07487908A0230|149 168|non-pancreatic origin
P07487908A0230|170 173|Rat 2
P07487908A0230|170 172|Rat
P07487908A0230|177 180|IEC 6
P07487908A0230|177 179|IEC
P07488247T0000|0 17|Functional analysis
P07488247T0000|20 73|aryl hydrocarbon receptor nuclear translocator interactions
P07488247T0000|20 61|aryl hydrocarbon receptor nuclear translocator
P07488247T0000|78 100|aryl hydrocarbon receptor
P07488247T0000|106 126|yeast two-hybrid system
P07488291A0934|0 26|Histopathologic observations
P07488291A0934|41 52|somatostatin
P07488291A0934|56 77|triamcinolone acetonide
P07488291A0934|88 104|inflammatory signs
P07488291A0934|110 124|joint structures
P07488291A0934|134 155|triamcinolone acetonide
P07488959T0000|13 32|biomathematical model
P07488959T0000|35 51|lymphocytopoiesis
P07489502A0000|3 26|influenza virus NS1 protein
P07489502A0000|17 26|NS1 protein
P07489502A0000|30 63|unique posttranscriptional regulator
P07489502A0000|74 83|activities
P07489502A0000|85 94|inhibition
P07489502A0000|100 112|nuclear export
P07489502A0000|115 135|poly A-containing mRNAs
P07489502A0000|139 148|inhibition
P07489502A0000|151 166|pre-mRNA splicing
P07490079A0825|11 17|regions
P07490079A0825|34 40|synteny
P07490079A0825|51 65|further evidence
P07490079A0825|73 81|human STEP
P07490079A0825|85 95|true homolog
P07490079A0825|101 114|murine STEP gene
P07490079T0000|0 15|Molecular cloning
P07490079T0000|21 32|human homolog
P07490079T0000|36 63|striatum-enriched phosphatase
P07490079T0000|65 68|STEP
P07490079T0000|77 94|chromosomal mapping
P07490079T0000|108 117|murine loci
P07490083A0000|0 17|Carbonic anhydrase V
P07490083A0000|19 21|CA V
P07490083A0000|36 54|mitochondrial matrix
P07490083A0000|65 83|several other tissues
P07490156A0647|0 8|Vitamin D3
P07490156A0647|13 29|nicotine treatment
P07490156A0647|38 54|parallel increases
P07490156A0647|57 67|cardiac mass
P07490156A0647|71 84|elastic modulus
P07490156A0647|91 112|significant correlation
P07490278A0799|3 14|latter domain
P07490278A0799|45 49|Num1p
P07490278A0799|55 70|mother cell cortex
P07490742A0636|43 61|dsRNA binding domains
P07490742A0636|80 107|separate functional subdomains
P07490766T0000|0 52|Preferential heterodimeric parallel coiled-coil formation
P07490766T0000|55 66|synthetic Max
P07490766T0000|64 66|Max
P07490766T0000|70 88|c-Myc leucine zippers
P07490766T0000|104 147|putative electrostatic interactions responsible
P07490766T0000|154 164|specificity
P07490766T0000|167 184|heterodimerization
P07490770A0267|0 9|Comparison
P07490770A0267|12 25|other coxI genes
P07490770A0267|17 25|coxI genes
P07490770A0267|35 45|966-bp group
P07490770A0267|47 52|intron
P07490770A0267|67 74|homology
P07490770A0267|82 106|related yeast coxI intron aI4
P07490770A0267|89 106|yeast coxI intron aI4
P07490770A0267|127 168|279-amino-acid site-specific DNA endonuclease
P07491111A0221|12 13|GR
P07491111A0221|16 26|DMS-79 cells
P07491111A0221|39 76|human ACTH-secreting small cell lung cancer
P07491111A0221|44 47|ACTH
P07491305A0102|27 38|localization
P07491305A0102|43 58|accessory pathway
P07491305A0102|85 92|polarity
P07491305A0102|98 107|QRS complex
P07491305A0102|114 124|sinus rhythm
P07491305A0102|130 139|surface ECG
P07491305A0102|153 169|delta wave polarity
P07491305A0102|178 188|many reports
P07491791A0263|3 18|promoter mutation
P07491791A0263|35 39|trans
P07491791A0263|42 52|E1A products
P07491791A0263|42 44|E1A
P07491791A0263|58 89|heterologous helper adenovirus type
P07491791A0263|92 94|Ad5
P07493327A0507|16 29|trans-splicing
P07493327A0507|53 54|U2
P07493327A0507|56 57|U4
P07493327A0507|62 69|U6 snRNAs
P07493627A0882|0 8|Treatment
P07493627A0882|11 14|PCC4
P07493627A0882|16 25|aza1R cells
P07493627A0882|32 51|RAR-selective agonist
P07493627A0882|32 34|RAR
P07493627A0882|80 87|EC-1 mRNA
P07493627A0882|80 83|EC-1
P07493627A0882|108 127|RXR-selective agonist
P07493627A0882|108 110|RXR
P07493627A0882|135 148|EC-1 expression
P07493627A0882|135 138|EC-1
P07494244A0335|14 19|E1A243
P07494244A0335|21 23|YY1
P07494244A0335|33 58|CRE-dependent transcription
P07494244A0335|61 65|c-fos
P07494244A0335|93 108|ATF/CREB proteins
P07494244A0335|93 95|ATF
P07494244A0335|122 124|CRE
P07494274A1015|0 20|Shift-down experiments
P07494274A1015|51 63|fold reduction
P07494274A1015|66 75|virus yield
P07494274A1015|81 104|nonpermissive temperature
P07494274A1015|116 126|disfunction
P07494274A1015|129 136|alpha TIF
P07494274A1015|165 180|virion maturation
P07494293A0585|5 11|results
P07494293A0585|38 47|early stage
P07494293A0585|53 83|T-cell signal transduction cascade
P07494293A0585|101 103|Lck
P07494293A0585|121 142|Lck-mediated activation
P07494303A0000|0 33|Human immunodeficiency virus type 1 Vpr
P07494303A0000|0 29|Human immunodeficiency virus type
P07494303A0000|31 33|Vpr
P07494303A0000|37 53|virion-associated
P07494303A0000|55 71|regulatory protein
P07494303A0000|89 113|efficient viral replication
P07494303A0000|116 136|monocytes/macrophages
P07494306A0240|28 66|VP16 protein-protein interactions specific
P07494306A0240|28 46|VP16 protein-protein
P07494306A0240|69 87|virus-infected cells
P07494306A0240|99 102|VP16
P07494306A0240|122 137|enriched fraction
P07494306A0240|143 164|single major polypeptide
P07494306A0240|185 218|virus-encoded structural protein VP22
P07494314A1287|5 29|transcriptional regulation
P07494314A1287|31 38|splicing
P07494314A1287|40 61|kinase interaction sites
P07494314A1287|66 88|tyrosine phosphorylation
P07494314A1287|94 106|LMP2A homologs
P07494314A1287|131 163|significant sequences heterogeneity
P07494314A1287|169 192|preterminal repeat regions
P07494314A1287|208 226|nonhuman primate EBVs
P07495059T0078|0 6|Results
P07495059T0078|12 39|ECAT Angina Pectoris Study Group
P07495120A0260|11 26|prospective Phase
P07495120A0260|69 76|efficacy
P07495120A0260|79 89|cryosurgery
P07495120A0260|99 114|radiation therapy
P07495120A0260|117 119|men
P07495120A0260|124 138|local recurrence
P07495726A1189|5 10|motifs
P07495726A1189|19 26|Chi motif
P07495726A1189|31 45|Chi-like element
P07495726A1189|66 91|recombination hotspot region
P07495726A1189|97 115|Bcl-2 proto-oncogene
P07495726A1189|126 147|chromosomal breakpoints
P07495726A1189|150 159|T-ALL lines
P07496184T0001|0 12|Common history
P07496184T0001|16 24|prospects
P07496184T0001|27 44|surgical gynecology
P07496184T0001|50 56|Charite
P07496184T0001|63 84|Vienna University Clinic
P07496400A0525|35 43|HMGR1 mRNA
P07496400A0525|45 54|HMGR1S mRNA
P07496400A0525|74 83|high levels
P07496400A0525|89 95|tissues
P07496400A0525|107 116|HMGR1L mRNA
P07496400A0525|138 146|low levels
P07496400A0525|165 174|restricted
P07496400A0525|183 191|seedlings
P07496400A0525|193 197|roots
P07496400A0525|201 214|inflorescences
P07498727A0724|24 27|rev3
P07498727A0724|46 48|G.C
P07498727A0724|52 67|T.A transversions
P07498727A0724|73 84|rad18 mutator
P07498727A0724|107 119|substitutions
P07498727A0724|140 155|rad6-mediated G.C
P07498727A0724|140 143|rad6
P07498727A0724|159 173|T.A transversion
P07498791A0680|3 23|second mutation present
P07498791A0680|29 42|original mutant
P07498791A0680|55 60|allele
P07498791A0680|64 72|known gene
P07498791A0680|74 77|PBS2
P07498791A0680|92 112|putative protein kinase
P07498791A0680|100 112|protein kinase
P07498791A0680|131 157|high osmolarity stress pathway
P07499242A0898|2 13|adult tissues
P07499242A0898|24 33|restricted
P07499242A0898|49 63|RAFTK expression
P07499242A0898|49 53|RAFTK
P07499252A0150|2 16|hGM-CSF receptor
P07499252A0150|18 21|hGMR
P07499252A0150|38 54|consensus sequence
P07499252A0150|58 64|binding
P07499252A0150|67 76|PI 3-kinase
P07499252A0150|78 81|hGMR
P07499252A0150|90 106|distinct mechanism
P07499252A0150|131 140|activation
P07499252A0150|143 152|PI 3-kinase
P07499394A0187|0 1|J.
P07499401A0444|18 24|hnRNPs H
P07499401A0444|28 28|H
P07499401A0444|34 34|%
P07499401A0444|43 43|H
P07499401A0444|47 47|F
P07499401A0444|50 50|%
P07499401A0444|62 62|H
P07499401A0444|67 67|F
P07499401A0444|70 70|%
P07499409A0367|0 3|TPBF
P07499409A0367|10 36|potential coiled-coil regions
P07499409A0367|39 49|basic region
P07499409A0367|52 69|proline-rich region
P07499409A0367|72 94|histidine-rich N terminus
P07499409A0367|100 123|nuclear targeting sequence
P07499421A0237|5 16|present study
P07499421A0237|42 56|primary cultures
P07499421A0237|59 80|rat hepatocytes plasmids
P07499421A0237|93 118|CYP3A1 5'-flanking sequences
P07499421A0237|93 98|CYP3A1
P07499421A0237|102 118|flanking sequences
P07499421A0237|127 173|chloramphenicol acetyltransferase reporter plasmid
P07499421A0237|127 158|chloramphenicol acetyltransferase
P07499848A0409|10 20|stimulation
P07499848A0409|30 42|splenic B cells
P07499848A0409|47 70|CD40L-expressing Sf9 cells
P07499848A0409|47 51|CD40L
P07499848A0409|78 92|germ-line gamma 1
P07499848A0409|78 91|germ-line gamma
P07499848A0409|96 113|epsilon transcripts
P07499848A0409|129 137|cytokines
P07500386A0870|12 32|GapIII protein activity
P07500386A0870|12 24|GapIII protein
P07500386A0870|34 43|constructs
P07500386A0870|54 79|different GapIII-GRD domains
P07500386A0870|63 68|GapIII
P07500386A0870|70 72|GRD
P07500386A0870|99 113|iral mutant yeast
P07500386A0870|130 144|relative ability
P07500386A0870|154 157|IRA1
P07500597A0212|16 25|latest BPVs
P07500597A0212|45 48|days
P07500597A0212|55 59|years
P07500597A0212|71 72|SD
P07500597A0212|76 80|years
P07500950A0000|1 16|tobacco homologue
P07500950A0000|18 22|trolC
P07500950A0000|29 36|rolC gene
P07500950A0000|42 74|Agrobacterium rhizogenes Ri-plasmid
P07500950A0000|100 119|Nicotiana tabacum L. cv
P07500953A0305|0 17|High ADR1 gene dosage
P07500953A0305|30 42|transcription
P07500953A0305|45 49|genes
P07500953A0305|58 76|peroxisomal proteins
P07500953A0305|101 108|ADR1 gene
P07501016T0000|1 22|water-vapour giga-maser
P07501016T0000|28 51|active galaxy TXFS2226-184
P07501458A0578|15 35|C/EBP family inhibitors
P07501458A0578|15 25|C/EBP family
P07501458A0578|37 42|Ig/EBP
P07501458A0578|44 46|LIP
P07501458A0578|50 56|CHOP-10
P07501458A0578|62 67|Ig/EBP
P07501700A0000|3 9|effects
P07501700A0000|17 42|24-hour pretreatment regimen
P07501700A0000|47 66|monophosphoryl lipid A
P07501700A0000|68 70|MLA
P07501700A0000|74 90|micrograms/kg i.v.
P07501700A0000|94 111|myocardial stunning
P07501700A0000|122 149|repetitive coronary occlusions
P07501700A0000|163 187|barbital-anesthetized dogs
P07501992A0125|5 12|incisors
P07501992A0125|26 88|scanning electron microscopy-energy dispersive spectroscopy analysis
P07501992A0125|90 96|SEM-EDS
P07501992A0125|101 115|light microscopy
P07501992A0125|128 147|calciotraumatic lines
P07501992A0125|150 158|strontium
P07501992A0125|164 185|rat incisor labial dentin
P07504171A0715|1 36|platelet-derived growth factor receptor
P07504171A0715|38 43|PDGF-R
P07504171A0715|45 58|phosphopeptide
P07504171A0715|69 75|Tyr-857
P07504171A0715|103 114|Src SH2 domain
P07504171A0715|136 152|PDGF-R binding site
P07504171A0715|156 158|Src
P07504171A1214|16 28|Src SH2 mutants
P07504171A1214|37 53|binding properties
P07504171A1214|75 81|results
P07504171A1214|94 123|recent crystal structure solution
P07504171A1214|130 141|Src SH2 domain
P07504712A0843|5 16|observations
P07504712A0843|21 39|actin plaque assembly
P07504712A0843|21 25|actin
P07504712A0843|51 71|cell substrate adhesion
P07505349A0702|3 16|early lethality
P07505349A0702|22 39|left-sided resectio
P07505349A0702|44 44|%
P07505349A0702|51 71|postoperative survival
P07505349A0702|78 83|months
P07505798A0000|11 26|immunogenic sites
P07505798A0000|32 55|type A influenza A/Japan/57
P07505798A0000|57 60|H2N2
P07505798A0000|62 74|hemagglutinin
P07505798A0000|76 77|HA
P07505798A0000|100 135|class I major histocompatibility complex
P07505798A0000|106 135|major histocompatibility complex
P07505798A0000|137 139|MHC
P07505798A0000|142 178|H-2Kd-restricted cytolytic T lymphocytes
P07505798A0000|142 146|H-2Kd
P07505798A0000|180 183|CTLs
P07506253A0742|4 11|enhancer
P07506253A0742|28 30|K19
P07506253A0742|34 49|TK basal promoters
P07506253A0742|52 60|HeLa cells
P07507187T0000|0 8|Mechanism
P07507187T0000|11 21|enhancement
P07507187T0000|24 46|DNA expression consequent
P07507187T0000|49 65|cointernalization
P07507187T0000|69 99|replication-deficient adenovirus
P07507187T0000|103 122|unmodified plasmid DNA
P07507207A0991|17 30|IRF binding site
P07507207A0991|48 60|IRF-2 promoter
P07507207A0991|80 88|IRF-2 gene
P07507207A0991|106 114|transient
P07507207A0991|118 138|stable IRF-1 expression
P07507207A0991|124 128|IRF-1
P07507458A0250|25 45|coagulopathic patients
P07507458A0250|72 81|prevalence
P07507458A0250|84 98|hepatitis C virus
P07507458A0250|100 102|HCV
P07507458A0250|104 113|antibodies
P07507458A0250|122 126|ELISA
P07507458A0250|130 140|RIBA methods
P07508082A0821|3 17|highest decrease
P07508082A0821|20 36|mutagenic activity
P07508082A0821|52 69|enzymatic bleaching
P07508082A0821|89 96|chlorine
P07508140A0448|0 23|Hepatitis B surface antigen
P07508140A0448|38 45|patients
P07508140A0448|51 81|negative hepatitis C virus antibody
P07508250A0537|19 40|significant correlation
P07508250A0537|48 66|total selenium intake
P07508250A0537|70 95|liver selenium concentration
P07508250A0537|97 98|r =
P07508250A0537|104 104|p
P07508250A0537|117 118|mo
P07508250A0537|138 154|time liver selenium
P07508441A0487|0 26|Antibodies affinity-purified
P07508441A0487|55 72|recombinant protein
P07508441A0487|86 99|56K autoantigen
P07508441A0487|103 117|HeLa cell extract
P07508441A0487|119 132|cDNA sequencing
P07508441A0487|148 160|56K cDNA shares
P07508441A0487|148 154|56K cDNA
P07508441A0487|162 171|high degree
P07508441A0487|174 181|homology
P07508441A0487|188 197|nucleotide
P07508441A0487|201 201|%
P07508441A0487|206 222|amino acid sequence
P07508441A0487|228 228|%
P07508441A0487|234 248|bovine annexin XI
P07508441A0487|267 273|56K cDNA
P07508441A0487|284 308|human homologue of annexin XI
P07508441A0487|284 297|human homologue
P07508441A0487|300 308|annexin XI
P07508441A0487|322 323|Ca
P07508441A0487|329 369|dependent phospholipid binding protein family
P07508954A0000|3 32|avidin-biotin complex peroxidase
P07508954A0000|3 8|avidin
P07508954A0000|10 32|biotin complex peroxidase
P07508954A0000|34 38|ABC-P
P07508954A0000|61 78|Mycobacterium bovis
P07508954A0000|86 92|results
P07508954A0000|127 139|Ziehl-Neelsen
P07508954A0000|141 142|ZN
P07509053A0139|14 22|processes
P07509053A0139|48 52|c-Myb
P07509053A0139|58 71|important early
P07509053A0139|95 114|hematopoietic lineage
P07509449A0000|24 44|avian sarcoma virus CT10
P07509449A0000|53 65|fusion protein
P07509449A0000|67 76|p47gag-crk
P07509449A0000|67 72|p47gag
P07509449A0000|74 76|crk
P07509449A0000|79 83|v-Crk
P07509449A0000|95 111|viral Gag sequences
P07509449A0000|119 135|cellular sequences
P07509449A0000|157 174|Src homology regions
P07509449A0000|181 183|SH2
P07509449A0000|187 198|SH3 sequences
P07509450A0705|4 29|specific methylation pattern
P07509450A0705|36 47|inactivation
P07509450A0705|53 61|HSV tk gene
P07509450A0705|68 78|methylation
P07509450A0705|84 99|cytosine residues
P07509450A0705|109 126|nucleotide sequence
P07509450A0705|155 171|HSV tk gene activity
P07509450A0705|155 163|HSV tk gene
P07509472A1320|0 9|CONCLUSION
P07509472A1320|15 28|study documents
P07509472A1320|33 42|regression
P07509472A1320|45 71|choroidal neovascularization
P07509472A1320|88 111|alpha interferon treatment
P07509472A1320|88 102|alpha interferon
P07509624T0000|0 16|Long-range mapping
P07509624T0000|22 32|11q23 region
P07509624T0000|43 63|chromosome aberrations
P07509624T0000|66 76|human tumors
P07509624T0000|79 108|pulsed-field gel electrophoresis
P07509624T0000|114 138|yeast artificial chromosome
P07509811A1357|0 3|GTRE
P07509811A1357|5 7|TRE
P07509811A1357|12 30|CRE oligonucleotides
P07509811A1357|59 72|protein binding
P07509811A1357|87 95|congeners
P07509811A1357|103 116|protein binding
P07509811A1357|130 157|other labeled oligonucleotides
P07509811A1357|176 179|GTRE
P07509811A1357|181 183|TRE
P07509811A1357|188 206|CRE oligonucleotides
P07509811A1357|225 228|GTRE
P07509811A1357|230 232|TRE
P07509811A1357|237 255|CRE oligonucleotides
P07509811A1357|278 291|common proteins
P07509811A1357|303 309|members
P07509811A1357|315 321|Jun/Fos
P07509811A1357|325 354|cAMP-responsive element-binding
P07509811A1357|373 392|transcription factors
P07509811A1357|394 401|CREB/ATF
P07509811A1357|394 397|CREB
P07509811A1357|399 401|ATF
P07509811A1357|403 410|families
P07509811A1357|413 432|transcription factors
P07509811A1357|436 450|chromaffin cells
P07510461A0731|20 36|test abnormalities
P07510635A0479|3 10|antibody
P07510635A0479|12 17|mAb1C2
P07510635A0479|23 38|synthetic peptide
P07510635A0479|52 58|epitope
P07510635A0479|86 98|transcription
P07510635A0479|103 117|TATA-containing
P07510635A0479|129 146|TATA-less promoters
P07510635A0479|190 194|Pol II
P07510635A0479|190 192|Pol
P07510635A0479|197 202|Pol III
P07510635A0479|197 199|Pol
P07510724A1208|3 12|lymph nodes
P07510724A1208|25 32|patients
P07510724A1208|37 55|rheumatoid arthritis
P07510724A1208|65 79|numerous sarcoid
P07510724A1208|84 94|granulomata
P07510724A1208|96 102|further
P07510724A1208|114 132|possible association
P07510724A1208|140 150|sarcoidosis
P07510724A1208|154 172|rheumatoid arthritis
P07511444A0728|0 11|HCV infection
P07511444A0728|33 35|BMT
P07511444A0728|46 64|mild acute hepatitis C
P07511444A0728|83 99|chronic hepatitis C
P07511444A0728|123 127|years
P07511444A0728|133 135|BMT
P07511444T0000|0 23|Hepatitis C virus infection
P07511444T0000|27 36|risk factor
P07511444T0000|40 51|liver failure
P07511444T0000|56 76|veno-occlusive disease
P07511444T0000|82 106|bone marrow transplantation
P07511496A1511|0 23|High plasma concentrations
P07511496A1511|26 42|soluble E-selectin
P07511496A1511|33 42|E-selectin
P07511496A1511|68 92|multiple-organ dysfunction
P07511818A0485|5 44|human IFN-beta-transformed cell populations
P07511818A0485|10 17|IFN-beta
P07511818A0485|62 83|constitutive production
P07511818A0485|86 93|human IFN
P07511818A0485|114 124|rate similar
P07511818A0485|133 150|untransformed cells
P07511818A0485|156 160|cells
P07511818A0485|179 191|control vector
P07511818A0485|201 221|human IFN-beta sequence
P07511818A0485|232 239|inactive
P07512159A0992|0 10|Improvement
P07512159A0992|16 34|polypyrimidine tract
P07512159A0992|51 68|splicing efficiency
P07512159A0992|117 135|branchpoint mutation
P07512258A0441|0 19|Liver transplantation
P07512258A0441|40 61|metabolic complications
P07512258A0441|78 85|PMN count
P07512258A0441|91 106|infectious status
P07512258A0441|113 123|neutropenia
P07512258A0441|138 142|G-CSF
P07512552A0270|0 3|Joys
P07512552A0270|7 8|F.
P07513703T0000|0 9|Activation
P07513703T0000|15 54|SH2-containing protein tyrosine phosphatase
P07513703T0000|56 62|SH-PTP2
P07513703T0000|66 99|phosphotyrosine-containing peptides
P07513703T0000|111 136|insulin receptor substrate-1
P07514295A0000|0 22|Tyrosine phosphorylation
P07514295A0000|25 40|cellular proteins
P07514295A0000|46 70|earliest identifiable event
P07514295A0000|80 100|T-cell antigen receptor
P07514295A0000|102 104|TCR
P07514295A0000|106 116|stimulation
P07514295A0000|144 171|downstream signaling machinery
P07514301A0000|3 46|interferon-induced RNA-dependent protein kinase
P07514301A0000|3 12|interferon
P07514301A0000|21 46|RNA-dependent protein kinase
P07514301A0000|48 50|PKR
P07514301A0000|72 84|important role
P07514301A0000|90 104|cellular defense
P07514301A0000|112 125|viral infection
P07514301A0000|162 180|tumor suppressor gene
P07514301A0000|193 220|growth-suppressive properties
P07516337A1119|9 11|Lck
P07516337A1119|50 55|p95Vav
P07516337A1119|63 75|stoichiometry
P07516337A1119|78 84|binding
P07516337A1119|96 122|anti-CD3-treated Jurkat cells
P07516337A1119|96 103|anti-CD3
P07516466A1054|11 19|injection
P07516466A1054|23 29|plasmid
P07516466A1054|38 63|simian virus 40 small t antigen
P07516466A1054|38 48|simian virus
P07516466A1054|51 63|small t antigen
P07516466A1054|83 86|PP2A
P07516466A1054|114 144|several phosphoprotein substrates
P07516466A1054|162 181|phosphorylation state
P07516466A1054|184 187|CREB
P07516466A1054|202 224|unstimulated NIH 3T3 cells
P07516469A1025|0 28|Several Src SH3-binding proteins
P07516469A1025|7 28|Src SH3-binding proteins
P07516469A1025|49 68|Src-transformed cells
P07516597A1017|25 45|proteolytic processing
P07516597A1017|51 84|MVE nonstructural polyprotein segment
P07516597A1017|98 115|viral proteinase NS3
P07516597A1017|118 134|antigen processing
P07516597A1017|155 189|MVE H-2Kk-restricted T cell determinant
P07516866A0000|1 22|full-length PRL receptor
P07516866A0000|24 27|PRLR
P07516866A0000|29 44|complementary DNA
P07516866A0000|49 55|pigeons
P07516866A0000|78 99|pigeon crop sac libraries
P07516866A0000|105 124|reverse transcription
P07516866A0000|136 158|polymerase chain reaction
P07517544A0515|6 9|days
P07517544A0515|12 32|spontaneous regression
P07517544A0515|38 59|morphologic alterations
P07517544A0515|68 101|caerulein-induced acute pancreatitis
P07517544A0515|130 146|secretory function
P07517544A0515|152 159|pancreas
P07517544A0515|199 203|L-364
P07517544A0515|242 250|mg/kg/day
P07517869A0411|14 30|dephosphorylation
P07517869A0411|50 67|DNA-binding ability
P07517869A0411|70 80|C/EBP-delta
P07517869A0411|102 119|potential increases
P07517869A0411|135 163|cellular phosphatase inhibitors
P07517869A0411|135 153|cellular phosphatase
P07517869A0411|171 181|okadaic acid
P07517869A0411|185 203|sodium orthovanadate
P07518257A0351|3 11|promoters
P07518257A0351|28 44|S1 nuclease mapping
P07518257A0351|28 37|S1 nuclease
P07518257A0351|46 47|P1
P07518257A0351|65 66|bp
P07518257A0351|82 95|structural gene
P07518257A0351|100 101|P2
P07518257A0351|119 120|bp
P07518426A0000|0 12|Interleukin-8
P07518426A0000|14 17|IL-8
P07518426A0000|22 47|potent inflammatory mediator
P07518426A0000|72 86|C-X-C chemokines
P07518460A0771|5 13|other hand
P07518460A0771|15 19|cells
P07518460A0771|31 35|PTP1C
P07518460A0771|46 58|catalytic site
P07518460A0771|84 94|mutagenesis
P07518460A0771|119 129|phosphatase
P07518561A0496|22 48|p72syk protein tyrosine kinase
P07518561A0496|78 91|TCR/CD3 complex
P07518561A0496|78 80|TCR
P07518561A0496|104 125|tyrosine phosphorylated
P07518561A0496|140 157|receptor triggering
P07518561A0496|164 169|T cells
P07518561A0496|177 182|p56lck
P07518578A0000|24 39|Rous sarcoma virus
P07518578A0000|41 49|pp60v-src
P07518578A0000|57 77|normal cellular homolog
P07518578A0000|79 87|pp60c-src
P07518578A0000|104 121|oncogenic potential
P07518578A0000|136 158|subcellular localization
P07518578A0000|162 187|cytoskeletal binding ability
P07518578A0000|189 197|pp60v-src
P07518578A0000|232 268|detergent-insoluble cytoskeletal matrix
P07518578A0000|277 285|pp60c-src
P07519447T0000|0 11|Organization
P07519447T0000|17 26|bovine gene
P07519447T0000|38 67|endothelial nitric oxide synthase
P07519463A0000|19 50|regional myocardial work efficiency
P07519463A0000|52 71|segment work/regional
P07519463A0000|103 128|surgically-augmented inflow
P07519481A1275|2 9|female Sl
P07519481A1275|16 17|Sl
P07519481A1275|19 21|pan
P07519481A1275|23 26|mice
P07519481A1275|28 53|ovarian follicle development
P07519481A1275|72 91|layered cuboidal stage
P07519481A1275|110 121|KL expression
P07519481A1275|110 111|KL
P07519481A1275|124 136|follicle cells
P07519481A1275|156 160|c-kit
P07519481A1275|163 174|oocyte growth
P07519606A1269|0 12|Anti-NPROSP-C
P07519606A1269|36 60|time-dependent appearances
P07519606A1269|63 82|5-10-kDa proSP-C forms
P07519606A1269|85 98|lamellar bodies
P07519606A1269|102 112|homogenates
P07520098A0211|5 39|B6-derived Db mutant B6.CH-2bm13 (bm13)
P07520098A0211|5 33|B6-derived Db mutant B6.CH-2bm13
P07520098A0211|35 38|bm13
P07520098A0211|56 70|class I Db antigen
P07520098A0211|62 87|Db antigen-presenting groove
P07520098A0211|99 122|class I Kb-encoded sequence
P07520098A0211|105 122|Kb-encoded sequence
P07521009A0377|5 11|mutants
P07521009A0377|13 16|pms1
P07521009A0377|18 21|pms2
P07521009A0377|25 28|pms3
P07521009A0377|49 56|MW104-1B
P07521009A0377|93 100|plasmids
P07521009A0377|112 124|DNA mismatches
P07521009A0377|126 128|G/T
P07521009A0377|130 132|A/C
P07521009A0377|134 136|G/G
P07521009A0377|136 136|G
P07521009A0377|138 141|etc.
P07521009A0377|150 155|Kramer
P07521009A0377|162 166|1989a
P07521285A1109|3 10|findings
P07521285A1109|21 33|high frequency
P07521285A1109|36 55|proximal nerve lesions
P07521285A1109|58 65|early GBS
P07521285A1109|69 72|CIDP
P07521285A1109|104 137|distal motor conduction abnormalities
P07521285A1109|165 187|multiple F wave parameters
P07521285A1109|191 216|particular chronodispersion
P07521285A1109|222 228|latency
P07521285A1109|236 244|amplitude
P07521285A1109|268 281|minimum latency
P07521285A1109|303 314|F wave studies
P07521601A0000|0 25|Hematopoietic growth factors
P07521601A0000|63 74|myelopoiesis
P07521601A0000|84 104|high-dose chemotherapy
P07521601A0000|107 120|cancer patients
P07521916T0000|0 6|Effects
P07521916T0000|9 19|alterations
P07521916T0000|22 48|primer-binding site sequences
P07521916T0000|51 80|human immunodeficiency virus type
P07521916T0000|82 92|replication
P07522163T0000|0 11|Presentation
P07522163T0000|15 37|horse cytochrome c peptide
P07522163T0000|40 56|multiple H-2b class
P07522163T0000|48 87|H-2b class I major histocompatibility complex
P07522163T0000|58 87|major histocompatibility complex
P07522163T0000|89 91|MHC
P07522163T0000|93 101|molecules
P07522163T0000|104 110|C57BL/6
P07522163T0000|115 146|bm1-derived cytotoxic T lymphocytes
P07522163T0000|159 180|single MHC anchor residue
P07522163T0000|190 228|efficient peptide-specific CTL recognition
P07523363A0440|13 43|striking HpaII tiny fragment island
P07523363A0440|21 25|HpaII
P07523363A0440|69 77|base pairs
P07523363A0440|91 119|USF2 translation initiation site
P07523710T0000|0 8|Diagnosis
P07523710T0000|11 28|prostatic carcinoma
P07523710T0000|40 67|serum prostate specific antigen
P07523710T0000|69 92|digital rectal examination
P07523710T0000|96 121|transrectal ultrasonography
P07524265T0000|9 43|granulocyte-colony stimulating factor
P07524265T0000|45 49|G-CSF
P07524265T0000|51 56|levels
P07524265T0000|59 66|neonates
P07524265T0000|71 92|perinatal complications
P07525548A1380|3 9|results
P07525548A1380|19 27|hierarchy
P07525548A1380|30 45|ligand affinities
P07525548A1380|63 78|adhesive activity
P07525548A1380|80 87|rsVCAM-1
P07525548A1380|89 107|fibronectin variants
P07525548A1380|118 120|CS1
P07525548A1380|123 146|other fibronectin variants
P07525548A1380|128 146|fibronectin variants
P07525596A0584|50 64|full-length Fpr3
P07525596A0584|79 97|COOH-terminal domain
P07525596A0584|112 135|detectable PPIase activity
P07525596A0584|122 127|PPIase
P07525843A0859|0 8|Dilutions
P07525843A0859|11 14|H-2b
P07525843A0859|17 30|H-2d NP peptides
P07525843A0859|47 50|logs
P07525843A0859|55 67|H-2b NP peptide
P07525843A0859|90 109|syngeneic target cells
P07525843A0859|113 129|CTL-specific lysis
P07525843A0859|157 166|affinities
P07525843A0859|169 172|H-2b
P07525843A0859|176 218|H-2d major histocompatibility complex molecules
P07525843A0859|227 247|peptides likely account
P07525843A0859|254 265|total removal
P07525843A0859|268 272|NP CTL
P07525843A0859|278 285|H-2b mice
P07525843A0859|278 281|H-2b
P07525843A0859|293 306|partial removal
P07525843A0859|309 316|H-2d mice
P07525843A0859|330 337|thymic NP
P07526609A0736|20 24|sigma
P07526609A0736|30 31|S4
P07526609A0736|35 40|UTR/S1
P07526609A0736|39 40|S1
P07526609A0736|59 78|PKR activator sequence
P07526609A0736|83 84|S1
P07526609A0736|97 99|UTR
P07526609A0736|102 103|S4
P07526609A0736|128 138|wild-type S4
P07527168A0524|0 11|Microvessels
P07527168A0524|26 34|x200 field
P07527168A0524|41 43|mm2
P07527168A0524|56 74|maximal angiogenesis
P07528028A1192|23 31|cell lines
P07528028A1192|39 63|FGF-1 cell surface receptors
P07528028A1192|86 92|studies
P07528028A1192|97 118|wild-type transfectants
P07528028A1192|122 131|refractory
P07528028A1192|134 147|exogenous FGF-1
P07528028A1192|143 147|FGF-1
P07528028A1192|159 177|mutant transfectants
P07528028A1192|195 202|ABSTRACT
P07528028A1192|217 221|WORDS
P07528325A0165|0 12|Recent studies
P07528325A0165|45 54|GH receptor
P07528325A0165|67 71|Stat1
P07528325A0165|74 103|cytoplasmic transcription factor
P07528325A0165|115 136|tyrosine phosphorylated
P07528325A0165|157 163|nucleus
P07528325A0165|187 206|specific DNA sequences
P07528325A0165|217 230|gene expression
P07528531A0904|2 16|viral infections
P07528531A0904|18 22|G-CSF
P07528531A0904|40 55|mononuclear cells
P07528531A0904|57 59|rs =
P07528531A0904|65 65|P
P07528531A0904|73 92|white blood cell counts
P07528531A0904|94 96|rs =
P07528531A0904|102 102|P
P07528531A0904|110 120|neutrophils
P07528531A0904|122 124|rs =
P07528531A0904|130 130|P
P07528531A0904|140 142|CRP
P07528531A0904|144 146|rs =
P07528531A0904|152 152|P
P07528667A0834|0 19|Minor initiation sites
P07528667A0834|31 39|positions
P07528746A1049|0 23|Phosphoamino acid analysis
P07528746A1049|38 50|ASGPR subunits
P07528746A1049|61 63|Ser
P07528746A1049|65 65|P
P07528746A1049|72 82|predominant
P07528746A1049|99 99|%
P07528746A1049|104 106|Thr
P07528746A1049|108 108|P
P07528746A1049|133 133|%
P07528746A1049|135 150|phosphoamino acid
P07528746A1049|157 167|polypeptide
P07528746A1049|193 195|Tyr
P07528746A1049|197 197|P
P07528746A1049|214 214|%
P07528746A1049|218 221|RHL1
P07528772A0616|18 39|structural requirements
P07528772A0616|43 59|ZAP-70 interaction
P07528772A0616|43 48|ZAP-70
P07528772A0616|67 69|TCR
P07528772A0616|83 94|binding assay
P07528772A0616|111 148|glutathione S-transferase fusion proteins
P07528772A0616|162 164|NH2
P07528772A0616|172 194|COOH-terminal SH2 domains
P07528772A0616|197 202|ZAP-70
P07528772A0616|207 230|soluble synthetic peptides
P07528772A0616|251 267|cytoplasmic region
P07528772A0616|273 284|TCR zeta chain
P07528772A0616|286 295|TCR zeta cyt
P07528772A0616|299 315|individual TCR zeta
P07528772A0616|309 315|TCR zeta
P07528772A0616|319 337|CD3 epsilon TAM motifs
P07528772A1539|13 45|tyrosine phosphorylated TAM peptides
P07528772A1539|35 45|TAM peptides
P07528772A1539|87 102|tandem SH2 domains
P07528772A1539|105 110|ZAP-70
P07529124A0119|3 28|three-dimensional structure
P07529124A0119|31 32|RT
P07529124A0119|57 77|asymmetric heterodimer
P07529124A0119|110 117|subunits
P07529124A0119|119 134|molecular weights
P07529124A0119|137 139|kDa
P07529124A0119|145 147|kDa
P07529124A0119|153 193|identical amino-terminal amino acid sequences
P07529124A0119|195 202|residues
P07529504A0000|0 14|Pharmacological
P07529504A0000|18 47|pharmacokinetic characteristics
P07529504A0000|53 97|non-ionic monomeric X-ray contrast agent iopromide
P07529504A0000|99 107|Ultravist
P07529504A0000|109 111|CAS
P07529504A0000|138 155|preclinical studies
P07529516A0474|3 20|subsequent patients
P07529516A0474|37 43|maximal
P07529516A0474|59 62|EDXR
P07529516A0474|66 74|mg/m2/day
P07530128A0578|3 22|median post-treatment
P07530128A0578|24 44|pre-operative serum PSA
P07530128A0578|42 44|PSA
P07530128A0578|51 55|ng/ml
P07530502A0974|0 7|Addition
P07530502A0974|10 35|soluble recombinant human SLF
P07530502A0974|38 53|SI4-h220 cultures
P07530502A0974|73 99|cell-surface c-kit expression
P07530502A0974|85 89|c-kit
P07530502A0974|106 123|protein degradation
P07530502T0000|0 24|Membrane-bound Steel factor
P07530502T0000|14 24|Steel factor
P07530502T0000|36 69|persistent tyrosine kinase activation
P07530502T0000|73 86|longer life span
P07530502T0000|89 112|c-kit gene-encoded protein
P07530502T0000|120 130|soluble form
P07530549A0956|0 7|Analysis
P07530549A0956|13 21|sequences
P07530549A0956|29 33|BLAST
P07530549A0956|37 49|GRAIL programs
P07530549A0956|58 86|additional independent evidence
P07530549A0956|102 107|clones
P07530549A0956|121 129|sequences
P07530549A0956|141 151|other clones
P07530549A0956|170 178|sequences
P07530549A0956|188 195|portions
P07530549A0956|198 205|new genes
P07531321A0369|0 7|Patients
P07531321A0369|23 33|PVC/24 hours
P07531321A0369|63 65|PVC
P07531321A0369|69 80|CI evaluation
P07532278A0833|0 6|Horvath
P07532278A0833|8 9|I.
P07533527A0128|0 8|Cell lines
P07533527A0128|23 28|tumors
P07533527A0128|43 53|fluorescent
P07533527A0128|60 72|hybridization
P07533527A0128|101 115|human chromosome
P07533527A0128|121 123|PCR
P07533527A0128|127 136|marker loss
P07533758A1038|3 20|amino acid sequences
P07533758A1038|35 38|RfbA
P07533758A1038|42 53|RfbB homologs
P07533758A1038|60 69|identities
P07533758A1038|76 76|%
P07533758A1038|82 97|% total similarity
P07533758A1038|106 106|%
P07533758A1038|112 127|% total similarity
P07533858A1503|8 35|multiple alanine substitutions
P07533858A1503|38 44|proline
P07533858A1503|46 64|helix-destabilizing
P07533858A1503|66 78|substitutions
P07533858A1503|92 106|oligomerization
P07533858A1503|121 127|GP64 EFP
P07533880T0000|3 13|FinO protein
P07533880T0000|16 27|IncF plasmids
P07533880T0000|33 48|FinP antisense RNA
P07533880T0000|62 69|traJ mRNA
P07533880T0000|82 96|duplex formation
P07534285A0155|23 35|ligand binding
P07534285A0155|43 65|tyrosine phosphorylation
P07534285A0155|68 76|BaF3 cells
P07534285A0155|99 115|murine Mpl receptor
P07534285A0155|117 125|BaF3/mMpl
P07534285A0155|117 120|BaF3
P07534285A0155|122 125|mMpl
P07534286A0842|1 19|chicken paxillin cDNA
P07534286A0842|78 87|% identical
P07534286A0842|90 103|human paxil-lin
P07534297A0141|9 42|4.1-kilobase pair HindIII DNA fragment
P07534297A0141|25 42|HindIII DNA fragment
P07534297A0141|50 63|region upstream
P07534297A0141|69 91|human AP endonuclease gene
P07534297A0141|93 95|APE
P07534297A0141|102 133|chloramphenicol acetyltransferase
P07534297A0141|135 137|CAT
P07534306A0444|3 41|overexpressed His6-tagged GrsA derivatives
P07534306A0444|16 41|His6-tagged GrsA derivatives
P07534306A0444|46 62|affinity-purified
P07534306A0444|70 88|catalytic properties
P07534306A0444|94 108|deletion mutants
P07534306A0444|123 140|biochemical studies
P07534306A0444|150 181|ATP-dependent amino acid activation
P07534306A0444|183 208|carboxyl thioester formation
P07534306A0444|251 263|phenylalanine
P07534306A0444|268 268|L
P07534306A0444|275 282|D-isomer
P07535593A0714|0 3|CD7+
P07535593A0714|0 2|CD7
P07535593A0714|5 7|CD3
P07535593A0714|9 24|T-cell precursors
P07535593A0714|32 44|V delta 2D delta
P07535593A0714|46 59|rearrangements
P07535768A1076|0 7|HVH2 mRNA
P07535768A1076|16 40|expression pattern distinct
P07535768A1076|45 49|CL100
P07535768A1076|51 64|human homologue
P07535768A1076|67 75|mouse MKP1
P07535768A1076|80 83|PAC1
P07535768A1076|108 128|MAP kinase phosphatases
P07537267A2094|25 40|sequences located
P07537267A2094|59 68|breakpoint
P07537267A2094|74 87|HPFH-3 deletion
P07537267A2094|130 137|enhancer
P07537267A2094|154 177|developmental specificity
P07537267A2094|183 204|fetal gamma-globin genes
P07537267A2094|247 255|adult life
P07537362A1112|24 49|Shb-SH3 domain proteins v-Src
P07537362A1112|24 26|Shb
P07537362A1112|45 49|v-Src
P07537362A1112|53 56|Eps8
P07537362A1112|70 90|coimmunoprecipitation
P07537736A0453|3 9|results
P07537736A0453|40 43|Jak2
P07537736A0453|47 50|PRLR
P07537736A0453|60 79|proline-rich sequence
P07537736A0453|85 106|membrane proximal region
P07537736A0453|112 119|receptor
P07537736A0453|145 160|different members
P07537736A0453|166 192|cytokine receptor superfamily
P07537851A0000|0 12|Transcription
P07537851A0000|18 46|vascular cell adhesion molecule 1
P07537851A0000|18 45|vascular cell adhesion molecule
P07537851A0000|48 53|VCAM-1
P07537851A0000|61 76|endothelial cells
P07537851A0000|88 105|lipopolysaccharide
P07537851A0000|112 149|inflammatory cytokines interleukin-1 beta
P07537851A0000|133 149|interleukin-1 beta
P07537851A0000|153 176|tumor necrosis factor alpha
P07537851A0000|178 186|TNF-alpha
P07537851A0891|0 10|Experiments
P07537851A0891|15 33|recombinant proteins
P07537851A0891|44 50|p50/p65
P07537851A0891|44 46|p50
P07537851A0891|48 50|p65
P07537851A0891|54 73|high-mobility-group I
P07537851A0891|75 75|Y
P07537851A0891|111 117|binding
P07537851A0891|120 124|IRF-1
P07537851A0891|130 137|VCAM1 IRF
P07537851A0891|130 134|VCAM1
P07537851A0891|135 148|IRF binding site
P07537851A0891|156 160|IRF-1
P07537851A0891|185 187|p50
P07537851A0891|195 214|high-mobility-group I
P07537851A0891|216 216|Y
P07538068A1094|12 18|results
P07538068A1094|22 42|minimal control element
P07538068A1094|44 45|AX
P07538068A1094|63 78|anterior boundary
P07538068A1094|81 93|Hox expression
P07538068A1094|81 83|Hox
P07538068A1094|109 122|Hoxa-7 enhancer
P07538122A0800|37 47|Fab fragment
P07538122A0800|49 53|Fab A8
P07538122A0800|63 82|high relative affinity
P07538122A0800|89 96|receptor
P07538122A0800|101 102|nM
P07538173A0307|0 45|MBP-Rep68 delta-mediated DNA-RNA helicase activity
P07538173A0307|0 2|MBP
P07538173A0307|54 66|ATP hydrolysis
P07538173A0307|83 85|Mg2
P07538173A0307|87 90|ions
P07538173A0307|108 124|high ionic strength
P07538818A0197|10 24|critical regions
P07538818A0197|34 57|growth signal transduction
P07538818A0197|60 66|hG-CSFR
P07538818A0197|68 76|deletions
P07538818A0197|79 113|site-directed amino acid substitutions
P07538818A0197|135 151|cytoplasmic domain
P07538818A0197|154 160|hG-CSFR
P07538818A0197|168 178|mutant cDNAs
P07538818A0197|201 219|murine interleukin-3
P07538818A0197|221 237|IL-3)-dependent Ba
P07538818A0197|221 224|IL-3
P07538818A0197|227 240|dependent Ba/F3
P07538818A0197|239 240|F3
P07538818A0197|244 256|FDCP cell lines
P07539119A0291|37 45|mutations
P07539119A0291|51 67|c-abl kinase domain
P07539119A0291|70 81|NH2-terminus
P07539119A0291|86 98|G128R mutation
P07539119A0291|125 136|double mutant
P07539119A0291|155 165|G128R mutant
P07539119A0291|186 190|cells
P07539119A0291|194 207|trivial reasons
P07539119A0985|4 12|mutations
P07539119A0985|32 38|binding
P07539119A0985|44 55|Abl SH3 domain
P07539119A0985|58 83|proline-rich target proteins
P07539119A0985|87 105|filter-binding assay
P07539314T0000|0 6|Changes
P07539314T0000|19 23|gills
P07539314T0000|26 33|milkfish
P07539314T0000|35 54|Chanos chanos Forsskal
P07539314T0000|56 66|fingerlings
P07539314T0000|72 84|acute exposure
P07539314T0000|87 98|nifurpirinol
P07539314T0000|100 107|Furanace
P07539314T0000|109 114|P-7138
P07540607A0709|0 10|Retreatment
P07540607A0709|19 22|dogs
P07540607A0709|63 81|human immunoglobulin
P07540773A0576|3 8|levels
P07540773A0576|11 13|NSE
P07540773A0576|17 19|MBP
P07540773A0576|25 28|IJVB
P07540773A0576|53 55|PVB
P07540866A1069|14 26|insulin effect
P07540866A1069|14 20|insulin
P07540866A1069|37 51|ras GTP formation
P07540866A1069|55 71|MAP kinase activity
P07540866A1069|55 63|MAP kinase
P07540866A1069|75 84|negligible
P07540866A1069|87 98|A/K1018 cells
P07540866A1069|111 121|supernormal
P07540866A1069|125 133|Y/F2 cells
P07541589A0652|0 19|Morphologic variables
P07541589A0652|28 39|cancer volume
P07541589A0652|41 55|histologic grade
P07541589A0652|57 75|capsular penetration
P07541589A0652|77 98|seminal vesicle invasion
P07541589A0652|103 121|lymph node metastasis
P07541912A0485|0 15|Sequence analysis
P07541912A0485|23 29|regions
P07541912A0485|37 43|CAAT box
P07541912A0485|54 59|exon 1a
P07541912A0485|63 83|high G-C content regions
P07541912A0485|94 95|P1
P07541912A0485|99 100|P2
P07542577A0438|3 16|fusion proteins
P07542577A0438|29 33|ELISA
P07542577A0438|37 46|reactivity
P07542577A0438|59 74|human anti-La sera
P07542577A0438|104 111|epitopes
P07542616A0313|0 4|GCD10
P07542616A0313|37 58|translational repressor
P07542616A0313|61 64|GCN4
P07542616A0486|0 4|GCD10
P07542616A0486|10 12|RNA
P07542616A0486|32 56|strong biochemical evidence
P07542616A0486|79 96|RNA-binding subunit
P07542616A0486|99 121|yeast initiation factor-3
P07542616A0486|123 127|eIF-3
P07542616A0486|130 134|eIF-3
P07542616A0486|138 156|multisubunit complex
P07542616A0486|171 191|translation initiation
P07542616A0486|201 221|several different steps
P07542698A0137|0 6|Sources
P07542698A0137|21 27|signals
P07542698A0137|43 54|preparations
P07542698A0137|69 93|potentiometric probe RH-414
P07543592A0624|1 30|transformation-competent mutant
P07543592A0624|39 56|wild-type E5 protein
P07543592A0624|66 73|receptor
P07543592A0624|77 114|induced receptor tyrosine phosphorylation
P07543592A0624|118 132|down-regulation
P07543684A1027|14 17|cAMP
P07543684A1027|32 34|PKA
P07543684A1027|40 57|essential regulator
P07543684A1027|60 82|basal CFTR gene expression
P07543684A1027|65 72|CFTR gene
P07543684A1027|98 106|induction
P07543684A1027|109 112|CFTR
P07543684A1027|115 133|responsive cell types
P07543868A0414|0 26|Appropriate restriction sites
P07543868A0414|62 73|cDNA fragment
P07543868A0414|91 114|epitope-specific sequence
P07543868A0414|125 132|long poly
P07543868A0414|134 134|A
P07544357A0808|4 8|PPC-1
P07544357A0808|12 23|ALVA-31 cells
P07544357A0808|31 43|tumorigenesis
P07544357A0808|47 58|invasiveness
P07544357A0808|61 68|nude mice
P07544357A0808|77 86|LNCap cells
P07544357A0808|95 116|less malignant phenotype
P07544357A0808|147 157|CD44 variant
P07544357A0808|159 163|CD44v
P07544357A0808|178 208|aggressive prostate tumor behavior
P07545510A0735|3 13|gene product
P07545510A0735|16 19|cotS
P07545510A0735|47 53|Cot40-2
P07545510A0735|56 63|SDS-PAGE
P07545510A0735|67 80|immunoblotting
P07545510A0735|116 122|plasmid
P07545510A0735|136 145|cotS region
P07545920A1336|3 11|such genes
P07545920A1336|23 32|hsiggll150
P07545920A1336|36 45|hsiggll295
P07545920A1336|73 82|genomic DNA
P07546256A0000|1 33|retrospective epidemiological study
P07546256A0000|58 65|injuries
P07546256A0000|71 78|children
P07546256A0000|112 121|Casablanca
P07546293A0968|3 9|results
P07546293A0968|21 34|protein binding
P07546293A0968|40 56|E2F-like sequences
P07546294A0000|3 15|RAD6/UBC2 gene
P07546294A0000|3 6|RAD6
P07546294A0000|8 11|UBC2
P07546294A0000|20 42|Saccharomyces cerevisiae
P07546294A0000|51 77|ubiquitin-conjugating enzyme
P07546294A0000|88 96|DNA repair
P07546294A0000|98 115|induced mutagenesis
P07546294A0000|120 130|sporulation
P07546794A0100|0 15|Echocardiography
P07546794A0100|24 56|right ventricular diastolic collapse
P07546794A0100|58 61|RVDC
P07546794A0100|70 82|physical signs
P07546794A0100|85 100|cardiac tamponade
P07547220A0229|2 28|on-going screening programmes
P07547220A0229|33 46|Haemoccult test
P07547220A0229|60 65|slides
P07547500A0066|22 35|a fusion protein
P07547500A0066|23 35|fusion protein
P07547500A0066|37 44|GAL4-p40
P07547500A0066|37 40|GAL4
P07547500A0066|42 44|p40
P07547500A0066|59 75|DNA-binding domain
P07547500A0066|78 81|GAL4
P07547500A0066|85 93|sequences
P07547500A0066|96 115|chicken l kappa B-alpha
P07547500A0066|117 119|p40
P07547500A0066|140 144|yeast
P07547510A0261|42 46|sites
P07547510A0261|56 72|HNF-3 beta promoter
P07547510A0261|105 111|factors
P07547510A0261|131 156|critical autoregulatory site
P07547510A0261|171 181|binding site
P07547510A0261|186 204|cell-specific factor
P07547510A0261|206 214|LF-H3 beta
P07547510A0261|244 266|HNF-3 beta gene expression
P07547510A0261|244 256|HNF-3 beta gene
P07547510A0261|269 279|hepatocytes
P07548425A0000|13 16|cats
P07548425A0000|21 27|effects
P07548425A0000|30 43|afferent inputs
P07548425A0000|48 70|hindlimb cutaneous nerves
P07548425A0000|72 90|sural cutaneous nerve
P07548425A0000|92 94|Sur
P07548425A0000|98 124|mono-and poly-synaptic reflex
P07548425A0000|137 157|tail muscle motoneurons
P07548425A0000|183 197|spinal lesioning
P07548425A0000|200 208|S2-3 level
P07548858A0000|3 10|flow rate
P07548858A0000|13 21|phosphate
P07548858A0000|30 35|saline
P07548858A0000|43 48|dermis
P07548858A0000|73 87|applied pressure
P07549005A0530|8 27|parallax measurements
P07549005A0530|55 66|Epon sections
P07550216A0195|14 25|normal limits
P07550216A0195|27 33|latency
P07551787A0917|15 26|optimization
P07551787A0917|32 46|seven-field plan
P07551787A0917|77 87|best results
P07551787A0917|118 147|conformal radiotherapy technique
P07552974A0217|0 19|Specific requirements
P07552974A0217|23 46|branched-chain amino acids
P07552974A0217|48 56|glutamine
P07552974A0217|61 68|arginine
P07553942A0810|3 16|pea rps10 intron
P07553942A0810|19 28|homologous
P07553942A0810|31 37|introns
P07553942A0810|40 44|rrn26
P07553942A0810|48 51|cox3
P07553942A0810|57 85|Marchantia mitochondrial genome
P07553942A0810|95 113|Marchantia rps10 gene
P07553942A0810|121 126|intron
P07554541A0587|3 13|optimal care
P07554541A0587|16 25|CHF patient
P07554541A0587|68 90|electrolyte disturbances
P07555373A0000|0 13|Serum magnesium
P07555373A0000|18 25|patients
P07555373A0000|28 47|gynecologic neoplasms
P07555373A0000|59 67|cisplatin
P07555373A0000|76 83|controls
P07557091A0314|0 6|METHODS
P07557091A0314|8 13|rHb1.1
P07557091A0314|8 11|rHb1
P07557091A0314|16 32|human serum albumin
P07557091A0314|70 83|male volunteers
P07557276A0526|0 22|Alanine aminotransferase
P07557276A0526|24 26|ALT
P07557276A0526|28 33|levels
P07557276A0526|41 48|elevated
P07557276A0526|55 60|months
P07557276A0526|66 73|patients
P07557276A0526|77 100|hepatitis B viral infection
P07557276A0526|104 114|replicative
P07557387A0241|38 46|C/EBP beta
P07557387A0241|62 78|adipogenic program
P07557387A0241|95 103|C/EBP beta
P07557387A0241|106 137|multipotential NIH-3T3 fibroblasts
P07557424A0124|0 3|XYL1
P07557424A0124|33 43|fusion clone
P07557424A0124|50 79|lacZ translational fusion library
P07557424A0124|50 53|lacZ
P07557446T0000|0 17|Various transcripts
P07557446T0000|37 45|VCSA1 gene
P07557446T0000|48 66|alternative splicing
P07557446T0000|70 73|poly
P07557446T0000|75 75|A
P07557446T0000|92 112|rat submandibular gland
P07557717A0184|21 36|chest wall muscles
P07557717A0184|49 57|diathermy
P07557717A0184|72 84|prolonged pain
P07557717A0184|88 96|morbidity
P07558263T0000|0 6|Closure
P07558263T0000|11 53|open high below-knee guillotine amputation wound
P07558263T0000|60 80|skin-stretching device
P07558583A0562|25 33|synthesis
P07558583A0562|40 50|derivatives
P07558583A0562|84 108|peptide substrates suitable
P07558583A0562|115 123|detection
P07558583A0562|129 158|Src-like tyrosine kinase activity
P07558583A0562|129 150|Src-like tyrosine kinase
P07558583A0562|162 198|active site-directed inhibitors specific
P07558583A0562|213 219|enzymes
P07559233A0534|0 22|Citrate synthase activity
P07559233A0534|0 14|Citrate synthase
P07559233A0534|40 49|medial head
P07559233A0534|53 53|%
P07559233A0534|55 55|P
P07559233A0534|69 79|red long head
P07559233A0534|83 83|%
P07559233A0534|85 85|P
P07559233A0534|98 117|triceps brachii muscle
P07559233A0534|120 124|R rats
P07559233A0534|136 148|white long head
P07559233A0534|152 152|%
P07559233A0534|154 155|P =
P07559347A0000|18 36|putative operon bglPH
P07559347A0000|32 36|bglPH
P07559347A0000|39 54|Bacillus subtilis
P07559347A0000|72 75|bglP
P07559347A0000|78 103|lacZ transcriptional fusions
P07559355A0066|13 36|contiguous genes necessary
P07559355A0066|40 53|urease activity
P07559355A0066|40 45|urease
P07559355A0066|84 110|transcriptional organization
P07559355A0066|126 138|specific genes
P07559355A0066|148 165|Proteus gene cluster
P07559356T0000|3 16|hypBFCDE operon
P07559356T0000|21 54|Rhizobium leguminosarum biovar viciae
P07559356T0000|72 87|Fnr-type promoter
P07559356T0000|99 109|mutagenesis
P07559356T0000|115 122|fnrN gene
P07559402A0622|18 19|VT
P07559402A0622|21 27|peptide
P07559402A0622|59 72|protein kinase C
P07559402A0622|74 76|PKC
P07559402A0622|94 107|protein kinase A
P07559402A0622|109 111|PKA
P07559430A0909|0 1|R.
P07559478A0389|13 19|O'Neill
P07559478A0389|21 22|T.
P07559488A0440|0 17|Control experiments
P07559488A0440|32 44|fusion protein
P07559488A0440|49 71|high affinity binding site
P07559488A0440|75 90|estradiol-17 beta
P07559488A0440|114 133|ERE-LacZ reporter gene
P07559488A0440|114 116|ERE
P07559488A0440|136 147|yeast similar
P07559488A0440|153 162|wild type ER
P07559510A0000|8 38|Micrococcus luteus UV endonuclease
P07559510A0000|60 71|18-kDa enzyme
P07559510A0000|76 91|possible homology
P07559510A0000|97 115|16-kDa endonuclease V
P07559510A0000|120 134|bacteriophage T4
P07559510A0000|136 141|Gordon
P07559510A0000|143 144|L.
P07559524A0000|0 24|Several different oncogenes
P07559524A0000|28 40|growth factors
P07559524A0000|48 65|G1 phase progression
P07559524A0741|0 23|Cyclin D1 promoter activity
P07559524A0741|0 15|Cyclin D1 promoter
P07559524A0741|39 52|overexpression
P07559524A0741|55 84|mitogen-activated protein kinase
P07559524A0741|86 92|p41MAPK
P07559524A0741|96 102|c-Ets-2
P07559524A0741|113 120|proximal
P07559524A0741|123 131|base pairs
P07559555A0557|7 9|ERM
P07559555A0557|13 17|c-Jun
P07559555A0557|45 51|EBS-CRE
P07559555A0557|67 88|apparent ternary complex
P07559563A0282|1 6|mutant
P07559563A0282|8 15|residues
P07559563A0282|28 38|complete Ca2
P07559563A0282|36 39|Ca2+
P07559563A0282|41 61|CaM-dependent activity
P07559563A0282|41 43|CaM
P07559639A0996|14 33|R206S HSF substitution
P07559639A0996|14 21|R206S HSF
P07559639A0996|42 78|constitutive transcriptional activation
P07559639A0996|84 95|consensus HSE
P07559639A0996|97 100|HSE2
P07559640A1230|6 10|bases
P07559640A1230|89 98|UAS element
P07559640A1230|110 114|bases
P07559640A1230|133 145|bHLH core motif
P07559650A0558|5 11|results
P07559650A0558|27 34|PCNA gene
P07559650A0558|38 53|likely target gene
P07559650A0558|56 58|E2F
P07560137T0000|0 22|Differential sensitivity
P07560137T0000|28 49|MMPI-2 depression scales
P07560137T0000|53 61|subscales
P07560662A0496|15 39|hypertonic saline challenge
P07562775A0596|10 20|eosinophils
P07562775A0596|29 29|%
P07562775A0596|43 67|peripheral white blood cells
P07562775A0596|73 77|nadir
P07562775A0596|80 80|%
P07563072A0773|0 10|Comparisons
P07563072A0773|13 33|rrnB P1-lacZ expression
P07563072A0773|13 16|rrnB
P07563072A0773|20 23|lacZ
P07563072A0773|36 55|different ppGpp levels
P07563072A0773|75 91|rpoD(P504L) mutant
P07563072A0773|75 78|rpoD
P07563072A0773|80 84|P504L
P07563072A0773|86 91|mutant
P07563072A0773|108 123|hypersensitivity
P07563072A0773|126 130|ppGpp
P07563076A0766|5 18|intron chimeras
P07563076A0766|27 45|peripheral sequences
P07563076A0766|52 59|elements
P07563076A0766|73 83|splice sites
P07563076A0766|98 118|self-splicing activity
P07563076A0766|129 143|central portions
P07563076A0766|157 170|catalytic cores
P07563076A0766|173 175|ai4
P07563076A0766|179 181|bi4
P07563076A0766|185 193|deficient
P07563076A0766|200 204|cores
P07563076A0766|211 223|likely targets
P07563076A0766|229 244|splicing proteins
P07563090A0124|32 54|plus-strand DNA synthesis
P07563090A0124|60 74|yeast Ty1 element
P07563090A0124|91 102|sites located
P07563090A0124|123 142|3' long terminal repeat
P07563090A0124|125 142|long terminal repeat
P07563090A0124|144 147|PPT1
P07563090A0124|170 176|pol gene
P07563090A0124|182 204|integrase coding sequence
P07563090A0124|182 190|integrase
P07563090A0124|206 209|PPT2
P07563090A0624|0 15|Characterization
P07563090A0624|23 26|ends
P07563090A0624|32 54|plus-strand DNA fragments
P07563090A0624|72 87|upstream fragment
P07563090A0624|105 108|PPT2
P07563090A0624|118 128|plus-strand
P07563090A0624|159 192|plus-strand strong-stop DNA fragments
P07563090A0624|207 235|minus-strand primer binding site
P07563090A0624|269 308|retroviral genomic RNA reverse transcription
P07563994A0488|3 10|patients
P07563994A0488|21 24|VTLB
P07563994A0488|41 61|shorter operative times
P07563994A0488|63 66|VTLB
P07563994A0488|80 82|min
P07563994A0488|86 88|OLB
P07563994A0488|102 104|min
P07563994A0488|106 106|p
P07563994A0488|116 128|less blood loss
P07563994A0488|130 133|VTLB
P07563994A0488|145 146|ml
P07563994A0488|149 151|OLB
P07563994A0488|164 165|ml
P07563994A0488|167 167|p
P07564004A0292|5 11|minutes
P07564004A0292|17 31|Cr2O3 inhalation
P07564004A0292|33 38|FEV1.0
P07564004A0292|55 55|%
P07564210A0557|4 40|combined intravenous anaesthetic regimen
P07564210A0557|45 59|good anaesthesia
P07564210A0557|63 71|analgesia
P07564210A0557|74 77|pigs
P07564210A0557|86 86|h
P07564210A0557|100 112|clinical signs
P07565031A0454|6 17|food products
P07565031A0454|38 49|V. cholerae O1
P07565031A0454|51 55|Ogawa
P07565031A0454|57 65|toxigenic
P07565031A0454|72 87|toxigenic strains
P07565031A0454|89 95|yoghurt
P07565031A0454|97 107|cream cheese
P07565031A0454|109 124|apricot marmelade
P07565031A0454|133 141|marmelade
P07565031A0454|143 152|mayonnaise
P07565031A0454|154 165|italian pasta
P07565031A0454|170 178|empanadas
P07565031A0454|196 206|meat sausage
P07565031A0454|215 228|spinach ravioli
P07565031A0454|230 238|margarine
P07565031A0454|240 250|milk dessert
P07565031A0454|260 264|cocoa
P07565031A0454|266 278|milk confiture
P07565031A0454|280 285|starch
P07565031A0454|289 297|additives
P07565031A0454|300 306|lettuce
P07565031A0454|308 315|tuna fish
P07565031A0454|317 323|ricotta
P07565049A1032|29 43|clinical outline
P07565049A1032|55 65|symptomatic
P07565049A1032|69 90|asymptomatic infected NB
P07565049A1032|105 118|gestational age
P07565049A1032|128 135|pre-term
P07565049A1032|174 175|g.
P07565104A0084|18 26|pilin gene
P07565104A0084|28 31|tcpA
P07565104A0084|48 51|ToxR
P07565104A0084|59 62|ToxT
P07565113A0000|3 44|chloramphenicol-resistance transposon Tn4451
P07565113A0000|3 38|chloramphenicol-resistance transposon
P07565113A0000|39 44|Tn4451
P07565113A0000|54 79|precise conjugative deletion
P07565113A0000|87 105|parent plasmid plP401
P07565113A0000|108 129|Clostridium perfringens
P07565113A0000|133 158|precise spontaneous excision
P07565113A0000|163 179|multicopy plasmids
P07565669T0000|0 8|Ras p21Val
P07565669T0000|17 26|myogenesis
P07565669T0000|45 54|DNA binding
P07565669T0000|57 81|transcriptional activities
P07565669T0000|87 122|myogenic basic helix-loop-helix factors
P07565672A0798|2 6|cells
P07565672A0798|42 46|arg-2
P07565672A0798|50 54|cpc-1
P07565672A0798|80 84|cox-5
P07565672A0798|93 105|translational
P07565672A0798|109 133|transcriptional components
P07565685A0420|3 18|peptide sequences
P07565685A0420|48 56|GABP alpha
P07565685A0420|60 68|GABP beta 1
P07565685A0420|60 67|GABP beta
P07565685A0420|73 75|Ets
P07565685A0420|79 89|Notch motifs
P07565688A0797|0 27|Immunofluorescence microscopy
P07565688A0797|31 55|cell fractionation analyses
P07565688A0797|69 82|110-kDa protein
P07565688A0797|115 128|150-kDa protein
P07565688A0797|148 156|cytoplasm
P07565688A0797|160 166|nucleus
P07565688A0797|169 178|human cells
P07565688T0000|0 9|Expression
P07565688T0000|25 34|interferon
P07565688T0000|38 83|double-stranded-RNA-specific adenosine deaminase
P07565688T0000|88 97|human cells
P07565688T0000|113 117|forms
P07565688T0000|123 131|deaminase
P07565709A0000|0 15|T-cell hybridomas
P07565709A0000|17 26|thymocytes
P07565709A0000|31 36|T cells
P07565709A0000|58 75|apoptotic cell death
P07565709A0000|78 87|activation
P07565709A0000|98 111|T-cell receptor
P07565712A0286|0 8|Deletions
P07565712A0286|26 33|LYS2 gene
P07565712A0286|51 63|156-bp inserts
P07565712A0286|76 82|inserts
P07565712A0286|89 105|apparent potential
P07565712A0286|109 126|secondary structure
P07565712A0286|138 153|quasipalindromes
P07565713A0634|0 13|Overexpression
P07565713A0634|16 19|SCS1
P07565713A0634|40 55|HSP60-null allele
P07565713A0634|71 81|suppression
P07565713A0634|107 119|Hsp60 activity
P07565713A0634|107 111|Hsp60
P07565720A0256|3 18|DNA binding domain
P07565720A0256|21 24|NirA
P07565720A0256|40 52|fusion protein
P07565720A0256|60 83|glutathione S-transferase
P07565720A0256|86 105|Schistosoma japonicum
P07565723A0200|3 8|kinase
P07565723A0200|29 49|normal phosphorylation
P07565723A0200|55 57|CTD
P07565723A0200|64 75|normal growth
P07565723A0200|79 93|differentiation
P07565731A1629|1 12|general model
P07565731A1629|16 42|ARE-mediated mRNA degradation
P07565731A1629|53 65|potential role
P07565731A1629|69 113|certain heterogeneous nuclear ribonucleoproteins
P07565731A1629|117 135|ARE-binding proteins
P07565736A2134|25 34|C/EBP alpha
P07565736A2134|51 77|GM-CSF receptor alpha promoter
P07565736A2134|80 94|nonmyeloid cells
P07565740T0000|0 10|Endocytosis
P07565740T0000|14 32|vacuolar degradation
P07565740T0000|38 104|plasma membrane-localized Pdr5 ATP-binding cassette multidrug transporter
P07565740T0000|62 104|Pdr5 ATP-binding cassette multidrug transporter
P07565775A1265|0 18|Individual mutations
P07565775A1265|21 26|motifs
P07565775A1265|37 37|V
P07565775A1265|41 58|distinctive effects
P07565775A1265|64 71|affinity
P07565775A1265|74 79|enzyme
P07565775A1265|83 85|GTP
P07565775A1265|96 112|covalent catalysis
P07565775A1265|114 125|EpG formation
P07565775A1265|143 145|GMP
P07565775A1265|150 155|enzyme
P07565775A1265|158 160|RNA
P07565775T0000|0 17|Mutational analysis
P07565775T0000|20 23|mRNA
P07565775T0000|31 36|enzyme
P07565775T0000|47 56|amino acids
P07565775T0000|67 76|GTP binding
P07565775T0000|78 102|enzyme-guanylate formation
P07565775T0000|107 117|GMP transfer
P07565775T0000|120 122|RNA
P07565776A0612|0 9|Disruption
P07565776A0612|15 18|HOG1
P07565776A0612|22 30|PBS2 genes
P07565776A0612|39 54|dramatic decrease
P07565776A0612|60 76|HSP12 inducibility
P07565776A0612|60 64|HSP12
P07565776A0612|79 95|osmostressed cells
P07565776A0612|104 117|overproduction
P07565776A0612|120 123|Hog1
P07565776A0612|133 148|fivefold increase
P07565776A0612|151 172|wild-type induced levels
P07565776A0612|186 206|high salt concentration
P07565797A0116|0 7|Deletion
P07565797A0116|10 21|inactivation
P07565797A0116|24 27|CRY1
P07565797A0116|39 61|10-fold-increased levels
P07565797A0116|64 71|CRY2 mRNA
P07567079A0014|26 43|Cryptosporidium spp
P07567079A0014|45 51|oocysts
P07567079A0014|56 60|feces
P07567079A0014|69 103|percoll discontinuous density gradient
P07567079A0014|139 150|large numbers
P07567079A0014|153 159|oocysts
P07567079A0014|162 173|C. parvum free
P07567079A0014|176 193|fecal contamination
P07567300T0000|0 25|Staphylococcal enterotoxin A
P07567300T0000|0 24|Staphylococcal enterotoxin
P07567300T0000|52 63|20-month-old
P07567830A0072|0 6|METHODS
P07567830A0072|18 35|maximal inspiratory
P07567830A0072|39 65|expiratory flow-volume curves
P07567830A0072|70 87|unselected patients
P07567830A0072|92 106|essential tremor
P07567830A0072|110 114|males
P07567830A0072|118 124|females
P07567830A0072|140 144|years
P07567979A1266|3 10|findings
P07567979A1266|49 54|assays
P07567979A1266|69 75|ligands
P07567979A1266|78 92|testis receptor 2
P07567979A1266|78 91|testis receptor
P07567979A1266|96 100|hERR1
P07567980T0000|4 31|p53 DNA-binding domain peptides
P07567980T0000|36 62|natural p53-response elements
P07567980T0000|43 62|p53-response elements
P07568026A0622|3 12|Stat5b mRNA
P07568026A0622|26 27|kb
P07568026A0622|51 60|amino acids
P07568116A0902|3 16|hydropathy plot
P07568116A0902|32 58|hydrophilic N-terminal region
P07568116A0902|75 98|hydrophobic signal peptide
P07568118A1267|5 11|results
P07568118A1267|23 61|G beta gamma-stimulated Shc phosphorylation
P07568118A1267|74 82|early step
P07568118A1267|88 94|pathway
P07568118A1267|104 119|p21ras activation
P07568118A1267|104 109|p21ras
P07568118A1267|152 186|growth factor tyrosine kinase receptors
P07568576A0074|41 53|Type A behavior
P07568576A0074|62 83|basic emotion dimensions
P07568865A0305|3 11|carcasses
P07568865A0305|22 34|contamination
P07568865A0305|39 63|aerobic mesophilic bacteria
P07568865A0305|96 107|CFU/ml liquid
P07568865A0305|120 120|%
P07568865A0305|129 145|sporulate bacteria
P07568865A0305|172 177|CFU/ml
P07568865A0305|179 184|Figure
P07569075A0585|16 33|lung cancer patients
P07569075A0585|35 36|CR
P07569075A0585|58 58|%
P07569075A0585|68 69|PR
P07569075A0585|76 76|%
P07569075A0585|110 125|chest radiography
P07569075A0585|127 128|CT
P07569075A0585|130 132|FBS
P07569075A0585|134 141|cytology
P07569075A0585|148 156|histology
P07569532T0001|0 26|Pediatric medical emergencies
P07569532T0001|30 45|regional hospital
P07569532T0001|47 63|appropriate locale
P07569640A0539|0 21|Protein electrophoresis
P07569640A0539|37 49|albumin levels
P07569640A0539|37 43|albumin
P07569640A0539|56 61|groups
P07569640A0539|67 77|lower values
P07569640A0539|80 81|G2
P07569770A0298|0 6|METHODS
P07569770A0298|18 31|non-responders
P07569770A0298|42 50|extra dose
P07569770A0298|56 66|same vaccine
P07569770A0298|68 73|months
P07569770A0298|79 97|primary immunization
P07569770A0298|102 112|booster dose
P07569770A0298|118 137|yeast-derived vaccine
P07569770A0298|139 143|years
P07571766A0122|12 25|high percentage
P07571766A0122|28 47|hypertensive patients
P07571766A0122|64 64|%
P07571766A0122|76 97|cardiac catheterization
P07571766A0122|107 117|anginal pain
P07571766A0122|124 160|exercise-induced ST-segment depressions
P07571766A0122|180 201|normal coronary arteries
P07571953T0000|0 16|Negative-staining
P07571953T0000|18 39|refractile mycobacteria
P07571953T0000|42 65|Romanowsky-stained smears
P07572582A0000|0 9|Mibefradil
P07572582A0000|11 12|Ro
P07572582A0000|24 45|novel calcium antagonist
P07572582A0000|51 66|new chemical class
P07572582A0000|104 123|T-type calcium channel
P07574064A1416|9 46|minimum alveolar concentration anesthesia
P07574064A1416|84 85|VE
P07574064A1416|89 92|PCO2
P07574064A1416|97 100|mmHg
P07574064A1416|126 132|l.min-1
P07574064A1416|146 159|rightward shift
P07574064A1416|165 184|response relationship
P07574682T0000|0 3|cDNA
P07574682T0000|13 69|functional feline liver/bone/kidney-type alkaline phosphatase
P07575416A0000|0 13|Protein kinase C
P07575416A0000|15 17|PKC
P07575416A0000|21 44|widely-distributed enzyme
P07575416A0000|72 97|many physiological processes
P07575416A0000|131 140|isoenzymes
P07575416A0000|154 171|tissue distribution
P07575416A0000|173 195|subcellular localization
P07575416A0000|197 216|regulatory properties
P07575416A1970|48 60|careful choice
P07575416A1970|63 77|oligonucleotide
P07575416A1970|81 90|cDNA probes
P07575416A1970|98 108|PKC zeta mRNA
P07575438A1409|23 45|helix-loop-helix factors
P07575438A1409|56 64|E1 element
P07575947T0000|13 21|electives
P07576178A0000|0 23|Polypeptide growth factors
P07576178A0000|27 35|cytokines
P07576178A0000|48 67|biochemical functions
P07576178A0000|80 98|responsive receptors
P07576179A0781|37 52|CpG dinucleotides
P07576307A0144|29 54|proximal regulatory cassette
P07576307A0144|64 65|bp
P07576307A0144|72 84|rat enkephalin
P07576307A0144|86 89|rENK
P07576307A0144|100 122|developmental regulation
P07576307A0144|128 146|enkephalin phenotype
P07576307A1654|16 33|ENK-specific motifs
P07576307A1654|57 84|abundant protein-DNA complexes
P07576307A1654|89 103|nuclear extracts
P07576307A1654|111 128|human tumor cell line
P07576307A1654|130 133|HeLa
P07576307A1654|155 157|ENK
P07577904A0141|0 9|Infant aged
P07577904A0141|13 17|years
P07577904A0141|26 36|persistence
P07577904A0141|39 60|primordial vitreous body
P07577904A0141|65 86|crystalline dislocation
P07577904A0141|92 103|camera aquosa
P07577904A0141|107 126|secondary buphthalmos
P07577904A0141|132 138|left eye
P07577904A0141|142 155|microphthalmos
P07577904A0141|160 170|dislocation
P07577904A0141|176 186|crystalline
P07577904A0141|192 203|vitreous body
P07577904A0141|209 216|right eye
P07579023A0214|9 20|dose-finding
P07579023A0214|25 32|patients
P07579023A0214|104 117|elevated levels
P07579023A0214|120 131|liver enzymes
P07579164A0409|14 17|cDNA
P07579164A0409|21 36|genomic sequences
P07579164A0409|41 56|RNA editing events
P07579164A0409|72 80|atp9 genes
P07579328A0653|0 4|MZF-1
P07579328A0653|14 38|CAT reporter gene expression
P07579328A0653|14 28|CAT reporter gene
P07579328A0653|42 57|GAL4 binding sites
P07579328A0653|63 93|nonhematopoietic cell lines NIH 3T3
P07579328A1345|9 36|heterologous DNA binding domain
P07579328A1345|38 42|MZF-1
P07579328A1345|52 73|reporter gene expression
P07579328A1345|76 100|nonhematopoietic cell lines
P07579328A1345|125 146|hematopoietic cell lines
P07579683A0660|0 7|Analyses
P07579683A0660|10 31|hGMR beta subunit mutants
P07579683A0660|43 60|cytoplasmic regions
P07579683A0660|71 80|activation
P07579683A0660|86 98|c-myc promoter
P07579683A0660|127 137|dispensable
P07579695A0336|20 38|synthetic phenotypes
P07579695A0336|46 54|mutations
P07579695A0336|57 60|MIF2
P07579695A0336|64 84|trans-acting mutations
P07579695A0336|97 128|yeast centromere protein genes-CEP1
P07579695A0336|125 128|CEP1
P07579695A0336|130 138|CBF1/CPF1
P07579695A0336|130 133|CBF1
P07579695A0336|135 138|CPF1
P07579695A0336|140 149|NDC10/CBF2
P07579695A0336|140 144|NDC10
P07579695A0336|146 149|CBF2
P07579695A0336|154 163|CEP3/CBF3B
P07579695A0336|154 157|CEP3
P07579695A0336|159 163|CBF3B
P07579695A0693|37 47|Mif2 protein
P07579695A0693|61 65|Cep1p
P07579695A0693|71 80|centromere
P07579695A0693|91 105|yeast centromere
P07579695A0693|121 149|higher order protein-DNA complex
P07579704A0085|17 27|actin cables
P07579704A0085|17 21|actin
P07579704A0085|31 37|patches
P07579704A0085|63 71|cell cycle
P07579704A0085|80 98|secretory components
P07579704A0085|101 116|appropriate sites
P07579704A0085|120 129|cell growth
P07580058A0000|3 9|effects
P07580058A0000|12 39|Codonopsis pilosula oral liquor
P07580058A0000|41 44|CPOL
P07580058A0000|48 78|tissue-type plasminogen activator
P07580058A0000|80 83|t-PA
P07580058A0000|88 116|plasminogen activator inhibitor
P07580058A0000|118 120|PAI
P07580058A0000|127 132|plasma
P07580058A0000|137 144|patients
P07580058A0000|147 166|coronary heart disease
P07580058A0000|171 181|blood stasis
P07580330A0331|9 20|daily intakes
P07580330A0331|22 25|EDIs
P07580330A0331|44 52|microgram
P07580330A0331|56 63|total HCH
P07580330A0331|69 77|microgram
P07580330A0331|81 89|gamma-HCH
P07580330A0331|95 103|microgram
P07580330A0331|107 114|dieldrin
P07580330A0331|120 129|micrograms
P07580330A0331|133 140|total DDT
P07580330A0331|149 157|microgram
P07580330A0331|161 163|HCB
P07580782T0000|0 14|Imaging features
P07580782T0000|17 37|splenic epidermoid cyst
P07580782T0000|42 62|pathologic correlation
P07581364A0500|5 16|further cases
P07581364A0500|39 41|SMA
P07581364A0500|50 58|deletions
P07581364A0500|74 79|Ag1-CA
P07581364A0500|83 86|C212
P07582316A0696|18 22|pairs
P07582316A0696|25 32|isolates
P07582316A0696|41 54|suspicious case
P07582316A0696|57 86|identical IS6110 banding patterns
P07582316A0696|106 124|identical MTB strains
P07582592A0545|0 3|HRES
P07582592A0545|47 62|histologic damage
P07582592A0545|72 90|pneumatic dilatation
P07582592A0545|109 111|LES
P07582592A0545|137 173|intrasphincter botulinum toxin injection
P07582592A0545|151 164|botulinum toxin
P07582592A0545|190 198|achalasia
P07583190A0306|5 28|early structural processes
P07583190A0306|57 69|anterior parts
P07583190A0306|75 88|left hemisphere
P07583190A0306|92 119|event-related brain potentials
P07583190A0306|158 182|phrase structure violations
P07583190A0306|200 219|circumscribed lesions
P07583190A0306|226 233|area lead
P07583190A0306|238 247|impairment
P07583190A0306|253 279|on-line structural assignment
P07583562A1826|2 4|men
P07583562A1826|9 11|BMI
P07583562A1826|19 20|OR
P07583562A1826|31 44|postprandial TG
P07583562A1826|46 47|P =
P07583562A1826|63 76|postprandial RP
P07583562A1826|78 79|P =
P07583562A1826|87 92|models
P07583562A1826|105 113|fasting TG
P07583562A1826|115 119|LDL-C
P07583562A1826|124 135|hypertension
P07585246T0000|0 16|SL1 trans-splicing
P07585246T0000|0 2|SL1
P07585246T0000|28 46|AU-rich synthetic RNA
P07585246T0000|67 95|Caenorhabditis elegans pre-mRNA
P07585559A0000|1 26|pyrazolo-quinoline compound
P07585559A0000|28 38|6-methoxy-4
P07585559A0000|45 60|2-hydroxyethoxyl
P07585559A0000|63 67|ethyl
P07585559A0000|69 73|amino
P07585559A0000|78 95|methyl-1M-pyrazo lo
P07585559A0000|97 101|3,4-b
P07585559A0000|103 111|quinoline
P07585559A0000|113 115|SCH
P07585559A0000|164 207|human smooth muscle alpha-actin promoter activity
P07585559A0000|210 229|ras-transformed cells
P07585559A0000|210 212|ras
P07586403A0765|17 25|relations
P07586403A0765|28 52|risk factor-selection scale
P07586403A0765|54 57|RFSS
P07586403A0765|95 112|appropriate weights
P07586403A0765|120 129|risk factor
P07588240A0000|3 46|Caenorhabditis elegans death susceptibility gene
P07588240A0000|48 52|ced-3
P07588240A0000|66 73|homologs
P07588240A0000|76 92|vertebrate species
P07588240A0000|103 119|interleukin-1 beta
P07588240A0000|121 146|IL-1 beta)-converting enzyme
P07588240A0000|121 128|IL-1 beta
P07588240A0000|141 146|enzyme
P07588240A0000|148 150|ICE
P07588240A0000|153 161|Ich-1long
P07588240A0000|166 170|CPP32
P07588245T0000|0 9|Repression
P07588245T0000|12 67|glucocorticoid receptor-mediated transcriptional activation
P07588245T0000|12 33|glucocorticoid receptor
P07588245T0000|70 101|unliganded thyroid hormone receptor
P07588245T0000|80 101|thyroid hormone receptor
P07588245T0000|103 104|TR
P07588245T0000|108 125|TR isoform-specific
P07588603A1054|3 9|results
P07588603A1054|18 40|considerable flexibility
P07588603A1054|46 52|spacing
P07588603A1054|60 76|DH regulatory sites
P07588608A1687|0 10|Obstruction
P07588608A1687|16 35|ERF repressor function
P07588608A1687|16 27|ERF repressor
P07588608A1687|56 62|members
P07588608A1687|68 83|ets family of genes
P07588608A1687|68 76|ets family
P07588608A1687|79 83|genes
P07588608A1687|85 99|i.e.gag-myb-ets
P07588608A1687|130 134|genes
P07588608A1687|145 161|cell proliferation
P07588608A1687|185 202|tumorigenic effects
P07588628A0318|0 13|Overexpression
P07588628A0318|16 27|wild-type p53
P07588628A0318|39 47|apoptosis
P07588628A0318|52 54|LCL
P07588633A0362|10 14|c-Fos
P07588633A0362|19 43|c-fos protooncogene product
P07588633A0362|68 89|unstable nuclear protein
P07588633A0362|168 178|NIH 3T3 cells
P07588633A0362|182 184|Mos
P07588750T0061|0 6|Cloning
P07588750T0061|8 17|sequencing
P07588750T0061|36 63|3-phosphoglycerate kinase gene
P07588750T0061|66 81|Pyrococcus woesei
P07588750T0061|102 117|characterization
P07588777A1524|5 16|observations
P07588777A1524|41 44|RNAP
P07588777A1524|47 49|CTD
P07588777A1524|86 92|p42mapk
P07588777A1524|96 112|p44mapk MAP kinases
P07589069A1245|37 41|forms
P07589069A1245|44 55|human CD6 cDNA
P07589069A1245|63 71|sequences
P07589069A1245|80 103|membrane-proximal regions
P07589069A1245|109 125|cytoplasmic domain
P07589069A1245|142 157|same reading frame
P07589069A1245|160 166|CD6-PB1
P07589069A1245|160 162|CD6
P07589069A1245|164 166|PB1
P07590264A0373|26 40|such differences
P07590264A0373|43 57|polyadenylation
P07590264A0373|67 84|steady-state levels
P07590264A0373|87 90|DHFR
P07590264A0373|94 98|mRNAs
P07590264A0373|118 123|allele
P07590264A0373|135 146|general sense
P07590264A0373|160 170|differences
P07590264A0373|175 190|end RNA processing
P07590264A0373|208 219|multiple poly
P07590264A0373|221 221|A
P07590264A0373|223 227|sites
P07590264A0373|238 247|final level
P07590264A0373|250 263|gene expression
P07590268A0350|38 39|Dm
P07590268A0350|41 44|cDNA
P07590268A0350|54 64|polypeptide
P07590268A0350|72 98|extensive sequence similarity
P07590268A0350|104 121|mammalian MAPKAPK-2
P07590268A0740|1 22|2.4-kb MAPKAPK-2 message
P07590268A0740|64 81|shorter transcripts
P07590268A0740|93 94|kb
P07590268A0740|131 138|germline
P07590283A0820|17 27|chimeric TdT
P07590283A0820|30 43|Pol beta protein
P07590283A0820|53 99|significant template-dependent polymerase activity
P07590283A0820|112 113|aa
P07590283A0820|120 126|Pol beta
P07590283A0820|140 158|template utilization
P07590283A0820|168 189|polymerization reaction
P07590283A0820|207 221|previous finding
P07590283A0820|229 249|8-kDa N-terminal domain
P07590283A0820|252 258|Pol beta
P07590283A0820|268 288|ssDNA-binding activity
P07590283A0820|290 294|Kumar
P07590283A0820|301 302|J.
P07590525A0811|3 15|average values
P07590525A0811|29 40|revertants/g
P07590525A0811|47 56|hamburgers
P07590525A0811|60 66|hot dogs
P07590657A0624|0 14|Cholangiography
P07590657A0624|32 36|cases
P07590657A0624|90 106|pediatric patients
P07590744A0829|17 28|cDNA sequence
P07590744A0829|71 83|genomic clones
P07590744A0829|95 102|GAR1 gene
P07592072A0217|2 6|Trial
P07592072A0217|31 36|farrow
P07592072A0217|47 47|d
P07592072A0217|52 53|NF
P07592072A0217|84 89|farrow
P07592072A0217|111 119|injection
P07592072A0217|122 141|prostaglandin F2 alpha
P07592072A0217|144 144|d
P07592072A0217|150 158|gestation
P07592220A0846|0 11|End-tidal PO2
P07592220A0846|25 41|minute ventilation
P07592220A0846|44 60|oxygen consumption
P07592220A0846|62 67|VE/VO2
P07592220A0846|83 88|PETCO2
P07592220A0846|92 97|higher
P07592220A0846|101 103|Hyp
P07592220A0846|105 105|P
P07592220A0846|109 109|=
P07592337A0891|5 11|results
P07592337A0891|25 28|NfxB
P07592337A0891|67 70|nfxB
P07592439A0000|0 3|A511
P07592439A0000|7 22|broad-host-range
P07592439A0000|24 39|virulent myovirus
P07592439A0000|43 63|Listeria monocytogenes
P07592467A0000|14 36|peroxisome proliferation
P07592485A0734|2 28|NCR-sensitive gene expression
P07592485A0734|52 58|pathway
P07592485A0734|95 108|NCR sensitivity
P07592485A0734|148 164|ure2 delta mutation
P07592647A0797|3 46|single-stranded DNA Pur alpha recognition element
P07592647A0797|60 68|complexes
P07592647T0000|0 10|Association
P07592647T0000|13 25|human Pur alpha
P07592647T0000|33 53|retinoblastoma protein
P07592647T0000|55 56|Rb
P07592647T0000|79 122|single-stranded DNA Pur alpha recognition element
P07592658A0309|3 35|insulin-induced DNA-binding complex
P07592658A0309|3 9|insulin
P07592658A0309|18 35|DNA-binding complex
P07592658A0309|54 71|p50/p65 heterodimer
P07592658A0309|54 56|p50
P07592658A0309|58 60|p65
P07592676A0466|12 21|conditions
P07592676A0466|28 44|distinct complexes
P07592676A0466|83 91|NIP region
P07592676A0466|122 138|repressor activity
P07592706A1465|0 7|Exchange
P07592706A1465|13 15|LPL
P07592706A1465|19 24|HL lids
P07592706A1465|19 20|HL
P07592706A1465|36 43|reversal
P07592706A1465|49 80|phospholipase/neutral lipase ratio
P07592706A1465|49 75|phospholipase/neutral lipase
P07592706A1465|97 109|important role
P07592706A1465|133 152|substrate specificity
P07592710T0000|3 38|interferon-inducible protein kinase PKR
P07592710T0000|51 75|transcriptional activation
P07592710T0000|78 100|immunoglobulin kappa gene
P07592711T0000|0 13|Truncated forms
P07592711T0000|17 33|novel yeast protein
P07592711T0000|22 33|yeast protein
P07592711T0000|45 53|lethality
P07592711T0000|57 86|G protein alpha subunit deficiency
P07592711T0000|57 76|G protein alpha subunit
P07592711T0000|107 117|beta subunit
P07592721A0827|7 20|common mutation
P07592721A0827|29 38|amino acids
P07592721A0827|59 74|specific contacts
P07592723A0814|0 12|Phorbol esters
P07592723A0814|23 37|phosphorylation
P07592723A0814|40 53|CSK 35H proteins
P07592723A0814|74 82|sequences
P07592723A0814|102 119|PKC binding activity
P07592723A0814|102 104|PKC
P07592723A0814|134 146|PKC substrates
P07592723A0814|134 136|PKC
P07592730A0204|0 5|Levels
P07592730A0204|8 20|TSG-14 protein
P07592730A0204|32 36|PTX-3
P07592730A0204|44 51|elevated
P07592730A0204|57 61|serum
P07592730A0204|64 67|mice
P07592730A0204|71 76|humans
P07592730A0204|82 90|injection
P07592730A0204|95 121|bacterial lipopolysaccharide
P07592730A0204|138 167|conventional acute phase proteins
P07592730A0204|178 192|TSG-14 synthesis
P07592730A0204|178 183|TSG-14
P07592730A0204|198 211|intact organism
P07592771A0258|3 27|mouse beta 2-syntrophin gene
P07592771A0258|32 40|kilobases
P07592771A0258|55 59|exons
P07592771A0258|75 84|homologues
P07592771A0258|90 110|corresponding position
P07592771A0258|116 136|alpha 1-syntrophin gene
P07592790A1457|29 32|PEDF
P07592790A1457|45 52|subgroup
P07592790A1457|55 74|noninhibitory serpins
P07592790A1457|68 74|serpins
P07592790A1457|85 100|N-terminal region
P07592790A1457|109 133|neurite-promoting activity
P07592946A0261|15 21|cloning
P07592946A0261|27 44|murine p44 MAP kinase
P07592946A0261|46 80|extracellular signal-regulated kinase
P07592946A0261|109 129|intron/exon boundaries
P07592946A0261|137 152|characterization
P07592946A0261|158 165|promoter
P07592946A0997|15 31|putative TATA boxes
P07592946A0997|48 67|main start sites region
P07592946A0997|72 78|AP-1 box
P07592946A0997|83 89|AP-2 box
P07592946A0997|94 100|Malt box
P07592946A0997|105 111|GAGA box
P07592946A0997|116 142|half serum-responsive element
P07592946A0997|147 166|putative binding sites
P07592946A0997|170 172|Sp1
P07592946A0997|180 199|GC-rich binding factor
P07592946A0997|207 213|CTF-NF1
P07592946A0997|220 222|Myb
P07592946A0997|229 231|p53
P07592946A0997|238 242|Ets-1
P07592946A0997|249 254|NF-IL6
P07592946A0997|261 264|MyoD
P07592946A0997|271 275|Zeste
P07592946A0997|285 309|hepatocyte nuclear factor-5
P07593266A1174|26 50|adenine-uridine rich region
P07593266A1174|64 87|11-base pair stem structure
P07593896A1053|18 40|new measurement technique
P07593896A1053|58 80|accurate P0.1 measurement
P07593896A1053|86 113|standard respiratory equipment
P07593896A1053|127 135|lung model
P07594047T0000|0 6|Effects
P07594047T0000|9 17|verapamil
P07594047T0000|21 31|propranolol
P07594047T0000|34 58|early afterdepolarizations
P07594047T0000|62 83|ventricular arrhythmias
P07594047T0000|93 103|epinephrine
P07594047T0000|106 129|congenital long QT syndrome
P07594592A0755|0 7|Deletion
P07594592A0755|13 41|NF-IL6 beta leucine zipper domain
P07594592A0755|92 99|proteins
P07595221A0733|5 9|cells
P07595221A0733|35 39|CIITA
P07595221A0733|41 58|endogenous MHC class
P07595221A0733|51 65|MHC class II genes
P07595221A0733|61 65|genes
P07595221A0733|97 115|MHC class II promoters
P07595221A0733|97 104|MHC class
P07595221A0733|107 115|promoters
P07595221A0733|128 139|transfection
P07595221A0733|166 186|CIITA-expressing cells
P07595221A0733|166 170|CIITA
P07595374A1215|3 9|domains
P07595374A1215|12 16|EBNA2
P07595374A1215|26 33|deletion
P07595374A1215|36 45|amino acids
P07595374A1215|91 100|activation
P07595374A1215|107 115|promoters
P07595374A1215|125 140|different domains
P07595374A1215|156 163|residues
P07595374A1215|202 213|LMP1 promoter
P07595857A0521|3 16|peak velocities
P07595857A0521|22 40|atrial systolic waves
P07595857A0521|46 56|transmitral
P07595857A0521|60 88|pulmonary venous flow velocities
P07595857A0521|90 90|A
P07595857A0521|94 96|PVA
P07595857A0521|114 130|first systolic wave
P07595857A0521|132 135|PVS1
P07595857A0521|139 157|pulmonary venous flow
P07595857A0521|159 167|durations
P07595857A0521|174 192|atrial systolic waves
P07595857A0521|197 205|amplitude
P07595857A0521|208 230|interatrial septal motion
P07595857A0521|237 249|atrial systole
P07595857A0521|275 278|days
P07595857A0521|284 296|cardioversion
P07595857A0521|334 346|cardioversion
P07595857A0521|352 359|patients
P07595857A0521|370 377|patients
P07595857A0521|382 402|dilated cardiomyopathy
P07596283A0396|16 21|enzyme
P07596283A0396|42 58|triglycerides such
P07596283A0396|61 68|olive oil
P07596283A0396|72 81|tributyrin
P07596283A0396|92 108|egg-yolk emulsions
P07596287A0183|3 20|nucleotide sequence
P07596287A0183|29 36|upstream
P07596287A0183|39 42|fimA
P07596287A0183|54 70|open reading frames
P07596287A0183|72 75|ORF5
P07596287A0183|79 82|ORF1
P07596287A0183|96 110|protein products
P07596287A0183|114 123|homologous
P07596287A0183|126 132|members
P07596287A0183|136 146|superfamily
P07596287A0183|149 192|ATP-binding cassette membrane transport proteins
P07596287A0183|207 217|prokaryotic
P07596287A0183|221 236|eukaryotic uptake
P07596287A0183|240 252|export systems
P07596287A1724|3 11|ORF3 probe
P07596287A1724|32 53|bp transcript consistent
P07596287A1724|67 70|ORF3
P07596287A1724|94 108|mutagenesis data
P07596287A1724|111 121|non-linkage
P07596558A0824|5 11|results
P07596558A0824|23 39|low concentrations
P07596558A0824|42 49|IL-1 beta
P07596558A0824|64 83|nonsurgical treatment
P07596558A0824|86 108|human vitreous hemorrhage
P07596697A0971|14 34|pancreatic polypeptide
P07596697A0971|38 53|motilin responses
P07596697A0971|38 44|motilin
P07596697A0971|75 92|encopretic children
P07596697A0971|99 106|children
P07596697A0971|112 123|control group
P07597030A0260|15 21|cloning
P07597030A0260|37 63|biochemical characterization
P07597030A0260|69 81|32-kDa subunit
P07597030A0260|90 90|h
P07597030A0260|92 96|TFIID
P07597030A0260|104 111|hTAFII32
P07597488T0000|0 19|Hemolytic jaundice due
P07597488T0000|22 35|G6PD deficiency
P07597488T0000|22 25|G6PD
P07597488T0000|43 53|kernicterus
P07597488T0000|57 69|female newborn
P07597804A1007|3 13|transcripts
P07597804A1007|19 20|kb
P07597804A1007|27 28|kb
P07597804A1007|34 43|coterminal
P07597804A1007|63 87|novel glycoprotein gene EUS4
P07597804A1007|68 87|glycoprotein gene EUS4
P07598106A0709|0 16|Mean growth changes
P07598106A0709|23 27|Class
P07598106A0709|78 89|male subjects
P07598106A0709|94 98|Class
P07598106A0709|100 112|malocclusions
P07598106A0709|120 132|same age period
P07598106A0709|157 179|postpubertal development
P07598106A0709|195 200|groups
P07598303A1728|11 20|few studies
P07598303A1728|32 55|antimicrobial prophylaxis
P07598303A1728|58 82|bone marrow transplantation
P07598303A1728|102 116|survival benefit
P07599449A0445|3 16|fracture groups
P07599449A0445|34 38|older
P07599449A0445|49 53|years
P07599449A0445|59 67|menopause
P07599449A0445|75 87|control groups
P07599653A0898|18 28|differences
P07599653A0898|34 40|binding
P07599653A0898|43 56|nuclear factors
P07599653A0898|61 66|shoots
P07599653A0898|77 81|roots
P07599653A0898|101 119|different activities
P07599653A0898|125 132|promoter
P07599653A0898|143 148|organs
P07600111A0000|3 12|prevalence
P07600111A0000|16 24|incidence
P07600111A0000|27 57|human immunodeficiency virus types
P07600111A0000|64 68|HIV-1
P07600111A0000|70 74|HIV-2
P07600111A0000|77 105|human T-lymphotropic virus types
P07600111A0000|113 121|HTLV-I/II
P07600111A0000|127 146|syphilitic infections
P07600111A0000|176 185|infections
P07600111A0000|203 208|cohort
P07600111A0000|211 224|police officers
P07600111A0000|227 239|Guinea-Bissau
P07600986A0605|9 28|immunoprecipitations
P07600986A0605|32 45|gel shift assays
P07600986A0605|62 68|classes
P07600986A0605|71 112|high affinity Engrailed-binding sites upstream
P07600986A0605|83 91|Engrailed
P07600986A0605|127 156|polyhomeotic transcription units
P07601078A1003|0 7|Subjects
P07601078A1003|13 33|short postexposure time
P07601078A1003|38 49|dioxin burden
P07601078A1003|54 58|pg/m3
P07601078A1003|76 85|higher risk
P07601078A1003|88 95|hypoergy
P07601078A1003|100 116|unexposed subjects
P07601078A1003|118 126|hypoergy I
P07601078A1003|128 130|OR =
P07601078A1003|138 141|% CI =
P07601078A1003|153 160|hypoergy
P07601078A1003|164 166|OR =
P07601078A1003|174 177|% CI =
P07601121A0153|0 7|Analysis
P07601121A0153|65 78|flanking region
P07601121A0153|87 94|proximal
P07601121A0153|107 119|transcription
P07601121A0153|128 161|several putative regulatory sequences
P07601445A0207|16 37|BAT1 translation product
P07601445A0207|43 49|homolog
P07601445A0207|55 74|rat p47 nuclear protein
P07601445A0207|79 102|WM6 Drosophila gene product
P07601445A0207|119 125|Ce08102
P07601445A0207|128 148|Caenorhabditis elegans
P07601445A0207|153 159|members
P07601445A0207|165 181|DEAD protein family
P07601445A0207|184 208|ATP-dependent RNA helicases
P07601827A0778|7 17|lacZ fusions
P07601827A0778|45 56|DNA sequences
P07601827A0778|74 90|nitrate repression
P07601827A0778|96 123|pfl promoter-regulatory region
P07601828A0095|26 41|characterization
P07601828A0095|47 72|early class II flagellar genes
P07601828A0095|47 56|early class
P07601828A0095|59 72|flagellar genes
P07601828A0095|87 100|orfX-fliP locus
P07601828A0095|92 95|fliP
P07603726T0000|0 28|Vestibular adaptation exercises
P07603726T0000|41 50|acute stage
P07603726T0000|56 79|acoustic neuroma resection
P07603956A0115|3 20|experimental design
P07603956A0115|35 54|factorial arrangement
P07603956A0115|57 66|treatments
P07603956A0115|76 88|dietary levels
P07603956A0115|91 103|incorporation
P07603956A0115|106 108|RSB
P07603956A0115|121 121|%
P07603956A0115|127 134|chickens
P07603956A0115|141 148|infected
P07603956A0115|151 160|uninfected
P07604047A0704|1 9|cDNA clone
P07604047A0704|28 62|putative GA 20-oxidase genomic sequence
P07604047A0704|84 113|reverse transcription-PCR method
P07604047A0704|134 142|cDNA clone
P07604047A0704|184 196|fusion protein
P07604047A0704|232 235|GA53
P07604047A0704|238 241|GA44
P07604047A0704|245 248|GA19
P07604047A0704|251 254|GA20
P07604783A0952|11 28|significant changes
P07604783A0952|40 59|fatty acid composition
P07604783A0952|62 76|biliary lecithin
P07604783A0952|84 102|bile acid composition
P07604783A0952|105 108|bile
P07604794A0958|0 15|Total cholesterol
P07604794A0958|44 44|%
P07604794A0958|48 53|mg/day
P07604794A0958|62 62|%
P07604794A0958|69 74|mg/day
P07604794A0958|94 94|%
P07604794A0958|99 99|=
P07604794A0958|102 107|mg/day
P07604794A0958|116 116|%
P07604794A0958|121 121|=
P07604794A0958|124 129|mg/day
P07605990A1110|8 21|further studies
P07605990A1110|47 57|precise role
P07605990A1110|60 64|PEBP2
P07605990A1110|70 91|GM-CSF promoter activity
P07605990A1110|96 110|present findings
P07605990A1110|138 150|relative ratio
P07605990A1110|153 174|different PEBP2 isoforms
P07605990A1110|162 174|PEBP2 isoforms
P07605990A1110|190 195|levels
P07605990A1110|201 216|promoter activity
P07606548T0000|0 7|Benefits
P07606548T0000|19 36|board certification
P07606548T0000|39 53|pharmacotherapy
P07606587A0266|0 22|Piperacillin-tazobactam
P07606587A0266|49 58|infections
P07606587A0266|67 79|gram-negative
P07606587A0266|81 93|gram-positive
P07606587A0266|95 101|aerobic
P07606587A0266|106 122|anaerobic bacteria
P07607197A1048|0 23|Basal plasma renin activity
P07607197A1048|11 15|renin
P07607197A1048|25 27|PRA
P07607197A1048|62 62|P
P07607197A1048|82 89|controls
P07607197A1048|93 105|post-training
P07607213A0140|14 52|anomalous structure/activity relationship
P07607213A0140|59 73|important issues
P07607213A0140|104 121|regulatory peptides
P07607213A0140|128 137|mechanisms
P07607233A0186|3 16|structural gene
P07607233A0186|28 54|novel lantibiotic epilancin K7
P07607233A0186|44 54|epilancin K7
P07607233A0186|84 85|K7
P07607233A0186|101 118|nucleotide sequence
P07607342A0703|22 41|experimental evidence
P07607342A0703|54 67|clinical trials
P07607342A0703|70 94|aldose reductase inhibitors
P07607342A0703|70 84|aldose reductase
P07607342A0703|97 112|diabetic patients
P07607342A0703|136 142|results
P07607342A0703|154 163|drug trials
P07607342A0703|171 178|patients
P07607537A0954|13 22|phenotypes
P07607537A0954|36 44|mutations
P07607537A0954|71 79|mutations
P07607537A0954|85 91|adaptor
P07607537A0954|98 117|VP16 activation domain
P07607537A0954|98 101|VP16
P07607607T0000|0 7|Increase
P07607607T0000|10 23|urinary calcium
P07607607T0000|27 33|oxalate
P07607607T0000|39 54|fructose infusion
P07607669A1112|5 18|flanking region
P07607669A1112|27 32|GC rich
P07607669A1112|38 56|multiple CpG doublets
P07607669A1112|69 88|multiple binding sites
P07607669A1112|92 94|Sp1
P07608268A0194|21 29|disorders
P07608268A0194|32 45|GnRH deficiency
P07608268A0194|32 35|GnRH
P07608268A0194|63 95|altered melatonin secretion profiles
P07608268A0194|107 128|untreated young males IGD
P07608268A0194|130 131|n =
P07608268A0194|137 138|DP
P07608268A0194|140 141|n =
P07608268A0194|146 171|normal pubertal male controls
P07608268A0194|173 174|n =
P07608649A1429|9 21|blood pressure
P07608649A1429|28 39|CyA treatment
P07608649A1429|67 76|ET-1 levels
P07608649A1429|67 70|ET-1
P07608968A0836|0 7|Analysis
P07608968A0836|10 26|several Tat mutants
P07608968A0836|17 26|Tat mutants
P07608968A0836|47 59|cysteine-rich
P07608968A0836|66 76|core domains
P07608968A0836|83 96|transactivator
P07608968A0836|132 144|transcription
P07608968A0836|149 151|TBP
P07609037A0775|11 19|depletion
P07609037A0775|22 26|Oct-1
P07609037A0775|34 47|nuclear extract
P07609037A0775|55 77|Oct-1-specific antiserum
P07609037A0775|55 59|Oct-1
P07609037A0775|81 113|sequence-specific DNA affinity resin
P07609037A0775|130 142|transcription
P07609037A0775|150 170|wild-type MMTV promoter
P07609037A0775|174 187|level identical
P07609037A0775|207 214|promoter
P07609037A0775|230 253|octamer-related sequences
P07609079A0387|0 14|Transactivation
P07609079A0387|20 27|HIV-1 LTR
P07609079A0387|30 37|T3R alpha
P07609079A0387|41 62|several receptor mutants
P07609079A0387|78 109|50-amino-acid N-terminal A/B region
P07609079A0387|112 119|T3R alpha
P07609079A0387|143 171|basal transcription factor TFIIB
P07609079A0387|186 195|activation
P07609079A0387|202 214|Tat-dependent
P07609079A0387|202 204|Tat
P07609079A0387|218 251|Tat-independent responsive sequences
P07609079A0387|218 220|Tat
P07609079A0387|257 259|LTR
P07609372A0261|0 5|M.M.C.
P07609372A0261|19 25|minutes
P07609372A0261|30 34|cases
P07609372A0261|38 47|HR patients
P07609372A0261|51 60|LR patients
P07609372A0261|70 76|minutes
P07609372A0261|81 85|cases
P07609372A0261|89 98|HR patients
P07609372A0261|102 111|LR patients
P07610052A1064|18 33|complexes similar
P07610052A1064|39 41|C25
P07610052A1064|43 45|C30
P07610052A1064|49 60|C35 complexes
P07610052A1064|72 95|rat cortex nuclear extracts
P07610052A1064|102 111|SAA element
P07610052A1064|114 128|EMSA experiments
P07610052A1064|143 151|relevance
P07610052A1064|164 175|observations
P07610052A1064|187 197|functioning
P07610052A1064|203 216|rat APP promoter
P07610324A0319|0 10|Oncological
P07610324A0319|23 42|psychological aspects
P07610324A0319|89 99|recent years
P07610324A0319|124 137|reconstruction
P07610324A0319|176 182|centers
P07610716A0117|16 31|prevalence values
P07610716A0117|51 68|global MS-frequency
P07610716A0117|89 99|geomagnetic
P07610716A0117|109 126|geographic latitude
P07610735A1471|0 8|Diltiazem
P07610735A1471|15 33|significant decrease
P07610735A1471|39 57|ventricular response
P07610735A1471|77 87|sinus rhythm
P07612174A1064|0 15|Subhuman primates
P07612174A1064|41 52|reproductive
P07612174A1064|56 74|other adverse effects
P07612174A1064|77 80|PCBs
P07612174A1064|85 90|humans
P07612557A0635|13 20|children
P07612557A0635|25 30|ocular
P07612557A0635|34 50|cerebral pathology
P07612557A0635|61 65|pairs
P07612557A0635|68 76|premature
P07612557A0635|80 94|control children
P07614762A0224|3 25|cryptococcal antigen test
P07614762A0224|46 63|latex agglutination
P07615541T0000|0 17|Functional analysis
P07615541T0000|20 45|DNase-I hypersensitive sites
P07615541T0000|51 88|mouse porphobilinogen deaminase gene locus
P07615634A0535|5 15|transcripts
P07615634A0535|29 46|untranslated region
P07615634A0535|50 69|NH2-terminal sequence
P07615634A0535|101 102|kD
P07616056A0278|4 5|mu
P07616056A0278|9 30|gamma 2b heavy chain genes
P07616056A0278|40 57|feedback inhibition
P07616056A0278|60 86|heavy chain gene rearrangement
P07616056A0278|60 73|heavy chain gene
P07616563A0532|8 11|CarP
P07616563A0532|29 46|carAB control region
P07616563A0532|65 70|DNase I
P07616563A0532|65 69|DNase
P07616563A0532|89 103|bp long stretches
P07616563A0532|117 123|located
P07616563A0532|143 154|GATC sequence
P07616569A0168|11 15|genes
P07616569A0168|29 36|subunits
P07616569A0168|42 58|cytochrome oxidase
P07616569A0168|60 63|cox1
P07616569A0168|69 82|apocytochrome b
P07616569A0168|84 86|cob
P07616569A0168|94 101|subunits
P07616569A0168|107 130|NADH dehydrogenase complex
P07616569A0168|132 135|nad1
P07616569A0168|140 144|nad4L
P07616569A0168|150 163|ATPase subunits
P07616569A0168|165 168|atp6
P07616569A0168|172 175|atp9
P07616569A0168|183 195|ribosomal RNAs
P07616569A0168|197 200|rrn5
P07616569A0168|202 204|srn
P07616569A0168|208 210|lrn
P07616569A0168|215 219|tRNAs
P07616569A0168|227 243|ribosomal proteins
P07616569A0168|245 248|rps3
P07616569A0168|250 254|rps11
P07616569A0168|256 260|rps12
P07616569A0168|264 268|rpl16
P07616802A0315|11 29|significant increase
P07616802A0315|32 44|platelet count
P07616802A0315|71 78|patients
P07616802A0315|90 96|heparin
P07616802A0315|98 98|p
P07616802A0315|121 132|initial value
P07616802A0315|138 153|heparin cessation
P07616802A0315|164 173|responders
P07618280A0550|6 22|nucleocapsid-like
P07618280A0550|24 33|structures
P07618280A0550|55 83|density gradient centrifugation
P07618548T0000|3 23|Babcock Surgical Clinic
P07620491T0000|0 8|Resources
P07620491T0000|19 26|patients
P07620491T0000|33 39|smoking
P07622058A0411|3 20|PEBP2 alpha proteins
P07622058A0411|29 42|128-amino-acid
P07622058A0411|44 45|aa
P07622058A0411|59 68|homologous
P07622058A0411|96 115|segmentation gene runt
P07622060A0967|2 24|human proliferative cells
P07622060A0967|29 52|NADP-dependent ME activity
P07622060A0967|29 44|NADP-dependent ME
P07622060A0967|79 87|inducible
P07622060A0967|90 104|thyroid hormones
P07622521A0418|7 21|previous mapping
P07622521A0418|27 49|G beta gamma binding region
P07622521A0418|52 58|beta ARK
P07622521A0418|72 79|residues
P07622521A0418|89 96|PH domain
P07622521A0418|124 130|mutants
P07622521A0418|136 151|carboxyl terminus
P07622521A0418|154 160|beta ARK
P07622521A0418|179 195|important residues
P07622521A0418|206 215|G beta gamma
P07622521A0418|219 229|PIP2 binding
P07622932T0000|0 24|Histopathological features
P07622932T0000|27 41|relapsed leprosy
P07623807A0162|14 23|mechanisms
P07623807A0162|25 33|wild-type
P07623807A0162|37 55|mutant Raf-1 proteins
P07623807A0162|96 110|plasma membranes
P07623807A0162|115 119|v-Ras
P07623807A0162|124 145|v-Src-transformed cells
P07623807A0162|124 128|v-Src
P07623807A0162|158 166|membranes
P07623814A1040|2 10|CV-1 cells
P07623814A1040|12 25|cotransfection
P07623814A1040|31 38|retinoid
P07623814A1040|42 58|estrogen receptors
P07623814A1040|64 79|mutual inhibition
P07623814A1040|108 129|RA-dependent inhibition
P07623814A1040|132 141|ER activity
P07623814A1040|132 133|ER
P07623814A1040|155 171|breast cancer cells
P07623821A0649|10 16|factors
P07623821A0649|18 22|HRF-1
P07623821A0649|35 44|cis element
P07623821A0649|59 82|inverted palindromic motif
P07623821T0000|0 9|Regulation
P07623821T0000|12 39|Gax homeobox gene transcription
P07623821T0000|12 26|Gax homeobox gene
P07623821T0000|56 70|positive factors
P07623821T0000|80 110|myocyte-specific enhancer factor 2
P07623821T0000|80 109|myocyte-specific enhancer factor
P07623825T0000|3 40|carboxyl-terminal transactivation domain
P07623825T0000|43 58|heat shock factor 1
P07623825T0000|43 57|heat shock factor
P07623825T0000|83 98|stress responsive
P07623838A1112|0 1|D.
P07623840A0352|20 46|synthetase-related sequences
P07623840A0352|49 52|GCN2
P07623840A0352|78 83|kinase
P07623840A0352|109 121|uncharged tRNA
P07623840A0352|143 161|amino acid limitation
P07623844A0639|14 18|Bcl-2
P07623844A0639|25 38|E1B 19K proteins
P07623844A0639|60 68|apoptosis
P07623844A0639|75 99|p53-dependent growth arrest
P07623844A0639|75 77|p53
P07623844A0639|101 115|H-ras expression
P07623844A0639|101 105|H-ras
P07623844A0639|125 136|DNA synthesis
P07623844A0639|140 156|cell proliferation
P07623844A0639|172 181|high levels
P07623844A0639|184 195|wild-type p53
P07624119A0528|12 15|PAX3
P07624119A0528|19 57|putative PAX3-FKHR transactivation domains
P07624119A0528|27 30|PAX3
P07624119A0528|66 88|C-terminal test fragments
P07624119A0528|94 126|heterologous GAL4 DNA-binding domain
P07624119A0528|106 126|GAL4 DNA-binding domain
P07624119A0528|136 145|activation
P07624119A0528|149 160|reporter gene
P07624119A0528|183 191|cell types
P07624581A0312|3 10|subjects
P07624581A0312|26 28|ECG
P07624581A0312|32 65|arterial blood pressure determination
P07624581A0312|83 85|TSH
P07624581A0312|87 100|thyroid hormone
P07624581A0312|102 104|PRL
P07624581A0312|106 112|glucose
P07624581A0312|114 123|creatinine
P07624581A0312|125 132|nitrogen
P07624581A0312|134 154|glutamine transaminase
P07624581A0312|170 194|triglycerides plasma levels
P07624581A0312|209 210|T0
P07624581A0312|220 232|treatment days
P07624581A0312|234 236|T30
P07624581A0312|249 259|days washout
P07624581A0312|261 263|T45
P07624615A0267|0 12|Acute decrease
P07624615A0267|15 29|body temperature
P07624615A0267|31 32|TB
P07624615A0267|41 45|PaCO2
P07624615A0267|57 60|mmHg
P07624615A0267|66 69|HCO3
P07624615A0267|79 83|mEq/L
P07624615A0267|91 95|mEq/L
P07624615A0267|107 109|pHa
P07624615A0267|141 142|OH
P07624615A0267|147 147|H
P07624615A0267|164 180|significant effect
P07624615A0267|184 186|SID
P07624615A0267|191 194|Atot
P07624615A0267|209 223|total phosphorus
P07624615A0267|225 226|PT
P07624615A0267|231 248|inorganic phosphate
P07624615A0267|250 251|Pi
P07626378T0000|0 16|Hepatitis B vaccine
P07626378T0000|29 36|problems
P07626469A1341|0 20|Basal promoter activity
P07626469A1341|34 51|functional M1 domain
P07626469A1341|54 88|LHR-expressing mouse Leydig tumor cells
P07626469A1341|90 93|MLTC
P07626469A1341|103 124|non-expressing CHO cells
P07626806A1098|3 10|RAT3 gene
P07626806A1098|20 40|1157-amino acid protein
P07626806A1098|60 77|other known proteins
P07627317A1502|3 4|Al
P07627317A1502|23 27|mg/m3
P07627317A1502|57 76|urinary concentration
P07627317A1502|100 120|microgram/g creatinine
P07628389A0145|0 24|Tumor necrosis factor-alpha
P07628389A0145|26 33|TNF alpha
P07628389A0145|37 59|proinflammatory cytokine
P07628389A0145|69 105|cAMP-stimulated testosterone production
P07628389A0145|108 123|mouse Leydig cells
P07628438T0000|3 34|Drosophila insulin receptor homolog
P07628438T0000|13 34|insulin receptor homolog
P07628438T0000|37 49|gene essential
P07628438T0000|53 72|embryonic development
P07628438T0000|83 98|receptor isoforms
P07628438T0000|103 129|different signaling potential
P07628451A0114|14 15|RA
P07628451A0114|19 21|E1A
P07628451A0114|28 42|phosphorylation
P07628451A0114|48 74|E1A-associated 300 kDa protein
P07628451A0114|48 61|E1A-associated
P07628451A0114|65 74|kDa protein
P07628451A0114|76 79|p300
P07628451A0114|90 104|differentiation
P07628451A0114|107 113|F9 cells
P07628456A0000|3 33|double-stranded RNA binding domain
P07628456A0000|35 39|dsRBD
P07628456A0000|60 73|amino acid motif
P07628456A0000|97 104|proteins
P07628456A0000|121 135|double-stranded
P07628456A0000|137 138|ds
P07628456A0000|140 142|RNA
P07628456A0000|150 172|Escherichia coli RNase III
P07628456A0000|165 169|RNase
P07628456A0000|179 199|dsRNA-dependent kinase
P07628456A0000|201 203|PKR
P07629103T0000|0 40|CCAAT/enhancer-binding protein isoforms beta
P07629103T0000|44 48|delta
P07629103T0000|63 84|mammary epithelial cells
P07629103T0000|94 106|multiple sites
P07629103T0000|112 134|beta-casein gene promoter
P07629113A0726|0 2|SCA
P07629113A0726|6 14|resistant
P07629113A0726|17 26|inhibitors
P07629113A0726|29 34|serine
P07629113A0726|36 43|aspartyl
P07629113A0726|48 63|metalloproteases
P07629113A0726|84 99|N-ethylmaleimide
P07629122A0323|0 17|Mutational analysis
P07629122A0323|39 58|phosphorylation sites
P07629122A0323|66 69|NIMA
P07629122A0323|71 75|NIM-1
P07629122A0323|80 100|related protein kinases
P07629122A0323|115 118|NIMA
P07629123A0885|9 23|similar mutation
P07629123A0885|27 40|leucine residue
P07629123A0885|43 50|arginine
P07629123A0885|72 81|alteration
P07629123A0885|84 101|heterodimerization
P07629123A0885|103 112|DNA binding
P07629123A0885|116 140|transcriptional activation
P07629150A0155|0 9|Expression
P07629150A0155|15 25|CYP11A1 gene
P07629150A0155|39 46|hormones
P07629150A0155|54 72|adrenocorticotropin
P07629150A0155|76 93|luteinizing hormone
P07629150A0155|114 126|growth factors
P07629150A0155|145 152|promoter
P07629150A0155|163 180|regulatory elements
P07629150A0155|194 227|multiple signal transduction pathways
P07629163A0770|0 2|NH2
P07629163A0770|7 35|COOH-terminal deletion analysis
P07629163A0770|55 56|PH
P07629163A0770|60 105|putative guanine nucleotide exchange factor domains
P07629163A0770|68 105|guanine nucleotide exchange factor domains
P07629163A0770|124 136|zinc butterfly
P07629163A0770|139 149|dispensable
P07629196A0274|30 52|GTPase-deficient mutants
P07629196A0274|55 59|alpha
P07629196A0274|63 74|alpha 12Q229L
P07629196A0274|78 82|alpha
P07629196A0274|86 97|alpha 13Q226L
P07629196A0274|106 121|robust activation
P07629196A0274|127 165|Jun kinase/stress-activated protein kinase
P07629196A0274|127 135|Jun kinase
P07629196A0274|137 165|stress-activated protein kinase
P07629196A0274|167 174|JNK/SAPK
P07629196A0274|167 169|JNK
P07629196A0274|171 174|SAPK
P07629196A0274|176 182|pathway
P07630687A0010|46 63|clinical conditions
P07630687A0010|65 77|family history
P07630687A0010|84 102|catheter association
P07630687A0010|111 130|radiologic evaluation
P07630687A0010|145 164|pulmonary involvement
P07630687A0010|166 175|prevalence
P07630687A0010|178 192|antithrombin III
P07630687A0010|178 189|antithrombin
P07630687A0010|194 201|protein C
P07630687A0010|205 224|protein S deficiencies
P07630687A0010|229 247|lupus anticoagulants
P07630687A0010|250 257|children
P07630687A0010|270 284|thrombotic event
P07630934A0343|0 4|Harel
P07630934A0343|6 9|E.M.
P07631267T0001|0 11|Radiotherapy
P07631267T0001|15 30|early orchiectomy
P07631267T0001|33 57|stage D1 prostatic carcinoma
P07633444T0000|0 21|Structural organization
P07633444T0000|25 54|developmental expression pattern
P07633444T0000|60 83|mouse WD-repeat gene DMR-N9
P07633444T0000|108 129|myotonic dystrophy locus
P07633756A0690|3 21|ARX2 procedure models
P07633756A0690|25 38|recorded signal
P07633756A0690|54 60|signals
P07633756A0690|68 88|background EEG activity
P07633756A0690|102 122|autoregressive process
P07633756A0690|132 141|white noise
P07633756A0690|165 179|reference signal
P07633756A0690|191 208|average information
P07633756A0690|234 242|signal due
P07633756A0690|248 272|ocular artefact propagation
P07635140A0172|33 38|enzyme
P07635140A0172|40 44|CYP19
P07635140A0172|67 90|tissue-specific promoters
P07635140A0172|106 135|alternative-splicing mechanisms
P07635312A0692|5 15|mutagenesis
P07635312A0692|36 44|mutations
P07635312A0692|50 74|second actin-binding domain
P07635312A0692|56 74|actin-binding domain
P07635312A0692|97 109|act1 mutations
P07635312A0692|97 100|act1
P07635572A1153|0 8|CIITA mRNA
P07635572A1153|19 27|inducible
P07635572A1153|30 38|IFN-gamma
P07635572A1153|48 60|non-inducible
P07635572A1153|62 78|RB-defective lines
P07635572A1153|93 105|re-expression
P07635572A1153|108 109|RB
P07635572A1153|123 146|CIITA mRNA induction levels
P07635572A1153|123 131|CIITA mRNA
P07636179A0000|3 17|normal cell cycle
P07636179A0000|31 46|several molecules
P07636179A0000|57 82|tumor-suppressor protein pRb
P07636179A0000|87 95|G1 cyclins
P07636179A0000|100 122|cyclin-dependent kinases
P07636179A0000|132 141|inhibitors
P07636187A0585|0 9|Consistent
P07636187A0585|17 37|protein expression data
P07636187A0585|39 43|V beta
P07636187A0585|47 61|gene transcripts
P07636187A0585|80 94|transgenic lines
P07636187A0585|102 118|wild-type promoter
P07636337A0687|5 11|results
P07636337A0687|41 45|doses
P07636337A0687|48 55|hormones
P07636337A0687|62 88|expected serum estradiol level
P07636337A0687|91 93|HRT
P07636337A0687|97 109|Japanese women
P07636408T0000|0 9|Comparison
P07636408T0000|15 19|Tesla
P07636408T0000|27 68|Tesla field strength magnetic resonance imaging
P07636408T0000|79 100|morphometric evaluation
P07636408T0000|106 133|lumbar intervertebral foramina
P07636648A1229|16 37|DTaP booster vaccination
P07636648A1229|43 48|groups
P07636648A1229|74 100|serum antibody concentrations
P07636648A1229|106 113|antigens
P07636648A1229|124 137|concentrations
P07636648A1229|153 169|pertussis antigens
P07636648A1229|174 179|higher
P07636648A1229|185 203|DTaP-primed children
P07636648A1229|205 205|p
P07636962A1288|18 42|amino-terminal determinant
P07636962A1288|66 77|HSV-alpha TIF
P07636962A1288|94 126|independent amino-terminal activity
P07636962A1883b|16 22|fusions
P07636962A1883b|30 45|DNA binding domain
P07636962A1883b|48 51|GAL4
P07636962A1883b|53 64|full activity
P07636962A1883b|76 93|entire BHV-alpha TIF
P07636962A1883b|82 93|BHV-alpha TIF
P07636962A1883b|107 111|amino
P07636962A1883b|115 129|carboxyl termini
P07636984A1349|16 28|potential role
P07636984A1349|31 33|SP1
P07636984A1349|45 59|nuclear extracts
P07636984A1349|64 81|HCMV-infected cells
P07637718A0218|14 26|messenger RNAs
P07637718A0218|35 50|trans-sialidases
P07637718A0218|64 70|repeats
P07637718A0218|86 98|epimastigotes
P07637718A0218|105 112|abundant
P07637718A0218|115 129|trypomastigotes
P07638517A0000|4 6|May
P07638517A0000|24 33|necropsies
P07638517A0000|52 69|Sao Paulo City Morgue
P07638517A0000|72 79|cadavers
P07638517A0000|82 103|individuals AIDS victims
P07638517A0000|109 123|unnatural deaths
P07638517A0000|135 154|police investigations
P07639106A0678|34 40|best fit
P07639106A0678|44 48|TBBMD
P07639106A0678|89 95|best fit
P07639106A0678|99 112|total body TBBMC
P07639703A1703|2 13|retinoic acid
P07639703A1703|17 30|thyroid hormone
P07639703A1703|54 85|developmental regulatory processes
P07639703A1703|142 165|islet cell differentiation
P07640309A0000|3 28|C-terminal peptide sequences
P07640309A0000|34 74|human lymphocyte-specific high mobility group
P07640309A0000|76 78|HMG
P07640309A0000|81 107|box transcription factor TCF-1
P07640309A0000|123 149|alternative splice mechanisms
P07640309A0000|162 166|exons
P07640309A0000|173 174|X.
P07640422A0649|0 12|Thromboxane B2
P07640422A0649|44 48|pg/ml
P07640422A0649|69 74|higher
P07640422A0649|81 103|heparin free hemodialysis
P07640422A0649|114 125|hemodialysis
P07640422A0649|130 136|heparin
P07640422A0649|138 139|p =
P07640422A0649|145 152|Wilcoxon
P07640422A0649|160 164|pairs
P07640422A0649|171 178|rank test
P07642490A0318|1 9|new vector
P07642490A0318|11 17|pHBK280
P07642538A0138|23 35|RSK activation
P07642538A0138|23 25|RSK
P07642538A0138|44 55|human RSK cDNA
P07642538A0138|49 55|RSK cDNA
P07642538A0138|57 60|RSK3
P07642538A0138|94 123|several site-directed RSK mutants
P07642538A0138|114 123|RSK mutants
P07642538A0138|125 128|K91A
P07642538A0138|130 134|N-Lys
P07642538A0138|136 164|NH2-terminal ATP-binding mutant
P07642538A0138|167 171|K444A
P07642538A0138|173 177|C-Lys
P07642538A0138|179 208|COOH-terminal ATP-binding mutant
P07642538A0138|211 217|N/C-Lys
P07642538A0138|219 241|double ATP-binding mutant
P07642538A0138|243 247|T570A
P07642538A0138|249 253|C-Thr
P07642538A0138|255 260|mutant
P07642538A0138|266 296|putative MAPK phosphorylation site
P07642538A0138|274 277|MAPK
P07642538A0138|299 311|subdomain VIII
P07642538A0138|317 324|C-domain
P07642538A0138|327 331|S218A
P07642538A0138|333 337|N-Ser
P07642538A0138|339 344|mutant
P07642538A0138|350 381|corresponding NH2-terminal residue
P07642538A0744|15 19|C-Lys
P07642538A0744|23 27|C-Thr
P07642538A0744|36 45|high levels
P07642538A0744|48 61|kinase activity
P07642538A0744|90 100|stimulation
P07642544A0868|22 78|human protein-tyrosine phosphatase alpha-overexpressing cells
P07642544A0868|22 58|human protein-tyrosine phosphatase alpha
P07642544A0868|83 99|phenylarsine oxide
P07642544A0868|115 143|constitutive NF-kappa B activity
P07642544A0868|127 135|NF-kappa B
P07642633T0000|1 17|TATA-less promoter
P07642633T0000|28 39|binding sites
P07642633T0000|43 72|ubiquitous transcription factors
P07642633T0000|81 107|cell type-specific regulation
P07642633T0000|120 148|transcription enhancer factor-1
P07642633T0000|150 154|TEF-1
P07644127A0000|5 25|electrical stimulation
P07644127A0000|28 35|neurones
P07644127A0000|54 63|cell bodies
P07644127A0000|71 84|neuronal fibres
P07644127A0000|118 152|cholinergic neurochemical stimulation
P07644127A0000|158 180|rat substantia innominata
P07644127A0000|182 183|SI
P07644127A0000|190 208|local microinjection
P07644127A0000|211 219|carbachol
P07644127A0000|224 230|effects
P07644127A0000|237 256|acetylcholine agonist
P07644127A0000|273 281|glutamate
P07644466A0578|23 27|assay
P07644466A0578|36 52|NS3-4A polyprotein
P07644466A0578|54 56|NS3
P07644466A0578|61 82|serine proteinase domain
P07644466A0578|87 96|N-terminal
P07644466A0578|100 107|residues
P07644466A0578|110 112|NS3
P07644466A0578|121 132|NS4A cofactor
P07644466A0578|147 166|cell-free translation
P07644466A0578|179 194|trans-processing
P07644466A0578|209 218|substrates
P07644503A0729|11 25|over-expression
P07644503A0729|28 34|RAR beta
P07644503A0729|53 67|differentiation
P07644503A0729|91 98|RAR gamma
P07644503A0729|105 114|activation
P07644503A0729|117 127|target genes
P07646439A0535|14 21|proteins
P07646439A0535|26 47|human platelet membranes
P07646439A0535|53 80|DEAE-Sepharose chromatography
P07646439A0535|91 118|mAb F11 affinity chromatography
P07646439A0535|91 96|mAb F11
P07647303T0000|3 18|homeobox gene ATK1
P07647303T0000|21 39|Arabidopsis thaliana
P07647303T0000|56 64|shoot apex
P07647303T0000|70 77|seedling
P07647303T0000|83 89|flowers
P07647303T0000|93 105|inflorescence
P07647303T0000|113 124|mature plants
P07647570A0713|7 23|likely explanation
P07647570A0713|68 79|Kupffer cells
P07647570A0713|83 93|renal cortex
P07647570A0713|102 106|cells
P07647570A0713|119 133|Type I deiodinase
P07647570A0713|119 122|Type
P07647570A0713|124 133|deiodinase
P07648338A0815|5 11|results
P07648338A0815|23 37|different models
P07648338A0815|40 57|intestinal ischemia
P07648338A0815|62 86|different cytokine profiles
P07648338A0815|97 112|early TNF response
P07648338A0815|127 143|SMA occlusion model
P07648338A0815|163 172|laparotomy
P07649098A0676|27 47|principal observations
P07649098A0676|52 72|transfection construct
P07649098A0676|90 100|nucleotides
P07649098A0676|102 103|nt
P07649098A0676|107 114|promoter
P07649098A0676|122 123|nt
P07649098A0676|132 134|UTR
P07649098A0676|143 179|full PGE2-stimulated reporter expression
P07649098A0676|183 218|maximal PGE2-driven reporter expression
P07649098A0676|240 241|nt
P07649098A0676|252 255|exon
P07649098A0676|285 297|IGF-I promoter
P07649098A0676|302 315|cotransfection
P07649098A0676|318 360|IGF-I promoter-luciferase-reporter constructs
P07649098A0676|318 330|IGF-I promoter
P07649098A0676|366 372|plasmid
P07649098A0676|384 396|alpha-isoform
P07649098A0676|402 417|catalytic subunit
P07649098A0676|420 452|murine cAMP-dependent protein kinase
P07649098A0676|454 456|PKA
P07649098A0676|466 482|results comparable
P07649098A0676|498 510|PGE2 treatment
P07649098A0676|519 532|cotransfection
P07649098A0676|538 544|plasmid
P07649098A0676|554 576|mutant regulatory subunit
P07649098A0676|579 581|PKA
P07649098A0676|596 599|cAMP
P07649098A0676|607 636|PGE2-induced reporter expression
P07650958A0123|3 9|changes
P07650958A0123|45 60|electromyography
P07650958A0123|66 72|sensory
P07650958A0123|76 91|motor improvement
P07650958A0123|110 128|auxiliary indicators
P07651131A1407|0 15|Band-shift assays
P07651131A1407|19 24|DNase I
P07651131A1407|19 23|DNase
P07651131A1407|25 47|footprinting experiments
P07651131A1407|63 81|kDa repressor isoform
P07651131A1407|95 98|CIRs
P07651131A1407|117 123|targets
P07651131A1407|127 133|binding
P07651141A0265|6 13|terminus
P07651141A0265|19 30|p-gvpF-M mRNA
P07651141A0265|34 40|located
P07651141A0265|44 62|nucleotides upstream
P07651141A0265|65 70|p-gvpF
P07651141A0265|77 82|p-gvpE
P07651340A0286|0 15|Retransformation
P07651340A0286|18 30|uvsH77 mutants
P07651340A0286|45 51|cosmids
P07651340A0286|59 84|MMS-resistant transformants
P07651340A0286|95 105|restoration
P07651340A0286|112 113|UV
P07651340A0286|117 129|MMS resistance
P07651340A0286|132 146|wild-type levels
P07651386A0925|30 41|p53 induction
P07651386A0925|30 32|p53
P07651386A0925|56 95|nonresponsive adenovirus major late promoter
P07651398A0257|2 6|flies
P07651398A0257|11 21|dShc protein
P07651398A0257|58 103|Drosophila epidermal growth factor receptor homolog
P07651398A0257|105 107|DER
P07651398A0257|139 146|tyrosine
P07651398A0257|149 151|DER
P07651398A0803|1 20|potential binding site
P07651398A0803|27 39|dShc PTB domain
P07651398A0803|42 48|located
P07651398A0803|51 58|Tyr-1228
P07651398A0803|61 63|DER
P07651398T0000|1 24|Drosophila shc gene product
P07651398T0000|14 24|gene product
P07651398T0000|39 47|signaling
P07651398T0000|53 77|DER receptor tyrosine kinase
P07651400A0335|4 13|inhibition
P07651400A0335|46 49|exon
P07651400A0335|58 67|splice site
P07651400A0335|102 126|relevant consensus sequence
P07651424A0487|0 18|Biochemical analysis
P07651424A0487|28 32|Ssm1p
P07651424A0487|36 52|structural protein
P07651424A0487|71 96|largest 60S ribosomal subunit
P07651424A0487|78 96|60S ribosomal subunit
P07651424A0487|124 135|free proteins
P07651424A0743|2 15|wild-type cells
P07651424A0743|17 32|SSM1b transcripts
P07651424A0743|60 75|SSM1a transcripts
P07651424A0743|91 95|SSM1b
P07651424A0743|128 136|Ssm1p pool
P07651424A0743|128 132|Ssm1p
P07651734A0961|0 19|Northern blot analysis
P07651734A0961|43 52|LIMK-1 mRNA
P07651734A0961|94 103|LIMK-2 mRNA
P07651734A0961|106 119|various tissues
P07651835A0652|11 33|relative binding affinity
P07651835A0652|40 45|motifs
P07652066A0677|16 30|anatomic concept
P07652066A0677|35 56|brachioplasty procedure
P07652066A0677|77 91|secure anchoring
P07652066A0677|97 103|arm flap
P07652066A0677|109 122|axillary fascia
P07652066A0677|132 167|strong superficial fascial system repair
P07652066A0677|170 178|incisions
P07652066A0677|218 222|scars
P07652066A0677|226 242|unnatural contours
P07652575A0435|12 25|microinjection
P07652575A0435|28 48|dominant negative forms
P07652575A0435|51 53|Rac
P07652575A0435|57 61|Cdc42
P07652575A0435|69 93|Rho inhibitor C3 transferase
P07652575A0435|69 71|Rho
P07652575A0435|101 125|serum-induced DNA synthesis
P07652582A0000|0 15|INF-alpha therapy
P07652582A0000|0 8|INF-alpha
P07652582A0000|24 39|major development
P07652582A0000|56 58|CML
P07653094A0169|9 36|amino terminal deletion mutants
P07653094A0169|38 40|d10
P07653094A0169|42 44|d20
P07653094A0169|46 48|d27
P07653094A0169|50 52|d31
P07653094A0169|54 56|d40
P07653094A0169|58 60|d44
P07653094A0169|65 67|d73
P07653094A0169|95 115|cell surface expression
P07653094A0169|138 157|biological attributes
P07653094A0169|160 180|recombinant expression
P07653094A0169|183 193|mutant genes
P07653094A0169|200 212|plasmid vector
P07653094A0169|214 229|pcDL-SR alpha-296
P07653094A0169|233 236|CV-1
P07653094A0169|240 248|HeLa cells
P07653812T0000|0 40|Intrathecal acetyl cholinesterase inhibitors
P07653812T0000|11 30|acetyl cholinesterase
P07653812T0000|48 56|analgesia
P07653812T0000|63 73|synergistic
P07653812T0000|78 85|morphine
P07653812T0000|89 97|clonidine
P07653812T0000|100 103|rats
P07653892A0306|16 28|isoflurane MAC
P07653892A0306|31 40|triplicate
P07653892A0306|42 46|birds
P07653892A0306|57 72|mu-opioid agonist
P07653892A0306|74 81|morphine
P07653892A0306|83 84|n =
P07653892A0306|90 108|kappa-opioid agonist
P07653892A0306|110 116|U50488H
P07653892A0306|118 119|n =
P07654239A0698|0 2|Max
P07654239A0698|40 47|low level
P07654239A0698|54 73|cell cycle progression
P07654712A0774|3 13|yeast enzyme
P07654712A0774|23 28|slower
P07654712A0774|36 51|mammalian enzymes
P07654712A0774|64 71|amenable
P07654712A0774|74 129|pre-steady-state stopped-flow spectroscopic kinetic analysis
P07654712A0774|134 141|degrees C
P07654712A0774|145 146|pH
P07654740A0563|0 7|Key areas
P07654740A0563|13 28|selection process
P07654740A0563|48 67|surgical alternatives
P07654740A0563|70 84|transplantation
P07654740A0563|105 121|transplant work-up
P07654740A0563|123 147|specific inclusion criteria
P07654740A0563|156 182|specific psychosocial factors
P07654740A0563|186 210|specific disease etiologies
P07654740A0563|214 227|co-morbidities
P07654740A0563|246 262|contraindications
P07655184A0852|36 63|chimeric transmembrane protein
P07655184A0852|79 94|ER leader sequence
P07655184A0852|120 134|original protein
P07655184A0852|147 156|ER sequence
P07655505A0527|6 11|shoots
P07655505A0527|15 19|roots
P07655505A0527|21 31|GT-2 protein
P07655505A0527|34 45|undetectable
P07655505A0527|48 65|meristematic tissue
P07655505A0527|87 97|later stages
P07655505A0527|100 118|cellular development
P07655505A0527|167 192|phytochrome A gene expression
P07655505A0527|167 182|phytochrome A gene
P07655509T0000|1 48|polymorphic bipartite motif signals nuclear targeting
P07655509T0000|51 78|early auxin-inducible proteins
P07655509T0000|88 115|PS-IAA4 from pea (Pisum sativum)
P07655509T0000|88 94|PS-IAA4
P07655509T0000|99 101|pea
P07655509T0000|103 114|Pisum sativum
P07656588A0101|0 29|Comparative DNA sequence analysis
P07656588A0101|39 67|Genethon microsatellite D19S596
P07656588A0101|47 67|microsatellite D19S596
P07656588A0101|75 76|kb
P07656588A0101|106 109|FUT1
P07656588A0101|161 164|FUT1
P07656588A0101|168 176|FUT2 genes
P07656588A0101|179 185|located
P07656588A0101|187 194|cM distal
P07656588A0101|197 203|D19S412
P07656588A0101|205 212|lod score
P07656588A0101|222 231|cM proximal
P07656588A0101|234 240|D19S571
P07656588A0101|242 249|lod score
P07657162A1412|14 36|transcription activation
P07657162A1412|39 43|LEF-1
P07657162A1412|54 79|chromatin-dependent process
P07657162A1412|93 124|functional trans-activation domain
P07657162A1412|140 148|HMG domain
P07657668A0642|0 12|TH-SH3 binding
P07657668A0642|0 1|TH
P07657668A0642|3 5|SH3
P07657668A0642|42 69|single amino acid substitutions
P07657668A0642|79 89|Btk TH domain
P07657668A0642|79 81|Btk
P07657668A0642|95 106|Fyn SH3 domain
P07657705A1181|5 11|results
P07657705A1181|24 33|K-glypican
P07657705A1181|37 57|novel GPI-anchored HSPG
P07657705A1181|42 57|GPI-anchored HSPG
P07657705A1181|68 87|embryonic development
P07658262A0944|0 13|Protein S levels
P07658262A0944|27 38|undetectable
P07658262A0944|79 87|infusions
P07658262A0944|90 106|fresh frozen plasma
P07658262A0944|115 124|correction
P07658262A0944|127 143|other procoagulant
P07658262A0944|147 166|anticoagulant factors
P07658471A0000|3 19|plant hormone auxin
P07658471A0000|46 55|early genes
P07658777A0400|28 35|patients
P07658777A0400|45 61|contraindications
P07659085A1520|3 50|ubiquitous transcription factor Oct-1 forms complexes
P07659085A1520|57 75|octamer motif present
P07659085A1520|82 85|FPIV
P07659085A1520|88 103|gel shift analysis
P07659085A1520|116 129|kidney extracts
P07659085A1520|137 141|Oct-1
P07659085A1520|144 162|intriguing candidate
P07659085A1520|179 196|androgen regulation
P07659515T0000|1 25|new non-LTR retrotransposon
P07659515T0000|45 81|multiple distinct site-specific elements
P07659515T0000|84 117|Crithidia fasciculata miniexon arrays
P07659529A0135|6 21|deletion analysis
P07659529A0135|25 42|transfection assays
P07659529A0135|47 68|reporter gene constructs
P07659529A0135|81 108|transcription control elements
P07659529A0135|116 129|flanking region
P07659529A0135|135 147|human EpoR gene
P07659746A1464|3 30|CVA16.4 proteolipid transcript
P07659746A1464|40 48|prevalent
P07659746A1464|57 75|proteolipid messages
P07659746A1464|87 92|ovules
P07659746A1464|104 117|d post-anthesis
P07659757A0191|0 9|Incubation
P07659757A0191|23 36|fusion proteins
P07659757A0191|42 50|gamma-32P
P07659757A0191|52 54|ATP
P07659757A0191|66 70|assay
P07659757A0191|85 92|proteins
P07659757A0191|106 124|autophosphorylation
P07660712A0118|14 35|specific immune response
P07660712A0118|41 57|immunized children
P07660712A0118|65 70|adults
P07660712A0118|83 95|high risk group
P07660712A0118|109 111|VHB
P07663138A0835|5 11|nadolol
P07663138A0835|13 21|heart rate
P07663138A0835|39 39|%
P07663138A0835|50 52|PBV
P07663138A0835|56 58|PBF
P07663160A0287|3 22|synthetic DNA sequence
P07663160A0287|46 65|efficient base pairing
P07663160A0287|70 99|Escherichia coli 16S ribosomal RNA
P07663160A0287|85 99|16S ribosomal RNA
P07663160A0287|101 109|avoidance
P07663160A0287|112 137|internal secondary structure
P07663160A0287|142 158|optimal codon usage
P07663160A0287|162 188|high-level protein expression
P07663160A0287|191 196|accord
P07663160A0287|204 219|known preferences
P07663963A1588|0 25|Adrenergic system activation
P07663963A1588|38 66|metanephrine/epinephrine ratio
P07663963A1588|93 97|males
P07663963A1588|124 135|cohabitation
P07663963A1588|137 144|turnover
P07663963A1588|155 160|levels
P07663963A1588|179 192|control animals
P07663998T0000|0 19|Transabdominal repair
P07663998T0000|28 59|thoraco-abdominal aortic aneurysms
P07664278A0135|0 1|A.
P07665172A0000|0 19|Transcription factors
P07665172A0000|31 51|basic helix-loop-helix
P07665172A0000|53 56|bHLH
P07665172A0000|58 62|motif
P07665172A0000|86 105|tissue-specific genes
P07665172A0000|117 125|mammalian
P07665172A0000|129 141|insect systems
P07665187A0208|0 14|Primer extension
P07665187A0208|18 28|cDNA cloning
P07665187A0208|67 76|Nramp1 mRNA
P07665187A0824|0 14|Primer extension
P07665187A0824|18 45|S1 nuclease mapping experiments
P07665187A0824|18 27|S1 nuclease
P07665187A0824|65 91|transcription initiation site
P07665187A0824|94 99|Nramp1
P07665187A0824|135 161|several minor initiation sites
P07665477A0901|0 3|EsaR
P07665477A0901|17 29|own expression
P07665477A0901|66 69|esaI
P07665567A0495|0 15|Sequence analysis
P07665567A0495|24 37|flanking region
P07665567A0495|43 50|CD69 gene
P07665567A0495|73 92|potential TATA element
P07665567A0495|95 111|base pairs upstream
P07665567A0495|117 148|major transcription initiation site
P07665567A0495|152 182|several putative binding sequences
P07665567A0495|186 214|inducible transcription factors
P07665567A0495|195 214|transcription factors
P07665567A0495|216 224|NF-kappa B
P07665567A0495|226 230|Egr-1
P07665567A0495|232 235|AP-1
P07665567A0495|258 276|inducible expression
P07665605A1127|3 18|plasmin-derived D
P07665605A1127|33 39|105-kDa
P07665605A1127|80 87|DD dimers
P07665633A0284|3 18|clinical isolates
P07665633A0284|44 56|disk diffusion
P07665633A0284|60 81|agar dilution procedures
P07665633A0284|97 113|National Committee
P07665633A0284|117 143|Clinical Laboratory Standards
P07665948A0591|0 8|IgE levels
P07665948A0591|0 2|IgE
P07665948A0591|15 26|higher values
P07665948A0591|37 53|normal individuals
P07665948A0591|57 65|IgE levels
P07665948A0591|57 59|IgE
P07665948A0591|70 75|higher
P07665948A0591|78 91|children groups
P07665948A0591|98 103|adults
P07666414A0614|0 24|Tissue-specific expression
P07666414A0614|30 38|tmy-1 gene
P07666414A0614|54 67|microinjection
P07666414A0614|70 78|a promoter
P07666414A0614|71 93|promoter/lacZ fusion gene
P07666414A0614|101 120|immunohistochemistry
P07666414A0614|128 176|affinity-purified tissue-specific anti-tropomyosins
P07666415A0000|3 20|nucleotide sequence
P07666415A0000|26 36|chloroplast
P07666415A0000|38 39|cp
P07666415A0000|48 52|maize
P07666415A0000|54 60|Zea mays
P07666523T0000|0 12|Investigation
P07666523T0000|27 64|coronavirus subgenomic mRNA transcription
P07666523T0000|72 111|T7-generated negative-sense RNA transcripts
P07666538A0000|0 9|Initiation
P07666538A0000|28 47|human hepatitis C virus
P07666538A0000|49 51|HCV
P07666538A0000|53 61|RNA genome
P07666538A0000|70 90|internal ribosome entry
P07666538A0000|100 114|noncoding region
P07666538A0000|118 120|NCR
P07666538A0000|125 145|cap-independent manner
P07666966A0207|0 24|Mean longitudinal extension
P07666966A0207|30 43|epidural lesion
P07666966A0207|50 66|vertebral segments
P07667097A0267|16 19|p255
P07667097A0267|24 40|splicing complexes
P07667097A0267|68 73|mAb CC3
P07667097A0267|91 98|splicing
P07667097A0267|102 134|immunoprecipitate pre-messenger RNA
P07667097A0267|138 153|splicing products
P07667195A0146|0 4|L-735
P07667195A0146|9 16|free base
P07667195A0146|19 29|sulfate salt
P07667195A0146|53 62|suspension
P07667195A0146|76 91|solid dosage forms
P07667195A0146|105 114|Beagle dogs
P07667621T0001|0 23|Doppler ultrasound studies
P07667621T0001|26 43|long-term follow-up
P07667621T0001|46 53|children
P07667621T0001|58 81|hemolytic-uremic syndrome
P07668009A0172|5 21|endemic cumlations
P07668009A0172|24 41|hepatitis A diseases
P07669351A1278|3 12|properties
P07669351A1278|18 20|phi
P07669351A1278|23 38|SSB-ssDNA complex
P07670504A0834|34 54|diffuse banding pattern
P07670504A0834|57 76|plant nuclear proteins
P07670504A0834|95 99|G-box
P07670504A0834|117 128|binding assay
P07670504A0834|141 154|recombinant GBF
P07670943A0308|21 34|female patients
P07670943A0308|39 46|early CAD
P07670943A0308|54 62|unrelated
P07670943A0308|85 92|families
P07670943A0308|110 121|other sibling
P07670943A0308|125 132|early CAD
P07672821A0763|3 17|physical linkage
P07672821A0763|23 26|FHR2
P07672821A0763|33 44|factor H genes
P07672821A0763|53 70|additional evidence
P07672821A0763|75 90|close relatedness
P07672821A0763|93 109|complement factor H
P07672821A0763|116 138|factor H-related proteins
P07672822T0000|0 15|Genomic structure
P07672822T0000|19 37|chromosomal location
P07672822T0000|43 74|mouse pre-T-cell receptor alpha gene
P07673128A0989|3 13|third domain
P07673128A0989|20 24|motif
P07673128A0989|28 46|cAMP response element
P07673128A0989|48 50|CRE
P07673154A0688|3 30|tyrosine-phosphorylated state
P07673154A0688|33 39|CAK beta
P07673154A0688|55 68|trypsinization
P07673154A0688|100 107|3Y1 cells
P07673154A0688|112 122|fibronectin
P07673178A0982|3 9|results
P07673178A0982|26 46|many muscle gene E-boxes
P07673178A0982|102 123|MDF/bH-L-H heterodimers
P07673178A0982|132 147|MCK-L type E-boxes
P07673178A0982|132 141|MCK-L type E
P07673178A0982|173 188|different factors
P07674649A0508|1 49|single-case experimental ABAB multiple baseline design
P07674649A0508|70 91|treatment effectiveness
P07675445A0463|5 10|clones
P07675445A0463|28 39|common domain
P07675445A0463|49 49|p
P07675445A0463|51 52|CA
P07675445A0463|54 61|n repeats
P07675445A0463|64 95|simple sequence length polymorphism
P07675445A0463|97 100|SSLP
P07675449A0848|5 24|glioblastoma cell line
P07675449A0848|27 44|Shc-associated p190
P07675449A0848|72 76|PDGFR
P07676492A1000|29 35|reports
P07676492A1000|40 51|other regions
P07676492A1000|53 89|Scandinavian renal transplant recipients
P07676492A1000|95 102|high risk
P07676492A1000|112 114|IHD
P07676587T0000|0 22|Veterinary certification
P07676587T0000|26 40|livestock export
P07676655A0214|3 20|serum concentration
P07676655A0214|23 24|iP
P07676655A0214|31 38|dialysis
P07676655A0214|40 41|HD
P07676655A0214|68 73|mmol/l
P07676655A0214|77 77|D
P07676655A0214|103 106|mmol
P07677573A0000|1 22|significant correlation
P07677573A0000|39 58|functional parameters
P07677573A0000|61 76|gastric secretion
P07677573A0000|78 86|incretion
P07677573A0000|90 108|histological changes
P07677573A0000|111 123|gastric mucosa
P07677573A0000|134 141|patients
P07677573A0000|146 161|chronic gastritis
P07677715A1076|3 11|TAF factor
P07677715A1076|48 50|OCD
P07677836A1356|0 23|Diffuse white matter injury
P07677836A1356|67 86|neurological deficits
P07677836A1356|91 109|leukoencephalopathy
P07677836A1356|140 151|chemotherapy
P07678006A0472|0 22|RNase protection analyses
P07678006A0472|0 4|RNase
P07678006A0472|41 56|61-kDa CaM PDE mRNA
P07678006A0472|71 88|related transcripts
P07678006A0472|97 119|different CaM PDE isoforms
P07678006A0472|106 119|CaM PDE isoforms
P07678006A0472|135 155|tissue-specific manner
P07678006A0901|0 5|Little
P07678006A0901|36 48|adrenal cortex
P07678006A0901|50 63|adrenal medulla
P07678006A0901|71 82|kidney cortex
P07678006A0901|84 89|spleen
P07678006A0901|93 112|T-lymphocyte total RNA
P07678051A1303|3 14|PDGFR mutants
P07678051A1303|40 47|PLC gamma
P07678051A1303|71 94|PDGF-dependent production
P07678051A1303|71 74|PDGF
P07678051A1303|97 114|inositol phosphates
P07678242A0473|8 24|direct correlation
P07678242A0473|35 40|levels
P07678242A0473|43 55|transcription
P07678242A0473|61 68|acc genes
P07678242A0473|81 94|cellular growth
P07678593A0708|14 18|clone
P07678593A0708|21 46|V. vulnificus chromosomal DNA
P07678593A0708|60 78|V. cholerae fur mutant
P07678602A0153|22 42|B lymphoblast cell lines
P07678602A0153|47 54|controls
P07678602A0153|64 71|patients
P07678602A0153|76 120|p47-phox-deficient chronic granulomatous disease
P07678602A0153|134 140|parents
P07678695A0604|3 19|ectopic expression
P07678695A0604|22 26|Oct-3
P07678695A0604|31 41|hybrid cells
P07678695A0604|48 67|constitutive promoter
P07678695A0604|83 107|transcriptional activation
P07678695A0604|112 136|octamer-dependent promoter
P07679390A0721|0 14|RNase protection
P07679390A0721|0 4|RNase
P07679390A0721|18 38|primer extension assays
P07679390A0721|57 70|non-coding exon
P07679390A0721|86 97|DDT1 aFGF mRNA
P07679390A0721|90 97|aFGF mRNA
P07679390A0721|106 132|major transcription start site
P07679390A0721|151 160|bp upstream
P07679390A0721|168 191|non-coding splice junction
P07679390A0721|198 201|exon
P07679836A0387|5 11|results
P07679836A0387|23 24|FK
P07679836A0387|31 58|useful immunosuppressive agent
P07679836A0387|61 81|kidney transplantation
P07680035A0221|3 7|roles
P07680035A0221|10 22|phorbol esters
P07680035A0221|26 34|cyclic AMP
P07680035A0221|49 60|GnRH response
P07680035A0221|49 52|GnRH
P07680120A1008|0 5|RT-PCR
P07680120A1008|11 29|1.D-specific primers
P07680120A1008|40 45|kidney
P07680120A1008|55 62|prostate
P07680120A1008|77 81|D mRNA
P07680120A1008|92 97|kidney
P07680120A1008|116 129|abundant source
P07680120A1008|133 143|aFGF protein
P07680629T0000|0 15|Molecular cloning
P07680629T0000|19 34|characterization
P07680629T0000|40 44|genes
P07680629T0000|53 57|gp138
P07680629T0000|60 82|cell surface glycoprotein
P07680629T0000|96 111|sexual cell fusion
P07680629T0000|114 136|Dictyostelium discoideum
P07681147A1420|0 36|Two-dimensional phosphotryptic analyses
P07681147A1420|49 63|phosphorylation
P07681147A1420|66 71|Ser-12
P07681147A1420|75 80|Ser-48
P07681147A1420|83 99|unstimulated cells
P07681147A1420|128 149|overexpressed pp60c-src
P07681147A1420|141 149|pp60c-src
P07681147A1420|162 186|beta-adrenergic signalling
P07681513A0000|0 9|Piroximone
P07681513A0000|13 32|new phosphodiesterase
P07681513A0000|16 35|phosphodiesterase III
P07681513A0000|36 44|inhibitor
P07681513A0000|57 65|inotropic
P07681513A0000|69 89|vasodilator properties
P07681539A0000|0 17|Cytogenetic studies
P07681539A0000|33 43|lymphocytes
P07681539A0000|48 62|hospital workers
P07681539A0000|72 79|low doses
P07681539A0000|101 103|mSv
P07682842A0294|18 43|different fMLF-R transcripts
P07682842A0294|27 43|fMLF-R transcripts
P07682842A0294|48 61|genetic linkage
P07682842A0294|64 87|chemotactic receptor genes
P07682842A0294|107 126|fMLF-R gene expression
P07682842A0294|107 116|fMLF-R gene
P07682842A0294|143 152|copy number
P07682842A0294|154 172|chromosomal location
P07682842A0294|174 195|structural organization
P07682842A0294|203 218|flanking sequence
P07682842A0294|224 238|human fMLF-R gene
P07682842A0771|3 11|first exon
P07682842A0771|21 22|bp
P07682842A0771|31 50|untranslated sequence
P07682842A0771|57 60|exon
P07682842A0771|72 77|coding
P07682842A0771|84 104|untranslated sequences
P07683131A0885|3 18|genomic structure
P07683131A0885|25 31|members
P07683131A0885|37 46|SRC-family
P07683131A0885|61 90|identical exon/intron boundaries
P07683131A0885|100 114|catalytic domain
P07683375A0000|19 25|effects
P07683375A0000|28 40|growth factors
P07683375A0000|44 47|cAMP
P07683375A0000|56 64|estradiol
P07683375A0000|66 67|E2
P07683375A0000|99 103|genes
P07683375A0000|119 134|estrogen receptor
P07683375A0000|136 137|ER
P07683375A0000|156 162|studies
P07683375A0000|187 196|activators
P07683375A0000|199 212|protein kinases
P07683375A0000|224 246|transcriptional activity
P07683375A0000|252 253|ER
P07685263A0503|8 30|polymerase chain reaction
P07685263A0503|32 59|Whipple-specific DNA fragments
P07685263A0503|65 73|base pairs
P07685263A0503|81 86|genome
P07685263A0503|92 107|Whipple bacterium
P07685263A0503|109 127|Tropheryma whippelii
P07685823A1234|0 12|RNA polymerase
P07685823A1234|26 34|A promoter
P07685823A1234|55 71|base-pair sequence
P07685823A1234|76 81|DNase I
P07685823A1234|76 80|DNase
P07685823A1234|82 90|digestion
P07685823A1234|104 112|start site
P07685874A0258|0 13|Salivary sodium
P07685874A0258|15 21|calcium
P07685874A0258|26 48|magnesium concentrations
P07685874A0258|66 71|higher
P07685874A0258|77 87|SLE patients
P07685874A0258|92 117|systemic lupus erythematosus
P07685874A0258|126 134|potassium
P07685874A0258|138 163|total protein concentrations
P07685874A0258|167 181|amylase activity
P07685874A0258|167 173|amylase
P07685874A0258|214 221|controls
P07686619A0704|0 3|Chem
P07687320A0526|0 23|Recombinant plasmid pFV100
P07687320A0526|61 86|complement B-band expression
P07687320A0526|89 91|ge6
P07687541A0200|22 60|temperature-sensitive fission yeast mutant
P07687541A0200|70 77|mutation
P07687541A0200|81 94|homologous gene
P07687541A0200|120 134|mtr1/prp20/srm1
P07687541A0200|120 123|mtr1
P07687541A0200|125 129|prp20
P07687541A0200|131 134|srm1
P07687541A0200|136 142|mutants
P07687541A0200|153 163|nuclear poly
P07687541A0200|165 165|A
P07687541A0200|168 170|RNA
P07687541A0200|175 183|degrees C.
P07687541A0992|5 9|RCC1p
P07687541A0992|16 19|GNRP
P07687541A0992|23 25|Ran
P07687541A0992|28 45|small nuclear GTPase
P07687541A0992|51 64|ras superfamily
P07687541A0992|85 92|homologs
P07687541A0992|95 97|Ran
P07687541A0992|113 116|CNR1
P07687541A0992|120 123|CNR2
P07687745T0000|3 24|immunosuppressant FK506
P07687745T0000|33 47|amino acid import
P07688112A0274|0 22|Prostate specific antigen
P07688112A0274|31 45|metastatic cases
P07688112A0274|53 62|correction
P07688112A0274|65 69|worse
P07688112A0274|75 98|prostatic acid phosphatase
P07689154A0168|0 21|Protein phosphorylation
P07689154A0168|36 47|critical role
P07689154A0168|50 66|uPA gene expression
P07689154A0168|50 56|uPA gene
P07689154A0168|74 78|cells
P07689154A0168|80 117|protein kinase C-activating phorbol esters
P07689154A0168|131 139|pp60v-src
P07689154A0168|165 171|uPA mRNA
P07689154A0168|180 217|cyclic AMP (cAMP)-dependent protein kinase
P07689154A0168|180 188|cyclic AMP
P07689154A0168|190 193|cAMP
P07689154A0168|196 234|dependent protein kinase-activating agents
P07689154A0168|241 251|8-bromo cAMP
P07689154A0168|260 272|uPA mRNA levels
P07689154A0168|260 266|uPA mRNA
P07689501A0420|7 14|carriers
P07689501A0420|35 46|asymptomatic
P07691837A1359|7 8|bp
P07691837A1359|12 27|upstream sequence
P07691837A1359|30 42|K3 keratin gene
P07691837A1359|70 98|keratinocyte-specific promoter
P07691837A1359|111 118|clusters
P07691837A1359|141 146|motifs
P07691837A1359|157 177|NFkB consensus sequence
P07691837A1359|157 160|NFkB
P07691837A1359|193 197|GC box
P07691885T0000|0 13|Identification
P07691885T0000|16 24|mutations
P07691885T0000|49 67|proto-oncogene c-kit
P07691885T0000|71 99|human mast cell leukemia cell line
P07691885T0000|107 134|ligand-independent activation
P07691885T0000|137 148|c-kit product
P07692366A0000|0 9|BACKGROUND
P07692366A0000|11 21|Delineation
P07692366A0000|27 44|morphologic aspects
P07692366A0000|47 76|age-related macular degeneration
P07692366A0000|78 81|ARMD
P07692366A0000|112 127|clinical features
P07692366A0000|162 173|pathogenesis
P07692668A0326|2 44|abundant 1.1-kb virion-sense polyadenylated RNA
P07692668A0326|52 88|complementary-sense polyadenylated RNAs
P07692668A0326|109 110|kb
P07692668A0326|131 155|northern blot hybridization
P07692668A0326|170 203|bidirectional transcription strategy
P07692668A0326|229 232|ORFs
P07692754T0000|0 10|Risk factors
P07692754T0000|26 43|high seroprevalence
P07692754T0000|46 69|hepatitis C virus infection
P07692754T0000|72 90|Egyptian blood donors
P07693132A0100|7 13|cloning
P07693132A0100|17 33|molecular analysis
P07693132A0100|39 47|Zm-ERabp1
P07693132A0100|49 57|Zm-ERabp4
P07693132A0100|62 75|Zm-ERabp5 genes
P07693372A0115|25 30|fungus
P07693372A0115|71 83|action similar
P07693372A0115|92 103|cyclosporine
P07693672A0259|0 5|DNase I
P07693672A0259|0 4|DNase
P07693672A0259|6 17|footprinting
P07693672A0259|23 38|proximal promoter
P07693672A0259|51 57|regions
P07693699A0831|25 49|nucleotide binding function
P07693699A0831|58 65|proteins
P07693699A0831|100 103|urea
P07693708A0000|0 40|Insulin-like growth factor-binding protein-2
P07693708A0000|42 49|IGF-BP-2
P07693708A0000|51 63|transcription
P07693708A0000|66 73|rat liver
P07693708A0000|84 99|developmental age
P07693708A0000|103 109|fasting
P07693967A0905|16 17|RV
P07693967A0905|23 32|SL sequence
P07693967A0905|39 60|primary enhancing effect
P07693975A1418|14 21|proteins
P07693975A1418|36 45|methionine
P07693975A1418|55 61|residue
P07693975A1418|75 90|natural N terminus
P07693975A1418|93 94|PR
P07693975A1418|107 125|specific proteolysis
P07693975T0000|0 19|Reverse transcriptase
P07693975T0000|23 40|protease activities
P07693975T0000|43 81|avian leukosis virus Gag-Pol fusion proteins
P07693975T0000|61 63|Gag
P07693975T0000|65 81|Pol fusion proteins
P07693975T0000|93 103|insect cells
P07695629A0489|13 40|mck1 mds1 mrk1 triple disruptant
P07695629A0489|13 16|mck1
P07695629A0489|17 20|mds1
P07695629A0489|21 24|mrk1
P07695629A0489|44 49|viable
P07696183A0567|21 30|properties
P07696183A0567|33 35|Rak
P07696183A0567|55 69|Src-like kinases
P07696183A0567|86 88|Rak
P07696183A0567|107 133|epithelial-derived cell lines
P07696183A0567|137 143|tissues
P07696183A0567|155 165|normal liver
P07696183A0567|169 174|kidney
P07696183A0567|179 187|cell lines
P07696183A0567|199 209|colon origin
P07696183A0567|214 216|Rak
P07696183A0567|233 260|NH2-terminal glycine essential
P07696183A0567|264 276|myristylation
P07696183A0567|280 299|membrane localization
P07696183A0567|307 309|Rak
P07696183A0567|320 361|putative bipartite nuclear localization signal
P07696183A0567|367 375|SH2 domain
P07696183A0567|380 410|subcellular fractionation studies
P07696183A0567|423 428|p54rak
P07696183A0567|454 460|nucleus
P07696450A0271|0 7|PATIENTS
P07696450A0271|11 17|METHODS
P07696450A0271|49 56|children
P07696450A0271|61 81|active small bowel Crohn
P07696450A0271|97 108|casein-based
P07696450A0271|97 102|casein
P07696450A0271|110 126|polymeric feed rich
P07696450A0271|129 137|TGF-beta 2
P07696450A0271|129 136|TGF-beta
P07696450A0271|139 159|Specific Polymeric Diet
P07696450A0271|161 174|Nestle-Clintec
P07696450A0271|176 180|Vevey
P07696450A0271|182 192|Switzerland
P07696450A0271|196 212|complete nutrition
P07696450A0271|217 221|weeks
P07696878A0222|3 16|leader sequence
P07696878A0222|30 38|cDNA clone
P07696878A0222|47 83|several small open reading frames upstream
P07696878A0222|89 103|initiation codon
P07696878A0222|109 131|largest open reading frame
P07696878A0222|144 161|homeodomain protein
P07697294A0329|1 11|small amount
P07697294A0329|14 24|HSP81-1 mRNA
P07697294A0329|42 46|roots
P07698219A0551|0 11|Cell adhesion
P07698219A0551|15 29|migration assays
P07698219A0551|45 55|alpha 6 beta 1
P07698219A0551|45 49|alpha
P07698219A0551|51 54|beta
P07698219A0551|61 80|major laminin receptor
P07698219A0551|66 80|laminin receptor
P07698219A0551|83 105|undifferentiated F9 cells
P07698219A0551|114 130|F9-derived PE cells
P07698727A0386|2 17|local destruction
P07698727A0386|64 75|HIV infection
P07699632A0522|8 23|mixed race persons
P07699632A0522|27 40|Chukcha-Eskimo
P07699632A0522|44 45|AS
P07699632A0522|50 63|Eskimo-Russian
P07699632A0522|67 84|psoriatic arthritis
P07699632A0522|86 88|PsA
P07699632A0715|3 28|data complement other studies
P07699632A0715|31 52|circumpolar populations
P07699632A0715|76 90|high prevalences
P07699632A0715|93 95|SPA
P07699632A0715|99 105|HLA-B27
P07699632A0715|116 126|populations
P07699845A0537|0 20|Clinical studies SY5555
P07699845A0537|40 47|patients
P07699845A0537|52 76|various infectious diseases
P07699845A0537|83 98|acute pharyngitis
P07699845A0537|105 120|acute tonsillitis
P07699845A0537|127 144|lacunar tonsillitis
P07699845A0537|155 169|acute bronchitis
P07699845A0537|171 179|pneumonia
P07699845A0537|183 191|pertussis
P07699845A0537|198 209|scarlet fever
P07699845A0537|216 233|impetigo contagiosa
P07699845A0537|240 266|acute urinary tract infections
P07699845A0537|273 287|balanoposthitis
P07699845A0537|300 320|cervical lymphadenitis
P07699845A0537|322 329|S.S.S.S.
P07699845A0537|331 338|vulvitis
P07699845A0537|342 353|acute colitis
P07699845A0537|357 366|daily doses
P07699845A0537|380 384|mg/kg
P07699845A0537|386 391|t.i.d.
P07699845A0537|400 403|days
P07700361A0125|8 31|most SH2-pTyr interactions
P07700361A0125|12 14|SH2
P07700361A0125|16 19|pTyr
P07700361A0125|47 60|different types
P07700361A0125|63 71|molecules
P07700361A0125|97 115|single molecular type
P07701266A0808|0 6|RESULTS
P07701266A0808|8 18|Closure time
P07701266A0808|21 28|fistulas
P07701266A0808|31 38|patients
P07701266A0808|48 50|TPN
P07701266A0808|52 63|somatostatin
P07701266A0808|80 86|shorter
P07701266A0808|117 120|days
P07701266A0808|142 144|TPN
P07702327T0000|0 30|Experimental adhesion prophylaxis
P07702327T0000|35 71|recombinant tissue plasminogen activator
P07702378A0668|23 30|children
P07702378A0668|35 50|atopic dermatitis
P07702378A0668|76 78|VO2
P07702752A0545|16 24|sequences
P07702752A0545|30 47|rat P450c17 promoter
P07702752A0545|67 71|basal
P07702752A0545|75 106|cAMP-stimulated gene transcription
P07702752A0545|75 93|cAMP-stimulated gene
P07702752A0545|108 125|deletion constructs
P07702752A0545|155 163|base pairs
P07702752A0545|169 179|flanking DNA
P07702752A0545|187 200|rat P450c17 gene
P07702752A0545|214 221|plasmids
P07702752A0545|235 256|reporter gene luciferase
P07702752A0545|247 256|luciferase
P07702752A0545|278 291|mouse cell lines
P07702752A0545|293 307|adrenal Y-1 cells
P07702752A0545|312 337|testicular Leydig MA-10 cells
P07702808A0427|0 26|Within-subject BP differences
P07702808A0427|34 40|fish oil
P07702808A0427|44 59|corn oil treatment
P07702808A0427|74 80|Dinamap
P07702808A0427|101 104|mm Hg
P07702808A0427|112 118|24-h ABP
P07702808A0427|139 142|mm Hg
P07702808A0427|152 166|more significant
P07704040A0000|27 39|mouse NMO1 cDNA
P07704040A0000|56 58|NAD
P07704040A0000|60 60|P
P07704040A0000|62 62|H
P07704040A0000|64 86|menadione oxidoreductase
P07704040A0000|98 100|NAD
P07704040A0000|102 102|P
P07704040A0000|104 104|H
P07704040A0000|107 121|quinone acceptor
P07704040A0000|123 136|oxidoreductase
P07704040A0000|138 153|quinone reductase
P07704040A0000|155 169|azo dye reductase
P07704040A0000|161 169|reductase
P07704040A0000|171 182|DT diaphorase
P07704040A0000|184 193|EC 1.6.99.2
P07704040A0000|184 185|EC
P07704273A0000|15 20|JRG582
P07704273A0000|25 50|ampD ampE deletion derivative
P07704273A0000|25 28|ampD
P07704273A0000|29 32|ampE
P07704273A0000|53 62|strain HfrH
P07704273A0000|116 142|inducible beta-lactamase gene
P07704273A0000|145 163|Citrobacter freundii
P07704273A0000|174 186|plasmid pNU305
P07704456A1014|22 33|acceleration
P07704456A1014|36 62|degenerative joint conditions
P07704456A1014|92 101|prevalence
P07704456A1014|104 117|such conditions
P07704456A1014|126 136|HMS subjects
P07704689T0000|0 20|Solitary thyroid nodule
P07704730T0000|0 16|Male contraception
P07704730T0000|18 22|ideas
P07705476A0292|5 19|daily food intake
P07705476A0292|52 70|dietary protein level
P07705476A0292|72 82|water intake
P07705476A0292|86 96|urine volume
P07705476A0292|123 136|dietary protein
P07705627A1107|13 15|Mad
P07705627A1107|19 23|Medea
P07705627A1107|30 60|rate-limiting components integral
P07705627A1107|63 73|dpp pathways
P07705627A1107|63 65|dpp
P07706273T0000|0 24|Transcriptional regulation
P07706273T0000|30 61|vacuolar H(+)-ATPase B2 subunit gene
P07706273T0000|30 38|vacuolar H
P07706273T0000|43 61|ATPase B2 subunit gene
P07706273T0000|79 88|THP-1 cells
P07706287A0698|11 19|inability
P07706287A0698|28 30|RNA
P07706287A0698|38 44|nucleus
P07706287A0698|50 58|cytoplasm
P07706287A0698|75 89|particular phase
P07706287A0698|95 111|cell division cycle
P07706291T0000|2 12|E box element
P07706291T0000|44 52|ad4bp gene
P07706291T0000|55 84|mammalian homologue of ftz-f1 gene
P07706291T0000|55 72|mammalian homologue
P07706291T0000|75 84|ftz-f1 gene
P07706291T0000|105 111|adrenal
P07706291T0000|115 132|gonadal development
P07706299A0563|0 15|Inhibition assays
P07706299A0563|35 50|different natural
P07706299A0563|54 62|synthetic
P07706299A0563|79 95|sulfated compounds
P07706299A0563|117 155|greater detail specific structural features
P07706299A0563|166 195|oligosaccharide-protein binding
P07706307A0914|3 19|amino acid sequence
P07706307A0914|48 64|specificity pocket
P07706307A0914|82 100|S. griseus proteases A
P07706307A0914|82 83|S.
P07706307A0914|91 99|proteases
P07706307A0914|102 102|B
P07706307A0914|107 108|C.
P07706396T0000|0 8|Mutations
P07706396T0000|14 22|VPS45 gene
P07706396T0000|25 37|SEC1 homologue
P07706396T0000|25 28|SEC1
P07706396T0000|47 61|vacuolar protein
P07706396T0000|69 75|defects
P07706396T0000|79 90|accumulation
P07706396T0000|93 108|membrane vesicles
P07707523A0704|5 9|cells
P07707523A0704|26 43|NF-kappa B inhibitor
P07707523A0704|45 57|I kappa B-alpha
P07707523A0704|69 87|stimulatory activity
P07707523A0704|90 92|LMP
P07707531A0550|4 21|experimental design
P07707531A0550|51 62|displacement
P07707531A0550|68 86|alpha 4-2 binding site
P07707531A0550|68 72|alpha
P07707531A0550|76 86|binding site
P07707531A0550|92 101|repression
P07707531A0550|104 113|alpha 4 gene
P07707531A0550|104 108|alpha
P07707531A0550|110 126|gene transcription
P07707531A0550|129 132|ICP4
P07707544T0000|0 27|Immediate-early transcription
P07707544T0000|35 59|channel catfish virus genome
P07707544T0000|61 76|characterization
P07707544T0000|82 107|immediate-early transcripts
P07708058A0178|3 5|GRE
P07708058A0178|8 17|nucleotide
P07708058A0178|25 36|composite GRE
P07708058A0178|38 41|cGRE
P07708058A0178|66 83|activator protein-1
P07708058A0178|85 88|AP-1
P07708058A0178|90 94|motif
P07708058A0178|101 114|c-jun homodimer
P07708058A0178|118 139|c-jun/c-fos heterodimer
P07708058A0178|118 122|c-jun
P07708058A0178|124 128|c-fos
P07708488A0151|16 22|results
P07708488A0151|50 69|close sequence variant
P07708488A0151|74 76|ref
P07708497A0000|0 24|Transcriptional activation
P07708497A0000|27 40|thyroid hormone
P07708497A0000|42 43|T3
P07708497A0000|53 64|interactions
P07708497A0000|75 84|T3 receptor
P07708497A0000|86 87|TR
P07708497A0000|92 109|T3 response elements
P07708497A0000|111 114|TREs
P07708497A0000|129 134|copies
P07708497A0000|137 145|sequences
P07708497A0000|155 160|AGGTCA
P07711667A0766|1 20|multivariate analysis
P07711667A0766|23 33|risk factors
P07711667A0766|37 43|relapse
P07711667A0766|56 58|WBC
P07711667A0766|71 80|blast count
P07711667A0766|105 116|marrow blasts
P07711667A0766|118 127|FAB subtype
P07711667A0766|140 164|remission induction courses
P07711667A0766|175 183|remission
P07711667A0766|185 202|maintenance therapy
P07711667A0766|204 223|consolidation therapy
P07711667A0766|225 238|marrow cell dose
P07711667A0766|240 257|donor-recipient sex
P07711667A0766|259 280|GVHD prophylaxis regimen
P07711667A0766|296 310|decontamination
P07711667A0766|313 331|laminar airflow rooms
P07711730A0000|0 35|Carnitine palmitoyltransferase (CPT) II
P07711730A0000|0 28|Carnitine palmitoyltransferase
P07711730A0000|30 32|CPT
P07711730A0000|36 45|deficiency
P07711730A0000|80 94|lipid metabolism
P07711730A0000|104 117|skeletal muscle
P07713421A1435a|20 42|gain-of-function mutants
P07713421A1435a|86 107|sex determination signal
P07713421A1435a|113 117|SxlM4
P07713421A1435a|126 134|strongest
P07713421A1435a|138 142|SxlM1
P07713421A1435a|146 152|weakest
P07713421A1435b|20 42|gain-of-function mutants
P07713421A1435b|86 107|sex determination signal
P07713421A1435b|113 117|SxlM4
P07713421A1435b|126 134|strongest
P07713421A1435b|138 142|SxlM1
P07713421A1435b|146 152|weakest
P07713936A0393|0 6|Binding
P07713936A0393|9 13|meAda
P07713936A0393|35 47|transcription
P07713936A0393|53 73|adaptive response genes
P07713936A0393|94 106|transcription
P07713936A0393|109 112|aidB
P07713936A0393|139 143|meAda
P07714608A1252|2 23|significant differences
P07714608A1252|45 50|groups
P07714608A1252|54 55|pH
P07714608A1252|57 61|PaCO2
P07714608A1252|63 82|intracranial pressure
P07714608A1252|84 92|heart rate
P07714608A1252|94 109|brain temperature
P07714608A1252|113 125|glucose levels
P07714758A1193|0 12|Blood pressure
P07714758A1193|31 39|lidocaine
P07714758A1193|42 47|mg kg-1
P07715200A0000|0 16|Anesthesiologists
P07715200A0000|60 73|target response
P07715200A0000|89 101|blood pressure
P07715602A1088|17 32|gene cluster codes
P07715602A1088|37 41|parts
P07715602A1088|46 77|multisubunit cytochrome c haem lyase
P07715922A0188|49 71|corneal endothelial cells
P07715922A0188|92 99|patients
P07715922A0188|110 115|months
P07715922A0188|121 123|PRK
P07717823A0328|0 23|Standard reference sources
P07717823A0328|38 64|able-bodied 11-year-old child
P07717823A0328|67 82|comparable height
P07717823A0328|96 101|kcal/d
P07717823A0328|114 136|basal metabolic functions
P07719527T0000|0 16|Weak allergenicity
P07719527T0000|19 44|recombinant hirudin CGP 39393
P07719527T0000|19 39|recombinant hirudin CGP
P07719527T0000|46 51|REVASC
P07719527T0000|55 79|immunocompetent volunteers
P07720572A0701|15 26|myoD promoter
P07720572A0701|31 42|myoD enhancer
P07720572A0701|48 67|striking conservation
P07720572A0701|75 80|humans
P07720572A0701|84 87|mice
P07720572A0701|111 124|distal position
P07720572A1584|9 23|clear difference
P07720572A1584|37 45|myoblasts
P07720572A1584|49 59|10T1/2 cells
P07720572A1584|64 87|other non-muscle cell types
P07720572A1584|94 111|chromatin structure
P07720572A1584|117 143|chromosomal myoD core enhancer
P07720572A1584|162 173|myoD enhancer
P07720572A1584|187 206|epigenetic mechanisms
P07720572A1584|209 219|10T1/2 cells
P07720709A0755|5 30|Ki-ras-transformed 3T3 cells
P07720709A0755|5 10|Ki-ras
P07720709A0755|34 44|model system
P07720709A0755|60 61|RA
P07720709A0755|82 90|retinoids
P07720709A0755|98 135|anchorage-independent cell proliferation
P07720709A0755|151 182|retinoid-induced growth inhibition
P07720709A0755|197 214|AP1 transrepression
P07720709A0755|197 199|AP1
P07720710A0861|3 5|Oct
P07720710A0861|9 20|HMG2 proteins
P07721074A0766|0 15|Atopic dermatitis
P07721074A0766|21 24|itch
P07721074A0766|30 35|rashes
P07721074A0766|43 46|rash
P07721074A0766|75 97|patient treatment program
P07721074A0766|114 125|multiplicity
P07721074A0766|128 150|potential trigger factors
P07721074A0766|166 172|itching
P07721422A0241|0 25|Primer extension experiments
P07721422A0241|47 74|transcription initiation sites
P07721422A0241|77 78|bp
P07721422A0241|89 97|mouse type
P07721422A0241|99 110|receptor gene
P07721878A1163|3 13|beta subunit
P07721878A1163|19 29|Fc epsilon R1
P07721878A1163|33 60|33-kDa tyrosine phosphoprotein
P07721878A1163|68 89|p33 Grb2-binding protein
P07721878A1163|104 116|present report
P07721878A1163|125 144|Fc epsilon R1 beta chain
P07723247A0187|10 19|mechanisms
P07723247A0187|42 62|transmembrane transfer
P07723247A0187|65 81|bacterial products
P07723247A0187|89 97|dialysate
P07723247A0187|111 122|computerized
P07723247A0187|130 142|dialysis model
P07723247A0187|156 182|continuous pressure recording
P07723247A0187|190 197|arterial
P07723247A0187|199 204|venous
P07723247A0187|206 220|dialysate inflow
P07723247A0187|224 235|outflow ports
P07723247A1161|7 20|hour incubation
P07723247A1161|22 47|total cell-associated IL-1Ra
P07723247A1161|42 47|IL-1Ra
P07723247A1161|51 58|IL-1 beta
P07723247A1161|73 96|specific radioimmunoassay
P07724452A0344|4 19|dietary treatment
P07724452A0344|50 55|chicks
P07724452A0344|67 68|d.
P07728201A0660|11 24|recent evidence
P07728201A0660|37 44|children
P07728201A0660|49 73|sickle-hemoglobin C disease
P07728201A0660|49 65|sickle-hemoglobin
P07728201A0660|86 103|functional asplenia
P07728201A0660|114 118|years
P07728201A0660|148 168|penicillin prophylaxis
P07729427A0942|0 15|Deletion analysis
P07729427A0942|29 31|TBP
P07729427A0942|35 42|hTAFII18
P07729427A0942|49 63|distinct domains
P07729427A0942|66 73|hTAFII28
P07729427A0942|75 82|hTAFII18
P07729427A0942|100 102|TBP
P07729427A0942|134 141|hTAFII28
P07729427A0942|145 152|hTAFII30
P07730273A1309|3 6|NarX
P07730273A1309|10 21|NarQ proteins
P07730273A1309|26 47|amino acid substitutions
P07730273A1309|67 83|histidine position
P07730273A1309|115 128|NarL-phosphate
P07730273A1309|115 118|NarL
P07730328A0000|0 23|Vascular endothelial cells
P07730328A0000|31 45|profound changes
P07730328A0000|50 67|cellular activation
P07730328A0000|100 129|cell activation-associated genes
P07730336A0606|7 11|ATF-1
P07730336A0606|15 18|CREM
P07730336A0606|35 54|cAMP response elements
P07730336A0606|56 58|CRE
P07730336A0606|65 82|functional sequence
P07730336A0606|94 100|kappa E3
P07730336A0606|103 105|CRE
P07730337A1439|3 8|Ng/RC3
P07730337A1439|12 25|PKC-gamma genes
P07730337A1439|31 54|similar expression pattern
P07730337T0000|0 8|Structure
P07730337T0000|42 90|neuron-specific protein kinase C substrate neurogranin
P07730337T0000|80 90|neurogranin
P07730337T0000|92 101|RC3 protein
P07730795A0104|3 20|amino acid sequences
P07730795A0104|31 45|largest subunits
P07730795A0104|48 52|DdRPs
P07730795A0104|57 72|different species
P07730795A0104|95 101|regions
P07731686A0000|3 11|TTG-2 gene
P07731686A0000|40 64|chromosomal translocations
P07731686A0000|67 85|acute T-cell leukemia
P07731686A0000|89 93|T-ALL
P07731898A0823|7 13|studies
P07731898A0823|18 27|blood cells
P07731898A0823|41 47|acetate
P07731898A0823|50 64|bicarbonate ions
P07731898A0823|67 80|concentrations
P07731898A0823|110 121|hemodialysis
P07731898A0823|147 150|ions
P07731898A0823|170 195|superoxide anions generation
P07731898A0823|197 212|erythrocyte SOD-1
P07731898A0823|208 212|SOD-1
P07731898A0823|216 233|catalase activities
P07731898A0823|216 223|catalase
P07731898A0823|237 272|erythrocyte membrane lipid peroxidation
P07733075A1200|0 11|Short therapy
P07733075A1200|16 25|omeprazole
P07733075A1200|28 31|mg/b
P07733075A1200|33 36|i.d.
P07733075A1200|38 51|clarithromycin
P07733075A1200|55 58|mg/b
P07733075A1200|60 63|i.d.
P07733075A1200|68 70|CBS
P07733075A1200|74 77|mg/q
P07733075A1200|79 82|i.d.
P07733075A1200|132 147|% eradication rate
P07733075A1200|150 157|H. pylori
P07733075A1200|161 185|duodenal ulcer healing rates
P07733075A1200|209 218|omeprazole
P07733075A1200|221 224|mg/d
P07733075A1200|238 239|wk
P07735590A0990|18 29|mite allergen
P07735590A0990|49 72|micrograms Der p milligrams
P07735590A0990|79 87|house dust
P07735590A0990|103 113|cat allergen
P07735590A0990|123 127|homes
P07735590A0990|141 164|micrograms Fel d milligrams
P07735590A0990|175 179|homes
P07735590A0990|193 216|micrograms Fel d milligrams
P07735833A1078|0 10|CONCLUSIONS
P07735833A1078|28 47|LysU crystal structure
P07735833A1078|28 31|LysU
P07735833A1078|55 64|structures
P07735833A1078|67 99|seryl- and aspartyl-tRNA synthetases
P07735833A1078|67 71|seryl
P07735833A1078|76 99|aspartyl-tRNA synthetases
P07737024A1003|0 19|Whole bowel irrigation
P07737024A1003|70 74|drugs
P07737024A1003|91 97|pylorus
P07737118A0317|3 22|MPS1 open reading frame
P07737118A0317|55 65|LexA protein
P07737118A0317|71 80|GST protein
P07737118A0317|95 104|constructs
P07737118A0317|115 119|yeast
P07737508A0649|4 5|Tb
P07737508A0649|7 8|U6
P07737508A0649|12 26|single-copy gene
P07737508A0649|33 41|tRNA genes
P07737508A0649|43 49|tRNAGln
P07737508A0649|53 59|tRNAIle
P07737944A0000|0 25|Hematopoietic growth factors
P07737944A0000|42 55|enormous impact
P07737944A0000|58 76|transfusion practice
P07737944A0000|110 133|red blood cell transfusions
P07737944A0000|146 157|anemic states
P07737944A0000|185 200|relative decrease
P07737944A0000|203 216|erythropoietin
P07738026A0216|56 60|forms
P07738026A0216|63 65|ADH
P07738839A0173|6 14|IC breaths
P07738839A0173|27 28|EC
P07738839A0173|32 40|VC breaths
P07738839A0173|48 67|end-tidal CO2 pressure
P07738839A0173|69 71|PET
P07738839A0173|73 75|CO2
P07738839A0173|96 99|mmHg
P07739382A0457|0 19|Phylogenetic analyses
P07739382A0457|24 41|amino acid sequences
P07739382A0457|45 63|related protein types
P07739382A0457|76 99|actin-associated proteins
P07739382A0457|109 116|gelsolin
P07739382A0457|120 131|monophyletic
P07739382A0457|135 148|common ancestor
P07739382A0457|159 176|flightless proteins
P07739520A1250|2 9|homologs
P07739520A1250|12 23|other members
P07739520A1250|29 46|Surfeit gene cluster
P07739520A1250|61 74|close proximity
P07739520A1250|80 81|D.
P07739520A1250|94 99|Surf-3
P07739520A1250|101 109|rpL7a gene
P07739520A1250|101 105|rpL7a
P07739542A1419|20 26|cyclin E
P07739542A1419|40 47|cyclin D1
P07739542A1419|66 79|G1/S transition
P07739542A1419|86 90|cells
P07739542A1419|98 126|retinoblastoma protein function
P07739542A1419|98 118|retinoblastoma protein
P07739544A0364|12 28|amino acid sequence
P07739544A0364|34 48|SGC1 gene product
P07739544A0364|68 88|substantial similarity
P07739544A0364|94 121|basic-helix-loop-helix domain
P07739544A0364|127 135|Myc family
P07739544A0364|127 129|Myc
P07739544A0364|138 156|DNA-binding proteins
P07739566A1076|10 33|Pax-6-BSAP fusion proteins
P07739566A1076|10 14|Pax-6
P07739566A1076|16 19|BSAP
P07739566A1076|56 76|short amino acid stretch
P07739566A1076|82 95|N-terminal part
P07739566A1076|101 112|paired domain
P07739566A1076|139 149|differences
P07739566A1076|152 173|DNA-binding specificity
P07740487A0167|12 30|possible association
P07740487A0167|38 62|familial dysfibrinogenemia
P07740487A0167|66 78|thrombophilia
P07740487A0167|86 90|cases
P07740487A0167|99 108|affections
P07740487A0167|153 167|SSC Subcommittee
P07740487A0167|170 179|Fibrinogen
P07740487A0167|185 204|International Society
P07740487A0167|207 216|Thrombosis
P07740487A0167|220 230|Haemostasis
P07740490T0000|10 18|estrogens
P07740490T0000|26 37|bleeding time
P07740490T0000|40 46|uraemia
P07740490T0000|49 60|possible role
P07740490T0000|63 71|serotonin
P07741255A0194|8 16|districts
P07741255A0194|35 37|km2
P07742024A0121|11 18|symptoms
P07742024A0121|20 24|signs
P07742024A0121|26 40|imaging features
P07742024A0121|42 58|operation findings
P07742024A0121|63 76|original places
P07742024A0121|83 101|expansive directions
P07742024A0121|136 148|clinical types
P07742024A0121|150 155|sellar
P07742024A0121|157 162|clival
P07742024A0121|164 180|occipito-temporal
P07742363A0135|3 18|mammalian enzymes
P07742363A0135|23 46|haem-controlled repressor
P07742363A0135|48 50|HCR
P07742363A0135|58 94|double-stranded RNA-activated inhibitor
P07742363A0135|96 98|dsI
P07742363A0135|114 119|Ser-51
P07742363A0135|125 136|alpha subunit
P07742363A0135|173 183|nucleotides
P07742363A0135|197 205|recycling
P07742363A0135|209 213|eIF-2
P07742363A0941|1 9|triple Ser
P07742363A0941|13 25|Ala mutant form
P07742363A0941|28 42|yeast eIF-2 alpha
P07742363A0941|90 94|yeast
P07742363A0941|98 119|mammalian) casein kinase
P07742363A0941|98 106|mammalian
P07742363A0941|108 129|casein kinase activities
P07742550A0407|3 7|cases
P07742550A0407|24 49|diffuse aggressive lymphomas
P07742550A0407|51 53|DAL
P07742550A0407|57 66|large-cell
P07742550A0407|69 78|mixed-cell
P07742550A0407|85 107|large-cell immunoblastic
P07742550A0407|123 141|aggressive lymphomas
P07742550A0407|153 171|follicular lymphomas
P07742550A0407|173 175|TFL
P07742550A0407|180 206|indolent follicular lymphomas
P07742550A0407|208 209|FL
P07742550A0407|214 232|mantle cell lymphomas
P07742550A0407|234 236|MCL
P07742550A0407|244 271|small noncleaved cell lymphomas
P07742550A0407|273 276|SNCL
P07742917T0001|0 6|Icterus
P07742917T0001|10 25|beta-thalassemia
P07742917T0001|28 44|Congolese children
P07742917T0001|47 57|Brazzaville
P07743472A0181|0 13|Female patients
P07743472A0181|18 29|breast cancer
P07743472A0181|59 84|Roswell Park Cancer Institute
P07743472A0181|86 89|RPCI
P07743472A0181|93 99|Buffalo
P07743472A0181|101 107|New York
P07743472A0181|138 160|cigarette smoking history
P07743515A0223|17 34|tissue distribution
P07743515A0223|37 40|AAMP
P07743515A0223|75 90|endothelial cells
P07743515A0223|92 107|cytotrophoblasts
P07743515A0223|132 155|colon adenocarcinoma cells
P07743515A0223|163 172|lymphatics
P07743697A0703|0 3|Data
P07743697A0703|11 16|V-HeFT
P07743697A0703|29 43|2-year follow-up
P07743697A0703|46 60|progressive rise
P07743697A0703|63 82|plasma norepinephrine
P07743697A0703|100 112|treatment arms
P07743697A0703|173 209|angiotensin-converting enzyme inhibitor
P07743697A0703|173 200|angiotensin-converting enzyme
P07743697A0703|211 219|enalapril
P07743697A0703|223 240|vasodilator therapy
P07743697A0703|245 275|hydralazine/isosorbide dinitrate
P07744763A0514|0 14|Binding activity
P07744763A0514|17 39|rat liver nuclear extracts
P07744763A0514|53 67|orphan receptors
P07744763A0514|80 115|electromobility supershift experiments
P07744763A0514|123 129|results
P07744763A0514|151 159|receptors
P07744763A0514|181 187|CYP2C11
P07744763A0514|198 202|HNF-4
P07744776A0617|0 17|Transcript analysis
P07744776A0617|29 53|lethal B block substitutions
P07744776A0617|60 73|U6 RNA synthesis
P07744776A0617|60 64|U6 RNA
P07744846A1006|0 7|Analysis
P07744846A1006|10 14|Bcl-2
P07744846A1006|16 36|Bcl-2 homodimerization
P07744846A1006|16 20|Bcl-2
P07744846A1006|53 65|binding assays
P07744846A1006|75 95|yeast two-hybrid method
P07744846A1006|124 140|head-to-tail model
P07744846A1006|144 148|Bcl-2
P07744846A1006|150 170|Bcl-2 homodimerization
P07744846A1006|150 154|Bcl-2
P07744846A1006|186 194|sequences
P07744846A1006|204 222|NH2-terminal A domain
P07744846A1006|277 285|carboxyl B
P07744846A1006|289 296|C domains
P07744954A0418|23 49|central alpha-helical portion
P07744954A0418|54 68|globular domains
P07744954A0418|75 77|NH2
P07744954A0418|81 91|COOH termini
P07744954A0418|99 105|epitope
P07744954A0418|111 128|monoclonal antibody
P07744954A0418|141 165|central alpha-helical stalk
P07745008A0892|0 17|Radioligand binding
P07745008A0892|21 37|indistinguishable
P07745008A0892|65 74|constructs
P07745311A0264|0 8|Diagnosis
P07745311A0264|11 14|FHCS
P07745311A0264|33 52|laparoscopic findings
P07745684T0000|0 33|Human papillomavirus type 31b late gene
P07745684T0000|0 22|Human papillomavirus type
P07745684T0000|26 43|late gene expression
P07745684T0000|62 91|protein kinase C-mediated changes
P07745684T0000|62 75|protein kinase C
P07745684T0000|94 106|RNA processing
P07745685A1442|14 20|virions
P07745685A1442|34 48|smaller proteins
P07745685A1442|64 81|antibodies specific
P07745685A1442|88 104|accessory proteins
P07745685A1442|113 114|SN
P07745685A1442|118 134|CAT fusion partners
P07745685A1442|118 120|CAT
P07745693A0914|0 6|Studies
P07745693A0914|14 22|inhibitor
P07745693A0914|26 43|mutant Lb proteinase
P07745693A0914|57 67|stimulation
P07745693A0914|70 91|IRES-driven translation
P07745693A0914|105 115|proteolysis
P07745693A0914|122 138|cellular component
P07745693A0914|140 140|s
P07745696A0932|0 25|Restriction mapping analysis
P07745696A0932|39 42|cDNA
P07745696A0932|48 81|HHV-6A(U1102) genomic BamHI G fragment
P07745696A0932|48 53|HHV-6A
P07745696A0932|55 59|U1102
P07745696A0932|61 81|genomic BamHI G fragment
P07745696A0932|88 95|right end
P07745696A0932|101 117|unique long segment
P07745696A0932|123 128|genome
P07745696A0932|137 141|SalI L
P07745696A0932|145 158|SalI O fragments
P07745696A0932|175 206|right terminal direct repeat regions
P07745726A0960|3 31|replication reporter constructs
P07745726A0960|37 38|E1
P07745726A0960|42 43|E2
P07745726A0960|57 61|trans
P07745726A0960|67 93|respective expression vectors
P07745726A0960|113 121|half sites
P07745726A0960|134 142|major role
P07745726A0960|157 169|relationships
P07745726A0960|173 182|measurable
P07745726A1496|36 50|18-bp palindrome
P07745726A1496|59 97|sufficient nucleotide sequence information
P07745726A1496|101 109|E1 binding
P07745726A1496|101 102|E1
P07745726A1496|127 151|minimal E1 recognition motif
P07745726A1496|169 176|half site
P07746397A0233|0 6|METHODS
P07746397A0233|16 23|patients
P07746397A0233|33 47|anticoagulation
P07746397A0233|55 58|July
P07746397A0233|66 73|December
P07746397A0233|81 88|patients
P07746397A0233|93 112|hemispheric embolisms
P07746397A0233|121 127|heparin
P07746397A0233|136 140|hours
P07746397A0233|145 149|onset
P07746397A0233|160 184|partial thromboplastin time
P07746397A0233|167 180|thromboplastin
P07746397A0233|186 189|aPTT
P07746397A0233|194 210|times control value
P07746794A0000|17 47|available intravenous formulation
P07746794A0000|50 61|Cyclosporin A
P07746794A0000|63 71|Sandimmun
P07746794A0000|90 98|castor oil
P07746794A0000|100 110|Cremophor EL
P07746794A0000|121 137|solubilizing agent
P07746937A0100|0 16|Lung function tests
P07746937A0100|18 20|EFR
P07746937A0100|42 49|patients
P07746937A0100|72 77|months
P07747462A0332|0 18|Sequence comparisons
P07747462A0332|21 44|prokaryotic RCR initiators
P07747462A0332|67 78|common motifs
P07747462A0332|92 120|putative metal coordination site
P07747462A0332|125 158|downstream active-site tyrosine motif
P07747462A0332|190 217|parvoviral replicator proteins
P07748451A0343|3 25|mean marginal discrepancy
P07748451A0343|28 50|provisional restorations
P07748451A0343|65 76|restorations
P07748451A0343|97 113|low-viscosity poly
P07748451A0343|115 127|vinyl siloxane
P07748451A0343|133 152|medium-viscosity poly
P07748451A0343|154 166|vinyl siloxane
P07748493A1045|16 29|Aplysia Afurin2
P07748493A1045|33 43|candidate PC
P07748493A1045|57 69|important role
P07748493A1045|87 103|egg-laying hormone
P07748493A1045|105 107|ELH
P07748493A1045|110 126|related precursors
P07748493A1045|132 145|secretory cells
P07748493A1045|151 161|atrial gland
P07748502A0794|0 3|Rats
P07748502A0794|15 23|8-OH-DPAT
P07748502A0794|31 38|impaired
P07748502A0794|61 80|visual discrimination
P07748502A0794|84 92|water maze
P07748848A0263|3 38|term endovascular papillary haemangioma
P07748952A0462|14 30|internal promoters
P07748952A0462|32 36|PmiaA
P07748952A0462|40 44|P1hfq
P07748952A0462|79 89|nucleotides
P07748952A0462|105 135|respective translation start sites
P07748952A1329|5 11|results
P07748952A1329|24 27|mutL
P07748952A1329|29 32|miaA
P07748952A1329|37 49|hfq expression
P07748952A1329|37 39|hfq
P07748952A1329|68 85|multiple mechanisms
P07748952A1329|104 118|cotranscription
P07748952A1329|123 135|upstream genes
P07748952A1329|137 146|modulation
P07748952A1329|149 172|internal promoter strength
P07748952A1329|179 192|RNase E activity
P07748952A1329|179 184|RNase E
P07749088A0119|0 9|Coronary T1
P07749088A0119|13 28|T2 weighted images
P07749461A0632|4 5|kb
P07749461A0632|11 24|flanking region
P07749461A0632|34 35|kb
P07749461A0632|41 62|entire sGTH alpha subunit
P07749461A0632|95 106|genomic clone
P07749461A0632|108 119|sGTH alpha-G1
P07749461A1022|0 17|Functional analysis
P07749461A1022|23 46|sGTH alpha subunit promoter
P07749461A1022|52 72|transient transfection
P07749461A1022|75 110|several sGTH alpha/CAT chimeric plasmids
P07749461A1022|82 90|sGTH alpha
P07749461A1022|92 94|CAT
P07749461A1022|115 140|rainbow trout pituitary cells
P07749461A1022|156 183|pituitary-specific expression
P07749461A1022|186 198|GSE-dependent
P07750217T0000|0 23|Indium-111 OncoScint CR/OV
P07750217T0000|27 33|F-18 FDG
P07750217T0000|36 45|colorectal
P07750217T0000|49 75|ovarian carcinoma recurrences
P07751848A0222|3 31|carnitine palmitoyltransferase
P07751848A0222|33 35|CPT
P07751848A0222|43 52|activities
P07751848A0222|68 85|nmol/min/mg protein
P07751848A0222|102 110|mean value
P07751848A0222|138 155|nmol/min/mg protein
P07751848A0222|172 186|control subjects
P07752223A0960|3 7|Myc LZ
P07752223A0960|25 47|homodimeric interactions
P07752223A0960|63 74|Myc inability
P07752223A0960|63 65|Myc
P07752454A0341|23 25|CNS
P07752454A0341|38 60|moderate resistance rates
P07752454A0341|63 73|methicillin
P07752454A0341|75 79|DMPPC
P07752644A1031|5 15|VF resistant
P07752644A1031|18 31|defibrillation
P07752644A1031|66 85|toxic plasma drug level
P07752644A1031|108 117|conduction
P07752886A0595|3 30|smallest active FecR derivative
P07752886A0595|42 58|amino acid residues
P07752886A0595|77 84|residues
P07752886A0595|87 99|wild-type FecR
P07753027A0240|3 20|gene pairs psbB-psbT
P07753027A0240|12 20|psbB-psbT
P07753027A0240|24 32|psbH-psbN
P07753027A0240|53 67|opposite strands
P07753030A0173|0 19|Hybridization signals
P07753030A0173|40 48|total DNAs
P07753030A0173|51 74|Rhizobium leguminosarum bv
P07753030A0173|76 83|phaseoli
P07753030A0173|85 105|Rhodobacter capsulatus
P07753030A0173|138 160|Xanthomonas campestris pv
P07753030A0173|162 171|campestris
P07753796A0625|12 28|amino acid sequence
P07753796A0625|37 52|regions identical
P07753796A0625|58 66|sequences
P07753796A0625|69 76|peptides
P07753796A0625|88 116|bovine liver eIF-2B alpha subunit
P07753796A0743|0 9|Expression
P07753796A0743|16 19|cDNA
P07753796A0743|34 40|peptide
P07753796A0743|60 77|natural eIF-2B alpha
P07753796A0743|67 77|eIF-2B alpha
P07753796A0743|80 101|SDS/polyacrylamide gels
P07753837A0724|4 6|RNA
P07753837A0724|18 27|tail domain
P07753837A0724|30 39|desmoglein
P07753837A0724|57 70|plakoglobin RNA
P07753837A0724|79 95|dorsalizing effect
P07753837A0724|99 117|nuclear accumulation
P07753837A0724|120 130|plakoglobin
P07754713A0227|10 13|NUC1
P07754713A0227|15 19|PRP21
P07754713A0227|31 35|SPP91
P07754713A0227|38 41|CDC6
P07754713A0227|43 46|CRY2
P07754713A0227|66 84|ribosomal protein S24
P07754713A0227|105 123|hypothetical protein
P07754713A0227|129 138|amino acids
P07755884A0000|0 18|Intrastriatal grafts
P07755884A0000|21 26|nigral
P07755884A0000|30 43|adrenal tissues
P07755884A0000|92 102|simple motor
P07755884A0000|106 125|sensorimotor deficits
P07755884A0000|140 146|lesions
P07755884A0000|152 178|nigrostriatal dopamine system
P07755914A0000|0 8|OBJECTIVE
P07755914A0000|49 62|clarithromycin
P07755914A0000|66 77|azithromycin
P07755914A0000|105 112|patients
P07755914A0000|136 160|Mycobacterium avium complex
P07755914A0000|162 165|DMAC
P07757315A1227|14 24|aggregation
P07757315A1227|44 49|% value
P07757315A1227|51 51|h
P07757315A1227|57 71|drug application
P07757315A1227|103 119|observation period
P07757315A1227|122 129|ABSTRACT
P07757315A1227|144 148|WORDS
P07758167A1488|0 11|Growth curves
P07758167A1488|25 37|proliferation
P07758167A1488|40 47|clone CA9
P07758167A1488|65 70|% serum
P07758167A1488|85 85|%
P07758167A1488|98 106|clone ME10
P07758246A0469|28 30|bps
P07758246A0469|49 54|intron
P07758246A0469|62 66|exons
P07758459A1277|3 5|UAS
P07758459A1277|11 18|AAC2 gene
P07758459A1277|37 50|distinct motifs
P07758459A1277|54 89|DNA-binding transcriptional activators
P07758459A1277|126 149|core HAP2/3/4 binding motif
P07758459A1277|171 198|ABF1 consensus binding sequence
P07758837A1118|28 43|regulatory region
P07758837A1118|49 62|GH receptor gene
P07758837A1118|96 101|probes
P07758837A1118|113 118|exon 1B
P07758837A1118|125 130|distal
P07758837A1118|133 146|intron boundary
P07758837A1118|181 196|genomic sequences
P07758837A1118|208 231|liver-specific P1 promoter
P07758837A1118|235 238|exon
P07759094A0634|1 23|polymorphic dinucleotide
P07759094A0634|25 29|GT/CA
P07759094A0634|31 37|n repeat
P07759094A0634|52 61|NHE5 cosmid
P07759094A0634|92 114|microsatellite PCR marker
P07759525A0417|3 10|proteins
P07759525A0417|24 33|% identical
P07759525A0417|54 72|protein kinase domain
P07759525A0417|85 94|% identical
P07759525A0417|97 113|other casein kinase
P07759525A0417|102 122|casein kinase I isoforms
P07759525A0417|115 122|isoforms
P07759529A0288|9 18|approaches
P07759529A0288|37 43|CDP/cut
P07759529A0288|37 39|CDP
P07759529A0288|41 43|cut
P07759529A0288|53 61|repressor
P07759529A0288|64 86|gp91-phox gene expression
P07759529A0288|64 67|gp91
P07759529A0288|69 76|phox gene
P07760790A0327|0 13|Serum induction
P07760790A0327|17 32|MEF2 reporter gene
P07760790A0327|56 66|NIH 3T3 cells
P07760790A0327|79 104|low MEF2 site binding activity
P07760819A0731|10 19|activation
P07760819A0731|27 39|intracellular
P07760819A0731|49 57|molecules
P07760819A0731|59 84|PDGF beta receptor activation
P07760819A0731|59 74|PDGF beta receptor
P07760819A0731|95 110|detectable effect
P07760819A0731|113 129|cell proliferation
P07760819A0731|132 146|differentiation
P07760841A0221|0 3|UAS1
P07760841A0221|9 19|binding site
P07760841A0221|26 54|transcriptional regulator Adr1p
P07760841A0221|50 54|Adr1p
P07760841A0647|17 44|ADH2 upstream regulatory region
P07760841A0647|55 58|UAS1
P07760841A0647|83 107|ADH2 basal promoter elements
P07760841A0647|109 136|UAS2-dependent gene activation
P07760841A0647|109 126|UAS2-dependent gene
P07760841A0647|163 172|copy number
P07760841A0647|177 186|helix phase
P07760844A0413|0 8|Induction
P07760844A0413|11 24|AP-1 DNA binding
P07760844A0413|40 68|concomitant GH trans-activation
P07760844A0413|71 75|c-jun
P07760844A0413|79 88|c-fos genes
P07761091A0294|0 11|Inactivation
P07761091A0294|14 23|MAP kinases
P07761091A0294|33 52|a specific phosphatase
P07761091A0294|34 52|specific phosphatase
P07761091A0294|54 58|MKP-1
P07761216T0000|0 31|Short-course amphotericin B therapy
P07761216T0000|35 44|candidemia
P07761216T0000|47 63|pediatric patients
P07761420A0909|12 29|45Ca-binding assays
P07761420A0909|42 46|CCaMK
P07761420A0909|60 62|Ca2
P07761434A1084|5 8|AP-1
P07761434A1084|13 29|important mediator
P07761434A1084|32 50|tumor promoter action
P07761434A1084|57 64|findings
P07761434A1084|78 105|anti-tumor-promoting activity
P07761434A1084|108 127|phenolic antioxidants
P07761467A0666|3 15|second complex
P07761467A0666|43 59|protein components
P07761467A0666|72 84|36-kDa protein
P07762431A0356|32 35|cDNA
P07762431A0356|53 65|culture medium
P07762431A0356|69 74|yields
P07762431A0356|83 84|mg
P07762431A0356|88 92|litre
P07762504A0648|40 53|oral amiodarone
P07762504A0648|57 65|mg/kg/day
P07762504A0648|70 73|days
P07762504A0648|84 88|doses
P07762504A0648|107 107|g
P07763727A1035|0 13|Plasmids pAMS12
P07763727A1035|15 20|pAMS13
P07763727A1035|24 29|pAMS14
P07763727A1035|50 65|laboratory strain
P07763727A1035|99 104|pAMS15
P07763727A1035|131 156|commercial wine yeast strains
P07765118A0967|3 18|maximum induction
P07765118A0967|21 42|ACC-oxidase transcripts
P07765118A0967|59 59|h
P07765118A0967|65 72|excision
P07765118A0967|82 102|maximum enzyme activity
P07765118A0967|118 119|h.
P07766885A0405|11 26|polypeptide chain
P07766885A0405|56 63|features
P07766885A0405|75 83|plant CDPK
P07766885A0405|80 83|CDPK
P07766885A0405|85 108|kinase catalytic sequences
P07766885A0405|121 151|calmodulin-like regulatory domain
P07766885A0405|160 173|junction region
P07767011A0689|0 5|Repair
P07767011A0689|12 20|insertion
P07767011A0689|23 45|homologous recombination
P07767011A0689|70 78|hprt locus
P07767011A0689|103 110|mutation
P07768824A0167|11 27|fla gene expression
P07768824A0167|11 17|fla gene
P07768824A0167|33 41|cell cycle
P07768824A0167|56 71|specialized forms
P07768824A0167|74 86|RNA polymerase
P07768824A0167|109 118|activation
P07768824A0167|121 138|regulatory proteins
P07768836A1126|0 25|Primer extension experiments
P07768836A1126|35 67|strong transcription initiation site
P07768836A1126|71 80|bp upstream
P07768836A1126|86 107|translational start site
P07768848A1880|0 11|Polypeptides
P07768848A1880|17 33|same apparent sizes
P07768848A1880|47 52|spores
P07768848A1880|56 69|cotE null mutant
P07768848A1880|56 59|cotE
P07768848A1880|97 104|products
P07768848A1880|110 119|cotJ operon
P07768848A1880|137 151|normal formation
P07768848A1880|157 167|inner layers
P07768848A1880|192 211|structural components
P07768898A0492|19 24|values
P07768898A0492|27 36|divergence
P07768898A0492|39 54|apobec1 sequences
P07768898A0492|67 73|numbers
P07768898A0492|76 85|synonymous
P07768898A0492|89 115|non-synonymous suhstitutions
P07768898A0492|135 141|apobec1
P07768953T0039|0 3|EEA1
P07768953T0039|16 53|alpha-helical peripheral membrane protein
P07768953T0039|63 70|cysteine
P07768953T0039|72 78|fingers
P07768953T0039|92 116|calmodulin-binding IQ motif
P07770033A0978|0 18|Nucleotide sequences
P07770033A0978|24 29|clones
P07770033A0978|45 49|clone
P07770033A0978|51 54|cap3
P07770033A0978|67 82|open reading frame
P07770033A0978|84 86|ORF
P07770033A0978|105 116|26-amino acid
P07770033A0978|118 137|cysteine-rich peptide
P07770033A0978|142 160|significant homology
P07770033A0978|163 199|Neurospora crassa copper metallothionein
P07771671T0000|44 59|carbon electrodes
P07771745A0442|0 8|Elevation
P07771745A0442|14 20|tissues
P07771745A0442|72 85|temporal region
P07771745A0442|94 103|cheekbones
P07772036A1000|18 41|ubiquitous nuclear factors
P07772036A1000|43 50|USF/MLTF
P07772036A1000|43 45|USF
P07772036A1000|47 50|MLTF
P07772036A1000|57 101|CAAT-binding transcription factor/nuclear factor
P07772036A1000|104 110|CTF/NF1
P07772036A1000|104 106|CTF
P07772036A1000|108 110|NF1
P07774137A0000|3 17|potential impact
P07774137A0000|26 44|rapid diagnostic test
P07774137A0000|46 54|Strep A OIA
P07774137A0000|58 66|detection
P07774137A0000|81 113|group A beta-hemolytic streptococcal
P07774137A0000|115 119|GABHS
P07774137A0000|121 131|pharyngitis
P07774137A0000|135 155|large-volume pediatric
P07774137A0000|159 174|adolescent clinic
P07774807A0405|3 14|bHLH proteins
P07774807A0405|25 55|potent transcriptional activators
P07774807A0405|58 77|tissue-specific genes
P07774807A0405|87 98|heterodimers
P07774807A0405|106 115|ubiquitous
P07774807A0405|119 146|cell-restricted family members
P07774925A0084|0 2|YAC
P07774925A0084|6 18|cosmid contigs
P07774925A0084|30 40|BRCA1 region
P07774925A0084|57 66|cDNA clones
P07774925A0084|71 75|pools
P07774925A0084|78 82|cDNAs
P07774925A0084|94 106|human placenta
P07774925A0084|108 116|HeLa cells
P07774925A0084|127 132|T cells
P07774925A0084|137 145|fetal head
P07775428A0172|11 16|clones
P07775428A0172|18 27|Ash-m and -s
P07775428A0172|18 22|Ash-m
P07775428A0172|27 27|s
P07775428A0172|32 59|nucleotide sequences identical
P07775428A0172|64 72|Ash-l cDNA
P07775428A0172|78 97|amino-terminal region
P07776685A0000|20 30|feasibility
P07776685A0000|34 41|toxicity
P07776685A0000|44 64|adoptive immunotherapy
P07776685A0000|86 96|lymphocytes
P07776685A0000|100 123|recombinant interleukin-2
P07776685A0000|128 135|patients
P07776685A0000|148 156|resection
P07776685A0000|168 191|non-small-cell lung cancer
P07776711A0295|0 7|MATERIAL
P07776711A0295|11 17|METHODS
P07776711A0295|26 28|men
P07776711A0295|34 38|women
P07776711A0295|53 57|years
P07776711A0295|69 83|hereditary motor
P07776711A0295|87 107|sensory neuropathy type
P07776711A0295|137 150|polyneuropathy
P07776882A0000|3 14|present study
P07776882A0000|27 44|cell volume dynamics
P07776882A0000|47 61|intact rat hearts
P07776882A0000|69 76|ischemia
P07776882A0000|85 95|reperfusion
P07776979A0702|11 17|COUP-TF
P07776979A0702|36 72|repCRS2-dependent reporter gene activity
P07777518A0483|0 12|DNA sequencing
P07777518A0483|16 35|Southern blot analyses
P07777518A0483|54 63|cDNA clones
P07777518A0483|81 94|different genes
P07779558T0000|0 19|Muscle GSH-Px activity
P07779558T0000|0 11|Muscle GSH-Px
P07779558T0000|25 41|prolonged exercise
P07779558T0000|55 77|selenium supplementation
P07779811A0901|0 7|Mutation
P07779811A0901|13 22|Sp1 element
P07779811A0901|38 47|Sp1 binding
P07779811A0901|38 40|Sp1
P07779811A0901|59 76|6-10-fold reduction
P07779811A0901|79 94|reporter activity
P07779812A0000|3 11|c-myc gene
P07779812A0000|39 48|tumor types
P07779812A0000|67 79|important role
P07779812A0000|85 98|abnormal growth
P07779812A0000|110 118|cell types
P07780148A1153|11 13|PML
P07780148A1153|29 38|lower level
P07780148A1153|41 41|S
P07780148A1153|43 44|G2
P07780148A1153|49 55|M phases
P07780148A1153|75 85|higher level
P07780148A1153|88 94|G1 phase
P07780525A0495|0 8|Schooling
P07780525A0495|29 38|good health
P07780525A0495|62 72|differences
P07780525A0495|75 96|observable health inputs
P07780719A0477|16 31|diastolic driving
P07780719A0477|36 43|abnormal
P07780738A0091|8 11|Cdks
P07780738A0091|17 18|G1
P07780738A0091|22 28|S phases
P07780738A0091|34 42|cell cycle
P07780738A0091|58 88|proliferating cell nuclear antigen
P07780738A0091|71 88|cell nuclear antigen
P07780738A0091|90 93|PCNA
P07780738A0091|104 117|DNA replication
P07782087A0559|14 46|minor transcription initiation sites
P07782087A0559|61 69|positions
P07782087A0559|122 143|ribonuclease protection
P07782087A0559|145 159|primer extension
P07782087A0559|166 177|RACE analyses
P07782113A0726|3 20|roxithromycin doses
P07782113A0726|43 49|studies
P07782113A0726|62 82|achievable blood levels
P07782302A0479|25 38|DEDDDL sequence
P07782302A0479|49 51|GDP
P07782302A0479|61 63|Ran
P07782302A0479|94 116|high affinity interaction
P07782302A0479|122 139|Ran-binding protein
P07782302A0479|141 152|HTF9A/RanBP1
P07782302A0479|141 145|HTF9A
P07782302A0479|147 152|RanBP1
P07782775A0889|11 14|ORFs
P07782775A0889|17 26|components
P07782775A0889|50 57|proteins
P07782775A0889|67 69|kDa
P07782775A0889|83 97|BBTV coat protein
P07783064A0452|0 25|Serial followup strength data
P07783064A0452|30 37|patients
P07783064A0452|60 75|creatinine kinase
P07783064A0452|77 78|CK
P07783064A0452|80 85|levels
P07783641A0591|0 3|CodY
P07783641A0591|18 27|homologues
P07783641A0591|33 42|data-bases
P07783822A0000|0 8|OBJECTIVE
P07783822A0000|26 34|incidence
P07783822A0000|52 66|acute pernicious
P07783822A0000|69 87|fulminating beriberi
P07783822A0000|91 113|general district hospital
P07784061A0894|6 28|most other small G proteins
P07784061A0894|59 61|TTF
P07784061A0894|82 97|hemopoietic cells
P07784061A0894|104 115|kb transcript
P07784078A1064|34 47|gene expression
P07784078A1064|64 69|levels
P07784078A1064|72 79|RAR alpha
P07784078A1064|82 84|PML
P07784078A1064|98 110|APL cell growth
P07784079A1018|0 11|Transfection
P07784079A1018|14 40|non-deleted expression vector
P07784079A1018|45 55|NIH3T3 cells
P07784079A1018|78 98|focus-forming activity
P07784079A1018|105 115|deleted form
P07784079A1018|118 133|expression vector
P07784079A1018|176 183|basic FGF
P07784197A0827|0 16|Cytosolic extracts
P07784197A0827|31 48|mammalian cell lines
P07784197A0827|50 59|monkey Cos7
P07784197A0827|61 85|several mouse fibrosarcomas
P07784197A0827|89 99|human HeLa S3
P07784197A0827|113 127|similar TGF-beta
P07784197A0827|120 148|TGF-beta 1 dependent RNA-protein
P07784197A0827|129 158|dependent RNA-protein band shifts
P07784197A0827|161 171|cell extract
P07784197A0827|176 200|BALB/c 3T3 mouse fibroblasts
P07784199A0000|3 18|ribosomal protein
P07784199A0000|20 21|rp
P07784199A0000|23 35|gene promoters
P07784199A0000|107 111|sites
P07784199A0000|118 141|global gene regulator Rap1p
P07784199A0000|137 141|Rap1p
P07784199A0000|168 179|global factor
P07784199A0000|181 185|Abf1p
P07784870A0119|3 20|provisional reports
P07784870A0119|39 57|macroscopic findings
P07784870A0119|69 80|final reports
P07784870A0119|112 142|supplementary investigations such
P07784870A0119|145 154|microscopy
P07784870A0119|156 169|histochemistry
P07784870A0119|181 198|electron microscopy
P07784870A0119|200 219|immunohistochemistry
P07784870A0119|226 237|microbiology
P07784942T0001|11 24|thrombomodulin
P07784942T0001|26 41|current knowledge
P07784942T0001|45 59|future prospects
P07786820A0284|0 5|CPT-11
P07786820A0284|24 44|30-minute i.v. infusion
P07786820A0284|57 61|mg/m2
P07786820A0284|74 87|ml normal saline
P07786820A0284|94 98|weeks
P07786821A2292|0 9|CONCLUSION
P07786821A2292|14 16|MTD
P07786821A2292|20 25|CPT-11
P07786821A2292|42 78|consecutive-days-every-3 weeks schedule
P07786821A2292|85 101|patient population
P07786821A2292|107 115|mg/m2/day
P07787179A0312|3 12|bp fragment
P07787179A0312|14 21|X1 region
P07787179A0312|28 41|PRB-1b promoter
P07787179A0312|43 49|located
P07787179A0312|57 65|positions
P07787179A0312|99 120|ethylene responsiveness
P07787179A0312|126 137|reporter gene
P07789275A0325|20 20|s
P07789275A0325|24 26|E74
P07789275A0325|33 45|metamorphosis
P07789275A0325|77 118|recessive loss-of-function mutations specific
P07789275A0325|125 141|transcription unit
P07789342A1352|11 29|extracellular domain
P07789342A1352|35 39|TSH-R
P07789342A1352|55 73|high affinity binding
P07789342A1352|76 78|TSH
P07789342A1352|97 107|hyt mutation
P07789342A1352|113 137|fourth transmembrane domain
P07789342A1352|148 157|TSH binding
P07789396A0504|0 7|Lipiodol
P07789396A0504|35 38|EDTB
P07789809A1246|9 20|Western blots
P07789809A1246|43 47|types
P07789809A1246|50 52|Ypt
P07789809A1246|59 60|Cr
P07789809A1246|64 65|Vc
P07789809A1246|86 88|Ypt
P07789809A1246|99 127|household functions responsible
P07789809A1246|131 146|vesicle transport
P07789809A1246|160 182|cellular differentiation
P07789971A0758|12 23|other regions
P07789971A0758|26 38|hybridization
P07789971A0758|68 83|related sequences
P07789971A0758|108 118|pseudogenes
P07789971A0758|142 147|genome
P07789971A0758|172 183|related genes
P07789971A0758|208 212|GSTT2
P07790271A1185|11 18|lens dose
P07790271A1185|23 36|Gy/25 fractions
P07790271A1185|41 46|higher
P07790271A1185|60 74|other techniques
P07790377A0561|0 9|Antibodies
P07790377A0561|15 24|human PTS1R
P07790377A0561|67 78|hamster cells
P07790719A0098|8 21|national effort
P07790719A0098|37 50|female patients
P07790719A0098|56 69|family violence
P07791760A0424|0 12|GnRH treatment
P07791760A0424|0 3|GnRH
P07791760A0424|34 48|phosphorylation
P07791760A0424|51 66|tyrosine residues
P07791760A0424|69 72|MAPK
P07791760A0424|86 97|MAPK activity
P07791760A0424|86 89|MAPK
P07791760A0424|115 138|immune complex kinase assay
P07791763T0000|0 15|Molecular cloning
P07791763T0000|20 62|amphibian insulin receptor substrate 1-like cDNA
P07791763T0000|79 106|phosphatidylinositol 3-kinase
P07791763T0000|109 146|insulin-induced Xenopus oocyte maturation
P07791763T0000|109 115|insulin
P07791764A0357|26 37|Jurkat T cells
P07791764A0357|39 41|Cbl
P07791764A0357|62 69|antibody
P07791764A0357|80 97|adapter protein Grb2
P07791768A0930|16 34|cell cycle regulators
P07791768A0930|53 57|rap1s
P07791768A0930|60 76|hmr delta A mutation
P07791768A0930|83 86|swi6
P07791768A0930|88 91|swi4
P07791768A0930|96 108|clb5 mutations
P07791768A0930|121 129|mutations
P07791768A0930|132 135|SIR1
P07791768A0930|178 186|silencing
P07791769A0826|0 3|ICP4
P07791769A0826|22 40|tripartite complexes
P07791769A0826|61 82|TATA box-binding protein
P07791769A0826|86 90|TFIIB
P07791769A0826|108 122|ICP4 binding site
P07791769A0826|127 133|TATA box
P07791769A0826|135 136|C.
P07791771A0183|0 3|Otte
P07791771A0183|5 7|Mol
P07791776T0000|0 15|Characterization
P07791776T0000|18 21|fus1
P07791776T0000|65 82|controlled function
P07791776T0000|92 102|conjugation
P07791783A0000|0 14|SRY-related cDNA
P07791783A0000|36 54|high-mobility-group
P07791783A0000|56 58|HMG
P07791783A0000|67 84|leucine zipper motif
P07791783A0000|104 109|SOX-LZ
P07791783A0000|127 155|rainbow trout testis cDNA library
P07793783A0189|0 9|Scalp flaps
P07793783A0189|47 56|noticeable
P07793783A0189|65 69|weeks
P07793783A0189|80 101|scalp flap transposition
P07793783A0189|105 115|easy closure
P07793783A0189|121 129|donor site
P07794556A0000|5 10|Center
P07794556A0000|14 26|Human Genetics
P07794556A0000|29 34|Leuven
P07794556A0000|36 56|predictive DNA-testing
P07794556A0000|60 69|Huntington
P07794556A0000|93 107|clinical service
P07794556A0000|113 120|November
P07794556A0000|137 147|DNA-linkage
P07794556A0000|156 158|mid
P07794556A0000|165 186|direct mutation analysis
P07795104T0000|0 4|Risks
P07795104T0000|7 16|chronicity
P07795104T0000|26 54|acute hepatitis B virus infection
P07795576A0126|0 10|Examination
P07795576A0126|13 31|neurohumoral factors
P07795576A0126|41 75|hyperactive sympathetic nervous system
P07795576A0126|91 109|plasma renin activity
P07796935A0284|13 28|inhibitory effect
P07796935A0284|49 61|mutant hTR beta
P07796935A0284|83 98|hTR alpha 1 mutants
P07796935A0284|83 90|hTR alpha
P07796935A0284|92 98|mutants
P07796935A0284|100 111|c-erbA alpha 2
P07796935A0284|100 110|c-erbA alpha
P07796935A0284|118 162|human peroxisome proliferator-activated receptor
P07796935A0284|164 168|hPPAR
P07796935A0284|177 205|prototypic T3-response elements
P07796935A0284|187 205|T3-response elements
P07796935A0284|207 210|TREs
P07796935A0284|213 219|TRE-PAL
P07796935A0284|221 224|DR + 4
P07796935A0284|221 222|DR
P07796935A0284|228 234|TRE-LAP
P07797077A0842|3 33|amino-terminal DNA-binding domain
P07797077A0842|36 38|Pip
P07797077A0842|48 57|high degree
P07797077A0842|60 67|homology
P07797077A0842|73 90|DNA-binding domains
P07797077A0842|93 99|members
P07797077A0842|105 130|interferon regulatory factor
P07797077A0842|132 141|IRF) family
P07797077A0842|132 134|IRF
P07797077A0842|156 160|IRF-1
P07797077A0842|162 166|IRF-2
P07797077A0842|168 172|ICSBP
P07797077A0842|177 186|ISGF3 gamma
P07797346T0000|2 9|outbreak
P07797346T0000|12 21|hepatitis A
P07797346T0000|27 39|homosexual men
P07797346T0000|42 50|Amsterdam
P07797476A1001|3 14|RAP74 subunit
P07797476A1001|17 21|TFIIF
P07797476A1001|39 57|stimulatory activity
P07797476A1001|64 86|minimal region sufficient
P07797476A1001|90 100|stimulation
P07797476A1001|114 134|COOH-terminal residues
P07797583A0222|15 38|various base substitutions
P07797583A0222|42 58|internal deletions
P07797583A0222|70 72|DRE
P07797583A0222|74 92|nucleotide positions
P07797583A0222|118 144|transcription initiation site
P07797583A0222|151 158|PCNA gene
P07797583A0222|194 200|effects
P07797583A0222|206 212|binding
P07797583A0222|215 218|DREF
P07797583A0222|220 236|DRE-binding factor
P07797583A0222|241 248|PCNA gene
P07797583A0222|274 290|Drosophila Kc cells
P07797583A0222|307 311|flies
P07798134T0000|3 17|hsp70 gene family
P07798134T0000|3 11|hsp70 gene
P07798134T0000|20 35|Neurospora crassa
P07798134T0000|37 43|cloning
P07798134T0000|45 60|sequence analysis
P07798134T0000|76 89|genetic mapping
P07798134T0000|95 121|major stress-inducible member
P07798207A0759|10 27|amino acid sequences
P07798207A0759|39 53|W3A1 ETF subunits
P07798207A0759|80 88|% identity
P07798207A0759|96 116|corresponding subunits
P07798207A0759|122 124|ETF
P07798207A0759|142 164|Paracoccus denitrificans
P07798207A0759|182 188|greater
P07798207A0759|195 204|% identical
P07798217T0000|1 24|secondary phosphorylation
P07798217T0000|27 33|CREB341
P07798217T0000|36 41|Ser129
P07798217T0000|58 77|cAMP-mediated control
P07798217T0000|80 93|gene expression
P07798217T0095|8 31|glycogen synthase kinase-3
P07798217T0095|46 59|gene expression
P07798271A0330|4 13|last region
P07798271A0330|25 29|sites
P07798271A0330|38 63|Ets-related proteins present
P07798271A0330|38 56|Ets-related proteins
P07798271A0330|66 85|liver nuclear extracts
P07798271A0330|94 104|recombinant
P07798271A0330|113 124|Ets-1 protein
P07799437A0656|0 10|Other assays
P07799437A0656|31 51|processive replication
P07799437A0656|54 63|pNeo.Myc-2
P07799437A0656|73 90|dispersive labeling
P07799437A0656|93 107|control plasmids
P07799925A0526|0 13|Reconstitution
P07799925A0526|16 24|complexes
P07799925A0526|35 37|p62
P07799925A0526|44 64|src family kinase p59fyn
P07799925A0526|67 75|HeLa cells
P07799925A0526|92 107|complex formation
P07799925A0526|118 140|tyrosine phosphorylation
P07799925A0526|143 145|p62
P07799925A0526|169 171|SH3
P07799925A0526|175 184|SH2 domains
P07799925A0526|187 192|p59fyn
P07799931A0287|36 57|transcriptional control
P07799931A0287|63 76|L7 gene insights
P07799931A0287|63 68|L7 gene
P07799931A0287|84 93|mechanisms
P07799931A0287|105 118|functional fate
P07799931A0287|139 151|nervous system
P07799931A1232|12 29|Maf-related protein
P07799931A1232|31 33|Nrl
P07799931A1232|53 64|c-Maf actions
P07799931A1232|53 57|c-Maf
P07799939A0628|3 16|27-base element
P07799939A0628|31 74|PDGF-activated serine/threonine phosphoprotein
P07799939A0628|102 108|nucleus
P07799939A0628|111 130|PDGF-treated 3T3 cells
P07799939A0628|111 114|PDGF
P07799948A0777|11 18|deletion
P07799948A0777|25 39|Ras-binding site
P07799948A0777|54 63|activation
P07799948A0777|66 76|Raf-1 kinase
P07799948A0777|79 81|Src
P07799948A0777|95 97|Src
P07799948A0777|101 103|Ras
P07799948A0777|115 119|Raf-1
P07799948A0777|127 147|independent mechanisms
P07799950A0282|2 8|studies
P07799950A0282|11 23|many different
P07799950A0282|38 50|distinct cells
P07799950A0282|55 57|CRE
P07799950A0282|63 86|somatostatin gene promoter
P07799950A0282|90 98|prototype
P07799950A0282|108 129|cAMP-responsive element
P07799950A0282|141 144|CREB
P07800479A0201|3 11|first gene
P07800479A0201|13 16|NSR1
P07800479A0201|69 90|ribosomal RNA maturation
P07800479A0201|115 122|proteins
P07800479A0201|130 136|nucleus
P07800505T0000|0 15|Characterization
P07800505T0000|21 28|promoter
P07800505T0000|35 72|human 85 kDa cytosolic phospholipase A2 gene
P07800505T0000|42 72|kDa cytosolic phospholipase A2 gene
P07801180A0197|21 30|advantages
P07801180A0197|34 44|limitations
P07801180A0197|50 68|main study approaches
P07802355T0000|0 15|Comparative study
P07802355T0000|21 51|differential white blood cell count
P07802355T0000|71 79|analyzers
P07802355T0000|81 91|Coulter STKS
P07802355T0000|93 100|Sysmex NE
P07802355T0000|108 119|Technicon H-1
P07802655T0000|0 15|Characterization
P07802655T0000|18 25|FIII/YY1
P07802655T0000|18 21|FIII
P07802655T0000|23 25|YY1
P07802655T0000|28 67|Xenopus laevis conserved zinc-finger protein
P07802655T0000|28 40|Xenopus laevis
P07802655T0000|50 74|zinc-finger protein binding
P07802655T0000|80 88|first exon
P07802655T0000|91 92|L1
P07802655T0000|96 119|L14 ribosomal protein genes
P07803809A1852|0 13|Further studies
P07803809A1852|32 49|Ep-induced increase
P07803809A1852|32 33|Ep
P07803809A1852|52 66|beta-globin mRNA
P07803809A1852|88 119|tyrosine kinase inhibitor genistein
P07803809A1852|88 101|tyrosine kinase
P07803809A1852|126 156|protein kinase C inhibitor Compound
P07803809A1852|126 139|protein kinase C
P07803809A1852|160 167|ABSTRACT
P07803809A1852|182 186|WORDS
P07806492A1162|15 23|cucumisin
P07806492A1162|63 79|inactive precursor
P07806507A0121|0 18|Molecular dissection
P07806507A0121|24 47|multimeric CD3-TCR complex
P07806507A0121|80 91|polypeptides
P07806507A0121|93 99|CD3 zeta
P07806507A0121|103 112|CD3 epsilon
P07806507A0121|126 156|couple antigenic recognition event
P07806507A0121|167 176|late events
P07806507A0121|182 214|intracytoplasmic activation cascade
P07806532A0659|0 11|Protein cHMGI
P07806532A0659|33 42|AT-rich DNA
P07806532A0659|48 67|half-saturation value
P07806532A0659|73 74|nM
P07806651A0097|37 50|racial identity
P07806651A0097|61 77|Mexican-Americans
P07806651A0097|95 95|L
P07806651A0097|97 97|K
P07806651A0097|102 109|MF scales
P07806651A0097|115 120|MMPI-2
P07806820A0091|9 16|elevated
P07806820A0091|20 40|single vascular pedicle
P07806820A0091|51 75|superficial temporal artery
P07806820A0091|80 111|double-layered temporal fascia flap
P07807002A0500|9 16|segments
P07807002A0500|31 35|flank
P07807002A0500|41 55|initiation sites
P07807002A0500|59 76|germline epsilon RNA
P07807002A0500|91 112|luciferase reporter gene
P07807002A0500|134 148|mouse B cell lines
P07807002A0500|182 184|IgE
P07808210A1510|3 25|negative predictive value
P07808210A1510|30 30|%
P07808210A1510|36 36|%
P07808210A1510|43 48|NCEP I.
P07809128T0000|0 16|Oncogenic capacity
P07809128T0000|22 29|E2F1 gene
P07809410A0606|11 15|cases
P07809410A0606|18 31|solitary lesion
P07809410A0606|33 46|serum TSH levels
P07809410A0606|38 40|TSH
P07809410A0606|48 71|serum thyroglobulin values
P07809410A0606|53 65|thyroglobulin
P07809410A0606|76 86|131I protein
P07809410A0606|94 99|iodine
P07809410A0606|101 108|131I-PBI
P07809410A0606|137 158|significant differences
P07809410A0606|179 197|unsuccessful therapy
P07811639A0222|0 16|Endo16 transcripts
P07811639A0222|33 54|definitive vegetal plate
P07811639A0222|57 76|blastula stage embryos
P07811639A0222|80 92|gastrula stage
P07811639A0222|125 135|archenteron
P07811639A0222|154 159|midgut
P07811964A1252|1 34|unique leucine-proline repeat element
P07811964A1252|40 49|N-terminal
P07811964A1252|55 71|DNA-binding domain
P07811964A1252|74 79|EmBP-1
P07811964A1252|106 116|DNA-binding
P07811964A1252|119 130|dimerization
P07812450A0849|7 13|full ORF
P07812450A0849|27 40|opposite strand
P07812450A0849|58 65|nspC gene
P07813466A0074|3 10|U14 genes
P07813466A0074|30 36|hamster
P07813466A0074|44 50|Xenopus
P07813466A0074|54 58|trout
P07813466A0074|75 81|introns
P07813466A0074|110 145|70-kDa-cognate-heat-shock protein gene
P07813466A0074|147 151|hsc70
P07813786A0641|3 14|related cDNAs
P07813786A0641|37 44|proteins
P07813786A0641|61 75|XMyoDa TATA motif
P07814321A0850|0 7|Deletion
P07814321A0850|14 17|prfA
P07814321A0850|21 24|ponA
P07814321A0850|44 53|slow growth
P07814321A0850|69 89|sporulation efficiency
P07814323A0313|0 8|Inclusion
P07814323A0313|23 30|proteins
P07814323A0313|43 46|FliQ
P07814323A0313|50 53|FliR
P07814323A0313|72 84|export pathway
P07814323A0313|96 112|flagellum assembly
P07814388A0662|2 22|broken L-cell membranes
P07814388A0662|33 48|wild type or mutant
P07814388A0662|33 40|wild type
P07814388A0662|43 55|mutant M6P/IGF
P07814388A0662|49 51|M6P
P07814388A0662|53 66|IGF II receptors
P07814388A0662|58 66|receptors
P07814388A0662|70 74|nM IGF
P07814388A0662|72 76|IGF II
P07814388A0662|98 128|pertussis toxin substrate activity
P07814388A0662|98 111|pertussis toxin
P07814403A0433|0 3|Chem
P07814405A1170|6 14|first time
P07814405A1170|25 32|deletion
P07814405A1170|36 49|point mutations
P07814405A1170|59 104|plasma membrane family of guanylyl cyclase receptors
P07814405A1170|59 78|plasma membrane family
P07814405A1170|81 104|guanylyl cyclase receptors
P07814405A1170|131 163|effective dominant negative proteins
P07814717A0669|0 7|Increase
P07814717A0669|10 18|blood NEFA
P07814717A0669|22 37|further augmented
P07814717A0669|47 63|AA supplementation
P07814717A0669|70 76|changes
P07814717A0669|79 92|concentrations
P07814717A0669|95 97|Lys
P07814717A0669|100 102|Met
P07815546A0411|0 4|Virol
P07815811A1487b|0 23|Coronary vasoconstriction
P07815811A1487b|32 43|endothelin-1
P07815811A1487b|56 75|ischemia-reperfusion
P07815811A1487b|81 101|norepinephrine present
P07815811A1487b|104 117|concentrations
P07815811A1487b|140 168|neonatal cardiopulmonary bypass
P07816025A0196|0 9|Comparison
P07816025A0196|22 38|amino acid sequence
P07816025A0196|41 53|gamma-kafirin
P07816025A0196|70 78|sequences
P07816025A0196|81 95|gamma-prolamins
P07816025A0196|98 102|maize
P07816025A0196|107 110|Coix
P07816025A0196|134 140|domains
P07816049A0686|0 5|Atcys1
P07816049A0686|7 12|Athyp1
P07816049A0686|14 19|AKin10
P07816049A0686|26 28|ORF
P07816049A0686|69 80|same polarity
P07816049A0686|91 107|intergenic regions
P07816049A0686|141 142|kb
P07816049A0686|150 176|regulatory elements necessary
P07816049A0686|185 194|initiation
P07816049A0686|198 208|termination
P07816049A0686|211 223|transcription
P07816049A1157|0 35|Southern blot hybridization experiments
P07816049A1157|65 70|Atcys1
P07816049A1157|72 77|Athyp1
P07816049A1157|81 86|AKin10
P07816049A1157|90 102|haploid genome
P07816049A1157|107 126|Northern blot analysis
P07816049A1157|151 155|genes
P07816049A1157|184 188|roots
P07816617A0763|5 11|results
P07816617A0763|23 26|HAC1
P07816617A0763|44 55|meiotic genes
P07816619A0000|20 48|Arabidopsis thaliana cDNA clones
P07816619A0000|67 82|sterile phenotype
P07816619A0000|88 121|Schizosaccharomyces pombe pde1 mutant
P07816619A0000|112 121|pde1 mutant
P07816619A0000|130 138|defective
P07816619A0000|141 161|cAMP phosphodiesterase
P07816619A0872|32 46|Dr1-like protein
P07816619A0872|49 58|A.thaliana
P07816619A0872|79 86|ubiquity
P07816619A0872|105 120|eukaryotic genera
P07816619A0872|156 178|transcription initiation
P07816619A0872|191 193|Dr1
P07816630A1333|25 26|bp
P07816630A1333|29 46|sequence downstream
P07816630A1333|52 75|translation terminator TGA
P07816630A1333|81 93|beta-tubulin 2
P07816630A1333|81 92|beta-tubulin
P07816630A1333|95 98|BTU2
P07816630A1333|138 145|H4-I gene
P07816808A1102|27 35|STR family
P07816808A1102|38 42|genes
P07816808A1102|59 66|nematode
P07816808A1102|127 136|Arthropoda
P07816808A1102|140 147|Chordata
P07818416A0895|3 5|pre
P07818416A0895|10 47|postoperative haemoglobin concentrations
P07818416A0895|23 33|haemoglobin
P07818416A0895|53 67|autologous group
P07818416A0895|86 88|g/L
P07818416A0895|108 117|primary THR
P07818416A0895|125 127|g/L
P07818416A0895|134 142|instances
P07818416A0895|148 158|revision THR
P07819225A1094|19 31|acidic residue
P07819225A1094|37 46|second site
P07819225A1094|62 72|suppression
P07819225A1094|78 92|Asn-285 mutation
P07819225A1094|100 106|Lys-220
P07819225A1094|110 134|Gln-220 second-site mutants
P07819225A1094|140 152|Asn-285 mutant
P07819225A1094|163 187|low tetracycline resistance
P07819225A1094|190 197|ABSTRACT
P07819225A1094|212 216|WORDS
P07820057A0000|0 23|Tumor necrosis factor alpha
P07820057A0000|28 35|cytokine
P07820057A0000|57 78|autocrine growth control
P07820057A0000|81 97|hairy cell leukemia
P07820057A0000|101 130|strong bone resorptive properties
P07821790A1084|1 3|iv)
P07821790A1084|12 16|UCRBP
P07821790A1084|47 70|transcriptional repressor
P07821790A1084|86 90|UCRBP
P07821790A1084|104 125|positive transactivator
P07821790A1084|145 155|UCR elements
P07821790A1084|166 186|co-transfection assays
P07822161A1172|13 23|monkey opsin
P07822161A1172|43 55|human sequence
P07822161A1172|61 70|nucleotide
P07822161A1172|77 91|amino acid levels
P07822161A1172|117 127|differences
P07822161A1172|136 143|residues
P07822329A0773|21 30|ubiquitous
P07822329A0773|34 41|enriched
P07822329A0773|44 56|lymphoid cells
P07822329A0773|73 79|binding
P07822329A0773|94 104|novel factor
P07822329A0773|111 131|apparent molecular mass
P07822329A0773|149 151|kDa
P07822333A0376|0 3|Chem
P07823919A1422|11 20|activation
P07823919A1422|23 27|Oct-3
P07823919A1422|30 37|promoter
P07823919A1422|40 42|RAR
P07823919A1422|44 58|RXR heterodimers
P07823919A1422|44 46|RXR
P07823919A1422|83 87|EAR-3
P07823919A1422|89 96|COUP-TFI
P07823919A1422|102 106|ARP-1
P07823919A1422|108 116|COUP-TFII
P07823951A1100|5 11|results
P07823951A1100|27 30|EKLF
P07823951A1100|40 69|crucial transactivation function
P07823951A1100|73 88|globin expression
P07823951A1100|73 78|globin
P07823951A1100|92 98|further
P07823951A1100|119 122|EKLF
P07823951A1100|127 144|important regulator
P07823951A1100|147 180|CACCC element-directed transcription
P07823951A1100|183 196|erythroid cells
P07823953A0777|15 33|I kappa B alpha mutants
P07823953A0777|49 53|dimer
P07823953A0777|60 85|single I kappa B alpha molecule
P07823953A0777|94 115|acidic C-terminal region
P07823953A0777|118 129|I kappa B alpha
P07823953A0777|146 167|protein-protein binding
P07823953A0777|146 160|protein-protein
P07823953A0777|185 209|nuclear localization signal
P07823953A0777|215 219|dimer
P07823953A0777|229 248|same C-terminal region
P07823953A0777|262 271|inhibition
P07823953A0777|274 283|DNA binding
P07823953A0777|296 305|inhibition
P07823953A0777|325 341|direct interaction
P07823953A0777|352 366|PEST-like region
P07823953A0777|373 389|DNA-binding region
P07823953A0777|400 407|subunits
P07823953A0777|413 417|dimer
P07823964A0922|3 28|negative regulatory activity
P07823964A0922|34 49|N-terminal domain
P07823964A0922|67 83|C-terminal segment
P07823964A0922|86 91|Pho81p
P07823964A0922|102 106|trans
P07824325A0714|2 15|different times
P07824325A0714|21 38|surgical procedures
P07824325A0714|40 52|thorax opening
P07824325A0714|56 62|closure
P07824325A0714|72 92|cardiopulmonary bypass
P07824325A0714|101 101|%
P07824325A0714|107 114|patients
P07824325A0714|126 149|vancomycin concentrations
P07824325A0714|162 168|tissues
P07824325A0714|177 179|MIC
P07824325A0714|207 217|microgram/g
P07824325A0714|249 260|micrograms/g
P07824464A0169|0 23|On-line angioscopic images
P07824464A0169|26 36|tissue flaps
P07824464A0169|50 54|lumen
P07824464A0169|64 80|structured thrombi
P07824464A0169|82 102|artery wall dissections
P07824464A0169|104 117|plaque ruptures
P07824464A0169|119 134|deep fissurations
P07824464A0169|138 160|sub-intimal haemorrhages
P07824464A0169|175 184|live colour
P07824464A0169|189 216|pathophysiological mechanisms
P07824464A0169|219 240|coronary artery stenosis
P07824657A1456|11 27|cysteine formation
P07824657A1456|31 41|pCSK4F plant
P07824657A1456|54 60|sulfite
P07824657A1456|78 86|leaf discs
P07824726A0454|25 33|subgroups
P07824726A0454|72 79|pancreas
P07824726A0454|86 108|intense fatty replacement
P07824726A0454|115 123|= negative
P07824726A0454|127 149|intense fatty replacement
P07824726A0454|151 164|type b = positive
P07824726A0454|168 190|intense fatty replacement
P07825888A0715|10 18|subgroups
P07825888A0715|21 37|dementia disorders
P07825888A0715|49 70|significant differences
P07825888A0715|73 91|basal cortisol levels
P07826412T0112|1 13|new hypothesis
P07826412T0112|16 25|mechanisms
P07826412T0112|39 55|catalytic subunits
P07826412T0112|58 71|gamma-subunits
P07826412T0112|75 84|activation
P07826412T0112|88 97|holoenzyme
P07826412T0112|100 109|transducin
P07826625X0000|0 14|Basal components
P07826625X0000|20 41|transcription apparatus
P07826625X0000|43 57|RNA polymerase II
P07826625X0000|43 55|RNA polymerase
P07826625X0000|59 77|TATA-binding protein
P07826625X0000|86 102|activation domains
P07826625X0000|109 134|repetitive C-terminal domain
P07826625X0000|119 134|C-terminal domain
P07826625X0000|136 138|CTD
P07826625X0000|142 154|RNA polymerase
P07826625X0000|159 180|portable enhancer domain
P07826625X0000|183 193|Regions rich
P07826625X0000|196 201|serine
P07826625X0000|203 211|threonine
P07826625X0000|216 230|proline residues
P07826625X0000|243 274|transcriptional activation domains
P07826625X0000|289 303|N-terminal parts
P07826625X0000|306 334|mammalian TATA-binding proteins
P07826625X0000|361 382|polyglutamine stretches
P07828584A0681|0 10|Mutagenesis
P07828584A0681|13 15|IM1
P07828584A0681|36 40|c-Fos
P07828584A0681|53 70|AP1 bearing promoter
P07828600A0095|0 6|Binding
P07828600A0095|9 11|SSP
P07828600A0095|17 36|stage selector element
P07828600A0095|38 40|SSE
P07828600A0095|47 74|proximal gamma-globin promoter
P07828600A0095|55 74|gamma-globin promoter
P07828600A0095|77 84|integral
P07828600A0095|90 109|competitive silencing
P07828600A0095|119 131|beta-promoter
P07828600A0095|134 168|embryonic/fetal stage erythroleukemia
P07828600A0095|170 173|K562
P07828600A0095|175 179|cells
P07828811A0556|20 38|regulated G1/S arrest
P07828811A0556|63 79|thermosensitivity
P07828811A0556|82 102|colony-forming ability
P07828824A0307|0 8|Mutations
P07828824A0307|18 43|photoreceptor cell structure
P07828824A0307|95 103|deletions
P07828852A0153|19 27|telomeres
P07828852A0153|36 41|nuclei
P07828852A0153|46 63|different functions
P07829057A1097|3 14|marker orders
P07829057A1097|32 37|RH maps
P07829057T0000|0 24|Integrated mapping analysis
P07829057T0000|30 49|Werner syndrome region
P07829057T0000|52 61|chromosome
P07829097A0000|16 20|DXS52
P07829097A0000|24 37|Factor VIII gene
P07829097A0000|24 29|Factor
P07829097A0000|43 66|human Xq28 chromosomal band
P07829097A0000|76 78|G+C
P07829097A0000|80 91|rich isochore
P07829097A0000|99 107|many genes
P07829102T0000|0 15|Haplotype mapping
P07829102T0000|19 34|sequence analysis
P07829102T0000|40 53|mouse Nramp gene
P07829102T0000|61 74|susceptibility
P07829102T0000|90 111|intracellular parasites
P07829519A1251|4 14|utilization
P07829519A1251|19 45|intronic polyadenylation site
P07829519A1251|53 72|alternative exon usage
P07829519A1251|121 139|membrane-bound forms
P07829519A1251|145 170|immunoglobulin mu heavy chain
P07829519A1251|183 200|single genetic locus
P07829554A0257|29 63|systemic humoral immune system response
P07829554A0257|66 85|weak hapten-syngeneic
P07829554A0257|88 114|allogeneic protein conjugates
P07829554A0257|116 124|corrosion
P07829554A0257|128 139|wear products
P07829554A0257|142 166|metallic orthopedic devices
P07829554A0257|170 209|sensitive enzyme-linked immunosorbent assay
P07829554A0257|211 215|ELISA
P07829554A0257|236 243|antibody
P07829554A0257|245 259|humoral immunity
P07829554A0257|263 268|metals
P07830112A0532|27 29|PFR
P07830112A0532|47 61|diastolic volume
P07830112A0532|63 65|EDV
P07830112A0532|70 81|stroke volume
P07830112A0532|83 84|SV
P07830112A0532|110 119|PFR-to-PER
P07830112A0532|131 131|p
P07830112A0532|145 147|PFR
P07830112A0532|149 152|TPFR
P07830112A0532|157 165|prolonged
P07830112A0532|167 167|p
P07830112A0532|178 218|echocardiographic left ventricular mass index
P07830112A0532|222 227|higher
P07830112A0532|229 229|p
P07830112A0532|239 246|patients
P07830112A0532|251 260|acromegaly
P07830112A0532|271 277|normals
P07831310A0000|1 28|genetic complementation system
P07831310A0000|48 63|tobacco etch virus
P07831310A0000|65 78|TEV) polymerase
P07831310A0000|65 67|TEV
P07831310A0000|69 78|polymerase
P07831310A0000|80 82|NIb
P07831310A0000|95 110|transgenic plants
P07831310A0000|113 123|protoplasts
P07831310A0000|142 164|NIb-defective TEV mutants
P07831310A0000|142 144|NIb
P07831310A0000|155 164|TEV mutants
P07831799T0000|0 17|Nucleotide sequence
P07831799T0000|21 43|transcriptional analysis
P07831799T0000|49 101|DNA polymerase gene of Bombyx mori nuclear polyhedrosis virus
P07831799T0000|49 65|DNA polymerase gene
P07831799T0000|68 73|Bombyx
P07831799T0000|78 101|nuclear polyhedrosis virus
P07831829A1324|0 9|Comparison
P07831829A1324|15 21|genomes
P07831829A1324|24 27|PMTV
P07831829A1324|29 33|BNYVV
P07831829A1324|38 42|SBWMV
P07831829A1324|52 62|furoviruses
P07831829A1324|70 94|considerable heterogeneity
P07831829A1324|97 114|genome organization
P07832086A1023|3 17|drug sensitivity
P07832086A1023|24 24|%
P07832086A1023|28 37|vancomycin
P07832086A1023|39 41|VCM
P07832086A1023|46 46|%
P07832086A1023|50 57|imipenam
P07832086A1023|59 61|IMP
P07832086A1023|66 66|%
P07832086A1023|70 78|minomycin
P07832086A1023|80 83|MINO
P07832086A1023|88 88|%
P07832086A1023|92 99|amikacin
P07832086A1023|101 103|AMK
P07832086A1023|110 110|%
P07832086A1023|114 123|fosfomycin
P07832086A1023|125 127|FOM
P07832779A0719|0 14|Deglycosylation
P07832779A0719|19 34|endoglycosidase H
P07832779A0719|48 62|mutant receptors
P07832779A0719|72 104|high-mannose oligosaccharide chains
P07834582A0115|0 16|Dietary supplement
P07834582A0115|21 27|fish oil
P07834582A0115|31 44|related n-3 EFAs
P07834582A0115|68 91|antihypertensive property
P07834582A0115|94 100|animals
P07834582A0115|104 109|humans
P07834582A0115|114 123|borderline
P07834582A0115|127 147|essential hypertension
P07835088A0238|3 8|HSD3B1
P07835088A0238|12 22|HSD3B2 genes
P07835088A0238|34 38|types
P07835088A0238|46 63|beta-HSD isoenzymes
P07835088A0238|112 124|hybridization
P07835088A0238|130 151|chromosome 1p13.1 region
P07835214A0603|12 22|prevalences
P07835214A0603|25 37|total diabetes
P07835214A0603|41 43|GDM
P07835214A0603|52 52|%
P07835214A0603|60 60|%
P07835273A0000|0 33|Insulin-stimulated glucose transport
P07835273A0000|36 45|adipocytes
P07835273A0000|61 75|insulin receptor
P07835273A0411|29 38|adipocytes
P07835273A0411|50 63|EGFR expression
P07835273A0411|50 53|EGFR
P07835273A0411|77 95|infectant adipocytes
P07835273A0411|145 168|parental 3T3-L1 adipocytes
P07835273A0411|171 179|5000/cell
P07835710T0000|0 19|Intron-exon structure
P07835710T0000|25 56|porcine I kappa B alpha-encoding gene
P07835826A0195|0 7|Fraction
P07835826A0195|22 23|OH
P07835826A0195|25 35|2-vitamin D3
P07835826A0195|37 45|vitamin D3
P07835826A0195|50 51|OH
P07835826A0195|54 62|vitamin D3
P07835826A0195|74 75|OH
P07835826A0195|77 87|3-vitamin D3
P07835886A0894|3 17|kallistatin gene
P07835886A0894|38 50|hybridization
P07835886A0894|53 76|human chromosome 14q31-q32
P07835886A0894|90 100|serpin genes
P07835886A0894|109 131|alpha 1-antichymotrypsin
P07835886A0894|133 149|protein C inhibitor
P07835886A0894|151 168|alpha 1-antitrypsin
P07835886A0894|173 202|corticosteroid-binding globulin
P07835888A0402|3 7|locus
P07835888A0402|19 24|XD gene
P07835888A0402|36 37|Xd
P07835888A0402|53 62|distal part
P07835888A0402|65 79|mouse chromosome
P07835888A0402|84 100|haplotype analysis
P07835888A0402|106 131|interspecific backcross mice
P07836218A0128|4 10|studies
P07836218A0128|35 55|beta-endorphin release
P07836218A0128|35 48|beta-endorphin
P07836218A0128|69 82|exertion levels
P07836218A0128|87 99|other evidence
P07836218A0128|112 119|acidosis
P07836218A0128|144 157|beta-endorphin
P07836228A1052|2 25|interatrial communication
P07836228A1052|38 47|impairment
P07836228A1052|50 59|LV function
P07836228A1052|67 71|acute
P07836228A1052|75 87|sustained drop
P07836228A1052|90 110|intrathoracic pressure
P07836364A0000|0 3|Self
P07836364A0000|6 28|foreign cellular proteins
P07836364A0000|36 43|peptides
P07836364A0000|61 90|major histocompatibility complex
P07836364A0000|92 94|MHC
P07836364A0000|102 110|molecules
P07836364A0000|125 146|antigen presenting cells
P07836364A0000|148 150|APC
P07836390A1152|3 17|characteristics
P07836390A1152|23 58|VirD1/VirD2-mediated cleavage reaction
P07836390A1152|23 27|VirD1
P07836390A1152|29 33|VirD2
P07836390A1152|92 102|relaxosomes
P07836390A1152|105 116|IncP plasmids
P07836390A1152|127 136|initiation
P07836390A1152|139 160|transfer DNA replication
P07836390A1152|167 186|bacterial conjugation
P07836406A0884|0 10|Isoelectric
P07836406A0884|21 35|tryptic peptides
P07836406A0884|49 53|MHC-B
P07836406A0884|72 81|cdc2 kinase
P07836406A0884|93 111|major phosphopeptide
P07836406A0884|129 176|reverse-phase high performance liquid chromatography
P07836471A0375|10 24|protein sequence
P07836471A0375|30 40|% homologous
P07836471A0375|49 53|hNUC I
P07836471A0375|49 52|hNUC
P07836471A0375|67 88|human osteosarcoma cells
P07838156A0789|8 28|cotransfection studies
P07838156A0789|41 43|RVR
P07838156A0789|59 71|transcription
P07838156A0789|80 101|hormone response element
P07838156A0789|113 124|reporter gene
P07838156A0789|141 166|potent competitive repressor
P07838156A0789|169 184|ROR alpha function
P07838156A0789|169 176|ROR alpha
P07840643A1006|16 49|Flavobacterium glycosylasparaginase
P07840643A1006|30 49|glycosylasparaginase
P07840643A1006|55 83|mammalian glycosylasparaginase
P07840643A1006|64 83|glycosylasparaginase
P07840643A1006|94 112|% structural identity
P07840643A1006|118 135|% overall similarity
P07840643A1006|146 156|prokaryotic
P07840643A1006|160 174|eukaryotic forms
P07840643A1006|180 185|enzyme
P07841230T0000|0 11|Dissociation
P07841230T0000|15 26|complexation
P07841230T0000|32 60|fluoroquinolone antimicrobials
P07841663A0685|0 18|Superoxide dismutase
P07841663A0685|20 22|SOD
P07841663A0685|56 60|sperm
P07841663A0685|78 92|electric current
P07841663A0685|141 158|electrolyzed medium
P07841663A0845|5 11|studies
P07841663A0845|40 60|electrical stimulation
P07841663A0845|69 89|reactive oxygen species
P07841663A0845|99 109|SOD activity
P07841663A0845|99 101|SOD
P07841663A0845|148 158|sperm motion
P07841663A0845|162 170|viability
P07844142A0640|0 15|Molecular cloning
P07844142A0640|19 28|sequencing
P07844142A0640|32 35|cDNA
P07844142A0640|44 49|SR beta
P07844142A0640|62 67|SR beta
P07844142A0640|71 90|transmembrane protein
P07844142A0640|99 105|SR alpha
P07844142A0640|109 113|SRP54
P07844142A0640|129 145|GTPase superfamily
P07844155A0327|25 59|receptor-linked tyrosine phosphatases
P07844155A0327|62 78|neural development
P07844155A0327|98 108|LAR isoforms
P07844155A0327|137 149|nervous system
P07844155A0327|153 169|cellular processes
P07844155A0327|180 201|LAR alternative splicing
P07844201T0000|0 11|Sex selection
P07844201T0000|15 28|albumin columns
P07844201T0000|15 21|albumin
P07844201T0000|32 36|years
P07844201T0000|39 45|results
P07844425A0289|3 10|students
P07844425A0289|32 40|eggs/10 ml
P07844425A0289|42 46|urine
P07844425A0289|65 73|eggs/10ml
P07844555A0406|20 41|E mu pim-1 transgenic mice
P07844555A0406|20 27|E mu pim-1
P07844555A0406|64 82|lymphoma development
P07844555A0406|99 113|wild-type M-MuLV
P07844555A0406|99 108|wild-type M
P07845672A0368|0 9|Comparison
P07845672A0368|20 37|murine blk sequences
P07845672A0368|62 79|% amino acid identity
P07845672A0368|111 125|catalytic domain
P07845672A0368|129 137|% identity
P07846153A0403|0 9|Chrispeels
P07846153A0403|16 20|EMBO J
P07846163A0422|3 7|mRNAs
P07846163A0422|13 20|GRF genes
P07846163A0422|36 40|exons
P07846163A0422|58 64|introns
P07846199A0000|11 17|ethanol
P07846199A0000|20 46|human sensorimotor reactivity
P07846199A0000|72 94|acoustic startle response
P07846942A0717|0 18|Digitalis glycosides
P07846942A0717|21 44|beta-receptor antagonists
P07846942A0717|21 33|beta-receptor
P07846942A0717|82 99|atrial fibrillation
P07846942A0717|113 131|antiarrhythmic drugs
P07846942T0001|0 17|Atrial fibrillation
P07846942T0001|24 45|autonomic nervous system
P07847036A0353|6 10|doses
P07847036A0353|14 24|times higher
P07847036A0353|42 54|haemophiliacs
P07847036A0353|62 70|inhibitor
P07848358A0254|15 47|aspartate aminotransferase activity
P07848358A0254|15 39|aspartate aminotransferase
P07848358A0254|66 74|mg/kg b.w.
P07848358A0254|76 83|d onwards
P07851643A1365|10 16|studies
P07851643A1365|32 45|104-kDa isoform
P07851643A1365|59 77|normal proliferation
P07851643A1365|80 98|female germline cells
P07851643A1365|112 132|oocyte differentiation
P07851758A0330|0 23|Physical analysis maps SAL6
P07851758A0330|20 23|SAL6
P07851758A0330|26 38|chromosome XVI
P07851758A0330|46 49|TPK2
P07851758A0330|53 57|spt14
P07852037A0548|15 41|DCT method yields reliable data
P07852037A0548|53 55|TBF
P07852361A0868|0 6|Removal
P07852361A0868|9 12|PDMP
P07852361A0868|20 29|cell medium
P07852361A0868|40 47|reversal
P07852361A0868|53 68|cell cycle changes
P07852361A0868|74 78|cells
P07852361A0868|93 98|S phase
P07852400A0519|0 26|Rho GDP/GTP exchange inhibitor
P07852400A0519|28 33|Rho GDI
P07852400A0519|49 52|Rac2
P07852400A0519|56 59|RhoA
P07852400A0519|67 70|Rac1
P07853448A0601|1 9|major task
P07853448A0601|13 28|sports scientists
P07853448A0601|86 99|sport performer
P07853476A0159|0 6|Schnell
P07853476A0159|8 9|J.
P07853488T0000|0 12|Encapsidation
P07853488T0000|15 33|poliovirus replicons
P07853488T0000|45 82|complete human immunodeficiency virus type
P07853488T0000|84 90|gag gene
P07853488T0000|99 119|complementation system
P07853488T0000|136 150|P1 capsid protein
P07853488T0000|153 157|trans
P07853524A1944|0 6|Removal
P07853524A1944|12 20|GST domain
P07853524A1944|25 31|GST-Tax
P07853524A1944|25 27|GST
P07853524A1944|29 31|Tax
P07853524A1944|34 41|thrombin
P07853524A1944|50 52|Tax
P07853524A1944|73 107|ternary Tax-CREB-21-bp-repeat complex
P07853524A1944|80 82|Tax
P07853524A1944|110 117|ABSTRACT
P07853524A1944|132 136|WORDS
P07854130A1387|16 19|PilE
P07854130A1387|22 36|pilus biogenesis
P07854130A1387|68 98|chromosomal pilE insertion mutants
P07854130A1387|103 107|pilus
P07854130A1387|112 138|twitching-motility deficient
P07854130T0000|3 17|pilE gene product
P07854130T0000|53 67|pilus biogenesis
P07854130T0000|69 99|shares amino acid sequence identity
P07854130T0000|107 115|N-termini
P07854130T0000|118 138|type 4 prepilin proteins
P07854130T0000|123 138|prepilin proteins
P07854324A0281|12 33|functional conservation
P07854324A0281|36 59|cell cycle control elements
P07854324A0281|77 90|vertebrate wee1
P07854324A0281|93 103|mik1 homolog
P07854324A0281|127 145|such lethal mutations
P07854324A0281|148 152|yeast
P07854324A0742|19 23|clone
P07854324A0742|27 57|wee1/mik1-deficient mutant causes
P07854324A0742|27 51|wee1/mik1-deficient mutant
P07854324A0742|69 81|cell phenotype
P07854324A0742|87 116|non-permissive growth conditions
P07856102A1616|21 35|phosphorylation
P07856102A1616|38 45|M protein
P07856102A1616|62 66|sites
P07856102A1616|84 96|virus assembly
P07857086A0949|15 15|%
P07857086A0949|19 34|Insulin Dependent
P07857086A0949|19 25|Insulin
P07857086A0949|50 50|%
P07857086A0949|55 73|Non Insulin Dependent
P07857086A0949|58 64|Insulin
P07857086A0949|80 80|D
P07857086A0949|82 82|F
P07857086A0949|84 89|H White
P07857086A0949|92 96|Class
P07857163A0551|13 30|6-fluoroquinolones
P07857163A0551|39 63|nonfluorinated derivatives
P07857344A0591|5 13|half-life
P07857344A0591|44 44|h
P07857344A0591|76 106|pidotimod administration schedule
P07857344A0591|118 118|h
P07857762A0611|3 18|MAP kinase cascade
P07857762A0611|3 11|MAP kinase
P07857762A0611|41 50|eukaryotes
P07857762A0611|64 88|numerous cellular responses
P07858986A0310|1 16|comparative study
P07858986A0310|19 43|holographic interferometry
P07858986A0310|49 74|porcine bioprosthetic valves
P07858986A0310|81 101|Carpentier-Edwards SAV
P07858986A0310|106 115|BioImplant
P07858986A0310|122 127|Valcor
P07858986A0310|137 153|human aortic valves
P07858986A0310|168 190|glutaraldehyde treatment
P07859238A1150|2 19|serious side effects
P07859301A0325|24 40|DNA-binding domain
P07859301A0325|45 89|basic-helix-loop-helix and leucine-zipper motifs
P07859301A0325|45 66|basic-helix-loop-helix
P07859301A0325|70 89|leucine-zipper motifs
P07859301A0325|91 104|features common
P07859301A0325|110 145|myc-related transcription factor family
P07859371A1246|0 14|Specific binding
P07859371A1246|42 55|orthologous rat
P07859371A1246|58 71|mouse fragments
P07859371A1246|84 97|rodent extracts
P07859665A0498|3 12|mean jitter
P07859665A0498|19 30|fiber density
P07859665A0498|75 86|microseconds
P07859665A0498|117 128|microseconds
P07859739T0000|0 3|Lack
P07859739T0000|6 25|cyclin D-Cdk complexes
P07859739T0000|28 43|Rb-negative cells
P07859739T0000|28 29|Rb
P07859739T0000|58 67|high levels
P07859739T0000|70 108|p16INK4/MTS1 tumour suppressor gene product
P07859739T0000|70 76|p16INK4
P07859777A0000|0 27|Recombinant human serum albumin
P07859777A0000|29 32|rHSA
P07859777A0000|52 63|fermentation
P07859777A0000|90 102|microcapsules
P07859777A0000|115 121|microns
P07859777A0000|124 131|diameter
P07859777A0000|135 147|radiolabelled
P07859777A0000|152 165|technetium-99m
P07859777A0000|188 203|stannous chloride
P07860208A0000|26 42|interleukin-1 beta
P07860208A0000|44 47|IL-1
P07860208A0000|52 77|tumour necrosis factor-alpha
P07860208A0000|79 81|TNF
P07860208A0000|85 105|unstimulated monocytes
P07860208A0000|109 117|monocytes
P07860208A0000|132 149|lipopolysaccharide
P07860208A0000|151 153|LPS
P07860208A0000|170 184|peripheral blood
P07860208A0000|190 197|patients
P07860208A0000|202 241|acute poststreptococcal glomerulonephritis
P07860208A0000|243 245|AGN
P07860208A0000|252 266|healthy controls
P07860646A1363|25 39|considerable use
P07860646A1363|57 86|angiogenesis-dependent diseases
P07860646A1363|96 100|FGF-2
P07862092A0302|17 21|clone
P07862092A0302|25 54|recessive extragenic suppressors
P07862092A0302|57 69|such ts mutants
P07862092A0302|71 74|sdp1
P07862092A0302|78 92|mutation pol3-14
P07862092A0302|96 101|sdp5-1
P07862092A0302|105 119|mutation pol3-11
P07862092A0302|135 174|thermoresistant haploid strains pol3-14 sdp1
P07862092A0302|164 174|pol3-14 sdp1
P07862092A0302|178 190|pol3-11 sdp5-1
P07862092A0302|195 219|wild-type genomic libraries
P07862092A0302|222 231|singlecopy
P07862092A0302|234 249|multicopy vectors
P07862108A0987|0 25|UV cross-linking experiments
P07862108A0987|34 36|TEP
P07862108A0987|42 62|apparent molecular mass
P07862108A0987|80 82|kDa
P07862129A1391|2 18|acute-phase livers
P07862129A1391|31 47|dramatic reduction
P07862129A1391|50 69|HNF-3 alpha expression
P07862129A1391|50 59|HNF-3 alpha
P07862129A1391|118 127|target gene
P07862129A1391|132 138|TTR gene
P07862141A0317|14 36|loss-of-function alleles
P07862141A0317|39 43|genes
P07862141A0317|55 62|cAPK lead
P07862141A0317|55 58|cAPK
P07862141A0317|68 76|inability
P07862141A0317|86 106|sexual differentiation
P07862141A1412|22 25|RFX1
P07862141A1412|30 48|transcription factor
P07862141A1412|62 66|viral
P07862141A1412|70 82|cellular genes
P07862150A0429|4 9|mutant
P07862150A0429|39 62|TGF-beta-inducible vector
P07862150A0429|39 46|TGF-beta
P07862150A0429|72 99|mink lung epithelial cell clones
P07862150A0429|108 136|normal TGF-beta binding activity
P07862150A0429|114 121|TGF-beta
P07862150A0429|148 164|antiproliferative
P07862150A0429|168 191|transcriptional responses
P07862150A0429|194 201|TGF-beta
P07862154A0340|0 6|Cloning
P07862154A0340|9 23|complementation
P07862154A0340|27 44|subsequent physical
P07862154A0340|48 62|genetic analysis
P07862154A0340|83 86|RAF1
P07862162A0408|15 22|inositol
P07862162A0408|26 32|choline
P07862162A0408|61 68|OPI1 gene
P07862162A0408|78 90|transcription
P07862162A0408|104 116|UASINO element
P07862165A0184|10 23|monkey COS cells
P07862165A0184|28 43|oligonucleotides
P07862165A0184|52 59|psoralen
P07862165A0184|84 92|mutations
P07862165A0184|96 106|simian virus
P07862165A0184|110 113|SV40
P07862165A0184|115 120|vector
P07862165A0184|139 143|cells
P07862165A0184|147 179|intracellular triple helix formation
P07862168A0000|3 33|interleukin 2 receptor alpha-chain
P07862168A0000|3 13|interleukin
P07862168A0000|15 33|receptor alpha-chain
P07862168A0000|35 49|IL-2R alpha) gene
P07862168A0000|35 44|IL-2R alpha
P07862168A0000|79 84|T cells
P07862168A0000|97 112|mitogenic stimuli
P07862533A0000|3 31|Wilms' tumour suppressor protein
P07862533A0000|3 7|Wilms
P07862533A0000|9 31|tumour suppressor protein
P07862533A0000|33 35|WT1
P07862533A0000|40 79|putative transcriptional regulatory protein
P07862533A0000|88 98|zinc fingers
P07862533A0000|123 147|extensive sequence homology
P07862533A0000|153 173|early growth response-1
P07862533A0000|175 179|EGR-1
P07863047A0229|0 9|OBJECTIVES
P07863047A0229|24 39|serum ACE activity
P07863047A0229|29 31|ACE
P07863047A0229|42 49|patients
P07863047A0229|54 57|COPD
P07863047A0229|79 111|continuous ambulatory oxygen therapy
P07863047A0229|113 116|CAOT
P07863047A0229|162 164|ACE
P07863047A0229|171 183|hematological
P07863047A0229|185 195|spirometric
P07863047A0229|198 216|gasometric parameter
P07863619A0098|23 29|contour
P07863619A0098|34 50|human visual system
P07863619A0098|75 83|fragments
P07863619A0098|99 110|common object
P07863619A0098|123 131|fragments
P07863619A0098|136 159|different objects separate
P07863992A0908|12 19|patients
P07863992A0908|25 38|positive result
P07863992A0908|41 64|head-up tilt-table testing
P07863992A0908|80 101|structural heart disease
P07863992A0908|103 115|mean follow-up
P07863992A0908|119 123|years
P07863992A0908|137 151|further episodes
P07863992A0908|154 160|syncope
P07863992A0908|206 225|least limited exercise
P07864652A0753|0 9|Constructs
P07864652A0753|34 37|E2L1
P07864652A0753|45 48|E2L1
P07864652A0753|50 51|H1
P07864652A0753|60 63|E2L2
P07864652A0753|74 77|E2H1
P07864652A0753|79 80|L2
P07864652A0753|93 96|E2L1
P07864652A0753|98 99|H1
P07864652A0753|101 102|L2
P07864652A0753|116 122|numbers
P07864652A0753|125 135|parentheses
P07864652A0753|143 159|amino acid sequence
P07864652A0753|166 173|portions
P07864652A0753|179 189|E2 component
P07864652A1901|19 40|lipoyl domain constructs
P07864652A1901|70 82|specific roles
P07864652A1901|85 88|E2L1
P07864652A1901|92 95|E2L2
P07864652A1901|110 118|catalytic
P07864652A1901|122 140|regulatory processes
P07864709A0324|0 6|METHODS
P07864709A0324|11 20|influenza A
P07864709A0324|22 25|H3N2
P07864709A0324|27 33|viruses
P07864709A0324|51 59|outbreaks
P07864709A0324|87 96|amantadine
P07864709A0324|100 110|rimantadine
P07864709A0324|113 117|means
P07864709A0324|122 138|enzyme immunoassay
P07864709A0324|144 153|sequencing
P07864709A0324|159 174|viral nucleic acid
P07864709A0324|189 207|transmembrane domain
P07864709A0324|213 221|M2 protein
P07865129A0293|16 22|ATF/CRE
P07865129A0293|16 18|ATF
P07865129A0293|20 22|CRE
P07865129A0293|26 47|TBP/TATA sequence motifs
P07865129A0293|26 28|TBP
P07865129A0293|30 47|TATA sequence motifs
P07865129A0293|56 66|87-bp region
P07865786A0457|0 13|Gene expression
P07865786A0457|23 37|circadian rhythm
P07865786A0457|57 62|leaves
P07865786A0457|65 82|dark-adapted plants
P07865787A1086|3 9|results
P07865787A1086|26 32|hexamer
P07865787A1086|39 51|octamer motifs
P07865787A1086|59 71|important role
P07865787A1086|73 73|s
P07865787A1086|89 109|replication-dependent
P07865787A1086|118 150|replication-independent expression
P07865787A1086|156 173|wheat histone H3 gene
P07865876A1292|3 27|tissue-specific expression
P07865876A1292|30 44|DP family members
P07865876A1292|73 90|DP/E2F heterodimers
P07865876A1292|73 74|DP
P07865876A1292|105 113|DRTF1/E2F
P07865876A1292|105 109|DRTF1
P07865876A1292|111 113|E2F
P07865876A1292|131 139|phenotype
P07865888A1309|12 30|mammalian cells PBP74
P07865888A1309|26 30|PBP74
P07865888A1309|47 57|pre-protein
P07865888A1309|70 102|membrane potential-dependent import
P07865888A1309|107 118|mitochondria
P07865888A1309|125 134|maturation
P07865895A0896|3 18|second experiment
P07865895A0896|30 51|18-h lung clearance assay
P07865895A0896|62 69|mAb 3.2.3
P07865895A0896|62 64|mAb
P07865895A0896|79 82|rats
P07865895A0896|85 95|LGL/NK cells
P07865895A0896|112 120|rationale
P07865895A0896|124 134|LGL/NK cells
P07865917A0191|0 8|Treatment
P07865917A0191|11 23|recurrent FSGS
P07865917A0191|35 51|high-dose steroids
P07865917A0191|53 73|high-dose cyclosporine
P07865917A0191|75 77|CSA
P07865917A0191|80 93|plasmapheresis
P07865917A0191|98 110|ACE inhibitors
P07865917A0191|98 100|ACE
P07865917A0191|115 126|mixed results
P07867604A1777|3 9|results
P07867604A1777|31 63|inhibin/activin beta B-subunit mRNAs
P07867604A1777|83 106|different initiation sites
P07867604A1777|114 122|promoters
P07867604A1777|140 174|up-stream negative regulatory elements
P07867604A1777|195 203|promoters
P07867604A1777|206 215|responsive
P07867604A1777|218 221|cAMP
P07867604A1777|228 240|phorbol esters
P07867604A1777|249 258|conditions
P07867622X0000|0 13|Promoter region
P07867622X0000|19 37|transcriptional unit
P07867622X0000|41 61|human alpha 1-chimaerin
P07867622X0000|64 102|neuron-specific GTPase-activating protein
P07867622X0000|106 111|p21rac
P07867622X0000|113 128|alpha 1-chimaerin
P07867622X0000|132 170|neuron-specific GTPase-activating protein
P07867622X0000|174 179|p21rac
P07867622X0000|199 217|morphological events
P07867944A0365|0 7|Upstream
P07867944A0365|15 37|transcription start point
P07867944A0365|39 41|tsp
P07867944A0365|45 62|nucleotide sequence
P07867944A0365|69 78|homologous
P07867944A0365|84 105|consensus sequence motif
P07867944A0365|112 138|sigma 35-recognized promoters
P07869721A0000|40 51|closing phase
P07869721A0000|57 64|occluder
P07869721A0000|68 108|mechanical monoleaflet heart valve prosthesis
P07869913A1076|6 19|ISO+AT infusion
P07869913A1076|21 41|abdominal fat blood flow
P07869913A1076|86 98|control values
P07869913A1076|108 120|obese subjects
P07869937A1142|16 33|kilogram body weight
P07869937A1142|39 41|GIT
P07869937A1142|56 62|dF group
P07869937A1142|71 71|%
P07869937A1142|78 78|%
P07869937A1142|84 86|RMR
P07869937A1142|93 111|significant decrease
P07869937A1142|120 120|%
P07869937A1142|127 127|%
P07869937A1142|133 138|P group
P07870305A1015|2 72|nucleus ventralis anterior thalami-nucleus ventralis lateralis thalami neurons
P07870305A1015|79 93|inhibitory input
P07870305A1015|98 120|nucleus entopeduncularis
P07870305A1015|135 144|inhibition
P07870305A1015|170 171|ms
P07870305A1015|173 173|P
P07870305A1015|188 207|haloperidol influence
P07871718A1132|8 16|inclusion
P07871718A1132|33 44|CGGAAR motifs
P07871718A1132|52 63|ICP4 promoter
P07871718A1132|74 89|factors GABP alpha
P07871718A1132|93 96|beta
P07871718A1132|108 134|strong synergistic activation
P07871721A0000|3 23|first open reading frame
P07871721A0000|29 53|blueberry scorch carlavirus
P07871721A0000|55 59|BBScV
P07871721A0000|61 66|genome
P07871721A0000|75 111|putative replication-associated protein
P07871721A0000|117 119|kDa
P07871721A0000|121 124|p223
P07871721A0392|4 21|sequence alignments
P07871721A0392|42 55|related viruses
P07871721A0392|66 76|tymoviruses
P07871721A0392|93 96|p223
P07871721A0392|107 133|papain-like proteinase domain
P07871721A0392|139 166|putative catalytic cysteine994
P07871721A0392|170 182|histidine1075
P07871754A0857|37 54|important mechanism
P07871754A0857|62 78|HPV gene expression
P07871754A0857|62 68|HPV gene
P07871754A0857|98 113|interesting model
P07871754A0857|127 154|transcriptional cooperativity
P07871755A0521|16 19|VLPs
P07871755A0521|34 53|quantities sufficient
P07871755A0521|57 79|further characterization
P07871757A0846|0 7|Analysis
P07871757A0846|13 28|sequence upstream
P07871757A0846|35 49|initiation codon
P07871757A0846|71 86|promotor sequence
P07871891A0227|0 4|SUP46
P07871891A0227|19 37|translation fidelity
P07871891A0227|51 69|ribosomal protein S13
P07872673A0332|12 33|functional relationship
P07872673A0332|41 45|c-fos
P07872673A0332|49 50|Rb
P07872673A0332|53 79|eukaryotic expression plasmid
P07872673A0332|107 115|c-fos gene
P07872673A0332|133 151|SV40 promoter complex
P07872673A0332|133 144|SV40 promoter
P07872788A1717|3 12|high degree
P07872788A1717|15 30|sequence identity
P07872788A1717|34 34|%
P07872788A1717|43 52|hydrolase B
P07872788A1717|56 56|C
P07872788A1717|77 94|untranslated region
P07872788A1717|111 115|genes
P07872788A1717|132 148|carboxylesterases
P07872788A1717|158 168|duplication
P07872788A1717|172 181|divergence
P07872788A1717|185 203|common ancestral gene
P07873631A0114|3 9|regions
P07873631A0114|15 27|tooth fracture
P07873831T0000|0 29|Secondary pancreatic involvement
P07873831T0000|32 47|mycosis fungoides
P07873831T0000|69 80|palpable mass
P07873876A1035|3 11|NR2 hybrid
P07873876A1035|15 26|powerful tool
P07873876A1035|33 39|mapping
P07873876A1035|42 50|new probes
P07873876A1035|84 111|new informative probes specific
P07873876A1035|118 125|deletion
P07873876A1035|128 145|subtractive cloning
P07874060A0810|0 4|TDEYA
P07874060A0810|7 11|doses
P07874060A0810|22 26|mg/kg
P07874060A0810|50 64|xanthine oxidase
P07874060A0810|66 67|XO
P07874060A0810|82 94|stomach tissue
P07874060A0810|107 124|oral administration
P07875595A0910|4 9|humans
P07875595A0910|14 27|PITSLRE PK genes
P07875595A0910|30 37|chickens
P07875595A0910|65 75|fluorescent
P07875595A0910|82 94|hybridization
P07875595A0910|96 99|FISH
P07875595A0910|101 112|localization
P07875595A0910|120 124|genes
P07875595A0910|128 155|single chicken microchromosome
P07876134A0348|16 31|characterization
P07876134A0348|64 71|AFAP-110
P07876134A0348|98 105|base pair
P07876134A0348|107 108|bp
P07876134A0348|112 127|open reading frame
P07876191A0808|0 9|Expression
P07876191A0808|12 25|class IV ADH mRNA
P07876191A0808|19 25|ADH mRNA
P07876191A0808|39 50|human stomach
P07876192A0443|2 9|ICE gamma
P07876192A0443|20 29|propeptide
P07876192A0443|31 40|amino acids
P07876192A0443|91 98|catalyst
P07876192A0443|102 118|ICE autoprocessing
P07876192A0443|102 104|ICE
P07876194T0000|0 10|Endocytosis
P07876194T0000|14 31|lysosomal targeting
P07876194T0000|34 63|epidermal growth factor receptors
P07876194T0000|77 104|distinct sequences independent
P07876194T0000|110 129|tyrosine kinase domain
P07876210A0275|35 44|eukaryotic
P07876210A0275|48 63|prokaryotic genes
P07876210A0275|72 86|flanking regions
P07876210A0275|108 136|barbiturate-inducible proteins
P07876210A0275|147 162|Barbie box element
P07876210A0751|0 7|Mutation
P07876210A0751|13 29|P450BM-3 Barbie box
P07876210A0751|71 78|P450BM-3
P07876210A0751|82 86|Bm3P1
P07876210A0751|95 110|small gene located
P07876210A0751|95 103|small gene
P07876210A0751|124 135|P450BM-3 gene
P07876210A0751|148 178|second putative regulatory protein
P07876210A0751|192 213|pentobarbital induction
P07876210A0751|224 244|basal levels unaffected
P07876300A0994|3 20|p97-depleted nuclei
P07876300A0994|3 5|p97
P07876300A0994|36 44|competent
P07876300A0994|48 67|nuclear protein import
P07876562A1646|1 16|potential outcome
P07876562A1646|24 41|biochemical effects
P07876562A1646|55 75|limited responsiveness
P07876562A1646|78 91|infected T cells
P07876562A1646|94 113|antigenic stimulation
P07876562A1646|128 141|HIV-1 infection
P07877308A1175|3 14|full protocol
P07877308A1175|31 38|patients
P07877308A1175|42 42|%
P07877308A1175|45 58|original cohort
P07877619A1284|22 45|cell-specific suppression
P07877619A1284|48 80|RA-stimulated zif268 gene expression
P07877619A1284|61 70|zif268 gene
P07877619A1284|101 126|base pair nucleotide sequence
P07877619A1284|128 134|located
P07877619A1284|150 168|RA-responsive region
P07877619A1284|174 183|zif268 gene
P07878029A0721|10 14|CBF-A
P07878029A0721|18 22|CBF-C
P07878029A0721|51 68|CBF-A-CBF-C complex
P07878029A0721|51 55|CBF-A
P07878029A0721|76 80|CBF-B
P07878029A0721|100 104|CBF-A
P07878029A0721|107 111|CBF-C
P07878029A0721|150 167|CBF-A-CBF-C complex
P07878029A0721|150 154|CBF-A
P07878040A0505|11 29|homologous sequences
P07878040A0505|46 58|mouse enhancer
P07878040A0505|72 90|tissue-specific loss
P07878040A0505|114 127|transgenic mice
P07879204T0000|0 14|OKT3 prophylaxis
P07879204T0000|0 3|OKT3
P07879204T0000|23 49|long-term renal graft survival
P07879204T0000|52 68|high-risk patients
P07879204T0000|81 92|cyclosporine
P07879204T0000|102 108|results
P07879204T0000|116 126|prospective
P07879204T0000|128 144|randomized Belgian
P07879204T0000|148 156|US studies
P07880442A0236|3 41|major PKC beta transcription initiation site
P07880442A0236|8 41|PKC beta transcription initiation site
P07880442A0236|57 71|primer extension
P07880442A0236|75 94|S1 nuclease protection
P07880442A0236|75 84|S1 nuclease
P07880449A0091|21 40|low dose X-rays effects
P07880449A0091|53 73|male ICR white Swiss mice
P07880449A0091|80 100|remarkable suppression
P07880449A0091|124 143|whole body irradiation
P07880449A0091|151 159|cGy X-rays
P07880650A0493|1 20|quantitative analysis
P07880650A0493|26 45|diffraction intensity
P07880650A0493|72 83|electron dose
P07880650A0493|124 142|diffraction patterns
P07880650A0493|166 193|single crotoxin complex crystal
P07881077A0195|0 29|Supplementary Phase Contraste RSE
P07881077A0195|32 56|Rapid Sequential Excitation
P07881077A0195|59 67|sequences
P07881077A0195|86 93|patients
P07883167A0157|2 6|yeast
P07883167A0157|11 18|products
P07883167A0157|24 27|UPF1
P07883167A0157|31 39|UPF3 genes
P07883167A0157|58 69|decay pathway
P07883167A0157|115 130|characterization
P07883167A0157|133 149|additional factors
P07883167A0157|161 170|rapid decay
P07883167A0157|173 196|nonsense-containing mRNAs
P07883168A0090|0 8|Mutations
P07883168A0090|11 18|UPF1 lead
P07883168A0090|11 14|UPF1
P07883168A0090|24 45|selective stabilization
P07883168A0090|48 52|mRNAs
P07883168A0090|63 84|early nonsense mutations
P07883168A0090|104 113|decay rates
P07883168A0090|116 129|most other mRNAs
P07883193A0000|1 11|DNA fragment
P07883193A0000|23 39|DNA-binding domain
P07883193A0000|41 50|amino acids
P07883193A0000|61 102|Escherichia coli fru transcriptional regulator
P07883193A0000|79 102|transcriptional regulator
P07883193A0000|119 131|pGEX-KT vector
P07883193A0000|175 198|glutathione S-transferase
P07883754A0993|5 24|gel retardation assays
P07883754A0993|29 47|HepG2 nuclear extract
P07883754A0993|77 91|specific protein
P07883754A0993|107 117|NRE fragment
P07885999A0000|0 20|Several nuclear factors
P07885999A0000|37 45|sequences
P07885999A0000|53 66|flanking region
P07885999A0000|72 90|mouse tyrosinase gene
P07885999A0000|110 118|band shift
P07885999A0000|122 150|methylation interference assays
P07886610A0000|46 53|patients
P07886610A0000|58 68|hemophilia A
P07886610A0000|71 75|India
P07886610A0000|85 94|prevalence
P07887226A0858|16 28|serum ferritin
P07887226A0858|32 55|hemoglobin determinations
P07887226A0858|32 41|hemoglobin
P07887226A0858|60 88|serum transferrin receptor assay
P07887226A0858|65 83|transferrin receptor
P07887226A0858|92 107|valuable addition
P07887226A0858|110 129|epidemiologic surveys
P07887226A0858|148 166|quantitative measure
P07887226A0858|169 192|functional iron deficiency
P07887226A0858|211 217|true IDA
P07887226A0858|225 230|anemia
P07887226A0858|233 246|chronic disease
P07887859A0315|10 28|consecutive patients
P07887859A0315|33 47|ischaemic ulcers
P07887859A0315|51 55|tcPO2
P07887859A0315|70 83|ankle/brachial
P07887859A0315|85 87|ABI
P07887859A0315|92 103|toe/brachial
P07887859A0315|105 107|TBI
P07887859A0315|109 115|indices
P07887859A0998|0 15|TcPO2 measurement
P07887859A0998|28 44|reliable technique
P07887859A0998|61 84|ischaemic ulcer management
P07888156A0169|12 29|University Hospital
P07888156A0169|32 37|Tromso
P07888156A0169|49 62|local hospitals
P07888156A0169|65 78|northern Norway
P07888156A0169|84 109|remote frozen section service
P07888156A0169|125 140|video conferences
P07888156A0169|155 173|microscopic findings
P07888156A0169|195 215|major diagnostic issues
P07888156T0000|0 12|Current status
P07888156T0000|15 27|telepathology
P07888306A1659|0 9|Expression
P07888306A1659|12 15|h6.1
P07888306A1659|18 27|COS-1 cells
P07888306A1659|49 59|typical type
P07888306A1659|56 64|type IV PDE
P07888306A1659|62 72|PDE activity
P07888306A1659|79 82|cAMP
P07888306A1659|90 93|cGMP
P07888306A1659|103 111|substrate
P07888306A1659|129 139|insensitive
P07888306A1659|148 151|Ca2+
P07888306A1659|148 150|Ca2
P07888306A1659|153 155|CaM
P07888306A1659|158 161|cGMP
P07888306A1659|179 195|low concentrations
P07888306A1659|198 205|rolipram
P07888306A1659|208 215|ABSTRACT
P07888306A1659|230 234|WORDS
P07888623A0721|0 12|PMEK1 displays
P07888623A0721|0 4|PMEK1
P07888623A0721|20 28|% identity
P07888623A0721|48 58|tobacco NTF3
P07888623A0721|62 85|Arabidopsis ATMPK1 kinases
P07888623A0721|96 96|%
P07888623A0721|115 141|related plant MAP kinase MsERK1
P07888623A0721|127 141|MAP kinase MsERK1
P07888623A0721|146 152|alfalfa
P07888629A0344|0 10|Translation
P07888629A0344|48 53|MsPRP2
P07888629A0344|74 81|chimeric
P07888629A0344|88 104|Da cell wall protein
P07888629A0344|111 138|amino-terminal signal sequence
P07888629A0344|141 170|repetitive proline-rich sequence
P07888629A0344|176 223|cysteine-rich carboxyl-terminal sequence homologous
P07888629A0344|226 257|nonspecific lipid transfer proteins
P07888788A1010|18 33|hypersensitivity
P07888788A1010|37 44|subgroup
P07888788A1010|47 59|aspergillomas
P07888788A1010|70 92|immunoallergic component
P07888788A1010|129 155|chronic inflammatory response
P07888788A1010|158 168|Aspergillus
P07888788A1010|175 187|aspergillomas
P07888828A0765|43 54|RH-like genes
P07888828A0765|57 72|non human primates
P07890485A0827|4 21|steady illumination
P07890485A0827|23 34|outer retinal
P07890485A0827|36 48|photoreceptor
P07890485A0827|50 52|QO2
P07890485A0827|73 74|ml
P07890485A0827|82 86|g.min
P07890485A0827|92 106|inner retinal QO2
P07890485A0827|115 123|unchanged
P07890485A0827|135 136|ml
P07890485A0827|144 148|g.min
P07890485A0827|152 155|cats
P07890599A0132|17 32|mouse cDNA library
P07890599A0132|37 48|MIN6 cell line
P07890599A0132|61 79|pancreatic beta cells
P07890599A0132|87 98|novel isoform
P07890599A0132|117 120|cDNA
P07890599A0132|130 149|593-amino acid protein
P07890599A0132|167 175|% identity
P07890599A0132|180 186|munc-18
P07890599A0132|188 193|n-Sec1
P07890599A0132|195 200|rbSec1
P07890599A0132|202 227|Caenorhabditis elegans unc18
P07890599A0132|232 259|Saccharomyces cerevisiae Sec1p
P07890599A0132|255 259|Sec1p
P07890674A0916|3 10|catenins
P07890674A0916|17 19|APC
P07890674A0916|23 32|E-cadherin
P07890674A0916|36 49|similar fashion
P07890674A0916|54 56|APC
P07890674A0916|60 69|E-cadherin
P07890674A0916|127 134|catenins
P07890680A1193|18 34|core DNA polymerase
P07890680A1193|40 59|preinitiation complex
P07890680A1193|80 89|holoenzyme
P07890680A1193|113 117|gamma
P07890680A1193|120 124|alpha
P07890680A1193|130 143|primer terminus
P07890740A0997|3 10|PSD2 gene
P07890740A0997|50 64|Sf-9 insect cells
P07890740A0997|69 90|recombinant baculovirus
P07890740A0997|104 118|10-fold increase
P07890740A0997|121 131|PSD activity
P07891638T0000|0 20|Computerized detection
P07891638T0000|23 39|abnormal asymmetry
P07891638T0000|42 64|digital chest radiographs
P07891685A1051|5 11|results
P07891685A1051|23 40|gluconeogenic genes
P07891685A1051|59 65|binding
P07891685A1051|68 72|Cat8p
P07891685A1051|79 87|synthesis
P07891685A1051|109 113|Cat4p
P07891685A1051|115 119|Mig1p
P07891685A1051|128 139|CAT8 promoter
P07891708A0690|4 6|Epo
P07891708A0690|8 12|HNF-4
P07891708A0690|26 31|kidney
P07891708A0690|42 51|Hep3B cells
P07891708A0690|60 68|HeLa cells
P07891708A1192|12 36|hypoxia-induced expression
P07891708A1192|42 58|endogenous Epo gene
P07891708A1192|86 95|Hep3B cells
P07891708A1192|117 128|HNF-4 delta C.
P07891708A1192|117 127|HNF-4 delta C
P07891709A1542|5 16|observations
P07891709A1542|37 54|multiple mechanisms
P07891709A1542|64 83|individual transcript
P07891709A1542|106 118|deadenylation
P07891713T0000|0 15|Small Maf proteins
P07891713T0000|34 36|Fos
P07891713T0000|48 68|competitive repressors
P07891713T0000|74 97|NF-E2 transcription factor
P07891720A0818|17 23|binding
P07891720A0818|26 28|C1F
P07891720A0818|67 77|calcium ions
P07892076A0578|0 7|Survival
P07892076A0578|26 45|symptomatic infection
P07892076A0578|47 49|P-2
P07892076A0578|65 80|transmission mode
P07892353A0667|4 10|factors
P07892353A0667|23 45|significant correlations
P07892353A0667|50 53|rCBF
P07892353A0667|59 80|medial prefrontal cortex
P07892353A0667|84 101|frontal polar cortex
P07892353A0667|133 146|unique patterns
P07892353A0667|149 160|correlations
P07892353A0667|165 185|posterior brain regions
P07894021A1130|36 38|DS2
P07894021A1130|62 71|nuclear DNA
P07894021A1130|76 86|desiccation
P07894359T0000|0 21|Glomerular hemodynamics
P07894359T0000|45 46|RU
P07894359T0000|53 58|sepsis
P07894359T0000|61 64|rats
P07894761A0000|12 29|retrospective study
P07894761A0000|52 63|certain cases
P07894761A0000|66 93|expulsive choroidal hemorrhage
P07894761A0000|95 97|ECH
P07894761A0000|99 115|anatomical success
P07894761A0000|119 130|useful vision
P07894761A0000|156 175|vitreoretinal surgery
P07896088A0720|16 29|C-terminal tail
P07896088A0720|32 50|telomere maintenance
P07896088A0720|74 94|RAP1 interacting factor
P07896088A0720|74 77|RAP1
P07896088A0720|89 98|factor RIF1
P07896088A0720|95 98|RIF1
P07896088A0720|100 119|rap1 alleles defective
P07896088A0720|100 110|rap1 alleles
P07896088A0720|129 142|C-terminal tail
P07896088A0720|146 167|RIF1 interaction domains
P07896088A0720|172 186|additive effects
P07896088A0720|189 202|telomere length
P07896291A0693|42 55|cytogenetic map
P07896291A0693|82 97|characterization
P07896291A0693|100 104|genes
P07896291A0693|127 138|WAGR syndrome
P07896615A0554|17 24|skin flow
P07896615A0554|30 36|changes
P07896615A0554|46 57|nm absorption
P07896615A0554|75 97|simultaneous measurement
P07896615A0554|100 107|skin flow
P07896615A0554|110 125|laser flow Doppler
P07896615A0554|129 141|NIR recordings
P07896615A0554|148 164|hot water immersion
P07896817A0204|0 7|Proteins
P07896817A0204|30 36|lysates
P07896817A0204|50 68|VEGF-stimulated BAEC
P07896817A0204|50 53|VEGF
P07896817A0204|73 80|antisera
P07896817A0204|83 102|phospholipase C-gamma
P07896817A0204|104 112|PLC-gamma
P07896817A0204|132 167|SDS-polyacrylamide gel electrophoresis
P07896817A0204|184 194|Immobilon-P
P07896846T0000|22 29|isoforms
P07896846T0000|32 65|cellular nucleic acid-binding protein
P07896846T0000|79 94|suppressor region
P07896846T0000|100 129|human beta-myosin heavy chain gene
P07896852T0000|0 10|Involvement
P07896852T0000|13 42|early growth response factor Egr-1
P07896852T0000|45 77|apolipoprotein AI gene transcription
P07896852T0000|45 64|apolipoprotein AI gene
P07897359A0354|3 11|wild-type
P07897359A0354|15 26|altered forms
P07897359A0354|32 39|F protein
P07897359A0354|55 60|BHK-21
P07897359A0354|64 74|HeLa T4 cells
P07897359A0354|85 135|recombinant vaccinia virus-encoding T7 polymerase system
P07897696A0000|0 45|Erythrocyte delta-aminolevulinic acid dehydratase
P07897696A0000|47 50|ALAD
P07897696A0000|61 89|erythrocyte zinc protoporphyrin
P07897696A0000|91 93|ZPP
P07897696A0000|96 104|heme ratio
P07897696A0000|109 129|urinary coproporphyrin
P07897696A0000|131 132|UC
P07897696A0000|165 184|biological indicators
P07897696A0000|187 219|moderate-to high-level lead exposure
P07897696A0000|236 246|blood levels
P07897696A0000|249 254|excess
P07897696A0000|259 271|micrograms/dl
P07897696A0000|275 287|human subjects
P07898178A0849|3 14|relative risk
P07898178A0849|17 25|graft loss
P07898178A0849|43 54|azathioprine
P07898178A0849|67 75|graft loss
P07898178A0849|93 104|azathioprine
P07898178A0849|117 138|cyclosporin maintenance
P07898178A0849|163 174|relative risk
P07898178A0849|177 188|patient death
P07898275A0254|5 11|classes
P07898275A0254|14 24|test objects
P07898275A0254|44 69|multicompartment test object
P07898275A0254|73 90|31P MRS measurements
P07898275A0254|104 127|slice-selective sequences
P07898275A0254|133 157|two-compartment test object
P07898275A0254|161 181|volume-selection 1H MRS
P07898275A0254|189 214|two-compartment test objects
P07898275A0254|243 261|experimental systems
P07898275A0254|267 270|ISIS
P07898275A0254|273 298|volume localization sequence
P07898275A0254|301 307|31P MRS.
P07898589T0000|4 15|tobacco issue
P07898840X0000|0 17|Pregnancy screening
P07898840X0000|20 50|uterine artery Doppler velocimetry
P07898840X0000|58 66|criterion
P07898840X0000|80 88|OBJECTIVE
P07898840X0000|112 125|Doppler studies
P07898840X0000|131 155|uteroplacental circulation
P07898840X0000|162 170|gestation
P07898840X0000|209 237|pregnancy-induced hypertension
P07898840X0000|241 262|fetal growth restriction
P07898840X0000|264 266|FGR
P07898840X0000|308 319|quantitative
P07898840X0000|323 344|qualitative assessments
P07898840X0000|350 373|uterine arterial waveforms
P07898840X0000|383 395|better results
P07899581A0000|14 39|Ca entry blocker nitrendipine
P07899581A0000|44 73|antioxidant superoxide dismutase
P07899581A0000|55 73|superoxide dismutase
P07899581A0000|75 77|SOD
P07899581A0000|97 108|nitrendipine
P07899581A0000|112 130|superoxide dismutase
P07899581A0000|133 157|postischemic renal function
P07899581A0000|174 179|groups
P07899581A0000|181 182|n =
P07899581A0000|188 191|rats
P07899634A0000|0 6|PURPOSE
P07899634A0000|41 53|bony anchorage
P07899634A0000|68 74|orderly
P07899634A0000|80 92|surface effect
P07899634A0000|97 107|alloy Ti Al Va
P07899634A0000|128 129|mu
P07900915A0000|38 58|gastrointestinal tract
P07900915A0000|66 76|restitution
P07900915A0000|79 89|blood volume
P07900915A0000|93 105|plasma protein
P07900915A0000|111 120|hemorrhage
P07900915A0000|122 124|fed
P07900915A0000|128 147|24-h-fasted awake rats
P07900915A0000|159 166|ml.kg-1 x
P07900915A0000|168 182|min-1 hemorrhage
P07900915A0000|187 197|restitution
P07900915A0000|200 210|blood volume
P07900915A0000|224 232|Evans blue
P07900915A0000|239 246|dilution
P07900915A0000|249 258|hematocrit
P07901121T0000|0 22|Cooperative dimerization
P07901121T0000|25 47|paired class homeo domains
P07901125A0416|20 29|high degree
P07901125A0416|32 49|aa sequence homology
P07901125A0416|57 62|DAHPSs
P07901125A0416|67 80|several species
P07901125A0416|90 103|ARO3 homologues
P07901125A0416|111 140|pathogenic yeast Candida albicans
P07902532A0312|29 34|BOX DNA
P07902532A0312|43 55|transcription
P07902532A0312|63 77|thymidine kinase
P07902532A0312|79 80|TK
P07902532A0312|82 89|promoter
P07902532A0312|92 105|various EC cells
P07902532A1655|0 15|Deletion analyses
P07902532A1655|45 57|transcription
P07902532A1655|60 68|BOXF1 gene
P07902532A1655|82 87|BOX DNA
P07902532A1655|105 127|undifferentiated EC cells
P07902532A1655|148 152|cells
P07902583A0545|0 7|Analysis
P07902583A0545|10 28|disassociation rates
P07902583A0545|45 65|Grf10-Swi5-DNA complex
P07902583A0545|45 49|Grf10
P07902583A0545|51 54|Swi5
P07902583A0545|76 84|half-life
P07902583A0545|89 108|protein-DNA complexes
P07902583A0545|124 127|Swi5
P07902583A0545|130 134|Grf10
P07903099A0918|15 31|unusual transcript
P07903099A0918|42 51|IVS2C beta 1
P07903099A0918|42 50|IVS2C beta
P07903099A0918|59 66|terminus
P07903099A0918|79 86|cleavage
P07903099A0918|92 105|splice acceptor
P07903099A0918|108 118|inefficient
P07903670A1202|3 14|mutant allele
P07903670A1202|20 37|alpha 1-tubulin gene
P07903670A1202|51 56|tua1-1
P07905413A0585|6 21|chronic treatment
P07905413A0585|27 46|plasma concentrations
P07905413A0585|68 74|ng.ml-1
P07905413A0585|78 78|h
P07905413A0585|84 90|ng.ml-1
P07905413A0585|95 106|h post-dosing
P07905413A0585|108 126|ST segment depression
P07905413A0585|143 160|comparable workload
P07905413A0585|190 190|%
P07905413A0585|203 209|placebo
P07905413A0585|211 211|P
P07905413A0585|225 230|points
P07905453A0281|0 6|Results
P07905453A0281|18 50|transcription-translation analysis
P07905453A0281|54 72|maxicell experiments
P07905453A0281|89 97|447-bp ORF
P07906265A0897|0 21|Preliminary experiments
P07906265A0897|60 70|fasD mutants
P07906265A0897|77 84|products
P07906265A0897|104 117|fimbrial export
P07906616A0191|6 30|electromyographic response
P07906616A0191|33 63|indirect supramaximal stimulation
P07906616A0191|67 68|Hz
P07906616A0191|86 95|adult goats
P07906616A0191|101 132|thiopentone-halothane anaesthesia
P07907846A0623|0 4|Group
P07907846A0623|14 26|physostigmine
P07907846A0623|31 39|mg/kg i.v.
P07907846A0623|55 79|cholinesterase degradation
P07907846A0623|55 68|cholinesterase
P07907846A0623|82 84|min
P07907846A0623|91 115|bupivacaine administration
P07907846A0623|120 124|Group
P07907846A0623|148 172|physostigmine pretreatment
P07907846A0623|176 201|electrical vagal stimulation
P07908012A0678|27 41|LNNB performance
P07908012A0678|47 65|schizophrenic groups
P07908012A0678|86 106|neuroleptic medication
P07908012A0678|108 115|analyses
P07908012A0678|153 168|medication levels
P07908012A0678|172 181|LNNB scores
P07908187T0000|0 3|ISIS
P07908187T0000|5 17|possibilities
P07908827A1200|8 25|specific antibodies
P07908827A1200|54 65|least RAR beta
P07908827A1200|77 96|DNA-protein complexes
P07908827A1200|113 121|sequences
P07908827A1200|126 135|single RARs
P07908827A1200|149 156|COS cells
P07908827A1200|203 231|canonical RAR responsive element
P07908827A1200|212 231|RAR responsive element
P07909936A0672|3 26|present treatment strategy
P07909936A0672|29 48|progressive disorders
P07909936A0672|67 85|complementary effect
P07909936A0672|88 113|intensive radiochemotherapy
P07909936A0672|115 148|autologous stem-cell transplantation
P07909936A0672|155 165|rational use
P07909936A0672|168 176|cytokines
P07909936A0672|184 208|colony-stimulating factors
P07910716A0359|3 14|study cohorts
P07910716A0359|28 35|patients
P07910716A0359|47 53|SC rIL-2
P07910716A0359|49 53|rIL-2
P07910716A0359|56 60|doses
P07910716A0359|78 86|IU/m2/day
P07910716A0359|90 93|days
P07910716A0359|113 117|weeks
P07910716A0359|121 128|patients
P07910716A0359|140 151|rIFN-alpha 2b
P07910716A0359|168 187|U/m2/day thrice weekly
P07910716A0359|200 204|weeks
P07910716A0359|211 218|patients
P07910716A0359|231 244|SC rIFN-alpha 2b
P07910716A0359|233 244|rIFN-alpha 2b
P07910716A0359|257 276|U/m2/day thrice weekly
P07910716A0359|281 287|SC rIL-2
P07910716A0359|283 287|rIL-2
P07910716A0359|306 314|IU/m2/day
P07910716A0359|317 320|days
P07910716A0359|347 355|IU/m2/day
P07910716A0359|358 361|days
P07910716A0359|373 388|consecutive weeks
P07910946A0323|0 7|Analysis
P07910946A0323|16 33|deletion constructs
P07910946A0323|36 62|transient transfection assays
P07910946A0323|72 95|heterologous reporter gene
P07910946A0323|97 106|luciferase
P07910946A0323|135 140|182-bp
P07910946A0323|144 157|flanking region
P07910946A0323|166 185|full promoter activity
P07910946A0323|188 209|IL-2-stimulated L2 cells
P07910946A0323|188 191|IL-2
P07911736A1715|5 7|MTD
P07911736A1715|10 18|mg/m2/day
P07911736A1715|24 44|dose-limiting toxicity
P07911736A1715|58 73|myelosuppression
P07912123A0711|0 37|Mitogen-induced lymphocyte proliferation
P07913080A0564|1 40|decanucleotide promoter sequence homologous
P07913080A0564|55 60|humans
P07913080A0564|64 67|mice
P07913080A0564|85 102|untranslated region
P07913080A0564|108 116|horse gene
P07913891A0174|11 17|targets
P07913891A0174|39 47|molecules
P07913891A0174|58 78|cell-cell interactions
P07913891A0174|130 137|Hox genes
P07913891A0174|141 165|other transcription factors
P07913891A0174|204 220|tissue specificity
P07913926A0878|0 15|Northern analysis
P07913926A0878|18 27|RNA samples
P07913926A0878|40 61|ammonium-grown cultures
P07913926A0878|67 76|ntcA mutant
P07913926A0878|90 96|amounts
P07913926A0878|99 109|glnA message
P07913926A0878|126 141|1.7-kb transcript
P07914192A0211|0 22|HER2 overexpressing cells
P07914192A0211|0 3|HER2
P07914192A0211|30 49|single prominent DNase
P07914192A0211|45 50|DNase I
P07914192A0211|51 68|hypersensitive site
P07914192A0211|94 123|unrecognized ets response element
P07914192A0211|106 123|ets response element
P07914192A0211|125 130|GAGGAA
P07914192A0211|133 139|located
P07914192A0211|142 157|bases down-stream
P07914192A0211|165 171|CAAT box
P07914192A0211|190 196|TATA box
P07914192A0211|202 218|human HER2 promoter
P07914192A0844|0 14|Gel-shift assays
P07914192A0844|19 33|nuclear extracts
P07914192A0844|37 60|oligonucleotide sequences
P07914192A0844|72 93|0.125-kb promoter region
P07914192A0844|104 128|ETS-immunoreactive complex
P07914192A0844|153 157|cells
P07914192A0844|172 175|HER2
P07914192A0844|182 201|high-affinity binding
P07914192A0844|215 235|GAGGAA response element
P07914507A1029|0 9|Comparison
P07914507A1029|12 24|cDNA sequences
P07914507A1029|43 53|mRNA species
P07914507A1029|70 81|alternate use
P07914507A1029|84 87|poly
P07914507A1029|89 89|A
P07914507A1029|92 104|addition sites
P07914700A0000|13 48|RNA-dependent eIF-2 alpha protein kinase
P07914700A0000|50 52|PKR
P07914700A0000|69 83|mouse genomic DNA
P07915144A0000|0 34|High-frequency electrical stimulation
P07915144A0000|40 50|hippocampus
P07915144A0000|70 85|synaptic efficacy
P07915144A0000|98 106|many hours
P07916003A0688|0 6|Similar
P07916003A0688|12 20|mouse gene
P07916003A0688|27 40|flanking region
P07916003A0688|43 56|human CD79 alpha
P07916003A0688|63 69|TATA box
P07916003A0688|85 98|mouse CD79 alpha
P07916003A0688|101 121|classical octamer motif
P07916003A0688|147 155|human gene
P07916326A0000|0 28|Detailed molecular organization
P07916326A0000|34 39|coding
P07916326A0000|43 67|upstream regulatory regions
P07916326A0000|73 104|murine homeodomain-containing gene
P07916326A0000|106 110|Msx-1
P07916327A0250|15 21|cloning
P07916327A0250|27 44|human goosecoid gene
P07916327A0250|46 48|GSC
P07916327A0250|55 68|genomic library
P07916577A0190|15 37|potential candidate genes
P07916577A0190|50 58|disorders
P07916577A0190|74 95|aberrant gene expression
P07916577A0190|107 130|Kruppel-related sequences
P07916577A0190|140 165|zinc finger-containing cDNAs
P07916588A0471|21 38|South African strain
P07916588A0471|41 66|passion fruit woodiness virus
P07916588A0471|68 70|PWV
P07916588A0471|83 92|CP sequence
P07916588A0471|117 119|CPs
P07916588A0471|136 142|strains
P07916588A0471|145 147|PWV
P07916588A0471|168 183|distinct subgroup
P07916588A0471|186 196|potyviruses
P07916588A0471|206 208|PWV
P07916685A0455|23 44|arogenate dehydrogenase
P07916685A0455|53 75|prephenate dehydrogenase
P07916685A0455|120 131|purification
P07916685A0455|142 151|activities
P07916685A0455|165 175|inseparable
P07916689A0312|11 20|POT1 clones
P07916689A0312|11 14|POT1
P07916689A0312|37 48|kb RNA species
P07916689A0312|89 94|oleate
P07916689A0312|101 112|carbon source
P07916689A1407|3 29|Y. lipolytica genomic POT1 gene
P07916689A1407|22 25|POT1
P07916689A1407|56 57|bp
P07916689A1407|84 86|kbp
P07916689A1407|104 123|Y. lipolytica LEU2 gene
P07916729T0000|1 19|leucine zipper domain
P07916729T0000|25 53|suppressor of Hairy-wing protein
P07916729T0000|25 34|suppressor
P07916729T0000|37 53|Hairy-wing protein
P07916729T0000|65 80|repressive effect
P07916729T0000|83 98|enhancer function
P07916983A0623|17 18|CT
P07916983A0623|46 53|patients
P07916983A0623|58 73|N1-N3 neck disease
P07916983A0623|88 120|proper electron-energy prescription
P07917016A0581|12 22|DNA-binding
P07917016A0581|24 54|zinc finger domain protein sequence
P07917540A0000|2 9|patients
P07917540A0000|26 40|randomised study
P07917540A0000|50 58|vindesine
P07917540A0000|61 70|mg/m2/week
P07917540A0000|76 93|interferon-alpha 2b
P07917540A0000|96 99|U/m2
P07917540A0000|101 105|times
P07917540A0000|116 124|vindesine
P07917540A0000|134 143|interferon
P07917540A0000|166 192|metastatic malignant melanoma
P07918097T0000|3 31|novel Notch homologue mouse Notch
P07918097T0000|8 12|Notch
P07918097T0000|27 32|Notch 3
P07918097T0000|38 74|specific epidermal growth factor-repeats
P07918097T0000|46 74|epidermal growth factor-repeats
P07918097T0000|104 118|neuroepithelium
P07918128A0000|0 9|BACKGROUND
P07918128A0000|38 40|MDL
P07918128A0000|47 48|EF
P07918128A0000|55 71|hydroxytryptamine
P07918128A0000|74 78|5-HT3
P07918128A0000|80 97|receptor antagonist
P07918128A0000|103 110|patients
P07918128A0000|120 141|emetogenic chemotherapy
P07918494A1163|39 49|thioredoxin
P07918494A1163|51 70|thioredoxin reductase
P07918494A1163|75 79|NADPH
P07918494A1163|101 107|mutants
P07918494A1163|142 146|dCTPs
P07918494A1163|150 153|mole
P07918494A1163|156 161|enzyme
P07919540A0240|5 22|genetic alterations
P07919540A0240|34 42|synthesis
P07919540A0240|48 64|major c-myc protein
P07919540A0240|53 64|c-myc protein
P07919540A0240|66 68|p64
P07919540A0240|93 105|first AUG codon
P07919540A0240|108 111|exon
P07919540A1119|18 21|exon
P07919540A1119|27 46|exon 2-initiated forms
P07919540A1119|52 63|c-Myc protein
P07919540A1119|74 86|transcription
P07919540A1119|90 124|Myc/Max-responsive reporter construct
P07919540A1119|90 92|Myc
P07919540A1119|128 139|similar level
P07922709T0000|0 19|Biological activities
P07922709T0000|22 47|hematopoietic growth factors
P07922709T0000|58 82|future clinical application
P07925022A0285|0 9|Expression
P07925022A0285|35 37|CNS
P07925022A0285|47 57|later stages
P07925097A1205|0 22|Immunoreactive AR content
P07925097A1205|14 15|AR
P07925097A1205|36 45|COS-1 cells
P07925097A1205|74 82|8-Br-cAMP
P07925282A0705|0 9|Disruption
P07925282A0705|27 31|genes
P07925282A0705|58 68|SRP proteins
P07925282A0705|78 91|slow cell growth
P07925282A0705|95 125|inefficient protein translocation
P07925282A0705|135 144|ER membrane
P07926729A0000|0 17|Genetic alterations
P07926729A0000|20 27|elements
P07926729A0000|30 63|normal signal transduction mechanisms
P07926729A0000|76 90|oncogenic events
P07926729A0000|107 124|aberrant activation
P07926729A0000|127 134|programs
P07926729A0000|137 153|gene transcription
P07926739A0766|3 19|expression pattern
P07926739A0766|22 24|GL2
P07926739A0766|48 60|hybridization
P07926739A0766|95 117|trichome progenitor cells
P07926739A0766|123 128|stages
P07926739A0766|143 161|trichome development
P07926748A0383|0 3|NOT4
P07926748A0383|17 20|NOT1
P07926748A0383|24 27|NOT3
P07926748A0383|33 47|two-hybrid assay
P07926748A0383|52 65|overexpression
P07926748A0383|68 71|NOT3
P07926748A0383|74 77|NOT4
P07926748A0383|88 91|not1
P07926748A0383|95 107|not2 mutations
P07926748A0383|95 98|not2
P07926749A0471|7 19|site selection
P07926749A0471|27 51|vitro-synthesized proteins
P07926749A0471|66 74|ROR alpha 1
P07926749A0471|66 73|ROR alpha
P07926749A0471|78 94|ROR alpha 2 isoforms
P07926749A0471|78 85|ROR alpha
P07926749A0471|87 94|isoforms
P07926749A0471|104 111|monomers
P07926749A0471|114 136|hormone response elements
P07926749A0471|148 166|6-bp AT-rich sequence
P07926749A0471|177 201|half-site core motif PuGGTCA
P07926749A0471|203 206|RORE
P07926774A0652|3 25|p73pct1/p85cdc10 complex
P07926774A0652|3 9|p73pct1
P07926774A0652|11 18|p85cdc10
P07926774A0652|53 55|MCB
P07926774A0652|62 64|SCB
P07926774A0652|67 74|E2F sites
P07926775A0895|13 14|en
P07926775A0895|15 21|stripes
P07926775A0895|40 55|slp mutant embryos
P07926775A0895|40 42|slp
P07926775A0895|63 73|slp activity
P07926775A0895|63 65|slp
P07926775A0895|78 96|absolute requirement
P07926775A0895|113 124|wg expression
P07926775A0895|113 114|wg
P07926775A0895|130 137|same time
P07926775A0895|142 156|wg transcription
P07926775A0895|142 143|wg
P07926775A0895|170 171|hh
P07926789A0960|3 21|DNA sequence adjacent
P07926789A0960|27 34|lacZ gene
P07926789A0960|57 77|vegetative fusion genes
P07926789A0960|83 90|products
P07926789A0960|99 107|localized
P07926789A0960|134 140|fusions
P07927130A0625|0 30|CMV hyperimmunoglobulin treatment
P07927130A0625|3 21|hyperimmunoglobulin
P07927130A0625|32 39|Cytotect
P07927130A0625|41 47|Biotest
P07927130A0625|61 67|ml/kg bw
P07927130A0625|83 87|ml/kg
P07927130A0625|90 93|days
P07927130A0625|116 126|eradication
P07927130A0625|132 149|residual infiltrate
P07927130A0625|153 159|CMV-DNA
P07927130A0625|165 174|myocardium
P07927267T0000|0 22|Internal biliary drainage
P07927267T0000|30 45|external drainage
P07927267T0000|65 76|regeneration
P07927267T0000|79 97|cholestatic rat liver
P07927267T0000|103 120|partial hepatectomy
P07927711A0698|0 2|ORF
P07927711A0698|23 40|hydrophobic protein
P07927711A0698|49 50|Da
P07927711A0698|58 90|potential membrane-spanning regions
P07927838A0000|7 12|groups
P07927838A0000|15 22|subjects
P07927838A0000|32 47|various hand-held
P07927838A0000|57 61|tools
P07927838A0000|79 83|years
P07927838A0000|88 102|prevalence rates
P07927838A0000|105 132|vibration-induced white finger
P07927838A0000|134 136|VWF
P07927838A0000|141 148|numbness
P07927838A0000|157 165|stiffness
P07927838A0000|179 194|lower extremities
P07928954A0545|0 18|DNA sequence analysis
P07928954A0545|42 47|bp long
P07928954A0545|59 79|175-amino-acid protein
P07928954A0545|85 99|molecular weight
P07928954A0545|119 159|21-residue typical lipoprotein signal peptide
P07928954A0545|163 199|consensus prolipoprotein processing site
P07929165T0000|0 10|DNA sequence
P07929165T0000|14 22|functions
P07929165T0000|28 38|actVI region
P07929165T0000|44 78|actinorhodin biosynthetic gene cluster
P07929165T0000|103 104|A3
P07929238A0734|6 13|Genomics
P07929411A0087|25 43|polypeptide sequence
P07929411A0087|49 65|Drosophila protein
P07929411A0087|73 90|equivalent subunits
P07929411A0087|103 107|yeast
P07929411A0087|165 171|regions
P07929411A0087|202 215|enzyme activity
P07929431A0949|0 7|Plasmids
P07929431A0949|30 48|mouse promoter region
P07929431A0949|60 103|reporter gene chloramphenicol acetyltransferase
P07929431A0949|72 103|chloramphenicol acetyltransferase
P07929431A0949|105 107|CAT
P07929431A0949|149 158|INS-1 cells
P07929431A0949|149 153|INS-1
P07929559A0000|0 16|Cytoplasmic dynein
P07929559A0000|20 31|multisubunit
P07929559A0000|33 74|microtubule-dependent mechanochemical enzyme
P07929559A0000|116 137|intracellular movements
P07929559A0000|148 174|minus-end-directed transport
P07929559A0000|177 186|organelles
P07929560T0000|0 13|Identification
P07929560T0000|19 43|plakoglobin-binding domain
P07929560T0000|46 55|desmoglein
P07929560T0000|68 81|plaque assembly
P07929560T0000|85 113|intermediate filament anchorage
P07931490A0237|0 7|PATIENTS
P07931490A0237|11 17|METHODS
P07931490A0237|40 65|chemotherapy-naive patients
P07931490A0237|75 92|high-dose cisplatin
P07931490A0237|101 105|mg/m2
P07931490A0237|139 154|granisetron doses
P07931490A0237|168 180|micrograms/kg
P07931490A0237|200 211|chemotherapy
P07932095A0000|4 33|new naphthalene related compounds
P07932095A0000|40 48|V, VII-XII
P07932095A0000|40 40|V
P07932095A0000|42 48|VII-XII
P07932095A0000|66 79|known compounds
P07932095A0000|88 89|VI
P07932095A0000|91 94|XIII
P07932095A0000|115 122|root bark
P07932095A0000|125 143|Oroxylum indicum Vent
P07932943A0113|52 68|awareness strategy
P07932943A0113|74 94|non-awareness strategy
P07932943A0113|100 124|Five-Step Approach strategy
P07932943A0113|132 147|control condition
P07933066T0000|8 27|exclusive interaction
P07933066T0000|33 46|adenovirus E4-6
P07933066T0000|62 86|retinoblastoma gene product
P07933066T0000|91 105|internal domains
P07933066T0000|108 112|E2F-1
P07933066T0000|116 119|DP-1
P07933076A0211|18 22|EBNA2
P07933076A0211|40 48|promoters
P07933076A0211|54 80|viral latent membrane proteins
P07933095A0000|22 26|v-Rel
P07933095A0000|31 41|oncoprotein
P07933095A0000|47 66|avian retrovirus Rev-T
P07933095A0000|93 101|promoters
P07933095A0000|119 123|sites
P07933095A0000|130 159|cellular transcription factor Sp1
P07933095A0000|162 185|chicken embryo fibroblasts
P07933095A0000|187 188|S.
P07933101A0131|0 14|Previous studies
P07933101A0131|38 48|TATA element
P07933101A0131|62 66|basal
P07933101A0131|70 99|Tat-induced HIV-1 gene expression
P07933101A0131|70 72|Tat
P07933101A0131|81 89|HIV-1 gene
P07933107A0991|16 33|nucleotide sequence
P07933107A0991|39 45|p54 gene
P07933107A0991|58 76|virulent ASFV strains
P07933107A0991|78 80|E70
P07933107A0991|84 86|E75
P07933107A0991|108 117|virus Ba71V
P07933107A0991|127 137|% similarity
P07933116A0412|3 9|p55 mRNA
P07933116A0412|12 23|undetectable
P07933116A0412|26 42|non-EBV-infected B
P07933116A0412|47 57|T-cell lines
P07933116A0412|63 84|myelomonocytic cell line
P07933116A0412|86 89|U937
P07934331T0037|1 18|simple registration
P07934666A0158|3 25|transverse magnetization
P07934666A0158|58 67|components
P07934666A0158|70 71|T2
P07934666A0158|77 79|T2f
P07934666A0158|85 90|T2 slow
P07934666A0158|92 94|T2s
P07935094A0516|0 6|RESULTS
P07935094A0516|11 27|diagnostic quality
P07935094A0516|30 38|FDG images
P07935094A0516|68 85|Tl-201 counterparts
P07935094A0516|91 109|less liver background
P07935094A0516|121 128|FDG study
P07935370A0000|26 28|CD4
P07935370A0000|32 34|CD8
P07935370A0000|41 57|T-cell development
P07935370A0000|81 95|maturation state
P07935370A0000|101 105|T cell
P07935375A1197|0 9|Expression
P07935375A1197|13 36|dominant-negative ras gene
P07935375A1197|47 65|TIS10/PGS2 induction
P07935375A1197|47 51|TIS10
P07935375A1197|53 56|PGS2
P07935375A1197|68 72|v-src
P07935379A0347|8 27|tTG-transfected cells
P07935379A0347|39 49|cytoplasmic
P07935379A0347|53 80|nuclear changes characteristic
P07935379A0347|83 87|cells
P07935379A0347|98 106|apoptosis
P07935383A0108|7 37|RNase H-mediated mapping technique
P07935383A0108|7 12|RNase H
P07935383A0108|52 64|64-kDa subunit
P07935383A0108|67 70|CstF
P07935383A0108|76 92|photo cross-linked
P07935383A0108|95 103|pre-mRNAs
P07935383A0108|106 125|U-rich regions located
P07935383A0108|141 152|cleavage site
P07935383A0108|158 168|simian virus
P07935383A0108|178 198|adenovirus L3 pre-mRNAs
P07935395A0094|22 24|kDa
P07935395A0094|41 56|zinc finger motifs
P07935395A0094|85 92|clusters
P07935395A0094|95 106|opposite ends
P07935415T0000|0 24|Tissue-specific expression
P07935415T0000|30 54|diazepam-binding inhibitor
P07935415T0000|80 86|cloning
P07935415T0000|101 112|localization
P07935418A0447|6 16|v-erbA probe
P07935418A0447|6 11|v-erbA
P07935418A0447|29 32|cDNA
P07935418A0447|46 71|novel 445-amino-acid protein
P07935418A0447|51 71|445-amino-acid protein
P07935418A0447|73 77|RLD-1
P07935418A0447|94 114|characteristic domains
P07935418A0447|117 132|nuclear receptors
P07935426A0714|12 19|isoforms
P07935426A0714|30 55|N-terminal zinc finger domain
P07935426A0714|87 104|TdT promoter binding
P07935426A0714|87 97|TdT promoter
P07935447A0972|17 30|direct evidence
P07935447A0972|35 37|USF
P07935447A0972|51 90|basic helix-loop-helix leucine zipper family
P07935447A0972|99 102|MLE1
P07935447A0972|104 108|HF-1a
P07935447A0972|113 121|PRE B sites
P07935447A0972|153 168|protein complexes
P07935447A0972|210 215|MLC-2v
P07935447A0972|219 246|alpha-myosin heavy-chain genes
P07935451T0000|0 27|Human T-cell leukemia virus type
P07935451T0000|29 41|Tax activation
P07935451T0000|44 56|NF-kappa B/Rel
P07935451T0000|65 79|phosphorylation
P07935451T0000|83 93|degradation
P07935451T0000|96 107|I kappa B alpha
P07935451T0000|111 114|RelA
P07935451T0000|116 118|p65
P07935451T0000|129 137|induction
P07935451T0000|143 151|c-rel gene
P07935468T0000|0 9|Activation
P07935468T0000|12 30|c-fos gene expression
P07935468T0000|12 20|c-fos gene
P07935468T0000|34 78|kinase-deficient epidermal growth factor receptor
P07935468T0000|50 78|epidermal growth factor receptor
P07935471A0613|7 38|endogenous HSF DNA-binding activity
P07935471A0613|47 64|anti-hHSF1 antibody
P07935471A0613|81 90|Xenopus HSF
P07935471A0613|115 128|mapping regions
P07935471A0613|131 135|hHSF1
P07935471A0613|173 186|monomeric state
P07935472A0276|0 8|Enhancers
P07935472A0276|28 44|Ets-1 binding sites
P07935472A0276|28 32|Ets-1
P07935472A0276|40 44|sites
P07935472A0276|57 81|transient expression assays
P07935472A0276|87 105|murine T-cell line EL4
P07935472A0276|107 108|E1
P07935472A0276|110 120|alterations
P07935472A0276|126 135|LVb element
P07935472A0276|144 171|constitutive enhancer activity
P07935472A0276|178 185|mutation
P07935472A0276|197 199|LVb
P07935472A0276|202 211|LVc element
P07935472A0276|221 256|phorbol ester-induced enhancer activity
P07935472A0790|3 28|predominant binding activity
P07935472A0790|35 39|Ets-1
P07935472A0790|52 82|independent DNA-protein complexes
P07935472A0790|99 117|mobility shift assays
P07935491A0495|5 15|RZR subtypes
P07935491A0495|5 7|RZR
P07935491A0495|25 31|members
P07935491A0495|35 43|new family
P07935491A0495|46 67|orphan nuclear receptors
P07935491A0495|72 81|most likely
P07935491A0495|90 111|specific gene expression
P07935491A1182|19 34|response elements
P07935491A1182|61 68|affinity
P07935491A1182|72 122|retinoic acid receptor-retinoid-X receptor heterodimers
P07935491A1182|72 91|retinoic acid receptor
P07935491A1182|93 110|retinoid-X receptor
P07935577A0305|0 8|Treatment
P07935577A0305|13 25|amphotericin B
P07935577A0305|29 39|flucytosine
P07935577A0305|61 68|symptoms
P07935577A0305|90 104|micro-organisms
P07935577A0305|112 129|cerebrospinal fluid
P07935577A0305|131 133|CSF
P07935626A1249|3 20|unexpected presence
P07935626A1249|26 29|tRNA
P07935626A1249|31 33|trp
P07935626A1249|36 38|CCA
P07935626A1249|41 54|gene transcript
P07935626A1249|57 68|mitochondria
P07935997A0000|3 12|parameters
P07935997A0000|15 40|nonspecific humoral immunity
P07935997A0000|43 62|serum immunoglobulins
P07935997A0000|66 80|immune complexes
P07935997A0000|98 112|irradiated group
P07935997A0000|115 122|patients
P07935997A0000|127 148|uterine cervix carcinoma
P07935997A0000|150 158|Stages IIB
P07935997A0000|162 165|IIIB
P07936635A1134|0 7|Mutation
P07936635A1134|10 13|KRKR
P07936635A1134|16 19|NGER
P07936635A1134|27 30|MO15
P07936635A1134|36 57|cytoplasmic compartment
P07936635A1134|68 83|wild-type protein
P07936635A1134|110 116|nucleus
P07936640A0900|12 18|binding
P07936640A0900|35 39|sites
P07936640A0900|42 46|cells
P07936640A0900|68 94|genomic footprinting analysis
P07936640A0900|113 128|TGF alpha promoter
P07936640A0900|151 177|rat liver epithelial cell lines
P07936640A0900|192 205|endogenous gene
P07936640A0900|215 220|levels
P07936650A0656|15 23|subdomain
P07936650A0656|51 85|unrelated N-terminal activating region
P07936650A0656|88 97|p58c-ets-2
P07936650A0656|113 115|BEC
P07936650A0656|119 128|Ets-1-beta
P07936650A0656|130 152|Ets-2-Conserved sequence
P07936650A1752|17 24|new model
P07936650A1752|31 35|ets-1
P07936650A1752|37 45|ets-2 gene
P07936650A1752|69 77|first time
P07936650A1752|97 115|functional evidences
P07937106A0100|3 15|v-ets oncogene
P07937106A0100|21 38|avian retrovirus E26
P07937106A0100|53 80|cellular progenitor p68c-ets-1
P07937106A0100|86 107|amino acid substitutions
P07937106A0100|109 115|alanine
P07937106A0100|122 131|isoleucine
P07937106A0100|137 143|c-ets-1
P07937106A0100|161 166|valine
P07937106A0100|169 173|v-ets
P07937106A0100|175 183|mutations
P07937106A0100|188 188|B
P07937106A0100|208 226|carboxy-terminal end
P07937106A0100|228 236|mutation C
P07937108A0325|12 26|functional mRNAs
P07937108A0325|42 66|endogenous RNA polymerase I.
P07937112A0220|3 20|individual subunits
P07937112A0220|23 24|Ku
P07937112A0220|55 64|human cells
P07937112A0220|72 83|denaturation
P07937112A0220|104 126|functional recombinant Ku
P07937112A0220|142 153|unsuccessful
P07937127A0645|34 69|strong enhancer-type activation domains
P07937127A0645|77 97|immediate early regions
P07937127A0645|103 115|herpesviruses
P07937127A0645|123 139|pseudorabies virus
P07937127A0645|143 159|bovine herpesvirus
P07937132A0819|11 13|U21
P07937132A0819|23 33|long stretch
P07937132A0819|37 38|nt
P07937132A0819|43 57|complementarity
P07937132A0819|86 92|28S rRNA
P07937147A0205|1 13|genetic system
P07937147A0205|35 50|pi protein mutants
P07937147A0205|75 76|IR
P07937147A0205|80 81|DR
P07937147A0205|83 86|York
P07937147A0205|93 96|Gene
P07937147A0205|98 101|Amst
P07937147A0205|118 121|York
P07937147A0205|125 134|Filutowicz
P07937147A0205|136 137|J.
P07937656A0182|0 28|Univariate statistical analysis
P07937656A0182|36 57|Kaplan-Meier-estimates
P07937656A0182|61 73|Log-Rank-Test
P07937656A0182|106 122|beneficial factors
P07937656A0182|124 142|Limited disease stage
P07937656A0182|144 145|p =
P07937656A0182|153 169|NSE serum level less
P07937656A0182|176 187|micrograms/l
P07937656A0182|189 190|p =
P07937656A0182|198 225|serum alkaline phosphatase less
P07937656A0182|233 235|U/l
P07937656A0182|237 238|p =
P07937656A0182|246 263|normal serum albumin
P07937656A0182|265 266|p =
P07937656A0182|276 288|activity index
P07937656A0182|303 303|p
P07937841A0790|5 11|results
P07937841A0790|30 35|bypass
P07937841A0790|38 93|p53-induced Waf1/Cip1-mediated cell cycle regulatory pathways
P07937841A0790|38 40|p53
P07937841A0790|49 52|Waf1
P07937841A0790|54 57|Cip1
P07937841A0790|108 124|myb oncogene family
P07937954A0612|0 2|HBx
P07937954A0612|19 24|levels
P07937954A0612|27 38|GTP-bound Ras
P07937954A0612|36 38|Ras
P07937954A0612|66 68|Raf
P07937954A0612|73 95|tyrosine-phosphorylated
P07937954A0612|108 116|MAP kinase
P07937965T0000|0 3|Role
P07937965T0000|6 10|c-myc
P07937965T0000|13 23|simian virus
P07937965T0000|26 62|large tumor antigen-induced DNA synthesis
P07937965T0000|65 95|quiescent 3T3-L1 mouse fibroblasts
P07938137A0384|3 8|groups
P07938137A0384|39 46|naloxone
P07938137A0384|51 55|mg/kg
P07938137A0384|62 83|distinctive environment
P07938137A0384|102 106|signs
P07938137A0384|109 124|opiate withdrawal
P07941174T0001|0 11|Laser therapy
P07941174T0001|14 28|penile carcinoma
P07941739A0000|5 14|kb fragment
P07941739A0000|20 30|yeast genome
P07941739A0000|48 64|centromeric region
P07941739A0000|67 79|chromosome XIV
P07941739A0000|82 95|genetic mapping
P07941750A0344|11 20|homologous
P07941750A0344|43 69|prokaryotic hydantoinase HyuA
P07941750A0344|43 65|prokaryotic hydantoinase
P07941750A0344|66 69|HyuA
P07941750A0344|78 86|other half
P07941750A0344|89 103|hydatoinase HyuB
P07941750A0344|89 99|hydatoinase
P07941750A0344|100 103|HyuB
P07942076A0497|14 36|estradiol concentrations
P07942076A0497|50 66|estradiol valerate
P07942076A0497|80 97|estradiol ingestion
P07942076A0497|141 158|constitutional type
P07942448A1227|10 17|patients
P07942448A1227|20 28|NYHA class
P07942448A1227|47 54|ABSTRACT
P07942448A1227|69 73|WORDS
P07942722T0000|0 11|Constipation
P07942722T0000|18 27|risk factor
P07942722T0000|31 41|hemorrhoids
P07942722T0000|44 60|case-control study
P07942722T0000|63 88|potential etiological agents
P07943556A0694|5 11|persons
P07943556A0694|29 29|%
P07943556A0694|35 50|antigen-positive
P07943556A0694|58 67|Og4C3 assay
P07943556A0694|58 62|Og4C3
P07944461A0321|0 5|TG-day
P07944461A0321|9 16|TG-night
P07944461A0321|31 31|%
P07944461A0321|43 43|%
P07944461A0321|49 51|mm3
P07944542T0000|0 17|Vibrio cholerae O139
P07944542T0000|20 27|Calcutta
P07945134A0079|3 12|volunteers
P07945134A0079|31 32|ft
P07945134A0079|39 39|m
P07945134A0079|73 74|ft
P07945134A0079|96 96|m
P07945134A0079|102 118|directional sounds
P07945134A0079|131 149|dummy head microphone
P07945330A0103|4 18|differentiation
P07945330A0103|23 34|retinoic acid
P07945330A0103|36 37|RA
P07945330A0103|40 52|transcription
P07945330A0103|58 66|Rex-1 gene
P07945937A0358|0 15|Sequence analysis
P07945937A0358|21 45|zebrafish egr1 coding region
P07945937A0358|21 33|zebrafish egr1
P07945937A0358|55 63|high level
P07945937A0358|66 73|homology
P07945937A0358|92 105|human Egr1 genes
P07945937A0358|113 128|notable exception
P07945937A0358|132 142|polymorphic
P07945937A0358|144 174|triplet nucleotide repeat sequence
P07945937A0358|198 210|amino terminus
P07945937A0358|216 226|Egr1 protein
P07947930A0499|3 12|fibrinogen
P07947930A0499|14 26|serum proteins
P07947930A0499|28 40|sodium heparin
P07947930A0499|44 51|membrane
P07947930A0499|65 66|Cm
P07947930A0499|71 71|%
P07947930A0499|75 75|%
P07947930A0499|78 78|%
P07947930A0499|84 84|%
P07948129A0297|7 13|vectors
P07948129A0297|17 42|chimeric long terminal repeat
P07948129A0297|44 48|chLTR
P07948129A0297|74 105|chloramphenicol acetyl transferase
P07948129A0297|107 109|CAT
P07948129A0297|111 122|reporter gene
P07948129A0297|141 176|internal SV40 virus early region promoter
P07948129A0297|188 215|neomycin phosphotransferase II
P07948129A0297|188 213|neomycin phosphotransferase
P07948129A0297|217 219|NEO
P07948921A0051|0 5|Optima
P07948921A0051|7 20|genomic library
P07948921A0051|38 73|elicitor-induced stilbene synthase cDNA
P07948921A0051|54 73|stilbene synthase cDNA
P07948921A0051|77 81|probe
P07949137A0000|11 36|acute leukemia adult patients
P07949137A0000|56 65|bone marrow
P07949137A0000|67 68|BM
P07949137A0000|78 88|mafosfamide
P07949137A0000|90 94|ASTA Z
P07949137A0000|113 119|January
P07949137A0000|126 132|January
P07949137A0532|3 22|pretransplant regimen
P07949137A0532|34 49|cyclophosphamide
P07949137A0532|54 58|mg/kg
P07949137A0532|63 82|total body irradiation
P07949164A0799|3 23|site-directed mutation
P07949164A0799|29 39|kappa B motif
P07949164A0799|42 45|IL-6
P07949164A0799|47 56|CAT plasmid
P07949164A0799|47 49|CAT
P07949164A0799|70 87|complete abrogation
P07949164A0799|90 109|IL-6 promoter activity
P07949164A0799|90 101|IL-6 promoter
P07949164A0799|117 121|cells
P07949205A0286|10 23|testololactone
P07949205A0286|27 33|earlier
P07949205A0286|55 71|aminoglutethimide
P07949205A0286|82 104|advanced breast carcinoma
P07949551A0000|0 2|Use
P07949551A0000|8 15|vena cava
P07949551A0000|27 40|right renal vein
P07949551A0000|44 65|cadaver transplantation
P07949770T0000|8 29|hepatic portal blood flow
P07949770T0000|39 53|prostaglandin E1
P07949770T0000|63 82|liver transplantation
P07949770T0000|85 88|pigs
P07951410A0647|3 6|HeLa
P07951410A0647|12 15|U937
P07951410A0647|20 28|A549 cells
P07951410A0647|45 49|E2F-1
P07951410A0647|51 54|DP-1
P07951410A0647|56 62|cyclin A
P07951410A0647|67 68|RB
P07951410A0647|97 105|complexes
P07951410A0647|134 149|factors different
P07951410A0647|154 158|E2F-1
P07951410A0647|161 164|DP-1
P07951410A1332|0 16|E1A autoactivation
P07951410A1332|0 2|E1A
P07951410A1332|32 36|sites
P07951410A1332|73 82|activation
P07951410A1332|98 116|complete E1A promoter
P07951874A0320|0 14|Cestode invasion
P07951874A0320|17 38|irradiated host organism
P07951874A0320|51 64|negative effect
P07951874A0320|89 107|hamster immune system
P07953785A0648|6 17|heat exposure
P07953785A0648|19 24|chicks
P07953785A0648|54 65|% restriction
P07953785A0648|70 95|non-metyrapone-treated food
P07953785A0648|99 112|lower H/L ratios
P07953785A0648|136 163|marble spleen disease infection
P07954475A0714|0 7|Analyses
P07954475A0714|10 25|additional tumors
P07954475A0714|35 38|mice
P07954475A0714|46 62|reciprocal crosses
P07954475A0714|64 76|A/J x C3H/HeJ F1
P07954475A0714|93 97|AC3F1
P07954475A0714|102 114|C3H/HeJ x A/J F1
P07954475A0714|131 135|C3AF1
P07954475A0714|160 171|inactivation
P07954475A0714|177 182|allele
P07954475A0714|188 205|putative chromosome
P07954475A0714|207 225|tumor suppressor gene
P07954891T0000|0 3|ERV1
P07954891T0000|19 36|cell-division cycle
P07954891T0000|56 75|mitochondrial genomes
P07956578A0851|0 14|Lesion diameters
P07956578A0851|17 23|greater
P07956578A0851|30 31|mm
P07956578A0851|38 68|large sessile-type configurations
P07956578A0851|73 79|factors
P07956578A0851|102 118|incomplete removal
P07956869A0000|37 54|breast cancer tissue
P07956869A0000|77 84|archives
P07956869A0000|90 108|Pathology laboratory
P07956869A0000|111 113|Dar
P07956869A0000|141 145|years
P07956869A0000|161 173|flow cytometry
P07956869A0000|177 185|DNA ploidy
P07956869A0000|189 203|S-phase fraction
P07957085A0207|0 3|Cbf3
P07957085A0207|17 24|proteins
P07957085A0207|26 30|Cbf3a
P07957085A0207|32 36|Cbf3b
P07957085A0207|40 44|Cbf3c
P07957106A0471|38 57|GST-POU fusion protein
P07957106A0471|38 40|GST
P07957106A0471|42 57|POU fusion protein
P07957106A0471|65 88|glutathione-agarose beads
P07957106A0875|5 13|mutations
P07957106A0875|17 25|localized
P07957106A0875|31 40|same region
P07957106A0875|49 69|HSV transactivator VP16
P07957106A0875|100 111|VP16 contacts
P07957106A0875|100 103|VP16
P07957158A1532|13 26|filtration rate
P07957158A1532|29 41|relevant areas
P07957158A1532|55 65|integrative
P07957158A1532|85 93|parameter
P07957158A1532|105 112|hormonal
P07957158A1532|116 133|neurogenic vascular
P07957158A1532|142 165|local interstitial control
P07957158A1532|171 184|Starling forces
P07957243A1316|13 20|residues
P07957243A1316|24 30|located
P07957243A1316|33 48|different domains
P07957559A1557|8 16|rapamycin
P07957559A1557|26 38|proliferation
P07957559A1557|41 52|Ba/F3-EpoRgp
P07957559A1557|41 42|Ba
P07957559A1557|44 45|F3
P07957559A1557|63 70|MEL cells
P07957559A1557|78 87|inhibition
P07957559A1557|90 108|p70 S6 kinase activity
P07957559A1557|90 100|p70 S6 kinase
P07957559A1557|115 119|cells
P07957632A0000|0 24|Intraventricular injection
P07957632A0000|28 29|2S
P07957632A0000|33 33|R
P07957632A0000|37 37|R
P07957632A0000|41 41|R
P07957632A0000|47 70|2,3-dicarboxycyclopropyl
P07957632A0000|72 78|glycine
P07957632A0000|80 85|DCG-IV
P07957632A0000|89 101|potent agonist
P07957632A0000|105 134|metabotropic glutamate receptors
P07957632A0000|117 134|glutamate receptors
P07957632A0000|138 141|rats
P07957632A0000|181 199|halothane anesthesia
P07957632A0000|203 211|dose range
P07957632A0000|223 230|pmol/rat
P07958446A0000|3 27|hepatocyte nuclear factor-3
P07958446A0000|29 33|HNF-3
P07958446A0000|36 43|forkhead
P07958446A0000|45 47|fkh
P07958446A0000|49 56|proteins
P07958446A0000|68 82|extensive family
P07958446A0000|85 99|tissue-specific
P07958446A0000|103 129|developmental gene regulators
P07958446A0000|140 147|homology
P07958446A0000|157 182|winged helix DNA binding motif
P07958865A1152|0 20|Homozygous null embryos
P07958865A1152|34 46|abnormalities
P07958865A1152|49 64|heart development
P07958865A1152|97 99|Tek
P07958865A1152|114 147|endocardial/myocardial interactions
P07958898A1050|14 23|dTFIIA-L/S
P07958898A1050|14 21|dTFIIA-L
P07958898A1050|23 23|S
P07958898A1050|56 80|transcriptional activation
P07958898A1050|83 110|upstream transcription factors
P07958898A1050|120 122|Sp1
P07958898A1050|124 127|VP16
P07958898A1050|132 136|NTF-1
P07958911A0500|1 26|strong trithorax binding site
P07958911A0500|7 26|trithorax binding site
P07958911A0500|40 58|cytological location
P07958911A0500|64 75|fork head gene
P07958911A0500|78 104|region-specific homeotic gene
P07958911A0500|108 114|located
P07958911A0500|122 136|homeotic complex
P07958915A1507|13 19|changes
P07958915A1507|22 37|intracellular Ca2
P07958915A1507|91 94|cAMP
P07958915A1507|106 118|transcription
P07958915A1507|144 156|specific forms
P07958915A1507|159 161|Ca2
P07958915A1507|164 197|calmodulin-dependent protein kinases
P07958920A1157|0 9|Antibodies
P07958920A1157|28 38|SNM1 protein
P07958920A1157|57 67|RNase MRP RNA
P07958920A1157|72 89|whole-cell extracts
P07958920A1157|140 155|related RNase P RNA
P07958920A1157|147 155|RNase P RNA
P07959011A0379a|0 9|C/EBP alpha
P07959011A0379a|26 33|promoter
P07959011A0379a|39 55|rat class-I ADH gene
P07959011A0379a|59 81|sequence-specific manner
P07959011A0379a|83 88|Potter
P07959011A0379a|95 98|Arch
P07959011A0379b|0 9|C/EBP alpha
P07959011A0379b|26 33|promoter
P07959011A0379b|39 55|rat class-I ADH gene
P07959011A0379b|59 81|sequence-specific manner
P07959011A0379b|83 88|Potter
P07959011A0379b|95 98|Arch
P07959015A0478|3 9|results
P07959015A0478|21 23|ORF
P07959015A0478|26 30|hAMPK
P07959015A0478|41 50|amino acids
P07959015A0478|52 53|aa
P07959015A0478|62 64|kDa
P07959015A0478|90 94|rAMPK
P07959015A0478|99 108|identities
P07959015A0478|120 120|%
P07959015A0478|126 127|aa
P07959015A0478|131 138|nt levels
P07959734A0194|2 11|human brain
P07959734A0194|13 21|contactin
P07959734A0194|42 54|amino terminal
P07959734A0194|58 74|peptide sequencing
P07959734A0194|80 117|lentil-lectin-binding glycoprotein Gp135
P07959760A0763|3 22|centromeric YAC contig
P07959760A0763|52 55|YACs
P07959760A0763|59 64|orders
P07959760A0763|67 86|sequence-tagged sites
P07959760A0763|88 91|STSs
P07959760A0763|113 114|Mb
P07959760A0763|126 147|Ewing sarcoma breakpoint
P07959760A0763|149 154|c-ets 1
P07959760A0763|149 153|c-ets
P07959760A0763|158 162|Fli-1
P07959760A0763|167 173|members
P07959760A0763|179 187|ets family
P07959760A0763|212 213|kb
P07959760A0763|240 245|contig
P07959760A0763|266 290|polymorphic microsatellite
P07959760A0763|292 298|D11S912
P07959760A0763|300 301|CA
P07959760A0763|303 303|n
P07959760A0763|334 342|Fli-1 gene
P07959952A1446|1 4|cDNA
P07959952A1446|24 33|pseudogene
P07959952A1446|54 74|mouse mast cell chymases
P07959952A1446|88 123|polymerase chain reaction amplification
P07959952A1446|129 166|mouse connective tissue-like mast cell line
P07959953A0423|0 4|IFI16
P07959953A0423|18 22|exons
P07959953A0423|41 47|introns
P07959953A0423|65 73|kilobases
P07959953A0423|75 76|kb
P07960608A0228|0 6|Courses
P07960608A0228|28 32|weeks
P07960796A0154|0 9|Peter Elfer
P07960796A0154|21 32|implications
P07961545A1314|0 17|Other adverse events
P07961545A1314|22 31|incidences
P07961545A1314|45 50|higher
P07961545A1314|59 65|placebo
P07961545A1314|70 78|dizziness
P07961545A1314|80 91|constipation
P07961545A1314|93 100|sweating
P07961545A1314|102 112|nervousness
P07961545A1314|117 135|abnormal ejaculation
P07961755A0474|0 7|Homology
P07961755A0474|33 62|putative transit peptide sequence
P07961755A0474|65 81|cysteine synthase C
P07961755A0474|85 127|other mitochondrion-targeting leader sequences
P07961957A1565|44 48|TEF-1
P07961957A1565|57 75|HF-1a-related factor
P07961957A1565|96 117|alpha-MHC gene EM element
P07961958T0000|0 24|Rat kidney carboxylesterase
P07963540A0795|0 23|Recombinant I-kappa B alpha
P07963540A0795|33 50|kappa B motif binding
P07963540A0795|33 43|kappa B motif
P07963540A0795|53 73|nuclear factor-kappa B1
P07963540A0795|75 78|RelA
P07963540A0795|83 87|c-Rel
P07963540A0795|101 107|studies
P07963540A0795|113 152|UV radiation-induced covalent cross-linking
P07963540A0795|156 205|bromodeoxyuridine-substituted kappa B oligonucleotide
P07963782A0000|14 30|chemical stability
P07963782A0000|47 51|drugs
P07963782A0000|79 86|epidural
P07963782A0000|89 104|intrathecal space
P07963782A0000|122 132|chronic pain
P07964162A0941|10 19|mechanisms
P07964162A0941|31 40|activation
P07964162A0941|46 61|MAP kinase cascade
P07964162A0941|46 54|MAP kinase
P07964162A0941|101 113|specification
P07964162A0941|116 132|cellular responses
P07964458A0179|1 13|candidate gene
P07964458A0179|17 19|Bcg
P07964458A0179|31 75|natural resistance-associated macrophage protein
P07964458A0179|77 81|Nramp
P07964458A0179|116 154|novel macrophage-specific membrane protein
P07964458A0179|121 154|macrophage-specific membrane protein
P07964458A0179|172 189|susceptible animals
P07964459A0845|4 8|motif
P07964459A0845|38 46|LIM domain
P07964459A0845|53 68|RING finger family
P07964459A0845|75 85|reminiscent
P07964459A0845|88 112|known metal-binding regions
P07964624A0491|3 9|P131 ORF
P07964624A0491|31 39|second ORF
P07964624A0491|66 83|partial readthrough
P07964624A0491|89 107|UGA termination codon
P07964624A0491|113 119|P131 ORF
P07964624A0491|130 140|polypeptide
P07964624A0491|143 143|M
P07964624A0491|145 145|r
P07964624A0491|154 157|P191
P07964770A0172|15 22|patients
P07964770A0172|47 58|arthroplasty
P07964814T0000|0 29|Elementary visual hallucinations
P07964814T0000|32 39|migraine
P07964814T0000|43 50|epilepsy
P07964918A0000|14 35|patient-related factors
P07964918A0000|38 62|inter-observer variability
P07964918A0000|80 96|neurological signs
P07965152A0764|0 7|Segments
P07965152A0764|23 33|BMIPP uptake
P07965152A0764|38 47|MIBI uptake
P07965152A0764|49 59|mismatching
P07965152A0764|73 88|normal wall motion
P07965152A0764|103 118|inotropic reserve
P07965152A0764|125 145|dobutamine stimulation
P07966565A0901|21 24|mRNA
P07966565A0901|31 41|nucleotides
P07966565A0901|68 76|1.9-kb RNA
P07966565A0901|99 114|replication cycle
P07966565A0901|129 139|early stages
P07966583A1268|0 21|Transient transfections
P07966583A1268|47 59|RNA transcript
P07966583A1268|69 75|clone B1
P07966583A1268|82 89|D17 cells
P07966583A1268|112 119|Env/Mlvi
P07966583A1268|112 114|Env
P07966583A1268|122 134|fusion protein
P07966583A1268|141 161|apparent molecular mass
P07966583A1268|166 168|kDa
P07966602A0130|0 6|Roizman
P07966602A0130|8 9|J.
P07966873A0693|0 7|Articles
P07966873A0693|18 37|valvular heart disease
P07966873A0693|40 60|heart failure secondary
P07966873A0693|63 87|acute myocardial infarction
P07966873A0693|90 95|Chagas
P07967360A1048|3 13|present data
P07967360A1048|30 37|patients
P07967360A1048|42 56|TGBM nephropathy
P07967360A1048|66 90|concomitant IgA nephropathy
P07967360A1048|77 79|IgA
P07967360A1048|94 133|mesangial proliferative glomerulonephritis
P07967725A0262|3 18|nuclear receptors
P07967725A0262|23 64|several well-characterized structural domains
P07967725A0262|85 101|DNA-binding domain
P07967725A0262|107 125|ligand binding domain
P07967725A0262|131 146|carboxyl terminus
P07967725A0262|152 159|receptor
P07968409A0123|23 43|HIV-infected-patients
P07968409A0123|69 85|Outpatient Service
P07968409A0123|91 108|Infectious Diseases
P07968409A0123|116 122|Bologna
P07968409A0123|126 141|Ospedale Maggiore
P07968409A0123|143 157|General Hospital
P07968409A0123|172 175|days
P07968409A0123|177 183|19-23rd
P07968409A0123|185 188|July
P07969115A0000|7 32|organello footprint analysis
P07969115A0000|57 82|human placental mitochondria
P07969115A0000|91 99|high level
P07969115A0000|102 119|protein-DNA binding
P07969115A0000|131 145|phased intervals
P07969115A0000|157 168|500-bp region
P07969115A0000|184 199|D-loop DNA origins
P07969115A0000|206 220|promoter regions
P07969116A0196|3 14|Nur77 protein
P07969116A0196|24 51|potent transcription activator
P07969116A0196|91 105|downstream genes
P07969116A0196|118 137|extracellular stimuli
P07969132A0268|10 17|plasmids
P07969132A0268|27 30|tRNA
P07969132A0268|36 40|genes
P07969132A0268|53 72|efficient suppression
P07969132A0268|81 85|cells
P07969132A0268|100 108|histidine
P07969132A0268|115 122|plasmids
P07969132A0268|134 145|gcn2 deletion
P07969132A0268|134 137|gcn2
P07969132A0268|183 190|gcn2-507
P07969135A0913|21 34|Cln2 PEST domain
P07969135A0913|62 80|heterologous protein
P07969136A0273|0 33|Electrophoretic mobility shift assays
P07969136A0273|49 57|sequences
P07969136A0273|70 78|complexes
P07969136A0273|83 101|mobilities identical
P07969136A0273|114 126|NF-kappa B site
P07969136A0273|134 153|kappa light-chain gene
P07969152A0721|9 59|carboxyl-terminal HSF transcriptional activation domain
P07969152A0721|76 85|activation
P07969152A0721|88 104|CUP1 transcription
P07969152A0721|88 91|CUP1
P07969152A0721|121 135|heat shock stress
P07969152A0721|139 155|glucose starvation
P07969152A0721|169 179|dispensable
P07969152A0721|183 210|transient heat shock activation
P07969152A0721|223 227|genes
P07969152A0721|236 242|members
P07969152A0721|248 264|S. cerevisiae hsp70
P07969152A0721|260 270|hsp70 family
P07969181A0313|22 31|high levels
P07969181A0313|34 40|CKB mRNA
P07969181A0313|43 51|HeLa cells
P07969181A0313|111 120|low amounts
P07969181A0313|123 139|p53 protein present
P07969181A0313|123 132|p53 protein
P07969181A0313|142 150|HeLa cells
P07969954T0000|0 29|Distal lower motor neuron syndrome
P07969954T0000|34 69|high-titer serum IgM anti-GM1 antibodies
P07969954T0000|91 103|immunotherapy
P07969954T0000|108 128|monthly plasma exchange
P07969954T0000|132 158|intravenous cyclophosphamide
P07971282A0000|0 20|Regulators responsible
P07971282A0000|27 35|pervasive
P07971282A0000|37 92|nonsex-specific alternative pre-mRNA splicing characteristic
P07971282A0000|95 103|metazoans
P07971709A0907|1 22|normal systemic response
P07971709A0907|56 62|rhG-CSF
P07971709A0907|83 92|solid state
P07972012A0956|1 20|full-length cDNA clone
P07972012A0956|34 47|rat lung library
P07972012A0956|69 81|55-kDa protein
P07972012A0956|97 109|amino terminus
P07972012A0956|140 168|ANP-receptor kinase-like domain
P07972012A0956|187 202|carboxyl terminus
P07972012A0956|204 242|putative protein-serine phosphatase domain
P07972237A0665|1 29|high-resolution restriction map
P07972237A0665|39 40|kb
P07972237A0665|43 55|contiguous DNA
P07972237A0665|66 70|N-myc
P07972237A0665|89 102|subcloning YACs
P07972237A0665|107 113|cosmids
P07972831A0563|0 10|PAI-1 levels
P07972831A0563|0 4|PAI-1
P07972831A0563|35 42|patients
P07972831A0563|54 60|iohexol
P07972831A0563|85 93|ioxaglate
P07973364A0325|5 18|present article
P07973364A0325|23 28|causes
P07973364A0325|38 46|ill-being
P07973364A0325|58 90|consecutive carcinogenicity studies
P07973364A0325|94 100|studies
P07973364A0325|109 111|OFA
P07973364A0325|113 134|Sprague-Dawley-derived
P07973364A0325|139 148|Wistar rats
P07973364A0325|153 159|studies
P07973364A0325|168 170|OF1
P07973364A0325|174 181|NMRI mice
P07973397T0001|0 12|Determination
P07973397T0001|15 29|potassium iodide
P07973397T0001|32 47|Polish edible salt
P07973825A0445|3 15|recovery value
P07973825A0445|18 33|systolic pressure
P07973825A0445|37 42|higher
P07973825A0445|47 63|diastolic pressure
P07973825A0445|67 79|pulse pressure
P07975763A0000|15 29|hepatitis C virus
P07975763A0000|31 33|HCV
P07975763A0000|54 72|chronic liver disease
P07975763A0000|108 132|serologic detection methods
P07975882T0000|0 18|Human adenovirus type
P07975882T0000|32 37|fibers
P07977239A1283|0 17|Outflow obstruction
P07977239A1283|20 34|pancreatic juice
P07977239A1283|42 57|relative stenosis
P07977239A1283|63 74|minor papilla
P07977239A1283|106 113|patients
P07977239A1283|124 130|papilla
P07977239A1283|149 156|patients
P07977239A1283|167 173|papilla
P07977239A1283|189 205|acute pancreatitis
P07977239A1283|219 230|poor drainage
P07977239A1283|233 247|pancreatic juice
P07977239A1283|251 267|excessive pressure
P07977239A1283|273 282|dorsal duct
P07977648A0880|0 9|Sequencing
P07977648A0880|15 29|TP53 transcripts
P07977648A0880|34 38|exons
P07977648A0880|65 73|mutations
P07977648A0880|88 93|allele
P07977648A0880|106 111|tumors
P07978229T0000|2 20|unusual complication
P07978229T0000|25 41|unsuitable patient
P07978406A0998|5 12|ISO group
P07978406A0998|16 22|pre-DEX
P07978406A0998|24 26|CBF
P07978406A0998|56 63|mL.min-1
P07978406A0998|68 70|g-1
P07978406A0998|83 93|hypercapnia
P07978406A0998|95 98|PCO2
P07978406A0998|114 117|mmHg
P07978406A0998|121 128|ABSTRACT
P07978406A0998|143 147|WORDS
P07979810A0340|17 26|parameters
P07979810A0340|36 43|motility
P07979810A0340|58 72|penetration test
P07979810A0340|82 90|unchanged
P07979810A0340|110 134|post-therapeutic pregnancy
P07979827A0722|0 6|KRN2391
P07979827A0722|10 19|cromakalim
P07979827A0722|29 50|dose-dependent increase
P07979827A0722|53 58|aortic
P07979827A0722|62 78|coronary blood flow
P07980440A0138|2 22|H4IIE rat hepatoma cells
P07980440A0138|24 38|glucocorticoids
P07980440A0138|40 51|retinoic acid
P07980440A0138|55 63|cyclic AMP
P07980440A0138|65 68|cAMP
P07980440A0138|70 99|increase PEPCK gene transcription
P07980440A0138|78 86|PEPCK gene
P07980440A0138|107 113|insulin
P07980440A0138|117 129|phorbol esters
P07980440A0138|137 150|opposite effect
P07980468A0298|0 3|Acta
P07980669A0373|0 19|Basal plasma AVP levels
P07980669A0373|11 13|AVP
P07980669A0373|23 32|AVP release
P07980669A0373|23 25|AVP
P07980669A0373|38 51|postural change
P07980669A0373|68 82|plasma NPY levels
P07980669A0373|74 76|NPY
P07980669A0373|100 110|same samples
P07981143A0633|12 22|nucleotides
P07981143A0633|40 45|IL-4RE
P07981143A0633|59 74|IL-4 inducibility
P07981143A0633|59 62|IL-4
P07981143A0633|84 105|nucleoprotein complexes
P07981143A0633|110 128|constitutive factors
P07981246A0112|3 15|previous study
P07981246A0112|29 42|pertussis toxin
P07981246A0112|44 46|IAP
P07981246A0112|49 75|sensitive GTP-binding protein
P07981246A0112|77 77|s
P07981246A0112|80 88|G-protein
P07981246A0112|114 128|differentiation
P07981246A0112|131 143|hormones/IBMX
P07981246A0112|158 171|c-fos induction
P07981246A0112|158 162|c-fos
P07982964A1017|0 2|ATX
P07982964A1017|8 11|PC-1
P07982964A1017|35 56|type I phosphodiesterase
P07982964A1017|40 89|phosphodiesterase substrate p-nitrophenyl thymidine-5
P07982964A1017|92 104|monophosphate
P07982995A0000|11 32|site-specific mutations
P07982995A0000|38 70|mouse platelet-derived growth factor
P07982995A0000|72 89|PDGF) beta-receptor
P07982995A0000|72 75|PDGF
P07982995A0000|77 89|beta-receptor
P07982995A0000|92 101|activation
P07982995A0000|107 108|Na
P07982995A0000|111 111|H
P07982995A0000|113 121|exchanger
P07982995A0000|135 168|normal murine mammary gland epithelial
P07982995A0000|170 174|NMuMG
P07982995A0000|179 197|Chinese hamster ovary
P07982995A0000|199 201|CHO
P07982995A0000|203 207|cells
P07983011A0617|0 15|Sequence analysis
P07983011A0617|28 48|kinase catalytic domain
P07983011A0617|69 91|serine/threonine kinases
P07983011A0617|95 100|hybrid
P07983011A0617|108 114|members
P07983011A0617|128 175|microtubule-associated protein kinase kinase kinases
P07983011A0617|182 217|fibroblast growth factor receptor family
P07983011A0617|224 263|putative alpha-helical leucine zipper motifs
P07983011A0617|276 287|25-amino acid
P07983011A0617|295 313|intermediate segment
P07983011A0617|326 348|NH2-terminal basic domain
P07983011A0617|355 367|COOH-terminal
P07983011A0617|371 411|NH2-terminal proline-rich domains suggestive
P07983011A0617|414 425|src homology 3
P07983011A0617|414 424|src homology
P07983011A0617|427 429|SH3
P07983011A0617|431 450|domain binding regions
P07983704A0330|0 3|Type
P07983704A0330|5 11|genomes
P07983704A0330|79 88|infectious
P07983704A0330|90 129|replication-competent retrovirus ancestors
P07983704A0330|135 146|HERV-K family
P07983704A0330|158 164|genomes
P07983712A0914|45 55|same plasmid
P07983712A0914|57 66|high levels
P07983712A0914|69 79|replication
P07983715A0996|0 13|Point mutations
P07983715A0996|38 44|binding
P07983715A0996|47 50|NF-Y
P07983715A0996|56 77|internal palindromic arm
P07983715A0996|101 118|resident P4 promoter
P07983715A0996|109 118|P4 promoter
P07983715A0996|140 155|complex formation
P07983715A0996|160 162|USF
P07983715A0996|184 208|transient expression assays
P07983715A0996|217 238|luciferase reporter gene
P07983716A1082|13 20|Northern
P07983716A1082|22 24|RNA
P07983716A1082|26 37|blot analysis
P07983716A1082|41 60|reverse transcriptase
P07983716A1082|48 65|transcriptase-PCRs
P07983716A1082|80 91|transfection
P07983716A1082|94 98|COS-7
P07983716A1082|101 109|HeLa cells
P07983716A1082|119 127|viral RNAs
P07983716A1082|140 143|Y88S
P07983716A1082|147 154|Y88L RNAs
P07983716A1082|175 183|low levels
P07983744A0920|13 24|nuclear forms
P07983744A0920|27 31|IE110
P07983744A0920|48 62|cytoplasmic form
P07983744A0920|65 69|IE175
P07983744A0920|74 98|nuclear punctate structures
P07983744A0920|104 118|cytoplasmic form
P07983744A0920|121 125|IE110
P07983744A0920|141 152|nuclear forms
P07983744A0920|155 159|IE175
P07983744A0920|162 190|cytoplasmic punctate structures
P07984088A0592|0 12|Transcription
P07984088A0592|25 35|ivanolysin O
P07984088A0592|51 60|other genes
P07984088A0592|66 85|virulence gene cluster
P07984088A0592|88 97|L. ivanovii
P07984088A0592|113 116|PrfA
P07984105A1509|11 25|complementation
P07984105A1509|31 42|WA fyuA mutant
P07984105A1509|54 61|fyuA gene
P07984105A1509|63 82|yersiniabactin uptake
P07984105A1509|86 99|mouse virulence
P07984261A0536|3 6|ICBF
P07984261A0536|12 26|ischaemic cortex
P07984261A0536|58 72|ischaemic centre
P07984261A0536|78 95|surrounding tissues
P07985305T0001|14 27|hydronephrosis
P07985305T0001|30 37|children
P07987924A0670|3 14|inflation hub
P07987924A0670|20 24|probe
P07987924A0670|48 78|standard USCI Tuohy-Borst Y adaptor
P07987924A0670|110 122|probe hypotube
P07988559A0836|3 14|other element
P07988559A0836|20 29|RBP-J kappa
P07988559A0836|34 44|low affinity
P07988730A0220|3 23|basal promoter strength
P07988730A0220|26 35|constructs
P07988730A0220|49 57|deletions
P07988730A0220|63 70|U5 region
P07988730A0220|76 78|LTR
P07988730A0220|92 123|chloramphenicol acetyltransferase
P07988730A0220|125 127|CAT
P07988730A0220|129 134|assays
P07988730A0220|144 155|transfection
P07988730A0220|158 166|HeLa cells
P07988730A0220|169 181|Jurkat T-cells
P07988730A0220|206 234|viral transactivator tax protein
P07988731A0002|58 75|inducible promoters
P07988731A0002|110 127|cis-acting elements
P07988731A0002|142 157|promoter activity
P07988731A0002|174 178|G-box
P07988731A0002|180 187|CCACGTGG
P07988731A1301|27 30|GF14
P07988731A1301|69 85|GBF protein complex
P07988945T0000|0 22|New diagnostic strategies
P07988945T0000|26 44|lupus anticoagulants
P07988945T0000|48 73|antiphospholipid antibodies
P07990136A1124|21 47|selectivity arrest elongation
P07990136A1124|50 55|polIII
P07990136A1124|65 73|positions
P07990136A1124|83 107|tRNA gene transcription unit
P07990136A1124|139 166|discrete functional properties
P07990136A1124|175 205|mammalian polIII ternary complexes
P07991437A1032|0 10|Propafenone
P07991437A1032|41 53|young patients
P07991582A1023b|0 17|Mutational analysis
P07991582A1023b|20 28|yeast CEG1
P07991582A1023b|67 72|motifs
P07991582A1023b|95 108|enzyme function
P07992027A0485|1 8|patients
P07992027A0485|12 12|%
P07992027A0485|17 36|significant morbidity
P07992027A0485|46 49|days
P07992027A0485|67 81|transplantation
P07993559A0233|1 11|recent index
P07993559A0233|13 30|Fluorosis Risk Index
P07993559A0233|43 49|Pendrys
P07994021A1223|0 18|Alternative splicing
P07994021A1223|24 38|cytoplasmic tail
P07994021A1223|56 78|multiple PECAM-1 isoforms
P07994021A1223|64 78|PECAM-1 isoforms
P07994021A1223|94 108|phosphorylation
P07994021A1223|110 132|cytoskeletal association
P07994021A1223|137 154|affinity modulation
P07994021A1223|160 172|mature protein
P07995173A0585|0 7|Transfer
P07995173A0585|35 48|gastric juice pH
P07995173A0585|50 51|r =
P07995173A0585|59 59|P
P07995910A0119|32 42|specificity
P07995910A0119|54 54|%
P07995910A0119|73 79|best way
P07995910A0119|90 105|nodal involvement
P07995910A0119|116 125|laparotomy
P07997174A0936|27 41|phosphorylation
P07997174A0936|44 50|His-304
P07997174A0936|76 89|known functions
P07997174A0936|92 107|A. vinelandii NifL
P07999066A0238|9 14|HIV tat
P07999066A0238|26 44|main enhancing factor
P07999066A0238|48 55|viral LTR
P07999066A0238|74 94|IL-2 gene transcription
P07999066A0238|74 81|IL-2 gene
P07999066A0238|118 136|transient expression
P07999066A0238|142 148|tat gene
P07999066A0238|151 162|phorbol ester
P07999066A0238|166 202|calcium ionophore-activated Jurkat cells
P07999066A0238|218 280|IL-2 promoter-chloramphenicol acetyltransferase reporter constructs
P07999066A0238|218 229|IL-2 promoter
P07999363A0000|6 15|variations
P07999363A0000|18 22|genes
P07999363A0000|35 58|transmembrane FGF receptor
P07999363A0000|60 63|FGFR
P07999363A0000|73 80|isoforms
P07999363A0000|94 103|ectodomain
P07999363A0000|105 136|intracellular juxtamembrane domain
P07999363A0000|144 168|intracellular kinase domain
P07999604A0139|16 27|such patients
P07999604A0139|59 73|atypical lesions
P07999982A0086|0 24|Cumulated maximum lod scores
P07999982A0086|32 35|FRDA
P07999982A0086|39 42|D9S5
P07999982A0086|53 56|FRDA
P07999982A0086|60 64|D9S15
P07999982A0086|97 117|recombination fraction
P07999982A0086|136 154|recombination events
P07999995A0000|0 26|A receptor-like protein kinase
P07999995A0000|1 26|receptor-like protein kinase
P07999995A0000|28 33|OsPK10
P07999995A0000|57 67|Oryza sativa
P08000074A0162|28 28|%
P08000074A0162|42 57|complete sequence
P08000074A0162|90 113|open reading frames present
P08000074A0162|120 139|kb DNA genomic fragment
P08000112T0000|0 10|Goodpasture
P08000112T0000|37 75|extracorporeal membrane oxygenator support
P08000427A0000|1 13|cDNA clone pCZ1
P08000427A0000|23 30|kb insert
P08000427A0000|48 81|NaCl-adapted tobacco cell cDNA library
P08000427A0000|105 115|full-length
P08000427A0000|118 127|kDa protein
P08000427A0000|132 141|amino acids
P08000427A0000|158 159|pI
P08000497A0179|0 6|METHODS
P08000497A0179|25 34|spirometry
P08000497A0179|39 65|methacholine provocation test
P08000497A0179|83 94|small airways
P08000497A0179|124 126|VTG
P08001136T0000|0 11|Relationship
P08001136T0000|14 33|CDK-activating kinase
P08001136T0000|37 51|RNA polymerase II
P08001136T0000|37 49|RNA polymerase
P08001136T0000|52 71|CTD kinase TFIIH/TFIIK
P08001136T0000|61 65|TFIIH
P08001136T0000|67 71|TFIIK
P08001792A0284|3 6|git1
P08001792A0284|8 11|git3
P08001792A0284|13 16|git5
P08001792A0284|18 21|git7
P08001792A0284|23 26|git8
P08001792A0284|30 39|git10 genes
P08001792A0284|43 50|upstream
P08001792A0284|53 68|adenylate cyclase
P08001792A0284|90 122|adenylate cyclase activation pathway
P08001966A0563|5 15|same regions
P08001966A0563|22 39|remarkable homology
P08001966A0563|45 64|invertebrate proteins
P08001966A0563|66 68|CNC
P08001966A0563|72 77|skin-1
P08001966A0563|99 118|embryonic development
P08001966A0563|146 166|Caenorhabditis elegans
P08002564A0249|0 18|DNA sequence analysis
P08002564A0249|39 46|mutation
P08002564A0249|57 72|C-terminal region
P08002564A0249|78 89|alpha subunit
P08002564A0249|100 113|leucine residue
P08002564A0249|130 138|histidine
P08002564A0249|140 148|rpoAL290H
P08002857A1070|0 10|CONCLUSIONS
P08002857A1070|17 24|findings
P08002857A1070|34 48|physical barrier
P08002857A1070|51 71|oesophageal surfactant
P08002857A1070|116 139|gastro-oesophageal reflux
P08002857A1070|165 169|prone
P08002857A1070|180 183|bile
P08003700T0000|0 20|Differential screening
P08003700T0000|23 48|mitochondrial cDNA libraries
P08003700T0000|53 64|male-fertile
P08003700T0000|68 100|cytoplasmic male-sterile sugar-beet
P08003700T0000|108 127|genome rearrangements
P08003700T0000|130 133|atp6
P08003700T0000|137 144|atpA loci
P08004442A0265|3 9|effects
P08004442A0265|12 26|social isolation
P08004442A0265|29 61|morphine-induced locomotor activity
P08004442A0265|80 86|animals
P08004442A0265|93 127|intact hypothalamo-pituitary-adrenal
P08004442A0265|129 131|HPA
P08004442A0265|133 136|axis
P08004442A0265|142 148|animals
P08004442A0265|156 192|stress-induced corticosterone secretion
P08004442A0265|205 217|adrenalectomy
P08005230A0222|9 26|reporter gene system
P08005230A0222|50 70|EPO-induced activation
P08005230A0222|50 52|EPO
P08005230A0222|76 88|c-fos promoter
P08005230A0222|127 135|elevation
P08005230A0222|138 163|cellular luciferase activity
P08005230A0222|146 155|luciferase
P08005412A0608|16 34|white gene expression
P08005412A0608|39 39|P
P08005412A0608|72 85|protein complex
P08005412A0608|107 122|engrailed PS sites
P08005412A0608|116 122|PS sites
P08005412A0608|138 149|interactions
P08005412A0608|154 171|flanking genomic DNA
P08005438A1185|0 4|SPP41
P08005438A1185|48 52|spp43
P08005438A1185|55 61|allelic
P08005438A1185|87 100|suppressor srn1
P08005438A1185|115 131|negative regulator
P08005438A1185|134 147|gene expression
P08006101A1142|0 35|Standard curve correlation coefficients
P08006101A1142|45 51|greater
P08006101A1142|70 90|validation experiments
P08006101A1142|104 115|study samples
P08006772A0000|8 20|pulse oximeter
P08006772A0000|34 38|fetus
P08006772A0000|45 50|labour
P08006772A0000|65 78|Caucasian women
P08006772A0000|81 105|normal uncomplicated labour
P08006773A0836|22 41|plasma concentrations
P08006773A0836|44 47|PGI2
P08006773A0836|60 63|TxA2
P08006773A0836|66 73|patients
P08006773A0836|78 96|normal blood pressure
P08006773A0836|98 113|mild preeclampsia
P08006773A0836|117 127|hypotension
P08006773A0836|138 155|severe preeclampsia
P08006773A0836|160 178|plasma concentration
P08006773A0836|181 184|PGI2
P08006773A0836|207 207|p
P08006773A0836|220 223|TxA2
P08006773A0836|237 242|higher
P08006773A0836|244 244|p
P08007835A0538|1 14|causal analysis
P08007835A0538|17 34|secondary variables
P08007835A0538|59 68|FB memories
P08007835A0538|143 159|affective response
P08007954A0374|0 14|Deletion studies
P08007954A0374|26 46|distal response element
P08007954A0374|70 85|cytokine response
P08007954A0374|92 101|properties
P08007954A0374|106 137|inducible transcriptional enhancer
P08007975A0000|3 10|IPL1 gene
P08007975A0000|24 57|high-fidelity chromosome segregation
P08007975A0000|70 74|yeast
P08011017A0169|8 23|oxygen saturation
P08011017A0169|25 28|SaO2
P08011017A0169|32 45|visual evidence
P08011017A0169|48 79|transient electroencephalographic
P08011017A0169|81 83|EEG
P08011017A0169|85 92|arousals
P08011017A0169|105 125|repeat polysomnography
P08011166A0207|3 26|complete gene organization
P08011166A0207|52 58|results
P08011166A0207|79 84|clones
P08011166A0207|98 113|characterization
P08011166A0207|116 163|polymerase chain reaction-amplified genomic segments
P08012448T0000|0 3|INO2
P08012448T0000|6 19|regulatory gene
P08012448T0000|22 50|yeast phospholipid biosynthesis
P08012448T0000|59 76|nuclear segregation
P08012448T0000|80 98|bud pattern formation
P08012566A0254|3 29|pentafluorobenzyl derivative
P08012566A0254|32 46|clonidine yields
P08012566A0254|49 66|intense ion fragment
P08012566A0254|69 71|m/z
P08012566A0254|82 91|lower limit
P08012566A0254|94 102|detection
P08012566A0254|110 114|ng/ml
P08012566A0254|119 134|1-ml plasma sample
P08013348A0143|0 12|Mammalian ABPs
P08013348A0143|16 20|SHBGs
P08013348A0143|25 35|sex steroids
P08013348A0143|40 51|high affinity
P08013348A0143|60 76|binding properties
P08013457A0342|0 10|Src homology
P08013457A0342|12 13|SH
P08013457A0342|15 56|domain dependent protein-protein interactions
P08013457A0342|71 110|tyrosine kinase receptor signal transduction
P08013457A0342|71 92|tyrosine kinase receptor
P08014228A0278|0 14|Sample treatment
P08014228A0278|44 61|complete extraction
P08014228A0278|64 88|labetalol diastereoisomers
P08014228A0278|99 110|racemization
P08014228A0278|117 126|extraction
P08014377A1277|12 21|conditions
P08014377A1277|23 36|activity levels
P08014377A1277|39 50|cardiac vagal
P08014377A1277|54 72|sympathetic outflows
P08014377A1277|98 117|healthy human subjects
P08014377A1277|121 141|peripheral interaction
P08014377A1277|147 154|manifest
P08014377A1277|165 182|autonomic divisions
P08014919A0530|4 17|proprioceptive
P08014919A0530|21 41|electroreceptive units
P08014919A0530|49 59|progression
P08014919A0530|62 76|receptive fields
P08014919A0530|81 88|anterior
P08014919A0530|91 103|posterior body
P08014919A0530|109 115|rostral
P08014919A0530|118 132|caudal direction
P08014919A0530|149 151|DGR
P08015672A1282|2 16|control patients
P08015672A1282|18 31|baseline images
P08015672A1282|41 44|Type
P08015672A1282|51 54|Type
P08015672A1282|67 70|Type
P08015672A1282|87 90|Type
P08015672A1282|118 121|Type
P08015672A1282|124 131|baseline
P08015850A1076|1 20|more complete analysis
P08015850A1076|23 34|dose response
P08015850A1076|49 64|Ga administration
P08015850A1076|66 74|preinjury
P08015850A1076|77 86|postinjury
P08015850A1076|106 107|Ga
P08015850A1076|117 134|blood-brain barrier
P08015850A1076|145 151|further
P08015850A1076|163 170|efficacy
P08016102A1238|13 31|regulatory sequences
P08016102A1238|38 44|binding
P08016102A1238|47 70|transcription factors such
P08016102A1238|73 81|NF-kappa B
P08016102A1238|85 88|AP-2
P08016102A1238|95 104|activation
P08016102A1238|124 140|immediate response
P08016102A1238|183 195|important role
P08016102A1238|201 204|HO-1
P08016102A1238|214 230|defense mechanisms
P08016102A1238|238 249|tissue injury
P08016189A0741|0 10|Granisetron
P08016189A0741|18 23|saline
P08016189A0741|34 41|vomiting
P08016189A0741|45 50|nausea
P08016189A0741|83 103|combined emetic regimen
P08017290A1347|3 39|femoroarterial coronary sinus difference
P08017290A1347|42 48|lactate
P08017290A1347|67 68|pH
P08017290A1347|70 73|PCO2
P08017290A1347|77 96|potassium differences
P08017290A1347|120 125|pacing
P08018361A0636|22 42|thermal neutron fluency
P08018361A0636|53 57|n/cm2
P08020702A0000|0 10|Endotoxemia
P08020702A0000|20 40|gram-negative bacteria
P08020702A0000|48 61|endotoxic shock
P08020702A0000|93 109|integral component
P08020702A0000|115 127|bacterial wall
P08020702A0000|130 136|lipid A.
P08020702A0137|32 57|lipid A monoclonal antibodies
P08020702A0137|67 92|hemodynamic disturbances due
P08020702A0137|95 105|endotoxemia
P08020702A0137|108 121|dog experiments
P08020702A0137|131 138|efficacy
P08020702A0137|144 167|antibodies administration
P08020806A0187|44 51|patients
P08020806A0187|56 66|active Crohn
P08020806A0187|97 115|nutritional outcomes
P08020806A0187|123 131|amino acid
P08020806A0187|152 155|% fat
P08020806A0187|167 177|feeding tube
P08020806A0187|191 197|peptide
P08020806A0187|219 222|% fat
P08020962A1226|24 33|V beta locus
P08020962A1226|44 56|average number
P08020962A1226|59 79|repetitive DNA elements
P08020962A1226|83 85|Alu
P08020962A1226|92 93|L1
P08020962A1226|100 102|MER
P08020962A1226|112 137|retrovirus-related elements
P08020965A0465|12 24|genomic region
P08020965A0465|59 80|longest known transcript
P08020965A0465|85 86|kb
P08020965A0465|100 110|precise ends
P08020965A0465|117 126|transcript
P08021175A0486|3 20|pexB upstream region
P08021175A0486|33 43|nucleotides
P08021175A0486|55 63|sequences
P08021175A0486|92 115|cyclic AMP receptor protein
P08021175A0486|119 139|integration host factor
P08021175A0486|147 151|sites
P08021175A0486|156 166|discernible
P08021177A0000|3 11|fepA-entD
P08021177A0000|3 6|fepA
P08021177A0000|8 11|entD
P08021177A0000|15 29|fes-entF operons
P08021177A0000|15 17|fes
P08021177A0000|19 22|entF
P08021177A0000|35 55|enterobactin synthesis
P08021177A0000|59 73|transport system
P08021177A0000|114 122|promoters
P08021177A0000|148 166|Fur repressor protein
P08021177A0000|172 193|iron-replete conditions
P08021225A0000|0 15|Sequence analysis
P08021225A0000|19 46|6.3-kbp genomic EcoRI-fragment
P08021225A0000|33 46|EcoRI-fragment
P08021225A0000|49 68|Alcaligenes eutrophus
P08021225A0000|104 149|dihydrolipoamide dehydrogenase-specific DNA probe
P08021225A0000|104 132|dihydrolipoamide dehydrogenase
P08021225A0000|151 152|A.
P08022212A0071|25 37|two-frequency
P08022212A0071|39 50|AC excitation
P08022212A0071|52 72|three-electrode method
P08022212A0071|77 95|admittance locus plot
P08022212A0071|97 99|ALP
P08022212A0071|106 124|low-frequency region
P08022212A0071|131 132|Hz
P08022212A0071|173 184|straight line
P08022212A0071|206 236|frequency-independent parameters
P08022212A0071|238 256|phase angle alpha pi/2
P08022212A0071|258 268|conductance
P08022212A0071|287 302|frequency G0 = 1/R0
P08022212A0071|307 326|ion relaxation time tau
P08023662T0000|0 24|Intraoperative measurement
P08023662T0000|36 60|partial thromboplastin time
P08023662T0000|43 56|thromboplastin
P08023662T0000|64 78|prothrombin time
P08023662T0000|64 74|prothrombin
P08023662T0000|84 100|new compact monitor
P08024139A0393|47 58|equal volumes
P08024139A0393|88 109|significant differences
P08024139A0393|148 166|anesthetic solutions
P08024139A0393|175 191|sensory impairment
P08025074A0000|21 25|nylon
P08025074A0000|57 79|lower laser energy density
P08025074A0000|89 99|suture lysis
P08025074A0000|110 119|single shot
P08025074A0000|134 139|Dacron
P08025074A0000|146 152|prolene
P08025669A0724|3 10|proteins
P08025669A0724|30 33|rpoN
P08025669A0724|62 68|sigma 54
P08025669A0724|62 66|sigma
P08028671A0687|16 29|microinjection
P08028671A0687|34 50|anti-CBP antiserum
P08028671A0687|55 65|fibroblasts
P08028671A0687|76 88|transcription
P08028671A0687|94 115|cAMP responsive promoter
P08029001A1020|5 11|results
P08029001A1020|35 63|proline-rich activator proteins
P08029001A1020|67 81|RNA polymerase II
P08029001A1020|67 79|RNA polymerase
P08029001A1020|90 105|common structural
P08029001A1020|109 127|functional component
P08029001A1020|151 160|same target
P08029001A1020|166 194|general transcription machinery
P08029334T0000|0 6|Cloning
P08029334T0000|9 46|higher plant omega-3 fatty acid desaturases
P08030239A0833|20 32|truncated form
P08030239A0833|38 50|IE polypeptide
P08030239A0833|58 76|IE amino acid residues
P08030239A0833|111 141|transcriptional activation domain
P08030239A0833|167 181|EHV-1 tk promoter
P08030239A0833|221 235|EHV-1 IE promoter
P08030243A1011|12 39|NS35-specific RNA capture assay
P08030243A1011|12 27|NS35-specific RNA
P08030243A1011|44 52|multimers
P08030243A1011|74 92|RNA-binding activity
P08030243A1011|118 121|NS35
P08030704A1503|0 9|CONCLUSION
P08030704A1503|11 27|Human preterm birth
P08030704A1503|57 96|lower progesterone/17 beta-estradiol ratios
P08030704A1503|108 112|women
P08030704A1503|117 128|preterm labor
P08031424T0000|0 7|Ketamine
P08031424T0000|24 35|bronchospasm
P08031424T0000|42 62|mechanical ventilation
P08033490A0875|16 26|disposition
P08033490A0875|29 39|venlafaxine
P08033490A0875|43 64|O-desmethylvenlafaxine
P08033490A0875|84 95|renal disease
P08033490A0875|106 121|dosage adjustment
P08033490A0875|136 143|patients
P08033490A0875|148 172|creatinine clearance values
P08033490A0875|180 185|ml/min
P08034318A0724|29 43|multiple species
P08034318A0724|76 82|UBE site
P08034318A0724|103 108|motifs
P08034318A0724|117 123|members
P08034318A0724|129 138|NF-1 family
P08034318A0724|141 160|transcription factors
P08034486A0579|3 11|incidence
P08034486A0579|14 34|HSV-2 positive subjects
P08034486A0579|14 18|HSV-2
P08034486A0579|36 40|HSV-2
P08034486A0579|42 59|HSV-1 antibody ratio
P08034486A0579|63 63|=
P08034486A0579|77 99|Jewish Israeli population
P08034486A0579|111 131|other demographic areas
P08034680A0180|19 25|zeta PKC
P08034680A0180|35 43|NF-kappa B
P08034680A0180|67 76|activation
P08034680A0180|80 100|putative I kappa B kinase
P08034680A0180|88 100|I kappa B kinase
P08034680A0180|103 115|molecular mass
P08034680A0180|131 133|kDa
P08034680A0180|168 175|I kappa B.
P08034680A0180|168 174|I kappa B
P08034682T0000|0 15|Stable expression
P08034682T0000|27 69|inositol 1,4,5-trisphosphate receptor subunits
P08034682T0000|72 85|3T3 fibroblasts
P08034708A0000|3 16|molecular basis
P08034708A0000|32 42|progenitors
P08034708A0000|48 64|eosinophil lineage
P08034708A0000|68 77|mechanisms
P08034708A0000|85 108|eosinophil-specific genes
P08034708A0000|139 153|differentiation
P08034741A0000|28 43|characterization
P08034741A0000|46 49|myr 4
P08034741A0000|46 48|myr
P08034741A0000|51 56|myosin
P08034741A0000|69 89|first mammalian myosin I
P08034741A0000|120 133|border myosin I.
P08034741A0000|126 132|myosin I
P08034742A0307|0 1|M.
P08034742A0307|6 7|D.
P08035498A0833|11 26|computer analysis
P08035498A0833|39 54|sequences similar
P08035498A0833|60 71|A stem element
P08035498A0833|96 113|AAV promoter regions
P08035499A0941|45 49|kinds
P08035499A0941|52 60|complexes
P08035499A0941|83 98|dissociation rate
P08035499A0941|104 117|A stem substrate
P08035499A0941|125 144|protein-DNA complexes
P08035499A0941|188 197|complete TR
P08035505A0586|0 9|Processing
P08035505A0586|15 32|NS3'-5B polyprotein
P08035505A0586|15 17|NS3
P08035505A0586|21 32|B polyprotein
P08035517A0753|12 19|promoter
P08035517A0753|31 35|IEP86
P08035517A0753|77 81|IEP72
P08035796A0890|0 11|32Pi labeling
P08035796A0890|14 24|isoelectric
P08035796A0890|43 52|eIF-2 alpha
P08035796A0890|57 79|conditional casein kinase
P08035796A0890|68 88|casein kinase II mutants
P08035796A0890|82 88|mutants
P08035796A0890|102 116|phosphorylation
P08035796A0890|119 128|eIF-2 alpha
P08035796A0890|158 162|forms
P08035796A0890|165 174|eIF-2 alpha
P08035796A0890|195 201|strains
P08035796A0890|215 241|restrictive growth conditions
P08035833A1556|5 8|YMIP
P08035833A1556|12 28|functional homolog
P08035833A1556|31 34|RMIP
P08035833A1556|49 60|new component
P08035833A1556|66 98|yeast mitochondrial import machinery
P08036004A0292|3 10|R2 region
P08036004A0292|20 33|class I enhancer
P08036004A0292|26 33|enhancer
P08036004A0292|41 55|negative element
P08036004A0292|58 78|Ad12-transformed cells
P08036004A0292|91 113|stronger binding activity
P08036004A0292|130 163|nontumorigenic Ad5-transformed cells
P08037338A0000|0 6|PURPOSE
P08037338A0000|21 28|kinetics
P08037338A0000|31 44|erythropoietin
P08037338A0000|46 48|EPO
P08037338A0000|73 84|pathogenesis
P08037338A0000|87 92|anemia
P08037338A0000|95 105|prematurity
P08037338A0000|117 125|EPO levels
P08037338A0000|117 119|EPO
P08037338A0000|128 134|infants
P08037338A0000|144 152|first year
P08039422A0000|3 27|nerve growth factor beta gene
P08039422A0000|29 32|NGFB
P08039422A0000|53 65|syntenic group
P08039422A0000|68 82|human chromosome
P08039422A0000|87 101|mouse Chromosome
P08040336A0435|14 28|upstream element
P08040336A0435|30 56|collagen element I (-370/-344)
P08040336A0435|30 44|collagen element
P08040336A0435|69 76|homology
P08040336A0435|84 104|LAP binding cis-element
P08040336A0435|110 124|albumin promoter
P08040336A0435|110 116|albumin
P08040336A0435|131 132|bp
P08040391T0000|0 5|Number
P08040391T0000|15 36|silver-stained nucleoli
P08040391T0000|38 51|Ag-NOR clusters
P08040391T0000|55 69|canine seminomas
P08040391T0000|86 105|histological features
P08040391T0000|109 123|tumour behaviour
P08040468A0303|15 35|mast cell degranulation
P08040468A0303|54 65|pathogenesis
P08040468A0303|68 78|necrobiosis
P08040468A0303|89 112|fibroblast enzyme activity
P08040468A0303|128 157|prolonged inflammatory reactions
P08041362T0000|0 15|Molecular cloning
P08041362T0000|19 38|cysteine synthase cDNA
P08041362T0000|43 59|Citrullus vulgaris
P08041362T0000|61 70|watermelon
P08041362T0000|74 95|genetic complementation
P08041362T0000|115 117|Cys
P08041362T0000|119 127|auxotroph
P08041793A0242|2 15|earlier studies
P08041793A0242|28 52|several regulatory elements
P08041793A0242|64 88|transcriptional activation
P08041793A0242|92 108|aerobic repression
P08041793A0242|121 125|genes
P08041793A0242|127 131|COX5b
P08043523A0000|8 26|elevated serum levels
P08043523A0000|29 38|antibodies
P08043523A0000|44 73|nicotinic acetylcholine receptor
P08043523A0000|75 79|nAChR
P08043523A0000|99 124|neuroleptic treated patients
P08043523A0000|129 145|tardive dyskinesia
P08043523A0000|147 160|such antibodies
P08043523A0000|184 214|comparable nondyskinetic patients
P08044794A0000|3 17|tumor suppressor
P08044794A0000|21 44|transcriptional factor p53
P08044794A0000|42 44|p53
P08044800A0550|4 32|DNA containing promoter activity
P08044800A0550|54 61|entirety
P08044800A0550|79 109|multiple putative regulatory sites
P08044802A0462|8 19|Southern blot
P08044802A0462|23 39|karyotype analyses
P08044802A0462|55 72|significant changes
P08044802A0462|75 84|copy number
P08044802A0462|87 105|gross rearrangements
P08044802A0462|111 117|p53 gene
P08044802A0462|128 130|p53
P08044802A0462|132 140|cell lines
P08045431A0894|0 3|HupI
P08045431A0894|10 23|strong identity
P08045431A0894|26 35|rubredoxin
P08045431A0894|39 61|rubredoxin-like proteins
P08045431A0894|66 82|many other bacteria
P08045834A0783|3 20|PCr resynthesis rate
P08045834A0783|22 22|P
P08045834A0783|35 54|effective maximal rate
P08045834A0783|57 81|mitochondrial ATP synthesis
P08045834A0783|83 83|P
P08046923A0000|29 36|patients
P08046923A0000|52 73|pronounced osteomalacia
P08046923A0000|83 98|gastric resection
P08048582A0821|8 19|regional MVO2
P08048582A0821|39 48|same extent
P08048582A0821|54 56|CFX
P08048582A0821|83 97|ml O2.min-1 times
P08048582A0821|101 103|g-1
P08048582A0821|111 119|LAD region
P08048582A0821|146 160|ml O2.min-1 times
P08048582A0821|164 166|g-1
P08048916A0000|0 3|IGF I
P08048916A0000|7 22|insulin receptors
P08048916A0000|26 43|homologous proteins
P08048916A0000|58 86|distinct physiological pathways
P08049401A0428|0 15|Immunodepression
P08049401A0428|44 65|glucocorticoid activity
P08049401A0428|68 80|adrenal cortex
P08049401A0428|89 106|significant changes
P08049401A0428|109 123|thyroid hormones
P08049444A0351|0 14|Tryptic cleavage
P08049444A0351|18 40|peptide sequence analysis
P08049444A0351|60 71|98-kD protein
P08049444A0351|108 136|special A-T-rich binding protein
P08049444A0351|115 137|A-T-rich binding protein 1
P08049444A0351|139 143|SATB1
P08049444A0351|168 207|nuclear matrix/scaffold-associated regions
P08049444A0351|214 222|MARs/SARs
P08049521T0000|0 29|Aberrant protein phosphorylation
P08049521T0000|32 39|tyrosine
P08049521T0000|59 81|growth-inhibitory action
P08049521T0000|84 92|pp60v-src
P08049521T0000|107 111|yeast
P08049885T0000|0 16|Acute pancreatitis
P08049885T0000|19 36|multisystem disease
P08051019A0365|0 19|Alginate biosynthesis
P08051019A0365|35 60|complex regulatory mechanism
P08051059A1000|3 18|sequence upstream
P08051059A1000|24 35|rhlA promoter
P08051059A1000|47 61|inverted repeats
P08051059A1000|73 92|putative binding sites
P08051059A1000|99 111|RhlR regulator
P08051074A0000|23 34|footprinting
P08051074A0000|36 48|region located
P08051074A0000|64 95|human immunodeficiency virus, type 1
P08051074A0000|64 89|human immunodeficiency virus
P08051074A0000|97 101|HIV-1
P08051074A0000|103 110|promoter
P08051074A0000|120 133|hypersensitive
P08051074A0000|136 141|DNase I
P08051074A0000|136 140|DNase
P08051074A0000|142 150|digestion
P08051102A0532|0 6|Heparin
P08051102A0532|20 60|rAC-st myosin light chain phosphatase activity
P08051102A0532|20 52|rAC-st myosin light chain phosphatase
P08051102A0532|70 93|B subunit-containing forms
P08051151A0347|3 19|relative abundance
P08051151A0347|46 49|mRNA
P08051151A0347|65 108|reverse transcription-polymerase chain reaction
P08051151A0347|65 100|reverse transcription-polymerase chain
P08051151A0347|111 129|various human tissues
P08051151A0347|133 141|cell lines
P08053697A0000|0 9|BACKGROUND
P08053697A0000|13 18|DESIGN
P08053697A0000|30 44|melanocytic nevi
P08053697A0000|49 61|eccentric foci
P08053697A0000|64 80|hyperpigmentation
P08053697A0000|83 95|small dark dots
P08053697A0000|123 124|mm
P08053697A0000|127 134|diameter
P08053697A0000|174 193|histologic correlates
P08053697A0000|199 206|dark dots
P08054281A0731|3 16|retention index
P08054281A0731|19 28|201Tl SPECT
P08054281A0731|32 46|useful indicator
P08054281A0731|49 67|metastatic potential
P08054281A0731|103 111|prognosis
P08054281A0731|157 167|201Tl uptake
P08054281A0731|171 180|malignancy
P08055939A0159|3 23|central globular domain
P08055939A0159|46 52|regions
P08055939A0159|57 72|other H1 molecules
P08055939A0159|62 72|H1 molecules
P08055939A0159|80 102|carboxyl-terminal domain
P08055939A0159|121 136|hexapeptide motif
P08055939A0159|138 145|variants
P08055939A0159|170 180|H1 molecules
P08055939A0707|14 30|approximate length
P08055939A0707|36 41|intron
P08055939A0707|72 87|Arabidopsis genes
P08055939A0707|96 101|intron
P08055939A0707|137 140|exon
P08055939A0707|150 170|central globular domain
P08055939A0707|172 175|exon
P08055941A1264|3 10|topology
P08055941A1264|14 25|chain folding
P08055941A1264|31 42|beta subunits
P08055941A1264|48 62|artifactual beta
P08055941A1264|65 70|capsid
P08055941A1264|86 96|native alpha
P08055941A1264|98 101|beta
P08055941A1264|104 109|enzyme
P08056474A0438|1 10|single NMSC
P08056474A0438|27 27|%
P08056474A0438|36 36|%
P08056474A0438|48 48|%
P08056474A0438|59 59|%
P08056474A0438|76 76|%
P08056474A0438|84 84|%
P08057356A0531|1 22|constitutive mutant form
P08057356A0531|28 45|single substitution
P08057356A0531|47 50|V88A
P08057356A0531|57 70|amino-terminal
P08057356A0531|72 88|response regulator
P08057356A1824|0 10|Comparisons
P08057356A1824|20 39|operon control regions
P08057356A1824|62 74|NarL heptamers
P08057356A1824|90 108|diverse orientations
P08057356A1824|112 118|spacing
P08057421A1583|0 12|Direct binding
P08057421A1583|16 32|competition assays
P08057421A1583|38 64|30-mer oligonucleotide probes
P08057421A1583|80 105|individual CBF1 binding sites
P08057421A1583|90 105|CBF1 binding sites
P08057421A1583|119 122|CBF1
P08057421A1583|148 159|CD23 promoter
P08057421A1583|166 186|EBV LMP-1 promoter sites
P08057421A1583|196 201|Cp site
P08057762A0878|12 38|satisfactory reproducibility
P08057762A0878|47 48|T1
P08057762A0878|53 53|%
P08057762A0878|55 56|T2
P08057762A0878|61 61|%
P08057762A0878|72 86|reproducibility
P08057762A0878|94 105|satisfactory
P08057762A0878|113 114|T1
P08057762A0878|120 120|%
P08057762A0878|122 123|T2
P08057762A0878|129 129|%
P08057833A0573|6 17|ParA proteins
P08057833A0573|44 75|independent translation initiation
P08057833A0573|81 100|different start codons
P08057833A0573|110 129|same open reading frame
P08058326A0463|5 19|further insights
P08058326A0463|27 45|molecular mechanisms
P08058326A0463|57 71|tal-1 expression
P08058326A0463|57 61|tal-1
P08058326A0463|89 97|sequences
P08058326A0463|103 112|murine gene
P08058326A0463|135 151|human counterparts
P08058948A0810|0 9|CONCLUSION
P08058948A0810|11 32|Sonographic angiography
P08058948A0810|37 48|possible role
P08058948A0810|54 62|detection
P08058948A0810|65 76|small nodules
P08058948A0810|79 86|patients
P08058948A0810|91 93|CRF
P08062824A0626|28 34|FKBP-33
P08062824A0626|51 91|peptidyl-prolyl cis-trans isomerase activity
P08062824A0626|51 83|peptidyl-prolyl cis-trans isomerase
P08062824A0626|107 129|lower specific activities
P08062824A0626|134 140|FKBP-12
P08062833A0000|10 11|nt
P08062833A0000|25 51|transcription initiation site
P08062833A0000|57 71|mouse desmin gene
P08062833A0000|87 90|E box
P08062833A0000|92 93|E1
P08062833A0000|99 109|binding site
P08062833A0000|115 148|helix-loop-helix myogenic regulators
P08062833A0000|171 203|low level muscle-specific expression
P08063108A0109|3 10|acfD gene
P08063108A0109|25 26|nt
P08063108A0109|53 65|88-amino-acid
P08063108A0109|67 68|aa
P08063766A0595|10 13|beta
P08063766A0595|16 18|PKC
P08063766A0595|33 53|nuclear envelope lamin B
P08063766A0595|61 65|times
P08063766A0595|75 82|alpha PKC
P08063766A0595|95 101|kinases
P08063766A0595|115 127|soluble lamin B
P08063766A0595|130 141|similar rates
P08063775T0000|0 9|Regulation
P08063775T0000|12 44|parathyroid hormone-related protein
P08063775T0000|46 50|PTHrP
P08063775T0000|52 65|gene expression
P08063791A1370|5 11|results
P08063791A1370|28 37|diverse set
P08063791A1370|40 70|carboxyl-terminal sequence motifs
P08063791A1370|74 103|posttranslational modifications
P08063791A1370|110 130|functional Ras proteins
P08063791A1370|133 137|yeast
P08063836A0904|14 18|c-Abl
P08063836A0904|28 45|c-myc transcription
P08063836A0904|28 32|c-myc
P08063836A0904|76 85|DNA binding
P08063836A0904|88 92|c-Abl
P08064351A1020|0 11|Long-latency
P08064351A1020|19 23|units
P08064351A1020|35 40|shocks
P08064351A1020|45 56|little jitter
P08064351A1020|60 70|long latency
P08064351A1020|76 77|ms
P08065310A1144|18 28|ninth heptad
P08065310A1144|47 64|heterodimerization
P08065310A1144|91 119|receptor-inhibitor interaction
P08065310A1144|91 108|receptor-inhibitor
P08065310A1144|138 146|inhibitor
P08065310A1144|150 162|related member
P08065310A1144|168 185|receptor gene family
P08065324A0458|29 38|snRNA genes
P08065324A0458|41 45|maize
P08065324A0458|48 68|monocotyledonous plant
P08065324A0458|73 75|USE
P08065324A0458|79 90|TATA elements
P08065324A0458|124 136|transcription
P08065327A0000|0 24|Extensive DNA rearrangement
P08065327A0000|56 74|somatic macronucleus
P08065327A0000|82 101|germ line micronucleus
P08065327A0000|104 121|ciliated protozoans
P08065331A0279|16 37|site selection procedure
P08065331A0279|56 67|DNA sequences
P08065331A0279|89 100|wild-type HLF
P08065331A0279|104 126|chimeric E2A-HLF proteins
P08065331A0279|139 146|various t
P08065331A0279|162 170|leukemias
P08065338T0000|3 21|Oct-2 glutamine-rich
P08065338T0000|25 53|proline-rich activation domains
P08065338T0000|81 90|duplicates
P08065338T0000|113 125|transcription
P08065365A0000|0 6|Binding
P08065365A0000|9 45|U2 small nuclear ribonucleoprotein (snRNP
P08065365A0000|9 39|U2 small nuclear ribonucleoprotein
P08065365A0000|41 45|snRNP
P08065365A0000|52 59|pre-mRNA
P08065365A0000|72 84|important step
P08065365A0000|87 105|spliceosome assembly
P08065366A0918|32 36|Dbf8p
P08065366A0918|44 56|essential role
P08065366A0918|59 79|chromosome segregation
P08065368A0839|0 4|Ariga
P08065368A0839|6 12|Biochem
P08065901A0997|3 9|results
P08065901A0997|25 41|KRAB domain present
P08065901A0997|25 34|KRAB domain
P08065901A0997|47 62|non-finger region
P08065901A0997|65 76|many ZFP genes
P08065901A0997|69 76|ZFP genes
P08065901A0997|85 97|transcription
P08065901A0997|111 145|specific protein-protein interactions
P08065901A0997|119 133|protein-protein
P08065901A0997|156 167|KRAB-A domain
P08065901A0997|171 180|components
P08065901A0997|186 217|proximal transcriptional apparatus
P08066094T0000|0 9|Marine oils
P08066094T0000|13 36|cardiovascular reactivity
P08067013T0001|3 24|diagnostic significance
P08067013T0001|27 57|creatine phosphokinase antibodies
P08067013T0001|27 47|creatine phosphokinase
P08067013T0001|63 75|cardiac muscle
P08067013T0001|78 112|non-coronarogenic myocardial diseases
P08067123A0248|14 20|results
P08067123A0248|23 28|assays
P08067123A0248|49 70|assay systems ORTHO ELISA
P08067123A0248|74 85|ABBOTT HCV EIA
P08067123A0248|87 89|USA
P08067123A0248|95 107|detection rate
P08067123A0248|110 124|anti-HCV-C100-3
P08067123A0248|130 147|primary blood donors
P08067123A0248|150 155|Moscow
P08067123A0248|163 163|%
P08067123A0248|195 207|HBsAg carriers
P08067123A0248|195 199|HBsAg
P08067123A0248|212 212|%
P08067123A0248|222 227|donors
P08067123A0248|232 246|anti-HCV-C100-3
P08067123A0248|261 261|%
P08067123A0248|264 264|p
P08067546A0000|30 55|coronary vasomotor responses
P08067546A0000|68 70|ETO
P08067546A0000|73 80|propofol
P08067546A0000|90 105|sodium thiopental
P08067546A0000|107 109|STP
P08067546A0000|129 146|contrasting effects
P08067546A0000|159 169|nitric oxide
P08067546A0000|171 172|NO
P08067546A0000|175 198|dependent vasodilator tone
P08067546A0000|210 242|adrenergic vasoconstrictor activity
P08067546A0000|248 256|intact dog
P08067607A0568|0 21|Significant alterations
P08067607A0568|24 33|CBC results
P08067607A0568|37 57|serum CRP concentration
P08067607A0568|42 44|CRP
P08067607A0568|71 84|baseline values
P08067607A0568|99 102|dogs
P08067607A0568|108 119|control group
P08069298A0492|5 29|alternative splice variants
P08069298A0492|44 46|RNA
P08069298A0492|59 72|several sources
P08069298A0492|83 109|primary leptomeningeal tissue
P08069298A0492|115 129|established line
P08069298A0492|132 150|leptomeningeal cells
P08069298A0492|152 154|LMC
P08069427T0000|0 25|Roux-en-Y gastroenterostomy
P08069427T0000|42 49|emptying
P08069427T0000|55 65|gallbladder
P08069481A0736|0 22|Surface-coil experiments
P08069481A0736|25 32|phantoms
P08069481A0736|38 53|human calf muscles
P08070004A0782|0 25|Large interpatient variation
P08070004A0782|28 46|peak PCZ plasma levels
P08070004A0782|55 59|ng/ml
P08070004A0782|76 90|plasma half-life
P08070004A0782|92 100|t1/2 alpha
P08070004A0782|122 124|min
P08070004A0782|127 134|patients
P08070004A0782|147 154|mg/m2 PCZ
P08070393A0631|3 15|maximal effect
P08070393A0631|28 35|ng/ml EGF
P08070393A0631|33 35|EGF
P08070393A0631|42 48|time lag
P08070393A0631|57 58|h.
P08070654A0000|0 3|KAR1
P08070654A0000|13 30|essential component
P08070654A0000|36 55|yeast spindle pole body
P08070654A0000|57 59|SPB
P08070654A0000|78 86|karyogamy
P08070654A0000|90 103|SPB duplication
P08070654A0574|0 4|CDC31
P08070654A0574|18 31|SPB duplication
P08070654A0574|43 64|calmodulin-like protein
P08070654A0574|91 108|caltractin/centrin
P08070654A0574|91 100|caltractin
P08070654A0574|102 108|centrin
P08070654A0574|135 156|Chlamydomonas basal body
P08071356A0232|6 25|transcript elongation
P08071356A0232|30 34|sizes
P08071356A0232|40 51|DNA footprint
P08071356A0232|58 91|single-stranded transcription bubble
P08071356A0232|109 130|transcription complexes
P08071356A0232|139 164|different template positions
P08071982T0000|18 39|skeletogenital syndrome
P08072352A0567|6 13|patients
P08072352A0567|17 22|polyps
P08072352A0567|29 29|%
P08072352A0567|34 39|asthma
P08072352A0567|46 46|%
P08072352A0567|51 68|aspirin sensitivity
P08072352A0567|75 75|%
P08072352A0567|80 91|eosinophilia
P08072352A0567|100 100|%
P08072352A0567|114 127|total IgE levels
P08072352A0567|119 121|IgE
P08072547A0690|0 43|Ras- and ultra-violet-responsive protein kinases
P08072547A0690|0 2|Ras
P08072547A0690|7 43|ultra-violet-responsive protein kinases
P08072547A0690|61 65|c-Jun
P08072547A0690|68 81|serine residues
P08072547A0690|84 92|positions
P08072547A0690|115 137|transcriptional activity
P08072547A1009|1 13|short sequence
P08072547A1009|28 54|major JNK phosphorylation site
P08072547A1009|33 35|JNK
P08072547A1009|57 61|c-Jun
P08072547A1009|75 79|c-Fos
P08072547A1009|94 109|activation domain
P08072547A1009|125 129|c-Fos
P08072547T0000|0 27|c-Fos transcriptional activity
P08072547T0000|0 4|c-Fos
P08072547T0000|40 75|H-Ras-activated protein kinase distinct
P08072547T0000|80 82|JNK
P08072547T0000|86 88|ERK
P08073505T0000|1 13|new generation
P08073505T0000|16 40|information retrieval tools
P08073505T0000|44 53|biologists
P08073505T0000|70 84|ExPASy WWW server
P08075070A1632|0 16|Essential features
P08075070A1632|43 56|DNA double helix
P08075070A1632|69 81|operator sites
P08075070A1632|86 101|repressor domains
P08075070A1632|109 126|sequence homologies
P08075070A1632|134 149|helix-turn-helix
P08075070A1632|151 153|HTH
P08075070A1632|155 160|motifs
P08075070A1632|163 186|other DNA-binding proteins
P08075070A1632|168 186|DNA-binding proteins
P08075421A0621a|3 12|partial ORF
P08075421A0621a|39 47|C terminus
P08075421A0621a|50 54|HrpJ2
P08075421A0621b|3 12|partial ORF
P08075421A0621b|39 47|C terminus
P08075421A0621b|50 54|HrpJ2
P08076631A0000|3 9|binding
P08076631A0000|12 34|transcription factor AP-1
P08076631A0000|38 53|vitamin D receptor
P08076631A0000|55 57|VDR
P08076631A0000|64 76|composite AP-1
P08076631A0000|73 76|AP-1
P08076631A0000|81 114|vitamin-D-responsive promoter region
P08076631A0000|116 124|AP-1 + VDRE
P08076631A0000|116 119|AP-1
P08076631A0000|121 124|VDRE
P08076631A0000|131 150|human osteocalcin gene
P08076631A0000|169 189|osteocalcin-producing
P08076631A0000|169 179|osteocalcin
P08076631A0000|191 195|MG-63
P08076631A0000|200 212|non-producing
P08076631A0000|214 218|U2-Os
P08076631A0000|220 225|SaOs-2
P08076631A0000|227 252|human osteosarcoma cell lines
P08076937A0851|0 13|Rapid detection
P08076937A0851|20 27|mutation
P08076937A0851|40 59|restriction digestion
P08076937A0851|62 84|PCR-amplified genomic DNA
P08076937A0851|87 100|mismatch primer
P08076937A0851|116 128|point mutation
P08076937A0851|137 156|Tru9I restriction site
P08077236A0243|0 7|Wild type
P08077236A0243|11 24|mutant Epo cDNAs
P08077236A0243|51 60|high levels
P08077236A0243|63 66|COS1
P08077236A0243|70 78|COS7 cells
P08078167A0000|0 8|OBJECTIVE
P08078167A0000|28 37|hepatitis A
P08078167A0000|40 61|international travelers
P08078167A0000|76 93|preventive measures
P08078416A0581|3 20|bactericidal effect
P08078416A0581|23 35|disinfectants
P08078416A0581|43 54|biofilm cells
P08078416A0581|102 115|concentrations
P08078416A0581|121 133|disinfectants
P08078473A1107|0 9|Expression
P08078473A1107|12 20|ME31B cDNA
P08078473A1107|23 24|S.
P08078473A1107|43 55|ste13 mutation
P08078473A1107|43 47|ste13
P08079268T0028|0 2|Use
P08079268T0028|5 25|Medi-Jector EZ dermojet
P08079268T0028|29 38|anesthesia
P08079268T0028|41 52|minor surgery
P08082215A0230|3 16|immune response
P08082215A0230|19 32|past-infection
P08082215A0230|35 49|cytomegalovirus
P08082215A0230|55 62|patients
P08082215A0230|65 68|RTID
P08082286A0748|0 16|Acupuncture effect
P08082286A0748|19 31|deep receptors
P08082286A0748|65 75|certain area
P08082286A0748|83 95|distant effect
P08082292T0000|7 16|NK activity
P08082292T0000|31 43|active disease
P08082292T0000|46 48|HIV
P08082292T0000|50 57|patients
P08082292T0000|62 101|multidrug-resistant pulmonary tuberculosis
P08082360A0411|0 13|Smoking history
P08082360A0411|17 37|awake oxygen saturation
P08082360A0411|39 42|SaO2
P08082440A0339a|1 3|LH P
P08082440A0339a|1 2|LH
P08082440A0339a|10 16|LH/FSH P
P08082440A0339a|10 11|LH
P08082440A0339a|13 15|FSH
P08083011A0584|3 11|relative R
P08083011A0584|16 29|L-brain weights
P08083011A0584|64 85|relative R-L brain weight
P08083011A0584|95 106|RH female cats
P08083011A0584|111 131|R-L brain weight smaller
P08083011A0584|141 152|testosterone
P08083011A0584|155 159|males
P08083011A0584|161 168|estrogen
P08083011A0584|171 177|females
P08083220A0988|10 32|ternary complex formation
P08083220A0988|62 69|promoter
P08083220A0988|75 92|c-fos protooncogene
P08083220A0988|113 126|ternary complex
P08083220A0988|143 155|prior assembly
P08083220A0988|161 196|serum response factor-DNA binary complex
P08083963A0795|3 23|LTR-binding activities
P08083963A0795|26 28|VBP
P08083963A0795|30 35|a1/EBP
P08083963A0795|40 66|B-cell nuclear extract protein
P08083963A0795|90 97|gel shift
P08083963A0795|99 104|DNase I
P08083963A0795|99 103|DNase
P08083963A0795|105 116|footprinting
P08083963A0795|121 149|methylation interference assays
P08083998A1723a|5 11|results
P08083998A1723a|23 39|leader-mRNA fusion
P08083998A1723a|42 65|coronavirus transcription
P08083998A1723a|80 103|direct RNA-RNA interaction
P08083998A1723a|111 132|complementary sequences
P08083998A1723b|5 11|results
P08083998A1723b|23 39|leader-mRNA fusion
P08083998A1723b|42 65|coronavirus transcription
P08083998A1723b|80 103|direct RNA-RNA interaction
P08083998A1723b|111 132|complementary sequences
P08083999A0501|0 22|Vaccinia virus-expressed
P08083999A0501|32 48|full-length HPV-16
P08083999A0501|52 66|BPV-1 E2 proteins
P08083999A0501|73 87|consensus E2 site
P08083999A0501|92 113|high specific affinities
P08083999A0501|115 117|Kd =
P08083999A0501|137 137|M
P08083999A0501|159 171|transcription
P08084339A0907|24 33|transcript
P08084339A0907|45 60|open reading frame
P08084339A0907|77 90|upstream J alpha
P08084339A0907|105 115|nucleotides
P08084339A0907|145 159|TCR C alpha region
P08084339A0907|185 204|amino acid polypeptide
P08084592A0145|2 5|HeLa
P08084592A0145|7 27|fibroblast cell hybrids
P08084592A0145|55 68|tumorigenicity
P08085228A0000|0 25|Demographic characteristics
P08085228A0000|29 42|risk factor data
P08085228A0000|52 58|clients
P08085228A0000|114 139|human immunodeficiency virus
P08085228A0000|141 143|HIV
P08085228A0000|169 185|testing facilities
P08085228A0000|188 194|Houston
P08085228A0000|196 199|Tex.
P08085609A0384|0 6|Results
P08085609A0384|19 24|KNM-LU
P08085609A0384|51 63|chimpanzee M1s
P08085609A0384|66 82|relative distances
P08085609A0384|99 108|dimensions
P08085609A0384|117 135|crown fissure termini
P08085782A0164|12 16|cases
P08085782A0164|21 34|papillary tumor
P08085782A0164|37 38|cm
P08086450A0467|0 9|Comparison
P08086450A0467|17 26|bovine gene
P08086450A0467|43 56|flanking region
P08086450A0467|62 70|hATP1 gene
P08086450A0467|76 102|unconserved guanine-cytosine
P08086450A0467|104 105|GC
P08086450A0467|107 116|rich region
P08086450A0467|127 146|several binding motifs
P08086450A0467|149 170|transcriptional factors
P08086450A0467|178 180|Sp1
P08086450A0467|182 185|AP-2
P08086450A0467|190 192|GCF
P08086453T0000|0 8|Structure
P08086453T0000|10 25|promoter analysis
P08086453T0000|29 49|chromosomal assignment
P08086453T0000|55 67|human APEX gene
P08087887A1067|3 19|polyubiquitin gene
P08087887A1067|47 61|Volvox life cycle
P08087887A1067|66 70|peaks
P08087887A1067|76 91|1.6-kb mRNA levels
P08087887A1067|98 109|pre-cleavage
P08087887A1067|111 118|cleavage
P08087887A1067|123 136|post-inversion
P08088022A1417|7 37|stress-induced arrhythmic disease
P08088022A1417|48 67|ischemic heart disease
P08088022A1417|72 92|main pathogenetic links
P08088022A1417|144 151|ischemia
P08088513A0419|14 28|genetic evidence
P08088513A0419|58 78|functional interaction
P08088513A0419|89 104|DEAH protein Prp16
P08088513A0419|89 99|DEAH protein
P08088513A0419|100 104|Prp16
P08088513A0419|112 113|U6
P08088513A0419|117 136|U2 spliceosomal snRNAs
P08088777A0754|3 20|consensus gene order
P08088777A0754|51 57|crosses
P08088777A0754|60 65|D2Mit1
P08088777A0754|68 70|Dbh
P08088777A0754|72 77|Notch1
P08088777A0754|81 86|Col5a1
P08088777A0754|88 91|Rxra
P08088777A0754|94 102|Spna2-Ab l
P08088777A0754|94 98|Spna2
P08088777A0754|105 107|Ak1
P08088777A0754|109 112|Fpgs
P08088777A0754|116 120|Grp78
P08088777A0754|122 125|Pbx3
P08088777A0754|129 134|Epb7.2
P08088777A0754|136 137|Hc
P08088777A0754|139 141|Gsn
P08088777A0754|144 147|Acra
P08088818A1053|3 11|high level
P08088818A1053|14 47|transformation-associated deletions
P08088818A1053|53 61|human YACs
P08088818A1053|98 126|recombination-deficient strain
P08088818A1053|140 148|RAD52 gene
P08089184A0825|14 27|megabase region
P08089184A0825|42 50|dagA locus
P08089834A0561|5 11|mutants
P08089834A0561|15 23|deletions
P08089834A0561|29 57|extreme amino-terminal residues
P08089834A0561|65 80|amino acid residue
P08089887A0742|0 22|SECONDARY OUTCOME MEASURE
P08089887A0742|25 65|Double-blind caffeine-withdrawal evaluation
P08090571T0001|0 10|Elimination
P08090571T0001|13 29|natural antibodies
P08090571T0001|32 51|discordant xenografts
P08090746A1288|2 13|8-bp sequence
P08090746A1288|15 22|ATTTCAAA
P08090746A1288|33 72|protected region shares significant homology
P08090746A1288|77 93|promoter sequences
P08090746A1288|105 126|ethylene responsiveness
P08090746A1288|134 159|tomato fruit-ripening E4 gene
P08090746A1288|154 159|E4 gene
P08090767A0000|21 38|DNA polymerase delta
P08090767A0000|67 72|enzyme
P08090767A0000|91 99|viability
P08090767A0000|103 124|chromosomal replication
P08090767A0000|143 160|base excision repair
P08090767A0000|163 191|exogenous DNA methylation damage
P08091655A0000|19 23|Marek
P08091655A0000|26 37|Disease Virus
P08091655A0000|39 47|MDV) genes
P08091655A0000|39 41|MDV
P08091655A0000|43 47|genes
P08091655A0000|57 71|EcoRI-B fragment
P08091655A0000|74 89|MDV-GA genomic DNA
P08091665T0000|0 10|Cowpox virus
P08091665T0000|22 27|copies
P08091665T0000|32 40|early gene
P08091665T0000|50 68|soluble secreted form
P08091665T0000|74 90|type II TNF receptor
P08091665T0000|80 90|TNF receptor
P08091669A0828|18 20|P35
P08091669A0828|37 47|39k promoter
P08091669A0828|62 64|IE1
P08091669A0828|69 87|p35 open reading frame
P08091669A0828|69 71|p35
P08091669A0828|117 127|ie1 promoter
P08093450A0688|0 10|Mutagenesis
P08093450A0688|17 26|NRF-1 motif
P08093450A0688|32 43|ALAS promoter
P08093450A0688|61 73|lowered levels
P08093450A0688|76 117|chloramphenicol acetyltransferase expression
P08093450A0688|76 107|chloramphenicol acetyltransferase
P08093450A0688|126 136|mutagenesis
P08093450A0688|143 153|NRF-1 motifs
P08093450A0688|173 184|complete loss
P08093616A1214|0 5|DNase I
P08093616A1214|0 4|DNase
P08093616A1214|6 25|footprinting analysis
P08093616A1214|39 42|DREF
P08093616A1214|53 66|24-bp DRE region
P08093616A1214|72 93|DNA polymerase alpha gene
P08093616A1214|101 124|8-bp palindromic sequences
P08093616T0000|0 22|Novel 8-base pair sequence
P08093616T0000|34 62|DNA replication-related element
P08093616T0000|67 87|specific binding factor
P08093616T0000|113 127|Drosophila genes
P08093616T0000|123 127|genes
P08093616T0000|131 148|DNA polymerase alpha
P08093616T0000|152 182|proliferating cell nuclear antigen
P08093616T0000|165 182|cell nuclear antigen
P08093642A0600|12 43|microsatellite repeat polymorphism
P08093642A0600|49 62|heterozygosity
P08093642A0600|67 67|%
P08093642A0600|73 80|RET locus
P08093642A0600|85 121|restriction fragment length polymorphism
P08093642A0600|127 140|heterozygosity
P08093642A0600|145 145|%
P08093642A0600|157 167|lambda clone
P08093642A0600|175 185|D10S94 locus
P08093642A0600|206 241|high-resolution genetic linkage mapping
P08093642A0600|245 271|predictive diagnostic testing
P08094464A0869|8 11|tyrA
P08094464A0869|43 58|internal promoter
P08094464A0869|96 99|aroF
P08094464A2014|9 12|span
P08094464A2014|15 30|attenuator region
P08094464A2014|47 65|stem-loop structures
P08094464A2014|68 93|mRNA secondary configuration
P08094464A2014|95 102|hot spots
P08094464A2014|105 126|base-residue divergence
P08094464A2014|131 139|localized
P08094464A2014|142 158|looped-out regions
P08094498A0614|0 3|Most
P08094498A0614|34 42|full truth
P08094498A0614|64 72|prognosis
P08094927A0311|0 14|Previous studies
P08094927A0311|25 33|mutations
P08094927A0311|39 47|6K protein
P08094927A0311|56 66|slow release
P08094927A0311|69 76|aberrant
P08094927A0311|78 105|multi-cored infectious virions
P08095698T0000|0 9|Metabolism
P08095698T0000|12 18|calcium
P08095698T0000|22 30|vitamin D3
P08095698T0000|33 40|patients
P08095698T0000|45 76|acute tubulointerstitial nephritis
P08095698T0000|88 95|patients
P08095698T0000|100 120|nephropathia epidemica
P08095872A1672|44 51|inotropy
P08095872A1672|56 62|timolol
P08095872A1672|69 91|uniform local contraction
P08095872A1672|117 130|LONG/CIRC ratio
P08095872A1672|159 177|contraction efficacy
P08095875T0000|0 6|Effects
P08095875T0000|9 27|moderate hypercapnia
P08095875T0000|30 40|hypothermia
P08095875T0000|50 58|cold He-O2
P08095875T0000|61 64|rats
P08096066A0623|3 14|RFLP patterns
P08096066A0623|20 27|isolates
P08096066A0623|42 49|patients
P08096066A0623|69 77|unchanged
P08096066A0623|82 88|strains
P08096066A0623|98 111|additional band
P08096066A0623|136 149|drug resistance
P08096944A0951|15 32|ovarian stimulation
P08096944A0951|53 67|valid indication
P08096944A0951|73 88|proper assessment
P08096944A0951|94 100|ovaries
P08096944A0951|109 113|women
P08096944A0951|124 141|ovarian stimulation
P08096944A0951|156 161|longer
P08097666A1135|0 5|A23187
P08097666A1135|21 33|modifications
P08097666A1135|39 60|endolymphatic potential
P08097666A1135|65 85|ampullar direct current
P08097666A1135|111 124|afferent spikes
P08097732A0000|0 9|Activation
P08097732A0000|15 47|aboral ectoderm-specific Spec2a gene
P08097732A0000|21 47|ectoderm-specific Spec2a gene
P08097732A0000|50 79|blastula-stage sea urchin embryos
P08097732A0000|90 113|upstream regulatory region
P08097732A0000|127 151|repetitive sequence element
P08097732A0000|153 155|RSR
P08097732A0000|174 189|Spec1/Spec2 genes
P08098228A0625|1 10|transcript
P08098228A0625|19 20|kb
P08098228A0625|38 40|PPO
P08098842A0660|0 8|Mutations
P08098842A0660|12 24|region located
P08098842A0660|31 32|bp
P08098842A0660|50 76|major transcription start site
P08098842A0660|86 97|good homology
P08098842A0660|114 122|first exon
P08098842A0660|125 129|c-fos
P08098842A0660|143 167|negative regulatory element
P08098842A0660|179 197|significant increase
P08098842A0660|200 218|basal gene expression
P08098882T0001|0 26|Salazopyrine desensitization
P08098914A0400|18 32|Pes-Ves relation
P08098914A0400|68 88|end-systolic elastance
P08098914A0400|90 92|Ees
P08098914A0400|130 131|SD
P08098914A0400|133 139|mmHg/ml
P08098914A0400|141 141|P
P08099443A0359|10 12|HRI
P08099443A0359|16 23|dsRNA-PK
P08099443A0359|37 51|yeast eIF-2 alpha
P08099443A0359|96 106|GCN2 protein
P08099443A0359|118 132|GCN4 translation
P08099443A0359|118 121|GCN4
P08099443A0359|135 139|yeast
P08100057A0577|0 14|Double-staining
P08100057A0577|37 55|separate populations
P08100057A0577|58 81|CD68-positive macrophages
P08100057A0577|58 61|CD68
P08100057A0577|85 109|XIIIa-positive dendrocytes
P08100765A0361|25 51|transgene expression patterns
P08100765A0361|61 70|cerebellum
P08100765A0361|76 80|lines
P08100765A0361|95 132|distinct anterior-posterior compartments
P08100843A0134|0 15|Southern analysis
P08100843A0134|18 27|genomic DNA
P08100843A0134|40 46|tissues
P08100843A0134|50 58|cell lines
P08100843A0134|63 81|several mouse strains
P08100843A0134|87 95|mCD22 cDNA
P08100843A0134|115 123|Cd22 locus
P08100843A0134|132 136|mCD22
P08100843A0134|140 153|single copy gene
P08100843A0134|159 159|=
P08100843A0134|162 163|kb
P08101134A0376|3 16|concentrations
P08101134A0376|19 28|plasma ACTH
P08101134A0376|25 28|ACTH
P08101134A0376|32 39|cortisol
P08101134A0376|53 53|%
P08101134A0376|59 59|%
P08101134A0376|65 77|MPTP treatment
P08101171A0924|11 17|results
P08101171A0924|36 50|Pc group products
P08101171A0924|58 69|stable memory
P08101171A0924|84 93|boundaries
P08101171A0924|128 146|pair-rule regulators
P08101839A0000|43 55|human mdr1 gene
P08101839A0000|73 84|mdr1 promoter
P08101839A0000|87 93|signals
P08101839A0000|104 120|cell proliferation
P08101843A0151|3 25|tyrosine hydroxylase gene
P08101843A0151|27 28|TH
P08101843A0151|39 48|single copy
P08101843A0151|52 63|consensus CRE
P08101843A0151|74 81|base pair
P08101843A0151|83 84|bp
P08101843A0151|86 93|upstream
P08101843A0151|99 125|transcription initiation site
P08102364A0000|0 33|Tobacco mosaic virus-infected tobacco
P08102364A0000|35 53|Nicotiana tabacum var
P08103379A0577|19 28|amino acids
P08103379A0577|45 54|MADS domain
P08103379A0577|62 69|proteins
P08103379A0577|94 127|conservative amino acid substitutions
P08103935T0000|0 8|Isolation
P08103935T0000|12 27|characterization
P08103935T0000|30 49|SRF accessory proteins
P08104189A1168|24 38|proSRIF cleavage
P08104189A1168|24 30|proSRIF
P08104189A1168|55 57|TGN
P08104189A1168|87 94|acidic pH
P08104189A1168|116 150|Golgi-associated vacuolar-type ATPase
P08105727A0099|0 9|Fenoldopam
P08105727A0099|12 34|dopamine receptor agonist
P08105727A0099|12 27|dopamine receptor
P08105727A0099|51 67|animal experiments
P08105727A0099|78 91|renal perfusion
P08105994T0000|0 14|Clinical aspects
P08105994T0000|17 29|early increase
P08105994T0000|32 61|serum gamma-glutamyl transferase
P08105994T0000|64 81|cerebral infarction
P08106087A0139|7 20|flanking region
P08106087A0139|26 38|27 kDa zein gene
P08106087A0139|28 38|kDa zein gene
P08106087A0139|40 66|several AATAAA-like sequences
P08106087A0139|92 115|mammalian GT-rich sequence
P08106087A0139|135 154|polyadenylation sites
P08106245A0325|3 26|indoor radon concentration
P08106245A0325|69 73|Bq m-3
P08106245A0325|125 129|Bq m-3
P08106245A0325|136 144|first year
P08106245A0325|147 158|measurements
P08106245A0325|174 178|Bq m-3
P08106245A0325|220 224|Bq m-3
P08106245A0325|253 262|second year
P08106245A0325|265 276|measurements
P08106313A1492|3 9|results
P08106313A1492|22 26|hrpRS
P08106313A1492|30 33|hrpL
P08106313A1492|44 60|regulatory cascade
P08106313A1492|68 71|HrpR
P08106313A1492|75 78|HrpS
P08106313A1492|99 102|hrpL
P08106313A1492|106 109|HrpL
P08106313A1492|112 130|putative sigma factor
P08106313A1492|120 130|sigma factor
P08106313A1492|151 170|HrpL-responsive genes
P08106325A0000|0 3|DtxR
P08106325A0000|8 56|iron-dependent sequence-specific DNA-binding protein
P08106325A0000|71 81|tox operator
P08106325A0000|85 124|inverted-repeat nucleotide sequence located
P08106325A0000|140 158|diphtheria toxin gene
P08106369A0000|0 10|Vasopressin
P08106369A0000|12 14|AVP
P08106369A0000|20 38|antidiuretic hormone
P08106369A0000|43 59|cyclic nonapeptide
P08106369A0000|84 124|G protein-coupled specific membrane receptors
P08106369A0000|158 165|subtypes
P08106369A0000|167 169|V1a
P08106369A0000|171 173|V1b
P08106369A0000|178 179|V2
P08106369A0000|189 212|distinct second messengers
P08106398A1003|5 11|results
P08106398A1003|25 32|cleavage
P08106398A1003|38 50|leader peptide
P08106398A1003|56 63|last step
P08106398A1003|66 80|nisin maturation
P08106398A1003|66 70|nisin
P08106398A1003|118 130|active peptide
P08106512A0522|7 20|promoter region
P08106512A0522|35 58|heterologous reporter gene
P08106512A0522|74 87|promoter region
P08106512A0522|90 98|inducible
P08106512A0522|105 115|interferons
P08106512A0522|117 132|interferon-alpha
P08106512A0522|137 141|gamma
P08106512A0522|146 172|interferon regulatory factor 1
P08106512A0522|146 171|interferon regulatory factor
P08107167A0222|0 17|Anti-B. burgdorferi
P08107167A0222|0 5|Anti-B
P08107167A0222|19 34|anti-B. turicatae
P08107167A0222|19 24|anti-B
P08107167A0222|26 34|turicatae
P08107167A0222|38 61|anti-B. parkeri antibodies
P08107167A0222|38 43|anti-B
P08107167A0222|45 61|parkeri antibodies
P08107167A0222|74 103|indirect immunofluorescent assay
P08107167A0222|105 107|IFA
P08107167A0222|139 139|%
P08107167A0222|145 156|serum samples
P08107167A0222|178 184|IFA-ABS
P08107167A0222|200 200|%
P08107208A0673|57 68|recombinants
P08107208A0673|88 107|EBV cosmid-cloned DNAs
P08107208A0673|109 110|B.
P08108099T0000|0 9|Evaluation
P08108099T0000|12 23|desmopressin
P08108099T0000|27 43|dental extractions
P08108099T0000|46 53|patients
P08108099T0000|58 76|hemostatic disorders
P08108343A0000|0 18|Comparative analysis
P08108343A0000|25 44|antiandrogen niftolid
P08108343A0000|48 60|synthetic GnRH
P08108343A0000|57 60|GnRH
P08108343A0000|78 91|normal subjects
P08108343A0000|95 102|patients
P08108343A0000|119 122|ones
P08108343A0000|127 147|secondary hypogonadism
P08108343A0000|155 162|patients
P08108343A0000|167 179|clinical signs
P08108343A0000|182 201|gonadal insufficiency
P08108343A0000|205 220|obscure diagnosis
P08108343A0000|242 270|pituitary gonadotropin reserves
P08108343A0000|242 262|pituitary gonadotropin
P08108413A0964|3 13|other normal
P08108413A0964|28 35|lymphoid
P08108413A0964|39 58|nonlymphoid cell lines
P08108413A0964|62 74|normal tissues
P08108413A0964|90 103|PANG expression
P08108413A0964|90 93|PANG
P08108413A0964|142 158|6.1-kb transcripts
P08111035A0098|3 32|cis-acting regulatory properties
P08111035A0098|40 57|bp promoter fragment
P08111035A0098|61 78|B. napus oleosin gene
P08111035A0098|68 78|oleosin gene
P08111035A0098|103 120|beta-glucuronidase
P08111035A0098|122 124|GUS
P08111035A0098|138 160|transgenic tobacco plants
P08111035A0098|173 212|oleosin promoter-GUS transcriptional fusion
P08111035A0098|173 187|oleosin promoter
P08111035A0098|189 191|GUS
P08111974A1034|36 37|CX
P08111974A1034|44 59|rapid degradation
P08111974A1034|62 72|tubulin mRNA
P08111974A1034|145 163|altered trans-factor
P08112341A1128|0 1|L.
P08112341A1128|3 7|Greer
P08112341A1128|9 10|J.
P08112341A1128|12 17|Carter
P08112341A1128|19 20|G.
P08112526A0443|13 45|extracellular calcium concentration
P08112526A0443|54 74|detrusor contractility
P08112526A0443|78 97|dose-dependent manner
P08112526A0443|124 131|bladders
P08112601T0000|0 21|Structural organization
P08112601T0000|42 69|human lipocalin tear prealbumin
P08112601T0000|42 55|human lipocalin
P08112601T0000|60 69|prealbumin
P08112601T0000|73 81|synthesis
P08112601T0000|87 104|recombinant protein
P08112611A0404|15 37|1092-bp open reading frame
P08112611A0404|59 68|amino acids
P08112870A0484|0 14|Western blotting
P08112870A0484|16 29|immunoblotting
P08112870A0484|37 45|antiserum
P08112870A0484|49 58|partial SOD
P08112870A0484|56 58|SOD
P08112870A0484|96 103|proteins
P08112870A0484|117 131|molecular masses
P08112870A0484|141 143|kDa
P08113736A0309|3 18|gene organization
P08113736A0309|21 29|CRSV RNA-1
P08113736A0309|48 70|red clover necrotic mosaic
P08113736A0309|72 76|RCNMV
P08113736A0309|81 105|sweet clover necrotic mosaic
P08113736A0309|107 111|SCNMV
P08113736A0309|113 126|dianthoviruses
P08113736A0309|147 155|CRSV RNA-1
P08113736A0309|180 190|terminal ORF
P08114702A0000|0 6|Members
P08114702A0000|12 50|myocyte-specific enhancer-binding factor 2
P08114702A0000|12 49|myocyte-specific enhancer-binding factor
P08114702A0000|52 55|MEF2
P08114702A0000|65 84|transcription factors
P08114702A0000|99 114|A/T-rich sequence
P08114702A0000|120 133|control regions
P08114702A0000|136 163|numerous muscle-specific genes
P08114710A0137|25 29|LBP-1
P08114710A0137|39 56|HIV-1 transcription
P08114710A0137|39 43|HIV-1
P08114710A0137|72 78|binding
P08114710A0137|81 85|TFIID
P08114710A0137|91 97|TATA box
P08114745A0953|5 11|results
P08114745A0953|24 36|important role
P08114745A0953|40 41|La
P08114745A0953|44 56|RNA production
P08114745A0953|92 107|termination sites
P08114745A0953|118 126|templates
P08114745A0953|144 155|efficient use
P08114745A0953|158 179|transcription complexes
P08114745A0953|182 187|pol III
P08114745A0953|182 184|pol
P08115744A0462|3 7|films
P08115744A0462|26 61|scanning helium-neon laser densitometer
P08115744A0462|67 79|small aperture
P08115744A0462|86 92|microns
P08115744A0846|3 18|GafChromic method
P08115744A0846|45 55|rapid method
P08115744A0846|99 121|quality assurance program
P08116245A0174|0 14|Viral genomic RNA
P08116245A0174|23 31|reactions
P08116245A0174|55 68|fecal specimens
P08116245A0174|71 88|infected infant rats
P08118044A0318|0 9|GATA-1 mRNA
P08118044A0318|22 37|equivalent levels
P08118044A0318|44 61|erythroid cell lines
P08118044A0318|69 76|low level
P08118044A0318|79 89|FDC-P1 cells
P08119149A0000|0 24|Tumor necrosis factor-alpha
P08119149A0000|26 33|TNF alpha
P08119149A0000|42 74|several autocrine/paracrine factors
P08119149A0000|87 109|potent inhibitory effects
P08119907A0000|27 47|cellular p21ras protein
P08119907A0000|50 56|insulin
P08119907A0000|60 85|insulin-like growth factor-I
P08119907A0000|87 91|IGF-I
P08119907A0000|93 109|signaling pathways
P08119958A0273|12 19|C2 domain
P08119958A0273|25 44|Ca(2+)-dependent PKCs
P08119958A0273|25 26|Ca
P08119958A0273|32 44|dependent PKCs
P08119958A0273|62 87|unique NH2-terminal sequence
P08119958A0273|93 114|potential signal peptide
P08119958A0273|119 137|transmembrane domain
P08119958A0273|149 153|PKC mu
P08119958A0273|157 167|novel member
P08119958A0273|173 180|subgroup
P08119958A0273|183 194|atypical PKCs
P08119958A0273|191 194|PKCs
P08119995A0814|36 54|T3R-RXR heterodimers
P08119995A0814|36 38|T3R
P08119995A0814|57 72|response elements
P08119995A0814|86 95|half-sites
P08119995A0814|135 145|nucleotides
P08119995A0814|160 169|major parts
P08119995A0814|178 193|flanking sequence
P08119995A0814|199 215|upstream half-site
P08120019A1500|13 22|Hm1 mutants
P08120019A1500|41 49|deficient
P08120019A1500|63 72|PI turnover
P08120019A1500|82 100|normal sequestration
P08120019A1500|112 129|distinct mechanisms
P08120029A0864|19 39|decay reaction mixtures
P08120029A0864|59 81|20-nt sense RNA transcript
P08120029A0864|92 104|stabilization
P08120029A0864|107 115|R2 message
P08122364A0954|0 15|Deletion analyses
P08122364A0954|21 30|pCD41 ORF-A
P08122364A0954|42 59|promoter constructs
P08122364A0954|75 100|internal functional promoter
P08122364A0954|110 122|pCD41 sequence
P08122364A0954|139 147|synthesis
P08122364A0954|153 175|trans-activating protein
P08122370A0331|15 26|counterparts
P08122370A0331|32 33|US
P08122370A0331|36 53|herpes simplex type 1
P08122370A0331|36 52|herpes simplex type
P08122370A0331|55 59|HSV-1
P08122370A0331|62 78|pseudorabies virus
P08122370A0331|80 82|PRV
P08122370A0331|88 108|equine herpesvirus type
P08122370A0331|111 115|EHV-1
P08123787A0554|11 27|amino acid sequence
P08123787A0554|33 57|cyanobacterial HemB protein
P08123787A0554|68 88|significant difference
P08123787A0554|94 117|metal cofactor requirement
P08123787A0554|125 143|higher-plant enzymes
P08123787A0554|164 177|overexpression
P08123787A0554|181 199|biochemical analysis
P08124785A0445|0 6|METHODS
P08124785A0445|10 16|RESULTS
P08124785A0445|22 31|open-chest
P08124785A0445|33 48|anesthetized dogs
P08124785A0445|50 84|progressive circumflex artery stenosis
P08124785A0445|91 108|concordant decrease
P08124785A0445|111 126|circumflex artery
P08124785A0445|137 149|hyperemic flow
P08124785A0445|151 169|coronary flow reserve
P08124785A0445|174 215|inverse angiographic mean transit time Tmicro-1
P08124785A0445|217 217|P
P08124912A0456|38 45|SF levels
P08124912A0456|38 39|SF
P08124912A0456|48 51|IL-8
P08124912A0456|63 69|lactate
P08124912A0456|71 73|LDH
P08124912A0456|75 93|beta 2-microglobulin
P08124912A0456|97 103|glucose
P08124956T0000|0 54|Sodium-taurocholate-induced acute necrotizing pancreatitis
P08124956T0000|68 85|jejunal oxygenation
P08124956T0000|88 91|pigs
P08125258A0142|8 15|inactive
P08125258A0142|18 22|cells
P08125258A0142|28 43|normal conditions
P08125258A0142|48 55|CHOP gene
P08125258A0142|85 100|cellular stresses
P08125258A0142|111 129|nutrient deprivation
P08125258A0142|133 154|metabolic perturbations
P08125319A1085|3 11|ipiO genes
P08125319A1085|28 50|identical 152-aa proteins
P08125319A1085|68 75|homology
P08125319A1085|80 95|sequences present
P08125319A1085|98 110|data libraries
P08125337A0940|0 13|Sterol analysis
P08125337A0940|28 33|mutant
P08125337A0940|49 60|accumulation
P08125337A0940|63 72|ignosterol
P08125337A0940|91 104|Erg24p activity
P08125337A0940|91 96|Erg24p
P08125949A1162|43 56|spinach L12 mRNA
P08125949A1162|67 81|tandem AUG codons
P08125949A1162|91 110|functional rpl12 genes
P08125949A1162|101 110|rpl12 genes
P08125949A1162|113 123|Arabidopsis
P08125949A1162|142 151|mechanisms
P08125949A1162|172 177|copies
P08125949A1162|180 202|L12/chloroplast ribosome
P08125949A1162|246 255|eubacteria
P08126096A0478|7 17|experiments
P08126096A0478|35 52|potential functions
P08126096A0478|58 62|alpha
P08126096A0478|64 80|cytoplasmic domain
P08126096A0478|92 101|homologies
P08126096A0478|118 131|human sequences
P08126096A0478|135 152|immunologic studies
P08126096A0478|160 190|anti-cytoplasmic domain antiserum
P08126096A0478|211 224|alternate forms
P08126096A1071|3 16|alpha 7A form RNA
P08126096A1071|40 50|nucleotides
P08126096A1071|64 68|B form
P08126096A1071|74 91|common coding region
P08126096A1071|97 97|A
P08126096A1071|101 109|B form RNAs
P08126096A1071|118 139|alternate reading frames
P08127950A0000|33 62|hypothalamic-pituitary-thyroid
P08127950A0000|64 66|HPT
P08127950A0000|69 72|axis
P08127950A0000|75 92|unipolar depression
P08127950A0000|97 103|authors
P08127950A0000|112 133|basal 0800h plasma levels
P08127950A0000|136 148|free thyroxine
P08127950A0000|150 152|FT4
P08127950A0000|155 174|free triiodothyronine
P08127950A0000|176 178|FT3
P08127950A0000|184 208|thyroid stimulating hormone
P08127950A0000|210 212|TSH
P08127950A0000|216 220|means
P08127950A0000|230 249|ultrasensitive assays
P08127950A0000|251 258|TSH-IRMA
P08127950A0000|251 253|TSH
P08127950A0000|264 278|healthy controls
P08127950A0000|291 301|simple major
P08127950A0000|308 335|melancholic depressed subjects
P08128629A1164|0 10|CRS function
P08128629A1164|0 2|CRS
P08128629A1164|16 44|LTR-linked gene expression assay
P08128629A1164|75 80|p60CRS
P08128629A1164|84 89|p40CRS
P08128629A1164|106 111|LTR RNA
P08129955A0572|0 11|Serial levels
P08129955A0572|14 22|troponin T
P08129955A0572|39 43|CK-MB
P08129955A0572|68 68|h
P08129955A0572|74 89|aortic unclamping
P08130942A0051|0 14|Regionalization
P08130942A0051|17 28|drug delivery
P08130942A0051|32 46|potential method
P08131545A0158|31 46|community members
P08131545A0158|50 52|men
P08131545A0158|57 61|women
P08131545A0158|78 82|years
P08131545A0158|121 125|acute
P08131545A0158|129 154|convalescent serologic tests
P08131545A0158|158 167|Mycoplasma
P08131545A0158|179 199|Legionella pneumophila
P08131545A0158|201 215|cytomegalovirus
P08131545A0158|217 226|adenovirus
P08131545A0158|228 243|Coxiella burnetii
P08131545A0158|248 256|Chlamydia
P08131746A0140|0 2|MEK
P08131746A0140|23 43|serine phosphorylation
P08131746A0140|46 69|upstream activator kinases
P08131746A0140|80 84|c-raf
P08131746A0140|86 88|mos
P08131746A0140|92 100|MEK kinase
P08132541A0000|0 15|Genomic DNA clones
P08132541A0000|29 55|T-cell-specific human MAL gene
P08132574A0831|0 6|Members
P08132574A0831|9 11|SVA
P08132574A0831|31 53|complement C2 gene located
P08132574A0831|61 69|kilobases
P08132574A0831|80 82|RP1
P08132574A0831|88 90|HLA
P08132574A0831|99 118|cytochrome CYP1A1 gene
P08132667T0000|0 9|Expression
P08132667T0000|15 52|dibasic proprotein processing enzyme furin
P08132667T0000|65 81|multiple promoters
P08133502T0105|0 26|European Community Huntington
P08133502T0105|29 58|Disease Collaborative Study Group
P08134108A0277|3 7|c-myc
P08134108A0277|11 42|skeletal alpha-actin gene promoters
P08134108A0277|50 64|YY1 binding sites
P08134108A0277|95 120|negative cis-acting elements
P08134115A1161|0 5|MSSP-1
P08134115A1161|25 37|fusion protein
P08134115A1161|42 44|GST
P08134115A1161|71 91|single-stranded TCTTAT
P08134115A1161|97 99|myc
P08134115A1161|101 103|H-P
P08134115A1161|111 117|ACT-ATT
P08134115A1161|126 128|myc
P08134115A1161|130 132|H-P
P08134115A1161|174 182|A/TCTA/TA
P08134115A1161|184 185|TT
P08136383A0359|8 12|hours
P08136383A0359|18 29|MR tomography
P08136383A0359|33 40|patients
P08138180A0593|0 29|Certain spt10 spontaneous alleles
P08138180A0593|7 11|spt10
P08138180A0593|33 47|good suppressors
P08138180A0593|56 71|normal growth rate
P08138180A0593|90 101|SPT10 protein
P08138180A0593|112 128|distinct functions
P08138364T0000|0 8|Varieties
P08138364T0000|11 27|envious experience
P08139001A1235|3 9|results
P08139001A1235|25 29|amino
P08139001A1235|33 46|carboxy termini
P08139001A1235|52 69|NS1 protein molecule
P08139001A1235|76 84|cysteines
P08139001A1235|87 94|residues
P08139001A1235|119 133|tubule formation
P08139004A0278|5 7|UTR
P08139004A0278|11 31|several stable hairpins
P08139004A0278|48 62|single-stranded
P08139004A0278|64 66|A/U
P08139004A0278|66 66|U
P08139004A0278|68 79|UGC sequences
P08139017A1465|12 20|major site
P08139017A1465|23 47|transcriptional initiation
P08139017A1465|68 82|primer extension
P08139017A1465|86 95|bp upstream
P08139017A1465|111 124|Ets-1 cDNA clone
P08139017A1465|149 159|normal cells
P08139017A1465|163 168|tumors
P08139017A1465|178 185|provirus
P08139017A1465|191 200|Tpl-1 locus
P08139031A1168|15 62|oligonucleotide-directed site-specific mutagenesis
P08139031A1168|85 100|cysteine residues
P08139031A1168|106 120|ORF4 polypeptide
P08139031A1168|126 130|C-421
P08139031A1168|134 138|C-426
P08139031A1168|154 175|transactivator function
P08139031A1168|195 210|cysteine residues
P08139031A1168|227 261|critical protein-protein interactions
P08139031A1168|272 302|protein-nucleic acid interactions
P08139031A1168|312 327|ORF4 inducibility
P08139539A0446|2 11|Rat 1a cells
P08139539A0446|13 26|m1R stimulation
P08139539A0446|13 15|m1R
P08139539A0446|29 46|phospholipase C beta
P08139539A0446|53 62|marked rise
P08139539A0446|65 84|intracellular calcium
P08139539A0446|95 103|cyclic AMP
P08139539A0446|105 108|cAMP
P08139539A0446|110 118|synthesis
P08139539A0446|134 143|activation
P08139539A0446|146 160|protein kinase A.
P08139539A0446|146 159|protein kinase A
P08139542A1229|3 11|mutations
P08139542A1229|27 36|repression
P08139542A1229|39 42|CPA1
P08139542A1229|45 52|arginine
P08139542T0000|10 13|mRNA
P08139542T0000|25 37|leader peptide
P08139542T0000|43 50|CPA1 gene
P08139542T0000|58 67|repression
P08139542T0000|70 77|arginine
P08139542T0000|81 111|heterologous yeast gene transcript
P08139543A0427|11 15|genes
P08139543A0427|35 50|SLK1-SLT2 pathway
P08139543A0427|35 38|SLK1
P08139543A0427|40 43|SLT2
P08139543A0427|53 84|synthetic lethal suppression screen
P08139543A1520|0 6|Genetic
P08139543A1520|10 27|phenotypic analysis
P08139543A1520|41 45|NHP6A
P08139543A1520|49 61|NHP6B function
P08139543A1520|49 53|NHP6B
P08139543A1520|74 77|SLT2
P08139562A0404|25 29|lines
P08139562A0404|47 55|ribosomes
P08139562A0404|71 74|GCN4
P08139562A0404|99 103|uORF1
P08139562A0404|112 119|scanning
P08139562A0404|140 152|GCN4 start site
P08139562A0404|140 143|GCN4
P08139577T0000|0 18|Identical components
P08139577T0000|21 48|yeast transcription factor IIIB
P08139577T0000|76 88|transcription
P08139577T0000|91 108|TATA box-containing
P08139577T0000|112 125|TATA-less genes
P08139914A0554|30 44|dnHLH protein Id1
P08139914A0554|30 41|dnHLH protein
P08139914A0554|42 44|Id1
P08139914A0554|53 67|differentiation
P08139914A0554|79 90|myeloid cells
P08139928T0000|0 3|RNP1
P08139928T0000|6 29|new ribonucleoprotein gene
P08139928T0000|35 39|yeast
P08140847X0001|0 4|Crohn
P08140847X0001|16 33|prolonged remission
P08140847X0001|51 71|protein-calorie intake
P08140847X0001|84 98|healthy subjects
P08140847X0001|115 134|year prospective study
P08140847X0001|155 164|adult Crohn
P08140847X0001|167 181|disease patients
P08140847X0001|184 201|prolonged remission
P08140847X0001|203 206|CDAI
P08140847X0001|235 244|body weight
P08140847X0001|281 307|protein-calorie intake higher
P08140847X0001|336 350|healthy controls
P08142875A0877|9 26|complete dissection
P08142875A0877|32 47|anterior vitreous
P08142875A0877|62 70|clear lens
P08142875A0877|80 104|first surgical intervention
P08142875A0877|115 119|cases
P08143198T0001|0 10|Restoration
P08143198T0001|13 20|opponens
P08143198T0001|33 47|transplantation
P08143198T0001|50 82|free composites dorsal pedal skin flap
P08143198T0001|93 116|m. extensor hallucis brevis
P08143236A1055|7 50|ethanol regimen impaired spontaneous alternation
P08143236A1055|59 71|g ethanol.kg-1
P08143236A1055|73 84|day-1 regimen
P08143236A1055|97 103|percent
P08143236A1055|113 118|trials
P08143667A0222|11 12|sd
P08143667A0222|14 36|intra-vesicular pressure
P08143667A0222|38 40|IVP
P08143667A0222|45 75|maximal urethral closure pressures
P08143667A0222|77 80|MUCP
P08143667A0222|115 119|cmH2O
P08143667A0222|152 155|MUCP
P08143667A0222|159 161|IVP
P08144035A0387|0 6|Several
P08144035A0387|22 28|regions
P08144035A0387|48 60|near N terminus
P08144035A0387|71 79|C terminus
P08144037A0000|0 10|Thioredoxin
P08144037A0000|12 13|TR
P08144037A0000|18 55|small ubiquitous dithiol-reductase enzyme
P08144037A0000|33 49|dithiol-reductase
P08144037A0000|84 89|plants
P08144470A0711|3 10|mutation
P08144470A0711|20 32|asgB480 allele
P08144470A0711|50 65|A-to-G transition
P08144470A0711|80 111|threonine-to-alanine substitution
P08144470A0711|126 139|protein product
P08144497T0000|3 21|cysteine-rich region
P08144497T0000|24 34|raf-1 kinase
P08144497T0000|43 46|zinc
P08144497T0000|62 70|liposomes
P08144497T0000|77 84|adjacent
P08144497T0000|104 110|GTP-ras
P08144504T0064|0 14|Kinetic coupling
P08144504T0064|32 44|ATP hydrolysis
P08144572A0786|0 2|ATP
P08144572A0786|22 39|polypeptide binding
P08144572A0786|42 48|Ssb1/2p
P08144572A0786|64 75|intermediate
P08144572A0786|101 116|Ssa Hsp70 proteins
P08144572A0786|126 128|BiP
P08144572A0786|132 135|DnaK
P08144615A0533|0 8|Digestion
P08144615A0533|11 16|NF-IL6
P08144615A0533|21 37|endoprotease Asp-N
P08144615A0533|47 59|domain smaller
P08144615A0533|67 69|TCD
P08144615A0533|71 87|NF-IL6 bZIP domains
P08144615A0533|89 92|NFBD
P08144631A0000|0 8|Signaling
P08144631A0000|11 25|tyrosine kinases
P08144631A0000|34 51|direct associations
P08144631A0000|59 66|proteins
P08144631A0000|71 82|Src homology 2
P08144631A0000|71 81|Src homology
P08144631A0000|84 86|SH2
P08144631A0000|88 94|domains
P08144631A0000|98 102|sites
P08144631A0000|105 127|tyrosine phosphorylation
P08144668A0802|25 29|exon V
P08144668A0802|52 55|exon
P08144668A0802|60 65|exon VI
P08144668A0802|83 98|open reading frame
P08144668A0802|114 120|GPHe(P2
P08144668A0802|114 117|GPHe
P08144668A0802|119 120|P2
P08144668A0802|137 158|new hydrophobic sequence
P08144668A0802|162 178|membrane anchoring
P08144852A0000|3 11|responses
P08144852A0000|18 31|stress hormones
P08144852A0000|33 40|cortisol
P08144852A0000|42 57|11-deoxycortisol
P08144852A0000|59 62|ACTH
P08144852A0000|64 74|vasopressin
P08144852A0000|76 78|AVP
P08144852A0000|84 111|corticotropin releasing factor
P08144852A0000|84 96|corticotropin
P08144852A0000|113 115|CRF
P08144852A0000|131 141|normal males
P08144852A0000|154 176|acute cortisol deficiency
P08144852A0000|189 216|11-beta-hydroxylase inhibitor
P08144852A0000|189 207|11-beta-hydroxylase
P08144852A0000|218 227|metyrapone
P08145646T0000|0 8|Structure
P08145646T0000|27 48|alternative sigma factor
P08145646T0000|38 48|sigma factor
P08145646T0000|50 53|RpoN
P08145646T0000|57 77|Rhodobacter capsulatus
P08145646T0000|79 100|physiological relevance
P08145646T0000|118 138|nifU2-rpoN superoperon
P08145646T0000|118 122|nifU2
P08145646T0000|124 127|rpoN
P08145770A1078|7 18|observations
P08145770A1078|29 42|functional link
P08145770A1078|53 55|PKC
P08145770A1078|59 74|retinoid pathways
P08145770A1078|109 130|antagonistic activities
P08145770A1078|133 156|differentiation processes
P08148463A0000|3 27|colony-stimulating factors
P08148463A0000|29 32|CSFs
P08148463A0000|70 80|neutrophils
P08148463A0000|84 92|monocytes
P08148463A0000|96 109|granulocyte CSF
P08148463A0000|111 135|granulocyte-macrophage CSF
P08148463A0000|137 149|macrophage CSF
P08148463A0000|154 165|interleukin 3
P08148463A0000|154 164|interleukin
P08148463A0000|182 190|multi-CSF
P08148756A0358|11 25|lung destruction
P08148756A0358|38 59|interstitial hemorrhage
P08148756A0358|82 98|hemoglobin content
P08148756A0358|82 91|hemoglobin
P08148756A0358|114 125|lavaged lungs
P08149484A0151|0 17|Expression plasmids
P08149484A0151|27 37|full-length
P08149484A0151|40 51|kinase domain
P08149484A0151|54 61|PKC alpha
P08149484A0151|65 72|PKC delta
P08149484A0151|74 82|PKC alpha K
P08149484A0151|86 94|PKC delta K
P08149484A1551|5 11|results
P08149484A1551|28 35|PKC alpha
P08149484A1551|37 52|calcium dependent
P08149484A1551|57 64|PKC delta
P08149484A1551|66 83|calcium independent
P08149484A1551|98 110|transcription
P08149484A1551|113 130|TPA-inducible genes
P08149484A1551|142 145|AP-1
P08149484A1551|149 165|non-AP-1 sequences
P08150970A0434|5 15|cutoff level
P08150970A0434|19 24|TSST-1
P08150970A0434|38 42|pg/ml
P08150970A0434|46 52|samples
P08150970A0434|67 74|patients
P08150970A0434|90 95|TSST-1
P08151787A0355|0 8|Insertion
P08151787A0355|11 31|short oligonucleotides
P08151787A0355|43 77|basic amino acid motifs 726-GRKRKSP-732
P08151787A0355|82 86|IE175
P08151787A0355|90 104|500-VRPRKRR-506
P08151787A0355|109 113|IE110
P08151787A0355|125 140|cytoplasmic forms
P08151787A0355|149 156|proteins
P08151787A0355|168 187|karyophilic phenotype
P08151787A0355|209 214|motifs
P08151787A0355|247 271|proper nuclear localization
P08151787T0000|0 6|Mapping
P08151787T0000|9 40|intracellular localization domains
P08151787T0000|55 80|colocalization interactions
P08151787T0000|91 95|IE110
P08151787T0000|99 132|IE175 nuclear transactivator proteins
P08151787T0000|99 103|IE175
P08151787T0000|135 152|herpes simplex virus
P08151790A0354|3 20|revertant TATA boxes
P08151790A0354|35 42|kinetics
P08151790A0354|45 58|HIV replication
P08151790A0354|86 88|LTR
P08151790A0354|100 110|Sp1 mutation
P08151790A0354|112 119|deletion
P08151790A0354|122 133|site specific
P08151790A0354|160 170|infectivity
P08151790A0354|173 184|wild-type HIV
P08151980T0001|0 18|Panlobular emphysema
P08152800A0357|8 16|ETS domain
P08152800A0357|25 33|localized
P08152800A0357|39 59|carboxy terminal region
P08152800A0357|84 84|%
P08152800A0357|90 99|% identical
P08152800A0357|108 111|PEA3
P08152800A0357|115 118|ER81
P08152800A0357|144 152|new member
P08152800A0357|154 181|Ets Related Molecule PEA3-like'
P08152800A0357|154 180|Ets Related Molecule PEA3-like
P08152800A0357|183 185|ERM
P08152800A0709|0 15|Gel shift analysis
P08152800A0709|32 52|full-length ERM protein
P08152800A0709|81 95|oligonucleotide
P08152800A0709|109 143|consensus nucleotide core sequence GGAA
P08152800A0709|159 169|Ets proteins
P08153130T0000|0 6|Effects
P08153130T0000|9 17|estradiol
P08153130T0000|20 29|worm burden
P08153130T0000|33 52|peripheral leukocytes
P08153130T0000|55 93|Parastrongylus malaysiensis-infected rats
P08153146A0327|0 9|Dotarizine
P08153146A0327|18 33|arterial dilation
P08153146A0327|40 47|systemic
P08153146A0327|51 70|pulmonary circulation
P08153146A0327|75 99|total peripheral resistance
P08153146A0327|111 127|femoral artery flow
P08153146A0327|133 138|aortic
P08153146A0327|142 160|pulmonary artery mean
P08153146A0327|164 181|diastolic pressures
P08153146A0327|194 210|systolic pressures
P08154171A0649|5 10|issues
P08154171A0649|26 30|LMWHs
P08154171A0649|33 40|patients
P08154171A0649|45 62|arterial thrombosis
P08154171A0649|65 84|myocardial infarction
P08154171A0649|92 102|conjunction
P08154171A0649|107 127|thrombolytic treatment
P08154171A0649|135 142|patients
P08154171A0649|147 163|pulmonary embolism
P08154182A0955|3 12|usefulness
P08154182A0955|18 27|lambda PG15
P08154182A0955|34 56|lambda AD5 cloning vectors
P08154182A0955|86 119|large Neurospora crassa cDNA libraries
P08156332T0000|0 35|Endoscopic transthoracic sympathectomy
P08156332T0000|38 54|adjuvant treatment
P08156332T0000|58 84|critical upper-limb ischaemia
P08157009A0264|0 18|Sequence comparisons
P08157009A0264|32 36|Aps1p
P08157009A0264|55 66|sigma subunit
P08157009A0264|72 106|Golgi-localized mammalian AP-1 complex
P08157009A0264|111 115|Aps2p
P08157009A0264|140 169|plasma membrane AP-2 sigma subunit
P08157009T0000|3 33|Saccharomyces cerevisiae APS1 gene
P08157009T0000|26 33|APS1 gene
P08157009T0000|42 48|homolog
P08157009T0000|54 65|small subunit
P08157009T0000|71 98|mammalian clathrin AP-1 complex
P08157009T0000|71 87|mammalian clathrin
P08157009T0000|111 131|functional interaction
P08157009T0000|136 143|clathrin
P08157009T0000|149 160|Golgi complex
P08157663A0882|5 11|results
P08157663A0882|39 60|structural organization
P08157663A0882|64 77|vertebrate gene
P08157663A0882|88 110|integral membrane protein
P08157663A0882|116 130|nuclear envelope
P08157663A0882|158 169|polypeptides
P08157674T0000|0 26|Biochemical characterization
P08157674T0000|29 53|valosin-containing protein
P08157674T0000|56 85|protein tyrosine kinase substrate
P08157674T0000|56 76|protein tyrosine kinase
P08157674T0000|88 105|hematopoietic cells
P08159174A0581|16 26|foreign gene
P08159174A0581|41 56|Southern analysis
P08160054A0224|3 10|patients
P08160054A0224|15 28|deterioriation
P08160054A0224|31 42|mental status
P08160054A0224|50 63|marked increase
P08160054A0224|66 77|liver enzymes
P08160054A0224|79 115|aspartate and alanine aminotransaminases
P08160054A0224|79 87|aspartate
P08160054A0224|91 115|alanine aminotransaminases
P08160054A0224|120 137|severe coagulopathy
P08160387T0000|0 29|Functional postnatal development
P08160387T0000|35 56|rat primary visual cortex
P08160387T0000|69 84|visual experience
P08160387T0000|86 96|dark rearing
P08160387T0000|100 119|monocular deprivation
P08160905A0217|6 13|patients
P08160905A0217|34 57|hepatitis B surface antigen
P08160905A0217|59 63|HBsAg
P08163183T0000|3 30|xylose isomerase-encoding gene
P08163183T0000|32 35|xylA
P08163183T0000|39 70|Clostridium thermosaccharolyticum
P08163183T0000|72 78|cloning
P08163183T0000|80 89|sequencing
P08163183T0000|93 101|phylogeny
P08163183T0000|104 114|XylA enzymes
P08163498A0789|3 17|phosphopeptides
P08163498A0789|31 32|RS
P08163498A0789|35 37|32P
P08163498A0789|39 52|SGASGLLTSEHHSR
P08163498A0789|56 56|S
P08163498A0789|59 61|32P
P08163498A0789|63 76|SGASGLLTSEHHSR
P08163498A0789|95 123|stoichiometric phosphorylation
P08163498A0789|127 140|trypsinization
P08163498A0789|146 152|peptide
P08163528T0000|0 38|Mitochondrial Mas70p signal anchor sequence
P08163546A1230|31 36|Ypt51p
P08163546A1230|38 43|Ypt52p
P08163546A1230|48 53|Ypt53p
P08163546A1230|82 97|endocytic pathway
P08163546A1230|104 117|correct sorting
P08163546A1230|120 137|vacuolar hydrolases
P08163546A1230|149 168|possible intersection
P08163546A1230|174 182|endocytic
P08163546A1230|190 211|vacuolar sorting pathway
P08164302A0547|8 24|basal TPN solutions
P08164302A0547|29 42|isonitrogenous
P08164302A0547|57 75|nutrient composition
P08164302A0547|101 111|energy level
P08164302A0547|133 139|glucose
P08164661A0414|13 23|TFIIIC alpha
P08164661A0414|29 36|homology
P08164661A0414|47 65|yeast TFIIIC subunits
P08164661A0414|91 107|significant degree
P08164661A0414|110 131|evolutionary divergence
P08164661A0414|135 157|RNA polymerase III factors
P08164661A0414|135 147|RNA polymerase
P08164661A0414|151 157|factors
P08164679A0809|0 20|Transactivation domain
P08164679A0809|23 29|located
P08164679A0809|45 76|128-amino-acid runt homology region
P08164679A0809|93 102|Runt domain
P08164680A1086|17 32|protease activity
P08164680A1086|37 55|least 35-fold greater
P08164680A1086|58 69|mature B cells
P08164680A1086|76 85|pre-B cells
P08164684A1266|3 8|ligand
P08164684A1266|12 14|RXR
P08164684A1266|16 32|9-cis retinoic acid
P08164684A1266|40 53|opposite effect
P08164684A1266|56 68|destabilizing
P08164684A1266|72 95|heterodimeric-DNA complex
P08166402A0631|0 17|Cerebral125 albumin
P08166402A0631|32 49|similar proportions
P08166402A0631|57 62|groups
P08166402A0631|74 88|hyperosmolality
P08167396A0154|20 26|neurons
P08167396A0154|54 91|ipsilateral substantia nigra pars compacta
P08167555A0972|0 7|Response
P08167555A0972|30 37|patients
P08167555A0972|42 57|less pretreatment
P08167555A0972|59 80|one-two prior treatments
P08167555A0972|95 108|pretreated ones
P08167555A0972|176 176|p
P08169201A0291|13 34|amino-terminal sequence
P08169201A0291|48 58|carA product
P08169201A0291|90 107|nucleotide sequence
P08169201A0291|114 122|organisms
P08169201A0291|144 163|additional amino acids
P08169709T0000|0 17|Aneurysmal bone cyst
P08169709T0000|23 26|jaws
P08169709T0000|40 44|cases
P08170400T0000|0 7|Location
P08170400T0000|47 80|Escherichia coli transcription factor
P08170400T0000|62 80|transcription factor
P08170400T0000|82 84|FNR
P08172416A0860|0 9|Moxidectin
P08172416A0860|14 18|times
P08172416A0860|22 36|therapeutic dose
P08172416A0860|48 65|deleterious effects
P08172416A0860|68 93|cow reproductive performance
P08172416A0860|110 125|folliculogenesis
P08172416A0860|127 135|ovulation
P08172416A0860|143 161|early embryonic phase
P08172598A0237|0 20|Northern-blot analysis
P08172598A0237|23 26|mRNA
P08172598A0237|31 55|Avicel-grown N. patriciarum
P08172598A0237|66 69|xynB
P08172598A0237|86 98|kb mRNA species
P08172653A1589|3 17|variable regions
P08172653A1589|20 48|vertebrate striated TnT isoforms
P08172653A1589|38 48|TnT isoforms
P08172653A1589|59 76|subsequent addition
P08172653A1589|80 91|modification
P08172653A1589|94 109|genomic sequences
P08172653A1589|122 128|members
P08172653A1589|134 151|TnT multigene family
P08172905A0000|3 73|class II Escherichia coli alanine tRNA synthetase aminoacylates RNA miniduplexes
P08172905A0000|25 45|alanine tRNA synthetase
P08172905A0000|59 73|RNA miniduplexes
P08172905A0000|94 104|acceptor end
P08172905A0000|107 117|alanine tRNA
P08172905A0000|125 134|critical G3
P08172905A0000|136 146|U70 base pair
P08173532A0000|0 17|Simple reaction time
P08173532A0000|19 20|RT
P08173532A0000|25 46|peripheral visual target
P08173532A0000|48 49|S2
P08173532A0000|67 84|non-informative cue
P08173532A0000|86 87|S1
P08173532A0000|103 112|S2 location
P08173532A0000|120 121|ms
P08173532A0000|128 138|target onset
P08173532A0000|140 156|early facilitation
P08173693A0390|1 16|second study group
P08173693A0390|22 45|intact cardiac innervation
P08173693A0390|60 67|patients
P08173693A0390|72 96|stable angina pectoris class
P08173814A0132|5 11|viruses
P08173814A0132|23 39|host cell machinery
P08173814A0132|61 72|interference
P08173814A0132|82 90|processes
P08173814A0132|114 141|other important host physiology
P08175031A0566|0 8|Treatment
P08175031A0566|12 25|well-tolerated
P08175188A0685|20 25|ppm SO2
P08175188A0685|46 59|baseline values
P08175188A0685|77 77|%
P08175188A0685|80 86|mean MCA
P08175188A0685|101 101|%
P08175188A0685|104 110|mean CBF
P08176742A0190|23 37|assay conditions
P08176742A0190|46 52|studies
P08176742A0190|58 77|transposition pathway
P08177143T0000|0 17|Renal cell carcinoma
P08177143T0000|20 27|children
P08177143T0000|30 46|single institution
P08178446A1160|18 22|ICP10
P08178446A1160|46 56|ras activity
P08178446A1160|46 48|ras
P08178446A1160|64 72|TM segment
P08178446A1160|79 90|critical role
P08178446A1160|93 131|transformation-related signaling pathways
P08178490A0879|23 36|signal function
P08178490A0879|44 57|anchor function
P08178490A0879|66 74|K SA domain
P08178572A1118|4 30|concensus poly A addition sites
P08178572A1118|34 40|located
P08178572A1118|49 57|base pairs
P08178572A1118|81 89|protein IX
P08179827T0000|0 6|Factors
P08179827T0000|21 45|intrafamilial transmission
P08179827T0000|48 71|hepatitis B virus infection
P08179827T0000|74 78|Korea
P08180129A1256|0 7|Exposure
P08180129A1256|10 32|higher TPA concentrations
P08180129A1256|59 69|transcripts
P08181755A0989|0 15|Northern analysis
P08181755A0989|29 43|pcbAB transcript
P08181755A0989|53 70|distinct transcript
P08181755A0989|99 102|mRNA
P08182041A1067|3 9|results
P08182041A1067|25 43|minimal requirements
P08182041A1067|47 55|induction
P08182041A1067|58 62|PEPCK
P08182041A1067|65 67|PKA
P08182041A1067|71 80|inhibition
P08182041A1067|83 89|insulin
P08182041A1067|103 122|CREB activation domain
P08182041A1067|129 145|PEPCK TATA sequence
P08182041A1067|152 182|insulin-responsive hepatoma cells
P08182041A1067|152 158|insulin
P08182056A0695|3 12|high degree
P08182056A0695|34 37|NQO2
P08182056A0695|41 60|NQO1 gene organization
P08182056A0695|41 48|NQO1 gene
P08182056A0695|85 92|NQO2 gene
P08182056A0695|104 115|second member
P08182056A0695|121 133|NQO gene family
P08182171A0000|3 10|efficacy
P08182171A0000|14 42|Propionibacterium acnes product
P08182171A0000|57 72|coliform mastitis
P08182171A0000|94 113|intramammary infusion
P08183552T0000|3 16|human eps15 gene
P08183552T0000|27 49|tyrosine kinase substrate
P08183552T0000|76 79|maps
P08183552T0000|82 89|1p31-p32
P08183915A0000|18 31|105-kDa protein
P08183915A0000|33 36|p105
P08183915A0000|38 46|precursor
P08183915A0000|52 61|p50 subunit
P08183915A0000|64 91|transcription factor NF-kappa B
P08183915A0000|104 120|p70 I kappa B protein
P08183915A0000|122 133|I kappa B gamma
P08183915A0000|156 165|C-terminal
P08183915A0000|169 178|amino acids
P08183915A0000|181 184|p105
P08183915T0000|0 18|Alternative splicing
P08183915T0000|21 34|RNA transcripts
P08183915T0000|47 69|murine p105 NF-kappa B gene
P08183915T0000|79 98|I kappa B gamma isoforms
P08183915T0000|103 131|different inhibitory activities
P08184923A0829|0 11|Topical L-NNA
P08184923A0829|25 43|hypercapnic increase
P08184923A0829|46 49|CoBF
P08184923A0829|58 58|%
P08184923A0829|62 65|CeBF
P08184923A0829|74 74|%
P08184923A0829|80 93|45-min exposure
P08185288A0106|30 50|female healthy subjects
P08185288A0106|62 72|24-hour stay
P08185288A0106|78 96|respiration chambers
P08185288A0106|135 144|min cycling
P08185288A0106|152 160|total work
P08185288A0106|168 171|kg m.
P08187085A0086|5 18|rearrangements
P08187085A0086|41 53|chimeric genes
P08187085A0086|64 83|tyrosine kinase domain
P08187085A0086|86 88|ret
P08187085A0086|103 114|end sequences
P08187085A0086|117 130|different genes
P08187088A0530|0 11|Frequent loss
P08187088A0530|14 27|heterozygosity
P08187088A0530|29 31|LOH
P08187088A0530|38 38|%
P08187088A0530|44 59|informative cases
P08187088A0530|73 85|chromosomes 3p
P08187088A0530|91 91|%
P08187088A0530|94 95|5q
P08187088A0530|101 101|%
P08187088A0530|104 105|6p
P08187088A0530|111 111|%
P08187088A0530|114 115|8p
P08187088A0530|121 121|%
P08187088A0530|124 125|9p
P08187088A0530|131 131|%
P08187088A0530|134 135|9q
P08187088A0530|141 141|%
P08187088A0530|144 146|11p
P08187088A0530|152 152|%
P08187088A0530|155 157|13q
P08187088A0530|163 163|%
P08187088A0530|166 168|17p
P08187088A0530|174 174|%
P08187088A0530|177 179|17q
P08187088A0530|185 185|%
P08187088A0530|188 190|18q
P08187088A0530|196 196|%
P08187088A0530|202 204|19q
P08187088A0530|210 210|%
P08187177A0405|1 21|single amino acid change
P08187177A0405|27 50|CPY vacuolar sorting signal
P08188258A0000|0 22|Glutamyl-tRNA synthetase
P08188258A0000|26 46|prolyl-tRNA synthetase
P08188258A0000|55 70|different classes
P08188258A0000|73 97|aminoacyl-tRNA synthetases
P08188258A0000|130 160|independent evolutionary pathways
P08188290A0544|8 19|sequence data
P08188290A0544|35 56|human TCRAC/TCRDC region
P08188290A0544|40 44|TCRAC
P08188290A0544|46 50|TCRDC
P08188290A0544|73 106|polymerase chain reaction-based assay
P08188290A0544|134 160|individual TCRAJ gene segments
P08188290A0544|144 160|TCRAJ gene segments
P08188603A0230|22 31|intact gene
P08188603A0230|33 36|arg4
P08188603A0230|46 55|high degree
P08188603A0230|58 65|homology
P08188603A0230|73 103|Saccharomyces cerevisiae CPA2 gene
P08188603A0230|96 103|CPA2 gene
P08188603A0230|115 126|large subunit
P08188603A0230|129 157|carbamoyl-phosphate synthetase
P08188603A0230|159 163|CPS-A
P08188606A1034|0 18|Restriction analysis
P08188606A1034|22 42|Southern hybridization
P08188606A1034|64 69|Tn5422
P08188606A1034|78 110|plasmid-mediated cadmium-resistant
P08188606A1034|126 132|strains
P08188606A1034|147 153|strains
P08188606A1034|162 178|cadmium resistance
P08188606A1034|184 193|chromosome
P08188978A0822|3 19|baroreflex latency
P08188978A0822|28 36|ECG R-wave
P08188978A0822|52 64|MSNA burst peak
P08188978A0822|96 96|s
P08188978A0822|123 141|pulse-synchronicity
P08189174A0148|0 5|DESIGN
P08189174A0148|9 23|randomised study
P08189174A0148|41 49|women aged
P08189174A0148|55 59|years
P08189174A0148|78 98|breast cancer screening
P08189174A0148|119 125|Utrecht
P08189498T0000|0 13|Identification
P08189498T0000|18 36|immediate-early gene
P08189498T0000|42 46|Marek
P08189498T0000|49 84|disease virus long internal repeat region
P08189498T0000|98 127|unique 14-kilodalton polypeptide
P08189503A0000|11 30|full-length cDNA clone
P08189503A0000|11 25|full-length cDNA
P08189503A0000|34 70|mouse hepatitis virus strain A59 defective
P08189503A0000|86 88|RNA
P08189503A0000|90 96|pMIDI-C
P08189503A0000|101 119|cassette mutagenesis
P08189503A0000|141 174|coronavirus subgenomic mRNA synthesis
P08189533A0203|10 27|structure-function
P08189533A0203|33 44|gene 5 product
P08189533A0203|46 63|wild-type and mutant
P08189533A0203|46 54|wild-type
P08189533A0203|58 68|mutant forms
P08189533A0203|71 74|NS53
P08189533A0203|95 132|recombinant baculovirus expression system
P08189533A0203|137 163|recombinant vaccinia virus/T7
P08189533A0203|165 170|vTF7-3
P08189533A0203|172 187|expression system
P08189533A0919|0 17|Gel electrophoresis
P08189533A0919|21 45|Western immunoblot analyses
P08189533A0919|48 69|intracellular fractions
P08189533A0919|81 93|infected cells
P08189533A0919|106 117|large amounts
P08189533A0919|120 123|NS53
P08189533A0919|140 146|cytosol
P08189533A0919|170 187|cytoskeletal matrix
P08190633A0000|3 25|transcription factor AP-2
P08190633A0000|22 25|AP-2
P08190633A0000|38 48|gene located
P08190633A0000|51 60|chromosome
P08190633A0000|69 76|HLA locus
P08190633A0273|3 16|mature AP-2 mRNA
P08190633A0273|9 16|AP-2 mRNA
P08190633A0273|31 35|exons
P08190633A0273|62 73|kb genomic DNA
P08191910A0228|0 8|San Martin
P08191910A0228|11 29|psychological traits
P08191910A0228|50 62|masonic lodges
P08191910A0228|89 97|abilities
P08191910A0228|100 109|strategist
P08191910A0228|113 126|political ruler
P08192140A0209|3 14|participants
P08192140A0209|19 31|homosexual men
P08192140A0209|34 56|hepatitis B vaccine trials
P08192140A0209|59 67|Amsterdam
P08192140A0209|69 70|n =
P08192140A0209|75 85|New York City
P08192140A0209|87 88|n =
P08192140A0209|97 108|San Francisco
P08192140A0209|110 111|n =
P08192451A0885|3 16|7-day treatment
P08192451A0885|38 56|mitochondrial uptake
P08192451A0885|59 63|Rh123
P08192451A0885|79 87|NAO uptake
P08192795T0000|0 32|Thrombotic thrombocytopenic purpura
P08192795T0000|35 60|systemic lupus erythematosus
P08193147A0831|0 9|Comparison
P08193147A0831|17 32|crystal structure
P08193147A0831|35 52|Desulfovibrio gigas
P08193147A0831|54 55|Dg
P08193147A0831|57 58|Fd
P08193147A0831|60 68|Kissinger
P08193147A0831|92 113|similar folding topology
P08193147A0831|123 156|several secondary structural elements
P08193147A0831|170 179|Pf relative
P08193147A0831|182 185|Dg Fd
P08194139A0498|0 10|CONCLUSIONS
P08194139A0498|12 39|Serum prolactin concentrations
P08194139A0498|12 25|Serum prolactin
P08194139A0498|44 63|age related variations
P08194139A0498|76 85|fertile men
P08194549A0000|18 29|male kayakers
P08194549A0000|74 86|critical power
P08194549A0000|88 89|CP
P08194549A0000|97 101|onset
P08194549A0000|104 127|blood lactate accumulation
P08194549A0000|129 132|OBLA
P08194753A0157|30 35|rhp51+
P08194753A0157|30 34|rhp51
P08194753A0157|45 63|MluI cell-cycle boxes
P08194753A0157|68 102|putative DNA damage-responsive element
P08194753A0157|108 121|upstream region
P08194970A0000|0 4|Women
P08194970A0000|7 19|opportunities
P08194970A0000|72 83|primary carer
P08194970A0000|106 115|Trudy Wynne
P08195186A0000|1 19|partial cDNA sequence
P08195186A0000|36 66|T lymphocyte early-activation gene
P08195186A0000|68 70|Tea
P08195186A0000|80 93|protein related
P08195186A0000|99 167|dual-function ecotropic retrovirus receptor/cationic amino acid transporter
P08195186A0000|112 138|ecotropic retrovirus receptor
P08195186A0000|140 167|cationic amino acid transporter
P08195186A0000|169 177|ecoR/CAT1
P08195186A0000|169 172|ecoR
P08195186A0000|174 177|CAT1
P08195186A0000|183 190|RNA blots
P08195186A0000|200 219|highest Tea expression
P08195186A0000|222 233|T lymphocytes
P08195186A0000|243 249|MacLeod
P08195186A0000|251 254|C.L.
P08195186A0000|256 261|Finley
P08195186A0000|263 264|K.
P08195186A0000|266 271|Kakuda
P08195186A0000|273 274|D.
P08195216A1022|28 31|HIS3
P08195216A1022|42 54|limited subset
P08195216A1022|57 74|TATA-like sequences
P08195216A1022|86 98|transcription
P08195216A1022|101 111|conjunction
P08195216A1022|116 120|GCN4p
P08195216A1022|122 152|many divergent TATA-like sequences
P08195216A1022|160 174|GCN4p activation
P08195216A1022|160 164|GCN4p
P08195216A1022|177 180|TRP3
P08195217A0799|46 81|reticulocyte lysate translation product
P08195217A0799|108 120|37-kDa protein
P08195217A0799|123 161|sodium dodecyl sulfate-polyacrylamide gels
P08195233A0147|15 20|kinase
P08195233A0147|79 83|genes
P08195233A0147|100 114|human chromosome
P08195233A0147|138 147|late stages
P08195233A0147|150 162|tumorigenesis
P08196607A0280|0 15|Deletion analysis
P08196607A0280|21 32|ICL1 promoter
P08196607A0280|59 66|upstream
P08196607A0280|77 91|sequence element
P08196607A0280|93 99|UASICL1
P08196607A0280|103 112|CATTCATCCG
P08196607A0280|152 183|carbon source-dependent regulation
P08196607A0280|187 210|heterologous reporter gene
P08196616A1112|30 35|ZAP-70
P08196616A1112|43 47|motif
P08196616A1112|79 94|ZAP-70 SH2 domains
P08196616A1112|107 122|tyrosine residues
P08196616A1112|128 132|motif
P08196616A1112|148 153|ZAP-70
P08196616A1112|170 192|phosphotyrosine residues
P08196616A1112|203 209|binding
P08196616A1112|218 227|SH2 domains
P08196618A0473|0 4|PRL-1
P08196618A0473|28 52|phosphotyrosine substrates
P08196618A0473|57 64|mutation
P08196618A0473|70 95|active-site cysteine residue
P08196624A0593|2 25|Mv1Lu lung epithelial cells
P08196624A0593|27 33|ActR-IB
P08196624A0593|37 50|T beta R-I signal
P08196624A0593|37 44|T beta R-I
P08196624A0593|52 60|common set
P08196624A0593|63 79|growth-inhibitory
P08196624A0593|83 106|transcriptional responses
P08196624A0593|129 148|corresponding ligands
P08196624A0593|158 166|receptors
P08198524A1134|2 4|kDa
P08198524A1134|15 17|kDa
P08199204A0746|0 2|H-7
P08199204A0746|46 58|PKC activation
P08199204A0746|46 48|PKC
P08199204A0746|73 95|tyrosine phosphorylation
P08199204A0746|99 104|PtdIns
P08199204A0746|110 121|P2 production
P08199878T0000|3 9|effects
P08199878T0000|12 39|systemic glucose concentration
P08199878T0000|42 56|brain metabolism
P08199878T0000|74 86|brain ischemia
P08200528A0970|33 44|Tn903 neo gene
P08200528A0970|51 99|Rhodosporidium toruloides phenylalanine ammonia lyase
P08200528A0970|101 103|PAL
P08200528A0970|126 147|transcriptional control
P08200528A0970|150 153|pPGK
P08200528A0970|156 159|REP2
P08201352A0239|11 38|congenital protein C deficiency
P08201352A0239|40 58|vitamin K antagonists
P08201352A0239|96 107|skin necrosis
P08201758A0125|0 19|A-69-year-old patient
P08201758A0125|24 58|postoperative small-bowel obstruction
P08201758A0125|68 77|laparotomy
P08201758A0125|83 87|times
P08201932A0355|2 20|physical examination
P08201932A0355|22 49|mild symmetrical polyarthritis
P08201932A0355|60 70|large joints
P08202546A1206|27 50|hUBF-promoter interaction
P08202546A1206|27 39|hUBF-promoter
P08202546A1206|73 91|antagonistic effects
P08202546A1206|94 113|cisplatin-DNA adducts
P08203260A1204|17 20|SIMV
P08203260A1204|38 45|neonates
P08203260A1204|53 62|ventilator
P08204348T0000|0 4|VP-16
P08204348T0000|6 15|ifosfamide
P08204348T0000|19 27|cisplatin
P08204348T0000|29 31|VIP
P08204348T0000|36 63|extensive small cell lung cancer
P08204403A0000|11 15|males
P08204403A0000|20 26|females
P08204403A0000|28 35|patients
P08204403A0000|54 71|retrospective study
P08204403A0000|99 121|radioimmunoscintigraphy
P08204403A0000|126 130|I-131
P08204403A0000|138 147|anti CEA/CA
P08204403A0000|138 144|anti CEA
P08204403A0000|146 171|CA 19-9 monoclonal antibodies
P08204403A0000|152 171|monoclonal antibodies
P08204426T0001|0 11|Simultaneous
P08204426T0001|13 21|bilateral
P08204426T0001|25 44|permanent ventilation
P08204426T0001|50 64|diaphragm pacing
P08204426T0001|80 100|implantation technique
P08204426T0001|104 114|indications
P08204824A0000|1 12|genomic clone
P08204824A0000|19 27|cyc07 gene
P08204824A0000|62 67|S phase
P08204824A0000|77 85|cell cycle
P08204824A0000|88 106|synchronous cultures
P08204824A0000|109 118|periwinkle
P08204824A0000|120 137|Catharanthus roseus
P08204824A0000|139 143|cells
P08205827A0940|0 10|CONCLUSIONS
P08205827A0940|12 24|Translocation
P08205827A0940|37 45|endotoxin
P08205827A0940|53 73|gastrointestinal tract
P08205827A0940|81 91|bloodstream
P08205827A0940|106 122|animal experiments
P08205827A0940|132 144|translocation
P08205827A0940|164 171|patients
P08205827A0940|176 191|hemorrhagic shock
P08206848A0296|3 6|pyrR
P08206848A0296|10 18|pyrP genes
P08206848A0296|26 37|polypeptides
P08206848A0296|52 66|molecular masses
P08206848A0296|80 82|kDa
P08206867A0874|0 23|Southern blotting analysis
P08206867A0874|34 43|occurrence
P08206867A0874|46 63|multiple COXVb genes
P08206867A0874|54 63|COXVb genes
P08206867A0874|69 77|rat genome
P08206991A0466|0 8|Acylation
P08206991A0466|16 30|palmitate analog
P08206991A0466|47 51|Gly-2
P08206991A0466|64 70|alanine
P08206991A0466|84 98|N-myristylation
P08206991A0466|112 124|palmitylation
P08206991A0466|139 143|Cys-3
P08206991A0466|146 150|Cys-6
P08206991A0466|163 168|serine
P08207022T0000|0 17|Subunit composition
P08207022T0000|21 35|domain structure
P08207022T0000|41 75|Spo0A sporulation transcription factor
P08207022T0000|78 93|Bacillus subtilis
P08207232A0503|0 35|Electrophoretic mobility shift analysis
P08207232A0503|49 55|NF-IL-6
P08207232A0503|65 83|other related members
P08207232A0503|118 128|NF-IL-6 site
P08207232A0503|134 145|IL-8 promoter
P08207405A0372|0 2|BYV
P08207405A0372|4 22|citrus tristeza virus
P08207405A0372|24 26|CTV
P08207405A0372|29 48|beet yellow stunt virus
P08207405A0372|50 53|BYSV
P08207405A0372|58 93|carnation necrotic fleck virus templates
P08207405A0372|103 125|kb amplification products
P08207405A0372|143 152|sequencing
P08207405A0372|164 172|fragments
P08207405A0372|178 197|respective HSP70 genes
P08207405A0372|188 197|HSP70 genes
P08207795A0409|13 27|precise location
P08207795A0409|33 51|phosphorylation site
P08207795A0409|57 69|64-kDa protein
P08207795A0409|72 104|step-by-step mutagenesis procedures
P08207805A0000|3 31|p53 tumor suppressor gene product
P08207805A0000|34 68|sequence-specific DNA-binding protein
P08207805A0000|51 68|DNA-binding protein
P08207805A0000|90 113|transcriptional activator
P08207805A0000|117 125|repressor
P08208247T0030|0 17|Mutational analysis
P08208247T0030|20 41|chromosomal segment 64AB
P08208247T0030|63 91|glutamic acid decarboxylase gene
P08208540A0000|0 13|Rearrangements
P08208540A0000|19 27|NFKB2 gene
P08208540A0000|45 64|lymphoid malignancies
P08208540A0000|72 93|functional significance
P08208540A0000|101 111|alterations
P08208540A0417|0 6|Cloning
P08208540A0417|10 19|sequencing
P08208540A0417|25 42|corresponding cDNAs
P08208540A0417|60 78|alternative splicing
P08208540A0417|83 96|rearranged gene
P08208540A0417|93 101|gene codes
P08208540A0417|108 115|proteins
P08208540A0417|125 126|kD
P08208540A0417|128 133|p84/85
P08208540A0417|149 168|DNA-binding rel domain
P08208540A0417|184 197|ankyrin repeats
P08208540A0417|184 190|ankyrin
P08208540A0417|215 230|carboxy-terminus
P08208540A0417|243 262|seventh ankyrin repeat
P08208540A0417|250 256|ankyrin
P08208540A1114|0 29|Transient co-transfection assays
P08208540A1114|39 60|NFKB2 expression vectors
P08208540A1114|39 43|NFKB2
P08208540A1114|64 92|kappa B-driven reporter plasmids
P08208540A1114|64 69|kappa B
P08208540A1114|105 112|NFKB2 p85
P08208540A1114|105 109|NFKB2
P08208540A1114|110 112|p85
P08208540A1114|123 162|transcriptional repressor functions typical
P08208540A1114|165 178|normal NFKB2 p52
P08208618A1334|5 10|HR21ap
P08208618A1334|19 25|HR21Xap
P08208618A1334|44 53|inhibition
P08208618A1334|56 65|Sp1 binding
P08208618A1334|56 58|Sp1
P08209051T0000|0 27|Intravenous antibiotic therapy
P08209051T0000|30 43|cystic fibrosis
P08209423T0000|11 16|frames
P08209423T0000|24 41|nucleotide sequence
P08209423T0000|48 70|MDV-1 BamHI-D DNA fragment
P08209423T0000|83 90|splicing
P08209423T0000|93 96|mRNA
P08209423T0000|102 125|new viral glycoprotein gene
P08209772A0167|3 9|ns2 gene
P08209772A0167|21 36|open reading frame
P08209772A0167|38 40|ORF
P08209772A0167|51 71|putative nonstructural
P08209772A0167|73 74|ns
P08209772A0167|88 97|amino acids
P08209772A0167|112 124|molecular mass
P08209772A0167|127 132|32-kDa
P08212571A0597|0 14|Co-transfection
P08212571A0597|18 20|tat
P08212571A0597|31 37|plasmid
P08212571A0597|47 53|viruses
P08212571A0597|67 81|tat ORF mutations
P08212571A0597|92 103|higher levels
P08212571A0597|106 120|virus production
P08212571A0597|141 147|effects
P08212571A0597|154 160|mutants
P08212571A0597|164 174|tat specific
P08212571A0971|0 7|Analysis
P08212571A0971|13 15|gag
P08212571A0971|19 29|rev proteins
P08212571A0971|46 50|cells
P08212571A0971|72 79|proteins
P08212571A0971|87 96|detectable
P08212571A0971|99 103|cells
P08212571A0971|122 131|tat mutants
P08212571A0971|164 172|mutations
P08212571A0971|191 195|trans
P08212571A0971|201 219|tat expression vector
P08212571A0971|201 203|tat
P08212897A0404|3 23|hydrophobicity profile
P08212897A0404|29 45|methyltransferase
P08212897A0404|77 105|potential transmembrane domains
P08213235A1024|0 10|Measurement
P08213235A1024|13 16|SaO2
P08213235A1024|19 34|moderate altitude
P08213235A1024|72 82|ill newborns
P08213235A1024|85 91|infants
P08213747A0000|21 36|excess prevalence
P08213747A0000|39 69|human immunodeficiency virus type 1
P08213747A0000|39 68|human immunodeficiency virus type
P08213747A0000|71 75|HIV-1
P08213747A0000|88 94|US black
P08213747A0000|98 126|Hispanic homosexual men relative
P08213747A0000|129 136|white men
P08213747A0000|153 163|differences
P08213747A0000|166 188|sociodemographic factors
P08213747A0000|207 225|transmitted diseases
P08213747A0000|238 254|drug-use behaviors
P08213747A0000|259 265|authors
P08213747A0000|276 298|cross-sectional analysis
P08213747A0000|301 327|baseline HIV-1 seroprevalence
P08213747A0000|331 346|HIV-1 risk factors
P08213747A0000|357 373|non-Hispanic white
P08213747A0000|378 390|Hispanic white
P08213747A0000|398 415|black homosexual men
P08213747A0000|424 430|centers
P08213747A0000|436 447|United States
P08213747A0000|449 468|Baltimore/Washington
P08213747A0000|470 471|DC
P08213747A0000|473 482|Pittsburgh
P08213747A0000|484 490|Chicago
P08213747A0000|495 504|Los Angeles
P08216115A0158|3 10|patients
P08216115A0158|24 44|intrauterine catheters
P08216115A0158|56 63|oxytocin
P08216115A0158|87 100|75th percentile
P08216115A0158|103 117|uterine activity
P08216115A0158|128 150|spontaneous normal labour
P08216115A0158|162 167|parity
P08217862A1336|25 47|rat conditioning paradigm
P08217862A1336|96 119|sympathetic nerve activity
P08217862A1336|129 141|awake subjects
P08217862A1336|148 158|large number
P08217862A1336|168 190|available genetic strains
P08217862A1336|202 224|human pathological states
P08218056A0000|3 16|ultrastructure
P08218056A0000|19 32|retinal vessels
P08218056A0000|51 54|eyes
P08218056A0000|59 74|diabetic patients
P08218056A0000|81 84|eyes
P08218056A0000|89 103|control subjects
P08218230A1505|3 18|regulatory region
P08218230A1505|27 41|sequence similar
P08218230A1505|47 57|binding site
P08218230A1505|62 94|liver-specific transcription factor
P08218230A1505|96 119|hepatocyte nuclear factor 1
P08218230A1505|96 118|hepatocyte nuclear factor
P08218230A1505|121 125|HNF-1
P08218230A1505|130 138|positions
P08218230A1920|22 34|GRE sufficient
P08218230A1920|47 76|full glucocorticoid inducibility
P08218230A1920|82 95|HNF-1 site close
P08218230A1920|82 90|HNF-1 site
P08218230A1920|101 108|promoter
P08218230A1920|116 132|major determinants
P08218230A1920|135 156|transcriptional control
P08218230A1920|162 194|Xenopus fibrinogen B beta subunit gene
P08218230A1920|197 201|cells
P08218230A1920|206 222|normal liver tissue
P08219072A0287|0 3|Acad
P08219081A0000|3 12|PRB-1b gene
P08219081A0000|24 42|basic-type component
P08219081A0000|48 84|pathogenesis-related PR-1 protein family
P08219227A0830|0 10|Replacement
P08219227A0830|16 18|CRE
P08219227A0830|24 33|second copy
P08219227A0830|39 46|AP-1 site
P08219227A0830|64 96|transcriptional activity comparable
P08219227A0830|110 126|wild-type sequence
P08219227A0830|147 154|AP-1 site
P08219227A0830|160 162|CRE
P08220494A0231|3 15|T-cyt promoter
P08220494A0231|27 41|bacterial origin
P08220494A0231|52 57|planta
P08220494A0231|64 79|30 bp cyt-1 element
P08220494A0231|66 79|bp cyt-1 element
P08220494A0231|82 88|located
P08220494A0231|120 140|T-cyt promotor activity
P08220494A0231|120 132|T-cyt promotor
P08220494A0231|155 163|root cells
P08220494A0231|166 178|tobacco plants
P08220621T0000|9 19|manuscripts
P08220621T0000|33 47|efficient system
P08221251A0239|13 14|CT
P08221251A0239|21 30|preferable
P08221251A0239|44 49|tumors
P08222384A0455|0 4|SIN-1
P08222384A0455|30 47|ischemic parameters
P08222384A0455|53 76|surface electrocardiogram
P08222384A0455|78 80|ECG
P08222384A0455|87 102|intracoronary ECG
P08222556T0000|0 5|Effect
P08222556T0000|8 12|aging
P08222556T0000|15 40|respiratory skeletal muscles
P08222618A0000|3 23|BASIC computer programs
P08222618A0000|29 47|logit transformation
P08222618A0000|64 77|S-shaped curves
P08223425T0000|3 15|yeast SSS1 gene
P08223425T0000|30 58|secretory protein translocation
P08223425T0000|91 110|endoplasmic reticulum
P08223554A0574|3 9|lengths
P08223554A0574|15 38|complete polypeptide chain
P08223554A0574|44 60|recombinant enzyme
P08223554A0574|67 80|transit peptide
P08223554A0574|92 99|residues
P08223576A1261|12 20|H4PteGlun
P08223576A1261|31 38|T protein
P08223576A1261|44 65|experimental conditions
P08223576A1261|82 90|H4PteGlun
P08223576A1261|117 124|T protein
P08223592A0424|0 3|TATA
P08223592A0424|7 16|CCAAT boxes
P08223592A0424|20 31|located 34-bp
P08223592A0424|35 39|68-bp
P08223592A0424|54 61|upstream
P08223592A0424|67 88|transcription start site
P08223592A0424|96 113|untranslated leader
P08223592A0424|118 128|nucleotides
P08223592A0424|140 153|intronless gene
P08223592A0424|167 195|different polyadenylation sites
P08223613A0105|0 3|GGS1
P08223613A0105|9 16|same gene
P08223613A0105|19 22|TPS1
P08223613A0105|52 58|subunit
P08223613A0105|64 111|trehalose-6-phosphate synthase/phosphatase complex
P08223613A0105|119 125|allelic
P08223613A0105|131 134|fdp1
P08223613A0105|136 139|byp1
P08223613A0105|141 144|glc6
P08223613A0105|148 160|cif1 mutations
P08223613A0519|38 55|homologous products
P08223613A0519|61 77|S. cerevisiae genes
P08223613A0519|73 81|genes TPS2
P08223613A0519|78 81|TPS2
P08223613A0519|85 88|TSL1
P08223613A0519|104 117|larger subunits
P08223613A0519|123 146|trehalose synthase complex
P08223613A0519|155 167|TSL1 homologue
P08223613A0519|169 172|TPS3
P08223613A0519|176 190|unknown function
P08223823T0000|0 17|Stroop interference
P08223823T0000|19 30|aging effects
P08223823T0000|46 65|Stroop Color-Word Test
P08223875A0711|0 10|Stimulation
P08223875A0711|14 15|3H
P08223875A0711|17 28|PA production
P08223875A0711|33 48|CD3 cross-linking
P08223875A0711|33 35|CD3
P08223875A0711|54 59|% lower
P08223875A0711|62 78|permeabilized CD45
P08223875A0711|75 78|CD45
P08223875A0711|80 84|cells
P08223875A0711|91 95|CD45+
P08223875A0711|91 94|CD45
P08223875A0711|96 100|cells
P08223875A0711|136 141|p59fyn
P08223875A0711|144 147|CD45
P08223875A0711|149 153|cells
P08224260A1248|0 9|CONCLUSION
P08224260A1248|35 61|transvaginal ultrasonography
P08224260A1248|81 81|%
P08224260A1248|99 111|endometriomas
P08224260A1248|116 133|other ovarian masses
P08224260A1248|139 149|specificity
P08224260A1248|154 154|%
P08224907A0000|0 26|Genomic Southern blot analysis
P08224907A0000|29 35|rat EFIA
P08224907A0000|37 62|gene encoding enhancer factor
P08224907A0000|64 71|subunit A
P08224907A0000|81 98|complex band pattern
P08224907A0000|103 123|cDNA subfragment probes
P08225657A0000|11 19|ibopamine
P08225657A0000|23 32|furosemide
P08225657A0000|38 45|patients
P08225657A0000|50 59|NYHA Class I
P08225657A0000|63 76|II heart failure
P08225657A0000|91 98|parallel
P08225657A0000|100 111|double-blind
P08225657A0000|123 157|placebo-controlled multi-centre trial
P08226616A0000|3 11|nit-3 gene
P08226616A0000|17 49|filamentous fungus Neurospora crassa
P08226616A0000|57 72|nitrate reductase
P08226616A0000|77 82|enzyme
P08226616A0000|100 108|first step
P08226616A0000|111 129|nitrate assimilation
P08226776A0990|26 41|two-state process
P08226776A0990|55 72|delta Hcalorimetric
P08226776A0990|75 82|delta Hva
P08226777A0936|1 25|Dictyostelium transformant
P08226777A0936|40 45|DdPTPa
P08226780A0160|4 8|motif
P08226780A0160|30 48|protein interactions
P08226780A0160|60 66|ankyrin
P08226780A0160|75 108|several other repeat-bearing proteins
P08226794A0501|1 5|Ala85
P08226794A0501|7 8|Dk
P08226794A0501|23 44|full biological activity
P08226798A1124|15 24|CaM binding
P08226798A1124|15 17|CaM
P08226798A1124|27 45|HIV envelope proteins
P08226798A1124|61 84|diverse modulatory effects
P08226798A1124|104 126|HIV-induced cytotoxicity
P08226798A1124|145 154|inhibition
P08226798A1124|157 186|CaM-regulated cellular functions
P08226798A1124|157 159|CaM
P08226956A1397|10 23|apparent effect
P08226956A1397|26 42|growth temperature
P08226956A1397|48 65|steady-state levels
P08226956A1397|68 75|fad7 mRNA
P08226956A1397|78 91|wild type plants
P08227129T0000|3 27|major myosin-binding domain
P08227129T0000|8 27|myosin-binding domain
P08227129T0000|30 49|skeletal muscle MyBP-C
P08227129T0000|51 58|C protein
P08227129T0000|72 84|COOH-terminal
P08227129T0000|86 106|immunoglobulin C2 motif
P08228805A0540|1 23|second important molecule
P08228805A0540|26 46|TCR signal transduction
P08228805A0540|26 28|TCR
P08228805A0540|52 82|guanine nucleotide binding protein
P08228805A0540|84 89|p21ras
P08228805A0540|110 112|TCR
P08228805A0540|116 154|protein tyrosine kinase dependent mechanism
P08228805A0540|116 136|protein tyrosine kinase
P08228997A0866|3 9|results
P08228997A0866|22 49|periseizure lipid accumulation
P08228997A0866|61 79|cortical oxygenation
P08229102A0768|17 33|QLMI questionnaire
P08229102A0768|37 49|good potential
P08229102A0768|76 77|QL
P08229102A0768|80 95|post-AMI patients
P08229102A0768|122 138|self-administered
P08229330A0000|0 10|Most smokers
P08229330A0000|28 34|smoking
P08229826A1145|3 20|inhibitory response
P08229826A1145|23 26|taps
P08229826A1145|41 56|protective reflex
P08229826A1145|100 117|jaw-closing muscles
P08229826A1145|144 154|hard objects
P08230418A0812|11 13|nef
P08230418A0812|30 32|LTR
P08230418A0812|48 50|nef
P08230418A0812|80 92|simian virus 40
P08230418A0812|80 90|simian virus
P08230418A0812|94 98|c-fms
P08230418A0812|100 128|urokinase plasminogen activator
P08230418A0812|137 159|acid phosphatase promoter
P08230418A0812|161 184|trans-activating activity
P08230418A0812|205 220|frameshift mutant
P08230418A0812|245 254|amino acids
P08230445A0000|15 33|vpr open reading frame
P08230445A0000|36 66|human immunodeficiency virus type 1
P08230445A0000|36 65|human immunodeficiency virus type
P08230445A0000|68 72|HIV-1
P08230445A0000|77 82|15-kDa
P08230445A0000|84 103|arginine-rich protein
P08230445A0000|119 125|virions
P08230445A0000|128 152|molar quantities equivalent
P08230445A0000|161 163|Gag
P08230452A0551|3 56|recombinant vaccinia virus-expressed mutant P1 polyproteins
P08230452A0551|72 99|proteolytic processing defects
P08230452A0551|102 106|cells
P08230452A0551|122 145|recombinant vaccinia virus
P08230452A0551|147 150|VVP3
P08230452A0551|168 188|poliovirus 3CD protease
P08230452A0551|208 222|assembly defects
P08230452A0551|231 256|trans complementation system
P08230452A0551|264 302|P1-expressing recombinant vaccinia viruses
P08230452A0551|310 324|capsid precursor
P08230452A0551|328 352|defective poliovirus genome
P08230452A0551|371 394|functional capsid proteins
P08230452A0551|381 394|capsid proteins
P08230452A0551|396 397|D.
P08230452A1489|11 24|capsid proteins
P08230452A1489|39 49|P1 precursor
P08230452A1489|55 72|valine substitution
P08230452A1489|78 90|amino terminus
P08230452A1489|93 95|VP1
P08230452A1489|97 105|VP1-G001V
P08230452A1489|116 135|empty capsid particles
P08230452A1489|143 151|deficient
P08230452A1489|164 184|RNA-containing virions
P08231398A0802|0 6|RESULTS
P08231398A0802|14 23|moth period
P08231398A0802|43 63|positive blood cultures
P08231398A0802|68 88|significant isolations
P08231398A0802|92 99|episodes
P08231398A0802|102 111|bacteremia
P08231398A0802|114 127|M. tuberculosis
P08231398A0802|143 156|prison patients
P08231398A0802|172 197|human immunodeficiency virus
P08231398A0802|212 234|severe immunosuppression
P08231398A0802|242 245|CD4 =
P08231398A0802|242 244|CD4
P08231398A0802|258 258|l
P08231577A1027|0 3|Acid
P08231577A1027|18 23|larynx
P08231577A1027|34 40|rabbits
P08231577A1027|51 72|significant obstructive
P08231577A1027|85 94|mixed apnea
P08231816A1473|7 27|total-protein extracts
P08231816A1473|32 38|mycelia
P08231816A1473|49 77|penicillin producing conditions
P08231816A1473|93 111|DNA-binding activity
P08231816A1473|135 157|promoter fragment located
P08231816A1473|187 193|IPNS tsp
P08232304A1166|12 20|deletions
P08232304A1166|59 61|TSS
P08232304A1166|68 90|highest promoter activity
P08232304A1166|107 113|greater
P08232304A1166|121 173|promoterless chloramphenicol acetyltransferase construct
P08232412A1342|3 12|lemdr1 gene
P08232412A1342|27 49|expression vector pALTNEO
P08232412A1342|68 87|wild-type L. enriettii
P08232412A1342|114 118|cells
P08232412A1342|123 131|resistant
P08232412A1342|134 144|vinblastine
P08232412A1342|150 160|lower levels
P08232412A1342|178 188|mutant cells
P08234166A0425|3 17|bioavailability
P08234166A0425|20 27|etodolac
P08234166A0425|32 39|capsules
P08234166A0425|49 66|stressed conditions
P08234166A0425|84 87|dogs
P08234166A0425|91 96|humans
P08234166A0425|99 106|capsules
P08234166A0425|115 126|RT conditions
P08234276A0556|0 27|Similar synergistic activation
P08234276A0556|44 55|IL-8 promoter
P08234276A0556|78 83|NF-IL6
P08234276A0556|87 107|NF-kappa B binding sites
P08234308T0000|0 5|Notice
P08234308T0000|8 17|retraction
P08237112A0553|2 9|homology
P08237112A0553|28 37|36K protein
P08237112A0553|41 55|known structures
P08237112A0553|58 65|proteins
P08237171A0000|10 16|odd case
P08237171A0000|19 35|marked enlargement
P08237171A0000|38 54|suprapineal recess
P08237171A0000|69 95|triventricular hydrocephalus
P08237578A0253|9 23|lipid metabolism
P08237578A0253|28 37|mean values
P08237578A0253|41 58|total triglycerides
P08237578A0253|72 86|LDL-cholesterol
P08237578A0253|90 104|HDL-cholesterol
P08237578A0253|123 127|years
P08237578A0253|130 145|Norplant-2 rod use
P08237578A0253|152 168|months postremoval
P08237578A0253|185 200|preinsertion mean
P08238626A0248|3 7|PaCO2
P08238626A0248|12 15|mmHg
P08238626A0248|17 32|baseline brain pHi
P08238626A0248|58 82|regional cortical blood flow
P08238626A0248|96 97|ml
P08238626A0248|102 104|g-1
P08238626A0248|106 110|min-1
P08239164A0551|0 3|CPAP
P08239164A0551|11 17|isotime
P08239164A0551|31 46|last common minute
P08239164A0551|58 60|VO2
P08239164A0551|64 70|dyspnea
P08239164A0551|78 85|patients
P08239164A0551|94 110|severe lung disease
P08239164A0551|120 125|values
P08239164A0551|155 162|patients
P08239164A0551|171 185|mild lung disease
P08239586T0000|0 6|Effects
P08239586T0000|9 17|diltiazem
P08239586T0000|20 51|netilmicin-induced nephrotoxicity
P08239586T0000|54 60|rabbits
P08240170A0000|4 8|forms
P08240170A0000|11 23|salmonellosis
P08240170A0000|40 47|feedlots
P08240170A0000|72 82|septicaemic
P08240170A0000|87 91|acute
P08240170A0000|93 100|subacute
P08240170A0000|104 117|chronic enteric
P08241139A0378|7 7|%
P08241139A0378|10 34|single-stranded DNA binding
P08241139A0378|61 66|MgdTDP
P08241139A0378|78 87|detectable
P08241139A0378|102 112|nucleotides
P08241656A0189|23 31|first case
P08241656A0189|40 58|probable association
P08241656A0189|66 79|cholelithiasis
P08241656A0189|83 93|Wildervanck
P08242861A0368|4 14|4,8-DiMeIQx
P08242861A0368|18 24|A alpha C
P08242861A0368|38 43|p.p.b.
P08243476A1177|5 12|cysteine
P08243476A1177|20 37|tryptophan residues
P08243476A1177|77 99|nitrous-oxide reductases
P08243476A1177|114 129|Paracoccus enzyme
P08244034T0000|0 43|Recombinant Leishmania surface glycoprotein GP63
P08244034T0000|28 43|glycoprotein GP63
P08244034T0000|59 85|baculovirus expression system
P08244034T0000|89 111|latent metalloproteinase
P08244034T0000|95 111|metalloproteinase
P08245013A0000|14 27|molecular basis
P08245013A0000|31 60|agonist-induced destabilization
P08245013A0000|63 66|mRNA
P08245013A0000|69 93|G-protein-linked receptors
P08245013A0000|111 133|receptor down-regulation
P08245013A0000|167 185|long-term regulation
P08245013A0000|188 196|receptors
P08245013A0000|199 205|agonist
P08245125A0822|0 7|Addition
P08245125A0822|10 43|phalloidin-stabilized F-actin nuclei
P08245125A0822|31 37|F-actin
P08245125A0822|47 56|phalloidin
P08245125A0822|65 74|L266D actin
P08245125A0822|99 107|degrees C.
P08245456A0501|5 9|cells
P08245456A0501|18 25|low level
P08245456A0501|28 31|IL-5
P08245456A0501|50 52|PMA
P08245456A0501|67 68|N6
P08245456A0501|70 85|O2-dibutyryl cAMP
P08245456A0501|87 93|Bt2cAMP
P08245456A0501|113 115|PMA
P08245456A0501|146 159|IL-5 production
P08245456A0501|146 149|IL-5
P08245456A0501|165 168|mRNA
P08245456A0501|175 187|protein levels
P08245461A0700|0 21|Hu-Met-1 mRNA expression
P08245461A0700|0 11|Hu-Met-1 mRNA
P08245461A0700|25 35|small number
P08245461A0700|38 57|human T cell tumor lines
P08245461A0700|80 98|particular phenotype
P08245933A0617|0 17|Partial engorgement
P08245933A0617|21 26|higher
P08245933A0617|32 41|treatments
P08246984A0512|0 7|Northern
P08246984A0512|9 11|RNA
P08246984A0512|45 59|human PI 3-kinase
P08246984A0512|65 71|tissues
P08246984A0512|75 83|cell lines
P08246984A0923|5 11|results
P08246984A0923|37 63|different PI 3-kinase isoforms
P08246984A0923|46 63|PI 3-kinase isoforms
P08246984A0923|82 86|genes
P08246984A0923|95 129|distinct PI 3-kinase catalytic subunits
P08246984A0923|103 112|PI 3-kinase
P08246984A0923|150 152|p85
P08246987A0260|15 42|protein-tyrosine kinase domain
P08246987A0260|44 49|p56lck
P08246987A0260|59 69|Src homology
P08246987A0260|76 78|SH2
P08246987A0260|82 84|SH3
P08246987A0260|86 92|domains
P08246987A0260|102 123|unique N-terminal region
P08247005A0584|0 6|Strains
P08247005A0584|17 35|drs2 mutation process
P08247005A0584|17 28|drs2 mutation
P08247005A0584|39 50|20S precursor
P08247005A0584|56 68|mature 18S rRNA
P08247005A0584|81 89|deficient
P08247005A0584|92 111|40S ribosomal subunits
P08247043T0000|0 9|Hepatitis B
P08247043T0000|13 32|liver transplantation
P08248246A0838|29 31|Sp1
P08248246A0838|56 78|S-phase-specific binding
P08248246A0838|91 100|direct role
P08248246A0838|106 141|cell-cycle-dependent R1 gene expression
P08248253A1785|5 24|combined observations
P08248253A1785|32 39|promoter
P08248253A1785|45 52|enhancer
P08248253A1785|59 74|chicken L-CAM gene
P08248688A0726|9 26|enzymic stimulation
P08248688A0726|42 48|nitrate
P08248688A0726|87 98|NO production
P08248688A0726|106 120|nitrate molecule
P08249319A0578|0 7|Clipping
P08249319A0578|19 40|serious mislocalization
P08249319A0578|68 92|epicortical potential field
P08249390A0111|3 10|duration
P08249390A0111|13 28|diabetes mellitus
P08249390A0111|36 43|patients
P08249390A0111|52 57|months
P08249390A0111|61 65|years
P08249390A0111|75 82|patients
P08249390A0111|93 117|first myocardial infarction
P08251506A0503|3 16|247-kDa complex
P08251506A0503|36 63|distinct protein-DNA complexes
P08251506A0503|88 90|kDa
P08251506A0503|107 114|proteins
P08251506A0503|140 163|single DRE oligonucleotide
P08251506A0503|183 198|115-kDa complexes
P08251506A0503|208 235|single protein-DRE cross-links
P08251622A0000|3 10|promoter
P08251622A0000|14 27|upstream region
P08251622A0000|33 69|Brassica napus 2S storage protein napA gene
P08251622A0000|91 109|cis-acting sequences
P08251622A0000|120 155|developmental seed-specific expression
P08252067A0917|8 25|limited comparisons
P08252067A0917|32 38|domains
P08252067A0917|44 46|NH2
P08252067A0917|50 60|COOH termini
P08252067A0917|70 79|high degree
P08252067A0917|102 123|functional conservation
P08252976A0467|0 4|Rinit
P08252976A0467|16 35|Newtonian resistances
P08252976A0467|39 43|Rdiff
P08252976A0467|57 102|viscoelastic/inhomogeneous pressure dissipations
P08253386A0800|39 65|fibronectin splicing enhancer
P08253386A0800|81 89|SE element
P08253386A0800|103 119|efficient assembly
P08253386A0800|122 143|early splicing complexes
P08253386A0800|158 177|efficient interaction
P08253386A0800|183 189|U2 snRNP
P08253386A0800|194 212|branch site sequences
P08253387A0801|0 9|Inspection
P08253387A0801|12 26|enhancer mutants
P08253387A0801|39 54|trans-activation
P08253387A0801|57 65|hLEF/GAL4
P08253387A0801|57 60|hLEF
P08253387A0801|62 65|GAL4
P08253387A0801|89 93|TCF-2
P08253387A0801|96 125|distinct T-cell-enriched protein
P08253387A0801|137 145|sequences
P08253387A0801|157 172|hLEF-binding site
P08253387A0801|178 185|enhancer
P08253387A1291|14 22|sequences
P08253387A1291|35 44|hLEF HMG box
P08253387A1291|60 85|context-specific activation
P08253387A1291|91 106|TCR alpha enhancer
P08253387A1291|123 134|interactions
P08253387A1291|142 145|hLEF
P08253387A1291|149 175|other T-cell-specific factors
P08253387A1291|190 197|enhancer
P08253777A0301|1 19|cAMP response element
P08253777A0301|21 23|CRE
P08253777A0301|25 39|consensus signal
P08253777A0301|61 75|noncoding region
P08253777A0301|77 80|cAMP
P08253777A0301|105 113|Kv1.5 gene
P08253777A0301|105 107|Kv1
P08253777A0301|117 135|cell-specific manner
P08253958A0000|9 24|serological tests
P08253958A0000|47 93|Helicobacter pylori-specific serum immunoglobulin G
P08253958A0000|95 97|IgG
P08254738A0428|14 28|mutant T antigens
P08254738A0428|40 63|recombinant baculoviruses
P08254738A0428|66 73|Sf9 cells
P08254738A0428|103 112|activities
P08254738A0428|119 123|TS677
P08254738A0428|131 135|TS677
P08254738A0428|161 175|T-antigen kinase
P08254738A0428|181 197|wild-type T antigen
P08255022A0827|11 23|hypoperfusion
P08255022A0827|54 57|FEV1
P08255022A0827|60 60|%
P08255022A0827|62 64|V25
P08255022A0827|68 71|PaO2
P08255022A0827|96 106|blood volume
P08255022A0827|110 137|peripheral red blood cell counts
P08255341A0554|3 10|patients
P08255341A0554|52 64|metronidazole
P08255341A0554|67 82|tissue amoebicide
P08255341A0554|87 96|diloxanide
P08255341A0554|99 115|lumenal amoebicide
P08255758A0000|23 40|untranslated region
P08255758A0000|46 75|Drosophila copia retrotransposon
P08255758A0000|61 75|retrotransposon
P08255758A0000|84 90|left LTR
P08255758A0000|104 128|transcriptional regulation
P08255758A0000|131 143|homeoproteins
P08257666A0662|5 16|present study
P08257666A0662|18 24|lesions
P08257666A0662|30 39|OPT complex
P08257666A0662|44 57|thalamic source
P08257666A0662|60 68|afferents
P08257666A0662|71 73|IHA
P08257666A0662|77 78|HD
P08257666A0662|105 137|color-reversal learning performance
P08257754A0711|3 12|fourth dose
P08257754A0711|21 36|favorable results
P08257754A0711|42 42|%
P08257754A0711|46 56|individuals
P08257754A0711|61 72|HB antibodies
P08257754A0711|88 92|IU/ml
P08257754A0711|96 110|unfavorable ones
P08257754A0711|115 115|%
P08257754A0711|125 136|HB antibodies
P08257754A0711|148 152|IU/ml
P08258025A1131|0 10|CONCLUSIONS
P08258025A1131|17 24|patients
P08258025A1131|44 61|treatment variables
P08258025A1131|74 87|Karnofsky index
P08258025A1131|92 115|graft-versus-host disease
P08258025A1131|126 141|important factors
P08258025A1131|153 166|early mortality
P08259650A0640|0 25|Nucleotide sequence analysis
P08259650A0640|31 36|HA gene
P08259650A0640|47 53|mutants
P08259650A0640|66 67|HA
P08259650A0640|69 77|phenotype
P08260635A0926|4 9|intron
P08260635A0926|57 62|intron
P08260635A0926|69 88|transit peptide region
P08260635A0926|91 111|chloroplast GAPDH genes
P08260635A0926|113 116|GapA
P08260635A0926|120 123|GapB
P08260635A0926|127 138|higher plants
P08261398A0392|3 35|drug-resistant cell lines P388/ADR/3
P08261398A0392|39 48|P388/ADR/7
P08261398A0392|66 69|topo
P08261398A0392|72 90|alpha mRNA transcript
P08261398A0392|106 128|native transcript present
P08261398A0392|134 161|drug-sensitive P388/4 cell line
P08261398A0838|9 26|rapid amplification
P08261398A0838|29 32|cDNA
P08261398A0838|58 62|cDNAs
P08261398A0838|81 87|termini
P08261398A0838|106 122|mutant transcripts
P08261398A0838|131 140|P388/ADR/3
P08261398A0838|144 158|P388/ADR/7 cells
P08262041A0727|3 14|phi AP3 factor
P08262041A0727|18 38|nuclear phosphoprotein
P08262041A0727|54 68|phosphorylation
P08262041A0727|89 97|cell cycle
P08262054A0565|13 39|N-terminal cytoplasmic domain
P08262054A0565|45 67|latent membrane protein 2A
P08262054A0565|69 73|LMP2A
P08262054A0565|80 101|Epstein-Barr virus (EBV)
P08262054A0565|80 96|Epstein-Barr virus
P08262054A0565|98 100|EBV
P08262054A0565|111 120|single copy
P08262054A0565|126 136|Tyr-X-X-Leu
P08262054A0565|138 156|Ile-containing motif
P08262054A0565|172 183|critical role
P08262054A0565|186 204|B cell transformation
P08262067A1608|3 20|functional homology
P08262067A1608|23 26|Cwg2
P08262067A1608|31 35|Cdc43
P08262067A1608|73 84|cell polarity
P08262067A1608|109 131|morphogenetic events such
P08262067A1608|149 160|cell polarity
P08262067A1608|164 183|cell wall biosynthesis
P08263933T0000|0 15|Molecular cloning
P08263933T0000|19 34|P-type ATPase gene
P08263933T0000|42 70|cyanobacterium Synechocystis sp
P08264579A1209|3 9|cloning
P08264579A1209|12 15|PTR2
P08264579A1209|29 40|first example
P08264579A1209|46 77|molecular genetic characterization
P08264579A1209|81 110|eucaryotic peptide transport gene
P08264582A0750|10 37|full-length cytoplasmic domain
P08264582A0750|41 47|mutants
P08264582A0750|52 87|progressive carboxy-terminal deletions
P08264582A0750|89 105|internal deletions
P08264582A0750|109 122|point mutations
P08264582A0750|147 163|amino acid residues
P08264582A0750|166 169|LIFR
P08264582A0750|175 196|minimal region necessary
P08264582A0750|200 208|signaling
P08264583A0520|12 27|biochemical basis
P08264583A0520|44 58|nuclear extracts
P08264583A0520|76 86|wide variety
P08264583A0520|89 106|mammalian cell lines
P08264583A0520|137 157|test plasmid substrates
P08264591A1190|24 37|largest subunit
P08264591A1190|40 54|RNA polymerase II
P08264591A1190|40 52|RNA polymerase
P08264591A1190|58 62|TFIIB
P08264591A1190|66 86|important determinants
P08264591A1190|89 119|transcription start site selection
P08264591A1190|204 211|proteins
P08264617A0000|0 20|Recombinant expression
P08264617A0000|24 40|chimeric EGFR/ErbB
P08264617A0000|32 35|EGFR
P08264617A0000|37 50|ErbB-3 receptor
P08264617A0000|43 50|receptor
P08264617A0000|53 69|NIH 3T3 fibroblasts
P08264617A0000|92 108|cytoplasmic events
P08264617A0000|123 146|ErbB-3 signal transduction
P08264617A0000|123 128|ErbB-3
P08264617A0000|151 166|ligand activation
P08264628A0418|0 25|Oligonucleotide competitors
P08264628A0418|47 59|accessibility
P08264628A0418|65 80|TATA-binding site
P08264628A0418|83 88|TIF-IB
P08264628A0418|90 94|TFIID
P08264628A0418|99 104|TFIIIB
P08264631A0746|3 18|227-to-239 region
P08264631A0746|26 37|ADR1 activity
P08264631A0746|26 29|ADR1
P08264631A0746|56 65|TAD present
P08264631A0746|56 58|TAD
P08264631A0746|68 71|ADR1
P08264631A0746|73 86|ADR1 DNA binding
P08264631A0746|91 119|specific ADH2 promoter sequences
P08264650A0925|0 7|Analysis
P08264650A0925|10 16|strains
P08264650A0925|28 43|mds1 null mutation
P08264650A0925|60 63|MDS1
P08264650A0925|84 105|normal vegetative growth
P08264650A0925|131 137|meiosis
P08264664A0128|0 7|TGF beta 1
P08264664A0128|0 6|TGF beta
P08264664A0128|42 64|AP-1 binding sites located
P08264664A0128|70 87|different promoters
P08265602T0000|0 2|Val
P08265602T0000|6 17|Ala mutations
P08265602T0000|34 51|helix-helix packing
P08265602T0000|57 76|transmembrane segment
P08265602T0000|79 97|phage M13 coat protein
P08265955T0000|0 14|Strategic change
P08265955T0000|20 22|NHS
P08267658A0391|9 25|expensive solution
P08267658A0391|30 31|UW
P08267658A0391|47 47|K
P08267658A0391|52 63|lactobionate
P08267658A0391|65 70|KH2PO4
P08267658A0391|72 76|MgSO4
P08267658A0391|80 88|raffinose
P08267658A0391|114 125|preservation
P08267658A0391|128 141|rat hepatocytes
P08267658A0391|147 148|hr
P08267658A0391|152 171|drug transport studies
P08267667A0748|0 21|Repeated administration
P08267667A0748|24 27|GRg2
P08267667A0748|30 34|mg/kg
P08267667A0748|63 94|CYP-induced recognitional deficits
P08267667A0748|63 65|CYP
P08267667A0748|110 126|CYP-decreased rate
P08267667A0748|110 112|CYP
P08267667A0748|155 155|d
P08267667A0748|157 175|learning acquisition
P08267667A0748|177 177|F
P08267667A0748|184 184|=
P08267667A0748|189 189|p
P08267667A0748|227 244|h memory acquisition
P08267667A0748|246 246|F
P08267667A0748|253 253|=
P08267667A0748|258 258|p
P08267667A0748|298 313|h memory retention
P08267667A0748|315 315|F
P08267667A0748|327 327|p
P08267667A0748|372 387|h memory retrieval
P08267667A0748|389 389|F
P08267667A0748|396 396|=
P08267667A0748|401 401|p
P08268718A0676|0 15|Human bcl3 protein
P08268718A0676|38 40|p50
P08268718A0676|42 55|2-DNA complexes
P08268833T0000|3 19|therapeutic action
P08268833T0000|22 33|cyclosporin A
P08268833T0000|35 43|Sandimmun
P08268833T0000|62 80|rheumatoid arthritis
P08268912A0657|7 28|translation experiments
P08268912A0657|37 55|human cDNA derived RNA
P08268912A0657|37 45|human cDNA
P08268912A0657|53 55|RNA
P08268912A0657|83 90|mobility
P08268912A0657|98 99|kD
P08268912A0657|102 122|SDS polyacrylamide gels
P08269424A0339|5 28|peripheral administration
P08269424A0339|35 37|CRF
P08269424A0339|41 43|TRH
P08269424A0339|45 54|ACTH levels
P08269424A0339|45 48|ACTH
P08269424A0339|72 77|higher
P08269424A0339|83 91|tumor side
P08269424A0339|97 104|patients
P08269439X0000|0 19|Pentazocine analgesia
P08269439X0000|29 33|niche
P08269439X0000|37 44|Talwin Nx
P08269439X0000|46 56|Pentazocine
P08269439X0000|63 82|useful analgesic agent
P08269439X0000|101 115|acute dental pain
P08270257A0551|1 24|sequence homology analysis
P08270257A0551|32 43|human nm23-H1
P08270257A0551|50 60|homolog gene
P08270257A0551|70 78|NDP-K beta
P08270257A0551|89 109|exon-intron boundaries
P08270580A0155|1 18|favourable response
P08270580A0155|48 60|amphotericin B
P08270580A0155|64 76|cotrimoxazole
P08270985A0590|0 16|Response durations
P08273122A0708|0 6|RESULTS
P08273122A0708|27 38|QA/QI process
P08273122A0708|40 49|monitoring
P08273122A0708|52 79|blood administration practices
P08273122A0708|93 100|variance
P08273122A0708|105 142|institutional blood administration policy
P08273122A0708|159 165|percent
P08273122A0708|176 196|component transfusions
P08274774A0958|11 21|REP21 plants
P08274774A0958|26 34|resistant
P08274774A0958|48 57|broad range
P08274774A0958|60 72|tobamoviruses
P08274774A0958|82 98|tomato mosaic virus
P08274774A0958|100 126|tobacco mild green mosaic virus
P08274774A0958|128 133|TMV-U5
P08274774A0958|135 164|green tomato atypical mosaic virus
P08274774A0958|169 187|ribgrass mosaic virus
P08275618A0457|0 9|Drug effect
P08275618A0457|21 28|postural
P08275618A0457|53 60|patients
P08275618A0457|65 73|cirrhosis
P08275618A0457|77 91|control subjects
P08275618A0457|112 121|effect area
P08275618A0457|137 153|concentration area
P08275618A0457|225 232|patients
P08275618A0457|237 245|cirrhosis
P08275618A0457|252 266|control subjects
P08276234A0119|21 23|YY1
P08276234A0119|47 64|DNA-binding protein
P08276234A0119|91 103|c-fos promoter
P08276234A0119|91 95|c-fos
P08276234A0119|130 141|DNA structure
P08276336A0371|3 23|retrospective analysis
P08276336A0371|26 53|first-time total colonoscopies
P08276336A0371|59 66|patients
P08276336A0371|104 115|hyperplastic
P08276336A0371|119 135|adenomatous polyps
P08276732A0799|9 17|decrement
P08276732A0799|20 33|DPOAE amplitude
P08276732A0799|39 58|prescribed time period
P08276732A0799|82 95|susceptibility
P08276732A0799|101 114|acoustic trauma
P08276762T0000|0 5|Effect
P08276762T0000|8 30|single base substitutions
P08276762T0000|33 48|glycine-870 codon
P08276762T0000|51 76|gramicidin S synthetase 2 gene
P08276762T0000|51 71|gramicidin S synthetase
P08276762T0000|79 95|proline activation
P08276851A0347|12 24|Pay4p sequence
P08276851A0347|36 61|putative ATP-binding domains
P08276851A0347|44 61|ATP-binding domains
P08276851A0347|70 92|structural relationships
P08276851A0347|95 127|other potential ATP-binding proteins
P08276851A0347|109 127|ATP-binding proteins
P08276851A0347|138 156|biological processes
P08276851A0347|168 187|peroxisome biogenesis
P08276851A0347|189 220|vesicle-mediated protein transport
P08276851A0347|222 237|cell cycle control
P08276851A0347|242 266|transcriptional regulation
P08276854A1894|3 9|results
P08276854A1894|35 53|decorin gene promoter
P08276854A1894|78 102|other proteoglycan promoter
P08276854A1894|139 152|pur/pyr segment
P08276854A1894|180 196|gene transcription
P08276865A1188|3 30|kinase inhibitor staurosporine
P08276865A1188|33 38|microM
P08276865A1188|46 56|LPA-induced
P08276865A1188|64 92|epidermal growth factor-induced
P08276865A1188|64 84|epidermal growth factor
P08276865A1188|94 103|activation
P08276865A1188|106 111|p21ras
P08276865A1188|115 123|MAP kinase
P08276865A1188|141 165|intermediate protein kinase
P08276865A1188|176 186|LPA receptor
P08276865A1188|189 204|p21ras activation
P08276865A1188|189 194|p21ras
P08276871A1001|26 40|overall identity
P08276871A1001|50 50|%
P08276871A1001|77 85|% identity
P08276871A1001|106 118|transmembrane
P08276871A1001|122 139|cytoplasmic domains
P08276900A0543|0 1|S.
P08276900A0543|3 4|K.
P08277632A0997|3 14|survival rate
P08277632A0997|22 27|months
P08277632A0997|32 39|patients
P08277632A0997|44 52|N2 disease
P08277632A0997|65 76|R2b operation
P08277632A0997|82 82|%
P08278423A0147|0 6|Mothers
P08278423A0147|11 39|severe anatomical abnormalities
P08278423A0147|47 57|HIV positive
P08278423A0147|63 70|active TB
P08278423A0147|78 85|children
P08278423A0147|106 129|disaccharide intolerances
P08278480T0002|0 1|G.
P08278548A0597|3 6|psaD
P08278548A0597|8 11|psaF
P08278548A0597|13 16|psaH
P08278548A0597|21 32|psaL products
P08278548A0597|40 47|isoforms
P08278548A0597|74 92|different mobilities
P08278548A0597|95 126|polyacrylamide gel electrophoresis
P08278548A0597|134 144|psaE product
P08278548A0597|152 159|isoforms
P08278929A0866|4 24|Hy-Vac SPF type V embryos
P08278929A0866|48 49|ml
P08278929A0866|52 59|% ethanol
P08278929A0866|62 64|CRS
P08278929A0866|73 77|ml CRS
P08278929A0866|79 86|controls
P08278929A0866|89 110|ethanol-treated embryos
P08278929A0866|118 129|VSD incidence
P08278929A0866|136 136|%
P08278929A0866|153 162|% incidence
P08278929A0866|168 175|controls
P08278929A0866|177 178|P =
P08279098T0001|0 39|Peripheral vitreochorioretinal dystrophies
P08279098T0001|42 55|myopia patients
P08280476A0602|5 11|studies
P08280476A0602|23 31|HIV-1 HXB2
P08280476A0602|23 27|HIV-1
P08280476A0602|28 31|HXB2
P08280476A0602|35 56|HIV-1 Z2Z6 core enhancers
P08280476A0602|35 39|HIV-1
P08280476A0602|67 76|Z2Z6 strain
P08280476A0602|67 70|Z2Z6
P08280476A0602|81 99|single point mutation
P08280476A0602|111 130|right ETS-binding site
P08280925A0261|30 46|antibody responses
P08280925A0261|49 63|male C57Bl/6 mice
P08280925A0261|68 73|higher
P08280925A0261|79 82|mice
P08280925A0261|104 107|mice
P08280925A0261|116 121|groups
P08280925A0261|123 133|differences
P08280925A0261|153 155|IgM
P08280925A0261|159 179|IgG anti-KLH antibodies
P08281153A0543|21 30|high degree
P08281153A0543|47 61|intron sequences
P08281536A0626|0 12|Interleukin-6
P08281536A0626|34 43|metastasis
P08281536A0626|46 58|cardiac myxoma
P08281634A1801|0 14|Other parameters
P08281634A1801|17 30|iron metabolism
P08281634A1801|41 48|ferritin
P08281740A0000|0 8|Responses
P08281740A0000|14 39|Plowright Rinderpest vaccine
P08281740A0000|44 49|calves
P08281740A0000|55 65|adult cattle
P08281740A0000|68 73|Uganda
P08281740A0000|103 115|IgG antibodies
P08281740A0000|134 138|weeks
P08281740A0000|147 156|ELISA assay
P08282501A0358|12 22|small number
P08282501A0358|25 53|visceral angiography procedures
P08282501A0358|70 90|definitive conclusions
P08282501A0358|110 120|differences
P08282501A0358|128 132|ionic
P08282501A0358|136 149|nonionic agents
P08282501A0358|159 165|grade-2
P08282501A0358|169 188|grade-3 adverse events
P08282576A0297|0 6|Tumours
P08282576A0297|12 20|cavum oris
P08282576A0297|24 33|oropharynx
P08282576A0297|36 43|T1-stage
P08282576A0297|65 69|cases
P08282749A1474|0 5|Thomas
P08282749A1474|7 22|Hospital solution
P08282749A1474|30 30|%
P08282749A1474|35 38|% CO2
P08282749A1474|50 64|metabolic demand
P08282749A1474|70 88|ischaemic myocardium
P08282749A1474|107 118|safe duration
P08282749A1474|121 133|cardiac arrest
P08283292A0779|0 5|Plasma
P08283292A0779|7 28|LDL and liver cholesterol
P08283292A0779|7 9|LDL
P08283292A0779|13 42|liver cholesterol concentrations
P08283292A0779|47 52|higher
P08283292A0779|58 78|hyperlipidemic control
P08283292A0779|86 109|nonhyperlipidemic control
P08283292A0779|123 128|groups
P08283292A0779|132 136|diets
P08283292A0779|147 152|pectin
P08283292A0779|174 199|hyperlipidemic control group
P08283531A0700|3 26|Stryker frame modification
P08283531A0700|32 61|standard Dornier HM3 lithotriptor
P08283531A0700|79 91|visualization
P08283531A0700|95 112|easier localization
P08283531A0700|115 135|distal ureteral calculi
P08283531A0700|149 162|standard gantry
P08284227A0336|0 23|Glomerular mesangial cells
P08284227A0336|35 42|abundant
P08284227A0336|46 61|kb mRNA transcript
P08284227A0336|65 67|Id1
P08284227A0336|84 104|other cell types Id1 mRNA
P08284227A0336|98 104|Id1 mRNA
P08284227A0336|131 142|cycling cells
P08284227A0336|148 161|serum-deprived
P08284227A0336|163 179|quiescent cultures
P08284337A0825|0 27|Routine psychometric screening
P08284337A0825|30 40|IHD patients
P08284337A0825|52 70|cost-effective means
P08284337A0825|81 93|cardiologists
P08284337A0825|97 106|internists
P08284337A0825|122 131|high levels
P08284337A0825|134 141|distress
P08284337A0825|152 159|patients
P08285710A0634|1 26|single 1.8-kb transcript mRNA
P08285710A0634|40 47|Northern
P08285710A0634|49 51|RNA
P08285710A0634|53 64|blot analysis
P08285710A0634|77 80|maps
P08285710A0634|94 95|bp
P08285710A0634|117 126|initiation
P08285710A0634|129 144|protein synthesis
P08286035A0587|13 31|sequence information
P08286035A0587|36 40|c11/1
P08286035A0587|45 62|c11/1-specific cDNA
P08286035A0587|79 82|poly
P08286035A0587|84 84|A
P08286035A0587|87 89|RNA
P08286035A0587|92 102|bovine PMNLs
P08286035A0587|105 124|reverse transcription
P08286035A0587|142 164|polymerase chain reaction
P08286035A0587|166 168|PCR
P08286035A0587|170 176|methods
P08288240A0304|3 20|sequence similarity
P08288240A0304|37 41|SCG10
P08288240A0304|45 52|stathmin
P08288240A0304|101 112|related genes
P08288240A1343|40 63|neuron-specific SCG10 gene
P08288240A1343|73 83|duplication
P08288240A1343|87 98|modification
P08288240A1343|124 141|stathmin/Lap18 gene
P08288240A1343|124 131|stathmin
P08288240A1343|133 137|Lap18
P08288554A0295|10 26|amino acid sequence
P08288554A0295|32 44|mouse HO-1 gene
P08288554A0295|64 66|p32
P08288554A0295|90 110|stress-induced protein
P08288554A0295|113 131|mouse BALBc/3T3 cells
P08288596A0663|11 12|T3
P08288596A0663|20 20|M
P08288596A0663|43 55|transcription
P08288596A0663|60 66|rGH-TRE
P08288596A0663|60 62|rGH
P08288596A0663|71 76|TREpal
P08288596A0663|85 90|ME-TRE
P08288596A0663|95 100|F2-TRE
P08288596A0663|113 121|templates
P08288596A0663|134 137|TREs
P08288596A0663|159 176|rGH minimal promoter
P08288596A0663|194 214|TATA box binding protein
P08288596A0663|225 251|other proximal binding protein
P08288606A0240|6 42|polymerase chain reaction-based approach
P08288606A0240|53 72|150-base pair fragment
P08288606A0240|76 88|new sialymotif
P08288606A0240|93 109|human placenta mRNA
P08288606A0240|130 134|probe
P08288606A0240|137 141|clone
P08288606A0240|145 166|complete coding sequence
P08288606A0240|172 188|corresponding gene
P08288606A0240|194 204|cDNA library
P08288622A0725|3 20|structural analysis
P08288622A0725|44 56|heterogeneity
P08288622A0725|62 68|HDC mRNA
P08288622A0725|81 89|insertion
P08288622A0725|95 115|seventh intron sequence
P08288622A0725|119 132|alternative use
P08288622A0725|138 157|splicing acceptor site
P08288622A0725|163 170|12th exon
P08288633A0144|1 16|complementary DNA
P08288633A0144|32 52|Caenorhabditis elegans
P08288633A0144|65 75|polypeptide
P08288633A0144|82 98|amino acid residues
P08288633A0144|100 104|CeGAP
P08288633A0144|130 147|sequence similarity
P08288633A0144|153 172|COOH-terminal segment
P08288633A0144|174 203|GTPase-activating protein region
P08288633A0144|207 209|Bcr
P08288633A0144|213 247|other known GTPase-activating proteins
P08288633A0144|223 247|GTPase-activating proteins
P08288633A0144|253 264|Rho subfamily
P08289339A0527|0 20|Additional exonuclease
P08289339A0527|54 63|core region
P08289339A0527|80 84|sides
P08289339A0527|100 101|E1
P08289339A0527|116 134|more distal sequences
P08289341A1202|0 9|Repression
P08289341A1202|36 37|E2
P08289341A1202|50 53|E2-C
P08289341A1202|55 77|promoter-proximal copies
P08289341A1202|80 84|E2-RS
P08289342A0931|1 6|mutant
P08289342A0931|12 36|AAV terminal resolution site
P08289342A0931|38 40|trs
P08289342A0931|45 53|defective
P08289342A0931|57 70|DNA replication
P08289342A0931|83 87|assay
P08289357A0724|3 9|results
P08289357A0724|22 24|rep
P08289357A0724|54 79|negative regulatory elements
P08289357A0724|85 87|LTR
P08289593A1404|30 33|rats
P08289593A1404|49 54|MK-801
P08289593A1404|74 90|lethal cocaine dose
P08289593A1404|102 106|mg/kg
P08289593A1404|108 109|n =
P08289593A1404|116 136|vehicle pretreated rats
P08289593A1404|150 154|mg/kg
P08289593A1404|156 157|n =
P08289593A1404|175 180|MK-801
P08289593A1404|199 209|respiratory
P08289593A1404|216 230|cardiac toxicity
P08289593A1404|242 265|urethane anesthetized rats
P08289783A0000|3 7|Oct-3
P08289783A0000|10 20|gene product
P08289783A0000|39 47|POU family
P08289783A0000|50 69|transcription factors
P08289783A0000|74 86|good candidate
P08289783A0000|100 130|initial differentiation decisions
P08289783A1476|5 28|site-directed mutagenesis
P08289783A1476|43 49|RAREoct
P08289783A1476|66 90|transcriptional activation
P08289783A1476|93 97|Oct-3
P08289783A1476|100 107|promoter
P08289783A1476|110 117|P19 cells
P08289783A1476|151 170|RA-induced repression
P08289783A1476|173 196|RA-differentiated EC cells
P08289784A0381|17 18|M.
P08289793A1226|15 43|negative transcriptional effect
P08289793A1226|46 53|COUP-TFs
P08289793A1226|92 129|Oct4 embryonic stem cell-specific enhancer
P08289831A0290|0 7|Analysis
P08289831A0290|10 34|mig/CAT chimeric constructs
P08289831A0290|10 12|mig
P08289831A0290|14 16|CAT
P08289831A0290|64 66|RAW
P08289831A0290|72 93|mouse monocytic cell line
P08289831A0290|103 135|unique IFN-gamma-responsive element
P08289831A0290|109 135|IFN-gamma-responsive element
P08289831A0290|137 145|gamma RE-1
P08289834A0341|20 28|test cells
P08289834A0341|30 34|Atr-I
P08289834A0341|49 56|TGF-beta
P08289834A0341|58 64|activin
P08289834A0341|68 91|bone morphogenetic protein
P08290278A0374|10 13|Mxi1
P08290278A0374|17 19|Mad
P08290278A0374|35 45|Myc function
P08290278A0374|35 37|Myc
P08290278A0374|52 80|candidate tumor suppressor genes
P08290421A0165|21 40|renal tubular acidosis
P08290421A0165|86 91|Alport
P08290421A0165|106 117|adult patient
P08291233A0000|1 9|cDNA clone
P08291233A0000|26 49|chicken embryo cDNA library
P08291233A0000|60 72|PCR-generated
P08291233A0000|85 97|probe specific
P08291233A0000|104 111|U3 region
P08291233A0000|117 135|Rous sarcoma virus LTR
P08291620A0372|3 15|basic patterns
P08291620A0372|18 34|locomotor behavior
P08291620A0372|38 65|corresponding torso morphology
P08291620A0372|76 92|extant anthropoids
P08291761A0416|0 8|Animal age
P08291761A0416|20 37|significant effects
P08291761A0416|40 53|CSF composition
P08291761A0416|58 78|serum IgG concentration
P08291761A0416|63 65|IgG
P08291886T0024|0 22|Fast continuous expansion
P08293412T0000|12 27|multicenter study
P08293412T0000|40 47|efficacy
P08293412T0000|51 62|tolerability
P08293412T0000|65 75|tropisetron
P08293412T0000|78 103|new 5-HT3 receptor antagonist
P08293412T0000|81 93|5-HT3 receptor
P08293412T0000|110 152|metoclopramide-containing antiemetic cocktail
P08293412T0000|170 192|cisplatin-induced emesis
P08293992A0432|22 23|nt
P08293992A0432|56 61|K/NPAG
P08293993A0948|0 2|ENV
P08293993A0948|22 31|P. pastoris
P08293993A0948|52 84|alpha-factor prepro secretion leader
P08293993A0948|91 111|S. cerevisiae invertase
P08293993A0948|103 125|invertase signal sequence
P08294386A0000|0 9|BACKGROUND
P08294386A0000|25 34|predictors
P08294386A0000|37 68|desipramine-refractory depression
P08294386A0000|73 79|authors
P08294386A0000|100 107|patients
P08294386A0000|112 126|major depression
P08294386A0000|145 159|general hospital
P08294386A0000|174 184|desipramine
P08294386A0000|197 214|adequate blood level
P08294429A0153|0 7|Analysis
P08294429A0153|13 25|intact hGH gene
P08294429A0153|19 25|hGH gene
P08294429A0153|28 30|hGH
P08294429A0153|34 44|flanking DNA
P08294429A0153|49 50|FR
P08294429A0153|64 70|hGh cDNA
P08294429A0153|73 104|chloramphenicol acetyltransferase
P08294429A0153|107 121|luciferase genes
P08294429A0153|136 139|cAMP
P08294429A0153|159 177|hGH promoter activity
P08294429A0153|159 169|hGH promoter
P08294459A0446|12 28|amino acid sequence
P08294459A0446|34 42|SAP-1 cDNA
P08294459A0446|53 63|mature SAP-1
P08294459A0446|79 88|amino acids
P08294459A0446|93 113|transmembrane-type PTP
P08294459A0446|130 154|single PTP-conserved domain
P08294459A0446|160 176|cytoplasmic region
P08294511A0639|36 47|69-kD protein
P08294511A0639|69 87|U1-specific, protein
P08294511A0639|69 79|U1-specific
P08294511A0639|115 132|snRNP core particles
P08294511A0639|135 160|protein-protein interaction
P08294511A0639|135 149|protein-protein
P08294865A0236|0 14|Several features
P08294865A0236|24 28|cells
P08294865A0236|43 50|mutation
P08294865A0236|59 86|normal intracellular formation
P08294865A0236|89 107|peptide/DR complexes
P08294906A1315|34 59|neurotransmitters glutamate
P08294906A1315|63 71|aspartate
P08294906A1315|95 114|excitatory amino acids
P08294906A1315|118 126|substrate
P08296434A1141|3 18|Harleco apparatus
P08296434A1141|36 56|cost-effective adjunct
P08296434A1141|89 113|life-threatening condition
P08297376A0236|0 14|Co-transfection
P08297376A0236|17 33|expression vectors
P08297376A0236|37 64|CCAAT/enhancer binding protein
P08297376A0236|66 76|C/EBP) alpha
P08297376A0236|66 70|C/EBP
P08297376A0236|72 76|alpha
P08297376A0236|80 88|C/EBP beta
P08297376A0236|107 141|rat uncoupling protein gene promoter due
P08297376A0236|107 130|rat uncoupling protein gene
P08297376A0236|144 152|sequences
P08297376A0236|160 173|proximal region
P08298129A0274|34 58|tissue-specific expression
P08298129A0274|80 83|beta
P08298129A0274|85 96|gene promoter
P08298129T0000|0 8|Isolation
P08298129T0000|12 27|characterization
P08298129T0000|31 47|TATA-less promoter
P08298129T0000|54 75|human beta 3 integrin gene
P08298129T0000|54 62|human beta
P08298129T0000|64 75|integrin gene
P08299181A1148|0 14|Subretinal fluid
P08299181A1148|32 40|poorer eye
P08299181A1148|45 48|eyes
P08299181A1148|54 54|%
P08299181A1148|64 72|better eye
P08299181A1148|76 79|eyes
P08299181A1148|85 85|%
P08299568A1401|21 30|activation
P08299568A1401|38 44|enzymes
P08299568A1401|66 81|acute stimulation
P08299568A1401|84 99|glucose transport
P08299725A0724|35 40|intron
P08299725A0724|74 87|tumor cell lines
P08299725A0724|98 108|readthrough
P08299725A0724|122 129|residues
P08299896A0626|0 10|Concordance
P08299896A0626|13 22|IBDQ scores
P08299896A0626|37 50|stable subjects
P08299896A0880|0 19|Regression line slopes
P08299896A0880|22 31|IBDQ scores
P08299896A0880|60 67|patients
P08299896A0880|111 111|b
P08299896A0880|119 119|P
P08300463A0581|0 11|Praziquantel
P08300463A0581|15 25|Albendazole
P08300463A0581|60 77|neurocysticercosis
P08300463A0581|91 108|serious side effects
P08300463A0581|126 130|cases
P08300463A0581|135 139|drugs
P08300463A0581|172 176|cases
P08300527T0000|0 9|Inhibition
P08300527T0000|12 32|erythromycin synthesis
P08300527T0000|35 44|disruption
P08300527T0000|47 84|malonyl-coenzyme A decarboxylase gene eryM
P08300527T0000|47 80|malonyl-coenzyme A decarboxylase gene
P08300527T0000|81 84|eryM
P08300527T0000|87 112|Saccharopolyspora erythraea
P08300601A0745|23 32|activation
P08300601A0745|35 44|DNA binding
P08300601A0745|47 50|MyoD
P08300601A0745|54 66|E12 homodimers
P08300601A0745|70 89|E12/MyoD heterodimers
P08300601A0745|70 72|E12
P08300601A0745|74 77|MyoD
P08300605A0432|0 22|Transcriptional analysis
P08300605A0432|34 48|deletion mutants
P08300605A0432|63 77|nuclear extracts
P08300605A0432|93 107|middle silk gland
P08300605A0432|110 135|2-day-old fifth instar larvae
P08300605A0432|157 193|multiple cis-regulatory elements located
P08300605A0432|198 205|upstream
P08300605A0432|209 218|downstream
P08300605A0432|224 237|initiation site
P08300605A0671|10 17|elements
P08300605A0671|22 47|homeodomain-binding element
P08300605A0671|71 88|negative regulation
P08300611A0341|0 23|Site-directed mutagenesis
P08300611A0341|29 46|traI structural gene
P08300611A0341|71 88|mutant TraI proteins
P08300611A0341|99 104|assays
P08300611A0341|124 143|functional importance
P08300611A0341|155 171|amino acid residues
P08300611T0000|0 14|Concerted action
P08300611T0000|22 36|distinct domains
P08300611T0000|42 68|DNA cleaving-joining reaction
P08300611T0000|80 87|relaxase
P08300611T0000|89 92|TraI
P08300611T0000|96 116|conjugative plasmid RP4
P08300625A1352|3 15|COOH-terminal
P08300625A1352|18 23|codons
P08300625A1352|26 29|slyD
P08300625A1352|37 75|remarkable histidine-rich peptide sequence
P08300625A1352|96 106|dispensable
P08300625A1352|110 121|slyD function
P08300625A1352|110 113|slyD
P08300625A1352|124 138|E-mediated lysis
P08301702A1083|0 21|Monospecific antibodies
P08301702A1083|35 55|rat cytochrome P-450 1A1
P08301702A1083|79 95|hepatic microsomes
P08301702A1083|101 123|double-crested cormorant
P08301702A1083|144 157|great blue heron
P08301702A1083|179 192|immunoblotting
P08301841A0000|9 28|GSH-Px enzyme activity
P08301841A0000|31 35|serum
P08301841A0000|41 65|acute myocardial infarction
P08301841A0000|67 69|AMI
P08301841A0000|74 95|unstable angina pectoris
P08301841A0000|97 99|UAP
P08302589A1132|3 25|HGF-induced cell motility
P08302589A1132|3 5|HGF
P08302589A1132|39 75|12-0-tetradecanoyl-phorbol-13-acetate
P08302589A1132|78 114|protein kinase C-activating phorbol ester
P08302589A1132|124 126|Ca2
P08302589A1132|128 136|ionophore
P08303233A0313|11 24|lexical priming
P08303233A0313|50 62|identity prime
P08304301A0331|0 6|METHODS
P08304301A0331|18 22|cases
P08304301A0331|27 53|intrahepatic multiple nodules
P08304301A0331|56 58|HCC
P08304301A0331|62 77|gross examination
P08304301A0331|87 109|consecutive resected HCCs
P08304342A0605|5 17|present report
P08304342A0605|21 43|hemochromatosis families
P08304342A0605|55 80|hemochromatosis chromosomes
P08304342A0605|87 103|normal chromosomes
P08304342A0605|108 117|RFLP-typed
P08304342A0605|132 137|probes
P08304342A0605|163 180|polymorphic markers
P08304342A0605|194 209|HLA-F loci located
P08304342A0605|194 202|HLA-F loci
P08304342A0605|219 229|kb telomeric
P08304342A0605|232 236|HLA-A
P08305058T0000|0 11|Pneumothorax
P08305058T0000|18 39|laparoscopic dissection
P08305058T0000|45 63|diaphragmatic hiatus
P08306356A0000|0 29|Different cortical malformations
P08306356A0000|44 47|rats
P08306356A0000|51 60|single dose
P08306356A0000|63 68|X-rays
P08306356A0000|73 75|cGy
P08306356A0000|84 96|different days
P08306356A0000|103 111|gestation
P08306834A0866|0 8|T2 cancers
P08306834A0866|44 66|preoperative irradiation
P08306959A0278|0 7|IFN alpha
P08306959A0278|11 30|IFN gamma inducibility
P08306959A0278|11 18|IFN gamma
P08306959A0278|44 56|single element
P08306959A0278|59 70|high affinity
P08306959A0278|78 95|palindromic version
P08306959A0278|101 122|IFN gamma activation site
P08306959A0278|124 126|GAS
P08307338A0227|0 8|Mutations
P08307338A0227|14 28|nuclear gene CBP1
P08307338A0227|62 72|degradation
P08307338A0227|75 107|mitochondrially encoded cytochrome b
P08307338A0227|97 107|cytochrome b
P08307338A0227|109 111|cob
P08307338A0227|113 115|RNA
P08307338A0227|125 129|cells
P08307564A0233|12 31|sequence-tagged sites
P08307564A0233|33 36|STSs
P08307564A0233|57 62|contig
P08307564A0233|94 95|kb
P08308008A0201|29 35|binding
P08308008A0201|41 57|GA-binding protein
P08308008A0201|59 62|GABP
P08308008A0201|66 82|ets sequence motifs
P08308008A0201|118 142|transcriptional activation
P08308008A0201|148 160|COXIV promoter
P08309726A0000|6 19|further insight
P08309726A0000|27 38|pathogenesis
P08309726A0000|44 75|adult respiratory distress syndrome
P08309726A0000|77 80|ARDS
P08309726A0000|86 92|authors
P08309726A0000|100 120|possible relationships
P08309726A0000|129 144|activation status
P08309726A0000|158 185|polymorphonuclear neutrophils
P08309726A0000|187 189|PMN
P08309726A0000|192 205|cytokine levels
P08309726A0000|213 220|severity
P08309726A0000|223 232|lung injury
P08309726A0000|237 244|patients
P08309726A0000|252 255|ARDS
P08309726A0000|262 289|severe pneumonia uncomplicated
P08309726A0000|292 295|ARDS
P08309726A0000|323 330|patients
P08309726A0000|342 345|ARDS
P08309726A0000|349 357|pneumonia
P08309912A0306|0 9|Amiodarone
P08309912A0306|23 41|first-line treatment
P08309912A0306|61 73|effective drug
P08309953A0776|5 11|results
P08309953A0776|27 53|dopamine receptor stimulation
P08309953A0776|27 42|dopamine receptor
P08309953A0776|56 80|different dopamine agonists
P08309953A0776|90 105|different pattern
P08309953A0776|108 114|effects
P08309953A0776|120 134|characteristics
P08309953A0776|140 159|reaction time response
P08309957A0000|3 13|experiments
P08309957A0000|37 55|vacuous jaw movements
P08309957A0000|65 68|rats
P08309957A0000|71 89|acute administration
P08309957A0000|95 127|monoamine-depleting agent reserpine
P08309975A0662|0 8|Depletion
P08309975A0662|11 18|dopamine
P08309975A0662|24 39|nucleus accumbens
P08309975A0662|46 58|dramatic shift
P08309975A0662|85 103|significant decrease
P08309975A0662|106 110|lever
P08309975A0662|123 141|significant increase
P08309975A0662|157 163|lab chow
P08312243A0177|32 36|NaFe3
P08312243A0177|38 41|EDTA
P08312243A0177|58 70|dietary levels
P08312243A0177|73 79|Na2EDTA
P08312243A0177|83 84|Zn
P08312243A0177|86 87|Cu
P08312243A0177|91 102|Ca metabolism
P08312243A0177|105 108|rats
P08312243A0177|114 126|Zn-sufficient
P08312243A0177|130 169|Zn-deficient soya-bean-isolate-based diets
P08314163T0000|0 7|Recovery
P08314163T0000|10 43|carbimazole-induced agranulocytosis
P08314163T0000|53 108|recombinant granulocyte-macrophage colony stimulating factor
P08314163T0000|110 117|rhGM-CSF
P08314922A0941|39 61|dynamic perfusion changes
P08314922A0941|69 80|brain surface
P08314922A0941|85 103|minimal tissue damage
P08316100A0586|3 9|neglect
P08316100A0586|12 19|Richards
P08316100A0586|50 56|factors
P08316100A0586|147 165|psychological theory
P08316209A0000|3 46|positive-acting global sulfur regulatory protein
P08316209A0000|48 51|CYS3
P08316209A0000|55 70|Neurospora crassa
P08316209A0000|102 124|unlinked structural genes
P08316209A0000|135 141|enzymes
P08316209A0000|144 159|sulfur catabolism
P08316240A1068|0 7|Analysis
P08316240A1068|13 38|upstream untranslated region
P08316240A1068|41 45|CHL15
P08316240A1068|70 83|hexamer element
P08316240A1068|85 90|ACGCGT
P08316240A1068|94 112|MluI restriction site
P08316240A1068|132 149|periodic expression
P08316240A1068|153 172|coordinate regulation
P08316240A1068|178 194|DNA synthesis genes
P08316240A1068|204 208|yeast
P08317092A0304|3 18|C-terminal region
P08317092A0304|24 37|150-kDa protein
P08317092A0304|48 71|NTP-binding helicase motif
P08317092A0304|78 94|readthrough region
P08317092A0304|98 115|RNA polymerase motif
P08317092A0304|150 157|proteins
P08317092A0304|167 194|RNA replication complex similar
P08317092A0304|204 209|tobamo
P08317092A0304|214 225|tobraviruses
P08317094A0778|5 8|ends
P08317094A0778|11 28|F3R late transcripts
P08317094A0778|33 39|located
P08317094A0778|44 44|A
P08317094A0778|65 69|TAAAG
P08317094A0778|73 74|nt
P08317094A0778|92 104|early promoter
P08317094A0778|110 111|nt
P08317094A0778|127 141|initiation codon
P08319396A0448|2 17|T2 weighted images
P08319396A0448|19 35|low intensity areas
P08319396A0448|41 48|thalamus
P08319396A0448|53 60|striatum
P08319396A0448|65 76|anterior limb
P08319396A0448|82 96|internal capsule
P08319396A0448|101 109|tegmentum
P08319396A0448|112 119|midbrain
P08319396A0448|121 138|high intensity areas
P08319396A0448|141 164|middle cerebellar peduncle
P08319396A0448|169 181|posterior limb
P08319396A0448|187 201|internal capsule
P08319396A0448|206 216|lateral part
P08319396A0448|222 237|cerebral peduncle
P08319396A0448|245 263|cerebral white matter
P08319907A0754|8 19|rap1t alleles
P08319907A0754|30 43|wild-type cells
P08319907A0754|59 78|telomere tract lengths
P08319907A0754|94 116|telomere position effects
P08319907A0754|137 143|changes
P08319907A0754|171 184|telomeric tract
P08320120A0361|0 24|Pronounced microangiopathy
P08320120A0361|40 54|avascular fields
P08320120A0361|56 63|enlarged
P08320120A0361|67 85|tortuous capillaries
P08320120A0361|98 120|transcapillary diffusion
P08320120A0361|123 139|sodium fluorescein
P08320120A0361|151 162|demonstrable
P08320120A0361|177 183|nodules
P08321199T0000|0 18|Epigenetic switching
P08321199T0000|21 41|transcriptional states
P08321199T0000|43 45|cis
P08321199T0000|50 68|trans-acting factors
P08321199T0000|93 101|silencing
P08321199T0000|107 114|HMR locus
P08321203A0840|0 11|NF-kappa B p65
P08321203A0840|13 15|p50
P08321203A0840|20 22|Rel
P08321203A0840|48 57|C/EBP alpha
P08321203A0840|59 67|C/EBP beta
P08321203A0840|72 81|C/EBP delta
P08321227A0854|33 45|culture medium
P08321227A0854|48 71|cDNA-transfected COS cells
P08321741A0396|3 12|first group
P08321741A0396|15 27|sequential BMB
P08321741A0396|35 53|significant progress
P08321741A0396|56 68|myelofibrosis
P08321741A0396|81 122|Chronic Megakaryocytic-Granulocytic Myelosis
P08321741A0396|150 182|Agnogenic Myeloid Metaplasia-AMM-in
P08321741A0396|187 187|%
P08321741A0396|194 201|patients
P08321741A0396|214 216|CML
P08321741A0396|221 246|megakaryocytic increase-CML
P08321741A0396|248 252|MI-in
P08321741A0396|257 257|%
P08322117A1019|6 12|methods
P08322117A1019|24 35|same patients
P08322117A1019|42 63|micturitional pressures
P08322117A1019|80 84|cmH2O
P08322117A1019|99 103|cmH2O
P08322117A1019|111 124|Sussett formula
P08322117A1019|136 141|higher
P08322117A1019|143 153|95th centile
P08322117A1019|155 160|cutoff
P08322823A0839|10 25|clear correlation
P08322823A0839|36 38|MFA
P08322823A0839|45 52|severity
P08322823A0839|58 69|UTS phenotype
P08323294T0000|0 49|Chicken sterol carrier protein 2/sterol carrier protein x
P08323294T0000|51 61|cDNA cloning
P08323294T0000|69 92|evolutionary conservation
P08324107A0000|3 31|plasmatic albumin concentration
P08324107A0000|3 18|plasmatic albumin
P08324107A0000|40 43|g/dl
P08324107A0000|62 62|%
P08324107A0000|68 85|total plasma protein
P08324280A0098|5 11|lesions
P08324280A0098|16 27|asymptomatic
P08324280A0098|65 81|central ulceration
P08324792T0000|11 22|minute period
P08324792T0000|25 41|rapid atrial pacing
P08324792T0000|54 64|infarct size
P08324792T0000|76 86|rabbit heart
P08325504A0226|7 10|RD19
P08325504A0226|14 30|RD21 mRNA synthesis
P08325504A0226|14 21|RD21 mRNA
P08325504A0226|34 43|responsive
P08325504A0226|54 63|heat stress
P08325639A0129|0 14|Previous studies
P08325639A0129|31 43|20S proteasome
P08325639A0129|47 59|catalytic core
P08325639A0129|65 85|26S proteolytic complex
P08325639A0129|100 137|latent multicatalytic proteinase activity
P08325639A0129|152 164|ATP-dependent
P08325639A0129|166 183|selective breakdown
P08325639A0129|186 193|proteins
P08325639A0129|203 211|ubiquitin
P08325720A0840|27 38|blood lactate
P08325720A0840|45 62|submaximal exercise
P08325720A0840|64 83|muscle enzyme activity
P08325720A0840|85 99|citrate synthase
P08325720A0840|101 131|3-hydroxyacyl-CoA-dehydrogenase
P08325720A0840|133 152|lactate dehydrogenase
P08325720A0840|163 179|muscle capillaries
P08325720A0840|181 189|%ST fibres
P08325720A0840|192 211|muscle buffer capacity
P08325883A0368|16 34|putative RBP1 protein
P08325883A0368|24 34|RBP1 protein
P08325883A0368|46 51|copies
P08325883A0368|56 74|RNA recognition motif
P08325883A0368|79 96|glutamine stretches
P08325883A0368|100 120|asparagine-rich region
P08325883A0368|123 143|methionine-rich region
P08325883A0368|151 176|long potential alpha-helixes
P08327488A0839|3 14|defective RNA
P08327488A0839|20 32|large deletion
P08327488A0839|38 52|p70 coding region
P08327488A0839|38 40|p70
P08327488A0839|108 119|helper genome
P08327488A0839|161 172|defective RNA
P08327488A0839|186 197|wild-type p70
P08331064A0440|0 6|Release
P08331064A0440|13 29|selective pressure
P08331064A0440|48 67|homologous resolution
P08331064A0440|73 93|cointegrate structures
P08331067T0000|0 25|Complete nucleotide sequence
P08331067T0000|31 54|bacteriophage K1F tail gene
P08331067T0000|63 86|endo-N-acylneuraminidase
P08331067T0000|88 93|endo-N
P08331067T0000|112 124|endo-N homolog
P08331067T0000|127 143|bacteriophage PK1E
P08331728A0686|0 6|Binding
P08331728A0686|9 39|U2 small nuclear ribonucleoprotein
P08332033T0000|0 27|Morphometrical quantification
P08332033T0000|30 46|brain edema related
P08332033T0000|49 82|experimental multiple micro-infarcts
P08332033T0000|85 88|mice
P08332033T0000|102 118|neurotropin effect
P08332033T0000|102 112|neurotropin
P08332492A0145|15 29|multigene family
P08332492A0145|31 36|GATA-3
P08332492A0145|65 76|T lymphocytes
P08332492A0145|79 92|cellular target
P08332492A0145|96 126|human immunodeficiency virus type 1
P08332492A0145|96 125|human immunodeficiency virus type
P08332492A0145|128 132|HIV-1
P08332492A0145|146 156|replication
P08332495A0408|7 22|significant level
P08332495A0408|25 35|CAT activity
P08332495A0408|25 27|CAT
P08332495A0408|49 71|human lung adenocarcinoma
P08332495A0408|73 78|A549-1
P08332495A0408|80 84|cells
P08332495A0408|120 134|T7 RNA polymerase
P08332495A0408|136 149|pT7-EMC-CAT DNA
P08332495A0408|153 176|DC-chol cationic liposomes
P08333643A0000|0 12|Pneumoscrotum
P08333643A0000|16 28|rare condition
P08333643A0000|41 56|little discussion
P08333643A0000|59 71|standard texts
P08333643A0000|74 80|urology
P08334158A0660|3 16|first gene codes
P08334158A0660|40 54|cystein residues
P08334158A0660|59 76|arrangement typical
P08334158A0660|80 91|Fe/S proteins
P08334304A0473|0 20|Triton-disrupted cells
P08334304A0473|40 49|activation
P08334304A0473|55 61|pathway
P08334304A0473|68 87|peptide growth factors
P08334304A0473|103 123|GTP-loaded p21 rasVal12
P08334304A0473|113 123|p21 rasVal12
P08334989A0070|68 77|cell-cycle
P08334989A0070|80 89|mouse B-myb
P08334989A0070|92 107|flanking sequence
P08334989A0070|124 136|cosmid library
P08334989A0070|168 180|transcription
P08334989A0070|184 205|luciferase reporter gene
P08334989A0070|225 241|NIH3T3 fibroblasts
P08335710A0338|15 31|high ionic strength
P08336012A0632|29 52|peripheral white blood cell
P08336012A0632|56 67|BAL fluid cell
P08336012A0632|102 103|FN
P08336543A0243|2 5|mice
P08336543A0243|12 24|major families
P08336543A0243|27 36|L1 elements
P08336543A0243|44 45|"A
P08336543A0243|45 45|A
P08336543A0243|49 49|F
P08336543A0243|56 56|V
P08336543A0243|109 116|terminus
P08336698T0000|0 3|TFEC
P08336698T0000|6 33|basic helix-loop-helix protein
P08336698T0000|40 51|heterodimers
P08336698T0000|56 59|TFE3
P08336698T0000|71 107|TFE3-dependent transcription activation
P08336698T0000|71 74|TFE3
P08336738A1273|18 28|third ligand
P08336738A1273|30 33|H-87
P08336738A1273|37 40|T-47
P08336738A1273|46 65|PSTAIRE sequence motif
P08337828A0895|0 13|Similar results
P08337828A0895|24 35|Western blots
P08337828A0895|38 62|Autographa californica MNPV
P08337828A0895|64 69|AcMNPV
P08337828A0895|72 104|infected Spodoptera frugiperda cells
P08337841A0612|2 23|infected mammalian cells
P08337841A0612|28 31|ARV G
P08337841A0612|35 42|GNS genes
P08337841A0612|69 85|polycistronic mRNA
P08337841A0612|113 129|consensus sequence
P08337841A0612|131 135|AACAG
P08337841A0612|152 156|G gene
P08337841A0612|176 196|polyadenylation signal
P08337841A0612|198 201|CATG
P08337841A0612|203 203|A
P08337841A0612|207 213|located
P08337841A0612|217 227|nucleotides
P08337841A0612|243 268|GNS protein termination codon
P08337841A0612|243 252|GNS protein
P08340400T0000|0 15|Molecular cloning
P08340400T0000|31 35|RPE65
P08340400T0000|38 92|novel retinal pigment epithelium-specific microsomal protein
P08342703A0966|3 11|mean power
P08342703A0966|15 17|mu W
P08342703A0966|47 54|flow rate
P08342703A0966|73 87|outflow pressure
P08342703A0966|105 112|flow rate
P08342703A0966|136 150|lymphatic vessel
P08343041A0000|8 26|antisperm antibodies
P08343041A0000|44 54|infertility
P08343041A0000|56 79|many hospital laboratories
P08343041A0000|97 106|antibodies
P08343216A0883|0 31|PPD-specific IgG subclass responses
P08343216A0883|52 64|IgG subclasses
P08343216A0883|52 54|IgG
P08343961A0000|0 18|Anterior body pattern
P08343961A0000|70 82|bicoid protein
P08343961A0000|84 86|bcd
P08343961A0000|103 118|subordinate genes
P08343961A0000|121 143|distinct anterior domains
P08344248A0910|0 4|GAP-N
P08344248A0910|26 29|p190
P08344248A0910|36 49|serum-deprived
P08344248A0910|53 80|growth factor-stimulated cells
P08345191A1140|3 17|peptide sequence
P08345191A1140|37 46|amino acids
P08345191A1140|68 72|bcl-2
P08345191A1140|98 114|bcl-2-related gene
P08345191A1140|116 119|MCL1
P08347677A0308|3 27|phosphorylation efficiency
P08347677A0308|61 86|N-terminal arginine residues
P08347677A0308|101 114|arginyl cluster
P08347677A0308|118 124|residue
P08347677A0308|143 148|serine
P08347677A0308|153 163|nonapeptide
P08347677A0308|165 167|Arg
P08347677A0308|169 189|4-Ala-Ala-Ser-Val-Ala
P08347677A0308|198 210|best substrate
P08347677A0308|222 234|short peptides
P08347677A0308|242 244|Km =
P08347677A0308|247 252|microM
P08348919T0000|0 13|Botulinum toxin
P08348919T0000|15 32|preferred treatment
P08348919T0000|36 50|hemifacial spasm
P08349104A0000|3 29|Saccharomyces cerevisiae GAL1
P08349104A0000|26 29|GAL1
P08349104A0000|33 42|GAL10 genes
P08349104A0000|85 93|galactose
P08349104A0000|97 103|glucose
P08349104A0000|137 144|proteins
P08349104A0000|152 159|adjacent
P08349104A0000|173 177|sites
P08349104A0000|180 183|UASG
P08349104A0450|16 22|results
P08349104A0450|25 42|several experiments
P08349104A0450|57 64|TSF genes
P08349104A0450|71 93|global regulatory factors
P08349104A0450|95 98|tsf1
P08349104A0450|101 113|tsf6 mutations
P08349104A0450|101 104|tsf6
P08349104A0450|139 165|yeast CYC-GAL hybrid promoters
P08349104A0450|174 177|lacZ
P08349104A0450|199 215|operator sequences
P08349104A0450|226 243|pleiotropic defects
P08349104A0450|246 255|cell growth
P08349104A0450|257 262|mating
P08349104A0450|267 277|sporulation
P08349499A1169|0 2|Sex
P08349499A1169|5 8|calf
P08349499A1169|10 16|variate
P08349499A1169|47 51|width
P08349499A1169|54 59|muzzle
P08349632A0679|0 17|Sequence comparison
P08349632A0679|31 35|exons
P08349632A0679|39 39|L
P08349632A0679|43 45|L/N
P08349632A0679|45 45|N
P08349632A0679|48 52|PSG12
P08349632A0679|56 63|PSG12 psi
P08349632A0679|69 78|% identical
P08349632A0679|93 99|L/N exon
P08349632A0679|105 116|PSG12 psi gene
P08349632A0679|126 134|stop codon
P08350061A0209|3 12|mechanisms
P08350061A0209|26 35|activation
P08350061A0209|38 48|suppression
P08350061A0209|54 60|CD8 gene
P08350061A0209|86 108|T cell development program
P08350398A1616|16 38|ER lumenal variable domain
P08350398A1616|41 45|gp19K
P08350398A1616|50 74|specific tertiary structure
P08350398A1616|105 120|polymorphic alpha
P08350398A1616|125 129|alpha
P08350398A1616|131 137|domains
P08350398A1616|152 156|alpha
P08350398A1616|158 163|chains
P08352066A0000|21 34|beta-estradiol
P08352066A0000|36 37|E2
P08352066A0000|56 69|bone resorption
P08352066A0000|87 99|bone formation
P08352066A0000|105 118|cancellous bone
P08352066A0000|121 130|female rats
P08352268A0000|0 29|Recombinant human erythropoietin
P08352268A0000|31 37|epoetin
P08352268A0000|70 80|intravenous
P08352268A0000|82 85|i.v.
P08352268A0000|89 100|subcutaneous
P08352268A0000|102 103|SC
P08355062A0000|0 20|Single-photon emission
P08355062A0000|29 38|tomography
P08355062A0000|40 44|SPECT
P08355062A0000|50 84|99mTc-hexamethylpropyleneamine oxime
P08355062A0000|86 90|HMPAO
P08355062A0000|112 118|changes
P08355062A0000|121 137|cerebral blood flow
P08355062A0000|145 152|patients
P08355062A0000|157 180|cortical visual impairment
P08355063A0456|3 11|rCBF ratio
P08355063A0456|30 41|frontal lobes
P08355063A0456|45 45|%
P08355539A0133|0 6|METHODS
P08355539A0133|18 25|patients
P08355539A0133|53 60|etiology
P08355539A0133|78 98|antiadrenal antibodies
P08355539A0133|137 154|autoimmune etiology
P08355539A0133|157 159|EAA
P08355539A0133|177 195|tuberculous etiology
P08355539A0133|198 200|EAT
P08355539A0133|211 224|serologic study
P08355539A0133|241 260|undetermined etiology
P08355539A0133|263 265|EAI
P08355680A0824|0 3|2-AP
P08355680A0824|11 16|marked
P08355680A0824|18 28|steady rises
P08355680A0824|31 46|mRNA accumulation
P08355680A0824|92 106|HIV-1 constructs
P08355680A0824|112 120|increases
P08355680A0824|127 140|endogenous gene
P08355680A0824|149 159|gamma-actin
P08355680A0824|162 192|glucose 6-phosphate dehydrogenase
P08355696A0236|3 13|UV induction
P08355696A0236|16 20|c-jun
P08355696A0236|36 53|UV response elements
P08355696A0236|66 83|AP-1-like sequences
P08355696A0236|95 107|control region
P08355697A0000|0 26|Protein tyrosine phosphatases
P08355697A0000|28 31|PTPs
P08355697A0000|46 67|protein tyrosine kinases
P08355697A0000|69 72|PTKs
P08355697A0000|103 116|cell activation
P08355697A0000|128 142|differentiation
P08355857A1293|0 10|ST elevation
P08355857A1293|20 27|patients
P08355857A1293|33 33|%
P08355857A1293|37 45|subgroup A
P08355857A1293|65 74|subgroup B.
P08356792A1275|13 23|p21X protein
P08356792A1275|34 43|N-terminus
P08356792A1275|46 49|Rex1
P08356792A1275|64 73|high levels
P08356792A1275|94 97|p21X
P08356792A1275|117 126|1.6-kb mRNA
P08356792A1275|161 170|proviruses
P08356792T0000|0 19|HTLV-1 gene expression
P08356792T0000|0 9|HTLV-1 gene
P08356792T0000|22 40|defective proviruses
P08356792T0000|45 62|infected T-cell line
P08356944A0589|26 50|sodium lauryl sulfate method
P08356944A0589|63 85|hemoglobin concentration
P08356944A0589|63 72|hemoglobin
P08356944A0589|90 111|appropriate alternative
P08356944A0589|117 139|cyanmethemoglobin method
P08356944A0589|117 133|cyanmethemoglobin
P08356944A0589|164 174|toxic wastes
P08357834A0285|25 42|amino acid sequences
P08357834A0285|51 70|human PKC-delta clones
P08357834A0285|84 98|mouse homologues
P08357834A0285|109 121|greater degree
P08357834A0285|124 141|sequence divergence
P08357834A0285|148 156|% homology
P08357834A0285|171 180|high degree
P08357834A0285|183 202|sequence conservation
P08357834A0285|215 240|other human PKC family members
P08357834A0285|249 269|mammalian counterparts
P08360112T0036|0 2|XII
P08360180A1041|16 26|barley PSI-K
P08360180A1041|30 34|PSI-G
P08360180A1041|50 87|PSI-K sequence from Synechococcus vulcanus
P08360180A1041|50 62|PSI-K sequence
P08360180A1041|134 146|ancestral gene
P08360180A1041|167 187|chloroplast progenitor
P08360180A1041|197 210|cyanobacterial
P08361754A0733|5 13|other hand
P08361754A0733|18 27|structures
P08361754A0733|33 43|b-Zip domain
P08361754A0733|70 88|Maf-related proteins
P08361755A0734|10 19|conditions
P08361755A0734|21 33|transfections
P08361755A0734|38 42|cDNAs
P08361755A0734|48 59|NF-kappa B p50
P08361755A0734|63 81|serum response factor
P08361755A0734|83 85|SRF
P08361755A0734|103 103|s
P08361755A0734|117 126|Tax binding
P08361755A0734|117 119|Tax
P08361755A0734|132 144|NF-kappa B site
P08361755A0734|151 157|CArG box
P08361761A0174|14 18|v-Rel
P08361761A0174|55 69|reporter plasmid
P08361761A0174|80 102|multiple Sp1 binding sites
P08361761A0174|88 90|Sp1
P08361761A0174|125 148|chicken embryo fibroblasts
P08361761A0174|150 153|CEFs
P08361761A0174|166 170|v-Rel
P08361761A0174|196 200|sites
P08361761A0174|202 206|v-Rel
P08361761A0174|235 249|reporter plasmid
P08361761A0174|261 291|human immunodeficiency virus type 1
P08361761A0174|261 290|human immunodeficiency virus type
P08361761A0174|293 297|HIV-1
P08361761A0174|299 316|long terminal repeat
P08361761A0174|318 320|LTR
P08361761A0174|332 349|kappa B binding sites
P08361761A0174|383 403|intact Sp1 binding sites
P08363332A0365|3 23|simultaneous recording
P08363332A0365|26 43|electrical activity
P08363332A0365|51 74|surface electrocardiogram
P08363332A0365|76 95|right ventricular apex
P08363332A0365|100 105|bundle
P08363332A0365|107 121|high right atrium
P08363332A0365|123 135|coronary sinus
P08363332A0365|157 171|mapping catheter
P08363332A0365|199 226|electrical activation sequence
P08365944A1537|0 9|CONCLUSION
P08365944A1537|15 35|retrospective analysis
P08365944A1537|53 60|efficacy
P08365944A1537|74 96|simultaneous Mitomycin-C
P08365944A1537|100 113|5-fluorouracil
P08365944A1537|139 159|full-dose radiotherapy
P08365944A1537|173 188|Iridium-192 boost
P08366034A0637|23 38|cysteine residues
P08366034A0637|40 57|carboxymethylation
P08366034A0637|93 106|disulfide bonds
P08366034A0637|135 139|cells
P08367388T0035|0 34|Cerebro-oculo-facioskeletal syndrome
P08367388T0035|36 55|Pena-Shokeir syndrome
P08367487A1014|37 47|17S U2 snRNPs
P08367487A1014|57 67|12S U2 snRNPs
P08367487A1014|71 90|HeLa splicing extracts
P08367487A1014|101 119|endogeneous U2 snRNPs
P08367487A1014|155 173|anti-PRP9 antibodies
P08367487A1014|190 210|mRNA-splicing activity
P08367487A1014|216 223|extracts
P08369887A0781|0 10|Differences
P08369887A0781|13 20|profiles
P08369887A0781|23 40|viscosity variables
P08369887A0781|48 56|subgroups
P08369887A0781|59 61|EAD
P08369887A0781|64 73|RA patients
P08370119A0642|13 29|single 1977-bp exon
P08370119A0642|44 45|bp
P08370119A0642|58 78|untranslated sequences
P08370119A0642|92 123|1077-bp open reading frame identical
P08370119A0642|137 177|vascular smooth muscle cell AT1a receptor cDNAs
P08370119A1521|0 7|Deletion
P08370119A1521|11 34|53-bp early promoter region
P08370119A1521|48 69|transcription start site
P08370119A1521|74 88|putative TATA box
P08370119A1521|120 135|upstream elements
P08370119A1521|143 155|transcription
P08370119A1521|161 174|luciferase cDNA
P08370275A0290|3 12|chimpanzee
P08370275A0290|32 44|larger numeral
P08370275A0290|64 78|nonadjacent pair
P08370275A0290|89 94|chimps
P08371650T0000|0 10|Dissipation
P08371650T0000|13 28|claudication pain
P08371650T0000|42 53|implications
P08371650T0000|57 73|endurance training
P08371713T0000|0 20|Alternative transcript
P08371713T0000|26 60|nonselective-type endothelin receptor
P08371713T0000|43 60|endothelin receptor
P08371713T0000|65 72|rat brain
P08371936T0000|3 31|Functional Independence Measure
P08371936T0000|34 49|comparative study
P08371936T0000|52 60|clinician
P08371936T0000|64 74|self ratings
P08373274A0546|0 9|Polymyxin B
P08373274A0546|35 46|week postburn
P08373274A0546|49 53|doses
P08373274A0546|85 95|endotoxemia
P08373972A0335|0 3|SvO2
P08374753A0335|3 26|transverse relaxation time
P08374753A0335|28 29|T2
P08374753A0335|34 61|apparent diffusion coefficient
P08375651T0000|13 34|clathrin heavy chain gene
P08375651T0000|21 34|heavy chain gene
P08375651T0000|36 51|clathrin function
P08375651T0000|36 43|clathrin
P08375651T0000|66 86|multicellular organism
P08376397A0788|3 20|binding specificity
P08376397A0788|53 60|human E2F
P08376397A0788|75 88|mutant E2F sites
P08376397A0788|91 101|competitors
P08376796A0172|12 20|VH regions
P08376796A0172|23 44|polyreactive antibodies
P08376796A0172|50 68|particular attention
P08376796A0172|116 118|IgG
P08376796A0172|125 128|IgG1
P08376796A0172|135 138|IgG3
P08376796A0172|140 142|mAb
P08376796A0172|149 154|B cells
P08376796A0172|160 173|healthy subject
P08376796A0172|187 219|insulin-dependent diabetes mellitus
P08376796A0172|187 193|insulin
P08376796A0172|235 237|SLE
P08376796A0172|254 272|various efficiencies
P08376796A0172|282 294|different self
P08376796A0172|298 306|foreign Ag
P08377199A1432|37 54|proper conformation
P08378082A1031|5 12|findings
P08378082A1031|21 40|functional cross-talk
P08378082A1031|48 56|RB protein
P08378082A1031|60 65|p21ras
P08378082A1031|83 95|cell phenotype
P08378082A1031|112 128|transformed states
P08380736A0895|3 10|7-kb mRNA
P08380736A0895|20 42|alternative splicing such
P08380736A0895|69 89|distinct amino terminus
P08380896A0938|0 7|Kinetics
P08380896A0938|13 22|inhibition
P08380896A0938|40 55|polymerase domain
P08380896A0938|66 81|viral replication
P08380896A0938|95 112|preinitiation stage
P08381121A0773|3 27|other transmembrane regions
P08381121A0773|39 57|nucleoplasmic domain
P08382296A0766|0 8|McCann III
P08382296A0766|10 11|F.
P08382300A0341|5 13|cell lines
P08382300A0341|48 58|replication
P08382300A0341|62 91|temperature-sensitive VP5 mutant
P08382300A0341|83 91|VP5 mutant
P08382300A0341|110 112|VP5
P08382300A0341|116 130|VP23 null mutants
P08382300A0341|116 119|VP23
P08382303A0507|3 25|E1 nuclear transport motif
P08382303A0507|57 77|human papillomaviruses
P08382303A0507|93 105|similar region
P08382303A0507|111 124|related E1 genes
P08382303T0000|3 22|E1 replication protein
P08382303T0000|25 49|bovine papillomavirus type 1
P08382303T0000|25 48|bovine papillomavirus type
P08382303T0000|60 92|extended nuclear localization signal
P08382303T0000|106 131|p34cdc2 phosphorylation site
P08382303T0000|106 112|p34cdc2
P08382359A0469|64 77|tumor induction
P08382359A0469|108 130|different point mutations
P08382359A0469|140 166|putative pRb-binding sequence
P08382359A0469|169 181|large T antigen
P08382359A0469|208 218|experiments
P08382359A0469|237 243|effects
P08382359A0469|257 284|biological activities relevant
P08382359A0469|287 300|tumor induction
P08382769A0924|31 41|nucleotides
P08382769A0924|88 122|sequence-specific recognition element
P08382769A0924|129 140|SRP54 protein
P08382778A0891|19 48|protein shares extensive homology
P08382778A0891|54 68|catalytic region
P08382778A0891|71 80|Raf kinases
P08382778A0891|104 108|TFIIE
P08382778A0891|114 133|transcription factors
P08383129A0776|3 36|low molecular mass polypeptide complex
P08383129A0776|60 78|antigen presentation
P08383129A0776|90 97|peptides
P08383129A0776|102 125|cytosolic protein antigens
P08383129A0776|158 179|cytotoxic T-lymphocytes
P08383129A0776|185 195|cell surface
P08383214A0389|0 16|Secondary cleavage
P08383214A0389|19 20|RT
P08383214A0389|23 37|Trp-595-Tyr-596
P08383214A0389|40 42|Pol
P08383214A0389|50 62|truncated form
P08383214A0389|73 94|C-terminal RNase H domain
P08383217A0357|3 12|C-terminal
P08383217A0357|28 37|amino acids
P08383217A0357|40 44|Bel-1
P08383217A0357|69 81|Bel-1 activity
P08383217A0357|69 73|Bel-1
P08383217A0357|117 142|C-terminal activation domain
P08383217A0357|145 148|VP16
P08383287A0611|37 44|estrogen
P08383287A0611|48 75|thyroid hormone responsiveness
P08383287A0611|95 125|composite hormone response element
P08383323A0000|0 16|Optimal activation
P08383323A0000|19 24|T cells
P08383323A0000|43 49|signals
P08383492A1205|37 64|interrupted aromatic aa stretch
P08383492A1205|83 93|differences
P08383492A1205|118 133|peculiar affinity
P08383492A1205|136 167|cyanobacterial cytochrome oxidases
P08383492A1205|171 193|acidic c-type cytochromes
P08383492A1205|177 193|c-type cytochromes
P08383526A0591|12 16|genes
P08383526A0591|22 37|similar structure
P08383526A0591|46 60|receptor protein
P08383526A0591|71 80|single exon
P08383622T0000|0 7|Identity
P08383622T0000|10 13|GABP
P08383622T0000|18 22|NRF-2
P08383622T0000|25 45|multisubunit activator
P08383622T0000|48 74|cytochrome oxidase expression
P08383622T0000|48 64|cytochrome oxidase
P08383622T0000|84 95|cellular role
P08383622T0000|101 118|ETS domain activator
P08383622T0000|121 134|viral promoters
P08383850A0206|5 16|present study
P08383850A0206|18 36|beta-funaltrexamine
P08383850A0206|38 45|beta-FNA
P08383850A0206|50 60|naltrindole
P08383850A0206|62 64|NTI
P08383850A0206|67 82|nonequilibrium mu
P08383850A0206|87 102|delta-antagonist
P08383850A0206|150 174|butorphanol-dependent rats
P08384309A0000|3 43|intracellular basic region/helix-loop-helix
P08384309A0000|45 48|bHLH
P08384309A0000|50 63|dioxin receptor
P08384309A0000|72 89|signal transduction
P08384309A0000|92 97|dioxin
P08384309A0000|99 133|2,3,7,8-tetrachlorodibenzo-p-dioxin
P08384309A0000|150 182|ligand-activated DNA binding protein
P08384309A0000|206 216|target genes
P08384309A0000|228 249|dioxin response elements
P08385131A0000|3 28|alpha 2A-adrenergic receptor
P08385131A0000|30 38|alpha 2AAR
P08385131A0000|61 69|effectors
P08385131A0000|73 115|pertussis toxin-sensitive GTP-binding proteins
P08385337A0282|1 18|sequence comparison
P08385337A0282|29 56|CCAAT/enhancer binding protein
P08385337A0282|58 62|C/EBP
P08385337A0282|64 81|consensus sequences
P08385337A0282|83 103|basic DNA binding region
P08385337A0282|107 120|leucine zippers
P08385337A0282|127 131|bZIP1
P08385337A0282|135 139|bZIP2
P08385581A0126|10 14|genes
P08385581A0126|16 21|REC114
P08385581A0126|60 65|REC114
P08385581A0126|69 101|meiosis-specific recombination gene
P08385581A0126|108 125|detectable function
P08385581A0126|128 134|mitosis
P08386279A1621|3 25|transactivation function
P08386279A1621|28 32|EBNA2
P08386279A1621|53 74|HeLa epithelial cell line
P08386279A1621|93 95|EBV
P08386279A1621|99 112|HIV-1 infection
P08386279A1621|115 124|non-B cells
P08386279A1621|136 158|HIV-1 promoter activation
P08386279A1621|136 148|HIV-1 promoter
P08386280T0000|0 7|Mutation
P08386280T0000|13 29|C/EBP binding sites
P08386280T0000|35 68|Rous sarcoma virus long terminal repeat
P08386280T0000|72 83|gag enhancers
P08386317T0000|0 26|Nuclear protein phosphatase 2A
P08386317T0000|43 75|protein kinase A-phosphorylated CREB
P08386317T0000|43 56|protein kinase A
P08386317T0000|72 75|CREB
P08386317T0000|88 117|CREB transcriptional stimulation
P08386317T0000|88 91|CREB
P08386318A1102|10 13|IL-6
P08386318A1102|23 29|JRE-IL6
P08386318A1102|39 57|H7-sensitive pathway
P08386318A1102|76 89|protein kinase C
P08386318A1102|91 115|cyclic AMP-dependent kinase
P08386318A1102|117 118|Ca
P08386318A1102|126 152|calmodulin-dependent kinases
P08386318A1102|154 156|Ras
P08386318A1102|158 162|Raf-1
P08386318A1102|166 171|NF-IL6
P08386318A1102|173 181|C/EBP beta
P08386319A1229|0 7|Mutation
P08386319A1229|13 23|presumptive
P08386319A1229|38 45|tyrosine
P08386319A1229|49 65|threonine residues
P08386319A1229|68 72|Mpk1p
P08386319A1229|87 99|phenylalanine
P08386319A1229|103 109|alanine
P08386319A1229|132 152|impaired Mpk1p function
P08386319A1229|140 144|Mpk1p
P08386592A0089|0 22|Growth factor stimulation
P08386592A0089|38 53|reversible change
P08386592A0089|59 81|electrophoretic mobility
P08386592A0089|87 100|ternary complex
P08386592A0089|124 138|phosphorylation
P08386592A0089|144 164|Elk-1 C-terminal region
P08386592A0089|173 182|activation
P08386592A0089|188 208|kd cellular Elk-1 kinase
P08386637A1220|26 39|mammalian cells
P08386637A1220|41 57|prolonged exposure
P08386637A1220|63 69|agonist
P08386637A1220|73 73|h
P08386637A1220|90 103|down regulation
P08386637A1220|120 120|%
P08386637A1220|126 134|receptors
P08387155A1248|4 20|stimulatory effect
P08387155A1248|42 46|c-Jun
P08387155A1248|66 71|topo II
P08387155A1248|66 69|topo
P08387155A1248|81 85|c-Fos
P08387155A1248|103 108|topo II
P08387155A1248|103 106|topo
P08387155A1248|121 125|assay
P08387507A1015|15 19|Myf-5
P08387507A1015|23 34|MyoD function
P08387507A1015|23 26|MyoD
P08387507A1015|38 58|cAMP-dependent pathway
P08387507A1015|78 92|external signals
P08387507A1015|104 108|serum
P08387507A1015|112 138|certain peptide growth factors
P08387507A1015|159 165|nucleus
P08387507A1015|176 197|dominant-acting factors
P08387507A1015|219 241|myoblast differentiation
P08387519A0000|28 57|high level human desmin expression
P08387519A0000|68 102|280-base pair muscle-specific enhancer
P08387519A0000|128 135|myotubes
P08387519A0000|155 168|gene expression
P08387519A0000|171 179|myoblasts
P08387662A0302|13 24|patients self
P08387662A0302|47 77|possible postsurgical medications
P08387662A0302|92 98|placebo
P08387662A0302|100 106|codeine
P08387662A0302|109 110|mg
P08387662A0302|115 123|ibuprofen
P08387662A0302|127 128|mg
P08387662A0302|161 175|severe intensity
P08387743A0624|0 10|Replacement
P08387743A0624|16 43|wild-type 5'-regulatory region
P08387743A0624|16 24|wild-type
P08387743A0624|28 43|regulatory region
P08387743A0624|59 65|mutants
P08387743A0624|67 93|cis-acting regulatory element
P08387743A0624|107 125|anaerobic expression
P08387743A0624|128 155|active Mn-superoxide dismutase
P08387994A0980|3 18|orf61 gene product
P08387994A0980|39 55|exogenous promoter
P08387994A0980|66 88|int-mediated integration
P08387994A0980|94 112|chromosomal attB site
P08388496A1117|0 9|Expression
P08388496A1117|12 26|established LCLs
P08388496A1117|51 69|virus producer status
P08388496A1117|140 157|BamHI-A transcripts
P08388496A1117|178 189|normal B cells
P08388496A1117|207 227|experimental infection
P08388496A1117|245 271|BamHI-C/W promoter-initiated
P08388496A1117|278 307|BamHI-F promoter-initiated mRNAs
P08388510A0891|0 7|Analysis
P08388510A0891|10 38|cell surface immunofluorescence
P08388510A0891|52 59|UL28 gene
P08388510A0891|88 105|viral glycoproteins
P08388510A0891|120 132|infected cells
P08388543A1263|13 26|mutant receptor
P08388543A1263|28 38|Y977F/Y989F
P08388543A1263|40 60|PLC gamma-binding sites
P08388543A1263|81 83|Ras
P08388543A1263|91 106|direct activation
P08388543A1263|109 122|protein kinase C
P08388543A1263|126 144|calcium mobilization
P08388543A1263|167 178|GDP/GTP state
P08388543A1263|181 183|Ras
P08388543A1263|190 197|cell line
P08388600A0000|0 16|Estrogen treatment
P08388600A0000|19 27|high doses
P08388600A0000|49 60|adult stature
P08388600A0000|79 87|tall girls
P08389074A1227|0 8|Mutations
P08389074A1227|14 30|extreme C-terminus
P08389074A1227|33 39|EIAV Tat
P08389074A1227|52 80|RNA binding and activation domain
P08389074A1227|52 61|RNA binding
P08389074A1227|65 89|activation domain functions
P08389074A1227|101 107|effects
P08389074A1227|121 137|tertiary structure
P08389365A1344|30 56|methyl-directed repair system
P08389365A1344|68 76|proximal d
P08389365A1344|78 81|GATC
P08389365A1344|99 108|correction
P08389453A0193|0 19|Uracil DNA glycosylase
P08389453A0193|32 42|initial step
P08389453A0193|48 60|repair pathway
P08389453A0193|83 97|mutagenic uracil
P08389453A0193|102 110|duplex DNA
P08390120A0785|0 20|Current clinical trials
P08390120A0785|56 73|therapeutic options
P08390665A0000|0 20|Lithium phthalocyanine
P08390665A0000|22 25|LiPc
P08390665A0000|30 38|prototype
P08390665A0000|60 68|synthetic
P08390665A0000|70 85|metallic-organic
P08390665A0000|87 110|paramagnetic crystallites
P08390665A0000|150 186|electron paramagnetic resonance oximetry
P08390747A0586|25 32|genetics
P08390747A0586|51 62|hep syn gB gene
P08390747A0586|83 91|syncytial
P08390747A0586|95 114|pathogenic phenotypes
P08390747A0586|119 121|syn
P08390831A0143|0 9|Recipients
P08390831A0143|14 27|acute leukaemia
P08390831A0143|30 43|first remission
P08390831A0143|46 68|chronic myeloid leukaemia
P08390831A0143|71 87|first chronic phase
P08390831A0143|102 109|good risk
P08390831A0143|130 135|stages
P08390831A0143|139 154|poor risk patients
P08391534A0828|0 6|Elledge
P08391534A0828|8 9|P.
P08391748A0452|0 4|Drugs
P08391748A0452|18 18|=
P08391748A0452|21 21|%
P08391748A0452|27 63|total premature ventricular contractions
P08391748A0452|69 76|patients
P08391748A0452|87 114|use-dependent QRS prolongation
P08391748A0452|125 151|use-dependent QT prolongation
P08391748A0452|157 157|%
P08391748A0452|160 167|patients
P08391748A0452|172 199|use-dependent QRS prolongation
P08391748A0452|210 210|%
P08391748A0452|215 248|reverse use-dependent QT prolongation
P08391748A0452|262 262|%
P08391748A0452|274 301|use-dependent QRS prolongation
P08391748A0452|305 338|reverse use-dependent QT prolongation
P08392221A0449|0 5|Losses
P08392221A0449|15 31|complete procedure
P08392221A0449|52 80|radioactive estrogen conjugates
P08392221A0449|90 99|first steps
P08392221A0449|116 142|deuterated internal standards
P08392221A0449|148 156|compounds
P08392221A0449|166 177|matairesinol
P08392221A0449|179 188|enterodiol
P08392221A0449|190 202|enterolactone
P08392221A0449|204 211|daidzein
P08392221A0449|213 233|O-desmethylangolensin
P08392221A0449|235 239|equol
P08392221A0449|244 252|genistein
P08392623A1374|0 18|IE2-IE2 interactions
P08392623A1374|49 84|putative helix-turn-helix motif located
P08392623A1374|57 77|helix-turn-helix motif
P08392623A1374|92 100|C terminus
P08392623A1374|103 105|IE2
P08392623A1374|114 123|amino acids
P08393143A1281|3 11|Sp1 region
P08393143A1281|47 55|strong TRE
P08393143A1281|61 74|viral tat factor
P08394019A0695|0 12|Precipitation
P08394019A0695|18 34|GST fusion proteins
P08394019A0695|45 50|Fyn SH2
P08394019A0695|45 47|Fyn
P08394019A0695|48 50|SH2
P08394019A0695|52 54|SH3
P08394019A0695|59 72|SH2/SH3 domains
P08394019A0695|59 61|SH2
P08394019A0695|63 72|SH3 domains
P08394019A0695|85 94|PI 3-kinase
P08394019A0695|116 124|SH3 domain
P08394019A0695|127 129|Fyn
P08394255A0000|1 26|sheep testicular cDNA library
P08394255A0000|40 51|pcDNA1 vector
P08394255A0000|68 72|probe
P08394255A0000|84 106|polymerase chain reaction
P08394255A0000|108 110|PCR
P08394255A0000|134 143|kb fragment
P08394255A0000|163 181|hormone receptor cDNA
P08394464A1080|3 21|putative Rev proteins
P08394464A1080|26 48|apparent molecular masses
P08394464A1080|58 60|kDa
P08394464A1080|76 79|p2/2
P08394464A1080|83 86|p176
P08394464A1080|93 95|p20
P08394464A1080|110 122|16-kDa species
P08394862A0565|11 18|patients
P08394862A0565|28 37|CMV disease
P08394862A0565|62 73|CMV hepatitis
P08395004A0141|12 24|spt2 mutations
P08395004A0141|38 64|transcriptional interference
P08395004A0141|76 111|delta promoter insertion his-4-912 delta
P08395004A0141|138 160|wild-type HIS4 mRNA levels
P08395004A0141|138 154|wild-type HIS4 mRNA
P08395004A0558|0 18|Nuclear localization
P08395004A0558|22 48|protein sequence similarities
P08395004A0558|65 80|SPT2/SIN1 protein
P08395004A0558|65 68|SPT2
P08395004A0558|98 129|nonhistone chromosomal protein HMG1
P08395010T0000|12 32|ninth C-terminal heptad
P08395010T0000|35 48|thyroid hormone
P08395010T0000|52 72|retinoic acid receptors
P08395010T0000|81 96|diverse responses
P08395010T0000|108 118|heterodimer
P08395010T0000|125 142|homodimer formation
P08395014A1364|0 18|Genetic interactions
P08395014A1364|26 29|BCK2
P08395014A1364|33 54|other pathway components
P08395014A1364|68 80|BCK2 functions
P08395014A1364|68 71|BCK2
P08395014A1364|84 102|common pathway branch
P08395014A1364|107 110|PPZ1
P08395014A1364|114 117|PPZ2
P08395654T0000|0 19|Steroidogenic factor 1
P08395654T0000|0 18|Steroidogenic factor
P08395654T0000|23 43|orphan nuclear receptor
P08395654T0000|72 87|rat aromatase gene
P08395654T0000|90 103|gonadal tissues
P08395681A0388|10 30|functional differences
P08395681A0388|38 50|cutaneous HPV5
P08395681A0388|54 60|HPV8 E7s
P08395681A0388|58 60|E7s
P08395681A0388|64 77|genital HPV16 E7
P08395681A0388|76 77|E7
P08395681A0388|96 114|E7 open reading frames
P08395681A0388|157 166|activities
P08395681A0388|171 184|binding ability
P08395681A0388|192 199|products
P08395681A0388|204 224|retinoblastoma protein
P08395681A0388|226 227|RB
P08395681A0388|237 259|complementation activity
P08395681A0388|263 294|RB-nonbinding adenovirus E1A mutant
P08396120A0690|3 28|rhaB transcription start site
P08396261A0388|0 11|Several lines
P08396261A0388|41 56|growth inhibition
P08396261A0388|65 81|active PKA subunits
P08396261A0388|85 88|cAMP
P08396261A0388|97 105|phenotype
P08396261A0388|119 122|cAMP
P08396261A0388|155 177|adenylyl cyclase activity
P08396261A0388|155 169|adenylyl cyclase
P08396261A0388|185 194|growth rate
P08396261A0388|202 214|transformants
P08396261A0388|217 222|slower
P08396261A0388|227 239|exogenous cAMP
P08396261A0388|252 263|normal growth
P08396261A0388|274 288|wild-type RI cDNA
P08396261A0388|302 313|mutant RI cDNA
P08396261A0388|323 331|RI protein
P08396261A0388|343 353|cAMP binding
P08396261A0388|382 390|phenotype
P08396261A0388|407 410|BL21
P08396261A0388|412 414|DE3
P08396261A0388|416 420|cells
P08396261A0388|429 435|soluble
P08396261A0388|437 455|active C alpha protein
P08396261A0388|443 455|C alpha protein
P08396657A0452|0 2|Liu
P08396657A0452|4 5|B.
P08396667T0000|0 6|BCR-ABL
P08396667T0000|0 2|BCR
P08396667T0000|4 6|ABL
P08396667T0000|10 23|v-abl oncogenes
P08396667T0000|30 45|distinct patterns
P08396667T0000|48 61|thymic lymphoma
P08396667T0000|71 96|different lymphocyte subsets
P08396713A0305|5 15|experiments
P08396713A0305|30 44|6-S liganded form
P08396713A0305|50 57|receptor
P08396713A0305|70 84|nuclear extracts
P08396713A0305|87 91|cells
P08396713A0305|103 137|2,3,7,8-tetrachlorodibenzo-p-dioxin
P08396713A0305|139 142|TCDD
P08396713A0305|155 171|Ah receptor protein
P08396713A0305|175 178|ARNT
P08396713A0305|188 209|90-kDa heat shock protein
P08396749A1112a|0 13|LDL cholesterol
P08396749A1112a|51 56|mmol/l
P08396749A1112a|63 67|weeks
P08396749A1112a|70 80|simvastatin
P08396749A1112a|82 82|P
P08396749A1112a|94 97|apo B
P08396749A1112a|124 128|mg/dl
P08396749A1112a|130 130|P
P08396749A1112b|0 13|LDL cholesterol
P08396749A1112b|51 56|mmol/l
P08396749A1112b|63 67|weeks
P08396749A1112b|70 80|simvastatin
P08396749A1112b|82 82|P
P08396749A1112b|94 97|apo B
P08396749A1112b|124 128|mg/dl
P08396749A1112b|130 130|P
P08396913A1379|4 18|negative element
P08396913A1379|56 82|cell type-specific expression
P08396913A1379|88 94|DGK gene
P08397123T0000|22 47|distal promoter-like element
P08397123T0000|53 91|human corticotropin-releasing hormone gene
P08397123T0000|95 121|secondary structural features
P08397123T0000|127 150|corresponding transcripts
P08399970T0000|1 29|new bioencapsulation technology
P08399970T0000|33 51|microbial inoculants
P08400240A0166|8 27|hypersensitivity site
P08400240A0166|30 32|HS2
P08400240A0166|41 58|locus control region
P08400240A0166|60 62|LCR
P08400240A0166|67 83|A gamma-globin gene
P08400240A0166|68 83|gamma-globin gene
P08400240A0166|85 91|A gamma*
P08400240A0166|105 110|marked
P08400240A0166|121 130|transcript
P08400240A0166|152 177|endogenous gamma-globin mRNA
P08400928A0318|0 12|INTERVENTIONS
P08400928A0318|15 22|Patients
P08400928A0318|47 81|levodopa/dopa decarboxylase inhibitor
P08400928A0318|94 135|levodopa/decarboxylase inhibitor/selegiline
P08400928A0318|94 115|levodopa/decarboxylase
P08400928A0318|158 170|bromocriptine
P08401570A0828|15 34|putative binding sites
P08401570A0828|38 59|transcription factor Sp1
P08401570A0828|57 59|Sp1
P08401570A0828|68 88|several short sequences
P08401570A0828|105 128|known cis-acting enhancers
P08401570A0828|138 142|sites
P08401570A0828|146 165|transcription factors
P08401614A0187|0 9|French bean
P08401614A0187|19 29|small family
P08401614A0187|32 36|genes
P08401614A0187|45 47|PAL
P08401614A0187|61 65|genes
P08401614A0187|67 70|PAL2
P08401614A0187|74 77|PAL3
P08401614A0187|124 132|mRNA level
P08401614A0187|135 145|bean tissues
P08403245A1234|0 24|Plasma thromboxane B2 levels
P08403245A1234|30 39|older group
P08403245A1234|62 75|younger piglets
P08403804A0754|2 41|stepwise linear multiple regression analysis
P08403804A0754|50 58|magnesium
P08403804A0754|84 105|cyclosporin trough level
P08403804A0754|109 124|total cholesterol
P08403804A0754|133 147|serum creatinine
P08403804A0754|158 167|transplant
P08403804A0754|179 189|cyclosporin
P08405433A0000|3 31|human insulin-like growth factor
P08405433A0000|35 45|IGF-II) gene
P08405433A0000|35 40|IGF-II
P08405433A0000|58 66|promoters
P08405433A0000|68 69|P1
P08405433A0000|71 72|P2
P08405433A0000|74 75|P3
P08405433A0000|79 80|P4
P08406004A0691|11 37|transient transfection assays
P08406004A0691|39 42|PU.1
P08406004A0691|57 74|reporter constructs
P08406004A0691|88 100|JB cis-element
P08406004A0691|108 117|activation
P08406004A0691|142 163|glutamine-rich sequence
P08406004A0691|169 189|amino-terminal portion
P08406004A0691|192 195|PU.1
P08406352A0172|0 11|Army veterans
P08406352A0172|17 34|yellow fever vaccine
P08406352A0172|51 65|hepatitis B virus
P08406352A0172|75 82|controls
P08406352A0172|90 106|case-control study
P08406352A0172|116 123|veterans
P08406352A0172|128 150|hepatocellular carcinoma
P08406352A0172|153 176|Veterans Affairs hospitals
P08406352A0172|188 195|controls
P08406352A0172|209 215|receipt
P08406419A0155|17 28|seropositive
P08406419A0155|32 41|antibodies
P08406419A0155|44 58|hepatitis C virus
P08406419A0155|61 84|second-generation testing
P08406419A0155|86 89|RIBA
P08406419A0155|92 116|Ortho Diagnostic Systems Inc
P08406419A0155|118 125|Westwood
P08406419A0155|127 128|MA
P08406497A0000|0 6|Defects
P08406497A0000|9 17|fibrillin
P08406497A0000|19 22|FBN1
P08406497A0000|26 46|glycoprotein component
P08406497A0000|52 75|extracellular microfibril
P08406497A0000|82 95|Marfan syndrome
P08407784A0850|18 22|recJ+
P08407784A0850|18 21|recJ
P08407784A0850|23 29|strains
P08407784A0850|31 43|srjA mutations
P08407784A0850|31 34|srjA
P08407784A0850|53 72|hyperrecombinational
P08407784A0850|76 94|hyper-UVr phenotypes
P08407784A0850|76 84|hyper-UVr
P08408194T0000|14 18|roles
P08408194T0000|24 44|membrane-cytoskeleton
P08408194T0000|48 55|cadherin
P08408194T0000|64 80|cell-cell adhesion
P08408194T0000|93 103|different Na
P08408194T0000|106 116|K(+)-ATPase
P08408194T0000|106 106|K
P08408194T0000|111 129|ATPase distributions
P08408194T0000|141 149|epithelia
P08408825A0000|0 25|Neonatal lupus erythematosus
P08408825A0000|51 64|autoantibodies
P08408825A0000|72 73|Ro
P08408825A0000|77 86|La antigens
P08408841A0281|0 19|Genetic abnormalities
P08408841A0281|35 45|mutagenesis
P08408841A0281|53 76|chromosomal abnormalities
P08408841A0281|80 99|single-gene mutations
P08408963A0048|8 9|L.
P08409284A0262|9 18|absorption
P08409284A0262|21 30|amino acids
P08409284A0262|36 45|NBB carrier
P08409284A0262|50 66|neutral amino acids
P08409284A0262|72 72|Y
P08409284A0262|84 100|dibasic amino acids
P08409284A0262|109 118|PHE carrier
P08409284A0262|123 131|operative
P08409284A0262|167 184|watery diarrhoea due
P08409284A0262|187 193|cholera
P08409593A0357|2 5|CFDN
P08409593A0357|7 10|AMPC
P08409593A0357|14 16|MNZ
P08409593A0357|24 50|potent antimicrobial activity
P08409593A0357|58 65|H. pylori
P08409593A0357|81 84|AMPC
P08409593A0357|92 117|marked bactericidal activity
P08409593A0357|121 129|short time
P08410042T0000|0 23|Creutzfeldt-Jakob disease
P08410042T0000|27 52|lyophilised dura mater grafts
P08410042T0000|65 69|cases
P08410097A0356|1 17|high mean intensity
P08410097A0356|20 24|CLTPA
P08410097A0356|26 74|standardized multivariate regression coefficient beta
P08410097A0356|82 83|p =
P08410097A0356|94 116|high maximal oxygen uptake
P08410097A0356|118 121|beta
P08410097A0356|129 129|p
P08410097A0356|162 177|plasma fibrinogen
P08410097A0356|168 177|fibrinogen
P08410097A0356|197 215|strongest covariates
P08411024T0000|4 14|young people
P08411024T0000|41 68|cystic fibrosis carrier testing
P08411276A0302|16 25|PIC patient
P08411276A0302|39 51|same mechanism
P08411276A0302|64 73|same coding
P08411276A0302|83 102|Trauma Score variables
P08411276A0302|104 124|Glascow Coma Scale score
P08411276A0302|126 146|systolic blood pressure
P08411276A0302|148 162|respiratory rate
P08411276A0302|184 207|Severity Characterization
P08411276A0302|210 215|Trauma
P08411276A0302|218 222|ASCOT
P08411276A0302|258 258|A
P08411276A0302|260 260|B
P08411276A0302|265 265|C
P08411276A0302|270 284|ASCOT components
P08411276A0302|288 302|serious injuries
P08412120A0839|0 3|Skin
P08412120A0839|7 15|bowel TPO2
P08412120A0839|26 28|DO2
P08412120A0839|42 42|P
P08412620A0688|23 24|bp
P08412620A0688|40 62|transcription start point
P08412620A0688|65 68|virB
P08412620A0688|101 114|full activation
P08412620A0688|121 128|promoter
P08412620A0688|131 134|VirF
P08412662A0333|15 20|cosmid
P08412662A0333|60 78|transposon insertion
P08412662A0333|81 86|257DH4
P08412662A0333|94 105|localized Tn5
P08412662A0333|103 105|Tn5
P08412662A0333|113 127|kb EcoRI fragment
P08412665A0000|3 12|scr regulon
P08412665A0000|15 20|pUR400
P08412665A0000|27 85|chromosomally encoded scr regulon of Klebsiella pneumoniae KAY2026
P08412665A0000|47 56|scr regulon
P08412665A0000|59 68|Klebsiella
P08412665A0000|79 85|KAY2026
P08412665A0000|115 132|a specific repressor
P08412665A0000|116 132|specific repressor
P08412665A0000|134 137|ScrR
P08413186A0077|11 29|molecular mechanisms
P08413186A0077|107 125|trans-acting factors
P08413186A0077|150 156|nitrate
P08413186A0077|160 180|nitrite reductase genes
P08413186A0077|196 207|first enzymes
P08413186A0077|213 219|pathway
P08413186A1199|3 10|Ntl1 gene
P08413186A1199|23 32|unique copy
P08413186A1199|38 68|diploid N. plumbaginifolia species
P08413205A0733|0 31|Transient transfection experiments
P08413205A0733|44 56|Pax-8 isoforms
P08413205A0733|44 48|Pax-8
P08413205A0733|61 61|b
P08413205A0733|69 69|c
P08413205A0733|73 73|d
P08413205A0733|92 104|transcription
P08413205A0733|110 117|promoter
P08413205A0733|131 136|copies
P08413205A0733|140 171|paired-domain recognition sequence
P08413209A0159|3 21|amino-terminal third
P08413209A0159|43 80|high-mobility-group motif characteristic
P08413209A0159|83 101|DNA-binding proteins
P08413215A0327|26 49|various NF-kappa B subunits
P08413215A0327|33 49|NF-kappa B subunits
P08413215A0327|70 82|transcription
P08413215A0327|91 102|IL-8 promoter
P08413223A0847|4 17|multiple copies
P08413223A0847|23 43|IL-1 beta NF-kappa B site
P08413223A0847|58 80|enhancerless simian virus
P08413223A0847|70 90|simian virus 40 promoter
P08413223A0847|83 90|promoter
P08413223A0847|119 130|phorbol ester
P08413223A0847|134 175|lipopolysaccharide-inducible gene expression
P08413239A0490|17 38|end-adjacent sequence CA
P08413239A0490|40 40|N
P08413239A0490|42 52|3-10AGTNNAA
P08413239A0490|65 94|plant Pol II-specific U snRNA genes
P08413239A0490|70 94|Pol II-specific U snRNA genes
P08413239A0490|116 127|end formation
P08413239A0490|130 142|U2 transcripts
P08413239A0490|159 168|vertebrate
P08413239A0490|183 190|tolerant
P08413239A0490|193 200|mutation
P08413260A1437|5 11|results
P08413260A1437|24 32|Rb protein
P08413260A1437|64 64|s
P08413260A1437|71 99|cell cycle-regulatory machinery
P08413260A1437|106 112|G2 phase
P08413274A0452|0 3|MDBP
P08413274A0452|8 11|HeLa
P08413274A0452|15 23|Raji cells
P08413274A0452|30 49|DNA-protein complexes
P08413274A0452|54 74|X-box oligonucleotides
P08413274A0452|115 131|standard MDBP sites
P08413291A1473|0 13|Transgenic mice
P08413291A1473|26 45|rat TnI-CAT fusion gene
P08413291A1473|83 96|skeletal muscle
P08414410A0270|0 6|METHODS
P08414410A0270|17 27|healthy eyes
P08414410A0270|32 53|ocular hypertensive eyes
P08414410A0270|58 75|normal visual fields
P08414410A0270|83 98|glaucomatous eyes
P08414410A0270|103 125|early visual field defects
P08414410A0270|143 153|qualitative
P08414410A0270|157 176|quantitative measures
P08414410A0270|179 194|structural damage
P08414410A0270|200 209|optic nerve
P08414410A0270|213 227|nerve fiber layer
P08414502A0244|0 9|Consistent
P08414502A0244|39 62|transcriptional regulator
P08414502A0244|64 82|wild-type p53 protein
P08414502A0244|103 115|transcription
P08414502A0244|118 133|several promoters
P08415637A0000|3 24|ADP-ribosylation factor
P08415637A0000|26 28|ARF
P08415637A0000|47 57|subfamilies
P08415637A0000|63 76|RAS superfamily
P08415637A0000|79 115|low molecular weight GTP-binding proteins
P08415637A0000|117 125|G proteins
P08415643A0555|3 8|E1 gene
P08415643A0555|11 17|located
P08415643A0555|27 37|first intron
P08415643A0555|50 53|RCC1
P08415643A0555|76 80|onset
P08415643A0555|83 89|mitosis
P08415712A1153|0 26|Genomic Southern blot analysis
P08415712A1153|30 46|chromosome mapping
P08415712A1153|57 61|GPRK6
P08415712A1153|84 95|related genes
P08415712A1153|105 115|chromosomes
P08415712A1153|154 164|GPRK located
P08415712A1153|154 157|GPRK
P08415712A1153|172 193|Huntington disease locus
P08415712A1153|196 205|chromosome
P08416952A0956|0 23|Metabolic labeling studies
P08416952A0956|41 53|co-expression
P08416952A0956|56 61|nmt72p
P08416952A0956|66 89|several protein substrates
P08416952A0956|92 96|Nmt1p
P08416952A0956|129 133|Leu99
P08416952A0956|140 151|substitution
P08416952A0956|173 181|acylation
P08416952A0956|197 213|protein substrates
P08416977A0892|5 14|CTD kinases
P08416977A0892|26 30|CTDK1
P08416977A0892|34 38|CTDK2
P08416977A0892|57 70|chromatography
P08416977A0892|73 78|Mono Q.
P08417117A0592|8 11|mRNA
P08417117A0592|23 24|kb
P08417117A0592|45 53|abundance
P08417330A0149|24 44|51-bp promoter fragment
P08417330A0149|46 55|oligo31/32
P08417330A0149|71 91|heat shock inducibility
P08417330A0149|97 129|heterologous CYC1-lacZ reporter gene
P08417330A0149|145 146|N.
P08417331A0745|16 23|HIR1 gene
P08417331A0745|34 46|88-kDa protein
P08417331A0745|56 62|repeats
P08417331A0745|66 70|motif
P08417331A0745|81 92|G beta subunit
P08417331A0745|95 111|retinal transducin
P08417331A0745|118 146|yeast transcriptional repressor
P08417331A0745|148 151|Tup1
P08417349A1633|25 35|replication
P08417349A1633|38 56|UV-damaged templates
P08417349A1633|95 105|replication
P08417349A1633|115 130|mutation fixation
P08418183A0000|10 16|factors
P08418183A0000|33 56|heterosexual transmission
P08418183A0000|59 94|human T cell leukemia/lymphoma virus type
P08418183A0000|97 102|HTLV-I
P08418183A0000|108 121|married couples
P08418183A0000|135 153|Miyazaki Cohort Study
P08418183A0000|161 168|November
P08418183A0000|176 180|April
P08418183A0000|199 224|husband HTLV-I-seropositive
P08418183A0000|226 226|H
P08418183A0000|230 245|wife seropositive
P08418183A0000|247 247|W
P08418183A0000|253 253|H
P08418183A0000|256 256|W
P08418183A0000|261 261|H
P08418183A0000|264 264|W
P08418183A0000|273 273|H
P08418183A0000|276 276|W
P08419318A1695|0 3|Biol
P08419333A0126|33 47|DNA repair enzyme
P08419333A0126|66 90|corresponding genomic clone
P08419338A0273|0 1|L.
P08419338A0273|3 8|Stange
P08419338A0273|10 11|G.
P08419338A0273|13 21|Markovich
P08419338A0273|23 24|D.
P08419338A0273|26 30|Biber
P08419338A0273|32 33|J.
P08419338A0273|35 40|Testar
P08419338A0273|42 43|X.
P08419338A0273|45 51|Zorzano
P08419338A0273|53 54|A.
P08419338A0273|56 62|Palacin
P08419338A0273|64 65|M.
P08419338A0273|70 74|Murer
P08419338A0273|76 77|H.
P08419376A0357|3 20|nucleotide sequence
P08419376A0357|39 49|polypeptide
P08419376A0357|55 64|amino acids
P08419376A0357|70 72|kDa
P08419376A0357|81 112|putative membrane-spanning domains
P08420230A0544|0 4|SAECG
P08420230A0544|6 21|echocardiography
P08420230A0544|25 43|thallium-201 imaging
P08420230A0544|86 96|angioplasty
P08420571A1880|14 18|PACE4
P08420571A1880|22 24|PC4
P08421295A0365|4 17|fusion proteins
P08421295A0365|22 44|stable specific complexes
P08421295A0365|50 63|short DNA duplex
P08421295A0365|76 79|CTGT
P08421295A0365|84 105|4ACAG consensus sequence
P08421295A0365|111 123|LexA repressor
P08421687A0397|3 24|selenocysteine residues
P08421823A1041|0 10|CONCLUSIONS
P08421823A1041|12 33|Free protein S deficiency
P08421823A1041|59 66|patients
P08421897A0000|9 18|past decade
P08421897A0000|20 33|different types
P08421897A0000|36 64|endogenous retroviral sequences
P08421897A0000|85 95|human genome
P08421897A0000|105 130|low stringency hybridization
P08421897A0000|140 148|DNA probes
P08421897A0000|151 162|evolutionary
P08421897A0000|172 192|animal retrovirus genes
P08421910A0599|5 14|components
P08421910A0599|22 30|complexes
P08421910A0599|43 47|TRBPs
P08421910A0599|49 51|p30
P08421910A0599|53 55|p37
P08421910A0599|57 59|p46
P08421910A0599|61 63|p50
P08421910A0599|68 70|p56
P08421910A0599|99 104|TAR RNA
P08421910A0599|122 141|uv cross-linking assay
P08422975A1205|3 28|obvious functional necessity
P08422975A1205|32 38|editing
P08422975A1205|41 65|kinetoplastid mitochondria
P08422975A1205|82 98|translatable mRNAs
P08423831A0523|53 69|significant issues
P08423831A0523|72 90|denervating diseases
P08423831A0523|112 124|different sets
P08423831A0523|127 136|parameters
P08425050A0898|2 24|extensive inverted repeat
P08425050A0898|38 41|rpeA
P08425050A0898|43 57|inverted repeats
P08425050A0898|81 89|PE operons
P08425221A0000|11 40|novel cytoplasmic tyrosine kinase
P08425221A0000|16 40|cytoplasmic tyrosine kinase
P08425221A0000|48 50|BPK
P08425221A0000|52 72|B cell progenitor kinase
P08425221A0000|96 101|stages
P08425221A0000|107 114|B lineage
P08425221A0000|120 131|myeloid cells
P08427501A0221|0 15|Large differences
P08427501A0221|26 31|groups
P08427501A0221|49 77|HA-synthesizing enzyme activity
P08427501A0221|49 69|HA-synthesizing enzyme
P08427501A0221|82 106|degradative enzyme activity
P08427501A0221|114 119|higher
P08427501A0221|122 156|aspirin-induced asthma-related polyps
P08427501A0221|163 172|other types
P08427501A0221|175 185|nasal polyps
P08428722A1123|5 24|multivariate analysis
P08428722A1123|29 37|variables
P08428722A1123|78 99|blood urea nitrogen level
P08428722A1123|101 135|serum aspartate aminotransferase level
P08428722A1123|137 154|community-acquired
P08428722A1123|158 185|hospital-acquired peritonitis
P08428722A1123|191 205|Child-Pugh score
P08428722A1123|209 213|ileus
P08428750T0000|0 11|Localization
P08428750T0000|17 30|intronless gene
P08428750T0000|40 64|calmodulin-like protein CLP
P08428750T0000|40 61|calmodulin-like protein
P08428750T0000|62 64|CLP
P08428750T0000|67 90|human chromosome 10p13-ter
P08428907A0653|11 21|stage larvae
P08428907A0653|26 38|OBP transcript
P08428907A0653|70 77|abundant
P08428907A0653|82 93|ribosomal RNA
P08428940A1763|3 12|such mutant
P08428940A1763|41 47|hexamer
P08428940A1763|50 51|PR
P08428940A1763|71 79|occupancy
P08428940A1763|86 89|MerR
P08428940A1763|93 105|RNA polymerase
P08428940A1763|124 159|inefficient transcriptional initiation
P08428940A1763|162 169|merR mRNA
P08428952A0399|8 16|L-plastin
P08428952A0399|31 39|many types
P08428952A0399|42 60|malignant human cells
P08428952A0399|63 83|non-hemopoietic origin
P08428952A0399|132 144|tumorigenesis
P08428952A0399|147 158|solid tissues
P08428952A1957|29 35|fimbrin
P08428952A1957|39 65|third distinct plastin isoform
P08428952A1957|96 105|high levels
P08428952A1957|111 124|small intestine
P08428953A1718|4 11|promoter
P08428953A1718|26 47|constitutive expression
P08428953A1718|53 78|reporter beta-galactosidase
P08428953A1718|61 78|beta-galactosidase
P08428953A1718|81 93|high frequency
P08428953A1718|107 114|colonies
P08428953A1718|128 132|cells
P08428953A1718|144 152|L-plastin
P08428953A1718|183 190|promoter
P08428953A1718|203 210|inactive
P08428953A1718|224 231|colonies
P08428953A1718|234 250|normal fibroblasts
P08428953A1718|266 277|low frequency
P08428953A1718|280 301|constitutive activation
P08428953A1718|315 322|colonies
P08428953A1718|332 358|SV40-transformed fibroblasts
P08428953A1718|377 395|L-plastin expression
P08428953A1718|377 385|L-plastin
P08428965A1868|3 11|half-life
P08428965A1868|17 50|serum-induced CBP/tk binding activity
P08428965A1868|30 32|CBP
P08428965A1868|34 35|tk
P08428965A1868|76 77|h.
P08428965A1868|79 86|ABSTRACT
P08428965A1868|101 105|WORDS
P08429019A0735|3 8|DNase I
P08429019A0735|3 7|DNase
P08429019A0735|9 17|footprint
P08429019A0735|33 46|silencer region
P08429019A0735|58 71|inverted repeat
P08429019A0735|75 93|six-nucleotide motif
P08429019A0735|95 101|epsilon
P08429019A0735|112 113|bp
P08429019A0735|120 125|shares
P08429019A0735|130 134|bases
P08429019A0735|142 164|GATA-1 consensus sequence
P08429019A2022|35 54|YY1 consensus sequence
P08429019A2022|66 80|protein B binding
P08429019A2022|110 143|perfect yeast ABF-1 consensus sequence
P08429019A2022|152 159|ABSTRACT
P08429019A2022|174 178|WORDS
P08429020A0495|20 24|exons
P08429020A0495|31 37|introns
P08429020A0495|47 55|kilobases
P08429020A0495|68 89|entire open reading frame
P08429020A0495|93 106|glycoprotein IX
P08429020A0495|93 104|glycoprotein
P08429020A0495|126 134|third exon
P08429568A0000|0 36|Rhizobium meliloti large plasmid pRmeGR4b
P08429568A0000|47 90|nodulation competitiveness locus nfe responsible
P08429568A0000|97 116|nodulation efficiency
P08429568A0000|120 137|competitive ability
P08429568A0000|140 148|strain GR4
P08429568A0000|151 162|alfalfa roots
P08430087A0467|20 34|recombinant beta
P08430087A0467|41 51|gamma chains
P08430087A0467|71 87|biochemical assays
P08430087A0467|90 106|beta gamma activity
P08430087A0467|90 98|beta gamma
P08430087A0467|121 136|membrane extracts
P08430087A0467|140 159|supernatant fractions
P08430087A0467|164 179|infected Sf9 cells
P08430095A0161|45 59|related function
P08430095A0161|61 64|SMD1
P08430095A0161|66 72|located
P08430095A0161|88 92|PRP38
P08430095A0913|18 22|Smd1p
P08430095A0913|48 72|cellular splicing apparatus
P08430095A0913|85 99|snRNA maturation
P08431100A0108|28 47|fine motor performance
P08431100A0108|65 85|brain-injured children
P08431100A0108|95 102|years old
P08431100A0108|139 143|hours
P08431100A0108|149 167|normal children group
P08432137A0000|13 47|parameters pleural adenosine deaminase
P08432137A0000|49 52|PADA
P08432137A0000|69 76|patients
P08432137A0000|82 99|PADA/serum ADA ratio
P08432137A0000|82 85|PADA
P08432137A0000|101 106|P/SADA
P08432137A0000|103 106|SADA
P08432137A0000|111 115|cases
P08432137A0000|118 132|pleural lysozyme
P08432137A0000|134 137|PLYS
P08432137A0000|142 146|cases
P08432137A0000|152 169|PLYS/serum LYS ratio
P08432137A0000|152 155|PLYS
P08432137A0000|157 164|serum LYS
P08432137A0000|171 176|P/SLYS
P08432137A0000|171 171|P
P08432137A0000|173 176|SLYS
P08432137A0000|181 185|cases
P08432137A0000|191 212|pleural interferon gamma
P08432137A0000|214 216|IFN
P08432137A0000|221 225|cases
P08432137A0000|263 289|tuberculous pleural effusions
P08432526A0580|5 9|exons
P08432526A0580|36 50|sequencing cDNAs
P08432526A0580|61 96|polymerase chain reaction amplification
P08432526A0580|100 120|fibroblast cDNA library
P08432696A1117|0 7|Deletion
P08432696A1117|13 20|apeA gene
P08432696A1117|41 48|deletion
P08432696A1117|51 66|other proteinases
P08432696A1117|68 75|protease
P08432696A1117|81 95|aminopeptidase N
P08432696A1117|119 128|cell growth
P08432696A1117|134 145|various media
P08435755A0938|2 11|Experiment
P08435755A0938|13 35|scopolamine hydrobromide
P08435755A0938|46 50|mg/kg
P08435755A0938|72 72|h
P08435755A0938|83 103|electrical stimulation
P08435755A0938|125 138|stage-3 seizure
P08435755A1078|0 2|PNT
P08435755A1078|4 6|ADD
P08435755A1078|10 12|BSS
P08435755A1078|18 29|initial stage
P08435755A1078|32 39|kindling
P08435755A1078|41 52|kindling rate
P08435755A1078|59 65|stage-3
P08435755A1078|71 78|seizures
P08435755A1078|80 96|seizure parameters
P08435755A1078|102 113|first stage-3
P08435755A1078|147 152|values
P08435755A1078|155 168|saline-treated
P08435755A1078|170 181|control group
P08435794A0658|0 10|CONCLUSIONS
P08435885A0787|9 27|positive correlation
P08435885A0787|35 63|pyridinium cross-link excretion
P08435885A0787|67 94|thyroid hormone concentrations
P08437521A0000|0 18|Mutations truncating
P08437521A0000|30 47|C-terminal residues
P08437521A0000|55 78|transcriptional activator
P08437521A0000|91 98|areA gene
P08437521A0000|109 136|nitrogen metabolite repression
P08437521A0000|139 157|Aspergillus nidulans
P08437521A0000|198 208|areA product
P08437521A0000|231 239|most genes
P08437521A0000|245 255|areA control
P08437521A0000|245 248|areA
P08437737A0100|0 13|Naval personnel
P08437737A0100|23 31|standards
P08437737A0100|35 37|%BF
P08437737A0100|56 65|active duty
P08438584A0524|0 19|Weak promoter activity
P08438584A0524|37 44|promoter
P08438584A0524|50 51|C1
P08438584A0524|55 60|C2 ORFs
P08438584A0524|62 70|C1-C2 gene
P08438584A0524|81 88|promoter
P08438584A0524|94 98|V1 ORF
P08438584T0000|16 34|coat protein promoter
P08438584T0000|51 61|mosaic virus
P08438584T0000|83 99|C1-C2 gene products
P08439564A0883|3 28|amino acid sequence alignment
P08439564A0883|31 34|TC II
P08439564A0883|31 32|TC
P08439564A0883|45 67|other Cbl binding proteins
P08439564A0883|50 67|Cbl binding proteins
P08439564A0883|69 86|rat intrinsic factor
P08439564A0883|88 107|human transcobalamin I
P08439564A0883|111 128|porcine haptocorrin
P08439564A0883|144 159|% overall homology
P08439597A0000|4 21|short communication
P08439597A0000|31 74|novel fluorimetric microplate enzyme immunoassay
P08439597A0000|76 79|FEIA
P08439597A0000|86 125|commercial time-resolved fluoroimmunoassay
P08439597A0000|147 157|thyrotropin
P08439597A0000|165 174|blood spots
P08439597A0176|31 54|retrospective study design
P08439597A0176|59 77|newborn blood samples
P08439597A0176|87 102|screening centres
P08440238T0000|12 21|C-terminus
P08440238T0000|24 33|adenovirus
P08440238T0000|37 46|E1a protein
P08440238T0000|76 97|cellular phosphoprotein
P08440238T0000|116 133|negative modulation
P08440238T0000|136 142|T24-ras
P08440238T0000|166 178|tumorigenesis
P08440238T0000|182 191|metastasis
P08440688A1509|5 11|studies
P08440688A1509|31 42|G alpha i genes
P08440688A1509|31 36|G alpha
P08440688A1509|38 42|genes
P08440688A1509|68 79|LLC-PK1 cells
P08440688A1509|93 107|differentiation
P08440688A1509|112 125|hormone signals
P08440720A1404|0 9|Constructs
P08440720A1404|23 42|full-length PfCPK cDNA
P08440720A1404|80 88|high level
P08440720A1404|100 123|60-kDa recombinant protein
P08441379A0912|16 48|proIL-1 beta cap site-proximal region
P08441379A0912|50 56|located
P08441379A0912|82 92|proIL-1 beta
P08441379A0912|99 127|simian virus 40 enhancer elements
P08441379A0912|99 109|simian virus
P08441379A0912|112 127|enhancer elements
P08441379A0912|155 163|monocytes
P08441379A0912|170 178|HeLa cells
P08441379A0912|199 207|competent
P08441379A0912|211 228|IL-1 beta expression
P08441379A0912|211 218|IL-1 beta
P08441394A1297|10 15|PC-PLC
P08441394A1297|31 55|signal transduction pathway
P08441394A1297|65 77|transcription
P08441394A1297|80 84|c-fos
P08441394A1297|88 91|junB
P08441394A1297|112 116|c-myc
P08441394A1297|135 143|PKC-delta
P08441394A1297|147 159|Ras activation
P08441394A1297|147 149|Ras
P08441411A1260|2 30|mitogen-stimulated splenocytes
P08441411A1260|32 46|Gfi-1 expression
P08441411A1260|32 36|Gfi-1
P08441411A1260|63 63|h
P08441411A1260|69 79|stimulation
P08441411A1260|94 103|high levels
P08441411A1260|111 111|h
P08441411A1260|156 161|events
P08441411A1260|192 195|IL-2
P08441411A1260|203 210|receptor
P08441411A1260|245 246|G1
P08441411A1260|252 257|S phase
P08441411A1260|263 271|cell cycle
P08441423A0145|33 36|GCD6
P08441423A0145|40 48|GCD7 genes
P08441423A0145|66 73|products
P08441423A0145|94 108|GCN4 translation
P08441423A0145|94 97|GCN4
P08441423A0145|114 136|nonstarvation conditions
P08441869A0334|3 17|plateau MO2 value
P08441869A0334|36 53|allometric relation
P08442384A0430|41 50|amino acids
P08442384A0430|54 77|upstream open reading frame
P08442384A0430|79 82|uORF
P08442384A0430|126 141|amino acid peptide
P08442384T0000|3 23|SCH9 protein kinase mRNA
P08442384T0000|50 70|small open reading frame
P08443122A0657|12 17|T cells
P08443122A0657|21 50|fibroblasts PILOT gene expression
P08443122A0657|32 40|PILOT gene
P08443122A0657|73 75|PMA
P08443122A0657|95 97|CyA
P08443339A1374|0 24|Histochemical localization
P08443339A1374|27 29|GUS
P08443339A1374|38 53|promoter function
P08443339A1374|56 68|leaf epidermis
P08443339A1374|70 78|mesophyll
P08443339A1374|82 96|vascular bundles
P08443339A1374|103 108|cortex
P08443339A1374|112 127|vascular cylinder
P08443340A0522|28 45|expression patterns
P08443340A0522|68 82|promoter regions
P08443340A0522|87 92|acidic
P08443340A0522|97 114|basic glucanase gene
P08443340A0522|120 137|beta-glucuronidase
P08443340A0522|139 141|GUS
P08443340A0522|143 154|reporter gene
P08443340A0522|183 192|constructs
P08443340A0522|195 217|transgenic tobacco plants
P08443341A0384|0 19|Southern blot analysis
P08443341A0384|25 30|probes
P08443341A0384|40 47|portions
P08443341A0384|53 59|genomic
P08443341A0384|63 71|B. napus MA
P08443341A0384|75 86|MB cDNA clones
P08443341A0384|97 113|MA type myrosinases
P08443341A0384|103 113|myrosinases
P08443341A0384|140 144|genes
P08443341A0384|151 167|MB type myrosinases
P08443341A0384|157 167|myrosinases
P08443341A0384|190 194|genes
P08443341A0384|197 203|B. napus
P08444184A0245|0 8|Sudomoina
P08444184A0245|10 11|A.
P08444344A0000|0 10|Zinc fingers
P08444344A0000|12 13|Zf
P08444344A0000|19 39|common structural motif
P08444344A0000|47 77|many nucleic acid-binding proteins
P08444345A0403|10 19|bovine EFIA
P08444345A0403|22 30|amino acid
P08444345A0403|32 33|aa
P08444345A0403|47 56|% identical
P08444345A0403|59 65|rat EFIA
P08444345A0403|72 81|% identical
P08444345A0403|84 100|human EFIA/DbpB/YB
P08444345A0403|94 97|DbpB
P08444345A0403|103 133|family member DNA-binding protein B
P08444345A0403|135 138|DbpB
P08445299T0000|0 5|Effect
P08445299T0000|8 27|tracheal insufflation
P08445299T0000|30 41|deferoxamine
P08445299T0000|44 61|acute ozone toxicity
P08445299T0000|64 67|rats
P08445655A1009|0 11|Localization
P08445655A1009|17 30|insertion locus
P08445655A1009|36 46|yeast genome
P08445655A1009|50 71|complementation studies
P08445655A1009|79 105|temperature-sensitive mutant
P08445655A1009|124 132|mutations
P08445655A1009|136 142|allelic
P08445729A0657|0 10|Replacement
P08445729A0657|16 29|spacer sequence
P08445729A0657|43 46|ARMs
P08445729A0657|52 65|shorter stretch
P08445729A0657|87 96|RNA binding
P08445792A0469|0 3|Type
P08445792A0469|34 38|forms
P08445792A0469|40 42|IIA
P08445792A0469|46 48|IIB
P08445792A0469|69 87|underscribed species
P08445792A0469|90 108|developmental stages
P08445792A0469|114 124|same species
P08446579A0784|10 34|transcription factor Gal-ER
P08446579A0784|50 55|potent
P08446579A0784|63 73|susceptible
P08446579A0784|76 101|cell type-specific variation
P08446579A0784|113 134|strong activating domain
P08446579A0784|140 161|herpesvirus protein VP16
P08446579A0784|169 177|C terminus
P08446579A1210|3 18|exogenous fos gene
P08446579A1210|38 50|maximal levels
P08446579A1210|60 61|hr
P08446579A1210|64 79|estrogen addition
P08447005T0001|0 10|Elimination
P08447005T0001|13 48|Haemophilus influenzae type b meningitis
P08447005T0001|68 78|vaccination
P08449133A0578|0 13|Endosonography
P08449133A0578|32 45|tumor extension
P08449133A0578|51 58|T2 tumors
P08449133A0578|62 69|T3 tumors
P08449133A0578|79 86|T4 tumors
P08449943A0225|5 16|present study
P08449943A0225|32 46|unique mechanism
P08449943A0225|57 65|8-Cl-cAMP
P08449943A0225|88 101|kinase isozymes
P08449943A0225|104 139|HL-60 human promyelocytic leukemia cells
P08449978A0000|0 7|Analysis
P08449978A0000|10 28|cell cycle regulation
P08449978A0000|41 45|yeast
P08449978A0000|82 111|central regulatory protein kinase
P08449978A0000|113 117|Cdc28
P08449978A0000|128 134|changes
P08449978A0000|155 163|cell cycle
P08449978A0000|181 194|distinct groups
P08449978A0000|197 203|cyclins
P08449978A0000|220 233|different times
P08449986A0455|0 16|Overlapping clones
P08449986A0455|29 44|full-length cDNAs
P08449986A0455|48 55|MMI alpha
P08449986A0455|72 81|mouse brain
P08450015A0175|17 36|preliminary isolation
P08450015A0175|39 48|oxiracetam
P08450015A0175|52 67|internal standard
P08450015A0175|72 77|plasma
P08450015A0175|80 100|solid-phase extraction
P08450015A0175|127 154|n-propyl carbamate derivatives
P08451187A0267|17 34|several differences
P08451187A0267|48 62|new ars sequences
P08451331T0000|0 7|Pathways
P08451331T0000|18 31|olfactory bulbs
P08451331T0000|39 72|medial preoptic anterior hypothalamus
P08451331T0000|88 106|intermale aggression
P08451331T0000|109 112|mice
P08453101A0128|0 14|Pokeweed mitogen
P08453101A0128|16 18|PWM
P08453101A0128|22 29|anti-CD3
P08453101A0128|52 73|c-jun messenger RNA (mRNA
P08453101A0128|52 68|c-jun messenger RNA
P08453101A0128|70 73|mRNA
P08453101A0128|75 80|levels
P08453101A0128|83 88|T cells
P08453950A0498|9 24|seizure induction
P08453950A0498|26 29|MABP
P08453950A0498|44 47|mm Hg
P08453950A0498|51 58|brain pHi
P08453950A0498|84 86|min
P08453950A0498|113 113|h
P08453950A0498|115 115|P
P08454077A0956|11 14|rats
P08454077A0956|24 30|U74500A
P08454077A0956|33 49|mg/kg i.v. infusion
P08454077A0956|62 64|min
P08454077A0956|72 88|revascularisation
P08454077A0956|107 110|GMBF
P08454077A0956|121 131|reperfusion
P08454077A0956|133 134|PI
P08454077A0956|137 139|min
P08454077A0956|160 162|min
P08454077A0956|183 185|min
P08454077A0956|203 203|p
P08454077A0956|212 219|controls
P08454077A0956|223 229|normals
P08454077A0956|235 255|complete muscle salvage
P08454077A0956|257 259|GMV
P08454077A0956|263 263|%
P08454077A0956|269 285|reperfused muscles
P08454077A0956|287 287|p
P08454077A0956|296 303|controls
P08454077A0956|320 321|NS
P08454077A0956|326 332|normals
P08454077A0956|337 346|h ischaemia
P08454077A0956|350 357|ABSTRACT
P08454077A0956|372 376|WORDS
P08454591A0692|0 9|Sequencing
P08454591A0692|13 32|1.3-kilobase fragment
P08454591A0692|41 54|flanking region
P08454591A0692|60 67|TSG6 gene
P08454591A0692|78 86|TATA-like
P08454591A0692|90 102|CAAT sequences
P08454591A0692|110 131|transcription start site
P08454591A1322|20 31|inducibility
P08454591A1322|34 37|IL-1
P08454591A1322|40 42|TNF
P08454591A1322|44 52|positions
P08454591A1322|71 91|potential binding sites
P08454591A1322|95 104|IRF-1 and -2
P08454591A1322|95 99|IRF-1
P08454591A1322|106 109|AP-1
P08454591A1322|114 120|NF-IL-6
P08454858A0285|0 7|Ig-alpha
P08454858A0285|11 17|Ig-beta
P08454858A0285|33 52|cytoplasmic structure
P08454858A0285|61 70|amino acids
P08454858A0285|101 120|cytoplasmic effectors
P08454858A0285|160 177|signal transduction
P08455598A0000|0 13|Sterile mutants
P08455598A0000|55 65|alpha * cells
P08455598A0000|75 95|a/alpha aar1-6 genotype
P08455598A0000|107 124|alpha mating ability
P08455598A0000|133 145|mating ability
P08455598A0000|158 163|defect
P08455598A0000|166 174|a1-alpha 2
P08455598A0000|166 173|a1-alpha
P08455598A0000|175 184|repression
P08455611A0000|12 32|functional interaction
P08455611A0000|40 72|human embryonic zeta 2 globin promoter
P08455611A0000|40 57|human embryonic zeta
P08455611A0000|59 72|globin promoter
P08455611A0000|79 106|alpha globin regulatory element
P08455611A0000|108 112|HS-40
P08455611A0000|114 120|located
P08455611A0000|123 124|kb
P08455611A0000|138 152|zeta 2 globin gene
P08455611A0000|138 141|zeta
P08455611A0000|143 152|globin gene
P08455611A0154|12 35|transient expression assay
P08455611A0154|40 44|HS-40
P08455611A0154|56 72|authentic enhancer
P08455611A0154|76 89|high-level zeta
P08455611A0154|86 104|zeta 2 globin promoter
P08455611A0154|91 112|globin promoter activity
P08455611A0154|115 123|K562 cells
P08455611A0154|127 143|erythroid cell line
P08455611A0154|146 154|embryonic
P08455611A0154|161 171|fetal origin
P08455623A0630|0 13|Initial results
P08455623A0630|30 40|23S pre-rRNA
P08455623A0630|72 80|depletion
P08455623A0630|86 125|small nucleolar RNA-associated proteins NOP1
P08455623A0630|86 121|small nucleolar RNA-associated proteins
P08455623A0630|122 125|NOP1
P08455623A0630|129 132|GAR1
P08455623A0630|140 156|snr10 mutant strain
P08455623A0630|140 150|snr10 mutant
P08455629A0335|0 8|Breitbart
P08455629A0335|10 11|L.
P08456378A0134|21 31|feasibility
P08456378A0134|34 67|indirect mesenteric lymphangiography
P08456378A0134|71 91|colonoscopic technique
P08456378A0134|95 105|canine model
P08456879A0000|0 8|OBJECTIVE
P08456879A0000|37 62|simultaneous concentrations
P08456879A0000|65 77|serum cotinine
P08456879A0000|84 88|fetal
P08456879A0000|92 104|maternal blood
P08457205A0240|0 24|Internal amino acid sequence
P08457205A0240|75 91|% sequence identity
P08457205A0240|96 104|sequences
P08457205A0240|114 130|mammalian G alpha 11
P08457205A0240|114 128|mammalian G alpha
P08457205A0240|134 145|G alpha q cDNAs
P08457205A0240|134 139|G alpha
P08457205A0240|141 145|cDNAs
P08457291A0170|0 8|Estradiol
P08457291A0170|36 57|certain proto-oncogenes
P08457291A0170|43 57|proto-oncogenes
P08457291A0170|80 105|potential regulatory regions
P08457291A0170|111 131|cellular c-fos oncogene
P08458660A0855|0 6|Air lead
P08458660A0855|14 43|significant explanatory variable
P08458849A0364|25 41|flaN transcription
P08458849A0364|25 28|flaN
P08458849A0364|58 72|sigma 54 promoter
P08458849A0364|58 62|sigma
P08458849A0364|65 72|promoter
P08458849A0364|79 96|ftr elements located
P08458849A0364|112 133|transcription start site
P08458849A0364|140 143|ftr2
P08458849A0364|148 151|+120
P08458849A0364|153 156|ftr3
P08458906A0827|1 12|micrograms/l
P08458906A0827|26 30|urine
P08458906A0827|64 70|persons
P08459012T0000|0 13|Fibular dimelia
P08459012T0000|18 27|deficiency
P08459012T0000|33 37|tibia
P08459465A0257|4 19|prospective study
P08459465A0257|39 56|energy expenditures
P08459465A0257|61 68|patients
P08459465A0257|74 92|indirect calorimetry
P08459465A0257|111 132|basal energy expenditure
P08459465A0257|147 169|Harris-Benedict equation
P08459465A0257|188 204|energy expenditure
P08459465A0257|216 242|basal energy expenditure times
P08459465A0257|246 259|activity factor
P08459465A0257|265 276|stress factor
P08460270A0205|21 30|infections
P08460270A0205|32 47|hypobiotic larvae
P08460346A0350|19 31|double blinded
P08460346A0350|44 66|placebo-controlled study
P08460918A0252|0 4|Group
P08460918A0252|20 41|noncholestatic patients
P08460918A0252|71 89|cholestatic patients
P08460918A0252|94 114|mild hepatic impairment
P08460918A0252|126 134|bilirubin
P08460918A0252|138 149|mumol liter-1
P08460918A0252|151 169|alkaline phosphatase
P08460918A0252|174 182|IU liter-1
P08460918A0252|184 211|gamma-glutamyltranspeptidase
P08460918A0252|216 224|IU liter-1
P08460918A0252|249 285|benign intrahepatic cholestatic patients
P08460918A0252|312 329|hyperbilirubinemia
P08460918A0252|335 346|mumol liter-1
P08461946A0386|39 57|renographic findings
P08461946A0386|59 66|t1/2 time
P08461946A0386|73 85|split function
P08461946A0386|91 98|patients
P08461946A0386|102 102|%
P08461981A0882|21 32|animals older
P08461981A0882|38 43|months
P08461981A0882|64 84|regeneration phenomena
P08461981A0882|90 104|3-month-old rats
P08461981A0882|118 125|immature
P08463284A1531|0 10|Nuclear beta
P08463284A1531|13 15|PKC
P08463284A1531|21 33|p34cdc2 kinase
P08463284A1531|56 87|nuclear lamina structural stability
P08463284A1531|94 102|cell cycle
P08463320A1219|6 38|copper-phenanthroline footprinting
P08463320A1219|41 79|individual gel shift assembly intermediates
P08463320A1219|94 113|302-nucleotide G4oric
P08463320A1219|126 137|SSB tetramers
P08463320A1219|171 186|more SSB tetramers
P08463320A1219|208 222|unique structure
P08463485T0000|0 6|Effects
P08463485T0000|9 37|intramammary endotoxin infusion
P08463485T0000|40 69|milking-induced oxytocin release
P08463485T0000|55 62|oxytocin
P08464056A0000|0 37|Finger associated box-zinc finger proteins
P08464056A0000|0 5|Finger
P08464056A0000|16 37|box-zinc finger proteins
P08464056A0000|39 46|FAX-ZFPs
P08464056A0000|59 67|subfamily
P08464056A0000|73 88|many C2H2 type ZFPs
P08464056A0000|77 88|C2H2 type ZFPs
P08464056A0000|91 103|Xenopus laevis
P08464056A0510|0 14|Further evidence
P08464056A0510|42 66|FAX-ZFP transcription units
P08464056A0510|79 98|Southern blot analysis
P08464056A0510|101 132|large genomic restriction fragments
P08464056A0510|144 176|transverse field gel electrophoresis
P08464056A0510|189 201|hybridization
P08464056A0510|204 220|intact chromosomes
P08464924A0243|1 7|rat cDNA
P08464924A0243|19 23|eIF-5
P08464924A0243|89 106|active eIF-5 protein
P08464924A0243|95 106|eIF-5 protein
P08466864A0878|0 17|Mutational analyses
P08466864A0878|49 57|sequences
P08466864A0878|70 78|bp segment
P08466864A0878|91 138|putative cyclic AMP responsive element binding protein
P08466864A0878|99 138|cyclic AMP responsive element binding protein
P08466864A0878|140 143|CREB
P08466864A0878|145 155|binding site
P08466864A0878|159 167|TGF-beta 1
P08466864A0878|159 166|TGF-beta
P08466864A0878|171 187|PMA responsiveness
P08466864A0878|191 202|putative PU-1
P08466864A0878|199 202|PU-1
P08466864A0878|206 220|Sp1 binding sites
P08466864A0878|224 244|basal promoter activity
P08468320A0941|6 7|J.
P08468475A1280|2 37|F42A-stimulated internalization assays
P08468475A1280|40 65|forskolin-induced YT-1 cells
P08468475A1280|57 60|YT-1
P08468475A1280|70 84|IL-2R alpha chain
P08468475A1280|125 140|IL-2R beta subunit
P08468475A1280|155 164|IL-2R alpha
P08468475A1280|190 210|F42A-IL-2R beta complex
P08468475A1280|224 236|alpha-subunit
P08468475A1280|259 266|affinity
P08468475A1280|272 290|F42A binding reaction
P08469831T0001|3 26|microcirculatory dynamics
P08469831T0001|29 43|prostaglandin E1
P08469831T0001|50 60|nicardipine
P08469831T0001|69 86|different reactions
P08469831T0001|92 96|hyper
P08469831T0001|101 116|hypodynamic state
P08469831T0001|119 129|septic shock
P08469831T0001|133 140|rat model
P08470021A0195|13 22|prevalence
P08470021A0195|25 37|IgG antibodies
P08470021A0195|45 60|Trypanosoma cruzi
P08470021A0195|70 80|blood donors
P08470021A0195|86 102|Instituto Nacional
P08470021A0195|105 115|Cardiologia
P08470021A0195|117 129|Ignacio Chavez
P08470021A0195|133 142|Mexico City
P08470895A1617|0 10|Examination
P08470895A1617|16 32|immediate sequence
P08470895A1617|40 52|mRNA start site
P08470895A1617|62 68|TATA box
P08470895A1617|72 101|multiple known enhancer sequences
P08471241T0000|3 21|short-term synthesis
P08471241T0000|25 47|infant-regulated removal
P08471241T0000|56 69|lactating women
P08471629A0816|0 14|Pseudosubstrate
P08471629A0816|37 46|C-terminus
P08471629A0816|49 71|Ca-dependent PKC isotypes
P08471629A0816|82 89|beta-PKC
P08471629A0816|96 107|nPKC activity
P08471629A0816|96 99|nPKC
P08471629A0816|119 129|Histone IIIS
P08471629A0816|132 138|peptide
P08471629A0816|148 156|substrate
P08471796A1654|12 18|results
P08471796A1654|21 28|new model
P08471796A1654|47 67|nif/fix gene expression
P08471796A1654|47 49|nif
P08471796A1654|70 82|A. caulinodans
P08472750A0999|0 20|Nitric oxide inhalation
P08472750A0999|39 59|pulmonary hypertension
P08472750A0999|62 82|porcine endotoxin shock
P08472750A0999|94 112|arterial oxygenation
P08472750A0999|116 117|pH
P08472750A0999|123 139|marked attenuation
P08472750A0999|142 162|sympathetic activation
P08473731A0149|0 17|B cell-specific mb-1
P08473731A0149|21 28|B29 genes
P08473731A0149|38 57|alpha/beta components
P08473731A0149|63 83|BCR-associated complex
P08473731A0149|86 95|mature sIgM
P08473731A0149|92 97|sIgM+ B
P08473731A0149|97 102|B cells
P08473967T0000|0 9|Bipolarity
P08473967T0000|12 28|Jungian type theory
P08473967T0000|35 59|Myers-Briggs Type Indicator
P08474438A0000|10 34|nuclear ribonucleoproteins
P08474438A0000|69 88|nascent RNA polymerase
P08474438A0000|76 101|RNA polymerase II transcripts
P08474438A0000|91 101|transcripts
P08474438A0000|127 165|subsequent nuclear RNA processing reactions
P08474438A0000|176 198|pre-mRNA polyadenylation
P08474438A0000|202 209|splicing
P08474438A0000|218 247|nucleocytoplasmic mRNA transport
P08474439A0877|0 8|Mutations
P08474439A0877|16 20|sites
P08474439A0877|25 37|larger effects
P08474439A0877|50 63|nonmuscle cells
P08474439A0877|67 86|A/T-rich site mutation
P08474439A0877|91 106|pronounced effect
P08474439A0877|113 131|striated muscle types
P08474439A0877|133 141|mutations
P08474439A0877|147 150|MEF1
P08474439A0877|157 161|E-box
P08474439A0877|202 215|skeletal muscle
P08474439A0877|220 228|mutations
P08474439A0877|234 241|CArG site
P08474439A0877|277 289|cardiac muscle
P08474456A1041|0 28|Transient transfection analysis
P08474456A1041|38 46|mutations
P08474456A1041|64 74|10-bp region
P08474456A1041|98 100|Ets
P08474456A1041|104 128|proximal LyF-1 binding sites
P08474456A1041|112 128|LyF-1 binding sites
P08474456A1041|142 151|D' activity
P08474464A0348|35 36|TR
P08474464A0348|38 44|Rev-Erb
P08474464A0348|38 40|Rev
P08474464A0348|42 44|Erb
P08474464A0348|58 71|TR binding sites
P08475104A0341|17 36|25-bp promoter element
P08475104A0341|71 84|G1-S activation
P08475104A0341|90 109|human thymidine kinase
P08475104A0341|111 113|htk
P08475104A0341|115 122|promoter
P08475104A0341|125 146|growth-stimulated cells
P08475104A0341|150 163|cellular target
P08475104A0341|166 172|cyclin A
P08475104A0341|179 194|p33cdk2 complexes
P08476087A0814|5 24|protective influences
P08476087A0814|64 72|pressures
P08476087A0814|91 94|mmHg
P08476854A0097|0 5|DNase I
P08476854A0097|0 4|DNase
P08476854A0097|6 17|footprinting
P08476854A0097|22 44|rat liver nuclear extracts
P08476854A0097|56 82|major protein-binding domains
P08476854A0097|89 90|P1
P08476854A0097|98 99|P7
P08476854A0097|106 124|base pair DNA fragment
P08476854A0097|126 134|base pairs
P08479742A0985|44 54|excess wt p53
P08479742A0985|52 54|p53
P08479742A0985|64 80|cell proliferation
P08479742A0985|99 117|neoplastic processes
P08481004A0321|7 11|clone
P08481004A0321|22 40|cognate endonuclease
P08482539A0913|0 19|Northern blot analysis
P08482539A0913|22 37|total cellular RNA
P08482539A0913|51 54|xylP
P08482539A0913|63 78|1.3-kb transcript
P08482539A0913|95 99|xylan
P08483412A0000|3 6|nifJ
P08483412A0000|10 22|nifH promoters
P08483412A0000|25 34|Klebsiella
P08483412A0000|70 95|sigma 54-dependent promoters
P08483412A0000|127 137|NifA protein
P08483479A1056|17 19|PTH
P08483479A1056|23 26|cAMP
P08483479A1056|37 60|collagen promoter activity
P08483479A1056|37 52|collagen promoter
P08483479A1056|63 71|calvariae
P08483479A1056|76 89|transgenic mice
P08483479A1056|108 112|alpha
P08483479A1056|117 132|collagen promoter
P08483479A1056|143 164|cis elements down-stream
P08483479A1056|171 179|kilobases
P08483479A1056|191 193|PTH
P08483479A1056|197 210|cAMP repression
P08483479A1056|213 234|collagen gene expression
P08483479A1056|213 224|collagen gene
P08484514A1536|24 33|isoflurane
P08484514A1536|44 63|baseline vein diameter
P08484514A1536|70 80|stimulation
P08484689T0000|0 9|Prevalence
P08484689T0000|12 30|rheumatoid arthritis
P08484689T0000|34 49|rheumatoid factor
P08484689T0000|52 56|women
P08484689T0000|70 83|secular decline
P08484891A0000|8 39|olfactory associative conditioning
P08484891A0000|42 52|newborn rats
P08484891A0000|61 76|marked structural
P08484891A0000|80 96|functional changes
P08484891A0000|102 114|olfactory bulb
P08484891A0000|116 129|recent evidence
P08484891A0000|142 160|extrabulbar circuits
P08484891A0000|189 201|early memories
P08485317A0000|3 23|fission yeast dsk1+ gene
P08485317A0000|3 18|fission yeast dsk1
P08485317A0000|26 44|multicopy suppressor
P08485317A0000|48 72|cold-sensitive dis1 mutants
P08485317A0000|62 72|dis1 mutants
P08485317A0000|82 104|novel 61-kd protein kinase
P08485317A0000|87 104|61-kd protein kinase
P08486035T0000|0 6|Closure
P08486035T0000|12 33|patent ductus arteriosus
P08486035T0000|39 46|Ligaclip
P08486035T0000|55 69|minithoracotomy
P08486276A0419|0 17|Sequence comparison
P08486276A0419|38 40|ORF
P08486276A0419|45 59|protein database
P08486276A0419|84 102|% aa sequence homology
P08486276A0419|105 126|bacterial transmembrane
P08486276A0419|128 129|TM
P08486276A0419|131 138|proteins
P08486276A0419|162 179|chloramphenicol (Cm
P08486276A0419|162 176|chloramphenicol
P08486276A0419|178 179|Cm
P08486276A0419|184 195|tetracycline
P08486276A0419|197 198|Tc
P08486276A0419|215 244|arabinose-proton symport protein
P08486705A0181|3 11|yeast gene
P08486705A0181|23 27|eIF-5
P08486705A0181|39 42|TIF5
P08486705A0181|109 126|active eIF-5 protein
P08486705A0181|115 126|eIF-5 protein
P08488700A0283|3 12|strategies
P08488700A0283|20 29|hepatitis B
P08488700A0283|33 42|hepatitis D
P08488700A0283|85 96|immunization
P08488700A0283|125 138|infective blood
P08488700A0283|141 156|blood derivatives
P08488700A0283|172 190|particular awareness
P08488700A0283|195 204|hepatitis B
P08490002A0620|0 5|Xylose
P08490002A0620|10 37|arabinose-containing polymers
P08490002A0620|63 71|cellulose
P08490002A0620|79 84|breads
P08491124A0517|3 23|technical construction
P08491124A0517|29 43|mouth protectors
P08491124A0517|72 86|instrumentation
P08491124A0517|93 97|costs
P08491124A0517|104 112|materials
P08491124A0517|139 153|mouth protectors
P08491383A0154|3 15|alpha-subunit
P08491383A0154|31 42|telomeric DNA
P08491383A1291|17 29|alpha-subunit
P08491383A1291|35 57|telomere-binding protein
P08491383A1291|63 86|many transcription factors
P08491383A1291|91 110|separable DNA-binding
P08491383A1291|114 146|protein-protein interaction domains
P08491383A1291|114 128|protein-protein
P08491683A0651|5 12|patients
P08491683A0651|23 30|patients
P08491683A0651|50 57|patients
P08491683A0651|61 95|poorly-differentiated adenocarcinoma
P08491683A0651|101 108|prostate
P08492164T0000|0 21|Spontaneous burst firing
P08492164T0000|24 47|cat primary auditory cortex
P08492164T0000|55 69|depth dependence
P08492164T0000|84 108|neural interaction measures
P08492290A0306|13 32|potentiometric method
P08492290A0306|36 48|aqueous medium
P08492290A0306|51 66|ionic strength mu =
P08492290A0306|74 91|stability constants
P08492290A0306|93 99|log beta
P08492290A0306|101 101|=
P08492290A0306|109 115|log beta
P08492290A0306|117 117|=
P08495786A0085|0 21|Cryopreservation straws
P08495786A0085|41 48|additive
P08495786A0085|78 93|unprocessed donor
P08496157A0000|3 11|bcl-2 gene
P08496157A0000|38 51|22-kDa proteins
P08496157A0000|73 85|carboxyl tails
P08496157A0000|97 124|alternative splicing mechanism
P08496184A0772|3 24|active open reading frame
P08496184A0772|30 34|clone
P08496184A0772|43 45|min
P08496184A0772|57 66|chromosome
P08496184A0772|94 112|wild type counterpart
P08496185A0484|0 16|Subsequent cloning
P08496185A0484|20 45|nucleotide sequence analysis
P08496185A0484|51 76|S. pombe adenylate kinase gene
P08496185A0484|51 52|S.
P08496185A0484|58 76|adenylate kinase gene
P08496185A0484|78 81|adk1
P08496185A0484|109 119|nucleotides
P08496475T0000|0 12|Calcification
P08496475T0000|16 38|cariogenic Streptococcus
P08496475T0000|44 58|Corynebacterium
P08496475T0000|60 71|Bacterionema
P08496475T0000|73 83|matruchotii
P08496599A0310|11 29|alternative splicing
P08496599A0310|34 40|BGP gene
P08496599A0310|70 88|distinct mRNA species
P08496601A1153|16 24|promoters
P08496601A1153|28 38|muMIP-1 beta
P08496601A1153|42 53|muMIP-1 alpha
P08496601A1153|71 81|CK-1 element
P08496601A1153|86 111|transient expression studies
P08496601A1153|114 116|RAW
P08496601A1153|122 132|macrophages
P08496601A1153|137 153|proximal fragments
P08496601A1153|165 175|muMIP-1 beta
P08496601A1153|181 202|muMIP-1 alpha 5' promoter
P08496601A1153|181 192|muMIP-1 alpha
P08496601A1153|195 202|promoter
P08496601A1153|211 260|human growth hormone reporter gene link LPS-inducibility
P08496601A1153|211 240|human growth hormone reporter gene
P08496601A1153|269 284|promoter segments
P08496601A1153|315 335|consensus CK-1 sequence
P08496601A1153|324 335|CK-1 sequence
P08496848A0692|8 35|essential contrast differences
P08496848A0692|54 65|FSE sequences
P08496848A0692|74 107|routine asymmetric dual SE counterpart
P08497190T0079|0 15|Sequence analysis
P08497190T0079|38 57|hyp regulatory mutants
P08497248A0000|18 25|receptor
P08497248A0000|29 63|macrophage colony-stimulating factor 1
P08497248A0000|29 62|macrophage colony-stimulating factor
P08497248A0000|65 69|CSF-1
P08497248A0000|75 92|c-fms protooncogene
P08497248A0000|118 125|immature
P08497248A0000|129 155|mature mononuclear phagocytes
P08497248A0000|159 170|trophoblasts
P08497259A0452|13 32|SUP4A53T61 transcript
P08497259A0452|45 50|higher
P08497259A0452|56 67|tap1-1 mutant
P08497259A0452|77 84|wild type
P08497269A0999|4 21|sequence similarity
P08497269A0999|46 49|GCN1
P08497269A0999|63 71|ribosomes
P08497269A0999|74 86|tRNA molecules
P08497269A0999|90 98|functions
P08497269A0999|101 111|conjunction
P08497269A0999|116 119|GCN2
P08497269A0999|132 150|uncharged tRNA levels
P08497269A0999|169 189|translation elongation
P08497273T0000|0 4|NF-HB
P08497273T0000|6 9|BSAP
P08497273T0000|14 22|repressor
P08497273T0000|28 73|murine immunoglobulin heavy-chain 3' alpha enhancer
P08497273T0000|28 58|murine immunoglobulin heavy-chain
P08497273T0000|61 73|alpha enhancer
P08497273T0000|76 86|early stages
P08497273T0000|89 109|B-cell differentiation
P08497280A0266|20 23|SWI4
P08497280A0266|37 62|normal cell cycle progression
P08497280A0266|83 85|cis
P08497280A0266|90 111|trans-acting regulators
P08497280A0266|114 130|SWI4 transcription
P08497280A0266|114 117|SWI4
P08497280A1397|32 38|pathway
P08497280A1397|55 71|SWI4 transcription
P08497280A1397|55 58|SWI4
P08497280A1397|86 89|SWI6
P08497280T0000|0 39|Multiple SWI6-dependent cis-acting elements
P08497280T0000|8 11|SWI6
P08497280T0000|47 63|SWI4 transcription
P08497280T0000|47 50|SWI4
P08497280T0000|74 82|cell cycle
P08498570A1118|13 19|changes
P08498570A1118|22 44|carotid sinus stimulation
P08498570A1118|51 59|blood flow
P08498570A1118|65 72|hindlimb
P08498570A1118|80 86|changes
P08498570A1118|93 97|Pcrit
P08498570A1118|101 102|Ra
P08499376A0000|0 11|Multizone PRK
P08499376A0000|41 54|predictability
P08499376A0000|57 79|higher myopic corrections
P08499903A0883|4 11|patients
P08499903A0883|16 24|deletions
P08499903A0883|29 42|parental origin
P08499903A0883|45 52|deletion
P08499916A0000|3 12|COL7A1 gene
P08499916A0000|26 40|type VII collagen
P08499916A0000|62 74|candidate gene
P08499916A0000|111 115|forms
P08499916A0000|118 147|dystrophic epidermolysis bullosa
P08500524A0424|18 36|productive gamma gene
P08500524A0424|57 68|variable exon
P08500524A0424|81 101|normal splicing signals
P08500524A0424|112 137|adjacent intron organization
P08500938A0408|22 25|BGCT
P08500938A0408|48 68|intralesional excision
P08500938A0408|80 96|articular surfaces
P08500938A0408|109 118|metaphysis
P08501030A0456|7 22|nitrate induction
P08501030A0456|25 48|aeg-46.5 operon expression
P08501030A0456|25 38|aeg-46.5 operon
P08501030A0456|74 88|narL null strains
P08501030A0456|74 77|narL
P08501030A0456|90 93|M.H.
P08501678A0498|4 15|new knowledge
P08501678A0498|49 84|successful immunoprophylactic strategy
P08501678A0498|99 108|Hib disease
P08503348A0226|3 27|HMG CoA reductase inhibitors
P08503348A0226|3 17|HMG CoA reductase
P08503348A0226|38 72|effective cholesterol-lowering agents
P08504707A0376|3 10|etiology
P08504707A0376|12 20|pathology
P08504707A0376|22 28|brain CT
P08504707A0376|33 40|features
P08504707A0376|42 63|clinical manifestations
P08504707A0376|83 91|accidents
P08504928T0000|0 27|Drosophila 230-kD TFIID subunit
P08504928T0000|10 27|230-kD TFIID subunit
P08504928T0000|30 46|functional homolog
P08504928T0000|52 76|human cell cycle gene product
P08504928T0000|97 106|DNA binding
P08504928T0000|112 133|TATA box-binding subunit
P08504928T0000|136 140|TFIID
P08504932A0123|3 17|enigmatic aspect
P08504932A0123|20 39|GATA factor expression
P08504932A0123|20 29|GATA factor
P08504932A0123|46 64|several GATA proteins
P08504932A0123|53 64|GATA proteins
P08504932A0123|89 118|same DNA-binding site specificity
P08504932A0123|136 149|erythroid cells
P08504933A0000|0 4|Pit-1
P08504933A0000|8 47|tissue-specific POU domain factor obligatory
P08504933A0000|23 37|POU domain factor
P08504933A0000|71 84|cell phenotypes
P08504933A0000|90 111|anterior pituitary gland
P08505075A0236|0 12|Maximum number
P08505075A0236|15 21|strains
P08505075A0236|27 27|%
P08505075A0236|33 41|resistant
P08505075A0236|44 61|S. bareilly serotype
P08505075A0236|91 91|%
P08505075A0236|103 109|S. typhi
P08505075A0236|115 115|%
P08505312A0285|0 3|Biol
P08505340T0000|0 15|Characterization
P08505340T0000|19 36|hormonal regulation
P08505340T0000|42 49|promoter
P08505340T0000|55 95|rat prostaglandin endoperoxide synthase 2 gene
P08505340T0000|55 90|rat prostaglandin endoperoxide synthase
P08505340T0000|98 111|granulosa cells
P08505495A0253|3 11|retention
P08505495A0253|14 21|75SeHCAT
P08505605A0461|0 21|Patient characteristics
P08505605A0461|36 45|deep wounds
P08505605A0461|64 93|wound characteristics predictive
P08505605A0461|107 113|healing
P08505605A0461|132 138|healing
P08506317A0000|0 6|Members
P08506317A0000|12 22|C/EBP family
P08506317A0000|25 43|basic-leucine zipper
P08506317A0000|45 48|bZip
P08506317A0000|50 69|transcription factors
P08506317A0000|74 85|heterodimers
P08506317A0000|98 104|CAAT box
P08506317A0000|108 142|other sequence-related enhancer motifs
P08506384A0146|2 15|mammalian cells
P08506384A0146|17 31|phosphorylation
P08506384A0146|34 43|eIF-2 alpha
P08506384A0146|65 70|eIF-2B
P08506384A0146|75 95|GDP-GTP exchange factor
P08506384A0146|99 103|eIF-2
P08507921A1021|18 29|observations
P08507921A1021|46 59|stratification
P08507921A1021|62 76|acute MI patients
P08507921A1021|79 92|plasma ANF level
P08507921A1021|85 87|ANF
P08507921A1021|96 119|useful non-invasive method
P08507921A1021|133 141|prognosis
P08507921A1021|159 169|individuals
P08507921A1021|172 179|high risk
P08507921A1021|182 193|cardiac death
P08508774A0242|0 7|Analysis
P08508774A0242|13 19|binding
P08508774A0242|22 24|Lrp
P08508774A0242|33 62|circularly permuted DNA fragments
P08508774A0242|90 92|Lrp
P08508778A0112|0 11|Yeast mutants
P08508778A0112|20 37|functional NOP1 gene
P08508778A0112|30 37|NOP1 gene
P08508778A0112|57 72|human fibrillarin
P08508778A0112|79 98|temperature sensitive
P08508778A0112|111 118|impaired
P08508778A0112|121 138|pre-rRNA processing
P08508861A0294|3 10|patients
P08508861A0294|26 34|ischaemia
P08508861A0294|38 56|non-ischaemia groups
P08508861A0294|80 101|lactate extraction ratio
P08508861A0294|108 123|balloon inflation
P08509051A0316|12 19|patients
P08509051A0316|32 44|mortality rate
P08509051A0316|49 49|%
P08509333A0843|1 13|36-kDa protein
P08509333A0843|21 29|localized
P08509333A0843|35 50|membrane fraction
P08509333A0843|64 72|minicells
P08509333A0843|83 90|plasmids
P08509333A0843|98 105|ftsN gene
P08509333A0843|121 124|FtsN
P08509333A0843|129 143|membrane protein
P08509335T0000|0 3|SSG1
P08509335T0000|19 56|sporulation-specific 1,3-beta-glucanase
P08509419A0785|0 9|Expression
P08509419A0785|47 54|tyrosine
P08509419A0785|76 86|suppression
P08509419A0785|94 122|yeast cytoplasmic TyrRS activity
P08509419A0785|94 114|yeast cytoplasmic TyrRS
P08509430A0372|3 30|first involved complementation
P08509430A0372|34 56|nonphotosynthetic mutant
P08509430A0372|59 71|Chlamydomonas
P08509430A0372|73 79|CC-2341
P08509430A0372|81 90|ac-u-g-2.3
P08509430A0372|102 119|frameshift mutation
P08509430A0372|125 132|psaB gene
P08509430A0372|148 174|photosynthetic transformants
P08509430A0372|177 189|minimal medium
P08510320A0000|10 16|strains
P08510320A0000|19 39|methicillin-resistant
P08510320A0000|61 64|MRSA
P08510320A0000|89 119|minimum inhibitory concentrations
P08510320A0000|121 124|MICs
P08510320A0000|138 156|antibacterial agents
P08510320A0000|166 174|arbekacin
P08510320A0000|176 178|ABK
P08510320A1249|36 40|MRSAs
P08510320A1249|52 56|Japan
P08510320A1249|94 102|many drugs
P08510320A1249|135 148|high resistance
P08510320A1249|156 167|beta-lactams
P08510647A1347|0 3|Beg2
P08510647A1347|7 10|Beg1
P08510647A1347|70 90|utilization properties
P08510647A1347|99 113|barley globulins
P08510924A0490|34 48|transactivation
P08510924A0490|54 71|human HSP70 promoter
P08510924A0490|74 84|Myb proteins
P08511994A0000|18 34|one-year-old carps
P08511994A0000|58 69|ichthiomycin
P08511994A0000|72 85|concentrations
P08511994A0000|99 112|micrograms/dm3
P08512728A0991|0 6|RESULTS
P08512728A0991|21 42|significant differences
P08512728A0991|94 101|patients
P08512728A0991|115 132|atrial fibrillation
P08512728A0991|137 146|conduction
P08512728A0991|152 167|accessory pathway
P08512728A0991|171 172|RR
P08512728A0991|176 176|=
P08512728A0991|180 183|msec
P08512728A0991|198 199|p =
P08513025A0000|20 36|skinfold thickness
P08513025A0000|60 83|serum total bilirubin level
P08513025A0000|87 109|transcutaneous bilirubin
P08513025A0000|111 113|TcB
P08513025A0000|115 122|readings
P08514757A1100|4 16|immunophilins
P08514757A1100|24 37|important roles
P08514757A1100|40 55|receptor assembly
P08514757A1100|72 82|new category
P08514757A1100|85 90|ligand
P08514757A1100|95 121|calcium-dependent modulators
P08514757A1100|124 138|protein function
P08514766A0732|3 16|GTPase activity
P08514766A0732|3 8|GTPase
P08514766A0732|19 25|CDC42Ce
P08514766A0732|50 65|human n-chimaerin
P08514766A0732|68 91|GTPase-activating protein
P08514766A0732|98 111|related p21 rac1
P08514766A0732|105 111|p21 rac1
P08515619A0184|0 16|Tl-201 uptake ratio
P08515619A0184|22 35|right ventricle
P08515619A0184|62 72|total counts
P08515619A0184|78 91|right ventricle
P08515619A0184|94 99|counts
P08515619A0184|123 128|Tl-201
P08515619A0184|133 138|higher
P08515619A0184|141 144|COPD
P08515619A0184|158 175|pulmonary emphysema
P08515619A0184|179 187|B type COPD
P08515619A0184|190 210|Burrows classification
P08515619A0184|217 224|controls
P08515776A0971|1 23|second hydrophobic domain
P08515776A0971|38 55|hydrophilic regions
P08515776A0971|73 91|transmembrane region
P08516301A0080|15 16|kb
P08516301A0080|36 40|exons
P08516301A0080|48 54|introns
P08516308A0669|12 14|RAD
P08516308A0669|16 20|cells
P08516308A0669|37 49|microcolonies
P08516308A0669|54 58|cells
P08516308A0669|80 98|shaped inviable cells
P08516324A0000|8 31|chromosomal translocation
P08516324A0000|52 63|Ewing sarcoma
P08516324A0000|67 95|primitive neuroectodermal tumor
P08516324A0000|106 121|chimeric molecule
P08516324A0000|131 160|amino-terminal-encoding portion
P08516324A0000|166 172|EWS gene
P08516324A0000|178 211|carboxyl-terminal DNA-binding domain
P08516324A0000|224 231|FLI1 gene
P08517737A0889|5 12|findings
P08517737A0889|32 59|microenvironmental conditions
P08517737A0889|79 90|water systems
P08517737A0889|101 119|variable populations
P08518797T0000|0 24|X-linked liver glycogenosis
P08518797T0000|26 37|localization
P08518797T0000|53 65|candidate gene
P08519621A0150|26 37|observations
P08519621A0150|43 60|immunologic changes
P08519621A0150|80 90|acute stages
P08519621A0150|140 162|toxin-producing bacteria
P08519621A0150|168 174|pharynx
P08519621A0150|178 198|gastrointestinal tract
P08519862T0001|0 10|Measurement
P08519862T0001|13 33|anti-HCV IgM antibodies
P08519862T0001|40 54|experimental kit
P08520646A0000|0 20|Embryo coculture system
P08520646A0000|49 58|mechanisms
P08520646A0000|82 90|fertility
P08520646A0000|95 99|aging
P08521414A1384|5 13|cell lines
P08521414A1384|23 33|methylation
P08521414A1384|39 47|CpG island
P08521414A1384|62 70|first exon
P08521414A1384|73 80|p16INK4A
P08521414A1384|93 106|abundant levels
P08521414A1384|110 126|nontranslated mRNA
P08521414A1384|139 158|alternative first exon
P08521414A1384|160 165|E1 beta
P08521414A1384|176 189|other cell lines
P08521414A1384|200 212|p16INK4A locus
P08521717A0126|2 25|immunoperoxidase reaction
P08521717A0126|2 17|immunoperoxidase
P08521717A0126|27 35|PAP method
P08521717A0126|44 52|antiserum
P08521717A0126|55 64|Factor VIII
P08521717A0126|55 60|Factor
P08521717A0126|70 84|primary antibody
P08521717A0126|104 122|endometrial biopsies
P08521717A0126|134 143|Factor VIII
P08521717A0126|134 139|Factor
P08521717A0126|157 178|endometrial endothelium
P08521717A0126|193 201|insertion
P08521717A0126|204 213|LNG-IUD-20
P08521780A0485|0 9|Umweltchem
P08522175A0306|0 4|Egd1p
P08522175A0306|7 16|homologous
P08522175A0306|19 28|human BTF3b
P08522175A0306|53 63|beta subunit
P08522175A0306|69 118|heterodimeric nascent-polypeptide-associated complex
P08522175A0306|120 122|NAC
P08522175A0306|142 179|signal-sequence-specific protein sorting
P08522175A0306|183 195|translocation
P08522175A0306|197 204|Wiedmann
P08522175A0306|211 216|Nature
P08522511A1250|8 10|PLB
P08522511A1250|17 36|optimal lyase activity
P08522511A1250|24 28|lyase
P08522511A1250|39 40|pH
P08522511A1578|5 19|flanking regions
P08522511A1578|26 29|pelA
P08522511A1578|33 36|pelB
P08522511A1578|66 87|beta-glucuronidase gene
P08522511A1578|66 83|beta-glucuronidase
P08522511A1578|105 116|F. solani f. sp
P08522511A1578|118 121|pisi
P08522511A1578|126 153|beta-glucuronidase activities
P08522511A1578|126 143|beta-glucuronidase
P08522511A1578|159 171|transformants
P08522530A1342|4 11|nifA mRNA
P08522530A1342|19 24|points
P08522530A1342|37 51|primer extension
P08522530A1342|58 80|minor upstream transcript
P08522530A1342|82 82|s
P08522530A1342|94 101|bp distal
P08522530A1342|107 115|anaerobox
P08522530A1342|120 144|major downstream transcript
P08522530A1342|155 162|bp distal
P08522530A1342|168 177|sigma 54 box
P08522530A1342|168 172|sigma
P08523031A0737|54 58|onset
P08523031A0737|61 75|initial seizures
P08523031A0737|81 99|acute ischemic stroke
P08523031A0737|103 112|recurrence
P08523545T0000|3 25|human papillomavirus type
P08523545T0000|28 36|E7 protein
P08523545T0000|48 79|adenovirus type 5 E1A amino-terminus
P08523545T0000|48 61|adenovirus type
P08523545T0000|63 104|E1A amino-terminus-dependent transactivation
P08523545T0000|107 131|adenovirus type 5 early genes
P08523545T0000|107 120|adenovirus type
P08523545T0000|122 131|early genes
P08523545T0000|144 146|ATF
P08523545T0000|150 172|Oct-1 DNA binding activity
P08523566A1106|1 19|chaotropic detergent
P08523566A1106|24 35|% Nonidet P-40
P08523566A1106|65 71|further
P08523566A1106|85 101|hydrophobic nature
P08524036A0747|0 7|Contrary
P08524036A0747|10 21|expectations
P08524036A0747|40 48|high level
P08524036A0747|65 85|stripe 2 enhancer region
P08524036A0747|65 70|stripe
P08524036A0747|72 85|enhancer region
P08524036A0747|96 113|point substitutions
P08524036A0747|117 135|insertion/deletions
P08524036A0747|145 149|sites
P08524036A0747|155 169|comparable level
P08524036A0747|186 206|other noncoding regions
P08524229T0000|0 10|Degradation
P08524229T0000|16 75|soybean ribulose-1,5-bisphosphate carboxylase small-subunit mRNA
P08524229T0000|16 32|soybean ribulose-1
P08524229T0000|36 75|bisphosphate carboxylase small-subunit mRNA
P08524229T0000|77 80|SRS4
P08524229T0000|95 117|endonucleolytic cleavage
P08524235A0695|0 6|Cloning
P08524235A0695|10 19|sequencing
P08524235A0695|32 35|dMax
P08524235A0695|45 52|deletion
P08524235A0695|64 74|basic region
P08524235A0695|78 82|helix
P08524235A0695|99 120|helix-loop-helix region
P08524235A0695|143 161|alternative splicing
P08524235A0695|164 169|max RNA
P08524241A0212|15 23|induction
P08524241A0212|26 30|HSP82
P08524241A0212|47 89|early meiotic IME1-IME2 transcriptional cascade
P08524241A0212|59 62|IME1
P08524241A0212|64 67|IME2
P08524260A0835|3 17|domain structure
P08524260A0835|20 31|bovine LTBP-2
P08524260A0835|56 66|human LTBP-2
P08524260A0835|80 87|examples
P08524260A0835|90 132|6-cysteine epidermal growth factor-like repeats
P08524260A0835|100 132|epidermal growth factor-like repeats
P08524260A0835|150 166|consensus sequence
P08524260A0835|170 183|calcium binding
P08524260A0835|198 205|examples
P08524260A0835|208 237|8-cysteine motifs characteristic
P08524260A0835|240 249|fibrillins
P08524260A0835|253 258|LTBP-1
P08524267A1022|45 73|wild-type prothymosin alpha gene
P08524267A1022|104 113|repertoire
P08524267A1022|116 131|myc-derived genes
P08524267A1022|142 144|myc
P08524267A1022|164 190|recessive negative myc mutants
P08524267A1022|181 190|myc mutants
P08524272T0000|0 21|Differential regulation
P08524272T0000|27 72|alpha/beta interferon-stimulated Jak/Stat pathway
P08524272T0000|27 46|alpha/beta interferon
P08524272T0000|58 60|Jak
P08524272T0000|62 65|Stat
P08524272T0000|78 122|SH2 domain-containing tyrosine phosphatase SHPTP1
P08524284A0309|38 42|cDNAs
P08524284A0309|51 58|PTF gamma
P08524284A0309|62 69|PTF delta
P08524284A0309|79 95|functional studies
P08524284A0309|100 116|cognate antibodies
P08524284A0309|133 148|native PTF complex
P08524284A0309|151 162|HeLa extracts
P08524292A1022|0 6|Results
P08524292A1022|14 27|mechanism study
P08524292A1022|44 46|YY1
P08524292A1022|62 76|transactivation
P08524292A1022|93 95|AP1
P08524292A1022|101 118|Sp1-related protein
P08524292A1022|123 144|YY1 suppressive activity
P08524292A1022|123 125|YY1
P08524292A1022|147 165|DNA binding dependent
P08524294A0652|3 11|skp1+ gene
P08524294A0652|3 6|skp1
P08524314A0216|3 6|TEA1
P08524314A0216|8 26|Ty enhancer activator
P08524314A0216|28 39|gene sequence
P08524314A0216|62 64|kDa
P08524314A0216|70 78|N terminus
P08524314A0216|88 98|zinc cluster
P08524314A0216|102 125|dimerization motif typical
P08524314A0216|131 145|Gal4-type family
P08524314A0216|148 166|DNA-binding proteins
P08525186A0288|0 7|Refugees
P08525186A0288|16 19|Lund
P08525186A0288|36 40|Chile
P08525186A0288|70 85|higher proportion
P08525186A0288|95 113|Swedish counterparts
P08525186A0288|121 129|odds ratio
P08526620A1344|34 64|terminal SC5b-9 complement complex
P08526620A1344|68 81|suitable marker
P08526620A1344|99 118|complement activation
P08526620A1344|125 145|cardiopulmonary bypass
P08528479A0000|0 17|Videonystagmoscopy
P08528479A0000|53 61|responses
P08528479A0000|67 82|vestibular system
P08528479A0000|98 105|patients
P08528479A0000|110 127|vestibular deficits
P08528796A1470|3 5|MCA
P08528796A1470|9 18|UA PI values
P08528796A1470|28 44|greatest deviation
P08528796A1470|51 72|single-vessel parameter
P08529098A0549|8 27|sequence similarities
P08529098A0549|36 36|%
P08529098A0549|54 79|yeast mitochondrial proteins
P08529098A0549|81 84|SMF1
P08529098A0549|88 91|SMF2
P08529098A0549|109 133|putative functional domains
P08529098A0549|135 138|exon
P08529098A0549|151 169|second transmembrane
P08529098A0549|194 221|murine susceptibility mutation
P08529098A0549|226 229|exon
P08529098A0549|250 263|transport motif
P08529630A0840|26 37|P protein mRNA
P08529630A0840|44 56|relative level
P08529630A0840|59 63|roots
P08529630A0840|88 97|detectable
P08529654A0589|3 47|B. germanica cyclophilin amino acid sequence shares
P08529654A0589|3 41|B. germanica cyclophilin amino acid sequence
P08529654A0589|50 58|% identity
P08529654A0589|66 92|cytosolic cyclophilin isoform
P08529654A0589|120 124|Cyp-1
P08529662A0507|29 39|soluble form
P08529662A0507|42 52|ERp57/GRP58
P08529662A0507|42 46|ERp57
P08529662A0507|48 52|GRP58
P08529662A0507|55 69|Western blotting
P08529662A0507|73 92|biosynthetic labeling
P08530105A0308|3 15|minimal region
P08530105A0308|27 57|Langer-Giedion syndrome deletions
P08530105A0308|93 100|patients
P08530105A0308|132 139|patients
P08530105A0308|145 153|deletions
P08530105A0308|163 171|endpoints
P08530107A1003|0 9|Consistent
P08530107A1003|17 23|hepatic
P08530107A1003|27 45|epidermal expression
P08530107A1003|48 56|histidase
P08530107A1003|81 102|histidase transcription
P08530107A1003|81 89|histidase
P08530107A1003|124 130|factors
P08530149A0689|0 9|Comparison
P08530149A0689|12 20|promoters
P08530149A0689|32 36|c-myc
P08530149A0689|45 65|weak consensus sequence
P08530149A0689|71 79|initiator
P08530149A0689|81 83|Inr
P08530149A0689|93 95|TCA
P08530149A0689|100 104|YYYNY
P08530342T0000|3 19|human gp39 promoter
P08530345A0880|0 19|Transfection analyses
P08530345A0880|32 39|mutation
P08530345A0880|55 66|TGACCT motifs
P08530345A0880|69 78|truncation
P08530345A0880|84 95|entire HD PPRE
P08530345A0880|90 91|HD
P08530345A0880|101 111|separate DR1
P08530345A0880|115 124|DR2 element
P08530345A0880|148 170|transcriptional response
P08530345A0880|173 178|HD PPRE
P08530345A0880|173 174|HD
P08530345A0880|181 203|peroxisome proliferators
P08530369A0099|9 27|autophosphorylation
P08530369A0099|30 35|Tyr397
P08530369A0099|57 88|consensus autophosphorylation site
P08530369A0099|91 119|other Src family tyrosine kinases
P08530369A0099|96 119|Src family tyrosine kinases
P08530384A0559|4 29|protein-protein interaction
P08530384A0559|47 65|simultaneous binding
P08530384A0559|68 78|Oct proteins
P08530384A0559|88 113|high resolution footprinting
P08530384A0559|119 136|Oct-DNA interaction
P08530384A0559|119 125|Oct-DNA
P08530384A0559|148 154|binding
P08530384A0559|157 161|BOB.1
P08530384A0559|157 159|BOB
P08530384A0559|163 167|OBF.1
P08530384A0559|166 167|.1
P08530384A0559|170 173|Oct1
P08530384A0559|176 179|Oct2
P08530418A1182|30 46|TR2 orphan receptor
P08530418A1182|53 67|master regulator
P08530418A1182|83 92|activation
P08530418A1182|98 104|key HREs
P08530418A1182|106 113|RARE beta
P08530418A1182|117 123|CRBPIIp
P08530418A1182|138 174|retinoic acid signal transduction pathway
P08530432A0093|14 27|mutant proteins
P08530432A0093|48 65|domains responsible
P08530432A0093|69 78|activation
P08530432A0093|81 90|repression
P08530503A1004|6 8|ARF
P08530503A1004|13 31|ARP immunoreactivity
P08530503A1004|45 59|plasma membranes
P08530503A1004|68 74|cytosol
P08530503A1004|89 99|3T3-L1 cells
P08531373A0470|21 44|recurrent annular erythema
P08531373A0470|48 72|specific skin manifestation
P08531373A0470|75 77|SjS
P08531373A0470|82 104|anti SS-A/SS-B antibodies
P08531373A0470|82 89|anti SS-A
P08531373A0470|91 104|SS-B antibodies
P08531669A0950|0 10|Competition
P08531669A0950|41 54|Central America
P08531669A0950|58 72|Caribean islands
P08531669A0950|101 117|biological control
P08531669A0950|120 135|planorbid species
P08532516A0000|21 30|properties
P08532516A0000|36 49|cdc10-C4 mutant
P08532516A0000|36 40|cdc10
P08532516A0000|55 66|fission yeast
P08532536A0925|0 13|TIEG expression
P08532536A0925|0 3|TIEG
P08532536A0925|16 24|hFOB cells
P08532536A0925|43 50|TGF-beta
P08532536A0925|54 79|bone morphogenetic protein-2
P08532536A0925|81 85|BMP-2
P08532536A0925|93 109|moderate induction
P08532536A0925|112 132|epidermal growth factor
P08532536A0925|134 136|EGF
P08532536A0925|144 152|induction
P08532536A0925|155 182|other growth factors/cytokines
P08532967A0364|2 17|infectious origin
P08532967A0364|45 68|specific etiologic therapy
P08533472A0777|12 26|protein products
P08533472A0777|29 37|ORFs N2417
P08533472A0777|41 64|N2403 present similarities
P08533472A0777|41 45|N2403
P08533472A0777|69 75|domains
P08533472A0777|80 87|proteins
P08533472A0777|90 103|other organisms
P08533472A0777|108 152|Candida maltosa cycloheximide-resistance protein
P08533472A0777|122 152|cycloheximide-resistance protein
P08533472A0777|157 194|human interleukin enhancer-binding factor
P08533472A0777|196 200|ILF-2
P08533473A0375|31 38|ADH1 gene
P08533473A0375|80 91|EST sequences
P08533757A0204|4 11|families
P08533757A0204|14 35|Ashkenazi Jewish descent
P08533757A0204|46 61|185delAG mutation
P08533757A0204|74 86|same haplotype
P08533757A0204|94 111|polymorphic markers
P08533757A0204|136 137|kb
P08533757A0204|140 144|BRCA1
P08534217A0402|3 10|subjects
P08534217A0402|21 27|regions
P08534217A0402|33 52|higher pollution level
P08534217A0402|56 63|lower FVC
P08534217A0402|67 76|FEV1 values
P08534217A0402|93 105|Viskovo region
P08534367A0984|0 5|PTP-S3
P08534367A0984|17 22|PTP-S4
P08534367A0984|32 39|deletion
P08534367A0984|44 53|amino acids
P08534367A0984|69 74|exon E1
P08534848A0188a|8 17|NR isoforms
P08534848A0188a|32 33|cv
P08534848A0188b|8 17|NR isoforms
P08534848A0188b|32 33|cv
P08534855A0000|3 21|Arabidopsis FAD7 gene
P08534855A0000|30 66|chloroplast omega-3 fatty acid desaturase
P08534855A0000|83 94|desaturation
P08534855A0000|97 125|lipid-linked dienoic fatty acids
P08535138A0857|18 37|G0-arrested leaf cells
P08535138A0857|57 68|cell division
P08535138A0857|84 96|plant hormones
P08535138A0857|98 116|cycMs4 transcription
P08535138A0857|98 103|cycMs4
P08535138A0857|136 140|onset
P08535138A0857|143 154|DNA synthesis
P08535537A0000|19 44|pharmacological backgrounds
P08535537A0000|66 78|drug treatment
P08535537A0000|81 101|essential hypertension
P08536694A0000|0 13|Protein kinases
P08536694A0000|18 29|pivotal roles
P08536694A0000|44 64|many cellular processes
P08537388A0825|27 35|deletions
P08537388A0825|50 63|distal promoter
P08537388A0825|81 107|full transcriptional activity
P08537388A0825|126 134|base pairs
P08537388A0825|137 142|WNT-5A
P08537388A0825|154 178|strongest promoter activity
P08537403A0336|3 22|protein kinase domains
P08537403A0336|25 29|LIMK1
P08537403A0336|33 37|LIMK2
P08537403A0336|66 108|unusual sequence motif Asp-Leu-Asn-Ser-His-Asn
P08537403A0336|111 122|subdomain VIB
P08537403A0336|133 143|basic insert
P08537403A0336|151 163|subdomains VII
P08537403A0336|167 170|VIII
P08538052A0000|1 25|human recombinant cDNA clone
P08538052A0000|40 57|amino acids residues
P08538052A0000|61 78|zinc-finger protein
P08538052A0000|80 86|THZif-1
P08538052A0000|109 119|cDNA library
P08538052A0000|132 166|human promyelocytic leukemia HL60 cells
P08538052A0000|171 205|synthetic oligodeoxynucleotide probes
P08538052A0000|227 244|amino acid sequences
P08538052A0000|247 261|tryptic peptides
P08538052A0000|276 301|DNA-binding protein specific
P08538052A0000|308 337|nuclease-hypersensitive element
P08538052A0000|339 341|NHE
P08538052A0000|348 361|human c-myc gene
P08538382A1012|0 12|Erythrocyte AA
P08538382A1012|15 20|FO+EPO
P08538382A1012|34 40|infants
P08538382A1012|70 93|placebo formula-fed levels
P08538483A0207|10 28|consideration weight
P08538483A0207|32 46|seasonal changes
P08538483A0207|49 56|bone mass
P08538483A0207|64 68|TBBMC
P08538483A0207|73 102|regional body bone mineral content
P08538483A0207|119 123|women
P08538483A0207|135 146|GnRH agonists
P08538483A0207|135 138|GnRH
P08538483A0207|151 156|months
P08538483A0207|160 172|endometriosis
P08538483A0207|175 185|leiomyomata
P08538702A0214|10 20|polypeptide
P08538702A0214|45 57|ABA-1 allergen
P08538702A0214|60 66|Ascaris
P08538702A0214|71 143|gp15/400 'ladder' protein of Brugia malayi, Brugia pahangi and Wuchereria bancrofti
P08538702A0214|71 78|gp15/400
P08538702A0214|96 107|Brugia malayi
P08538702A0214|109 121|Brugia pahangi
P08538702A0214|149 161|15-kDa antigen
P08538702A0214|164 181|Dirofilaria immitis
P08541499A0306|0 24|Certain transcript patterns
P08541499A0306|27 42|Epifagus plastids
P08541499A0306|78 91|tobacco operons
P08541793A0796|0 18|Spontaneous recovery
P08541793A0796|33 35|min
P08541793A0796|39 41|hrs
P08542026A0792|0 2|DAF
P08542026A0792|6 21|70 kD glycoprotein
P08542026A0792|8 21|kD glycoprotein
P08542026A0792|32 72|complement regulatory short consensus repeats
P08542026A0792|74 77|SCRs
P08542026A0792|89 95|located
P08542026A0792|113 132|complement activation
P08542026A0792|134 136|RCA
P08542026A0792|138 148|gene cluster
P08542026A0792|151 160|chromosome
P08542026A0792|174 175|kb
P08542027A1471|3 9|XS2 gene
P08542027A1471|53 59|LU genes
P08542027A1471|88 91|CD44
P08542746T0000|0 11|Diabetes care
P08542746T0000|28 37|facilities
P08542746T0000|76 84|standards
P08543173A0314|9 15|TATA box
P08543173A0314|25 50|transcriptional start points
P08543173A0314|52 54|tsp
P08543173A0314|71 93|primer extension analysis
P08543275A0130|31 41|recent burst
P08543275A0130|44 61|pseudoterranovosis
P08543275A0130|111 118|sea lions
P08543275A0130|141 152|Arctic region
P08543275A0130|170 185|northern Japan Sea
P08543275A0130|195 214|intermediate host fish
P08543595A1093|13 22|efficacies
P08543595A1093|25 43|adjuvant carboplatin
P08543595A1093|49 69|abdominal radiotherapy
P08543810A0000|19 23|genes
P08543810A0000|35 59|LPS-activated coelomocytes
P08543810A0000|86 91|clones
P08543810A0000|121 131|cDNA library
P08543810A0000|156 167|sequence tags
P08543810A0000|169 172|ESTs
P08544820T0000|0 15|Characterization
P08544820T0000|20 47|EcR/USP heterodimer target site
P08544820T0000|20 22|EcR
P08544820T0000|24 26|USP
P08544820T0000|60 81|ecdysone responsiveness
P08544820T0000|87 105|Drosophila Lsp-2 gene
P08544820T0000|97 105|Lsp-2 gene
P08545502A0914|5 9|SPECT
P08545502A0914|29 31|PET
P08545502A0914|38 51|activation task
P08546707T0000|0 24|Transcriptional activation
P08546707T0000|30 48|chicken lysozyme gene
P08546707T0000|51 62|NF-kappa Bp65
P08546707T0000|64 67|RelA
P08546707T0000|72 76|c-Rel
P08546707T0000|86 97|NF-kappa Bp50
P08547205A1060|3 9|results
P08547205A1060|25 50|bradycardic agents alinidine
P08547205A1060|54 64|zatebradine
P08547205A1060|75 96|antiarrhythmic efficacy
P08547205A1060|104 106|SVT
P08547205A1060|120 147|subacute myocardial infarction
P08547205A1060|150 162|conscious dogs
P08548291A1059|7 25|selective activation
P08548291A1059|28 32|SAPKs
P08548291A1059|57 70|ternary complex
P08548291A1059|81 85|Elk-1
P08548291A1059|87 105|serum response factor
P08548291A1059|112 131|serum response element
P08548291A1059|144 171|Elk-1-dependent transcription
P08548291A1059|144 148|Elk-1
P08549706T0000|12 35|hepatitis B virus infection
P08549706T0000|41 60|intravenous drug users
P08549706T0000|63 69|Iceland
P08549859A1604|42 53|chromosome 3p
P08549859A1604|56 98|Centre d'Etude du Polymorphisme Humain pedigrees
P08550425A1401|12 19|subunits
P08550425A1401|27 36|homologous
P08550425A1401|42 51|dimeric POR
P08550425A1401|49 51|POR
P08550425A1401|57 74|mesophilic archaeon
P08550425A1401|76 96|Halobacterium halobium
P08550425A1401|100 108|% identity
P08550460A0374|3 28|transposon-inactivated gene
P08550460A0374|40 43|pilP
P08550460A0374|50 51|bp
P08550460A0374|77 100|19.1-kDa protein precursor
P08550460A0374|114 153|typical membrane lipoprotein leader sequence
P08550461A0284|0 5|Cheung
P08550461A0284|9 10|S.
P08550462A0815|0 7|Upstream
P08550462A0815|13 19|dra gene
P08550462A0815|22 37|open reading frame
P08550462A0815|43 52|amino acids
P08550467A0863|0 25|Sucrose-specific regulation
P08550467A0863|28 31|scrB
P08550467A0863|47 54|deletion
P08550467A0863|58 59|bp
P08550467A0863|63 81|palindromic sequence
P08550467A0863|83 84|OB
P08550467A0863|94 102|positions
P08550467A0863|110 119|downstream
P08550467A0863|125 152|scrB transcriptional start site
P08550467A0863|125 128|scrB
P08550470A1021|9 12|CheW
P08550470A1021|24 39|physical coupling
P08550470A1021|45 53|receptors
P08550470A1021|59 68|kinase CheA
P08550470A1021|65 68|CheA
P08550476A0610|3 10|promoter
P08550476A0610|16 24|first gene
P08550476A0610|26 29|epiF
P08550476A0610|45 64|activator protein EpiQ
P08550476A0610|78 103|palindromic sequence similar
P08550476A0610|109 123|EpiQ binding site
P08550476A0610|129 140|epiA promoter
P08550476A0610|164 167|EpiQ
P08550564T0000|0 12|CXC chemokines
P08550564T0000|19 28|unique sets
P08550564T0000|31 53|selectivity determinants
P08550564T0000|108 122|multiple domains
P08550564T0000|125 152|human interleukin-8 receptor B.
P08551572A0155|0 29|Oligodeoxynucleotides antisense
P08551572A0155|44 71|translation initiation regions
P08551572A0155|74 77|ICP4
P08551572A0155|81 89|pp38 mRNAs
P08551572A0155|99 111|proliferation
P08551572A0155|114 122|MSB1 cells
P08551572A0155|129 137|MDCC-CU91
P08551572A0155|139 142|CU91
P08551572A0155|144 186|reticuloendotheliosis virus-transformed cells
P08551577A0000|0 20|Retroviral replication
P08551577A0000|46 63|primary transcripts
P08551577A0000|77 87|proviral DNA
P08551577A0000|106 109|mRNA
P08551577A0000|116 130|envelope protein
P08551577A0000|136 151|Rous sarcoma virus
P08551577A0000|154 160|src mRNA
P08552042A1497|21 39|promoter methylation
P08552042A1497|66 77|T-DNA borders
P08552042A1497|113 128|steady-state poly
P08552042A1497|130 130|A
P08552042A1497|133 142|mRNA levels
P08552042A1497|181 187|meiosis
P08552042A1497|191 202|reactivation
P08552042A1497|209 226|several generations
P08552045A0973|8 25|consensus sequences
P08552045A0973|29 49|phosphatase regulation
P08552045A0973|56 66|GCACGTGGG-3
P08552045A0973|74 84|GCACGTTTT-3
P08552045A0973|104 119|binding sequences
P08552045A0973|126 137|Cpflp protein
P08552045A0973|126 130|Cpflp
P08552045A0973|149 161|transcription
P08552045A0973|167 171|genes
P08552045A0973|174 195|methionine biosynthesis
P08552045A0973|202 219|centromere function
P08552082A0480|19 36|proline-rich region
P08552082A0480|39 41|CAP
P08552082A0480|59 68|SH3 domains
P08552082A0480|71 85|several proteins
P08552082A0480|99 131|yeast actin-associated protein Abp1p
P08552086A0150|33 55|vitamin D response element
P08552086A0150|57 60|VDRE
P08552086A0150|67 74|promoter
P08552086A0150|77 81|c-fos
P08552092A1678|12 25|protein binding
P08552092A1678|28 36|sequences
P08552092A1678|71 83|transcription
P08552092A1678|85 103|genomic footprinting
P08552092A1678|109 128|entire promoter region
P08552092A1678|144 156|protein factor
P08552092A1678|183 193|first intron
P08552092A1678|199 206|rep3 gene
P08552093A0657|0 14|Differentiation
P08552093A0657|34 51|cellular expression
P08552093A0657|54 74|GTPase-deficient forms
P08552093A0657|54 59|GTPase
P08552093A0657|77 83|alpha i2
P08552093A0657|86 91|alpha 0
P08552093A0657|86 90|alpha
P08552093A0657|103 113|selectivity
P08552093A0657|120 127|Gq family
P08552093A0657|130 138|G proteins
P08552095A0686|0 9|Consistent
P08552095A0686|15 26|possible role
P08552095A0686|29 41|transcription
P08552095A0686|43 47|Paf1p
P08552095A0686|50 58|localized
P08552095A0686|64 70|nucleus
P08552095A0758|14 23|abundances
P08552095A0758|26 45|many yeast transcripts
P08552095A0758|48 64|isogenic wild-type
P08552095A0758|56 64|wild-type
P08552095A0758|68 84|paf1 mutant strains
P08552095A0758|68 77|paf1 mutant
P08552095A0758|102 106|genes
P08552095A0758|134 137|PAF1
P08552095A1115|0 4|Paf1p
P08552095A1115|45 62|negative regulation
P08552095A1115|65 71|subsets
P08552095A1115|74 83|yeast genes
P08552096A0151|6 33|high-copy suppression strategy
P08552096A0151|52 60|yeast gene
P08552096A0151|62 65|UBS1
P08552096A0151|72 89|elevated expression
P08552096A0151|103 129|conditional cell cycle defects
P08552096A0151|144 157|cdc34 mutations
P08552096A0151|144 148|cdc34
P08552387A0000|0 24|Molecular characterization
P08552387A0000|27 43|malignant melanoma
P08552387A0000|46 54|soft parts
P08552387A0000|57 82|soft tissue clear cell sarcoma
P08552387A0000|94 94|t
P08552387A0000|102 124|chromosome translocation
P08552387A0000|133 138|fusion
P08552387A0000|141 143|EWS
P08552387A0000|149 178|transcriptional factor gene ATF-1
P08552643A0261|0 5|Clones
P08552643A0261|19 21|DBD
P08552643A0261|32 56|dominant negative phenotype
P08552643A0261|72 88|antiviral activity
P08552643A0261|96 119|vesicular stomatitis virus
P08552643A0261|121 123|VSV
P08552643A0261|138 149|IFN treatment
P08552643A0261|138 140|IFN
P08552670A0665|0 3|Abp1
P08552670A0665|25 37|multiple sites
P08552670A0665|40 42|ARS
P08552670A0665|55 68|DNA polymer poly
P08552670A0665|70 70|d
P08552670A0665|72 74|A.T
P08552670T0000|0 13|Identification
P08552670T0000|15 26|purification
P08552670T0000|31 46|molecular cloning
P08552670T0000|72 94|sequence-binding protein
P08552670T0000|100 111|fission yeast
P08553580A0102|1 21|short open reading frame
P08553580A0102|23 26|ORF2
P08553580A0102|31 45|unknown function
P08553580A0102|61 71|FIV isolates
P08554069A0743|13 22|homozygous
P08554069A0743|39 46|mutation
P08554069A0743|66 66|G
P08554069A0743|70 82|T transversion
P08554069A0743|92 109|acceptor splice site
P08554069A0743|117 122|intron
P08554069A0743|127 130|exon
P08554069A0743|143 159|normal RNA splicing
P08554540A1480|5 11|regions
P08554540A1480|26 52|HIT protein similarity regions
P08554723A0187|10 13|rats
P08554723A0187|47 65|ibotenic acid lesions
P08554723A0187|71 73|PBN
P08554723A0187|75 78|PBNx
P08554723A0187|115 129|LiCl-induced CTA
P08554723A0187|132 140|l-alanine
P08554723A0187|145 145|M
P08554723A0187|161 174|sodium appetite
P08554723A0187|184 202|furosemide treatment
P08554723A0187|206 220|overnight access
P08554723A0187|223 241|sodium deficient chow
P08555076A0333|0 22|Liposomal Amphotericin-B
P08555076A0333|34 41|patients
P08555076A0333|46 66|culture-proven mycosis
P08555076A0333|91 101|Aspergillus
P08555076A0333|103 104|n =
P08555076A0333|110 116|Candida
P08555076A0333|118 119|n =
P08555168A0390|0 2|Mg2
P08555168A0390|7 9|Mn2
P08555168A0390|28 32|sites
P08555168A0390|53 65|lower affinity
P08555289A0207|0 22|Magnetic storm indicators
P08555289A0207|47 56|geophysics
P08555289A0207|63 77|special purposes
P08555446A0000|0 22|Transgenic tobacco plants
P08555446A0000|24 28|ppa-1
P08555446A0000|54 83|Escherichia coli pyrophosphatase
P08555446A0000|69 83|pyrophosphatase
P08555446A0000|93 107|35S CaMV promoter
P08555446A0000|118 127|high levels
P08555446A0000|130 142|soluble sugars
P08555446A0000|150 155|leaves
P08555498A0427|0 9|Human LAF-4
P08555498A0427|31 35|genes
P08555498A0427|73 82|gene family
P08555498A0427|111 129|vertebrate evolution
P08555597A0808|0 7|Hb levels
P08555597A0808|0 1|Hb
P08555597A0808|25 27|Hb =
P08555597A0808|40 43|g/dl
P08555597A0808|61 66|months
P08555753A0591|0 2|CBT
P08555753A0591|33 45|Wisconsin Card
P08555753A0591|53 56|Test
P08555753A0591|60 91|potential cognitive activation task
P08555753A0591|95 116|functional neuroimaging
P08555753A0591|122 133|frontal lobes
P08556707A1390|29 34|218leu
P08556707A1390|42 70|normal transactivation activity
P08556707A1390|74 84|p53 promoter
P08556707A1390|87 91|yeast
P08556707A1390|94 118|physiological temperatures
P08556707A1390|136 152|normal p53 function
P08556707A1390|142 144|p53
P08556707A1390|169 180|248trp allele
P08556707A1390|183 193|SNU-C5 cells
P08558187A0403|0 5|Cycles
P08558187A0403|24 28|weeks
P08561607A1443|19 28|infections
P08561607A1443|38 52|transplantation
P08561893A0100|9 17|great deal
P08561893A0100|38 48|bHLH factors
P08561893A0100|57 73|gene transcription
P08561893A0100|77 102|E-box DNA consensus sequences
P08561893A0100|104 110|studies
P08561893A0100|113 130|bHLH factor function
P08561893A0100|113 122|bHLH factor
P08561893A0100|133 148|higher eukaryotes
P08561893A0100|185 205|multiple family members
P08561897A0604|0 7|Mobility
P08561897A0604|11 26|supershift assays
P08561897A0604|43 67|upstream stimulatory factor
P08561897A0604|69 71|USF
P08561897A0604|76 78|Sp1
P08561897A0604|88 101|former elements
P08561897A0604|105 126|competition experiments
P08561897A0604|140 147|CREB/ATF
P08561897A0604|140 143|CREB
P08561897A0604|145 147|ATF
P08561897A0604|151 154|AP-1
P08561897A0604|164 177|CRE/TRE element
P08562688A0968|0 7|Upstream
P08562688A0968|19 39|untranslated sequences
P08562688A0968|45 52|isolates
P08563483A0094|7 11|cases
P08563483A0094|29 54|human chorionic gonadotropin
P08563483A0094|56 58|hCG
P08563483A0094|60 65|levels
P08563483A0094|79 87|TSH levels
P08563483A0094|79 81|TSH
P08563483A0094|99 101|hCG
P08563483A0094|105 123|thyrotropic activity
P08564488A1359|0 19|High fibrinogen levels
P08564488A1359|4 13|fibrinogen
P08564488A1359|39 61|perioperative thrombosis
P08564588A1318|0 18|Strontium chloride Sr
P08564588A1318|33 51|preliminary analysis
P08564588A1318|76 97|management expenditures
P08564588A1318|107 114|ABSTRACT
P08564588A1318|129 133|WORDS
P08565330A1783|13 30|epigenetic features
P08565330A1783|33 54|tissue-specific control
P08565330A1783|72 88|allelic expression
P08565548A0196|22 43|arthritogenic potential
P08565548A0196|46 56|silicone gel
P08565548A0196|77 92|bovine collagen II
P08565548A0196|77 90|bovine collagen
P08565548A0196|94 96|BII
P08565548A0196|111 121|silicone gel
P08565548A0196|129 134|DA rats
P08566747A0756|0 2|SBF
P08566747A0756|13 20|promoter
P08566747A0756|31 40|activation
P08566747A0756|43 55|transcription
P08566747A0756|58 63|late G1
P08566747A0756|79 93|Cln/Cdc28 kinase
P08566747A0756|130 132|SBF
P08566747A0756|143 155|transcription
P08566751A0455|19 30|open question
P08566751A0455|38 55|vertebrate Hox genes
P08566751A0455|82 110|Drosophila regulatory sequences
P08566751A0455|92 110|regulatory sequences
P08566751A0455|137 154|Drosophila Hox genes
P08566751A0455|147 154|Hox genes
P08566751A0788|18 24|gHoxb-1
P08566751A0788|32 67|normal embryonic spatiotemporal context
P08566754A0783|6 23|splice site sequence
P08566754A0783|46 60|polyadenylation
P08566754A0783|83 121|U1 small nuclear ribonucleoproteins (snRNPs
P08566754A0783|83 114|U1 small nuclear ribonucleoproteins
P08566754A0783|116 121|snRNPs
P08566754A0783|126 165|alternative splicing factor/splicing factor
P08566754A0783|168 174|ASF/SF2
P08566754A0783|168 170|ASF
P08566754A0783|172 174|SF2
P08566756A0752|24 29|SAP 145
P08566756A0752|24 26|SAP
P08566756A0752|47 68|other SF3a/SF3b subunits
P08566756A0752|52 55|SF3a
P08566756A0752|57 60|SF3b
P08566756A0752|70 82|UV cross-links
P08566756A0752|85 92|pre-mRNA
P08566756A0752|96 122|20-nucleotide region upstream
P08566756A0752|128 130|BPS
P08566773A1023|13 16|CTS1
P08566773A1023|20 23|CTS2
P08566773A1023|26 27|Ci
P08566773A1023|31 37|members
P08566773A1023|43 57|distinct classes
P08566773A1023|60 75|fungal chitinases
P08566773A1023|115 126|single fungus
P08567556A0000|24 38|myoglobin-bound
P08567556A0000|24 32|myoglobin
P08567556A0000|42 45|MbO2
P08567556A0000|47 52|stores
P08567556A0000|55 65|seal muscles
P08567556A0000|87 97|seal muscles
P08567556A0000|104 124|laboratory simulations
P08567556A0000|127 132|diving
P08567556A0000|156 172|normal field diving
P08567556A0000|180 191|measurements
P08567556A0000|194 202|heart rate
P08567556A0000|206 222|lactate production
P08567556A0000|227 243|marked differences
P08567556A0000|251 272|profound diving response
P08567556A0000|288 296|immersion
P08567683A0401|3 15|human purH cDNA
P08567683A0401|22 30|base pairs
P08567683A0401|51 73|591-amino acid polypeptic
P08567683A0401|75 77|Mr =
P08567717T0000|26 59|spindle pole body duplication gene MPS1
P08567717T0000|69 85|mitotic checkpoint
P08567847A1005|16 27|SM-CMA system
P08567847A1005|42 53|shortcomings
P08567847A1005|59 72|user-interface
P08567847A1005|84 102|versatile instrument
P08567847A1005|119 135|human semen samples
P08567847A1005|141 157|desirable features
P08569443A0123|55 65|differences
P08569443A0123|68 69|T1
P08569443A0123|73 74|T2
P08569443A0123|82 87|tumors
P08569443A0123|111 121|differences
P08569443A0123|127 142|fractional volume
P08569443A0123|148 171|extracellular compartment
P08569680A0636|1 17|mutant areA product
P08569680A0636|46 56|last residue
P08569680A0636|77 99|GATA (DNA-binding) domain
P08569680A0636|77 80|GATA
P08569680A0636|82 92|DNA-binding
P08569680A0636|107 121|partial function
P08569684A0000|0 15|Oligonucleotides
P08569684A0000|46 78|flanking amino acid sequence segments
P08569684A0000|88 102|catalytic domain
P08569684A0000|105 128|eukaryotic protein kinase C
P08569684A0000|130 132|PKC
P08569684A0000|134 141|proteins
P08569684A0000|153 159|primers
P08569684A0000|163 186|polymerase chain reactions
P08569684A0000|197 224|427-bp chromosomal DNA fragment
P08569684A0000|232 265|filamentous fungus Trichoderma reesei
P08570615T0000|0 9|Disruption
P08570615T0000|12 17|RB/E2F
P08570615T0000|12 13|RB
P08570615T0000|15 19|E2F-1
P08570615T0000|33 52|single point mutations
P08570615T0000|55 59|E2F-1
P08570615T0000|68 79|S-phase entry
P08570615T0000|83 91|apoptosis
P08572616A0000|0 11|Apparent loss
P08572616A0000|14 35|differentiation markers
P08572616A0000|49 74|advanced malignant neoplasms
P08573083A0645|19 23|motif
P08573083A0645|28 42|partial identity
P08573083A0645|50 60|binding site
P08573083A0645|67 120|ubiquitous transcription factor upstream stimulatory factor
P08573083A0645|122 124|USF
P08573083A0645|142 161|human insulin promoter
P08573637A0434|57 67|paracetamol
P08573637A0434|70 95|pharmaceutical formulations
P08573637A0434|99 114|biological fluids
P08574414A1037|5 11|primers
P08574414A1037|20 29|PCR product
P08574414A1037|33 52|characteristic length
P08574414A1037|59 80|most Xanthomonas species
P08574414A1037|84 92|pathovars
P08574583A0658|3 12|Clb5 kinase
P08574583A0658|27 32|S phase
P08574583A0658|56 69|G2-phase arrest
P08574583A0658|72 76|cells
P08574583A0658|82 95|parental strain
P08574583A0658|128 137|sim mutants
P08575609A0526|3 10|C/D ratio
P08575609A0526|33 37|cases
P08575609A0526|41 44|eyes
P08575609A0526|53 58|values
P08575609A0526|63 74|inconsistent
P08575609A0526|86 89|eyes
P08575609A0526|94 94|%
P08575609A0526|100 107|patients
P08575614A0264|0 10|Rad6 mutants
P08575614A0264|29 48|pleiotropic phenotype
P08575614A0264|73 100|DNA damage-induced mutagenesis
P08575614A0264|102 122|postreplication repair
P08575614A0264|124 133|repression
P08575614A0264|136 153|retrotransposition
P08575614A0264|158 168|sporulation
P08575618A1138|0 20|RNase protection assays
P08575618A1138|0 4|RNase
P08575618A1138|51 56|levels
P08575618A1138|59 64|dorsal
P08575618A1138|68 88|ventral skin expression
P08575618A1138|93 127|pigmentation/phaeomelanin phenotypes
P08575754T0000|0 15|Molecular cloning
P08575754T0000|17 33|expression pattern
P08575754T0000|38 60|chromosomal localization
P08575754T0000|63 79|human CDKN2D/INK4d
P08575754T0000|68 73|CDKN2D
P08575754T0000|75 79|INK4d
P08575754T0000|83 91|inhibitor
P08575754T0000|94 117|cyclin D-dependent kinases
P08576042A0765|0 13|Overproduction
P08576042A0765|16 26|HrcA protein
P08576042A0765|32 41|second copy
P08576042A0765|44 47|hrcA
P08576042A0765|60 66|plasmid
P08576042A0765|68 73|phrcA+
P08576042A0765|68 72|phrcA
P08576042A0765|77 95|B. subtilis wild-type
P08576042A0765|99 114|delta hrcA strains
P08576042A0765|104 107|hrcA
P08576042A0765|124 141|heat shock induction
P08576042A0765|147 150|dnaK
P08576042A0765|154 164|groE operons
P08576042A0765|177 189|transcription
P08576042A0765|227 233|amounts
P08576042A0765|236 239|mRNA
P08576042A0765|243 256|low temperature
P08576131A0151|11 26|molecular cloning
P08576131A0151|30 55|functional characterization
P08576131A0151|58 69|USF2 isoforms
P08576131A0151|87 99|44-kDa subunit
P08576131A0151|101 105|USF2a
P08576131A0151|111 126|new 38-kDa subunit
P08576131A0151|114 126|38-kDa subunit
P08576131A0151|128 132|USF2b
P08576131A0151|145 164|differential splicing
P08576131A0685|3 32|preferential heterodimerization
P08576131A0685|35 45|USF subunits
P08576131A0685|106 113|subunits
P08576131A0685|117 138|recombinant USF proteins
P08576179A0126|9 11|PKR
P08576179A0126|23 27|dimer
P08576179A0126|48 97|eukaryotic translation initiation factor 2 alpha subunit
P08576179A0126|48 84|eukaryotic translation initiation factor
P08576179A0126|86 97|alpha subunit
P08576179A0126|99 108|cIF-2 alpha
P08576179A0126|119 144|polypeptide chain initiation
P08576245A0000|0 4|GRP78
P08576245A0000|7 24|molecular chaperone
P08576245A0000|39 58|endoplasmic reticulum
P08576245A0000|64 87|glucose-regulated protein
P08576245A0000|98 112|stress responses
P08576245A0000|124 130|glucose
P08576245A0000|133 153|intracisternal calcium
P08576245A0000|172 194|glycoprotein trafficking
P08576262A0160|3 14|IL-8 receptor
P08576262A0160|18 52|seven-transmembrane spanning receptor
P08576262A0160|62 92|specific heterotrimeric G proteins
P08576262A0160|70 92|heterotrimeric G proteins
P08576262A0160|102 103|Gi
P08576262A0160|107 109|G16
P08576546A0975|3 14|second series
P08576546A0975|17 27|experiments
P08576546A0975|32 39|efficacy
P08576546A0975|42 50|PDC/HDC Ac
P08576546A0975|42 44|PDC
P08576546A0975|46 50|HDC Ac
P08576546A0975|78 98|multiple dose regiments
P08580083A0259|14 35|functional significance
P08580083A0259|38 40|Fyn
P08580083A0259|58 71|viral promoters
P08580083A0259|87 106|Fyn-expression vector
P08580083A0259|87 89|Fyn
P08580083A0259|120 134|reporter plasmid
P08580083A0259|148 183|chloramphenicol acetyltransferase gene
P08580083A0259|192 197|HIV LTR
P08580083A0259|203 216|human T cell line
P08580083A0259|218 223|Jurkat
P08580671A0137|12 22|prospective
P08580671A0137|24 48|randomized controlled trial
P08580671A0137|51 60|metoprolol
P08580671A0137|63 83|selective beta-blocker
P08580671A0137|99 122|gastrointestinal bleeding
P08580671A0137|127 144|portal hypertension
P08580671A0137|149 168|non-selected patients
P08580671A0137|173 184|liver disease
P08580671A0137|188 219|previous gastrointestinal bleeding
P08581174A0472|11 27|molecular analysis
P08581174A0472|30 53|non-inducible qutA mutants
P08581174A0472|43 53|qutA mutants
P08581174A0472|69 77|mutations
P08581174A0472|98 111|N-terminal half
P08581174A0472|124 134|QUTA protein
P08582143A0614|5 11|studies
P08582143A0614|27 41|acidimetric test
P08582143A0614|65 98|chromogenic cephalosporin substrates
P08582143A0614|106 115|nitrocefin
P08582143A0614|119 120|S1
P08582143A0614|143 166|beta-lactamase production
P08582143A0614|143 156|beta-lactamase
P08582633T0000|0 10|Suppressors
P08582633T0000|13 30|defective silencing
P08582633T0000|33 37|yeast
P08582633T0000|39 45|effects
P08582633T0000|48 72|transcriptional repression
P08582633T0000|78 85|HMR locus
P08582633T0000|87 96|cell growth
P08582633T0000|100 116|telomere structure
P08583783A0870|8 10|ANP
P08583783A0870|18 44|systemic capillary filtration
P08583783A0870|51 54|calf
P08583783A0870|56 65|filtration
P08583783A0870|80 82|ANP
P08583846A0121|0 15|Recent literature
P08583846A0121|32 48|beta-2 transferrin
P08583846A0121|65 78|clinical marker
P08583846A0121|82 90|perilymph
P08583846A0807|4 38|current methodology beta-2 transferrin
P08583846A0807|22 38|beta-2 transferrin
P08583846A0807|57 78|reliable clinical marker
P08583846A0807|82 90|perilymph
P08583846A0807|96 111|operative setting
P08584026A0115|3 12|hIGF-I gene
P08584026A0115|19 27|promoters
P08584026A0115|29 30|P1
P08584026A0115|34 35|P2
P08584035A0740|0 21|Gel mobility shift assays
P08584035A0740|46 60|nuclear proteins
P08584035A0740|65 83|distinct biochemical
P08584035A0740|87 103|binding properties
P08584035A0740|130 144|3 beta I-A element
P08584035A0740|131 144|beta I-A element
P08584035A0740|158 177|DNA-protein complexes
P08584035A0740|179 180|R1
P08584035A0740|183 184|R4
P08584074A0000|10 17|patients
P08584074A0000|19 22|aged
P08584074A0000|31 35|years
P08584074A0000|37 42|months
P08584074A0000|48 52|years
P08584074A0000|76 104|resistant temporal lobe epilepsy
P08584074A0000|106 108|TLE
P08584074A0000|139 144|months
P08584074A0000|147 166|Bethel Epilepsy Center
P08584530A0545|0 22|Significant correlations
P08584530A0545|37 40|FEV1
P08584530A0545|47 65|corresponding values
P08584530A0545|68 70|Raw
P08584530A0545|72 76|MEF50
P08584530A0545|80 84|MEF25
P08584530A0545|103 135|considerable individual differences
P08584530A0545|143 153|test results
P08585324A0467|28 35|SSC1 gene
P08585324A0467|37 41|Smith
P08585324A0823|38 54|Leu-tRNA precursor
P08585324A0823|59 65|remnant
P08585324A0823|69 78|tau element
P08585639T0000|0 19|Occupational exposure
P08585639T0000|22 36|hepatitis B virus
P08585639T0000|40 65|human immunodeficiency virus
P08585639T0000|68 90|comparative risk analysis
P08585883A0381|0 15|Hybrid female mice
P08585883A0381|17 25|C57BL x CBA
P08585883A0381|41 52|breeder males
P08585883A0381|54 57|CD-1
P08585883A0381|62 71|LNG pellets
P08585883A0381|105 119|copulation plugs
P08585883A0381|149 164|postcoital period
P08585957A0101|16 42|putative transcription factor
P08585957A0101|47 53|regions
P08585957A0101|56 63|homology
P08585957A0101|66 85|several other proteins
P08585957A0101|98 108|zinc fingers
P08585957A0101|112 123|other domains
P08585957A0101|129 158|Drosophila trithorax gene product
P08585957A0101|148 158|gene product
P08585957A0101|167 173|AT-hook
P08585957A0101|175 190|DNA-binding motif
P08585957A0101|193 217|high mobility group proteins
P08585994A0567|5 19|reference probes
P08585994A0567|22 38|internal standards
P08585994A0567|53 72|ost transcription unit
P08585994A0567|75 81|located
P08585994A0567|91 117|cytogenetic band interval 89A1
P08585994A0567|125 132|right arm
P08585994A0567|138 152|third chromosome
P08585994A0567|169 212|diagnostic segmentation gene expression patterns
P08585994A0567|218 223|embryo
P08586643A0951|11 27|recombinant enzyme
P08586643A0951|37 62|specific phosphoryl transfer
P08586643A0951|67 69|ATP
P08586643A0951|72 74|UMP
P08586643A0951|78 80|CMP
P08586874T0000|0 6|Studies
P08586874T0000|12 20|life cycle
P08586874T0000|23 39|Haplorchis pumilio
P08586874T0000|41 45|Looss
P08586874T0000|52 56|Looss
P08586874T0000|66 91|morphological redescription
P08586874T0000|94 99|larval
P08586874T0000|103 113|adult stages
P08587075T0000|10 23|microaneurysms
P08587075T0000|27 31|cases
P08587075T0000|34 74|hepatitis B virus related polyarteritis nodosa
P08588852A0236|9 49|following pregnancy ultrasonographic studies
P08588852A0236|55 63|male fetus
P08588852A0236|69 76|16th week
P08588852A0236|79 87|gestation
P08588852A0236|96 113|severe micrognathia
P08588852A0236|123 132|wide thumbs
P08588852A0236|137 143|big toes
P08588852A0236|153 158|tibiae
P08589315A1029|9 27|overall survival rate
P08589315A1029|32 32|%
P08589315A1029|53 58|varied
P08589315A1029|73 73|%
P08589315A1029|85 100|diagnostic groups
P08589315A1029|102 119|tumor lysis syndrome
P08589315A1029|123 148|systemic lupus erythematosus
P08589315A1029|153 160|patients
P08589315A1029|169 169|%
P08589315A1029|172 194|hemolytic uremic syndrome
P08589315A1029|199 206|patients
P08589315A1029|210 210|%
P08589358A0235|10 17|units/kg
P08589358A0235|20 49|recombinant human erythropoietin
P08589358A0235|51 55|rhEPO
P08589358A0235|80 84|times
P08589358A0235|94 98|weeks
P08589358A0841|1 13|3-week regimen
P08589358A0841|16 29|erythropoietin
P08589358A0841|67 92|allogeneic blood transfusion
P08589358A0841|101 115|initial Hb levels
P08589358A0841|108 109|Hb
P08589358A0841|128 137|milligrams
P08589735A0577|7 16|constructs
P08589735A0577|18 30|GUS expression
P08589735A0577|18 20|GUS
P08589735A0577|42 56|promoter regions
P08589735A0577|71 101|Arabidopsis alcohol dehydrogenase
P08589735A0577|103 106|Adh1
P08589735A0577|109 122|maize ubiquitin
P08589735A0577|124 127|Ubi1
P08589735A0577|130 138|rice actin
P08589735A0577|140 143|Act1
P08589735A0577|148 159|CaMV 35S genes
P08590465A0773|43 44|S.
P08590465A0773|50 64|URA1 gene product
P08590465A0773|100 114|URA2 gene product
P08591700A0972|3 19|mean body mass index
P08591700A0972|21 23|BMI
P08591700A0972|38 42|kg/m2
P08591700A0972|56 60|kg/m2
P08591700A0972|63 67|women
P08591700A0972|71 73|men
P08592590A0822|5 12|findings
P08592590A0822|28 48|haemodialysis patients
P08592590A0822|53 69|chronic hepatitis C
P08592590A0822|83 101|interferon treatment
P08592590A0822|83 92|interferon
P08592590A0822|110 126|long-term response
P08592590A0822|140 153|high proportion
P08592590A0822|156 163|patients
P08592713T0001|0 19|Synthetic enantiomers
P08592713T0001|22 26|drugs
P08593813A0967|0 15|Polysome analysis
P08593813A0967|41 65|germ cell-specific Sp1 mRNAs
P08593813A0967|58 65|Sp1 mRNAs
P08593813A0967|91 105|lower efficiency
P08593813A0967|113 129|somatic transcript
P08595012A0817|2 13|nondiabetics
P08595012A0817|27 31|tcPO2
P08595012A0817|40 42|LDF
P08595012A0817|61 66|values
P08595184A0407|19 27|estimator
P08595184A0407|31 60|such global synchronizing effects
P08595184A0407|65 85|unit-pair correlations
P08595184A0407|93 112|local field potentials
P08595184A0407|114 117|LFPs
P08595414A0000|13 25|sequence ready
P08595414A0000|27 53|high-resolution physical maps
P08595414A0000|91 97|contigs
P08595414A0000|117 128|model genomes
P08595414A0000|137 157|accurate determination
P08595414A0000|185 198|adjacent clones
P08595414A0000|212 230|relative orientation
P08595627A1513|13 16|KATP
P08595627A1513|28 37|inhibition
P08595627A1513|61 82|functional consequences
P08595627A1513|85 101|coronary occlusion
P08595627A1513|111 121|KATP opening
P08595627A1513|132 152|reperfusion-induced VF
P08595627A1513|167 184|ischemia-induced VF
P08595658A0961|3 22|DNA sequences upstream
P08595658A0961|30 36|termini
P08595658A0961|44 51|homology
P08595658A0961|54 87|plant mitochondrial-processing sites
P08595658A0961|101 108|proximal
P08595658A0961|111 114|ends
P08595658A0961|141 153|RNA processing
P08595836T0000|6 14|shrinkage
P08595836T0000|18 34|volumetric changes
P08595836T0000|37 82|resin-modified glass ionomer restorative materials
P08595878A0201|6 27|present genetic evidence
P08595878A0201|42 54|PP2A functions
P08595878A0201|42 45|PP2A
P08595878A0201|67 70|Ras1
P08595878A0201|76 106|Sevenless receptor tyrosine kinase
P08595878A0201|76 84|Sevenless
P08595878A0201|85 106|receptor tyrosine kinase
P08595878A0201|108 110|RTK
P08595878A0201|112 136|signal transduction pathway
P08595878A0201|150 172|R7 photoreceptor cell fate
P08595878A0201|188 200|Drosophila eye
P08597108A0642|0 4|QBMDs
P08597108A0642|10 16|% change
P08597108A0642|28 33|QBMD05
P08597108A0642|68 85|corresponding NOAEL
P08597177T0000|0 6|Effects
P08597177T0000|17 25|exposures
P08597177T0000|28 43|hydrogen sulphide
P08597177T0000|46 62|rat hippocampal EEG
P08597596A0135|16 34|ATP-binding cassette
P08597596A0135|36 49|ABC transporter
P08597636A0000|3 12|T-box motif
P08597636A0000|33 37|genes
P08597636A0000|43 60|structural features
P08597636A0000|64 81|expression patterns
P08597636A0000|107 133|developmental gene regulation
P08598051T0000|0 16|Molecular analysis
P08598051T0000|20 43|novel schizosaccharomyces
P08598051T0000|66 104|RNP consensus-sequence RNA-binding domains
P08598359X0000|2 21|overall treatment time
P08598359X0000|23 31|field size
P08598359X0000|36 71|treatment energy influence local control
P08598359X0000|74 100|T1-T2 squamous cell carcinomas
P08598359X0000|106 118|glottic larynx
P08598359X0000|120 126|PURPOSE
P08598359X0000|150 180|patient related prognostic factors
P08598359X0000|197 208|local control
P08598359X0000|225 250|T1-T2 squamous cell carcinoma
P08598359X0000|256 268|glottic larynx
P08598449A0784|15 23|signaling
P08598449A0784|35 53|surface Ig engagement
P08598449A0784|42 43|Ig
P08598449A0784|56 67|B lymphocytes
P08598449A0784|69 80|CD38 ligation
P08598449A0784|69 72|CD38
P08598449A0784|101 123|tyrosine phosphorylation
P08598449A0784|129 161|src-like protein tyrosine kinases lyn
P08598449A0784|129 158|src-like protein tyrosine kinases
P08598449A0784|163 165|fyn
P08598449A0784|170 172|btk
P08598449A0784|178 180|vav
P08598449A0784|185 212|ras-GTPase-activating protein
P08598449A0784|228 244|detectable changes
P08598449A0784|247 258|cytosolic CA2
P08598449A0784|260 273|concentrations
P08599945T0000|0 8|Mutations
P08599945T0000|14 27|alpha-amanitin
P08599945T0000|48 61|largest subunit
P08599945T0000|64 84|yeast RNA polymerase III
P08599945T0000|64 81|yeast RNA polymerase
P08599945T0000|99 109|RNA cleavage
P08599945T0000|113 138|transcriptional transitions
P08599946A0999|39 48|p40 complex
P08599946A0999|52 75|ribonucleoprotein complex
P08599946A0999|86 92|L1Hs RNA
P08599946A0999|94 94|s
P08599946A0999|103 129|protein-protein interactions
P08599946A0999|103 117|protein-protein
P08599946A0999|137 157|alpha-helix structures
P08599946A0999|173 191|example coiled-coils
P08600028A1129|18 33|trans-activation
P08600028A1129|41 65|prothymosin intron enhancer
P08600028A1129|69 86|faithful reflection
P08600028A1129|104 113|properties
P08600028A1129|119 128|Myc protein
P08600048T0000|0 29|Pseudomembranous conjunctivitis
P08600048T0000|39 63|bone marrow transplantation
P08600048T0000|65 82|immunopathological
P08600048T0000|86 105|ultrastructural study
P08601283A0875|21 33|SECIS elements
P08601283A0875|39 55|open reading frames
P08601283A0875|57 60|ORFs
P08601283A0875|64 86|bacterial selenoproteins
P08601283A0875|100 106|effects
P08601283A0875|112 126|type 1 deiodinase
P08601283A0875|117 126|deiodinase
P08601283A0875|141 143|ORF
P08601283A0875|151 162|SECIS element
P08601283A0875|199 211|SECIS function
P08601284A0000|24 29|spacer
P08601284A0000|31 33|ETS
P08601284A0000|46 53|pre-rRNA
P08601284A0000|102 103|bp
P08601284A0000|106 127|perfect complementarity
P08601284A0000|133 140|U3 snoRNA
P08601490A0659|5 11|animals
P08601490A0659|16 21|viable
P08601490A0659|25 31|fertile
P08601616A0726|4 16|spindle defect
P08601616A0726|19 29|pds1 mutants
P08601616A0726|42 66|temperature-sensitive step
P08601616A0726|86 97|G1/S boundary
P08601616A0726|112 126|spindle assembly
P08601806A0875|20 24|RPF-1
P08601806A0875|47 56|early steps
P08601806A0875|62 76|differentiation
P08601806A0875|79 86|amacrine
P08601806A0875|90 102|ganglion cells
P08602169A0484|5 15|point mutant
P08602169A0484|26 37|normal repair
P08602169A0484|40 58|endonuclease III site
P08602169A0484|40 51|endonuclease
P08602169A0484|66 73|wild type
P08602169A0484|90 93|CPDs
P08602169A0484|99 106|MAT alpha
P08602169A0484|110 121|HML alpha loci
P08602608A1056|14 27|evaluable cases
P08602608A1056|32 43|performances
P08602608A1056|49 54|CD3500
P08602608A1056|61 64|STKS
P08602608A1056|116 139|manual reference procedure
P08603921A1346|0 33|Carboxy-terminal Spc110p truncations
P08603921A1346|16 22|Spc110p
P08603921A1346|44 64|calmodulin binding site
P08603921A1346|108 131|cell cycle-specific manner
P08604338A0198|4 12|EWS-FLI-1
P08604338A0198|4 6|EWS
P08604338A0198|8 12|FLI-1
P08604338A0198|16 28|FLI-1 proteins
P08604338A0198|39 58|transcription factors
P08604338A0198|81 92|ets sequences
P08604338A0198|97 104|ets boxes
P08604338A0198|115 130|promoter elements
P08604338A0885|2 27|electromobility shift assays
P08604338A0885|29 44|EWS-FLI-1 binding
P08604338A0885|29 31|EWS
P08604338A0885|33 37|FLI-1
P08604338A0885|50 52|SRE
P08604338A0885|55 64|detectable
P08604338A0885|79 81|SRF
P08604338A0885|92 98|binding
P08604338A0885|101 105|FLI-1
P08604338A0885|167 189|ternary complex formation
P08604338A0885|192 196|FLI-1
P08604708A1086|0 16|Additional studies
P08604708A1086|49 66|cellulose dialyzers
P08604708A1086|85 104|mL/min blood flow rates
P08604708A1086|109 115|minutes
P08604708A1086|132 134|BTG
P08605302A1770|0 13|DNA methylation
P08605302A1770|47 61|deoxyadenosines
P08605302A1770|70 79|GATC motifs
P08605302A1770|89 97|first exon
P08605302A1770|114 124|first intron
P08605302A1770|130 141|rice CatA gene
P08605302A1770|134 141|CatA gene
P08605302A1770|173 192|CatA promoter activity
P08605302A1770|173 184|CatA promoter
P08605302A1770|208 221|transient assay
P08605324A0434|3 10|viral LTR
P08605324A0434|23 30|promoter
P08605326A0772|0 20|Overlapping cDNA clones
P08605705A0676|13 23|IgM class CIC
P08605705A0676|13 15|IgM
P08605705A0676|29 42|predominant CIC
P08605705A0676|45 59|acute hepatitis A
P08605705A0676|77 91|disease activity
P08605931A0777|0 13|Epitope mapping
P08605931A0777|36 41|clones
P08605931A0777|61 89|identical epitope domain present
P08605931A0777|95 112|C-terminal RNP motif
P08605931A0777|118 127|U1A protein
P08606267A0740|0 8|Variables
P08606267A0740|30 48|weekly anginal events
P08606267A0740|58 82|ergometric exercise testing
P08606267A0740|87 130|simultaneous electrocardiographic registration
P08606267A0740|132 157|semiquantitative evaluation
P08606267A0740|160 192|Tc-99m 2-methoxy isobutyl isonitrile
P08606267A0740|194 197|MIBI
P08606267A0740|199 203|scans
P08606267A0740|207 224|rheologic variables
P08608126A0811|16 24|fatty acid
P08608126A0811|38 52|binding affinity
P08608126A0811|64 75|myristic acid
P08608126A0811|92 92|K
P08608126A0811|94 94|d
P08608126A0811|108 109|nM
P08608126A0811|114 125|medium-chain
P08608126A0811|127 138|decanoic acid
P08608126A0811|148 158|short-chain
P08608126A0811|160 171|octanoic acid
P08608126A0811|177 182|lipids
P08608222T0000|3 34|membrane-distal cytoplasmic region
P08608222T0000|37 84|human granulocyte colony-stimulating factor receptor
P08608222T0000|98 102|STAT3
P08608222T0000|109 131|STAT1 homodimer formation
P08608447A0806|20 43|nonsense codon recognition
P08608447A0806|50 63|TPI transcripts
P08608447A0806|88 95|splicing
P08608447A0806|104 113|unresolved
P08608448A0353|12 19|residues
P08608448A0353|28 35|reactive
P08608448A0353|42 57|dimethylsulphate
P08608448A0353|61 68|kethoxal
P08608448A0353|71 77|regions
P08608448A0353|91 98|unpaired
P08608448A0353|104 138|phylogenetic secondary structure model
P08608448A0353|144 147|S RNA
P08608448A0353|161 170|reactivity
P08608448A0353|184 191|residues
P08608448A0353|194 206|internal loops
P08608448A0353|213 220|reactive
P08610272A0265|0 6|Ongoing
P08610272A0265|10 29|future investigations
P08610272A0265|48 62|optimal approach
P08610272A0265|66 77|local control
P08610272A0265|82 96|optimal duration
P08610272A0265|99 121|maintenance chemotherapy
P08610272A0265|129 140|possible role
P08610272A0265|143 167|biologic response modifiers
P08610272A0265|171 183|growth factors
P08610272A0265|186 192|further
P08610272A0265|215 222|patients
P08610328A0228|0 6|SUMMARY
P08610328A0228|9 14|REVIEW
P08610328A0228|44 64|such studies comparable
P08610328A0228|78 88|experiences
P08610328A0228|91 103|recent studies
P08610582A0150|10 17|patients
P08610582A0150|22 35|pleural lesions
P08610582A0150|48 54|CT scans
P08610582A0150|81 89|MR imaging
P08610582A0150|95 96|T.
P08611280A0820|4 16|atrial volumes
P08611280A0820|21 27|greater
P08611280A0820|45 57|young subjects
P08611280A0820|59 65|maximal
P08611280A0820|74 79|cm3/m2
P08611280A0820|88 93|cm3/m2
P08611280A0820|95 96|p =
P08611280A0820|104 108|onset
P08611280A0820|111 123|atrial systole
P08611280A0820|131 136|cm3/m2
P08611280A0820|145 150|cm3/m2
P08611280A0820|152 153|p =
P08611280A0820|175 180|cm3/m2
P08611280A0820|188 193|cm3/m2
P08611280A0820|195 196|p =
P08612852A0553|0 6|RESULTS
P08612852A0553|8 29|Basal plasma IGF-I levels
P08612852A0553|38 50|body mass index
P08612852A0553|52 54|BMI
P08612852A0553|67 85|amenorrheic patients
P08612852A0553|92 106|healthy controls
P08614403A0557|10 23|abundant levels
P08614403A0557|26 42|Rev-erbA alpha mRNA
P08614403A0557|53 66|C2C12 myoblasts
P08614403A0557|94 98|cells
P08614403A0557|117 149|postmitotic multinucleated myotubes
P08614403A0989|24 49|GAL4-REV-erbA alpha chimeras
P08614403A0989|65 66|AB
P08614403A0989|85 85|E
P08614403A0989|102 114|transcription
P08614403A0989|117 136|GAL4 response elements
P08614403A0989|152 160|8-Br-cAMP
P08614403A0989|169 188|ligand-binding domain
P08614403A0989|190 192|LBD
P08614403A0989|204 232|active transcriptional silencer
P08614410A0000|3 19|alpha T3-1 cell line
P08614410A0000|22 55|GnRH-responsive gonadotroph cell line
P08614410A0000|75 85|oncogenesis
P08614410A0000|88 101|transgenic mice
P08614410A0000|132 163|glycoprotein hormone alpha-subunit
P08614410A0000|166 172|activin
P08615012A0627|0 13|Cotransfection
P08615012A0627|21 27|ie1 gene
P08615012A0627|39 54|dramatic increase
P08615012A0627|74 80|enzymes
P08615012A0627|106 110|cells
P08615025A1214|11 23|glycosylation
P08615025A1214|26 28|Env
P08615025A1214|41 47|mutants
P08615025A1214|80 101|glycosylation phenotype
P08615025A1214|106 122|similar quantities
P08615025A1214|125 127|Env
P08615025A1214|151 166|immunoreactivity
P08615025A1214|169 170|V3
P08615025A1214|187 191|gp160
P08615025A1214|217 221|gp120
P08615025A1214|225 228|gp41
P08615025A1214|234 236|Env
P08615025A1214|252 263|cell membrane
P08615025A1214|276 280|gp120
P08615025A1214|286 288|CD4
P08615025A1214|297 308|membrane gp41
P08615025A1214|324 337|membrane fusion
P08615025A1214|342 345|CD4+
P08615025A1214|342 344|CD4
P08615025A1214|346 350|cells
P08615183T0000|0 6|Effects
P08615183T0000|9 33|posteroventral pallidotomy
P08615183T0000|36 44|Parkinson
P08616743T0000|12 14|Dr.
P08617216A0584|12 23|complete DnaJ
P08617216A0584|40 43|DnaK
P08617216A0584|48 59|third protein
P08617216A0584|61 64|GrpE
P08617216A0584|68 76|refolding
P08617216A0584|86 102|firefly luciferase
P08617216A0584|93 102|luciferase
P08617237A0489|6 26|different phosphoforms
P08617237A0489|29 33|STAT5
P08617237A0489|54 74|DNA binding specificity
P08617237A0489|78 87|reactivity
P08617237A0489|92 114|tyrosine phosphopeptides
P08617237A0489|132 151|cellular localization
P08617238A0334|0 11|TNF Treatment
P08617238A0334|0 2|TNF
P08617238A0334|30 48|p38 MAP kinase pathway
P08617238A0334|30 41|p38 MAP kinase
P08617238A0334|71 85|phosphorylation
P08617238A0334|88 99|p38 MAP kinase
P08617238A0334|107 116|activation
P08617238A0334|122 151|substrate protein MAPKAP kinase-2
P08617238A0334|138 151|MAPKAP kinase-2
P08617238A0334|172 186|phosphorylation
P08617238A0334|192 209|heat shock protein 27
P08617238A0334|192 207|heat shock protein
P08617238A0334|211 215|hsp27
P08617243A0336|15 26|novel protein
P08617243A0336|41 55|nuclear extracts
P08617243A0336|91 102|second region
P08617311A0979|16 33|sequence similarity
P08617311A0979|44 56|membrane exons
P08617311A0979|59 67|avian mIgY
P08617311A0979|71 83|mammalian mIgG
P08617311A0979|87 89|IgE
P08617311A0979|104 120|overall similarity
P08617311A0979|125 135|Xenopus mIgY
P08617800A0150|0 6|Control
P08617800A0150|9 21|transcription
P08617800A0150|27 36|erbB-2 gene
P08617800A0150|41 60|important determinant
P08617800A0150|63 80|receptor expression
P08617800A0675|0 5|DNase I
P08617800A0675|0 4|DNase
P08617800A0675|6 17|footprinting
P08617800A0675|21 54|electrophoretic mobility shift assays
P08617800A0675|67 69|PBP
P08617800A0675|80 88|half-site
P08617800A0675|95 104|palindrome
P08617800A0675|112 140|core recognition sequence TGGGAG
P08617802A0993|5 11|results
P08617802A0993|27 35|sequences
P08617802A0993|41 57|SH2/SH3/SH2 region
P08617802A0993|41 43|SH2
P08617802A0993|45 47|SH3
P08617802A0993|60 66|p120 GAP
P08617802A0993|60 63|p120
P08617802A0993|64 66|GAP
P08617802A0993|81 101|full catalytic activity
P08617802A0993|108 110|Ras
P08618433A0000|3 42|novel hematopoietic growth factor FLT3 ligand
P08618433A0000|8 42|hematopoietic growth factor FLT3 ligand
P08618433A0000|44 45|FL
P08618433A0000|52 64|cognate ligand
P08618433A0000|71 74|FLT3
P08618433A0000|76 97|tyrosine kinase receptor
P08618433A0000|99 99|R
P08618433A0000|118 122|FLK-2
P08618433A0000|126 130|STK-1
P08618433A1720|15 33|selective expression
P08618433A1720|39 46|receptor
P08618433A1720|48 59|FL expression
P08618433A1720|79 79|%
P08618433A1720|85 100|various cell types
P08618433A1720|103 119|leukemia cell lines
P08618433A1720|127 151|hematopoietic cell lineages
P08618864A0754|0 14|Further analysis
P08618864A0754|36 46|mutagenesis
P08618864A0754|63 73|hydrophobic
P08618864A0754|77 90|acidic residues
P08618882A0343|0 7|Analysis
P08618882A0343|10 24|RAR alpha mutants
P08618882A0343|27 45|transfection studies
P08618882A0343|60 75|DNA binding domain
P08618882A0343|91 100|inhibition
P08618882A0343|103 115|BZLF1 activity
P08618882A0343|103 107|BZLF1
P08619866A0000|10 36|serum hepatocyte growth factor
P08619866A0000|15 36|hepatocyte growth factor
P08619866A0000|38 40|HGF
P08619866A0000|44 51|patients
P08619866A0000|56 80|acute myocardial infarction
P08619866A0000|82 95|angina pectoris
P08619866A0000|100 117|other heart diseases
P08619910A0000|3 17|neural mechanism
P08619910A0000|20 44|parkinsonian motor symptoms
P08619910A0000|51 58|rigidity
P08619910A0000|60 65|tremor
P08619910A0000|69 76|akinesia
P08619910A0000|97 127|nigrostriatal dopamine deficiency
P08619910A0000|146 166|long-term observations
P08619910A0000|180 187|surgical
P08619910A0000|191 214|pharmacological treatment
P08619910A0000|242 266|neuropathological findings
P08619910A0000|276 302|substantia nigra zona compacta
P08619910A0000|304 306|SNc
P08620003T0000|0 14|Protein splicing
P08620003T0000|29 48|N-O acyl rearrangement
P08620003T0000|54 64|initial step
P08620003T0000|70 84|splicing process
P08620856A1172|25 46|western blot experiments
P08620856A1172|54 61|antibody
P08620856A1172|80 102|carboxy-terminal portion
P08620856A1172|108 124|mouse c-kit protein
P08620856A1172|136 146|polypeptide
P08620856A1172|171 186|open reading frame
P08620856A1172|192 218|spermatid-specific c-kit cDNA
P08620856A1172|236 247|latest stages
P08620856A1172|250 264|spermatogenesis
P08620856A1172|270 290|epididymal spermatozoa
P08620889A0771|17 19|G+C
P08620889A0771|22 32|rich element
P08620889A0771|38 54|aldolase C promoter
P08620889A0771|62 74|transcription
P08620889A0771|77 84|neuronal
P08620889A0771|95 110|nonneuronal cells
P08621017A1186|0 7|LY290181
P08621017A1186|24 44|uPA promoter activation
P08621017A1186|24 34|uPA promoter
P08621017A1186|55 84|phorbol ester-stimulated binding
P08621017A1186|87 101|nuclear proteins
P08621017A1186|107 116|uPA PEA3/12
P08621017A1186|120 166|tetradecanoylphorbol 13-acetate responsive element
P08621017A1186|168 170|TRE
P08621384A0935|0 8|Treatment
P08621384A0935|11 23|keratinocytes
P08621384A0935|35 69|normal epidermal growth factor receptor
P08621384A0935|41 69|epidermal growth factor receptor
P08621384A0935|71 74|EGFR
P08621384A0935|80 87|TGFalpha
P08621384A0935|90 110|epidermal growth factor
P08621384A0935|115 117|min
P08621384A0935|125 155|PKCdelta tyrosine phosphorylation
P08621384A0935|125 132|PKCdelta
P08621420A1166|14 18|bands
P08621420A1166|36 43|antibody
P08621420A1166|46 48|p50
P08621420A1166|57 66|antibodies
P08621420A1166|69 71|p65
P08621420A1166|74 95|other NF-kappaB proteins
P08621448A0862|11 26|complementary DNA
P08621448A0862|28 31|cDNA
P08621448A0862|33 37|clone
P08621448A0862|44 66|RL95-2 expression library
P08621448A0862|81 101|C1 site-binding protein
P08621451A0552|0 3|Biol
P08621453A0815|11 40|anti-phosphotyrosine antibodies
P08621453A0815|59 63|80K-H
P08621453A0815|68 78|cell lysates
P08621453A0815|81 94|FGF-stimulated
P08621453A0815|81 83|FGF
P08621453A0815|105 122|control fibroblasts
P08621542A0535|3 21|novel protein kinases
P08621542A0535|8 21|protein kinases
P08621542A0535|23 46|c-Jun NH2-terminal kinases
P08621542A0535|48 51|JNKs
P08621542A0535|54 83|stress-activated protein kinases
P08621542A0535|103 111|TNF-alpha
P08621542A0535|113 116|IL-1
P08621542A0535|121 137|CD28 costimulation
P08621542A0535|121 124|CD28
P08621628A1233|5 11|hGRbeta
P08621628A1233|35 59|dominant negative inhibitor
P08621628A1233|62 77|hGRalpha activity
P08621628A1233|62 69|hGRalpha
P08621659A0189|0 3|Gas6
P08621659A0189|14 34|NH2-terminal Gla domain
P08621659A0189|49 81|epidermal growth factor-like repeats
P08621659A0189|85 98|tandem globular
P08621659A0189|100 100|G
P08621659A0189|102 108|domains
P08621661A1035|4 18|P5CDh cDNA clones
P08621661A1035|4 12|P5CDh cDNA
P08621661A1035|26 47|single 3.2-kb transcript
P08621661A1035|50 62|Northern blots
P08621661A1035|65 84|multiple human tissues
P08621661A1035|99 106|long cDNA
P08621661A1035|123 140|untranslated intron
P08621661A1035|154 174|predominant transcript
P08621664A1430|0 13|Polymerization
P08621664A1430|16 36|neurofilament L protein
P08621664A1430|58 72|phosphorylation
P08621664A1430|75 95|neurofilament L protein
P08621664A1430|98 100|PKN
P08621714A0361|31 44|disulfide bonds
P08621714A0361|49 62|free thiol group
P08621714A0361|65 69|Cys25
P08621719A0000|34 59|c-cbl proto-oncogene product
P08621719A0000|70 84|earliest targets
P08621719A0000|87 109|tyrosine phosphorylation
P08621719A0000|114 137|T cell receptor stimulation
P08621719A0000|114 126|T cell receptor
P08621719A0568|1 19|substantial fraction
P08621719A0568|22 24|Cbl
P08621719A0568|56 59|Grb2
P08621719A0568|91 104|Grb2 SH3 domains
P08621719A0568|91 94|Grb2
P08621730T0000|2 20|AP-1 binding sequence
P08621730T0000|50 60|human alpha2
P08621730T0000|64 71|collagen
P08621730T0000|73 78|COL1A2
P08621730T0000|80 95|promoter activity
P08621730T0000|98 126|transforming growth factor-beta
P08621730T0000|110 126|growth factor-beta
P08622030A0667|2 23|significant differences
P08622030A0667|44 52|age groups
P08622030A0667|55 77|baseline characteristics
P08622030A0667|88 104|treatment protocol
P08622030A0667|106 122|performance status
P08622030A0667|127 151|serum lactate dehydrogenase
P08622030A0667|153 155|LDH
P08622070A0889|7 14|patients
P08622070A0889|19 19|%
P08622070A0889|25 26|CA
P08622070A0889|49 67|clinical progression
P08622596A0189|3 5|men
P08622596A0189|51 62|saturated fat
P08622596A0189|68 77|visible fat
P08622645A1026|15 17|VDR
P08622645A1026|34 42|vitamin D3
P08622645A1026|53 68|9-cis RA induction
P08622645A1026|75 95|RXR-responsive element
P08622668A1155|5 11|results
P08622668A1155|31 51|unanticipated function
P08622668A1155|54 58|U6 RNA
P08622668A1155|63 72|modulation
P08622668A1155|76 113|phosphorylation-dephosphorylation cycle
P08622668A1155|116 129|C1 hnRNP protein
P08622668A1155|147 161|binding affinity
P08622668A1155|178 185|pre-mRNA
P08622675A0587|0 8|Inclusion
P08622675A0587|14 30|extended N terminus
P08622675A0587|74 91|striking similarity
P08622675A0587|97 115|lymphoid factor Lef-1
P08622698T0000|9 23|mammalian Notch1
P08622698T0000|33 57|CBF1/RBPJk-repressed genes
P08622698T0000|33 36|CBF1
P08622698T0000|38 42|RBPJk
P08622698T0000|86 107|Epstein-Barr virus EBNA2
P08622887A1026|0 33|Electrophoretic mobility shift assays
P08622887A1026|35 39|EMSAs
P08622887A1026|54 91|glucocorticoid receptor DNA binding domain
P08622887A1026|93 95|DBD
P08622887A1026|117 121|GRE-2
P08622887A1026|127 132|motifs
P08622887A1026|145 147|DBD
P08622887A1026|151 187|oligonucleotide competition experiments
P08622887A1026|212 230|different affinities
P08622887A1026|234 236|DBD
P08622893A0000|3 16|large subfamily
P08622893A0000|19 41|receptor tyrosine kinases
P08622893A0000|43 46|RTKs
P08622893A0000|56 58|EPH
P08622893A0000|64 72|prototype
P08622893A0000|77 87|likely roles
P08622893A0000|90 115|intercellular communication
P08622893A0000|122 147|normal mammalian development
P08622893A0000|155 183|biochemical signalling pathways
P08623554A1058|3 15|17-kDa protein
P08623554A1058|32 48|systemic infection
P08623554A1058|51 56|plants
P08624445A0257|14 46|detailed genomic sequencing analysis
P08624445A0257|52 78|cytosine methylation patterns
P08624445A0257|84 106|transposase binding sites
P08624445A0257|84 94|transposase
P08624445A0257|117 118|Ac
P08624445A0257|128 132|wx-m9
P08624445A0257|135 142|Ac allele
P08624445A0257|149 150|Ac
P08624445A0257|168 176|tenth exon
P08624445A0257|182 189|Waxy gene
P08625806A0263|0 6|Krox-20
P08625806A0263|9 22|zinc finger gene
P08625806A0263|64 65|r3
P08625806A0263|69 70|r5
P08625806A0263|117 128|mouse embryos
P08625900T0000|0 46|Pituitary adenylate cyclase-activating polypeptide
P08625900T0000|56 80|prolactin promoter activity
P08625900T0000|85 114|protein kinase A-mediated pathway
P08625900T0000|137 158|transcriptional pathway
P08625900T0000|169 196|thyrotropin-releasing hormone
P08625924A0411|0 8|Clones 33F
P08625924A0411|12 14|34B
P08625924A0411|22 47|identical aromatase proteins
P08625924A0411|31 39|aromatase
P08625924A0411|53 62|amino acids
P08625924A0411|77 83|size due
P08625924A0411|86 122|alternative polyadenylation signal usage
P08625924A0411|129 146|corresponding mRNAs
P08625987A1086|8 32|bone marrow cells expression
P08625987A1086|39 48|VpreB genes
P08625987A1086|62 73|pro-B/pre-BI
P08625987A1086|77 93|large pre-BII cells
P08625987A1086|103 122|RNA steady state levels
P08625987A1086|149 160|small pre-BII
P08625987A1086|164 184|immature/mature B cells
P08626065A0000|25 47|3574-bp Bacillus subtilis
P08626065A0000|49 50|Bs
P08626065A0000|52 69|DNA fragment located
P08626065A0000|80 83|nrdA
P08626065A0000|87 95|citB genes
P08626065A0000|106 112|degrees
P08626065A0000|118 127|chromosome
P08626290T0000|0 19|Aeromonas salmonicida
P08626290T0000|32 36|genes
P08626290T0000|45 52|homologs
P08626290T0000|58 82|major outer membrane protein
P08626290T0000|84 87|OmpA
P08626313A1037|0 9|Expression
P08626313A1037|12 14|Msp
P08626313A1037|38 50|entire msp gene
P08626313A1037|44 50|msp gene
P08626325A0543|50 53|UmuD
P08626325A0543|57 60|UmuD
P08626325A0543|79 88|homodimers
P08626325A0543|90 98|UmuD-UmuD
P08626325A0543|90 93|UmuD
P08626325A0543|95 98|UmuD
P08626325A0543|102 105|UmuD
P08626325A0543|108 111|UmuD
P08626325A0543|118 128|heterodimer
P08626325A0543|130 138|UmuD-UmuD
P08626437A0332|0 8|Lyn kinase
P08626437A0332|31 37|lysates
P08626437A0332|40 52|irradiated BCP
P08626437A0332|62 96|full-length glutathione S-transferase
P08626437A0332|98 100|GST
P08626437A0332|103 156|Lyn fusion protein-phosphorylated recombinant human p34cdc2
P08626437A0332|159 166|tyrosine
P08626493A1468|0 8|Mutations
P08626493A1468|32 34|CR2
P08626493A1468|38 40|E1A
P08626493A1468|55 61|binding
P08626493A1468|64 66|E1A
P08626493A1468|72 96|retinoblastoma gene product
P08626493A1468|98 100|pRb
P08626493A1468|120 130|stimulation
P08626493A1468|133 145|transcription
P08626493A1468|153 165|PEPCK promoter
P08626493A1468|169 174|3-fold
P08626493A1468|187 197|wild type E1A
P08626529A0000|5 18|autoantibodies
P08626529A0000|24 30|Sjogren
P08626529A0000|33 47|syndrome patient
P08626529A0000|76 107|230-kDa peripheral membrane protein
P08626529A0000|125 137|cytosolic face
P08626529A0000|143 153|trans-Golgi
P08626529A0000|155 158|Kooy
P08626529A0000|160 161|J.
P08626529A0000|163 165|Toh
P08626529A0000|167 168|B.
P08626529A0799|12 30|proline-rich regions
P08626529A0799|32 41|amino acids
P08626529A0799|59 62|p230
P08626529A0799|76 88|high frequency
P08626529A0799|91 103|heptad repeats
P08626529A0799|121 133|alpha-helices
P08626529A0799|142 169|dimeric coiled-coil structures
P08626529A0799|171 174|p230
P08626529A0799|190 207|sequence ESLALEELEL
P08626529A0799|209 218|amino acids
P08626529A0799|229 233|motif
P08626529A0799|244 255|granin family
P08626529A0799|258 278|acidic proteins present
P08626529A0799|281 297|secretory granules
P08626529A0799|300 318|neuroendocrine cells
P08626539T0000|0 17|Binding specificity
P08626539T0000|21 30|modulation
P08626539T0000|36 57|ApoA-I promoter activity
P08626539T0000|36 49|ApoA-I promoter
P08626539T0000|60 63|homo
P08626539T0000|68 79|heterodimers
P08626539T0000|82 97|nuclear receptors
P08626540A1007|26 48|nanomolar concentrations
P08626540A1007|52 59|turnover
P08626540A1007|85 92|ceramide
P08626540A1007|94 109|glucosylceramide
P08626540A1007|114 129|lactosylceramide
P08626596A0000|26 60|mammalian AMP-activated protein kinase
P08626596A0000|62 65|AMPK
P08626596A0000|89 93|cells
P08626596A0000|98 105|stresses
P08626596A0000|115 126|ATP depletion
P08626596A0000|141 173|ATP-consuming biosynthetic pathways
P08626610A0931|0 25|Sterol-mediated suppression
P08626610A0931|28 35|cleavage
P08626610A0931|38 44|SREBP-1
P08626610A0931|71 96|extreme COOH-terminal region
P08626610A0931|98 104|residue
P08626610A0931|114 125|COOH terminus
P08626610A0931|144 148|forms
P08626610A0931|160 178|alternative splicing
P08626612A1040|0 1|Am
P08626667A1372|0 25|EMSA competition experiments
P08626667A1372|36 44|mutations
P08626667A1372|54 66|direct repeats
P08626667A1372|85 91|binding
P08626667A1372|97 111|nuclear proteins
P08626667A1372|121 143|wild type oligonucleotide
P08626667A1517|0 12|Transcription
P08626667A1517|20 27|promoter
P08626667A1517|48 60|direct repeats
P08626667A1517|117 131|motifs functions
P08626667A1517|147 163|GPT gene expression
P08626667A1517|147 153|GPT gene
P08626698A0989|10 24|10-fold increase
P08626698A0989|27 38|ERK3 activity
P08626698A0989|27 30|ERK3
P08626698A0989|45 63|PKC beta transfectant
P08626698A0989|45 51|PKC beta
P08626698A0989|74 92|immunoprecipitation
P08626698A0989|97 123|anti-ERK3 monoclonal antibody
P08626698A0989|140 163|immune complex kinase assay
P08626698A0989|170 183|gel kinase assay
P08626777A0537|0 15|Sequence analysis
P08626777A0537|22 41|100-bp Col2a1 enhancer
P08626777A0537|28 41|Col2a1 enhancer
P08626777A0537|50 77|several sequence motifs similar
P08626777A0537|80 92|motifs present
P08626777A0537|102 117|regulatory region
P08626777A0537|123 137|link protein gene
P08626777A0537|146 158|cartilage gene
P08626785A0674|0 27|Retinoid-dependent activation
P08626785A0674|33 62|tissue transglutaminase promoter
P08626785A0674|77 100|proximal regulatory region
P08626785A0674|111 119|sequences
P08626785A0674|156 191|mouse tissue transglutaminase promoters
P08626785A0674|196 207|distal region
P08626785A0674|221 254|30-base pair retinoid response element
P08626785A0674|256 262|mTGRRE1
P08626785A0674|265 271|mTGRRE1
P08626785A0674|285 308|hexanucleotide half-sites
P08626785A0674|313 321|canonical
P08626785A0674|328 340|non-canonical
P08626785A0674|345 356|DR7/DR5 motif
P08626785A0674|345 347|DR7
P08626785A0674|369 387|RAR*RXR heterodimers
P08626785A0674|369 371|RAR
P08626785A0674|373 387|RXR heterodimers
P08626785A0674|391 403|RXR homodimers
P08626809A0729|14 17|pPKR
P08626809A0729|56 60|Ser51
P08626809A0729|64 89|synthetic eIF-2alpha peptide
P08626809A0729|92 108|key characteristic
P08626809A0729|114 135|eIF-2alpha kinase family
P08627354A0000|0 18|Vertebrate synapsins
P08627354A0000|38 53|synaptic proteins
P08627354A0000|86 108|neurotransmitter release
P08627649A0734|0 33|Electrophoretic mobility shift assays
P08627649A0734|39 51|crude extracts
P08627649A0734|56 65|FREJ4 cells
P08627649A0734|77 83|binding
P08627649A0734|94 94|s
P08627649A0734|101 109|Ets family
P08627649A0734|112 131|transcription factors
P08627649A0734|137 141|P4 EBS
P08627649A0734|170 176|members
P08627649A0734|182 190|Sp1 family
P08627649A0734|192 194|Sp1
P08627649A0734|198 200|Sp3
P08627649A0734|209 221|adjacent GC box
P08627667A0132|0 4|ZEBRA
P08627667A0132|8 33|cellular AP-1 bZip activators
P08627667A0132|41 45|c-Fos
P08627667A0132|51 78|homologous DNA-binding domains
P08627667A0132|88 111|DNA-binding specificities
P08627688A1520|23 32|mutant I299
P08627688A1520|46 64|cap-binding activity
P08627719A0784|0 25|UV cross-linking experiments
P08627719A0784|42 53|HSV infection
P08627719A0784|68 74|binding
P08627719A0784|77 90|protein factors
P08627719A0784|104 118|64-kDa component
P08627719A0784|121 145|cleavage stimulation factor
P08627719A0784|147 150|CstF
P08627719A0784|155 158|poly
P08627719A0784|160 160|A
P08627719A0784|162 169|site RNAs
P08627719A0784|174 183|virus genes
P08627719A0784|189 203|temporal classes
P08627719A0784|223 229|binding
P08627719A0784|250 253|IE63
P08628251A1455|0 6|CM-ACO3
P08628251A1455|20 26|flowers
P08628251A1455|52 58|stimuli
P08628254A0665|19 33|Jun/eb1 chimeras
P08628254A0665|19 21|Jun
P08628254A0665|23 25|eb1
P08628254A0665|37 57|potent transactivators
P08628254A0665|60 67|AP1 sites
P08628254A0665|95 102|c-Ha-Ras
P08628254A0665|111 114|foci
P08628255A0932|14 22|HeLa cells
P08628255A0932|36 53|luciferase activity
P08628255A0932|36 45|luciferase
P08628255A0932|80 91|DNA synthesis
P08628255A0932|124 138|E2F-binding site
P08628255A0932|144 156|H2A.1 promoter
P08628260A0895|9 36|transient transfection studies
P08628260A0895|39 48|HepG2 cells
P08628260A0895|65 72|deletion
P08628260A0895|88 110|promoter sequences distal
P08628260A0895|113 122|nucleotide
P08628260A0895|126 132|results
P08628260A0895|150 162|small increase
P08628260A0895|165 180|promoter activity
P08628284A0181|14 32|yeast reporter strain
P08628284A0181|46 53|lacZ gene
P08628284A0181|74 85|CYC1 promoter
P08628284A0181|105 110|copies
P08628284A0181|113 117|TRE-1
P08628302A0683|2 7|hnRNP K
P08628302A0683|11 29|transcription factor
P08628302A0683|35 46|interactions
P08628302A0683|54 68|RNA polymerase II
P08628302A0683|54 66|RNA polymerase
P08628302A0683|69 90|transcription apparatus
P08628681A0364|28 33|kb mRNA
P08628681A0364|48 60|Northern blots
P08628681A0364|63 71|oocyte RNA
P08628681A0364|80 91|X.laevis cDNA
P08628681A0821|0 19|Sequence conservation
P08628681A0821|33 40|residues
P08628681A0821|55 67|active centers
P08628681A0821|73 75|exo
P08628681A0821|79 88|pol domains
P08628681A0821|94 113|E.coli DNA polymerase I
P08628681A0821|100 112|DNA polymerase
P08629348A0237|10 33|favourable natural history
P08629348A0237|36 42|acute BI
P08629348A0237|61 86|severe posttraumatic changes
P08629348A0237|106 125|cicatricial-adhesive
P08629348A0237|129 145|atrophic processes
P08629348A0237|147 164|intracerebral cysts
P08629348A0237|192 212|posttraumatic epilepsy
P08629348A0237|214 226|hydrocephalus
P08630542A1421|5 12|findings
P08630542A1421|37 37|V
P08630542A1421|78 78|Q
P08630548A0000|0 15|Several cytokines
P08630548A0000|24 33|high degree
P08630548A0000|36 53|temporal regulation
P08630548A0000|62 78|somnogenic potency
P08630548A0000|85 97|interleukin-1
P08630548A0000|99 102|IL-1
P08630548A0000|105 129|tumor necrosis factor-alpha
P08630548A0000|131 139|TNF-alpha
P08630583A1056|2 3|pH
P08630583A1056|7 8|Hb
P08630583A1056|22 42|mixed venous CO2 content
P08630583A1056|55 55|Q
P08630599A0534|14 40|elastin peptide concentration
P08630599A0534|14 27|elastin peptide
P08630599A0534|59 79|emphysematous patients
P08630599A0534|83 97|control subjects
P08630599A0534|106 108|SD =
P08630599A0534|120 132|micrograms/ml
P08630599A0534|135 142|patients
P08630599A0534|160 172|micrograms/ml
P08630599A0534|175 183|policemen
P08630599A0534|198 210|micrograms/ml
P08630599A0534|213 222|coal miners
P08631667A0851|0 13|Identification
P08631667A0851|31 43|E. coli tmk gene
P08631667A0851|37 43|tmk gene
P08631667A0851|58 82|functional complementation
P08631667A0851|86 127|yeast dTMP kinase temperature-sensitive mutant
P08631667A0851|140 150|enzyme assay
P08631667A0851|156 180|thymidylate kinase activity
P08631667A0851|156 172|thymidylate kinase
P08631667A0851|183 194|cell extracts
P08631667A0851|210 234|tmk-overproducing plasmids
P08631667A0851|210 212|tmk
P08631685A0000|3 16|structural gene
P08631685A0000|20 25|copper
P08631685A0000|30 67|topa quinone-containing monoamine oxidase
P08631685A0000|69 72|maoA
P08631685A0000|79 101|unknown amine oxidase gene
P08631685A0000|123 125|min
P08631685A0000|146 155|chromosome
P08631760A0609|30 38|SH2 domain
P08631760A0609|41 43|Crk
P08631760A0609|66 79|phosphopeptide
P08631760A0609|93 111|Crk-SH2 binding motif
P08631797A0982|0 9|Consistent
P08631797A0982|14 19|ErbB-2
P08631797A0982|26 46|shared receptor subunit
P08631797A0982|51 73|tyrosine phosphorylation
P08631797A0982|92 110|heterologous ligands
P08631797A0982|125 146|trans-inhibitory effect
P08631797A0982|149 151|NDF
P08631797A0982|154 163|EGF binding
P08631797A0982|154 156|EGF
P08631817T0000|0 13|Identification
P08631817T0000|17 72|consensus cyclin-dependent kinase phosphorylation site unique
P08631817T0000|26 47|cyclin-dependent kinase
P08631817T0000|78 88|nuclear form
P08631817T0000|91 138|human deoxyuridine triphosphate nucleotidohydrolase
P08631820A0755|3 6|cDNA
P08631820A0755|25 32|FPS1 gene
P08631820A0755|46 70|functional complementation
P08631820A0755|74 99|mutant yeast strain defective
P08631820A0755|102 112|FPS activity
P08631820A0755|114 121|Delourme
P08631820A0755|123 124|D.
P08631820A0755|126 133|Lacroute
P08631820A0755|135 136|F.
P08631820A0755|141 145|Karst
P08631820A0755|147 148|F.
P08631822A0677|11 26|plasmin fragments
P08631822A0677|29 32|VEGF
P08631822A0677|58 71|heparin binding
P08631822A0677|88 107|soluble VEGF receptors
P08631822A0677|95 107|VEGF receptors
P08631822A0677|128 153|endothelial cell mitogenesis
P08631908A0224|0 6|VDR/RXR
P08631908A0224|0 2|VDR
P08631908A0224|4 6|RXR
P08631908A0224|21 25|VDREs
P08631908A0224|31 33|DR4
P08631908A0224|37 39|DR5
P08631908A0224|48 80|electrophoretic mobility shift assay
P08631934A0000|3 9|members
P08631934A0000|15 23|Myb family
P08631934A0000|26 45|transcription factors
P08631934A0000|58 65|homology
P08631934A0000|71 87|DNA-binding domain
P08631934A0000|99 113|Myb-binding site
P08631934A0000|115 117|MBS
P08631934A0000|128 129|YG
P08631934A0000|131 133|A/G
P08631934A0000|135 135|C
P08631934A0000|137 141|A/C/G
P08631934A0000|143 145|GTT
P08631934A0000|147 149|G/A
P08631944A0663|18 24|isoform
P08631944A0663|38 52|C epsilon4 domain
P08631944A0663|72 77|M2 exon
P08631944A0663|79 87|IgE grande
P08631944A0663|105 117|J558L cell line
P08631944A0663|158 185|cell line-dependent regulation
P08631944A0663|188 196|secretion
P08631958T0000|0 51|Human cytomegalovirus immediate-early protein IE2 tethers
P08631958T0000|0 44|Human cytomegalovirus immediate-early protein IE2
P08631958T0000|53 83|transcriptional repression domain
P08631958T0000|86 88|p53
P08632009A1067|3 13|specificity
P08632009A1067|24 41|C/EBP family members
P08632009A1067|61 75|characteristics
P08632009A1067|101 118|expression profiles
P08632009A1067|123 142|DNA binding affinities
P08632009A1067|147 155|cofactors
P08632009A1067|180 202|DNA binding specificities
P08632015A0879|3 12|antibodies
P08632015A0879|37 49|transcription
P08632015A0879|52 77|DNA polymerase alpha promoter
P08632015A1226|0 25|Immunocytochemical analysis
P08632015A1226|51 65|DREF polypeptide
P08632015A1226|68 73|nuclei
P08632015A1226|82 107|eighth nuclear division cycle
P08632015A1226|123 141|nuclear accumulation
P08632015A1226|144 147|DREF
P08632015A1226|165 191|coordinate zygotic expression
P08632015A1226|194 220|DNA replication-related genes
P08632015A1226|229 240|DRE sequences
P08632018A0587|1 11|DNA fragment
P08632018A0587|25 35|nucleotides
P08632018A0587|53 66|flanking region
P08632018A0587|72 81|UGT1A1 gene
P08632018A0587|94 104|MC induction
P08632463A1508|36 47|beta' subunit
P08632463A1508|36 39|beta
P08632463A1508|41 47|subunit
P08632463A1508|55 67|essential role
P08632463A1508|94 116|transcription elongation
P08632779A0351|3 12|XPG regions
P08632779A0351|17 27|putative NLS
P08632779A0351|29 37|amino acid
P08632779A0351|39 40|AA
P08632779A0351|54 58|NLS-B
P08632779A0351|60 61|AA
P08632779A0351|75 79|NLS-C
P08632779A0351|81 82|AA
P08632779A0351|133 140|beta-gal
P08632779A0351|156 156|%
P08632779A0351|163 169|nucleus
P08632779A0351|172 180|HeLa cells
P08633855A1064|3 10|lacS gene
P08633855A1064|24 56|E. coli-Streptococcus shuttle vector
P08633855A1064|79 100|lacS deletion derivative
P08633855A1064|79 82|lacS
P08633855A1064|103 116|S. thermophilus
P08633855A1064|123 139|pNZ63-cured strain
P08633855A1064|149 154|NZ6091
P08634290A0000|3 8|genome
P08634290A0000|14 25|retroviruses
P08634290A0000|39 51|identical RNAs
P08634357A0527|3 20|extraction recovery
P08634357A0527|23 35|Amphotericin B
P08634357A0527|43 60|cerebrospinal fluid
P08634357A0527|63 68|higher
P08634357A0527|75 75|%
P08634357A0527|83 99|entire linear range
P08634420A1784|0 8|HuEpo-R Ab
P08634420A1784|18 50|Epo-induced parental UT-7 cell growth
P08634420A1784|18 20|Epo
P08634420A1784|64 68|cells
P08634420A1784|71 75|clone
P08634420A1784|96 102|muEpo-R
P08634420A1784|117 142|human UT-7 cell proliferation
P08634423A0498|14 25|integrations
P08634423A0498|35 47|transcription
P08634423A0498|53 60|lacZ gene
P08634423A0498|80 80|%
P08634423A0498|86 97|integrations
P08634423A0498|108 108|%
P08634423A0498|128 142|differentiation
P08634423A0498|145 152|32D cells
P08634423A0498|160 170|neutrophils
P08634697A1155|22 26|cDNAs
P08634697A1155|38 51|useful reagents
P08634697A1155|78 82|Brca1
P08634697A1155|148 154|domains
P08635771A0000|30 35|ONLINE
P08635771A0000|39 56|EMIT II immunoassays
P08635771A0000|61 96|gas chromatographic/mass spectrometric
P08635771A0000|98 102|GC/MS
P08635771A0000|114 136|methaqualone metabolites
P08635771A0000|139 143|urine
P08635771A0000|149 155|samples
P08635771A0000|169 181|clinical study
P08636031A1413|0 10|Interaction
P08636031A1413|16 27|Fur repressor
P08636031A1413|33 46|150-bp fragment
P08636031A1413|62 73|pvdS promoter
P08636031A1413|100 116|Fur titration assay
P08636031A1413|100 102|Fur
P08636031A1413|138 162|gel retardation experiments
P08636031A1413|185 198|Fur preparation
P08636031A1413|185 187|Fur
P08636124A0410|24 27|cDNA
P08636124A0410|46 52|p150TSP
P08636124A0410|57 70|TPR-containing
P08636124A0410|72 96|SH2-binding phosphoprotein
P08636124A0410|101 107|located
P08636124A0410|126 132|nucleus
P08636149A0220|4 18|mutant receptors
P08636149A0220|37 47|cell surface
P08636149A0220|56 62|insulin
P08636149A0220|89 115|impaired autophosphorylation
P08636149A0220|128 134|insulin
P08636211A0983|0 5|EMBO J.
P08636428A1363|17 23|results
P08636428A1363|36 87|thrombin-stimulated vascular smooth muscle proliferation
P08636428A1363|36 43|thrombin
P08636428A1363|134 154|more autocrine mitogens
P08637006A0000|0 12|Transcription
P08637006A0000|17 42|adenovirus E2-early promoter
P08637006A0000|58 68|unique array
P08637006A0000|75 92|cis-acting elements
P08637006A0000|107 121|atypical TBP site
P08637006A0000|115 121|TBP site
P08637006A0000|126 140|E2F sites present
P08637006A0000|126 133|E2F sites
P08637006A0000|145 171|inverted orientation relative
P08637006A0000|189 195|ATF site
P08637711A1121|27 30|IL-6
P08637711A1121|32 46|interferon gamma
P08637711A1121|48 55|IFN gamma
P08637711A1121|57 71|response element
P08637711A1121|77 89|IRF-1 promoter
P08637711A1121|91 96|IR/IRF
P08637711A1121|91 92|IR
P08637711A1121|94 98|IRF-1
P08637711A1121|115 130|Stat-binding site
P08637711A1121|136 155|adjacent CRE-like site
P08637711A1121|166 200|IL-6-induced binding complexes similar
P08637711A1121|166 169|IL-6
P08637711A1121|203 213|JRE-IL6-BCs
P08637711A1121|203 209|JRE-IL6
P08637717A0817|1 13|second peptide
P08637717A0817|15 24|amino acids
P08637717A0817|46 57|p21-activity
P08637717A0817|46 48|p21
P08637717A0817|66 72|peptide
P08637717A0817|97 99|p21
P08637717A0817|114 125|cyclin E/Cdk2
P08637717A0817|114 120|cyclin E
P08637717A0817|122 125|Cdk2
P08637717A1231|1 10|p21 peptide
P08637717A1231|19 28|amino acids
P08637717A1231|50 53|PCNA
P08637717A1231|57 74|filter binding assay
P08637717A1231|82 88|peptide
P08637717A1231|99 128|recombinant p21-PCNA interaction
P08638435A0522|0 6|Results
P08638435A0522|25 43|agar diffusion method
P08638435A0522|47 62|Y. enterocolitica
P08638435A0522|71 88|inhibition activity
P08638435A0522|103 114|A. hydrophila
P08639310A0548|0 2|OND
P08639310A0548|4 12|mg tid days
P08639310A0548|21 32|mg tid prn days
P08639310A0548|39 50|prednisolone
P08639310A0548|57 65|mg qds days
P08639310A0548|74 76|MCP
P08639310A0548|101 106|mg i.v.
P08639310A0548|113 114|CT
P08639310A0548|118 120|MCP
P08639310A0548|123 128|mg p.r.
P08639310A0548|139 139|h
P08639521A1032|3 19|dynamic properties
P08639521A1032|26 40|protein fragment
P08639521A1032|73 81|isotropic
P08639521A1032|85 101|anisotropic models
P08639521A1032|104 118|molecular motion
P08639561T0000|0 8|Adduction
P08639561T0000|14 28|human N-ras codon
P08639561T0000|48 49|7S
P08639561T0000|52 52|R
P08639561T0000|55 55|R
P08639561T0000|59 59|S
P08639561T0000|66 76|dihydroxy-9
P08639561T0000|81 87|epoxy-7
P08639561T0000|96 110|tetrahydrobenzo
P08639561T0000|114 119|pyrene
P08639561T0000|121 140|structural refinement
P08639561T0000|146 161|intercalated SRSR
P08639561T0000|173 174|7S
P08639561T0000|177 177|R
P08639561T0000|180 180|S
P08639561T0000|184 184|R
P08639561T0000|204 218|tetrahydrobenzo
P08639561T0000|222 228|pyrenyl
P08639561T0000|235 253|deoxyadenosyl adduct
P08639561T0000|258 262|1H NMR
P08639742T0000|0 8|Isolation
P08639742T0000|11 13|PCR
P08639742T0000|17 25|cDNA clone
P08639742T0000|30 38|pea petals
P08639742T0000|55 61|petunia
P08639742T0000|65 87|wheat zinc finger proteins
P08639837A0268|19 44|several trans-acting factors
P08639837A0268|62 67|GATA-1
P08639837A0268|71 77|members
P08639837A0268|83 91|Ets family
P08640866A0473|0 7|Exposure
P08640866A0473|10 30|peripheral blood T cells
P08640866A0473|35 47|young subjects
P08640866A0473|50 52|PHA
P08640866A0473|55 94|cross-linked anti-CD3 monoclonal antibodies
P08640866A0473|67 94|anti-CD3 monoclonal antibodies
P08640866A0473|105 118|rapid increases
P08640866A0473|121 124|MAPK
P08640866A0473|128 147|MEK enzymatic activity
P08640866A0473|128 130|MEK
P08641705A0986|5 25|different observations
P08641705A0986|34 47|heterozygosity
P08641705A0986|53 53|A
P08641705A0986|57 65|G mutation
P08641705A0986|68 76|codon beta
P08641705A0986|89 106|deletion comparable
P08641705A0986|115 130|Hbs Lepore or Kenya
P08641705A0986|115 123|Hbs Lepore
P08641705A0986|126 130|Kenya
P08641705A0986|135 160|beta-globin gene duplication
P08641705A0986|173 197|nontraditional inheritance
P08641705A0986|200 210|Hb Costa Rica
P08642282A1009|9 24|first description
P08642282A1009|43 60|regulatory elements
P08642282A1009|98 120|B7 costimulatory molecule
P08642285A1548|0 16|DNA-STAT complexes
P08642285A1548|34 61|Bcr/Abl-transformed cell lines
P08642285A1548|34 36|Bcr
P08642285A1548|38 40|Abl
P08642285A1548|87 96|antibodies
P08642285A1548|104 108|STAT1
P08642285A1548|112 116|STAT5
P08642313A0770|21 39|appropriate cell line
P08642313A0770|41 46|TAN-1C
P08642313A0770|56 86|kappa B-dependent transactivation
P08642313A0770|56 61|kappa B
P08642313A0770|89 115|transient reporter gene assays
P08642313A0770|119 132|fashion similar
P08642313A0770|150 163|related protein
P08642313A0770|165 169|Bcl-3
P08642313T0000|0 72|T cell leukemia-associated human Notch/translocation-associated Notch homologue
P08642313T0000|76 95|I kappa B-like activity
P08642313T0000|122 149|nuclear factor-kappa B proteins
P08642313T0000|152 157|T cells
P08642693T0000|0 20|Polyprotein processing
P08642693T0000|23 38|Southampton virus
P08642693T0000|56 83|3C-like protease cleavage sites
P08642693T0000|93 103|mutagenesis
P08643111A0855|3 14|humanized LL2
P08643111A0855|12 14|LL2
P08643111A0855|16 19|hLL2
P08643111A0855|29 65|light chain variable region glycosylation
P08643111A0855|76 93|immunoreactivities
P08643111A0855|120 130|chimeric LL2
P08643111A0855|132 135|cLL2
P08643111A0855|167 198|antigen-binding properties similar
P08643111A0855|204 220|murine counterpart
P08643111A0855|239 265|VK-appended oligosaccharides
P08643111A0855|273 276|mLL2
P08643111A0855|295 308|antigen binding
P08643382A0752|2 33|apparent N-terminal transit peptide
P08643382A0752|57 60|poly
P08643382A0752|62 62|A
P08643382A0752|78 86|cDNA clone
P08643382A0752|104 121|chloroplast protein
P08643513A0361|0 15|Deletion analysis
P08643513A0361|18 71|rOC promoter-chloramphenicol acetyltransferase constructs
P08643513A0361|18 28|rOC promoter
P08643513A0361|90 110|AML-1-binding sequence
P08643513A0361|120 135|proximal promoter
P08643513A0361|147 148|nt
P08643513A0361|165 165|%
P08643513A0361|178 202|osteocalcin gene expression
P08643557A0259|6 21|critical question
P08643557A0259|27 37|HOX proteins
P08643557A0259|47 57|correct sets
P08643557A0259|60 70|target genes
P08643578A0000|0 8|RAS2val19
P08643578A0000|11 31|dominant activated form
P08643578A0000|34 60|Saccharomyces cerevisiae Ras2
P08643578A0000|57 60|Ras2
P08643578A0000|76 92|filamentous growth
P08643578A0000|109 133|transcriptional reporter FG
P08643578A0000|135 137|TyA
P08643578A0000|141 144|lacZ
P08643578A0000|164 188|mating pathway reporter FUS1
P08643578A0000|191 194|lacZ
P08643578A0532|12 32|Rho family protein Cdc42
P08643578A0532|28 32|Cdc42
P08643578A0532|44 64|morphogenetic G protein
P08643578A0532|73 87|potent regulator
P08643578A0532|90 106|filamentous growth
P08643578A0532|110 111|FG
P08643578A0532|113 115|TyA
P08643578A0532|119 132|lacZ expression
P08643578A0532|119 122|lacZ
P08643633A1187|4 20|immunoprecipitate
P08643633A1187|40 50|N1(deltaEC)
P08643633A1187|40 41|N1
P08643633A1187|43 49|deltaEC
P08643633A1187|54 57|CBF1
P08643646A0479|18 21|verA
P08643646A0479|24 37|structural gene
P08643646A0479|68 81|ST biosynthesis
P08643646A0479|111 121|transcripts
P08643646A0479|147 148|kb
P08643646A0479|184 205|ST-producing conditions
P08643682A0268|0 23|Subcellular localizations
P08643682A0268|29 44|wild-type CBFbeta
P08643682A0268|51 76|CBFbeta-SMMHC fusion protein
P08643682A0268|51 57|CBFbeta
P08643682A0268|59 63|SMMHC
P08643682A0268|93 110|immunofluorescence
P08643682A0268|113 123|NIH 3T3 cells
P08643682A0268|139 147|wild-type
P08643682A0268|150 162|fusion protein
P08643759A0338|0 19|Menstrual-cycle phase
P08643759A0338|45 64|personality variables
P08644734A0404|22 41|human cDNAs homologous
P08644734A0404|47 67|Drosophila dishevelled
P08644734A0404|57 67|dishevelled
P08644734A0404|69 71|dsh
P08644734A0404|73 92|segment-polarity gene
P08645214A1052|15 18|BL21
P08645214A1052|20 22|DE3
P08645214A1052|24 28|plysS
P08645214A1052|41 58|recombinant plasmid
P08645214A1052|72 94|catalase-peroxidase gene
P08645214A1052|105 115|large amount
P08645214A1052|118 125|proteins
P08645214A1052|143 150|SDS/PAGE
P08645214A1052|158 169|native enzyme
P08645219A1377|0 2|Ca2
P08645219A1377|13 15|Zn2
P08645219A1377|17 23|binding
P08645219A1377|26 33|S100 beta
P08645219A1377|63 67|MRP14
P08645219A1377|86 88|Zn2
P08645219A1377|90 100|binding site
P08645219A1377|138 140|Ca2
P08645219A1377|142 155|binding domains
P08647086A0622|0 3|Cdk2
P08647086A0622|22 29|cyclin D1
P08647086A0720|3 23|Cdk2-cyclin-D1 complex
P08647086A0720|3 6|Cdk2
P08647086A0720|52 61|substrates
P08647086A0720|69 77|H1 histone
P08647086A0720|79 81|pRB
P08647086A0720|83 99|SV40 large T antigen
P08647086A0720|101 103|p53
P08647086A0720|105 109|E2F-1
P08647086A0720|126 140|nuclear proteins
P08647086A0720|145 153|HeLa cells
P08647086A0720|166 178|Cdk2-cyclin-E
P08647086A0720|166 169|Cdk2
P08647086A0720|171 178|cyclin-E
P08647086A0720|182 194|Cdk2-cyclin-A
P08647086A0720|182 185|Cdk2
P08647086A0720|187 194|cyclin-A
P08647086A0720|214 221|proteins
P08647086T0000|0 23|Cyclin-dependent kinase-2
P08647086T0000|25 28|Cdk2
P08647086T0000|37 51|inactive complex
P08647086T0000|56 63|cyclin D1
P08647086T0000|69 72|Cdk2
P08647086T0000|87 94|cyclin D1
P08647086T0000|116 128|Cdk7-cyclin-H
P08647086T0000|116 119|Cdk7
P08647086T0000|121 128|cyclin-H
P08647091A0592|14 19|clones
P08647091A0592|32 48|complete Adh-2 gene
P08647091A0592|63 67|exons
P08647091A0592|71 81|12-kb region
P08647091A0592|101 107|introns
P08647091A0592|130 151|other mammalian ADH genes
P08647091A0592|135 151|mammalian ADH genes
P08647264T0000|0 7|Ligation
P08647264T0000|10 13|CD40
P08647264T0000|21 47|Ramos-Burkitt lymphoma B cells
P08647264T0000|52 67|calcium ionophore
P08647264T0000|72 105|antigen receptor-triggered apoptosis
P08647264T0000|118 127|activation
P08647264T0000|133 158|cysteine protease CPP32/Yama
P08647264T0000|133 148|cysteine protease
P08647264T0000|149 153|CPP32
P08647264T0000|155 158|Yama
P08647264T0000|162 169|cleavage
P08647264T0000|175 187|substrate PARP
P08647434A1124|0 12|Large T antigen
P08647434A1124|38 47|antibodies
P08647434A1124|50 66|epitope-tagged TBP
P08647434A1124|64 66|TBP
P08647434A1124|68 80|endogenous TBP
P08647434A1124|78 80|TBP
P08647434A1124|82 88|hTAF(II
P08647434A1124|82 85|hTAF
P08647434A1124|94 97|hTAF
P08647434A1124|109 115|hTAF(II
P08647434A1124|109 112|hTAF
P08647434A1124|126 135|conditions
P08647434A1124|141 150|holo-TFIID
P08647451A0663|0 24|Northern blot hybridization
P08647451A0663|41 47|HEP-COP
P08647451A0663|63 71|wide range
P08647451A0663|74 83|human adult
P08647451A0663|87 98|fetal tissues
P08647802A0000|1 32|human cytoplasmic signaling protein
P08647802A0000|62 86|same structural arrangement
P08647802A0000|89 106|SH3-SH2-SH3 domains
P08647802A0000|109 112|Grb2
P08647822T0000|1 10|direct role
P08647822T0000|14 50|sterol regulatory element binding protein
P08647822T0000|53 62|activation
P08647822T0000|65 98|3-hydroxy-3-methylglutaryl coenzyme
P08647822T0000|100 112|reductase gene
P08647884A0547|18 37|endoplasmic reticulum
P08647884A0547|52 69|MHC class I molecules
P08647884A0547|52 59|MHC class
P08647884A0547|61 69|molecules
P08647884A0547|107 117|cell surface
P08648408A0792|7 9|PHT
P08648408A0792|13 21|CSA groups
P08648408A0792|35 43|Hyp levels
P08648408A0792|61 66|higher
P08648408A0792|72 77|PHT-GO
P08648408A0792|93 98|CSA-GO
P08648665A0956|8 19|LE6 deletions
P08648665A0956|8 10|LE6
P08648665A0956|39 62|transformation efficiency
P08648665A0956|85 89|cells
P08648665A0956|112 123|wild-type LE6
P08648665A1320|0 12|ORF E8 colinear
P08648665A1320|0 4|ORF E8
P08648665A1320|17 21|ORF E6
P08648665A1320|42 61|50-amino-acid protein
P08648665A1320|67 84|hydrophobic segment
P08648665A1320|101 105|cells
P08648665A1320|123 135|pZipNeo vector
P08648726A0713|0 6|Cloning
P08648726A0713|9 27|individual ZI domains
P08648726A0713|39 53|minimal promoter
P08648726A0713|73 75|ZIA
P08648726A0713|77 79|ZIC
P08648726A0713|84 93|ZID domains
P08648726A0713|104 112|ZIB domain
P08648726A0713|117 129|TPA responsive
P08649372A0501|0 15|Clb2/Cdc28 kinase
P08649372A0501|0 3|Clb2
P08649372A0501|35 44|repression
P08649372A0501|47 86|MCB-binding factor transcriptional activity
P08649372A0501|47 63|MCB-binding factor
P08649372A0501|89 90|G2
P08649372A0501|94 99|M phase
P08649372A0755|3 17|carboxy terminus
P08649372A0755|20 23|Mbp1
P08649372A0755|54 57|Swi6
P08649372A0755|65 79|carboxy terminus
P08649372A0755|82 85|Swi6
P08649372A0755|114 117|Mbp1
P08649373T0000|0 33|Multiple single-stranded cis elements
P08649373T0000|60 68|chromatin
P08649373T0000|74 87|human c-myc gene
P08649386A1032|1 24|new UASH consensus sequence
P08649386A1032|40 57|mutational analysis
P08649386A1032|73 85|consensus Abf1
P08649386A1032|82 96|Abf1 binding site
P08649389A0000|25 43|human CTCF cDNA clones
P08649389A0000|83 106|11-zinc-finger factor CTCF
P08649389A0000|158 166|% identity
P08649389A0000|174 178|avian
P08649389A0000|182 204|human amino acid sequences
P08649389A0692|0 17|Mutational analysis
P08649389A0692|23 48|P2-proximal CTCF binding site
P08649389A0692|52 86|transient-cotransfection experiments
P08649389A0692|102 105|CTCF
P08649389A0692|109 132|transcriptional repressor
P08649389A0692|138 151|human c-myc gene
P08649393A0000|1 30|chromosome transmission fidelity
P08649393A0000|32 34|ctf
P08649393A0000|36 41|mutant
P08649393A0000|43 46|s138
P08649393A0000|91 100|centromere
P08649393A0000|102 104|CEN
P08649393A0000|106 140|transcriptional readthrough phenotype
P08649393A0000|161 180|kinetochore integrity
P08649403A0963|3 14|growth defect
P08649403A0963|18 37|reg1 reg2 double mutant
P08649403A0963|18 21|reg1
P08649403A0963|22 37|reg2 double mutant
P08649403A0963|53 76|loss-of-function mutation
P08649403A0963|82 106|SNF1-encoded protein kinase
P08649405T0000|0 2|Sp1
P08649405T0000|11 15|sites
P08649405T0000|21 33|CD11c promoter
P08649405T0000|54 65|myeloid cells
P08649405T0000|83 85|AP1
P08649405T0000|96 108|transcription
P08649424A0000|0 9|Expression
P08649424A0000|15 42|phenylalanine hydroxylase gene
P08649424A0000|45 50|livers
P08649424A0000|54 60|kidneys
P08649424A0000|63 69|rodents
P08649424A0000|102 116|glucocorticoids
P08649424A0000|120 128|cyclic AMP
P08649425A0373|14 15|bp
P08649425A0373|21 28|enhancer
P08649425A0373|31 49|transcriptional core
P08649425A0373|57 62|DNase I
P08649425A0373|57 61|DNase
P08649425A0373|63 81|hypersensitive early
P08649425A0373|84 100|B-cell development
P08649425T0000|25 42|chromatin structure
P08649425T0000|48 71|mouse immunoglobulin kappa
P08649425T0000|74 81|enhancer
P08649427A0689|32 35|cDNA
P08649427A0689|48 56|new member
P08649427A0689|62 85|GTPase-activating protein
P08649427A0689|87 89|GAP
P08649427A0689|99 114|GTPase regulators
P08649428A1227|51 59|synthesis
P08649428A1227|65 84|c-mos oncogene product
P08649428A1227|108 117|activation
P08649428A1227|120 123|Cdc2
P08649440T0000|3 15|heterogeneity
P08649440T0000|18 33|bovine IgG2--VIII
P08649440T0000|18 27|bovine IgG2
P08649440T0000|30 33|VIII
P08649773A1374|12 16|BCL-6
P08649773A1374|30 53|transcriptional repressor
P08649773A1374|90 101|B lymphocytes
P08649773A1374|104 127|diffuse large cell lymphoma
P08649841A0956|15 18|uORF
P08649841A0956|47 60|Kozak sequences
P08649841A0956|70 89|heterologous promoter
P08649841A0956|94 97|SV40
P08649841A0956|102 116|CAT reporter gene
P08649841A0956|127 142|marked inhibition
P08649841A0956|145 164|CAT protein production
P08649841A0956|145 154|CAT protein
P08649841A0956|183 189|CAT mRNA
P08650818A0000|1 15|secondary spread
P08650818A0000|28 48|methicillin-resistant
P08650818A0000|76 79|MRSA
P08650818A0000|86 98|other patients
P08650818A0000|114 131|Danish surgical ward
P08650818A0000|153 181|multitraumatized index-patient
P08650818A0000|223 239|Mediterranean area
P08651853A0607|0 22|Mesial temporal sclerosis
P08651853A0607|41 58|severe neuronal loss
P08651853A0607|72 78|gliosis
P08651853A0607|93 108|CA1/prosubiculum
P08651853A0607|112 119|patients
P08651853A0607|124 124|%
P08651853A0607|139 150|dentate gyrus
P08651853A0607|154 161|patients
P08651853A0607|165 165|%
P08651853A0607|176 184|CA4 region
P08651853A0607|188 195|patients
P08651853A0607|199 199|%
P08651853T0000|0 22|Mesial temporal sclerosis
P08652081A1953|4 24|specific adverse events
P08652081A1953|52 74|dose-limiting toxicities
P08652081A1953|83 93|hypotension
P08652081A1953|98 101|IL-1
P08652081A1953|103 116|severe headache
P08652081A1953|119 126|skin rash
P08652081A1953|131 134|IL-3
P08652081A1953|139 153|nasal congestion
P08652081A1953|157 177|gastroduodenal lesions
P08652081A1953|182 185|IL-4
P08654200A0274|10 33|magnetic resonance imaging
P08654200A0274|52 62|liver volume
P08654200A0274|65 73|pediatric
P08654200A0274|77 94|adolescent patients
P08654200A0274|102 118|systemic clearance
P08654200A0274|126 140|model substrates
P08654200A0274|142 150|lorazepam
P08654200A0274|156 160|mg/kg
P08654200A0274|163 172|antipyrine
P08654200A0274|176 180|mg/kg
P08654200A0274|186 201|indocyanine green
P08654200A0274|203 205|ICG
P08654200A0274|210 214|mg/kg
P08654375A0544|1 18|mutational analysis
P08654375A0544|44 53|amino acids
P08654375A0544|55 64|amino acids
P08654375A0544|76 85|N-terminus
P08654375A0544|88 91|Bob1
P08654375A0544|124 142|DNA binding POU domain
P08654375A0544|124 136|DNA binding POU
P08654375A0544|145 149|Oct-1
P08654375A0544|152 156|Oct-2
P08654390A0000|0 13|Heme oxygenase 1
P08654390A0000|0 12|Heme oxygenase
P08654390A0000|18 32|essential enzyme
P08654390A0000|35 48|heme catabolism
P08654390A0000|60 63|heme
P08654390A0000|70 79|biliverdin
P08654390A0000|89 102|carbon monoxide
P08654435A0540|2 15|inactive analog
P08654435A0540|18 27|wortmannin
P08654435A0540|29 32|WM12
P08654435A0540|46 74|TCR/CD3-induced Erk2 activation
P08654435A0540|46 48|TCR
P08654435A0540|50 52|CD3
P08654435A0540|61 64|Erk2
P08654435A0540|79 88|wortmannin
P08654435A0540|115 118|Erk2
P08654435A0540|148 153|assays
P08654946A0475|3 4|aa
P08654946A0475|6 11|shares
P08654946A0475|14 22|% identity
P08654946A0475|30 44|analogous region
P08654946A0475|47 63|Xenopus laevis FGF3
P08654946A0475|69 77|% identity
P08654946A0475|110 125|related human gene
P08654946A0986|3 25|transcription start point
P08654946A0986|31 46|proximal promoter
P08654946A0986|61 75|mouse promoter P3
P08654972A0000|0 6|Defects
P08654972A0000|37 38|Sp
P08654972A0000|40 65|cell cycle-controlling genes
P08654972A0000|76 95|cell cycle progression
P08654983A0000|14 38|signal recognition particle
P08654983A0000|40 42|SRP
P08654983A0000|45 55|SRP receptor
P08654983A0000|57 59|Srb
P08654983A0000|69 84|Bacillus subtilis
P08654983A0000|86 87|Bs
P08654983A0000|101 109|Bs srb gene
P08654983A0000|124 132|homologue
P08654983A0000|138 170|mammalian SRP receptor alpha-subunit
P08654983A0000|172 176|Oguro
P08654983A0000|183 188|DNA Res
P08655497A0000|1 9|novel gene
P08655497A0000|20 22|cmr
P08655497A0000|41 43|min
P08655497A0000|64 73|K-12 genome
P08655497A0000|104 118|chloramphenicol
P08655497A0000|142 156|multicopy vector
P08655555A0772|13 21|deletions
P08655555A0772|38 47|bp upstream
P08655555A0772|53 75|transcription start point
P08655555A0772|84 90|greater
P08655555A0772|97 113|% promoter activity
P08655555A0772|135 141|hexamer
P08655555A0772|160 175|promoter activity
P08655555A1368|3 13|DNA sequence
P08655555A1368|43 49|hexamer
P08655555A1368|62 69|TGn motif
P08655555A1368|102 121|prokaryotic promoters
P08656672A0678|2 30|apparent ufo mRNA overexpression
P08656672A0678|10 16|ufo mRNA
P08656672A0678|52 76|positive leukemia cell lines
P08656672A0678|99 121|drug-resistant subclones
P08656672A0678|127 153|cervix carcinoma cell line HeLa
P08657135A1444|19 25|studies
P08657135A1444|30 33|CKII
P08657135A1444|43 59|positive regulator
P08657135A1444|62 71|myogenesis
P08657135A1444|84 101|E protein homodimers
P08657135A1444|115 142|muscle gene regulatory elements
P08657150A1049|9 30|negative regulators such
P08657150A1049|33 36|NCE3
P08657150A1049|68 75|SIN5 gene
P08657150A1049|93 111|promoter specificity
P08657150A1049|114 133|homologous activators
P08657157A0000|0 24|Transcriptional regulators
P08657157A0000|37 61|POU domain DNA-binding motif
P08657157A0000|81 111|multi-protein complexes dependent
P08657157A0000|117 125|POU domain
P08657157A0000|138 156|flexible recognition
P08657157A0000|159 188|various octamer sequence elements
P08657183A0145|7 27|strand selective repair
P08657183A0145|30 41|DNA fragments
P08657183A0145|51 61|active genes
P08657183A0145|63 66|DHFR
P08657183A0145|72 90|unknown gene adjacent
P08657183A0145|93 96|DHFR
P08657918A0360|0 8|MATERIALS
P08657918A0360|12 18|METHODS
P08657918A0360|20 38|Coronal 3D GRE imaging
P08657918A0360|56 60|volar
P08657918A0360|72 85|dorsal portions
P08657918A0360|91 93|SLL
P08657918A0360|98 105|patients
P08657918A0360|128 136|normal SLL
P08657918A0360|146 160|cadaveric wrists
P08657918A0360|169 177|normal SLL
P08657918A0360|188 197|dissection
P08659545A0000|27 39|transcript map
P08659545A0000|42 56|human chromosome
P08659545A0000|83 97|pathophysiology
P08659545A0000|100 106|trisomy
P08659545A0000|120 131|exon trapping
P08659545A0000|142 150|fragments
P08659545A0000|153 162|chromosome
P08659545A0000|165 169|genes
P08660733X0000|11 21|populations
P08660733X0000|28 32|aphid
P08660733X0000|52 61|Puerto Rico
P08660733X0000|64 68|April
P08660748X0000|28 48|predator-prey dynamics
P08660748X0000|58 78|reasonable predictions
P08660748X0000|81 98|population patterns
P08660866A0504|2 19|cuticular positions
P08660866A0504|33 35|Brd
P08660866A0504|43 55|loss phenotype
P08660866A0504|75 81|progeny
P08660866A0504|97 100|SOPs
P08660866A0504|125 131|neurons
P08660866A0504|135 142|thecogen
P08660866A0504|144 149|sheath
P08660866A0504|151 155|cells
P08660866A0504|168 176|trichogen
P08660866A0504|178 182|shaft
P08660866A0504|187 194|tormogen
P08660866A0504|196 201|socket
P08660866A0504|203 207|cells
P08660892A1044|0 22|Transcriptional blockade
P08660892A1044|36 51|co-transfections
P08660892A1044|55 82|wild-type SRF expression vector
P08660892A1044|55 66|wild-type SRF
P08660892A1044|117 136|other myogenic factors
P08660892A1044|144 147|MyoD
P08660892A1044|151 156|Mef-2C
P08660998A0851|3 16|mMIWC1 promoter
P08660998A0851|42 45|TATA
P08660998A0851|47 50|CAAT
P08660998A0851|52 55|GATA
P08660998A0851|60 71|AP-2 elements
P08660998A0851|73 87|primer extension
P08660998A0851|96 123|mMIWC transcription initiation
P08660998A0851|96 100|mMIWC
P08660998A0851|129 130|bp
P08660998A0851|146 178|mMIWC1 translational initiation site
P08660998A0851|146 151|mMIWC1
P08661007T0000|0 14|Human MN/CA9 gene
P08661007T0000|17 27|novel member
P08661007T0000|33 55|carbonic anhydrase family
P08661007T0000|69 72|exon
P08661007T0000|75 100|protein domain relationships
P08661100A0285|3 25|exon-intron distribution
P08661100A0285|28 32|Cdebp
P08661100A0285|68 74|App gene
P08661100A0285|80 86|regions
P08661100A0285|107 113|domains
P08661100A0285|120 137|divergent structure
P08661100A0285|143 152|other parts
P08661101A0396|0 18|DNA sequence analysis
P08661101A0396|58 67|homologous
P08661101A0396|70 76|rat CRP1
P08661104A0687|36 45|1.5-kb mRNA
P08661104A0687|48 80|most nonlymphoid human cells/tissues
P08661104A0687|90 97|prostate
P08661104A0687|113 117|colon
P08661114A0564|11 17|domains
P08661114A0564|22 45|striking sequence homology
P08661114A0564|50 57|human SIM
P08661114A0564|55 57|SIM
P08661114A0564|74 81|proteins
P08661116A0963|0 15|Promoter activity
P08661116A0963|25 33|cell lines
P08661116A0963|47 56|high levels
P08661116A0963|59 74|endogenous D3 mRNA
P08661116A0963|89 108|Northern blot analyses
P08661116A0963|143 150|promoter
P08661116A0963|169 170|bp
P08661119A0085|17 44|human EP4 receptor gene sequence
P08661119A0085|61 77|structure relative
P08661119A0085|80 87|EP4R cDNA
P08661119A0085|103 128|peripheral blood lymphocytes
P08661613A0691|4 8|users
P08661613A0691|32 49|management measures
P08661613A0691|51 60|other users
P08661613A0691|139 159|enforcement activities
P08662193A0404|5 32|separate activation subdomains
P08662193A0404|40 60|negative-acting region
P08662193A0404|77 81|yeast
P08662193A0404|86 92|located
P08662193A0404|98 120|carboxyl-terminal region
P08662193A0404|123 126|NIT4
P08662499A0484|9 9|F
P08662499A0484|50 52|RNA
P08662617A2051|34 36|HIP
P08662617A2051|40 75|membrane-associated HP-binding protein
P08662617A2051|59 75|HP-binding protein
P08662617A2051|99 125|normal human uterine epithelia
P08662617A2051|129 154|uterine epithelial cell lines
P08662789A0673|3 19|corresponding gene
P08662789A0673|38 54|GenBankTM data base
P08662789A0673|57 73|sequence alignment
P08662789A0673|83 88|RPS30A
P08662852A1297|13 24|multiple GRK2
P08662852A1297|21 24|GRK2
P08662852A1297|28 51|GRK5 phosphoacceptor sites
P08662852A1297|57 79|extreme carboxyl terminus
P08662852A1297|85 91|beta2AR
P08662852A1297|100 110|reminiscent
P08662852A1297|113 140|GRK1-mediated phosphorylation
P08662852A1297|113 116|GRK1
P08662852A1297|143 151|rhodopsin
P08662928A1153|65 76|STAT proteins
P08662928T0000|0 8|Receptors
P08662928T0000|12 29|interleukin (IL)-10
P08662928T0000|12 22|interleukin
P08662928T0000|24 25|IL
P08662928T0000|33 50|IL-6-type cytokines
P08662928T0000|33 36|IL-6
P08662928T0000|54 79|similar signaling mechanisms
P08662928T0000|91 103|transcription
P08662928T0000|111 130|IL-6 response elements
P08662936A0428|23 44|FR-19 amino acid sequence
P08662936A0428|72 87|% overall identity
P08662936A0428|90 102|chicken TEF-1A
P08662936A0428|104 113|mouse TEF-1
P08662936A0428|118 157|mouse embryonic TEA domain-containing factor
P08662980A0762|27 36|DNA binding
P08662980A0762|55 62|receptor
P08662980A0762|80 92|hormone-bound
P08662980A0762|126 135|active form
P08662980A0762|152 159|receptor
P08663000A0000|3 10|receptor
P08663000A0000|14 23|hyaluronan
P08663000A0000|32 39|motility
P08663000A0000|41 45|RHAMM
P08663000A0000|47 60|gene expression
P08663000A0000|71 78|elevated
P08663000A0000|81 93|fibrosarcomas
P08663000A0000|103 132|transforming growth factor-beta1
P08663000A0000|115 132|growth factor-beta1
P08663000A0000|134 142|TGF-beta1
P08663120T0000|0 13|Oncogenic Raf-1
P08663120T0000|23 33|p70 S6 kinase
P08663120T0000|38 86|mitogen-activated protein kinase-independent pathway
P08663120T0000|38 67|mitogen-activated protein kinase
P08663127A0697|0 17|Hydropathy analysis
P08663127A0697|20 23|KCC1
P08663127A0697|33 50|structural homology
P08663127A0697|53 56|NKCC
P08663127A0697|69 88|transmembrane domains
P08663127A0697|91 112|large extracellular loop
P08663127A0697|117 151|potential N-linked glycosylation sites
P08663127A0697|156 167|cytoplasmic N
P08663127A0697|172 188|C-terminal regions
P08663141T0000|1 27|cis-acting DNA element located
P08663141T0000|35 41|TATA box
P08663141T0000|45 71|transcription initiation site
P08663141T0000|94 112|regulatory sequences
P08663141T0000|115 138|human angiotensinogen gene
P08663141T0000|120 138|angiotensinogen gene
P08663172A0311|16 39|hydrophobic amino terminus
P08663219A0246|3 10|promoter
P08663219A0246|16 27|rat PGS-2 gene
P08663219A0246|37 76|CAAT enhancer-binding protein consensus site
P08663219A0246|78 84|CAAT box
P08663219A0246|100 118|hormone inducibility
P08663219A0246|122 126|PGS-2
P08663219A0246|128 142|CAT reporter gene
P08663219A0246|153 171|putative E-box region
P08663310A0157|8 10|SRF
P08663310A0157|28 39|key regulator
P08663310A0157|42 48|members
P08663310A0157|59 79|cellular response genes
P08663310A0157|86 105|immediate-early genes
P08663310A0157|107 110|IEGs
P08663310A0157|159 168|cell growth
P08663310A0157|172 186|differentiation
P08663326A0000|3 37|final sigma54-dependent DmpR activator
P08663326A0000|8 37|sigma54-dependent DmpR activator
P08663326A0000|47 59|transcription
P08663326A0000|65 73|dmp operon
P08663326A0000|88 94|enzymes
P08663326A0000|98 107|catabolism
P08663326A0000|111 116|methyl
P08663326A0000|118 124|phenols
P08663392A0215|27 39|human DSG3 gene
P08663392A0215|54 78|transcriptional regulation
P08664229T0000|0 17|Clinical evaluation
P08664229T0000|23 38|Allergan Humphrey
P08664229T0000|42 54|autorefractor
P08664229T0000|61 85|Nidek AR-1000 autorefractor
P08664347A0923|0 3|None
P08664347A0923|13 41|proprotein processing proteases
P08664347A0923|69 80|human pro-LPH
P08664347A0923|127 136|maturation
P08664347A0923|143 148|enzyme
P08664462A1404|5 11|changes
P08664462A1404|69 93|neuromuscular transmission
P08664462A1404|109 127|muscle contractility
P08664462A1404|137 145|other hand
P08664462A1404|166 180|plasma clearance
P08664462A1404|187 197|hypothermia
P08664667A0093|9 13|Delhi
P08664667A0093|15 24|urban India
P08665853A0228|7 34|interleukin-3-dependent cells
P08665853A0228|7 19|interleukin-3
P08665853A0228|65 76|ErbB proteins
P08665853A0228|84 95|combinations
P08665853A0228|108 113|ErbB-3
P08665853A0228|116 121|devoid
P08665853A0228|127 144|biological activity
P08665853A0228|152 157|ErbB-1
P08665853A0228|161 166|ErbB-2
P08665853A0228|194 216|potent mitogenic activity
P08666102A0820|0 3|ZIOS
P08666102A0820|40 56|subsequent methods
P08666102A0820|61 63|Ptc
P08666102A0820|100 103|FEV1
P08666238T0000|0 29|Selective translation initiation
P08666238T0000|32 39|ribosome
P08666238T0000|49 67|adenovirus-infected
P08666238T0000|71 87|heat-shocked cells
P08666241A0930|29 39|43-bp region
P08666241A0930|45 56|24p3 promoter
P08666241A0930|71 87|Dex responsiveness
P08666383A1252|5 12|findings
P08666383A1252|24 40|direct cDNA mapping
P08666383A1252|46 57|fluorescence
P08666383A1252|64 76|hybridization
P08666383A1252|98 110|rapid approach
P08666383A1252|148 158|human genome
P08666398T0000|0 2|YAC
P08666398T0000|6 18|cosmid contigs
P08666398T0000|30 47|Batten disease (CLN3
P08666398T0000|30 42|Batten disease
P08666398T0000|44 47|CLN3
P08666398T0000|57 69|16p12.1-p11.2
P08666404A0311|0 8|Isolation
P08666404A0311|12 30|near full-length cDNA
P08666404A0311|36 61|human fetal brain cDNA library
P08666404A0311|71 104|protein serine-threonine phosphatase
P08666404A0311|110 131|tetratricopeptide motif
P08666404A0311|150 159|human PPP5C
P08666404A0311|161 163|PP5
P08666404A0311|174 183|homologous
P08666404A0311|186 191|rat PPT
P08666913A0000|0 4|Ly-49
P08666913A0000|8 17|family type
P08666913A0000|20 40|transmembrane proteins
P08666913A0000|51 61|gene cluster
P08666913A0000|64 79|murine chromosome
P08668124A0744|3 11|Dox-A2 ORF
P08668124A0744|23 34|TDH3 promoter
P08668124A0744|50 58|phenotype
P08668124A0744|78 81|sun2
P08668142A1048|17 21|hARF4
P08668142A1048|27 31|cells
P08668142A1048|59 67|cytosolic
P08668142A1048|71 99|membrane-associated Sec7p pools
P08668142A1048|90 94|Sec7p
P08668158A0765|30 34|Rpm1r
P08668158A0765|55 64|substrates
P08668158A0765|66 73|tRNA met f
P08668158A0765|66 69|tRNA
P08668158A0765|77 83|tRNAPro
P08668158A0765|90 104|promoter located
P08668158A0765|118 129|tRNA met f gene
P08668158A0765|118 121|tRNA
P08668158A0765|171 184|second promoter
P08668158A0765|186 192|located
P08668158A0765|203 214|tRNA met f gene
P08668158A0765|203 206|tRNA
P08668158A0765|218 221|RPM1
P08668158A1252|12 18|strains
P08668158A1252|23 37|mutant RPM1 genes
P08668158A1252|52 65|precursor Rpm1r
P08668158A1252|81 89|mutations
P08668158A1252|111 134|similar biogenesis defects
P08668190A1364|0 23|Vacuolar membrane vesicles
P08668190A1364|28 38|hum1 mutants
P08668190A1364|46 48|Ca2
P08668190A1364|51 51|H
P08668190A1364|53 68|antiport activity
P08668190A1364|87 91|Hum1p
P08668190A1364|114 116|Ca2
P08668190A1364|121 121|H
P08668190A1364|132 152|yeast vacuolar membrane
P08668201A1059|0 18|Detailed mutagenesis
P08668201A1059|33 66|rare-codon/AU-rich sequence boundary
P08668201A1059|82 102|destabilizing activity
P08668201A1059|108 118|MATalpha1 IE
P08668201A1059|136 148|terminal codon
P08668201A1059|163 180|rare-codon interval
P08668203A1230|0 2|FTF
P08668203A1230|33 40|pancreas
P08668203A1230|52 75|differentiation functions
P08668203A1230|78 98|endodermal sublineages
P08668203A1230|109 112|SF-1
P08668203A1230|115 134|steroidogenic tissues
P08668209A0406|0 5|Merlie
P08668209A0406|7 26|Cold Spring Harbor Symp
P08668210A0000|0 18|Substantial evidence
P08668210A0000|28 39|critical role
P08668210A0000|46 55|activation
P08668210A0000|61 65|Raf-1
P08668210A0000|67 107|MEK/mitogen-activated protein kinase pathway
P08668210A0000|67 69|MEK
P08668210A0000|71 100|mitogen-activated protein kinase
P08668210A0000|110 144|oncogenic Ras-mediated transformation
P08669274T0000|0 26|Stylohyoid chain ossification
P08669274T0000|39 54|surgical approach
P08669676A1644|3 11|incidence
P08669676A1644|14 25|cardiac death
P08669676A1644|40 46|Q wave MI
P08669676A1644|48 55|propofol
P08669676A1644|57 58|n =
P08669676A1644|61 69|midazolam
P08669676A1644|71 72|n =
P08669676A1644|75 76|P =
P08669676A1644|85 94|non Q wave MI
P08669676A1644|96 103|propofol
P08669676A1644|105 106|n =
P08669676A1644|110 118|midazolam
P08669676A1644|120 121|n =
P08669676A1644|125 126|P =
P08669676A1644|151 165|treatment groups
P08670556A0425|4 13|micromol/1
P08670556A0425|15 15|p
P08670556A0425|37 65|plasma concentration-time curve
P08670556A0425|80 90|infinity AUC
P08670556A0425|93 102|0-infinity
P08670853A0000|0 15|Cluster formation
P08670853A0000|18 27|E-cadherin
P08670853A0000|33 43|cell surface
P08670853A0000|60 74|major importance
P08670853A0000|78 94|cell-cell adhesion
P08670910A0156|0 13|DNA polymerase E
P08670910A0156|15 26|DNA ligase III
P08670910A0156|15 23|DNA ligase
P08670910A0156|31 72|DNA structure-specific endonuclease co-purify
P08670910A0156|84 101|polypeptide complex
P08672242A0517|7 28|reporter gene constructs
P08672242A0517|43 59|upstream sequences
P08672242A0517|65 74|P1 promoter
P08672242A0517|82 95|several regions
P08673026T0000|3 17|factor structure
P08673026T0000|21 31|schizotypal
P08673026T0000|33 38|traits
P08673026T0000|41 61|large replication study
P08675026A0420|26 35|homologous
P08675026A0420|54 65|sequence tags
P08675026A0420|67 69|EST
P08675026A0420|73 87|unknown function
P08675026A0420|92 112|Caenorhabditis elegans
P08675026A0420|114 124|Oryza sativa
P08675026A0420|128 138|Homo sapiens
P08675395A0751|0 6|RESULTS
P08675395A0751|11 23|bilinear model
P08675395A0751|46 54|better fit
P08675395A0751|60 76|acuity outcome data
P08675608T0000|0 6|Outcome
P08675608T0000|9 38|severe congenital hypothyroidism
P08675763A0788|0 11|Mean increase
P08675763A0788|14 29|milk protein yield
P08675763A0788|35 37|g/d
P08675763A0788|42 44|Met
P08675763A0788|49 51|Lys
P08675763A0788|70 87|true protein content
P08675763A0788|94 97|g/kg
P08675769A0158|0 13|Nonreturn rates
P08675769A0158|31 62|more elementary biological measures
P08675769A0158|66 87|reproductive efficiency
P08675769A0158|95 108|conception rate
P08675769A0158|112 122|calving rate
P08675769A0158|162 174|nonreturn rate
P08675769A0158|194 202|fertility
P08675769A0158|230 241|AI technician
P08675821A0657|10 13|EMPD
P08675821A0657|25 34|glans penis
P08675821A0657|37 48|perianal area
P08675821A0657|60 77|internal malignancy
P08676266A0838|3 12|mean values
P08676266A0838|15 30|protease activity
P08676266A0838|48 53|higher
P08676266A0838|59 68|test groups
P08676266A0838|78 89|control group
P08676266A0838|92 99|baseline
P08676383A0518|4 15|half molecule
P08676383A0518|28 44|disulfide linkages
P08676383A0518|52 62|cis peptides
P08676454A0731|18 20|Pra
P08676454A0731|22 23|N0
P08676454A0731|27 28|Nb
P08676454A0731|33 37|ICP35
P08676454A0731|39 43|ICP35
P08676454A0731|60 67|B capsids
P08676454A0731|89 98|precursors
P08676454A0731|101 113|mature virions
P08676456A0879|1 25|chimeric VP16-Tat construct
P08676456A0879|9 12|VP16
P08676456A0879|39 54|leucine mutations
P08676456A0879|72 89|AP-1 responsiveness
P08676456A0879|72 75|AP-1
P08676456A0879|115 134|VP16 activation domain
P08676456A0879|115 118|VP16
P08676495A0129|13 22|splice site
P08676495A0129|24 30|located
P08676495A0129|33 42|nucleotide
P08676495A0129|44 45|nt
P08676495A0129|76 93|most BPV-1 pre-mRNAs
P08676495A0129|80 93|BPV-1 pre-mRNAs
P08676495A0129|96 121|BPV-1-transformed C127 cells
P08676495A0129|96 100|BPV-1
P08676495A0129|134 150|intermediate times
P08676495A0129|165 177|infected warts
P08676858A0309|8 14|cloning
P08676858A0309|18 33|characterization
P08676858A0309|36 47|S-RNase genes
P08676858A0309|64 71|Rosaceae
P08676858A0309|79 93|Malus x domestica
P08676858A0309|98 109|Japanese pear
P08676858A0309|111 123|Pyrus serotina
P08676858A0309|144 152|sequences
P08676858A0309|175 192|other T2-type RNases
P08676858A0309|180 192|T2-type RNases
P08676858A1084|1 16|phylogenetic tree
P08676858A1084|19 25|members
P08676858A1084|31 51|T2/S-RNase superfamily
P08676858A1084|54 59|plants
P08677443A0238|3 22|Hoosier Oncology Group
P08677443A0238|47 75|extensive-disease SCLC patients
P08677443A0238|77 79|VIP
P08677443A0238|124 133|median time
P08677443A0238|136 146|progression
P08677443A0238|155 160|months
P08677443A0238|163 181|median survival times
P08677443A0238|190 195|months
P08677443A0238|206 224|3-year survival rates
P08677443A0238|228 228|%
P08677443A0238|231 231|%
P08677443A0238|236 236|%
P08677443A0238|239 239|%
P08677678A0258|30 55|immunomodulator neurotropin
P08677678A0258|45 55|neurotropin
P08677678A0258|57 59|NSP
P08677678A0258|70 92|more steady consolidation
P08677678A0258|96 104|retention
P08677678A0258|107 113|feeding
P08677678A0258|117 133|avoidance behavior
P08677678A0258|142 169|neurophysiological mechanisms
P08677678A0258|176 184|phenomena
P08678959A0640|0 20|Sestamibi scintigraphy
P08678959A0640|35 42|patients
P08678959A0640|64 78|ultrasonography
P08678959A0640|82 82|%
P08679131T0000|0 12|Atopic allergy
P08679131T0000|16 38|other hypersensitivities
P08680702A0548|7 26|significant lethality
P08680702A0548|30 54|cardiovascular dysfunction
P08680702A0548|61 71|septic group
P08680702A0548|74 77|Days
P08680702A0548|84 89|septic
P08680702A0548|96 109|control animals
P08680702A0548|115 136|significant differences
P08680702A0548|139 155|mean metabolic cart
P08680702A0548|165 170|Vo2DIR
P08680702A0548|172 180|ml/kg/min
P08680702A0548|182 184|Day
P08680702A0548|202 203|p =
P08680702A0548|209 211|Day
P08680702A0548|229 230|p =
P08680702A0548|252 272|intravascular catheter
P08680702A0548|284 291|Vo2INDIR
P08680702A0548|293 301|ml/kg/min
P08680702A0548|303 305|Day
P08680702A0548|323 324|p =
P08680702A0548|330 332|Day
P08680702A0548|350 351|p =
P08680706A0889|6 6|h
P08680706A0889|9 19|reperfusion
P08680706A0889|21 33|PO2/FlO2 ratio
P08680706A0889|69 75|Therapy
P08680706A0889|85 88|mm Hg
P08680706A0889|99 116|Recipient Instilled
P08680706A0889|126 129|mm Hg
P08680706A0889|134 146|Control groups
P08680706A0889|155 158|mm Hg
P08680706A0889|165 182|intermediate values
P08680706A0889|185 200|Donor Aerosol dogs
P08680706A0889|210 213|mm Hg
P08682155A0902|3 25|euglobulin clot lysis time
P08682155A0902|3 12|euglobulin
P08682155A0902|48 54|smokers
P08682155A0902|64 74|non-smokers
P08682155A0902|85 106|experimental situations
P08682155A0902|114 124|differences
P08682317A0900|0 13|HS inducibility
P08682317A0900|25 27|HSE
P08682317A0900|43 65|HS transcription factor-1
P08682317A0900|67 71|HSF-1
P08682317A0900|82 89|extracts
P08682317A0900|102 106|cells
P08682317A0900|116 117|HS
P08682868A0738|11 24|DSK2-1 mutation
P08682868A0738|41 47|residue
P08682868A0738|53 77|Dsk2p ubiquitin-like domain
P08682868A0738|53 57|Dsk2p
P08682868A0738|58 77|ubiquitin-like domain
P08682868A0738|89 99|differences
P08682868A0738|102 106|Dsk2p
P08682868A0738|109 123|Cdc31p stability
P08682868A0738|109 114|Cdc31p
P08683106A0374|8 11|IL-2
P08683106A0374|15 23|IFN-alpha
P08683106A0374|33 42|STAT1 alpha
P08683106A0374|46 50|STAT5
P08683106A0374|52 55|IL-2
P08683106A0374|78 82|STAT5
P08683106A0374|89 97|IFN-alpha
P08683106A0374|120 129|STAT1 alpha
P08683108A0965|0 9|Consistent
P08683108A0965|33 47|recombinant CREB
P08683108A0965|61 87|transcription factor proteins
P08683108A0965|96 111|junB CRE-like site
P08683108A0965|96 99|junB
P08683108A0965|135 152|mutant CRE-like site
P08683108A1501|18 24|results
P08683108A1501|36 45|components
P08683108A1501|51 80|protein kinase A signaling pathway
P08683108A1501|51 64|protein kinase A
P08683108A1501|95 97|mIg
P08683108A1501|106 122|junB transcription
P08683108A1501|106 109|junB
P08683983A0785|23 30|D protein
P08683983A0785|86 104|active leukemia cells
P08683983A1163|3 9|results
P08683983A1163|35 40|intron
P08683983A1163|44 68|transcriptional regulation
P08683983A1163|74 82|c-myb gene
P08683983A1163|123 149|complex regulatory mechanisms
P08683983A1163|152 161|activation
P08683983A1163|168 196|myelomonocytic differentiation
P08683983A1163|200 224|leukemic cell growth control
P08684522A0415|0 27|Immunofluorescence microscopy
P08684522A0415|36 54|extensive deposition
P08684522A0415|57 81|such extracellular matrices
P08684522A0415|90 97|collagen
P08684522A0415|101 107|laminin
P08684522A0415|113 124|vascular wall
P08684742A0000|0 8|OBJECTIVE
P08684742A0000|19 40|pregnancy complications
P08684742A0000|43 47|women
P08684742A0000|54 73|genetic amniocentesis
P08684742A0000|81 85|weeks
P08684742A0000|107 119|amniocentesis
P08684742A0000|127 131|weeks
P08684742A0000|133 141|gestation
P08686381A0527|5 8|ORFs
P08686381A0527|10 20|9765orfR002
P08686381A0527|22 32|9765orfR011
P08686381A0527|36 46|9765orfR013
P08686381A0527|61 70|homologous
P08686381A0527|99 125|polyadenylate binding protein
P08686381A0527|142 168|hypothetical 38.1-kDa protein
P08686381A0527|174 176|BCR
P08686381A0527|189 222|transcription regulatory protein Swi3
P08686381A0527|219 222|Swi3
P08688190A0000|3 22|new flavone glucosides
P08688190A0000|24 53|nevadensin 5-O-beta-D-glucoside
P08688190A0000|57 85|nevadensin 5-O-beta-D-glucosyl
P08688190A0000|93 108|beta-D-glucoside
P08688190A0000|133 143|aerial parts
P08688190A0000|146 166|Lysionotus pauciflorus
P08688556A0242|56 75|multicopy suppressors
P08688556A0242|89 101|lethal strains
P08688556A0242|104 136|clathrin heavy chain-deficient yeast
P08688556A0242|138 140|Chc
P08688556A0242|142 147|scd1-i
P08688556A0242|151 159|viability
P08689520T0000|0 17|Reproductive period
P08689520T0000|25 35|water intake
P08689520T0000|38 65|heat-stressed dehydrated goats
P08690118A0845|3 28|logistic regression analysis
P08690118A0845|34 45|manual method
P08690118A0845|47 72|percentage normal morphology
P08690118A0845|77 80|IVOS
P08690118A0845|102 111|predictors
P08690118A0845|114 126|fertilization
P08690198A0346|0 6|METHODS
P08690198A0346|8 11|Rats
P08690198A0346|20 49|continuous intragastric infusion
P08690198A0346|52 64|elemental diet
P08690198A0346|71 85|supplementation
P08690198A0346|88 94|oatbase
P08690198A0346|96 119|Lactobacillus reuteri R2LC
P08690198A0346|124 148|Lactobacillus plantarum DSM
P08690198A0346|168 179|fermentation
P08691106A0733|8 16|D8 binding
P08691106A0733|30 47|nuclease protection
P08691106A0733|52 61|lactotroph
P08691106A0733|71 104|somatotroph-like cell nuclear protein
P08691962T0000|0 10|Limited role
P08691962T0000|14 31|PCR-based diagnosis
P08691962T0000|34 40|Whipple
P08691962T0000|54 84|peripheral blood mononuclear cells
P08692885A0663|12 14|A20
P08692885A0663|22 40|NF-kappaB activation
P08692885A0663|22 30|NF-kappaB
P08692885A0663|55 80|C-terminal zinc finger domain
P08692892A0330|3 9|Pro-258
P08692892A0330|13 15|Leu
P08692892A0330|17 21|P258L
P08692892A0330|23 30|mutation
P08692892A0330|37 65|constitutive receptor signaling
P08692892A0330|92 92|%
P08692892A0330|98 109|maximum level
P08692892A0330|120 133|wild-type cells
P08692892A0330|148 159|alpha-factor
P08692924A0328|8 18|DNA sequence
P08692924A0328|46 61|recombinant BCL-6
P08692924A0328|84 88|BCL-6
P08692924A0328|100 119|DNA-binding complexes
P08692924A0328|122 136|nuclear extracts
P08692924A0328|141 158|various B-cell lines
P08697728A1199|3 17|predictive value
P08697728A1199|21 32|positive flag
P08697728A1199|40 40|%
P08698756A1240|0 10|CONCLUSIONS
P08698756A1240|15 22|findings
P08698756A1240|34 46|pre-treatment
P08698756A1240|51 61|coenzyme Q10
P08698756A1240|70 83|protective role
P08698756A1240|90 114|routine vascular procedures
P08698756A1240|124 143|abdominal aortic cross
P08698756A1240|176 193|peroxidative damage
P08700531A1420|7 17|chromosome X
P08700531A1420|40 60|structural alterations
P08700531A1420|63 90|neoplastic Syrian hamster cells
P08700531A1420|104 122|chemical carcinogens
P08700531A1420|126 141|oncogenic viruses
P08700531A1420|146 157|localization
P08700531A1420|163 170|cph locus
P08700531A1420|177 186|chromosome
P08700531A1420|211 221|cph oncogene
P08700531A1420|237 255|malignant conversion
P08700531A1420|279 296|hamster fibroblasts
P08702517A0000|12 16|genes
P08702517A0000|21 38|oncogenic potential
P08702517A0000|53 90|murine B6SUtA1 myeloid progenitor cell line
P08702543A0000|0 10|Gap1(IP4BP)
P08702543A0000|0 3|Gap1
P08702543A0000|5 9|IP4BP
P08702543A0000|26 53|Ras GTPase-activating proteins
P08702543A0000|75 115|specific inositol 1,3,4,5-tetrakisphosphate
P08702543A0000|83 135|inositol 1,3,4,5-tetrakisphosphate (IP4)-binding protein
P08702543A0000|117 119|IP4
P08702543A0000|122 135|binding protein
P08702543A0000|137 142|Cullen
P08702543A0000|144 145|P.
P08702556A0000|24 35|purification
P08702556A0000|40 72|83-kDa phosphatidic acid phosphatase
P08702556A0000|74 76|PAP
P08702556A0000|85 106|porcine thymus membranes
P08702556A0000|108 112|Kanoh
P08702556A0000|114 115|H.
P08702556A0000|117 120|Imai
P08702556A0000|122 126|S.-i.
P08702556A0000|128 133|Yamada
P08702556A0000|135 136|K.
P08702556A0000|140 145|Sakane
P08702556A0000|147 148|F.
P08702556A0000|155 156|J.
P08702633A0164|20 54|Gbetagamma subunit-mediated increases
P08702633A0164|20 29|Gbetagamma
P08702633A0164|57 79|tyrosine phosphorylation
P08702633A0164|85 101|Shc adapter protein
P08702633A0164|103 105|Shc
P08702633A0164|107 126|Grb2 complex formation
P08702633A0164|131 141|recruitment
P08702633A0164|144 185|Ras guanine nucleotide exchange factor activity
P08702633A0164|144 177|Ras guanine nucleotide exchange factor
P08702644A0499|1 4|cDNA
P08702644A0499|16 29|amino-terminal
P08702644A0499|32 32|%
P08702644A0499|35 38|apoB
P08702644A0499|40 45|apoB17
P08702644A0499|58 61|cDNA
P08702644A0499|80 89|amino acids
P08702644A0499|92 115|decay-accelerating factor
P08702644A0499|117 119|DAF
P08702644A0499|147 190|glycosylphosphatidylinositol anchor attachment
P08702728A1325|26 37|wild-type Shc
P08702728A1325|40 53|Y317F mutant Shc
P08702728A1325|58 66|HIRc cells
P08702756A0000|3 16|small GTPase Rho
P08702756A0000|3 13|small GTPase
P08702756A0000|14 16|Rho
P08702756A0000|31 52|physiological functions
P08702756A0000|67 91|actin-myosin filaments such
P08702756A0000|67 87|actin-myosin filaments
P08702756A0000|94 104|cytokinesis
P08702756A0000|106 117|cell motility
P08702756A0000|128 144|muscle contraction
P08702807A0964|11 20|activation
P08702807A0964|27 42|signaling pathway
P08702807A0964|72 87|active MKK1 mutant
P08702807A0964|78 87|MKK1 mutant
P08702807A0964|109 132|cyclin D1 promoter activity
P08702807A0964|109 124|cyclin D1 promoter
P08702807A0964|136 160|cyclin D1 protein expression
P08702807A0964|136 150|cyclin D1 protein
P08702807A0964|165 194|growth factor-independent manner
P08702826A0870|12 28|upstream insertion
P08702826A0870|34 53|GSTP1 silencer element
P08702826A0870|80 99|heterologous promoter
P08702826A0870|102 110|MCF7 cells
P08702845A0000|18 33|structural motifs
P08702845A0000|44 60|substrate affinity
P08702845A0000|81 104|human dopamine transporter
P08702845A0000|106 108|DAT
P08702845A0000|122 123|3H
P08702845A0000|125 146|dopamine uptake kinetics
P08702845A0000|151 152|3H
P08702845A0000|154 178|CFT binding characteristics
P08702845A0000|181 190|COS-7 cells
P08702845A0000|212 221|mutant DATs
P08702845A0000|232 243|COOH terminus
P08702936A0168|2 18|expression library
P08702936A0168|46 66|portion-enriched cDNAs
P08702936A0168|71 130|phytohemagglutinin-stimulated peripheral blood mononuclear cells
P08702936A0168|71 88|phytohemagglutinin
P08702936A0168|135 142|upstream
P08702936A0168|145 173|signal sequence-deleted CD4 cDNA
P08702936A0168|178 207|Epstein-Barr virus shuttle vector
P08702936A0984|12 26|recombinant TARC
P08702936A0984|46 55|T cell lines
P08702936A0984|59 74|peripheral T cells
P08702936A0984|83 91|monocytes
P08702936A0984|94 105|granulocytes
P08703005A0645|3 20|cis-acting elements
P08703005A0645|32 47|promoter activity
P08703005A0645|62 66|sites
P08703005A0645|70 92|transcription factors Sp1
P08703005A0645|90 92|Sp1
P08703005A0645|96 103|alphaCbf
P08703005A0645|106 134|60-kDa CCAAT box-binding protein
P08703010A0905|27 43|cis-acting element
P08703010A0905|48 54|E1 E-box
P08703010A0905|56 62|located
P08703010A0905|68 87|GAP-43 promoter region
P08703010A0905|147 156|GAP-43 gene
P08703010A0905|173 193|E-box-binding proteins
P08703908A1814|16 23|findings
P08703908A1814|39 42|SF-1
P08703908A1814|49 55|key role
P08703908A1814|72 76|basal
P08703908A1814|80 104|cAMP-stimulated expression
P08703908A1814|110 117|StAR gene
P08703959A0659|28 43|proton resonances
P08703959A0659|48 70|three-nucleotide segment
P08703959A0659|87 96|lesion site
P08703959A0659|113 131|tentative assignment
P08703959A0659|138 149|sugar protons
P08703959A0659|155 163|C7 residue
P08703959A0659|182 193|adduct duplex
P08704124A0420|16 24|fragments
P08704124A0420|26 31|CPK3-8
P08704124A0420|45 63|2022 bp cDNA (VrCDPK-1
P08704124A0420|49 54|bp cDNA
P08704124A0420|56 63|VrCDPK-1
P08704124A0420|70 98|Vigna radiata lambda gt11 library
P08704240A1111|10 18|TF-1 cells
P08704240A1111|10 13|TF-1
P08704240A1111|26 31|GM-CSF
P08704240A1111|38 47|starvation
P08704240A1111|49 67|CREB phosphorylation
P08704240A1111|49 52|CREB
P08704240A1111|81 87|minutes
P08704240A1111|93 110|PIXY321 stimulation
P08704240A1111|93 99|PIXY321
P08705056T0000|0 16|Workplace violence
P08705056T0000|19 24|nurses
P08706368A1024|0 6|RESULTS
P08706368A1024|11 29|LV maximum brightness
P08706368A1024|56 86|significant negative correlations
P08706368A1024|88 89|p =
P08706368A1024|104 107|FIO2
P08706368A1024|117 133|minimum brightness
P08706368A1024|141 170|significant positive correlation
P08706368A1024|172 173|p =
P08706662A1125|3 9|results
P08706662A1125|35 52|perforin expression
P08706662A1125|35 42|perforin
P08706662A1125|55 72|non-cytotoxic cells
P08706662A1125|86 96|suppression
P08706662A1125|102 110|induction
P08706662A1125|116 158|killer-cell-specific trans-acting factor NF-P2
P08706662A1125|154 158|NF-P2
P08706731A1303|10 48|considerable spatio-temporal similarities
P08706731A1303|64 81|expression patterns
P08706731A1303|84 93|Ypr10 genes
P08706731A1303|97 113|ribonuclease genes
P08706731A1303|136 164|significant sequence similarity
P08706731A1303|170 188|ginseng ribonuclease
P08706731A1303|213 232|ribonuclease function
P08706731A1303|236 248|PR-10 proteins
P08706731A1303|272 294|possible biological roles
P08707424A0709|15 25|ERV3 env mRNA
P08707424A0709|38 63|differentiation-associated
P08707424A0709|69 82|high expression
P08707424A0709|96 105|late stages
P08707424A0709|108 127|monocytic development
P08707516A0194|0 15|Initial estimates
P08707516A0194|51 57|receipt
P08707516A0194|70 91|mental handicap services
P08707825A0063|25 41|smooth muscle cells
P08707825A0063|44 59|Northern blotting
P08707825A0063|63 89|immunohistochemical analysis
P08707825A0063|112 124|"smoothelin."
P08707825A0063|113 122|smoothelin
P08707825A0063|126 153|human smooth muscle cDNA library
P08707825A0063|172 192|monoclonal antibody R4A
P08707825A0063|198 210|full-size cDNA
P08707840A0753|5 32|immunogold electron microscopy
P08707840A0753|45 51|p58/p45
P08707840A0753|45 47|p58
P08707840A0753|49 51|p45
P08707840A0753|55 57|p54
P08707840A0753|61 69|localized
P08707840A0753|76 80|sides
P08707840A0753|86 103|nuclear pore complex
P08707840A0753|109 111|p62
P08707846A2308|0 9|Concurrent
P08707846A2308|14 35|ligand-dependent uptake
P08707846A2308|53 60|receptor
P08707846A2308|70 97|ligand-induced ubiquitination
P08707846A2308|113 134|receptor ubiquitination
P08707846A2308|151 177|ligand-dependent endocytosis
P08707846A2308|183 198|a-factor receptor
P08707846A2308|212 234|constitutive endocytosis
P08707922A0334|0 27|Transcription initiation sites
P08707922A0334|33 50|rat II beta-, III beta
P08707922A0334|38 41|beta
P08707922A0334|44 50|III beta
P08707922A0334|55 71|O beta-globin genes
P08707922A0334|92 100|base pairs
P08707922A0334|102 103|bp
P08707922A0334|108 115|upstream
P08707922A0334|121 146|translation initiation codon
P08707922A0334|148 150|ATG
P08707922A0334|165 187|primer extension analysis
P08708984T0000|27 38|indomethacin
P08708984T0000|41 60|chronic gastric lesion
P08709224T0000|0 31|Epstein-Barr virus nuclear protein 2
P08709224T0000|0 30|Epstein-Barr virus nuclear protein
P08709224T0000|33 37|EBNA2
P08709224T0000|61 79|human SNF-SWI complex
P08709224T0000|66 68|SNF
P08709224T0000|70 72|SWI
P08709224T0000|81 90|hSNF5/Ini1
P08709224T0000|81 85|hSNF5
P08709224T0000|87 90|Ini1
P08709245A1521|3 9|studies
P08709245A1521|43 57|phosphorylation
P08709245A1521|60 64|Ser-2
P08709245A1521|66 72|Ser-123
P08709245A1521|76 82|Ser-210
P08709245A1521|87 91|roles
P08709245A1521|97 121|trans-suppression activity
P08709245A1521|127 135|large HDAg
P08709245A1521|152 178|empty virus-like HDAg particle
P08709245A1521|188 203|nuclear transport
P08709245A1521|206 210|HDAgs
P08709251A0000|0 22|Homologous recombination
P08709251A0000|33 77|Autographa californica nuclear polyhedrosis virus
P08709251A0000|79 83|AcNPV
P08709251A0000|85 90|genome
P08709251A0000|95 117|0.6-kbp-long DNA fragment
P08709251A0000|132 154|putative DNA helicase gene
P08709251A0000|140 190|DNA helicase gene of Bombyx mori nuclear polyhedrosis virus
P08709251A0000|157 162|Bombyx
P08709251A0000|167 190|nuclear polyhedrosis virus
P08709251A0000|200 208|eh2-AcNPV
P08709251A0000|212 241|expanded-host-range AcNPV mutant
P08709251A0000|243 244|S.
P08709637A1471|29 44|IL-7R alpha chains
P08709637A1471|69 78|activation
P08709637A1471|81 84|JAKs
P08709637A1471|88 92|STATs
P08709637A1471|101 109|major role
P08709637A1471|112 133|proliferative signaling
P08709637A1471|136 150|precursor B cells
P08709831A0599|15 21|potency
P08709831A0599|24 34|Dacarbacine
P08709831A0599|51 65|carcinoid tumors
P08710151A0782|21 29|mean value
P08710151A0782|51 55|pnx s.
P08710151A0782|58 63|class A
P08710151A0782|77 77|%
P08710151A0782|88 93|class B
P08710151A0782|116 121|class A
P08710151A0782|143 149|class B.
P08710371A0000|37 64|oncogenic human polyomavirus BK
P08710371A0000|66 68|BKV
P08710371A0000|77 102|tumor-suppressor protein p53
P08710371A0000|159 173|basic mechanisms
P08710371A0000|176 193|p53 transactivation
P08710371A0000|176 178|p53
P08710371A0499|0 7|Site S-II
P08710371A0499|20 29|bp sequence
P08710371A0499|43 69|tandem consensus binding sites
P08710371A0499|79 96|base pair mismatches
P08710371A0499|110 125|base pair deletion
P08710377A0577|0 2|Cbl
P08710377A0577|33 42|SH3 domains
P08710377A0577|45 48|Grb2
P08710377A0577|71 90|amino-terminal domain
P08710377A0577|117 119|Shc
P08710377A0577|124 137|BCR stimulation
P08710377A0577|124 126|BCR
P08710504A0995|0 9|Activation
P08710504A0995|20 24|Cat8p
P08710504A0995|36 45|detectable
P08710504A0995|49 58|cat1 mutant
P08711631A0989|0 8|Treatment
P08711631A0989|25 34|prednisone
P08711631A0989|38 53|cyclophosphamide
P08712799A0123|0 14|Unaided attempts
P08712799A0123|21 27|smoking
P08712799A0123|40 51|unsuccessful
P08713933A0606|0 19|Laboratory evaluation
P08713933A0606|33 44|neuroimaging
P08713933A0606|60 70|obstruction
P08713933A0606|73 78|venous
P08713933A0606|81 97|lymphatic drainage
P08716757T0001|0 22|Microcomputer management
P08716757T0001|25 66|chronic hepatitis B virus asymptomatic patients
P08717391A0466|5 10|fusion
P08717391A0466|16 25|N-terminus
P08717391A0466|35 40|linker
P08717391A0466|49 65|surface accessible
P08717391A0466|71 76|fusion
P08717391A0466|82 91|N-terminus
P08717391A0466|100 109|C-terminus
P08717391A0466|113 122|compatible
P08717391A0466|127 142|particle assembly
P08717391A0466|158 175|native antigenicity
P08717391A0466|179 192|immunogenicity
P08717391A0466|195 199|HBcAg
P08717559A0223|3 16|standard dosage
P08717559A0223|19 24|anti-D
P08717559A0223|44 58|gestational ages
P08717559A0223|62 68|ampoule
P08717559A0223|82 91|micrograms
P08717559A0223|94 99|anti-D
P08719155A0105|15 30|molecular cloning
P08719155A0105|34 57|putative adhesive molecule
P08719155A0105|62 73|P. falciparum
P08719155A0105|99 120|structural similarities
P08719155A0105|126 150|sporozoite surface molecule
P08719155A0105|155 164|Plasmodium
P08719155A0105|174 211|thrombospondin-related anonymous protein
P08719155A0105|213 216|TRAP
P08719155A0105|225 236|lesser extent
P08719155A0105|245 260|circumsporozoite
P08719155A0105|262 263|CS
P08719156A0953|10 16|introns
P08719156A0953|45 67|9360-bp open reading frame
P08719156A0953|79 92|377-kDa protein
P08719697A0221|0 6|METHODS
P08719697A0221|8 10|DSF
P08719697A0221|48 49|CF
P08719697A0221|55 63|fellow eye
P08719697A0221|68 81|normal subjects
P08719697A0221|89 96|patients
P08719697A0221|101 103|KCS
P08719832A0397|18 41|lateral rhinotomy approach
P08719832A0397|44 65|transsphenoidal surgery
P08719832A0397|68 77|acromegaly
P08719832A0397|85 94|favourable
P08720407A1386|0 9|CONCLUSION
P08720407A1386|14 20|results
P08720407A1386|47 66|lumbar disc herniation
P08720407A1386|68 92|inflammatory cytokines such
P08720407A1386|95 112|interleukin-1 alpha
P08720407A1386|139 163|prostaglandin E2 production
P08721526A0000|3 13|predominant
P08721526A0000|25 33|allergens
P08721526A0000|36 59|Swedish asthmatic children
P08721526A0000|63 78|furred pet animals
P08721989A1012|3 9|results
P08721989A1012|25 50|distinct cytoplasmic domains
P08721989A1012|58 74|cytokine receptors
P08721989A1012|81 107|convergent signaling pathways
P08721989A1012|130 134|beta c
P08721989A1012|138 154|IL-2R beta function
P08721989A1012|138 146|IL-2R beta
P08721989A1012|158 181|complete signal transducer
P08721999A0432|22 35|common features
P08721999A0432|67 75|snoRNA U14
P08721999A0727|0 2|U24
P08721999A0727|19 41|nt long complementarities
P08721999A0727|60 64|tract
P08721999A0727|67 73|28S rRNA
P08722011A0103|25 36|GTPase domain
P08722011A0103|42 57|large subunit rRNA
P08722011A0103|73 83|binding site
P08722011A0103|89 124|protein L11-like eukaryotic counterpart
P08722011A0103|126 158|Saccharomyces cerevisiae protein L15
P08722011A0103|149 158|protein L15
P08722011A0103|162 180|mammalian protein L12
P08722568A1001|0 18|Chromatin repression
P08722568A1001|26 41|replacement genes
P08722568A1001|79 100|constitutive expression
P08722568A1001|103 127|replacement H3 histone genes
P08722568A1001|114 127|H3 histone genes
P08722568A1001|130 135|plants
P08723352A0084|37 70|G1-specific cyclin-dependent kinases
P08723352A0084|72 75|cdks
P08723352A0084|107 140|retinoblastoma tumour suppressor gene
P08723352A0084|142 144|pRb
P08723365T0000|0 19|Possible relationship
P08723365T0000|27 42|hyperinsulinemia
P08723365T0000|46 66|glomerular hypertrophy
P08723365T0000|69 83|nephrosclerosis
P08723883A0823|0 18|Blood GSH-Px activity
P08723883A0823|5 10|GSH-Px
P08723883A0823|35 51|spectrophotometer
P08723883A0823|59 70|modification
P08723883A0823|93 97|assay
P08723883A1684|3 16|concentrations
P08723883A1684|19 36|vitamin A precursors
P08723883A1684|40 47|vitamin E
P08723883A1684|85 97|dietary levels
P08723883A1684|101 106|llamas
P08723883A1684|111 120|alfalfa hay
P08723883A1684|139 154|unreliable source
P08723883A1684|157 164|vitamins
P08723883A1684|169 169|E
P08726024A0244|5 8|cats
P08726024A0244|21 28|H. pylori
P08726024A0532|22 24|PCR
P08726024A0532|29 43|primers specific
P08726024A0532|50 62|26-kDa product
P08726024A0532|77 80|cats
P08726024A0532|88 96|weeks p.t.
P08726024A0532|100 118|gastric fluid samples
P08726024A0532|139 146|H. pylori
P08726024A0532|162 165|cats
P08726024A0532|169 177|weeks p.t.
P08726024A0532|181 192|dental plaque
P08726024A0532|212 219|H. pylori
P08726247A0175|8 39|quantitative concentration changes
P08726247A0175|44 55|measurements
P08726247A0175|58 73|light attenuation
P08726247A0175|78 94|optical path length
P08727192A0000|0 10|STUDY DESIGN
P08727992A0570|12 20|injection
P08727992A0570|23 31|PGF2 alpha
P08727992A0570|33 39|heifers
P08727992A0570|63 67|signs
P08727992A0570|70 75|estrus
P08727992A0570|92 94|min
P08728040T0000|0 21|Differential activation
P08728040T0000|27 61|extracellular signal-regulated kinase
P08728040T0000|63 71|Jun kinase
P08728040T0000|75 98|Janus kinase-Stat pathways
P08728040T0000|75 85|Janus kinase
P08728040T0000|87 90|Stat
P08728040T0000|101 111|oncostatin M
P08728040T0000|115 141|basic fibroblast growth factor
P08728040T0000|144 161|AIDS-derived Kaposi
P08728040T0000|164 175|sarcoma cells
P08730470A0000|7 22|general agreement
P08730470A0000|30 44|hepatitis C virus
P08730470A0000|93 109|viral transmission
P08730470A0000|114 120|mothers
P08730470A0000|123 128|babies
P08730470A0000|141 166|non-sexual household contact
P08731155A0499|3 7|weeks
P08731155A0499|13 26|reconstruction
P08731155A0499|43 48|nerves
P08731155A0499|65 76|normal nerves
P08731222A0000|32 42|projections
P08731222A0000|50 74|spinal cervical enlargement
P08731222A0000|77 105|subnucleus reticularis dorsalis
P08731222A0000|107 109|SRD
P08731222A0000|117 142|neighbouring Cuneate nucleus
P08731222A0000|144 145|Cu
P08731222A0000|176 190|microinjections
P08731222A0000|193 224|Phaseolus vulgaris leucoagglutinin
P08731222A0000|226 230|PHA-L
P08731222A0000|236 251|different laminae
P08731222A0000|261 267|C7 level
P08731511A0625|3 8|levels
P08731511A0625|11 20|fibrinogen
P08731511A0625|29 43|antithrombin III
P08731511A0625|29 40|antithrombin
P08731511A0625|45 49|ATIII
P08731511A0625|54 70|heparin cofactor II
P08731511A0625|54 68|heparin cofactor
P08731511A0625|72 75|HCII
P08731511A0625|77 86|activities
P08731511A0625|110 128|loop-bearing animals
P08732665A0000|0 12|Amplification
P08732665A0000|16 29|overexpression
P08732665A0000|35 46|c-erbB-2 gene
P08732665A0000|49 54|21MT-2
P08732665A0000|58 88|21MT-1 human breast carcinoma cells
P08732665A0000|111 124|elevated levels
P08732665A0000|141 173|tyrosine-phosphorylated p185erbB-2
P08732665A0000|193 227|progressive insulin-like growth factor
P08732665A0000|204 227|insulin-like growth factor
P08732665A0000|229 231|IGF
P08732665A0000|244 268|IGF/epidermal growth factor
P08732665A0000|244 246|IGF
P08732665A0000|248 268|epidermal growth factor
P08732665A0000|270 272|EGF
P08733123A0000|0 35|Facioscapulohumeral muscular dystrophy
P08733123A0000|37 40|FSHD
P08733123A0000|46 62|autosomal dominant
P08733123A0000|64 84|neuromuscular disorder
P08733123A0000|100 118|progressive weakness
P08733123A0000|121 127|muscles
P08733123A0000|149 156|upper arm
P08733123A0951|3 18|mature chromosome
P08733123A0951|20 33|FRG1 transcript
P08733123A0951|40 41|bp
P08733123A0951|65 69|exons
P08733123A0951|82 96|putative protein
P08733123A0951|102 118|amino acid residues
P08733874A0000|0 7|Patients
P08733874A0000|24 36|thyroidectomy
P08733874A0000|40 55|thyroid carcinoma
P08733874A0000|80 86|periods
P08733874A0000|96 115|severe hypothyroidism
P08733874A0000|132 152|131I whole body scanning
P08733874A0000|169 175|serum TG
P08733881A0343|0 25|Full thyroid function testing
P08733881A0343|59 65|samples
P08733881A0343|70 84|normal TSH values
P08733881A0343|76 78|TSH
P08733881A0343|94 101|subjects
P08733881A0343|106 122|abnormal TSH levels
P08733881A0343|114 116|TSH
P08734538A0613|3 17|third experiment
P08734538A0613|19 27|crossover
P08734538A0613|37 54|dissimilar textures
P08734538A0613|91 109|more salient textures
P08738510A0254|3 25|relative tumor FDG-uptake
P08738510A0254|27 33|Q-MRGlu
P08738510A0254|36 60|tumor/contralateral cortex
P08738510A0254|67 77|meningiomas
P08739209A0700|0 10|Zatebradine
P08739209A0700|29 50|ectopic ventricular rate
P08739209A0700|60 74|arrhythmic ratio
P08739209A0700|80 101|ventricular arrhythmias
P08739209A0700|111 135|two-stage coronary ligation
P08739209A0700|138 138|h
P08739209A0700|147 154|ligation
P08739209A0700|157 169|conscious dogs
P08739260T0000|0 4|Catha
P08739260T0000|25 42|amphetamine effects
P08740416A0239|20 24|Seb1p
P08740416A0239|38 47|amino acids
P08740416A0239|62 93|potential membrane-spanning region
P08740416A0239|99 108|C-terminus
P08740416A0239|114 137|N-terminal signal sequence
P08740416A0919|3 15|SEB1 homologue
P08740416A0919|3 6|SEB1
P08740416A0919|29 32|SEB2
P08740416A0919|51 60|% identical
P08740416A0919|63 67|Seb1p
P08741206A1551|16 35|ventricular afferents
P08741206A1551|39 60|certain special settings
P08741206A1551|92 103|vasodilation
P08741206A1551|107 117|hypotension
P08741280A0374|0 8|Large ones
P08741280A0374|31 38|main lobe
P08741280A0374|42 50|small ones
P08741280A0374|87 94|main lobe
P08742135A0000|0 8|Fragments
P08742135A0000|12 18|analogs
P08742135A0000|24 34|hormone ACTH
P08742135A0000|31 34|ACTH
P08742135A0000|60 75|beneficial effect
P08742135A0000|90 99|head injury
P08742135A0000|106 119|elevated levels
P08742135A0000|122 135|corticosterone
P08742135A0000|137 138|CS
P08742385A0211|7 20|frequent causes
P08742385A0211|26 35|meningitis
P08742385A0211|42 68|external ventricular drainage
P08742385A0211|74 74|%
P08742385A0211|77 94|post-neurosurgical
P08742385A0211|99 99|%
P08742385A0211|104 113|head injury
P08742385A0211|121 121|%
P08745669A0000|9 16|patients
P08745669A0000|21 37|primary refractory
P08745669A0000|48 64|malignant lymphoma
P08745669A0000|68 78|non-Hodgkin
P08745669A0000|81 88|lymphoma
P08745669A0000|96 102|Hodgkin
P08745669A0000|129 154|new chemotherapeutic regimen
P08745669A0000|156 166|cisplatinum
P08745669A0000|168 176|methyl GAG
P08745669A0000|178 187|bleomocyin
P08745669A0000|189 205|methyl prednisolon
P08746605A0377|22 34|ACE inhibitors
P08746605A0377|22 24|ACE
P08746605A0377|39 47|incidence
P08746605A0377|50 71|rare adverse effects such
P08746605A0377|85 102|lethal pancreatitis
P08746981A0154|3 12|treatments
P08746981A0154|50 67|mg probiotic/kg food
P08747078T0000|0 14|Low-dose aspirin
P08747078T0000|18 37|recurrent miscarriage
P08747343A0790|0 11|Protein films
P08747343A0790|36 53|mechanical profiles
P08747343A0790|63 67|films
P08747343A0790|74 87|other materials
P08748033A0874|12 15|cpxA
P08748033A0874|17 25|mutations
P08748033A0874|37 44|toxicity
P08748033A0874|59 80|LamB-LacZ hybrid protein
P08748033A0874|59 62|LamB
P08748033A0874|64 67|LacZ
P08748033A0874|96 102|effects
P08748033A0874|108 116|cytoplasm
P08748033A0874|133 136|DegP
P08749393A0783|3 14|PI3K_68D cDNA
P08749393A0783|35 37|kDa
P08749393A0783|49 57|sequences
P08749393A0783|77 91|p110 PI 3-kinases
P08749393A0783|77 80|p110
P08749393A0783|81 91|PI 3-kinases
P08749393A0783|94 111|p85 adaptor proteins
P08749393A0783|126 159|amino-terminal proline-rich sequence
P08749393A0783|177 186|SH3 domains
P08749393A0783|192 215|carboxy-terminal C2 domain
P08749394A0874|7 24|interaction studies
P08749394A0874|31 38|proteins
P08749394A0874|46 70|glutathione-S-transferase
P08749394A0874|82 91|RBP-J kappa
P08749394A0874|95 96|Su
P08749394A0874|98 98|H
P08749394A0874|117 128|RAM23 regions
P08749394A0874|131 141|mouse Notch1
P08749394A0874|145 159|Drosophila Notch
P08750173A0000|0 11|AIMS/METHODS
P08750173A0000|13 45|Reticuloendothelial system function
P08750173A0000|59 67|clearance
P08750173A0000|70 90|radiolabelled bacteria
P08750173A0000|106 121|acute liver injury
P08750173A0000|131 145|D-galactosamine
P08750173A0000|148 151|rats
P08750173A0000|179 198|% liver resection model
P08750190A0000|31 49|alternative splicing
P08750190A0000|59 63|exons
P08750190A0000|67 91|discrete extracellular site
P08750190A0000|134 144|CD44 variant
P08750190A0000|146 150|CD44v
P08750190A0000|152 159|isoforms
P08750702A0183|0 10|Study groups
P08750702A0183|45 85|alpha1-adrenoceptor-subtype blockers WB4101
P08750702A0183|45 71|alpha1-adrenoceptor-subtype
P08750702A0183|90 98|mg/kg i.v.
P08750702A0183|102 121|chloroethylclonidine
P08750702A0183|126 134|mg/kg i.v.
P08751635A0135|10 29|severe cortical damage
P08751635A0135|33 44|neuronal loss
P08751635A0135|47 69|hippocampus subfields CA1
P08751635A0135|71 73|CA3
P08751635A0135|78 82|hilus
P08752714A0000|3 12|occurrence
P08752714A0000|15 32|multiple malignancy
P08752714A0000|48 55|patients
P08752714A0000|60 82|hematologic malignancies
P08752714A0000|129 133|years
P08754777A1214|3 7|upTRE
P08754777A1214|13 29|more T3R homodimers
P08754777A1214|17 29|T3R homodimers
P08754777A1214|33 55|less T3R-RXR heterodimers
P08754777A1214|37 39|T3R
P08754777A1214|41 43|RXR
P08754777A1214|63 67|dnTRE
P08754777A1214|72 73|T3
P08754777A1214|96 113|heterodimer binding
P08754777A1214|119 120|dn
P08754777A1214|131 135|upTRE
P08754802T0000|0 21|Transcriptional control
P08754802T0000|25 35|nuclear gene
P08754802T0000|45 81|mitochondrial fatty acid oxidation enzyme
P08754802T0000|84 97|transgenic mice
P08754802T0000|106 121|nuclear receptors
P08754802T0000|124 130|cardiac
P08754802T0000|134 155|brown adipose expression
P08754827A0231|0 5|Hoeben
P08754827A0231|7 10|F.J.
P08754834A1097|6 21|genomic fragments
P08754834A1097|32 52|novel response elements
P08754834A1097|72 88|transcription unit
P08754834A1097|113 119|NN-84AG
P08754840A0793|9 30|glucan synthase activity
P08754840A0793|9 22|glucan synthase
P08754840A0793|50 54|Rho1p
P08754840A0793|84 98|deltabem4 mutant
P08754852A0960|2 21|gel retardation assays
P08754852A0960|25 47|RCS cell-specific protein
P08754852A0960|65 78|related protein
P08754852A0960|94 101|RCS cells
P08754852A0960|105 123|primary chondrocytes
P08754852A0960|132 144|10-bp sequence
P08754852A0960|154 159|18-mer
P08755898A0339|3 9|classes
P08755898A0339|12 31|Xanthomonas pathogens
P08755898A0339|39 55|Bs2 host resistance
P08755898A0339|117 122|avrBs2
P08756332A0000|0 6|Members
P08756332A0000|12 23|Ras subfamily
P08756332A0000|26 49|small GTP-binding proteins
P08756332A0000|67 77|promiscuous
P08756332A0000|95 123|putative effector molecules such
P08756332A0000|129 146|protein kinase c-Raf
P08756332A0000|153 195|Ral-specific guanine nucleotide exchange factor
P08756332A0000|197 203|Ral-GEF
P08756433A0282|8 23|characterization
P08756433A0282|29 42|promoter region
P08756433A0282|61 78|regulatory elements
P08756433A0282|90 104|neuron-specific
P08756433A0282|108 130|developmental expression
P08756433A0282|136 144|MAP1B gene
P08756556A0406|3 6|cDNA
P08756556A0406|15 27|mature protein
P08756556A0406|33 42|amino acids
P08756556A0406|54 79|29-amino acid signal sequence
P08756597A0854|0 6|Mutants
P08756597A0854|19 27|stem-loop
P08756597A0854|40 49|% reduction
P08756597A0854|62 69|psaB mRNA
P08756609A0498|10 26|amino acid sequence
P08756609A0498|54 62|wide range
P08756609A0498|65 74|eukaryotes
P08756609A0498|76 86|vertebrates
P08756609A0498|88 100|invertebrates
P08756609A0498|102 106|fungi
P08756609A0498|108 113|plants
P08756609A0498|117 124|protozoa
P08756617A1204|0 3|Biol
P08756636T0000|0 20|Semidominant mutations
P08756636T0000|26 42|yeast Rad51 protein
P08756636T0000|51 63|relationships
P08756636T0000|71 82|Srs2 helicase
P08756642A0230|0 10|Alterations
P08756642A0230|16 31|5q23-q31 interval
P08756642A0230|55 68|myelodysplasia
P08756642A0230|72 86|myeloid leukemia
P08756712A0227|0 14|Previous studies
P08756712A0227|38 46|amino acid
P08756712A0227|48 60|70-kDa subunit
P08756712A0227|63 65|RPA
P08756712A0227|67 71|RPA 70
P08756712A0227|67 69|RPA
P08756712A0227|85 120|multiple structural/functional domains
P08757265A0466|0 6|Neurons
P08757265A0466|20 21|mV
P08757265A0466|30 53|voltage-dependent effects
P08757943A0876|15 29|negative element
P08757943A0876|50 72|thymidine kinase promoter
P08757943A0876|90 101|inducibility
P08759870A1128|14 33|fbpA operator sequence
P08759870A1128|37 38|bp
P08759870A1128|55 74|footprinting analysis
P08759870A1128|91 97|binding
P08759870A1128|103 120|Fur repressor dimers
P08760286A0696|3 22|structural similarity
P08760286A0696|30 32|Vav
P08760286A0696|36 72|other guanine nucleotide exchange factors
P08760286A0696|41 72|guanine nucleotide exchange factors
P08760286A0696|76 99|small GTP-binding proteins
P08760286A0696|116 135|recent identification
P08760286A0696|138 162|biochemical routes specific
P08760286A0696|166 172|members
P08760286A0696|178 180|Ras
P08760286A0696|184 192|Rho family
P08760286A0696|184 186|Rho
P08760286A0696|195 201|GTPases
P08760286A0696|229 232|MAPK
P08760286A0696|235 237|JNK
P08760286A0696|241 260|downstream components
P08760286A0696|266 285|Vav signaling pathways
P08760286A0696|266 268|Vav
P08760776A1559|0 9|CONCLUSION
P08760776A1559|16 29|daily treatment
P08760776A1559|41 61|fluticasone propionate
P08760776A1559|64 73|micrograms
P08760776A1559|79 88|micrograms
P08760776A1559|122 133|theophylline
P08760776A1559|150 171|mild-to-moderate asthma
P08760872A0696|3 9|results
P08760872A0696|32 34|E2F
P08760872A0696|39 60|CDE-mediated repression
P08760872A0696|70 84|different stages
P08760872A0696|90 98|cell cycle
P08760872A0696|114 141|promoter-specific CHR elements
P08760889A0170|3 11|cDNA clone
P08760889A0170|22 36|homologous probe
P08760889A0170|56 67|genomic clone
P08760889A0170|76 79|H2A1
P08760889A0531|0 9|Comparison
P08760889A0531|22 39|amino acid sequences
P08760889A0531|44 59|protein sequences
P08760889A0531|74 77|H2As
P08760889A0531|99 109|differences
P08760889A0531|136 145|amino acids
P08760889A0531|149 152|H2A1
P08760889A0531|160 169|amino acids
P08760889A0531|173 176|H2A2
P08760889A0531|194 198|genes
P08760889A0531|213 222|divergence
P08761169T0000|0 25|Cognitive visual dysfunction
P08761169T0000|38 51|cerebral damage
P08761480A0331|0 10|Interaction
P08761480A0331|39 60|N-terminal splice region
P08761480A0331|63 68|RPDE-6
P08761480A0331|75 99|PDE4A splice variant RPDE-39
P08761480A0331|93 99|RPDE-39
P08761480A0331|117 122|RPDE-6
P08761480A0331|128 144|extreme N-terminus
P08761480A0331|167 175|v-Src-SH3
P08761480A0331|167 171|v-Src
P08761480A0331|173 175|SH3
P08761480A0331|177 184|met26RD1
P08761480A0331|191 193|RD1
P08761480A0331|200 208|dunc-like
P08761480A0331|210 212|PDE
P08761480A0331|226 247|N-terminal splice region
P08761480A0331|277 285|v-Src-SH3
P08761480A0331|283 285|SH3
P08761480A0331|306 311|RPDE-6
P08761480A0331|315 323|v-Src-SH3
P08761480A0331|321 323|SH3
P08761480A0331|337 349|fusion protein
P08761480A0331|363 384|N-terminal splice region
P08762021A0156|11 34|load-insensitive measures
P08762021A0156|37 58|ventricular performance
P08762021A0156|93 106|closed-chested
P08762021A0156|108 126|anesthetized rabbits
P08762172A0178|0 21|Large strain differences
P08762172A0178|37 45|variables
P08762172A0178|84 88|males
P08762172A0178|136 146|transitions
P08762172A0178|166 174|dark boxes
P08762472A0000|11 35|ligustrazine hydrochloride
P08762472A0000|37 39|LTH
P08762472A0000|43 79|depressing pulmonary artery hypertension
P08762472A0000|95 107|recent studies
P08763207A0402|7 19|oxidation peak
P08763207A0402|43 53|acidic media
P08763207A0402|60 60|V
P08763207A0402|83 85|DPV
P08763207A0402|104 115|accumulation
P08763207A0402|118 128|clenbuterol
P08763207A0402|134 151|Nafion-modified CPE
P08763311A0189|0 12|Phenylephrine
P08763311A0189|16 47|pure alpha-1 adrenoreceptor agonist
P08763311A0189|20 40|alpha-1 adrenoreceptor
P08763311A0189|62 91|marked systemic vasoconstriction
P08763311A0189|105 116|hypertension
P08763311A0189|121 155|occasional profound reflex bradycardia
P08763925A0588|26 37|genes located
P08763925A0588|49 54|c-gvpD
P08763925A0588|58 63|c-gvpE
P08763925A0588|83 93|Western blot
P08763925A0588|95 104|immunoblot
P08763925A0588|106 113|analyses
P08763925A0588|119 126|antisera
P08763925A0588|145 152|proteins
P08763953A0805|14 17|traA
P08763953A0805|19 22|traF
P08763953A0805|27 30|traB
P08763953A0805|53 56|traC
P08763953A0805|58 61|traD
P08763953A0805|66 69|traG
P08764015A0284|0 1|A.
P08764136A0000|19 23|genes
P08764136A0000|57 65|mRNA level
P08764136A0000|72 94|oncogenic transformation
P08764136A0000|97 123|human mammary epithelial cells
P08764136A0000|125 128|MECs
P08764136A0000|142 165|subtractive hybridization
P08764136A0000|173 190|normal MEC strain 76N
P08764136A0000|197 244|radiation-transformed tumorigenic derivative 76R-30
P08766049A0000|0 9|CASE REPORT
P08766049A0000|29 51|right corneal perforation
P08766049A0000|56 71|cellular reaction
P08766049A0000|74 88|anterior chamber
P08766049A0000|123 149|single intravitreal injection
P08766049A0000|155 156|ml
P08766049A0000|159 160|mg
P08766049A0000|162 169|Amikacin
P08766049A0000|176 177|ml
P08766049A0000|180 181|mg
P08766049A0000|183 192|Vancomycin
P08766781A0322|5 14|same period
P08766781A0322|39 48|hematocrit
P08766781A0322|56 56|%
P08766781A0322|61 61|%
P08766781A0322|71 72|Hb
P08766781A0322|87 90|g/dl
P08768374A0765|3 6|P-wr
P08768374A0765|10 26|P-rr cDNA sequences
P08768374A0765|50 56|regions
P08768377A1387|10 20|hcf109 locus
P08768377A1387|45 56|centimorgans
P08768377A1387|64 79|phytochrome C gene
P08768377A1387|84 108|molecular characterization
P08768377A1387|111 127|positional cloning
P08769132A0000|3 23|human MSH-2 gene product
P08769132A0000|59 66|proteins
P08769132A0000|85 114|post-replication mismatch repair
P08769132A0000|116 121|hMSH-2
P08769132A0000|124 133|homologous
P08769132A0000|159 162|MutS
P08769132A0000|166 192|Sacchromyces cerevisiae MSH-1
P08769132A0000|188 192|MSH-1
P08769132A0000|196 208|MSH-2 proteins
P08769132A0000|224 238|heteroduplex DNA
P08769132A0000|244 248|sites
P08769132A0000|254 273|single base mismatches
P08769132A0000|277 285|deletions
P08769132A0000|288 297|insertions
P08769132A0000|303 311|base pairs
P08769132A0000|313 318|hMSH-2
P08769132A0000|329 394|hereditary non-polyposis colorectal cancer (HNPCC) tumor suppressor genes
P08769132A0000|329 367|hereditary non-polyposis colorectal cancer
P08769132A0000|369 373|HNPCC
P08769132A0000|375 394|tumor suppressor genes
P08769132A0000|405 423|human chromosome 2p16
P08769409A0114|26 50|tissue-specific expression
P08769409A0114|56 67|RAR beta 2 gene
P08769409A0114|56 62|RAR beta
P08769409A0114|70 81|mouse embryos
P08769409A0114|98 115|translational level
P08769409A0114|118 147|short upstream open reading frames
P08769409A0114|149 153|uORFs
P08769409A0114|163 180|untranslated region
P08769409A0114|182 187|Zimmer
P08769409A0114|189 190|A.
P08769409A0114|192 195|A.M.
P08769566A0000|25 28|cDNA
P08769566A0000|33 51|transcription factor
P08769566A0000|64 68|Zfhep
P08769566A0000|70 113|zinc finger homeodomain enhancer-binding protein
P08769566A0000|128 152|separate zinc finger domains
P08769566A0000|136 152|zinc finger domains
P08769566A0000|154 156|ZD1
P08769566A0000|160 162|ZD2
P08769566A0000|188 198|homeodomain
P08769568A0949|19 23|genes
P08769568A0949|33 46|common ancestor
P08769568A0949|53 68|viperid PLA2 genes
P08770021T0000|9 23|PTHRP production
P08770021T0000|9 13|PTHRP
P08770021T0000|27 48|tyrosine kinase oncogene
P08770021T0000|50 56|Tpr-Met
P08770021T0000|67 85|Ras signaling pathway
P08770021T0000|67 69|Ras
P08770896A1121|0 9|Subsequent
P08770896A1121|17 25|secretion
P08770896A1121|30 35|IGF-II
P08770896A1121|38 41|xz97
P08770896A1121|45 52|G11 cells
P08770896A1121|69 85|conditioned medium
P08770896A1121|126 130|appMr
P08770896A1121|134 136|17K
P08770896A1121|140 142|14K
P08770920A1220|14 25|coexpression
P08770920A1220|48 55|inactive
P08770920A1220|80 98|IDX-1 mutant proteins
P08770920A1220|113 126|wild-type IDX-1
P08770920A1220|154 170|marked enhancement
P08770920A1220|173 187|transactivation
P08770920A1220|193 228|transcriptional TAAT-1 element reporter
P08770981A0328|3 10|patients
P08770981A0328|14 40|abnormal von Willebrand factor
P08770981A0328|22 40|von Willebrand factor
P08770981A0328|42 44|vWF
P08770981A0328|46 58|fragmentation
P08770981A0328|81 99|high molecular weight
P08770981A0328|112 141|low molecular weight vWF multimers
P08770981A0328|147 157|circulation
P08771781A0103|34 49|intergenic region
P08771781A0103|60 66|oleosin
P08771781A0103|71 92|second open reading frame
P08771781A0103|94 98|ORFII
P08771781A0103|102 118|Brassica napus (L.)
P08771781A0103|102 114|Brassica napus
P08771781A0103|116 117|L.
P08771781A0103|122 138|divergent promoter
P08771781A0103|164 168|ORFII
P08771781A0103|170 189|cDNA clones homologous
P08771781A0103|214 228|leaf cDNA library
P08771781A1103|3 18|ORFII gene product
P08771781A1103|34 44|chloroplast
P08771781A1103|67 78|previous data
P08771781A1103|102 113|PMSR activity
P08771781A1103|102 105|PMSR
P08771781A1103|119 129|chloroplast
P08771787T0000|0 15|Characterization
P08771787T0000|18 20|LRP
P08771787T0000|23 40|leucine-rich repeat
P08771787T0000|42 44|LRR
P08771787T0000|57 68|tomato plants
P08771787T0000|90 101|pathogenesis
P08774732A0271|13 15|Sp1
P08774732A0271|19 28|zif268/egr
P08774732A0271|47 51|motif
P08774732A0271|53 72|gel retardation assays
P08775674A0000|0 9|OBJECTIVES
P08775674A0000|42 64|clinical characteristics
P08775674A0000|90 97|patients
P08775674A0000|102 117|hydatidiform mole
P08776735A0000|17 27|human kidney
P08776735A0000|31 35|cells
P08776735A0000|49 72|wild type rat LH/CG receptor
P08776735A0000|74 77|rLHR
P08776735A0000|81 89|receptors
P08776735A0000|94 108|C-terminal tails
P08776735A0000|120 127|residues
P08776735A0000|152 160|rLHR-t653
P08776735A0000|162 170|rLHR-t631
P08776735A0000|175 183|rLHR-t628
P08776735A0000|242 263|hormonal responsiveness
P08776748T0000|3 19|low P300 amplitudes
P08776748T0000|30 42|schizophrenia
P08776792A0626|0 4|Sleep
P08776792A0626|39 42|days
P08776792A0626|47 51|hours
P08776793A0811|3 10|patients
P08776793A0811|17 33|healthy adult males
P08776901A0000|0 17|Chloroplast mutator
P08776901A0000|19 21|chm
P08776901A0000|25 35|Arabidopsis
P08776901A0000|39 62|recessive nuclear mutation
P08776901A0000|81 96|white variegation
P08776901A0000|99 104|leaves
P08776901A0000|122 141|non-Mendelian fashion
P08777374A1471|0 19|Indoor concentrations
P08777374A1471|48 68|outdoor concentrations
P08777374A1471|81 97|personal exposures
P08777374A1471|130 150|outdoor concentrations
P08778265A0422|1 29|neuropsychological test battery
P08778265A0422|53 65|Wisconsin card
P08778265A0422|78 97|Street completion test
P08778265A0422|99 108|Stroop test
P08778265A0422|111 124|dichotic memory
P08778265A0422|143 163|facial recognition test
P08778700A0476|29 34|rarity
P08778700A0476|37 62|left ventricular involvement
P08778700A0476|77 80|ARVD
P08780339A0142|13 24|single-blind
P08780339A0142|26 26|x
P08780339A0142|28 44|Latin-square study
P08780339A0142|49 59|corrections
P08780339A0142|66 81|carryover effects
P08780339A0142|85 89|males
P08780339A0142|95 101|females
P08780339A0142|110 120|supplements
P08780339A0142|131 137|glucose
P08780339A0142|140 154|resistant starch
P08780339A0142|156 157|RS
P08780339A0142|163 187|raw high-amylose cornstarch
P08780339A0142|189 191|RS2
P08780339A0142|210 231|high-amylose cornstarch
P08780339A0142|233 235|RS3
P08781119A0723|5 18|flanking region
P08781119A0723|24 41|mouse Met-ase-1 gene
P08781119A0723|52 70|considerable regions
P08781119A0723|90 103|flanking region
P08781119A0723|109 124|rat Met-ase-1 gene
P08781144A1520|4 6|18F
P08781144A1520|8 16|FMISO TMRR
P08781144A1520|39 49|useful index
P08781144A1520|62 74|tumour hypoxia
P08781144A1520|77 79|NPC
P08783180A0000|8 14|methods
P08783180A0000|60 90|neotropical short-tailed fruit bat
P08783180A0000|92 112|Carollia perspicillata
P08783180A0000|118 134|easily-reproduced
P08783180A0000|136 152|laboratory setting
P08783666A0957|20 30|engraftment
P08783666A0957|47 53|shorter
P08783666A0957|59 71|amifostine arm
P08783666A0957|78 84|cohorts
P08784787A0383|11 26|thrombin receptor
P08784787A0383|28 31|PAR2
P08784787A0383|51 61|hexapeptide
P08784787A0383|80 112|tethered ligand sequence independent
P08784787A0383|115 130|receptor cleavage
P08787110A0981|14 17|CPET
P08787110A0981|21 39|useful investigation
P08787110A0981|57 64|patients
P08787110A0981|69 90|cardiopulmonary disease
P08787110A0981|108 133|various other investigations
P08787110A0981|144 170|pulmonary function laboratory
P08789441A0339|5 16|fluorescence
P08789441A0339|23 35|hybridization
P08789441A0339|48 70|chromosome-17 breakpoint
P08789441A0339|85 99|acampomelic CMPD
P08789441A0339|103 113|sex reversal
P08789441A0339|132 146|constitutional t
P08789441A0339|154 166|translocation
P08789441A0339|178 195|known cosmid markers
P08790288A0068|33 37|cDNAs
P08790288A0068|42 48|spinach
P08790288A0068|50 65|Spinacia oleracea
P08790288A0068|70 75|barley
P08790288A0068|77 92|Hordeum vulgare cv
P08790291A1022|38 41|thi1
P08790291A1022|61 78|DNA damage tolerance
P08790291A1022|81 90|plant cells
P08790387A0299|5 16|rat rnu allele
P08790387A0299|32 47|nonsense mutation
P08790387A0299|50 53|exon
P08790387A0299|60 66|whn gene
P08792217A1407|19 55|steady-state testicular TIMP-2 mRNA level
P08792217A1407|31 50|testicular TIMP-2 mRNA
P08792217A1407|84 96|up-regulation
P08792217A1407|99 107|germ cells
P08792217A1407|115 123|germ cells
P08792217A1407|138 149|Sertoli cells
P08792217A1407|179 216|Sertoli cell steady-state TIMP-2 mRNA level
P08792217A1407|202 211|TIMP-2 mRNA
P08793029A0246|0 16|Control intact rats
P08793029A0246|21 31|age-matched
P08793029A0246|37 58|different treated groups
P08793693A0237|0 5|DESIGN
P08793693A0237|8 27|cross-sectional study
P08794254A2957|5 7|SPK
P08794254A2957|11 21|PTA category
P08794254A2957|23 40|anti-T-cell therapy
P08794254A2957|23 28|anti-T
P08794254A2957|70 78|graft loss
P08794326A0405|17 43|strong Tas-responsive element
P08794326A0405|23 43|Tas-responsive element
P08794326A0405|55 57|TRE
P08794326A0405|59 60|GP
P08794326A0405|80 86|gag gene
P08794326A0405|102 108|pol gene
P08794326A0405|111 115|SFV-1
P08794339A1162|11 17|binding
P08794339A1162|20 24|IE2 86
P08794339A1162|20 22|IE2
P08794339A1162|27 58|nonphosphorylated full-length CREB
P08794339A1162|44 58|full-length CREB
P08794339A1162|61 69|deltaCREB
P08794339A1162|80 84|IE2 86
P08794339A1162|80 82|IE2
P08794339A1162|93 101|complexes
P08794339A1162|106 109|p300
P08794339A1162|116 134|CREB-binding protein
P08794339A1162|136 138|CBP
P08794339A1162|158 161|CREB
P08794339A1162|175 189|adaptor proteins
P08794339A1162|193 204|CREB function
P08794339A1162|193 196|CREB
P08794348A1067|1 30|transgenic complementation assay
P08794348A1067|51 53|NIa
P08794348A1067|64 68|trans
P08794348A1067|80 114|amplification-defective viral genomes
P08794348A1067|123 140|altered NIa proteins
P08794363A0259|15 36|bZIP structural homology
P08794363A0259|38 40|meq
P08794363A0259|53 62|only member
P08794363A0259|68 84|jun-fos gene family
P08794363A0259|95 99|viral
P08794547A0648|3 6|rCBF
P08794547A0648|10 19|vasomotion
P08794547A0648|34 55|laser-doppler fluxmetry
P08794547A1403|8 19|basal vessels
P08794547A1403|32 55|distal parenchymal vessels
P08794547A1403|73 75|SAH
P08794601A0000|3 19|triple combination
P08794601A0000|22 31|nizatidine
P08794601A0000|33 46|clarithromycin
P08794601A0000|51 67|bismuth subcitrate
P08794601A0000|80 95|ulcer healing rate
P08794601A0000|100 100|%
P08794601A0000|106 128|H. pylori eradication rate
P08794601A0000|133 133|%
P08794869A0274|0 11|Several lines
P08794869A0274|46 53|PKC-zeta
P08794869A0274|66 83|alpha 2 integrin gene
P08794869A0274|66 70|alpha
P08794869A0274|72 93|integrin gene expression
P08795304T0000|0 19|Plasma thrombomodulin
P08795304T0000|6 19|thrombomodulin
P08795304T0000|31 56|microvascular complications
P08795304T0000|59 74|diabetes mellitus
P08797362T0037|0 5|Update
P08797362T0037|7 24|diphtheria epidemic
P08797362T0037|35 51|independent states
P08797362T0037|57 66|former USSR
P08797362T0037|68 84|January 1995-March
P08798420A0207|3 18|characterization
P08798420A0207|24 37|promoter region
P08798420A0207|56 81|distinct regulatory elements
P08798420A0207|99 113|AP-1 binding site
P08798420A0207|117 119|TRE
P08798420A0207|123 140|PRDII/kappaB domain
P08798420A0207|146 152|CAAT box
P08798420A0207|169 178|activation
P08798420A0207|181 184|pp60
P08798420A0207|186 191|v-)src
P08798420A0207|189 191|src
P08798443A0660|0 5|Serine
P08798443A0660|33 48|several cell lines
P08798443A0660|53 64|substitution
P08798443A0660|67 72|serine
P08798443A0660|78 84|alanine
P08798443A0660|86 90|S528A
P08798443A0660|122 124|Myb
P08798443A0660|141 157|synthetic promoter
P08798443A0660|172 177|copies
P08798443A0660|183 209|mim-1A Myb-responsive element
P08798443A0660|214 236|minimal herpes tk promoter
P08798443A0660|221 236|herpes tk promoter
P08798443A1218|3 12|DNA binding
P08798443A1218|16 40|multimerization activities
P08798443A1218|43 47|c-Myb
P08798443A1218|58 67|unaffected
P08798443A1218|73 89|S528A substitution
P08798443A1218|105 119|phosphorylation
P08798443A1218|122 127|serine
P08798443A1218|155 190|transcription transactivating activity
P08798443A1218|193 197|c-Myb
P08798443A1218|210 221|interactions
P08798443A1218|226 238|other proteins
P08798512A1197|16 22|factors
P08798512A1197|35 42|GEO cells
P08798512A1197|53 61|u-PAR gene
P08798610A0843|0 3|PIP2
P08798610A0843|25 58|phosphatidylcholine carrier vesicles
P08798610A0843|77 106|guanine nucleotide-depleted form
P08798610A0843|109 115|Cdc42Hs
P08798610A0843|130 142|GDP-bound form
P08798610A0843|148 165|GTP-binding protein
P08798610A0843|182 197|GTP-bound Cdc42Hs
P08798610A0843|191 197|Cdc42Hs
P08798610A0843|229 242|Dbl oncoprotein
P08798635A0870|8 16|spleen GAP
P08798635A0870|28 37|hydrolysis
P08798635A0870|40 42|GTP
P08798635A0870|50 64|recombinant ARF1
P08798635A0870|66 69|ARF3
P08798635A0870|71 74|ARF5
P08798635A0870|79 82|ARF6
P08798635A0870|94 119|NH2-terminal myristoylation
P08798641A0400|0 3|Biol
P08798643T0000|1 34|novel phosphotyrosine-binding domain
P08798643T0000|40 67|N-terminal transforming region
P08798643T0000|70 72|Cbl
P08798643T0000|108 113|ZAP-70
P08798643T0000|116 121|T cells
P08798648A1816|0 6|Cys-757
P08798648A1816|17 21|Fe4S4
P08798648A1816|24 45|siroheme-binding domain
P08798648A1816|61 80|native enzyme activity
P08798700A0134|3 15|transcription
P08798700A0134|69 82|heme deficiency
P08798700A0134|105 114|repression
P08798700A0134|124 128|Rox1p
P08798700A0134|140 149|activation
P08798700A0134|162 187|upstream activation sequence
P08798700A0134|189 191|UAS
P08798762A1279|14 20|results
P08798762A1279|36 58|transcriptional activity
P08798762A1279|61 71|Cut proteins
P08798762A1279|85 87|PKC
P08798782A0976|0 2|Lck
P08798782A0976|40 42|SH2
P08798782A0976|46 55|SH3 domains
P08798893A0611|12 19|freezing
P08798893A0611|35 51|bovine lactalbumin
P08798893A0611|63 77|good maintenance
P08798893A0611|83 99|cellular viability
P08798893A0611|108 124|CCCD heterogeneity
P08798893A0611|136 145|fresh cells
P08801403T0001|0 25|Myelomatous pleural effusion
P08801403T0001|28 43|presentation form
P08801403T0001|46 60|multiple myeloma
P08803710A0701|0 17|Five-year survivals
P08803710A0701|31 31|%
P08803710A0701|37 37|%
P08803710A0701|43 43|%
P08803710A0701|49 49|%
P08803710A0701|56 56|%
P08803710A0701|60 65|stages
P08803710A0701|75 77|IVA
P08803710A0701|81 83|IVB
P08803845A0665|13 35|unidentified macroscopic
P08803845A0665|38 56|microscopic clusters
P08803845A0665|59 73|neoplastic cells
P08803845A0665|114 122|insertion
P08803845A0665|125 130|lesion
P08803845A0665|169 183|excision useless
P08804012A0662|3 19|partial categories
P08804012A0662|25 27|SIP
P08804012A0662|57 66|recreation
P08804012A0662|70 77|pastimes
P08804012A0662|79 92|home management
P08804389A0893|0 19|Northern blot analysis
P08804389A0893|29 46|Ltp4-specific probe
P08804389A0893|29 32|Ltp4
P08804389A0893|61 83|Xanthomonas campestris pv
P08804389A0893|85 95|translucens
P08804389A0893|117 127|basal levels
P08804389A0893|130 137|Ltp4 mRNA
P08804389A0893|163 164|pv
P08804389A0893|166 173|japonica
P08805338A1061|8 17|disruption
P08805338A1061|23 30|OGG1 gene
P08805338A1061|33 37|yeast
P08805338A1061|47 78|second OG glycosylase/lyase protein
P08805338A1061|96 99|Ogg2
P08805338A1061|117 120|Ogg1
P08805338A1061|149 150|OG
P08805338A1061|152 153|G.
P08805824A1155|20 28|zero-loss
P08805824A1155|55 81|exit wavefront reconstruction
P08805824A1155|122 128|effects
P08805824A1155|131 145|multiple elastic
P08805824A1155|149 167|inelastic scattering
P08805824A1155|171 204|microscope objective lens aberrations
P08806491A0542|0 10|Transcripts
P08806491A0542|18 24|ODV-E18
P08806491A0542|28 35|ODV-EC27
P08806491A0542|57 66|TAAG motifs
P08806491A0542|71 81|transcripts
P08806491A0542|108 113|hr p.i.
P08806693A0584|23 31|sequences
P08806693A0584|37 50|GATA-1 promoter
P08806693A0584|64 73|activation
P08806693A0584|79 94|ME26 viral protein
P08806693A0584|102 110|deletions
P08806693A0584|116 123|promoter
P08806693A0584|140 165|luciferase expression vector
P08806693A0584|140 149|luciferase
P08806693A0584|190 205|mouse fibroblasts
P08806693A0584|224 229|GATA-1
P08806817A0244|0 15|Sequence analysis
P08806817A0244|29 40|genomic clone
P08806817A0244|56 71|DNA binding domain
P08806817A0244|78 91|orphan receptor
P08806817A0244|98 107|homologous
P08806817A0244|113 128|human TR2 receptor
P08806817A0716|0 22|Genomic DNA hybridization
P08806817A0716|35 40|SpSHR2
P08806817A0716|44 58|single-copy gene
P08806817A0716|64 81|S. purpuratus genome
P08807245A0843|1 23|3-yr retrospective review
P08807245A0843|47 47|%
P08807245A0843|53 62|undercalls
P08807288T0000|0 8|Isolation
P08807288T0000|28 32|genes
P08807288T0000|43 70|UAS2-dependent ADH2 expression
P08807288T0000|43 60|UAS2-dependent ADH2
P08807408A0524|0 6|METHODS
P08807408A0524|10 16|RESULTS
P08807408A0524|19 34|64-year-old woman
P08807408A0524|48 74|AV nodal reentrant tachycardia
P08807408A0524|96 106|slow pathway
P08807408A0524|108 121|AV modification
P08807408A0524|127 157|single radiofrequency application
P08808120A0774|0 7|Patients
P08808120A0774|12 25|low probability
P08808120A0774|34 49|aluminum overload
P08808120A0774|51 65|serum iron levels
P08808120A0774|69 80|micrograms/L
P08808120A0774|84 86|DAI
P08808120A0774|91 102|micrograms/L
P08808120A0774|120 131|higher values
P08808120A0774|134 142|serum iron
P08808120A0774|144 168|iron transferrin saturation
P08808120A0774|173 191|serum ferritin levels
P08808120A0774|178 185|ferritin
P08808120A0774|209 216|patients
P08808120A0774|222 236|high probability
P08808120A0774|245 260|aluminum overload
P08808120A0774|262 280|serum aluminum levels
P08808120A0774|284 295|micrograms/L
P08808120A0774|299 301|DAI
P08808120A0774|306 317|micrograms/L
P08808275A1193|11 26|RAD23 equivalents
P08808275A1193|11 15|RAD23
P08808275A1193|62 75|mammalian genes
P08808275A1193|92 112|UV-inducible phenotype
P08808275A1193|120 135|yeast counterpart
P08808707A0631|0 8|Ha-RasV12
P08808707A0631|21 28|proteins
P08808707A0631|38 66|extra-cellular regulated kinase
P08808707A0631|68 70|ERK
P08808707A0631|78 106|stress-activated protein kinase
P08808707A0631|108 111|SAPK
P08808707A0631|115 133|Jun N-terminal kinase
P08808707A0631|135 137|JNK
P08808707A0631|139 146|cascades
P08808707A0631|170 196|PEA3-mediated gene expression
P08808707A0631|170 186|PEA3-mediated gene
P08808756A0587|0 15|Sequence analysis
P08808756A0587|46 49|cDNA
P08808756A0587|63 70|total RNA
P08808756A0587|94 98|cells
P08808756A0587|141 148|products
P08808756A0587|166 180|additional bases
P08808756A0587|192 203|accumulation
P08808756A0587|206 218|unspliced mRNA
P08808924A0326|3 19|hydropathy profile
P08808924A0326|33 50|transmembrane spans
P08808924A0326|55 78|hydrophilic amino terminus
P08808924A0326|97 104|residues
P08808924A0326|134 155|amphiphilic alpha-helix
P08808924A0326|157 160|L-61
P08808924A0326|163 166|F-97
P08808924A0326|170 183|close proximity
P08808924A0326|202 219|hydrophobic segment
P08808924A0326|222 225|ProW
P08808927A0417|1 28|1.5-kb HindIII genomic fragment
P08808927A0417|7 28|HindIII genomic fragment
P08808927A0417|40 47|vspA gene
P08808927A0417|52 62|M. bovis PG45
P08808939A0000|0 25|Carbon catabolite repression
P08808939A0000|31 39|gnt operon
P08808939A0000|42 57|Bacillus subtilis
P08808939A0000|73 100|catabolite control protein CcpA
P08808939A0000|106 108|HPr
P08808939A0000|111 131|phosphocarrier protein
P08808939A0000|137 160|phosphotransferase system
P08809680T0000|0 8|Melatonin
P08809680T0000|12 22|seasonality
P08810040A0955|1 16|subsequent screen
P08810040A0955|42 68|selectable target locus marker
P08810040A0955|99 113|modest frequency
P08810040A0955|117 117|%
P08810278A0682|28 42|cellular protein
P08810278A0682|51 57|BCR/ABL
P08810278A0682|51 53|BCR
P08810278A0682|55 57|ABL
P08810278A0682|68 81|CRKL-SH2 domain
P08810278A0682|68 71|CRKL
P08810278A0682|84 87|p130
P08810278A0682|89 91|CAS
P08810278A0682|94 97|p130
P08810278A0682|99 101|CAS
P08810278A0682|115 136|tyrosine phosphorylated
P08810278A0682|154 157|CRKL
P08810278A0682|160 185|BCR/ABL expressing cell lines
P08810278A0682|160 162|BCR
P08810278A0682|164 166|ABL
P08810278A0682|191 197|samples
P08810278A0682|210 212|CML
P08810278A0682|216 226|ALL patients
P08810278A0682|236 242|samples
P08810278A0682|247 254|controls
P08810323A0735|12 30|polyglutamine motifs
P08810323A0735|47 67|histidine-rich regions
P08812012T0000|3 9|effects
P08812012T0000|12 31|procedural variations
P08812012T0000|45 57|Stroop effects
P08812020A0597|3 17|third experiment
P08812020A0597|20 30|Chessmaster
P08812020A0597|60 65|boards
P08812020A0597|84 89|higher
P08812020A0597|96 111|% average accuracy
P08812020A0597|139 144|pieces
P08812106T0000|0 7|PCNA mRNA
P08812106T0000|14 25|UTR antisense
P08812106T0000|28 44|yellow crescent RNA
P08812106T0000|50 58|localized
P08812106T0000|61 72|ascidian eggs
P08812106T0000|76 82|embryos
P08812490A0000|1 15|1.8-kb cDNA clone
P08812490A0000|25 28|hKID
P08812490A0000|30 44|gene symbol AQP2L
P08812490A0000|50 57|homology
P08812490A0000|63 72|aquaporins
P08812490A0000|89 110|human kidney cDNA library
P08812490A0542|0 23|PCR/Southern blot analysis
P08812490A0542|26 40|human kidney cDNA
P08812490A0542|46 52|primers
P08812490A0542|64 67|hKID
P08812490A0542|103 117|full-length mRNA
P08812490A0542|121 136|short transcripts
P08812490A0542|141 151|partial exon
P08812490A0542|156 166|partial exon
P08812490A0542|168 176|deletions
P08812490A1509|3 22|high sequence homology
P08812490A1509|24 46|similar genomic structure
P08812490A1509|51 74|identical chromosomal loci
P08812490A1509|77 80|hKID
P08812490A1509|82 84|MIP
P08812490A1509|89 93|AQP-2
P08812490A1509|102 121|MIP family gene cluster
P08812490A1509|124 143|chromosome locus 12q13
P08813766A0605|3 10|third ORF
P08813766A0605|21 30|transcript
P08813766A0605|36 37|kb
P08813766A0605|61 68|residues
P08813766A0605|79 90|perfect match
P08813766A0605|96 112|consensus sequence
P08813766A0605|116 135|C2H2 zinc finger domain
P08813766A0605|146 159|strong homology
P08813766A0605|164 173|yeast Mig1p
P08813766A0605|177 181|Cre-A
P08813766A0605|186 196|Aspergillus
P08813766A0605|198 207|Emericella
P08813900A1088|6 12|phytase
P08813900A1088|16 17|nP
P08813900A1088|29 39|orderliness
P08813900A1088|54 67|mineralization
P08813900A1088|84 92|cartilage
P08813900A1088|96 104|bone cells
P08813900A1088|122 128|effects
P08813900A1088|131 141|P deficiency
P08813900A1088|147 158|histological
P08813900A1088|162 175|gross structure
P08813900A1088|181 186|tibias
P08814651A0000|15 29|temporal factors
P08814651A0000|46 53|severity
P08814651A0000|56 77|ethanol withdrawal signs
P08814651A0000|104 114|rating scale
P08814651A0000|116 121|tremor
P08814651A0000|126 149|acoustic startle paradigms
P08816052A0238|0 3|Data
P08816052A0238|16 22|brevity
P08816052A0238|28 44|WISC-III short form
P08816052A0238|51 75|criterion-related validity
P08816052A0238|85 90|K-FAST
P08816052A0238|97 145|Kaufman Short Neuropsychological Assessment Procedure
P08816052A0238|147 152|K-SNAP
P08816438A0316|0 19|Quantitative analysis
P08816438A0316|22 37|plasmid loss rates
P08816438A0316|40 54|cdc28-1N strains
P08816438A0316|40 47|cdc28-1N
P08816438A0316|63 70|plasmids
P08816438A0316|75 100|multiple replication origins
P08816438A0316|114 119|defect
P08816438A0316|132 145|DNA replication
P08816438A0316|164 183|plasmid loss phenotype
P08816443A1674|8 28|multidomained ROK alpha
P08816443A1674|21 28|ROK alpha
P08816443A1674|50 63|reorganization
P08816443A1674|69 80|cytoskeleton
P08816443A1674|89 89|N
P08816443A1674|93 100|C termini
P08816443A1674|120 137|negative regulators
P08816443A1674|157 168|kinase domain
P08816443A1674|205 216|stress fibers
P08816443A1674|220 241|focal adhesion complexes
P08816452A0936|5 12|findings
P08816452A0936|19 48|differential tissue distribution
P08816452A0936|51 53|p54
P08816452A0936|69 82|novel SR protein
P08816452A0936|74 82|SR protein
P08816452A0936|111 129|alternative splicing
P08816452A0936|143 167|substrate-dependent manner
P08816453A0000|3 11|elevation
P08816453A0000|14 22|cyclic AMP
P08816453A0000|24 27|cAMP
P08816453A0000|29 34|levels
P08816453A0000|73 83|Raf-1 kinase
P08816459A0090|2 18|interaction screen
P08816459A0090|26 41|repression domain
P08816459A0090|47 66|orphan receptor RevErb
P08816459A0090|77 81|N-CoR
P08816459A0090|86 96|corepressor
P08816459A0090|100 121|thyroid hormone receptor
P08816459A0090|123 124|TR
P08816459A0090|129 148|retinoic acid receptor
P08816459A0090|150 152|RAR
P08816460A1769|5 11|results
P08816460A1769|24 33|inhibition
P08816460A1769|36 54|Jun kinase activation
P08816460A1769|36 44|Jun kinase
P08816460A1769|77 93|Ras transformation
P08816460A1769|77 79|Ras
P08816460A1769|122 126|Erk-2
P08816461A0892|23 27|Upf1p
P08816461A0892|31 52|multifunctional protein
P08816461A0892|57 75|separable activities
P08816461A0892|89 100|mRNA turnover
P08816461A0892|104 122|nonsense suppression
P08816472T0000|0 13|Identification
P08816472T0000|16 19|Ste4
P08816472T0000|23 40|potential regulator
P08816472T0000|43 46|Byr2
P08816472T0000|52 72|sexual response pathway
P08816482A0234|10 24|related variants
P08816482A0234|27 31|Stat5
P08816482A0234|33 38|Stat5a
P08816482A0234|42 47|Stat5b
P08816482A0234|61 73|distinct genes
P08816483A0869|0 8|Mutations
P08816483A0869|16 19|loci
P08816483A0869|21 24|SIC1
P08816483A0869|26 29|SWI5
P08816483A0869|34 37|RIC3
P08816498A0000|3 29|serine/threonine kinase Raf-1
P08816498A0000|51 54|Rats
P08816498A0000|58 82|signal transduction cascade
P08816498A0000|97 112|mitogenic stimuli
P08816498A0000|120 133|plasma membrane
P08816498A0000|139 145|nucleus
P08816504T0000|0 47|Platelet-derived growth factor-dependent activation
P08816504T0000|50 77|phosphatidylinositol 3-kinase
P08816504T0000|91 105|receptor binding
P08816504T0000|108 136|SH2-domain-containing proteins
P08816504T0000|151 161|Ras activity
P08816504T0000|151 153|Ras
P08816507A1125|2 28|transient cotransfections E1A
P08816507A1125|26 28|E1A
P08816507A1125|56 66|p53 promoter
P08816507A1125|70 78|high level
P08816507A1125|80 85|12S E1A
P08816507A1125|111 116|13S E1A
P08816507A1125|135 137|YY1
P08816507A1125|148 163|composite element
P08816507A1125|183 183|%
P08816507A1125|190 198|induction
P08816759A0000|3 23|retinoid Z receptor beta
P08816759A0000|25 31|RZR beta
P08816759A0000|36 49|orphan receptor
P08816759A0000|65 84|retinoic acid receptor
P08816759A0000|86 88|RAR
P08816759A0000|91 112|thyroid hormone receptor
P08816759A0000|114 115|TR
P08816759A0000|117 125|subfamily
P08816759A0000|128 143|nuclear receptors
P08816792A0000|0 25|DNA-dependent protein kinase
P08816792A0000|27 32|DNA-PK
P08816792A0000|45 64|heterodimeric protein
P08816792A0000|66 67|Ku
P08816792A0000|73 93|large catalytic subunit
P08816792A0000|95 102|DNA-PKcs
P08817323A0714|6 29|complete sequence identity
P08817323A0714|58 69|DXS6673E gene
P08817323A0714|85 96|sequence tags
P08817323A0714|98 101|ESTs
P08817323A0714|126 137|DXS6673E gene
P08817323A0714|142 150|third EST.
P08817324A1070|0 9|Sequencing
P08817324A1070|15 17|16p
P08817324A1070|23 48|Xq28 duplication breakpoints
P08817324A1070|73 123|repetitive immunoglobulin-like CAGGG pentamer sequences
P08817324A1070|83 123|immunoglobulin-like CAGGG pentamer sequences
P08817324A1070|135 152|paralogy boundaries
P08818436A0557|11 30|multivariate analysis
P08818436A0557|57 71|previous history
P08818436A0557|74 95|cardiovascular diseases
P08818436A0557|97 108|female gender
P08818718A1229|19 44|single intravenous injection
P08818718A1229|50 66|bicistronic vector
P08818718A1229|78 94|cationic liposomes
P08818718A1229|99 111|recipient mice
P08818718A1229|123 126|MDR1
P08818718A1229|130 136|GC cDNAs
P08818718A1229|156 161|organs
P08820324A1699|3 8|limits
P08820324A1699|27 29|DBS
P08820324A1699|33 44|TOF responses
P08820642A0173|3 25|harpin-encoding hrpZ gene
P08820642A0173|3 8|harpin
P08820642A0173|18 25|hrpZ gene
P08820642A0173|28 34|located
P08820642A0173|39 44|operon
P08820642A0173|60 88|Hrp secretion pathway components
P08820642A0173|60 62|Hrp
P08820642A0173|103 119|functional cluster
P08820642A0173|122 129|hrp genes
P08820642A0173|139 150|cosmid pHIR11
P08820642A0173|162 180|saprophytic bacteria
P08820642A0173|236 237|HR
P08820648A0123|23 55|additional ribonucleotide reductase
P08820648A0123|33 55|ribonucleotide reductase
P08820648A0123|60 78|nrdAB-encoded enzyme
P08820648A0123|95 107|aerobic growth
P08820648A0123|124 145|nrdAB-defective mutants
P08820648A0123|165 170|viable
P08822208A1364|14 20|results
P08822208A1364|42 49|isoforms
P08822208A1364|56 71|similar responses
P08822208A1364|85 95|differences
P08822399A0518|0 18|Motivational factors
P08822399A0518|29 37|attitudes
P08822399A0518|48 61|susceptibility
P08822399A0518|77 92|normative factors
P08823163T0000|0 23|High-resolution structure
P08823163T0000|29 52|diphtheria toxin repressor
P08823163T0000|66 71|cobalt
P08823163T0000|75 83|manganese
P08823163T0000|93 111|SH3-like third domain
P08823163T0000|93 95|SH3
P08823163T0000|124 135|possible role
P08823163T0000|138 146|phosphate
P08823163T0000|149 162|co-corepressor
P08823187A1020|0 8|Titration
P08823187A1020|22 36|porcine proteins
P08823187A1020|41 67|2-nitro-5-thiosulfabenzoate
P08823187A1020|81 99|membrane dipeptidase
P08823187A1020|124 147|intrachain disulfide bonds
P08823260A1161|0 3|FEV1
P08823260A1161|29 36|patients
P08823260A1161|44 48|acute
P08823260A1161|51 61|chronic GVHD
P08823260A1161|74 80|earlier
P08823260A1161|87 94|patients
P08823260A1161|102 133|posttransplant pulmonary infection
P08823646A1012|0 13|Administration
P08823646A1012|16 25|adrenaline
P08823646A1012|37 55|large overestimation
P08823646A1012|61 64|SaO2
P08823646A1012|74 85|measurements
P08823709A0220|0 6|Therapy
P08823709A0220|11 29|dietary modification
P08823709A0220|33 57|triglyceride lowering drugs
P08823709A0220|80 87|symptoms
P08823709A0220|91 97|parotid
P08824201A0270|0 7|Chernoff
P08824585A0260|13 30|novel protein kinase
P08824585A0260|18 30|protein kinase
P08824585A0260|38 67|hematopoietic progenitor kinase 1
P08824585A0260|38 66|hematopoietic progenitor kinase
P08824585A0260|69 72|HPK1
P08824585A0260|105 122|hematopoietic cells
P08824585A0260|133 152|early progenitor cells
P08824798A0761|0 20|Human ESP1/CRP2 protein
P08824798A0761|27 36|LIM domains
P08824798A0761|45 50|shares
P08824798A0761|55 55|%
P08824798A0761|65 82|% identical residues
P08824798A0761|87 111|human cysteine-rich protein
P08824798A0761|113 115|CRP
P08824798A0761|120 126|rat CRIP
P08824800A0808|3 11|fragments
P08824800A0808|42 66|agarose gel electrophoresis
P08824805A0832|0 6|Several
P08824805A0832|12 25|exon boundaries
P08824805A0832|41 50|boundaries
P08824805A0832|53 69|functional domains
P08824805A0832|75 84|p55 protein
P08824881A0133|0 13|Linkage studies
P08824881A0133|23 40|locus heterogeneity
P08824881A0133|48 54|TSC gene
P08824881A0133|63 76|chromosome 9q34
P08824881A0133|89 95|16p13.3
P08824884A0000|3 23|cytogenetic expression
P08824884A0000|29 54|folate sensitive fragile site
P08824884A0000|56 60|FRAXE
P08824884A0000|84 92|GCC repeat
P08824884A0000|95 106|proximal Xq28
P08824884A0000|112 127|human X chromosome
P08824884A0000|148 155|mild form
P08824884A0000|158 171|mental handicap
P08825087A0213|0 18|DNA sequence analysis
P08825087A0213|26 45|bp BamHI-ClaI fragment
P08825087A0213|28 45|BamHI-ClaI fragment
P08825087A0213|63 79|open reading frames
P08825087A0213|81 84|ORFs
P08825087A0213|102 116|same orientation
P08825178A0071|3 28|initial inpatient experience
P08825178A0071|32 42|individuals
P08825178A0071|47 59|HIV-related TB
P08825178A0071|65 71|pivotal
P08825178A0071|107 119|ongoing TB care
P08825554A0000|0 14|Tristetraprolin
P08825554A0000|16 18|TTP
P08825554A0000|25 33|prototype
P08825554A0000|44 72|potential transcription factors
P08825554A0000|89 114|more unusual CCCH zinc fingers
P08825556A0522|18 24|CREsp-a
P08825556A0522|26 33|TGACCTCA
P08825556A0522|48 57|nucleotide
P08825556A0522|63 76|palindromic CRE
P08825556A0522|78 83|CREpal
P08825556A0522|85 92|TGACGTCA
P08825556A0522|113 116|CREB
P08825556A0522|120 128|homodimer
P08825633A0304|0 7|Analysis
P08825633A0304|10 24|human genomic DNA
P08825633A0304|34 51|intronless sequence
P08825633A0304|56 69|strong homology
P08825633A0304|72 82|human G alpha
P08825633A0304|84 87|cDNA
P08825636T0000|3 30|complete exon-intron structure
P08825636T0000|36 55|156-kb human gene NFKB1
P08825636T0000|72 75|p105
P08825636T0000|79 89|p50 proteins
P08825636T0000|92 120|transcription factors NF-kappa B
P08825636T0000|112 120|NF-kappa B
P08825636T0000|124 136|I kappa B-gamma
P08825636T0000|138 149|implications
P08825636T0000|153 188|NF-kappa B-mediated signal transduction
P08825636T0000|153 161|NF-kappa B
P08825639A0827|2 25|inverted Alu repeat element
P08825639A0827|36 55|nonamer direct repeats
P08825639A0827|108 114|cap site
P08827783A0499|3 6|ewes
P08827783A0499|21 28|normoxia
P08827783A0499|33 42|monitoring
P08827783A0499|59 60|h.
P08828142A0000|0 20|Feline leukemia viruses
P08828142A0000|22 26|FeLVs
P08828142A0000|37 73|replication-competent oncoretroviruses
P08828142A0000|79 96|domestic cat species
P08828142A0000|126 144|natural environments
P08828152A1238|0 9|Comparison
P08828152A1238|15 32|amino acid sequences
P08828152A1238|38 53|RPO1 polypeptides
P08828152A1238|56 59|IIV6
P08828152A1238|61 64|LCDV
P08828152A1238|69 73|MCV-1
P08828152A1238|81 104|corresponding prokaryotic
P08828152A1238|106 115|eukaryotic
P08828152A1238|120 132|viral proteins
P08828152A1238|141 151|differences
P08828152A1238|154 172|amino acid similarity
P08828152A1238|176 200|phylogenetic relationships
P08828152A1825|3 6|RPO1
P08828152A1825|9 12|LCDV
P08828152A1825|21 37|highest similarity
P08828152A1825|43 46|RPO1
P08828152A1825|49 52|IIV6
P08828152A1825|56 81|significant lower similarity
P08828152A1825|87 107|eukaryotic polymerases
P08828152A1825|129 149|archaebacteral subunit
P08828857A2423|8 21|primary GE cells
P08828857A2423|35 44|convenient
P08828857A2423|61 72|further study
P08828857A2423|78 86|endocrine
P08828857A2423|88 96|paracrine
P08828857A2423|101 116|autocrine factors
P08828857A2423|127 151|endometrial gene expression
P08829393A0083|11 26|dipole estimation
P08829393A0083|29 34|spikes
P08829393A0083|38 50|SEP components
P08829393A0083|53 69|identical patients
P08831364A1252|4 12|verapamil
P08831364A1252|16 26|propranolol
P08831364A1252|37 51|additive effects
P08831364A1252|56 64|adenosine
P08831364A1252|77 97|AV nodal conduction time
P08831364A1252|111 119|verapamil
P08831364A1252|138 146|adenosine
P08831364A1252|164 175|AV nodal block
P08832146A0959|0 10|Proximal CBD
P08832146A0959|37 59|bone alkaline phosphatase
P08832146A0959|61 62|r =
P08832146A0959|69 69|p
P08832146A0959|79 87|intact PTH
P08832146A0959|85 87|PTH
P08832146A0959|89 90|r =
P08832146A0959|97 97|p
P08833153A0628|27 44|hCHLR gene sequences
P08833153A0628|49 66|available databases
P08833153A0628|81 92|large portion
P08833153A0628|100 104|genes
P08833153A0628|115 119|exons
P08833153A0628|131 147|functional domains
P08833153A0628|153 175|carboxyl-terminal region
P08833153A0628|183 190|proteins
P08833153A0628|218 251|larger human telomeric repeat sequence
P08833153A0628|259 278|many human chromosomes
P08833653A0304|17 45|LIM domain homeobox protein isl-1
P08833653A0304|17 40|LIM domain homeobox protein
P08833653A0304|41 45|isl-1
P08833653A0304|58 74|rat amylin promoter
P08833653A0304|81 90|fibroblast
P08833653A0304|94 107|islet cell lines
P08833653A0783|8 12|isl-1
P08833653A0783|27 33|insulin
P08833653A0783|37 62|amylin gene promoter elements
P08833653A0783|76 84|sequences
P08833653A0783|92 108|marked differences
P08833653A0783|116 148|relative transcriptional properties
P08833653A0783|160 167|adjacent
P08833653A0783|171 190|heterologous promoter
P08833653A0783|209 212|InR1
P08833653A0783|214 225|G9 islet cells
P08835393A2829|14 26|other pathways
P08835393A2829|34 66|alternate signal transduction events
P08835393A2829|73 91|calcium mobilization
P08835393A2829|96 119|promoter response elements
P08835393A2829|126 128|SRE
P08835895A1292|3 10|CD4 count
P08835895A1292|3 5|CD4
P08835895A1292|18 26|remission
P08835895A1292|43 68|severe immunodeficiency such
P08835895A1292|80 100|AIDS-related infection
P08835969A0000|8 28|diagnostic laparoscopy
P08835969A0000|49 65|standard reference
P08835969A0000|82 97|ectopic pregnancy
P08835969A0000|99 100|EP
P08835969A0000|108 143|high-resolution endovaginal sonography
P08835969A0000|147 157|conjunction
P08835969A0000|162 183|qualitative serum assays
P08835969A0000|189 199|beta subunit
P08835969A0000|202 227|human chorionic gonadotropin
P08835969A0000|229 236|beta-hCG
P08835969A0000|245 253|detection
P08835969A0000|256 262|earlier
P08835969A0000|266 275|smaller EPs
P08836032T0000|0 14|Bifunctionality
P08836032T0000|20 49|AcMNPV homologous region sequence
P08836032T0000|51 53|hr1
P08836032T0000|56 63|enhancer
P08836032T0000|67 78|ori functions
P08836032T0000|83 111|different sequence requirements
P08836172A1382|0 2|RVR
P08836172A1382|19 25|studies
P08836172A1382|28 54|constitutive over-expression
P08836172A1382|58 82|dominant negative RVR delta E
P08836172A1382|74 82|RVR delta E
P08836172A1382|102 107|levels
P08836172A1382|110 121|p21Cip1/Waf1
P08836172A1382|110 116|p21Cip1
P08836172A1382|118 121|Waf1
P08836172A1382|125 137|myogenin mRNAs
P08836172A1382|143 157|serum withdrawal
P08836740A1025|7 10|CES1
P08836740A1025|14 17|CES4
P08836740A1025|32 41|cell growth
P08836740A1025|47 66|double deletion mutant
P08836740A1025|69 74|viable
P08837503A0392|8 19|repeat motifs
P08837503A0392|45 63|well-ordered pattern
P08837503A0392|94 100|SbHRGP3
P08837503A0392|111 118|new group
P08837503A0392|121 128|proteins
P08837503A0392|138 149|repeat motifs
P08837503A0392|155 168|distinct groups
P08837503A0392|171 184|dicot extensins
P08837746A0951|26 38|BrAAP activity
P08837746A0951|53 63|postproline
P08837746A0951|68 88|postglutamate cleavage
P08837746A0951|105 122|broader specificity
P08838144A0107|12 33|functional significance
P08838144A0107|41 50|subdomains
P08838144A0107|53 62|PRL binding
P08838144A0107|53 55|PRL
P08838144A0107|66 83|signal transduction
P08838144A0107|85 99|deletion mutants
P08838144A0107|102 121|S1 or/and S2 subdomains
P08838148A1218|1 26|stable heterologous cell line
P08838148A1218|40 55|mouse TRH receptor
P08838148A1218|72 83|transfection
P08838148A1218|86 97|nonexcitable
P08838148A1218|101 105|cells
P08838148A1218|116 131|L channel activity
P08838314A0129|50 53|V1aR
P08838314A0129|71 92|genomic characteristics
P08838314A0129|94 109|tissue expression
P08838314A0129|111 133|chromosomal localization
P08838314A0129|138 152|regional mapping
P08838314A0129|158 170|human V1aR gene
P08838314A0129|172 177|AVPR1A
P08838585A0968|31 54|overall backbone deviation
P08838585A0968|71 77|ras-p21
P08838805T0000|0 18|Genomic organization
P08838805T0000|24 44|human beta-catenin gene
P08838805T0000|46 51|CTNNB1
P08839498A0507|23 42|regional distribution
P08839498A0507|45 58|lean tissue mass
P08839498A0507|72 75|legs
P08839498A0507|100 122|different pubertal stages
P08839498A0507|127 146|regional distribution
P08839498A0507|155 161|altered
P08839498A0507|202 211|peripheral
P08839832A0729|17 28|CD30v protein
P08839832A0729|45 61|cytoplasmic region
P08839832A0729|74 86|extracellular
P08839832A0729|90 109|transmembrane domains
P08839832A1220|0 26|Constitutive phosphorylation
P08839832A1220|32 43|CD30v protein
P08839832A1220|68 75|labeling
P08839832A1220|81 83|32P
P08839911A0716|4 4|%
P08839911A0716|7 12|cycles
P08840501A0345|27 46|new actin-related gene
P08840501A0345|30 46|actin-related gene
P08840501A0345|78 81|ACT4
P08840506A0544|8 11|ORFs
P08840506A0544|35 44|longer ones
P08840506A0544|75 79|G2850
P08840997A0765|0 8|MVR typing
P08840997A0765|11 28|rare-length alleles
P08840997A0765|60 80|disorganized sequences
P08840997A0765|106 116|resemblance
P08840997A0765|127 139|common alleles
P08842143A0000|0 12|Plasmid pAL618
P08842143A0000|24 42|genetic determinants
P08842143A0000|46 53|H2 uptake
P08842143A0000|55 57|hup
P08842143A0000|85 86|bv
P08842143A0000|88 93|viciae
P08842143A0000|116 120|genes
P08842143A0000|126 149|hupSLCDEFGHIJK-hypABFCDE
P08843411A0801|3 9|classes
P08843411A0801|12 28|inactive receptors
P08843411A0801|58 82|transcriptional activation
P08843411A0801|86 97|dimerization
P08843411A0801|134 158|transcriptional activation
P08843412A0543|15 44|transferable 40-amino acid region
P08843412A0543|54 57|LBDs
P08843412A0543|60 62|RXR
P08843412A0543|64 66|RAR
P08843412A0543|68 69|TR
P08843412A0543|74 124|chicken ovalbumin upstream promoter transcription factor
P08843412A0543|166 189|heterodimeric interaction
P08843412A0543|196 218|high-affinity DNA binding
P08843419A1290|0 2|OKA
P08843419A1290|6 15|calyculin A
P08843419A1290|29 56|OCFRE DNA-protein interactions
P08843419A1290|29 33|OCFRE
P08843419A1290|72 107|important protein-protein interactions
P08843419A1290|111 121|phosphatase
P08844448A0000|2 11|open-label
P08844448A0000|13 30|placebo-controlled
P08844448A0000|43 63|two-way crossover study
P08844448A0000|80 96|healthy volunteers
P08844448A0000|112 116|years
P08844448A0000|142 149|orlistat
P08844448A0000|152 182|gastrointestinal lipase inhibitor
P08844448A0000|152 173|gastrointestinal lipase
P08844448A0000|194 213|dietary fat absorption
P08844448A0000|236 248|weight control
P08844448A0000|251 257|obesity
P08844448A0000|264 273|absorption
P08844448A0000|276 283|vitamins
P08844448A0000|288 289|E.
P08844577A0000|0 9|Tilmicosin
P08844577A0000|13 36|novel macrolide antibiotic
P08844577A0000|49 60|exclusive use
P08844577A0000|63 80|veterinary medicine
P08844712A0000|0 5|Effect
P08844712A0000|8 19|nitrous oxide
P08844712A0000|21 23|N2O
P08844712A0000|30 47|somatosympathetic A
P08844712A0000|52 61|C-reflexes
P08844712A0000|104 119|rats anesthetized
P08844712A0000|124 139|alpha-chloralose
P08844712A0000|143 150|urethane
P08845378A0368|0 23|Restriction enzyme mapping
P08845378A0368|27 42|Southern analysis
P08845378A0368|66 79|human MZF-1 gene
P08845378A0368|83 97|single-copy gene
P08846775A0110|14 17|Swi4
P08846775A0110|21 37|Swi6 cell viability
P08846775A0110|21 24|Swi6
P08846775A0110|63 79|ectopic expression
P08846775A0110|85 92|G1 cyclin
P08846775A0110|101 105|genes
P08846775A0110|107 110|CLN1
P08846775A0110|113 116|CLN2
P08847138A0609|3 16|detection ratio
P08847138A0609|25 28|ages
P08847138A0609|69 73|years
P08847403T0000|3 13|many embryos
P08847403T0000|26 33|patients
P08847403T0000|44 46|IVF
P08847723A2351|0 11|IMPLICATIONS
P08847723A2351|21 29|small size
P08847723A2351|47 59|inconsistency
P08847723A2351|62 68|results
P08847723A2351|77 97|few prospective studies
P08847723A2351|100 112|ovarian cancer
P08847723A2351|133 144|associations
P08847723A2351|146 157|replications
P08847723A2351|165 172|findings
P08847723A2351|182 190|desirable
P08848013A1469|3 21|nonconsensus TATA box
P08848013A1469|24 32|promoter B
P08848013A1469|43 55|important role
P08848013A1469|58 73|promoter activity
P08848013A1469|81 87|TATA box
P08848013A1469|90 99|promoter A.
P08848052A0733|5 14|properties
P08848052A0733|27 30|Gle1
P08848052A0733|35 50|RNA-export factor
P08848052A0733|58 60|Rev
P08848052A0733|71 84|viral RNA export
P08848052A0733|109 112|Gle1
P08849208A1022|0 7|Demispan
P08849208A1022|22 40|reproducible measure
P08849208A1022|43 49|stature
P08849569A0615|3 12|techniques
P08849569A0615|20 36|assay coefficients
P08849569A0615|75 96|normal circadian pattern
P08849569A0615|99 106|cortisol
P08849778A0226|15 33|toeprinting analyses
P08849778A0226|36 43|repA mRNA
P08849778A0226|46 54|plasmid R1
P08849778A0226|69 74|duplex
P08849778A0226|82 93|antisense RNA
P08849778A0226|95 98|CopA
P08849778A0598|0 11|Previous work
P08849778A0598|22 42|repA (initiator protein
P08849778A0598|22 25|repA
P08849778A0598|27 42|initiator protein
P08849778A0598|66 78|leader peptide
P08849834A0000|28 41|volume flow rate
P08849834A0000|75 114|transverse colour Doppler ultrasound imaging
P08850585A0602|3 18|enzyme activities
P08850585A0602|29 45|important elements
P08850585A0602|51 65|pathophysiology
P08850585A0602|68 79|dental caries
P08850585A0602|103 118|virulence factors
P08851337A1092|0 12|Tonsillectomy
P08851337A1092|17 30|effective means
P08851337A1092|33 43|prophylaxis
P08851337A1092|47 71|upper respiratory infection
P08851337A1092|74 95|habitual angina patients
P08851434A0383|2 9|lean mice
P08851434A0383|14 36|fat/water intensity ratio
P08851434A0383|64 73|normal mice
P08853303A0431|0 24|Pharmacokinetic parameters
P08853303A0431|38 43|values
P08853303A0431|67 77|intravenous
P08853303A0431|84 96|intraarterial
P08853303A0431|98 99|IA
P08853303A0431|101 118|bolus MMC injections
P08853303A0431|120 124|Tmax =
P08853303A0431|128 130|min
P08853303A0431|154 164|MMC infusion
P08853303A0431|166 169|Vss =
P08853303A0431|174 177|1/kg
P08853303A0431|179 181|C1 =
P08853303A0431|185 190|ml/min
P08853303A0431|192 193|kg
P08853303A0431|195 204|T1/2 alpha =
P08853303A0431|208 210|min
P08853303A0431|212 220|T1/2 beta =
P08853303A0431|225 227|min
P08853893A0158|28 54|distinct E2F complexes present
P08853893A0158|57 60|aged
P08853893A0158|64 78|senescent normal
P08853893A0158|80 102|human diploid fibroblasts
P08854459A0000|16 23|overview
P08854459A0000|29 41|global pattern
P08854459A0000|44 53|casualties
P08854459A0000|56 66|earthquakes
P08854459A0000|89 102|30-month period
P08854459A0000|108 116|September
P08854459A0000|125 132|February
P08854844A0637|21 37|non-visualization
P08854844A0637|43 44|GB
P08854844A0637|48 61|h post injection
P08854844A0637|67 75|criterion
P08854844A0637|93 94|AC
P08854844A0637|99 116|diagnostic accuracy
P08854844A0637|128 128|%
P08855804A1528|5 11|results
P08855804A1528|31 45|subsequent study
P08855804A1528|55 68|hypogonadal men
P08855804A1528|89 91|SLT
P08855804A1528|93 94|mg
P08855804A1528|100 104|times
P08855804A1528|114 119|months
P08856077T0000|0 20|Alternative processing
P08856077T0000|26 56|tryptophanyl-tRNA synthetase mRNA
P08856077T0000|61 88|interferon-treated human cells
P08856077T0000|61 70|interferon
P08856132T0000|0 7|Evidence
P08856132T0000|32 56|intra-uterine kinin release
P08856132T0000|32 49|intra-uterine kinin
P08856132T0000|75 110|late hypertonic saline-induced abortion
P08858211A0694|4 14|GAP activity
P08858211A0694|4 6|GAP
P08858211A0694|28 49|3T3-L1 adipocyte lysates
P08858211A0694|76 85|hydrolysis
P08858211A0694|92 100|alpha-32P
P08858211A0694|102 104|GTP
P08858211A0694|112 119|GST-Rab4
P08858211A0694|112 114|GST
P08858211A0694|116 119|Rab4
P08858211A0694|125 133|alpha-32P
P08858211A0694|135 137|GDP
P08858268A1307|0 9|CONCLUSION
P08858268A1307|17 32|chronic treatment
P08858268A1307|37 56|haemodynamic response
P08858268A1307|59 72|oral cilazapril
P08858268A1307|110 128|clinical improvement
P08858268A1307|131 138|patients
P08858268A1307|143 145|CHF
P08858268A1307|148 150|CLZ
P08858268A1307|171 194|acute haemodynamic effects
P08858463A0853|17 28|AIDS patients
P08858463A0853|33 46|cryptococcosis
P08858463A0853|59 65|ILd-AmB
P08858463A0853|86 96|daily dosage
P08858463A0853|110 114|mg/kg
P08858463A0853|122 127|higher
P08858463A0853|131 146|mg/kg daily dosage
P08858463A0853|166 181|unacceptable rate
P08858463A0853|184 197|nephrotoxicity
P08861955A0927|12 38|second RCC1-like motif located
P08861955A0927|18 31|RCC1-like motif
P08861955A0927|44 57|amino-terminus
P08861955A0927|60 63|p619
P08861955A0927|74 98|guanine nucleotide exchange
P08861955A0927|101 104|ARF1
P08861955A0927|110 116|members
P08861955A0927|122 139|related Rab proteins
P08861955A0927|129 139|Rab proteins
P08861955A0927|149 180|other small GTP binding proteins such
P08861955A0927|154 176|small GTP binding proteins
P08861955A0927|183 185|Ran
P08861955A0927|188 193|R-Ras2
P08861955A0927|195 198|TC21
P08861963A0375b|3 29|reconstituted RNA polymerases
P08861963A0375b|16 29|RNA polymerases
P08861963A0375b|43 61|mutant alpha subunits
P08861963A0375b|92 114|transcription activation
P08861963A0375b|117 124|cAMP-CRP
P08861963A0375b|131 145|rrnBP1 UP element
P08861963T0000|0 36|Transcription factor recognition surface
P08861963T0000|42 66|RNA polymerase alpha subunit
P08861963T0000|93 110|DNA enhancer element
P08862522A0690|0 9|Consistent
P08862522A0690|32 45|cdc28-P8 mutant
P08862522A0690|57 75|unspliced precursors
P08862522A0690|81 102|restrictive temperature
P08862743A0603|11 23|erythrocyte Mn
P08862743A0603|43 48|nmol/L
P08862743A0603|59 59|p
P08863824A0509|0 6|Cloning
P08863824A0509|10 25|sequence analyses
P08863824A0509|35 44|second cDNA
P08863824A0509|50 62|95-nt deletion
P08863824A0509|86 116|putative second intracellular loop
P08863824A0509|123 147|fourth transmembrane domain
P08863824A0509|153 160|5-HT2C-R
P08864061A0000|0 9|Expression
P08864061A0000|12 30|thymidine kinase gene
P08864061A0000|33 55|normal human diploid cells
P08864061A0000|62 70|cell cycle
P08864061A0000|75 87|age-dependent
P08864219A0178|3 33|minimum inhibitory concentrations
P08864219A0178|35 38|MICs
P08864219A0178|42 53|ketoconazole
P08864219A0178|55 64|miconazole
P08864219A0178|66 77|itraconazole
P08864219A0178|79 89|fluconazole
P08864219A0178|94 106|amphotericin B
P08864219A0178|139 150|inoculum size
P08864219A0178|167 176|techniques
P08866485A0125|23 43|export proteins capable
P08866485A0125|46 65|specific interactions
P08866485A0125|70 104|key mammalian cell regulatory molecules
P08866485A0125|123 137|normal functions
P08866485A0125|143 147|cells
P08867519A0557|3 12|elevations
P08867519A0557|23 26|LDEE
P08867519A0557|32 35|s.c.
P08867519A0557|40 45|higher
P08867519A0557|98 110|longer periods
P08868473A1287|13 15|p28
P08868473A1287|28 38|limited role
P08868473A1287|48 70|early embryonic cleavages
P08868473A1287|115 125|somatic type
P08868473A1287|128 136|cell cycle
P08868660A0087|3 9|main aim
P08868660A0087|63 73|Rivista dell
P08868660A0087|75 84|Infermiere
P08868660A0087|143 151|strengths
P08868660A0087|155 161|novelty
P08868660A0087|165 174|weaknesses
P08868660A0087|180 200|hypothesis formulation
P08868660A0087|202 208|methods
P08868660A0087|212 222|instruments
P08868660A0087|240 246|results
P08868954A0648|27 33|effects
P08868954A0648|36 56|antihypertensive drugs
P08868954A0648|76 93|first-choice agents
P08868954A0648|99 116|calcium antagonists
P08868954A0648|123 149|angiotensin converting enzyme
P08868954A0648|123 133|angiotensin
P08868954A0648|144 159|enzyme inhibitors
P08868954A0648|163 184|intrarenal hemodynamics
P08869358A0121|0 15|Many human viruses
P08869358A0121|32 49|suitable strategies
P08869358A0121|62 70|apoptosis
P08869358A0121|73 91|virus-infected cells
P08869358A0121|97 114|virus-primed T cells
P08869763A0378|28 44|clinical phenomena
P08869763A0378|57 64|morphine
P08869763A0378|81 91|differences
P08869763A0378|124 145|opioid receptor subtypes
P08869763A0378|148 155|migraine
P08869825A0000|0 14|Previous studies
P08869825A0000|34 64|flavin-containing monooxygenases
P08869825A0000|66 68|FMO
P08869825A0000|85 105|tissue-specific manner
P08870266A0651|19 30|observations
P08870266A0651|46 55|C-terminal
P08870266A0651|58 67|amino acids
P08870266A0651|84 96|NodO secretion
P08870266A0651|84 87|NodO
P08870266A0651|108 121|region adjacent
P08870266A0651|149 167|secretion efficiency
P08871542A1352|27 52|common regulatory mechanisms
P08871542A1352|57 73|available evidence
P08871542A1352|90 107|Mtx minimal promoter
P08871542A1352|134 152|Thbs3 gene expression
P08871542A1352|134 142|Thbs3 gene
P08871567A0000|0 11|MSSP proteins
P08871567A0000|37 43|binding
P08871567A0000|48 62|upstream element
P08871567A0000|65 69|c-myc
P08871567A0629|0 3|Gene
P08871635A0000|0 19|B cell antigen receptor
P08871635A0000|21 23|BCR
P08871635A0000|33 41|apoptosis
P08871635A0000|47 71|WEHI-231 B lymphoma cell line
P08871635A0000|96 99|CD40
P08872162A0884|4 10|alleles
P08872162A0884|58 61|CD4+
P08872162A0884|58 60|CD4
P08872162A0884|63 65|CD8
P08872162A0884|67 78|T cell subsets
P08872671A0573|24 45|blood flow shunt fraction
P08872671A0573|47 51|Qs/QT
P08872671A0573|75 111|oxygen sine-wave amplitude perturbations
P08872671A0573|125 138|end-expired air
P08872671A0573|142 149|arterial
P08872671A0573|153 169|mixed-venous blood
P08872671A0573|180 194|simple equations
P08873063A0493|10 26|amino acid sequence
P08873063A0493|29 34|LvUSF2
P08873063A0493|54 59|LvUSF1
P08873063A0493|71 78|amino end
P08873063A0493|99 107|divergent
P08873063A0875|0 12|ECM disruption
P08873063A0875|15 31|Lytechinus embryos
P08873063A0875|39 50|relative drop
P08873063A0875|53 76|USF RNA accumulation levels
P08873063A0875|53 58|USF RNA
P08873063A0875|94 94|%
P08873063A0875|97 110|control embryos
P08873063A0875|117 141|LpS1 RNA accumulation levels
P08873063A0875|117 123|LpS1 RNA
P08873063A0875|160 160|%
P08873159A0791|16 23|patients
P08873159A0791|45 62|8-in-1 chemotherapy
P08874399A0277|5 8|days
P08874399A0277|39 53|tetanic tensions
P08874399A0277|78 93|extracellular Ca2
P08874399A0277|110 111|Ca
P08874399A0277|113 113|o
P08874399A0277|121 126|groups
P08874399A0277|131 132|B.
P08874631A1133|0 13|Discrimination
P08874631A1133|21 25|HIV-1
P08874631A1133|29 33|HIV-2
P08874631A1133|64 68|HIV-1
P08876167A0322|10 36|intrinsic DNA-binding subunit
P08876167A0322|40 45|HiNF-D
P08876167A0717|3 8|HiNF-D
P08876167A0717|10 16|CDP/cut
P08876167A0717|10 12|CDP
P08876167A0717|14 16|cut
P08876167A0717|32 41|H4 promoter
P08876167A0717|44 57|immunoreactive
P08876167A0717|62 71|antibodies
P08876167A0717|79 85|CDP/cut
P08876167A0717|89 91|pRB
P08876167A0717|98 101|p107
P08876167A0717|113 126|CDP/cut complex
P08876167A0717|132 149|nonhistone promoter
P08876167A0717|151 159|gp91-phox
P08876167A0717|151 154|gp91
P08876167A0717|156 159|phox
P08876167A0717|175 177|CDP
P08876167A0717|181 194|p107 antibodies
P08876167A0717|181 184|p107
P08876701A0177|19 37|related UmuC-homolog
P08876701A0177|26 37|UmuC-homolog
P08876701A0177|39 42|DinB
P08877103A0081|22 35|mdr2 expression
P08877103A0081|22 25|mdr2
P08877103A0081|40 47|promoter
P08877103A0081|53 60|mdr2 gene
P08877103A0081|81 115|murine vinblastine-resistant cell line
P08877103A0081|117 123|J7.V2-1
P08877103A0081|120 123|V2-1
P08877818A0184|3 15|amplification
P08877818A0184|35 41|primers
P08877818A0184|59 79|TRH progenitor sequence
P08877818A0184|81 95|Lys/Arg-Arg-Gln
P08877818A0184|81 83|Lys
P08877818A0184|85 87|Arg
P08877818A0184|97 111|His-Pro-Gly-Lys
P08877818A0184|113 119|Arg-Arg
P08878019A0357|3 28|intranodal mesothelial cells
P08878019A0357|40 48|sinusoids
P08878019A0357|54 63|lymph nodes
P08878019A0357|96 105|metastatic
P08878019A0357|113 124|ovarian tumor
P08878037A0000|3 10|gene ccpA
P08878037A0000|22 49|catabolite control protein CcpA
P08878044A1390|2 19|InlC deletion mutant
P08878044A1390|32 40|virulence
P08878044A1390|55 75|intravenous mouse model
P08878044A1390|80 103|intracellular replication
P08878044A1390|109 114|mutant
P08878044A1390|117 122|Caco-2
P08878044A1390|126 134|J774 cells
P08878044A1390|169 183|wild-type strain
P08878045A0606|8 19|N-Nus complex
P08878045A0606|40 47|contacts
P08878045A0606|55 57|CTD
P08878045A0606|63 74|alpha subunit
P08878045A0606|77 89|RNA polymerase
P08878045A0606|103 120|regulatory proteins
P08878045A0606|135 144|initiation
P08878045A0606|147 159|transcription
P08878573A1370|0 13|Administration
P08878573A1370|16 19|RIFA
P08878573A1370|25 33|mg/kg/day
P08878573A1370|51 53|ATO
P08878573A1370|59 67|mg/kg/day
P08878573A1370|79 96|marked prolongation
P08878573A1370|126 129|mice
P08878573A1370|142 144|ATO
P08878573A1370|147 150|RIFA
P08879080A0265|10 14|ACOAs
P08879080A0265|68 79|path analysis
P08879080A0265|84 92|LISREL VII
P08879237A0744|10 24|initiation sites
P08879237A0744|39 56|sequence homologous
P08879237A0744|62 83|consensus promoter motif
P08879237A0744|99 107|CRTA motif
P08879237A0744|114 114|R
P08879237A0744|120 120|G
P08879237A0744|127 143|rice mitochondrion
P08880405A1170|0 8|Selection
P08880405A1170|14 18|SC EPD
P08880405A1170|39 57|phenotypic selection
P08880405A1170|73 79|puberty
P08880405A1170|82 90|daughters
P08881036A0351|13 15|PCR
P08881036A0351|18 26|VL element
P08881036A0351|39 41|CL2
P08881542T0000|0 34|Sodium polystyrene sulfonate treatment
P08881542T0000|38 52|lithium toxicity
P08881542T0000|54 60|effects
P08881542T0000|63 90|serum potassium concentrations
P08882492A0000|3 30|mammalian homeodomain proteins
P08882492A0000|40 47|Hox genes
P08882492A0000|54 66|important role
P08882492A0000|69 88|embryonic development
P08882492A0000|100 115|positional queues
P08882492A0000|127 149|developmental identities
P08882492A0000|158 176|anteroposterior axis
P08882492A0000|189 197|organisms
P08882710A0000|0 30|Interferon stimulated gene factor 3
P08882710A0000|0 9|Interferon
P08882710A0000|20 29|gene factor
P08882710A0000|32 36|ISGF3
P08882710A0000|41 67|trimeric transcription factor
P08882710A0000|90 94|cells
P08882710A0000|99 114|interferon-alpha
P08882710A0000|118 121|beta
P08882710A0000|128 131|IFNs
P08884273A1413|3 17|TYAC/P1 resource
P08884273A1413|19 32|derivative STSs
P08884273A1413|37 49|polymorphisms
P08884273A1413|80 93|further studies
P08884273A1413|96 112|telomere structure
P08884273A1413|128 132|means
P08884273A1413|147 167|genetic map integration
P08884273A1413|171 177|closure
P08884757A0653|0 21|Confirmatory statistics
P08884757A0653|40 63|Clinical Global Impression
P08884757A0653|65 67|CGI
P08884757A0653|73 82|total score
P08884757A0653|88 120|Sandoz Clinical Assessment Geriatric
P08884757A0653|122 125|SCAG
P08884757A0653|136 143|subscale
P08884757A0653|177 193|geriatric patients
P08884757A0653|195 235|Beurteilungsskala fur geriatrische Patienten
P08884757A0653|237 239|BGP
P08884757A0653|247 256|total score
P08884757A0653|262 290|Short Cognitive Performance Test
P08884757A0653|292 307|Syndrom-Kurztest
P08884757A0653|309 311|SKT
P08885270A0428|5 11|mutants
P08885270A0428|48 51|PAO1
P08886845A1274|28 43|myogenin promoter
P08886845A1274|60 73|multiple copies
P08886845A1274|83 89|vectors
P08886845A1274|101 118|expression activity
P08886845A1274|121 128|myotubes
P08886845A1274|184 192|myoblasts
P08887643A1167|14 34|common upstream signals
P08887643A1167|40 49|activation
P08887643A1167|52 54|Ras
P08887643A1167|58 61|TC21
P08887643A1167|75 96|TC21 controls cell growth
P08887643A1167|75 78|TC21
P08887643A1167|100 149|distinct Raf-independent downstream signaling pathways
P08887643A1167|108 110|Raf
P08887647T0000|0 16|Fission yeast mal2+
P08887647T0000|0 15|Fission yeast mal2
P08887647T0000|30 50|chromosome segregation
P08887652A0341|0 8|Selection
P08887652A0341|33 53|integrated DNA fragment
P08887652A0341|67 97|con-10 promoter-regulatory region
P08887652A0341|111 124|initial segment
P08887652A0341|130 151|con-10 open reading frame
P08887652A0341|171 222|bacterial hygromycin B phosphotransferase structural gene
P08887652A0341|224 234|con10'-'hph
P08887652A0341|224 228|con10
P08887652A0341|232 234|hph
P08887659A0753|0 8|Mutations
P08887659A0753|25 29|sites
P08887659A0753|31 36|serine
P08887659A0753|43 51|threonine
P08887661A0138|0 4|IRF-1
P08887661A0138|12 35|transcriptional activator
P08887661A0138|42 46|IRF-2
P08887661A0138|54 62|repressor
P08887661A1061|11 24|cotransfection
P08887661A1061|27 31|TFIIB
P08887661A1061|35 39|IRF-1
P08887661A1061|44 54|NIH 3T3 cells
P08887661A1061|66 89|dose-dependent repression
P08887661A1061|92 109|promoter activation
P08887661A1061|126 145|TATA-dependent manner
P08887667A0992|16 38|Tyr-19 dephosphorylation
P08887667A0992|42 56|spindle assembly
P08887667A0992|76 85|conditions
P08887667A0992|93 108|spindle formation
P08887667A0992|124 130|mitosis
P08887667A0992|162 176|Cdc28/Clb kinase
P08887667A0992|162 166|Cdc28
P08887667A0992|179 191|SPB separation
P08887674A0630|1 6|subset
P08887674A0630|14 37|DMP1 recognition sequences
P08887674A0630|49 68|GGA trinucleotide core
P08887674A0630|86 107|Ets-responsive elements
P08887674A0920|6 13|settings
P08887674A0920|38 61|cyclin D-dependent kinases
P08887674A0920|80 102|transcriptional activity
P08887674A0920|132 145|such mechanisms
P08887678A0000|0 9|Expression
P08887678A0000|15 36|proapoptotic protein Bax
P08887678A0000|55 67|GAL10 promoter
P08887678A0000|103 130|galactose-inducible cell death
P08890537A0355|28 35|patients
P08890537A0355|41 58|unicameral bone cyst
P08891131A0000|0 25|Enterococcus faecium strains
P08891131A0000|30 64|vanA-mediated glycopeptide resistance
P08891131A0000|79 95|enrichment culture
P08891131A0000|103 112|intestines
P08891131A0000|116 120|feces
P08891131A0000|123 142|several animal species
P08891131A0000|150 155|horses
P08891131A0000|159 162|dogs
P08891131A0000|165 173|% positive
P08891131A0000|176 183|chickens
P08891131A0000|186 194|% positive
P08891131A0000|200 203|pigs
P08891131A0000|206 214|% positive
P08891337A0614|3 22|amino-terminal region
P08891337A0614|25 27|E1A
P08891337A0614|33 66|several high molecular weight proteins
P08891337A0614|81 114|transcriptional coactivator function
P08891337A0614|117 120|p300
P08891337A0614|127 155|homologous cAMP response element
P08891337A0614|157 175|CRE)-binding protein
P08891337A0614|157 159|CRE
P08891337A0614|162 175|binding protein
P08891341A0724|0 26|Transient transfection assays
P08891341A0724|32 53|reporter gene constructs
P08891341A0724|64 77|various lengths
P08891341A0724|83 98|5' mdr1b sequences
P08891341A0724|85 98|mdr1b sequences
P08891341A0724|114 139|sequence located between-247
P08891341A0724|146 147|bp
P08891341A0724|181 192|reporter gene
P08891341A0724|195 216|many different cell lines
P08891345A0684|15 31|UTR characteristic
P08891345A0684|34 57|testis-specific c-mos mRNA
P08891345A0684|75 93|translation relative
P08891345A0684|112 122|transcripts
P08891345A0684|137 139|UTR
P08891345A0684|151 165|beta-globin mRNA
P08891345A0684|194 198|uORFs
P08891346A1217|12 27|biological effect
P08891346A1217|30 54|specific isoform expression
P08891346A1217|56 66|NIH3T3 cells
P08891346A1217|87 112|eukaryotic expression vector
P08891346A1217|123 126|cDNA
P08891346A1217|130 134|FGF8a
P08891346A1217|136 140|FGF8b
P08891346A1217|144 148|FGF8e
P08891474A0667|5 12|findings
P08891474A0667|27 32|F-wave
P08891474A0667|48 57|motoneuron
P08891474A0667|60 91|different depolarization threshold
P08891474A0667|106 111|larger
P08891474A0667|121 131|nerve fibers
P08891474A0667|138 151|lower threshold
P08891474A0667|154 167|depolarization
P08892755A0186|11 18|carp JAK1
P08892755A0186|24 45|higher sequence homology
P08892755A0186|48 60|mammalian JAK1
P08892755A0186|70 80|kinase-like
P08892755A0186|82 84|JH2
P08892755A0186|89 94|kinase
P08892755A0186|96 98|JH1
P08892755A0186|100 106|domains
P08892755A0186|123 131|% identity
P08892755A0981|8 18|DNA fragment
P08892755A0981|41 72|chloramphenicol acetyltransferase
P08892755A0981|74 76|CAT
P08892755A0981|78 89|reporter gene
P08892755A0981|109 122|carp CF cell line
P08892755A0981|139 147|synthesis
P08892755A0981|150 158|CAT enzyme
P08892755A0981|161 165|times
P08892755A0981|188 209|promoterless pCAT-Basic
P08892755A0981|200 209|pCAT-Basic
P08892757T0000|0 15|Molecular cloning
P08892757T0000|18 22|Elk-3
P08892757T0000|25 33|new member
P08892757T0000|39 47|Ets family
P08892757T0000|63 80|mouse embryogenesis
P08892757T0000|97 129|transcriptional repression activity
P08892859A0563|21 59|MDV-transformed T-lymphoblastoid cell line
P08892859A0563|61 62|T9
P08892859A0563|74 83|high levels
P08892859A0563|96 107|C-MYB protein
P08892859A0563|119 132|RAV integration
P08892859A0563|142 152|c-myb allele
P08893779A0229|13 52|extensor digitorum longus muscle tendon units
P08893779A0229|69 79|lower values
P08893779A0229|97 97|p
P08893779A0229|129 129|p
P08893779A0229|156 156|p
P08893779A0229|186 210|different anatomic location
P08893779A0229|212 212|p
P08893779A0229|232 253|fascia-muscle interface
P08893779A0229|285 308|musculotendinous junction
P08893779A0229|314 323|fresh units
P08893822A0560|0 15|Northern analysis
P08893822A0560|21 35|3.1-kb PWP2H cDNA
P08893822A0560|49 69|3.3-kb major transcript
P08893822A0560|95 111|human adult tissues
P08894144A0330|11 46|10-12-week-old male Sprague-Dawley rats
P08894144A0330|81 84|days
P08894144A0330|89 102|CsA vehicle p.o.
P08894144A0330|107 117|FB vehicle sc
P08894144A0330|122 124|CsA
P08894144A0330|128 132|mg/kg
P08894144A0330|134 137|p.o.
P08894144A0330|142 152|FB vehicle sc
P08894144A0330|157 170|CsA vehicle p.o.
P08894144A0330|175 176|FB
P08894144A0330|181 185|mg/kg
P08894144A0330|187 188|sc
P08894144A0330|196 198|CsA
P08894144A0330|202 206|mg/kg
P08894144A0330|208 211|p.o.
P08894144A0330|216 217|FB
P08894144A0330|222 226|mg/kg
P08894144A0330|228 229|sc
P08894144A1173|0 2|CsA
P08894144A1173|18 37|elevated bone turnover
P08894826A0228|0 10|Individuals
P08894826A0228|23 35|GUM Department
P08894826A0228|41 54|Royal Infirmary
P08894826A0228|57 65|Edinburgh
P08894826A0228|102 113|HIV infection
P08894826A0228|115 126|genital warts
P08894826A0228|128 140|genital herpes
P08894826A0228|142 169|non-specific genital infection
P08894826A0228|171 174|NSGI
P08894826A0228|177 186|gonorrhoea
P08894826A0228|190 197|syphilis
P08895522T0000|0 18|Oncogenic activation
P08895522T0000|24 43|tyrosine kinase domain
P08895522T0000|49 70|human trk proto-oncogene
P08895522T0000|73 78|fusion
P08895522T0000|82 101|cell adhesion molecule
P08895579A0583|0 15|Northern blotting
P08895579A0583|26 29|MDMX
P08895579A0583|35 38|MDM2
P08895579A0583|56 62|tissues
P08895579A0583|77 88|several mRNAs
P08895579A0583|92 95|MDMX
P08895997A0336|0 6|Physiol
P08896272A0000|3 20|nucleotide sequence
P08896272A0000|29 30|bp
P08896272A0000|36 42|left arm
P08896272A0000|45 54|chromosome
P08896280A0860|24 41|steady-state levels
P08896280A0860|44 47|IME1
P08896280A0860|51 58|IME2 mRNA
P08896280A0860|83 101|non-specific adverse
P08896280A0860|111 131|nucleic acid metabolism
P08896280A0860|143 156|yvh1 disruption
P08896280A0860|143 146|yvh1
P08896402A0587|0 15|Natural FL protein
P08896402A0587|36 50|stromal cell line
P08896402A0587|66 109|kD nondisulfide-linked homodimeric glycoprotein
P08896402A0587|123 132|kD subunits
P08896402A0587|150 151|kD
P08896402A0587|154 154|N
P08896402A0587|159 172|O-linked sugars
P08896473A0282|49 52|HHCA
P08896473A0282|56 78|other serological factors
P08896473A0282|99 101|VGS
P08896590T0000|7 11|exons
P08896590T0000|14 31|adenovirus late RNAs
P08896590T0000|46 50|snRNP
P08896590T0000|54 74|specific nuclear domain
P08896795A0166|5 9|Spurr
P08896795A0166|12 16|resin
P08896795A0166|49 62|thick specimens
P08896795A0166|67 91|oil immersion objective lens
P08896795A0166|107 116|coverslips
P08896795A0166|127 136|air bubbles
P08896795A0166|144 151|specimen
P08896804A0000|3 14|present study
P08896804A0000|27 40|dose dependence
P08896804A0000|44 60|time course effects
P08896804A0000|66 79|benzodiazepine
P08896804A0000|81 83|BDZ
P08896804A0000|85 105|partial inverse agonist
P08896804A0000|107 115|RO19-4603
P08896804A0000|127 131|mg/kg
P08896804A0000|162 193|BDZ receptor antagonists flumazenil
P08896804A0000|162 172|BDZ receptor
P08896804A0000|195 196|ZK
P08896804A0000|206 208|CGS
P08896804A0000|216 220|mg/kg
P08896804A0000|239 256|alcohol-preferring
P08896804A0000|258 258|P
P08896804A0000|260 263|rats
P08896804A0000|273 292|two-bottle choice test
P08896804A0000|300 306|ethanol
P08896804A0000|308 311|EtOH
P08896804A0000|316 319|% v/v
P08896804A0000|326 343|palatable saccharin
P08896804A0000|351 354|% g/v
P08897663T0000|9 13|Tower
P08897663T0000|16 20|Babel
P08897663T0000|23 34|nomenclature
P08897663T0000|38 48|suicidology
P08897721A0000|0 8|Infection
P08897721A0000|13 21|Neisseria
P08897721A0000|34 39|group B
P08897721A0000|82 95|bacterial group
P08897721A0000|98 111|polysaccharide
P08897721A0000|115 127|weak immunogen
P08898336A0268|0 22|RNase protection analysis
P08898336A0268|0 4|RNase
P08898336A0268|28 40|rRNA fragments
P08898336A0268|46 50|genes
P08898336A0268|54 61|adjacent
P08898336A0268|82 104|polycistronic transcript
P08898336A0268|115 123|sequences
P08898336A0268|141 157|separate small RNAs
P08898365A0274|0 4|Rss1p
P08898365A0274|13 33|novel essential protein
P08898365A0274|39 48|amino acids
P08898365A0274|82 98|coiled-coil domain
P08898365A0274|104 110|located
P08898365A0274|117 136|nuclear pore complexes
P08898365A0274|138 141|NPCs
P08898365A0274|151 159|cytoplasm
P08898866A0458|9 43|regulatory serine phosphorylation site
P08898866A0458|56 91|baculovirus-mediated expression system
P08898866A0458|95 112|wild-type annexin II
P08898866A0458|95 110|wild-type annexin
P08898866A0458|128 143|annexin II mutants
P08898866A0458|128 134|annexin
P08898866A0458|137 143|mutants
P08898866A0458|158 170|substitutions
P08898866A0458|178 202|more serine residues present
P08898866A0458|208 223|N-terminal domain
P08898893A0202|3 11|PAI-2 gene
P08898893A0202|26 44|TNF-responsive genes
P08898893A0202|77 117|phorbol ester phorbol 12-myristate 13-acetate
P08898893A0202|119 121|PMA
P08898893A0202|129 148|phosphatase inhibitor
P08898893A0202|150 160|okadaic acid
P08898893A0202|168 186|HT-1080 fibrosarcoma
P08898893A0202|190 210|U-937 histiocytic cells
P08899719A0318|8 14|contigs
P08899719A0318|33 49|open reading frames
P08899719A0318|51 54|ORFs
P08899719A0318|63 77|putative operons
P08899719A0318|81 84|ORFs
P08899719A0318|106 124|reasonable certainty
P08900164A0188|0 1|T.
P08900164A0188|3 7|Patel
P08900164A0188|9 10|S.
P08900190A0430|0 12|Growth factors
P08900190A0430|37 84|immediate early gene products MAP kinase phosphatase-1
P08900190A0430|37 62|immediate early gene products
P08900190A0430|63 84|MAP kinase phosphatase-1
P08900190A0430|86 90|MKP-1
P08900190A0430|93 97|c-Fos
P08900190A0430|101 105|c-Jun
P08900296A0000|3 15|up-regulation
P08900296A0000|18 27|E-selectin
P08900296A0000|37 53|adhesion molecules
P08900296A0000|59 69|endothelium
P08900296A0000|75 88|important event
P08900296A0000|94 102|mediation
P08900296A0000|108 127|inflammatory response
P08901135A1132|3 13|NIT2 protein
P08901135A1132|16 24|localised
P08901135A1132|27 32|nuclei
P08901135A1132|59 77|cytoplasmic fraction
P08901135A1132|80 84|cells
P08901135A1132|96 115|nitrogen derepression
P08901135A1132|118 135|nitrogen repression
P08901135A1132|154 166|nuclear import
P08901135A1132|169 172|NIT2
P08901635A0000|9 18|much effort
P08901635A0000|68 73|enzyme
P08901635A0000|75 75|s
P08901635A0000|91 99|synthesis
P08901635A0000|102 110|cellulose
P08901635A0000|115 134|major cell wall polymer
P08901635A0000|137 142|plants
P08901658A0498|0 16|Vascular responses
P08901658A0498|19 35|reactive hyperemia
P08901658A0498|41 52|flow increase
P08901658A0498|62 90|endothelium-dependent dilation
P08901658A0498|97 124|sublingual glyceryl trinitrate
P08901658A0498|126 128|GTN
P08901658A0498|130 160|endothelium-independent dilation
P08902214A1486|33 54|additional exogenous PRL
P08902214A1486|52 54|PRL
P08902214A1486|70 86|further activation
P08902214A1486|88 94|binding
P08902214A1486|101 111|Stat factors
P08902548A0144|0 28|Intraperitoneal administration
P08902548A0144|31 51|L-5-hydroxytryptophan
P08902548A0144|53 59|L-5-HTP
P08902548A0144|63 67|doses
P08902548A0144|77 81|mg/kg
P08902548A0144|102 111|defecation
P08902548A0144|114 117|mice
P08902641A0930|5 14|VA-SMV mode
P08902641A0930|40 53|valved conduits
P08902641A0930|61 66|LV apex
P08902641A0930|68 73|inflow
P08902641A0930|89 93|aorta
P08902641A0930|95 101|outflow
P08902641A0930|104 105|n =
P08902641A0930|116 118|DAo
P08902641A0930|120 121|n =
P08902847A1946|54 61|affinity
P08902847A1946|88 95|subunits
P08902847A1946|99 106|impaired
P08902847A1946|123 144|first order rate constant
P08902847A1946|147 159|hCG alpha 1 beta
P08902847A1946|147 154|hCG alpha
P08902847A1946|156 159|beta
P08902847A1946|161 163|km =
P08902847A1946|174 178|min-1
P08902847A1946|182 183|pH
P08902847A1946|191 198|degrees C
P08902847A1946|216 239|magnitude greater relative
P08902847A1946|242 246|rehCG
P08902847A1946|248 250|kw =
P08902847A1946|261 265|min-1
P08902988A0258|0 12|Factor V Leiden
P08902988A0258|16 30|genetic disorder
P08902988A0258|62 77|venous thrombosis
P08903339A0264|9 26|first determination
P08903339A0264|32 57|complete secondary structure
P08903339A0264|62 64|RNA
P08903339A0264|75 85|spliceosome
P08905819A0531|16 20|cases
P08905819A0531|25 27|0-I
P08905819A0531|30 44|0-III components
P08905819A0531|49 50|sm
P08906056A1290|5 12|patients
P08906056A1290|33 55|better pulmonary function
P08906056A1290|59 75|nutritional status
P08906056A1290|96 107|higher degree
P08906056A1290|110 130|health care utilization
P08906139A2935|23 39|careful monitoring
P08906139A2935|42 48|calcium
P08906139A2935|52 76|alkaline phosphatase values
P08906139A2935|52 70|alkaline phosphatase
P08906139A2935|80 98|possible adjustments
P08906139A2935|101 114|vitamin D intake
P08906139A2935|119 128|fortifiers
P08906139A2935|139 153|extended periods
P08909546A0810|15 18|PEA2
P08909546A0810|39 45|bipolar
P08909546A0810|77 88|novel protein
P08909546A0810|103 119|coiled-coil domain
P08910292T0000|0 8|Signaling
P08910292T0000|16 43|small GTP-binding proteins Rac1
P08910292T0000|16 39|small GTP-binding proteins
P08910292T0000|40 43|Rac1
P08910292T0000|47 51|Cdc42
P08910292T0000|57 114|c-Jun N-terminal kinase/stress-activated protein kinase pathway
P08910292T0000|57 77|c-Jun N-terminal kinase
P08910292T0000|79 107|stress-activated protein kinase
P08910373A0315|0 16|Percent identities
P08910373A0315|22 29|mouse PP2
P08910373A0315|32 38|mouse Y1
P08910373A0315|40 50|mouse Y4/PP1
P08910373A0315|45 46|Y4
P08910373A0315|48 50|PP1
P08910373A0315|54 69|human Y2 receptors
P08910550A0501|18 36|previous observation
P08910550A0501|41 50|CBF binding
P08910550A0501|56 63|78C1 site
P08910550A0501|76 79|EGTA
P08910550A0501|83 86|EDTA
P08910550A0501|93 115|divalent cation chelators
P08910550A0501|137 162|78C1-directed transcription
P08910567A2269|3 19|human gene fragment
P08910567A2269|32 65|minimal rat liver glucokinase promoter
P08910567A2269|39 57|rat liver glucokinase
P08910567A2269|84 91|enhancer
P08910567A2269|97 124|hepatocyte transfection system
P08912232A0260|15 16|ML
P08912232A0260|19 39|human reproductive axis
P08912232A0260|44 58|healthy children
P08912232A0260|62 65|boys
P08912232A0260|71 75|girls
P08912807A0411|20 31|deer receptor
P08912807A0411|44 68|C-terminal tyrosine residue
P08912807A0411|74 92|intracellular domain
P08912807A0411|124 133|activation
P08912807A0411|139 157|beta-casein promoter
P08913186A0431|18 32|further evidence
P08913186A0431|39 43|riMLF
P08913186A0431|58 65|downgaze
P08913186A0431|71 80|synkinesis
P08913186A0431|115 144|convergence retraction nystagmus
P08913387A1010|0 8|Rifabutin
P08913387A1010|12 30|substantial efficacy
P08913387A1010|47 57|other agents
P08913974A0533|11 17|percent
P08913974A0533|23 25|EPs
P08913974A0533|30 34|tubal
P08913974A0533|41 41|%
P08913974A0533|47 51|tubes
P08913974A0533|65 81|pathologic changes
P08913974A0533|92 109|chronic salpingitis
P08913974A0533|115 115|%
P08913974A0533|120 140|follicular salpingitis
P08913974A0533|144 144|%
P08914388A1645|19 19|H
P08914388A1645|21 32|liquid medium
P08914388A1645|38 49|former author
P08914388A1645|65 80|potent activities
P08914388A1645|87 93|CS-940*
P08914388A1645|97 108|sparfloxacin
P08914388A1645|110 113|SPFX
P08914388A1645|126 133|AM-1155*
P08914388A1645|135 147|ciprofloxacin
P08914388A1645|149 152|CPFX
P08914388A1645|155 166|levofloxacin
P08914388A1645|168 171|LVFX
P08914388A1645|174 183|OPC-17116*
P08914388A1645|185 190|NM-394
P08914522A0118|3 11|STE20 gene
P08914522A0118|22 34|protein kinase
P08914522A0118|46 72|pheromone signal transduction
P08914522A0118|102 114|genetic screen
P08914522A0118|118 144|high-gene-dosage suppressors
P08914522A0118|118 126|high-gene
P08914522A0118|154 175|defective G beta mutation
P08914532A0598|4 9|enzyme
P08914532A0598|30 64|beta-xylan endohydrolase isoenzyme X-I
P08915051T0000|0 23|Magnetic resonance imaging
P08915051T0000|26 46|coccidioidal arthritis
P08915508A0000|0 25|Moloney murine leukemia virus
P08915508A0000|27 30|MMLV
P08915508A0000|40 70|pUCMoTiN-based retroviral vectors
P08915508A0000|92 103|constitutive
P08915508A0000|107 109|Tat
P08915508A0000|111 125|trans-activator
P08915508A0000|128 140|transcription
P08915508A0000|143 161|inducible expression
P08915508A0000|168 186|hammerhead ribozymes
P08915508A0000|217 225|sequences
P08915508A0000|235 246|group antigen
P08915508A0000|248 250|Gag
P08915508A0000|253 260|protease
P08915508A0000|267 286|reverse transcriptase
P08915508A0000|288 289|RT
P08915508A0000|292 294|tat
P08915508A0000|299 306|envelope
P08915508A0000|308 310|Env
P08915508A0000|312 324|coding regions
P08915508A0000|327 358|human immunodeficiency virus type-1
P08915508A0000|360 364|HIV-1
P08915508A0000|366 368|RNA
P08915559A0366|0 18|REM sleep deprivation
P08915559A0366|39 55|platform technique
P08916928A0950|3 13|same ligands
P08916928A0950|26 48|similar inhibitory effect
P08916928A0950|51 67|PDGF-BB-dependent
P08916928A0950|51 57|PDGF-BB
P08916928A0950|69 70|3H
P08916928A0950|72 93|thymidine incorporation
P08916928A0950|96 103|PAE cells
P08916928A0950|117 134|PDGF beta-receptors
P08916960A0350|10 30|serial biopsy specimens
P08916960A0350|40 47|patients
P08916960A0350|52 53|FL
P08916960A0350|57 76|secondary alterations
P08916960A0350|92 100|bcl-2 gene
P08916960A0350|106 115|breakpoint
P08916960A0350|119 134|open reading frame
P08916960A0350|136 138|ORF
P08916960A0350|140 146|regions
P08916960A1331|10 14|cases
P08916960A1331|23 24|FL
P08916960A1331|28 35|DLL cells
P08916960A1331|42 52|alterations
P08916960A1331|55 72|bcl-2 gene sequences
P08916960A1331|78 93|breakpoint region
P08916960A1331|105 120|high conservation
P08916960A1331|126 134|bcl-2 gene
P08916960A1331|145 145|t
P08916960A1331|153 165|translocation
P08916960A1331|169 193|morphologic transformation
P08916960A1331|199 205|FL cells
P08917270A0229|0 9|BACKGROUND
P08917270A0229|14 31|Bazett-corrected QT
P08917270A0229|33 35|QTc
P08917270A0229|82 96|ischemic disease
P08917270A0229|98 120|arrhythmogenic substrate
P08917270A0229|127 140|long QT syndrome
P08917435A0481|2 14|essential role
P08917435A0481|17 21|c-Jun
P08917435A0481|25 29|c-Fos
P08917435A0481|32 36|basal
P08917435A0481|40 66|PMA-stimulated transcription
P08917435A0481|72 80|PAI-1 gene
P08917435A0481|111 124|antisense c-jun
P08917435A0481|128 153|c-fos oligodeoxynucleotides
P08917435A0481|128 132|c-fos
P08917435A0481|173 177|basal
P08917435A0481|181 208|PMA-stimulated PAI-1 synthesis
P08917435A0481|195 199|PAI-1
P08917449A0000|0 24|Leukemia-inhibitory factor
P08917449A0000|26 28|LIF
P08917449A0000|33 48|neuropoietin able
P08917449A0000|33 44|neuropoietin
P08917449A0000|62 76|differentiation
P08917449A0000|93 105|many cell types
P08917449A0000|123 141|neuronal populations
P08917696A0485|23 39|fos/jun activation
P08917696A0485|42 45|TCDD
P08917696A0485|56 83|electrophoretic mobility shift
P08917696A0485|87 111|transient expression assays
P08917696A0485|114 135|reporter gene constructs
P08917696A0485|146 161|response elements
P08917696A0485|165 201|12-O-tetradecanoyl-phorbol-13-acetate
P08917696A0485|203 205|TRE
P08917696A0485|208 212|serum
P08917696A0485|214 216|SRE
P08917696A0485|219 222|cAMP
P08917696A0485|224 226|CRE
P08917696A0485|232 251|aromatic hydrocarbons
P08917696A0485|253 256|AhRE
P08917696A0485|265 267|fos
P08917696A0485|271 278|jun genes
P08917696A0485|289 309|firefly luciferase gene
P08917696A0485|330 348|SV40 minimal promoter
P08918456A0455|3 17|optimal sequence
P08918456A0455|36 38|mu 2
P08918456A0455|36 37|mu
P08918456A0455|46 49|AP-2
P08918456A0455|53 60|tyrosine
P08918456A0455|65 70|anchor
P08918456A0455|81 88|arginine
P08918456A0455|91 99|position Y
P08918456A0455|105 111|leucine
P08918456A0455|114 122|position Y
P08918464A0225|0 32|STK/RON-expressing Ba/F3 pro-B cells
P08918464A0225|0 2|STK
P08918464A0225|4 6|RON
P08918464A0225|18 19|Ba
P08918464A0225|34 40|BaF/STK
P08918464A0225|34 36|BaF
P08918464A0225|38 40|STK
P08918464A0225|51 69|MSP-dependent growth
P08918464A0225|78 80|STK
P08918464A0225|82 121|RON-expressing mouse erythroleukaemia cells
P08918464A0225|82 84|RON
P08918464A0225|123 125|MEL
P08918464A0225|127 129|STK
P08918464A0225|140 159|MSP-induced apoptosis
P08918810A0967|7 12|DNase I
P08918810A0967|7 11|DNase
P08918810A0967|13 24|footprinting
P08918810A0967|35 44|OxyR-C199S
P08918810A0967|54 57|Pmom
P08918810A0967|76 84|top strand
P08918810A0967|97 127|protection pattern characteristic
P08918810A0967|137 149|wild-type OxyR
P08918885A0811|0 3|Kss1
P08918885A0811|24 37|GST-Dig1 fusion
P08918885A0811|55 71|other yeast protein
P08918885A1087|11 23|dig1 dig2 cells
P08918885A1087|11 14|dig1
P08918885A1087|15 18|dig2
P08918885A1087|44 53|agar medium
P08918885A1087|63 87|dig1 dig2 ste12 triple mutant
P08918885A1087|63 66|dig1
P08918885A1087|67 70|dig2
P08918885A1087|71 75|ste12
P08918885A1087|110 113|Dig1
P08918885A1087|117 120|Dig2
P08918885A1087|156 176|invasive growth pathway
P08918918T0000|0 18|Paracrine activation
P08918918T0000|24 39|HIV-1 LTR promoter
P08918918T0000|45 59|viral Tat protein
P08918918T0000|86 101|trans-activation
P08918934A0424|0 9|Comparison
P08918934A0424|15 23|sequences
P08918934A0424|29 46|xFxFG repeat regions
P08918934A0424|49 51|p62
P08918934A0424|55 59|Nsplp
P08918934A0424|73 76|NTF2
P08918934A0424|106 133|phenylalanine-containing core
P08918934A0424|141 147|repeats
P08918934A0424|168 185|hydrophilic linkers
P08919289A0402|9 19|first report
P08919289A0402|25 43|successful resection
P08919289A0402|47 49|MFH
P08919289A0402|66 84|renal capsular tissue
P08919289A0402|104 119|inferior vena cava
P08919907A0763|0 18|Transient expression
P08919907A0763|21 25|VSF-1
P08919907A0763|28 38|protoplasts
P08919907A0763|49 71|vs-1 dependent activation
P08919907A0763|87 101|minimal promoter
P08919986A1262|16 27|limited range
P08919986A1262|36 42|dosages
P08919986A1262|44 53|advantages
P08919986A1262|57 69|disadvantages
P08919986A1262|104 122|experimental results
P08920499A0164|0 22|Blood sampling procedures
P08921387A1182|0 7|Analysis
P08921387A1182|13 16|cDNA
P08921387A1182|27 46|unusual splicing event
P08921387A1182|56 59|EZH1
P08921387A1182|78 85|gene GPR2
P08921387A1182|98 115|potential mechanism
P08921387A1182|131 141|EZH1 protein
P08921387A1182|156 171|C-terminal domain
P08921667A0294|1 26|given standard input function
P08921667A0294|43 60|distribution volume
P08921667A0294|62 63|Vd
P08921667A0294|75 89|rCBF measurement
P08921667A0294|123 134|dynamic study
P08921667A0294|140 155|normal volunteers
P08921865A1293|33 34|ss
P08921865A1293|36 50|DNA binding motif
P08921865A1293|66 87|large terminase proteins
P08921865A1293|90 95|T4 gp17
P08921865A1293|134 145|ssDNA regions
P08921865A1293|173 177|T4DNA
P08922344A1539|22 41|normotensive subjects
P08922344A1539|43 50|uric acid
P08922344A1539|54 68|xanthine oxidase
P08922344A1539|73 94|significant association
P08922344A1539|99 111|blood pressure
P08922344A1539|130 140|many factors
P08922344A1539|177 188|hypertension
P08922384A0466|0 13|Immunoblotting
P08922384A0466|25 43|recombinant proteins
P08922384A0466|51 71|monoclonal 08L antibody
P08922384A0466|84 93|08L epitope
P08922384A0466|99 109|carboxyl end
P08922385A0622|14 39|dominant negative inhibition
P08922385A0622|55 71|direct proteolysis
P08922385A0622|77 102|beta-galactosidase tetramer
P08922385A0622|108 120|fusion subunit
P08922385A0622|124 129|detour
P08922385A0622|135 142|tetramer
P08922385A0622|148 155|lysosome
P08922390A0361|3 14|current study
P08922390A0361|25 32|vinculin
P08922390A0361|37 58|FAK-interaction domains
P08922390A0361|61 68|paxillin
P08922390A0361|85 114|principal paxillin focal adhesion
P08922390A0361|94 101|paxillin
P08922390A0361|124 128|motif
P08922390A0793|34 50|single binding site
P08922390A0793|54 61|vinculin
P08922390A0793|83 87|sites
P08922390A0793|91 93|FAK
P08922390A0793|137 146|amino acids
P08922390A2076|24 31|paxillin
P08922390A2076|43 67|focal adhesions independent
P08922390A2076|70 81|interactions
P08922390A2076|86 93|vinculin
P08922390A2076|100 102|FAK
P08922390A2076|120 147|first definitive demonstration
P08922390A2076|150 159|LIM domains
P08922390A2076|174 191|primary determinant
P08922390A2076|194 223|protein subcellular localization
P08922390A2076|226 239|focal adhesions
P08922391A0304|1 33|single protease-resistant structure
P08922391A0304|45 52|entirety
P08922391A0304|59 68|PDZ repeats
P08922391A0304|75 80|PDZ1-2
P08922391A0304|93 114|protein 4.1-binding site
P08922488A0187|0 12|Several agents
P08922488A0187|53 68|toxic side effects
P08923258A0353|0 6|Jerseys
P08923258A0353|10 38|higher hepatic Cu concentrations
P08923258A0353|46 54|Holsteins
P08923258A0353|57 57|d
P08923460A0565|0 9|RUSH-1 beta
P08923460A0565|13 18|95-kDa
P08923460A0565|37 47|RUSH-1 alpha
P08923460A0565|63 81|alternative splicing
P08923460A0565|85 93|57-bp exon
P08923460A0565|107 120|genomic cloning
P08923469A1391|5 11|results
P08923469A1391|47 54|polarity
P08923469A1391|57 77|RXR heterodimer binding
P08923469A1391|57 59|RXR
P08923469A1391|80 111|bipartite hormone response elements
P08923469A1391|120 122|VDR
P08923469A1391|140 151|half-element
P08923470A0458|0 18|PPAR gamma mRNA levels
P08923470A0458|0 12|PPAR gamma mRNA
P08923470A0458|34 34|%
P08923470A0458|40 58|nM TNF alpha treatment
P08923470A0458|42 49|TNF alpha
P08923470A0458|64 65|h.
P08924211A0941|0 4|Exons
P08924211A0941|48 65|untranslated region
P08924211A0941|90 94|types
P08924211A0941|97 99|PST
P08924211A0941|102 109|AST cDNAs
P08924381T0000|0 11|Growth factor
P08924381T0000|18 47|effective dose-intensive regimen
P08924381T0000|50 77|advanced breast cancer patients
P08925545T0001|0 24|Recombinant erythropoietin
P08925545T0001|26 32|r-HuEPO
P08925545T0001|50 55|anemia
P08925545T0001|58 72|multiple myeloma
P08927169A0178|29 36|body lice
P08927169A0178|52 56|times
P08927169A0178|61 68|patients
P08927169A0178|96 117|Community Health Service
P08927169A0178|120 126|Utrecht
P08927612T0000|0 5|Ki-ras
P08927612T0000|9 20|p53 mutations
P08927612T0000|9 11|p53
P08927612T0000|23 52|pancreatic ductal adenocarcinoma
P08927841A0053|0 18|Epidemiological data
P08927841A0053|43 53|sudden death
P08927841A0053|99 112|rare occurrence
P08929089A0231|11 19|ratio M/Pc
P08929089A0231|29 39|useful index
P08929089A0231|69 83|metabolic demand
P08929563T0000|0 15|Rat liver catalase
P08929563T0000|26 36|peroxisomes
P08929563T0000|42 72|C-terminal tripeptide Ala-Asn-Leu
P08929563T0000|82 105|internal Ser-Lys-Leu motif
P08931388A0806|3 20|mobility shift assay
P08931388A0806|28 29|bp
P08931388A0806|53 66|nuclear extract
P08931388A0806|74 91|dark-adapted sample
P08931388A0806|100 113|additional band
P08931388A0806|129 145|light-grown sample
P08931991A1026|16 29|strong evidence
P08931991A1026|34 36|E2F
P08931991A1026|41 70|E2F-related transcription factor
P08931991A1026|98 122|nonmuscle myosin expression
P08931991A1026|98 112|nonmuscle myosin
P08932363A0807|7 19|E1A N-terminus
P08932363A0807|41 61|squelshing experiments
P08932363A0807|73 93|CBP-induced activation
P08932363A0807|73 75|CBP
P08932363A0807|96 103|E2F1/DP1
P08932363A0807|96 99|E2F1
P08932363A0807|101 103|DP1
P08932363A0807|114 122|E1A mutant
P08932363A0807|130 146|CBP binding ability
P08932363A0807|130 132|CBP
P08932385T0000|0 15|Small Maf proteins
P08932385T0000|31 70|human transcription factor TCF11/Nrf1/LCR-F
P08932385T0000|31 54|human transcription factor
P08932385T0000|55 59|TCF11
P08932385T0000|61 64|Nrf1
P08932385T0000|66 71|LCR-F1
P08933487A0325|5 22|third occasion water
P08933487A0325|24 24|W
P08933640A0000|11 27|maternal ingestion
P08933640A0000|40 64|energy sweetener erythritol
P08933640A0000|82 84|KBL
P08933640A0000|86 108|JW strain pregnant rabbits
P08934533A0784|12 24|same mutations
P08934533A0784|44 47|junB
P08934533A0784|50 60|flanking DNA
P08934533A0784|67 75|chromatin
P08934540A0673|3 9|nm23-H1
P08934540A0673|11 49|nm23-H2 gene transcriptional activity ratio
P08934540A0673|11 21|nm23-H2 gene
P08934540A0673|70 77|cell line
P08935931A0787|0 9|CONCLUSION
P08935931A0787|11 43|Intravenous diazepam administration
P08935931A0787|50 52|EGD
P08935931A0787|62 76|significant fall
P08935931A0787|79 82|SpO2
P08935931A0787|123 142|continuous monitoring
P08935931A0787|145 148|SpO2
P08935931A0787|167 169|EGD
P08935991A0844|3 29|nucleotide sequence alignment
P08935991A0844|45 51|human CA
P08935991A0844|54 58|shows
P08935991A0844|61 69|% identity
P08935991A0844|98 118|exon-intron boundaries
P08935991A0844|140 144|sizes
P08935991A0844|150 156|introns
P08936128A0611|0 10|Discordance
P08936128A0611|16 28|cost dimension
P08936128A0611|53 55|G Hb
P08936128A0611|67 87|better glycemic control
P08936128A0611|92 110|greater disagreement
P08936640A0105|0 10|DATA SOURCES
P08936640A0105|12 31|Epidemiologic studies
P08936640A0105|33 47|research studies
P08936640A0105|49 62|review articles
P08936640A0105|67 83|government reports
P08936640A0105|96 107|epidemiology
P08936640A0105|110 119|lung cancer
P08937112A0561|0 6|RESULTS
P08937112A0561|11 25|age distribution
P08937112A0561|35 42|years old
P08937112A0561|55 59|years
P08937631A1223|0 18|Histological changes
P08937631A1223|29 50|cortical cell involution
P08937631A1223|54 63|hemorrhage
P08937631A1223|82 95|neonatal period
P08937631A1223|112 127|crucial relevance
P08937631A1223|133 142|remodeling
P08937631A1223|148 165|adrenal vasculature
P08937981A0840|12 24|co-expression
P08937981A0840|31 33|p46
P08937981A0840|37 47|p54 subunits
P08937981A0840|66 88|subcellular distribution
P08937981A0840|91 93|p46
P08937981A0840|107 109|p46
P08937981A0840|131 137|nucleus
P08937981A0840|153 155|p54
P08937989A1365|3 9|results
P08937989A1365|37 37|N
P08937989A1365|42 58|C-terminal regions
P08937989A1365|61 65|talin
P08937989A1365|70 74|actin
P08937989A1365|79 88|properties
P08937989A1365|99 105|regions
P08938418A0099|0 3|Merr
P08938418A0099|6 18|embryo library
P08938420A0862|3 14|accumulation
P08938420A0862|21 24|LHA4
P08938420A0862|28 36|LHA2 mRNAs
P08938420A0862|61 75|exogenous sugars
P08938420A0862|83 91|induction
P08938420A0862|114 124|sugar uptake
P08938420A0862|128 137|metabolism
P08938420A0862|146 153|mannitol
P08938420A0862|157 173|3-O-methylglucose
P08938420A0862|188 203|mRNA accumulation
P08939891A0285|8 28|yeast one-hybrid screen
P08939891A0285|43 45|NRE
P08939891A0285|49 59|flanking DNA
P08939891A0285|62 65|bait
P08939891A0285|70 85|predominant clone
P08939891A0285|97 105|bovine Nrl
P08939891A0285|103 105|Nrl
P08939966A0816|11 26|protein synthesis
P08939966A0816|42 58|late embryogenesis
P08939966A0816|60 65|levels
P08939966A0816|68 72|SEC-1
P08939966A0816|79 96|cognate mRNA decline
P08940132A1120|5 12|findings
P08940132A1120|24 40|fodrin proteolysis
P08940132A1120|24 29|fodrin
P08940132A1120|70 84|multiple ICE/Ced
P08940132A1120|78 95|ICE/Ced-3 proteases
P08940132A1120|87 95|proteases
P08940132A1120|101 118|partial sensitivity
P08940132A1120|121 128|DEVD-CHO
P08940132A1120|138 156|limited contribution
P08940132A1120|161 165|CPP32
P08940132A1120|171 187|ICE/Ced-3 protease
P08940132A1120|171 177|ICE/Ced
P08940132A1120|180 187|protease
P08940132A1120|205 209|CPP32
P08940132A1120|212 229|DEVD-CHO inhibition
P08940134A0705|2 4|3Y1
P08940134A0705|8 38|3Y1 v-crk-transformed fibroblasts
P08940134A0705|11 15|v-crk
P08940134A0705|54 63|total PTP1B
P08940134A0705|59 63|PTP1B
P08940134A0705|74 74|%
P08940134A0705|77 85|total p130
P08940134A0705|82 85|p130
P08940134A0705|87 89|Cas
P08940134A0705|91 101|co-sediment
P08940134A0705|106 114|membranes
P08940134A0705|134 153|endoplasmic reticulum
P08940298A0962|9 16|residues
P08940298A0962|26 33|delta419
P08940298A0962|50 59|AF-2 domain
P08940298A0962|67 83|vitamin D3 receptor
P08940298A0962|89 104|estrogen receptor
P08940298A0962|115 122|receptor
P08940298A0962|127 135|wild-type
P08940298A0962|138 163|low transcriptional activity
P08942999T0000|0 26|Recurrent G-to-A substitution
P08942999T0000|30 40|single codon
P08942999T0000|43 73|SREBP cleavage-activating protein
P08942999T0000|80 95|sterol resistance
P08942999T0000|103 136|mutant Chinese hamster ovary cell lines
P08943032A0000|3 30|Escherichia coli tet-repressor
P08943032A0000|18 30|tet-repressor
P08943032A0000|32 35|TetR
P08943032A0000|37 50|operator system
P08943032A0000|82 101|yeast two-hybrid assay
P08943032A0000|109 119|disruptions
P08943032A0000|122 148|protein-protein interactions
P08943032A0000|122 136|protein-protein
P08943032A0000|167 183|positive selection
P08943354A0295|0 12|Recent studies
P08943354A0295|30 34|SHP-1
P08943354A0295|57 80|Jak family tyrosine kinases
P08943354A0295|94 116|constitutive association
P08943354A0295|124 133|Tyk2 kinase
P08943354A0295|140 159|hyperphosphorylation
P08943354A0295|162 171|Jak kinases
P08943354A0295|177 190|motheaten cells
P08943354A0295|199 213|functional SHP-1
P08943354A0295|209 213|SHP-1
P08943928A1137|0 13|Administration
P08943928A1137|17 26|second dose
P08943928A1137|45 52|outbreak
P08943934A0604|6 14|Theriault
P08943934A0604|24 35|improvements
P08943934A0604|87 104|consistent findings
P08944755A0211|0 3|Biol
P08945479T0000|0 14|Structural basis
P08945479T0000|18 27|activation
P08945479T0000|30 53|human lymphocyte kinase Lck
P08945479T0000|30 50|human lymphocyte kinase
P08945479T0000|51 53|Lck
P08945479T0000|58 80|tyrosine phosphorylation
P08945810T0001|0 18|Evolutive morphology
P08945810T0001|24 36|olfactory bulb
P08945810T0001|45 67|certain non-human mammals
P08946166A0568|9 15|results
P08946166A0568|36 38|ORF
P08946166A0568|44 51|FRDS gene
P08946668A0077|0 4|FK506
P08946668A0077|24 29|potent
P08946668A0077|34 45|cyclosporin A
P08946668A0077|58 71|organ rejection
P08946668A0077|77 84|toxicity
P08947028A0992|5 11|results
P08947028A0992|23 27|Rho1p
P08947028A0992|37 62|cytoskeletal reorganization
P08947028A0992|77 81|Bni1p
P08947028A0992|85 89|Pkc1p
P08948440A0628|3 22|ERH expression profile
P08948440A0628|3 5|ERH
P08948440A0628|41 43|An3
P08948440A0628|64 79|animal hemisphere
P08948440A0628|82 88|oocytes
P08948440A0628|118 123|embryo
P08950144A0172|0 6|Waves N1
P08950144A0172|8 9|P3
P08950144A0172|13 15|CNV
P08950144A0172|35 45|CNV paradigm
P08950144A0172|49 70|simple reaction time task
P08950144A0172|76 104|constant interstimulus interval
P08950144A0172|106 108|ISI
P08950144A0172|113 115|sec
P08950352A0525|17 23|Chilean
P08950352A0525|30 44|Japanese samples
P08950352A0525|56 69|high-risk areas
P08950352A0525|76 95|higher mutagenic rates
P08950352A0525|103 114|Japanese ones
P08950352A0525|118 129|low-risk area
P08950352A0525|136 158|statistical significance
P08950352A0525|160 160|p
P08950352A0525|169 182|chi-square test
P08951815A0465|0 9|Regulation
P08951815A0465|12 15|ASN1
P08951815A0465|19 32|ASN2 expression
P08951815A0465|19 22|ASN2
P08951815A0465|48 58|lacZ fusions
P08951815A0465|66 70|genes
P08951815A0465|84 95|several times
P08951815A0465|126 152|transcription activator Gcn4p
P08951815A0465|148 152|Gcn4p
P08952483A0207|0 24|Several particular features
P08952483A0207|31 49|polypeptide fragment
P08952483A0207|57 83|hamster lysyl-tRNA synthetase
P08952483A0207|128 133|enzyme
P08952483A0207|143 164|multisynthetase complex
P08952796A0743|13 17|years
P08952796A0743|23 29|relapse
P08952965A1182|0 9|Comparison
P08952965A1182|27 39|nonsynonymous
P08952965A1182|41 42|pN
P08952965A1182|47 56|synonymous
P08952965A1182|58 59|pS
P08952965A1182|61 73|substitutions
P08952965A1182|96 121|tamarin variable region genes
P08952965A1182|146 147|pN
P08952965A1182|153 168|framework regions
P08952965A1182|181 182|pN
P08952965A1182|188 212|presumed MHC contact regions
P08952965A1182|196 212|MHC contact regions
P08952965A1182|214 217|CDR1
P08952965A1182|221 224|CDR2
P08953340A0000|3 9|effects
P08953340A0000|12 29|oral vanadyl sulfate
P08953340A0000|31 35|VOSO4
P08953340A0000|41 49|mg/kg/day
P08953340A0000|53 65|anthropometry
P08953340A0000|67 81|body composition
P08953340A0000|116 122|12-week
P08953340A0000|124 135|double-blind
P08953340A0000|137 159|placebo-controlled trial
P08953340A0000|169 193|weight-training volunteers
P08954725A1175|19 32|Tbx6 expression
P08954725A1175|19 22|Tbx6
P08954725A1175|35 44|restricted
P08954725A1175|47 56|presomitic
P08954725A1175|58 73|paraxial mesoderm
P08954725A1175|82 88|tail bud
P08954725A1175|125 132|mesoderm
P08955071T0000|0 9|Disruption
P08955071T0000|12 32|re-replication control
P08955071T0000|35 48|overexpression
P08955071T0000|51 59|human ORC1
P08955071T0000|62 73|fission yeast
P08955111A0989|3 9|results
P08955111A0989|28 35|promoter
P08955111A0989|39 53|enhancer regions
P08955111A0989|97 121|efficient promoter activity
P08955111A0989|127 154|human activin betaA subunit gene
P08955136A0606|0 10|Recombinant
P08955136A0606|32 42|PIP5KIalpha
P08955136A0606|52 64|PIP5K activity
P08955136A0606|52 56|PIP5K
P08955136A0606|71 84|immunoreactive
P08955136A0606|89 113|erythroid PIP5KI antibodies
P08955159A0000|0 18|Human acid ceramidase
P08955159A0000|21 22|AC
P08955159A0000|24 54|N-acylsphingosine amidohydrolase
P08955159A0000|56 57|EC
P08955189A1198|3 27|0.22-kb NheI/BglII promoter
P08955189A1198|10 13|NheI
P08955189A1198|15 19|BglII
P08955189A1198|37 51|PMA inducibility
P08955189A1198|54 65|myeloid cells
P08955189A1198|79 99|PMA-responsive element
P08955189A1198|112 114|Sp1
P08955189A1198|118 142|EGR-1 transcription factors
P08955306A0224|0 7|Northern
P08955306A0224|9 11|RNA
P08955306A0224|13 24|blot analyses
P08955306A0224|41 48|cdh genes
P08955306A0224|64 71|subunits
P08955306A0224|77 92|open reading frame
P08955306A0224|94 97|ORF1
P08955306A0224|103 117|unknown function
P08955306A0224|148 154|acetate
P08955402A0288|3 9|classes
P08955402A0288|12 20|mutations
P08955402A0288|70 73|HOL1
P08955402A0288|103 112|histidinol
P08955402A0288|121 139|cis-acting mutations
P08955402A0288|152 173|mutant HOL1-1 background
P08955402A0288|158 163|HOL1-1
P08955402A0288|203 213|Hol1 protein
P08955928A0390|0 5|Damage
P08955928A0390|11 13|BBB
P08955928A0390|25 37|extravasation
P08955928A0390|40 48|Evans Blue
P08955928A0390|50 51|EB
P08955928A0390|93 93|h
P08955928A0390|99 103|onset
P08955928A0390|106 109|MCAo
P08958137A0534|0 23|Lipid hydroperoxide levels
P08958137A0534|26 31|plasma
P08958137A0534|35 37|LDL
P08958137A0534|46 54|unchanged
P08958720A1204|26 32|maximal
P08958720A1204|34 37|mPAP
P08958720A1204|52 54|SVI
P08958720A1204|65 66|HR
P08958720A1204|70 78|unchanged
P08958720A1204|83 84|CO
P08958720A1204|88 90|VO2
P08959062A0372|15 24|vasculitis
P08959062A0372|26 34|cutaneous
P08959062A0372|38 47|neurologic
P08959062A0372|74 95|selective immunodeficit
P08959062A0372|103 105|EBV
P08959062A0372|116 122|Purtilo
P08959117A0708|18 42|potential endocrine changes
P08959117A0708|55 69|acute hypoxaemia
P08959117A0708|99 118|unspecific influences
P08959117A0708|135 144|ICU setting
P08959117A0708|149 160|measurements
P08959117A0708|193 213|healthy reference group
P08959117A0708|215 217|REF
P08959117A0708|223 259|comparable acute experimental hypoxaemia
P08959778A0292|11 32|significant differences
P08959778A0292|35 47|graft survival
P08959778A0292|55 60|groups
P08959778A0292|65 82|early graft function
P08959778A0292|84 86|EGF
P08959778A0292|91 93|DGF
P08959778A0292|103 123|first transplantations
P08959778A0292|126 143|retransplantations
P08960827A1169|5 11|results
P08960827A1169|28 35|GG motifs
P08960827A1169|52 77|cell-specific transcription
P08960827A1169|83 98|human insulin gene
P08960827A1169|119 125|binding
P08960827A1169|131 160|sequence-specific nuclear factor
P08961873T0000|0 34|Abnormal urinary coproporphyrin levels
P08961873T0000|37 44|patients
P08961873T0000|55 69|hepatitis C virus
P08961873T0000|83 108|human immunodeficiency virus
P08962614A0000|18 32|immunoglobulin E
P08962614A0000|34 36|IgE
P08962614A0000|38 47|antibodies
P08962614A0000|55 76|several laboratory tests
P08962614A0000|80 94|skin-prick tests
P08962614A0000|99 128|appropriate challenge procedures
P08962614A0000|153 169|atopic individuals
P08962614A0000|174 190|outcome predictors
P08962614A0000|193 206|wheezy children
P08964067A0188|0 9|Thrombosis
P08964067A0188|15 23|renal vein
P08964067A0188|47 58|renal failure
P08964172A0221|0 5|Filter
P08964172A0221|9 34|cytocentrifuge preparations
P08964172A0221|40 44|urine
P08964172A0221|62 66|cases
P08964172A0221|93 102|aggregates
P08964172A0221|105 120|single tumor cells
P08964172A0221|125 146|inflammatory background
P08967870A0000|9 17|protocols
P08967870A0000|20 41|postmortem examinations
P08967870A0000|46 61|Moscow hospitals N
P08967963A1735|3 17|promoter segment
P08967963A1735|21 28|inactive
P08967963A1735|50 70|rat glioma cell line C6B4
P08967963A1735|75 105|rat submandibular cell line RSMT-A5
P08967963A1735|113 144|rat pancreatic beta cell line RIN-5AH
P08967963A1735|171 194|endogenous alpha2c-AR gene
P08967963A1735|181 194|alpha2c-AR gene
P08969495A0256|3 12|sequencing
P08969495A0256|18 48|conditional lethal mutation ts-A13
P08969495A0256|50 58|localized
P08969495A0256|64 74|nrdE cistron
P08969495A0256|82 90|lethality
P08969495A0256|93 112|insertional mutations
P08969495A0256|126 139|internal region
P08969495A0256|142 145|nrdE
P08969495A0256|149 152|nrdF
P08969495A0256|169 181|essential role
P08969495A0256|188 192|locus
P08969777A0771|3 26|microdensitometric scores
P08969777A0771|35 57|side-to-side differences
P08969777A0771|60 67|patients
P08969777A0771|95 118|serum 25-OHD concentration
P08969777A0771|147 155|paralysis
P08970352A0880|29 31|LDD
P08970352A0880|46 56|progression
P08970352A0880|59 62|MSOF
P08970352A0880|65 70|sepsis
P08970951A0823|25 30|levels
P08970951A0823|41 58|hepatitis B e antigen
P08970951A0823|41 50|hepatitis B
P08970951A0823|52 58|antigen
P08970951A0823|71 89|intracellular levels
P08970951A0823|99 109|Pol proteins
P08970951A0823|113 142|replicative HBV DNA intermediates
P08970979A1246|11 18|extracts
P08970979A1246|24 36|mutant virions
P08970979A1246|48 61|wild-type level
P08970979A1246|64 76|transcription
P08970979A1246|83 99|exogenous template
P08970979A1246|112 124|early promoter
P08970984A0765|3 14|SCMV SNE sites
P08970984A0765|42 69|core recognition binding motifs
P08970984A0765|73 75|SRF
P08970984A0765|77 88|Rel/NFkappaB
P08970984A0765|77 79|Rel
P08970984A0765|81 88|NFkappaB
P08970984A0765|90 92|ETS
P08970984A0765|97 124|YY1 class transcription factors
P08970984A0765|149 153|serum
P08970984A0765|156 179|tumor necrosis factor alpha
P08970991A0747|4 18|serum withdrawal
P08970991A0747|24 44|permissive temperature
P08970991A0747|46 66|p53-mediated apoptosis
P08970991A0747|46 48|p53
P08970991A0747|85 85|%
P08970991A0747|91 95|cells
P08971009A0860|25 46|simple two-step strategy
P08971009A0860|64 87|essential cis-acting sites
P08971009A0860|132 142|natural loci
P08971009A0860|145 164|large viral DNA genomes
P08971721A1314|12 29|serological studies
P08971721A1314|58 61|HspA
P08971721A1314|77 96|immunodominant domain
P08971835A1057|2 6|Group
P08971835A1057|9 12|dogs
P08971835A1057|25 33|alpha-MSH
P08971835A1057|44 54|reperfusion
P08971835A1057|56 60|BAEPs
P08971835A1057|93 97|% more
P08971835A1057|104 110|Group II
P08971835A1057|120 140|late reperfusion period
P08972182A0000|3 13|Fas receptor
P08972182A0000|23 39|signalling cascade
P08972182A0000|61 69|cell death
P08972182A0000|71 79|apoptosis
P08972182A0000|87 91|hours
P08972182A0000|94 114|receptor cross-linking
P08972182A0527|0 2|Fas
P08972182A0527|24 26|ICE
P08972182A0527|28 61|interleukin-1 beta-converting enzyme
P08972182A0527|63 77|family proteases
P08972182A0527|86 94|apoptosis
P08972182A0527|99 105|studies
P08972182A0527|118 146|cowpox ICE inhibitor protein CrmA
P08972182A0527|143 146|CrmA
P08972182A0527|151 191|synthetic tetrapeptide ICE inhibitor YVAD-CMK
P08972182A0527|172 174|ICE
P08972182A0527|184 191|YVAD-CMK
P08972182A0527|199 233|tripeptide pan-ICE inhibitor Z-VAD-FMK
P08972211A0059|3 21|imprinted expression
P08972211A0059|27 40|endogenous gene
P08972211A0059|61 64|mice
P08972211A0059|73 86|14-kb transgene
P08972211A0059|100 101|kb
P08972211A0059|107 122|flanking sequence
P08972211A0059|125 126|kb
P08972211A0059|132 147|flanking sequence
P08972211A0059|168 193|endoderm-specific enhancers
P08972211A0059|217 230|structural gene
P08972232A0365|30 34|hGCN5
P08972232A0365|43 45|HAT
P08972232A0365|55 78|same substrate specificity
P08972232A0365|81 85|yGCN5
P08973185T0061|14 30|arginine mutations
P08973185T0061|33 56|oxidative phosphorylation
P08973185T0061|60 72|AAC expression
P08973527A0000|0 16|Complementary DNAs
P08973527A0000|32 42|coat protein
P08973527A0000|52 66|adjacent regions
P08973527A0000|69 88|Agropyron mosaic virus
P08973527A0000|90 93|AgMV
P08973527A0000|98 115|Hordeum mosaic virus
P08973527A0000|117 120|HoMV
P08973630A0923|6 10|cases
P08973630A0923|12 38|factor-induced Rac activation
P08973630A0923|26 28|Rac
P08973630A0923|48 60|Rho activation
P08973630A0923|48 50|Rho
P08973630A0923|65 93|factor-induced Cdc42 activation
P08973630A0923|79 83|Cdc42
P08973630A0923|101 113|Rac activation
P08973630A0923|101 103|Rac
P08973630A0923|129 156|specific morphological changes
P08973917A0632|0 11|Several cDNAs
P08973917A0632|30 42|human PWP2 gene
P08973917T0000|0 8|Isolation
P08973917T0000|12 27|genomic structure
P08973917T0000|31 42|human homolog
P08973917T0000|48 77|yeast periodic tryptophan protein
P08973917T0000|80 83|PWP2
P08973917T0000|85 95|gene mapping
P08973917T0000|98 104|21q22.3
P08974103A0451|0 7|Patterns
P08974103A0451|17 28|combinations
P08974103A0451|40 64|abnormal laboratory results
P08974103A0451|92 94|PEM
P08974103A0451|101 105|all-2
P08974103A0451|108 119|all-0 pattern
P08974135A0052|16 23|thiamine
P08974135A0052|25 33|vitamin B1
P08974135A0052|35 44|deficiency
P08974135A0052|61 87|recurrent aphthous stomatitis
P08974135A0052|98 112|vitamin B1 levels
P08974135A0052|117 124|patients
P08974135A0052|129 155|recurrent aphthous stomatitis
P08974135A0052|163 169|members
P08974135A0052|173 184|control group
P08975532T0001|0 12|Liver injuries
P08975713A0454|12 22|cDNA library
P08975713A0454|28 32|probe
P08975713A0454|44 52|sequences
P08975713A0454|68 81|p53p2 start site
P08975713A0454|112 115|cDNA
P08975713A0454|131 134|mRNA
P08975713A0454|172 184|p53p2 promoter
P08976253A0637|42 46|serum
P08976253A0637|50 71|seminal plasma PSA levels
P08976253A0637|63 65|PSA
P08977013A0788|3 14|implications
P08977013A0788|18 26|estimates
P08977013A0788|29 49|cortical magnification
P08977013A0788|53 71|possible differences
P08977013A0788|77 91|specializations
P08977013A0788|94 99|foveal
P08977013A0788|103 118|peripheral vision
P08977235A0134|0 4|G-CSF
P08977235A0134|31 39|molecules
P08977235A0134|53 56|JAK1
P08977235A0134|60 70|JAK2 kinases
P08977235A0134|77 100|STAT transcription factors
P08977235A0588|0 6|Mutants
P08977235A0588|17 32|tyrosine residues
P08977235A0588|38 54|cytoplasmic domain
P08977235A0588|85 89|STAT5
P08977235A0588|93 97|STAT1
P08977235A0588|115 119|STAT3
P08977235A0588|133 137|STAT5
P08977235A0588|141 155|STAT1 activation
P08977235A0588|141 145|STAT1
P08977235A0588|170 200|receptor tyrosine phosphorylation
P08977401A0227|3 13|RI alpha gene
P08977401A0227|36 40|exons
P08977401A0227|50 56|lengths
P08977401A0227|69 75|introns
P08977401A0227|91 101|total length
P08977401A0227|113 114|kb
P08977401A0227|119 131|recent cloning
P08977401A0227|144 160|RI alpha pseudogene
P08977401A0227|169 192|noncoding region different
P08977401A0227|218 240|RI alpha complementary RNA
P08977401A0227|257 267|RI alpha gene
P08977401A0227|275 293|multiple leader exons
P08977401A0227|324 336|messenger RNAs
P08977401A0227|338 342|mRNAs
P08978690A0262|15 23|Rad3/Mec1
P08978690A0262|15 18|Rad3
P08978690A0262|20 23|Mec1
P08978690A0262|73 95|DNA structure checkpoints
P08978690A0262|102 118|yeast model systems
P08978817A0620|11 23|double mutants
P08978817A0620|34 43|dim1-delta
P08978817A0620|46 51|dim2-1
P08978817A0620|58 81|endocytosis mutants end4-1
P08978817A0620|69 81|mutants end4-1
P08978817A0620|84 89|act1-1
P08978817A0620|99 120|synthetic growth defects
P08978817A0620|139 153|DIM gene products
P08978817A0620|173 196|parallel endocytic pathway
P08978996A0000|22 36|hepatitis C virus
P08978996A0000|42 51|major cause
P08978996A0000|54 65|liver disease
P08978996A0000|72 87|dialysis patients
P08978996A0000|93 110|transplant patients
P08978996A0000|135 146|epidemiology
P08978996A0000|187 199|patient groups
P08979089A1197|0 17|Stable transfection
P08979089A1197|23 36|BL cell line Raji
P08979089A1197|41 50|constructs
P08979089A1197|61 81|core promoter mutations
P08979089A1197|98 112|proximal Sp1 site
P08979089A1197|106 112|Sp1 site
P08979089A1197|119 125|TATA box
P08979089A1197|144 153|activation
P08979089A1197|156 165|promoter P1
P08979089A1197|171 186|Ig kappa enhancers
P08979828A1561|0 27|Such multisensory interactions
P08980413A0500|3 5|P13
P08980413A0500|9 11|N22
P08980413A0500|14 19|ppSEPs
P08980413A0500|23 47|phase reversal relationship
P08980413A0500|55 56|P2
P08980413A0500|60 61|N2
P08980413A0500|77 79|PES
P08980522A0280|3 6|cDNA
P08980522A0280|9 12|cpm7
P08980522A0280|28 41|related protein
P08980522A0280|48 50|kDa
P08980533A1160|11 26|C-terminal region
P08980533A1160|29 33|ENBP1
P08980533A1160|39 52|strong homology
P08980533A1160|99 110|testis tissue
P08980536A1196|24 28|G-box
P08980536A1196|32 36|H-box
P08980536A1196|39 59|different CHS promoters
P08980536A1196|87 102|regulatory motifs
P08980819A0193|0 8|Mortality
P08980819A0193|14 22|last ranch
P08980819A0193|66 71|groups
P08980819A0193|74 80|turkeys
P08980819A0193|93 96|toms
P08980819A0193|98 109|heavier birds
P08980819A0193|114 118|birds
P08980819A0193|130 147|stressful event such
P08980819A0193|150 171|artificial insemination
P08981371A2049a|11 21|PIP2 content
P08981371A2049a|32 41|kDa protein
P08981371A2049a|64 77|CSF-1 treatment
P08981371A2049a|64 68|CSF-1
P08981371A2049b|11 21|PIP2 content
P08981371A2049b|32 41|kDa protein
P08981371A2049b|64 77|CSF-1 treatment
P08981371A2049b|64 68|CSF-1
P08985109A1285|24 37|anterior margin
P08985109A1285|41 44|apex
P08985109A1285|50 59|iliac crest
P08985109A1285|89 97|small cone
P08985115A1571|3 21|first identification
P08985115A1571|27 45|active 37LRP/p40 gene
P08985115A1571|33 37|37LRP
P08985115A1571|69 80|critical step
P08985115A1571|104 125|corresponding human gene
P08985115A1571|150 168|molecular mechanisms
P08985115A1571|182 194|up-regulation
P08985115A1571|216 228|tumor invasion
P08985115A1571|232 241|metastasis
P08985122A0501|3 16|promoter region
P08985122A0501|18 19|P1
P08985122A0501|39 47|main group
P08985122A0501|50 77|transcription initiation sites
P08985122A0501|80 85|devoid
P08985122A0501|88 91|TATA
P08985122A0501|95 103|CAAT boxes
P08985122A0501|110 129|putative binding sites
P08985122A0501|136 157|transcription factor SP1
P08985122A0501|174 179|large G
P08985122A0501|181 192|C-rich domain
P08985122A0501|196 204|CpG island
P08985122A0501|225 233|promoters
P08985122A0501|259 275|housekeeping genes
P08985415A1096|3 24|STAT-1 signaling pathway
P08985415A1096|3 8|STAT-1
P08985415A1096|55 64|activation
P08985415A1096|70 76|CAEV LTR
P08985415A1096|79 87|IFN-gamma
P08985415A1096|90 98|monocytes
P08986190A0927|0 10|Reperfusion
P08986190A0927|18 35|transient reduction
P08986190A0927|38 54|lactate production
P08986190A0927|59 77|significant increase
P08986190A0927|80 89|LDH release
P08986190A0927|80 82|LDH
P08986214A0000|13 39|hepatic regenerative response
P08986214A0000|42 49|patients
P08986214A0000|54 74|alcoholic liver disease
P08986214A0000|76 79|sera
P08986214A0000|87 94|patients
P08986214A0000|99 122|severe alcoholic hepatitis
P08986214A0000|129 137|cirrhosis
P08986214A0000|153 174|hepatocyte growth factor
P08986214A0000|176 178|HGF
P08986214A0000|183 199|alpha-fetoprotein
P08986214A0000|201 203|AFP
P08986228A0000|0 7|Children
P08986228A0000|16 38|chronic alcoholic mothers
P08986228A0000|48 75|behavioral teratogenic effects
P08986228A0000|94 119|morphological malformations
P08986692A0306|0 11|INTERVENTION
P08986692A0306|13 13|S
P08986692A0306|26 45|hemostasis parameters
P08986692A0306|67 74|patients
P08986692A0306|85 90|IVF-ET
P08986770A0268|31 49|I-POU/tI-POU message
P08986770A0268|31 35|I-POU
P08986770A0268|52 58|maximal
P08986770A0268|68 81|embryonic phase
P08986770A0268|109 113|I-POU
P08986770A0268|119 140|preferred splice variant
P08986812A1214|6 17|wild-type p53
P08986812A1214|22 41|delta proAE mutant cDNA
P08986812A1214|76 84|cell lines
P08986812A1214|89 118|few immediate detrimental effects
P08987009A0400|31 43|prerequisites
P08987009A0400|46 62|expressive freedom
P08987009A0400|85 97|psychoanalyst
P08987225A0675|7 22|common risk factor
P08987225A0675|50 69|other hepatitis C cases
P08987225A0675|92 98|drug use
P08987225A0675|123 127|cases
P08987225A0675|157 158|NT
P08987225A0675|163 165|ACT
P08987225A0675|169 178|Queensland
P08988257A1256|0 8|Silencing
P08988257A1256|35 42|telomere
P08988257A1256|47 48|kb
P08988257A1256|56 72|reporter construct
P08988257A1256|78 86|insertion
P08988257A1256|92 93|bp
P08988257A1256|96 123|yeast telomeric repeat sequence
P08988257A1256|141 161|chromosomal truncation
P08988913A0821|14 35|previous two-pool models
P08988913A0821|37 46|provisions
P08988913A0821|58 71|folate turnover
P08988913A0821|74 95|urinary folate excretion
P08988913A0821|117 130|fecal excretion
P08988913A0821|134 151|catabolic processes
P08989025A0359|4 22|voltage-operated Ca2
P08989025A0359|24 31|channels
P08989025A0359|33 35|VOC
P08989025A0359|50 59|nifedipine
P08989025A0359|61 69|midazolam
P08989025A0359|73 90|concentrations more
P08989025A0359|96 101|microM
P08989025A0359|117 122|phasic
P08989025A0359|126 139|tonic responses
P08989763A0605|0 15|Several artifacts
P08989763A0605|42 54|visualization
P08989763A0605|60 68|diaphragm
P08990168A0688|8 23|p48 gene induction
P08990168A0688|8 14|p48 gene
P08990168A0688|37 41|STAT1
P08990168A0688|45 48|JAK1
P08990168A0688|59 63|STAT1
P08990168A0688|77 80|GATE
P08990194A0000|25 38|thyroid hormone
P08990194A0000|56 87|elevated serum free thyroid hormones
P08990194A0000|106 134|pituitary thyrotropin secretion
P08990194A0000|106 125|pituitary thyrotropin
P08990194A0000|139 170|variable peripheral refractoriness
P08990194A0000|173 185|hormone action
P08990397A1437|8 31|nonphotosynthetic mutants
P08990397A1437|45 74|tscA-lacking photosystem I mutant
P08990397A1437|45 67|tscA-lacking photosystem
P08990397A1437|69 74|mutant
P08990397A1437|76 78|H13
P08990397A1437|100 128|light-stimulated RNA processing
P08992115A0199|3 13|progression
P08992115A0199|16 30|acute bronchitis
P08992115A0199|47 73|elevated blood concentrations
P08992115A0199|76 94|acute-phase proteins
P08992115A0199|96 108|KKS activation
P08992115A0199|96 98|KKS
P08992115A0199|122 134|high serotonin
P08992115A0199|138 154|lactic acid content
P08993393A0498|12 32|potential implications
P08993393A0498|40 47|findings
P08993393A0498|50 64|human physiology
P08993393A0498|77 88|hPACAP-R gene
P08993393T0000|0 20|Differential signaling
P08993393T0000|24 52|immediate-early gene activation
P08993393T0000|24 42|immediate-early gene
P08993393T0000|59 72|splice variants
P08993393T0000|78 137|human pituitary adenylate cyclase-activating polypeptide receptor
P08993393T0000|83 137|pituitary adenylate cyclase-activating polypeptide receptor
P08993393T0000|139 146|hPACAP-R
P08993831A0000|6 30|skeletal muscle development
P08993831A0000|32 45|different types
P08993831A0000|48 59|muscle fibers
P08993831A0000|85 105|different combinations
P08993831A0000|108 134|muscle-specific gene products
P08993836A0699|14 20|results
P08993836A0699|37 60|transcriptional induction
P08993836A0699|66 79|HNF-3 alpha gene
P08993836A0699|82 102|respiratory epithelium
P08993836A0699|109 121|embryogenesis
P08994825A0000|0 9|BACKGROUND
P08994825A0000|11 17|Mitosis
P08994825A0000|31 33|MPF
P08994825A0000|35 44|maturation
P08994825A0000|65 74|active form
P08994825A0000|77 100|Cdc2/28-cyclin B complexes
P08994825A0000|77 80|Cdc2
P08994832A0782|0 16|Ectopic expression
P08994832A0782|19 23|Apo-3
P08994832A0782|26 31|HEK293
P08994832A0782|34 42|HeLa cells
P08994832A0782|50 64|marked apoptosis
P08994968A0926|2 14|N-terminal arm
P08994968A0926|23 29|subunit
P08994968A0926|44 69|dinucleotide-binding domain
P08994968A0926|74 88|adjacent subunit
P08994968A0926|101 111|adenine ring
P08994968A0926|114 117|NADP
P08995054A0618|0 9|Similarity
P08995054A0618|29 45|zinc knuckle region
P08995054A0618|48 67|region characteristic
P08995054A0618|70 77|gag genes
P08995054A0618|80 117|most replication-competent retroelements
P08995054A1368|0 1|D.
P08995054A1368|14 18|HeT-A
P08995054A1368|25 33|sequences
P08995054A1368|39 55|polymorphic region
P08995054A1368|60 79|insertions/deletions
P08995054A1368|86 91|codons
P08995054A1368|95 115|many nucleotide changes
P08995410A0000|0 26|Eukaryotic initiation factor 3
P08995410A0000|0 25|Eukaryotic initiation factor
P08995410A0000|28 31|eIF3
P08995410A0000|36 59|large multisubunit complex
P08995410A0000|77 90|ternary complex
P08995410A0000|92 99|eIF2 x GTP
P08995410A0000|101 104|tRNA
P08995410A0000|106 108|Met
P08995410A0000|122 132|mRNA binding
P08995410A0000|140 156|S ribosomal subunit
P08995410A0000|158 161|eIF3
P08995410A0000|178 214|ribosome subunit anti-association factor
P08995410A1109|27 33|Hershey
P08995410A1109|37 46|co-workers
P08995410A1109|59 71|mammalian eIF3
P08995410A1109|93 100|subunits
P08995410A1109|102 105|p170
P08995410A1109|107 110|p116
P08995410A1109|112 116|hPrt1
P08995410A1109|119 122|p110
P08995410A1109|124 126|p66
P08995410A1109|128 130|p48
P08995410A1109|132 134|p47
P08995410A1109|136 138|p44
P08995410A1109|140 142|p40
P08995410A1109|144 146|p36
P08995410A1109|151 153|p35
P08995614T0000|0 13|Identification
P08995614T0000|17 33|cis-acting element
P08995614T0000|45 96|major histocompatibility complex gene promoter responsive
P08995614T0000|99 108|activation
P08995614T0000|111 129|retroviral sequences
P08995652A0812|3 9|results
P08995652A0812|30 42|intact capsids
P08995652A0812|63 73|full-length
P08995652A0812|97 106|C-terminal
P08995652A0812|109 118|amino acids
P08995652A0812|120 132|UL80.5 protein
P08995652A0812|154 163|C-terminal
P08995652A0812|166 175|amino acids
P08995652A0812|181 193|UL80.5 protein
P08995652A0812|213 222|C-terminal
P08995652A0812|225 234|amino acids
P08995652A0812|240 252|UL26.5 protein
P08995652A0812|254 266|intact capsids
P08995652A0812|278 294|direct interaction
P08995652A0812|300 312|UL80.5 protein
P08995652A0812|317 319|VP5
P08995652A0812|347 359|intact capsids
P08995652A0812|401 410|amino acids
P08995652A0812|416 428|UL80.5 protein
P08995652A0812|443 454|RRIFVA ALNKLE
P08995652A0812|457 468|RRIFVAAMMKLE
P08995652A0812|474 489|self-interaction
P08995652A0812|495 510|scaffold proteins
P08995652A0812|523 540|sequences N terminal
P08995652A0812|546 567|maturation cleavage site
P08995652A0812|578 583|UL26.5
P08995652A0812|587 600|UL80.5 proteins
P08995652A0812|622 639|scaffold structures
P08995659A0563|0 5|Fourth
P08995659A0563|13 33|region splice junctions
P08995659A0563|39 42|MSRs
P08995659A0563|49 54|latent
P08995659A0563|58 76|productive infection
P08995659A0563|93 117|sequencing RNA-PCR products
P08995659A0563|131 137|primers
P08995659A0563|152 163|splice region
P08995681A0518|4 8|ICP27
P08995681A0518|30 46|less modified forms
P08995681A0518|49 52|ICP4
P08996730A1146|0 3|Lack
P08996730A1146|6 19|sufficient data
P08996730A1146|22 42|vibration measurements
P08996730A1146|46 64|employment durations
P08996730A1146|89 98|variations
P08996730A1146|101 114|tool conditions
P08996730A1146|116 128|grinder wheels
P08996730A1146|137 156|inherent difficulties
P08997490A1127|0 9|C/EBP beta V
P08997490A1127|35 40|subset
P08997490A1127|43 52|C/EBP sites
P08997490A1127|64 71|DBP sites
P08997490A1127|79 94|oligonucleotides
P08997490A1127|107 121|natural contexts
P08997490A1127|127 133|albumin
P08997490A1127|137 167|cholesterol hydroxylase promoters
P08997532A0116|0 10|Specific IgG
P08997532A0116|8 10|IgG
P08997532A0116|12 22|specific IgE
P08997532A0116|20 22|IgE
P08997532A0116|26 48|total IgE immunoglobulins
P08997532A0116|31 48|IgE immunoglobulins
P08997532A0116|56 95|Toxocara canis excretory/secretory antigens
P08997532A0116|56 63|Toxocara
P08997532A0116|69 95|excretory/secretory antigens
P08997532A0116|97 99|TES
P08997532A0116|120 133|ELISA technique
P08998115A0114|0 20|SUMMARY BACKGROUND DATA
P08998115A0114|22 33|Melanoma care
P08998115A0114|71 75|years
P08998115A0114|96 123|elective lymph node dissections
P08999414A0819|3 13|differences
P08999414A0819|19 27|subgenera
P08999414A0819|33 48|genus Dermacentor
P08999857A0801|11 15|E-box
P08999857A0801|36 49|flanking region
P08999857A0801|81 91|enhancement
P08999857A0801|94 116|transcriptional activity
P08999857A0801|122 127|alpha1
P08999857A0801|131 150|collagen gene promoter
P08999882T0000|0 9|Expression
P08999882T0000|12 25|neuronal traits
P08999882T0000|28 46|pancreatic beta cells
P09000049A1341|13 15|Mnt
P09000049A1341|17 19|Max
P09000049A1341|21 33|Sin3 complexes
P09000049A1341|21 24|Sin3
P09000049A1341|60 62|Myc
P09000049A1341|64 76|Max activities
P09000049A1341|64 66|Max
P09000049A1341|91 107|cell proliferation
P09000108A0330|3 22|transcription product
P09000108A0330|28 33|kb mRNA
P09000108A0330|37 50|polyadenylated
P09000108A0330|68 108|consensus eukaryotic polyadenylation signals
P09000108A0330|121 132|bp downstream
P09000108A0330|138 164|translation termination codon
P09000108A0330|168 171|CG30
P09000146T0000|0 16|Phenotypic changes
P09000146T0000|26 33|wild type
P09000146T0000|37 53|variant c-src genes
P09000146T0000|44 48|c-src
P09000146T0000|62 90|C-terminal sequence alterations
P09000589A0000|3 12|resurgence
P09000589A0000|15 35|drug-resistant malaria
P09000589A0000|41 46|urgent
P09000589A0000|62 82|new antimalarial agents
P09000632A2341|5 14|p51 subunit
P09000632A2341|19 34|Cys181 side-chain
P09000632A2341|48 63|similar direction
P09000632A2341|69 84|Tyr181 side-chain
P09000632A2341|90 105|wild-type complex
P09001213A1111|13 34|high level transcription
P09001213A1111|59 83|polymorphic chromosome ends
P09001213A1111|86 97|P. falciparum
P09001213A1111|153 173|active expression sites
P09001213A1111|177 184|var genes
P09001245A0187|0 5|NUP145
P09001245A0187|37 64|genetic synthetic lethal screen
P09001313A0000|0 9|Prevalence
P09001313A0000|12 36|sleep-disordered breathing
P09001313A0000|38 40|SDB
P09001313A0000|64 78|menopausal women
P09001667A0312|5 9|cases
P09001667A0312|13 23|antigenemia
P09001667A0312|27 35|transient
P09001667A0312|48 70|28th day post-vaccination
P09001828A0222|12 18|men aged
P09001828A0222|25 29|years
P09001828A0222|53 61|first time
P09001828A0222|64 73|physicians
P09001828A0222|82 84|BPH
P09002648A0202|0 4|BCL-2
P09002648A0202|8 16|inhibitor
P09002648A0202|19 27|apoptosis
P09002648A0202|31 41|wide variety
P09002648A0202|44 52|cell types
P09002648A0202|78 109|oxidative stress-induced cell death
P09002672A0439|23 31|mTRF1 cDNA
P09002672A0439|45 54|kDa protein
P09002672A0439|66 83|TTAGGG repeat arrays
P09002672A0439|85 89|mTRF1
P09002672A0439|102 124|same sequence specificity
P09002672A0439|127 131|hTRF1
P09002672A0439|143 148|arrays
P09002672A0439|151 163|TTAGGG repeats
P09002672A0439|167 182|binding substrate
P09002672A0439|187 192|TTAGGC
P09002672A0439|196 208|TTGGGG repeats
P09003001A1593|24 37|E12 bHLH protein
P09003001A1593|51 82|numerous cell-specific bHLH factors
P09003001A1909|3 15|E-box sequence
P09003001A1909|21 31|SE2 fragment
P09003001A1909|37 55|transferrin promoter
P09003001A1909|59 64|CATCTG
P09003001A1909|80 88|gel shifts
P09003001A1909|94 115|consensus E-box elements
P09003001A1909|117 122|CANNTG
P09003311A0478|1 17|5.3-kb DNA fragment
P09003311A0478|35 59|entire structural porin gene
P09003311A0478|66 70|porCa
P09003311A0478|78 92|flanking regions
P09003312A0740|0 17|Full-length AT-PHH1
P09003312A0740|26 32|AT-PHH1
P09003312A0740|36 52|AT-PHH1 delta C-513
P09003312A0740|89 112|microbial photolyase genes
P09003312A0740|114 118|cDNAs
P09003312A0740|153 157|yeast
P09003312A0740|176 196|mutants hypersensitive
P09003312A0740|199 214|ultraviolet light
P09003410A0000|3 18|human p100 protein
P09003410A0000|43 53|coactivator
P09003410A0000|59 90|Epstein-Barr virus nuclear antigen 2
P09003410A0000|59 89|Epstein-Barr virus nuclear antigen
P09003462A0792|12 27|new mutation sites
P09003462A0792|29 31|S61
P09003462A0792|33 35|SL1
P09003462A0792|37 39|S29
P09003462A0792|41 44|SL11
P09003462A0792|46 50|SL196
P09003462A0792|54 58|SL126
P09003462A0792|74 83|nrdB intron
P09003462A0792|74 77|nrdB
P09003462A0792|94 106|self-splicing
P09003463A0198|33 48|characterization
P09003463A0198|57 70|flanking region
P09003463A0198|75 76|kb
P09003463A0198|81 84|exon
P09003463A0198|91 107|human RII alpha gene
P09003617A0000|1 6|cohort
P09003617A0000|9 23|Swedish children
P09003617A0000|41 46|months
P09003617A0000|51 55|years
P09004304A0000|31 45|reproducibility
P09004304A0000|67 82|clearance methods
P09004304A0000|88 128|chromium-51 ethylenediamine tetraacetic acid
P09004304A0000|130 138|51Cr-EDTA
P09004304A0000|164 191|multiple blood sample technique
P09004504A0000|3 18|primary structure
P09004504A0000|26 38|bp DNA fragment
P09004504A0000|49 55|pla gene
P09004504A0000|65 84|plasminogen activator
P09004504A0000|100 110|replication
P09004504A0000|116 151|wild-type Yersinia pestis plasmid pYP358
P09004987T0001|0 21|Serotonin concentration
P09004987T0001|34 41|patients
P09004987T0001|46 61|hemorrhagic fever
P09004987T0001|66 78|renal syndrome
P09005273A0322|0 18|MAIN OUTCOME MEASURES
P09005273A0322|20 31|Associations
P09005273A0322|34 64|factor analysis-derived syndromes
P09005273A0322|69 79|risk factors
P09005273A0322|83 102|chemical interactions
P09005273A0322|114 134|butyrylcholinesterase
P09005273A0322|138 161|neuropathy target esterase
P09005273A1558|0 9|CONCLUSION
P09005273A1558|15 29|Gulf War veterans
P09005273A1558|45 70|chronic neurotoxic syndromes
P09005273A1558|75 89|wartime exposure
P09005273A1558|92 103|combinations
P09005273A1558|106 114|chemicals
P09005273A1558|126 146|butyrylcholinesterase
P09005273A1558|150 173|neuropathy target esterase
P09005609A0299|0 17|Control examination
P09005836A0977|31 36|horses
P09005836A0977|43 55|antibody level
P09005979A0841|3 9|GHR mRNA
P09005979A0841|11 23|GHBP mRNA ratio
P09005979A0841|48 56|unchanged
P09005979A0841|63 77|differentiation
P09006007A0997|3 9|results
P09006007A0997|31 61|selenocysteine-specific UGA codon
P09006007A0997|86 95|conditions
P09006007A0997|104 124|homologous SelB protein
P09006007A0997|127 132|absent
P09006007A0997|156 166|specificity
P09006007A0997|172 191|SelB-mRNA interaction
P09006007A0997|172 180|SelB-mRNA
P09006007A0997|194 216|structural compatibility
P09006007A0997|222 238|quaternary complex
P09006007A0997|246 253|ribosome
P09006010A0527|3 25|linker-peptide insertion
P09006010A0527|31 43|RsaA C terminus
P09006010A0527|45 53|amino acid
P09006010A0527|71 87|S-layer biogenesis
P09006010A0527|102 110|amino acid
P09006010A0527|124 132|secretion
P09006010A0527|160 163|RsaA
P09006010A0527|174 188|secretion signal
P09006010A0527|194 202|C terminal
P09006010A0527|205 213|amino acid
P09006010A0527|233 241|amino acid
P09006022A0252|17 28|gene products
P09006022A0252|33 40|cvaA gene
P09006022A0252|82 104|T7 RNA polymerase promoter
P09006051A1162|0 3|PrpB
P09006051A1162|10 17|homology
P09006051A1162|20 89|carboxyphosphonoenolpyruvate phosphonomutase of Streptomyces hygroscopicus
P09006051A1162|20 62|carboxyphosphonoenolpyruvate phosphonomutase
P09006051A1162|98 104|homolog
P09006051A1162|110 138|carnation Dianthus caryophyllus
P09006051A1162|140 143|PrpC
P09006051A1162|147 156|homologous
P09006051A1162|163 170|archaeal
P09006051A1162|174 198|bacterial citrate synthases
P09006051A1162|200 203|PrpD
P09006051A1162|210 217|homology
P09006051A1162|220 224|yeast
P09006051A1162|228 251|Bacillus subtilis proteins
P09006051A1162|254 268|unknown function
P09006051A1162|270 273|PrpE
P09006051A1162|280 287|homology
P09006051A1162|290 315|acetyl coenzyme A synthetases
P09006555A0738|0 18|MAIN OUTCOME MEASURES
P09006555A0738|20 27|Systemic
P09006555A0738|31 51|pulmonary hemodynamics
P09006555A0738|53 81|arterial blood gas determination
P09006555A0738|83 110|bronchoalveolar lavage protein
P09006555A0738|114 130|neutrophil content
P09006555A0738|132 153|neutrophil oxidant burst
P09006555A0738|155 180|lung myeloperoxidase content
P09006555A0738|155 173|lung myeloperoxidase
P09006555A0738|185 219|scanning electron micrographic studies
P09006902A0370|15 18|cDNA
P09006902A0370|27 36|human MEKK3
P09006910A0000|16 25|mechanisms
P09006910A0000|39 60|transcriptional control
P09006910A0000|63 79|retinoid X receptor
P09006910A0000|81 88|RXR) gene
P09006910A0000|81 83|RXR
P09006910A0000|85 98|gene expression
P09006910A0000|106 119|flanking region
P09006910A0000|125 145|human RXRgamma2 isoform
P09006914A0812|0 2|JNK
P09006914A0812|6 8|p38
P09006914A0812|38 44|nucleus
P09006914A0812|49 62|DNA-bound c-JUN
P09006914A0812|58 62|c-JUN
P09006914A0812|66 70|ATF-2
P09006914A0812|91 93|JNK
P09006914A0812|97 99|p38
P09006914A1127|3 9|effects
P09006914A1127|31 35|forms
P09006914A1127|41 63|JNK/p38 signaling pathway
P09006914A1127|41 43|JNK
P09006914A1127|45 47|p38
P09006914A1127|79 88|activation
P09006914A1127|96 102|kinases
P09006914A1127|116 155|cytokine-induced E-selectin gene expression
P09006914A1127|132 145|E-selectin gene
P09006935A0590|0 2|Sp1
P09006935A0590|11 19|CTC repeat
P09006935A0590|26 33|affinity
P09006935A0590|35 37|KD =
P09006935A0590|42 43|nM
P09006935A0590|63 76|consensus GC box
P09006936T0000|0 13|Identification
P09006936T0000|27 46|actin-binding protein
P09006936T0000|61 77|cytoplasmic domain
P09006936T0000|80 98|glycoprotein IBalpha
P09008301A0193|0 16|Mutant enzyme forms
P09008301A0193|43 67|initial autoprocessing site
P09008301A0193|81 105|active single-chain protein
P09008301A0193|109 133|structure-function studies
P09009208A0337|3 8|primer
P09009208A0337|23 30|cleavage
P09009208A0337|48 52|bases
P09009208A0337|65 71|Tf1 mRNA
P09010223A0667|30 33|ELK1
P09010223A0667|35 39|SAP1a
P09010223A0667|41 44|FLI1
P09010223A0667|46 53|EWS-FLI1
P09010223A0667|55 58|ETS1
P09010223A0667|60 63|ETS2
P09010223A0667|65 68|PEA3
P09010223A0667|72 83|PU.1 proteins
P09010223A0667|91 106|ternary complexes
P09010223A0667|111 113|SRF
P09010223A0667|119 126|Egr1 SREI
P09010223A1850|4 11|R-domain
P09010223A1850|41 43|SRF
P09010223A1850|83 86|FLI1
P09010223A1850|90 97|EWS-FLI1
P09010223A1850|115 127|novel function
P09010223A1850|136 158|ETS transcription factors
P09010223A1850|179 186|Egr1 gene
P09011591A0309|3 13|total number
P09011591A0309|16 24|specimens
P09011591A0309|37 46|nonsmokers
P09011591A0309|52 58|smokers
P09011744A0790|3 28|murine chromosomal locations
P09011744A0790|38 64|NMDA receptor channel subunits
P09011744A0790|69 76|epsilon 1
P09011744A0790|69 75|epsilon
P09011744A0790|78 83|Grin2a
P09011744A0790|86 93|epsilon 2
P09011744A0790|86 92|epsilon
P09011744A0790|95 100|Grin2b
P09011744A0790|103 110|epsilon 3
P09011744A0790|103 109|epsilon
P09011744A0790|112 117|Grin2c
P09011744A0790|120 126|epsilon
P09011744A0790|129 134|Grin2d
P09011744A0790|139 143|zeta 1
P09011744A0790|139 142|zeta
P09011744A0790|145 149|Grinl
P09011744A0790|151 158|subunits
P09011744A0790|181 214|interspecific backcross mapping panel
P09011744A0790|226 232|crosses
P09011744A0790|237 246|C57BL/6JxM
P09011744A0790|248 254|spretus
P09011744A0790|256 266|F1xC57BL/6J
P09011744A0790|268 271|mice
P09011745T0000|0 10|CDNA cloning
P09011745T0000|13 86|chick brain alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors
P09011745T0000|129 157|post-transcriptional processes
P09011745T0000|162 179|mammalian receptors
P09012405A0785|15 19|TTD-A
P09012405A0785|23 33|XP-D defects
P09012405A0785|51 58|subunits
P09012405A0785|61 65|TFIIH
P09012405A0785|68 91|basal transcription factor
P09012405A0785|97 110|second function
P09012405A0785|113 121|DNA repair
P09012636A0723|0 9|Adjustment
P09012636A0723|17 32|total cholesterol
P09012636A0723|34 47|HDL cholesterol
P09012636A0723|49 61|triglycerides
P09012636A0723|63 76|current smoking
P09012636A0723|81 96|systolic pressure
P09012636A0723|133 142|fibrinogen
P09012636A0723|146 160|atherosclerosis
P09013499A0198|2 11|Experiment
P09013499A0198|14 17|pups
P09013499A0198|35 43|injection
P09013499A0198|49 106|noncompetitive N-methyl-D-aspartate receptor antagonist MK-801
P09013499A0198|111 115|mg/kg
P09013499A0198|130 132|min
P09013499A0198|157 168|conditioning
P09013499A0198|174 181|less time
P09013499A0198|189 203|conditioned odor
P09013499A0198|208 229|saline-treated controls
P09013760A0000|0 42|Cholesterol side-chain cleavage cytochrome P450
P09013760A0000|44 49|CYP11A
P09013760A0000|51 57|P450scc
P09013760A0000|59 72|gene expression
P09013760A0000|86 98|gonadotropins
P09013760A0000|102 105|cAMP
P09013760A0000|111 115|ovary
P09013760A0000|121 124|ACTH
P09013760A0000|128 131|cAMP
P09013760A0000|134 153|adrenal cortical cells
P09015543A0210|3 18|possible solution
P09015543A0210|22 46|thin radial forearm free flap
P09015757T0000|0 17|Structural analysis
P09015757T0000|21 36|characterization
P09015757T0000|48 75|hormonal responsive expression
P09015757T0000|81 101|avian bone sialoprotein
P09015757T0000|103 105|BSP
P09015799T0000|0 17|Serotonin receptors
P09015799T0000|20 33|suicide victims
P09015799T0000|38 52|major depression
P09016566A0655|3 23|Y-type structural motif
P09016566A0655|53 69|divergent BiP mRNAs
P09016566A0655|62 69|BiP mRNAs
P09017443A0734|1 25|false positive marker screen
P09017443A0734|46 55|occurrence
P09017443A0734|58 74|hand-foot syndrome
P09017443A0734|94 100|regimen
P09017443A0734|118 131|stratification
P09017443A0734|133 134|p =
P09018122A1389|3 11|detection
P09018122A1389|14 27|ORF-1 sequences
P09018122A1389|30 40|human tumors
P09018122A1389|64 75|prerequisite
P09018122A1389|100 115|tumor development
P09018133A0244|0 19|Phylogenetic analysis
P09018133A0244|36 64|close evolutionary relationship
P09018133A0244|72 77|PhHV-1
P09018133A0244|81 87|members
P09018133A0244|93 111|Varicellovirus genus
P09018133A0244|117 135|alpha-Herpesvirinae
P09018133A0244|139 154|canid herpesvirus
P09019302A0600|13 15|PLP
P09019302A0600|18 23|plasma
P09019302A0600|43 57|high sensitivity
P09019302A0600|63 76|derivatization
P09019302A0600|81 95|sodium bisulfite
P09019302A0600|101 111|mobile phase
P09020138A0833|4 7|HEF1
P09020138A0833|11 13|Cas
P09020138A0833|39 72|related adhesion focal tyrosine kinase
P09020138A0833|74 78|RAFTK
P09020138A0833|88 109|tyrosine phosphorylated
P09020138A0833|118 136|adapter molecule CrkL
P09020138A0833|133 136|CrkL
P09020169A0552|0 3|SIM1
P09020169A0552|7 10|SIM2
P09020169A0552|20 29|homodimers
P09020169A0552|55 57|AHR
P09020172A0964|0 8|Complexes
P09020172A0964|11 16|qTBP42
P09020172A0964|25 43|complementary strand
P09020172A0964|46 57|telomeric DNA
P09020172A0964|65 79|quadruplex forms
P09020172A0964|85 102|guanine-rich strand
P09020172A0964|114 136|nM dissociation constants
P09020172A0964|138 139|Kd
P09020172A0964|148 156|complexes
P09020172A0964|161 187|double-stranded telomeric DNA
P09020172A0964|203 216|higher Kd values
P09020856A0560|27 30|TIS1
P09020856A0560|43 51|selective
P09020856A0560|58 68|MCK promoter
P09021684A1418|0 15|Experimental data
P09021684A1418|31 46|abnormal proteins
P09021684A1418|64 72|localized
P09021684A1418|78 84|nucleus
P09021684A1418|97 136|transcriptional repressor functions typical
P09021684A1418|139 157|normal NF-kappa B2p52
P09021684A1418|145 157|NF-kappa B2p52
P09021684A1418|175 197|transactivation activity
P09022040A0263|7 25|L-plastin expression
P09022040A0263|7 15|L-plastin
P09022040A0263|62 67|humans
P09022040A0263|71 77|rodents
P09022040A0263|93 109|similar mechanisms
P09022040A0263|118 140|L-plastin gene expression
P09022040A0263|118 130|L-plastin gene
P09022040A0263|151 161|rodent cells
P09022040A0263|215 233|nucleotide sequences
P09022040A0263|247 274|murine L-plastin gene promoters
P09022632T0000|11 21|gynecologic
P09022632T0000|25 42|obstetrical surgery
P09023197T0000|3 12|dnaK operon
P09023197T0000|15 30|Bacillus subtilis
P09023197T0000|33 46|heptacistronic
P09023378A0959|21 24|CBF1
P09023378A0959|27 31|yeast
P09023378A0959|50 62|transcription
P09023378A0959|65 77|reporter genes
P09023378A0959|91 102|C-repeat/DRE
P09023378A0959|91 98|C-repeat
P09023378A0959|100 102|DRE
P09023378A0959|107 131|upstream activator sequence
P09023378A0959|138 151|mutant versions
P09023378A0959|157 166|DNA element
P09024039A0247|9 25|ASA physical status
P09024039A0247|31 43|adult patients
P09024039A0247|69 87|h surgical procedures
P09024039A0247|118 120|CCA
P09024039A0247|125 134|desflurane
P09024039A0247|137 146|isoflurane
P09024039A0247|151 161|ventilation
P09024039A0247|173 183|spontaneous
P09024039A0247|186 195|controlled
P09024097A0000|0 8|OBJECTIVE
P09024097A0000|38 60|chlamydia-infected women
P09024097A0000|66 75|higher rate
P09024097A0000|78 97|febrile complications
P09024097A0000|103 125|postpartum tubal ligation
P09024793A1325|5 37|electrophoresis mobility shift assay
P09024793A1325|43 57|nuclear extracts
P09024793A1325|63 75|myogenic cells
P09024793A1325|77 80|MyoD
P09024793A1325|84 91|myogenin
P09024793A1325|102 111|right E-box
P09024793A1325|117 130|enhancer region
P09024793A1325|136 142|MCK gene
P09024793A1325|162 166|BMP-2
P09024805A0905b|1 29|heterologous promoter construct
P09024805A0905b|45 51|repeats
P09024805A0905b|55 70|consensus Sp1 site
P09024805A0905b|64 70|Sp1 site
P09024805A0905b|89 98|single copy
P09024805A0905b|104 106|ZII
P09024805A0905b|108 111|CREB
P09024805A0905b|113 115|AP1
P09024805A0905b|131 143|BZLF1 promoter
P09024805A0905b|155 172|beta-globin TATA box
P09024805A0905b|183 206|phorbol ester inducibility
P09025122A0374|0 20|Subsequent experiments
P09025122A0374|31 42|motoric tasks
P09025122A0374|53 68|cognitive aspects
P09025122A0374|74 81|COWA task
P09025122A0374|108 132|finger-tapping performance
P09025549A0000|41 50|competence
P09025549A0000|68 88|few local practitioners
P09025549A0000|100 132|Vancouver sex therapist Bianca Rucker
P09025549A0000|165 174|colleagues
P09025549A0000|178 184|mentors
P09025549A0000|187 199|related fields
P09027346A1957|8 22|antibody binding
P09027346A1957|25 32|site IIIa
P09027346A1957|38 58|hCG-ectodomain complex
P09027346A1957|78 92|anti-peptide mAb
P09027346A1957|109 115|peptide
P09027346A1957|128 137|eighth exon
P09027346A1957|139 141|pE x
P09027346A1957|149 151|LHR
P09027506T0000|0 10|cDNA cloning
P09027506T0000|12 29|expression analysis
P09027506T0000|34 56|chromosomal localization
P09027506T0000|68 79|high homology
P09027506T0000|82 89|wheat eIF
P09027506T0000|92 94|iso
P09027506T0000|96 97|4F
P09027506T0000|101 115|mammalian eIF-4G
P09028089A0183|32 43|hypertension
P09028089A0183|51 75|appropriate renal blood flow
P09028089A0183|88 114|renal transplantation surgery
P09028308A0590|3 17|initial patients
P09028308A0590|29 31|AZQ
P09028308A0590|35 47|mitroxantrone
P09028308A0590|59 88|prolonged bone marrow suppression
P09028308A0590|103 119|subsequent cohorts
P09028308A0590|135 139|G-CSF
P09028308A0590|142 154|micrograms/kg
P09028308A0590|176 185|completion
P09028308A0590|191 200|third cycle
P09028308A0590|203 214|chemotherapy
P09028942A0000|0 50|Human granulocyte-macrophage colony-stimulating factor
P09028942A0000|52 58|hGM-CSF
P09028942A0000|75 83|genes such
P09028942A0000|86 90|c-fos
P09028942A0000|92 94|jun
P09028942A0000|96 98|myc
P09028942A0000|103 126|early growth response gene 1
P09028942A0000|103 125|early growth response gene
P09028942A0000|128 132|egr-1
P09028998A0143|16 35|adequate local control
P09028998A0143|55 69|cosmetic outcome
P09028998A0143|82 93|breast tissue
P09028998A0143|113 115|BCT
P09029091A0881|21 55|TCR-mediated tyrosine phosphorylation
P09029091A0881|21 23|TCR
P09029091A0881|58 77|phospholipase C gamma 1
P09029091A0881|58 76|phospholipase C gamma
P09029091A0881|96 106|Jurkat cells
P09029091A0881|120 132|A2/HCP chimera
P09029091A0881|120 121|A2
P09029091A0881|123 125|HCP
P09029104A0226|3 17|14.1(IGLL1) gene
P09029104A0226|8 12|IGLL1
P09029104A0226|32 38|lineage
P09029104A0226|43 64|stage-restricted manner
P09029159A0000|3 12|interferon
P09029159A0000|14 16|IFN
P09029159A0000|26 43|double-stranded RNA
P09029159A0000|45 80|dsRNA)-activated Ser/Thr protein kinase
P09029159A0000|45 49|dsRNA
P09029159A0000|61 80|Ser/Thr protein kinase
P09029159A0000|82 84|PKR
P09029159A0000|101 109|antiviral
P09029159A0000|113 136|antiproliferative effects
P09029159A0000|139 141|IFN
P09029713A1120|27 47|cAMP-dependent control
P09029713A1120|53 59|amounts
P09029713A1120|65 77|activator SF-1
P09029713A1120|84 99|repressor COUP-TF
P09029713A1120|93 99|COUP-TF
P09029713A1120|114 140|CRS2-dependent transcription
P09029956T0000|0 14|Object relations
P09029956T0000|36 60|psychic structure formation
P09030581A0990|15 24|COS-7 cells
P09030581A0990|26 30|MKP-4
P09030581A0990|37 46|activation
P09030581A0990|49 58|MAP kinases
P09030581A0990|66 79|selectivity ERK
P09030581A0990|77 79|ERK
P09030581A0990|81 92|p38 = JNK/SAPK
P09030581A0990|81 83|p38
P09030581A0990|85 87|JNK
P09030581A0990|89 92|SAPK
P09030688A0435|2 12|rlf2 mutants
P09030688A0435|14 31|telomeric chromatin
P09030688A0435|44 61|Telomeric silencing
P09030688A0435|74 90|Rap1p localization
P09030688A0435|74 78|Rap1p
P09030781A0734|0 10|Most kinases
P09030781A0734|41 51|roscovitine
P09030781A0734|53 64|cdc2/cyclin B
P09030781A0734|66 77|cdk2/cyclin A
P09030781A0734|66 69|cdk2
P09030781A0734|71 77|cyclin A
P09030781A0734|79 90|cdk2/cyclin E
P09030781A0734|79 82|cdk2
P09030781A0734|84 90|cyclin E
P09030781A0734|94 101|cdk5/p35
P09030781A0734|94 97|cdk5
P09030781A0734|99 101|p35
P09030781A0734|132 141|IC50 values
P09030781A0734|162 167|microM
P09030781A0734|183 195|cdk4/cyclin D1
P09030781A0734|183 186|cdk4
P09030781A0734|188 195|cyclin D1
P09030781A0734|199 211|cdk6/cyclin D2
P09030781A0734|199 202|cdk6
P09030781A0734|204 211|cyclin D2
P09030781A0734|236 246|roscovitine
P09030781A0734|248 251|IC50
P09030781A0734|256 261|microM
P09031639A0474|8 13|kb cDNA
P09031639A0474|24 39|open reading frame
P09031639A0474|41 43|ORF
P09031639A0474|50 51|bp
P09031639A0474|61 71|polypeptide
P09031639A0474|77 86|amino acids
P09031639A0474|88 89|aa
P09031639A0474|139 154|human U1-C protein
P09032233T0000|0 10|Interaction
P09032233T0000|13 17|Ets-1
P09032233T0000|24 50|POU-homeodomain protein GHF-1
P09032233T0000|52 56|Pit-1
P09032233T0000|70 101|pituitary-specific gene expression
P09032248A0239|8 12|Pho85
P09032248A0239|30 38|viability
P09032248A0239|40 66|Pcl1,2-Pho85 kinase complexes
P09032248A0239|40 57|Pcl1,2-Pho85 kinase
P09032248A0239|85 89|Start
P09032248A0239|104 122|Cln1,2-Cdc28 kinases
P09032250A0257|8 28|yeast two-hybrid system
P09032250A0257|40 47|proteins
P09032250A0257|65 68|Tax1
P09032250A0257|83 90|B subunit
P09032250A0257|96 118|CCAAT binding protein NF-Y
P09032250A0257|124 138|HeLa cDNA library
P09032254A0724|0 15|Enhancer activity
P09032254A0724|31 38|AP-1 site
P09032254A0724|47 63|adjacent sequences
P09032258A0395|0 6|Studies
P09032258A0395|12 47|HLA-DR-B7-1-LFA-3 triple transfectants
P09032258A0395|24 28|LFA-3
P09032258A0395|61 96|LFA-3-induced NF-AT DNA binding activity
P09032258A0395|61 65|LFA-3
P09032258A0395|121 137|B7-1 costimulation
P09032258A0395|121 124|B7-1
P09032259A0150|0 21|Constitutive activation
P09032259A0150|24 27|Rac1
P09032259A0150|31 34|RhoA
P09032259A0150|41 65|tumorigenic transformation
P09032259A0150|68 78|NIH 3T3 cells
P09032259A0150|88 96|functions
P09032259A0150|113 133|full Ras transformation
P09032259A0972|12 25|Rac1 activation
P09032259A0972|12 15|Rac1
P09032259A0972|28 30|JNK
P09032259A0972|33 35|SRF
P09032259A0972|39 47|induction
P09032259A0972|50 61|lamellipodia
P09032259A0972|98 121|Rac1 transforming activity
P09032259A0972|98 101|Rac1
P09032267A0850|0 13|Overexpression
P09032267A0850|19 39|bZip interaction domain
P09032267A0850|42 44|CBP
P09032267A0850|69 85|positive cross talk
P09032267A0850|93 94|TR
P09032267A0850|98 105|p45/NF-E
P09032267A0850|98 100|p45
P09032267A0850|102 106|NF-E2
P09032275A1133|4 19|inhibitory domain
P09032275A1133|57 74|AHC deletion mutants
P09032304T0000|0 13|Identification
P09032304T0000|17 54|promoter-specific transactivation domain
P09032304T0000|60 98|herpes simplex virus regulatory protein ICP4
P09032328A0650|0 12|DNA sequencing
P09032328A0650|16 27|17-kb segment
P09032328A0650|41 70|gammaherpesvirus divergent locus
P09032328A0650|72 75|DL-B
P09032328A0650|84 88|ORF11
P09032328A0650|92 96|ORF17
P09032328A0650|122 130|viral ORFs
P09032328A0650|144 155|gene products
P09032328A0650|165 180|cellular proteins
P09034337A0251|0 6|Studies
P09034337A0251|9 22|mammalian cells
P09034337A0251|37 45|induction
P09034337A0251|48 65|inhibitory tyrosine
P09034337A0251|69 71|Y15
P09034337A0251|73 87|phosphorylation
P09034337A0251|90 96|p34cdc2
P09034337A0251|114 122|DNA damage
P09035307A0000|24 37|30-year-old man
P09035307A0000|44 79|ectopic mediastinal parathyroid adenoma
P09035307A0000|93 135|99mTc-methoxyisobutylisonitrile scintigraphy
P09035307A0000|137 146|99mTc-MIBI
P09035612T0000|0 23|Cardiac endothelin release
P09035612T0000|27 37|infarct size
P09035612T0000|39 57|myocardial blood flow
P09035612T0000|62 80|ventricular function
P09035612T0000|83 98|canine infarction
P09035612T0000|102 112|reperfusion
P09036529A0343|3 8|workup
P09036529A0343|17 25|skin tests
P09036529A0343|32 43|microgram/ml
P09036529A0343|45 53|Pharmacia
P09036529A0343|69 84|specific serum IgE
P09036529A0343|89 96|RAST-CAP
P09036529A0343|98 106|Pharmacia
P09036529A0343|112 115|CAST
P09036529A0343|125 138|concentrations
P09036529A0343|145 157|Apis mellifera
P09036529A0343|162 165|wasp
P09036529A0343|167 177|Vespula spec
P09036529A0343|180 184|venom
P09036529A0343|186 195|Aquagen ALK
P09037032T0000|3 39|proliferation potential protein-related
P09037032T0000|41 45|P2P-R
P09037032T0000|55 61|domains
P09037032T0000|70 117|heterogeneous nuclear ribonucleoprotein association
P09037032T0000|121 130|Rb1 binding
P09037032T0000|121 123|Rb1
P09037032T0000|161 183|terminal differentiation
P09037064A0183|0 16|Recent application
P09037064A0183|19 47|recombinant canarypox ALVAC/HIV
P09037064A0183|50 56|vectors
P09037064A0183|59 75|vaccine immunogens
P09037064A0183|78 82|HIV-1
P09037064A0183|85 105|noninfected volunteers
P09037064A0183|117 128|CTL responses
P09037064A0183|132 148|significant number
P09037064A0183|151 159|vaccinees
P09037163A1652|3 11|relevance
P09037163A1652|19 26|elements
P09037163A1652|39 56|anaerobic induction
P09037163A1652|59 76|gpc4 gene expression
P09037163A1652|59 66|gpc4 gene
P09038166A0818|0 7|Exons A1a
P09038166A0818|11 13|A1b
P09038166A0818|42 61|124-nucleotide intron
P09038192A0846|1 21|MEK-specific inhibitor
P09038192A0846|23 30|PD098059
P09038192A0846|33 38|Dudley
P09038192A0846|40 41|D.
P09038202A1951|30 47|repression activity
P09038202A1951|50 58|NRSF/REST
P09038202A1951|50 53|NRSF
P09038202A1951|55 58|REST
P09038202A1951|82 89|promoter
P09038202A1951|117 124|proteins
P09038202A1951|140 148|promoters
P09039744T0000|8 26|period-peak analysis
P09039744T0000|29 50|electro-encephalograms
P09039744T0000|57 72|fast sinc function
P09040011A1316|10 12|p56
P09040011A1316|14 16|lck
P09040011A1316|36 49|G1/S transition
P09040011A1316|52 70|immature thymoblasts
P09040011A1316|83 95|cell viability
P09040011A1316|99 110|transduction
P09040011A1316|113 151|constitutive activation signals downstream
P09040011A1316|154 163|components
P09040011A1316|169 187|Ras/Raf/MAPK pathway
P09040011A1316|169 171|Ras
P09040011A1316|173 175|Raf
P09040011A1316|177 180|MAPK
P09041123A0195|23 35|cognate ligand
P09041123A0195|42 65|accessory cellular factors
P09041123A0195|98 121|transcriptional responses
P09041123A0195|125 146|heterodimer-DNA complex
P09042078A0202|17 19|MBF
P09042078A0202|22 29|incisors
P09042078A0202|52 61|dimensions
P09042078A0202|65 84|different jaw openings
P09042078A0202|90 97|subjects
P09042269A1007|5 12|findings
P09042269A1007|24 59|intraarterial neoadjuvant chemotherapy
P09042269A1007|79 100|advanced cervical cancer
P09042683A0492|3 18|FBF questionnaire
P09042683A0492|35 68|characteristic basic symptoms profile
P09042683A0492|71 93|schizoaffective disorder
P09042683A0492|111 134|bipolar affective disorder
P09042683A0492|138 150|schizophrenia
P09042755T0000|3 30|alternative sigma factor sigmaB
P09042755T0000|14 30|sigma factor sigmaB
P09042755T0000|69 78|sigB operon
P09042755T0000|91 101|growth phase
P09042755T0000|105 113|heat shock
P09042911A0626|0 22|Cognate promoter elements
P09042911A0626|35 48|glucocorticoid
P09042911A0626|53 75|cAMP-mediated regulation
P09042911A0626|93 99|myeloid
P09042911A0626|105 133|lymphocyte-specific expression
P09042911A0626|137 143|located
P09042911A0626|155 170|flanking sequence
P09043534A1600|10 31|meaningful decreases due
P09043534A1600|34 47|alkalinization
P09043534A1600|61 67|minutes
P09043768A0139|16 26|biokinetics
P09043768A0139|29 31|BLM
P09043768A0139|43 52|indium-111
P09043768A0139|54 59|In-111
P09045636A0789|0 15|CD3 cross-linking
P09045636A0789|0 2|CD3
P09045636A0789|23 45|tyrosine phosphorylation
P09045636A0789|48 52|Sam68
P09045636A0789|55 70|uninfected T cells
P09045805A0945|0 26|Acetoin-dependent expression
P09045805A0945|32 44|acoABCD operon
P09045805A0945|65 81|E. coli acoK mutants
P09045805A0945|71 81|acoK mutants
P09045805A0945|94 100|plasmid
P09045805A0945|111 120|intact acoK
P09045805A0945|117 120|acoK
P09045805A0945|133 155|transactivating function
P09045805A0945|161 171|gene product
P09045842T0000|0 8|Mutations
P09045842T0000|14 18|alpha
P09045842T0000|22 37|sigma-70 subunits
P09045842T0000|40 52|RNA polymerase
P09045842T0000|74 82|mer operon
P09045919A1250|48 58|an activator
P09045919A1250|50 58|activator
P09045919A1250|60 62|NFE
P09045919A1250|89 91|p50
P09045919A1250|95 107|c-Rel proteins
P09045919A1250|121 148|transcription factor machinery
P09045919A1250|164 179|enhancer activity
P09045919A1250|203 210|IgH locus
P09045919A1250|213 238|late B lymphocyte development
P09046013A0000|3 25|neuroprotective efficacy
P09046013A0000|31 83|selective N-type voltage-sensitive calcium channel blocker
P09046013A0000|85 91|SNX-111
P09046013A0000|120 135|hypertensive rats
P09046013A0000|149 151|min
P09046013A0000|154 174|focal cerebral ischemia
P09046013A0000|177 193|permanent ligation
P09046013A0000|199 222|right common carotid artery
P09046013A0000|226 243|temporary occlusion
P09046013A0000|249 273|right middle cerebral artery
P09046090T0000|3 7|genes
P09046090T0000|19 45|transcription factor yTAFII60
P09046090T0000|50 60|G4p1 protein
P09046090T0000|65 90|putative glucose transporter
P09046090T0000|73 90|glucose transporter
P09046090T0000|110 122|kb DNA fragment
P09046090T0000|128 134|left arm
P09046090T0000|160 172|chromosome VII
P09046186A0189|3 11|protector
P09046186A0189|31 42|fall distance
P09046186A0189|46 53|fracture
P09046186A0189|59 68|trochanter
P09046384A0403|0 21|Marinol/marijuana usage
P09046384A0403|39 50|depressed CD4
P09046384A0403|48 51|CD4+
P09046384A0403|52 57|counts
P09046384A0403|61 81|elevated amylase levels
P09046384A0403|69 75|amylase
P09046384A0403|91 101|DDI subgroup
P09047252A0209|0 6|METHODS
P09047252A0209|19 26|patients
P09047252A0209|40 63|curative hepatic resection
P09047252A0209|67 69|HCC
P09047252A0209|78 98|preoperative AFP levels
P09047252A0209|107 111|ng/ml
P09047344A0000|0 24|Calmodulin-binding peptide
P09047344A0000|26 28|CBP
P09047344A0000|32 38|peptide
P09047344A0000|43 52|amino acids
P09047344A0000|64 91|muscle myosin light chain kinase
P09047344A0000|93 96|MLCK
P09047344A0000|106 115|calmodulin
P09047344A0000|120 136|nanomolar affinity
P09048617A0648|23 44|tyrosine kinase receptor
P09048617A0648|87 96|cAMP effect
P09049198A0289|20 38|possible involvement
P09049198A0289|41 43|p21
P09049198A0289|46 60|liver cell growth
P09049198A0289|93 99|p21 gene
P09049198A0289|114 125|rodent models
P09049198A0289|128 144|liver regeneration
P09049198A0289|148 156|specimens
P09049198A0289|159 176|human liver diseases
P09049270A0488|0 19|Northern blot analysis
P09049270A0488|22 25|LeMT
P09049270A0488|27 27|A
P09049270A0488|32 37|LeMT(B
P09049270A0488|32 35|LeMT
P09049270A0488|37 37|B
P09049270A0488|49 59|transcripts
P09049270A0488|66 77|MT-like genes
P09049270A0488|86 93|abundant
P09049270A0488|96 101|leaves
P09049270A0488|106 110|roots
P09049270A0488|113 124|tomato plants
P09049270A0488|147 160|extra metal ions
P09049270A0488|185 187|MTs
P09049304A1193|2 23|co-transfection studies
P09049304A1193|27 30|AP-2
P09049304A1193|39 59|Egr-1 expression vector
P09049304A1193|39 43|Egr-1
P09049304A1193|69 89|VPF/VEGF transcription
P09049304A1193|69 71|VPF
P09049304A1193|73 76|VEGF
P09049304A1193|109 119|AP-2 protein
P09049304A1193|145 182|TGF alpha-induced VPF/VEGF gene expression
P09049304A1193|145 152|TGF alpha
P09049304A1193|161 163|VPF
P09049304A1193|165 172|VEGF gene
P09049306A0830|3 9|HBP gene
P09049306A0830|27 31|exons
P09049306A0830|44 45|kb
P09049306A0830|51 58|short arm
P09049306A0830|61 70|chromosome
P09049313A0116|6 14|instances
P09049313A0116|67 75|proteases
P09049313A0116|90 97|cleavage
P09049313A0116|100 120|initiation factor eIF4G
P09049313A0116|116 120|eIF4G
P09050689A0685|3 25|best endometrial ablation
P09050689A0685|37 41|SnET2
P09050689A0685|52 77|intrauterine administration
P09050689A0685|82 95|light treatment
P09050689A0685|101 104|J/cm
P09050689A0685|107 111|hours
P09050847A0180|17 44|III-specific TBP-TAF complexes
P09050847A0180|29 31|TBP
P09050847A0180|49 67|corresponding murine
P09050847A0180|71 129|human class I-specific transcription initiation factor TIF-IB/SL1
P09050847A0180|127 129|SL1
P09050847A0180|139 159|pronounced selectivity
P09050847A0180|166 183|homologous promoter
P09050849A0000|0 10|Cytohesin-1
P09050849A0000|13 27|protein abundant
P09050849A0000|30 34|cells
P09050849A0000|40 51|immune system
P09050849A0000|73 84|human homolog
P09050849A0000|90 127|Saccharomyces cerevisiae Sec7 gene product
P09050849A0000|113 127|Sec7 gene product
P09050849A0000|145 160|protein transport
P09050849A1459|43 62|BFA-sensitive ARF-GEP
P09050849A1459|56 58|ARF
P09050849A1459|60 62|GEP
P09050849A1459|76 85|Sec7 domain
P09050861A0903|32 34|DEK
P09050861A0903|41 56|43-kDa pets factor
P09050867A0542|5 12|elements
P09050867A0542|22 32|binding site
P09050867A0542|36 47|Krox proteins
P09050867A0542|55 68|nuclear factor 1
P09050867A0542|55 67|nuclear factor
P09050867A0542|72 83|octamer motif
P09050867A0542|93 115|POU-homeodomain proteins
P09050867A0542|121 141|novel TN control element
P09051656A0390|0 12|Tissue samples
P09051656A0390|35 38|rats
P09051656A0390|90 108|day morphine infusion
P09051656A0390|111 114|sham
P09051656A0390|122 136|control subjects
P09053309A1103|13 41|impaired floor plate development
P09053309A1103|44 53|oep mutants
P09053309A1103|82 101|floor plate inducer shh
P09053494A0612|0 6|RESULTS
P09053494A0612|11 17|medians
P09053494A0612|20 35|average daily CD34
P09053494A0612|37 46|cell yields
P09053494A0612|50 57|patients
P09053494A0612|69 78|paclitaxel
P09053494A0612|83 84|CY
P09053494A0612|86 87|CE
P09053494A0612|92 94|CEP
P09053494A0612|99 103|G-CSF
P09053494A0612|133 134|kg
P09053494A0612|172 173|kg
P09053494A0612|179 192|reference group
P09053494A0612|205 206|CY
P09053494A0612|211 215|G-CSF
P09053494A0612|217 218|P =
P09053835A0865|9 19|p53 activity
P09053835A0865|9 11|p53
P09053835A0865|29 30|OP
P09053835A0865|41 55|elevated p53 mRNA
P09053835A0865|49 55|p53 mRNA
P09053835A0865|61 73|protein levels
P09053973A1252|0 9|CONCLUSION
P09053973A1252|11 31|Chronic administration
P09053973A1252|34 44|misoprostol
P09053973A1252|59 83|negative natriuretic effect
P09053973A1252|86 102|cirrhotic patients
P09053973A1252|107 113|ascites
P09055221A0288|17 21|SSTEs
P09055221A0288|33 47|magnitude larger
P09055221A0288|61 64|MSEs
P09055221A0288|81 94|signal contrast
P09055221A0288|101 107|effects
P09056761A0000|2 16|eukaryotic cells
P09056761A0000|18 37|premature termination
P09056761A0000|53 66|nonsense codons
P09056761A0000|106 130|posttranscriptional events
P09056761A0000|141 154|rapid mRNA decay
P09056761A0000|160 168|cytoplasm
P09056761A0000|174 180|nucleus
P09056761A0000|182 207|altered splice site selection
P09056761A0000|212 215|exon
P09057325A0177|11 21|plasmid pCM2
P09057325A0177|33 55|pathogenicity locus pat-1
P09057325A0177|51 55|pat-1
P09057325A0177|67 82|deletion analysis
P09057325A0177|86 107|complementation studies
P09057325A0177|111 137|1.5-kb Bg/II/SmaI DNA fragment
P09057325A0177|123 126|SmaI
P09057648A0422|0 22|Transient cotransfection
P09057648A0422|25 31|tat cDNA
P09057648A0422|34 49|sense orientation
P09057648A0422|51 55|tat/S
P09057648A0422|71 77|plasmid
P09057648A0422|91 103|c-fos promoter
P09057648A0422|105 107|FC3
P09057648A0422|135 175|bacterial chloramphenicol acetyltransferase
P09057648A0422|177 179|CAT
P09057648A0422|206 216|CAT activity
P09057648A0422|206 208|CAT
P09057648A0422|219 229|Jurkat cells
P09057648A0422|256 270|% fetal calf serum
P09057648A0422|272 274|FCS
P09057648A0422|279 309|micrograms/mL phytohemagglutinin
P09057648A0422|292 309|phytohemagglutinin
P09057648A0422|320 347|mol/L phorbol myristate acetate
P09057648A0422|349 351|PMA
P09057648A0422|356 364|U937 cells
P09057648A0422|378 381|% FCS
P09057648A0422|390 397|mol/L PMA
P09057703A1389|0 13|Snail mortality
P09057703A1389|34 59|various treatment conditions
P09057840A0946|3 20|recombinant protein
P09057840A0946|34 44|homogeneity
P09057840A0946|48 50|NH4
P09057840A0946|52 69|2SO4-precipitation
P09057840A0946|73 94|affinity chromatography
P09057840A0946|99 111|AMP-Sepharose
P09057841T0000|0 11|Derepression
P09057841T0000|14 27|gene expression
P09057841T0000|43 56|upstream region
P09057841T0000|62 80|isocitrate lyase gene
P09057841T0000|83 99|Candida tropicalis
P09057841T0000|117 142|distinct regulatory pathways
P09058002T0000|0 20|Exploratory-motor task
P09058002T0000|31 52|right frontal lobe damage
P09058250A0128|7 19|complications
P09058250A0128|21 48|accurate quantitative analysis
P09058250A0128|51 52|NO
P09058250A0128|56 58|NO2
P09058323A1287|3 9|results
P09058323A1287|25 35|cis elements
P09058323A1287|56 61|alpha 3
P09058323A1287|56 60|alpha
P09058323A1287|65 68|beta
P09058323A1287|76 82|regions
P09058323A1287|119 139|restricted CNS patterns
P09058323A1287|142 145|beta
P09058323A1287|148 152|alpha
P09058323A1287|158 167|alpha 5 gene
P09058323A1287|158 162|alpha
P09058323A1287|164 180|gene transcription
P09058373A0670|0 25|RNase protection experiments
P09058373A0670|0 4|RNase
P09058373A0670|51 65|GHR1-279 variant
P09058373A0670|68 76|IM-9 cells
P09058373A0670|80 89|human liver
P09058373A1620|0 14|Functional tests
P09058373A1620|21 32|reporter gene
P09058373A1620|44 64|Stat5-binding elements
P09058373A1620|87 97|variant form
P09058373A1620|101 108|inactive
P09058373A1620|148 166|full-length receptor
P09058378A1134|20 42|glucocorticoid receptors
P09058378A1134|56 78|transactivation function
P09058378A1134|81 83|p53
P09058378A1134|90 104|transrepression
P09058378A1134|107 109|p53
P09058378A1134|120 129|unaffected
P09059039A0850|0 10|99mTc-HMPAO
P09059039A0850|30 40|territories
P09059039A0850|46 48|ACA
P09059039A0850|52 54|MCA
P09059039A0850|63 70|patients
P09059039A0850|89 109|intraarterial infusion
P09059039A0850|112 121|papaverine
P09059039A0850|129 137|C4 segment
P09059039A0850|179 181|ACA
P09059039A0850|188 195|patients
P09059039A0850|214 234|intraarterial infusion
P09059039A0850|237 246|papaverine
P09059039A0850|254 262|C1 segment
P09059039A0850|266 271|ml/min
P09060045A0576|4 22|brief review analyses
P09060045A0576|28 39|interactions
P09060045A0576|50 65|clinical settings
P09060045A0576|71 104|antibiotic-induced endotoxin release
P09060444A0557|4 18|promoter segment
P09060444A0557|42 63|luciferase reporter gene
P09060444A0557|76 107|correct transcriptional initiation
P09060444A0557|138 155|EGF-responsiveness
P09060444A0557|138 140|EGF
P09060444A0557|179 188|native gene
P09060622A1679|9 19|first report
P09060622A1679|28 57|vitro-synthesized alphavirus RNA
P09060622A1679|66 69|poly
P09060622A1679|71 71|A
P09060622A1679|109 133|polyadenylated viral genome
P09060623A0961|3 17|human coreceptor
P09060623A0961|34 39|simian
P09060623A0961|43 50|SIV entry
P09060676A1634|5 11|changes
P09060676A1634|14 31|virus entry features
P09060676A1634|43 55|coronaviruses
P09060676A1634|60 84|novel pathogenic properties
P09060971A0982|0 6|RESULTS
P09060971A0982|13 17|women
P09060971A0982|22 39|age-related decline
P09060971A0982|42 44|BMD
P09060971A0982|50 71|non-spine skeletal sites
P09060971A0982|113 126|largest decline
P09060971A0982|136 146|femoral neck
P09060971A0982|154 160|g/cm2/y
P09060971A0982|162 162|p
P09060971A0982|175 182|smallest
P09060971A0982|188 197|trochanter
P09060971A0982|213 219|g/cm2/y
P09060971A0982|221 222|p =
P09061697A0629|13 13|%
P09061697A0629|15 22|patients
P09061697A0629|42 44|MBq
P09061697A0629|47 49|mCi
P09061697A0629|51 67|99Tcm-tetrofosmin
P09061697A0629|83 83|h
P09061697A0629|94 96|MBq
P09061697A0629|100 102|mCi
P09061697A0629|121 131|day protocol
P09061697A0629|146 146|%
P09061697A0629|148 155|patients
P09061697A0629|166 185|stress imaging studies
P09061697A0629|191 202|separate days
P09061697A0629|217 219|MBq
P09061697A0629|223 225|mCi
P09061697A0629|233 249|99Tcm-tetrofosmin
P09061697A0629|269 279|day protocol
P09061697T0000|0 20|Myocardial SPET imaging
P09061697T0000|25 41|99Tcm-tetrofosmin
P09061697T0000|44 59|clinical practice
P09061697T0000|83 100|day imaging protocol
P09061698A0177|0 12|99Tcm-DMP-HSA
P09061698A0177|27 44|identical behaviour
P09061698A0177|62 74|red blood cells
P09061698A0177|76 79|RBCs
P09061698A0177|112 128|reference standard
P09061698A0177|132 146|blood pool agents
P09062130A0116|0 5|Relief
P09062130A0116|10 23|autoinhibition
P09062130A0116|28 55|subsequent 10-60-fold increase
P09062130A0116|58 58|V
P09062130A0116|60 62|max
P09062130A0116|84 104|N-SH2 domain engagement
P09062130A0116|84 94|N-SH2 domain
P09062130A0116|108 135|specific phosphotyrosyl ligand
P09062130A0116|142 149|deletion
P09062130A0116|155 164|SH2 domains
P09062130A0116|175 195|catalytic PTPase domain
P09064659A1055|23 43|first mammalian homolog
P09064659A1055|46 54|yeast UPF1
P09064659A1055|77 82|levels
P09064659A1055|85 96|nonsense mRNA
P09064659A1055|122 138|protein human HUPF1
P09064659A1055|143 154|human homolog
P09064659A1055|157 160|UPF1
P09064868T0001|1 11|miracle cure
P09065170A0853|13 22|zidovudine
P09065463A1012|0 16|DNA strand exchange
P09065463A1012|28 39|Rad51 protein
P09065463A1012|65 67|RPA
P09065690A0463|0 4|Ume6p
P09065690A0463|38 54|early meiotic genes
P09065690A0463|65 78|CAR1 expression
P09065690A0463|65 68|CAR1
P09065690A0463|101 103|URS
P09065690A0463|118 137|nitrogen availability
P09065768A0862|3 13|second class
P09065768A0862|16 19|cDNA
P09065768A0862|35 46|kb transcript
P09065768A0862|86 105|mammalian lactase mRNA
P09067577A0307|2 10|cell lines
P09067577A0307|24 30|BCR/ABL
P09067577A0307|24 26|BCR
P09067577A0307|28 30|ABL
P09067577A0307|32 35|CRKL
P09067577A0307|39 60|tyrosine phosphorylated
P09067577A0307|67 69|CRK
P09067577A0721|2 19|untransformed cells
P09067577A0721|26 38|major proteins
P09067577A0721|57 60|CRKL
P09067577A0721|74 76|C3G
P09067577A0721|78 80|SOS
P09067577A0721|84 88|c-ABL
P09068989T0000|0 5|Effect
P09068989T0000|8 49|Azadirachta indica hydroalcoholic leaf extract
P09068989T0000|55 74|cardiovascular system
P09071308A0376|0 6|RESULTS
P09071308A0376|8 23|Nodular opacities
P09071308A0376|31 43|centrilobular
P09071308A0376|70 82|common finding
P09071308A0376|95 95|%
P09071308A0376|105 105|%
P09071308A0376|109 116|patients
P09071308A0376|121 123|MTB
P09071308A0376|127 130|NTMB
P09071407T0000|11 18|oxytocin
P09071407T0000|21 34|male guinea pigs
P09071407T0000|48 65|female cohabitation
P09071407T0000|69 89|reproductive condition
P09072361A0357|2 28|cellular supernatant fraction
P09072361A0357|30 34|SHRSP
P09072361A0357|52 60|magnesium
P09072361A0357|63 73|many tissues
P09072361A0357|79 87|elevation
P09072361A0357|93 99|calcium
P09072361A0357|102 115|magnesium ratio
P09072361A0357|130 143|age-matched WKY
P09072361A0357|147 151|SHRSR
P09073074T0000|0 21|Antisense transcription
P09073074T0000|25 46|murine FGFR-3 psuedogene
P09073074T0000|53 69|fetal developement
P09073582A0444|1 14|previous report
P09073582A0444|29 52|548-bp BglII-SmaI fragment
P09073582A0444|35 39|BglII
P09073582A0444|41 44|SmaI
P09073582A0444|58 68|SSO activity
P09073582A0444|70 73|ori2
P09073582A0444|75 81|Kataoka
P09073582A0444|88 90|Mol
P09074508A0397|3 15|human CD38 gene
P09074508A0397|27 31|exons
P09074508A0397|52 53|kb
P09074508A0397|59 69|human genome
P09075739A0827|0 3|Type
P09075739A0827|6 18|splice pattern
P09075739A0827|30 35|exon U3
P09075739A0827|39 39|S
P09075739A0827|54 59|kidney
P09075739A0827|63 67|ovary
P09076336A0281|0 11|GH deficiency
P09076336A0281|0 1|GH
P09076336A0281|73 85|constellation
P09076336A0281|99 114|hormonal findings
P09076336A0281|140 161|low normal GH sufficiency
P09076336A0281|164 180|absent GH secretion
P09077076A0219|0 14|Positive CRP test
P09077108A0458|9 21|febrile period
P09077108A0458|23 33|pleocytosis
P09077108A0458|51 60|high levels
P09077108A0458|63 65|IgG
P09077108A0458|67 70|IL-6
P09077108A0458|72 80|TNF-alpha
P09077108A0458|85 88|PGE2
P09077108A0458|94 111|cerebrospinal fluid
P09077437T0000|0 20|Recognition mechanisms
P09077437T0000|26 43|minus-strand origin
P09077437T0000|46 52|phage f1
P09077437T0000|55 82|Escherichia coli RNA polymerase
P09077437T0000|70 82|RNA polymerase
P09077438A0076|13 29|essential subunits
P09077438A0076|33 44|RNA synthesis
P09079625A0935|0 9|Syndecan-4
P09079625A0935|13 34|focal adhesion component
P09079625A0935|69 71|PKC
P09079625A0935|95 99|sites
P09079625A0935|109 117|adhesions
P09079638A0883|3 13|3ASubE cells
P09079638A0883|24 28|CXCR2
P09079638A0883|33 40|mutation
P09079638A0883|43 49|Ser-346
P09079638A0883|65 71|alanine
P09079638A0883|79 86|mutation
P09079638A0883|96 101|serine
P09079638A0883|153 158|ligand
P09079638A0883|170 170|%
P09079638A0883|195 216|initial ligand challenge
P09079650A0136|0 6|Members
P09079650A0136|12 21|MAPK family
P09079650A0136|32 59|extracellular response kinases
P09079650A0136|61 64|ERKs
P09079650A0136|67 72|p42/44
P09079650A0136|74 77|MAPK
P09079650A0136|84 109|c-Jun amino-terminal kinases
P09079650A0136|111 114|JNKs
P09079650A0136|123 129|p38/Hog
P09079650A0136|123 125|p38
P09079650A0136|127 144|Hog 1 protein kinases
P09079650A0136|131 144|protein kinases
P09079689A0472|0 3|MOP5
P09079689A0472|16 38|characteristic PAS domain
P09079689A0472|43 59|variable C terminus
P09079689A0472|80 83|cDNA
P09079689A0472|93 102|bHLH domain
P09079689A0472|110 131|entire open reading frame
P09079817A0928|10 21|NO production
P09079817A0928|29 33|cells
P09079817A0928|51 59|low levels
P09079817A0928|62 65|mRNA
P09079817A0928|68 88|inducible NO synthetase
P09079817A0928|77 88|NO synthetase
P09079878A0000|7 8|kb
P09079878A0000|14 42|Lactobacillus sake plasmid pCIM1
P09079878A0000|86 102|open reading frames
P09079878A0000|104 107|ORFs
P09079878A0000|123 126|lasA
P09079878A0000|140 153|pre-lactocin S.
P09079878A0000|140 152|pre-lactocin S
P09079902A0713|8 10|Pra
P09079902A0713|47 60|pyruvate kinase
P09079902A0713|62 63|Pk
P09079902A0713|66 67|Pk
P09079902A0713|71 73|Pra
P09079902A0713|100 108|12-kDa Ndk
P09079902A0713|110 111|Pk
P09079902A0713|116 118|Pra
P09079902A0713|133 134|Pk
P09079902A0713|139 152|higher affinity
P09079902A0713|157 159|Pra
P09079902A0713|185 193|12-kDa Ndk
P09079904A0995|9 22|iron regulation
P09079904A0995|24 37|sodA expression
P09079904A0995|24 27|sodA
P09079904A0995|51 57|changes
P09079904A0995|60 70|DNA topology
P09079904A0995|80 91|coumermycin A
P09079904A0995|103 136|global virulence regulatory Bvg system
P09079915T0000|0 24|Molecular characterization
P09079915T0000|52 65|motility operon
P09079915T0000|85 108|consensus sigma70 promoter
P09079915T0000|94 108|sigma70 promoter
P09079928A0525|0 11|M. leprae OxyR
P09079928A0525|15 26|overproduced
P09079928A0525|45 51|binding
P09079928A0525|57 81|oxyR-ahpC intergenic region
P09079928A0525|84 91|M. leprae
P09079928A1319|3 13|binding site
P09079928A1319|17 20|OxyR
P09079928A1319|31 36|P1oxyR
P09079928A1319|38 48|reminiscent
P09079928A1319|54 72|autoregulatory loops
P09079928A1319|96 99|oxyR
P09079928A1319|102 116|enteric bacteria
P09079928A1319|139 153|LysR superfamily
P09080250A0212|5 16|present study
P09080250A0212|44 71|several p15E cDNA gene fragments
P09080250A0212|83 87|means
P09080250A0212|90 112|polymerase chain reaction
P09080250A0212|114 116|PCR
P09080250A0212|131 134|P815
P09080250A0212|151 159|P815/DTIC
P09080250A0212|161 171|tumour cells
P09080517A0215|11 18|patients
P09081389A1088|0 4|Grade
P09081389A1088|8 16|mucositis
P09081389A1088|31 31|%
P09081389A1088|37 42|cycles
P09081392A0174|22 45|tolerable salvage regimens
P09082335A0730|0 3|None
P09082335A0730|11 31|organic manifestations
P09082335A0730|47 64|scintigraphic means
P09083291A1378|5 13|TGF-beta1
P09083291A1378|29 53|mitogen-induced expression
P09083291A1378|57 65|abundance
P09083291A1378|68 82|G1 phase cyclin D1
P09083291A1378|86 89|cdks
P09083291A1378|97 99|MCs
P09083291A1378|111 121|cyclin E-cdk
P09083291A1378|111 117|cyclin E
P09083291A1378|119 122|cdk 2
P09083291A1378|146 176|mitogen-elicited phosphorylation
P09083291A1378|180 191|inactivation
P09083291A1378|194 196|pRb
P09083291A1378|199 205|G1 phase
P09083291A1378|221 226|S phase
P09083345A0851|18 23|values
P09083345A0851|34 43|suggestive
P09083345A0851|66 74|districts
P09083345A0851|79 95|contrasting values
P09083345A0851|98 102|SYPLR
P09083345A0851|119 137|inter-relationships
P09083345A0851|145 175|sociodemographic characteristics
P09083345A0851|177 184|duration
P09083345A0851|187 194|symptoms
P09083345A0851|196 215|clinical presentation
P09083345A0851|219 235|treatment efficacy
P09083563A0971|3 18|prominent lesions
P09083563A0971|36 55|cerebral surface layer
P09083563A0971|59 78|leptomeningeal tissue
P09083563A0971|91 106|arachnoid vessels
P09083563A0971|131 148|cerebrospinal fluid
P09083563A0971|168 184|necrotizing toxins
P09083563A0971|217 224|B. cereus
P09084174A0667|24 33|C-terminal
P09084174A0667|36 46|nucleotides
P09084174A0667|49 52|leuB
P09084174A0667|62 91|3-isopropylmalate dehydrogenase
P09084174A0667|93 95|asd
P09084174A0667|105 144|aspartate-beta-semialdehyde dehydrogenase
P09084174A0667|146 148|Asd
P09084174A0667|154 157|orfA
P09084174A0667|192 202|Asd proteins
P09084174A0667|207 215|Vibrio spp
P09084176A0601|0 22|Transcriptional activity
P09084176A0601|36 57|slot-blot hybridization
P09084176A0601|62 76|steady-state RNA
P09084176A0601|89 104|lacZ+ M. smegmatis
P09084176A0601|89 92|lacZ
P09084176A0601|94 110|M. smegmatis clones
P09084227A0833|0 9|Hovenitin I
P09084227A0833|17 26|ampelopsin
P09084227A0833|43 62|principal ingredients
P09084227A0833|68 82|active fractions
P09084227A0833|91 105|natural medicine
P09084227A0833|124 141|inhibitory activity
P09084227A0833|147 177|ethanol-induced muscle relaxation
P09084227A0833|180 183|rats
P09084621A0374|0 11|Movement time
P09084621A0374|15 38|kinematic characteristics
P09084621A0374|77 93|cerebral blood flow
P09084621A0374|104 108|areas
P09084621A0374|111 136|brain activity proportionate
P09084621A0374|146 162|movement variables
P09084621A2567|0 4|Areas
P09084621A2567|22 32|greater rCBF
P09084621A2567|52 66|left motor cortex
P09084621A2567|72 90|intraparietal sulcus
P09084621A2567|99 105|caudate
P09085842A0181|0 12|Recent studies
P09085842A0181|36 42|U1 snRNP
P09085842A0181|61 70|splice site
P09085842A0181|73 99|protein/protein interactions
P09085842A0181|73 87|protein/protein
P09085842A0181|112 120|SR domains
P09085842A0181|126 138|U1-70K protein
P09085842A0181|142 148|SF2/ASF
P09085842A0181|142 144|SF2
P09085842A0181|146 148|ASF
P09085842A1559|8 35|tri-snRNP-specific 27K protein
P09085842A1559|64 108|SR protein-mediated protein/protein interactions
P09085842A1559|129 148|phosphorylation state
P09085842A1559|162 177|pre-mRNA splicing
P09086268A0611|8 9|P7
P09086268A0611|30 38|particles
P09086268A0611|46 47|P7
P09086268A0611|51 59|particles
P09086268A0611|71 72|P2
P09086268A0611|74 86|RNA polymerase
P09086268A0611|91 92|P7
P09087430A1046|11 24|same U1A peptide
P09087430A1046|15 24|U1A peptide
P09087430A1046|42 44|BSA
P09087430A1046|54 66|vertebrate PAP
P09088371T0000|0 11|Plasma levels
P09088371T0000|14 21|protein C
P09088371T0000|23 30|protein S
P09088371T0000|35 49|antithrombin III
P09088371T0000|35 46|antithrombin
P09088371T0000|52 59|patients
P09088371T0000|64 86|subarachnoid haemorrhage
P09088416A0000|0 57|Idiopathic bilateral recurrent branch retinal arterial occlusion
P09088416A0000|59 65|IBRBRAO
P09088416A0000|70 81|rare syndrome
P09088416A0000|97 113|migraine headaches
P09088416A0000|115 122|tinnitus
P09088416A0000|124 130|vertigo
P09088416A0000|132 142|hearing loss
P09088416A0000|147 183|recurrent branch retinal artery occlusion
P09088416A0000|186 200|unknown etiology
P09088737T0000|0 9|Epithelial
P09088737T0000|13 40|corneal thickness measurements
P09088737T0000|49 66|confocal microscopy
P09088737T0000|83 86|CMTF
P09089093A0373|0 8|Sequences
P09089093A0373|27 38|human CA genes
P09089093A0373|58 83|homologous enhancer elements
P09089653A0615|0 18|Recombinant plasmids
P09089653A0615|41 42|nt
P09089653A0615|45 47|UTR
P09089653A0615|50 53|exon
P09089653A0615|63 71|nt segment
P09089653A0615|76 91|flanking sequence
P09089653A0615|102 119|luciferase activity
P09089653A0615|102 111|luciferase
P09089653A0615|128 138|times higher
P09089653A0615|144 169|promoterless control plasmid
P09089653A1112|0 7|Analysis
P09089653A1112|11 33|DNA-protein interactions
P09089653A1112|11 21|DNA-protein
P09089653A1112|43 61|DNase-I footprinting
P09089653A1112|43 49|DNase-I
P09089653A1112|73 83|broad region
P09089653A1112|109 110|nt
P09090050A0419|8 17|homologous
P09090050A0419|20 37|other sugar carriers
P09090054A0186|20 23|loci
P09090054A0186|51 55|genes
P09090054A0186|70 77|permease
P09090054A0186|81 97|alpha-glucosidase
P09090054A0186|104 113|fourth gene
P09090054A0186|127 152|extra alpha-glucosidase gene
P09090054A0186|164 175|MAL1 adjacent
P09090054A0186|181 192|usual cluster
P09090054A0186|200 204|genes
P09090592A0175|8 14|methods
P09090592A0175|35 53|activation fMR images
P09090592A0175|77 89|motional error
P09090592A0175|101 110|incomplete
P09090592A0175|143 160|spatial orientation
P09091010A1003|5 9|women
P09091010A1003|17 36|abnormal endocervical
P09091010A1003|45 62|cytology suggestive
P09091010A1003|65 79|residual disease
P09091125A0161|0 23|Autorosette-forming cells
P09091125A0161|43 54|high activity
P09091125A0161|57 83|alkaline and acid phosphatases
P09091125A0161|57 64|alkaline
P09091125A0161|68 83|acid phosphatases
P09091125A0161|87 103|low NBT-test values
P09091403T0001|0 7|Analysis
P09091403T0001|10 31|homologous DNA sequences
P09091403T0001|41 51|first intron
P09091403T0001|65 78|human mts1 genes
P09091403T0001|80 90|kB-like site
P09091403T0001|94 110|microsatellite DNA
P09092493A0861|19 25|VIP CyRE
P09092493A0861|19 21|VIP
P09092493A0861|22 25|CyRE
P09092493A0861|31 38|Jak-Stat
P09092493A0861|31 33|Jak
P09092493A0861|35 38|Stat
P09092493A0861|42 62|AP-1 signaling pathways
P09092493A0861|42 45|AP-1
P09092493A0861|67 91|other pre-existing proteins
P09092493A0861|101 117|cellular mechanism
P09092493A0861|129 154|cytokine-specific signaling
P09092580A1354|5 11|studies
P09092580A1354|38 53|MAP kinase pathway
P09092580A1354|38 46|MAP kinase
P09092580A1354|59 68|activation
P09092580A1354|71 84|monocytic cells
P09092580A1354|91 104|transmigration
P09092580A1354|107 123|inflammatory sites
P09092636A0802|3 9|results
P09092636A0802|21 54|temperature-sensitive rad54-3 allele
P09092636A0802|61 80|mitotic recombination
P09092636A0802|104 125|DYZ3 satellite sequences
P09092636A0802|153 189|human DYZ5 satellite-containing YAC clone
P09092636A0802|153 161|human DYZ5
P09092675A0283|1 16|P22 R17 derivative
P09092675A0283|23 31|OcRNA site
P09092675A0283|33 38|P22 R17
P09092675A0283|40 40|A
P09092675A0283|46 46|U
P09092675A0283|91 97|strains
P09093867T0000|12 27|Ac/Ds transposons
P09093867T0000|12 13|Ac
P09094093A0578|25 31|TATA box
P09094093A0578|38 49|somatic cells
P09094315A0541|41 53|B-Myb activity
P09094315A0541|41 45|B-Myb
P09094315A0541|56 66|cyclin-Cdks
P09094671A1192|0 28|Candidate tumor suppressor genes
P09094671A1192|30 33|Mts1
P09094671A1192|35 42|p16INK4a
P09094671A1192|47 50|Mts2
P09094671A1192|52 59|p15INK4b
P09094671A1192|94 113|Southern blot analysis
P09094671A1192|117 135|homozygous deletions
P09096229T0000|0 13|Excision repair
P09096229T0000|29 38|nucleotide
P09096229T0000|44 74|Saccharomyces cerevisiae MFA2 gene
P09096229T0000|67 74|MFA2 gene
P09096229T0000|76 82|mapping
P09096229T0000|120 125|strand
P09096229T0000|162 182|partial rad16 requisite
P09096229T0000|169 173|rad16
P09096229T0000|195 218|upstream control sequences
P09096234T0000|2 9|aromatic
P09096234T0000|36 43|subunits
P09096234T0000|56 77|DNA sequence specificity
P09096234T0000|79 104|operator site discrimination
P09096234T0000|107 128|phage lambda cI repressor
P09096958A0000|28 47|monoclonal antibodies
P09096958A0000|61 78|human platelet talin
P09096958A0000|81 95|Western blotting
P09096958A0000|97 115|immune precipitation
P09096958A0000|120 137|immunofluorescence
P09096958A0000|151 165|antibodies TA205
P09096958A0000|169 172|TD77
P09096958A0000|180 196|actin stress fibers
P09096958A0000|200 213|focal adhesions
P09096958A0000|225 236|cell motility
P09096958A0000|258 273|human fibroblasts
P09098066A0119|4 8|locus
P09098066A0119|29 31|kbp
P09098066A0119|39 43|genes
P09098066A0119|52 86|cytadherence-associated proteins HMW1
P09098066A0119|52 82|cytadherence-associated proteins
P09098066A0119|83 86|HMW1
P09098066A0119|90 93|HMW3
P09098066A0119|101 110|insertions
P09098066A0119|137 144|proteins
P09098066A0119|149 170|hemadsorption-negative
P09098066A0119|176 184|phenotype
P09098066A0119|198 236|designation cytadherence-regulatory locus
P09098066A0119|209 236|cytadherence-regulatory locus
P09098066A0119|238 240|crl
P09098899A0000|0 12|Coliphage 186 B
P09098899A0000|0 8|Coliphage
P09098899A0000|12 12|B
P09098899A0000|16 34|72-amino acid protein
P09098899A0000|49 57|Ogr family
P09098899A0000|49 51|Ogr
P09098899A0000|60 95|analogous transcription factors present
P09098899A0000|98 109|P2-like phage
P09098899A0000|124 175|Cys-X2-Cys-X22-Cys-X4-Cys presumptive zinc-finger motif
P09098899A0000|160 175|zinc-finger motif
P09098899A0435|3 22|UV absorption spectrum
P09098899A0435|45 46|nm
P09098899A0435|64 70|CysS-Cd
P09098899A0435|75 115|ligand-to-metal charge-transfer transitions
P09098899A0435|123 153|difference absorption coefficient
P09098899A0435|159 171|acidification
P09098899A0435|173 184|delta epsilon
P09098899A0435|191 198|mM-1 cm-1
P09098899A0435|223 224|Cd
P09098899A0435|226 230|Cys-S
P09099683A0000|0 19|Diacylglycerol kinase
P09099683A0000|21 23|DGK
P09099683A0000|35 40|levels
P09099683A0000|43 71|second messenger diacylglycerol
P09099683A0000|74 78|cells
P09099683A0000|98 105|putative
P09099683A0000|107 115|messenger
P09099683A0000|117 132|phosphatidic acid
P09099702A0000|26 32|cloning
P09099702A0000|38 54|germ cell-specific
P09099702A0000|56 97|nuclear orphan receptor germ cell nuclear factor
P09099702A0000|99 102|GCNF
P09099702A0000|105 107|RTR
P09099702A0692|23 29|conRTRE
P09099702A0692|41 52|putative RTRE
P09099702A0692|49 52|RTRE
P09099702A0692|66 70|P2-RE
P09099702A0692|79 101|promoter-flanking region
P09099702A0692|107 125|mouse protamine 2 gene
P09099702A0692|107 120|mouse protamine
P09099702A0692|150 158|same stage
P09099702A0692|161 175|spermatogenesis
P09099702A0692|178 180|RTR
P09099743A0585|15 26|purification
P09099743A0585|33 42|larger form
P09099743A0585|60 74|320-kDa particle
P09099743A0585|87 93|mRNP3+4
P09099743A0585|101 122|additional polypeptides
P09099743A0585|133 156|mRNA-binding polypeptides
P09099743A0585|166 168|kDa
P09099743A0585|173 179|doublet
P09099743A0585|189 191|kDa
P09099743A0585|206 214|nucleolin
P09099745A1446|0 14|Active complexes
P09099745A1446|24 44|higher molecular weight
P09099745A1446|49 65|inactive complexes
P09099745A1446|81 89|deficient
P09099745A1446|96 98|p21
P09099745A1446|102 104|p27
P09099745A1446|118 121|Cdk2
P09099745A1446|135 143|threonine
P09099745A1446|147 161|phosphorylation
P09099745A1446|189 198|activation
P09099745A1446|201 212|cyclin E-Cdk2
P09099745A1446|233 255|CDK inhibitor association
P09099745A1446|233 235|CDK
P09099745A1446|259 302|CDK-activating kinase-mediated phosphorylation
P09099745A1446|259 278|CDK-activating kinase
P09099745A1446|305 308|Cdk2
P09100202A0000|6 10|Class
P09100202A0000|15 31|Class II recessions
P09100202A0000|36 43|patients
P09100202A0000|68 110|subepithelial connective tissue graft procedure
P09101085A0686|3 13|derivatives
P09101085A0686|28 36|cell lines
P09101085A0686|67 80|p27Kip1 protein
P09101085A0686|84 93|inhibition
P09101085A0686|96 105|cell growth
P09101910A0394|3 24|perioperative mortality
P09101910A0394|30 37|patients
P09101910A0394|44 44|%
P09101910A0394|60 72|patients older
P09101910A0394|79 83|years
P09101910A0394|90 90|%
P09102113A0739|0 26|Chronic renal failure patients
P09102113A0739|45 64|cardiovascular causes
P09102113A0739|83 109|malignant disease responsible
P09102113A0739|135 135|%
P09103382T0000|3 19|new FIGO definition
P09103382T0000|22 42|cervical cancer stage IA
P09103382T0000|45 52|critique
P09104816A0610|11 13|Vpu
P09104816A0610|22 31|biogenesis
P09104816A0610|45 54|more detail
P09104816A0610|61 98|Vpu-expressing recombinant vaccinia virus
P09104816A0610|61 63|Vpu
P09104816A0610|100 101|VV
P09105042A1497|25 33|phenotype
P09105042A1497|36 55|myofibrillar disarray
P09105042A1497|62 72|HCM patients
P09105042A1497|100 108|mutations
P09105042A1497|145 173|mutant myosin heavy chain protein
P09105042A1497|191 206|normal sarcomeres
P09105042A1497|223 237|secondary effect
P09105042A1497|262 274|chronic stress
P09105042A1497|286 300|beta MHC function
P09105042A1497|286 292|beta MHC
P09105363A0636|18 49|plasma atomic emission spectroscopy
P09105363A0636|72 96|tissue silicon measurements
P09105530A0000|2 11|egg protein
P09105530A0000|13 20|lysozyme
P09105530A0000|30 46|unlabeled additive
P09105530A0000|62 78|cheese preparation
P09106057A0000|13 37|simultaneous determination
P09106057A0000|43 50|N-methyl
P09106057A0000|53 61|N-ethyl-8
P09106057A0000|65 83|anhydroerythromycin
P09106057A0000|85 98|6,9-hemiacetal
P09106057A0000|100 104|EM523
P09106057A0000|119 129|metabolites
P09106057A0000|132 142|human plasma
P09106057A0000|146 150|urine
P09106057A0000|172 207|high-performance liquid chromatography
P09106057A0000|209 212|HPLC
P09106057A0000|218 234|chemiluminescence
P09106057A0000|236 237|CL
P09106057A0000|239 247|detection
P09108029A0399|13 31|DNA-binding activity
P09108029A0399|34 50|activator protein 1
P09108029A0399|34 49|activator protein
P09108029A0399|52 55|AP-1
P09108029A0399|70 84|DNA repair enzyme
P09108029A0399|86 97|redox factor 1
P09108029A0399|86 96|redox factor
P09108029A0399|99 103|Ref-1
P09108029A0399|125 139|DNA repair enzyme
P09108029A0399|141 154|AP endonuclease
P09108038A1128|8 16|LRR domain
P09108038A1128|22 38|SH3-binding domain
P09108038A1128|40 46|Acan125
P09108038A1128|53 70|C. elegans homologue
P09108038A1128|78 88|novel family
P09108038A1128|91 117|bifunctional binding proteins
P09108207A0306|42 64|oropharyngeal irritation
P09108207A0306|67 73|unclear
P09108279A0431|19 24|8-OxoG
P09108279A0431|42 58|cell-free extracts
P09108279A0431|61 69|wild-type
P09108279A0431|73 83|ogg1 strains
P09108279A0431|73 76|ogg1
P09108279A0431|90 105|34mer DNA fragment
P09108279A0431|117 135|single 8-OxoG residue
P09108279A0431|147 154|cytosine
P09108279A0431|156 163|8-OxoG/C
P09108279A0431|168 176|substrate
P09108451A0160|0 6|Results
P09108451A0160|17 33|other laboratories
P09108451A0160|51 56|UCN-01
P09108451A0160|64 95|preferential G1-phase accumulation
P09108451A0160|98 123|several human tumor cell lines
P09110176A0890|0 7|Northern
P09110176A0890|11 24|RT-PCR analysis
P09110176A0890|27 41|Ube3a expression
P09110176A0890|27 31|Ube3a
P09110176A0890|44 55|mouse tissues
P09110176A0890|60 66|animals
P09110176A0890|71 79|segmental
P09110176A0890|81 105|paternal uniparental disomy
P09110176A0890|142 157|absent expression
P09110176A0890|175 181|animals
P09110176A0890|213 239|maternal-specific expression
P09110176A0890|248 252|locus
P09111004A0732|3 20|predominant effects
P09111004A0732|37 46|Xaa residue
P09111004A0732|52 86|dual phosphorylation motif Thr-Xaa-Tyr
P09111004A0732|106 140|L12 influence p38 substrate specificity
P09111004A0732|118 120|p38
P09111004A0732|160 162|L12
P09111004A0732|169 177|major role
P09111004A0732|191 209|autophosphorylation
P09111048X0000|7 35|testis-specific mRNA transcript
P09111048X0000|46 57|NH2-terminal
P09111048X0000|67 86|nitric-oxide synthase
P09111048X0000|88 100|mRNA diversity
P09111048X0000|112 121|major theme
P09111048X0000|124 151|neuronal nitric-oxide synthase
P09111048X0000|153 156|nNOS
P09111048X0000|158 171|gene expression
P09111048X0000|174 193|somatic cells/tissues
P09111059A0327|9 25|MAR-binding domain
P09111059A0327|30 40|homeodomain
P09111059A0327|71 84|low specificity
P09111309A0674|0 13|Cotransfection
P09111309A0674|16 20|Ets-2
P09111309A0674|24 50|p44 mitogen-activated protein
P09111309A0674|24 26|p44
P09111309A0674|27 50|mitogen-activated protein
P09111309A0674|52 61|MAP) kinase
P09111309A0674|52 54|MAP
P09111309A0674|56 78|kinase expression vectors
P09111309A0674|98 121|HB-EGF promoter activation
P09111309A0674|134 143|deltaRaf-1
P09111309A0674|145 146|ER
P09111314A0970|0 7|Cyclin D1
P09111314A0970|31 34|cdk4
P09111314A0970|40 67|resistant 184A1L5R cell lysates
P09111314A1243|15 41|posttranslational regulation
P09111314A1243|44 51|p15INK4B
P09111314A1243|54 61|TGF-beta
P09111314A1243|96 121|TGF-beta-resistant 184A1L5R
P09111314A1243|96 103|TGF-beta
P09111314A1243|134 146|p15 transcript
P09111314A1243|157 171|p15INK4B protein
P09111314A1243|211 233|cyclin D1-cdk association
P09111314A1243|211 218|cyclin D1
P09111314A1243|220 222|cdk
P09111314A1243|237 252|kinase activation
P09111331A0119|3 13|Rlm1 protein
P09111331A0119|27 39|MADS box family
P09111331A0119|42 61|transcription factors
P09111331A0119|63 71|functions
P09111331A0119|84 87|Mpk1
P09111331A0119|93 99|pathway
P09111340A0240|10 27|cis-acting elements
P09111340A0240|38 46|c-myc mRNA
P09111340A0240|50 63|downregulation
P09111340A0240|70 79|myogenesis
P09111340A0240|100 109|C2C12 cells
P09111340A0240|114 127|mutant myc genes
P09111340A0240|130 142|chimeric genes
P09111340A0240|150 168|various myc sequences
P09111340A0240|157 168|myc sequences
P09111340A0240|183 202|human beta-globin gene
P09111340A0240|210 250|bacterial chloramphenicol acetyltransferase
P09111340A0240|252 254|CAT
P09111367A1098|12 22|experiments
P09111367A1098|27 58|32D temperature-sensitive p53 cells
P09111367A1098|51 53|p53
P09111367A1098|71 93|aberrant tal-1 expression
P09111367A1098|79 83|tal-1
P09111367A1098|99 119|permissive temperature
P09111367A1098|133 151|proliferative effect
P09111367A1098|161 181|p53-mediated apoptosis
P09111367A1098|161 163|p53
P09111367A1098|191 214|tal-1 proliferative effect
P09111367A1098|241 260|cell cycle checkpoints
P09111367A1098|266 273|host cell
P09111367A1098|288 292|c-myc
P09111367A1098|296 309|other oncogenes
P09111367A1098|311 332|tal-1 mutant experiments
P09111367A1098|345 363|ectopic tal-1 effects
P09111367A1098|384 394|DNA-binding
P09111367A1098|401 425|heterodimerization domains
P09111367A1098|435 467|N-terminally truncated tal-1 variant
P09111367A1098|435 446|N-terminally
P09111367A1098|456 467|tal-1 variant
P09111367A1098|469 470|M3
P09111367A1098|483 501|T-ALL malignant cells
P09111367A1098|511 517|effects
P09111367A1098|523 538|wild-type protein
P09111863A0743|18 29|common region
P09111863A0743|32 40|deletions
P09111863A0743|54 68|tumor suppressor
P09111863A0743|89 99|coincidence
P09111863A0743|117 134|chromosome fragment
P09111863A0743|146 159|tumorigenicity
P09111863A0743|178 187|tumor cells
P09112400A1155|0 18|DNA-binding activity
P09112400A1155|49 57|forskolin
P09112400A1155|60 65|thecal
P09112400A1155|68 78|luteal cells
P09114972A1366|4 12|induction
P09114972A1366|15 17|SOS
P09114972A1366|19 27|viability
P09115242A0934|13 19|Western
P09115242A0934|21 30|supershift
P09115242A0934|35 58|promoter deletion analyses
P09115242A0934|76 109|CCAAT/enhancer-binding protein-beta
P09115242A0934|111 120|C/EBP-beta
P09115242A0934|122 132|binding site
P09115242A0934|165 177|transcription
P09115242A0934|180 192|collagenase-1
P09115242A0934|195 208|monocytic cells
P09115247A2069|0 24|11-Aminoundecanoyl-SK-NH2
P09115247A2069|28 52|11-aminoundecanoyl-SH-NH2
P09115247A2069|67 85|simple alkyl backbone
P09115247A2069|99 117|appropriate distance
P09115247A2069|130 145|elements critical
P09115247A2069|165 176|fungal enzyme
P09115247A2069|179 197|peptide-binding site
P09115247A2069|200 229|simple omega-terminal amino group
P09115247A2069|232 244|beta-hydroxyl
P09115247A2069|251 268|epsilon-amino group
P09115247A2069|273 281|imidazole
P09115265A1160|3 29|carboxyl-terminal CCCC module
P09115265A1160|56 72|DNA-binding domain
P09115265A1160|78 111|erythroid transcription factor GATA-1
P09115279A0345|0 18|Cdc2 co-precipitates
P09115279A0345|0 3|Cdc2
P09115279A0345|23 26|Pch1
P09115279A0345|29 30|S.
P09115279A0345|36 46|cell lysates
P09115279A0345|56 59|Cdc2
P09115279A0345|71 91|major catalytic partner
P09115279A0345|95 104|Pch1 kinase
P09115357A0073|0 5|Little
P09115357A0073|51 67|rapid facile assays
P09115357A0073|81 107|immunoglobulin hypermutation
P09115357A0073|81 94|immunoglobulin
P09115357A0073|139 152|culture systems
P09115357A0073|156 174|hypermutating B cells
P09115357A0073|198 217|individuals deficient
P09115365A0000|0 9|Expression
P09115365A0000|15 41|human heat shock protein 70 gene
P09115365A0000|15 35|human heat shock protein
P09115365A0000|43 47|hsp70
P09115365A0000|60 71|various kinds
P09115365A0000|85 93|oncogenes
P09115395A0478|7 14|proteins
P09115395A0478|67 73|mitosis
P09115395A0478|75 96|epithelial-microtubule
P09115395A0478|107 117|protein-115
P09115395A0478|119 123|Oct91
P09115395A0478|125 146|Elongation factor 1gamma
P09115395A0478|148 151|BRG1
P09115395A0478|155 174|Ribosomal protein L18A
P09115395A0478|193 200|proteins
P09115395A0478|217 221|roles
P09115395A0478|224 230|mitosis
P09115395A0478|232 253|epithelial-microtubule
P09115395A0478|264 274|protein-115
P09115395A0478|300 303|Cdc5
P09115395A0478|305 326|innercentrosome protein
P09115395A0478|328 331|BRG1
P09115395A0478|338 351|RNA helicase WM6
P09115395A0478|373 392|transcription factors
P09115395A0478|394 397|BRG1
P09115395A0478|399 421|negative co-factor 2alpha
P09115395A0478|423 427|Oct91
P09115395A0478|429 430|S.
P09115395A0478|436 439|Cdc5
P09115395A0478|441 445|HoxD1
P09115395A0478|447 450|Sox3
P09115395A0478|452 456|Vent2
P09115395A0478|464 471|isoforms
P09115395A0478|474 478|Xbr1b
P09115989A0993|30 48|psoralen cross-links
P09115989A0993|57 70|different steps
P09115989A0993|76 92|initiation process
P09117345A0945|0 9|Activation
P09117345A0945|12 22|alpha 4 beta 1
P09117345A0945|12 16|alpha
P09117345A0945|18 21|beta
P09117345A0945|27 32|TS2/16
P09117345A0945|45 66|cytoplasmic protrusions
P09117345A0945|70 82|cell migration
P09117345A0945|110 124|phosphorylation
P09118196A0281|0 10|Performance
P09118196A0281|16 46|verbal measures-the National Adult
P09118196A0281|54 65|Test-Revised
P09118196A0281|67 72|NART-R
P09118196A0281|80 96|Vocabulary subtest
P09118196A0281|104 141|Wechsler Adult Intelligence Scale-Revised
P09118196A0281|143 148|WAIS-R
P09118196A0281|157 174|strong correlations
P09118664A1734|0 11|L-canavanine
P09118664A1734|14 31|selective inhibitor
P09118664A1734|37 64|inducible nitric oxide synthase
P09118664A1734|46 64|nitric oxide synthase
P09118664A1734|78 104|mean systemic filling pressure
P09118664A1734|122 133|venous return
P09118664A1734|145 154|conditions
P09118704A0771|0 6|RESULTS
P09118704A0771|15 22|patients
P09118704A0771|34 55|concurrent chemotherapy
P09118704A0771|59 63|G-CSF
P09118704A0771|71 71|%
P09118704A0771|75 93|% confidence interval
P09118704A0771|95 96|CI
P09118704A0771|109 109|%
P09118704A0771|139 166|significant bleomycin toxicity
P09119031A1036|3 35|different holoenzyme RNA polymerases
P09119031A1036|68 74|mutants
P09119031A1036|92 108|core RNA polymerase
P09119031A1036|110 123|alpha2beta beta
P09119031A1036|142 164|transcriptional activity
P09119031A1036|182 187|enzyme
P09119031A1036|198 217|wild-type sigma factor
P09119112A1350|39 44|GATA-5
P09119112A1350|82 99|restricted function
P09119112A1350|105 118|embryonic heart
P09119391A0870|3 16|exonic sequence
P09119391A0870|37 46|amino acids
P09119391A0870|91 105|protein sequence
P09119391A0870|108 117|human GPT-1
P09121424A0296|20 42|S. cerevisiae Swi3 homolog
P09121424A0296|32 42|Swi3 homolog
P09121424A0296|44 47|Swh3
P09121424A0296|52 66|present evidence
P09121424A0296|98 108|Snf2 homolog
P09121424A0296|110 113|Sthl
P09121430A0132|0 2|Shc
P09121430A0132|13 46|Ras/mitogen-activated protein kinase
P09121430A0132|13 15|Ras
P09121430A0132|17 46|mitogen-activated protein kinase
P09121430A0132|48 51|MAPK
P09121430A0132|79 82|Grb2
P09121430A0132|102 111|tyrosine (Y
P09121430A0132|102 109|tyrosine
P09121430A0132|111 111|Y
P09121430A0132|113 119|residue
P09121430A1075|11 22|Y239/240F Shc
P09121430A1075|30 37|Y317F Shc
P09121430A1075|49 71|EGF-induced c-myc message
P09121430A1075|49 51|EGF
P09121430A1075|60 64|c-myc
P09121432A0000|3 37|Ras guanine nucleotide-binding protein
P09121432A0000|50 64|molecular switch
P09121432A0000|67 86|signalling downstream
P09121432A0000|89 111|protein-tyrosine kinases
P09121433A0463|10 13|Rlm1
P09121433A0463|17 20|Smp1
P09121433A0463|25 60|MEF2-related DNA-binding specificities
P09121433A0463|62 65|Rlm1
P09121433A0463|78 92|same specificity
P09121433A0463|95 98|MEF2
P09121433A0463|100 102|CTA
P09121433A0463|104 106|T/A
P09121433A0463|108 111|4TAG
P09121433A0463|118 121|SMP1
P09121433A0463|132 156|extended consensus sequence
P09121433A0463|158 164|ACTACTA
P09121433A0463|166 168|T/A
P09121433A0463|170 173|4TAG
P09121435A1183|0 6|Domains
P09121435A1183|15 15|B
P09121435A1183|43 59|TFIIIB-DNA complex
P09121435A1183|75 93|protein footprinting
P09121452A0538|0 22|Domain switch experiments
P09121452A0538|33 49|C/EBP beta proteins
P09121452A0538|69 81|leucine zipper
P09121452A0538|87 102|activation domain
P09121452A0538|105 114|C/EBP alpha
P09121452A0538|138 148|2D5 promoter
P09121452A0538|186 203|artificial promoter
P09121452A0538|212 233|high-affinity C/EBP site
P09121452A0538|225 233|C/EBP site
P09121454A1328|3 19|similar phenotypes
P09121454A1328|22 25|bur6
P09121454A1328|29 32|bur3
P09121454A1328|34 37|mot1
P09121454A1328|39 47|mutations
P09121454A1328|59 63|Bur6p
P09121454A1328|67 71|Mot1p
P09121454A1328|100 108|functions
P09121454A1328|137 165|general transcription machinery
P09121476T0000|0 4|PRH75
P09121476T0000|7 32|new nucleus-localized member
P09121476T0000|38 58|DEAD-box protein family
P09121476T0000|63 74|higher plants
P09121774A0611|5 14|activities
P09121774A0611|32 42|stimulation
P09121774A0611|45 54|cell growth
P09121774A0611|57 64|middle-T
P09121774A0611|76 82|members
P09121774A0611|88 102|MAP kinase family
P09121774T0000|11 24|small GTPase Rac
P09121774T0000|27 72|polyomavirus middle-T antigen-mediated activation
P09121774T0000|27 53|polyomavirus middle-T antigen
P09121774T0000|78 97|serum response element
P09121774T0000|103 120|cell transformation
P09121998A0663|0 18|Time-activity curves
P09121998A0663|26 38|gastric region
P09121998A0663|63 72|subjection
P09121998A0663|75 105|appropriate corrective procedures
P09121998A0663|121 142|mean gastric transit time
P09121998A0663|144 146|MTT
P09121998A0663|169 176|test meal
P09121998A0663|204 206|min
P09121998A0663|208 210|F90
P09122168A1427|18 36|direct demonstration
P09122168A1427|47 56|G betagamma
P09122168A1427|71 101|agonist-stimulated translocation
P09122168A1427|104 107|GRK2
P09122168A1427|111 114|GRK3
P09122168A1427|119 138|intact cellular system
P09122168A1427|154 171|isoform specificity
P09122168A1427|195 204|components
P09122176A0970|3 9|results
P09122176A0970|22 42|RA-mediated repression
P09122176A0970|48 55|hMGP gene
P09122176A0970|63 69|binding
P09122176A0970|72 86|liganded RAR/RXR
P09122176A0970|80 82|RAR
P09122176A0970|84 86|RXR
P09122176A0970|90 119|novel negative RA response element
P09122198A0478|0 13|Point mutations
P09122198A0478|23 38|tyrosine residues
P09122198A0478|44 60|cytoplasmic domain
P09122198A0478|66 73|receptor
P09122198A0478|106 116|conclusions
P09122215A0335|11 21|novel method
P09122215A0335|62 88|protein-truncating mutations
P09123055T0000|0 19|Hepatocellular injury
P09123055T0000|26 37|preservation
P09123055T0000|40 50|human livers
P09123055T0000|55 56|UW
P09123055T0000|60 70|HTK solution
P09123787A0486|32 40|responses
P09123787A0486|54 68|early R1 response
P09123787A0486|74 106|orbicularis oculi muscle ipsilateral
P09123787A0486|118 128|stimulation
P09123787A0486|131 151|bilateral late response
P09123787A0486|153 165|ipsilateral R2
P09123787A0486|169 183|contralateral Rc
P09123787A0486|195 204|R3 response
P09123787A0486|211 243|ipsilateral orbicularis oculi muscle
P09124054A1164|3 11|prognosis
P09124054A1164|19 26|patients
P09124054A1164|38 42|ABSCT
P09124054A1164|77 84|patients
P09124054A1164|96 114|conventional therapy
P09126487A1399|6 8|Hum
P09126622A0466|3 18|pigment intensity
P09126622A0466|25 41|melanized colonies
P09126622A0466|45 55|appressoria
P09126622A0466|58 73|CAL transformants
P09126622A0466|77 82|weaker
P09126622A0466|96 103|wild type
P09128730A0000|0 22|Malonate decarboxylation
P09128730A0000|25 40|Malonomonas rubra
P09128730A0000|63 71|malonyl-S
P09128730A0000|74 92|acyl-carrier protein
P09128730A0000|98 105|acetyl-S
P09128730A0000|108 126|acyl-carrier protein
P09128730A0000|131 138|malonate
P09128730A0000|140 155|carboxyltransfer
P09128730A0000|159 171|biotin protein
P09128730A0000|178 192|decarboxylation
P09128730A0000|208 216|delta mu Na
P09129147A0644|3 20|Jem peptide sequence
P09129147A0644|28 41|leucine-zipper
P09129147A0644|43 59|dimerisation motif
P09129147A0644|64 78|limited homology
P09129147A0644|81 87|Fos/Jun
P09129147A0644|81 83|Fos
P09129147A0644|85 87|Jun
P09129147A0644|91 106|ATF/CREB proteins
P09129147A0644|91 93|ATF
P09129147A0644|110 144|several putative phosphorylation sites
P09130595A0478|15 21|cloning
P09130595A0478|45 56|enhancer site
P09130700A0676|0 13|Further support
P09130700A0676|18 34|direct interaction
P09130700A0676|37 41|Tub4p
P09130700A0676|43 48|Spc98p
P09130700A0676|52 57|Spc97p
P09130700A0676|70 77|toxicity
P09130700A0676|80 104|strong SPC97 overexpression
P09130700A0676|86 90|SPC97
P09130700A0676|124 140|co-overexpression
P09130700A0676|143 146|TUB4
P09130700A0676|149 153|SPC98
P09130718A0497|0 8|Sequences
P09130718A0497|18 41|iron-regulated expression
P09130718A0497|44 47|sid1
P09130718A0497|52 60|localized
P09130718A0497|67 74|bp region
P09130718A0497|91 92|kb
P09130718A0497|106 108|ATG
P09130720A0417|1 13|genetic screen
P09130720A0417|23 29|mutants
P09130720A0417|35 50|branch site region
P09130720A0417|63 71|positions
P09130720A0417|86 100|TACTAAC sequence
P09130720A0417|116 132|intron recognition
P09131139T0000|0 10|Implication
P09131139T0000|13 15|PAF
P09131139T0000|19 33|acetylhydrolase
P09131139T0000|35 40|PAF-AH
P09131139T0000|52 69|periodontal disease
P09132011A0298|0 9|Comparison
P09132011A0298|15 25|p50 sequence
P09132011A0298|39 46|proteins
P09132011A0298|57 65|% homology
P09132011A0298|71 102|glycosaminoglycan-binding protein
P09132011A0298|108 116|% homology
P09132011A0298|121 153|Drosophila cell cycle control protein
P09132011A0298|155 157|cdc
P09132057A0559|1 11|polypeptide
P09132057A0559|24 26|NTS
P09132057A0559|29 44|open reading frame
P09132057A0559|48 65|sequence similarity
P09132057A0559|71 85|catalytic domain
P09132057A0559|88 116|several receptor protein kinases
P09132057A0559|95 116|receptor protein kinases
P09132057A0559|121 126|plants
P09132057A0559|139 155|S-receptor kinases
P09132057A0559|171 179|rejection
P09132057A0559|182 192|self-pollen
P09132057A0559|195 209|Brassica species
P09132057A0559|216 229|Pto gene product
P09132057A0559|263 279|bacterial pathogen
P09132061A0828|3 6|atp 1
P09132061A0828|3 5|atp
P09132061A0828|10 13|atp 2
P09132061A0828|10 12|atp
P09132061A0828|14 18|types
P09132061A0828|21 33|cDNA sequences
P09132061A0828|45 53|redundant
P09132061A0828|64 86|different isoperoxidases
P09132061A0828|73 86|isoperoxidases
P09132061A0828|110 119|peroxidase
P09132061A0828|128 131|ESTs
P09133122A0656|0 20|Additional information
P09133122A0656|30 55|echocardiographic sequences
P09133122A0656|57 83|perioperative video sequences
P09133122A0656|85 97|x-ray analysis
P09133122A0656|99 108|angiograms
P09135066A0653|30 39|active Mek1
P09135066A0653|36 39|Mek1
P09135066A0653|53 59|p96h2bk
P09135066A0653|74 85|oncogenic Ras
P09135149A0000|43 90|M-phase-inducing Cdc2/Cdc13 cyclin-dependent kinase
P09135149A0000|59 62|Cdc2
P09135149A0000|64 68|Cdc13
P09135149A0000|69 90|cyclin-dependent kinase
P09135149A0000|104 107|Wee1
P09135149A0000|111 129|Mik1 tyrosine kinases
P09135149A0000|145 149|Cdc25
P09135149A0000|153 176|Pyp3 tyrosine phosphatases
P09135772T0000|0 15|Glycemic response
P09135772T0000|34 39|roller
P09135772T0000|45 56|wheat-legume
P09135772T0000|62 66|foods
P09135772T0000|69 82|normal subjects
P09135928A0912|11 16|mmol/l
P09135928A0912|18 18|P
P09135928A0912|29 47|systolic BP responses
P09135928A0912|50 74|intravenous norepinephrine
P09135928A0912|78 90|angiotensin II
P09135928A0912|78 88|angiotensin
P09135928A0912|108 113|higher
P09135928A0912|116 128|glibenclamide
P09135928A0912|135 143|metformin
P09135928A0912|145 145|P
P09135928A0912|154 154|P
P09136015A0529|3 12|sequencing
P09136015A0529|15 35|Stellate copies located
P09136015A0529|15 22|Stellate
P09136015A0529|44 63|discontinuous cluster
P09136015A0529|73 86|complex pattern
P09136015A0529|89 103|diversification
P09136080A1469|3 9|results
P09136080A1469|22 35|DNA methylation
P09136080A1469|37 54|chromatin structure
P09136080A1469|59 73|transactivation
P09136080A1469|78 84|Sp1 site
P09136080A1469|106 125|restricted expression
P09136080A1469|132 164|myelomonocytic lineage specific gene
P09138076A1099|2 23|gel mobility shift assays
P09138076A1099|25 38|factors present
P09138076A1099|41 55|nuclear extracts
P09138076A1099|81 90|osteoblast
P09138076A1099|98 118|oligonucleotide probes
P09138076A1099|132 137|E-box 1
P09138076A1099|132 136|E-box
P09138076A1099|141 154|E-box 2 elements
P09138076A1099|141 145|E-box
P09138076A1099|147 154|elements
P09138492A0806|0 13|Laboratory exam
P09138492A0806|15 17|IDR
P09138492A0806|23 32|tuberculin
P09138492A0806|36 47|high positive
P09138492A0806|49 64|chest radiography
P09138492A0806|70 97|hilar bilateral calcifications
P09138492A0806|99 105|ORL exam
P09138492A0806|131 140|epiglottis
P09138492A0806|144 166|anatomopathological exam
P09138492A0806|189 207|epidermoid carcinoma
P09139665A0784|18 30|PhLP complexes
P09139665A0784|18 21|PhLP
P09139665A0784|53 62|Gbetagamma
P09139694A0789|0 8|CTF1alpha
P09139694A0789|63 72|palindrome
P09139694A0789|74 84|DNA fragment
P09139694A0789|93 102|palindrome
P09139694A0789|106 121|mutant palindrome
P09139694A0789|123 134|DNA fragments
P09139694A0789|146 160|specific binding
P09139694A0789|163 171|CTF1alpha
P09139694A0789|174 183|palindrome
P09139721A0183|0 7|Cyclin G2
P09139721A0183|30 41|immune system
P09139721A0183|47 98|immunologic tolerance subjects self-reactive lymphocytes
P09139721A0183|101 117|negative selection
P09139721A0183|121 134|clonal deletion
P09139721A0183|138 146|apoptosis
P09139737A0000|1 24|sterol-regulated protease
P09139737A0000|46 65|NH2-terminal segments
P09139737A0000|68 106|sterol regulatory element-binding proteins
P09139737A0000|108 113|SREBPs
P09139737A0000|119 131|cell membranes
P09139737A0000|162 168|nucleus
P09139737A0000|183 195|transcription
P09139737A0000|198 202|genes
P09139737A0000|216 221|uptake
P09139737A0000|225 233|synthesis
P09139737A0000|250 259|fatty acids
P09139892A1150|20 23|orfX
P09139892A1150|27 38|vfr promoters
P09139892A1150|53 75|back-to-back orientation
P09139892A1150|89 111|face-to-face orientation
P09139892A1150|117 120|dorf
P09139892A1150|124 135|crp promoters
P09139910A0350|0 15|Sequence analysis
P09139910A0350|24 34|PCR products
P09139910A0350|60 89|different nifV-like DNA fragments
P09139910A0350|69 89|nifV-like DNA fragments
P09139910A0350|118 121|nifV
P09139910A0350|126 144|leuA-specific probes
P09139910A0350|161 178|clone XbaI fragments
P09139910A0350|166 178|XbaI fragments
P09139910A0350|184 186|kbp
P09139910A0350|188 192|pOST4
P09139910A0350|200 202|kbp
P09139910A0350|204 208|pOST2
P09139910A1572|14 27|Anabaena strain
P09139910A1572|32 39|leuA gene
P09139910A1572|59 70|nifV mutation
P09139910A1572|73 77|R229I
P09140079A2528|34 36|TRs
P09140079A2528|44 46|TRE
P09140474T0000|2 21|leishmaniasis endemic
P09140474T0000|35 41|Minorca
P09140474T0000|43 47|Spain
P09140474T0000|51 67|human visceral case
P09140474T0000|81 85|years
P09140474T0000|88 94|Minorca
P09142146A0887|0 6|RESULTS
P09142146A0887|21 31|PAF blockade
P09142146A0887|21 23|PAF
P09142146A0887|67 81|WEB-2086 animals
P09142146A0887|92 105|vehicle animals
P09142146A0887|107 108|p =
P09142146A0887|117 137|depressed cardiac index
P09142146A0887|155 159|hours
P09142146A0887|161 161|p
P09143328A1002|16 27|first example
P09143328A1002|30 40|utilization
P09143328A1002|43 76|noncomplementary dinucleotide primer
P09143328A1002|81 93|RNA polymerase
P09143465A0838|0 5|Pure T1
P09143465A0838|9 21|dual-T1 images
P09143465A0838|46 57|image quality
P09143465A0838|59 60|IQ
P09143465A0838|65 79|five-point scale
P09143465A0838|82 94|= unacceptable
P09143465A0838|98 107|= excellent
P09144165A0614|13 26|ternary complex
P09144165A0614|40 54|NFAT nearest AP-1
P09144165A0614|40 43|NFAT
P09144165A0614|51 54|AP-1
P09144165A0614|60 74|Rel insert region
P09144165A0614|76 78|RIR
P09144165A0614|95 101|notable
P09144165A0614|108 123|hypervariability
P09144165A0614|150 156|members
P09144165A0614|162 189|Rel transcription factor family
P09144165A1275|21 27|NFAT RIR
P09144165A1275|35 51|essential dual role
P09144165A1275|54 67|DNA recognition
P09144165A1275|71 88|cooperative binding
P09144165A1275|91 120|AP-1 family transcription factors
P09144195A1051|21 32|PS1 fragments
P09144195A1051|54 59|cycles
P09144195A1051|62 94|phosphorylation/dephosphorylation
P09144195A1051|100 105|PS1 CTF
P09144770A0906|4 12|conformer
P09144770A0906|22 25|Type
P09144770A0906|27 35|beta-turn
P09144770A0906|42 69|extensive hydrophobic contacts
P09144770A0906|77 96|FKBP12 binding surface
P09144770A0906|77 82|FKBP12
P09144958A0047|32 39|promoter
P09144958A0047|44 95|Arabidopsis light-harvesting chlorophyll a/b protein gene
P09144958A0047|97 103|Lhcb1*3
P09144958A0047|97 101|Lhcb1
P09144958A0047|139 149|phytochrome
P09146027A0809|10 15|Group B
P09146027A0809|19 34|severe athetoid CP
P09146027A0809|39 48|spasticity
P09146071T0001|0 15|Dystonic movement
P09146071T0001|21 33|left upper limb
P09146071T0001|46 67|right pontine hemorrhage
P09147420A0623|28 38|HCMV IE1/IE2
P09147420A0623|36 38|IE2
P09147420A0623|68 75|HIV-1 LTR
P09147420T0000|0 2|TAR
P09147420T0000|6 35|Sp1-independent transactivation
P09147420T0000|6 8|Sp1
P09147420T0000|38 58|HIV long terminal repeat
P09147420T0000|64 73|Tat protein
P09147420T0000|89 115|human cytomegalovirus IE1/IE2
P09147420T0000|89 111|human cytomegalovirus IE1
P09147420T0000|113 115|IE2
P09147788A0458|0 29|Respiratory chain enzyme activity
P09147832A0174|0 7|Children
P09147832A0174|10 20|temperament
P09147832A0174|24 44|maternal socialization
P09147832A0174|47 50|Time
P09147832A0174|53 54|n =
P09147832A0174|59 62|aged
P09147832A0174|66 70|years
P09147832A0174|86 95|predictors
P09147832A0174|98 113|future conscience
P09147832A0174|128 143|new observational
P09147832A0174|147 163|narrative measures
P09148770A0977|0 10|Cellular Csk
P09148770A0977|28 49|several phosphoproteins
P09148770A0977|84 95|Csk SH2 domain
P09148770A0977|84 86|Csk
P09148903A1715|8 14|studies
P09148903A1715|26 46|pV-mediated activation
P09148903A1715|49 64|HIV-1 LTR activity
P09148903A1715|49 56|HIV-1 LTR
P09148903A1715|82 101|nuclear translocation
P09148903A1715|107 134|NF-kappaB transcription factor
P09148903A1715|153 185|IkappaBalpha serine phosphorylation
P09148903A1715|153 164|IkappaBalpha
P09148903A1715|189 199|degradation
P09148903A1715|216 252|undefined NF-kappaB-independent pathway
P09148903A1715|225 233|NF-kappaB
P09148929A0372|3 16|P1 genomic clone
P09148929A0372|23 48|subsequent plasmid subclones
P09148929A0372|78 100|exon-intron organization
P09148929A0372|106 114|Ctpct gene
P09148935A0805|0 28|FN-stimulated c-Src PTK activity
P09148935A0805|18 20|PTK
P09148935A0805|42 62|wild type FAK expression
P09148935A0805|50 52|FAK
P09148935A0805|71 93|FN-stimulated activation
P09148935A0805|71 72|FN
P09148935A0805|96 99|ERK2
P09148935A0805|127 155|c-Src binding site Phe-397 mutant
P09148935A0805|158 160|FAK
P09149825A0151|1 18|promising new cement
P09149825A0151|20 44|4-META/MMA-TBB opaque resin
P09149825A0151|54 81|remarkable adhesive properties
P09149825A0151|85 94|bone cement
P09149929A0750|0 8|Congruent
P09149929A0750|13 32|empirical predictions
P09149929A0750|41 56|homesick children
P09149929A0750|66 75|low control
P09149929A0750|80 91|homesickness
P09150334A0559|63 65|min
P09150334A0559|71 78|sampling
P09150566A0316|21 26|grains
P09150566A0316|43 58|complex molecules
P09150566A0316|61 87|interstellar molecular clouds
P09150595A0225|7 15|elicitors
P09150595A0225|21 42|hypersensitive reaction
P09150595A0225|44 45|HR
P09150595A0225|57 70|E. chrysanthemi
P09150595A0225|72 80|HarpinEch
P09150595A0225|85 95|E. amylovora
P09150595A0225|97 104|HarpinEa
P09150595A0225|117 129|36-kDa protein
P09150595A0225|145 165|typical signal sequence
P09150595A0225|181 211|putative membrane-spanning domain
P09150595T0000|0 24|Molecular characterization
P09150595T0000|43 70|Erwinia carotovora hrpNEcc gene
P09150595T0000|86 93|elicitor
P09150595T0000|99 120|hypersensitive reaction
P09150728A0596|3 6|mRNA
P09150728A0596|26 29|HES1
P09150728A0596|78 91|skeletal muscle
P09150774A0616|0 9|Anesthesia
P09150774A0616|27 36|isoflurane
P09150774A0616|38 40|ISO
P09150774A0616|43 45|N2O
P09150774A0616|49 58|inhalation
P09151152A0174|12 36|depressed protein C activity
P09151152A0174|55 55|p
P09151152A0174|103 114|hemodialysis
P09151152A0174|120 126|factor X
P09151152A0174|130 138|factor VII
P09151152A0174|149 149|p
P09151152A0174|156 156|p
P09151152A0174|170 183|heparinization
P09151152A0174|204 219|serum lipoprotein
P09151376A0000|22 45|hyperbetalipoproteinemia
P09151376A0000|87 98|unrecognized
P09151376A0000|123 134|misdiagnosed
P09151376A0000|139 157|rheumatoid arthritis
P09151376A0000|166 169|gout
P09151806A1125|31 39|2.0-kb LAT
P09151806A1125|44 49|intron
P09151806A1125|55 66|mLAT pre-mRNA
P09151806A1125|72 88|unique branch point
P09151828A0919|3 26|altered amino acid residues
P09151828A0919|37 59|mutant 9ORF1 polypeptides
P09151828A0919|80 94|separate regions
P09151828A0919|115 122|residues
P09151828A0919|140 147|residues
P09151828A0919|159 174|C-terminal region
P09151828A0919|179 186|residues
P09151837A0723|0 24|Rep-Rep protein interaction
P09151837A0723|51 82|coimmunoprecipitation experiments
P09151837A0723|108 148|maltose-binding protein-Rep78 fusion protein
P09151837A0723|108 129|maltose-binding protein
P09151837A0723|131 135|Rep78
P09151837A0723|167 169|35S
P09151837A0723|171 193|methionine-labeled Rep78
P09151837A0723|189 193|Rep78
P09151837A0723|222 252|transcription-translation system
P09151925A0479|3 7|C-LIP
P09151925A0479|27 57|transcather arterial embolization
P09151925A0479|59 61|TAE
P09151925A0479|63 67|C-LIP
P09151925A0479|78 90|gelatin sponge
P09151925A0479|95 129|percutaneous ethanol injection therapy
P09151925A0479|131 134|PEIT
P09152656A0149|8 15|patients
P09152656A0149|20 47|New York Heart Association class
P09152656A0149|50 71|congestive heart failure
P09152656A0149|87 98|double-blind
P09152656A0149|100 114|cross-over study
P09153010A0499|3 16|main advantages
P09153010A0499|19 35|Multi-MUP analysis
P09153010A0499|43 58|quick acquisition
P09153010A0499|61 68|many MUPs
P09153010A0499|73 94|simultaneous collection
P09153010A0499|97 107|several MUPs
P09153010A0499|157 172|low threshold MUPs
P09153010A0499|177 184|less bias
P09153010A0499|201 204|MUPs
P09153010A0499|214 228|reproducibility
P09153010A0499|234 240|results
P09153010A0499|253 271|same reference values
P09153010A0499|282 302|different laboratories
P09153319A0844|21 38|preformed triplexes
P09153319A0844|73 79|ethanol
P09153319A1332|0 22|Transfection experiments
P09153319A1332|28 45|preformed triplexes
P09153319A1332|51 65|reporter plasmid
P09153319A1332|79 102|collagen promoter sequence
P09153319A1332|109 129|significant inhibition
P09153319A1332|132 144|transcription
P09153319A1332|162 187|control phosphorothioate ODN
P09153348A0647|17 25|plasma TBG
P09153348A0647|23 25|TBG
P09153348A0647|39 53|adrenal androgen
P09153348A0647|57 89|mineralocorticoid steroid secretion
P09153348A0647|97 113|cortisol secretion
P09153348A0647|119 134|endocrine markers
P09153348A0647|138 148|progression
P09153348A0647|163 170|patients
P09153348A0647|175 187|HIV-infection
P09153795A0298|2 15|several studies
P09153795A0298|19 22|RDFS
P09154283A0307|0 10|Latanoprost
P09154283A0307|21 39|additional reduction
P09154283A0307|42 60|intraocular pressure
P09154283A0307|62 64|IOP
P09154283A0307|91 97|timolol
P09154283A0307|99 109|pilocarpine
P09154283A0307|111 123|acetazolamide
P09154283A0307|127 136|dipivefrin
P09154621A1475|5 11|results
P09154621A1475|23 51|dietary safflower phospholipids
P09154621A1475|58 75|valuable ingredient
P09154621A1475|78 83|layers
P09154621A1475|95 112|liver triglycerides
P09154621A1475|116 131|serum cholesterol
P09154621A1475|142 155|adverse effects
P09154795A0628|5 21|various techniques
P09154795A0628|40 57|systematic analysis
P09154795A0628|63 100|natural TATA-less human DNA polymerase beta
P09154795A0628|102 109|beta-pol
P09154795A0628|111 122|gene promoter
P09154797A0777|0 27|Saturable spermidine transport
P09154797A0777|30 33|stk2
P09154797A0777|36 46|lacZ mutants
P09154797A0777|65 86|fivefold-lower affinity
P09154797A0777|90 106|twofold-lower Vmax
P09154797A0777|116 129|parental strain
P09154819A0501|0 22|Transient overexpression
P09154819A0501|25 29|c-Jun
P09154819A0501|37 56|tenascin-C expression
P09154819A0501|37 46|tenascin-C
P09154819A0501|59 68|primary REF
P09154819A0501|74 78|FR3T3
P09154819A0501|82 110|established fibroblast cell line
P09154822T0000|0 9|Inhibition
P09154822T0000|15 25|Raf-1 kinase
P09154822T0000|28 44|cyclic AMP agonists
P09154822T0000|51 59|apoptosis
P09154822T0000|62 83|v-abl-transformed cells
P09154822T0000|62 66|v-abl
P09154827A0158|0 14|Previous studies
P09154827A0158|33 47|hamster cell line
P09154827A0158|49 52|ts13
P09154827A0158|59 71|point mutation
P09154827A0158|77 79|TAF
P09154827A0158|84 91|250/CCG1
P09154827A0158|93 95|TAF
P09154827A0158|113 143|temperature-sensitive expression
P09154827A0158|147 152|subset
P09154827A0158|155 159|genes
P09154827A0158|163 169|arrests
P09154827A0158|172 177|late G1
P09154827A0158|184 192|degrees C.
P09155015A0140|17 34|protein kinase MEKK1
P09155015A0140|17 29|protein kinase
P09155015A0140|30 34|MEKK1
P09155015A0140|44 65|reporter gene expression
P09155015A0140|73 95|atrial natriuretic factor
P09155015A0140|97 99|ANF
P09155015A0140|101 108|promoter
P09155015A0140|111 123|genetic marker
P09155015A0140|151 161|hypertrophy
P09155024A0955|0 13|Overexpression
P09155024A0955|16 19|EFG1
P09155024A0955|22 31|C. albicans
P09155024A0955|47 63|filamentous growth
P09155024A0955|75 94|extended pseudohyphae
P09155024A0955|108 117|solid media
P09156883A0294|8 17|parameters
P09156883A0294|19 27|heart rate
P09156883A0294|29 30|HR
P09156883A0294|33 53|arterial blood pressure
P09156883A0294|55 57|ABP
P09156883A0294|62 69|arterial
P09156883A0294|72 81|saturation
P09156883A0294|83 86|SaO2
P09156883A0294|99 110|pulsoximetry
P09157100A0583|13 19|signing
P09157100A0583|53 55|SIB
P09157100A0583|79 88|extinction
P09157337A0545|20 33|married couples
P09157337A0545|47 55|hepatitis
P09157337A0545|58 77|unidentified etiology
P09157337A0545|82 102|Infectology Department
P09157337A0545|107 111|years
P09157760A0000|4 15|quantitative
P09157760A0000|19 37|qualitative analysis
P09157760A0000|40 79|individual cytoarchitectonic peculiarities
P09157760A0000|82 88|Meynart
P09157760A0000|91 97|nucleus
P09157760A0000|108 119|external part
P09157760A0000|122 139|dorsomedial nucleus
P09157760A0000|142 149|thalamus
P09157760A0000|172 188|normal individuals
P09159111A0437|37 53|circular dichroism
P09159111A0437|55 56|CD
P09159111A0437|61 74|NMR experiments
P09159111A0437|80 88|Skn domain
P09159111A0437|105 112|proteins
P09159160A0000|0 16|Positional cloning
P09159160A0000|38 46|sequences
P09159160A0000|59 68|human genes
P09159160A0000|83 98|specific diseases
P09159183A0119|0 4|Genes
P09159183A0119|8 31|ocs element binding factors
P09159183A0119|33 36|OBFs
P09159183A0119|51 63|specific class
P09159183A0119|66 116|basic-region leucine zipper (bZIP) transcription factors
P09159183A0119|66 90|basic-region leucine zipper
P09159183A0119|92 95|bZIP
P09159183A0119|97 116|transcription factors
P09159183A0119|145 150|plants
P09160361A0858|3 17|30-day mortality
P09160361A0858|23 30|CPB group
P09160361A0858|37 48|non-CPB group
P09160361A0858|55 55|%
P09160361A0858|62 62|%
P09160361A0858|112 113|p =
P09160881A0491|18 40|co-precipitation studies
P09160881A0491|45 65|yeast two-hybrid screen
P09160881A0491|79 105|protein-protein interactions
P09162084A0956|36 48|Src-SH2 domain
P09162084A0956|57 63|PECAM-1
P09162084A0956|84 108|GST-Src-SH2 affinity matrix
P09162084A0956|92 94|SH2
P09162092A0675|0 22|MKK3 autophosphorylation
P09162092A0675|0 3|MKK3
P09162092A0675|26 35|activation
P09162092A0675|38 40|p38
P09162092A0675|65 76|coexpression
P09162092A0675|79 82|MKK3
P09162092A0675|87 91|MEKK3
P09162092A0675|103 107|MEKK2
P09162097A0776|22 36|MAdCAM-1 variant
P09162097A0776|59 62|exon
P09162097A0776|75 85|mucin domain
P09162097A0776|100 116|leukocyte adhesion
P09162097A0776|119 124|LPAM-1
P09162097A0776|132 139|adhesion
P09162097A0776|145 161|alternate receptor
P09162097A0776|163 172|L-selectin
P09162097A1258|51 67|human MAdCAM-1 cDNA
P09162097A1258|87 100|human homologue
P09162097A1258|103 115|mouse MAdCAM-1
P09162097A1258|124 143|gross dissimilarities
P09162097A1258|149 176|MAdCAM-1 C-terminal structures
P09162097A1258|149 157|MAdCAM-1 C
P09163332A0275|11 42|site-directed mutagenesis approach
P09163332A0275|58 60|Xaa
P09163332A0275|64 70|hydroxy
P09163332A0275|72 78|Ser/Thr
P09163332A0275|80 96|amino acid residues
P09163332A0275|99 105|sequons
P09163332A0275|115 142|core-glycosylation efficiency
P09164543A0219|0 7|MATERIAL
P09164543A0219|11 17|METHODS
P09164543A0219|22 28|authors
P09164543A0219|39 45|persons
P09164543A0219|79 83|years
P09164543A0219|88 93|months
P09164543A0219|114 130|selective vagotomy
P09164543A0219|139 145|truncal
P09164543A0219|148 164|selective vagotomy
P09164543A0219|169 190|gastroduodenal drainage
P09164856A0980|26 48|identifiable TATA element
P09164856A0980|64 76|transcription
P09164856A0980|82 96|glutaminase gene
P09164856A0980|108 124|TATA-less promoter
P09165004A1700|0 10|SRE activity
P09165004A1700|29 38|activation
P09165004A1700|41 55|phosphorylation
P09165004A1700|59 78|ternary complex factor
P09165004A1700|96 116|ternary complex factors
P09165004A1700|119 123|Elk-1
P09165035A0842|0 31|Serum alkaline phosphatase activity
P09165035A0842|33 52|bone mass measurements
P09165035A0842|54 90|dual energy x-ray absortiometric analysis
P09165035A0842|93 106|mineral density
P09165035A0842|111 133|mechanical testing values
P09165035A0842|136 144|vertebrae
P09165035A0842|148 153|femora
P09165035A0842|160 170|D Sal animals
P09165035A0842|208 218|D Sal animals
P09165039A0728|3 15|monkey LHR cDNA
P09165039A0728|30 53|% overall sequence homology
P09165039A0728|61 82|other mammalian LHR cDNAs
P09165039A0728|66 82|mammalian LHR cDNAs
P09165039A1372|13 29|marmoset monkey LHR
P09165039A1372|67 70|exon
P09165039A1372|78 84|LHR gene
P09165039A1372|87 107|other mammalian species
P09165118A0311|2 13|unc-4 mutants
P09165118A0311|15 28|VA motor neurons
P09165118A0311|47 59|synaptic input
P09165118A0311|84 100|lineal sister cells
P09165118A0311|105 118|VB motor neurons
P09165118A0311|129 139|normal input
P09165118A0311|145 147|VAs
P09165118A0311|176 189|movement defect
P09167421A0234|0 23|Intracavitary irradiation
P09167421A0234|42 58|microSelectron HDR
P09167421A0234|91 92|Gy
P09167421A0234|108 116|fractions
P09168083A0987|26 28|HAT
P09168083A0987|30 31|P =
P09168134A0858|0 17|Sequence comparison
P09168134A0858|27 44|kb promoter sequence
P09168134A0858|52 60|promoters
P09168134A0858|66 73|Sm-E gene
P09168134A0858|77 88|U1 snRNA genes
P09168134A0858|97 119|several homologous motifs
P09168134A0858|135 139|genes
P09168134A0858|151 165|snRNP components
P09168218A0216|0 6|METHODS
P09168218A0216|11 19|responses
P09168218A0216|23 38|31-year-old woman
P09168218A0216|43 73|complex regional pain syndrome type
P09168218A0216|76 101|reflex sympathetic dystrophy
P09168218A0216|106 117|thermal grill
P09168218A0216|145 165|stellate ganglion block
P09168511A0640|30 45|developments such
P09168511A0640|51 63|successful use
P09168511A0640|76 92|steroid budesonide
P09168511A0640|96 112|oral dexamethasone
P09168511A0640|146 153|steroids
P09168623A0614|1 25|xylE transcriptional fusion
P09168623A0614|1 4|xylE
P09168623A0614|31 50|putative mxbD promoter
P09168623A0614|39 50|mxbD promoter
P09168623A0614|57 75|low-level expression
P09168623A0614|78 91|wild-type cells
P09168623A0614|99 108|one-carbon
P09168623A0614|110 111|C1
P09168623A0614|113 121|compounds
P09168623A0614|127 146|detectable expression
P09168623A0614|149 153|cells
P09168623A0614|161 169|succinate
P09168879A0219|2 24|AcMNPV-infected Sf9 cells
P09168879A0219|26 52|late transcription initiation
P09168879A0219|74 90|upstream TAAG sites
P09168879A0219|106 124|downstream TAAG sites
P09168892A1016|0 7|Mutation
P09168892A1016|10 28|nucleotides adjacent
P09168892A1016|34 57|AP-1 cis-response elements
P09168892A1016|71 86|trans-activation
P09169127A0371|3 16|close proximity
P09169127A0371|25 50|neuropeptide Y receptor genes
P09169127A0371|83 102|gene duplication event
P09169127A0371|110 120|small intron
P09169127A0371|155 160|y1 gene
P09169127A0371|180 197|functional sequence
P09169127A0371|207 212|y5 gene
P09169127A0371|222 249|reverse complementary sequence
P09169127A0371|287 290|exon
P09169127A0371|297 302|y1 gene
P09169420A0000|3 36|mammalian phosphoinositide 3-kinases
P09169420A0000|38 42|PI3Ks
P09169420A0000|44 57|p110alpha, beta
P09169420A0000|44 52|p110alpha
P09169420A0000|54 57|beta
P09169420A0000|62 82|delta form heterodimers
P09169420A0000|87 98|Src homology 2
P09169420A0000|87 97|Src homology
P09169420A0000|100 102|SH2
P09169420A0000|104 132|domain-containing adaptors such
P09169420A0000|135 142|p85alpha
P09169420A0000|145 147|p55
P09169420A0000|149 151|PIK
P09169475A0272|5 11|studies
P09169475A0272|31 44|flanking region
P09169475A0272|50 63|human gp130 gene
P09169475A0272|81 108|transcription initiation sites
P09169475A0772|0 11|Localization
P09169475A0772|17 39|cytokine response element
P09169475A0772|45 60|deletion analysis
P09169475A0772|64 87|site-directed mutagenesis
P09169475A0772|97 117|cis-acting binding site
P09169475A0772|130 142|STAT complexes
P09169475A0772|130 133|STAT
P09169593T0000|0 16|Insulin regulation
P09169593T0000|0 6|Insulin
P09169593T0000|19 54|mitogen-activated protein kinase kinase
P09169593T0000|56 58|MEK
P09169593T0000|61 90|mitogen-activated protein kinase
P09169593T0000|94 105|casein kinase
P09169593T0000|111 121|cell nucleus
P09169593T0000|124 135|possible role
P09169593T0000|153 166|gene expression
P09169852A0235|0 9|Sequencing
P09169852A0235|20 31|pag-3 alleles
P09169852A0235|45 63|apparent null alleles
P09169852A0235|71 86|nonsense mutation
P09169852A0235|96 106|zinc fingers
P09169852A0235|111 126|missense mutation
P09169852A0235|132 147|fourth zinc finger
P09169852A0235|172 180|histidine
P09169852A0235|184 191|tyrosine
P09169853A0000|0 4|Pax-3
P09169853A0000|8 30|paired-type homeobox gene
P09169853A0000|63 68|dorsal
P09169853A0000|72 90|posterior neural tube
P09170159A0348|21 34|dendritic cells
P09170159A0348|46 74|melanogenic marker proteins such
P09170159A0348|77 115|tyrosinase and tyrosinase-related protein 1
P09170159A0348|77 86|tyrosinase
P09170159A0348|90 114|tyrosinase-related protein
P09170159A0721|5 13|mutations
P09170159A0721|24 29|codons
P09170159A0721|32 35|exon
P09170159A0721|83 90|proteins
P09170159A0721|98 104|HLH-Zip
P09170159A0721|107 118|Zip structure
P09171038A0219|12 18|Sjogren
P09171038A0219|74 89|dental complaints
P09171038A0219|94 111|long-term treatment
P09171038A0219|114 120|Sjogren
P09171038A0219|123 130|patients
P09171081T0000|0 6|Cloning
P09171081T0000|10 25|characterization
P09171081T0000|29 32|cDNA
P09171081T0000|42 72|bacteriophage-type RNA polymerase
P09171081T0000|80 106|higher plant Chenopodium album
P09171235A0851|10 23|overexpression
P09171235A0851|51 58|COUP-TFI
P09171235A0851|66 80|COUP-TFI delta35
P09171235A0851|95 111|silencing activity
P09171235A0851|117 132|unliganded TRbeta
P09171235A0851|127 132|TRbeta
P09171239A1118|8 17|amino acids
P09171239A1118|29 44|amphipathic helix
P09171239A1118|71 93|nuclear hormone receptors
P09171239A1118|108 117|core domain
P09171239A1118|123 161|ligand-dependent transactivation function
P09171239A1118|163 166|AF-2
P09171239A2146|16 51|RXR-specific ligand 9-cis-retinoic acid
P09171239A2146|16 18|RXR
P09171239A2146|59 65|binding
P09171239A2146|68 72|SRC-1
P09171239A2146|78 89|RXR component
P09171239A2146|78 80|RXR
P09171239A2146|95 114|TRE-bound heterodimer
P09171363A0149|2 9|ciliates
P09171363A0149|15 24|mechanisms
P09171389A0549|10 19|occurrence
P09171389A0549|22 48|several transcription signals
P09171389A0549|54 77|Thermus pyr promoter region
P09171389A0549|81 113|strong amino acid sequence identities
P09171389A0549|122 122|%
P09171389A0549|131 141|Thermus PyrR
P09171389A0549|148 170|PyrR attenuation proteins
P09171389A0549|176 186|Bacillus sp.
P09171389A0549|198 216|regulatory mechanism
P09171389A0549|226 251|transcriptional attenuation
P09171389A0549|261 277|pyr gene expression
P09171389A0549|280 286|Thermus
P09171468T0000|0 24|Diver respiratory responses
P09171468T0000|28 66|tunable closed-circuit breathing apparatus
P09171969A1165|0 10|Measurement
P09171969A1165|16 27|time constant
P09171969A1165|30 32|VO2
P09171969A1165|36 46|oxygen pulse
P09171969A1165|53 76|constant work rate exercise
P09171969A1165|92 110|objective evaluation
P09171969A1165|116 129|training effect
P09171969A1165|132 139|patients
P09171969A1165|144 147|COPD
P09172312T0000|0 15|Characterization
P09172312T0000|18 42|CR1 repeat random PCR markers
P09172312T0000|56 68|chicken genome
P09172414A0000|1 51|reversed-phase high-performance liquid chromatographic
P09172414A0000|53 56|HPLC
P09172414A0000|85 102|cocaine metabolites
P09172414A0000|120 141|serum and liver esterases
P09172414A0000|120 124|serum
P09172414A0000|128 141|liver esterases
P09172641A0181|0 16|Mutational studies
P09172641A0181|59 68|side chains
P09172641A0181|71 79|subdomain
P09172641A0181|87 102|specific contacts
P09172641A0181|110 120|nucleotides
P09172812A0660|17 27|fludarabine
P09172812A0660|37 47|useful agent
P09172812A0660|50 52|CLL
P09173733A0404|5 23|different techniques
P09173733A0404|26 35|EA analysis
P09173733A0404|61 81|Fourier transformation
P09173733A0404|83 85|FFT
P09173733A0404|89 90|EA
P09173733A0404|94 102|broad band
P09173733A0404|119 135|alternative method
P09173733A0404|138 158|non-harmonic expansion
P09173733A0404|164 172|EEG curves
P09173733A0404|203 216|factor analysis
P09173733A0404|222 240|EA spectral densities
P09174049A1788|14 43|p34CDC2 histone H1 kinase activity
P09174049A1788|14 20|p34CDC2
P09174049A1788|21 35|histone H1 kinase
P09174049A1788|76 90|latter cell lines
P09174049A1788|128 153|radiation-induced cell death
P09175708A1526|5 9|PRL-R
P09175708A1526|25 34|N-terminal
P09175708A1526|37 53|C-terminal regions
P09175708A1526|59 72|mature receptor
P09175708A1526|158 164|nucleus
P09175858A1449|8 16|B-S mutant
P09175858A1449|43 61|chloroplastic GAPDHs
P09175858A1449|66 75|long-range
P09175858A1449|82 100|second-layer effects
P09175858A1449|111 121|predictable
P09175858A1449|126 141|visual inspection
P09175858A1449|144 170|three-dimensional structures
P09175858A1449|214 231|chloroplastic-like
P09175858A1449|233 238|mutant
P09175858A1449|241 254|cytosolic GAPDH
P09176340A1194|0 12|Transcription
P09176340A1194|20 24|genes
P09176340A1194|32 39|elevated
P09176340A1194|58 65|freezing
P09176340A1194|70 79|mRNA levels
P09176340A1194|87 93|tissues
P09176837A0211|0 15|Computer software
P09176837A0211|33 36|CSAO
P09176837A0211|61 64|PN Ca
P09176837A0211|66 76|P solubility
P09176837A0211|81 92|clinical data
P09176837A0211|102 113|parenteral Ca
P09176837A0211|117 131|P administration
P09177169A0935|1 14|similar chimera
P09177169A0935|37 42|halves
P09177169A0935|77 93|different bacteria
P09177857A0000|3 12|conditions
P09177857A0000|25 39|titanium dioxide
P09177857A0000|47 77|substrates titanium tetrachloride
P09177857A0000|105 126|surgical stainless steel
P09177857A0000|145 150|plasma
P09177857A0000|159 188|chemical vapour deposition method
P09178269A0107|6 10|genes
P09178491A0262|13 19|regions
P09178491A0262|30 53|preS2/S gene transcription
P09178491A0262|30 34|preS2
P09178491A0262|36 40|S gene
P09178491A0262|59 71|HBV adw subtype
P09178491A0262|76 90|diverged TATA box
P09178491A0262|95 118|putative initiator element
P09178494A1123|18 24|folding
P09178494A1123|38 56|untranslated regions
P09178494A1123|65 72|patterns
P09178494A1123|82 95|loop structures
P09178494A1123|111 132|tick-borne flaviviruses
P09178494A1123|165 176|preservation
P09178494A1123|179 209|essential RNA secondary structures
P09178494A1123|232 251|translational control
P09178494A1123|255 265|replication
P09178752A0574|0 2|EGF
P09178752A0574|18 22|means
P09178752A0574|25 49|transactivation domain AF-1
P09178752A0574|58 61|cAMP
P09178752A0574|69 93|transactivation domain AF-2
P09178752A0574|99 100|ER
P09180687A0096|24 27|SulA
P09180687A0096|45 54|inhibition
P09180687A0096|57 68|cell division
P09180687A0096|92 101|N-terminal
P09180687A0096|105 123|C-terminal deletions
P09180687A0096|126 129|SulA
P09180687A0096|142 167|alanine substitution mutants
P09181130A1067|17 23|Krox-20
P09181130A1067|26 48|homologous recombination
P09181130A1067|51 57|ES cells
P09181130A1067|80 87|mutation
P09181130A1067|98 105|deletion
P09181130A1067|108 109|r3
P09181130A1067|113 114|r5
P09181130A1587a|24 39|detailed analysis
P09181130A1587a|42 68|specific neuronal populations
P09181130A1587a|82 89|mutation
P09181130A1587a|99 106|new light
P09181130A1587a|118 124|Krox-20
P09181130A1587a|130 141|segmentation
P09181130A1587a|150 174|physiological consequences
P09181130A1587a|180 191|inactivation
P09182281A0197|30 41|Cyclosporin A
P09182281A0197|51 80|selective immunosuppressive drug
P09182527A0443|0 9|Consistent
P09182527A0443|23 39|p53 ubiquitination
P09182527A0443|23 25|p53
P09182527A0443|41 46|mE6-AP
P09182527A0443|64 70|nucleus
P09182527A0443|74 80|cytosol
P09182527A0443|87 92|Nedd-4
P09182527A0443|110 116|cytosol
P09182707A0254|0 2|SPP
P09182707A0254|14 45|transient tyrosine phosphorylation
P09182707A0254|48 66|focal adhesion kinase
P09182707A0254|68 71|p125
P09182707A0254|73 75|FAK
P09182707A0254|80 102|cytosolic tyrosine kinase
P09182707A0254|118 131|focal adhesions
P09182707A0254|141 178|cytoskeleton-associated protein paxillin
P09182707A0254|171 178|paxillin
P09182990A0245|6 35|conditional-lethal mutant allele
P09182990A0245|38 42|SUP45
P09182990A0245|44 50|sup45-2
P09182990A0245|85 94|approaches
P09182990A0245|128 136|SUP45 gene
P09182990A0245|138 143|Sup45p
P09182990A0245|146 149|eRF1
P09182990A0245|171 192|translation termination
P09182990A0245|195 199|yeast
P09183145T0001|0 9|Evaluation
P09183145T0001|12 30|myocardial perfusion
P09183145T0001|33 54|99mTc-tetrofosmin SPECT
P09183145T0001|69 119|emergent percutaneous transluminal coronary angioplasty
P09183145T0001|123 147|acute myocardial infarction
P09183406A0637|1 34|neonatal alloimmune thrombocytopenia
P09183406A0637|41 46|HPA-3a
P09183406A0637|48 51|Baka
P09183406A0637|53 67|incompatibility
P09185183A0089|17 23|unaided
P09185183A0089|27 31|years
P09185183A0089|45 64|progressive worsening
P09185183A0089|67 80|motor abilities
P09185183T0000|0 41|Merosin positive congenital muscular dystrophy
P09185183T0000|0 6|Merosin
P09185183T0000|46 61|mental deficiency
P09185183T0000|63 70|epilepsy
P09185183T0000|74 83|MRI changes
P09185183T0000|89 107|cerebral white matter
P09185586A0000|0 18|Most eukaryotic mRNAs
P09185586A0000|36 51|scanning ribosome
P09185645T0000|0 9|Comparison
P09185645T0000|12 42|Tc-99m sestamibi perfusion imaging
P09185645T0000|46 61|echocardiography
P09185645T0000|69 86|arbutamine infusion
P09185645T0000|93 101|detection
P09185645T0000|104 124|coronary artery disease
P09186056A0514|5 27|transient overexpression
P09186056A0514|43 52|C2C12 cells
P09186056A0514|63 75|transcription
P09186056A0514|79 90|CAT-reporter
P09186056A0514|104 111|E12/MyoD
P09186056A0514|104 106|E12
P09186056A0514|108 111|MyoD
P09186056A0514|118 125|enhancer
P09186430A0341|15 20|ocular
P09186430A0341|23 44|oculocutaneous albinism
P09186507A0882|11 24|126-nucleotide
P09186507A0882|27 54|untranscribed genomic sequence
P09186507A0882|59 72|466-nucleotide
P09186507A0882|75 95|noncoding cDNA sequence
P09186507A0882|100 113|592-nucleotide
P09186507A0882|116 124|CpG island
P09186507A0882|131 134|TATA
P09186507A0882|138 146|CAAT boxes
P09186507A0882|160 173|high G+C content
P09186507A0882|189 204|CpG dinucleotides
P09186507A0882|219 242|potential Sp1-binding site
P09186507A0882|228 242|Sp1-binding site
P09186507A0882|257 266|compatible
P09186507A0882|272 287|housekeeping gene
P09187136A0000|0 5|SSeCKS
P09187136A0000|7 21|pronounced essex
P09187136A0000|31 58|major protein kinase C substrate
P09187136A0000|98 107|src- and ras
P09187136A0000|98 100|src
P09187136A0000|105 136|ras-transformed rodent fibroblasts
P09187136A0000|145 176|raf-transformed rodent fibroblasts
P09187136A0000|178 179|X.
P09187277A0118|0 3|Type
P09187277A0118|5 29|position-vestibular-pause
P09187277A0118|31 34|PVP I
P09187277A0118|39 53|vestibular-only
P09187277A0118|55 56|V I
P09187277A0118|58 64|neurons
P09187277A0118|75 87|smaller number
P09187277A0118|90 98|other type
P09187277A0118|109 134|eye-plus-vestibular neurons
P09187371A0450|10 26|1.3-kb mRNA species
P09187371A0450|57 69|2.6-kb species
P09187371A0450|89 94|kidney
P09187371A0450|112 125|skeletal muscle
P09187637A1199|0 16|Taurine deficiency
P09187637A1199|42 50|amplitude
P09187637A1199|53 55|OP1
P09187637A1199|59 61|OP4
P09188094A0934|15 18|mcs4
P09188094A0934|20 24|cells
P09188094A0934|28 36|defective
P09188094A0934|39 48|activation
P09188094A0934|51 54|Spc1
P09188094A0934|67 78|various forms
P09188699A1388|3 25|extended rat SP-A isoforms
P09188699A1388|14 25|SP-A isoforms
P09188699A1388|67 87|multimeric SP-A species
P09188699A1388|77 80|SP-A
P09188699A1388|99 110|SDS-PAGE gels
P09188863A0954|0 18|Alternative splicing
P09188863A0954|21 26|CDC25B
P09188863A0954|63 79|cell proliferation
P09189783A0000|57 76|several small feedings
P09189783A0000|79 101|preexercise carbohydrate
P09189783A0000|103 105|CHO
P09189783A0000|119 129|single bolus
P09189783A0000|142 153|blood glucose
P09189783A0000|157 172|insulin responses
P09189783A0000|157 163|insulin
P09189896A0611|3 10|findings
P09189896A0611|22 31|ERP effects
P09189896A0611|34 56|distinct memory processes
P09189896A0611|97 108|instructions
P09190202A0166|4 14|coat protein
P09190202A0166|25 29|Sar1p
P09190202A0166|34 53|Sec23p protein complex
P09190202A0166|34 46|Sec23p protein
P09190202A0166|64 69|Sec23p
P09190202A0166|73 78|Sec24p
P09190202A0166|86 105|Sec13p protein complex
P09190202A0166|86 98|Sec13p protein
P09190202A0166|116 121|Sec13p
P09190202A0166|126 144|novel 150-kDa protein
P09190202A0166|131 144|150-kDa protein
P09190202A0166|146 149|p150
P09190821A0707|3 21|second primary mutant
P09190821A0707|32 55|proline-to-leucine change
P09190821A0707|70 74|P243L
P09190940A0127|0 8|Induction
P09190940A0127|27 45|germline transcripts
P09190940A0127|66 77|switch region
P09190940A0127|81 93|recombination
P09190940A0127|97 105|switching
P09191052A0850|8 10|PCE
P09191052A0850|17 31|Pbx dimer partner
P09191052A0850|17 19|Pbx
P09191052A0850|49 65|Class I Hox proteins
P09191052A0850|49 53|Class
P09191052A0850|55 65|Hox proteins
P09192732A1384|15 33|NH2-terminal portion
P09192732A1384|39 47|homologue
P09192732A1384|73 85|outer membrane
P09192732A1384|96 112|COOH-terminal part
P09192769T0000|0 15|Molecular cloning
P09192769T0000|19 34|characterization
P09192769T0000|38 41|cDNA
P09192769T0000|43 48|CHEMR1
P09192769T0000|59 75|chemokine receptor
P09192769T0000|81 88|homology
P09192769T0000|94 118|human C-C chemokine receptor
P09192769T0000|120 124|CCR-4
P09192786T0000|0 11|Organization
P09192786T0000|17 27|human LU gene
P09192786T0000|31 44|molecular basis
P09192786T0000|50 51|Lu
P09192786T0000|56 57|Lu
P09192786T0000|59 59|b
P09192786T0000|61 82|blood group polymorphism
P09192842A0988|5 29|mouse-human somatic hybrids
P09192842A0988|33 44|FISH analysis
P09192842A0988|49 56|PE-2 gene
P09192842A0988|59 67|localized
P09192842A0988|70 91|human chromosome 19q13.2
P09192842A0988|110 123|translocations
P09192842A0988|127 135|deletions
P09192842A0988|138 146|leukemias
P09192842A0988|150 167|several solid tumors
P09192842A0988|187 200|novel ETS factor
P09192842A0988|192 200|ETS factor
P09192842A0988|215 228|carcinogenesis
P09192998A0356|10 22|mutant enzymes
P09192998A0356|45 58|late terminator
P09192998A0356|61 65|T7 DNA
P09192998A0356|67 67|T
P09192998A0356|69 71|phi
P09192998A0356|77 82|rrnB T2
P09192998A0356|77 80|rrnB
P09192998A0356|113 128|termination sites
P09192998A0356|131 136|rrnB T1
P09192998A0356|131 134|rrnB
P09192998A0356|163 165|PTH
P09192998A0356|169 177|CJ signals
P09193072A0199|0 14|Cytological data
P09193072A0199|29 38|transgenes
P09193072A0199|53 61|nucleolus
P09193077A0000|0 18|Light regulatory unit
P09193077A0000|21 24|LRU1
P09193077A0000|62 86|light-dependent activation
P09193077A0000|92 107|chalcone synthase
P09193077A0000|109 127|CHS) minimal promoter
P09193077A0000|109 111|CHS
P09193077A0000|113 127|minimal promoter
P09193077A0000|130 148|Petroselinum crispum
P09193080A0904|0 17|Sequence divergence
P09193080A0904|30 48|untranslated regions
P09193080A0904|75 93|gene-specific probes
P09193671A0347|3 13|active state
P09193671A0347|28 37|hydrolysis
P09193671A0347|45 47|GTP
P09193671A0347|58 72|inactive ARF-GDP
P09194250A0708|25 35|World Summit
P09194250A0708|39 46|Children
P09194250A0708|49 73|under-five mortality target
P09194250A0708|89 108|intraregional targets
P09194250A0708|117 140|geographical inequalities
P09194250A0708|143 161|under-five mortality
P09195923A0125|3 14|immunophilin
P09195923A0125|31 35|FK506
P09195923A0125|39 63|cyclosporin A-binding class
P09195923A0125|72 76|hsp90
P09195923A0125|83 105|tetratricopeptide repeat
P09195923A0125|107 109|TPR
P09195923A0125|121 152|different receptor heterocomplexes
P09195923A0125|176 187|immunophilin
P09195923A0125|199 215|TPR-binding region
P09195923A0125|218 222|hsp90
P09197241A0770|2 20|adherent macrophages
P09197241A0770|31 34|CD45
P09197241A0770|43 62|hyperphosphorylation
P09197241A0770|66 80|hyperactivation
P09197241A0770|83 88|p56/59
P09197241A0770|90 92|hck
P09197241A0770|97 102|p53/56
P09197241A0770|104 106|lyn
P09197241A0770|117 119|p58
P09197241A0770|121 125|c-fgr
P09197342T0000|0 8|Secretion
P09197342T0000|18 39|transplacental transfer
P09197342T0000|52 55|oils
P09197342T0000|57 66|Lipiodol UF
P09197342T0000|70 76|Oriodol
P09197342T0000|80 86|rabbits
P09197408A0126|0 9|Sequencing
P09197408A0126|15 22|facB gene
P09197408A0126|66 86|N-terminal GAL4-like Zn
P09197408A0126|76 89|GAL4-like Zn(II
P09197408A0126|91 95|2Cys6
P09197408A0126|99 104|C6 zinc
P09197408A0126|106 121|binuclear cluster
P09197408A0126|125 171|DNA binding, leucine zipper-like heptad repeat motifs
P09197408A0126|125 134|DNA binding
P09197408A0126|136 171|leucine zipper-like heptad repeat motifs
P09197408A0126|185 220|C-terminal acidic alpha-helical regions
P09197408A0126|185 205|C-terminal acidic alpha
P09197408A0126|248 282|DNA-binding transcriptional activator
P09199167A0942|0 13|Overexpression
P09199167A0942|16 20|Sed5p
P09199167A0942|48 52|Vti1p
P09199286A0086|17 20|mkh1
P09199286A0086|39 48|single exon
P09199286A0086|58 80|1,116-amino-acid protein
P09199292A0536|11 35|stoichiometric association
P09199292A0536|38 41|p107
P09199292A0536|44 47|p130
P09199292A0536|58 69|cyclin E-cdk2
P09199292A0536|58 64|cyclin E
P09199292A0536|66 69|cdk2
P09199292A0536|72 83|cyclin A-cdk2
P09199292A0536|72 78|cyclin A
P09199292A0536|80 83|cdk2
P09199292A0536|94 103|activities
P09199292A0536|111 117|kinases
P09199318A1147|12 15|p150
P09199318A1147|26 38|actin gelation
P09199318A1147|26 30|actin
P09199318A1147|56 80|smooth muscle alpha-actinin
P09199322T0000|0 11|Denaturation
P09199322T0000|17 27|simian virus
P09199322T0000|38 48|replication
P09199322T0000|59 83|human replication protein A.
P09199327A1250|29 35|EM motif
P09199327A1250|41 66|promoter-reporter construct
P09199327A1250|99 132|synergistic transactivation function
P09199327A1250|138 164|TEF-1-Max heterotypic complex
P09199327A1250|138 142|TEF-1
P09199327A1250|144 146|Max
P09199327A1250|182 188|binding
P09199327A1250|206 212|EM motif
P09199328T0000|14 21|residues
P09199328T0000|29 39|small region
P09199328T0000|42 45|VP16
P09199328T0000|58 62|Oct-1
P09199328T0000|64 66|HCF
P09199348A0156|22 50|other important U14 interactions
P09199348A0156|53 67|stem-loop domain
P09199348A0156|89 118|Saccharomyces cerevisiae U14 RNAs
P09199348A0156|112 118|U14 RNAs
P09199348A0156|123 129|Y domain
P09199348A0156|150 175|detailed mutational analysis
P09199353A1924|12 18|results
P09199353A1924|29 33|Cdc68
P09199353A1924|65 82|chromatin structure
P09199353A1924|99 113|polymerase alpha
P09199353A1924|134 141|proteins
P09199353A1924|159 166|template
P09199353A1924|171 177|origins
P09199353A1924|180 190|replication
P09199413A0518|11 22|inoculum size
P09199413A0518|53 61|CFU/mouse
P09199413A0518|66 66|%
P09199413A0518|72 93|RB6-8C5-treated animals
P09199413A0518|72 78|RB6-8C5
P09199413A0518|105 108|days
P09199626A0613|4 8|cases
P09199626A0613|13 13|%
P09199932A1357|0 28|Promoter recognition algorithms
P09199932A1357|39 63|divergent promoter elements
P09199932A1357|73 81|CpG island
P09199932A1357|102 104|ATM
P09199932A1357|108 120|E14/NPAT genes
P09199932A1357|108 110|E14
P09199932A1357|144 175|putative second ATM promoter located
P09199932A1357|158 168|ATM promoter
P09199932A1357|182 187|intron
P09199932A1357|225 228|exon
P09199970A1101|0 21|Recombinant soluble pMCP
P09199970A1101|32 44|transmembrane
P09199970A1101|48 65|cytoplasmic domains
P09199970A1101|75 83|I cofactor
P09199970A1101|76 91|cofactor activity
P09199970A1101|94 104|C3b cleavage
P09199970A1101|94 96|C3b
P09199970A1101|157 166|homologous
P09199970A1101|169 171|MCP
P09200029A0211|0 7|Clinical
P09200029A0211|11 29|haematological signs
P09200029A0211|81 100|histological features
P09200029A0211|108 128|bone marrow examination
P09200498T0000|0 11|Spatial zones
P09200498T0000|15 32|muscle coactivation
P09200498T0000|48 64|postural stability
P09200530A0411|0 30|Liquid chromatographic separation
P09200530A0411|45 70|Zorbax RX C8 analytical column
P09200530A0411|76 90|gradient elution
P09200811T0000|3 20|linear plasmid pDHL1
P09200811T0000|66 75|homologous
P09200811T0000|81 106|pGKL1-plasmid DNA polymerase
P09201946A0000|3 13|RNA-binding
P09201946A0000|17 41|RNA-DNA helicase activities
P09201946A0000|47 94|Escherichia coli transcription termination factor rho
P09201946A0000|62 94|transcription termination factor rho
P09201946A0000|120 138|natural RNA molecules
P09201946A0000|155 172|nucleotide residues
P09201946A0000|198 201|trp t
P09201946A0000|203 234|rho-dependent termination sequence
P09201980A0910|3 15|p20-CGGBP gene
P09201980A0910|32 38|mammals
P09201980A0910|49 56|homology
P09201980A0910|59 79|non-vertebrate species
P09202147A0866|24 28|yeast
P09202147A0866|32 37|plants
P09202147A0866|39 54|certain subfamily
P09202147A0866|57 59|UBC
P09202147A0866|87 108|proteolytic degradation
P09202147A0866|111 126|abnormal proteins
P09202669A0614|3 8|pWP-19
P09202669A0614|23 48|AAV inverted terminal repeats
P09202669A0614|66 76|replication
P09202669A0614|83 127|herpes virus thymidine kinase promoter-driven gene
P09202669A0614|131 148|neomycin resistance
P09202669A0614|150 153|neoR
P09202669A1530|16 46|rAAV-mediated gene transfer system
P09202669A1530|53 74|rat preproinsulin II gene
P09202669A1530|53 68|rat preproinsulin
P09202859A0091|3 13|serum levels
P09202859A0091|16 46|beta-human chorionic gonadotropin
P09202859A0091|48 50|HCG
P09202859A0091|55 82|placental alkaline phosphatase
P09202859A0091|84 87|PLAP
P09202859A0091|96 103|elevated
P09203585A0660|1 15|striking feature
P09203585A0660|21 40|recombinant H19 allele
P09203585A0660|46 55|occurrence
P09203585A0660|59 73|parental imprint
P09203585A0660|82 103|neo replacement cassette
P09203586A1197|17 27|recruitment
P09203586A1197|30 42|large T antigen
P09203586A1197|48 59|rRNA promoter
P09203586A1197|62 64|SL1
P09203586A1197|77 87|crucial step
P09203586A1197|93 109|activation process
P09203731A0497|9 31|International Commission
P09203731A0497|38 50|Certification
P09203731A0497|53 63|Eradication
P09203731A0497|66 89|Poliomyelitis Eradication
P09203731A0497|91 95|ICCPE
P09203731A0497|116 144|Pan American Health Organization
P09203731A0497|183 193|interrupted
P09204566T0000|0 9|Functional
P09204566T0000|13 30|regulatory analysis
P09204566T0000|39 44|copies
P09204566T0000|50 62|fixNOQP operon
P09204566T0000|65 96|Rhizobium leguminosarum strain VF39
P09204570A0110|19 32|new MADS box gene
P09204570A0110|22 32|MADS box gene
P09204570A0110|34 38|nmhC5
P09204570A0110|54 57|nmh7
P09204570A0110|59 60|J.
P09205113A0587|4 6|E14
P09205113A0587|9 13|TG3B1
P09205113A0587|17 32|useful ES cell line
P09205113A0587|48 58|mouse genome
P09205113A0587|67 74|HPRT gene
P09205113A0587|78 92|selection marker
P09205113A0587|114 126|high frequency
P09205113A0587|134 146|mouse germ line
P09205677A0577|0 3|Lung
P09205677A0577|7 24|multi-system damage
P09205677A0577|29 43|early indicators
P09205677A0577|46 56|poor outcome
P09205677A0577|59 80|severe non-fatal disease
P09205965A1249|3 9|results
P09205965A1249|24 51|bulbospinal micturition reflex
P09205965A1249|60 73|bladder filling
P09205965A1249|77 82|L-dopa
P09205965A1249|102 108|pathway
P09205965A1249|144 169|spinal alpha 1-adrenoceptors
P09206230A0000|0 8|OBJECTIVE
P09206230A0000|42 52|common cause
P09206230A0000|55 64|asthenopia
P09206230A0000|66 81|mixed astigmatism
P09206968A0000|0 10|Disturbance
P09206968A0000|13 24|regeneration
P09206968A0000|30 55|above pathological condition
P09206968A0000|78 90|tunica propria
P09206968A0000|126 146|structural homeostasis
P09208214A0572|0 18|Sternocleidomastoid
P09208214A0572|26 38|facial muscles
P09208214A0572|66 70|cases
P09208930T0000|0 13|Identification
P09208930T0000|20 27|new genes
P09208930T0000|48 64|interleukin-1beta
P09208930T0000|75 84|enzyme gene
P09208930T0000|101 119|functional proteases
P09209031A0350|3 24|C-terminal mature region
P09209031A0350|44 71|other serine carboxypeptidases
P09209031A0350|49 71|serine carboxypeptidases
P09209312A0968|3 14|RNA construct
P09209312A0968|34 44|nucleotides
P09209312A0968|46 47|nt
P09209312A0968|53 54|nt
P09209312A0968|60 61|nt
P09209312A0968|72 91|heterodimeric complex
P09209312A0968|99 101|RNA
P09209312A0968|121 131|nucleotides
P09209312A0968|136 137|nt
P09209312A0968|143 144|nt
P09209372A0345|21 25|AML1a
P09209372A0345|43 49|effects
P09209372A0345|53 76|transcriptional regulator
P09209372A0345|98 122|transcriptional activation
P09209372A0345|125 129|AML1b
P09209372A0345|138 142|AML1a
P09209372A0345|154 167|higher affinity
P09209372A0345|171 181|DNA-binding
P09209372A0345|186 190|AML1b
P09209406A1021|25 41|homologous regions
P09209406A1021|46 77|guanine nucleotide exchange factors
P09209406A1021|80 104|GTPase-activating proteins
P09209406A1021|110 118|c-cbl gene
P09209438A0994|13 33|ATL-16T nuclear extract
P09209438A0994|53 58|GATA-4
P09209438A0994|64 86|only GATA-binding protein
P09209438A0994|68 86|GATA-binding protein
P09209438A0994|96 121|specific DNA-protein complex
P09209438A0994|132 139|GATA site
P09210012A0000|11 23|social support
P09210012A0000|29 41|relationships
P09210012A0000|44 57|gay male couples
P09210478A0000|24 48|hypoxia-inducible factor-1
P09210478A0000|50 54|HIF-1
P09210478A0000|81 91|large number
P09210478A0000|94 114|oxygen-regulated genes
P09211354A0000|0 12|Stromelysin-1
P09211354A0000|14 38|matrix metalloproteinase-3
P09211354A0000|40 44|MMP-3
P09211354A0000|51 72|important endopeptidase
P09211354A0000|95 106|somatic cells
P09211354A0000|109 120|organ tissues
P09211605A0478|0 5|Tendon
P09211605A0478|24 36|extensibility
P09211675A0392|0 11|Surveillance
P09211675A0392|15 26|preeclampsia
P09211675A0392|41 56|personnel unaware
P09211675A0392|59 84|treatment-group assignments
P09211675A0392|91 114|standardized measurements
P09211675A0392|117 129|blood pressure
P09211675A0392|133 155|urinary protein excretion
P09211675A0392|176 189|prenatal visits
P09211675A0392|191 199|protocols
P09211675A0392|218 229|measurements
P09211675A0392|239 253|hospitalization
P09211675A0392|269 275|reviews
P09211675A0392|278 291|medical records
P09211675A0392|294 320|unscheduled outpatient visits
P09211675A0392|327 342|hospitalizations
P09211913A0000|0 41|Aryl hydrocarbon receptor nuclear translocator
P09211913A0000|43 46|ARNT
P09211913A0000|65 84|transcription factors
P09211913A0000|86 108|aryl hydrocarbon receptor
P09211913A0000|110 112|AhR
P09211913A0000|117 140|hypoxia-inducible factor 1
P09211913A0000|117 139|hypoxia-inducible factor
P09211913A0000|165 175|target genes
P09211913A0000|183 188|CYP1A1
P09211913A0000|192 205|erythropoietin
P09211913A0000|219 248|xenobiotic aromatic hydrocarbons
P09211934A0722|0 5|DNase I
P09211934A0722|0 4|DNase
P09211934A0722|6 22|footprint analysis
P09211934A0722|34 48|protected region
P09211981A0526|25 28|gar2
P09211981A0526|55 57|p13
P09211981A0526|59 62|suc1
P09211981A0526|65 85|Sepharose-bound kinase
P09211981A0526|114 121|extracts
P09211981A0526|134 167|cell cycle-regulated activity similar
P09211981A0526|179 181|p34
P09211981A0526|183 193|cdc2(kinase
P09211981A0526|183 186|cdc2
P09211981A0526|188 193|kinase
P09212059A1356|21 52|metal affinity chromatography assay
P09212059A1356|54 69|self-association
P09212059A1356|72 75|PR-A
P09212059A1356|119 123|DhLBD
P09212059A1356|126 139|hLBD constructs
P09212059A1856|3 16|overall results
P09212059A1856|65 84|carboxyl-terminal LBD
P09212059A1856|112 125|PR dimerization
P09212059A1856|133 147|multiple regions
P09212059A1856|161 165|hinge
P09212059A1856|169 191|amino-terminal sequences
P09212059A1856|231 246|homodimerization
P09212059A1856|249 250|PR
P09212063A0425|28 34|A-phage
P09212063A0425|38 49|cosmid clones
P09212063A0425|70 71|kb
P09212063A0425|74 81|human DNA
P09212063A0425|97 109|entire VDR gene
P09212063A0425|103 105|VDR
P09214274T0001|0 18|Colorectal carcinoma
P09214274T0001|20 38|therapeutic approach
P09214274T0001|41 48|patients
P09214274T0001|67 85|metastasis resection
P09215525A0581|16 25|Dox effects
P09215525A0581|28 36|cell cycle
P09215525A0581|41 47|changes
P09215525A0581|50 64|E2F/DP complexes
P09215525A0581|50 52|E2F
P09215525A0581|93 105|C2C12 myocytes
P09215891A0000|3 10|products
P09215891A0000|16 42|Saccharomyces cerevisiae CIN1
P09215891A0000|39 42|CIN1
P09215891A0000|44 47|CIN2
P09215891A0000|51 59|CIN4 genes
P09215891A0000|74 92|nonessential pathway
P09215891A0000|104 128|normal microtubule function
P09216017A0621|0 9|Vitrectomy
P09216017A0621|19 39|significant risk factor
P09216017A0621|44 55|macular holes
P09216936T0000|7 15|editorial
P09216936T0000|19 23|Acute
P09216936T0000|27 40|chronic effects
P09216936T0000|53 64|leptin levels
P09216936T0000|53 58|leptin
P09216936T0000|67 72|humans
P09218436A0443|4 12|promoters
P09218436A0443|18 24|TATA box
P09218436A0443|29 32|Pint
P09218436A0443|45 54|MED-1 class
P09218436A0443|57 65|promoters
P09218436A0443|80 92|transcription
P09218436A0443|95 107|multiple sites
P09218459A0000|0 18|Serum response factor
P09218459A0000|20 22|SRF
P09218459A0000|36 48|ancient family
P09218459A0000|51 69|DNA-binding proteins
P09218459A0000|94 122|ubiquitous transcription factor
P09218459A0000|143 170|growth factor-responsive genes
P09218520A0075|15 21|studies
P09218520A0075|32 57|candidate signal transducers
P09218520A0075|78 92|cytosolic domain
P09218520A0075|94 95|cd
P09218520A0075|102 106|IL-1R
P09218599A0184|30 39|mechanisms
P09218599A0184|62 81|antimitogenic effects
P09218599A0184|84 87|IL-4
P09218775A0000|21 27|strains
P09218775A0000|37 44|patients
P09218775A0000|49 62|cystic fibrosis
P09218775A0000|64 65|CF
P09218775A0000|75 92|mucoid phenotype due
P09218775A0000|95 108|overproduction
P09218775A0000|111 118|alginate
P09218775A1229|0 7|Activity
P09218775A1229|10 14|palgD
P09218775A1229|20 29|cysB mutant
P09218775A1229|33 35|CHA
P09218775A1229|44 62|non-mucoid strain PAO
P09218775A1229|85 114|transcriptional algD-xylE fusion
P09218775A1229|100 103|algD
P09218775A1229|105 108|xylE
P09219526A0383|3 29|Man9-mannosidase specificity
P09219526A0383|3 18|Man9-mannosidase
P09219526A0383|35 47|cDNA construct
P09219526A0383|82 97|peptide sequences
P09219526A0383|142 161|active 49-kDa fragment
P09220158A0537|1 20|soluble 62-kDa protein
P09220158A0537|8 20|62-kDa protein
P09220158A0537|42 62|proteolytic processing
P09220158A0537|93 102|amino acids
P09220158A0537|113 117|ORF-2
P09220158A0537|121 147|baculovirus expression vector
P09220158A0537|159 176|corresponding virus
P09220158A0537|185 192|Sf9 cells
P09220177A0564|3 17|CPK-MB isoenzyme
P09220177A0564|26 43|percentage increase
P09220177A0564|46 59|total CPK higher
P09220177A0564|65 65|%
P09220177A0564|87 87|h
P09220177A0564|126 133|attempts
P09220177A0564|136 148|cardioversion
P09222057A0176|0 4|Serum
P09222057A0176|8 30|peritoneal dialysis fluid
P09222057A0176|32 34|PDF
P09222057A0176|52 56|assay
P09222057A0176|93 96|days
P09222115A0545|0 6|Results
P09222115A0545|31 69|endogenous corticotropin-releasing factor
P09222115A0545|87 107|peripheral binding site
P09222115A0545|122 159|active behavioral response characteristic
P09222115A0545|162 165|pups
P09222115A0545|175 184|early phase
P09222115A0545|198 214|novel surroundings
P09223042A0000|0 23|Liver regional blood volume
P09223042A0000|25 28|LRBV
P09223042A0000|41 60|several disease states
P09223042A0000|64 75|various drugs
P09223122A0774|3 23|gray matter NAA/mI ratio
P09223122A0774|46 51|groups
P09223229A0565|9 14|murine
P09223229A0565|18 31|human mb-1 genes
P09223229A0565|49 62|bovine mb-1 gene
P09223229A0565|70 76|TATA box
P09223475A0898|0 37|Chloramphenicol acetyltransferase assays
P09223475A0898|0 31|Chloramphenicol acetyltransferase
P09223475A0898|59 62|IE86
P09223475A0898|87 105|HCMV major IE promoter
P09223475A0898|119 135|HCMV early promoter
P09223475A0898|142 152|2.2-kb class
P09223475A0898|155 158|RNAs
P09223475A0898|174 192|functional integrity
P09223475A0898|198 208|IE86 protein
P09223479A1193|0 4|ORF M1
P09223479A1193|8 23|striking homology
P09223479A1193|26 40|poxvirus serpins
P09223479A1193|34 40|serpins
P09223479A1193|47 52|ORF M11
P09223479A1193|61 76|potential homolog
P09223479A1193|79 97|Bcl-2-like molecules
P09223479A1193|107 129|other gammaherpesviruses
P09223479A1193|139 141|HVS
P09223479A1193|145 148|KSHV
P09223479A1193|155 163|BHRF1 gene
P09223479A1193|166 168|EBV
P09223506T0000|0 40|Transcription factor binding sites downstream
P09223506T0000|46 76|human immunodeficiency virus type 1
P09223506T0000|46 75|human immunodeficiency virus type
P09223506T0000|77 98|transcription start site
P09223506T0000|114 129|virus infectivity
P09223647T0000|0 15|Crystal structure
P09223647T0000|20 27|oligomer
P09223647T0000|30 48|proteolytic zymogens
P09223647T0000|50 79|detailed conformational analysis
P09223647T0000|85 104|bovine ternary complex
P09223647T0000|108 119|implications
P09223647T0000|128 137|activation
P09223667A0139|7 27|transient transfection
P09223667A0139|30 50|NIH3T3 fibroblast cells
P09223667A0139|54 75|gel mobility shift assays
P09223667A0139|80 100|functional binding site
P09223667A0139|104 112|localized
P09223667A0139|116 126|short region
P09223667A0139|138 139|bp
P09223667A0139|147 168|transcription start site
P09223667A0139|179 191|CTCCC sequence
P09223880A1147|17 30|injection speed
P09223880A1147|37 44|.2 ml.s-1
P09223880A1147|59 74|spinal anesthesia
P09224655T0000|0 18|Alternative splicing
P09224655T0000|21 25|ClC-6
P09224655T0000|39 63|CIC chloride-channel family
P09224655T0000|65 75|transcripts
P09224655T0000|99 106|isoforms
P09224655T0000|118 123|ClC-6c
P09224655T0000|127 141|kidney-specific
P09224811A0000|3 14|current study
P09224811A0000|31 55|T3-activated transcription
P09224811A0000|61 65|NADPH
P09224811A0000|67 94|cytochrome P450 oxidoreductase
P09224811A0000|96 105|P450R) gene
P09224811A0000|96 100|P450R
P09224811A0000|122 142|thyroid hormonal status
P09224811A0000|163 177|transcriptional
P09224811A0000|181 208|post-transcriptional pathways
P09224811A0000|238 259|cellular P450R mRNA level
P09224811A0000|246 254|P450R mRNA
P09225151T0000|13 26|different types
P09225151T0000|29 51|polytetrafluoroethylene
P09225151T0000|53 56|PTFE
P09225151T0000|58 67|prostheses
P09225151T0000|73 97|reparative scarring process
P09225151T0000|100 119|abdominal wall defects
P09225506A0462|3 14|control group
P09225506A0462|36 47|higher levels
P09225506A0462|50 69|coagulation factors II
P09225506A0462|50 67|coagulation factors
P09225506A0462|71 78|V and VIII
P09225506A0462|71 71|V
P09225506A0462|75 78|VIII
P09225506A0462|93 102|index group
P09225682A0579|14 43|positive anti-GM1 antibody titers
P09225682A0579|22 37|anti-GM1 antibody
P09225682A0579|49 78|Guillain-Barre syndrome patients
P09225682A0579|83 85|PEN
P09225682A0579|88 95|isolates
P09225682A0579|99 104|higher
P09225682A0579|118 139|Guillain-Barre syndrome
P09225682A0579|143 148|Fisher
P09225682A0579|151 166|syndrome patients
P09225682A0579|174 176|PEN
P09225682A0579|179 186|isolates
P09225686A0683|0 34|Stereotactic radiofrequency lesioning
P09225686A0683|40 48|hamartoma
P09225686A0683|59 74|seizure remission
P09225686A0683|82 94|complications
P09225686A0683|97 102|months
P09225998A0000|0 32|NF-kappa B/Rel transcription factors
P09225998A0000|49 58|activation
P09225998A0000|61 73|numerous genes
P09225998A0000|84 112|immune regulation/inflammation
P09225998A0000|122 130|cytokines
P09225998A0000|132 151|cell surface receptors
P09225998A0000|153 169|adhesion molecules
P09225998A0000|174 191|acute phase proteins
P09226113A0857|22 38|source water sample
P09226113A0857|43 50|borehole
P09226113A0857|74 81|borehole
P09226345A0436|12 21|food intake
P09226345A0436|29 34|% group
P09226345A0436|51 58|ACT group
P09226345A0436|60 60|p
P09226345A0436|89 89|p
P09226345A0436|103 110|SEP group
P09226345A0436|125 141|amounts equivalent
P09226345A0436|146 146|%
P09226345A0436|149 164|daily requirement
P09227099A0106|31 42|modification
P09227099A0106|46 62|bar superstructure
P09227099A0106|78 87|advantages
P09227099A0106|168 177|angulation
P09227099A0106|180 187|implants
P09227332A1798|10 12|DDC
P09227332A1798|20 28|receptors
P09227332A1798|33 42|broad panel
P09227332A1798|45 53|cytokines
P09227332A1798|59 67|receptors
P09227332A1798|71 79|cytokines
P09227332A1798|85 91|effects
P09227332A1798|94 95|DC
P09227799A0254|15 28|diagnostic tool
P09227799A0254|32 58|epidemiological surveillance
P09227799A0254|91 110|other diagnostic tests
P09227799A0254|112 127|stool examination
P09227799A0254|129 133|ELISA
P09227799A0254|138 154|soluble egg antigen
P09227799A0254|156 158|SEA
P09227799A0254|166 189|circumoval precipitin test
P09227799A0254|176 185|precipitin
P09227799A0254|191 194|COPT
P09228042A0109|16 42|dermatan sulfate proteoglycan
P09228042A0109|44 52|epiphycan
P09228042A0109|58 64|decorin
P09228042A0109|68 75|biglycan
P09228042A0109|83 104|dissociative extraction
P09228042A0109|107 136|bovine fetal epiphyseal cartilage
P09228042A0109|148 169|sequential ion-exchange
P09228042A0109|171 183|gel permeation
P09228042A0109|185 195|hydrophobic
P09228042A0109|200 202|Zn2
P09228042A0109|204 230|chelate chromatographic steps
P09228092A1779|5 12|analyses
P09228092A1779|31 45|dUTPase isoforms
P09228092A1779|61 68|same gene
P09228092A1779|73 99|isoform-specific transcripts
P09228092A1779|135 139|exons
P09228202A0581|3 45|selective 5-HT3 receptor antagonists ramosetron
P09228202A0581|12 24|5-HT3 receptor
P09228202A0581|47 51|YM060
P09228202A0581|54 58|YM114
P09228202A0581|60 66|KAE-393
P09228202A0581|69 79|granisetron
P09228202A0581|83 93|ondansetron
P09228202A0581|112 121|benzamides
P09228202A0581|123 147|5-HT4 receptor agonist/5-HT
P09228202A0581|123 135|5-HT4 receptor
P09228202A0581|144 156|5-HT3 receptor
P09228202A0581|149 167|receptor antagonists
P09228202A0581|169 186|cisapride mosapride
P09228202A0581|190 197|SC-53116
P09228202A0581|222 236|gastric emptying
P09228202A0581|239 248|normal rats
P09229420A0158|0 12|Re-evaluation
P09229420A0158|18 31|biopsy specimen
P09229420A0158|39 46|right hip
P09229420A0158|66 81|initial operation
P09229420A0158|88 92|areas
P09229420A0158|95 108|chondrosarcoma
P09229420A0158|133 154|synovial chondromatosis
P09229595A0618|3 16|corneal buttons
P09229595A0618|33 47|histopathologic
P09229595A0618|51 76|electron microscopic studies
P09230129A0039|11 29|apparent homogeneity
P09230129A0039|37 42|% yield
P09230129A0039|45 66|affinity chromatography
P09230129A0039|76 88|DNA-cellulose
P09230129A0039|93 98|purity
P09230129A0039|104 119|final preparation
P09230129A0039|133 140|SDS/PAGE
P09230129A0039|148 160|contamination
P09230129A0039|163 176|other nucleases
P09230129A0039|193 212|monospecific antibody
P09230129A0039|223 228|enzyme
P09230216T0000|0 30|Human thymine-DNA glycosylase maps
P09230216T0000|0 26|Human thymine-DNA glycosylase
P09230216T0000|33 51|chromosome 12q22-q24
P09230216T0000|64 71|high loss
P09230216T0000|74 87|heterozygosity
P09230216T0000|90 102|gastric cancer
P09230307A0329|0 2|FOG
P09230307A0329|20 25|GATA-1
P09230307A0329|32 51|embryonic development
P09230307A0329|57 65|erythroid
P09230307A0329|69 87|megakaryocytic cells
P09230384A0725|3 11|mean times
P09230384A0725|14 22|detection
P09230384A0725|28 39|mycobacteria
P09230384A0725|44 49|BACTEC
P09230384A0725|54 55|MB
P09230384A0725|59 64|BACTEC
P09230384A0725|68 69|TB
P09230384A0725|93 96|days
P09230384A1056|9 14|BACTEC
P09230384A1056|19 26|MB system
P09230384A1056|43 62|respiratory specimens
P09230384A1056|122 133|mycobacteria
P09230384A1056|138 154|clinical specimens
P09230384A1056|159 184|various extrapulmonary sites
P09230894A0422|18 24|KmMig1p
P09230945A0089|1 24|pre-boutonniere deformity
P09230945A0089|28 36|simulated
P09230945A0089|50 60|central slip
P09230986A0000|0 20|Autoimmune neutropenia
P09230986A0000|22 24|AIN
P09230986A0000|29 41|frequent cause
P09230986A0000|44 61|chronic neutropenia
P09230986A0000|74 89|youngest children
P09232593A0946|15 45|characteristic expression pattern
P09232593A0946|48 56|DJ protein
P09232593A0946|63 107|conspicuous repeat units possible functional roles
P09233487A1386|0 13|Future analysis
P09233487A1386|16 39|long-term outcome measures
P09233487A1386|99 110|ear selection
P09233487A1386|119 127|Prom-EABR
P09233772A0136|22 25|p532
P09233772A0136|45 59|molecular weight
P09233772A0136|61 65|EMBO J
P09233772A0136|88 112|multiple structural domains
P09233772A0136|125 131|regions
P09233772A0136|139 153|internal repeats
P09233772A0136|172 193|cell cycle regulator RCC1
P09233772A0136|190 193|RCC1
P09233772A0136|196 226|guanine nucleotide exchange factor
P09233772A0136|233 258|small GTP-binding protein Ran
P09233772A0136|265 296|beta-repeat domains characteristic
P09233772A0136|302 312|beta subunit
P09233772A0136|315 337|heterotrimeric G proteins
P09233772A0136|344 366|putative SH3 binding sites
P09233772A0136|352 366|SH3 binding sites
P09233772A0136|369 390|putative leucine-zipper
P09233772A0136|395 434|carboxy-terminal HECT domain characteristic
P09233772A0136|437 462|E3 ubiquitin-protein ligases
P09233801A1180|8 18|L45 sequence
P09233801A1180|26 41|kinase subdomains
P09233801A1180|47 47|V
P09233801A1180|57 78|TGF-beta responsiveness
P09233801A1180|57 64|TGF-beta
P09233801A1180|84 96|type I receptor
P09233801A1180|89 96|receptor
P09233809A0381|6 15|mouse lines
P09233809A0381|27 51|unfragmented Hnf3g-lacZ YAC
P09233809A0381|39 43|Hnf3g
P09233809A0381|45 48|lacZ
P09233809A0381|58 72|tissue-specific
P09233809A0381|74 93|copy number-dependent
P09233809A0381|97 126|position-independent expression
P09233809A0381|142 143|kb
P09233809A0381|149 158|Hnf3g locus
P09233809A0381|149 153|Hnf3g
P09233809A0381|169 185|elements important
P09233809A0381|203 207|Hnf3g
P09233809A0815|7 31|plasmid-derived transgenes
P09233809A0815|35 47|gene targeting
P09233809A0815|53 76|endogenous Hnf3g gene locus
P09233809A0815|108 121|flanking region
P09233809A0815|163 184|reporter gene expression
P09233809A0815|193 200|pancreas
P09233809A0815|212 225|small intestine
P09233811A0072|25 39|HMG-box proteins
P09233811A0072|44 77|ubiquitous Ste11 transcription factor
P09233811A0072|54 77|Ste11 transcription factor
P09233811A0072|84 114|M cell-controlling protein Mat1-Mc
P09233811A0072|108 114|Mat1-Mc
P09234677A0770|36 51|short transcripts
P09234677A0770|55 62|proteins
P09234677A0770|80 95|short transcripts
P09234677A0770|115 125|respiration
P09234690A0242|0 7|Upstream
P09234690A0242|18 26|sequences
P09234690A0242|28 31|UASs
P09234690A0242|49 69|Ste12p-dependent genes
P09234690A0242|49 54|Ste12p
P09234690A0242|116 127|multiple PREs
P09234690A0242|131 139|single PRE
P09234690A0242|150 160|binding site
P09234690A0242|165 177|second protein
P09234696A0238|0 29|Prominent protein kinase cascades
P09234696A0238|50 73|mitogen-activated protein
P09234696A0238|75 85|MAP) kinases
P09234696A0238|75 77|MAP
P09234696A0238|79 85|kinases
P09234703A0192|0 2|JNK
P09234703A0192|31 53|Ras-related G proteins Rac
P09234703A0192|31 50|Ras-related G proteins
P09234703A0192|51 53|Rac
P09234703A0192|57 61|Cdc42
P09234713A0754|37 56|ligation-mediated PCR
P09234713A0754|79 106|recombination-activating gene
P09234713A0754|108 110|RAG
P09234713A0754|113 140|dependent double-strand breaks
P09234713A0754|142 145|DSBs
P09234713A0754|149 152|RSSs
P09234713A0754|157 163|Ddelta3
P09234713A0754|171 177|Jdelta1
P09234717A0000|0 12|Recent studies
P09234717A0000|33 35|Cbl
P09234717A0000|40 60|120-kDa protein product
P09234717A0000|66 84|c-cbl proto-oncogene
P09234717A0000|95 103|substrate
P09234717A0000|115 145|receptor-coupled tyrosine kinases
P09234717A0000|149 162|forms complexes
P09234717A0000|167 169|SH3
P09234717A0000|173 200|SH2 domain-containing proteins
P09234717A0000|221 238|signal transduction
P09234720A1015|38 40|MEK
P09234720A1015|42 47|MEK-2E
P09234720A1015|52 56|v-Src
P09234720A1015|100 109|H19-7 cells
P09234720A1015|111 122|coexpression
P09234720A1015|148 150|MEK
P09234720A1015|154 158|v-Src
P09234720A1015|166 181|neurite outgrowth
P09234723A0846|27 36|other cases
P09234723A0846|39 56|splicing regulation
P09234723A0846|59 61|PTB
P09234723A0846|92 101|splice site
P09234725A1892|17 47|ligand-dependent transactivation
P09234725A1892|53 70|interaction surface
P09234725A1892|94 108|transrepression
P09234725A1892|111 122|AP-1 activity
P09234725A1892|111 114|AP-1
P09234727A0770|0 20|Gal4-Eed fusion protein
P09234727A0770|30 42|transcription
P09234727A0770|46 57|reporter gene
P09234727A0770|67 74|promoter
P09234727A0770|87 109|Gal4-binding DNA elements
P09234736A0999|6 26|hybridization analysis
P09234736A0999|29 42|adult rat tissue
P09234736A0999|50 64|good correlation
P09234736A0999|96 102|drm mRNA
P09234736A0999|126 136|nondividing
P09234736A0999|164 168|cells
P09234736A0999|176 182|neurons
P09234736A0999|189 197|lung cells
P09234736A0999|202 212|goblet cells
P09234743A0475|14 21|proteins
P09234743A0475|55 66|alpha-globin
P09234743A0475|69 71|UTR
P09234743A0475|110 117|non-poly
P09234743A0475|119 119|C
P09234743A0475|121 135|binding proteins
P09234743A0475|141 153|alpha-complex
P09235073A0000|2 6|years
P09235073A0000|11 32|months old female patient
P09235073A0000|52 65|Weaver syndrome
P09235424A1200|10 17|measures
P09235424A1200|24 29|nurses
P09235424A1200|46 49|ABPM
P09235424A1200|53 57|women
P09235618A0000|11 18|patients
P09235618A0000|23 36|neuroinfection
P09235618A0000|38 48|Lyme disease
P09235618A0000|50 70|Guillain Barre syndrome
P09235618A0000|72 86|demyelinization
P09235618A0000|109 116|epilepsy
P09235618A0000|136 161|antiphospholipid antibodies
P09235618A0000|164 166|IgG
P09235618A0000|170 180|IgM subtypes
P09235618A0000|170 172|IgM
P09235618A0000|194 213|anticoagulant factors
P09235618A0000|223 234|thrombocytes
P09235618A0000|236 252|sedimentation rate
P09235618A0000|255 266|erythrocytes
P09235995A0339|1 5|1996a
P09235995A0339|7 18|Biochemistry
P09235998A0788|10 27|membrane expression
P09235998A0788|30 34|alpha
P09235998A0788|38 49|beta subunits
P09235998A0788|77 94|17-ketocholesterol
P09235998A0788|114 129|HMG-CoA reductase
P09236118A1455|3 9|results
P09236118A1455|21 23|Lrp
P09236118A1455|30 51|central palindromic site
P09236118A1455|84 94|major groove
P09236118A1455|100 108|DNA target
P09236118A1455|117 132|additional dimers
P09236118A1455|147 151|sites
P09236118A1455|159 188|nucleoprotein activation complex
P09236224A0939|0 18|Sustained activation
P09236224A0939|21 33|p21 expression
P09236224A0939|21 23|p21
P09236224A0939|85 87|NGF
P09236224A0939|105 120|PC12 growth arrest
P09236224A0939|127 141|differentiation
P09236441A0639|14 21|patients
P09236441A0639|31 40|recordings
P09236441A0639|43 45|ECG
P09236441A0639|47 82|beat-to-beat arterial oxygen saturation
P09236441A0639|84 87|SaO2
P09236441A0639|93 103|respiration
P09236441A0639|114 124|spontaneous
P09236441A0639|128 146|controlled breathing
P09236656A0124|3 25|mean total white cell count
P09236656A0124|40 47|baseline
P09236656A0124|61 61|L
P09236656A0124|63 64|SD
P09236656A0124|82 82|L
P09236656A0124|84 85|SD
P09237695A0000|1 29|prospective observational study
P09237695A0000|52 66|early indicators
P09237695A0000|69 93|acute dengue virus infection
P09237862A0782|5 20|experimental eyes
P09237862A0782|31 45|marked reduction
P09237862A0782|56 70|complete absence
P09237862A0782|73 88|adrenergic nerves
P09237862A0782|94 97|iris
P09238467A0763|5 11|lesions
P09238467A0763|26 36|propranolol
P09238467A0763|39 50|phentolamine
P09238850A0785|12 15|ICER
P09238850A0785|42 60|alternative promoter
P09238850A0785|77 88|feedback loop
P09238850A2042|4 23|night-day oscillation
P09238850A2042|37 51|endogenous clock
P09238850A2042|53 59|located
P09238850A2042|65 86|suprachiasmatic nucleus
P09238850A2042|88 90|SCN
P09238860A0175|16 22|nucleus
P09238860A0175|28 32|cells
P09238860A0175|86 128|cyclic AMP response element binding proteins CREB
P09238860A0175|125 128|CREB
P09238860A0175|132 138|CREM tau
P09238860A0175|142 156|manner analogous
P09238860A0175|159 173|protein kinase A.
P09238860A1974|5 9|cells
P09238860A1974|27 33|signals
P09238860A1974|49 52|CREB
P09238860A1974|85 105|cytokine Interleukin-2
P09238860A1974|93 105|Interleukin-2
P09238860A1974|107 110|IL-2
P09238860A1974|124 129|agents
P09238860A1974|140 163|increase intracellular Ca2
P09238860A1974|179 193|protein kinase C.
P09238860A1974|179 192|protein kinase C
P09239635A0477|11 14|dogs
P09239635A0477|18 28|low serum IgG
P09239635A0477|26 28|IgG
P09239635A0477|38 42|mg/ml
P09239635A0477|50 65|second littermate
P09239635A0477|80 87|serum IgA
P09239635A0477|85 87|IgA
P09239635A0477|99 103|mg/ml
P09241092A1108|0 10|CONCLUSIONS
P09241092A1108|12 20|Valproate
P09241092A1108|40 54|glucuronidation
P09241092A1108|57 72|carbamazepine-10
P09241092A1108|77 86|trans-diol
P09241092A1108|126 141|carbamazepine-10
P09241092A1108|146 152|epoxide
P09241092A1108|159 178|trans-diol derivative
P09241092A1108|209 222|latter reaction
P09241232A0653|3 13|Ogg1 protein
P09241232A0653|33 41|DNA duplex
P09241232A0653|48 62|preformed AP site
P09241232A0653|57 62|AP site
P09241232A0653|80 87|cytosine
P09241232A0653|89 92|AP/C
P09241232A1154|1 17|consensus sequence
P09241232A1154|43 55|lysine residue
P09241232A1154|57 60|K120
P09241232A1154|63 74|endonuclease
P09241232A1154|80 83|K241
P09241232A1154|86 89|Ogg1
P09242375A1313|13 20|findings
P09242375A1313|36 49|mutations E768D
P09242375A1313|53 57|V804L
P09242375A1313|61 85|gain-of-function mutations
P09242375A1313|101 114|long RET isoform
P09242375A1313|134 149|biological effect
P09242375A1313|164 172|mutations
P09242375A1313|203 207|MEN2A
P09242375A1313|211 224|MEN2B mutations
P09242375A1313|211 215|MEN2B
P09242499A0505|0 9|Volunteers
P09242499A0505|31 35|backs
P09242499A0505|40 53|suberythemal UV
P09242499A0505|63 63|d
P09242499A0505|85 94|sunscreens
P09242499A0505|103 112|base lotion
P09242499A0505|115 128|different sites
P09242506A1033|0 2|E2F
P09242506A1033|6 25|heterodimeric complex
P09242506A1033|38 53|E2F family members
P09242506A1033|62 71|DP proteins
P09242506A1033|73 75|1-3
P09242551A0653|0 8|EBER1 mRNA
P09242551A0653|11 26|consistent marker
P09242551A0653|29 40|viral latency
P09242551A0653|58 65|PEL cases
P09242551A0653|77 87|lower levels
P09242551A0653|97 114|non-PEL controls due
P09242551A0653|117 131|EBER1 expression
P09242551A0653|117 121|EBER1
P09242551A0653|139 152|variable subset
P09242551A0653|155 167|lymphoma cells
P09243267A0401|0 6|METHODS
P09243267A0401|24 31|patients
P09243267A0401|50 70|squamous cell carcinoma
P09243267A0401|76 85|oral cavity
P09243267A0401|99 114|primary treatment
P09243267A0401|117 139|Roswell Park Cancer Center
P09243267A0401|141 144|RPCI
P09243385A1314|15 27|presaturation
P09243385A1314|44 66|myocardial motion studies
P09243385A1314|72 89|cine PC velocity data
P09243505A1194|14 35|DNA-binding experiments
P09243505A1194|61 71|MADS domains
P09243505A1194|75 79|dimer
P09243505A1194|104 135|particular DNA-binding specificity
P09243505A1194|155 163|sequences
P09243505A1194|174 198|amino-terminal basic region
P09243505A1194|204 213|MADS domain
P09243505A1194|224 228|cases
P09243505A1194|245 266|DNA-binding specificity
P09243505A1194|272 279|proteins
P09243587A0000|0 17|PURPOSE/OBJECTIVES
P09243587A0000|50 77|early first full-term pregnancy
P09243587A0000|79 82|FFTP
P09243587A0000|99 110|breast cancer
P09243587A0000|121 132|interruption
P09243587A0000|160 192|abortion increases breast cancer risk
P09243840A0663|3 16|related studies
P09243840A0663|35 44|week period
P09243840A0663|61 68|HLA-DQA1
P09243840A0663|89 99|autopsy room
P09243840A0663|103 133|Forensic DNA Laboratory structures
P09244100A0194|10 13|rats
P09244100A0194|33 38|groups
P09244282A1371|0 10|Mutagenesis
P09244282A1371|16 35|pecT regulatory region
P09244282A1371|60 64|sites
P09244282A1371|72 81|insertions
P09244282A1371|95 108|pec-1 phenotype
P09244282A1371|95 99|pec-1
P09244350A0000|0 4|BRCA1
P09244350A0000|7 20|familial breast
P09244350A0000|24 54|ovarian cancer susceptibility gene
P09244350A0000|62 83|nuclear phosphoproteins
P09244350A0000|98 113|tumor suppressors
P09244350A0000|116 137|human breast cancer cells
P09244430A0693|3 24|alternative splice sites
P09244430A0693|31 52|smallest adducin isoform
P09244430A0693|54 59|beta-3
P09244430A0693|64 79|alternative donor
P09244430A0693|83 95|acceptor sites
P09244430A0693|102 106|exons
P09246343T0000|0 10|Proteinuria
P09246343T0000|14 21|young man
P09246585T0000|0 13|Neural blockade
P09246585T0000|26 35|cancer pain
P09247645A0000|3 33|new temperature-sensitive alleles
P09247645A0000|36 39|SEC3
P09247645A0000|46 64|late-acting SEC genes
P09247645A0000|87 92|fusion
P09247645A0000|95 121|post-Golgi secretory vesicles
P09247645A0000|127 140|plasma membrane
P09247645A0000|191 227|temperature-sensitive secretory mutants
P09247645A0000|248 253|lethal
P09247645A0000|258 263|sec4-8
P09248639A0152|4 14|cell strains
P09248639A0152|17 38|human dermal fibroblasts
P09248639A0152|63 69|samples
P09248639A0152|76 87|blister fluid
P09248639A0152|121 131|contraction
P09248639A0152|146 180|fibroblast populated collagen lattices
P09248639A0152|165 172|collagen
P09248639A0152|182 185|FPCL
P09249039A0124|16 25|key enzymes
P09249039A0124|39 70|triiodothyronine-mediated control
P09249039A0124|80 94|differentiation
P09249039A0124|98 112|basal metabolism
P09249039A0124|115 125|vertebrates
P09249070A0989|0 3|Cell
P09249710A0331|10 27|ELISA-positive sera
P09249710A0331|60 95|plaque reduction neutralization testing
P09250554A0402|0 7|Patients
P09250554A0402|22 32|diltiazem CD
P09250554A0402|36 37|mg
P09250554A0402|40 54|placebo once/day
P09250554A0402|80 97|antianginal therapy
P09251843A0189|0 26|Reactive lymphoid hyperplasia
P09251843A0189|39 43|cases
P09251843A0189|46 50|cases
P09251843A0189|54 87|angiofollicular lymphoid hyperplasia
P09251843A0189|90 98|Castleman
P09251843A0189|109 145|atypical lymphoid hyperplasia suggestive
P09251843A0189|148 164|malignant lymphoma
P09251843A0189|179 183|cases
P09251843A0189|188 204|malignant lymphoma
P09251843A0189|232 236|cases
P09252397A0081|23 33|repair rates
P09252397A0081|36 62|cyclobutane pyrimidine dimers
P09252397A0081|65 84|nucleotide resolution
P09252397A0081|93 104|human JUN gene
P09252397A0081|107 123|normal fibroblasts
P09252397A0081|136 150|efficient repair
P09252397A0081|153 161|sequences
P09252397A0081|169 195|transcription initiation site
P09252397A0081|199 208|slow repair
P09252397A0081|217 224|promoter
P09252406A0511|0 7|Tyrosine
P09252406A0511|18 42|multisubstrate binding site
P09252406A0511|49 52|Grb2
P09252406A0511|56 73|Shc adaptor proteins
P09252406A0511|78 87|p85 subunit
P09252406A0511|90 118|phosphatidylinositol 3'-kinase
P09252406A0511|90 109|phosphatidylinositol
P09252406A0511|113 118|kinase
P09252406A0511|120 138|phospholipase Cgamma
P09252406A0511|143 154|a phosphatase
P09252406A0511|144 154|phosphatase
P09252406A0511|156 159|SHP2
P09252879A0470|16 27|HRCT findings
P09252879A0470|35 50|clinical features
P09252879A0470|52 69|pulmonary functions
P09252879A0470|73 88|methacholine PC20
P09252879A0470|90 94|PC20M
P09252879A0470|111 130|clinical significance
P09254678A0106|0 6|Gtx mRNA
P09254678A0106|20 27|parallel
P09254678A0106|35 38|RNAs
P09254678A0106|50 72|major structural proteins
P09254678A0106|75 80|myelin
P09254678A0106|82 99|myelin basic protein
P09254678A0106|101 103|MBP
P09254678A0106|109 126|proteolipid protein
P09254678A0106|128 130|PLP
P09254678A0106|138 162|postnatal brain development
P09254678A0106|164 170|Gtx mRNA
P09254678A0106|182 189|parallel
P09254678A0106|194 196|MBP
P09254678A0106|200 207|PLP mRNAs
P09254678A0106|213 218|brains
P09254678A0106|221 240|myelin-deficient rats
P09254678A0106|252 264|point mutation
P09254678A0106|270 276|PLP gene
P09254709T0000|0 7|Contacts
P09254709T0000|15 61|Bacillus subtilis catabolite regulatory protein CcpA
P09254709T0000|58 61|CcpA
P09254709T0000|65 78|amyO target site
P09254709T0000|65 68|amyO
P09255349A0836|20 43|GTPase activating proteins
P09255349A0836|20 25|GTPase
P09255349A0836|36 43|proteins
P09255349A0836|53 56|IRA1
P09255349A0836|60 63|IRA2
P09256973A0455|3 4|E2
P09256973A0455|35 35|G
P09256973A0455|44 45|G2
P09256973A0455|47 48|mg
P09256973A0455|51 65|itraconazole/kg
P09256973A0455|67 74|capsules
P09256973A0455|90 94|weeks
P09256973A0673|0 6|RESULTS
P09256973A0673|11 12|E1
P09256973A0673|14 48|itraconazole plasma drug concentration
P09256973A0673|91 103|micrograms/ml
P09256973A0673|112 124|residence time
P09256973A0673|126 128|MRT
P09256973A0673|140 144|hours
P09257651T0000|3 17|human U4/U6 snRNP
P09257651T0000|8 9|U4
P09257651T0000|11 17|U6 snRNP
P09257651T0000|31 42|90kD proteins
P09257651T0000|62 71|homologous
P09257651T0000|77 101|yeast splicing factors Prp4p
P09257651T0000|97 101|Prp4p
P09257651T0000|105 109|Prp3p
P09257887A0457|0 4|G-CSF
P09257887A0457|34 46|microg/kg/day
P09257887A0457|76 88|last apheresis
P09257887A0457|95 117|absolute neutrophil count
P09258439A1001|7 22|expression system
P09258439A1001|49 53|forms
P09258439A1001|56 61|SsEF-2
P09258439A1001|72 82|mutagenesis
P09258439A1001|88 104|corresponding gene
P09258606A0822|0 8|Crosstalk
P09258606A0822|17 24|pathways
P09258606A0822|42 46|forms
P09258606A0822|87 96|malignancy
P09259052A0568|0 15|Supershift assays
P09259052A0568|22 24|Jun
P09259052A0568|28 61|Fos family member-specific antibodies
P09259052A0568|73 88|protein complexes
P09259052A0568|97 121|AtT-20 cell nuclear extracts
P09259052A0568|132 144|c-jun AP-1 site
P09259052A0568|160 175|Jun family members
P09259052A0568|177 180|JunD
P09259052A0568|182 185|JunB
P09259052A0568|190 193|cJun
P09259313A0950|13 28|PI kinase activity
P09259313A0950|13 20|PI kinase
P09259313A0950|41 54|cbl-associated
P09259313A0950|41 43|cbl
P09259313A0950|60 73|PRL stimulation
P09259313A0950|60 62|PRL
P09259315A0809|0 7|Mutation
P09259315A0809|10 13|Enh4
P09259315A0809|17 44|essential GT-IIC-like enhanson
P09259315A0809|26 44|GT-IIC-like enhanson
P09259315A0809|62 75|intact enhancer
P09259315A0809|86 101|silencer activity
P09259315A0809|106 132|multimerized GT-IIC enhansons
P09259315A0809|118 132|GT-IIC enhansons
P09259315A0809|141 177|intact CSEn enhancer/silencer activities
P09259315A0809|147 167|CSEn enhancer/silencer
P09259315A0809|180 183|BeWo
P09259315A0809|187 193|GC cells
P09259320A0830|5 33|lectin-affinity chromatography
P09259320A0830|35 45|discordance
P09259320A0830|65 79|O-glycosylation
P09259320A0830|82 85|SSBP
P09259320A0830|89 92|DSBP
P09259328A0440|0 25|Deletion mapping experiments
P09259328A0440|43 51|sequences
P09259328A0440|63 74|full activity
P09259328A0440|77 86|MSC-1 cells
P09259328A0440|108 109|bp
P09259328A0440|115 123|start site
P09259328A0440|137 150|several regions
P09259328A0440|176 193|luciferase activity
P09259328A0440|176 185|luciferase
P09259328A0440|202 203|bp
P09259328A0440|210 211|bp
P09259328A0440|217 218|bp
P09259328A0440|225 226|bp
P09259328A0440|235 236|bp
P09259328A0440|242 248|regions
P09261155A0833|15 16|PH
P09261155A0833|20 29|PTB domains
P09261155A0833|20 22|PTB
P09261155A0833|39 48|homologous
P09261155A0833|59 68|% identical
P09261155A0833|84 108|insulin receptor substrates
P09261155A0833|118 122|IRS-1
P09261155A0833|124 128|IRS-2
P09261155A0833|133 137|IRS-3
P09261178T0000|3 42|mouse extracellular signal-regulated kinase
P09261184A0170|16 39|gel mobility shift analysis
P09261184A0170|43 63|supershift experiments
P09261184A0170|65 69|FIRE1
P09261184A0170|71 77|located
P09261184A0170|120 123|NF-Y
P09261200T0001|0 8|MR imaging
P09261200T0001|11 31|traumatic head injuries
P09261200T0001|37 50|FLAIR technique
P09261397A0509|0 23|Gag protein sequence motifs
P09261397A0509|29 36|NC domain
P09261397A0509|39 57|primate foamy viruses
P09261397A0509|79 97|genome encapsidation
P09261397A0509|115 118|FeFV
P09263010T0000|0 8|Induction
P09263010T0000|11 24|B cell apoptosis
P09263010T0000|43 46|CD23
P09263010T0000|50 52|sIg
P09263010T0000|61 78|aberrant regulation
P09263010T0000|81 85|c-myc
P09263010T0000|102 106|bcl-2
P09263094A0799|0 11|MEASUREMENTS
P09263094A0799|15 25|MAIN RESULTS
P09263094A0799|27 39|Lung elastance
P09263094A0799|41 42|EL
P09263094A0799|58 59|RL
P09263094A0799|79 90|measurements
P09263094A0799|93 106|airway pressure
P09263094A0799|108 125|esophageal pressure
P09263094A0799|130 139|airway flow
P09263094A0799|146 157|anesthetized
P09263094A0799|159 171|paralyzed dogs
P09263094A0799|178 187|sinusoidal
P09263094A0799|198 223|constant mean airway pressure
P09263094A0799|228 232|cmH2O
P09263094A0799|236 244|wide range
P09263094A0799|247 266|breathing frequencies
P09263094A0799|276 277|Hz
P09263094A0799|280 288|intervals
P09263094A0799|298 309|tidal volumes
P09263094A0799|330 331|mL
P09263856A0563|13 29|theoretical models
P09263856A0563|36 38|Gla
P09263856A0563|42 53|EGF-1 modules
P09263856A0563|56 62|human PS
P09263856A0563|79 89|prothrombin
P09263856A0563|93 121|factor X experimental structures
P09264466A0947|3 13|Cut9 subunit
P09264466A0947|46 58|APC/ cyclosome
P09264466A0947|46 48|APC
P09264466A0947|50 66|cyclosome function
P09264466A0947|74 100|protein-protein interactions
P09264466A0947|74 88|protein-protein
P09264466A0947|104 118|phosphorylation
P09265534A0455|12 32|Gy/20 fractions/5 weeks
P09265642A0668|10 28|biosynthetic pathway
P09265642A0668|34 40|vacuole
P09265642A0668|58 73|endocytic pathway
P09265642A0668|75 89|internalization
P09265642A0668|93 121|bulk membrane endocytic marker FM
P09265642A0668|141 150|sop mutants
P09265932A0575|6 10|women
P09265932A0575|23 40|mg plain bupivacaine
P09265932A0575|44 64|subarachnoid injection
P09265932A0575|70 83|L2-3 interspace
P09267306A0381|48 51|apo B
P09267306A0381|63 80|reasonable standard
P09267306A0381|83 101|laboratory precision
P09267306A0381|126 147|widespread introduction
P09267306A0381|150 169|clinical laboratories
P09267431A0000|3 19|soybean cDNA clones
P09267431A0000|21 25|SPK-3
P09267431A0000|29 33|SPK-4
P09267431A0000|43 64|putative protein kinases
P09267431A0000|51 64|protein kinases
P09267439A0000|0 4|Genes
P09267439A0000|19 32|ras superfamily
P09267439A0000|39 81|low-molecular-weight GTP/GDP-binding proteins
P09267439A0000|63 81|GDP-binding proteins
P09267439A0000|106 116|wide variety
P09267439A0000|119 127|organisms
P09267542A0126|0 9|Naltrexone
P09267542A0126|38 41|Food
P09267542A0126|45 62|Drug Administration
P09267542A0126|80 96|alcohol dependence
P09268298T0000|0 18|Ent-kaurene synthase
P09268298T0000|26 46|fungus Phaeosphaeria sp
P09268387A0293|52 71|ELL functional domains
P09268387A0293|100 114|RNA polymerase II
P09268387A0293|100 112|RNA polymerase
P09268387A0293|121 144|ternary elongation complex
P09268578A0225|12 24|cDNA sequences
P09268631A0316|12 35|transcription orientation
P09268631A0316|40 54|imprinted status
P09268631A0316|60 64|genes
P09268631A0316|84 88|Igf2r
P09268638A0332|15 49|directional chromosome walking studies
P09268638A0332|62 67|D8S260
P09268638A0332|76 81|D8S285
P09268652A0116|11 32|novel zinc finger protein
P09268652A0116|16 32|zinc finger protein
P09268652A0116|34 42|dsRBP-ZFa
P09268652A0116|65 81|expression library
P09268652A0116|86 90|dsRNA
P09268661A1405|3 9|results
P09268661A1405|25 56|retroplasmid reverse transcriptase
P09268661A1405|37 56|reverse transcriptase
P09268661A1405|84 96|cDNA synthesis
P09268661A1405|113 123|CCA sequence
P09269879A0266|0 14|Nasal absorption
P09269879A0266|24 43|nasal bioavailability
P09269879A0266|49 49|%
P09269879A0266|57 58|iv
P09269879A0266|62 85|nasal elimination profiles
P09269900A1035|14 20|results
P09269900A1035|32 42|EGF/Ras/Raf
P09269900A1035|32 34|EGF
P09269900A1035|36 38|Ras
P09269900A1035|40 42|Raf
P09269900A1035|50 62|transcription
P09269900A1035|66 83|combined activation
P09269900A1035|86 95|ATF3/c-Jun
P09269900A1035|86 89|ATF3
P09269900A1035|91 95|c-Jun
P09269900A1035|100 118|52-kDa nuclear factor
P09269900A1035|127 130|JunD
P09269900A1035|138 146|repressor
P09271393A1333|38 50|Tax anchors CBP
P09271393A1333|38 40|Tax
P09271393A1333|48 50|CBP
P09271393A1333|56 69|HTLV-1 promoter
P09271393A1333|75 105|strong transcriptional activation
P09271393A1333|122 145|CBP-associated activities
P09271393A1333|122 124|CBP
P09271393A1333|148 167|nucleosome remodeling
P09271393A1333|171 181|recruitment
P09271393A1333|187 215|general transcription machinery
P09271394A0558|0 5|DNase I
P09271394A0558|0 4|DNase
P09271394A0558|9 46|1,10-phenanthroline-copper footprinting
P09271394A0558|49 68|MURA-Mu1 TIR complexes
P09271394A0558|49 52|MURA
P09271394A0558|54 56|Mu1
P09271394A0558|57 59|TIR
P09271394A0558|81 84|MURA
P09271394A0558|115 125|32-bp region
P09271394A0558|131 133|TIR
P09271394A0558|136 138|Mu1
P09271397A1596|0 9|Consistent
P09271397A1596|25 42|synthetic construct
P09271397A1596|58 69|tandem copies
P09271397A1596|75 100|native LDL receptor SREBP site
P09271397A1596|81 91|LDL receptor
P09271397A1596|110 122|single Sp1 site
P09271397A1596|116 122|Sp1 site
P09271397A1596|155 183|buttonhead-independent fashion
P09271397A1596|155 164|buttonhead
P09271400A0475|0 12|Various assays
P09271400A0475|24 39|promoter activity
P09271400A0475|71 83|normal control
P09271400A0475|86 99|E2F2 expression
P09271400A0475|86 89|E2F2
P09271400A0475|107 123|growth stimulation
P09271417A0585|5 14|adult mouse
P09271417A0585|16 23|ERR alpha
P09271417A0585|47 52|kidney
P09271417A0585|63 77|brown adipocytes
P09271417A0585|79 85|tissues
P09271417A0585|115 124|fatty acids
P09271417A1011|3 37|MCAD nuclear receptor response element 1
P09271417A1011|3 36|MCAD nuclear receptor response element
P09271417A1011|39 44|NRRE-1
P09271417A1011|66 73|ERR alpha
P09271417A1011|85 94|COS-7 cells
P09271496T0000|0 14|Mapping features
P09271496T0000|17 30|HIV-1 integrase
P09271496T0000|43 47|sites
P09271496T0000|50 54|viral
P09271496T0000|58 75|target DNA molecules
P09271496T0000|80 102|active enzyme-DNA complex
P09271496T0000|105 123|photo-cross-linking
P09272108A1295a|0 7|Analysis
P09272108A1295a|15 28|flanking region
P09272108A1295a|63 74|multiple TATA
P09272108A1295a|78 90|CAAT sequences
P09272108A1295b|0 7|Analysis
P09272108A1295b|15 28|flanking region
P09272108A1295b|63 74|multiple TATA
P09272108A1295b|78 90|CAAT sequences
P09272138A1153|3 18|complete response
P09272138A1153|20 21|CR
P09272138A1153|32 32|%
P09272138A1153|38 41|CODE
P09272138A1153|46 57|rhG-CSF group
P09272138A1153|46 52|rhG-CSF
P09272138A1153|63 63|%
P09272138A1153|69 72|CODE
P09272138A1153|87 100|median survival
P09272138A1153|111 115|weeks
P09272138A1153|137 142|groups
P09272138A1153|144 145|P =
P09275159T0000|0 38|Heterogeneous nuclear ribonucleoprotein A1
P09275159T0000|49 78|transcription-regulatory region
P09275159T0000|81 102|mouse hepatitis virus RNA
P09275164A0000|3 21|m7GpppN cap structure
P09275164A0000|24 37|eukaryotic mRNA
P09275164A0000|70 85|sequential action
P09275164A0000|93 99|enzymes
P09275164A0000|101 117|RNA triphosphatase
P09275164A0000|119 140|RNA guanylyltransferase
P09275164A0000|145 147|RNA
P09275164A0000|149 157|guanine-7
P09275164A0000|160 176|methyltransferase
P09275990A0938|5 13|first part
P09275990A0938|28 46|highest mutagenicity
P09275990A0938|60 69|TA98 strain
P09275990A0938|77 95|enzymatic activation
P09275990A0938|108 142|direct-acting mutagenicity prevalence
P09275990A0938|145 161|diesel particulate
P09276882A0479|25 26|CC
P09276882A0479|30 31|CC
P09276882A0479|33 45|SW by-products
P09276882A0479|56 68|pH values lower
P09276882A0479|70 70|P
P09276882A0479|102 104|Day
P09276882A0479|116 137|% carbohydrate treatment
P09276882A0479|158 159|pH
P09276882A0479|170 182|% carbohydrate
P09277472A1070|0 26|Myocardial interstitial edema
P09277472A1070|40 57|potential mechanism
P09277472A1070|60 79|diastolic dysfunction
P09277472A1070|85 92|DC shocks
P09277629A0268|3 13|experiments
P09277629A0268|15 16|N =
P09277629A0268|58 72|ERP negativities
P09277629A0268|76 97|visuospatial memory task
P09277629A0268|105 129|auditory spatial memory task
P09278441A0163|0 3|Biol
P09278441A1160|21 38|CARP mRNA expression
P09278441A1160|21 28|CARP mRNA
P09278441A1160|49 67|transient expression
P09278441A1160|85 88|days
P09278441A1160|113 118|Nkx2.5
P09278441A1160|113 116|Nkx2
P09278441A1160|120 122|Csx
P09278441A1160|125 139|putative homolog
P09278441A1160|142 147|tinman
P09278441A1160|152 177|Drosophila melanogaster gene
P09278441A1160|174 188|gene responsible
P09278441A1160|192 209|cardiac development
P09278441A1777|0 13|Overexpression
P09278441A1777|16 19|CARP
P09278441A1777|22 35|cardiomyocytes
P09278441A1777|46 61|cardiac troponin C
P09278441A1777|65 100|atrial natriuretic factor transcription
P09278441A1777|65 87|atrial natriuretic factor
P09278445T0000|0 19|Substrate specificity
P09278445T0000|25 37|RNase activity
P09278445T0000|25 29|RNase
P09278445T0000|40 60|yeast RNA polymerase III
P09278445T0000|40 57|yeast RNA polymerase
P09278450A1338|0 33|Electrophoretic mobility shift assays
P09278450A1338|37 58|competition experiments
P09278450A1338|69 73|site A
P09278450A1338|90 99|NF1 protein
P09278454A1261|0 10|Examination
P09278454A1261|16 31|MMP-2 RE1 sequence
P09278454A1261|42 64|incomplete Y-box sequence
P09278454A1261|66 77|CTGCTGGGCAAG
P09278454A1261|111 125|recombinant YB-1
P09278454A1261|128 160|DMS protection footprinting analysis
P09278475A0465|6 10|scs32
P09278475A0465|37 47|ts phenotype
P09278475A0465|73 85|Ino-phenotype
P09278475A0465|88 95|rpo26-31
P09278494A0762|15 17|Sp1
P09278494A0762|21 31|ETS proteins
P09278494A0762|55 74|full promoter activity
P09278494A0762|80 94|Surf-1 direction
P09278494A0762|80 85|Surf-1
P09278758A1636|0 9|CONCLUSION
P09278758A1636|11 21|Patients wit
P09278758A1636|32 50|palpable neck disease
P09278758A1636|52 55|N1-3
P09278758A1636|58 77|histological evidence
P09278758A1636|80 101|metastatic nodal disease
P09278758A1636|103 121|extracapsular spread
P09278758A1636|133 154|more positive lymph nodes
P09278758A1636|160 170|greater risk
P09278758A1636|192 203|distant sites
P09279379A0310|19 44|pBR322 deoxyribonucleic acid
P09279379A0310|50 58|sequences
P09279379A0310|95 100|spacer
P09279379A0310|109 114|spacer
P09279379A0310|120 133|H2B histone gene
P09279889A1124|0 3|Area
P09279889A1124|12 39|drug concentration-time curves
P09279889A1124|41 49|AUC0-24 hr
P09279889A1124|54 56|MTX
P09279889A1124|72 73|ng
P09279889A1124|84 87|PG-2
P09279889A1124|90 95|% Azone
P09279889A1124|99 102|PG-7
P09279889A1124|105 117|% Azone systems
P09280747A0195|16 39|hydralazine hydrochloride
P09280747A0195|43 61|isosorbide dinitrate
P09280747A0195|86 101|direct comparison
P09280747A0195|108 115|regimens
P09280747A0195|136 155|less favourable effect
P09280747A0195|169 181|ACE inhibitors
P09280747A0195|169 171|ACE
P09282329A0527|9 18|mechanisms
P09282329A0527|29 40|interactions
P09282329A0527|43 65|Site II regulatory factors
P09282329A0527|43 46|Site
P09282329A0527|49 65|regulatory factors
P09282329A0527|74 96|cell cycle control element
P09282329A0527|121 132|determinants
P09282329A0527|135 159|transcriptional regulation
P09282329A0527|165 183|G1/S phase transition
P09282329A0527|186 219|FDC-P1 hematopoietic progenitor cells
P09282911A0277|31 50|neuronal cell cultures
P09282911A0277|62 76|RC3/neurogranin
P09282911A0277|62 64|RC3
P09282911A0277|66 76|neurogranin
P09282911A0277|110 111|T3
P09282985A0961|9 19|differences
P09282985A0961|27 31|males
P09282985A0961|33 33|p
P09282985A0961|52 66|characteristics
P09283828A0484|5 22|circadian responses
P09283828A0484|29 34|photic
P09283828A0484|38 51|non-photic cues
P09285715A1257|8 19|previous data
P09285715A1257|37 39|Rev
P09285715A1257|47 63|same export pathway
P09285715A1257|66 92|uracil-rich small nuclear RNAs
P09285715A1257|96 109|5S ribosomal RNA
P09285715A1257|114 116|CTE
P09285715A1257|159 165|factors
P09285715A1257|185 202|cellular mRNA export
P09285789A0712|0 7|Human Duo
P09285789A0712|17 47|guanine nucleotide exchange factor
P09285789A0712|49 51|GEF
P09285789A0712|75 87|rac1-specific
P09285789A0712|75 78|rac1
P09285789A0712|90 107|pleckstrin homology
P09285789A0712|109 110|PH
P09285789A0712|121 144|spectrin-like repeat units
P09286115T0000|0 2|S2F
P09286115T0000|5 35|leaf-specific trans-acting factor
P09286115T0000|45 66|novel cis-acting element
P09286115T0000|96 104|RPL21 gene
P09286981A0147|0 3|ArgR
P09286981A0147|17 21|dimer
P09286981A0147|27 39|equal subunits
P09286981A0147|50 62|molecular mass
P09286981A0147|71 72|Da
P09287036A0457|0 25|Plasma leptin concentrations
P09287036A0457|6 11|leptin
P09287036A0457|30 35|higher
P09287036A0457|38 42|women
P09287036A0457|47 49|men
P09287036A0457|76 86|differences
P09287036A0457|89 95|fat mass
P09287036A0457|103 107|ng/ml
P09287036A0457|111 115|women
P09287352A0930|0 9|Consistent
P09287352A0930|14 20|effects
P09287352A0930|23 36|STAT activation
P09287352A0930|23 26|STAT
P09287352A0930|38 59|altered SHP-1 expression
P09287352A0930|45 49|SHP-1
P09287352A0930|72 92|EGF-induced activation
P09287352A0930|72 74|EGF
P09287352A0930|98 134|mitogen-activated protein kinase pathway
P09287352A0930|98 127|mitogen-activated protein kinase
P09287352A0930|148 152|SHP-1
P09287352A0930|155 157|Cys
P09287352A0930|161 163|Ser
P09287352A0930|184 186|MEK
P09287352A0930|204 204|%
P09287352A0930|225 229|SHP-1
P09287352A0930|256 264|% increase
P09287362A0589|26 34|SH3 region
P09287362A0589|37 39|p50
P09287362A0589|41 43|csk
P09287362A0589|49 66|proline-rich region
P09287362A0589|68 84|PPPLPERTPESFVLADM
P09287362A0589|96 110|catalytic region
P09287362A0589|113 120|PTP-PEST
P09287362A0589|113 115|PTP
P09288848A0780|12 13|Gy
P09288848A0780|15 25|HbO2 changes
P09288848A0780|15 18|HbO2
P09288916T0000|0 18|Polarised expression
P09288916T0000|21 82|human intestinal N-benzoyl-L-tyrosyl-p-aminobenzoic acid hydrolase
P09288916T0000|84 94|human meprin
P09288916T0000|96 100|alpha
P09288916T0000|104 115|beta subunits
P09288916T0000|118 145|Madin-Darby canine kidney cells
P09290207A0731|7 12|mutant
P09290207A0731|22 33|derepression
P09290207A0731|39 58|silent mating type loci
P09290571A0420|7 14|patients
P09290571A0420|19 39|inducible reentrant VTs
P09290571A0420|52 74|electrophysiologic study
P09290571A0420|76 78|EPS
P09290571A0420|83 85|VTs
P09290571A0420|91 98|patients
P09290571A0799|3 13|cycle length
P09290571A0799|23 24|VT
P09290571A0799|26 27|n =
P09290571A0799|30 32|VTs
P09290571A0799|45 48|msec
P09291077T0000|0 23|Transient hyperammonaemia
P09291077T0000|28 49|adult German shepherd dog
P09291098A0452|23 31|kb mRNA V-1
P09291098A0452|41 52|kb GGT mRNA V-2
P09291098A0452|62 78|alternate splicing
P09291098A0452|85 101|primary transcript
P09291098A0452|114 127|distal promoter
P09291098A0452|133 142|rat GGT gene
P09291098T0000|1 22|specific distal promoter
P09291098T0000|31 72|gamma-glutamyl transpeptidase gene expression
P09291098T0000|31 62|gamma-glutamyl transpeptidase gene
P09291098T0000|75 93|undifferentiated rat
P09291098T0000|105 114|liver cells
P09292499A0887|5 18|repressor sites
P09292499A0887|22 35|pyrimidine rich
P09292499A0887|54 86|polypyrimidine tract binding protein
P09292499A0887|88 90|PTB
P09292499A0887|94 112|HeLa nuclear extracts
P09292499A0887|127 158|UV crosslinking/competition assays
P09293006A1412|3 18|higher expression
P09293006A1412|21 24|lipA
P09293006A1412|27 36|S. lividans
P09293006A1412|63 81|strong aphII promoter
P09293006A1412|69 81|aphII promoter
P09294139A0729|7 30|135-bp core homology region
P09294139A0729|35 52|human HS12 enhancers
P09294139A0729|71 80|% identical
P09294139A0729|86 98|murine homolog
P09294139A0729|109 121|several motifs
P09294139A0729|173 186|murine enhancer
P09294139A0729|188 205|additional segments
P09294139A0729|208 231|high sequence conservation
P09294139A0729|265 292|unrecognized functional motifs
P09294161A0650|15 30|wild-type protein
P09294161A0650|44 51|p45 NF-E2
P09294161A0650|63 78|activation domain
P09294161A0650|83 99|NF-E2 null cell line
P09294161A0650|83 87|NF-E2
P09294161A0650|114 144|enhancer-dependent transcription
P09294161A0650|147 161|transient assays
P09294161A1103|5 12|findings
P09294161A1103|23 40|potential mechanism
P09294161A1103|44 60|direct recruitment
P09294161A1103|63 85|distal regulatory regions
P09294161A1103|91 100|globin loci
P09294161A1103|106 124|individual promoters
P09294262A0885|3 16|promoter region
P09294262A0885|25 40|consensus TATA box
P09294262A0885|54 58|CCAAT
P09294262A0885|62 70|CreA boxes
P09294262A0885|103 129|carbon-catabolite regulation
P09294262A0885|132 146|fungal promoters
P09294422A1223|6 28|cysteine residues located
P09294422A1223|35 50|additional region
P09294422A1223|81 95|disulfide bridge
P09294422A1223|113 129|activation process
P09294422A1223|135 151|catalytic activity
P09294422A1376|3 9|por gene
P09294422A1376|33 41|first time
P09294422A1376|87 145|isopropyl-beta-D-thiogalactopyranoside-inducible tac promoter
P09294422A1376|135 145|tac promoter
P09294422A1376|173 175|POR
P09294422A1376|181 190|active form
P09294452A2107|7 24|downstream operator
P09294452A2107|45 61|fourfold reduction
P09294452A2107|64 83|reporter enzyme levels
P09294453A0949|3 12|ORF3 mutant
P09294453A0949|28 33|levels
P09294453A0949|36 43|tabtoxin
P09294453A0949|59 62|ORF3
P09294453A0949|77 94|T beta L biosynthesis
P09294471A1198|7 15|Cox models
P09294471A1198|22 29|CD4 count
P09294471A1198|22 24|CD4
P09294471A1198|32 41|150/microL
P09294471A1198|52 61|200/microL
P09294471A1198|75 76|I0
P09294471A1198|80 81|I1
P09294471A1198|109 117|better fit
P09296251A0163|20 26|reports
P09296251A0163|37 47|small number
P09296251A0163|50 57|patients
P09296251A0163|61 71|limited data
P09297698A0933|5 15|transcripts
P09297698A0933|28 31|ends
P09297698A0933|34 50|mature UbCRBP mRNAs
P09297698A0933|40 50|UbCRBP mRNAs
P09297698A0933|65 70|UbCRBP
P09297698A0933|81 96|intergenic region
P09297698A0933|102 120|significant distance
P09297698A0933|130 140|enolase gene
P09299696A1074|17 30|cryptosporidia
P09299696A1074|36 44|intestine
P09299696A1074|56 69|cryptosporidia
P09299696A1074|73 83|ileal villus
P09299696A1074|86 97|different DPI
P09299696A1074|118 141|detailed characterization
P09299696A1074|158 161|kids
P09299696A1074|173 201|experimental cryptosporidiosis
P09300323A1182|13 54|subendocardial/subepicardial blood flow ratio
P09300323A1182|56 63|ENDO/EPI
P09300323A1182|95 109|control stenosis
P09300323A1182|128 130|ITF
P09300323A1182|138 158|micrograms/kg/min i.v.
P09300323A1182|181 183|NTG
P09300697A0000|0 10|Proteasomes
P09300697A0000|17 36|multisubunit protease
P09300697A0000|62 69|peptides
P09300697A0000|81 98|MHC class I molecules
P09300697A0000|81 88|MHC class
P09300697A0000|90 98|molecules
P09300698A1219|46 49|MQ9b
P09300698A1219|68 81|motif-positive
P09300698A1219|83 115|pathogen-derived synthetic peptides
P09301114A0573|0 8|Takahashi
P09301114A0573|10 11|H.
P09301350A0946|3 21|sputum interleukin-8
P09301350A0946|41 69|true treatment median difference
P09301350A0946|75 79|pg/ml
P09301350A0946|83 101|% confidence interval
P09301350A0946|103 104|CI
P09301350A0946|113 117|pg/ml
P09301350A0946|121 126|favour
P09301350A0946|129 135|placebo
P09301350A0946|145 165|maximal expiratory flow
P09301350A0946|170 170|%
P09301350A0946|177 177|%
P09301350A0946|188 206|forced vital capacity
P09301350A0946|242 257|percentage points
P09301350A0946|259 260|pp
P09301350A0946|265 267|% CI
P09301350A0946|273 274|pp
P09301350A0946|276 298|mean treatment difference
P09301350A0946|301 306|favour
P09301350A0946|309 315|placebo
P09303437A0875|16 23|deletion
P09303437A0875|26 28|Fp1
P09303437A0875|34 43|hCRBP1 gene
P09303437A0875|60 70|CAT activity
P09303437A0875|60 62|CAT
P09303437A0875|87 112|negative regulatory function
P09303437A0875|137 145|insertion
P09303437A0875|159 174|p12 basal promoter
P09303437A0875|186 214|impressive positive stimulation
P09303437A0875|217 233|CAT gene expression
P09303437A0875|217 223|CAT gene
P09303635A0000|0 6|Gaucher
P09303635A0000|19 39|rare metabolic disorder
P09303635A0000|64 92|beta-glucocerebrosidase enzyme
P09304123A0079|5 17|discoloration
P09304123A0079|34 44|several ways
P09304123A0079|58 71|tooth structure
P09304123A0079|90 107|irreversible manner
P09304123A0079|124 137|sufficient bulk
P09304123A0079|144 165|new restorative material
P09305592A0000|7 44|chromosomal translocation characteristic
P09305592A0000|47 49|CML
P09305592A0000|65 75|bcr/abl gene
P09305592A0000|65 67|bcr
P09305592A0000|81 101|abnormal fusion protein
P09305592A0000|103 113|p210bcr/abl
P09305592A0000|103 109|p210bcr
P09305592A0000|111 113|abl
P09305631A0770|0 13|Overexpression
P09305631A0770|16 20|BAG-1
P09305631A0770|34 49|certain cell lines
P09305631A0770|54 79|heat shock-induced cell death
P09305755A0540|5 18|flanking region
P09305755A0540|27 47|potential binding sites
P09305755A0540|51 69|TATA-binding protein
P09305755A0540|71 73|Sp1
P09305755A0540|75 88|nuclear factor 1
P09305755A0540|75 87|nuclear factor
P09305755A0540|90 92|NF1
P09305755A0540|95 116|CAAT-box binding protein
P09305755A0540|118 122|C/EBP
P09305755A0540|125 148|hepatocyte nuclear factors
P09305755A0540|155 158|HNF1
P09305755A0540|160 163|HNF5
P09305755A0540|168 184|activator proteins
P09305755A0540|191 193|AP1
P09305755A0540|195 197|AP2
P09305870A0894|3 24|recognition specificity
P09305870A0894|30 41|p55 PDZ domain
P09305870A0894|30 32|p55
P09305870A0894|33 41|PDZ domain
P09305870A0894|73 82|PDZ domains
P09305870A0894|85 88|hDlg
P09305870A0894|90 113|human lymphocyte homologue
P09305870A0894|129 153|discs large tumor suppressor
P09305870A0894|167 183|cytoplasmic domain
P09305870A0894|186 198|glycophorin C.
P09305870A0894|186 197|glycophorin C
P09305944A0621|14 27|RanGAP activity
P09305944A0621|14 19|RanGAP
P09305944A0621|61 82|rna1p mutant derivatives
P09305944A0621|103 116|acidic sequence
P09305944A0621|122 137|C-terminal domain
P09305944A0621|144 156|yeast proteins
P09305944A0621|159 171|indispensable
P09305944A0621|185 209|Ran-mediated GTP hydrolysis
P09305944A0621|185 187|Ran
P09307065A0553|14 23|MHC class II
P09307065A0553|14 21|MHC class
P09307065A0553|33 45|soluble D10 TCR
P09307065A0553|73 85|enterotoxin C2
P09307065A0553|92 106|association rate
P09307065A0553|126 126|M
P09307065A0553|131 133|sec
P09307065A0553|142 157|dissociation rate
P09307065A0553|177 179|sec
P09307065A0553|192 211|dissociation constant
P09307065A0553|217 222|microM
P09307312A0172|0 7|Evidence
P09307312A0172|11 24|such peak shifts
P09307312A0172|42 50|responses
P09307312A0172|53 71|auditory nerve fibers
P09307312A0172|73 92|cochlear microphonics
P09307312A0172|100 108|responses
P09307312A0172|111 124|outer hair cells
P09307312A0172|138 142|cells
P09307312A0172|148 154|cochlea
P09307312A0172|166 201|basilar membrane vibration measurements
P09307312A0172|219 236|psychophysical data
P09308234A0225|0 2|Mnt
P09308234A0225|4 15|Max complexes
P09308234A0225|4 6|Max
P09308234A0225|39 61|Myc-dependent activation
P09308234A0225|39 41|Myc
P09308234A0225|69 80|same promoter
P09308738A1216|5 26|United States high-MW HES
P09308738A1216|88 93|larger
P09308738A1216|100 101|MW
P09308738A1216|105 122|subsequent decrease
P09308738A1216|125 160|factor VIII/von Willebrand factor levels
P09308738A1216|125 134|factor VIII
P09308738A1216|136 154|von Willebrand factor
P09309457A0680|0 5|Assays
P09309457A0680|8 23|total cholesterol
P09309457A0680|35 37|HDL
P09309457A0680|39 42|HDL2
P09309457A0680|44 46|LDL
P09309457A0680|48 60|triglycerides
P09309457A0680|62 73|endothelin-1
P09309457A0680|75 85|lipoprotein
P09309457A0680|90 98|estradiol
P09309457A0680|102 104|FSH
P09309457A0680|123 130|baseline
P09309457A0680|146 148|ERT
P09309457A0680|158 163|months
P09309457A0680|166 168|ERT
P09310836A1019|3 15|tandem repeats
P09310836A1019|21 28|P element
P09310836A1019|40 51|SV40 promoter
P09310836A1019|63 91|phorbol 12-myristate 13-acetate
P09310836A1019|104 116|other elements
P09311164A0245|14 28|current density J
P09311164A0245|68 76|motor unit
P09311568A0595|3 20|cleavage dipeptides
P09311568A0595|23 38|C1YVV NIa protease
P09311568A0595|42 42|Q
P09311568A0595|44 44|E
P09311568A0595|47 47|S
P09311568A0595|49 49|A
P09311568A0595|51 51|G
P09311796A0218|5 19|previous studies
P09311796A0218|21 45|transcriptional activation
P09311796A0218|69 80|IEP86 binding
P09311796A0218|69 73|IEP86
P09311796A0218|90 111|TATA-box binding protein
P09311796A0218|113 115|TBP
P09311796A0218|123 141|transcription factor
P09311808A0341|31 40|p4 molecule
P09311810A0814|7 18|accumulation
P09311810A0814|21 35|cyclin D3 protein
P09311810A0814|38 46|Vero cells
P09311810A0814|61 80|alpha0 deletion mutant
P09311810A0814|107 111|cells
P09311810A0814|124 137|wild-type virus
P09311810A0814|141 156|recombinant virus
P09311810A0814|174 188|alpha0 sequences
P09311835A0147|11 48|preliminary biochemical characterization
P09311835A0147|54 62|T antigens
P09311835A0147|77 87|SV40 mutants
P09311835A0147|129 136|residues
P09311835A0147|152 167|ATP binding pocket
P09312025A0373|5 11|effects
P09312025A0373|27 39|co-expression
P09312025A0373|42 64|kinase-deficient PKC zeta
P09312025A0373|58 64|PKC zeta
P09312025A0373|68 77|inhibition
P09312025A0373|80 120|phosphatidylinositol 3-kinase p85alpha-p110
P09312025A0373|80 107|phosphatidylinositol 3-kinase
P09312025A0373|108 115|p85alpha
P09312025A0373|117 120|p110
P09312025A0373|123 132|wortmannin
P09312025A0373|134 141|LY294002
P09312025A0373|146 168|dominant-negative mutant
P09312025A0373|171 178|p85alpha
P09312025T0000|0 19|Protein phosphatase 2A
P09312025T0000|23 39|critical regulator
P09312025T0000|42 68|protein kinase C zeta signaling
P09312025T0000|42 59|protein kinase C zeta
P09312025T0000|79 88|SV40 small t
P09312025T0000|98 107|cell growth
P09312025T0000|111 129|NF-kappaB activation
P09312025T0000|111 119|NF-kappaB
P09312028A0975|17 49|RXRalphaF318A constitutive activity
P09312028A0975|17 29|RXRalphaF318A
P09312028A0975|65 76|heterodimers
P09312028A0975|92 97|BMS614
P09312028A0975|124 126|RXR
P09312028A0975|130 143|RAR AF-2 domains
P09312032A0165|5 11|introns
P09312032A0165|23 39|single snoRNA genes
P09312032A0165|66 86|exonucleolytic release
P09312032A0165|92 97|snoRNA
P09312032A0165|102 124|debranched intron lariats
P09312087A0000|0 12|Recent studies
P09312087A0000|29 41|Src homology-2
P09312087A0000|43 45|SH2
P09312087A0000|47 90|domain-containing protein-tyrosine phosphatase
P09312087A0000|92 96|SHP-2
P09312087A0000|115 131|cytoplasmic domain
P09312087A0000|134 140|PECAM-1
P09312087A0000|152 174|tyrosine-phosphorylated
P09312087A0000|181 199|platelet aggregation
P09312087A0000|234 262|small synthetic phosphopeptides
P09312087A0000|281 297|cytoplasmic domain
P09312087A0000|300 306|PECAM-1
P09312087A0000|319 341|tyrosine residues Tyr-663
P09312087A0000|344 350|Tyr-686
P09313755A0816|13 22|clustering
P09313755A0816|30 42|risk variables
P09313755A0816|52 58|factors
P09314306A0571|0 14|Supplementation
P09314306A0571|29 34|pl-ALB
P09314306A0571|45 48|g/dL
P09314487T0000|0 8|Detection
P09314487T0000|11 43|airborne Mycobacterium tuberculosis
P09314487T0000|46 58|air filtration
P09314487T0000|62 84|polymerase chain reaction
P09314537A1600|5 12|findings
P09314537A1600|21 25|EBP50
P09314537A1600|44 70|relevant ezrin binding protein
P09314537A1600|52 70|ezrin binding protein
P09314554A0149|25 46|scanthrough translation
P09314554A0149|66 68|AUG
P09314554A0149|72 94|primary open reading frame
P09314554A0149|147 161|cryptic epitopes
P09314554A0149|166 189|alternative reading frames
P09314554A0149|199 232|influenza A PR/8/34 nucleoprotein gene
P09314570A0153|12 19|proteins
P09314570A0153|25 37|GC-rich motifs
P09314570A0153|57 69|gene promoters
P09314570A0153|82 99|distinct activation
P09314570A0153|102 111|repression
P09314570A0153|114 138|transcriptional activities
P09315631A1064|0 7|Deletion
P09315631A1064|13 20|POR2 gene
P09315631A1064|31 49|detectable phenotype
P09315631A1064|56 61|yeasts
P09315631A1064|66 74|deletions
P09315631A1064|84 87|POR1
P09315631A1064|91 99|POR2 genes
P09315631A1064|104 109|viable
P09315631A1064|125 132|glycerol
P09315631A1064|137 144|degrees C
P09315631A1064|166 187|delta por1 single mutants
P09315632A1137|15 30|novel observation
P09315632A1137|63 79|FGFR3 kinase domain
P09315632A1137|112 122|fibroblasts
P09315632A1137|135 147|dysregulation
P09315632A1137|150 154|FGFR3
P09315632A1137|183 196|human neoplasia
P09315633A0333|10 26|amino acid sequence
P09315633A0333|39 57|significant homology
P09315633A0333|63 89|interferon regulatory factors
P09315633A0333|91 94|IRFs
P09315651T0000|0 10|Involvement
P09315651T0000|13 16|AP-2
P09315651T0000|34 43|R-FABP gene
P09315651T0000|59 69|chick retina
P09315678A0278|8 12|Cbf5p
P09315678A0278|25 33|nucleolar
P09315678A0278|45 54|homologous
P09315678A0278|60 83|rat nucleolar protein NAP57
P09315678A0278|114 120|Nopp140
P09315678A0278|155 184|nucleolar-cytoplasmic shuttling
P09315678A0278|186 187|U.
P09316937A0133|53 65|discrepancies
P09316937A0133|76 80|Vitek
P09316937A0133|84 110|API 20E identification systems
P09317131A0000|0 25|Ig heavy chain class switching
P09317131A0000|0 11|Ig heavy chain
P09317131A0000|38 46|cytokines
P09317131A0000|55 67|transcription
P09317131A0000|72 90|unrearranged CH genes
P09317131A1332|3 15|available data
P09317131A1332|30 58|NF kappa B2 nucleoprotein complex
P09317131A1332|75 88|DNA-bound STAT6
P09317131A1332|84 88|STAT6
P09317131A1332|98 121|IL-4-dependent activation
P09317131A1332|98 101|IL-4
P09317131A1332|127 146|human IgE germline gene
P09317757T0000|0 7|EXERCISE
P09317757T0000|13 63|TERRESTRIAL CHRISTMAS ISLAND RED CRAB GECARCOIDEA NATALIS
P09317757T0000|65 74|ENERGETICS
P09317757T0000|77 86|LOCOMOTION
P09317830T0000|12 24|SONG FREQUENCY
P09317830T0000|27 33|CICADAS
P09321406T0000|3 26|pheromone response pathway
P09321406T0000|36 48|transcription
P09321406T0000|51 76|Ty5 retrotransposons located
P09321406T0000|51 69|Ty5 retrotransposons
P09321406T0000|83 97|silent chromatin
P09321657A0439|27 35|mutations
P09321657A0439|43 63|corresponding elements
P09321657A0439|69 81|cox3 promoters
P09321657A0439|101 111|core element
P09321657A0439|126 145|cox3 promoter activity
P09321657A0439|126 137|cox3 promoter
P09321657A0439|147 170|upstream element mutations
P09321930A0567|11 38|multiple tumor suppressor genes
P09321930A0567|19 38|tumor suppressor genes
P09321930A0567|45 47|p53
P09321930A0567|49 51|DCC
P09321930A0567|53 55|APC
P09321930A0567|57 59|MCC
P09321930A0567|61 65|BRCA1
P09321930A0567|70 78|WAF1/CIP1
P09321930A0567|70 73|WAF1
P09321930A0567|75 78|CIP1
P09321930A0567|97 116|different frequencies
P09321930A0567|120 136|various mechanisms
P09321930A0567|149 162|heterozygosity
P09321930A0567|164 166|LOH
P09321930A0567|186 188|LOE
P09321930A0567|191 198|mutation
P09321930A0567|203 214|inactivation
P09321930A0567|217 238|cellular binding protein
P09322738A0510|3 22|histidine-tagged gene
P09322738A0510|24 30|rpoCHIS
P09322738A0510|51 65|wild-type allele
P09322738A0510|71 80|chromosome
P09322738A0510|83 94|S. coelicolor
P09322738A0510|98 107|S. lividans
P09322872A0745|10 17|deletion
P09322872A0745|29 34|TK gene
P09322872A0745|49 59|gancyclovir
P09322872A0745|67 71|cells
P09322872A0745|90 102|recombination
P09323366A0000|3 20|malate synthase gene
P09323366A0000|22 25|MLS1
P09323366A0000|32 36|yeast
P09323366A0000|93 104|carbon source
P09323366A0000|110 121|growth medium
P09323366A0299|2 17|deletion analysis
P09323366A0299|23 39|MLS1 control region
P09323366A0299|23 26|MLS1
P09323366A0299|56 60|sites
P09323366A0299|62 65|UAS1
P09323366A0299|69 72|UAS2
P09323366A0299|88 108|efficient derepression
P09323612A0374|0 3|Lack
P09323612A0374|6 33|controlled prospective studies
P09323612A0374|36 61|sleep electroencephalograms
P09323612A0374|63 65|EEG
P09323612A0374|92 99|children
P09323612A0374|104 125|developmental dysphasia
P09323612A0374|134 163|appropriate treatment strategies
P09323612A0374|166 173|children
P09323612A0374|178 202|severe developmental speech
P09323612A0374|206 222|language disorders
P09324720A0317|7 11|meals
P09324720A0317|16 20|times
P09324720A0317|30 40|tablespoons
P09324720A0317|43 48|Alzoon
P09324878A0952|13 31|abdominal aortic wall
P09324878A0952|36 56|ultrasound examination
P09324878A0952|71 89|incidental diagnosis
P09324878A0952|103 128|unsuspected type B dissection
P09324922T0065|0 18|Fermentation process
P09324922T0065|24 38|supplementation
P09324922T0065|41 47|nitrate
P09324922T0065|49 55|nitrite
P09324922T0065|57 74|lactic acid bacteria
P09324922T0065|78 87|formic acid
P09324988X0000|0 9|Substrates
P09324988X0000|20 22|p21
P09324988X0000|24 26|ras
P09324988X0000|28 35|proteins
P09324988X0000|37 49|nuclear lamins
P09324988X0000|63 77|retinal proteins
P09325022A0192|0 6|Ovaries
P09325022A0192|11 17|animals
P09325022A0192|32 38|studies
P09325022A0192|41 48|CD-1 mice
P09325022A0192|64 66|C3H
P09325022A0192|70 80|C57BL/6 mice
P09325022A0192|105 110|microm
P09325135A0737|3 21|Trx-CT fusion protein
P09325135A0737|3 5|Trx
P09325135A0737|51 51|%
P09325135A0737|54 80|total soluble cellular protein
P09325273A1240|5 11|results
P09325273A1240|23 27|UBP41
P09325273A1240|37 49|important role
P09325273A1240|55 63|recycling
P09325273A1240|66 74|ubiquitin
P09325273A1240|77 86|hydrolysis
P09325273A1240|97 116|poly-ubiquitin chains
P09325273A1240|141 151|S proteasome
P09325273A1240|154 188|poly-ubiquitinated protein substrates
P09325273A1240|215 227|free ubiquitin
P09325273A1240|232 257|linear poly-ubiquitin chains
P09325273A1240|263 286|certain ribosomal proteins
P09325273A1240|291 313|ubiquitin fusion proteins
P09325278A0458|1 22|data base homology search
P09325278A0458|47 66|ER1 amino acid sequence
P09325278A0458|80 86|regions
P09325278A0458|110 122|human proteins
P09325278A0458|135 159|metastasis-associated gene
P09325278A0458|161 164|mta1
P09325278A0458|172 178|regions
P09325278A0458|196 224|Caenorhabditis elegans sequence
P09325278A0458|240 243|mta1
P09325284A0469|12 15|cDNA
P09325284A0469|25 44|704-amino acid protein
P09325284A0469|47 56|% identical
P09325284A0469|59 78|human progelatinase B.
P09325284A0469|59 77|human progelatinase B
P09325322A1293|3 12|inhibition
P09325322A1293|15 26|cytosolic Ca2
P09325322A1293|50 62|cooperativity
P09325322A1293|76 79|EC50
P09325322A1293|86 110|higher InsP3 concentrations
P09326163A0942|0 6|RESULTS
P09326163A0942|11 36|standardised mortality ratio
P09326163A0942|38 40|SMR
P09326163A0942|48 65|malignant neoplasms
P09326163A0942|74 76|% CI
P09326246A0567|0 15|Sequence analysis
P09326246A0567|41 66|eight-bp repetitive elements
P09326246A0567|71 78|deletion
P09326246A0567|94 108|wild-type levels
P09326246A0567|111 128|luciferase activity
P09326246A0567|111 120|luciferase
P09326246A0567|139 155|bp reporter plasmid
P09326263A0410|7 10|RACE
P09326263A0410|21 37|transcription-PCR
P09326263A0410|39 44|RT-PCR
P09326263A0410|46 58|methodologies
P09326263A0410|73 81|sequences
P09326263A0410|94 101|placenta
P09326263A0410|156 160|exons
P09326263A0410|185 197|noncoding exon
P09326263A0410|199 200|1A
P09326263A0410|206 228|novel 97-bp noncoding exon
P09326263A0410|230 231|1B
P09326317A0372|9 18|first study
P09326317A0372|26 42|mutation screening
P09326317A0372|69 72|EXT1
P09326317A0372|76 84|EXT2 genes
P09326317A0372|95 109|linkage analysis
P09326727T0000|3 15|regurgitation
P09326727T0000|18 40|large vitreous injections
P09327881T0000|0 37|Positron emission tomography radioligands
P09327881T0000|41 60|dopamine transporters
P09327881T0000|64 70|studies
P09327881T0000|81 96|nonhuman primates
P09328341A1449|0 10|Attenuation
P09328341A1449|18 34|vit A2 consensus ERE
P09328341A1449|62 71|DNA binding
P09328341A1449|77 99|TR alpha DNA binding mutant
P09328341A1449|121 146|E-dependent transactivation
P09328343A0181|0 9|Expression
P09328343A0181|39 63|heteromeric protein complex
P09328343A0181|74 83|ubiquitous
P09328343A0181|92 94|E2A
P09328343A0181|99 117|HEB-encoded proteins
P09328343A0181|122 142|islet-enriched members
P09328343A0181|148 157|bHLH family
P09328349A1679|8 15|CCAAT box
P09328349A1679|23 52|tissue-specific characteristics
P09328349A1679|89 105|alpha-subunit gene
P09328349A1679|108 119|trophoblasts
P09328476A0068|0 9|U4/U6 snRNP
P09328476A0068|0 1|U4
P09328476A0068|3 9|U6 snRNP
P09328476A0068|21 58|essential small nuclear ribonucleoprotein
P09328476A0068|60 64|snRNP
P09328476A0068|66 74|particles
P09328476A0068|76 77|U1
P09328476A0068|79 80|U2
P09328476A0068|82 83|U5
P09328476A0068|87 91|U4/U6
P09328476A0068|87 88|U4
P09328476A0068|90 91|U6
P09328476A0068|105 115|spliceosome
P09328476A0374|0 5|Hprp3p
P09328476A0374|11 20|kDa protein
P09328476A0374|29 38|homologous
P09328476A0374|44 85|Saccharomyces cerevisiae splicing factor Prp3p
P09328476A0374|67 85|splicing factor Prp3p
P09328824A0000|3 28|growth-promoting properties
P09328824A0000|34 57|retroviral v-erbA oncogene
P09328824A0000|85 113|chicken thyroid hormone receptor
P09328824A0000|115 116|TR
P09328824A0000|118 122|alpha
P09328824A0000|156 173|dominant repression
P09328824A0000|179 196|antimitogenic roles
P09328824A0000|199 200|TR
P09328824A0000|204 224|retinoic acid receptors
P09328833A0588|9 20|complete cDNA
P09328833A0588|25 26|kb
P09328833A0588|31 33|HET
P09328833A0588|40 55|MCF-7 cDNA library
P09331119A0659|7 17|common grade
P09331119A0659|19 26|toxicity
P09331119A0659|30 40|neutropenia
P09331119A0659|42 57|thrombocytopenia
P09331119A0659|62 73|parasthesias
P09331119A0659|88 88|%
P09331119A0659|91 96|cycles
P09331864A0230|0 18|Serum concentrations
P09331864A0230|21 22|E2
P09331864A0230|26 29|TBOH
P09331864A0230|44 44|d
P09331864A0230|94 100|heifers
P09331864A0230|125 134|treatments
P09331864A0230|148 150|MGA
P09331864A0230|154 155|mg
P09331864A0230|159 164|heifer
P09331864A0230|173 181|Revalor-H
P09331864A0230|186 190|mg TBA
P09331864A0230|194 197|mg E2
P09331864A0230|202 210|Revalor-H
P09331864A0230|212 214|MGA
P09331864A0230|218 227|Finaplix-H
P09331864A0230|232 236|mg TBA
P09331864A0230|244 253|Finaplix-H
P09331864A0230|255 257|MGA
P09331864A0848|0 20|Serum E2 concentrations
P09331864A0848|60 60|d
P09331864A0848|70 77|controls
P09331864A0848|81 83|MGA
P09331864A0848|97 104|controls
P09331864A0848|111 113|MGA
P09333018A0000|0 25|Interferon Regulatory Factor
P09333018A0000|27 32|IRF)-1
P09333018A0000|27 29|IRF
P09333018A0000|57 81|important growth regulatory
P09333018A0000|85 119|immunomodulatory transcription factor
P09333026A0397|3 18|genomic structure
P09333026A0397|21 23|brk
P09333026A0397|35 39|exons
P09333026A0397|46 55|boundaries
P09333026A0397|71 103|other non-receptor PTK family members
P09333026A0397|76 87|non-receptor
P09333026A0397|134 153|functional divergence
P09333026A0851|41 46|tumour
P09333026A0851|54 60|brk cDNA
P09333026A0851|63 87|mouse embryonic fibroblasts
P09333026A0851|91 117|human mammary epithelial cells
P09333026A0851|126 151|anchorage independent growth
P09333026A0851|181 197|mitogenic response
P09333026A0851|200 220|epidermal growth factor
P09333168A0310|0 19|Anti-hepatitis A virus
P09333168A0310|21 23|HAV
P09333168A0310|25 29|titer
P09333168A0310|35 45|vaccination
P09333168A0310|61 72|HIV-positive
P09333168A0310|78 92|HIV-negative men
P09334264A0540|13 26|calf thymus CstF
P09334264A0540|49 57|novel form
P09334264A0540|63 75|64-kDa subunit
P09334264A0540|81 93|molecular mass
P09334264A0540|98 100|kDa
P09334330A0252|0 12|Null mutations
P09334330A0252|15 19|daf-3
P09334330A0252|28 36|mutations
P09334330A0252|39 43|genes
P09334330A0252|56 69|TGF-beta signal
P09334330A0252|56 63|TGF-beta
P09334330A0252|74 82|receptors
P09334330A0252|97 126|Smad signal transduction proteins
P09334330A0252|128 132|daf-3
P09334330A0252|141 151|Smad protein
P09334330A0252|178 190|mammalian DPC4
P09334330A0252|238 244|tissues
P09334330A0252|267 282|dauer development
P09334331A0910|3 9|results
P09334331A0910|36 56|Drosophila EGF receptor
P09334331A0910|46 64|EGF receptor DER/Egfr
P09334331A0910|57 59|DER
P09334331A0910|61 64|Egfr
P09334331A0910|79 86|EMA cells
P09334331A0910|99 106|receptor
P09334331A0910|110 113|Vein
P09334475A0327|0 7|PATIENTS
P09334475A0327|11 17|METHODS
P09334475A0327|24 42|consecutive patients
P09334475A0327|50 72|Chilean National Registry
P09334475A0327|75 99|Acute Myocardial Infarction
P09334475A0327|125 133|chest pain
P09334475A0327|137 154|ST segment elevation
P09334475A0327|161 161|%
P09334475A0327|178 180|min
P09334475A0327|182 193|abrupt CK rise
P09334475A0327|201 201|h
P09334475A0327|205 218|T wave inversion
P09334475A0327|221 237|infarct related EKG
P09334475A0327|259 259|h
P09334475A0327|265 276|thrombolysis
P09335267A0142|12 26|operon structure
P09335267A0142|42 63|traditional methods such
P09335267A0142|66 87|insertional mutagenesis
P09335267A0142|111 122|polar effects
P09335267A0142|125 139|downstream genes
P09335267A0142|150 167|secondary mutations
P09335267A0142|182 187|genome
P09335298A0529|24 35|parCBA operon
P09335298A0529|44 68|plasmid partitioning system
P09335298A0529|70 71|M.
P09335298A1227|15 23|insertion
P09335298A1227|29 40|ColE1 cer site
P09335298A1227|48 57|RK2 plasmid
P09335298A1227|71 79|par region
P09335298A1227|100 106|plasmid
P09335298A1227|112 124|MC1061K strain
P09335298A1227|143 168|multimer resolution activity
P09335298A1227|178 183|parCBA
P09335298A1227|214 234|stabilization activity
P09335298A1227|250 255|operon
P09335298A2129|23 41|apparent differences
P09335298A2129|44 67|postsegregational killing
P09335298A2129|87 93|strains
P09335298A2129|95 114|transformation assays
P09335298A2129|143 163|relative sensitivities
P09335298A2129|169 175|strains
P09335298A2129|181 196|ParE toxin protein
P09335608T0000|0 22|Splice-junction elements
P09335608T0000|26 42|intronic sequences
P09335608T0000|51 69|alternative splicing
P09335608T0000|85 114|myosin heavy chain gene transcript
P09335619A0583|0 25|Nucleotide sequence analysis
P09335619A0583|28 28|R
P09335619A0583|40 51|similarities
P09335619A0583|57 65|R1 plasmid
P09335619A0583|77 99|South American maize races
P09335619A0583|104 114|RU cytoplasm
P09335619A0583|121 129|M1 plasmid
P09335619A0583|148 150|Zea
P09335619A0583|160 167|teosinte
P09335619A0583|174 194|atp9 mitochondrial gene
P09335619A0583|203 218|flanking sequence
P09335619A0583|243 252|orf221 gene
P09336455A0000|17 24|kinetics
P09336455A0000|40 52|mRNA synthesis
P09336455A0000|58 71|inducible GAL10
P09336455A0000|67 71|GAL10
P09336455A0000|75 83|RNR3 genes
P09336455A0000|99 108|yeast cells
P09336455A0000|111 121|ultraviolet
P09336455A0000|123 124|UV
P09337861T0000|0 6|Cloning
P09337861T0000|10 38|human phosphoinositide 3-kinase
P09337861T0000|44 51|C2 domain
P09337861T0000|87 105|inhibitor wortmannin
P09338414A0430|0 6|Ea value
P09338414A0430|35 72|steady-state end-systolic aortic pressure
P09338414A0430|74 77|ESAP
P09338414A0430|81 92|stroke volume
P09338414A0430|94 107|thermodilution
P09339900A0939|0 17|Functional analysis
P09339900A0939|20 35|promoter activity
P09339900A0939|44 57|flanking region
P09339900A0939|60 67|cyclin D2
P09339900A0939|111 115|C/EBP
P09339900A0939|117 120|PEA3
P09339900A0939|122 124|AP2
P09339900A0939|126 129|NF-Y
P09339900A0939|131 135|c-Myc
P09339900A0939|140 142|Sp1
P09339900A0939|151 181|major positive regulatory activity
P09339900A0939|197 204|cyclin D2
P09340641T0001|0 5|Effect
P09340641T0001|17 45|minimal effective nCPAP pressure
P09341139A0690|11 25|resensitization
P09341139A0690|29 63|sequestration-impaired beta2AR mutant
P09341139A0690|51 57|beta2AR
P09341139A0690|65 69|Y326A
P09341139A0690|99 112|overexpression
P09341139A0690|121 124|GRK2
P09341139A0690|127 140|beta-arrestin 1
P09341139A0690|127 139|beta-arrestin
P09341158A0167|3 14|medium chains
P09341158A0167|22 30|complexes
P09341158A0167|32 34|mu1
P09341158A0167|38 40|mu2
P09341158A0167|65 69|types
P09341158A0167|99 103|beta1
P09341158A0167|107 117|beta2 chains
P09341158A0167|123 144|corresponding complexes
P09341158A0167|161 188|tyrosine-based sorting signals
P09341182A0605|61 73|BTB/POZ domain
P09341182A0605|61 63|BTB
P09341182A0605|65 73|POZ domain
P09341182A0605|78 81|PLZF
P09341182A0605|83 94|PLZF-BTB/POZ
P09341182A0605|83 86|PLZF
P09341182A0605|88 90|BTB
P09341192T0000|0 11|Osmotic shock
P09341192T0000|22 39|GLUT4 translocation
P09341192T0000|22 26|GLUT4
P09341192T0000|42 56|3T3L1 adipocytes
P09341192T0000|60 85|novel tyrosine kinase pathway
P09341192T0000|65 78|tyrosine kinase
P09341193A0362|16 18|Sp1
P09341193A0362|20 22|Sp3
P09341193A0362|27 36|NGFI-A/Egr
P09341193A0362|27 32|NGFI-A
P09341193A0362|34 38|Egr-1
P09341193A0362|44 77|primary nuclear transcription factors
P09341193A0362|87 90|TRE1
P09341193A0362|103 119|Tax responsiveness
P09341193A0362|103 105|Tax
P09343208A1405|14 27|segment nesting
P09343208A1405|54 63|copy number
P09343208A1405|66 70|genes
P09343208A1405|80 87|segment W
P09343208A1405|106 131|unusual genomic organization
P09343208A1405|134 137|PDVs
P09343208A1405|162 176|unique functions
P09343208A1405|193 222|obligate mutualistic association
P09343208A1405|227 240|parasitic wasps
P09343210A1112|12 19|deletion
P09343210A1112|23 38|mutation analyses
P09343210A1112|44 57|VCAM-1 promoter
P09343210A1112|44 49|VCAM-1
P09343210A1112|71 112|chloramphenicol acetyltransferase constructs
P09343210A1112|125 127|Tax
P09343210A1112|131 135|trans
P09343210A1112|149 162|VCAM-1 promoter
P09343210A1112|169 189|NF-kappaB sites present
P09343210A1112|169 182|NF-kappaB sites
P09343210A1112|192 193|bp
P09343210A1112|208 225|VCAM-1 gene promoter
P09343210A1112|260 280|Tax-induced expression
P09343210A1112|260 262|Tax
P09343210A1112|287 302|adhesion molecule
P09343222A0415|3 5|AGM
P09343222A0415|9 34|NIH/Swiss mouse CCR5 proteins
P09343222A0415|23 34|CCR5 proteins
P09343222A0415|48 48|%
P09343222A0415|56 65|% identical
P09343222A0415|71 82|human protein
P09343398A1193|0 11|Processivity
P09343398A1193|14 25|DNA synthesis
P09343398A1193|31 46|mutant holoenzyme
P09343398A1193|57 63|pcna-79
P09343398A1193|67 76|unaffected
P09343398A1193|79 82|poly
P09343398A1193|84 85|dA
P09343398A1193|88 92|oligo
P09343398A1193|94 95|dT
P09343398A1193|125 139|natural template
P09343398A1193|144 161|secondary structure
P09343426A0456|0 27|Alanine substitution mutations
P09343426A0456|33 51|Zta activation domain
P09343426A0456|78 80|Zta
P09343426A0456|95 104|D-A complex
P09343432A0209|3 5|Scm
P09343432A0209|9 18|ph proteins
P09343432A0209|25 38|homology domain
P09343432A0209|45 53|% identity
P09343432A0209|69 78|amino acids
P09343432A0209|89 97|SPM domain
P09343432A0209|105 111|located
P09343432A0209|119 136|respective C termini
P09343433A0000|28 32|genes
P09343433A0000|46 60|RNA polymerase II
P09343433A0000|46 58|RNA polymerase
P09343433A0000|62 65|RNAP
P09343433A0000|89 105|effect variegation
P09343433A0000|121 134|yeast telomeres
P09343433A0360|9 18|rad6-delta
P09343433A0360|26 34|silencing
P09343433A0360|40 82|telomere-located RNAP II-transcribed genes URA3
P09343433A0360|86 89|ADE2
P09343982A0890|3 11|amplitude
P09343982A0890|14 33|detrusor contractions
P09343982A0890|46 50|hours
P09343982A0890|59 79|significant difference
P09343982A0890|93 100|controls
P09344650A0967|14 32|transmembrane domain
P09344650A0967|34 41|Casr-rs2
P09344650A0967|45 52|Casr-rs3
P09344650A0967|58 67|% identical
P09344650A0967|70 77|Casr-rs1
P09345037A0886|9 13|roles
P09345037A0886|41 65|nuclear trans-factor GATA-1
P09345037A0886|78 104|progenitor cell proliferation
P09345495A0000|0 19|PET activation studies
P09345495A0000|45 62|human brain function
P09346238T0000|0 12|F-box proteins
P09346238T0000|16 24|receptors
P09346238T0000|50 59|substrates
P09346238T0000|65 90|SCF ubiquitin-ligase complex
P09346238T0000|65 83|SCF ubiquitin-ligase
P09346621A1181|14 35|liver allograft shortage
P09346621A1181|40 46|results
P09346621A1181|60 62|ELT
P09346621A1181|85 92|patients
P09346621A1181|97 110|cardiac failure
P09346621A1181|123 125|OSF
P09346621A1181|131 138|APACHE II
P09346621A1181|144 149|higher
P09346925A0660|3 12|SH3 domains
P09346925A0660|15 18|Grb2
P09346925A0660|33 58|specific proline-rich motifs
P09346925A0660|64 71|HPK1 tail
P09346925A0660|64 67|HPK1
P09346925A0660|111 123|stable binding
P09346925A0660|126 129|Grb2
P09346925A0660|132 135|HPK1
P09346925A0660|149 157|Cos1 cells
P09346935A0459|2 20|far-Western analysis
P09346935A0459|24 51|coimmunoprecipitation studies
P09346935A0459|70 74|ZNF74
P09346935A0459|91 106|zinc finger domain
P09346935A0459|134 147|largest subunit
P09346935A0459|150 164|RNA polymerase II
P09346935A0459|150 162|RNA polymerase
P09346935A0459|166 171|pol IIo
P09346935A0927|5 24|ZNF74 sublocalization
P09346935A0927|5 9|ZNF74
P09346935A0927|27 40|nuclear domains
P09346935A0927|51 75|pre-mRNA maturating factors
P09346935A0927|80 97|RNA binding activity
P09346935A0927|105 137|direct phosphodependent interaction
P09346935A0927|145 150|pol IIo
P09346935A0927|162 174|RNA polymerase
P09346935A0927|201 203|pre
P09346935A0927|205 218|mRNA processing
P09346935A0927|250 277|KRAB multifinger protein family
P09346935A0927|280 292|RNA processing
P09346938A1680|0 30|Ki-ras4BVal-12 transfectant cells
P09346938A1680|0 13|Ki-ras4BVal-12
P09346938A1680|40 66|2-fold elevated protein levels
P09346938A1680|72 106|lysosomal cysteine protease cathepsin B
P09346938A1680|127 150|cathepsin B mRNA expression
P09346938A1680|127 140|cathepsin B mRNA
P09346953A0000|3 14|cellular rate
P09346953A0000|17 55|anticoagulant heparan sulfate proteoglycan
P09346953A0000|57 63|HSPGact
P09346953A0000|119 136|microsomal activity
P09346953A0000|138 160|HSact conversion activity
P09346953A0000|205 252|heparan sulfate D-glucosaminyl 3-O-sulfotransferase
P09346953A0000|254 258|3-OST
P09346953A0000|261 267|Shworak
P09346953A0000|269 270|N.
P09348226A0852|14 16|EGF
P09348226A0852|24 30|insulin
P09348226A0852|42 64|tyrosine phosphorylation
P09348226A0852|67 71|c-cbl
P09348226A0852|93 98|Crk-II
P09348931T0000|10 16|lottery
P09349501A0196|25 47|N-terminal portion common
P09349501A0196|50 75|various chimeric MLL products
P09349501A0196|87 94|MLL-LTG9
P09349501A0196|98 106|MLL-LTG19
P09349501A0196|122 127|nuclei
P09349501A0196|167 179|important role
P09349501A0196|182 195|leukemogenesis
P09349967A0653|3 9|results
P09349967A0653|33 43|blood supply
P09349967A0653|59 80|structural organisation
P09349967A0653|83 100|mature lamellar bone
P09351242A0719|0 8|Induction
P09351242A0719|11 33|AtP5CS1 mRNA accumulation
P09351242A0719|11 21|AtP5CS1 mRNA
P09351242A0719|36 56|salt-treated seedlings
P09351242A0719|67 103|immediate early transcriptional response
P09351242A0719|115 127|ABA signalling
P09351242A0719|148 160|cycloheximide
P09351242A0719|179 188|deficiency
P09351242A0719|191 205|ABA biosynthesis
P09351242A0719|211 231|aba1 Arabidopsis mutant
P09351823A0414|17 29|MAPK functions
P09351823A0414|17 20|MAPK
P09351823A0414|32 48|meiotic maturation
P09351823A0414|61 76|unfertilized eggs
P09351823A0414|95 120|parthenogenetic development
P09352016A1110|6 17|AF G-CSF level
P09352016A1110|6 12|AF G-CSF
P09352016A1110|23 24|pg
P09352016A1110|26 27|ml
P09352016A1110|31 53|strong positive predictor
P09352016A1110|56 58|CAM
P09352127A0953|1 19|positive correlation
P09352127A0953|27 40|serum myoglobin
P09352127A0953|44 62|CA III concentrations
P09352127A0953|44 48|CA III
P09352127A0953|64 66|rs =
P09352127A0953|73 73|P
P09352127A0953|94 113|hemodialyzed patients
P09352127A0953|118 136|chronic renal failure
P09353247A0922|15 39|over-replication phenotype
P09353247A0922|54 67|mutant p65cdc18
P09353247A0922|70 78|resistant
P09353247A0922|90 114|mitotic cyclin/CDK activity
P09353247A0922|117 130|known inhibitor
P09353247A0922|133 148|over-replication
P09353255A0159|0 4|Rip1p
P09353255A0159|7 17|inessential
P09353255A0159|33 52|nuclear pore complexes
P09353255A0159|81 100|FG-nucleoporin family
P09353255A0159|103 114|pore proteins
P09353296A0510|3 12|CNXA domain
P09353296A0510|27 40|amino acid level
P09353296A0510|46 75|Escherichia coli moaA gene product
P09353296A0510|61 75|moaA gene product
P09353296A0510|82 85|CNXC
P09353296A0510|100 116|E. coli moaC product
P09353296A0510|106 116|moaC product
P09353296A0510|126 139|E. coli products
P09353296A0510|132 139|products
P09353296A0510|149 165|different cistrons
P09353304A0732|0 8|Deletions
P09353304A0732|22 28|regions
P09353304A0732|36 55|membrane localization
P09353304A0732|58 62|Tiam1
P09353304A0732|66 81|membrane ruffling
P09353328A0736|18 38|kinase catalytic domain
P09353328A0736|42 72|double leucine/isoleucine zippers
P09353328A0736|84 102|significant homology
P09353328A0736|107 119|known proteins
P09353343A0919|0 14|RNA polymerase II
P09353343A0919|0 12|RNA polymerase
P09353343A0919|15 24|inhibition
P09353343A0919|37 43|binding
P09353343A0919|50 61|AUBP activity
P09353343A0919|66 69|poly
P09353343A0919|71 71|U
P09353343A0919|74 82|Sepharose
P09353343A0919|85 102|cytoplasmic hnRNP A1
P09353343A0919|109 129|nuclear hnRNP A1 binding
P09353343A0919|109 122|nuclear hnRNP A1
P09353343A0919|133 142|unaffected
P09353343T0000|0 9|Modulation
P09353343T0000|12 38|AUUUA response element binding
P09353343T0000|41 79|heterogeneous nuclear ribonucleoprotein A1
P09353343T0000|82 98|human T lymphocytes
P09354349A0338|0 17|Histological slides
P09354349A0338|23 28|biopsy
P09354349A0338|43 56|formalin-fixed
P09354349A0338|60 76|paraffin-embedded
P09354349A0338|102 107|Giemsa
P09354349A0338|109 110|MG
P09354349A0338|116 129|Warthin-Starry
P09354349A0338|131 132|WS
P09354349A0338|140 164|immunohistochemical method
P09354349A0338|166 168|IMM
P09354349A0338|183 209|polyclonal H. pylori antiserum
P09354349A0338|211 218|DAKO B471
P09354644A0124|5 16|biosynthesis
P09354644A0124|28 43|linear precursors
P09354644A0124|64 89|beta1,6-GlcNAc transferases
P09354644A0124|91 95|IGnT6
P09354644A0124|97 102|GlcNAc
P09354644A0124|105 107|Gal
P09354676A1714|5 12|findings
P09354676A1714|28 28|t
P09354676A1714|36 40|p16.3
P09354676A1714|42 44|q32
P09354676A1714|63 95|recurrent chromosomal translocation
P09354676A1714|98 99|MM
P09354676A1714|118 126|FGFR3 gene
P09354676A1714|147 157|abnormality
P09354676A1714|177 189|tumorigenesis
P09354676A1714|192 193|MM
P09354684A1158|11 18|mutation
P09354684A1158|24 30|Sp1 site
P09354684A1158|55 70|promoter activity
P09354757A1444|0 16|Amino acid residues
P09354757A1444|19 22|beta
P09354757A1444|26 31|alpha A
P09354757A1444|34 39|alpha B
P09354757A1444|62 67|His539
P09354757A1444|73 84|RNase H domain
P09354757A1444|100 111|primer strand
P09354757A1444|117 121|dsDNA
P09356645A0672|26 32|sarcoma
P09356645A0672|46 65|leg-sparing procedure
P09356645A0672|69 91|sciatic nerve enlargement
P09358045A0000|3 24|full length cDNA sequence
P09358045A0000|28 31|Type
P09358045A0000|33 61|transforming growth factor-beta
P09358045A0000|45 61|growth factor-beta
P09358045A0000|63 79|TGF-beta) receptor
P09358045A0000|63 70|TGF-beta
P09358045A0000|72 79|receptor
P09358045A0000|102 139|filarial parasitic nematode Brugia pahangi
P09358055A0590|21 28|homology
P09358055A0590|34 69|methylation-sensitive promoter element
P09358055A0590|71 74|Enh2
P09358055A0590|88 90|LTR
P09358055A0590|93 123|mouse intractisternal A-particles
P09358069T0000|0 16|Codon optimization
P09358069T0000|20 39|high-level expression
P09358069T0000|42 60|human erythropoietin
P09358069T0000|62 64|EPO
P09358069T0000|68 81|mammalian cells
P09358837T0000|0 14|Parodoxical rise
P09358837T0000|17 36|urinary albumin levels
P09358837T0000|53 73|essential hypertension
P09359844A0674|2 2|%
P09359844A0674|5 23|total HSL transcripts
P09359844A0674|10 23|HSL transcripts
P09359844A0674|26 52|human subcutaneous adipocytes
P09359887A1168|32 44|Rat7p/Nup159p
P09359887A1168|32 36|Rat7p
P09359887A1168|38 44|Nup159p
P09359887A1168|64 66|NPC
P09359887A1168|77 93|coiled-coil region
P09359887A1168|97 113|adjacent sequences
P09360422A0135|12 19|patients
P09360422A0135|24 49|obliterative arteriopathies
P09360422A0135|55 64|lower limbs
P09360422A0135|68 79|plasma levels
P09360422A0135|82 95|thrombomodulin
P09360422A0135|97 98|TM
P09360422A0135|101 119|betathromboglobulin
P09360422A0135|121 127|beta-TG
P09360422A0135|130 136|D-dimer
P09360422A0135|138 139|DD
P09360422A0135|144 173|plasminogen activator-inhibitor
P09360422A0135|175 179|pAI-1
P09360422A0135|210 215|values
P09360422A0135|230 246|healthy volunteers
P09360953A1057|5 12|residues
P09360953A1057|14 19|Ile244
P09360953A1057|25 40|extracellular end
P09360953A1057|43 60|transmembrane helix
P09360953A1057|66 71|Tyr318
P09360953A1057|77 96|COOH-terminal portion
P09360953A1057|99 116|extracellular loop 2
P09360953A1057|99 115|extracellular loop
P09360953A1057|131 133|Leu
P09360953A1057|137 139|Ile
P09360953A1057|145 157|PTH-1 receptor
P09360956A0840|24 38|phosphorylation
P09360956A0840|41 50|14-3-3 zeta
P09360956A0840|47 50|zeta
P09360956A0840|56 67|CKIalpha site
P09360956A0840|69 75|Thr-233
P09360956A0840|99 105|binding
P09360956A0840|108 112|c-Raf
P09360956A0840|133 162|Raf-mediated signal transduction
P09360956A0840|133 135|Raf
P09360993T0000|0 21|Mouse mast cell protease 9
P09360993T0000|0 20|Mouse mast cell protease
P09360993T0000|24 34|novel member
P09360993T0000|40 49|chromosome
P09360993T0000|60 74|serine proteases
P09360993T0000|103 118|uterine mast cells
P09361007A0922|1 25|DNase I-hypersensitive site
P09361007A0922|48 73|258-base pair enhancer region
P09362105X0422|1 27|Pulmonary vascular resistance
P09362105X0422|29 31|PVR
P09362105X0422|41 47|% O2-PVR
P09362105X0422|56 62|% O2/PVR
P09362105X0422|71 71|%
P09362105X0422|90 121|hypoxic pulmonary vasoconstriction
P09362105X0422|123 125|HPV
P09362473A1540|12 18|results
P09362473A1540|27 32|tinman
P09362473A1540|56 79|discrete enhancer elements
P09362473A1540|110 134|differential genetic inputs
P09362473A1540|159 167|activator
P09362473A1540|171 191|repressor binding sites
P09362473A1540|200 219|early-acting enhancer
P09362473A1540|234 246|twist activity
P09362473A1540|234 238|twist
P09362473A1540|249 261|specific areas
P09362473A1540|271 291|twist expression domain
P09362473A1540|271 275|twist
P09362480A0452|2 23|unusual cysteine triplet
P09362480A0452|38 46|sequences
P09362480A0452|49 57|TB domains
P09362480A0452|60 68|localized
P09362480A0452|74 88|hydrophobic core
P09362480A0452|95 104|C-terminus
P09362480A0452|109 119|alpha-helix
P09362499A0000|3 12|Fis protein
P09362499A0000|22 46|site-specific DNA inversion
P09362499A0000|67 79|DNA invertases
P09362499A0000|92 124|cis-acting recombinational enhancer
P09363759A0000|0 18|Protein phosphatases
P09363759A0000|24 35|critical role
P09363759A0000|56 74|eukaryotic cell cycle
P09363759A0000|78 95|signal transduction
P09364211A0319|3 43|cell cycle-regulated transcription factor E2F
P09364211A0319|41 43|E2F
P09364211A0319|68 74|binding
P09364440A2206|22 37|modular structure
P09364440A2206|43 57|FSH receptor gene
P09364440A2206|67 72|motifs
P09364440A2206|83 90|coupling
P09364440A2206|93 110|different effectors
P09364750T0000|0 24|Transcriptional regulation
P09364750T0000|27 31|SUP35
P09364750T0000|35 39|SUP45
P09365201A2018|5 11|studies
P09365201A2018|33 55|further characterization
P09365201A2018|61 79|regulatory mechanism
P09365201A2018|82 100|aromatase expression
P09365201A2018|82 90|aromatase
P09365201A2018|103 119|human breast cancer
P09365201A2018|123 126|ASCs
P09365272T0000|0 25|Xenopus Ran-binding protein 1
P09365272T0000|0 24|Xenopus Ran-binding protein
P09365272T0000|27 47|molecular interactions
P09365272T0000|51 57|effects
P09365272T0000|60 74|nuclear assembly
P09365272T0000|77 94|Xenopus egg extracts
P09365431A0314|29 43|benzodiazepines
P09365431A0314|50 91|acetylcholinesterase inhibitor physostigmine
P09365431A0314|50 69|acetylcholinesterase
P09366456A0234|0 6|METHODS
P09366456A0234|8 27|Total muscle paralysis
P09366456A0234|43 59|general anesthesia
P09366456A0234|70 81|obese persons
P09366456A0234|83 84|n =
P09366456A0234|87 99|body mass index
P09366456A0234|107 108|kg
P09366456A0234|127 141|nonobese persons
P09366456A0234|143 144|n =
P09366456A0234|147 158|body mas index
P09366456A0234|166 167|kg
P09366517A0835|0 2|PKA
P09366517A0835|17 19|WT1
P09366517A0835|22 28|Ser-365
P09366517A0835|32 38|Ser-393
P09366517A0835|57 71|additional sites
P09366517A0835|80 94|phosphorylation
P09366517A0835|107 125|DNA-binding activity
P09366517A0835|128 130|WT1
P09366517A1828|3 10|findings
P09366517A1828|21 33|first evidence
P09366517A1828|51 53|WT1
P09366517A1828|73 87|phosphorylation
P09366628T0000|0 1|Re
P09366628T0000|27 35|causality
P09366628T0000|38 59|cross-sectional studies
P09367288A0115|1 9|second aim
P09367288A0115|44 70|muscle-tendon unit rest length
P09367288A0115|81 103|prolonged immobilisation
P09367288A0115|145 155|adaptations
P09367288A0115|169 174|tendon
P09367392A0567|15 32|additional sequence
P09367392A0567|35 45|nucleotides
P09367392A0567|67 70|RNA3
P09367392A0567|79 97|template recognition
P09367392A0567|100 103|RdRp
P09367392A0567|114 125|accumulation
P09367392A0567|128 131|RNA3
P09367392A0567|140 154|wild-type levels
P09367426A1354|14 24|primary role
P09367426A1354|27 28|hh
P09367426A1354|42 49|polarity
P09367426A1354|59 82|anterior compartment cells
P09367426A1354|125 145|symmetric polarization
P09367676A0275|0 23|Restriction enzyme mapping
P09367676A0275|25 34|subcloning
P09367676A0275|39 59|DNA sequencing analysis
P09367676A0275|62 83|recombinant phage lambda
P09367676A0275|87 94|P1 clones
P09367676A0275|87 88|P1
P09367676A0275|107 111|exons
P09367676A0275|123 139|1.9-kb mouse TS mRNA
P09367676A0275|160 171|kb genomic DNA
P09367676A1115|0 19|Transfection analyses
P09367676A1115|48 53|Tbxas1
P09367676A1115|75 79|70-bp
P09367676A1115|81 106|positive regulatory sequence
P09367676A1115|110 142|several upstream repressive elements
P09368006A1332|3 9|results
P09368006A1332|32 48|NF-kappaB activity
P09368006A1332|32 40|NF-kappaB
P09368006A1332|86 111|cell cycle regulatory protein
P09368006A1332|113 117|E2F-1
P09368014A0740|3 17|lysozyme FEF site
P09368014A0740|36 37|PU
P09368026A0000|0 10|Osteocalcin
P09368026A0000|12 13|OC
P09368026A0000|18 45|matrix calcium-binding protein
P09368026A0000|57 67|osteoblasts
P09368026A0000|71 82|odontoblasts
P09368026A0000|93 106|mineralization
P09368026A0435|24 30|effects
P09368026A0435|33 46|Msx2 expression
P09368026A0435|33 36|Msx2
P09368026A0435|49 68|OC promoter activation
P09368026A0435|49 58|OC promoter
P09368026A0435|70 87|luciferase reporter
P09368026A0435|91 98|FGF2/FSK
P09368026A0435|91 94|FGF2
P09368026A0435|96 98|FSK
P09368026A0435|102 111|calcitriol
P09368026A0435|114 132|MC3T3-E1 osteoblasts
P09368057A1083|11 23|other proteins
P09368057A1083|41 51|SRF activity
P09368057A1083|41 43|SRF
P09368057A1083|56 72|repressor activity
P09368057A1083|90 103|GC-rich element
P09368057A1083|134 149|direct inhibition
P09368057A1083|152 161|SRF binding
P09368057A1083|152 154|SRF
P09368058A0969|11 52|CAK-phosphorylated phosphopeptide comigrates
P09368058A0969|11 13|CAK
P09368058A0969|58 90|Cdc2-phosphorylated phosphopeptide
P09368058A0969|58 61|Cdc2
P09368058A0969|110 125|mitosis-specific
P09368058A0969|150 152|CAK
P09368100A1354|3 27|mHIF-1 alpha structural gene
P09368100A1354|42 46|exons
P09368190A1053|20 43|upstream IRE-like sequence
P09368190A1053|58 61|EMSA
P09368190A1053|64 88|DNA binding pattern distinct
P09368190A1053|120 128|IFN-gamma
P09368190A1053|150 169|prolonged stimulation
P09368190A1053|178 186|IFN-alpha
P09368190A1053|190 198|IFN-gamma
P09368419A0000|2 12|Arabidopsis
P09368419A0000|17 25|induction
P09368419A0000|29 54|dehydration-responsive gene
P09368419A0000|56 59|rd22
P09368419A0000|73 84|abscisic acid
P09368419A0000|86 88|ABA
P09368419A0000|101 119|protein biosynthesis
P09368419A0000|123 149|ABA-dependent gene expression
P09368419A0000|123 139|ABA-dependent gene
P09368419A0628|1 4|cDNA
P09368419A0628|14 41|MYC-related DNA binding protein
P09368419A0628|55 80|DNA-ligand binding screening
P09368419A0628|90 100|67-bp region
P09368419A0628|104 108|probe
P09368419A0628|123 129|rd22BP1
P09368760A0665|0 8|Human PDK1
P09368760A0665|11 20|homologous
P09368760A0665|26 55|Drosophila protein kinase DSTPK61
P09368760A0665|96 113|sex differentiation
P09368760A0665|115 123|oogenesis
P09368760A0665|127 141|spermatogenesis
P09369450A1358|8 25|synergistic effects
P09369450A1358|28 36|HNF-1beta
P09369450A1358|43 44|GR
P09369450A1358|47 86|dexamethasone-stimulated promoter activity
P09369450A1358|115 123|HNF-1 site
P09369450A1358|130 132|GRE
P09369450A1358|160 186|protein-protein interactions
P09369450A1358|160 174|protein-protein
P09369450A1358|197 216|transcription factors
P09369450A1358|237 263|basal transcription machinery
P09369450A1358|267 292|steroid receptor coactivator
P09369451A0693|0 17|Mutational analysis
P09369451A0693|33 48|AP-1 like sequence
P09369451A0693|33 36|AP-1
P09369451A0693|60 69|TGAATCATCA
P09369451A0693|76 104|A/T-rich myocyte enhancer factor
P09369451A0693|84 104|myocyte enhancer factor
P09369451A0693|106 123|MEF)-2 like sequence
P09369451A0693|106 108|MEF
P09369451A0693|135 147|TTAAAAATAAAAA
P09369451A0693|154 164|33-bp region
P09369451A0693|183 192|OP-1 effect
P09369451A0693|183 186|OP-1
P09369453A0273|6 21|most other members
P09369453A0273|27 37|Bcl-2 family
P09369453A0273|39 41|BAD
P09369453A0273|43 52|Bcl-xL/Bcl
P09369453A0273|65 77|death promoter
P09369453A0273|81 93|death enhancer
P09369453A0273|100 128|C-terminal transmembrane domain
P09369453A0273|146 171|outer mitochondrial membrane
P09369453A0273|175 189|nuclear envelope
P09369482A0690|0 19|Electromobility shift
P09369482A0690|23 42|cotransfection assays
P09369482A0690|59 67|HNF1alpha
P09369482A0690|75 78|HNF4
P09369482A0690|90 100|cognate site
P09369482A0690|118 137|G6Pase gene expression
P09369482A0690|118 127|G6Pase gene
P09370276A0781|2 17|open reading frame
P09370276A0781|24 25|bp
P09370276A0781|38 53|amino acid protein
P09370307A0093|13 21|AACA motif
P09370307A0093|40 56|negative regulator
P09370307A0093|59 73|non-seed tissues
P09370307A0093|96 129|barley gibberellin responsive element
P09370307A0093|142 167|MYB-like DNA binding proteins
P09371431A1172|0 11|Strain CFN037
P09371431A1172|16 27|R. etli mutant
P09371431A1172|38 58|single Tn5mob insertion
P09371431A1172|44 49|Tn5mob
P09371431A1172|64 77|promoter region
P09371431A1172|83 100|thiCOGE gene cluster
P09371431T0000|0 9|Expression
P09371431T0000|12 35|thiamin biosynthetic genes
P09371431T0000|37 43|thiCOGE
P09371431T0000|60 87|symbiotic terminal oxidase cbb3
P09371431T0000|90 102|Rhizobium etli
P09371455A0000|40 51|lipase operon
P09371455A0000|56 63|putative
P09371455A0000|75 104|uncharacterized metalloprotease
P09371455A0000|107 122|Vibrio cholerae O1
P09371564A0713|23 32|tRNA(3Lys)
P09371564A0713|23 26|tRNA
P09371564A0713|28 31|3Lys
P09371564A0713|50 57|viral RNA
P09371564A0713|67 73|viruses
P09371564A0713|113 126|wild-type virus
P09371566A1384|26 44|HeLa nuclear extracts
P09371566A1384|48 59|S100 extracts
P09371566A1384|63 68|absent
P09371566A1384|73 93|SR protein preparations
P09371566A1384|73 81|SR protein
P09371566A1384|117 134|classical SR protein
P09371596T0000|0 21|Differential regulation
P09371596T0000|27 31|pre-C
P09371596T0000|35 53|pregenomic promoters
P09371596T0000|56 75|human hepatitis B virus
P09371596T0000|78 84|members
P09371596T0000|90 115|nuclear receptor superfamily
P09371612A1964|0 3|Acad
P09371622A0779|0 7|Chimeras
P09371622A0779|18 28|IE1 peptides
P09371622A0779|50 62|transcription
P09371622A0779|68 80|basal promoter
P09371622A0779|89 108|lac operator sequences
P09371626A1345|3 9|results
P09371626A1345|12 26|replicase assays
P09371626A1345|12 20|replicase
P09371626A1345|40 48|mutant VP2
P09371626A1345|60 67|deletion
P09371626A1345|73 89|RNA-binding domain
P09371626A1345|105 117|essential role
P09371626A1345|121 123|VP2
P09371626A1345|126 136|replication
P09371626A1345|175 186|mRNA template
P09371626A1345|190 210|minus-strand synthesis
P09371657A0165|24 46|alanine cluster mutations
P09371657A0165|48 50|R77
P09371657A0165|53 53|A
P09371657A0165|55 58|R77A
P09371657A0165|61 64|K79A
P09371657A0165|68 78|E192A-E194A
P09371657A0165|110 132|triphosphatase component
P09371698A1254|0 11|Transfection
P09371698A1254|14 18|HepG2
P09371698A1254|22 33|SK-N-MC cells
P09371698A1254|38 47|constructs
P09371698A1254|70 86|flanking fragments
P09371698A1254|122 139|bp promoter fragment
P09371698A1254|153 166|pseudo-TATA box
P09371698A1254|173 196|putative SP1-binding sites
P09371698A1254|181 196|SP1-binding sites
P09371731A0627|4 10|inserts
P09371731A0627|14 19|larger
P09371731A0627|29 38|homologues
P09371731A0627|41 57|eIF-2alpha kinases
P09372287A0296|5 23|monopolar electrodes
P09372287A0296|50 81|right lateral vestibulospinal tract
P09372287A0296|83 86|LVST
P09372287A0296|91 116|medial vestibulospinal tract
P09372287A0296|118 121|MVST
P09372287A0296|128 136|C1 segment
P09372287A0296|152 158|pathway
P09372287A0296|161 165|axons
P09372451T0000|0 7|Epitopes
P09372451T0000|10 48|adhesion-perturbing monoclonal antibodies
P09372451T0000|68 86|alpha-helical domain
P09372451T0000|92 103|integrin beta
P09372451T0000|105 111|subunit
P09372908A1068|0 31|Polyhomeotic and Posterior Sex Combs
P09372908A1068|0 11|Polyhomeotic
P09372908A1068|15 31|Posterior Sex Combs
P09372908A1068|53 83|general transcriptional mechanism
P09372908A1068|103 116|gene repression
P09372908A1068|128 136|inclusion
P09372908A1068|139 153|Polycomb protein
P09372908A1068|168 171|PREs
P09372908A1068|179 193|stable silencing
P09372924A0758|16 29|rhHR23 proteins
P09372924A0758|48 56|NER system
P09372924A0758|82 89|proteins
P09372924A0758|101 117|direct involvement
P09372924A0758|120 132|hHR23 proteins
P09372924A0758|138 154|DNA repair reaction
P09372924A0758|173 175|XPC
P09372937T0000|3 45|yeast silent information regulator Sir4p anchors
P09372937T0000|49 66|partitions plasmids
P09372950A1283|5 11|results
P09372950A1283|22 59|precursor-specific base-paired structure
P09372950A1283|69 77|sequences
P09372950A1283|84 88|sides
P09372950A1283|94 111|mature cleavage site
P09372950A1283|131 140|human U2 RNA
P09372960A0456|0 15|Polysome analyses
P09372960A0456|19 51|temperature-sensitive fal1-1 mutant
P09372960A0456|40 51|fal1-1 mutant
P09372960A0456|56 75|Fal1p-depleted strain
P09372960A0456|56 60|Fal1p
P09372960A0456|104 123|40S ribosomal subunits
P09372968A0532|0 15|Sequence analysis
P09372968A0532|37 46|cDNA clones
P09372968A0532|49 53|Dlc-1
P09372968A0532|79 95|9-kDa human homolog
P09372968A0532|101 133|outer-arm dynein light-chain protein
P09372968A0996|14 17|HeLa
P09372968A0996|24 28|cells
P09372968A0996|30 39|endogenous
P09372968A0996|54 65|I kappaB alpha
P09372968A0996|55 65|kappaB alpha
P09372968A0996|90 99|Myc-tagged
P09372968A0996|90 92|Myc
P09372968A0996|102 116|endogenous Dlc-1
P09372968A0996|112 116|Dlc-1
P09373140A0000|3 35|mouse M-lysozyme downstream enhancer
P09373140A0000|68 80|several levels
P09373140A0000|83 96|gene regulation
P09373155T0000|0 13|Identification
P09373155T0000|16 36|dynein heavy chain genes
P09373155T0000|56 66|mouse testis
P09373155T0000|68 90|chromosomal localization
P09373155T0000|95 112|axonemal dynein gene
P09373651A0255|0 12|Bitter cassava
P09373651A0255|21 40|cyanogenic glycosides
P09373651A0255|68 85|acetone cyanohydrin
P09373651A0255|89 103|hydrogen cyanide
P09374082A0504|22 33|effect states
P09374082A0504|43 54|2-ethylhexyl
P09374082A0504|56 64|phthalate
P09374082A0504|66 69|MEHP
P09374082A0504|75 98|primary hydrolysis product
P09374082A0504|101 104|DEHP
P09374082A0504|123 136|prostaglandins
P09374082A0504|138 139|PG
P09374082A0504|141 143|PGD
P09374082A0504|148 153|9alpha
P09374082A0504|157 164|betaPGF2
P09374082A0504|169 177|PGF2alpha
P09374082A0504|182 193|thromboxanes
P09374082A0504|199 203|lungs
P09374082A0504|239 250|inflammation
P09374082A0504|256 262|airways
P09374082A0504|288 293|asthma
P09374541A0277|9 27|protein binding sites
P09374541T0000|0 21|Constitutive protection
P09374541T0000|24 46|E2F recognition sequences
P09374541T0000|52 79|human thymidine kinase promoter
P09374541T0000|86 105|cell cycle progression
P09376325A0167|0 9|Comparison
P09376325A0167|12 26|genomic sequence
P09376325A0167|39 45|ph locus
P09376325A0167|53 62|duplicated
P09376325A0167|81 88|proximal
P09376325A0167|92 115|distal transcription units
P09376626A0737|0 8|Radiation
P09376626A0737|21 26|levels
P09376626A0737|29 30|T4
P09376626A0737|34 35|T3
P09376626A0737|37 37|h
P09376626A0737|43 43|h
P09376626A0737|46 51|group C
P09376626A0737|55 60|group A
P09376626A0737|65 65|h
P09376626A0737|69 74|group B
P09376626A0737|79 91|h postexposure
P09376782A0328|30 52|major MMT general practice
P09376782A0328|57 71|hepatitis C virus
P09376782A0328|73 75|HCV
P09377355A0362|17 32|extensive own data
P09377355A0362|49 66|particular features
P09377355A0362|69 91|cardiovascular disorders
P09377355A0362|94 116|chronic renal impairement
P09377355A0362|132 152|modern diagnostic tools
P09377374A0000|12 27|characterization
P09377374A0000|48 66|biochemical features
P09377374A0000|69 77|VH B course
P09377374A0000|100 109|narcomania
P09379301A2036|3 9|microns
P09379301A2036|13 27|A. microcephalum
P09379301A2036|34 40|microns
P09379301A2036|44 50|A. wedli
P09379301A2036|56 66|fewer testes
P09379301A2036|70 79|proglottis
P09380504A1255|3 11|ZnF20 cDNA
P09380504A1255|24 42|multiple transcripts
P09380504A1255|46 66|thyroid cancer cell line
P09380504A1255|79 80|kb
P09380504A1255|100 121|cycloheximide treatment
P09380504A1255|134 134|h
P09380504A1255|150 162|actinomycin D.
P09380507A0514|0 23|Glutathione S-transferase
P09380507A0514|25 27|GST
P09380507A0514|30 32|E2F
P09380507A0514|36 55|GST-DP fusion proteins
P09380507A0514|36 38|GST
P09380507A0514|95 102|E2F sites
P09380507A0514|108 137|DNA polymerase alpha gene promoter
P09380697T0000|3 39|sterol regulatory element-like sequences
P09380697T0000|47 59|up-regulation
P09380697T0000|62 86|caveolin gene transcription
P09380697T0000|62 73|caveolin gene
P09380697T0000|99 134|low density lipoprotein free cholesterol
P09380707A0714|12 29|DNA-bound LAZ3/BCL6
P09380707A0714|21 24|LAZ3
P09380707A0714|26 29|BCL6
P09380707A0714|38 41|SMRT
P09380707A0714|56 76|overexpressed proteins
P09380707A0714|99 109|nuclear dots
P09381261A0970|0 10|CONCLUSIONS
P09381261A0970|22 36|normal EPO levels
P09381261A0970|28 30|EPO
P09381261A0970|40 46|mothers
P09381261A0970|50 57|newborns
P09381261A0970|102 105|ones
P09381950A0209|0 8|Ischaemia
P09381950A0209|22 32|low flow rate
P09381950A0209|38 44|mL min-1
P09381950A0209|50 52|min
P09381950A0209|71 90|40-minute reperfusion
P09382498A0618|9 12|MCTs
P09382498A0618|19 31|long electrode
P09382498A0618|34 35|cm
P09382498A0618|61 71|central area
P09382498A0618|91 94|MCTs
P09382498A0618|98 111|short electrode
P09382498A0618|114 115|cm
P09382498A0618|136 145|peripheral
P09382498A0618|149 163|surrounding area
P09382850A0000|0 9|BACKGROUND
P09382850A0000|11 28|Checkpoint pathways
P09382850A0000|36 56|cell-cycle progression
P09382850A0000|69 78|DNA lesions
P09382886A1061|0 10|Direct proof
P09382886A1061|28 49|renal cellular apoptosis
P09382886A1061|52 54|PKD
P09382886A1061|76 78|p53
P09382886A1061|92 108|successive matings
P09382886A1061|116 118|SBM
P09382886A1061|122 124|p53
P09382886A1061|130 133|mice
P09382924A0131|37 47|stimulation
P09382924A0131|52 67|interferon-gamma
P09382924A0131|69 77|IFN-gamma
P09382924A0131|85 101|beta-type subunits
P09382924A0131|113 116|LMP2
P09382924A0131|118 121|LMP7
P09382924A0131|126 131|PSMB10
P09382924A0131|155 167|20S proteasome
P09382924A0131|183 211|housekeeping beta-type subunits
P09382924A0131|222 226|PSMB6
P09382924A0131|228 232|PSMB5
P09382924A0131|237 241|PSMB7
P09383156A0691|3 28|major RNase E cleavage product
P09383156A0691|8 28|RNase E cleavage product
P09383156A0691|37 42|pSok-6
P09383156A0691|63 89|polynucleotide phosphorylase
P09383156A0691|91 96|PNPase
P09383188A0654|30 39|lower match
P09383188A0654|45 59|ARG box consensus
P09383188A0654|65 75|O(rocD) site
P09383188A0654|65 65|O
P09383188A0654|67 70|rocD
P09385169T0000|3 6|AONE
P09385169T0000|9 15|experts
P09385169T0000|24 45|productivity indicators
P09386074A0694|3 6|pigs
P09386074A0694|10 41|significant regional LV dysfunction
P09386074A0694|52 69|LV ejection fraction
P09386074A0694|78 78|%
P09387333T0001|13 33|morphological research
P09387333T0001|39 57|parabrachial nucleus
P09387999A1053|3 12|amplitudes
P09387999A1053|15 19|DPOAE
P09387999A1053|36 48|greater extent
P09387999A1053|52 70|outer hair cell losses
P09387999A1053|90 106|R-PIA-treated ears
P09387999A1053|90 90|R
P09388198A1396|30 65|signal transduction pathway independent
P09388198A1396|68 70|JNK
P09388198A1396|72 74|ERK
P09388198A1396|79 90|p38 MAP kinase
P09388198A1396|108 116|induction
P09388198A1396|119 122|rhoB
P09388198A1396|125 139|genotoxic stress
P09388198A1396|164 177|autoregulation
P09388198A1396|180 183|rhoB
P09388199A0948|12 26|separate domains
P09388199A0948|29 32|FadR
P09388199A0948|44 53|DNA binding
P09388199A0948|55 66|dimerization
P09388199A0948|71 83|ligand binding
P09388199A0948|85 106|chimeric protein fusions
P09388199A0948|117 132|DNA binding domain
P09388199A0948|135 138|LexA
P09388199A0948|142 157|different regions
P09388199A0948|160 163|FadR
P09388200A0639|0 9|Inhibition
P09388200A0639|29 37|titration
P09388200A0639|40 66|general transcription factors
P09388200A0639|74 91|MDM2 overexpression
P09388200A0639|74 77|MDM2
P09388200A0639|100 104|c-fos
P09388200A0639|113 126|other promoters
P09388200A0639|136 153|basal transcription
P09388201A1027|2 3|PU
P09388201A1027|7 8|PD
P09388201A1027|18 30|canonical TATA
P09388201A1027|33 42|CAAT motifs
P09388201A1027|50 56|AT-rich
P09388246A0903|12 58|immunogold electron microscopy immunocytochemistry
P09388246A0903|63 74|amphiphysin I
P09388246A0903|63 73|amphiphysin
P09388246A0903|77 85|localized
P09388246A0903|91 113|nerve terminal cytomatrix
P09388246A0903|142 163|endocytic intermediates
P09388271A1243|3 15|mobility shift
P09388271A1243|29 36|proteins
P09388271A1243|63 72|inhibitors
P09388271A1243|75 77|PKC
P09388271A1243|80 149|mitogen-activated protein kinase/extracellular signal-related kinase kinase
P09388271A1243|80 109|mitogen-activated protein kinase
P09388271A1243|111 149|extracellular signal-related kinase kinase
P09389137A0763|18 25|apoplexy
P09389137A0763|34 37|C1-7
P09389137A0763|39 42|T1-9
P09389137A0763|46 49|L2-4
P09389198A0363|9 17|aftermath
P09389198A0363|20 29|excitation
P09389198A0363|35 54|skin sympathetic nerve
P09389198A0363|57 73|mental arithmetics
P09389198A0363|79 89|A delta units
P09389198A0363|105 115|active state
P09389198A0363|129 147|mechanical threshold
P09389492A0520|3 16|similar fashion
P09389492A0520|26 37|stromal cells
P09389492A0520|39 43|serum
P09389492A0520|68 80|dexamethasone
P09389492A0520|97 127|phorbol ester-stimulated activity
P09389666A0538|5 17|Hex expression
P09389666A0538|5 7|Hex
P09389666A0538|26 77|earliest unequivocal molecular anteroposterior asymmetry
P09389666A0538|83 93|mouse embryo
P09389666A0538|113 131|anteroposterior axis
P09389666A0538|137 142|embryo
P09389666A0538|168 189|proximodistal asymmetry
P09389666A0538|206 229|primitive endoderm lineage
P09389669A1009|5 7|dpp
P09389669A1009|11 13|omb
P09389669A1009|25 41|dorsal leg cell fate
P09389669A1009|50 89|transdetermination-competent leg disc cells
P09389982A1383|0 10|CONCLUSIONS
P09389982A1383|17 29|INR correction
P09389982A1383|51 62|above methods
P09389982A1383|76 90|log reference INR
P09389982A1383|96 115|local prothrombin time
P09389982A1383|101 111|prothrombin
P09389982A1383|118 141|linear regression analysis
P09389982A1383|147 154|simplest
P09390125A0379|0 6|RESULTS
P09390125A0379|11 20|overall FNF
P09390125A0379|35 35|%
P09390125A0379|46 46|%
P09390125A0379|52 52|%
P09390125A0379|57 57|%
P09390125A0379|64 64|%
P09390125A0379|68 85|successive quarters
P09390183A1027|0 18|Western blot analysis
P09390183A1027|21 40|various bovine tissues
P09390183A1027|45 67|human NMT peptide antibody
P09390183A1027|78 110|common prominent immunoreactive band
P09390183A1027|117 137|apparent molecular mass
P09390183A1027|147 149|kDa
P09390183A1027|155 161|tissues
P09391173A0811|0 22|Transcription start sites
P09391173A0811|28 45|plastid ACCase genes
P09391173A0811|35 45|ACCase genes
P09391173A0811|66 82|longest cDNA clones
P09391173A0811|96 99|RACE
P09391173A0811|101 118|rapid amplification
P09391173A0811|121 128|cDNA ends
P09392979T0000|0 11|AIDS-related
P09392979T0000|24 37|histoplasmosis
P09392979T0000|40 51|San Francisco
P09392979T0000|53 62|California
P09393706A1171|5 7|Fis
P09393706A1171|16 48|accessory transcriptional activator
P09393706A1171|54 64|mar promoter
P09393706A1171|57 64|promoter
P09393717A1517|5 16|observations
P09393717A1517|24 36|strong support
P09393717A1517|63 72|mutant tRNA
P09393717A1517|83 98|mutator phenotype
P09393717A1517|112 136|UVM-constitutive phenotype
P09393717A1517|147 150|mutA
P09393717A1517|154 162|mutC cells
P09393717A1517|154 157|mutC
P09393771A1659|0 16|TNF-alpha exposure
P09393771A1659|0 8|TNF-alpha
P09393771A1659|44 69|several RNA-binding proteins
P09393771A1659|51 69|RNA-binding proteins
P09393771A1659|82 88|novel Mr
P09393771A1659|102 119|RNA-binding protein
P09393875A0873|18 45|human papillomavirus late mRNAs
P09393875A0873|73 78|copies
P09393875A0873|84 101|virus genome present
P09393875A0873|104 116|infected cells
P09393875A0873|132 141|c-fos mRNAs
P09393875A0873|145 172|destabilizing cellular factors
P09393875A0873|193 216|elevated Fos protein levels
P09393875A0873|201 210|Fos protein
P09393875A0873|219 250|human papillomavirus infected cells
P09393966A0190|10 38|related IgH constant region genes
P09393966A0190|17 19|IgH
P09393966A0190|20 38|constant region genes
P09393966A0190|40 42|CHA
P09393966A0190|46 48|CHB
P09394650A0121|57 72|normal lymph nodes
P09394650A0121|75 102|high-resolution mediastinal US
P09395456A0424|16 31|heavy chain motifs
P09395456A0424|34 53|substrate recognition
P09395456A0424|63 70|variants
P09395456A0424|73 107|recombinant bovine proenteropeptidase
P09395456A0424|84 107|bovine proenteropeptidase
P09395456A0424|137 155|transmembrane domain
P09395456A0424|161 173|signal peptide
P09395470A0294|0 11|CKbeta4GT-II
P09395470A0294|38 62|transmembrane glycoprotein
P09395470A0294|67 69|kDa
P09395470A0294|78 112|potential N-linked glycosylation sites
P09395525A0395|20 48|CCAAT/enhancer-binding protein
P09395525A0395|50 54|C/EBP
P09395525A0395|56 60|delta
P09395525A0395|64 77|major component
P09395525A0395|81 113|PGE2-stimulated DNA-protein complex
P09395525A0395|96 106|DNA-protein
P09395525A0395|123 126|HS3D
P09395525A0395|138 147|C/EBPdelta
P09395525A0395|162 175|IGF-I promoter 1
P09395525A0395|162 174|IGF-I promoter
P09396402A0264|0 7|PATIENTS
P09396402A0264|11 17|METHODS
P09396402A0264|19 31|Semen analyses
P09396402A0264|49 56|patients
P09396402A0264|61 66|stages
P09396402A0264|72 73|HD
P09396402A0264|96 107|chemotherapy
P09396402A0264|119 128|sperm count
P09396402A0264|145 151|effects
P09396402A0264|154 174|abdominal radiotherapy
P09396402A0264|192 203|chemotherapy
P09396427A1488|17 45|residual infarct-zone viability
P09396427A1488|59 66|patients
P09396427A1488|77 110|progressive left ventricular dilation
P09396427A1488|116 128|reperfused AMI
P09396427A1488|149 177|normal left ventricular geometry
P09396437A0878|5 13|BMI cutoff
P09396437A0878|23 40|cardiac NE spillover
P09396437A0878|46 51|% lower
P09396437A0878|57 69|obese subjects
P09396437A0878|89 100|lean subjects
P09396437A0878|102 103|P=
P09396722A0185|8 12|ApxII
P09396722A0185|26 67|chloroplastic ascorbate peroxidase isoenzymes
P09396796A1173|31 35|CDF-1
P09396796A1173|43 57|E2F family member
P09396796A1173|61 66|points
P09396796A1173|69 87|profound differences
P09396796A1173|93 111|cell cycle regulation
P09396796A1173|114 118|CDF-1
P09396796A1173|122 124|E2F
P09396823T0000|23 51|Escherichia coli DNA polymerase I
P09396823T0000|38 50|DNA polymerase
P09396823T0000|55 62|other DNA
P09396823T0000|69 89|RNA exonuclease domains
P09397261A0940|0 18|Interleukin-1 levels
P09397261A0940|0 12|Interleukin-1
P09397723T0001|0 20|Responsibility matters
P09397723T0001|30 46|scientific council
P09398267A0440|0 19|Southern blot analysis
P09398267A0440|22 52|endonuclease-digested genomic DNA
P09398267A0440|57 85|primary chick embryo fibroblasts
P09398267A0440|87 89|CEF
P09398267A0440|104 107|MEK2
P09398267A0440|111 125|single-copy gene
P09398267A0440|132 148|vertebrate species
P09398332A0732|0 8|Sequences
P09398332A0732|33 35|mu2
P09398332A0732|39 44|CTLA-4
P09398332A0732|49 57|localized
P09398332A0732|60 67|residues
P09398332A0732|69 76|161TTGVY
P09398332A0732|79 84|CTLA-4
P09398332A0732|100 109|N-terminal
P09398332A0732|150 164|SH2 binding motif
P09398332A0732|166 172|165YVKM
P09398332A0732|184 198|CTLA-4 signaling
P09398332A0732|184 189|CTLA-4
P09398598A0256|29 47|Chinese hamster ovary
P09398598A0256|49 51|CHO
P09398598A0256|53 60|cell line
P09398598A0256|72 88|murine CD4 fragment
P09398598A0256|110 126|N-terminal domains
P09398598A0256|139 156|monomeric molecules
P09398598A0256|160 184|disulfide-linked multimers
P09398855A0438|0 4|SCID V
P09398855A0438|4 4|V
P09398855A0438|6 6|D
P09398855A0438|8 21|J recombination
P09398855A0438|42 54|T-lymphocytes
P09398855A0438|63 80|DNA-damaging agents
P09398855A0438|82 98|gamma-irradiation
P09398855A0438|102 110|bieomycin
P09398855A0438|115 126|null mutation
P09398855A0438|132 138|p53 gene
P09398855A0438|168 192|elevated DNA repair activity
P09398855A0438|205 213|DNA damage
P09398855A0438|225 233|apoptosis
P09398855A0438|248 250|p53
P09400613A0594|0 11|Coexpression
P09400613A0594|14 21|mouse PKR
P09400613A0594|34 60|Gal4 DNA-binding domain fusion
P09400613A0594|34 54|Gal4 DNA-binding domain
P09400613A0594|74 100|catalytic-deficient human PKR
P09400613A0594|108 118|K296R mutant
P09400613A0594|123 151|RNA-binding-deficient human PKR
P09400613A0594|159 180|K64E/K296R double mutant
P09400613A0594|184 200|wild-type mouse PKR
P09400613A0594|212 253|full-length PKR-Gal4 activation domain fusions
P09400613A0594|227 230|Gal4
P09400613A0594|264 273|activation
P09400613A0594|279 282|HIS3
P09400613A0594|286 298|lacZ reporters
P09400613A0594|286 289|lacZ
P09400613A1209|5 31|GST-PKR fusion chromatography
P09400613A1209|5 7|GST
P09400613A1209|9 11|PKR
P09400613A1209|33 57|direct physical interaction
P09400613A1209|76 91|human PKR homologs
P09400738A1046|6 32|greater inflammatory response
P09400738A1046|49 73|intratracheal instillation
P09400738A1046|76 79|ufCB
P09400738A1046|92 105|CB instillation
P09402029A1632|17 36|avirulent strain H37Ra
P09402029A1632|43 59|weak hybridization
P09402029A1632|72 77|probes
P09402029A1632|98 102|genes
P09402029A1632|128 142|avirulent strain
P09402029A1632|157 174|limited copy numbers
P09402029A1632|196 214|virulent strain H37Rv
P09402088A2250|5 11|defects
P09402088A2250|28 34|folding
P09402088A2250|38 59|configuration necessary
P09402088A2250|63 78|normal processing
P09402088A2250|84 99|AVP gene precursor
P09402139A1121|0 11|Similarities
P09402139A1121|22 29|hIGFBP-1
P09402139A1121|33 57|phosphoenolpyruvate kinase
P09402139A1121|59 63|PEPCK
P09402139A1121|65 73|promoters
P09402139A1121|84 90|regions
P09402139A1121|101 107|insulin
P09402139A1121|109 122|glucocorticoid
P09402139A1121|127 164|cyclic adenosine-monophosphate responses
P09402139A1121|186 203|previous hypothesis
P09402139A1121|208 214|IGFBP-1
P09402139A1121|239 255|glucose metabolism
P09403059A0209|4 15|binary repeat
P09403059A0209|24 44|repetitive DNA elements
P09403059A0209|56 60|LINES
P09403059A0209|62 66|SINES
P09403059A0209|68 100|medium reiteration frequency repeats
P09403059A0209|106 127|transposon-like element
P09404725A0644|4 7|days
P09404725A0644|19 30|gangliosides
P09404725A0644|36 47|average lower
P09404725A0644|50 56|females
P09404725A0644|63 67|males
P09405195A0320|0 21|Large genomic constructs
P09405195A0320|36 50|endogenous locus
P09405195A0320|53 75|homologous recombination
P09405195A0320|80 100|cDNA-derived sequences
P09405195A0320|108 120|long stretches
P09405195A0320|123 142|contiguous genomic DNA
P09405195A0320|149 162|intron excision
P09405195A0320|186 199|chromosomal DNA
P09405195A0320|202 227|nonhomologous recombination
P09405380A0800|22 31|categories
P09405380A0800|34 40|strains
P09405380A0800|48 63|new genetic system
P09405380A0800|74 83|properties
P09405380A0800|87 117|potential invertebrate retrovirus
P09405536A0777|9 29|conditioning procedure
P09405536A0777|34 46|C-fiber reflex
P09405536A0777|62 68|wind-up
P09405536A0777|73 97|stimulus-dependent fashion
P09405536A0777|107 125|anesthetized animals
P09405536A0777|161 179|conditioning stimuli
P09405536A0777|209 217|responses
P09405536A0777|226 232|plateau
P09405685A0113|3 48|sequence-specific DNA binding transcription factor
P09405685A0113|20 48|DNA binding transcription factor
P09405685A0113|50 52|p53
P09405685A0113|73 91|20-bp consensus motif
P09405685A0113|95 101|PuPuPuC
P09405685A0113|103 105|A/T
P09405685A0113|108 110|T/A
P09405685A0113|112 125|GPyPyPyPuPuPuC
P09405685A0113|127 129|A/T
P09405685A0113|132 134|T/A
P09405685A0113|136 144|GPyPyPy-3
P09407026A0426|0 11|TSA treatment
P09407026A0426|42 62|enhancer factor binding
P09407026A0426|68 78|positioning
P09407026A0426|81 85|nuc-1
P09407026A0426|104 121|chromatin templates
P09407026A0426|136 153|protein acetylation
P09407026A0426|157 175|chromatin remodeling
P09407026A0426|189 193|steps
P09407026A0426|226 243|competent templates
P09407026A0426|251 260|remodeling
P09407026A0426|263 267|nuc-1
P09407026A0426|276 292|additional factors
P09407031A0557|4 11|UV damage
P09407031A0557|13 16|Crb2
P09407031A0557|67 79|similar timing
P09407031A0557|82 96|phosphorylation
P09407031A0557|99 108|Chk1 kinase
P09407031A0557|135 148|Cdc2 activation
P09407031A0557|135 138|Cdc2
P09407031A0974|9 30|moderate overexpression
P09407031A0974|33 36|Chk1
P09407031A0974|50 59|phenotypes
P09407031A0974|62 65|cut5
P09407031A0974|69 79|crb2 mutants
P09407036T0000|0 10|Tcn1p/Crz1p
P09407036T0000|0 4|Tcn1p
P09407036T0000|6 10|Crz1p
P09407036T0000|13 52|calcineurin-dependent transcription factor
P09407036T0000|80 93|gene expression
P09407090T0000|0 8|Structure
P09407090T0000|12 23|localization
P09407090T0000|29 37|human gene
P09407090T0000|46 54|SR-BI/CLA
P09407090T0000|46 50|SR-BI
P09407090T0000|52 56|CLA-1
P09407642A0305|15 26|gel technique
P09407642A0305|30 41|routine assay
P09407642A0305|45 61|antibody detection
P09408516T0000|0 8|Stability
P09408516T0000|11 23|pyrimethamine
P09408516T0000|27 49|liquid dosage formulation
P09408516T0000|64 69|months
P09408796A0648|0 25|Multiple regression analyses
P09408796A0648|38 74|WAIS-R factor scores Verbal Comprehension
P09408796A0648|78 84|Freedom
P09408796A0648|89 103|Distractibility
P09408796A0648|122 122|%
P09408796A0648|128 135|variance
P09408796A0648|138 142|WMS-R
P09408796A0648|146 156|CVLT indices
P09409416A0111|0 21|Bilateral basal arteries
P09409416A0111|39 59|transtemporal approach
P09409416A0111|66 91|MHz pulsed Doppler instrument
P09409416A0111|93 102|TC-2 64B EME
P09409774A0214|5 16|genomic level
P09409774A0214|21 29|sequences
P09409774A0214|35 41|members
P09409774A0214|67 85|rat Rattus norvegicus
P09409774A0214|90 98|VCSA1 gene
P09409774A0214|111 140|prohormone-like polypeptide SMR1
P09409774A0214|148 156|VCSB1 gene
P09409774A0214|167 193|salivary Pro-rich polypeptide
P09409821T0000|3 34|Saccharomyces cerevisiae RAD30 gene
P09409821T0000|26 34|RAD30 gene
P09409821T0000|37 45|homologue
P09409821T0000|48 66|Escherichia coli dinB
P09409821T0000|63 66|dinB
P09409821T0000|70 73|umuC
P09409821T0000|77 94|DNA damage inducible
P09409821T0000|98 106|functions
P09409821T0000|110 154|novel error-free postreplication repair mechanism
P09411459A0729|11 23|new experiment
P09411459A0729|34 45|deletion task
P09411459A0729|61 70|puppet game
P09411459A0729|79 89|pretraining
P09411459A0729|104 116|vowel deletion
P09411459A0729|132 142|higher level
P09411459A0729|168 175|children
P09411459A0729|190 201|CVCC material
P09412079T0001|0 10|Diet therapy
P09412079T0001|15 25|soy proteins
P09412079T0001|29 48|chronic stomach ulcers
P09413375A1486|2 12|ICU patients
P09413375A1486|17 26|LIS related
P09413375A1486|32 48|postoperative rise
P09413375A1486|51 59|IL-6 level
P09413375A1486|51 54|IL-6
P09413375A1486|84 103|plasma concentrations
P09413375A1486|106 114|cytokines
P09414074A0827|0 17|Resistance training
P09414074A0827|27 36|power curve
P09414074A0827|40 56|positive direction
P09414074A0827|64 75|measurements
P09414074A0827|93 105|absolute loads
P09414074A0827|150 172|absolute performance task
P09414074A0827|180 182|SSP
P09414287A0637|0 14|Gel-shift assays
P09414287A0637|28 42|Sp1 binding sites
P09414319A1442|0 5|Y15170
P09414319A1442|7 12|Surf-2
P09414319A1442|14 19|Surf-4
P09414319A1442|22 27|Y15171
P09414319A1442|29 34|Surf-3
P09414319A1442|36 41|Surf-1
P09414319A1442|43 48|Surf-6
P09414319A1442|54 59|Y15172
P09414319A1442|61 66|Surf-5
P09415711A1348|0 15|Gel mobility shift
P09415711A1348|19 35|super-shift assays
P09415711A1348|41 60|liver nuclear extracts
P09415711A1348|71 78|rat liver
P09415711A1348|81 93|DDT1MF-2 cells
P09415711A1348|113 115|CRE
P09415711A1348|121 134|alpha 1B-AR gene
P09415711A1348|140 156|CRE binding protein
P09416467A0959|5 11|results
P09416467A0959|30 46|experimental model
P09416467A0959|48 60|ACE inhibitors
P09416467A0959|48 50|ACE
P09416467A0959|69 79|arrhythmias
P09416467A0959|89 108|ischemia-reperfusion
P09416467A0959|112 138|free radical scavenging action
P09416467A0959|146 150|drugs
P09416467A0959|163 183|major contributory role
P09416467A0959|191 206|protective effect
P09416898A1798|3 12|mean values
P09416898A1798|28 37|components
P09416898A1798|69 80|ARVD patients
P09416898A1798|84 98|control subjects
P09417082A0127|11 26|signaling cascade
P09417082A0127|40 56|urokinase receptor
P09417108A0000|3 21|murine Htf9-a/RanBP1
P09417108A0000|9 14|Htf9-a
P09417108A0000|16 21|RanBP1
P09417108A0000|25 35|Htf9-c genes
P09417108A0000|66 88|shared TATA-less promoter
P09417493A0823|2 11|accordance
P09417493A0823|16 34|clinical improvement
P09417493A0823|53 72|laboratory indicators
P09417493A0823|75 86|inflammation
P09417493A0823|88 104|C-reactive protein
P09417493A0823|106 121|alpha 2-globuline
P09417493A0823|123 137|prostaglandin E2
P09417870A0105|28 36|depletion
P09417870A0105|39 52|protein kinase C
P09417870A0105|55 72|long-term treatment
P09417870A0105|75 95|B16 mouse melanoma cells
P09417870A0105|100 116|phorbol dibutyrate
P09417870A0105|118 121|PDBu
P09417870A0105|132 165|cell density-dependent melanogenesis
P09417928A0980|0 10|Replacement
P09417928A0980|13 20|residues
P09417928A0980|23 31|positions
P09417928A0980|35 43|His128Asn
P09417928A0980|48 49|+2
P09417928A0980|51 59|Gln155Lys
P09417928A0980|66 79|reading helices
P09417928A0980|82 88|fingers
P09417928A0980|117 123|binding
P09417941A1287|3 19|disulphide bridges
P09417941A1287|43 63|spermadhesin molecules
P09417941A1287|67 80|many CUB domains
P09417941A1287|91 96|loop LA
P09417941A1287|100 109|strand beta
P09417941A1287|114 120|loops LE
P09417941A1287|124 125|LG
P09417941A1287|142 154|opposite edges
P09417941A1287|160 167|same face
P09418040T0000|0 11|Mg-chelatase
P09418040T0000|39 54|Chl D cDNA sequence
P09418040T0000|64 75|third subunit
P09418040T0000|111 118|subunits
P09418040T0000|126 146|yeast two-hybrid system
P09418040T0000|151 164|reconstitution
P09418040T0000|170 183|enzyme activity
P09418040T0000|186 198|co-expression
P09418040T0000|201 215|recombinant CHL D
P09418040T0000|217 220|CHL H
P09418040T0000|224 228|CHL I.
P09418040T0000|224 227|CHL I
P09418057A0684|3 7|R-EST
P09418057A0684|14 29|Pto-like sequence
P09418057A0684|45 53|locations
P09418861A0623|3 22|multidomain structure
P09418861A0623|32 49|cysteine-rich motif
P09418861A0623|67 80|protein kinase C
P09418861A0623|84 94|n-chimaerin
P09418861A0623|99 130|putative pleckstrin homology domain
P09418861A0623|107 130|pleckstrin homology domain
P09418871A0620|21 23|DDB
P09418871A0620|27 30|E2F1
P09418871A0620|50 81|coimmunoprecipitation experiments
P09418882A0760|13 22|antibodies
P09418882A0760|40 60|epitope-tagged version
P09418882A0760|63 68|Prp42p
P09418882A0760|92 98|U1 snRNA
P09418882A0760|103 115|yeast extracts
P09418905A1396|5 11|results
P09418905A1396|36 58|Grb2-mediated activation
P09418905A1396|36 39|Grb2
P09418905A1396|61 63|Ras
P09418905A1396|65 96|PLC-gamma1-mediated DAG production
P09418905A1396|65 74|PLC-gamma1
P09418905A1396|110 112|EGF
P09418905A1396|117 140|PDGF-induced S-phase entry
P09418905A1396|117 120|PDGF
P09418905A1396|144 157|gene expression
P09418905A1396|174 183|activation
P09418905A1396|186 188|PKC
P09419415A0236|26 39|STAT activation
P09419415A0236|50 74|rodent fibroblast cell lines
P09419415A0236|94 117|diverse viral oncoproteins
P09419421A0385|2 22|serum-stimulated cells
P09419421A0385|27 33|binding
P09419421A0385|36 43|NF-Y/CBF
P09419421A0385|36 39|NF-Y
P09419421A0385|41 43|CBF
P09419421A0385|46 49|TKC1
P09419421A0385|78 84|plateau
P09419421A0385|90 95|S phase
P09419680A1112|0 9|CONCLUSION
P09419680A1112|16 26|animal model
P09419680A1112|28 55|blood-brain barrier disruption
P09419680A1112|60 71|reproducible
P09419680A1112|73 87|integral finding
P09419680A1112|90 104|single-fraction
P09419680A1112|106 131|high-dose irradiation injury
P09420219A0284|30 39|parameters
P09420219A0284|50 64|selective export
P09420219A0284|67 90|adenovirus-infected cells
P09420219A0284|106 134|marked human beta-actin minigene
P09420219A0284|155 195|glucocorticoid-inducible enhancer-promoter
P09420219A0284|198 219|mouse mammary tumor virus
P09420219A0284|242 248|left end
P09420219A0284|254 268|adenovirus type 5
P09420219A0284|254 267|adenovirus type
P09420219A0284|270 272|Ad5
P09420219A0284|274 279|genome
P09420220A0070|0 40|Cell factor-mediated regulatory interactions
P09420220A0070|67 86|restricted expression
P09420220A0070|92 115|HCMV major immediate-early
P09420220A0070|117 118|IE
P09420220A0070|125 126|J.
P09420234A0654|0 7|MpB GroEL
P09420234A0654|11 37|extensive sequence similarity
P09420234A0654|41 41|%
P09420234A0654|47 66|Escherichia coli GroEL
P09420234A0654|62 66|GroEL
P09420234A0654|70 81|other members
P09420234A0654|87 105|chaperonin-60 family
P09420239A1937|3 19|critical mutations
P09420239A1937|51 59|dispersed
P09420239A1937|70 79|elongation
P09420239A1937|85 86|TM
P09420239A1937|90 107|Nef coding sequences
P09420239A1937|109 115|changes
P09420239A1937|118 131|RNA splice donor
P09420239A1937|135 147|acceptor sites
P09420239A1937|149 160|TATA box sites
P09420239A1937|165 172|Sp1 sites
P09420239A1937|174 188|multiple changes
P09420239A1937|194 201|V2 region
P09420239A1937|204 205|SU
P09420239A1937|217 246|consensus neutralization epitope
P09420239A1937|255 283|new N-linked glycosylation sites
P09420239A1937|286 287|SU
P09420251A1363|0 1|C.
P09420252A0092|11 28|long terminal repeat
P09420252A0092|30 32|LTR
P09420252A0092|34 41|promoter
P09420252A0092|72 94|viral structural proteins
P09420252A0092|100 121|second internal promoter
P09420252A0092|123 129|located
P09420252A0092|150 156|env gene
P09420252A0092|184 205|viral auxiliary proteins
P09420269A0000|13 22|genomic RNA
P09420269A0000|25 36|rubella virus
P09420269A0000|38 40|RUB
P09420269A0000|51 63|14-nucleotide
P09420269A0000|65 66|nt
P09420269A0000|68 88|single-stranded leader
P09420269A0000|90 98|ss-leader
P09420269A0000|111 132|stem-and-loop structure
P09420269A0000|139 140|SL
P09420269A0000|143 144|nt
P09420269A0000|156 165|complement
P09420269A0000|188 202|minus-strand RNA
P09420269A0000|209 210|SL
P09420269A0000|240 247|promoter
P09420269A0000|251 259|synthesis
P09420269A0000|262 268|genomic
P09420269A0000|273 279|strands
P09420275A0682|16 27|requirements
P09420275A0682|31 41|CBF2 binding
P09420275A0682|31 34|CBF2
P09420275A0682|65 80|oligonucleotides
P09420275A0682|89 115|double transversion mutations
P09420275A0682|140 151|core sequence
P09420275A0682|155 178|outside flanking sequences
P09420275A1111|14 23|affinities
P09420275A1111|26 29|CBF2
P09420275A1111|45 49|LMP-1
P09420275A1111|51 55|LMP-2
P09420275A1111|60 72|CD23 promoters
P09420671A1190|0 10|CONCLUSIONS
P09420671A1190|15 30|myocardial uptake
P09420671A1190|33 46|99mTc sestamibi
P09420671A1190|49 62|normal subjects
P09420671A1190|66 73|patients
P09420671A1190|78 98|coronary artery disease
P09420671A1190|125 136|dipyridamole
P09420671A1190|141 155|adenosine stress
P09421507A0000|3 17|SR protein family
P09421507A0000|30 41|constitutive
P09421507A0000|45 69|regulated pre-mRNA splicing
P09421507A0000|114 130|metazoan organisms
P09421508A0696|26 30|TCF11
P09421508A0696|82 85|MafG
P09421508A0696|98 123|transient transfection assay
P09421511A0827|8 23|other comparisons
P09421511A0827|59 83|RNA-polymerase specificity
P09421511A0827|59 72|RNA-polymerase
P09421511A0827|86 112|telomerase RNA-gene promoters
P09421511A0827|146 161|template sequence
P09421511A0827|167 179|telomerase RNA
P09421516A1516|0 12|Deadenylation
P09421516A1516|16 20|decay
P09421516A1516|23 37|beta-globin mRNA
P09421516A1516|40 48|K562 cells
P09421516A1516|82 92|NIH 3T3 cells
P09421516A1516|137 151|beta-globin mRNA
P09421516A1516|154 162|K562 cells
P09421516A1516|186 202|deadenylation step
P09421521T0000|0 24|Holliday junction resolvase
P09421521T0000|54 82|identical endonuclease activity
P09421521T0000|88 104|CCE1 homologue YDC2
P09421521T0000|101 104|YDC2
P09422351A0000|0 2|Ca2
P09422351A0000|5 37|calmodulin-dependent protein kinase
P09422351A0000|41 44|CaMK
P09422351A0000|51 94|multifunctional serine/threonine protein kinase
P09422351A0000|66 94|serine/threonine protein kinase
P09422351A0000|108 118|ion channels
P09422351A0000|120 135|metabolic enzymes
P09422351A0000|137 156|cytoskeletal proteins
P09422351A0000|169 188|transcription factors
P09422727A0196|1 27|cAMP-responsive element-like
P09422727A0196|29 36|CRE-like
P09422727A0196|38 45|TGACGTGA
P09422727A0196|47 62|promoter sequence
P09422727A0196|67 96|protein kinase A signaling pathway
P09422727A0196|67 80|protein kinase A
P09422727A0196|114 122|induction
P09422727A0196|127 136|activation
P09422727A0196|143 159|CRE binding protein
P09422727A0196|161 164|CREB
P09422727A0196|179 199|transcription factor-2
P09422727A0196|201 205|ATF-2
P09422727A0196|222 233|above process
P09423123A0000|0 3|IVOX
P09423123A0000|16 22|acronym
P09423123A0000|26 48|intravascular oxygenator
P09423310A0251|0 18|Histopathologically
P09423310A0251|21 38|cystic lymphangioma
P09423310A0251|63 83|morphological features
P09423310A0251|90 117|immunohistochemical stainings
P09423310A0251|120 123|CD34
P09423310A0251|127 150|Factor VIII related antigen
P09423310A0251|127 132|Factor
P09423310A0251|137 150|related antigen
P09423310A0251|168 184|positive reactions
P09423310A0251|187 202|endothelial cells
P09423310A0251|208 212|cysts
P09423856A1098|0 17|Protease activities
P09423856A1098|20 27|cultures
P09423856A1098|33 52|streptococcal strains
P09423856A1098|80 103|different molecular masses
P09423856A1098|123 125|kDa
P09423856A1098|137 163|posttranslational processing
P09423856A1098|183 197|autoproteolysis
P09423856A1098|200 223|post-proline peptide bonds
P09423856A1098|229 243|N-terminal parts
P09423856A1098|249 257|molecules
P09423968A0039|22 34|such analgesia
P09423968A0039|98 130|interconnected motivational systems
P09423968A0039|164 182|developmental course
P09423968A0039|195 205|nociception
P09423968A0039|212 220|processes
P09423968A0039|239 251|early ontogeny
P09423968A0039|254 257|rats
P09424012A1774|5 29|large field placement errors
P09424012A1774|34 41|patients
P09424012A1774|57 67|mm distances
P09424012A1774|86 103|simulated isocenter
P09424012A1774|136 156|degree rotational error
P09424012A1774|183 195|smaller errors
P09425036A0649|25 39|inactive version
P09425036A0649|45 59|Src family member
P09425036A0649|61 63|Lck
P09425036A0649|65 82|lymphoid cell kinase
P09425036A0649|122 133|Csk substrate
P09425036A0649|122 124|Csk
P09425038A0752|0 1|A.
P09425038A0752|3 7|Swift
P09425038A0752|9 10|A.
P09425676A0000|0 17|Neuronal mechanisms
P09425676A0000|28 44|stimulus-response
P09425676A0000|46 48|S-R
P09425676A0000|50 61|associations
P09425676A0000|64 84|S-R compatibility tasks
P09425676A0000|102 112|experiments
P09425676A0000|117 123|monkeys
P09426068A0826|3 21|c-myc/TGF-alpha HCCs
P09426068A0826|3 7|c-myc
P09426068A0826|9 17|TGF-alpha
P09426068A0826|58 73|strong expression
P09426068A0826|76 84|TGF-alpha
P09426068A0826|92 108|low apoptotic index
P09426068A0826|121 130|high levels
P09426068A0826|133 141|apoptosis
P09426068A0826|144 162|peritumorous tissues
P09426068A0826|166 174|c-myc HCCs
P09426068A0826|166 170|c-myc
P09426143A1358|35 53|antagonistic effects
P09426143A1358|56 58|CRP
P09426143A1358|62 65|KdgR
P09426143A1358|86 102|pectinolysis genes
P09426143A1358|110 128|different mechanisms
P09426143A1358|139 155|direct competition
P09426143A1358|169 178|regulators
P09426143A1358|191 199|repressor
P09426143A1358|203 215|RNA polymerase
P09426143A1358|235 249|common DNA region
P09426143A1358|255 265|target genes
P09426183A0000|3 31|well-known Rel/NF-kappaB family
P09426183A0000|13 15|Rel
P09426183A0000|17 25|NF-kappaB
P09426183A0000|34 63|vertebrate transcription factors
P09426183A0000|113 120|proteins
P09426183A0000|134 139|dimers
P09426183A0000|169 187|subcellular location
P09426239A0386|3 11|cglIM gene
P09426239A0386|27 39|unusual operon
P09426239A0386|68 72|genes
P09426239A0386|81 114|stress-sensitive restriction enzymes
P09426595T0000|0 28|Lysine-ketoglutarate reductase
P09426595T0000|32 56|saccharopine dehydrogenase
P09426595T0000|61 79|Arabidopsis thaliana
P09426595T0000|81 98|nucleotide sequence
P09426595T0000|102 117|characterization
P09426907A0391|43 56|new formulation
P09426907A0391|59 76|silver sulfadiazine
P09426907A0391|80 94|water soluble gel
P09426907A0391|96 104|poloxamer
P09426958A0110|3 12|study goals
P09426958A0110|27 42|full-length clone
P09426958A0110|51 55|CO-Ag
P09426958A0110|61 84|bovine corneal cDNA library
P09426958A0110|101 105|clone
P09427544A0000|3 9|pel gene
P09427544A0000|16 26|Amycolata sp
P09427544A0000|37 48|pectate lyase
P09427544A0000|50 58|EC 4.2.2.2
P09427544A0000|50 51|EC
P09427544A0000|91 107|genomic DNA library
P09427544A0000|130 133|TK24
P09427551A0501|18 22|exons
P09427551A0501|41 49|kb introns
P09427551A0501|60 68|localized
P09427551A0501|74 89|murine chromosome
P09427551A0501|93 107|linkage analysis
P09427627A0802|2 15|Xenopus embryos
P09427627A0802|30 48|PDGF receptor protein
P09427627A0802|70 77|mesoderm
P09427627A0802|82 100|animal-pole explants
P09427627A0802|105 126|FK1012-dependent manner
P09427627A0930|1 16|cytosolic variant
P09427627A0930|38 66|efficient transphosphorylation
P09427627A0930|104 106|p70
P09427627A0930|108 110|S6k
P09427627A0930|114 122|MAP kinase
P09427627A0930|145 150|FK1012
P09427627T0000|0 20|Small-molecule control
P09427627T0000|0 13|Small-molecule
P09427627T0000|23 29|insulin
P09427627T0000|33 53|PDGF receptor signaling
P09427627T0000|33 44|PDGF receptor
P09427627T0000|66 83|membrane attachment
P09427844A0739|14 31|inactive dAK subunit
P09427844A0739|22 31|dAK subunit
P09427844A0739|76 78|dGK
P09427844A0739|81 90|dCK subunit
P09427844A0739|121 138|heterotropic affect
P09427844A0739|141 144|dGuo
P09427844A0739|147 150|dCyd
P09427844A0739|169 175|subunit
P09428389A1805|0 10|CONCLUSIONS
P09428389A1805|13 26|50-mg daily dose
P09428389A1805|29 40|bicalutamide
P09428389A1805|94 99|LHRH-A
P09428389A1805|94 97|LHRH
P09428389A1805|111 127|serum testosterone
P09428389A1805|132 142|higher doses
P09428389A1805|145 156|bicalutamide
P09428389A1805|188 198|monotherapy
P09428787A0138|1 12|genomic clone
P09428787A0138|41 42|kb
P09428787A0138|51 64|flanking region
P09428787A0138|71 79|first exon
P09428787A0138|85 108|p69/71 2-5A synthetase gene
P09428799A0897|30 36|smaller
P09428799A0897|44 53|human genes
P09428799A0897|57 81|other mitochondrial enzymes
P09428799A0897|86 108|intron/exon organization
P09428799A0897|141 147|P450scc
P09429913A0528|0 6|RESULTS
P09429913A0528|33 40|benefits
P09429913A0528|79 90|sound studies
P09429913A0528|104 111|efficacy
P09429913A0528|115 118|EMDR
P09429913A0528|127 135|disorders
P09429913A0528|150 168|psychiatric disorder
P09430461A0742|5 17|clinical study
P09430461A0742|22 31|defect size
P09430461A0742|39 50|BMIPP imaging
P09430461A0742|54 60|greater
P09430461A0742|63 70|anterior
P09430461A0742|77 92|inferior infarcts
P09430461A0742|94 94|p
P09430461A0742|126 133|risk area
P09430461A0742|144 167|contrast ventriculography
P09430461A0742|169 170|r =
P09430461A0742|176 176|p
P09430461A0742|185 194|CONCLUSION
P09430461A0742|204 218|preliminary data
P09430461A0742|235 244|small group
P09430461A0742|247 254|patients
P09430461A0742|267 289|tomographic BMIPP imaging
P09430461A0742|300 321|accurate quantification
P09430461A0742|324 333|defect size
P09430461A0742|336 340|means
P09430461A0742|344 367|simple threshold technique
P09430461A0742|377 389|subacute phase
P09430461A0742|424 433|myocardium
P09430461A0742|445 469|acute myocardial infarction
P09430661A0796|0 22|Transient overexpression
P09430661A0796|25 44|mutant EphB1 receptors
P09430661A0796|46 50|Y594F
P09430661A0796|59 72|Nck recruitment
P09430661A0796|59 61|Nck
P09430661A0796|75 79|EphB1
P09430661A0796|91 113|downstream JNK activation
P09430661A0796|101 103|JNK
P09430661A0796|125 147|cell attachment responses
P09430668A0172a|3 10|promoter
P09430668A0172a|14 28|HMG-CoA synthase
P09430668A0172a|47 51|sites
P09430668A0172a|58 96|sterol regulatory element-binding proteins
P09430668A0172a|98 103|SREBPs
P09430730A0374|0 1|S.
P09430730A0374|6 11|Walter
P09430730A0374|13 14|P.
P09431812A0576|21 22|Hh
P09431812A0576|26 32|Patched
P09431812A0576|34 36|Ptc
P09431812A0576|53 66|Ci binding sites
P09431812A0576|87 123|Ci-dependent transcriptional activation
P09431812A0576|126 132|S2 cells
P09431828A1472|14 27|median increase
P09431828A1472|30 45|cyclosporine DR/C
P09431828A1472|47 54|SS trough
P09431828A1472|61 64|l h-1
P09431828A1472|76 79|l h-1
P09431828A1472|77 79|h-1
P09431828A1472|81 98|interquartile range
P09432752A0109|0 7|Patients
P09432752A0109|16 24|relatives
P09432752A0109|47 86|available effective treatment possibilities
P09432752A0109|98 108|right moment
P09432752A0109|132 148|individual patient
P09434160A0767|0 13|Several PTPases
P09434160A0767|7 13|PTPases
P09434160A0767|42 72|5-FU-treated bone marrow stem cells
P09434160A2078|0 9|Expression
P09434160A2078|12 16|PTPRO
P09434160A2078|34 42|human CD34
P09434160A2078|44 58|bone marrow cells
P09434160A2078|62 97|5-FU-treated murine primitive stem cells
P09434185A0902|17 25|SPP1 genes
P09434185A0902|39 49|replication
P09434185A0902|51 62|DNA packaging
P09434185A0902|66 86|phage assembly proteins
P09434185A0902|113 117|genes
P09434185A0902|120 136|equivalent regions
P09434185A0902|154 177|double-stranded DNA phages
P09434979A0790|3 9|results
P09434979A0790|33 52|primary photon fluence
P09434979A0790|57 80|extra-focal photon fluence
P09434979A0790|88 104|primary collimator
P09434979A0790|132 132|%
P09434979A0790|136 136|%
P09434979A0790|142 150|isocenter
P09434979A0790|164 164|%
P09435056A0128|3 24|functional mature domain
P09435056A0128|27 43|pediocin AcH (Lys+1
P09435056A0128|27 37|pediocin AcH
P09435056A0128|39 41|Lys
P09435056A0128|46 48|Cys
P09435056A0128|79 87|machinery
P09435056A0128|104 112|periplasm
P09435056A0128|115 124|active form
P09435056A0128|146 157|COOH terminus
P09435056A0128|163 200|secretory protein maltose-binding protein
P09435056A0128|202 204|MBP
P09435116A0437|0 6|Isomers
P09435116A0437|35 43|MS-MS data
P09435116A0437|49 85|trofluoroacetyl-biphenylol derivatives
P09435789A0961a|8 12|RAD17
P09435789A0961a|14 18|RAD24
P09435789A0961a|22 25|MEC3
P09435789A0961a|43 57|cell cycle arrest
P09435789A0961a|62 67|S phase
P09435789A0961a|81 91|hydroxyurea
P09435789A0961a|93 94|HU
P09435789A0961a|118 126|viability
P09435789A0961a|129 138|yeast cells
P09435789A0961a|159 160|HU
P09435789A0961a|206 224|HU-induced DNA damage
P09435806T0001|0 12|Clinical value
P09435806T0001|18 27|estimation
P09435806T0001|30 43|growth kinetics
P09435806T0001|46 76|primary ovarian cancer recurrences
P09435806T0001|79 83|CA125
P09436657A0303|46 53|pathways
P09436657A0303|56 69|carcinogenesis
P09436657A0303|82 85|ways
P09436657A0303|109 119|risk factors
P09436706A0168|22 57|intracytoplasmic sperm injection cycles
P09436706A0168|62 88|thawed epididymal spermatozoa
P09436706A0168|104 113|pharmacist
P09436706A0168|124 141|ovarian stimulation
P09436706A0168|171 218|long-acting gonadotrophin-releasing hormone agonist
P09436706A0168|182 211|gonadotrophin-releasing hormone
P09436706A0168|220 234|leuprolide depot
P09436706A0168|239 252|gonadotrophins
P09436795A0350|0 17|Protein C deficiency
P09436795A0350|20 37|protein S deficiency
P09436795A0350|58 67|risk factor
P09436795A0350|74 74|%
P09436795A0350|77 84|patients
P09436795A0350|93 93|%
P09436795A0350|96 103|patients
P09436795A0350|128 135|children
P09436989A1011|34 50|essential function
P09436989A1011|53 63|late mitosis
P09436989A1011|65 68|MOB1
P09436989A1011|83 113|cell cycle reset function necessary
P09436989A1011|120 129|initiation
P09436989A1011|135 160|spindle pole body duplication
P09437001A0769|11 24|overproduction
P09437001A0769|27 31|Der3p
P09437001A0769|34 39|lethal
P09437001A0769|43 55|sec61-2 strain
P09437001A0769|43 49|sec61-2
P09437001A0769|61 81|permissive temperature
P09437001A0769|86 94|degrees C.
P09438165A0405|0 13|Normal baseline
P09438165A0405|15 19|day-8
P09438165A0405|21 28|PC levels
P09438165A0405|37 37|%
P09438165A0405|64 71|patients
P09438165A0405|83 98|VOD manifestation
P09438165A0405|132 132|%
P09438427A0727|22 31|CE2 element
P09438427A0727|44 58|Hoxa1 expression
P09438427A0727|44 48|Hoxa1
P09438427A0727|66 79|transgenic mice
P09438427A0727|106 140|Hoxa1 beta-galactosidase reporter gene
P09438427A0727|154 161|mutation
P09438427A0727|167 176|CE2 element
P09438427T0000|2 13|evolutionary
P09438427T0000|44 49|somite
P09438427T0000|53 81|adjacent mesenchymal expression
P09438427T0000|87 95|Hoxa1 gene
P09440166A0857|0 6|RESULTS
P09440166A0857|11 34|bovine cDNA insert sequence
P09440166A0857|41 51|nucleotides
P09440166A0857|66 75|entire mRNA
P09440166A0857|92 102|nucleotides
P09440166A0857|110 127|untranslated region
P09440166A0857|131 141|nucleotides
P09440166A0857|149 166|untranslated region
P09440166A0857|171 174|poly
P09440166A0857|176 176|A
P09440616A0422|20 29|activities
P09441664A0377|27 59|liver-enriched transcription factor
P09441664A0377|61 65|HNF-6
P09441664A0377|85 109|HNF-3 beta promoter activity
P09441664A0377|85 101|HNF-3 beta promoter
P09441664A0377|130 145|regulatory region
P09441664A0377|148 179|numerous hepatocyte-specific genes
P09441746A0546|1 9|cDNA clone
P09441746A0546|32 54|second GHS-R-related gene
P09441746A0546|38 54|GHS-R-related gene
P09441746A0546|56 60|GPR39
P09442017A0435|6 12|Science
P09442024A0236|0 1|P.
P09442024A0236|3 8|Peyron
P09442024A0236|10 11|J.
P09442024A0708|1 14|hybridoma clone
P09442024A0708|16 18|7H1
P09442024A0708|36 41|fusion
P09442024A0708|49 57|CEMLAI/NP
P09442024A0708|61 94|human embryonic fibroblasts MRC5 cells
P09442024A0708|107 118|large amounts
P09442024A0708|121 123|P47
P09442024A0708|144 156|Jacalin lectin
P09442024A0708|169 177|O-glycans
P09442031A0586|28 37|estimation
P09442031A0586|67 81|subunit relative
P09442031A0586|93 133|C-terminal truncated TSHR ectodomain variants
P09442031A0586|93 102|C-terminal
P09442031A0586|112 133|TSHR ectodomain variants
P09442031A0586|135 152|places cleavage Site
P09442031A0586|159 166|vicinity
P09442031A0586|179 186|upstream
P09442031A0586|190 196|residue
P09442072A0716|7 12|DNase I
P09442072A0716|7 11|DNase
P09442072A0716|13 24|footprinting
P09442072A0716|30 49|200-bp proximal region
P09442072A0716|55 62|promoter
P09442072A0716|68 77|murine Hepa
P09442072A0716|81 98|cell nuclear extract
P09442072A0716|108 121|clear footprint
P09442072A0716|154 155|bp
P09442072A0716|161 174|murine fVII gene
P09442072A0716|190 201|liver factors
P09442080A0856|1 22|reciprocal binding assay
P09442080A0856|28 36|IM-9 cells
P09442080A0856|48 52|SHP-1
P09442080A0856|56 60|SHP-2
P09442080A0856|69 87|specific association
P09442080A0856|90 94|SHP-2
P09442080A0856|102 106|SHP-1
P09442080A0856|113 142|glutathione S-transferase fusion
P09442080A0856|113 136|glutathione S-transferase
P09442080A0856|156 183|GHR cytoplasmic domain residues
P09442080A0856|204 209|fusion
P09442080A0856|226 248|tyrosine-phosphorylated
P09442172A0908|14 21|basal FSH
P09442172A0908|19 21|FSH
P09442172A0908|68 89|total gonadotrophin dose
P09442172A0908|73 85|gonadotrophin
P09442172A0908|109 115|oocytes
P09442172A0908|128 140|pregnancy rate
P09443948A0000|1 16|comparative study
P09443948A0000|39 75|enzymatic immunohistochemical technique
P09443948A0000|77 79|EIT
P09443948A0000|107 125|human trichinellosis
P09443948A0000|132 161|indirect immunofluorescence test
P09443948A0000|163 165|IIF
P09443948A0000|177 180|sera
P09443948A0000|185 193|outbreaks
P09443948A0000|196 214|human trichinellosis
P09443948A0000|217 225|Argentina
P09443972A1145|3 9|results
P09443972A1145|19 22|GKLF
P09443972A1145|26 67|sequence-specific transcription factor likely
P09443972A1145|102 116|endogenous genes
P09443973A1028|0 3|CES4
P09443973A1028|7 22|multicopy plasmid
P09443973A1028|42 50|tif1-A79V
P09443978A0262|26 30|cells
P09443978A0262|57 64|human Sp1
P09443978A0262|85 97|transcription
P09443978A0262|102 119|synthetic promoters
P09443978A0262|130 138|TATA boxes
P09443978A0262|150 158|promoters
P09443978A0262|172 180|initiator
P09443978A0262|191 197|TATA box
P09444316A0388|2 32|apparent clinical signs indicative
P09444316A0388|35 50|systemic toxicity
P09444316A0388|68 69|F0
P09444316A0388|73 81|F1 animals
P09445056A0215|10 47|mutation-directed chemical cross-linking
P09445056A0215|52 54|bis
P09445056A0215|56 72|sulfosuccinimidyl
P09445056A0215|74 81|suberate
P09445056A0215|83 85|BS3
P09445056A0215|120 131|gp41 oligomer
P09445488A0230|23 38|USH1C disease gene
P09445488A0230|74 80|markers
P09445488A0230|83 108|yeast artificial chromosomes
P09445488A0230|110 113|YACs
P09445488A0230|134 150|STS content mapping
P09445488A0230|154 173|Alu-PCR hybridization
P09445488A0230|154 156|Alu
P09445488A1169|0 17|PowerBLAST analysis
P09445488A1169|31 38|clusters
P09445488A1169|50 61|sequence tags
P09445488A1169|63 66|ESTs
P09445488A1169|72 81|known genes
P09445488A1169|83 85|BIR
P09445488A1169|87 90|SUR1
P09445488A1169|151 166|unmapped gene NEFA
P09445488A1169|159 166|gene NEFA
P09445488A1169|168 206|DNA binding/EF hand/acidic amino-acid-rich
P09446600A0260|1 13|fusion protein
P09446600A0260|24 41|beta-galactosidase
P09446600A0260|45 58|full-length Ahr
P09446600A0260|78 86|cytoplasm
P09446600A0260|92 98|nucleus
P09446600A0260|102 123|ligand-dependent manner
P09446616A0780|0 13|Reconstitution
P09446616A0780|16 28|Raf-1 activity
P09446616A0780|16 20|Raf-1
P09446616A0780|48 63|kinase active Jak1
P09446616A0780|60 63|Jak1
P09446616A0780|70 78|cell lines
P09446815A1021|21 36|regulatory region
P09446815A1021|61 62|bp
P09447917A0000|15 21|Geisler
P09447917A0000|23 30|Brain Res
P09447962A0452|3 18|second transcript
P09447962A0452|20 25|rhis4l
P09447962A0452|29 39|bicistronic
P09447962A1027|0 9|Consistent
P09447962A1027|34 43|mutant form
P09447962A1027|46 49|XRN1
P09447962A1027|69 79|exonuclease
P09447962A1027|98 117|extragenic suppressor
P09447962A1027|134 142|half-life
P09447962A1027|145 153|rhis4 mRNA
P09447962A1027|165 179|10-fold increase
P09447962A1027|182 203|steady-state mRNA levels
P09447962A1027|217 238|wild-type HIS4 mRNA level
P09447962A1027|217 233|wild-type HIS4 mRNA
P09447963A0223|0 3|Sip1
P09447963A0223|54 57|SC35
P09447963A0223|60 73|splicing factor
P09447963A0223|79 86|SR family
P09447973A0168|0 9|Consistent
P09447973A0168|14 28|previous reports
P09447973A0168|41 60|myristoylation signal
P09447973A0168|63 67|mSos1
P09447973A0168|69 75|MyrSos1
P09447973A0168|102 112|NIH 3T3 cells
P09447973A0168|116 123|deletion
P09447973A0168|129 141|mSos C terminus
P09447973A0168|143 156|MyrSos1-deltaC
P09447979A1430|0 12|Such mutations
P09447979A1430|35 51|dominant phenotype
P09447979A1430|54 66|sequestration
P09447979A1430|72 102|guanine nucleotide exchange factor
P09447979A1430|104 107|GNEF
P09447994A0000|0 13|Several studies
P09447994A0000|34 57|upstream regulatory region
P09447994A0000|60 64|c-fos
P09447994A0000|79 96|cis-acting elements
P09447994A0000|106 136|cyclic AMP (cAMP) response elements
P09447994A0000|106 114|cyclic AMP
P09447994A0000|116 119|cAMP
P09447994A0000|121 136|response elements
P09447994A0000|138 141|CREs
P09447994A0000|161 178|c-fos transcription
P09447994A0000|161 165|c-fos
P09447994A0000|201 220|extracellular stimuli
P09448268A0186|13 18|kinase
P09448268A0186|20 22|Nlk
P09448268A0186|31 43|murine homolog
P09448268A0186|49 62|Drosophila nemo
P09448268A0186|64 66|nmo
P09448574A0964|3 10|findings
P09448574A0964|22 32|striatal FDG
P09448574A0964|48 52|RACLO
P09448574A0964|68 84|effective measures
P09448574A0964|87 102|striatal function
P09448574A0964|127 134|patients
P09448574A0964|139 159|multiple system atrophy
P09449018T0000|0 19|Childhood misbehavior
P09449018T0000|41 47|drug use
P09450932A0142|0 14|Genetic analysis
P09450932A0142|40 50|subpathways
P09450932A0142|56 78|DNA structure checkpoints
P09450932A0142|92 107|reversible arrest
P09450932A0142|110 121|DNA synthesis
P09451003A0894|5 21|Esigma54 promoters
P09451003A0894|25 34|responsive
P09451003A0894|37 39|CRP
P09451003A0894|42 57|protein unrelated
P09451003A0894|60 76|sigma54 activators
P09451003A0894|84 93|repression
P09451003A0894|106 117|direct result
P09451003A0894|140 147|Esigma54
P09451003A0894|154 168|CRP-cAMP complex
P09451003A0894|154 156|CRP
P09451016A1037|0 5|GlcNAc
P09451016A1037|10 40|GlcNAc2-PP-Dolichol biosynthesis
P09451016A1037|77 85|membranes
P09451016A1037|90 94|cells
P09451016A1037|107 124|recombinant plasmid
P09451016A1037|135 141|glucose
P09451016A1037|157 169|transcription
P09451016A1037|175 188|endogenous gene
P09451857T0001|0 12|Demonstration
P09451857T0001|15 27|tissue lesions
P09451857T0001|33 54|intramuscular injection
P09451857T0001|72 85|creatine kinase
P09452421A1042|0 9|Antibodies
P09452421A1042|23 31|GST mSH2-B
P09452421A1042|43 57|cellular protein
P09452421A1042|62 64|kDa
P09452421A1042|100 102|Tyr
P09452444A0000|0 12|Interleukin-6
P09452444A0000|14 17|IL-6
P09452444A0000|22 40|pleiotropic cytokine
P09452444A0000|59 70|inflammatory
P09452444A0000|74 88|immune responses
P09452444A0000|90 108|acute phase reactions
P09452444A0000|113 125|hematopoiesis
P09452444A0450|14 28|various deletion
P09452444A0450|32 52|point-mutated variants
P09452444A0450|58 78|human IL-6 gene promoter
P09452444A0450|89 100|reporter gene
P09452444A0450|134 153|transcription factors
P09453537A0863|28 36|CCAATC box
P09453537A0863|42 58|reverse complement
P09453537A0863|62 75|several GC boxes
P09453537A0863|83 98|recognition sites
P09453537A0863|102 104|SP1
P09453689A0000|26 39|intact perianal
P09453689A0000|41 44|S4-5
P09453689A0000|46 57|pin sensation
P09453689A0000|59 61|PPS
P09453689A0000|66 80|bulbocavernosus
P09453689A0000|82 85|S2-4
P09453689A0000|87 92|reflex
P09453689A0000|94 96|BCR
P09453689A0000|110 125|spinal cord injury
P09453689A0000|127 129|SCI
P09453689A0000|134 143|predictive
P09453689A0000|146 168|bladder function recovery
P09454719A0181|3 20|correct termination
P09454719A0181|23 43|retroviral transcripts
P09454719A0181|51 65|LTR R/U5 junction
P09454719A0181|91 126|canonical AAUAAA polyadenylation signal
P09454719A0181|166 195|polyadenylation signal sequences
P09454719A0181|201 210|properties
P09454719A0181|214 245|selectable murine retroviral vector
P09454735A1782|0 5|Levels
P09454735A1782|11 29|MEK inhibitor PD98059
P09454735A1782|11 13|MEK
P09454735A1782|39 60|EGF-induced mitogenesis
P09454735A1782|39 41|EGF
P09454735A1782|64 87|MAP kinase phosphorylation
P09454735A1782|64 72|MAP kinase
P09454735A1782|100 134|EGF-induced focal adhesion disassembly
P09454735A1782|100 102|EGF
P09454735A1782|138 149|cell motility
P09455695A0762|0 8|ALT levels
P09455695A0762|0 2|ALT
P09455695A0762|11 20|responders
P09455695A0762|36 36|%
P09455695A0762|40 48|AST levels
P09455695A0762|64 64|%
P09455695A0762|72 76|weeks
P09455695A0762|79 95|vitamin E treatment
P09456312A1064|16 34|COOH-terminal domain
P09456312A1064|37 43|RanGAP1
P09456312A1064|65 89|nuclear localization signal
P09458021A1373|4 4|%
P09458021A1373|6 7|P=
P09458021A1373|20 22|MMF
P09458021A1373|32 40|AZA groups
P09458030A0192|43 45|MMF
P09458030A0192|54 74|bone mineral metabolism
P09459241A0707|0 3|Pao2
P09459241A0707|27 29|kPa
P09459241A0707|39 42|mm Hg
P09459241A0707|56 58|kPa
P09459241A0707|68 71|mm Hg
P09459241A0707|74 74|P
P09459685T0001|0 20|Typical configurations
P09459685T0001|23 47|psychosocial stress factors
P09459685T0001|65 83|conspicuous children
P09459685T0001|87 97|adolescents
P09459835A0297|4 7|cats
P09459835A0297|16 19|PMEA
P09459835A0297|23 28|dosage
P09459835A0297|33 47|mg/kg body weight
P09459835A0297|53 56|cats
P09459835A0297|65 69|FPMPA
P09459835A0297|73 78|dosage
P09459835A0297|83 97|mg/kg body weight
P09460171T0000|0 9|Resistance
P09460171T0000|12 25|thyroid hormone
P09460171T0000|27 38|implications
P09460171T0000|42 67|neurodevelopmental research
P09460171T0000|73 79|effects
P09460171T0000|82 105|thyroid hormone disruptors
P09461594A0000|36 53|DT40 lymphoma B cells
P09461594A0000|56 84|low energy electromagnetic field
P09461594A0000|86 88|EMF
P09461594A0000|100 133|tyrosine kinase-dependent activation
P09461594A0000|100 113|tyrosine kinase
P09461594A0000|136 155|phospholipase Cgamma2
P09461594A0000|157 166|PLC-gamma2
P09461594A0000|186 213|inositol phospholipid turnover
P09463174A0670|12 29|preliminary results
P09463174A0670|42 49|patients
P09463174A0670|71 80|mean period
P09463174A0670|85 90|months
P09463380A1050|9 15|xTAK1KN
P09463380A1050|41 66|ventral mesoderm marker genes
P09463380A1050|76 80|Smad1
P09463560A0124|0 7|PATIENTS
P09463560A0124|11 16|METHOD
P09463560A0124|30 37|patients
P09463560A0124|42 51|irradiated
P09463964A0243|3 7|assay
P09463964A0243|17 28|dynamic range
P09463964A0243|38 50|micrograms l-1
P09463964A0243|57 74|monoclonal antibody
P09463964A0243|92 104|micrograms l-1
P09463964A0243|109 113|mg l-1
P09463964A0243|131 148|available antiserum
P09463991T0000|11 15|audit
P09464248A0289|1 16|canonical TATA box
P09464525T0000|0 9|Expression
P09464525T0000|13 28|characterization
P09464525T0000|31 55|recombinant single-chain Fv
P09464525T0000|59 69|Fv fragments
P09464525T0000|87 105|catalytic antibodies
P09465035A1032|1 17|putative inhibitor
P09465035A1032|19 19|s
P09465035A1032|43 58|inactive fraction
P09465035A1032|73 73|L
P09465035A1032|75 79|alpha
P09465783A0449|0 18|Platelet aggregation
P09465783A0449|33 53|micrograms collagen/ml
P09465783A0449|43 50|collagen
P09465783A0449|68 75|parallel
P09465783A0449|94 96|ASA
P09466267A1192|5 15|himA mutants
P09466267A1192|32 34|IHF
P09466267A1192|50 78|molybdate-dependent regulation
P09466267A1192|81 99|dmsA-lacZ expression
P09466267A1192|81 84|dmsA
P09466267A1192|86 89|lacZ
P09466931T0000|0 12|Cross-talking
P09466931T0000|18 43|Drosophila nuclear receptors
P09466931T0000|28 43|nuclear receptors
P09466931T0000|49 74|promiscuous response element
P09466931T0000|80 83|ng-1
P09466931T0000|87 104|ng-2 intermolt genes
P09467044A0973|3 35|ipsilateral breast tumor relapse rate
P09467044A0973|56 59|PALP
P09467044A0973|63 73|MGDET groups
P09467707T0000|0 17|Sibling aggregation
P09467707T0000|27 60|high-density lipoprotein cholesterol
P09467707T0000|64 79|apolipoproteins B
P09467707T0000|83 91|A-I levels
P09467707T0000|83 85|A-I
P09467707T0000|102 114|white children
P09467707T0000|119 136|Bogalusa Heart Study
P09467900A0701|3 15|CAPLC1 protein
P09467900A0701|29 49|several unique features
P09467900A0701|61 72|novel stretch
P09467900A0701|80 96|amino acid residues
P09467900A0701|106 112|X domain
P09467900A0701|127 140|long N-terminus
P09467900A0701|160 180|recognizable EF-hand Ca
P09467900A0701|186 198|binding domain
P09467955A0468|33 42|occurrence
P09467955A0468|45 60|PEA3 binding sites
P09467955A0468|66 77|PEA3 promoter
P09467955A0468|97 100|PEA3
P09467955A0468|120 127|promoter
P09468386A0594|0 4|Pet-1
P09468386A0594|27 49|PEA3 ETS DNA-binding motif
P09468386A0594|64 76|transcription
P09468386A0594|79 105|synthetic promoter constructs
P09468386A0594|109 131|sequence-specific manner
P09468509A0463|21 29|F2771 cDNA
P09468509A0463|43 50|COS cells
P09468509A0463|53 61|localized
P09468509A0463|67 75|cytoplasm
P09468514A1065|0 15|Northern analysis
P09468514A1065|25 46|differential expression
P09468514A1065|59 75|highest expression
P09468515A0621|7 21|further deletion
P09468515A0621|27 40|promoter region
P09468515A0621|43 52|nucleotide
P09468515A0621|78 92|SF-1 binding site
P09468515A0621|128 140|exogenous SF-1
P09468515A0621|137 140|SF-1
P09469415A1337|18 23|beta 2m
P09469415A1337|46 52|peptide
P09469415A1337|73 91|CTL target structures
P09469415A1337|105 120|new possibilities
P09469415A1337|133 141|induction
P09469415A1337|144 171|epitope-specific CTL responses
P09469415A1337|180 194|DNA immunization
P09469415A1337|197 205|injection
P09469415A1337|219 238|epitope-linked beta 2m
P09469415A1337|233 238|beta 2m
P09469820A0151|3 7|mRNAs
P09469820A0151|15 19|genes
P09469820A0151|43 50|YAP1 uORF
P09469820A0151|59 67|YAP2 uORF1
P09469820A0151|71 75|uORF2
P09469820A0151|85 101|open reading frames
P09469820A0151|103 125|uORF-mediated modulation
P09469820A0151|128 149|post-termination events
P09469820A0151|158 175|untranslated region
P09469820A0151|180 182|UTR
P09469820A0151|191 209|differential control
P09469820A0151|239 247|mRNA decay
P09469833A0533|34 48|site specificity
P09469833A0533|55 69|deletion mutants
P09469833A0533|78 87|bp sequence
P09469933A1060|5 11|tissues
P09469933A1060|44 51|CLIP-170
P09469933A1060|59 66|abundant
P09469933A1060|78 83|Restin
P09471984A0000|0 9|BACKGROUND
P09471984A0000|11 19|Chemicals
P09471984A0000|43 58|intrinsic ability
P09471984A0000|66 90|allergic contact dermatitis
P09472038T0000|0 23|Cytoskeletal polarization
P09472038T0000|26 31|T cells
P09472038T0000|47 108|immunoreceptor tyrosine-based activation motif-dependent mechanism
P09472608A0253|33 51|cellular protein YB-1
P09472608A0253|62 74|transcription
P09472608A0253|80 92|HIV-1 promoter
P09472608A0253|96 118|human astrocytic cell line
P09472608A0253|120 125|U-87MG
P09472608A0253|129 144|neuronal cell line
P09472608A0253|146 152|SK-N-MC
P09472608A0253|157 169|lymphoid cells
P09472608A0253|171 176|Jurkat
P09472608A0253|180 196|transfection assay
P09472616A1004|15 24|amino acids
P09472616A1004|30 45|antigenic regions
P09472616A1004|48 48|B
P09472616A1004|52 52|C
P09472616A1004|55 57|VP7
P09472616A1004|86 105|phylogenetic lineages
P09473040A1303a|9 16|alcR gene
P09473040A1303a|27 31|trans
P09473040A1303a|45 71|siderophore system activities
P09473040A1303a|77 83|mutants
P09473040A1303b|9 16|alcR gene
P09473040A1303b|27 31|trans
P09473040A1303b|45 71|siderophore system activities
P09473040A1303b|77 83|mutants
P09473317X2131|0 8|Copyright
P09473317X2131|13 25|Academic Press
P09473483A0953|24 37|particular care
P09473483A0953|60 82|trans-dominant Rev mutant
P09473483A0953|106 119|genetic therapy
P09473483A0953|127 140|HIV-I infection
P09473483A0953|144 154|individuals
P09473483A0953|171 175|HIV-I
P09473483A0953|179 184|HTLV-1
P09473755A0318|0 7|PATIENTS
P09473755A0318|11 17|METHODS
P09473755A0318|26 32|January
P09473755A0318|40 43|June
P09473755A0318|50 52|St.
P09474001A0825|14 16|SPs
P09474001A0825|38 49|severe groups
P09474001A0825|66 71|higher
P09474001A0825|82 89|patients
P09474001A0825|95 105|normal MMFCV
P09474001A0825|107 107|p
P09474001A0825|119 122|arms
P09474001A0825|128 138|normal MMFCV
P09474001A0825|147 147|%
P09474001A0825|154 155|SP
P09474648A0298|13 19|P-SAECG
P09474648A0298|32 46|frequency domain
P09474648A0298|51 58|patients
P09474648A0298|63 65|Paf
P09474648A0298|71 78|controls
P09475378A1449|0 54|Competitive reverse transcription-polymerase chain reaction
P09475378A1449|58 69|HPLC analysis
P09475378A1449|80 90|RUSH-1alpha
P09475378A1449|96 130|progesterone-dependent splice variant
P09475724T0000|0 3|TOR2
P09475724T0000|15 38|related signaling pathways
P09475724T0000|51 60|cell growth
P09475898T0000|0 25|Transcervical amnioinfusion
P09476399A0141|20 37|large tea plantation
P09476399A0141|40 44|Kandy
P09476520A1326|0 11|Simple models
P09476520A1326|14 35|bimolecular interaction
P09476520A1326|60 74|kinetic profiles
P09476520A1326|90 107|parental antibodies
P09476520A1326|114 120|hybrids
P09476520A1326|163 189|conformational heterogeneity
P09476520A1326|197 205|molecules
P09477316A0140|20 26|pathway
P09477316A0140|38 53|Hox gene induction
P09477316A0140|38 44|Hox gene
P09477316A0140|81 96|Hox gene regulator
P09477316A0140|101 139|leucine zipper transcription factor MafB/Kr
P09477316A0140|133 136|MafB
P09477316A0140|138 139|Kr
P09477316A0140|180 199|environmental signals
P09478921A0126|0 9|Substrates
P09478921A0126|13 16|p210
P09478921A0126|18 24|bcr-abl
P09478921A0126|18 20|bcr
P09478921A0126|22 24|abl
P09478921A0126|52 63|pathogenesis
P09478921A0126|66 68|CML
P09478971A1896|0 17|Reporter constructs
P09478971A1896|29 42|parallel manner
P09478971A1896|60 66|key role
P09478971A1896|72 74|AhR
P09478971A1896|77 88|constitutive
P09478971A1896|97 118|TCDD-induced expression
P09478971A1896|121 126|Cyp1B1
P09478971A1896|129 150|mouse embryo fibroblasts
P09478976A0718|0 18|Transfection studies
P09478976A0718|36 43|deletion
P09478976A0718|46 54|sequences
P09478976A0718|70 93|transcriptional start site
P09478976A0718|117 119|OSM
P09478976A0718|121 133|fold induction
P09478976T0000|0 10|Oncostatin M
P09478976T0000|21 25|c-Fos
P09478976T0000|50 70|responsive AP-1 element
P09478976T0000|60 70|AP-1 element
P09478976T0000|80 94|tissue inhibitor
P09478976T0000|97 123|metalloproteinase-1 promoter
P09479498A0000|15 37|new human RING-finger gene
P09479498A0000|39 42|RNF4
P09479498A0000|56 76|190-amino-acid protein
P09480831A0272|14 32|regulatory mechanism
P09480831A0272|35 55|human AM gene expression
P09480831A0272|35 45|human AM gene
P09480831A0272|57 74|functional elements
P09480831A0272|80 93|flanking region
P09480831A0272|96 101|AM gene
P09480831A0272|115 141|human aortic endothelial cells
P09480831A0272|143 146|HAEC
P09480843A0848|3 21|COOH-terminal region
P09480843A0848|27 37|transcripts
P09480843A0848|54 67|triplet repeats
P09480843A0848|69 71|GCT
P09480843A0848|73 79|alanine
P09480843A0848|83 92|nucleotide
P09480843A0848|143 149|rat RL14
P09480929T0000|0 30|Soluble FasR ligand-binding domain
P09480929T0000|7 10|FasR
P09480929T0000|32 51|high-yield production
P09480929T0000|54 65|active fusion
P09480929T0000|69 97|non-fusion recombinant proteins
P09480929T0000|106 133|baculovirus/insect cell system
P09481826T0000|0 6|Control
P09481826T0000|9 26|fatty liver syndrome
P09481826T0000|30 39|Jersey herd
P09481826T0000|66 95|recombinant bovine somatotrophin
P09481826T0000|83 95|somatotrophin
P09482107A0551|3 12|inhibition
P09482107A0551|15 28|focus formation
P09482107A0551|52 54|C3G
P09482107A0551|66 77|toxic effects
P09482107A0551|80 92|cell viability
P09482107A0551|110 117|C3G cells
P09482107A0551|110 112|C3G
P09482107A0551|130 141|same survival
P09482107A0551|145 155|growth rates
P09482107A0551|158 181|untransfected NIH3T3 cells
P09482107A0551|184 188|cells
P09482107A0551|204 216|plasmid vector
P09482902A0423|0 7|C.D2-Chr
P09482902A0423|9 23|congenic strains
P09482902A0423|33 44|DBA/2 alleles
P09482902A0423|62 71|Pctr1 locus
P09482902A0423|81 85|DBA/2
P09482902A0423|87 95|resistant
P09482902A0423|97 103|alleles
P09482902A0423|109 130|CDK4/CDK6 inhibitors p16
P09482902A0423|109 112|CDK4
P09482902A0423|114 117|CDK6
P09482902A0423|128 130|p16
P09482902A0423|134 136|p15
P09482902A0942|14 22|wild-type
P09482902A0942|24 28|DBA/2
P09482902A0942|30 32|p16
P09482902A0942|38 42|A134C
P09482902A0942|46 73|G232A BALB/c-specific variants
P09482902A0942|56 73|c-specific variants
P09482902A0942|76 78|p16
P09482902A0942|83 93|inefficient
P09482902A0942|130 142|cyclin D2/CDK4
P09482902A0942|130 137|cyclin D2
P09482902A0942|139 142|CDK4
P09482902A0942|145 156|kinase assays
P09482902A0942|161 181|retinoblastoma protein
P09482902A0942|197 205|defective
P09482902A0942|216 221|allele
P09482902A0942|229 241|important role
P09482902A0942|247 267|genetic susceptibility
P09482902A0942|270 279|BALB/c mice
P09482902A0942|283 303|plasmacytoma induction
P09482902A0942|311 313|p16
P09482902A0942|315 319|INK4a
P09482902A0942|324 338|strong candidate
P09482902A0942|345 354|Pctr1 locus
P09483596A0626|46 55|conditions
P09483596A0626|73 87|excellent/5 good
P09483596A0626|93 110|suxamethonium group
P09483596A0626|116 130|excellent/3 good
P09483596A0626|136 150|rocuronium group
P09484463T0000|0 6|Cloning
P09484463T0000|25 29|genes
P09484463T0000|38 58|auxin-binding proteins
P09484781A1233|12 28|direct association
P09484781A1233|33 56|D3 phosphatidylinositides
P09484781A1233|78 87|activation
P09484781A1233|90 96|PKB/Akt
P09484781A1233|90 92|PKB
P09484781A1233|94 96|Akt
P09485308A1165|3 11|FMN moiety
P09485308A1165|22 27|3Fe-4S
P09485308A1165|41 47|subunit
P09485790T0000|0 22|Alison Bell Memorial Award
P09486035A0051|0 6|METHODS
P09486035A0051|9 24|population survey
P09486035A0051|46 56|individuals
P09486035A0051|69 78|prevalence
P09486035A0051|93 98|causes
P09486035A0051|101 109|blindness
P09486035A0051|112 118|Lebanon
P09486531A0638|6 18|organogenesis
P09486531A0638|20 34|HFH-8 expression
P09486531A0638|20 24|HFH-8
P09486531A0638|47 64|splanchnic mesoderm
P09486531A0638|67 81|close apposition
P09486531A0638|87 97|gut endoderm
P09486531A0638|116 146|mesenchymal-epithelial induction
P09486531A0638|156 171|gut morphogenesis
P09486890A0234|8 18|laparoscopy
P09486890A0234|36 48|inoperability
P09486890A0234|54 58|cases
P09486890A0234|61 75|carcinoma spread
P09486890A0234|78 82|areas
P09486890A0234|98 122|laparoscopic visualization
P09487130A0383|14 27|telomere length
P09487130A0383|37 43|mutants
P09487130A0383|69 72|Cdc2
P09487130A0383|90 105|DNA repair mutants
P09487130A0383|125 139|longer telomeres
P09487130A0383|150 157|wild type
P09487590A0657|3 14|mean duration
P09487590A0657|17 26|pain relief
P09487590A0657|33 37|weeks
P09487841A0132|3 6|ESEM
P09487841A0132|18 32|conventional SEM
P09487841A0132|41 57|sample preparation
P09487841A0132|78 95|artifactual changes
P09488441A0615|0 2|Sp1
P09488441A0615|14 26|transcription
P09488441A0615|34 66|immunoglobulin kappa-chain enhancer
P09488441A0615|69 100|P-selectin promoter NF-kappaB sites
P09488441A0615|102 114|p50 homodimers
P09488441A0615|102 104|p50
P09488441A0615|122 124|Sp1
P09488441A0615|132 149|P-selectin promoter
P09488441A0615|159 173|site competition
P09488441A0615|197 221|basal Sp1-driven expression
P09488441A0615|202 204|Sp1
P09488441A0615|238 242|Bcl-3
P09488466A0695|35 49|full-length mRNA
P09488466A0695|63 87|actinomycin D-treated cells
P09488466A0695|100 128|precursor-product relationship
P09488486A0000|3 24|TATA box-binding protein
P09488486A0000|26 28|TBP
P09488486A0000|37 49|essential role
P09488486A0000|52 64|transcription
P09488486A0000|75 117|eukaryotic nuclear RNA polymerases, polymerases
P09488486A0000|75 105|eukaryotic nuclear RNA polymerases
P09488486A0000|107 117|polymerases
P09488486A0000|119 121|Pol
P09488486A0000|131 133|III
P09488486A0906|1 16|triple-mutant TBP
P09488486A0906|18 22|R231E
P09488486A0906|24 28|R235E
P09488486A0906|30 34|R239S
P09488486A0906|64 92|yeast U6 snRNA gene transcription
P09488486A0906|116 120|Pol II
P09488486A0906|116 118|Pol
P09488486A0906|121 138|basal transcription
P09488491A0000|0 10|E2F activity
P09488491A0000|0 2|E2F
P09488491A0000|33 52|retinoblastoma family
P09488491A0000|55 77|tumor suppressor proteins
P09488713A0886|15 32|complete inhibition
P09488713A0886|35 48|Site-1 cleavage
P09488713A0886|35 40|Site-1
P09488713A0886|66 90|concomitant overexpression
P09488713A0886|93 107|full-length SCAP
P09488725A0904|14 34|true molecular identity
P09488725A0904|37 39|SFD
P09488725A0904|54 71|57-kDa polypeptides
P09488725T0000|0 24|Molecular characterization
P09488725T0000|36 49|57-kDa subunits
P09488725T0000|55 78|bovine vacuolar proton pump
P09489670A1157|2 11|C. albicans
P09489670A1157|13 16|HST6
P09489670A1157|44 53|high levels
P09489670A1157|59 76|different cell types
P09489670A1157|86 90|yeast
P09489670A1157|92 97|hyphae
P09489670A1157|107 112|opaque
P09489670A1157|132 148|HST6 transcription
P09489670A1157|132 135|HST6
P09489670A1157|169 180|diploid yeast
P09489670A1157|190 196|diploid
P09489670A1157|224 246|basic biological function
P09489670A1157|253 268|Hst6p transporter
P09489670A1157|253 257|Hst6p
P09489670A1157|271 280|C. albicans
P09490676A0800|12 18|binding
P09490676A0800|21 34|recombinant Myb
P09490676A0800|38 49|Ets-2 protein
P09490676A0800|57 65|fragments
P09490676A0800|87 92|excess
P09490676A0800|95 129|double stranded oligodeoxynucleotides
P09490676A0800|140 148|canonical
P09490676A0800|164 166|Myb
P09490676A0800|170 185|Ets-binding sites
P09490727A1041|4 41|structure interconnects specific triplets
P09490727A1041|47 57|basal bodies
P09490727A1041|65 83|microtubular bundles
P09490727A1041|101 114|basal apparatus
P09491074A0104|15 33|regulatory mechanism
P09491074A0104|60 73|low temperature
P09491074A0104|78 91|promoter region
P09492038A0352|5 16|current study
P09492038A0352|21 25|roles
P09492038A0352|31 56|putative cis-acting elements
P09492038A0352|82 90|basal exon
P09492038A0352|92 107|promoter activity
P09492038A0352|126 136|mutagenesis
P09492038A0352|140 170|nuclear protein-DNA binding assays
P09494078A1362|6 18|5HT5A receptor
P09494078A1362|32 40|yohimbine
P09494078A1362|62 74|smaller effect
P09495283A0000|14 25|reporter gene
P09495283A0000|27 34|beta-gal
P09495283A0000|56 89|human heat shock transcription factors
P09495283A0000|96 99|HSF1
P09495283A0000|103 106|HSF2
P09495283A0000|110 118|HeLa cells
P09495283A0000|124 128|yeast
P09495771A0379|0 20|Localized fluorescence
P09495771A0379|24 33|detectable
P09495771A0379|40 44|cells
P09495771A0379|56 81|visible midcell constriction
P09495771A0379|97 100|FtsK
P09495771A0379|131 139|late stage
P09495771A0379|142 150|septation
P09498553A0702|2 8|TATA box
P09498553A0702|22 43|putative promoter region
P09498553A0702|48 62|multiple GC boxes
P09498553A0702|81 88|cap sites
P09498553A0702|121 138|housekeeping nature
P09498553A0702|141 149|CYP51 gene
P09498553A0702|170 205|multiple transcription initiation sites
P09498553T0000|0 9|Structural
P09498553T0000|13 31|evolutionary studies
P09498553T0000|34 57|sterol 14-demethylase P450
P09498553T0000|59 63|CYP51
P09498553T0000|82 98|P450 monooxygenase
P09498553T0000|100 101|I.
P09498769A0095|3 19|expression pattern
P09498769A0095|38 63|many B cell-specific proteins
P09498769A0095|42 63|B cell-specific proteins
P09498769A0095|85 100|B cell development
P09498769A0095|104 113|activation
P09498769A0095|139 144|B cells
P09498769A0095|175 185|plasma cells
P09499031A0000|3 29|intercistronic gene junctions
P09499031A0000|32 55|vesicular stomatitis virus
P09499031A0000|57 59|VSV
P09499031A0000|77 92|sequence elements
P09499031A0000|112 126|polyadenylation
P09499031A0000|130 153|transcription termination
P09499031A0000|156 173|upstream transcript
P09499031A0000|182 193|reinitiation
P09499031A0000|196 208|transcription
P09499031A0000|211 230|downstream transcript
P09499048A1003|0 27|Infectious mutant virus progeny
P09499048A1003|58 75|gK-expressing cells
P09499048A1003|58 59|gK
P09499048A1003|91 92|gK
P09499048A1003|98 114|important function
P09499048A1003|120 135|replication cycle
P09499061A0000|0 7|Cleavage
P09499061A0000|21 29|reactions
P09499061A0000|43 73|human immunodeficiency virus type 1
P09499061A0000|43 72|human immunodeficiency virus type
P09499061A0000|75 89|HIV-1) integrase
P09499061A0000|75 79|HIV-1
P09499061A0000|81 89|integrase
P09499061A0000|114 130|covalent insertion
P09499061A0000|133 140|HIV-1 DNA
P09499061A0000|148 157|host genome
P09499254A1309|3 12|DSF regimen
P09499254A1309|26 44|significant activity
P09499254A1309|47 54|patients
P09499254A1309|62 100|metastatic pancreatic islet-cell carcinoma
P09499254A1309|105 120|patient tolerance
P09499254A1309|126 132|regimen
P09499254A1309|159 178|further investigation
P09501093A0071|0 9|Activation
P09501093A0071|15 37|mitogen activated protein
P09501093A0071|15 21|mitogen
P09501093A0071|39 48|MAP) kinase
P09501093A0071|39 41|MAP
P09501093A0071|43 48|kinase
P09501093A0071|52 69|primary consequence
P09501093A0071|72 84|Ras activation
P09501093A0071|72 74|Ras
P09501093A0071|94 100|key role
P09501093A0071|112 132|Ras signal transduction
P09501093A0071|112 114|Ras
P09501169A0000|0 23|Histone acetylation levels
P09501169A0000|26 30|cells
P09501169A0000|42 59|dynamic equilibrium
P09501169A0000|76 107|histone acetylases and deacetylases
P09501169A0000|76 92|histone acetylases
P09501169A0000|96 107|deacetylases
P09501982A1178|0 10|CONCLUSIONS
P09501982A1178|12 16|XCoe2
P09501982A1178|25 35|pivotal role
P09501982A1178|41 62|transcriptional cascade
P09501982A1178|76 89|primary neurons
P09501982A1178|92 105|Xenopus embryos
P09501982A1178|120 140|Delta-Notch signalling
P09501982A1178|126 130|Notch
P09501982A1178|142 146|XCoe2
P09501982A1178|160 180|higher neural potential
P09501982A1178|191 205|progenitor cells
P09501982A1178|217 224|X-ngnr-1
P09501982A1178|254 269|neural competence
P09501982A1178|273 294|irreversible commitment
P09501982A1178|298 307|neural fate
P09501982A1178|322 344|neuronal differentiation
P09501982A1178|357 373|XNeuroD expression
P09501982A1178|357 363|XNeuroD
P09502627A0705|0 6|RESULTS
P09502627A0705|8 15|Patients
P09502627A0705|18 23|Group A
P09502627A0705|28 42|higher incidence
P09502627A0705|45 81|posterolateral wall motion abnormalities
P09502627A0705|83 83|p
P09502627A0705|93 120|radionuclide ventriculography
P09502627A0705|123 139|larger infarct area
P09502627A0705|154 183|higher peak creatine kinase levels
P09502627A0705|164 177|creatine kinase
P09502627A0705|186 186|p
P09502627A0705|206 232|ventricular ejection fraction
P09502627A0705|234 237|LVEF
P09502627A0705|241 257|hospital discharge
P09502627A0705|259 259|p
P09502627A0705|278 284|Group B.
P09502720A0214|0 17|CyIIa transcription
P09502720A0214|0 4|CyIIa
P09502720A0214|40 49|downstream
P09502720A0214|56 75|initial specification
P09502720A0214|83 98|embryonic domains
P09502720T0000|0 23|Cis-regulation downstream
P09502720T0000|26 46|cell type specification
P09502720T0000|49 68|single compact element
P09502720T0000|80 96|complex expression
P09502720T0000|102 110|CyIIa gene
P09502720T0000|113 128|sea urchin embryos
P09503017A1021|25 34|human HYAL1
P09503017A1021|50 68|uncharacterized gene
P09503017A1021|99 114|chromosome 3p21.3
P09503017A1021|142 180|several small-cell lung carcinoma cell lines
P09503526A0614|2 9|patients
P09503526A0614|14 20|myalgia
P09503526A0614|22 28|Raynaud
P09503526A0614|40 53|skin vasculitis
P09503526A0614|57 90|vascular diseases WFAg concentrations
P09503526A0614|73 76|WFAg
P09503526A0614|95 100|higher
P09503526A0614|107 114|patients
P09504423A0114|26 35|4E-BP1 gene
P09504423A0114|104 107|BL21
P09504423A0114|109 111|DE3
P09504423A0114|117 126|fusion gene
P09504423A0114|134 158|glutathione-S-transferase
P09504423A0114|160 162|GST
P09504423A0114|174 200|prokaryotic gene fusion vector
P09504423A0114|174 188|prokaryotic gene
P09504423A0114|202 210|pGEX-4T-2
P09504423A0114|227 238|gene sequence
P09504423A0114|248 259|cleavage site
P09504423A0114|264 279|specific protease
P09504423A0114|281 294|alpha-thrombin
P09504514T0000|0 19|Randomised comparison
P09504514T0000|32 67|autologous bone-marrow transplantation
P09504514T0000|70 90|intensive chemotherapy
P09504514T0000|94 114|acute myeloid leukaemia
P09504514T0000|117 130|first remission
P09504514T0000|132 138|results
P09504514T0000|141 146|MRC AML
P09504553T0000|0 13|Therapeutic use
P09504553T0000|16 23|cannabis
P09504906A0099|0 7|Analysis
P09504906A0099|10 29|intragenic revertants
P09504906A0099|63 71|amino acid
P09504906A0099|84 103|first cysteine residue
P09504906A0099|109 125|DNA-binding domain
P09504906A0099|128 132|Hap1p
P09505135A0182|0 22|Peripheral visual stimuli
P09505135A0182|26 49|monoaural auditory stimuli
P09505135A0182|60 66|targets
P09505733A0246|9 15|studies
P09505733A0246|43 47|shows
P09505733A0246|64 76|common factors
P09505733A0246|89 109|psychological distress
P09505733A0246|122 142|functional limitations
P09505733A0246|154 161|patients
P09506439A2179|0 8|PKC-gamma
P09506439A2179|29 41|keratinocytes
P09506439A2179|54 77|involucrin gene expression
P09506439A2179|54 67|involucrin gene
P09506439A2179|81 101|TPA-independent manner
P09506439A2179|121 129|SVHK cells
P09506959T0000|0 13|Identification
P09506959T0000|17 32|characterization
P09506959T0000|35 62|specific DNA-binding complexes
P09506959T0000|43 62|DNA-binding complexes
P09506959T0000|73 79|members
P09506959T0000|85 102|Myc/Max/Mad network
P09506959T0000|85 87|Myc
P09506959T0000|89 91|Max
P09506959T0000|93 95|Mad
P09506959T0000|105 129|transcriptional regulators
P09506962A1000|17 36|proteolytic targeting
P09506962A1000|39 47|calpain II
P09506962A1000|39 45|calpain
P09506962A1000|54 63|proteasome
P09506962A1000|72 98|different structural elements
P09506962A1000|101 103|YY1
P09506983A0304|0 6|Primers
P09506983A0304|10 25|subsequent rounds
P09506983A0304|28 31|RACE
P09506983A0304|54 57|ends
P09506983A0304|69 80|RACE products
P09506990T0000|0 15|Human ZFM1 protein
P09506990T0000|5 15|ZFM1 protein
P09506990T0000|19 42|transcriptional repressor
P09506990T0000|63 91|transcription activation domain
P09506990T0000|94 123|stage-specific activator protein
P09507032A1144|16 31|CSF1R/IRDelta960
P09507032A1144|16 20|CSF1R
P09507032A1144|22 31|IRDelta960
P09507032A1144|51 58|CSF1R/IR
P09507032A1144|51 55|CSF1R
P09507032A1144|57 58|IR
P09507032A1144|70 84|CSF-1 protection
P09507032A1144|70 74|CSF-1
P09507032A1144|87 91|cells
P09507032A1144|96 125|staurosporine-induced apoptosis
P09508119A0498|0 10|CONCLUSIONS
P09508119A0498|15 41|special clinical presentation
P09508119A0498|53 67|possible Gardner
P09508377A0863|5 11|results
P09508377A0863|29 45|high UV sensitivity
P09508377A0863|62 77|high phaeomelanin
P09508377A0863|81 98|low eumelanin levels
P09508377A0863|113 139|eumelanin/phaeomelanin ratio
P09508377A0863|143 164|novel chemical parameter
P09508377A0863|193 203|individuals
P09508377A0863|206 213|high risk
P09508377A0863|217 226|skin cancer
P09508377A0863|230 237|melanoma
P09508511A0588|2 8|ferrets
P09508511A0588|30 39|H. mustelae
P09508511A0588|42 51|single dose
P09508511A0588|55 59|mg/kg
P09508511A0588|64 65|os
P09508511A0588|69 80|fluorofamide
P09508511A0588|100 114|bacterial urease
P09508775A0293|3 32|cAMP-dependent mitogenic pathway
P09508775A0293|60 99|mitogen-activated protein kinase activation
P09508775A0293|60 89|mitogen-activated protein kinase
P09508775A0293|114 143|growth factor-dependent pathways
P09508775A0293|171 212|several protooncogenes/transcription factors
P09509226A1235|0 10|CONCLUSIONS
P09509226A1235|12 14|Use
P09509226A1235|20 30|first method
P09509226A1235|63 74|time patients
P09509226A1235|88 90|ICU
P09509226A1235|121 127|savings
P09509226A1235|130 140|nursing time
P09509226A1235|151 157|methods
P09509226A1235|181 196|clinical outcomes
P09510189A0192|19 41|exon-intron organization
P09510189A0192|47 65|entire human CD58 gene
P09510189A0192|58 65|CD58 gene
P09510189A0192|92 100|kilobases
P09510189A0192|102 103|kb
P09510189A0192|110 120|flanking DNA
P09510398A1138|3 13|risk factors
P09510398A1138|17 25|hematuria
P09510398A1138|28 35|patients
P09510398A1138|40 56|renal hypouricemia
P09510398A1138|63 71|elevation
P09510398A1138|74 98|urinary urate concentration
P09510398A1138|105 112|subtypes
P09510398A1138|115 118|Post
P09510398A1138|122 130|Secretion
P09510582A0157|20 27|patients
P09510582A0157|40 43|DCBM
P09510582A0157|80 82|geG
P09510582A0157|87 88|mg
P09510582A0157|90 95|geG-25
P09510582A0157|100 102|geG
P09510582A0157|106 107|mg
P09510582A0157|109 114|geG-50
P09510582A0157|119 121|HBB
P09510582A0157|124 125|mg
P09510582A0157|128 141|hypotonic agent
P09510925A0389|5 28|haemoglobin concentration
P09510925A0389|5 15|haemoglobin
P09510925A0389|30 31|Hb
P09510925A0389|46 50|g dL-1
P09510925A0389|69 78|week course
P09510925A0389|81 95|ferrous sulphate
P09511724A0483|5 9|cells
P09511724A0483|14 25|accumulation
P09511724A0483|28 47|high Dsg protein levels
P09511724A0483|32 41|Dsg protein
P09511724A0483|56 62|calcium
P09511724A0483|82 91|low calcium
P09511724A0483|102 103|mM
P09511760A0221|7 31|restriction enzyme analysis
P09511760A0221|33 45|Southern blots
P09511760A0221|47 77|polymerase chain reaction analysis
P09511760A0221|81 93|DNA sequencing
P09511760A0221|132 137|clones
P09511760A0221|154 168|entire cHO-1 gene
P09511760A0221|160 168|cHO-1 gene
P09511760A0221|193 194|kb
P09511760A0221|200 214|flanking regions
P09511760A0221|221 224|ends
P09512416A0460|0 6|RESULTS
P09512416A0460|29 41|dbEST database
P09512416A0460|53 64|sequence tags
P09512416A0460|78 100|Arabidopsis thaliana gene
P09512416A0460|102 105|GCR1
P09512416A0460|144 167|membrane-spanning domains
P09512416A0460|171 197|other features characteristic
P09512416A0460|200 211|7TM receptors
P09512550T0000|0 2|E1A
P09512550T0000|12 43|apolipoprotein AI enhancer activity
P09512550T0000|12 35|apolipoprotein AI enhancer
P09512550T0000|46 55|liver cells
P09512550T0000|64 66|pRb
P09512550T0000|71 92|CBP-independent pathway
P09512550T0000|71 73|CBP
P09512559T0000|0 29|Position-independent expression
P09512559T0000|33 77|human nerve growth factor-luciferase reporter gene
P09512559T0000|87 117|yeast artificial chromosome vector
P09513759A0716|0 16|Calcitriol therapy
P09513759A0716|45 59|serum iPTH levels
P09513759A0716|50 53|iPTH
P09514156A1147|0 10|Alterations
P09514156A1147|13 18|DNase I
P09514156A1147|13 17|DNase
P09514156A1147|19 28|reactivity
P09514156A1147|34 57|GC-response element region
P09514156A1147|69 90|GC receptor-GC complexes
P09514156A1147|107 121|transient manner
P09514156A1147|130 137|promoter
P09514156A1147|163 174|control state
P09514159A0562|0 39|Most pituitary hormone-coding gene promoters
P09514159A0562|54 57|Ptx1
P09514260A1083|10 21|small inteins
P09514260A1083|29 36|inactive
P09514260A1083|41 52|pseudo intein
P09514260A1083|58 64|results
P09514260A1083|73 91|modular architecture
P09514260A1083|95 101|inteins
P09514260A1083|138 157|other protein families
P09514260A1083|168 193|recent experimental findings
P09514260A1083|199 213|functional roles
P09514260A1083|216 222|intein N
P09514260A1083|224 224|C
P09514260A1083|229 236|EN motifs
P09514272A0482|0 11|Purification
P09514272A0482|14 25|MvaT enriched
P09514272A0482|14 17|MvaT
P09514272A0482|32 43|polypeptides
P09514272A0482|46 69|approximate molecular mass
P09514272A0482|72 74|kDa
P09514272A0482|80 82|kDa
P09514272A0482|94 96|P15
P09514272A0482|100 102|P16
P09514962A0841|0 3|M-66
P09514962A0841|17 29|14-kDa protein
P09514962A0841|39 42|MMTV
P09514962A0841|50 63|T-cell lymphoma
P09514962A0841|65 68|EL-4
P09515031A1020|5 11|results
P09515031A1020|24 32|TGF-betaf
P09515031A1020|47 54|c-fos SRE
P09515031A1020|47 51|c-fos
P09515031A1020|66 68|PKC
P09515031A1020|79 92|SRF binding site
P09515032A1230|0 5|RT-PCR
P09515032A1230|19 25|p21 mRNA
P09515032A1230|62 74|2-day neonatal
P09515032A1230|76 88|7-day neonatal
P09515032A1230|93 103|adult stages
P09515032A1230|131 146|17-day fetal stage
P09515665T0000|0 10|Ganciclovir
P09515665T0000|14 30|foscarnet efficacy
P09515665T0000|33 64|AIDS-related CMV polyradiculopathy
P09515858A0000|0 9|BACKGROUND
P09515858A0000|11 19|Defensins
P09515858A0000|32 54|human neutrophil peptides
P09515858A0000|59 86|antimicrobial peptides present
P09515858A0000|92 108|azurophil granules
P09515858A0000|111 121|neutrophils
P09515921A1662|3 21|spontaneous mutation
P09515921A1662|30 46|pca gene expression
P09515921A1662|30 36|pca gene
P09515921A1662|50 56|located
P09515921A1662|62 69|promoter
P09515921A1662|76 84|pca operon
P09515924A0104|7 7|g
P09515924A0104|10 14|cells
P09515924A0104|27 28|mg
P09515924A0104|31 40|PDH complex
P09515924A0104|46 61|specific activity
P09515924A0104|68 71|U/mg
P09515924A0553|3 26|PDH complex-encoding genes
P09515924A0553|43 66|hybridization experiments
P09515924A0553|70 85|sequence analysis
P09515924A0553|91 109|separate gene regions
P09515924A0553|115 120|genome
P09515924A0553|123 131|Z. mobilis
P09516472A0292|19 36|functional elements
P09516472A0292|42 48|located
P09516472A0292|66 74|TATA motif
P09516472A0292|87 105|Id4 promoter activity
P09516472A0292|87 97|Id4 promoter
P09517646A0149|0 11|Azithromycin
P09517646A0149|15 46|new generation macrolide antibiotic
P09517646A0149|61 85|favorable pharmacokinetics
P09517646A0149|104 117|promising agent
P09517646A0149|121 136|innovative anti-H
P09517646A0149|138 151|pylori regimens
P09517989A0476|19 35|people co-infected
P09517989A0476|40 42|CMV
P09517989A0476|46 48|HIV
P09517989A0476|64 71|CD4 count
P09517989A0476|64 66|CD4
P09517989A0476|90 96|cells/l
P09518383A0000|0 9|BACKGROUND
P09518383A0000|13 22|OBJECTIVES
P09518383A0000|35 53|transmitted diseases
P09518383A0000|55 57|STD
P09518383A0000|59 72|control program
P09518383A0000|76 91|female sex workers
P09518383A0000|93 95|FSW
P09518383A0000|99 102|Lima
P09518383A0000|104 107|Peru
P09518383A0000|117 140|periodic serological tests
P09518383A0000|144 151|syphilis
P09518383A0000|155 168|cervical smears
P09518383A0000|172 180|gonococci
P09518383A0000|201 203|STD
P09518383A0000|206 212|condoms
P09518808T0000|0 20|National certification
P09518808T0000|23 36|vital component
P09518808T0000|39 54|quality assurance
P09519757A0482|3 20|rare novel mutations
P09519757A0482|22 26|D811N
P09519757A0482|29 32|exon
P09519757A0482|38 42|R835C
P09519757A0482|45 48|exon
P09519757A0482|71 97|first nucleotide-binding fold
P09519757A0482|99 101|NBF
P09519757A0482|117 131|important region
P09519757A0482|134 137|SUR1
P09519757A0482|160 172|heterozygotes
P09519828A0809|0 24|Chimaeric VP16-E2 molecules
P09519828A0809|9 12|VP16
P09519828A0809|39 81|epithelial specific transcriptional activation
P09519828A0809|87 102|BPV-4 LCR promoter
P09519828A0809|118 140|E2 transactivation domain
P09519830A0282|19 31|potential role
P09519830A0282|34 57|transcriptional silencing
P09519830A0282|64 87|productive HSV-1 infection
P09519830A0282|89 106|recombinant viruses
P09519830A0282|127 135|wild-type
P09519830A0282|138 148|mutant ICP34
P09519830A0282|151 159|promoters
P09519830A0282|187 230|chloramphenicol acetyltransferase reporter gene
P09519830A0282|250 268|thymidine kinase gene
P09519830A0282|274 284|viral genome
P09520398A0124|5 11|changes
P09520398A0124|48 64|acetylation levels
P09520398A0124|74 85|core histones
P09521907A0190|0 22|Drosophila orthodenticle
P09521907A0190|24 26|otd
P09521907A0190|31 44|murine Otx genes
P09521907A0190|72 89|expression patterns
P09521907A0190|93 108|mutant phenotypes
P09521909A0081|0 18|APETALA3 transcripts
P09521909A0081|38 55|meristematic region
P09521909A0081|77 81|petal
P09521909A0081|85 99|stamen primordia
P09521909A0081|144 164|subsequent development
P09521909A0081|172 177|organs
P09521913A0400|15 23|mutations
P09521913A0400|29 35|60A gene
P09521913A0400|55 76|TGF-beta-related factor
P09522297A0744|0 8|Cell lines
P09522297A0744|46 51|tumors
P09522297A0744|54 61|nude mice
P09522297A0744|87 95|karyotype
P09522979T0000|0 30|Cervicovaginal foetal fibronectin
P09522979T0000|14 30|foetal fibronectin
P09522979T0000|48 60|preterm labour
P09522979T0000|64 81|low-risk population
P09523478A0572|11 13|IgM
P09523478A0572|19 24|absent
P09523478A0572|27 34|children
P09523478A0572|39 61|congenital toxoplasmosis
P09523478A0572|64 71|subjects
P09523478A0572|76 96|secondary reactivation
P09523551A0367|4 11|variants
P09523551A0367|22 48|seven-transmembrane topology
P09523551A0367|65 89|G protein-coupled receptors
P09524122A0336|1 18|constitutive allele
P09524122A0336|21 24|GPA2
P09524122A0336|65 72|RAS genes
P09524222A0769|3 15|COOH-terminus
P09524222A0769|22 31|new isoform
P09524222A0769|49 53|beta 4
P09524222A0769|49 52|beta
P09524222A0769|63 96|amino acid lysine-rich sequence common
P09524222A0769|106 122|human red cell alpha
P09524222A0769|127 146|beta-adducin subunits
P09524222A0769|150 159|homologous
P09524222A0769|186 191|MARCKS
P09524222A0769|194 215|filamentous actin-cross
P09524222A0769|241 254|protein kinase C
P09524222A0769|258 275|calcium/calmodulin
P09524222A0769|266 289|calmodulin. beta 4-adducin
P09524222A0769|277 289|beta 4-adducin
P09524222A0769|320 342|calmodulin binding domain
P09524222A1113|0 10|PCR analysis
P09524222A1113|28 49|new beta-adducin isoform
P09524222A1113|31 49|beta-adducin isoform
P09524222A1113|63 72|fetal brain
P09524222A1113|82 91|bone marrow
P09524222A1113|96 99|NT-2
P09524222A1113|101 115|neuroepithelial
P09524222A1113|117 121|cells
P09524222A1113|141 159|several other tissues
P09524229A0000|3 11|gene lac-1
P09524229A0000|24 36|enzyme laccase
P09524229A0000|30 36|laccase
P09524229A0000|71 75|genes
P09524229A0000|81 100|chestnut blight fungus
P09524229A0000|102 124|Cryphonectria parasitica
P09524229A0000|144 154|hypoviruses
P09524229A0000|164 195|virulence-attenuating mycoviruses
P09524229A0000|197 201|lac-1
P09524229A0000|250 266|low concentrations
P09524229A0000|272 306|translational inhibitor cycloheximide
P09524229A0000|308 310|CHX
P09524229A0000|320 349|immunosuppressant cyclosporin A.
P09524250A0767|4 19|TRE-like elements
P09524250A0767|40 42|AP1
P09524259A0301|3 18|hp55 gamma protein
P09524259A0301|52 56|IGFIR
P09524259A0301|70 98|kinase-negative mutant receptor
P09524259A0301|100 108|hp55 gamma
P09524259A0301|129 143|insulin receptor
P09524259A0301|145 146|IR
P09524259A0301|153 173|yeast two-hybrid system
P09524267A1023|3 14|plant protein
P09524267A1023|30 46|functional domains
P09524267A1023|57 69|other proteins
P09524267A1023|80 104|nuclear localization signal
P09524267A1023|106 122|DNA-binding domain
P09524267A1023|126 139|helicase motifs
P09524267A1023|180 204|RNA transcription apparatus
P09524267A1023|214 237|nucleotide excision repair
P09524267A1023|240 249|plant cells
P09524273A0205|21 39|genomic organization
P09524273A0205|42 52|mouse gC1qBP
P09524273A0205|47 52|gC1qBP
P09524273A0205|59 74|characterization
P09524273A0205|82 95|flanking region
P09524276A0939|0 11|LysR proteins
P09524276A0939|35 61|urease in Klebsiella aerogenes
P09524276A0939|35 40|urease
P09524276A0939|43 61|Klebsiella aerogenes
P09524276A0939|63 65|NAC
P09524276A0939|71 78|catalase
P09524276A0939|97 100|OxyR
P09524276A0939|117 148|intracellular bacterium protection
P09524276A0939|153 171|phagolysosome damage
P09525105A0298|8 34|anti-inflammatory activities
P09525105A0298|39 52|aqueous extract
P09525105A0298|55 69|Buddleia cordata
P09525105A0298|76 100|principal glycoside linarin
P09525598A0325|0 9|Regulation
P09525598A0325|15 23|Raf kinase
P09525598A0325|26 31|T cells
P09525598A0325|43 50|findings
P09525598A0325|65 73|cell lines
P09525598A0325|81 95|catalytic domain
P09525598A0325|98 100|Raf
P09525598A0325|102 104|Raf
P09525598A0325|106 116|delta26-303
P09525888A1482|0 20|Full-length FLAP clones
P09525888A1482|0 14|Full-length FLAP
P09525888A1482|38 67|mouse skeletal muscle cDNA library
P09525891T0000|0 6|Members
P09525891T0000|12 16|meis1
P09525891T0000|20 48|pbx homeodomain protein families
P09525891T0000|67 89|cAMP-responsive sequence
P09525891T0000|91 94|CRS1
P09525891T0000|100 110|bovine CYP17
P09527921A1178|16 35|DNA-protein complexes
P09527921A1178|38 55|electron microscopy
P09527921A1178|60 72|high-affinity
P09527921A1178|86 98|WDV Rep protein
P09527921A1178|108 118|core element
P09527921A1178|155 156|bp
P09527921A1178|172 185|initiation site
P09527921A1178|197 205|start site
P09527921A1178|209 240|complementary-sense transcription
P09527921A1178|247 253|TATA box
P09528758T0000|0 4|Rex-1
P09528758T0000|20 38|transcription factor
P09528758T0000|53 63|early embryo
P09528758T0000|79 83|Oct-3
P09528758T0000|89 100|Oct-6 binding
P09528758T0000|89 93|Oct-6
P09528758T0000|105 115|octamer site
P09528758T0000|120 131|novel protein
P09528758T0000|133 137|Rox-1
P09528758T0000|150 161|adjacent site
P09528766A0915|8 17|inhibition
P09528766A0915|27 33|ERK/RSK
P09528766A0915|27 29|ERK
P09528766A0915|31 33|RSK
P09528766A0915|40 55|p38/MAPKAP kinase
P09528766A0915|40 42|p38
P09528766A0915|44 56|MAPKAP kinase 2
P09528766A0915|57 64|pathways
P09528766A0915|84 120|NGF-induced CREB Ser-133 phosphorylation
P09528766A0915|84 86|NGF
P09528768A0000|0 4|Cells
P09528768A0000|17 28|accumulation
P09528768A0000|39 46|proteins
P09528768A0000|52 71|endoplasmic reticulum
P09528768A0000|73 74|ER
P09528768A0000|91 103|transcription
P09528768A0000|109 113|genes
P09528768A0000|122 149|ER-resident chaperone proteins
P09528770A1379|3 49|RAS-cyclic AMP-dependent protein kinase cAPK pathway
P09528770A1379|3 5|RAS
P09528770A1379|7 38|cyclic AMP-dependent protein kinase
P09528770A1379|39 42|cAPK
P09528770A1379|61 71|UAS activity
P09528770A1379|74 77|IREu
P09528770A1379|93 99|glucose
P09528770A1379|105 120|sole carbon source
P09528770A1379|130 159|transcriptional activators Msn2p
P09528770A1379|155 159|Msn2p
P09528770A1379|163 167|Msn4p
P09528770A1379|178 188|UAS activity
P09528770A1379|216 222|acetate
P09528784A0000|3 11|mei4+ gene
P09528784A0000|3 6|mei4
P09528784A0000|17 28|fission yeast
P09528784A0000|64 88|functional complementation
P09528792A0000|0 18|Alternative splicing
P09528792A0000|21 51|fibroblast growth factor receptor 2
P09528792A0000|21 50|fibroblast growth factor receptor
P09528792A0000|53 58|FGF-R2
P09528792A0000|88 106|alternative splicing
P09528792A0000|114 122|exons IIIb
P09528792A0000|126 129|IIIc
P09528792A0000|152 166|exclusive manner
P09528792A0000|169 186|different cell types
P09528858A0205|6 10|cases
P09528858A0205|15 33|aberrant methylation
P09528858A0205|36 39|CpGs
P09528858A0205|48 64|regulatory regions
P09528858A0205|73 83|suppression
P09528858A0205|86 97|gene activity
P09528950A0716|3 18|genomic fragments
P09528950A0716|41 62|luciferase reporter gene
P09528987A1348|0 21|Cotransfection analyses
P09528987A1348|27 58|T/EBP promoter-reporter constructs
P09528987A1348|64 84|T/EBP expression vector
P09528987A1348|89 103|human HepG2 cells
P09528987A1348|122 126|T/EBP
P09528987A1348|141 154|autoregulation
P09528987A1348|191 214|human T/EBP gene expression
P09529156A1238|0 7|Deletion
P09529156A1238|20 30|Ser residues
P09529156A1238|44 59|PKC consensus site
P09529156A1238|65 76|receptor tail
P09529156A1238|91 142|phorbol 12-myristate 13-acetate-induced desensitization
P09529156A1238|147 147|%
P09529216A0644|0 11|Flap survival
P09529216A0644|38 48|small number
P09529216A0644|51 69|vascular connections
P09529216A0644|77 83|vessels
P09529216A0644|98 104|pedicle
P09529216A0644|119 131|dermal vessels
P09529649A0307|0 7|Jean Klig
P09529649A0307|15 30|recent literature
P09529649A0307|36 65|lower respiratory tract infection
P09529649A0307|68 75|children
P09529721A0000|0 18|Potential indicators
P09529721A0000|40 54|classifications
P09529721A0000|57 82|protein-energy malnutrition
P09529721A0000|88 97|guidelines
P09529721A0000|123 138|childhood illness
P09529721A0000|140 157|severe malnutrition
P09529721A0000|172 188|immediate referral
P09529721A0000|207 215|low weight
P09529721A0000|248 269|nutritional counselling
P09529721A0000|273 281|follow-up
P09530251A0766|0 3|SNAC
P09530251A0766|6 8|PBS
P09530251A0766|25 25|h
P09530251A0766|38 40|min
P09530251A0766|47 54|ischemia
P09530251A0766|81 88|duration
P09530251A0766|91 101|reperfusion
P09531538A0983|24 57|enhancer-dependent splicing activity
P09531538A0983|69 83|dU2AF38 RS domain
P09531538A0983|91 101|inessential
P09531549A0658|7 20|binding studies
P09531549A0658|26 42|GST fusion proteins
P09531549A0658|46 58|yeast extracts
P09531549A0658|81 85|sites
P09531549A0658|88 94|yAP180A
P09531549A0658|98 102|Pan1p
P09531549A0658|106 113|clathrin
P09531549A0658|115 128|yAP180 proteins
P09531549A0658|132 136|Pan1p
P09531549A0658|142 146|actin
P09531549A0658|158 174|peripheral patches
P09531549A0658|183 196|plasma membrane
P09531559A1153|7 22|affinity analyses
P09531559A1153|39 62|recombinant 130-kD protein
P09531559A1153|84 87|ZO-1
P09531559A1153|94 110|cytoplasmic domain
P09531559A1153|113 120|occludin
P09531559A1153|132 135|ZO-2
P09533030T0000|0 10|Cytochrome b
P09533030T0000|13 26|human complex II
P09533030T0000|13 24|human complex
P09533030T0000|28 61|succinate-ubiquinone oxidoreductase
P09533030T0000|64 74|cDNA cloning
P09533030T0000|80 89|components
P09533030T0000|92 108|liver mitochondria
P09533030T0000|112 131|chromosome assignment
P09533030T0000|137 141|genes
P09533030T0000|154 157|SDHC
P09533030T0000|168 171|SDHD
P09533030T0000|173 180|subunits
P09533030T0000|183 186|1q21
P09533030T0000|190 194|11q23
P09533109A0449|1 16|possible decrease
P09533109A0449|19 30|theophylline
P09533109A0449|56 59|days
P09533109A0449|100 110|chloroquine
P09533109A0449|155 177|statistical significance
P09533109A0449|179 180|p =
P09535082A0537|14 34|Paf-containing extract
P09535082A0537|48 72|significant protein binding
P09535082A0537|86 100|target sequences
P09535082A0537|115 118|PrfA
P09535082A0537|141 144|CIII
P09535082A0537|158 161|PrfA
P09535082A0537|171 172|bp
P09535082A0537|176 186|DNA fragment
P09535082A0537|190 195|slower
P09535082A0537|205 223|PrfA-Paf-DNA complex
P09535082A0537|205 208|PrfA
P09535082A0537|225 226|CI
P09535579A1105|16 26|assumptions
P09535579A1105|33 44|steady-state
P09535579A1105|47 52|uptake
P09535579A1105|68 87|proper interpretation
P09535579A1105|90 106|energy expenditure
P09535579A1105|113 116|EPOC
P09535579A1105|119 119|l
P09535579A1105|125 125|=
P09535579A1105|130 131|kJ
P09535833A0228|12 28|amino acid sequence
P09535833A0228|31 36|m-Staf
P09535833A0228|45 54|homologous
P09535833A0228|63 66|Staf
P09535833A0228|75 109|selenocysteine tRNA gene transcription
P09535833A0228|128 140|Xenopus laevis
P09535835A0279|0 5|ROCK-I
P09535835A0279|7 14|Kinectin
P09535835A0279|19 23|mDia2
P09535835A0279|34 46|wild type forms
P09535835A0279|53 56|RhoA
P09535835A0279|60 64|Cdc42
P09535835A0279|68 86|GTP-dependent manner
P09535851A0591|10 17|isoforms
P09535851A0591|22 32|beta isoform
P09535851A0591|39 55|greatest Vmax value
P09535851A0591|62 77|PtdIns(4)P kinase
P09535851A0591|62 67|PtdIns
P09535851A0591|71 85|P kinase activity
P09535851A0591|92 103|gamma isoform
P09535851A0591|130 145|phosphatidic acid
P09535892A0000|3 13|beta subunit
P09535892A0000|19 41|heterotrimeric G proteins
P09535892A0000|55 61|signals
P09535892A0000|71 84|plasma membrane
P09535892A0000|97 130|amino-terminal alpha-helical segment
P09535892A0000|155 159|units
P09535892A0000|166 167|WD
P09535892A0000|169 175|Trp-Asp
P09535892A0000|169 171|Trp
P09535892A0000|177 183|repeats
P09535892A0000|203 219|different proteins
P09535908A0321|26 36|LNX messages
P09535908A0321|54 61|proteins
P09535908A0321|75 89|molecular masses
P09535908A0321|94 96|kDa
P09535908A0321|98 100|LNX
P09535908A0321|105 115|70 kDa (LNX-b
P09535908A0321|107 109|kDa
P09535908A0321|111 115|LNX-b
P09536028A0945|14 30|contractile action
P09536028A0945|33 47|arachidonic acid
P09536028A0945|53 81|presumed cyclooxygenase product
P09536028A0945|61 81|cyclooxygenase product
P09536028A0945|97 108|contractions
P09536028A0945|121 122|TF
P09536028A0945|126 128|EGF
P09536028A0945|153 180|signal pathway probe inhibitors
P09536440A0000|0 12|Recent studies
P09536440A0000|25 45|unconventional myosin V
P09536440A0000|39 45|myosin V
P09536440A0000|52 85|important actin-based molecular motor
P09536440A0000|96 112|vesicular movement
P09536901A0362|3 18|separate occasion
P09536901A0362|22 31|T1 weighted
P09536901A0362|35 52|T2 weighted sagittal
P09536901A0362|56 79|T2 weighted axial sequences
P09536901A0362|112 128|initial assessment
P09537295A0951|13 26|minor start site
P09537295A0951|30 38|localized
P09537295A0951|42 51|bp upstream
P09537295A0951|57 65|major site
P09537295A0951|71 114|reverse transcriptase-polymerase chain reaction
P09537295A0951|71 106|reverse transcriptase-polymerase chain
P09537295A0951|119 134|various P1 primers
P09537295A0951|136 148|primer walking
P09537295A0951|151 165|primer extension
P09537295A0951|170 180|cDNA cloning
P09537295T0000|0 7|Analysis
P09537295T0000|10 17|promoter
P09537295T0000|21 47|androgen regulatory sequences
P09537295T0000|59 78|optimal transcription
P09537295T0000|84 113|rat androgen-binding protein gene
P09537361A0149|3 16|iron dependence
P09537361A0149|19 31|transcription
P09537361A0149|47 50|cvaA
P09537361A0149|65 91|transporter accessory protein
P09537361A0149|96 98|cvi
P09537361A0149|111 133|colicin V immunity protein
P09537361A0149|151 160|conditions
P09537361A0149|163 172|iron excess
P09537361A0149|175 183|depletion
P09537375A0198|3 20|gntR deletion mutant
P09537375A0198|38 52|chromosomal gntT
P09537375A0198|55 64|lacZ fusion
P09537375A0198|78 89|constitutive
P09537375A0198|105 108|GntR
P09537375A0198|114 130|negative regulator
P09537375A0198|133 136|gntT
P09537378A1227|15 22|deletion
P09537378A1227|25 27|bcp
P09537378A1227|35 44|chromosome
P09537378A1227|58 75|gcv-lacZ expression
P09537378A1227|58 60|gcv
P09537378A1227|62 65|lacZ
P09537651A0366|7 11|sites
P09537651A0366|13 16|PEA3
P09537651A0366|20 23|STAT
P09537651A0366|49 57|induction
P09537651A0366|60 64|v-src
P09537651A0366|85 92|elements
P09537651A0366|111 119|induction
P09537651A0366|125 159|phorbol ester phorbol myristate acetate
P09537651A0366|161 163|PMA
P09538156A0130|0 11|BRCA1 protein
P09538156A0130|22 50|amino-terminal zinc finger motif
P09538156A0130|55 82|carboxy-terminal acidic region
P09538220A0000|3 31|mitochondrial regulatory region
P09538220A0000|33 35|mrr
P09538220A0000|37 43|located
P09538220A0000|54 60|tRNAPhe
P09538220A0000|64 75|tRNAPro genes
P09538220A0000|78 93|mitochondrial DNA
P09538220A0000|95 99|mtDNA
P09538220A0000|127 137|replication
P09538220A0000|141 153|transcription
P09538220A0000|159 177|mitochondrial genome
P09538258A0200|48 60|Ras activation
P09538258A0200|48 50|Ras
P09538258A0200|65 75|stimulation
P09538258A0200|86 90|types
P09538258A0200|93 101|receptors
P09538258A0200|104 121|hematopoietic cells
P09539421A0970|5 15|Sir proteins
P09539421A0970|20 27|K. lactis
P09539421A0970|32 36|roles
P09539421A0970|43 51|silencing
P09539421A0970|55 79|telomere length maintenance
P09539421A0970|100 115|functional themes
P09539721A0599|24 27|DnaA
P09539721A0599|41 51|beta subunit
P09539721A0599|54 66|RNA polymerase
P09539721A0599|73 82|activation
P09539721A0599|88 97|pR promoter
P09539746A0781|0 9|Expression
P09539746A0781|12 17|Bcl-XL
P09539746A0781|43 48|Apaf-1
P09539746A0781|53 61|caspase-9
P09539746A0781|64 77|mammalian cells
P09539779A0621|0 10|Whole-mount
P09539779A0621|17 29|hybridization
P09539779A0621|32 48|early mouse embryos
P09539779A0621|59 62|days
P09539779A0621|73 86|complex pattern
P09539779A0621|89 102|Arp1 expression
P09539779A0621|89 92|Arp1
P09539779A0621|142 145|All1
P09540062A0755|5 11|mutants
P09540062A0755|47 67|Site II cognate proteins
P09540062A0755|47 50|Site
P09540062A0755|53 67|cognate proteins
P09540062A0755|111 135|H4 transcriptional activity
P09540062A0755|141 178|chimeric H4 promoter/CAT fusion constructs
P09540062A0755|160 162|CAT
P09540062A0755|181 198|different cell types
P09541280A0404|9 17|plasma IgE
P09541280A0404|15 17|IgE
P09541280A0404|39 44|NC mice
P09541280A0404|62 74|FK506 ointment
P09541280A0404|85 98|plasma IgE level
P09541636T0000|0 20|Creatine kinase release
P09541636T0000|0 13|Creatine kinase
P09541636T0000|26 50|hepatic artery embolization
P09541636T0000|53 60|patients
P09541636T0000|65 79|carcinoid tumors
P09541721A0894|17 55|ischemia/angiotension II-induced AHF model
P09541721A0894|26 39|angiotension II
P09541721A0894|57 59|NIC
P09541721A0894|69 104|left ventricular end-diastolic pressure
P09541721A0894|106 110|LVEDP
P09543227A0815|0 5|Group A
P09543227A0815|17 21|years
P09543227A0815|34 41|patients
P09543227A0815|50 60|risk factors
P09543227A0815|62 62|B
P09543227A0815|74 78|years
P09543227A0815|90 100|risk factors
P09543227A0815|105 105|C
P09543227A0815|117 121|years
P09543227A0815|135 149|more risk factors
P09544987A1583|24 33|RU486-PR-B
P09544987A1583|30 33|PR-B
P09544987A1583|57 60|NCoR
P09544991A0483|0 10|PRL receptor
P09544991A0483|24 28|SHP-2
P09544991A0483|31 58|cytosolic tyrosine phosphatase
P09544991A0750|3 24|dominant negative mutant
P09544991A0750|27 31|SHP-2
P09544991A0750|52 60|induction
P09544991A0750|63 85|tyrosine phosphorylation
P09544991A0750|89 107|DNA-binding activity
P09544991A0750|110 117|m-Stat5a
P09544991A0750|119 126|m-Stat5b
P09544991A0750|134 181|carboxyl-terminal deletion variant m-Stat5adelta749
P09544991A0750|166 181|m-Stat5adelta749
P09544991A0750|194 217|transactivation potential
P09544991A0750|220 227|m-Stat5a
P09544991A0750|231 238|m-Stat5b
P09545146A0884|0 10|CONCLUSIONS
P09545146A0884|47 67|quantitative estimates
P09545146A0884|70 76|changes
P09545146A0884|79 88|CBZ Cl/F due
P09545146A0884|91 102|comedication
P09545146A0884|108 126|age-related decrease
P09545146A0884|129 132|Cl/F
P09545146A0884|143 161|regression equations
P09545146A0884|181 194|concentrations
P09545146A0884|198 218|separate validation set
P09545293A0590|0 4|Sites
P09545293A0590|12 18|lumican
P09545293A0590|22 30|keratocan
P09545293A0590|37 54|homologous location
P09545312A1197|3 14|observations
P09545312A1197|26 32|members
P09545312A1197|38 48|HMG-I family
P09545312A1197|55 67|important role
P09545312A1197|70 95|SRF-dependent transcription
P09545312A1197|70 72|SRF
P09545312A1197|136 161|protein-protein interaction
P09545323T0000|0 20|ATP-dependent assembly
P09545323T0000|24 37|ternary complex
P09545323T0000|51 61|DNA mismatch
P09545323T0000|68 81|yeast MSH2-MSH6
P09545323T0000|78 81|MSH6
P09545323T0000|85 109|MLH1-PMS1 protein complexes
P09545323T0000|85 88|MLH1
P09545323T0000|90 93|PMS1
P09545332A0137|0 7|Mutation
P09545332A0137|13 25|central Tyr497
P09545332A0137|28 30|Phe
P09545332A0137|40 62|tyrosine phosphorylation
P09545332A0137|68 92|insulin receptor substrate 1
P09545332A0137|68 91|insulin receptor substrate
P09545332A0137|94 97|IRS1
P09545332A0137|112 124|proliferation
P09545332A0137|137 140|IL-4
P09545353A1071|22 41|tandem kappaB elements
P09545353A1071|46 105|variant activating transcription factor/cAMP response element site
P09545353A1071|83 105|cAMP response element site
P09545353A1071|128 132|sites
P09545353A1071|138 151|E-selectin gene
P09545353A1071|170 178|TNF-alpha
P09545353A1071|182 204|LPS-inducible expression
P09545638A0330a|24 56|single yeast hnRNP methyltransferase
P09545638A0330a|30 56|yeast hnRNP methyltransferase
P09545638A0330a|58 61|HMT1
P09545638A0330b|24 56|single yeast hnRNP methyltransferase
P09545638A0330b|30 56|yeast hnRNP methyltransferase
P09545638A0330b|58 61|HMT1
P09545638A0836|0 24|Recombinant HRMT1L2 protein
P09545638A0836|50 56|variant
P09545638A0836|66 90|methyltransferase activity
P09545638A1181|3 15|possible roles
P09545638A1181|18 24|HRMT1L1
P09545638A1181|28 34|HRMT1L2
P09545638A1181|37 48|human disease
P09545638T0000|0 13|Identification
P09545638T0000|17 32|characterization
P09545638T0000|38 76|putative human arginine methyltransferases
P09545638T0000|46 76|human arginine methyltransferases
P09545638T0000|78 84|HRMT1L1
P09545638T0000|88 94|HRMT1L2
P09546424A1550|26 42|PDGF beta-receptor
P09546424A1550|60 70|Crk proteins
P09547311A1394|12 23|interactions
P09547311A1394|45 64|endogenous E-cadherin
P09547311A1394|71 77|chimera
P09547311A1394|91 119|E-cadherin extracellular domain
P09547311A1394|126 135|desmoglein
P09547311A1394|137 155|intracellular domain
P09547311A1394|201 219|lateral interactions
P09547311A1394|222 251|E-cadherin extracellular domains
P09547349A0000|3 72|ether phospholipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine
P09547349A0000|74 83|ET-18-OCH3
P09547349A0000|85 94|edelfosine
P09547349A0000|99 111|potent inducer
P09547349A0000|114 122|apoptosis
P09547349A0000|125 139|human tumor cells
P09548481A0000|36 43|promoter
P09548481A0000|45 46|P1
P09548481A0000|73 86|second promoter
P09548481A0000|93 111|human IL-5Ralpha gene
P09549179A0774|0 10|Serum levels
P09549179A0774|13 24|testosterone
P09549179A0774|37 54|significant changes
P09549179A0774|67 67|p
P09549179A0774|69 69|p
P09549179A0774|72 74|DDE
P09549179A0774|83 92|conditions
P09549398A1463|0 15|Overall agreement
P09549398A1463|23 80|rest/postnitroglycerin technetium-99m tetrofosmin SPET studies
P09549398A1463|84 102|rest/redistribution
P09549398A1463|105 143|rest/reinjection thallium-201 SPET studies
P09549398A1463|167 185|myocardial viability
P09549398A1463|192 192|%
P09549398A1463|198 198|%
P09549632A1189|34 34|%
P09549632A1189|39 49|specificity
P09549632A1189|54 54|%
P09549632A1189|67 80|predictability
P09549632A1189|83 91|ALT levels
P09549632A1189|83 85|ALT
P09549660A0782|19 26|data sets
P09549660A0782|32 39|subjects
P09549660A0782|48 56|simulated
P09549660A0782|71 82|data scenario
P09549783T0000|0 14|Spatial accuracy
P09549783T0000|27 56|secondary memory-guided saccades
P09549783T0000|59 79|schizophrenic patients
P09550591A0454|0 18|Successful treatment
P09550591A0454|23 59|nasal continuous positive airway pressure
P09550591A0454|70 74|cmH2O
P09550591A0454|80 83|days
P09550591A0454|91 109|significant decrease
P09550591A0454|112 128|mean blood pressure
P09550591A0454|131 134|OSAS
P09550919A0365|24 39|cumulative manner
P09550919A0365|54 73|intravenous adenosine
P09550919A0365|75 76|mg
P09550919A0365|79 80|mg
P09550919A0365|83 84|mg
P09550919A0365|90 91|mg
P09550919A0365|99 106|episodes
P09550919A0365|109 112|PSVT
P09550919A0365|118 125|episodes
P09550919A0365|129 129|%
P09550919A0365|134 141|episodes
P09550919A0365|145 145|%
P09550919A0365|150 157|episodes
P09550919A0365|161 161|%
P09550919A0365|168 175|episodes
P09550919A0365|179 179|%
P09551096A0108|0 3|RNAs
P09551096A0108|14 32|essential components
P09551096A0108|39 55|ribosomal subunits
P09551096A0108|85 91|factors
P09551096A0108|98 114|particle formation
P09551182A0212|7 24|retinoid signalling
P09551182A0212|27 42|zebrafish embryos
P09551182A0212|56 66|novel method
P09551182A0212|75 93|endogenous retinoids
P09551182A0212|102 108|embryos
P09551182A0212|116 128|fusion protein
P09551182A0212|134 169|ligand inducible transactivation domain
P09551182A0212|173 192|retinoic acid receptor
P09551182A0212|197 224|heterologous DNA binding domain
P09551938A0318|10 33|nuclear regulatory factors
P09551938A0318|79 94|CCR5 gene promoter
P09551972A1033|0 11|Fluorescence
P09551972A1033|18 30|hybridization
P09551972A1033|33 48|metaphase spreads
P09551972A1033|51 60|chromosome
P09551972A1033|73 97|hybrid cell line 706-B6 clone
P09551972A1033|101 105|CL-17
P09551972A1033|111 122|cosmid c101F1
P09551972A1033|133 140|9804 gene
P09551972A1033|137 145|gene close
P09551972A1033|151 158|telomere
P09551972A1033|161 166|8q24.3
P09552469A0225|21 29|piroxicam
P09552469A0225|33 41|poloxamer
P09552469A0225|54 72|x-ray diffractometry
P09552469A0225|74 76|XRD
P09552469A0225|88 89|IR
P09552469A0225|91 102|spectroscopy
P09552469A0225|106 132|differential thermal analysis
P09552469A0225|134 136|DTA
P09552469A0225|143 157|solid dispersion
P09552469A0225|175 189|physical mixture
P09553040A0651|0 11|Cell survival
P09553040A0651|14 16|Epo
P09553040A0651|30 39|activation
P09553040A0651|42 68|other known signaling pathways
P09553040A0651|78 87|PI-3 kinase
P09553040A0651|89 97|PLC-gamma
P09553040A0651|99 101|Ras
P09553040A0651|104 108|Stats
P09553134A0596|3 38|N-syndecan-dependent neurite outgrowth
P09553134A0596|55 89|tyrosine kinase inhibitors herbimycin A
P09553134A0596|55 68|tyrosine kinase
P09553134A0596|93 95|PP1
P09553143A0729|8 22|ZAP-70 substrate
P09553143A0729|8 13|ZAP-70
P09553143A0729|24 29|SLP-76
P09553143A0729|43 55|Erk activation
P09553143A0729|43 45|Erk
P09553143A0729|74 96|tyrosine-phosphorylated
P09553143A0729|99 109|Jurkat cells
P09553143A0729|119 127|P116 cells
P09553143A0729|146 149|H2O2
P09553686A0000|3 25|pharmacokinetic patterns
P09553686A0000|28 36|estradiol
P09553686A0000|38 40|CAS
P09553686A0000|54 60|estrone
P09553686A0000|62 64|CAS
P09553686A0000|93 97|women
P09553686A0000|109 125|surgical menopause
P09553686A0000|149 176|new estradiol transdermal patch
P09553686A0000|181 192|active matrix
P09553686A0000|203 221|absorption enhancers
P09553686A0000|233 256|epicutaneous applications
P09553686A0000|260 263|days
P09553686A0000|283 289|patch 7D
P09555046A1617|3 9|results
P09555046A1617|22 37|single base change
P09555046A1617|43 70|branchpoint consensus sequence
P09555046A1617|75 80|intron
P09555046A1617|89 100|human disease
P09555046A1617|140 146|mammals
P09556557A1238|14 27|central regions
P09556561A0671|8 19|H/ACA snoRNAs
P09556561A0671|34 38|Gar1p
P09556561A0671|58 67|large group
P09556561A0671|70 76|snoRNAs
P09556561A0671|98 102|yeast
P09556561A0671|113 118|guides
P09556561A0671|122 143|pseudouridine synthesis
P09556561A0671|151 166|pre-rRNA molecule
P09556566A0174|9 24|vitamin D receptor
P09556566A0174|26 28|VDR
P09556566A0174|36 61|retinoic acid Xalpha receptor
P09556566A0174|63 70|RXRalpha
P09556566A0174|77 98|human T cell line MT2 cells
P09556573A1062|0 13|Further studies
P09556573A1062|33 47|PPARalpha ligand
P09556573A1062|33 41|PPARalpha
P09556573A1062|50 50|S
P09556573A1062|53 79|hydroxyeicosatetraenoic acid
P09556573A1062|112 120|PPARalpha
P09556573A1062|128 146|co-activator RIP-140
P09556573A1062|175 183|PPARalpha
P09556573A1062|191 206|co-repressor SMRT
P09556573A1062|203 206|SMRT
P09556861A1018|10 26|current literature
P09556861A1018|31 40|mechanisms
P09556861A1018|54 61|toxicity
P09556861A1018|64 65|OA
P09556861A1018|79 90|major effects
P09556861A1018|95 104|inhibition
P09556861A1018|107 130|mitochondrial respiration
P09556861A1018|146 154|depletion
P09556861A1018|157 159|ATP
P09556861A1018|164 173|inhibition
P09556861A1018|176 190|tRNA-synthetase
P09556861A1018|212 227|protein synthesis
P09556861A1018|243 259|lipid peroxidation
P09557678A0140|28 42|acute expression
P09557678A0140|48 72|bovine papillomavirus type 1
P09557678A0140|48 71|bovine papillomavirus type
P09557678A0140|74 77|BPV1
P09557678A0140|79 87|E2 protein
P09557678A0140|90 93|HeLa
P09557678A0140|97 126|HT-3 cervical carcinoma cell lines
P09557678A0140|141 161|cellular proliferation
P09557678A0140|173 201|specific G1/S phase growth arrest
P09557682A0490|4 19|possible isoforms
P09557682A0490|21 30|hGli2 alpha
P09557682A0490|32 35|beta
P09557682A0490|37 41|gamma
P09557682A0490|46 50|delta
P09557682A0490|63 74|combinations
P09557682A0490|80 110|independent alternative splicings
P09557682A0490|121 128|isoforms
P09557682A0490|141 148|DNA motif
P09557682A0490|150 154|TRE2S
P09557682A0490|161 163|LTR
P09557708A1426|0 20|Specialized actin tails
P09557708A1426|11 15|actin
P09557708A1426|31 42|IEV particles
P09557708A1426|48 56|periphery
P09557708A1426|60 81|virus-tipped microvilli
P09557708A1426|95 117|wild-type-infected cells
P09557708A1426|123 128|absent
P09557708A1426|131 135|cells
P09557708A1426|148 156|vA33delta
P09557912A0699|5 11|mean IOP
P09557912A0699|20 21|SD
P09557912A0699|26 29|mmHg
P09557912A0699|37 45|induction
P09557912A0699|48 57|anesthesia
P09557912A0699|64 65|SD
P09557912A0699|70 73|mmHg
P09557912A0699|85 97|eyelash reflex
P09557912A0699|107 115|injection
P09557912A0699|118 130|methohexitone
P09557912A0699|137 138|SD
P09557912A0699|143 146|mmHg
P09557912A0699|152 160|cessation
P09557912A0699|163 182|muscle fasciculations
P09557912A0699|192 204|suxamethonium
P09557912A0699|211 212|SD
P09557912A0699|217 220|mmHg
P09557912A0699|226 234|cessation
P09557912A0699|237 246|convulsion
P09557912A0699|255 256|SD
P09557912A0699|261 264|mmHg
P09557912A0699|274 283|resumption
P09557912A0699|286 314|regular spontaneous respiration
P09560221A0282|1 4|cDNA
P09560221A0282|6 11|cak1At
P09560221A0282|41 51|CAK mutation
P09560221A0282|61 65|yeast
P09560221A0282|89 109|fission yeast CAK mutant
P09560221A0282|101 109|CAK mutant
P09560221A0282|111 116|cak1At
P09560221A0282|141 150|animal CAKs
P09560325A1285|0 34|Post-translational modifications such
P09560325A1285|37 49|glycosylation
P09560325A1285|53 67|phosphorylation
P09560325A1285|85 105|potential explanations
P09560325A1285|112 131|protein heterogeneity
P09560390A0771|21 37|checkpoint control
P09560390A0771|39 52|overexpression
P09560390A0771|55 59|sum1+
P09560390A0771|55 58|sum1
P09560390A0771|71 93|normal cell cycle response
P09560390A0771|96 108|osmotic stress
P09560430A0000|0 3|Ime1
P09560430A0000|10 20|pivotal role
P09560430A0000|26 35|initiation
P09560430A0000|38 44|meiosis
P09560430A0000|47 65|a/alpha diploid cells
P09561560A0579|0 13|Rhesus macaques
P09561560A0579|17 26|BALB/c mice
P09561560A0579|44 68|Mengo virus SIV recombinants
P09561560A0579|84 95|CTL responses
P09561560A0579|106 120|SIV gene products
P09561560A0579|135 153|HIV-Nef recombinants
P09561560A0579|162 176|weak CTL response
P09561560A0579|179 182|mice
P09561560A0579|195 208|HIV1 Nef peptide
P09561560A0579|217 225|positions
P09561616A0142|0 11|Deltamethrin
P09561616A0142|33 47|thatched surface
P09561616A0142|62 71|% mortality
P09561616A0142|77 94|culicifacies adults
P09561616A0142|101 105|weeks
P09561616A0142|127 136|lowest dose
P09561616A0142|142 146|mg/m2
P09562398A0848|0 16|Trichloroethylene
P09562398A0848|37 39|AUC
P09562398A0848|50 51|.4
P09562398A0848|80 81|.4
P09562398A0848|107 125|corresponding values
P09562398A0848|129 136|n-hexane
P09562398A0848|150 151|.1
P09562398A0848|179 180|.9
P09562558T0000|0 16|Solution structure
P09562558T0000|22 43|IRF-2 DNA-binding domain
P09562558T0000|46 58|novel subgroup
P09562558T0000|64 91|winged helix-turn-helix family
P09564860A2139|11 35|receptor/G protein coupling
P09564860A2139|44 53|unaffected
P09564860A2139|68 80|loop 3i domains
P09564860A2139|95 103|receptors
P09564860A2139|113 113|G
P09564860A2139|115 117|i/o
P09564860A2139|119 126|proteins
P09564860A2139|128 173|M2Ach-muscarinic and alpha2A-adrenergic receptors
P09564860A2139|128 143|M2Ach-muscarinic
P09564860A2139|147 173|alpha2A-adrenergic receptors
P09564860A2315|24 45|third intracellular loop
P09564860A2315|51 59|rat GnRH-R
P09564860A2315|72 80|receptor G
P09564860A2315|82 85|q/11
P09564860A2315|87 101|protein coupling
P09564860A2315|108 118|selectivity
P09564860A2315|128 130|GGH
P09564860A2315|136 143|cell line
P09564860A2315|169 186|signal transduction
P09564860A2315|205 220|Gs protein pathway
P09564917A0900|9 14|levels
P09564917A0900|17 34|alpha2-antiplasmin
P09564917A0900|56 66|mediastinum
P09564917A0900|82 85|U/mL
P09564917A0900|87 87|p
P09565576T0000|1 15|catalytic domain
P09565576T0000|18 45|eukaryotic DNA topoisomerase I.
P09565576T0000|18 44|eukaryotic DNA topoisomerase I
P09565584A0770|10 24|basic amino acids
P09565584A0770|26 29|KKKR
P09565584A0770|54 62|sequences
P09565584A0770|75 90|constitutive exon
P09565584A0770|99 113|alternative exon
P09565584A0770|134 149|nuclear targeting
P09565584A0770|155 155|H
P09565584A0770|173 204|site-directed mutagenesis analysis
P09565606A0520|7 15|stem-loop
P09565606A0520|49 52|repY
P09565606A0520|73 79|rCGCC-3
P09565606A0520|95 118|repZ ribosome-binding site
P09566731A0458|8 12|genes
P09566731A0458|39 49|small region
P09566731A0458|52 79|human chromosome 16p12.1-p11.2
P09566731A0458|81 90|homologous
P09566731A0458|93 107|mouse chromosome
P09566731A0458|116 133|somatic cell hybrids
P09566731A0458|137 148|cosmid clones
P09566871A0343|2 12|fus3 mutants
P09566871A0343|17 22|levels
P09566871A0343|25 30|Ty1 RNA
P09566871A0343|32 47|protein synthesis
P09566871A0343|52 72|proteolytic processing
P09566871A0343|80 94|altered relative
P09566871A0343|104 114|FUS3 strains
P09566871A0343|104 107|FUS3
P09566871A0343|118 135|steady-state levels
P09566871A0343|138 140|TyA
P09566871A0343|142 150|integrase
P09566871A0343|155 182|reverse transcriptase proteins
P09566871A0343|186 192|Ty1 cDNA
P09566871T0000|0 26|Posttranslational regulation
P09566871T0000|29 49|Ty1 retrotransposition
P09566871T0000|29 31|Ty1
P09566871T0000|52 85|mitogen-activated protein kinase Fus3
P09566876A0000|3 31|general transcription factor IIA
P09566876A0000|33 37|TFIIA
P09566876A0000|55 72|TATA binding protein
P09566876A0000|74 76|TBP
P09566876A0000|81 91|promoter DNA
P09566876A0000|101 123|transcription activation
P09566882A0693|31 34|Pho2
P09566882A0693|40 47|promoter
P09566882A0693|58 75|cooperative binding
P09566882A0693|78 81|Pho4
P09566882A0693|94 97|Pho2
P09566918A1115|0 11|Substitution
P09566918A1115|17 28|Ser-Thr sites
P09566918A1115|36 52|phosphomimetic Asp
P09566918A1115|77 86|active form
P09566918A1115|89 93|IRF-3
P09566918A1115|115 129|strong activator
P09566918A1115|132 140|promoters
P09566918A1115|151 161|PRDI-PRDIII
P09566918A1115|151 154|PRDI
P09566918A1115|156 161|PRDIII
P09566918A1115|164 185|ISRE regulatory elements
P09568445T0000|0 14|New-onset angina
P09568445T0000|24 48|acute myocardial infarction
P09568445T0000|73 91|contractile recovery
P09568445T0000|97 108|thrombolysis
P09568549A0188|23 41|acute administration
P09568549A0188|44 55|various doses
P09568549A0188|58 66|malathion
P09568549A0188|77 88|dermal routes
P09568549A0188|91 94|mice
P09568549A0188|98 101|rats
P09568549A0188|104 114|serum levels
P09568549A0188|117 125|histamine
P09570030T0000|0 21|Fetal growth retardation
P09570030T0000|32 57|impaired ovarian development
P09570107A0355|10 25|PCDFs/PCDDs ratio
P09570107A0355|28 33|ESP ash
P09570107A0355|52 60|boiler ash
P09570133A0474|12 34|DNA-protein interactions
P09570133A0474|12 22|DNA-protein
P09570133A0474|36 62|protein-protein interactions
P09570133A0474|36 50|protein-protein
P09570133A0474|67 81|partner proteins
P09570133A0474|91 100|major roles
P09570133A0474|112 129|ETS-domain proteins
P09570133A0474|132 148|specific promoters
P09570944T0000|0 11|Localization
P09570944T0000|16 20|exons
P09570944T0000|24 32|YAC contig
P09570944T0000|44 45|Mb
P09570944T0000|55 83|multidrug resistance gene region
P09570944T0000|86 106|human chromosome 7q21.1
P09570952A0000|3 33|complete exon-intron organization
P09570952A0000|39 48|murine gene
P09570952A0000|57 65|M-protein
P09570952A0000|68 84|structural protein
P09570952A0000|87 106|sarcomeric myofibrils
P09571563A0000|0 6|PURPOSE
P09571563A0000|21 33|image analysis
P09571563A0000|39 44|cornea
P09571563A0000|47 72|photorefractive keratectomy
P09571563A0000|74 76|PRK
P09571563A0000|81 92|preoperative
P09571563A0000|96 126|early postoperative determination
P09571563A0000|129 135|changes
P09571563A0000|155 160|cornea
P09572428A0526|0 3|Mean
P09572428A0526|7 31|SD serum VEGF concentrations
P09572428A0526|14 17|VEGF
P09572428A0526|49 54|higher
P09572428A0526|56 56|P
P09572428A0526|66 70|women
P09572428A0526|75 77|PCO
P09572428A0526|81 84|PCOS
P09572428A0526|108 112|ng/ml
P09572428A0526|138 142|women
P09572428A0526|147 159|normal ovaries
P09572428A0526|170 174|ng/ml
P09572491A1044|16 20|cells
P09572491A1044|29 44|missense mutation
P09572491A1044|50 56|p53 gene
P09572491A1044|59 63|codon
P09572491A1044|68 70|p53
P09572491A1044|94 100|alanine
P09572491A1044|104 110|glycine
P09572511A0148|3 14|new algorithm
P09572511A0148|22 28|RBI-MAP
P09572511A0148|50 65|block iterative EM
P09572511A0148|67 72|RBI-EM
P09572511A0148|74 82|algorithm
P09572965A1235|1 8|third ORF
P09572965A1235|10 13|ORF5
P09572965A1235|20 27|homology
P09572965A1235|32 39|gene agrB
P09572965A1235|111 128|virulence phenotype
P09572990A0630|20 23|hSIE
P09572990A0630|27 32|Stat-3
P09572990A0630|27 30|Stat
P09572990A0630|38 50|MHC-I ligation
P09572990A0630|38 42|MHC-I
P09572990A0630|89 94|Stat-3
P09572990A0630|99 113|nuclear extracts
P09572990A0630|130 138|hSIE probe
P09572990A0630|130 133|hSIE
P09572990A0630|142 162|avidin-coupled agarose
P09572990A0630|142 147|avidin
P09573187T0000|0 24|Transcriptional repression
P09573187T0000|35 56|LysR-type regulator CatR
P09573187T0000|64 83|multiple binding sites
P09573202A0900|29 34|levels
P09573202A0900|40 51|alpha subunit
P09573202A0900|66 77|substitution
P09573202A0900|80 86|glycine
P09573202A0900|93 111|aspartic acid residue
P09573202A0900|131 146|N-terminal domain
P09573244A0523|8 18|mRNA species
P09573244A0523|32 67|differential polyadenylation site usage
P09573374A0687|5 24|Southern blot analysis
P09573374A0687|28 45|restriction mapping
P09573374A0687|48 57|genomic YAC
P09573374A0687|59 83|yeast artificial chromosome
P09573374A0687|88 99|cosmid clones
P09573374A0687|113 124|human RIL gene
P09573374A0687|132 142|kb telomeric
P09573374A0687|148 155|IRF1 gene
P09573374A0687|175 190|genomic structure
P09573378A0761|0 2|U73
P09573378A0761|11 11|C
P09573378A0761|13 13|D
P09573378A0761|17 23|D' boxes
P09573378A0761|28 64|12-nucleotide antisense complementarity
P09573378A0761|70 84|28S ribosomal RNA
P09573884A0392|8 25|mandibular position
P09573884A0392|27 31|S-N-B
P09573884A0392|35 41|S-N-Pog
P09573884A0392|68 80|more retrusive
P09573884A0392|83 87|Class
P09573884A0392|106 110|Class
P09573884A0392|112 119|subjects
P09574799A1072|0 14|Echinostomiasis
P09574799A1072|29 52|socioeconomic factors such
P09574799A1072|63 74|malnutrition
P09574799A1072|96 110|free-food market
P09574799A1072|119 142|supervised food inspection
P09574799A1072|150 171|insufficient sanitation
P09574799A1072|173 190|other helminthiases
P09574799A1072|204 221|economic conditions
P09575143A1189|3 14|localization
P09575143A1189|17 22|ZAP-70
P09575143A1189|28 37|cell cortex
P09575143A1189|75 91|SRC-family kinases
P09575143A1189|135 178|immunoreceptor tyrosine-based activation motifs
P09575143A1189|184 186|TCR
P09575187A1558|16 24|NF-kappaB
P09575187A1558|37 45|apoptosis
P09575187A1558|55 70|ER calcium release
P09575187A1558|103 111|sAPPalpha
P09575187A1558|120 148|thapsigargin-induced apoptosis
P09575187A1558|167 180|kappaB decoy DNA
P09575187A1558|167 172|kappaB
P09575217A0000|0 20|Many cytokine receptors
P09575217A0000|27 53|Janus protein tyrosine kinases
P09575217A0000|55 58|Jaks
P09575217A0000|63 79|signal transducers
P09575217A0000|83 92|activators
P09575217A0000|95 107|transcription
P09575217A0000|109 113|Stats
P09575217A0000|118 133|nuclear signaling
P09575217A0971|1 26|site-directed R618K mutation
P09575217A0971|32 45|Stat5 SH2 domain
P09575217A0971|58 72|phosphorylation
P09575217A0971|75 78|Jak2
P09575217A0971|85 92|deletion
P09575217A0971|98 106|C terminus
P09575217A0971|112 136|Stat5 hyperphosphorylation
P09575217A0971|112 116|Stat5
P09576230T0000|11 38|nitric oxide synthase inhibitor
P09576230T0000|11 29|nitric oxide synthase
P09576230T0000|41 57|reperfusion injury
P09576230T0000|73 100|hypothermic circulatory arrest
P09576915A0269|13 25|recombination
P09576915A0269|28 30|HMR
P09576915A0269|47 51|rings
P09576915A0269|65 65|E
P09576915A0269|70 78|silencers
P09577365A0747|2 15|angiodysplasia
P09577365A0747|17 30|ectatic vessels
P09577365A0747|36 41|mucosa
P09577365A0747|59 74|less collagen type
P09577365A0747|63 76|collagen type IV
P09577365A0747|95 101|vessels
P09577365A0747|107 115|submucosa
P09577365A0747|131 137|vessels
P09577365A0747|148 156|many cases
P09577365A0747|163 170|staining
P09577365A0747|186 202|muscularis mucosae
P09577395A0000|12 38|human vestibulo-ocular reflex
P09577395A0000|40 42|VOR
P09577395A0000|61 68|impulses
P09577395A0000|77 89|unpredictable
P09577395A0000|91 97|passive
P09577395A0000|99 115|high-acceleration
P09577395A0000|125 134|degrees/s2
P09577395A0000|137 149|low-amplitude
P09577395A0000|156 162|degrees
P09577395A0000|168 176|rotations
P09578042A0363|16 37|seizure-offset patterns
P09578042A0363|61 74|seizure outcome
P09578042A0363|85 93|SEEG/ECoG
P09578042A0363|97 108|similar group
P09578042A0363|111 118|patients
P09578042A0363|123 142|temporal lobe epilepsy
P09578042A0363|144 146|TLE
P09578570A0200|36 43|protein Z
P09578570A0200|102 117|PCR amplification
P09578570A0200|120 131|leukocyte DNA
P09578570A0200|146 156|phage clones
P09578570A0200|162 180|human genomic library
P09579602A1720|5 17|modifications
P09579602A1720|31 60|interlaboratory reproducibility
P09579602A1720|63 83|CD34 determinations due
P09579602A1720|63 66|CD34
P09579602A1720|100 113|sample handling
P09579602A1720|130 136|results
P09579789A0974|3 16|present results
P09579789A0974|32 35|rats
P09579789A0974|50 62|small remnants
P09579789A0974|68 80|olfactory bulb
P09579789A0974|101 113|odor detection
P09579789A0974|117 135|discrimination tasks
P09579789A0974|158 165|controls
P09579808A0000|0 9|UDP-GlcNAc
P09579808A0000|11 35|alpha-6-D-mannoside beta-1
P09579808A0000|39 69|N-acetylglucosaminyltransferase
P09579808A0000|73 77|GnT II
P09579808A0000|73 75|GnT
P09579808A0000|79 89|EC 2.4.1.143
P09579808A0000|79 80|EC
P09579808A0000|108 121|normal assembly
P09579808A0000|124 147|complex Asn-linked glycans
P09580062A0100|5 12|patients
P09580062A0100|30 56|intravenous cyclophosphamide
P09580062A0100|60 67|steroids
P09580062A0100|95 111|oral cyclosporine A
P09580062A0100|123 131|mg/kg/day
P09580563A0331|12 28|amino acid sequence
P09580563A0331|35 44|% identical
P09580563A0331|50 76|cytoplasmic dynein heavy chain
P09580563A0331|79 94|Neurospora crassa
P09580563A0331|100 109|% identical
P09580563A0331|118 136|Aspergillus nidulans
P09580563A0331|144 153|% identical
P09580700A0841|3 22|DNA binding activities
P09580700A0841|33 53|repressor preparations
P09580700A0841|70 78|fragments
P09580700A0841|89 92|CIRs
P09580700A0841|94 102|CIR3-CIR6
P09580700A0841|111 130|essential early region
P09580700A0841|133 141|templates
P09580700A0841|145 150|DNase I
P09580700A0841|145 149|DNase
P09580700A0841|151 162|footprinting
P09581552A1323|0 17|Molecular modelling
P09581552A1323|34 54|tetramerization domain
P09581552A1323|59 74|four-helix bundle
P09581552A1323|88 99|interactions
P09581552A1323|116 133|aromatic amino acids
P09581775A0185|5 16|present study
P09581775A0185|46 74|constitutive NF-kappaB activity
P09581775A0185|58 66|NF-kappaB
P09581775A0185|88 117|HIV-1-infected promonocytic U937
P09581775A0185|119 125|U9-IIIB
P09581775A0185|130 148|myeloblastic PLB-985
P09581775A0185|150 157|PLB-IIIB
P09581775A0185|159 163|cells
P09581775A0185|171 188|apoptotic signaling
P09581834A2578|19 25|results
P09581834A2578|37 45|silymarin
P09581834A2578|55 82|strong anticarcinogenic effect
P09581834A2578|90 92|PCA
P09581834A2578|127 136|impairment
P09581834A2578|139 172|erbB1-SHC-mediated signaling pathway
P09581834A2578|139 143|erbB1
P09581834A2578|145 147|SHC
P09581834A2578|174 182|induction
P09581834A2578|185 189|CDKIs
P09581834A2578|195 211|resultant G1 arrest
P09581872A0000|2 17|connective tissue
P09581872A0000|19 31|cell structure
P09581872A0000|45 57|type I collagen
P09581872A0000|50 67|collagen expression
P09582267A0326|22 41|human SINA-homologous
P09582267A0326|27 55|SINA-homologous (Siah) proteins
P09582267A0326|43 46|Siah
P09582267A0326|48 55|proteins
P09582267A0326|57 74|expression plasmids
P09582267A0326|83 89|Siah-1A
P09582267A0326|123 137|epithelial cells
P09582267A0326|141 160|GM701 fibroblast cells
P09582267A0326|173 184|growth arrest
P09582267A0326|192 200|induction
P09582267A0326|203 211|apoptosis
P09582306T0000|1 13|point mutation
P09582306T0000|16 22|Galphao
P09582306T0000|26 33|Galphai1
P09582306T0000|66 90|G protein signaling proteins
P09582306T0000|66 73|G protein
P09582308A1165|44 69|disulfide-linked homodimers
P09582308A1165|91 94|homo
P09582308A1165|99 110|heterodimers
P09582326A0151|0 1|N.
P09582326A0151|6 12|Fanning
P09582326A0151|14 15|E.
P09582327A0295|25 32|GH3 cells
P09582327A0295|51 69|rat GnRH receptor cDNA
P09582327A0295|71 76|GGH3-1
P09582327A0295|78 82|cells
P09582327A0295|120 129|fusion gene
P09582327A0295|143 151|base pairs
P09582327A0295|154 166|rat LHbeta gene
P09582327A0295|170 185|flanking sequence
P09582327A0295|198 206|base pairs
P09582327A0295|215 232|untranslated region
P09582327A0295|241 276|luciferase reporter (-797/+5LHbetaLUC)
P09582327A0295|241 258|luciferase reporter
P09582327A0295|267 275|LHbetaLUC
P09582327A0295|290 300|GnRH agonist
P09582327A0295|290 293|GnRH
P09582327A0295|306 323|10-fold stimulation
P09582331A0506|6 19|flanking region
P09582331A0506|25 34|nucleotide
P09582331A0506|54 57|TATA
P09582331A0506|61 77|inverted CAAT boxes
P09582331A0506|86 91|GATA-1
P09582331A0506|93 141|SP1 erythroid-specific cis-acting regulatory elements
P09582331A0506|93 95|SP1
P09582343A0000|16 40|radiosensitive cell line SX9
P09582343A0000|45 72|mammary carcinoma cell line FM3A
P09582350A0165|2 9|patients
P09582350A0165|14 41|type IA maple syrup urine disease
P09582350A0165|46 59|E1alpha subunit
P09582350A0165|91 92|E1
P09582350A0165|96 149|branched-chain ketoacid dehydrogenase catalytic activities
P09582350A0165|96 130|branched-chain ketoacid dehydrogenase
P09582635A0523|0 6|Results
P09582635A0523|20 35|mean bond strength
P09582635A0523|38 52|H.T.V. specimens
P09582635A0523|73 78|kg/cm2
P09582635A0523|88 103|mean bond strength
P09582635A0523|106 120|R.T.V. specimens
P09582635A0523|141 146|kg/cm2
P09582953A0000|0 9|OBJECTIVES
P09582953A0000|20 40|coagulation factor VIII
P09582953A0000|42 50|coagulant
P09582953A0000|52 57|F.VIII
P09582953A0000|59 59|C
P09582953A0000|64 83|C1-esterase inhibitor
P09582953A0000|64 74|C1-esterase
P09582953A0000|85 90|C1-INH
P09582953A0000|93 140|hemostasis-associated acute-phase reactant proteins
P09582953A0000|144 164|coagulation factors VII
P09582953A0000|166 170|F.VII
P09582953A0000|176 179|F.IX
P09582953A0000|176 177|F.
P09582953A0000|185 185|X
P09582953A0000|187 189|F.X
P09582953A0000|192 209|hemostasis proteins
P09582953A0000|229 247|acute-phase response
P09582953A0000|252 267|select population
P09582953A0000|270 275|horses
P09582953A0000|280 284|colic
P09582953A0000|288 310|hemostasis abnormalities
P09582953A0000|329 346|acute-phase changes
P09582953A1097|0 6|RESULTS
P09582953A1097|8 13|Horses
P09582953A1097|18 22|colic
P09582953A1097|39 67|higher fibrinogen concentration
P09582953A1097|45 54|fibrinogen
P09582953A1097|69 83|greater alpha 2AP
P09582953A1097|87 104|protein C activities
P09582953A1097|109 116|longer PT
P09582953A1097|120 123|APTT
P09582953A1097|131 143|healthy horses
P09582953A1670|18 28|plasminogen
P09582953A1670|30 37|alpha 2AP
P09582953A1670|42 47|C1-INH
P09582953A1670|67 91|equine acute-phase proteins
P09583201A0759|0 3|None
P09583201A0759|9 16|patients
P09583201A0759|20 24|obese
P09583208A0171|0 14|Marked elevation
P09583208A0171|17 30|creatine kinase
P09583208A0171|47 58|serum albumin
P09583208A0171|60 73|immunoglobulin
P09583208A0171|78 87|complement
P09583592A0263|0 5|DESIGN
P09583592A0263|9 15|METHODS
P09583592A0263|17 25|Case study
P09583823A0238|0 6|METHODS
P09583823A0238|18 21|pigs
P09583823A0238|38 45|ligation
P09583823A0238|48 67|left marginal arteries
P09583823A0238|69 83|infarction group
P09583823A0238|85 86|n =
P09583823A0238|92 95|TMLR
P09583823A0238|101 115|left lateral wall
P09583823A0238|122 128|holmium
P09583823A0238|130 152|yttrium-aluminium garnet
P09583823A0238|154 155|Ho
P09583823A0238|157 159|YAG
P09583823A0238|167 176|laser group
P09583823A0238|178 179|n =
P09583823A0238|193 213|laser-infarction group
P09583823A0238|215 216|n =
P09584165T0000|0 4|RACK1
P09584165T0000|7 14|receptor
P09584165T0000|27 33|C kinase
P09584165T0000|38 44|homolog
P09584165T0000|50 60|beta subunit
P09584165T0000|63 71|G proteins
P09584165T0000|91 108|src tyrosine kinases
P09584165T0000|120 130|NIH 3T3 cells
P09584179A0673|0 15|Peptide sequences
P09584179A0673|21 40|zinc finger protein Ttk
P09584179A0673|47 70|transcription factor Adf-1
P09584180A0701|3 32|same IL-4-inducible reporter gene
P09584180A0701|7 32|IL-4-inducible reporter gene
P09584180A0701|68 82|endogenous Stat6
P09584180A0701|86 102|NF-kappaB proteins
P09584180A0701|105 139|IL-4-stimulated I.29mu B lymphoma cells
P09584194A0000|0 3|HEF1
P09584194A0000|5 8|p130
P09584194A0000|10 12|Cas
P09584194A0000|18 24|Efs/Sin
P09584194A0000|18 20|Efs
P09584194A0000|22 24|Sin
P09584194A0000|44 69|multidomain docking proteins
P09584194A0000|121 132|cell adhesion
P09584194A1305|21 27|spindle
P09584194A1305|29 54|two-hybrid library screening
P09584194A1305|59 62|HEF1
P09584194A1305|76 87|human homolog
P09584194A1305|93 126|G2/M spindle-regulatory protein Dim1p
P09584194A1305|93 94|G2
P09584194A1305|96 126|M spindle-regulatory protein Dim1p
P09584194A1305|130 147|specific interactor
P09584194A1305|161 164|HEF1
P09584194A1305|178 180|p55
P09584194A1305|182 185|HEF1
P09585253A1147|17 26|activation
P09585253A1147|32 45|raf-ERK pathway
P09585253A1147|32 34|raf
P09585253A1147|36 38|ERK
P09585253A1147|51 60|activation
P09585253A1147|63 74|TF expression
P09585253A1147|63 64|TF
P09585253A1147|77 96|breast carcinoma cells
P09585253A1147|113 134|constitutive activation
P09585253A1147|141 147|pathway
P09585253A1147|155 170|high TF expression
P09585253A1147|173 187|MDA-MB-231 cells
P09585253A1147|173 178|MDA-MB
P09585540A0440|9 27|zinc-depleted enzyme
P09585540A0440|44 60|prolonged dialysis
P09585540A0440|88 111|agent 1,10-phenanthroline
P09586285A0551|3 10|patients
P09586285A0551|22 47|H. influenza type b meningitis
P09586285A0551|61 68|years old
P09586832A0229|3 7|lines
P09586832A0229|22 33|postsynaptic
P09586832A0229|41 51|presynaptic
P09586832A0229|53 67|5-HT1A receptors
P09587549T0001|0 16|Convulsive seizure
P09587549T0001|37 51|interferon alpha
P09587549T0001|55 76|chronic viral hepatitis C
P09588228A0370|22 46|anticytokeratin 19 antibody
P09588228A0370|22 36|anticytokeratin
P09588228A0370|39 46|antibody
P09588228A0370|55 68|strong staining
P09588228A0370|75 84|epithelial
P09588228A0370|88 108|sarcomatous MPM tissues
P09590294A0453|0 13|Genetic studies
P09590294A0453|54 70|several components
P09590294A0453|76 87|Notch pathway
P09590294A0453|76 80|Notch
P09590540A0513|3 10|bZP2 cDNA
P09590540A0513|20 21|nt
P09590540A0513|26 27|kb
P09590540A0513|39 47|sequences
P09590540A0513|57 80|N-terminal signal sequence
P09590540A0513|84 116|C-terminal transmembranelike domain
P09590540A0513|121 123|PCR
P09590540A0513|136 162|Sac1-Sal1 restricted fragment
P09590540A0513|136 139|Sac1
P09590540A0513|141 144|Sal1
P09590540A0513|171 185|frame downstream
P09590540A0513|191 200|T5 promoter
P09590540A0513|209 226|lac operator control
P09590540A0513|209 219|lac operator
P09590540A0513|230 241|pQE-30 vector
P09591221A0137|0 14|Control subjects
P09591221A0137|22 31|potentials
P09591221A0137|33 35|EPs
P09591221A0137|58 74|initial positivity
P09591221A0137|86 92|ms range
P09591221A0137|94 95|P1
P09591221A0137|102 122|temporo-occipital site
P09592125A0000|0 26|Class I alpha1,2-mannosidases
P09592125A0000|0 4|Class
P09592125A0000|6 26|alpha1,2-mannosidases
P09592125A0000|33 45|essential role
P09592125A0000|51 61|elaboration
P09592125A0000|74 80|hybrid N
P09592125A0000|82 88|glycans
P09592125A0000|91 104|mammalian cells
P09592168T0000|0 17|Structural features
P09592168T0000|23 45|minimal DNA binding domain
P09592168T0000|47 54|M98-F219
P09592168T0000|58 96|human nucleotide excision repair protein XPA
P09592208A0470|7 20|other qualities
P09592208A0470|72 103|elaborate theoretical construction
P09592208A0470|111 123|empirical data
P09592208A0470|141 153|possibilities
P09592208A0470|164 194|late 19th-century moral statistics
P09592219A0652|3 9|results
P09592219A0652|38 60|educational intervention
P09593302A1165|3 25|mechanistic implications
P09593302A1165|28 53|aromatic non-responsiveness
P09593302A1165|77 84|A-domain
P09593302A1165|121 126|phenol
P09594299A0468|0 6|RESULTS
P09594299A0468|8 22|Acetabular index
P09594299A0468|111 134|developmental dislocation
P09595496A0000|18 27|high levels
P09595496A0000|30 41|endothelin-1
P09595496A0000|43 46|ET-1
P09595496A0000|65 80|pericardial fluid
P09595496A0000|83 90|patients
P09595496A0000|101 114|cardiac surgery
P09596536A0219|28 45|knee loading changes
P09596536A0219|55 68|ACL transection
P09596536A0219|91 111|cartilage degeneration
P09596542A0542|13 20|surfaces
P09596542A0542|23 45|tracheal cartilage matrix
P09596542A0542|49 61|collagen-rich
P09596542A0542|49 56|collagen
P09596542A0542|74 94|proteoglycan-rich core
P09596638T0000|0 17|Comparative mapping
P09596638T0000|23 42|Brassica S locus region
P09596638T0000|49 56|homeolog
P09596638T0000|59 69|Arabidopsis
P09596738T0000|0 4|Roles
P09596738T0000|10 61|Candida albicans mitogen-activated protein kinase homolog
P09596738T0000|63 67|Cek1p
P09596738T0000|71 87|hyphal development
P09596738T0000|91 109|systemic candidiasis
P09598205A0430|20 34|monosaccharides
P09598205A0430|41 53|disaccharides
P09598205A0430|58 69|beta-alanine
P09598205A0430|94 99|maltol
P09598894A0732|2 13|most subjects
P09598894A0732|15 21|markers
P09598894A0732|24 36|bone formation
P09598894A0732|40 49|resorption
P09599102A1191|0 7|Analysis
P09599102A1191|11 21|Mac1p mutant
P09599102A1191|23 32|refractile
P09599102A1191|36 61|copper-dependent repression
P09599102A1191|67 68|Cu
P09599102A1191|72 85|transport genes
P09599102A1191|95 109|aberrant pattern
P09599102A1191|112 125|CUP1 expression
P09599102A1191|112 115|CUP1
P09599102A1191|129 145|copper sensitivity
P09599664A0881|3 15|DNA sequencing
P09599664A0881|21 37|recombinant clones
P09599664A0881|61 68|RXR alpha
P09599664A0881|72 78|RXR beta
P09599724A0193|1 22|stratified random sample
P09599724A0193|27 41|active employees
P09599724A0193|47 52|cohort
P09599724A0193|55 77|phenoxy herbicide workers
P09599724A0193|109 112|PCDD
P09599724A0193|116 128|PCDF congeners
P09599724A0193|131 141|blood lipids
P09599724A0193|161 168|past PCDD
P09599724A0193|172 183|PCDF exposure
P09599724A0193|190 195|cohort
P09599724A0193|230 256|site-specific cancer findings
P09599724A0193|262 272|total cohort
P09599897A0000|14 31|laboratory features
P09599897A0000|36 43|children
P09599897A0000|48 70|Henoch-Schonlein purpura
P09599897A0000|72 74|HSP
P09599897A0000|110 121|associations
P09599897A0000|132 148|laboratory indices
P09599897A0000|160 173|white blood cell
P09599897A0000|175 177|WBC
P09599897A0000|186 207|serum C-reactive protein
P09599897A0000|209 211|CRP
P09599897A0000|213 218|levels
P09599897A0000|220 227|platelet
P09599897A0000|229 231|PLT
P09599897A0000|247 268|clinical manifestations
P09599897A0000|271 278|acute HSP
P09601007A0223|9 30|community metabolic data
P09601007A0223|47 58|large changes
P09601007A0223|61 76|CO2 concentration
P09601007A0223|87 101|coral reef waters
P09601007A0223|105 127|biogeochemical processes
P09601007A0223|153 166|photosynthesis
P09601007A0223|168 178|respiration
P09601007A0223|180 192|calcification
P09601007A0223|197 212|CaCO3 dissolution
P09601510A0215|12 33|other known retroviruses
P09601510A0215|38 47|FV pol genes
P09601510A0215|70 80|transcripts
P09601516A0695|0 11|Substitution
P09601516A0695|14 37|bulky hydrophobic residues
P09601516A0695|49 56|residues
P09601516A0695|63 66|PEP1
P09601516A0695|77 90|fusion activity
P09601516A0695|96 103|S protein
P09601516A0695|133 149|surface expression
P09601921A0000|0 10|Tributyltin
P09601921A0000|17 33|breakdown products
P09601921A0000|43 53|di-butyltin
P09601921A0000|71 80|water birds
P09601921A0000|94 102|Lake Huron
P09601921A0000|107 116|Great Lakes
P09601921A0000|119 143|marine coastal United States
P09601921A0000|151 159|west coast
P09601921A0000|162 176|British Columbia
P09601921A0000|178 183|Canada
P09601940A0280|5 18|flanking region
P09601940A0280|24 30|CD1 gene
P09601940A0280|43 55|binding motifs
P09601940A0280|62 99|cytokine-inducible transcription factors
P09601940A0280|101 108|NF-IL2-A
P09601940A0280|112 117|NF-IL6
P09602124A0127|0 6|Fregnac
P09602124A0127|8 9|M.
P09603345A1257|0 6|GLRaV-2
P09603345A1257|12 28|only closterovirus
P09603345A1257|50 67|genome organization
P09603345A1257|73 82|type member
P09603345A1257|94 96|BYV
P09603345A1257|136 151|definitive member
P09603345A1257|157 174|genus Closterovirus
P09604052A0166|0 10|Demographic
P09604052A0166|14 25|clinical data
P09604052A0166|43 54|control group
P09604052A0166|60 82|healthy age-matched women
P09604052A0166|102 106|women
P09604052A0166|111 123|wrist fracture
P09605137A0677|20 24|c-Jun
P09605137A0677|28 30|p65
P09605137A0677|38 58|vigorous transcription
P09605137A0677|61 72|IL-2 promoter
P09605137A0677|77 107|CD28RE-driven reporter constructs
P09605137A0677|114 118|LFA-3
P09605137A0677|123 150|B7-1-costimulated Jurkat cells
P09605930A1428|0 15|Identical results
P09605930A1428|32 44|transfections
P09605930A1428|48 66|mobility shift assays
P09605930A1428|82 102|primary rat hepatocytes
P09605930A1428|113 129|endogenous ALS gene
P09605930A1428|123 129|ALS gene
P09605934A0801|4 15|E box sequence
P09605934A0801|17 22|CACGTG
P09605934A0801|40 53|binding element
P09605934A0801|57 59|USF
P09605934A0801|61 85|upstream stimulatory factor
P09605934A0801|100 121|helix-loop-helix family
P09605934A0801|124 143|transcription factors
P09606633A0523|0 20|Interferon beta therapy
P09606633A0523|0 13|Interferon beta
P09606633A0523|40 44|weeks
P09606924T0000|0 26|Liquid chromatographic method
P09606924T0000|40 70|all-rac-alpha-tocopheryl acetate
P09606924T0000|74 89|retinyl palmitate
P09606924T0000|92 114|milk-based infant formula
P09606924T0000|120 146|matrix solid-phase dispersion
P09609342A0000|19 23|types
P09609342A0000|26 35|turbo pumps
P09609342A0000|38 52|centrifugal pump
P09609342A0000|54 56|CFP
P09609342A0000|60 72|mixed flow pump
P09609342A0000|74 76|MFP
P09609342A0000|84 96|axial flow pump
P09609342A0000|98 100|AFP
P09609705A0895|0 10|Examination
P09609705A0895|16 54|mitochondrial bc1 complex crystal structure
P09609705A0895|16 38|mitochondrial bc1 complex
P09609705A0895|56 60|Zhang
P09609705A0895|62 63|Z.
P09609705A0895|65 69|Huang
P09609705A0895|71 72|L.
P09609705A0895|74 84|Shulmeister
P09609705A0895|86 87|V.
P09609720A0357|3 29|protease-resistant fragments
P09609720A0357|41 41|N
P09609720A0357|46 61|C-terminal halves
P09609720A0357|67 74|nuclease
P09609720A0357|94 111|different proteases
P09609720A0357|138 147|same region
P09610755A1731|3 24|side-to-side difference
P09610755A1731|54 56|EXT
P09610755A1731|59 67|degrees/s
P09610755A1731|73 81|degrees/s
P09610755A1731|83 83|p
P09611016A0652|0 9|CONCLUSION
P09611016A0652|13 17|women
P09611016A0652|34 55|conservative management
P09611016A0652|64 71|prolapse
P09611016A0652|93 105|single pessary
P09611016A0652|124 132|pessaries
P09611229A1664|32 35|FAS1
P09611229A1664|38 60|nmt1-451Dino2 Delta cells
P09611229A1664|38 55|nmt1-451Dino2 Delta
P09611229A1664|90 108|transcription factor
P09611229A1664|112 118|factors
P09611229A1664|125 143|expression/activity
P09611229A1664|164 176|overall levels
P09611229A1664|179 210|cellular protein N-myristoy-lation
P09611234A0098|0 17|Rev-erbAalpha/beta
P09611234A0098|0 2|Rev
P09611234A0098|20 24|Mxi-1
P09611234A0098|28 46|Mad bHLH-zip proteins
P09611234A0098|53 68|oncoproteins PLZF
P09611234A0098|65 68|PLZF
P09611234A0098|72 80|LAZ3/BCL6
P09611234A0098|72 75|LAZ3
P09611234A0098|77 80|BCL6
P09611234A0098|96 112|corepressors N-CoR
P09611234A0098|108 112|N-CoR
P09611234A0098|116 119|SMRT
P09611877A0455|13 20|isolates
P09611877A0455|23 25|CSF
P09611877A0455|49 52|ECHO
P09611877A0455|59 62|ECHO
P09611877A0455|70 73|ECHO
P09612351A0386|23 43|persistent oscillation
P09612351A0386|53 59|ULF band
P09612775A0726|3 17|ParaSight-F test
P09612775A0726|39 56|serum antigen levels
P09612775A0726|75 82|patients
P09613574A0905|11 28|recombinant protein
P09613574A0905|45 58|enzyme activity
P09613574A0905|82 83|3H
P09613574A0905|85 96|methyl groups
P09613574A0905|104 115|substrate DNA
P09613574A0905|121 131|MGMT protein
P09613574A0905|166 173|degrees C
P09613574A0905|186 188|min
P09613946A0194|1 25|deproteinization procedure
P09613946A0194|41 68|reversed-phase HPLC separation
P09613946A0194|75 79|250x4
P09613946A0194|82 87|mm I.D.
P09614065A0966|0 10|Elimination
P09614065A0966|16 32|inducible response
P09614065A0966|41 60|simultaneous mutation
P09614065A0966|67 75|sequences
P09614065A0966|102 111|intact EpRE
P09614065A0966|115 130|upstream AP-1 site
P09614065A0966|133 142|irrelevant
P09614065A0966|145 153|induction
P09614106T0000|5 35|high mobility group-like sequences
P09614106T0000|43 61|48-base pair enhancer
P09614106T0000|67 76|Col2a1 gene
P09614106T0000|91 118|cartilage-specific expression
P09617765A0174|21 36|open reading frame
P09617765A0174|43 44|nt
P09617765A0174|50 66|virus-sense strand
P09617765A0174|71 88|untranslated region
P09617765A0174|95 96|nt
P09617765A0174|103 106|poly
P09617765A0174|108 108|A
P09617807A0929|1 20|phylogenetic analysis
P09617807A0929|26 51|reverse transcriptase domain
P09617807A0929|26 45|reverse transcriptase
P09617807A0929|63 91|differential genetic assessment
P09617807A0929|96 102|Cyclops
P09617807A0929|107 109|pea
P09617807A0929|113 124|novel element
P09617807A0929|131 150|specific relationship
P09617807A0929|175 192|Gypsy-like elements
P09617807A0929|197 202|plants
P09618150A0127|2 19|physiological doses
P09618150A0127|27 51|insulin-like growth factor I
P09618150A0127|53 57|IGF-I
P09618150A0127|61 67|insulin
P09618150A0127|83 88|potent
P09618150A0127|91 103|dibutyryl cAMP
P09618150A0127|105 110|dbcAMP
P09618150A0127|124 148|UCP1 gene transcription rate
P09618150A0127|124 131|UCP1 gene
P09618150A0127|151 151|h
P09618150A0127|160 179|UCP1 mRNA accumulation
P09618150A0127|160 167|UCP1 mRNA
P09618150A0127|182 182|h
P09618150A0127|190 202|maximal effect
P09618150A0127|204 218|15-fold increase
P09618150A0127|245 246|h.
P09618150A1464|11 17|insulin
P09618150A1464|25 46|AP-1 DNA binding activity
P09618150A1464|94 107|MEK-1 inhibitor
P09618150A1464|94 98|MEK-1
P09618164A0709|15 15|O
P09618164A0709|17 42|methyl oligoribonucleotides
P09618164A0709|46 51|OMeRNA
P09618164A0709|71 76|nuclei
P09618164A0709|79 97|primary mdx myoblasts
P09618475A0747|1 13|large deletion
P09618475A0747|19 34|CTD-binding motif
P09618475A0747|41 55|down-regulation
P09618475A0747|75 91|essential function
P09618475A0747|94 97|Nrd1
P09618481T0000|0 9|Regulation
P09618481T0000|15 40|human p21/WAF1/Cip1 promoter
P09618481T0000|24 27|WAF1
P09618481T0000|29 32|Cip1
P09618481T0000|43 54|hepatic cells
P09618481T0000|57 78|functional interactions
P09618481T0000|86 88|Sp1
P09618481T0000|92 108|Smad family members
P09619631A0344|0 6|RESULTS
P09619631A0344|19 31|C. elegans cDNA
P09619631A0344|82 91|homologous
P09619631A0344|96 115|mammalian p120 Ras-GAP
P09619777A1583|3 22|weak base ketoconazole
P09619777A1583|29 47|complete dissolution
P09619777A1583|53 69|tablet formulation
P09619777A1583|72 92|Simulated Gastric Fluid
P09619777A1583|100 105|pepsin
P09619777A1583|107 111|SGFsp
P09619777A1583|121 127|minutes
P09619777A1583|131 142|% dissolution
P09619777A1583|146 150|hours
P09619777A1583|159 194|state simulated upper jejunal conditions
P09619777A1583|203 214|% dissolution
P09619777A1583|218 222|hours
P09619777A1583|228 248|fasted state conditions
P09620273A0189|2 8|mammals
P09620273A0189|13 21|Rb protein
P09620273A0189|47 59|D-type cyclins
P09620273A0189|72 88|cell proliferation
P09620273A0189|91 97|binding
P09620273A0189|111 133|E2F transcription factors
P09620606A0000|15 21|signals
P09620606A0000|32 39|ligation
P09620606A0000|45 47|TCR
P09620606A0000|49 54|T cells
P09620606A0000|70 90|co-stimulatory signals
P09620873A1710|33 59|luteal HSP-27 phosphorylation
P09620873A1710|69 81|late pregnancy
P09620873A1710|87 95|PKC-delta
P09620873A1710|98 105|abundant
P09620873A1710|128 149|select PKC family members
P09620873A1710|162 186|sHSP phosphorylation events
P09620873A1710|162 165|sHSP
P09620955A0370|33 42|leader mRNA
P09620955A0370|53 64|program Mfold
P09620955A0370|82 87|nested
P09620955A0370|91 107|internal deletions
P09620955A0370|133 153|promoterless lac operon
P09620955A0370|145 153|lac operon
P09621062A0810|20 24|sites
P09621062A0810|28 52|transcriptional activation
P09621062A0810|65 88|site-directed mutagenesis
P09621062A0810|99 122|promoter function analysis
P09621062A0810|128 134|mutants
P09621062A0810|140 185|chloramphenicol acetyltransferase reporter system
P09621372A0369|0 22|Routine blood examination
P09621372A0369|29 40|leukocytosis
P09621372A0369|42 57|thrombocytopenia
P09621372A0369|59 69|positive CRP
P09621372A0369|67 69|CRP
P09621372A0369|74 98|elevated myocardial enzymes
P09621893A0000|0 14|Previous studies
P09621893A0000|47 55|increases
P09621893A0000|59 72|responsiveness
P09621893A0000|75 102|vascular alpha2-adrenoceptors
P09622055A0207|3 9|members
P09622055A0207|15 23|Cbl family
P09622055A0207|46 52|mammals
P09622055A0207|54 58|c-Cbl
P09622055A0207|62 66|Cbl-b
P09622055A0207|74 82|C. elegans
P09622055A0207|84 88|Sli-1
P09622055A0207|109 113|D-Cbl
P09622121A0525|0 17|Anti-PTB antibodies
P09622121A0525|34 40|binding
P09622121A0525|43 45|PTB
P09622121A0525|48 50|RNA
P09622121A0525|72 97|supershift RNA-PTB complexes
P09622121T0000|8 17|antibodies
P09622121T0000|23 55|polypyrimidine tract binding protein
P09622121T0000|57 59|PTB
P09622121T0000|73 89|protein components
P09622121T0000|124 132|pre-mRNAs
P09622121T0000|140 158|distant branch points
P09623830A0000|3 16|therapeutic use
P09623830A0000|19 32|botulinum toxin
P09623830A0000|34 38|Botox
P09625762A0426|3 21|viral oncoprotein E1A
P09625762A0426|19 21|E1A
P09625762A0426|30 58|NFAT-dependent transactivation
P09625762A0426|30 33|NFAT
P09625762A0426|62 81|p300-dependent manner
P09625762A0426|62 65|p300
P09625807A0000|16 44|mRNA differential display method
P09625807A0000|64 68|mRNAs
P09625807A0000|85 126|normal nasopharyngeal epithelial cell cultures
P09625807A0000|134 165|nasopharyngeal carcinoma cell lines
P09626662A1076|0 17|Similar experiments
P09626662A1076|22 23|TR
P09626662A1076|34 45|high affinity
P09626662A1076|48 53|RIP140
P09626662A1076|59 68|RXR subunit
P09626662A1076|105 121|TR/RXR heterodimer
P09626662A1076|105 106|TR
P09626662A1076|108 110|RXR
P09626662A1076|147 152|ligand
P09627285A0160|0 6|SETTING
P09627285A0160|8 31|University hospital-based
P09627285A0160|33 61|tertiary care infertility center
P09627285A0554|0 5|RESULT
P09627285A0554|7 7|S
P09627285A0554|12 19|patients
P09627285A0554|24 40|elevated FSH levels
P09627285A0554|32 34|FSH
P09627285A0554|43 50|cycle day
P09627285A0554|54 67|low oocyte yield
P09627285A0554|94 103|high number
P09627285A0554|106 112|ampules
P09627285A0554|115 117|hMG
P09627598A0384|0 6|RESULTS
P09627598A0384|13 20|patients
P09627598A0384|30 30|%
P09627598A0384|47 59|greater values
P09627598A0384|62 85|directional preponderance
P09627598A0384|91 98|OVAR test
P09627598A0384|110 131|otolith system imbalance
P09627598A0384|145 159|control subjects
P09628375A0700|5 18|ePTFE specimens
P09628375A0700|20 33|tissue coverage
P09628419A0812|16 19|Wing
P09628419A0812|23 40|Kristofferson model
P09628419A0812|45 53|durations
P09628419A0812|56 69|successive ISIs
P09628821A1194|18 31|KG1a EST dataset
P09628821A1194|35 44|candidates
P09628821A1194|48 60|new human genes
P09628821A1194|72 76|roles
P09628821A1194|79 117|hematopoietic differentiative progression
P09628821A1194|121 137|lineage commitment
P09628890A0455|20 36|Specific mutations
P09628890A0455|48 75|precise carbohydrate structure
P09628890A0455|79 85|folding
P09628890A0455|91 98|HA trimer
P09629449A0540|3 9|results
P09629449A0540|18 30|ROS production
P09629449A0540|33 49|viable spermatozoa
P09629449A0540|90 100|PMN elastase
P09629449A0540|119 137|peroxidase-positive
P09629449A0540|119 128|peroxidase
P09629449A0540|141 150|round cells
P09630245A0102|0 11|Yeast U1 snRNP
P09630245A0102|44 62|metazoan counterpart
P09630245A0102|77 95|possible differences
P09630245A0102|103 107|yeast
P09630245A0102|111 117|metazoa
P09630245A0102|120 138|early splicing events
P09630245A0903|0 11|Yeast U1 snRNP
P09630245A0903|31 47|different proteins
P09630245A0903|63 79|snRNP core proteins
P09630245A0903|86 95|homologues
P09630245A0903|101 132|metazoan U1 snRNP-specific proteins
P09630245A0903|140 168|yeast-specific U1 snRNP proteins
P09631366A0951|8 17|first cycle
P09631366A0951|21 25|cases
P09631366A0951|39 47|dose level
P09631366A0951|56 66|second cycle
P09631366A0951|70 74|cases
P09631366A0951|88 96|dose level
P09632217A0477|3 28|opioid antagonist naltrexone
P09632217A0477|38 42|mg/kg
P09632217A0477|58 86|discriminative stimulus effects
P09632217A0477|89 94|heroin
P09632217A0477|99 108|naltrexone
P09632217A0477|111 115|doses
P09632217A0477|122 126|mg/kg
P09632217A0477|143 171|discriminative stimulus effects
P09632637A0361|21 49|hepatic stellate cell regulation
P09632637A0361|52 71|M6P/IGFIIR expression
P09632637A0361|52 54|M6P
P09632637A0361|56 61|IGFIIR
P09632637A0361|84 113|M6P/IGFIIR mRNA transcript levels
P09632637A0361|84 86|M6P
P09632637A0361|88 93|IGFIIR
P09632637A0361|125 137|stellate cells
P09632637A0361|142 145|rats
P09632637A0361|155 173|carbon tetrachloride
P09632637A0361|175 178|CCl4
P09632637A0361|182 206|potent fibrogenic stimulant
P09632709A0464|3 11|cDNA clone
P09632709A0464|22 28|NCoA-62
P09632709A0464|41 53|000-Da protein
P09632709A0464|75 78|BX42
P09632709A0464|81 116|Drosophila melanogaster nuclear protein
P09632709A0464|103 116|nuclear protein
P09632709A0464|127 159|ecdysone-stimulated gene expression
P09632734A0081|20 27|proteins
P09632734A0081|34 49|C-terminal region
P09632734A0081|59 85|significant sequence homology
P09632734A0081|96 118|GDP/GTP exchange proteins
P09632734A0081|125 134|Rab3 family
P09632734A0081|137 159|small GTP binding proteins
P09632734A0943|7 19|p82 expression
P09632734A0943|7 9|p82
P09632734A0943|33 46|ERK2 activation
P09632734A0943|33 36|ERK2
P09632734A0943|49 52|p126
P09632734A0943|54 56|p70
P09632785A0000|3 28|pre-mRNA splicing factor U2AF
P09632785A0000|25 28|U2AF
P09632785A0000|30 68|U2 small nuclear ribonucleoprotein particle
P09632785A0000|70 74|snRNP
P09632785A0000|76 90|auxiliary factor
P09632785A0000|98 109|critical role
P09632785A0000|114 132|splice site selection
P09633171A0321|3 10|brackets
P09633171A0321|42 55|bovine incisors
P09633171A0321|75 82|tap water
P09633171A0321|85 99|room temperature
P09633171A0321|105 109|hours
P09633171A0321|140 148|shear mode
P09633171A0321|155 177|universal testing machine
P09633274A0000|0 15|Exercise training
P09633274A0000|62 81|heart failure patients
P09633630A0740|11 13|Aer
P09633630A0740|15 24|hydrophila
P09633630A0740|27 57|filter-sterilized lettuce extract
P09633630A0740|85 85|%
P09633630A0740|87 89|v/v
P09633630A0740|91 93|BMC
P09633630A0740|107 108|Ps
P09633630A0740|110 120|fluorescens
P09633630A0740|151 151|%
P09633630A0740|153 155|v/v
P09633630A0740|157 159|BMC
P09633879A0246|7 26|continuous compliance
P09633879A0246|28 48|unexplained resurgence
P09633879A0246|51 69|serum ferritin levels
P09633879A0246|83 90|patients
P09633879A0246|118 122|years
P09633879A0246|125 126|L1
P09635149A1148|0 9|Hematocrit
P09635149A1148|13 16|PaO2
P09635276A1608|0 9|Regulation
P09635276A1608|12 36|myosin phosphatase activity
P09635276A1608|12 28|myosin phosphatase
P09635276A1608|45 51|changes
P09635276A1608|54 72|subunit interactions
P09635276A1608|82 100|molecular mechanisms
P09636119T0000|0 27|Commutative saccadic generator
P09636119T0000|50 63|3-D ocular plant
P09636119T0000|68 74|pulleys
P09636358A0000|3 24|virus-associated VAI RNA
P09636358A0000|27 36|adenovirus
P09636358A0000|51 63|structured RNA
P09636358A0000|84 103|efficient translation
P09636358A0000|106 113|cellular
P09636358A0000|117 126|viral mRNAs
P09636358A0000|129 137|late times
P09636670T0000|0 8|Structure
P09636670T0000|29 67|human cyclin-dependent kinase inhibitor p18
P09636670T0000|71 88|mutational analysis
P09636670T0000|91 102|breast cancer
P09636708A0460|3 13|YccA protein
P09636708A0460|38 57|FtsH-dependent manner
P09636708A0460|38 41|FtsH
P09636708A0460|85 103|YccA11 mutant protein
P09636708A0460|117 133|amino acid residues
P09636708A0460|143 173|amino-terminal cytoplasmic domain
P09636708A0460|178 187|refractory
P09636708A0460|193 203|degradation
P09637689A0150|3 11|major type
P09637689A0150|20 36|activator proteins
P09637689A0150|47 57|DNA adjacent
P09637689A0150|68 80|RNA polymerase
P09637689A0150|82 85|RNAP
P09637689A0150|87 96|holoenzyme
P09637689A0150|121 131|recruitment
P09637689A0150|137 140|RNAP
P09637689A0150|146 153|promoter
P09638342T0000|17 18|L1
P09638342T0000|22 38|transmembrane link
P09638342T0000|46 61|neuronal adhesion
P09638342T0000|65 92|membrane cytoskeleton assembly
P09638485A0111|0 17|Atmospheric benzene
P09638485A0111|19 36|urinary muconic acid
P09638485A0111|38 42|tt-MA
P09638485A0111|47 82|leukocyte alkaline phosphatase activity
P09638485A0111|47 74|leukocyte alkaline phosphatase
P09638485A0111|84 87|LAPA
P09638485A0111|109 120|car mechanics
P09638485A0111|124 140|road tanker drivers
P09638485A0111|147 163|nonexposed workers
P09638650A0169|14 28|noncoding region
P09638650A0169|30 32|NCR
P09638650A0169|38 48|nucleotides
P09638650A0169|54 70|open reading frames
P09638650A0169|72 75|ORFs
P09638650A0169|92 99|proteins
P09638650A0169|104 104|M
P09638650A0169|106 106|r
P09638650A0169|111 139|kDa RNA-dependent RNA polymerase
P09638650A0169|141 144|ORF1
P09638650A0169|147 167|26 kDa movement protein 1
P09638650A0169|149 166|kDa movement protein
P09638650A0169|169 172|ORF2
P09638650A0169|177 194|kDa movement protein
P09638650A0169|197 200|ORF3
P09638650A0169|205 222|kDa movement protein
P09638650A0169|225 228|ORF4
P09638650A0169|233 246|kDa coat protein
P09638650A0169|248 251|OFR5
P09638650A0169|260 262|NCR
P09638650A0169|267 277|nucleotides
P09638793A1446|5 36|profound normovolemic hemodilution
P09638793A1446|38 40|Hct
P09638793A1446|42 42|%
P09638793A1446|44 54|superiority
P09638793A1446|57 60|LV MC
P09638793A1446|64 84|LV diastolic properties
P09638793A1446|98 118|myocardial oxygenation
P09638793A1446|133 154|i.v. perflubron emulsion
P09639074A0707|0 2|Sp1
P09639074A0707|9 19|Sp3 isoforms
P09639074A0707|37 63|primary cellular constituents
P09639074A0707|66 85|DNA-protein complexes
P09639074A0707|99 120|NF-kappaB-proximal site
P09639410A3282|5 9|genes
P09639410A3282|22 39|interesting targets
P09639410A3282|43 66|new therapeutic strategies
P09639558A0957|18 40|C1q-dependent haemolysis
P09639558A0957|18 20|C1q
P09639558A0957|47 49|IgG
P09639558A0957|54 79|IgM-sensitized erythrocytes
P09639558A0957|54 56|IgM
P09639565A0225|8 13|distal
P09639565A0225|39 54|enhancer activity
P09639565A0225|57 70|pituitary cells
P09639565A0225|94 105|SV40 promoter
P09640162A0242|3 15|second patient
P09640162A0242|27 56|pituitary-derived growth hormone
P09640162A0242|71 93|growth hormone deficiency
P09640162A0242|71 83|growth hormone
P09640162A0242|107 128|third ventricle teratoma
P09640162A0242|138 139|yr
P09640802A0467|28 47|cosmetic consequences
P09640802A0467|53 63|chinese flap
P09640802A0467|75 92|other possibilities
P09640802A0467|98 107|flap choice
P09641167A1359|0 9|CONCLUSION
P09641167A1359|11 18|TNF alpha
P09641167A1359|20 26|TGF beta
P09641167A1359|28 31|PDGF
P09641167A1359|35 42|IL-1beta
P09641167A1359|52 69|LDLr gene expression
P09641167A1359|52 59|LDLr gene
P09641167A1359|82 99|sterol-independent
P09641167A1359|103 142|mitogenesis-independent gene transcription
P09642042A0646|0 16|Binding affinities
P09642042A0646|19 41|different nucleotide mono
P09642042A0646|50 62|triphosphates
P09642042A0646|66 88|non-hydrolyzable analogs
P09642042A0646|104 123|beta-phosphate moiety
P09642042A0646|137 152|substrate binding
P09642200A0956|16 23|one-half
P09642200A0956|48 59|proteolipids
P09642200A0956|64 84|M. thermoautotrophicum
P09642200A0956|88 99|M. jannaschii
P09642200A0956|114 117|ahaK
P09642200A0956|173 191|cytoplasmic membrane
P09642200A0956|202 225|different chemical natures
P09642200A0956|228 233|lipids
P09642200A0956|238 244|archaea
P09642214A0244|30 61|protein-tyrosine phosphatase SHP-2
P09642214A0244|30 56|protein-tyrosine phosphatase
P09642214A0244|57 61|SHP-2
P09642214A0244|64 86|ErbB-mediated activation
P09642214A0244|64 67|ErbB
P09642214A0244|89 118|mitogen-activated protein kinase
P09642214A0244|120 123|MAPK
P09642214A0244|141 152|SHP-2 mutants
P09642214A0244|155 164|COS-7 cells
P09642227A0000|0 11|Osteoadherin
P09642227A0000|32 47|bone proteoglycan
P09642227A0000|58 71|keratan sulfate
P09642238A0532|0 5|Intron
P09642238A0532|16 55|strong erythroid-specific enhancer activity
P09642238A0532|22 47|erythroid-specific enhancer
P09642238A0532|64 84|orientation-dependent
P09642238A1285|3 8|intron
P09642238A1285|10 23|enhancer region
P09642238A1285|41 46|GATA-1
P09642238A1285|59 61|Sp1
P09642238A1285|64 89|transactivation experiments
P09642238A1285|92 101|COS-1 cells
P09642238A1285|129 145|related Sp1 protein
P09642238A1285|157 183|unidentified erythroid factor
P09642276A0881|3 10|cleavage
P09642276A0881|13 15|Fak
P09642276A0881|18 25|caspases
P09642276A0881|39 51|important role
P09642276A0881|71 84|suicide program
P09642276A0881|99 120|anti-apoptotic function
P09642276A0881|123 125|Fak
P09642764A0469|32 42|QCM response
P09642764A0469|53 69|Sauerbrey equation
P09642764A0469|106 130|other analytical techniques
P09642764A0469|143 156|enzymatic assay
P09642764A0469|216 218|QCM
P09643153T0000|1 9|Treatment
P09643153T0000|12 39|early T1 small T2N breast cancers
P09643546A0436|0 22|Transcription initiation
P09643546A0436|49 80|putative sigmaA-dependent promoter
P09643546A0436|57 80|sigmaA-dependent promoter
P09643546A0436|103 107|cells
P09643546A0436|126 141|stress conditions
P09643548A0000|3 7|genes
P09643548A0000|17 22|2Fe-2S
P09643548A0000|24 44|plant-like ferredoxins
P09643548A0000|71 104|cyanobacterium Synechocystis PCC6803
P09645576A0148|0 2|RNA
P09645576A0148|5 9|GBV-C
P09645576A0148|28 28|%
P09645576A0148|30 37|patients
P09645576A0148|44 46|BMT
P09645942A1164|1 9|major pool
P09645942A1164|12 35|Dsg-plakoglobin complexes
P09645942A1164|12 14|Dsg
P09645942A1164|16 26|plakoglobin
P09645942A1164|48 49|8S
P09645942A1164|66 78|stoichiometry
P09645961A1158|3 9|results
P09645961A1158|25 31|binding
P09645961A1158|34 41|CBF/NF-Y
P09645961A1158|34 36|CBF
P09645961A1158|38 41|NF-Y
P09645961A1158|47 62|inverted CCAAT box
P09645961A1158|79 103|transcriptional activation
P09645961A1158|109 116|nTPH gene
P09647233A0336|2 12|macrophages
P09647233A0336|14 45|LPS-inducible HIV-1 gene expression
P09647233A0336|27 35|HIV-1 gene
P09647233A0336|64 70|binding
P09647233A0336|73 81|NF-kappa B
P09647233A0336|84 117|identical tandem binding sites located
P09647233A0336|127 144|long terminal repeat
P09647233A0336|146 148|LTR
P09647240A0000|14 16|p53
P09647240A0000|19 61|cytokine-triggered Janus kinase-STAT signaling
P09647240A0000|37 47|Janus kinase
P09647240A0000|49 52|STAT
P09647240A0000|79 105|human hepatoma Hep3B cell lines
P09647240A0000|142 174|temperature-sensitive Val135 mutant
P09647240A0000|163 174|Val135 mutant
P09647240A0000|177 179|p53
P09649069A0490|24 49|various laryngeal parameters
P09649069A0490|62 81|videotaped endoscopic
P09649069A0490|85 108|stroboscopic examinations
P09649265A1575|0 10|CONCLUSIONS
P09649265A1575|15 29|consecutive sets
P09649265A1575|32 52|transrectal ultrasound
P09649265A1575|59 73|sextant biopsies
P09649265A1575|79 86|prostate
P09649265A1575|99 115|single office visit
P09649265A1575|126 153|cost-effective biopsy strategy
P09649265A1575|157 159|men
P09649265A1575|176 207|abnormal digital rectal examination
P09649265A1575|214 229|elevated serum PSA
P09649315A0943|0 10|Examination
P09649315A0943|13 36|nuclear magnetic resonance
P09649315A0943|38 40|NMR
P09649315A0943|42 48|spectra
P09649315A0943|60 97|N-terminally truncated MIP-1 beta variants
P09649315A0943|60 71|N-terminally
P09649315A0943|81 97|MIP-1 beta variants
P09649315A0943|114 121|proteins
P09649426A0636|14 24|PKA activity
P09649426A0636|14 16|PKA
P09649426A0636|27 37|dispensable
P09649426A0636|54 58|Msn2p
P09649426A0636|62 74|Msn4p activity
P09649426A0636|62 66|Msn4p
P09649437A1140|20 37|direct interactions
P09649437A1140|45 50|C/EBPs
P09649437A1140|54 77|specific Ets family members
P09649437A1140|62 77|Ets family members
P09649437A1140|91 96|GATA-1
P09649437A1140|113 142|eosinophil lineage determination
P09649438A0182|10 49|human transcription elongation factor P-TEFb
P09649438A0182|63 72|CDK9 kinase
P09649438A0182|74 80|cyclin T
P09649438A0182|84 105|other associated factors
P09649438A0182|133 135|Tat
P09649438A0182|145 157|Tat activation
P09649438A0182|145 147|Tat
P09649438A0182|160 177|HeLa nuclear extract
P09649438A0182|188 193|P-TEFb
P09649501A0358|13 30|hydrophobic repeats
P09649501A0358|36 58|HSF1 trimerization domain
P09649501A0358|64 101|yeast two-hybrid protein interaction assay
P09649501A0358|112 141|heat shock factor binding protein 1
P09649501A0358|112 140|heat shock factor binding protein
P09649501A0358|143 147|HSBP1
P09649501A0358|167 186|76-amino-acid protein
P09649501A0358|202 215|extended arrays
P09649501A0358|218 235|hydrophobic repeats
P09649501A0358|255 271|HSF1 heptad repeats
P09649537A0000|0 6|Genomic
P09649537A0000|10 29|cDNA clones homologous
P09649537A0000|35 59|yeast GCN2 eIF-2alpha kinase
P09649537A0000|61 65|yGCN2
P09650180A1130|3 22|general recombination
P09650180A1130|26 42|polarizing voltage
P09650180A1130|48 48|V
P09650180A1130|60 60|%
P09650180A1130|64 73|dose-rates
P09650180A1130|86 93|mGy min-1
P09650186A1043|3 11|low number
P09650186A1043|14 27|false positives
P09650186A1043|68 78|radiologist
P09650186A1043|91 103|normal regions
P09650275T0000|16 42|biological weapons convention
P09650275T0000|46 57|implications
P09650275T0000|63 76|pharmaceutical
P09650275T0000|80 100|biotechnology industry
P09650299A0000|0 4|VirD2
P09650299A0000|15 49|key Agrobacterium tumefaciens proteins
P09650299A0000|60 74|T-DNA processing
P09650299A1334|38 53|VirD2 omega domain
P09650299A1334|68 92|efficient T-DNA integration
P09650403A0868|3 13|DHEAS levels
P09650403A0868|19 24|stages
P09650403A0868|36 38|BMD
P09650403A0868|84 92|normal BMD
P09650789A0185|0 10|Orientation
P09650789A0185|16 32|nuclear spin system
P09650789A0185|35 41|optical
P09650789A0185|57 71|Overhauser shift
P09650789A0185|77 109|excitonic energy levels proportional
P09650789A0185|123 140|nuclear orientation
P09651321A0000|0 8|Cystatin A
P09651321A0000|11 37|cysteine proteinase inhibitor
P09651321A0000|49 65|precursor proteins
P09651321A0000|68 88|cornified cell envelope
P09651321A0000|91 103|keratinocytes
P09651321A0000|127 135|late stage
P09651321A0000|138 164|keratinocyte differentiation
P09651367T0000|8 13|RalGDS
P09651367T0000|18 33|novel Ras effector
P09651367T0000|23 25|Ras
P09651367T0000|39 60|Ras-mediated inhibition
P09651367T0000|39 41|Ras
P09651367T0000|63 80|skeletal myogenesis
P09651375T0000|0 5|GTPase
P09651375T0000|16 26|specificity
P09651375T0000|29 33|RGS12
P09651375T0000|37 54|binding specificity
P09651375T0000|79 81|PDZ
P09651375T0000|83 88|PSD-95
P09651375T0000|90 95|Dlg/ZO
P09651375T0000|90 92|Dlg
P09651375T0000|94 97|ZO-1
P09651383A0967|8 16|mutations
P09651383A0967|22 37|HNF-4 binding site
P09651383A0967|40 50|element CIIB
P09651383A0967|54 63|inhibition
P09651383A0967|66 79|HNF-4 synthesis
P09651383A0967|66 70|HNF-4
P09651383A0967|82 91|HepG2 cells
P09651383A0967|94 117|antisense HNF-4 constructs
P09651383A0967|130 151|apoCII promoter activity
P09651383A0967|130 143|apoCII promoter
P09651383A0967|159 159|%
P09651383A0967|187 191|HNF-4
P09651383A0967|195 211|positive regulator
P09651383A0967|217 226|apoCII gene
P09652736A1205|21 25|E2F-1
P09652736A1205|34 42|apoptosis
P09652736A1205|45 47|p53
P09652736A1205|51 61|tumour cells
P09652736A1205|65 75|further p300
P09652736A1205|72 75|p300
P09652736A1205|98 109|co-activator
P09652736A1205|116 132|E2F/DP heterodimer
P09652736A1205|116 118|E2F
P09652736A1205|145 161|apoptotic activity
P09652736A1205|164 168|E2F-1
P09652737A1244|7 30|shift/supershift analysis
P09652737A1244|44 66|Fos family member proteins
P09652737A1244|77 81|Fra-1
P09652737A1244|85 89|Fra-2
P09652737A1244|102 112|progression
P09652737A1244|118 124|changes
P09652737A1244|135 157|Jun family member proteins
P09652737A1244|185 188|AP-1
P09652737A1244|190 206|DNA binding complex
P09652742A0455|24 35|unmutated p53
P09652742A0455|33 35|p53
P09652742A0455|57 81|premalignant mammary glands
P09652742A0455|87 99|mammary tumors
P09652742A0455|114 129|MMTV-c-myc strain
P09652742A0455|114 123|MMTV-c-myc
P09653182A1298|17 37|heterologous virus RNAs
P09653182A1298|39 42|BSMV
P09653182A1298|54 65|primer donors
P09653182A1298|69 76|MStV mRNA
P09653182A1298|83 105|RNA-primed transcription
P09653182A1298|114 127|infected plants
P09653641A0471|0 12|Human isoforms
P09653641A0471|53 62|start codon
P09653648A0445|0 9|Comparison
P09653648A0445|12 15|cDNA
P09653648A0445|19 34|genomic sequences
P09653648A0445|47 56|ZNF189 gene
P09653648A0445|77 78|kb
P09653648A0445|108 112|exons
P09653648A0445|125 131|end exon
P09653648A0445|144 167|complete zinc finger domain
P09653648A0445|176 193|untranslated region
P09653745A0180|0 6|Malaria
P09653745A0180|38 47|early 1940s
P09653745A0180|56 67|paper queries
P09653745A0180|99 113|control projects
P09653745A0180|119 126|thirties
P09653745A0180|144 155|such projects
P09653745A0180|204 210|malaria
P09653745A0180|221 232|problem today
P09655248A0000|3 19|gp330/Megalin/LRP
P09655248A0000|3 7|gp330
P09655248A0000|9 15|Megalin
P09655248A0000|17 28|LRP-2 protein
P09655248A0000|41 80|low-density lipoprotein receptor gene family
P09655248A0000|108 124|endocytic receptor
P09655248A0000|131 136|uptake
P09655248A0000|139 150|lipoproteins
P09655248A0000|154 169|many other ligands
P09655916A0415|5 33|DNA recognition helix of finger II
P09655916A0415|5 23|DNA recognition helix
P09655916A0415|47 49|Arg
P09655916A0415|63 76|N-terminal side
P09655916A0415|82 112|first zinc-coordinating histidine
P09655916A0415|127 129|Leu
P09655916A0415|132 134|Gln
P09656414A0220|0 5|Dosage
P09656414A0220|12 16|cases
P09656414A0220|23 26|g/m2
P09656485A0351|4 19|additional copies
P09656485A0351|22 33|Lian elements
P09656485A0351|55 74|restriction digestion
P09657003T0000|0 24|Evolutionary relationships
P09657003T0000|30 64|putative RNA-dependent RNA polymerases
P09657003T0000|38 64|RNA-dependent RNA polymerases
P09657003T0000|75 100|mitochondrial virus-like RNA
P09657003T0000|106 126|Dutch elm disease fungus
P09657003T0000|128 146|Ophiostoma novo-ulmi
P09657003T0000|150 161|other viruses
P09657003T0000|165 178|virus-like RNAs
P09657003T0000|187 216|Arabidopsis mitochondrial genome
P09658104T0000|0 3|Role
P09658104T0000|9 40|transcription start site core region
P09658104T0000|44 65|transcription factor YY1
P09658104T0000|63 65|YY1
P09658104T0000|68 117|Rous sarcoma virus long terminal repeat promoter activity
P09658104T0000|68 109|Rous sarcoma virus long terminal repeat promoter
P09658122T0000|0 11|Fowlpox virus
P09658122T0000|19 38|nonessential homologs
P09658122T0000|41 58|cellular alpha-SNAP
P09658122T0000|60 63|PC-1
P09658122T0000|70 87|orphan human homolog
P09658122T0000|99 113|nematode protein
P09658403A1207|0 7|Addition
P09658403A1207|10 12|Rap
P09658403A1207|15 18|KN62
P09658403A1207|34 38|cells
P09658403A1207|41 62|progesterone agonist Org
P09658403A1207|80 88|induction
P09658403A1207|91 101|CAT activity
P09658403A1207|91 93|CAT
P09658405A0000|3 11|Dax-1 gene
P09658405A0000|54 60|members
P09658405A0000|66 97|orphan nuclear receptor superfamily
P09658769A0058|17 38|recombinant IFN alpha-2b
P09658769A0058|28 38|IFN alpha-2b
P09658769A0058|58 75|chronic hepatitis C.
P09660823A0934|8 29|Ser/Thr phosphorylation
P09660823A0934|32 53|downstream molecules Akt
P09660823A0934|51 53|Akt
P09660823A0934|57 67|p70 S6 kinase
P09660836A0983|0 21|Quantitative evaluation
P09660836A0983|27 45|steady state kinetics
P09660836A0983|48 60|MEK inhibition
P09660836A0983|48 50|MEK
P09660836A0983|68 76|compounds
P09660836A0983|88 92|U0126
P09660836A0983|117 130|higher affinity
P09660836A0983|134 155|deltaN3-S218E/S222D MEK
P09660836A0983|134 146|deltaN3-S218E
P09660836A0983|148 155|S222D MEK
P09660836A0983|164 171|PD098059
P09660838A0920|0 9|Regulation
P09660838A0920|14 21|degrees C
P09660838A0920|57 77|protein kinase cascades
P09660838A0920|89 92|HSF1
P09660838A0920|100 114|phosphorylation
P09660838A0920|117 130|serine residues
P09660838A0920|180 196|heat shock response
P09661676T0000|0 18|Clinical implication
P09661676T0000|21 33|protein levels
P09661676T0000|36 39|IL-5
P09661676T0000|49 54|sputum
P09661676T0000|57 73|asthmatic patients
P09662339A0744|7 11|cells
P09662339A0744|13 33|ras-induced transition
P09662339A0744|13 15|ras
P09662339A0744|50 64|strong induction
P09662339A0744|67 86|AP-1-binding activity
P09662339A0744|67 70|AP-1
P09662339A0744|117 124|CD44 mRNA
P09662443A0402|33 51|genomic organization
P09662443A0402|55 77|developmental expression
P09662443A0402|83 100|caveolin gene family
P09663062A0175|0 19|Tensile bond strengths
P09663062A0175|27 40|resin composite
P09663062A0175|44 55|bovine dentin
P09663062A0175|61 81|dentin adhesive systems
P09663062A0175|83 101|Clearfil Liner Bond II
P09663062A0175|103 104|LB
P09663062A0175|108 130|Scotchbond Multi-Purpose
P09663062A0175|132 133|MP
P09663062A0175|135 148|bonding systems
P09663062A0175|156 167|large scatter
P09663062A0175|173 180|students
P09663062A0175|184 191|dentists
P09664033A1204|30 51|polycistronic precursor
P09664033A1204|69 77|nucleolus
P09664033A1204|96 108|mature snoRNAs
P09664033A1204|128 144|processing pathway
P09664033A1204|153 164|coiled bodies
P09665361T0000|0 17|Suppressive therapy
P09665361T0000|21 34|thyroid nodules
P09665503A0526|8 28|healthy male volunteers
P09665720A0325|14 16|Mg2
P09665720A0325|20 45|hydrophobic exonuclease site
P09665720A0325|62 75|polymerase site
P09665720A0325|94 107|primer terminus
P09665720A1145|5 20|high-affinity Mg2
P09665720A1145|22 33|binding sites
P09665720A1145|47 60|primer terminus
P09665720A1145|76 90|exonuclease site
P09665720A1145|112 131|polymerase active site
P09666103A0496|3 16|missense allele
P09666103A0496|18 22|P236S
P09666103A0496|28 39|complete loss
P09666103A0496|54 61|degreesC
P09666103A0496|69 83|missense alleles
P09666103A0496|85 89|L173F
P09666103A0496|91 95|E225K
P09666103A0496|97 101|S269L
P09666103A0496|105 109|E274K
P09666103A0496|125 153|temperature sensitive phenotype
P09666114A0389|0 17|Structural analysis
P09666114A0389|23 41|5'-regulatory region
P09666114A0389|26 41|regulatory region
P09666114A0389|56 68|c-met promoter
P09666114A0389|74 77|TATA
P09666114A0389|80 91|CAAT elements
P09666114A0389|109 122|high G-C content
P09666114A0389|126 148|multiple Sp1 binding sites
P09667482A0978|22 41|possible contribution
P09667482A0978|44 56|stress factors
P09667482A0978|71 104|therapy resistant periodontal disease
P09667482A0978|112 118|results
P09667482A0978|127 140|understandable
P09667482A0978|160 190|stress system disorder perspective
P09667795A0000|0 16|Acute pancreatitis
P09667795A0000|26 48|common abdominal disorder
P09668063A0274|27 37|Ets proteins
P09668063A0274|40 56|Ras transformation
P09668063A0274|40 42|Ras
P09668063A0274|78 84|effects
P09668063A0274|113 126|Ets2 constructs
P09668063A0274|129 149|Ras-transformed NIH3T3
P09668063A0274|129 131|Ras
P09668063A0274|151 152|DT
P09668063A0274|154 158|cells
P09668096A0806|61 68|partners
P09668098A0868|13 31|human FGF-BP promoter
P09668098A0868|47 62|deletion analysis
P09668098A0868|67 87|TPA regulatory elements
P09668098A0868|117 133|base pairs upstream
P09668098A0868|139 160|transcription start site
P09668108A1017|0 11|Manipulation
P09668108A1017|17 36|checkpoint regulators
P09668108A1017|47 61|cell cycle arrest
P09668108A1017|65 73|apoptosis
P09668108A1017|89 101|novel strategy
P09668108A1017|104 116|cancer therapy
P09668119A0496|0 33|Electrophoretic mobility shift assays
P09668119A0496|46 74|specific nuclear protein binding
P09668119A0496|88 107|single point mutations
P09668119A0496|117 143|important binding nucleotides
P09668119A0496|166 178|critical bases
P09668119A0496|197 203|CTCCT-3
P09669641A0425|3 20|diagnostic accuracy
P09669641A0425|23 31|serum PE-1
P09669641A0425|49 55|amylase
P09670034A0340|17 21|Ddc1p
P09670034A0340|51 55|Mec3p
P09670034A0340|83 88|Rad17p
P09670912T0000|1 14|Complex partial
P09670912T0000|16 23|seizures
P09670943T0000|0 19|B cell antigen receptor
P09670943T0000|21 23|BCR
P09670943T0000|46 63|SHP-2-pp120 complex
P09670943T0000|46 50|SHP-2
P09670943T0000|52 56|pp120
P09670943T0000|70 79|inhibition
P09670943T0000|82 107|Fc gamma RIIB1-BCR coligation
P09670943T0000|82 93|Fc gamma RIIB1
P09670943T0000|95 97|BCR
P09671313A0334|0 4|Chem.
P09671313A0334|28 38|MT Hartsough
P09671313A0334|45 46|J.
P09671464A0316|8 11|SNF1
P09671464A0316|21 27|meiosis
P09671464A0316|42 46|steps
P09671464A0316|66 72|glucose
P09671464A0316|88 94|glucose
P09671464A0316|101 107|meiosis
P09671464A0316|120 123|Snf1
P09671496A0557|26 30|c-Cbl
P09671496A0557|47 57|homeostasis
P09671496A0557|60 63|mice
P09671496A0557|66 83|targeted disruption
P09671496A0557|89 98|c-Cbl locus
P09671496A0557|100 118|c-Cbl-deficient mice
P09671496A0557|100 104|c-Cbl
P09671496A0557|123 128|viable
P09671496A0557|130 136|fertile
P09671576A0900|19 34|visceral endoderm
P09671576A0900|44 68|proper streak morphogenesis
P09671579A1168|13 20|noi/pax2
P09671579A1168|13 15|noi
P09671579A1168|17 22|pax2.1
P09671579A1168|37 64|sequential signaling processes
P09671579A1168|68 80|key integrator
P09671579A1168|83 119|midbrain-hindbrain boundary development
P09671791T0000|0 27|Ligand-independent activation
P09671791T0000|30 65|platelet-derived growth factor receptor
P09671791T0000|69 89|necessary intermediate
P09671791T0000|92 107|lysophosphatidic
P09671791T0000|109 140|acid-stimulated mitogenic activity
P09671791T0000|143 148|L cells
P09673037A0358|0 6|METHODS
P09673037A0358|8 22|Fibrotic changes
P09673037A0358|32 41|bone marrow
P09673037A0358|92 117|reticulin fiber impregnation
P09673037A0358|127 132|Gomori
P09673436A0898|2 23|canrenoate-treated rats
P09673436A0898|25 35|ANP infusion
P09673436A0898|42 57|greater increases
P09673436A0898|60 74|sodium excretion
P09673436A0898|76 79|FENA
P09673436A0898|108 108|%
P09673436A0898|110 110|P
P09673436A0898|117 118|n =
P09673436A0898|125 138|saline infusion
P09673436A0898|140 143|FENA
P09673436A0898|172 172|%
P09673436A0898|174 175|n =
P09673436A0898|189 198|hypocapnia
P09675154A0690|17 41|unrelated Japanese families
P09675154A0690|46 51|GSD-Ib
P09675154A0690|66 79|novel mutations
P09675154A0690|82 116|four-base deletion/two-base insertion
P09675154A0690|119 131|point mutation
P09675154A0690|139 164|consensus splicing donor site
P09675154A0690|170 185|missense mutation
P09675154A0690|187 191|W118R
P09675896A0959|0 6|Removal
P09675896A0959|12 25|carboxyl region
P09675896A0959|41 65|transcriptional activation
P09676349A0000|2 7|Level A
P09676349A0000|52 79|sustained release theophylline
P09676349A0000|81 83|CAS
P09676349A0000|104 116|Bronchoretard
P09676419A0158|0 5|METHOD
P09676419A0158|9 27|consecutive children
P09676419A0158|37 42|months
P09676419A0158|47 51|years
P09676419A0158|90 103|questionnaires
P09676419A0158|116 130|family histories
P09676419A0158|132 156|serological screening tests
P09676419A0158|160 186|common inhalational allergens
P09676419A0158|188 193|CAP SX1
P09676419A0158|214 238|total serum immunoglobulin E
P09676419A0158|240 242|IgE
P09676419A0158|249 270|latex-specific serum IgE
P09676419A0158|273 295|solid-phase immunoassays
P09677330A0584|3 41|PDE4A-subfamily-specific linker region LR1
P09677330A0584|3 38|PDE4A-subfamily-specific linker region
P09677330A0584|53 56|UCR1
P09677330A0584|60 63|UCR2
P09677330A0584|79 83|exons
P09677330A0584|92 94|LR2
P09677330A0584|106 109|UCR2
P09677330A0584|115 127|catalytic unit
P09677330A0584|141 150|single exon
P09677405A0856|0 16|Pol32Delta strains
P09677405A0856|0 9|Pol32Delta
P09677405A0856|20 35|weak antimutators
P09677405A0856|42 50|defective
P09677405A0856|54 78|damage-induced mutagenesis
P09677410A1059|5 12|same time
P09677410A1059|17 23|results
P09677410A1059|36 38|p53
P09677410A1059|45 57|defensive role
P09677410A1059|65 67|HBV
P09677410A1059|100 114|HBV core promoter
P09677410A1059|122 145|liver-specific enhancer II
P09677410A1059|122 143|liver-specific enhancer
P09677410A1059|149 151|HBx
P09677410A1059|178 195|inhibitory function
P09677410A1059|198 200|p53
P09678579A0768|35 43|AtCP1 gene
P09678579A0768|45 64|northern blot analysis
P09678837A0736|33 46|responsiveness
P09678837A0736|49 66|bronchoprovocation
P09678837A0736|71 82|methacholine
P09678837A0736|85 92|subjects
P09678837A0736|98 113|allergic rhinitis
P09678837A0736|131 142|pollen season
P09678837A0736|147 159|total serum IgE
P09678837A0736|163 178|blood eosinophils
P09679066A1352|5 11|results
P09679066A1352|22 39|first demonstration
P09679066A1352|46 54|SR protein
P09679066A1352|67 74|splicing
P09679066A1352|77 93|specific pre-mRNAs
P09679750A0304|28 56|prostate cancer chemoprevention
P09679750A0304|62 95|nonsteroidal anti-inflammatory drugs
P09679750A0304|97 121|cyclo-oxygenase inhibitors
P09679750A0304|97 111|cyclo-oxygenase
P09679750A0304|123 128|NSAIDs
P09679750A0304|141 155|little attention
P09680994A0169|31 43|P. hybrida gene
P09680994A0169|45 49|jaf13
P09680994A0169|60 87|basic helix-loop-helix protein
P09680994A0169|105 120|sequence homology
P09680994A0169|124 143|intron/exon structure
P09680994A0169|158 176|P. hybrida orthologue
P09680994A0169|182 193|Z. mays r genes
P09681822A0520|0 26|Identical c-erbB3 transcripts
P09681822A0520|9 26|c-erbB3 transcripts
P09681822A0520|41 67|normal human placental tissues
P09682897A0218|14 18|years
P09682897A0218|21 36|purposeful search
P09682897A0218|47 64|electrocardiograms
P09682897A0218|79 98|reversible QRS changes
P09682897A0218|116 133|acute injury pattern
P09683576A0542|9 46|potential cleavage site located N-terminal
P09683576A0542|52 65|protease domain
P09683576A0542|67 81|Gln2526-Asp2527
P09685021A0127|0 6|METHODS
P09685021A0127|8 40|Millipore ultrafiltration membranes
P09685021A0127|48 65|different pore sizes
P09685021A0127|76 98|model lenticule materials
P09685021A0127|103 126|nominal membrane pore sizes
P09685021A0127|134 139|microm
P09685021A0127|145 150|microm
P09685021A0127|156 161|microm
P09685021A0127|166 181|surface roughness
P09685021A0127|196 204|same order
P09685021A0127|208 216|membranes
P09685021A0127|232 240|thin layer
P09685021A0127|243 251|collagen I
P09685021A0127|267 280|circular pocket
P09685021A0127|286 299|anterior cornea
P09685021A0127|302 310|adult cats
P09685021A0127|352 368|epithelialization
P09685021A0127|375 385|persistence
P09685021A0127|388 407|epithelial attachment
P09685226A0000|9 18|calcitonin
P09685226A0000|23 35|other agonists
P09685226A0000|52 62|cAMP pathway
P09685226A0000|76 88|transcription
P09685226A0000|94 131|human parathyroid hormone-related protein
P09685226A0000|133 137|PTHrP
P09685226A0000|161 183|human lung cancer cell line
P09685226A0000|185 187|BEN
P09685346A0419|16 20|Pitx2
P09685346A0419|31 48|homeodomain protein
P09685346A0419|50 54|Pit-1
P09685346A0419|64 91|synergistic 55-fold activation
P09685346A0419|97 113|prolactin promoter
P09685346A0419|116 133|transfection assays
P09686344T0000|3 13|biochemical
P09686344T0000|17 33|molecular spectrum
P09686344T0000|36 70|ornithine transcarbamylase deficiency
P09686344T0000|36 60|ornithine transcarbamylase
P09686603A0124|28 45|cis-acting elements
P09686603A0124|53 72|regulatory mechanisms
P09686603A0124|94 116|transcriptional promoter
P09686603A0124|127 144|germline expression
P09686603A0124|147 165|TCR beta gene segments
P09687498A1173|3 9|results
P09687498A1173|24 34|crucial role
P09687498A1173|40 48|mutations
P09687498A1173|59 64|v-erbA
P09687498A1173|69 76|oncogene
P09687498A1173|89 94|c-ErbA
P09687498A1173|96 102|TRalpha
P09687498A1173|108 119|non-liganded
P09687498A1173|121 142|repressive conformation
P09687498A1173|161 174|overexpression
P09687511A1091|0 13|Downregulation
P09687511A1091|16 28|FUS expression
P09687511A1091|16 18|FUS
P09687511A1091|31 59|BCR/ABL-expressing 32Dcl3 cells
P09687511A1091|31 33|BCR
P09687511A1091|35 37|ABL
P09687511A1091|77 87|suppression
P09687511A1091|90 128|growth factor-independent colony formation
P09687511A1091|130 140|restoration
P09687511A1091|143 182|G-CSF-induced granulocytic differentiation
P09687511A1091|143 147|G-CSF
P09687511A1091|193 212|tumorigenic potential
P09687514A0521|23 59|mammalian cell-free transcription system
P09687514A0521|81 99|recombinant proteins
P09687514A0521|103 137|epitope-tagged multiprotein complexes
P09688264A1029|4 12|repressor
P09688264A1029|39 41|spi
P09688264A1029|47 63|UTR silencer action
P09688264A1029|87 100|rat hepatocytes
P09689047A0253|1 12|prerequisite
P09689047A0253|19 27|synthesis
P09689047A0253|40 54|glycoconjugates
P09689047A0253|69 92|sugar-nucleotide cytidine
P09689047A0253|96 130|monophosphate N-acetylneuraminic acid
P09689047A0253|132 141|CMP-Neu5Ac
P09689047A0253|158 166|substrate
P09689047A0253|170 192|Golgi sialyltransferases
P09689919A1192|8 21|bovine PEDF cDNA
P09689919A1192|43 59|functional soluble
P09689919A1192|60 83|secreted PEDF glycoprotein
P09689919A1192|68 83|PEDF glycoprotein
P09691031A1050|22 33|Sro7 function
P09691031A1050|22 25|Sro7
P09691031A1050|49 57|targeting
P09691031A1050|63 76|myosin proteins
P09691031A1050|84 100|intrinsic pathways
P09691037A0355|7 15|sequences
P09691037A0355|29 37|insertion
P09691037A0355|40 55|wild-type strains
P09691037A0355|58 65|N. crassa
P09691037A0355|69 90|other Neurospora species
P09692965A0904|4 11|cysteine
P09692965A0904|31 37|helices
P09692965A0904|62 69|patterns
P09692965A0904|72 86|solvent exposure
P09692965A0904|90 95|burial
P09693035T0000|0 8|Human ULK1
P09693035T0000|11 44|novel serine/threonine kinase related
P09693035T0000|16 37|serine/threonine kinase
P09693035T0000|47 58|UNC-51 kinase
P09693035T0000|61 81|Caenorhabditis elegans
P09693035T0000|83 93|cDNA cloning
P09693035T0000|109 129|chromosomal assignment
P09693134A0782|17 32|molecular markers
P09693134A0782|45 76|particular neuroectodermal domains
P09693134A0782|81 91|neuroblasts
P09693134A0782|94 114|individual neuroblasts
P09693134A0782|128 143|DER mutant embryos
P09693134A0782|147 175|intermediate column neuroblasts
P09693134A0782|189 211|medial column neuroblasts
P09693134A0782|224 246|identities inappropriate
P09693134A0782|272 289|lateral neuroblasts
P09693306T0000|0 28|Cochlear microphonic potentials
P09693306T0000|31 38|patients
P09693306T0000|43 63|vestibular schwannomas
P09694034A0713|5 11|results
P09694034A0713|16 24|clozapine
P09694034A0713|39 40|LI
P09694034A0713|54 67|antipsychotics
P09694034A0713|131 132|LI
P09694034A0713|136 144|test model
P09694034A0713|160 181|antipsychotic potential
P09694034A0713|184 193|novel drugs
P09694514A0000|3 36|complement C3a anaphylatoxin receptor
P09694514A0000|38 41|C3aR
P09694514A0000|46 103|seven-transmembrane G-protein coupled chemoattractant receptor
P09694514A0000|46 73|seven-transmembrane G-protein
P09694514A0000|81 103|chemoattractant receptor
P09694514A0000|120 135|C3a peptide ligand
P09694514A0000|144 168|numerous cellular responses
P09694514A0000|179 194|histamine release
P09694514A0000|199 207|mast cells
P09694514A0000|209 231|smooth muscle contraction
P09694514A0000|239 255|directed migration
P09694514A0000|258 268|eosinophils
P09694599A1355|0 10|CONCLUSIONS
P09694599A1355|12 32|Significant elevations
P09694599A1355|35 43|IL-1alpha
P09694599A1355|47 54|IL-1beta
P09694599A1355|62 69|patients
P09694599A1355|74 90|bacterial cystitis
P09694599A1355|94 113|microscopic hematuria
P09694725A0500|0 15|Band-shift assays
P09694725A0500|37 65|LPS-and IL-1-responsive element
P09694725A0500|44 65|IL-1-responsive element
P09694725A0500|67 71|LILRE
P09694725A0500|73 87|oligonucleotide
P09694725A0500|90 127|gamma interferon activation site-like site
P09694725A0500|146 166|human IL-1beta promoter
P09694860A0498|3 18|C-terminal region
P09694860A0498|30 43|PTP-like domain
P09694860A0498|55 70|N-terminal region
P09694860A0498|78 85|homology
P09694860A0498|91 111|known mammalian protein
P09694869A0932|41 45|STATs
P09694869A0932|51 60|activation
P09694869A0932|66 76|p21 promoter
P09694869A0932|78 91|overexpression
P09694869A0932|94 98|Stat3
P09694869A0932|113 126|cytokine effect
P09694869A0932|132 142|p21 promoter
P09694869A0932|152 172|dominant negative Stat3
P09694869A0932|168 172|Stat3
P09694869A0932|177 184|mutation
P09694869A0932|190 208|STAT response element
P09694869A0932|214 221|promoter
P09694869A0932|246 259|cytokine effect
P09694897T0000|3 55|heterogeneous nuclear ribonucleoprotein C protein tetramer
P09694897T0000|61 62|U1
P09694897T0000|64 65|U2
P09694897T0000|70 77|U6 snRNAs
P09694897T0000|88 115|high affinity RNA binding domain
P09694897T0000|120 133|bZIP-like motif
P09695194T0000|27 37|proportions
P09696164A0000|8 19|simple system
P09696164A0000|26 34|detection
P09696164A0000|37 61|sudden infant death syndrome
P09696164A0000|63 66|SIDS
P09696819A0450|12 18|mutants
P09696819A0450|38 39|gE
P09696819A0450|45 75|vaccinia virus-based vTF7-3 system
P09696819A0450|95 114|endoplasmic reticulum
P09696819A0450|116 117|ER
P09696819A0450|120 136|to-Golgi transport
P09696819A0450|142 165|hetero-oligomeric complex
P09698457A0778|0 19|Homozygous mutant mice
P09698457A0778|31 45|Cux/CDPDeltaCR1
P09698457A0778|31 33|Cux
P09698457A0778|35 45|CDPDeltaCR1
P09698457A0778|55 63|phenotype
P09698457A0778|79 92|curly vibrissae
P09698457A0778|96 103|wavy hair
P09698457A0976|3 15|mutant protein
P09698457A0976|27 32|levels
P09698457A0976|41 47|greater
P09698457A0976|52 60|wild-type
P09698457A0976|76 97|same tissue distribution
P09698457A0976|100 115|wild-type protein
P09698457A0976|136 149|normal affinity
P09698457A0976|153 172|known target sequences
P09698457A0976|218 231|first cut repeat
P09698457A0976|235 241|binding
P09698512A0296|0 6|METHODS
P09698512A0296|36 74|adult cadaveric renal transplant recipients
P09700644T0000|13 44|age-associated brain abnormalities
P09700644T0000|65 91|histopathological correlates
P09701609A0116|37 64|phosducin-like orphan proteins
P09701609A0116|66 71|PhLOP1
P09701609A0116|75 80|PhLOP2
P09701609A0116|114 123|Gbetagamma
P09701616A0108|0 43|Reverse transcriptase-polymerase chain reaction
P09701616A0108|0 35|Reverse transcriptase-polymerase chain
P09701616A0108|45 50|RT-PCR
P09701616A0108|69 92|eyestalk complementary DNA
P09701616A0108|98 123|sand shrimp Metapenaeus ensis
P09701821A1108|11 23|transcription
P09701821A1108|38 44|opuE P-1
P09701821A1108|46 51|sigma A
P09701821A1108|74 91|external osmolarity
P09701821A1108|110 119|high levels
P09701895A0119|19 30|children aged
P09701895A0119|32 41|months-3 yr
P09701895A0119|87 96|prevalence
P09701895A0119|99 116|nutritional anaemia
P09703021A0000|2 8|insects
P09703021A0000|10 43|arylalkylamine N-acetyltransferases
P09703021A0000|45 50|AANATs
P09703021A0000|72 100|several physiological processes
P09703021A0000|111 124|sclerotization
P09703021A0000|126 137|inactivation
P09703021A0000|140 163|certain neurotransmitters
P09703021A0000|191 201|vertebrates
P09703021A0000|203 211|catalysis
P09703021A0000|217 233|rate-limiting step
P09703021A0000|236 256|melatonin biosynthesis
P09703213A0280|2 12|experiments
P09703213A0280|20 34|D1 antagonist SCH
P09703213A0280|20 21|D1
P09703213A0280|41 71|buprenorphine-induced depression
P09703213A0280|98 109|facilitation
P09703213A0280|113 122|unaffected
P09703276A2346|5 11|results
P09703276A2346|25 37|hydroquinones
P09703276A2346|44 55|mutagenicity
P09703276A2346|59 73|carcinogenicity
P09703816A0139|0 4|IA-CT
P09703816A0139|9 17|cisplatin
P09703816A0139|20 21|mg
P09703816A0139|25 35|doxorubicin
P09703816A0139|38 39|mg
P09703816A0139|60 69|shot method
P09703816A0139|72 101|bilateral internal iliac arteries
P09704006A0224|0 8|Arnt3 mRNA
P09704006A0224|29 42|skeletal muscle
P09704006A0224|44 58|13.5-day embryos
P09704006A0224|63 70|P19 cells
P09704006A0224|82 93|retinoic acid
P09704296T0000|0 37|Acute idiopathic thrombocytopenic purpura
P09704296T0000|49 62|high serum level
P09704296T0000|65 79|immunoglobulin E
P09704296T0000|83 94|eosinophilia
P09704296T0000|99 112|elderly patient
P09704569T0000|3 18|genomic structure
P09704569T0000|22 40|chromosomal location
P09704569T0000|46 67|human TR2 orphan receptor
P09704569T0000|81 106|steroid receptor superfamily
P09704857T0000|0 10|Correlation
P09704857T0000|13 25|skin disorders
P09704857T0000|30 42|CD4 lymphocyte
P09704857T0000|30 32|CD4
P09704857T0000|51 58|patients
P09704857T0000|63 70|HIV/AIDS
P09704927A0479|0 4|E2F-6
P09704927A0479|5 29|shares significant homology
P09704927A0479|34 40|E2Fs 1-5
P09704927A0479|34 37|E2Fs
P09704927A0479|61 70|DNA binding
P09704927A0479|72 89|heterodimerization
P09704927A0479|93 108|marked box domains
P09705258A0837|3 16|IE13.1 cell line
P09705258A0837|37 52|recombinant virus
P09705258A0837|64 69|copies
P09705258A0837|75 80|IE gene
P09705258A0837|95 103|insertion
P09705258A0837|109 131|Escherichia coli lacZ gene
P09705258A0837|124 131|lacZ gene
P09705324A0213|0 5|DNase I
P09705324A0213|0 4|DNase
P09705324A0213|6 17|footprinting
P09705324A0213|21 56|electrophoretic mobility shift analyses
P09705324A0213|68 92|hepatocyte nuclear factor-1
P09705324A0213|94 97|HNF1
P09705324A0213|105 133|CCAAT/enhancer-binding protein
P09705324A0213|135 139|C/EBP
P09705324A0213|148 197|consensus palindromic thyroid hormone response elements
P09705324A0213|215 223|base pairs
P09705324A0213|225 226|bp
P09705324A0213|233 248|promoter sequence
P09705324A0213|251 256|rat Std
P09705324A1602|10 16|studies
P09705324A1602|19 40|rat Std promoter function
P09705324A1602|19 32|rat Std promoter
P09705324A1602|56 59|HNF1
P09705324A1602|63 67|C/EBP
P09705324A1602|85 100|liver specificity
P09705324A1602|106 115|rat Std gene
P09705324A1602|121 140|androgenic repression
P09705324A1602|179 183|OCT-1
P09705324A1602|187 199|C/EBP elements
P09705324A1602|207 215|positions
P09705324A1602|236 237|AR
P09705324A1602|249 272|negative regulatory effect
P09705324A1602|290 316|transcriptional interference
P09705324A1602|319 323|OCT-1
P09705324A1602|327 331|C/EBP
P09705324A1602|350 372|direct DNA-AR interaction
P09705352A0879|8 11|Hsk1
P09705352A0879|29 33|Cdc19
P09705352A0879|35 38|Mcm2
P09705352A0879|40 46|subunit
P09705352A0879|52 100|six-member minichromosome maintenance protein complex
P09705352A0879|113 124|fission yeast
P09705497A0227|3 15|yeast MMS2 gene
P09705497A0227|52 84|methyl methanesulfonate sensitivity
P09705497A0227|90 101|mms2-1 mutant
P09705497A0227|132 156|DNA post-replication repair
P09705564T0000|0 9|Expression
P09705564T0000|15 49|human papillomavirus type 11 E5A protein
P09705564T0000|15 37|human papillomavirus type
P09705564T0000|40 49|E5A protein
P09705564T0000|57 73|E1E4,E5 transcript
P09705564T0000|57 60|E1E4
P09705564T0000|62 73|E5 transcript
P09706565A1072|0 9|Anesthesia
P09706565A1072|14 16|M/K
P09706565A1072|14 14|M
P09706565A1072|16 16|K
P09706565A1072|37 39|min
P09706565A1072|42 55|immobilization
P09706565A1072|60 70|atipamezole
P09707498A0262|0 19|MK-801 administration
P09707498A0262|31 46|biphasic response
P09707498A0262|49 62|seizure latency
P09707577A1047|28 43|endocytic markers
P09708450A0648|0 7|Toxicity
P09708450A0648|17 33|therapeutic period
P09708450A0648|56 65|study group
P09708450A0648|81 97|historical control
P09708450A0648|113 123|same regimen
P09708450A0648|131 135|G-CSF
P09708565A0000|37 43|factors
P09708565A0000|68 77|antibodies
P09708565A0000|79 91|radionuclides
P09708565A0000|103 109|methods
P09708565A0000|128 145|radioimmunotherapy
P09708565A0000|147 149|RIT
P09708565A0000|154 164|non-Hodgkin
P09708565A0000|167 174|lymphoma
P09708565A0000|176 178|NHL
P09708565A0000|185 207|single clinical study site
P09708565A0000|215 231|multicenter trials
P09708565A0000|235 251|commercialization
P09710131A0374|4 10|methods
P09710131A0374|26 51|various focal-film distances
P09710131A0374|53 77|image intensifier tube modes
P09710131A0374|81 99|laser printer formats
P09710582A0535|11 13|Rho
P09710582A0535|16 19|AP-1
P09710582A0535|38 74|mitogen-activated protein kinase pathway
P09710582A0535|38 67|mitogen-activated protein kinase
P09710582A0535|79 98|dominant-negative MEK
P09710582A0535|103 114|MEK inhibitor
P09710582A0535|103 105|MEK
P09710582A0535|116 122|PD98059
P09710582A0535|136 158|Rho-induced AP-1 activity
P09710582A0535|136 138|Rho
P09710582A0535|147 150|AP-1
P09710589A1111|0 23|Site-directed mutagenesis
P09710589A1111|26 33|residues
P09710589A1111|47 50|R82A
P09710589A1111|52 55|K85A
P09710589A1111|57 60|K88A
P09710589A1111|65 68|V89A
P09710589A1111|80 87|proteins
P09710589A1111|121 129|HTLV-1 LTR
P09710591A0981|0 8|Mutations
P09710591A0981|18 26|C terminus
P09710591A0981|29 33|c-fos
P09710591A0981|36 49|serine residues
P09710591A0981|57 78|phosphorylation targets
P09710591A0981|82 94|growth factors
P09710591A0981|98 106|MAP kinase
P09710591A0981|125 139|transactivation
P09710591A0981|143 159|block potentiation
P09710591A0981|162 170|MAP kinase
P09710599A0310|5 15|former cells
P09710599A0310|17 21|ets-2
P09710599A0310|26 57|CSF-1 immediate-early response gene
P09710599A0310|76 80|ets-2
P09710599A0310|101 101|h
P09710599A0310|103 112|coincident
P09710599A0310|129 140|ets-2 protein
P09710599T0000|0 19|Persistent activation
P09710599T0000|22 55|mitogen-activated protein kinases p42
P09710599T0000|22 52|mitogen-activated protein kinases
P09710599T0000|53 55|p42
P09710599T0000|59 61|p44
P09710599T0000|65 84|ets-2 phosphorylation
P09710599T0000|65 69|ets-2
P09710599T0000|97 136|colony-stimulating factor 1/c-fms signaling
P09710599T0000|97 121|colony-stimulating factor 1
P09710599T0000|123 127|c-fms
P09710614T0000|0 13|Identification
P09710614T0000|17 36|proline-rich sequence
P09710614T0000|42 69|CD2 cytoplasmic domain critical
P09710614T0000|85 109|integrin-mediated adhesion
P09710614T0000|85 92|integrin
P09710614T0000|113 122|activation
P09710614T0000|125 148|phosphoinositide 3-kinase
P09710615T0000|0 4|Vam7p
P09710615T0000|7 26|SNAP-25-like molecule
P09710615T0000|31 35|Vam3p
P09710615T0000|38 52|syntaxin homolog
P09710615T0000|72 102|yeast vacuolar protein trafficking
P09710621A0598|42 58|consecutive series
P09710621A0598|61 81|cysteine substitutions
P09710621A0598|87 108|Neu juxtamembrane domain
P09710621A0598|123 134|dimerization
P09710621A0598|149 161|interreceptor
P09710641A0000|35 39|Pax-6
P09710641A0000|42 53|paired domain
P09710641A0000|55 56|PD
P09710641A0000|59 69|homeodomain
P09710641A0000|71 72|HD
P09710641A0000|74 100|transcription factor critical
P09710641A0000|104 117|eye development
P09710641A0000|135 144|activation
P09710641A0000|150 196|alphaB-, alphaA-, delta1-, and zeta-crystallin genes
P09710641A0000|150 155|alphaB
P09710641A0000|158 163|alphaA
P09710641A0000|166 171|delta1
P09710641A0000|177 196|zeta-crystallin genes
P09712037A0470|0 13|Tctex-1 binding
P09712037A0470|0 6|Tctex-1
P09712037A0470|32 41|amino acids
P09712037A0470|44 46|Fyn
P09712037A0470|64 77|lysine residues
P09712037A0470|135 149|Fyn interactions
P09712037A0470|135 137|Fyn
P09712037A0470|157 200|immunoreceptor tyrosine-based activation motifs
P09712037A0470|202 206|ITAMs
P09712037A0470|210 230|lymphocyte Ag receptors
P09712297T0000|3 32|prothrombin gene G20210A mutation
P09712297T0000|48 63|Japanese patients
P09712297T0000|68 85|deep vein thrombosis
P09712297T0000|89 106|healthy individuals
P09712644T0000|0 24|Transcriptional regulation
P09712644T0000|30 38|GluR2 gene
P09712644T0000|40 64|neural-specific expression
P09712644T0000|66 82|multiple promoters
P09712644T0000|87 104|regulatory elements
P09712859A1110|3 9|binding
P09712859A1110|12 17|NF-ATp
P09712859A1110|30 35|NF-AT4
P09712859A1110|43 50|enhancer
P09712859A1110|70 93|HTLV-I-mediated infection
P09712859A1110|70 75|HTLV-I
P09712859A1110|96 122|human peripheral blood T-cells
P09712898A0911|5 9|TRAF2
P09712898A0911|19 22|SAPK
P09712898A0911|26 38|p38 activation
P09712898A0911|26 28|p38
P09712898A0911|51 72|proximal protein kinases
P09712898A0911|59 72|protein kinases
P09712898A0911|74 76|GCK
P09712898A0911|80 82|RIP
P09712898T0000|0 27|Tumor necrosis factor signaling
P09712898T0000|0 18|Tumor necrosis factor
P09712898T0000|30 58|stress-activated protein kinase
P09712898T0000|60 63|SAPK
P09712898T0000|66 86|Jun NH2-terminal kinase
P09712898T0000|88 90|JNK
P09712898T0000|95 97|p38
P09712915A0672|16 30|minimal promoter
P09712915A0672|72 81|activities
P09712915A0672|87 109|transcription factors Sp1
P09712915A0672|107 109|Sp1
P09712915A0672|111 113|Sp3
P09712915A0672|118 121|NF-Y
P09712919A0307|5 11|studies
P09712919A0307|55 70|signaling pathway
P09712919A0307|72 72|s
P09712919A0307|95 108|CREB activation
P09712919A0307|95 98|CREB
P09712919A0307|111 122|normal T cells
P09713584A1193|0 10|Respondents
P09713584A1193|24 37|spouse/partner
P09713584A1193|64 83|unfavorable BMI status
P09713584A1193|107 112|groups
P09713990T0000|0 8|Isolation
P09713990T0000|12 30|novel TP53 target gene
P09713990T0000|17 30|TP53 target gene
P09713990T0000|36 54|colon cancer cell line
P09713990T0000|79 107|wild-type TP53 expression system
P09713990T0000|79 91|wild-type TP53
P09713996A0262|0 13|Overexpression
P09713996A0262|16 19|MDR1
P09713996A0262|41 51|many cancers
P09713996A0262|59 71|patient tumors
P09713996A0262|77 85|cell lines
P09713996A0262|108 129|chemotherapeutic agents
P09713996T0000|0 10|Cytogenetic
P09713996T0000|14 38|molecular characterization
P09713996T0000|41 71|random chromosomal rearrangements
P09713996T0000|85 102|drug resistance gene
P09713996T0000|104 122|MDR1/P-glycoprotein
P09713996T0000|104 107|MDR1
P09713996T0000|109 122|P-glycoprotein
P09713996T0000|126 147|drug-selected cell lines
P09713996T0000|151 158|patients
P09713996T0000|163 179|drug refractory ALL
P09714109A0000|0 9|BACKGROUND
P09714109A0000|36 42|smoking
P09714109A0000|52 64|blood pressure
P09714109A0000|76 105|muscle sympathetic nerve activity
P09714109A0000|107 109|SNA
P09714109A0785|7 27|blood pressure increase
P09714109A0785|40 46|smoking
P09714109A0785|59 79|nitroprusside infusion
P09714109A0785|90 105|striking increase
P09714109A0785|108 116|muscle SNA
P09714835A0345|16 32|carboxypeptidase D
P09714835A0345|34 36|CPD
P09714835A0345|65 79|bovine pituitary
P09714835A0345|99 120|novel carboxypeptidase E
P09714835A0345|104 120|carboxypeptidase E
P09714835A0345|122 136|CPE)-like enzyme
P09714835A0345|122 124|CPE
P09714835A0345|131 136|enzyme
P09714835A0345|142 160|many characteristics
P09714835A0345|173 181|duck gp180
P09714835A0345|177 181|gp180
P09714835A0345|183 186|Song
P09714835A0345|188 189|L.
P09714835A0345|191 197|Fricker
P09714835A0345|199 202|L.D.
P09715278A1079|0 11|RA-treatment
P09715278A1079|19 31|transfectants
P09715278A1079|39 49|morphologic
P09715278A1079|53 78|immunophenotypic maturation
P09715278A1079|80 86|changes
P09715278A1079|89 105|RA-regulated genes
P09715278A1079|111 127|G1 cell cycle arrest
P09715278A1079|131 143|manner similar
P09715278A1079|146 164|parental NT2/D1 cells
P09715278A1526|3 16|histopathology
P09715278A1526|20 37|neovascularization
P09715278A1526|68 82|xenograft tumors
P09715278A1526|94 112|FGF4 over-expressing
P09715278A1526|94 97|FGF4
P09715278A1526|119 138|control transfectants
P09715384A0235|3 16|smaller vessels
P09715384A0235|22 29|diameter
P09715384A0235|35 36|mm
P09715384A0235|38 47|treatments
P09715384A0235|57 61|J/cm2
P09715384A0235|68 78|good results
P09715384A0235|88 88|%
P09715384A0235|105 111|vessels
P09715384A0235|117 118|mm
P09715384A0235|128 128|%
P09716095T0000|0 13|Pressure ulcers
P09716179A0974|0 18|RXR-gamma expression
P09716179A0974|0 8|RXR-gamma
P09716179A0974|27 46|significant reduction
P09716179A0974|49 54|levels
P09716179A0974|57 74|RA-responsive genes
P09716179A0974|87 130|cyclin-dependent kinase inhibitors p21Cip1/WAF1
P09716179A0974|87 108|cyclin-dependent kinase
P09716179A0974|119 125|p21Cip1
P09716179A0974|127 130|WAF1
P09716179A0974|134 140|p27Kip1
P09716179A0974|162 165|cdc2
P09716179A0974|169 186|cdk2 kinase activity
P09716179A0974|169 178|cdk2 kinase
P09716179A0974|190 206|RB phosphorylation
P09716179A0974|190 191|RB
P09716183A1036|0 2|TBP
P09716183A1036|31 38|extracts
P09716183A1036|41 49|U937 cells
P09716183A1036|83 86|ERK2
P09716183A1036|91 110|phosphorylation sites
P09716183A1036|123 145|ERK kinase consensus sites
P09716183A1036|151 173|TBP amino-terminal domain
P09716435A1004|9 17|CR/PP diet
P09716435A1004|25 34|HS subjects
P09716435A1004|48 65|stress-induced rise
P09716435A1004|88 93|vigour
P09716435A1004|97 113|cortisol elevation
P09716435A1004|136 144|PR/CP diet
P09717246A0526|9 11|ILC
P09717246A0526|15 24|ILVF values
P09717246A0526|48 59|exposure time
P09717246A0526|64 76|rate constants
P09717246A0526|98 102|day-1
P09717246A0526|110 120|lipid weight
P09717246A0526|125 127|ILC
P09717246A0526|141 145|day-1
P09717246A0526|149 152|ILVF
P09717835A0941|5 20|sequence analyses
P09717835A0941|32 37|xIRS-u
P09717835A0941|41 51|novel member
P09717835A0941|57 65|IRS family
P09717835A0941|77 90|Xenopus homolog
P09717887A0239|3 14|present study
P09717887A0239|50 56|VO2peak
P09717887A0239|59 92|peripheral arterial occlusive disease
P09717887A0239|94 97|PAOD
P09717887A0239|99 106|patients
P09717887A0239|111 134|intermittent claudication
P09717887A0239|149 169|independent predictors
P09717887A0239|172 178|VO2peak
P09718372T0000|0 7|Evidence
P09718372T0000|12 41|novel MAPKKK-independent pathway
P09718372T0000|17 22|MAPKKK
P09718372T0000|71 88|Sty1/Spc1 MAP kinase
P09718372T0000|71 74|Sty1
P09718372T0000|76 79|Spc1
P09718372T0000|80 88|MAP kinase
P09718372T0000|91 102|fission yeast
P09718671A0000|3 24|Abbreviated Injury Scale
P09718671A0000|26 28|AIS
P09718671A0000|31 49|Injury Severity Scale
P09718671A0000|53 68|TRISS methodology
P09718671A0000|92 102|sound system
P09718671A0000|119 126|injuries
P09718671A0000|130 144|injured patients
P09719636A1134|36 44|mutations
P09719636A1134|61 74|histidine pairs
P09719636A1134|79 94|H382-X2-H385 pair
P09719636A1134|99 114|H411-X2-H414 pair
P09719636A1134|121 136|H430-X5-H436 pair
P09719636A1134|156 175|histidine-rich region
P09719636A1134|183 191|C terminus
P09719636A1134|194 197|gp17
P09721207A0637|5 21|backcross analysis
P09721207A0637|27 31|exons
P09721207A0637|46 59|proximal region
P09721207A0637|62 77|murine Chromosome
P09721207A0637|79 95|indistinguishable
P09721207A0637|103 115|vacillans gene
P09721798A1734|12 18|percent
P09721798A1734|21 28|children
P09721798A1734|41 56|second transplant
P09721798A1734|60 71|HCV hepatitis
P09721798A1734|75 99|early histologic recurrence
P09721798A1734|109 120|liver failure
P09722043A2070|12 20|TPN groups
P09722043A2070|28 41|marked increase
P09722043A2070|44 53|activities
P09722043A2070|56 76|liver lysosomal enzymes
P09722161A3065|0 9|Regulation
P09722161A3065|12 26|embryonic growth
P09722161A3065|30 47|lysosomal targeting
P09722161A3065|53 73|imprinted Igf2/Mpr gene
P09722161A3065|62 65|Igf2
P09722161A3065|67 69|Mpr
P09722508A0953|30 42|Galpha11 Q209L
P09722508A0953|53 75|Src family kinase activity
P09722508A0953|53 67|Src family kinase
P09722508A0953|86 108|tyrosine phosphorylation
P09722508A0953|111 125|several proteins
P09722508A0953|128 139|HEK-293 cells
P09722766A0706|3 21|micturition pressure
P09722766A0706|56 64|injection
P09722766A0706|69 73|BUP-4
P09722766A0706|99 102|rats
P09723896A0000|0 40|Peroxisome proliferator-activated receptors
P09723896A0000|42 45|PPAR
P09723896A0000|55 67|transcription
P09723896A0000|79 125|specific peroxisome proliferator-response elements
P09723896A0000|87 125|peroxisome proliferator-response elements
P09723896A0000|127 130|PPRE
P09723896A0000|139 156|heterodimerization
P09723896A0000|164 188|9-cis retinoic acid receptor
P09723896A0000|190 192|RXR
P09724654A0761|21 38|late-firing origins
P09724654A0761|66 76|recruitment
P09724654A0761|81 90|Mcm protein
P09724654A0761|108 112|RPA's
P09724654A0761|108 110|RPA
P09724654A0761|113 123|recruitment
P09724654A1120|20 31|active S-CDKs
P09724654A1120|35 43|Dbf4/Cdc7
P09724654A1120|35 38|Dbf4
P09724654A1120|40 43|Cdc7
P09724654A1120|45 48|Mcms
P09724654A1120|56 62|origins
P09724654A1120|86 92|loading
P09724654A1120|95 97|RPA
P09724754A0173|0 7|Tyrosine
P09724754A0173|22 34|STATs dimerize
P09724754A0173|22 26|STATs
P09724754A0173|56 62|nucleus
P09724754A0173|73 85|specific genes
P09724763T0000|0 24|Nonsynonymous substitution
P09724763T0000|27 56|abalone sperm fertilization genes
P09724763T0000|64 75|substitution
P09724763T0000|78 84|introns
P09724763T0000|88 103|mitochondrial DNA
P09724772A0840|0 19|Gel retardation assays
P09724772A0840|28 50|ZiaR-dependent complexes
P09724772A0840|28 31|ZiaR
P09724772A0840|65 84|zia operator-promoter
P09724772A0840|88 102|ZiaR-DNA binding
P09724772A0840|88 91|ZiaR
P09724772A0840|130 143|metal-chelator
P09725292A1473|0 9|CONCLUSION
P09725292A1473|19 30|quantitative
P09725292A1473|34 52|qualitative criteria
P09725292A1473|66 75|fatty liver
P09725292A1473|78 86|helical CT
P09725292A1473|110 126|protocol-specific
P09725651A0077|3 14|PC-based RTPS
P09725651A0077|35 50|Microsoft Windows
P09725651A0077|75 82|versions
P09725651A0077|88 96|computers
P09725651A0077|114 130|Pentium processors
P09725854A1060|29 52|apparent regulatory action
P09725854A1060|58 62|genes
P09725854A1060|74 91|allelic differences
P09725854A1060|102 117|IS1112C Rf3 allele
P09725854A1060|102 108|IS1112C
P09725854A1060|109 117|Rf3 allele
P09725854A1060|131 137|alleles
P09725854A1060|140 154|maintainer lines
P09725854A1060|184 189|orf107
P09725854A1060|193 218|urf209 processing activities
P09725854A1060|193 198|urf209
P09726201T0000|0 4|JCAHO
P09726979T0000|0 15|Molecular cloning
P09726979T0000|19 44|functional characterization
P09726979T0000|47 69|murine sphingosine kinase
P09726987T0000|1 48|human SPT3-TAFII31-GCN5-L acetylase complex distinct
P09726987T0000|6 9|SPT3
P09726987T0000|11 17|TAFII31
P09726987T0000|19 22|GCN5
P09726987T0000|24 33|L acetylase
P09726987T0000|53 74|transcription factor IID
P09726988A0275|0 5|Oleate
P09726988A0275|13 30|steady-state levels
P09726988A0275|33 42|M-CPT I mRNA
P09726991T0000|0 6|Mapping
P09726991T0000|12 27|DNA binding domain
P09726991T0000|33 72|copper-responsive transcription factor Mac1
P09727045A0817|1 16|further mechanism
P09727045A0817|27 44|specific activation
P09727045A0817|61 69|receptors
P09727045A0817|83 90|weak HREs
P09727045A0817|133 143|AR N terminus
P09727045A0817|147 165|ligand binding domain
P09727046A0000|27 44|DNA-binding protein
P09727046A0000|46 51|HS2NF5
P09727046A0000|93 110|hypersensitive site
P09727046A0000|113 115|HS2
P09727046A0000|122 155|human beta-globin locus control region
P09727046A0000|157 159|LCR
P09727046A0000|162 164|Lam
P09727046A0000|166 167|L.
P09727046A0784|3 10|CBF1 site
P09727046A0784|17 19|HS2
P09727046A0784|31 35|sites
P09727046A0784|39 65|hematopoietic regulators such
P09727046A0784|68 73|GATA-1
P09727046A0784|75 79|NF-E2
P09727046A0784|84 87|TAL1
P09729481A0000|3 43|rat branched-chain-2-oxo-acid dehydrogenase
P09729481A0000|45 48|BCOD
P09729481A0000|50 59|kinase mRNA
P09729481A0000|78 94|TATA-less promoter
P09729481A0000|102 117|GC-rich sequences
P09729481A0000|124 146|putative Sp1 binding sites
P09729481A0000|154 175|transcription start site
P09729481A1177|0 14|Co-transfection
P09729481A1177|20 39|Sp1 expression plasmid
P09729481A1177|20 22|Sp1
P09729481A1177|49 65|promoter construct
P09729481A1177|80 93|Schneider cells
P09729481A1177|106 108|Sp1
P09729481A1177|125 151|kinase basal promoter activity
P09729481A1177|166 182|non-consensus site
P09730413A0642|5 22|such investigations
P09730413A0642|60 76|adjuvant treatment
P09730413A0642|79 90|questionable
P09730413A0642|98 107|TME surgery
P09730413A0642|124 138|treatment option
P09730413A0642|142 164|Stage T1-T3 rectal cancers
P09731354A0963|14 21|degrees C
P09731354A0963|27 27|%
P09731354A0963|34 47|surface density
P09731354A0963|50 58|NH2 groups
P09731354A0963|78 79|hr
P09731354A0963|115 116|hr
P09731513A1090|19 25|results
P09731513A1090|53 81|transcription factors NF-kappaB
P09731513A1090|73 81|NF-kappaB
P09731513A1090|85 88|AP-1
P09731513A1090|103 117|transactivation
P09731513A1090|120 127|IL-8 gene
P09731513A1090|130 138|HTLV-I Tax
P09731704A0000|20 37|cooperative effects
P09731704A0000|41 67|human estrogen receptor-alpha
P09731704A0000|46 67|estrogen receptor-alpha
P09731704A0000|69 75|ERalpha
P09731704A0000|77 83|isoform
P09731704A0000|86 93|estrogen
P09731704A0000|95 96|E2
P09731704A0000|107 120|gene activation
P09731704A0000|123 144|U2-OS osteosarcoma cells
P09731704A1472|0 11|Transfection
P09731704A1472|24 30|amounts
P09731704A1472|33 61|delta5ERalpha expression vector
P09731704A1472|33 45|delta5ERalpha
P09731704A1472|67 74|ERalpha+
P09731704A1472|67 73|ERalpha
P09731704A1472|76 82|OS cells
P09731704A1472|93 104|potentiation
P09731704A1472|107 133|E2-stimulated ERELuc activity
P09731704A1472|107 108|E2
P09731704A1472|120 125|ERELuc
P09731704A1472|137 147|synergistic
P09731704A1472|149 168|dose-dependent manner
P09731705A2126|0 6|Studies
P09731705A2126|15 35|yeast two-hybrid system
P09731705A2126|79 110|VDR-TR protein-protein interaction
P09731705A2126|79 81|VDR
P09731705A2126|83 99|TR protein-protein
P09733493A0493|3 9|results
P09733493A0493|24 48|thermodynamical standpoint
P09733493A0493|50 58|melatonin
P09733493A0493|78 93|hydroxyl radicals
P09733493A0493|111 125|aqueous solution
P09733647A1960|13 47|Thr-Gly-X-X-Gly-Asp-Gly-Lys-Ile-Phe
P09733647A1960|63 68|B-loop
P09733647A1960|86 96|wide variety
P09733647A1960|99 107|organisms
P09733647A1960|128 132|algae
P09733647A1960|136 149|archeabacteria
P09733794A1323|18 24|changes
P09733794A1323|27 31|Bcl-2
P09733794A1323|34 54|Bcl-2-related proteins
P09733794A1323|56 60|Bcl-x
P09733794A1323|62 64|Bax
P09733794A1323|69 71|Bad
P09733794A1323|84 105|KCREB-transfected cells
P09733794A1323|84 88|KCREB
P09733794A1323|132 133|Tg
P09733815T0000|0 7|Tyrosine
P09733815T0000|13 35|latent membrane protein 2A
P09733815T0000|50 77|protein tyrosine kinase loading
P09733815T0000|50 70|protein tyrosine kinase
P09733815T0000|93 116|Epstein-Barr virus latency
P09733854A0198|3 29|only abundant viral transcript
P09733854A0198|45 51|latency
P09733854A0198|57 71|latency-related
P09733854A0198|73 74|LR
P09733854A0198|76 78|RNA
P09734808A0000|9 22|test efficiency
P09734808A0000|57 78|contrast/color card test
P09734808A0000|100 111|test stimulus
P09734808A0000|134 140|stimuli
P09734808A0000|147 164|experimental phases
P09735286A0599|3 8|defect
P09735286A0599|16 23|proteins
P09735286A0599|58 60|Mn2
P09735286A0599|68 77|Mu B protein
P09735286A0599|93 95|ATP
P09735286A0599|99 107|target DNA
P09735366A1180|5 29|homology cloning techniques
P09735366A1180|44 57|mouse homologue
P09735366A1180|60 60|E
P09735366A1180|62 63|Pc
P09735366A1180|72 75|Epc1
P09735366A1180|78 89|yeast protein
P09735366A1180|100 103|EPL1
P09735366A1180|116 129|additional ESTs
P09735366A1180|134 154|Caenorhabditis elegans
P09735366A1180|156 159|mice
P09735366A1180|163 168|humans
P09735368A0636|10 20|wild-type m8
P09735368A0636|23 25|UTR
P09735368A0636|41 52|accumulation
P09735368A0636|55 77|heterologous transcripts
P09735368A0636|110 122|K box sequences
P09735371A0227|13 18|unc-86
P09735371A0227|27 52|POU-type homeodomain protein
P09735371A0227|80 89|touch cells
P09735371A0227|96 100|mec-3
P09735371A0227|109 134|LIM-type homeodomain protein
P09735371A0227|147 161|differentiation
P09735371A0227|167 176|touch cells
P09736239A0436|9 29|2h resuscitation period
P09736239A0436|31 52|extracellular aspartate
P09736239A0436|56 78|glutamate concentrations
P09736239A0436|84 99|cerebral striatum
P09736239A0436|104 109|higher
P09736239A0436|116 138|hypoxaemic resuscitation
P09736239A0436|140 141|p =
P09736239A0436|150 151|p =
P09736239A0436|181 193|resuscitation
P09736239A0436|200 200|%
P09736239A0436|208 208|%
P09736239A0436|224 247|unfavourable accumulation
P09736239A0436|250 267|potent excitotoxins
P09736239A0436|274 296|hypoxaemic resuscitation
P09736697A0783|0 9|Expression
P09736697A0783|26 35|active MEK1
P09736697A0783|32 35|MEK1
P09736697A0783|40 45|kinase
P09736697A0783|59 62|ERKs
P09736697A0783|66 79|overexpression
P09736697A0783|82 85|ERK2
P09736697A0783|93 96|JNK1
P09736697A0783|107 121|Stat3 activation
P09736697A0783|107 111|Stat3
P09736697A1107|0 3|MEKs
P09736697A1107|7 10|ERKs
P09736697A1107|20 33|IL-6 activation
P09736697A1107|20 23|IL-6
P09736697A1107|36 40|Stat3
P09736697A1107|51 58|mutation
P09736697A1107|61 70|serine-727
P09736697A1107|75 83|major site
P09736697A1107|87 107|serine phosphorylation
P09736697A1107|118 127|inhibition
P09736697A1107|130 143|wild-type Stat3
P09736697A1107|157 172|Janus kinases Jak1
P09736697A1107|157 168|Janus kinases
P09736697A1107|169 172|Jak1
P09736697A1107|176 179|Jak2
P09736697A1107|190 194|Stat3
P09736697A1107|200 224|Jak-STAT-signaling pathway
P09736697A1107|200 202|Jak
P09736715A0729|12 31|phosphatidylinositol
P09736715A0729|39 51|trisphosphate
P09736715A0729|87 89|ILK
P09736715A0729|112 119|membrane
P09736715A0729|143 150|active Pi
P09736715A0729|154 154|K
P09736715A0729|164 166|ILK
P09736770A0351|0 11|Transfection
P09736770A0351|22 35|binding studies
P09736770A0351|52 65|HEFT1 a promoter
P09736770A0351|52 56|HEFT1
P09736770A0351|58 65|promoter
P09736770A0351|71 83|basal activity
P09736770A0351|93 97|GC box
P09736770A0351|109 111|Sp1
P09736770A0351|114 116|Sp3
P09737453A0557|0 5|Plasma
P09737453A0557|39 40|SD
P09737453A0557|42 45|days
P09737453A0557|57 69|IgG antibodies
P09737453A0557|84 105|heparin/platelet factor
P09737453A0557|114 125|standardized
P09737453A0557|136 166|enzyme-linked immunosorbent assay
P09737453A0557|168 172|ELISA
P09737921T0000|0 15|Genome plasticity
P09737921T0000|21 40|distal tail fiber locus
P09737921T0000|46 64|T-even bacteriophage
P09737921T0000|66 78|recombination
P09737921T0000|95 123|motifs swaps adhesin specificity
P09738010A0305|3 13|FAS promoter
P09738010A0305|31 37|insulin
P09738010A0305|48 78|proximal insulin response sequence
P09738010A0305|91 100|E-box motif
P09738010A0305|110 125|base pair position
P09738087A0583|11 31|independent predictors
P09738087A0583|56 73|Cox regression model
P09738087A0583|99 107|illnesses
P09738693T0000|0 6|Effects
P09738693T0000|9 15|rhG-CSF
P09738693T0000|18 36|neutrophil functions
P09738693T0000|50 55|sepsis
P09738693T0000|63 74|diabetic rats
P09739401A0000|0 8|OBJECTIVE
P09739401A0000|43 60|balance instruments
P09739401A0000|85 89|years
P09739401A0000|116 130|home environment
P09739913A0194|0 9|CASE REPORT
P09739913A0194|22 48|congenital skin defect located
P09741391A0581|13 35|single-chambered body box
P09741391A0581|37 45|PenH units
P09741391A0581|55 59|Pause
P09741391A0581|133 142|expiration
P09741783A0000|0 10|Anastrozole
P09741783A0000|16 38|first aromatase inhibitor
P09741783A0000|21 29|aromatase
P09741783A0000|46 73|significant survival advantage
P09741783A0000|78 93|megestrol acetate
P09741783A0000|96 115|post-menopausal women
P09741783A0000|120 139|advanced breast cancer
P09742129A0491|0 1|W.
P09743128A0969|0 6|Moritta
P09743128A0969|19 25|Bis-GMA
P09743233A0526|0 7|Mutation
P09743233A0526|19 22|AP-1
P09743233A0526|28 39|ets component
P09743233A0526|63 78|promoter activity
P09743233A0526|81 84|SMCs
P09743720A0268|0 6|ANIMALS
P09743720A0268|13 16|dogs
P09743720A0268|40 41|DM
P09744095A1016|13 25|double mutants
P09744095A1016|31 43|shy2-1D mutant
P09744095A1016|51 81|phytochrome-deficient mutants hy2
P09744095A1016|51 78|phytochrome-deficient mutants
P09744095A1016|79 81|hy2
P09744095A1016|83 85|hy3
P09744095A1016|87 92|phyB-1
P09744095A1016|97 102|fre1-1
P09744095A1016|104 111|phyA-201
P09744095A1016|126 149|photomorphogenic response
P09744095A1016|165 179|longer hypocotyl
P09744095A1016|182 204|longer inflorescence stem
P09744095A1016|210 229|lower level expression
P09744095A1016|235 241|CAB gene
P09744095A1016|249 267|shy2-1D single mutant
P09745797A0943|21 36|underpredictions
P09745797A0943|57 66|disruption
P09745797A0943|69 80|primary tasks
P09745797A0943|84 102|physiological impact
P09745797A0943|106 111|higher
P09747651A0000|0 12|Laser ablation
P09747651A0000|31 48|therapeutic measure
P09747651A0000|52 76|chronic pulmonary emphysema
P09747873T0000|3 35|SH2-containing adapter protein GRB10
P09747873T0000|3 30|SH2-containing adapter protein
P09747873T0000|31 35|GRB10
P09747873T0000|49 55|BCR-ABL
P09748261A0000|0 22|Saccharomyces cerevisiae
P09748261A0000|35 58|known acyl-CoA synthetases
P09748261A0000|40 58|acyl-CoA synthetases
P09748261A0000|60 86|fatty acid activation proteins
P09748261A0000|88 92|Faaps
P09748286A0000|19 43|placenta-specific enhancer
P09748286A0000|49 85|human leukemia inhibitory factor receptor
P09748286A0000|87 90|LIFR
P09748286A0000|106 129|detailed characterization
P09748286A0000|135 154|226-base pair enhancer
P09748286A0000|167 177|nucleotides
P09748513X1360|0 8|Copyright
P09748513X1360|13 31|Elsevier Science B.V.
P09748669A0414|26 34|dichotomy
P09748669A0414|42 43|AD
P09748669A0414|47 49|VaD
P09749533A0764|0 4|Clone
P09749533A0764|11 17|homolog
P09749533A0764|20 27|CONSTANS
P09749533A0764|65 77|flowering time
P09749533A0764|80 90|Arabidopsis
P09749988A0000|0 6|Badcock
P09749988A0000|10 19|Westheimer
P09749988A0000|21 33|Spatial Vision
P09749988A0000|39 42|3-11
P09749988A0000|60 75|thin vertical line
P09749988A0000|83 93|nearby zones
P09749988A0000|109 117|repulsion
P09749988A0000|140 146|results
P09749988A0000|172 181|horizontal
P09749988A0000|185 199|vertical extents
P09749988A0000|205 217|repulsion zone
P09749988A0000|230 244|illusory contour
P09749988A0000|253 261|repulsion
P09750325A0000|3 9|effects
P09750325A0000|12 38|high intensity light emissions
P09750325A0000|51 87|novel pulsed power energization technique
P09750325A0000|89 92|PPET
P09750325A0000|110 129|bacterial populations
P09750325A0000|132 148|verocytotoxigenic
P09750325A0000|165 172|serotype
P09750325A0000|178 179|H7
P09750325A0000|184 204|Listeria monocytogenes
P09750325A0000|206 215|serotype 4b
P09750540A0000|0 26|Multiple chemical sensitivity
P09750540A0000|28 30|MCS
P09750540A0000|50 65|multiple symptoms
P09750540A0000|85 109|low-level chemical exposure
P09751061A0000|0 17|POU-domain proteins
P09751061A0000|28 56|pituitary-specific factor Pit-1
P09751061A0000|61 67|members
P09751061A0000|73 89|homeodomain family
P09751061A0000|92 99|proteins
P09751061A0000|133 143|homeostasis
P09751061A0000|179 205|signal-transduction pathways
P09751061A0000|246 258|specific genes
P09751114A0967|0 8|Wild-type
P09751114A0967|12 21|mutant MyoD
P09751114A0967|18 21|MyoD
P09751114A0967|40 44|cells
P09751114A0967|52 53|E1
P09751114A0967|55 80|E3-deleted adenoviral vector
P09751114A0967|55 56|E3
P09751114A1987|5 11|results
P09751114A1987|23 28|Thr115
P09751114A1987|38 50|important role
P09751114A1987|68 79|MyoD function
P09751114A1987|68 71|MyoD
P09751114A1987|85 94|conditions
P09751114A1987|97 111|high mitogenesis
P09751166A1460|7 21|previous results
P09751166A1460|36 38|CRE
P09751166A1460|42 48|Sp1 site
P09751166A1460|75 89|TH transcription
P09751166A1460|75 76|TH
P09751166A1460|93 123|promoter context-dependent manner
P09751458A0845|0 19|desmethyltrimebutine
P09751458A0845|23 30|inactive
P09753241A0524|0 21|Endoscopic examinations
P09753241A0524|23 46|peripheral white blood cell
P09753241A0524|48 50|WBC
P09753241A0524|62 67|assays
P09753241A0524|70 92|myeloperoxidase activity
P09753241A0524|70 84|myeloperoxidase
P09753241A0524|94 96|MPO
P09753241A0524|100 110|homogenates
P09753241A0524|113 123|colon mucosa
P09753241A0524|151 159|% DSS model
P09753241A0524|169 173|weeks
P09753241A0524|176 184|% DSS model
P09753730A0881|0 14|T7 transcription
P09753730A0881|42 56|different levels
P09753730A0881|59 80|constitutive expression
P09753730A0881|97 113|promoter mutations
P09753769A0362|3 9|primers
P09753769A0362|14 27|degenerate sets
P09753769A0362|30 45|oligonucleotides
P09753769A0362|62 79|amino acid sequences
P09753769A0362|85 97|PBAN precursor
P09753774A1642|0 5|Plants
P09753774A1642|24 41|35S-1-sst construct
P09753774A1642|24 32|35S-1-sst
P09753774A1642|56 77|oligofructans 1-kestose
P09753774A1642|79 81|GF2
P09753774A1642|84 94|1,1-nystose
P09753774A1642|96 98|GF3
P09753774A1642|103 124|1,1,1-fructosylnystose
P09753774A1642|126 128|GF4
P09753774A2246|34 51|amino acid sequences
P09753774A2246|54 58|1-sst
P09753774A2246|62 66|1-fft
P09753774A2246|78 112|other plant fructosyl transferase genes
P09753774A2246|88 112|fructosyl transferase genes
P09753774A2246|133 149|plant fructan genes
P09753774A2246|138 149|fructan genes
P09753774A2246|165 183|plant invertase genes
P09753774A2246|170 178|invertase
P09753775A0734|8 11|ICK1
P09753775A0734|24 26|ABA
P09753775A0734|40 52|ICK1 induction
P09753775A0734|40 43|ICK1
P09753775A0734|72 103|Cdc2-like histone H1 kinase activity
P09753775A0734|72 95|Cdc2-like histone H1 kinase
P09754571A0169|1 16|5.0-kb transcript
P09754571A0169|30 59|differential display amplicon 3G1
P09754571A0169|91 108|RAG1 mRNA expression
P09754571A0169|91 98|RAG1 mRNA
P09754571A0169|111 131|various human cell lines
P09754571A1257|3 11|hBRAG gene
P09754571A1257|15 23|localized
P09754571A1257|29 35|long arm
P09754571A1257|38 47|chromosome
P09754571A1257|51 55|10q26
P09755191A0553|17 22|swa5-1
P09755191A0553|26 55|new temperature-sensitive allele
P09755191A0553|61 82|clathrin heavy chain gene
P09755191A0553|84 89|chc1-5
P09755191A0553|105 122|frameshift mutation
P09755191A0553|140 159|CHC1 open reading frame
P09755191A0553|140 143|CHC1
P09755199A0373|19 34|molecular lesions
P09755199A0373|41 56|Scm mutant alleles
P09755199A0373|71 92|functional requirements
P09755199A0373|96 110|specific domains
P09755199A0559|18 40|hypomorphic Scm mutations
P09755199A0559|58 66|mbt repeat
P09755199A0559|80 91|PcG mutations
P09755199A0559|80 82|PcG
P09755199A0559|110 123|Scm null alleles
P09755478A0366|0 15|Northern analysis
P09755478A0366|26 45|detectable expression
P09755478A0366|51 60|transcript
P09755478A0366|63 70|diapause
P09755478A0366|74 95|nondiapause-programmed
P09755478A0366|105 110|larvae
P09755478A0366|119 133|trace expression
P09755478A0366|136 153|nondiapausing pupae
P09756687A0981|10 25|characterization
P09756687A0981|44 60|experimental setup
P09756687A0981|69 81|rate constants
P09756687A0981|126 131|values
P09756895A0322|0 11|Genomic locus
P09756895A0322|14 19|chCTCF
P09756895A0322|29 51|GC-rich untranslated exon
P09756895A0322|76 80|exons
P09756895A0322|84 93|long intron
P09757012A0942|13 15|PDZ
P09757012A0942|19 28|SAM domains
P09757012A0942|34 43|KS5 protein
P09757012A0942|67 82|molecular adaptor
P09757012A0942|118 142|signal transduction pathway
P09759180A0000|0 9|BACKGROUND
P09759180A0000|11 26|Fluoroquinolones
P09759180A0000|28 29|FQ
P09759180A0000|51 58|children
P09759180A0000|77 91|cartilage damage
P09759691A1051|2 9|analyses
P09759691A1051|24 40|multiple variables
P09759691A1051|42 53|relative risk
P09759691A1051|57 72|microalbuminuria
P09759691A1051|74 96|urinary albumin excretion
P09759691A1051|104 113|microg/min
P09759691A1051|117 119|men
P09759691A1051|123 127|women
P09759691A1051|162 171|mm Hg higher
P09759691A1051|174 175|SD
P09759691A1051|177 197|systolic blood pressure
P09759691A1051|228 235|1.0-mmol
P09759691A1051|237 237|L
P09759691A1051|241 245|mg/dL
P09759691A1051|247 274|higher plasma cholesterol level
P09759691A1051|304 310|smokers
P09759691A1051|313 322|nonsmokers
P09759691A1051|357 380|kg/m2 higher body mass index
P09759865A0673|13 20|IL-1beta
P09759865A0673|24 32|TNF-alpha
P09759865A0673|44 57|nuclear binding
P09759865A0673|63 76|Rel proteins p50
P09759865A0673|63 73|Rel proteins
P09759865A0673|74 76|p50
P09759865A0673|80 82|p65
P09759865A0673|87 119|NF-kappaB consensus oligonucleotide
P09759865A0673|87 95|NF-kappaB
P09759865A0673|122 135|gel shift assays
P09759865A0673|145 164|transient degradation
P09759865A0673|167 175|inhibitor
P09759865A0673|178 192|NF-kappaB-alpha
P09759865A0673|194 206|IkappaB-alpha
P09759865A0673|213 221|cytoplasm
P09759865A0673|224 237|myofibroblasts
P09759865A0673|243 250|IL-1beta
P09759865A0673|262 272|PDGF-Ralpha
P09760243A0970|0 14|Cotransfections
P09760243A0970|19 23|ATF-2
P09760243A0970|27 49|HNF-4 expression plasmids
P09760243A0970|27 31|HNF-4
P09760243A0970|60 82|additive transactivation
P09760243A0970|88 102|apoCIII promoter
P09760341T0000|0 24|Phosphocreatine hydrolysis
P09760341T0000|31 48|submaximal exercise
P09760341T0000|61 64|FIO2
P09761711A0000|0 18|Pseudocontact shifts
P09761711A0000|31 61|isotropic reorientational average
P09761711A0000|67 81|dipolar coupling
P09761711A0000|89 104|unpaired electron
P09761711A0000|108 113|nuclei
P09761711A0000|130 161|magnetic susceptibility anisotropy
P09761723A0226|0 5|GETS-1
P09761723A0226|19 29|many tissues
P09761723A0226|46 51|retina
P09761791A0489|16 21|U1-70K
P09761791A0489|29 39|SRZ proteins
P09761791A0489|71 86|blot overlay assay
P09763421A1199|3 17|major phenotypes
P09763421A1199|31 53|Fab1p kinase inactivation
P09763421A1199|31 41|Fab1p kinase
P09763421A1199|61 87|temperature-sensitive growth
P09763421A1199|89 116|vacuolar acidification defects
P09763421A1199|121 137|dramatic increases
P09763421A1199|140 151|vacuolar size
P09763446A0000|0 11|Small GTPases
P09763446A0000|17 29|Ypt/Rab family
P09763446A0000|17 19|Ypt
P09763446A0000|21 29|Rab family
P09763446A0000|58 75|vesicular transport
P09763446A1234|3 5|GEF
P09763446A1234|9 21|GAP activities
P09763446A1234|9 11|GAP
P09763446A1234|25 29|Ypt1p
P09763446A1234|40 67|particulate cellular fractions
P09763470A0000|0 23|Dopamine beta-hydroxylase
P09763470A0000|25 27|DBH
P09763470A0000|53 60|dopamine
P09763470A0000|63 75|noradrenaline
P09763470A0000|103 115|noradrenergic
P09763470A0000|119 135|adrenergic neurons
P09763470A0000|139 157|neuroendocrine cells
P09763470A1756|33 44|critical role
P09763470A1756|47 52|Phox2a
P09763470A1756|64 82|functional synergism
P09763470A1756|87 111|other transcription factors
P09763470A1756|118 121|CREB
P09763470A1756|123 125|AP2
P09763470A1756|130 132|Sp1
P09763470A1756|136 160|transcriptional activation
P09763470A1756|166 172|DBH gene
P09763522A2545|16 23|antibody
P09763522A2545|31 37|N-SMase
P09763522A2545|49 54|Ox-LDL
P09763522A2545|59 84|TNF-alpha-induced apoptosis
P09763522A2545|59 67|TNF-alpha
P09763522A2545|117 123|studies
P09763522A2545|126 134|apoptosis
P09763522A2545|137 155|experimental animals
P09763607A0521|11 28|virulent Ngo strains
P09763607A0521|35 49|phosphorylation
P09763607A0521|53 62|activation
P09763607A0521|65 67|JNK
P09763607A0521|76 84|p38 kinase
P09764741A0092|7 11|beams
P09764741A0092|14 41|classical light ablate elements
P09764741A0092|47 67|cell division machinery
P09764741A0092|80 86|beating
P09764741A0092|89 94|hearts
P09764741A0092|98 110|cellular basis
P09765261A0000|3 38|human T cell lymphotropic retrovirus type
P09765261A0000|41 62|HTLV-I) trans-activator
P09765261A0000|41 46|HTLV-I
P09765261A0000|48 62|trans-activator
P09765261A0000|64 66|Tax
P09765261A0000|96 122|basic-domain/leucine-zipper
P09765261A0000|124 127|bZip
P09765261A0000|137 169|cAMP response element binding protein
P09765261A0000|171 174|CREB
P09765261A0000|187 212|viral Tax-responsive element
P09765261A0000|230 256|imperfect 21-base pair repeats
P09765261A0000|267 289|cAMP response element core
P09765261A0000|299 315|G/C-rich sequences
P09765271A1108|30 52|insulin response sequence
P09765271A1108|30 36|insulin
P09765271A1108|63 78|regulatory region
P09765271A1108|81 90|other genes
P09765271A1108|112 122|insulin such
P09765271A1108|112 118|insulin
P09765271A1108|138 169|phosphoenolpyruvate carboxykinase
P09765271A1108|171 194|tyrosine aminotransferase
P09765271A1108|199 238|insulin-like growth factor-binding protein 1
P09765271A1108|199 237|insulin-like growth factor-binding protein
P09765277A0000|3 45|murine facilitative glucose transporter isoform
P09765277A0000|48 51|Glut
P09765277A0000|109 115|neurons
P09765277A0000|119 130|trophoblasts
P09765285A0998|19 27|half-site
P09765285A0998|33 55|consensus sequence AGGTCA
P09765285A0998|57 63|IRper-1
P09765285A0998|74 80|binding
P09765285A0998|83 93|AaEcR.AaUSP
P09765285A0998|83 87|AaEcR
P09765285A0998|89 93|AaUSP
P09765285A0998|105 111|IRhsp-1
P09765285A0998|121 128|same time
P09765285A0998|140 149|stringency
P09765285A0998|155 177|spacer length requirement
P09765285A0998|183 189|IRper-0
P09765285A0998|192 198|IRper-5
P09765285A0998|206 222|detectable binding
P09765285A1763|3 8|levels
P09765285A1763|11 25|transactivation
P09765285A1763|46 72|respective binding affinities
P09765285A1763|78 93|response elements
P09765285A1763|95 101|IRper-1
P09765285A1763|103 106|DR-4
P09765285A1763|108 114|IRhsp-1
P09765372A0669|3 13|high density
P09765372A0669|16 31|tegumental spines
P09765372A0669|34 46|posterior half
P09765372A0669|82 89|papillae
P09765372A0669|92 104|dorsal surface
P09765372A0669|138 146|C. armatus
P09765388T0000|0 11|Inactivation
P09765388T0000|14 16|p53
P09765388T0000|23 25|p73
P09765388T0000|28 88|adenovirus type 5 E1B 55-kilodalton and E4 34-kilodalton oncoproteins
P09765388T0000|28 41|adenovirus type
P09765388T0000|43 58|E1B 55-kilodalton
P09765388T0000|62 88|E4 34-kilodalton oncoproteins
P09765394A0000|3 36|Epstein-Barr virus transactivator Zta
P09765394A0000|45 63|lytic gene expression
P09765394A0000|81 91|replication
P09765394A0000|97 107|lytic origin
P09765394A0000|109 114|oriLyt
P09765394A1590|0 13|Cotransfection
P09765394A1590|19 42|helicase-primase proteins
P09765394A1590|65 92|heterologous activation domain
P09765394A1590|99 126|Zta-dependent superactivation
P09765394A1590|99 101|Zta
P09765394A1590|129 141|CAT expression
P09765394A1590|129 131|CAT
P09765411A0991|0 18|Sequence comparisons
P09765411A0991|41 44|S27a
P09765411A0991|51 59|ubiquitin
P09765411A0991|66 74|sequences
P09765411A0991|85 90|genome
P09765411A0991|93 97|CP Rit
P09765411A0991|118 127|bovine mRNA
P09765411A0991|137 149|hybrid protein
P09765411A0991|157 188|structure NH2-ubiquitin-S27a-COOH
P09765411A0991|170 178|ubiquitin
P09765411A0991|180 183|S27a
P09765466A0231|0 1|J.
P09765754A1727|19 25|studies
P09765754A1727|35 37|PVI
P09767504A1371|1 16|single rectal dose
P09767504A1371|21 25|mg/kg
P09767504A1371|40 57|lower concentration
P09767504A1371|65 65|h
P09767504A1371|103 104|h.
P09767575A0657|19 26|adjacent
P09767575A0657|43 52|SD sequence
P09767575A0657|68 82|ribosome binding
P09767575A0657|94 114|single-stranded region
P09767593A0130|8 11|YopH
P09767593A0130|21 29|active PTP
P09767593A0130|27 29|PTP
P09767593A0130|55 60|subset
P09767593A0130|63 93|tyrosine-phosphorylated proteins
P09767593A0130|96 104|host cells
P09767593A0130|115 121|p130Cas
P09767687T0000|0 19|Phylogenetic position
P09767687T0000|25 35|Phacotaceae
P09767687T0000|45 61|Chlamydophyceaeas
P09767687T0000|82 88|18S rDNA
P09767687T0000|92 104|rbcL sequences
P09769209A0100|0 21|Previous genetic studies
P09769209A0100|44 50|nitrate
P09769209A0100|54 69|nitrite induction
P09769209A0100|72 91|nasF operon expression
P09769209A0100|72 81|nasF operon
P09769209A0100|107 145|transcriptional antitermination mechanism
P09769910A1700|3 12|activation
P09769910A1700|24 39|endothelial cells
P09769910A1700|49 51|TNF
P09769910A1700|55 83|other proinflammatory cytokines
P09769910A1700|98 109|local effects
P09769910A1700|117 125|mediators
P09770241A0000|13 26|thermal imaging
P09770241A0000|41 56|human brain cortex
P09770241A0000|64 84|infrared optical system
P09770378A0641|0 9|EGFR levels
P09770378A0641|0 3|EGFR
P09770378A0641|23 30|elevated
P09770415A0139|21 26|THOV NP
P09770415A0139|36 40|motif
P09770415A0139|42 56|KRxxxxxxxxxKTKK
P09770415A0139|60 77|amino acid positions
P09770415A0139|100 142|classical bipartite nuclear localization signal
P09770415A0139|144 146|NLS
P09770493A0499|2 5|PP2A
P09770493A0499|20 36|cellular functions
P09770493A0499|46 64|cell cycle regulation
P09770493A0499|68 88|cell fate determination
P09770493A0499|120 126|embryos
P09770493A0499|147 162|postimplantation
P09770493A0499|170 181|embryonic day
P09770686A0484|7 24|frequent risk factor
P09770686A0484|28 36|ischaemic
P09770686A0484|40 51|hypertension
P09771555A0499|3 9|results
P09771555A0499|22 44|anthraquinone sennoside B
P09771555A0499|48 52|rhein
P09771555A0499|62 70|genotoxic
P09771967A1052|12 18|LB1 gene
P09771967A1052|27 41|chromosome 13q14
P09771967A1052|72 92|chromosomal breakpoint
P09771967A1052|95 98|DLBL
P09771985A0238|2 9|subjects
P09771985A0238|14 20|repatch
P09771985A0238|29 48|ethylmercury chloride
P09771985A0238|50 55|EtHgCl
P09771985A0238|62 70|solutions
P09771985A0238|81 91|EtHgCl mixed
P09771985A0238|96 105|L-cysteine
P09771985A0238|109 119|glutathione
P09773975A1873|0 21|Wild-type AT1A receptors
P09773975A1873|34 57|Chinese hamster ovary cells
P09773975A1873|83 98|Ang II stimulation
P09773975A1873|100 103|t1/2
P09773975A1873|107 109|min
P09773975A1873|111 122|maximal level
P09773975A1873|125 139|internalization
P09773975A1873|141 144|Ymax
P09773975A1873|150 150|%
P09773975A1873|158 172|mutant receptors
P09773975A1873|181 205|single acidic substitutions
P09773975A1873|207 211|T332E
P09773975A1873|213 216|t1/2
P09773975A1873|220 222|min
P09773975A1873|224 227|Ymax
P09773975A1873|232 232|%
P09773975A1873|234 238|S335D
P09773975A1873|240 243|t1/2
P09773975A1873|247 249|min
P09773975A1873|251 254|Ymax
P09773975A1873|259 259|%
P09773975A1873|261 265|T336E
P09773975A1873|267 270|t1/2
P09773975A1873|274 276|min
P09773975A1873|278 281|Ymax
P09773975A1873|286 286|%
P09773975A1873|288 292|S338D
P09773975A1873|294 297|t1/2
P09773975A1873|301 303|min
P09773975A1873|305 308|Ymax
P09773975A1873|313 313|%
P09773981A0415b|12 33|glucocorticoid receptor
P09773981A0415b|51 55|Stat5
P09773981A0415b|67 104|Stat5-mediated transcriptional induction
P09773981A0415b|67 71|Stat5
P09774403A0107|0 1|T.
P09774403A0107|3 10|Mahasneh
P09774403A0107|12 13|A.
P09774403A0107|18 21|Cote
P09774403A0107|23 24|G.
P09774444A0351|3 26|carboxyl-terminal portion
P09774444A0351|29 32|UKLF
P09774444A0351|46 56|zinc fingers
P09774444A0351|62 74|Cys2-His2 type
P09774444A0351|95 104|CACCC motif
P09774444A0351|110 128|beta-globin promoter
P09774444A0351|137 158|Sp1 recognition sequence
P09774450A0000|25 35|mouse enzyme
P09774450A0000|42 68|gamma-glutamyl leukotrienase
P09774450A0000|70 72|GGL
P09774450A0000|86 98|leukotriene C4
P09774450A0000|100 103|LTC4
P09774450A0000|107 119|leukotriene D4
P09774450A0000|121 124|LTD4
P09774484T0000|0 15|UGA codon position
P09774484T0000|38 64|selenocysteine incorporation
P09774484T0000|69 91|glutathione peroxidase-1
P09774641A0824|0 8|Forskolin
P09774641A0824|30 59|heregulin-stimulated expression
P09774641A0824|30 38|heregulin
P09774641A0824|62 68|cyclin D
P09774641A0824|72 86|phosphorylation
P09774641A0824|92 116|retinoblastoma gene product
P09774662A0958|3 13|ARF promoter
P09774662A0958|36 45|responsive
P09774662A0958|48 61|E2F1 expression
P09774662A0958|48 51|E2F1
P09774662A0958|76 90|previous results
P09774662A0958|96 103|RNA level
P09776293A0777|0 6|RESULTS
P09776293A0777|11 17|binding
P09776293A0777|20 25|99mTc d
P09776293A0777|27 33|1-HMPAO
P09776293A0777|36 48|human placenta
P09776293A0777|63 63|%
P09776293A0777|70 70|%
P09776293A0777|77 77|%
P09776293A0777|84 84|%
P09776293A0777|89 106|ml standard solution
P09776360A0620|0 1|CM
P09776360A0620|12 33|nuclear binding activity
P09776360A0620|36 58|transcription factor AP-1
P09776360A1781|0 8|NF-kappaB
P09776360A1781|37 49|basal activity
P09776360A1781|55 72|human NOS II promoter
P09776360A1781|55 62|human NOS
P09776360A1781|65 72|promoter
P09776360A1781|97 109|major effector
P09776360A1781|112 113|CM
P09776360A1781|116 125|DLD-1 cells
P09777477A0000|0 8|Observers
P09777477A0000|13 23|brain injury
P09777477A0000|27 45|control participants
P09777477A0000|56 68|vigilance task
P09777477A0000|92 105|periodic whiffs
P09777477A0000|108 119|unscented air
P09777477A0000|122 131|air scented
P09777477A0000|136 145|peppermint
P09777600A0000|1 22|simple analytical method
P09777600A0000|26 34|l-menthol
P09777600A0000|37 72|high-performance liquid chromatography
P09777600A0000|87 105|photometric detector
P09777999A0796|0 6|RESULTS
P09777999A0796|11 22|cardiac index
P09777999A0796|54 64|PaCO2 levels
P09777999A0796|66 75|hypocapnia
P09777999A0796|79 79|%
P09777999A0796|81 91|hypercapnia
P09777999A0796|95 95|%
P09778006A0718|14 25|baseline Vmca
P09778006A0718|29 43|partial pressure
P09778006A0718|46 58|carbon dioxide
P09778006A0718|61 73|arterial blood
P09778006A0718|75 79|PaCO2
P09778006A0718|93 96|mmHg
P09778006A0718|105 106|SD
P09778006A0718|109 120|measurements
P09778006A0718|136 139|PaCO
P09778006A0718|152 155|mmHg
P09778006A0718|163 185|carbon dioxide reactivity
P09778006A0718|187 199|absolute value
P09778006A0718|201 202|cm
P09778006A0718|204 204|s
P09778006A0718|210 213|mmHg
P09778006A0718|219 231|relative value
P09778006A0718|245 261|baseline Vmca/mmHg
P09778068A1129|0 30|Multivariate Cox survival analysis
P09778068A1129|41 50|baseline EF
P09778068A1129|54 54|=
P09778068A1129|57 57|%
P09778068A1129|69 98|significant mitral regurgitation
P09778068A1129|110 117|ablation
P09778068A1129|138 163|improved cardiac performance
P09778068A1129|177 184|ablation
P09778068A1129|190 214|only independent predictors
P09778191A0000|16 24|new method
P09778191A0000|28 37|estimation
P09778191A0000|40 50|regional CBF
P09778191A0000|52 55|rCBF
P09778191A0000|60 89|cerebrovascular reserve capacity
P09778191A0000|93 111|pixel-by-pixel basis
P09778191A0000|114 118|means
P09778191A0000|121 151|dynamic magnetic resonance imaging
P09778191A0000|153 155|MRI
P09778197A0415|0 25|Cost-effectiveness analysis
P09778197A0415|35 47|rational means
P09778197A0415|60 85|limited health care resources
P09778197A0415|114 118|costs
P09778197A0415|121 141|lipid-lowering therapy
P09778197A0415|167 222|beta-hydroxy-beta-methylglutaryl-CoA (coenzyme A) reductase
P09778197A0415|167 202|beta-hydroxy-beta-methylglutaryl-CoA
P09778197A0415|204 212|coenzyme A
P09778197A0415|214 232|reductase inhibitors
P09778197A0415|234 240|statins
P09778197A0415|250 254|costs
P09778197A0415|257 271|atherosclerosis
P09780002A0996|8 13|E2FBP1
P09780002A0996|22 42|transactivation domain
P09780002A0996|56 85|E2F site-dependent transcription
P09780002A0996|56 62|E2F site
P09780002A0996|103 107|E2F-1
P09780228A0122|0 9|Sequencing
P09780228A0122|13 27|40-kb DNA segment
P09780228A0122|33 48|FK506 gene cluster
P09780228A0613|12 27|domain structures
P09780228A0613|30 33|FkbB
P09780228A0613|37 40|FkbC
P09780228A0613|44 52|analogous
P09780228A0613|61 64|FkbA
P09780228A0613|78 96|fatty-acid-synthase
P09780228A0613|98 100|FAS
P09780228A0613|107 113|domains
P09780228A0613|125 131|modules
P09780336A0771|0 7|Analysis
P09780336A0771|10 27|Msy2 mRNA expression
P09780336A0771|10 17|Msy2 mRNA
P09780336A0771|30 40|prepubertal
P09780336A0771|44 59|adult mouse testes
P09780336A0771|74 84|populations
P09780336A0771|87 95|germ cells
P09780336A0771|104 120|maximal expression
P09780336A0771|123 148|postmeiotic round spermatids
P09780336A0771|151 158|cell type
P09780336A0771|163 177|abundant amounts
P09780336A0771|186 212|messenger ribonucleoproteins
P09781761A0384|3 15|Ho Chi Minh City
P09781761A0384|38 55|latex agglutination
P09781761A0384|64 81|cerebrospinal fluid
P09781761A0384|83 87|urine
P09781761A0384|91 102|pleural fluid
P09781871A0404|0 16|Glycogen synthesis
P09781871A0404|20 29|catabolism
P09781871A0404|31 45|gluconeogenesis
P09781871A0404|47 56|glycolysis
P09781871A0404|58 65|motility
P09781871A0404|67 87|cell surface properties
P09781871A0404|91 99|adherence
P09781871A0404|114 117|csrA
P09781871A0404|171 186|virulence factors
P09781871A0404|191 229|plant hypersensitive response elicitor HrpN
P09781871A0404|226 229|HrpN
P09781871A0404|231 233|Ecc
P09781871A0404|251 275|other secondary metabolites
P09781871A0404|290 312|rsmA in Erwinia carotovora
P09781871A0404|290 293|rsmA
P09781871A0404|296 312|Erwinia carotovora
P09781874A1061|3 16|cwg2-1 mutation
P09781874A1061|33 39|guanine
P09781874A1061|42 60|adenine substitution
P09781874A1061|63 72|nucleotide
P09781874A1061|108 118|change A202T
P09781874A1061|124 128|cwg2p
P09784063A0621|0 15|Deletion analysis
P09784063A0621|31 45|essential domain
P09784063A0621|52 59|promoter
P09784063A0621|70 98|ORF5/deltaX transcript promoter
P09784063A0621|108 118|nucleotides
P09784192A1027|9 15|peptide
P09784192A1027|17 26|MBP fusions
P09784192A1027|48 70|surface plasmon resonance
P09784245T0000|0 28|Cardiac myosin-binding protein C
P09784245T0000|30 35|MyBP-C
P09784245T0000|54 67|protein kinase A
P09784245T0000|71 104|protein kinase C phosphorylation sites
P09784245T0000|71 84|protein kinase C
P09785114A1026|10 12|PND
P09785114A1026|28 45|elevated CORT levels
P09785114A1026|56 61|groups
P09786197A0322|0 7|Analysis
P09786197A0322|10 31|chromosomal DNA sequence
P09786197A0322|58 76|transposon insertion
P09786197A0322|90 106|open reading frames
P09786197A0322|118 121|csrR
P09786197A0322|125 128|csrS
P09786197A0322|144 161|sequence similarity
P09786197A0322|164 202|bacterial two-component regulatory systems
P09786404A0541|9 21|aggregates/ml
P09786404A0541|25 27|rpm
P09786404A0541|29 29|P
P09786926A0095|34 59|fatty-acid synthase promoter
P09786926A0095|83 111|obesity-related overexpression
P09786926A0095|117 134|fatty-acid synthase
P09786926A0095|136 138|FAS
P09786926A0095|183 200|downstream promoter
P09786926A0095|213 228|obese rat fat cells
P09786926A1372|20 33|binding studies
P09786926A1372|47 52|SREBP2
P09786926A1372|70 87|ADD1/SREBP1 binding
P09786926A1372|70 73|ADD1
P09786926A1372|75 80|SREBP1
P09786926A1372|95 117|sterol regulatory element
P09786926A1372|119 121|SRE
P09786932A1042|5 9|IRF-7
P09786932A1042|18 37|functional similarity
P09786932A1042|40 44|IRF-3
P09786932A1042|57 78|preferential expression
P09786932A1042|81 85|IRF-7
P09786932A1042|88 100|lymphoid cells
P09786932A1042|105 112|cell type
P09786932A1042|126 129|IFNA
P09786932A1042|143 147|IRF-7
P09786932A1042|156 167|critical role
P09786932A1042|183 200|IFNA gene expression
P09786932A1042|183 190|IFNA gene
P09786949A0114|0 1|J.
P09787323A0000|0 6|PURPOSE
P09787323A0000|11 27|role interleukin-6
P09787323A0000|15 27|interleukin-6
P09787323A0000|29 32|IL-6
P09787323A0000|50 76|congenital thrombocytopenias
P09788739A1096|0 3|CKII
P09788739A1096|7 33|CD44-associated serine kinase
P09788739A1096|55 71|important molecule
P09788739A1096|75 90|signaling cascade
P09788739A1096|113 129|cellular responses
P09788739A1096|132 154|MDA231 breast cancer cells
P09789025A0149|0 6|Galphaq
P09789025A0149|8 15|Galpha12
P09789025A0149|20 27|Galpha13
P09789025A0149|35 41|Galphai
P09789025A0149|51 53|SRF
P09789025A0149|61 64|RhoA
P09789795A0607|19 36|subjects adrenaline
P09789795A0607|38 38|A
P09789795A0607|43 55|noradrenaline
P09789795A0607|57 58|NA
P09789795A0607|60 73|concentrations
P09790499A0545|0 19|Northern blot analyses
P09790499A0545|31 44|hBub1 mRNA level
P09790499A0545|31 39|hBub1 mRNA
P09790499A0545|68 74|tissues
P09790499A0545|77 81|cells
P09790499A0545|87 102|high mitotic index
P09790767A0372|31 47|sequence tag clones
P09790767A0372|55 67|genomic contig
P09790767A0372|70 84|human chromosome
P09790767A0372|87 93|band q31
P09790768A0621|0 10|Htra2-beta3
P09790768A0621|70 80|liver testis
P09790768A0621|93 98|kidney
P09790771A0956|0 16|Gng3lg transcripts
P09790771A0956|41 47|tissues
P09790771A0956|69 74|testes
P09790771A1032|7 33|interspecific backcross panel
P09790771A1032|50 53|Gng3
P09790771A1032|57 62|Gng3lg
P09790771A1032|68 76|same locus
P09790771A1032|79 88|chromosome
P09790986A0689|13 30|polyclonal antibody
P09790986A0689|41 77|glutathione S-transferase fusion protein
P09790986A0689|91 102|NH2-terminal
P09790986A0689|105 114|amino acids
P09790986A0689|117 127|human NRAMP2
P09792439T0000|0 9|Inhibition
P09792439T0000|15 54|apolipoprotein B mRNA editing enzyme-complex
P09792439T0000|15 33|apolipoprotein B mRNA
P09792439T0000|57 70|hnRNP C1 protein
P09792439T0000|74 90|40S hnRNP complexes
P09792627A0441|0 4|SRC-1
P09792627A0441|18 45|NF-kappaB-mediated repression
P09792627A0441|18 26|NF-kappaB
P09792627A0441|48 57|GR activity
P09792627A0441|48 49|GR
P09792630A1127|32 57|transcription start site CTCA
P09792630A1127|59 60|+1
P09792630A1127|62 65|TTCC
P09792630A1127|81 93|consensus CTCA
P09792630A1127|95 96|+1
P09792630A1127|98 101|NTCT
P09792630A1127|103 103|N
P09792630A1127|109 118|nucleoside
P09792630A1127|125 140|initiator element
P09792630A1127|148 182|terminal deoxynucleotidyltransferase
P09792630A1127|215 219|genes
P09792682A0713|5 11|results
P09792682A0713|27 37|total number
P09792682A0713|40 47|subunit c
P09792682A0713|50 51|F0
P09792702A0754|0 9|Expression
P09792702A0754|13 35|dominant-negative mutant
P09792702A0754|38 41|JNK1
P09792702A0754|56 95|glucose deprivation-induced JNK1 activation
P09792702A0754|82 85|JNK1
P09792702A0754|104 122|HSP70 gene expression
P09792702A0754|104 112|HSP70 gene
P09792714A1408|16 19|AF-1
P09792714A1408|24 31|proteins
P09792714A1408|44 56|distinct steps
P09792714A1408|59 71|transcription
P09792714A1408|95 115|synergistic activation
P09792714A1408|118 131|gene expression
P09792714A1408|134 137|AF-1
P09794414T0000|9 31|protein kinase C signaling
P09794414T0000|9 22|protein kinase C
P09794414T0000|43 58|DRA transcription
P09794414T0000|43 45|DRA
P09794795A0183|0 12|Ligand binding
P09794795A0183|18 32|receptor complex
P09794795A0183|40 62|tyrosine phosphorylation
P09794795A0183|66 75|activation
P09794795A0183|78 89|Janus kinases
P09794795A0183|91 93|Jak
P09794795A0183|96 110|phosphorylation
P09794795A0183|116 144|signal transducing subunit gp130
P09794795A0183|156 166|recruitment
P09794795A0183|170 184|phosphorylation
P09794795A0183|190 205|signal transducer
P09794795A0183|209 217|activator
P09794795A0183|220 244|transcription factors STAT3
P09794795A0183|240 244|STAT3
P09794795A0183|248 252|STAT1
P09794795A0183|259 275|src homology domain
P09794795A0183|277 317|SH2)-containing protein tyrosine phosphatase
P09794795A0183|277 279|SH2
P09794795A0183|292 317|protein tyrosine phosphatase
P09794795A0183|319 322|SHP2
P09795130A0742|50 66|deleterious effect
P09795130A0742|69 89|translation efficiency
P09795170A0774|16 49|polyadenylation site 504bp downstream
P09795170A0774|55 57|TGA
P09795170A0774|62 66|codon
P09795170A0774|88 103|kb transcript size
P09795213A0129|0 11|RBP56 protein
P09795213A0129|25 32|hTAFII68
P09795213A0129|52 86|TATA-binding protein associated factor
P09795213A0129|52 70|TATA-binding protein
P09795213A0129|88 90|TAF
P09795213A0129|97 110|sub-population
P09795213A0129|113 126|TFIID complexes
P09795213A0129|128 139|Bertolotti A.
P09795213A0129|141 144|Lutz
P09795213A0129|146 147|Y.
P09795213A0129|149 153|Heard
P09795213A0129|155 158|D.J.
P09795213A0129|160 166|Chambon
P09795213A0129|168 169|P.
P09795213A0129|171 174|Tora
P09795213A0129|176 177|L.
P09795213A0129|184 191|hTAFII68
P09795213A0129|194 222|novel RNA/ssDNA-binding protein
P09795213A0129|227 234|homology
P09795213A0129|240 264|proto-oncoproteins TLS/FUS
P09795213A0129|240 257|proto-oncoproteins
P09795213A0129|258 260|TLS
P09795213A0129|262 264|FUS
P09795213A0129|268 270|EWS
P09795213A0129|291 295|TFIID
P09795213A0129|299 313|RNA polymerase II
P09795213A0129|299 311|RNA polymerase
P09795341A0806|2 34|electrophoretic mobility shift assay
P09795341A0806|64 78|binding property
P09795341A0806|81 83|TR2
P09795341A0806|99 105|isoform
P09797189A0559|0 24|Gel-mobility shift analysis
P09797189A0559|47 56|CCAAT motif
P09797456A0000|0 9|BACKGROUND
P09797456A0000|14 32|c-myc proto-oncogene
P09797456A0000|55 62|key roles
P09797456A0000|65 81|cell proliferation
P09797456A0000|83 97|differentiation
P09797456A0000|116 124|apoptosis
P09797456A0883|0 4|AMY-1
P09797456A0883|8 16|localized
P09797456A0883|22 30|cytoplasm
P09797456A0883|33 37|cells
P09797456A0883|48 52|c-myc
P09797456A0883|55 63|low levels
P09797456A0883|73 79|nucleus
P09797456A0883|85 89|cells
P09797456A0883|93 111|high c-myc expression
P09797456A0883|136 140|cells
P09798068A0290|0 6|RESULTS
P09798068A0290|21 35|full-length cDNA
P09798068A0290|42 57|open reading frame
P09798068A0290|64 65|bp
P09798068A0290|103 112|amino acids
P09798068A0290|123 129|greater
P09798068A0290|136 144|% homology
P09798068A0290|152 177|rat gamma-aminobutyric acid B
P09798068A0290|179 183|GABAB
P09798068A0290|185 192|receptor
P09798100A0705|2 4|Day
P09798100A0705|10 15|CIDR-B
P09798100A0705|32 53|micrograms cloprostenol
P09798100A0705|63 64|IM
P09798263T0000|0 28|Antidepressant-like properties
P09798263T0000|35 58|serotonin receptor ligands
P09798263T0000|62 86|calcium channel antagonists
P09798263T0000|102 119|forced swimming test
P09798263T0000|122 125|mice
P09799086A0725|7 30|tentative hotspot mutation
P09799086A0725|36 47|third patient
P09799086A0725|50 59|frame shift
P09799086A0725|69 88|G nucleotide insertion
P09799086A0725|92 107|monotonous repeat
P09799086A0725|113 114|Gs
P09799086A0725|117 124|HPRT exon
P09799086A0725|159 173|other LN patients
P09799237A0624|0 19|SRF-deficient embryos
P09799237A0624|0 2|SRF
P09799237A0624|33 56|severe gastrulation defect
P09799362A0507|5 36|characteristic structural features
P09799362A0507|56 71|abbreviation AZF1
P09799362A0507|68 71|AZF1
P09799362A0507|73 104|Asparagine-rich Zinc Finger protein
P09799362A1463|0 14|Over-expression
P09799362A1463|17 21|Azf1p
P09799362A1463|27 35|yeast cell
P09799362A1463|55 69|expression level
P09799362A1463|75 111|mitochondrial transcription factor Mtf1p
P09799362A1463|141 145|Azf1p
P09799362A1463|151 161|suppression
P09799362A1463|167 205|special mitochondrial RNA polymerase mutant
P09799362A1463|174 205|mitochondrial RNA polymerase mutant
P09799362A1463|210 217|indirect
P09799634A0161|16 28|computer model
P09799634A0161|34 49|C-terminal domain
P09799634A0161|58 66|repressor
P09799634A0161|77 92|crystal structure
P09799634A0161|98 119|homologous UmuD' protein
P09799634A0161|98 111|homologous UmuD
P09799793T0000|0 20|Large-scale sequencing
P09799793T0000|26 32|regions
P09799793T0000|35 53|human chromosome 7q22
P09799793T0000|68 69|kb
P09799793T0000|72 86|genomic sequence
P09799793T0000|96 98|EPO
P09799793T0000|102 110|CUTL1 loci
P09799793T0000|120 124|genes
P09800187A0100|7 11|Trp53
P09800187A0100|16 27|mouse homolog
P09800187A0100|30 38|human TP53
P09800187A0100|42 48|located
P09800187A0100|53 55|Tk1
P09800187A0100|58 67|chromosome
P09800187A0100|95 111|cellular responses
P09800187A0100|131 147|DNA damaging agents
P09800187A0100|175 192|mouse lymphoma cells
P09800187A0100|199 207|mutations
P09800187A0100|210 214|Trp53
P09801156A0220|10 18|fragments
P09801156A0220|27 58|highest amino acid sequence homology
P09801156A0220|64 93|insect ecdysone inducible gene E75
P09801333A0174|3 18|full-length N gene
P09801333A0174|29 44|open reading frame
P09801333A0174|63 79|Canadian PRRS virus
P09801333A0174|81 84|PA-8
P09802206A1058|7 22|sequence homology
P09802206A1058|27 31|genes
P09802206A1058|48 93|TEF, encoding translation elongation factor-1 alpha
P09802206A1058|48 50|TEF
P09802206A1058|60 93|translation elongation factor-1 alpha
P09802206A1058|97 100|RPS7
P09802206A1058|110 127|ribosomal protein S7
P09802902A0225|25 28|ARNO
P09802902A0225|43 56|plasma membrane
P09802902A0225|86 107|ARF6 nucleotide exchange
P09803081T0000|0 13|Renal pathology
P09803081T0000|17 32|long-term outcome
P09803081T0000|35 46|childhood SLE
P09804779A0000|0 19|Transcription factors
P09804779A0000|25 34|Stat family
P09804779A0000|50 63|protein kinases
P09804779A1163|16 23|pathways
P09804779A1163|32 57|Stat5 serine phosphorylation
P09804779A1163|32 36|Stat5
P09804779A1163|68 86|prolactin-activated
P09804779A1163|68 76|prolactin
P09804779A1163|90 106|PD98059-resistant
P09804779A1163|142 158|PD98059-sensitive
P09804779A1163|183 188|Stat5a
P09804836A0000|15 38|37-kDa cytoplasmic protein
P09804836A0000|48 70|tyrosine-phosphorylated
P09804836A0000|86 109|mouse BAC1.2F5 macrophages
P09804836A0000|112 136|colony stimulating factor-1
P09804836A0000|138 142|CSF-1
P09804836A0000|145 148|pp37
P09804836A0000|167 183|cytosolic fraction
P09804836A0000|186 193|anti-Tyr
P09804836A0000|195 195|P
P09804836A0000|197 218|affinity chromatography
P09804836A0000|220 246|size exclusion chromatography
P09804836A0000|251 296|C4 reverse phase high pressure liquid chromatography
P09805052A0119|0 3|Dose
P09805052A0119|8 9|ig
P09805052A0119|49 54|months
P09805052A0119|72 85|immunogenicity
P09805052A0119|115 120|months
P09805052A0119|129 137|first dose
P09805977A0143|3 22|various available data
P09805977A0143|43 66|environmental toxic origin
P09805977A0143|74 82|sperm fall
P09805977A0143|140 149|substances
P09805977A0143|154 166|xenoestrogens
P09806516A1212|45 52|patients
P09806516A1212|76 85|recurrence
P09806516A1689|0 9|CONCLUSION
P09806516A1689|11 22|Local control
P09806516A1689|26 32|highest
P09806516A1689|37 41|Preop
P09806516A1689|44 51|patients
P09806516A1689|75 86|gross disease
P09806516A1689|95 100|Postop
P09806516A1689|103 110|patients
P09806516A1689|139 156|gross total excision
P09806546A1270|18 21|RFX5
P09806546A1270|25 29|RFXAP
P09806546A1270|44 50|binding
P09806546A1270|56 65|RFX complex
P09806546A1270|68 82|MHC-II promoters
P09806826A0244|25 30|defect
P09806826A0244|33 39|RIIIS/J
P09806826A0244|42 55|distal mouse Chr
P09806826A0244|74 81|Vwf locus
P09806826A0244|84 86|Chr
P09806826A1773|24 35|localization
P09806826A1773|38 53|other disease loci
P09806826A1773|92 119|tricho-dento-osseous syndrome
P09806826A1773|124 134|murine locus
P09806826A1773|138 151|susceptibility
P09806826A1773|154 181|ozone-induced acute lung injury
P09806830X1174|0 8|Copyright
P09806830X1174|13 25|Academic Press
P09806857A0854|2 17|open reading frame
P09806857A0854|44 64|significant similarity
P09806857A0854|67 76|invertases
P09806857A0854|80 89|resolvases
P09806857A0854|93 99|located
P09806857A0854|111 118|upstream
P09806857A0854|124 138|Pac25I R-M operon
P09806857A0854|124 129|Pac25I
P09806857A0854|130 138|R-M operon
P09806858T0000|0 13|Identification
P09806858T0000|17 23|new gene
P09806858T0000|29 52|streptococcal plasmid pLS1
P09806858T0000|57 64|rnaI gene
P09806919A0447|7 9|usp
P09806919A0447|22 42|late third instar larvae
P09806919A0447|46 69|appropriate developmental
P09806919A0447|73 96|transcriptional responses
P09806919A0447|102 114|ecdysone pulse
P09806919A0447|127 143|puparium formation
P09807755A0146|2 26|intact neurovascular supply
P09807755A0146|44 52|viability
P09807755A0146|56 65|muscle flap
P09808155A0813|0 10|Examination
P09808155A0813|17 39|protein binding complexes
P09808155A0813|42 58|gel-shift analysis
P09808155A0813|72 85|nuclear factors
P09808155A0813|94 106|proliferative
P09808155A0813|110 129|growth-arrested cells
P09808155A0813|140 150|DNA fragment
P09808155A0813|168 169|bp
P09808216A0000|0 9|BACKGROUND
P09808216A0000|11 17|Studies
P09808216A0000|20 26|lean men
P09808216A0000|31 44|poor regulation
P09808216A0000|54 55|EB
P09808216A0000|60 69|fat balance
P09808216A0000|71 72|FB
P09808216A0000|80 91|manipulation
P09808216A0000|94 106|dietary ratios
P09808366A0828|0 12|Fatal apneusis
P09808366A0828|38 47|conditions
P09808366A0828|52 66|Persistent apnea
P09808366A0828|84 105|single KA microinjection
P09808366A0828|120 126|VRG-Apa
P09808366A0828|129 135|animals
P09808441A0320|1 19|comparative analysis
P09808441A0320|33 65|MOCT-associated malignant melanomas
P09808441A0320|79 89|singularity
P09808441A0320|104 122|amelanotic character
P09808441A0320|128 135|melanoma
P09808441A0320|140 152|lymphotropism
P09808441A0320|159 169|coexistence
P09808441A0320|172 200|invasive squamous cell carcinoma
P09810087A0379|0 6|RESULTS
P09810087A0379|10 31|herpetic seroconversion
P09810087A0379|61 78|herpes simplex virus
P09810087A0379|80 83|HSV I
P09810087A0379|85 96|nucleic acids
P09810087A0379|113 124|aqueous humor
P09811695A1146|5 11|results
P09811695A1146|24 40|HIV-1 Gag sequences
P09811695A1146|56 81|viral PR-mediated processing
P09811695A1146|87 105|MuLV TM Env protein p15
P09811695A1146|107 107|E
P09811718A0979a|5 11|results
P09811718A0979a|24 42|specific association
P09811718A0979a|45 47|SIV
P09811718A0979a|51 58|HIV-2 nef
P09811718A0979a|66 73|HIV-1 nef
P09811718A0979a|79 85|TCRzeta
P09811730A1396|0 14|Competition EMSA
P09811730A1396|53 67|nuclear proteins
P09811730A1396|76 85|KCS element
P09811730A1396|98 122|KCS protein binding activity
P09811730A1396|98 107|KCS protein
P09811730A1396|137 152|promoter activity
P09811730A1396|158 191|transient transfection reporter assay
P09811730T0000|0 8|Mechanism
P09811730T0000|11 26|interferon action
P09811730T0000|11 20|interferon
P09811730T0000|44 61|essential positions
P09811730T0000|71 97|novel 15-base-pair KCS element
P09811730T0000|109 133|transcriptional activation
P09811730T0000|139 171|RNA-dependent protein kinase pkr gene
P09813041A1122|0 1|GH
P09813041A1122|19 33|phosphorylation
P09813041A1122|36 45|activation
P09813041A1122|48 66|Jun N-terminal kinase
P09813041A1122|75 84|conditions
P09813063T0000|0 9|Expression
P09813063T0000|13 44|novel murine phospholipase D homolog
P09813063T0000|58 80|late neuronal development
P09813063T0000|86 94|forebrain
P09813093A0624|28 34|YCL024W
P09813093A0624|66 73|deletion
P09813093A0624|76 79|GIN4
P09813098A0521|0 9|Paralemmin
P09813098A0521|37 40|mRNA
P09813098A0521|67 81|tissue-specific
P09813110A0982|10 26|amino acid sequence
P09813110A0982|29 33|CBP90
P09813110A0982|39 59|significant similarity
P09813110A0982|65 76|other protein
P09813110A0982|87 104|proline-rich domain
P09813110A0982|110 125|C-terminal region
P09813203T0000|11 40|low-profile serine substitutions
P09813203T0000|46 51|V3 loop
P09813203T0000|54 71|HIV-1 gp120 IIIB/LAI
P09813203T0000|54 67|HIV-1 gp120 IIIB
P09813203T0000|69 71|LAI
P09813203T0000|77 90|immunogenicity
P09813203T0000|96 110|envelope protein
P09813207A0434|0 28|Transcription start site mapping
P09813207A0434|54 88|aphidicolin-sensitive late transcript
P09813207A0434|101 116|TAAG motif located
P09813207A0434|123 133|nucleotides
P09813207A0434|139 176|aphidicolin-insensitive early transcript
P09813207A0434|193 208|TTGT motif located
P09813207A0434|211 231|nucleotides downstream
P09813207A0434|235 241|TATA box
P09813207A0434|248 258|nucleotides
P09813207A0434|278 280|ATG
P09813207A0434|283 286|lef2
P09813254A0000|14 27|oligoadenylate
P09813254A0000|29 32|2-5A
P09813254A0000|34 44|synthetases
P09813254A0000|48 54|members
P09813254A0000|58 73|family interferon
P09813254A0000|75 77|IFN
P09813254A0000|80 106|inducible anti-viral proteins
P09813259A1097|3 10|findings
P09813259A1097|23 44|dose-dependent blockade
P09813259A1097|50 70|mechanical sensitivity
P09813259A1097|80 96|mild thermal injury
P09813259A1097|103 105|GBP
P09813259A1097|109 111|IBG
P09813635A0678|5 14|striations
P09813635A0678|44 52|sharp edge
P09813635A0678|58 68|upper canine
P09813635A0678|75 76|P3
P09813635A0678|90 111|canine/premolar complex
P09814637A1214|0 15|Low PbrO2 readings
P09814637A1214|40 60|local microhemorrhages
P09814637A1214|62 73|undetectable
P09814637A1214|76 77|CT
P09814637A1214|80 82|MRI
P09814905A0598|3 14|consequences
P09814905A0598|17 40|intensive swine production
P09814905A0598|60 76|possible solutions
P09814905A0598|79 83|means
P09814905A0598|86 94|nutrition
P09815578A1245|25 34|alteration
P09815578A1245|37 41|CDKN2
P09815578A1245|56 83|frequent genetic abnormalities
P09815578A1245|86 99|prostate cancer
P09815578A1245|118 139|prostate carcinogenesis
P09815948A1065|3 27|pharmacokinetic parameters
P09815948A1065|51 60|toxicities
P09815948A1065|89 103|peak plasma level
P09817131A0296|9 10|HK
P09817131A0296|12 26|SF-36 survey form
P09817131A0296|43 69|iterative translation process
P09817190A0074|16 27|cyclosporin A
P09817190A0074|55 64|prevalence
P09817190A0074|67 78|hypertension
P09817190A0074|81 106|kidney transplant recipients
P09817373A0000|0 6|PURPOSE
P09817373A0000|22 28|effects
P09817373A0000|31 50|hypercholesterolemia
P09817373A0000|54 114|atherosclerosis-induced chronic cavernosal arterial insufficiency
P09817373A0000|117 142|cavernosal smooth muscle tone
P09817373A0000|144 162|nitric oxide synthase
P09817373A0000|164 166|NOS
P09817373A0000|179 203|cavernosal tissue synthesis
P09817373A0000|206 227|constrictor eicosanoids
P09817601T0000|0 15|Characterization
P09817601T0000|21 37|regulatory regions
P09817601T0000|43 56|human aromatase
P09817601T0000|58 65|P450arom
P09817601T0000|81 107|placenta-specific expression
P09819038A0448|0 15|Recombinant FVIIa
P09819038A0448|30 41|infusion pump
P09819038A0448|45 55|several days
P09819038A0448|58 72|room temperature
P09819038A0448|81 81|h
P09819038A0448|84 98|body temperature
P09819110A0703|0 12|CD4 lymphocyte
P09819110A0703|0 2|CD4
P09819110A0703|16 30|viral load levels
P09819110A0703|42 56|optimal response
P09819110A0703|59 68|ARV therapy
P09819110A0703|74 79|time LD
P09819216A0220|6 17|Biochemistry
P09819288A0578|0 5|Levels
P09819288A0578|8 15|serum IgE
P09819288A0578|39 46|nasal IgE
P09819288A0578|44 46|IgE
P09819377A1209|1 8|mutation
P09819377A1209|16 25|C2U4 repeat
P09819377A1209|32 48|underaccumulation
P09819377A1209|51 56|snR13F
P09819377A1209|65 73|mutations
P09819377A1209|81 90|C2U4 repeat
P09819377A1209|99 110|accumulation
P09819377A1209|116 124|novel RNAs
P09819377A1209|141 151|500-nt range
P09819391A1123|29 32|Arfs
P09819391A1123|36 50|tyrosine kinases
P09819391A1123|71 80|cell growth
P09819391A1123|84 107|cytoskeletal organization
P09819391A1123|109 113|ASAP1
P09819391A1123|129 152|membrane remodeling events
P09819391A1123|162 170|processes
P09819411A0897|2 7|DNase I
P09819411A0897|2 6|DNase
P09819411A0897|8 24|footprint analysis
P09819411A0897|30 39|PNR element
P09819411A0897|42 51|palindrome
P09819411A0897|57 85|high-affinity Ets-binding sites
P09819411A0897|70 85|Ets-binding sites
P09819411A0897|87 98|CTTCCCTGGAAG
P09819414A1103|12 17|nexins
P09819414A1103|39 49|long isoform
P09819414A1103|55 68|leptin receptor
P09819414A1103|90 103|medium isoforms
P09819421A0000|0 11|Cyclophilins
P09819421A0000|15 49|cis-trans-peptidyl-prolyl isomerases
P09819421A0000|80 108|immunosuppressant cyclosporin A
P09819421A0000|110 112|CsA
P09819422A0768|7 33|protein retention experiments
P09819422A0768|41 60|Hsp90 heterocomplexes
P09819422A0768|65 76|precipitated
P09819422A0768|87 101|coprecipitation
P09819422A0768|104 107|Cns1
P09819430A0000|3 20|Ras-related GTPases
P09819430A0000|35 48|25-kDa proteins
P09819430A0000|68 88|inactive GDP-bound form
P09819430A0000|94 113|active GTP-bound state
P09819440A0000|10 22|transcription
P09819440A0000|24 40|regulatory factors
P09819440A0000|56 80|basal transcription factors
P09819440A0000|87 100|RNA polymerases
P09819440A0000|113 116|ways
P09819440A0783|0 12|Endogenous RMP
P09819440A0783|63 66|RPB5
P09819440A0783|69 81|RNA polymerase
P09819440A0783|84 97|mammalian cells
P09819507A0000|12 18|rabbits
P09819507A0000|40 59|sutured wound reaction
P09819507A0000|64 68|Dexon
P09819507A0000|71 75|nylon
P09819507A0000|81 96|conjunctival flap
P09819507A0000|110 113|days
P09819507A0000|119 139|trabeculectomy surgery
P09819507A0000|161 171|mitomycin-C
P09820163A0565|3 9|mapping
P09820163A0565|26 41|Southern blotting
P09820163A0565|45 63|restriction analysis
P09820205A0000|3 15|zona pellucida
P09820205A0000|17 18|ZP
P09820205A0000|24 46|extracellular glycocalyx
P09820205A0000|63 68|oocyte
P09820205A0000|90 116|homologous gamete interaction
P09820611T0000|0 13|Therapeutic use
P09820611T0000|16 45|continuous subcutaneous infusion
P09820611T0000|48 77|recombinant human erythropoietin
P09820611T0000|80 116|malnourished predialysis anemic patients
P09820611T0000|121 139|diabetic nephropathy
P09820621A0067|8 34|pathological thyroid function
P09820621A0067|46 52|changes
P09820621A0067|55 71|energy expenditure
P09820621A0067|75 89|body composition
P09820621A0067|94 110|possible influence
P09820621A0067|113 124|leptin levels
P09820621A0067|113 118|leptin
P09821978A1255|5 21|cognitive deficits
P09821978A1255|37 43|animals
P09821978A1255|55 60|MK-801
P09821978A1255|67 68|SE
P09822602A0237|35 44|activation
P09822602A0237|47 56|HIF-1alpha
P09822602A0237|60 76|multi-step process
P09822602A0237|90 119|hypoxia-dependent nuclear import
P09822602A0237|123 132|activation
P09822602A0237|134 145|derepression
P09822602A0237|152 172|transactivation domain
P09822602A0237|185 195|recruitment
P09822602A0237|201 219|CREB-binding protein
P09822602A0237|221 223|CBP
P09822602A0237|226 240|p300 coactivator
P09822602A1172|5 34|hypoxia-inducible nuclear import
P09822602A1172|38 52|transactivation
P09822602A1172|55 65|recruitment
P09822602A1172|68 70|CBP
P09822602A1172|118 130|critical roles
P09822602A1172|133 150|signal transduction
P09822602A1172|153 162|HIF-1alpha
P09822647A0000|3 18|rat aldolase C gene
P09822647A0000|27 42|glycolytic enzyme
P09822647A0000|62 71|adult brain
P09822652A1118|1 17|synergistic effect
P09822652A1118|20 38|HCK promoter activity
P09822652A1118|20 30|HCK promoter
P09822652A1118|52 69|high concentrations
P09822652A1118|72 74|Sp1
P09822661T0073|0 20|Quinone-binding domain
P09822661T0073|24 40|amino acid residues
P09822661T0073|51 64|quinone binding
P09822685A0596|0 14|Western analyses
P09822685A0596|19 26|antisera
P09822685A0596|40 56|Lu-ECAM-1 peptides
P09822685A0596|68 83|N-terminal region
P09822685A0596|98 113|open reading frame
P09822685A0596|132 149|larger size proteins
P09822690A0000|0 21|Mammalian sperm motility
P09822690A0000|36 42|cascade
P09822690A0000|45 86|cAMP-dependent protein phosphorylation events
P09822690A0000|45 65|cAMP-dependent protein
P09822690A0000|97 111|protein kinase A.
P09822690A0000|97 110|protein kinase A
P09822825A0141|27 30|BAP2
P09822825A0141|50 57|BAP3 gene
P09822825A0141|96 119|branched-chain amino acids
P09823014T0000|0 5|Effect
P09823014T0000|8 33|enteral nutritional products
P09823014T0000|65 71|indices
P09823014T0000|89 103|lipid metabolism
P09823014T0000|106 113|patients
P09823014T0000|118 122|NIDDM
P09823561T0001|0 27|Low-grade gastric MALT lymphoma
P09823561T0001|31 52|helicobacter heilmannii
P09823561T0001|54 75|Gastrospirillum hominis
P09823775A1122|5 11|studies
P09823775A1122|30 33|HMG I
P09823775A1122|35 35|Y
P09823775A1122|41 57|important cofactor
P09823775A1122|61 81|HLA-DRA gene activation
P09823775A1122|61 71|HLA-DRA gene
P09823775A1122|84 89|Oct-2A
P09823775A1122|100 107|insights
P09824001A1665|12 22|hemodynamic
P09824001A1665|26 52|histopathological predictors
P09824001A1665|64 66|vWF
P09824001A1665|68 69|Ag
P09824001A1665|84 101|invasive techniques
P09824021A1263|0 9|CONCLUSION
P09824021A1263|33 40|features
P09824021A1263|43 55|disease likely
P09824021A1263|85 98|useful response
P09824021A1263|108 116|NO therapy
P09824021A1263|125 134|parameters
P09824158A1336|10 32|BCL-6 POZ domain mutations
P09824158A1336|10 14|BCL-6
P09824158A1336|62 66|N-CoR
P09824158A1336|70 73|SMRT
P09824158A1336|89 101|transcription
P09826434T0000|0 22|Partial characterization
P09826434T0000|28 71|active site human platelet cAMP phosphodiesterase
P09826434T0000|43 71|platelet cAMP phosphodiesterase
P09826434T0000|73 77|PDE3A
P09826434T0000|81 104|site-directed mutagenesis
P09826658A0691|4 15|core sequence
P09826658A0691|26 67|additional nonspecific downstream nucleotides
P09826658A0691|84 101|partial suppression
P09826658A0691|104 122|spliceosome assembly
P09826658A0691|126 133|splicing
P09826658A0691|136 149|BPV-1 pre-mRNAs
P09826778A0943|0 14|Over-expression
P09826778A0943|20 31|cofactor p300
P09826778A0943|28 31|p300
P09826778A0943|50 60|coactivator
P09826778A0943|63 88|myoD-mediated transcription
P09826778A0943|63 66|myoD
P09826778A0943|100 109|repression
P09826778A0943|112 120|COUP-TF II
P09826778A0943|112 118|COUP-TF
P09827446T0001|0 26|Familial autoimmune hepatitis
P09827446T0001|30 41|C4 deficiency
P09827446T0001|30 31|C4
P09827724A1362|2 10|mutations
P09827724A1362|22 39|follicular adenomas
P09827878A0091|5 25|glutathione peroxidase
P09827878A0091|27 29|GPX
P09827878A0091|34 52|superoxide dismutase
P09827878A0091|54 56|SOD
P09827878A0091|63 77|significant role
P09827878A0091|80 110|erythrocyte antioxidative defence
P09827878A0091|176 182|workers
P09827993A0000|0 29|Retroviral nucleocapsid proteins
P09827993A0000|31 34|NCPs
P09827993A0000|39 65|CCHC-type zinc finger proteins
P09827993A0000|77 102|virion RNA binding activities
P09827993A0000|117 134|retrovirus assembly
P09827993A0000|138 160|genomic RNA encapsidation
P09828137A0000|27 30|rad1
P09828137A0000|32 61|cell cycle checkpoint control gene
P09828137A0000|75 81|S-phase
P09828137A0000|85 94|G2/M arrest
P09828137A0000|111 119|DNA damage
P09828137A0000|123 146|incomplete DNA replication
P09829836A0000|26 36|progression
P09829836A0000|47 65|eukaryotic cell cycle
P09829836A0000|80 91|oscillations
P09829836A0000|107 129|cyclin- dependent kinases
P09829836A0000|107 112|cyclin
P09829836A0000|114 129|dependent kinases
P09829836A0000|131 134|CDKs
P09829836A0815|0 24|Positive genetic selections
P09829836A0815|28 37|inhibition
P09829836A0815|40 57|cyclin/CDK function
P09829836A0815|83 91|E. coli neo
P09829836A0815|95 108|yeast LEU2 genes
P09829843A0119|3 40|hematopoietic colony-stimulating factors
P09829843A0119|42 44|CSF
P09829843A0119|68 83|clinical practice
P09829843A0119|86 113|additional supportive measures
P09829843A0119|130 138|incidence
P09829843A0119|141 163|infectious complications
P09829843A0119|166 173|patients
P09829843A0119|187 197|neutropenia
P09829843A0819|3 12|injections
P09829843A0819|15 17|CSF
P09829843A0819|35 44|initiation
P09829843A0819|47 57|neutropenia
P09829843A0819|78 87|occurrence
P09829843A0819|92 117|absolute neutrophil recovery
P09829843A0819|119 127|rHu GM-CSF
P09829843A0819|131 138|rHu G-CSF
P09829843A0819|169 175|microg m
P09829843A0819|191 198|microg kg
P09829843A0819|244 266|absolute neutrophil count
P09829843A0819|270 287|neutrophil function
P09829843A0819|312 334|chemiluminescence system
P09829916T0000|0 9|Expression
P09829916T0000|12 15|lacZ
P09829916T0000|23 30|promoter
P09829916T0000|36 59|Escherichia coli spc operon
P09829916T0000|54 59|operon
P09829916T0000|70 76|vectors
P09829916T0000|88 104|W205 trp-lac fusion
P09832099A0000|11 44|regional right ventricular wall motion
P09832099A0000|51 57|systole
P09832099A0000|60 67|patients
P09832099A0000|90 98|tetralogy
P09832099A0000|101 106|Fallot
P09832099A0000|108 110|TOF
P09832099A0000|117 135|color kinesis imaging
P09832436A0738|0 13|RT-PCR analysis
P09832436A0738|24 28|PLP-H
P09832436A0738|37 41|PLP-C
P09832436A0738|45 49|PLP-D
P09832436A0738|67 76|rat strains
P09832436A0738|100 111|PLP diversity
P09832436A0738|128 138|differences
P09832436T0000|0 15|Molecular cloning
P09832436T0000|19 34|characterization
P09832436T0000|38 46|new member
P09832436T0000|52 72|rat placental prolactin
P09832436T0000|74 76|PRL
P09832436T0000|85 101|PRL-like protein H.
P09832504A0596|45 47|Tat
P09832504A0596|51 56|hCycT1
P09832504A0596|65 68|zinc
P09832504A0596|77 101|essential cysteine residues
P09832504A0596|108 115|proteins
P09832505A0903|23 38|activation target
P09832505A0903|42 55|human activator
P09832505A0903|57 61|Oct-1
P09832505A0903|72 103|cognate basal transcription complex
P09832511A0269|6 22|early neurogenesis
P09832511A0269|24 33|Vnd protein
P09832511A0269|36 45|restricted
P09832511A0269|48 73|ventral column neuroectoderm
P09832511A0269|77 87|neuroblasts
P09832511A0269|109 122|complex pattern
P09832511A0269|125 131|neurons
P09832518A0615|3 18|repression domain
P09832518A0615|32 49|entire Cdc68 protein
P09832518A0615|38 49|Cdc68 protein
P09832518A0615|94 115|Cdc68 functional homolog
P09832518A0615|123 146|yeast Kluyveromyces lactis
P09832518A0615|152 167|database searches
P09833610A0626|3 11|exodomain
P09833610A0626|23 41|high affinity hormone
P09833610A0626|80 93|hormonal signal
P09833740A1112|0 25|Pyrrolidine dithiocarbamate
P09833740A1112|28 57|potent transcriptional inhibitor
P09833740A1112|63 70|viral LTR
P09833740A1112|84 100|cytokine responses
P09833740A1112|107 108|U1
P09833740A1112|112 121|ACH-2 cells
P09833740A1112|134 181|common TNF-alpha-mediated transcriptional mechanism
P09833740A1112|140 148|TNF-alpha
P09833740A1112|189 197|cell types
P09833740A1112|210 223|different modes
P09833740A1112|226 240|provirus latency
P09834070A0793|12 32|synergistic activation
P09834070A0793|35 38|ERK2
P09834070A0793|61 67|changes
P09834070A0793|70 85|intracellular Ca2
P09834070A0793|106 115|inhibition
P09834070A0793|118 139|protein kinase C activity
P09834070A0793|118 131|protein kinase C
P09834070A0793|154 168|separate pathway
P09834070A0793|176 179|CD19
P09834070A0793|189 201|B cell function
P09834521A0000|3 25|retrovesical hydatid cyst
P09834521A0000|33 40|rare site
P09835615A0574|0 18|Biochemical analysis
P09835615A0574|30 32|KS1
P09835615A0574|36 49|nuclear protein
P09835615A0574|63 93|transcriptional repressor domains
P09835615A0574|95 96|R1
P09835615A0574|100 101|R2
P09836881A0441|11 18|BCH group
P09836881A0441|25 53|inferior gross motor performance
P09836881A0441|59 81|Bruininks-Oseretsky Test
P09836881A0441|84 99|Motor Proficiency
P09836881A0441|101 109|Bruininks
P09837714A1068|3 9|results
P09837714A1068|33 34|pH
P09837714A1068|42 72|post-translational modifications
P09837714A1068|75 79|DdRPA
P09837714A1068|93 98|events
P09837714A1068|107 123|cell proliferation
P09837714A1068|133 147|differentiation
P09837714A1068|150 162|Dictyostelium
P09837715A0581|21 34|constant amount
P09837715A0581|62 93|chloramphenicol acetyltransferase
P09837715A0581|95 97|CAT
P09837715A0581|99 102|mRNA
P09837715A0581|116 134|Vpr-expressing cells
P09837715A0581|146 150|HIV-1
P09837715A0581|154 185|murine leukemia virus (MLV) SL3-3 LTR
P09837715A0581|154 172|murine leukemia virus
P09837715A0581|174 176|MLV
P09837715A0581|178 206|SL3-3 LTR-CAT reporter construct
P09837824A0419|12 26|telSMN mutations
P09837824A0419|12 17|telSMN
P09837824A0419|38 65|unrelated SMA-like individuals
P09837824A0419|75 84|single copy
P09837824A0419|87 92|telSMN
P09837824A0419|109 127|frameshift mutations
P09837824A0419|129 136|800ins11
P09837824A0419|140 147|542delGT
P09837824A0419|157 173|missense mutations
P09837824A0419|175 177|A2G
P09837824A0419|179 183|S262I
P09837824A0419|188 192|T274I
P09837907A0857|13 24|TNF receptors
P09837907A0857|27 30|IL-4
P09837907A0857|47 61|down-regulation
P09837907A0857|64 84|TNF-induced activities
P09837907A0857|64 66|TNF
P09837907A0857|95 106|cytotoxicity
P09837907A0857|108 126|caspase-3 activation
P09837907A0857|108 116|caspase-3
P09837907A0857|128 136|NF-kappaB
P09837907A0857|140 153|AP-1 activation
P09837907A0857|140 143|AP-1
P09837907A0857|158 187|c-Jun N-terminal kinase induction
P09837907A0857|158 178|c-Jun N-terminal kinase
P09837913A0000|0 14|Type 2 deiodinase
P09837913A0000|0 3|Type
P09837913A0000|5 14|deiodinase
P09837913A0000|16 17|D2
P09837913A0000|34 45|deiodination
P09837913A0000|48 56|thyroxine
P09837913A0000|70 85|triiodothyronine
P09837913A0419|39 55|sequence tag clones
P09837913A0419|79 84|4.4-kb
P09837913A0419|88 90|UTR
P09837913A0419|96 102|human D2
P09837913A0419|104 106|hD2
P09837913A0419|108 111|cDNA
P09837914A0844|0 3|Biol
P09837920A0222|25 46|structural requirements
P09837920A0222|50 61|consequences
P09837920A0222|64 88|regulatory phosphorylation
P09837920A0222|113 117|c-Jun
P09837920A0222|121 123|JNK
P09837933T0000|0 5|P-CIP1
P09837933T0000|8 19|novel protein
P09837933T0000|40 54|cytosolic domain
P09837933T0000|57 99|peptidylglycine alpha-amidating monooxygenase
P09837933T0000|117 125|endosomes
P09837945A0820|0 17|Immunolocalization
P09837945A0820|20 24|Sop1p
P09837945A0820|34 56|cytoplasmic distribution
P09837945A0820|60 83|cell fractionation studies
P09837945A0820|95 113|significant fraction
P09837945A0820|116 120|Sop1p
P09837945A0820|136 155|sedimentable fraction
P09837945A0820|161 177|cytosolic material
P09837978T0093|0 18|Resultant activation
P09837978T0093|21 71|c-Jun N-terminal kinase/stress-activated protein kinase
P09837978T0093|21 41|c-Jun N-terminal kinase
P09837978T0093|43 71|stress-activated protein kinase
P09837978T0093|73 80|JNK/SAPK
P09837978T0093|73 75|JNK
P09837978T0093|77 80|SAPK
P09838122A0489|15 43|full-length coding cDNA sequence
P09838122A0489|49 68|mouse homologue of MPP3
P09838122A0489|49 62|mouse homologue
P09838122A0489|65 68|MPP3
P09840822A0462|23 29|tagging
P09840822A0462|32 37|venous
P09840822A0462|58 95|asymmetric magnetization transfer effects
P09840928A0884|0 9|Consistent
P09840928A0884|27 29|Dlk
P09840928A0884|44 57|core histones H3
P09840928A0884|48 57|histones H3
P09840928A0884|59 61|H2A
P09840928A0884|65 66|H4
P09840928A0884|69 87|exogenous substrates
P09840928A0884|91 109|endogenous histone H3
P09840928A0884|112 123|kinase assays
P09840928A0884|128 142|nuclear extracts
P09840932A0365|32 36|B-Myb
P09840932A0365|40 64|direct physiological target
P09840932A0365|68 79|cyclin A/Cdk2
P09840932A0365|68 74|cyclin A
P09840932A0365|76 79|Cdk2
P09840934A0435|7 12|Ha-Ras
P09840934A0435|14 17|G12V
P09840934A0435|19 22|T35S
P09840934A0435|25 36|Ha-RasV12S35
P09840934A0435|56 75|Rafl signaling pathway
P09840934A0435|56 59|Rafl
P09840934A0435|80 85|Ha-Ras
P09840934A0435|87 90|G12V
P09840934A0435|92 95|E37G
P09840934A0435|98 109|Ha-RasV12G37
P09840934A0435|130 142|RalGDS pathway
P09840934A0435|130 135|RalGDS
P09840934A0435|154 171|significant effects
P09840934A0435|174 199|factor-withdrawal apoptosis
P09840934A0435|202 213|myeloid cells
P09840943A0144|15 30|novel human cyclin
P09840943A0144|20 30|human cyclin
P09840943A0144|32 39|cyclin E2
P09840943A0144|53 71|significant homology
P09840943A0144|74 81|cyclin E.
P09840943A0144|74 80|cyclin E
P09842517A0497|0 16|Initial experience
P09842517A0497|24 36|new technology
P09842517A0497|50 57|SieScape
P09842517A0497|75 90|other methods such
P09842517A0497|93 94|CT
P09842517A0497|98 100|MRI
P09843378A0187|3 20|dopamine D4 receptor
P09843378A0187|29 63|many other catecholaminergic receptors
P09843378A0187|71 102|several putative SH3 binding domains
P09843378A0187|86 102|SH3 binding domains
P09843412A0130|9 35|amyloidogenic 42-residue form
P09843412A0130|38 42|Abeta
P09843412A0130|44 50|Abeta42
P09843412A0130|57 68|first species
P09843412A0130|88 95|sporadic
P09843412A0130|99 108|familial AD
P09843572A0944|22 32|experiments
P09843572A0944|44 57|Cdr2 associates
P09843572A0944|44 47|Cdr2
P09843572A0944|65 90|N-terminal regulatory domain
P09843572A0944|93 96|Wee1
P09843572A0944|99 109|cell lysates
P09843572A0944|127 130|Wee1
P09843577A0000|24 28|cells
P09843577A0000|38 56|nutrient deprivation
P09843577A0000|67 85|G2/M cell size control
P09843944A0976|0 7|A-tracts
P09843944A0976|49 55|hexamer
P09843944A0976|69 79|helical turn
P09843944A0976|119 125|optimal
P09843944A0976|129 145|UP element function
P09843944A0976|129 137|UP element
P09844106A0835|0 18|Pyk2 phosphorylation
P09844106A0835|0 3|Pyk2
P09844106A0835|32 40|adherence
P09844106A0835|43 45|FLG
P09844106A0835|50 54|cells
P09844106A0835|57 67|fibronectin
P09844106A0835|73 87|ST2 stromal cells
P09844921A0000|0 2|Raf
P09844921A0000|6 37|key serine-threonine protein kinase
P09844921A0000|9 37|serine-threonine protein kinase
P09844921A0000|81 94|anti-apoptotic
P09844921A0000|98 120|differentiation messages
P09845043A0000|3 21|US National Institute
P09845043A0000|24 35|Alcohol Abuse
P09845043A0000|39 48|Alcoholism
P09845043A0000|50 54|NIAAA
P09845043A0000|69 73|forms
P09845043A0000|76 94|problematic drinking
P09845043A0000|97 115|willful alcohol abuse
P09845043A0000|119 136|behavioural problem
P09845043A0000|142 158|alcohol dependence
P09845043A0000|162 180|true medical disorder
P09845043A0000|196 211|genetic component
P09845662A0085|0 7|Collagen
P09845662A0085|44 58|type III collagen
P09845662A0085|51 58|collagen
P09845662A0085|74 78|means
P09845662A0085|81 133|sodium dodecyl sulfate-polyacrylamide gel electrophoresis
P09845662A0085|135 142|SDS-PAGE
P09845856A0560|0 6|RESULTS
P09845856A0560|17 28|7-year period
P09845856A0560|36 67|symptomatic duodenal ulcer diseases
P09846033A0488|0 6|RESULTS
P09846033A0488|8 25|Significant changes
P09846033A0488|30 41|pretreatment
P09846033A0488|44 56|posttreatment
P09846033A0488|70 70|p
P09846482A0441|39 57|enzymatic activation
P09846482A0441|63 89|p21-activated protein kinase 1
P09846482A0441|63 88|p21-activated protein kinase
P09846482A0441|104 122|actin polymerization
P09846927A0227|24 34|perforation
P09846927A0227|40 59|posterior stomach wall
P09847371A0000|0 19|Jembrana disease virus
P09847371A0000|21 23|JDV
P09847371A0000|43 58|bovine lentivirus
P09847371A0000|84 114|bovine immunodeficiency virus (BIV
P09847371A0000|84 110|bovine immunodeficiency virus
P09847371A0000|112 114|BIV
P09847397A0935|15 15|%
P09847397A0935|21 28|residues
P09847397A0935|54 62|sequences
P09847397A0935|75 81|viruses
P09847397A0935|94 109|response elements
P09847397A0935|113 127|glucocorticoids
P09847397A0935|153 162|CCAAT boxes
P09847397A0935|188 196|TATA boxes
P09848653A0597|0 4|Nhp2p
P09848653A0597|14 25|basic protein
P09848653A0597|48 74|putative RNA-binding proteins
P09848653A0597|56 74|RNA-binding proteins
P09849421A0332|38 47|Norwegians
P09849421A0332|55 59|years
P09849421A0332|79 98|European Organization
P09849421A0332|102 109|Research
P09849421A0332|113 121|Treatment
P09849421A0332|124 140|Cancer Core Quality
P09849421A0332|143 159|Life Questionnaire
P09849421A0332|161 172|EORTC QLQ-C30
P09849722A0797|20 41|happy facial expressions
P09849722A0797|54 67|signal increase
P09849722A0797|86 111|left anterior cingulate gyrus
P09849722A0797|113 143|bilateral posterior cingulate gyri
P09849722A0797|145 163|medial frontal cortex
P09849722A0797|167 189|right supramarginal gyrus
P09849722A0797|191 202|brain regions
P09849722A0797|225 236|visuospatial
P09849722A0797|240 261|emotion processing tasks
P09849961A0387|0 14|Down-regulation
P09849961A0387|17 21|IRS-1
P09849961A0387|35 64|serine phosphorylation dependent
P09849961A0387|67 84|PI 3-kinase activity
P09849961A0387|67 76|PI 3-kinase
P09849961A0387|106 120|differentiation
P09849961A0387|131 135|IRS-1
P09849961A0387|176 209|nondifferentiating myoblast cell line
P09849965A0000|20 44|mammalian two-hybrid system
P09849965A0000|63 68|ligand
P09849965A0000|74 85|dimerization
P09849965A0000|88 112|human progesterone receptor
P09849965A0000|114 116|hPR
P09851614A0109|8 21|unique features
P09851614A0109|53 71|untranslated regions
P09851614A0109|73 75|UTR
P09851614A0109|81 91|nucleotides
P09851614A0109|93 95|nts
P09851614A0109|104 118|apparent absence
P09851614A0109|124 136|cap structures
P09851614A0109|144 148|mRNAs
P09851700A0000|15 50|human tissue-type plasminogen activator
P09851700A0000|52 55|t-PA
P09851700A0000|71 94|cell-type-specific manner
P09851988A0085|17 24|arginine
P09851988A0085|28 39|anaerobiosis
P09851988A0085|58 66|induction
P09851988A0085|72 78|pathway
P09852005A1287|0 10|Competition
P09852005A1287|16 50|putative MADS box consensus binding site
P09852005A1287|24 50|MADS box consensus binding site
P09852005A1287|58 65|promoter
P09852005A1287|92 120|opaque-phase-specific gene PEP1
P09852005A1287|122 125|SAP1
P09852005A1287|133 164|human MADS box consensus binding site
P09852005A1287|168 186|serum response factor
P09852005A1287|216 224|complexes
P09852005A1287|247 257|OP4 sequence
P09852068A0150b|3 27|human SHBG proximal promoter
P09852068A0150b|41 46|DNase I
P09852068A0150b|41 45|DNase
P09852068A0150b|47 58|footprinting
P09852068A0150b|66 87|functional significance
P09852068A0150b|91 108|footprinted regions
P09852068A0150b|110 116|FP1-FP6
P09852068A0150b|127 142|proximal promoter
P09852068A0150b|155 183|human HepG2 hepatoblastoma cells
P09852109A1475|35 49|profile analysis
P09852109A1475|63 74|transcripts C
P09852109A1475|78 78|E
P09852109A1475|97 128|similar translational efficiencies
P09852109A1475|149 155|greater
P09852109A1475|166 176|transcript D
P09852109A1475|195 213|untranslated regions
P09852109A1475|225 244|translational control
P09852136A0174|17 24|mutation
P09852136A0174|26 30|Ser36
P09852136A0174|34 36|Asn
P09852136A0174|54 57|p190
P09852136A0174|87 103|guanine nucleotide
P09852136A0174|120 132|hemagglutinin
P09852136A0174|134 135|HA
P09852136A0174|153 160|COS cells
P09852136A0507|0 14|Wild type HA-p190
P09852136A0507|23 31|phenotype
P09852136A0507|34 45|rounded cells
P09852136A0507|55 77|beaded extensions similar
P09852136A0507|92 102|Rho function
P09852136A0507|92 94|Rho
P09852136A0507|116 131|ADP-ribosylation
P09852752A0950|15 39|ANCA-associated vasculitis
P09852752A0950|49 69|important complication
P09852752A0950|72 73|RA
P09854034A0536|3 12|downstream
P09854034A0536|14 30|TATA-less promoter
P09854034A0536|34 47|high G+C content
P09854034A0536|52 57|exon 1b
P09854034A0536|94 104|mRNA species
P09855111A0905|23 36|overexpression
P09855111A0905|42 61|COOH-terminal domains
P09855111A0905|108 122|SREBP processing
P09855111A0905|108 112|SREBP
P09855111A0905|137 146|disruption
P09855111A0905|152 191|SREBP-dependent transcriptional regulation
P09855111A0905|152 156|SREBP
P09855111A0905|194 205|several genes
P09855111A0905|210 219|mRNA levels
P09855111A0905|223 257|3-hydroxy-3-methylglutaryl coenzyme A
P09855111A0905|259 273|HMG CoA) synthase
P09855111A0905|259 264|HMG CoA
P09855111A0905|266 273|synthase
P09855111A0905|284 292|cell lines
P09855111A0905|309 330|sterol-dependent manner
P09856397A0099|0 14|Dry matter intake
P09856397A0099|16 46|apparent nutrient digestibilities
P09856397A0099|48 69|serum chemistry profiles
P09856397A0099|71 96|sphingolipid concentrations
P09856397A0099|101 111|persistency
P09856397A0099|114 116|FB1
P09856397A0099|119 125|tissues
P09856732A0114|10 16|studies
P09856732A0114|69 83|hazardous effect
P09856732A0114|86 94|lidocaine
P09857038A1374|0 1|E.
P09857038A1374|3 7|Scott
P09857038A1374|9 10|J.
P09857197A0289|0 4|Yap1p
P09857197A0289|31 40|crm1 mutant
P09857197A0289|45 49|Crm1p
P09857197A0289|58 78|nuclear export sequence
P09857197A0289|80 82|NES
P09857197A0289|99 103|Yap1p
P09857197A0289|119 124|RanGTP
P09857265A0669|0 9|Mean intake
P09857265A0669|12 19|vitamin A
P09857265A0669|39 46|mg RE/day
P09857265A0669|50 52|men
P09857265A0669|56 60|women
P09857265A0669|78 90|contributions
P09857265A0669|98 101|fats
P09857265A0669|105 108|oils
P09857265A0669|110 119|vegetables
P09857265A0669|123 135|dairy products
P09857265A0669|138 148|total intake
P09857265A0669|155 155|%
P09857265A0669|159 159|%
P09857265A0669|163 163|%
P09857265A0669|170 170|%
P09858094A0583|8 16|amplitude
P09858094A0583|22 42|oscillatory potentials
P09858094A0583|44 45|O1
P09858094A0583|50 51|O3
P09858094A0583|53 54|O4
P09858094A0583|84 107|early postoperative period
P09858531A1017|12 30|RING1 overexpression
P09858531A1017|12 16|RING1
P09858531A1017|63 82|proto-oncogenes c-jun
P09858531A1017|63 77|proto-oncogenes
P09858531A1017|78 82|c-jun
P09858531A1017|86 90|c-fos
P09858571T0000|3 15|yeast RER2 gene
P09858571T0000|29 76|endoplasmic reticulum protein localization mutations
P09858571T0000|85 105|cis-prenyltransferase
P09858571T0000|108 116|key enzyme
P09858571T0000|119 135|dolichol synthesis
P09858572A0000|3 25|yeast retrotransposon Ty5
P09858572A0000|54 60|regions
P09858572A0000|63 77|silent chromatin
P09858577A1186|9 12|SKO1
P09858577A1186|31 44|ENA1 expression
P09858577A1186|31 34|ENA1
P09858577A1186|48 57|hog1 mutant
P09858577A1186|83 106|osmotic stress sensitivity
P09858577A1186|118 122|Sko1p
P09858577A1186|126 143|downstream effector
P09858577A1186|149 158|HOG pathway
P09858577A1186|149 151|HOG
P09858581A0183|0 17|Elevated expression
P09858581A0183|31 49|uncharacterized gene
P09858581A0183|51 56|SPP381
P09858581A0183|91 105|splicing defects
P09858581A0183|109 129|temperature-sensitive
P09858581A0183|131 132|Ts
P09858581A0183|134 146|mutant prp38-1
P09858588A1046|3 37|slower-electrophoretic-mobility form
P09858588A1046|40 42|p68
P09858588A1046|46 51|absent
P09858588A1046|54 63|human cells
P09858588A1046|66 69|G1/S
P09858588A1046|86 90|cells
P09858588A1046|98 101|G2/M
P09858593A0334|16 33|amino acid sequences
P09858593A0334|36 44|mammalian
P09858593A0334|48 67|Xenopus NeuroD1/BETA2
P09858593A0334|55 61|NeuroD1
P09858593A0334|63 67|BETA2
P09858593A0334|87 107|insulin gene expression
P09858593A0334|87 97|insulin gene
P09858593A0334|111 129|ectopic neurogenesis
P09858599A0392|4 22|NUP98-HOXA9 chimeras
P09858599A0392|4 8|NUP98
P09858599A0392|10 14|HOXA9
P09858599A0392|34 50|NIH 3T3 fibroblasts
P09858599A0392|84 95|HOXA9 domains
P09858599A0392|99 108|DNA binding
P09858599A0392|112 125|PBX interaction
P09858599A0392|112 114|PBX
P09858619A0356|0 12|Recent studies
P09858619A0356|30 33|Y319
P09858619A0356|56 69|ZAP-70 function
P09858619A0356|56 61|ZAP-70
P09858713A1174|0 6|Genetic
P09858713A1174|10 22|molecular data
P09858713A1174|35 46|wild-type Pan
P09858713A1174|50 52|CiD
P09858713A1174|72 74|Arm
P09858713A1174|97 108|transduction
P09858713A1174|114 121|Wg signal
P09858713A1174|124 138|heterozygous ciD
P09858713A1174|141 147|animals
P09858713A1174|154 172|dramatic enhancement
P09858713A1174|178 201|gain-of-function activity
P09858713A1174|204 206|CiD
P09858713A1174|209 225|homozygous mutants
P09858714A1171|7 9|ORF
P09858714A1171|11 22|dda.2 located
P09858714A1171|11 15|dda.2
P09858714A1171|30 33|modA
P09858714A1171|37 39|dda
P09858714A1171|41 64|shares sequence similarity
P09858714A1171|69 75|sigma70
P09858714A1171|88 90|srd
P09858745A1350|16 18|IBS
P09858745A1350|28 45|catB structural gene
P09858745A1350|50 62|cooperativity
P09858745A1350|73 91|footprinting studies
P09858745A1350|102 108|studies
P09858745A1350|123 125|IBS
P09858745A1350|156 159|CatR
P09858745A1350|167 186|upstream binding sites
P09858745A2033|7 25|transcription assays
P09858745A2033|44 64|TCA-cycle intermediate
P09858745A2033|66 73|fumarate
P09858745A2033|123 136|clcA transcript
P09858883A1106|0 14|BIAcore analysis
P09858883A1106|20 23|Kaff
P09858883A1106|36 38|M-1
P09858883A1106|45 51|binding
P09858883A1106|54 57|N-A3
P09858883A1106|60 64|T84.1
P09858883A1106|78 80|M-1
P09858883A1106|87 93|binding
P09858883A1106|96 99|N-A3
P09858883A1106|102 104|T84
P09860979A0521|0 9|Expression
P09860979A0521|12 15|p130
P09860979A0521|17 19|Cas
P09860979A0521|22 24|Cas
P09860979A0521|28 46|major binding protein
P09860979A0521|53 65|Crk SH2-domain
P09860979A0521|78 90|JNK activation
P09860979A0521|78 80|JNK
P09860979A0521|112 121|SH2-mutant
P09860979A0521|124 126|Crk
P09861099A1011|0 19|Positive correlations
P09861099A1011|38 49|measurements
P09861099A1011|53 65|protein intake
P09861099A1011|67 68|r =
P09861099A1011|73 74|P =
P09861099A1011|81 92|energy intake
P09861099A1011|94 95|r =
P09861099A1011|100 100|P
P09861099A1011|114 128|mean differences
P09861099A1011|135 140|g/kg/d
P09861099A1011|142 143|SD
P09861099A1011|152 162|kcal/kg/day
P09861099A1011|164 165|SD
P09861365A0000|3 38|Og4C3 enzyme-linked immunosorbent assay
P09861365A0000|3 7|Og4C3
P09861365A0000|40 44|ELISA
P09861365A0000|65 90|Wuchereria bancrofti antigen
P09861365A0000|84 90|antigen
P09861365A0000|97 102|microL
P09861365A0000|105 109|serum
P09862343A0225|13 29|gp200-MR6 ligation
P09862343A0225|13 17|gp200
P09862343A0225|19 21|MR6
P09862343A0225|42 45|IL-4
P09862343A0225|55 97|anti-proliferative pro-maturational influence
P09862343A0225|107 118|immune system
P09862343A0225|127 139|up-regulation
P09862343A0225|142 164|co-stimulatory molecules
P09862343A0225|167 178|B lymphocytes
P09862481A0000|3 15|Mig1 repressor
P09862481A0000|19 35|zinc finger protein
P09862481A0000|48 64|glucose repression
P09862481A0000|67 71|yeast
P09862496A0187|0 7|Ethylene
P09862496A0187|20 35|endosperm rupture
P09862496A0187|39 66|high-level betaGLU I expression
P09862496A0187|49 56|betaGLU I
P09862496A0187|90 96|spatial
P09862496A0187|100 114|temporal pattern
P09862496A0187|117 134|betaGLU I expression
P09862496A0187|117 124|betaGLU I
P09863624A0629|3 12|divergence
P09863624A0629|15 30|primary structure
P09863624A0629|41 49|sheep CRF1
P09863624A0629|56 74|other mammalian CRF1s
P09863624A0629|61 74|mammalian CRF1s
P09863624A0629|86 94|localized
P09863624A0629|100 131|extracellular amino terminal domain
P09863624A0629|137 144|receptor
P09863624A0629|152 168|divergent residues
P09863624A0629|170 174|ovine
P09863624A0629|177 185|human CRF1
P09863624A2301|0 37|Agonist-induced receptor internalization
P09863624A2301|54 60|percent
P09863624A2301|69 72|125I
P09863624A2301|74 82|Tyr0-oCRF
P09863624A2301|88 94|located
P09863624A2301|100 121|acid-resistant fraction
P09863624A2301|135 137|Cos
P09863624A2301|139 143|cells
P09863624A2301|167 169|min
P09863624A2301|174 181|degrees C
P09863624A2301|190 198|wild-type
P09863624A2301|202 213|variant oCRF1
P09863720T0000|0 33|Recurrent arterial thrombotic disease
P09863720T0000|36 45|young onset
P09863720T0000|49 66|protein S deficiency
P09864141A0528|12 16|Stat3
P09864141A0528|20 28|Stat3beta
P09864141A0528|33 40|affinity
P09864141A0528|54 68|phosphopeptides
P09864141A0528|79 82|Y704
P09864141A0528|86 89|Y744
P09864141A0528|98 130|nonphosphorylated peptide analogues
P09864141A0528|135 149|phosphopeptides
P09864141A0528|160 163|Y729
P09864141A0528|167 170|Y764
P09864335A1226|17 23|results
P09864335A1226|39 46|FCR1 gene
P09864335A1226|57 73|negative regulator
P09864335A1226|76 89|drug resistance
P09864335A1226|92 101|C. albicans
P09864335A1226|118 130|first evidence
P09864335A1226|135 147|FCZ resistance
P09864335A1226|164 175|inactivation
P09864335A1226|179 198|regulatory factor such
P09864335A1226|201 205|Fcr1p
P09864689A1408|5 12|findings
P09864689A1408|24 32|late MYO/M
P09864689A1408|49 59|washout rate
P09864689A1408|90 104|heart failure due
P09864689A1408|107 109|DCM
P09865775A0162|35 42|couplers
P09865775A0162|69 73|ALGO2
P09865775A0162|79 96|spectral properties
P09866068A1058|0 10|CONCLUSIONS
P09866068A1058|12 23|Pretreatment
P09866068A1058|28 30|OCs
P09866068A1058|38 57|pituitary suppression
P09866068A1058|63 82|early follicular phase
P09866068A1058|92 111|ovarian cyst formation
P09866068A1058|122 135|apparent effect
P09866068A1058|138 168|subsequent follicular recruitment
P09866068A1058|171 184|pregnancy rates
P09867159A1444|15 36|optimal threshold values
P09867159A1444|52 62|specificity
P09867159A1444|70 70|%
P09867159A1444|74 74|%
P09867159A1444|80 80|%
P09867159A1444|84 84|%
P09867159A1444|89 94|FDG PET
P09867159A1444|108 108|%
P09867159A1444|112 112|%
P09867159A1444|118 118|%
P09867159A1444|122 122|%
P09867253A0229|4 16|c-Jun activity
P09867253A0229|4 8|c-Jun
P09867253A0229|30 34|c-Fos
P09867253A0229|43 58|protooncoprotein
P09867253A0229|78 82|c-Jun
P09867253A0229|92 114|transcription factor AP-1
P09867855T0000|0 47|Dorsal root ganglia neuron-specific promoter activity
P09867855T0000|53 105|rabbit beta-galactoside alpha1,2-fucosyltransferase gene
P09868412A1628|0 9|CONCLUSION
P09868412A1628|31 42|total body BMD
P09868412A1628|46 59|femoral neck BMD
P09868412A1628|77 82|higher
P09868412A1628|88 97|study group
P09868412A1628|111 133|weight-bearing exercises
P09868412A1628|140 154|control subjects
P09868412A1628|159 174|swimming exercise
P09868412A1628|188 190|BMD
P09868412A1628|220 240|bone-building exercise
P09868412A1628|284 301|grip muscle strength
P09869297A1807|12 16|roles
P09869297A1807|27 29|CE1
P09869297A1807|33 43|CE2 elements
P09869297A1807|56 74|Hoxb1 gene expression
P09869297A1807|56 64|Hoxb1 gene
P09869356A0926|0 6|CAL gain
P09869356A0926|26 27|mm
P09869356A0926|31 31|%
P09869356A0926|37 43|defects
P09869356A0926|51 57|CAL gain
P09869356A0926|61 61|=
P09869356A0926|63 64|mm
P09869400A0203|0 10|Comparisons
P09869400A0203|15 31|other known germins
P09869400A0203|25 31|germins
P09869400A0203|35 53|germin-like proteins
P09869400A0203|71 95|Arabidopsis GLP subfamilies
P09869400A0203|109 119|wheat germin
P09869400A0203|114 119|germin
P09869528T0000|0 11|Lead fixation
P09869528T0000|14 17|dogs
P09869528T0000|30 37|RF energy
P09871353A0174|36 58|A. salmonicida infections
P09871353A0174|72 83|furunculosis
P09871353A0174|112 115|loch
P09872326A0566|22 42|EIA-inducible CBF/cdc2
P09872326A0566|35 37|CBF
P09872326A0566|39 42|cdc2
P09872326A0566|57 59|CBF
P09872326A0566|86 101|heat shock protein
P09872326A0566|104 111|promoter
P09872337A0000|3 24|percutaneous absorption
P09872337A0000|27 37|clindamycin
P09872337A0000|50 70|healthy male volunteers
P09872337A0000|84 107|investigative clindamycin
P09872337A0000|109 112|% w/v
P09872337A0000|115 123|tretinoin
P09872337A0000|130 133|% w/v
P09872337A0000|135 138|gels
P09872337A0000|150 174|clindamycin phosphate ester
P09872337A0000|178 191|clindamycin HCl
P09872337A0000|217 242|clindamycin phosphate lotion
P09872337A0000|245 256|% clindamycin
P09872337A0000|258 265|Dalacin T
P09872832A1262|3 19|BAL concentrations
P09872832A1262|29 37|cytokines
P09872832A1262|64 76|affected lungs
P09872832A1262|90 102|interleukin-6
P09872832A1262|104 107|IL-6
P09872832A1262|110 113|IL-8
P09872832A1262|115 119|IL-12
P09872832A1262|121 145|tumor necrosis factor-alpha
P09872832A1262|147 155|TNF-alpha
P09872832A1262|161 175|interferon gamma
P09872832A1262|177 185|IFN-gamma
P09872832A1262|193 214|significant differences
P09872832A1262|216 216|p
P09873060A0901|0 22|Phosphorylation analyses
P09873060A0901|36 45|inhibition
P09873060A0901|48 52|ERK-1
P09873060A0901|64 98|okadaic acid-elevated phosphorylation
P09873060A0901|101 104|JunD
P09873060A0901|108 111|FosB
P09873291A0620|0 14|Two-way analysis
P09873291A0620|17 24|variance
P09873291A0620|50 72|composite knowledge score
P09873291A0620|86 98|patient groups
P09874803A0000|3 45|human pathogenic bacterium group A Streptococcus
P09874803A0000|56 84|extracellular cysteine protease
P09874803A0000|86 116|streptococcal pyrogenic exotoxin B
P09874803A0000|118 121|SpeB
P09874803A0000|131 153|critical virulence factor
P09874803A0000|157 179|invasive disease episodes
P09875541A0210|3 15|orbitofrontal
P09875541A0210|30 45|anteromedial part
P09875541A0210|51 69|dorsal premotor areas
P09875541A0210|102 131|self-initiated hand movement task
P09875541A0210|133 136|SELF
P09876794T0000|0 8|Improving
P09876794T0000|12 23|evidence base
P09876794T0000|27 37|anaesthesia
P09877417A0704|0 14|Plasma CCK levels
P09877417A0704|6 8|CCK
P09877417A0704|31 46|regular intervals
P09878256A0000|3 31|peroxisome biogenesis disorders
P09878256A0000|33 36|PBDs
P09878256A0000|47 67|lethal genetic diseases
P09878256A0000|83 114|peroxisomal metabolic deficiencies
P09878256A0000|116 139|multisystem abnormalities
P09878256A0000|141 157|mental retardation
P09878256A0000|162 175|premature death
P09878437A0967|3 12|active site
P09878437A0967|24 39|acidic triad Asp53
P09878437A0967|50 64|phosphorylation
P09878437A0967|67 71|Asp10
P09878437A0967|75 78|Glu9
P09878542A1151|0 9|Consistent
P09878542A1151|19 26|findings
P09878542A1151|38 65|weak transcriptional silencing
P09878542A1151|71 79|native VDR
P09878542A1151|77 79|VDR
P09878542A1151|99 113|osteopontin VDRE
P09878542A1151|99 109|osteopontin
P09879766A0402|2 6|PAV-3
P09879766A0402|11 19|E1A region
P09879766A0402|22 28|located
P09879766A0402|45 52|map units
P09880029A0703|3 27|putative MDV genome products
P09880029A0703|41 43|Rep
P09880029A0703|51 65|non-Rep proteins
P09880029A0703|85 85|%
P09880029A0703|87 103|amino acid identity
P09880029A0703|109 121|corresponding
P09880029A0703|125 137|FBNYV proteins
P09880029A0703|149 164|other Rep proteins
P09880029A0703|154 164|Rep proteins
P09880029A0703|174 179|MDV-C2
P09880029A0703|183 184|C3
P09880029A0703|192 192|%
P09880029A0703|200 209|% identical
P09880029A0703|226 232|SCSV-C2
P09880029A0703|236 237|C6
P09880103A0387|0 2|MPO
P09880103A0387|18 24|mCi 125I
P09880103A0387|39 51|self-labeling
P09880103A0387|73 89|M hydrogen peroxide
P09880327A0322|23 55|mammalian Golgi-associated proteins
P09880327A0322|64 73|yeast Uso1p
P09880327A0322|69 73|Uso1p
P09880327A0322|77 92|essential protein
P09880327A0322|103 109|docking
P09880327A0322|112 147|endoplasmic reticulum-derived vesicles
P09880327A0322|153 161|cis-Golgi
P09880512A1251|19 22|Bmp2
P09880512A1251|44 70|retinoic acid-bound receptors
P09880512A1251|74 76|Sp1
P09880513A1013|4 11|proteins
P09880513A1013|53 59|tubulin
P09880543A0570|0 3|HEED
P09880543A0570|20 28|MA protein
P09880543A0570|60 69|yeast cells
P09880544A0693|0 32|Fas-resistant DT-40 lymphoma B-cells
P09880544A0693|41 53|BTK-deficient
P09880544A0693|41 43|BTK
P09880544A0693|69 78|disruption
P09880544A0693|84 90|btk gene
P09880544A0693|93 123|homologous recombination knockout
P09880544A0693|133 141|apoptosis
P09880544A0693|147 157|Fas ligation
P09880544A0693|162 180|wild-type DT-40 cells
P09880544A0693|183 205|BTK-deficient DT-40 cells
P09880544A0693|183 185|BTK
P09880544A0693|223 243|wild-type human btk gene
P09881666A0535|1 5|motif
P09881666A0535|7 14|TGATGTCA
P09881666A0535|29 36|CREB site
P09881666A0535|53 60|AP-1 site
P09881666A0535|63 70|embedded
P09881666A0535|77 79|ER2
P09881692A0094|19 42|nominal allotypic variants
P09881692A0094|44 45|b4
P09881692A0094|47 48|b5
P09881692A0094|50 51|b6
P09881692A0094|55 56|b9
P09881692A0094|101 116|Ckappa1 gene locus
P09881692A1109|31 41|latent genes
P09881692A1109|49 81|allotype-specific oligonucleotides
P09881692A1109|85 86|b5
P09881692A1109|88 89|b6
P09881692A1109|93 94|b9
P09881692A1109|97 105|probe DNAs
P09881692A1109|123 146|T. brucei-infected rabbits
P09881692A1109|149 164|Southern blotting
P09882303A1413|0 4|TRAF2
P09882303A1413|27 31|TRADD
P09882303A1413|49 94|dominant-negative N-terminal deletion TRAF2 mutant
P09882303A1413|121 145|LMP1-induced JNK activation
P09882303A1413|121 124|LMP1
P09882303A1413|133 135|JNK
P09882303A1413|151 155|cells
P09882303A1984|30 34|TRADD
P09882303A1984|38 42|TRAF2
P09882303A1984|45 57|JNK activation
P09882303A1984|45 47|JNK
P09882303A1984|72 75|LMP1
P09882303A1984|84 103|signalling mechanisms
P09882303A1984|113 134|TNF receptor/CD40 family
P09882303A1984|113 123|TNF receptor
P09882303A1984|125 128|CD40
P09882303A1984|146 166|pleiotropic activities
P09882303T0000|0 46|Epstein-Barr virus-encoded latent membrane protein 1
P09882303T0000|0 45|Epstein-Barr virus-encoded latent membrane protein
P09882303T0000|59 68|JNK pathway
P09882303T0000|59 61|JNK
P09882303T0000|79 94|extreme C terminus
P09882303T0000|117 121|TRADD
P09882303T0000|125 129|TRAF2
P09882321A0948|33 37|cells
P09882321A0948|48 53|EBNA-3
P09882321A0948|63 77|sixfold increase
P09882321A0948|80 102|EBNA-3 protein expression
P09882321A0948|80 92|EBNA-3 protein
P09882321A0948|110 126|genomic EBNA-3 gene
P09882321A0948|137 146|EBNA-3 cDNA
P09882334A0822|8 21|serial passages
P09882334A0822|24 38|fetal lamb kidney
P09882334A0822|40 42|FLK
P09882334A0822|44 48|cells
P09882334A0822|82 84|BLV
P09882334A0822|91 111|transient transfection
P09882334A0822|124 131|mutation
P09882334A0822|135 155|second tyrosine residue
P09882334A0822|161 175|N-terminal motif
P09882334A0822|198 208|propagation
P09882337A0000|0 39|Varicella-zoster virus (VZV) glycoprotein gI
P09882337A0000|0 20|Varicella-zoster virus
P09882337A0000|22 24|VZV
P09882337A0000|26 39|glycoprotein gI
P09882337A0000|43 72|type 1 transmembrane glycoprotein
P09882337A0000|48 72|transmembrane glycoprotein
P09882337A0000|97 111|heterodimeric gE
P09882337A0000|113 131|gI Fc receptor complex
P09882348A0611|23 43|phosphorylation status
P09882348A0611|47 78|universal tyrosine kinase substrate
P09882348A0611|95 111|Shc adapter protein
P09882348A0611|115 125|fibroblasts
P09882348A0611|139 151|viral oncogene
P09882451A0195|5 9|genes
P09882451A0195|26 54|Saccharomyces cerevisiae mutant
P09882451A0195|49 54|mutant
P09882451A0195|65 92|endogenous ferrochelatase gene
P09882451A0195|94 98|HEM15
P09882451A0195|121 130|phenotypes
P09882451A0195|136 148|transformants
P09882489A0451|57 78|specific mef2 expression
P09882489A0451|65 68|mef2
P09882489A0451|94 105|complex array
P09882489A0451|108 134|cis-acting regulatory modules
P09882489A0451|142 151|responsive
P09882489A0451|154 176|different genetic signals
P09882499A0231|17 41|transgenic mouse technology
P09882499A0231|53 85|independent cis-regulatory elements
P09882499A0231|100 124|tissue-specific expression
P09882499A0231|127 130|Pax6
P09882593A0996|5 20|second experiment
P09882593A0996|23 41|stable nickel isotope
P09882593A0996|43 46|61Ni
P09882593A0996|58 70|drinking water
P09882593A0996|75 96|nickel-sensitized women
P09882593A0996|102 120|age-matched controls
P09882593A0996|126 131|groups
P09882593A0996|138 156|vesicular hand eczema
P09882593A0996|162 174|pompholyx type
P09882638A0235|15 35|crimped collagen fibers
P09882638A0235|22 29|collagen
P09882638A0235|41 55|tunica albuginea
P09882638A0235|80 87|erection
P09883639A0000|0 5|Number
P09883639A0000|8 15|patients
P09883639A0000|28 53|nontuberculous mycobacteria
P09883639A0000|55 57|NTM
P09883639A0000|83 93|recent years
P09884232A0286|0 9|Comparison
P09884232A0286|15 23|sequences
P09884232A0286|26 29|attP
P09884232A0286|31 34|attB
P09884232A0286|38 67|bacteria-prophage junctions attL
P09884232A0286|64 67|attL
P09884232A0286|71 74|attR
P09884232A0286|84 103|bp common core sequence
P09884232A0286|110 122|recombination
P09884232A0286|151 163|integrase gene
P09884275T0000|0 24|Interferon-alpha treatment
P09884275T0000|0 15|Interferon-alpha
P09884275T0000|27 67|posttransplant lymphoproliferative disorder
P09884275T0000|70 79|recipients
P09884275T0000|82 102|solid organ transplants
P09884747A0477|0 19|Immunological testing
P09884747A0477|37 50|brewery workers
P09884747A0477|58 74|control volunteers
P09884747A0477|80 95|skin prick testing
P09884747A0477|105 110|barley
P09884747A0477|115 127|yeast antigens
P09884747A0477|136 164|other nonoccupational allergens
P09884747A0477|182 200|total serum IgE levels
P09885431A0000|0 8|OBJECTIVE
P09885431A0000|48 52|crown
P09885431A0000|56 73|bridge restorations
P09885431A0000|82 136|twin mix putty/wash silicone elastomeric impression materials
P09885431A0000|142 155|different types
P09885431A0000|158 166|stock tray
P09886602A0000|0 9|OBJECTIVES
P09886602A0000|31 42|pretreatment
P09886602A0000|46 83|post-treatment prostate-specific antigen
P09886602A0000|85 87|PSA
P09886602A0000|89 100|measurements
P09886602A0000|102 119|clinical tumor stage
P09886602A0000|121 130|tumor grade
P09886602A0000|132 141|Gleason sum
P09886602A0000|155 167|radiation dose
P09886602A0000|180 189|recurrence
P09886602A0000|192 205|prostate cancer
P09886602A0000|215 242|external beam radiation therapy
P09886602A0000|244 246|XRT
P09886602A0000|270 272|PSA
P09886602A0000|276 286|tumor marker
P09886602A0000|292 309|tertiary care center
P09886843A0339|20 28|human gene
P09886843A0339|44 57|thyroid hormone
P09886843A0339|75 95|T3-responsive elements
P09886843A0339|98 101|NRGN
P09886843A0339|108 123|genomic fragments
P09886843A0339|135 143|whole gene
P09886850A0145|3 25|transcriptional activity
P09886850A0145|28 36|PPARgamma
P09886850A0145|60 72|ligand binding
P09886850A0145|97 111|phosphorylation
P09886850A0145|125 147|MEK/ERK signaling pathway
P09886850A0145|125 127|MEK
P09886850A0145|129 131|ERK
P09887544A0000|0 9|BACKGROUND
P09887544A0000|11 18|Diazepam
P09887544A0000|28 46|benzodiazepine group
P09887544A0000|49 61|tranquilizers
P09887544A0000|73 86|adjunctive drug
P09887544A0000|90 97|sedation
P09887544A0000|135 142|epilepsy
P09888711A0781|0 20|Bioplastique granuloma
P09888711A0781|33 61|irregularly shaped cystic spaces
P09888711A0781|92 102|translucent
P09888711A0781|104 131|nonbirefringent foreign bodies
P09888711A0781|139 155|Artecoll granuloma
P09888711A0781|161 181|numerous round vacuoles
P09888711A0781|249 259|translucent
P09888711A0781|261 288|nonbirefringent foreign bodies
P09888994A0858|4 21|Tbx6-subfamily gene
P09888994A0858|45 69|paraxial mesoderm formation
P09888994A0858|73 85|somitogenesis
P09888994A0858|88 98|human embryo
P09889202T0000|0 25|Structure-function analysis
P09889202T0000|31 55|Z-DNA-binding domain Zalpha
P09889202T0000|58 85|dsRNA adenosine deaminase type I
P09889202T0000|58 84|dsRNA adenosine deaminase type
P09889202T0000|109 113|alpha
P09889202T0000|115 118|beta
P09889202T0000|128 151|helix-turn-helix proteins
P09889306A0321|26 45|Glvr-1 gene expression
P09889306A0321|26 35|Glvr-1 gene
P09889306A0321|53 73|potential applications
P09889306A0321|76 86|gene therapy
P09889306A0321|93 109|retroviral vectors
P09889306A0321|118 155|gibbon ape leukemia virus envelope proteins
P09889306A0321|166 177|gene delivery
P09889306A0321|182 199|different cell types
P09890778T0000|0 12|Carbohydrates
P09890778T0000|16 48|glycoconjugates biophysical methods
P09891009T0000|0 15|Molecular cloning
P09891009T0000|18 38|mouse glycolate oxidase
P09891046A0269|23 25|PKR
P09891046A0269|34 43|cell growth
P09891046A0269|54 62|apoptosis
P09891046A0269|71 80|disruption
P09891046A0269|83 100|normal PKR signaling
P09891046A0269|89 91|PKR
P09891046A0269|110 130|unregulated cell growth
P09891046A0554|11 29|ribosomal protein L18
P09891046A0554|47 49|PKR
P09891049A0761|0 9|Processing
P09891049A0761|15 36|polycistronic precursor
P09891049A0761|45 53|nucleases
P09891049A0761|68 81|rRNA processing
P09891049A0761|88 92|Rnt1p
P09891049A0761|96 100|Rat1p
P09891061A0373|11 35|transcriptional regulators
P09891061A0373|57 68|SpHE promoter
P09891061A0373|79 103|several individual elements
P09891061A0373|116 131|conventional bait
P09891061A0373|145 166|multimerized cis element
P09891061A1240|14 49|positive SpHE transcriptional regulator
P09891061A1240|22 49|SpHE transcriptional regulator
P09891061A1240|62 81|SpEts4 gene expression
P09891061A1240|62 71|SpEts4 gene
P09891061A1240|93 111|transient expression
P09891061A1240|114 117|SpHE
P09891061A1240|127 148|early sea urchin blastula
P09891065A1493|12 37|rhoA-mediated SRE activation
P09891065A1493|12 15|rhoA
P09891065A1493|50 72|dominant negative mutants
P09891065A1493|75 83|PKC-alpha
P09891065A1493|86 96|PKC-epsilon
P09891085A0815|0 18|Nip7p-depleted cells
P09891085A0815|0 4|Nip7p
P09891085A0815|31 41|same defects
P09891085A0815|44 62|Nop8p-depleted cells
P09891085A0815|44 48|Nop8p
P09891085A0815|89 101|27S precursors
P09891092A1000|13 26|Sm-binding site
P09891092A1000|30 38|stem-loop
P09891092A1000|42 51|structures
P09891092A1000|77 88|end formation
P09891707A0000|4 20|different subtypes
P09891707A0000|23 41|spondyloarthropathy
P09891707A0000|43 45|SpA
P09892017A2151|0 17|Further experiments
P09892017A2151|58 61|ELE1
P09892017A2151|64 89|nuclear receptor functioning
P09892021A0712|0 13|Overexpression
P09892021A0712|16 19|PTTG
P09892021A0712|33 43|NIH 3T3 cells
P09892021A0712|71 79|secretion
P09892021A0712|82 108|basic fibroblast growth factor
P09892021A0712|111 152|human pituitary tumor growth-regulating factor
P09892422A1096|3 38|perifascicular connective tissue sheath
P09892422A1096|65 75|contraction
P09892422A1096|81 90|myocardium
P09892422A1096|103 115|lateral spread
P09892422A1096|118 127|conduction
P09892422A1096|176 186|termination
P09892422A1096|192 204|purkinje fibre
P09892642A0172|0 1|E1
P09892642A0172|4 14|DNA helicase
P09892642A0172|35 46|HPV E2 protein
P09892642A0172|49 72|ori-dependent replication
P09892662A0334|15 32|mutant alpha subunit
P09892662A0334|50 84|receptor-mediated hormonal activation
P09892662A0334|87 88|Gs
P09892662A0334|93 112|stimulatory regulator
P09892662A0334|115 129|adenylyl cyclase
P09892736A0343|1 12|gapped search
P09892736A0343|20 35|C-terminal region
P09892736A0343|38 46|CDED/LIOR
P09892736A0343|38 41|CDED
P09892736A0343|43 46|LIOR
P09892736A0343|61 71|% similarity
P09892736A0343|74 88|several proteins
P09892736A0343|98 115|signal transduction
P09892736A0343|119 133|cell replication
P09892736A0343|141 144|ORC1
P09892736A0343|148 150|KSR
P09893060A0767|0 19|Northern blot analysis
P09893060A0767|35 54|ubiquitous expression
P09893060A0767|60 61|kb
P09893262A1272|23 39|regulatory schemes
P09893262A1272|50 57|temporal
P09893262A1272|64 81|spatial restriction
P09893262A1272|84 100|TGF-beta responses
P09893262A1272|84 91|TGF-beta
P09893913A0656|0 8|Induction
P09893913A0656|11 21|anaesthesia
P09893913A0656|38 45|fentanyl
P09893913A0656|48 60|micrograms/kg
P09893913A0656|63 73|thiopentone
P09893913A0656|76 80|mg/kg
P09893913A0656|83 92|atracurium
P09893913A0656|97 101|mg/kg
P09894962T0000|16 30|clinical profile
P09894962T0000|33 54|cavernous malformations
P09894962T0000|79 97|venous malformations
P09895323T0000|12 24|distinct roles
P09895323T0000|27 34|kreisler
P09895323T0000|52 66|paralogous Hoxa3
P09895323T0000|62 66|Hoxa3
P09895323T0000|70 79|Hoxb3 genes
P09897032T0000|19 37|optical self-pulsing
P09897032T0000|41 58|nonlinear resonator
P09900679T0000|0 14|Wave cybernetics
P09900679T0000|17 27|simple model
P09900679T0000|30 53|wave-controlled nonlinear
P09900679T0000|57 84|nonlocal cooperative phenomena
P09903722T0000|0 18|Autoionization rates
P09903722T0000|22 33|energy levels
P09903722T0000|36 44|triplet nf
P09903722T0000|49 61|Rydberg states
P09903722T0000|64 65|H2
P09904139T0000|0 20|Unitary-group approach
P09904139T0000|23 45|spin-dependent operators
P09911328T0000|0 15|Nonlocal approach
P09911328T0000|18 27|scattering
P09911328T0000|31 52|one-dimensional problem
P09913308T0000|0 15|Soft-x-ray lasing
P09913308T0000|22 23|nm
P09913308T0000|26 38|Ne-like Ti ions
P09913308T0000|49 49|J
P09913308T0000|65 81|650-ps laser pulses
P09914156A1496|15 21|regions
P09914156A1496|27 34|promoter
P09914156A1496|63 90|tenascin-C promoter constructs
P09914156A1496|97 105|deletions
P09914156A1496|119 161|denatured collagen-dependent promoter activity
P09914156A1496|128 153|collagen-dependent promoter
P09914156A1496|176 194|122-base pair element
P09914156A1496|196 202|located
P09914156A1496|212 221|bp upstream
P09914156A1496|227 238|RNA start site
P09914500A0000|0 18|Nuclear factor kappa B
P09914500A0000|20 28|NF-kappaB
P09914500A0000|34 61|important transcription factor
P09914500A0000|68 72|genes
P09914500A0000|75 102|many pro-inflammatory proteins
P09914500A0000|130 151|cytokines interleukin-1
P09914500A0000|139 151|interleukin-1
P09914500A0000|155 173|tumor necrosis factor
P09914500A0000|175 177|TNF
P09914500A0000|179 183|alpha
P09914500A0000|189 217|various pathological conditions
P09914518A1217|13 23|enhancement
P09914518A1217|26 50|transcriptional activation
P09914518A1217|53 60|COUP-TFI
P09914518A1217|84 110|AF-1 transactivation function
P09914518A1217|84 87|AF-1
P09914518A1217|113 114|ER
P09914518A1217|146 147|E2
P09914518A1217|150 167|4-hydroxytamoxifen
P09914518A1217|174 176|ICI
P09914525A0890|0 13|Recombinant Ffh
P09914525A0890|18 29|melting point
P09914525A0890|32 34|tm =
P09914525A0890|37 44|degreesC
P09915118T0000|0 23|Unilateral naris occlusion
P09915118T0000|30 54|rat accessory olfactory bulb
P09915798A1077|12 16|hsp90
P09915798A1077|25 56|ATP-independent chaperone activity
P09915798A1077|69 91|hsp90 dimerization domain
P09915798A1077|69 73|hsp90
P09915798A1077|104 130|structural elements important
P09915798A1077|134 159|steroid receptor interaction
P09915798A1077|134 148|steroid receptor
P09915860A0000|3 10|promoter
P09915860A0000|16 32|rat pgp2/mdr1b gene
P09915860A0000|19 22|pgp2
P09915860A0000|24 32|mdr1b gene
P09915860A0000|37 49|GC-rich region
P09915860A0000|51 56|pgp2GC
P09915860A0000|81 88|mdr genes
P09915860A0000|102 117|consensus Sp1 site
P09915860A0000|111 117|Sp1 site
P09915860A0119|0 2|Sp1
P09915860A0119|11 25|transactivation
P09915860A0119|31 48|pgp2/mdr1b promoter
P09915860A0119|31 34|pgp2
P09915860A0119|70 83|Schneider cells
P09916786A0811|0 11|Measurements
P09916786A0811|20 37|bone mineral density
P09916786A0811|43 53|lumbar spine
P09916786A0811|57 69|proximal femur
P09916786A0811|73 102|dual-energy X-ray absorptiometry
P09916786A0811|107 124|biochemical markers
P09916786A0811|127 140|bone remodeling
P09916786A0811|142 178|serum bone-specific alkaline phosphatase
P09916786A0811|181 191|immunoassay
P09916786A0811|195 216|urine deoxypyridinoline
P09916786A0811|219 251|high-pressure liquid chromatography
P09916809A0405|0 7|Human MGP
P09916809A0405|11 42|10-kD skeletal extracellular matrix
P09916809A0405|44 46|ECM
P09916809A0405|71 88|84-aa mature protein
P09916809A0405|93 123|19-aa transmembrane signal peptide
P09917064T0000|0 8|Dual roles
P09917064T0000|11 13|p82
P09917064T0000|18 32|clam CPEB homolog
P09917064T0000|22 32|CPEB homolog
P09917064T0000|36 61|cytoplasmic polyadenylation
P09917064T0000|65 84|translational masking
P09917387T0000|3 41|RNA polymerase III-recruiting factor TFIIIB
P09917387T0000|50 56|DNA bend
P09917387T0000|67 73|TATA box
P09917387T0000|80 103|transcriptional start site
P09917389A1239|12 26|RNase E digestion
P09917389A1239|12 17|RNase E
P09917389A1239|29 38|finP305 RNA
P09917389A1239|51 54|FinP
P09917389A1239|59 66|GST-FinO
P09917389A1239|59 61|GST
P09917389A1239|63 66|FinO
P09917389A1239|80 89|finP305 RNA
P09917389A1239|94 101|cleavage
P09917391A0380|0 23|Transcription readthrough
P09917391A0380|31 45|inverted repeats
P09917391A0380|49 60|little effect
P09917555T0001|0 7|Analysis
P09917555T0001|10 47|hematopoietic growth factor prescriptions
P09917555T0001|10 34|hematopoietic growth factor
P09917555T0001|52 70|french cancer centers
P09918096A0520|5 14|second case
P09918096A0520|18 30|epidermal cyst
P09918715A0304|0 3|MotA
P09918715A0304|14 24|DNA sequence
P09918715A0304|27 33|MotA box
P09918715A1158|13 16|MotA
P09918715A1158|20 23|AsiA
P09918715A1158|39 59|certain eukaryotic TAFs
P09918715A1158|46 59|eukaryotic TAFs
P09918715A1158|61 78|TATA binding protein
P09918715A1158|80 82|TBP
P09918715A1158|84 100|associated factors
P09918715A1158|107 113|binding
P09918715A1158|116 125|TBP results
P09918715A1158|116 118|TBP
P09918715A1158|128 140|transcription
P09918715A1158|145 168|new core promoter sequences
P09918720A0998|3 14|S229A variant
P09918720A0998|36 40|bases
P09918720A0998|83 103|adenine-binding pocket
P09918720A0998|119 124|Ser229
P09918720A0998|154 160|adenine
P09918842A0184|3 18|high conservation
P09918842A0184|26 33|terminus
P09918842A0184|76 83|proteins
P09918842A0184|98 107|initiation
P09918842A0184|110 123|RNA replication
P09920539A0272|3 14|stimulations
P09920539A0272|37 42|GnRH-a
P09920539A0272|62 73|long protocol
P09920539A0272|80 102|gonadotropin stimulation
P09920539A0272|80 91|gonadotropin
P09920775A0075|19 28|bp relative
P09920775A0075|34 55|transcription start site
P09920775A0075|78 99|reporter gene expression
P09920775A0075|114 138|mesodermal differentiation
P09920775A0075|141 148|P19 cells
P09920882A0287|0 3|Chem
P09920896A1230|2 23|significant differences
P09920896A1230|48 63|wild type peptides
P09920896A1230|95 106|substitution
P09920896A1230|112 124|intact protein
P09920896A1230|133 142|disruption
P09920896A1230|161 175|local structures
P09920903A1045|5 11|results
P09920903A1045|26 34|c-met gene
P09920903A1045|50 66|p53 gene regulation
P09920903A1045|50 56|p53 gene
P09920930A0521|0 6|C3 toxin
P09920930A0521|26 37|RhoA function
P09920930A0521|26 29|RhoA
P09920930A0521|57 59|SRE
P09920930A0521|61 71|Luc activity
P09920930A0521|61 63|Luc
P09920930A0521|89 117|LPA-stimulated c-Fos expression
P09920930A0959|8 14|C3 toxin
P09920930A0959|39 51|growth factors
P09920930A0959|67 70|AP-1
P09920930A0959|72 82|Luc activity
P09920930A0959|72 74|Luc
P09920930A0959|108 128|synergistic activation
P09920930A0959|131 134|AP-1
P09920930A0959|136 138|Luc
P09920930A0959|159 172|co-stimulation
P09920930A0959|177 189|growth factors
P09920930A0959|193 202|Ro-31-8220
P09920982A0253|11 22|present study
P09920982A0253|38 64|antimicrobial susceptibility
P09920982A0253|82 100|antimicrobial agents
P09920982A0253|105 111|strains
P09920982A0253|114 115|P.
P09920982A0253|133 143|acne lesions
P09920982A0253|163 177|Rap ID ANA II panel
P09921179T0001|9 38|intraoperative echocardiography
P09921179T0001|61 72|large vessels
P09922230A1482|17 23|results
P09922230A1482|39 42|CAP1
P09922230A1482|55 73|multidrug resistance
P09922230A1482|77 99|oxidative stress response
P09922230A1482|102 111|C. albicans
P09922856A0459|0 9|Trinipatch
P09922856A0459|19 29|transparent
P09922856A0459|31 39|matricial
P09922856A0459|41 54|monolayer patch
P09922856A0459|61 78|absorption promoter
P09922856A0459|93 106|dose-strengths
P09922856A0459|109 114|mg/24 h
P09922856A0459|120 125|mg/24 h
P09922856A0459|129 150|Laboratoires Synthelabo
P09923245A0482|3 6|RMRI
P09923245A0482|19 39|interrater reliability
P09923245A0482|50 58|simulated
P09923245A0482|64 77|actual patients
P09924675A0412|41 51|conceptions
P09924675A0412|65 69|ICIDH
P09924675A0412|94 101|mainstay
P09924675A0412|113 123|diagnostics
P09924675A0412|163 186|essential characteristics
P09924675A0412|192 208|diagnostic process
P09924987A0000|0 23|Pokeweed antiviral protein
P09924987A0000|25 27|PAP
P09924987A0000|33 51|Phytolacca americana
P09924987A0000|61 81|specific N-glycosidase
P09924987A0000|69 81|N-glycosidase
P09924987A0000|90 104|adenine residues
P09924987A0000|106 110|A4324
P09924987A0000|113 119|28S rRNA
P09924987A0000|123 127|A2660
P09924987A0000|130 136|23S rRNA
P09924987A0000|142 156|intact ribosomes
P09924987A0000|163 172|eukaryotes
P09924987A0000|176 186|prokaryotes
P09925120A0074|0 8|OBJECTIVE
P09925120A0074|14 26|meta-analysis
P09925120A0074|31 46|controlled trials
P09925120A0074|72 97|cholesterol-lowering effect
P09925120A0074|100 117|major dietary fibers
P09925372A0458|13 16|ZFPs
P09925372A0458|19 30|novel ZFP cDNA
P09925372A0458|36 39|HFHZ
P09925372A0458|41 58|human fetal heart ZFP
P09925372A0458|64 79|sequence homology
P09925372A0458|83 103|Kruppel-associated box
P09925372A0458|105 108|KRAB
P09925372A1063|11 26|higher expression
P09925372A1063|32 41|fetal heart
P09925372A1063|51 60|adult heart
P09925372A1063|73 80|HFHZ mRNA
P09925777A1195|7 25|high affinity hnRNP A1
P09925777A1195|19 36|hnRNP A1 binding site
P09925777A1195|55 73|beta-globin reporter
P09925777A1195|75 77|Rev
P09925777A1195|98 114|cytoplasmic levels
P09925777A1195|117 130|unspliced mRNAs
P09925777A1195|135 135|%
P09927193A0107|10 21|such proteins
P09927193A0107|23 26|PLZF
P09927193A0107|30 34|LAZ-3
P09927193A0107|36 40|BCL-6
P09927193A0107|62 72|oncogenesis
P09927449A0421|0 13|Overexpression
P09927449A0421|16 19|POG1
P09927449A0421|28 55|alpha-factor-induced G1 arrest
P09927449A0421|28 39|alpha-factor
P09927449A0421|59 83|transcriptional repression
P09927449A0421|89 92|CLN1
P09927449A0421|96 104|CLN2 genes
P09927570A0507|13 25|RNU2 fragility
P09927570A0507|13 16|RNU2
P09927570A0507|40 51|transfection
P09927570A0507|58 73|expression vector
P09927570A0507|82 88|Ad12 E1B
P09927570A0507|91 93|kDa
P09927570A0507|109 116|E1 vector
P09927570A0507|128 137|E1 products
P09927570A0507|139 150|3 E1A proteins
P09927570A0507|140 150|E1A proteins
P09927570A0507|163 186|E1B 19 kDa and 55 kDa proteins
P09927570A0507|163 165|E1B
P09927570A0507|168 170|kDa
P09927570A0507|176 186|kDa proteins
P09927585A0796|0 30|Competitionsupershift EMSA assays
P09927585A0796|43 58|multiple proteins
P09927585A0796|73 97|bandshift complex formation
P09927585A0796|102 104|KCS
P09927585A0796|131 139|factor Sp1
P09927585A0796|137 139|Sp1
P09927589T0000|0 9|Similarity
P09927589T0000|12 21|DNA binding
P09927589T0000|25 49|transcriptional regulation
P09927589T0000|52 77|Caenorhabditis elegans MAB-3
P09927589T0000|81 105|Drosophila melanogaster DSX
P09927589T0000|103 105|DSX
P09927589T0000|128 151|sex determining mechanisms
P09929088A0000|0 6|CONTEXT
P09929088A0000|8 15|ThinPrep
P09929088A0000|17 23|AutoPap
P09929088A0000|28 33|Papnet
P09929088A0000|38 52|new technologies
P09929088A0000|88 110|cervical cancer screening
P09929811A0000|0 10|Experiments
P09929811A0000|13 26|narcotized cats
P09929811A0000|46 56|derivatives
P09929811A0000|59 81|2-mercaptobenzimidazole
P09929811A0000|95 104|properties
P09929811A0000|107 131|specific bradycardic agents
P09929811A0000|142 147|CM-251
P09929811A0000|149 154|CM-266
P09929811A0000|159 164|CM-345
P09929811A0000|175 182|mean rise
P09929811A0000|185 193|segment ST
P09929811A0000|196 208|numerous leads
P09929811A0000|214 234|epicardial electrogram
P09929811A0000|241 254|5-min occlusion
P09929811A0000|260 267|anterior
P09929811A0000|289 306|left coronary artery
P09931118A1072|10 15|p42/44
P09931118A1072|22 31|JNK pathway
P09931118A1072|22 24|JNK
P09931118A1072|56 63|IL-1beta
P09931191A0434|17 33|different subjects
P09931191A0434|43 45|Con
P09931191A0434|49 59|Ecc arm curls
P09931191A0434|80 105|postexercise muscle ischemia
P09931191A0434|117 130|same resistance
P09931216A0566|0 6|Airflow
P09931216A0566|23 44|custom-designed turbine
P09931216A0566|49 53|45-ft
P09931216A0566|75 96|volume-measuring module
P09931252A1055|4 12|mutations
P09931252A1055|19 40|amino acid substitutions
P09931252A1055|46 61|viral coat protein
P09931252A1055|78 94|relative abilities
P09931252A1055|107 131|foreign scaffolding protein
P09931391A0944|0 15|Complete recovery
P09931391A0944|18 30|liver function
P09931435A0357|12 22|transcripts
P09931435A0357|40 44|exons
P09931435A0357|46 49|exon
P09931435A0357|54 58|ZIS-2
P09931435A0357|70 74|ZIS-1
P09931435A0357|87 90|exon
P09931435A0357|94 101|10th exon
P09931435A0357|105 109|ZIS-1
P09931435A0357|112 117|larger
P09931435A0357|137 142|longer
P09931435A0357|146 148|UTR
P09932288A0378|0 9|Expression
P09932288A0378|15 24|second gene
P09932288A0378|26 28|XT3
P09932288A0378|53 63|human kidney
P09932288A0378|68 82|partial sequence
P09932288A0378|99 114|human cDNA library
P09933428A0351|0 8|IFN-gamma
P09933428A0351|12 19|elevated
P09933428A0351|26 33|active TB
P09933428A0351|50 64|healthy controls
P09933641A0241|12 20|sequences
P09933641A0241|38 55|rapid amplification
P09933641A0241|58 65|cDNA ends
P09933641A0241|83 98|NHE5 genomic clone
P09933641A0241|115 123|sequences
P09933641A0241|141 158|rapid amplification
P09933641A0241|161 168|cDNA ends
P09933848A1008|4 17|alloantibodies
P09933848A1008|30 44|further analysis
P09933848A1008|74 87|autoantibodies
P09934611A1054|4 13|dependence
P09934611A1054|39 49|large extent
P09934611A1054|60 69|min LVdP/dt
P09934611A1054|72 89|mean aortic pressure
P09935377T0108|0 4|Genoa
P09935377T0108|6 10|Italy
P09935377T0108|17 22|August
P09936001T0000|0 18|Electronic structure
P09936001T0000|21 25|delta
P09936001T0000|27 35|plutonium
P09936001T0000|41 48|single Al
P09936001T0000|50 51|Ga
P09936001T0000|56 67|Sc impurities
P09936001T0000|70 74|delta
P09936001T0000|76 84|plutonium
P09938097T0000|0 20|Bound-exciton transfer
P09938097T0000|24 57|photoluminescence undulation spectra
P09938097T0000|61 69|acceptors
P09938097T0000|72 75|ZnTe
P09940132T0000|0 12|Unified theory
P09940132T0000|15 58|segregated-stack organic charge-transfer solids
P09940132T0000|60 77|Magnetic properties
P09943651T0000|0 12|Internal modes
P09943651T0000|16 22|soliton
P09944066T0073|0 1|II
P09945838T0000|0 34|Envelope-function matching conditions
P09945838T0000|38 41|GaAs
P09945838T0000|44 45|Al
P09945838T0000|47 48|Ga
P09945838T0000|52 66|heterojunctions
P09947191T0000|0 28|Neutron scattering measurements
P09947191T0000|31 47|critical exponents
P09947191T0000|50 56|CsMnBr3
P09947191T0000|59 60|Z2
P09947191T0000|65 65|=
P09947191T0000|67 81|antiferromagnet
P09949160A0600|3 23|Erythroid 32D Epo1 cells
P09949160A0600|15 18|Epo1
P09949160A0600|31 40|lower level
P09949160A0600|43 66|bulk PKC catalytic activity
P09949160A0600|47 49|PKC
P09949160A0600|89 95|epsilon
P09949160A0600|99 112|eta PKC isoforms
P09949160A0600|130 147|absent upregulation
P09949160A0600|162 169|isoforms
P09949160A0600|177 181|betaI
P09949160A0600|187 196|readdition
P09949160A0600|199 201|Epo
P09949160A0600|204 228|growth factor-starved cells
P09949178A0264|33 45|interleukin-6
P09949178A0264|47 50|IL-6
P09949178A0264|86 106|pre-B-cell variant line
P09949178A0264|108 112|1A9-M
P09949312A0524|0 6|Airflow
P09949312A0524|17 24|dust trap
P09949312A0524|43 52|vacuum pump
P09950213A1660|7 43|normal intestinal epithelial goblet cells
P09950213A1660|45 51|TbetaRI
P09950213A1660|55 62|TbetaRII
P09950213A1660|75 83|autocrine
P09950213A1660|90 106|exogenous TGF-beta
P09950213A1660|99 106|TGF-beta
P09950213A1660|132 140|TbetaRIII
P09950394A0336|23 45|carboxyhemoglobin levels
P09950394A0336|23 39|carboxyhemoglobin
P09952378A0529|3 11|odds ratio
P09952378A0529|15 17|CHD
P09952378A0529|28 46|% confidence interval
P09952378A0529|64 81|positive serostatus
P09952378A0529|84 104|specific IgG antibodies
P09952378A0529|123 132|covariates
P09952425A0893|14 17|HIPP
P09952425A0893|22 40|HCX-lesioned animals
P09952425A0893|53 57|tasks
P09952425A0893|66 71|lesion
P09952425A0893|85 95|impairments
P09952425A0893|134 159|extrahippocampal structures
P09952425A0893|175 180|lesion
P09952425A0893|202 212|hippocampus
P09959737T0000|10 18|neutrinos
P09959737T0000|23 29|SN 1987A
P09961326T0000|9 20|fluctuations
P09961326T0000|23 46|one-dimensional interface
P09961326T0000|57 62|models
P09961682T0000|0 4|Model
P09961682T0000|7 28|spatiotemporal dynamics
P09961682T0000|31 46|stick-slip motion
P09964171T0000|0 2|NMR
P09964171T0000|14 18|atoms
P09964171T0000|22 41|periodic porous medium
P09964171T0000|58 80|nonuniform magnetic field
P09964770T0000|0 13|Microstructure
P09964770T0000|17 28|conductivity
P09964770T0000|31 60|hierarchical laminate composites
P09965234T0000|0 23|Anisotropic heat transport
P09965234T0000|29 46|octylcyanobiphenyl
P09965234T0000|48 50|8CB
P09965234T0000|52 64|liquid crystal
P09965909T0000|0 13|Direct approach
P09965909T0000|26 45|soliton perturbations
P09971776A0838|0 8|Mutations
P09971776A0838|22 34|CD4 regulation
P09971776A0838|22 24|CD4
P09971776A0838|43 50|residues
P09971776A0838|78 84|binding
P09971776A0838|87 89|Nef
P09971776A0838|96 103|receptor
P09971776A0838|111 113|W57
P09971776A0838|117 119|L58
P09971776A0838|133 159|AP-recruiting dileucine motif
P09971776A0838|167 181|acidic dipeptide
P09971776A0838|187 202|C-terminal region
P09971790A0856|0 15|Several mutations
P09971790A0856|28 50|endonuclease and helicase
P09971790A0856|28 39|endonuclease
P09971790A0856|43 60|helicase activities
P09971790A0856|77 117|amino-terminal-charge cluster mutant protein
P09971790A0856|119 132|D40A-D42A-D44A
P09971790A0856|148 175|AAV hairpin DNA binding activity
P09971806A1585|3 12|lytic cycle
P09971806A1585|15 18|KSHV
P09971806A1585|36 49|initial control
P09971806A1585|55 66|KSHV/Rta gene
P09971806A1585|91 107|tumor pathogenesis
P09971815A2094|33 60|several candidate latency genes
P09971815A2094|63 77|murine gammaHV68
P09971815A2094|95 99|genes
P09971815A2094|106 112|latency
P09971815A2094|129 143|different organs
P09971815A2094|159 181|multiple latency programs
P09971815A2094|188 208|multiple cellular sites
P09971815A2094|211 217|latency
P09971815A2094|227 233|regions
P09971815A2094|239 249|viral genome
P09971815A2094|251 261|v-bcl-2 gene
P09971815A2094|263 271|v-GCR gene
P09971815A2094|303 309|latency
P09971815A2094|318 326|gammaHV68
P09971815A2094|330 354|primate gammaherpesviruses
P09971822A1542|18 31|functional role
P09971822A1542|35 36|U1
P09971822A1542|39 68|NRS-mediated splicing inhibition
P09973351A1522|19 33|DcuS-DcuR system
P09973351A1522|19 22|DcuS
P09973351A1522|24 27|DcuR
P09973351A1522|44 61|external substrates
P09973607A0254|34 49|characterization
P09973607A0254|52 84|several Sp100 splice variant proteins
P09973607A0254|111 121|elucidation
P09973607A0254|138 146|Sp100 gene
P09974642T0000|0 8|Crossover
P09974642T0000|14 25|specific heat
P09974642T0000|34 40|magnets
P09974642T0000|50 74|critical spin-wave dynamics
P09976626T0000|0 6|Erratum
P09976626T0000|8 14|Absence
P09976626T0000|17 32|precursor effects
P09976626T0000|41 65|martensitic transformation
P09976626T0000|69 81|virgin crystal
P09976626T0000|84 90|Li metal
P09980944T0000|0 17|Interplane coupling
P09980944T0000|23 47|superconductor Y2Ba4Cu7O15
P09980944T0000|60 86|NQR spin-echo double resonance
P09982923T0000|0 18|Electronic structure
P09982923T0000|28 32|NiSi2
P09982923T0000|35 44|CoSi2 layer
P09982923T0000|47 52|bulk Si
P09983871T0000|0 17|Raman investigation
P09983871T0000|20 41|YBa2-xLaxCu3O7 ceramics
P09984526T0000|0 6|Effects
P09984526T0000|9 20|point defects
P09984526T0000|23 39|lattice parameters
P09984526T0000|42 55|semiconductors
P09985302T0000|0 22|Chaotic electron dynamics
P09985302T0000|48 60|shaped antidot
P09986796A1761|8 16|deletions
P09986796A1761|22 30|C terminal
P09986796A1761|37 46|amino acids
P09986796A1761|54 71|substantial effects
P09987176A0260|5 10|months
P09987176A0260|19 36|initial vaccination
P09987176A0260|41 49|vaccinees
P09987176A0260|61 75|annual follow-up
P09987176A0260|84 99|protective levels
P09987176A0260|102 109|anti-HAV
P09987634A1265|13 15|PRK
P09987634A1265|19 23|weeks
P09987634A1265|30 47|partial retreatment
P09987634A1265|53 64|necessary due
P09987634A1265|67 76|regression
P09987634A1265|82 90|PRK effect
P09987961A0093|3 14|early lesions
P09987961A0093|34 45|angiomatosis
P09987961A0093|47 58|vasculopathy
P09987961A0093|63 75|proliferation
P09987961A0093|78 89|synoviocytes
P09987961A0093|93 103|fibroblasts
P09988682T0033|0 15|Molecular cloning
P09988682T0033|18 26|human cDNA
P09988682T0033|36 79|novel beta1,6-N-acetylglucosaminyltransferase
P09988767A1496|0 35|Interspecific mouse back-cross analysis
P09988767A1496|49 52|loci
P09988767A1496|56 69|mouse 3Ost genes
P09988767A1496|73 91|syntenic assignments
P09988767A1496|107 118|human isologs
P09988767A1496|159 184|sequence-tagged site markers
P09988850A0000|3 8|Scales
P09988850A0000|11 29|Cognitive Impairment
P09988850A0000|39 58|Institutional Records
P09988850A0000|60 66|SCIRFIR
P09988850A0000|96 120|dementia rating instruments
P09988850A0000|136 142|records
P09988850A0000|158 174|institutionalized
P09988850A0000|176 203|elderly schizophrenia patients
P09988850A0000|248 262|long-term course
P09988850A0000|265 279|cognitive change
P09988850A0000|282 294|schizophrenia
P09988850A0000|310 334|available autopsy materials
P09989334A0964|24 40|processing signals
P09989334A0964|46 55|transcript
P09989334A0964|65 80|donor splice sites
P09989334A0964|87 112|polyadenylation site located
P09989334A0964|118 138|muscle-specific intron
P09989339A0968|33 43|brain weight
P09989339A0968|47 55|clearance
P09990057T0000|0 12|Recombination
P09990057T0000|16 28|transcription
P09990057T0000|34 60|endogenous Ig heavy chain locus
P09990057T0000|76 113|Ig heavy chain intronic enhancer core region
P09990057T0000|131 153|matrix attachment regions
P09990060A0803|10 15|motifs
P09990060A0803|44 71|inducible dyad symmetry element
P09990060A0803|97 114|remote IL-2 enhancer
P09990060A0803|103 114|IL-2 enhancer
P09990060A0803|121 132|CD18 promoter
P09990060A0937|16 49|coactivator CREB binding protein/p300
P09990060A0937|27 44|CREB binding protein
P09990060A0937|46 49|p300
P09990060A0937|69 77|GABPalpha
P09990060A0937|82 88|binding
P09990060A0937|91 99|GABPalpha
P09990060A0937|104 107|beta
P09990060A0937|113 131|dyad symmetry element
P09990060A0937|143 151|induction
P09990060A0937|154 166|IL-16 promoter
P09990060A0937|169 174|T cells
P09990315A0205|0 2|TPO
P09990315A0205|25 28|ERK1
P09990315A0205|30 33|ERK2
P09990315A0205|37 50|protein kinase C
P09990315A0205|52 54|PKC
P09990315A0205|64 66|TPO
P09990315A0205|86 108|PKC-dependent activation
P09990315A0205|86 88|PKC
P09990315A0205|111 114|ERKs
P09990315A0205|124 136|other agonists
P09990315A0205|146 153|thrombin
P09990315A0205|157 169|phorbol esters
P09990315A0205|190 202|PKC activation
P09990315A0205|190 192|PKC
P09990315A0205|210 217|agonists
P09990507A0000|0 9|BACKGROUND
P09990507A0000|16 52|ubiquitin-dependent proteolysis pathway
P09990507A0000|16 24|ubiquitin
P09990507A0000|55 69|ubiquitin ligase
P09990507A0000|71 72|E3
P09990507A0000|90 109|substrate selectivity
P09990507A0000|121 131|degradation
P09990507A0763|0 10|CONCLUSIONS
P09990507A0763|12 26|Fission yeast SCF
P09990507A0763|39 42|Pop1
P09990507A0763|46 49|Pop2
P09990507A0763|88 121|independent F-box/WD-repeat proteins
P09990507A0763|99 121|F-box/WD-repeat proteins
P09994942T0000|3 12|NMR studies
P09994942T0000|15 46|ABF4-type layered antiferromagnets
P09995847T0000|0 24|Optical-absorption spectra
P09995847T0000|26 50|crystal-field energy levels
P09995847T0000|55 77|transition line strengths
P09995847T0000|80 86|holmium
P09995847T0000|89 99|trigonal Na3
P09995897T0000|0 10|Observation
P09995897T0000|13 31|dipolar interactions
P09995897T0000|39 48|Pb0 defects
P09995897T0000|59 74|Si/SiO2 interface
P09999256T0000|0 24|Quantum-statistical theory
P09999256T0000|27 54|high-field transport phenomena
P09999742T0000|0 2|NH3
P09999742T0000|6 18|NO interaction
P09999742T0000|23 24|Si
P09999742T0000|36 43|surfaces
P10000253T0000|0 14|Chirality-glass
P10000253T0000|18 39|spin-glass correlations
P10000253T0000|45 77|two-dimensional random-bond XY model
P10001333T0038|0 13|Echo modulation
P10001333T0038|16 18|Pr3
P10001333T0038|21 25|YAlO3
P10001541T0000|0 9|Mechanisms
P10001541T0000|12 32|visible-light emission
P10001541T0000|37 65|electro-oxidized porous silicon
P10002245T0000|0 11|Far-infrared
P10002245T0000|19 30|conductivity
P10002245T0000|36 44|CuO chains
P10002245T0000|48 69|single-domain YBa2Cu3O7
P10002245T0000|71 82|delta crystal
P10006319T0000|0 15|Surface spin waves
P10006319T0000|19 39|Heisenberg ferrimagnet
P10006319T0000|45 64|single-ion anisotropy
P10006319T0000|66 73|uniaxial
P10006319T0000|77 87|nonuniaxial
P10007469T0000|17 23|librons
P10007469T0000|27 33|phonons
P10007469T0000|36 49|crystalline C60
P10007564T0000|0 28|Multilayer-relaxation geometry
P10007564T0000|32 50|electronic structure
P10007564T0000|54 54|W
P10008261T0000|0 20|Temperature dependence
P10008261T0000|26 59|sublattice spontaneous magnetization
P10008261T0000|62 70|YBa2Cu3O6
P10009565T0000|0 19|GW Gamma approximation
P10009565T0000|23 43|electron self-energies
P10009565T0000|46 59|semiconductors
P10009565T0000|63 72|insulators
P10013227T0000|0 19|Precision measurement
P10013227T0000|25 45|pion mass difference m pi
P10013227T0000|48 50|m pi
P10019841T0000|16 40|second post-Newtonian order
P10019841T0000|43 62|field-theory approach
P10021333A0674|0 17|Genetic experiments
P10021333A0674|23 38|mutants defective
P10021333A0674|41 47|apontic
P10021333A0674|51 55|bruno
P10021333A0674|63 83|functional interaction
P10021333A0674|96 100|genes
P10021350A0093|5 16|current model
P10021350A0093|18 35|Wingless/Wnt signal
P10021350A0093|18 25|Wingless
P10021350A0093|27 29|Wnt
P10021350A0093|46 67|Armadillo/beta-catenin
P10021350A0093|46 54|Armadillo
P10021350A0093|56 67|beta-catenin
P10021350A0093|91 96|nuclei
P10021350A0093|105 125|TCF/LEF family proteins
P10021350A0093|105 107|TCF
P10021350A0093|109 125|LEF family proteins
P10021350A0093|134 162|bipartite transcription factors
P10021350A0093|176 188|transcription
P10021350A0093|191 217|Wingless/Wnt responsive genes
P10021350A0093|191 198|Wingless
P10021350A0093|200 217|Wnt responsive genes
P10022032A0000|11 36|clinical antianginal studies
P10022032A0000|41 61|vasodilator nicorandil
P10022032A0000|63 65|NIC
P10022032A0000|85 129|beta-adrenergic receptor antagonists propranolol
P10022032A0000|85 107|beta-adrenergic receptor
P10022032A0000|138 145|atenolol
P10022032A0000|147 149|ATN
P10022032A0000|161 190|calcium channel blocker diltiazem
P10022032A0000|192 194|DTZ
P10022032A0000|212 225|cardiovascular
P10022032A0000|229 255|pharmacokinetic interactions
P10022210A0620|0 6|Factors
P10022210A0620|18 33|direct-immersion
P10022210A0620|35 36|DI
P10022210A0620|39 49|SPME process
P10022850A0929|13 34|amino-terminal fragment
P10022850A0929|48 57|C/H1 domain
P10022850A0929|74 85|coactivation
P10022850A0929|88 103|Zta transcription
P10022850A0929|88 90|Zta
P10022850A0929|107 131|viral reactivation function
P10022858A0985|12 41|potent splicing enhancer sequence
P10022858A0985|82 96|20-kDa SR protein
P10022867A1069a|0 10|Elimination
P10022867A1069a|13 16|ETH1
P10022867A1069a|19 29|apn1 strains
P10022867A1069a|19 22|apn1
P10022867A1069a|43 66|spontaneous mutation rates
P10022867A1069a|71 77|31-fold
P10022867A1069a|91 98|wild type
P10022867A1069a|113 121|reversion
P10022867A1069a|124 130|adenine
P10022867A1069a|133 149|lysine prototrophy
P10022867A1069b|0 10|Elimination
P10022867A1069b|13 16|ETH1
P10022867A1069b|19 29|apn1 strains
P10022867A1069b|19 22|apn1
P10022867A1069b|43 66|spontaneous mutation rates
P10022867A1069b|71 77|31-fold
P10022867A1069b|91 98|wild type
P10022867A1069b|113 121|reversion
P10022867A1069b|124 130|adenine
P10022867A1069b|133 149|lysine prototrophy
P10022875A1265|20 36|other Ras effectors
P10022875A1265|25 27|Ras
P10022875A1265|55 64|PI 3-kinase
P10022875A1265|91 93|Pak
P10022880A0000|0 35|Mammalian Ras GTPase-activating protein
P10022880A0000|37 39|GAP
P10022880A0000|42 52|p120 Ras-GAP
P10022880A0000|50 52|GAP
P10022880A0000|78 90|downregulator
P10022880A0000|94 101|effector
P10022880A0000|104 114|Ras proteins
P10022880A0000|122 132|precise role
P10022880A0000|135 172|Ras-mediated signal transduction pathways
P10022880A0000|135 137|Ras
P10022880A0000|175 181|unclear
P10022905A0446|5 16|mog-1 alleles
P10022905A0446|24 42|premature stop codons
P10022905A0446|59 69|null alleles
P10022905A0446|80 95|missense mutation
P10022905A0446|115 130|residual activity
P10022905A0446|132 140|mog-1 mRNA
P10022905A0446|158 165|germ line
P10022905A0446|169 182|somatic tissues
P10022905A0446|197 206|ubiquitous
P10022921A0608|17 24|SIN3 gene
P10022921A0608|27 49|Saccharomyces cerevisiae
P10022921A0608|51 54|pst1
P10022921A0608|72 84|cell viability
P10022925A0870|3 21|Nmd3 protein sequence
P10022925A0870|43 60|recognizable motifs
P10022925A0870|63 75|known function
P10022978A1261|20 33|various repeats
P10022978A1261|71 97|beta-heterochromatic regions
P10022978A1261|114 132|major chromosome arms
P10024383T0000|0 9|Calcitonin
P10024383T0000|37 58|periosteal hyperostosis
P10024383T0000|62 81|trabecular osteopenia
P10024383T0000|87 109|spinal hyperostotic mouse
P10024383T0000|111 117|twy/twy
P10024383T0000|111 113|twy
P10024383T0000|115 117|twy
P10024498A0783|0 34|Electrophoretic mobility-shift assays
P10024498A0783|51 56|HNF-3 X
P10024498A0783|60 65|Y sites
P10024498A0783|86 90|sites
P10024498A0783|110 119|HNF-3alpha
P10024498A0783|123 131|HNF-3beta
P10024882A0541|25 28|cdk7
P10024882A0541|48 69|carboxy-terminal domain
P10024882A0541|71 73|CTD
P10024882A0541|77 84|RNA pol II
P10024882A0541|77 82|RNA pol
P10024882A0541|99 113|promoter opening
P10025050A1052|15 35|H2-receptor antagonist
P10025050A1052|15 25|H2-receptor
P10025050A1052|58 72|triple therapies
P10025050A1052|77 86|omeprazole
P10025050A1052|89 100|lansoprazole
P10025506A0079|2 7|humans
P10025506A0079|14 43|tissue-specific plastin isoforms
P10025506A1078|2 5|TATA
P10025506A1078|8 18|Inr sequence
P10026146A0680|3 12|inhibition
P10026146A0680|18 31|RIalpha subunit
P10026146A0680|54 76|nanomolar concentrations
P10026146A0680|79 82|cAMP
P10026146A0680|84 86|Ka =
P10026146A0680|89 90|nM
P10026146A0680|114 117|PrKX
P10026146A0680|132 158|cAMP-dependent protein kinase
P10026146A0680|176 198|lower cAMP concentrations
P10026146A0680|206 215|holoenzyme
P10026146A0680|223 235|Calpha subunit
P10026146A0680|238 264|cAMP-dependent protein kinase
P10026211A0136|0 7|Proteins
P10026211A0136|22 29|PEPCK CRE
P10026211A0136|40 57|CRE-binding protein
P10026211A0136|59 62|CREB
P10026211A0136|67 73|members
P10026211A0136|79 107|CCAAT/enhancer-binding protein
P10026211A0136|109 113|C/EBP
P10026211A0543|20 33|pDeltaCREC/EBP
P10026211A0543|20 29|pDeltaCREC
P10026211A0543|31 33|EBP
P10026211A0543|40 49|C/EBPalpha
P10026211A0543|53 56|beta
P10026211A0543|63 66|CREB
P10026211A0543|87 116|complete glucocorticoid response
P10026211A0543|147 167|H4IIE rat hepatoma cells
P10026229A0950|18 28|mutagenesis
P10026229A0950|35 43|Engrailed
P10026229A0950|47 55|Pbx1 sites
P10026229A0950|69 90|other unidentified sites
P10026229A0950|111 136|transcriptional enhancement
P10026229A0950|152 167|intronic fragment
P10026275A0549|0 32|Several secondary structure elements
P10026784A0331|22 43|developmental functions
P10026784A0331|57 76|transcription factors
P10026784A0331|95 112|POU DNA binding motif
P10026784A0331|119 123|roles
P10026784A0331|126 145|mammalian development
P10026784A0929|0 35|High-affinity site-specific DNA binding
P10026784A0929|38 66|POU domain transcription factors
P10026784A0929|82 93|POU-specific
P10026784A0929|82 84|POU
P10026784A0929|100 114|POU-homeodomain
P10026784A2166|5 16|Oct-1 crystal
P10026784A2166|5 9|Oct-1
P10026784A2166|21 38|POU-specific domain
P10026784A2166|50 62|GCAT half-site
P10026784A2166|72 92|corresponding sequence
P10026784A2166|108 130|Pit-1 POU-specific domain
P10026784A2166|108 112|Pit-1
P10026784A2166|113 130|POU-specific domain
P10026784A2166|132 135|GTAT
P10026784A2166|152 157|strand
P10026824A0309|0 27|Systematic functional analysis
P10026824A0309|30 50|V1a/V2 hybrid receptors
P10026824A0309|30 32|V1a
P10026824A0309|64 86|second intracellular loop
P10026824A0309|92 102|V1a receptor
P10026824A0309|129 145|efficient coupling
P10026824A0309|148 152|Gq/11
P10026824A0309|164 185|third intracellular loop
P10026824A0309|191 200|V2 receptor
P10026824A0309|227 234|coupling
P10026824A0309|237 238|Gs
P10027498A0536|0 17|Most other end points
P10027498A0536|75 85|U.S. program
P10027498A0536|103 103|p
P10029337A0406|3 17|fatigue exercise
P10029337A0406|34 62|high blood lactate concentration
P10029337A0406|69 70|SD
P10029337A0406|75 78|mmol
P10029337A0406|80 80|l
P10029337A0406|101 119|serum creatine kinase
P10029337A0406|121 122|CK
P10029337A0406|142 145|days
P10029337A0406|151 152|SD
P10029337A0406|157 157|U
P10029337A0406|159 159|l
P10029860A0605|5 23|radiological aspects
P10029860A0605|44 53|categories
P10029860A0605|57 97|type I-presenting variable sinusoidal filling
P10029917A0366|0 6|Results
P10029917A0366|36 49|myofibroblasts
P10029917A0366|109 128|muscle cell dispersion
P10029917A0366|149 185|medium-sized damaged portal vein branches
P10031854T0000|0 19|New Langevin equations
P10031854T0000|60 72|asymmetric top
P10032519T0000|0 19|Radiative corrections
P10032519T0000|22 30|beta decay
P10032519T0000|51 66|fourth generation
P10032581T0000|0 43|Depth-controlled grazing-incidence diffraction
P10032581T0000|46 56|synchrotron
P10033973T0000|0 18|Oscillatory exchange
P10033973T0000|21 25|atoms
P10033973T0000|33 37|traps
P10033973T0000|48 62|Bose condensates
P10034615T0000|0 21|Structure determination
P10034615T0000|26 66|adsorbate-induced multilayer reconstruction
P10034615T0000|70 70|x
P10034615T0000|74 77|H/Ni
P10035841T0000|0 15|Magnetic trapping
P10035841T0000|18 45|spin-polarized atomic hydrogen
P10036181A0603|0 11|Northern blot
P10036181A0603|21 41|hybridization analyses
P10036181A0603|50 69|GPR34 mRNA transcripts
P10036181A0603|72 83|several human
P10036181A0603|87 101|rat brain regions
P10036191A0000|3 20|microphthalmia-TFE
P10036191A0000|22 24|MiT
P10036191A0000|26 34|subfamily
P10036191A0000|37 100|basic helix-loop-helix leucine zipper (bHLH-ZIP) transcription factors
P10036191A0000|37 70|basic helix-loop-helix leucine zipper
P10036191A0000|72 79|bHLH-ZIP
P10036191A0000|81 100|transcription factors
P10036191A0000|111 114|TFE3
P10036191A0000|116 119|TFEB
P10036191A0000|121 124|TFEC
P10036191A0000|129 132|Mitf
P10036191A0000|168 196|tissue-specific gene expression
P10036191A0000|168 186|tissue-specific gene
P10036191A0000|199 217|several cell lineages
P10037004A0000|11 22|patients aged
P10037004A0000|26 30|years
P10037004A0000|35 60|acute lymphoblastic leukemia
P10037004A0000|62 64|ALL
P10037004A0000|76 90|third bone marrow
P10037004A0000|92 93|BM
P10037004A0000|95 101|relapse
P10037004A0000|104 113|refractory
P10037004A0000|116 132|first-line therapy
P10037004A0000|149 171|Italian cooperative study
P10037378A0176|3 14|dorsal nerves
P10037378A0176|20 24|penis
P10037378A0176|29 40|anesthetized
P10037378A0176|56 64|lidocaine
P10037460A0221|11 29|muscarinic receptors
P10037460A0221|45 58|memory function
P10037460A0221|81 99|ligand acetylcholine
P10037576T0000|0 25|Early-onset scleral necrosis
P10037576T0000|31 36|iodine
P10037576T0000|41 58|plaque radiotherapy
P10037576T0000|62 83|ciliochoroidal melanoma
P10037681A0494|0 20|Successful interaction
P10037681A0494|23 25|ARF
P10037681A0494|29 37|PKC-alpha
P10037681A0494|42 45|PLD1
P10037681A0494|65 82|C-terminal fragment
P10037681A0494|85 93|human PLD1
P10037681A0494|103 104|D4
P10037681A0494|124 135|active mutant
P10037681A0494|138 141|RhoA
P10037681A0494|143 152|RhoAVal-14
P10037774A0366|29 54|signal transduction pathways
P10037774A0366|72 98|OM-induced LDLR transcription
P10037774A0366|82 85|LDLR
P10041728T0000|0 18|Vacuum Rabi splitting
P10041728T0000|31 53|linear-dispersion theory
P10041728T0000|55 62|Analysis
P10041728T0000|66 89|experimental observations
P10043466T0000|0 19|High-pressure effects
P10043466T0000|22 49|ultrafast-relaxation kinetics
P10043466T0000|52 59|excitons
P10043466T0000|62 81|polydiacetylene 4BCMU
P10044519T0000|15 28|turbulent flows
P10044519T0000|31 38|polymers
P10046849T0000|0 40|Large scale electronic structure calculations
P10047970T0013|0 21|Current world literature
P10049357A0608|5 11|results
P10049357A0608|20 22|Ski
P10049357A0608|40 50|HDAC complex
P10049357A0608|58 60|Ski
P10049357A0608|77 101|transcriptional repression
P10049359A1073|0 13|Recombinant unr
P10049359A1073|37 50|recombinant PTB
P10049359A1073|62 81|translation dependent
P10049359A1073|87 100|rhinovirus IRES
P10049742T0000|0 7|Analysis
P10049742T0000|13 36|consensus binding sequence
P10049742T0000|43 59|DNA-binding domain
P10049742T0000|62 64|ZF5
P10049775T0000|0 6|Mapping
P10049775T0000|12 54|human Voltage-Dependent Anion Channel isoforms 1
P10049775T0000|12 53|human Voltage-Dependent Anion Channel isoforms
P10049912T0000|0 13|Identification
P10049912T0000|16 21|RNase T
P10049912T0000|25 43|high-copy suppressor
P10049912T0000|49 61|UV sensitivity
P10049912T0000|76 112|single-strand DNA exonuclease deficiency
P10050883A0967|0 9|Inhibition
P10050883A0967|12 39|phosphatidylinositol-3 kinase
P10050883A0967|51 67|significant effect
P10050883A0967|70 84|p53 conformation
P10050883A0967|70 72|p53
P10050883A0967|103 119|significant effect
P10050883A0967|122 142|Tpo-enhanced viability
P10050883A0967|122 124|Tpo
P10051030A1080|26 30|males
P10051030A1080|33 47|semen production
P10051030A1080|63 69|strains
P10051030A1080|71 78|CP levels
P10051030A1080|89 96|regimens
P10051400A0000|3 15|Lp mouse mutant
P10051400A0000|36 62|severe human neural tube defect
P10051400A0000|64 66|NTD
P10051400A0000|69 87|cranio-rachischisis
P10051488A1293|0 14|Further analysis
P10051488A1293|17 40|AP-1 DNA binding activities
P10051488A1293|47 59|14-day culture
P10051488A1293|69 72|HSCs
P10051488A1293|92 116|high mobility AP-1 complexes
P10051488A1293|118 123|HMAP-1
P10051488A1610|0 8|Mutations
P10051488A1610|14 21|AP-1 site
P10051488A1610|27 40|TIMP-1 promoter
P10051488A1610|65 70|HMAP-1
P10051488A1610|80 84|% loss
P10051488A1610|117 120|HSCs
P10052371A0171|0 10|STUDY DESIGN
P10052371A0171|12 40|Salivary immunoglobulin A levels
P10052371A0171|12 34|Salivary immunoglobulin A
P10052371A0171|51 58|subjects
P10052371A0171|76 84|occasions
P10052371A0171|115 121|smoking
P10052371A0171|131 134|days
P10052371A0171|140 148|cessation
P10052371A0171|151 157|smoking
P10052371A0171|170 176|14th day
P10052371A0171|182 190|cessation
P10052878A0135|10 27|high set-up accuracy
P10052878A0135|31 45|reproducibility
P10052878A0135|49 57|mandatory
P10053852T0000|0 3|Role
P10053852T0000|6 7|g2
P10053852T0000|21 29|Schwinger
P10053852T0000|33 61|Gerasimov-Drell-Hearn sum rules
P10054976T0000|0 11|Spectroscopy
P10054976T0000|14 25|negative ions
P10054976T0000|35 55|multiphoton detachment
P10054976T0000|59 77|Raman coupling regime
P10055173T0000|0 19|Band structure effects
P10055173T0000|22 40|transport properties
P10055173T0000|43 66|icosahedral quasicrystals
P10059496T0000|0 26|Acoustic transmission spectra
P10059496T0000|32 45|Penrose lattice
P10063122T0000|0 22|Two-Channel Kondo Lattice
P10063122T0000|26 40|Incoherent Metal
P10063739A0601|0 49|Basal midexpiratory lower esophageal sphincter pressure
P10063739A0601|65 74|study group
P10063739A0601|81 82|SD
P10063739A0601|93 96|mmHg
P10063739A0601|101 108|controls
P10063739A0601|119 122|mmHg
P10063739A0601|157 159|EVS
P10063739A0601|162 164|EVL
P10064604A0824|0 3|CPDs
P10064604A0824|16 20|sites
P10064604A0824|41 46|TFIIIA
P10064604A0824|63 73|rapid repair
P10065176A0657|25 45|hormone receptor status
P10065176A0657|56 60|cases
P10065176A0657|68 86|lymph node metastases
P10065176A0657|94 112|lymph node metastases
P10065176A0657|115 125|clandestine
P10065176A0657|129 143|macrometastases
P10065684A0916|5 13|other hand
P10065684A0916|15 22|subjects
P10065684A0916|27 37|air trapping
P10065684A0916|39 52|residual volume
P10065684A0916|54 55|RV
P10065684A0916|58 74|total lung capacity
P10065684A0916|76 78|TLC
P10065684A0916|83 83|%
P10065684A0916|102 108|higher n
P10065684A0916|110 112|mit
P10065684A0916|143 151|mt x microm
P10065684A0916|157 157|p
P10065684A0916|167 183|shorter sarcomeres
P10065684A0916|185 185|L
P10065684A0916|187 189|sar
P10065684A0916|196 203|subjects
P10065684A0916|215 235|functional abnormality
P10065684A0916|261 266|microm
P10065684A0916|268 268|p
P10066790A0497|0 12|Gel filtration
P10066790A0497|14 34|sedimentation velocity
P10066790A0497|39 68|immunoprecipitation experiments
P10066790A0497|81 85|beta4
P10066790A0497|101 119|multisubunit complex
P10066790A0497|121 124|AP-4
P10066790A0497|145 161|sigma4 polypeptide
P10066790A0497|168 199|additional adaptor subunit homologs
P10066790A0497|205 207|mu4
P10066790A0497|209 215|mu-ARP2
P10066790A0497|220 226|epsilon
P10066798A0391|0 32|Cyclin D1-associated kinase activity
P10066798A0391|0 24|Cyclin D1-associated kinase
P10066798A0391|36 48|protein levels
P10066798A0391|64 76|mammary tumors
P10066798A0391|81 108|murine mammary tumor virus-pp60
P10066798A0391|105 108|pp60
P10066798A0391|110 118|c-src527F
P10066798A0391|120 133|transgenic mice
P10066815T0000|3 30|SH2 domain-containing inositol
P10066815T0000|34 44|phosphatase
P10066815T0000|46 49|SHIP
P10066815T0000|62 71|p85 subunit
P10066815T0000|74 97|phosphoinositide 3-kinase
P10066815T0000|104 134|FcgammaRIIb1-mediated inhibition
P10066815T0000|104 115|FcgammaRIIb1
P10066815T0000|137 158|B cell receptor signaling
P10066815T0000|137 149|B cell receptor
P10068040A0136|13 23|mouse genome
P10068040A0136|36 41|copies
P10068040A0136|47 55|ubc-9 gene
P10068418A1194|12 29|bone mineral density
P10068418A1194|41 48|total hip
P10068418A1194|53 61|total body
P10068418A1194|81 90|raloxifene
P10068418A1194|123 130|estrogen
P10068418A1194|133 150|alendronate therapy
P10068446A0124|15 24|studies due
P10068446A0124|40 50|thiol agents
P10068446A0124|56 70|PKC preparations
P10068446A0124|56 58|PKC
P10068446A0124|75 91|sensitive reaction
P10068446A0124|94 96|BPO
P10068446A0124|101 128|redox-active cysteine residues
P10068446A0124|131 133|PKC
P10068637A1320|14 21|Csx/Nkx2
P10068637A1320|14 16|Csx
P10068637A1320|18 21|Nkx2
P10068674A0644|42 47|Lyp RNA
P10068674A0644|49 52|Lyp2
P10068834A0713|3 7|costs
P10068834A0713|12 13|DM
P10068834A0713|24 25|PE
P10068834A0713|27 28|DM
P10068834A0713|39 40|VR
P10068834A0713|44 45|DM
P10068834A0713|55 57|MR.
P10069815A0285|34 54|functional interaction
P10069815A0285|62 65|Doa4
P10069815A0285|72 81|proteasome
P10070158A0573|0 24|Independent splicing events
P10070158A0573|56 68|cassette exons
P10070158A0573|104 128|second transmembrane domain
P10071205A0833|11 15|genes
P10071205A0833|25 43|putative upstream ORF
P10071205A0833|50 53|STA2
P10071205A0833|78 86|AUG codons
P10071205A0833|94 105|major cistron
P10071212A0399|18 32|O. australiensis
P10071761A2374|11 17|mapping
P10071761A2374|23 36|promoter region
P10071761A2374|59 93|putative promoter regulatory sequences
P10071761A2374|118 142|transcriptional regulation
P10071761A2374|145 158|UCP2 expression
P10071761A2374|145 148|UCP2
P10071761A2374|200 206|factors
P10071806A0377|9 21|resectability
P10071806A0377|30 43|5-year survival
P10072205A0167|44 45|ML
P10072205A0167|49 60|MAP estimates
P10072205A0167|71 80|conditions
P10072205A0167|91 108|point approximation
P10072205A0167|111 123|density values
P10072205A0167|129 151|conditional distribution
P10072205A0167|154 166|such estimates
P10072774A0537|0 5|RT-PCR
P10072774A0537|41 72|degenerate oligonucleotide primers
P10072774A0537|78 96|ligand binding domain
P10072774A0537|98 100|LBD
P10072774A0537|109 128|beta integrin subunits
P10072774A0537|132 138|Bge cDNA
P10073899A0740|3 26|lowest culture failure rate
P10073899A0740|35 38|cent
P10073899A0740|52 54|EAF
P10073899A0740|73 76|cent
P10073899A0740|82 84|CVS
P10073940A0335|0 16|Ectopic expression
P10073940A0335|19 24|d-axin
P10073940A0335|34 50|Wingless signaling
P10073940A0335|34 41|Wingless
P10073947A1110|3 26|corresponding differences
P10073947A1110|29 33|FVIIa
P10073947A1110|37 41|PAI-1
P10074135T0000|0 6|Primary
P10074135T0000|10 36|secondary structural elements
P10074135T0000|48 56|synthesis
P10074135T0000|59 94|barley yellow dwarf virus subgenomic RNA1
P10074282A0236|5 13|other side
P10074282A0236|22 31|aortic ring
P10074282A0236|47 51|L-NNA
P10074282A0236|53 73|NO-synthesis inhibitor
P10074282A0236|77 89|methylene blue
P10074282A0236|91 113|soluble cGMPase inhibitor
P10074282A0236|98 104|cGMPase
P10074282A0236|119 125|changes
P10074425A0729|13 24|inactivation
P10074425A0729|30 48|cyclin E-Cdk2 complex
P10074425A0729|61 77|mitogen starvation
P10074425A0729|94 97|MEFs
P10074425A0729|107 124|homozygous deletion
P10074425A0729|130 136|p27 gene
P10074520T0000|0 13|Identification
P10074520T0000|17 32|characterization
P10074520T0000|35 40|IS2404
P10074520T0000|44 49|IS2606
P10074520T0000|70 78|sequences
P10074520T0000|82 90|detection
P10074520T0000|93 113|Mycobacterium ulcerans
P10074520T0000|116 118|PCR
P10074903A0915|19 25|results
P10074903A0915|61 71|p202 protein
P10074903A0915|88 116|cell growth retardation activity
P10074903A0915|122 125|IFNs
P10074903A0915|153 168|p21 protein levels
P10074903A0915|153 162|p21 protein
P10074921A1169|0 13|Similar results
P10074921A1169|35 61|HepG2 hepatoblastoma cell line
P10074921A1169|70 74|wt p53
P10075415A1178|0 16|Partial sequencing
P10075415A1178|22 37|region downstream
P10075415A1178|40 46|ORF-Pto
P10075415A1178|55 62|homology
P10075415A1178|68 77|ru/AB genes
P10075415A1178|89 100|UV resistance
P10075415A1178|106 117|plasmid pPSR1
P10076007A0656|3 6|MSY2
P10076007A0656|17 22|kinase
P10076007A0656|28 40|casein kinase 2
P10076007A0656|28 39|casein kinase
P10076007A0656|45 50|kinase
P10076007A0656|74 80|mRNP3+4
P10076007A0656|83 89|oocytes
P10076007A0656|98 115|unidentified kinase
P10077188A1172|16 33|helicase-like genes
P10077188A1172|52 63|biosynthesis
P10077188A1172|66 77|nucleic acids
P10077188A1172|81 88|proteins
P10077188A1172|100 104|genes
P10077188A1172|138 146|heat shock
P10077188A1172|174 182|synthesis
P10077188A1172|185 188|mRNA
P10077533A0976|19 32|molecular tools
P10077533A0976|39 57|final identification
P10077533A0976|63 65|MKS
P10077533A0976|72 79|MUL genes
P10078734A0480|3 23|H-reflex recovery curve
P10078734A0480|40 50|stimulation
P10078734A0480|56 66|median nerve
P10078734A0480|96 114|flexor carpi radialis
P10078876A0000|3 9|origins
P10078876A0000|21 32|light changes
P10078876A0000|47 62|neuronal activity
P10078876A0000|64 77|optical signals
P10078876A0000|97 118|rat somatosensory cortex
P10078876A0000|123 136|optical imaging
P10078876A0000|138 159|microspectrophotometry
P10078876A0000|164 185|laser-Doppler flowmetry
P10078876A0000|190 203|dynamic changes
P10078876A0000|206 233|local hemoglobin concentration
P10078876A0000|211 220|hemoglobin
P10078876A0000|237 247|oxygenation
P10079173A0000|0 29|Human neuronal Elav-like proteins
P10079173A0000|42 69|RNP-type RNA recognition motifs
P10079173A0000|71 74|RRMs
P10080436T0000|0 9|Comparison
P10080436T0000|12 22|frequencies
P10080436T0000|25 42|atrial fibrillation
P10080436T0000|48 67|coronary artery bypass
P10080436T0000|98 118|cardiopulmonary bypass
P10080875A0772|3 9|results
P10080875A0772|12 29|supershift analysis
P10080875A0772|35 52|specific antibodies
P10080875A0772|60 79|transcription factors
P10080875A0772|104 112|complexes
P10080875A0772|125 146|NF-kappaB components p50
P10080875A0772|125 133|NF-kappaB
P10080875A0772|144 146|p50
P10080875A0772|150 152|p65
P10080875A0772|170 191|other NF-kappaB proteins
P10080875A0772|175 191|NF-kappaB proteins
P10080875A0772|193 195|p52
P10080875A0772|197 201|c-Rel
P10080875A0772|203 206|Rel B
P10080875A0772|209 220|AP-1 proteins
P10080875A0772|222 226|c-Fos
P10080875A0772|228 232|C-Jun
P10080875A0772|235 238|CREB
P10080875A0772|241 249|C/EBPbeta
P10080875A0772|251 256|NF-IL6
P10080901A0271|6 13|peptides
P10080901A0271|32 49|individual elements
P10080901A0271|52 69|secondary structure
P10080901A0271|84 99|N-terminal domain
P10080901A0271|105 122|ribosomal protein L9
P10082137A0262|3 9|results
P10082137A0262|20 28|IFN-gamma
P10082137A0262|42 58|rapid accumulation
P10082137A0262|61 85|interferon regulated factor
P10082137A0262|87 96|IRF)-1 mRNA
P10082137A0262|87 89|IRF
P10082137A0262|93 96|mRNA
P10082137A0262|119 142|dose-dependent inhibition
P10082137A0262|145 168|alpha1(I) procollagen mRNA
P10082137A0262|145 150|alpha1
P10082137A0262|154 178|procollagen mRNA expression
P10082137A0262|181 195|skin fibroblasts
P10082137A0262|200 221|several different donors
P10082554T0000|0 16|Functional domains
P10082554T0000|19 46|c-myc promoter binding protein 1
P10082554T0000|19 45|c-myc promoter binding protein
P10082554T0000|57 81|transcriptional repression
P10082554T0000|85 104|cell growth regulation
P10082570A0440|25 33|gene UBP43
P10082570A0440|29 33|UBP43
P10082573A1015|5 11|results
P10082573A1015|46 48|HS2
P10082573A1015|50 52|HS3
P10082573A1015|57 59|HS4
P10082573A1015|73 84|integral unit
P10082573A1015|95 122|human globin gene transcription
P10082573A1015|95 109|human globin gene
P10082573A1015|126 136|holocomplex
P10082573A1015|186 191|DNase I
P10082573A1015|186 190|DNase
P10082573A1015|192 216|hypersensitive holocomplex
P10082573A1015|249 281|high-level globin gene transcription
P10082573A1015|259 268|globin gene
P10082585A0512|10 33|additional non-Sir factors
P10082585A0512|44 56|rDNA silencing
P10082585A0512|70 82|genetic screen
P10082585A0512|100 108|mutations
P10082585A0512|134 146|reporter genes
P10082585A0512|166 169|rDNA
P10084294A0219|14 22|great need
P10084294A0219|35 68|EPO-stimulated erythroid progenitors
P10084294A0219|35 37|EPO
P10084294A0219|87 99|serum ferritin
P10084294A0219|103 129|transferrin saturation levels
P10084294A0219|103 113|transferrin
P10084294A0219|155 166|microg/liter
P10084294A0219|172 172|%
P10085088A0918|5 11|results
P10085088A0918|27 36|p33 subunit
P10085088A0918|39 42|eIF3
P10085088A0918|50 62|important role
P10085088A0918|68 82|initiation phase
P10085088A0918|85 100|protein synthesis
P10085088A0918|111 127|RNA-binding domain
P10085088A0918|141 155|optimal activity
P10085120A0000|23 39|signaling pathways
P10085120A0000|49 67|photodynamic therapy
P10085120A0000|69 71|PDT
P10085120A0000|77 85|hypericin
P10085140A1004|5 11|results
P10085140A1004|24 28|ATF-2
P10085140A1004|35 45|central role
P10085140A1004|48 64|TGF-beta signaling
P10085140A1004|48 55|TGF-beta
P10085140A1004|76 94|common nuclear target
P10085140A1004|101 104|Smad
P10085140A1004|108 119|TAK1 pathways
P10085140A1004|108 111|TAK1
P10085383A1367|0 7|KEY WORDS
P10085383A1367|9 17|Melaleuca
P10085383A1367|19 32|Lake Okeechobee
P10085383A1367|34 45|Littoral zone
P10085383A1367|47 56|Water level
P10085383A1367|58 75|Regulation schedule
P10085505A1184|3 14|systolic peak
P10085505A1184|17 29|pulmonary vein
P10085505A1184|33 38|higher
P10085505A1184|46 58|diastolic peak
P10085505A1184|70 74|cases
P10085605A0239|0 8|Specimens
P10085605A0239|23 39|alpha-fetoprotein
P10085605A0239|41 59|unconjugated estriol
P10085605A0239|61 72|free alpha hCG
P10085605A0239|65 72|alpha hCG
P10085605A0239|77 84|total hCG
P10085605A0239|82 84|hCG
P10085697T0000|0 39|FASEB Federal Funding Consensus Conference FY
P10086544A0504|42 58|intensive care unit
P10086544A0504|72 76|hours
P10086544A0504|82 92|termination
P10086544A0504|95 97|CPB
P10086544A0504|99 107|heart rate
P10086544A0504|109 121|blood pressure
P10086544A0504|127 140|atrial pressure
P10086544A0504|142 180|central-peripheral temperature difference
P10086544A0504|182 229|arterial-central venous oxygen saturation difference
P10086544A0504|231 241|urine output
P10086544A0504|243 257|serum creatinine
P10086544A0504|259 265|lactate
P10086544A0504|269 292|neutrophil elastase levels
P10086544A0504|269 286|neutrophil elastase
P10086544A0504|297 327|Doppler echocardiographic factors
P10086544A0504|349 394|preejection period/left-ventricular ejection time
P10086544A0504|399 413|cumulative doses
P10086544A0504|416 429|catecholamines
P10086544A0504|431 441|epinephrine
P10086544A0504|444 452|enoximone
P10086544A0504|457 466|furosemide
P10086725A0000|0 8|MDS1/EVI1
P10086725A0000|0 3|MDS1
P10086725A0000|5 8|EVI1
P10086725A0000|10 16|located
P10086725A0000|19 28|chromosome
P10086725A0000|30 36|band q26
P10086725A0000|46 89|zinc-finger DNA-binding transcription activator
P10086725A0000|103 126|normal hematopoietic cells
P10086725A0000|141 160|several normal tissues
P10087213A0878|0 7|Analysis
P10087213A0878|13 28|protein sequences
P10087213A0878|39 48|replicases
P10087213A0878|85 118|H. pylori plasmid replication proteins
P10087213A0878|143 155|distinct class
P10087213A0878|158 180|H. pylori plasmid proteins
P10087549A0720|3 10|JTc delta
P10087549A0720|24 29|groups
P10087549A0720|49 56|JTc delta
P10087549A0720|62 68|VT group
P10087549A0720|74 75|ms
P10087549A0720|81 82|ms
P10087549A0720|87 94|JTc delta
P10087549A0720|100 107|PVC group
P10087549A0720|113 116|msec
P10087549A0720|122 125|msec
P10087549A0720|133 140|JTc delta
P10087549A0720|146 157|control group
P10087549A0720|163 164|ms
P10087549A0720|170 172|ms.
P10087993A0782|11 18|deletion
P10087993A0782|24 38|upstream portion
P10087993A0782|44 56|delta promoter
P10087993A0782|65 76|fold decrease
P10087993A1352|0 23|Site-directed mutagenesis
P10087993A1352|33 37|sites
P10087993A1352|44 63|repressor proteins BP1
P10087993A1352|67 69|BP2
P10087993A1352|75 89|upstream portion
P10087993A1352|95 122|beta globin gene flanking region
P10087993A1352|132 143|fold increase
P10087993A1352|146 161|promoter activity
P10090125A0750|15 38|alpha1 antagonist prazosin
P10090125A0750|57 57|M
P10090125A0750|62 71|relaxation
P10090146T0000|0 21|Differential expression
P10090146T0000|24 32|AP-2alpha
P10090146T0000|36 43|AP-2beta
P10090146T0000|59 69|chick retina
P10090146T0000|71 80|repression
P10090146T0000|83 104|R-FABP promoter activity
P10090146T0000|83 96|R-FABP promoter
P10090146T0000|107 110|AP-2
P10090535A1194|3 11|algorithm
P10090535A1194|16 24|limited TG
P10090535A1194|34 34|%
P10090535A1194|36 39|apoB
P10090535A1194|48 48|%
P10090535A1194|53 54|Lp
P10090535A1194|67 67|%
P10090535A1194|78 92|high-risk groups
P10090943A1426|3 11|mean value
P10090943A1426|17 21|CD79b
P10090943A1426|27 31|CD79b
P10090943A1426|68 69|SD
P10090943A1426|72 83|normal donors
P10090943A1426|98 99|SD
P10090943A1426|102 106|B-CLL
P10090943A1426|108 109|P =
P10090943A1976|2 13|normal B cells
P10090943A1976|29 35|variant
P10090943A1976|51 84|CD79b posttranscriptional regulation
P10090943A1976|51 55|CD79b
P10090943A1976|100 114|activation stage
P10090943A1976|120 130|normal B cell
P10090943A1976|140 144|B-CLL
P10091594A0284|0 20|Conformational studies
P10091594A0284|30 58|secondary structure predictions
P10091594A0284|60 61|CD
P10091594A0284|65 79|NMR spectroscopy
P10091594A0284|92 102|ELISA assays
P10091594A0284|117 123|greater
P10091594A0284|129 138|propensity
P10091594A0284|144 150|epitope
P10091594A0284|154 167|helix formation
P10091594A0284|171 176|higher
P10091594A0284|195 203|anti-K159
P10091619A0104|0 5|Schwab
P10091619A0104|9 24|England ADL scores
P10091619A0104|56 56|%
P10091619A0104|77 82|scores
P10091619A0104|94 94|%
P10092132A0285|0 14|High-level gains
P10092132A0285|16 19|HLGs
P10092132A0285|21 30|indicative
P10092132A0285|33 50|gene amplifications
P10092132A0285|67 71|11q13
P10092132A0285|77 81|cases
P10092132A0285|101 107|2q33-34
P10092132A0285|109 115|3q25-29
P10092132A0285|117 127|5p15.1-15.2
P10092132A0285|129 135|7q21-22
P10092132A0285|137 143|11p11.2
P10092132A0285|145 154|12p11.2-12
P10092132A0285|159 163|13q34
P10092847A0455|30 39|active MREs
P10092847A0455|47 60|promoter region
P10092847A0455|65 75|hMT-IIA gene
P10092847A0455|101 126|mouse metallothionein-I gene
P10092847A0455|101 120|mouse metallothionein
P10092847A0455|122 126|I gene
P10092847A0455|142 155|MRE arrangement
P10092847A0455|163 177|important factor
P10092847A0455|181 195|metal regulation
P10092856A0798|3 6|cDNA
P10092856A0798|64 100|yeast triose phosphate isomerase promoter
P10094314A0935|17 28|RNA sequences
P10094314A0935|49 69|zinc knuckle 9G8 variant
P10094314A0935|96 100|SRp20
P10094314A0935|131 133|RBD
P10094314A0935|136 138|9G8
P10094314A0935|142 146|SRp20
P10094396A0000|0 14|Topoisomerase II
P10094396A0000|18 28|major target
P10094396A0000|34 59|protein kinase casein kinase 2
P10094396A0000|34 58|protein kinase casein kinase
P10094396A0000|61 65|PK CK2
P10094701A0000|0 9|Recent work
P10094701A0000|54 66|acetate kinase
P10094701A0000|68 71|ackA
P10094701A0000|75 95|Sinorhizobium meliloti
P10094701A0000|122 140|phosphate limitation
P10095059A1003|3 9|numbers
P10095059A1003|17 35|nucleotide positions
P10095059A1003|41 64|wild-type HIV-1 transcript
P10095061A0592|0 15|Sequence analysis
P10095061A0592|31 41|MEMA protein
P10095061A0592|61 70|kDa nuclear
P10095061A0592|72 81|domain rich
P10095061A0592|84 90|serines
P10095061A0592|93 95|DRS
P10095061A0592|122 132|nucleoplasm
P10095061A0592|138 167|U2-ribonucleoprotein structures
P10095062A0558|16 32|complete structure
P10095062A0558|38 66|human topoisomerase IIalpha gene
P10095062A0558|85 89|exons
P10095062A0558|102 103|kb
P10096469T0000|0 21|Dopaminergic modulation
P10096469T0000|24 44|transcallosal activity
P10096469T0000|47 69|cat motor cortical neurons
P10096573A0207|0 14|Previous studies
P10096573A0207|29 46|cytokine-inducible
P10096573A0207|48 70|functional nuclear factor
P10096573A0207|58 70|nuclear factor
P10096573A0207|72 73|NF
P10096573A0207|76 97|kappaB consensus element
P10096573A0207|114 129|regulatory region
P10096573A0207|135 152|MGSA/GRO-alpha gene
P10096573A0207|135 138|MGSA
P10096573A0207|140 152|GRO-alpha gene
P10096573A0207|158 159|bp
P10097120T0000|2 5|exon
P10097120T0000|30 39|mature mRNA
P10097932A0915|4 22|CsA-treated patients
P10097932A0915|44 55|elevated UAER
P10097932A0915|59 64|mg/24 h
P10097932A0915|66 67|n =
P10097932A0915|73 88|microalbuminuria
P10097932A0915|106 128|placebo-treated patients
P10097932A0915|132 141|normal UAER
P10097932A0915|146 151|mg/24 h
P10097932A0915|159 163|years
P10097932A0915|166 174|follow-up
P10098601A1320|0 17|Mutational analysis
P10098601A1320|43 62|JEG-3 nuclear proteins
P10098601A1320|107 118|SF-1 sequence
P10098744A0630|35 43|phenotype
P10098744A0630|47 56|unstressed
P10098744A0630|58 63|clones
P10098744A0630|95 104|parameters
P10098744A0630|106 122|proliferation rate
P10098744A0630|125 133|monolayer
P10098744A0630|135 150|serum-dependence
P10098744A0630|154 166|proliferation
P10098744A0630|178 191|tumorigenicity
P10098744A0630|193 210|cellular morphology
P10098744A0630|214 250|tissue-specific differentiation markers
P10099247A1051|1 13|high reactor pH
P10099247A1051|22 44|short solid retention time
P10099247A1051|50 53|days
P10099247A1051|73 96|substantial SRB population
P10099247A1051|102 109|inoculum
P10099247A1051|149 168|acetate-utilising SRB
P10099247A1051|181 182|MB
P10099576A0666|12 17|valves
P10099576A0666|49 53|shear
P10099576A0666|57 72|parameter related
P10099576A0666|78 90|inner geometry
P10099576A0666|96 100|valve
P10099576A0666|115 124|conditions
P10100605A0392|10 25|respiratory burst
P10100605A0392|46 81|intracellular oxidative transformation
P10100605A0392|84 99|dihydrorhodamine
P10100605A0392|108 118|fluorescent
P10100605A0392|122 130|rhodamine
P10100605A0392|137 149|flow cytometry
P10101159A0742|1 8|mutation
P10101159A0742|20 27|SOC1 gene
P10101159A0742|48 65|recessive mutations
P10101159A0742|78 90|cbp1 ts alleles
P10101159A0742|103 124|many mitochondrial mRNAs
P10101198A0632|1 24|deletion mutation analysis
P10101198A0632|30 47|recombinant protein
P10101198A0632|63 78|N-terminal region
P10101198A0632|88 101|leucine zippers
P10101198A0632|120 126|binding
P10101198A0946|1 14|database search
P10101198A0946|35 55|significative homology
P10101198A0946|69 116|human mitochondrial transcription termination factor
P10101198A0946|118 122|mTERF
P10101198A0946|152 158|monomer
P10101198A0946|175 188|leucine zippers
P10101198A0946|196 221|intramolecular interactions
P10101744A0917|5 10|trials
P10101744A0917|12 27|antigen challenge
P10101744A0917|37 37|h
P10101744A0917|46 58|last treatment
P10102000A1206|10 17|patients
P10102000A1206|33 43|ERA-II group
P10102000A1206|53 64|ERA-III group
P10102000A1206|71 88|crude mortality rate
P10102000A1206|94 94|%
P10102136A0220|11 18|total PSA
P10102136A0220|16 18|PSA
P10102136A0220|37 46|cyst fluids
P10102136A0220|59 59|%
P10102136A0220|62 71|female sera
P10102136A0646|0 3|Type
P10102136A0646|5 9|cysts
P10102136A0646|16 20|high K
P10102136A0646|23 24|Na
P10102136A0646|42 55|higher total PSA
P10102136A0646|60 63|Type
P10102136A0646|66 70|cysts
P10102627A0217|11 28|DNA binding activity
P10102627A0217|30 49|AP-1 reporter activity
P10102627A0217|70 74|cells
P10103002A0705|1 32|single N-glycosylation site present
P10103002A0705|35 45|chicken gp42
P10103002A0705|76 83|proteins
P10103002A0705|85 104|carbohydrate analysis
P10103002A0705|107 110|gp42
P10103002A0705|133 154|complex type glycan chain
P10103057A0251|17 28|optimization
P10103057A0251|32 47|characterization
P10103057A0251|51 69|140-residue fragment
P10103057A0251|84 93|Runt domain
P10103057A0251|96 99|AML1
P10103057A0251|119 135|structural studies
P10119827T0000|0 11|Judge OKs docs
P10119827T0000|19 33|Chicago hospital
P10120952T0000|0 4|HANYS
P10120952T0000|15 47|laparoscopic gall bladder guidelines
P10125354T0000|0 11|Groups dicker
P10125354T0000|15 25|price breaks
P10125354T0000|28 40|anesthetic gas
P10125354T0000|45 56|multi-source
P10132730T0000|0 18|Troubled CareNetwork
P10132730T0000|23 26|pact
P10132730T0000|31 49|largest teacher union
P10132730T0000|52 55|Wis.
P10134977T0000|0 4|JCAHO
P10134977T0000|12 20|hospitals
P10146207A0223|0 14|Ultrasonography
P10146207A0223|23 55|excellent intraoperative evaluation
P10146207A0223|58 73|spinal cord injury
P10153759A0360|0 3|UPMC
P10153759A0360|12 27|only organization
P10153759A0360|36 65|controlled NHBC organ procurement
P10171173A0955|9 16|concerns
P10171173A0955|26 68|blood transfusion-related communicable disease
P10171173A0955|81 104|immune deficiency syndrome
P10171173A0955|108 112|non-A
P10171173A0955|114 127|non-B hepatitis
P10171173A0955|152 165|research effort
P10171173A0955|170 199|postoperative hemorrhage related
P10171173A0955|202 222|cardiopulmonary bypass
P10171173A0955|227 251|extracorporeal circulation
P10181397A0641|12 17|trends
P10181397A0641|20 28|fertility
P10181397A0641|30 49|life expectancy ratios
P10181397A0641|54 70|gender differences
P10181397A0641|78 86|countries
P10181397A0641|94 111|Hispanic population
P10181397A0641|117 128|United States
P10184191T0045|0 5|Holger
P10187317T0000|0 7|Hospital
P10187317T0000|20 34|AHERF physicians
P10187798A1098|0 13|Overexpression
P10187798A1098|22 26|DAP-1
P10187798A1098|29 35|sentrin
P10187798A1098|42 50|apoptosis
P10187798A1098|53 87|TNF-sensitive L929 fibroblast cell line
P10187798A1098|53 55|TNF
P10187798A1098|97 129|TNF-resistant osteosarcoma cell line
P10187798A1098|97 99|TNF
P10187798A1098|131 134|U2OS
P10187842A1155|18 27|PPARgamma2
P10187842A1155|73 82|single site
P10187842A1155|86 90|motif
P10187842A1155|100 109|homologous
P10187842A1155|115 119|sites
P10187842A1155|134 142|PPARalpha
P10187864A1372|5 11|results
P10187864A1372|19 22|KCC3
P10187864A1372|26 34|new member
P10187864A1372|40 48|KCC family
P10187864A1372|60 77|distinct regulation
P10187864A1372|82 85|KCC1
P10190324A0000|17 27|elastin gene
P10190324A0000|31 50|mutations responsible
P10190324A0000|54 80|supravalvular aortic stenosis
P10190324A0000|82 85|SVAS
P10190324A0000|120 127|families
P10190324A0000|141 152|nonsyndromic
P10190324A0000|154 157|SVAS
P10191090A0000|0 23|Spatiotemporal expression
P10191090A0000|29 36|PAX3 gene
P10192134A1088|0 7|25-OH-D3
P10192134A1088|29 40|animal health
P10192134A1088|54 61|use level
P10192134A1088|66 82|micrograms/kg feed
P10192134A1088|96 104|vitamin D3
P10192134A1088|107 119|turkey rations
P10192432A0214|9 13|names
P10192432A0214|32 49|diagnostic criteria
P10192432A0214|65 78|Consensus Panel
P10192432A0214|83 96|Italian experts
P10192432A0214|132 138|core set
P10192638T0000|0 22|Methanesulfonyl fluoride
P10192638T0000|24 26|MSF
P10192638T0000|30 41|double-blind
P10192638T0000|43 65|placebo-controlled study
P10192638T0000|77 84|efficacy
P10192638T0000|101 114|senile dementia
P10192638T0000|120 132|Alzheimer type
P10193950A0478|0 6|METHODS
P10193950A0478|15 20|August
P10193950A0478|28 31|June
P10193950A0478|40 42|men
P10193950A0478|47 56|clinical T2
P10193950A0478|59 60|T3
P10193950A0478|72 74|TNM
P10193950A0478|76 92|prostate carcinoma
P10193950A0478|120 127|high risk
P10193950A0478|130 149|lymph node involvement
P10193950A0478|160 182|111In-capromab pendetide
P10193950A0478|194 215|staging lymphadenectomy
P10194225A1132|0 13|Voluntary wheel
P10194225A1132|57 63|alanine
P10194225A1132|66 77|pyruvate Gneo
P10194225A1132|80 97|absolute glycerol Ra
P10194230A0817|24 36|dialysate PGE2
P10194230A0817|40 62|adenosine concentrations
P10194230A0817|88 89|nM
P10194451A0000|12 37|probable causal relationship
P10194451A0000|45 60|constitutive p210
P10194451A0000|57 60|p210
P10194451A0000|62 68|bcr/abl
P10194451A0000|62 64|bcr
P10194451A0000|70 98|protein tyrosine kinase activity
P10194451A0000|102 115|manifestations
P10194451A0000|118 156|chronic-phase chronic myelogenous leukemia
P10194451A0000|158 160|CML
P10194451A0000|162 177|myeloid expansion
P10194451A0000|181 187|key goal
P10194451A0000|200 221|relevant p210 substrates
P10194451A0000|208 211|p210
P10194451A0000|224 274|primary chronic-phase CML hematopoietic progenitor cells
P10194762A0648|7 19|precipitation
P10194762A0648|25 63|glutathione-S-transferase-fusion protein
P10194762A0648|77 107|C-terminal transactivation domain
P10194762A0648|110 115|STAT5a
P10194762A0648|122 144|GH-regulated association
P10194762A0648|147 152|ERK1/2
P10194762A0648|160 172|fusion protein
P10194762A0648|197 202|serine
P10194762A0648|208 213|STAT5a
P10194762A0648|226 232|alanine
P10194769A0146|3 13|such element
P10194769A0146|15 16|1P
P10194769A0146|31 35|clone
P10194769A0146|41 73|rat pituitary cDNA expression library
P10194769A0146|75 101|novel 417-amino acid WD protein
P10194769A0146|80 101|417-amino acid WD protein
P10194769A0146|113 116|PREB
P10194769A0146|118 144|PRL regulatory element binding
P10195425T0000|0 15|Characterization
P10195425T0000|21 44|transcription factor MTF-1
P10195425T0000|52 69|Japanese pufferfish
P10195425T0000|71 82|Fugu rubripes
P10195425T0000|91 114|evolutionary conservation
P10195425T0000|117 140|heavy metal stress response
P10195690A0000|3 43|peroxisome proliferator-activated receptors
P10195690A0000|45 49|PPARs
P10195690A0000|54 60|members
P10195690A0000|66 98|nuclear hormone receptor superfamily
P10195697A0456|8 20|F-SRC-1 mutant
P10195697A0456|28 48|CBP-interacting domain
P10195697A0456|28 30|CBP
P10195697A0456|54 79|preserved enhancing activity
P10196127A1059|3 15|catalytic site
P10196127A1059|21 28|S1 pocket
P10196127A1059|47 65|hydrophobic residues
P10196127A1059|82 100|pyroglutamyl residue
P10196248A0482|3 27|complete circular TTV genome
P10196248A0482|38 50|novel sequence
P10196248A0482|56 57|nt
P10196248A0482|59 60|nt
P10196248A0482|72 72|=
P10196248A0482|105 108|arms
P10196248A0482|118 137|117-nt GC-rich stretch
P10196248A0482|139 147|GC content
P10196248A0482|153 153|%
P10196248A0482|156 157|nt
P10196266A0000|3 24|Asian mouse Mus castaneus
P10196266A0000|27 35|resistant
P10196266A0000|52 83|polytropic mink cell focus-inducing
P10196266A0000|85 87|MCF
P10196266A0000|89 96|subgroup
P10196266A0000|99 119|murine leukemia viruses
P10196266A0000|121 125|MuLVs
P10196316A0715|24 28|VZV gK
P10196316A0715|31 41|virus growth
P10196316A0715|52 68|gK deletion mutants
P10196316A0715|88 99|VZV cosmid DNA
P10196316A0715|114 122|Oka strain
P10196318T0000|0 23|CCAAT displacement protein
P10196318T0000|53 75|human papillomavirus type
P10196318T0000|77 78|E6
P10196318T0000|80 81|E7
P10196318T0000|86 96|E1 promoters
P10196597A0510|9 16|findings
P10196597A0510|32 38|studies
P10196597A0510|62 82|social characteristics
P10196597A0510|85 96|drink drivers
P10197763A0580|5 35|different site-directed mutations
P10197763A0580|41 64|cyclic AMP response element
P10197763A0580|79 101|nerve growth factor effect
P10197763A0580|107 107|%
P10197985A0145|7 27|RNase H protection assay
P10197985A0145|7 12|RNase H
P10197985A0145|47 62|oligonucleotides
P10197985A0145|90 102|5' splice-site
P10197985A0145|92 102|splice-site
P10197985A0145|106 107|ss
P10197985A0145|112 130|branchpoint sequence
P10197985A0145|132 134|BPS
P10197985A0145|136 143|elements
P10197985A0145|146 148|U11
P10197985A0145|152 160|U12 snRNPs
P10197985A0145|183 201|strong cooperativity
P10197985A0145|216 220|sites
P10197985A0145|226 242|pre-mRNA substrate
P10197985A0145|226 233|pre-mRNA
P10197985A0145|246 270|efficient complex formation
P10198003A1505|0 7|Analysis
P10198003A1505|10 35|lacZ transcriptional fusions
P10198003A1505|48 64|KdgR-binding sites
P10198003A1505|96 99|rsmB
P10198056A0000|0 32|Many eukaryotic cell surface proteins
P10198056A0000|49 60|lipid bilayer
P10198056A0000|68 95|glycosylphosphatidylinositol
P10198056A0000|97 99|GPI
P10198061A0339|5 24|cell-free import assay
P10198061A0339|26 37|beta-catenin
P10198061A0339|60 66|nucleus
P10198061A0339|77 93|exogenous addition
P10198061A0339|96 102|cytosol
P10198061A0339|104 106|Ran
P10198061A0339|110 116|ATP/GTP
P10199539A1353|2 9|ischemic
P10199539A1353|13 26|hypoxic hypoxia
P10199539A1353|29 45|strong correlation
P10199539A1353|61 63|cyt
P10199539A1353|66 81|a3 oxidation level
P10199539A1353|85 87|VO2
P10199539A1353|94 101|ischemic
P10199539A1353|105 118|hypoxic hypoxia
P10199539A1353|120 122|r2 =
P10200473A0171|2 29|endogenous mammalian regulator
P10200473A0171|49 55|Usurpin
P10200473A0171|75 81|aliases
P10200473A0171|85 91|Usurpin
P10200473A0171|99 102|CASH
P10200473A0171|104 109|Casper
P10200473A0171|111 115|CLARP
P10200473A0171|117 123|FLAME-1
P10200473A0171|125 128|FLIP
P10200473A0171|130 136|I-FLICE
P10200473A0171|140 143|MRIT
P10201468A0297|0 12|Plasma glucose
P10201468A0297|14 34|immunoreactive insulin
P10201468A0297|36 38|IRI
P10201468A0297|41 49|C-peptide
P10201468A0297|51 58|glucagon
P10201468A0297|63 73|GLP-1 levels
P10201468A0297|63 67|GLP-1
P10201468A0297|80 88|time point
P10201468A0297|95 98|OGTT
P10202006A0546|4 21|recombinant product
P10202006A0546|26 38|fusion protein
P10202006A0546|44 50|B domain
P10202006A0546|53 74|Staphylococcal protein A
P10202006A0546|76 78|SPA
P10202006A1266|0 13|Polypyrimidine
P10202006A1266|17 28|ssDNA binding
P10202006A1266|42 49|VH domain
P10202006A1266|52 83|immunization-induced anti-Z-DNA Ab
P10202006A1266|72 83|anti-Z-DNA Ab
P10202006A1266|106 126|natural autoantibodies
P10202006A1266|142 160|VH-dependent binding
P10202006A1266|164 169|ligand
P10202006A1266|180 194|polypyrimidines
P10202006A1266|209 222|B cell selection
P10202006A1266|229 240|immunization
P10202006A1266|245 249|Z-DNA
P10203611T0000|0 52|Technetium-99m methylene diphosphonate scintimammography
P10203611T0000|68 87|palpable breast masses
P10205099A0377|0 12|INTERVENTIONS
P10205099A0377|14 26|Study patients
P10205099A0377|54 67|parallel groups
P10205099A0377|83 93|terbinafine
P10205099A0377|97 98|mg
P10205099A0377|112 116|weeks
P10205099A0377|118 126|groups T12
P10205099A0377|130 132|T16
P10205099A0377|136 147|itraconazole
P10205099A0377|151 152|mg
P10205099A0377|173 177|weeks
P10205099A0377|187 191|weeks
P10205099A0377|193 200|groups I3
P10205099A0377|204 205|I4
P10205176A0000|0 15|Nuclear receptors
P10205176A0000|17 19|NRs
P10205176A0000|34 63|ligandinducible transregulators
P10205176A0000|70 78|mammalian
P10205176A0000|82 91|yeast cells
P10205176A0000|107 123|important features
P10205176A0000|126 147|transcriptional control
P10205176A0704|4 11|tethered
P10205176A0704|15 43|heterologous DNA-binding domain
P10205176A0704|27 43|DNA-binding domain
P10205176A0704|45 48|PSU1
P10205176A0704|60 72|transcription
P10205588A0000|0 8|OBJECTIVE
P10205588A0000|12 20|follow-up
P10205588A0000|34 41|patients
P10205588A0000|46 54|arthritis
P10205588A0000|73 99|beta-haemolytic streptococci
P10205588A0000|102 117|Lancefield group A
P10205588A0000|119 125|beta HSA
P10205588A0000|142 164|clinical characteristics
P10205588A0000|168 186|serological features
P10205933A0699|0 7|Bacteria
P10205933A0699|21 33|labyrinthitis
P10205933A0699|53 60|inner ear
P10205933A0699|73 90|Treponemas Pallidum
P10205933A0699|93 103|spirochaete
P10205933A0699|115 122|syphilis
P10205933A0699|147 157|spirochaete
P10205933A0699|168 178|Lyme Disease
P10206152A1024|48 54|mitosis
P10206152A1024|67 68|G1
P10206152A1024|107 118|messenger RNA
P10206698A2041|5 12|findings
P10206698A2041|28 54|signature-tagged mutagenesis
P10206698A2041|58 71|viable approach
P10206698A2041|82 95|bacterial genes
P10206698A2041|131 142|urinary tract
P10206959A0368|0 5|Pathol
P10207041A0065|3 21|eukaryotic cell cycle
P10207041A0065|43 63|periodic transcription
P10207041A0065|66 76|cyclin genes
P10207041A0065|83 97|protein products
P10207041A0065|135 157|cyclin-dependent kinases
P10207049A0693|3 10|GAC1 gene
P10207049A0693|21 37|regulatory subunit
P10207049A0693|47 87|serine/threonine phosphoprotein phosphatase
P10207049A0693|89 92|Glc7
P10207049A1001|3 9|results
P10207049A1001|28 42|Glc7 phosphatase
P10207049A1001|49 86|Gac1 regulatory subunit play positive roles
P10207049A1001|89 101|HSF activation
P10207049A1001|89 91|HSF
P10207049A1001|104 120|CUP1 transcription
P10207049A1001|104 107|CUP1
P10207087A0956|0 2|MEF
P10207087A0956|6 10|AML1B
P10207087A0956|42 52|interleukin
P10207087A0956|54 82|promoter reporter gene construct
P10207087A0956|90 107|activating activity
P10207087A0956|110 112|MEF
P10207087A0956|129 131|MEF
P10207087A0956|150 157|AML1/ETO
P10207087A0956|150 153|AML1
P10207087A0956|155 157|ETO
P10207090A0801|32 34|GRR
P10207090A0801|48 65|further degradation
P10207090A0801|68 70|p50
P10207092A0924|4 18|phosphorylation
P10207092A0924|36 95|break-ended double-stranded DNA-activated protein kinase activity
P10207092A0924|103 118|sea urchin nucleus
P10207115A0389|17 34|total cellular level
P10207115A0389|37 39|p21
P10207115A0389|49 59|severalfold
P10207115A0389|64 91|posttranscriptional mechanism
P10208865A1246|23 40|osteoclast cultures
P10208865A1246|42 48|mrIhh-N
P10208865A1246|81 94|resorption pits
P10208865A1246|97 109|dentine slices
P10208893A0839|11 17|results
P10208893A0839|29 46|resistant genotypes
P10208893A0839|60 76|WAD goat population
P10209021A0212|3 20|molecular mechanism
P10209021A0212|28 32|Gle2p
P10209021A0212|39 70|Gle2p-Nup116p interaction function
P10209021A0212|39 43|Gle2p
P10209021A0212|45 51|Nup116p
P10209021A0212|73 82|mRNA export
P10209031A0832|3 16|Fyn NH2 terminus
P10209031A0832|63 66|zeta
P10209031A0832|74 82|Fyn kinase
P10209031A0832|86 95|SH2 domains
P10209031A0832|118 132|phosphorylation
P10209031A0832|135 151|zeta ITAM tyrosines
P10209031A0832|135 142|zeta ITAM
P10209031A0832|164 187|zeta ITAM phosphotyrosines
P10209031A0832|164 171|zeta ITAM
P10209119A0076|9 13|yeast
P10209119A0076|18 29|protein Skp1p
P10209119A0076|25 29|Skp1p
P10209119A0076|34 58|cullin-family member Cdc53p
P10209119A0076|53 58|Cdc53p
P10209119A0076|66 92|F-box/WD-repeat protein Cdc4p
P10209119A0076|66 87|F-box/WD-repeat protein
P10209119A0076|88 92|Cdc4p
P10209119A0076|100 129|SCFCdc4p ubiquitin ligase complex
P10209119A0076|100 107|SCFCdc4p
P10209119A0076|146 167|cyclin-dependent kinase
P10209119A0076|169 171|Cdk
P10209119A0076|173 186|inhibitor Sic1p
P10209119A0076|182 186|Sic1p
P10209119A0076|190 200|proteolysis
P10209119A0594|40 61|functional similarities
P10209119A0594|66 69|pop1
P10209119A0594|73 81|pop2 genes
P10209119A0594|109 126|deletion phenotypes
P10209119A0594|153 165|non-redundant
P10209119A0594|181 194|interdependent
P10209119A0594|196 204|functions
P10209119A0594|207 217|proteolysis
P10209759T0000|0 14|Antithrombin III
P10209759T0000|25 66|min warm intestinal ischemia reperfusion injury
P10209759T0000|69 72|rats
P10210952A0261|2 11|retrospect
P10210952A0261|16 24|diagnoses
P10210952A0261|49 62|strict criteria
P10211329A0457|5 16|observations
P10211329A0457|19 37|elevated serum lipase
P10211329A0457|41 47|serum CA
P10211329A0457|54 60|Sjogren
P10211329A0457|88 97|malignancy
P10211329A0457|108 128|pancreatic involvement
P10211422T0000|0 16|Acute pancreatitis
P10211422T0000|20 31|complication
P10211422T0000|34 52|polyarteritis nodosa
P10211919A0846|13 30|greater improvement
P10211919A0846|32 32|p
P10211919A0846|44 58|sertraline group
P10211919A0846|98 103|Y-BOCS
P10211919A0846|110 128|CGI Improvement scale
P10211919A0846|143 147|weeks
P10211919A0846|172 175|NIMH
P10211919A0846|179 194|CGI Severity scale
P10212278A0387|0 36|Stress-inducible protein kinases capable
P10212278A0387|49 63|c-jun expression
P10212278A0387|49 53|c-jun
P10212278A0387|71 128|stress-activated protein kinase/c-Jun N-terminal protein kinase
P10212278A0387|71 99|stress-activated protein kinase
P10212278A0387|101 128|c-Jun N-terminal protein kinase
P10212278A0387|130 137|SAPK/JNK
P10212278A0387|130 133|SAPK
P10212278A0387|135 137|JNK
P10212278A0387|142 151|p38 members
P10212278A0387|157 186|mitogen-activated protein kinase
P10212278A0387|188 191|MAPK
P10212278A0387|193 203|superfamily
P10212278A0387|215 223|molecules
P10212284A0000|0 23|Transforming growth factor
P10212284A0000|12 23|growth factor
P10212284A0000|25 34|TGF)-beta1
P10212284A0000|25 27|TGF
P10212284A0000|30 34|beta1
P10212284A0000|42 70|extracellular matrix deposition
P10212284A0000|74 86|proliferation
P10212284A0000|89 104|mesenchymal cells
P10212332T0000|0 17|Chronotherapeutics
P10212332T0000|20 40|cardiovascular disease
P10212426A1067|0 25|Group psychometric functions
P10212426A1067|29 37|listeners
P10212426A1067|42 52|hearing loss
P10212426A1067|89 101|largest values
P10212426A1067|104 108|delta
P10212969A0470|0 11|Uroflowmetry
P10212969A0470|21 27|dysuria
P10212969A0470|72 79|subjects
P10214610A0900|0 20|Marked racial variation
P10214610A0900|23 44|birthweight percentiles
P10214610A0900|47 60|gestational age
P10215485A0837|0 22|Significant correlations
P10215485A0837|30 41|mental status
P10215485A0837|57 83|Mini-Mental State Examination
P10215485A0837|87 91|NA/mI
P10215485A0837|93 97|mI/Cr
P10215485A0837|93 94|mI
P10215485A0837|101 102|NA
P10215594A1728|0 7|Glucagon
P10215594A1728|19 29|LUC activity
P10215594A1728|19 21|LUC
P10215594A1728|49 52|CRE1
P10215594A1728|56 64|CRE2 sites
P10215594A1728|78 86|induction
P10215594A1728|93 96|CRE1
P10215594A1728|100 103|CRE2
P10215594A1728|105 123|2SV40-LUC constructs
P10215594A1728|151 153|pO2
P10215608A0161|35 50|characterization
P10215608A0161|56 69|entire rat GSTA3
P10215608A0161|62 69|rat GSTA3
P10215608A0161|71 77|rGST Yc1
P10215608A0161|79 89|subunit gene
P10215803T0000|24 42|intravenous infusion
P10215803T0000|45 60|calcium gluconate
P10215811A0635|0 13|Initial control
P10215811A0635|16 23|bleeding
P10215811A0635|37 47|eradication
P10215811A0635|60 72|fewer sessions
P10215811A0635|77 79|EVL
P10215850A0754|23 41|genomic organization
P10215850A0754|47 60|human TrxR2 gene
P10215850A0754|79 83|exons
P10215850A0754|99 100|kb
P10215850A0754|108 130|chromosomal localization
P10215850A0754|133 147|position 22q11.2
P10216052A0105|3 6|aims
P10216052A0105|66 81|visual disability
P10216052A0105|84 93|daily tasks
P10216052A0105|105 120|glaucoma patients
P10216052A0105|134 146|interrelation
P10216052A0105|154 165|disabilities
P10216052A0105|171 184|factor analysis
P10216052A0105|220 235|visual difficulty
P10216052A0105|252 259|severity
P10216052A0105|262 276|visual field loss
P10216052A0105|288 311|glaucoma specific subgroup
P10216052A0105|314 322|questions
P10216052A0105|365 372|subgroup
P10216052A0105|375 383|questions
P10216052A1682|29 37|new subset
P10216052A1682|40 48|questions
P10216052A1682|73 74|r=
P10216052A1682|81 81|p
P10216052A1682|125 132|severity
P10216052A1682|135 158|binocular visual field loss
P10216052A1682|165 173|mean score
P10216052A1682|179 187|variables
P10216052A1682|197 220|glaucoma specific subgroup
P10216052A1682|223 231|questions
P10216161A1530|0 17|Sequence comparison
P10216161A1530|20 32|cytochromes bd
P10216161A1530|41 48|homologs
P10216161A1530|53 68|various organisms
P10216161A1530|88 95|proteins
P10216161A1530|118 128|subfamilies
P10216161A1530|131 149|proteobacterial type
P10216161A1530|159 166|E. coli bd
P10216161A1530|165 166|bd
P10216161A1530|208 233|B. stearothermophilus enzyme
P10216161A1530|252 261|latter type
P10216161A1530|278 282|older
P10217683A0509|0 20|Canalith repositioning
P10217683A0509|26 33|mainstay
P10218109T0000|0 16|Solution structure
P10218109T0000|34 57|MutT pyrophosphohydrolase
P10218200A0534|4 7|eyes
P10218200A0534|37 46|micrograms
P10218200A0534|49 85|recombinant tissue plasminogen activator
P10218200A0534|112 114|hrs
P10218357A0486|0 6|RESULTS
P10218357A0486|10 20|CONCLUSIONS
P10218357A0486|22 27|Brandt
P10218357A0486|30 45|double cuff-tubes
P10218357A0486|47 48|G2
P10218357A0486|67 86|uncontrolled increase
P10218357A0486|89 101|cuff-pressure
P10218357A0486|108 118|anaesthesia
P10218357A0486|123 125|N2O
P10219091A0246|28 35|gene CTL1
P10219091A0246|37 72|capping enzyme RNAtriphosphatase-like 1
P10219091A0246|44 71|enzyme RNAtriphosphatase-like
P10220275A0694|3 9|binding
P10220275A0694|12 20|PH domains
P10220275A0694|23 32|Gbetagamma
P10220275A0694|47 59|preincubation
P10220275A0694|62 71|Gbetagamma
P10220275A0694|79 87|GDP-bound
P10220275A0694|97 109|GTP-bound form
P10220275A0694|112 118|Gialpha
P10220364A0087|5 14|afterglows
P10220364A0087|30 39|supernovae
P10220364A0087|61 70|hypernovae
P10221467T0000|0 23|Constrictive pericarditis
P10221467T0000|27 48|pleuropulmonary disease
P10221467T0000|62 83|dopamine agonist therapy
P10221467T0000|85 95|cabergoline
P10221467T0000|100 108|Parkinson
P10221820A0902|2 14|undilated type
P10221820A0902|17 20|APBD
P10221820A0902|47 49|AMT
P10221820A0902|77 86|clinicians
P10221820A0902|103 121|possible coexistence
P10221820A0902|124 127|APBD
P10221820A0902|131 133|AMT
P10223338A1601|40 60|chimeric fusion protein
P10223338A1601|73 80|HIV-2 gag
P10223338A1601|85 93|V3 domains
P10223338A1601|85 86|V3
P10223338A1601|96 104|HIV-1IIIB
P10223338A1601|106 112|HIV-1MN
P10223338A1601|114 121|HIV-1SF2
P10223338A1601|125 131|HIV-1RF
P10223338A2186|3 9|results
P10223338A2186|22 31|V3 peptides
P10223338A2186|39 49|major clades
P10223338A2186|52 56|HIV-1
P10223338A2186|66 73|HIV-2 gag
P10223338A2186|86 109|potential HIV/AIDS vaccine
P10223498A0479|0 7|Efficacy
P10223498A0479|23 31|responses
P10223498A0479|62 69|erection
P10223498A0479|103 110|erection
P10223498A0479|117 141|15-item International Index
P10223498A0479|144 159|Erectile Function
P10223498A0479|161 164|IIEF
P10224244T0000|0 7|Evidence
P10224244T0000|30 49|Glc7-Reg1 phosphatase
P10224244T0000|30 33|Glc7
P10224244T0000|56 70|Snf1-Snf4 kinase
P10224244T0000|56 59|Snf1
P10224244T0000|88 104|INO1 transcription
P10224244T0000|88 91|INO1
P10224257A0079|2 8|XO males
P10224257A0079|13 22|her-1 mRNAs
P10224257A0079|24 29|her-1a
P10224257A0079|33 38|her-1b
P10224257A0079|61 77|separate promoters
P10224257A0079|79 80|P1
P10224257A0079|82 88|located
P10224257A0079|97 110|flanking region
P10224257A0079|115 116|P2
P10224257A0079|118 124|located
P10224257A0079|130 146|large second intron
P10224289T0000|0 8|Induction
P10224289T0000|11 29|Fas ligand expression
P10224289T0000|11 19|Fas ligand
P10224289T0000|32 34|HIV
P10224289T0000|59 61|Nef
P10224289T0000|69 90|T cell receptor zeta chain
P10224293A0000|0 34|Receptor protein tyrosine phosphatases
P10224293A0000|36 40|RPTPs
P10224293A0000|59 66|proteins
P10224293A0000|78 108|intracellular phosphatase domains
P10224293A0000|114 123|ectodomain
P10224293A0000|128 155|putative ligand-binding motifs
P10224293A2021|5 34|well-characterized brain regions
P10224293A2021|54 66|future studies
P10224293A2021|69 86|RPTP-kappa function
P10224293A2021|69 78|RPTP-kappa
P10224513A0240|12 20|stressors
P10224513A0240|24 40|mental arithmetics
P10224513A0240|42 52|speech tasks
P10224513A0240|57 66|Stroop test
P10224513A0240|68 83|videogame playing
P10224513A0240|85 89|films
P10224513A0240|92 101|videotapes
P10224513A0240|105 114|interviews
P10224758A0202|3 14|control group
P10224758A0202|24 40|afterbirth samples
P10224758A0202|45 77|physiological full-term pregnancies
P10225279A0450|35 42|MDV2 UL54
P10225279A0450|46 54|UL55 genes
P10225279A0450|59 66|homology
P10225279A0450|72 79|first ORF
P10225279A0450|81 85|ORF-1
P10225279A0450|95 109|herpesvirus type
P10225279A0450|114 130|corresponding gene
P10225279A0450|143 159|pseudorabies virus
P10225945A0436|20 31|MAD2 staining
P10225945A0436|20 23|MAD2
P10225945A0436|34 40|meiosis
P10225945A0436|61 88|initial microtubule attachment
P10225945A0436|145 154|homologous
P10225945A0436|157 174|sister kinetochores
P10225945A0436|178 184|meiosis
P10226029A0905|2 16|epithelial cells
P10226029A0905|21 28|PH domain
P10226029A0905|31 46|Akt/PKB localised
P10226029A0905|31 33|Akt
P10226029A0905|35 37|PKB
P10226029A0905|49 53|sites
P10226029A0905|56 64|cell-cell
P10226029A0905|68 85|cell-matrix contact
P10226029A0905|99 111|focal contacts
P10226029A0905|131 135|serum
P10226074A0637|5 16|untranslated
P10226074A0637|26 32|regions
P10226074A0637|53 57|exons
P10226074A0637|66 92|translation start site located
P10226074A0637|102 110|first exon
P10226838A1011|3 10|motility
P10226838A1011|13 17|sperm
P10226838A1011|33 40|adjacent
P10226838A1011|47 56|electrodes
P10226838A1011|75 85|stimulation
P10226838A1011|89 91|60s
P10226838A1011|101 120|high electrical energy
P10228009A0600|0 8|Induction
P10228009A0600|14 25|CINC promoter
P10228009A0600|28 32|IL-17
P10228009A0600|35 44|IEC-6 cells
P10228009A0600|48 77|TNF receptor-associated factor-6
P10228009A0600|79 83|TRAF6
P10228009A0600|92 96|TRAF2
P10228155A1293|0 6|SCFFWD1
P10228155A1293|23 38|tumor development
P10228155A1293|42 52|suppression
P10228155A1293|72 99|beta-catenin protein stability
P10228157T0000|1 39|Bub2p-dependent spindle checkpoint pathway
P10228157T0000|1 5|Bub2p
P10228157T0000|52 62|Dbf2p kinase
P10228157T0000|72 76|yeast
P10228561A0539|13 31|modular organization
P10228561A0539|34 50|DNA polymerase beta
P10228561A0539|63 70|residues
P10228561A0539|88 100|DNA phosphates
P10228561A0539|105 113|localized
P10228561A0539|120 126|modules
P10228795A0842|0 6|RESULTS
P10228795A0842|8 24|Cholinergic nerves
P10228795A0842|59 79|enteric nerve responses
P10228795A0842|82 84|EFS
P10228795A0842|90 98|normal IAS
P10229084A0000|0 32|Two-dimensional gel electrophoresis
P10229084A0000|35 63|anti-p59fyn immunoprecipitates
P10229084A0000|35 45|anti-p59fyn
P10229084A0000|76 90|non-transformed
P10229084A0000|98 114|human T lymphocytes
P10229084A0000|146 169|oligomeric protein complex
P10229084A0000|204 206|Fyn
P10229084A0000|210 241|several additional phosphoproteins
P10229084A0000|243 246|pp43
P10229084A0000|248 251|pp72
P10229084A0000|253 256|pp85
P10229084A0000|261 285|protein tyrosine kinase Pyk2
P10229084A0000|261 281|protein tyrosine kinase
P10229084A0000|282 285|Pyk2
P10229084A0000|315 329|adaptor proteins
P10229084A0000|331 336|SKAP55
P10229084A0000|340 347|SLAP-130
P10229668A0190|10 26|other cdc33 mutants
P10229668A0190|15 26|cdc33 mutants
P10229668A0190|39 40|G1
P10229668A0560|1 13|cdc33-1 strain
P10229668A0560|1 7|cdc33-1
P10229668A0560|30 40|stable Cln3p
P10229668A0560|36 40|Cln3p
P10229668A0560|42 48|Cln3-1p
P10229668A0560|53 62|hybrid UBI4
P10229668A0560|59 73|UBI4 5'-CLN3 mRNA
P10229668A0560|66 73|CLN3 mRNA
P10229668A0560|108 117|dependence
P10229668A0560|120 124|eIF4E
P10229668A0560|147 155|cell cycle
P10229682A1151|0 15|Regulatory motifs
P10229682A1151|19 36|gene expression such
P10229682A1151|39 85|nuclear-factor-kappaB-binding-site-like sequence
P10229682A1151|87 96|kappaB site
P10229682A1151|101 154|nuclear-factor-interleukin-6-binding-site-like sequence
P10229682A1151|156 166|NF-IL-6 site
P10229682A1151|185 208|upstream regulatory region
P10231026A0253|3 15|gene structure
P10231026A0253|18 21|Elk1
P10231026A0253|31 32|kb
P10231026A0253|51 55|exons
P10231026A0253|62 68|introns
P10231454A0731|0 16|Total serum calcium
P10231454A0731|29 33|mg/dl
P10231454A0731|49 55|calcium
P10231454A0731|68 72|mg/dl
P10231454A0731|74 83|phosphorus
P10231454A0731|93 97|mg/dl
P10231454A0731|102 120|alkaline phosphatase
P10231454A0731|131 137|U/liter
P10231485A0342|0 15|Sequence analysis
P10231485A0342|28 31|TtrA
P10231485A0342|41 80|molybdopterin guanine dinucleotide cofactor
P10231485A0342|86 91|4Fe-4S
P10231485A0342|105 108|TtrB
P10231485A0342|119 124|4Fe-4S
P10231485A0342|126 133|clusters
P10231485A0342|142 145|TtrC
P10231485A0342|150 172|integral membrane protein
P10231485A0342|184 202|quinol oxidation site
P10231513T0000|0 23|Cranio-caudal differences
P10231513T0000|26 51|granulation tissue formation
P10231513T0000|55 71|experimental study
P10231581A1125|0 23|Site-directed mutagenesis
P10231581A1125|37 60|adjacent SP1 sites proximal
P10231581A1125|63 66|exon
P10231581A1125|100 120|basal promoter activity
P10231862A1117|0 23|Breast-fed newborn infants
P10231862A1117|34 71|n-6 long-chain polyunsaturated fatty acids
P10231862A1117|88 96|first week
P10231862A1117|124 142|endogenous synthesis
P10231862A1117|148 187|total plasma long-chain polyunsaturated pool
P10232078A0552|0 7|Ischemia
P10232078A0552|11 21|reperfusion
P10232078A0552|51 66|6-keto-PGF1 alpha
P10232078A0552|70 73|TXB2
P10232600T0000|0 23|Prostate-specific antigen
P10232600T0000|25 27|PSA
P10232600T0000|29 71|promoter-driven androgen-inducible expression
P10232600T0000|74 94|sodium iodide symporter
P10232600T0000|97 119|prostate cancer cell lines
P10232872A0081|13 23|subclinical
P10232872A0081|27 34|silent CD
P10232872A0081|43 55|large subgroup
P10232872A0081|61 76|celiac population
P10233147A0218|0 4|Ras2p
P10233147A0218|14 27|invasive growth
P10233147A0218|44 70|downstream signaling pathways
P10233147A0218|75 91|filamentation MAPK
P10233147A0218|88 91|MAPK
P10233147A0218|93 110|Cdc42p/Ste20p/MAPK
P10233147A0218|93 98|Cdc42p
P10233147A0218|100 105|Ste20p
P10233147A0218|107 110|MAPK
P10233147A0218|112 118|cascade
P10233147A0218|124 150|cAMP-dependent protein kinase
P10233147A0218|152 165|Cyr1p/cAMP/PKA
P10233147A0218|152 156|Cyr1p
P10233147A0218|167 173|pathway
P10233885A0899|0 9|Consistent
P10233885A0899|29 41|transfections
P10233885A0899|49 75|hematopoietic cell line Jurkat
P10233885A0899|90 107|2.5-fold activation
P10233885A0899|113 125|mim-1 promoter
P10233885A0899|131 133|p32
P10233885A0899|137 147|p30 isoforms
P10233946A0000|0 11|Previous work
P10233946A0000|24 42|spleen necrosis virus
P10233946A0000|44 46|SNV
P10233946A0000|48 66|long terminal repeats
P10233946A0000|68 71|LTRs
P10233946A0000|90 136|Rex/Rex-responsive element-independent expression
P10233946A0000|90 92|Rex
P10233946A0000|94 114|Rex-responsive element
P10233946A0000|139 160|bovine leukemia virus RNA
P10233946A0000|189 194|SNV RNA
P10233946A0000|204 220|cis-acting element
P10233946A0000|238 261|cellular Rex-like proteins
P10234698A0728|18 35|detrimental effects
P10234698A0728|38 51|CNS development
P10234698A0728|62 74|animal studies
P10234698A0728|88 99|pretreatment
P10234698A0728|104 118|corticosteroids
P10234698A0728|150 171|hypoxia-ischemic injury
P10234698A0728|191 203|such treatment
P10235265A0197|27 62|ubiquitin-dependent proteolytic system
P10235265A0197|73 105|APC-dependent proteolysis machinery
P10235265A0197|73 75|APC
P10235265A0197|118 124|mitotic
P10235265A0197|126 128|Clb
P10235265A0197|130 142|cyclin subunit
P10236651T0000|0 9|Predictors
P10236651T0000|21 34|pharmacy school
P10236651T0000|36 39|PCAT
P10236651T0000|43 64|other admission criteria
P10240361T0000|0 13|Canadian survey
P10240361T0000|21 45|widespread dissatisfaction
P10240361T0000|51 60|physicians
P10243927A0000|13 31|full-scale fire tests
P10243927A0000|33 45|investigators
P10243927A0000|51 70|IIT Research Institute
P10243927A0000|88 107|automatic door control
P10243927A0000|119 128|fire origin
P10243927A0000|162 171|toxic smoke
P10243927A0000|175 179|gases
P10271171A0458|0 10|Online LATCH
P10271171A0458|77 101|interactive resource center
P10281637A0000|0 8|Reporting
P10281637A0000|11 23|adverse events
P10281637A0000|39 52|clinical trials
P10281637A0000|55 74|investigational drugs
P10281637A0000|88 105|controversial issue
P10304090T0000|0 18|Medicare SNF benefits
P10308312A0203|15 27|current status
P10308312A0203|51 71|interaction mechanisms
P10308312A0203|74 83|ultrasound
P10308312A0203|88 102|biological media
P10308312A0203|109 115|factors
P10308312A0203|126 151|different biological effects
P10318806A0000|0 6|Members
P10318806A0000|12 34|mitogen activated protein
P10318806A0000|12 18|mitogen
P10318806A0000|36 51|MAP) kinase family
P10318806A0000|36 38|MAP
P10318806A0000|40 51|kinase family
P10318806A0000|53 87|extracellular signal-regulated kinase
P10318806A0000|89 119|stress-activated protein kinase-1
P10318806A0000|121 143|c-Jun NH2-terminal kinase
P10318806A0000|148 150|p38
P10318806A0000|155 169|central elements
P10318806A0000|203 215|growth factors
P10318806A0000|217 225|cytokines
P10318806A0000|239 244|agents
P10318806A0476|5 16|present study
P10318806A0476|39 52|functional role
P10318806A0476|58 72|other MAP kinases
P10318806A0476|63 72|MAP kinases
P10318806A0476|75 104|PDGF-mediated cellular responses
P10318806A0476|75 78|PDGF
P10318806A0918|0 7|Analyses
P10318806A0918|10 45|tyrosine residue-mutated PDGF receptors
P10318806A0918|54 64|Src homology
P10318806A0918|66 90|domain-containing proteins
P10318806A0918|100 115|Src family kinases
P10318806A0918|117 144|phosphatidylinositol 3-kinase
P10318806A0918|149 172|GTPase-activating protein
P10318806A0918|175 177|Ras
P10318806A0918|182 221|Src homology 2 domain-containing phosphatase
P10318806A0918|182 192|Src homology
P10318806A0918|194 226|domain-containing phosphatase SHP-2
P10318806A0918|222 226|SHP-2
P10318806A0918|228 247|phospholipase C-gamma
P10318806A0918|252 254|Crk
P10318806A0918|265 273|major role
P10318806A0918|288 309|PDGF-induced activation
P10318806A0918|288 291|PDGF
P10318806A0918|312 314|p38
P10318859A0535|14 22|calpeptin
P10318859A0535|31 50|tyrosine phosphatases
P10318859A0535|61 83|tyrosine phosphorylation
P10318859A0535|98 105|paxillin
P10318900A0637|0 33|Three-dimensional structural studies
P10318900A0637|39 60|electron cryomicroscopy
P10318900A0637|74 80|binding
P10318900A0637|86 88|Fab
P10318900A0637|90 95|8H2/G5
P10318900A0637|90 92|8H2
P10318900A0637|94 95|G5
P10318900A0637|113 124|conformation
P10318900A0637|130 135|capsid
P10318900A0637|155 168|mRNA production
P10318900A0637|189 210|native subviral particle
P10318918A0824|8 25|mutational analysis
P10318918A0824|28 31|NS5A
P10318918A0824|43 59|SH3-binding region
P10318918A0824|63 79|proline-rich motif
P10318918A0824|106 117|HCV genotypes
P10319320A1022|19 26|findings
P10319320A1022|35 41|16K hPRL
P10319320A1022|53 77|VEGF-induced Ras activation
P10319320A1022|53 56|VEGF
P10319320A1022|65 67|Ras
P10319320A1022|83 92|antagonism
P10319320A1022|123 140|important mechanism
P10319320A1022|156 167|angiogenesis
P10319327A1237|0 7|Analysis
P10319327A1237|10 49|SRE oligonucleotide gel mobility shift assays
P10319327A1237|54 68|nuclear extracts
P10319327A1237|73 84|Sertoli cells
P10319327A1237|117 119|SRF
P10319327A1237|147 164|bHLH protein E12/E47
P10319327A1237|162 164|E47
P10319955A0941|12 22|differences
P10319955A0941|25 42|late occlusion rates
P10319955A0941|48 51|chi2
P10319955A0941|53 62|chi-square
P10319955A0941|82 92|differences
P10319955A0941|109 110|P=
P10320177A0487|0 27|Baseline electrocorticography
P10320177A0487|47 58|temporal lobe
P10320177A0487|62 85|depth electrode recordings
P10320177A0487|91 98|amygdala
P10320177A0487|102 112|hippocampus
P10320177A0487|138 140|min
P10320177A0487|169 186|i.v. administration
P10320177A0487|193 202|alfentanil
P10320177A0487|205 213|microg/kg
P10320177A0487|217 224|fentanyl
P10320177A0487|227 235|microg/kg
P10320480A0451|11 23|genetic system
P10320480A0451|27 33|further
P10320480A0451|60 76|extreme C-terminus
P10320480A0451|82 92|beta subunit
P10320480A0451|95 113|E. coli RNA polymerase
P10320480A0451|101 113|RNA polymerase
P10320579A1831|13 16|FlgN
P10320579A1831|20 23|FliT
P10320579A1831|27 63|substrate-specific flagellar chaperones
P10320579A1831|75 89|oligomerization
P10320579A1831|95 98|HAPs
P10320579A1831|115 128|helical domains
P10321158T0000|0 3|Post
P10321158T0000|7 21|core fabrication
P10321158T0000|25 39|divergent canals
P10321158T0000|45 52|cast post
P10321158T0000|64 81|prefabricated dowel
P10322022A0263|0 5|Rep63A
P10322022A0263|10 19|amino acids
P10322022A0263|21 22|aa
P10322022A0263|38 47|largest ORF
P10322022A0263|58 73|strong similarity
P10322022A0263|77 85|% identity
P10322022A0263|92 110|replication proteins
P10322022A0263|115 130|plasmids pAMbeta1
P10322022A0263|132 137|pIP501
P10322022A0263|142 149|pSM19035
P10322022A0263|168 180|pAW63 replicon
P10322022A0263|193 206|pAMbeta1 family
P10322022A0263|209 246|gram-positive theta-replicating plasmids
P10322629A0198|15 21|cloning
P10322629A0198|25 40|characterization
P10322629A0198|43 54|Xenopus Pax-5
P10322629A0198|58 62|Pax-8
P10322629A0198|67 77|orthologues
P10322629A0198|83 87|Pax-2
P10322629A0198|92 101|gene family
P10323225A0244|0 7|Km values
P10323225A0244|11 18|ammonium
P10323225A0244|20 33|2-oxoglutarate
P10323225A0244|35 38|NADH
P10323225A0244|40 48|glutamate
P10323225A0244|52 54|NAD
P10323225A0244|85 86|mM
P10323463T0000a|0 15|Interferon-alpha
P10323463T0000a|29 74|cryoblobulinemia-related ischemic manifestations
P10323463T0000a|78 90|adverse effect
P10323463T0000a|114 136|anti-angiogenic activity
P10323463T0000b|0 15|Interferon-alpha
P10323463T0000b|29 74|cryoblobulinemia-related ischemic manifestations
P10323463T0000b|78 90|adverse effect
P10323463T0000b|114 136|anti-angiogenic activity
P10323863A0852|43 69|active recombinant telomerase
P10323863A0852|87 110|rabbit reticulocyte lysate
P10323863A0852|123 147|ribonucleoprotein assembly
P10325413A1211|11 17|binding
P10325413A1211|20 24|c-Abl
P10325413A1211|27 63|DNA containing 5-methylcytosine residues
P10325413A1211|88 97|propensity
P10325413A1211|103 113|double helix
P10325413A1211|143 166|protein-induced reduction
P10326221A0531|0 17|Homozygous mutation
P10326221A0531|23 30|children
P10326221A0531|36 45|amputation
P10326221A0531|48 54|legs due
P10326221A0531|64 72|fulminans
P10326654A0351|11 26|pilot experiments
P10326654A0351|42 57|various durations
P10326654A0351|60 80|global no-flow ischemia
P10326654A0351|98 104|minutes
P10326654A0351|109 117|durations
P10326654A0351|134 145|present study
P10326654A0351|149 155|minutes
P10326654A0351|172 194|ventricular fibrillation
P10326654A0351|196 197|VF
P10326654A0351|205 219|predominant form
P10326654A0351|222 232|arrhythmias
P10326654A0351|239 245|minutes
P10326654A0351|265 274|prevalence
P10326654A0351|277 278|VF
P10326654A0351|305 319|small difference
P10326654A0351|325 332|duration
P10326654A0351|335 342|ischemia
P10326856T0000|2 33|end-to-end pancreaticojejunostomy
P10326856T0000|40 67|mechanical purse-string device
P10327051A0688|27 57|Stress-Activated-Protein-Kinase
P10327051A0688|59 62|SAPK
P10327051A0688|64 74|target sites
P10327051A0688|77 80|ATF2
P10327051A0688|82 86|Thr69
P10327051A0688|90 94|Thr71
P10327051A0688|129 140|p300/CBP-ATF
P10327051A0688|129 132|p300
P10327051A0688|134 136|CBP
P10327051A0688|138 141|ATF2
P10327051A0688|142 160|multiprotein complex
P10328351A0443|0 11|Blood samples
P10328351A0443|39 59|supplementation period
P10328351A0443|64 64|d
P10328351A0443|76 76|d
P10329135A1326|5 11|results
P10329135A1326|23 47|mitochondrial presequences
P10329135A1326|63 70|mt-hsp70
P10329135A1326|84 109|mitochondrial protein import
P10329566A0610|5 12|terminus
P10329566A0610|18 23|genome
P10329566A0610|40 66|tRNA-like secondary structure
P10329566A0610|75 89|valine anticodon
P10329566A0610|94 111|tRNA-like structure
P10329566A0610|118 127|pseudoknot
P10329566A0610|133 145|aminoacyl stem
P10329566A0610|148 160|feature common
P10329566A0610|167 172|genera
P10329566A0610|175 186|tetraviruses
P10329574A1733|0 15|O. novo-ulmi RNA-7
P10329574A1733|40 56|satellite-like RNA
P10329574A1733|70 81|defective RNA
P10329574A1733|94 105|OnuMV4-Ld RNA
P10329574A1733|108 132|multiple internal deletions
P10329586A0414|12 22|fibronectin
P10329586A0414|24 25|FN
P10329586A0414|52 58|60-fold
P10329586A0414|62 73|LNCaP-r cells
P10329586A0414|107 120|overexpression
P10329586A0414|123 124|FN
P10329586A0414|127 140|prostate cancer
P10329625A0715|18 31|cell surface CD4
P10329625A0715|35 37|CD8
P10329625A0715|41 43|CD3
P10329625A0715|47 51|cells
P10329625A0715|66 73|TCR genes
P10329625A0715|87 100|Id3-transduced
P10329625A0715|87 89|Id3
P10329625A0715|111 138|control-transduced pre-T cells
P10329625A0715|143 146|FTOC
P10329736A0681|23 43|yeast two-hybrid system
P10329736A0681|45 49|mIRS3
P10329736A0681|68 77|p85 subunit
P10329736A0681|80 107|phosphatidylinositol 3-kinase
P10329736A1106|0 17|Insulin stimulation
P10329736A1106|0 6|Insulin
P10329736A1106|42 46|mIRS3
P10329736A1106|51 53|p85
P10329736A1106|55 58|SHP2
P10329736A1106|60 62|Nck
P10329736A1106|67 69|Shc
P10330134A0765|3 16|mRNA expression
P10330134A0765|19 22|RFX1
P10330134A0765|24 27|RFX2
P10330134A0765|32 35|RFX3
P10330134A0765|65 92|transient-transfection assays
P10330134A0765|94 120|multimerized RFX binding sites
P10330134A0765|106 120|RFX binding sites
P10330134A0765|131 143|basal promoter
P10330134A0765|178 199|lineage-specific manner
P10330146A0730|14 31|unspliceable intron
P10330146A0730|33 42|repression
P10330146A0730|45 70|luciferase expression likely
P10330146A0730|45 54|luciferase
P10330146A0730|82 102|AUF1-binding sequences
P10330146A0730|109 128|luciferase expression
P10330146A0730|109 118|luciferase
P10330146A0730|143 150|deletion
P10330146A0730|158 162|sites
P10330159A1258|5 7|VDR
P10330159A1258|31 40|components
P10330159A1258|52 61|activation
P10330159A1258|68 84|promoter/enhancer
P10330159A1258|100 104|NFAT1
P10330159A1258|120 132|composite site
P10330159A1258|151 158|adjacent
P10330159A1258|161 167|Jun-Fos
P10330168A0135|26 32|kinases
P10330168A0135|37 43|cyclin B
P10330168A0135|45 47|Clb
P10330168A0135|50 71|cyclin-dependent kinase
P10330168A0135|73 82|Cdk/Cdc28p
P10330168A0135|73 75|Cdk
P10330168A0135|77 82|Cdc28p
P10330168A0135|87 91|Cdc7p
P10330168A0135|115 125|factor Dbf4p
P10330168A0135|121 125|Dbf4p
P10330168A0135|144 145|G1
P10330168A0135|156 169|DNA replication
P10330396A0387|3 22|RanQ69L preincubation
P10330396A0387|3 9|RanQ69L
P10330396A0387|30 41|accumulation
P10330396A0387|44 47|CRM1
P10330396A0387|53 72|cytoplasmic periphery
P10330396A0387|78 95|nuclear pore complex
P10330396A0387|97 99|NPC
P10330396A0387|121 130|p62 complex
P10330396A0387|134 143|Can/Nup214
P10330396A0387|134 136|Can
P10330396A0387|138 143|Nup214
P10331276A0298|8 15|elements
P10331276A0298|26 41|uniform structure
P10331646A0595|21 37|amino acid sequence
P10331646A0595|41 52|second family
P10331646A0595|54 57|ART5
P10331646A0595|61 72|transferases
P10331646A0595|84 102|murine lymphoma cells
P10331646A0595|117 129|high abundance
P10331646A0595|132 137|testis
P10331646A0595|148 171|hydrophobic amino terminus
P10331646A0595|188 201|signal sequence
P10331646A0595|212 236|hydrophobic signal sequence
P10331646A0595|242 257|carboxyl terminus
P10331730A0504|0 6|RESULTS
P10331730A0504|28 28|%
P10331730A0504|31 35|cases
P10331730A0504|42 49|Sardinia
P10331730A0504|68 68|%
P10331730A0504|79 86|patients
P10331730A0504|104 114|study period
P10331730A0504|130 151|regional medical centres
P10331875A0523|4 17|dimer interface
P10331875A0523|51 72|DNA-binding specificity
P10331875A0523|76 83|affinity
P10331875A0523|89 100|trimeric form
P10331875A0523|103 105|HSF
P10331875A0523|128 140|cooperativity
P10331875A0523|148 162|adjacent trimers
P10332733A0000|3 21|paramyxovirus fusion
P10332733A0000|23 31|F) protein
P10332733A0000|23 23|F
P10332733A0000|40 53|membrane fusion
P10333481A1102|13 28|deletion analysis
P10333481A1102|34 60|UCP2 promoter-PLAP constructs
P10333481A1102|34 45|UCP2 promoter
P10333481A1102|77 89|minimal region
P10333481A1102|103 118|promoter activity
P10333481A1102|122 128|located
P10333481A1102|136 137|nt
P10333481A1102|157 170|strong enhancer
P10333481A1102|190 191|bp
P10333481A1102|200 213|promoter region
P10333526A0459|3 11|hTERT gene
P10333526A0459|50 54|exons
P10333529A0277|4 14|betaAPP mRNA
P10333529A0277|18 28|Abeta levels
P10333529A0277|18 22|Abeta
P10333529A0277|43 49|trisomy
P10334888A0960|2 13|reperfusion B
P10334888A0960|22 34|diabetic group
P10334888A0960|48 66|significant increase
P10334888A0960|69 86|IL-8 concentrations
P10334888A0960|69 72|IL-8
P10334888A0960|95 97|min
P10334888A0960|108 119|nondiabetics
P10336495A0547|4 13|repression
P10336495A0547|25 32|agonists
P10336495A0547|41 48|receptor
P10336495A0547|63 83|functional interaction
P10336495A0547|91 94|NCoR
P10336495A0547|98 106|PPARalpha
P10336495A0547|108 137|RXRalpha heterodimeric complexes
P10336495A0547|108 115|RXRalpha
P10336495A0547|140 153|mammalian cells
P10339552A0361|5 16|present study
P10339552A0361|28 37|SRm160/300
P10339552A0361|52 65|purine-rich ESE
P10339552A0361|78 85|splicing
P10339552A0361|89 96|pre-mRNA
P10339552A0361|111 133|Drosophila doublesex gene
P10339566A0602|0 5|Spc42p
P10339566A0602|38 61|cytoplasmic SPB subcomplex
P10339566A0602|72 83|Spc94p/Nud1p
P10339566A0602|72 77|Spc94p
P10339566A0602|79 83|Nud1p
P10339566A0602|85 90|Cnm67p
P10339566A0602|95 100|Spc42p
P10340447A0424|3 21|average coefficients
P10340447A0424|60 62|QMF
P10340447A0424|69 77|QIT system
P10340883A1266|3 10|5-year OS
P10340883A1266|14 22|stage IIIB
P10340883A1266|30 30|%
P10340883A1266|45 45|%
P10341219A0481|12 32|heparin lyase treatment
P10341219A0481|12 23|heparin lyase
P10341219A0481|35 42|extracts
P10341219A0481|45 49|cells
P10341219A0481|60 86|recombinant YD-repeat protein
P10341219A0481|110 136|high molecular mass aggregates
P10342511A0909|3 13|coefficient
P10342511A0909|30 31|r2
P10342511A0909|38 48|other scores
P10342536A0954|23 36|protein content
P10342536A0954|42 49|formulae
P10342536A0954|56 71|valid information
P10342536A0954|73 91|RAST/EAST inhibition
P10342536A0954|95 101|highest
P10342536A0954|147 157|whey formula
P10342536A0954|178 195|whey/casein formula
P10342536A0954|183 188|casein
P10342536A0954|197 219|soy/pork collagen formula
P10342536A0954|197 212|soy/pork collagen
P10342536A0954|227 242|amino acid formula
P10342829A0236|24 28|GnRHR
P10342829A0236|33 51|molecular mechanisms
P10342829A0236|65 89|transcriptional regulation
P10342829A0236|95 104|human GnRHR
P10342829A0236|106 111|hGnRHR
P10342829A0236|124 131|key issue
P10342829A0236|147 163|human reproduction
P10342829A1370|0 29|Competitive mobility shift assays
P10342829A1370|41 63|alphaT3-1 nuclear extract
P10342829A1370|66 87|recombinant SF-1 protein
P10342829A1370|108 111|SF-1
P10342829A1370|148 157|GSE element
P10343189A0911|0 4|Grade
P10343189A0911|6 14|mucositis
P10344736A0796|0 19|CDK4 kinase activities
P10344736A0796|0 9|CDK4 kinase
P10344736A0796|24 33|unaffected
P10344736A0796|44 49|levels
P10344736A0796|55 80|CDK inhibitor p21Cip1 present
P10344736A0796|55 57|CDK
P10344736A0796|67 73|p21Cip1
P10344736A0796|83 104|cyclin E immunocomplexes
P10347144A0516|3 13|recombinant
P10347144A0516|43 59|baculovirus system
P10347144A0516|65 88|approximate molecular size
P10347144A0516|91 93|kDa
P10347144A0516|98 119|amino-terminal sequence
P10347144A0516|122 126|AVQGP
P10347197A0502|0 8|Induction
P10347197A0502|14 30|urokinase promoter
P10347197A0502|33 38|HGF/SF
P10347197A0502|33 35|HGF
P10347197A0502|37 38|SF
P10347197A0502|45 55|Met receptor
P10347197A0502|68 80|co-expression
P10347197A0502|84 104|dominant-negative Grb2
P10347197A0502|108 130|Sos1 expression construct
P10347197A0502|108 111|Sos1
P10347203A0832|0 20|Serine phosphorylation
P10347203A0832|23 27|STAT3
P10347203A0832|48 68|somatostatin treatment
P10347203A0832|48 59|somatostatin
P10347203A0832|86 99|pertussis toxin
P10347203A0832|102 103|PD
P10347203A0832|125 143|associated increases
P10347203A0832|146 158|proliferation
P10347220A1477|33 58|entire three-component yeast
P10347220A1477|66 74|apparatus
P10347220A1477|88 107|RNA 5'-triphosphatase
P10347220A1477|88 90|RNA
P10347220A1477|94 107|triphosphatase
P10347220A1477|109 113|Cet1p
P10347220A1477|116 137|RNA guanylyltransferase
P10347220A1477|139 143|Ceg1p
P10347220A1477|149 153|Abd1p
P10347220A1477|180 210|two-component mammalian apparatus
P10347220A1477|224 274|bifunctional triphosphatase-guanylyltransferase Mce1p
P10347220A1477|236 274|triphosphatase-guanylyltransferase Mce1p
P10347220A1477|281 301|methyltransferase Hcm1
P10347220A1477|311 312|p.
P10347839A0434|3 12|IC50 values
P10347839A0434|22 38|dog urinary bladder
P10347839A0434|53 53|M
P10347839A0434|67 67|M
P10348859A0292|16 36|potential binding sites
P10348859A0292|49 61|MerR homodimer
P10348859A0292|74 75|Hg
P10348859A0292|80 82|ion
P10348859A0292|93 97|Cys82
P10348859A0292|105 111|monomer
P10348859A0292|115 120|Cys117
P10348859A0292|124 129|Cys126
P10349084T0000|14 44|Epstein-Barr virus seropositivity
P10349084T0000|50 57|efficacy
P10349084T0000|60 84|intravenous immune globulin
P10349084T0000|71 84|immune globulin
P10349084T0000|87 94|children
P10349084T0000|99 127|immune thrombocytopenic purpura
P10349443A0358|3 9|results
P10349443A0358|21 30|field tests
P10349443A0358|38 47|high levels
P10349443A0358|50 60|infestation
P10349443A0358|63 68|larvae
P10349443A0358|73 78|values
P10349443A0358|97 97|%
P10349443A0358|111 111|%
P10350027A0942|0 10|Amisulpride
P10350027A0942|14 15|mg
P10350027A0942|19 39|several adverse effects
P10350027A0942|42 52|psychomotor
P10350027A0942|78 97|cognitive performance
P10350027A0942|103 110|fifth day
P10350454A0000|0 3|MutY
P10350454A0000|8 29|adenine-DNA glycosylase
P10350454A0000|34 44|specificity
P10350454A0000|48 57|mismatches
P10350454A0000|67 78|8-oxoguanine
P10350454A0000|80 81|oG
P10350454A0000|87 93|guanine
P10350454A0000|95 97|G.A
P10350484A0346|3 10|kinetics
P10350484A0346|13 26|kinase activity
P10350484A0346|38 46|complexes
P10350484A0346|57 60|CheA
P10350484A0346|90 98|% decrease
P10350484A0346|104 105|KM
P10350484A0346|109 111|ATP
P10350484A0346|137 140|Vmax
P10350638A0000|0 6|Latexin
P10350638A0000|9 34|carboxypeptidase A inhibitor
P10350638A0000|50 72|cell type-specific manner
P10350638A0000|89 112|peripheral nervous systems
P10353073A0118|0 17|Regression analyses
P10353073A0118|37 53|protective factors
P10353880A0257|54 60|infants
P10353880A0257|71 80|live births
P10353880A0257|96 98|HSV
P10353880A0257|100 101|P=
P10355085A1119|0 6|Subsets
P10355085A1119|9 16|patients
P10355085A1119|44 51|severity
P10355085A1119|61 63|ISS
P10355085A1119|93 114|different injury pattern
P10355085A1119|119 127|survivors
P10355085A1119|134 145|nonsurvivors
P10355536A0172|3 11|median age
P10355536A0172|17 21|years
P10355536A0172|33 37|years
P10355910A0369|0 21|Developmental follow-up
P10355910A0369|28 32|years
P10357751A0866|5 14|whole group
P10357751A0866|17 32|infected children
P10357751A0866|36 47|age-specific
P10357751A0866|72 74|FFM
P10357751A0866|128 139|relative risk
P10357751A0866|143 145|% CI
P10357751A0866|147 147|=
P10357751A0866|197 208|only children
P10357751A0866|217 229|severe disease
P10358031A0303|16 20|cells
P10358031A0303|40 63|multiple nuclei indicative
P10358031A0303|67 75|G2/M delay
P10358031A0303|78 92|nuclear division
P10358031A0303|101 106|defect
P10358031A0303|109 119|cytokinesis
P10358031A0303|126 139|cell separation
P10358075A0984|0 4|DAF16
P10358075A0984|29 44|signaling pathway
P10358075A0984|96 105|homologues
P10358075A0984|111 121|insulin/IGF
P10358075A0984|111 117|insulin
P10358075A0984|119 131|IGF-1 receptor
P10358075A0984|124 131|receptor
P10358075A0984|133 146|PtdIns 3-kinase
P10358075A0984|150 152|PKB
P10358079A0391|8 51|neu differentiation factor-induced heterodimers
P10358079A0391|54 58|ErbB2
P10358079A0391|62 66|ErbB4
P10358079A0391|76 80|Stat5
P10358080A1114|8 20|linker regions
P10358080A1114|23 42|transcription factors
P10358080A1114|61 81|DNA binding specificity
P10358080A1114|86 92|studies
P10358080A1114|107 121|human HSF1 linker
P10358080A1114|146 167|HSF1 binding preferences
P10358080A1114|146 149|HSF1
P10358080A1114|180 198|critical determinant
P10358080A1114|214 242|HSF1 monomer-trimer equilibrium
P10358080A1114|214 224|HSF1 monomer
P10358080T0000|0 9|Modulation
P10358080T0000|12 44|human heat shock factor trimerization
P10358080T0000|12 31|human heat shock factor
P10358080T0000|50 61|linker domain
P10358083A0263|4 21|functional analyses
P10358083A0263|24 39|undifferentiated
P10358083A0263|57 63|F9 cells
P10358083A0263|67 82|characterization
P10358083A0263|85 104|DNA-protein complexes
P10358083A0263|129 148|sequence motifs GTGACT
P10358083A0263|150 150|C
P10358083A0263|153 157|ATTGT
P10358083A0263|162 165|GATA
P10358083A0263|171 192|key transcription factor
P10358083A0263|200 204|sites
P10358138A0672|5 11|results
P10358138A0672|26 34|phenotype
P10358138A0672|37 39|XLP
P10358138A0672|62 70|signaling
P10358138A0672|85 88|SLAM
P10358138A0672|97 121|other cell surface molecules
P10358138A0672|133 135|SAP
P10358138A0672|139 161|signaling adaptor protein
P10359014A1077|18 42|Fra-2 phosphorylation sites
P10359014A1077|18 22|Fra-2
P10359014A1077|45 48|MAPK
P10359014A1077|56 64|threonine
P10359014A1077|73 86|serine residues
P10359014A1077|92 110|COOH-terminal region
P10359014A1077|113 117|means
P10359014A1077|120 143|site-directed mutagenesis
P10359014A1077|160 176|threonine residues
P10359014A1077|185 195|susceptible
P10359014A1077|198 201|MAPK
P10359575A0317|46 54|FcalphaRI
P10359575A0317|60 67|human IgA
P10359575A0317|65 67|IgA
P10359575A0317|69 72|hIgA
P10359575A0317|80 89|bovine IgG2
P10359575A0317|91 95|bIgG2
P10359575A0317|105 114|bFcgamma2R
P10359575A0317|120 124|bIgG2
P10359575A0317|131 134|hIgA
P10359603A0430|0 4|Vac1p
P10359603A0430|22 41|Sec1p homologue Vps45p
P10359603A0430|22 35|Sec1p homologue
P10359603A0430|36 41|Vps45p
P10359663A0425|3 35|heterologous transcriptional system
P10359663A0425|46 60|upstream regions
P10359663A0425|63 69|oIFNtau
P10359663A0425|91 103|simian virus 40
P10359663A0425|91 101|simian virus
P10359663A0425|105 117|SV40) promoter
P10359663A0425|105 108|SV40
P10359663A0425|110 117|promoter
P10359663A0425|122 128|regions
P10359663A0425|136 140|bases
P10359663A0425|176 189|enhancer region
P10359663A0425|201 231|oIFNtau-SV40-CAT transactivation
P10359663A0425|201 207|oIFNtau
P10359663A0425|209 216|SV40-CAT
P10359663A1280|2 23|co-transfection studies
P10359663A1280|40 44|c-Jun
P10359663A1280|49 53|c-Fos
P10359663A1280|65 79|transactivation
P10359663A1280|82 92|oIFNtau-CAT
P10359663A1280|82 88|oIFNtau
P10359663A1280|90 92|CAT
P10359663A1280|111 116|GATA-1
P10359663A1280|118 123|GATA-2
P10359663A1280|126 131|GATA-3
P10359664A0579|15 19|sites
P10359664A0579|21 45|Cdk2-phosphorylated MARCKS
P10359664A0579|21 24|Cdk2
P10359664A0579|40 45|MARCKS
P10359664A0579|61 77|lysyl endoprotease
P10359664A0579|91 105|electrospray MS.
P10359673A0000|3 15|yeast LPD1 gene
P10359673A0000|24 45|lipoamide dehydrogenase
P10359673A0000|60 73|general control
P10359673A0000|76 96|amino acid biosynthesis
P10359673A0000|110 132|GCN4 transcription factor
P10359673A0000|110 113|GCN4
P10359792A0610|13 23|mild defects
P10359792A0610|34 44|Rpd3 mutants
P10359792A0610|77 83|Groucho
P10359792A0610|87 110|dCtBP corepressor proteins
P10359792A0610|140 150|recruitment
P10359792A0610|153 171|histone deacetylases
P10360454A0916|11 33|serum TNF-a concentration
P10360454A0916|58 65|patients
P10360454A0916|75 88|pentoxifylline
P10360454A0916|90 94|basal
P10360454A0916|104 108|pg/ml
P10360454A0916|110 117|6th month
P10360454A0916|127 131|pg/ml
P10360454A0916|133 133|p
P10360454A0916|152 163|control group
P10360839A1338|36 52|individual members
P10360839A1338|58 66|subfamily
P10360839A1338|69 87|KRAB zinc finger genes
P10360839A1338|90 99|restricted
P10360839A1338|102 134|specific hematopoietic cell lineages
P10360947A1113|9 32|fluorescence spectroscopy
P10360947A1113|36 52|circular dichroism
P10360947A1113|69 75|binding
P10360947A1113|78 80|Ca2
P10360947A1113|84 88|ALG-2
P10360947A1113|96 127|significant conformational changes
P10360947A1113|137 146|N-terminal
P10360947A1113|150 166|C-terminal domains
P10361038A0281|15 30|similar locations
P10361038A0281|36 44|promoters
P10361038A0281|47 79|several other ribosomal protein genes
P10361038A0281|59 79|ribosomal protein genes
P10362652A0350|4 12|carbachol
P10362652A0350|17 22|microM
P10362652A0350|27 29|EGF
P10362652A0350|33 34|nM
P10362652A0350|43 55|Ras activation
P10362652A0350|43 45|Ras
P10362652A1456|0 18|Dominant negative Sos
P10362652A1456|16 18|Sos
P10362652A1456|31 50|carbachol stimulation
P10362652A1456|53 59|HA-ERK2
P10362652A1456|53 54|HA
P10362652A1456|56 59|ERK2
P10362652A1456|75 91|stimulatory effect
P10362652A1456|94 96|EGF
P10362652A1456|101 101|%
P10362897A0545|0 6|RESULTS
P10362897A0545|8 28|Transpulmonary passage
P10362897A0545|49 65|sufficient amounts
P10362897A0545|92 104|Doppler signal
P10362897A0545|125 132|duration
P10363517A0401|12 22|such lesions
P10363517A0401|28 32|cases
P10363517A0401|48 62|ultrasonography
P10364076A0429|5 11|regions
P10364076A0429|19 42|inverted E-box palindromic
P10364076A0429|45 62|direct repeat motifs
P10364076A0429|70 76|SREBP-1
P10364076A0429|81 99|different affinities
P10364159A0813|14 22|questions
P10364159A0813|25 51|recombinant FRAP/mTOR protein
P10364159A0813|36 39|FRAP
P10364159A0813|41 44|mTOR
P10364159A0813|56 81|FRAP/mTOR immunoprecipitate
P10364159A0813|56 59|FRAP
P10364159A0813|61 64|mTOR
P10364159A0813|103 114|kinase assays
P10364159A0813|130 135|4E-BP1
P10364163A0092|0 2|Hrs
P10364163A0092|7 32|FYVE double zinc finger domain
P10364163A0092|56 77|phosphatidylinositol(3
P10364163A0092|56 75|phosphatidylinositol
P10364163A0092|80 88|phosphate
P10364163A0092|105 119|several proteins
P10364163A0092|130 145|vesicular traffic
P10364202A0646|3 14|coexpression
P10364202A0646|17 47|full-length expression constructs
P10364202A0646|55 57|DBP
P10364202A0646|61 81|hepatic leukemia factor
P10364202A0646|93 108|dramatic increase
P10364202A0646|111 120|activation
P10364202A0646|134 155|GAL4-DBP fusion proteins
P10364202A0646|134 137|GAL4
P10364202A0646|193 203|coactivator
P10364314A0919|5 14|subgenomes
P10364314A0919|34 44|nucleotides
P10364314A0919|70 76|NS2 gene
P10364319A0109|0 1|Cp
P10364319A0109|15 26|main promoter
P10364319A0109|30 47|EBNA mRNA initiation
P10364319A0109|64 69|EBNA3C
P10364319A0109|84 116|negative autoregulatory control loop
P10364425A0610|5 15|indications
P10364425A0610|29 38|signalling
P10364425A0610|53 60|tyrosine
P10364425A0610|83 101|sustained activation
P10364425A0610|104 108|STAT3
P10364523A0826|4 15|exon trapping
P10364523A0826|35 48|potential exons
P10364523A0826|56 64|YAC 946E12
P10364523A0826|113 118|contig
P10364523A0826|124 131|vicinity
P10364523A0826|137 147|breakpoints
P10364523T0000|0 42|Campomelic dysplasia translocation breakpoints
P10364523T0000|60 69|Mb proximal
P10364523T0000|72 75|SOX9
P10364523T0000|90 110|extended control region
P10365883A1355|7 27|common characteristics
P10365883A1355|30 40|VRE patients
P10365883A1355|45 68|recent prior vancomycin use
P10365883A1355|70 112|recent prior susceptible enterococcal infection
P10365883A1355|114 124|coinfection
P10365883A1355|129 151|other microbial pathogens
P10365883A1355|156 180|concurrent fungal infection
P10366446A0893|1 17|coiled-coil domain
P10366446A0893|62 86|potential interaction motif
P10366446A0893|90 95|FLI LRR
P10366503A0812|0 16|Binding affinities
P10366503A0812|24 40|recombinant phages
P10366503A0812|58 66|retention
P10366503A0812|74 79|phages
P10366503A0812|83 89|His-tag
P10366503A0812|101 110|gp17 column
P10366503A0812|101 104|gp17
P10366503A0812|117 138|co-immunoprecipitation
P10366503A0812|151 159|terminase
P10366503A0812|172 185|specific nature
P10366503A0812|191 203|portal protein
P10366503A0812|207 231|terminase interaction sites
P10366503A1506|11 19|terminase
P10366503A1506|47 63|gp20 portal peptide
P10366503A1506|65 82|polyclonal antibody
P10366503A1506|93 105|portal peptide
P10366503A1506|134 148|native structure
P10366503A1506|160 178|intimate association
P10366503A1506|181 184|gp20
P10366503A1506|188 191|gp17
P10366503A1506|212 227|terminase regions
P10366503A1506|237 242|portal
P10366503A1506|248 263|packasome complex
P10366559A0605|3 15|hybrid viruses
P10366559A0605|39 48|high levels
P10366559A0605|51 64|infected plants
P10366559A0605|72 84|stable virions
P10366559A0605|105 117|transmissible
P10366722T0000|0 3|cDNA
P10366722T0000|7 28|structural organization
P10366722T0000|34 42|gene Pole1
P10366722T0000|49 89|mouse DNA polymerase epsilon catalytic subunit
P10367240A1354|12 27|cryopreservation
P10367240A1354|30 40|spermatozoa
P10367240A1354|67 68|SP
P10367240A1354|72 91|biological substances
P10367240A1354|104 127|acceptable cryoprotection
P10367240A1354|130 140|spermatozoa
P10367240A1354|151 181|assisted fertilization procedures
P10367240A1354|196 225|intracytoplasmic sperm injection
P10367385A0000|1 27|liquid chromatographic method
P10367385A0000|52 64|beta-carotene
P10367385A0000|67 77|medical food
P10367460A0191|3 16|FCMS conditions
P10367460A0191|32 66|kW maximum electrical power consumption
P10367460A0191|71 94|V maximum capacitor voltage
P10367460A0191|99 120|microseconds pulsewidth
P10367460A0191|125 136|microseconds
P10367460A0191|154 164|Hz frequency
P10367646A0569|0 14|Severe hemolysis
P10367646A0569|38 55|significant changes
P10367646A0569|61 70|mean values
P10367646A0569|76 88|above analytes
P10367646A0569|113 121|increases
P10367646A0569|123 145|alanine aminotransferase
P10367646A0569|147 153|calcium
P10367646A0569|158 171|serum globulins
P10367646A0569|173 173|P
P10367646A0569|184 190|albumin
P10367646A0569|194 205|total protein
P10367646A0569|207 207|P
P10369418A0644|0 3|EMSA
P10369418A0644|8 27|crude nuclear extracts
P10369418A0644|44 54|stimulation
P10369418A0644|59 63|CD40L
P10369418A0644|76 84|induction
P10369418A0644|87 104|NF-kappaB complexes
P10369418A0644|129 142|NF-kappaB sites
P10369418A0644|165 167|p50
P10369418A0644|171 174|RelB
P10369418A0644|190 194|c-Rel
P10369418A0644|198 200|p65
P10369625A0942|0 16|Optimal monitoring
P10369625A0942|19 21|ODA
P10369625A0942|29 37|undefined
P10369757A0000|3 27|major transcription factors
P10369757A0000|39 56|arginine metabolism
P10369757A0000|77 92|Bacillus subtilis
P10369757A0000|94 97|ArgR
P10369757A0000|101 104|AhrC
P10369757A0000|122 149|homologous multimeric proteins
P10369757A0000|158 158|l
P10369757A0000|160 204|arginine-dependent DNA-binding complexes capable
P10369757A0000|217 229|transcription
P10369757A0000|235 251|biosynthetic genes
P10369757A0000|269 281|transcription
P10369757A0000|284 297|catabolic genes
P10369757A0000|299 302|AhrC
P10369757A0000|322 343|plasmid dimer resolution
P10369775A0178|10 25|protein fragments
P10369775A0178|35 55|residues Arg183-His267
P10369775A0178|61 67|human ER
P10369775A0178|71 91|residues Lys438-Gln520
P10369775A0178|97 101|rat GR
P10369926A0251|3 6|exon
P10369926A0251|8 22|intron structure
P10369926A0251|25 34|chicken IL8
P10369926A0251|67 74|human IL8
P10369926A0251|96 131|other known mammalian CXC chemokine genes
P10369926A0251|106 131|mammalian CXC chemokine genes
P10369965A0000|3 13|Aa-Pri2 gene
P10369965A0000|42 67|basidiocarp differentiation
P10369965A0000|73 96|mushroom Agrocybe aegerita
P10370675A0649|3 12|main causes
P10370675A0649|15 26|liver disease
P10370675A0649|32 39|patients
P10370675A0649|44 46|HCC
P10370675A0649|51 65|hepatitis C virus
P10370675A0649|67 69|HCV
P10370675A0649|74 74|%
P10370675A0649|77 88|alcohol abuse
P10370675A0649|92 92|%
P10370675A0649|114 116|HCV
P10370675A0649|120 131|alcohol abuse
P10370675A0649|135 135|%
P10370778A0000|5 26|new aromatase inhibitors
P10370778A0000|8 16|aromatase
P10370778A0000|79 100|metastatic breast cancer
P10370778A0000|103 122|post-menopausal women
P10370778A0000|155 170|tamoxifen therapy
P10370778A0000|172 182|anastrozole
P10370778A0000|184 191|ARIMIDEX
P10370778A0000|193 198|Zeneca
P10370778A0000|201 209|letrozole
P10370778A0000|211 216|FEMARA
P10370778A0000|218 225|Novartis
P10370778A0000|230 237|vorozole
P10370778A0000|239 245|RIVIZOR
P10370778A0000|247 253|Janssen
P10371097A0963|0 10|CONCLUSIONS
P10371097A0963|12 20|Turbutest
P10371097A0963|24 35|valuable tool
P10371097A0963|38 54|asthmatic patients
P10371097A0963|105 133|inadequate inhalation technique
P10371097A0963|138 147|Turbuhaler
P10372627A0530|7 14|injuries
P10372627A0530|19 23|cases
P10372627A0530|28 43|snowboard related
P10372627A0530|50 54|cases
P10372627A0530|59 68|ski related
P10373029A0204|3 20|femoral artery/vein
P10373029A0204|27 32|soleus
P10373029A0204|36 55|gastrocnemius muscles
P10373029A0204|70 95|healthy human male volunteers
P10373507A0680|0 8|SRFDelta5
P10373507A0680|34 65|dominant negative regulatory mutant
P10373507A0680|76 107|SRF-dependent skeletal alpha-actin
P10373507A0680|109 126|cardiac alpha-actin
P10373507A0680|128 144|smooth alpha-actin
P10373507A0680|146 154|SM22alpha
P10373507A0680|159 198|SRF promoter-luciferase reporter activities
P10373507A0680|159 169|SRF promoter
P10373523A0924|2 16|serum-free media
P10373523A0924|18 23|p50E4F
P10373523A0924|35 54|E1A-induced apoptosis
P10373523A0924|35 37|E1A
P10374632A0818|3 9|potency
P10374632A0818|23 25|Nim
P10374632A0818|30 36|mg.kg-1
P10374632A0818|60 62|NBP
P10374632A0818|66 72|mg.kg-1
P10374632A0897|0 9|CONCLUSION
P10374632A0897|11 26|NBP pre-treatment
P10374632A0897|29 42|post-treatment
P10374632A0897|62 65|rCBF
P10374632A0897|68 75|striatum
P10374632A0897|78 86|RMCAO rats
P10375107A1138|0 10|Progression
P10375107A1138|16 37|first-line chemotherapy
P10375107A1138|68 80|worse survival
P10375107A1138|84 91|patients
P10375107A1138|96 105|metastasis
P10375638A0859|0 8|Mutations
P10375638A0859|15 23|human UTR1
P10375638A0859|32 46|NRF-1 expression
P10375638A0859|32 36|NRF-1
P10375638A0859|64 90|mRNA translational efficiency
P10375638A0859|104 108|cells
P10375638A0859|123 139|translation system
P10375640A0153|18 35|nucleotide sequence
P10375640A0153|41 44|cDNA
P10375640A0153|46 50|CBS-1
P10375640A0153|61 76|open reading frame
P10375640A0153|92 101|amino acids
P10375640A0153|108 122|molecular weight
P10375640A0153|129 131|kDa
P10375694T0000|0 14|Corticostriatal
P10375694T0000|18 45|corticosubthalamic input zones
P10375694T0000|53 77|presupplementary motor area
P10375694T0000|83 95|macaque monkey
P10375694T0000|114 123|input zones
P10375694T0000|131 152|supplementary motor area
P10375718A0000|0 26|Basic fibroblast growth factor
P10375718A0000|28 31|bFGF
P10375718A0000|53 64|angiogenesis
P10375718A0000|67 85|various animal models
P10375718A0000|93 99|methods
P10375718A0000|150 157|feasible
P10376065A0881|4 10|filters
P10376065A0881|31 39|elevation
P10376065A0881|42 60|iliac venous pressure
P10376065A0881|62 67|median
P10376065A0881|78 81|mm Hg
P10376065A0881|83 84|n =
P10376065A0881|94 105|spring filter
P10376065A0881|109 118|RF02 filter
P10376446A0000|2 13|healthy women
P10376446A0000|23 27|years
P10376446A0000|49 54|2-hour
P10376446A0000|65 74|passive leg
P10376446A0000|82 84|PLR
P10376446A0000|88 97|follicular
P10376446A0000|99 100|FP
P10376446A0000|105 110|luteal
P10376446A0000|112 113|LP
P10376446A0000|115 120|phases
P10376446A0000|123 142|normal ovulatory cycle
P10376873A0706|5 10|sgRNA2
P10376873A0706|28 30|UTR
P10376874A0759|5 27|single mutational defects
P10376874A0759|33 52|eRF1-eRF3 interaction
P10376874A0759|33 36|eRF1
P10376874A0759|38 41|eRF3
P10376874A0759|85 96|protein eRF3C
P10376874A0759|92 96|eRF3C
P10376874A0759|111 129|altered eRF1 proteins
P10376874A0759|118 121|eRF1
P10376874A0759|144 159|authentic protein
P10376874A0759|170 183|further support
P10376874A0759|201 221|C-terminal interaction
P10376877A0611|0 6|Removal
P10376877A0611|20 37|contiguous segments
P10376877A0611|45 58|N-terminal half
P10376877A0611|93 101|5.8Ss rRNA
P10376877A0611|96 101|Ss rRNA
P10376877A0611|127 142|C-terminal region
P10376877A0611|180 186|18S rRNA
P10376991A0977|0 2|Ras
P10376991A0977|25 32|tegument
P10377345A0740|0 36|Green fluorescent protein-tagged UNC-49B
P10377345A0740|30 36|UNC-49B
P10377345A0740|40 54|UNC-49C subunits
P10377345A0740|71 81|muscle cells
P10377345A0740|101 115|synaptic regions
P10377438A0647|19 22|UBC9
P10377438A0647|49 51|TEL
P10378989A0000|36 53|spontaneous reports
P10378989A0000|65 84|adverse drug reactions
P10378989A0000|96 110|elderly patients
P10378989A0000|118 122|years
P10378989A0000|131 136|Sicily
P10378989A0000|138 142|Italy
P10378989A0000|164 170|January
P10378989A0000|179 186|December
P10379547A0000|0 8|Molecules
P10379547A0000|11 13|NH3
P10379547A0000|54 58|MASER
P10379899A0446|3 15|major findings
P10379899A0446|21 27|studies
P10379899A0446|53 69|detectable signals
P10379899A0446|76 99|GDF-9-deficient follicles
P10379899A0446|103 130|several theca cell layer markers
P10379942A0956|27 34|residues
P10379942A0956|63 82|carboxy-terminal part
P10379942A0956|88 102|MDV2 UL10 protein
P10379942T0000|0 13|Identification
P10379942T0000|31 35|Marek
P10379942T0000|38 57|disease virus serotype
P10379942T0000|59 75|glycoprotein M gene
P10379942T0000|91 108|glycoprotein M genes
P10379942T0000|111 129|Herpesviridae family
P10380232A0000|0 8|OBJECTIVE
P10380232A0000|20 45|cost-effectiveness analysis
P10380232A0000|47 49|CEA
P10380232A0000|59 98|standard antiemetic regimen-chlorpromazine
P10380232A0000|100 112|dexamethasone
P10380232A0000|114 120|CPM-DEX
P10380232A0000|127 161|5-HT3 receptor antagonist-tropisetron
P10380232A0000|127 139|5-HT3 receptor
P10380232A0000|163 166|TROP
P10380232A0000|184 194|acute emesis
P10380232A0000|210 231|emetogenic chemotherapy
P10380232A0000|234 241|children
P10380232A0000|257 276|analytic perspectives
P10380232A0000|289 296|patients
P10380659A0545|0 11|Baseline data
P10380659A0545|30 35|adults
P10380800A0194|16 25|nucleotide
P10380800A0194|36 53|amino acid sequences
P10380800A0194|59 69|core regions
P10380800A0194|75 107|RNA-dependent RNA polymerase domains
P10380800A0194|125 130|dsRNAs
P10380800A0194|149 154|dsRNAs
P10380800A0194|193 201|host plant
P10380800A0194|207 220|common ancestor
P10380878A0542|0 9|Consistent
P10380878A0542|31 43|non-MBD region
P10380878A0542|46 49|Bin1
P10380878A0542|73 90|repression function
P10380878A0542|103 111|unrelated
P10380878A0542|114 131|histone deacetylase
P10380890A0619|11 19|sequences
P10380890A0619|48 60|IR-responsive
P10380890A0619|90 91|IR
P10381257A0000|26 33|metaxin 1
P10381257A0000|26 32|metaxin
P10381257A0000|56 78|preprotein import complex
P10381257A0000|84 96|outer membrane
P10381257A0000|102 123|mammalian mitochondrion
P10381377T0000|0 15|Molecular cloning
P10381377T0000|18 53|rat SH2-containing inositol phosphatase
P10381377T0000|56 60|SHIP2
P10381377T0000|89 104|insulin signaling
P10381377T0000|89 95|insulin
P10381570A1355|0 3|Slp1
P10381570A1355|13 25|transcription
P10381570A1355|33 43|binding site
P10381570A1355|46 55|yeast cells
P10381570A1355|81 95|direct repressor
P10381570A1355|98 107|ftz stripes
P10381570A1355|98 100|ftz
P10381570A1355|110 127|interstripe regions
P10381570A1355|134 143|late stages
P10381570A1355|146 158|embryogenesis
P10383764A1809|3 9|results
P10383764A1809|17 23|studies
P10383764A1809|44 54|VirB4 dimers
P10383764A1809|57 69|homomultimers
P10383764A1809|80 100|structural information
P10383764A1809|118 146|transenvelope channel competent
P10383764A1809|150 173|bidirectional DNA transfer
P10383764A1809|184 204|ATP-dependent activity
P10383764A1809|243 264|dedicated export machine
P10383966A0000|3 27|penicillin binding proteins
P10383966A0000|29 32|PBPs
P10383966A0000|54 66|peptidoglycan
P10383966A0000|71 89|structural component
P10383966A0000|95 111|bacterial cell wall
P10384129A0000|0 7|TCR alpha
P10384129A0000|9 12|TCRA
P10384129A0000|37 46|RNA samples
P10384129A0000|51 54|PBMC
P10384129A0000|66 76|populations
P10384129A0000|79 82|CD4+
P10384129A0000|79 81|CD4
P10384129A0000|84 87|CD8+
P10384129A0000|84 86|CD8
P10384129A0000|92 99|DN T cells
P10384129A0000|106 123|healthy individuals
P10385384A0654|0 13|Similar results
P10385384A0654|30 36|xylitol
P10385384A0654|40 48|activator
P10385384A0654|54 76|pentose phosphate pathway
P10385395A0000|3 24|high density lipoprotein
P10385395A0000|26 37|HDL) receptor
P10385395A0000|26 28|HDL
P10385395A0000|30 37|receptor
P10385395A0000|49 54|uptake
P10385395A0000|71 87|cholesteryl esters
P10385395A0000|89 98|substrates
P10385395A0000|102 116|steroidogenesis
P10385395A0000|124 134|HDL particle
P10385395A0000|140 151|adrenal gland
P10385395A0000|155 160|gonads
P10385915A1341|0 6|D3S1261
P10385915A1341|19 25|located
P10385915A1341|37 45|MITF locus
P10385915A1341|52 58|D3S2465
P10385915A1341|62 68|D3S1766
P10385915A1341|83 87|locus
P10385915A1341|99 115|cM genetic distance
P10388670A1976|3 13|percentages
P10388670A1976|37 47|storage time
P10388670A1976|70 79|dispersant
P10388670A1976|81 90|Tris-Tween
P10388670A1976|133 140|adhesion
P10390158A1150|0 13|Point mutations
P10390158A1150|37 48|Pit-1 binding
P10390158A1150|37 41|Pit-1
P10390158A1150|64 87|full tiGH promoter activity
P10390158A1150|68 79|tiGH promoter
P10390538T0000|1 37|human Raf-responsive zinc-finger protein
P10390538T0000|6 37|Raf-responsive zinc-finger protein
P10390538T0000|49 66|divergent sequences
P10391075A0000|16 26|autopsy case
P10391075A0000|39 60|acute multiple sclerosis
P10391075A0000|98 107|brain tumor
P10391075A0000|110 120|MRI findings
P10391246A0756|12 16|MOM-4
P10391246A0756|20 23|TAK1
P10391246A0756|28 42|related proteins
P10391246A0756|59 74|kinase activities
P10391277A0000|0 9|BACKGROUND
P10391277A0000|14 21|MAZE-III
P10391277A0000|27 43|surgical treatment
P10391277A0000|64 91|refractory atrial fibrillation
P10391903T0000|0 3|Gab2
P10391903T0000|6 57|new pleckstrin homology domain-containing adapter protein
P10391903T0000|9 57|pleckstrin homology domain-containing adapter protein
P10391903T0000|73 81|signaling
P10391903T0000|86 94|ERK kinase
P10391903T0000|97 101|Elk-1
P10392266A0111|13 30|cutaneous xanthomas
P10392266A0111|35 56|normal serum lipid levels
P10392266A0111|67 93|antibetalipoproteic activity
P10392266A0111|99 122|monoclonal immunoglobulin
P10392669A0935|22 30|incidence
P10392669A0935|33 68|NSAID-induced gastrointestinal lesions
P10392669A0935|82 91|approaches
P10392669A0935|120 151|prostaglandin analogue misoprostol
P10392669A0935|162 174|antiulcer drug
P10392669A0935|225 244|NSAID-induced gastric
P10392669A0935|248 261|duodenal ulcers
P10392669A0935|280 320|serious upper gastrointestinal complications
P10392669A0935|326 355|histamine H2 receptor antagonists
P10392669A0935|326 344|histamine H2 receptor
P10392669A0935|357 369|H2 antagonists
P10392669A0935|357 358|H2
P10392669A0935|376 385|ranitidine
P10392669A0935|387 396|cimetidine
P10392669A0935|400 409|famotidine
P10392669A0935|442 468|NSAID-induced duodenal ulcers
P10392669A0935|475 491|long term treatment
P10392669A0935|516 541|NSAID-induced gastric ulcers
P10392669A0935|548 567|proton pump inhibitors
P10392669A0935|569 581|e.g omeprazole
P10392669A0935|586 597|pantoprazole
P10392669A0935|604 611|efficacy
P10392669A0935|624 645|NSAID-associated ulcers
P10392669A0935|681 693|barrier agents
P10392669A0935|736 753|prophylactic agents
P10392669A0935|763 786|NSAID-induced gastropathy
P10392710A1000|0 13|Lung mesenchyme
P10392710A1000|24 31|compleat
P10392710A1000|33 39|inducer
P10392710A1000|42 58|lung morphogenesis
P10392710A1000|70 96|soluble peptide growth factors
P10392900A1020|3 12|activation
P10392900A1020|18 28|HIV promoter
P10392900A1020|40 58|nuclear localization
P10392900A1020|61 65|c-Abl
P10392900A1020|99 121|tyrosine phosphorylation
P10392900A1020|124 138|RNA polymerase II
P10392900A1020|124 136|RNA polymerase
P10392903A0000|3 31|bovine papillomavirus E2 protein
P10392903A0000|45 57|proliferation
P10392903A0000|60 68|HT-3 cells
P10392903A0000|71 107|p53-negative cervical carcinoma cell line
P10392903A0000|71 73|p53
P10392903A0000|128 150|human papillomavirus type
P10392903A0889|0 19|E2 point mutants unable
P10392903A0889|29 38|cell growth
P10392903A0889|52 57|cdc25A
P10392903A0889|61 76|cdc25B expression
P10392903A0889|61 66|cdc25B
P10392903A0889|87 116|cell cycle inhibitors hydroxyurea
P10392903A0889|120 127|mimosine
P10392914A0000|0 17|BACKGROUND/PURPOSE
P10392914A0000|19 38|Anomalous arrangement
P10392914A0000|44 65|pancreaticobiliary duct
P10392914A0000|67 71|AAPBD
P10392914A0000|91 117|congenital biliary dilatation
P10392914A0000|145 166|biliary tract malignancy
P10393192A0792|0 21|Neurospora crassa CYT-18
P10393192A0792|35 44|exonic trap
P10393192A0792|48 60|intron mutants
P10393192A0792|72 87|structural defect
P10393197A0543|0 3|DDP1
P10393197A0543|19 33|heterochromatin
P10393197A0543|36 51|interphase nuclei
P10393197A0543|54 70|larval neuroblasts
P10393201A0654|16 35|human DNA repair system
P10393201A0654|46 62|DNA polymerase beta
P10393201A0654|66 83|DNA ligase III-XRCC1
P10393201A0654|66 77|DNA ligase III
P10393201A0654|79 83|XRCC1
P10393201A0654|107 127|mismatched base residue
P10393201A0654|131 148|single-strand break
P10393201A0654|175 185|exonuclease
P10393251A0283|3 10|PAC clone
P10393251A0283|17 26|insert size
P10393251A0283|29 33|120kb
P10393251A0283|56 74|restriction analysis
P10393251T0000|0 7|Sequence
P10393251T0000|10 19|10q24 locus
P10393251T0000|34 46|HOX11 oncogene
P10393251T0000|55 65|new gene HUG1
P10393251T0000|78 90|T-ALL cell line
P10393422A0476|7 8|kb
P10393422A0476|19 23|LAMB2
P10393422A0476|57 89|non-processed LAMB2-like pseudogene
P10393422A0476|70 89|LAMB2-like pseudogene
P10393422A0476|91 96|LAMB2L
P10393910A0705|0 23|Site-directed mutagenesis
P10393910A0705|29 37|R2 protein
P10393910A0705|70 74|motif
P10393910A0705|90 99|active site
P10393910A0705|105 116|endonuclease
P10393969A0000|3 24|infected cell protein no.
P10393969A0000|27 30|ICP0
P10393969A0000|34 52|herpes simplex virus 1
P10393969A0000|34 51|herpes simplex virus
P10393969A0000|56 80|promiscuous transactivator
P10393969A0000|110 114|genes
P10393969A0000|130 134|cells
P10393969A0000|148 159|transfection
P10394116T0000|0 15|Wrist measurement
P10394116T0000|18 30|blood pressure
P10394116T0000|36 50|critical remarks
P10394116T0000|53 64|oscillometry
P10394900A1166|0 23|G-box-directed expression
P10394900A1166|26 31|leaves
P10394900A1166|55 68|enhancer region
P10394900A1166|76 97|cauliflower mosaic virus
P10394900A1166|99 114|CaMV) 35S promoter
P10394900A1166|99 102|CaMV
P10394900A1166|104 114|35S promoter
P10394919A1058|7 22|element necessary
P10394919A1058|39 47|amplitude
P10394919A1058|53 63|oscillation
P10395199A0792|4 7|scFv
P10395199A0792|35 45|experiments
P10395199A0792|58 69|anti-Ras scFv
P10395199A0792|71 78|Y259 scFv
P10395199A0792|106 123|anti-Ras mAb Y13-259
P10395199A0792|135 144|Ras pathway
P10395199A0792|135 137|Ras
P10395199A0792|160 174|tumor regression
P10395199A0792|178 191|nude mouse model
P10395199A0792|193 198|Cochet
P10395199A0792|200 201|O.
P10395199A0792|203 212|Kenigsberg
P10395199A0792|214 215|M.
P10395199A0792|217 224|Delumeau
P10395199A0792|226 227|I.
P10395199A0792|229 240|Virone-Oddos
P10395199A0792|242 243|A.
P10395199A0792|245 250|Multon
P10395199A0792|252 255|M.C.
P10395199A0792|257 263|Fridman
P10395199A0792|265 268|W.H.
P10395199A0792|270 282|Schweighoffer
P10395199A0792|284 285|F.
P10395199A0792|287 294|Teillaud
P10395199A0792|296 299|J.L.
P10395199A0792|301 306|Tocque
P10395199A0792|308 309|B.
P10395283A0960|28 35|activin A
P10395283A0960|39 42|OP-1
P10395283A0960|60 64|Smad4
P10395283A0960|102 123|common signal transducer
P10395283A0960|161 179|biological responses
P10395378A1198|53 74|HA envelope glycoprotein
P10395378A1198|83 89|ligands
P10395378A1198|95 111|amino-terminal end
P10395378A1198|131 144|fusion activity
P10395827A1297|19 40|parallel beta helix model
P10395827A1297|44 54|compact coil
P10395827A1297|77 87|beta strands
P10395827A1297|98 114|parallel beta sheet
P10395908A0236|24 41|315-residue protein
P10395908A0236|57 81|hydrophobic helical regions
P10395908A0236|88 115|amino acid motif characteristic
P10395908A0236|121 129|R7G family
P10395908A0236|132 140|G-protein
P10395908A0236|148 170|membrane-bound receptors
P10395911A0288|0 15|Characterisation
P10395911A0288|21 48|chicken apolipoprotein A-I gene
P10395911A0288|52 65|flanking region
P10395920A1424|5 11|results
P10395920A1424|23 29|members
P10395920A1424|35 43|ATF family
P10395920A1424|69 93|transcriptional regulation
P10395920A1424|99 105|KGF gene
P10395920A1424|118 137|extracellular stimuli
P10395920A1424|142 166|novel CRE regulatory element
P10396343A0754|10 23|high proportion
P10396343A0754|26 37|blood samples
P10396343A0754|43 54|random sample
P10396343A0754|69 76|suspects
P10396343A0754|94 116|trypanosome-specific DNA
P10396343A0754|119 121|PCR
P10396343A0754|127 127|%
P10396343A0754|131 143|T. b. gambiense
P10396343A0754|151 151|%
P10396343A0754|155 169|T. b. rhodesiense
P10396343T0000|1 22|multi-centre evaluation
P10396343T0000|28 56|card indirect agglutination test
P10396343T0000|60 74|trypanosomiasis
P10396343T0000|76 88|TrypTect CIATT
P10396793A0815|0 6|Results
P10396793A0815|10 12|men
P10396793A0815|28 33|drinks
P10396793A0815|56 73|dependence criteria
P10396793A0815|78 84|invalid
P10396793A0815|86 95|reductions
P10396793A0815|101 110|prevalence
P10396793A0815|113 130|specific indicators
P10396793A0815|133 149|alcohol dependence
P10396793A0815|167 167|%
P10396793A0815|173 173|%
P10397257A1142|0 10|Mutagenesis
P10397257A1142|16 30|CDE/CHR elements
P10397257A1142|34 41|Sp1 sites
P10397257A1142|83 105|transcriptional activity
P10397257A1142|113 113|%
P10397257A1142|137 141|cells
P10397257A1142|154 173|cell cycle periodicity
P10397257A1142|176 197|G2-M-synchronized cells
P10398286A0678|5 11|Scheffe
P10398286A0678|27 38|illustration
P10398286A0678|40 50|comparisons
P10398286A0678|60 81|usual sample size methods
P10398286A0678|106 121|stochastic nature
P10398286A0678|124 126|S2p
P10398682A0365|3 18|crystal structure
P10398682A0365|24 31|VP16 core
P10399136A0389|0 6|Ozagrel
P10399136A0389|8 17|ifenprodil
P10399136A0389|19 29|cinnarizine
P10399136A0389|33 39|dilazep
P10399136A0389|61 74|pentoxifylline
P10399136A0389|87 90|rCBF
P10399136A0389|96 98|HPC
P10400032A0304|3 14|latter method
P10400032A0304|32 47|inferior vena cava
P10400032A0304|63 73|hypotension
P10400032A0304|84 111|invasive anesthetic management
P10400593A1084|11 15|PvirE
P10400593A1084|18 39|Plac promoter constructs
P10400593A1084|47 61|functional VirE2
P10400593A1084|57 61|VirE2
P10400593A1084|68 72|virE1
P10400593A1084|91 95|virE2
P10400712A0000|0 23|Simian parainfluenza virus
P10400712A0000|26 28|SV5
P10400712A0000|33 41|prototype
P10400712A0000|47 67|Paramyxoviridae family
P10400712A0000|70 105|nonsegmented negative-sense RNA viruses
P10400712A0577|16 24|functions
P10400712A0577|27 28|GE
P10400712A0577|30 31|IG
P10400712A0577|36 46|GS sequences
P10400712A0577|49 61|transcription
P10400712A0577|76 83|plasmids
P10400712A0577|94 98|cDNAs
P10400712A0577|104 123|full-length SV5 genome
P10400712A0577|134 154|gene junction sequences
P10400712A0577|156 157|GE
P10400712A0577|159 160|IG
P10400712A0577|165 175|GS sequences
P10400712A0577|177 183|located
P10400712A0577|194 220|hemagglutinin-neuraminidase
P10400712A0577|222 223|HN
P10400712A0577|231 240|polymerase
P10400712A0577|242 242|L
P10400712A0577|244 248|genes
P10400712A0577|268 287|counterpart sequences
P10400712A0577|292 309|other gene junctions
P10400757A0000|0 4|CXCR4
P10400757A0000|8 24|chemokine receptor
P10400757A0000|29 38|coreceptor
P10400757A0000|42 59|T-cell-line-tropic
P10400757A0000|61 62|X4
P10400757A0000|67 77|dual-tropic
P10400757A0000|79 82|R5X4
P10400757A0000|84 114|human immunodeficiency virus type 1
P10400757A0000|84 113|human immunodeficiency virus type
P10400757A0000|116 120|HIV-1
P10400757A0000|122 129|isolates
P10400757A1498|21 32|better detail
P10400757A1498|36 62|CXCR4 structural requirements
P10400757A1498|36 40|CXCR4
P10400757A1498|74 94|different HIV-1 strains
P10400757A1498|83 87|HIV-1
P10400757A1498|108 132|further mutagenesis efforts
P10400757A1498|157 163|domains
P10400757A1498|166 170|CXCR4
P10400757A1498|184 213|HIV-1 Env-mediated fusion process
P10400757A1498|184 188|HIV-1
P10400757A1498|189 191|Env
P10400760A0663|3 9|results
P10400760A0663|17 24|analyses
P10400760A0663|40 49|proteinase
P10400760A0663|59 84|amino acid residues E960-A961
P10400760A0663|86 96|E1071-S1072
P10400760A0663|98 108|E1345-T1346
P10400760A0663|113 123|E1419-G1420
P10400760A0663|136 153|cleavage efficiency
P10400774A0240|0 1|y.
P10400785A0912|0 1|SM
P10400785A0912|37 51|other components
P10400785A0912|57 60|CRM 1
P10400785A0912|57 59|CRM
P10400785A0912|61 73|export pathway
P10400785A0912|87 100|small GTPase Ran
P10400785A0912|107 127|nucleoporin CAN/Nup214
P10400785A0912|118 120|CAN
P10400785A0912|122 127|Nup214
P10400794T0000|0 13|Identification
P10400794T0000|32 37|Kaposi
P10400794T0000|40 68|sarcoma-associated herpesvirus
P10400794T0000|89 100|similarities
P10400794T0000|103 124|latent membrane proteins
P10400794T0000|129 130|2A
P10400794T0000|133 149|Epstein-Barr virus
P10402022A0432|0 13|Auditory clicks
P10402022A0432|34 34|s
P10402467T0000|0 21|Myosin light chain kinase
P10402467T0000|43 49|Ras/ERK
P10402467T0000|43 45|Ras
P10402467T0000|47 49|ERK
P10402467T0000|70 119|urokinase-type plasminogen activator-stimulated cells
P10402467T0000|70 103|urokinase-type plasminogen activator
P10402467T0000|124 147|integrin-selective manner
P10402467T0000|124 131|integrin
P10403575A1401|3 12|inhibition
P10403575A1401|15 35|StAR gene transcription
P10403575A1401|15 22|StAR gene
P10403575A1401|38 42|DAX-1
P10403575A1401|46 59|dose-dependent
P10403575A1401|68 80|transcription
P10403575A1401|84 84|%
P10403575A1401|87 99|control levels
P10403690A0000|3 28|prospective randomized study
P10403690A0000|33 40|patients
P10403690A0000|45 75|advanced non-small cell lung cancer
P10403690A0000|77 81|NSCLC
P10403690A0000|83 91|stage IIIb
P10403690A0000|100 120|ECOG performance status
P10403690A0000|122 123|PS
P10403690A0000|166 183|best supportive care
P10403690A0000|185 187|BSC
P10403690A0000|191 204|supportive care
P10403690A0000|209 231|combination chemotherapy
P10403690A0000|233 242|IEP regimen
P10403690A0000|244 253|ifosfamide
P10403690A0000|255 259|gm/m2
P10403690A0000|266 283|mesna uroprotection
P10403690A0000|285 294|epirubicin
P10403690A0000|297 301|mg/m2
P10403690A0000|313 321|cisplatin
P10403690A0000|324 328|mg/m2
P10403690A0000|340 349|MVP regimen
P10403690A0000|351 361|mitomycin-C
P10403690A0000|363 367|mg/m2
P10403690A0000|369 377|cisplatin
P10403690A0000|381 385|mg/m2
P10403690A0000|395 405|vinblastine
P10403690A0000|407 411|mg/m2
P10403690A0000|416 419|days
P10403839A0140|5 23|sequence information
P10403839A0140|28 37|human BMAL1
P10403839A0140|39 44|hBMAL1
P10403839A0140|46 50|cDNAs
P10403839A0140|115 119|cDNAs
P10403839A0140|133 146|splice variants
P10403839A0140|152 161|mouse BMAL1
P10403839A0140|163 168|mBMAL1
P10403839A1459|0 9|Comparison
P10403839A1459|17 35|bHLH/PAS family genes
P10403839A1459|51 74|intron/exon splice pattern
P10403839A1459|77 82|mBMAL1
P10403839A1459|110 113|mAhr
P10403839A1459|132 136|BMAL1
P10403839A1459|140 142|Ahr
P10403839A1459|154 165|same subclass
P10403839A1459|186 205|common primordial gene
P10405635A0374|3 27|transcriptional activities
P10405635A0374|33 51|full-length promoter
P10405635A0374|73 90|deletion constructs
P10405635A0374|146 159|resistant cells
P10406047A1244|18 39|significant differences
P10406047A1244|42 67|functional residual capacity
P10406047A1244|112 128|respiratory system
P10406047A1244|148 157|lung volume
P10406047A1244|163 172|ILD infants
P10406047A1244|186 200|healthy controls
P10406047A1244|203 209|infants
P10406047A1244|216 219|PPHN
P10406047A1244|240 243|PFTs
P10406047A1244|248 262|sensitive enough
P10406047A1244|274 293|abnormal lung function
P10406047A1244|300 307|age group
P10406122T0000|1 26|13-bp cis-regulatory element
P10406122T0000|32 42|LTR promoter
P10406122T0000|48 73|tobacco retrotransposon Tto1
P10406122T0000|86 99|responsiveness
P10406122T0000|102 114|tissue culture
P10406122T0000|125 139|methyl jasmonate
P10406122T0000|143 157|fungal elicitors
P10406459A0000|25 52|platelet-derived growth factor
P10406459A0000|54 57|PDGF
P10406459A0000|60 93|12-O-tetradecanoyl-phorbol-acetate
P10406459A0000|95 97|TPA
P10406459A0000|103 111|forskolin
P10406459A0000|119 122|CREB
P10406459A0000|124 160|cAMP-responsive element-binding protein
P10406459A0000|162 183|Ser-133 phosphorylation
P10406459A0000|188 206|comparable magnitude
P10406459A0000|210 217|kinetics
P10406459A0000|220 230|NIH 3T3 cells
P10406462A1127|40 44|SRC-1
P10406462A1127|47 76|dimerization-induced activation
P10406462A1127|79 90|OR1/RXRalpha
P10406462A1127|79 81|OR1
P10406462A1127|83 90|RXRalpha
P10406464A0687|11 32|mTRAP100 coprecipitates
P10406464A0687|11 18|mTRAP100
P10406464A0687|64 74|TRAP complex
P10406464A0687|76 82|TRAP220
P10406464A0687|98 107|contacts TR
P10406464A0687|114 129|vitamin D receptor
P10406464A0687|133 154|ligand-dependent manner
P10406465A0589|23 25|VDR
P10406465A0589|29 50|vitamin D responsiveness
P10406465A0589|54 73|heterologous promoter
P10406466A0000|0 40|Classical ligand-activated nuclear receptors
P10406466A0000|25 40|nuclear receptors
P10406466A0000|42 67|e.g. thyroid hormone receptor
P10406466A0000|46 67|thyroid hormone receptor
P10406466A0000|69 88|retinoic acid receptor
P10406466A0000|91 112|orphan nuclear receptors
P10406843A1265|0 9|Expression
P10406843A1265|12 24|GlcNAc-TI mRNA
P10406843A1265|56 61|RT-PCR
P10406954A0715|0 21|Chemical stability tests
P10406954A0715|25 48|site-specific mutagenesis
P10406954A0715|59 72|amino acids H219
P10406954A0715|76 78|D63
P10406954A0715|81 84|RegS
P10406954A0715|88 91|RegR
P10406954A0715|125 132|residues
P10407184A0149|2 15|overexpression
P10407184A0149|21 31|betaAPP gene
P10407184A0149|34 45|certain areas
P10407184A0149|51 57|AD brain
P10407184A0149|80 94|important factor
P10407184A0149|100 113|neuropathology
P10407184A0149|116 117|AD
P10407184A0520|3 19|functional studies
P10407184A0520|24 38|promoter regions
P10407184A0520|62 73|reporter gene
P10407184A0520|75 106|chloramphenicol acetyl transferase
P10407184A0520|108 110|CAT
P10407184A0520|116 124|phbetaE-B
P10407184A0520|129 135|plasmid
P10407184A0520|157 157|h
P10407184A0520|159 172|promoter region
P10407184A0520|195 197|URE
P10407184A0520|206 215|prhbetaE-B
P10407184A0520|220 226|plasmid
P10407184A0520|242 247|rhesus
P10407184A0520|249 250|rh
P10407184A0520|252 265|promoter region
P10407184A0520|275 277|URE
P10407184A0520|291 298|bp region
P10407184A0520|304 319|hbetaAPP promoter
P10407269A0000a|5 6|bp
P10407269A0000a|9 28|contiguous DNA located
P10407269A0000a|36 47|markers cdc18
P10407269A0000a|43 47|cdc18
P10407269A0000a|51 55|cdc14
P10407269A0000a|61 68|right arm
P10407269A0000a|71 92|fission yeast chromosome
P10407269A0000a|122 134|European Union
P10407269A0000a|159 181|genome sequencing project
P10407269A0000b|5 6|bp
P10407269A0000b|9 28|contiguous DNA located
P10407269A0000b|36 47|markers cdc18
P10407269A0000b|43 47|cdc18
P10407269A0000b|51 55|cdc14
P10407269A0000b|61 68|right arm
P10407269A0000b|71 92|fission yeast chromosome
P10407269A0000b|122 134|European Union
P10407269A0000b|159 181|genome sequencing project
P10407985A0574|0 4|G-CSF
P10407985A0574|9 18|micrograms
P10407985A0574|34 37|s.c.
P10407985A0574|55 60|GM-CSF
P10407985A0574|65 78|micrograms s.c.
P10407985A0574|84 105|chemotherapeutic cycles
P10409656A1016|0 13|Overexpression
P10409656A1016|16 23|H411 cDNA
P10409656A1016|29 31|RAW
P10409656A1016|37 54|macrophage cell line
P10409656A1016|74 83|growth rate
P10409656A1016|111 114|H411
P10409656A1016|126 150|proliferative cell response
P10409656A1016|153 155|LPS
P10409699A0292|0 4|Human
P10409699A0292|14 30|sequence tag clones
P10409699A0292|47 64|sequence similarity
P10409699A0292|67 75|mammalian
P10409699A0292|79 121|yeast oligosaccharide-processing mannosidases
P10409699A0292|129 151|full-length coding region
P10409699A0292|157 182|putative mannosidase homolog
P10409699A0292|165 182|mannosidase homolog
P10409699A0292|213 230|rapid amplification
P10409699A0292|233 240|cDNA ends
P10409699A0292|244 272|direct polymerase chain reaction
P10409699A0292|277 294|human placental cDNA
P10409724A1021|0 9|Activation
P10409724A1021|12 17|ERK1/2
P10409724A1021|34 42|induction
P10409724A1021|48 75|immediate-early response genes
P10409730A0597|3 15|transcription
P10409730A0597|18 28|most RP genes
P10409730A0597|45 61|Rap1p binding sites
P10409730A0597|71 72|bp
P10409730A0597|88 97|initiation
P10409730A0597|100 112|transcription
P10409741A0382|19 31|mutant alleles
P10409741A0382|34 37|CDC4
P10409741A0382|39 45|cdc4-10
P10409741A0382|47 53|cdc4-11
P10409741A0382|58 64|cdc4-16
P10409741A0382|82 102|nuclear division defect
P10409741A0382|105 116|cdc20-1 cells
P10409741A0382|105 111|cdc20-1
P10409749T0000|0 3|Role
P10409749T0000|6 23|secondary structure
P10409749T0000|47 58|constitutive
P10409749T0000|62 80|inducible activators
P10409755A1846|10 11|Ca
P10409755A1846|17 35|dependent activation
P10409755A1846|38 49|NO production
P10409755A1846|58 66|apoptosis
P10409755A1846|72 81|TG exposure
P10409755A1846|84 94|JT/Neo cells
P10411139A0887|0 11|Accumulation
P10411139A0887|17 27|U4/U6 duplex
P10411139A0887|17 18|U4
P10411139A0887|20 21|U6
P10411139A0887|41 54|overexpression
P10411139A0887|57 71|wild-type Prp44p
P10411139A1344|3 9|results
P10411139A1344|53 59|results
P10411139A1344|69 78|direct role
P10411139A1344|82 87|Prp44p
P10411139A1344|104 113|U4/U6 helix
P10411139A1344|104 105|U4
P10411140A0499|17 25|125-nt RNA
P10411140A0499|42 55|RNase E cleavage
P10411140A0499|42 47|RNase E
P10411140A0499|66 79|terminal region
P10411140A0499|85 89|mRNAs
P10411140A0499|100 109|terminator
P10411160T0000|3 11|mysteries
P10411160T0000|14 34|geographic variability
P10411160T0000|37 66|nonmelanoma skin cancer incidence
P10413604A0063|28 48|cAMP-dependent kinases
P10413604A0063|50 53|PKAs
P10413604A0063|62 78|cytoplasmic growth
P10413604A0063|93 117|growth-regulated mechanism
P10413604A0063|138 149|DNA synthesis
P10413607A0085|37 97|other extracellular matrix molecules pepsin-solubilized collagen VI
P10413607A0085|70 75|pepsin
P10413607A0085|88 97|collagen VI
P10413607A0085|99 101|CVI
P10413607A0085|115 126|DNA synthesis
P10413607A0085|129 155|various mesenchymal cell types
P10413607A0085|180 214|integrin-mediated signal transduction
P10413607A0085|180 187|integrin
P10413662A0193|1 21|recombinant derivative
P10413662A0193|34 56|pMJ101 replication region
P10413662A0193|67 76|compatible
P10413662A0193|81 84|pJM1
P10413662A0193|87 93|plasmid
P10413662A0193|107 127|iron acquisition system
P10413662A0193|142 150|virulence
P10413662A0193|153 165|V. anguillarum
P10413662A0193|177 193|important pathogen
P10413662A0193|204 212|vibriosis
P10413676A0000|0 2|FAK
P10413676A0000|14 18|sites
P10413676A0000|21 59|transmembrane integrin receptor clustering
P10413676A0000|21 49|transmembrane integrin receptor
P10413676A0000|74 101|intracellular signaling events
P10413676A0595|0 9|Expression
P10413676A0595|12 28|various FAK mutants
P10413676A0595|19 28|FAK mutants
P10413676A0595|34 36|FAK
P10413676A0595|38 42|cells
P10413676A0595|53 69|FAK kinase activity
P10413676A0595|53 61|FAK kinase
P10413676A0595|74 80|Tyr-397
P10413676A0595|82 90|SH2 domain
P10413676A0595|109 141|first proline-rich SH3 binding region
P10413676A0595|126 141|SH3 binding region
P10413676A0595|147 165|FAK C-terminal domain
P10413676A0595|197 215|full FAK-mediated FAK
P10413676A0595|201 203|FAK
P10413676A0595|213 215|FAK
P10413676A0595|217 229|cell migration
P10413676A0595|232 233|FN
P10413676A0595|241 261|direct paxillin binding
P10413676A0595|247 254|paxillin
P10413676A0595|264 266|FAK
P10413676A1193|4 26|dominant-negative effect
P10413676A1193|29 32|FRNK
P10413676A1193|47 59|point mutation
P10413676A1193|61 68|Leu-1034
P10413676A1193|71 73|Ser
P10413676A1193|89 104|FRNK localization
P10413676A1193|107 123|focal contact sites
P10414451A0093|8 20|young patients
P10414451A0093|28 29|yr
P10414451A0093|35 51|doppler-proven DVT
P10414451A0093|105 112|protein C
P10414451A0093|114 118|APC-R
P10414451A0093|121 138|lupus anticoagulant
P10414451A0093|140 141|LA
P10414451A0093|144 168|anticardiolipin antibodies
P10414451A0093|172 183|deficiencies
P10414451A0093|186 193|protein C
P10414451A0093|195 202|protein S
P10414451A0093|204 218|ATIII activities
P10414451A0093|204 208|ATIII
P10416429A0221|0 5|DESIGN
P10416429A0221|7 16|Comparison
P10416429A0221|27 31|women
P10416429A0221|36 42|PKU aged
P10416429A0221|48 52|years
P10416429A0221|58 71|NSW PKU database
P10416429A0221|117 130|population data
P10416558A0000|0 6|PURPOSE
P10416558A0000|11 18|purposes
P10416558A0000|24 35|present study
P10416558A0000|51 57|effects
P10416558A0000|61 75|12-wk laboratory
P10416558A0000|81 102|aerobic exercise program
P10416558A0000|105 127|cardiopulmonary function
P10416558A0000|129 140|CD4 cell count
P10416558A0000|129 131|CD4
P10416558A0000|145 174|physician-assessed health status
P10416558A0000|180 221|symptomatic pre-AIDS HIV-infected individuals
P10416558A0000|223 224|N =
P10416558A0000|281 295|exercise relapse
P10417331A1008|3 8|enzyme
P10417331A1008|17 31|optimal activity
P10417331A1008|42 51|mM pantoate
P10417331A1008|53 53|k
P10417331A1008|63 63|s
P10417331A1008|74 75|pH
P10417703A1326|19 25|results
P10417703A1326|44 45|RP
P10417703A1326|54 66|20S proteasome
P10417703A1326|111 120|eukaryotes
P10417703A1326|139 154|plant RPT subunits
P10417703A1326|165 181|yeast counterparts
P10417703A1326|187 208|non-redundant functions
P10419006A0378|0 20|Epidemiologic evidence
P10419006A0378|34 59|estrogen replacement therapy
P10419006A0378|65 73|menopause
P10419006A0378|83 98|breast cancer risk
P10419521A0136|15 32|elongation activity
P10419521A0136|34 36|ELL
P10419521A0136|46 54|novel type
P10419521A0136|57 71|RNA polymerase II
P10419521A0136|57 69|RNA polymerase
P10419521A0136|72 88|interaction domain
P10419521A0136|114 131|polymerase activity
P10419521A0136|134 163|promoter-specific transcription
P10422291A0572|12 35|IgA lambda multiple myeloma
P10422291A0572|12 20|IgA lambda
P10422291A0572|40 60|peritoneal involvement
P10422342A0535|3 17|radiation burden
P10422342A0535|45 56|examinations
P10422342A0535|59 73|nuclear medicine
P10422342A0535|88 100|effective dose
P10422342A0535|120 134|radiation burden
P10422342A0535|137 163|radiodiagnostic examinations
P10422342A0535|190 201|preparations
P10422342A0535|206 209|131I
P10422342A0535|211 215|201Tl
P10422342A0535|217 220|67Ga
P10422342A0535|224 228|111In
P10422342A0535|241 246|higher
P10422468A0524|17 28|malformation
P10422468A0524|31 38|children
P10422468A0524|48 51|ICSI
P10422468A0524|98 117|genetic abnormalities
P10422468A0524|126 128|NOA
P10422468A0524|145 157|sex chromosome
P10422468A0524|161 174|microdeletions
P10422468A0524|180 190|Y chromosome
P10422468A0524|203 214|congenital OA
P10422468A0524|216 224|mutations
P10422468A0524|230 247|cystic fibrosis gene
P10423156A0265|0 11|TaV particles
P10423156A0265|17 30|buoyant density
P10423156A0265|38 42|g/cm3
P10423156A0265|45 48|CsCl
P10423156A0265|64 77|capsid proteins
P10423156A0265|86 88|kDa
P10423193A1309|0 9|CONCLUSION
P10423193A1309|16 22|results
P10423193A1309|34 67|vibration-induced neural involvement
P10423193A1309|90 110|pure digital neuropathy
P10423193A1309|115 125|definite CTS
P10423292A0782|10 25|bp upstream region
P10423292A0782|28 32|Spam1
P10423292A0782|63 89|multiple transcription factor
P10423292A0782|97 101|sites
P10423292A0782|112 114|CRE
P10423292A0782|116 137|cAMP-responsive element
P10425094A1006|10 19|relaxivity
P10425094A1006|39 39|s
P10425094A1006|44 45|mM
P10425445T0000|0 8|Structure
P10425445T0000|27 84|mouse growth hormone receptor/growth hormone binding protein gene
P10426450A1458|0 16|Bacterial recovery
P10426450A1458|19 20|SA
P10426450A1458|28 39|liver/spleen
P10426450A1458|46 56|cecal tonsil
P10426450A1458|59 71|contact poults
P10426450A1458|75 76|SG
P10426450A1458|81 93|contact chicks
P10426450A1458|105 107|ILK
P10426450A1458|144 167|non-treated contact poults
P10426450A1458|171 176|chicks
P10426878A0367|3 9|results
P10426878A0367|15 25|ISIS-2 trial
P10426878A0367|43 63|Antiplatelet Trialists
P10426878A0367|65 77|Collaboration
P10426878A0367|91 97|aspirin
P10426878A0367|100 108|mandatory
P10426878A0367|111 118|patients
P10426878A0367|123 147|acute myocardial infarction
P10426878A0367|154 172|secondary prevention
P10427654A0000|38 68|additional diagnostic laparoscopy
P10427654A0000|74 92|preoperative staging
P10427654A0000|95 102|patients
P10427654A0000|107 120|adenocarcinoma
P10427654A0000|126 134|esophagus
P10427654A0000|136 148|gastric cancer
P10427654A0000|152 167|pancreatic cancer
P10427654A0000|183 197|curative surgery
P10428091A0322|18 35|state-specific MMRs
P10428091A0322|59 79|persistent disparities
P10428091A0322|82 98|maternal mortality
P10428091A0322|114 123|white women
P10428294A0227|0 21|Preheparin LPL mass level
P10428294A0227|49 59|individuals
P10428294A0227|70 77|years old
P10428294A0227|86 88|men
P10428294A0227|92 96|women
P10428759A0743|11 47|insulin-induced receptor kinase activity
P10428759A0743|73 89|chimeric receptors
P10428811A0628|0 4|Cat-1
P10428811A0628|39 52|binding partner
P10428811A0628|59 87|beta-adrenergic receptor kinase
P10428811A0628|89 95|betaARK
P10428811A0628|98 102|GRK-2
P10428811A0628|124 138|Arf-GAP activity
P10428811A0628|124 126|Arf
P10428811A0628|128 130|GAP
P10428811A1067|0 10|Cat proteins
P10428811A1067|14 36|tyrosine-phosphorylated
P10428811A1067|55 59|cells
P10428811A1067|67 88|focal adhesion kinase Fak
P10428811A1067|67 85|focal adhesion kinase
P10428811A1067|86 88|Fak
P10428811A1067|92 94|Src
P10428862A0834|0 29|Immunoprecipitation experiments
P10428862A0834|35 57|DokR-specific antibodies
P10428862A0834|86 99|endogenous DokR
P10428862A0834|104 117|150-kDa protein
P10428862A0834|124 146|tyrosine-phosphorylated
P10428862A0834|149 172|EGF-stimulated BaF/3 cells
P10428862A0834|149 151|EGF
P10429184A0000|0 8|Expansins
P10429184A0000|21 28|proteins
P10429184A0000|41 58|long-term extension
P10429184A0000|69 85|plant cell walls due
P10429184A0000|95 121|unknown biochemical mechanism
P10429740A0000|23 38|clinical evidence
P10429740A0000|48 63|current therapies
P10429740A0000|66 87|irritable bowel syndrome
P10429740A0000|89 91|IBS
P10429946A0473|3 18|responsive region
P10429946A0473|24 29|alpha 2
P10429946A0473|24 28|alpha
P10429946A0473|31 44|V) collagen gene
P10429946A0473|31 31|V
P10429946A0473|33 44|collagen gene
P10429946A0473|48 56|localized
P10429946A0473|80 81|bp
P10429946A0473|84 96|basal promoter
P10429946A0473|103 104|bp
P10429946A0473|107 110|exon
P10429946A0473|112 120|sequences
P10429946A0473|139 154|CRE-like elements
P10429946A0988|22 66|B-Myb-glutathionine S-transferase fusion protein
P10429946A0988|22 26|B-Myb
P10429946A0988|76 91|complex formation
P10430421T0000|0 17|APOE-epsilon4 count
P10430421T0000|0 3|APOE
P10430421T0000|33 42|prevalence
P10430421T0000|45 55|AD increases
P10430421T0000|73 88|Cache County Study
P10430580A0000|0 5|Repair
P10430580A0000|8 26|double-strand breaks
P10430580A0000|28 31|DSBs
P10430580A0000|35 48|chromosomal DNA
P10430580A0000|51 74|nonhomologous end-joining
P10430580A0000|76 79|NHEJ
P10430580A0000|108 112|yeast
P10430583A0000|1 16|new DNA repair gene
P10430583A0000|49 56|homology
P10430583A0000|59 62|RecA
P10430883A0000|5 24|mucus-secreting cells
P10430883A0000|29 51|gastric gland mucous cells
P10430883A0000|53 59|Brunner
P10430883A0000|62 67|glands
P10430883A0000|69 83|accessory glands
P10430883A0000|86 108|pancreaticobiliary tract
P10430883A0000|113 127|pancreatic ducts
P10430883A0000|138 154|gastric metaplasia
P10430883A0000|189 193|mucin
P10430883A0000|206 219|paradoxical Con
P10430883A0000|217 220|Con A
P10430883A0000|221 228|staining
P10430883A0000|239 256|periodate oxidation
P10430883A0000|258 283|sodium borohydride reduction
P10430883A0000|285 288|Con A
P10430883A0000|293 321|horseradish peroxidase reaction
P10430883A0000|293 313|horseradish peroxidase
P10430886A0838|3 19|C-terminal mutants
P10430886A0838|44 47|TraR
P10430886A0838|74 88|heteromultimers
P10430886A0838|96 113|wild-type activator
P10430890A1059|5 12|elongin C
P10430890A1059|55 89|significant structural rearrangements
P10430890A1059|94 100|binding
P10430890A1059|106 129|different partner proteins
P10430944A1298|16 32|JAK/STAT signaling
P10430944A1298|16 18|JAK
P10430944A1298|20 23|STAT
P10430944A1298|43 68|EBV-associated malignancies
P10430980A0465|11 13|men
P10430980A0465|20 24|women
P10433729A1559|0 1|A.
P10433729A1559|3 8|Bowers
P10433729A1559|10 12|K.E
P10433729A1559|17 24|Matthews
P10433729A1559|26 27|C.
P10433970A0279|0 5|Spfkh1
P10433970A0279|24 39|open reading frame
P10433970A0279|55 70|DNA binding domain
P10433970A0279|72 96|nuclear localization signal
P10433970A0279|100 120|transactivation domain
P10435595A0203|3 20|molecular mechanism
P10435595A0203|23 50|Tax-mediated trans-activation
P10435595A0203|23 25|Tax
P10436016A0337|0 12|Gel filtration
P10436016A0337|16 45|co-immunoprecipitation analyses
P10436016A0337|56 60|Mad2p
P10436016A0337|89 114|spindle checkpoint component
P10436016A0337|116 120|Mad1p
P10437043A0164|0 6|METHODS
P10437043A0164|20 24|cases
P10437043A0164|29 30|SS
P10437043A0164|43 50|biopsies
P10438540A1185|14 43|several regulatory domain mutants
P10438540A1185|51 52|Cd
P10438540A1185|71 82|mutant strain
P10438540A1185|86 102|transport activity
P10438593A0000|3 34|human immunodeficiency virus type-1
P10438593A0000|36 51|HIV-1) Tat protein
P10438593A0000|36 40|HIV-1
P10438593A0000|42 51|Tat protein
P10438593A0000|61 73|transcription
P10438593A0000|87 111|RNA polymerase processivity
P10438593A0000|87 99|RNA polymerase
P10438607A0330|10 14|SEBPs
P10438607A0330|16 20|SEBP2
P10438607A0330|49 68|homeotic gene fork head
P10438627A0885|0 15|Identity elements
P10438627A0885|18 21|tRNA
P10438627A0885|25 28|mono
P10438627A0885|33 54|dimethylation reactions
P10438627A0885|60 77|recombinant pfTrm1p
P10438627A0885|104 116|T7 transcripts
P10438627A0885|121 128|variants
P10438627A0885|131 134|tRNA
P10438627A0885|136 138|Asp
P10438627A0885|143 146|tRNA
P10438627A0885|148 150|Phe
P10438627A0885|156 160|yeast
P10438924A1009|2 24|insulin-responsive cells
P10438924A1009|26 28|Akt
P10438924A1009|60 105|serine/threonine kinase glycogen synthase kinase-3
P10438924A1009|60 81|serine/threonine kinase
P10438924A1009|82 105|glycogen synthase kinase-3
P10438924A1009|107 111|GSK-3
P10438924T0000|3 22|B cell antigen receptor
P10438924T0000|35 37|Akt
P10438924T0000|39 52|protein kinase B
P10438924T0000|55 94|glycogen synthase kinase-3 signaling pathway
P10438924T0000|55 78|glycogen synthase kinase-3
P10438924T0000|98 125|phosphatidylinositol 3-kinase
P10438941A1197|0 23|Fewer recombination events
P10438941A1197|41 50|different B
P10438941A1197|54 63|T cell lines
P10438941A1197|80 98|switch recombination
P10438941A1197|106 120|endogenous genes
P10438950A0580|0 3|IL-1
P10438950A0580|7 39|TNF increase AND-34 transcript levels
P10438950A0580|7 9|TNF
P10438950A0580|42 64|thymic cortical reticular
P10438950A0580|66 76|thymic nurse
P10438950A0580|81 99|fibroblast cell lines
P10439040A0658|15 23|role eIF4E
P10439040A0658|19 23|eIF4E
P10439040A0658|35 49|c-myc expression
P10439040A0658|35 39|c-myc
P10439040A0658|54 58|c-myc
P10439040A0658|61 78|untranslated region
P10439040A0658|80 82|UTR
P10439040A0658|102 113|CAT reporters
P10439040A0658|129 148|derivative constructs
P10440923A0684|0 7|Analysis
P10440923A0684|10 26|cell cycle proteins
P10440923A0684|39 39|h
P10440923A0684|42 60|lovastatin treatment
P10440923A0684|66 77|control cells
P10440923A0684|86 94|elevation
P10440923A0684|100 105|levels
P10440923A0684|111 144|cyclin-dependent kinase inhibitor p27
P10440923A0684|111 132|cyclin-dependent kinase
P10440923A0684|142 144|p27
P10440923A0684|146 149|kip1
P10440923A0684|152 161|inhibition
P10440923A0684|168 174|cyclin E
P10440923A0684|179 209|cyclin A-dependent kinase activity
P10440923A0684|179 201|cyclin A-dependent kinase
P10440923A0684|223 228|levels
P10440923A0684|250 270|retinoblastoma protein
P10440923A0684|272 274|pRb
P10441243A0443|0 6|RESULTS
P10441243A0443|19 38|leptin concentrations
P10441243A0443|19 24|leptin
P10441243A0443|71 75|ng/ml
P10441243A0443|78 92|control subjects
P10441449X1212|0 8|Copyright
P10441449X1212|13 25|Academic Press
P10441483A0454|0 20|Oligonucleotide probes
P10441483A0454|36 44|wild-type
P10441483A0454|48 66|mutant EpRE sequences
P10441483A0454|77 85|gel-shift
P10441483A0454|89 107|super-shift analyses
P10441483A0454|118 125|proteins
P10441506A0098|0 6|PKNbeta
P10441506A0098|10 29|high sequence homology
P10441506A0098|34 41|PKNalpha
P10441506A0098|61 63|PKN
P10441506A0098|80 86|repeats
P10441506A0098|96 115|amino acid-rich region
P10441506A0098|120 146|leucine-zipper like sequences
P10441506A0098|120 133|leucine-zipper
P10441506A0098|138 146|sequences
P10441506A0098|148 159|CZ region/HR1
P10441506A0098|148 155|CZ region
P10441506A0098|157 159|HR1
P10441506A0098|167 198|carboxyl-terminal catalytic domain
P10441506A0098|221 236|amino acid stretch
P10441506A0098|238 248|D region/HR2
P10441506A0098|238 244|D region
P10441506A0098|246 248|HR2
P10441506A0098|251 257|located
P10441506A0098|265 276|CZ region/HR1
P10441506A0098|283 297|catalytic domain
P10442493A0815|2 9|baseline
P10442493A0815|11 21|serum levels
P10442493A0815|24 31|lycopene
P10442493A0815|35 38|FLOP
P10442493A0815|60 68|serum FLOP
P10442493A0815|99 122|plasma cyclosporine levels
P10442493A0815|124 125|r =
P10442493A0815|132 133|p =
P10443990A0000|0 9|BACKGROUND
P10443990A0000|11 35|Chronic alcohol consumption
P10443990A0000|59 69|deleterious
P10443990A0000|72 81|bone health
P10444597A0586|23 31|induction
P10444597A0586|42 50|heat shock
P10444597A0586|52 59|high salt
P10444597A0586|63 69|ethanol
P10444597A0586|71 80|conditions
P10444597A0586|95 104|mRNA export
P10444597A0586|115 119|Npl3p
P10444597A0586|142 148|nucleus
P10444813A0448|3 19|symptomatic relief
P10444813A0448|23 32|inhibition
P10444813A0448|49 70|metastases interferon-a
P10444813A0448|59 70|interferon-a
P10444813A0448|74 94|somatostatin analogues
P10444813A0448|74 85|somatostatin
P10445161A1565|13 35|no-adverse-effect-level
P10445161A1565|69 71|ppm
P10445161A1565|89 98|weight gain
P10445161A1565|101 110|female rats
P10445161A1565|117 140|slight organ weight changes
P10445161A1565|147 151|sexes
P10445161A1565|158 160|ppm
P10445506A0073|17 41|gigantic sperm several times
P10445506A0073|45 63|total male body length
P10445945T0000|0 16|John leonard dawson
P10446131A0132|0 16|PDGF A-chain levels
P10446131A0132|0 10|PDGF A-chain
P10446131A0132|35 59|vascular smooth muscle cells
P10446131A0132|61 64|SMCs
P10446131A0132|75 78|ATII
P10446149A0809|0 4|M-Ras
P10446149A0809|24 43|yeast two-hybrid assay
P10446149A0809|48 67|multiple Ras effectors
P10446149A0809|56 58|Ras
P10446149A0809|78 84|c-Raf-1
P10446149A0809|86 90|A-Raf
P10446149A0809|92 96|B-Raf
P10446149A0809|98 125|phosphoinositol-3 kinase delta
P10446149A0809|127 132|RalGDS
P10446149A0809|137 140|Rin1
P10446206A0000|0 14|Deletion mapping
P10446206A0000|20 36|human presenilin-1
P10446206A0000|38 40|PS1
P10446206A0000|42 49|promoter
P10446206A0000|67 80|active fragment
P10446206A0000|110 131|transcription start site
P10446206A0000|156 180|human neuroblastoma SK-N-SH
P10446206A0000|184 201|hepatoma HepG2 cells
P10446833T0000|0 26|Microcirculatory oxygenation
P10446833T0000|30 37|shunting
P10446833T0000|40 45|sepsis
P10446910A0147|0 7|Analysis
P10446910A0147|13 28|E2F1 gene promoter
P10446910A0147|71 87|E2-responsiveness
P10446910A0147|90 116|transient transfection assays
P10446910A0147|121 155|subsequent deletion/mutation analysis
P10446910A0147|167 187|single upstream GC-rich
P10446910A0147|194 221|downstream CCAAT-binding sites
P10446910A0147|237 251|transactivation
P10446910A0147|254 255|E2
P10446912A0883|29 38|mechanisms
P10446912A0883|46 48|OF5
P10446912A0883|52 54|OF3
P10446912A0883|64 83|CYP11A1 transcription
P10446912A0883|64 70|CYP11A1
P10446912A0883|96 98|OF5
P10446912A0883|102 104|OF3
P10446912A0883|110 112|Sp1
P10446912A0883|116 118|Sp3
P10446912A0883|121 130|JEG-3 cells
P10446998A0375|14 28|differentiation
P10446998A0375|56 60|cells
P10446998A0375|75 97|mitogenic responsiveness
P10446998A0375|100 103|junB
P10446998A0375|106 122|c-fos inducibility
P10446998A0375|106 110|c-fos
P10446998A0955|0 23|Adipocyte differentiation
P10446998A0955|26 44|nontransformed cells
P10446998A0955|78 80|SRF
P10446998A0955|92 98|junB SRE
P10446998A0955|92 95|junB
P10446998A0955|103 110|c-fos SRE
P10446998A0955|103 107|c-fos
P10446998A0955|115 123|other SREs
P10446998A0955|139 151|mobility shift
P10446998A0955|155 173|gel supershift assays
P10446998A0955|194 218|DNA binding characteristics
P10446998A0955|224 241|nuclear protein SP-1
P10446998T0000|0 13|Transformation
P10446998T0000|20 52|differentiation-induced inhibition
P10446998T0000|55 85|serum response factor interactions
P10446998T0000|55 73|serum response factor
P10446998T0000|90 110|serum response elements
P10447593A0144|3 12|core enzyme
P10447593A0144|15 24|homologous
P10447593A0144|34 49|bacteriophages T3
P10447593A0144|51 52|T7
P10447593A0144|56 58|SP6
P10447593A0144|69 85|specificity factor
P10447593A0144|91 102|similarities
P10447593A0144|107 127|bacterial sigma factors
P10447597A1004|3 14|Cr.psbA-4 ORF
P10447597A1004|25 34|H-N-H motif
P10447597A1004|48 59|GIY-YIG motif
P10448036A0748|16 20|zf4-6
P10448036A0748|25 40|full-length 5 S RNA
P10448036A0748|25 35|full-length
P10448036A0748|37 40|S RNA
P10448036A0748|62 96|non-specific competitor concentration
P10448036A0748|107 111|zf4-7
P10448036A0748|114 128|S RNA interaction
P10448036A0748|172 179|affinity
P10448036A0748|183 193|specificity
P10448036A0748|208 221|RNA interaction
P10448095A0865|3 25|STAT protein accumulation
P10448095A0865|39 53|C/EBP expression
P10448095A0865|39 43|C/EBP
P10448095A0865|76 98|morphological conversion
P10448095A0865|101 111|fibroblasts
P10448095A0865|114 123|adipocytes
P10448095A0865|139 164|expression profile identical
P10448095A0865|182 197|mature adipocytes
P10448285A1035|3 17|median durations
P10448285A1035|32 43|survival time
P10448285A1035|49 57|late phase
P10448285A1035|72 77|months
P10448285A1035|84 89|months
P10448440T0020|10 29|scientific psychiatry
P10448440T0020|33 53|understanding patients
P10448440T0020|58 77|chronic schizophrenia
P10448440T0020|80 104|severe personality disorder
P10448902A0921|0 27|Myocardial antioxidant enzymes
P10448902A0921|29 36|catalase
P10448902A0921|38 58|glutathione peroxidase
P10448902A0921|62 80|superoxide dismutase
P10448902A0921|87 101|MCT-treated rats
P10448902A0921|135 138|rats
P10449072A0560|3 12|second goal
P10449072A0560|30 51|somatotopic arrangement
P10449072A0560|57 59|GPi
P10449072A0560|62 63|PD
P10449899A0881|5 18|overall results
P10449899A0881|50 57|PERV copy
P10449899A0881|61 75|integration site
P10450815A0180|3 22|present investigation
P10450815A0180|58 73|aware individuals
P10450815A0180|79 86|age range
P10450815A0180|92 96|years
P10450815A0180|143 156|tobacco smoking
P10450815A0180|160 180|supragingival calculus
P10450815A0180|192 228|account possible confounding factors such
P10450815A0180|242 252|oral hygiene
P10450815A0180|256 275|gingival inflammation
P10451209A0000|0 8|OBJECTIVE
P10451209A0000|44 54|misoprostol
P10451209A0000|63 79|gastric hemorrhage
P10451209A0000|82 92|healthy dogs
P10451209A0000|104 112|high doses
P10451209A0000|115 147|methylprednisolone sodium succinate
P10451209A0000|149 152|MPSS
P10452306A0502|0 7|Patients
P10452306A0502|23 39|cardiac MIBG uptake
P10452306A0502|52 78|norepinephrine concentration
P10452306A0502|80 83|LVEF
P10452306A0502|85 91|peak Vo2
P10452306A0502|93 116|x-ray cardiothoracic ratio
P10452306A0502|118 155|M-mode echographic end-diastolic diameter
P10452306A0502|159 199|right-sided heart catheterization parameters
P10452951A0000|0 22|Nuclear hormone receptors
P10452951A0000|24 26|NRs
P10452951A0000|31 66|ligand-inducible transcription factors
P10452951A0000|78 94|critical functions
P10452951A0000|97 107|many species
P10452991A0331|5 9|cells
P10452991A0331|20 49|present influenza virus particles
P10452991A0331|52 80|HLA-DR1-restricted T cell clones
P10452991A0331|52 58|HLA-DR1
P10453006A0000|0 9|Sequencing
P10453006A0000|12 20|zebrafish
P10453006A0000|22 31|Danio rerio
P10453006A0000|33 61|bacterial artificial chromosome
P10453006A0000|65 107|P1 artificial chromosome genomic clone fragments
P10453006A0000|113 122|cDNA clones
P10453006A0000|154 160|new loci
P10453006A0000|170 194|beta subunits of proteasomes
P10453006A0000|170 181|beta subunits
P10453006A0000|184 194|proteasomes
P10453006A0000|196 199|PSMB
P10453006A0478|12 21|homologues
P10453006A0478|27 41|human genes PSMB5
P10453006A0478|27 36|human genes
P10453006A0478|37 41|PSMB5
P10453006A0478|49 53|PSMB9
P10453006A0478|58 65|new genes
P10453006A0478|67 72|PSMB11
P10453006A0478|76 81|PSMB12
P10453006A0478|114 136|known corresponding genes
P10453006A0478|139 144|humans
P10453248A0094|9 12|Udry
P10453248A0094|15 34|biosocial perspective
P10453248A0094|76 93|sociological models
P10453248A0094|96 111|premarital sexual
P10453248A0094|115 135|reproductive behaviour
P10453371A0640|0 5|Weight
P10453371A0640|9 22|height z-scores
P10453371A0640|54 64|BMD z-scores
P10453721A0445|1 23|limited sampling strategy
P10453721A0445|39 74|bayesian parameter estimation algorithm
P10453721A0445|90 111|ADAPT II software package
P10454533A0859|0 10|Interaction
P10454533A0859|13 15|HRI
P10454533A0859|20 24|Hsc70
P10454533A0859|58 60|HRI
P10454533A0859|67 94|Hsc70 antagonist clofibric acid
P10454533A0859|67 71|Hsc70
P10454533A0859|107 113|folding
P10454533A0859|116 118|HRI
P10454533A0859|124 151|mature-competent conformation
P10454540A0392|3 23|amino acid changes D206A
P10454540A0392|27 31|D208A
P10454540A0392|63 81|exonuclease activity
P10454550A0960|0 27|Previous experimental evidence
P10454550A0960|44 47|Reg1
P10454550A0960|59 62|Glc7
P10454550A0960|65 85|nuclear substrates such
P10454550A0960|91 107|Snf1 kinase complex
P10454557A0000|12 16|yeast
P10454557A0000|42 52|replicators
P10454557A0000|74 83|chromosome
P10454557A0000|118 120|ARS
P10454557A0000|122 129|elements
P10454557A0000|145 154|chromosome
P10454557A0000|159 169|certain ARSs
P10454557A0000|194 211|silent HML locus show
P10454557A0000|214 238|replication origin activity
P10454557A0975|5 11|results
P10454557A0975|30 42|HML ARS cluster
P10454557A0975|44 49|ARS303
P10454557A0975|51 56|ARS320
P10454557A0975|61 66|ARS302
P10454557A0975|69 78|inactivity
P10454557A0975|81 87|origins
P10454557A0975|103 131|local transcriptional silencing
P10454557A0975|143 149|origins
P10454557A0975|153 161|silencers
P10454557A0975|167 172|key cis
P10454557A0975|177 198|trans-acting components
P10454561A0594|5 16|present study
P10454561A0594|47 61|TD-IkappaBalpha
P10454561A0594|69 110|phorbol myristate acetate-phytohemagglutinin
P10454561A0594|93 110|phytohemagglutinin
P10454561A0594|113 173|tumor necrosis factor alpha-induced IkappaBalpha gene transcription
P10454561A0594|113 136|tumor necrosis factor alpha
P10454561A0594|145 160|IkappaBalpha gene
P10454561A0594|186 212|NF-kappaB DNA binding activity
P10454561A0594|231 254|cytoplasmic sequestration
P10454561A0594|257 260|RelA
P10454561A0594|262 264|p65
P10454561A0594|268 282|TD-IkappaBalpha
P10454568A0815|1 1|i
P10454568A0815|3 25|Complete Grb10 expression
P10454568A0815|11 15|Grb10
P10454568A0815|30 33|cDNA
P10454568A0815|40 82|ecdysone-regulated transient expression system
P10454568A0815|93 99|PDGF-BB
P10454568A0815|102 106|IGF-I
P10454568A0815|111 117|insulin
P10454568A0815|125 145|epidermal growth factor
P10454568A0815|147 149|EGF
P10454568A0815|159 170|DNA synthesis
P10454568A0815|175 204|ecdysone dose-responsive fashion
P10454570A0846|16 61|distinct mitogen-activated protein kinase pathways
P10454570A0846|24 53|mitogen-activated protein kinase
P10454570A0846|71 129|stress-activated protein kinase-Jun N-terminal kinase activation
P10454570A0846|71 119|stress-activated protein kinase-Jun N-terminal kinase
P10454570A0846|145 159|phosphorylation
P10454570A0846|162 166|ATF-2
P10454570A0846|168 172|c-Jun
P10454570A0846|177 180|JunD
P10454570A0846|205 208|IL-1
P10454570A0846|223 244|TPA-dependent induction
P10454570A0846|254 287|extracellular signal-related kinase 1
P10454570A0846|254 286|extracellular signal-related kinase
P10454570A0846|289 293|ERK-1
P10454570A0846|298 312|ERK-2 activation
P10454570A0846|328 330|TPA
P10454570A0846|343 367|IL-1-dependent stimulation
P10454570A0846|343 346|IL-1
P10454570A0846|373 383|uPA enhancer
P10455087A1400|0 10|CONCLUSIONS
P10455087A1400|14 31|healthy individuals
P10455087A1400|33 59|whole body insulin sensitivity
P10455087A1400|87 104|anaerobic threshold
P10455143T0000|0 19|Interdomain signaling
P10455143T0000|23 40|two-domain fragment
P10455143T0000|46 72|human glucocorticoid receptor
P10455183A0530|14 27|xtRNA(Sec) gene
P10455183A0530|14 18|xtRNA
P10455183A0530|20 22|Sec
P10455183A0530|36 42|binding
P10455183A0530|53 67|Staf zinc fingers
P10455183A0530|75 79|Oct-1
P10455183A0530|84 113|optimal transcriptional capacity
P10455183A0930|18 24|results
P10455183A0930|36 58|differential utilization
P10455183A0930|61 75|Staf zinc finger 1
P10455183A0930|61 74|Staf zinc finger
P10455183A0930|91 109|critical determinant
P10455183A0930|115 148|transcriptional activation mechanism
P10455183A0930|155 165|Xenopus tRNA
P10455183A0930|167 169|Sec
P10455183A0930|174 190|human U6 snRNA genes
P10455189A0104|2 7|B cells
P10455189A0104|9 12|HEF1
P10455189A0104|32 62|cytoskeleton-dependent mechanism
P10455189A0104|80 95|integrin ligation
P10455189A0104|80 87|integrin
P10455189A0427|3 43|calcitonin-induced tyrosine phosphorylation
P10455189A0427|3 12|calcitonin
P10455189A0427|46 49|HEF1
P10455189A0427|70 89|dose-dependent manner
P10457075A1198|0 36|Independent protrudor muscle stimulation
P10457075A1198|46 47|VI
P10457075A1198|49 51|max
P10457075A1198|53 64|peak increase
P10457075A1198|67 67|%
P10457075A1198|69 69|P
P10457075A1198|89 93|Pcrit
P10457075A1198|107 108|Rn
P10457075A1198|110 121|peak decrease
P10457075A1198|126 126|%
P10457075A1198|128 128|P
P10458905A0000|40 77|1.7-Mb sequence-ready YAC/BAC clone contig
P10458905A0000|80 87|8p22-p23
P10458907A0543|3 13|human RAD30B
P10458907A0543|17 42|mouse Rad30b mRNA transcripts
P10458907A0543|48 65|many repair proteins
P10458907A0543|90 95|testis
P10458914A0674|0 7|Analysis
P10458914A0674|13 25|mouse STAP gene
P10458914A0674|41 54|genomic library
P10458914A0674|70 77|STAP gene
P10458914A0674|98 99|kb
P10458914A0674|117 121|exons
P10459809A1262|8 25|matrix distribution
P10459809A1262|37 47|cell density
P10459809A1262|65 71|biofilm
P10460015A0465|7 12|months
P10460015A0465|41 48|estrogen
P10460015A0465|98 115|bone mineral density
P10460015A0465|119 125|bone age
P10460171A0842|0 19|Viscosity experiments
P10460171A0842|25 55|catalytic fragment kinase reaction
P10460171A0842|84 101|phosphoryl transfer
P10460172A0823|0 20|Velocity sedimentation
P10460172A0823|22 34|cross-linking
P10460172A0823|39 65|immunoprecipitation analyses
P10460172A0823|68 96|detergent-solubilized rat brain
P10460172A0823|119 133|kDa polypeptides
P10460172A0823|146 160|heterotetramers
P10463057A0534|7 22|expression levels
P10463057A0534|28 44|different plasmids
P10463242A0316|2 4|EEG
P10463242A0316|9 23|single slow waves
P10463242A0316|29 46|left temporal region
P10464185T0000|0 24|Molecular characterization
P10464185T0000|27 78|type-specific capsular polysaccharide biosynthesis genes
P10464185T0000|81 109|Streptococcus agalactiae type Ia
P10464250A0275|6 12|FASEB J.
P10464291A0597|0 7|IL-1beta
P10464291A0597|11 15|ng/ml
P10464291A0597|41 50|PDGFalphaR
P10464291A0597|54 87|CCAAT/enhancer-binding protein delta
P10464291A0597|89 98|C/EBPdelta
P10464291A0597|100 109|mRNA levels
P10464291A0597|113 131|time dependent manner
P10464302A1109b|3 13|recruitment
P10464302A1109b|44 47|p185
P10464302A1109b|49 51|neu
P10464302A1109b|68 91|mitogenic pathway proteins
P10464302A1109b|98 134|membrane-microfilament interaction site
P10464302A1109b|144 156|physical model
P10464302A1109b|187 202|mitogenic pathway
P10464302A1109b|224 241|growth factor signal
P10464302A1109b|247 258|cytoskeleton
P10464310A0218|0 31|Transient tyrosine phosphorylation
P10464310A0218|34 36|Crk
P10464310A0218|39 89|fibroblast growth factor-2-stimulated endothelial cells
P10464310A0218|39 62|fibroblast growth factor-2
P10464310A0218|107 134|juxtamembrane tyrosine residue
P10464310A0218|140 145|FGFR-1
P10464310A0218|151 162|Crk SH2 domain
P10464310A0218|175 180|FGFR-1
P10464310A0218|198 204|Tyr-463
P10464310A0218|216 237|direct complex formation
P10464310A0218|245 247|Crk
P10464310A0218|251 256|FGFR-1
P10466306A0000|0 46|ECG-gated myocardial Technetium-99m sestamibi SPECT
P10466306A0000|50 64|useful technique
P10466306A0000|74 92|myocardial perfusion
P10466825T0000|0 3|Role
P10466825T0000|11 28|untranslated region
P10466825T0000|31 48|baculovirus p10 mRNA
P10466825T0000|51 70|high-level expression
P10466825T0000|73 84|foreign genes
P10467004A0116|3 11|intron RNA
P10467004A0116|26 36|nucleotides
P10467004A0116|58 75|secondary structure
P10467004A0116|94 107|sequence motifs
P10467004A0116|110 129|subgroup-IIA1 introns
P10467004A0116|131 136|Michel
P10467004A0683|3 8|intron
P10467004A0683|20 27|splicing
P10467004A0683|53 61|EBS1/IBS1
P10467004A0683|53 56|EBS1
P10467004A0683|58 61|IBS1
P10467004A0683|68 90|EBS2/IBS2 sequence motifs
P10467004A0683|68 71|EBS2
P10467004A0683|73 76|IBS2
P10467004A0683|115 129|correct splicing
P10467004A0683|152 153|bp
P10467403A0000|3 31|Trk/Nerve Growth Factor receptor
P10467403A0000|43 57|rapid activation
P10467403A0000|69 98|intracellular signaling proteins
P10467403A0000|109 136|phosphatidylinositol 3-kinase
P10467403A0000|138 147|PI 3-kinase
P10467465T0000|16 34|significance testing
P10467465T0000|36 49|misconceptions
P10467465T0000|53 64|alternatives
P10468033T0000|0 13|Chemical uptake
P10468033T0000|18 36|human stratum corneum
P10468033T0000|47 54|volatile
P10468033T0000|58 77|non-volatile solvents
P10468585A0980|4 13|DNA binding
P10468585A0980|15 40|transcriptional enhancement
P10468585A0980|65 93|located basic amino acid residues
P10468585A0980|103 126|carboxyl-terminal portion
P10468585A0980|129 133|Hap46
P10468585A0980|154 169|hsp70 interaction
P10468585A0980|154 158|hsp70
P10469140A0336|28 62|potential NF-kappaB-like sites present
P10469140A0336|37 55|NF-kappaB-like sites
P10469140A0336|68 88|PAI-2 proximal promoter
P10469140A0336|92 105|responsiveness
P10469140A0336|108 115|TNFalpha
P10469140A0336|121 172|chloramphenicol acetyl transferase reporter gene deletion
P10469140A0336|121 164|chloramphenicol acetyl transferase reporter gene
P10469140A0336|176 191|mutation analyses
P10469174A0678|0 25|N-terminal sequence analysis
P10469174A0678|29 43|NMR measurements
P10469174A0678|85 94|C-terminal
P10469174A0678|97 104|residues
P10469174A0678|107 110|MBF1
P10469174A0678|123 148|structured C-terminal domain
P10469174A0678|151 154|MBF1
P10469174A0678|156 162|MBF1CTD
P10469656T0000|3 21|nucleosomal response
P10469656T0000|36 63|immediate-early gene induction
P10469656T0000|36 54|immediate-early gene
P10469656T0000|77 104|alternative MAP kinase cascades
P10469656T0000|106 109|MSK1
P10469656T0000|113 134|potential histone H3/HMG
P10469656T0000|122 130|histone H3
P10469656T0000|138 143|kinase
P10470220A1011|21 33|cutoff-levels
P10470220A1011|57 57|%
P10470220A1011|61 71|specificity
P10470220A1011|76 76|%
P10470220A1011|80 90|Protein S100
P10470220A1011|105 107|RIA
P10470220A1011|130 130|%
P10470220A1011|134 144|specificity
P10470220A1011|149 149|%
P10470220A1011|164 166|LIA
P10471587A0239|7 13|strains
P10471587A0239|16 28|C. trachomatis
P10471587A0239|31 46|triplicate assays
P10471587A0239|58 69|RT-PCR method
P10471587A0239|102 122|conventional technique
P10471587A0239|134 147|antimicrobials
P10471587A0239|159 171|resultant MICs
P10471587A0239|184 189|RT-PCR
P10471587A0239|209 214|higher
P10471587A0239|216 227|erythromycin
P10471587A0239|233 233|=
P10471587A0239|242 247|higher
P10471587A0239|249 259|amoxicillin
P10471696A0734|0 10|Null alleles
P10471696A0734|13 16|SAS4
P10471696A0734|20 23|SAS5
P10471696A0734|44 59|Abf1p binding site
P10471696A0734|65 77|HMR-E silencer
P10471696A0734|96 98|ACS
P10471696A0734|101 116|Rap1p binding site
P10471721A0141|0 22|Recent molecular analysis
P10471721A0141|41 46|S locus
P10471721A0141|55 65|polymorphic
P10471721A0141|77 88|several genes
P10471721A0141|95 97|SLG
P10471721A0141|99 101|SRK
P10471721A0141|106 135|as-yet-unidentified pollen S gene
P10471721A0141|137 137|s
P10471721A0141|154 158|genes
P10471743A0000|1 4|cDNA
P10471743A0000|14 24|putative RNA
P10471743A0000|31 41|DNA helicase
P10471743A0000|61 92|Arabidopsis thaliana cDNA libraries
P10471746A1102|7 10|MyoD
P10471746A1102|23 37|tryptophan motif
P10471746A1102|45 63|chromatin remodeling
P10471746A1102|69 84|Myogenin promoter
P10471746A1102|98 118|Myogenin transcription
P10471746A1102|98 105|Myogenin
P10472314A0717|0 6|RESULTS
P10472314A0717|11 17|Periods
P10472314A0717|20 22|TTP
P10472314A0717|25 28|PUNP
P10472314A0717|43 45|men
P10472314A0717|54 58|women
P10472836A0189|0 9|Feed intake
P10472836A0189|13 19|BW gains
P10472836A0189|34 34|P
P10472836A0189|43 59|dietary treatments
P10472836A0189|70 71|M.
P10473589A0189|3 11|N terminus
P10473589A0189|14 17|beta
P10473589A0189|21 23|kDa
P10473589A0189|38 42|alpha
P10473589A0189|50 64|integrase domain
P10473589A0189|78 86|C terminus
P10473589A0189|90 92|kDa
P10473598A0691|0 5|Skn-1a
P10473598A0691|16 31|C-terminal region
P10473598A0691|46 67|transactivation ability
P10473598A0691|86 93|promoter
P10473598A0691|118 132|transactivation
P10473598A0691|135 146|normal Skn-1a
P10473598A0691|141 146|Skn-1a
P10473598A0691|149 165|competition assays
P10473623A0081|2 20|early Xenopus embryos
P10473623A0081|25 59|transforming growth factor-beta member
P10473623A0081|37 66|growth factor-beta member activin
P10473623A0081|60 66|activin
P10473623A0081|77 85|gene Mix.2
P10473623A0081|114 132|multiprotein complex
P10473623A0081|134 157|activin-responsive factor
P10473623A0081|159 161|ARF
P10474898A0629|36 56|evolutionary synthesis
P10474898A0629|62 76|CMT1A-REP repeat
P10474898A0629|78 88|fluorescent
P10474898A0629|95 107|hybridization
P10474898A0629|109 112|FISH
P10474898A0629|125 151|heterologous PCR-based assays
P10474898A0629|178 185|primates
P10475610A1289|0 4|Natl.
P10475972A0269|14 21|outbreak
P10475972A0269|43 53|vaccination
P10475972A0269|67 72|deaths
P10476970A0542|15 26|novel isoform
P10476970A0542|29 56|Rapl GTPase-activating protein
P10476970A0542|64 72|rap1GAPII
P10476970A0542|96 109|alpha-subunits
P10476970A0542|115 115|G
P10476970A0542|127 150|heterotrimeric G-proteins
P10477545T0000|3 12|B-oligomer
P10477545T0000|15 28|pertussis toxin
P10477545T0000|40 58|CC chemokine receptor
P10477545T0000|76 95|M-tropic HIV-1 strains
P10477545T0000|76 88|M-tropic HIV-1
P10477583A0000a|16 30|B cell Ag receptor
P10477583A0000a|32 34|BCR
P10477583A0000a|45 55|Fc receptors
P10477583A0000a|59 61|IgG
P10477583A0000a|63 70|Fc gamma R
P10477583A0000a|80 97|G1-to-S progression
P10477583A0000b|16 30|B cell Ag receptor
P10477583A0000b|32 34|BCR
P10477583A0000b|45 55|Fc receptors
P10477583A0000b|59 61|IgG
P10477583A0000b|63 70|Fc gamma R
P10477583A0000b|80 97|G1-to-S progression
P10477597A0126|0 4|TRAF2
P10477597A0126|8 22|potent activator
P10477597A0126|26 53|95-kDa serine/threonine kinase
P10477597A0126|60 86|germinal center kinase related
P10477597A0126|88 91|GCKR
P10477597A0126|109 112|KHS1
P10477597A0126|127 136|activation
P10477597A0126|142 152|SAPK pathway
P10477597A0126|142 145|SAPK
P10477599T0000|2 29|activation-responsive element
P10477599T0000|32 45|single C motif-1
P10477599T0000|47 66|lymphotactin promoter
P10477599T0000|47 58|lymphotactin
P10477599T0000|76 87|constitutive
P10477599T0000|91 122|inducible DNA-protein interactions
P10477599T0000|100 110|DNA-protein
P10477599T0000|132 144|nuclear factor
P10477599T0000|156 160|T cell
P10477620A0580|0 42|Cytokine-induced NF-kappa B DNA binding activity
P10477620A0580|44 67|RelA nuclear translocation
P10477620A0580|69 91|I kappa B alpha degradation
P10477620A0580|93 107|I kappa B serine 32
P10477620A0580|93 105|I kappa B serine
P10477620A0580|108 122|phosphorylation
P10477620A0580|127 139|I kappa B kinase
P10477620A0580|141 143|IKK
P10477620A0580|166 182|curcumin treatment
P10477748A1076|10 13|p193
P10477748A1076|40 53|mitotic spindle
P10478275A1230|3 12|main issues
P10478275A1230|46 62|unknown mechanisms
P10478275A1230|81 91|natural diet
P10478275A1230|103 121|minimum coronary risk
P10478275A1230|137 141|foods
P10478275A1230|152 167|modern technology
P10478844A1604|0 13|Cotransfection
P10478844A1604|19 48|coactivator CREB-binding protein
P10478844A1604|30 48|CREB-binding protein
P10478844A1604|60 84|transcriptional repression
P10478844A1604|87 97|PPARalphawt
P10478844A1604|100 110|PPARalphatr
P10478844A1604|129 150|dominant negative effect
P10478844A1604|153 163|PPARalphatr
P10478844A1604|195 215|essential coactivators
P10478848A0331|0 3|SF-1
P10478848A0331|17 35|N-terminal AF1 domain
P10479025A0528|13 21|locations
P10479025A0528|24 30|sources
P10479025A0528|38 54|TF-MUSIC algorithm
P10479025A0528|38 39|TF
P10479025A0528|69 80|target region
P10479025A0528|86 96|spectrogram
P10479025A0528|102 123|somatosensory responses
P10479382A1098|14 20|results
P10479382A1098|53 74|nutritional constraints
P10479382A1098|81 106|odonate development patterns
P10479492A0000|0 8|OBJECTIVE
P10479492A0000|14 25|Surveillance
P10479492A0000|27 38|Epidemiology
P10479492A0000|43 52|End Results
P10479492A0000|54 57|SEER
P10479492A0000|77 95|% 5-year survival rate
P10479492A0000|99 132|corpus uteri adenocarcinoma FIGO stage
P10480937A0000|1 35|novel Drosophila A kinase anchor protein
P10480937A0000|6 35|Drosophila A kinase anchor protein
P10480937A0000|37 69|Drosophila A kinase anchor protein 200
P10480937A0000|47 66|A kinase anchor protein
P10480937A0000|71 78|DAKAP200
P10480937A0000|138 144|signals
P10480937A0000|154 157|cAMP
P10480937A0000|159 160|Ca
P10480937A0000|169 182|diacylglycerol
P10480937A0000|184 185|Li
P10480937A0000|187 188|Z.
P10480937A0000|190 194|Rossi
P10480937A0000|196 197|E.
P10482516A1158|7 26|transcription results
P10482516A1158|45 62|structure functions
P10482516A1158|68 87|attenuation mechanism
P10482516A1158|94 101|deletion
P10482516A1158|107 115|stem-loop
P10482516A1158|134 157|transcription readthrough
P10482516T0000|3 14|RNA stem-loop
P10482516T0000|32 64|transcription attenuation mechanism
P10482516T0000|92 122|Bacillus subtilis trpEDCFBA operon
P10482565A0469|0 35|Single-alanine-substitution mutations
P10482565A0469|53 59|effects
P10482565A0469|62 88|S-induced cell-to-cell fusion
P10482620A1009|29 41|transcription
P10482620A1009|49 57|MMTV 5' LTR
P10482620A1009|49 52|MMTV
P10482620A1009|55 57|LTR
P10482620A1009|86 91|Stat5a
P10482620A1009|94 112|transcription factor
P10482620A1009|154 166|transcription
P10482620A1009|174 180|MMTV LTR
P10483124T0000|0 29|Regional insertional mutagenesis
P10483124T0000|32 44|specific genes
P10483124T0000|50 68|CIC5F11/CIC2B9 locus
P10483124T0000|50 56|CIC5F11
P10483124T0000|58 63|CIC2B9
P10483124T0000|71 99|Arabidopsis thaliana chromosome
P10483124T0000|109 123|Ac/Ds transposon
P10483124T0000|109 110|Ac
P10483124T0000|144 161|cDNA scanning method
P10483945A0641|0 6|RESULTS
P10483945A0641|8 21|CK-MB elevation
P10483945A0641|8 12|CK-MB
P10483945A0641|38 45|patients
P10483945A0641|51 51|%
P10483945A0641|58 61|1-3x
P10483945A0641|68 68|%
P10483945A0641|70 73|3-5x
P10483945A0641|79 79|%
P10483945A0641|84 91|5x normal
P10483945A0641|97 97|%
P10483945A0641|100 107|patients
P10484695A0791|5 21|NART-R performance
P10484695A0791|31 43|valid estimate
P10484695A0791|46 55|baseline IQ
P10484695A0791|59 66|patients
P10484695A0791|71 89|neurologic disorders
P10484695A0791|103 120|language impairment
P10484818A0292|9 13|areas
P10484818A0292|34 38|means
P10484818A0292|41 65|cross-correlation analysis
P10485353T0000|0 64|Natural Haemophilus influenzae type b capsular polysaccharide antibodies
P10485353T0000|70 76|infants
P10485353T0000|80 87|children
P10485353T0000|92 101|West Africa
P10485353T0000|103 114|Burkina-Faso
P10485353T0000|119 124|France
P10485353T0000|127 151|cross-sectional serosurvey
P10485470A0242|24 26|Sp1
P10485470A0242|30 32|Sp3
P10485470A0242|35 46|major factors
P10485470A0242|59 66|Sp1 sites
P10485470A0242|72 92|p21/WAF1/Cip1 promoter
P10485470A0242|72 74|p21
P10485470A0242|76 79|WAF1
P10485470A0242|81 84|Cip1
P10485470A0242|95 103|MG63 cells
P10485470A0242|111 144|electrophoretic mobility shift assays
P10485470A0242|158 169|TSA treatment
P10485470A0242|187 203|binding activities
P10485585A0175|0 6|Galoyan
P10485585A0175|23 29|results
P10485585A0175|46 70|cardioactive neurohormones
P10486210A0126|39 64|human aldehyde reductase gene
P10486210A0126|68 75|promoter
P10487040A0453|0 26|Immunohistochemical staining
P10487040A0453|31 35|MIB-1
P10487040A0453|39 51|p53 antibodies
P10487040A0453|64 64|%
P10487040A0453|69 84|negative reaction
P10487217A0735|3 9|C2C-Prx
P10487217A0735|3 5|C2C
P10487217A0735|7 9|Prx
P10487217A0735|22 31|preprotein
P10487217A0735|37 46|amino acids
P10487217A0735|58 92|putative chloroplast-targeting signal
P10487217A0735|97 106|amino acids
P10487217A0735|112 121|N-terminus
P10487307A0768|17 31|surgery patients
P10487307A0768|46 70|intravenous hydrocortisone
P10487307A0768|74 75|mg
P10487307A0768|78 84|placebo
P10487307A0768|94 110|double-blind order
P10487744T0000|1 27|tyrosine-based sorting signal
P10487744T0000|33 62|beta2 integrin cytoplasmic domain
P10487744T0000|74 82|recycling
P10487744T0000|88 101|plasma membrane
P10487744T0000|118 142|ligand-supported migration
P10487753A0788|3 11|injection
P10487753A0788|14 25|XDRP1 protein
P10487753A0788|40 50|Xenopus eggs
P10487753A0788|58 78|embryonic cell division
P10487759A0630|5 28|transgenic Xenopus embryos
P10487759A0630|69 77|sequences
P10487759A0630|92 115|correct spatial expression
P10487759A0630|119 150|Xbra2 promoter-driven reporter gene
P10487760A0336|18 30|such cofactors
P10487760A0336|60 73|inactive mutant
P10487760A0336|76 87|Xenopus MEF2D
P10487760A0336|91 111|yeast two-hybrid screen
P10487762A0252|0 3|NuA4
P10487762A0252|9 29|apparent molecular mass
P10487762A0252|35 37|MDa
P10487921A0132|0 16|ATF1 transcription
P10487921A0132|0 3|ATF1
P10487921A0132|40 60|unsaturated fatty acids
P10487953A0765|3 10|patients
P10487953A0765|15 29|recurrent tumors
P10487953A0765|33 52|high S-phase fractions
P10487953A0765|62 83|first resected specimens
P10487953A0765|101 115|second operation
P10488087A0340|0 7|Mutation
P10488087A0340|10 27|TTF-1-binding sites
P10488087A0340|29 31|TBE
P10488087A0340|71 93|transcriptional activity
P10488087A0340|96 150|SP-A promoter-chloramphenicol acetyltransferase constructs
P10488087A0340|96 107|SP-A promoter
P10488087A0340|109 140|chloramphenicol acetyltransferase
P10488087A0340|161 177|SP-A gene sequences
P10488088T0000|0 25|Insulin-like growth factor-I
P10488088T0000|33 45|bcl-2 promoter
P10488088T0000|56 109|transcription factor cAMP-response element-binding protein
P10488129T0058|0 8|Synthesis
P10488129T0058|11 22|antisense RNA
P10488129T0058|26 48|S phase-dependent binding
P10488129T0058|51 62|E2F complexes
P10488129T0058|65 70|intron
P10488147A1176|0 13|Identification
P10488147A1176|16 24|eotaxin-3
P10488147A1176|73 93|eosinophil trafficking
P10488147A1176|97 133|other CCR3-mediated biological phenomena
P10488147A1176|102 105|CCR3
P10488148A0111|0 8|NF-kappaB
P10488148A0111|15 26|critical role
P10488148A0111|29 38|activation
P10488148A0111|41 59|HIV-1 gene expression
P10488148A0111|41 49|HIV-1 gene
P10488148A0111|62 70|cytokines
P10488148A0111|74 85|other stimuli
P10488148A0111|93 118|signal transduction pathways
P10488148A0111|144 149|latent
P10488148A0111|152 170|productive infection
P10488148A1267|5 11|studies
P10488148A1267|23 26|MAPK
P10488148A1267|44 47|AP-1
P10488148A1267|52 69|subsequent physical
P10488148A1267|73 93|functional interaction
P10488148A1267|96 99|AP-1
P10488148A1267|104 112|NF-kappaB
P10488148A1267|169 176|HIV-1 LTR
P10488148T0000|0 31|ERK MAP kinase links cytokine signals
P10488148T0000|0 11|ERK MAP kinase
P10488148T0000|34 43|activation
P10488148T0000|46 65|latent HIV-1 infection
P10488148T0000|80 101|cooperative interaction
P10488148T0000|104 107|AP-1
P10488148T0000|111 119|NF-kappaB
P10488337T0000|1 31|human nuclear-localized chaperone
P10488337T0000|45 56|dimerization
P10488337T0000|58 67|DNA binding
P10488337T0000|72 94|transcriptional activity
P10488337T0000|97 108|bZIP proteins
P10488875A0000|0 22|Clinical differentiation
P10488875A0000|25 32|patients
P10488875A0000|37 61|mild diplegic cerebral palsy
P10488875A0000|63 64|CP
P10488875A0000|69 88|idiopathic toe walking
P10488875A0000|90 92|ITW
P10489680A0927|0 9|Sputum IL-8
P10489680A0927|13 15|MPO
P10489680A0927|47 49|BPT
P10489680A0927|56 58|TDI
P10489680A0927|63 78|grain dust-asthma
P10489680A0927|80 80|P
P10489822T0000|0 10|Montelukast
P10489822T0000|18 47|airway eosinophilic inflammation
P10489822T0000|50 55|asthma
P10490065T0000|0 8|Treatment
P10490065T0000|11 24|unstable angina
P10490065T0000|32 52|antithrombotic therapy
P10490604A0601|22 32|kinase-dead
P10490604A0601|39 52|wild-type forms
P10490604A0601|55 57|Fyn
P10490604A0601|59 61|Lck
P10490604A0601|66 105|ZAP-70 block 70Z Cbl-mediated NFAT activation
P10490604A0601|66 71|ZAP-70
P10490604A0601|80 82|Cbl
P10490604A0601|92 95|NFAT
P10490609A0413|0 12|Substitutions
P10490609A0413|26 43|synthetic sequences
P10490609A0413|56 71|specific sequence
P10490609A0413|81 87|repeats
P10490609A0413|97 119|more consecutive adenines
P10490609A0413|122 129|thymines
P10490609A0413|138 149|interruption
P10490609A0413|152 158|guanine
P10490609A0413|161 168|cytosine
P10490609A0413|187 197|ARS activity
P10490609A0413|187 189|ARS
P10490639A0000|26 30|PHO85
P10490639A0000|39 67|cyclin-dependent protein kinase
P10490639A0000|69 71|Cdk
P10490639A0000|73 88|catalytic subunit
P10490639A0000|93 115|multiple regulatory roles
P10490639A0000|153 175|different cyclin partners
P10490639A0000|162 175|cyclin partners
P10490639A0000|177 180|Pcls
P10490662A0431|0 6|Mutants
P10490662A0431|11 25|mild lace alleles
P10490662A0431|38 43|adults
P10490662A0431|48 75|multiple aberrant morphologies
P10490662A0431|81 90|appendages
P10490662A0431|92 102|compound eye
P10490662A0819|7 17|SPT activity
P10490662A0819|36 53|epitope-tagged Lace
P10490662A0819|50 53|Lace
P10490662A0819|67 90|epitope-specific antibody
P10490816A0000|0 8|Mutations
P10490816A0000|14 20|RET gene
P10490816A0000|31 52|receptor tyrosine kinase
P10490816A0000|88 107|cancer syndromes MEN 2A
P10490816A0000|111 115|MEN 2B
P10490822A1167|5 11|results
P10490822A1167|20 28|targeting
P10490822A1167|31 37|Ras-GAP
P10490822A1167|31 33|Ras
P10490822A1167|35 37|GAP
P10490822A1167|53 75|novel anticancer approach
P10490826T0000|0 3|EB-1
P10490826T0000|6 41|tyrosine kinase signal transduction gene
P10490826T0000|76 78|t(1
P10490826T0000|76 76|t
P10490826T0000|83 88|subset
P10490826T0000|91 98|pre-B ALL
P10490826T0000|112 130|oncoprotein E2a-Pbx1
P10490826T0000|123 125|E2a
P10490826T0000|127 130|Pbx1
P10490835T0000|0 55|Protein kinase A-Ialpha subunit-directed antisense inhibition
P10490835T0000|58 80|ovarian cancer cell growth
P10490835T0000|82 90|crosstalk
P10490835T0000|95 124|tyrosine kinase signaling pathway
P10490835T0000|95 108|tyrosine kinase
P10490843A0159|0 3|BCL6
P10490843A0159|12 30|POZ/Zn finger protein
P10490843A0159|33 48|structure similar
P10490843A0159|71 93|developmental regulators
P10490843A0159|124 151|human hematopoietic malignancy
P10490843A0159|153 156|PLZF
P10490955T0000|0 12|Beta 1 integrin
P10490955T0000|0 3|Beta
P10490955T0000|5 12|integrin
P10490955T0000|17 48|proteoglycan-mediated stimulation
P10490955T0000|51 71|T lymphoma cell adhesion
P10490955T0000|75 113|mitogen-activated protein kinase signaling
P10490955T0000|75 104|mitogen-activated protein kinase
P10490955T0000|116 131|thrombospondin-1
P10490955T0000|135 158|thrombospondin-1 peptides
P10491133A0365|0 8|Optical CD
P10491133A0365|13 20|spectral
P10491133A0365|24 39|activity analyses
P10491133A0365|57 66|reactivity
P10491133A0365|69 78|HO isozymes
P10491133A0365|83 91|NO species
P10491133A0365|102 109|NO donors
P10491187T0000|3 26|phosphotransferase system
P10491187T0000|28 30|PTS
P10491187T0000|73 91|biochemical analysis
P10491187T0000|95 127|histidine phosphocarrier protein HPr
P10491187T0000|125 127|HPr
P10491187T0000|140 147|gene ptsH
P10491187T0000|144 147|ptsH
P10491213A0263|0 18|Serum concentrations
P10491213A0263|21 51|bone specific alkaline phosphatase
P10491213A0263|53 56|BALP
P10491213A0263|61 71|osteocalcin
P10491213A0263|73 86|bone Gla protein
P10491213A0263|88 90|BGP
P10491213A0263|93 105|urinary levels
P10491213A0263|108 119|pyridinoline
P10491213A0263|121 123|Pyr
P10491213A0263|128 144|deoxypyridinoline
P10491213A0263|146 149|Dpyr
P10491213A0263|162 171|tomography
P10491213A0263|173 174|CT
P10491213A0263|176 187|measurements
P10491213A0263|193 212|cross-sectional areas
P10491213A0263|218 226|vertebrae
P10491213A0263|233 238|femurs
P10491213A0263|243 257|apparent density
P10491213A0263|260 273|cancellous bone
P10491213A0263|279 287|vertebrae
P10491213A0263|307 321|material density
P10491213A0263|324 335|cortical bone
P10491213A0263|341 346|femurs
P10491213A0263|366 369|boys
P10491213A0263|376 380|girls
P10491213A0263|382 385|ages
P10491213A0263|390 394|years
P10492127A0914|15 39|intravenous administration
P10492127A0914|42 51|devazepide
P10492127A0914|54 96|specific cholecystokinin-A receptor antagonist
P10492127A0914|110 117|mg/kg/hr
P10492127A0914|128 130|min
P10492127A0914|137 160|postprandial saline intake
P10492127A0914|177 178|hr
P10492169A0939|36 48|unrelated ESTs
P10492169A0939|55 59|genes
P10492169A0939|61 95|pregnancy-associated plasma protein-A
P10492169A0939|97 102|PAPP-A
P10492169A0939|108 116|novel gene
P10492169A0939|134 140|EST-YD1
P10493203T0000|0 14|Prognostic value
P10493203T0000|18 39|treadmill exercise score
P10493203T0000|42 60|symptomatic patients
P10493203T0000|65 92|nonspecific ST-T abnormalities
P10493203T0000|102 104|ECG
P10493575T0000|0 16|Structural changes
P10493575T0000|22 31|C-terminus
P10493575T0000|34 36|Ca2
P10493575T0000|44 51|rat S100B
P10493575T0000|53 60|beta beta
P10493575T0000|76 82|peptide
P10493575T0000|97 122|C-terminal regulatory domain
P10493575T0000|125 127|p53
P10493580A1126|13 17|Gly84
P10493580A1126|27 34|putative
P10493580A1126|36 47|oxyanion hole
P10493580A1126|62 74|stabilization
P10493580A1126|80 101|transition state similar
P10493580A1126|107 112|C group
P10493580A1126|118 138|esterase/lipase family
P10493876A0000|3 19|solution structure
P10493876A0000|25 30|adduct
P10493876A0000|45 59|covalent bonding
P10493876A0000|65 75|fjord region
P10493876A0000|81 83|11S
P10493876A0000|85 87|12R
P10493876A0000|89 91|13R
P10493876A0000|93 95|14S
P10493876A0000|97 108|stereoisomer
P10493876A0000|111 114|anti
P10493876A0000|122 133|dihydroxy-13
P10493876A0000|138 145|epoxy-11
P10493876A0000|153 170|14-tetrahydrobenzo
P10493876A0000|172 172|g
P10493876A0000|174 181|chrysene
P10493876A0000|187 190|anti
P10493876A0000|192 192|B
P10493876A0000|194 194|g
P10493876A0000|196 198|CDE
P10493876A0000|205 214|exocyclic N
P10493876A0000|218 227|amino group
P10493876A0000|233 249|adenine residue dA6
P10493876A0000|266 275|trans-anti
P10493876A0000|278 278|B
P10493876A0000|280 280|g
P10493876A0000|282 282|C
P10493876A0000|284 286|dA6
P10493876A0000|289 306|positioned opposite
P10493876A0000|308 325|thymine residue dT17
P10493876A0000|331 349|DNA sequence context d
P10493876A0000|351 364|C1-T2-C3-T4-C5
P10493876A0000|367 367|B
P10493876A0000|369 369|g
P10493876A0000|371 371|C
P10493876A0000|373 391|A6-C7-T8-T9-C10-C11
P10493876A0000|394 394|d
P10493876A0000|396 430|G12-G13-A14-A15-G16-T17-G18-A19-G20
P10493876A0000|435 441|A21-G22
P10493876A0000|455 455|B
P10493876A0000|457 457|g
P10493876A0000|459 459|C
P10493876A0000|461 462|dA
P10493876A0000|464 477|dT 11-mer duplex
P10493876A0000|499 519|structural information
P10493876A0000|531 537|NMR data
P10493876A0000|555 571|molecular dynamics
P10493876A0000|573 574|MD
P10493876A0000|576 587|calculations
P10495573A0365|5 14|sildenafil
P10495573A0365|52 55|MUSE
P10495573A0365|72 89|comparative studies
P10495573A0365|94 106|better results
P10495573A0365|110 119|sildenafil
P10495573A0365|124 127|MUSE
P10495573A0365|131 131|%
P10495573A0365|136 136|%
P10495573A0365|154 169|better acceptance
P10496161A0503|0 14|Serum antibodies
P10496161A0503|38 38|%
P10496161A0503|44 61|infected guinea pigs
P10496161A0503|73 75|WPI
P10496161A0503|79 82|rats
P10496161A0503|94 96|WPI
P10496284A0115|10 31|encephalopathy episodes
P10496284A0115|33 42|CSF protein
P10496284A0115|46 60|immunoglobulin G
P10496284A0115|62 64|IgG
P10496284A0115|66 71|levels
P10496284A0115|76 83|elevated
P10496284A0115|102 109|IgG index
P10496284A0115|102 104|IgG
P10496284A0115|112 127|IgG synthesis rate
P10496284A0115|112 114|IgG
P10496303A1968|0 10|CONCLUSIONS
P10496303A1968|17 23|results
P10496303A1968|36 58|daily oral valganciclovir
P10496303A1968|69 77|exposures
P10496303A1968|80 90|ganciclovir
P10496303A1968|92 96|AUC24
P10496303A1968|125 146|intravenous ganciclovir
P10496303A1968|149 153|mg/kg
P10496388A1956a|9 20|nonperfusion
P10496388A1956a|23 48|neurosensory retinal vessels
P10496388A1956a|52 60|light dose
P10496388A1956a|66 70|J/cm2
P10496388A1956a|74 91|other adverse events
P10496388A1956b|9 20|nonperfusion
P10496388A1956b|23 48|neurosensory retinal vessels
P10496388A1956b|52 60|light dose
P10496388A1956b|66 70|J/cm2
P10496388A1956b|74 91|other adverse events
P10496553A1004|3 13|healing rate
P10496553A1004|16 35|HIV-positive patients
P10496553A1004|41 47|percent
P10496553A1004|55 59|weeks
P10496553A1004|66 72|percent
P10496553A1004|80 84|weeks
P10496553A1004|89 108|corresponding figures
P10496553A1004|112 119|patients
P10496553A1004|132 155|immunodeficiency syndrome
P10496553A1004|166 172|percent
P10497117A0358|3 7|P mRNA
P10497117A0358|21 28|third ORF
P10497117A0358|35 42|V protein
P10497117A0358|56 62|unclear
P10497117A0358|79 81|ORF
P10497199A0559|1 13|genetic screen
P10497199A0559|16 20|yeast
P10497199A0559|44 76|novel transcriptional factor binding
P10497199A0559|82 85|GlRE
P10497199A0559|94 147|chicken ovalbumin upstream promoter-transcription factor II
P10497199A0559|94 145|chicken ovalbumin upstream promoter-transcription factor
P10497199A0559|149 157|COUP-TFII
P10497262A0000|15 29|single-copy gene
P10497262A0000|36 60|trans -spliceosomal U5 snRNA
P10497262A0000|36 40|trans
P10497262A0000|42 60|spliceosomal U5 snRNA
P10497262A0000|68 106|trypanosomatid species Leptomonas seymouri
P10497262A0000|113 134|U5 RNA affinity selection
P10497262A0000|138 148|cDNA cloning
P10497800A0000|3 8|MMPI-A
P10497800A0000|10 16|Butcher
P10497800A0000|36 44|older MMPI
P10497800A0000|46 53|Hathaway
P10497800A0000|55 62|McKinley
P10497800A0000|90 97|anorexia
P10497800A0000|101 107|bulimia
P10497874A0925|5 13|other hand
P10497874A0925|15 34|phosphatidyl inositol
P10497874A0925|38 49|bisphosphate
P10497874A0925|51 54|PIP2
P10497874A0925|56 65|hydrolysis
P10497874A0925|74 94|direct phosphorylation
P10497874A0925|97 111|tyrosine residue
P10497874A0925|117 133|PLC-gamma1 isozyme
P10498616A0157|1 10|G22V mutant
P10498616A0157|13 17|M-Ras
P10498616A0157|61 73|interleukin-3
P10498616A0157|75 78|IL-3
P10498616A0157|81 119|dependent mast cell/megakaryocyte cell line
P10498616A0157|161 164|IL-3
P10498616A0157|183 186|IL-4
P10498616A0157|194 213|high expression levels
P10498616A0157|217 240|factor-independent growth
P10498616A1280|0 13|Mammalian M-Ras
P10498616A1280|18 55|Caenorhabditis elegans orthologue exhibit
P10498616A1280|65 82|structural features
P10498616A1280|110 119|activation
P10498616A1280|122 146|distinctive signaling paths
P10498616A1280|161 168|parallel
P10498616A1280|176 185|downstream
P10498616A1280|188 193|p21 Ras
P10498706A1219|32 35|PecS
P10498706A1219|46 49|pelD
P10498706A1219|53 66|pelE expression
P10498706A1219|53 56|pelE
P10498706A1219|86 98|true repressor
P10498706A1219|103 106|KdgR
P10498717A1048|5 16|observations
P10498717A1048|30 33|RsmC
P10498717A1048|53 69|rsmB transcription
P10498717A1048|53 56|rsmB
P10498717A1048|90 103|RsmA production
P10498717A1048|90 93|RsmA
P10499121A0542|7 32|experienced hearing aid users
P10499121A0542|40 62|linear Class D instruments
P10499121A0542|67 82|input compression
P10499121A0542|107 116|enrollment
P10499357A0439|0 10|SCOB testing
P10499357A0439|13 34|food-restricted animals
P10499357A0439|42 59|multiple fixed ratio
P10499357A0439|61 62|FR
P10499357A0439|79 80|FI
P10499357A0439|91 94|FR20
P10499357A0439|96 100|FI120
P10499357A0439|147 161|operant behavior
P10499357A0439|174 178|Weeks
P10499357A0439|217 229|neurotoxicity
P10501034A0839|0 27|Ribonuclease protection assays
P10501034A0839|40 43|hmg1
P10501034A0839|47 50|hmg2
P10501034A0839|99 123|spatially-modulated manner
P10501034A0839|130 142|morphogenesis
P10501034A0839|156 188|terpenoid-containing pigment glands
P10501034A0839|191 197|embryos
P10501656A1415|0 21|Differential expression
P10501656A1415|36 55|Northern blot analysis
P10501656A1415|65 78|multiple normal
P10501656A1415|82 95|tumor cell lines
P10501936T0000|0 11|Inactivation
P10501936T0000|17 70|Neurospora crassa mitochondrial outer membrane protein TOM70
P10501936T0000|73 99|repeat-induced point mutation
P10501936T0000|101 103|RIP
P10501936T0000|111 117|defects
P10501936T0000|120 145|mitochondrial protein import
P10501936T0000|149 158|morphology
P10501965A0879|0 11|Several genes
P10501965A0879|14 33|transcriptional units
P10501965A0879|68 84|ribosomal s6 kinase
P10501965A0879|86 89|Rsk3
P10501965A0879|105 114|intronless
P10501965A0879|118 130|ORF-less genes
P10501965A0879|135 139|Gpr31
P10501965A0879|143 152|intronless
P10501965A0879|154 170|putative G-protein
P10501965A0879|162 185|G-protein coupled receptor
P10501965A0879|178 185|receptor
P10501969A1329|3 9|results
P10501969A1329|21 26|GATA-5
P10501969A1329|34 58|specific downstream targets
P10501969A1329|66 71|GATA-4
P10501969A1329|121 133|cardiogenesis
P10502216A0289|32 39|efficacy
P10502216A0289|42 50|efegatran
P10502216A0289|55 67|streptokinase
P10502216A0289|74 80|heparin
P10502216A0289|96 121|tissue plasminogen activator
P10502216A0289|123 125|TPA
P10502216A0289|129 147|coronary reperfusion
P10502216A0289|150 156|acute MI
P10502402A0129|9 25|cell-surface TRAIL
P10502402A0129|21 25|TRAIL
P10502402A0129|70 86|mouse T lymphocytes
P10502402A0129|113 117|TRAIL
P10502402A0129|135 160|T cell-mediated cytotoxicity
P10502402A0129|167 182|immune regulation
P10502402A0533|8 30|pharmacologic inhibitors
P10502402A0533|54 79|signal transduction pathways
P10502402A0533|90 107|TRAIL gene induction
P10502402A0533|90 98|TRAIL gene
P10502402A0533|117 137|T lymphocyte activation
P10502434A0367|4 11|February
P10502434A0367|18 23|August
P10502434A0367|32 39|patients
P10502434A0367|44 63|endometrial carcinoma
P10502434A0367|94 132|high-dose-rate vaginal vault brachytherapy
P10502434A0367|138 158|only adjuvant treatment
P10502434A0604|6 13|patients
P10502434A0604|17 25|stage IBG3
P10502434A0604|32 35|ICG1
P10502434A0604|41 44|ICG2
P10502434A0604|53 63|ICG3 disease
P10502522A0000|0 23|Defective provirus genomes
P10502522A0000|26 54|human T-cell leukemia virus type I
P10502522A0000|26 53|human T-cell leukemia virus type
P10502522A0000|78 88|lymphocytes
P10502522A0000|93 111|infected individuals
P10502522A0000|117 133|infected cell lines
P10503540A0602|11 21|primer pairs
P10503540A0602|26 53|interpretable banding patterns
P10503540A0602|61 61|%
P10503540A0602|88 94|alleles
P10503540A0602|97 120|native polyacrylamide gels
P10503812A1450|1 30|population pharmacokinetic study
P10503812A1450|33 43|cyclosporin
P10503812A1450|46 68|organ transplant patients
P10503812A1450|79 104|elderly allograft recipients
P10503812A1450|111 115|years
P10503812A1450|142 151|covariable
P10503812A1450|163 189|cyclosporin pharmacokinetics
P10504332A0701|0 20|Immunofluoresence data
P10504332A0701|48 61|mutant receptor
P10504332A0701|63 84|fluorescent-labeled RAP
P10504332A0701|82 84|RAP
P10504332A0701|101 107|markers
P10504332A0701|113 128|endosomal pathway
P10504332A0701|140 144|cells
P10504332A0701|158 174|wild-type receptor
P10504332A0701|176 190|RAP fluorescence
P10504332A0701|207 222|lysosomal markers
P10505694A0000|0 13|Interleukin-12
P10505694A0000|15 19|IL-12
P10505694A0000|24 31|cytokine
P10505694A0000|42 72|peripheral blood mononuclear cells
P10505694A0000|74 77|PBMC
P10505694A0000|89 104|interferon-gamma
P10505694A0000|106 114|IFN-gamma
P10505694A0000|129 139|enhancement
P10505694A0000|142 166|cell-mediated cytotoxicity
P10505694A0739|0 14|IL-12 production
P10505694A0739|0 4|IL-12
P10505694A0739|32 47|C3a concentration
P10505694A0739|69 80|hemodialyzer
P10505694A0739|88 90|min
P10505694A0739|93 100|dialysis
P10505694A0739|102 103|r =
P10505694A0739|109 109|P
P10506143A0610|2 10|HeLa cells
P10506143A0610|15 37|JNKK2-JNK1 fusion protein
P10506143A0610|15 19|JNKK2
P10506143A0610|21 24|JNK1
P10506143A0610|44 65|significant JNK activity
P10506143A0610|55 57|JNK
P10506143A0610|95 98|JNK1
P10506143A0610|110 120|many stimuli
P10506143A0610|124 133|activators
P10506143A0610|144 146|EGF
P10506143A0610|148 156|TNF-alpha
P10506143A0610|158 167|anisomycin
P10506143A0610|169 181|UV irradiation
P10506143A0610|183 187|MEKK1
P10506143A0610|192 218|small GTP binding proteins Rac1
P10506143A0610|192 214|small GTP binding proteins
P10506143A0610|215 218|Rac1
P10506143A0610|222 228|Cdc42Hs
P10506160A0297|0 1|J.
P10508522A1598|3 9|results
P10508522A1598|19 29|TGF-beta RII
P10508522A1598|33 44|direct target
P10508522A1598|47 54|EWS-FLI1
P10509768A1118|14 38|saturated fatty acids intake
P10509768A1118|78 83|mmol/l
P10509768A1118|88 88|%
P10509768A1118|101 126|total serum cholesterol level
P10509768A1118|106 121|serum cholesterol
P10510295A0606|11 41|ethanol repression autoregulation
P10510295A0606|43 45|ERA
P10510295A0606|48 66|twelve-fold TA repeat
P10510295A0606|68 70|TAB
P10510295A0606|72 87|repressor element
P10510295A0606|110 123|promoter region
P10510295A0606|129 136|GLK1 gene
P10510379A0105|1 26|crucial transcription factor
P10510379A0105|42 46|STAT6
P10510379A0105|61 78|specific DNA element
P10510379A0105|83 100|cytokine activation
P10511216A0654|0 10|CONCLUSIONS
P10511216A0654|12 41|Congenital horizontal tarsal kink
P10511554T0000|7 18|high-density
P10511554T0000|20 51|single-nucleotide polymorphism map
P10511554T0000|58 88|clone Caenorhabditis elegans cdf-1
P10511554T0000|63 88|Caenorhabditis elegans cdf-1
P10512699A0364|4 12|machinery
P10512699A0364|22 39|secondary structure
P10512699A0364|41 52|SECIS element
P10512699A0364|59 84|selenoprotein-encoding mRNA
P10512699A0364|95 117|selenocysteine insertion
P10512699A0364|135 138|opal
P10512699A0364|140 142|UGA
P10512699A0364|144 148|codon
P10512699A0364|168 178|termination
P10512699T0000|0 19|High-level expression
P10512699T0000|39 86|selenocysteine-containing rat thioredoxin reductase
P10512699T0000|64 86|rat thioredoxin reductase
P10512699T0000|96 106|gene fusions
P10512699T0000|121 147|bacterial-type SECIS elements
P10512699T0000|151 163|co-expression
P10512699T0000|171 174|selA
P10512699T0000|176 179|selB
P10512699T0000|183 191|selC genes
P10512857A0000|2 13|Wnt signaling
P10512857A0000|2 4|Wnt
P10512857A0000|15 26|beta-catenin
P10512857A0000|30 40|plakoglobin
P10512857A0000|50 56|signals
P10512857A0000|62 68|nucleus
P10512857A0000|76 87|interactions
P10512857A0000|92 119|TCF-type transcription factors
P10512882A0137|0 7|Assembly
P10512882A0137|25 27|FAK
P10512882A0137|31 40|Src kinases
P10512882A0137|62 84|subcellular localization
P10512882A0137|91 107|enzymatic activity
P10512882A0137|110 116|members
P10512882A0137|122 139|Src family of kinases
P10512882A0137|122 130|Src family
P10512882A0137|133 139|kinases
P10513756A0584|3 5|EPV
P10513756A0584|33 33|%
P10513756A0584|50 65|8-predictor model
P10513756A0584|84 113|conventional selection criterion
P10513756A0584|122 127|alpha =
P10513922A1237|24 43|significant increases
P10513922A1237|57 78|larger myelinated fibers
P10513922A1237|90 99|repair site
P10513922A1237|119 126|neonatal
P10513922A1237|130 140|adult groups
P10513922A1237|142 142|p
P10514493A0199|5 37|SO-induced neuronal differentiation
P10514493A0199|40 64|N1E-115 neuroblastoma cells
P10514493A0199|96 114|endogenous Ntr-1 gene
P10514493A0199|118 130|reporter genes
P10514493A0199|139 160|NTR-1 promoter sequences
P10514493A0199|163 170|3-4-fold
P10514808T0000|0 17|Cortical dysplasias
P10514808T0000|19 26|genetics
P10514808T0000|31 45|epileptogenesis
P10516011A0471|28 41|peptide mapping
P10516011A0471|43 58|mass spectrometry
P10516011A0471|63 86|site-directed mutagenesis
P10516011A0471|100 103|sets
P10516011A0471|106 128|pAP phosphorylation sites
P10516011A0471|106 108|pAP
P10516026A0270|4 13|HERV-K type
P10516026A0270|19 24|clones
P10516072A0146|0 3|Duch
P10516072A0146|8 9|F.
P10516738A0925|5 15|time-points
P10516738A0925|17 28|most patients
P10516738A0925|32 32|=
P10516738A0925|35 35|%
P10516738A0925|50 64|irbesartan/HCTZ
P10516878T0000|0 11|Modification
P10516878T0000|14 39|dopamine D2 receptor activity
P10516878T0000|14 31|dopamine D2 receptor
P10516878T0000|42 50|pergolide
P10516878T0000|53 61|Parkinson
P10516878T0000|87 89|PET
P10517666A1069|0 24|High-affinity binding sites
P10517666A1069|32 33|GR
P10517666A1069|37 54|AP-1 nucleoproteins
P10517666A1069|71 86|adjacent elements
P10517666A1069|96 99|nGRE
P10517672A1417|7 19|73-bp fragment
P10517672A1417|32 65|alpha1-globin promoter-CAT construct
P10517672A1417|32 52|alpha1-globin promoter
P10517672A1417|86 110|CCAAT transcription factor 1
P10517672A1417|86 109|CCAAT transcription factor
P10517672A1417|112 115|CTF1
P10517672A1417|118 120|NF1
P10517672A1417|125 157|Drosophila Schneider SL2 insect cells
P10517672A1417|168 183|NF1-like proteins
P10517672A1417|185 200|trans-activation
P10517672A1417|203 213|CAT activity
P10517672A1417|203 205|CAT
P10517675A0809|0 18|Western blot analysis
P10517675A0809|26 51|rapid corresponding increase
P10517675A0809|54 72|p21WAF1/CIP1 protein
P10517675A0809|54 60|p21WAF1
P10517675A0809|62 65|CIP1
P10517675A0809|81 93|protein levels
P10517675A0809|114 150|cyclin-dependent kinase inhibitor family
P10517675A0809|152 158|p27kip1
P10517675A0809|164 172|unchanged
P10518496A0952|0 10|Aggregation
P10518496A0952|13 45|vHnf1-deficient embryonic stem cells
P10518496A0952|13 17|vHnf1
P10518496A0952|50 75|wild-type tetraploid embryos
P10518496A0952|105 125|extraembryonic tissues
P10518496A0952|134 158|periimplantation lethality
P10518496A0952|191 208|early organogenesis
P10518502T0000|0 4|nos-1
P10518502T0000|8 12|nos-2
P10518502T0000|17 28|genes related
P10518502T0000|31 45|Drosophila nanos
P10518502T0000|55 83|primordial germ cell development
P10518502T0000|97 117|Caenorhabditis elegans
P10518561A0261|8 25|upstream regulators
P10518561A0261|28 43|Tec family kinases
P10518561A0261|93 111|downstream effectors
P10518561A0261|119 125|enzymes
P10518561A0885|0 23|Efficient phosphorylation
P10518561A0885|26 30|BRDG1
P10518561A0885|33 35|Tec
P10518561A0885|47 48|PH
P10518561A0885|52 61|SH2 domains
P10518561A0885|73 84|kinase domain
P10518822A1037|0 9|CONCLUSION
P10518822A1037|16 23|findings
P10518822A1037|33 39|eotaxin
P10518822A1037|73 83|acute asthma
P10518822A1037|95 103|biomarker
P10518822A1037|120 143|CCR3 receptor ligand system
P10518822A1037|172 177|asthma
P10518937A0572|3 20|expression analysis
P10518937A0572|26 35|KlHIS4 gene
P10518937A0572|41 59|phosphate starvation
P10518937A0572|62 78|high adenine supply
P10518937A0572|88 94|factors
P10518937A0572|102 105|Bas1
P10518937A0572|108 111|Bas2
P10518937A0572|126 137|basal control
P10518937A0572|155 166|different way
P10518937A0572|169 176|K. lactis
P10518956A0137|5 25|thyroid hormone changes
P10518956A0137|47 55|cytokines
P10518956A0137|58 83|other inflammatory mediators
P10518956A0137|106 117|hypothalamus
P10518956A0137|121 134|pituitary gland
P10518956A0137|139 150|thyroid gland
P10518956A0137|158 180|hepatic deiodinase system
P10518956A0137|158 174|hepatic deiodinase
P10518956A1212|0 6|ESS type
P10518956A1212|13 18|FT3 low
P10518956A1212|22 24|FT4
P10518956A1212|28 36|TSH normal
P10518956A1212|47 58|frequent form
P10520800A0307|0 6|METHODS
P10520800A0307|19 37|symptomatic patients
P10520800A0307|42 45|HOCM
P10520800A0307|49 51|men
P10520800A0307|68 72|years
P10520800A0307|88 102|septal reduction
P10520800A0307|108 123|echocardiography
P10520800A0307|127 143|electrocardiogram
P10520800A0307|145 147|ECG
P10521345A0202|0 20|Paleoceanographic data
P10521345A0202|28 40|Laurentian Fan
P10521345A0202|49 53|proxy
P10521345A0202|57 77|sea surface temperature
P10521345A0202|89 111|surface slope waters north
P10521345A0202|117 126|Gulf Stream
P10521345A0202|154 165|Little Ice Age
P10521345A0202|171 174|16th
P10521345A0202|177 189|19th centuries
P10521345A0202|213 235|NAO-driven coupled system
P10521443A0486|21 32|IR activation
P10521443A0486|54 63|IR mutation
P10521443A0486|66 74|tyrosines
P10521443A0486|93 111|NF-kappaB activation
P10521443A0486|93 101|NF-kappaB
P10521443A0486|133 146|overexpression
P10521443A0486|149 178|dominant-negative IkappaB-alpha
P10521443A0486|180 185|A32/36
P10521443A0486|200 213|overexpression
P10521443A0486|219 239|NF-kappaB c-Rel subunit
P10521447A0606|19 19|B
P10521447A0606|47 60|sequence TGTGGT
P10521447A0606|63 71|core motif
P10521447A0606|84 90|members
P10521447A0606|96 132|AML/CBFalpha transcription factor family
P10521447A1190|12 25|overexpression
P10521447A1190|28 41|AML3/CBFalpha1
P10521447A1190|28 31|AML3
P10521447A1190|33 41|CBFalpha1
P10521447A1190|56 73|AML1-ETO repression
P10521447A1190|56 59|AML1
P10521447A1190|61 63|ETO
P10521450A0437|10 22|Akt activation
P10521450A0437|10 12|Akt
P10521450A0437|25 27|Lyn
P10521450A0437|30 32|Syk
P10521450A0437|37 58|Btk-deficient DT40 cells
P10521450A0437|37 39|Btk
P10521450A0437|62 67|B cells
P10521450A0437|72 74|Lyn
P10521450A0437|80 83|mice
P10521509A0000|0 9|Regulators
P10521509A0000|12 28|G protein signaling
P10521509A0000|12 19|G protein
P10521509A0000|30 32|RGS
P10521509A0000|34 41|proteins
P10521509A0000|53 55|DEP
P10521509A0000|57 66|disheveled
P10521509A0000|68 73|EGL-10
P10521509A0000|75 84|pleckstrin
P10521509A0000|89 91|GGL
P10521509A0000|93 117|G protein gamma subunit-like
P10521509A0000|119 125|domains
P10521509A0000|131 139|subfamily
P10521509A0000|155 178|mammalian RGS proteins RGS6
P10521509A0000|155 174|mammalian RGS proteins
P10521509A0000|175 178|RGS6
P10521509A0000|180 183|RGS7
P10521509A0000|185 188|RGS9
P10521509A0000|193 197|RGS11
P10521544T0000|0 6|Cloning
P10521544T0000|23 55|specific human alpha 1,2-mannosidase
P10521544T0000|65 75|Man9GlcNAc2
P10521544T0000|78 95|Man8GlcNAc2 isomer B
P10521544T0000|102 121|N-glycan biosynthesis
P10521796A0872|3 5|ORs
P10521796A0872|8 9|GC
P10521796A0872|59 75|baseline diagnoses
P10521796A0872|78 108|superficial intestinal metaplasia
P10521796A0872|110 111|IM
P10521796A0872|133 138|deep IM
P10521796A0872|141 153|mild dysplasia
P10521796A0872|155 157|DYS
P10521796A0872|161 162|IM
P10521796A0872|167 182|glandular atrophy
P10521796A0872|186 200|neck hyperplasia
P10521796A0872|232 240|severe DYS
P10521796A0872|256 263|subjects
P10521796A0872|268 287|superficial gastritis
P10521796A0872|289 290|SG
P10521796A0872|294 317|chronic atrophic gastritis
P10521796A0872|319 321|CAG
P10521796A0872|325 332|baseline
P10523319A0209|16 20|Dbp5p
P10523319A0209|24 28|Rat7p
P10523319A0209|49 64|Nterminal domains
P10523520A0986|8 20|nematode genes
P10523520A0986|31 38|homologs
P10523520A0986|41 51|Hh molecules
P10523520A0986|54 63|other phyla
P10523634A1404|1 6|subset
P10523634A1404|9 17|mutations
P10523634A1404|23 39|Psi synthase domain
P10523634A1404|63 82|altered Cbf5p proteins
P10523634A1404|95 109|box H/ACA snoRNAs
P10523634A1404|98 109|H/ACA snoRNAs
P10523634A1404|128 152|functional catalytic domain
P10523640A0367|11 27|Src tyrosine kinase
P10523640A0367|35 66|constitutive Stat3 phosphorylation
P10523640A0367|47 51|Stat3
P10523640A0367|69 76|tyrosine
P10523640A0367|78 87|activation
P10523640A0367|90 117|Stat3-mediated gene regulation
P10523640A0367|90 94|Stat3
P10523640A0367|130 137|tyrosine
P10523640A0367|141 161|serine phosphorylation
P10523640A0367|164 168|Stat3
P10523647A0000|3 25|transcription factor CHOP
P10523647A0000|22 25|CHOP
P10523647A0000|27 48|C/EBP homologous protein
P10523647A0000|55 65|bZIP protein
P10523647A0000|85 91|stimuli
P10523647A0000|101 123|cellular stress responses
P10523647A0000|147 156|cell growth
P10523647A0000|179 187|cell death
P10523647A1001|5 8|CHOP
P10523647A1001|30 46|positive regulator
P10523647A1001|49 64|C/EBP target genes
P10523647A1001|77 84|tethered
P10523647A1001|87 97|AP-1 factors
P10523647A1001|110 124|AP-1 target genes
P10523663A0404|4 8|motif
P10523663A0404|30 62|Drosophila homeobox activator DEAF-1
P10523663A0404|40 62|homeobox activator DEAF-1
P10523663A0404|91 123|metazoan transcriptional modulators
P10523674A0000|0 7|RNase MRP
P10523674A0000|11 43|ribonucleoprotein endoribonuclease
P10523674A0000|66 70|roles
P10523674A0000|77 103|mitochondrial DNA replication
P10523674A0000|117 131|S rRNA processing
P10524258A0286|32 41|FGFR-1 gene
P10524258A0286|43 47|cek-1
P10524258A0286|51 71|avian myogenic cultures
P10524258A0286|74 92|immunocytochemistry
P10524258A0286|96 115|Northern blot analysis
P10524258T0000|0 9|Regulation
P10524258T0000|12 47|avian fibroblast growth factor receptor 1
P10524258T0000|12 46|avian fibroblast growth factor receptor
P10524258T0000|49 59|FGFR-1) gene
P10524258T0000|49 54|FGFR-1
P10524258T0000|56 69|gene expression
P10524258T0000|76 104|skeletal muscle differentiation
P10525413A1408|3 18|backbone dynamics
P10525413A1408|21 28|residues
P10525413A1408|53 56|CRP2
P10525413A1408|58 61|LIM2
P10525413A1408|63 67|R122A
P10525413A1408|91 105|proton-detected
P10525413A1408|110 125|N NMR spectroscopy
P10526670A0236|0 2|Rac
P10526670A0236|9 17|uncapping
P10526670A0236|20 33|actin filaments
P10526670A0236|35 41|F-actin
P10526670A0236|48 56|plus-ends
P10526670A0236|65 84|phosphatidylinositol
P10526670A0236|88 99|bisphosphate
P10526670A0236|101 104|PIP2
P10526670A0236|127 142|membrane ruffling
P10526670A1828|9 27|specific ICE/caspase
P10526670A1828|17 19|ICE
P10526670A1828|21 29|caspase-1
P10526670A1828|30 38|inhibitor
P10526670A1828|45 49|N1445
P10526670A1828|72 90|CK-induced apoptosis
P10526670A1828|72 73|CK
P10526670A1828|105 107|PKB
P10526670A1828|131 151|CK-induced suppression
P10526670A1828|131 132|CK
P10526670A1828|154 170|Ras transformation
P10526670A1828|154 156|Ras
P10527106A0384|0 8|OBJECTIVE
P10527106A0384|21 33|preponderance
P10527106A0384|36 43|findings
P10527106A0384|59 67|transient
P10527106A0384|91 99|sustained
P10527106A0384|134 150|specific depiction
P10527158T0000|3 9|AL-R8 SI
P10527158T0000|14 43|next generation staging container
P10527158T0000|47 59|plutonium pits
P10527158T0000|65 80|USDOE Pantex Plant
P10527180A0869|0 6|RESULTS
P10527180A0869|8 14|Factors
P10527180A0869|43 43|P
P10527180A0869|64 79|treatment failure
P10527180A0869|83 105|Cox multivariate analysis
P10527180A0869|114 121|age older
P10527180A0869|128 132|years
P10527180A0869|134 147|relative hazard
P10527180A0869|156 174|% confidence interval
P10527180A0869|176 177|CI
P10527180A0869|191 219|Karnofsky performance score less
P10527180A0869|226 226|%
P10527180A0869|235 237|% CI
P10527180A0869|259 274|hormone receptors
P10527180A0869|283 285|% CI
P10527180A0869|298 305|prior use
P10527180A0869|308 327|adjuvant chemotherapy
P10527180A0869|336 338|% CI
P10527180A0869|351 385|initial disease-free survival interval
P10527180A0869|391 407|adjuvant treatment
P10527180A0869|422 427|months
P10527180A0869|436 438|% CI
P10527180A0869|451 460|metastases
P10527180A0869|479 481|% CI
P10527180A0869|495 514|central nervous system
P10527180A0869|523 525|% CI
P10527180A0869|537 558|approaches significance
P10527180A0869|563 572|soft tissue
P10527180A0869|589 597|more sites
P10527180A0869|600 616|metastatic disease
P10527180A0869|625 627|% CI
P10527180A0869|643 660|incomplete response
P10527180A0869|663 678|complete response
P10527180A0869|681 705|standard-dose chemotherapy
P10527180A0869|714 716|% CI
P10527426A0521|12 29|SBEI gene transcript
P10527426A0521|32 47|12-day old kernels
P10527426A0521|60 82|exon I+II+III combination
P10527426A0521|101 110|other forms
P10527426A0521|121 129|inclusion
P10527426A0521|132 137|intron
P10527426A0521|141 149|exclusion
P10527426A0521|152 155|exon
P10527426A0521|158 166|sequences
P10527475A0643|5 13|rare MNGCs
P10527475A0643|17 38|intranuclear inclusions
P10527475A0643|42 48|grooves
P10528035A1102|2 8|percent
P10528035A1102|10 10|P
P10528035A1102|22 43|sustained normalization
P10528035A1102|46 79|serum alanine aminotransferase levels
P10528035A1102|46 73|serum alanine aminotransferase
P10528035A1102|83 89|percent
P10529198A0068|3 27|C-terminal catalytic domain
P10529198A0068|60 73|homologues p140
P10529198A0068|70 73|p140
P10529198A0068|75 81|ras-GRF
P10529198A0068|75 77|ras
P10529198A0068|79 81|GRF
P10529198A0068|86 88|Sos
P10529354A0375|3 12|proteasome
P10529354A0375|16 27|large complex
P10529354A0375|43 64|multisubunit structures
P10529354A0375|69 71|20S
P10529354A0375|75 77|19S
P10529354A0375|79 83|PA700
P10529354A0375|87 98|P28 complexes
P10529354A0375|120 131|26S particles
P10531334A0525|2 7|assays
P10531334A0525|20 26|enzymes
P10531334A0525|28 36|wild-type
P10531334A0525|43 51|PTPS-S19A
P10531334A0525|43 46|PTPS
P10531334A0525|48 51|S19A
P10531334A0525|56 72|specific substrate
P10531334A0525|79 105|cGMP-dependent protein kinase
P10531334A0525|107 109|cGK
P10531340A1275|0 1|R.
P10531340A1275|3 13|Fleischmann
P10531340A1275|15 16|R.
P10531340A1275|18 23|Venter
P10531340A1275|25 26|J.
P10531342A0348|3 18|N-terminal domain
P10531342A0348|36 38|kDa
P10531342A0348|49 73|imperfect amino acid repeats
P10531342A0348|86 93|homology
P10531342A0348|96 127|promastigote surface glycoproteins
P10531342A0348|133 148|psa2/gp46 complex
P10531342A0348|133 136|psa2
P10531342A0348|138 141|gp46
P10531342A1111|35 54|proteophosphoglycans
P10531342A1111|59 73|ppg1 gene product
P10531342A1111|89 107|membrane-associated
P10531342A1111|129 151|promastigote cell surface
P10531360A0958|28 32|cells
P10531360A0958|39 57|adenoviral construct
P10531360A0958|72 77|mutant
P10531360A0958|90 98|induction
P10531360A0958|101 108|VEGF mRNA
P10531360A0958|114 123|conditions
P10531360A0958|133 139|hypoxia
P10531446A0203|0 9|Neuregulin
P10531446A0203|20 24|ErbB2
P10531446A0203|26 30|ErbB3
P10531446A0203|35 39|ErbB4
P10531446A0203|41 47|members
P10531446A0203|53 62|ErbB family
P10531446A0203|65 87|receptor tyrosine kinases
P10532354A1374|3 9|results
P10532354A1374|21 25|Anu2p
P10532354A1374|31 44|yeast homologue
P10532354A1374|47 66|mammalian epsilon-COP
P10532354A1374|73 90|abrupt accumulation
P10532354A1374|96 105|ER membrane
P10532354A1374|115 122|blockage
P10532354A1374|128 155|early protein transport pathway
P10532354A1374|163 172|alteration
P10532354A1374|175 191|nuclear morphology
P10532354A1374|204 213|yeast cells
P10532805A0792|2 10|PC12 cells
P10532805A0792|12 28|nerve growth factor
P10532805A0792|36 58|neuronal differentiation
P10532805A0792|83 87|nrg-1
P10532805A1084|3 16|PC12 cell mutant
P10532805A1084|23 31|deficient
P10532805A1084|34 55|protein kinase A activity
P10532805A1084|34 47|protein kinase A
P10532805A1084|57 58|AB
P10532805A1084|87 92|agents
P10532805A1084|118 126|nrg-1 mRNA
P10533066A0758|0 12|TSC1 mutations
P10533066A0758|23 39|nonsense mutations
P10533066A0758|45 54|insertions
P10533066A0758|64 78|splice mutations
P10533066A1197|6 13|patients
P10533066A1197|21 33|abnormalities
P10533066A1197|39 41|PTT
P10533066A1197|60 76|missense mutations
P10533066A1197|88 91|TSC2
P10534048A0297|3 16|first algorithm
P10534048A0297|18 25|FOREPROJ
P10534048A0297|30 60|fast-forward projection algorithm
P10534048A0297|87 117|3-D attenuation correction factors
P10534048A0297|119 121|ACF
P10534048A0297|138 152|two-dimensional
P10534048A0297|154 156|2-D
P10534048A0297|204 217|attenuation map
P10534048A0297|236 238|3-D
P10534402A0126|12 15|cDNA
P10534402A0126|19 28|genomic DNA
P10534402A0126|33 41|mouse gene
P10534402A0126|62 90|significant sequence similarity
P10534402A0126|102 108|domains
P10534402A0126|116 123|proteins
P10534402A0126|129 140|Spo11p family
P10534402A0659|0 5|RT-PCR
P10534402A0659|15 35|hybridization analyses
P10534402A0659|39 48|time course
P10534402A0659|51 75|juvenile testis development
P10534402A0659|88 102|Spo11 expression
P10534402A0659|88 92|Spo11
P10534402A0659|111 130|early meiotic Prophase
P10534402A0659|143 156|pachytene stage
P10534402A0659|172 183|accumulation
P10534402A0659|186 189|mRNA
P10534402A0659|200 213|pachytene stage
P10534691A0542|0 6|Animals
P10534691A0542|22 26|weeks
P10534691A0542|38 43|grafts
P10534691A0542|80 99|microbiologic culture
P10534691A0542|103 130|standard histologic procedures
P10535715A0268|3 5|RMR
P10535715A0268|53 53|F
P10535715A0268|60 60|=
P10535715A0268|76 85|follicular
P10535715A0268|91 96|kJ/24 h
P10535715A0268|104 109|luteal
P10535715A0268|115 120|kJ/24 h
P10535715A0268|122 127|phases
P10536125A0093|0 10|Oseltamivir
P10536125A0093|12 17|GS4104
P10536125A0093|54 60|prodrug
P10536125A0093|63 68|GS4071
P10536125A0093|71 76|potent
P10536125A0093|80 97|selective inhibitor
P10536125A0093|100 127|influenzavirus neuraminidases
P10536369A0662|2 23|gel mobility shift assays
P10536369A0662|45 72|VDR-TR heterodimer interaction
P10536369A0662|45 47|VDR
P10536369A0662|49 50|TR
P10536369A1280|3 20|relative importance
P10536369A1280|31 40|mechanisms
P10536369A1280|52 81|response element-specific manner
P10536788A0931|7 7|d
P10536788A0931|10 20|overfeeding
P10536788A0931|22 38|hepatic PL profiles
P10536788A0931|60 65|breeds
P10536788A0931|84 96|control livers
P10536788A0931|98 117|choline-containing PL
P10536788A0931|132 132|%
P10536788A0931|135 141|total PL
P10540015A0664|0 11|C-SP duration
P10540015A0664|37 47|ALS patients
P10540015A0664|58 65|controls
P10540015A0664|68 90|low stimulation intensity
P10540015A0664|108 119|MEP threshold
P10540015A0664|133 133|%
P10540292A1179|20 36|spv virulence genes
P10540292A1179|59 73|several regulons
P10540292A1179|109 121|spv expression
P10540292A1179|109 111|spv
P10540292A1179|127 136|fine-tuned
P10540292A1179|149 175|multiple environmental inputs
P10540553A0980|0 17|Intensive synthesis
P10540553A0980|20 22|PNA
P10540553A0980|28 32|cells
P10540553A0980|35 51|microvascular wall
P10540553A0980|68 89|high functional activity
P10540553A0980|97 105|synthesis
P10540553A0980|138 150|proliferation
P10540553A0980|152 155|i.g.
P10540915A0697|0 19|Tracheal transsection
P10540915A0697|32 44|hilar ligation
P10540915A0697|46 50|TL&PL
P10540915A0697|76 76|%
P10540915A0697|78 81|n.s.
P10541432A0185|0 27|Kinase-deficient erbB proteins
P10541432A0185|35 55|epidermal growth factor
P10541432A0185|57 59|EGF
P10541432A0185|69 91|tyrosine phosphorylation
P10541432A0185|94 114|endogenous Shc proteins
P10541432A0185|104 114|Shc proteins
P10541432A0185|141 177|sustained EGF-induced ERK MAPK activities
P10541432A0185|150 152|EGF
P10541432A0185|180 201|human glioblastoma cells
P10541432A0185|211 232|basal ERK MAPK activities
P10541432A0185|237 246|unaffected
P10541550A0487|5 22|immunolocalization
P10541550A0487|37 40|ACE3
P10541550A0487|43 62|440-bp chorion element
P10541550A0487|75 95|information sufficient
P10541550A0487|103 115|amplification
P10541550A0487|124 140|DmORC localization
P10541550A0487|124 128|DmORC
P10541550A0487|143 155|follicle cells
P10541865A1301|10 31|homozygous co-deletions
P10541865A1301|34 39|CDKN2A
P10541865A1301|43 48|CDKN2B
P10541865A1301|59 67|mutations
P10541865A1301|77 97|individual transcripts
P10541865A1301|129 134|tumors
P10542237A0357|15 28|aortic explants
P10542237A0357|41 58|PPARalpha-null mice
P10542237A0357|41 49|PPARalpha
P10542237A0357|68 86|exacerbated response
P10542237A0357|89 107|inflammatory stimuli
P10542237A0357|115 132|lipopolysaccharide
P10542237A0357|134 136|LPS
P10542237A0357|164 176|IL-6 secretion
P10542237A0357|164 167|IL-6
P10542249A0415|0 16|Albumin expression
P10542249A0415|0 6|Albumin
P10542249A0415|55 92|liver-enriched transcription factors such
P10542249A0415|95 121|CAAT enhancer-binding protein
P10542249A0415|123 133|C/EBP)alpha
P10542249A0415|123 127|C/EBP
P10542249A0415|129 133|alpha
P10542249A0415|137 145|C/EBPbeta
P10542260A0832|17 35|proteolytic activity
P10542260A0832|42 46|FVIIa
P10542260A0832|50 52|FXa
P10542260A0832|65 91|protease-activated receptors
P10542269A0000|0 18|Amyloid beta-protein
P10542269A0000|20 24|Abeta
P10542269A0000|31 45|main constituent
P10542269A0000|48 61|amyloid fibrils
P10542269A0000|69 81|senile plaques
P10542269A0000|85 99|cerebral vessels
P10542269A0000|102 110|Alzheimer
P10542269A0000|121 122|AD
P10542269A0000|138 148|proteolysis
P10542269A0000|156 183|beta-amyloid precursor protein
P10542269A0000|185 187|APP
P10542274A1376|14 23|activation
P10542274A1376|26 39|protein kinase A
P10542274A1376|41 43|PKA
P10542274A1376|45 53|signaling
P10542274A1376|81 107|caveolin-1 protein expression
P10542274A1376|81 97|caveolin-1 protein
P10542274A1376|111 126|promoter activity
P10542277A0000|3 15|importin alpha
P10542277A0000|17 31|beta heterodimer
P10542277A0000|40 52|nuclear import
P10542277A0000|55 62|proteins
P10542277A0000|73 107|classical nuclear localization signals
P10542281A0382|12 16|G1-G2
P10542281A0382|28 37|hyaluronan
P10542281A0382|41 51|link protein
P10542281A0382|69 92|immunoglobulin-fold motif
P10542281A0382|96 124|proteoglycan tandem repeat loops
P10542281A0382|130 137|G1 domain
P10542281A2021|3 9|results
P10542281A2021|48 61|keratan sulfate
P10542281A2021|64 74|native G1-G2
P10542281A2021|101 110|atrolysin C
P10542281A2021|123 127|sites
P10543270A1054|7 24|i.v. steroid therapy
P10543270A1054|27 31|NOexh
P10543270A1054|41 48|elevated
P10543270A1054|78 80|ppb
P10543270A1054|82 82|p
P10543270A1054|95 103|discharge
P10543270A1054|115 117|ppb
P10543270A1054|119 119|p
P10543727A0282|17 21|sites
P10543727A0282|25 51|several transcription factors
P10543727A0282|68 96|well-characterized binding site
P10543727A0282|100 132|rel/NF-kappaB transcription factors
P10543727A0282|100 102|rel
P10543727A0282|148 152|H2TF1
P10543727A0282|155 168|kappaB1 element
P10543727A0282|176 191|second kappaB site
P10543727A0282|182 191|kappaB site
P10543727A0282|196 209|kappaB2 element
P10543727A0282|219 225|located
P10543727A0282|237 244|adjacent
P10543727A0282|252 263|H2TF1 element
P10543727A0282|286 293|p65/relA
P10543727A0282|286 288|p65
P10543727A0282|290 293|relA
P10543727A0282|299 312|human HLA system
P10543727A0282|324 327|AP-1
P10543727A0282|329 350|ATF recognition sequence
P10543727A0282|362 368|EnA-TRE
P10543728A0358|3 16|tumorigenic E1A
P10543728A0358|14 16|E1A
P10543728A0358|18 29|cHa-ras cells
P10543728A0358|18 24|cHa-ras
P10543728A0358|55 86|constitutive DNA binding activities
P10543728A0358|89 92|AP-1
P10543728A0358|106 124|nontransformed cells
P10543728A0358|131 138|E1A cells
P10543728A0358|131 133|E1A
P10543730A0000|3 31|yeast C-type cyclin Ume3p/Srb11p
P10543730A0000|20 24|Ume3p
P10543730A0000|26 31|Srb11p
P10543730A0000|38 59|cyclin-dependent kinase
P10543730A0000|61 63|Cdk
P10543730A0000|65 69|Ume5p
P10543730A0000|87 100|full repression
P10543730A0000|103 107|genes
P10543730A0000|121 134|stress response
P10543730A0000|137 143|meiosis
P10543949A0686|16 17|S1
P10543949A0686|19 33|specificity site
P10543949A0686|50 66|hydrophobic cavity
P10544037A0617|0 3|FZD4
P10544037A0617|6 15|homologous
P10544037A0617|18 21|FZD9
P10544037A0617|25 29|FZD10
P10544037A0617|34 57|overall amino acid identity
P10544037A0617|70 73|FZD4
P10544037A0617|76 79|FZD9
P10544037A0617|85 85|%
P10544037A0617|87 90|FZD4
P10544037A0617|93 97|FZD10
P10544037A0617|103 103|%
P10544037A0617|105 108|FZD9
P10544037A0617|111 115|FZD10
P10544037A0617|121 121|%
P10544088A0308|3 38|NF-kappaB responsive reporter construct
P10544088A0308|41 45|PRDII
P10544088A0308|51 53|CAT
P10544088A0308|71 83|transcription
P10544088A0308|97 105|NF-kappaB
P10544088A0308|117 119|Tat
P10544089A1208|3 16|RNA transcripts
P10544089A1208|41 50|I(2) sgRNAs
P10544089A1208|45 50|sgRNAs
P10544089A1208|53 57|TMV U1
P10544089A1208|61 65|crTMV
P10544089A1208|81 96|hairpin structure
P10544089A1208|98 98|H
P10544089A1208|111 118|upstream
P10544089A1208|121 124|IRES
P10544089A1208|126 127|MP
P10544089A1208|139 140|MP
P10544089A1208|148 162|CR)-MP-CP-3'UTR
P10544089A1208|148 149|CR
P10544089A1208|152 158|MP-CP-3
P10544089A1208|160 162|UTR
P10544089A1208|170 171|MP
P10544089A1208|177 178|U1
P10544089A1208|181 187|MP-CP-3
P10544089A1208|189 191|UTR
P10544089A1208|214 219|MP gene
P10544113A0293|0 25|EIAV LTR sequence variability
P10544113A0293|0 6|EIAV LTR
P10544113A0293|45 56|small portion
P10544113A0293|62 69|enhancer
P10544113A0293|79 87|U3 segment
P10544113A0293|93 95|LTR
P10545192T0000|0 38|Phosphatidylinositol 3-kinase requirement
P10545192T0000|0 27|Phosphatidylinositol 3-kinase
P10545192T0000|41 50|activation
P10545192T0000|56 64|ras/C-raf
P10545192T0000|56 58|ras
P10545192T0000|60 66|C-raf-1
P10545192T0000|68 74|MEK/ERK
P10545192T0000|68 70|MEK
P10545192T0000|72 74|ERK
P10545192T0000|78 80|p70
P10545192T0000|82 84|s6k
P10545192T0000|86 101|signaling cascade
P10545192T0000|107 140|insulinomimetic agent vanadyl sulfate
P10545248A0567|13 20|enhancer
P10545248A0567|55 66|binding sites
P10545248A0567|73 96|homeodomain protein Tinman
P10545248A0567|73 90|homeodomain protein
P10545248A0567|91 96|Tinman
P10545248A0567|98 100|Tin
P10545248A0567|124 130|cardiac
P10545248A0567|132 138|somatic
P10545248A0567|143 164|visceral muscle lineages
P10545281A0836|25 35|immunogenic
P10545281A0836|39 62|purification tag sequences
P10545281A0836|70 91|C-terminal coding region
P10545281A0836|114 124|bop gene mRNA
P10545281A0836|128 146|protein accumulation
P10548434A1549|15 29|striking ability
P10548434A1549|32 53|polyoma middle T antigens
P10548434A1549|63 97|retinoic acid-induced differentiation
P10548434A1549|114 116|ERK
P10548434A1549|124 130|JNK/SPK
P10548434A1549|124 126|JNK
P10548434A1549|128 130|SPK
P10548434A1549|133 144|p38 signaling
P10548434A1549|133 135|p38
P10548622A0906|15 31|paracervical block
P10548622A0906|36 45|lignocaine
P10548622A0906|60 70|conjunction
P10548622A0906|75 96|i.v. sedation/analgesia
P10548622A0906|103 115|egg collection
P10548622A0906|135 151|transvaginal route
P10548622A0906|157 174|ultrasound guidance
P10548622A0906|176 180|TUGOR
P10548722A0099|3 6|loci
P10548722A0099|12 30|similar organization
P10548722A0099|41 44|H1.8
P10548722A0099|59 71|TcP2beta genes
P10548722A0099|82 87|tandem
P10548722A0099|103 125|short repetitive sequence
P10548722A0099|132 135|SIRE
P10548722A0099|154 170|repetitive element
P10548722A0099|202 210|first gene
P10548722A0099|216 221|tandem
P10548722A0099|225 234|downstream
P10549354A1782|13 39|APC wild-type colon carcinomas
P10549354A1782|43 51|melanomas
P10549354A1782|64 87|constitutive nuclear Tcf-4
P10549354A1782|89 109|beta-catenin complexes
P10549354A1782|121 137|dominant mutations
P10549354A1782|143 151|N terminus
P10549354A1782|154 165|beta-catenin
P10549354A1782|178 188|insensitive
P10549354A1782|191 204|downregulation
P10549354A1782|207 209|APC
P10549354A1782|211 218|GSK3 beta
P10549354A1782|223 236|Axin/Conductin
P10549354A1782|223 226|Axin
P10549354A1782|228 236|Conductin
P10549354A2371|0 16|Similar mechanisms
P10549354A2371|26 37|deregulation
P10549354A2371|40 60|Tcf target gene activity
P10549354A2371|40 52|Tcf target gene
P10549354A2371|84 91|melanoma
P10549354A2371|95 104|other forms
P10549912A0136|32 72|previous inferior acute myocardial infarction
P10549912A0136|85 110|right ventricular infarction
P10549912A0136|115 155|significant anterior lead ST segment elevation
P10549912A0136|157 161|V1-V4
P10549912A0136|183 211|large right ventricular branches
P10549912A0136|219 237|coronary angioplasty
P10549912A0136|243 261|right coronary artery
P10550139A0191|0 7|PATIENTS
P10550139A0191|11 17|METHODS
P10550139A0191|36 55|radical prostatectomy
P10550139A0191|57 75|bone marrow aspirates
P10550139A0191|84 88|sides
P10550139A0191|94 103|iliac crest
P10550139A0191|120 127|patients
P10550571A0000|0 6|PURPOSE
P10550571A0000|8 49|Previous WR-2721 human pharmacokinetic studies
P10550571A0000|63 74|plasma levels
P10550571A0000|77 84|patients
P10550571A0000|94 116|platinum-based compounds
P10550571A0000|136 142|effects
P10550571A0000|145 151|WR-2721
P10550571A0000|154 169|endogenous thiols
P10550574A1038|12 35|nonhematologic toxicities
P10550574A1038|37 44|diarrhea
P10550574A1038|58 89|elevated serum alkaline phosphatase
P10550574A1038|119 119|%
P10550574A1038|122 127|cycles
P10550574A1038|136 144|tolerable
P10550574A1038|148 157|reversible
P10551788A0229|0 5|LHbeta
P10551788A0229|19 43|pituitary gonadotrope cells
P10551788A0229|47 52|CGbeta
P10551788A0229|66 90|placental trophoblast cells
P10551796T0000|0 9|Regulation
P10551796T0000|12 29|HIV-1 transcription
P10551796T0000|12 16|HIV-1
P10551816A0162|0 10|Human LTBP-1
P10551816A0162|27 40|different forms
P10551848A0000|4 15|earlier study
P10551848A0000|17 22|Kimura
P10551848A0000|24 25|Y.
P10551848A0000|27 38|Kurzydlowski
P10551848A0000|40 41|K.
P10551848A0000|43 46|Tada
P10551848A0000|48 49|M.
P10551848A0000|54 62|MacLennan
P10551848A0000|64 65|D.
P10551867A0350|16 32|amino acid residues
P10551867A0350|43 60|9-kilobase pair mRNA
P10551867A0350|62 82|several splice variants
P10551867A0350|109 124|rat cDNA libraries
P10551879T0000|0 38|Cyclic AMP-dependent protein kinase binding
P10551879T0000|0 31|Cyclic AMP-dependent protein kinase
P10551879T0000|41 65|A-kinase anchoring proteins
P10551879T0000|68 78|living cells
P10551879T0000|81 115|fluorescence resonance energy transfer
P10551879T0000|118 154|green fluorescent protein fusion proteins
P10552357A1936|0 10|CONCLUSIONS
P10552357A1936|27 37|superiority
P10552357A1936|40 75|octafluoropropane-filled microspheres
P10552357A1936|78 99|air-filled microspheres
P10552357A1936|103 117|LV opacification
P10552357A1936|122 129|efficacy
P10552357A1936|132 135|OCTA
P10552357A1936|148 157|unaffected
P10552357A1936|160 177|impaired LV function
P10552357A1936|187 197|susceptible
P10552357A1936|203 209|effects
P10552357A1936|212 227|poor echogenicity
P10552357A1936|232 234|AIR
P10553551A0000|0 17|Factor XI deficiency
P10553551A0000|0 7|Factor XI
P10553551A0000|21 50|rare hereditary bleeding disorder
P10553551A0000|63 78|intrinsic pathway
P10553959A0812|3 16|Ishasha samples
P10553959A0812|44 56|trophic levels
P10554946A0082|3 22|more traditional SERMS
P10554946A0082|24 40|clomiphene citrate
P10554946A0082|44 52|tamoxifen
P10554946A0082|77 91|such modern drugs
P10554946A0082|94 103|raloxifene
P10554946A0082|107 114|faslodex
P10554946A0082|137 143|actions
P10554946A0082|153 158|uterus
P10554946A0082|167 172|lipids
P10555079A0254|0 1|Ti
P10555079A0254|12 33|feather-like morphology
P10555285A1065|28 44|duplication events
P10555285A1065|65 92|primate FUT3-FUT5-FUT6 cluster
P10555285A1065|72 75|FUT3
P10555285A1065|77 80|FUT5
P10555285A1065|82 85|FUT6
P10555285A1065|118 165|long-interspersed-nuclear-element-based mechanism
P10555285A1065|168 174|unequal
P10555285A1065|205 217|globin cluster
P10555964A0778|0 1|S.
P10555964A0778|3 5|Kim
P10555964A0778|7 8|S.
P10556028A0292|3 11|cop region
P10556028A0292|32 53|plasmid incompatibility
P10556028A0292|55 57|inc
P10556028A0292|72 89|stem-loop structure
P10556028A0292|94 105|repA promoter
P10556028A0292|107 110|Prep
P10556028A0292|123 146|distinct RepA binding sites
P10556028A0292|131 146|RepA binding sites
P10556028A0292|148 151|BD-1
P10556028A0292|155 158|BD-2
P10556029A0852|0 11|WA constructs
P10556029A0852|30 48|positive topoisomers
P10556029A0852|53 71|cyclization kinetics
P10556029A0852|81 99|slow interconversion
P10556029A0852|102 111|precursors
P10556029A0852|120 130|topoisomers
P10556033A0000|3 18|RFX protein family
P10556033A0000|27 33|members
P10556033A0000|38 42|yeast
P10556033A0000|45 50|humans
P10556033A0000|67 90|various biological systems
P10556033A0000|101 117|DNA-binding domain
P10556033A0000|131 146|C-terminal region
P10556044A0913|0 6|Binding
P10556044A0913|9 19|sulphatides
P10556044A0913|26 51|alpha-dystroglycan receptor
P10556044A0913|59 66|stronger
P10556044A0913|88 96|LG modules
P10556046A0328|20 31|antagonistic
P10556046A0328|33 70|BMP/ALK2/Smad-mediated signaling pathway
P10556046A0328|33 35|BMP
P10556046A0328|37 40|ALK2
P10556046A0328|42 45|Smad
P10556046A0328|84 92|right side
P10556046A0328|98 110|Xenopus embryo
P10556063A0092|5 11|kinases
P10556063A0092|21 39|new subfamily related
P10556063A0092|45 56|Trk subfamily
P10556089A0901|19 23|etr-1
P10556089A0901|38 54|muscle development
P10556089A0901|57 65|C. elegans
P10556089A0901|90 119|post-transcriptional processing
P10556089A0901|126 140|muscle component
P10556089A0901|160 179|possible conservation
P10556089A0901|182 193|gene function
P10556089A0901|198 208|human CUG-bp
P10556145A1034|0 9|Gentamicin
P10556145A1034|17 19|DPI
P10556145A1034|23 25|SVN
P10556145A1034|51 66|sputum Psa density
P10556145A1034|68 68|p
P10556263A1035|0 10|CONCLUSIONS
P10556263A1035|15 26|largest value
P10556263A1035|32 41|joint space
P10556263A1035|65 86|rheumatoid AC joint space
P10556595A0391|25 38|mutant recN gene
P10556595A0391|48 48|G
P10556595A0391|50 50|C
P10556595A0391|53 53|T
P10556595A0391|56 67|transversion
P10556751A0758|24 49|potential transmission rates
P10556751A0758|52 54|HGV
P10556751A0758|67 87|effective immunization
P10556751A0758|89 91|HGV
P10556751A0758|111 137|potential occupational hazard
P10556751A0758|151 161|dental staff
P10557008T0000|0 8|Detection
P10557008T0000|11 19|poisoning
P10557008T0000|22 27|Impila
P10557072A0127|34 43|human cDNAs
P10557072A0127|52 68|UNC-51-like kinase
P10557072A0127|70 73|ULK1
P10557072A0418|0 3|ULKs
P10557072A0418|7 12|UNC-51
P10557072A0418|19 40|typical domain structure
P10557072A0418|45 70|amino-terminal kinase domain
P10557072A0418|73 97|central proline/serine rich
P10557072A0418|99 100|PS
P10557072A0418|113 128|carboxy-terminal
P10557072A0418|130 130|C
P10557072A1218|5 11|results
P10557072A1218|23 26|ULK2
P10557072A1218|50 80|uncharacterized signaling pathway
P10557072A1218|83 96|mammalian cells
P10557308A0000|0 16|Connector enhancer
P10557308A0000|19 21|KSR
P10557308A0000|23 25|CNK
P10557308A0000|30 47|multidomain protein
P10557308A0000|59 70|RAS signaling
P10557308A0000|59 61|RAS
P10559207A0207|2 17|simpler organisms
P10559207A0207|22 35|ATP sulfurylase
P10559207A0207|39 56|APS kinase reactions
P10559207A0207|39 47|APS kinase
P10559207A0207|71 85|separate enzymes
P10559207A0207|105 109|genes
P10559207A0207|126 131|fusion
P10559207A0207|134 146|separate genes
P10559207A0207|185 202|bifunctional enzyme
P10559303A0000|0 43|Epstein-Barr virus (EBV) latent membrane protein 1
P10559303A0000|0 16|Epstein-Barr virus
P10559303A0000|18 20|EBV
P10559303A0000|22 42|latent membrane protein
P10559303A0000|45 48|LMP1
P10559303A0000|64 89|EBV-mediated transformation
P10559303A0000|92 110|primary B lymphocytes
P10559320A0080|3 20|amino-terminal half
P10559320A0080|23 24|1a
P10559320A0080|28 41|distant homolog
P10559320A0080|44 77|alphavirus nonstructural protein nsP1
P10559320A0080|110 118|viral RNAs
P10559324A0716|10 22|recombinant Ad
P10559324A0716|33 43|Ad5 E4orf6/7
P10559324A0716|51 59|apoptosis
P10559324A0716|62 69|rat cells
P10559324A0716|88 112|wild-type p53-expressing Ad
P10559324A0716|88 99|wild-type p53
P10559364A0846|2 5|HCMV
P10559364A0846|7 11|Towne
P10559364A0846|14 28|infected HF cells
P10559364A0846|37 37|h
P10559364A0846|39 41|IE2
P10559364A0846|70 100|viral DNA replication compartments
P10559364A0846|114 141|polymerase processivity factor
P10559364A0846|143 146|UL44
P10559364A0846|152 183|single-stranded DNA binding protein
P10559364A0846|185 187|SSB
P10559364A0846|189 192|UL57
P10559364A0846|198 222|UL112-113 accessory protein
P10559364A0846|244 260|bromodeoxyuridine
P10559364A0846|262 265|BrdU
P10560014A0000|0 10|Macroscopic
P10560014A0000|23 42|heart vascularization
P10560014A0000|63 79|angioarchitecture
P10560014A0000|121 136|normal myocardium
P10560997A1072|0 9|CONCLUSION
P10560997A1072|11 11|S
P10560997A1072|23 37|urinary LH levels
P10560997A1072|42 56|excellent method
P10560997A1072|71 79|ovulation
P10561095A2141|8 18|reoperation
P10561095A2141|22 41|bulky cervical disease
P10561095A2141|65 86|normal calcitonin levels
P10561095A2141|71 80|calcitonin
P10561095A2141|107 119|high incidence
P10561095A2141|122 148|permanent hypoparathyroidism
P10561153A0225|16 24|carcinoma
P10561153A0225|62 64|SSc
P10561153A0225|93 122|dialysis-dependent renal failure
P10561251A0000|0 6|PURPOSE
P10561251A0000|21 40|disease-free survival
P10561251A0000|42 44|DFS
P10561251A0000|49 63|overall survival
P10561251A0000|65 66|OS
P10561251A0000|69 85|prognostic factors
P10561251A0000|90 115|treatment-related mortality
P10561251A0000|118 122|women
P10561251A0000|127 159|stage IIIB inflammatory breast cancer
P10561251A0000|161 163|IBC
P10561251A0000|176 198|combined modality therapy
P10561251A0000|200 202|CMT
P10561251A0000|207 227|high-dose chemotherapy
P10561251A0000|229 232|HDCT
P10561251A0000|238 271|autologous stem-cell transplantation
P10561460A0615|3 17|GPI anchor moiety
P10561460A0615|26 31|absent
P10561460A0615|48 55|low level
P10561460A0615|61 71|polypeptide
P10561460A0615|88 91|cDNA
P10561460A0615|112 124|signal peptide
P10561460A0615|128 145|GPI signal sequences
P10561546A0000|13 40|novel 100-kDa mammalian protein
P10561546A0000|64 83|anti-peptide antibody
P10561546A0000|64 75|anti-peptide
P10561546A0000|93 135|epitope-containing nuclear localization signal
P10561546A0000|138 156|NF-kappaB p65 subunit
P10562418A0238|0 22|Insulin-regulated events
P10562418A0238|42 46|cells
P10562456T0000|0 16|Regulatory regions
P10562456T0000|22 29|promoter
P10562456T0000|33 43|third intron
P10562456T0000|49 65|growth hormone gene
P10562456T0000|68 79|rainbow trout
P10562456T0000|81 105|Oncorhynchus mykiss walbaum
P10562495A0188|8 19|most SFV genes
P10562495A0188|24 31|homologs
P10562495A0188|41 61|other Chordopoxvirinae
P10562495A0188|66 74|SFV genome
P10562495A0188|81 87|key gene
P10562495A0188|114 140|extracellular enveloped virus
P10563212A0514|21 38|SF-36 questionnaire
P10563212A0514|47 49|QoL
P10563212A0514|96 113|historical controls
P10563605A0773|40 43|IENF
P10563605A0773|47 82|sural nerve unmyelinated fiber densities
P10563605A0773|84 85|r =
P10563605A0773|91 92|p =
P10563789A1951|26 42|F beta alpha/CG beta
P10563789A1951|52 64|high-affinity
P10563789A1951|78 79|CG
P10563789A1951|83 94|FSH receptors
P10563836A1234|11 29|AP-2 binding activity
P10563836A1234|11 14|AP-2
P10563836A1234|46 52|greater
P10563836A1234|55 63|T47D cells
P10563836A1234|68 79|Western blots
P10563836A1234|98 114|AP-2 protein levels
P10563836A1234|98 108|AP-2 protein
P10563836A1234|122 126|cells
P10564231A0315|0 8|N. van Hoek
P10564231A0315|13 14|M.
P10564280A0140|16 52|tyrosine-phosphorylated nuclear protein
P10564280A0140|54 60|YT521-B
P10564280A0140|91 147|nuclear transcriptosomal component scaffold attachment factor B
P10564280A0140|155 172|68-kDa Src substrate
P10564280A0140|155 163|68-kDa Src
P10564280A0140|189 195|mitosis
P10564280A0140|197 201|Sam68
P10564472A0853|5 11|mutants
P10564472A0853|38 47|TraR fusion
P10564472A0853|38 41|TraR
P10564472A0853|53 68|two-hybrid system
P10564474T0000|0 18|PhoP-PhoQ homologues
P10564474T0000|0 3|PhoP
P10564474T0000|5 8|PhoQ
P10564474T0000|65 89|outer-membrane protein OprH
P10564474T0000|93 112|polymyxin B resistance
P10564479A0384|0 7|Deletion
P10564479A0384|10 13|fdsR
P10564479A0384|23 42|dual regulatory effect
P10564479A0384|45 48|FdsR
P10564479A0384|54 62|fds operon
P10564479A0384|73 96|transcriptional activator
P10564479A0384|112 118|formate
P10564479A0384|123 131|repressor
P10564479A0384|146 152|formate
P10564484A0859|4 13|constructs
P10564484A0859|27 37|binding site
P10564484A0859|57 64|promoter
P10564484A0859|97 118|positional requirements
P10564484A0859|162 169|promoter
P10564495A0444|19 29|Opa proteins
P10564495A0444|32 35|C751
P10564495A0444|53 61|HeLa cells
P10564495A0444|77 80|cDNA
P10564495A0444|92 114|carcinoembryonic antigen
P10564495A0444|116 118|CEA
P10564495A0444|120 124|CD66e
P10564495A0444|127 134|subgroup
P10564495A0444|140 149|CD66 family
P10564495A0444|158 172|distinct tropism
P10564495A0444|176 179|CGM1
P10564495A0444|182 186|CD66d
P10564495A0444|191 193|NCA
P10564495A0444|195 199|CD66c
P10564495A0444|212 216|cells
P10564593A0428|0 3|FISH
P10564593A0428|10 24|whole chromosome
P10564593A0428|43 64|multiple rearrangements
P10564593A0428|74 83|chromosome
P10564593A0428|87 99|MCF-7 AdVp3000
P10564593A0428|103 109|MCF-7 MX
P10564593A0428|116 123|S1-M1-80
P10564593A0428|138 166|simple reciprocal translocation
P10564593A1618|3 9|MXR gene
P10564593A1618|18 33|half-transporter
P10564593A1618|49 67|cytogenetic evidence
P10564593A1618|70 84|coamplification
P10564593A1618|87 98|other regions
P10564593A1618|154 172|MXR half-transporter
P10564593A1618|195 207|drug transport
P10564939A0981|11 17|smoking
P10564939A0981|46 53|such data
P10566630A0371|0 29|Serum insulin-like growth factor I
P10566630A0371|31 35|IGF-I
P10566630A0371|37 43|SD score
P10566630A0371|70 72|men
P10566630A0371|76 80|women
P10566630A0371|110 115|months
P10566630A0371|133 138|months
P10566862A0000|0 9|BACKGROUND
P10566862A0000|11 21|Measurement
P10566862A0000|24 35|stereoacuity
P10566862A0000|45 53|distances
P10566862A0000|63 93|simulated depth stereoacuity tests
P10566862A0000|121 128|patients
P10566862A0000|133 150|binocular imbalance
P10566862A0000|153 162|strabismus
P10567430A0785|0 16|Additional studies
P10567430A0785|29 45|bovine brain Galpha
P10567430A0785|47 50|q/11
P10567430A0785|69 87|N-terminal construct
P10567430A0785|90 93|GRK2
P10567430A0785|102 108|binding
P10567430A0785|111 116|Galpha
P10567430A0785|118 121|q/11
P10567430A0785|124 129|Galpha
P10567430A0785|131 131|s
P10567430A0785|134 139|Galpha
P10567430A0785|146 151|Galpha
P10567430A0785|161 180|comparable constructs
P10567430A0785|183 186|GRK5
P10567430A0785|189 192|GRK6
P10567524T0000|3 21|elm1 kinase functions
P10567524T0000|3 12|elm1 kinase
P10567524T0000|25 47|mitotic signaling network
P10567524T0000|57 61|yeast
P10567533A0818|0 19|Reverse transcription
P10567533A0818|21 22|RT
P10567533A0818|25 35|PCR products
P10567533A0818|58 74|degenerate primers
P10567533A0818|98 103|motifs
P10567533A0818|106 127|various tyrosine kinases
P10567533A0818|113 127|tyrosine kinases
P10567538A1028|11 30|the acetyltransferase
P10567538A1028|14 38|acetyltransferase activity
P10567538A1028|41 44|p300
P10567538A1028|82 108|essential activation function
P10567538A1028|114 140|CH3 domain/E1A-binding region
P10567538A1028|114 122|CH3 domain
P10567581A0119|3 29|proliferation-specific HNF-3
P10567581A0119|25 29|HNF-3
P10567581A0119|31 56|fork head homolog-11B protein
P10567581A0119|58 64|HFH-11B
P10567581A0119|77 83|Trident
P10567581A0119|87 89|Win
P10567581A0119|94 105|family member
P10567581A0119|111 150|winged helix/fork head transcription factors
P10567581A0119|206 220|hepatocyte entry
P10567581A0119|225 238|DNA replication
P10567581A0119|240 245|S phase
P10567582A1334|11 15|CtBP1
P10567582A1334|31 36|embryo
P10567582A1334|48 52|CtBP2
P10567582A1334|76 88|embryogenesis
P10567589A1268|3 19|multiple functions
P10567589A1268|22 26|Pmt3p
P10567589A1268|51 72|several nuclear proteins
P10567589A1268|87 102|Pmt3p conjugation
P10567589A1268|87 91|Pmt3p
P10568275A0679|20 25|sea ice
P10568275A0679|33 39|Kara Sea
P10568275A0679|47 57|Arctic Ocean
P10568275A0679|72 84|small subgroup
P10568275A0679|87 92|GEOMAR
P10568455A0000|20 34|single injection
P10568455A0000|37 64|slow-release estradiol-17beta
P10568455A0000|66 69|SRE2
P10568455A0000|82 96|pseudopregnancy
P10568455A0000|99 103|gilts
P10568455A0000|114 122|PGF2alpha
P10568455A0000|138 149|corpora lutea
P10568455A0000|151 152|CL
P10568455A0000|156 170|pseudopregnancy
P10568728A1445|10 28|serum creatine kinase
P10568728A1445|50 53|days
P10568728A1445|59 63|ESWIB
P10568744A0728|19 23|sites
P10568744A0728|36 44|promoters
P10568744A0728|47 70|known alpha-specific genes
P10568744A0728|52 70|alpha-specific genes
P10568744A0728|77 86|other sites
P10568744A0728|93 117|alpha2-Mcm1-dependent role
P10568744A0728|93 98|alpha2
P10568744A0728|100 103|Mcm1
P10568744A0728|145 163|mating type switching
P10570262A0000|0 9|Activation
P10570262A0000|12 17|T cells
P10570262A0000|24 26|TCR
P10570262A0000|30 56|other costimulatory receptors
P10570262A0000|74 90|signaling cascades
P10570996A1213|1 20|phylogenetic analysis
P10570996A1213|28 36|TK domains
P10570996A1213|46 54|sequences
P10570996A1213|71 87|novel scavenger RTK
P10570996A1213|76 87|scavenger RTK
P10570996A1213|92 98|domains
P10570996A1213|125 142|TK class II receptors
P10570996A1213|125 131|TK class
P10570996A1213|134 142|receptors
P10570996A1213|183 189|insulin
P10570996A1213|193 213|insulin-like receptors
P10571047A1009|0 30|Several 7SL RNA-encoding sequences
P10571047A1009|7 30|7SL RNA-encoding sequences
P10571047A1009|34 57|various intergenic spacers
P10571047A1009|78 103|individual HindIII fragments
P10571047A1009|88 103|HindIII fragments
P10571047A1009|120 121|kb
P10571474A0571|0 6|Results
P10571474A0571|34 52|CA3 dendritic atrophy
P10571474A0571|56 65|tianeptine
P10572087A0326|15 28|binding partner
P10572087A0326|35 60|Fanconi anemia group C protein
P10572087A0326|62 66|FANCC
P10572087A0326|70 93|yeast two-hybrid screening
P10572130A1623|5 11|results
P10572130A1623|27 49|transcription activators
P10572130A1623|72 88|different subunits
P10572130A1623|91 103|RNA polymerase
P10572130A1623|135 151|proper DNA geometry
P10572131A0000|0 16|Klebsiella oxytoca
P10572131A0000|30 36|nitrate
P10572131A0000|40 46|nitrite
P10572131A0000|54 60|enzymes
P10572131A0000|73 87|nasFEDCBA operon
P10572866A0481|0 14|Marked hemolysis
P10572866A0481|37 48|plasma values
P10572866A0481|51 59|potassium
P10572866A0481|61 70|phosphorus
P10572866A0481|72 83|total protein
P10572866A0481|88 112|aspartate aminotransferase
P10573781A0631|0 6|Studies
P10573781A0631|40 51|numerous loci
P10573781A0631|54 71|certain chromosomes
P10573781A0631|75 80|excess
P10573781A0631|85 95|chromosomes
P10574913A1108|22 56|GRK-mediated receptor phosphorylation
P10574913A1108|22 41|GRK-mediated receptor
P10574913A1108|58 92|beta-arrestin-mediated processes such
P10574913A1108|58 70|beta-arrestin
P10574913A1108|95 108|Src recruitment
P10574913A1108|95 97|Src
P10574913A1108|112 143|clathrin-mediated internalization
P10574913A1108|112 119|clathrin
P10574913A1108|164 189|GPCR-mediated ERK activation
P10574913A1108|164 167|GPCR
P10574913A1108|177 179|ERK
P10574913A1108|217 236|further ERK activation
P10574913A1108|224 226|ERK
P10574929A0583|7 30|subcellular fractionation
P10574929A0583|35 53|47-kDa P-CIP2 protein
P10574929A0583|62 70|cytosolic
P10574982A1075|0 14|Supershift EMSAs
P10574982A1075|29 60|upstream stimulatory factor-1 and -2
P10574982A1075|29 55|upstream stimulatory factor-1
P10574982A1075|62 66|USF-1
P10574982A1075|88 96|complexes
P10574992A0901|11 20|E1A binding
P10574992A0901|11 13|E1A
P10574992A0901|27 34|p300/CBP
P10574992A0901|27 30|p300
P10574992A0901|32 34|CBP
P10574992A0901|56 73|PARP enzyme activity
P10574992A0901|56 65|PARP enzyme
P10574992A0901|91 113|cell death susceptibility
P10574992A0901|116 126|irradiation
P10574992A0901|163 199|PARP chemical inhibitor 3-aminobenzamide
P10575231A0355|0 7|Analysis
P10575231A0355|13 25|genomic region
P10575231A0355|41 53|13-kb Cdc6 gene
P10575231A0355|46 53|Cdc6 gene
P10575231A0355|69 73|exons
P10575231A0355|78 84|introns
P10575545A0147|15 19|CACCC
P10575545A0147|23 32|CAAT motifs
P10575642T0000|0 12|Skin pH changes
P10575642T0000|27 39|iontophoresis
P10576177A0308|55 74|straightforward range
P10576177A0308|77 85|prognoses
P10576177A0308|90 117|ambiguous clinical implication
P10576545A0926|17 44|potent regulatory DNA cassettes
P10576545A0926|57 77|murine D1A gene promoter
P10576545A0926|96 122|neuronal-specific expression
P10576545A0926|125 134|transgenes
P10578528A0730|46 48|EEG
P10578528A0730|75 87|manifestation
P10578528A0730|105 134|neuropsychologic symptomatology
P10579331A1225|3 9|results
P10579331A1225|17 23|studies
P10579331A1225|42 68|rat HDL receptor SR-BI promoter
P10579331A1225|80 101|sterol response elements
P10579331A1225|103 106|pSRE
P10579331A1225|110 113|dSRE
P10579331A1225|127 134|SREBP-1a
P10579331A1225|153 165|transcription
P10579722T0000|0 14|Phosphorylation
P10579722T0000|17 37|myosin-binding subunit
P10579722T0000|39 41|MBS
P10579722T0000|45 61|myosin phosphatase
P10579722T0000|64 73|Rho-kinase
P10580071A0436|7 14|patients
P10580071A0436|49 63|transplantation
P10580071A0436|86 109|first cadaveric transplant
P10580438A0508|2 34|electrophoretic mobility shift assay
P10580438A0508|36 39|EMSA
P10580438A0508|46 66|GLUT4 repressor element
P10580438A0508|68 71|G4RE
P10580438A0508|82 94|specific bands
P10580438A0508|99 113|nuclear extracts
P10580438A0508|118 130|preadipocytes
P10580438A0508|142 151|adipocytes
P10582831T0000|0 8|Syndromes
P10582831T0000|11 35|abnormal fat redistribution
P10582831T0000|39 60|metabolic complications
P10582831T0000|63 82|HIV-infected patients
P10584138T0001|0 13|Cytoprotection
P10584138T0001|18 27|amifostine
P10584138T0001|30 41|radiotherapy
P10584138T0001|44 61|radio-chemotherapy
P10584138T0001|71 80|neck tumors
P10584704A0913|0 26|Immunohistochemical staining
P10584704A0913|41 45|S-100
P10584704A0913|52 56|cases
P10584704A0913|76 81|HMB-45
P10584704A0913|88 88|%
P10584704A0913|109 119|cytokeratin
P10584704A0913|126 130|cases
P10584704A0913|138 151|myxoid melanoma
P10584704A0913|175 190|previous sections
P10585311A0494|0 7|Patients
P10585311A0494|12 16|types
P10585311A0494|24 27|MPGN
P10585311A0494|47 59|apparent onset
P10585311A0494|90 102|apparent onset
P10585311A0494|105 112|symptoms
P10585311A0494|125 130|biopsy
P10585311A1542|0 27|Residual urinary abnormalities
P10585311A1542|59 66|patients
P10585311A1542|87 90|MPGN
P10585417A1412|14 24|differences
P10585417A1412|27 35|signaling
P10585417A1412|39 54|tissue expression
P10585417A1412|69 89|human intermediate PRLr
P10585417A1412|104 111|long PRLr
P10585417A1412|114 134|physiological function
P10585440A0204|15 48|Drosophila melanogaster FAK homologue
P10585440A0204|37 48|FAK homologue
P10585440A0204|50 55|DFak56
P10585440A0204|68 74|band 56D
P10585440A0204|80 87|right arm
P10585440A0204|93 108|second chromosome
P10585453A1029|10 19|Pit-1 sites
P10585453A1029|25 41|hGH-N gene promoter
P10585453A1029|45 56|insufficient
P10585453A1029|60 77|such gene activation
P10585453A1029|104 144|unique chromatin-mediated developmental role
P10585453A1029|148 152|Pit-1
P10585453A1029|158 163|hGH LCR
P10585463A0859|0 29|Recombinant prenylcysteine lyase
P10585463A0859|44 74|baculovirus-Sf9 expression system
P10585480A0157|17 30|third SH3 domain
P10585480A0157|22 30|SH3 domain
P10585480A0157|38 40|Sos
P10585480A0157|43 73|guanine nucleotide exchange factor
P10585480A0157|77 79|Ras
P10585480A0157|83 85|Rac
P10585480A0265|0 13|Point mutations
P10585480A0265|19 32|third SH3 domain
P10585480A0265|45 66|vinexin-Sos interaction
P10585480A0265|45 51|vinexin
P10585480A0265|53 55|Sos
P10585491A0945|2 23|gel mobility shift assays
P10585491A0945|25 42|low binding activity
P10585491A0945|45 47|CBF
P10585491A0945|53 81|wild-type AtpC promoter sequence
P10585491A0945|97 111|nuclear extracts
P10585491A0945|126 148|low AtpC expression levels
P10585491A0945|129 132|AtpC
P10585491A0945|154 161|extracts
P10585491A0945|191 199|seedlings
P10585491A0945|208 226|high binding activity
P10585491A0945|230 239|detectable
P10585491A0945|244 251|extracts
P10585491A0945|256 262|tissues
P10585491A0945|267 290|high AtpC expression levels
P10585491A0945|271 274|AtpC
P10585491A0945|296 303|extracts
P10585491A0945|308 327|light-grown seedlings
P10585491A0945|340 348|seedlings
P10585491A0945|360 368|cytokinin
P10585808A0000|0 26|Mycoplasma hominis infections
P10585808A0000|49 67|conventional methods
P10585808A0000|71 88|bacterial detection
P10586074A0129|30 46|plasmid constructs
P10586074A0129|55 68|different forms
P10586074A0129|74 94|envelope glycoprotein E
P10586074A0129|100 136|flavivirus tick-borne encephalitis virus
P10586107A0160|24 28|types
P10586107A0160|41 60|transduction pathways
P10586107A0160|64 92|different cell surface receptors
P10586115A0477|24 53|major pro-inflammatory cytokines
P10586115A0477|63 71|IL-1alpha
P10586115A0477|73 80|IL-1beta
P10586115A0477|82 90|TNF-alpha
P10586115A0477|94 97|IL-6
P10586115A0477|103 106|IL-6
P10586115A0477|132 137|PKCeta
P10586115A0477|149 153|cells
P10586115A0477|164 180|additional inducer
P10586115A0477|183 208|serum-supplemented cultures
P10586115A0477|212 215|% FCS
P10586626A0607|0 20|Demyelinating diseases
P10586626A0607|33 42|grey matter
P10586626A0607|86 115|symmetrical thalamic involvement
P10586626A0607|118 125|patients
P10586626A0607|130 133|ADEM
P10587460A0302|11 34|minimal VDRE binding domain
P10587460A0302|38 45|human VDR
P10587460A0302|43 45|VDR
P10587460A0302|47 50|hVDR
P10587460A0302|62 73|C-terminally
P10587460A0302|83 93|hVDR mutants
P10587460A0302|95 102|Delta134
P10587460A0302|104 111|Delta113
P10587460A0302|113 120|Delta102
P10587460A0302|122 128|Delta90
P10587460A0302|130 136|Delta84
P10587460A0302|138 144|Delta80
P10587460A0302|149 155|Delta60
P10587461A0341|4 23|induced-fit mechanism
P10587461A0341|25 32|contacts
P10587461A0341|40 48|anticodon
P10587461A0341|72 92|robust transition state
P10587576A0596|5 8|REPs
P10587576A0596|12 19|clusters
P10587576A0596|22 35|paralogous loci
P10587576A0596|46 47|kb
P10587576A0596|51 56|harbor
P10587576A0596|68 71|ESTs
P10587576A0596|86 100|SH3GL pseudogene
P10588946A0432|25 49|novel OSBP-related proteins
P10588946A0432|30 49|OSBP-related proteins
P10588946A0432|61 65|ORP-1
P10588946A0432|68 72|ORP-6
P10589562A1208|20 28|inability
P10589562A1208|38 46|radiative
P10589562A1208|56 66|BB resonator
P10589562A1208|79 100|low RF power requirements
P10589711A1228|11 24|narZ expression
P10589711A1228|11 14|narZ
P10589711A1228|48 54|20-fold
P10589711A1228|72 109|Madin-Darby canine kidney epithelial cells
P10589711A1228|122 145|intracellular salts medium
P10589711A1228|172 190|intracellular milieu
P10590092A0124|8 17|mechanisms
P10590092A0124|28 46|HIV-1 gene expression
P10590092A0124|28 36|HIV-1 gene
P10590092A0124|52 54|CNS
P10590368X0000|2 21|radical trachelectomy
P10590368X0000|23 37|safe alternative
P10590368X0000|40 58|radical hysterectomy
P10590368X0000|62 69|patients
P10590368X0000|74 91|stage IA-B carcinoma
P10590368X0000|97 102|cervix
P10590368X0000|104 113|BACKGROUND
P10590368X0000|118 126|prognosis
P10590368X0000|141 157|lymph node negative
P10590368X0000|159 177|early stage carcinoma
P10590368X0000|183 188|cervix
P10590368X0000|205 230|5-year survival rates greater
P10590368X0000|237 237|%
P10591633A0138|1 8|key event
P10591633A0138|27 46|selective recognition
P10591633A0138|52 65|target membrane
P10591633A0138|71 77|vesicle
P10591633A0138|84 94|current view
P10591633A0138|101 124|SNARE protein interactions
P10591633A0138|101 112|SNARE protein
P10591633A0138|136 146|central role
P10591633A0138|149 173|vesicle-target recognition
P10591633A0138|179 192|membrane fusion
P10591933A0798|13 16|Type
P10591933A0798|18 30|configuration
P10591933A0798|46 54|low values
P10591933A0798|61 79|coraco-glenoid angle
P10591933A0798|83 90|coracoid
P10591933A0798|131 157|short coraco-humeral distance
P10591976A0317|0 11|Measurements
P10591976A0317|17 23|LWS p.a.
P10591976A0317|25 30|LWS lat
P10591976A0317|37 40|Ward
P10591976A0317|43 50|triangle
P10591976A0317|72 79|patients
P10591990A0178|10 47|DSM-IV paranoid schizophrenic in-patients
P10591990A0178|65 69|times
P10591990A0178|78 81|SAPS
P10591990A0178|83 86|SANS
P10591990A0178|88 91|BPRS
P10591990A0178|95 97|PAS
P10592791A0370|16 23|TECRA kit
P10592791A0370|55 56|SE
P10592791A0370|66 72|strains
P10592791A0370|78 85|SET-RPLA
P10592791A0370|89 102|RIDASCREEN kits
P10592791A0370|117 144|epidemiological investigation
P10592791A0370|147 153|SE types
P10592791A0370|190 197|long time
P10592791A0370|220 230|SET-RPLA kit
P10592791A0370|234 247|high background
P10592791A0370|257 269|RIDASCREEN kit
P10592791A0370|305 329|complicated test procedures
P10592791A0370|368 379|practicality
P10592791A0370|382 391|SET-EIA kit
P10592791A0370|406 436|epidemiological research purposes
P10592791T0001|0 9|Comparison
P10592791T0001|12 26|immunoassay kits
P10592791T0001|30 38|detection
P10592791T0001|41 66|staphylococcal enterotoxins
P10592824A1157|10 22|high frequency
P10592824A1157|25 40|natural infection
P10592824A1157|45 61|seropositive rates
P10592824A1157|64 74|JEV antibody
P10592824A1157|130 130|%
P10592824A1157|145 145|%
P10592824A1157|156 156|%
P10592824A1157|168 168|%
P10592824A1157|179 186|children
P10592824A1157|212 221|JE vaccines
P10592824A1157|236 236|P
P10592824A1157|244 253|Chi-square
P10592824A1157|257 265|trend test
P10593939A0747|28 64|protein-protein interaction experiments
P10593939A0747|78 88|SR33 protein
P10593939A0747|115 125|SR45 protein
P10593939A0747|139 150|other members
P10593939A0747|152 156|SRZ21
P10593939A0747|160 164|SRZ22
P10593939A0747|171 178|SR family
P10593939A0747|208 234|Arabidopsis full-length U-70K
P10593950A1113|10 12|WT1
P10593950A1113|25 29|oligo
P10593950A1113|31 32|dT
P10593950A1113|34 47|chromatography
P10593950A1113|54 59|U2AF65
P10593950A1113|64 102|U5 small nuclear RNP-associated protein p116
P10593950A1113|64 98|U5 small nuclear RNP-associated protein
P10593950A1113|99 102|p116
P10593950A1113|106 112|hnRNP A1
P10594130A0652|11 16|hearts
P10594130A0652|21 45|macerated stillborn infants
P10594130A0652|59 65|degrees
P10594130A0652|68 83|positive staining
P10594239A0614|0 7|Tih1 maps
P10594239A0614|0 3|Tih1
P10594239A0614|10 23|distal mouse Chr
P10594239A0614|28 39|human Chr 1q31
P10594239A0614|41 58|chromosomal regions
P10594239A0614|112 114|Ipl
P10594239A0614|116 119|Tih1
P10594239A0614|146 160|parental alleles
P10594239T0000|1 41|novel pleckstrin homology-related gene family
P10594239T0000|51 59|Ipl/Tssc3
P10594239T0000|51 53|Ipl
P10594239T0000|55 59|Tssc3
P10594239T0000|61 66|TDAG51
P10594239T0000|71 74|Tih1
P10594239T0000|76 100|tissue-specific expression
P10594239T0000|102 120|chromosomal location
P10594903A0000|21 41|reactive nanoparticles
P10594903A0000|43 45|RNP
P10594903A0000|91 109|toxic substances such
P10594903A0000|115 129|warfare agents GA
P10594903A0000|131 132|GB
P10594903A0000|134 135|HD
P10594903A0000|139 140|VX
P10595315A0344|9 30|minimal negative effects
P10595315A0344|33 55|hematological parameters
P10595315A0344|57 71|acid-base status
P10595315A0344|76 85|blood gases
P10596955A1032|13 32|renal failure patients
P10596955A1032|36 44|troponin I
P10596955A1032|36 43|troponin
P10596955A1032|53 60|microg/l
P10596955A1032|66 76|Axsym method
P10596955A1032|84 89|levels
P10596955A1032|101 108|microg/l
P10596955A1032|114 119|Immuno
P10597222A1371|23 25|p27
P10597222A1371|37 51|crucial molecule
P10597222A1371|54 66|HMBA signaling
P10597222A1371|89 91|p21
P10597223A0339|0 8|Transient
P10597223A0339|10 33|high-level Ras-expression
P10597223A0339|20 22|Ras
P10597223A0339|41 65|transcriptional activation
P10597223A0339|68 70|p21
P10597223A0339|82 94|GC-rich region
P10597223A0339|97 107|p21 promoter
P10597223A0339|114 123|bp relative
P10597223A0339|129 155|transcription initiation site
P10597223A0339|166 177|binding sites
P10597223A0339|181 210|Sp1-family transcription factors
P10597232A0000|3 23|RET/PTC3 rearrangement
P10597232A0000|3 5|RET
P10597232A0000|7 10|PTC3
P10597232A0000|34 39|fusion
P10597232A0000|45 48|ELE1
P10597232A0000|52 59|RET genes
P10597232A0000|72 80|prevalent
P10597232A0000|83 139|radiation-induced post-Chernobyl papillary thyroid carcinomas
P10597317A1156|0 8|Apoptosis
P10597317A1156|11 20|small cells
P10597317A1156|41 55|co-transfection
P10597317A1156|58 60|JBD
P10597317A1156|64 67|LMP1
P10597317A1156|82 104|few apoptotic HD-MyZ cells
P10597317A1156|119 131|nuclear masses
P10597317A1156|159 176|specific inhibition
P10597317A1156|179 181|JNK
P10597317A1156|193 201|apoptosis
P10597317A1156|204 207|LMP1
P10597317A1156|215 221|RS cells
P10598101A0000|15 32|bZIP protein Opaque2
P10598101A0000|34 35|O2
P10598101A0000|46 79|other maize endosperm nuclear proteins
P10598101A0000|105 124|kDa zein gene promoters
P10598101A0754|3 16|mEmBP-1 protein
P10598101A0754|28 40|transcription
P10598101A0754|55 62|promoter
P10598101A0754|74 81|pentamer
P10598101A0754|95 104|yeast cells
P10598101A0754|125 146|regulated transcription
P10598101A0754|150 166|22 kDa zein promoter
P10598101A0754|152 166|kDa zein promoter
P10598101A0754|170 193|transient expression assay
P10598101A0754|207 225|maize endosperm cells
P10598316A1534|0 2|GHB
P10598316A1534|5 6|CB
P10598316A1534|8 10|HMB
P10598316A1534|26 41|recent substances
P10599013A0505|11 16|deaths
P10599013A0505|42 50|avoidable
P10599727A1567|8 9|GH
P10599727A1567|13 36|estrogen treatment regimen
P10599727A1567|38 46|most girls
P10599727A1567|51 52|TS
P10599727A1567|80 89|conformity
P10599727A1567|99 110|healthy peers
P10600171A1066|23 36|responsiveness
P10600171A1066|39 44|CYP3A2
P10600171A1066|58 76|preferential binding
P10600171A1066|79 85|COUP-TF
P10600171A1066|91 107|CYP3A2 DexRE-1 site
P10600171A1432|0 25|Higher CYP3A23 basal activity
P10600171A1432|6 12|CYP3A23
P10600171A1432|44 48|E-box
P10600171A1432|51 59|3A23SiteA
P10600171A1432|77 80|USF1
P10600171A1432|83 129|ubiquitous bHLH/leucine zipper transcription factor
P10600171A1432|93 129|bHLH/leucine zipper transcription factor
P10601280A0674|14 34|TPA-responsive element
P10601280A0674|50 77|base-line ST3 promoter activity
P10601280A0674|100 109|activation
P10601290A0742|35 54|cell surface stability
P10601290A0742|67 82|wild-type peptide
P10601290A0742|101 111|differences
P10601290A0742|114 129|T cell recognition
P10601290A0742|137 139|I1Y
P10601290A0742|143 145|I1F
P10601290A0742|162 183|x-ray crystal structures
P10601290A0742|192 208|class I MHC-peptide
P10601290A0742|198 217|MHC-peptide complexes
P10601335A0892|0 13|Redistribution
P10601335A0892|16 27|mannosidase I
P10601335A0892|16 26|mannosidase
P10601335A0892|45 49|cells
P10601335A0892|63 71|degrees C.
P10601344A1653|16 40|biochemical activity assays
P10601344A1653|44 58|Rho-like GTPases
P10601344A1653|85 90|beta1A
P10601344A1653|92 97|beta1D
P10601344A1653|101 111|IL2R-beta1A
P10601344A1653|114 117|GE11
P10601344A1653|120 128|GD25 cells
P10601344A1653|137 146|activation
P10601344A1653|153 156|RhoA
P10601344A1653|160 163|Rac1
P10601344A1653|173 177|Cdc42
P10601410A0977|40 43|IVIg
P10601410A0977|49 61|remyelination
P10601410A0977|64 93|stable multiple sclerosis lesions
P10601410A0977|106 126|central conduction time
P10601606A0152|3 21|rhabdomyosarcoma R1H
P10601606A0152|34 43|right flank
P10601606A0152|46 60|male WAG/Rij rats
P10601606A0152|78 78|h
P10601606A0152|83 90|degrees C
P10601606A0152|95 103|degrees C.
P10601747A0482|0 7|Relative
P10601747A0482|10 29|coherent control words
P10601747A0482|48 83|discourse-dependent semantic anomalies
P10601747A0482|93 107|large N400 effect
P10601747A0482|132 135|msec
P10601747A0482|141 149|word onset
P10602419A1253|5 22|synergistic effects
P10602419A1253|35 53|Jem-1 dose-dependent
P10602502A0422|7 16|Tob protein
P10602502A0422|18 21|Tob2
P10602502A0422|31 50|cell cycle progression
P10602502A0422|58 62|G0/G1
P10602502A0422|65 71|S phases
P10602507A0652|3 20|coordinate increase
P10602507A0652|23 30|cyclin D1
P10602507A0652|34 36|p21
P10602507A0652|78 93|absolute activity
P10602507A0652|96 108|cyclin D1/cdk4
P10602507A0652|96 103|cyclin D1
P10602507A0652|105 108|cdk4
P10602507A0652|110 112|p53
P10602507A0652|132 145|CSF-1 induction
P10602507A0652|132 136|CSF-1
P10602507A0652|148 150|p21
P10602507A0652|154 163|unaffected
P10602507A0652|166 195|dominant-negative p53 expression
P10602507A0652|166 185|dominant-negative p53
P10602516A0182|11 13|SLK
P10602516A0182|22 33|high homology
P10602516A0182|36 46|microtubule
P10602516A0182|75 79|M-NAP
P10602516A0182|84 89|AT1-46
P10602516A0182|97 111|unknown function
P10602838A0127|13 20|patients
P10602838A0127|24 30|females
P10602838A0127|35 39|males
P10603349A1667|3 25|signalling molecules Wnt1
P10603349A1667|22 25|Wnt1
P10603349A1667|29 41|Sonic hedgehog
P10603349A1667|58 67|activation
P10603349A1667|70 73|Myf5
P10603349A1667|76 98|myogenic progenitor cells
P10603349A1667|104 109|somite
P10603349A1667|131 139|viscinity
P10603349A1667|145 164|Myf5 expression domain
P10603349A1667|145 148|Myf5
P10603349A1667|170 182|mesencephalon
P10604246A0523|0 10|STUDY DESIGN
P10604246A0523|14 20|METHODS
P10604246A0523|64 68|PBPCs
P10604246A0523|76 84|new device
P10604246A0523|89 96|AutoPBSC
P10604246A0523|106 106|V
P10604246A0523|115 131|AutoPBSC tubing set
P10604246A0523|148 150|MNC
P10604246A0523|152 166|mononuclear cell
P10604246A0523|178 179|V4
P10604246A0523|186 203|white cell tubing set
P10604246A0523|209 216|patients
P10604246A0523|220 232|healthy donors
P10604583T0000|0 14|Albumin dialysis
P10604583T0000|0 6|Albumin
P10604583T0000|16 31|effective removal
P10604583T0000|34 39|copper
P10604583T0000|54 75|fulminant Wilson disease
P10604583T0000|99 118|liver transplantation
P10604583T0000|121 134|new possibility
P10604583T0000|141 151|elimination
P10604583T0000|154 172|protein-bound toxins
P10604945A0731|4 31|artificial promoter constructs
P10604945A0731|42 57|multiple Sp1 sites
P10604945A0731|50 57|Sp1 sites
P10604945A0731|68 77|responsive
P10604945A0731|80 86|ethanol
P10604945A0731|139 160|proximal promoter region
P10604945A0731|166 181|additional factor
P10604945A0731|197 211|ethanol response
P10606245A0906|0 13|Overexpression
P10606245A0906|16 22|CDP/cut
P10606245A0906|16 18|CDP
P10606245A0906|20 22|cut
P10606245A0906|25 27|ROS
P10606245A0906|34 50|osteosarcoma cells
P10606245A0906|60 69|repression
P10606245A0906|72 89|OC promoter activity
P10606245A0906|72 81|OC promoter
P10606245A0906|95 104|repression
P10606245A0906|126 132|OC box I.
P10606245A0906|126 131|OC box I
P10606272A1241|0 8|Injection
P10606272A1241|11 28|double-stranded RNA
P10606272A1241|33 41|C. elegans
P10606272A1241|51 68|embryonic lethality
P10606272A1241|78 84|SF1 gene
P10606272A1241|105 109|yeast
P10606272A1241|129 136|metazoan
P10606515A0389|4 10|domains
P10606515A0389|26 43|specific DNA binding
P10606515A0389|49 80|beta-retinoic acid receptor element
P10606515A0389|92 97|DNase I
P10606515A0389|92 96|DNase
P10606515A0389|98 106|footprint
P10606515A0389|131 136|strand
P10606664A0000|0 18|Snail family proteins
P10606664A0000|22 56|zinc finger transcriptional regulators
P10606664A0000|93 105|critical roles
P10606664A0000|108 128|cell fate determination
P10607566A0880|0 9|Consistent
P10607566A0880|26 37|beta-catenin
P10607566A0880|63 72|RA receptor
P10607566A0880|74 76|RAR
P10607566A0880|81 104|retinoid-dependent manner
P10607566A0880|119 135|retinoid X receptor
P10607566A0880|137 139|RXR
P10607566A0880|145 147|RAR
P10607566A0880|160 162|TCF
P10607566A0880|166 184|beta-catenin binding
P10607899A0605|0 15|Sequence analysis
P10607899A0605|21 34|promoter region
P10607899A0605|43 49|TATA box
P10607899A0605|63 84|consensus binding motifs
P10607899A0605|88 90|Sp1
P10607899A0605|92 95|CREB
P10607899A0605|100 108|half sites
P10607899A0605|114 140|estrogen receptor binding site
P10607900T0000|0 21|Sak kinase gene structure
P10607900T0000|25 49|transcriptional regulation
P10608053A0923|0 11|Thrombolysis
P10608053A0923|26 40|similar increase
P10608053A0923|43 58|platelet activity
P10608053A0923|63 75|maximal values
P10608053A0923|88 94|3rd hour
P10608053A0923|101 106|groups
P10608053A0923|116 120|IU/ml
P10608053A0923|123 127|Group
P10608053A0923|142 146|Group
P10608053A0923|149 149|p
P10608053A0923|154 170|001versus baseline
P10608053A0923|174 176|p NS
P10608053A0923|187 192|groups
P10608893A0727|0 6|Similar
P10608893A0727|9 13|Hp140
P10608893A0727|23 26|Hp55
P10608893A0727|39 54|moderate strength
P10608893A0727|62 72|specificity
P10608893A0727|76 108|double-stranded primer-template DNA
P10610716A1127|13 32|new missense mutations
P10610716A1127|34 38|E138V
P10610716A1127|40 44|R254G
P10610716A1127|49 53|P362R
P10610716A1127|74 84|human AC gene
P10610716A1127|89 98|FD patients
P10611225A1127|37 41|eIF4A
P10611225A1127|49 60|middle region
P10611225A1127|63 68|eIF4GI
P10611225A1127|118 122|eIF4A
P10611225A1127|130 145|C-terminal region
P10611225A1127|152 165|modulatory role
P10611228A1388|3 23|DAP5/p86 apoptotic form
P10611228A1388|3 6|DAP5
P10611228A1388|8 10|p86
P10611228A1388|31 36|potent
P10611228A1388|41 48|DAP5/p97
P10611228A1388|41 44|DAP5
P10611228A1388|46 48|p97
P10611228A1388|56 71|functional assays
P10611235A1927|20 26|key step
P10611235A1927|43 52|activation
P10611235A1927|58 66|MAPK Fus3p
P10611235A1927|77 77|G
P10611235A1927|79 87|betagamma
P10611235A1927|90 112|dependent relocalization
P10611235A1927|118 134|Ste5p-MAPK cascade
P10611235A1927|118 122|Ste5p
P10611235A1927|124 127|MAPK
P10611235A1927|140 153|plasma membrane
P10611242A0541|0 9|Consistent
P10611242A0541|26 38|wild-type SAGA
P10611242A0541|47 56|TBP binding
P10611242A0541|47 49|TBP
P10611242A0541|62 73|HIS3 promoter
P10611242A0541|87 90|SAGA
P10611242A0541|98 101|Spt3
P10611242A0541|104 107|Spt8
P10611242A0541|113 122|inhibitory
P10611320A0816|0 22|Saccharomyces cerevisiae
P10611320A0816|59 71|proven CAK gene
P10611320A0816|65 71|CAK gene
P10611320A0816|73 76|CAK1
P10611320A0816|90 125|monomeric 44-kDa Cak1p protein unrelated
P10611320A0816|99 116|44-kDa Cak1p protein
P10611320A0816|128 131|Cdk7
P10611353A0458|0 11|Northern blot
P10611353A0458|22 46|transcription-PCR analyses
P10611353A0458|49 64|human mRNA samples
P10611353A0458|80 82|RNR
P10611353A0458|110 115|retina
P10611353A0458|121 131|transcripts
P10611353A0458|150 151|kb
P10611353A0458|169 170|kb
P10611353A0458|191 192|kb
P10611353A0458|195 214|Northern blot analysis
P10612044A1180|42 56|AP-4 binding site
P10612044A1180|66 84|nucleotides upstream
P10612044A1180|90 116|transcription initiation site
P10612044A1180|123 131|Aal-rpL34
P10612044A1180|123 125|Aal
P10612044A1180|127 131|rpL34
P10612044A1180|135 147|Aal-rpL8 genes
P10612044A1180|135 137|Aal
P10612044A1180|139 142|rpL8
P10612505A1317|37 48|power greater
P10612505A1317|64 64|%
P10612505A1317|73 88|group differences
P10612505A1317|91 105|treatment effect
P10612505A1317|108 114|greater
P10612505A1317|130 130|%
P10612505A1317|135 135|%
P10612773A1210|0 10|CONCLUSIONS
P10612773A1210|12 22|Serum levels
P10612773A1210|25 33|S-100beta
P10612773A1210|37 51|reliable markers
P10612773A1210|55 79|adverse neurologic outcomes
P10612773A1210|85 98|cardiac surgery
P10612805A0716|10 26|genetic alteration
P10612805A0716|48 54|cancers
P10612918A0318|3 10|problems
P10612918A0318|44 49|screws
P10613816X0000|0 6|Statins
P10613816X0000|8 18|lower lipids
P10613816X0000|22 32|better bones
P10613816X0000|42 48|statins
P10613816X0000|64 88|cholesterol-lowering drugs
P10613816X0000|91 101|recent study
P10613816X0000|119 127|compounds
P10613816X0000|132 146|anabolic effects
P10613816X0000|176 188|new treatments
P10613816X0000|192 222|common metabolic bone diseases such
P10613816X0000|225 236|osteoporosis
P10613843A0107|14 21|products
P10613843A0107|24 47|ancient duplication events
P10613843A0107|76 80|genes
P10613843A0107|89 107|voltage-dependent Ca
P10613843A0107|112 122|ion channels
P10613863T0000|3 23|VirR response regulator
P10613863T0000|28 49|Clostridium perfringens
P10613863T0000|73 101|imperfect direct repeats located
P10613863T0000|115 126|pfoA promoter
P10613874A0663|0 6|Cloning
P10613874A0663|10 19|sequencing
P10613874A0663|25 38|upstream region
P10613874A0663|41 44|pepX
P10613874A0663|69 72|ORFs
P10613874A0663|86 87|bp
P10613874A0663|117 124|proteins
P10613874A0663|129 140|high homology
P10613874A0663|143 146|GlnR
P10613874A0663|150 161|GlnA proteins
P10614676A0000|0 8|Objective
P10614676A0000|20 39|endometrial thickness
P10614676A0000|46 54|incidence
P10614676A0000|57 71|uterine bleeding
P10614676A0000|74 92|postmenopausal women
P10614676A0000|104 111|tibolone
P10614676A0000|115 116|mg
P10614676A0000|119 136|continuous combined
P10614676A0000|138 148|mg estradiol
P10614676A0000|153 175|mg norethisterone acetate
P10614676A0000|177 182|E+NETA
P10614676A0000|191 215|hormone replacement therapy
P10614857A0584|0 16|Leukocyte cultures
P10614857A0584|51 58|children
P10614857A0584|62 67|months
P10614857A0584|82 92|lower yields
P10614857A0584|95 97|IFN
P10614857A0584|123 130|children
P10614857A0584|150 159|adenovirus
P10614857A0584|161 161|P
P10614857A0584|170 180|coronavirus
P10614857A0584|182 182|P
P10614857A0584|192 201|rhinovirus
P10614857A0584|203 204|P=
P10616948A0998|5 21|BF ECT group the-age
P10616948A0998|67 94|initial seizure threshold level
P10617126A1005|0 19|Histological analysis
P10617126A1005|33 44|neuronal loss
P10617126A1005|50 66|DHED-treated group
P10617126A1005|89 103|hippocampal area
P10617126A1005|105 107|CA1
P10617126A1005|111 122|ischemic rats
P10617126A1005|131 142|dentate gyrus
P10617126A1005|146 160|hippocampal area
P10617126A1005|162 164|CA1
P10617126A1005|168 170|CA3
P10617126A1005|174 188|EC-lesioned rats
P10617126A1005|204 218|nontreated group
P10617144A0386|3 9|extents
P10617144A0386|12 26|phosphorylation
P10617144A0386|29 33|Ser44
P10617144A0386|37 41|Ser64
P10617144A0386|71 80|minor sites
P10617144A0386|99 99|%
P10617232A0393|0 11|Serum HBV-DNA
P10617232A0393|13 25|viral serology
P10617232A0393|30 41|liver enzymes
P10617232A0393|67 80|liver histology
P10617232A0393|117 124|patients
P10617613A1192|0 3|Chem
P10618645A0750|0 15|Maximum induction
P10618645A0750|18 21|AP-1
P10618645A0750|53 58|nmol/L
P10618645A0750|61 64|CalC
P10619062T0000|0 23|Haycocknema perplexum n. g.
P10619062T0000|25 28|n. sp
P10619169A0411|0 3|Rams
P10619169A0411|18 27|testis size
P10619169A0411|42 51|orchimetry
P10619169A0411|58 67|time period
P10619254A1055|0 12|Animal studies
P10619254A1055|23 38|beam equalization
P10619254A1055|60 71|fluoroscopic
P10619254A1055|75 98|angiographic image quality
P10619353T0000|0 3|Role
P10619353T0000|6 27|estrogen receptor ligand
P10619353T0000|31 61|estrogen response element sequence
P10619353T0000|79 129|chicken ovalbumin upstream promoter transcription factor
P10619353T0000|131 137|COUP-TF
P10620010A1155|0 9|CONCLUSION
P10620010A1155|13 16|Cdks
P10620010A1155|41 49|cell cycle
P10620010A1155|51 73|tyrosine phosphorylation
P10620010A1155|76 85|inhibitory
P10620010A1155|91 100|activation
P10620010A1155|103 108|kinase
P10620010A1155|120 134|phosphorylation
P10620010A1155|137 145|threonine
P10620010A1155|151 156|T-loop
P10620010A1155|171 180|activation
P10620335A0749|16 18|AHR
P10620335A0749|32 38|COUP-TF
P10620335A0749|52 60|CV-1 cells
P10620777A1399|0 7|AB004534
P10622574A0000|3 12|prevalence
P10622574A0000|15 29|hepatitis C virus
P10622574A0000|31 33|HCV
P10622574A0000|75 97|anti-HCV prevalence rates
P10622574A0000|107 107|%
P10622574A0000|113 124|Western world
P10622576A0552|0 4|Clear
P10622576A0552|8 33|evidenced-based information
P10622576A0552|52 59|patients
P10622576A0552|67 71|means
P10622576A0552|88 103|special attention
P10622576A0552|106 129|individual risk groups such
P10622576A0552|134 144|drug abusers
P10623758A0947|6 12|latency
P10623758A0947|23 23|%
P10623758A0947|26 32|neurons
P10623758A0947|35 41|ganglia
P10623758A0947|58 64|footpad
P10623758A0947|74 91|beta-galactosidase
P10623758A0947|108 120|positive cells
P10623758A0947|149 154|months
P10623804A0808|4 22|alternative approach
P10623804A0808|54 60|effects
P10623804A0808|83 86|SHIP
P10623804A0808|88 92|SHP-1
P10623804A0808|96 127|SHP-2 SH2-containing decoy proteins
P10623804A0808|96 100|SHP-2
P10623804A0808|130 150|Fc gamma RIIB1 signaling
P10623804A0808|130 141|Fc gamma RIIB1
P10624787A0432|19 38|normal renal functions
P10624787A0432|45 52|patients
P10624787A0432|57 61|older
P10624787A0432|63 63|P
P10624787A0432|67 67|=
P10624787A0432|90 111|elevated blood pressures
P10624787A0432|113 113|P
P10624787A0432|121 122|P =
P10624787A0432|145 148|Type
P10624787A0432|150 151|DM
P10624787A0432|158 176|higher body mass index
P10624787A0432|178 179|P =
P10624787A0432|190 203|waist-hip ratio
P10624787A0432|205 205|P
P10625438A1429|5 11|tissues
P10625438A1429|24 42|transcripts positive
P10625438A1429|58 68|bp insertion
P10625438A1429|103 112|conditions
P10625438A1429|123 128|% level
P10625438A1429|138 155|negative transcript
P10625438A1429|191 212|prepared control samples
P10625494A1059|5 11|results
P10625494A1059|23 33|CAAT-region
P10625494A1059|61 72|MDR1 promoter
P10625494A1059|75 87|HL60/VCR cells
P10625683A0091|4 12|receptors
P10625683A0091|20 41|protein tyrosine kinases
P10625683A0091|43 46|PTKs
P10625683A0091|54 68|phosphorylation
P10625683A0091|87 95|molecules
P10625683A0091|139 147|receptors
P10625721T0101|0 10|Hypothermia
P10625721T0101|16 28|Cardiac Arrest
P10625721T0101|30 33|HACA
P10625721T0101|35 44|Study Group
P10627518A0544|3 22|synergistic effect due
P10627518A0544|62 68|greater
P10627518A0544|84 96|contributions
P10627518A0544|102 115|individual UTRs
P10627532A0739|21 21|R
P10627532A0739|25 25|Z
P10627532A0739|37 74|cellular stress mitogen-activated protein
P10627532A0739|51 74|mitogen-activated protein
P10627532A0739|76 86|MAP) kinases
P10627532A0739|76 78|MAP
P10627532A0739|80 86|kinases
P10627532A0739|88 90|p38
P10627532A0739|94 96|JNK
P10627532A0739|109 123|phosphorylation
P10627532A0739|128 137|activation
P10627532A0739|144 174|cellular transcription factor ATF2
P10627834A0178|3 23|US commercial cultivars
P10627834A0178|25 30|Tehama
P10627834A0178|34 37|Vina
P10627834A0178|45 71|European commercial cultivars
P10627834A0178|73 81|Esterhazy
P10627834A0178|87 90|G120
P10627834A0178|99 118|New Zealand selections
P10627834A0178|120 122|Rex
P10627834A0178|124 129|Dublin
P10627834A0178|132 136|Glory
P10627834A0178|138 143|Meyric
P10627834A0178|145 153|McKinster
P10627834A0178|155 161|Stanley
P10628490T0000|0 6|Anatomy
P10628490T0000|12 24|uterine artery
P10628748A0344|8 17|activation
P10628748A0344|23 33|cAMP pathway
P10628748A0344|57 78|inhibin alpha expression
P10628748A0344|57 68|inhibin alpha
P10628748A0344|98 104|actions
P10628748A0344|107 110|SF-1
P10628748A0746|0 7|Deletion
P10628748A0746|11 34|site-directed mutagenesis
P10628748A0746|45 70|novel SF-1 regulatory element
P10628748A0746|50 70|SF-1 regulatory element
P10628748A0746|72 80|TCA GGGCCA
P10628748A0746|93 100|adjacent
P10628748A0746|104 130|variant cAMP-response element
P10628748A0746|111 130|cAMP-response element
P10628748A0746|132 134|CRE
P10628750A0298|26 29|APRE
P10628750A0298|33 40|cytokine
P10628750A0298|42 66|tumor necrosis factor-alpha
P10628750A0298|68 75|TNFalpha
P10628750A0298|79 95|inducible enhancer
P10628750A0298|108 140|heterodimeric nuclear factor-kappaB
P10628750A0298|142 150|NF-kappaB
P10628750A0298|152 161|complex Rel
P10628750A0298|163 173|x NF-kappaB1
P10628750A0298|164 173|NF-kappaB1
P10628750T0000|0 12|Angiotensin II
P10628750T0000|0 10|Angiotensin
P10628750T0000|20 32|nuclear factor
P10628750T0000|34 52|NF)-kappaB1 isoforms
P10628750T0000|34 35|NF
P10628750T0000|38 52|kappaB1 isoforms
P10628750T0000|62 106|angiotensinogen gene acute-phase response element
P10628750T0000|62 80|angiotensinogen gene
P10628750T0000|109 132|stimulus-specific pathway
P10628750T0000|136 154|NF-kappaB activation
P10628750T0000|136 144|NF-kappaB
P10628755A0000|0 15|Synthetic ligands
P10628755A0000|63 82|pulsatile GH secretion
P10628755A0000|103 131|orphan GH-secretagogue receptor
P10628755A0000|133 137|GHS-R
P10628971A0824|15 21|mutants
P10628971A0824|32 34|TGN
P10628971A0824|42 48|defects
P10628971A0824|57 63|members
P10628971A0824|68 76|mutations
P10628971A0824|99 125|vacuolar protein sorting genes
P10628971A0824|127 129|VPS
P10628971A0824|144 166|dynamin family member VPS1
P10628971A0824|144 150|dynamin
P10628971A0824|163 166|VPS1
P10628971A1165|19 25|mutants
P10628971A1165|30 32|TGN
P10628971A1165|40 46|defects
P10628971A1165|50 57|isolates
P10628971A1165|62 70|mutations
P10628971A1165|86 89|RIC1
P10628971A1165|140 157|ribosome biogenesis
P10628971A1165|159 162|LUV1
P10628971A1165|201 207|vacuole
P10628971A1165|211 233|microtubule organization
P10628971A1165|238 242|INP53
P10628971A1165|253 303|synaptojanin-like inositol polyphosphate 5-phosphatase
P10629035A0827|3 20|single strandedness
P10629035A0827|36 52|terminal extension
P10629035A0827|58 71|G-rich strand (G
P10629035A0827|58 69|G-rich strand
P10629035A0827|71 76|G tails
P10629035A0827|105 114|telomerase
P10629035A0827|130 146|cdc17/pol1 mutants
P10629035A0827|130 134|cdc17
P10629035A0827|154 160|defects
P10629035A0827|163 194|telomeric lagging-strand synthesis
P10629176A0887|11 16|CaMig1
P10629176A0887|23 39|specific complexes
P10629176A0887|47 56|URS1 region
P10629176A0887|62 81|S. cerevisiae FBP1 gene
P10629176A0887|74 81|FBP1 gene
P10629938A1352|15 30|wide distribution
P10629938A1352|36 50|GFP-POLO protein
P10629938A1352|36 38|GFP
P10629938A1352|40 43|POLO
P10629938A1352|56 67|compartments
P10629938A1352|73 88|mitotic apparatus
P10629938A1352|98 109|valuable tool
P10629938A1352|113 125|future studies
P10629938A1352|128 136|cell cycle
P10630471T0000|2 10|ASIC-chip
P10630471T0000|14 38|stereoscopic depth analysis
P10630471T0000|41 55|video-real-time
P10630471T0000|63 88|visual cortical cell behavior
P10630630A0614|8 18|calphostin C
P10630630A0614|21 37|specific inhibitor
P10630630A0614|40 42|PKC
P10630630A0614|56 74|TPA-induced increase
P10630630A0614|77 89|CFI mRNA levels
P10630630A0614|77 83|CFI mRNA
P10633075A1111|0 11|Preimmune IgG
P10633075A1111|13 33|anti-GalT Fab fragments
P10633075A1111|35 52|irrelevant polymers
P10633075A1111|56 83|monomeric N-acetylglucosamine
P10633075A1111|65 83|N-acetylglucosamine
P10633499A1306|0 22|Arhythmacanthus Yamaguti
P10633499A1306|43 49|synonym
P10633499A1306|103 111|hook types
P10633499A1306|118 126|equivocal
P10633499A1306|154 159|apical
P10633499A1306|163 176|subapical hooks
P10633499A1306|179 185|gradual
P10634007A0202|17 37|acetaminophen overdose
P10634007A0202|60 71|hemodialysis
P10634007A0202|73 74|HD
P10634007A0202|79 84|NAC due
P10634007A0202|87 104|severe intoxication
P10634007A0202|108 124|slow drug clearance
P10635209A0419|9 20|conditioning
P10635209A0419|23 32|single coat
P10635209A0419|35 42|adhesive
P10635209A0419|56 66|light-cured
P10637149A0806|0 9|Downstream
P10637149A0806|15 28|G-A anastomosis
P10637149A0806|33 34|RD
P10637149A0806|36 37|CC
P10637149A0806|39 39|E
P10637149A0806|41 41|p
P10637149A0806|46 54|loop areas
P10637149A0806|85 87|REF
P10637149A0806|118 120|A-A
P10637230A0332|19 23|c-myc
P10637230A0332|49 61|proliferation
P10637230A0332|64 78|Stat1-null cells
P10637230A0332|64 68|Stat1
P10637230A0332|91 94|IFNs
P10637238A0291|0 40|Eastern Cooperative Oncology Group trial E3186
P10637337A0545|15 23|DNA repair
P10637337A0545|36 59|TFA1 conditional mutations
P10637337A0545|36 39|TFA1
P10638607A0000|5 12|articles
P10638607A0000|26 32|results
P10638607A0000|35 53|multi-institutional
P10638607A0000|72 77|trials
P10638607A0000|95 102|patients
P10638607A0000|107 115|localized
P10638607A0000|117 126|T1-3 N0-1 M0
P10638607A0000|128 158|esophageal squamous cell carcinoma
P10638607A0000|160 162|SCC
P10638607A0000|166 189|esophageal adenocarcinoma
P10639585A0157|0 6|Studies
P10639585A0157|9 25|MPO gene regulation
P10639585A0157|67 96|abnormal myeloid differentiation
P10640683A0204|0 11|NDRF/NeuroD2
P10640683A0204|0 3|NDRF
P10640683A0204|5 11|NeuroD2
P10640683A0204|34 36|PKN
P10640683A0204|44 49|lysate
P10640683A0204|52 61|COS-7 cells
P10640683A0204|81 100|expression constructs
P10640683A0204|104 115|NDRF/NeuroD2
P10640683A0204|104 107|NDRF
P10640683A0204|109 115|NeuroD2
P10640683A0204|119 121|PKN
P10640683A0670|0 26|Transient transfection assays
P10640683A0670|32 39|P19 cells
P10640683A0670|64 75|NDRF/NeuroD2
P10640683A0670|64 67|NDRF
P10640683A0670|69 75|NeuroD2
P10640683A0670|88 102|transactivation
P10640683A0670|108 133|rat insulin promoter element 3
P10640683A0670|108 132|rat insulin promoter element
P10640683A0670|135 139|RIPE3
P10640683A0670|141 148|enhancer
P10640683A0670|166 172|12-fold
P10640683A0670|180 192|co-expression
P10640683A0670|208 217|active form
P10640683A0670|220 222|PKN
P10640683A0670|230 255|kinase-deficient derivative
P10640683A0670|268 291|further threefold increase
P10640683A0670|294 327|NDRF/NeuroD2-mediated transcription
P10640683A0670|294 297|NDRF
P10640683A0670|299 305|NeuroD2
P10640701T0000|3 23|Pax2/5/8-binding sites
P10640701T0000|26 35|Engrailed2
P10640701T0000|50 65|proper initiation
P10640701T0000|68 100|endogenous mid-hindbrain expression
P10640734A0190|4 26|tyrosine phosphorylation
P10640734A0190|32 36|ITIMs
P10640734A0190|43 51|molecules
P10640734A0190|59 94|SH2 domain-containing phosphatases such
P10640734A0190|59 90|SH2 domain-containing phosphatases
P10640734A0190|97 131|SH2-containing tyrosine phosphatase-1
P10640734A0190|153 164|cell activity
P10641037A1371|0 7|AF154055
P10641688A0341|0 8|Alignment
P10641688A0341|14 26|cervical spine
P10641688A0341|28 49|vertebral abnormalities
P10641688A0341|54 64|disc changes
P10642524A0156|3 24|concomitant interaction
P10642524A0156|27 31|mSTI1
P10642524A0156|36 40|hsp70
P10642524A0156|44 48|hsp90
P10642524A0156|54 54|N
P10642524A0156|59 67|C-termini
P10642524A0156|95 117|tetratricopeptide repeat
P10642524A0156|119 121|TPR
P10642524A0156|123 128|motifs
P10642524A0156|136 142|regions
P10642531A2322|0 21|Competition experiments
P10642531A2322|34 63|negative allosteric relationship
P10642531A2322|76 94|RGD recognition sites
P10642889A0393|0 15|Sequence analysis
P10642889A0393|32 53|flanking region upstream
P10642889A0393|59 66|ATG codon
P10642889A0393|81 99|conventional TATA box
P10643313A0345|5 22|i.v. administration
P10643313A0345|28 42|mg acetazolamide
P10643313A0345|46 57|disinfection
P10643313A0345|63 73|conjunctiva
P10643313A0345|77 91|micrograms rt-PA
P10643313A0345|97 98|ml
P10643313A0345|100 102|BSS
P10643313A0345|110 114|ml SF6
P10644357A0935|5 11|results
P10644357A0935|23 25|VP1
P10644357A0935|56 62|nucleus
P10644357A0935|66 74|localized
P10644357A0935|80 104|discrete subnuclear regions
P10644357A0935|118 120|VP2
P10644357A0935|124 126|VP3
P10644414T0000|0 21|Differential expression
P10644414T0000|37 54|20-hydroxyecdysone
P10644414T0000|57 85|mosquito ultraspiracle isoforms
P10644753A0725|8 15|isoforms
P10644753A0725|28 58|anti-FLAG antibody affinity column
P10644753A0725|28 44|anti-FLAG antibody
P10644753A0725|70 76|sulfate
P10644753A0725|79 92|heparan sulfate
P10644753A0725|96 102|heparin
P10644753A0725|111 133|other glycosaminoglycans
P10644760A0000|3 17|differentiation
P10644760A0000|35 59|neurotransmitter phenotype
P10644760A0000|86 98|exogenous cues
P10644760A0000|103 127|intrinsic genetic machinery
P10644760A0956|0 7|Analysis
P10644760A0956|10 26|functional domains
P10644760A0956|29 32|Arix
P10644760A0956|42 67|N-terminal activation domain
P10644760A0956|72 97|C-terminal repression domain
P10645921A0000|0 9|BACKGROUND
P10645921A0000|15 36|ventricular hypertrophy
P10645921A0000|40 60|heterogeneous disorder
P10645921A0000|65 84|distinct morphologies
P10645921A1320|0 21|Multivariate predictors
P10645921A1320|26 45|concentric remodeling
P10645921A1320|47 47|P
P10645921A1320|56 64|odds ratio
P10645921A1320|76 102|ventricular ejection fraction
P10645921A1320|105 106|SD
P10645921A1320|119 119|P
P10645921A1320|132 165|single-vessel left circumflex disease
P10645921A1320|167 167|P
P10645921A1320|176 184|odds ratio
P10646820T0000|23 37|lymphadenectomy
P10646820T0000|42 59|positive lymph nodes
P10646820T0000|74 92|radical hysterectomy
P10646820T0000|96 112|cervical carcinoma
P10646863A0838|0 13|Overexpression
P10646863A0838|16 21|ICBP90
P10646863A0838|24 45|COS-1-transfected cells
P10646863A0838|75 104|endogenous topoisomerase IIalpha
P10647177A0599|3 12|RNA aptamer
P10647177A0599|49 62|two-base bulges
P10647177A0599|75 91|unanticipated fold
P10647177A0599|103 117|junctional sites
P10647177A0599|136 154|base triple formation
P10647633A1685|31 49|anatomical sphincter
P10647633A1685|55 57|RSJ
P10647633A1685|90 95|stools
P10647633A1685|103 114|sigmoid colon
P10647633A1685|120 125|rectum
P10647817T0000|0 8|Isolation
P10647817T0000|11 15|cDNAs
P10647817T0000|24 72|gibbon and monkey platelet and T cell activation antigen 1
P10647817T0000|24 29|gibbon
P10647817T0000|33 46|monkey platelet
P10647817T0000|50 71|T cell activation antigen
P10647817T0000|74 77|PTA1
P10647859A0000|13 38|mechanical inhibitory effect
P10647859A0000|41 84|nasal intermittent positive pressure ventilation
P10647859A0000|86 89|IPPV
P10647859A0000|93 111|inspiratory activity
P10647859A0000|117 125|diaphragm
P10647859A0000|158 165|subjects
P10647859A0000|171 179|occasions
P10647859A0000|182 204|respiratory rates similar
P10647859A0000|207 220|quiet breathing
P10647859A0000|222 223|QB
P10647859A0000|235 240|levels
P10647859A0000|243 257|applied pressure
P10647859A0000|259 263|Pappl
P10647859A0000|275 279|cmH2O
P10647859A0000|291 300|hypocapnia
P10647859A0000|302 302|P
P10647859A0000|304 306|CO2
P10647859A0000|329 336|eucapnia
P10647859A0000|338 340|CO2
P10647859A0000|348 358|inspired gas
P10648020A0151|0 6|METHODS
P10648020A0151|8 26|Von Willebrand factor
P10648020A0151|28 30|vWF
P10648020A0151|38 82|fibrinolytic factors tissue plasminogen activator
P10648020A0151|57 82|tissue plasminogen activator
P10648020A0151|84 86|tPA
P10648020A0151|99 109|tPA capacity
P10648020A0151|99 101|tPA
P10648020A0151|114 143|plasminogen activator inhibitor 1
P10648020A0151|114 142|plasminogen activator inhibitor
P10648020A0151|145 149|PAI-1
P10648020A0151|152 160|platelets
P10648020A0151|162 171|fibrinogen
P10648020A0151|176 194|inflammatory markers
P10648020A0151|211 218|patients
P10648020A0151|223 242|active seropositive RA
P10648211A0000|0 26|Neuronal signaling properties
P10648211A0000|76 86|ion channels
P10648489A1117|0 8|Treatment
P10648489A1117|19 51|significant dose dependent reduction
P10648489A1117|62 80|ST segment depression
P10648489A1117|87 92|trough
P10648489A1117|96 113|peak concentrations
P10648619A0000|35 61|specific TATA-binding protein
P10648619A0000|43 61|TATA-binding protein
P10648619A0000|63 65|TBP
P10648619A0000|68 83|TATA interactions
P10648619A0000|89 104|promoter activity
P10648619A0000|131 142|silkworm tRNA
P10648619A0000|144 144|C
P10648619A0000|147 149|Ala
P10648619A0000|187 213|similar interactions accounts
P10648619A0000|220 238|low promoter activity
P10648619A0000|242 263|silk gland-specific tRNA
P10648619A0000|265 266|SG
P10648619A0000|269 271|Ala
P10649449A0413|3 11|sequences
P10649449A0413|18 36|extensive homologies
P10649449A0413|41 61|squalene synthase genes
P10649449A0413|65 71|enzymes
P10649449A0413|85 98|other organisms
P10649449A0413|102 129|extreme amino acid conservation
P10649449A0413|139 145|binding
P10649449A0413|149 164|catalytic domains
P10649456A1061|3 8|clones
P10649456A1061|12 18|strains
P10649456A1061|49 73|EUROFAN genetic stock centre
P10649456A1061|75 83|EUROSCARF
P10649456A1061|85 93|Frankfurt
P10649738A0953|3 10|episodes
P10649738A0953|13 23|peritonitis
P10649738A0953|55 58|CAPD
P10649738A0953|61 69|episode/3
P10649738A0953|72 85|patient-months
P10650104X0284|0 8|Copyright
P10650104X0284|16 27|Royal College
P10650104X0284|30 41|Radiologists
P10650938T0000|3 18|estrogen receptor
P10650938T0000|20 21|ER
P10650938T0000|23 30|isoforms
P10650938T0000|35 63|different estrogen dependencies
P10650938T0000|83 93|trout ER gene
P10650939A0789|0 8|Induction
P10650939A0789|22 33|coexpression
P10650939A0789|36 40|A-Fos
P10650939A0789|43 58|dominant negative
P10650939A0789|61 64|AP-1
P10650939A1542|2 14|myometrial SMC
P10650939A1542|20 27|isoforms
P10650939A1542|33 52|progesterone receptor
P10650939A1542|54 57|PR-B
P10650939A1542|61 64|PR-A
P10650939A1542|73 98|ligand-dependent activation
P10650939A1542|101 109|PGDH-2368
P10650939A1542|111 114|luc3
P10650958A1315|0 7|Element B
P10650958A1315|34 42|% homology
P10650958A1315|46 66|consensus c-myb element
P10650958A1315|55 66|c-myb element
P10650958A1315|80 96|specific complexes
P10650958A1315|119 123|c-myb
P10650958A1315|129 161|electrophoretic mobility shift assay
P10651076T0000|0 13|High resolution
P10651076T0000|22 31|tomography
P10651076T0000|37 41|lungs
P10651076T0000|44 51|patients
P10651076T0000|56 74|rheumatoid arthritis
P10651805A1600|0 17|Stable transfection
P10651805A1600|39 55|folate carrier cDNA
P10651805A1600|60 82|mouse L1210 leukemia cells
P10651805A1600|93 110|folate accumulation
P10651805A1600|126 135|leucovorin
P10651805A1600|139 165|folic acid growth requirements
P10651805A1600|197 208|methotrexate
P10651805T0000|0 15|Characterization
P10651805T0000|60 72|folate carrier
P10651805T0000|83 100|folate accumulation
P10651805T0000|103 123|parental leukemia cells
P10652093A0139|0 18|Electron microscopic
P10652093A0139|22 38|enzymatic analyses
P10652093A0139|54 63|A118 genome
P10652093A0139|67 72|linear
P10652093A0139|74 91|circularly permuted
P10652093A0139|103 121|redundant collection
P10652093A0139|124 150|double-stranded DNA molecules
P10652102A0620|22 27|dosage
P10652102A0620|30 42|wild-type Fus3
P10652102A0620|57 66|inhibition
P10652102A0620|73 88|Ty1 transposition
P10652102A0620|73 75|Ty1
P10652102A0620|92 105|invasive growth
P10652228A0759|13 22|activation
P10652228A0759|25 45|c-Jun N-terminal kinase
P10652228A0759|58 85|Rho family GTP-binding proteins
P10652228A0759|105 107|Dbl
P10652228A0759|111 133|tyrosine-phosphorylated
P10652324A0177|26 40|collagen binding
P10652324A0177|26 33|collagen
P10652362A0933|32 47|carboxyl terminus
P10652362A0933|50 53|CFTR
P10652362A0933|63 97|tyrosine-based internalization signal
P10652362A0933|118 144|endocytic adaptor complex AP-2
P10652362A0933|141 144|AP-2
P10652362A0933|157 170|efficient entry
P10652362A0933|173 176|CFTR
P10652362A0933|181 203|clathrin-coated vesicles
P10652362A0933|181 188|clathrin
P10652800A0984|3 23|insulin therapy regimen
P10652800A0984|3 9|insulin
P10652800A0984|53 60|patients
P10652800A0984|66 88|significant relationship
P10652800A0984|121 128|duration
P10652800A0984|140 157|daily insulin dosage
P10652800A0984|160 175|metabolic control
P10652800A0984|187 189|BMI
P10653359A1297|0 8|Scmh1 maps
P10653359A1297|0 4|Scmh1
P10653359A1297|11 18|4D1-D2.1
P10653359A1297|21 24|mice
P10653400A0000|3 15|applicability
P10653400A0000|18 45|laparoscopic donor nephrectomy
P10653400A0000|47 49|LDN
P10653400A0000|74 83|obese donor
P10653550A1120|0 18|Hyaluronan treatment
P10653550A1120|29 46|collagen remodeling
P10653550A1120|29 36|collagen
P10653550A1120|52 67|peripheral region
P10653550A1120|93 100|meniscus
P10653550A1120|114 124|inner region
P10653693A0429|20 25|issues
P10653693A0429|62 65|KRAB
P10653693A0429|67 87|KAP-1-RBCC interaction
P10653693A0429|67 71|KAP-1
P10653693A0429|73 76|RBCC
P10653693A0429|101 110|components
P10653693A0903|3 12|RING finger
P10653693A0903|14 18|B2 box
P10653693A0903|23 39|coiled-coil region
P10653693A0903|54 68|oligomerization
P10653693A0903|71 80|KAP-1-RBCC
P10653693A0903|71 75|KAP-1
P10653693A0903|77 80|RBCC
P10653693A0903|84 94|KRAB binding
P10653693A0903|84 87|KRAB
P10653693A0903|98 106|mutations
P10653693A0903|114 120|domains
P10653693A0903|148 156|functions
P10653697A0133|0 5|Actins
P10653697A0133|13 26|different forms
P10653697A0133|29 57|N-terminal processing dependent
P10653697A0133|65 82|N-terminal sequence
P10653733A0596|7 13|domains
P10653733A0596|27 56|proline-threonine-rich peptides
P10654032A1133|0 3|JPEG
P10654032A1133|19 34|compression ratio
P10654032A1133|62 82|diagnostic performance
P10655164A0546|18 47|current systematic uncertainties
P10655164A0546|63 83|primordial Li abundance
P10655164A0546|94 110|much tighter limits
P10655164A0546|117 121|parl0
P10655164A0546|123 124|Li
P10655164A0546|130 134|solm0
P10655164A0546|136 136|H
P10655164A0546|142 146|parr0
P10655164A0546|148 149|p=
P10655164A0546|164 169|x10-10
P10655230A0685|9 24|yeast counterpart
P10655230A0685|29 45|mouse GCN2 isoforms
P10655230A0685|53 74|HisRS-related sequences
P10655230A0685|90 110|kinase catalytic domain
P10656154A0722|4 8|women
P10656154A0722|14 14|%
P10656154A0722|30 32|PMS
P10656161A0316|0 2|MBI
P10656161A0316|6 9|MMBI
P10656161A0316|16 32|similar Cmax values
P10656161A0316|57 62|slower
P10656161A0316|68 72|serum
P10656161A0316|102 116|larger AUC values
P10656802A1724|7 19|long insertion
P10656802A1724|25 51|cathepsin X amino acid sequence
P10656802A1724|58 69|beta-hairpin
P10656802A1724|89 98|active site
P10657238A0541|0 22|Transfection experiments
P10657238A0541|45 58|flanking region
P10657238A0541|76 84|mStaf gene
P10657238A0541|91 103|transcription
P10657238A0541|106 120|mouse NMuMG cells
P10657238A0541|179 208|highest transcriptional activity
P10657658A0165|0 13|Further studies
P10657658A0165|16 24|T-24 cells
P10657658A0165|41 51|HA fragments
P10657658A0165|63 89|I kappa B alpha phosphorylation
P10657658A0165|63 74|I kappa B alpha
P10657658A0165|93 103|degradation
P10657658A0165|105 139|kappa B-linked reporter gene expression
P10657658A0165|105 129|kappa B-linked reporter gene
P10657658A0165|144 165|ICAM-1 promoter activity
P10657658A0165|144 157|ICAM-1 promoter
P10657658A0165|170 194|NF-kappa B-dependent manner
P10657658A0165|170 178|NF-kappa B
P10657899A0685|0 11|Pretreatment
P10657899A0685|14 18|cells
P10657899A0685|21 29|mouse skin
P10657899A0685|34 58|antisense oligonucleotides
P10657899A0685|61 95|PKCzeta impaired UV-induced activation
P10657899A0685|61 67|PKCzeta
P10657899A0685|98 101|AP-1
P10657899A0685|104 111|JB6 cells
P10657899A0685|122 150|AP-1-luciferase transgenic mice
P10657899A0685|122 125|AP-1
P10657899A0685|127 136|luciferase
P10658425A1567|10 29|subclinical infection
P10658425A1567|35 35|%
P10658425A1567|41 56|seropositive dogs
P10658445A0208|0 6|METHODS
P10658445A0208|11 21|former group
P10658445A0208|30 37|patients
P10658445A0208|70 92|PGE1 alpha-ciclodestrina
P10658445A0208|94 118|short-term treatment cycles
P10658445A0208|144 167|historical reference group
P10658445A0208|182 195|prostaglandins
P10658588A0304|0 26|Desmethylferrochloroquine 1a
P10658588A0304|30 56|didesmethylferrochloroquine
P10658588A0304|69 74|potent
P10658588A0304|82 95|schizontocides
P10658588A0304|100 101|CQ
P10658588A0304|119 125|strains
P10658588A0304|127 129|HB3
P10658588A0304|133 135|Dd2
P10658588A0304|139 158|Plasmodium falciparum
P10660069A0819|3 19|rrd1,2delta mutant
P10660069A0819|41 52|inactivation
P10660069A0819|55 58|HOG1
P10660069A0819|61 64|PBS2
P10660069A0819|99 106|RRD genes
P10660069A0819|113 142|Hog1p signal transduction pathway
P10660069A0819|113 117|Hog1p
P10660304A0522|0 6|Members
P10660304A0522|12 24|JAK/Tyk family
P10660304A0522|12 14|JAK
P10660304A0522|16 18|Tyk
P10660304A0522|27 41|tyrosine kinases
P10660304A0522|49 63|phosphorylation
P10660304A0522|66 70|STAT3
P10660304A0522|73 78|Tyr705
P10660304A0522|85 97|CNTF signaling
P10660304A0522|85 88|CNTF
P10660304A0522|110 126|kinase responsible
P10660304A0522|130 144|phosphorylation
P10660304A0522|147 157|STAT3 Tyr727
P10660304A0522|147 151|STAT3
P10660304A0522|182 202|extracellular stimulus
P10660304A0522|209 223|cellular context
P10660604A0748|7 22|CARbeta/RXRalpha
P10660604A0748|7 13|CARbeta
P10660604A0748|15 22|RXRalpha
P10660604A0748|32 44|transcription
P10660604A0748|51 84|HD-PPRE luciferase reporter construct
P10660676A0000|0 15|Zebrafish cyclops
P10660676A0000|9 15|cyclops
P10660676A0000|17 19|cyc
P10660676A0000|29 56|Transforming Growth Factor beta
P10660676A0000|41 56|Growth Factor beta
P10660676A0000|58 64|TGFbeta
P10660676A0000|66 80|signaling factor
P10660676A0000|97 106|mouse Nodal
P10662550A0679|5 8|SOX8
P10662550A0679|12 28|good candidate gene
P10662550A0679|46 71|mental retardation phenotype
P10662550A0679|78 91|ATR-16 patients
P10662614A0000|3 20|genome organization
P10662614A0000|26 63|mite-transmitted wheat streak mosaic virus
P10662614A0000|65 68|WSMV
P10662614A0000|93 99|members
P10662614A0000|105 115|Potyviridae
P10662614A0000|120 137|monopartite genomes
P10662614A0000|150 184|substantial amino acid dissimilarities
P10662614A0000|189 214|other potyviral polyproteins
P10662614A0972|3 17|two-hybrid assay
P10662614A0972|39 54|full-length genes
P10662614A0972|57 58|CI
P10662614A0972|60 65|HC-Pro
P10662614A0972|67 68|P1
P10662614A0972|70 71|P3
P10662614A0972|76 77|CP
P10662614A0972|84 107|heterologous interactions
P10663558T0000|0 27|Diverse endogenous light chains
P10663558T0000|40 65|basement membrane reactivity
P10663558T0000|68 94|nonautoimmune mice transgenic
P10663558T0000|100 123|anti-laminin Ig heavy chain
P10663558T0000|100 111|anti-laminin
P10663558T0000|112 123|Ig heavy chain
P10664876A0000|0 8|Patch test
P10664876A0000|28 57|corticosteroid allergic patients
P10664876A0000|69 93|large corticosteroid series
P10664876A0000|106 126|earlier classification
P10664876A0000|129 151|corticosteroid molecules
P10664876A0000|158 163|groups
P10664876A0000|180 188|molecules
P10664876A0000|195 200|group A
P10664876A0000|202 219|hydrocortisone type
P10664876A0000|222 227|group B
P10664876A0000|229 238|acetonides
P10664876A0000|241 246|group C
P10664876A0000|248 268|betamethasone type-non
P10664876A0000|283 288|group D
P10664876A0000|290 295|esters
P10665308T0001|0 9|Mechanisms
P10665308T0001|12 24|tachyphylaxis
P10665308T0001|27 44|regional anesthesia
P10665308T0001|47 58|long duration
P10665798A0598|22 33|serum enzymes
P10665798A0598|41 61|aspartate transaminase
P10665798A0598|63 81|alkaline phosphatase
P10665798A0598|83 103|creatine phosphokinase
P10665798A0598|105 124|lactate dehydrogenase
P10665798A0598|130 153|D. russelli venom injection
P10665798A0598|156 165|albino rats
P10665798A0598|168 177|indicative
P10665798A0598|186 197|tissue damage
P10665949A1131|3 19|partial farm budget
P10665949A1131|54 72|sub-clinical lesions
P10665949A1131|76 82|feedlot
P10666222A0330|14 48|full-length murine survivin cDNA clones
P10666222A0330|87 110|distinct survivin proteins
P10666238A1322|8 16|induction
P10666238A1322|19 28|E2F binding
P10666238A1322|19 21|E2F
P10666238A1322|34 46|E2F-1 promoter
P10666238A1322|52 55|E4-6
P10666238A1322|94 108|transactivation
P10666238A1322|111 131|E2F-1 promoter activity
P10666238A1322|111 123|E2F-1 promoter
P10666253A1291|10 22|stabilization
P10666253A1291|28 34|hairpin
P10666253A1291|53 62|tRNA primer
P10666253A1291|82 84|PBS
P10666509A0494|0 34|Ischemia-induced biphasic arrhythmias
P10666509A0494|55 65|zatebradine
P10666509A0494|69 85|propranolol groups
P10667597A0668|0 2|ZK7
P10667597A0668|6 15|HZF16 genes
P10667597A0668|29 42|splice variants
P10667597A0668|61 68|same gene
P10668701A1311|0 9|CONCLUSION
P10668701A1311|11 18|Presence
P10668701A1311|21 34|APOE epsilon4/*
P10668701A1311|21 32|APOE epsilon4
P10668701A1311|60 67|dementia
P10668701A1311|71 72|AD
P10668701A1311|99 110|dyslipidemia
P10668701A1311|114 126|atherogenesis
P10669319A1722|2 20|definite conclusions
P10669319A1722|44 54|small number
P10669319A1722|57 64|patients
P10669594A0000|11 28|Salmonella fimbrins
P10669594A0000|21 28|fimbrins
P10669594A0000|30 33|AgfA
P10669594A0000|37 40|SefA
P10669594A0000|52 79|thin aggregative fimbriae SEF17
P10669594A0000|75 79|SEF17
P10669594A0000|83 87|SEF14
P10669594A0000|138 140|PT3
P10669594A0000|144 191|alpha-helical 16-amino acid Leishmania T-cell epitope
P10669594A0000|206 224|metalloprotease gp63
P10669594A0000|206 220|metalloprotease
P10669594A0000|221 224|gp63
P10669594A0969|2 15|marked contrast
P10669594A0969|18 21|AgfA
P10669594A0969|32 51|chimeric SefA proteins
P10669594A0969|80 87|fimbriae
P10669596A0430|0 15|Productive growth
P10669596A0430|18 25|phage P22
P10669596A0430|28 36|wild-type
P10669596A0430|85 88|Abc2
P10669596A0430|111 123|absolute level
P10669596A0430|126 154|ATP-dependent nuclease activity
P10669596A0430|126 146|ATP-dependent nuclease
P10669596A0430|167 183|qualitative change
P10669596A0430|197 239|Abc2-modified RecBCD nuclease activity relative
P10669596A0430|197 200|Abc2
P10669596A0430|210 223|RecBCD nuclease
P10669596A0430|245 256|native enzyme
P10669633A0391|29 47|molecular mechanisms
P10669633A0391|61 79|inducible expression
P10669633A0391|85 93|flt-1 gene
P10669633A0391|103 112|activation
P10669633A0391|115 124|THP-1 cells
P10669633A0391|115 119|THP-1
P10669736A0903|9 26|2.4-fold difference
P10669736A0903|29 31|CAT
P10669736A0903|49 59|transcripts
P10669736A0903|62 70|HeLa cells
P10669736A0903|85 107|greater natural abundance
P10669736A0903|110 112|PTB
P10669751T0000|0 54|Multiple mitogen-activated protein kinase signaling pathways
P10669751T0000|8 37|mitogen-activated protein kinase
P10669751T0000|65 78|cot oncoprotein
P10669751T0000|84 96|c-jun promoter
P10669751T0000|102 123|cellular transformation
P10670358A0143|0 10|Dermatology
P10671224A0254|5 16|present study
P10671224A0254|38 56|regulatory mechanism
P10671224A0254|60 74|CD95L expression
P10671224A0254|60 64|CD95L
P10671519A0641|0 22|Protein sequence analysis
P10671519A0641|34 43|MAN1 shares
P10671519A0641|34 37|MAN1
P10671519A0641|54 67|globular domain
P10671519A0641|85 94|amino acids
P10671519A0641|110 118|LEM module
P10671519A0641|124 179|inner nuclear membrane proteins lamina-associated polypeptide
P10671519A0641|152 180|lamina-associated polypeptide 2
P10671519A0641|184 189|emerin
P10671520T0000|0 15|Molecular cloning
P10671520T0000|19 57|novel human I-mfa domain-containing protein
P10671520T0000|82 110|human T-cell leukemia virus type I
P10671520T0000|82 109|human T-cell leukemia virus type
P10671520T0000|114 128|HIV-1 expression
P10671520T0000|114 118|HIV-1
P10671554A0492|10 27|amino acid sequences
P10671554A0492|33 49|full-length bovine
P10671554A0492|53 64|porcine cDNAs
P10671554A0492|94 110|amino acid residues
P10671554A0492|166 181|Edman degradation
P10671606A0884|4 23|chemical shift imaging
P10671606A0884|28 42|signal intensity
P10671606A0884|57 74|out-of-phase images
P10671606A0884|90 90|%
P10671606A0884|92 99|patients
P10671606A0884|104 106|APA
P10671606A0884|126 126|%
P10671606A0884|128 135|patients
P10671606A0884|140 142|BAH
P10672433A0199|31 51|subjective measurement
P10672433A0199|54 60|bedtime
P10672433A0199|62 69|wake time
P10672433A0199|81 83|TIB
P10672433A0199|110 116|minutes
P10672433A0199|128 137|sleep onset
P10672433A0199|139 142|WASO
P10672433A0199|145 153|alertness
P10672433A0199|156 164|awakening
P10672899A0078|0 3|Acad
P10673335X0782|0 8|Copyright
P10673335X0782|13 25|Academic Press
P10673426A0168|11 11|R
P10673426A0168|35 58|receptor-binding activity
P10673426A0168|69 87|N-terminal (T) domain
P10673426A0168|69 78|N-terminal
P10673426A0168|80 80|T
P10673426A0168|96 108|translocation
P10673426A0168|130 154|C-terminal cytotoxic domain
P10673426A0168|175 182|receptor
P10673426A0168|197 208|cytotoxicity
P10674395A0262|57 80|reproductive neuropeptide
P10674395A0262|82 85|GnRH
P10674395A0262|103 124|glutamate/NO/cyclic GMP
P10674395A0262|126 129|cGMP
P10674395A0262|131 155|signal transduction pathway
P10674395A0262|163 189|cGMP-dependent protein kinase
P10674395A0262|195 241|hypothalamic GnRH-secreting neuronal cell line GT1-7
P10674484A0633|20 34|combined lesions
P10674484A0633|37 47|cholinergic
P10674484A0633|51 69|serotonergic neurons
P10674484A0633|75 82|rat brain
P10674484A0633|93 111|olfactory perception
P10674484A0633|114 138|olfactory short-term memory
P10675154T0000|0 13|Extreme potency
P10675154T0000|16 29|botulinum toxin
P10675331A0600|11 15|c-Src
P10675331A0600|27 39|isoproterenol
P10675331A0600|45 67|tyrosine phosphorylation
P10675331A0600|70 72|Shc
P10675331A0600|76 98|subsequent Erk activation
P10675331A0600|86 88|Erk
P10675331A0600|106 128|tyrosine phosphorylation
P10675331A0600|131 139|cortactin
P10675331A0600|142 146|Stat3
P10675610A0279|0 4|MSSPs
P10675610A0279|26 39|DNA replication
P10675610A0279|41 53|transcription
P10675610A0279|55 64|apopotosis
P10675610A0279|68 87|cell cycle progression
P10675610A0279|108 119|C-MYC protein
P10677214A1045|3 14|wild type MutT
P10677214A1045|11 14|MutT
P10677214A1045|21 24|E53D
P10677214A1045|28 38|E44D mutants
P10677214A1045|40 44|plots
P10677214A1045|51 51|k
P10677214A1045|64 65|pH
P10677214A1045|118 121|hump
P10677214A1045|154 155|pH
P10677214A1045|168 174|plateau
P10677214A1045|184 193|apparent pK
P10677214A1045|197 202|values
P10677214A1045|231 243|essential base
P10677214A1045|248 271|nonessential acid catalyst
P10677214A1045|291 313|active quaternary MutT-Mg
P10677214A1045|319 325|dGTP-Mg
P10677214A2842|0 16|Structural changes
P10677214A2842|37 53|damaged E44D mutant
P10677214A2842|67 67|H
P10677214A2842|73 84|N HSQC spectra
P10677214A2842|108 118|loop I-helix
P10677214A2842|120 124|motif
P10677214A2842|140 145|Glu-44
P10677214A2842|159 174|active site region
P10677297A0933|50 57|nonsense
P10677297A0933|61 77|missense mutations
P10677297A0933|99 124|altered subcellular location
P10677297A0933|147 151|cells
P10678144A0509|5 8|i.v.
P10678968A1096|0 7|Immunity
P10678968A1096|18 21|mice
P10678968A1096|28 54|I. scapularis nymphal activity
P10678968A1096|57 67|early summer
P10678968A1096|79 93|large proportion
P10678968A1096|99 113|mouse population
P10678968A1096|129 144|E. phagocytophila
P10678968A1096|162 175|larval activity
P10679015A0216|22 28|studies
P10679015A0216|31 35|yeast
P10679015A0216|53 59|snoRNPs
P10679015A0216|73 81|unique set
P10679015A0216|84 91|proteins
P10679065A0711|0 15|BCR cross-linking
P10679065A0711|0 2|BCR
P10679065A0711|34 70|MAPK-activated protein kinase-2 activity
P10679065A0711|34 62|MAPK-activated protein kinase-2
P10679065A0711|74 79|enzyme
P10679065A0711|113 119|p38 MAPK
P10679065A0711|121 164|MAPK-activated protein kinase-2 immune complexes
P10679065A0711|180 195|peptide substrate
P10679065A0711|209 241|CREB serine 133 phosphoacceptor motif
P10679065A0711|209 218|CREB serine
P10679065A0711|222 241|phosphoacceptor motif
P10679065A1217|0 9|Activation
P10679065A1217|13 70|CRE-dependent junB promoter/chloramphenicol acetyltransferase
P10679065A1217|26 37|junB promoter
P10679065A1217|39 70|chloramphenicol acetyltransferase
P10679065A1217|72 74|CAT
P10679065A1217|76 87|reporter gene
P10679065A1217|93 95|BCR
P10679065A1217|112 119|SB203580
P10679190A0693|24 47|upstream open reading frame
P10679190A0693|49 52|uORF
P10679190A0693|82 112|downstream major open reading frame
P10679190A0693|114 117|mORF
P10679649A0311|0 6|METHODS
P10679649A0311|8 22|TBN measurements
P10679649A0311|40 56|female outpatients
P10679649A0311|61 75|breast carcinoma
P10679649A0311|93 116|standard cyclophosphamide
P10679649A0311|118 129|methotrexate
P10679649A0311|134 147|5-fluorouracil
P10679649A0311|149 151|CMF
P10679649A0311|159 170|chemotherapy
P10679649A0311|172 180|median age
P10679649A0311|184 188|years
P10679649A0311|201 205|years
P10679781A1183|4 31|bp Glucocorticoid Response Unit
P10679781A1183|33 35|GRU
P10679781A1183|55 77|glucocorticoid induction
P10679781A1183|91 104|dibutyryl-cAMP
P10679781A1183|117 129|phorbol esters
P10679922A1110|2 17|somatic mutations
P10679922A1110|37 43|samples
P10679922A1110|59 62|ING1
P10679922A1110|69 93|tumor suppressor gene target
P10679922A1110|103 112|neck cancer
P10681520A0525|0 7|Ras-GRF1
P10681520A0525|0 2|Ras
P10681520A0525|4 7|GRF1
P10681520A0525|32 36|v-Src
P10681520A0525|40 62|tyrosine-phosphorylated
P10681520A0525|72 93|significant GEF activity
P10681520A0525|100 102|Rac
P10681520A0525|110 112|Rho
P10681520A0525|116 120|Cdc42
P10681520A0525|157 166|Gbetagamma
P10681562A0263|4 31|complete PPARgamma antagonists
P10681562A0263|12 20|PPARgamma
P10681562A0263|76 106|dominant-negative mutant receptor
P10681562A0263|116 139|wild-type PPARgamma action
P10681562A0263|125 133|PPARgamma
P10681588A0899a|0 3|EMSA
P10681588A0899a|14 28|nuclear proteins
P10681588A0899a|33 36|PC12
P10681588A0899a|43 44|C6
P10681588A0899a|47 55|Rat2 cells
P10681588A0899a|63 65|CRE
P10681588A0899a|96 114|transcription factor
P10681588A0899a|116 121|ATF)-4
P10681588A0899a|116 118|ATF
P10681588A0899a|125 156|CCAAT enhancer-binding protein beta
P10681588A0899a|167 170|PC12
P10681588A0899a|174 194|C6 cell nuclear extracts
P10681588A0899a|213 221|CCAAT-box
P10681588A0899a|242 256|nuclear factor Y.
P10681588A0899b|0 3|EMSA
P10681588A0899b|14 28|nuclear proteins
P10681588A0899b|33 36|PC12
P10681588A0899b|43 44|C6
P10681588A0899b|47 55|Rat2 cells
P10681588A0899b|63 65|CRE
P10681588A0899b|96 114|transcription factor
P10681588A0899b|116 121|ATF)-4
P10681588A0899b|116 118|ATF
P10681588A0899b|125 156|CCAAT enhancer-binding protein beta
P10681588A0899b|167 170|PC12
P10681588A0899b|174 194|C6 cell nuclear extracts
P10681588A0899b|213 221|CCAAT-box
P10681588A0899b|242 256|nuclear factor Y.
P10681679A0220|22 33|solid portion
P10681679A0220|45 53|serial MRI
P10681679A0220|60 70|enlargement
P10681679A0220|74 89|bilobar tumor cyst
P10681679A0220|91 95|years
P10681679A0220|104 120|original diagnosis
P10682570A0453|0 2|LPO
P10682570A0453|6 14|SOD levels
P10682570A0453|6 8|SOD
P10682570A0453|33 38|points
P10683072T0000|0 30|Sustained ventricular tachycardia
P10683072T0000|37 57|successful prophylaxis
P10683072T0000|64 97|high-dose bolus interleukin-2 therapy
P10683072T0000|78 90|interleukin-2
P10683072T0000|101 128|metastatic renal cell carcinoma
P10683244A0939|14 26|NBF1+R protein
P10683244A0939|14 17|NBF1
P10683244A0939|19 26|R protein
P10683244A0939|31 41|NBF2 protein
P10683244A0939|62 69|proteins
P10683244A0939|103 129|molecular sieve chomatography
P10683244A0939|169 174|NBF1+R
P10683244A0939|169 172|NBF1
P10683244A0939|174 174|R
P10683244A0939|177 180|NBF2
P10683244A1860|18 28|experiments
P10683244A1860|44 47|CFTR
P10683244A1860|50 61|NBF1+R region
P10683244A1860|50 53|NBF1
P10683244A1860|55 61|R region
P10683244A1860|68 77|NBF2 domain
P10683244A1860|84 90|folding
P10683244A1860|103 115|distinct units
P10683244A1860|122 137|strong propensity
P10683244A1860|197 207|nucleotides
P10683244A1860|228 242|phosphorylation
P10683244X2359|0 8|Copyright
P10683244X2359|13 25|Academic Press
P10683259A0774|0 18|Sulfhydryl titration
P10683259A0774|23 35|iodoacetamide
P10683259A0774|63 76|residual thiols
P10683259A0774|95 113|maleimide derivative
P10683259A0774|116 121|biotin
P10683259A0774|132 149|striking difference
P10683259A0774|155 164|apparent pK
P10683259A0774|168 173|values
P10683259A0774|179 187|cysteines
P10683259A0774|196 210|splice junctions
P10683989A0251|5 25|nitric oxide inhalation
P10683989A0251|30 36|results
P10683989A0251|43 59|moderate increases
P10683989A0251|62 65|PaO2
P10683989A0251|69 72|SaO2
P10683989A0251|74 74|P
P10683989A0251|85 103|significant decrease
P10683989A0251|106 117|Qs/Q tau ratio
P10683989A0251|119 119|P
P10684069A0508|3 9|results
P10684069A0508|20 22|MIP
P10684069A0508|24 27|MMIF
P10684069A0508|29 31|FIC
P10684069A0508|33 37|Wimax
P10684069A0508|39 42|P0.1
P10684069A0508|46 62|minute ventilation
P10684069A0508|64 65|Vr
P10684069A0508|114 129|methylphenidatum
P10684069A0508|133 145|aminophylline
P10684097A0175|5 26|4-month old SD female rats
P10684097A0175|54 59|groups
P10684097A0175|67 79|sham operation
P10684097A0175|81 100|bilateral ovariectomy
P10684097A0175|102 112|ovariectomy
P10684097A0175|117 145|supplementary ethinyl estradiol
P10684097A0175|163 165|g B.
P10684111A1411|32 51|extracellular factors
P10684111A1411|68 74|MAPK p44
P10684111A1411|68 71|MAPK
P10684111A1411|72 74|p44
P10684111A1411|78 84|MAPK p42
P10684111A1411|78 81|MAPK
P10684111A1411|82 84|p42
P10684111A1411|87 103|MAPK family members
P10684111A1411|87 90|MAPK
P10684265T0000|0 19|Covalent modification
P10684265T0000|25 52|transactivator protein IE2-p86
P10684265T0000|55 74|human cytomegalovirus
P10684265T0000|77 87|conjugation
P10684265T0000|93 126|ubiquitin-homologous proteins SUMO-1
P10684265T0000|93 120|ubiquitin-homologous proteins
P10684265T0000|121 126|SUMO-1
P10684265T0000|130 135|hSMT3b
P10684304A1242|21 21|U
P10684304A1242|23 23|L
P10684534A0634|0 8|Protamine
P10684534A0634|12 23|heparin doses
P10684534A0634|34 43|Sigma-dose
P10684534A0634|48 59|differential
P10684534A0634|61 70|Delta-dose
P10684534A0634|72 76|doses
P10684534A0634|90 102|clotting times
P10684646A0224|13 27|common mechanism
P10684646A0224|70 91|FC-dependent expression
P10684646A0224|94 101|caveolin
P10684660A1266|0 9|Comparison
P10684660A1266|15 30|plant nuclear tRNA
P10684660A1266|33 48|processing enzyme
P10684660A1266|56 73|plant mitochondrial
P10684660A1266|93 102|activities
P10684660A1266|106 121|different enzymes
P10684941A0722|18 32|complementarity
P10684941A0722|37 52|ligation reaction
P10684941A0722|67 73|results
P10684941A0722|79 90|nt insertions
P10684941A0722|119 122|nick
P10684967A0000|0 5|NKX2.1
P10684967A0000|20 28|NK2 family
P10684967A0000|31 72|homeodomain-containing transcription factors
P10684967A0000|78 95|targeted disruption
P10684967A0000|124 136|thyroid tissue
P10684967A0000|149 169|abnormal lung phenotype
P10687366A0000|0 19|National abortion laws
P10687366A0000|50 55|foetus
P10687366A0000|71 76|viable
P10687366A0000|87 100|gestational age
P10687366A0000|110 114|weeks
P10687855A1197|0 9|Expression
P10687855A1197|12 34|early postnatal pituitary
P10687855A1197|40 61|pre-somatotrophic cells
P10687855A1197|74 78|Zn-16
P10687855A1197|95 114|pituitary development
P10687855A1197|122 147|somatotroph differentiation
P10687855T0000|0 41|Mouse growth hormone transcription factor Zn-16
P10687855T0000|43 66|unique bipartite structure
P10687855T0000|93 109|zinc finger domains
P10687855T0000|123 130|rat Zn-15
P10687862A1980|3 26|CCAAT core sequence mutants
P10687862A1980|38 41|CIII
P10687862A1980|45 50|CI/CII
P10687862A1980|81 96|promoter activity
P10687945A0000|0 10|Deglutition
P10687945A0000|27 34|immature
P10687945A0000|37 43|infants
P10688639A1310|4 13|repression
P10688639A1310|31 49|PU.1 transactivation
P10688639A1310|31 34|PU.1
P10688639A1310|52 62|PEST domains
P10688639A1310|84 97|p300 expression
P10688639A1310|84 87|p300
P10688646A0535|6 28|human erythroid K562 cells
P10688646A0535|49 70|various HS-40 mutants cis
P10688646A0535|80 128|human alpha-globin promoter-growth hormone hybrid gene
P10688646A0535|143 161|genomic footprinting
P10688646A0535|165 182|expression analysis
P10688660A0992|32 34|CBP
P10688660A0992|40 54|nuclear extracts
P10688660A0992|57 65|T47D cells
P10688660A0992|84 95|progesterone
P10688660A0992|100 124|PR-dependent transcription
P10688660A0992|130 144|nucleosome-free
P10688660A0992|146 172|progesterone response element
P10688660A0992|174 176|PRE
P10688660A0992|185 203|reporter DNA template
P10688661A0237|3 23|cognate binding protein
P10688661A0237|25 33|REST/NRSF
P10688661A0237|25 28|REST
P10688661A0237|30 33|NRSF
P10688661A0237|39 66|essential transcription factor
P10688661A0237|71 83|null mutations
P10688661A0237|92 109|embryonic lethality
P10688661A0237|117 139|dominant negative mutants
P10688661A0237|147 164|aberrant expression
P10688661A0237|167 186|neuron-specific genes
P10688663A0207|0 6|Removal
P10688663A0207|12 33|core histone tail domains
P10688663A0207|36 60|limited trypsin proteolysis
P10688663A0207|63 73|acetylation
P10688663A0207|79 94|core histone tails
P10688663A0207|120 129|inhibition
P10688663A0207|139 144|TFIIIA
P10688663A0207|154 166|high-affinity
P10688663A0207|176 189|nucleosomal DNA
P10688666A1010|22 35|ASK1 activation
P10688666A1010|22 25|ASK1
P10688666A1010|52 71|homo-oligomerization
P10690702A0065|0 6|OUTCOME
P10690702A0065|8 38|Acetylcholine receptor antibodies
P10690702A0065|42 67|single-fibre electromyogram
P10690702A0065|94 109|myasthenia gravis
P10690725A1037|3 15|other patients
P10690725A1037|25 28|PRFR
P10690866A0783|3 12|variations
P10690866A0783|25 38|opposite shifts
P10690866A0783|41 64|TSH frequency distribution
P10690866A0783|67 73|mothers
P10690866A0783|77 84|neonates
P10691972T0000|0 15|Characterization
P10691972T0000|24 37|flanking region
P10691972T0000|43 73|human multidrug resistance protein
P10691972T0000|76 79|MRP2
P10691972T0000|103 145|comparison withthe multidrug resistance protein
P10691972T0000|120 146|multidrug resistance protein 3
P10691972T0000|148 151|MRP3
P10692167A0364|38 60|preliminary observations
P10692167A0364|63 72|M. synoviae
P10692374A1873|5 11|results
P10692374A1873|26 37|M. jannaschii
P10692374A1873|46 74|related archaeal 20S proteasomes
P10692374A1873|53 74|archaeal 20S proteasomes
P10692374A1873|83 105|nucleotidase complex such
P10692374A1873|108 110|PAN
P10692374A1873|123 148|energy-dependent hydrolysis
P10692374A1873|151 174|folded-substrate proteins
P10692374A1873|185 194|N-terminal
P10692374A1873|197 213|amino acid residues
P10692374A1873|216 218|PAN
P10692433A0000|3 24|transcription factor E2F
P10692433A0000|22 24|E2F
P10692433A0000|32 44|important role
P10692433A0000|47 49|G(1
P10692433A0000|47 47|G
P10692433A0000|53 68|S phase transition
P10692433A0000|74 98|higher eukaryotic cell cycle
P10693246A0252|2 25|two-field nodal dissection
P10693246A0252|30 39|components
P10693246A0252|56 70|modern two-field
P10693246A0252|82 101|traditional two-field
P10693246A0252|103 117|nodal dissection
P10693246A0252|128 156|recurrent laryngeal nerve chains
P10693246A0252|162 177|upper mediastinum
P10693314A0521|8 15|patients
P10693314A0521|24 35|CK-MB results
P10693314A0521|24 28|CK-MB
P10693314A0521|55 55|%
P10693314A0521|57 64|patients
P10693314A0521|66 68|ECG
P10693314A0521|77 79|AMI
P10693314A0521|87 87|%
P10693314A0521|89 96|patients
P10694189A0469|11 13|MIB
P10694189A0469|19 36|dose-response curve
P10694189A0469|56 68|noradrenaline
P10694210A0385|3 18|regional blockade
P10694210A0385|21 23|H1R
P10694210A0385|46 52|frontal
P10694210A0385|54 61|temporal
P10694210A0385|65 89|anterior cingulate cortices
P10694210A0385|97 121|intravenous administration
P10694210A0385|124 141|d-chlorpheniramine
P10694210A0385|145 159|therapeutic dose
P10694210A0385|162 163|mg
P10694210A0385|178 178|%
P10694210A0385|181 183|H1R
P10694210A0385|189 203|frontal cortices
P10694511A0570|18 21|yam8
P10694511A0570|25 28|cDNA
P10694511A0570|34 48|mid1 mutant cells
P10694511A0570|34 43|mid1 mutant
P10694511A0570|71 82|mid phenotype
P10694511A0570|97 110|slight increase
P10694511A0570|113 114|Ca
P10694511A0570|119 132|uptake activity
P10694605A1327|10 30|overall infection rates
P10694605A1327|32 53|events/100 patient-days
P10694605A1327|71 80|heart-lung
P10694605A1327|97 107|double-lung
P10694605A1327|109 112|P = NS
P10694605A1327|117 122|months
P10694609A0309|0 5|Static
P10694609A0309|9 25|dynamic compliance
P10694609A0309|42 50|induction
P10694609A0309|53 62|anesthesia
P10694609A0309|89 98|filtration
P10694609A0309|104 119|operating theater
P10694609A0309|142 167|pediatric intensive care unit
P10694609A0309|174 178|hours
P10695685T0000|0 17|Antipyretic therapy
P10695685T0000|19 38|physiologic rationale
P10695685T0000|40 61|diagnostic implications
P10695685T0000|66 85|clinical consequences
P10696007A1325|27 45|C2-C3 disk morphology
P10698516T0000|0 2|KFC
P10698516T0000|5 20|Ste20-like kinase
P10698516T0000|25 42|mitogenic potential
P10698516T0000|69 83|SAPK/JNK pathway
P10698516T0000|69 72|SAPK
P10698516T0000|74 76|JNK
P10698937T0000|0 4|TIP30
P10698937T0000|10 32|intrinsic kinase activity
P10698937T0000|44 56|up-regulation
P10698937T0000|60 65|subset
P10698937T0000|68 81|apoptotic genes
P10698974A0951|15 28|human STAG3 gene
P10698974A0951|34 43|7q22 region
P10698974A0951|46 55|chromosome
P10698974A0951|61 83|human STAG3-related genes
P10698974A0951|119 132|functional gene
P10698974A0951|185 195|breakpoints
P10698974A0951|221 248|Williams-Beuren syndrome (WBS)
P10698974A0951|221 243|Williams-Beuren syndrome
P10698974A0951|245 247|WBS
P10698974A0951|249 256|deletion
P10699354A0557|0 11|Reaction time
P10699354A0557|13 14|RT
P10699354A0557|19 22|P300
P10699653A0967|16 19|rats
P10699653A0967|23 32|free access
P10699653A0967|38 44|bottles
P10699653A0967|65 72|tap water
P10699653A0967|102 108|ethanol
P10699653A0967|111 111|%
P10699653A0967|116 122|sucrose
P10699653A0967|125 125|%
P10699684A0661|12 16|Zelen
P10699684A0661|51 58|patients
P10699684A0661|76 81|groups
P10699684A0661|104 105|M.
P10699896A0455|0 6|RESULTS
P10699896A0455|21 28|patients
P10699896A0455|30 39|male gender
P10699896A0455|41 42|P =
P10700262A0000|0 23|Selective visual attention
P10700262A0000|32 47|dynamic interplay
P10700262A0000|55 79|attentional control systems
P10700262A0000|83 104|sensory brain structures
P10701534A0164|22 50|left-sided low-frequency tremor
P10701534A0164|54 65|hemidystonia
P10701534A0164|72 87|severe head trauma
P10701534A0164|101 105|years
P10702241A0357|11 19|a1 isoform
P10702241A0357|58 59|a2
P10702241A0357|70 75|kidney
P10702241A0357|80 81|a3
P10702241A0357|107 112|spleen
P10702241A0357|117 122|kidney
P10702253A0357|9 15|cloning
P10702253A0357|18 61|reverse transcriptase-polymerase chain reaction
P10702253A0357|18 53|reverse transcriptase-polymerase chain
P10702253A0357|67 88|human HIF-1alpha subunit
P10702253A0357|103 112|cDNA clones
P10702253A0357|132 150|alternative splicing
P10702253A0357|156 169|HIF-1alpha gene
P10702285A0855|30 30|G
P10702285A0855|32 32|q
P10702285A0855|35 35|G
P10702285A0855|55 98|phosphatidylinositol 3-kinase dependent pathway
P10702285A0855|55 82|phosphatidylinositol 3-kinase
P10702285A0855|113 152|dominant-interfering p85 regulatory subunit
P10702285A0855|133 152|p85 regulatory subunit
P10702285A0855|162 180|wortmannin treatment
P10702285A0855|190 207|insulin-stimulated
P10702285A0855|190 196|insulin
P10702285A0855|214 223|G(q)/Q209L
P10702285A0855|214 214|G
P10702285A0855|216 216|q
P10702285A0855|219 257|Q209L-stimulated GLUT4-EGFP translocation
P10702285A0855|235 239|GLUT4
P10702285A0855|241 244|EGFP
P10702389A1148|2 10|endemic BL
P10702389A1148|15 26|RB2/p130 gene
P10702389A1148|15 17|RB2
P10702389A1148|19 26|p130 gene
P10702389A1148|47 51|cases
P10702389A1148|68 77|restricted
P10702389A1148|83 91|cytoplasm
P10702794A1495|26 29|ERK2
P10702794A1495|44 55|direct target
P10702794A1495|58 62|HePTP
P10702794A1495|96 100|HePTP
P10702794A1495|120 131|ERK2 activity
P10702794A1495|120 123|ERK2
P10702794A1495|141 157|feedback mechanism
P10702926T0089|0 13|Cross-reaction
P10702926T0089|22 39|monoclonal antibody
P10702926T0089|46 68|alpha beta T cell receptors
P10703633A0747|0 15|Strontium nitrate
P10703633A0747|25 36|glycolic acid
P10703633A0747|54 65|glycolic acid
P10703633A0747|81 81|p
P10703633A0747|100 107|duration
P10703633A0747|113 131|irritation sensation
P10703633A0747|154 156|SEM
P10703633A0747|158 160|min
P10703633A0747|180 182|SEM
P10703633A0747|184 186|min
P10703633A0747|205 205|p
P10703633A0747|222 234|mean magnitude
P10703633A0747|240 258|irritation sensation
P10703633A0747|264 273|time points
P10704196A1051|3 32|pCMBS-reactive sulfhydryl groups
P10704196A1051|37 43|located
P10704196A1051|60 72|exofacial half
P10704196A1051|78 91|plasma membrane
P10704196A1051|112 123|helical model
P10704196A1051|145 151|helices
P10704283A0649a|0 7|Analysis
P10704283A0649a|11 12|Mb
P10704283A0649a|56 62|synteny
P10704283A0649a|65 87|human chromosome 5q31-q33
P10704283A0649a|100 113|gene candidates
P10704283A0649a|135 139|genes
P10704283A0649a|145 172|human IL-4 cytokine gene cluster
P10704285A0536|0 11|Human AP-2rep
P10704285A0536|25 42|reporter expression
P10704285A0536|70 86|AP-2alpha promoter
P10704285A0536|93 115|endogenous AP-2alpha gene
P10704285A0536|103 115|AP-2alpha gene
P10704285A0536|152 160|AP-2alpha
P10704338A0354|13 25|deeper insight
P10704338A0354|42 61|amino-terminal domain
P10704338A0354|67 69|p24
P10704338A0354|71 72|CA
P10704338A0354|87 102|viral replication
P10704338A0354|124 138|proline residues
P10704338A0354|153 157|turns
P10704338A0354|172 184|alpha-helices
P10704338A0354|194 213|p24 tertiary structure
P10704338A0354|194 196|p24
P10704338A0354|229 242|leucine residue
P10704338A0354|244 255|P-position-L
P10704410T0000|0 15|Clb/Cdc28 kinases
P10704410T0000|0 2|Clb
P10704410T0000|23 35|nuclear export
P10704410T0000|41 74|replication initiator proteins Mcm2-7
P10704410T0000|69 72|Mcm2
P10704499A0682|14 25|PC12-E2 cells
P10704499A0682|54 63|antibodies
P10704499A0682|69 90|fibroblast growth factor
P10704499A0682|92 103|FGF) receptor
P10704499A0682|92 94|FGF
P10704499A0682|96 103|receptor
P10704499A0682|105 114|inhibitors
P10704499A0682|120 147|nonreceptor tyrosine kinase p59
P10704499A0682|149 151|fyn
P10704499A0682|154 156|PLC
P10704499A0682|158 160|PKC
P10704499A0682|164 166|MEK
P10704499A0682|172 180|activator
P10704499A0682|183 185|PKC
P10704499A0682|187 217|phorbol-12-myristate-13-acetate
P10704499A0682|219 221|PMA
P10704853T0000|0 15|Cooperative roles
P10704853T0000|18 31|Bozozok/Dharma
P10704853T0000|18 24|Bozozok
P10704853T0000|26 31|Dharma
P10704853T0000|35 55|Nodal-related proteins
P10704853T0000|75 89|dorsal organizer
P10704853T0000|92 100|zebrafish
P10704975A0479|0 16|Thiopentone sodium
P10704975A0479|38 40|min
P10704975A0479|58 60|min
P10704975A0479|76 80|NOC-5
P10704975A0479|122 144|NO-induced neurotoxicity
P10704975A0479|157 164|controls
P10705380A0629|34 51|Xretpos transcripts
P10705380A0629|55 64|restricted
P10705380A0629|67 97|ventro-posterior specific regions
P10705380A0629|110 123|UV-irradiation
P10705380A0629|127 145|BMP-4 overexpression
P10705380A0629|127 131|BMP-4
P10705380A0629|148 173|cycloheximide-dependent way
P10705380A0629|175 181|genesis
P10705783A0433|5 14|other cases
P10705783A0433|16 35|vestibular neurectomy
P10705783A0433|38 70|chemical vestibular labyrinthectomy
P10705783A0433|74 78|means
P10705783A0433|81 119|intratympanic low concentration gentamicin
P10705783A0433|123 127|mg/mL
P10706475A0644|27 30|DSPP
P10706475A0644|44 46|DSP
P10706475A0644|50 52|DPP
P10706513A0843|6 19|grave prognosis
P10706513A0843|27 36|% mortality
P10706513A0843|40 45|months
P10706513A0843|54 74|mechanical ventilation
P10706688A0376|11 22|TCR signaling
P10706688A0376|11 13|TCR
P10706688A0376|30 40|AP-1 binding
P10706688A0376|30 33|AP-1
P10706688A0376|66 85|fasl promoter function
P10706688A0376|66 77|fasl promoter
P10706688A0376|89 104|fashion dependent
P10706688A0376|107 122|NF-kappaB binding
P10706688A0376|107 115|NF-kappaB
P10706736A1091|5 12|patients
P10706736A1091|17 34|metastatic melanoma
P10706736A1091|41 48|tolerant
P10706736A1091|51 57|gp100 Ag
P10706736A1091|56 57|Ag
P10706736A1091|68 76|detection
P10706736A1091|79 81|CD8
P10706736A1091|83 96|T cells specific
P10706736A1091|100 112|multiple HLA-A
P10706736A1091|108 117|HLA-A*0201
P10706736A1091|114 128|0201-restricted
P10706736A1091|130 150|gp100-derived epitopes
P10706887A0281|15 15|%
P10706887A0281|18 22|ALCLs
P10706887A0281|34 36|ALK
P10706887A0281|52 52|t
P10706887A0281|73 97|other genetic abnormalities
P10706887A0281|109 129|aberrant ALK expression
P10706887A0281|117 119|ALK
P10706887A1457|19 27|decreases
P10706887A1457|30 50|ATIC enzymatic function
P10706887A1457|53 80|ATIC-ALK-containing lymphomas
P10706887A1457|53 56|ATIC
P10706887A1457|58 60|ALK
P10706887A1457|95 100|tumors
P10706887A1457|116 134|antifolate drugs such
P10706887A1457|137 148|methotrexate
P10708243A0000|27 54|non-organ-specific antibodies
P10708243A0000|69 81|pregnancy loss
P10708243A0000|85 96|preeclampsia
P10708243A0000|107 130|organ-specific antibodies
P10708424A0800|0 12|Manganese ions
P10708424A0800|38 56|autophosphorylation
P10708424A0800|59 63|BGLF4
P10708424A0800|68 76|magnesium
P10708769A0433|3 22|Mif1 5' flanking region
P10708769A0433|3 6|Mif1
P10708769A0433|9 22|flanking region
P10708769A0433|32 67|functional ER stress-responsive element
P10708769A0433|88 96|induction
P10708769A0433|99 109|tunicamycin
P10709705T0000|0 28|Rigid point feature registration
P10709705T0000|34 50|mutual information
P10710499A0000|0 11|Methysergide
P10710499A0000|15 33|serotonin antagonist
P10710499A0000|64 77|wound blood flow
P10710499A0000|81 94|edema formation
P10710742T0000|0 24|Serum leptin concentrations
P10710742T0000|5 10|leptin
P10710742T0000|27 31|women
P10710742T0000|38 66|gonadotropin stimulation cycles
P10710742T0000|38 49|gonadotropin
P10710985T0000|7 14|families
P10710985T0000|16 33|social work practice
P10710985T0000|38 45|families
P10710985T0000|51 70|strengths perspective
P10711674A0000|0 6|PURPOSE
P10711674A0000|9 51|two-generation consanguineous Pakistani family
P10711674A0000|56 97|autosomal recessive Leber congenital amaurosis
P10711674A0000|99 101|LCA
P10711674A0000|103 105|MIM
P10711674A0000|117 127|keratoconus
P10712512A0506|0 5|Ste18p
P10712512A0506|22 35|plasma membrane
P10712512A0506|54 64|prenylation
P10712512A0506|67 79|thioacylation
P10712599A0349|15 19|IRF-1
P10712599A0349|36 62|ubiquitin-proteasome pathway
P10712599A0349|36 55|ubiquitin-proteasome
P10712618A0181|2 29|amino-acid sequence comparison
P10712618A0181|42 64|Bacillus YM55-1 aspartase
P10712618A0181|73 81|% homology
P10712618A0181|86 110|Bacillus subtilis aspartase
P10712618A0181|116 116|%
P10712618A0181|139 170|Pseudomonas fluorescens aspartases
P10712618A0181|161 170|aspartases
P10713083A0170|0 5|Unique
P10713083A0170|32 35|TraR
P10713083A0170|61 73|antiactivator
P10713083A0170|80 83|TraM
P10713083A0560|13 24|genetic assay
P10713083A0560|37 59|AAI-dependent DNA binding
P10713083A0560|61 64|TraM
P10713083A0560|74 85|TraR function
P10713083A0560|74 77|TraR
P10713083A0560|103 121|transcription factor
P10713083A0560|135 152|DNA recognition site
P10713155A0151|14 33|IIIa pre-mRNA splicing
P10713155A0151|63 77|nuclear extracts
P10713155A0151|90 117|late adenovirus-infected cells
P10713155A0151|119 123|Ad-NE
P10713155A0151|135 167|uninfected HeLa cell nuclear extracts
P10713155A0151|169 175|HeLa-NE
P10713161A0985|0 11|Inactivation
P10713161A0985|14 17|Ulp2
P10713161A0985|32 42|several ulp1
P10713161A0985|39 45|ulp1(ts
P10713161A0985|44 45|ts
P10713161A0985|47 53|defects
P10713161A0985|61 72|double mutant
P10713161A0985|87 113|fewer Smt3-protein conjugates
P10713161A0985|92 103|Smt3-protein
P10713161A0985|124 135|single mutant
P10713175A1399|16 22|results
P10713175A1399|34 43|ARF binding
P10713175A1399|34 36|ARF
P10713175A1399|46 49|Mdm2
P10713175A1399|58 77|conformational change
P10713175A1399|93 107|nucleolar import
P10713175A1399|113 127|ARF-Mdm2 complex
P10713175A1399|113 115|ARF
P10713175A1399|117 120|Mdm2
P10713175A1399|131 158|p53-dependent cell cycle arrest
P10713175A1399|131 133|p53
P10713176A0422|0 16|Cyclin A expression
P10713176A0422|0 6|Cyclin A
P10713176A0422|30 43|quiescent cells
P10713176A0422|46 48|E2F
P10713176A0422|57 67|conjunction
P10713176A0422|75 97|pocket protein partners Rb
P10713176A0422|96 97|Rb
P10713176A0422|99 102|p107
P10713176A0422|107 110|p130
P10713176A0422|120 124|v-Jun
P10713176A0422|167 168|Rb
P10713176A0422|172 210|proliferation-specific E2F-p107 complexes
P10713176A0422|194 196|E2F
P10713176A0422|198 201|p107
P10713176A0422|225 241|mitogen withdrawal
P10713176A0885|0 19|D-cyclin-cdk activity
P10713176A0885|0 7|D-cyclin
P10713176A0885|9 11|cdk
P10713176A0885|33 49|Rb phosphorylation
P10713176A0885|33 34|Rb
P10713176A0885|52 73|v-Jun-transformed cells
P10713176A0885|52 56|v-Jun
P10713176A0885|80 96|ectopic expression
P10713176A0885|102 105|cdk4
P10713176A0885|110 134|cdk6-specific inhibitor p16
P10713176A0885|110 113|cdk6
P10713176A0885|132 134|p16
P10713176A0885|136 140|INK4A
P10713176A0885|154 165|DNA synthesis
P10713176A0885|169 185|cell proliferation
P10713239A0988|0 9|CONCLUSION
P10713239A0988|12 30|valve-like mechanism
P10713239A0988|42 57|capsulorhexis rim
P10713239A0988|79 86|IOL optic
P10713453A0172|30 50|monoclonal antibody Q18
P10713453A0172|63 73|gene located
P10713453A0172|76 78|57A
P10713453A0172|81 99|polytene chromosomes
P10713453A0172|127 132|Hrb57A
P10714985A1057|2 23|RNA boundary experiments
P10714985A1057|69 71|G/U
P10714985A1057|73 81|AG repeats
P10714985A1057|93 126|stable TRAP-trp leader RNA association
P10714985A1057|99 102|TRAP
P10714985A1057|104 106|trp
P10715322A0000|0 12|Gene silencing
P10715322A0000|35 46|DNA sequences
P10715322A0000|65 78|many eukaryotes
P10715322A0000|89 94|plants
P10715325A0834|3 12|AtERF genes
P10715325A0834|42 49|ethylene
P10715325A0834|55 77|abiotic stress conditions
P10715325A0834|85 92|wounding
P10715325A0834|99 110|high salinity
P10715325A0834|114 120|drought
P10715325A0834|125 145|ETHYLENE-INSENSITIVE2
P10715325A0834|147 150|EIN2
P10715325A0834|165 183|independent pathways
P10715602A0149|0 6|Animals
P10715602A0149|22 34|dexamethasone
P10715602A0149|38 42|mg/kg
P10715602A0149|58 97|protein-free surfactant preparation Exosurf
P10715602A0149|99 115|pure phospholipids
P10715602A0149|126 135|surfactant
P10715602A0149|137 148|Wellcome GmbH
P10715602A0149|150 158|Burgwedel
P10715602A0149|160 166|Germany
P10715602A0149|172 176|rSP-C
P10715602A0149|182 191|surfactant
P10717612A0000|0 9|BACKGROUND
P10717612A0000|45 57|response rates
P10717612A0000|61 68|toxicity
P10717612A0000|74 81|regimens
P10717612A0000|92 137|granulocyte-macrophage-colony stimulating factor
P10717612A0000|139 144|GM-CSF
P10717612A0000|163 175|interleukin-2
P10717612A0000|177 180|IL-2
P10717612A0000|198 205|patients
P10717612A0000|210 237|metastatic renal cell carcinoma
P10720434A0291|9 17|injection
P10720434A0291|20 33|synthetic mRNAs
P10720434A0291|42 71|cis-acting sequences responsible
P10720434A0291|75 84|repression
P10720434A0291|87 98|cyclin B1 mRNA
P10720434A0291|116 118|UTR
P10721698A1195|35 56|dodecamer repeat located
P10721698A1195|62 77|proximal promoter
P10721698A1195|80 83|CSTB
P10721698A1195|116 123|promoter
P10721698A1195|141 153|transcription
P10721698A1195|156 159|CSTB
P10721704A1155|13 31|genomic organization
P10721704A1155|34 37|mHuA
P10721704A1155|52 75|neural-restricted members
P10721704A1155|81 90|Elav family
P10721704A1155|95 109|promoter element
P10721704A1155|136 151|sequence analysis
P10721704A1155|155 177|transcriptional activity
P10721704A1155|180 198|non-neural cell types
P10721704X0000|0 7|Analysis
P10721704X0000|23 33|mouse Elavl1
P10721704X0000|35 38|mHuA
P10721704X0000|52 83|transcriptional regulatory element
P10721704X0000|107 125|genomic organization
P10721704X0000|127 130|mHuA
P10721704X0000|132 137|Elavl1
P10721704X0000|172 176|genes
P10721704X0000|185 203|RNA-binding proteins
P10721704X0000|222 231|cell growth
P10721704X0000|235 247|proliferation
P10721704X0000|270 282|mRNA stability
P10721714A1087|0 33|Electrophoretic mobility shift assays
P10721714A1087|46 48|Sp1
P10721714A1087|59 74|different regions
P10721714A1087|80 95|proximal promoter
P10721714A1087|98 118|typical Sp1 site located
P10721714A1087|105 111|Sp1 site
P10721714A1087|134 147|G/C-rich region
P10721717A0676|0 3|Fgd3
P10721717A0676|7 10|FGD1
P10721717A0676|17 26|high degree
P10721717A0676|29 44|sequence identity
P10721717A0676|58 84|contiguous amino acid residues
P10721726T0000|0 15|Molecular cloning
P10721726T0000|18 43|mouse thioredoxin reductases
P10722063A0328|3 12|HPLC method
P10722063A0328|23 43|octadecylsilane column
P10722063A0328|48 55|degrees C
P10722063A0328|67 104|water-acetonitrile-orthophosphoric acid
P10722063A0328|116 118|v/v
P10722063A0328|122 132|mobile phase
P10722063A0328|136 144|detection
P10722063A0328|150 151|nm
P10722509A0392|5 12|patients
P10722509A0392|24 25|mg
P10722509A0392|28 44|adefovir dipivoxil
P10722509A0392|48 49|kg
P10722509A0392|52 61|body weight
P10722509A0392|69 76|patients
P10722509A0392|88 89|mg
P10722509A0392|92 108|adefovir dipivoxil
P10722509A0392|112 113|kg
P10722661A0146|0 3|CYC2
P10722661A0146|12 24|24-kDa protein
P10722661A0146|32 47|sequence identity
P10722661A0146|53 73|Neurospora crassa PREG1
P10722661A0146|80 102|S. cerevisiae PHO80 cyclin
P10722661A0146|92 102|PHO80 cyclin
P10722661A0406|13 16|CYC2
P10722661A0406|58 87|trypanosome cdc2-related kinases
P10722661A0406|89 92|CRKs
P10722661A0406|98 105|CYC2 gene
P10722661A0406|119 130|TY epitope tag
P10722661A0406|149 165|trypanosome genome
P10722661A0406|184 199|inducible control
P10722737A1726|5 12|findings
P10722737A1726|37 39|Sp1
P10722737A1726|45 47|Inr
P10722737A1726|50 76|non-cell-specific regulation
P10722737A1726|81 111|Kruppel-like transcription factor
P10722737A1726|115 117|Sp1
P10722737A1726|123 145|cell-specific regulation
P10722737A1726|151 153|LTC
P10722737A1726|157 161|S gene
P10723723A0781|16 28|mouse promoter
P10723723A0781|39 44|copies
P10723723A0781|48 82|CT dinucleotide repeat sequence located
P10723723A0781|99 100|bp
P10723723A0781|105 108|exon
P10723727A0713|31 36|intron
P10723727A0713|74 103|polyadenylation signal sequences
P10724436A0085|11 48|enriched U3O8 standard reference materials
P10724483A0540|13 31|positive cAMP control
P10724483A0540|37 47|hypoxic SRP1
P10724483A0540|44 47|SRP1
P10724483A0540|51 60|HEM13 genes
P10724483A0540|80 89|HOG pathway
P10724483A0540|80 82|HOG
P10724519A1185|28 41|regulatory RNAs
P10724519A1185|55 74|transposable elements
P10725017A0673|19 42|middleware-based approach
P10725017A0673|52 57|CEN ENV
P10725017A0673|71 93|specialisation necessary
P10725017A0673|100 115|healthcare record
P10725017A0673|123 128|CEN ENV
P10725017A0673|135 172|Electronic Healthcare Record Architecture
P10725382A0398|0 15|Sequence analyses
P10725382A0398|18 34|sos2 mutant alleles
P10725382A0398|52 76|N-terminal catalytic domain
P10725382A0398|83 108|C-terminal regulatory domain
P10725382A0398|111 114|SOS2
P10725433A0543|1 8|mutation
P10725433A0543|26 32|binding
P10725433A0543|40 46|factors
P10725433A0543|54 71|Wp reporter activity
P10725433A0543|86 95|B cell lines
P10725433A0543|105 112|mutation
P10725433A0543|136 164|consensus CREB-binding sequence
P10725433A0543|145 164|CREB-binding sequence
P10725433A0543|174 198|wild-type promoter function
P10727247A0461|17 23|cloning
P10727247A0461|25 56|tissue-specific expression pattern
P10727247A0461|61 86|functional characterization
P10727247A0461|92 109|novel TEF-1 isoforms
P10727247A0461|97 109|TEF-1 isoforms
P10727247A0461|111 119|TEF-1beta
P10727247A0461|123 132|TEF-1gamma
P10727413A1244|12 23|binding sites
P10727413A1244|27 47|liver-enriched factors
P10727413A1244|61 89|hamster CYP7A1 proximal promoter
P10727413A1244|92 104|close vicinity
P10727413A1244|143 165|regulatory unit important
P10727413A1244|169 190|basal hepatic expression
P10727413A1244|194 210|tissue restriction
P10727413A1244|224 235|hormones such
P10727413A1244|238 244|insulin
P10727426A1280|3 16|kinase activity
P10727426A1280|19 23|PfPK6
P10727426A1280|37 53|CDK inhibitors such
P10727426A1280|37 39|CDK
P10727426A1280|56 65|olomoucine
P10727426A1280|69 79|roscovitine
P10727428A0000|8 10|MAP
P10727428A0000|12 43|mitogen-activated protein) kinases
P10727428A0000|12 35|mitogen-activated protein
P10727428A0000|37 43|kinases
P10727428A0000|59 75|cell proliferation
P10727428A0000|79 93|differentiation
P10727428A0000|96 108|many cell types
P10727428A0000|119 128|MAP kinases
P10727428A0000|131 148|cardiac hypertrophy
P10727428A0000|156 162|unclear
P10727433A0560|0 11|Transfection
P10727433A0560|17 39|CSF-1R expression plasmid
P10727433A0560|17 22|CSF-1R
P10727433A0560|49 73|CSF-1-dependent activation
P10727433A0560|49 53|CSF-1
P10727433A0560|79 95|signalling pathway
P10727433A0560|107 113|Ets/AP1
P10727433A0560|107 109|Ets
P10727433A0560|115 130|activator protein
P10727433A0560|145 155|uPA promoter
P10727433A0560|195 206|oncogenic ras
P10727433A0560|210 231|protein kinase C pathways
P10727433T0000|0 9|Regulation
P10727433T0000|12 57|urokinase plasminogen activator gene transcription
P10727433T0000|12 44|urokinase plasminogen activator gene
P10727433T0000|63 92|RAW264 murine macrophage cell line
P10727433T0000|95 128|macrophage colony-stimulating factor
P10727433T0000|130 134|CSF-1
P10727433T0000|161 180|cell-surface receptor
P10727511A0294|0 7|Molecule
P10727511A0294|9 9|s
P10727511A0294|21 36|neuronal cultures
P10727511A0294|53 61|induction
P10727511A0294|64 68|GLT-1
P10727511A0294|94 110|signaling pathways
P10727515A1202|0 11|Coactivation
P10727515A1202|14 23|endogenous
P10727515A1202|26 35|exogenous G
P10727515A1202|35 55|G(q)-coupled receptors
P10727515A1202|37 37|q
P10727515A1202|47 55|receptors
P10727515A1202|63 82|delta-opioid receptor
P10727515A1202|91 108|strong stimulations
P10727515A1202|111 117|PLCbeta
P10727515A1202|121 133|such responses
P10727515A1202|159 172|pertussis toxin
P10728945A0233|0 7|Patients
P10728945A0233|21 30|Integrilin
P10728945A0233|41 59|Platelet Aggregation
P10728945A0233|63 83|Coronary Thrombosis-II
P10728945A0233|85 93|IMPACT-II
P10728986A0000|3 21|Wnt signaling pathway
P10728986A0000|3 5|Wnt
P10728986A0000|50 66|animal development
P10728986A0000|76 92|cell fate decisions
P10729151A1160|4 11|mutation
P10729151A1160|32 90|HPV-11 upstream regulatory region-controlled reporter expression
P10729155A0653|5 26|icosahaedral MVMi capsid
P10729155A0653|48 57|carboxy end
P10729155A0653|63 85|amphipathic beta-strand I
P10729155A0653|87 91|betaI
P10729155A0653|103 115|basic residues
P10729155A0653|159 176|unassembled subunit
P10729155A0653|193 199|solvent
P10729220A0000|6 19|contiguous IGF2
P10729220A0000|16 19|IGF2
P10729220A0000|21 49|human insulin-like growth factor
P10729220A0000|56 63|H19 genes
P10729220A1569|3 23|asymmetric methylation
P10729220A1569|41 65|tissue-specific disruption
P10729220A1569|68 77|H19 genomic
P10729220A1569|90 99|fetal brain
P10729221A0798|18 35|expression patterns
P10729221A0798|41 61|known Kv4 family members
P10729221A0798|46 61|Kv4 family members
P10729221A0798|67 84|subtype specificity
P10730292T0000|0 22|Early treatment mechanics
P10730292T0000|28 42|Class II division
P10730292T0000|44 55|malocclusion
P10730763A1491|0 13|Preliminary use
P10730763A1491|19 47|Nottingham Eczema Severity Score
P10730763A1491|60 77|further development
P10730763A1491|81 92|research tool
P10730763A1491|97 112|simple assessment
P10730763A1491|115 129|disease severity
P10730763A1491|147 168|epidemiological studies
P10731411A0958|37 49|residues other
P10731411A0958|62 67|motifs
P10731411A0958|94 113|DEAD-box RNA helicases
P10731411A0958|156 156|A
P10731411A0958|158 164|residue
P10731411A0958|175 178|DEAD
P10731411A0958|180 184|motif
P10731926A0775|0 14|Advanced adenoma
P10731926A0775|29 41|adenoma larger
P10731926A0775|48 49|mm
P10731926A0775|54 60|adenoma
P10731926A0775|74 89|villous component
P10731926A0775|91 109|high-grade dysplasia
P10731926A0775|112 128|invasive carcinoma
P10732669A0510|2 16|transient assays
P10732669A0510|23 50|rice suspension-cultured cells
P10732669A0510|64 82|particle bombardment
P10732669A0510|106 111|Oshox1
P10732669A0510|152 173|reporter gene constructs
P10732669A0510|178 203|upstream HD-Zip binding sites
P10732669A1336|0 6|Results
P10732669A1336|9 24|two-hybrid assays
P10732669A1336|28 61|electrophoretic mobility shift assays
P10732669A1336|84 97|HD-Zip proteins
P10732669A1336|100 107|families
P10732669A1336|121 130|homodimers
P10732669A1336|138 149|heterodimers
P10732669A1336|157 170|HD-Zip proteins
P10732669A1336|176 185|same family
P10733569A0364|5 17|mammalian HSFs
P10733569A0364|19 22|HSF1
P10733569A0364|66 97|heat-induced stress gene expression
P10733569A0364|78 87|stress gene
P10733569A0364|119 122|HSF2
P10733569A0364|125 138|stress response
P10733569A0364|141 147|unclear
P10733581A1391|12 32|concomitant expression
P10733581A1391|35 46|constitutive
P10733581A1391|56 58|Raf
P10733581A1391|62 70|V12N38 Ras
P10733581A1391|86 97|complete loss
P10733581A1391|100 112|TTF-1 activity
P10733581A1391|100 104|TTF-1
P10733591A0146|9 29|many downstream targets
P10733591A0146|40 49|remodeling
P10733591A0146|55 71|actin cytoskeleton
P10733591A0146|73 82|activation
P10733591A0146|85 87|p70
P10733591A0146|89 90|S6
P10733591A0146|92 97|kinase
P10733591A0146|101 121|c-jun N-terminal kinase
P10733591A0146|123 125|JNK
P10733591A0146|143 155|transcription
P10733591A0146|159 175|cell proliferation
P10733591A0533|0 9|Expression
P10733591A0533|21 32|Cdc42 results
P10733591A0533|21 25|Cdc42
P10733591A0533|38 50|translocation
P10733591A0533|53 61|PKClambda
P10733591A0533|69 75|nucleus
P10733591A0533|83 89|cytosol
P10733591A0533|94 98|Cdc42
P10733591A0533|102 110|PKClambda
P10733591A0533|126 139|plasma membrane
P10733591A0533|148 156|cytoplasm
P10733880X1783|0 8|Copyright
P10733880X1783|13 25|Academic Press
P10734312A0503|19 33|Shc localization
P10734312A0503|19 21|Shc
P10734312A0503|36 48|membrane rafts
P10734312A0503|71 81|Shc function
P10734312A0503|71 73|Shc
P10734312A0503|97 106|Shc chimera
P10734312A0503|120 147|Ras membrane localization motif
P10734312A0503|153 162|C-terminus
P10735272A0649|0 15|Southern blotting
P10735272A0649|19 62|single strand conformation polymorphism analyses
P10735272A0649|73 97|tumor-specific alterations
P10735272A0649|110 116|gliomas
P10735272A0649|120 132|RT-PCR studies
P10735272A0649|151 165|glioma cell lines
P10735272A0649|181 185|ANOVA
P10735272A0649|194 231|chromosome 19q glioma tumor suppressor gene
P10735848A1440|0 3|RegA
P10735848A1440|18 38|nonessential regulator
P10735848A1440|41 58|tol-oprL expression
P10735848A1440|41 43|tol
P10735848A1440|45 48|oprL
P10736161T0000|0 6|Enzyme I
P10736161T0000|12 54|phosphoenolpyruvate:sugar phosphotransferase
P10736161T0000|12 30|phosphoenolpyruvate
P10736161T0000|32 60|sugar phosphotransferase system
P10736223A1227|31 43|transcription
P10736223A1227|46 49|prgX
P10736223A1227|68 77|Qa promoter
P10736223A1227|80 83|prgQ
P10736223A1227|88 91|PrgX
P10736223A1227|108 120|transcription
P10736223A1227|138 163|transcriptional readthrough
P10736223A1227|176 188|mRNA stability
P10737366A0280|20 30|intrathecal
P10737366A0280|33 51|intraperitoneal PTFL
P10737366A0280|64 83|nociceptive threshold
P10737366A0280|87 103|mechanical stimuli
P10737366A0280|109 120|formalin test
P10737366A0280|123 126|rats
P10738139A0681|0 15|Molecular mimicry
P10738139A0681|18 30|human cytokine
P10738139A0681|34 61|cytokine response pathway genes
P10738139A0681|64 67|KSHV
P10739408A0896|0 16|Family environment
P10739408A0896|22 39|important influence
P10739408A0896|42 67|interpersonal relationships
P10739408A0896|69 80|substance use
P10739408A0896|85 97|social support
P10739671A0136|2 35|electrophoresis mobility shift assays
P10739671A0136|41 46|probes
P10739671A0136|62 78|different segments
P10739671A0136|84 107|putative human c-myb intron
P10739671A0136|109 132|transcription pause region
P10739671A0136|136 150|nuclear extracts
P10739671A0136|155 171|myeloid leukemia HL
P10739671A0136|177 188|fibroblast WI
P10739671A0136|191 195|cells
P10739671A0136|208 239|HL-60-specific DNA-protein complex
P10739671A0136|245 258|123-bp fragment
P10739671A0136|269 280|binding sites
P10739671A0136|287 313|interferon regulatory factors
P10739671A0136|315 318|IRFs
P10739671A0136|320 334|nuclear proteins
P10740602A0141|0 10|STUDY DESIGN
P10740602A0141|12 46|Fine needle aspiration cytologic smears
P10740602A0141|53 57|cases
P10740602A0141|60 83|invasive lobular carcinoma
P10740602A0141|85 87|ILC
P10740602A0141|112 142|detailed cytomorphologic analysis
P10741850A0452|0 27|Electrophile Response Elements
P10741850A0452|29 33|EpREs
P10741850A0452|36 42|located
P10741850A0452|48 64|flanking sequences
P10741850A0452|74 77|GCSh
P10741850A0452|81 96|GCSl subunit genes
P10741850A0452|138 150|gene induction
P10741850A0452|160 177|xenobiotic exposure
P10741947T0000|1 12|new technique
P10741947T0000|23 40|artificial stenosis
P10741947T0000|46 54|native LAD
P10741947T0000|61 68|hemoclip
P10742114A0486|0 3|Dll3
P10742114A0486|18 46|X-ray-induced mouse mutant pudgy
P10742114A0486|31 46|mouse mutant pudgy
P10742114A0486|48 49|pu
P10742114A0486|69 96|vertebrocostal defects similar
P10742114A0486|99 110|SD phenotypes
P10742216A0555|0 7|Schlegel
P10742216A0555|9 10|J.
P10743608A1154|0 15|TbRAB31 behaviour
P10743608A1154|0 6|TbRAB31
P10743608A1154|39 47|cell cycle
P10743608A1154|49 55|TbRAB31
P10743608A1154|74 90|discrete structure
P10743608A1154|116 122|mitosis
P10743608A1154|137 149|daughter cells
P10743608A1154|153 168|coordinate manner
P10743608A1154|176 184|basal body
P10743608A1154|188 198|kinetoplast
P10743608A1154|226 237|microtubules
P10743719A0223|3 9|early dg
P10743719A0223|13 21|rejection
P10743719A0223|35 48|acute rejection
P10743719A0223|54 71|adequate management
P10743719A0223|92 124|future chronic rejection nephropathy
P10744026A0000|0 9|Invertases
P10744026A0000|30 38|breakdown
P10744026A0000|41 47|sucrose
P10744026A0000|50 57|fructose
P10744026A0000|61 67|glucose
P10744749A0315|16 34|molecular mechanisms
P10744749A0315|41 62|Tax-mediated inhibition
P10744749A0315|41 43|Tax
P10744749A0315|88 110|transcriptional activity
P10744749A0315|116 134|myogenic MyoD protein
P10744749A0315|151 158|paradigm
P10744749A0315|161 171|bHLH factors
P10744749T0000|3 42|human T cell leukemia/lymphotropic virus type
P10744749T0000|44 53|Tax protein
P10744749T0000|63 89|MyoD-dependent transcription
P10744749T0000|63 66|MyoD
P10744749T0000|102 113|MyoD-binding
P10744749T0000|102 105|MyoD
P10744749T0000|119 127|KIX domain
P10744749T0000|130 133|p300
P10744974T0000|0 14|Phosphorylation
P10744974T0000|18 44|spindle pole body localization
P10744974T0000|50 85|Cdc15p mitotic regulatory protein kinase
P10744974T0000|95 99|yeast
P10745563A0409|12 22|hyperplasia
P10745563A0409|26 48|thrombotic complications
P10745563A0409|100 109|gold stents
P10745563A0409|121 135|greater capacity
P10745563A0409|158 182|functional neo-endothelium
P10747053A1102|3 11|cell cycle
P10747053A1102|15 36|transcriptional defects
P10747053A1102|45 49|taf17
P10747053A1102|51 56|slm7-1
P10747053A1102|84 86|TAF
P10747053A1102|94 103|modulators
P10747053A1102|106 130|transcriptional activation
P10747053A1102|152 156|TAF17
P10747053A1102|169 178|activation
P10747053A1102|181 183|SBF
P10747053A1102|187 189|MBF
P10747099A0507|0 28|Extracellular-regulated kinase
P10747099A0507|30 32|ERK
P10747099A0507|34 43|activation
P10747099A0507|47 63|molecular coupling
P10747099A0507|69 110|adaptor proteins p130 Crk-associated substrate
P10747099A0507|112 114|CAS
P10747099A0507|119 125|c-CrkII
P10747099A0507|127 129|Crk
P10747099A0507|143 158|distinct pathways
P10747099A0507|169 180|cell invasion
P10747099A0507|191 195|cells
P10747099A0507|200 208|apoptosis
P10747099A0507|212 242|three-dimensional collagen matrix
P10747782A0390|0 10|Proteolysis
P10747782A0390|13 16|Mbp1
P10747782A0390|20 43|Swi4 DNA-protein complexes
P10747782A0390|71 79|sequences
P10747782A0390|104 112|molecules
P10747782A0390|138 155|DNA binding activity
P10747782A0390|169 179|core domains
P10747879A0607|17 40|CCR5 cis-regulatory region
P10747879A0607|50 65|open reading frame
P10747879A0607|79 94|different domains
P10747879A0607|100 115|open reading frame
P10747890A1096|5 11|results
P10747890A1096|24 30|residue
P10747890A1096|44 56|protein sensor
P10747890A1096|60 89|altered minor groove interactions
P10747890A1096|108 127|base pair interactions
P10747890A1096|145 151|lesions
P10747987A0658|3 20|recombinant enzymes
P10747987A0658|28 35|monomers
P10748054T0048|1 7|pathway
P10748054T0048|23 67|B lymphocyte antigen receptor-induced calcium flux
P10748054T0048|23 48|B lymphocyte antigen receptor
P10748113A0187|14 29|second RIM protein
P10748113A0187|20 29|RIM protein
P10748113A0187|37 40|RIM2
P10748113A0187|54 63|homologous
P10748113A0187|66 69|RIM1
P10748125A0000|0 10|Inhibitor-1
P10748125A0000|12 14|I-1
P10748125A0000|19 29|inhibitor-2
P10748125A0000|31 33|I-2
P10748125A0000|53 92|type 1 protein serine/threonine phosphatases
P10748125A0000|58 92|protein serine/threonine phosphatases
P10748125A0000|94 96|PP1
P10748164A1284|0 16|Scanning mutations
P10748164A1284|30 38|AC element
P10748164A1284|53 61|induction
P10748164A1284|97 101|sites
P10748164A1284|105 121|regulatory factors
P10748164A1284|124 125|AC
P10748164A1284|137 142|probes
P10748164A1284|162 168|factors
P10748175A0000|3 12|substrates
P10748175A0000|16 30|glycan synthesis
P10748175A0000|36 40|lumen
P10748175A0000|46 50|Golgi
P10748175A0000|54 69|nucleotide sugars
P10748175A0000|98 104|cytosol
P10748175A0000|107 140|specific membrane-bound transporters
P10748194T0000|0 16|Synaptic targeting
P10748194T0000|22 53|postsynaptic density protein PSD-95
P10748194T0000|65 95|tyrosine-based trafficking signal
P10748204A0238|6 7|J.
P10748672A0130|0 4|Bites
P10748672A0130|19 24|adders
P10748672A0130|26 36|Vipera aspis
P10748672A0130|40 50|Vipera berus
P10748672A0130|82 98|multiorgan failure
P10749145T0000|25 36|PCPH proteins
P10749145T0000|41 62|guanosine diphosphatase
P10749145T0000|50 70|diphosphatase activity
P10749145T0000|81 91|oncoprotein
P10749145T0000|106 108|Ras
P10749145T0000|121 159|extracellular signal-regulated kinase ERK1
P10749166A0991|5 11|results
P10749166A0991|24 48|virulence-associated genes
P10749166A0991|57 85|overall chromosomal arrangement
P10749166A0991|119 128|B. henselae
P10749166A0991|132 161|other gram-negative bacteria such
P10749166A0991|164 176|A. tumefaciens
P10749849A0000|2 19|important mechanism
P10749849A0000|30 47|tumor suppressor p53
P10749849A0000|57 72|genomic stability
P10749849A0000|83 97|cell cycle arrest
P10749849A0000|105 114|activation
P10749849A0000|120 153|cyclin-dependent kinase inhibitor p21
P10749849A0000|120 141|cyclin-dependent kinase
P10749849A0000|151 153|p21
P10749849A0000|155 163|WAF1/Cip1
P10749849A0000|155 158|WAF1
P10749849A0000|160 163|Cip1
P10749932A0000|0 7|Paxillin
P10749932A0000|16 30|adaptor molecule
P10749932A0000|33 49|integrin signaling
P10749932A0000|33 40|integrin
P10750020A0843|5 26|growth factor activation
P10750020A0843|29 30|ER
P10750020A0843|41 55|transactivation
P10750020A0843|58 70|ER/Sp1 binding
P10750020A0843|58 59|ER
P10750020A0843|61 63|Sp1
P10750020A0843|73 84|GC-rich sites
P10750020A0843|99 110|novel pathway
P10750020A0843|114 139|ligand-independent ER action
P10750021A0728|22 56|deletion promoter-reporter constructs
P10750021A0728|69 81|basal activity
P10750021A0728|84 85|P2
P10750021A0728|98 111|proximal region
P10750021A0728|114 115|P2
P10750524A0724|0 6|RESULTS
P10750524A0724|8 25|Auditory thresholds
P10750524A0724|41 56|audiometric tests
P10750524A0724|110 126|hypertensive group
P10750524A0724|128 128|p
P10751398A1135|14 26|transcription
P10751398A1135|29 42|c-IAP2 promoter
P10751398A1135|70 73|CD40
P10751398A1135|76 114|Epstein-Barr virus latent membrane protein 1
P10751398A1135|76 113|Epstein-Barr virus latent membrane protein
P10752450A0288|25 52|self-applied fluoride products
P10752450A0288|68 93|new fluoride delivery systems
P10752475A1376|5 11|studies
P10752475A1376|32 56|signal-transduction events
P10752475A1376|70 78|apoptosis
P10752475A1376|81 95|malignant B cells
P10752475A1376|118 125|ligation
P10752475A1376|128 131|CD20
P10752475A1376|134 152|anti-CD20 antibodies
P10752475A1376|168 194|Fc-receptor-expressing cells
P10752475A1376|168 178|Fc-receptor
P10752475A1376|197 214|secondary goat anti-
P10752475A1376|216 222|mouse Ig
P10752475A1376|224 233|antibodies
P10752475A1376|260 275|tumor regressions
P10752475A1376|286 296|mouse models
P10752475A1376|300 313|clinical trials
P10752807A1598|0 9|CONCLUSION
P10752807A1598|11 19|Treatment
P10752807A1598|22 27|sepsis
P10752807A1598|35 75|platelet-activating factor antagonist BB-882
P10752807A1598|35 59|platelet-activating factor
P10752807A1598|97 103|placebo
P10752807A1598|115 131|hemodynamic status
P10752807A1598|133 151|respiratory function
P10752807A1598|155 172|organ failure scores
P10753553T0000|0 8|Phenazone
P10753553T0000|23 44|local anaesthetic effect
P10753553T0000|47 55|lidocaine
P10753553T0000|58 61|mice
P10754312A0798|3 12|solubility
P10754312A0798|28 35|proteins
P10756007A0575|9 29|identical RBE sequences
P10756007A0575|50 63|other locations
P10756007A0575|69 79|human genome
P10756007A1512|0 9|EM analysis
P10756007A1512|33 46|Rep-DNA complex
P10756007A1512|58 71|ch-19 target DNA
P10756020A0571|35 56|vaccinia virus particles
P10756020A0571|64 72|membranes
P10756020A0571|75 82|immature
P10756020A0571|86 98|mature virions
P10756020A0571|119 136|electron microscopy
P10756020A0571|139 151|infected cells
P10756032A0599|6 32|dimethyl sulfate footprinting
P10756032A0599|38 52|cyclin E promoter
P10756032A0599|61 74|several regions
P10756032A0599|90 105|hypersensitivity
P10756032A0599|122 134|infected cells
P10756094A0671|11 14|STSs
P10756094A0671|35 36|Mb
P10756094A0671|46 68|average marker resolution
P10756094A0671|92 93|kb
P10756100A0457|10 17|mutation
P10756100A0457|23 36|amino-terminus
P10756100A0457|39 41|IB1
P10756225A1464|0 9|CONCLUSION
P10756225A1464|11 14|More
P10756225A1464|21 21|%
P10756225A1464|24 31|patients
P10756225A1464|36 52|perennial rhinitis
P10756225A1464|56 58|CRS
P10756225A1464|113 121|more cells
P10756225A1464|132 139|IL-5 mRNA
P10756225A1464|145 158|ethmoid sinuses
P10757975A0509|0 3|Biol
P10757983A0733|20 30|CRS sequence
P10757983A0733|52 74|tentative identification
P10757983A0733|78 94|zinc finger protein
P10757983A0733|96 104|Adx factor
P10757983A0733|125 153|Kruppel-like zinc finger protein
P10757983A0733|156 175|mouse ZBP-89 homologue
P10758289A0141|0 6|METHODS
P10758289A0141|15 32|distal muscle fibres
P10758289A0141|47 70|superficial finger flexors
P10758289A0141|96 107|pisiform bone
P10758289A0141|112 129|cadaveric specimens
P10758489A0206|28 31|ICK2
P10758489A0206|59 65|Cdc2aAt
P10758489A0206|78 86|second CDK
P10758489A0206|84 86|CDK
P10758489A0206|91 101|Arabidopsis
P10758489A0206|103 109|Cdc2bAt
P10758726T0000|0 13|Systemic impact
P10758726T0000|16 39|risk-sharing arrangements
P10759693A0201|0 6|METHODS
P10759693A0201|22 30|odds ratio
P10759693A0201|32 33|OR
P10759693A0201|51 62|relative risk
P10759693A0201|80 99|potential interaction
P10759693A0201|121 141|H2-receptor antagonist
P10759693A0201|121 131|H2-receptor
P10759693A0201|143 152|cimetidine
P10759693A0201|167 196|noninteracting agents ranitidine
P10759693A0201|198 207|famotidine
P10759693A0201|211 220|nizatidine
P10759693A0201|223 227|users
P10759693A0201|231 238|nonusers
P10759693A0201|241 248|warfarin
P10759693A0201|250 258|phenytoin
P10759693A0201|262 273|theophylline
P10760109A1050|3 12|prevalence
P10760109A1050|15 26|malnutrition
P10760109A1050|32 32|%
P10760109A1050|40 47|patients
P10760109A1050|55 57|CVD
P10760109A1050|77 82|higher
P10760109A1050|86 86|%
P10760109A1050|88 88|P
P10760109A1050|103 110|patients
P10760109A1050|115 117|CVD
P10760109A1050|129 137|lower tHcy
P10760109A1050|139 142|SAlb
P10760109A1050|144 154|plasma IGF-1
P10760109A1050|150 154|IGF-1
P10760109A1050|156 170|serum creatinine
P10760109A1050|172 174|SCr
P10760109A1050|180 194|blood hemoglobin
P10760109A1050|185 194|hemoglobin
P10760132A1169|28 42|high temperature
P10760132A1169|45 64|critical minimal level
P10760132A1169|67 87|Ypt protein prenylation
P10760132A1169|112 130|vesicle polarization
P10760169A1142|3 22|second functional pair
P10760169A1142|25 33|CreA sites
P10760169A1142|36 42|located
P10760169A1142|56 83|transcription initiation sites
P10760950A1133|1 23|distinct staining pattern
P10760950A1133|30 39|N-utrophin
P10760950A1133|46 55|detectable
P10760950A1133|93 109|actin stress fibers
P10760950A1133|93 97|actin
P10761263A1108|4 12|Newcastle
P10761263A1108|34 42|Hotelling
P10761263A1108|45 55|T2 statistic
P10761263A1108|93 114|systematic displacement
P10761263A1108|123 138|prostate patients
P10762254A0954|3 5|MMA
P10762254A0954|7 9|DMA
P10762254A0954|14 34|TMA methyltransferases
P10762254A0954|41 48|homologs
P10762254A0954|65 88|MMA methyltransferase gene
P10762254A0954|93 97|genes
P10762254A0954|109 135|DMA and TMA methyltransferases
P10762254A0954|109 111|DMA
P10762254A0954|115 135|TMA methyltransferases
P10762254A0954|162 171|amber codon
P10762348A0269|5 19|phosphorylation
P10762348A0269|21 32|STAT proteins
P10762348A0269|54 60|nucleus
P10762348A0269|71 93|transcriptional activity
P10763823A0824|0 13|Overexpression
P10763823A0824|16 20|mcl-1
P10763823A0824|49 57|apoptosis
P10763823A0824|64 75|transfection
P10763823A0824|79 99|mcl-1 antisense plasmid
P10763823A0824|79 83|mcl-1
P10763823A0824|106 114|cell death
P10763827A1158|13 38|multiple senescence pathways
P10763827A1158|64 74|ras oncogene
P10763827A1158|76 87|inactivation
P10763827A1158|90 106|TGFbeta1 secretion
P10763827A1158|90 97|TGFbeta1
P10763827A1158|139 155|senescence program
P10764150A0000|15 23|abilities
P10764150A0000|26 37|constitutive
P10764150A0000|41 56|conditional forms
P10764150A0000|67 76|Raf kinases
P10764150A0000|90 107|cytokine dependency
P10764150A0000|110 120|FDC-P1 cells
P10764574A0718|0 10|Application
P10764574A0718|25 41|representative set
P10764574A0718|46 55|known genes
P10764574A0718|60 78|Arabidopsis thaliana
P10764574A0718|85 106|significant improvement
P10764574A0718|109 126|prediction accuracy
P10764574A0718|152 167|alignment methods
P10764729A1846|3 22|complete cDNA sequence
P10764729A1846|25 42|human betaV spectrin
P10764729A1846|58 64|GenBank
P10764729A1846|66 67|TM
P10764729A1846|71 85|accession number
P10764760T0000|0 14|Transactivation
P10764760T0000|35 58|HIV-1 long terminal repeats
P10764760T0000|64 82|JNK signaling pathway
P10764760T0000|64 66|JNK
P10764802A1258|20 36|alpha-helix domain
P10764802A1258|39 41|p57
P10764802A1258|43 46|Kip2
P10764802A1258|70 84|Cip/Kip proteins
P10764802A1258|70 72|Cip
P10764802A1258|100 125|protein-protein interaction
P10764802A1258|100 114|protein-protein
P10764802A1258|137 163|specific regulatory mechanism
P10764802A1258|179 200|Cdk-inhibitory activity
P10764802A1258|212 214|p57
P10764802A1258|216 219|Kip2
P10764802A1258|221 233|family members
P10764802A1258|249 271|myogenic differentiation
P10764970A1009|21 45|quinupristin/dalfopristin
P10764970A1009|63 72|A-negative
P10764970A1009|75 77|PCR
P10764970A1009|88 92|cases
P10764970A1009|117 147|streptogramin-resistant isolates
P10764970A1009|175 192|antimicrobial class
P10764970A1009|197 217|human clinical practice
P10765095A0308|31 42|PRL secretion
P10765095A0308|31 33|PRL
P10765095A0308|45 76|metastatic prostate cancer patients
P10765095A0308|83 97|basal conditions
P10765095A0308|113 118|L-Dopa
P10765095A0308|122 135|metoclopramide
P10765095A0308|159 177|classical inhibitory
P10765095A0308|181 196|stimulatory tests
P10765095A0308|200 211|PRL secretion
P10765095A0308|200 202|PRL
P10766246A0000|0 24|Integrin adhesion receptors
P10766246A0000|34 40|signals
P10766246A0000|52 71|complex cell functions
P10766246A0000|99 112|gene expression
P10766246A0000|120 132|proliferation
P10766246A0000|134 148|differentiation
P10766493T0000|0 12|Recombination
P10766493T0000|14 24|replication
P10766556T0000|3 21|somatoform conundrum
P10766556T0000|34 50|nosological valves
P10767091A0133|0 24|Intra-operative ultrasound
P10767091A0133|26 29|IOUS
P10767091A0133|74 85|difficulties
P10767091A0133|104 124|two-dimensional nature
P10767091A0133|126 146|inter-user variability
P10767091A0133|151 167|image obliteration
P10767091A0133|172 179|ablative
P10767091A0133|182 202|resectional techniques
P10767251A1046|0 10|CONCLUSIONS
P10767251A1046|16 30|randomized study
P10767251A1046|40 60|Vivostat fibrin sealant
P10767251A1046|48 53|fibrin
P10767251A1046|84 93|air leakage
P10767251A1046|99 117|small lung resections
P10767251A1046|120 123|pigs
P10767251A1046|131 154|high inspiratory pressures
P10767338T0000|0 19|Hailey-Hailey disease
P10767338T0000|30 38|mutations
P10767338T0000|41 46|ATP2C1
P10767338T0000|56 62|novel Ca
P10767338T0000|61 65|Ca(2+
P10767553A0100|0 2|Hex
P10767553A0100|29 43|liver coincident
P10767553A0100|51 89|forkhead/winged helix transcription factor
P10767553A0100|51 58|forkhead
P10767553A0100|60 89|winged helix transcription factor
P10767553A0100|91 118|Hepatocyte Nuclear Factor 3beta
P10767553A0100|120 127|HNF3beta
P10767560A0105|18 43|structural characterization
P10767560A0105|49 71|exon-intron organization
P10767560A0105|77 88|mouse Pkr gene
P10767560A0105|126 147|mouse Pkr promoter region
P10767560A0105|159 184|IFN-inducible transcription
P10769144A0000|3 5|CRE
P10769144A0000|10 19|TGACGTCA-3
P10769144A0000|43 59|consensus sequence
P10769144A0000|66 76|cis-element
P10769144A0000|88 115|cAMP-regulated gene expression
P10769144A0000|88 105|cAMP-regulated gene
P10770041A0731|0 11|Kidney length
P10770041A0731|65 75|kidney width
P10770041A0731|77 93|cortical thickness
P10770041A0731|105 105|p
P10770065A0264|3 15|clinical stage
P10770065A0264|21 26|T1N0M0
P10770065A0264|32 52|S2 sleeve segmentectomy
P10770065A0264|57 75|lymph node dissection
P10770065A0264|77 77|R
P10770065A0264|79 79|b
P10770471T0000|0 10|Benztropine
P10770471T0000|14 43|venlafaxine-induced night sweats
P10771528T0036|18 36|alkaline phosphatase
P10771528T0036|39 46|children
P10771709A0291|3 12|physicians
P10771709A0291|26 33|patients
P10771709A0291|48 58|acute Q fever
P10771709A0291|60 73|seroconversion
P10771709A0291|90 92|IgM
P10771709A0291|96 108|chronic Q fever
P10771709A0291|110 125|prolonged disease
P10771709A0291|132 147|IgG antibody titer
P10771709A0291|132 142|IgG antibody
P10771709A0291|150 155|phase I
P10771709A0291|158 173|Coxiella burnetii
P10771709A0291|177 177|=
P10771709A0291|224 235|computerized
P10772856X1492|0 8|Copyright
P10772856X1492|13 25|Academic Press
P10772977A0222|0 24|Viral cell-to-cell movement
P10772977A0222|27 37|PVX CP mutant
P10772977A0222|55 72|Nicotiana tabacum cv
P10773351A0672|0 8|Induction
P10773351A0672|11 24|CD86 expression
P10773351A0672|11 14|CD86
P10773351A0672|27 37|stimulation
P10773351A0672|40 48|U937 cells
P10773351A0672|53 61|IFN-gamma
P10773351A0672|86 98|functional GAS
P10773351A0672|96 98|GAS
P10773351A0672|100 129|gamma-interferon activation site
P10773351A0672|131 138|elements
P10773455A1268|17 43|proximal GATA-1-binding sites
P10773455A1268|25 43|GATA-1-binding sites
P10773455A1268|69 81|region located
P10773455A1268|98 99|bp
P10773455A1268|105 122|mouse ALAS2 promoter
P10773455A1268|139 163|transcriptional activation
P10773455A1268|187 201|differentiation
P10773455A1268|204 211|MEL cells
P10773455A1268|248 267|erythroid specificity
P10773455A1268|273 302|ALAS2 transcriptional activation
P10773455A1268|273 277|ALAS2
P10773458A0000|0 6|SNAP-23
P10773458A0000|14 26|important role
P10773458A0000|44 61|vesicle trafficking
P10773458A0000|64 77|mammalian cells
P10773667A0351|3 11|HMG domain
P10773667A0351|18 30|HMG20 proteins
P10773667A0351|52 61|yeast NHP6A
P10773667A0351|65 65|%
P10773667A0351|70 70|%
P10773951A0000|0 2|IgM
P10773951A0000|6 13|IgG anti A
P10773951A0000|17 35|anti B antibody status
P10773951A0000|17 29|anti B antibody
P10773951A0000|41 62|antenatal O group mothers
P10773951A0000|70 86|non O group husbands
P10775038A0142|23 36|Wee1 regulation
P10775038A0142|23 26|Wee1
P10775038A0142|43 51|cell cycle
P10775038A0142|53 76|yeast two-hybrid screening
P10775038A0142|94 112|Wee1-binding protein
P10775038A0142|114 114|s
P10775267A0363|0 21|Retroviral transduction
P10775267A0363|24 26|T/T
P10775267A0363|24 24|T
P10775267A0363|28 28|L
P10775267A0363|44 73|fatal myeloproliferative disease
P10775267A0363|77 102|murine bone marrow transplant
P10775267A0363|104 106|BMT
P10775267A0363|121 123|T/T
P10775267A0363|121 121|T
P10775267A0363|123 123|T
P10775267A0363|125 125|F
P10775267A0363|134 145|long-latency
P10775267A0363|147 177|pre-B-cell lymphoblastic lymphoma
P10775585A0754|0 12|Ab-MLV strains
P10775585A0754|23 28|P70/S2
P10775585A0754|23 25|P70
P10775585A0754|27 28|S2
P10775585A0754|46 56|NIH 3T3 cells
P10775585A0754|104 118|signaling events
P10775585A0754|136 172|Ras-dependent mitogen-activated protein
P10775585A0754|174 183|MAP) kinase
P10775585A0754|174 176|MAP
P10775585A0754|178 190|kinase pathway
P10775623A0120|3 12|codon usage
P10775623A0120|39 41|gag
P10775623A0120|43 45|pol
P10775623A0120|50 57|env genes
P10777217A0536|3 20|p53-homolog p73beta
P10777217A0536|3 13|p53-homolog
P10777217A0536|14 20|p73beta
P10777217A0536|37 48|PIG3 promoter
P10777217A0536|65 67|p53
P10777217A0536|72 89|proline-rich domain
P10777217A0536|92 98|p73beta
P10777217A0536|100 107|residues
P10777217A0536|118 128|dispensable
P10777217A0536|140 151|PIG3 promoter
P10777499A0883|0 6|Results
P10777499A0883|11 25|transient assays
P10777499A0883|36 42|mutants
P10777499A0883|56 58|DE1
P10777499A0883|67 73|signals
P10777499A0883|78 90|phytochromes A
P10777499A0883|78 89|phytochromes
P10777499A0883|94 94|B
P10777499A0883|133 155|light-responsive element
P10777586A1022|0 21|Co-immunoprecipitation
P10777586A1022|25 49|DNA affinity chromatography
P10777586A1022|59 61|Sp1
P10777586A1022|81 86|ZBP-89
P10777586A1022|101 115|silencer element
P10777586A1022|124 141|DNA-protein complex
P10777586A1022|147 154|mobility
P10777586A1022|157 173|indistinguishable
P10777586A1022|193 210|HeLa nuclear extract
P10777586A1022|213 227|band shift assays
P10777669A0582|3 12|ZNF274 gene
P10777669A0582|21 26|distal
P10777669A0582|29 39|marker RP S28
P10777669A0582|46 72|human chromosome 19qter region
P10777669A0582|76 84|RH mapping
P10778740A1493|3 27|C-terminal Cdk2 truncations
P10778740A1493|41 54|non-functional
P10778740A1493|62 68|strains
P10778740A1493|101 117|pho85 coding region
P10778740A1493|101 105|pho85
P10778740A1493|136 146|mutant pho85
P10778740A1493|149 168|HIS3 chromosomal locus
P10778757A0000|17 31|molecular nature
P10778757A0000|36 52|EMS-induced mutant
P10778757A0000|54 59|mn1-89
P10778757A0000|62 84|leaky semidominant allele
P10778757A0000|90 99|Miniature1
P10778757A0000|101 103|Mn1
P10778757A0000|105 113|seed locus
P10778757A0000|126 155|seed-specific cell wall invertase
P10778757A0000|157 161|INCW2
P10779313A1842|21 34|atrial myocytes
P10779313A1842|40 53|Xenopus oocytes
P10779313A1842|55 80|beta-adrenergic stimulation
P10779313A1842|95 116|ACh-evoked GIRK channels
P10779313A1842|121 127|pathway
P10779313A1842|140 167|PKA-catalyzed phosphorylation
P10779313A1842|140 142|PKA
P10779313A1842|182 187|beta(2
P10779313A1842|182 185|beta
P10779313A1842|189 190|AR
P10779329T0000|0 3|Slap
P10779329T0000|23 42|Src mitogenic function
P10779329T0000|23 25|Src
P10779329T0000|59 90|Src-induced cell morphology changes
P10779329T0000|59 61|Src
P10779352T0000|0 13|Identification
P10779352T0000|17 32|novel E2F3 product
P10779352T0000|22 32|E2F3 product
P10779352T0000|65 75|specificity
P10779352T0000|78 87|repression
P10779352T0000|90 99|Rb proteins
P10779508A0452|2 7|DNase I
P10779508A0452|2 6|DNase
P10779508A0452|8 37|footprinting protection analysis
P10779508A0452|43 46|SFRE
P10779508A0452|50 59|ERE regions
P10779508A0452|75 121|glutathione S-transferase-ERRalpha1 fusion protein
P10779508A0452|75 98|glutathione S-transferase
P10779508A0452|100 108|ERRalpha1
P10779508A0897|17 27|coactivator
P10779508A0897|29 33|SRC1a
P10779508A0897|36 40|GRIP1
P10779508A0897|42 48|further
P10779508A0897|57 96|ERRalpha1-induced transcriptional activity
P10779508A0897|57 65|ERRalpha1
P10779508T0000|0 37|Estrogen receptor-related receptor alpha 1
P10779508T0000|0 36|Estrogen receptor-related receptor alpha
P10779508T0000|51 61|coactivator
P10779508T0000|91 114|estrogen response elements
P10779508T0000|120 139|human lactoferrin gene
P10780018A0539|9 21|current models
P10780018A0539|27 33|effects
P10780018A0539|36 40|aging
P10780018A0539|43 58|mean response time
P10780518A1270|3 9|effects
P10780518A1270|17 25|mutations
P10780518A1270|28 42|protein function
P10780518A1270|50 67|further examination
P10780764A0722|3 14|median levels
P10780764A0722|17 25|particles
P10780764A0722|32 59|% cut-off aerodynamic diameters
P10780764A0722|65 68|PM10
P10780764A0722|76 81|microm
P10780764A0722|83 85|PM2
P10780764A0722|128 136|micro x m-3
P10780883T0000|0 5|Kaposi
P10780883T0000|8 67|sarcoma-associated herpesvirus viral interferon regulatory factor
P10780883T0000|42 67|interferon regulatory factor
P10780883T0000|90 112|antiproliferative effect
P10780883T0000|115 130|interferon-alpha
P10781109T0000|0 7|Specific
P10781109T0000|11 38|heritable genetic interference
P10781109T0000|41 58|double-stranded RNA
P10781109T0000|61 79|Arabidopsis thaliana
P10781423A0993|0 9|Comparison
P10781423A0993|12 20|sequences
P10781423A0993|33 34|bp
P10781423A0993|45 65|consensus binding sites
P10781423A0993|72 129|homeodomain transcription factor thyroid transcription factor-1
P10781423A0993|131 135|TTF-1
P10781541A1063|3 31|additional cis-acting sequences
P10781541A1063|62 70|promoters
P10781541A1063|110 118|sequences
P10781541A1063|124 143|coordinate regulation
P10781541A1063|146 158|transcription
P10781541A1063|168 176|promoters
P10781552A0000|0 27|Purple photosynthetic bacteria
P10781552A0000|50 63|cellular energy
P10781552A0000|68 81|several sources
P10781552A0000|92 105|photosynthesis
P10781552A0000|107 117|respiration
P10781552A0000|122 124|H(2
P10781552A0000|122 122|H
P10781552A0000|126 134|oxidation
P10781604A0827|12 28|synthetic peptides
P10781604A0827|38 55|minimal CTD sequence
P10781604A0827|83 100|second Rsp5 WW domain
P10781604A0827|89 100|Rsp5 WW domain
P10781604A0827|102 108|Rsp5 WW2
P10781604A0827|122 142|yeast two-hybrid assays
P10781611A1023|12 40|bone marrow-derived macrophages
P10781611A1023|45 61|LAT-deficient mice
P10781611A1023|78 97|phagocytic efficiency
P10781611A1023|115 125|macrophages
P10781611A1023|130 142|wild-type mice
P10781990A0455|0 13|T1-weighted MRI
P10781990A0455|19 38|49th postoperative day
P10781990A0455|51 59|bilateral
P10781990A0455|63 92|symmetrical hyperintense lesions
P10781990A0455|98 111|globus pallidus
P10782640A0444|29 47|aberration constants
P10782640A0444|51 71|CM300 FEG/UT microscope
P10782640A0444|76 85|correction
P10782640A0444|91 111|three-fold astigmatism
P10782989A0575|45 81|correct amino-terminal DNA binding domain
P10782989A0575|87 104|amino acid sequences
P10782989A0575|115 130|DNA binding domain
P10782989A0575|144 153|amino acids
P10784367A0133|0 5|METHOD
P10784367A0133|18 25|subjects
P10784367A0133|41 72|Suffolk County Mental Health Project
P10784367A0133|75 104|longitudinal epidemiologic study
P10784367A0133|107 132|first-hospitalized subjects
P10784367A0133|137 154|psychotic disorders
P10784367A0133|159 170|present study
P10784367A0133|180 187|patients
P10784367A0133|192 213|schizophrenic disorders
P10784393A0000|0 14|Marrow dysplasia
P10784393A0000|18 36|major characteristic
P10784393A0000|39 46|patients
P10784393A0000|51 73|myelodysplastic syndrome
P10784393A0000|75 77|MDS
P10784393A0000|89 103|marrow blastosis
P10784393A0000|105 113|cytopenia
P10784393A0000|117 136|cytogenetic anomalies
P10785294A0720|10 36|non-acceptable inlays/onlays
P10785294A0720|49 66|direct restorations
P10785294A0720|88 96|other ones
P10785294A0720|113 126|resin composite
P10785668A0000|3 8|plants
P10785668A0000|36 45|herbivores
P10785668A0000|49 57|pathogens
P10785668A0000|98 117|considerable research
P10785668A0000|124 142|molecular biologists
P10785668A0000|146 155|ecologists
P10785880A0947|0 9|CONCLUSION
P10785880A0947|14 24|probability
P10785880A0947|27 54|cardiopulmonary complications
P10785880A0947|81 88|patients
P10785880A0947|102 114|HELLP syndrome
P10786671A0182|3 19|rate-limiting step
P10786671A0182|23 40|telomerase activity
P10786671A0182|23 32|telomerase
P10786671A0182|68 83|catalytic subunit
P10786671A0182|89 94|enzyme
P10786671A0182|108 142|human telomerase reverse transcriptase
P10786671A0182|144 148|hTERT
P10786742A0670|5 16|control group
P10786742A0670|18 32|platelet markers
P10786742A0670|43 43|h
P10787437A1616|11 25|element proximal
P10787437A1616|31 52|transcription start site
P10787437A1616|69 73|SRE-1
P10787804T0000|0 13|AMDA white paper
P10787804T0000|24 27|ways
P10787804T0000|37 54|pharmaceutical care
P10787804T0000|57 60|SNFs
P10788320A1034|5 12|proteins
P10788320A1034|23 33|TPR elements
P10788320A1034|56 90|multiple protein-protein interactions
P10788320A1034|64 78|protein-protein
P10788320A1034|108 119|102kD protein
P10788320A1034|138 146|tri-snRNP
P10788320A1034|158 159|U5
P10788320A1034|163 173|U4/U6 snRNPs
P10788320A1034|163 164|U4
P10788320A1034|166 173|U6 snRNPs
P10788320A1034|193 201|particles
P10788476A0891|0 9|Antibodies
P10788476A0891|24 40|C-terminal portion
P10788476A0891|43 67|Sec31A co-precipitate Sec13
P10788476A0891|43 48|Sec31A
P10788476A0891|63 67|Sec13
P10788476A0891|78 94|ER-Golgi transport
P10788476A0891|78 79|ER
P10788476A0891|97 143|temperature-arrested vesicular stomatitis G protein
P10788476A0891|147 166|semi-intact cell assay
P10788480T0000|0 9|Regulation
P10788480T0000|12 83|mitochondrial single-stranded DNA-binding protein gene expression links nuclear
P10788480T0000|12 61|mitochondrial single-stranded DNA-binding protein gene
P10788480T0000|87 113|mitochondrial DNA replication
P10788480T0000|116 125|drosophila
P10790390X0000|0 6|Genetic
P10790390X0000|10 28|molecular complexity
P10790390X0000|34 69|position effect variegation modifier mod
P10790390X0000|67 69|mod
P10790390X0000|71 74|mdg4
P10790390X0000|89 91|mod
P10790390X0000|93 96|mdg4
P10790390X0000|110 110|E
P10790390X0000|112 114|var
P10790390X0000|116 120|3-93D
P10790390X0000|144 152|processes
P10790390X0000|160 172|gene silencing
P10790390X0000|175 199|position effect variegation
P10790390X0000|201 203|PEV
P10790390X0000|218 240|gypsy insulator sequences
P10790390X0000|254 275|homeotic gene expression
P10790390X0000|254 265|homeotic gene
P10790390X0000|290 298|cell death
P10791251A0110|16 24|many kinds
P10791251A0110|33 38|things
P10791251A0110|48 56|functions
P10791251A0110|75 80|humans
P10791251A0110|85 91|unclear
P10791819A0771|14 22|likely due
P10791819A0771|34 54|nucleotide composition
P10791819A0771|60 74|asparagus genome
P10791819A0771|91 112|translational selection
P10791819A0771|116 129|specific codons
P10791901A0609|0 11|Transduction
P10791901A0609|17 41|human leukemic cell line K562
P10791901A0609|52 77|viral MRP1-PG13 supernatants
P10791901A0609|52 60|viral MRP1
P10791901A0609|98 105|MRP1 gene
P10791901A0609|123 123|%
P10791901A0609|126 140|target K562 cells
P10791901A0609|213 231|toxic concentrations
P10791901A0609|234 242|etoposide
P10792583A0000|0 9|Regulation
P10792583A0000|12 43|pituitary vasopressin V1b receptors
P10792583A0000|12 31|pituitary vasopressin
P10792583A0000|32 43|V1b receptors
P10792583A0000|50 61|critical role
P10792583A0000|74 108|pituitary adrenocorticotropic hormone
P10792583A0000|110 113|ACTH
P10792583A0000|115 123|secretion
P10792583A0000|130 139|adaptation
P10792718T0000|0 13|Identification
P10792718T0000|18 30|AfsA homologue
P10792718T0000|32 35|BarX
P10792718T0000|65 84|pleiotropic regulator
P10792718T0000|96 120|autoregulator biosynthesis
P10792718T0000|122 146|virginiamycin biosynthesis
P10792718T0000|150 174|virginiamycin M1 resistance
P10793143A1533|10 24|mutant defective
P10793143A1533|27 36|DNA binding
P10793143A1533|57 83|Abf1 ARS1 DNA-binding activity
P10793143A1533|57 60|Abf1
P10793143A1533|88 94|results
P10793143A1533|106 128|Cdc6 DNA-binding activity
P10793143A1533|106 109|Cdc6
P10793143A1533|137 147|pivotal role
P10793143A1533|153 162|initiation
P10793143A1533|165 178|DNA replication
P10793991A0569|8 24|relative longevity
P10793991A0569|30 32|Web
P10793991A0569|34 47|TIE researchers
P10793991A0569|59 72|unique position
P10793991A0569|82 87|trends
P10793991A0569|90 101|telemedicine
P10794405A0000|3 17|structural study
P10794405A0000|20 27|peptides
P10794405A0000|42 56|terminal domains
P10794405A0000|59 67|histone H1
P10794405A0000|127 128|H1
P10794405A0000|131 139|chromatin
P10794936A0241|3 15|recovery rates
P10794936A0241|22 28|MB/BacT
P10794936A0241|30 33|MGIT
P10794936A0241|41 50|solid media
P10794936A0241|72 72|%
P10794936A0241|93 104|mycobacteria
P10794936A0241|109 121|recovery rates
P10794936A0241|143 143|%
P10794936A0241|161 181|M. tuberculosis complex
P10794936A0241|208 208|%
P10794936A0241|229 254|nontuberculous mycobacteria
P10795098A0253|0 26|Cerebral vasculitis secondary
P10795098A0253|29 33|Crohn
P10795098A0253|57 70|rare phenomenon
P10796465A0373|0 16|SELECTION CRITERIA
P10796465A0373|18 27|Randomised
P10796465A0373|49 54|trials
P10796465A0373|60 70|acupuncture
P10796465A0373|78 83|asthma
P10796465A0373|87 105|asthma-like symptoms
P10796486A0817|0 16|SELECTION CRITERIA
P10796486A0817|18 33|Randomised trials
P10796486A0817|43 50|children
P10796486A0817|61 77|systematic therapy
P10796486A0817|99 109|conjunction
P10796486A0817|114 129|asthma medication
P10796486A0817|135 142|children
P10796486A0817|149 164|asthma medication
P10797125A0000|23 49|progestin-mediated increases
P10797125A0000|59 73|core temperature
P10797125A0000|80 103|core temperature threshold
P10797125A0000|107 119|sweating onset
P10797125A0000|137 144|estrogen
P10797125A0000|160 164|women
P10797125A0000|172 173|yr
P10797125A0000|179 190|degrees C rest
P10797125A0000|200 202|min
P10797125A0000|205 218|passive heating
P10797125A0000|222 229|degrees C
P10797125A0000|243 245|min
P10797125A0000|260 268|degrees C.
P10797586A0402|3 8|models
P10797586A0402|44 55|disturbances
P10797586A0402|61 74|afferent signal
P10797586A0402|82 88|bladder
P10798607A1359|19 35|phagocytic killing
P10798607A1359|38 49|meningococci
P10798607A1359|65 79|consistent assay
P10798607A1359|84 102|antibody titer levels
P10798607A1359|106 130|antimeningococcal immunity
P10798607A1359|144 164|LCC-deficient patients
P10799501A1391|5 11|studies
P10799501A1391|21 39|additional component
P10799501A1391|42 60|cellular environment
P10799501A1391|74 87|SPRK activation
P10799501A1391|74 77|SPRK
P10799501A1391|90 94|Cdc42
P10799576A0196|0 1|M.
P10799590A0431|0 21|Jkappa DNA-binding sites
P10799590A0431|44 53|activation
P10799590A0431|59 84|mutant EBNA-3C protein unable
P10799590A0431|91 96|Jkappa
P10799590A0431|106 118|transcription
P10799590A0431|134 149|wild-type EBNA-3C
P10799590A0431|165 171|EBNA-3C
P10799590A0431|183 195|transcription
P10799590A0431|232 237|Jkappa
P10799595A1454|9 11|YY1
P10799595A1454|15 17|CDP
P10799595A1454|28 45|negative regulators
P10799595A1454|51 88|differentiation-induced HPV-6 E1 promoter
P10799595A1454|74 88|HPV-6 E1 promoter
P10799595A1454|102 113|HPV life cycle
P10799863T0000|0 17|Sequential cleavage
P10799863T0000|20 36|metallopeptidases
P10799863T0000|40 50|proteasomes
P10799863T0000|73 87|HIV-1 ENV epitope
P10799863T0000|91 108|endogenous MHC class
P10799863T0000|101 116|MHC class I antigen
P10799863T0000|110 128|antigen presentation
P10799879T0000|0 6|Cloning
P10799879T0000|10 25|characterization
P10799879T0000|28 35|human Lnk
P10799879T0000|39 52|adaptor protein
P10799879T0000|57 74|pleckstrin homology
P10799879T0000|78 88|Src homology
P10799879T0000|90 96|domains
P10799879T0000|111 125|T cell activation
P10801244A0578|0 13|Vancomycin data
P10801244A0578|38 61|one-compartment open model
P10801244A0578|71 109|NONMEM population pharmacokinetic software
P10801330A1714|8 10|Cas
P10801330A1714|26 32|cytosol
P10801330A1714|36 64|membrane cytoskeleton fractions
P10801330A1714|94 102|unchanged
P10801330A1714|109 127|platelet aggregation
P10801330A1714|133 135|FAK
P10801330A1714|153 172|cytoskeletal fraction
P10801482A0968|14 16|p65
P10801482A0968|29 35|targets
P10801482A0968|46 58|equal affinity
P10801482A0968|66 82|different residues
P10801482A0968|87 99|variable roles
P10801482A0968|109 130|different kappaB targets
P10801482A0968|118 130|kappaB targets
P10801809T0000|0 24|Transcriptional regulation
P10801809T0000|30 46|yeast PHO8 promoter
P10801809T0000|64 86|coregulated PHO5 promoter
P10801809T0000|75 86|PHO5 promoter
P10801860A0000|3 9|Siglecs
P10801860A0000|14 22|subfamily
P10801860A0000|25 37|I-type lectins
P10801860A0000|39 71|immunoglobulin superfamily proteins
P10801860A0000|80 85|sugars
P10801860A0000|112 122|sialic acids
P10802669A1434|15 36|biochemical explanation
P10802669A1434|55 63|phenotype
P10802669A1434|71 73|A-T
P10802669A1434|77 79|NBS
P10802909A0478|0 26|PATIENTS OR OTHER PARTICIPANTS
P10802909A0478|34 41|children
P10804379T0001|0 5|Update
P10804379T0001|8 31|maternal-fetal infections
P10804379T0001|34 43|hepatitis C
P10804379T0001|45 47|HIV
P10804379T0001|51 65|cytomegalovirus
P10805286A0233|5 16|present study
P10805286A0233|33 44|cis-elements
P10805286A0233|50 61|human PCI gene
P10805286A0233|88 111|hepatoma-derived cell line
P10805286A0233|113 122|HepG2 cells
P10805286A0233|140 159|rat PCI mRNA expression
P10805286A0233|143 149|PCI mRNA
P10805286A0233|186 193|androgen
P10805286A0233|196 217|rat reproductive tissues
P10805286A0914|12 28|PCI mRNA expression
P10805286A0914|12 18|PCI mRNA
P10805286A0914|34 51|reproductive organs
P10805286A0914|66 75|rat PCI cDNA
P10805286A0914|103 110|androgen
P10805286A0914|116 132|PCI mRNA expression
P10805286A0914|116 122|PCI mRNA
P10805390A0340|27 38|measurements
P10805390A0340|41 57|photoluminescence
P10805390A0340|60 86|GaAs/AlGaAs heterostructures
P10805729A0987|3 15|stoichiometry
P10805729A0987|21 29|complexes
P10805729A0987|43 65|dodeca-satellite C strand
P10805729A0987|81 84|DDP1
P10805729A0987|91 110|consecutive KH domains
P10805729A0987|144 169|nucleic acid binding surfaces
P10805737T0000|0 17|Mutational analysis
P10805737T0000|20 56|mammalian translation initiation factor 5
P10805737T0000|20 55|mammalian translation initiation factor
P10805737T0000|58 61|eIF5
P10805737T0000|91 101|beta subunit
P10805737T0000|104 107|eIF2
P10805737T0000|111 114|eIF5
P10805737T0000|117 128|eIF5 function
P10805737T0000|117 120|eIF5
P10805738A0799|0 11|Much evidence
P10805738A0799|25 27|p38
P10805738A0799|32 40|activator
P10805738A0799|43 46|MyoD
P10805738A0799|51 67|p38 kinase activity
P10805738A0799|51 59|p38 kinase
P10805738A0799|96 115|MyoD-responsive genes
P10805738A0799|129 137|induction
P10805738A0799|140 142|p38
P10805738A0799|156 178|transcriptional activity
P10805738A0799|182 203|Gal4-MyoD fusion protein
P10805738A0799|182 185|Gal4
P10805738A0799|187 190|MyoD
P10805738A0799|213 231|efficient activation
P10805738A0799|234 262|chromatin-integrated reporters
P10805738A0799|265 268|MyoD
P10805738A0799|278 309|MyoD-dependent myogenic conversion
P10805738A0799|278 281|MyoD
P10805738A0799|321 345|mouse embryonic fibroblasts
P10805738A0799|357 364|p38alpha
P10805738A0799|370 376|embryos
P10805739A0343|26 41|complex formation
P10805739A0343|49 66|other eIF2B subunits
P10805739A0343|54 66|eIF2B subunits
P10805739A0640|13 29|nonsense mutations
P10805739A0640|46 54|C terminus
P10805739A0640|57 68|eIF2Bepsilon
P10805739A0640|70 77|residues
P10805739A0640|104 120|catalytic activity
P10805739A0640|139 142|eIF2
P10805747A0633|11 19|mutations
P10805747A0633|40 59|Nim1p-related kinases
P10805747A0633|75 79|Hsl1p
P10805747A0633|83 87|Kcc4p
P10805747A0633|98 113|detectable effect
P10805747A0633|116 133|septin organization
P10805823A1920|0 10|CONCLUSIONS
P10805823A1920|12 28|Physiologic pacing
P10805823A1920|37 49|little benefit
P10805823A1920|54 70|ventricular pacing
P10805823A1920|97 104|death due
P10805823A1920|107 126|cardiovascular causes
P10807900A0933|5 18|non-cirrhotics
P10807900A0933|26 48|portal vein visualisation
P10807900A0933|55 66|% sensitivity
P10807900A0933|70 81|% specificity
P10807900A0933|85 108|% negative predictive value
P10807900A0933|115 138|% positive predictive value
P10807900A0933|155 186|pre-sinusoidal portal hypertension
P10807903A0362|0 4|D5/D1
P10807903A0362|6 7|CT
P10807903A0362|11 16|D5/D1D
P10807903A0362|18 19|CT
P10807903A0362|21 43|tail substitution mutants
P10807903A0362|54 62|rank order
P10807903A0362|65 71|potency
P10807903A0362|75 91|agonist affinities
P10807903A0362|110 118|wild-type
P10807903A0362|120 121|wt
P10807903A0362|123 133|D1 receptors
P10807903A0362|150 162|ligand binding
P10807903A0362|166 206|dopamine-stimulated cAMP accumulation assays
P10807903A0362|221 233|wt D1 receptors
P10807903A0362|241 275|exhibit receptor constitutive activity
P10807903A0362|278 291|responsiveness
P10807903A0362|294 308|inverse agonists
P10809233A0606|0 7|Modeling
P10809233A0606|25 45|hydrophobic surface due
P10809233A0606|60 62|H12
P10809233A0606|72 79|residues
P10809233A0606|84 93|H3, loop 3-4
P10809233A0606|84 85|H3
P10809233A0606|95 96|H4
P10809233A0606|101 103|H11
P10810083A1283|3 28|serine-threonine kinase gene
P10810083A1283|31 46|likely functional
P10810083A1283|58 72|zinc finger motif
P10810083A1283|75 93|likely nonfunctional
P10810294A0730|0 13|Stat activation
P10810294A0730|0 3|Stat
P10810294A0730|26 27|GH
P10810294A0730|31 34|IL-6
P10810294A0730|50 70|reporter gene induction
P10810745A0677|0 6|HFA 134a
P10810745A0677|11 25|greater tendency
P10810745A0677|34 41|moisture
P10810745A0677|67 69|HFA
P10811079A0555|0 6|RESULTS
P10811079A0555|8 30|Abnormal color perception
P10811079A0555|43 43|%
P10811079A0555|49 64|epilepsy patients
P10811079A0555|76 96|vigabatrin monotherapy
P10811079A0555|102 102|%
P10811079A0555|108 123|epilepsy patients
P10811079A0555|135 158|carbamazepine monotherapy
P10811079A1277|5 21|SPP2 screening test
P10811079A1277|24 32|few plates
P10811079A1277|50 55|groups
P10811804A0000|0 23|Mitogen-activated protein
P10811804A0000|25 47|MAP) kinase phosphatase-3
P10811804A0000|25 27|MAP
P10811804A0000|29 47|kinase phosphatase-3
P10811804A0000|49 53|MKP-3
P10811804A0000|58 83|dual specificity phosphatase
P10811804A0000|99 133|extracellular signal-regulated kinase
P10811804A0000|135 137|ERK
P10811804A0000|139 148|MAP kinases
P10811804A0800|0 9|Consistent
P10811804A0800|29 36|peptides
P10811804A0800|49 60|docking sites
P10811804A0800|70 90|target substrates Elk-1
P10811804A0800|86 90|Elk-1
P10811804A0800|94 96|p90
P10811804A0800|98 100|rsk
P10811804A0800|109 131|ERK-dependent activation
P10811804A0800|109 111|ERK
P10811804A0800|134 138|MKP-3
P10811908A0938|0 24|HPLC phosphopeptide mapping
P10811908A0938|26 44|amino acid sequencing
P10811908A0938|49 72|site-directed mutagenesis
P10811908A0938|87 90|NCLK
P10811908A0938|105 107|Ser
P10811908A0938|114 116|I-1
P10812294X0000|7 16|entire diet
P10812294X0000|28 30|SBF
P10812294X0000|32 50|voluntary feed intake
P10812294X0000|76 78|SBF
P10812294X0000|95 100|ponies
P10812294X0000|106 126|sole dietary ingredient
P10814989T0000|0 23|Hepatitis C virus infection
P10814989T0000|27 53|lymphoproliferative diseases
P10814989T0000|56 61|France
P10814989T0000|64 76|national study
P10815410A0000|3 14|immune system
P10815410A0000|41 60|neuroendocrine system
P10815410A0000|65 90|infection-induced increases
P10815410A0000|93 105|cytokines such
P10815410A0000|108 111|IL-1
P10815410A0000|113 116|IL-6
P10815410A0000|120 122|TNF
P10815410A0000|127 141|numerous effects
P10815410A0000|147 166|central nervous system
P10815807A1271|24 36|transcription
P10815807A1271|44 66|endogenous c-Myb promoter
P10815807A1271|80 92|several HTLV-I
P10815807A1271|104 114|T-cell lines
P10817754T0000|0 2|H19
P10817754T0000|6 30|Igf2 monoallelic expression
P10817754T0000|6 9|Igf2
P10817754T0000|47 58|distinct ways
P10817754T0000|62 70|shared cis
P10817754T0000|77 100|regulatory region upstream
P10817754T0000|103 105|H19
P10819327T0000|0 14|C. elegans KLP-11
P10819327T0000|16 20|OSM-3
P10819327T0000|22 26|KAP-1
P10819327T0000|28 36|orthologs
P10819327T0000|42 60|sea urchin kinesin-II
P10819327T0000|65 100|mouse KIF3A/KIFB/KAP3 kinesin complexes
P10819327T0000|70 74|KIF3A
P10819327T0000|76 79|KIFB
P10820829T0000|0 9|Flavonoids
P10820829T0000|14 32|Brosimum acutifolium
P10820904A0000|0 9|BACKGROUND
P10820904A0000|11 31|Hepatic encephalopathy
P10820904A0000|35 58|neuropsychiatric syndrome
P10820904A0000|73 89|acute liver failure
P10820904A0000|91 120|chronic parenchymal liver disease
P10820904A0000|123 147|portal systemic anastomosis
P10821836A0842|5 32|natural antisense S transcripts
P10821836A0842|56 80|abundant sense S transcripts
P10822117A1386|5 26|such adjustment possible
P10822117A1386|69 80|observations
P10822117A1386|114 127|subject-models
P10822117A1386|145 154|untestable
P10823630A1124|21 30|effacement
P10823630A1124|56 73|practical parameter
P10823837A1213|10 19|compatible
P10823837A1213|35 50|YLL031c transfers
P10823837A1213|35 41|YLL031c
P10823837A1213|54 74|ethanolaminephosphate
P10823837A1213|80 106|inner alpha1-2-linked mannose
P10823837A1213|132 145|GPI lipid anchor
P10823837A1213|148 155|proteins
P10823837A1213|164 168|Mcd4p
P10823837A1213|172 205|Gpi7p transfer ethanolaminephosphate
P10823837A1213|172 176|Gpi7p
P10823837A1213|213 220|alpha1-4
P10823837A1213|225 247|alpha1-6-linked mannoses
P10823837A1213|253 261|GPI anchor
P10823961A0664|3 11|C terminus
P10823961A0664|14 17|TRBP
P10823961A0664|25 32|CBP/p300
P10823961A0664|25 27|CBP
P10823961A0664|29 32|p300
P10823961A0664|36 42|DRIP130
P10823961A0664|59 78|DRIP/TRAP/ARC complex
P10823961A0664|59 62|DRIP
P10823961A0664|64 67|TRAP
P10823961A0664|69 71|ARC
P10823961A0664|97 100|TRBP
P10823961A0664|112 124|transcription
P10823961A0664|127 131|means
P10823961A0664|134 149|such interactions
P10824485A0393|3 10|patients
P10824485A0393|27 46|mucocutaneous disease
P10824485A0393|54 59|low CD4
P10824485A0393|61 77|T lymphocyte counts
P10824485A0393|107 115|illnesses
P10824958A1109|9 21|dietary energy
P10824958A1109|31 33|PAB
P10824958A1109|50 58|dietary CO
P10824958A1109|69 70|PF
P10824958A1109|80 83|PSHL
P10824958A1109|86 100|broiler breeders
P10824958A1109|115 116|wk
P10825000A1245|3 24|gene amplification model
P10825000A1245|27 34|Coquelle
P10825200T0000|0 8|Hierarchy
P10825200T0000|11 32|protein tyrosine kinases
P10825200T0000|35 47|interleukin-2
P10825200T0000|49 52|IL-2
P10825200T0000|54 62|signaling
P10825200T0000|64 73|activation
P10825200T0000|76 78|syk
P10825200T0000|88 91|Jak3
P10825200T0000|108 110|Syk
P10825200T0000|114 116|Lck
P10825200T0000|130 156|IL-2-mediated STAT activation
P10825200T0000|130 133|IL-2
P10825200T0000|143 146|STAT
P10825293T0000|11 16|dimers
P10825293T0000|19 38|N-cadherin-Fc chimera
P10825293T0000|19 28|N-cadherin
P10825293T0000|30 31|Fc
P10825293T0000|44 80|cadherin-mediated cell contact formation
P10825293T0000|100 109|outside-in
P10825293T0000|113 129|inside-out signals
P10825294A0473|11 20|OC promoter
P10825294A0473|35 58|C terminus dependent manner
P10825294A0473|63 65|MDR
P10825294A0473|67 69|LTR
P10825294A0473|73 84|BSP promoters
P10825294A0473|104 121|distinct mechanisms
P10825294A0473|156 167|AML C terminus
P10825294A0473|196 222|C-terminal pentapeptide VWRPY
P10826861A0000|3 34|monoclonal immunoglobulin products
P10826861A0000|37 54|plasma cell neoplasm
P10826861A0000|78 91|manifestations
P10826861A0000|101 114|hyperviscosity
P10826861A0000|116 126|amyloidosis
P10826861A0000|128 143|cryoglobulinemia
P10826861A0000|145 154|neuropathy
P10826861A0000|159 170|renal failure
P10826946A1198|0 12|Investigation
P10826946A1198|18 32|structural basis
P10826946A1198|56 63|human Igs
P10826946A1198|67 71|gp120
P10826946A1198|84 96|viral gp120 SAg
P10826946A1198|117 122|subset
P10826946A1198|125 130|human V
P10826946A1198|132 132|H
P10826946A1198|136 138|Igs
P10827885T0059|0 11|Double-blind
P10827885T0059|13 35|placebo-controlled trial
P10827952A0158|18 25|TAFII250
P10827952A0158|30 43|largest subunit
P10827952A0158|46 50|TFIID
P10827952A0158|63 86|tandem bromodomain modules
P10827952A0158|126 142|histone H4 peptides
P10828022A0877|0 18|Endostatin treatment
P10828022A0877|24 30|minutes
P10828022A0877|35 39|hours
P10828022A0877|47 69|tyrosine phosphorylation
P10828022A0877|72 74|Shb
P10828022A0877|89 109|multiprotein complexes
P10828319A0342|10 16|analogs
P10828319A0342|19 27|vitamin D3
P10828319A0342|59 64|trials
P10828319A0342|85 93|psoriasis
P10828591A0080|3 12|transcript
P10828591A0080|38 56|partial cDNA sequence
P10828591A0080|83 95|transcript map
P10828591A0080|114 128|markers D11S1765
P10828591A0080|121 128|D11S1765
P10828591A0080|132 142|uteroglobin
P10828591A0080|173 183|Best disease
P10828751A2258|3 15|real challenge
P10828751A2258|49 56|patients
P10828751A2258|74 92|first-line treatment
P10829973T0000|0 24|Iodine deficiency disorders
P10829973T0000|27 36|Bangladesh
P10830395A0408|3 18|network evolution
P10830395A0408|55 64|Flory model
P10831972A0744|0 6|RESULTS
P10831972A0744|8 24|Soluble CD23 levels
P10831972A0744|15 18|CD23
P10831972A0744|42 47|higher
P10831972A0744|50 54|women
P10831972A0744|59 71|endometriosis
P10831972A0744|96 109|normal controls
P10831972A1091|0 9|CONCLUSION
P10831972A1091|14 21|findings
P10831972A1091|33 45|endometriosis
P10831972A1091|55 71|soluble CD23 levels
P10831972A1091|62 65|CD23
P10831972A1091|103 109|danazol
P10831972A1091|112 137|leuprolide acetate injection
P10833461A0603|19 41|P-1 artificial chromosome
P10833461A0603|43 45|PAC
P10833461A0603|70 90|full length UGT2B7 probe
P10833461A0603|70 85|full length UGT2B7
P10833461A0603|95 99|clone
P10833461A0603|118 119|kb
P10833486A0598|0 2|Age
P10833486A0598|5 5|=
P10833486A0598|8 12|years
P10833486A0598|14 22|odds ratio
P10833486A0598|24 25|OR
P10833486A0598|34 36|BMI
P10833486A0598|39 39|=
P10833486A0598|42 45|kg/m
P10833486A0598|50 51|OR
P10833486A0598|58 70|triglycerides
P10833486A0598|73 73|=
P10833486A0598|77 82|mmol/L
P10833486A0598|84 85|OR
P10833486A0598|93 115|alanine aminotransferase
P10833486A0598|117 119|ALT
P10833486A0598|123 125|= 2N
P10833486A0598|127 128|OR
P10833486A0598|165 178|septal fibrosis
P10834707A1533|12 29|significant amounts
P10834707A1533|32 55|platelet activating factor
P10834707A1533|73 79|sorbent
P10834707A1533|89 107|entire treatment time
P10834781A0693|11 22|elderly group
P10834781A0693|52 65|residence times
P10834781A0693|67 70|MRTs
P10834781A0693|75 94|lower plasma clearance
P10834781A0693|97 105|lidocaine
P10834781A0693|136 145|adult group
P10834781A0693|147 147|P
P10835355A0225|18 38|zinc finger protein Gis1
P10835355A0225|46 71|dosage-dependent suppressor
P10835355A0225|77 92|rim15Delta defect
P10835355A0225|77 86|rim15Delta
P10835355A0225|95 147|nutrient limitation-induced transcriptional derepression
P10835355A0225|150 153|SSA3
P10835485A0941|13 15|SH3
P10835485A0941|29 40|linker domain
P10835485A0941|58 89|species-specific sequence identity
P10835485A0941|101 117|amino acid residues
P10835485A0941|124 130|factors
P10835732A0911|2 12|differences
P10835732A0911|15 36|total cholesterol levels
P10835732A0911|56 63|mapuches
P10835732A0911|67 73|aymaras
P10836542A0363|6 6|%
P10836542A0363|12 26|total UV exposure
P10836542A0363|42 53|UV-A waveband
P10836542A0363|62 63|nm
P10836786A0516|33 43|RNA subunits
P10836786A0516|46 59|enzyme function
P10836786A0516|63 82|substrate specificity
P10836786A0516|96 112|hairpin structures
P10836786A0516|114 117|MRP3
P10836786A0516|121 122|P3
P10836786A0516|131 141|RNase MRP RNA
P10836786A0516|145 153|RNase P RNA
P10837126A1004|5 9|genes
P10837126A1004|24 34|pMesogenin1
P10837126A1004|37 42|Xwnt-8
P10837126A1004|45 59|signaling factor
P10837126A1004|72 88|similar repertoire
P10837126A1004|91 101|marker genes
P10837126A1004|106 129|similar cellular phenotype
P10838139A1447|14 24|Ha-ras codon
P10838139A1447|27 35|mutations
P10838139A1447|49 73|EtNU-induced mammary tumors
P10838399A0525|0 18|False positive PET FDG
P10838399A0525|33 45|lung infection
P10838399A0525|47 69|degenerative bone disease
P10838399A0525|74 95|reconstruction artifact
P10838531A0675|0 10|Tumor stages
P10838531A0675|15 17|IIB
P10838531A0675|19 22|T3 N0
P10838531A0675|28 28|%
P10838531A0675|30 33|IIIA
P10838531A0675|38 38|%
P10838531A0675|43 46|IIIB
P10838531A0675|51 51|%
P10838531A0675|54 61|patients
P10839470A1148|22 41|percentage reductions
P10839470A1148|44 52|heart rate
P10839470A1148|55 60|supine
P10839470A1148|90 104|measure analysis
P10839470A1148|114 119|Malays
P10839470A1148|139 150|higher change
P10839470A1148|172 173|p =
P10839547A0978|0 9|Consistent
P10839547A0978|23 33|CTCF binding
P10839547A0978|23 26|CTCF
P10839547A0978|47 60|DNA methylation
P10839593A0000|0 8|OBJECTIVE
P10839593A0000|24 31|efficacy
P10839593A0000|43 69|amphotericin B oral suspension
P10839593A0000|71 74|ABOS
P10839593A0000|93 128|fluconazole refractory oral candidiasis
P10839593A0000|131 137|persons
P10839593A0000|142 153|HIV infection
P10840001A0188|0 18|Mucin gene expression
P10840001A0188|0 8|Mucin gene
P10840001A0188|44 65|many intestinal diseases
P10840001A0188|79 85|cancers
P10840001A0188|91 111|gastrointestinal tract
P10841537A0669|23 29|regions
P10841537A0669|32 35|RPB5
P10841537A0669|51 62|interactions
P10841537A0669|86 123|surface-exposed alpha-helical structures
P10841593A0780|27 36|% reduction
P10841593A0780|39 58|cigarette consumption
P10841593A0780|92 106|nicotine patches
P10841601T0000|0 9|Paper alert
P10843716A0406|3 15|tryptase locus
P10843716A0406|39 62|tryptase-like pseudogenes
P10843716A0406|73 78|mastin
P10843716A0406|96 99|dogs
P10843716A0406|108 113|humans
P10843810A0802|3 14|cellular part
P10843810A0802|20 37|third chimeric clone
P10843810A0802|43 61|significant homology
P10843810A0802|66 69|exon
P10843810A0802|75 103|human tyrosine phosphatase 1 gene
P10843810A0802|75 98|human tyrosine phosphatase
P10843810A0802|126 143|antisense direction
P10843810A0802|157 167|adjacent LTR
P10845522A0000|0 8|OBJECTIVE
P10845522A0000|42 54|relative roles
P10845522A0000|57 88|99mTc-sestamibi scintimammography
P10845522A0000|92 101|sonography
P10845522A0000|119 131|breast lesions
P10845522A0000|139 151|indeterminate
P10845522A0000|166 176|mammography
P10845522A0000|179 197|clinical examination
P10846054A0573|0 17|Mutational analyses
P10846054A0573|40 45|codons
P10846054A0573|71 73|RNA
P10846054A0573|75 78|ORFs
P10846054A0573|91 102|accumulation
P10846054A0573|105 118|progeny LIYV RNA
P10846054A0573|112 119|LIYV RNA 1
P10846054A0573|122 125|RNA 2
P10846054A0573|122 124|RNA
P10846054A0573|141 144|RNA 2
P10846054A0573|141 143|RNA
P10846054A0573|158 174|proteins necessary
P10846054A0573|178 195|LIYV RNA replication
P10846069T0000|0 3|Role
P10846069T0000|6 7|NH
P10846069T0000|15 34|COOH-terminal domains
P10846069T0000|40 47|P protein
P10846069T0000|50 76|human parainfluenza virus type
P10846069T0000|80 92|transcription
P10846069T0000|96 106|replication
P10848605T0000|0 14|Phosphorylation
P10848605T0000|17 32|tyrosine residues
P10848605T0000|38 49|kinase domain
P10848605T0000|53 71|juxtamembrane region
P10848605T0000|97 115|catalytic activities
P10848605T0000|118 129|Eph receptors
P10848848A0413|0 6|RESULTS
P10848848A0413|8 15|Fournier
P10848848A0413|18 25|gangrene
P10848993A0000|0 19|Genomic DNA sequencing
P10848993A0000|25 32|vicinity
P10848993A0000|35 61|methylmalonyl-CoA mutase gene
P10848993A0000|63 67|mutAB
P10848993A0000|74 122|rifamycin SV-producing Amycolatopsis mediterranei U32
P10848993A0000|134 138|clone
P10848993A0000|174 207|novel serine/threonine protein kinase
P10848993A0000|179 207|serine/threonine protein kinase
P10848993A0000|209 211|amk
P10850329A0248|0 3|IL-2
P10850329A0248|17 33|standard treatment
P10850329A0248|63 74|chemotherapy
P10850329A0248|77 86|biotherapy
P10850329A0248|104 121|metastatic melanoma
P10850329A0248|125 152|metastatic renal cell carcinoma
P10850453A0713|21 35|antisense Ha-Ras
P10850453A0713|38 58|dominant negative Raf-1
P10850453A0713|71 85|mitogenic effect
P10850453A0713|88 96|TGF-beta1
P10850453A0713|99 105|TSU-Pr1
P10850453A0713|113 131|TGF-beta1 inhibition
P10850453A0713|113 121|TGF-beta1
P10850453A0713|134 138|DU145
P10850453A0713|152 162|stimulation
P10850453A0713|165 185|V12Ha-Ras transfection
P10850453A0713|165 173|V12Ha-Ras
P10850453A1292|32 49|prostate carcinomas
P10850453A1292|57 81|Ras/MAPK pathway activation
P10850453A1292|57 59|Ras
P10850453A1292|61 64|MAPK
P10850453A1292|92 115|selective growth advantage
P10850453A1292|118 145|autocrine TGF-beta1 production
P10850453A1292|127 135|TGF-beta1
P10850719A0680|0 12|Vbeta segments
P10850719A0680|26 45|DJbeta rearrangements
P10850719A0680|26 31|DJbeta
P10850719A0680|61 71|direct Vbeta
P10850719A0680|67 71|Vbeta
P10850719A0680|74 78|Jbeta
P10850719A0680|99 111|compatibility
P10850719A0680|114 125|Vbeta 23-RSSs
P10850719A0680|129 140|Jbeta12-RSSs
P10850849A0730|3 20|oral administration
P10850849A0730|22 34|AUC0-infinity
P10850849A0730|51 61|microg x h/ml
P10850849A0730|63 70|t1/2beta
P10850849A0730|86 90|hours
P10850849A0730|92 111|maximum concentration
P10850849A0730|113 116|Cmax
P10850849A0730|133 141|microg/ml
P10850849A0730|149 152|Cmax
P10850849A0730|167 171|hours
P10850849A0730|177 190|absorption time
P10850849A0730|205 209|hours
P10850849A0730|214 228|bioavailability
P10850849A0730|241 241|%
P10850942A0989|28 42|gastric emptying
P10850942A0989|47 54|% peptone
P10850942A0989|59 66|% glucose
P10850942A0989|82 85|rats
P10850942A0989|95 97|TPN
P10850942A0989|115 135|intragastric nutrition
P10850942A0989|145 148|days
P10850997A1016|11 32|H-NS negative regulation
P10850997A1016|59 61|Fur
P10851089A1248|5 7|SAG
P10851089A1248|24 43|cell cycle progression
P10851089A1248|46 50|yeast
P10851089A1248|62 75|ubiquitination
P10851089A1248|79 89|degradation
P10851089A1248|92 118|cell cycle regulatory proteins
P10851267A0000|0 4|E2F -1
P10851267A0000|0 2|E2F
P10851267A0000|8 26|transcription factor
P10851267A0000|40 59|cell cycle progression
P10851267A0000|64 70|S-phase
P10851745A0624|21 33|negative moods
P10851745A0624|38 51|impaired health
P10852221A0422|34 47|graft recipient
P10852221A0422|62 72|short period
P10852221A0422|98 112|favorable effect
P10852221A0422|135 153|dopaminergic neurons
P10852460A0170|3 15|relationships
P10852460A0170|21 39|blood concentrations
P10852460A0170|42 56|thyroid hormones
P10852460A0170|60 67|selenium
P10852460A0170|69 72|zinc
P10852460A0170|74 80|retinol
P10852460A0170|85 100|alpha-tocopherol
P10852460A0170|116 155|healthy Northern Italian oldest-old subjects
P10852460A0170|157 164|age range
P10852460A0170|172 173|yr
P10852460A0170|202 216|SENIEUR protocol
P10852485A0477|0 12|Chinese Spring
P10852485A0477|14 15|CS
P10852485A0477|28 32|Q gene
P10852485A0477|43 64|chromosome deletion line
P10852485A0477|67 68|CS
P10852485A0477|77 78|q5
P10852485A0477|92 92|%
P10852485A0477|95 97|5AL
P10852485A0477|110 114|Q gene
P10852953A0000|0 13|Investigations
P10852953A0000|19 35|hippocampal slices
P10852953A0000|73 78|bursts
P10852953A0000|81 106|oscillatory field potentials
P10852953A0000|112 130|gamma frequency range
P10852953A0000|137 138|Hz
P10852953A0000|154 170|slower oscillation
P10852953A0000|176 179|beta
P10852953A0000|192 193|Hz
P10853059X0751|0 7|Karger AG
P10853059X0751|9 13|Basel
P10853778A0316|6 21|surgery bone cysts
P10853778A0316|44 53|bone grafts
P10853850A1103|0 10|Urinary LTE4
P10853850A1103|29 38|challenges
P10853850A1103|51 56|higher
P10853850A1103|82 102|inhalation provocation
P10853850A1103|104 105|p=
P10854004A0788|0 7|Basal FVR
P10854004A0788|35 35|%
P10854004A0788|38 40|ERT
P10854004A0788|44 46|HRT
P10854004A0788|51 62|FVR responses
P10854004A0788|65 77|noradrenaline
P10854004A0788|79 91|angiotensin II
P10854004A0788|79 89|angiotensin
P10854004A0788|93 105|acetylcholine
P10854004A0788|109 121|nitroprusside
P10854004A0788|126 135|unaffected
P10854699A0424|5 15|FGF-AS cDNAs
P10854699A0424|32 52|full-length FGF-AS mRNA
P10854699A0424|59 83|alternative splice variants
P10854699A0424|91 94|exon
P10854699A0424|98 102|exons
P10854699A0424|113 126|FGF-AS sequence
P10855690A0870|19 25|results
P10855690A0870|38 46|MAP kinase
P10855690A0870|60 72|hPL-B enhancer
P10855690A0870|77 100|NF-IL-6-dependent pathway
P10855690A0870|77 83|NF-IL-6
P10855793A1418|0 15|Characterization
P10855793A1418|18 32|polymorphic TNRs
P10855793A1418|47 56|known genes
P10855793A1418|68 82|human spinal cord
P10855793A1418|118 130|new candidates
P10855793A1418|134 138|genes
P10855793A1418|149 174|neurodegenerative disorders
P10855796A1160|14 36|RNA hybridization studies
P10855796A1160|50 64|specific pattern
P10855796A1160|67 95|EphA8 gene expression restricted
P10855796A1160|67 75|EphA8 gene
P10855796A1160|101 113|rostral region
P10855796A1160|116 129|midbrain tectum
P10855796A1160|136 155|embryonic development
P10856298A0798|0 11|Transfection
P10856298A0798|14 18|cDNAs
P10856298A0798|27 39|mutant enzymes
P10856298A0798|44 76|FPGS-null Chinese hamster ovary cells
P10856298A0798|44 47|FPGS
P10856298A0798|100 111|clonal growth
P10856298A0798|121 131|T339I mutant
P10856298A0798|150 164|level comparable
P10856298A0798|176 190|wild-type enzyme
P10856491A0178|0 6|SETTING
P10856491A0178|8 17|University
P10856491A0178|20 35|Paris VII hospital
P10856491A0178|37 43|Patient
P10856491A0178|45 45|s
P10856491A0178|52 56|women
P10856491A0178|60 71|embolization
P10856491A0178|75 90|symptomatic myoma
P10856491A0178|98 108|pregnancies
P10856805T0000|0 29|Improving fissure sealant quality
P10856805T0000|31 51|mechanical preparation
P10857215A0000|3 24|Menopause-Rating-Scale
P10857215A0000|26 29|MRS I
P10857215A0000|40 55|clinical practice
P10857215A0806|3 7|MRS II
P10857215A0806|14 39|high methodological standard
P10857215A0806|44 65|instrument standardized
P10857262A0186|22 35|fruA transcript
P10857262A0186|58 83|D. melanogaster type A protein
P10857262A0186|58 59|D.
P10857262A0186|72 83|type A protein
P10857262A0186|100 131|BTB protein-protein-binding domain
P10857262A0186|149 153|exons
P10857262A0186|168 168|%
P10857751A0304|14 26|mouse ortholog
P10857751A0304|28 41|Mharp/Smarcal1
P10857751A0304|28 32|Mharp
P10857751A0304|34 41|Smarcal1
P10857751A0304|59 87|Caenorhabditis elegans ortholog
P10857751A0304|89 94|CEHARP
P10857751A0304|114 128|GenBank database
P10858355A0920|0 11|Sparfloxacin
P10858355A0920|15 27|clinafloxacin
P10858355A0920|48 72|Enterococcus faecium SF2149
P10858355A0920|76 100|Enterococcus faecalis WH245
P10858988A0786|0 2|ECP
P10858988A0786|6 19|tryptase levels
P10858988A0786|6 13|tryptase
P10858988A0786|22 26|serum
P10858988A0786|56 72|last oral challenge
P10860131A0847|0 15|Tolterodine users
P10860131A0847|23 27|times
P10860131A0847|59 73|spasmolytic drug
P10860131A0847|75 76|RR
P10860131A0847|83 85|% CI
P10860196A0876|5 23|unsupervised program
P10860196A0876|28 32|costs
P10860196A0876|58 66|first year
P10860196A0876|79 93|additional years
P10860752A1601|18 28|putative RNA
P10860752A1601|26 42|RNA- binding domain
P10860752A1601|30 42|binding domain
P10860752A1601|75 88|autoregulation
P10860752A1601|91 127|bacteriophage T4 DNA polymerase synthesis
P10860752A1601|142 148|own mRNA
P10860827A0399|0 7|Deletion
P10860827A0399|11 28|mutational analyses
P10860827A0399|40 69|positive cis-regulatory elements
P10860827A0399|101 114|CSX1 expression
P10860827A0399|101 104|CSX1
P10860827A0399|117 130|cardiomyocytes
P10860846A0480|0 16|Functional studies
P10860846A0480|33 40|mutation
P10860846A0480|46 65|AP2 core binding region
P10860846A0480|74 98|cotransfection experiments
P10860846A0480|106 124|AP2 expression vector
P10860846A0480|106 108|AP2
P10860846A0480|137 139|AP2
P10860846A0480|147 160|repressive role
P10860846A0480|166 188|HGF gene promoter activity
P10860846A0480|166 180|HGF gene promoter
P10861080A0433|5 22|adenoviral transfer
P10861080A0433|25 36|IkappaBalpha
P10861080A0433|38 63|IkappaBalpha overexpression
P10861080A0433|38 49|IkappaBalpha
P10861080A0433|81 89|TNF-alpha
P10861080A0433|99 106|whole GBS
P10861080A0433|127 127|%
P10861086A0259|2 26|reconstitution experiments
P10861086A0259|60 62|RAW
P10861086A0259|68 75|cell line
P10861086A0259|78 96|C-terminal Src kinase
P10861086A0259|98 100|Csk
P10861086A0259|121 137|membrane-anchored
P10861086A0259|139 157|gain-of-function Csk
P10861086A0259|155 157|Csk
P10861086A0259|170 195|Fc gamma R-mediated signaling
P10861086A0259|170 177|Fc gamma R
P10861086A0259|207 218|phagocytosis
P10861086A0259|222 243|kinase-dependent manner
P10861086A0904|11 32|c-Src-derived construct
P10861086A0904|34 38|a-Src
P10861086A0904|60 87|detergent-resistant membranes
P10861086A0904|115 135|phagocytosis signaling
P10861906A0999|3 20|delta srb10 mutation
P10861906A0999|40 55|transcript levels
P10861906A0999|58 78|meiosis-inducing genes
P10861906A0999|85 88|IME1
P10861906A0999|92 95|IME2
P10861906A0999|100 107|mutation
P10861906A0999|119 133|transcript level
P10861906A0999|136 139|IME1
P10861906A0999|156 159|IME2
P10861906A0999|172 185|partial defects
P10861906A0999|188 209|premeiotic DNA synthesis
P10861906A0999|213 219|meiosis
P10861906A1479|15 37|environmental conditions
P10861906A1479|41 47|meiosis
P10861906A1479|65 80|transcript levels
P10861906A1479|83 87|KIN28
P10861906A1479|91 94|CCL1
P10861906A1479|104 121|nitrogen starvation
P10861906A1479|142 163|subsequent alkalization
P10861909A0502|3 12|pJR vectors
P10861909A0502|37 52|selectable marker
P10861909A0502|54 84|Saccharomyces cerevisiae LEU 2 gene
P10861909A0502|77 79|LEU
P10861909A0502|102 117|S. pombe leu1- gene
P10861909A0502|102 103|S.
P10861909A0502|121 122|S.
P10861909A0502|128 132|ura4+
P10861909A0502|128 131|ura4
P10861909A0502|136 145|his3+ genes
P10861909A0502|136 139|his3
P10861909A0502|141 145|genes
P10861909A0502|154 185|thiamine-repressible nmt1 promoter
P10861909A0502|174 185|nmt1 promoter
P10861909A0502|187 188|3X
P10861909A0502|190 192|41X
P10861909A0502|196 198|81X
P10861909A0502|227 252|low transcription efficiency
P10861909A0502|277 295|multiple cloning site
P10861909A0502|315 319|sites
P10861909A0502|327 342|restriction sites
P10862289A0289|1 3|GUT
P10862289A0289|5 8|Sera
P10862289A0289|13 40|montoux negative healthy adults
P10862289A0289|42 48|age/sex
P10862289A0289|86 98|IgG anti bodies
P10862289A0289|101 110|A60 antigen
P10863048A0000|11 15|acute
P10863048A0000|17 45|mid-cervical spinal cord lesions
P10863048A0000|48 55|neuronal
P10863048A0000|59 72|reflex activity
P10863048A0000|84 106|noxious visceral stimulus
P10863048A0000|108 127|colorectal distension
P10863048A0000|129 131|CRD
P10863048A0000|135 138|mmHg
P10863048A0000|142 142|s
P10863048A0000|160 185|halothane-anesthetized rats
P10863352T0001|0 12|Franz Schubert
P10863352T0001|31 38|diseases
P10864271A0504|3 9|results
P10864271A0504|30 42|S. argyrostoma
P10864271A0504|48 60|dissemination
P10864271A0504|63 79|Trichinella larvae
P10864271A0504|126 132|mammals
P10864271A0504|137 145|scavenger
P10864271A0504|149 169|cannibalistic behavior
P10864496A0401|3 40|equilibrium dissociation binding constant
P10864496A0401|60 63|TnrA
P10864496A0401|71 91|nrgAB promoter fragment
P10864496A0401|98 99|nM
P10864496A0401|108 117|conditions
P10864641A1400|5 11|results
P10864641A1400|27 35|N-glycans
P10864641A1400|47 66|receptor-binding site
P10864641A1400|72 81|HA molecule
P10864641A1400|85 100|potent regulators
P10864641A1400|103 122|influenza virus growth
P10864641A1400|131 136|glycan
P10864641A1400|139 144|Asn149
P10864641A1400|167 172|Asn123
P10864989A0484|0 6|RESULTS
P10864989A0484|28 31|PAIP
P10864989A0484|55 55|p
P10864989A0484|87 90|WBCs
P10864989A0484|92 97|median
P10864989A0484|113 119|numbers
P10864989A0484|128 130|FIP
P10864989A0484|132 137|median
P10864989A0484|168 185|separation efficacy
P10864989A0484|189 189|%
P10864989A0484|194 207|separation time
P10865422A0138|16 28|serum ferritin
P10865422A0138|30 31|SF
P10865422A0138|34 43|hemoglobin
P10865422A0138|45 46|Hb
P10865422A0138|64 80|detailed histories
P10865422A0138|83 91|donations
P10865422A0138|95 113|iron supplementation
P10865838A0000|0 30|Vascular endothelial growth factor
P10865838A0000|32 35|VEGF
P10865838A0000|39 51|potent agonist
P10865838A0000|74 78|cells
P10865838A0000|110 133|vascular endothelial cells
P10865940A0000|3 44|antioxidant agent pyrrolidine dithiocarbamate
P10865940A0000|46 49|PDTC
P10865940A0000|72 87|endothelial cells
P10865940A0000|89 90|EC
P10865940A0000|96 119|pro-inflammatory-induced
P10865940A0000|123 160|pro-oxidant-induced NF-kappaB activation
P10865940A0000|142 150|NF-kappaB
P10866323A0666|19 25|effects
P10866323A0666|28 48|SIE-1 hypermethylation
P10866323A0666|28 32|SIE-1
P10866323A0666|51 66|p21WAF1 induction
P10866323A0666|51 57|p21WAF1
P10866323A0666|69 82|STAT activation
P10866323A0666|69 72|STAT
P10866677A1839|0 33|Phd antibody-immunoreactive peptides
P10866677A1839|43 76|light-adapted mouse retinal cytosolic
P10866677A1839|80 94|nuclear extracts
P10866689A0295|5 10|pRb(-)
P10866689A0295|5 7|pRb
P10866689A0295|11 24|SAOS-2 cell line
P10866689A0295|52 66|reporter plasmid
P10866689A0295|80 95|tal-1 binding site
P10866689A0295|97 99|pRb
P10866689A0295|111 133|transcriptional activity
P10866689A0295|136 149|tal-1-E12-Lmo2
P10866689A0295|136 140|tal-1
P10866689A0295|142 144|E12
P10866689A0295|146 149|Lmo2
P10866689A0295|153 180|tal-1-E12-Lmo2-Ldb1 complexes
P10866689A0295|153 157|tal-1
P10866689A0295|159 161|E12
P10866689A0295|163 166|Lmo2
P10866689A0295|168 171|Ldb1
P10866689A0295|194 213|tal-1-E12 heterodimer
P10866689A0295|194 198|tal-1
P10866886A1277|22 32|conjunction
P10866886A1277|37 45|oxycodone
P10866886A1277|48 78|morphine-like mu-receptor agonist
P10867199A0230|15 35|morphological criteria
P10867199A0230|40 55|few data available
P10867199A0230|60 72|recent studies
P10867199A0230|78 89|genetic level
P10867199A0230|107 110|EPVs
P10867199A0230|120 140|different insect orders
P10867496T0001|0 16|Neurofibromatosis
P10867496T0001|42 64|Morbus von Recklinghausen
P10868488A0921|5 27|premating period male rate
P10868488A0921|73 89|testosterone level
P10869076A1384|5 11|results
P10869076A1384|51 60|tryptophan
P10869076A1384|64 71|ribosome
P10869076A1384|83 86|tnaC
P10869076A1384|93 95|Rho
P10869076A1384|109 112|boxA
P10869076A1384|116 123|rut sites
P10869076A1384|142 165|transcription termination
P10869465A1054|6 18|hybridization
P10869465A1054|26 43|antisense RNA probes
P10869465A1054|63 79|expression changes
P10869465A1054|90 95|clones
P10869465A1054|111 117|changes
P10869465A1054|120 141|multiple germ cell stages
P10869465A1054|150 163|other cell types
P10869465A1054|165 171|Sertoli
P10869465A1054|173 184|interstitial
P10869465A1054|188 203|peritubular cells
P10870043A0621|22 32|GnRH agonist
P10870043A0621|22 25|GnRH
P10870043A0621|43 60|bone mineral density
P10870043A0621|66 75|whole femur
P10870043A0621|82 82|%
P10870043A0621|94 105|control group
P10870391T0034|0 9|Prevention
P10870391T0034|11 31|differential diagnosis
P10870391T0034|44 57|travel diarrhea
P10871045A1221|18 26|C/EBPbeta
P10871045A1221|32 54|predominant C/EBP isoform
P10871045A1221|71 83|stellate cells
P10871045A1221|100 115|C/EBPbeta protein
P10871045A1221|119 134|C/EBPbeta binding
P10871045A1221|119 127|C/EBPbeta
P10871045A1221|138 161|proximal C/EBP binding site
P10871045A1221|146 161|C/EBP binding site
P10871045A1221|167 174|promoter
P10871045A1221|204 215|acetaldehyde
P10871347A0477|0 15|Mutation analysis
P10871347A0477|35 45|motif TCCCCT
P10871347A0477|59 74|PyRo1 interaction
P10871347A0477|59 63|PyRo1
P10871379A0261|6 9|VP16
P10871379A0261|14 36|transactivation function
P10871379A0261|39 43|Luman
P10871379A0261|61 63|HCF
P10871412A0369|8 23|successive rounds
P10871412A0369|37 55|focus formation assay
P10871412A0369|58 77|transforming ribozyme
P10871412A0369|70 77|ribozyme
P10871412A0369|79 83|Rz007
P10871615A0368|0 1|G.
P10871615A0368|6 9|Hyde
P10871615A0368|11 12|C.
P10871842A0988|3 9|results
P10871842A0988|21 40|proteasome inhibition
P10871842A0988|48 59|upregulation
P10871842A0988|62 76|specific members
P10871842A0988|79 105|transcription factor families
P10871842A0988|117 138|cellular stress response
P10871842A0988|142 154|proliferation
P10872473A2286|3 15|ATR-X syndrome
P10872473A2286|27 35|mutations
P10872473A2286|41 47|XH2 gene
P10872473A2286|49 55|located
P10872473A2286|61 71|X chromosome
P10872473A2286|73 78|Xq13.3
P10872473A2286|124 137|gene expression
P10872535A0000|0 3|AIMS
P10872535A0000|24 56|environmental intra-uterine factors
P10872535A0000|73 84|birthweights
P10872535A0000|87 91|twins
P10872535A0000|105 118|susceptibility
P10872535A0000|132 141|discordant
P10872535A0000|145 161|abnormal responses
P10872535A0000|167 190|oral glucose tolerance test
P10872535A0000|192 195|OGTT
P10872535A0000|209 227|possible association
P10872535A0000|230 262|within-pair birthweight differences
P10872535A0000|266 287|metabolic abnormalities
P10872535A0000|290 298|adult life
P10872756A1325|2 10|NASCIS III
P10872756A1325|13 34|randomization imbalance
P10872756A1325|57 78|disproportionate number
P10872756A1325|81 88|patients
P10872756A1325|95 106|motor deficit
P10872756A1325|145 165|lower dose control group
P10872827A0000|0 16|Penicillin acylase
P10872827A0000|18 19|PA
P10872827A0000|40 48|ATCC11105
P10872827A0000|52 73|periplasmic heterodimer
P10872827A0000|89 103|kDa small subunit
P10872827A0000|110 124|kDa large subunit
P10872831A0000|1 6|murine
P10872831A0000|16 26|sequence tag
P10872831A0000|28 30|EST
P10872831A0000|39 46|homology
P10872831A0000|51 72|erythropoietin receptor
P10872831A0000|74 77|EPOR
P10872831A0000|97 107|EST database
P10872851A0714|7 9|LCx
P10872851A0714|22 29|occluded
P10872851A0714|31 55|mild PM-induced tachycardia
P10872851A0714|75 77|AoP
P10872851A0714|79 80|P=
P10872851A0714|106 107|SV
P10872851A0714|109 110|P=
P10872851A0714|121 125|LVEDP
P10872851A0714|139 140|P=
P10873158A0000|0 9|Activation
P10873158A0000|12 24|nuclear factor
P10873158A0000|26 35|NF)-kappaB
P10873158A0000|26 27|NF
P10873158A0000|30 35|kappaB
P10873158A0000|39 77|subsequent proinflammatory gene expression
P10873158A0000|80 105|human airway epithelial cells
P10873158A0000|119 133|oxidative stress
P10873286X0000|0 11|GAP JUNCTIONS
P10873286X0000|17 21|BRAIN
P10873286X0000|23 29|PREFACE
P10873386A0000|45 53|mouse gene
P10873386A0000|60 68|C2 subunit
P10873386A0000|74 86|20S proteasome
P10873387A0816|19 27|human gene
P10873387A0816|42 56|Cacna1f gene maps
P10873387A0816|42 52|Cacna1f gene
P10873387A0816|64 65|kb
P10873387A0816|81 102|mouse synaptophysin gene
P10873387A0816|106 122|region orthologous
P10873387A0816|125 128|Xp11
P10873388A0623|7 23|human Rhotekin cDNA
P10873388A0623|27 31|probe
P10873388A0623|33 53|Northern hybridization
P10873388A0623|67 82|4.0-kb transcript
P10873388A0623|98 106|high level
P10873388A0623|109 116|prostate
P10873388A0623|123 133|middle level
P10873388A0623|142 148|tissues
P10873388A0623|189 199|lung tissues
P10874044A0647|10 22|co-expression
P10874044A0647|26 48|dominant-negative mutant
P10874044A0647|51 58|p38alpha
P10874044A0647|68 71|ERK1
P10874044A0647|73 76|ERK2
P10874044A0647|78 81|JNK1
P10874044A0647|85 88|JNK2
P10874044A0647|97 101|basal
P10874044A0647|105 134|cadmium-induced pE1-luc activity
P10874044A0647|120 126|pE1-luc
P10874151A0000|0 9|BACKGROUND
P10874151A0000|11 32|Gamma knife radiosurgery
P10874151A0000|34 36|GKR
P10874151A0000|48 67|effective alternative
P10874151A0000|80 98|intracranial lesions
P10878398A0542|2 21|hemodialyzed patients
P10878398A0542|23 25|Epo
P10878398A0542|29 40|Non-Epo group
P10878398A0542|42 53|leptin levels
P10878398A0542|71 76|higher
P10878398A0542|91 102|CAPD patients
P10878398A0542|104 106|Epo
P10878398A0542|110 121|Non-Epo group
P10878398A0542|110 112|Non
P10878606A0876|23 38|neural structures
P10878606A0876|54 59|organs
P10878606A0876|75 108|epithelial-mesenchymal interactions
P10878675A1278|0 9|CONCLUSION
P10878675A1278|14 48|alpha2-adrenergic antagonist idazoxan
P10878675A1278|58 91|glucose-induced sympathetic activity
P10878675A1278|98 114|energy expenditure
P10878675A1278|117 129|obese subjects
P10878944A0000|0 52|ID-PaGIA diphtheria toxin polymer particle diagnostic agent
P10878944A0000|8 22|diphtheria toxin
P10878944A0000|67 74|DiaMed AG
P10878944A0000|76 86|Switzerland
P10878944A0000|98 122|bacteriological laboratory
P10878944A0000|125 133|Institute
P10878944A0000|136 154|Childhood Infections
P10878944A0000|157 159|St.
P10880486A0790|18 37|EMS-induced mutations
P10880486A0790|79 84|zipper
P10880486A0790|86 88|Ebr
P10880486A0790|101 109|RhoA locus
P10880486A0790|101 104|RhoA
P10880702A0966|13 19|results
P10880702A0966|50 60|amphetamine
P10880702A0966|63 73|apomorphine
P10880702A0966|86 111|context-dependent component
P10880702A0966|114 126|sensitization
P10880702A0966|129 139|amphetamine
P10880702A0966|143 180|apomorphine-induced stereotyped behavior
P10881275T0000|10 24|serum IgM binding
P10881275T0000|15 17|IgM
P10881275T0000|27 40|GM1 ganglioside
P10881275T0000|43 58|clinical practice
P10882163A1077|0 17|Objective responses
P10882163A1077|32 38|studies
P10882163A1077|51 63|sequential use
P10882163A1077|66 75|exemestane
P10882163A1077|90 106|aminoglutethimide
P10882163A1077|110 110|%
P10882163A1077|115 124|exemestane
P10882163A1077|128 133|mg/day
P10882163A1077|137 172|other nonsteroidal aromatase inhibitors
P10882163A1077|154 162|aromatase
P10882163A1077|177 177|%
P10882163A1077|182 191|exemestane
P10882163A1077|194 199|mg/day
P10882213A0163|0 5|Topics
P10882213A0163|56 63|myositis
P10882213A0163|80 101|appropriate evaluations
P10882213A0163|105 114|malignancy
P10882213A0163|118 132|myositis patient
P10882213A0163|161 168|patients
P10882213A0163|173 199|dermatomyositis sine myositis
P10882213A0163|204 213|usefulness
P10882213A0163|219 237|clinicopathological
P10882213A0163|241 266|serological classifications
P10882213A0163|300 312|adult myositis
P10882213A0163|325 341|different entities
P10882213A0163|357 373|prognostic factors
P10882213A0163|389 406|clinical management
P10882213A0163|409 424|myositis patients
P10882213A0163|426 442|current approaches
P10882213A0163|451 461|limitations
P10882213A0163|474 488|disease activity
P10882462T0000|12 28|tissue engineering
P10882850A0000|0 14|Endonuclease III
P10882850A0000|0 11|Endonuclease
P10882850A0000|16 18|Nth
P10882850A0000|22 36|Escherichia coli
P10882850A0000|40 62|DNA glycosylase essential
P10882850A0000|40 53|DNA glycosylase
P10882850A0000|78 107|oxidised pyrimidine base residues
P10884978A0633|3 10|duration
P10884978A0633|13 29|reactive hyperemia
P10884978A0633|43 47|aging
P10884978A0633|72 76|males
P10884978A0633|80 86|females
P10885708T0000|8 23|bile duct blockage
P10885708T0000|32 49|hepatobiliary agent
P10885708T0000|56 74|intrahepatic abscess
P10885731A0915|39 57|synthesis conditions
P10885731A0915|60 70|block length
P10885731A0915|74 86|crystallinity
P10885731A0915|120 132|crystallinity
P10885731A0915|136 145|solubility
P10885731A0915|151 158|polymers
P10885750A0236|35 48|normal function
P10885750A0236|51 56|CREB-2
P10885750A0236|59 78|mammalian development
P10885750A0236|81 95|organ physiology
P10886067A0520|3 15|outer diameter
P10886067A0520|22 30|thickness
P10886067A0520|36 40|rotor
P10886067A0520|46 47|mm
P10886067A0520|52 53|mm
P10887912A0740|7 10|MVBF
P10887912A0740|17 34|maximum EMG activity
P10887912A0740|40 52|right masseter
P10887912A0740|59 87|left anterior temporalis muscles
P10887912A0740|120 129|muscle pain
P10887912A0740|137 147|subjects bit
P10887912A0740|153 163|painful side
P10887921A0718|0 10|CONCLUSIONS
P10887921A0718|33 42|topography
P10887921A0718|49 64|visual field areas
P10887921A0718|75 78|SWAP
P10887921A0718|85 117|inferotemporal neuroretinal rim area
P10887921A0718|153 161|follow-up
P10887921A0718|173 180|glaucoma
P10888570A0678|3 16|total alkaloids
P10888570A0678|37 43|Atzimba
P10888570A0678|45 49|Lopez
P10888570A0678|51 58|Marciana
P10888570A0678|60 67|Montsama
P10888570A0678|69 73|Murca
P10888570A0678|78 83|Puebla
P10888570A0678|99 104|limits
P10888570A0678|119 128|food safety
P10889399A0243|3 22|detection success rate
P10889399A0243|39 54|different markers
P10889399A0243|64 66|MEK
P10890911A0470|17 21|Smad3
P10890911A0470|48 59|HMG box domain
P10890911A0470|62 65|LEF1
P10890911A0470|73 79|TGFbeta
P10890911A0470|83 93|Wnt pathways
P10890911A0470|83 85|Wnt
P10890911A0470|113 125|transcription
P10890911A0470|131 153|Xenopus homeobox gene twin
P10890911A0470|131 149|Xenopus homeobox gene
P10890911A0470|150 153|twin
P10890911A0470|155 158|Xtwn
P10891093A0000|3 23|transmembrane topology
P10891093A0000|26 27|Na
P10891093A0000|32 32|H
P10891093A0000|36 48|exchanger NHE3
P10891093A0000|45 48|NHE3
P10891093A0000|75 99|transcription/translation
P10891093A0000|105 109|types
P10891093A0000|112 124|fusion vectors
P10891093A0000|139 165|membrane insertion properties
P10891093A0000|168 180|cDNA sequences
P10891093A0000|189 208|putative NHE3 membrane
P10891093A0000|217 223|domains
P10891093A0000|225 228|msds
P10891266A0421|0 4|ACE-2
P10891266A0421|9 28|hydrophobic C terminus
P10891266A0421|31 35|H type
P10891286A0000|0 6|Members
P10891286A0000|12 45|titin/myosin light chain kinase family
P10891286A0000|12 16|titin
P10891286A0000|52 64|essential role
P10891286A0000|87 110|actin/myosin cytoskeleton
P10891286A0000|87 91|actin
P10891286A0000|93 98|myosin
P10891286A0000|124 140|sarcomere assembly
P10891399A1185|15 24|activation
P10891399A1185|27 33|c-fosER
P10891399A1185|42 66|transcriptional inhibition
P10891399A1185|69 71|p21
P10891399A1185|73 81|Cip1/WAF1
P10891399A1185|73 76|Cip1
P10891399A1185|78 81|WAF1
P10891399A1185|101 123|uncharacterized AP-1 site
P10891399A1185|116 123|AP-1 site
P10891399A1185|136 148|important role
P10891399A1185|152 156|c-fos
P10891399A1185|159 173|negative control
P10891399A1185|176 199|cell cycle regulatory genes
P10891441A0871|13 36|pTyr317 Shc phosphopeptide
P10891441A0871|58 61|Grb2
P10891441A0871|63 66|Sos1
P10891441A0871|68 71|SHIP
P10891441A0871|79 88|p85 subunit
P10891441A0871|91 118|phosphatidylinositol 3' kinase
P10891441A0871|91 110|phosphatidylinositol
P10891441A0871|113 118|kinase
P10891441A0871|123 131|mast cells
P10891441A0871|150 165|mass spectrometry
P10891489A0152|32 46|HMG-I/Y proteins
P10891489A0152|63 83|cellular proliferation
P10891489A0152|85 108|neoplastic transformation
P10891489A0152|113 131|several human cancers
P10891489A0152|147 154|proteins
P10891489A0152|160 171|pathogenesis
P10891489A0152|174 183|malignancy
P10891489A0152|191 197|unclear
P10891632A0435|3 34|naltrexone/lofexidine combination
P10891632A0435|57 71|rapid resolution
P10891632A0435|77 100|opiate withdrawal syndrome
P10891632A0435|106 142|7-day lofexidine-only treatment schedule
P10891632A0435|151 170|substantial increases
P10891632A0435|173 190|withdrawal symptoms
P10891632A0435|193 215|hypotensive side-effects
P10892300A0268|3 15|first symptoms
P10892300A0268|18 35|enzootic calcinosis
P10892300A0268|47 51|March
P10892300A0268|70 73|cows
P10892300A0268|83 104|locomotor abnormalities
P10892823A1040|0 8|Screening
P10892823A1040|46 59|illicit drug use
P10892823A1040|68 86|essential components
P10892823A1040|89 108|comprehensive HBP care
P10893243T0000|0 24|Transcriptional regulation
P10893243T0000|30 89|mouse cytosolic chaperonin subunit gene Ccta/t-complex polypeptide
P10893243T0000|93 167|selenocysteine tRNA gene transcription activating factor family zinc finger proteins
P10893243T0000|93 127|selenocysteine tRNA gene transcription
P10893243T0000|138 167|factor family zinc finger proteins
P10893258T0000|11 25|protein response
P10893258T0000|35 49|multiple aspects
P10893258T0000|52 60|secretory
P10893258T0000|64 88|membrane protein biogenesis
P10893258T0000|92 125|endoplasmic reticulum quality control
P10894149T0000|0 3|PNRC
P10894149T0000|6 51|proline-rich nuclear receptor coregulatory protein
P10894149T0000|65 89|transcriptional activation
P10894149T0000|92 115|multiple nuclear receptors
P10894149T0000|125 142|orphan receptors SF1
P10894149T0000|125 139|orphan receptors
P10894149T0000|140 142|SF1
P10894149T0000|144 162|steroidogenic factor
P10894149T0000|168 176|ERRalpha1
P10894149T0000|178 207|estrogen related receptor alpha-1
P10894149T0000|178 185|estrogen
P10894149T0000|193 207|receptor alpha-1
P10894816A0836|0 6|Studies
P10894816A0836|13 27|reporter plasmid
P10894816A0836|54 77|sterol-responsive element
P10894816A0836|79 84|SRE)-1
P10894816A0836|79 81|SRE
P10894816A0836|101 119|stimulatory response
P10894816A0836|122 125|IL-6
P10894886A0375|21 26|subset
P10894886A0375|29 34|tumors
P10894886A0375|50 56|changes
P10894886A0375|64 68|genes
P10895417A0000|18 25|epidural
P10895417A0000|27 29|EPI
P10895417A0000|41 48|morphine
P10895417A0000|63 85|multivesicular liposomes
P10895417A0000|87 112|DepoFoam drug delivery system
P10895417A0000|123 140|sustained clearance
P10895417A0000|143 150|morphine
P10895417A0000|155 172|prolonged analgesia
P10895417A0669|9 17|EPI-C0401
P10895417A0669|25 30|saline
P10895417A0669|33 47|DepoFoam vehicle
P10895417A0669|58 66|transient
P10895417A0669|71 72|hr
P10895417A0669|85 99|food consumption
P10895417A0669|101 107|arousal
P10895417A0669|109 126|hindlimb muscle tone
P10895417A0669|131 145|body temperature
P10895851A0696|0 16|Bailey Instruments
P10895851A0696|20 39|Owen Mumford filaments
P10895851A0696|66 66|%
P10895851A0696|87 87|g
P10895851A0696|92 93|g.
P10896008A0531|0 11|PARTICIPANTS
P10896008A0531|13 29|Convenience sample
P10896008A0531|32 52|ambulatory outpatients
P10896008A0531|57 71|hereditary motor
P10896008A0531|75 91|sensory neuropathy
P10896008A0531|99 100|n =
P10896008A0531|104 128|myotonic muscular dystrophy
P10896008A0531|130 131|n =
P10896008A0531|139 157|able-bodied controls
P10896008A0531|159 160|n =
P10896859A0000|11 26|water deprivation
P10896859A0000|32 32|h
P10896859A0000|35 50|renal Na excretion
P10896859A0000|53 77|conscious adrenalectomized
P10896859A0000|79 81|ADX
P10896859A0000|101 127|constant intravenous infusion
P10896859A0000|130 140|aldosterone
P10896859A0000|144 151|cortisol
P10896859A0000|153 176|ADX-constant steroid sheep
P10896859A0838|12 21|major cause
P10896859A0838|24 58|rehydration-induced renal Na retention
P10897233A1057|0 9|CONCLUSION
P10897233A1057|11 24|Rheumatic fever
P10897233A1057|30 41|Nazareth area
P10897233A1057|49 56|manifest
P10897973T0001|0 24|Antithrombin III deficiency
P10897973T0001|0 14|Antithrombin III
P10897973T0001|30 39|substitute
P10897973T0001|45 51|heparin
P10897973T0001|53 65|Thrombosis ABC
P10897973T0001|78 92|antithrombin III
P10897973T0001|78 89|antithrombin
P10898795A0527|0 12|Specific class
P10898795A0527|19 37|histone deacetylases
P10898795A0527|39 43|HDACs
P10898795A0527|63 66|BCoR
P10898795A0527|82 85|BCoR
P10898795A0527|113 119|classes
P10898795A0527|122 126|HDACs
P10899128A0661|9 20|first example
P10899128A0661|24 59|eukaryotic transcription factor complex
P10899128A0661|75 82|MADS-box
P10899128A0661|87 101|forkhead protein
P10899128A0661|111 131|important implications
P10899128A0661|150 172|mammalian gene expression
P10899128A0661|150 162|mammalian gene
P10899142A0000|17 24|Berkeley
P10899142A0000|35 55|Genome Project database
P10899142A0000|60 68|sequences
P10899142A0000|95 144|Leu-rich repeats-containing G protein-coupled receptor
P10899142A0000|121 144|G protein-coupled receptor
P10899142A0000|146 148|LGR
P10899142A0000|165 170|DLGR-1
P10899142A0000|186 195|second gene
P10899142A0000|200 211|different LGR
P10899142A0000|209 211|LGR
P10899142A0000|213 218|DLGR-2
P10899142A0000|232 235|cDNA
P10900129A0138|0 26|Degenerate primers homologous
P10900129A0138|44 50|regions
P10900129A0138|53 71|known CYP3A sequences
P10900129A0138|58 71|CYP3A sequences
P10900129A0138|83 96|initial RT-PCRs
P10900269A0396|4 8|cells
P10900269A0396|30 33|TFOs
P10900269A0396|51 69|30-bp polypurine site
P10900269A0396|91 97|TK genes
P10900269A0396|99 111|recombination
P10900269A0396|125 135|frequencies
P10900269A0396|149 149|%
P10901133A0381|0 15|Methyllevamisole
P10901133A0381|28 43|internal standard
P10902348A0566|0 15|Resistance ratios
P10902348A0566|22 38|other field strains
P10902348A0566|66 73|R5 strain
P10902348A0566|96 113|topical application
P10902348A0566|135 148|glass jar method
P10903440A0515|4 22|transcripts specific
P10903440A0515|26 31|TSGF-2
P10903440A0515|45 49|ovary
P10903440A0515|53 65|testes tissues
P10903440A0515|68 73|adults
P10903440A0515|84 90|puparia
P10903440A0515|128 152|larval developmental stages
P10903495A0533|3 21|gel retardation assay
P10903495A0533|27 46|HepG2 nuclear extracts
P10903495A0533|53 68|flanking sequence
P10903583T0000|0 10|Reliability
P10903583T0000|13 25|cervical range
P10903583T0000|42 46|OSI CA
P10903583T0000|51 69|spine motion analyser
P10903583T0000|72 83|asymptomatic
P10903583T0000|87 105|symptomatic subjects
P10903733A0540|0 31|Coimmunoprecipitation experiments
P10903733A0540|54 58|cells
P10903733A0540|69 72|BCMA
P10903733A0540|87 107|TNFR-associated factor
P10903733A0540|109 112|TRAF
P10903733A0540|116 120|TRAF2
P10903733A0540|125 144|TRAF3 adaptor proteins
P10903837A1208|8 15|RINX gene
P10903837A1208|26 33|ortholog
P10903837A1208|39 54|goldfish Vsx1 gene
P10903837A1208|70 73|VSX1
P10903837A1208|79 108|Human Gene Nomenclature Committee
P10903843A0447|3 25|chromosomal localization
P10903843A0447|28 43|distal chromosome
P10903843A0447|65 78|imprinted genes
P10903843A0447|111 115|Tapa1
P10903843A0447|119 128|Kcnq1 genes
P10903877A0879|0 9|Activation
P10903877A0879|12 14|PKA
P10903877A0879|17 33|8-bromo-cyclic AMP
P10903877A0879|36 44|forskolin
P10903877A0879|49 58|inhibition
P10903877A0879|61 63|PKC
P10903877A0879|66 76|calphostin C
P10903877A0879|89 107|significant decrease
P10903877A0879|110 120|3TP activity
P10903877A0879|136 152|ERK kinase activity
P10903877A0879|136 144|ERK kinase
P10903877A0879|155 158|CRAC
P10904191A0000|3 14|present study
P10904191A0000|53 63|specificity
P10904191A0000|66 70|AMP CT
P10904191A0000|72 92|Gen-Probe Incorporated
P10904191A0000|94 101|San Diego
P10904191A0000|103 104|CA
P10904191A0000|106 108|USA
P10904191A0000|112 130|urogenital specimens
P10904191A0000|140 158|symptomatic patients
P10904191A0000|164 177|first void urine
P10904191A0000|179 181|FVU
P10904191A0000|183 191|specimens
P10904191A0000|196 215|asymptomatic patients
P10905349A0329|0 5|Mus81p
P10905349A0329|16 23|homology
P10905349A0329|28 33|motifs
P10905349A0329|44 69|XPF endonuclease superfamily
P10905349A0609|0 19|Double mutant analysis
P10905349A0609|32 37|Rad54p
P10905349A0609|41 46|Mus81p
P10905349A0609|55 61|pathway
P10905349A0609|91 109|UV-induced DNA damage
P10905352A0000|3 20|linear plasmid pCLU1
P10905352A0000|28 51|yeast Kluyveromyces lactis
P10905352A0000|75 83|cytoplasm
P10905352A0000|100 123|helper linear plasmid pGKL2
P10905352A0000|130 144|terminal protein
P10905352A0000|146 147|TP
P10905352A0000|152 157|primer
P10906176A0000|3 15|repetitive ETn
P10906176A0000|17 31|early transposon
P10906176A0000|41 49|sequences
P10906176A0000|69 81|mobile mutagen
P10906176A0000|88 98|mouse genome
P10906317A0351|6 30|main experimental variables
P10906317A0351|46 54|hemifield
P10906317A0351|86 91|trials
P10906317A0351|117 125|hemifield
P10906317A0351|129 129|%
P10906317A0351|134 134|%
P10906999T0000|16 17|NO
P10906999T0000|20 36|biological systems
P10906999T0000|42 58|chemiluminescence
P10907348A0508|0 22|Biochemical examinations
P10907348A0508|25 52|calcium-phosphorus metabolism
P10907348A0508|61 64|ions
P10907348A0508|68 84|PTH concentrations
P10907348A0508|68 70|PTH
P10907348A0508|87 96|blood serum
P10907348A0508|114 126|bone isoenzyme
P10907348A0508|129 130|AP
P10907971A0806|0 11|Atorvastatin
P10907971A0806|22 60|cost-effective HMG-CoA reductase inhibitor
P10907971A0806|36 51|HMG-CoA reductase
P10907971T0000|0 25|Pharmacoeconomic assessment
P10907971T0000|28 59|HMG-CoA reductase inhibitor therapy
P10907971T0000|28 43|HMG-CoA reductase
P10907971T0000|81 91|CURVES study
P10908317A1459|22 29|E domains
P10908317A1459|40 48|receptors
P10908317A1459|95 98|rtER
P10908317A1459|104 119|human counterpart
P10908317A1459|130 155|higher estradiol sensitivity
P10908317A1459|185 199|transactivation
P10908364A0000|0 4|G-DNA
P10908364A0000|8 32|four-stranded DNA structure
P10908364A0000|37 66|diverse putative biological roles
P10908462A3159|18 20|NRT
P10908462A3159|66 82|additional support
P10908462A3159|96 101|smoker
P10908478A0717|0 16|SELECTION CRITERIA
P10908478A0717|21 36|controlled trials
P10908478A0717|42 47|adults
P10908478A0717|52 64|schizophrenia
P10908478A0717|67 82|similar illnesses
P10908478A0717|99 108|quetiapine
P10908478A0717|110 116|placebo
P10908478A0717|119 139|other neuroleptic drugs
P10908478A0717|158 173|relevant outcomes
P10908822A0519|1 1|%
P10908822A0519|5 7|% CI
P10908822A0519|16 18|.3%
P10909973A1508|22 26|GLP-1
P10909973A1508|32 34|CRE
P10909973A1508|50 63|cotransfection
P10909973A1508|68 74|M1-CREB
P10909973A1508|68 69|M1
P10909973A1508|71 74|CREB
P10909973A1508|78 84|isoform
P10909973A1508|95 116|consensus serine residue
P10909973A1508|126 134|substrate
P10909973A1508|138 164|PKA-mediated phosphorylation
P10909973A1508|138 140|PKA
P10910073A0876|10 25|PDGFbetaR fusions
P10910073A0876|50 57|splicing
P10910073A0876|61 70|common exon
P10910073A0876|96 113|rapid amplification
P10910073A0876|116 119|cDNA
P10910073A0876|124 126|PCR
P10910073A0876|129 138|patient RNA
P10910439A1196|0 10|CONCLUSIONS
P10910439A1196|14 34|essential hypertension
P10910439A1196|37 52|acute protein load
P10910439A1196|71 73|GFR
P10910439A1196|95 119|antihypertensive treatment
P10910908A0767|27 51|PI3K-Akt activation pathway
P10910908A0767|27 30|PI3K
P10910908A0767|32 34|Akt
P10910908A0767|70 88|antiapoptotic effect
P10910908A0767|91 93|EPO
P10913094A0424|4 15|DNA fragments
P10913094A0424|56 75|histidine-tagged AdpA
P10913094A0424|72 75|AdpA
P10913094A0424|90 95|cycles
P10913094A0424|99 124|gel mobility shift-PCR method
P10913172A0442|21 36|NTP-binding motif
P10913172A0442|51 63|Rad24 function
P10913172A0442|51 55|Rad24
P10913172A0442|86 91|lysine
P10913172A0442|97 103|residue
P10913172A0442|110 114|motif
P10913276A0510|3 37|carboxyl-terminal proline-rich domain
P10913276A0510|40 43|SOS1
P10913276A0510|77 95|PLC-gamma1 SH3 domain
P10913276A0684|4 29|transient expression studies
P10913276A0684|56 64|SH3 domain
P10913276A0684|67 76|PLC-gamma1
P10913276A0684|109 112|SOS1
P10913304A0894|3 18|distinct Ets mRNAs
P10913304A0894|11 18|Ets mRNAs
P10913304A0894|34 37|Ets2
P10913304A0894|39 42|Fli1
P10913304A0894|44 52|GABPalpha
P10913304A0894|54 57|SAP1
P10913304A0894|59 62|Elk1
P10913304A0894|67 69|PE1
P10913304A1180|2 13|kb transcript
P10913304A1180|61 70|kDa protein
P10913304A1180|102 125|known N-terminal Ets domain
P10913304A1180|107 125|N-terminal Ets domain
P10913304A1180|128 130|PE1
P10913304A1180|135 155|novel C-terminal domain
P10913304A1180|140 155|C-terminal domain
P10913304A1180|160 177|signficant homology
P10913304A1180|180 188|murine ERF
P10915728A0216|6 21|eligible patients
P10915728A0216|26 34|cirrhosis
P10915728A0216|56 61|groups
P10915728A0216|65 72|patients
P10915728A0216|92 96|units
P10915728A0216|99 113|natural IFN-beta
P10915728A0216|106 113|IFN-beta
P10915728A0216|129 134|months
P10915728A0216|140 147|patients
P10915728A0216|155 164|IFN therapy
P10915728A0216|155 157|IFN
P10915780A1063|0 18|Wnt-1 overexpression
P10915780A1063|0 4|Wnt-1
P10915780A1063|21 42|mammary epithelial cells
P10915780A1063|50 61|cyclin D1 mRNA
P10915780A1063|73 86|overexpression
P10915780A1063|89 93|Wnt-1
P10915780A1063|99 110|mammary gland
P10915780A1063|113 126|transgenic mice
P10915780A1063|140 150|ILK activity
P10915780A1063|140 142|ILK
P10915780A1063|154 167|cyclin D1 levels
P10915780A1063|154 161|cyclin D1
P10917402T0000|0 10|Intravenous
P10917402T0000|17 34|oral administration
P10917402T0000|37 49|amitriptyline
P10917402T0000|52 59|patients
P10917402T0000|64 78|major depression
P10918059A0569|0 7|Deletion
P10918059A0569|13 21|RVH domain
P10918059A0569|38 39|Ca
P10918059A0569|45 63|dependent activation
P10918164A0878|0 25|Logistic regression analysis
P10918164A0878|38 47|physicians
P10918164A0878|55 59|times
P10918164A0878|78 88|thin lesions
P10918164A0878|92 92|=
P10918164A0878|97 98|mm
P10918164A0878|112 132|nonphysician detectors
P10918164A0878|136 154|% confidence interval
P10918164A0878|158 160|% CI
P10918164A0878|171 172|P =
P10918440T0000|0 28|Erythema exsudativum multiforme
P10918440T0000|38 72|granulocyte colony-stimulating factor
P10918440T0000|77 114|allogeneic peripheral blood stem cell donor
P10918572A0794|0 2|VaI
P10918572A0794|6 9|VaII
P10918572A0794|35 39|ErbB2
P10918572A0794|51 55|ErbB1
P10918572A0794|57 61|ErbB3
P10918572A0794|65 69|ErbB4
P10918572A1547|5 16|interactions
P10918572A1547|19 20|WT
P10918572A1547|24 39|variant TGF-alpha
P10918572A1547|31 39|TGF-alpha
P10918572A1547|47 51|ErbBs
P10918572A1547|63 77|ErbB2 activation
P10918572A1547|63 67|ErbB2
P10918572A1547|90 120|different biological consequences
P10918572A1547|139 164|various TGF-alpha precursors
P10918572A1547|146 164|TGF-alpha precursors
P10918572A1547|187 199|ErbB signaling
P10918572A1547|187 190|ErbB
P10918596A0000|26 38|p53 C-terminus
P10918596A0000|45 55|central role
P10918596A0000|85 101|wild-type molecule
P10918599A0071|12 27|full-length E2F-3
P10918599A0071|54 65|G1/S boundary
P10918599A0071|67 72|E2F-3B
P10918599A0071|96 104|cell cycle
P10918599A0071|109 118|peak levels
P10918599A0071|121 122|GO
P10918599A0071|146 147|Rb
P10918612A0000|3 24|transcription factor Jun
P10918612A0000|26 30|c-Jun
P10918612A0000|55 80|extracellular growth signals
P10918612A0000|100 107|patterns
P10918612A0000|110 123|gene expression
P10918943T0000|0 20|Developmental toxicity
P10918943T0000|34 62|antiarrhythmic agent almokalant
P10918943T0000|65 68|mice
P10918948A0110|17 39|main bioactive metabolite
P10918948A0110|42 52|trimebutine
P10918948A0110|56 63|Debridat
P10918948A0110|65 67|CAS
P10918948A0110|82 94|antispasmodic
P10918948A0110|108 125|intestinal diseases
P10919971A0606|36 53|neutrophil response
P10919971A0606|56 72|eccentric exercise
P10919971A0606|74 81|vitamin E
P10919971A0606|89 103|greater increase
P10919971A0606|117 138|creatine kinase activity
P10919971A0606|117 130|creatine kinase
P10919971A0606|166 185|skeletal muscle repair
P10920186A0528|25 42|stem-loop templates
P10920186A0528|50 60|fusion point
P10920186A0528|66 83|chimeric transcript
P10920186A0528|104 113|MLL primers
P10920186A0528|116 127|two-sided PCR
P10920906A0759|0 9|CONCLUSION
P10920906A0759|14 20|authors
P10920906A0759|37 53|initial management
P10920906A0759|56 65|primary STS
P10920906A0759|96 106|safty margin
P10920906A0759|112 112|=
P10920906A0759|114 115|cm
P10921197A0179|0 11|Measurements
P10921197A0179|31 66|computerised treatment planning systems
P10921197A0179|69 81|Theraplan VO5B
P10921197A0179|85 99|ADAC Pinnacle3 V4
P10921197A0179|102 103|b.
P10924061A0588|0 9|Activation
P10924061A0588|13 20|biphasic
P10924061A0588|35 37|min
P10924061A0588|43 43|h
P10925159A1353|7 12|MARTA1
P10925159A1353|22 31|detectable
P10925159A1353|34 45|crude lysates
P10925159A1353|47 55|cytosolic
P10925159A1353|59 85|ribosomal salt-wash fractions
P10925159A1353|92 106|nuclear extracts
P10925159A1353|108 113|MARTA2
P10925159A1353|140 168|ribosomal salt-wash preparation
P10925207A0634|12 16|exons
P10925207A0634|30 41|kb transcript
P10925207A0634|66 71|1218bp
P10925207A0634|75 79|701bp
P10925207A0634|94 112|untranslated regions
P10925207A0634|114 117|UTRs
P10926776A0731|9 20|PDP1 isoforms
P10926776A0731|32 43|substitution
P10926776A0731|46 54|insertion
P10926776A0731|57 66|amino acids
P10926776A0731|78 87|N-terminal
P10928179A0101|3 18|optimum technique
P10928179A0101|25 47|pathological examination
P10928179A0101|50 67|sentinel lymph nodes
P10928179A0101|69 72|SLNs
P10928337A0590|0 16|Partial correction
P10928337A0590|19 24|anemia
P10928337A0590|29 64|recombinant human erythropoietin likely
P10928337A0590|76 90|ventricular mass
P10928477A0764|28 42|PFA-100 analyzer
P10928477A0764|62 90|vWF-dependent platelet function
P10928477A0764|62 64|vWF
P10928477A0764|100 119|other platelet defects
P10928477A0764|125 139|high shear stress
P10928477A0764|142 166|complex patient populations
P10930526A0174|21 36|molecular cloning
P10930526A0174|40 51|PL scramblase
P10930526A0174|60 67|HuPLSCR1
P10930526A0174|72 82|mouse origin
P10931524A0313|12 29|regulatory activity
P10931524A0313|32 34|Gtx
P10931524A0313|56 81|optimal Gtx-binding sequence
P10931524A0313|63 81|Gtx-binding sequence
P10931524A0313|96 111|DNA-binding assay
P10931927A0655|7 20|oligomer duplex
P10931927A0655|24 24|A
P10931927A0655|26 31|GGGTTA
P10931927A0655|44 49|TAACCC
P10931927A0655|54 56|T-3
P10931927A0655|61 75|template-primer
P10931927A0655|94 107|Klenow fragment
P10931927A0655|110 138|Escherichia coli DNA polymerase I
P10931927A0655|125 137|DNA polymerase
P10931927A0655|142 164|HIV reverse transcriptase
P10931927A0655|176 195|telomere DNA sequences
P10931927A0655|209 223|products greater
P10931927A0655|240 250|template DNA
P10931950A0869|0 3|Cdk2
P10931950A0869|7 10|MAPK
P10931950A0869|27 47|untreated tumor lysates
P10931950A0869|62 84|recombinant wild-type p27
P10931950A0869|73 84|wild-type p27
P10931950A0869|94 104|T187A mutant
P10931960A0630|9 26|avirulence activity
P10931960A0630|36 44|mutations
P10931960A0630|50 86|acidic transcriptional activation domain
P10931960A0630|113 128|activation domain
P10931960A0630|136 164|herpes simplex viral protein VP16
P10932196A0359|0 8|Mutations
P10932196A0359|14 21|RP2 locus
P10932196A0359|24 29|Xp11.3
P10932196A0359|42 48|further
P10932196A0359|54 54|%
P10932196A0359|57 68|XLRP patients
P10932196A0359|85 98|linkage studies
P10932329A0597|18 22|cecum
P10932329A0597|38 42|colon
P10932329A0597|67 91|sulcus cecocolicus dorsalis
P10932329A0597|95 103|ventralis
P10932527A0947|13 14|HD
P10932527A0947|24 30|healing
P10932527A0947|60 76|epithelialization
P10932527A0947|86 107|protracted inflammation
P10932527T0000|21 44|haemodialysate Solcoseryl
P10932527T0000|48 75|second-intention wound healing
P10932527T0000|78 83|horses
P10932527T0000|87 92|ponies
P10932679A0049|15 28|little evidence
P10932679A0049|33 47|diet composition
P10932679A0049|64 76|important role
P10932679A0049|82 91|absorption
P10932679A0049|94 104|expenditure
P10932679A0049|139 148|food intake
P10933154A1118|5 12|findings
P10933154A1118|46 55|restricted
P10933154A1118|64 79|donor transplants
P10933154A1118|87 100|acute rejection
P10933728A1398|5 11|results
P10933728A1398|28 40|important role
P10933728A1398|44 47|CBF2
P10933728A1398|59 78|EBNA2 transactivation
P10933728A1398|59 63|EBNA2
P10933728A1398|95 110|hnRNP protein AUF1
P10933728A1398|114 127|major component
P10933728A1398|130 133|CBF2
P10933728A1398|147 159|first evidence
P10933728A1398|163 185|cis-acting sequence other
P10933728A1398|191 208|CBF1 binding element
P10933728A1398|227 240|responsiveness
P10933728A1398|243 247|EBNA2
P10933732A0000|3 8|genome
P10933732A0000|14 29|human herpesvirus
P10933732A0000|32 36|HHV-8
P10933732A0000|56 72|open reading frames
P10933732A0000|74 77|ORFs
P10933732A0000|87 94|proteins
P10933732A0000|99 106|homology
P10933732A0000|112 139|cellular transcription factors
P10933732A0000|145 170|interferon regulatory factor
P10933732A0000|172 174|IRF
P10934073A1433|12 22|limitations
P10934073A1433|26 37|CHIME monitor
P10934073A1433|67 83|physiological data
P10934073A1433|94 104|unavailable
P10934310A0698|0 12|DATA SYNTHESIS
P10934310A0698|14 36|Intracoronary ultrasound
P10934310A0698|74 83|weaknesses
P10934310A0698|86 104|coronary angiography
P10934640A1114|0 9|TB bone area
P10934640A1114|11 11|p
P10934640A1114|27 27|p
P10934640A1114|35 39|years
P10934640A1114|42 54|present colony
P10934640A1114|56 57|p =
P10934640A1114|67 72|menses
P10934640A1114|74 74|p
P10934640A1114|90 94|TB BMC
P10934751T0001|0 12|CREST syndrome
P10934751T0001|23 42|clinical significance
P10935488A1033|0 11|Troglitazone
P10935488A1033|25 53|endogenous PPARgamma target gene
P10935488A1033|35 43|PPARgamma
P10935488A1033|56 63|T24 cells
P10935488A1033|65 101|adipocyte-type fatty acid binding protein
P10935488A1033|103 108|A-FABP
P10935488A1033|145 172|bladder cancer differentiation
P10935880A1049|0 6|Viruses
P10935880A1049|24 28|lungs
P10935880A1049|35 39|PI-3V
P10935880A1049|46 56|NCP BVDV type
P10935880A1049|71 76|BVHV-1
P10935880A1049|80 83|BVDV
P10936051T0000|3 49|RS447 human megasatellite tandem repetitive sequence
P10936051T0000|3 7|RS447
P10936051T0000|8 49|human megasatellite tandem repetitive sequence
P10936051T0000|58 84|novel deubiquitinating enzyme
P10936051T0000|90 107|functional promoter
P10936920A0105|0 17|Previous experience
P10936920A0105|21 34|contextual cues
P10936920A0105|38 54|essential elements
P10936920A0105|73 92|subjective prediction
P10938102A0265|36 42|targets
P10938102A0265|45 68|NS1 influenza virus protein
P10938102A0265|74 99|cellular translation factors
P10938102A1359|62 64|NS1
P10938102A1359|73 78|eIF4GI
P10938102A1359|98 115|untranslated region
P10938102A1359|119 121|UTR
P10938102A1359|128 136|viral mRNA
P10938102A1359|152 174|preferential translation
P10938102A1359|180 203|influenza virus messengers
P10938102T0000|0 39|Eukaryotic translation initiation factor 4GI
P10938102T0000|43 56|cellular target
P10938102T0000|60 69|NS1 protein
P10938102T0000|72 93|translational activator
P10938102T0000|96 109|influenza virus
P10938105A0000|0 7|Splicing
P10938105A0000|13 32|K-SAM alternative exon
P10938105A0000|38 72|fibroblast growth factor receptor 2 gene
P10938105A0000|38 67|fibroblast growth factor receptor
P10938105A0000|96 113|U-rich sequence IAS1
P10938105A0000|96 109|U-rich sequence
P10938105A0000|110 113|IAS1
P10938105A0000|149 158|splice site
P10938109A1361|12 16|cells
P10938109A1361|18 24|PKCbeta
P10938109A1361|31 55|unique Ras-independent role
P10938109A1361|37 39|Ras
P10938109A1361|67 73|insulin
P10938109A1361|80 82|EGF
P10938109A1361|85 117|other growth factor mitogenic signals
P10938113A0388|48 59|isoforms Vav2
P10938113A0388|56 59|Vav2
P10938113A0388|63 66|Vav3
P10938113A0388|106 119|similar classes
P10938113A0388|122 130|receptors
P10938113A0388|154 164|Vav isoforms
P10938113A0388|172 200|identical functional activities
P10938120A1093|0 24|Transcriptional regulation
P10938120A1093|27 48|fbp1 promoter constructs
P10938120A1093|63 66|UAS1
P10938120A1093|69 72|UAS2
P10938120A1093|88 90|PKA
P10938120A1093|94 107|MAPK regulation
P10938120A1093|94 97|MAPK
P10938120A1093|124 128|sites
P10938130A0338|0 24|X-ray crystallographic data
P10938130A0338|36 52|PLZF BTB/POZ domain
P10938130A0338|36 39|PLZF
P10938130A0338|40 42|BTB
P10938130A0338|44 52|POZ domain
P10938130A0338|60 76|obligate homodimer
P10938130A0338|82 99|extensive interface
P10938135A0259|12 15|SMRT
P10938135A0259|36 55|transcription factors
P10938135A0259|75 84|repression
P10938135A0259|106 115|activation
P10938135A0259|118 148|tyrosine kinase signaling pathways
P10938135A0259|118 131|tyrosine kinase
P10938135A0259|176 204|epidermal growth factor receptor
P10938556A0248|14 33|ketamine-treated rats
P10938556A0248|41 47|neurons
P10938556A0248|51 60|glial cells
P10938556A0248|75 84|ventricles
P10939030A0986|3 13|differences
P10939030A0986|31 51|overall response rate p =
P10939030A0986|67 68|p =
P10939030A0986|76 76|%
P10939030A0986|81 90|survival p =
P10939030A0986|106 123|granulocytopenia p =
P10939030A0986|134 153|febrile neutropenia p =
P10939785A0540|0 7|Patients
P10939785A0540|46 68|ACE inhibitor perindopril
P10939785A0540|46 48|ACE
P10939785A0540|76 93|diuretic indapamide
P10939785A0540|108 125|definite indication
P10939785A0540|131 146|contraindication
P10939785A0540|163 170|diuretic
P10939785A0540|182 188|placebo
P10939785A0540|190 190|s
P10940413A1153|3 9|results
P10940413A1153|25 42|open-section effect
P10940413A1153|55 72|torsional stiffness
P10940413A1153|76 101|stress concentration effects
P10940413A1153|113 129|torsional strength
P10940413A1153|133 140|long bone
P10940413A1153|146 163|longitudinal defect
P10940553A0912|5 11|regions
P10940553A0912|41 58|tissue-specificity
P10940553A0912|66 84|circadian regulation
P10940553A0912|91 117|human hPer1 gene transcription
P10940553A0912|91 104|human hPer1 gene
P10940557A1687|13 27|putative CF1/USP
P10940557A1687|21 23|CF1
P10940557A1687|25 27|USP
P10940557A1687|31 71|Broad Complex Z2 transcription factor elements
P10940557A1687|86 100|upstream regions
P10940557A1687|103 105|MIH
P10940557A1687|109 118|MO-IH genes
P10940562A0379|0 15|Sequence analysis
P10940562A0379|45 53|oasA2 gene
P10940562A0379|65 74|pseudogene
P10940562T0000|0 6|Genomic
P10940562T0000|10 35|functional characterization
P10940562T0000|41 53|oas gene family
P10940562T0000|62 88|O-acetylserine (thiol) lyases
P10940562T0000|62 75|O-acetylserine
P10940562T0000|77 81|thiol
P10940562T0000|83 88|lyases
P10940562T0000|90 96|enzymes
P10940562T0000|110 118|final step
P10940562T0000|121 140|cysteine biosynthesis
P10940562T0000|143 161|Arabidopsis thaliana
P10940892A0573|3 37|distinct recessive susceptibility loci
P10940892A0573|41 50|vasculitis
P10940892A0573|63 72|chromosome
P10940892A0573|74 76|Chr
P10940892A0573|81 87|D4Mit89
P10940892A0573|91 98|D4Mit147
P10940892A0573|105 113|progenies
P10942587A0981|19 38|phosphorylation state
P10942587A0981|41 42|Rb
P10942587A0981|76 79|mRNA
P10942587A0981|86 98|HPV E6/E7 genes
P10942587A0981|86 90|HPV E6
P10942587A0981|117 134|significant changes
P10942587A0981|140 148|E7 protein
P10942587A0981|179 184|levels
P10942587A0981|187 188|Rb
P10942587A0981|211 227|anti-E7 antibodies
P10942599A1298|0 22|Further characterization
P10942599A1298|30 54|putative Hoxa-1 target genes
P10942599A1298|78 86|functions
P10942599A1298|92 104|Hoxa-1 protein
P10942599A1298|110 133|differentiation processes
P10942599A1298|150 162|embryogenesis
P10943891A1062|12 24|U6-U57 mutants
P10943891A1062|39 46|fidelity
P10943891A1062|53 62|branch site
P10943891A1062|68 88|splice site recognition
P10943891A1062|105 114|nucleotide
P10943891A1062|148 157|active site
P10943891A1062|159 159|s
P10943891A1062|166 176|spliceosome
P10944466A0451|33 42|WNT-2B gene
P10945010T0001|9 20|daunorubicin
P10945010T0001|23 38|induction therapy
P10945010T0001|42 66|adult acute myeloid leukemia
P10945781A0412|9 24|Aeromonas strains
P10945781A0412|33 47|V cholerae non-O1
P10945781A0412|63 81|enterotoxin activity
P10946303A0000|0 8|TNF-alpha
P10946303A0000|25 46|time-dependent increase
P10946303A0000|49 64|cyclooxygenase-2
P10946303A0000|66 70|COX-2
P10946303A0000|85 97|PGE2 formation
P10946303A0000|100 127|human NCI-H292 epithelial cells
P10947274A0839|3 13|therapy time
P10947274A0839|26 43|NCS therapeutic dose
P10947274A0839|51 57|RBE-cGy
P10947274A0839|63 73|times longer
P10947274A0839|78 82|157Gd
P10947274A0839|98 100|10B
P10947840A0762|0 3|Mis3
P10947840A0762|29 42|18S ribosome RNA
P10947840A0762|71 78|proteins
P10947840A0762|93 100|coupling
P10950398T0100|0 19|Losartan Intervention
P10950398T0100|23 30|Endpoint
P10950415A0866|0 9|CONCLUSION
P10950415A0866|11 20|Vitrectomy
P10950415A0866|24 41|vitreous hemorrhage
P10950415A0866|44 57|Terson syndrome
P10950415A0866|68 85|effective procedure
P10950415A0866|104 123|prolonged improvement
P10950924A0393|0 2|RNA
P10950924A0393|9 21|hybridization
P10950924A0393|24 36|brain sections
P10950924A0393|39 56|normal human embryos
P10950924A0393|66 79|strong labeling
P10950924A0393|82 96|restricted areas
P10950924A0393|102 115|cerebral cortex
P10950935A0111|12 23|manipulation
P10950935A0111|26 46|large genomic sequences
P10950935A0111|93 115|P1 artificial chromosomes
P10950935A0111|117 120|PACs
P10950935A0111|126 151|yeast artificial chromosomes
P10950935A0111|153 156|YACs
P10951579A1238|5 21|gamma-irradiation
P10951579A1238|36 42|F9 cells
P10951579A1238|50 58|apoptosis
P10951579A1238|71 117|wt-p53 likely triggers pro-apoptotic gene expression
P10951579A1238|71 76|wt-p53
P10951579A1238|130 134|cells
P10951848A0230|0 11|Mobilization
P10951848A0230|16 31|cyclophosphamide
P10951848A0230|35 69|granulocyte-colony stimulating factor
P10951848A0230|91 95|CD34+
P10951848A0230|91 94|CD34
P10951848A0230|96 104|cell shift
P10951848A0230|107 121|peripheral blood
P10951848A0230|128 147|good quality autograft
P10951848A0230|161 181|haematopoetic recovery
P10951848A0230|187 202|megachemotherapy
P10952828A2638|16 46|cardiovascular magnetic resonance
P10952828A2638|52 69|preferred technique
P10952828A2638|82 107|ejection fraction estimation
P10952828A2638|110 129|heart failure patients
P10952828A2638|143 152|3D approach
P10952828A2638|156 178|non-symmetric ventricles
P10952828A2638|182 201|superior image quality
P10954093A0000|1 23|degenerate DNA transposon
P10954093A0000|25 27|Pat
P10954093A0000|47 53|genomes
P10954093A0000|56 78|various wild-type strains
P10954093A0000|84 117|filamentous fungus Podospora anserina
P10954525A1161|21 23|Tax
P10954525A1161|65 72|proteins
P10954525A1161|80 84|TRE-2
P10954564A1262|21 36|functional domain
P10954564A1262|42 53|ORF 50 protein
P10954564A1262|42 44|ORF
P10954564A1262|57 82|immediate-early gene product
P10954564A1262|104 106|ORF
P10954913A0152|1 26|2.3-kb full-length cDNA clone
P10954913A0152|31 51|Atlantic halibut Mx gene
P10954913A0152|68 83|liver cDNA library
P10955313A0000|0 5|PLUS-3
P10955313A0000|9 26|new Swedish protocol
P10955313A0000|29 41|natural speech
P10955313A0000|44 61|3-year-old children
P10955913A0827|4 8|HIT II
P10955913A0827|21 27|heparin
P10955913A0827|32 59|low-molecular-weight heparins
P10955998A1124|25 43|glycosylase activity
P10955998A1124|25 35|glycosylase
P10955998A1124|78 86|S120K MutY
P10955998A1124|96 107|DNA mutations
P10958271A0365|0 6|METHODS
P10958271A0365|10 16|RESULTS
P10958271A0365|53 64|measurements
P10958271A0365|67 97|left ventricular ejection fraction
P10958271A0365|99 102|LVEF
P10958271A0365|107 113|volumes
P10958271A0365|118 145|rest-injected gated Technetium
P10958271A0365|150 154|Tc99m
P10958271A0365|156 169|perfusion SPECT
P10958271A0365|174 213|equilibrium radionuclide angiocardiography
P10958271A0365|215 218|ERNA
P10958271A0365|224 231|patients
P10958271A0365|250 265|regional function
P10958271A0365|270 285|echocardiography
P10958271A0365|290 297|patients
P10958456A0529|4 8|cDNAs
P10958456A0529|35 44|respective
P10958456A0529|47 65|untranslated regions
P10958456A0529|72 73|bp
P10958456A0529|76 77|Cp
P10958456A0529|79 80|F6
P10958456A0529|86 87|bp
P10958456A0529|90 95|Cp.F10
P10958456A0529|90 91|Cp
P10958456A0529|93 95|F10
P10958456A0529|111 139|putative polyadenylation signal
P10958673A0142|4 25|intracellular signaling
P10958673A0142|45 59|protein response
P10958673A0142|61 63|UPR
P10958673A0142|81 113|cis-acting ER stress response element
P10958673A0142|115 118|ERSE
P10958673A0142|122 128|mammals
P10958688A0265|1 23|Y. lipolytica Kar2p mutant
P10958688A0265|64 74|Sls1p mutant
P10958688A0265|108 112|Sls1p
P10958688A0265|120 129|nucleotide
P10958688A0265|136 156|conformation dependent
P10958698A0280|33 53|systematic mutagenesis
P10958698A0280|59 72|Cse4p N terminus
P10958698A0485|3 9|spacing
P10958698A0485|15 39|essential N-terminal domain
P10958698A0485|41 43|END
P10958698A0485|58 60|HFD
P10958698A0485|95 108|apparent effect
P10958698A0485|111 123|Cse4p function
P10958698A0485|111 115|Cse4p
P10959676A0200|3 7|bases
P10959838A0153|2 14|invertebrates
P10959838A0153|16 19|Fhit
P10959838A0153|32 44|fusion protein
P10959838A0153|49 51|Nit
P10959838A0153|65 84|nitrilase superfamily
P10961046A0342|0 13|Platelet counts
P10961046A0342|33 42|fibrinogen
P10961046A0342|46 64|von Willebrand factor
P10961046A0342|66 68|vWF
P10961046A0342|70 75|levels
P10961585A0273|3 16|manifestations
P10961585A0273|30 53|moderate thrombocytopenia
P10961585A0273|71 79|hemolysis
P10962564A0883|1 26|beta2 RARE reporter construct
P10962564A0883|37 68|methylation-susceptible cytosines
P10962564A0883|74 84|sense strand
P10962564A0883|99 105|thymine
P10962564A0883|115 124|marked loss
P10962564A0883|148 172|chromatin-dependent manner
P10962593A0580|0 23|Non-poliomyelitis AFP rate
P10962738A0000|0 12|Consciousness
P10962881A0900|0 10|Multiparity
P10962881A0900|15 30|protective effect
P10962881A0900|39 46|less risk
P10962881A0900|50 52|% CI
P10963577T0016|0 6|Picture
P10963735A0193|39 53|oxidative stress
P10963735A0193|56 70|healthy controls
P10963735A0193|72 74|CTL
P10963735A0193|88 90|CRF
P10963735A0193|94 103|HD patients
P10963735A0193|111 116|pre-HD
P10963735A0193|127 133|post-HD
P10963735A0193|138 152|dialysis session
P10963735A0193|167 212|high biocompatible polyacrylonitrile membrane AN69
P10963735A0651|0 27|Indirect plasma parameters such
P10963735A0651|30 37|vitamin E
P10963735A0651|39 43|thiol
P10963735A0651|47 60|uric acid levels
P10964833A1696|11 22|participants
P10964833A1696|27 27|%
P10964833A1696|33 44|definite POAG
P10964833A1696|89 89|%
P10964833A1696|105 115|undiagnosed
P10964833A1696|119 125|IOP less
P10964833A1696|132 135|mmHg
P10964995A2152|46 50|women
P10964995A2152|55 56|ER
P10964995A2152|60 66|cancers
P10964995A2152|97 114|endocrine treatment
P10964995A2152|120 125|tumors
P10964995A2152|141 145|HER-2
P10965135A0735|0 15|Promoter activity
P10965135A0735|46 59|cotransfection
P10965135A0735|70 72|ras
P10965135A0735|75 86|mos oncogenes
P10965135A0735|91 108|oncogene inhibition
P10965135A0735|126 140|overall activity
P10965135A0735|154 158|cells
P10965135A0735|177 191|MAP kinase kinase
P10965135A0735|193 195|MKK
P10965135A0735|197 212|inhibitor PD98059
P10965135A1207|3 9|results
P10965135A1207|37 44|Cktsf1b1
P10965135A1207|65 80|early development
P10965135A1207|84 101|cell transformation
P10965135A1207|116 124|MKK levels
P10965135A1207|116 118|MKK
P10965135A1207|145 180|multiple transcription factor complexes
P10965830A0305|0 12|INTERVENTIONS
P10965830A0305|14 34|Subcutaneous tissue PO2
P10965830A0305|38 49|PCO2 tensions
P10965830A0305|72 79|patients
P10965830A0305|95 103|fasciitis
P10965830A0305|109 125|healthy volunteers
P10965830A0305|132 141|normobaric
P10965830A0305|145 164|hyperbaric conditions
P10965905A1618|7 29|GH-induced Akt activation
P10965905A1618|17 19|Akt
P10965905A1618|58 62|cells
P10965905A1618|68 84|same concentration
P10965905A1618|87 94|LY294002
P10965905A1618|101 108|findings
P10965905A1618|124 144|wortmannin sensitivity
P10965905A1618|154 170|IRS-1-independent
P10965905A1618|154 158|IRS-1
P10965905A1618|175 212|dependent GH-induced MAP kinase activation
P10965905A1618|194 202|MAP kinase
P10965905A1618|243 268|wortmannin-sensitive target
P10965905A1618|270 270|s
P10965905A1618|284 287|PI3K
P10965905A1618|290 298|mediation
P10965905A1618|301 329|GH-induced MAP kinase activation
P10965905A1618|301 302|GH
P10965905A1618|311 319|MAP kinase
P10965905A1618|337 341|cells
P10965905T0000|0 45|Insulin receptor substrate-1-mediated enhancement
P10965905T0000|0 25|Insulin receptor substrate-1
P10965905T0000|48 108|growth hormone-induced mitogen-activated protein kinase activation
P10965905T0000|69 98|mitogen-activated protein kinase
P10967361A0000|0 33|Functional magnetic resonance imaging
P10967361A0000|35 38|fMRI
P10967361A0000|73 90|human brain function
P10967361A0000|99 117|non-invasive feature
P10967361A0000|121 141|good spatial resolution
P10967531A1025|20 24|aorta
P10967531A1025|39 49|severe edema
P10967531A1025|51 68|local fibre necrosis
P10967531A1025|73 80|adhesion
P10967531A1025|83 92|leucocytes
P10967531A1025|101 116|muscle fibre areas
P10967531A1025|131 135|micro
P10967531A1025|139 144|microm
P10967531A1025|172 177|microm
P10967890A1120|3 9|results
P10967890A1120|44 56|comprehension
P10967890A1120|83 97|different stages
P10970048A0352|27 33|RH level
P10970048A0352|43 55|current values
P10970048A0352|61 66|orders
P10970048A0352|79 90|contrariwise
P10970048A0352|95 107|voltage values
P10970048A0352|124 128|times
P10970048A0352|142 143|RH
P10972688A1272|2 19|long-term follow-up
P10972688A1272|31 51|significant difference
P10972688A1272|57 65|incidence
P10972688A1272|68 83|hospitalizations
P10972894A0488|0 15|Genomic libraries
P10972894A0488|28 41|frozen cultures
P10972894A0488|45 57|96-well format
P10972894A0488|97 104|colonies
P10972894A0488|108 113|plates
P10972894A0488|117 128|small library
P10972894A0488|137 154|medium-size library
P10972894A0488|165 176|large library
P10972980A0295|2 17|several cell lines
P10972980A0295|19 22|mTOR
P10972980A0295|28 44|downstream targets
P10972980A0295|61 92|phosphatidylinositol (PI) 3-kinase
P10972980A0295|61 80|phosphatidylinositol
P10972980A0295|82 83|PI
P10972980A0295|85 92|3-kinase
P10972980A0295|94 108|protein kinases A
P10972980A0295|110 110|B
P10972980A0295|115 115|C
P10972980A0295|117 140|heterotrimeric G-proteins
P10972980A0295|143 165|PD98059-sensitive kinase
P10972980A0295|168 174|calcium
P10972980A0295|186 195|amino acids
P10972990A0196|3 28|tumor-suppressor protein p53
P10972990A0196|52 67|genomic stability
P10972990A0526|0 9|Abrogation
P10972990A0526|12 22|p53 function
P10972990A0526|12 14|p53
P10972990A0526|25 26|E6
P10972990A0526|52 81|spontaneous mutation frequencies
P10972990A0526|87 113|heterozygous thymidine kinase
P10972990A0526|99 113|thymidine kinase
P10972990A0526|115 116|TK
P10972990A0526|118 122|locus
P10972990A0526|134 180|hemizygous hypoxanthine phosphoribosyl transferase
P10972990A0526|144 180|hypoxanthine phosphoribosyl transferase
P10972990A0526|182 185|HPRT
P10972990A0526|187 191|locus
P10972990A0966|0 18|Cytogenetic analysis
P10972990A0966|21 30|LOH mutants
P10972990A0966|33 50|chromosome painting
P10972990A0966|61 66|mosaic
P10972990A0966|69 90|chromosomal aberrations
P10972990A0966|100 109|chromosome
P10972990A0966|120 145|partial chromosome deletions
P10972990A0966|147 160|amplifications
P10972990A0966|165 186|multiple translocations
P10972990A0966|213 224|single mutant
P10972990A1518|5 11|results
P10972990A1518|32 41|p53 protein
P10972990A1518|71 86|genomic integrity
P10972990A1518|94 114|recombinational repair
P10973151A0883|19 43|new epidemiological profile
P10973151A0883|46 60|schistosomiasis
P10973151A0883|66 70|State
P10973151A0883|73 82|Pernambuco
P10973151A0883|123 146|drastic human interference
P10973385A1423|2 9|patients
P10973385A1423|20 25|tumors
P10973385A1423|39 53|lymphatic spread
P10973385A1423|83 93|paracardial
P10973385A1423|95 109|lesser curvature
P10973385A1423|118 135|gastric artery nodes
P10973385A1423|137 149|esophagectomy
P10973385A1423|159 173|survival benefit
P10973385A1423|186 196|gastrectomy
P10973385A1423|204 211|patients
P10973400A0664|0 6|RESULTS
P10973400A0664|10 31|significant deformation
P10973400A0664|34 52|vertebral artery flow
P10973400A0664|66 89|flexion-distraction Stage
P10973400A0664|91 98|injuries
P10973400A0664|108 123|physiologic range
P10973400A0664|126 140|cervical flexion
P10974541A0389|11 25|K562 cDNA library
P10974541A0389|39 54|novel transcripts
P10974541A0389|56 60|MZF1B
P10974541A0389|64 68|MZF1C
P10975465A0134|3 21|human cDNA clone NFBD1
P10975465A0134|43 50|KIAA0170
P10975465A0134|60 71|novel protein
P10975465A0134|77 86|amino acids
P10975465A0134|106 118|molecular mass
P10975465A0134|126 126|D
P10975465A0134|132 150|possible BRCT domains
P10975465A0134|156 170|carboxy terminus
P10975465A0134|172 188|amino acid residues
P10976413A0514|0 6|RESULTS
P10976413A0514|15 27|basal FSH level
P10976413A0514|20 22|FSH
P10976413A0514|31 48|stimulated FSH level
P10976413A0514|41 43|FSH
P10976413A0514|71 91|significant predictors
P10976413A0514|94 103|IVF success
P10976413A0514|131 138|FSH level
P10976413A0514|131 133|FSH
P10976413A0514|144 149|mIU/ml
P10976413A0514|168 175|FSH level
P10976413A0514|181 186|mIU/ml
P10980416T0000|0 27|Parathyroid hormone regulation
P10980416T0000|0 17|Parathyroid hormone
P10980416T0000|30 45|bone sialoprotein
P10980416T0000|47 49|BSP
P10980416T0000|51 67|gene transcription
P10980416T0000|86 124|pituitary-specific transcription factor-1
P10980416T0000|126 130|Pit-1
P10980416T0000|132 136|motif
P10980416T0000|142 159|rat BSP gene promoter
P10981094A0779|0 18|Recent target BP goals
P10981094A0779|35 45|Sixth Report
P10981094A0779|53 74|Joint National Committee
P10981094A0779|76 80|JNC VI
P10981094A0779|164 179|pretreatment risk
P10982076A0000|7 49|continuous community-based morbidity recording
P10982076A0000|52 72|influenza-like illness
P10982076A0000|74 76|ILI
P10982076A0000|82 100|virological sampling
P10982076A0000|140 157|earliest indicators
P10982076A0000|171 187|influenza activity
P10982143A0346|3 8|muskox
P10982143A0346|12 24|new host record
P10982143A0346|28 35|T. gondii
P10982391A0425|12 21|NPF repeats
P10982391A0425|24 42|leucine heptad repeat
P10982391A0425|60 67|residues
P10982391A0425|73 92|proline-rich SH3-like
P10982391A0425|85 118|SH3-like and/or WW domain-binding site
P10982391A0425|99 118|WW domain-binding site
P10982391A0425|124 139|N-terminal domain
P10982391A0425|159 170|membrane core
P10982391A0425|185 210|putative transmembrane spans
P10982391A0425|219 237|amphiphilic segments
P10982391A0425|267 284|structural elements
P10982825A0363|49 63|Mot3 binding site
P10982825A0363|66 68|OpA
P10983344A0000|22 31|diagnosing
P10983344A0000|35 44|correction
P10983344A0000|47 64|reversible ischemia
P10983344A0000|70 78|intestine
P10983857A0923|0 17|Mucosal application
P10983857A0923|20 27|NCX-4016
P10983857A0923|48 58|PD reduction
P10983857A0923|62 69|luminal H
P10983857A0923|88 102|marked hyperemia
P10983857A0923|150 165|STZ-diabetic rats
P10983979T0000|0 20|Functional recognition
P10983979T0000|25 34|splice site
P10983979T0000|37 41|U4/U6
P10983979T0000|37 38|U4
P10983979T0000|43 53|U5 tri-snRNP
P10983979T0000|62 83|novel ATP-dependent step
P10983979T0000|86 109|early spliceosome assembly
P10984122A0911|13 17|cells
P10984122A0911|37 47|DNA mixtures
P10984122A0911|58 69|vector mU6-C1
P10984122A0911|72 77|mU6-C2
P10987280A0604|3 19|amino acid sequence
P10987280A0604|22 33|matrilysin-2
P10987280A0604|47 70|threonine residue adjacent
P10987280A0604|76 89|Zn-binding site
P10987280A0604|111 125|specific feature
P10987280A0604|128 137|matrilysin
P10987301A0332|54 83|active G protein-coupled receptor
P10987301A0332|60 83|G protein-coupled receptor
P10987301A0332|85 88|GPCR
P10987301A0332|102 107|Kaposi
P10987301A0332|110 138|sarcoma-associated herpes virus
P10987301A0332|140 143|KSHV
P10987301A0332|146 161|human herpes virus
P10987301A0332|151 162|herpes virus 8
P10987301A0332|165 173|oncogenic
P10987301A0332|187 198|angiogenesis
P10987301A0332|214 222|secretion
P10987301A0332|225 255|vascular endothelial growth factor
P10987301A0332|257 260|VEGF
P10987301A0332|271 293|key angiogenic stimulator
P10987301A0332|298 312|critical mitogen
P10987301A0332|332 337|Kaposi
P10987301A0332|340 346|sarcoma
P10989777A1286|2 17|specific subgroup
P10989777A1286|20 26|clients
P10989777A1286|44 46|URD
P10989777A1286|57 72|prospective study
P10989777A1286|82 97|random assignment
P10991383A0289|5 11|lattice
P10991383A0289|15 15|%
P10991383A0289|21 25|sites
P10991383A0289|40 40|%
P10991383A0289|46 50|atoms
P10991383A0289|59 86|lowest energy magnetic sublevel
P10991383A0289|93 93|%
P10991383A0289|102 125|lowest 3D vibrational state
P10991648T0000|21 30|horizontal
P10991648T0000|38 50|half syndromes
P10992299A0745|17 23|members
P10992299A0745|29 42|gene expression
P10992299A0745|58 70|tumorigenesis
P10992299A0745|72 85|PI12 expression
P10992299A0745|72 75|PI12
P10992299A0745|114 130|tumor brain tissues
P10992299A0745|139 158|brain cancer cell lines
P10992299A0745|160 165|U-87 MG
P10992299A0745|169 170|H4
P10992983T0000|28 44|sexual orientation
P10992983T0000|48 57|penile size
P10992983T0000|62 63|A.
P10993773A0717|12 18|further
P10993773A0717|44 54|min ischemia
P10993773A0717|67 77|microm/mmHg
P10993773A0717|96 108|control values
P10993773A0717|132 141|myocardium
P10993773A0717|146 156|min ischemia
P10993773A0717|169 179|microm/mmHg
P10993787A0369|11 13|MAP
P10993787A0369|17 28|MSNA increase
P10993787A0369|35 37|SHG
P10993787A0369|56 58|SHG
P10993787A0369|61 63|PHI
P10993787A0369|82 99|transient reduction
P10993787A0369|102 104|MAP
P10993787A0369|117 125|elevation
P10993787A0369|128 131|MSNA
P10993787A0369|162 168|factors
P10995121A0569|0 7|Analysis
P10995121A0569|10 38|Standard Reference Material 1846
P10995121A0569|40 52|Infant Formula
P10995121A0569|59 67|mean value
P10995121A0569|82 94|mg vitamin K/kg
P10995121A0569|96 96|K
P10995121A0569|99 100|K1
P10995121A0569|104 105|n =
P10995121A0569|114 124|coefficient
P10995751A0093|28 62|CCAAAT/enhancer-binding protein-beta
P10995751A0093|64 73|C/EBP-beta
P10995751A0093|82 98|gene transcription
P10995751A0093|107 129|novel IFN response element
P10995751A0093|112 129|IFN response element
P10995751A0093|139 179|gamma-IFN-activated transcriptional element
P10997330A0361|0 19|Northern blot analysis
P10997330A0361|39 47|STORP gene
P10997330A0361|52 68|ubiquitous pattern
P10997330A0361|71 87|expression similar
P10997330A0361|99 105|PML gene
P10997863A0753|5 15|TLE patients
P10997863A0753|19 21|NAA
P10997863A0753|23 30|Cr ratios
P10997863A0753|47 58|seizure focus
P10997863A0753|70 80|FLE patients
P10997863A0753|110 121|seizure focus
P10997904A1258|3 15|Spo0F residues
P10997904A1258|27 42|hydrophobic patch
P10997904A1258|62 79|response regulators
P10997904A1258|97 103|binding
P10997904A1258|125 136|same residues
P10997904A1258|153 181|response regulator-kinase pairs
P10998679A0500|3 20|psychologic factors
P10998679A0500|31 47|wth serious illness
P10998679A0500|49 65|terminal prognoses
P10998679A0500|124 139|nonmalignant pain
P10999205A0607|13 29|spatial resolution
P10999205A0607|66 79|pathologic area
P10999205A0607|85 100|contralateral VOI
P10999205A0607|125 143|single-voxel spectra
P10999301A0000|0 21|Quantitative evaluation
P10999301A0000|24 48|magneto-optical parameters
P10999301A0000|74 108|scanning near-field optical microscope
P10999301A0000|110 113|SNOM
P10999301A0000|137 145|magnetism
P10999301A0000|151 165|mesoscopic scale
P10999369A0192|14 22|amplitude
P10999369A0192|28 35|cortical
P10999369A0192|42 51|potentials
P10999369A0192|53 61|amplitude
P10999369A0192|67 75|N2/P2 peak
P10999369A0192|99 104|microV
P10999369A0192|108 109|mA
P10999369A0192|122 127|microV
P10999369A0192|132 133|mA
P11000203A0752|5 13|mutations
P11000203A0752|16 20|K-Rev
P11000203A0752|48 57|properties
P11000203A0752|69 99|K-Rev-dependent nuclear RNA export
P11000203A0752|101 119|several K-Rev mutants
P11000203A0752|136 143|wild type
P11000203A0752|168 187|individual activities
P11000203A0752|203 211|defective
P11000203A0752|215 223|RNA export
P11000250A0200|0 4|LMP-1
P11000250A0200|20 33|plasma membrane
P11000250A0200|47 50|TRAF
P11000250A0200|52 56|TRADD
P11000250A0200|61 72|JAK molecules
P11000250A0200|83 91|NF-kappaB
P11000250A0200|94 97|AP-1
P11000250A0200|103 124|STAT-dependent pathways
P11000250A0200|103 106|STAT
P11000250A0200|131 134|CD40
P11000266T0000|0 13|Identification
P11000266T0000|18 25|enhancer
P11000266T0000|31 49|alternative promoter
P11000266T0000|55 65|first intron
P11000266T0000|71 91|alpha-fetoprotein gene
P11000521A0588|8 37|intracellular signaling pathways
P11000521A0588|59 81|malignant transformation
P11000521A0588|84 90|Ret-9bp
P11000521A0588|101 111|NIH3T3 cells
P11000521A0588|131 161|Ret-9bp dependent phosphorylation
P11000521A0588|131 137|Ret-9bp
P11000521A0588|164 189|insulin receptor substrate-2
P11000521A0588|191 195|IRS-2
P11000521A0588|201 221|consecutive activation
P11000521A0588|224 251|phosphatidylinositol 3-kinase
P11000521A0588|253 262|PI 3-kinase
P11000521A0588|267 280|protein kinase B
P11000521A0588|282 288|PKB/AKT
P11000521A0588|282 284|PKB
P11000521A0588|286 288|AKT
P11002236A0328|0 6|METHODS
P11002236A0328|13 24|current study
P11002236A0328|28 34|authors
P11002236A0328|45 52|PPB cases
P11002236A0328|58 84|national retrospective search
P11002236A0328|98 116|Italian Associations
P11002236A0328|120 138|Pediatric Hematology
P11002236A0328|142 156|Oncology centers
P11003471A1149|0 19|Phylogenetic analysis
P11003471A1149|33 45|ToLCV isolates
P11003471A1149|50 58|Bangalore
P11003471A1149|77 83|viruses
P11003471A1149|104 116|Northern India
P11003641A0811|11 33|Fcp1p-binding motif KEFGK
P11003641A0811|11 15|Fcp1p
P11003641A0811|39 43|RAP74
P11003641A0811|45 49|Tfg1p
P11003641A0811|51 57|subunit
P11003641A0811|60 64|TFIIF
P11003641A0811|81 99|synthetic phenotypes
P11003641A0811|102 129|certain fcp1 tfg1 double mutants
P11003641A0811|109 112|fcp1
P11003641A0811|113 116|tfg1
P11003641A0811|150 154|Fcp1p
P11003641A0811|165 177|transcription
P11003641A0811|198 205|tethered
P11003641A0811|209 216|promoter
P11003652A0961|5 11|results
P11003652A0961|23 28|Cdc42p
P11003652A0961|48 64|pheromone response
P11003652A0961|90 98|PAK Ste20p
P11003652A0961|90 92|PAK
P11003652A0961|93 98|Ste20p
P11003653A0198|0 7|Deletion
P11003653A0198|12 36|intergenic DNA-binding site
P11003653A0198|56 85|human beta-globin locus construct
P11003653A0198|56 76|human beta-globin locus
P11003653A0198|102 111|human gamma
P11003653A0198|115 134|beta-globin switching
P11003653A0198|137 150|transgenic mice
P11003653A0198|169 178|PYR complex
P11003669A0000|12 20|rat gene 33
P11003669A0000|12 18|rat gene
P11003669A0000|38 62|ErbB-2-interacting protein
P11003669A0000|66 81|two-hybrid screen
P11003669A0000|94 112|ErbB-2 juxtamembrane
P11003669A0000|116 128|kinase domains
P11003669A0000|131 134|bait
P11003805A0443|0 6|Studies
P11003805A0443|21 24|DGOR
P11003805A0443|32 41|acid reflux
P11003805A0443|53 60|symptoms
P11003805A0443|70 79|acid reflux
P11003805A0443|118 129|oesophagitis
P11003807A0303|0 7|Symptoms
P11003807A0303|44 55|oesophagitis
P11003807A0303|63 76|severe symptoms
P11003807A0303|97 120|greater oesophageal damage
P11004369A0000|0 8|OBJECTIVE
P11004369A0000|42 50|blood flow
P11004369A0000|71 92|color Doppler ultrasound
P11004369A0000|94 111|microvessel density
P11004369A0000|116 152|vascular endothelial growth factor levels
P11004369A0000|116 146|vascular endothelial growth factor
P11004369A0000|155 174|endometrial carcinoma
P11005808A1082|5 11|results
P11005808A1082|23 25|Ras
P11005808A1082|30 61|Raf-independent ERK MAPK activation
P11005808A1082|30 32|Raf
P11005808A1082|71 83|cell viability
P11005808A1082|93 101|heat shock
P11005831A0242|5 9|cDNAs
P11005831A0242|18 66|basic leucine zipper (bZIP)-type ABRE-binding proteins
P11005831A0242|18 35|basic leucine zipper
P11005831A0242|37 40|bZIP
P11005831A0242|43 66|type ABRE-binding proteins
P11005831A0242|89 109|yeast one-hybrid system
P11005831A0242|127 131|AREB1
P11005831A0242|133 137|AREB2
P11005831A0242|142 146|AREB3
P11005831A0242|148 182|ABA-responsive element binding protein
P11006283A1180|0 18|Recombinant AROM-p64
P11006283A1180|11 14|AROM
P11006283A1180|16 18|p64
P11006283A1180|28 38|high binding
P11006283A1180|41 58|single-stranded DNA
P11006283A1180|62 65|poly
P11006283A1180|67 67|A
P11006283A1180|69 80|homopolymers
P11006283A1180|122 146|mRNA maturation/metabolism
P11006284T0000|3 27|protein-tyrosine kinase fer
P11006284T0000|51 59|complexes
P11006284T0000|70 95|insulin receptor substrate-1
P11006284T0000|99 126|phosphatidylinositol 3-kinase
P11006331A0319|3 19|variable phenotype
P11006331A0319|25 39|allotetraploids
P11006331A0319|61 84|cytological abnormalities
P11007509A1271|5 17|PMR target area
P11007509A1271|29 42|nontreated area
P11007509A1271|58 86|regional myocardial flow reserve
P11007509A1271|95 106|wall segments
P11007509A1271|147 161|stress perfusion
P11007777A0813|0 7|Analysis
P11007777A0813|10 30|intron/exon boundaries
P11007777A0813|36 51|genomic BAC clones
P11007777A0813|67 73|junctin
P11007777A0813|75 82|junctate
P11007777A0813|87 110|aspartyl beta-hydroxylase
P11007777A0813|121 139|alternative splicing
P11007777A0813|145 152|same gene
P11007949A1395|20 38|inactivation mutants
P11007949A1395|41 44|PTEN
P11007949A1395|54 54|%
P11007949A1395|60 64|forms
P11007949A1395|67 77|solid tumors
P11007949A1607|35 37|ILK
P11007949A1607|54 61|elevated
P11007949A1607|64 78|PTEN mutant cells
P11007949A1607|64 73|PTEN mutant
P11007954A0170|3 35|growth factor receptor-bound protein
P11007954A0170|38 41|Grb2
P11007954A0170|43 49|adaptor
P11007954A0170|67 69|Sos
P11007954A0170|71 84|Son of sevenless
P11007954A0170|71 73|Son
P11007954A0170|76 84|sevenless
P11007954A0170|90 103|exchange factor
P11007954A0170|106 108|Ras
P11007954A0170|135 166|tyrosine kinase-activated receptor
P11007954A0170|169 171|Ras
P11007954A0170|184 186|Sos
P11007954A0170|192 199|membrane
P11007954A0170|209 218|activation
P11007954A0170|221 223|Ras
P11007961A0930|0 8|Mutations
P11007961A0930|11 15|genes
P11007961A0930|24 37|PR65/A subunits
P11007961A0930|58 85|several different human cancers
P11007961A0930|92 104|PP2A inhibitor
P11007961A0930|92 95|PP2A
P11007961A0930|112 121|fostriecin
P11007961A0930|140 153|anticancer drug
P11007968A0255|25 27|dxr
P11007968A0255|85 87|PCR
P11007968A0255|93 108|oligonucleotides
P11007968A0255|121 127|regions
P11008139T0000|0 17|Perceptual learning
P11008139T0000|22 46|pattern discrimination task
P11008420A0580|3 10|detector
P11008420A0580|39 57|ST segment deviations
P11008420A0580|61 84|entire ST-T complex changes
P11008420A0580|102 122|wider characterization
P11008420A0580|128 150|potential ischemic events
P11011139A0000|32 46|SIN4 gene product
P11011139A0000|62 76|mediator complex
P11011139A0000|91 105|RNA polymerase II
P11011139A0000|91 103|RNA polymerase
P11011139A0000|107 120|various studies
P11011139A0000|144 147|Sin4
P11011139A0000|153 162|alteration
P11011139A0000|165 194|higher-order chromatin structure
P11012568A0192|0 29|Primary adrenal hypersensitivity
P11012568A0192|32 40|ACTH drive
P11012568A0192|32 35|ACTH
P11012568A0192|43 49|obesity
P11012671A0576|12 40|noncanonical C/EBP-binding site
P11012671A0576|24 40|C/EBP-binding site
P11012671A0576|50 68|Gadd45gamma promoter
P11012671A0576|74 82|C/EBPbeta
P11012671A0576|86 95|C/EBPdelta
P11012671A0576|121 153|electrophoretic mobility shift assay
P11012671A0576|155 158|EMSA
P11012671A0576|163 182|reporter gene analysis
P11012680A0676|0 12|Src activation
P11012680A0676|0 2|Src
P11012680A0676|22 25|FGF1
P11012680A0676|41 49|SH2 domain
P11012680A0676|52 54|Src
P11012680A0676|58 60|PP2
P11012680A0676|63 79|specific inhibitor
P11012680A0676|82 84|Src
P11012680A1020|11 35|PLCgamma inhibitory peptide
P11012680A1020|37 44|neomycin
P11012680A1020|51 73|calcium chelator BAPTA-AM
P11012680A1020|76 82|oocytes
P11012680A1020|93 97|FGFR1
P11012680A1020|103 113|stimulation
P11012680A1020|116 122|PDGF-BB
P11012680A1020|125 131|oocytes
P11012680A1020|142 152|PDGFR-FGFR1
P11012680A1020|142 146|PDGFR
P11012680A1020|148 152|FGFR1
P11012680A1020|165 183|PLCgamma binding site
P11012680A1020|194 197|GVBD
P11012680A1020|201 219|ERK2 phosphorylation
P11012680A1020|201 204|ERK2
P11013079A0927|0 30|Multiple transcription start sites
P11013079A0927|45 67|primer extension analysis
P11013079A0927|73 81|mouse gene
P11013079A0927|86 107|transfection constructs
P11013079A0927|121 139|prospective promoter
P11013079A0927|149 181|transcriptional activity comparable
P11013079A0927|193 204|SV40 promoter
P11014197A0339|7 24|inhibitor scaffolds
P11014197A0339|42 47|potent
P11014197A0339|51 69|selective inhibitors
P11014197A0339|83 89|kinases
P11014197A0339|98 116|distinct subfamilies
P11014213A1019|31 38|arsenite
P11014213A1019|46 66|hormone-binding domain
P11014213A1019|76 93|receptor activation
P11014213A1019|95 104|COS-1 cells
P11014213A1019|140 162|chimeric receptors GAL-ER
P11014213A1019|180 200|hormone-binding domain
P11014213A1019|203 209|ERalpha
P11014213A1019|216 232|DNA-binding domain
P11014213A1019|238 260|transcription factor GAL4
P11014213A1019|257 260|GAL4
P11014213A1019|266 295|GAL4-responsive CAT reporter gene
P11014215A1092|16 30|deletion studies
P11014215A1092|49 65|248-bp DNA fragment
P11014215A1092|92 111|translation start site
P11014215A1092|121 134|flanking region
P11014215A1092|140 153|human GnRHR gene
P11014215A1092|177 205|GnRHa-mediated down-regulation
P11014215A1092|208 233|human GnRHR promoter activity
P11014215A1092|208 225|human GnRHR promoter
P11014465A0479|3 9|mean day
P11014465A0479|23 50|periventricular echodensities
P11014465A0479|59 62|days
P11014465A0479|73 76|days
P11014465A0479|84 92|cystic PVL
P11014465A0479|99 102|days
P11014465A0479|113 116|days
P11014821T0000|3 21|LAMMER protein kinase
P11014821T0000|3 8|LAMMER
P11014821T0000|34 41|Doa locus
P11014821T0000|44 53|Drosophila
P11014821T0000|70 76|somatic
P11014821T0000|80 92|germline cells
P11014821T0000|123 141|cytoplasmic isoforms
P11015197A0310|15 22|cysteine
P11015197A0310|37 55|consecutive residues
P11015197A0310|61 69|fourth TMS
P11015197A0310|71 73|TM4
P11015200A0156|6 7|J.
P11016014A0181|0 9|HYPOTHESIS
P11016014A0181|47 69|oxidative susceptibility
P11016014A0181|72 109|apolipoprotein B-containing lipoproteins
P11016014A0181|113 129|antioxidant status
P11016014A0181|132 139|patients
P11016014A0181|144 165|acute coronary syndromes
P11016014A0181|169 195|chronic stable angina pectoris
P11016724A0536|2 7|group B
P11016724A0536|10 12|MBq
P11016724A0536|18 23|microL
P11016724A0536|26 45|99mTc-HSA nanocolloid
P11016724A0536|84 84|h
P11016724A0536|102 109|aliquots
P11016737A0275|0 30|Post-operative functional outcome
P11016737A0275|42 70|pre-operative functional status
P11016850A0423|9 19|DNA fragment
P11016850A0423|31 44|N-terminal part
P11016850A0423|59 79|significant similarity
P11016850A0423|82 88|members
P11016850A0423|94 130|LysR family of transcriptional regulators
P11016850A0423|94 103|LysR family
P11016850A0423|106 130|transcriptional regulators
P11016850A0423|132 136|LTTRs
P11016954A0438|0 3|AGO1
P11016954A0438|15 19|QDE-2
P11016954A0438|42 46|RDE-1
P11016954A0438|58 61|RNAi
P11017876A0787|0 31|Intracellular localization studies
P11017876A0787|40 45|mDAP-3
P11017876A0787|47 63|EGFP fusion protein
P11017876A0787|47 50|EGFP
P11017876A0787|65 81|cell fractionation
P11017876A0787|85 128|protease protection experiments localized mDAP-3
P11017876A0787|123 128|mDAP-3
P11017876A0787|134 152|mitochondrial matrix
P11018028A0263|34 60|cAMP-dependent protein kinase
P11018028A0263|62 64|PKA
P11018028A0263|71 85|phosphorylation
P11018028A0263|88 94|CDC25Mm
P11018028A0263|97 107|fibroblasts
P11018028A0263|126 131|RasGEF
P11018028A0263|142 172|mouse brain synaptosomal membranes
P11018264A0397|0 29|Reporter gene expression analyses
P11018264A0397|46 58|WASP promoters
P11018264A0397|63 72|high levels
P11018264A0397|87 117|different hematopoietic cell lines
P11019257A0159|10 16|3T1-3T2
P11019257A0159|27 42|pronounced effect
P11019257A0159|48 56|line shape
P11019257A0159|60 77|radiative decay rate
P11019257A0159|95 102|3T2 state
P11019257A0159|160 184|nontetrahedral distortions
P11020375A0134|11 36|1-day-old Ross broiler chicks
P11020375A0134|52 66|treatment groups
P11020375A0134|98 100|CLI
P11020375A0134|104 106|g kg
P11020375A0134|119 123|parts
P11020375A0134|135 137|ppb
P11020375A0134|139 140|AF
P11020375A0134|144 148|ppb AF
P11020375A0134|153 155|CLI
P11020375A0134|160 164|ppb AF
P11020375A0134|163 164|AF
P11020375A0134|169 173|ppb AF
P11020375A0134|178 180|CLI
P11020375A0134|187 190|days
P11023074A1105|32 33|CC
P11023074A1105|35 38|kEIA
P11023074A1105|42 46|PACE2
P11023832A1038|15 21|results
P11023832A1038|36 44|KG1a cells
P11023832A1038|46 53|TNFalpha
P11023832A1038|68 81|parallel PC-PLC
P11023832A1038|85 87|PLD
P11023832A1038|94 106|lipid products
P11023832A1038|117 150|turn mitogen-activated protein kinase
P11023832A1038|121 150|mitogen-activated protein kinase
P11023832A1038|152 160|MAP kinase
P11023832A1038|165 183|NF-kappaB signalling
P11023832A1038|165 173|NF-kappaB
P11023853A0188|24 40|weather conditions
P11023853A0188|48 70|time-activity budget data
P11023853A0188|73 88|free-living birds
P11023853A0188|92 105|laboratory data
P11023853A0188|115 127|metabolic rate
P11023853A0188|139 161|time-activity laboratory
P11023853A0188|163 165|TAL
P11023853A0188|167 175|estimates
P11023853A0188|178 199|daily energy expenditure
P11023853A0188|201 203|DEE
P11023853A0188|210 218|partition
P11023853A0188|222 228|verdins
P11023853A0188|230 241|energy budget
P11023853A0188|246 261|thermoregulatory
P11023853A0188|274 288|basal components
P11023934A0855|0 2|L/H
P11023934A0855|9 11|chi
P11023934A0855|15 15|=
P11023934A0855|21 21|P
P11023934A0855|34 58|restrictive filling pattern
P11023934A0855|60 62|chi
P11023934A0855|66 66|=
P11023934A0855|71 71|P
P11023934A0855|83 103|independent predictors
P11023934A0855|106 111|events
P11024026A0133|3 17|high selectivity
P11024026A0133|20 28|arrestins
P11024026A0133|36 59|particular functional form
P11024026A0133|62 69|receptor
P11024026A0133|82 94|timely binding
P11024026A0133|98 109|dissociation
P11024036A0984|19 29|fibroblasts
P11024036A0984|35 60|C/EBP alpha expression vector
P11024036A0984|35 44|C/EBP alpha
P11024036A0984|62 83|reporter gene expression
P11024036A0984|108 126|wild-type constructs
P11024047A0626|0 9|Expression
P11024047A0626|13 33|dominant negative Smad2
P11024047A0626|29 33|Smad2
P11024047A0626|64 89|luciferase reporter activity
P11024047A0626|64 81|luciferase reporter
P11024047A0626|99 112|nodal treatment
P11024182A0781|0 11|Normal alpha1
P11024182A0781|15 26|collagen mRNA
P11024182A0781|35 54|significant reduction
P11024182A0781|59 60|AR
P11024182A0781|63 64|IR
P11024182A0781|84 104|pHbetaAPr-1-neo vector
P11024182A0781|120 120|%
P11024182A0781|125 144|significant reduction
P11024182A0781|155 162|ribozyme
P11024182A0781|182 184|pCI
P11024182A0781|186 194|neo vector
P11024300A1579|0 5|Nature
P11024300A1579|25 42|amino acid sequences
P11024300A1579|45 60|peptide fragments
P11024300A1579|74 84|polypeptide
P11024300A1579|102 109|proteins
P11024300A1579|120 137|chromatin structure
P11024300A1579|139 141|ARC
P11024300A1579|157 164|portions
P11024300A1579|177 192|open reading frame
P11024300A1579|195 203|TIG-1 mRNA
P11025367A1009|0 12|Abnormalities
P11025367A1009|15 35|plasma cholecystokinin
P11025367A1009|54 61|patients
P11025367A1009|73 87|gastric emptying
P11027027A0061|2 16|Sunset Yellow FCF
P11027027A0061|37 73|liquid chromatography/mass spectrometry
P11027027A0061|75 79|LC/MS
P11027027A0061|85 106|electrospray ionization
P11027267A0752|0 7|Polysome
P11027267A0752|11 30|40S ribosome fractions
P11027267A0752|11 21|40S ribosome
P11027267A0752|57 66|krr1 mutant
P11027267A0752|70 88|Kri1p-depleted cells
P11027267A0752|70 74|Kri1p
P11027274A1682|29 55|PI 3-kinase catalytic activity
P11027274A1682|29 38|PI 3-kinase
P11027274A1682|61 76|different extents
P11027274A1682|92 116|unique N-terminal structure
P11027274A1682|123 129|isoform
P11027280A0536|0 10|Cam kinase II
P11027280A0536|0 8|Cam kinase
P11027280A0536|24 38|phosphorylation
P11027280A0536|41 45|Smad2
P11027280A0536|49 53|Smad4
P11027280A0536|61 72|lesser extent
P11027280A0536|74 78|Smad3
P11027289A0000|3 45|Drosophila melanogaster suppressor of sable gene
P11027289A0000|25 34|suppressor
P11027289A0000|37 45|sable gene
P11027289A0000|50 50|s
P11027289A0000|67 97|150-kDa nuclear RNA binding protein
P11027289A0000|99 100|SU
P11027289A0000|102 102|S
P11027289A0000|128 142|RNA accumulation
P11027289A0000|147 159|mutant alleles
P11027289A0000|162 171|other genes
P11027289A0000|180 199|transposon insertions
P11027289A0321|26 44|arginine-rich motifs
P11027289A0321|46 49|ARM1
P11027289A0321|53 56|ARM2
P11027289A0321|72 89|RNA binding activity
P11027289A0321|92 93|SU
P11027289A0321|95 95|S
P11027294A0483|26 57|histone acetyltransferase activity
P11027294A0483|26 49|histone acetyltransferase
P11027294A0483|60 63|p300
P11027294A0483|76 91|drastic reduction
P11027294A0483|94 122|nucleosomal histone acetylation
P11027294A0483|126 135|alteration
P11027294A0483|138 155|chromatin structure
P11027724A0335|0 17|Recombinant BRI1-KD
P11027724A0335|38 43|serine
P11027724A0335|45 47|Ser
P11027724A0335|52 60|threonine
P11027724A0335|62 64|Thr
P11027724A0335|66 73|residues
P11027724A0335|78 82|p-Ser
P11027833A0362|0 11|Flow cytomery
P11027833A0362|22 38|cell cycle analysis
P11028131A1374|0 14|Further research
P11028131A1374|27 55|better measure treatment effects
P11028131A1374|57 68|modification
P11028131A1374|71 86|MS natural history
P11028131A1374|91 106|net societal costs
P11028131A1374|109 118|IFN beta-1b
P11028131A1374|121 124|RRMS
P11028131T0000|0 17|Cost-effectiveness
P11028131T0000|20 36|interferon beta-1b
P11028131T0000|46 83|multiple sclerosis disability progression
P11028944A1020|7 10|Cmax
P11028944A1020|14 22|AUC values
P11029045A0000|0 14|Hyperactivation
P11029045A0000|17 20|Cdc2
P11029045A0000|23 34|fission yeast
P11029045A0000|41 45|cells
P11029045A0000|56 77|lethal premature mitosis
P11029045A0000|84 101|mitotic catastrophe
P11029262T0000|0 4|Diary
P11029458A0000|0 4|Cells
P11029458A0000|30 56|various extracellular stimuli
P11029459A0000|0 29|Transforming growth factor-beta1
P11029459A0000|12 29|growth factor-beta1
P11029459A0000|31 39|TGF-beta1
P11029459A0000|50 64|tumor suppressor
P11029459A0000|68 80|tumor promoter
P11029459A0000|95 109|characteristics
P11029459A0000|115 127|malignant cell
P11029467T0000|0 26|Vasoactive intestinal peptide
P11029467T0000|30 76|pituitary adenylate cyclase-activating polypeptide
P11029467T0000|84 127|nuclear factor-kappa B-dependent gene activation
P11029467T0000|84 117|nuclear factor-kappa B-dependent gene
P11029467T0000|130 143|multiple levels
P11029467T0000|149 175|human monocytic cell line THP-1
P11029656A0640|0 2|Mn2
P11029656A0640|20 34|junction binding
P11029656A0640|46 55|activities
P11029656A0640|61 74|mutant proteins
P11029700A0295|5 13|Pt;cycH;1
P11029700A0295|5 6|Pt
P11029700A0295|8 11|cycH
P11029700A0295|17 25|Os;cycH;1
P11029700A0295|17 18|Os
P11029700A0295|20 23|cycH
P11029700A0295|44 50|tissues
P11029700A0295|63 73|transcripts
P11029700A0295|105 109|cells
P11029700A0746|18 31|pull-down assay
P11029700A0746|42 50|Os;CycH;1
P11029700A0746|42 43|Os
P11029700A0746|45 48|CycH
P11029700A0746|70 71|R2
P11029700A0746|80 92|other rice CDKs
P11029700A0746|85 92|rice CDKs
P11029704A0378|2 18|transient analysis
P11029704A0378|24 42|particle bombardment
P11029704A0378|45 63|tobacco leaf sections
P11029704A0378|66 73|tetramer
P11029704A0378|79 87|distB ABRE
P11029704A0378|89 118|abscisic acid-responsive element
P11029704A0378|120 142|mediated transactivation
P11029704A0378|145 148|ABI3
P11029704A0378|152 173|ABI3-dependent response
P11029704A0378|152 155|ABI3
P11029704A0378|176 178|ABA
P11029704A0378|188 195|tetramer
P11029704A0378|201 220|composite RY/G complex
P11029704A0378|232 240|RY repeats
P11029704A0378|245 249|G-box
P11029704A0378|263 292|ABA-independent transactivation
P11029704A0378|295 298|ABI3
P11030066A0142|3 33|major neurological manifestations
P11030066A0142|36 46|brain injury
P11030066A0142|54 59|babies
P11030066A0142|63 82|spastic motor deficits
P11030476A0685|0 5|Spores
P11030476A0685|10 27|Rhizopus stolonifer
P11030476A0685|43 56|distilled water
P11030476A0685|65 73|spores/mL
P11030744A0763|0 13|Overexpression
P11030744A0763|16 21|Trdpm1
P11030744A0763|25 28|dpm1
P11030744A0763|34 44|his7/dpm1(+
P11030744A0763|34 42|his7/dpm1
P11030744A0763|46 47|S.
P11030744A0763|53 59|diploid
P11030744A0763|71 84|4-fold increase
P11030744A0763|87 113|specific DPM synthase activity
P11030744A0763|95 105|DPM synthase
P11031252A0646|3 10|LMW FGF-2
P11031252A0646|26 41|PKC epsilon levels
P11031252A0646|26 35|PKC epsilon
P11031252A0646|66 75|HMW isoform
P11031252A0646|104 113|PKC isotype
P11031252A0646|121 126|3-fold
P11031252A0646|150 157|PKC delta
P11031366T0001|0 17|Helicobacter pylori
P11031366T0001|21 35|stomach diseases
P11031366T0001|41 53|clinical point
P11031773A0174|31 39|capsaicin
P11031773A0174|43 62|formalin induced-pain
P11031773A0174|65 68|mice
P11032599T0000|12 26|recommendations
P11032599T0000|38 75|hematopoietic colony-stimulating factors
P11032599T0000|77 90|evidence-based
P11032599T0000|92 117|clinical practice guidelines
P11032677A0230|0 16|Prominent findings
P11032677A0230|21 39|chronic pancreatitis
P11032677A0230|44 49|acinar
P11032677A0230|53 63|ductal plugs
P11032677A0230|65 77|granulomatous
P11032677A0230|81 114|necrotizing peripancreatic steatitis
P11032677A0230|116 135|degenerative myopathy
P11032677A0230|137 153|testicular atrophy
P11032677A0230|155 165|candidiasis
P11032677A0230|169 197|bacterial necrotizing glossitis
P11034392A1072|33 56|multiple survival pathways
P11034392A1072|76 83|receptor
P11034392A1072|92 104|NF-kappaB/Rel
P11034392A1072|92 100|NF-kappaB
P11034392A1072|102 104|Rel
P11034392A1072|108 112|PI-3K
P11034392A1072|126 150|CD40-induced proliferation
P11034392A1072|126 129|CD40
P11034547A0674|8 11|Arix
P11034547A0674|15 20|NBPhox
P11034547A0674|25 48|DNA-independent multimers
P11034547A0674|59 76|cooperative binding
P11034547A0674|82 101|DB1 regulatory element
P11034547A0674|119 145|homeodomain recognition sites
P11034547A1355|27 30|Arix
P11034547A1355|34 39|NBPhox
P11034547A1355|47 63|indistinguishable
P11034547A1355|67 112|independent transcriptional regulatory properties
P11034547A1355|118 128|DBH promoter
P11034933A0389|0 6|METHODS
P11034933A0389|10 16|RESULTS
P11034933A0389|18 24|Studies
P11034933A0389|50 64|guinea pig hearts
P11034933A0389|83 114|reverse use-dependent prolongation
P11034933A0389|117 137|cardiac repolarization
P11034933A0389|143 159|nmol/L domperidone
P11035037A0183|3 24|N-terminal small segment
P11035037A0183|27 37|yeast TAF145
P11035037A0183|39 45|yTAF145
P11035037A0183|54 56|TBP
P11035037A0183|75 85|TBP function
P11035037A0183|75 77|TBP
P11035867A0000|0 8|OBJECTIVE
P11035867A0000|23 40|overall performance
P11035867A0000|44 84|new oscillometric wrist blood pressure monitor
P11035867A0000|86 105|Braun PrecisionSensor
P11035867A0000|107 115|Braun GmbH
P11035867A0000|117 124|Kronberg
P11035867A0000|126 132|Germany
P11035867A0000|148 175|ANSI/AAMI SP10-1992 guidelines
P11035867A0000|225 233|algorithm
P11035867A0000|248 266|blood pressure values
P11035867A0000|274 305|oscillometric blood pressure curves
P11036786A0628|12 18|results
P11036786A0628|21 44|toxicological experiments
P11036786A0628|50 62|target animals
P11036786A0628|64 98|Toxicological Drinking Water Standards
P11036786A0628|102 108|Animals
P11036938A1162|12 33|hypothalamic expression
P11036938A1162|51 63|erbB receptors
P11036938A1162|84 103|pubertal augmentation
P11036938A1162|106 128|gonadal steroid secretion
P11036938A1162|156 177|first preovulatory surge
P11036938A1162|180 192|gonadotropins
P11036939A2149|0 2|Dsh
P11036939A2149|19 35|different pathways
P11036939A2149|40 49|Wnt pathway
P11036939A2149|40 42|Wnt
P11036939A2149|53 73|planar polarity pathway
P11037759T0000|0 13|Catch-up growth
P11037759T0000|17 38|craniofacial dimensions
P11037759T0000|67 96|antineoplastic agent vincristine
P11037759T0000|99 107|young rats
P11037823A1134|0 10|CONCLUSIONS
P11037823A1134|12 27|LSCC malformation
P11037823A1134|33 62|other inner ear malformations such
P11037823A1134|65 87|large vestibular aqueduct
P11037823A1134|91 111|X-linked mixed deafness
P11037823A1134|116 130|perilymph gusher
P11037823A1134|151 153|CHL
P11037823A1134|155 158|SNHL
P11037823A1134|162 174|normal hearing
P11038042A0948|0 9|Escalation
P11038042A0948|15 19|mg/m2
P11038042A0948|39 62|white blood cell nadir count
P11038042A0948|77 77|l
P11038042A0948|81 98|platelet nadir count
P11038118A0000|0 12|Methyl formate
P11038118A0000|25 31|solvent
P11038118A0000|34 57|biodegradable oligoesters
P11038118A0000|64 74|fabrication
P11038118A0000|77 88|microspheres
P11038118A0000|105 122|bovine serum albumin
P11038118A0000|124 126|BSA
P11038317A0000|3 35|small monomeric GTP-binding proteins
P11038317A0000|17 35|GTP-binding proteins
P11038317A0000|41 52|RAB subfamily
P11038317A0000|56 76|key regulatory elements
P11038317A0000|82 90|machinery
P11038317A0000|103 117|membrane traffic
P11038317A0000|120 134|eukaryotic cells
P11038366A1322|18 28|methylation
P11038366A1322|70 87|yeast B-type subunit
P11038366A1322|89 93|Rts1p
P11038366A1417|5 15|methylation
P11038366A1417|18 23|Pph21p
P11038366A1417|49 60|PP2A trimeric
P11038366A1417|49 52|PP2A
P11038366A1417|64 79|dimeric complexes
P11038366A1417|100 111|PP2A function
P11038366A1417|100 103|PP2A
P11039341A0180|36 58|temporal characteristics
P11039341A0180|65 78|spatial mapping
P11039341A0180|84 104|independent components
P11039341A0180|117 119|ICA
P11039341A0180|143 160|finger-tapping task
P11039780A0770|3 9|authors
P11039780A0770|27 33|studies
P11039780A0770|68 79|animal models
P11039780A0770|82 95|osteoarthritis
P11039780A0770|101 111|gene therapy
P11039780A0770|125 132|overview
P11039780A0770|135 151|several strategies
P11039780A0770|171 181|gene therapy
P11039780A0770|184 206|osteoarthritis treatment
P11040101A1180|14 20|results
P11040101A1180|33 40|IL-1 beta
P11040101A1180|48 65|VEGF gene expression
P11040101A1180|48 55|VEGF gene
P11040101A1180|72 86|transcriptional
P11040101A1180|90 115|post-transcriptional levels
P11040101A1180|120 127|IL-1 beta
P11040101A1180|134 140|p38 MAPK
P11040101A1180|144 156|JNK signalings
P11040101A1180|144 146|JNK
P11040101A1180|181 193|transcription
P11040101A1180|199 206|VEGF gene
P11040101A1180|214 229|Sp1-binding sites
P11040219A0548|0 6|Binding
P11040219A0548|9 12|NusA
P11040219A0548|15 17|RNA
P11040219A0548|33 37|alpha
P11040219A0548|40 40|N
P11040219A0548|51 80|amino-terminal S1 homology region
P11040219A0548|96 103|inactive
P11040219A0548|106 120|full-length NusA
P11041308A0156|3 10|subjects
P11041308A0156|36 69|DSM-IV pathological gambling criteria
P11041308A0156|85 98|Turkish Version
P11041308A0156|101 123|South Oaks Gambling Screen
P11041308A0156|125 128|SOGS
P11042197A0386|0 2|Lys
P11042197A0386|11 13|Arg
P11042197A0386|20 26|located
P11042197A0386|32 47|COOH-terminal end
P11042197A0386|50 51|HD
P11042197A0386|68 79|dimerization
P11042199A0572|0 8|Elevation
P11042199A0572|11 25|intracellular Ca
P11042199A0572|30 35|levels
P11042199A0572|71 96|receptor-associated protein
P11042199A0572|98 107|nifedipine
P11042199A0572|109 113|MK801
P11042199A0572|124 125|Ca
P11042199A0572|146 155|dantrolene
P11042199A0572|174 189|calcium elevation
P11042199A0572|205 214|activation
P11042199A0572|217 220|CREB
P11042204A0186|3 14|present study
P11042204A0186|24 80|phosphatidylinositol 3-kinase-dependent p38 kinase activation
P11042204A0186|24 51|phosphatidylinositol 3-kinase
P11042204A0186|62 70|p38 kinase
P11042204A0186|90 107|Akt phosphorylation
P11042204A0186|90 92|Akt
P11042204A0186|121 136|human neutrophils
P11042703A0875|4 7|BFDS
P11042703A0875|31 40|W/A Z scores
P11042703A0875|47 74|consistent positive increments
P11042703A0875|87 91|girls
P11042703A0875|96 97|mo
P11042703A0875|100 103|boys
P11043469A0440|5 27|probable border sequences
P11043469A0440|54 72|other known T-regions
P11043469A0440|83 96|second T-region
P11043469A0440|99 106|pTiChry5
P11043469A0440|114 120|T-right
P11043469A0440|122 123|TR
P11043469A0440|152 164|Amadoriopines
P11044097A0422|13 27|recombinant HMG I
P11044097A0422|13 26|recombinant HMG
P11044097A0422|45 64|several high-affinity
P11044097A0422|72 76|sites
P11044097A0422|89 116|important transcription factor
P11044097A0422|124 128|sites
P11044097T0000|0 25|High-mobility-group protein
P11044097T0000|38 44|binding
P11044097T0000|47 66|transcription factors
P11044097T0000|72 79|U5 region
P11044097T0000|85 131|human immunodeficiency virus type 1 proviral promoter
P11044097T0000|85 114|human immunodeficiency virus type
P11044097T0000|116 131|proviral promoter
P11044105A0616|7 23|cis-acting element
P11044105A0616|25 48|exonic splicing suppressor
P11044105A0616|51 54|ESS1
P11044105A0616|74 75|nt
P11044105A0616|82 91|splice site
P11045180A1892|0 10|Leptinaemia
P11045180A1892|42 65|mean blood pressure reading
P11045180A1892|80 91|hypertension
P11045180A1892|109 122|classification
P11045607A0239|3 14|RACE analysis
P11045607A0239|25 57|single transcription initiation site
P11045607A0239|61 62|bp
P11045607A0239|78 99|translational start site
P11046146A1202|5 20|diamide treatment
P11046146A1202|23 37|nuclear extracts
P11046146A1202|56 62|binding
P11046146A1202|65 75|NFI proteins
P11046146A1202|93 112|higher concentrations
P11046146A1202|115 128|dithiothreitol
P11046146A1202|131 145|nuclear extracts
P11046146A1202|150 164|TG-treated cells
P11046146A1202|173 186|NFI-DNA binding
P11046146A1202|173 179|NFI-DNA
P11046146A1202|189 194|levels
P11046146A1202|197 204|extracts
P11046146A1202|209 222|untreated cells
P11046148A0716|0 4|LMP2A
P11046148A0716|13 15|Lyn
P11046148A0716|19 35|Syk ubiquitination
P11046148A0716|19 21|Syk
P11046148A0716|78 95|Nedd4 family members
P11046148A0716|78 82|Nedd4
P11046148A0716|113 127|destabilization
P11046148A0716|133 149|Lyn tyrosine kinase
P11046153A1052|8 28|Tax-mediated apoptosis
P11046153A1052|8 10|Tax
P11046153A1052|54 70|ectopic expression
P11046153A1052|76 90|p300 coactivator
P11046517A0619|3 9|results
P11046517A0619|34 34|Z
P11046517A0619|51 51|Z
P11048832A0271|0 5|Fisher
P11048832A0271|8 16|exact test
P11048832A0271|19 25|Pearson
P11048832A0271|28 35|chi2 test
P11048832A0271|47 65|statistical analysis
P11049241A0659|0 6|RESULTS
P11049241A0659|13 25|pregnant group
P11049241A0659|27 49|serum PP14 concentrations
P11049241A0659|32 35|PP14
P11049241A0659|76 77|ET
P11049241A0659|83 103|significant difference
P11049241A0659|114 126|pregnant group
P11049241A0659|133 148|nonpregnant group
P11049241A0659|161 164|days
P11049241A0659|174 175|ET
P11049241A0659|177 177|p
P11049889A1271|0 18|Thromboelastography
P11049889A1271|70 84|anticoagulation
P11049889A1271|95 119|low molecular weight heparin
P11050084A0000|0 13|High expression
P11050084A0000|19 63|peroxisome proliferator-activated receptor alpha
P11050084A0000|65 73|PPARalpha
P11050084A0000|89 96|brown fat
P11050084A0000|124 135|high capacity
P11050084A0000|138 151|lipid oxidation
P11050084A0888|27 35|PPARalpha
P11050084A0888|39 47|PPARgamma
P11050084A0888|52 65|brown fat nuclei
P11050168A1185|5 11|results
P11050168A1185|19 32|direct evidence
P11050168A1185|36 61|differential susceptibility
P11050168A1185|64 93|endonuclease-mediated mRNA decay
P11050168A1185|110 129|differential affinity
P11050168A1185|133 150|RNA-binding protein
P11050168A1185|154 184|cis-acting stability determinants
P11051364A0890|0 6|RESULTS
P11051364A0890|21 21|%
P11051364A0890|23 30|patients
P11051364A0890|34 36|PHG
P11051364A0890|44 49|group A
P11051364A0890|59 59|%
P11051364A0890|70 72|PHG
P11051364A0890|78 96|variceal eradication
P11051364A0890|98 103|group B
P11051370A1906|0 7|Response
P11051370A1906|26 41|African Americans
P11051370A1906|54 64|HCV genotype
P11053009A0000|0 6|Aspirin
P11053009A0000|13 24|peptic ulcers
P11053009A0000|48 75|gastric mucosal cyclooxygenase
P11053009A0000|77 79|COX
P11053009A0000|92 113|prostaglandin synthesis
P11053263A0200|12 17|clones
P11053263A0200|41 50|sequencing
P11053370A0708|0 9|Expression
P11053370A0708|13 25|hybrid protein
P11053370A0708|39 63|cytoplasmic C-terminal half
P11053370A0708|66 69|UhpB
P11053370A0708|77 100|glutathione S-transferase
P11053370A0708|102 104|GST
P11053370A0708|124 135|Uhp signaling
P11053370A0708|124 126|Uhp
P11054011A1685|0 10|CONCLUSIONS
P11054011A1685|15 22|surgical
P11054011A1685|25 46|multimodality treatment
P11054011A1685|49 52|MSGT
P11054011A1685|65 87|good locoregional control
P11054011A1685|91 91|%
P11054011A1685|98 113|% 10-year survival
P11054011A1685|125 132|patients
P11054011A1685|145 162|oncology department
P11054011A1685|166 180|general hospital
P11054011A1685|183 187|Quito
P11054011A1685|189 195|Ecuador
P11054341A0599|0 6|RESULTS
P11054341A0599|8 23|Glaucoma suspects
P11054341A0599|42 47|groups
P11054341A0599|64 67|SWAP
P11054341A0599|76 83|high risk
P11054341A0599|89 105|SWAP abnormalities
P11054341A0599|110 116|low risk
P11054341A0599|122 137|normal SWAP result
P11054539A0114|26 30|exons
P11054539A0114|38 49|short introns
P11054539A0114|57 72|open reading frame
P11054539A0114|87 95|base pairs
P11054539A0114|97 98|bp
P11054539A0114|118 128|polypeptide
P11054539A0114|135 151|amino acid residues
P11054565A0654|7 16|p190-B exon
P11054565A0654|21 29|first exon
P11054565A0654|32 37|p190-A
P11054565A0654|58 59|kb
P11054565A0654|85 90|GTPase
P11054565A0654|94 106|middle domains
P11054565A0654|108 115|residues
P11054565A0654|142 150|GAP domain
P11054565A0654|163 178|high conservation
P11054565A0654|181 196|genomic structure
P11054565A0654|207 215|p190 genes
P11054571A0230|3 23|entire human teneurin-1
P11054571A0230|9 23|human teneurin-1
P11054571A0230|25 28|TEN1
P11054571A0230|52 60|PAC clones
P11054571A0230|82 101|chromosomal locus Xq25
P11054970A0282|3 23|plexiform neurofibroma
P11054970A0282|27 56|multiple localized neurofibromas
P11054970A0282|76 78|NF1
P11055513A0564|2 16|general lookback
P11055513A0564|21 28|patients
P11055513A0564|65 74|hepatitis C
P11055786A0306|11 19|algorithm
P11055786A0306|30 41|several steps
P11056007A0224|16 30|extra amino acids
P11056007A0224|33 39|FVVLNLQ
P11056007A0224|45 56|short stretch
P11056007A0224|59 71|extra sequence
P11056007A0224|87 89|Gln
P11056007A0224|98 100|Phe
P11056007A0224|115 117|SET
P11056007A0224|119 126|Suvar3-9
P11056007A0224|128 144|Enhancer-of-zeste
P11056007A0224|146 154|Trithorax
P11056007A0224|174 176|SID
P11056007A0224|180 183|rMTM
P11056019A0926|0 3|MED1
P11056019A0926|8 30|weak glycosylase activity
P11056019A0926|12 22|glycosylase
P11056019A0926|36 50|mutagenic adduct
P11056019A0926|53 53|N
P11056019A0926|58 71|ethenocytosine
P11056019A0926|74 83|metabolite
P11056019A0926|86 98|vinyl chloride
P11056019A0926|102 115|ethyl carbamate
P11058008A0159|11 19|instances
P11058008A0159|22 38|major flap necrosis
P11058008A0159|50 54|flaps
P11058008A0159|61 72|tip ischaemia
P11058119A0957|5 11|results
P11058119A0957|23 26|XAB1
P11058119A0957|30 51|novel cytoplasmic GTPase
P11058119A0957|35 51|cytoplasmic GTPase
P11058119A0957|62 80|nuclear localization
P11058119A0957|83 85|XPA
P11058120A0256|10 16|factors
P11058120A0256|18 22|IRF-2
P11058120A0256|46 68|antagonistic counterpart
P11058120A0256|71 75|IRF-1
P11058120A0256|80 97|oncogenic potential
P11058132A0264|8 16|total CDSs
P11058132A0264|21 35|% match sequences
P11058132A0264|38 45|proteins
P11058132A0264|57 72|Bacillus subtilis
P11058132A0264|80 80|%
P11058132A0264|118 125|proteins
P11058132A0264|128 143|various organisms
P11058132A0264|154 163|B.subtilis
P11058406A0447|0 19|Tobramycin-loaded SLN
P11058406A0447|32 35|i.v.
P11058406A0447|43 66|prolonged circulation time
P11058406A0447|80 83|i.v.
P11058406A0447|96 113|tobramycin solution
P11059492A0376|0 8|Bacteriol
P11059777A0813|0 64|Terminal deoxynucleotidyl transferase-mediated nick end labeling assays
P11059777A0813|0 34|Terminal deoxynucleotidyl transferase
P11059777A0813|77 94|hormonal activation
P11059777A0813|100 113|PAX3 repressors
P11059777A0813|121 138|extensive apoptosis
P11059777A0813|157 171|down-regulation
P11059777A0813|174 178|BCL-X
P11059777A0813|180 180|L
P11059786A0682|0 19|VEGF promoter activity
P11059786A0682|0 11|VEGF promoter
P11059786A0682|22 43|transient transfections
P11059786A0682|64 78|pharmacological
P11059786A0682|81 97|genetic inhibition
P11059786A0682|100 103|EGFR
P11059786A0682|105 107|Ras
P11059786A0682|111 139|phosphatidylinositol 3'-kinase
P11059786A0682|111 130|phosphatidylinositol
P11059786A0682|134 139|kinase
P11059786A0682|141 142|PI
P11059786A0682|146 151|kinase
P11059786T0000|0 28|Epidermal growth factor receptor
P11059786T0000|58 98|vascular endothelial growth factor expression
P11059786T0000|58 88|vascular endothelial growth factor
P11059786T0000|101 122|human glioblastoma cells
P11059786T0000|127 133|pathway
P11059786T0000|143 171|phosphatidylinositol 3'-kinase
P11059786T0000|143 162|phosphatidylinositol
P11059786T0000|166 171|kinase
P11059786T0000|200 206|hypoxia
P11062047A1208|5 9|IHHNV
P11062047A1208|28 39|densoviruses
P11062047A1208|45 64|genus Brevidensovirus
P11062047A1208|70 87|family Parvoviridae
P11062047A1208|122 155|virus Penaeus stylirostris densovirus
P11062047A1208|157 162|PstDNV
P11062067A0000|0 29|Stress-activated protein kinase 1
P11062067A0000|0 28|Stress-activated protein kinase
P11062067A0000|31 35|SAPK1
P11062067A0000|48 68|c-Jun N-terminal kinase
P11062067A0000|70 72|JNK
P11062067A0000|109 133|pro-inflammatory cytokines
P11062067A0000|136 151|cellular stresses
P11062068T0000|0 18|Catalytic activation
P11062068T0000|21 44|mitogen-activated protein
P11062068T0000|46 68|MAP) kinase phosphatase-1
P11062068T0000|46 48|MAP
P11062068T0000|50 68|kinase phosphatase-1
P11062068T0000|80 91|p38 MAP kinase
P11062068T0000|93 104|critical role
P11062068T0000|110 128|p38 C-terminal domain
P11062068T0000|134 151|negative regulation
P11062257A0977|8 24|class C-Vps complex
P11062257A0977|8 13|class C
P11062257A0977|15 17|Vps
P11062257A0977|32 48|multiple reactions
P11062257A0977|58 64|docking
P11062257A0977|68 73|fusion
P11062257A0977|76 83|vesicles
P11062257A0977|91 97|vacuole
P11062257A0977|126 143|overall specificity
P11062257A0977|163 178|transport process
P11062274T0000|8 18|intravenous
P11062274T0000|22 72|intra-arterial recombinant tissue plasminogen activator
P11062274T0000|47 72|tissue plasminogen activator
P11062274T0000|75 93|acute ischemic stroke
P11062705A0658|43 47|ATF-2
P11062705A0658|51 69|human cancer cell line
P11063127A0000|0 17|Signal transduction
P11063127A0000|21 30|modulation
P11063127A0000|33 47|phosphorylation
P11063127A0000|53 71|selective inhibition
P11063127A0000|74 91|protein phosphatase
P11063127A0000|93 94|PP
P11063127A0000|103 106|PP2A
P11063127A0000|127 137|okadaic acid
P11063127A0000|139 140|OA
P11063127A0000|151 157|effects
P11063169T0000|0 14|Botulinum toxin A
P11063169T0000|31 55|hemiplegic spastic foot drop
P11063169T0000|69 86|functional outcomes
P11063252A0437|0 4|Exon A
P11063252A0437|7 13|located
P11063252A0437|28 29|kb
P11063252A0437|37 59|HSL translation start site
P11063742A0000|0 8|NF-kappaB
P11063742A0000|12 45|redox-sensitive transcription factor
P11063742A0000|66 80|oxidative stress
P11063742A0000|100 119|biological reductants
P11064829T0058|0 24|Cardiovascular risk factors
P11064829T0058|28 52|antihypertensive treatment
P11066245T0000|20 35|compliance review
P11066245T0000|39 52|common mistakes
P11066245T0000|59 62|SNFs
P11067797A1306|0 10|CONCLUSIONS
P11067797A1306|12 25|EBCT technology
P11067797A1306|41 58|invasive evaluation
P11067797A1306|61 99|intramyocardial microcirculatory function
P11067797A1306|122 148|microvascular BV distribution
P11067797A1306|151 179|different functional components
P11067928A0532|8 11|mAbs
P11067928A0532|19 23|same V
P11067928A0532|25 25|H
P11067928A0532|30 30|J
P11067928A0532|32 32|H
P11067928A0532|34 45|gene segments
P11067928A0532|50 59|different D
P11067928A0532|61 66|Vkappa
P11067928A0532|71 81|Jkappa genes
P11069011A0224|0 13|SSF experiments
P11069011A0224|30 51|bench-scale bioreactors
P11069011A0224|65 67|CO2
P11069011A0224|71 90|volatile organic traps
P11069011A0224|112 135|lignocellulosic materials
P11069011A0224|152 160|pesticide
P11069075T0000|0 15|Characterization
P11069075T0000|19 52|Xenopus laevis CXC chemokine receptor 4
P11069075T0000|19 51|Xenopus laevis CXC chemokine receptor
P11069075T0000|54 65|implications
P11069075T0000|69 96|hematopoietic cell development
P11069075T0000|102 117|vertebrate embryo
P11069223A0593|0 7|Patients
P11069223A0593|17 29|adequate liver
P11069223A0593|31 35|renal
P11069223A0593|40 54|marrow functions
P11069307A0546|0 9|Inhibition
P11069307A0546|12 26|RNA2 translation
P11069307A0546|12 15|RNA2
P11069307A0546|30 38|selective
P11069307A0546|54 79|general cellular translation
P11069307A0546|95 128|BMV RNA1-encoded replication factor 1a
P11069307A0546|98 128|RNA1-encoded replication factor 1a
P11069307A0546|149 151|p20
P11069307A0546|154 171|cellular antagonist
P11069307A0546|174 185|DED1 function
P11069307A0546|174 177|DED1
P11069756A2618|0 12|Abbreviations
P11069756A2618|14 16|CAS
P11069756A2618|18 40|CRK-associated substrate
P11069756A2618|42 43|CH
P11069756A2618|45 67|calponin-homology domain
P11069756A2618|69 71|CSK
P11069756A2618|73 91|C-terminal SRC kinase
P11069756A2618|93 94|E6
P11069756A2618|96 118|Papillomavirus E6 protein
P11069756A2618|120 122|FAK
P11069756A2618|124 142|focal adhesion kinase
P11069756A2618|144 146|GIT
P11069756A2618|148 160|GRK interacter
P11069756A2618|162 165|GPCR
P11069756A2618|167 206|heterotrimeric-G-protein-coupled receptor
P11069756A2618|208 210|GRK
P11069756A2618|212 243|G-protein-coupled-receptor kinase
P11069756A2618|245 248|MAPK
P11069756A2618|250 279|mitogen-activated protein kinase
P11069756A2618|281 283|ERK
P11069756A2618|285 287|p38
P11069756A2618|289 291|JNK
P11069756A2618|294 296|PAK
P11069756A2618|298 316|p21-activated kinase
P11069756A2618|318 320|PBS
P11069756A2618|322 346|paxillin-binding subdomain
P11069756A2618|348 350|PIX
P11069756A2618|352 380|PAK-interacting exchange factor
P11069756A2618|382 384|PKL
P11069756A2618|386 405|paxillin kinase linker
P11069756A2618|407 410|POR1
P11069756A2618|421 423|Rac
P11069756A2618|425 426|PS
P11069756A2618|428 440|phosphoserine
P11069756A2618|442 443|PT
P11069756A2618|445 460|phosphothreonine
P11069756A2618|462 463|PY
P11069756A2618|465 479|phosphotyrosine
P11069756A2618|481 483|RTK
P11069756A2618|485 518|growth factor receptor tyrosine kinase
P11069756A2618|520 521|SH
P11069756A2618|523 540|SRC-homology domain
P11069788A0531|4 23|ventilator-dependent
P11069788A0531|25 26|SB
P11069788A0531|47 54|patients
P11069788A0531|70 83|difference PEEP
P11069788A0531|92 94|Pga
P11069788A0531|96 105|total decay
P11069788A0531|114 115|SD
P11069788A0531|126 128|cm H
P11069788A0531|132 132|O
P11069788A0531|151 154|PEEP
P11069788A0531|159 164|dyn ref
P11069788A0531|175 177|cm H
P11069788A0531|181 181|O
P11069791A0226|5 20|eligible subjects
P11069791A0226|32 44|supervised IPT
P11069791A0226|57 58|mg
P11069791A0226|74 75|mo
P11069791A0226|77 84|Regimen A
P11069791A0226|97 111|unsupervised IPT
P11069791A0226|115 116|mg
P11069791A0226|132 133|mo
P11069791A0226|135 142|Regimen B
P11069791A0226|158 172|unsupervised IPT
P11069791A0226|176 177|mg
P11069791A0226|187 188|mo
P11069791A0226|190 197|Regimen C
P11069825A0530|12 16|cases
P11069825A0530|19 30|tuberculosis
P11069825A0530|48 49|yr
P11069825A0530|52 60|follow-up
P11069825A0530|62 81|crude annual incidence
P11069897A1112|5 11|results
P11069897A1112|25 30|BACH1t
P11069897A1112|39 43|BACH1
P11069897A1112|49 55|nucleus
P11069897A1112|63 91|BTB domain-mediated interaction
P11069999A1602|3 9|U17/U16
P11069999A1602|3 5|U17
P11069999A1602|7 9|U16
P11069999A1602|16 18|U16
P11069999A1602|20 31|gene products
P11069999A1602|49 54|HIV LTR
P11070007A0136|0 12|Transcription
P11070007A0136|21 29|EBNA genes
P11070007A0136|50 78|EBV-immortalized primary B cells
P11070007A0136|98 106|promoters
P11070007A0136|108 109|Cp
P11070007A0136|113 114|Wp
P11070007A0136|116 122|located
P11070007A0136|130 136|left end
P11070007A0136|142 152|viral genome
P11070056A0704|3 17|Cili-2 sequences
P11070056A0704|40 51|RNaseH domain
P11070056A0704|54 61|Lian-Aa1
P11070056A0704|64 93|mosquito non-LTR retrotransposon
P11070078A1153|4 18|dynamic response
P11070078A1153|42 44|p53
P11070078A1153|48 72|Rb tumor suppressor pathways
P11070078A1153|84 92|HeLa cells
P11070078A1153|100 109|repression
P11070078A1153|112 116|HPV E6
P11070078A1153|120 121|E7
P11070078A1153|136 143|pathways
P11070078A1153|148 161|orderly fashion
P11070078A1153|171 193|growth inhibitory signals
P11070078A1153|199 203|cells
P11071651A1308|16 39|RARalpha-specific pathway
P11071651A1308|16 23|RARalpha
P11071651A1308|42 72|retinoid-induced differentiation
P11071651A1308|92 108|retinoid induction
P11071651A1308|111 127|FR-beta expression
P11071651A1308|111 117|FR-beta
P11071789T0000|2 11|more better
P11071789T0000|18 27|dose levels
P11071789T0000|30 42|ACE inhibitors
P11071789T0000|30 32|ACE
P11071789T0000|45 63|chronic heart failure
P11071852A0297|18 23|SOCS-3
P11071852A0297|38 42|IGFIR
P11071852A0297|52 62|human SOCS-3
P11071852A0297|65 108|reverse transcription-polymerase chain reaction
P11071852A0297|65 100|reverse transcription-polymerase chain
P11071852A0297|113 135|human skeletal muscle mRNA
P11071924A0588|18 20|SH2
P11071924A0588|24 40|RING finger domains
P11071924A0588|59 73|chimeric protein
P11071924A0588|81 83|SH2
P11071924A0588|87 103|RING finger domains
P11071924A0588|106 110|SLI-1
P11071924A0588|124 140|equivalent domains
P11071924A0588|143 147|c-Cbl
P11071974A0155|13 19|effects
P11071974A0155|22 24|HRT
P11071974A0155|32 38|factors
P11071974A0155|41 61|end-stage renal disease
P11071974A0155|63 66|ESRD
P11071974A0155|68 75|patients
P11071974A0155|91 97|changes
P11071974A0155|100 111|lipid profile
P11071974A0155|113 123|coagulation
P11071974A0155|127 145|fibrinolysis markers
P11071974A0155|150 173|plasma homocysteine levels
P11072155A0764|9 34|weak significant correlation
P11072155A0764|42 49|TGF beta 1
P11072155A0764|42 48|TGF beta
P11072155A0764|50 55|levels
P11072155A0764|59 84|normal cell radiosensitivity
P11072155A0764|86 98|lymphocyte SF2
P11072388T0000|0 15|Acute feasibility
P11072388T0000|28 51|smoking reduction strategy
P11072388T0000|55 61|smokers
P11072388T0000|66 78|schizophrenia
P11073163A0131|14 35|proteasomal degradation
P11073163A0131|38 53|proteins critical
P11073163A0131|57 72|cell cycle control
P11073163A0131|90 99|proteasome
P11073163A0131|113 129|cell proliferation
P11073163A0131|133 144|cell survival
P11073218A0800|3 17|sixth nucleotide
P11073218A0800|51 57|U.G pair
P11073218A0800|63 83|adjacent helical region
P11073539A0866|0 17|Functional analysis
P11073539A0866|23 34|mutant desmin
P11073539A0866|37 40|SW13
P11073539A0866|42 44|vim
P11073539A0866|47 51|cells
P11073539A0866|58 68|aggregation
P11073539A0866|71 90|abnormal coarse clumps
P11073539A0866|93 114|desmin positive material
P11073539A0866|137 145|cytoplasm
P11073870A0375|0 7|Patients
P11073870A0375|12 18|lesions
P11073870A0375|31 33|PRC
P11073870A0375|47 49|PHC
P11073870A0375|54 61|patients
P11073870A0375|66 72|lesions
P11073870A0375|86 88|PRC
P11073870A0375|92 94|PHC
P11073870A0375|107 116|oculomotor
P11073870A0375|124 135|response task
P11073870A0375|153 170|varied memory delays
P11073870A0375|179 180|s.
P11073919A0631|13 29|amino acid residues
P11073919A0631|31 33|K69
P11073919A0631|35 37|D88
P11073919A0631|39 41|E94
P11073919A0631|43 46|D134
P11073919A0631|48 51|R154
P11073919A0631|53 56|K169
P11073919A0631|58 61|H197
P11073919A0631|63 66|D233
P11073919A0631|68 71|G235
P11073919A0631|73 76|G236
P11073919A0631|78 81|G237
P11073919A0631|83 86|F238
P11073919A0631|88 91|E274
P11073919A0631|93 96|G276
P11073919A0631|98 101|R277
P11073919A0631|103 106|Y278
P11073919A0631|108 111|K294
P11073919A0631|113 116|Y323
P11073919A0631|118 121|Y331
P11073919A0631|123 126|D332
P11073919A0631|128 131|C360
P11073919A0631|133 136|D361
P11073919A0631|138 141|D364
P11073919A0631|143 146|G387
P11073919A0631|148 151|Y389
P11073919A0631|156 159|F397
P11073919A0631|161 177|mouse ODC numbering
P11073919A0631|166 168|ODC
P11073919A0631|222 253|pyridoxal phosphate-binding domain
P11073919A0631|231 253|phosphate-binding domain
P11073919A0631|260 282|substrate-binding domain
P11073919A0631|288 305|dimer stabilization
P11073919A0631|313 326|eukaryotic ODCs
P11073919A0631|323 326|ODCs
P11073919A0631|347 362|S. ruminantium LDC
P11073919A0631|360 362|LDC
P11073954A0337|3 10|Psc2 cDNA
P11073954A0337|22 47|open reading frame homologous
P11073954A0337|50 66|CP2 family proteins
P11074003A0741|3 9|results
P11074003A0741|22 24|Shh
P11074003A0741|33 48|continued cycling
P11074003A0741|51 58|immature
P11074003A0741|73 77|CGNPs
P11074210A0623|3 12|QT interval
P11074210A0623|25 41|various components
P11074210A0623|47 71|insulin resistance syndrome
P11074210A0623|47 53|insulin
P11074210A0623|82 83|BP
P11074210A0623|87 104|insulin sensitivity
P11074210A0623|87 93|insulin
P11075678A0298|3 13|wavenumbers
P11075678A0298|32 42|normal modes
P11075678A0298|45 53|vibration
P11075678A0298|76 78|DFT
P11075678A0298|80 86|B3LYP/6
P11075678A0298|90 90|G
P11075678A0298|94 106|approximation
P11075678A0298|139 144|values
P11075678A0298|180 189|force field
P11075929A1657|14 27|strong evidence
P11075929A1657|32 35|ThlA
P11075929A1657|51 60|metabolism
P11075929A1657|74 89|solvent formation
P11075929A1657|101 121|physiological function
P11075929A1657|124 127|ThlB
P11075944A0691|11 14|npm3
P11075944A0691|45 48|fgf8
P11075944A0691|51 63|MMTV insertion
P11075944A0691|85 93|androgens
P11075944A0691|96 104|SC-3 cells
P11076860A0872|0 10|Experiments
P11076860A0872|15 36|epitope-tagged proteins
P11076860A0872|45 49|UEV1A
P11076860A0872|53 66|nuclear protein
P11076860A0872|79 81|Kua
P11076860A0872|85 91|Kua-UEV
P11076860A0872|85 87|Kua
P11076860A0872|89 91|UEV
P11076860A0872|102 122|cytoplasmic structures
P11076860A0872|141 149|Kua domain
P11076860A0872|163 185|cytoplasmic localization
P11076860A0872|188 194|Kua-UEV
P11076860A0872|188 190|Kua
P11076860A0872|192 194|UEV
P11078726X0000|0 28|Stoichiometric phosphorylation
P11078726X0000|31 38|human p53
P11078726X0000|41 46|Ser315
P11078726X0000|57 82|p53-dependent transcription
P11078726X0000|84 101|p53 protein activity
P11078726X0000|105 123|transcription factor
P11078726X0000|146 155|antibodies
P11078726X0000|169 202|C-terminal negative regulatory domain
P11078726X0000|217 231|cellular enzymes
P11078726X0000|277 303|p53-dependent gene expression
P11078726X0000|277 293|p53-dependent gene
P11080796A0883|18 31|mutant cell line
P11080796A0883|52 71|IKK regulatory protein
P11080796A0883|73 80|IKKgamma
P11080796A1277|3 25|Tax/IKKgamma interaction
P11080796A1277|3 5|Tax
P11080796A1277|7 14|IKKgamma
P11080796A1277|41 43|Tax
P11080796A1277|49 68|IKK catalytic subunits
P11080796A1277|70 77|IKKalpha
P11080796A1277|81 87|IKKbeta
P11080796A1277|96 106|recruitment
P11080796A1277|120 137|essential mechanism
P11080796A1277|145 147|Tax
P11080796A1277|171 173|IKK
P11081962T0000|10 13|AFLP
P11081962T0000|18 41|retrotransposon-based map
P11081962T0000|44 55|diploid Avena
P11082185A0415|24 32|novel type
P11082185A0415|35 50|inhibitory domain
P11082185A0415|56 65|N-terminal
P11082185A0415|68 77|amino acids
P11082185A0415|80 84|IRF-1
P11082185A0415|109 131|transcriptional activity
P11082587X0000|0 6|Effects
P11082587X0000|9 15|spatial
P11082587X0000|19 35|temporal smoothing
P11082587X0000|48 66|brillouin scattering
P11082587X0000|72 101|independent-hot-spot model limit
P11082587X0000|116 133|laser beam smoothing
P11082587X0000|146 168|Brillouin backscattering
P11082587X0000|170 173|SBBS
P11082587X0000|211 233|independent hot spot model
P11082715X0001|0 24|Simultaneous determination
P11082715X0001|27 38|theophylline
P11082715X0001|45 55|metabolites
P11082715X0001|58 61|HPLC
P11082715X0001|64 98|high performance liquid chromatography
P11082715X0001|100 103|HPLC
P11082715X0001|133 157|simultaneous determination
P11082715X0001|160 171|theophylline
P11082715X0001|178 188|metabolites
P11082715X0001|194 201|caffeine
P11082715X0001|208 218|metabolites
P11083154A0881|3 7|males
P11083154A0881|21 34|test conditions
P11083154A0881|38 52|oxygen uptake VO2
P11083154A0881|54 62|heart rate
P11083154A0881|64 82|minute ventilation VE
P11083154A0881|93 100|exertion
P11083154A0881|104 118|spinal shrinkage
P11083358A1071|0 9|CONCLUSION
P11083358A1071|11 13|SPT
P11083358A1071|30 32|WST
P11083358A1071|50 57|patients
P11083358A1071|71 80|aspiration
P11083432A0332|7 12|groups
P11083432A0332|20 35|untreated control
P11083432A0332|37 38|n =
P11083432A0332|45 48|FK-1
P11083432A0332|50 51|n =
P11083432A0332|57 60|FK-3
P11083432A0332|62 63|n =
P11083868A0386|0 9|DNA binding
P11083868A0386|13 51|glutathione S-transferase pull-down assays
P11083868A0386|13 36|glutathione S-transferase
P11083868A0386|67 73|binding
P11083868A0386|82 86|Elk-1
P11083868A0386|103 133|C-terminal transactivation domain
P11084022A1178|13 25|ALK7 signaling
P11084022A1178|13 16|ALK7
P11084022A1178|35 50|remarkable change
P11084022A1178|53 66|cell morphology
P11084022A1178|82 95|cell flattening
P11084022A1178|99 109|elaboration
P11084022A1178|112 116|blunt
P11084022A1178|118 135|short cell processes
P11084334A0590|3 14|swa2-1 allele
P11084334A0590|31 44|original screen
P11084334A0590|53 65|point mutation
P11084334A0590|71 93|tetratricopeptide repeat
P11084334A0590|95 97|TPR
P11084334A0590|107 111|motif
P11084334A0590|122 128|auxilin
P11084334A0590|139 151|other proteins
P11084334A0590|176 193|heat-shock proteins
P11084556T0000|0 10|Association
P11084556T0000|46 52|numbers
P11084556T0000|55 68|nucleated cells
P11084556T0000|72 99|hematopoietic progenitor cells
P11084556T0000|102 119|umbilical cord blood
P11084649A0497|10 21|older embryos
P11084649A0497|39 44|skewed
P11084649A0497|59 64|embryo
P11084649A0497|70 71|E6
P11084649A0497|80 84|onset
P11084649A0497|87 98|gastrulation
P11084649A0497|122 129|epiblast
P11084649A0497|131 146|visceral endoderm
P11084649A0497|148 162|nascent mesoderm
P11084649A0497|170 184|primitive streak
P11085267A0562|0 13|Transformation
P11085267A0562|19 30|sconC3 mutant
P11085267A0562|35 40|sconB+
P11085267A0562|35 39|sconB
P11085267A0562|52 69|wild-type phenotype
P11085600A0123|3 9|authors
P11085600A0123|31 46|convergent inputs
P11085600A0123|52 67|entorhinal cortex
P11086872A0000|0 8|Influence
P11086872A0000|11 22|oil emulsions
P11086872A0000|26 33|diphenyl
P11086872A0000|36 72|post-harvest physiconutritional changes
P11086872A0000|75 84|Kagzi limes
P11086872A0000|86 103|Citrus aurantifolia
P11087141A0977|0 15|Detailed analysis
P11087141A0977|18 38|alpha1,3GT transcripts
P11087141A0977|18 23|alpha1
P11087141A0977|26 38|GT transcripts
P11087141A0977|50 81|major alternative splicing patterns
P11087141A0977|90 107|untranslated region
P11087141A0977|112 114|UTR
P11087141A0977|130 150|minor splicing activity
P11087141A0977|164 184|tissue-specific manner
P11088635A0200|1 37|thermal Kubo-Martin-Schwinger condition
P11088635A0200|52 59|coupling
P11088635A0200|74 93|strong periodic source
P11088635A0200|113 131|weekly usage patterns
P11089911A1267|3 25|non-homologous sequences
P11089911A1267|33 51|untranslated regions
P11089911A1267|76 88|transcription
P11089911A1267|95 112|retrotransposition
P11089911A1267|118 129|ATLN elements
P11090172A0612|3 12|time course
P11090172A0612|15 29|RNA1 replication
P11090172A0612|33 45|RNA3 synthesis
P11090172A0612|33 36|RNA3
P11090172A0612|55 59|yeast
P11090172A0612|76 80|yeast
P11090172A0612|96 114|natural FHV virion RNA
P11090272A1240|3 15|transcription
P11090272A1240|19 37|alternative splicing
P11090272A1240|40 48|human ORL1
P11090272A1240|52 55|GAIP
P11090272A1240|59 75|cell-type specific
P11090762A0527|0 6|RESULTS
P11090762A0527|11 20|main effect
P11090762A0527|23 32|muscle pain
P11090762A0527|44 65|non-painful stimulation
P11090762A0527|85 104|long-lasting increase
P11090762A0527|107 111|delta
P11090762A0527|116 117|Hz
P11090762A0527|129 135|alpha-1
P11090762A0527|141 142|Hz
P11090762A0527|144 156|power increase
P11090762A0527|164 189|contralateral parietal locus
P11092770A0238|3 12|extraction
P11092770A0238|61 78|Pell-Gregory class C
P11092770A0238|82 90|predictor
P11092770A0238|105 114|extraction
P11092770A0238|116 126|specificity
P11092770A0238|132 132|%
P11092770A0238|157 157|%
P11092809A0823|14 20|results
P11092809A0823|29 32|ERKs
P11092809A0823|36 40|PI3Ks
P11092809A0823|62 69|ectoderm
P11092809A0823|74 81|mesoderm
P11092850A1023|7 33|16S rRNA gene sequence analysis
P11092850A1023|7 13|16S rRNA
P11092850A1023|56 63|tuf genes
P11092850A1023|72 85|common ancestor
P11092850A1023|137 155|enterococcal lineage
P11092850A1023|166 179|common ancestor
P11092886A0341|13 37|protein kinase A stimulation
P11092886A0341|13 26|protein kinase A
P11092886A0341|45 53|CREMalpha
P11092886A0341|67 87|complex native promoter
P11092886A0341|93 124|phosphoenolpyruvate carboxykinase
P11092886A0341|126 130|PEPCK
P11093745A0563|7 22|putative HNF3 site
P11093745A0563|15 22|HNF3 site
P11093745A0563|25 39|close apposition
P11093745A0563|43 53|NF1/CTF site
P11093745A0563|43 45|NF1
P11093745A0563|47 53|CTF site
P11093745A0563|57 73|localized upstream
P11093745A0563|79 98|silencer-like element
P11094066A0505|4 28|transcriptional regulation
P11094066A0505|42 51|modulation
P11094066A0505|57 90|forkhead transcription factor FKHR-L1
P11094066A0505|57 83|forkhead transcription factor
P11094066A0505|84 90|FKHR-L1
P11094066A0505|95 98|IL-3
P11094066A0505|108 122|FKHR-L1 activity
P11094066A0505|108 114|FKHR-L1
P11094066A0505|126 145|PI3K-dependent manner
P11094066A0505|126 129|PI3K
P11094066A1194|19 30|observations
P11094066A1194|43 52|inhibition
P11094066A1194|55 57|p27
P11094066A1194|59 62|KIP1
P11094066A1194|64 76|transcription
P11094066A1194|84 117|PI3K-induced FKHR-L1 phosphorylation
P11094066A1194|84 87|PI3K
P11094066A1194|96 102|FKHR-L1
P11094066A1194|127 140|novel mechanism
P11094066A1194|153 177|cytokine-mediated survival
P11094066A1194|181 193|proliferation
P11094072A0842|0 5|DNase I
P11094072A0842|0 4|DNase
P11094072A0842|6 24|genomic footprinting
P11094072A0842|40 48|c-Myb site
P11094072A0842|62 83|tissue-specific fashion
P11094072A1234|14 18|c-Myb
P11094072A1234|31 43|RAG-2 promoter
P11094072A1234|46 51|T cells
P11094072A1234|67 80|consensus c-Myb
P11094073A0000|17 25|new member
P11094073A0000|31 47|Vav family proteins
P11094073A0000|49 52|Vav3
P11094073A0000|73 104|Ros receptor protein tyrosine kinase
P11094073A0000|106 109|RPTK
P11094073A0000|131 154|yeast two-hybrid screening
P11094075A0257|26 37|reexpression
P11094075A0257|43 54|r-PTPeta gene
P11094075A0257|63 86|malignant rat thyroid cells
P11094075A0257|100 111|retroviruses
P11094075A0257|123 127|v-mos
P11094075A0257|131 147|v-ras-Ki oncogenes
P11094075A0257|163 180|malignant phenotype
P11094087T0000|19 22|Rnd3
P11094087T0000|64 78|epithelial cells
P11094087T0000|84 133|Raf-MEK-extracellular signal-regulated kinase pathway
P11094087T0000|84 86|Raf
P11094087T0000|88 90|MEK
P11094087T0000|92 126|extracellular signal-regulated kinase
P11094091A0000|16 38|transcription factor CREB
P11094091A0000|52 71|extracellular stimuli
P11094091A0000|87 101|phosphorylation
P11094091A0000|105 125|critical serine residue
P11094091A0000|127 132|Ser133
P11094109A0600|0 6|RESULTS
P11094109A0600|8 17|Average age
P11094109A0600|20 31|symptom onset
P11094109A0600|39 43|years
P11094590A0617|6 11|fields
P11094590A0617|26 43|strong relationship
P11094590A0617|82 93|Gram staining
P11094590A0617|100 113|final diagnosis
P11094590A0617|116 118|VAP
P11094590A0617|123 125|PSB
P11094590A0617|129 131|PTC
P11094590A0617|163 163|%
P11094590A0617|165 175|specificity
P11094590A0617|184 184|%
P11094590A0617|186 208|positive predictive value
P11094590A0617|217 217|%
P11094590A0617|219 241|negative predictive value
P11094590A0617|249 249|%
P11095248A0423|9 25|mammalian proteins
P11095248A0423|27 31|XFGF3
P11095248A0423|64 75|glycoprotein
P11095248A0423|77 80|gp31
P11095248A0423|96 114|proteolytic cleavage
P11095248A0423|126 155|NH2-terminally truncated product
P11095248A0423|126 139|NH2-terminally
P11095248A0423|157 160|gp27
P11095248A1523|0 11|NH2-terminal
P11095248A1523|22 28|Xenopus
P11095248A1523|32 45|mammalian FGF3s
P11095248A1523|61 72|prerequisite
P11095248A1523|75 99|optimal biological activity
P11095981A0254|22 33|cis-elements
P11095981A0254|45 55|replication
P11095981A0254|68 77|bp promoter
P11095981A0254|107 114|plasmids
P11095981A0254|123 138|various mutations
P11095981A0254|142 150|deletions
P11096662T0000|0 8|Tranilast
P11096662T0000|14 20|Therapy
P11096662T0000|23 43|Coronary Artery Disease
P11097040A0000|3 12|objectives
P11097040A0000|18 29|present study
P11097040A0000|47 53|effects
P11097040A0000|62 66|Equex
P11097040A0000|70 82|TRIS-extender
P11097040A0000|95 99|semen
P11097040A0000|106 110|steps
P11097040A0000|112 119|freezing
P11097040A0000|132 138|methods
P11097040A0000|150 154|rates
P11097040A0000|162 173|interactions
P11097040A0000|186 195|treatments
P11097040A0000|202 218|post-thaw survival
P11097040A0000|221 234|dog spermatozoa
P11097040A0000|239 247|degrees C.
P11097079A0525|12 18|further
P11097079A0525|26 44|extensive validation
P11097079A0525|50 58|clinician
P11097079A0525|64 73|NIMH-LCM-p
P11098217A0674|3 11|Aie1 locus
P11098217A0674|23 43|mouse chromosome 7A2-A3
P11098217A0674|46 56|fluorescent
P11098217A0674|63 75|hybridization
P11098420A0175|0 19|Psychiatric disorders
P11098420A0175|22 29|children
P11098420A0175|33 43|adolescents
P11098420A0175|49 69|considerable morbidity
P11098420A0175|98 117|significant mortality
P11099377T0000|0 15|Molecular cloning
P11099377T0000|31 47|human UDP-d-Xylose
P11099377T0000|49 96|proteoglycan core protein beta-d-xylosyltransferase
P11099377T0000|103 119|first isoform XT-II
P11100515A0282|0 16|Thyrotoxicosis due
P11100515A0282|19 28|amiodarone
P11100515A0282|75 97|pro-arrhythmic potential
P11100515A0282|100 113|thyrotoxicosis
P11100515A0282|120 145|fading antiarrhythmic effect
P11100515A0282|151 170|amiodarone withdrawal
P11101008A0649|0 14|Chaperones/HSPs
P11101008A0649|23 36|important roles
P11101008A0649|43 60|cell cycle processes
P11101847A0159|0 18|Oncogenic signalling
P11101847A0159|21 24|E2F1
P11101847A0159|48 60|stabilization
P11101847A0159|64 73|activation
P11101847A0159|79 97|tumour suppressor p53
P11101847A0159|99 102|refs
P11102367A1170|23 33|conclusions
P11102367A1170|52 59|proteins
P11102367A1170|90 102|nervous system
P11102367A1170|105 114|Drosophila
P11102367A1170|138 154|molecular approach
P11102367A1170|171 201|masse transposon-tagged mutations
P11102367A1170|214 227|genetic screens
P11102458A0000|30 52|initial characterization
P11102458A0000|55 66|neurobeachin
P11102458A0000|69 101|neuron-specific multidomain protein
P11102458A0000|107 109|kDa
P11102458A0000|115 127|high-affinity
P11102458A0000|140 140|K
P11102458A0000|142 142|d
P11102458A0000|147 148|nm
P11102458A0000|162 178|regulatory subunit
P11102458A0000|181 194|protein kinase A
P11102458A0000|196 201|PKA RII
P11103472A0802|0 7|Children
P11103472A0802|12 14|ADD
P11103472A0802|33 53|frontal CNV-1 amplitude
P11103472A0802|79 83|CNV-1
P11103472A0802|87 110|CNV-2 occipital amplitudes
P11103601T0025|5 9|UMDNJ
P11103792A0755|0 13|Overexpression
P11103792A0755|16 20|c-Myc
P11103792A0755|23 40|serum-starved human
P11103792A0755|43 61|mouse embryonic cells
P11103792A0755|69 77|apoptosis
P11103792A0755|120 147|growth factor-containing serum
P11103792A0755|149 170|c-Myc-induced apoptosis
P11103792A0755|182 190|deficient
P11103792A0755|193 200|bax-null
P11103792A0755|193 195|bax
P11103792A0755|215 252|bax-wild-type mouse embryonic fibroblasts
P11103792A0755|215 217|bax
P11105129T0000|0 26|Antimicrobial Susceptibility
P11105129T0000|29 38|Klebsiella
P11105129T0000|49 88|Producing Extended-Spectrum beta-lactamase
P11105129T0000|58 88|Extended-Spectrum beta-lactamase
P11105129T0000|90 93|ESBL
P11105129T0000|105 113|Hospitals
P11105129T0000|116 121|Brazil
P11105716A0782|0 9|CONCLUSION
P11105716A0782|14 20|results
P11105716A0782|32 48|AIF peak saturation
P11105716A0782|57 82|significant systematic error
P11105716A0782|103 105|CBV
P11105716A0782|109 117|CBF values
P11105716A0782|158 199|dynamic contrast-enhanced MR perfusion studies
P11105717A0123|0 6|METHODS
P11105717A0123|8 9|T2
P11105717A0123|12 19|weighted
P11105717A0123|21 56|three-dimensional gradient-echo images
P11105717A0123|84 115|magnetic susceptibility difference
P11105717A0123|148 157|hemoglobin
P11105717A0123|163 173|vasculature
P11105717A0123|177 192|microvasculature
P11106216A0918|5 16|COPD patients
P11106216A0918|21 31|variability
P11106216A0918|34 46|Delta-inst Rrs
P11106216A0918|50 50|%
P11106216A0918|55 61|greater
P11106216A0918|72 77|FOT Rrs
P11106216A0918|81 81|%
P11106428A0635|24 40|synthetic proteins
P11106428A0635|54 68|catalytic domain
P11106428A0635|71 75|FAP-1
P11106428A0635|77 86|C-terminal
P11106428A0635|90 99|amino acids
P11106428A0635|106 117|inactive form
P11106428A0635|119 125|Cys2408
P11106428A0635|129 131|Ser
P11106428A0635|140 164|glutathione-S-transferase
P11106428A0635|166 168|GST
P11106667A1061|5 11|Pet111p
P11106667A1061|21 29|dual roles
P11106667A1061|36 55|membrane localization
P11106667A1061|71 84|Cox2p synthesis
P11106667A1061|71 75|Cox2p
P11106667A1061|91 102|mitochondria
P11106668A0875|12 23|transfection
P11106668A0875|26 30|cells
P11106668A0875|38 54|spacer-RING domain
P11106668A0875|73 93|antiapoptotic function
P11106668A0875|99 117|N-terminal BIR domain
P11106668A0875|120 125|c-IAP1
P11106668A0875|136 144|apoptosis
P11107637X0001|21 32|double bounds
P11107637X0001|35 50|blood serum lipids
P11107637X0001|53 61|titration
P11107637X0001|66 70|ozone
P11107637X0001|75 89|pathophysiology
P11107637X0001|93 114|diagnostic significance
P11107637X0001|152 164|double binders
P11107637X0001|167 172|lipids
P11107637X0001|175 184|blood serum
P11107637X0001|187 194|patients
P11107637X0001|199 215|different diseases
P11107637X0001|225 239|atherosclerosis
P11107637X0001|243 262|ischemic heart disease
P11107637X0001|268 279|use titration
P11107637X0001|282 286|ozone
P11108151A0560|0 27|Ang II-induced fibronectin mRNA
P11108151A0560|13 27|fibronectin mRNA
P11108151A0560|44 56|PKC inhibitors
P11108151A0560|44 46|PKC
P11108151A0560|59 70|PKC depletion
P11108151A0560|59 61|PKC
P11108151A0560|79 96|specific inhibition
P11108151A0560|99 111|EGF-R function
P11108151A0560|115 141|dominant negative EGF-R mutant
P11108151A0560|145 160|tyrphostin AG1478
P11108151A0560|170 178|induction
P11108151A0560|181 195|fibronectin mRNA
P11108374A1466|0 5|Acoust
P11108523A0326|0 10|Video images
P11108523A0326|16 23|nostrils
P11108523A0326|59 67|perimeter
P11108523A0326|69 76|centroid
P11108523A0326|78 90|principal axis
P11108523A0326|92 98|moments
P11108523A0326|115 123|minor axes
P11108523A0326|125 127|I11
P11108523A0326|129 131|I22
P11108523A0326|134 143|anisometry
P11108523A0326|145 153|bulkiness
P11108523A0326|155 161|lateral
P11108523A0326|169 185|internostril angle
P11108523A0326|190 204|rotational angle
P11108548A0710|0 16|MS characteristics
P11108548A0710|19 27|coumarins
P11108548A0710|29 37|psoralens
P11108548A0710|57 64|flavones
P11108548A0710|69 97|different substitution patterns
P11108548A0710|150 162|APcI interface
P11108616A0000|0 8|Young fish
P11108616A0000|10 31|Oreochromis mossambicus
P11108616A0000|46 57|microgravity
P11108616A0000|59 64|micro g
P11108616A0000|74 77|days
P11108616A0000|84 102|space missions STS-55
P11108616A0000|106 111|STS-84
P11108616A0000|117 128|hypergravity
P11108616A0000|130 131|hg
P11108616A0000|137 140|days
P11108720A0124|0 3|S6K2
P11108720A0124|12 21|homologous
P11108720A0124|24 27|S6K1
P11108720A0124|33 42|core kinase
P11108720A0124|46 68|linker regulatory domains
P11108720A0124|83 86|S6K1
P11108720A0124|92 92|N
P11108720A0124|97 113|C-terminal regions
P11108720A0124|130 138|localized
P11108720A0124|153 159|nucleus
P11108720A0124|170 210|C-terminal nuclear localization signal unique
P11108720A0124|213 216|S6K2
P11108720A1130|0 11|Pretreatment
P11108720A1130|14 18|cells
P11108720A1130|26 91|mitogen-activated protein-extracellular signal-regulated kinase kinase
P11108720A1130|93 95|MEK
P11108720A1130|97 110|inhibitor U0126
P11108720A1130|120 133|S6K2 activation
P11108720A1130|120 123|S6K2
P11108720A1130|137 149|greater extent
P11108720A1130|154 157|S6K1
P11108839A0401|0 5|T cells
P11108839A0401|16 23|isoforms
P11108839A0401|26 29|S6k1
P11108839A0401|32 53|70 kDa cytoplasmic kinase
P11108839A0401|34 53|kDa cytoplasmic kinase
P11108839A0401|61 70|kDa isoform
P11108839A0401|79 104|classic nuclear localisation
P11110040A0000|0 9|Ketanserin
P11110040A0000|12 26|hypotensive drug
P11110040A0000|31 53|5-HT2 receptor antagonism
P11110040A0000|31 43|5-HT2 receptor
P11110040A0000|73 87|topical infusion
P11110040A0000|95 106|% w/v solution
P11110040A0000|109 115|corneal
P11110040A0000|119 137|scleral applications
P11110040A0000|149 172|lower intraocular pressure
P11110040A0000|181 185|times
P11110040A0000|205 214|metabolite
P11110040A0000|216 227|ketanserinol
P11110528A0414|19 33|2D axial sequence
P11110528A0414|38 53|velocity encoding
P11110528A0414|59 79|craniocaudal direction
P11110528A0414|85 98|cervical region
P11110528A0414|108 115|velocity
P11110528A0414|123 126|cm/s
P11111051A0051|26 30|Tip60
P11111051A0051|34 57|histone acetyltransferase
P11111051A0051|59 61|HAT
P11112417A1126|15 38|multiple MLSN1 transcripts
P11112417A1126|23 38|MLSN1 transcripts
P11112417A1126|70 78|inducible
P11112417A1126|100 121|pigmented melanoma cells
P11112417A1126|137 151|MLSN1 expression
P11112417A1126|137 141|MLSN1
P11112417A1126|182 194|transcription
P11112417A1126|198 211|mRNA processing
P11112438X0847|0 8|Copyright
P11112438X0847|13 25|Academic Press
P11112700A1936|0 6|Plectin
P11112700A1936|10 20|desmoplakin
P11112700A1936|25 45|GSR-containing domains
P11112700A1936|53 61|C-termini
P11112700A1936|92 111|GSR-containing domain
P11112700A1936|114 120|plectin
P11112700A1936|128 138|desmoplakin
P11112700A1936|149 151|MTs
P11112700T0000|0 15|Characterization
P11112700T0000|21 44|microtubule binding domain
P11112700T0000|47 80|microtubule actin crosslinking factor
P11112700T0000|82 85|MACF
P11112700T0000|105 114|novel group
P11112700T0000|117 127|microtubule
P11112700T0000|138 145|proteins
P11112790A0989|5 11|results
P11112790A0989|39 56|additional elements
P11112790A0989|62 64|UPR
P11113179A0541|22 25|SRC1
P11113179A0541|27 39|direct binding
P11113179A0541|42 44|CBP
P11113179A0541|50 65|estrogen receptor
P11113179A0541|87 99|SRC1 functions
P11113179A0541|87 90|SRC1
P11113179A0541|113 119|adaptor
P11113179A0541|129 131|CBP
P11113179A0541|135 138|p300
P11113179A1020|36 43|residues
P11113179A1020|73 83|LXXLL motifs
P11113179A1020|90 98|AD1 region
P11113179A1020|101 104|SRC1
P11113179A1020|114 138|strong coactivator activity
P11113179A1020|144 149|assays
P11113199A0800|5 7|MEK
P11113199A0800|15 31|cytoplasmic anchor
P11113199A0800|38 41|ERKs
P11113199A0800|53 66|MEK interaction
P11113199A0800|53 55|MEK
P11113199A0800|80 106|aberrant nuclear localization
P11113199A0800|109 130|ERK2-Delta19-25 mutants
P11113199A0800|109 112|ERK2
P11113199A0800|114 130|Delta19-25 mutants
P11113199A0800|133 150|serum-starved cells
P11113201A1114|0 3|Pmt2
P11113201A1114|16 32|six-protein family
P11113201A1114|35 39|yeast
P11113201A1114|56 64|first step
P11113201A1114|67 80|O mannosylation
P11113201A1114|83 96|target proteins
P11113546A0728|0 11|Fecal samples
P11113546A0728|51 61|trial period
P11113546A0728|80 107|gastrointestinal nematode eggs
P11113546A0728|111 121|Giardia cyst
P11113692A0169|34 44|risk factors
P11113692A0169|48 76|background diabetic retinopathy
P11113692A0169|78 80|BDR
P11113692A0169|85 87|PDR
P11113692A0169|102 117|Japanese patients
P11113692A0169|122 136|early-onset type
P11113692A0169|163 167|years
P11113692A0169|174 180|mean age
P11113692A0169|188 200|blood pressure
P11113692A0169|214 217|mm Hg
P11113822A0999|7 23|quadrants positive
P11113822A0999|29 36|controls
P11113822A0999|76 86|jaw pathoses
P11113823A0197|4 8|cases
P11113823A0197|11 32|synovial chondromatosis
P11114294A0075|0 14|Previous studies
P11114294A0075|31 79|pro-inflammatory cytokines tumor necrosis factor alpha
P11114294A0075|56 79|tumor necrosis factor alpha
P11114294A0075|83 97|interferon gamma
P11114294A0075|122 168|cystic fibrosis transmembrane conductance regulator
P11114294A0075|170 178|CFTR) gene
P11114294A0075|170 173|CFTR
P11114294A0075|180 183|CFTR
P11114294A0075|187 191|HT-29
P11114294A0075|195 202|T84 cells
P11114521A0282|0 9|Regulation
P11114521A0282|12 15|RhoA
P11114521A0282|36 43|adhesion
P11114521A0282|46 60|stationary cells
P11114521A0282|82 94|cell spreading
P11114718A0349|12 27|mouse fibroblasts
P11114718A0349|47 51|v-Src
P11114718A0349|56 59|mRNA
P11114718A0349|63 75|protein levels
P11114718A0349|78 80|p21
P11114718A0349|82 90|WAF1/CIP1
P11114718A0349|82 85|WAF1
P11114718A0349|87 90|CIP1
P11114718A0349|93 100|cyclin D1
P11114718A0349|105 111|cyclin E
P11114718A0349|115 122|elevated
P11114924A0808|0 3|ORFA
P11114924A0808|7 10|ccdA
P11114924A0808|56 78|primer extension analysis
P11116084A0000|0 10|Mouse Impact
P11116084A0000|79 93|unknown function
P11116131A0863|5 9|cells
P11116131A0863|18 20|P2Y
P11116131A0863|25 28|mRNA
P11116148A0741|0 18|Coexpression studies
P11116148A0741|31 37|insulin
P11116148A0741|41 43|PKB
P11116148A0741|52 66|transactivation
P11116148A0741|69 77|C/EBPbeta
P11116148A0741|85 94|C/EBPalpha
P11116148A0741|103 134|N-terminal transactivation domains
P11116148A0741|137 145|C/EBPbeta
P11117263A0570|10 28|graminaceous species
P11117263A0570|36 49|Ids3 expression
P11117263A0570|36 39|Ids3
P11117263A0570|67 83|Fe-deficient roots
P11117263A0570|86 94|H. vulgare
P11117263A0570|98 110|Secale cereale
P11117263A0570|134 150|deoxymugineic acid
P11117263A0570|152 154|DMA
P11117263A0570|164 175|mugineic acid
P11117263A0570|177 178|MA
P11117263A0570|183 206|3-epihydroxymugineic acid
P11117263A0570|208 213|epiHMA
P11117263A0570|215 223|H. vulgare
P11117263A0570|229 249|3-hydroxymugineic acid
P11117263A0570|251 253|HMA
P11117263A0570|255 263|S. cereale
P11117523A0650|11 32|high COUP-TFI expression
P11117523A0650|15 22|COUP-TFI
P11117523A0650|43 65|neuronal differentiation
P11117523A0650|68 75|P19 cells
P11117523A0650|87 88|RA
P11117523A0650|101 112|cell cultures
P11117523A0650|120 126|neurons
P11117826A0788|7 9|PET
P11117826A0788|28 39|pretreatment
P11117826A0788|43 61|follow-up evaluation
P11117826A0788|71 85|stereotactic PET
P11117826A0788|93 100|patients
P11117826A0788|112 129|accurate comparison
P11117826A0788|132 153|PET-based metabolic data
P11117826A0788|158 179|MR-based anatomical data
P11118062A1691|31 42|localization
P11118062A1691|48 55|mutation
P11118062A1691|61 69|K-ras gene
P11118062A1691|84 97|different level
P11118062A1691|100 113|aggressiveness
P11118062A1691|131 139|phenotype
P11118438A0411|29 34|MdPin1
P11118438A0411|37 49|Pin1 homologue
P11118438A0411|37 40|Pin1
P11118438A0411|57 73|plant species apple
P11118438A0411|75 88|Malus domestica
P11118438A0411|109 156|same phosphorylation-specific substrate specificity
P11118438A0411|176 182|juglone
P11118438A0411|205 208|Pin1
P11118440T0000|0 22|Differential association
P11118440T0000|25 32|products
P11118440T0000|35 56|alternative transcripts
P11118440T0000|62 89|candidate tumor suppressor ING1
P11118440T0000|97 140|mSin3/HDAC1 transcriptional corepressor complex
P11118440T0000|97 101|mSin3
P11118440T0000|103 107|HDAC1
P11118619A0835|8 16|other data
P11118619A0835|37 39|TAg
P11118619A0835|44 49|models
P11118619A0835|51 78|host cell transcription factors
P11118619A0835|97 110|viral infection
P11118712A1296|4 22|sensitivity analysis
P11118712A1296|36 50|practical limits
P11118712A1296|73 85|screening test
P11118712A1296|99 108|estimation
P11118712A1296|114 131|true herd prevalence
P11118712A1296|138 163|reasonable confidence limits
P11118712A1296|175 202|within-herd PTB true prevalence
P11118712A1296|237 251|herd specificity
P11118712A1296|255 259|herds
P11118712A1296|264 282|larger adult herd size
P11119611A0428|0 7|ORFK10.5
P11119611A0428|0 5|ORFK10
P11119611A0428|24 55|latency-associated nuclear antigen
P11119611A0428|58 62|LANA2
P11119611A0428|83 115|KSHV-infected hematopoietic tissues
P11119611A0428|126 128|PEL
P11119611A0428|132 133|CD
P11119611A0428|140 148|KS lesions
P11120441A1193|15 23|believers
P11120441A1193|40 71|higher right hemispheric activation
P11120441A1193|82 101|hemispheric asymmetry
P11120441A1193|104 123|functional complexity
P11121043A0074|2 8|Xenopus
P11121043A0074|10 13|BMPs
P11121043A0074|19 35|epidermal inducers
P11121043A0074|45 62|negative regulators
P11121043A0074|65 76|neurogenesis
P11121118A0075|13 26|unique variants
P11121118A0075|35 54|distinct GAF sequences
P11121118A0075|43 54|GAF sequences
P11121118A0075|60 75|N-terminal region
P11121118T0000|0 18|Genomic organization
P11121118T0000|24 55|human phosphodiesterase PDE11A gene
P11121118T0000|29 55|phosphodiesterase PDE11A gene
P11121397A0587|3 17|present findings
P11121397A0587|33 44|rib-2 protein
P11121397A0587|49 94|unique alpha1,4-N-acetylglucosaminyltransferase
P11121397A0587|108 129|biosynthetic initiation
P11121397A0587|133 142|elongation
P11121397A0587|145 158|heparan sulfate
P11121434A0915|0 9|Inhibition
P11121434A0915|15 28|Mek/Erk pathway
P11121434A0915|15 17|Mek
P11121434A0915|19 21|Erk
P11121434A0915|31 43|Rat1/ras cells
P11121434A0915|31 34|Rat1
P11121434A0915|36 38|ras
P11121434A0915|53 64|Mek inhibitor
P11121434A0915|53 55|Mek
P11121434A0915|66 72|PD98059
P11121434A0915|84 111|complete cytoskeletal recovery
P11121434A0915|113 129|indistinguishable
P11121434A0915|147 150|HR12
P11121490A0000|3 37|transcription factor CHOP/GADD153 gene
P11121490A0000|22 25|CHOP
P11121490A0000|27 33|GADD153
P11121490A0000|49 62|cellular stress
P11121490A0000|87 95|apoptosis
P11122381A0908|0 7|Addition
P11122381A0908|10 49|synthetic tyrosine-phosphorylated peptides
P11122381A0908|61 85|betac cytoplasmic tyrosines
P11122381A0908|93 109|GM-CSF stimulation
P11122381A0908|93 98|GM-CSF
P11122381A0908|129 138|activation
P11122381A0908|141 145|STAT5
P11122588A0549|0 18|MAIN OUTCOME MEASURES
P11122588A0549|20 35|Percentage change
P11122588A0549|41 59|apnea-hypopnea index
P11122588A0549|61 63|AHI
P11122588A0549|65 75|apnea events
P11122588A0549|77 90|hypopnea events
P11122588A0549|125 145|moderate-to-severe SDB
P11122588A0549|158 160|AHI
P11122588A0549|164 164|=
P11122588A0549|167 172|events
P11123054T0000|0 31|Paraneoplastic rheumatic syndromes
P11123089A0362|18 34|recent information
P11123089A0362|50 64|characteristics
P11123089A0362|69 96|possible pathogenic mechanisms
P11123089A0362|102 113|vasculitides
P11123089A0362|125 132|patients
P11123089A0362|140 167|main connective tissue diseases
P11123316T0000|0 17|Tec kinase signaling
P11123316T0000|0 8|Tec kinase
P11123316T0000|20 25|T cells
P11123316T0000|39 66|phosphatidylinositol 3-kinase
P11123316T0000|73 99|Tec pleckstrin homology domain
P11123316T0000|73 75|Tec
P11123316T0000|76 99|pleckstrin homology domain
P11123701A0442|0 14|Current evidence
P11123701A0442|28 75|DNA supercoiling-dependent transcriptional coupling
P11123701A0442|100 109|activities
P11123701A0442|112 120|promoters
P11123701A0442|142 154|DNA constructs
P11123701A0442|171 190|transcription complex
P11123701A0442|225 237|DNA supercoils
P11123701A0442|255 263|diffusion
P11123701A0442|277 285|DNA duplex
P11123912A0306|17 29|free SH2 domain
P11123912A0306|21 29|SH2 domain
P11123912A0306|56 58|SH2
P11123912A0306|93 99|peptide
P11123912A0306|111 136|polyomavirus middle T antigen
P11123912A0306|138 139|MT
P11124024A1098|28 32|sites
P11124024A1098|36 51|protein complexes
P11124024A1098|54 63|palindrome
P11124024A1098|66 77|direct repeat
P11124024A1098|83 93|C+T sequence
P11124024A1098|116 125|GAGA motifs
P11124024A1098|142 147|strand
P11124902X1337|0 8|Copyright
P11124902X1337|13 25|Academic Press
P11125151T0000|0 17|Nucleotide sequence
P11125151T0000|19 36|genome organization
P11125151T0000|40 59|phylogenetic analysis
P11125151T0000|62 100|pineapple mealybug wilt-associated virus-2
P11125363A0525|0 7|Patients
P11125363A0525|17 38|pretreatment cystoscopy
P11125363A0525|42 61|detailed tumor mapping
P11125363A0525|83 84|mg
P11125363A0525|87 88|m.
P11125363A0525|90 98|cisplatin
P11125363A0525|109 110|gm
P11125363A0525|113 114|m.
P11125363A0525|122 135|5-fluorouracil
P11125363A0525|138 141|days
P11125363A0525|149 170|definitive radiotherapy
P11125411A0857|4 20|untreated patients
P11125411A0857|30 40|laparoscopy
P11125411A0857|58 72|intra-abdominal
P11125411A0857|94 99|testes
P11125411A0857|105 118|atrophic testis
P11125411A0857|124 136|inguinal canal
P11125872A0133|33 42|compound RP
P11125872A0133|50 74|specific phosphodiesterase
P11125872A0133|77 85|inhibitor
P11125872A0133|146 160|pulmonary routes
P11126275A1068|9 14|levels
P11126275A1068|17 46|anticardiolipin immunoglobulin G
P11126275A1068|59 66|bleeding
P11126353A0582|0 6|RESULTS
P11126353A0582|8 17|Prevalence
P11126353A0582|20 26|obesity
P11126353A0582|28 33|BMI SDS
P11126353A0582|44 44|%
P11126353A0582|73 73|%
P11126353A0582|76 77|3y
P11126806A0206|8 15|sequelae
P11126806A0206|21 47|antiphospholipid-antibodies
P11126806A0206|52 84|impaired uteroplacental circulation
P11127161T0000|0 8|Bupropion
P11127161T0000|14 29|smoking cessation
P11127200A1024|6 28|natural dominant negative
P11127200A1024|32 58|AP-1 transcriptional activity
P11127200A1024|32 35|AP-1
P11127200A1024|61 63|ROS
P11127200A1024|70 74|cells
P11127200A1024|92 115|AP-1 transcription factors
P11127200A1024|92 95|AP-1
P11127200A1024|124 132|TGF-beta1
P11127200A1024|137 161|BMP-2-regulated expression
P11127200A1024|137 141|BMP-2
P11127200A1024|168 187|alpha1) collagen I gene
P11127200A1024|168 173|alpha1
P11127200A1024|175 187|collagen I gene
P11127200A1024|196 224|TGF-beta1-regulated expression
P11127200A1024|196 204|TGF-beta1
P11127200A1024|230 247|parathyroid hormone
P11127200A1024|249 251|PTH
P11127200A1024|254 271|PTH-related peptide
P11127200A1024|273 277|PTHrP
P11127200A1024|279 286|receptor
P11127250A1111|8 17|mg/kg daily
P11127250A1111|23 34|standard dose
P11127250A1111|37 38|SB
P11127250A1111|44 47|days
P11127250A1111|81 82|SB
P11127250A1111|95 103|final cure
P11127250A1111|107 114|patients
P11127250A1111|119 120|VL
P11127250A1111|123 127|Bihar
P11127250A1111|129 133|India
P11127955X0001|0 14|Adjuvant therapy
P11127955X0001|18 28|colon cancer
P11127955X0001|30 36|Surgery
P11127955X0001|56 73|considerable number
P11127955X0001|91 102|colon cancers
P11128312A1238|9 30|significant differences
P11128312A1238|32 32|p
P11128312A1238|49 56|fracture
P11128312A1238|60 76|nonfracture groups
P11128312A1238|82 94|total femur BMD
P11128312A1238|98 98|%
P11128312A1238|101 113|trabecular BMD
P11128312A1238|119 130|distal radius
P11128312A1238|133 133|%
P11128312A1238|142 157|fractal dimension
P11128312A1238|163 173|radiographs
P11128312A1238|175 177|FD2
P11128312A1238|181 181|%
P11128925A0000|0 9|BACKGROUND
P11128925A0000|52 64|interleukin-6
P11128925A0000|66 69|IL-6
P11128925A0000|71 76|levels
P11128925A0000|79 101|gingival crevicular fluid
P11128925A0000|103 105|GCF
P11128925A0000|110 136|clinical periodontal findings
P11128925A0000|139 146|patients
P11128925A0000|151 169|rheumatoid arthritis
P11128925A0000|171 172|RA
P11128925A0000|177 194|adult periodontitis
P11128925A0000|196 197|AP
P11129515A0000|3 13|prospective
P11129515A0000|15 30|multicentre trial
P11129515A0000|34 41|efficacy
P11129515A0000|46 71|Vitex agnus castus L extract Ze
P11129515A0000|94 101|patients
P11129515A0000|106 126|pre-menstrual syndrome
P11129515A0000|128 130|PMS
P11129724A0904|0 6|Studies
P11129724A0904|38 50|contamination
P11129724A0904|54 66|potential role
P11129724A0904|69 89|MRSA-contaminated milk
P11129724A0904|109 112|MRSA
P11129724A0904|115 122|neonates
P11131321T0000|0 6|Effects
P11131321T0000|9 24|Trypanosoma vivax
P11131321T0000|38 49|Yankasa sheep
P11131321T0000|56 62|results
P11131321T0000|65 91|homidum chloride chemotherapy
P11131634A0955|0 7|NF kappa B
P11131634A0955|27 39|greater extent
P11131634A0955|42 52|roscovitine
P11131634A0955|58 64|WT cells
P11131634A0955|71 77|Y8 cells
P11132063A0250|11 28|treatment exposures
P11132063A0250|34 50|at-risk population
P11132063A0250|64 90|life-threatening late effects
P11132063A0250|98 115|cirrhosis secondary
P11132063A0250|118 127|hepatitis C
P11132063A0250|130 174|late-onset anthracycline-induced cardiomyopathy
P11132063A0250|178 201|life-changing late effects
P11132063A0250|209 228|cognitive dysfunction
P11132148A0162|13 34|locus-specific residues
P11132148A0162|48 67|entire promoter region
P11132148A0162|91 105|various HLA class
P11132148A0162|98 110|HLA class I loci
P11132148A0162|107 110|loci
P11132195A0000|18 27|parameters
P11132195A0000|39 52|Volterra series
P11132195A0000|109 120|nonlinearity
P11132195A0000|122 128|methods
P11132195A0000|148 153|models
P11132195A0000|158 169|measurements
P11132195A0000|172 187|input/output data
P11132195A0000|200 215|low-order systems
P11132195A0000|230 242|short memories
P11132790A0609|3 16|standard method
P11132790A0609|34 47|composite score
P11132790A0609|53 55|S-B
P11132790A0609|66 73|subtests
P11132790A0609|79 86|raw score
P11132790A0609|148 163|high risk children
P11133741A0617|0 3|NiCl
P11133741A0617|15 28|MCP-1 synthesis
P11133741A0617|15 19|MCP-1
P11133741A0617|37 46|activation
P11133741A0617|49 57|NF-kappaB
P11133741A0617|63 70|mutation
P11133741A0617|73 94|NF-kappaB-binding sites
P11133741A0617|100 107|promoter
P11133741A0617|118 129|complete loss
P11133741A0617|132 156|inducible promoter activity
P11133830A0174|0 9|Engagement
P11133830A0174|12 19|human CD2
P11133830A0174|22 35|mitogenic pairs
P11133830A0174|38 48|anti-CD2 mAb
P11133830A0174|56 78|tyrosine phosphorylation
P11133830A0174|90 110|intracellular proteins
P11133830A0174|124 140|kDa phosphoprotein
P11133830A0174|160 178|proto-oncogene c-Cbl
P11133927T0000|0 7|Validity
P11133927T0000|10 24|NIR spectroscopy
P11133927T0000|51 78|muscle oxidative metabolic rate
P11133986A0350|0 14|Previous studies
P11133986A0350|35 71|tissue-restricted transcription factors
P11133986A0350|81 84|PU.1
P11133986A0350|88 109|PU.1 interaction partner
P11133986A0350|111 113|PIP
P11133986A0350|142 146|c-Fos
P11133986A0350|151 155|c-Jun
P11133986A0350|170 186|kappaE3'-enhancer
P11133986A0350|170 176|kappaE3
P11133986A0350|179 186|enhancer
P11133986A0350|189 196|3T3 cells
P11134033A0000|3 18|murine int-6 locus
P11134033A0000|33 55|frequent integration site
P11134033A0000|58 81|mouse mammary tumor viruses
P11134033A0000|93 110|48-kDa eIF3e subunit
P11134033A0000|113 143|translation initiation factor eIF3
P11134033A0639|2 13|int6 deletion
P11134033A0639|15 23|int6Delta
P11134033A0639|25 30|mutant
P11134033A0639|34 39|viable
P11134033A0639|55 67|minimal medium
P11134351A1405|13 18|MIP-2A
P11134351A1405|30 53|cell growth regulatory role
P11134351A1405|56 60|MBP-1
P11134508A0317|10 25|transgenic plants
P11134508A0317|39 60|antisense Arabidopsis HD
P11134508A0317|62 66|AtHD1
P11134822A0629|11 11|P
P11134822A0629|21 44|large accelerations/30 min
P11137296A0923|4 31|transcription initiation sites
P11137296A0923|52 98|full-length RNA ligase-mediated rapid amplification
P11137296A0923|52 71|full-length RNA ligase
P11137296A0923|101 108|cDNA ends
P11137296A0923|110 117|RLM-RACE
P11137296A0923|135 136|bp
P11137296A0923|144 169|translation initiation codon
P11137296A0923|171 202|Reverse transcription-PCR analysis
P11137296A0923|215 219|PFK-A
P11137296A0923|221 225|PFK-B
P11137296A0923|229 238|PFK-C genes
P11137296A0923|258 269|mouse tissues
P11137296A0923|286 291|levels
P11137296A1216|0 8|PFK-A mRNA
P11137296A1216|40 46|tissues
P11137296A1216|58 62|PFK-B
P11137296A1216|66 75|PFK-C genes
P11137367A0297|9 25|Toshiba IIDR system
P11137367A0297|46 58|X-ray TV system
P11137367A0297|63 74|digital image
P11137551A0437|2 13|whole sardine
P11137551A0437|15 24|domoic acid
P11137551A0437|38 43|levels
P11137551A0437|65 79|regulatory limit
P11138009A1032|26 34|mutations
P11138009A1032|36 45|Delta M1281
P11138009A1032|49 53|IVS51
P11138009A1032|56 56|G
P11138009A1032|65 81|German USH1 patient
P11138231T0000|0 6|Closeup
P11138231T0000|20 25|nurses
P11138694A0000|1 3|18F
P11138694A0000|11 32|fluorobenzyltrozamicol
P11138694A0000|34 36|FBT
P11138694A0000|65 97|vesicular acetylcholine transporter
P11138694A0000|103 130|presynaptic cholinergic neuron
P11138694A0000|159 170|useful ligand
P11138694A0000|184 209|cholinergic terminal density
P11138694A0000|215 226|basal ganglia
P11138694A0000|231 233|PET
P11139148A0421|30 44|murine homologue
P11139148A0421|47 51|SAF-A
P11139148A0421|88 91|MARs
P11139148A0421|114 134|satMa-binding activity
P11139148A0421|114 118|satMa
P11139148A0421|140 163|chromatographic fractions
P11139336A0257|3 23|molecular associations
P11139336A0257|33 46|INCENP behavior
P11139336A0257|33 38|INCENP
P11139336A0257|53 59|mitosis
P11139469A0402|0 4|Ang II
P11139469A0402|25 45|Ang2 mRNA accumulations
P11139469A0402|25 32|Ang2 mRNA
P11139469A0402|62 65|Ang1
P11139469A0402|68 81|Tie2 expression
P11139469A0402|68 71|Tie2
P11139469A0402|102 125|protein kinase C inhibitors
P11139469A0402|102 115|protein kinase C
P11139469A0402|131 145|intracellular Ca
P11139469A0402|159 164|agents
P11139473A0696|0 15|Promoter analysis
P11139473A0696|35 51|sequence identical
P11139473A0696|54 84|consensus cAMP-responsive element
P11139473A0696|63 84|cAMP-responsive element
P11139473A0696|86 88|CRE
P11139473A0696|90 96|located
P11139473A0696|108 120|SMemb promoter
P11139473A0696|135 151|Hex responsiveness
P11139473A0696|135 137|Hex
P11139567A1440|0 22|LH/CG receptor activation
P11139567A1440|25 28|ARNO
P11139567A1440|44 53|activation
P11139567A1440|56 83|phosphatidylinositol 3-kinase
P11139567A1440|85 94|PI 3-kinase
P11139567A1440|100 124|G protein beta gamma subunits
P11139605A0811|0 15|Deletion analysis
P11139605A0811|68 95|constitutive promoter activity
P11139605A0811|99 113|auto-activation
P11139605A0811|117 150|electrophoretic mobility shift assays
P11139605A0811|177 182|C/EBPs
P11139605A0811|186 188|Sp1
P11139974A0762|0 10|Termination
P11139974A0762|20 21|VT
P11139974A0762|27 38|first attempt
P11139974A0762|56 63|BV pacing
P11139974A0762|69 69|%
P11139974A0762|77 84|RV pacing
P11139974A0762|90 90|%
P11140472A0497|12 18|results
P11140472A0497|25 33|algorithm
P11140472A0497|41 47|results
P11140472A0497|63 77|other algorithms
P11140472A0497|82 97|optimal algorithm
P11140472A0497|101 130|monochannel nonoverlapping noise
P11140472A0497|137 152|optimal algorithm
P11140472A0497|156 180|multichannel additive noise
P11140472A0497|201 216|cases improvement
P11141003T0000|0 6|Changes
P11141003T0000|9 25|stimulation levels
P11141003T0000|36 42|nucleus
P11141003T0000|45 52|cochlear
P11141003T0000|60 64|users
P11142380A0389|0 7|Nuclease
P11142380A0389|18 46|structure-directed mutagenesis
P11142380A0389|62 69|105-nt TE
P11142380A0389|71 75|TE105
P11142380A0389|83 109|cruciform secondary structure
P11142380A0389|124 130|helices
P11142380A0389|142 163|single-stranded regions
P11143384A0267|0 8|Tele-Talk
P11143384A0267|15 29|extra capability
P11143384A0267|43 66|live conference situations
P11143384A0267|72 86|microphone input
P11145562A0000|1 14|marked decrease
P11145562A0000|20 48|type 1 insulin-like growth factor
P11145562A0000|25 48|insulin-like growth factor
P11145562A0000|50 61|IGF) receptor
P11145562A0000|50 52|IGF
P11145562A0000|54 61|receptor
P11145562A0000|63 68|IGF-IR
P11145562A0000|78 100|prostate epithelial cells
P11145562A0000|128 133|benign
P11145562A0000|139 153|metastatic state
P11145562A0468|3 13|P69 cell line
P11145562A0468|26 40|immortalization
P11145562A0468|43 77|human primary prostate epithelial cells
P11145562A0468|82 103|simian virus-40 T antigen
P11145562A0468|115 125|tumorigenic
P11145563A0202|22 38|human StAR promoter
P11145563A0202|41 50|responsive
P11145563A0202|53 91|sterol regulatory element-binding proteins
P11145563A0202|93 98|SREBPs
P11145563A0303|0 9|Expression
P11145563A0303|12 19|SREBP-1a
P11145563A0303|30 49|StAR promoter activity
P11145563A0303|30 41|StAR promoter
P11145563A0303|64 73|COS-1 cells
P11145563A0303|77 102|human granulosa-lutein cells
P11145566A0000|10 40|high-density lipoprotein receptor
P11145566A0000|42 46|HDL-R
P11145566A0000|51 60|key element
P11145566A0000|63 84|cholesterol homeostasis
P11145566A0000|89 114|potential therapeutic target
P11145566A0000|118 142|hypercholesterolemic drugs
P11145566A0000|161 175|HDL-R regulation
P11145566A0000|161 165|HDL-R
P11145571A0788|0 25|IFN-stimulated gene factor-3
P11145571A0788|29 43|STAT1 homodimers
P11145571A0788|60 88|IFN-stimulated response element
P11145571A0788|90 93|ISRE
P11145571A0788|98 120|gamma-activated sequence
P11145571A0788|122 124|GAS
P11145590A0217|25 43|molecular mechanisms
P11145590A0217|46 60|TGF-beta1 action
P11145590A0217|46 54|TGF-beta1
P11145590A0217|63 75|thyroglobulin
P11145590A0217|77 83|TG) gene
P11145590A0217|77 78|TG
P11145590A0217|80 93|gene expression
P11145590A0217|118 136|TGF-beta1 regulation
P11145590A0217|118 126|TGF-beta1
P11145590A0217|139 174|thyroid-specific transcription factors
P11145717A0936|3 25|epitope-protected lysine
P11145717A0936|27 27|K
P11145717A0936|42 57|30-aa TPO fragment
P11145717A0936|65 84|N-terminal sequencing
P11145717A0936|98 101|K713
P11145743A0170|15 33|molecular regulation
P11145743A0170|41 45|genes
P11145743A0170|48 59|thyroid cells
P11145743A0170|72 98|thyroid transcription factor 1
P11145743A0170|72 97|thyroid transcription factor
P11145743A0170|100 104|TTF-1
P11145743A0170|112 142|paired domain-containing protein 8
P11145743A0170|112 141|paired domain-containing protein
P11145743A0170|144 148|Pax-8
P11145743A0170|155 177|transcriptional activity
P11145743A0170|183 201|deiodinase promoters
P11145813A0668|0 16|Regional blood blow
P11145813A0668|30 34|means
P11145813A0668|37 48|microspheres
P11145813A0668|51 67|predefined regions
P11145813A0668|73 74|C6
P11145813A0668|76 78|T11
P11145813A0668|83 93|L6 vertebrae
P11145887A1393|0 9|Activation
P11145887A1393|12 24|transcription
P11145887A1393|35 42|AP-1 site
P11145887A1393|45 55|Jurkat cells
P11145887A1393|58 61|JunD
P11145887A1393|68 72|Fra-2
P11145887A1393|81 85|c-Jun
P11145887A1393|87 90|JunB
P11145887A1393|95 109|c-Fos activation
P11145887A1393|95 99|c-Fos
P11145887A1393|113 119|greater
P11145887A1393|161 163|Tax
P11145955A0189|14 50|ligand-activated estrogen receptor alpha
P11145955A0189|30 50|estrogen receptor alpha
P11145955A0189|52 58|ERalpha
P11145955A0189|61 79|dependent activation
P11145955A0189|82 95|gene expression
P11145955A0189|106 108|SRE
P11145955A0189|124 141|mutational analysis
P11145955A0189|147 154|promoter
P11145955A0189|166 195|mitogen-activated protein kinase
P11145955A0189|197 200|MAPK
P11145955A0189|202 218|pathway activation
P11145955A0189|221 222|E2
P11145955A0189|227 255|transforming growth factor alpha
P11145955A0189|239 255|growth factor alpha
P11145955A0189|257 265|TGF-alpha
P11145955A0189|270 284|positive control
P11146961T0000|0 17|Perfusion technique
P11146961T0000|21 64|perfusion-assisted direct coronary artery bypass
P11146961T0000|66 71|PADCAB
P11148042A1258|7 14|mixtures
P11148042A1258|18 19|LA
P11148042A1258|32 45|longer chain PEs
P11148042A1258|53 85|unusual biomodal enthalpy variations
P11148042A1258|97 116|peptide immiscibility
P11148042A1258|119 141|thicker gel state bilayers
P11148589A1124|0 10|CONCLUSIONS
P11148589A1124|17 44|current immunization practices
P11148589A1124|49 55|authors
P11148589A1124|88 110|Pacific Islander children
P11148589A1124|122 138|United States today
P11148589A1124|149 156|infected
P11148589A1124|161 163|HBV
P11148589A1124|198 217|liver carcinoma deaths
P11149472A1257|10 30|NP/NMP4/CIZ expression
P11149472A1257|13 16|NMP4
P11149472A1257|18 20|CIZ
P11149472A1257|33 42|osteocytes
P11149472A1257|44 54|osteoblasts
P11149472A1257|59 70|chondrocytes
P11149472A1257|73 79|rat bone
P11150114T0000|0 8|Chlamydia
P11150114T0000|12 25|cervical cancer
P11150114T0000|28 42|real association
P11150315A0226|1 13|novel approach
P11150315A0226|40 68|transcription factor activities
P11150315A0226|83 95|NGF-activated
P11150315A0226|83 85|NGF
P11150315A0226|103 115|EGF-activated
P11150315A0226|103 105|EGF
P11150315A0226|117 125|signaling
P11150315A0226|132 158|random oligonucleotide clones
P11150315A0226|164 184|DNA recognition library
P11150315A0226|194 219|specific DNA binding proteins
P11150315A0226|224 242|PC12 nuclear extracts
P11150315A0844|0 2|NGF
P11150315A0844|15 21|delayed
P11150315A0844|25 51|sustained ERK phosphorylation
P11150315A0844|34 36|ERK
P11150315A0844|56 58|EGF
P11150315A0844|74 88|previous reports
P11150315A1126|0 2|NGF
P11150315A1126|10 12|EGF
P11150315A1126|25 34|upper bands
P11150315A1126|65 69|Fra-2
P11150439A0701|0 16|Energy expenditure
P11150439A0701|41 54|3-hour infusion
P11150439A0701|57 59|NaH
P11150439A0701|64 65|CO
P11150439A0701|81 82|CO
P11150439A0701|86 108|enrichment determination
P11150439A0701|111 138|isotope ratio mass spectroscopy
P11150439A0701|160 185|standard regression equation
P11151826T0000|0 7|Workload
P11151826T0000|9 12|UAPs
P11152070A0573|3 10|actA gene
P11152070A0573|23 32|single copy
P11152070A0573|38 43|genome
P11152070A0573|46 58|A. chrysogenum
P11152070A0573|66 80|expression level
P11152070A0573|92 95|pcbC
P11152070A0573|99 133|cefEF cephalosporin biosynthetic genes
P11152070A0573|150 174|cephalosporin fermentation
P11152070A0573|184 205|single 1.4-kb transcript
P11152081A0413|8 16|mmol SDS/l
P11152081A0413|22 40|transient inhibition
P11152081A0413|43 55|acidification
P11152081A0413|57 75|metal solubilization
P11152081A0413|79 93|sulfur oxidation
P11152283A0223|27 29|NGF
P11152283A0223|42 58|gene transcription
P11152283A0223|61 64|PC12
P11152283A0223|68 77|INS-1 cells
P11152283A0223|104 121|NGF-regulated genes
P11152344A0416|4 10|animals
P11152344A0416|19 32|control animals
P11152344A0416|43 49|animals
P11152344A0416|59 76|focal arachnoid scar
P11152344A0416|79 83|C1-C2
P11152344A0416|115 139|kaolin-soaked fibrin sponge
P11152344A0416|128 133|fibrin
P11152344A0416|145 160|posterior surface
P11152344A0416|166 175|spinal cord
P11152451A0529|3 29|Schistosoma mansoni homologue
P11152451A0529|31 37|SmSmad2
P11152451A0529|68 88|Sj26-GST fusion protein
P11152451A0529|68 71|Sj26
P11152451A0529|103 120|specific antibodies
P11152451A1580|24 30|SmSmad2
P11152451A1580|44 58|TGF-beta signals
P11152451A1580|44 51|TGF-beta
P11152451A1580|76 84|receptor I
P11152451A1580|138 144|nucleus
P11152451A1580|165 187|target gene transcription
P11152451A1580|210 231|specific TGF-beta effect
P11152451A1580|218 225|TGF-beta
P11152521A0181|0 31|Intact Flag-tagged protein products
P11152521A0181|58 81|genomic expression vectors
P11152521A0181|94 111|ORF40/41 transcript
P11152521A0181|121 145|primase-helicase component
P11152521A0181|168 179|127-bp intron
P11152963A0000|0 9|Expression
P11152963A0000|15 26|src homology 3
P11152963A0000|15 25|src homology
P11152963A0000|28 30|SH3
P11152963A0000|53 73|tumorigenic astrocytes
P11152963A0000|75 78|SETA
P11152963A0000|100 122|astrocyte transformation
P11152963A0000|135 140|tumors
P11152963A0000|146 155|adult brain
P11153302A0000|0 22|Naltrexone hydrochloride
P11153302A0000|26 58|synthetic opioid receptor antagonist
P11153302A0000|73 79|efforts
P11153302A0000|89 113|rapid opioid detoxification
P11154491A0322|0 6|METHODS
P11154491A0322|26 44|consecutive patients
P11154491A0322|55 59|years
P11154491A0322|65 85|focal pancreatic masses
P11154491A0322|97 98|CT
P11154491A0322|109 115|EUS-FNA
P11154491A0322|124 148|linear-array echoendoscope
P11154491A0322|152 166|22-gauge needles
P11155096A0222|0 6|METHODS
P11155096A0222|8 20|Thyroid status
P11155096A0222|34 41|baseline
P11155096A0222|71 85|serum antibodies
P11155096A0222|88 104|thyroid peroxidase
P11155096A0222|106 112|TPO-Abs
P11155096A0222|126 130|IU/ml
P11155096A0222|133 146|serum TSH levels
P11155096A0222|138 140|TSH
P11155096A0222|155 157|TSH
P11155096A0222|161 168|abnormal
P11155096A0222|180 183|mU/l
P11155096A0222|186 204|serum thyroxin levels
P11155096A0222|206 207|T4
P11156303A1098|13 37|ventriculopleural shunting
P11156303A1098|61 80|preferred alternative
P11156303A1098|83 100|peritoneal drainage
P11156303A1098|103 110|children
P11156303A1098|115 138|intra-abdominal adhesions
P11156303A1098|155 179|recent peritoneal infection
P11156413T0000|0 9|Derivation
P11156413T0000|13 35|initial characterization
P11156413T0000|39 63|mouse mammary tumor cell line
P11156413T0000|75 100|polyomavirus middle T antigen
P11156413T0000|127 149|novel cancer therapeutics
P11156484A0223|0 10|TBARS levels
P11156484A0223|12 25|oxygen-radical
P11156484A0223|35 47|capacity assay
P11156484A0223|51 60|AFR release
P11156484A0223|71 99|electron paramagnetic resonance
P11156484A0223|101 103|EPR
P11156484A0223|136 150|oxidative stress
P11156618T0000|0 19|Long-range comparison
P11156618T0000|30 41|mouse SCL loci
P11156618T0000|43 58|localized regions
P11156618T0000|74 97|restriction endonucleases
P11156618T0000|121 125|peaks
P11156618T0000|137 154|noncoding sequences
P11156789A1669|28 46|other possible causes
P11156789A1669|63 74|CSF pulsation
P11156789A1669|77 84|children
P11156789A1669|93 106|motion artifact
P11156789A1669|108 114|changes
P11156789A1669|117 152|arterial oxygen concentration intrinsic
P11156789A1669|155 162|propofol
P11156789A1669|177 194|supplemental oxygen
P11156789A1669|218 224|changes
P11156789A1669|227 242|CSF protein levels
P11156789A1669|227 236|CSF protein
P11156789A1669|252 266|propofol binding
P11156789A1669|269 276|proteins
P11156789A1669|280 285|uptake
P11156789A1669|290 292|CSF
P11157035A1405|3 11|utilities
P11157035A1405|52 80|quality-of-life determinations
P11157035A1405|83 96|clinical trials
P11157035A1405|99 117|adjuvant IFN alpha-2b
P11157035A1405|107 117|IFN alpha-2b
P11157035A1405|130 139|net benefit
P11157334A1107|0 7|Serum PTH
P11157334A1107|29 35|WL group
P11157334A1107|47 53|WM group
P11157334A1107|55 55|P
P11157763T0000|0 8|Structure
P11157763T0000|14 25|EMAPII domain
P11157763T0000|28 63|human aminoacyl-tRNA synthetase complex
P11157763T0000|71 94|evolutionary dimer mimicry
P11157774A0789|0 22|Hypomorphic dSLBP alleles
P11157774A0789|11 22|dSLBP alleles
P11157774A0789|30 47|zygotic development
P11157774A0789|56 70|female sterility
P11157784A0141|11 19|DGCR6 gene
P11157784A0141|22 36|chromosome 22q11
P11157784A0141|44 56|low copy repeat
P11157784A0141|64 67|sc11
P11157784A0141|86 95|second copy
P11157784A0141|106 111|DGCR6L
P11157784A0141|131 135|locus
P11157784A0141|143 146|sc11
P11157784A0141|149 150|b.
P11157879A0192|0 6|METHODS
P11157879A0192|11 17|passive
P11157879A0192|21 35|active transport
P11157879A0192|38 48|fluorescein
P11157879A0192|59 61|BRB
P11157879A0192|78 96|vitreous fluorometry
P11158236A0000|0 16|Nerve growth factor
P11158236A0000|18 20|NGF
P11158236A0000|25 36|retinoic acid
P11158236A0000|38 39|RA
P11158236A0000|46 61|important actions
P11158236A0000|64 72|PC12 cells
P11158288T0000|0 10|Recruitment
P11158288T0000|15 27|RNA polymerase
P11158288T0000|52 79|constitutive activation domain
P11158288T0000|82 85|CREB
P11158288T0000|102 120|CREB phosphorylation
P11158288T0000|102 105|CREB
P11158290A0728|23 29|serines
P11158290A0728|32 41|homologous
P11158290A0728|47 70|N-terminal destruction box
P11158290A0728|73 84|IkappaBalpha
P11158290A0728|87 90|beta
P11158290A0728|96 102|epsilon
P11158295A0158|30 41|kinase domain
P11158295A0158|44 46|Csk
P11158295A0158|58 69|Src homology 3
P11158295A0158|58 68|Src homology
P11158295A0158|71 73|SH3
P11158295A0158|78 87|SH2 regions
P11158310A0993|24 27|ERSF
P11158310A0993|37 40|NF-Y
P11158310A0993|44 62|ATF6alpha and/or beta
P11158310A0993|44 52|ATF6alpha
P11158310A0993|59 62|beta
P11158310A0993|84 87|ERSE
P11158310A0993|109 119|cellular UPR
P11158324A1073|11 20|phenotypes
P11158324A1073|41 59|selective disruption
P11158324A1073|62 100|very-low-density lipoprotein secretion due
P11158324A1073|124 128|genes
P11158324A1073|137 151|apolipoprotein B
P11158324A1073|155 191|microsomal triglyceride transfer protein
P11158324A1073|209 235|hepatic cholesterol uptake due
P11158324A1073|262 297|major high-density lipoprotein receptor
P11158324A1073|267 297|high-density lipoprotein receptor
P11158324A1073|299 317|scavenger receptor BI
P11158324A1073|338 351|bile acid uptake
P11158324A1073|357 364|liver due
P11158324A1073|367 381|down-regulation
P11158324A1073|387 460|major basolateral bile acid transporters sodium taurocholate cotransporter protein
P11158324A1073|464 493|organic anion transporter protein
P11158326A1032|5 11|effects
P11158326A1032|27 31|SHIP2
P11158326A1032|43 50|mutation
P11158326A1032|56 64|SH2 domain
P11158326A1032|66 69|R47G
P11158337A0000|3 22|gonadotrope-specific
P11158337A0000|26 44|regulated expression
P11158337A0000|50 61|GnRH receptor
P11158337A0000|63 68|GnRH-R
P11158337A0000|87 114|multiple transcription factors
P11158337A0000|134 151|noncanonical GnRH-R
P11158337A0000|171 174|GRAS
P11158337A0000|180 197|activator protein-1
P11158337A0000|199 202|AP-1
P11158337A0000|218 238|steroidogenic factor-1
P11158337A0000|240 243|SF-1
P11158337A0000|245 255|binding site
P11158456A0223|0 6|METHODS
P11158456A0223|9 27|structured interview
P11158456A0223|52 70|initial consultation
P11158456A0223|76 100|subsequent 1-year intervals
P11158456A0223|116 118|BHS
P11158456A0223|131 136|spells
P11158456A0223|159 166|sequelae
P11158456A0223|168 180|family history
P11158456A0223|190 200|termination
P11158456A0223|203 208|spells
P11159081A1155|7 11|cases
P11159081A1155|17 17|%
P11159081A1155|23 31|MR imaging
P11159081A1155|60 75|microscopic tumor
P11159081A1155|90 95|seroma
P11159081A1155|98 107|reexcision
P11159363A1251|0 10|Methylation
P11159363A1251|17 32|cytosine residues
P11159363A1251|38 47|E2F element
P11159363A1251|50 50|m
P11159363A1251|52 53|CG
P11159363A1251|55 55|m
P11159363A1251|57 58|CG
P11159363A1251|70 113|new methylcytosine-specific DNA-protein complex
P11160096A1067|5 13|mutations
P11160096A1067|28 50|wild-type fliF background
P11160096A1067|28 40|wild-type fliF
P11160096A1067|57 71|mutant phenotype
P11160280A1275|7 33|IFN-gamma-induced expression
P11160280A1275|7 15|IFN-gamma
P11160280A1275|36 40|IRF-1
P11160280A1275|47 53|binding
P11160280A1275|59 68|IRF element
P11160307A0394|13 21|wH22xeGFP
P11160307A0394|36 70|entire humanized anti-FcgammaRI mAb H22
P11160307A0394|42 67|humanized anti-FcgammaRI mAb
P11160307A0394|68 70|H22
P11160307A0394|75 78|eGFP
P11160307A0394|100 112|C-terminal end
P11160307A0394|119 127|CH3 domain
P11160307A0394|129 137|wH22xeGFP
P11160307A0394|152 171|ligand-binding region
P11160307A0394|177 181|Fc end
P11160307A0394|201 220|ligand-binding region
P11160307A0394|226 228|Fab
P11160307A0394|241 262|cross-linking FcgammaRI
P11160307A0394|254 262|FcgammaRI
P11160656A0000|0 9|Inactivity
P11160656A0000|15 34|human cytomegalovirus
P11160656A0000|36 39|HCMV
P11160656A0000|41 76|major immediate-early regulatory region
P11160656A0000|78 82|MIERR
P11160656A0000|102 109|promoter
P11160656A0000|111 118|enhancer
P11160656A0000|120 131|unique region
P11160656A0000|136 144|modulator
P11160656A0000|162 176|HCMV replication
P11160656A0000|187 199|infected cells
P11160656A0000|205 231|other nonpermissive cell types
P11160656A0000|242 270|human embryonal NTera2 carcinoma
P11160656A0000|272 274|NT2
P11160656A0000|276 280|cells
P11160683A1220|17 26|reciprocal
P11160683A1220|33 49|C/EBP dimer binding
P11160683A1220|33 42|C/EBP dimer
P11160683A1220|53 67|strong C/EBP site
P11160683A1220|59 67|C/EBP site
P11160683A1220|83 99|CREB-1 recruitment
P11160683A1220|83 88|CREB-1
P11160683A1220|102 114|ATF/CREB sites
P11160683A1220|102 104|ATF
P11160683A1220|106 114|CREB sites
P11160683A1220|135 138|CREB
P11160688A1726|3 17|metabolic events
P11160688A1726|60 67|cyclin D3
P11160688A1726|76 88|translocation
P11160688A1726|91 94|ICP0
P11160688A1726|100 108|cytoplasm
P11160721A0932|0 21|Transient transfections
P11160721A0932|33 46|single mutation
P11160721A0932|48 51|556M
P11160721A0932|62 81|TBLV enhancer activity
P11160721A0932|62 73|TBLV enhancer
P11160721A0932|101 120|different T-cell lines
P11160732A0464|0 11|Vector stocks
P11160732A0464|22 37|envelope proteins
P11160732A0464|47 67|different SIVmac clones
P11160732A0464|76 84|SIVmac239
P11160732A0464|86 103|T-lymphocyte tropic
P11160732A0464|105 112|T-tropic
P11160732A0464|116 124|SIVmac316
P11160732A0464|126 141|macrophage tropic
P11160732A0464|143 150|M-tropic
P11160732A0464|157 166|SIVmac1A11
P11160732A0464|168 177|dualtropic
P11160732A1199|0 21|Quantitative PCR studies
P11160732A1199|35 43|synthesis
P11160732A1199|58 66|vector DNA
P11160732A1199|74 80|nucleus
P11160732A1199|95 105|macrophages
P11160732A1199|121 125|clone
P11160732A1199|135 145|pseudotypes
P11160732A1199|178 195|SIVmac239 infection
P11160732A1199|203 222|reverse transcription
P11160732A1199|226 238|nuclear import
P11160732A1199|241 248|viral DNA
P11160738A1414|8 31|anti-interferon functions
P11160738A1414|8 22|anti-interferon
P11160738A1414|34 39|vIRF-2
P11160738A1414|83 97|latent infection
P11160742A0696|4 4|Z
P11160742A0696|8 18|R expression
P11160742A0696|8 8|R
P11160742A0696|29 41|PML dispersion
P11160742A0696|44 60|EBV-positive cells
P11160860A0662|27 39|IkappaB kinase
P11160860A0662|41 48|IKK-beta
P11160860A0662|63 75|essential role
P11160860A0662|78 96|NF-kappaB activation
P11160860A0662|78 86|NF-kappaB
P11160860A0662|104 125|IkappaB phosphorylation
P11160860A0662|104 110|IkappaB
P11160860A0662|147 169|paclitaxel-treated cells
P11160860A0662|181 207|IkappaBalpha phosphorylation
P11160860A0662|181 192|IkappaBalpha
P11160896A0713|0 24|Immunofluorescence studies
P11160896A0713|27 39|C2C12 myotubes
P11160896A0713|48 52|Smad2
P11160896A0713|56 71|MEF2A co-localise
P11160896A0713|56 60|MEF2A
P11160896A0713|77 83|nucleus
P11160896A0713|86 105|multinuclear myotubes
P11160896A0713|112 126|differentiation
P11160902A0962|13 16|TFOs
P11160902A0962|27 46|therapeutic potential
P11160902A0962|84 109|c-sis/PDGF-B proto-oncogene
P11160902A0962|84 88|c-sis
P11160902A0962|90 109|PDGF-B proto-oncogene
P11160902A0962|112 136|various pathologic settings
P11160902A0962|142 163|constitutive expression
P11160929T0000|0 13|Rapid evolution
P11160929T0000|19 33|DNA-binding site
P11160929T0000|36 63|LAGLIDADG homing endonucleases
P11161455A1286|0 19|Southern blot analysis
P11161455A1286|22 31|genomic DNA
P11161455A1286|36 53|somatic cell hybrids
P11161455A1286|64 95|endothelial-TACC-related cDNA maps
P11161455A1286|64 91|endothelial-TACC-related cDNA
P11161455A1286|98 107|chromosome
P11161720X1294|0 8|Copyright
P11161720X1294|13 25|Academic Press
P11161793A1033|13 37|truncated receptor isoforms
P11161793A1033|22 37|receptor isoforms
P11161793A1033|40 53|diverse species
P11161793A1033|71 78|proteins
P11161793A1033|86 109|important functional roles
P11161793A1033|122 133|EGFR activity
P11161793A1033|122 125|EGFR
P11161816A0851|17 28|similarities
P11161816A0851|36 53|endophilin proteins
P11161816A0851|62 75|entire sequence
P11161816A0851|81 92|SH3GLB family
P11161816A0851|105 114|common fold
P11161816A0851|129 138|common mode
P11162278A0629|0 13|Mental rotation
P11162278A0629|16 28|paired figures
P11162278A0629|39 48|activation
P11162278A0629|54 79|left superior parietal lobule
P11162278A0629|86 108|right frontal medial gyrus
P11162576A0213|38 71|corresponding alternative first exons
P11162576A0213|77 92|intronic promoter
P11162576A0213|98 111|human PDE5A gene
P11162666A0442|3 28|glucose/insulin stimulation
P11162666A0442|11 17|insulin
P11162666A0442|56 80|polyunsaturated fatty acids
P11162936A2727|26 32|ligands
P11162936A2727|47 64|selective estrogens
P11162936A2727|67 79|antiestrogens
P11162936A2727|83 89|ERalpha
P11162936A2727|92 97|ERbeta
P11162936A2727|118 134|tissue selectivity
P11162936A2727|142 147|agents
P11162936A2727|151 185|menopausal hormone replacement therapy
P11162936A2727|216 227|breast cancer
P11163932A0000|0 15|Behavioural tests
P11163932A0000|23 30|specimen
P11163932A0000|36 65|roman garden snail Helix pomatia L.
P11163932A0000|105 121|thermopreferendum
P11163932A0000|128 136|pulmonate
P11163932A0000|177 186|substratum
P11163932A0000|196 209|air temperature
P11163968A0152|5 15|present work
P11163968A0152|20 42|complete genome sequences
P11163968A0152|45 64|Pyrococcus horikoshii
P11163968A0152|68 83|Pyrococcus abyssi
P11163968A0152|98 102|genus
P11163968A0152|105 129|hyperthermophilic archaeon
P11163968A0152|131 145|archaebacterium
P11163968A0152|168 191|large genome polymorphisms
P11163968A0152|202 237|restriction-modification gene homologs
P11164078A0833|4 14|animal model
P11164078A0833|17 24|dystonia
P11164078A0833|44 46|NAD
P11164078A0833|59 67|viewpoint
P11164078A0833|70 87|treatment-response
P11166478T0000|0 9|Peripheral
P11166478T0000|13 43|preemptive opioid antinociception
P11166478T0000|47 68|mouse visceral pain model
P11166863A0167|13 13|%
P11166863A0167|18 20|% CI
P11166863A0167|27 27|%
P11166863A0167|29 36|patients
P11166863A0167|51 56|=grade
P11166863A0167|58 70|acute toxicity
P11166863A0167|72 75|RTOG
P11167019A1249|3 6|TATA
P11167019A1249|8 12|motif
P11167019A1249|39 47|GABPalpha
P11167019A1249|50 81|ATPsynCF6 transcription start sites
P11167019A1249|50 58|ATPsynCF6
P11167111A0957|13 40|higher lung function parameters
P11167111A0957|55 73|extubated recipients
P11167111A0957|76 93|LPD preserved grafts
P11167111A0957|95 99|weeks
P11167111A0957|105 106|TX
P11167778T0000|8 29|antithrombin deficiency
P11167778T0000|8 19|antithrombin
P11167778T0000|32 37|sepsis
P11168366A0569|26 40|genomic fragment
P11168366A0569|58 63|distal
P11168366A0569|66 74|sequences
P11168366A0569|80 91|major GGT mRNA
P11168366A0569|94 103|HepG2 cells
P11168422A0248|6 11|Nature
P11168422A0248|42 58|metal fluoride ions
P11168422A0248|67 75|phosphate
P11168422A0248|84 99|ATP-binding sites
P11168422A0248|105 115|iron protein
P11168422A0248|117 119|Kp2
P11168446T0000|9 31|erythropoietin synthesis
P11168446T0000|9 22|erythropoietin
P11168446T0000|34 41|patients
P11168446T0000|46 49|COLD
P11168446T0000|52 67|left heart failure
P11168446T0000|79 89|alterations
P11168446T0000|92 109|renal haemodynamics
P11168588T0000|0 9|Expression
P11168588T0000|12 37|herpes simplex virus type 2 US3
P11168588T0000|12 33|herpes simplex virus type
P11168588T0000|35 37|US3
P11168588T0000|48 63|Cdc42/Rac pathway
P11168588T0000|48 52|Cdc42
P11168588T0000|54 56|Rac
P11168588T0000|77 107|c-Jun N-terminal kinase activation
P11168588T0000|77 97|c-Jun N-terminal kinase
P11169080T0000|35 43|ignorance
P11169080T0000|46 48|Bok
P11169080T0000|51 53|Law
P11169113A0555|22 24|p16
P11169113A0555|29 39|phi29 mutant
P11169113A0555|51 70|suppressible mutation
P11169149A0097|24 28|SNTCS
P11169149A0097|37 45|malignant
P11170476A1546|3 24|extraordinary stability
P11170476A1546|27 48|peptide--gp96 complexes
P11170476A1546|27 33|peptide
P11170476A1546|36 48|gp96 complexes
P11170476A1546|55 64|plasticity
P11170476A1546|70 90|peptide-binding pocket
P11170476A1546|109 113|relay
P11170476A1546|116 130|diverse peptides
P11170476A1546|133 135|MHC
P11170476A1546|142 155|other molecules
P11170476A1546|159 178|molecular recognition
P11171118A0836|0 19|High-affinity binding
P11171118A0836|22 25|NF-1
P11171118A0836|28 32|PSE-B
P11171118A0836|42 46|PSE-A
P11171118A0836|75 97|DNA-protein interactions
P11171118A0836|75 85|DNA-protein
P11171118A0836|105 119|NF-1 DNA elements
P11171118A0836|123 132|antibodies
P11171320A0894|0 11|Coexpression
P11171320A0894|17 20|p120
P11171320A0894|22 24|ctn
P11171320A0894|39 56|N-terminal deletion
P11171320A0894|77 113|potential tyrosine phosphorylation sites
P11171320A0894|132 158|single amino acid substitution
P11171320A0894|160 167|tyrosine
P11171320A0894|175 187|phenylalanine
P11171320A0894|214 224|aggregation
P11171320A0894|227 245|v-Src-transformed EL
P11171320A0894|227 231|v-Src
P11171320A0894|249 261|EalphaCL cells
P11172610A0508|10 12|p73
P11172610A0508|49 56|cellular
P11172610A0508|60 73|viral promoters
P11172944A0548|0 6|RESULTS
P11172944A0548|15 22|patients
P11172944A0548|28 32|Grade
P11172944A0548|34 44|pneumonitis
P11172944A0548|54 58|Grade
P11172944A0548|60 70|pneumonitis
P11172944A0826|26 47|significant correlation
P11172944A0826|55 68|plasma TNFalpha
P11172944A0826|61 68|TNFalpha
P11172944A0826|72 91|radiation pneumonitis
P11175333A0336|5 41|immunochemical co-precipitation methods
P11175333A0336|64 71|proteins
P11176098A0342|0 6|METHODS
P11176098A0342|15 18|pigs
P11176098A0342|51 61|shock groups
P11176290T0000|0 13|Identification
P11176290T0000|16 36|pulmonary vein stenosis
P11176290T0000|42 63|radiofrequency ablation
P11176290T0000|67 84|atrial fibrillation
P11176290T0000|90 92|MRI
P11177538A0655|0 13|Tumor cell lines
P11177538A0655|28 30|MOI
P11177538A0655|38 41|days
P11177538A0655|50 72|% gene transfer efficiency
P11177686A0243|0 8|Treatment
P11177686A0243|31 45|surgical options
P11177686A0243|51 64|medical therapy
P11177686A0243|89 101|pharmacologic
P11177686A0243|105 121|pneumatic dilation
P11178248A1042|21 51|differential screening techniques
P11178248A1042|86 95|occurrence
P11178248A1042|98 111|false positives
P11178696A0301|0 13|Serial US images
P11178696A0301|75 75|s
P11178696A0301|81 100|intravenous injection
P11178696A0301|104 104|g
P11178696A0301|107 119|contrast agent
P11178696A0301|140 151|harmonic PD US
P11178765A0642|16 22|effects
P11178765A0642|25 47|exogenous hyaluronic acid
P11178765A0642|65 83|port-site metastasis
P11178765A0642|100 132|mouse adenocarcinoma cell-line colon
P11178765A0642|135 139|cells
P11179272T0000|0 14|Cytomegalovirus
P11179272T0000|16 24|Chlamydia
P11179272T0000|39 69|Helicobacter pylori IgG antibodies
P11179272T0000|57 69|IgG antibodies
P11179272T0000|73 82|restenosis
P11179272T0000|88 104|stent implantation
P11179272T0000|108 119|angiographic
P11179272T0000|123 150|intravascular ultrasound study
P11179400T0000|0 8|Responses
P11179400T0000|11 46|single-unit carotid body chemoreceptors
P11179400T0000|49 57|adult rats
P11179664T0000|0 11|Architecture
P11179664T0000|15 21|anatomy
P11179664T0000|27 38|genomic locus
P11179664T0000|50 102|human leukemia-associated transcription factor RUNX1/AML1
P11179664T0000|50 92|human leukemia-associated transcription factor
P11179664T0000|93 97|RUNX1
P11179664T0000|99 102|AML1
P11179668A0869|29 36|proteins
P11179668A0869|53 62|PLTP family
P11179687A0280|14 45|tyrosine dephosphorylating enzymes
P11179687A0280|50 77|protein-tyrosine phosphatases
P11179687A0280|79 82|PTPs
P11179687A0280|119 129|subfamilies
P11179687A0280|134 144|soluble PTPs
P11179687A0280|141 144|PTPs
P11179687A0280|151 162|receptor PTPs
P11179687A0280|164 168|RPTPs
P11179687A1118|3 12|Ig-related
P11179687A1118|14 28|typical metazoan
P11179687A1118|30 35|module
P11179687A1118|53 62|disulphide
P11179687A1118|70 78|Ig members
P11179687A1118|95 120|phylogenetic earliest member
P11179689A0000|3 15|Sox gene family
P11179689A0000|17 19|Sry
P11179689A0000|24 33|HMG box gene
P11179689A0000|62 72|DNA sequence
P11179689A0000|105 114|amino acids
P11179689A0000|136 161|sequence specific DNA binding
P11179956A1818|10 16|results
P11179956A1818|52 58|effects
P11179956A1818|64 79|C-terminal domain
P11179956A1818|82 98|nucleotide binding
P11179956A1818|123 134|interactions
P11179956A1818|142 158|N-terminal domains
P11179956A1818|180 194|proton transport
P11180027A1306|0 20|Respiratory parameters
P11180027A1306|34 36|M6G
P11180027A1306|45 69|less respiratory depression
P11180027A1306|74 81|morphine
P11180255A0776|12 28|previous arguments
P11180255A0776|35 47|improbability
P11180255A0776|50 66|biological effects
P11180255A0776|69 82|UHF frequencies
P11180688A0000|11 29|maximum oxygen uptake
P11180688A0000|31 31|V
P11180688A0000|35 37|max
P11180688A0000|41 63|Hong Kong Chinese children
P11180688A0000|94 113|respiratory illnesses
P11180688A0000|129 149|Multistage Fitness Test
P11180688A0000|151 153|MFT
P11180688A0000|157 167|20-m shuttle
P11180688A0000|183 200|schoolchildren aged
P11180688A0000|212 216|years
P11181516A0119|14 55|deletion insulin promoter-reporter constructs
P11181516A0119|58 79|transient transfections
P11181516A0119|82 102|clonal INS-1 beta-cells
P11181516A0119|88 96|INS-1 beta
P11181516A0119|106 112|located
P11181516A0119|123 142|Hh-responsive regions
P11181516A0119|152 170|rat insulin I promoter
P11181516A0119|185 211|glucose-response elements Far
P11181516A0119|213 214|E2
P11181516A0119|219 222|Flat
P11181516A0119|224 228|A2/A3
P11181516A0119|224 225|A2
P11181516A0119|227 228|A3
P11181525T0000|3 18|androgen receptor
P11181525T0000|20 21|AR
P11181525T0000|23 36|amino-terminus
P11181525T0000|44 70|androgen-specific regulation
P11181525T0000|73 88|AR gene expression
P11181525T0000|73 78|AR gene
P11181525T0000|94 107|exonic enhancer
P11181531A0464|1 14|major mechanism
P11181531A0464|22 30|estrogens
P11181531A0464|38 49|osteoporosis
P11181531A0464|59 68|repression
P11181531A0464|71 83|transcription
P11181531A0464|86 105|NF-kappa B target genes
P11181531A0464|116 158|osteoclast-activating cytokines interleukin-6
P11181531A0464|146 158|interleukin-6
P11181531A0464|162 174|interleukin-1
P11181548A0214|13 45|important cis-DNA regulatory element
P11181548A0214|47 47|s
P11181548A0214|81 103|cell-specific expression
P11181548A0214|109 119|mE-RABP gene
P11181548A0214|124 138|5-kb DNA fragment
P11181564A0733|15 19|genes
P11181564A0733|31 47|syntenic region 8E1
P11181564A0733|50 59|chromosome
P11181995A1093|0 7|Analysis
P11181995A1093|13 26|genome sequence
P11181995A1093|41 67|protein-encoding transcripts
P11181995A1093|84 110|strong corroborating evidence
P11181995A1093|167 171|genes
P11181995A1093|176 187|mouse matches
P11181995A1093|190 198|other weak
P11182520A0889|3 23|corresponding genotype
P11182520A0889|42 69|restriction enzyme-based assay
P11182746A0872|13 20|patients
P11182746A0872|29 40|normal levels
P11182746A0872|45 65|adjunctive drug therapy
P11185475T0034|2 8|Caveman
P11187016T0000|0 15|Multistage models
P11187016T0000|22 39|A-bomb survivor data
P11187016T0000|41 52|implications
P11187016T0000|56 77|carcinogenic mechanisms
P11188971A0000|3 16|revitalization
P11188971A0000|29 37|Parkinson
P11188971A0000|48 49|PD
P11188971A0000|78 92|best methodology
P11188993A0298|0 6|Corneal
P11188993A0298|19 35|deep stromal biopsy
P11188993A0298|61 81|microscopic evaluation
P11188993A0298|86 104|periodic acid-Schiff
P11188993A0298|106 111|Giemsa
P11188993A0298|116 121|Gomori
P11188993A0298|124 146|methenamine silver stains
P11189314A1000|5 11|results
P11189314A1000|24 27|BACM
P11189314A1000|31 40|antiplaque
P11189314A1000|44 73|stronger antidegradation effects
P11189314A1000|78 81|GLCM
P11191208A0000|0 18|Multidrug resistance
P11191208A0000|64 77|overexpression
P11191208A0000|80 84|genes
P11191208A0000|97 115|membrane efflux pumps
P11191208A0000|120 136|major facilitators
P11191208A0000|143 172|ABC binding cassette transporters
P11191208A0000|191 216|key transcription regulators
P11191208A0000|229 232|PDR1
P11191208A0000|236 244|PDR3 genes
P11191365A0682|0 13|Susceptibility
P11191365A0682|16 42|ischemia-induced arrhythmias
P11191365A0682|53 67|1-week diabetics
P11191365A0682|75 75|%
P11191365A0682|78 91|diabetic hearts
P11191365A0682|101 122|ventricular tachycardia
P11191365A0682|124 125|VT
P11191365A0682|132 132|%
P11191365A0682|136 148|short episodes
P11191365A0682|151 173|ventricular fibrillation
P11191365A0682|175 176|VF
P11191365A0682|190 191|VT
P11191365A0682|195 195|%
P11191365A0682|199 200|VF
P11191365A0682|203 203|%
P11191365A0682|214 224|sustained VF
P11191365A0682|227 227|%
P11191365A0682|234 246|non-diabetics
P11191365A0682|248 248|P
P11193045A1193|26 33|gradient
P11193045A1193|49 51|p53
P11193045A1193|53 55|p73
P11193045A1193|57 59|p63
P11193045A1193|71 86|tumor suppression
P11193666A1269|15 33|subsequent outbreaks
P11193666A1269|36 56|Babesia carrier animals
P11193666A1269|82 85|herd
P11193704A0000|0 30|Contagious bovine pleuropneumonia
P11193704A0000|34 44|major threat
P11193704A0000|56 61|Africa
P11194101A0532|0 16|Baseline BMD values
P11194101A0532|44 65|oligo-amenorrheic group
P11194101A0532|96 106|lumbar spine
P11194101A0532|108 126|anteroposterior view
P11194101A0532|143 159|oligo-amenorrheic
P11194101A0532|190 193|g x cm
P11194101A0532|199 199|P
P11194101A0532|212 223|eumenorrheic
P11194101A0532|227 249|contraceptive user groups
P11194101A0532|272 293|weight-bearing bone such
P11194101A0532|296 303|proximal
P11194101A0532|307 319|midshaft femur
P11194147A1496|17 34|red rice cultivation
P11194147A1496|37 44|Sri Lanka
P11194147A1496|47 56|coincident
P11194147A1496|64 75|HIDD villages
P11194183A0866|21 33|terminal hairs
P11194183A0866|52 60|hairs more
P11194183A0866|67 72|microm
P11194183A0866|75 82|diameter
P11194183A0866|107 115|cm square =
P11194183A0866|120 126|cm2 area
P11194183A0866|133 159|procyanidin B-2 group subjects
P11194183A0866|168 179|6-month trial
P11194183A0866|196 202|greater
P11194183A0866|216 242|placebo control group subjects
P11194183A0866|244 257|procyanidin B-2
P11194183A0866|278 279|SD
P11194183A0866|286 288|cm2
P11194183A0866|290 296|placebo
P11194183A0866|318 319|SD
P11194183A0866|326 328|cm2
P11194183A0866|330 330|P
P11194183A0866|337 351|two-sample t test
P11195338A0494|0 16|Ectopic expression
P11195338A0494|22 44|dominant mutant Lg3 allele
P11195338A0494|65 73|phenotype
P11195401A1030|0 18|High plasma AVP levels
P11195401A1030|10 12|AVP
P11195401A1030|35 39|cases
P11195401A1030|51 55|SSRIs
P11195401A1030|65 76|AVP secretion
P11195401A1030|65 67|AVP
P11195401A1030|92 96|SIADH
P11196191A1789|7 30|T47D breast carcinoma cells
P11196191A1789|32 35|IL-6
P11196191A1789|42 48|synergy
P11196191A1789|53 80|EGF receptor autocrine activity
P11196191A1789|53 63|EGF receptor
P11196191A1789|99 115|MAPK/PI3K pathways
P11196191A1789|99 102|MAPK
P11196191A1789|104 107|PI3K
P11196199T0000|0 13|Human homologue
P11196199T0000|16 33|yeast Rad23 protein A
P11196199T0000|47 85|p300/cyclic AMP-responsive element binding
P11196199T0000|47 50|p300
P11196199T0000|52 78|cyclic AMP-responsive element
P11196199T0000|87 90|CREB
P11196199T0000|93 106|binding protein
P11196199T0000|122 144|transcriptional activity
P11196199T0000|147 149|p53
P11196340A1046|3 22|immunological methods
P11196340A1046|40 51|such antigens
P11196340A1046|56 80|intermolecular variability
P11196340A1046|90 112|structural aescin analogs
P11196340A1046|118 132|unknown validity
P11197288A0855|0 11|Most patients
P11197288A0855|21 33|metronidazole
P11197288A0855|38 68|clarithromycin-resistant strains
P11197288A0855|87 95|equal rate
P11197288A0855|112 119|regimens
P11197328T0000|0 6|Binding
P11197328T0000|9 40|cell type-specific nuclear proteins
P11197328T0000|49 62|flanking region
P11197328T0000|65 105|maize C4 phosphoenolpyruvate carboxylase gene
P11197328T0000|116 140|differential transcription
P11197328T0000|143 156|mesophyll cells
P11197549A0748|0 6|RESULTS
P11197549A0748|17 35|stabilization period
P11197549A0748|37 41|PaCO2
P11197549A0748|50 51|SD
P11197549A0748|62 65|mm Hg
P11197549A0748|70 80|arrhythmias
P11197926A0000|0 9|BACKGROUND
P11197926A0000|11 25|Previous studies
P11197926A0000|60 74|12-item versions
P11197926A0000|80 105|General Health Questionnaire
P11197926A0000|107 109|GHQ
P11197926A0000|114 119|liable
P11197926A0000|128 134|effects
P11197926A0000|162 174|multiple times
P11197926A0000|179 192|short intervals
P11198053T0000|0 11|Acute effects
P11198053T0000|14 15|LI
P11198053T0000|20 26|extract
P11198053T0000|29 47|Hypericum perforatum
P11198053T0000|49 54|St John
P11198053T0000|57 60|wort
P11198053T0000|73 84|constituents
P11198053T0000|87 109|neuroendocrine responses
P11198289T0000|9 26|serum ceruloplasmin
P11198289T0000|30 41|copper levels
P11198289T0000|44 59|cervical dystonia
P11198385A0000|1 14|microsporidian
P11198385A0000|16 33|Nosema algerae Vavra
P11198385A0000|37 42|undeen
P11198385A0000|52 69|parasitizing larvae
P11198385A0000|73 78|adults
P11198385A0000|82 97|laboratory colony
P11198385A0000|100 113|Culex pipiens L.
P11198385A0000|128 145|Gharbia Governorate
P11198424T0000|0 15|Molecular cloning
P11198424T0000|19 34|characterization
P11198424T0000|37 41|OsPSK
P11198424T0000|57 65|precursor
P11198424T0000|69 88|phytosulfokine-alpha
P11198424T0000|101 121|rice cell proliferation
P11200568A0830|0 4|Blood
P11200568A0830|9 12|dams
P11200568A0830|32 42|inoculation
P11200568A0830|54 61|necropsy
P11200568A0830|78 80|IgM
P11200568A0830|84 96|IgG antibodies
P11200568A0830|99 108|M. pulmonis
P11201250A0849|0 21|Plasma DHE concentration
P11201250A0849|40 44|ng/ml
P11201250A0849|69 75|PSA tape
P11201250A0849|96 106|hairless rat
P11202434T0000|0 27|Single amino acid substitutions
P11202434T0000|33 54|acyl-CoA-binding domain
P11202434T0000|33 41|acyl-CoA-
P11202434T0000|67 67|C
P11202434T0000|69 88|palmitoyl-CoA binding
P11202434T0000|91 95|ACBP2
P11202434T0000|99 132|Arabidopsis acyl-CoA-binding protein
P11202434T0000|137 150|ankyrin repeats
P11202434T0000|137 143|ankyrin
P11202705A1112|0 11|Implications
P11202705A1112|14 26|biomonitoring
P11202705A1112|40 59|accumulation patterns
P11202705A1112|76 91|different tissues
P11202705A1112|94 110|Posidonia oceanica
P11203702A1307|5 10|Xlim-1
P11203702A1307|27 61|unique tyrosine-rich activation domain
P11203702A1307|78 101|negative regulatory domain
P11203702A1307|104 112|CT239-403
P11203702A1307|125 150|complex regulatory mechanism
P11203702A1307|164 186|transcriptional activity
P11203702A1307|189 194|Xlim-1
P11203702A1307|200 208|organizer
P11204897A0797|20 29|absorption
P11204897A0797|31 42|participants
P11204897A0797|53 71|bridge simulator task
P11207216A0296|3 18|bovine PGHS-2 cDNA
P11207216A0296|44 87|reverse transcription-polymerase chain reaction
P11207216A0296|44 79|reverse transcription-polymerase chain
P11207216A0296|91 110|cDNA library screening
P11207216A0719|15 24|PGHS-2 mRNA
P11207216A0719|47 61|primary cultures
P11207216A0719|64 88|bovine uterine stromal cells
P11207216A0719|103 131|phorbol 12-myristate 13-acetate
P11207216A0719|133 135|PMA
P11207216A0719|140 141|nM
P11207261A1421|0 17|Functional analysis
P11207261A1421|20 53|various PTP-deficient DT40 B cell lines
P11207261A1421|70 114|wild-type chimeric Fc gamma RIIB1-PECAM-1 receptor
P11207261A1421|87 98|Fc gamma RIIB1
P11207261A1421|100 114|PECAM-1 receptor
P11207261A1421|128 180|cytoplasmic Src homology 2-domain-containing phosphatases
P11207261A1421|182 186|SHP-1
P11207261A1421|190 194|SHP-2
P11207261A1421|235 262|inhibitory negative regulation
P11207261A1421|267 276|coligation
P11207261A1421|279 288|BCR complex
P11207261A1421|279 281|BCR
P11207261A1421|293 310|inhibitory receptor
P11207269A0745|0 16|Anti-nucleolin mAb
P11207269A0745|36 54|antigenic properties
P11207269A0745|61 72|p95 component
P11207282A0729|12 27|stable expression
P11207282A0729|45 54|active form
P11207282A0729|57 69|chicken Notch1
P11207282A0729|72 77|Notch2
P11207282A0729|81 89|B cell line
P11207282A0729|100 114|down-regulation
P11207282A0729|117 136|surface IgM expression
P11207282A0729|124 126|IgM
P11207282A0729|172 189|IgH gene transcripts
P11207288A0897|0 12|Substitutions
P11207288A0897|18 36|YFV Ag-binding region
P11207288A0897|38 40|ABR
P11207288A0897|78 85|residues
P11207288A0897|105 111|binding
P11207288A0897|114 123|peptide-Ag
P11207288A0897|129 144|class Ia molecules
P11207308A0999|10 17|curcumin
P11207308A0999|19 35|diferuloylmethane
P11207308A0999|40 61|anti-inflammatory agent
P11207308A0999|73 106|OSM-stimulated STAT1 phosphorylation
P11207308A0999|87 91|STAT1
P11207308A0999|108 126|DNA-binding activity
P11207308A0999|129 133|STAT1
P11207308A0999|138 168|c-Jun N-terminal kinase activation
P11207308A0999|138 158|c-Jun N-terminal kinase
P11207308A0999|185 188|JAK1
P11207308A0999|190 193|JAK2
P11207308A0999|195 198|JAK3
P11207308A0999|200 205|ERK1/2
P11207308A0999|210 227|p38 phosphorylation
P11207308A0999|210 212|p38
P11207609A0994|26 34|QKTT motif
P11207609A0994|38 57|TGN46 cytoplasmic tail
P11207609A0994|66 91|steady-state ER localization
P11207609A0994|94 129|vesicular stomatitis virus glycoprotein
P11207609A0994|103 129|stomatitis virus glycoprotein
P11207609A0994|131 134|VSVG
P11207609A0994|136 143|chimeras
P11207609A0994|146 149|HeLa
P11207609A0994|153 160|NRK cells
P11207609A0994|174 195|significant differences
P11207609A0994|198 222|early secretory trafficking
P11208017A0070|1 9|cDNA clone
P11208017A0070|18 43|C2H2-type zinc finger protein
P11208017A0070|45 50|SCOF-1
P11208017A0070|67 73|soybean
P11208814A0673|0 9|Consistent
P11208814A0673|17 27|specificity
P11208814A0673|55 65|DmCKIIalpha
P11208814A0673|75 86|bHLH proteins
P11208814A0673|88 104|sequence alignment
P11208814A0673|121 122|m5
P11208814A0673|124 125|m7
P11208814A0673|130 131|m8
P11208814A0673|140 152|consensus site
P11208814A0673|156 170|phosphorylation
P11208814A0673|173 176|CKII
P11208814A0673|184 198|subdomain unique
P11208814A0673|211 218|proteins
P11209100A0069|9 31|antimicrobial properties
P11209100A0069|33 42|recent data
P11209100A0069|55 57|PMN
P11209100A0069|67 90|anti-inflammatory effects
P11209100A0069|93 103|stimulation
P11209100A0069|116 138|cytokine antagonists such
P11209100A0069|141 171|interleukin-1 receptor antagonist
P11209100A0069|141 161|interleukin-1 receptor
P11209100A0069|173 178|IL-1ra
P11209814A0243|42 69|morphological characteristics
P11209814A0243|75 94|fibrous tissue capsule
P11209814A0243|111 122|implantation
P11209814A0243|125 148|aluminum calcium phosphate
P11209814A0243|150 154|ALCAP
P11209814A0243|159 172|hydroxyapetite
P11209814A0243|174 175|HA
P11209814A0243|177 187|bioceramics
P11210401A0000|0 21|Sevelamer hydrochloride
P11210401A0000|23 29|Renagel
P11210401A0000|34 68|nonabsorbed phosphate-binding polymer
P11210401A0000|94 110|hyperphosphatemia
P11210401A0000|113 125|adult patients
P11210401A0000|135 146|hemodialysis
P11210401A0544|3 25|pharmacokinetic profiles
P11210401A0544|28 34|digoxin
P11210401A0544|38 45|warfarin
P11210401A0544|65 76|simultaneous
P11210401A0544|105 113|sevelamer
P11210839A0282|6 22|PO3 administration
P11210839A0282|41 41|%
P11210839A0282|48 55|patients
P11210839A0282|72 91|antituberculous drugs
P11210839A0282|93 103|ethambutole
P11210839A0282|107 117|ethionamide
P11210839A0282|120 130|ethambutole
P11210839A0282|134 145|oprofloxacin
P11210988T0000|25 32|patients
P11210988T0000|37 67|hormone-resistant prostate cancer
P11211759A0165|0 7|Patients
P11211759A0165|32 44|Control group A
P11211759A0165|53 61|hot-water
P11211759A0165|89 94|group B
P11211759A0165|103 122|transtracheal heating
P11211759A0165|126 145|humidification system
P11211759A0165|148 161|ANAMED HUMITUBE
P11211759A0165|176 197|gastric cancer operation
P11211936A1490|3 13|present data
P11211936A1490|33 49|ectopic expression
P11211936A1490|52 55|blr1
P11211936A1490|65 80|JNK/SAPK activity
P11211936A1490|65 67|JNK
P11211936A1490|69 72|SAPK
P11211936A1490|85 87|JNK
P11211936A1490|89 102|SAPK activation
P11211936A1490|89 92|SAPK
P11211936A1490|129 153|RA-induced differentiation
P11211936A1490|157 168|growth arrest
P11212249A0993|3 9|effects
P11212249A0993|26 34|receptors
P11212249A0993|53 62|antagonism
P11212249A0993|65 81|activator protein 1
P11212249A0993|65 80|activator protein
P11212249A0993|83 86|AP-1
P11212327A1564|0 12|Recent studies
P11212327A1564|26 38|rat adipocytes
P11212327A1564|63 74|PIG compounds
P11212327A1564|82 110|IRS1/3 tyrosine phosphorylation
P11212327A1564|82 87|IRS1/3
P11212327A1564|113 124|p59Lyn kinase
P11212327A1564|136 145|cross-talk
P11212327A1564|150 167|negative regulation
P11212327A1564|192 199|caveolin
P11212327A1564|223 225|PIG
P11213342A0492|0 6|RESULTS
P11213342A0492|11 23|parameters SF2
P11213342A0492|67 82|4-year test period
P11214177A1125|19 27|antisense
P11214177A1125|43 48|nt RNAs
P11214177A1125|64 69|satRNA
P11214354A1104|0 12|VE-DEF animals
P11214354A1104|29 34|higher
P11214354A1104|36 36|p
P11214354A1104|43 48|levels
P11214354A1104|51 77|myocardial lipid peroxidation
P11214354A1104|87 87|p
P11214354A1104|94 106|protein thiols
P11214354A1104|116 118|I-R
P11214354A1104|132 141|CON animals
P11215622A0949|0 7|Grippers
P11215622A0949|22 47|piezoresistive force sensors
P11218739A0811|0 9|Transition
P11218739A0811|17 17|P
P11218739A0811|22 27|H-BPPV
P11218739A0811|39 43|cases
P11220166A0616|3 20|contrasting effects
P11220166A0616|23 45|dopaminergic stimulation
P11220166A0616|51 66|motor performance
P11220166A0616|76 82|aspects
P11220166A0616|85 103|cognitive processing
P11220166A0616|125 143|complex interactions
P11220166A0616|150 152|pre
P11220166A0616|157 190|postsynaptic brain dopamine receptors
P11220166A0616|221 254|basal ganglia-prefrontal cortex loops
P11220166A0616|265 282|cognitive behaviour
P11220306A0911|0 5|HexA71
P11220306A0911|23 26|RpoS
P11220306A0911|33 38|levels
P11220306A0911|45 66|alternative sigma factor
P11220306A0911|56 66|sigma factor
P11220306A0911|70 75|higher
P11220306A0911|81 91|HexA- mutant
P11220306A0911|81 84|HexA
P11220306A0911|86 91|mutant
P11220306A0911|101 105|HexA+
P11220306A0911|101 104|HexA
P11220306A1753|0 13|Multiple copies
P11220306A1753|16 19|rsmB
P11220306A1753|30 38|other hand
P11220306A1753|49 67|exoenzyme production
P11220306A1753|82 96|negative effects
P11220306A1753|100 114|chromosomal copy
P11220306A1753|117 121|hexA+
P11220306A1753|117 120|hexA
P11220486A0686|1 1|%
P11220486A0686|6 10|IL-12
P11220486A0686|16 16|%
P11220487T0000|0 15|Systematic review
P11220487T0000|18 32|diagnostic tests
P11220487T0000|36 56|vaginal trichomoniasis
P11220857T0000|0 3|CHAP
P11220857T0000|10 19|Department
P11220857T0000|22 36|Veterans Affairs
P11221836A0981|20 25|fusion
P11221836A0981|40 55|effective vaccine
P11221836A0981|67 84|significant potency
P11221836A0981|103 131|E7-expressing metastatic tumors
P11221845A0295|23 39|methylation status
P11221845A0295|47 57|normal liver
P11221845A0295|61 71|liver tumors
P11221845A0295|74 101|SV40 T/t antigen transgenic mice
P11221845A0295|103 111|MT-D2 mice
P11221845A0295|118 151|Restriction Landmark Genomic Scanning
P11221845A0295|155 165|Methylation
P11221845A0295|167 172|RLGS-M
P11221845A0295|187 203|several loci/spots
P11221845A0295|242 252|liver tumors
P11221845A0800|3 17|Genescan program
P11221845A0800|29 44|open reading frame
P11221845A0800|54 76|intron-less gene adjacent
P11221845A0800|82 89|B236 spot
P11221845A0800|102 129|putative 493-amino acid protein
P11221845A0800|143 160|SNAG repressor motif
P11221845A0800|166 183|NH2-terminal region
P11221845A0800|191 215|C2H2-type zinc finger motifs
P11221845A0800|221 237|COOH-terminal half
P11221845A1370|0 19|Northern blot analysis
P11221845A1370|32 35|mlt 1
P11221845A1370|32 34|mlt
P11221845A1370|63 68|spleen
P11221845A1370|70 76|stom ach
P11221845A1713|0 8|Treatment
P11221845A1713|11 22|N18TG-2 cells
P11221845A1713|28 45|demethylating agent
P11221845A1713|47 65|5-aza-deoxycytidine
P11221845A1713|91 94|mlt 1
P11221845A1713|91 93|mlt
P11221845A1713|113 122|repression
P11221845A1713|125 128|mlt 1
P11221845A1713|125 127|mlt
P11221845A1713|131 142|attributable
P11221845A1713|145 155|methylation
P11221845A1713|161 164|mlt 1
P11221845A1713|161 163|mlt
P11221845A1713|168 182|novel target gene
P11221845A1713|199 209|methylation
P11221845A1713|216 233|liver tumorigenesis
P11221845A1713|245 256|SV40 T antigen
P11222387A1497|9 24|nontoxic compound
P11222387A1497|41 54|action distinct
P11222387A1497|65 91|ABL tyrosine kinase inhibition
P11222387A1497|65 81|ABL tyrosine kinase
P11222387A1497|93 103|FTI SCH66336
P11222387A1497|133 155|BCR/ABL-induced leukemia
P11222387A1497|133 135|BCR
P11222387A1497|137 139|ABL
P11222639A1273|5 11|results
P11222639A1273|22 33|critical role
P11222639A1273|37 51|tyrosine residue
P11222639A1273|73 85|L1 endocytosis
P11222720A1699|14 17|RPMS
P11222720A1699|25 41|negative regulator
P11222720A1699|44 48|EBNA2
P11222720A1699|52 64|Notch activity
P11222720A1699|52 56|Notch
P11222720A1699|75 86|interactions
P11222720A1699|94 126|CBF1-associated corepressor complex
P11223131A0000|0 15|Folate metabolism
P11223131A0000|21 60|human malaria parasite Plasmodium falciparum
P11223131A0000|65 81|essential activity
P11223131A0000|85 94|cell growth
P11223131A0000|98 108|replication
P11223131A0000|126 139|important class
P11223131A0000|142 158|therapeutic agents
P11223131A0000|161 173|widespread use
P11223153A0533|3 11|BFA System
P11223153A0533|18 25|text file
P11223153A0533|30 34|flows
P11223153A0533|48 78|fluorescent microsphere technique
P11223153A0533|83 92|constructs
P11223153A0533|96 106|lung anatomy
P11223153A0533|111 126|volumetric pixels
P11223153A0533|137 141|flows
P11223153A0533|147 157|color schema
P11223164A0000|0 8|Retinoids
P11223164A0000|25 29|onset
P11223164A0000|32 46|differentiation
P11223164A0000|48 56|apoptosis
P11223164A0000|63 72|inhibition
P11223164A0000|84 94|wide variety
P11223164A0000|106 119|cancerous cells
P11223186A1095|0 14|Transactivation
P11223186A1095|17 50|oIFNtau enhancer-reporter constructs
P11223186A1095|17 23|oIFNtau
P11223186A1095|79 85|regions
P11223186A1095|96 103|AP-1 site
P11223186A1095|105 108|GATA
P11223186A1095|129 129|s
P11223186A1095|131 142|unidentified
P11223199A0751|5 11|results
P11223199A0751|46 54|S. neurona
P11223199A0751|57 66|WB analysis
P11223199A0751|69 73|serum
P11223199A0751|91 101|young horses
P11223240A0655|0 19|Drosophila Menin1 gene
P11223240A0655|10 30|Menin1 gene transcripts
P11223240A0655|34 64|alternative polyadenylation sites
P11223240A0655|82 93|5-kb messages
P11223246A0359|0 15|Sequence analysis
P11223246A0359|29 47|RBP21 shares homology
P11223246A0359|29 33|RBP21
P11223246A0359|52 86|other retinoblastoma-binding proteins
P11223246A0359|57 86|retinoblastoma-binding proteins
P11223246A0359|92 112|pRb-binding motif LxCxE
P11223246A0359|92 107|pRb-binding motif
P11223246A0359|118 133|C-terminal region
P11223255A1034|14 36|consensus amino acid motif
P11223255A1034|40 69|serine threonine receptor kinases
P11223256A1212|34 47|flanking region
P11223256A1212|53 64|pea 33RNP gene
P11223256A1212|56 64|33RNP gene
P11223257A0404|0 5|OsBBPI
P11223257A0404|34 49|rice seedling leaf
P11223257A0404|66 86|exogenous jasmonic acid
P11223257A0404|88 89|JA
P11223257A0404|98 123|potent protein phosphatase 2A
P11223257A0404|104 123|protein phosphatase 2A
P11223257A0404|125 128|PP2A
P11223257A0404|130 139|inhibitors
P11223257A0404|141 151|cantharidin
P11223257A0404|153 154|CN
P11223257A0404|159 167|endothall
P11223257A0404|169 170|EN
P11223257A0404|176 185|light/dark
P11223257A0404|196 215|dose-dependent manner
P11223257A0404|221 229|induction
P11223257A0404|254 266|cycloheximide
P11223257A0404|268 270|CHX
P11223257A0404|304 319|protein synthesis
P11223257A0404|325 333|induction
P11223938X1218|0 8|Copyright
P11223938X1218|13 21|John Wiley
P11223938X1218|23 26|Sons
P11223938X1218|28 31|Ltd.
P11224226A0000|3 9|effects
P11224226A0000|12 27|chlordiazepoxide
P11224226A0000|37 41|mg/kg
P11224226A0000|45 77|full benzodiazepine receptor agonist
P11224226A0000|82 91|bretazenil
P11224226A0000|101 105|mg/kg
P11224226A0000|109 144|partial benzodiazepine receptor agonist
P11224226A0000|116 137|benzodiazepine receptor
P11224226A0000|163 193|murine elevated plus-maze paradigm
P11226228A0899|8 15|plasmids
P11226228A0899|27 40|yeast TyrRS gene
P11226752A0750|2 28|mammalian tissue culture cells
P11226752A0750|30 43|overexpression
P11226752A0750|58 76|mouse deltex homologs
P11226752A0750|90 112|transcriptional activity
P11226752A0750|115 117|E47
P11226752A0750|120 140|basic helix-loop-helix
P11226752A0750|142 145|bHLH
P11226752A0750|158 170|manner similar
P11226752A0750|173 183|suppression
P11226752A0750|188 200|activated form
P11226752A0750|203 213|human Notch1
P11226752A0750|216 224|human DTX1
P11227039A0953|0 15|Multiparous women
P11227039A0953|25 33|higher BMI
P11227039A0953|35 36|P =
P11227039A0953|45 47|PBF
P11227039A0953|49 50|P =
P11227039A0953|68 72|primi
P11227039A0953|77 93|nulliparous groups
P11227182A1475|3 9|authors
P11227182A1475|25 47|significant correlations
P11227182A1475|55 64|parameters
P11227182A1475|70 75|lipids
P11227182A1475|78 87|bone marrow
P11227182A1475|91 102|leptin levels
P11227182A1475|91 96|leptin
P11227182A1475|105 109|serum
P11227182A1475|113 122|bone marrow
P11227484T0000|0 24|Fluorimetric determination
P11227484T0000|27 39|methylmercury
P11227484T0000|44 65|ion-association complex
P11227484T0000|70 79|rhodamine B
P11227484T0000|95 100|iodide
P11230145A0732|3 9|results
P11230145A0732|24 34|central role
P11230145A0732|40 49|Notch-CBF1
P11230145A0732|40 44|Notch
P11230145A0732|46 49|CBF1
P11230145A0732|51 76|RBP-Jkappa signaling pathway
P11230145A0732|51 53|RBP
P11230145A0732|55 60|Jkappa
P11230145A0732|79 95|cell fate decisions
P11230145A0732|105 115|susceptible
P11230145A0732|118 125|pathways
P11230145A0732|128 143|viral replication
P11230145A0732|147 165|oncogenic conversion
P11230169A0480|6 16|novel method
P11230169A0480|26 53|chromatin immunoprecipitation
P11230169A0480|57 81|genomic array hybridization
P11230169A0480|100 128|460-kb CENP-A-binding DNA domain
P11230169A0480|132 144|neocentromere
P11230169A0480|159 169|20p12 region
P11230169A0480|174 179|invdup
P11230169A0480|181 183|20p
P11230169A0480|185 205|human marker chromosome
P11230534A0688|20 32|DEAH helicases
P11230889A1151|3 7|cases
P11230889A1151|12 38|marked chronic arm lymphoedema
P11230889A1151|55 76|persistent improvements
P11230889A1151|79 87|arm volume
P11230889A1151|100 105|months
P11230889A1151|124 127|HBO2
P11231287A0158|16 45|human neuroblastoma cells SK-N-SH
P11231287A0158|55 63|apoptosis
P11231287A0158|73 84|thapsigargin
P11232947A1451|0 30|Prophylactic lymph node dissection
P11232947A1451|33 48|radiation therapy
P11232947A1451|54 63|nodal chain
P11232947A1451|75 89|local recurrence
P11232947A1451|118 132|overall survival
P11233643A0000|13 23|clinical use
P11233643A0000|26 46|5-aminolaevulinic acid
P11233643A0000|48 50|ALA
P11233643A0000|59 74|protoporphyrin IX
P11233643A0000|59 72|protoporphyrin
P11233643A0000|76 79|PPIX
P11233643A0000|84 102|photodynamic therapy
P11233643A0000|104 106|PDT
P11233643A0000|138 148|oral ALA dose
P11233643A0000|152 156|mg/kg
P11234223A1451|13 23|antibiotics
P11234223A1451|31 36|groups
P11234223A1451|44 70|initial bactericidal activity
P11234223A1451|101 111|antibiotics
P11234223A1451|118 140|rapid initial killing such
P11234223A1451|143 145|AMK
P11234223A1451|147 149|IPM
P11234223A1451|153 156|PAPM
P11234223A1451|168 170|CAZ
P11234223A1451|172 175|MEPM
P11234223A1451|183 200|slow initial killing
P11235335T0000|8 10|HIV
P11235777A0878|2 12|Klinefelter
P11235777A0878|24 28|47XXY
P11235777A0878|31 53|serum testosterone levels
P11235777A0878|62 69|lower end
P11235777A0878|75 85|normal range
P11235777A0878|89 113|dihydrotestosterone levels
P11235817A0000|3 32|histamine H1 receptor antagonists
P11235817A0000|3 21|histamine H1 receptor
P11235817A0000|34 47|antihistamines
P11235817A0000|54 67|important class
P11235817A0000|70 80|medications
P11235817A0000|99 112|common symptoms
P11235817A0000|127 151|hyperhistaminic conditions
P11235817A0000|163 170|children
P11235817A0000|174 179|adults
P11236056A0374|0 9|Conclusion
P11236056A0374|14 15|Lp
P11236056A0374|19 24|levels
P11236056A0374|32 39|children
P11237038A0889|1 6|subset
P11237038A0889|9 16|patients
P11237038A0889|18 19|n=
P11237038A0889|32 62|multichannel pressure flow studies
P11237038A0889|85 99|transrectal HIFU
P11237038A0889|107 131|bladder outflow obstruction
P11237491A0000|0 3|AIMS
P11237491A0000|17 24|baseline
P11237491A0000|28 54|intraindividual fluctuations
P11237491A0000|60 75|tumour markers CEA
P11237491A0000|73 75|CEA
P11237491A0000|77 78|CA
P11237491A0000|84 85|CA
P11237491A0000|91 98|patients
P11237491A0000|108 123|colorectal cancer
P11237491A0000|151 169|serum concentrations
P11237491A0000|173 199|intraindividual fluctuations
P11237491A0000|218 231|concentrations
P11237491A0000|234 255|cancer-free individuals
P11237598A0962|3 32|homologous active-site framework
P11237598A0962|40 46|enzymes
P11237598A0962|51 68|distinct structures
P11237598A0962|77 95|convergent evolution
P11237598A0962|99 122|common catalytic mechanism
P11238105A0959|0 4|Cells
P11238105A0959|15 27|alpha subunits
P11238105A0959|39 50|distal domain
P11238105A0959|52 57|term-3
P11238105A0959|87 105|alpha-2 distal domain
P11238105A0959|145 167|tyrosine phosphorylation
P11238105A0959|170 174|Jak-2
P11238105A0959|181 190|substrates
P11238105A0959|206 209|CD86
P11238375A0617|11 14|RhoA
P11238375A0617|27 45|linear kinase cascade
P11238375A0617|58 67|activation
P11238375A0617|70 73|ERK6
P11238375A0617|75 82|p38 gamma
P11238375A0617|115 123|p38 family
P11238375A0617|126 130|MAPKs
P11238402A0191|10 41|several heme-responsive mechanisms
P11238402A0191|59 79|DAN/TIR gene expression
P11238402A0191|59 61|DAN
P11238405A0817|2 8|strains
P11238405A0817|16 20|tup11
P11238405A0817|24 28|tup12
P11238405A0817|33 65|atf1-pcr1 transcriptional activator
P11238405A0817|33 36|atf1
P11238405A0817|38 41|pcr1
P11238405A0817|82 92|central role
P11238405A0817|95 113|fbp1-lacZ expression
P11238405A0817|95 98|fbp1
P11238405A0817|100 103|lacZ
P11238405A0817|123 145|spc1 MAPK phosphorylation
P11238405A0817|123 130|spc1 MAPK
P11238405A0817|148 151|atf1
P11238405A0817|177 186|activation
P11238447A0524|7 20|binding studies
P11238447A0524|36 41|eIF-5A
P11238447A0524|55 74|efficient interaction
P11238447A0524|77 83|Rev-NES
P11238447A0524|77 79|Rev
P11238447A0524|88 101|CRM1/exportin1
P11238447A0524|88 91|CRM1
P11238447A0524|93 101|exportin1
P11238447A0524|109 114|eIF-5A
P11238447A0524|131 152|nucleoporins CAN/nup214
P11238447A0524|143 145|CAN
P11238447A0524|147 152|nup214
P11238447A0524|154 159|nup153
P11238447A0524|161 165|nup98
P11238447A0524|170 174|nup62
P11238586A0000|0 16|Structural studies
P11238586A0000|30 65|class I major histocompatibility complex
P11238586A0000|36 65|major histocompatibility complex
P11238586A0000|67 69|MHC
P11238586A0000|72 110|restricted peptide-specific T cell receptor
P11238586A0000|98 110|T cell receptor
P11238586A0000|112 114|TCR
P11238586A0000|117 127|alpha/betas
P11238586A0000|132 147|multiple contacts
P11238586A0000|155 160|alpha1
P11238586A0000|164 176|alpha2 helices
P11238586A0000|182 184|MHC
P11238586A0000|193 199|unclear
P11238586A0000|221 232|interactions
P11238586A0000|245 261|functional binding
P11238882A0157|26 29|eIF6
P11238882A0157|42 65|single-copy essential gene
P11238884A0892|0 13|Mice homozygous
P11238884A0892|20 30|dlg mutation
P11238884A0892|20 22|dlg
P11238884A0892|38 54|growth retardation
P11238884A0892|57 61|utero
P11238884A0892|67 76|hypoplasia
P11238884A0892|82 91|premaxilla
P11238884A0892|95 102|mandible
P11238884A0892|109 128|cleft secondary palate
P11238916A0838|27 32|PTP phi
P11238916A0838|34 41|paxillin
P11238916A0838|47 79|paxillin-associated tyrosine kinase
P11238916A0838|81 84|Pyk2
P11238916A0838|113 129|macrophage lysates
P11238916A0838|137 151|catalytic domain
P11238916A0838|154 159|PTP phi
P11238916A0838|176 183|paxillin
P11238916A0838|187 190|Pyk2
P11238947A0636|1 16|single base change
P11238947A0636|18 20|A8G
P11238947A0636|45 58|hnRNP A2 binding
P11238947A0636|45 51|hnRNP A2
P11238947A0636|74 79|A2RE-2
P11238947A0636|89 100|RNA transport
P11239184A1340|0 16|Baseline variables
P11239184A1340|31 32|CD
P11239184A1340|46 56|frequent use
P11239184A1340|59 74|prestroke aspirin
P11239184A1340|79 93|higher incidence
P11239184A1340|96 109|early CT changes
P11239184A1340|112 116|edema
P11239184A1340|119 128|mass effect
P11239184A1340|131 159|dense middle cerebral artery sign
P11239529A0981|0 7|IL-1beta
P11239529A0981|24 29|higher
P11239529A0981|32 43|endometrioma
P11239529A0981|50 56|lesions
P11239529A0981|59 76|other localizations
P11240600A0523|1 19|complete drug history
P11240600A0523|54 61|duration
P11240600A0523|64 76|VGB medication
P11241166A0677|0 13|TaqMan analysis
P11241166A0677|16 29|gene expression
P11241166A0677|39 56|chronic FA treatment
P11241166A0677|92 105|leptin receptor
P11241166A0677|107 110|Ob-R
P11241166A0677|112 115|mRNA
P11241166A0677|135 152|negative regulators
P11241166A0677|155 168|STAT signalling
P11241166A0677|155 158|STAT
P11241166A0677|170 174|SOCS3
P11241166A0677|176 186|suppressors
P11241166A0677|189 206|cytokine signalling
P11241166A0677|210 234|cytokine inducible sequence
P11241166A0677|236 238|CIS
P11241215A0566|3 17|mutant receptors
P11241215A0566|27 34|sBMPR-IA
P11241215A0566|51 64|fusion proteins
P11241215A0566|69 79|thioredoxin
P11241215A0566|114 160|reverse phase high performance liquid chromatography
P11241215A0566|162 168|RP-HPLC
P11241215A0566|175 183|digestion
P11241215A0566|188 199|enterokinase
P11241243A0693|3 9|authors
P11241243A0693|20 40|retrospective analysis
P11241243A0693|43 51|pathology
P11241243A0693|56 69|quantification
P11241243A0693|87 110|papillary serous component
P11241243A0693|112 115|% PSC
P11241243A0693|120 132|p53 expression
P11241243A0693|120 122|p53
P11241332A0393|53 69|fixation strengths
P11241332A0393|75 84|variations
P11241332A0393|90 115|swellable bone anchor designs
P11241332A0393|118 129|smooth anchor
P11241332A0393|134 144|screw anchor
P11241332A0393|163 176|different foams
P11241332A0393|201 218|different densities
P11241356T0000|0 26|Constitutive phosphorylation
P11241356T0000|30 48|nuclear localization
P11241356T0000|51 55|Smad3
P11241356T0000|82 106|collagen gene transcription
P11241356T0000|82 93|collagen gene
P11241356T0000|118 137|hepatic stellate cells
P11241672T0000|0 6|Cloning
P11241672T0000|10 25|characterization
P11241672T0000|31 40|murine beta
P11241672T0000|44 63|integrin gene promoter
P11241672T0000|83 112|interleukin-4 responsive element
P11241672T0000|128 133|STAT-6
P11243306A0961|0 10|CONCLUSIONS
P11243306A0961|23 28|levels
P11243306A0961|31 45|oxLDL antibodies
P11243306A0961|63 79|early hypertension
P11243306A0961|93 113|coronary artery disease
P11243306A0961|139 150|hypertension
P11243306A0961|164 179|anti-oxLDL levels
P11243306A0961|164 173|anti-oxLDL
P11243336A0000|0 9|GafChromic
P11243336A0000|11 17|MD-55-2
P11243336A0000|19 34|radiochromic film
P11243336A0000|66 84|medical applications
P11243336A0000|110 131|brachytherapy dosimetry
P11243494A0833|0 6|RESULTS
P11243494A0833|15 18|days
P11243494A0833|23 28|groups
P11243494A0833|53 58|heroin
P11243494A0833|64 66|CRF
P11243494A0833|69 80|rates similar
P11243494A0833|88 108|pre-lesion performance
P11243777A0000|0 22|Cis-acting CCAAT elements
P11243777A0000|43 67|eukaryotic promoter regions
P11243980A0510|11 18|patients
P11243980A0510|31 45|PET examinations
P11243980A0510|55 71|staging procedures
P11244568A0506|3 8|Gap69C
P11244568A0506|12 26|single-copy gene
P11244568A0506|37 51|major 2.1-kb mRNA
P11244568A0506|99 104|larvae
P11244733A0782|0 4|Cases
P11244733A0782|7 16|lung cancer
P11244733A0782|21 44|intramedullary metastasis
P11245986T0000|1 33|novel growth-related nuclear protein
P11245986T0000|6 33|growth-related nuclear protein
P11245986T0000|50 73|rat aldolase B gene promoter
P11246679A0000|0 8|OBJECTIVE
P11246679A0000|44 71|complete congenital heart block
P11246679A0000|73 76|CCHB
P11246679A0000|83 87|fetus
P11246679A0000|91 102|adult disease
P11246887A0000|26 49|cholesteryl ester transfer
P11246887A0000|51 53|CET
P11246887A0000|56 86|cholesteryl ester transfer protein
P11246887A0000|88 91|CETP
P11246887A0000|105 131|phospholipid transfer protein
P11246887A0000|133 136|PLTP
P11246887A0000|160 169|prevalence
P11246887A0000|172 198|coronary artery calcification
P11246887A0000|200 202|CAC
P11246887A0000|206 221|diabetic subjects
P11246887A0000|234 252|nondiabetic subjects
P11246887A0000|270 282|sex difference
P11246887A0000|285 287|CAC
P11247663A1447|3 10|families
P11247663A1447|15 35|concordant inheritance
P11247663A1447|38 49|DNAH9 alleles
P11247663A1447|52 70|affected individuals
P11248463A0187|3 13|blood levels
P11248463A0187|16 22|lactate
P11248463A0187|24 31|pyruvate
P11248463A0187|35 44|amino acids
P11248463A0187|52 59|elevated
P11248626T0000|0 7|Efficacy
P11248626T0000|10 33|first-generation Cavermap
P11248626T0000|63 77|cavernous nerves
P11248626T0000|84 103|radical prostatectomy
P11248626T0000|106 134|multi-institutional evaluation
P11248626T0000|137 155|experienced surgeons
P11250196A0455|4 12|two-motif
P11250196A0455|14 23|domain fold
P11250196A0455|39 57|calcium binding sites
P11250196A0455|84 140|two-domain prokaryotic betagamma-crystallin fold family member
P11250196A0455|84 93|two-domain
P11250196A0455|142 150|Protein S.
P11250196A0455|142 149|Protein S
P11250942A0626|0 17|Deletional analyses
P11250942A0626|20 22|VDR
P11250942A0626|36 40|GRIP1
P11250942A0626|44 47|RAC3
P11250942A0626|58 84|intact VDR activation function
P11250942A0626|64 66|VDR
P11250942A0626|86 89|AF-2
P11250942A0626|100 119|efficient interaction
P11250942A0626|141 155|distinct regions
P11250942A0626|161 163|VDR
P11251083T0000|0 8|Mechanism
P11251083T0000|14 30|sequential control
P11251083T0000|33 46|cell morphology
P11251083T0000|50 60|S phase entry
P11251083T0000|63 83|epidermal growth factor
P11251083T0000|92 117|distinct MEK/ERK activations
P11251083T0000|100 102|MEK
P11251083T0000|104 106|ERK
P11251104A0526|15 27|alpha-amylase
P11251104A0526|52 75|transcription factor GAMyb
P11251104A0526|71 75|GAMyb
P11251104A0526|99 101|GA.
P11251252A0494|0 17|3D image-processing
P11251252A0494|34 47|ultrasound data
P11251252A0494|68 83|orthogonal planes
P11251252A0494|85 95|section mode
P11251252A0494|101 116|realistic 3D views
P11251276A0793|8 15|patients
P11251276A0793|42 49|resected
P11251276A0793|67 76|inoperable
P11251697T0000|0 33|Direct superoxide scavenging activity
P11251697T0000|36 69|nonsteroidal anti-inflammatory drugs
P11251697T0000|86 106|electron spin resonance
P11251697T0000|115 128|spin trap method
P11251951A0000|0 9|BACKGROUND
P11251951A0000|11 20|Dermoscopy
P11251951A0000|24 43|noninvasive technique
P11251951A0000|60 77|diagnostic accuracy
P11251951A0000|80 99|pigmented skin lesions
P11251951A0000|136 143|patients
P11251951A0000|148 164|cutaneous melanoma
P11251951A0000|172 175|CMIS
P11251951A0000|180 200|early invasive melanoma
P11254134A0648|9 12|PTax
P11254134A0648|22 47|higher background activities
P11254134A0648|52 54|PTF
P11254134A0648|86 110|synthetic regulatory region
P11254134A0648|123 138|background levels
P11254504A0766|11 24|promoter region
P11254504A0766|33 74|several potential cis-regulatory elements such
P11254504A0766|77 79|Sp1
P11254504A0766|81 101|early growth response-1
P11254504A0766|103 120|activator protein-2
P11254504A0766|122 125|MyoD
P11254504A0766|127 130|p300
P11254504A0766|132 151|nuclear factor-kappaB
P11254504A0766|153 178|myeloid zinc finger protein-1
P11254504A0766|180 211|caudal-related homeobox (Cdx) gene A
P11254504A0766|180 201|caudal-related homeobox
P11254504A0766|203 205|Cdx
P11254504A0766|207 211|gene A
P11254504A0766|216 239|Cdx protein-2 binding sites
P11254713A1029|21 23|Tat
P11254713A1029|31 40|components
P11254713A1029|47 71|rel/AP1 cooperative complex
P11254713A1029|47 49|rel
P11254713A1029|51 53|AP1
P11254713A1029|85 96|quantitative
P11254713A1029|100 121|qualitative alterations
P11254713A1029|137 146|activation
P11254713A1029|180 200|IL-2 gene transcription
P11254713A1029|180 187|IL-2 gene
P11254864T0000|0 7|Adjuvant
P11254864T0000|11 30|neoadjuvant treatment
P11254864T0000|33 44|breast cancer
P11255035A0331|6 25|other progenitor cells
P11255035A0331|37 55|SVZa progenitor cells
P11255035A0331|101 117|neuronal phenotype
P11255252A0961|1 18|minimal ER3 sequence
P11255252A0961|27 33|further
P11255252A0961|59 64|FXR HRE
P11255252A0961|85 111|FXR-expressing yeast extracts
P11255252A0961|85 87|FXR
P11255423A0211|0 8|OBJECTIVE
P11255423A0211|37 54|depressive symptoms
P11255423A0211|59 78|HIV-related mortality
P11255423A0211|91 103|CD4 lymphocyte
P11255423A0211|91 93|CD4
P11255423A0211|115 119|women
P11255423A0211|124 126|HIV
P11256845A0340|2 17|economic analysis
P11256845A0340|23 26|West
P11256845A0340|29 59|Scotland Coronary Prevention Study
P11256845A0340|61 67|WOSCOPS
P11256845A0340|69 76|findings
P11256845A0340|90 104|statin treatment
P11256845A0340|126 131|events
P11256845A0340|141 148|patients
P11256845A0340|152 168|population similar
P11256845A0340|177 183|WOSCOPS
P11256845A0340|195 205|% annual risk
P11256845A0340|209 227|cardiovascular event
P11256845A0340|232 245|discounted cost
P11256845A0340|249 257|life-year
P11256845A0340|272 277|pounds
P11256944A1144|15 26|soluble forms
P11256944A1144|29 32|ATF6
P11256944A1144|39 52|G13 gene product
P11256944A1144|70 88|several point mutants
P11256944A1144|94 126|cis-acting ER stress response element
P11256944A1144|153 160|ER stress
P11256962A0233|0 15|Sequence analysis
P11256962A0233|24 45|significant differences
P11256962A0233|69 83|beta subunit gene
P11256962A0233|90 109|corresponding regions
P11256962A0233|115 145|homologous GlyR alpha subunit genes
P11256962A0233|164 172|novel exon
P11256962A0233|174 177|exon
P11256962A0233|203 221|untranslated portion
P11256962A0233|227 238|GlyR beta mRNA
P11257870A0000|3 14|present study
P11257870A0000|51 73|hybrid biological reactor
P11257870A0000|100 101|TF
P11257870A0000|115 127|sludge process
P11257870A0000|129 131|ASP
P11257870A0000|141 150|wastewater
P11257870A0000|161 177|trichloroethylene
P11257870A0000|179 181|TCE
P11257870A0000|185 202|ambient temperature
P11257870A0000|205 235|different hydraulic retention time
P11257870A0000|237 239|HRT
P11258906A0743|2 27|DNA strand exchange reactions
P11258906A0743|33 48|oligonucleotides
P11258906A0743|61 64|Rec2
P11258906A0743|75 85|pairing bias
P11258906A0743|106 109|RecA
P11259347A0000|0 20|Anecdotal observations
P11259347A0000|70 74|clues
P11259347A0000|87 96|variations
P11259347A0000|99 104|humans
P11259347A0000|121 136|dietary chemicals
P11259503A0212|0 17|Forskolin treatment
P11259503A0212|21 26|microM
P11259503A0212|44 48|cells
P11259503A0212|56 56|h
P11259503A0212|73 82|luciferase
P11259593A1094|0 7|Analysis
P11259593A1094|10 23|ace2Delta cells
P11259593A1094|35 39|Ace2p
P11259593A1094|53 66|cell separation
P11260468A1179|3 9|results
P11260468A1179|31 33|AR1
P11260468A1179|39 65|promoter-proximal CAP subunit
P11260468A1179|56 65|CAP subunit
P11260468A1179|80 97|papBA transcription
P11260468A1179|80 84|papBA
P11260468A1179|119 141|histone-like protein H-NS
P11260662X0000|0 1|A.
P11260662X0000|3 9|Slatkin
P11260662X0000|11 12|D.
P11263622A0683|0 6|RESULTS
P11263622A0683|9 30|significant correlation
P11263622A0683|32 32|p
P11263622A0683|54 70|mean wall thickness
P11263622A0683|74 87|vessel wall area
P11263622A0683|95 97|MRI
P11263622A0683|101 114|histopathology
P11263622A0683|116 117|r =
P11263622A0683|125 126|r =
P11263664A1085|19 22|SIP1
P11263664A1085|42 59|XBra gene expression
P11263664A1085|42 49|XBra gene
P11263664A1085|65 72|mesoderm
P11263664T0000|0 3|SIP1
P11263664T0000|5 26|Smad interacting protein
P11263664T0000|32 39|deltaEF1
P11263664T0000|41 77|delta-crystallin enhancer binding factor
P11263664T0000|94 125|similar transcriptional repressors
P11264176A0181|0 4|B-myb
P11264176A0181|19 32|G1/S transition
P11264176A0181|71 90|cyclin A2/cdk2 complex
P11264176A0181|71 78|cyclin A2
P11264176A0181|80 83|cdk2
P11264177T0000|0 17|Nucleotide sequence
P11264177T0000|19 34|transcription map
P11264177T0000|39 54|mutation analysis
P11264177T0000|60 81|13q14 chromosomal region
P11264177T0000|91 122|B-cell chronic lymphocytic leukemia
P11264182A0000|0 28|Human T-cell leukemia virus type I
P11264182A0000|0 27|Human T-cell leukemia virus type
P11264182A0000|30 35|HTLV-I
P11264182A0000|37 39|Tax
P11264182A0000|43 72|potent transcriptional regulator
P11264182A0000|97 117|specific cellular genes
P11264182A0000|154 167|leukemogenesis
P11264182A0000|170 188|adult T-cell leukemia
P11264372T0000|0 11|Requirements
P11264372T0000|18 49|nuclear-cytoplasmic translocation
P11264372T0000|52 71|infected-cell protein
P11264372T0000|75 93|herpes simplex virus 1
P11264372T0000|75 92|herpes simplex virus
P11264375A0000|3 22|human cytomegalovirus
P11264375A0000|24 27|HCMV
P11264375A0000|29 58|major immediate-early protein IE2
P11264375A0000|62 82|nuclear phosphoprotein
P11264375A0000|102 113|key regulator
P11264375A0000|120 124|lytic
P11264375A0000|128 143|latent infections
P11264561A0167|0 8|OBJECTIVE
P11264561A0167|28 31|RSTD
P11264561A0167|40 54|coronary anatomy
P11264561A0167|61 82|acute coronary occlusion
P11265853A0000|3 9|Novacor
P11265853A0000|14 36|Ventricular Assist System
P11265853A0000|38 41|LVAS
P11265853A0000|44 54|Novacor Corp
P11265853A0000|56 62|Oakland
P11265853A0000|64 65|CA
P11265853A0000|79 91|console-based
P11265853A0000|123 143|wearable configuration
P11266184A0000|0 7|Atheroma
P11266184A0000|22 43|low signal intensity area
P11266184A0000|46 72|2-dimensional time-of-flight
P11266184A0000|74 76|TOF
P11266184A0000|78 94|magnetic resonance
P11266184A0000|96 97|MR
P11266184A0000|99 104|images
P11266184A0000|112 121|components
P11266184A0000|126 149|various signal intensities
P11266184A0000|152 160|spin-echo
P11266184A0000|162 163|SE
P11266184A0000|165 170|images
P11266194A0743|0 18|Body fat distribution
P11266194A0743|34 60|abdominal computed tomography
P11266227A0295|3 11|flux rates
P11266227A0295|14 24|p-toluidine
P11266227A0295|39 45|pH value
P11266227A0295|51 63|donor solution
P11266540A0328|18 51|known mammalian Groucho family members
P11266540A0328|93 122|individual Tcf/Lef family members
P11266558A1470|24 43|transcription extract
P11266558A1470|53 67|binding activity
P11266558A1470|88 103|initiator element
P11266558A1470|127 149|recruiting RNA polymerase
P11266558A1470|137 151|RNA polymerase II
P11266558A1470|157 173|SL RNA gene promoter
P11266615A0258|25 36|major domains
P11266615A0258|49 71|hydrophobic linker region
P11266615A0258|76 92|amino acid residues
P11267679A0102|6 20|bp EcoRI fragment
P11267679A0102|40 60|Southern hybridization
P11267679A0102|71 86|open reading frame
P11267679A0102|112 121|amino acids
P11268459A0167|14 25|present study
P11268459A0167|60 76|DOX binding ability
P11268459A0167|78 80|%DB
P11268459A0167|88 105|histologic response
P11268459A0167|123 133|tumor volume
P11268459A0167|136 160|malignant soft tissue tumors
P11268459A0167|166 189|preoperative chemotherapy
P11268459A0167|193 201|prognosis
P11268887A1174|7 24|misinterpretations
P11268887A1174|26 47|special reference values
P11268887A1174|66 79|preadolescents
P11268887A1174|100 102|FVC
P11268887A1174|106 109|FEV1
P11271297T0000|0 13|Nephrotoxicity
P11271297T0000|19 48|orthotopic liver transplantation
P11271297T0000|51 62|cyclosporin A
P11271297T0000|66 86|FK 506-treated patients
P11273995A1148|12 32|normal control subjects
P11273995A1148|39 49|TOF patients
P11273995A1148|62 69|systolic
P11273995A1148|73 101|diastolic myocardial velocities
P11273995A1148|112 135|isovolumic relaxation time
P11274109A0129|0 6|Acetoin
P11274109A0129|37 51|stationary phase
P11274109A0129|56 73|other carbon sources
P11274149A0625|0 17|Mutational analysis
P11274149A0625|31 35|U-box
P11274149A0625|44 53|RING finger
P11274149A0625|56 68|other proteins
P11274149A0625|78 90|physical basis
P11274149A0625|112 120|E2 enzymes
P11274179A0610|8 14|studies
P11274179A0610|21 33|Rac/Cdc42/Pak
P11274179A0610|21 23|Rac
P11274179A0610|25 29|Cdc42
P11274179A0610|31 33|Pak
P11274179A0610|37 42|module
P11274179A0610|53 57|Raf-1
P11274179A0610|67 76|activation
P11274179A0610|79 99|microtubule disruption
P11274184A0000|0 3|Nrf2
P11274184A0000|25 29|genes
P11274184A0000|38 44|enzymes
P11274184A0000|49 59|antioxidant
P11274184A0000|65 79|heme oxygenase-1
P11274184A0000|81 84|HO-1
P11274184A0000|89 112|xenobiotic detoxification
P11274184A1068|5 11|results
P11274184A1068|24 27|ATF4
P11274184A1068|37 41|basal
P11274184A1068|45 48|CdCl
P11274184A1068|75 82|ho-1 gene
P11274184A1068|86 104|cell-specific manner
P11274184A1068|130 133|Nrf2
P11274357A0724|5 13|other hand
P11274357A0724|21 34|overexpression
P11274357A0724|40 47|wild type
P11274357A0724|58 81|kinase-inactivated mutant
P11274357A0724|84 89|nm23H1
P11274357A0724|103 116|GDP-bound forms
P11274357A0724|119 122|Rac1
P11274357A0724|124 128|Cdc42
P11274357A0724|133 136|RhoA
P11274357A0724|144 157|GTP-bound forms
P11274357A0724|170 204|nucleoside diphosphate kinase activity
P11274357A0724|170 196|nucleoside diphosphate kinase
P11274357A0724|209 214|nm23H1
P11274357A0724|246 258|GTP-bound form
P11274357A0724|266 272|GTPases
P11274368A0469|41 56|protein synthesis
P11274368A0469|76 101|histone deacetylase activity
P11274368A0469|76 93|histone deacetylase
P11274368A0818|0 7|Deletion
P11274368A0818|13 37|potential initiator element
P11274368A0818|51 60|repression
P11274368A0818|66 76|p21 promoter
P11274368A0818|79 83|c-Myc
P11274563T0000|0 14|Fetal lung volume
P11274563T0000|16 25|estimation
P11274563T0000|28 51|MR imaging-initial results
P11275986A0091|5 16|gene products
P11275986A0091|18 19|E6
P11275986A0091|41 65|p53 tumor suppressor protein
P11275986A0091|68 108|ubiquitin/proteasome-dependent degradation
P11275986A0091|68 87|ubiquitin/proteasome
P11276426A0501|8 12|Mmip1
P11276426A0501|14 22|Mad member
P11276426A0501|46 54|Smc3 share
P11276426A0501|46 49|Smc3
P11276426A0501|57 73|% sequence identity
P11276426A0501|80 87|products
P11276426A0501|93 100|same gene
P11277913T0000|20 37|untranslated region
P11277913T0000|40 53|human Hsp70 mRNA
P11277913T0000|66 80|general enhancer
P11277913T0000|83 97|mRNA translation
P11278286A0456|2 19|SN-48 neuronal cells
P11278286A0456|31 32|MR
P11278286A0456|34 35|GR
P11278286A0456|40 54|5-HT1A receptors
P11278286A0456|56 63|deletion
P11278286A0456|66 77|inactivation
P11278286A0456|83 86|nGRE
P11278286A0456|88 98|negative GRE
P11278286A0456|110 127|negative regulation
P11278286A0456|133 141|rat 5-HT1A
P11278286A0456|144 164|heterologous promoters
P11278286A0456|167 181|corticosteroids
P11278286A0456|193 201|inclusion
P11278286A0456|211 242|corticosteroid-induced inhibition
P11278286A0456|246 265|heterologous promoter
P11278286A1083|0 47|Corticosteroid-mediated transcriptional inhibition
P11278286A1083|51 57|greater
P11278286A1083|61 65|MR/GR
P11278286A1083|61 62|MR
P11278286A1083|64 65|GR
P11278286A1083|86 87|MR
P11278286A1083|90 91|GR
P11278290A1220|7 11|Smad2
P11278290A1220|38 45|TGF-beta
P11278290A1220|62 78|initial activation
P11278290A1220|81 93|Agc expression
P11278290A1220|81 83|Agc
P11278290A1220|96 109|confluent cells
P11278290A1220|111 125|Smad2 activation
P11278290A1220|111 115|Smad2
P11278290A1220|157 165|high level
P11278290A1220|168 180|Agc expression
P11278290A1220|168 170|Agc
P11278310A1516|16 37|kinase-deficient mutant
P11278310A1516|47 82|2-MeSADP-induced caspase-3 stimulation
P11278310A1516|63 71|caspase-3
P11278310A1516|89 106|associated decrease
P11278310A1516|109 118|cell number
P11278390A0632|0 49|Reverse transcriptase-polymerase chain reaction assays
P11278390A0632|0 35|Reverse transcriptase-polymerase chain
P11278390A0632|60 69|PKRDeltaE7
P11278390A0632|84 93|broad range
P11278390A0632|96 107|human tissues
P11278390A0632|110 123|variable levels
P11278400A0668|4 13|pancreatic
P11278400A0668|17 35|intestinal cell lines
P11278400A0668|63 65|POU
P11278400A0668|67 76|OCT binding
P11278400A0668|78 96|homeodomain proteins
P11278400A0668|107 139|electrophoretic mobility shift assay
P11278440A0095|0 2|SV1
P11278440A0095|7 24|33-amino acid insert
P11278440A0095|30 50|S1 transmembrane domain
P11278440A0095|67 89|S1 overall hydrophobicity
P11278440A0095|102 112|S0-S1 linker
P11278461A0637|0 19|Polyclonal antibodies
P11278461A0637|30 43|N-terminal part
P11278461A0637|45 54|amino acids
P11278461A0637|68 81|C-terminal part
P11278461A0637|83 92|amino acids
P11278461A0637|103 131|rainbow trout HIF-1alpha protein
P11278461A0637|142 153|rainbow trout
P11278461A0637|157 186|chinook salmon HIF-1alpha protein
P11278461A0637|189 207|Western blot analysis
P11278488T0000|3 16|v-Src SH3 domain
P11278488T0000|29 63|cell adhesion-independent association
P11278488T0000|68 86|focal adhesion kinase
P11278521A0849|1 26|20-base pair oligonucleotide
P11278521A0849|41 47|nonamer
P11278521A0849|55 67|up-regulation
P11278521A0849|70 76|hypoxia
P11278521A0849|80 89|inhibition
P11278521A0849|92 112|unsaturated fatty acids
P11278521A0849|134 153|heterologous promoter
P11278521A0849|157 177|lacZ reporter construct
P11278563A0917|0 15|Deletion analyses
P11278563A0917|28 37|N-terminal
P11278563A0917|41 50|amino acids
P11278563A0917|53 57|Grb14
P11278563A0917|61 74|ankyrin repeats
P11278563A0917|61 67|ankyrin
P11278563A0917|82 91|tankyrase 2
P11278563A0917|82 90|tankyrase
P11278583A0873|0 10|Mutagenesis
P11278583A0873|13 16|SNT1
P11278583A0873|18 20|IRS
P11278583A0873|22 23|CX
P11278583A0873|39 45|classes
P11278583A0873|48 61|effector motifs
P11278583A0873|68 78|SNT critical
P11278583A0873|86 107|sustained ERK activation
P11278583A0873|95 97|ERK
P11278583A0873|111 133|neuronal differentiation
P11278583A0873|141 161|phosphotyrosine motifs
P11278583A0873|173 183|recruitment
P11278583A0873|186 189|Grb2
P11278583A0873|196 216|phosphotyrosine motifs
P11278583A0873|228 238|recruitment
P11278583A0873|241 244|Shp2
P11278583A0873|252 266|C-terminal motif
P11278583A0873|298 300|Sos
P11278594A0618|13 27|human propeptide
P11278594A0618|34 40|chimera
P11278594A0618|54 64|murine MIC-1
P11278594A0618|67 85|TGF-beta1 propeptide
P11278594A0618|96 104|secretion
P11278594A0618|110 120|unprocessed
P11278594A0618|122 137|monomeric chimera
P11278594A0618|150 168|specific interaction
P11278594A0618|179 198|human MIC-1 propeptide
P11278594A0618|202 214|mature peptide
P11278604A0300|12 31|biantennary N-glycans
P11278604A0300|51 56|5Lec20
P11278604A0300|76 90|less ricin-bound
P11278604A0300|95 108|similar species
P11278604A0300|113 128|parental CHO cells
P11278604A0300|133 149|Lec20 cell extracts
P11278604A0300|186 188|Gal
P11278604A0300|191 217|GlcNAc-terminating acceptors
P11278610A0902|14 20|SOCS box
P11278610A0902|35 42|Cullin-2
P11278610A0902|54 67|ubiquitination
P11278610A0902|70 77|TEL-JAK2
P11278610A0902|70 72|TEL
P11278610A0902|74 77|JAK2
P11278671T0000|0 27|Neuron-specific Bcl-2 homology
P11278671T0000|29 52|domain-only splice variant
P11278671T0000|55 57|Bak
P11278671T0000|60 73|anti-apoptotic
P11278671T0000|76 82|neurons
P11278671T0000|87 99|pro-apoptotic
P11278671T0000|102 118|non-neuronal cells
P11278713A1054|8 26|10-nucleotide region
P11278713A1054|38 61|exon 4 protein-binding site
P11278713A1054|38 41|exon
P11278713A1054|43 61|protein-binding site
P11278713A1054|64 73|homologous
P11278713A1054|76 94|instability elements
P11278713A1054|105 120|other transcripts
P11278713A1054|137 165|common coding region determinant
P11278819A0565|0 17|Sequence comparison
P11278819A0565|21 34|binding studies
P11278819A0565|40 68|18-bp MOK2-binding sites present
P11278819A0565|40 61|18-bp MOK2-binding sites
P11278819A0565|71 76|intron
P11278819A0565|86 91|bovine
P11278819A0565|96 109|mouse IRBP genes
P11278819A0565|124 135|half sequence
P11278819A0565|141 160|essential core element
P11278819A0565|164 174|MOK2 binding
P11278819A0565|164 167|MOK2
P11278848A1316|12 19|SB203580
P11278848A1316|29 49|LPS-induced activation
P11278848A1316|52 54|Sp1
P11278848A1316|67 82|promoter activity
P11278848A1316|85 89|cells
P11278848A1316|106 112|plasmid
P11278848A1316|126 145|Sp1 consensus sequence
P11278855A0205|32 34|TLS
P11278855A0205|38 40|p65
P11278855A0205|46 59|pull-down assay
P11278855A0205|73 103|coimmunoprecipitation experiment
P11278855A0205|114 124|Western blot
P11278870A0123|0 7|Analysis
P11278870A0123|10 26|regulatory regions
P11278870A0123|32 39|promoter
P11278870A0123|45 72|ctr4(+) copper transporter gene
P11278870A0123|45 48|ctr4
P11278870A0123|52 72|copper transporter gene
P11278870A0123|75 86|fission yeast
P11278870A0123|141 163|copper-signaling element
P11278870A0123|165 168|CuSE
P11278870A0123|193 215|transcription factor Cuf1
P11278928A1634|7 20|mutational data
P11278928A1634|24 44|possible mRNA structure
P11278928A1634|76 88|mRNA structure
P11278928A1634|110 134|major C/EBPepsilon isoforms
P11278928A1634|115 134|C/EBPepsilon isoforms
P11278928A1634|136 138|p32
P11278928A1634|142 144|p30
P11279038A0194|0 10|WRN helicase
P11279038A0194|19 40|alternate DNA structures
P11279038A0194|50 58|tetraplex
P11279038A0194|62 71|triplex DNA
P11279038A0194|76 92|Holliday junctions
P11279086A1350|20 28|ADAM-TS12
P11279086A1350|36 40|roles
P11279086A1350|43 56|pulmonary cells
P11279086A1350|63 78|fetal development
P11279086A1350|83 96|tumor processes
P11279086A1350|107 125|proteolytic activity
P11279086A1350|172 183|cell adhesion
P11279108T0000|0 6|Binding
P11279108T0000|9 27|serum response factor
P11279108T0000|30 45|CArG box sequences
P11279108T0000|83 96|gene expression
P11279108T0000|99 123|arterial smooth muscle cells
P11279207A0904|14 20|results
P11279207A0904|29 32|HPK1
P11279207A0904|36 47|new component
P11279207A0904|50 61|TCR signaling
P11279207A0904|50 52|TCR
P11279217A0273|0 3|Biol
P11279324A0710|12 18|infarct
P11279324A0710|40 67|creatine kinase integral method
P11279324A0710|40 53|creatine kinase
P11279385A3917|1 29|new echocardiographic technique
P11279385A3917|46 62|conventional M mode
P11279385A3917|75 76|2D
P11279385A3917|80 94|tissular Doppler
P11279385A3917|104 120|comparable ability
P11279385A3917|134 150|anomalous pathways
P11279385A3917|153 170|electric conduction
P11279385A3917|177 194|non-invasive method
P11279720A0844|0 16|SELECTION CRITERIA
P11279720A0844|18 43|Randomised controlled trials
P11279720A0844|46 56|cabergoline
P11279720A0844|63 69|placebo
P11279720A0844|72 79|patients
P11279720A0844|85 101|clinical diagnosis
P11279720A0844|104 122|idiopathic Parkinson
P11279720A0844|135 156|long-term complications
P11279720A0844|159 173|levodopa therapy
P11280495A1330|0 10|CONCLUSIONS
P11280495A1330|17 32|icodextrin-based
P11280495A1330|42 62|glucose-based PD fluids
P11280495A1330|93 106|Amadori albumin
P11280495A1330|100 106|albumin
P11280495A1330|110 113|AGEs
P11280799A1025|11 28|exogenous PTHrP1-34
P11280799A1025|36 43|peptides
P11280799A1025|69 82|IL-8 production
P11280799A1025|69 72|IL-8
P11280799A1025|93 120|PTHrP-neutralizing antibodies
P11280799A1025|149 152|IL-8
P11280799A1025|166 170|PTHrP
P11281201T0000|0 19|Deterministic effects
P11281268A0000|0 31|Unusual two-domain arginine kinases
P11281268A0000|33 35|AKs
P11281268A0000|65 69|times
P11281268A0000|76 93|molecular evolution
P11281268A0000|96 112|phosphagen kinases
P11281268A0000|114 116|AKs
P11281268A0000|124 164|primitive sea anemone Anthopleurura japonicus
P11281268A0000|175 204|clam Pseudocardium sachalinensis
P11282029A0075|3 35|mouse platelet-derived growth factor
P11282029A0075|37 62|PDGF) beta-receptor promoter
P11282029A0075|37 40|PDGF
P11282029A0075|42 62|beta-receptor promoter
P11282029A0075|72 81|CCAAT motif
P11282029A0075|86 89|NF-Y
P11282029A0075|97 109|essential role
P11282029A0075|115 127|transcription
P11282088A0837|0 10|Baseline MBF
P11282088A0837|13 19|females
P11282088A0837|37 37|P
P11282088A0837|45 50|higher
P11282088A0837|57 61|males
P11282394A0841|2 25|preferential VH/VL-chains
P11282394A0841|50 77|different antigen reactivities
P11282394A0841|86 89|mAbs
P11282394A0841|100 126|identical cross-reactivities
P11282395A0530|31 44|RAG1/2 proteins
P11282395A0530|54 64|DNA hairpins
P11282395A0530|79 90|same activity
P11282395A0530|111 124|protein complex
P11282395A0530|130 162|DNA repair proteins Nbs1/Mre11/Rad50
P11282395A0530|147 150|Nbs1
P11282395A0530|152 156|Mre11
P11282395A0530|158 162|Rad50
P11282395A1073|25 46|significant differences
P11282395A1073|49 61|CDR3 sequences
P11282395A1073|64 82|endogenous Ig lambdaL
P11282395A1073|86 104|kappaL chain gene loci
P11282395A1073|115 140|peripheral blood lymphocytes
P11282395A1073|145 154|NBS patient
P11282395A1073|160 177|healthy individuals
P11282433T0000|0 4|Phase
P11282433T0000|14 23|paclitaxel
P11282433T0000|27 39|oral etoposide
P11282433T0000|42 49|patients
P11282433T0000|71 103|metastatic non-small cell lung cancer
P11282761A0531|0 18|Oral supplementation
P11282761A0531|21 30|L-arginine
P11282761A0531|53 70|plasma L-citrulline
P11282761A0531|86 96|enhancement
P11282761A0531|99 110|NO production
P11283010A0701|4 13|activation
P11283010A0701|30 38|CGS 12066A
P11283014A0921|3 9|results
P11283014A0921|21 24|WASP
P11283014A0921|34 46|transcription
P11283014A0921|56 69|TCR stimulation
P11283014A0921|56 58|TCR
P11283014A0921|107 140|Arp2/3-directed actin polymerization
P11283014A0921|107 112|Arp2/3
P11283014A0921|122 126|actin
P11283168A0738|3 28|independent transgenic lines
P11283168A0738|70 76|Gus gene
P11283168A0738|94 102|endosperm
P11283168A0738|109 123|mid-development
P11283168A0738|143 143|d
P11283168A0738|149 156|anthesis
P11283256A0258|21 30|native MRCK
P11283256A0258|39 68|high-molecular-weight complexes
P11283354A0548|25 31|pathway
P11283354A0548|39 68|sequential histone modifications
P11283354A0548|80 90|histone code
P11283354A0548|107 127|epigenetic inheritance
P11283354A0548|130 152|heterochromatin assembly
P11285054A0781|0 17|Regression analyses
P11285054A0781|28 49|SOREMP dream occurrences
P11285054A0781|87 94|REM sleep
P11285054A0781|101 121|NREMP dream occurrences
P11285054A0781|135 142|arousals
P11285054A0781|147 155|NREM sleep
P11285235A0466|8 12|TRPS1
P11285235A0466|45 69|transcriptional activation
P11285235A0466|80 95|other GATA factors
P11285235A0466|85 95|GATA factors
P11285329A0682|6 8|% CI
P11285329A0682|18 27|micromol/L
P11285329A0682|33 37|women
P11285329A0682|39 40|P =
P11286833A0959|5 12|patients
P11286833A0959|21 36|additional cycles
P11286833A0959|39 52|5-fluorouracil
P11286833A0959|56 65|leucovorin
P11286833A0959|68 90|maintenance chemotherapy
P11286833A0959|92 98|RESULTS
P11286833A0959|106 110|males
P11286833A0959|116 122|females
P11286833A0959|128 136|median age
P11286833A0959|141 145|years
P11286833A0959|158 162|years
P11287555A1057|3 16|Delta6CCI virus
P11287555A1057|41 59|replication capacity
P11287555A1057|71 84|infectiousness
P11287555A1057|88 94|CEMx174
P11287555A1057|98 105|MT4 cells
P11287578A1311|0 8|Secretion
P11287578A1311|11 23|interleukin-8
P11287578A1311|25 30|RANTES
P11287578A1311|32 66|macrophage inflammatory protein 1alpha
P11287578A1311|71 106|10-kappaDa IFN-gamma-inducible protein
P11287578A1311|137 149|keratinocytes
P11287578A1311|152 153|E6
P11287579A1084|7 12|mutant
P11287579A1084|14 18|T255A
P11287579A1084|40 45|E4orf6
P11287579A1084|63 86|viral late-gene expression
P11287579A1084|63 76|viral late-gene
P11287611A0802|6 14|PPARgamma
P11287611A0802|40 46|15d-PGJ
P11287611A0802|53 55|PGD
P11287611A0802|62 77|synthetic ligands
P11287611A0802|79 86|BRL49653
P11287611A0802|90 101|troglitazone
P11287611A0802|139 150|cyclin D1 gene
P11287623A0286|24 79|Ras-activated Raf-MEK-extracellular signal-regulated kinase
P11287623A0286|41 43|MEK
P11287623A0286|45 79|extracellular signal-regulated kinase
P11287623A0286|81 83|ERK
P11287623A0286|85 100|signaling pathway
P11287623A0286|138 163|individual integrin subunits
P11287623A0286|148 163|integrin subunits
P11287623A0286|184 197|mouse cell lines
P11287654A0150|0 3|PABP
P11287654A0150|7 20|modular protein
P11287654A0150|30 57|N-terminal RNA-binding domains
P11287654A0150|63 80|extensive C terminus
P11288208A0712|0 7|Children
P11288208A0712|20 50|lower respiratory tract infections
P11288208A0712|53 55|PCP
P11288208A0712|68 72|rates
P11288208A0712|84 96|CD4 cell counts
P11288208A0712|84 86|CD4
P11288208A0712|112 117|months
P11288930A0000|3 21|reproductive effects
P11288930A0000|43 76|4-chloro-2-methylphenoxyacetic acid
P11288930A0000|78 81|MCPA
P11288930A0000|85 88|rats
P11288930A0000|112 122|generations
P11288930A0000|135 140|mating
P11288930A0000|152 157|mating
P11288930A0000|161 169|gestation
P11288930A0000|173 181|lactation
P11289135A0975|0 9|Coexposure
P11289135A0975|12 13|FP
P11289135A0975|33 42|pronounced
P11289135A0975|46 64|sustained activation
P11289135A0975|70 155|mitogen-activated protein kinase kinase/extracellular signal-regulated protein kinase cascade
P11289135A0975|70 105|mitogen-activated protein kinase kinase
P11289135A0975|107 148|extracellular signal-regulated protein kinase
P11289135A0975|161 172|PMA treatment
P11289135A0975|182 191|disruption
P11289135A0975|198 204|pathway
P11289135A0975|210 246|mitogen-activated protein kinase kinase 1
P11289135A0975|210 245|mitogen-activated protein kinase kinase
P11289135A0975|247 260|inhibitor U0126
P11289135A0975|274 285|potentiation
P11289135A0975|288 296|apoptosis
P11289149A0658|8 17|EWS protein
P11289149A0658|28 40|transcription
P11289149A0658|54 87|COOH-terminal transactivation domain
P11289149A0658|93 119|cofactor CREB-binding protein
P11289149A0658|101 119|CREB-binding protein
P11289149A0658|121 123|CBP
P11290415A0288|5 16|present study
P11290415A0288|37 55|ICBP90 gene structure
P11290415A0288|70 96|human placenta genomic library
P11290415A0288|100 110|PCR analysis
P11290906T0000|0 21|Tumor-like accumulation
P11290906T0000|24 34|Tl-201 SPECT
P11290906T0000|37 73|subacute hemorrhagic cerebral infarction
P11291552A0156|0 6|METHODS
P11291552A0156|11 18|patients
P11291552A0156|46 48|MFH
P11292335A0852|18 24|dnaE173
P11292335A0852|27 55|potent mutator mutation specific
P11292335A0852|59 78|sequence substitution
P11292335A0852|87 107|single-base frameshift
P11292335A0852|139 164|hot-spot frameshift mutation
P11292839A0531|3 15|transcription
P11292839A0531|25 30|pol III
P11292839A0531|25 27|pol
P11292839A0531|42 52|same factors
P11292839A0531|58 63|U6 gene
P11292839A0531|71 84|major exception
P11292839A0531|100 107|TATA-box
P11292839A0531|141 159|TATA-binding protein
P11292839A0531|161 170|TBP) mutant
P11292839A0531|161 163|TBP
P11292839A0531|165 170|mutant
P11292839A0531|172 178|TBP-DR2
P11292839A0531|190 201|TBP wild-type
P11292839A0531|190 192|TBP
P11292839A0531|193 201|wild-type
P11292839A0531|203 207|TBPwt
P11292844A0081|0 2|HSF
P11292844A0081|14 19|trimer
P11292844A0081|24 40|additional trimers
P11294895A0292|24 42|spo20(+) gene product
P11294895A0292|24 28|spo20
P11294895A0292|32 42|gene product
P11294895A0292|57 66|homologous
P11294895A0292|69 96|Saccharomyces cerevisiae Sec14
P11294895A0292|92 96|Sec14
P11294895A0292|101 140|major phosphatidylinositol transfer protein
P11294895A0292|106 140|phosphatidylinositol transfer protein
P11294895A0292|150 154|yeast
P11295470A0954|20 40|linkage disequilibrium
P11295470A0954|51 65|polymorphic site
P11295470A0954|71 91|B cell specific promoter
P11295470A0954|107 109|UTR
P11295523A0218|5 11|numbers
P11295523A0218|42 50|mid-1970s
P11295760A1374|0 20|Specimen mass reduction
P11295760A1374|34 43|irradiance
P11295760A1374|54 54|%
P11295760A1374|60 70|initial mass
P11295760A1374|79 82|W/cm
P11296288A1107|18 27|derivative
P11296288A1107|30 37|pCMVJS21
P11296288A1107|39 53|pCMVJS21DeltaGP
P11296288A1107|65 67|gag
P11296288A1107|69 71|pol
P11296288A1107|76 80|orf-x
P11296288A1107|88 96|sequences
P11296288A1107|127 130|foci
P11296442A0565|13 20|tube size
P11296442A0565|32 35|Cole
P11296442A0565|54 60|smaller
P11296442A0565|76 94|appropriate tube size
P11296442A0565|98 123|pediatric cardiac anesthesia
P11296442A0565|146 155|new formula
P11296442A0565|169 176|tube size
P11297419A0894|2 6|F222W
P11297419A0894|8 31|W21F rGST A1-1 double mutant
P11297419A0894|41 63|direct fluorescence probe
P11297419A0894|66 72|changes
P11297419A0894|94 110|C-terminal residue
P11297514A0218|3 23|recessive hos1 mutation
P11297514A0218|12 15|hos1
P11297514A0218|38 46|induction
P11297514A0218|52 74|CBF transcription factors
P11297514A0218|77 90|low temperature
P11297514A0218|106 135|downstream cold-responsive genes
P11297545A0948|0 17|Stable transfection
P11297545A0948|20 32|human CHOP cDNA
P11297545A0948|37 57|mammary carcinoma cells
P11297545A0948|74 77|CHOP
P11297545A0948|94 101|mediator
P11297545A0948|104 128|hGH-stimulated mitogenesis
P11297545A0948|104 106|hGH
P11297545A0948|163 171|apoptosis
P11297545A0948|182 184|hGH
P11297545A0948|188 210|p38 MAPK-dependent manner
P11297866A0484|18 28|I. argentina
P11297866A0484|32 41|I. theezans
P11297866A0484|60 61|BF
P11297866A0484|64 83|intestinal propulsion
P11298326A0677|16 36|duplicated Vkappa genes
P11298326A0677|26 36|Vkappa genes
P11298326A0677|45 61|positive selection
P11298326A0677|67 100|complementarity-determining regions
P11298326A0677|106 120|duplicated genes
P11298326A0677|123 136|point mutations
P11301189A1396|14 33|ubiquitous expression
P11301189A1396|36 38|p19
P11301189A1396|40 44|INK4d
P11301189A1396|84 103|murine B-lineage cells
P11302072A0508|3 9|results
P11302072A0508|18 37|cognitive stimulation
P11302072A0508|62 77|Boston Naming Test
P11302072A0508|82 104|Word List Recognition Task
P11302072A0508|106 125|physical intervention
P11302072A0508|146 168|statistical significance
P11302566A1318|8 26|affective flattening
P11302566A1318|48 74|dopamine receptor sensitivity
P11302566A1318|78 95|psychomotor slowing
P11302704T0000|0 19|Homo-oligomerisation
P11302704T0000|23 41|nuclear localisation
P11302704T0000|44 66|mouse histone deacetylase
P11303027A0954|16 29|complex network
P11303027A0954|32 43|interactions
P11303027A0954|51 57|GTPases
P11303027A0954|63 71|ARF family
P11303027A0954|80 88|effectors
P11303027A0954|111 120|cross-talk
P11303638A0559|4 20|NEU overexpression
P11303638A0559|22 33|nodal control
P11303638A0559|49 49|%
P11303638A0559|54 54|%
P11303638A0559|56 57|p =
P11303890A0996|14 34|blind therapeutic doses
P11303890A0996|36 47|Tg-off values
P11303890A0996|64 71|microg/l
P11305129T0000|0 6|Effects
P11305129T0000|10 20|booster dose
P11305129T0000|23 35|tetanus toxoid
P11305129T0000|41 63|different primary courses
P11305129T0000|66 76|vaccination
P11305129T0000|78 89|implications
P11305129T0000|100 113|immune globulin
P11306101A0000|5 18|RACE techniques
P11306101A0000|51 98|hamster liver 3-hydroxy-hexobarbital dehydrogenases
P11306101A0000|119 132|cyclic alcohols
P11306101A0000|140 162|17beta-hydroxy-steroids
P11306101A0000|166 187|3alpha-hydroxysteroids
P11306463A0383|1 8|mutation
P11306463A0383|14 20|C domain
P11306463A0383|23 24|Rb
P11306463A0383|26 30|L901Q
P11306463A0383|72 93|cdk4/D1 phosphorylation
P11306463A0383|72 75|cdk4
P11306463A0383|77 78|D1
P11306463A0383|107 113|C domain
P11306511A1476|86 94|mdm2 mRNAs
P11306511A1476|105 124|progesterone receptor
P11306845A0168|0 22|Histological examination
P11306845A0168|29 44|lichenoid changes
P11306845A0168|46 73|acantholytic blister formation
P11306845A0168|77 98|apoptotic keratinocytes
P11308851A0333|13 28|response function
P11308851A0333|52 55|GSER
P11308851A0333|67 90|particular frequency range
P11308851A0333|106 123|material parameters
P11308851A0333|133 136|bead
P11308877A0213|20 32|periodic input
P11308877A0213|70 80|input phases
P11308877A0213|83 107|consecutive discharge times
P11308877A0213|113 122|restricted
P11308877A0213|126 144|piecewise continuous
P11308877A0213|146 175|orientation preserving circle map
P11309077A0953|4 10|strains
P11309077A0953|25 28|Camp
P11309077A0953|30 35|jejuni
P11309077A0953|42 47|jejuni
P11309077A0953|72 75|ones
P11309077A0953|78 86|biotype I.
P11309373A0783|0 7|Analysis
P11309373A0783|10 18|mCTR mRNAs
P11309373A0783|42 61|alternative promoters
P11309373A0783|84 95|mCTR isoforms
P11309373A0783|132 150|untranslated regions
P11309373A0783|157 172|different lengths
P11309389A0273|26 36|proteolysis
P11309389A0273|64 104|phorbol ester phorbol 12-myristate 13-acetate
P11309389A0273|106 108|PMA
P11309389A0273|122 144|metalloprotease activity
P11309389A0273|122 136|metalloprotease
P11309389A0273|165 168|GHBP
P11309389A0273|173 232|membrane-associated GHR transmembrane/cytoplasmic domain remnant
P11309389A0273|248 262|down-regulation
P11309389A0273|265 276|GHR abundance
P11309389A0273|280 290|GH signaling
P11309389A0273|280 281|GH
P11309400T0000|0 6|Effects
P11309400T0000|11 31|terminus modifications
P11309400T0000|34 52|mRNA functional decay
P11309400T0000|66 81|protein synthesis
P11309677A0000|1 38|comprehensive neuropsychological battery
P11309677A0000|58 65|veterans
P11309677A0000|70 83|Gulf War Illness
P11309677A0000|85 87|GWI
P11309677A0000|104 116|severe fatigue
P11309677A0000|118 121|GV-F
P11309677A0000|128 142|healthy veterans
P11309677A0000|144 147|GV-H
P11309678A0489|0 31|Reverse transcription-PCR analysis
P11309678A0489|34 37|mRNA
P11309678A0489|42 49|patients
P11309678A0489|74 82|mutations
P11309678A0489|92 107|aberrant splicing
P11310937A0548|0 6|RESULTS
P11310937A0548|8 24|Coronary mortality
P11310937A0548|34 52|median follow-up time
P11310937A0548|57 62|months
P11310937A0548|72 77|higher
P11310937A0548|83 96|highest tertile
P11310937A0548|100 102|CRP
P11310937A0548|106 109|IL-6
P11310937A0548|121 126|higher
P11310937A0548|132 145|highest tertile
P11310937A0548|149 158|fibrinogen
P11310937A0548|162 170|TNF-alpha
P11310937A0548|180 210|respective combined lower tertiles
P11311153T0000|20 40|factor V Leiden mutation
P11311153T0000|46 74|deletion-deletion polymorphism
P11311153T0000|80 106|angiotensin converting enzyme
P11311153T0000|80 90|angiotensin
P11311153T0000|101 106|enzyme
P11311153T0000|109 141|postoperative thromboembolic events
P11311153T0000|151 172|total joint arthroplasty
P11311464A0362|5 13|disorders
P11311464A0362|21 32|low-back pain
P11311464A0362|34 49|saddle anesthesia
P11311464A0362|51 67|bilateral sciatica
P11311464A0362|73 85|motor weakness
P11311464A0362|91 106|lower extremities
P11311464A0362|109 125|chronic paraplegia
P11311464A0362|130 147|bladder dysfunction
P11311480A0079|0 15|Sural nerve biopsy
P11311480A0079|41 51|perineurium
P11311480A0079|53 71|vascular alterations
P11311480A0079|76 103|inflammatory cell infiltration
P11311480A0079|109 119|perineurium
P11311480A0079|124 137|remarkable loss
P11311480A0079|148 168|small myelinated fibers
P11311550A0253|9 33|transcriptional regulation
P11311550A0253|39 50|rat eIF4E gene
P11311550A0253|55 56|kB
P11311550A0253|62 83|rat eIF4E promoter region
P11311550A0253|113 128|specific elements
P11311550A0253|141 153|transcription
P11311550A0253|169 183|primary cultures
P11311550A0253|186 199|rat cardiocytes
P11311550A0253|206 212|murine C
P11311550A0253|216 216|C
P11311550A0253|221 236|myoblast cell line
P11311563A0423|8 15|CCAAT box
P11311563A0423|32 60|heterologous promoter construct
P11311563A0423|62 72|OA induction
P11311563A0423|89 102|intact CCAAT box
P11311687A0231|3 8|JHRLSS
P11311687A0231|22 33|prior studies
P11311687A0231|42 52|RLS severity
P11311687A0231|104 111|measures
P11311687A0231|117 125|morbidity
P11311687A0231|140 142|RLS
P11311909A0938|22 29|aneurysm
P11311909A0938|47 57|proximal end
P11311909A0938|73 86|A1 fenestration
P11311980A1049|0 9|GABA(B)R1g
P11311980A1049|0 3|GABA
P11311980A1049|5 5|B
P11311980A1049|7 9|R1g
P11311980A1049|36 52|peripheral tissues
P11312108A2853|0 3|Raes
P11312108A2853|5 6|P.
P11312120A1311|0 25|NF-kappaB pathway activation
P11312120A1311|0 8|NF-kappaB
P11312120A1311|70 87|classical oncogenes
P11312120A1311|98 104|Bcr/Abl
P11312120A1311|98 100|Bcr
P11312120A1311|102 104|Abl
P11312120A1311|106 108|Ras
P11312120A1311|112 114|Rac
P11312326A0169|7 9|rev
P11312326A0169|14 33|RRE-defective HIV type
P11312326A0169|14 16|RRE
P11312326A0169|27 34|HIV type 1
P11312326A0169|36 40|HIV-1
P11312326A0169|42 55|molecular clone
P11312326A0169|58 83|complementation experiments
P11312326A0169|108 121|rapid isolation
P11312326A0169|124 160|posttranscriptional regulatory elements
P11312326A0169|168 182|mammalian genome
P11312326A0169|205 220|virus replication
P11312584X1846|0 8|Copyright
P11312584X1846|13 25|Academic Press
P11313249T0000|1 61|novel myeloid-restricted zebrafish CCAAT/enhancer-binding protein
P11313249T0000|33 61|CCAAT/enhancer-binding protein
P11313249T0000|67 103|potent transcriptional activation domain
P11313342A0224|25 44|alanine substitutions
P11313342A0224|50 74|active center cleft residues
P11313342A0224|97 108|depurinating
P11313342A0224|112 137|ribosome inhibitory activity
P11313342A0224|140 142|PAP
P11313386A0704|0 18|SH2D1A protein levels
P11313386A0704|0 12|SH2D1A protein
P11313386A0704|36 52|CD40 cross-linking
P11313386A0704|36 39|CD40
P11313386A0704|72 92|B cell receptor ligation
P11313386A0704|72 84|B cell receptor
P11313398A0687|0 20|Cross-linking FcalphaR
P11313398A0687|13 20|FcalphaR
P11313398A0687|23 29|wt-ITAM
P11313398A0687|32 44|IIA-ITAM cells
P11313398A0687|32 39|IIA-ITAM
P11313398A0687|54 93|equivalent PI 3-kinase-dependent activation
P11313398A0687|64 73|PI 3-kinase
P11313398A0687|96 103|PKBalpha
P11313946A0449|0 7|RPM/RGL3
P11313946A0449|0 2|RPM
P11313946A0449|4 7|RGL3
P11313946A0449|17 20|AF-6
P11313946A0449|24 28|Nore1
P11313946A0449|68 78|active M-Ras
P11313946A0449|82 87|p21 Ras
P11313946T0000|1 22|novel potential effector
P11313946T0000|25 29|M-Ras
P11313946T0000|33 38|p21 Ras
P11313946T0000|58 85|p21 Ras-mediated gene induction
P11313946T0000|89 98|cell growth
P11313961A1323|3 6|mice
P11313961A1323|45 61|spontaneous tumors
P11313961A1323|66 73|early age
P11313961A1323|87 95|knock-out
P11313961A1323|97 104|p53(-/-)
P11313961A1323|97 99|p53
P11313961A1323|106 112|strains
P11313961A1323|118 133|defective p53 gene
P11314030A1264|3 9|results
P11314030A1264|24 39|C-terminal region
P11314030A1264|42 44|Crk
P11314030A1264|53 87|negative regulatory elements important
P11314030A1264|95 97|Abl
P11314030A1264|101 126|FAK dependent signal pathways
P11314030A1264|101 103|FAK
P11314030A1264|138 145|paradigm
P11314030A1264|151 170|autoinhibitory region
P11314030A1264|176 204|SH3 linker/C-terminal SH3 domain
P11314046A0000|0 6|Cyclins
P11314046A0000|18 36|pivotal determinants
P11314046A0000|47 66|cell cycle progression
P11314373T0000|0 17|Evidence-based care
P11314373T0000|20 29|new formula
P11314373T0000|35 44|old problem
P11314428A0651|11 32|osteo-retentive ability
P11314428A0651|38 51|hydroxyapatite
P11314428A0651|57 63|sockets
P11314428A0651|103 124|months width differences
P11314428A0651|131 142|canine region
P11314428A0651|144 145|P =
P11314428A0651|152 154|LHS
P11314428A0651|159 160|P =
P11314428A0651|167 169|RHS
P11315633A0920|3 14|cleavage site
P11315633A0920|22 24|VPg
P11315633A0920|28 52|RNA dependent RNA polymerase
P11315633A0920|69 77|E445-T446
P11315633A0920|88 112|amino acid sequence analysis
P11315633A0920|118 128|polyprotein
P11315633A0920|133 154|different sobemoviruses
P11316127A0485|3 8|%SVend
P11316127A0485|11 15|HCM-I
P11316127A0485|44 59|respective values
P11316127A0485|65 70|HCM-II
P11316127A0485|74 86|Control groups
P11317256A0361|9 16|isolates
P11317256A0361|19 31|S. intermedius
P11317256A0361|39 46|isolates
P11317256A0361|49 62|S. constellatus
P11317256A0361|73 73|%
P11317256A0361|83 93|S. anginosus
P11317256A0361|113 119|abscess
P11318363A0085|0 5|DESIGN
P11318363A0085|7 24|Retrospective study
P11318608A0669|0 29|Human brain cDNA library screening
P11318608A0669|35 52|rapid amplification
P11318608A0669|55 58|cDNA
P11318608A0669|70 89|full-length DENTT cDNA
P11318608A0669|102 124|1899-bp open reading frame
P11318608A0669|143 163|633-amino-acid protein
P11318608A0669|172 206|potential nuclear localization signals
P11318608A0669|208 211|NLSs
P11318608A0669|219 236|coiled-coil regions
P11318608A1155|0 11|Transfection
P11318608A1155|14 50|EGFP-tagged DENTT NLS deletion constructs
P11318608A1155|14 17|EGFP
P11318608A1155|25 29|DENTT
P11318608A1155|61 74|bipartite NLS-1
P11318608A1155|94 102|nucleolus
P11319098A0164|5 9|genes
P11319098A0164|17 32|tryptophanyl tRNA
P11319098A0164|37 67|protein translocase component SecE
P11319098A0164|37 54|protein translocase
P11319098A0164|64 67|SecE
P11319098A0164|72 96|antiterminator protein NusG
P11319098A0164|104 123|ribosomal proteins L11
P11319098A0164|127 128|L1
P11319098A0164|141 144|PkwR
P11319098A0164|147 171|putative regulatory protein
P11319098A0164|177 191|LacI-GalR family
P11319098A0164|177 180|LacI
P11319098A0164|182 185|GalR
P11319880A1108|0 8|Rapamycin
P11319880A1108|10 27|FRAP/mTOR inhibitor
P11319880A1108|10 13|FRAP
P11319880A1108|15 18|mTOR
P11319880A1108|36 56|4E-BP1 phosphorylation
P11319880A1108|36 41|4E-BP1
P11319880A1108|65 76|predominance
P11319880A1108|82 86|alpha
P11321187A0355|14 35|seropositive MS patients
P11321187A0355|41 41|%
P11321187A0355|49 68|intrathecal synthesis
P11321187A0355|71 94|C. pneumoniae-specific IgG
P11321187A0355|109 128|seropositive controls
P11321187A0355|133 133|%
P11323411A0505|0 21|Far Western blot analysis
P11323411A0505|38 53|tandem SH2 domains
P11323411A0505|56 59|SHP2
P11323411A0505|66 69|Gab1
P11323411A0505|73 91|specific orientation
P11323411A0505|103 113|N-SH2 domain
P11323411A0505|121 135|phosphotyrosine
P11323411A0505|137 139|Tyr
P11323411A0505|141 141|P
P11323411A0505|154 164|C-SH2 domain
P11323411A0505|172 174|Tyr
P11323411A0505|176 176|P
P11323419T0000|0 15|Molecular cloning
P11323419T0000|17 30|genomic mapping
P11323419T0000|50 72|secretor blood group alpha
P11323419T0000|74 100|1,2)fucosyltransferase genes
P11323419T0000|78 100|fucosyltransferase genes
P11323419T0000|126 147|mouse uterine epithelium
P11323419T0000|151 171|gastrointestinal tract
P11323716A0413|3 12|UBA domains
P11323716A0413|15 19|RAD23
P11323716A0413|23 26|DDI1
P11323716A0413|46 57|interactions
P11324516A0159|14 38|intrathecal administration
P11324516A0159|40 43|i.t.
P11324516A0159|47 71|D2 receptor agonist LY171555
P11324516A0159|47 56|D2 receptor
P11324516A0159|74 104|D1/D2 receptor agonist apomorphine
P11324516A0159|114 126|pain threshold
P11324516A0159|134 151|potentiating effect
P11324516A0159|154 155|AA
P11325195A0661|3 4|R2
P11325195A0661|12 14|MFI
P11325195A0661|25 36|frozen muscle
P11325195A0661|54 57|lamb
P11325195A0661|61 75|pork longissimus
P11325391A0498|8 12|doses
P11325391A0498|15 27|d-amphetamine
P11325391A0498|59 67|saline key
P11325391A0498|77 85|schedules
P11325685A1624|0 30|Intravenous L-carnitine treatment
P11325685A1624|40 68|plasma carnitine concentrations
P11325685A1624|78 100|patient-assessed fatigue
P11325685A1624|127 146|peak exercise capacity
P11325685A1624|149 168|hemodialysis patients
P11325944A0511|0 17|Elevated expression
P11325944A0511|20 34|full-length UhpB
P11325944A0511|40 59|soluble hybrid protein
P11325944A0511|61 66|GST-Bc
P11325944A0511|75 98|glutathione S-transferase
P11325944A0511|100 102|GST
P11325944A0511|114 141|cytoplasmic C-terminal portion
P11325944A0511|144 147|UhpB
P11325944A0511|158 173|complete blockage
P11325944A0511|176 189|uhpT expression
P11325944A0511|176 179|uhpT
P11325944A0511|193 195|uhp
P11327292A0190|4 17|unique location
P11327292A0190|20 40|cavernous malformation
P11327292A0190|64 76|permanent loss
P11327698A0191|14 16|PKC
P11327698A0191|20 40|p44/p42MAPK signalings
P11327698A0191|20 22|p44
P11327698A0191|24 30|p42MAPK
P11327698A0191|58 111|HBx-induced Sp1-mediated IGF-II P4 transcriptional activity
P11327698A0191|58 60|HBx
P11327698A0191|120 132|PKC activation
P11327698A0191|135 137|PMA
P11327698A0191|140 158|PKC expression vector
P11327698A0191|168 185|Sp1 phosphorylation
P11327698A0191|168 170|Sp1
P11327698A0191|189 198|P4 activity
P11327698A0191|201 225|HBx-transfected HepG2 cells
P11327698A0191|231 243|PKC inhibition
P11327698A0191|246 263|PKC inhibitor Go6976
P11327698A0191|246 248|PKC
P11327698A0191|271 288|Sp1 phosphorylation
P11327698A0191|271 273|Sp1
P11327698A0191|290 299|P4 activity
P11327698A0191|304 313|IGF-II mRNA
P11327698A0191|316 340|HBx-transfected HepG2 cells
P11327698A0191|353 362|inhibition
P11327698A0191|365 377|MEK activation
P11327698A0191|365 367|MEK
P11327698A0191|380 384|U0126
P11327698A0191|392 409|Sp1 phosphorylation
P11327698A0191|392 394|Sp1
P11327698A0191|411 420|P4 activity
P11327698A0191|424 433|IGF-II mRNA
P11327698A0191|436 460|HBx-transfected HepG2 cells
P11327858A0087|10 24|novel mechanisms
P11327858A0087|26 28|Arf
P11327858A0087|40 54|oncoprotein Hdm2
P11327858A0087|57 73|negative regulator
P11327858A0087|76 78|p53
P11328699A0000|5 33|free-swimming rotatory test mice
P11328699A0000|112 132|aversive test situation
P11328853A0644|0 10|Examination
P11328853A0644|13 42|various promoter deletion mutants
P11328853A0644|56 59|SF-1
P11328853A0644|74 95|proximal promoter region
P11328853A0644|99 123|upstream promoter sequences
P11331589A0113|3 12|MSL complex
P11331589A0113|27 35|localized
P11331589A0113|41 55|male X chromosome
P11331596A0710|0 3|Prrp
P11331596A0710|27 36|EVH1 domain
P11331596A0710|39 42|Mena
P11331596A0710|51 81|microfilament-associated protein
P11331604A0267|0 4|Srb10
P11331604A0267|8 29|physiological regulator
P11331604A0267|32 44|Gcn4 stability
P11331604A0267|32 35|Gcn4
P11331604A0267|56 70|phosphorylation
P11331604A0267|74 81|turnover
P11331604A0267|84 87|Gcn4
P11331604A0267|103 114|srb10 mutants
P11331613A0827|0 16|Consistent effects
P11331613A0827|19 30|pVHL function
P11331613A0827|19 22|pVHL
P11331613A0827|49 57|mutations
P11331613A0827|68 75|subclass
P11333263A0240|1 9|new intron
P11333263A0240|15 23|base pairs
P11333263A0240|51 76|untranslated leader sequence
P11333263A0240|108 123|promoter activity
P11333268A1521|36 47|interactions
P11333268A1521|50 52|Sos
P11333268A1521|77 83|regions
P11333268A1521|86 88|Ras
P11333268A1521|93 122|distinct functional consequences
P11333268A1521|160 168|anchoring
P11333268A1521|171 173|Ras
P11333268A1521|176 178|Sos
P11333268A1521|219 228|disruption
P11333268A1521|234 255|nucleotide-binding site
P11333268A1521|259 273|GDP dissociation
P11334124A0903|1 23|log-linear dose-response
P11334124A0903|41 55|average increase
P11334124A0903|58 61|FEV1
P11334124A0903|67 67|h
P11334124A0903|69 75|AUC0-6 h
P11334124A0903|80 87|peak FEV1
P11334124A0903|97 105|dose range
P11334124A0903|120 127|Respimat
P11335116A1099|0 19|Bandshift experiments
P11335116A1099|35 40|BmHR3A
P11335116A1099|60 63|RORE
P11335116A1099|65 113|Retinoic acid-related Orphan receptor Response Element
P11335116A1099|120 128|sequences
P11335116A1099|134 142|promoters
P11335116A1099|149 153|genes
P11335116A1099|170 179|direct role
P11335116A1099|183 188|BmHR3A
P11335116A1099|216 225|BmGATAbeta
P11335116A1099|229 236|ESP genes
P11335116A1099|243 256|vitellogenesis
P11335710A0320|11 20|pronounced
P11335710A0320|30 41|initial phase
P11335710A0320|44 56|Erk activation
P11335710A0320|44 46|Erk
P11336211A0132|3 17|iterative method
P11336211A0132|28 36|Bengtsson
P11336211A0132|38 41|Appl
P11336698A0075|15 18|Rsc3
P11336698A0075|22 26|Rsc30
P11336698A0075|29 43|novel components
P11336698A0075|49 81|essential yeast remodeler RSC complex
P11336698A0075|58 81|yeast remodeler RSC complex
P11337859A0651|3 5|COD
P11337859A0651|9 21|color removals
P11337859A0651|40 40|%
P11337859A0651|45 49|FeCl3
P11337859A0651|62 72|coagulation
P11337859A0651|74 80|dosages
P11337859A0651|83 101|two-step coagulation
P11337859A0651|119 123|mol/L
P11337859A0651|143 186|ferrous hydrogen peroxide oxidation pretreatment
P11337859A0651|190 199|H2O2 dosage
P11337859A0651|206 210|mol/L
P11340048A0432|17 31|high correlation
P11340048A0432|42 54|flux densities
P11340048A0432|76 85|new sensors
P11340048A0432|87 108|significant differences
P11340048A0432|114 126|flux densities
P11340048A0432|137 153|duplicated sensors
P11340080A0096|10 17|proteins
P11340080A0096|28 46|checkpoint signaling
P11340080A0096|48 51|Rad1
P11340080A0096|53 56|Hus1
P11340080A0096|61 64|Rad9
P11340080A0096|91 109|immunoprecipitation
P11340080A0096|113 134|yeast two-hybrid studies
P11340085A0211|47 53|regions
P11340085A0211|101 112|coactivators
P11340085A0211|127 143|amino acid sequence
P11340085A0211|146 155|C/EBPalpha
P11340085A0211|160 175|different species
P11340085A0211|177 180|frog
P11340085A0211|221 227|regions
P11340085A0211|229 235|CR1-CR4
P11340085A0211|229 231|CR1
P11340085A0211|233 235|CR4
P11340085A0211|246 266|transactivation domain
P11340516A0509|0 8|Tolerance
P11340516A0509|11 16|ADAL-2
P11340516A0509|35 46|Vicryl suture
P11340516A0509|61 66|ADAL-2
P11340516A0509|86 94|Tisuacryl
P11340525A0737|5 12|patients
P11340525A0737|19 25|regimen
P11340525A0737|36 49|study end points
P11340525A0737|60 60|%
P11340525A0737|68 75|regimen A
P11340525A0737|86 86|%
P11340525A0737|94 101|regimen B
P11340525A0737|115 115|%
P11340525A0737|123 130|regimen C
P11340525A0737|137 161|treatment success criterion
P11341349T0000|0 14|Early indicators
P11341349T0000|29 56|breast cancer screening program
P11341349T0000|60 74|low-income women
P11341405A0146|6 15|POPULATION
P11341405A0146|17 19|MCB
P11341405A0146|25 40|racing Greyhounds
P11341405A0146|56 71|reasons unrelated
P11341405A0146|74 89|MCB abnormalities
P11341405A1154|0 10|CONCLUSIONS
P11341405A1154|14 30|CLINICAL RELEVANCE
P11341405A1154|41 57|cortical thickness
P11341405A1154|61 79|geometric properties
P11341405A1154|82 91|left MCB-IV
P11341405A1154|96 96|V
P11341405A1154|99 108|Greyhounds
P11341405A1154|122 136|altered turnover
P11341405A1154|153 159|osteons
P11341405A1154|165 179|dorsal quadrants
P11341405A1154|182 188|left MCB
P11341405A1154|193 222|site-specific adaptive responses
P11341405A1154|237 259|asymmetric cyclic loading
P11341405A1154|271 276|racing
P11341405A1154|279 292|circular tracks
P11341828A0744|0 5|Linear
P11341828A0744|14 35|nine-residue D-peptides
P11341828A0744|50 69|pocket-binding domain
P11341828A0744|75 89|cyclic molecules
P11342479A0430|0 6|METHODS
P11342479A0430|10 16|RESULTS
P11342479A0430|18 36|Palmaz-Schatz stents
P11342479A0430|41 50|dip-coated
P11342479A0430|55 64|paclitaxel
P11342479A0430|80 94|microgram/stent
P11342479A0430|98 106|immersion
P11342479A0430|109 127|ethanolic paclitaxel
P11342479A0430|131 141|evaporation
P11342479A0430|147 153|solvent
P11344530A0320|0 10|Percentages
P11344530A0320|24 31|overload
P11344530A0320|35 47|dilution tests
P11344530A0320|67 67|%
P11345435A0199|17 29|RNA subdomains
P11345435A0199|41 42|P3
P11345435A0199|81 101|nucleolar localization
P11345445A0533|2 18|Cd-spiked OECD soil
P11345445A0533|20 35|internal Cd levels
P11345445A0533|57 80|external Cd concentrations
P11345445A0533|92 102|springtails
P11345445A0533|113 131|fixed internal levels
P11345445A0533|134 135|Cu
P11345445A0533|139 140|Zn
P11345445A0533|153 172|spiked concentrations
P11347201X0001|0 16|Nutritional status
P11347201X0001|19 24|adults
P11347201X0001|42 56|traditional diet
P11347201X0001|58 67|BACKGROUND
P11347201X0001|69 77|Plant food
P11347201X0001|83 92|vitamin B12
P11347201X0001|94 101|vitamin D
P11347201X0001|105 138|higher n-3 polyunsaturated fatty acids
P11348318A0940|14 20|adjunct
P11348318A0940|23 33|mammography
P11348318A0940|41 48|patients
P11348318A0940|69 80|dense breasts
P11348318A0940|87 102|characterization
P11348318A0940|105 118|palpable masses
P11349796A0950|0 11|Measurements
P11349796A0950|40 56|traumatic exposure
P11349796A0950|58 59|D0
P11349796A0950|67 70|days
P11349796A0950|80 95|first measurement
P11349796A0950|97 98|D3
P11349796A0950|111 114|days
P11349796A0950|121 123|D30
P11350038A0459|28 37|distal half
P11350038A0459|39 42|Stem
P11350038A0459|59 82|base-paired stem structure
P11350038A0459|93 98|hY RNAs
P11350038A0459|109 120|critical role
P11350038A0459|126 138|export process
P11350165A1606|0 6|Changes
P11350165A1606|12 21|DB sequence
P11350165A1606|51 63|stem structure
P11350165A1606|69 81|drastic losses
P11350165A1606|84 104|translation efficiency
P11350175A0173|22 28|members
P11350175A0173|35 47|protein family
P11350175A0173|59 73|prolyl isomerase
P11350175A0173|77 93|chaperone activity
P11350812A0829|0 9|Inhibition
P11350812A0829|15 34|Raf-1 target ERK kinase
P11350812A0829|36 38|MEK
P11350812A0829|67 74|Rp-cAMPS
P11350812A0829|79 102|PKI-induced ERK activation
P11350812A0829|79 81|PKI
P11350812A0829|90 92|ERK
P11350812A0829|104 127|caldesmon phosphorylation
P11350812A0829|104 112|caldesmon
P11350812A0829|132 151|stress fiber formation
P11350957A0457|0 8|PACAP mRNA
P11350957A0457|29 44|most human tissues
P11350957A0457|59 63|cells
P11350957A0457|65 69|PACAP
P11350957A0457|96 104|cytoplasm
P11350982A0560|16 28|first evidence
P11350982A0560|48 67|GCN1-GCN2 interaction
P11350982A0560|48 51|GCN1
P11350982A0560|53 56|GCN2
P11350982A0560|70 79|activation
P11350982A0560|82 85|GCN2
P11352423A0084|3 19|radial forearm flap
P11352423A0084|49 62|lateral arm flap
P11352423A0084|71 74|flap
P11352423A0084|85 101|certain situations
P11352663A0138|15 36|nontumorigenic Ad5 cells
P11352663A0138|56 62|high due
P11352663A0138|65 81|negligible binding
P11352663A0138|84 90|COUP-TF
P11352663A0138|94 106|strong binding
P11352663A0138|109 117|NF-kappaB
P11352671A0492|17 31|reverse genetics
P11352671A0492|48 63|nucleotide change
P11352671A0492|65 67|UCU
P11352671A0492|70 72|ACU
P11352671A0492|76 94|immediate downstream
P11352671A0492|100 114|RNA-editing site
P11352671A0492|120 124|V gene
P11352671A0492|130 149|full-length hPIV2 cDNA
P11352671A0492|169 185|infectious viruses
P11352671A0492|187 192|rPIV2V
P11352671A0492|204 207|cDNA
P11353392A1127|3 12|frameshift
P11353392A1127|24 28|ADEx2
P11353392A1127|49 69|regular coding sequence
P11353392A1127|80 107|loss-of-function ASIP mutation
P11353770A0085|14 27|latter activity
P11353770A0085|47 48|S3
P11353770A0085|57 85|vigorous N-glycosylase activity
P11353770A0085|65 77|N-glycosylase
P11353770A0085|101 120|8-oxoguanine residues
P11353770A0085|136 148|baseless sites
P11353770A0085|156 161|places
P11353774A0255|27 42|characterization
P11353774A0255|48 64|forkhead homologue
P11353774A0255|67 82|rhabdomyosarcoma
P11353774A0255|84 87|FKHR
P11353774A0255|119 169|hepatocyte nuclear factor 3/forkhead homeotic gene family
P11353774A0255|119 142|hepatocyte nuclear factor 3
P11353774A0255|174 195|nuclear hormone receptor
P11353774A0255|197 198|NR
P11353774A0255|200 218|intermediary protein
P11354406A1373|11 31|CSF outflow conductance
P11354406A1373|46 67|intracranial compliance
P11354406A1373|85 107|pathological ICP waveform
P11354975A0850|1 10|new species
P11354975A0850|13 23|Euspondylus
P11354975A0850|62 70|bromeliad
P11354975A0850|81 86|El Humo
P11354975A0850|88 92|Sucre
P11354975A0850|94 114|northeastern Venezuela
P11355576A1125|3 9|cyclins
P11355576A1125|30 32|CDK
P11355576A1125|46 60|phosphorylation
P11355576A1125|69 78|inhibition
P11355576A1125|85 106|tumor suppressor protein
P11355576A1125|108 110|pRb
P11355576A1125|112 132|pRb controls commitment
P11355576A1125|112 114|pRb
P11355576A1125|150 151|G1
P11355576A1125|154 159|S phase
P11355576A1125|202 224|E2F transcription factors
P11355576A1125|239 255|cell proliferation
P11355615A0766|0 18|Additional education
P11355615A0766|47 62|further direction
P11355615A0766|81 93|incorporation
P11355668T0000|0 24|Proliferative vasculopathy
P11355668T0000|28 47|cutaneous hemorrhages
P11355668T0000|50 64|porcine neonates
P11355668T0000|80 98|porcine reproductive
P11355668T0000|102 125|respiratory syndrome virus
P11356214A0794|15 22|hardness
P11356214A0794|33 50|composite specimens
P11356214A0794|67 91|Knoop hardness measurements
P11356214A0794|108 121|bottom surfaces
P11356214A0794|124 137|resin specimens
P11356214A0794|145 154|Teflon mold
P11356214A0794|158 171|same dimensions
P11356214A0794|177 182|cavity
P11356214A0794|193 198|dentin
P11356716A0372|2 18|18-kb genomic clone
P11356716A0372|28 36|sequences
P11356716A0372|54 66|GHS-R variants
P11356835A0000|0 22|Saccharomyces cerevisiae
P11356835A0000|33 49|regulatory network
P11356835A0000|57 70|general control
P11356835A0000|95 111|sufficient amounts
P11356835A0000|114 130|protein precursors
P11356835A0000|137 155|amino acid starvation
P11356853A0429|2 10|Ka13 cells
P11356853A0429|12 15|CoCl
P11356853A0429|42 63|luciferase reporter gene
P11356853A0429|82 113|15-kilobase pair mouse ho-1 promoter
P11356853A0429|115 122|pHO15luc
P11356853A0554|0 15|Mutation analyses
P11356853A0554|29 54|cobalt-responsive sequences
P11356853A0554|60 82|stress-response elements
P11356853A0554|84 88|StREs
P11356853A0873|0 6|Members
P11356853A0873|12 26|AP-1 superfamily
P11356853A0873|29 54|basic-leucine zipper factors
P11356853A0873|64 67|StRE
P11357063A0138|0 11|Descriptions
P11357063A0138|18 22|locus
P11357063A0138|59 90|relevant molecular genetic features
P11357063A0138|93 104|other species
P11357063A0138|106 119|homologous loci
P11357063A0138|132 160|single-copy equid LH/CGbeta gene
P11357063A0138|148 149|LH
P11357063A0138|151 156|CGbeta
P11357063A0138|167 202|primate LHbeta-CGbeta gene cluster locus
P11357063A0138|174 179|LHbeta
P11357063A0138|181 186|CGbeta
P11357063A1053|7 34|consensus mammalian LHbeta gene
P11357063A1053|16 34|mammalian LHbeta gene
P11357063A1053|42 55|flanking region
P11357063A1053|61 75|gpLH/CGbeta gene
P11357063A1053|61 64|gpLH
P11357063A1053|66 71|CGbeta
P11357063A1053|85 102|single TATA sequence
P11357063A1053|105 114|bp upstream
P11357063A1053|120 140|translation start codon
P11358801A1046|15 24|situations
P11358801A1046|27 41|separated breaks
P11358801A1046|43 56|NHEJ deficiency
P11358801A1046|64 84|genomic rearrangements
P11358801A1046|101 118|chromosomal studies
P11358958A0878|0 9|Expression
P11358958A0878|12 21|human RACK1
P11358958A0878|41 68|E1A-mediated growth inhibition
P11358958A0878|41 43|E1A
P11358958A0878|71 74|HF7c
P11358958A0878|86 100|human tumor cells
P11358958A0878|105 124|E1A-induced apoptosis
P11358958A0878|105 107|E1A
P11358962A0344|0 4|Foxp1
P11358962A0344|8 12|Foxp2
P11358962A0344|27 36|high levels
P11358962A0344|55 57|E12
P11358962A0344|62 77|mouse development
P11358962A0344|82 106|Foxp2 expression restricted
P11358962A0344|82 86|Foxp2
P11358962A0344|112 127|airway epithelium
P11359568T0000|0 16|Molecular analysis
P11359568T0000|22 43|pRA2 partitioning region
P11359568T0000|45 48|ParB
P11359568T0000|62 79|parAB transcription
P11359568T0000|62 66|parAB
P11359568T0000|89 108|nucleoprotein complex
P11359568T0000|116 135|plasmid partition site
P11359568T0000|137 140|parS
P11359827T0000|0 12|Immunological
P11359827T0000|16 42|biochemical characterization
P11359827T0000|45 76|streptococcal pyrogenic exotoxins I
P11359827T0000|45 75|streptococcal pyrogenic exotoxins
P11359827T0000|80 80|J
P11359827T0000|82 86|SPE-I
P11359827T0000|90 94|SPE-J
P11359907A0099|0 23|Several dozen HIF-1 targets
P11359907A0099|12 23|HIF-1 targets
P11359907A0099|57 87|vascular endothelial growth factor
P11359907A0099|89 92|VEGF
P11360190A0178|24 26|Tax
P11360190A0178|34 53|cell cycle progression
P11360190A0178|58 67|G0/G1 phase
P11360190A0178|70 70|S
P11360190A0178|74 83|G2/M phases
P11360190A0178|86 103|human T-cell line Kit
P11360190A0178|107 111|cells
P11361338A0093|0 33|Most yeast peroxisomal matrix proteins
P11361338A0093|42 82|type 1C-terminal peroxisomal targeting signal
P11361338A0093|84 87|PTS1
P11361338A0093|104 116|tripeptide SKL
P11361338A0093|120 138|conservative variant
P11361338A0447|8 22|PEX5-TPR domains
P11361338A0447|8 11|PEX5
P11361338A0447|44 51|nematode
P11361338A0447|69 95|TPR-less yeast Pex5p construct
P11361338A0447|82 86|Pex5p
P11361338A0447|106 119|Pex5p chimaeras
P11361338A0447|106 110|Pex5p
P11361493T0000|0 4|HIV-1
P11361493T0000|8 32|hepatitis B virus infections
P11361493T0000|35 45|adolescents
P11361493T0000|54 71|security institutes
P11361493T0000|74 84|Buenos Aires
P11367523A1684|0 24|Immunofixation experiments
P11367523A1684|27 29|C4A
P11367523A1684|33 35|C4B
P11367523A1684|50 58|allotypes
P11367523A1684|67 73|classes
P11367523A1684|76 83|proteins
P11367523A2624|8 18|C4B proteins
P11367523A2624|28 48|monomodular short genes
P11367523A2624|66 85|higher concentrations
P11367523A2624|99 110|long C4A genes
P11368363A0129|25 44|transcription factors
P11368363A0129|65 84|human myeloperoxidase
P11368363A0129|86 88|MPO
P11368363A0129|90 97|promoter
P11368363A0129|107 115|first time
P11368363A0129|139 142|cDNA
P11368363A0129|146 155|genomic DNA
P11368363A0129|159 167|human HBP1
P11368363A0129|169 193|HMG-Box containing protein 1
P11368363A0129|169 192|HMG-Box containing protein
P11368363A0129|208 224|high mobility group
P11368363A0129|227 256|non-histone chromosomal proteins
P11368363A1103|3 22|human protein sequence
P11368363A1103|32 63|putative DNA-binding domain similar
P11368363A1103|76 82|rat HBP1
P11368363A1103|91 98|homology
P11368363A1103|106 115|activation
P11368363A1103|119 134|repressor domains
P11368363A1103|162 171|rat protein
P11368787A0180|0 30|Promoter transcriptional activity
P11368787A0180|66 83|human annexin A5 gene
P11368787A0180|89 90|bp
P11368787A0180|122 160|several discrete transcription start points
P11368901A0327|21 37|mouse BCNT proteins
P11368901A0327|48 57|repeat unit
P11368901A0327|68 87|RTE-1-derived portion
P11368901A0327|68 72|RTE-1
P11368911T0000|0 22|Molecular identification
P11368911T0000|25 29|smg-4
P11368911T0000|42 57|mRNA surveillance
P11368911T0000|60 68|C. elegans
P11368914T0071|19 23|exons
P11368914T0071|33 53|complement C3 gene locus
P11368914T0071|62 70|alternate
P11368914T0071|79 89|proximal ORF
P11368914T0071|108 128|bidirectional promoter
P11369066A1210|0 10|CONCLUSIONS
P11369066A1210|18 20|MMF
P11369066A1210|23 49|potent topical corticosteroid
P11369066A1210|55 68|emollient cream
P11369066A1210|114 127|emollient cream
P11369066A1210|143 166|acute radiation dermatitis
P11369106A0428|0 13|Recent advances
P11369106A0428|27 40|volatile sulfur
P11369106A0428|52 73|ecological interactions
P11369106A0428|77 99|transformation processes
P11369106A0428|107 124|planktonic food webs
P11369410A0949|3 17|first hypothesis
P11369410A0949|44 62|stimulus differences
P11369410A0949|74 82|behaviour
P11369410A0949|99 127|successful attentive processing
P11369410A0949|130 147|normal participants
P11369453A1083|20 33|protein binding
P11369453A1083|58 73|peptide treatment
P11369700A0074|0 2|CSR
P11369700A0074|15 40|specific heavy chain isotypes
P11369700A0074|43 51|cytokines
P11369700A0074|55 69|B cell activators
P11369700A0074|80 92|transcription
P11369700A0074|100 111|unrearranged
P11369700A0074|115 122|germline
P11369700A0074|124 125|GL
P11369700A0074|128 128|C
P11369700A0074|130 130|H
P11369700A0074|132 142|region genes
P11369700A0616|6 15|manuscript
P11369700A0616|36 49|tandem Ets sites
P11369700A0616|42 49|Ets sites
P11369700A0616|55 74|mouse GL alpha promoter
P11369700A0616|82 106|transcription factors Elf-1
P11369700A0616|110 113|PU.1
P11369700A0616|158 179|luciferase reporter gene
P11369700A0616|191 205|GL alpha promoter
P11369759A0605|0 3|Cell
P11370174A0447|3 26|mean serum creatinine level
P11370174A0447|54 59|months
P11370174A0447|77 79|MMF
P11371115A0962|18 25|biopsies
P11371115A0962|35 46|seropositive
P11371115A0962|50 59|HBs antigen
P11371115A0962|67 67|%
P11371115A0962|89 91|MGN
P11371115A0962|94 104|MPGN pattern
P11371160A0193|16 36|nucleotides equivalent
P11371160A0193|39 53|base-pair C1-G72
P11371160A0193|57 76|discriminator base A73
P11371160A0193|82 105|amino acid-acceptor branch
P11371160A0854|20 41|canonical anticodon loop
P11371160A0854|47 67|tyrosine anticodon acts
P11371160A0854|72 77|anchor
P11371160A0854|81 96|TyrRS interaction
P11371160A0854|81 85|TyrRS
P11371160A0854|107 122|better efficiency
P11371160A0854|125 136|tyrosylation
P11371343A0125|15 23|cell cycle
P11371343A0125|25 32|separase
P11371343A0125|39 46|inactive
P11371343A0125|60 76|inhibitory protein
P11371343A0125|83 89|securin
P11371417A0744|0 20|Mechanical ventilation
P11371417A0744|23 34|control lungs
P11371417A0744|46 54|% decrease
P11371417A0744|57 71|chord compliance
P11371417A0744|85 100|lung lavage levels
P11371417A0744|103 121|tumor necrosis factor
P11371417A0744|123 132|TNF)-alpha
P11371417A0744|123 125|TNF
P11371417A0744|128 132|alpha
P11371417A0744|143 147|pg/ml
P11371417A0744|150 170|interleukin (IL)-1beta
P11371417A0744|150 160|interleukin
P11371417A0744|162 163|IL
P11371417A0744|167 170|beta
P11371417A0744|181 185|pg/ml
P11371417A0744|191 221|macrophage inflammatory protein-2
P11371417A0744|223 227|MIP-2
P11371417A0744|239 243|pg/ml
P11371417A0744|259 267|low levels
P11371417A0744|270 278|cytokines
P11371417A0744|289 306|preventilation data
P11371417A0744|333 357|surfactant large aggregates
P11371417A0744|359 360|LA
P11372882A1143|0 8|Maternal p
P11372882A1143|10 10|p
P11372882A1143|12 14|DDE
P11372882A1143|18 31|beta-HCH levels
P11372882A1143|54 66|newborn levels
P11372882A1143|71 76|levels
P11372882A1143|79 82|PCBs
P11372959A1447|0 25|Multiple regression analysis
P11372959A1447|47 69|long-term abiotic factors
P11372959A1447|73 88|nymphal abundance
P11372959A1447|91 103|positive sites
P11372959A1447|110 125|high relationship
P11372959A1447|127 140|R2 coefficients
P11372959A1447|150 164|habitat category
P11372959A1447|180 180|%
P11372959A1447|197 209|tick abundance
P11373277A0812|27 50|adenoviral oncoprotein E1A
P11373277A0812|60 72|transcription
P11373277A0812|80 102|endogenous AP-2alpha gene
P11373277A0812|90 102|AP-2alpha gene
P11373277A0812|124 150|transcriptional derepression
P11373277A0812|156 172|AP-2alpha promoter
P11373277A0812|188 190|E1A
P11373277A0812|198 220|AP-2rep corepressor CtBP1
P11373277A0812|198 204|AP-2rep
P11373277A0812|216 220|CtBP1
P11374051A0437|0 20|Additional factors such
P11374051A0437|23 33|advanced age
P11374051A0437|35 48|concomitant use
P11374051A0437|51 65|corticosteroids
P11374051A0437|68 81|anticoagulants
P11374051A0437|88 105|ulcer complications
P11374051A0437|109 125|co-morbid diseases
P11374051A0437|153 160|bleeding
P11374559A0103|0 10|SERS spectra
P11374559A0103|25 41|vacuum evaporation
P11374559A0103|45 51|casting
P11374559A0103|54 58|p-NTP
P11374559A0103|63 79|silver island films
P11374559A0103|92 115|colloidal silver solutions
P11374866X0914|0 8|Copyright
P11374866X0914|13 25|Academic Press
P11375392T0000|3 14|core promoter
P11375392T0000|17 42|human thioredoxin reductase 1
P11375392T0000|17 41|human thioredoxin reductase
P11375392T0000|44 50|cloning
P11375392T0000|52 74|transcriptional activity
P11375392T0000|79 83|Oct-1
P11375392T0000|85 87|Sp1
P11375392T0000|92 101|Sp3 binding
P11375392T0000|92 94|Sp3
P11375392T0000|109 133|housekeeping-type promoter
P11375392T0000|140 167|AU-rich element-regulated gene
P11376007A0584|14 40|phosphorylation-induced loss
P11376007A0584|46 66|protein kinase activity
P11376007A0584|46 58|protein kinase
P11376007A0584|69 74|DNA-PK
P11376007A0584|111 126|catalytic subunit
P11376007A0584|135 153|protein phosphatase 1
P11376007A0584|135 152|protein phosphatase
P11376007A0584|156 175|protein phosphatase 2A
P11376007A0584|177 180|PP2A
P11376007A0584|193 204|reactivation
P11376007A0584|219 251|potent protein phosphatase inhibitor
P11376007A0584|225 242|protein phosphatase
P11376007A0584|253 263|microcystin
P11376119A0346|3 11|first exon
P11376119A0346|13 18|exon 1A
P11376119A0346|44 61|untranslated region
P11376119A0346|67 75|GHR 1A mRNA
P11376119A0346|85 86|bp
P11376119A0346|99 102|exon
P11376119A0346|109 115|GHR gene
P11376134A1506|5 15|corrections
P11376134A1506|28 36|sequences
P11376134A1506|58 76|transcription factor
P11376134A1506|84 88|sites
P11376165T0000|0 2|FLP
P11376165T0000|6 27|Cre recombinase function
P11376165T0000|6 19|Cre recombinase
P11376165T0000|30 43|Xenopus embryos
P11376279A0000|9 55|three-station three-dimensional magnetic resonance
P11376279A0000|57 58|MR
P11376279A0000|60 70|angiography
P11376279A0000|76 91|lower extremities
P11376279A0000|96 121|segmented volume acquisition
P11376687A0344|1 28|single nucleotide polymorphism
P11376687A0344|30 32|SNP
P11376687A0344|36 39|exon
P11376687A0344|70 72|SNP
P11376687A0344|74 84|GTG83/ATG83
P11376687A0344|96 116|additional alternative
P11376687A0344|125 127|AUG
P11376687A0344|130 144|B-type MTH1 mRNAs
P11376687A0344|156 176|fourth MTH1 polypeptide
P11376687A0344|162 176|MTH1 polypeptide
P11376687A0344|178 180|p26
P11376687A0344|196 233|additional mitochondrial targeting signal
P11376946A0000|3 17|previous studies
P11376946A0000|31 35|SHP-1
P11376946A0000|38 84|SH2 domain-containing protein-tyrosine phosphatase
P11376946A0000|106 110|cells
P11376946A0000|113 133|hematopoietic lineages
P11376946A0000|144 169|many non-hematopoietic cells
P11376946A0000|189 222|alternative tissue-specific promoter
P11376946A0000|200 222|tissue-specific promoter
P11376946A0000|224 225|P1
P11377975A0898|13 36|Arg1-expressing COS1 cells
P11377975A0898|45 73|significant proteinase activity
P11377975A0898|94 103|substrates
P11377975A0898|118 133|acidic conditions
P11378898A0164|0 3|ORF1
P11378898A0164|9 10|bp
P11378898A0164|12 23|EMBL databank
P11378898A0164|25 36|Accession No.
P11379106A0372|43 67|deammonification processes
P11379106A0372|71 104|continuous flow moving-bed pilot plant
P11380028A0000|44 50|methods
P11380028A0000|54 63|estimation
P11380028A0000|66 77|Technetium Tc
P11380028A0000|82 86|99mTc
P11380028A0000|89 97|pentetate
P11380028A0000|101 118|orthoiodohippurate
P11380028A0000|124 131|131I-OIH
P11380028A0000|133 147|plasma clearance
P11380028A0000|150 153|dogs
P11380028A0000|157 160|cats
P11380028A0000|170 181|blood samples
P11380370A0000|23 33|skin lesions
P11380370A0000|44 49|Kaposi
P11380370A0000|52 58|sarcoma
P11380370A0000|60 61|KS
P11380837A1505|0 12|Interventions
P11380837A1505|25 41|specific mediators
P11380837A1505|45 53|processes
P11380837A1505|86 101|significant human
P11380837A1505|105 117|economic costs
P11380837A1505|120 144|vascular access dysfunction
P11381094A0797|11 17|stonin 2
P11381094A0797|11 16|stonin
P11381094A0797|28 37|C2B domains
P11381094A0797|40 53|synaptotagmins
P11382701A0688|4 21|partial transection
P11382701A0688|33 43|vasopressin
P11382701A0688|69 78|larger rise
P11382701A0688|81 105|plasma sodium concentration
P11382948A0793|13 33|USPIO-enhanced MRI data
P11382948A0793|59 84|tumor microvessel properties
P11382948A0793|91 107|breast cancer model
P11382948A0793|109 133|microvascular permeability
P11382948A0793|150 154|USPIO
P11382948A0793|183 192|tumor grade
P11383860A0661|3 8|images
P11383860A0661|34 49|urinary excretion
P11383860A0661|52 69|99mTc ciprofloxacin
P11383860A0661|80 90|absent brain
P11383860A0661|99 114|bone marrow uptake
P11383860A0661|118 131|low liver uptake
P11383860A0661|135 143|excretion
P11384225A0634|12 29|expression cassette
P11384225A0634|53 75|green fluorescent protein
P11384225A0634|77 79|GFP
P11384225A0634|100 144|EAV-specific transcription-regulating sequences
P11384229A1669|11 22|N63S mutation
P11384229A1669|28 49|wild-type VP5 background
P11384229A1669|28 39|wild-type VP5
P11384229A1669|87 112|beta-galactosidase activity
P11384229A1669|87 104|beta-galactosidase
P11384229A1669|143 153|PR7 mutation
P11384576A1132|11 26|severe vision loss
P11384576A1132|40 78|interferon alfa-2b-associated retinopathy
P11384576A1132|40 56|interferon alfa-2b
P11384880A0719|17 25|induction
P11384880A0719|28 45|3beta-HSD type 1 gene
P11384880A0719|28 40|3beta-HSD type
P11384880A0719|42 55|gene expression
P11384880A0719|81 109|ZR-75-1 human breast cancer cells
P11385840A1684|12 23|RTC algorithm
P11385840A1684|30 50|urban wastewater system
P11385840A1684|67 76|parameters
P11385840A1684|101 133|various global optimization routines
P11387208T0000|0 33|SKP1-SnRK protein kinase interactions
P11387208T0000|0 3|SKP1
P11387208T0000|5 8|SnRK
P11387208T0000|41 58|proteasomal binding
P11387208T0000|62 84|plant SCF ubiquitin ligase
P11387208T0000|67 84|SCF ubiquitin ligase
P11387351A0092|0 7|PATIENTS
P11387351A0092|11 17|METHODS
P11387351A0092|26 29|June
P11387351A0092|37 44|December
P11387351A0092|67 104|nucleoside analog 2-chlorodeoxyadenosine
P11387351A0092|106 110|2-CDA
P11387351A0092|116 123|children
P11387351A0092|128 137|primary AML
P11387351A0092|143 150|children
P11387351A0092|155 166|secondary AML
P11387351A0092|169 191|myelodysplastic syndrome
P11387351A0092|193 195|MDS
P11387940A0647|3 10|severity
P11387940A0647|13 29|pathologic changes
P11387940A0647|57 66|percussion
P11387950X0001|0 16|Experimental study
P11387950X0001|19 28|ta chengchi
P11387950X0001|33 41|decoction
P11387950X0001|54 63|lung injury
P11387950X0001|70 97|acute necrotizing pancreatitis
P11387950X0001|102 111|objectives
P11387950X0001|142 148|changes
P11387950X0001|151 171|leukocyte adhesiveness
P11387950X0001|175 193|tumor necrosis factor
P11387950X0001|195 197|TNF
P11387950X0001|204 213|early stage
P11387950X0001|216 243|acute necrotizing pancreatitis
P11387950X0001|245 247|ANP
P11387950X0001|283 289|changes
P11387950X0001|292 301|lung injury
P11387950X0001|304 306|ANP
P11387950X0001|324 340|prohibitive effect
P11387950X0001|343 352|ta chengchi
P11387950X0001|357 365|Decoction
P11387950X0001|368 384|leukocyte adhesion
P11387950X0001|388 399|TNF secretion
P11387950X0001|388 390|TNF
P11389077A0000|10 43|receptor-mediated signaling pathways
P11389077A0000|74 104|negative extracellular regulators
P11389085A0290|0 6|TT cells
P11389085A0290|9 24|human MTC cell line
P11389085A0290|35 46|MEN 2A type RET
P11389085A0290|72 81|active RelA
P11389085A0290|78 81|RelA
P11389085A0290|83 85|p65
P11389085A0290|92 98|nucleus
P11389085A1032|0 9|Inhibition
P11389085A1032|12 40|constitutive NF-kappaB activity
P11389085A1032|24 32|NF-kappaB
P11389085A1032|50 58|cell death
P11389085A1032|61 67|TT cells
P11389085A1032|77 90|focus formation
P11389085A1032|100 113|oncogenic forms
P11389085A1032|116 118|RET
P11389085A1032|121 131|NIH 3T3 cells
P11390395A1018|13 28|HMGI-C expression
P11390395A1018|13 18|HMGI-C
P11390395A1018|53 76|PIAS3-mediated repression
P11390395A1018|53 57|PIAS3
P11390395A1018|79 108|STAT3-dependent transactivation
P11390395A1018|79 83|STAT3
P11390581A1203|1 14|central finding
P11390581A1203|37 51|GC-rich sequence
P11390581A1203|64 71|Cp region
P11390581A1203|90 112|oriPI-EBNA1-independent
P11390581A1203|96 100|EBNA1
P11390581A1203|121 149|oriPI-EBNA1-dependent activity
P11390581A1203|127 131|EBNA1
P11390581A1203|155 162|promoter
P11390650A0562|0 26|Additional deletion mutations
P11390650A0562|40 68|67-amino-acid functional domain
P11390650A0562|78 95|proline-rich region
P11390650A0562|98 103|SLP-76
P11390650A0562|125 133|P-1 domain
P11390663A1400|8 16|profiling
P11390663A1400|20 34|gcn4Delta mutant
P11390663A1400|46 81|alternative induction pathway operating
P11390663A1400|84 103|many Gcn4p target genes
P11390663A1400|106 127|histidine-starved cells
P11390684A1170|0 7|Evidence
P11390684A1170|13 33|Northern hybridization
P11390684A1170|47 60|jadM expression
P11390684A1170|47 50|jadM
P11390684A1170|77 95|jadomycin B synthesis
P11390684A1170|77 86|jadomycin B
P11391303A0807|5 7|LHR
P11391303A0807|9 13|R-LHR
P11391303A0807|26 42|best interobserver
P11391303A0807|46 73|intraobserver reproducibility
P11391303A1023|0 10|CONCLUSIONS
P11391303A1023|15 25|methodology
P11391303A1023|28 41|LHR measurement
P11391303A1023|68 87|clinical contribution
P11391303A1023|90 115|Tl-201 lung uptake evaluation
P11391531A1157|0 7|Mutation
P11391531A1157|13 25|NF-kappaB site
P11391531A1157|31 43|Mdr1b promoter
P11391531A1157|55 63|induction
P11391531A1157|66 74|TNF-alpha
P11391793A0856|14 30|genomic complexity
P11391793A0856|60 65|tumors
P11391793A0856|79 89|physical map
P11391793A0856|99 101|SRO
P11391793A0856|127 169|bacteriophage P1-derived artificial chromosome
P11391793A0856|171 173|PAC
P11391793A0856|175 180|clones
P11392306T0000|0 13|Online teaching
P11392306T0000|24 33|techniques
P11392772A0182|19 31|biotechnology
P11392772A0182|37 42|plants
P11392772A0182|60 77|surface storm waters
P11392772A0182|85 106|industrial zone Telychka
P11392772A0182|118 121|Kyiv
P11392772A0182|144 152|petroleum
P11392772A0182|172 178|Dnieper
P11392772A0182|206 210|times
P11393463A0274|0 3|Data
P11393463A0274|21 47|undergraduate student samples
P11393463A0274|50 65|self-report group
P11393463A0274|67 68|n =
P11393463A0274|84 103|NEO-PI-R self-ratings
P11393463A0274|107 115|occasions
P11393463A0274|132 145|14-day interval
P11393463A0274|151 164|informant group
P11393463A0274|166 167|n =
P11393463A0274|183 189|ratings
P11393463A0274|192 208|well-known friends
P11393463A0274|211 219|relatives
P11393463A0274|223 231|occasions
P11393463A0274|245 257|month interval
P11393791A1153|0 19|Northern blot analysis
P11393791A1153|22 25|RNAs
P11393791A1153|39 50|mouse tissues
P11393791A1153|62 66|Atp6i
P11393791A1153|93 103|osteoclasts
P11393791A1153|112 132|predominant expression
P11393791A1153|147 190|reverse-transcription polymerase chain reaction
P11393791A1153|147 182|reverse-transcription polymerase chain
P11393791A1153|192 197|RT-PCR
P11393791A1153|199 203|assay
P11393791A1153|207 233|immunohistochemical analysis
P11395469A1373|7 14|mutation
P11395469A1373|27 32|motifs
P11395469A1373|66 69|sid1
P11395469A1373|81 102|differential regulation
P11395469A1373|105 108|sid2
P11396685A0477|12 18|results
P11396685A0477|27 29|DTD
P11396685A0477|75 85|small amount
P11396685A0477|110 111|mg
P11396685A0477|124 146|quantitative information
P11396685A0477|155 164|main groups
P11396685A0477|167 182|compounds present
P11396685A0477|185 191|cheeses
P11397652A0381|0 9|Guidelines
P11397652A0381|24 41|routine spiral assay
P11397652A0381|58 79|alternative test methods
P11397652A0381|108 128|technical difficulties
P11397652A0381|136 163|restricted sample availability
P11397652A0381|165 179|sample viscosity
P11397652A0381|182 191|volatility
P11397652A0381|193 196|etc.
P11398134A1565|13 19|obesity
P11398134A1565|21 33|alcohol intake
P11398134A1565|38 60|multimetabolic disorders
P11398134A1565|79 99|independent predictors
P11398134A1565|119 131|hyperuricemia
P11398899A1183|0 3|Fans
P11398899A1183|6 12|tunnels
P11398899A1183|16 26|open windows
P11398899A1183|29 48|aboveground locations
P11398899A1183|87 107|high PH3 concentrations
P11398899A1183|110 122|enclosed areas
P11399064T0000|0 13|Autoregulation
P11399064T0000|21 37|different pathways
P11399064T0000|47 78|CCAAT/enhancer binding protein beta
P11399064T0000|80 88|C/EBP beta
P11399064T0000|90 102|transcription
P11399834T0000|3 11|first case
P11399834T0000|14 30|HCV seroconversion
P11399834T0000|33 40|Portugal
P11399834T0000|63 77|HCV NAT screening
P11400644A0435|15 27|uncertainties
P11400644A0435|33 41|estimates
P11400644A0435|45 61|individual sources
P11400644A0435|66 80|90th percentiles
P11400644A0435|83 96|PCDD/F releases
P11400644A0435|117 124|g I-TEQ/y
P11401105T0000|0 9|Gabapentin
P11401105T0000|13 34|opiod-related myoclonus
P11401105T0000|37 50|cancer patients
P11401611A1703|0 10|CONCLUSIONS
P11401611A1703|15 27|meta-analysis
P11401611A1703|40 55|controlled trials
P11401611A1703|58 60|HRT
P11401611A1703|80 99|significant reduction
P11401611A1703|102 122|nonvertebral fractures
P11402674T0000|0 28|Newcastle disease antibody titre
P11402674T0000|42 66|serum calcium concentration
P11403173A0192|10 17|patients
P11403173A0192|22 42|malignant brain tumours
P11403663A0359|0 6|Net lift
P11403663A0359|10 21|combined drag
P11403663A0359|30 37|bearings
P11403663A0359|43 58|4-bladed impeller
P11403663A0359|74 84|predictions
P11403663A0359|92 100|2-D theory
P11403719A1257|3 9|results
P11403719A1257|22 25|Gab1
P11403719A1257|50 64|egr-1 expression
P11403719A1257|50 54|egr-1
P11403719A1257|76 82|insulin
P11404010A0235|11 19|triplexes
P11404016A1922|3 14|co-existence
P11404016A1922|17 25|TE domains
P11404016A1922|32 42|modular PKSs
P11404016A1922|39 42|PKSs
P11404016A1922|72 88|monofunctional TEs
P11404016A1922|86 88|TEs
P11404016A1922|90 94|TE IIs
P11404016A1922|123 139|modular polyketide
P11404016A1922|143 171|non-ribosomal peptide synthases
P11404016A1922|173 176|NRPS
P11404019A0532|26 41|mGSTM2 regulation
P11404019A0532|26 31|mGSTM2
P11404019A0532|73 86|promoter region
P11404312A0660|10 17|pmol/24 h
P11404312A0660|19 19|P
P11404312A0660|37 44|elevated
P11406007A0292|0 16|SELECTION CRITERIA
P11406007A0292|21 46|randomised controlled trials
P11406007A0292|56 59|IUSs
P11406007A0292|64 73|other forms
P11406007A0292|76 99|reversible contraceptives
P11406007A0292|114 135|pre-determined outcomes
P11406007A0292|138 142|women
P11406007A0292|145 161|reproductive years
P11406025A0204|0 9|OBJECTIVES
P11406025A0204|73 85|acceptability
P11406025A0204|91 99|diaphragm
P11406025A0204|114 123|spermicide
P11406277A0598|28 35|elements
P11406277A0598|50 65|promoter activity
P11406277A0598|80 105|reporter expression activity
P11406277A0598|108 115|segments
P11406277A0598|126 134|mutations
P11406277A0598|142 149|elements
P11406277A0598|167 191|parent Hlx promoter sequence
P11406642A0792|12 16|cases
P11406642A0792|43 47|genes
P11406642A0792|51 56|absent
P11407289A1507|0 10|CONCLUSIONS
P11407289A1507|12 49|Ketamine-induced dissociative anesthesia
P11407289A1507|70 85|elevated BIS index
P11407289A1507|106 114|thiamylal
P11407289A1507|135 167|other conventional anesthetic agents
P11407448A0815|3 9|results
P11407448A0815|49 56|patients
P11407448A0815|67 95|free jejunum flap reconstruction
P11407448A0815|101 144|hypopharyngo-esophageal tract voice restoration
P11407448A0815|172 186|voice prosthesis
P11407448A0815|195 229|secondary tracheo-esophageal puncture
P11407448A0815|242 264|intensive speech training
P11407650A0661|0 12|Hypercalcemia
P11407650A0661|27 55|elevated serum PTH concentration
P11407650A0661|40 42|PTH
P11407650A0661|66 91|primary hyperparathyroidism
P11407650A0661|103 112|BC patients
P11407650A0661|115 115|%
P11407650A0661|128 139|healthy women
P11407650A0661|142 149|patients
P11407650A0661|154 166|thyroid cancer
P11408099A0518|0 7|Positive
P11408099A0518|11 33|significant correlations
P11408099A0518|53 57|weeks
P11408099A0518|72 79|Se levels
P11408099A0518|82 87|kidney
P11408099A0518|89 90|r=
P11408099A0518|97 98|P=
P11408099A0518|114 115|r=
P11408099A0518|122 123|P=
P11408338A1686|21 23|PSP
P11408338A1686|71 82|misdiagnosed
P11408338A1686|103 107|cases
P11408338A1686|133 144|neurologists
P11408575A0000|35 41|mitosis
P11408575A0000|50 59|activation
P11408575A0000|65 91|cyclin-dependent kinase Cdc28
P11408575A0000|97 103|cyclin B
P11408575A0000|105 107|Clb
P11408591A0000|29 38|hyaluronan
P11408591A0000|40 41|HA
P11408591A0000|57 68|cell motility
P11408591A0000|71 75|cells
P11408591A0000|89 100|v-src mutants
P11408604A1440|3 9|results
P11408604A1440|22 22|D
P11408604A1440|29 29|D
P11408604A1440|31 32|2L
P11408604A1440|34 42|receptors
P11408604A1440|54 69|ERK kinase cascade
P11408604A1440|54 62|ERK kinase
P11408604A1440|87 95|signaling
P11408604A1440|101 112|PDGF receptor
P11408604A1440|127 146|subsequent activation
P11408604A1440|149 154|ERK1/2
P11408604A1440|157 164|pathways
P11408604A1440|183 204|receptor tyrosine kinase
P11408774X0893|0 7|Karger AG
P11408774X0893|9 13|Basel
P11409425A0000|12 24|plasma samples
P11409425A0000|32 39|patients
P11409425A0000|45 61|National Institute
P11409425A0000|64 83|Neurological Diseases
P11409425A0000|87 92|Stroke
P11409425A0000|94 98|NINDS
P11409425A0000|100 125|tissue plasminogen activator
P11409425A0000|127 130|t-PA
P11409425A0000|132 142|Stroke Trial
P11409425A0000|176 196|apolipoprotein (Apo) E2
P11409425A0000|176 189|apolipoprotein
P11409425A0000|191 193|Apo
P11409425A0000|195 196|E2
P11409425A0000|201 214|Apo E4 phenotype
P11409425A0000|219 234|favorable outcome
P11409425A0000|236 241|months
P11409425A0000|263 285|intracerebral hemorrhage
P11409425A0000|303 324|intravenous t-PA therapy
P11410110A0190|0 3|NIRS
P11410110A0190|17 39|quantitative measurement
P11410110A0190|42 48|muscle O
P11410110A0190|64 65|mV
P11410110A0190|67 67|O
P11410110A0190|75 90|forearm blood flow
P11410110A0190|92 94|FBF
P11410110A0190|100 114|healthy subjects
P11410563A0363|2 23|dominant clinical factor
P11410563A0363|42 67|multiple regression analysis
P11410563A0363|82 96|body surface area
P11410563A0363|98 106|valve size
P11410563A0363|108 128|shop order fracture rate
P11410563A0363|133 151|manufacturing period
P11410563A0363|154 164|risk factors
P11410563A0363|168 170|OSF
P11410664A0963|37 70|human breast carcinoma MDA-MB231 cells
P11410664A0963|85 92|human MPG
P11410664A0963|115 127|up-regulation
P11410664A0963|133 143|initial step
P11410664A0963|146 148|BER
P11410664A0963|176 183|other BER
P11410664A0963|181 183|BER
P11410664A0963|185 189|hOGG1
P11410664A0963|193 199|APE/ref
P11410664A0963|205 218|direct reversal
P11410664A0963|220 223|MGMT
P11410664A0963|225 240|repair activities
P11410679A0000|3 21|selective alteration
P11410679A0000|27 32|genome
P11410679A0000|38 51|Cre recombinase
P11410679A0000|63 75|rearrangement
P11410679A0000|78 82|genes
P11410679A0000|92 114|LOX recognition sequences
P11410679A0000|137 161|separate genetic constructs
P11410679A0000|164 168|trans
P11410679A0000|183 185|cre
P11410679A0000|233 240|LOX sites
P11411198A0711|0 15|Colorectal cancer
P11411198A0711|54 66|Ashkenazi Jews
P11411198A0711|98 104|ovarian
P11411198A0711|106 115|pancreatic
P11411198A0711|119 131|stomach cancer
P11411198A0711|136 146|non-Hodgkin
P11411198A0711|149 156|lymphoma
P11411623T0000|0 8|Influence
P11411623T0000|11 28|compression therapy
P11411623T0000|31 38|symptoms
P11411623T0000|48 63|soft tissue injury
P11411623T0000|68 91|maximal eccentric exercise
P11411961A0735|0 24|Keratoconjunctivitis sicca
P11411961A0735|37 60|common ocular complication
P11411961A0735|67 74|children
P11411961A0735|79 81|JRA
P11411961A0735|108 127|comprehensive battery
P11411961A0735|130 134|tests
P11413148A0573|0 14|STAT5A mutations
P11413148A0573|0 5|STAT5A
P11413148A0573|20 31|Src homology 2
P11413148A0573|20 30|Src homology
P11413148A0573|33 35|SH2
P11413148A0573|40 49|SH3 domains
P11413148A0573|64 98|BTK-mediated tyrosine phosphorylation
P11413148A0573|64 66|BTK
P11413277A1121|13 31|primary chemotherapy
P11413277A1121|39 49|high dose MTX
P11413277A1121|53 57|ara-C
P11413277A1121|77 81|PCNSL
P11413310A0148|0 5|RANTES
P11413310A0148|20 29|activation
P11413310A0148|39 44|T-cell
P11413310A0148|79 89|CC chemokine
P11413310A0148|115 123|monocytes
P11413310A0148|125 135|lymphocytes
P11413310A0148|140 150|eosinophils
P11413310A0148|155 170|cell types present
P11413310A0148|176 201|lung inflammatory infiltrate
P11413310A0148|211 222|RSV infection
P11413319A0000|0 12|Reovirus mRNAs
P11413319A0000|43 51|host cells
P11413319A0000|73 91|polyadenylated tails
P11413641A0373|0 7|Analyses
P11413641A0373|20 31|scale matters
P11413641A0373|57 67|quadrat area
P11413760A0000|0 9|Myasthenia
P11413760A0000|20 36|autoimmune disease
P11413760A0000|65 74|antibodies
P11413760A0000|85 96|ACh receptors
P11413760A0000|102 121|neuromuscular synapse
P11414754X1099|0 8|Copyright
P11414754X1099|13 25|Academic Press
P11415633A1253|8 15|postural
P11415633A1253|19 27|force data
P11415633A1253|38 58|3-D biomechanical model
P11415633A1253|63 90|lumbosacral spinal compression
P11415952A0369|0 5|Angina
P11415952A0369|7 7|Q
P11415952A0369|9 19|persistence
P11415952A0369|26 43|marked associations
P11415952A0369|48 75|previous myocardial infarction
P11415952A0369|86 91|angina
P11415952A0369|93 117|electrocardiogram ischemia
P11415952A0369|122 162|subsequent major ischemic heart disease events
P11415952A0369|167 168|Q5
P11415958A0000|5 14|past decade
P11415958A0000|29 44|enormous advances
P11415958A0000|55 73|Bayesian methodology
P11415958A0000|87 103|epidemiologic data
P11415958A0000|119 141|many practical advantages
P11415958A0000|147 162|Bayesian approach
P11416012A1982|8 41|more specific PKA-dependent mediation
P11416012A1982|20 22|PKA
P11416012A1982|44 45|LH
P11416012A1982|70 82|hormonal drive
P11416012A1982|87 97|LDL receptor
P11416012A1982|109 110|bp
P11416012A1982|112 126|reporter plasmid
P11416012A1982|148 194|full-sequence rabbit muscle protein kinase inhibitor
P11416012A1982|148 160|full-sequence
P11416012A1982|196 198|PKI
P11416012A1982|200 207|minigene
P11416012A1982|231 254|Rous sarcoma virus promoter
P11416012A2511|16 29|convergent role
P11416012A2511|35 62|insulin/IGF-I effector pathway
P11416012A2511|35 41|insulin
P11416012A2511|43 47|IGF-I
P11416012A2511|72 92|bihormonal stimulation
P11416012A2511|95 123|LDL receptor promoter expression
P11416012A2511|95 113|LDL receptor promoter
P11416012A2511|136 156|granulosa-luteal cells
P11416012A2511|176 178|min
P11416012A2511|186 203|specific inhibitors
P11416012A2511|206 232|phophatidylinositol 3-kinase
P11416012A2511|234 243|wortmannin
P11416012A2511|248 249|nM
P11416012A2511|254 255|LY
P11416012A2511|265 270|microM
P11416012A2511|277 312|mitogen-activated protein kinase kinase
P11416012A2511|314 315|PD
P11416012A2511|324 329|microM
P11416012A2511|332 336|U0126
P11416012A2511|340 345|microM
P11416012A2511|361 378|inactive derivative
P11416012A2511|380 384|U0124
P11416012A2511|388 393|microM
P11416012T0000|0 33|Concerted transcriptional activation
P11416012T0000|39 71|low density lipoprotein receptor gene
P11416012T0000|74 80|insulin
P11416012T0000|84 101|luteinizing hormone
P11416012T0000|112 139|porcine granulosa-luteal cells
P11416012T0000|141 159|possible convergence
P11416012T0000|162 174|protein kinase
P11416012T0000|177 204|phosphatidylinositol 3-kinase
P11416012T0000|209 255|mitogen-activated protein kinase signaling pathways
P11416012T0000|209 238|mitogen-activated protein kinase
P11416132A1351|5 11|studies
P11416132A1351|27 50|site-specific recognition
P11416132A1351|56 61|bxd PRE
P11416132A1351|64 64|d
P11416132A1351|66 67|GA
P11416132A1351|70 70|n
P11416132A1351|72 94|repeat binding activities
P11416132A1351|103 124|PcG-dependent silencing
P11416132A1351|103 105|PcG
P11416144A1324|3 10|findings
P11416144A1324|39 44|ZBP-89
P11416144A1324|54 70|cell proliferation
P11416144A1324|82 95|novel mechanism
P11416144A1324|106 115|p53 protein
P11416260A0000|1 18|computerized method
P11416260A0000|35 44|focal point
P11416260A0000|47 64|electrical activity
P11416260A0000|80 99|parkinsonian patients
P11416260A0000|117 160|on-line quantitative physiological data analysis
P11416393A0000|4 13|modalities
P11416393A0000|16 41|nonpharmacologic approaches
P11416393A0000|68 88|lifestyle modification
P11416393A0000|101 130|arterial blood pressure elevation
P11416393A0000|134 148|weight reduction
P11416393A0000|151 165|ideal body weight
P11416393A0000|187 198|hypertension
P11416393A0000|207 236|overall cardiovascular morbidity
P11416393A0000|252 275|dietary sodium restriction
P11416393A0000|287 287|g
P11416393A0000|300 308|assurance
P11416393A0000|328 343|arterial pressure
P11416393A0000|367 372|dosage
P11416393A0000|376 382|numbers
P11416393A0000|395 415|antihypertensive drugs
P11416393A0000|419 428|moderation
P11416393A0000|431 448|alcohol consumption
P11416393A0000|460 464|ounce
P11416393A0000|473 502|regular isotonic exercise program
P11416393A0000|509 517|cessation
P11416393A0000|520 537|tobacco consumption
P11416650T0000|8 27|Systolic Hypertension
P11416650T0000|31 36|Update
P11416737T0000|0 4|Ga-67
P11416737T0000|8 25|Tl-201 scintigraphy
P11416737T0000|28 53|extramedullary plasmacytoma
P11416737T0000|56 65|case report
P11416879A1589|0 23|Arterial blood gas tensions
P11416879A1589|44 59|ventilation modes
P11418130A0499|11 33|homologous loxP sequences
P11418130A0499|54 78|Cre-mediated recombination
P11418662A0917|3 19|N-terminal portion
P11418662A0917|22 26|Notch
P11418662A0917|28 29|IC
P11418662A0917|40 52|p50 DNA binding
P11418662A0917|40 42|p50
P11418662A0917|82 91|p50 subunit
P11418662A0917|96 98|p65
P11418662A0917|101 109|NF-kappaB
P11419938T0000|0 20|Conformational changes
P11419938T0000|26 54|ferric uptake regulation protein
P11419938T0000|59 73|metal activation
P11419938T0000|77 86|DNA binding
P11419938T0000|88 100|first evidence
P11419938T0000|103 122|structural homologies
P11419938T0000|130 153|diphtheria toxin repressor
P11420612A0303|3 12|complement
P11420612A0303|15 32|genome-wide mapping
P11420612A0303|36 52|sequencing efforts
P11420612A0303|82 93|detailed maps
P11420612A0303|97 108|sequence data
P11420612A0303|112 126|specific regions
P11422200A0000|0 34|Granulocyte colony-stimulating factor
P11422200A0000|36 40|G-CSF
P11422200A0000|86 102|defence mechanisms
P11422200A0000|121 137|different microbes
P11422757A0737|5 15|individuals
P11422757A0737|25 31|changes
P11422757A0737|58 66|ACR levels
P11422757A0737|58 60|ACR
P11422757A0737|69 76|baseline
P11423991A1393|17 31|toxic p53 mutants
P11423991A1393|22 31|p53 mutants
P11423991A1393|34 38|yeast
P11423991A1393|50 65|novel p53 variants
P11423991A1393|55 65|p53 variants
P11423991A1393|93 95|p53
P11423991A1393|105 121|cellular responses
P11423991A1393|137 160|p53-based cancer therapies
P11423991A1393|137 139|p53
P11424992A0712|17 36|psychiatric diagnoses
P11424992A0712|85 102|biological criteria
P11425076A0364|28 45|physiological flows
P11425076A0364|62 66|alpha
P11425076A0364|85 94|high values
P11425076A0364|100 113|Reynolds number
P11425076A0364|123 143|non-negligible inertia
P11425076A0364|161 185|perturbation theory results
P11425076A0364|203 222|numerical integration
P11425076A0364|228 236|full model
P11425877A1026|0 4|Cells
P11425877A1026|12 15|p116
P11425877A1026|24 37|striking defect
P11425877A1026|59 82|macropinocytic structures
P11425877A1026|85 104|concomitant reduction
P11425877A1026|116 136|fluid phase pinocytosis
P11425877A1026|139 157|significant decrease
P11425877A1026|175 196|chemotactic aggregation
P11425877A1026|212 233|cellular F-actin content
P11427329A1077|16 20|FPS-R
P11427329A1077|24 30|further
P11427329A1077|42 67|strong positive correlations
P11427329A1077|75 77|VAS
P11427329A1077|79 80|r=
P11427329A1077|86 87|N=
P11427329A1077|97 99|CAS
P11427329A1077|101 102|r=
P11427329A1077|108 109|N=
P11427329A1077|119 132|clinical sample
P11427611A0000|3 16|susceptibility
P11427611A0000|19 38|Aspergillus fumigatus
P11427611A0000|41 53|mulundocandin
P11427611A0000|57 81|echinocandin-like compound
P11427611A0000|86 106|other antifungal agents
P11427611A0000|123 139|National Committee
P11427611A0000|143 169|Clinical Laboratory Standards
P11427611A0000|171 175|NCCLS
P11427611A0000|177 187|M38-P method
P11427611A0000|190 196|2,3-bis
P11427611A0000|198 228|2-methoxy-4-nitro-5-sulfophenyl
P11427611A0000|235 246|phenyl-amino
P11427611A0000|248 255|carbonyl
P11427611A0000|259 280|H-tetrazolium hydroxide
P11427611A0000|282 284|XTT
P11427611A0000|292 308|colorimetric assay
P11427611A0000|328 349|morphologic alterations
P11427611A0000|352 361|microscopy
P11428276A0352|3 5|Van
P11428276A0352|9 13|Hoeve
P11428276A0352|16 30|syndrome lesions
P11428276A0352|55 68|low calcium salt
P11428276A0352|72 87|apparent increase
P11428276A0352|90 99|phosphates
P11428283A0228|1 17|5-month-old infant
P11428283A0228|22 48|persistent congenital stridor
P11428283A0228|52 75|acute respiratory distress
P11428435A0446|0 5|DESIGN
P11428435A0446|8 31|retrospective chart review
P11428435A0446|39 46|patients
P11428435A0446|57 74|surgical procedures
P11428435A0446|80 92|period January
P11428435A0446|99 106|December
P11428487T0000|0 17|Pulmonary vein varix
P11428487T0000|35 64|bilateral pulmonary vein stenosis
P11428897A0318|0 21|Biochemical experiments
P11428897A0318|35 38|CopG
P11428897A0318|68 76|target DNA
P11428897A0318|79 88|low protein
P11428897A0318|90 98|DNA ratios
P11428897A0318|124 135|helical turns
P11428897A0318|141 148|same face
P11428897A0318|154 164|double helix
P11428897A0318|171 180|directions
P11428897A0318|188 201|inverted repeat
P11428897A0318|220 236|CopG primary target
P11428897A0318|220 223|CopG
P11429702A0917|24 46|serum-starved conditions
P11429702A0917|48 53|KMS-11
P11429702A0917|57 66|OPM-2 cells
P11429702A0917|74 90|appreciable levels
P11429702A0917|107 118|FGFR3 mutants
P11429702A0917|130 151|constitutive activation
P11429702A0917|157 178|Y373C and K650E receptors
P11429702A0917|157 161|Y373C
P11429702A0917|165 178|K650E receptors
P11429702A0917|196 205|aFGF ligand
P11429702A0917|232 254|receptor phosphorylation
P11430042A0000|19 40|Stille coupling reaction
P11430042A0000|59 102|1-butyl-3-methylimidazolium tetrafluoroborate
P11430042A0000|104 110|BMIM BF4
P11430042A0000|114 140|room-temperature ionic liquid
P11430042A0000|142 145|RTIL
P11430976X0000|0 12|Special issues
P11430976X0000|25 36|biosynthesis
P11430976X0000|39 59|woody plant biopolymers
P11430976X0000|63 79|related substances
P11431348A0000|0 11|Interactions
P11431348A0000|22 46|checkpoint abrogator UCN-01
P11431348A0000|41 46|UCN-01
P11431348A0000|50 81|several pharmacological inhibitors
P11431348A0000|87 116|mitogen-activated protein kinase
P11431348A0000|118 128|MAPK) kinase
P11431348A0000|118 121|MAPK
P11431348A0000|123 128|kinase
P11431348A0000|130 132|MEK
P11431348A0000|135 145|MAPK pathway
P11431348A0000|135 138|MAPK
P11431348A0000|174 195|human leukemia cell lines
P11431472A0540|0 17|Low affinity binding
P11431472A0540|20 28|Rab6A-GTP
P11431472A0540|45 45|K
P11431472A0540|47 47|d
P11431472A0540|49 49|=
P11431472A0540|52 57|microm
P11431472A0540|67 71|Rab1B
P11431472A0540|87 87|A
P11431857A0186|3 10|students
P11431857A0186|17 38|abnormal urine screening
P11431857A0186|51 59|first time
P11431857A0186|69 87|second urine analysis
P11431857A0186|94 97|days
P11431857A0186|115 135|abnormal urine analysis
P11432112A0000|0 6|PURPOSE
P11432112A0000|42 60|first embryo cleavage
P11432112A0000|62 64|FEC
P11432112A0000|71 71|h
P11432112A0000|77 106|intracytoplasmic sperm injection
P11432112A0000|108 111|ICSI
P11432112A0000|116 124|parameter
P11432112A0000|131 152|embryo selection process
P11432748T0000|0 9|Regulation
P11432748T0000|12 42|laminin beta2 chain gene expression
P11432748T0000|12 32|laminin beta2 chain gene
P11432748T0000|45 64|human cancer cell lines
P11432776A0421|0 7|Northern
P11432776A0421|11 29|Western blot analyses
P11432776A0421|46 50|Graf2
P11432776A0421|64 77|several tissues
P11432776A0421|86 102|highest expression
P11432776A0421|105 118|skeletal muscle
P11433014A0683|25 34|nucleosome
P11433014A0683|37 42|fusion
P11433014A0683|45 58|core histone H2A
P11433014A0683|61 63|H2B
P11433014A0683|68 82|non-histone tail
P11433014A0683|68 78|non-histone
P11433014A0683|90 92|MCB
P11433014A0683|124 140|endogenous protein
P11433018A0756|20 38|proper direct binding
P11433018A0756|41 45|Nhp2p
P11433018A0756|48 59|H/ACA snoRNAs
P11433018A0756|86 97|H/ACA snoRNPs
P11433018A0756|134 143|components
P11433024A0260|0 9|Telomerase
P11433024A0260|13 36|ribonucleoprotein complex
P11433024A0260|52 63|telomeric DNA
P11433024A0260|68 78|chromosomes
P11433024A0260|87 98|RNA component
P11433024A0260|101 108|template
P11433379A0000|0 2|SIT
P11433379A0000|4 46|SHP2-interacting transmembrane adaptor protein
P11433379A0000|69 95|transmembrane adaptor protein
P11433379A0000|115 125|lymphocytes
P11434084A0508|11 20|patients DD
P11434084A0508|40 54|microlatex tests
P11434084A0508|57 65|Tinaquant
P11434084A0508|69 77|BC d-dimer
P11435428A0000|0 28|Cytosolic acetyl-CoA synthetase
P11435428A0000|30 35|AceCS1
P11435428A0000|46 52|acetate
P11435428A0000|64 68|cells
P11435428A0000|73 82|acetyl-CoA
P11435428A0000|86 99|lipid synthesis
P11435517A0396|0 19|Ileal digestibilities
P11435517A0396|22 23|DM
P11435517A0396|25 26|OM
P11435517A0396|28 29|CP
P11435517A0396|31 47|total dietary fiber
P11435517A0396|49 51|TDF
P11435517A0396|60 70|gross energy
P11435517A0396|72 73|GE
P11435517A0396|85 85|P
P11435517A0396|95 98|dogs
P11435517A0396|102 106|diets
P11435517A0396|117 133|supplemental fiber
P11435517A0396|146 149|dogs
P11435517A0396|156 166|control diet
P11435560A1322|29 38|HFV R region
P11435560A1322|48 54|nucleus
P11435560A1322|66 80|cytoplasmic fate
P11435560A1322|83 95|target HFV mRNA
P11435578A0760|5 8|TxRE
P11435578A0760|16 43|cyclic AMP-responsive elements
P11435578A0760|45 47|CRE
P11435578A0760|69 76|TGACGTCA
P11435578A0760|116 126|viral strain
P11435578A0760|133 140|AGACGTCA
P11435578A0760|142 149|TGACGGCA
P11435578A0760|151 158|TGACCTCA
P11435578A2231|20 33|reconstitution
P11435578A2231|37 48|consensus CRE
P11435578A2231|59 72|21-bp enhancers
P11435578A2231|82 88|binding
P11435578A2231|91 106|CREB/ATF proteins
P11435578A2231|91 94|CREB
P11435578A2231|96 106|ATF proteins
P11435578A2231|119 133|basal repression
P11435578A2231|136 160|LTR-directed transcription
P11435605A0587|0 23|Site-directed mutagenesis
P11435605A0587|26 28|CAR
P11435605A0587|41 56|CAR residues Leu73
P11435605A0587|60 65|Lys121
P11435605A0587|72 77|Lys123
P11435605A0587|81 103|critical contact residues
P11435605A0587|109 113|Tyr80
P11435605A0587|117 121|Tyr83
P11435605A0587|152 169|binding interaction
P11435605A0587|177 179|Ad5
P11435605A0587|181 183|Ad9
P11435605A0587|185 188|Ad12
P11435605A0587|193 207|Ad41L fiber knobs
P11435688A0262|4 12|subfamily
P11435688A0262|15 19|genes
P11435688A0262|28 50|single ATP-binding domain
P11435688A0262|34 50|ATP-binding domain
P11435688A0262|56 65|N-terminus
P11435688A0262|70 88|single C-terminal set
P11435688A0262|91 111|transmembrane segments
P11435983T0000|0 8|Tolerance
P11435983T0000|11 30|renal transplantation
P11435983T0000|36 86|allogeneic bone marrow transplantation-6-year follow-up
P11437439A0201|3 18|promoter activity
P11437439A0201|24 37|proximal region
P11437439A0201|50 59|restricted
P11437439A0201|63 68|subset
P11437439A0201|71 83|prestalk cells
P11437660A1219|0 11|Substitution
P11437660A1219|14 27|serine residues
P11437660A1219|33 42|C-terminus
P11437660A1219|62 81|phosphorylation sites
P11437660A1219|111 123|transcription
P11437660A1219|127 137|replication
P11438651A1365|5 27|replication fork movement
P11438651A1365|32 34|HML
P11438651A1365|44 55|silent origin
P11438651A1365|63 71|competent
P11438651A1365|75 95|replication initiation
P11438651A1365|116 120|Orc2p
P11438651A1365|137 156|replication initiator
P11438654A1237|5 12|findings
P11438654A1237|27 37|adapter Gab1
P11438654A1237|34 37|Gab1
P11438654A1237|49 62|c-Met signaling
P11438654A1237|49 53|c-Met
P11438654A1237|70 73|PI3K
P11438654A1237|83 111|c-Akt/Pak1 cell survival pathway
P11438654A1237|89 92|Pak1
P11438666A0555|13 29|novel mouse protein
P11438666A0555|18 29|mouse protein
P11438666A0555|31 33|TAF
P11438666A0555|54 56|HFD
P11438666A0555|61 76|plant homeodomain
P11438666A0555|78 80|PHD
P11438666A0555|110 128|immunoprecipitation
P11438666A0555|134 156|mammalian TFIID component
P11438838A0788|3 16|other inhibitor
P11438838A0788|21 34|single TAR decoy
P11438838A0788|27 29|TAR
P11438838A0788|47 71|U6 small nuclear RNA promoter
P11438838A0788|73 76|U6-P
P11439343A0785|12 15|MPc3
P11439343A0785|36 47|Pc protein M33
P11439343A0785|36 44|Pc protein
P11439343A0785|45 47|M33
P11439343A0785|67 69|AF9
P11441163T0000|0 9|Foreigners
P11441311X0001|0 15|Long-term results
P11441311X0001|20 26|MACOP-B
P11441311X0001|30 45|radiation therapy
P11441311X0001|49 67|aggressive lymphomas
P11441311X0001|69 78|BACKGROUND
P11441311X0001|80 95|Long-term results
P11441311X0001|115 134|chemotherapy regimens
P11441311X0001|138 154|prognostic factors
P11441311X0001|157 167|non-Hodgkin
P11441311X0001|170 178|lymphomas
P11441311X0001|180 182|NHL
P11441952A0414|4 7|days
P11441952A0414|9 9|D
P11441952A0414|17 30|months post-TBI
P11441952A0414|32 45|irradiated rats
P11441952A0414|63 77|lower percentage
P11441952A0414|80 88|avoidance
P11441952A0414|93 100|controls
P11441952A0414|106 126|statistical difference
P11441952A0414|138 151|months post-TBI
P11441952A0414|153 153|b
P11441952A0414|155 174|Two-way avoidance test
P11441952A0414|205 207|TBI
P11441974A0320|31 51|pulmonary hemolymph PO2
P11441974A0320|68 70|kPa
P11441974A0320|78 87|hemocyanin
P11441974A0320|96 104|saturated
P11441974A0320|117 129|venous reserve
P11441974A0320|140 148|unchanged
P11441974A0320|156 161|mmol x l
P11443509A0293|0 5|DESIGN
P11443509A0293|7 28|Prospective cohort study
P11443509A0293|36 51|y follow-up period
P11443509A0293|56 74|First National Health
P11443509A0293|78 94|Examination Survey
P11443509A0293|96 101|NHANES
P11443509A0293|104 130|Epidemiologic Follow-up Study
P11443509A0293|132 136|NHEFS
P11443999A0573|0 19|Mean Hg concentrations
P11443999A0573|25 30|livers
P11443999A0573|33 36|mice
P11443999A0573|43 47|sites
P11443999A0573|50 59|Isle Royale
P11443999A0573|85 86|P =
P11443999A0573|96 111|Hg concentrations
P11443999A0573|128 145|government agencies
P11443999A0573|150 158|unhealthy
P11443999A0573|162 177|human consumption
P11444762A0373|8 29|many different proposals
P11444762A0373|36 54|statistical analysis
P11444762A0373|72 81|early onset
P11445008A0816|3 7|assay
P11445008A0816|44 71|relative FGFR expression levels
P11445008A0816|52 55|FGFR
P11445008A0816|84 96|single RNA pool
P11445008A0816|105 126|multiple RNA pool samples
P11447490A0598|18 25|effusion
P11447490A0598|56 75|diagnostic assessment
P11448051A0093|40 72|constant small intestine transit time
P11448051A0093|85 103|drug-containing core
P11448051A0093|115 129|polymeric matrix
P11448051A0093|155 158|NaCl
P11448051A0093|160 167|mannitol
P11448051A0093|172 176|Emdex
P11448051A0093|183 194|inert polymer
P11448051A0093|196 208|Eudragit RS100
P11449014A0000|0 13|STUDY OBJECTIVE
P11449014A0000|32 59|several methodological aspects
P11449014A0000|90 113|controlled clinical trials
P11449014A0000|115 118|CCTs
P11449014A0000|152 181|epidemiologist/biostatistician
P11449014A0000|183 185|E/B
P11450490A0565|3 46|median preoperative best-corrected visual acuity
P11450490A0565|54 71|range hand motions/0
P11450490A0565|94 98|lines
P11450490A0565|102 151|median final postoperative best-corrected visual acuity
P11450490A0565|175 176|P =
P11450776T0000|1 8|rare case
P11450776T0000|11 22|primary group
P11450776T0000|24 47|streptococcal peritonitis
P11451447A0205|0 4|Gimpl
P11451447A0205|6 7|F.
P11451682A0190|3 21|present chemotherapy
P11451682A0190|24 25|AE
P11451682A0190|54 86|benzimidazole carbamate derivatives
P11451682A0190|94 104|mebendazole
P11451682A0190|108 118|albendazole
P11451995T0000|0 10|Topological
P11451995T0000|14 31|mutational analysis
P11451995T0000|34 62|Saccharomyces cerevisiae Ste14p
P11451995T0000|57 62|Ste14p
P11451995T0000|83 130|isoprenylcysteine carboxyl methyltransferase family
P11454004T0000|0 17|Hormonal regulation
P11454004T0000|20 36|multiple promoters
P11454004T0000|42 94|rat mitochondrial glycerol-3-phosphate dehydrogenase gene
P11454004T0000|113 142|complex hormone-response element
P11454004T0000|148 167|ubiquitous promoter B.
P11454190A0000|0 14|BACKGROUND/AIMS
P11454190A0000|16 25|Hepatitis C
P11454190A0000|29 57|nonalcoholic fatty liver disease
P11454190A0000|59 62|NAFL
P11454190A0000|77 87|common forms
P11454190A0000|90 101|liver disease
P11454190A0000|107 118|United States
P11454239A0478|0 18|Statistical Analysis
P11454239A0478|27 31|ANOVA
P11454239A0478|36 77|Pearson Product Moment Correlation Coefficient
P11454239A0478|79 105|Principal Components Analysis
P11454239A0478|109 136|Discriminant Function Analysis
P11454239A0478|156 163|Cronbach
P11454239A0478|166 176|alpha (alpha
P11454239A0478|166 170|alpha
P11454239A0478|172 176|alpha
P11454239A0478|178 184|RESULTS
P11454239A0478|190 200|Sensitivity
P11454239A0478|204 214|specificity
P11454239A0478|234 242|Chronbach
P11454239A0478|245 249|alpha
P11454239A0478|256 265|total scale
P11454703A0000|3 41|telomerase RNA-protein complex responsible
P11454703A0000|58 69|telomeric DNA
P11454703A0000|72 85|chromosome ends
P11454703A0000|96 103|inactive
P11454703A0000|106 133|most primary somatic human cells
P11454703A0000|172 186|immortalization
P11454703A0000|196 208|tumorigenesis
P11456259A0142|3 7|titer
P11456259A0142|10 42|TSH binding inhibitor immunoglobulin
P11456259A0142|44 47|TBII
P11456259A0142|65 65|%
P11456259A0142|68 86|initial presentation
P11456259A0142|98 98|%
P11456259A0142|102 106|weeks
P11457139A0604|3 9|results
P11457139A0604|18 20|CVN
P11457139A0604|47 66|nanomolar affinity Man
P11457139A0604|70 75|GlcNAc
P11457139A0604|85 94|D1D3 isomer
P11457139A0604|97 99|Man
P11457139A0604|103 108|GlcNAc
P11459048A0485|27 39|uncertainties
P11459048A0485|45 50|models
P11459048A0485|52 69|terrestrial planets
P11459048A0485|74 88|dense atmosphere
P11459048A0485|93 97|Venus
P11459048A0485|124 145|possible rotation states
P11459304T0078|0 19|Enantiomer separation
P11459304T0078|22 32|venlafaxine
P11459304T0078|36 57|O-desmethylvenlafaxine
P11459304T0078|60 70|human plasma
P11459794A1172|0 10|TE-671 cells
P11459794A1172|34 68|cAMP response element mutant constructs
P11459794A1172|92 104|basal activity
P11459794A1172|110 124|GnRH-II promoter
P11459960A1109|23 41|separable components
P11459960A1109|46 55|heat stable
P11459960A1109|62 76|other heat labile
P11459962A0785|27 31|genes
P11459962A0785|37 69|Rad52 recombinational repair pathway
P11459962A0785|37 41|Rad52
P11459962A0785|97 113|rad27 Delta strains
P11459962A0785|97 106|rad27 Delta
P11459962A0785|120 129|permissive
P11459962A0785|133 140|degrees C
P11459962A0785|145 158|semipermissive
P11459962A0785|162 169|degrees C
P11459962A0785|171 182|temperatures
P11460035A0548|5 12|last case
P11460035A0548|18 35|hydroxychloroquine
P11460035A0548|37 49|carbamazepine
P11460035A0548|53 63|fluvoxamine
P11460035A0548|68 85|common imputability
P11460035A0548|94 102|plausible
P11461595A0000|16 31|reaction kinetics
P11461595A0000|34 56|small spherical particles
P11461595A0000|61 67|inertia
P11461595A0000|76 90|coalescence type
P11461595A0000|102 104|B+B
P11461595A0000|108 108|B
P11461595A0000|128 146|hydrodynamical flows
P11461595A0000|151 163|time-periodic
P11462004A0886|12 17|Vp1 DBD
P11462004A0886|67 94|NLS phenotypic complementation
P11462004A0886|96 97|N.
P11462004A1500|5 13|nonviable
P11462004A1500|21 30|mutant Vp1s
P11462004A1500|64 70|nucleus
P11462004A1500|77 79|Vp2
P11462004A1500|83 85|Vp3
P11462004A1500|114 117|NLS1
P11462004A1500|126 139|dominant signal
P11462004A1500|146 168|cytoplasmic localization
P11462004A1500|171 173|Vp1
P11462024A0306|0 2|Zhu
P11462024A0306|4 5|V.
P11462952A1040|7 19|gastrin levels
P11462952A1040|7 13|gastrin
P11462952A1040|21 31|normal range
P11462952A1040|39 42|mU/L
P11462952A1040|59 62|mU/L
P11462952A1040|81 84|mU/L
P11463359A0167|18 32|phorbol ester PMA
P11463359A0167|46 50|basal
P11463359A0167|54 89|dexamethasone/cAMP-induced expression
P11463359A0167|93 106|luciferase gene
P11463359A0167|127 140|G6Pase promoter
P11463359A0167|165 182|H4IIE hepatoma cells
P11463834A0606|7 25|deletion mutagenesis
P11463834A0606|37 46|amino acids
P11463834A0606|59 61|CBP
P11463834A0606|74 96|carboxy-terminal region 2
P11463834A0606|74 95|carboxy-terminal region
P11463834A0606|98 100|CR2
P11463834A0606|108 120|minimal region
P11463834A0606|124 137|Tax interaction
P11463834A0606|124 126|Tax
P11464997A0566|0 12|Such knowledge
P11465518A0000|0 9|BACKGROUND
P11465518A0000|47 59|investigators
P11465518A0000|88 91|ways
P11465518A0000|109 118|treatments
P11465518A0000|160 174|such individuals
P11465518A0000|177 192|unnecessary risks
P11465655A0439|5 12|next week
P11465655A0439|17 49|beta-adrenergic antagonist atenolol
P11465655A0439|62 72|initial dose
P11465655A0439|77 82|mg/day
P11465655A0439|98 103|mg/day
P11465844T0000|0 3|Lack
P11465844T0000|24 39|Kawasaki syndrome
P11465844T0000|56 72|Rickettsia conorii
P11465844T0000|74 88|Rickettsia typhi
P11465844T0000|90 105|Coxiella burnetii
P11465844T0000|108 135|Ehrlichia phagocytophila group
P11466227A1665|13 20|AS-oligo
P11466227A1665|26 38|further effect
P11466227A1665|44 65|FSH-mediated activation
P11466227A1665|44 46|FSH
P11466227A1665|71 90|EB*-mTf-CAT construct
P11466227A1665|71 72|EB
P11466227A1665|75 90|mTf-CAT construct
P11466227A1665|101 123|cAMP-mediated activation
P11467349A0452|7 21|challenging task
P11467349A0452|31 44|direct measures
P11467349A0452|47 56|ISF glucose
P11468958A0122|11 17|results
P11468958A0122|21 42|detailed policy analysis
P11468958A0122|53 72|CJD-related decisions
P11468958A0122|106 115|classic CJD
P11468958A0122|141 149|donations
P11468958A0122|154 164|individuals
P11468958A0122|170 189|6-month travel history
P11468958A0122|195 196|UK
P11468958A0122|220 227|concerns
P11468958A0122|237 246|variant CJD
P11469701A0377|3 15|novel approach
P11469701A0377|18 38|insulin administration
P11469701A0377|18 24|insulin
P11469701A0377|46 89|chronic intermittent intravenous insulin therapy
P11469701A0377|76 82|insulin
P11469701A0377|91 95|CIIIT
P11469701A0377|105 111|insulin
P11469701A0377|115 130|pulsatile fashion
P11469701A0377|142 174|physiological insulin concentration
P11469701A0377|180 189|portal vein
P11469737A1791|12 25|isokinetic test
P11469737A1791|32 61|impaired muscle function recovery
P11469737A1791|68 68|%
P11469737A1791|73 73|%
P11469737A1791|83 92|manual test
P11469737A1791|105 116|full recovery
P11469853A0702|21 35|domain shuffling
P11469853A0702|60 68|C1 domains
P11469853A0702|73 86|human Raf kinase
P11469853A0702|90 98|rat PKC eta
P11469853A0702|101 105|yeast
P11469853A1053|22 36|further evidence
P11469853A1053|57 67|small GTPase
P11469853A1053|73 94|main regulatory function
P11469853A1053|100 107|C1 domain
P11469853A1053|110 114|yeast
P11469926T0000|0 25|Breast cancer risk assessment
P11469926T0000|38 53|magic crystal ball
P11469970A0873|0 7|Patients
P11469970A0873|12 18|type III
P11469970A0873|19 21|SOD
P11469970A0873|29 48|visceral hyperalgesia
P11469970A0873|58 72|antidepressants
P11469970A0873|76 91|therapeutic trial
P11469970A0873|96 118|botulinum toxin injection
P11469970A0873|96 109|botulinum toxin
P11469970A0873|126 132|ampulla
P11469970A0873|162 186|invasive endoscopic therapy
P11470914A0305|13 16|Rac1
P11470914A0305|24 41|STAT3 translocation
P11470914A0305|24 28|STAT3
P11470914A0305|47 63|nucleus coincident
P11470914A0305|68 96|STAT3-dependent gene expression
P11471077A0382|0 6|RESULTS
P11471077A0382|16 33|considerable amount
P11471077A0382|55 61|results
P11471077A0382|64 67|TRA1
P11471077A0382|71 74|TRA2
P11471077A0382|88 94|results
P11471077A0382|101 103|TRA
P11471077A0382|112 129|door-to-door survey
P11471231A0964|16 23|patients
P11471231A0964|32 43|quantitative
P11471231A0964|47 68|qualitative differences
P11471231A0964|76 108|infectious microbiological spectrum
P11471231A0964|118 135|clean-contaminated
P11471231A0964|152 174|dirty surgical procedures
P11472523A0535|0 9|CONCLUSION
P11472523A0535|11 26|Extrusion cooking
P11472523A0535|44 55|inactivation
P11472523A0535|58 60|DON
P11472523A0535|68 79|limited value
P11472523A0535|83 86|AFB1
P11472523A0535|94 107|metabisulphite
P11472696A0387|3 13|differences
P11472696A0387|19 23|CPIgG
P11472696A0387|25 27|CRP
P11472696A0387|32 47|fibrinogen levels
P11472696A0387|32 41|fibrinogen
P11472696A0387|50 57|patients
P11472696A0387|78 80|ACS
P11472696A0387|103 109|non-ACS
P11473254A0000|0 3|NaeI
P11473254A0000|6 25|novel DNA endonuclease
P11473254A0000|11 25|DNA endonuclease
P11473254A0000|32 58|topoisomerase and recombinase
P11473254A0000|32 44|topoisomerase
P11473254A0000|48 68|recombinase activities
P11473254A0000|74 83|Lys residue
P11473254A0000|100 102|Leu
P11473261A0587|0 3|Mss4
P11473261A0587|25 66|inefficient guanine nucleotide exchange factor
P11473261A0587|36 66|guanine nucleotide exchange factor
P11473261A0587|68 70|GEF
P11474642A1451|3 12|decrements
P11474642A1451|15 39|cerebrovascular resistance
P11474642A1451|49 61|hexamethonium
P11474642A1451|65 70|mm Hg ml
P11474642A1451|76 78|min
P11478627A0573|3 22|desirability function
P11478627A0573|45 57|global optimum
P11478627A0573|59 60|D =
P11478627A0573|63 64|Y1
P11478627A0573|66 67|Y2
P11478627A0573|73 74|Yn
P11478627A0573|120 137|dimensionless scale
P11478627A0573|145 153|criterion
P11479104A0446|21 52|positive anti-cardiolipin antibody
P11479104A0446|29 52|anti-cardiolipin antibody
P11479104A0446|67 84|diagnostic criteria
P11479104A0446|88 113|systemic lupus erythematosis
P11479104A0446|115 124|CONCLUSION
P11479104A0446|139 160|known autoimmune disease
P11479104A0446|173 175|POF
P11479104A0446|196 204|clinician
P11479104A0446|223 243|potential genetic cause
P11479501A0744|0 6|RESULTS
P11479501A0744|24 39|wide distribution
P11479501A0744|47 57|coefficient
P11479501A0744|70 77|SD/mean x
P11479501A0744|81 81|%
P11479501A0744|86 104|different valve sizes
P11479501A0744|118 118|%
P11479501A0744|123 123|%
P11479501A0744|129 146|St Jude Medical valve
P11479501A0744|156 156|%
P11479501A0744|161 161|%
P11479501A0744|167 181|Omnicarbon valve
P11480490A0443|9 33|electrocardiographic signs
P11480490A0443|58 65|blockade
P11480490A0443|70 71|Kr
P11480490A0443|97 106|occurrence
P11480490A0443|109 118|arrhythmia
P11480497T0000|0 6|Effects
P11480497T0000|9 32|aerosol-vapor JP-8 jet fuel
P11480497T0000|38 67|functional observational battery
P11480555A0928|15 22|ceramide
P11480555A0928|36 42|fixture
P11480555A0928|55 63|cell death
P11481625A0202|23 30|subjects
P11481625A0202|49 74|standard three-times-weekly
P11481625A0202|76 78|TIW
P11481625A0202|80 100|interferon alfa-2b dose
P11481625A0202|80 96|interferon alfa-2b
P11481625A0202|103 105|MIU
P11481625A0202|112 122|once-weekly
P11481625A0202|124 125|QW
P11481625A0202|127 146|peginterferon alfa-2b
P11481625A0202|161 169|microg/kg
P11484028T0000|2 14|cross purposes
P11484578A1132|0 9|CONCLUSION
P11484578A1132|21 31|differences
P11484578A1132|37 51|measurement data
P11484578A1132|76 96|actual measurement data
P11484578A1132|121 153|computer-aided dental design program
P11486032A1261|8 27|transcription factors
P11486032A1261|47 68|Groucho-related protein
P11486032A1261|74 78|RUNX1
P11486032A1261|108 114|E2A-HLF
P11486141A0424|0 10|Many factors
P11486141A0424|25 42|educational outcome
P11486141A0424|45 52|students
P11486141A0424|56 76|large statistical power
P11486141A0424|84 95|meta analysis
P11486141A0424|123 133|many sources
P11486399A0000|16 25|ifosfamide
P11486399A0000|27 36|epirubicin
P11486399A0000|40 48|etoposide
P11486399A0000|50 52|IEV
P11486399A0000|58 80|effective salvage regimen
P11486399A0000|84 109|lymphoproliferative disease
P11486476A0147|1 16|prospective trial
P11486476A0147|44 66|clinical characteristics
P11486476A0147|69 76|patients
P11486476A0147|81 89|chest pain
P11486476A0147|101 123|cardiac markers troponin T
P11486476A0147|115 123|troponin T
P11486476A0147|125 133|myoglobin
P11486476A0147|137 145|CK-MB mass
P11486476A0147|163 169|cardiac
P11486476A0147|173 191|noncardiac chest pain
P11486476A0147|211 218|patients
P11486476A0147|223 225|ACS
P11486476A0147|237 243|markers
P11486476A0147|252 279|helpful additional information
P11486476A1512|0 22|Cardiac markers troponin T
P11486476A1512|14 22|troponin T
P11486476A1512|24 32|CK-MB mass
P11486476A1512|36 44|myoglobin
P11486476A1512|61 81|differential diagnosis
P11486476A1512|84 92|chest pain
P11486476A1512|105 107|ECG
P11486476A1512|111 122|unremarkable
P11486476A1512|125 135|nonspecific
P11489597A0379|2 12|termination
P11489597A0379|14 15|gd
P11489597A0379|20 44|confirmed-pregnant females
P11489597A0379|77 90|clinical status
P11489597A0379|94 111|gestational outcome
P11489597A0379|117 123|fetuses
P11489597A0379|148 155|visceral
P11489597A0379|160 180|skeletal malformations
P11489597A0561|3 15|maternal death
P11489597A0561|24 33|body weight
P11489597A0561|45 54|weight gain
P11489597A0561|69 76|high dose
P11489597A0561|87 100|pregnancy rates
P11489597A0561|112 112|%
P11490862A0141|5 22|further development
P11490862A0141|25 45|bladder neck suspension
P11490862A0141|57 70|Stamey-Pereyra
P11490862A0141|80 99|miniature bone anchors
P11490862A0141|108 126|considerable support
P11494391A0579|3 9|results
P11494391A0579|28 28|%
P11494391A0579|34 60|hepatic artery-alone ALT graft
P11494391A0579|73 87|normal structure
P11494391A0579|128 140|bile secretion
P11495833T0000|39 43|means
P11495833T0000|47 71|4-degrees-of-freedom model
P11495833T0000|76 99|time-dependent properties
P11495920A0504|1 18|1-base pair mismatch
P11495920A0504|28 46|corresponding region
P11495920A0504|52 61|CYP3A4 gene
P11495920A0504|79 106|differential enhancer activity
P11496495A0000|3 9|authors
P11496495A0000|26 52|social-economical conditions
P11496495A0000|64 76|possibilities
P11496495A0000|88 105|cardiosurgical care
P11496495A0000|108 115|children
P11496617A0301|0 6|METHODS
P11496617A0301|21 32|male patients
P11496617A0301|43 56|thyroid surgery
P11496617A0301|114 125|double-blind
P11496617A0301|135 151|antiemetic regimes
P11496617A0301|155 166|mg dolasetron
P11496617A0301|180 186|minutes
P11496617A0301|194 202|induction
P11496617A0301|205 215|anaesthesia
P11496617A0301|229 240|mg dolasetron
P11496617A0301|265 273|induction
P11496617A0301|276 286|anaesthesia
P11496617A0301|301 305|mg DHB
P11496617A0301|330 338|induction
P11496617A0301|341 351|anaesthesia
P11496617A0301|364 370|placebo
P11498795A0716|4 18|slow progression
P11498795A0716|29 41|early G1-phase
P11498795A0716|61 75|phosphorylation
P11498795A0716|81 89|RB protein
P11498795A0716|93 107|subsequent delay
P11498795A0716|115 130|S phase transition
P11500377A0518|2 8|mammals
P11500377A0518|13 37|transcriptional repressors
P11500377A0518|43 52|Wnt pathway
P11500377A0518|43 45|Wnt
P11500512A0000|3 16|human ABCG1 gene
P11500512A0000|36 54|ATP-binding cassette
P11500512A0000|56 58|ABC
P11500512A0000|60 70|superfamily
P11500512A0000|73 91|transporter proteins
P11500512A0000|114 124|macrophages
P11500512A0000|141 150|oxysterols
P11500571A0976|7 24|abundant expression
P11500571A0976|27 44|NtmybAS transcripts
P11500571A0976|47 58|mature pollen
P11500571A0976|60 75|gPAL1 transcripts
P11500571A0976|83 92|detectable
P11500571A0976|95 100|pollen
P11500913A1238|0 11|C/EBPbeta LIP
P11500913A1238|26 34|HC11 cells
P11500913A1238|48 62|beta-casein mRNA
P11500913A1238|64 105|mammary epithelial cell differentiation marker
P11500913A1238|119 136|lactogenic hormones
P11502738A1457|0 15|Identical effects
P11502738A1457|32 41|inhibitors
P11502738A1457|45 67|dominant negative mutants
P11502738A1457|92 99|bp region
P11502738A1457|105 120|cyclin D1 promoter
P11502758A0869|5 12|findings
P11502758A0869|21 48|novel ankyrin-independent role
P11502758A0869|26 32|ankyrin
P11502758A0869|52 63|LAD-1 related
P11502758A0869|66 78|FGFR signaling
P11502758A0869|66 69|FGFR
P11502778A0941|9 18|elderly men
P11502778A0941|23 49|bioavailable estradiol levels
P11502778A0941|58 63|median
P11502778A0941|67 76|pmol/liter
P11502778A0941|80 84|pg/ml
P11502778A0941|103 113|higher rates
P11502778A0941|116 123|bone loss
P11502778A0941|127 132|levels
P11502778A0941|135 155|bone resorption markers
P11502778A0941|160 162|men
P11502778A0941|167 193|bioavailable estradiol levels
P11502778A0941|201 210|pmol/liter
P11504545A0393|0 38|Competition electrophoretic mobility shift
P11504545A0393|42 58|immunoshift assays
P11504545A0393|72 88|NF1 factors present
P11504545A0393|72 81|NF1 factors
P11504545A0393|91 105|nuclear extracts
P11504545A0393|108 111|HeLa
P11504545A0393|115 123|CV-1 cells
P11504545A0393|133 139|BKV-MLP
P11504709A0981|25 43|inducible expression
P11504709A0981|62 64|PMA
P11504709A0981|67 69|TPO
P11504709A0981|90 96|Ets site
P11504709A0981|102 117|proximal promoter
P11504709A0981|120 123|GPIX
P11504709A0981|145 162|upstream activation
P11504709A0981|165 204|MAPK/extracellular signal-regulated kinase
P11504709A0981|165 168|MAPK
P11504709A0981|170 204|extracellular signal-regulated kinase
P11505407A0461|0 6|RESULTS
P11505407A0461|30 48|significant activity
P11505407A0461|51 68|EpCAM positive cells
P11505407A0461|51 55|EpCAM
P11505407A0461|98 121|tumor necrosis factor alpha
P11505407A0461|123 130|TNFalpha
P11509266A0955|2 47|Cox proportional hazards regression adenocarcinoma
P11509266A0955|49 50|P=
P11509266A0955|74 76|BPF
P11509266A0955|78 79|P=
P11509266A0955|87 94|older age
P11509266A0955|96 97|P=
P11509266A0955|106 128|higher pathological stage
P11509266A0955|130 131|P=
P11509266A0955|141 168|independent adverse predictors
P11509615T0000|0 27|Phosphatidylinositol 3-kinase
P11509615T0000|58 75|T cell proliferation
P11509615T0000|89 100|IL-2 receptor
P11509673A0574|5 23|stable transfectants
P11509673A0574|25 32|BM3 cells
P11509673A0574|45 76|mutant bacterial P450 AA epoxygenase
P11509673A0574|51 76|bacterial P450 AA epoxygenase
P11509673A0574|78 84|F87V BM3
P11509673A0574|127 141|arachidonic acid
P11509673A0574|148 156|14,15-EET
P11509673A0574|158 159|AA
P11509673A0574|172 180|apoptosis
P11509673A0574|200 223|agonist-induced apoptosis
P11511544T0000|3 12|loop domain
P11511544T0000|15 43|heat shock transcription factor 1
P11511544T0000|15 42|heat shock transcription factor
P11511544T0000|52 73|DNA-binding specificity
P11511544T0000|77 85|responses
P11511544T0000|88 97|heat stress
P11512925A0000|0 16|EXAFS measurements
P11512925A0000|26 33|Ge-K edge
P11512925A0000|55 71|liquid Ge-Si alloys
P11512925A0000|78 86|first time
P11512925A0000|103 116|local structure
P11512925A0000|124 129|Ge atom
P11513121T0000|0 15|Progressive study
P11513121T0000|19 32|robustness test
P11513121T0000|35 43|QSAR model
P11513121T0000|51 75|quantum chemical parameters
P11513121T0000|89 91|BCF
P11513121T0000|117 132|organic compounds
P11513121T0000|134 138|PCOCs
P11513180A1257|8 12|cases
P11513180A1257|15 32|malignant polyposis
P11513180A1257|57 58|CT
P11513180A1257|85 108|small bowel follow-through
P11513579A0372|8 23|two-hybrid system
P11513579A0372|35 51|nonprenylated Rac1
P11513579A0372|48 51|Rac1
P11513579A0372|75 81|Rho-GDI
P11513579A0372|96 110|predominant role
P11513579A0372|113 139|protein-isoprene interaction
P11513579A0372|142 157|complex formation
P11516890A0236|24 38|cytochrome P-450
P11516890A0236|40 42|CYP
P11516890A0236|51 61|venlafaxine
P11516890A0236|70 81|CYP 2D6 and 3A4
P11516890A0236|70 75|CYP 2D6
P11516890A0236|79 81|3A4
P11516890A0236|88 99|lesser extent
P11516890A0236|109 113|SSRIs
P11517190A0352|0 7|Analysis
P11517190A0352|13 28|promoter sequence
P11517190A0352|51 79|major transcriptional start site
P11517190A0352|82 97|canonical TATA box
P11517190A0352|101 129|putative cis regulatory elements
P11517190A0352|133 159|pituitary specific expression
P11517190A0352|170 188|E-responsive element
P11517190T0000|0 20|Novel intronic promoter
P11517190T0000|26 50|rat ER alpha gene responsible
P11517190T0000|57 78|transient transcription
P11517190T0000|82 96|variant receptor
P11517269A0472|0 4|Pitx2
P11517269A0472|15 44|GABAergic differentiation defect
P11517269A0472|67 78|axon guidance
P11517269A0472|82 101|behavioral phenotypes
P11517269A0472|104 116|unc-30 mutants
P11517269A0472|129 138|high degree
P11517269A0472|141 162|functional conservation
P11517269A0472|189 200|related genes
P11517399A0858|3 10|patterns
P11517399A0858|13 21|early mRNA
P11517399A0858|25 41|protein expression
P11517399A0858|54 60|mutants
P11517399A0858|91 98|mutation
P11517399A0858|104 104|T
P11517399A0858|111 122|acceptor site
P11517399A0858|136 146|utilization
P11517399A0858|149 166|cryptic splice sites
P11517399A0858|185 188|new T
P11517445A0221|9 13|cases
P11517445A0221|16 22|cholera
P11517445A0221|35 46|V. cholerae O1
P11518505A0107|54 70|particular tissues
P11518505A0107|74 79|organs
P11518868A0559|34 54|nonsexual risk behavior
P11518868A0559|79 93|hepatitis C virus
P11518868A0559|98 128|healthcare provider communication
P11519466A0196|0 15|Low-selenium diet
P11519466A0196|20 42|human unfavourable impact
P11520436A0705|5 14|BALB/c mice
P11520436A0705|32 48|appropriate strain
P11520436A0705|51 54|mice
P11520436A0705|64 70|studies
P11520436A0705|76 93|possible connection
P11520436A0705|114 120|T. canis
P11520436A0705|124 137|allergic asthma
P11521191A0000|28 50|adenoviral 12S E1A protein
P11521191A0000|63 83|phosphorylation status
P11521191A0000|86 89|p130
P11521191A0000|93 96|p107
P11521191A0000|104 118|apparent changes
P11521191A0000|124 156|cell cycle dependent phosphorylation
P11521191A0000|162 182|retinoblastoma protein
P11522431A0673|3 12|prevalence
P11522431A0673|15 31|tobacco dependence
P11522431A0673|55 68|ICD-10 criteria
P11522431A0673|72 77|higher
P11522431A0673|80 107|alcohol-dependent individuals
P11522431A0673|113 113|%
P11522431A0673|121 131|nondrinkers
P11522431A0673|134 147|social drinkers
P11522431A0673|153 153|%
P11522584A0882|0 14|Diffuse myalgias
P11522584A0882|33 40|patients
P11522584A0882|58 66|MMF lesion
P11522584A0882|69 87|deltoid muscle biopsy
P11522584A0882|89 89|P
P11522626A1374|12 29|hormonal regulation
P11522626A1374|32 32|G
P11522626A1374|36 52|gene transcription
P11522626A1374|72 91|additional activation
P11522626A1374|97 104|Mek-Erk1
P11522626A1374|97 99|Mek
P11522626A1374|101 106|Erk1/2
P11522626A1374|107 113|pathway
P11522626A1374|116 132|estrogen receptors
P11522658A0086|25 44|ErbB1/ErbB2 signaling
P11522658A0086|25 29|ErbB1
P11522658A0086|31 35|ErbB2
P11522658A0086|79 126|ErbB kinase inhibitor AG1478in ErbB2-dependent BT-474
P11522658A0086|79 88|ErbB kinase
P11522658A0086|106 110|ErbB2
P11522658A0086|130 157|SKBR-3 human breast cancer cells
P11522658A0870|18 32|phosphorylation
P11522658A0870|35 37|p27
P11522658A0870|40 43|MAPK
P11522658A0870|66 68|p27
P11522658A0870|87 97|nuclear Cdk2
P11522658A0870|100 116|high stoichiometry
P11522658A0870|132 145|kinase activity
P11523446A0523|0 2|ICA
P11523446A0523|8 24|reference solution
P11523446A0523|43 44|LC
P11523446A0523|48 61|time-of-flight
P11523446A0523|63 65|TOF
P11523446A0523|67 68|MS
P11523446A0523|84 118|LC chemiluminescent nitrogen detection
P11523446A0523|120 126|LC-CLND
P11524015A0937|18 23|BZAP45
P11524015A0937|42 51|H4 promoter
P11524015A0937|53 54|nt
P11524015A0937|65 87|CAT reporter gene activity
P11524015A0937|65 79|CAT reporter gene
P11524815A0753|0 16|Local control rates
P11524815A0753|23 23|%
P11524815A0753|27 46|metastatic lung cancer
P11524815A0753|50 50|%
P11524815A0753|54 70|primary lung cancer
P11524815A0753|76 76|%
P11524815A0753|80 81|T1
P11524815A0753|83 92|2N0M0 cases
P11524823X0001|0 6|Utility
P11524823X0001|9 19|OAE screener
P11524823X0001|21 23|GSI
P11524823X0001|45 81|distortion product otoacoustic emissions
P11524823X0001|135 148|OAE screener GSI
P11524823X0001|163 177|cochlea function
P11524823X0001|180 187|neonates
P11524823X0001|189 195|infants
P11524823X0001|199 204|adults
P11525102A0970|14 30|systematic reviews
P11525102A0970|40 53|ACP Journal Club
P11525102A0970|55 56|n =
P11525102A0970|65 78|PubMed strategy
P11525102A0970|103 103|%
P11525102A0970|105 106|CI
P11525102A0970|110 110|%
P11525102A0970|115 115|%
P11525486A0350|14 22|CaCO3-CO2
P11525486A0350|24 25|N2
P11525486A0350|65 66|pH
P11525640A0560|0 9|Inhibition
P11525640A0560|12 15|JNK1
P11525640A0560|19 37|ERK kinase activities
P11525640A0560|19 27|ERK kinase
P11525640A0560|61 86|dominant negative mutant JNK1
P11525640A0560|83 86|JNK1
P11525640A0560|105 130|selective chemical inhibitor
P11525640A0560|133 135|ERK
P11525640A0560|137 144|PD098059
P11525640A0560|171 181|UV induction
P11525640A0560|187 200|GADD45 promoter
P11528127A1402|5 13|GC content
P11528127A1402|18 18|%
P11528127A1402|58 59|H1
P11528127A1402|67 78|other segment
P11528127A1402|82 84|% GC
P11528127A1402|95 97|% GC
P11528127A1402|117 121|L1/L2
P11528253X1211|0 8|Copyright
P11528253X1211|13 14|S.
P11528500A0571|2 9|mutation
P11528500A0571|15 21|NRL gene
P11528500A0571|43 50|families
P11529914T0000|0 8|NF-kappaB
P11529914T0000|36 40|CD154
P11529914T0000|42 51|CD40 ligand
P11529914T0000|65 82|primary human T cells
P11530684A0667|5 15|nerve injury
P11530684A0667|20 39|nociceptive responses
P11530684A0667|52 58|neurons
P11530684A0667|68 84|polymodal C-fibers
P11530684A0667|88 114|drive NK1-receptor mechanisms
P11530684A0667|117 138|spinal pain transmission
P11530684A0667|169 175|changes
P11530684A0667|184 187|ones
P11530684A0667|197 213|polymodal C-fibers
P11530684A0667|217 244|drive NMDA receptor-mechanisms
P11530684A0667|222 233|NMDA receptor
P11530684A0667|258 261|ones
P11530684A0667|271 291|capsaicin-insensitive
P11530684A0667|301 308|A-fibers
P11530684A0667|313 340|drive NMDA-receptor mechanisms
P11530684A0667|318 330|NMDA-receptor
P11530829A0000|45 56|ECG simulator
P11530829A0000|84 94|calibration
P11530829A0000|111 139|electrocardiographic equipment
P11532556A0000|0 38|Subacute diencephalic angioencephalopathy
P11532556A0000|40 43|SDAE
P11532556A0000|55 66|fatal disease
P11532556A0000|69 83|unknown etiology
P11532556A0000|99 105|thalami
P11532856A1175|0 4|Third
P11532856A1175|30 45|N-acetylcysteine
P11532856A1175|56 72|stimulatory effect
P11532856A1175|75 77|HGF
P11532856A1175|80 101|stress kinase activities
P11532856A1175|80 91|stress kinase
P11532856A1175|108 135|p42/44 mitogen activated kinase
P11532856A1175|137 140|MAPK
P11532856A1175|145 154|unmodified
P11532856A1175|181 202|c-Jun-N-terminal kinase
P11532856A1175|204 206|JNK
P11532856A1175|211 217|p38 MAPK
P11532856A1175|220 234|HIF-1 activation
P11532856A1175|220 224|HIF-1
P11533238A1137|0 7|Mutation
P11533238A1137|13 26|octamer element
P11533238A1137|63 67|HDAC1
P11533238A1137|76 85|repression
P11533238A1137|88 121|inducible HLA-DRA promoter activation
P11533238A1137|97 111|HLA-DRA promoter
P11533340A1285|10 30|significant difference
P11533340A1285|33 51|developmental scores
P11533340A1285|59 64|months
P11533340A1285|74 83|PDF infants
P11533340A1285|101 114|point advantage
P11533340A1285|117 138|Bayley motor score scales
P11533863A0125|5 14|single case
P11533863A0125|18 28|restoration
P11533863A0125|32 53|structured daily routine
P11533863A0125|67 80|presupposition
P11533863A0125|85 100|cognitive therapy
P11534132A0219|12 24|search engines
P11534132A0219|36 56|such cumbersome results
P11534132A0219|61 81|domain specific experts
P11534900A0000|3 8|binary
P11534900A0000|12 31|tertiary combinations
P11534900A0000|34 76|plant-derived molluscicides Azadirachta indica
P11534900A0000|80 95|Cedrus deodara oil
P11534900A0000|100 116|synergists MGK-264
P11534900A0000|118 134|piperonyl butoxide
P11534900A0000|136 137|PB
P11534900A0000|142 152|fruit powder
P11534900A0000|155 166|Embelia ribes
P11534900A0000|185 200|Lymnaea acuminata
P11535014A1157|7 18|above results
P11535014A1157|39 49|seizure type
P11535014A1157|52 54|TLE
P11535014A1157|59 71|high frequency
P11535014A1157|74 80|seizure
P11535014A1157|87 120|major independent precipitate factors
P11535014A1157|124 140|abnormal latencies
P11535014A1157|143 146|P300
P11535014A1157|152 168|epileptic patients
P11535140T0000|0 19|Audiological findings
P11535532A0189|3 29|deubiquitinating enzyme DUB-2
P11535532A0189|25 29|DUB-2
P11535532A0189|51 54|IL-2
P11535832A0586|3 9|isoform
P11535832A0586|21 26|HDAC9a
P11535832A0586|33 41|aa shorter
P11535832A0586|47 55|C terminus
P11535832A0586|60 64|HDAC9
P11536063A0178|0 19|Pulmonary embolectomy
P11536063A0178|23 41|lung transplantation
P11536063A0178|48 62|main indications
P11536063A0178|74 91|heart-lung-machine
P11538437A0568|2 15|such conditions
P11538437A0568|29 44|kinetic reactions
P11538437A0568|61 62|N2
P11538437A0568|64 64|A
P11538437A0568|67 68|N2
P11538437A0568|70 70|A
P11538437A0568|75 76|N2
P11538437A0568|78 78|C
P11538437A0568|80 80|B
P11538437A0568|82 82|V
P11538437A0568|86 87|N2
P11538437A0568|89 89|X
P11538437A0568|92 93|N2
P11538437A0568|95 95|A
P11538437A0568|98 99|N2
P11538437A0568|101 101|X
P11538437A0568|103 103|V
P11538437A0568|110 111|N2
P11538437A0568|113 113|X
P11538437A0568|116 117|N2
P11538437A0568|119 119|B
P11538437A0568|121 121|V
P11538437A0568|126 146|pure N2 post-discharges
P11538437A0568|150 151|N2
P11538437A0568|153 153|A
P11538437A0568|156 158|CH4
P11538437A0568|162 169|products
P11538437A0568|171 171|C
P11538437A0568|173 173|N
P11538437A0568|175 176|M2
P11538437A0568|180 181|CN
P11538437A0568|183 183|B
P11538437A0568|185 185|V
P11538437A0568|189 190|M2
P11538437A0568|192 193|N2
P11538437A0568|195 195|X
P11538437A0568|197 197|V
P11538437A0568|202 203|CN
P11538437A0568|207 208|N2
P11538437A0568|210 210|X
P11538437A0568|213 214|CN
P11538437A0568|216 216|B
P11538437A0568|218 218|A
P11538437A0568|220 220|V
P11538437A0568|230 248|% CH4 post-discharges
P11539522A0612|3 16|NAUSICAA system
P11539522A0612|23 35|good knowledge
P11539522A0612|38 47|LET spectra
P11539522A0612|54 62|first time
P11539522A0612|65 78|space dosimetry
P11540991A0127|22 28|effects
P11540991A0127|30 34|tests
P11540991A0127|53 84|NASA MSFC Neutral Buoyancy Simulator
P11540991A0127|91 100|NASA KC-135
P11540991A0127|103 117|parabolic flight
P11540991A0127|136 146|EASE program
P11540991A0127|156 181|Shuttle Atlantis mission 61-B
P11542677A0411|37 50|Generic Systems
P11542677A0411|66 82|basic alternatives
P11542677A0411|85 108|composting facility design
P11542780A0086|0 34|Different thermoluminescent detectors
P11542780A0086|36 38|TLD
P11542780A0086|81 112|low linear energy transfer component
P11542780A0086|114 116|LET
P11542780A0086|120 133|keV/micrometer
P11542780A0086|138 165|plastic nuclear track detectors
P11542780A0086|167 170|PNTD
P11542780A0086|178 200|high linear energy tranfer
P11542780A0086|202 204|LET
P11543154T0000|0 8|Responses
P11543154T0000|11 20|TLD Mg2SiO4
P11543154T0000|22 23|Tb
P11543154T0000|27 52|radiophotoluminescent glass
P11543154T0000|67 75|particles
P11543154T0000|79 92|space radiation
P11543317A0203|55 63|detectors
P11543317A0203|72 91|luminescent dosemeter
P11543317A0203|94 100|Mg2SiO4
P11543317A0203|102 103|Tb
P11543317A0203|105 108|TDMS
P11543317A0203|113 139|plastic nuclear track detector
P11543317A0203|141 144|PNTD
P11543662A0562|8 19|gstC' mutants
P11543662A0562|8 11|gstC
P11543662A0562|13 19|mutants
P11543662A0562|35 48|C-terminal half
P11543662A0562|51 51|C
P11543662A0562|64 69|defect
P11543662A0562|88 95|L protein
P11545594A1556|23 32|Myb domains
P11545594A1556|75 83|Myb domain
P11545594A1556|96 112|amino acid residues
P11545594A1556|120 126|located
P11547819A0532|0 6|METHODS
P11547819A0532|8 18|Experiments
P11547819A0532|29 39|new catheter
P11547819A0532|67 74|catheter
P11547819A0532|103 122|laser output beam sizes
P11547819A0532|126 136|divergences
P11547819A0532|153 179|particulate matter generation
P11547819A0532|186 193|ablation
P11547819A0532|196 216|atherosclerotic tissue
P11547819A0532|234 250|ablation hole sizes
P11547819A0532|254 275|tissue penetration rates
P11547819A0532|280 305|histopathologic examination
P11547819A0532|308 320|laser-induced
P11547819A0532|327 342|vessel wall injury
P11548027A0163|13 33|performance indicators
P11548027A0163|49 63|different groups
P11548027A0163|86 105|structural indicators
P11548027A0163|107 127|operational indicators
P11548027A0163|137 160|service quality indicators
P11548027A0163|162 180|personnel indicators
P11548027A0163|184 201|economic indicators
P11550795A2583|0 13|Overexpression
P11550795A2583|16 23|RORgamma
P11550795A2583|45 75|T cell receptor-mediated apoptosis
P11550795A2583|45 57|T cell receptor
P11550795A2583|78 92|T cell hybridomas
P11550795A2583|108 116|induction
P11550795A2583|119 128|Fas-ligand
P11550795A2583|132 143|interleukin 2
P11550795A2583|132 142|interleukin
P11552058A0235|4 6|ICP
P11552058A0235|14 27|critical values
P11552058A0235|32 35|mm Hg
P11552058A0235|37 46|herniation
P11552058A0235|71 74|days
P11552058A0833|0 13|Other therapies
P11552058A0833|40 63|hypertonic saline solution
P11552058A0833|65 68|THAM
P11552058A0833|70 101|Tris-hydroxy-methyl-aminomethane
P11552058A0833|103 108|buffer
P11552058A0833|113 133|high-dose barbiturates
P11552724A0527|0 10|CONCLUSIONS
P11552724A0527|12 33|ChromaFlo-enhanced IVUS
P11552724A0527|55 63|blood flow
P11552724A0527|73 83|vessel lumen
P11552724A0527|115 131|echolucent disease
P11552724A0527|136 151|luminal blood flow
P11552724A0527|177 199|peripheral interventions
P11552724A0527|202 209|patients
P11552724A0527|214 225|renal failure
P11552724A0527|228 234|allergy
P11552724A0527|252 264|contrast media
P11552922A0361|0 14|CYP2C19 genotype
P11552922A0361|33 99|polymerase chain reaction-restriction fragment length polymorphism method
P11553091A1472|3 9|results
P11553091A1472|55 71|molar relationship
P11553091A1472|105 114|correction
P11553091A1472|117 121|Class
P11553091A1472|124 140|molar relationship
P11553704A0674|0 10|Similar data
P11553704A0674|37 62|dominant negative EGFR-CD533
P11553704A0674|53 56|EGFR
P11553704A0674|58 62|CD533
P11553704A0674|65 86|dominant negative Ras N17
P11553704A0674|102 115|MAPK activation
P11553704A0674|102 105|MAPK
P11554469A1386|5 12|analyses
P11554469A1386|44 52|CesA genes
P11554469A1386|59 76|cellulose synthases
P11554469A1386|95 110|sub-class members
P11554469A1386|120 138|other non-cellulosic
P11554469A1386|125 165|non-cellulosic (1-->4)beta-glycan synthases
P11554469A1386|146 165|beta-glycan synthases
P11554469A1386|168 173|plants
P11554566A0668|3 19|hatcher incubators
P11554566A0668|26 34|companies
P11554566A0668|118 125|company A
P11554566A0668|156 164|company B.
P11554566A0833|6 19|companies sites
P11554566A0833|65 69|Tr104
P11554566A0833|102 117|various locations
P11554727A0890|3 21|mutation experiments
P11554727A0890|39 54|critical sequence
P11554727A0890|61 70|repression
P11554727A0890|73 75|PTH
P11554727A0890|82 95|GGGGGAGGGGAG-3
P11554727A0890|108 112|PTHSR
P11555516A0639|0 12|Cardiac output
P11555516A0639|15 32|anaerobic threshold
P11555516A0639|34 37|COAT
P11555516A0639|42 42|=
P11555516A0639|46 50|L/min
P11555516A0639|57 71|best cutoff value
P11555516A0639|86 117|multivessel coronary artery disease
P11555516A0639|119 130|relative risk
P11555669A0464|0 9|Experience
P11555669A0464|14 32|xylene-free sections
P11555669A0464|47 62|Vrinnevi Hospital
P11555669A0983|19 26|sections
P11555669A0983|30 36|samples
P11555669A0983|39 45|tissues
P11555669A0983|48 53|stains
P11555669A0983|70 74|pairs
P11556809A2085|17 46|CYP71D20-encoded enzyme activity
P11556809A2085|17 38|CYP71D20-encoded enzyme
P11556809A2085|73 91|5-epi-aristolochene
P11556809A2085|95 110|1-deoxycapsidiol
P11556809A2085|113 121|capsidiol
P11556809A2085|161 170|P450 enzyme
P11556809A2085|184 197|hydroxylations
P11556809A2085|203 222|hydrocarbon substrate
P11557127A0991|13 16|NF-Y
P11557127A0991|20 34|Sp1 binding sites
P11557127A0991|40 51|decisive role
P11557127A0991|57 71|basal expression
P11557127A0991|77 87|rat mrp2 gene
P11557127A0991|97 109|human MRP2 gene
P11559366T0000|0 37|E2F1-mediated transcriptional inhibition
P11559366T0000|0 3|E2F1
P11559366T0000|43 75|plasminogen activator inhibitor type
P11559547T0000|0 24|Transcriptional regulation
P11559547T0000|30 72|estrogen-inducible pS2 breast cancer marker gene
P11559547T0000|78 86|ERR family
P11559547T0000|89 110|orphan nuclear receptors
P11559564A0459|0 5|NB-506
P11559564A0459|37 50|topoisomerase I
P11559564A0459|37 49|topoisomerase
P11559564A0459|78 123|human splicing factor 2/alternative splicing factor
P11559564A0459|78 97|human splicing factor 2
P11559564A0459|99 123|alternative splicing factor
P11559564A0459|125 131|SF2/ASF
P11559564A0459|125 127|SF2
P11559564A0459|129 131|ASF
P11559789A0314|26 51|replication-deficient virus
P11559789A0314|65 85|ASF/SF2 splicing factor
P11559789A0314|65 67|ASF
P11559789A0314|69 85|SF2 splicing factor
P11559789A0314|91 134|progesterone antagonist-inducible gene cassette
P11559789A0314|152 158|ASF/SF2
P11559789A0314|152 154|ASF
P11559789A0314|156 158|SF2
P11559789A0314|174 189|significant level
P11559789A0314|198 213|producer cell line
P11559789A0314|233 239|inducer
P11559821A1315|0 15|DNA binding assays
P11559821A1315|28 39|interference
P11559821A1315|42 44|p30
P11559821A1315|66 78|CREB-Tax-p300
P11559821A1315|66 69|CREB
P11559821A1315|71 73|Tax
P11559821A1315|75 78|p300
P11559821A1315|80 103|CBP multiprotein complexes
P11559821A1315|80 82|CBP
P11559821A1315|106 132|21-bp repeat oligonucleotides
P11560292A0557|17 36|categorical structure
P11560292A0557|39 49|domain model
P11560292A0557|51 62|prototype DSS
P11560292A0557|66 86|dipslide urine cultures
P11560509T0000|0 13|DNA recognition
P11560509T0000|16 28|F factor TraI36
P11560509T0000|23 28|TraI36
P11560509T0000|36 59|sequence-specific binding
P11560509T0000|62 79|single-stranded DNA
P11560990A0272|0 15|E47 protein levels
P11560990A0272|0 9|E47 protein
P11560990A0272|34 65|double positive developmental stage
P11560990A0272|99 112|moderate levels
P11560990A0272|120 126|further
P11560990A0272|159 177|single positive stage
P11560992A0000|3 54|dual specificity kinases mitogen-activated protein kinase
P11560992A0000|25 54|mitogen-activated protein kinase
P11560992A0000|56 66|MAPK) kinase
P11560992A0000|56 59|MAPK
P11560992A0000|61 66|kinase
P11560992A0000|68 70|MKK
P11560992A0000|76 79|MKK4
P11560992A0000|86 98|only molecules
P11560992A0000|125 167|stress kinases stress-activated protein kinases
P11560992A0000|138 167|stress-activated protein kinases
P11560992A0000|169 173|SAPKs
P11560992A0000|176 197|c-Jun N-terminal kinases
P11560992A0000|199 202|JNKs
P11560992A0000|231 246|mitogenic stimuli
P11560992A0651|0 17|SAPK/JNK activation
P11560992A0651|0 3|SAPK
P11560992A0651|5 7|JNK
P11560992A0651|54 57|MKK7
P11560992A0651|81 84|MKK4
P11560992A0651|109 117|mkk7(-/-)
P11560992A0651|109 112|mkk7
P11560992A0651|118 130|mast cell lines
P11560992A0651|135 149|phosphorylation
P11560992A0651|152 155|MKK4
P11560992A0651|184 204|multiple stress stimuli
P11560992A1184|5 8|MKK7
P11560992A1184|25 41|specific regulator
P11560992A1184|44 75|stress-induced SAPK/JNK activation
P11560992A1184|58 61|SAPK
P11560992A1184|63 65|JNK
P11560992A1184|78 86|mast cells
P11560992A1184|90 93|MKK7
P11560992A1184|113 124|growth factor
P11560992A1184|128 162|antigen receptor-driven proliferation
P11560992A1184|165 182|hematopoietic cells
P11561623A0897|3 40|small copepod Pseudonychocamptus proximus
P11561623A0897|65 81|large Tisbe furcata
P11561623A0897|84 94|sand filters
P11561623A0897|137 149|large increase
P11561623A0897|152 168|meiofaunal biomass
P11561626A0197|13 28|aqueous solutions
P11561626A0197|31 36|TMT-55
P11561626A0197|38 53|aqueous solutions
P11561626A0197|62 78|reagent-grade zinc
P11561626A0197|80 86|cadmium
P11561626A0197|94 98|salts
P11561626A0197|110 120|crystalline
P11561626A0197|122 127|Zn-TMT
P11561626A0197|130 138|amorphous
P11561626A0197|141 151|crystalline
P11561626A0197|153 158|Cd-TMT
P11561626A0197|162 170|amorphous
P11561626A0197|172 177|Pb-TMT
P11561626A0197|180 181|M3
P11561626A0197|183 188|S3C3N3
P11561626A0197|192 195|nH2O
P11561626A0197|202 206|M=Cd2
P11561626A0197|209 211|Pb2
P11561626A0197|217 219|Zn2
P11561626A0197|224 224|n
P11561626A0197|228 228|=
P11562278A0169|0 3|Many
P11562278A0169|9 22|important genes
P11562278A0169|37 48|G1 regulation
P11562278A0169|69 75|key role
P11562278A0169|78 90|proliferation
P11562278A0169|92 106|differentiation
P11562278A0169|110 132|oncogenic transformation
P11562278A0169|146 154|cell death
P11562278A0169|156 164|apoptosis
P11562870A0892|3 13|probability
P11562870A0892|29 39|lamotrigine
P11562870A0892|61 66|months
P11562870A0892|72 72|%
P11562870A0892|83 88|months
P11562870A0892|91 91|%
P11562870A0892|103 107|years
P11562870A0892|110 110|%
P11564871A1184|5 11|results
P11564871A1184|33 64|TATA-unified transcription systems
P11564871A1184|67 88|contemporary eukaryotes
P11564871A1184|113 124|residual need
P11564871A1184|128 130|TBP
P11564871A1184|141 144|Pols
P11564871A1184|147 161|other eukaryotes
P11564871A1184|176 187|TATA elements
P11564871A1184|195 203|promoters
P11564893A1068|21 32|conformation
P11564893A1068|48 56|6RG lesion
P11564893A1068|58 61|MGMT
P11564893A1068|75 89|DNA repair factor
P11564893A1068|93 114|transcription regulator
P11564893A1068|116 121|R-MGMT
P11564893A1068|163 170|mutagens
P11565747A1020|0 3|Data
P11565747A1020|15 28|splicing assays
P11565747A1020|30 43|UV crosslinking
P11565747A1020|47 79|RNA-binding competition experiments
P11565747A1020|90 106|strong correlation
P11565747A1020|117 133|binding affinities
P11565747A1020|136 138|PSI
P11565747A1020|145 158|SELEX sequences
P11565747A1020|184 191|splicing
P11565747A1020|194 205|P element IVS3
P11565747A1020|194 201|P element
P11565747A1020|202 205|IVS3
P11566874T0000|1 16|split motor domain
P11566874T0000|20 36|cytoplasmic dynein
P11566948A1217|2 28|hypertensive nephrosclerosis
P11566948A1217|49 52|ACEI
P11566948A1217|96 104|incidence
P11566948A1217|107 117|renal events
P11566961A0472|0 18|Body weight reduction
P11566961A0472|28 45|insulin sensitivity
P11566961A0472|28 34|insulin
P11566961A0472|61 72|blood glucose
P11566961A0472|76 95|blood pressure control
P11566996A1391|17 20|uvrA
P11566996A1391|27 57|nucleotide excision repair pathway
P11566996A1391|82 102|acid-induced DNA damage
P11566996A1391|123 142|successful adaptation
P11566996A1391|145 152|S. mutans
P11566996A1391|155 160|low pH.
P11568988A0960|3 21|best regression model
P11568988A0960|35 41|changes
P11568988A0960|47 50|WCXR
P11568988A0960|65 84|first positive culture
P11568988A0960|88 100|antibody titer
P11568988A0960|104 113|Pa elastase
P11569800T0000|0 21|Temperature measurement
P11569800T0000|24 42|microfluidic systems
P11569800T0000|49 80|temperature-dependent fluorescent
P11569900A0660|0 13|APC-resistance
P11569900A0660|0 2|APC
P11569900A0660|32 47|functional method
P11569900A0660|52 66|high sensitivity
P11569900A0660|70 80|specificity
P11569900A0660|87 107|factor V Leiden mutation
P11569949A2087|0 4|Zarix
P11569949A2087|13 29|patient enrollment
P11569949A2087|32 52|Canadian clinical sites
P11569949A2087|62 67|Spring
P11570735A1097|0 6|RESULTS
P11570735A1097|11 18|subjects
P11570735A1097|24 45|augmented feedback group
P11570735A1097|71 101|peak vertical ground reaction force
P11570735A1097|108 126|post-test conditions
P11570735A1097|128 153|2-minute post-test reduction
P11570735A1097|167 190|1-week post-test reduction
P11570735A1097|219 225|sensory
P11570735A1097|248 261|feedback groups
P11570820T0000|4 24|casein kinase I isoforms
P11570820T0000|4 15|casein kinase
P11570820T0000|17 24|isoforms
P11570820T0000|60 66|nucleus
P11570820T0000|70 78|cytoplasm
P11572377T0000|0 2|Use
P11572377T0000|6 27|dual-pulse lithotripter
P11572377T0000|39 47|localized
P11572377T0000|62 76|cavitation field
P11572388A0000|21 27|results
P11572388A0000|32 43|initial study
P11572388A0000|62 95|linear solvation energy relationships
P11572388A0000|97 101|LSERs
P11572388A0000|120 144|internal standard compounds
P11572388A0000|147 181|reversed-phase liquid chromatographic
P11572388A0000|183 186|RPLC
P11572388A0000|188 204|method development
P11572467A0658|7 15|blood clot
P11572467A0658|29 42|vitreous cavity
P11572467A0658|44 64|intravitreal injection
P11572467A0658|67 70|t-PA
P11572467A0658|81 91|plasminogen
P11572467A0658|94 100|plasmin
P11572467A0658|113 116|clot
P11572467T0000|0 9|Management
P11572467T0000|12 51|postvitrectomy diabetic vitreous hemorrhage
P11572467T0000|56 81|tissue plasminogen activator
P11572467T0000|83 86|t-PA
P11572467T0000|91 127|volume homeostatic fluid-fluid exchanger
P11573771T0000|0 5|Effect
P11573771T0000|8 21|heat treatments
P11573771T0000|27 37|meltability
P11573771T0000|40 46|cheeses
P11573891A0525|0 6|RESULTS
P11573891A0525|16 19|cent
P11573891A0525|22 37|African Americans
P11573891A0525|49 66|community outbreaks
P11573891A0525|71 81|TST positive
P11573891A0525|98 98|%
P11573891A0525|101 106|whites
P11573891A0525|116 134|comparable exposures
P11574088A1687|30 47|pancreas transplant
P11574088A1687|54 57|days
P11574088A1687|61 63|SPK
P11574088A1687|70 73|days
P11574088A1687|77 89|PAK recipients
P11574088A1687|91 92|P =
P11574105A0727|0 7|Patients
P11574105A0727|12 24|antibody peaks
P11574105A0727|35 42|fivefold
P11574105A0727|45 58|higher increase
P11574105A0727|61 73|antibody titer
P11574105A0727|87 105|lowest antibody titer
P11574105A0727|121 123|GBS
P11574105A0727|128 149|higher disability scores
P11574105A0727|167 171|weeks
P11574105A0727|174 176|GBS
P11574105A0727|181 200|worse clinical outcome
P11574105A0727|202 212|anti-GM1 IgG
P11574105A0727|216 240|anti-GD1a IgM antibody peaks
P11574105A0727|216 235|anti-GD1a IgM antibody
P11574105A0727|245 256|axonal damage
P11574105A0727|258 282|anti-GD1a IgM antibody peaks
P11574105A0727|258 277|anti-GD1a IgM antibody
P11574105A0727|295 302|patients
P11574105A0727|310 327|peak antibody titers
P11575109A0214|9 35|baseline clinical examination
P11575109A0214|39 63|initial periodontal therapy
P11575109A0214|67 74|patients
P11575109A0214|83 101|mucogingival surgery
P11575109A0214|106 123|free gingival grafts
P11575109A0214|138 149|insufficient
P11575109A0214|158 164|gingiva
P11575977A1133|8 15|patients
P11575977A1133|28 45|office hypertension
P11575977A1133|49 88|fewer previous cardiovascular complications
P11576158A1371|5 16|TVD-patients
P11576158A1371|28 40|skin blood flow
P11576158A1371|67 81|healthy controls
P11576776T0081|5 17|dynamic moduli
P11576776T0081|20 44|microcrystalline cellulose
P11577094A1226|5 12|findings
P11577094A1226|26 42|intracellular WT-1
P11577094A1226|39 42|WT-1
P11577094A1226|44 55|HSAL2 pathway
P11577094A1226|44 48|HSAL2
P11577094A1226|84 96|hematopoiesis
P11578685A0077|0 5|ICAM-1
P11578685A0077|23 31|predictor
P11578685A0077|37 41|onset
P11578685A0077|44 45|GO
P11579100T0000|0 21|Phosphotyrosyl peptides
P11579100T0000|27 58|Stat3-mediated DNA binding activity
P11579100T0000|27 31|Stat3
P11579100T0000|60 73|gene regulation
P11579100T0000|78 95|cell transformation
P11580173A0181|0 16|Plane wave geometry
P11580173A0181|19 29|impractical
P11580173A0181|33 43|clinical use
P11580173A0181|50 56|results
P11580173A0181|81 87|further
P11580173A0181|98 112|P3 approximation
P11580173A0181|117 133|spherical geometry
P11580301A1161|14 25|HCV arthritis
P11580301A1161|28 35|patients
P11580301A1161|40 63|positive rheumatoid factor
P11580301A1161|67 98|chronic inflammatory polyarthritis
P11580757A0304|0 6|METHODS
P11580757A0304|35 46|TFCD patients
P11580757A0304|69 87|intractable epilepsy
P11580757A0304|111 127|magnetic resonance
P11580757A0304|129 130|MR
P11580757A0304|133 148|detectable lesion
P11580757A0304|158 174|epileptogenic zone
P11580757A0304|184 222|stereoelectroencephalographic recordings
P11580941A0815|0 6|RESULTS
P11580941A0815|10 26|latest examination
P11580941A0815|32 38|UPDRS II
P11580941A0815|42 50|III scores
P11580941A0815|66 66|%
P11580941A0815|70 80|stimulation
P11580941A0815|103 112|% reduction
P11583428A0191|2 4|Exp
P11583621A0301|0 30|Several distinct apoptotic stimuli
P11583621A0301|53 77|caspase-dependent cleavage
P11583621A0301|53 59|caspase
P11583621A0301|80 83|hTAF
P11583621A0301|90 94|delta
P11583621A0301|96 99|hTAF
P11583621A0301|106 110|delta
P11583621A0301|118 124|hTAF(II
P11583621A0301|118 121|hTAF
P11583621A0301|135 151|TFIID-like complex
P11583621A0301|159 165|hTAF(II
P11583621A0301|159 162|hTAF
P11583880T0000|0 25|Endovascular aneurysm repair
P11583880T0000|33 49|AneuRx stent-graft
P11584107T0000|0 25|Chronic nutritional diseases
P11584107T0000|28 43|infectious origin
P11584107T0000|60 71|nascent field
P11584328A0532|0 15|Drug interactions
P11584328A0532|33 37|drugs
P11584328A0532|55 74|same CYP450 isoenzymes
P11584328A0532|59 74|CYP450 isoenzymes
P11584328A0532|77 83|statins
P11585856A0285|0 6|METHODS
P11585856A0285|20 34|clinical benefit
P11585856A0285|37 53|depth-dependent RR
P11585856A0285|55 66|nonuniform AC
P11585856A0285|73 90|scanning line source
P11585856A0285|95 111|scatter correction
P11585856A0285|113 132|photon energy recovery
P11585856A0285|134 136|PER
P11585856A0285|159 172|backprojection
P11586096A0699|9 19|differences
P11586096A0699|22 43|patient characteristics
P11586096A0699|45 63|control measurements
P11586096A0699|80 91|normal muscle
P11586096A0699|97 104|patients
P11587514A0758|11 27|abi1-1 gene product
P11587514A0758|44 57|ABA suppression
P11587514A0758|61 90|GA-responsive alpha-amylase gene
P11587980A1039|2 15|children unable
P11587980A1039|25 49|forced expiratory maneuvers
P11587980A1039|51 52|n =
P11587980A1039|57 59|FOT
P11587980A1039|61 68|contrary
P11587980A1039|74 93|interrupter technique
P11587980A1039|113 120|subgroup
P11587980A1039|123 135|young children
P11587980A1039|140 159|high resistance values
P11587980A1039|162 169|baseline
P11587980A1039|197 211|bronchodilation
P11589568A0744|9 13|yeast
P11589568A0744|19 42|latter checkpoint response
P11589568A0744|54 65|proteins Mad1
P11589568A0744|71 74|Bub1
P11589568A0744|78 81|Bub3
P11589568A0744|88 109|vertebrate counterparts
P11589568A0744|120 141|unattached kinetochores
P11589779T0000|0 5|HTLV-1
P11589779T0000|15 21|Th2 type
P11589779T0000|24 37|immune response
P11589779T0000|40 47|patients
P11589779T0000|52 67|strongyloidiasis
P11590364A1056|11 29|beta5L splice variant
P11590364A1056|47 52|retina
P11592315A0325|0 8|PROCEDURE
P11592315A0325|10 17|Cannulas
P11592315A0325|47 58|abomasal body
P11592315A0325|62 74|pyloric antrum
P11592315A0325|81 84|calf
P11592532A0188|0 6|METHODS
P11592532A0188|8 33|Humphrey Field Analyzer model
P11592532A0188|38 40|HFA
P11592532A0188|59 69|rectangular
P11592532A0188|71 77|degrees
P11592532A0188|80 90|degrees grid
P11592532A0188|104 131|conventional perimetric method
P11593394A0000|0 28|Transforming growth factor-beta
P11593394A0000|12 28|growth factor-beta
P11593394A0000|30 37|TGF-beta
P11593394A0000|46 57|growth arrest
P11593394A0000|60 64|cells
P11593394A0000|88 97|activities
P11593394A0000|104 104|D
P11593394A0000|109 135|E-type cyclin kinase complexes
P11593394A0000|181 183|p15
P11593394A0000|185 189|Ink4b
P11593394A0000|194 196|p27
P11593394A0000|198 201|Kip1
P11593394A0000|203 224|cyclin kinase inhibitors
P11593394A0000|203 214|cyclin kinase
P11595170A0582|0 8|Alignment
P11595170A0582|11 24|different cDNAs
P11595170A0582|30 34|NR5A2
P11595170A0582|36 39|hB1F
P11595170A0582|52 66|genomic sequence
P11595170A0582|81 91|delineation
P11595170A0582|97 118|structural organization
P11595170A0582|137 138|kb
P11595170A0582|157 161|exons
P11595170A0582|180 186|introns
P11595176T0000|3 18|genomic structure
P11595176T0000|24 37|human SPEC1 gene
P11595176T0000|45 59|complex splicing
P11595176T0000|63 84|close promoter proximity
P11595176T0000|90 110|AF1q translocation gene
P11595478A1014|0 18|Hp positive relatives
P11595478A1014|21 33|gastric cancer
P11595478A1014|46 61|higher prevalence
P11595478A1014|64 70|atrophy
P11595478A1014|84 95|Hp negativity
P11595478A1014|103 117|cancer relatives
P11595813A0633|0 19|Peripheral metabolism
P11595813A0633|22 30|androgens
P11595813A0633|43 54|various areas
P11595813A0633|64 80|pilosebaceous unit
P11595813A0633|95 110|local differences
P11595813A0633|116 125|activities
P11595813A0633|128 136|aromatase
P11595813A0633|138 153|5alpha-reductase
P11595813A0633|180 196|androgen receptors
P11595840A0000|3 8|uptake
P11595840A0000|11 39|fluorine-18 fluorodeoxyglucose
P11595840A0000|41 47|F-18 FDG
P11595840A0000|52 65|malignant tumor
P11595840A0000|78 94|blood glucose level
P11596104A0614|0 19|Northern blot analysis
P11596104A0614|32 37|PARNAs
P11596104A0614|53 66|abundant signal
P11596104A0614|85 93|kilobases
P11596104A0614|95 96|kb
P11596104A0614|110 118|cell lines
P11596838A1357|28 48|fluticasone propionate
P11596838A1357|51 56|microg
P11596838A1357|69 87|first-line treatment
P11596838A1357|90 97|patients
P11596838A1357|102 117|persistent asthma
P11596838A1357|139 163|short-acting beta2-agonist
P11597185A0477|7 58|space-discrete/continuous metapopulation dynamic models
P11597185A0477|62 80|computer simulations
P11597185A0477|116 131|different regimes
P11597185A0477|134 155|metapopulation dynamics
P11597936A0570|5 15|CAD patients
P11597936A0570|35 49|treated patients
P11597936A0570|61 65|years
P11597936A0570|68 96|baseline low density lipoprotein
P11597936A0570|102 106|mg/dL
P11597936A0570|112 124|triglycerides
P11597936A0570|131 135|mg/dL
P11597936A0570|166 184|lipid-lowering drugs
P11597936A0570|199 206|controls
P11599079A1040|3 30|corresponding orifice voltages
P11599079A1040|42 52|instruments
P11599079A1040|65 65|V
P11599079A1040|67 69|API
P11599079A1040|84 84|V
P11599079A1040|86 88|API
P11599079A1040|106 106|V
P11599079A1040|108 110|API
P11599797A0732|0 6|RESULTS
P11599797A0732|9 17|novel gene
P11599840A0813|3 8|moduli
P11599840A0813|11 20|elasticity
P11599840A0813|33 43|white matter
P11599840A0813|57 59|kPa
P11599840A0813|68 84|standard deviation
P11599840A0813|98 100|kPa
P11599840A0813|106 117|axial section
P11599840A0813|126 128|kPa
P11599840A0813|141 143|kPa
P11599840A0813|149 162|frontal section
P11599840A0813|176 178|kPa
P11599840A0813|191 193|kPa
P11599840A0813|199 213|sagittal section
P11600252A0795|3 4|LA
P11600252A0795|23 34|combined data
P11600252A0795|54 66|earlier series
P11600252A0795|96 112|significant change
P11600314A0000|0 24|Direct current polarography
P11600314A0000|28 64|differential pulse polarographic methods
P11600314A0000|88 98|qualitative
P11600314A0000|107 126|quantitative analysis
P11600314A0000|129 137|vitamin B1
P11600314A0000|139 140|B2
P11600314A0000|144 145|B6
P11600365A0471|7 28|gram-positive organisms
P11600365A0471|30 35|E-4767
P11600365A0471|39 44|E-5065
P11600365A0471|91 102|tosufloxacin
P11600365A0471|118 123|potent
P11600365A0471|129 146|reference compounds
P11600467A1436|20 40|significant alteration
P11600467A1436|43 69|small intestinal permeability
P11602353A0770|13 21|HNF-3 beta
P11602353A0770|23 27|HFH-1
P11602353A0770|29 33|HFH-2
P11602353A0770|35 39|HFH-3
P11602353A0770|41 45|C/EBP
P11602353A0770|50 58|C/EBP beta
P11602353A0770|90 122|tissue-specific expression profiles
P11603271T0001|8 14|vertigo
P11603271T0001|18 33|vertigo syndromes
P11604152A0526|3 6|MABP
P11604152A0526|10 21|MCBFV signals
P11604152A0526|26 33|bandpass
P11604152A0526|51 68|low-frequency range
P11604152A0526|70 72|VLF
P11604152A0526|84 85|Hz
P11604152A0526|88 105|low-frequency range
P11604152A0526|107 108|LF
P11604152A0526|119 120|Hz
P11604152A0526|145 146|HF
P11604152A0526|157 158|Hz
P11604152A0526|174 176|CCF
P11604152A0526|211 229|different bandwidths
P11604152A0526|244 251|mean CCFs
P11605207T0001|0 8|Treatment
P11605207T0001|11 30|ischemic heart disease
P11605598A0785|0 9|Hepatitis B
P11605598A0785|13 32|C seroprevalence rates
P11605598A0785|38 57|high-risk adolescents
P11605598A0785|68 73|El Paso
P11605598A0785|80 104|other similar US populations
P11605598A0785|118 129|ideal climate
P11605598A0785|133 150|prevention programs
P11606538A1002|1 16|twelfth insertion
P11606538A1002|28 32|genes
P11606538A1002|34 36|Nrk
P11606538A1002|39 75|"neurospecific" receptor tyrosine kinase
P11606538A1002|40 52|neurospecific
P11606538A1002|54 75|receptor tyrosine kinase
P11606538A1002|80 82|Tpp
P11606538A1002|97 110|neuropeptidase
P11614398T0000|1 14|peculiar people
P11614398T0000|20 39|physiological aspects
P11614398T0000|42 50|Mormonism
P11626110T0000|3 11|Available
P11639485A0478|4 13|unique work
P11639485A0478|66 69|Urdu
P11639485A0478|73 86|other languages
P11639485A0478|105 122|present day students
P11639485A0478|126 133|scholars
P11642687T0000|0 9|Comparison
P11642687T0000|12 33|German language versions
P11642687T0000|39 44|QWB-SA
P11642687T0000|48 52|SF-36
P11642687T0000|63 70|outcomes
P11642687T0000|74 81|patients
P11642687T0000|86 100|prostate disease
P11653491T0000|0 17|Disciplinary action
P11653491T0000|21 32|DNA violation
P11669281A0653|0 21|Epithelial cytotoxicity
P11669281A0653|24 42|combined antibiotics
P11669281A0653|46 53|additive
P11669281A0653|84 92|synergism
P11669476A0346|0 23|Pro-inflammatory cytokine
P11669476A0346|25 49|tumor necrosis factor-alpha
P11669476A0346|51 59|TNF-alpha
P11669476A0346|74 87|adipose tissues
P11669476A0346|90 102|obese subjects
P11669476A0346|118 132|predominant role
P11669476A0346|143 159|insulin resistance
P11669476A0346|143 149|insulin
P11675912A0131|49 68|analgesic preparation
P11675912A0131|80 86|aspirin
P11675912A0131|90 102|acetaminophen
P11675912A0131|107 117|alleviation
P11675912A0131|120 128|headaches
P11676899A0704|7 26|important risk factors
P11676899A0704|43 59|Epstein-Barr virus
P11676899A0704|61 83|infectious mononucleosis
P11676899A0704|88 97|congenital
P11676899A0704|109 124|immunodeficiency
P11676899A0704|128 147|occupational exposure
P11676899A0704|152 163|wood industry
P11677363A0775|7 22|important finding
P11677363A0775|39 47|IMT values
P11677363A0775|65 68|h SBP
P11677363A0775|71 89|PP standard deviation
P11677363A0775|91 91|P
P11677363A0775|110 119|overall SBP
P11677363A0775|122 134|PP variability
P11677839A0876|23 30|patients
P11677839A0876|37 44|controls
P11677839A0876|73 74|p =
P11678437A0000|11 26|crude oil spillage
P11678437A0000|51 64|nutrient uptake
P11678437A0000|67 71|maize
P11678437A0000|73 81|Zea mays L.
P11678437A0000|97 109|pot experiment
P11678437A0000|117 137|Evwreni manifold sample
P11678437A0000|141 167|petroleum development company
P11678437A0000|178 192|specific gravity
P11679441A0429|0 12|NO metabolites
P11679441A0429|45 59|nitrate/nitrite
P11679441A0429|61 63|NOx
P11679441A0429|65 87|micromol/mmol creatinine
P11679441A0429|92 119|cyclic guanosine monophosphate
P11679441A0429|121 124|cGMP
P11679441A0429|126 144|nmol/mmol creatinine
P11679441A0429|148 153|plasma
P11679441A0429|157 161|urine
P11680835A0756|5 21|base-case analysis
P11680835A0756|23 38|total direct costs
P11680835A0756|60 73|zoledronic acid
P11680835A0756|84 94|pamidronate
P11683558A0446|9 16|migrants
P11683558A0446|36 49|macronutrients
P11683558A0446|63 76|micronutrients
P11683558A0446|78 88|differences
P11683558A0446|96 111|general Dutch diet
P11684665A0000|0 21|C. elegans embryogenesis
P11684665A0000|33 51|stereotyped sequence
P11684665A0000|54 76|asymmetric cell divisions
P11684665A0000|120 135|nematode body plan
P11685047A0301|9 25|chromogenic method
P11685047A0301|41 58|thrombin inhibition
P11685047A0301|41 48|thrombin
P11685047A0301|65 79|substrate S-2238
P11685284X0000|1 12|Diabetologia
P11685284X0000|22 26|Suppl
P11685284X0000|30 36|B37-B44
P11686239A0464|5 20|flanking sequence
P11686239A0464|26 31|3B gene
P11686239A0464|45 49|T rich
P11686239A0464|65 80|G/C rich stretches
P11686239A0464|99 101|7bp
P11686239A0464|116 139|strong sequence similarity
P11686239A0464|145 150|G boxes
P11686239A0464|195 212|Dictyostelium genes
P11686378A0326|18 24|reactor
P11686378A0326|52 60|discharge
P11686378A0326|68 72|LD50 =
P11686378A0326|76 81|values
P11686378A0326|104 109|E. coli
P11686378A0326|110 123|concentrations
P11686378A0326|146 157|= E coli/cfu mL
P11686378A0326|165 165|=
P11686378A0326|186 206|nonexponential Pn decay
P11686378A0326|209 221|single-strain
P11686378A0326|228 235|colonies
P11686378A0326|263 275|inactive cells
P11686378A0326|298 311|smaller numbers
P11686378A0326|314 324|viable cells
P11686378A0326|330 332|EHD
P11687083A0218|0 9|OBJECTIVES
P11687083A0218|49 55|effects
P11687083A0218|58 85|prophylactic prostaglandin use
P11687083A0218|91 100|third stage
P11687083A0218|103 108|labour
P11687180A3209|5 12|long term
P11687180A3209|14 22|questions
P11687180A3209|46 63|pre-dialysis rHu EPO
P11687180A3209|58 63|rHu EPO
P11687180A3209|70 75|speeds
P11687180A3209|80 85|delays
P11687180A3209|89 93|onset
P11687180A3209|96 103|dialysis
P11687352A0215|0 6|METHODS
P11687352A0215|12 30|retrospective review
P11687352A0215|44 47|eyes
P11687352A0215|55 59|LASIK
P11687352A0215|67 75|September
P11687352A0215|83 91|September
P11687517A1619|2 6|ISREs
P11687517A1619|29 41|mouse promoter
P11687737A0000|0 9|BACKGROUND
P11687737A0000|11 30|Ischemic heart disease
P11687737A0000|36 47|primary cause
P11687737A0000|50 58|morbidity
P11687737A0000|76 84|diabetics
P11687737A0000|116 123|young age
P11687869A0000|1 16|38-year-old woman
P11687869A0000|21 37|ulcerative colitis
P11687869A0000|59 69|sarcoidosis
P11689217T0000|0 30|Cholesteryl ester transfer protein
P11689217T0000|34 48|atherosclerosis
P11689217T0000|51 66|Japanese subjects
P11689217T0000|81 99|coronary angiography
P11691585A1174|0 33|Electrophoretic mobility shift assays
P11691585A1174|37 64|coimmunoprecipitation studies
P11691585A1174|76 79|homo
P11691585A1174|84 101|heterodimerization
P11691585A1174|115 132|cKrox family members
P11691585T0000|3 18|hcKrox gene family
P11691585T0000|28 59|multiple extracellular matrix genes
P11692004A1200|33 60|comprehensive clinical studies
P11692004A1200|110 112|NF1
P11692004A1200|116 136|intracranial aneurysms
P11693461A1649|5 19|utilisation data
P11693461A1649|25 39|annual drug costs
P11693461A1649|53 54|US
P11693461A1649|65 66|US
P11693461A1649|79 92|TNF antagonists
P11693461A1649|79 81|TNF
P11693461A1649|96 97|RA
P11695481A0310|8 17|conditions
P11695481A0310|22 37|combination O3/UV
P11695481A0310|54 68|degradation rate
P11695481A0310|79 87|ozonation
P11697760A0000|28 32|boron
P11697760A0000|57 72|17beta-estradiol
P11697760A0000|74 75|E2
P11697760A0000|79 96|parathyroid hormone
P11697760A0000|98 100|PTH
P11697760A0000|111 121|bone quality
P11697760A0000|138 144|OVX rats
P11703464A0560|12 30|control subjects rCBF
P11703464A0560|42 48|regions
P11703464A0560|66 78|meso-striatal
P11703464A0560|82 107|meso-corticolimbic circuits
P11703464A0560|124 137|monetary reward
P11703464A0560|141 164|nonmonetary reinforcement
P11703558A0000|0 10|Doxorubicin
P11703558A0000|12 14|DOX
P11703558A0000|47 59|hematological
P11703558A0000|63 73|solid tumors
P11704380A1608|3 11|event rate
P11704380A1608|14 21|patients
P11704380A1608|26 40|chronic Irr-rMFP
P11704380A1608|43 50|Un-nrMFP
P11704380A1608|62 67|higher
P11704380A1608|88 95|Rev-rMFP
P11704380A1608|88 90|Rev
P11704380A1608|98 106|Sta-nrMFP
P11704829A0312|0 23|Subtraction hybridization
P11704829A0312|34 56|melanoma differentiation
P11704829A0312|67 72|gene-7
P11704829A0312|74 78|mda-7
P11704829A0312|106 125|physiological changes
P11704829A0312|128 145|human melanoma cells
P11705093A2016|10 27|vitamin D3 analogues
P11705093A2016|33 62|substantial antipsoriatic effect
P11706668A0000|0 9|Hydrocoele
P11706668A0000|20 22|men
P11706668A0000|35 56|bancrofti-endemic areas
P11706668A0000|89 108|surgical intervention
P11706949T0000|0 12|Growth hormone
P11706949T0000|16 49|insulin-like growth factor I receptors
P11706949T0000|55 76|temporomandibular joint
P11707977A0750|5 13|other hand
P11707977A0750|15 44|hepatic arterial infusion therapy
P11707977A0750|66 75|H3 patients
P11708032A0183|28 56|hepatic intra-arterial infusion
P11708032A0183|59 70|levoforinate
P11708032A0183|72 75|l-LV
P11708032A0183|80 81|mg
P11708032A0183|85 98|5-fluorouracil
P11708032A0183|100 103|5-FU
P11708032A0183|108 109|mg
P11708032A0183|113 145|combined multiple hepatic metastases
P11708032A0183|156 171|postoperative day
P11708032A0183|183 193|medications
P11708032A0183|216 220|hours
P11708032A0183|233 243|infuser pump
P11708362A0889|3 15|astronaut crew
P11708362A0889|27 33|payload
P11708431A0904|8 15|patients
P11708431A0904|34 49|separate category
P11708431A0904|59 72|oligoarthritis
P11708431A0904|75 79|onset
P11708431A0904|110 132|comparable patient groups
P11708761A1388|32 40|arguments
P11708761A1388|58 70|ACE inhibitors
P11708761A1388|58 60|ACE
P11708761A1388|82 89|patients
P11708761A1388|94 109|diabetes mellitus
P11709561T0000|0 4|Phase
P11709561T0000|17 22|anti-G
P11709561T0000|24 25|D2
P11709561T0000|27 47|monoclonal antibody 3F8
P11709561T0000|51 96|granulocyte-macrophage colony-stimulating factor
P11709561T0000|100 112|neuroblastoma
P11709890T0000|0 28|Hepatitis A infected food handler
P11709890T0000|33 40|Edmonton
P11709890T0000|42 66|Alberta retail food facility
P11709890T0000|68 99|public health protection strategies
P11710233T0000|0 8|Hydrogels
P11710233T0000|12 28|tissue engineering
P11710685A0994a|14 19|subset
P11710685A0994a|22 26|ASCUS
P11710685A0994a|37 50|ASCUS/SIL ratio
P11710685A0994a|100 115|Papanicolaou test
P11710685A0994b|14 19|subset
P11710685A0994b|22 26|ASCUS
P11710685A0994b|37 50|ASCUS/SIL ratio
P11710685A0994b|100 115|Papanicolaou test
P11711701A0602|3 27|nuclear medicine physicians
P11711701A0602|40 55|surgical findings
P11711701A0602|70 84|available images
P11711701A0602|88 121|various Tc-99m MIBI image combinations
P11711701A0602|126 132|minutes
P11711701A0602|141 147|minutes
P11711701A0602|152 156|hours
P11711701A0602|160 166|minutes
P11711701A0602|171 175|hours
P11711701A0602|182 188|minutes
P11711701A0602|197 201|hours
P11711701A0602|220 257|correlative pertechnetate thyroid imaging
P11714429X0000|2 20|clopidogrel superior
P11714429X0000|23 29|aspirin
P11714429X0000|32 50|secondary prevention
P11714429X0000|53 67|vascular disease
P11714429X0000|72 82|cornerstone
P11714429X0000|85 100|clinical evidence
P11714429X0000|106 121|relative efficacy
P11714429X0000|124 138|thienopyridines
P11714429X0000|140 150|clopidogrel
P11714429X0000|152 162|ticlopidine
P11714429X0000|170 176|aspirin
P11714429X0000|182 200|secondary prevention
P11714429X0000|203 217|vascular disease
P11714429X0000|223 233|Clopidogrel
P11714429X0000|240 246|Aspirin
P11714429X0000|249 256|Patients
P11714429X0000|259 262|Risk
P11714429X0000|265 284|Ischaemic Events trial
P11715079A1016|17 30|proprioception
P11715079A1016|54 66|efference copy
P11715079A1016|99 111|perturbations
P11715079A1016|123 141|potential mismatches
P11715079A1016|149 170|eye movement information
P11715079A1016|185 199|efferent command
P11715079A1016|206 217|actual motion
P11715079A1016|241 260|proprioceptive organs
P11716043A0380|22 29|patients
P11716043A0380|49 58|primary PTC
P11716043A0380|64 73|Department
P11716043A0380|76 82|Surgery
P11716043A0380|84 116|Helsinki University Central Hospital
P11716441A0585|0 2|ISS
P11716441A0585|9 23|acute physiology
P11716441A0585|27 49|chronic health evaluation
P11716441A0585|51 56|APACHE
P11718197A1282|42 51|sternotomy
P11722993A0276|0 10|Paul Monagle
P11722993A0276|23 34|epidemiology
P11722993A0276|37 54|neonatal thrombosis
P11722993A0276|67 86|central nervous system
P11722993A0276|93 100|arterial
P11722993A0276|104 118|venous locations
P11722993A0276|139 143|utero
P11723500X0000|1 8|Clinical
P11723500X0000|12 41|epidemiological characteristics
P11723500X0000|44 64|squamous cell carcinoma
P11723500X0000|70 79|oral cavity
P11723500X0000|82 86|women
P11723500X0000|88 97|BACKGROUND
P11723500X0000|99 119|Squamous cell carcinoma
P11723500X0000|121 123|SCC
P11723500X0000|130 139|oral cavity
P11723500X0000|157 170|male population
P11723511A0780|9 23|gestational risk
P11723511A0780|30 34|drugs
P11723511A0780|42 42|%
P11723511A0780|54 66|category A risk
P11723511A0780|78 78|%
P11723511A0780|82 90|category B
P11723511A0780|102 102|%
P11723511A0780|106 114|category C
P11723511A0780|123 123|%
P11723511A0780|127 135|category D
P11723511A0780|146 146|%
P11723511A0780|150 159|category X.
P11723675A1022|3 10|severity
P11723675A1022|13 26|clinical course
P11723675A1022|41 45|means
P11723675A1022|48 56|SOFA score
P11723675A1022|58 63|group A
P11723675A1022|71 77|.3 point
P11723675A1022|79 84|group B
P11723675A1022|102 107|group C
P11723675A1022|113 114|.3
P11723675A1022|128 140|APACHE II score
P11723675A1022|142 147|group A
P11723675A1022|165 170|group B
P11723675A1022|190 195|group C
P11723675A1022|203 204|.2
P11723928A0294|29 44|river reclamation
P11723928A0294|47 60|Yangpu District
P11723928A0294|63 74|Shanghai City
P11723928A0294|76 80|China
P11724510T0000|0 17|Physical principles
P11724510T0000|20 39|therapeutic apheresis
P11726022A0909|5 11|results
P11726022A0909|31 39|estimates
P11726022A0909|42 52|penetration
P11726022A0909|57 80|steady-state calculations
P11726022A0909|82 91|square root
P11726022A0909|94 109|time calculations
P11726022A0909|132 148|mathematical model
P11726068A0539|0 3|Rind
P11726068A0539|18 32|main conclusions
P11726068A0539|54 65|original data
P11726164A0215|2 13|major concern
P11726164A0215|16 29|food processors
P11726164A0215|35 58|inadvertent cross-contact
P11726164A0215|61 72|food products
P11726164A0215|77 94|allergenic residues
P11726164A0215|125 149|life-threatening reactions
P11726164A0215|162 172|food allergy
P11726262A0692|0 22|Lactate accumulation peak
P11726262A0692|26 35|unaffected
P11726262A0692|38 52|supplementation
P11726262A0692|54 56|HMB
P11726262A0692|67 68|mM
P11726262A0692|70 72|LEU
P11726262A0692|83 84|mM
P11726262A0692|86 88|CON
P11726262A0692|99 100|mM
P11726413A1756|12 20|clearance
P11726413A1756|31 42|young infants
P11726413A1756|57 68|other opioids
P11726574A1304|5 11|results
P11726574A1304|16 21|robust
P11726574A1304|24 30|changes
P11726574A1304|36 54|baseline assumptions
P11727073A0842|0 9|CONCLUSION
P11727073A0842|24 30|novices
P11727073A0842|36 67|MIST-VR yields quantifiable changes
P11727073A0842|82 93|transferable
P11727073A0842|97 110|simple real task
P11727073A0842|129 135|results
P11727073A0842|148 167|conventional training
P11727209A0502|3 10|patients
P11727209A0502|19 26|families
P11727209A0502|52 74|full clinical examination
P11727209A0502|91 101|orthostasia
P11728771A0187|50 65|contrast material
P11730182A0984|22 43|significant correlation
P11730182A0984|51 87|simultaneous weekly average pollen levels
P11730182A0984|90 101|Philadelphia
P11730182A0984|107 116|Cherry Hill
P11730182A0984|118 121|Acer
P11730182A0984|123 123|r
P11730182A0984|125 125|p
P11730182A0984|127 127|=
P11730182A0984|134 140|Quercus
P11730182A0984|142 142|r
P11730182A0984|144 144|p
P11730182A0984|146 146|=
P11730182A0984|153 158|Betula
P11730182A0984|160 160|r
P11730182A0984|162 162|p
P11730182A0984|164 164|=
P11730182A0984|171 175|Pinus
P11730182A0984|177 177|r
P11730182A0984|179 179|p
P11730182A0984|181 181|=
P11730182A0984|188 199|Cupressaceae
P11730182A0984|201 201|r
P11730182A0984|203 203|p
P11730182A0984|205 205|=
P11730182A0984|212 218|Poaceae
P11730182A0984|220 220|r
P11730182A0984|222 222|p
P11730182A0984|224 224|=
P11730182A0984|231 238|Ambrosia
P11730182A0984|240 240|r
P11730182A0984|242 242|p
P11730182A0984|244 244|=
P11730182A0984|254 258|Rumex
P11730182A0984|260 260|r
P11730182A0984|262 262|p
P11730182A0984|264 264|=
P11730182A0984|271 271|P
P11730262A0874|13 22|Dutch study
P11730262A0874|28 46|etidronate/fluoride
P11730262A0874|49 77|corticoid-induced osteoporosis
P11730262A0874|91 100|pilot study
P11730262A0874|105 107|men
P11730262A0874|112 147|severe established primary osteoporosis
P11730262A0874|164 173|etidronate
P11730262A0874|179 182|days
P11730262A0874|193 200|fluoride
P11730262A0874|205 220|calcium/vitamin D
P11730262A0874|226 229|days
P11730712A0416|0 16|Treadmill training
P11730712A0416|28 32|weeks
P11730712A0416|45 58|infarction size
P11730712A0416|62 66|edema
P11730712A0416|75 86|MCA occlusion
P11730712A0416|88 88|P
P11732088A0471|20 40|false positive readings
P11732088A0471|58 75|sphincter manometry
P11732088A0471|92 99|secretin
P11732088A0471|110 129|endoscopic ultrasound
P11732088A0471|131 135|SSEUS
P11732088A0471|146 169|pancreatic ductal response
P11732088A0471|174 189|adjunctive method
P11732417A0571|3 34|cut-off percentage positivity value
P11732417A0571|57 76|brucellosis-positive
P11732417A0571|83 114|brucellosis-negative serum samples
P11732417A0571|143 152|sample data
P11732417A0571|161 176|indirect ELISA kit
P11736254A0000|43 56|solvable models
P11736254A0000|70 82|strong glasses
P11736254A0000|97 108|partitioning
P11736254A0000|114 133|free-energy landscape
P11736254A0000|136 153|inherent structures
P11736792A0204|9 20|semen samples
P11736792A0204|51 59|subnormal
P11736792A0204|61 62|G1
P11736792A0204|80 81|G2
P11736792A0204|90 120|World Health Organization criteria
P11736792A0204|131 140|morphology
P11736792A0204|170 183|strict criteria
P11737056A0680|6 14|timepoint
P11737056A0680|16 29|many leucocytes
P11737056A0680|35 36|ME
P11737056A0680|40 47|ET mucosa
P11737056A0680|63 66|BrdU
P11737056A0680|82 82|%
P11737056A0680|92 98|subsets
P11737158A1517|0 21|Modality-specific areas
P11737158A1517|28 40|right Wernicke
P11737158A1517|46 58|fusiform gyrus
P11737158A1517|60 68|Broca BA44
P11737158A1517|70 87|supramarginal gyrus
P11737158A1517|109 128|computations relevant
P11737158A1517|153 174|more abstract dimensions
P11737900A0700|27 35|plasma COP
P11737900A0700|39 48|body weight
P11737900A0700|54 60|same age
P11737900A0700|62 64|r2 =
P11737900A0700|70 71|P =
P11738404A0120|5 22|chemical structures
P11738404A0120|40 44|alpha
P11738404A0120|47 82|alpha-diacetoxy-8 beta-isobutanoyloxy
P11738404A0120|85 103|alpha-benzoyloxy-13
P11738404A0120|106 117|alpha-methyl
P11738404A0120|119 135|butanoyloxy-4 beta
P11738404A0120|138 174|beta-dihydroxy-beta-dihydroagarofuran
P11738404A0120|180 184|alpha
P11738404A0120|187 207|alpha-diacetoxy-8 beta
P11738404A0120|210 213|beta
P11738404A0120|215 230|furancarbonyloxy
P11738404A0120|234 273|alpha-benzoyloxy-13-isobutanoyloxy-4 beta
P11738404A0120|276 312|beta-dihydroxy-beta-dihydroagarofuran
P11738404A0120|320 324|alpha
P11738404A0120|327 330|beta
P11738404A0120|333 409|alpha,13-tetraacetoxy-9 alpha-benzoyloxy-2 alpha-hydroxy-beta-dihydroagarofuran
P11738404A0120|421 431|analyses NMR
P11738404A0120|435 448|MS spectral data
P11740571A0114|4 9|toxins
P11740571A0114|37 67|maximum permissible concentration
P11740571A0114|87 107|glutathione peroxidase
P11740571A0114|110 120|brain tissue
P11740571A0114|131 137|toluene
P11740571A0114|147 172|chemiluminescence intensity
P11740571A0114|189 198|activation
P11740571A0114|201 220|free radical processes
P11740806X0810|0 14|Saunders Company
P11741259A1233|16 36|pH-sensitive particles
P11741259A1233|95 103|upper part
P11741259A1233|109 117|intestine
P11741259A1233|121 129|molecular
P11741259A1233|132 144|amorphous form
P11741554T0000|0 9|Comparison
P11741554T0000|12 43|remnant-like lipoprotein particles
P11741554T0000|46 64|postmenopausal women
P11741554T0000|79 99|coronary artery disease
P11741554T0000|105 107|men
P11741554T0000|112 132|coronary artery disease
P11742432A0798|7 13|results
P11742432A0798|32 37|trials
P11742432A0798|46 60|minimal efficacy
P11742432A0798|73 86|MAC prophylaxis
P11742432A0798|89 96|patients
P11742432A0798|109 146|potent combination antiretroviral therapy
P11742432A0798|159 171|high incidence
P11742432A0798|174 213|macrolide-resistant bacterial colonization
P11742432A0798|219 234|respiratory tract
P11742432A0798|257 271|discontinuation
P11742432A0798|274 293|macrolide prophylaxis
P11742432A0798|299 310|AIDS patients
P11742432A0798|316 324|CD4 counts
P11742432A0798|316 318|CD4
P11742432A0798|342 353|cells/microL
P11743360A2491|0 10|Acute stress
P11743360A2491|14 17|rats
P11743360A2491|34 43|mean amount
P11743360A2491|46 49|IL-6
P11743360A2491|63 67|urine
P11743360A2491|74 74|%
P11743360A2491|107 108|pg
P11743360A2491|111 112|ml
P11743612A1179|0 7|Patients
P11743612A1179|12 13|CF
P11743612A1179|17 29|meconium ileus
P11743612A1179|40 60|poor nutritional status
P11743612A1179|76 92|lower survival rate
P11743612A1179|106 124|general CF population
P11744290T0045|1 9|Cactaceae
P11744290T0045|11 21|waste matter
P11744953A0878|0 10|Skin cancers
P11744953A0878|22 42|gastrointestinal tract
P11744953A0878|46 62|male genital system
P11744953A0878|77 92|older age patients
P11752821A1365|0 9|CONCLUSION
P11752821A1365|11 13|MMF
P11752821A1365|18 22|g/day
P11752821A1365|44 48|signs
P11752821A1365|51 82|mucocutaneous Adamantiades-Behcet
P11755894A0466|16 34|opioid naive patients
P11755894A0466|65 71|opioids
P11755894A0466|75 83|acute pain
P11755894A0466|85 91|oral ADL
P11755894A0466|102 103|mg
P11755894A0466|128 145|postoperative ileus
P11755894A0466|147 149|POI
P11755894A0466|179 197|normal bowel function
P11755894A0466|213 224|hospital stay
P11760398A0553|0 6|METHODS
P11760398A0553|11 29|consecutive patients
P11760398A0553|34 35|BS
P11760398A0553|42 49|patients
P11760398A0553|54 83|other rheumatological conditions
P11760398A0553|124 131|features
P11760398A0553|134 135|BS
P11760398A0553|138 142|means
P11760398A0553|146 157|standard form
P11760398A0553|189 199|ISG criteria
P11760796A0698|0 7|Evidence
P11760796A0698|20 33|PHACES syndrome
P11760796A0698|40 56|random association
P11760796A0698|61 76|true phakomatosis
P11760796A0698|78 91|further studies
P11760796A0698|116 140|possible genetic background
P11761601A0133|1 15|computer program
P11761601A0133|17 26|ACCESS-IAQ
P11761601A0133|52 65|airflow pattern
P11761601A0133|70 80|time history
P11761601A0133|86 110|contaminant concentrations
P11761601A0133|116 127|occupied zone
P11761601A0133|135 153|inhalation exposures
P11763176A0918|10 23|severe decrease
P11763176A0918|26 45|antithrombin activity
P11763176A0918|26 37|antithrombin
P11763176A0918|69 79|experiments
P11763176A0918|123 123|%
P11764062A0000|3 29|Penn State Worry Questionnaire
P11764062A0000|33 40|Children
P11764062A0000|42 47|PSWQ-C
P11764062A0000|52 82|14-item self-report questionnaire
P11764062A0000|116 123|children
P11764062A0000|159 177|uncontrollable worry
P11764062A0000|179 186|Chorpita
P11764062A0000|193 197|Behav
P11764226A0798|0 13|Classification
P11764226A0798|28 39|ILAR criteria
P11764226A0798|56 63|patients
P11764226A0798|68 75|patients
P11764226A0798|80 94|disease duration
P11764226A0798|98 98|=
P11764226A0798|100 105|months
P11764226A0798|137 149|EULAR criteria
P11765448A0588|9 23|X-ray projection
P11765448A0588|41 48|patients
P11766747A0000|23 38|pathologic review
P11766747A0000|45 52|patients
P11766747A0000|57 79|immature ovarian teratoma
P11768467A0000|0 21|Pyrethroid insecticides
P11768467A0000|51 67|private households
P11769229A0357|3 20|sorption mechanisms
P11769229A0357|32 41|adsorption
P11769229A0357|44 52|partition
P11769229A0357|67 85|repetitious sorption
P11771979A1141|11 17|spatial
P11771979A1141|21 39|temporal variability
P11771979A1141|42 51|LDF signals
P11771979A1141|60 83|cerebrocortical microflow
P11771979A1141|91 99|same range
P11771979A1141|106 117|other methods
P11771979A1141|123 133|other organs
P11771979A1141|135 159|LDF cerebrocortical mapping
P11771979A1141|177 189|large temporal
P11771979A1141|193 212|spatial heterogeneity
P11771979A1141|218 243|cerebrocortical vasculature
P11773168A0915|3 23|5-year overall survival
P11773168A0915|25 26|OS
P11773168A0915|31 54|progression-free survival
P11773168A0915|56 58|PFS
P11773168A0915|60 64|rates
P11773168A0915|73 73|%
P11773168A0915|81 81|%
P11773168A0915|85 88|arm A
P11773168A0915|96 96|%
P11773168A0915|104 104|%
P11773168A0915|108 111|arm B
P11773168A0915|113 114|P =
P11773168A0915|122 123|P =
P11773921A0397|0 6|METHODS
P11773921A0397|8 27|P-selectin expression
P11773921A0397|8 17|P-selectin
P11773921A0397|30 42|nonstimulated
P11773921A0397|46 68|ADP-stimulated platelets
P11773921A0397|107 117|clopidogrel
P11773921A0397|135 149|consecutive days
P11773921A0397|154 161|patients
P11773921A0397|166 186|coronary artery disease
P11773921A0397|190 197|patients
P11773921A0397|217 218|mg
P11773921A0397|221 231|clopidogrel
P11773921A0397|237 253|stent implantation
P11773921A0397|259 266|patients
P11773921A0397|286 308|higher 450-mg clopidogrel
P11773921A0397|331 339|daily dose
P11773921A0397|344 345|mg
P11773921A0397|348 358|clopidogrel
P11773921A0397|366 371|groups
P11775180A0379|0 29|Traditional surgical exploration
P11775180A0379|54 73|gamma-detecting probe
P11775301A0797|27 42|depression scores
P11776922A0830|11 19|sclerosis
P11776922A0830|23 32|resorption
P11776922A0830|38 46|skull base
P11776922A0830|49 53|cases
P11776922A0830|62 68|lesions
P11776922A0830|80 86|lesions
P11777575A0363|30 39|bulgaricus
P11777575A0363|41 54|S. thermophilus
P11777575A0363|77 82|pellet
P11777575A0363|85 88|PyMS
P11777575A0363|114 137|artificial neural networks
P11777575A0363|139 142|ANNs
P11777632A1678|0 1|AF
P11777632A1678|9 39|mixed nuclear/cytoplasmic pattern
P11777632A1678|57 66|epithelial
P11777632A1678|68 78|endothelial
P11777632A1678|83 98|stromal component
P11777632A1678|104 115|normal breast
P11777632A1678|119 131|benign lesions
P11777632A1678|142 155|impressive loss
P11777632A1678|158 169|AF expression
P11777632A1678|158 159|AF
P11777632A1678|189 208|invasive breast cancer
P11777632A1678|212 224|tumoral stroma
P11778044A0000|8 43|joint probability density distributions
P11778044A0000|52 73|key uncertain properties
P11778044A0000|79 91|climate system
P11778044A0000|100 128|optimal fingerprinting approach
P11778044A0000|138 148|simulations
P11778044A0000|153 186|intermediate complexity climate model
P11778044A0000|196 214|distinct diagnostics
P11778044A0000|217 241|recent climate observations
P11778804A0179|0 8|Frequency
P11778804A0179|17 22|curves
P11778804A0179|60 62|FDT
P11781615A0000|0 30|Chronic graft-versus-host disease
P11781615A0000|32 36|cGVHD
P11781615A0000|41 57|major complication
P11781615A0000|60 101|allogeneic hematopoietic cell transplantation
P11782218A0349|10 23|white-on-white
P11782218A0349|25 27|W-W
P11782218A0349|29 37|perimetry
P11782218A0349|39 42|SWAP
P11782218A0349|65 82|greater variability
P11782218A0349|100 109|estimation
P11782218A0349|122 142|ocular media absorption
P11782218A0349|153 171|examination duration
P11782218A0349|177 200|additional learning effect
P11783457A0000|0 12|Preservatives
P11783457A0000|18 35|important component
P11783457A0000|38 59|ophthalmic preparations
P11783457A0000|70 90|antimicrobial activity
P11783457A0000|115 127|decomposition
P11783457A0000|130 139|active drug
P11785085X0001|0 18|Comparative analysis
P11785085X0001|21 37|various techniques
P11785085X0001|40 56|prostatic drainage
P11785085X0001|59 66|patients
P11785085X0001|71 99|chronic obstructive prostatitis
P11785085X0001|104 111|efficacy
P11785085X0001|114 130|prostatic drainage
P11785085X0001|136 164|transurethral vacuum aspiration
P11785085X0001|166 177|Introl-4 unit
P11785085X0001|182 210|transrectal pneumovibromassage
P11785085X0001|212 219|PVM-R-01
P11785085X0001|238 245|patients
P11785085X0001|250 278|chronic obstructive prostatitis
P11785827A0986|3 9|results
P11785827A0986|34 49|acoustical models
P11785827A0986|52 67|sound propagation
P11785827A0986|71 80|physiology
P11785827A0986|102 128|height-dependent degradation
P11785827A0986|146 171|important selection pressure
P11785827A0986|175 190|transmissibility
P11785827A0986|193 210|avian communication
P11786248A1162|0 10|Consumption
P11786248A1162|14 21|% sucrose
P11786248A1162|38 55|excitotoxic lesions
P11786248A1162|61 64|PPTg
P11786248A1162|69 72|PPTg
P11786248A1162|81 84|rats
P11786248A1162|112 112|%
P11786248A1162|118 125|% sucrose
P11786248A1162|130 141|sham controls
P11786945A0958|0 15|Actuarial freedom
P11786945A0958|20 41|ventricular arrhythmias
P11786945A0958|44 58|4-year follow-up
P11786945A0958|72 72|%
P11786945A0958|75 80|group A
P11787041A0167|0 16|Mental development
P11787322X0001|0 8|Influence
P11787322X0001|11 26|different methods
P11787322X0001|29 48|chemical disinfection
P11787322X0001|54 71|physical properties
P11787322X0001|83 89|V gypsum
P11787322X0001|95 112|Several instruments
P11787322X0001|116 124|materials
P11787322X0001|141 154|prosthodontics
P11787322X0001|174 190|dental impressions
P11787322X0001|192 211|interocclusal records
P11787322X0001|233 248|dental literature
P11787322X0001|252 259|vehicles
P11787322X0001|276 293|infectious diseases
P11787720A1313|25 38|slight decrease
P11787720A1313|41 52|linoleic acid
P11787720A1313|54 56|C18
P11787720A1313|59 60|n6
P11787720A1313|66 66|%
P11787720A1313|76 77|P =
P11787720A1313|87 101|arachidonic acid
P11787720A1313|103 105|C20
P11787720A1313|108 109|n6
P11787720A1313|115 115|%
P11787720A1313|117 118|P =
P11787746A0374|0 9|Vitrectomy
P11787746A0374|30 42|lens fragments
P11787746A0374|51 66|good visual acuity
P11787746A0374|77 93|secondary glaucoma
P11787746A0374|109 116|patients
P11789206A1182|0 10|CONCLUSIONS
P11789206A1182|26 29|MIRI
P11789206A1182|32 43|Qi deficiency
P11789206A1182|47 57|blood stasis
P11789206A1182|60 62|TCM
P11789206A1182|75 84|principles
P11789206A1182|102 103|Qi
P11789206A1182|118 128|blood stasis
P11789216T0001|0 6|Effects
P11789216T0001|19 34|blood circulation
P11789216T0001|43 53|blood stasis
P11789216T0001|56 68|barrier action
P11789216T0001|71 81|gastric wall
P11789216T0001|84 107|chronic atrophic gastritis
P11790897T0000|0 16|Proteomic patterns
P11790897T0000|19 24|nipple
P11790897T0000|33 38|fluids
P11790897T0000|49 57|SELDI-TOF
P11790897T0000|71 83|new biomarkers
P11790897T0000|105 116|breast cancer
P11791292A0193|48 60|neural network
P11791571T0000|1 48|high-efficiency cross-flow micronebulizer interface
P11791571T0000|52 75|capillary electrophoresis
P11791571T0000|97 118|plasma mass spectrometry
P11791585A0287|3 12|electrodes
P11791853A0532|3 21|experimental results
P11791853A0532|35 69|coagulation-electrooxidation process
P11791853A0532|106 108|COD
P11791853A0532|116 124|simulated
P11791853A0532|128 137|wastewater
P11792586A0290|0 12|Cyclic loading
P11792586A0290|25 43|normal daily activity
P11792586A0290|65 75|microcracks
P11792586A0290|85 96|tissue matrix
P11792586A0290|99 109|compact bone
P11793172A0545|3 23|weight-bearing surface
P11793172A0545|29 34|PE head
P11793172A0545|41 48|smoother
P11793172A0545|62 64|THA
P11793172A0545|72 90|friction coefficient
P11793172A0545|128 139|unused PE head
P11793614A0000|0 8|OBJECTIVE
P11793614A0000|38 63|steady-state concentrations
P11793614A0000|66 75|cilomilast
P11793614A0000|78 101|new oral phosphodiesterase
P11793614A0000|103 111|inhibitor
P11793614A0000|129 162|chronic obstructive pulmonary disease
P11793614A0000|166 196|warfarin-induced anticoagulation
P11796977T0000|0 7|Postdocs
P11796977T0000|12 19|hardship
P11796977T0000|26 39|mainland Europe
P11800119A0814|3 17|design principle
P11800119A0814|26 45|uniform vibration mode
P11800586A1090|10 17|DPPD gene
P11800586A1090|32 53|non-tuberculous bacilli
P11800586A1090|60 66|results
P11800586A1090|97 110|additional tool
P11800586A1090|119 135|specific diagnosis
P11800586A1090|138 149|tuberculosis
P11800878T0000|0 13|Dynamic imaging
P11800878T0000|16 35|nuclear wave functions
P11800878T0000|40 62|ultrashort UV laser pulses
P11801459T0000|0 7|Efficacy
P11801459T0000|19 25|aspirin
P11801459T0000|31 49|long-term management
P11801459T0000|52 67|atherothrombosis
P11802580A0000|3 33|General Practice Research Database
P11802580A0000|35 38|GPRD
P11802580A0000|52 78|largest computerized database
P11802580A0000|81 116|anonymized longitudinal patient records
P11802580A0000|121 135|general practice
P11802580A0000|142 171|unique public health research tool
P11802601A0107|19 25|results
P11802601A0107|29 43|laboratory study
P11802601A0107|46 53|aldicarb
P11802601A0107|60 74|main metabolites
P11802601A0107|76 90|aldicarb sulfone
P11802601A0107|94 110|aldicarb sulfoxide
P11803325A0868|7 21|DC cardioversion
P11803325A0868|38 45|HBS group
P11803325A0868|55 56|DC
P11803325A0868|62 69|CBC group
P11803325A0868|79 80|DC
P11803325A0868|86 93|GIK group
P11804081A0552|5 10|August
P11804081A0552|19 22|ENRP
P11804081A0552|38 47|metric tons
P11804081A0552|50 51|TP
P11804081A0552|84 93|Everglades
P11804100A0365a|17 29|disappearance
P11804100A0365a|32 35|BOD5
P11804100A0365a|39 43|NH3-N
P11804100A0365a|68 86|first-order kinetics
P11804100A0365a|94 101|kinetics
P11804100A0365a|104 112|TP removal
P11804100A0365a|117 123|unclear
P11804100A0365b|17 29|disappearance
P11804100A0365b|32 35|BOD5
P11804100A0365b|39 43|NH3-N
P11804100A0365b|68 86|first-order kinetics
P11804100A0365b|94 101|kinetics
P11804100A0365b|104 112|TP removal
P11804100A0365b|117 123|unclear
P11804510A0730|0 5|Losses
P11804510A0730|8 20|dichlofluanid
P11804510A0730|24 24|%
P11804510A0730|27 38|chlozolinate
P11804510A0730|42 42|%
P11804510A0730|48 58|etridiazole
P11804510A0730|62 62|%
P11804510A0730|96 112|ambient processing
P11804510A0730|115 120|apples
P11804510A0730|141 157|significant levels
P11804510A0730|170 170|%
P11804510A0730|187 205|cryogenic processing
P11806132A0253|3 13|TB incidence
P11806132A0253|20 24|AIRIN
P11806132A0253|43 53|% TB patients
P11806132A0253|71 81|highest rate
P11810685A0147|16 39|displacement distribution
P11810685A0147|50 59|q-space MRI
P11810685A0147|69 85|large displacement
P11810685A0147|92 97|large r
P11810685A0147|105 119|long-wavelength
P11810685A0147|126 131|small q
P11810685A0147|133 138|limits
P11810685A0147|144 181|same 3D Gaussian displacement distribution
P11810685A0147|191 196|DT-MRI
P11811743A0800|26 34|retention
P11811743A0800|38 52|mandibular molar
P11811743A0800|58 67|Class III FI
P11811743A0800|71 86|manner acceptable
P11811743A0800|109 117|clinician
P11811825A0972|3 9|results
P11811825A0972|15 49|ten-fold cross-validation experiments
P11811825A0972|93 103|specificity
P11811825A0972|133 148|sensitivity level
P11815644A0081|3 25|physical characteristics
P11815644A0081|33 37|calls
P11815644A0081|63 72|variations
P11815644A0081|96 103|patterns
P11815644A0081|106 133|respiratory muscle recruitment
P11815644A0081|140 151|echolocation
P11816458A0319|11 18|Examples
P11816458A0319|22 33|Explanations
P11816458A0319|36 42|APA Form
P11816458A0319|53 62|help system
P11816458A0319|67 74|examples
P11816458A0319|80 94|various sections
P11816458A0319|98 110|review article
P11816458A0319|112 125|journal article
P11816458A0319|149 162|journal article
P11816458A0319|175 189|more experiments
P11816779A0343|3 13|drug packets
P11816779A0343|23 35|acetyl aspirin
P11816779A0343|37 49|acetaminophen
P11816779A0343|53 67|chloramphenicol
P11818675X0897|0 7|Karger AG
P11818675X0897|9 13|Basel
P11819326A0000|0 2|AIM
P11819326A0000|25 41|nutritional status
P11819326A0000|44 60|cirrhotic patients
P11819326A0000|68 103|clinical porto-systemic encephalopathy
P11819326A0000|105 107|PSE
P11819326A0000|110 116|METHODS
P11819326A0000|127 147|non-alcoholic patients
P11819326A0000|152 160|cirrhosis
P11819326A0000|168 170|PSE
P11819326A0000|212 228|healthy volunteers
P11821098A0269|0 17|MAIN OUTCOME MEASURE
P11821098A0269|19 19|S
P11821098A0269|22 32|Serum levels
P11821098A0269|35 37|FSH
P11821098A0269|39 40|LH
P11821098A0269|45 52|inhibin A
P11821098A0269|56 57|B.
P11822790A0907|13 25|total SIP score
P11822790A0907|30 46|individual patient
P11822790A0907|53 53|%
P11822790A0907|87 95|mean score
P11822790A0907|101 115|study population
P11822790A0907|144 144|%
P11822790A0907|162 166|items
P11822790A0907|194 213|reproducibility noise
P11822811A0319|0 4|Group
P11822811A0319|16 27|adult Collies
P11822811A0319|50 72|microg/kg ivermectin p.o.
P11822811A0319|94 97|VMTH
P11822811A0319|99 103|hours
P11822811A0319|109 120|intoxication
P11824701A0894|0 7|Patients
P11824701A0894|13 33|secondary cardiac event
P11824701A0894|41 50|common Type
P11824701A0894|52 67|behavior patterns
P11824701A0894|71 89|higher Bortner scores
P11824701A0894|94 101|patients
P11824701A0894|110 130|secondary cardiac event
P11824801A0661|14 25|continuation
P11824801A0661|31 47|interferon therapy
P11824801A0661|31 40|interferon
P11824801A0661|64 91|mild-to-moderate exacerbation
P11824801A0661|94 104|sarcoidosis
P11824801A0661|127 134|patients
P11824801A0661|139 165|noncritical organ involvement
P11825801A1212|11 32|tumor-related mortality
P11825801A1212|50 62|mean follow-up
P11825801A1212|67 72|months
P11826141T0000|0 17|Dissociable effects
P11826141T0000|20 40|lidocaine inactivation
P11826141T0000|46 52|rostral
P11826141T0000|56 80|caudal basolateral amygdala
P11826141T0000|100 112|reinstatement
P11826141T0000|115 137|cocaine-seeking behavior
P11826141T0000|140 143|rats
P11828186A0239|33 35|men
P11828186A0239|43 51|women aged
P11828186A0239|57 61|years
P11828186A0239|70 89|coronary heart disease
P11828186A0239|97 111|CRP measurements
P11828186A0239|117 135|Third National Health
P11828186A0239|139 164|Nutrition Examination Survey
P11828186A0239|166 174|NHANES III
P11830544A0335|0 8|Herceptin
P11830544A0335|28 32|HER-2
P11830544A0335|34 43|neu antigen
P11830544A0335|50 60|similar size
P11830544A0335|64 65|nm
P11830544A0335|73 79|1B4M-Gd
P11830544A0335|118 129|WIBC-9 tumors
P11830544A0335|150 166|control MC-5 tumors
P11830544A0335|183 200|normal angiogenesis
P11831512A0468|11 14|pigs
P11831512A0468|37 37|d
P11831512A0468|74 83|treatments
P11831512A0468|98 104|lactose
P11831512A0468|110 127|carbohydrate source
P11831512A0468|131 137|lactose
P11831512A0468|147 150|gram
P11831512A0468|154 157|gram
P11831512A0468|163 165|CSS
P11831512A0468|167 184|dextrose equivalent
P11831512A0468|186 187|DE
P11831512A0468|199 205|lactose
P11831512A0468|218 222|DE-42
P11832019A0668|0 10|CONCLUSIONS
P11832019A0668|12 15|AMVT
P11832019A0668|37 58|lethal emergency disease
P11833863A0987|22 34|apnea duration
P11833863A0987|45 50|supine
P11833863A0987|54 67|prone positions
P11834476A1187|13 28|large animal model
P11834476A1187|31 52|permanent focal ischemia
P11834476A1187|60 70|transfusion
P11834476A1187|79 81|min
P11834476A1187|87 94|ischemia
P11834476A1187|96 138|tetrameric cross-linked hemoglobin transfusion
P11834476A1187|118 127|hemoglobin
P11834476A1187|149 163|oxygen transport
P11834476A1187|169 182|ischemic cortex
P11835109A0000|77 97|health-related quality
P11835109A0000|105 108|HRQL
P11835109A0000|112 119|patients
P11835109A0000|124 150|chronic respiratory disorders
P11835109A0000|161 174|clinical trials
P11836046A0549|43 44|mg
P11836046A0549|47 62|calcium carbonate
P11836046A0549|67 68|mg
P11836046A0549|71 86|elemental calcium
P11836046A0549|108 112|times
P11836046A0549|118 123|group A
P11836046A0549|125 126|n=
P11836046A0549|132 147|calcium carbonate
P11836046A0549|153 162|same manner
P11836046A0549|172 177|mg/day
P11836046A0549|190 203|equine estrogen
P11836046A0549|208 228|mg medrogestone acetate
P11836046A0549|250 255|group B
P11836046A0549|257 258|n=
P11836303A0518|0 7|TNFalpha
P11836303A0518|11 20|IL-6 levels
P11836303A0518|11 14|IL-6
P11836303A0518|40 58|culture supernatants
P11836303A1191|38 56|prenatal disturbance
P11836303A1191|67 79|lasting change
P11836303A1191|82 96|cytokine biology
P11836303A1191|124 128|fetal
P11836303A1191|132 142|infant stage
P11837409A0584|3 10|two-wave
P11837409A0584|21 45|National Longitudinal Study
P11837409A0584|48 63|Adolescent Health
P11837409A0584|78 101|depressive symptomatology
P11837409A0584|109 124|12-month interval
P11838058A0084|0 6|METHODS
P11838058A0084|9 13|cases
P11838058A0084|16 54|conventional intermittent tissue expansion
P11838058A0084|56 59|CITE
P11838058A0084|65 69|cases
P11838058A0084|72 115|continuous pressure-controlled tissue expansion
P11838058A0084|117 120|CPTE
P11838102T0001|0 6|Wegener
P11838102T0001|9 22|granulomatosis
P11840365A0949|9 25|significant effect
P11840365A0949|28 37|hematocrit
P11840365A0949|43 60|General Health scale
P11840365A0949|66 70|SF-36
P11840365A0949|72 73|P =
P11842037A0327|7 24|analytic precisions
P11842037A0327|31 53|% urine-plasma difference
P11842037A0327|65 76|cut-off value
P11842728X0001|18 32|schistosomiasis
P11842728X0001|34 47|Schistosomosis
P11842728X0001|51 67|parasitic diseases
P11842728X0001|76 86|blood flukes
P11842728X0001|92 107|Schistosoma genus
P11843252A0907|1 18|global response rate
P11843252A0907|24 24|%
P11843252A0907|28 46|% confidence interval
P11843252A0907|50 52|% CI
P11843252A0907|56 56|%
P11843252A0907|60 60|%
P11843252A0907|68 88|median overall survival
P11843252A0907|94 99|months
P11844591A0329|14 25|new parameter
P11844591A0329|37 53|maximal peak torque
P11844591A0329|55 57|APT
P11844812A0915|12 21|ng/mL model
P11844812A0915|26 28|AUC
P11844812A0915|34 44|ANN ROC curve
P11844812A0915|61 66|higher
P11844812A0915|74 77|AUCs
P11844812A0915|93 99|free PSA
P11844812A0915|101 102|P =
P11844812A0915|110 115|PSA-TZ
P11844812A0915|117 118|P =
P11844812A0915|129 138|PSA density
P11844812A0915|142 160|total prostate volume
P11844812A0915|162 162|P
P11845547A0449|0 18|Potential treatments
P11845547A0449|26 35|dobutamine
P11845547A0449|37 57|KATP channel activators
P11845547A0449|62 77|21-aminosteroids
P11846167A0000|0 7|Selenium
P11846167A0000|12 27|essential element
P11846167A0000|31 36|humans
P11846167A0000|38 44|animals
P11846167A0000|61 74|microorganisms
P11846187A0894|3 21|GT-foreign-pictures
P11846187A0894|45 57|other subjects
P11846187A0894|71 77|hedonic
P11846187A0894|81 102|permeability directions
P11847580T0000|0 25|Emphysematous cholecystitis
P11847580T0000|27 45|sonographic findings
P11849417A0900|0 2|Age
P11849417A0900|25 30|groups
P11849417A0900|57 63|RESULTS
P11849417A0900|70 79|initiation
P11849417A0900|82 99|dialysis PD patients
P11849417A0900|118 129|years younger
P11849417A0900|131 131|P
P11849417A0900|144 153|HD patients
P11849796A0452|0 6|RESULTS
P11849796A0452|11 20|target dose
P11849796A0452|39 44|3D-CRT
P11849796A0452|48 56|IMRT plans
P11849796A0452|66 77|improvements
P11849796A0452|102 111|IMRT fields
P11851941A0372|19 49|radiolabelled serumalbumin method
P11851941A0372|32 43|serumalbumin
P11851941A0372|61 71|blood volume
P11851941A0372|77 89|haemodilution
P11851941A0372|117 127|haemoglobin
P11851941A0372|146 162|reference solution
P11851941A0372|165 182|hydroxyethyl starch
P11851941A0372|184 186|HES
P11852907A0871|3 30|equilibrium phosphorus content
P11852907A0871|32 35|EPC0
P11852907A0871|39 49|surface soil
P11852907A0871|62 67|higher
P11852907A0871|75 84|SRP content
P11852907A0871|75 77|SRP
P11852907A0871|87 99|drainage water
P11853943A0122|3 21|long-term prediction
P11853943A0122|33 41|algorithm
P11853943A0122|45 65|R-R interval estimation
P11858256A0102|7 26|considerable research
P11858256A0102|60 66|elusive
P11858548A0241|43 46|mono
P11858548A0241|51 73|bidimensional NMR spectra
P11858548A0241|77 92|mass spectrometry
P11858635A0896|20 34|general property
P11858635A0896|37 46|QSAR models
P11858635A0896|61 79|LOO cross-validation
P11859400A0229|13 20|efficacy
P11859400A0229|24 28|costs
P11859400A0229|31 42|valacyclovir
P11859400A0229|55 69|HSV reactivation
P11859400A0229|75 128|HSV seropositive autologous progenitor cell transplantation
P11859400A0229|130 133|APCT
P11859400A0229|135 142|patients
P11859400A0229|147 164|historical controls
P11859400A0229|171 190|intravenous acyclovir
P11859400A0229|195 208|HSV prophylaxis
P11859943A0150|3 8|adults
P11859943A0150|21 37|outpatient clinics
P11859943A0150|41 62|dermatological hospital
P11859943A0150|65 81|predetermined days
P11859943A0150|94 126|12-item General Health Questionnaire
P11860097A1695|0 3|Data
P11860097A1695|6 18|prosthesis use
P11860097A1695|43 56|follow-up study
P11860097A1695|81 97|functional outcome
P11860097A1695|101 115|prosthesis users
P11860097A1695|119 127|non-users
P11860723A0182|1 10|mail survey
P11860723A0182|13 26|Georgia members
P11860723A0182|32 46|American College
P11860723A0182|49 61|Obstetricians
P11860723A0182|65 77|Gynecologists
P11860876A0409|0 12|HIV-1 C subtype
P11860876A0409|15 18|IDUs
P11860876A0409|35 35|%
P11861092A0730|5 11|plateau
P11861092A0730|14 24|enhancement
P11861092A0730|37 48|single lesion
P11861092A0730|80 111|different continuous scanning modes
P11861092A0730|113 132|fundamental grey scale
P11861092A0730|134 136|FGS
P11861092A0730|139 162|fundamental colour Doppler
P11861092A0730|164 166|FCD
P11861092A0730|169 191|fundamental power Doppler
P11861092A0730|193 195|FPD
P11861092A0730|198 220|second harmonic grey scale
P11861092A0730|222 224|HGS
P11861092A0730|235 247|inversion mode
P11861092A0730|249 251|Pim
P11861092A0730|260 273|HDI5000 scanner
P11861092A0730|277 285|C5-2 probe
P11861092A0730|277 280|C5-2
P11861092A0730|287 289|ATL
P11861092A0730|291 297|Bothell
P11861092A0730|299 300|WA
P11862350T0000|1 16|comparative study
P11862350T0000|22 28|effects
P11862350T0000|31 43|carbamazepine
P11862350T0000|50 81|NMDA receptor antagonist remacemide
P11862350T0000|50 61|NMDA receptor
P11862350T0000|84 95|road tracking
P11862350T0000|99 122|car-following performance
P11862350T0000|125 137|actual traffic
P11863811A0259|21 33|Nusselt number
P11863811A0259|50 50|%
P11863811A0259|65 66|Pr
P11864173T0000|0 4|Viral
P11864173T0000|8 24|atypical pathogens
P11864173T0000|27 32|causes
P11864173T0000|40 57|acute exacerbations
P11864173T0000|60 76|chronic bronchitis
P11865218A0069|0 8|Treatment
P11865218A0069|44 55|wax softening
P11865218A0069|74 86|cerumenolytic
P11866130A0419|11 20|benzocaine
P11866130A0419|24 39|2-phenoxyethanol
P11866130A0419|49 66|complement activity
P11866130A0419|70 81|phagocytosis
P11866130A0419|88 92|MS222
P11866130A0419|96 113|quinaldine sulphate
P11867388A0502|3 4|EC
P11867388A0502|12 22|suppression
P11867388A0502|25 39|long-term memory
P11867388A0502|77 77|%
P11867388A0502|81 96|fear conditioning
P11867388A0502|113 113|%
P11867388A0502|128 128|%
P11867388A0502|144 146|SEM
P11867388A0502|155 170|fear conditioning
P11867388A0502|184 184|%
P11867388A0502|199 199|%
P11867388A0502|202 202|P
P11870646A0668|12 23|such analyses
P11870646A0668|37 67|ceramic/substrate bilayer systems
P11870646A0668|71 87|optimal resistance
P11870646A0668|90 115|lifetime-threatening damage
P11872359A0000|21 37|insulin resistance
P11872359A0000|21 27|insulin
P11872359A0000|39 40|IR
P11872359A0000|61 81|cardiovascular disease
P11872359A0000|83 85|CVD
P11872359A0000|87 97|risk factors
P11872359A0000|112 128|metabolic syndrome
P11872359A0000|131 133|CVD
P11872359A0000|151 168|premature mortality
P11872359A0000|174 194|indigenous Australians
P11872570T0000|0 7|Dementia
P11872570T0000|24 26|NHS
P11872570T0000|30 39|social care
P11873003X0000|0 13|HIV-1 infection
P11873003X0000|16 26|rural Africa
P11873003X0000|48 57|median time
P11873003X0000|93 115|industrialized countries
P11873003X0000|117 126|OBJECTIVES
P11873003X0000|141 156|progression times
P11873003X0000|159 172|HIV-1 infection
P11873003X0000|177 190|seroconversion
P11873003X0000|247 257|rural Uganda
P11874637A0212|14 40|active antiretroviral therapy
P11874637A0212|42 46|HAART
P11874637A0212|61 83|significant improvements
P11874637A0212|100 111|HIV infection
P11874637A0212|136 144|incidence
P11874637A0212|148 155|severity
P11874637A0212|173 196|immune deficiency syndrome
P11874637A0212|204 222|related malignancies
P11875695A0718|0 3|Time
P11875695A0718|6 16|progression
P11875695A0718|21 26|months
P11875695A0718|31 36|months
P11875695A0718|43 56|median survival
P11875695A0718|61 72|registration
P11875695A0718|78 83|months
P11875695A0718|87 89|% CI
P11875695A0718|94 99|months
P11876937A0261|0 6|Heparin
P11876937A0261|11 11|U
P11876937A0261|13 14|kg
P11876937A0261|58 61|rats
P11876937A0261|64 69|H group
P11876937A0261|75 86|normal saline
P11876937A0261|96 101|N group
P11879108A0719|0 17|MAIN OUTCOME MEASURE
P11879108A0719|19 37|A positive test result
P11879108A0719|41 50|gonococcal
P11879108A0719|53 71|chlamydial infection
P11879108A0719|77 100|ligase chain reaction assay
P11879108A0719|102 124|secondary outcome measure
P11879108A0719|129 146|positive test result
P11879108A0719|150 175|human immunodeficiency virus
P11879108A0719|177 179|HIV
P11881268A0000|55 98|meaningful exercise self-efficacy questionnaire
P11881268A0000|102 126|older Mexican American women
P11881923A1256|0 9|Neutrophil
P11881923A1256|11 25|lymphocyte ratio
P11881923A1256|27 43|plasma haptoglobin
P11881923A1256|33 43|haptoglobin
P11881923A1256|48 56|CBG levels
P11881923A1256|48 50|CBG
P11881923A1256|61 67|greater
P11881923A1256|69 69|P
P11881923A1256|85 97|INITIAL period
P11881923A1256|111 113|PRE
P11881923A1256|116 126|POST periods
P11881923A1256|149 158|treatments
P11882054A0568|0 7|Adjacent
P11882054A0568|15 21|lesions
P11882054A0568|28 60|homologous contralateral structures
P11882054A0568|62 71|FMZ binding
P11882054A0568|89 93|pairs
P11882054A0568|96 103|cortical
P11882054A0568|110 116|regions
P11882054A0568|128 131|ROIs
P11882054A0568|141 150|transaxial
P11882054A0568|154 166|coronal slices
P11882054A0568|194 205|lesion volume
P11882054A0568|212 223|mirror region
P11882054A1250|8 23|close correlation
P11882054A1250|31 47|regional decreases
P11882054A1250|50 59|FMZ binding
P11882054A1250|63 77|spiking activity
P11882054A1250|103 123|neocortical epilepsies
P11882054A1250|125 155|abnormal peri-lesional FMZ binding
P11882054A1250|180 189|mechanisms
P11882054A1250|192 206|epileptogenesis
P11882054A1250|209 229|symptomatic epilepsies
P11882747A0354|0 1|CD
P11882747A0354|23 42|Farnsworth D-15 method
P11883682A0162|18 27|monitoring
P11883682A0162|33 47|accidental spill
P11883682A0162|50 69|vertical distribution
P11883682A0162|72 82|heavy metals
P11883682A0162|88 105|estuarine sediments
P11883763A1062|3 13|large fluxes
P11883763A1062|23 24|Pu
P11883763A1062|44 67|episodic lateral transport
P11883763A1062|70 78|particles
P11883763A1062|94 109|continental slope
P11883763A1062|117 130|nepheloid layer
P11883763A1062|174 184|Pu transport
P11883763A1062|190 205|continental slope
P11883763A1062|211 222|East China Sea
P11884014A0665|0 25|Rigorous treatment protocols
P11884014A0665|29 40|diet delivery
P11884014A0665|44 70|EEN-related GI adverse effects
P11885053A1897|30 35|Volkan
P11885053A1897|39 44|groups
P11885053A1897|54 60|objects
P11885053A1897|93 103|undescribed
P11885053A1897|115 121|objects
P11885053A1897|139 152|memorial shrine
P11885737A1713|23 40|spermatozoa/microl
P11885737A1713|54 73|reasonable compromise
P11886473A0796|0 13|Gastritis score
P11886473A0796|42 45|CagA
P11886473A0796|47 54|children
P11886473A0796|66 69|CagA
P11886473A0796|72 73|p =
P11886473A0796|85 89|CagA+
P11886473A0796|85 88|CagA
P11886473A0796|91 92|p =
P11886473A0796|106 110|CagA+
P11886473A0796|106 109|CagA
P11886473A0796|112 112|p
P11886473A0796|129 134|antrum
P11886473A0796|138 143|corpus
P11887803A1455|3 15|mean thickness
P11887803A1455|21 38|visceral peritoneum
P11887803A1455|58 63|groups
P11887803A1455|66 72|animals
P11887803A1455|98 111|severe fibrosis
P11887803A1455|125 134|peritoneum
P11887803A1455|137 140|rats
P11887803A1455|150 153|CAPD
P11887803A1455|169 175|animals
P11887803A1455|187 190|CAPD
P11887803A1455|192 198|Balance
P11887803A1455|200 200|p
P11888183A0541|1 15|further analysis
P11888183A0541|48 63|maximum intensity
P11888183A0541|72 79|duration
P11888183A0541|92 94|hrs
P11888183A0541|99 115|annual daily maxima
P11888867A0000|0 9|BACKGROUND
P11888867A0000|32 54|postoperative serum level
P11888867A0000|57 63|TA90-IC
P11888867A0000|67 79|immune complex
P11888867A0000|83 111|90-kDa tumor-associated antigen
P11888867A0000|118 125|antibody
P11888867A0000|137 158|significant correlation
P11888867A0000|163 172|recurrence
P11888867A0000|186 193|patients
P11888867A0000|198 218|thick primary melanomas
P11890354A0000|0 16|Genetics Institute
P11890354A0000|40 49|oprelvekin
P11890354A0000|51 57|rhIL-11
P11890354A0000|59 65|Neumega
P11890354A0000|69 83|recombinant form
P11890354A0000|86 95|human IL-11
P11890438A0838|0 7|Patients
P11890438A0838|45 48|days
P11890438A0838|58 63|wounds
P11890438A0838|74 82|dressings
P11893403A0252|0 7|Elements
P11893403A0252|31 46|safety evaluation
P11893403A0252|49 65|flavor ingredients
P11893403A0252|82 98|structural analogy
P11893403A0252|100 109|metabolism
P11893403A0252|111 126|pharmacokinetics
P11893403A0252|130 139|toxicology
P11893767A0356|3 15|mass-specific
P11893767A0356|23 39|minute ventilation
P11893767A0356|41 41|E
P11893767A0356|49 69|ventilatory equivalent
P11893767A0356|71 72|VE
P11893767A0356|75 75|O
P11893767A0356|113 116|ages
P11893767A0356|123 138|breathing pattern
P11893767A0356|152 157|deeper
P11893767A0356|161 166|slower
P11894605A1429|0 13|INTERPRETATION
P11894605A1429|19 26|probable
P11894605A1429|34 52|cognitive dissonance
P11894605A1429|62 82|more health information
P11894605A1429|85 91|smoking
P11894605A1429|109 127|necessary motivation
P11894605A1429|156 171|strategic changes
P11895024A1054|4 8|cases
P11895024A1054|11 13|GBS
P11895024A1054|23 24|TM
P11895024A1054|38 58|active AFP surveillance
P11895024A1054|76 91|hospital searches
P11895184A0000|12 15|rats
P11895184A0000|29 46|hippocampal lesions
P11895184A0000|56 67|object-place
P11895184A0000|69 78|odor-place
P11895184A0000|82 112|object-odor paired-associate task
P11895184A0000|127 150|cheeseboard maze apparatus
P11897449A0566|13 34|earliest activation site
P11897449A0566|56 62|esmolol
P11897449A0566|91 93|RFA
P11897449A0566|95 101|RESULTS
P11897449A0566|106 114|heart rate
P11897449A0566|126 139|drug-free state
P11897449A0566|161 169|beats/min
P11897449A0566|182 190|beats/min
P11897888A0590|0 11|Urine samples
P11897888A0590|50 60|supplements
P11897950A0617|0 10|CONCLUSIONS
P11897950A0617|12 29|Lymphoscintigraphy
P11897950A0617|35 57|cynomolgus monkey eyelids
P11897950A0617|65 97|discrete lymphatic drainage pathways
P11897950A0617|112 123|lower eyelids
P11897950A0617|128 138|dual pathway
P11897950A0617|145 162|central upper eyelid
P11898018T0000|0 13|Data management
P11898018T0000|16 37|practice-based research
P11898797A0124|31 36|levels
P11898797A0124|39 70|choline acetyltransferase activity
P11898797A0124|39 62|choline acetyltransferase
P11898797A0124|76 89|cerebral cortex
P11898797A0124|92 99|patients
P11898797A0124|113 122|head injury
P11898797A0124|155 184|cortical cholinergic innervation
P11899479A0122|11 16|smears
P11899479A0122|21 27|lesions
P11899479A0122|33 42|oral mucosa
P11899479A0122|51 56|cheeks
P11899479A0122|58 63|palate
P11899479A0122|71 94|contiguous denture surface
P11899479A0122|97 111|cotton wool swabs
P11899479A0122|134 153|Sabouraud glucose agar
P11899479A0122|157 172|CHROMagar Candida
P11899479A0122|174 195|individual yeast species
P11899479A0122|213 220|germ tube
P11899479A0122|222 232|filamentous
P11899479A0122|237 253|assimilation tests
P11899479A0122|266 287|commercial kit AuxaColor
P11899489A0119|3 9|effects
P11899489A0119|12 35|pharmacological treatment
P11899489A0119|39 54|professional care
P11899489A0119|79 86|dementia
P11899489A0119|101 110|early stage
P11900770T0000|19 28|incentives
P11900770T0000|30 40|attenuation
P11900770T0000|43 60|motivational impact
P11900770T0000|67 92|dopamine receptor antagonism
P11902068T0000|3 12|CKD patient
P11902738A0185|0 7|PATIENTS
P11902738A0185|11 17|METHODS
P11902738A0185|31 54|retrospective cohort study
P11902738A0185|60 67|children
P11902738A0185|89 105|single institution
P11902738A0185|118 128|neutropenia
P11902738A0185|141 163|absolute neutrophil count
P11902738A0185|168 176|cells/mm3
P11902738A0185|181 192|1-year period
P11902781A0550|0 13|Concentrations
P11902781A0550|16 16|N
P11902781A0550|18 19|O3
P11902781A0550|23 23|N
P11902781A0550|27 27|N
P11902781A0550|29 30|H3
P11902781A0550|34 34|N
P11902781A0550|37 45|Deoprayag
P11902781A0550|79 82|mg/L
P11904017A0000|8 32|pathophysiological process
P11904017A0000|49 57|blood flow
P11904017A0000|66 90|low-resistance vascular bed
P11904017A0000|135 154|central nervous system
P11907691A0214|3 14|orientations
P11907691A0214|20 34|contact surfaces
P11907691A0214|43 59|locations relative
P11908529A0553|3 9|results
P11908529A0553|21 24|flux
P11908529A0553|34 38|stars
P11908529A0553|42 44|cm3
P11908529A0553|57 60|ions
P11908529A0553|76 89|other detectors
P11908529A0553|91 98|plastics
P11908529A0553|100 111|AgCl crystals
P11908529A0553|113 115|LiF
P11908529A0553|118 127|energy loss
P11908529A0553|143 159|biological objects
P11909404A0000|0 11|Nodal domains
P11909404A0000|15 21|regions
P11909404A0000|39 50|definite sign
P11910310A0279|0 5|DESIGN
P11910310A0279|7 17|Prospective
P11910310A0279|30 41|double-blind
P11910310A0279|43 57|controlled trial
P11910344A1119|0 10|CONCLUSIONS
P11910344A1119|16 45|retrospective uncontrolled study
P11910344A1119|57 64|patients
P11910344A1119|74 76|HRS
P11910344A1119|78 97|terlipressin-induced
P11910344A1119|106 118|renal function
P11911552A0776|2 9|patients
P11911552A0776|22 31|quetiapine
P11911552A0776|62 72|optimal dose
P11911552A0776|86 94|remission
P11911552A0776|120 123|mg/d
P11912261A0284|0 17|Calcimimetic agents
P11912261A0284|33 44|PTH secretion
P11912261A0284|33 35|PTH
P11912261A0284|60 82|calcium-sensing receptor
P11912261A0284|88 104|parathyroid glands
P11912261A0284|109 126|clinical experience
P11912677A0281|4 15|such analysis
P11912677A0281|27 36|hypotheses
P11912677A0281|56 72|latent variability
P11912677A0281|85 91|data set
P11913427A0290|3 10|subjects
P11913427A0290|62 74|accelerations
P11913427A0290|111 112|g.
P11915436A0491|11 24|incidence rates
P11915436A0491|47 51|rates
P11915436A0491|57 73|general population
P11917061A0922|3 15|only predictor
P11917061A0922|28 37|tacrolimus
P11917061A0922|42 57|previous response
P11917061A0922|60 70|cyclosporin
P11917061A0922|74 83|prednisone
P11917061A0922|104 119|partial remission
P11917061A0922|121 133|remission rate
P11917061A0922|136 136|%
P11917061A0922|144 145|P=
P11917882A0326|8 25|morphological study
P11917882A0326|31 52|resin-dentine interface
P11917882A0326|55 68|broad selection
P11917882A0326|71 92|dentine adhesive systems
P11917882A0326|120 136|adhesion-strategy
P11920455X1195|0 8|Copyright
P11920455X1195|13 33|American Cancer Society
P11920455X1195|35 37|DOI
P11920455X1195|46 55|cncr.10318
P11920896A0298|30 31|DR
P11920896A0298|41 52|combined test
P11920896A0298|58 77|unselected population
P11920896A0298|80 105|self-referred pregnant women
P11920896A0298|109 126|false-positive rate
P11920896A0298|128 130|FPR
P11920896A0298|140 140|%
P11921126A1196|15 20|PDQ-39
P11921126A1196|22 28|STN-DBS
P11921126A1196|50 65|important aspects
P11921126A1196|68 70|QoL
P11921126A1196|73 80|patients
P11921126A1196|85 94|advanced PD
